CN103006667A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	tanshinone$$$15$$$25$$$I	IIA$$$26$$$29$$$I	or$$$30$$$32$$$O	pharmaceutically$$$33$$$49$$$O	acceptable$$$50$$$60$$$O	salt$$$61$$$65$$$O	in$$$66$$$68$$$O	preparation$$$69$$$80$$$O	of$$$81$$$83$$$O	medicament$$$84$$$94$$$O	for$$$95$$$98$$$O	treating$$$99$$$107$$$O	or$$$108$$$110$$$O	inhibiting$$$111$$$121$$$O	mucus$$$122$$$127$$$O	in$$$128$$$130$$$O	wind$$$131$$$135$$$O	pipe$$$136$$$140$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	application$$$27$$$38$$$O	of$$$39$$$41$$$O	tanshinone$$$42$$$52$$$I	IIA$$$53$$$56$$$I	or$$$57$$$59$$$O	pharmaceutically$$$60$$$76$$$O	acceptable$$$77$$$87$$$O	salt$$$88$$$92$$$O	in$$$93$$$95$$$O	preparation$$$96$$$107$$$O	of$$$108$$$110$$$O	medicament$$$111$$$121$$$O	for$$$122$$$125$$$O	treating$$$126$$$134$$$O	or$$$135$$$137$$$O	inhibiting$$$138$$$148$$$O	mucus$$$149$$$154$$$O	in$$$155$$$157$$$O	a$$$158$$$159$$$O	wind$$$160$$$164$$$O	pipe.$$$165$$$170$$$O	The$$$171$$$174$$$O	tanshinone$$$175$$$185$$$I	IIA$$$186$$$189$$$I	or$$$190$$$192$$$O	pharmaceutically$$$193$$$209$$$O	acceptable$$$210$$$220$$$O	salt$$$221$$$225$$$O	can$$$226$$$229$$$O	obviously$$$230$$$239$$$O	inhibit$$$240$$$247$$$O	the$$$248$$$251$$$O	hypersecretion$$$252$$$266$$$O	of$$$267$$$269$$$O	mucoprotein$$$270$$$281$$$O	in$$$282$$$284$$$O	the$$$285$$$288$$$O	wind$$$289$$$293$$$O	pipe$$$294$$$298$$$O	of$$$299$$$301$$$O	the$$$302$$$305$$$O	lung$$$306$$$310$$$O	tissue.$$$311$$$318$$$O	Compared$$$319$$$327$$$O	with$$$328$$$332$$$O	the$$$333$$$336$$$O	commonly$$$337$$$345$$$O	used$$$346$$$350$$$O	mucolytic$$$351$$$360$$$O	agents,$$$361$$$368$$$O	the$$$369$$$372$$$O	tanshinone$$$373$$$383$$$I	IIA$$$384$$$387$$$I	or$$$388$$$390$$$O	pharmaceutically$$$391$$$407$$$O	acceptable$$$408$$$418$$$O	salt$$$419$$$423$$$O	can$$$424$$$427$$$O	obviously$$$428$$$437$$$O	inhibit$$$438$$$445$$$O	the$$$446$$$449$$$O	expression$$$450$$$460$$$O	and$$$461$$$464$$$O	the$$$465$$$468$$$O	secretion$$$469$$$478$$$O	of$$$479$$$481$$$O	mucoprotein,$$$482$$$494$$$O	and$$$495$$$498$$$O	the$$$499$$$502$$$O	obvious$$$503$$$510$$$O	side$$$511$$$515$$$O	and$$$516$$$519$$$O	toxic$$$520$$$525$$$O	effects$$$526$$$533$$$O	can$$$534$$$537$$$O	not$$$538$$$541$$$O	be$$$542$$$544$$$O	found.$$$545$$$551$$$O
WO2009031627A1
Para-terphenyl$$$0$$$14$$$I	compound$$$15$$$23$$$O	or$$$24$$$26$$$O	pharmacologically$$$27$$$44$$$O	acceptable$$$45$$$55$$$O	salt$$$56$$$60$$$O	thereof,$$$61$$$69$$$O	method$$$70$$$76$$$O	for$$$77$$$80$$$O	production$$$81$$$91$$$O	of$$$92$$$94$$$O	the$$$95$$$98$$$O	same,$$$99$$$104$$$O	and$$$105$$$108$$$O	use$$$109$$$112$$$O	of$$$113$$$115$$$O	the$$$116$$$119$$$O	same$$$120$$$124$$$O
Disclosed$$$0$$$9$$$O	are:$$$10$$$14$$$O	a$$$15$$$16$$$O	para-terphenyl$$$17$$$31$$$I	compound$$$32$$$40$$$O	represented$$$41$$$52$$$O	by$$$53$$$55$$$O	the$$$56$$$59$$$O	formula$$$60$$$67$$$O	(1)$$$68$$$71$$$O	or$$$72$$$74$$$O	a$$$75$$$76$$$O	pharmacologically$$$77$$$94$$$O	acceptable$$$95$$$105$$$O	salt$$$106$$$110$$$O	thereof;$$$111$$$119$$$O	a$$$120$$$121$$$O	method$$$122$$$128$$$O	for$$$129$$$132$$$O	producing$$$133$$$142$$$O	the$$$143$$$146$$$O	para-terphenyl$$$147$$$161$$$I	compound$$$162$$$170$$$O	or$$$171$$$173$$$O	the$$$174$$$177$$$O	pharmacologically$$$178$$$195$$$O	acceptable$$$196$$$206$$$O	salt$$$207$$$211$$$O	thereof;$$$212$$$220$$$O	and$$$221$$$224$$$O	use$$$225$$$228$$$O	of$$$229$$$231$$$O	the$$$232$$$235$$$O	para-terphenyl$$$236$$$250$$$I	compound$$$251$$$259$$$O	or$$$260$$$262$$$O	the$$$263$$$266$$$O	pharmacologically$$$267$$$284$$$O	acceptable$$$285$$$295$$$O	salt$$$296$$$300$$$O	thereof.$$$301$$$309$$$O	(1)$$$310$$$313$$$O	[wherein$$$314$$$322$$$O	R1$$$323$$$325$$$O	and$$$326$$$329$$$O	R2$$$330$$$332$$$O	independently$$$333$$$346$$$O	represent$$$347$$$356$$$O	an$$$357$$$359$$$O	alkyl,$$$360$$$366$$$I	cyclic$$$367$$$373$$$I	alkyl,$$$374$$$380$$$I	alkoxyalkyl,$$$381$$$393$$$I	siloxyalkyl$$$394$$$405$$$I	or$$$406$$$408$$$O	phenyl$$$409$$$415$$$I	group$$$416$$$421$$$O	having$$$422$$$428$$$O	1$$$429$$$430$$$O	to$$$431$$$433$$$O	6$$$434$$$435$$$O	carbon$$$436$$$442$$$I	atoms$$$443$$$448$$$O	or$$$449$$$451$$$O	an$$$452$$$454$$$O	alkylene$$$455$$$463$$$I	group$$$464$$$469$$$O	having$$$470$$$476$$$O	3$$$477$$$478$$$O	or$$$479$$$481$$$O	4$$$482$$$483$$$O	carbon$$$484$$$490$$$I	atoms;$$$491$$$497$$$O	and$$$498$$$501$$$O	R3$$$502$$$504$$$O	and$$$505$$$508$$$O	R4$$$509$$$511$$$O	independently$$$512$$$525$$$O	represent$$$526$$$535$$$O	a$$$536$$$537$$$O	hydrogen$$$538$$$546$$$I	or$$$547$$$549$$$O	a$$$550$$$551$$$O	protective$$$552$$$562$$$O	group$$$563$$$568$$$O	for$$$569$$$572$$$O	a$$$573$$$574$$$O	hydroxyl$$$575$$$583$$$I	group.]$$$584$$$591$$$O	Thus,$$$592$$$597$$$O	a$$$598$$$599$$$O	compound$$$600$$$608$$$O	having$$$609$$$615$$$O	an$$$616$$$618$$$O	inhibitory$$$619$$$629$$$O	activity$$$630$$$638$$$O	on$$$639$$$641$$$O	the$$$642$$$645$$$O	production$$$646$$$656$$$O	of$$$657$$$659$$$O	tumor$$$660$$$665$$$O	necrosis$$$666$$$674$$$O	factor$$$675$$$681$$$O	(TNF)-Î±$$$682$$$690$$$O	can$$$691$$$694$$$O	be$$$695$$$697$$$O	produced$$$698$$$706$$$O	by$$$707$$$709$$$O	a$$$710$$$711$$$O	chemical$$$712$$$720$$$O	synthesis.$$$721$$$731$$$O	The$$$732$$$735$$$O	compound$$$736$$$744$$$O	has$$$745$$$748$$$O	no$$$749$$$751$$$O	toxic$$$752$$$757$$$O	activity,$$$758$$$767$$$O	and$$$768$$$771$$$O	is$$$772$$$774$$$O	therefore$$$775$$$784$$$O	useful$$$785$$$791$$$O	as$$$792$$$794$$$O	a$$$795$$$796$$$O	therapeutic$$$797$$$808$$$O	agent$$$809$$$814$$$O	for$$$815$$$818$$$O	an$$$819$$$821$$$O	autoimmune$$$822$$$832$$$O	disease,$$$833$$$841$$$O	an$$$842$$$844$$$O	allergic$$$845$$$853$$$O	disease$$$854$$$861$$$O	or$$$862$$$864$$$O	the$$$865$$$868$$$O	like.$$$869$$$874$$$O
CN101596202A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	tanshinone$$$15$$$25$$$I	IIA$$$26$$$29$$$I	emulsion$$$30$$$38$$$O	on$$$39$$$41$$$O	treating$$$42$$$50$$$O	liver$$$51$$$56$$$O	diseases$$$57$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	application$$$28$$$39$$$O	of$$$40$$$42$$$O	tanshinone$$$43$$$53$$$I	IIA$$$54$$$57$$$I	emulsion$$$58$$$66$$$O	on$$$67$$$69$$$O	treating$$$70$$$78$$$O	liver$$$79$$$84$$$O	diseases.$$$85$$$94$$$O	After$$$95$$$100$$$O	intravenous$$$101$$$112$$$O	injection$$$113$$$122$$$O	of$$$123$$$125$$$O	tanshinone$$$126$$$136$$$I	IIA$$$137$$$140$$$I	emulsion,$$$141$$$150$$$O	the$$$151$$$154$$$O	medicine$$$155$$$163$$$O	can$$$164$$$167$$$O	be$$$168$$$170$$$O	rapidly$$$171$$$178$$$O	distributed$$$179$$$190$$$O	to$$$191$$$193$$$O	a$$$194$$$195$$$O	liver$$$196$$$201$$$O	in$$$202$$$204$$$O	a$$$205$$$206$$$O	targeted$$$207$$$215$$$O	way.$$$216$$$220$$$O	The$$$221$$$224$$$O	tanshinone$$$225$$$235$$$I	IIA$$$236$$$239$$$I	emulsion$$$240$$$248$$$O	has$$$249$$$252$$$O	good$$$253$$$257$$$O	effect$$$258$$$264$$$O	on$$$265$$$267$$$O	treating$$$268$$$276$$$O	liver$$$277$$$282$$$O	diseases$$$283$$$291$$$O	including$$$292$$$301$$$O	steatohepatitis,$$$302$$$318$$$O	viral$$$319$$$324$$$O	hepatitis,$$$325$$$335$$$O	hepatic$$$336$$$343$$$O	fibrosis,$$$344$$$353$$$O	liver$$$354$$$359$$$O	cancer,$$$360$$$367$$$O	and$$$368$$$371$$$O	the$$$372$$$375$$$O	like.$$$376$$$381$$$O
CN102058584B
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	potassium$$$22$$$31$$$I	clavulanate/microcrystalline$$$32$$$60$$$I	cellulose$$$61$$$70$$$O	composition$$$71$$$82$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	of$$$45$$$47$$$O	a$$$48$$$49$$$O	potassium$$$50$$$59$$$I	clavulanate/microcrystalline$$$60$$$88$$$I	cellulose$$$89$$$98$$$O	composition,$$$99$$$111$$$O	belonging$$$112$$$121$$$O	to$$$122$$$124$$$O	the$$$125$$$128$$$O	preparation$$$129$$$140$$$O	field$$$141$$$146$$$O	of$$$147$$$149$$$O	pharmaceutical$$$150$$$164$$$O	raw$$$165$$$168$$$O	materials.$$$169$$$179$$$O	The$$$180$$$183$$$O	preparation$$$184$$$195$$$O	method$$$196$$$202$$$O	of$$$203$$$205$$$O	the$$$206$$$209$$$O	invention$$$210$$$219$$$O	comprises$$$220$$$229$$$O	the$$$230$$$233$$$O	following$$$234$$$243$$$O	steps$$$244$$$249$$$O	of:$$$250$$$253$$$O	dissolving$$$254$$$264$$$O	clavulanic$$$265$$$275$$$O	tert-butylamine$$$276$$$291$$$I	powder$$$292$$$298$$$O	as$$$299$$$301$$$O	a$$$302$$$303$$$O	raw$$$304$$$307$$$O	material$$$308$$$316$$$O	in$$$317$$$319$$$O	an$$$320$$$322$$$O	isopropyl$$$323$$$332$$$I	alcohol$$$333$$$340$$$I	solution$$$341$$$349$$$O	to$$$350$$$352$$$O	prepare$$$353$$$360$$$O	a$$$361$$$362$$$O	clavulanic$$$363$$$373$$$I	tert-butylamine-isopropylalcohol$$$374$$$406$$$I	solution;$$$407$$$416$$$O	then,$$$417$$$422$$$O	dipping$$$423$$$430$$$O	a$$$431$$$432$$$O	potassium$$$433$$$442$$$I	ethylhexanoate-isopropyl$$$443$$$467$$$I	alcohol$$$468$$$475$$$I	solution$$$476$$$484$$$O	to$$$485$$$487$$$O	the$$$488$$$491$$$O	clavulanic$$$492$$$502$$$I	tert-butylamine-isopropyl$$$503$$$528$$$I	alcohol$$$529$$$536$$$I	solution$$$537$$$545$$$O	until$$$546$$$551$$$O	complete$$$552$$$560$$$O	crystallization$$$561$$$576$$$O	is$$$577$$$579$$$O	finished;$$$580$$$589$$$O	then,$$$590$$$595$$$O	adding$$$596$$$602$$$O	microcrystalline$$$603$$$619$$$O	cellulose$$$620$$$629$$$O	powder$$$630$$$636$$$O	in$$$637$$$639$$$O	60-70$$$640$$$645$$$O	percent$$$646$$$653$$$O	by$$$654$$$656$$$O	weight$$$657$$$663$$$O	of$$$664$$$666$$$O	the$$$667$$$670$$$O	clavulanic$$$671$$$681$$$I	tert-butylamine$$$682$$$697$$$I	powder;$$$698$$$705$$$O	and$$$706$$$709$$$O	finally,$$$710$$$718$$$O	carrying$$$719$$$727$$$O	out$$$728$$$731$$$O	suction$$$732$$$739$$$O	filtration,$$$740$$$751$$$O	washing$$$752$$$759$$$O	and$$$760$$$763$$$O	drying$$$764$$$770$$$O	to$$$771$$$773$$$O	obtain$$$774$$$780$$$O	the$$$781$$$784$$$O	potassium$$$785$$$794$$$I	clavulanate/microcrystalline$$$795$$$823$$$I	cellulose$$$824$$$833$$$O	composition.$$$834$$$846$$$O	The$$$847$$$850$$$O	adopted$$$851$$$858$$$O	preparation$$$859$$$870$$$O	method$$$871$$$877$$$O	of$$$878$$$880$$$O	the$$$881$$$884$$$O	invention$$$885$$$894$$$O	has$$$895$$$898$$$O	low$$$899$$$902$$$O	cost,$$$903$$$908$$$O	high$$$909$$$913$$$O	safety$$$914$$$920$$$O	factor$$$921$$$927$$$O	and$$$928$$$931$$$O	short$$$932$$$937$$$O	process$$$938$$$945$$$O	flows$$$946$$$951$$$O	and$$$952$$$955$$$O	is$$$956$$$958$$$O	suitable$$$959$$$967$$$O	for$$$968$$$971$$$O	mass$$$972$$$976$$$O	production.$$$977$$$988$$$O
CN103755771A
Camellia$$$0$$$8$$$O	saponin$$$9$$$16$$$I	compound,$$$17$$$26$$$O	preparation$$$27$$$38$$$O	method$$$39$$$45$$$O	and$$$46$$$49$$$O	application$$$50$$$61$$$O	thereof$$$62$$$69$$$O	and$$$70$$$73$$$O	anti-tumour$$$74$$$85$$$O	drug$$$86$$$90$$$O	prepared$$$91$$$99$$$O	from$$$100$$$104$$$O	same$$$105$$$109$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	pharmacochemistry$$$48$$$65$$$O	and$$$66$$$69$$$O	discloses$$$70$$$79$$$O	a$$$80$$$81$$$O	camellia$$$82$$$90$$$O	saponin$$$91$$$98$$$I	compound,$$$99$$$108$$$O	a$$$109$$$110$$$O	preparation$$$111$$$122$$$O	method$$$123$$$129$$$O	and$$$130$$$133$$$O	application$$$134$$$145$$$O	thereof$$$146$$$153$$$O	and$$$154$$$157$$$O	an$$$158$$$160$$$O	anti-tumour$$$161$$$172$$$O	drug$$$173$$$177$$$O	prepared$$$178$$$186$$$O	from$$$187$$$191$$$O	the$$$192$$$195$$$O	same.$$$196$$$201$$$O	The$$$202$$$205$$$O	oil-tea$$$206$$$213$$$O	camellia$$$214$$$222$$$O	saponin$$$223$$$230$$$I	chemical$$$231$$$239$$$O	compound$$$240$$$248$$$O	adopts$$$249$$$255$$$O	the$$$256$$$259$$$O	structure$$$260$$$269$$$O	shown$$$270$$$275$$$O	in$$$276$$$278$$$O	the$$$279$$$282$$$O	formula$$$283$$$290$$$O	I,$$$291$$$293$$$O	has$$$294$$$297$$$O	remarkable$$$298$$$308$$$O	effects$$$309$$$316$$$O	on$$$317$$$319$$$O	inhibiting$$$320$$$330$$$O	liver$$$331$$$336$$$O	cancer$$$337$$$343$$$O	cell,$$$344$$$349$$$O	breast$$$350$$$356$$$O	cancer$$$357$$$363$$$O	cell,$$$364$$$369$$$O	melanoma$$$370$$$378$$$O	cell$$$379$$$383$$$O	and$$$384$$$387$$$O	lung$$$388$$$392$$$O	cancer$$$393$$$399$$$O	cell,$$$400$$$405$$$O	and$$$406$$$409$$$O	can$$$410$$$413$$$O	effectively$$$414$$$425$$$O	inhibit$$$426$$$433$$$O	the$$$434$$$437$$$O	growth$$$438$$$444$$$O	of$$$445$$$447$$$O	liver$$$448$$$453$$$O	tumour,$$$454$$$461$$$O	so$$$462$$$464$$$O	that$$$465$$$469$$$O	the$$$470$$$473$$$O	oil-tea$$$474$$$481$$$O	camellia$$$482$$$490$$$O	saponin$$$491$$$498$$$O	chemical$$$499$$$507$$$O	compound$$$508$$$516$$$O	has$$$517$$$520$$$O	remarkable$$$521$$$531$$$O	tumour$$$532$$$538$$$O	resisting$$$539$$$548$$$O	activity$$$549$$$557$$$O	and$$$558$$$561$$$O	can$$$562$$$565$$$O	be$$$566$$$568$$$O	used$$$569$$$573$$$O	for$$$574$$$577$$$O	the$$$578$$$581$$$O	preparation$$$582$$$593$$$O	of$$$594$$$596$$$O	anti-tumour$$$597$$$608$$$O	drugs.$$$609$$$615$$$O	(The$$$616$$$620$$$O	formula$$$621$$$628$$$O	I$$$629$$$630$$$O	is$$$631$$$633$$$O	shown$$$634$$$639$$$O	in$$$640$$$642$$$O	the$$$643$$$646$$$O	specification).$$$647$$$662$$$O
CN103476432A
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	producing$$$12$$$21$$$O	aqueous$$$22$$$29$$$O	solution$$$30$$$38$$$O	containing$$$39$$$49$$$O	fat-soluble$$$50$$$61$$$O	substance$$$62$$$71$$$O
The$$$0$$$3$$$O	purpose$$$4$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	present$$$19$$$26$$$O	invention$$$27$$$36$$$O	is$$$37$$$39$$$O	to$$$40$$$42$$$O	provide$$$43$$$50$$$O	a$$$51$$$52$$$O	process$$$53$$$60$$$O	for$$$61$$$64$$$O	producing$$$65$$$74$$$O	an$$$75$$$77$$$O	aqueous$$$78$$$85$$$O	solution$$$86$$$94$$$O	containing$$$95$$$105$$$O	a$$$106$$$107$$$O	fat-soluble$$$108$$$119$$$O	substance.$$$120$$$130$$$O	A$$$131$$$132$$$O	combination$$$133$$$144$$$O	of$$$145$$$147$$$O	a$$$148$$$149$$$O	super$$$150$$$155$$$O	dissolution$$$156$$$167$$$O	aid,$$$168$$$172$$$O	cyclodextrin$$$173$$$185$$$O	and$$$186$$$189$$$O	a$$$190$$$191$$$O	fat-soluble$$$192$$$203$$$O	substance$$$204$$$213$$$O	or$$$214$$$216$$$O	a$$$217$$$218$$$O	combination$$$219$$$230$$$O	of$$$231$$$233$$$O	the$$$234$$$237$$$O	super$$$238$$$243$$$O	dissolution$$$244$$$255$$$O	aid$$$256$$$259$$$O	and$$$260$$$263$$$O	a$$$264$$$265$$$O	cyclodextrin$$$266$$$278$$$O	complex$$$279$$$286$$$O	of$$$287$$$289$$$O	the$$$290$$$293$$$O	fat-soluble$$$294$$$305$$$O	substance$$$306$$$315$$$O	is$$$316$$$318$$$O	used$$$319$$$323$$$O	for$$$324$$$327$$$O	dissolving$$$328$$$338$$$O	the$$$339$$$342$$$O	fat-soluble$$$343$$$354$$$O	substance,$$$355$$$365$$$O	whereby$$$366$$$373$$$O	it$$$374$$$376$$$O	becomes$$$377$$$384$$$O	possible$$$385$$$393$$$O	to$$$394$$$396$$$O	provide$$$397$$$404$$$O	an$$$405$$$407$$$O	aqueous$$$408$$$415$$$O	solution$$$416$$$424$$$O	containing$$$425$$$435$$$O	the$$$436$$$439$$$O	fat-soluble$$$440$$$451$$$O	substance$$$452$$$461$$$O	at$$$462$$$464$$$O	a$$$465$$$466$$$O	high$$$467$$$471$$$O	concentration$$$472$$$485$$$O	and$$$486$$$489$$$O	an$$$490$$$492$$$O	aqueous$$$493$$$500$$$O	solution$$$501$$$509$$$O	having$$$510$$$516$$$O	improved$$$517$$$525$$$O	transdermal$$$526$$$537$$$O	absorbability$$$538$$$551$$$O	of$$$552$$$554$$$O	the$$$555$$$558$$$O	fat-soluble$$$559$$$570$$$O	substance$$$571$$$580$$$O	contained$$$581$$$590$$$O	therein.$$$591$$$599$$$O
CA2230690C
Administration$$$0$$$14$$$O	of$$$15$$$17$$$O	ketamine$$$18$$$26$$$I	to$$$27$$$29$$$O	manage$$$30$$$36$$$O	pain$$$37$$$41$$$O	and$$$42$$$45$$$O	to$$$46$$$48$$$O	reduce$$$49$$$55$$$O	drug$$$56$$$60$$$O	dependency$$$61$$$71$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	management$$$37$$$47$$$O	of$$$48$$$50$$$O	pain$$$51$$$55$$$O	without$$$56$$$63$$$O	requiring$$$64$$$73$$$O	or$$$74$$$76$$$O	allowing$$$77$$$85$$$O	for$$$86$$$89$$$O	reduction$$$90$$$99$$$O	in$$$100$$$102$$$O	the$$$103$$$106$$$O	level$$$107$$$112$$$O	of$$$113$$$115$$$O	administration$$$116$$$130$$$O	of$$$131$$$133$$$O	narcotics,$$$134$$$144$$$O	and$$$145$$$148$$$O	to$$$149$$$151$$$O	self-management$$$152$$$167$$$O	of$$$168$$$170$$$O	pain$$$171$$$175$$$O	on$$$176$$$178$$$O	an$$$179$$$181$$$O	outpatient$$$182$$$192$$$O	basis.$$$193$$$199$$$O	Accordingly,$$$200$$$212$$$O	the$$$213$$$216$$$O	present$$$217$$$224$$$O	invention$$$225$$$234$$$O	is$$$235$$$237$$$O	broadly$$$238$$$245$$$O	directed$$$246$$$254$$$O	to$$$255$$$257$$$O	a$$$258$$$259$$$O	method$$$260$$$266$$$O	for$$$267$$$270$$$O	treating$$$271$$$279$$$O	pain$$$280$$$284$$$O	in$$$285$$$287$$$O	a$$$288$$$289$$$O	subject$$$290$$$297$$$O	comprising$$$298$$$308$$$O	administering$$$309$$$322$$$O	via$$$323$$$326$$$O	a$$$327$$$328$$$O	transmucosal,$$$329$$$342$$$O	transdermal,$$$343$$$355$$$O	or$$$356$$$358$$$O	oral$$$359$$$363$$$O	route$$$364$$$369$$$O	a$$$370$$$371$$$O	dose$$$372$$$376$$$O	of$$$377$$$379$$$O	ketamine$$$380$$$388$$$I	effective$$$389$$$398$$$O	to$$$399$$$401$$$O	alleviate$$$402$$$411$$$O	pain$$$412$$$416$$$O	to$$$417$$$419$$$O	a$$$420$$$421$$$O	subject$$$422$$$429$$$O	suffering$$$430$$$439$$$O	from$$$440$$$444$$$O	pain.$$$445$$$450$$$O	The$$$451$$$454$$$O	invention$$$455$$$464$$$O	is$$$465$$$467$$$O	further$$$468$$$475$$$O	directed$$$476$$$484$$$O	to$$$485$$$487$$$O	a$$$488$$$489$$$O	method$$$490$$$496$$$O	for$$$497$$$500$$$O	synergistically$$$501$$$516$$$O	treating$$$517$$$525$$$O	pain$$$526$$$530$$$O	in$$$531$$$533$$$O	a$$$534$$$535$$$O	subject$$$536$$$543$$$O	comprising$$$544$$$554$$$O	administering$$$555$$$568$$$O	via$$$569$$$572$$$O	any$$$573$$$576$$$O	route$$$577$$$582$$$O	a$$$583$$$584$$$O	dose$$$585$$$589$$$O	of$$$590$$$592$$$O	ketamine$$$593$$$601$$$I	effective$$$602$$$611$$$O	to$$$612$$$614$$$O	allow$$$615$$$620$$$O	for$$$621$$$624$$$O	reduction$$$625$$$634$$$O	in$$$635$$$637$$$O	the$$$638$$$641$$$O	level$$$642$$$647$$$O	of$$$648$$$650$$$O	an$$$651$$$653$$$O	ongoing$$$654$$$661$$$O	pain$$$662$$$666$$$O	therapy,$$$667$$$675$$$O	or$$$676$$$678$$$O	decrease$$$679$$$687$$$O	pain$$$688$$$692$$$O	(improve$$$693$$$701$$$O	the$$$702$$$705$$$O	level$$$706$$$711$$$O	of$$$712$$$714$$$O	pain$$$715$$$719$$$O	relief),$$$720$$$728$$$O	or$$$729$$$731$$$O	both.$$$732$$$737$$$O	Transmucosal,$$$738$$$751$$$O	transdermal,$$$752$$$764$$$O	and$$$765$$$768$$$O	oral$$$769$$$773$$$O	administration$$$774$$$788$$$O	of$$$789$$$791$$$O	ketamine$$$792$$$800$$$I	advantageously$$$801$$$815$$$O	allows$$$816$$$822$$$O	for$$$823$$$826$$$O	patient$$$827$$$834$$$O	self$$$835$$$839$$$O	administration$$$840$$$854$$$O	of$$$855$$$857$$$O	the$$$858$$$861$$$O	drug,$$$862$$$867$$$O	which$$$868$$$873$$$O	provides$$$874$$$882$$$O	for$$$883$$$886$$$O	pain$$$887$$$891$$$O	management$$$892$$$902$$$O	on$$$903$$$905$$$O	an$$$906$$$908$$$O	outpatient$$$909$$$919$$$O	basis.$$$920$$$926$$$O	Moreover,$$$927$$$936$$$O	ketamine$$$937$$$945$$$I	administration$$$946$$$960$$$O	in$$$961$$$963$$$O	transdermal$$$964$$$975$$$O	devices$$$976$$$983$$$O	(suppositories,$$$984$$$999$$$O	candies,$$$1000$$$1008$$$O	buccal$$$1009$$$1015$$$O	patches)$$$1016$$$1024$$$O	is$$$1025$$$1027$$$O	generally$$$1028$$$1037$$$O	socially$$$1038$$$1046$$$O	acceptable.$$$1047$$$1058$$$O	In$$$1059$$$1061$$$O	a$$$1062$$$1063$$$O	specific$$$1064$$$1072$$$O	example,$$$1073$$$1081$$$O	a$$$1082$$$1083$$$O	patient$$$1084$$$1091$$$O	suffering$$$1092$$$1101$$$O	from$$$1102$$$1106$$$O	intractable$$$1107$$$1118$$$O	bladder$$$1119$$$1126$$$O	pain$$$1127$$$1131$$$O	controlled$$$1132$$$1142$$$O	breakthrough$$$1143$$$1155$$$O	pain$$$1156$$$1160$$$O	by$$$1161$$$1163$$$O	transmucosal$$$1164$$$1176$$$O	(nasal)$$$1177$$$1184$$$O	administration$$$1185$$$1199$$$O	of$$$1200$$$1202$$$O	about$$$1203$$$1208$$$O	16$$$1209$$$1211$$$O	mg$$$1212$$$1214$$$O	to$$$1215$$$1217$$$O	about$$$1218$$$1223$$$O	32$$$1224$$$1226$$$O	mg$$$1227$$$1229$$$O	of$$$1230$$$1232$$$O	ketamine$$$1233$$$1241$$$I	per$$$1242$$$1245$$$O	dose.$$$1246$$$1251$$$O
CN102379844A
Itraconazole$$$0$$$12$$$I	isomer$$$13$$$19$$$O	injection$$$20$$$29$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	itraconazole$$$27$$$39$$$I	isomer$$$40$$$46$$$O	injection,$$$47$$$57$$$O	which$$$58$$$63$$$O	comprises$$$64$$$73$$$O	itraconazole,$$$74$$$87$$$I	cyclodextrin$$$88$$$100$$$O	or$$$101$$$103$$$O	a$$$104$$$105$$$O	derivative$$$106$$$116$$$O	thereof$$$117$$$124$$$O	and$$$125$$$128$$$O	other$$$129$$$134$$$O	auxiliary$$$135$$$144$$$O	materials,$$$145$$$155$$$O	wherein$$$156$$$163$$$O	the$$$164$$$167$$$O	itraconazole$$$168$$$180$$$I	is$$$181$$$183$$$O	2S4R$$$184$$$188$$$I	itraconazole;$$$189$$$202$$$I	the$$$203$$$206$$$O	solubility$$$207$$$217$$$O	of$$$218$$$220$$$O	the$$$221$$$224$$$O	2S4R$$$225$$$229$$$I	itraconazole$$$230$$$242$$$I	in$$$243$$$245$$$O	an$$$246$$$248$$$O	aqueous$$$249$$$256$$$O	medium$$$257$$$263$$$O	containing$$$264$$$274$$$O	hydroxypropyl-beta-cyclodextrin$$$275$$$306$$$O	is$$$307$$$309$$$O	far$$$310$$$313$$$O	higher$$$314$$$320$$$O	than$$$321$$$325$$$O	racemization$$$326$$$338$$$O	mixtures$$$339$$$347$$$O	of$$$348$$$350$$$O	four$$$351$$$355$$$O	isomers$$$356$$$363$$$O	of$$$364$$$366$$$O	the$$$367$$$370$$$O	itraconazole,$$$371$$$384$$$I	namely$$$385$$$391$$$O	only$$$392$$$396$$$O	a$$$397$$$398$$$O	smaller$$$399$$$406$$$O	amount$$$407$$$413$$$O	of$$$414$$$416$$$O	hydroxypropyl-beta-cyclodextrin$$$417$$$448$$$O	is$$$449$$$451$$$O	used$$$452$$$456$$$O	as$$$457$$$459$$$O	a$$$460$$$461$$$O	solubilizer$$$462$$$473$$$O	under$$$474$$$479$$$O	the$$$480$$$483$$$O	condition$$$484$$$493$$$O	of$$$494$$$496$$$O	medicines$$$497$$$506$$$O	with$$$507$$$511$$$O	the$$$512$$$515$$$O	same$$$516$$$520$$$O	concentration,$$$521$$$535$$$O	so$$$536$$$538$$$O	the$$$539$$$542$$$O	using$$$543$$$548$$$O	amount$$$549$$$555$$$O	of$$$556$$$558$$$O	the$$$559$$$562$$$O	hydroxypropyl-beta-cyclodextrin$$$563$$$594$$$O	is$$$595$$$597$$$O	reduced,$$$598$$$606$$$O	the$$$607$$$610$$$O	clinical$$$611$$$619$$$O	using$$$620$$$625$$$O	dose$$$626$$$630$$$O	of$$$631$$$633$$$O	the$$$634$$$637$$$O	medicines$$$638$$$647$$$O	are$$$648$$$651$$$O	improved,$$$652$$$661$$$O	the$$$662$$$665$$$O	administration$$$666$$$680$$$O	period$$$681$$$687$$$O	of$$$688$$$690$$$O	the$$$691$$$694$$$O	medicines$$$695$$$704$$$O	is$$$705$$$707$$$O	prolonged,$$$708$$$718$$$O	a$$$719$$$720$$$O	clinical$$$721$$$729$$$O	treatment$$$730$$$739$$$O	effect$$$740$$$746$$$O	is$$$747$$$749$$$O	increased,$$$750$$$760$$$O	and$$$761$$$764$$$O	adverse$$$765$$$772$$$O	effects$$$773$$$780$$$O	are$$$781$$$784$$$O	reduced;$$$785$$$793$$$O	and$$$794$$$797$$$O	the$$$798$$$801$$$O	hydroxypropyl-beta-cyclodextrin$$$802$$$833$$$O	is$$$834$$$836$$$O	expensive,$$$837$$$847$$$O	so$$$848$$$850$$$O	the$$$851$$$854$$$O	production$$$855$$$865$$$O	cost$$$866$$$870$$$O	of$$$871$$$873$$$O	the$$$874$$$877$$$O	injection$$$878$$$887$$$O	can$$$888$$$891$$$O	be$$$892$$$894$$$O	reduced$$$895$$$902$$$O	by$$$903$$$905$$$O	reducing$$$906$$$914$$$O	the$$$915$$$918$$$O	using$$$919$$$924$$$O	amount$$$925$$$931$$$O	of$$$932$$$934$$$O	the$$$935$$$938$$$O	hydroxypropyl-beta-cyclodextrin.$$$939$$$971$$$O	Therefore,$$$972$$$982$$$O	compared$$$983$$$991$$$O	with$$$992$$$996$$$O	the$$$997$$$1000$$$O	conventional$$$1001$$$1013$$$O	itraconazole$$$1014$$$1026$$$I	vein$$$1027$$$1031$$$O	injection,$$$1032$$$1042$$$O	the$$$1043$$$1046$$$O	invention$$$1047$$$1056$$$O	has$$$1057$$$1060$$$O	the$$$1061$$$1064$$$O	advantage$$$1065$$$1074$$$O	that:$$$1075$$$1080$$$O	the$$$1081$$$1084$$$O	using$$$1085$$$1090$$$O	amount$$$1091$$$1097$$$O	of$$$1098$$$1100$$$O	the$$$1101$$$1104$$$O	hydroxypropyl-beta-cyclodextrin$$$1105$$$1136$$$O	required$$$1137$$$1145$$$O	to$$$1146$$$1148$$$O	be$$$1149$$$1151$$$O	used$$$1152$$$1156$$$O	in$$$1157$$$1159$$$O	the$$$1160$$$1163$$$O	injection$$$1164$$$1173$$$O	prepared$$$1174$$$1182$$$O	from$$$1183$$$1187$$$O	the$$$1188$$$1191$$$O	2S4R$$$1192$$$1196$$$I	itraconazole$$$1197$$$1209$$$I	serving$$$1210$$$1217$$$O	as$$$1218$$$1220$$$O	active$$$1221$$$1227$$$O	ingredients$$$1228$$$1239$$$O	is$$$1240$$$1242$$$O	reduced$$$1243$$$1250$$$O	by$$$1251$$$1253$$$O	over$$$1254$$$1258$$$O	5$$$1259$$$1260$$$O	times,$$$1261$$$1267$$$O	and$$$1268$$$1271$$$O	the$$$1272$$$1275$$$O	itraconazole$$$1276$$$1288$$$I	isomer$$$1289$$$1295$$$O	injection$$$1296$$$1305$$$O	is$$$1306$$$1308$$$O	suitable$$$1309$$$1317$$$O	to$$$1318$$$1320$$$O	be$$$1321$$$1323$$$O	used$$$1324$$$1328$$$O	as$$$1329$$$1331$$$O	an$$$1332$$$1334$$$O	angiogenesis$$$1335$$$1347$$$O	inhibitor$$$1348$$$1357$$$O	for$$$1358$$$1361$$$O	treating$$$1362$$$1370$$$O	various$$$1371$$$1378$$$O	tumor$$$1379$$$1384$$$O	diseases$$$1385$$$1393$$$O	clinically.$$$1394$$$1405$$$O
WO2012039793A1
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	treating$$$29$$$37$$$O	lung$$$38$$$42$$$O	cancer$$$43$$$49$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	and$$$39$$$42$$$O	compositions$$$43$$$55$$$O	for$$$56$$$59$$$O	treating$$$60$$$68$$$O	lung$$$69$$$73$$$O	cancer$$$74$$$80$$$O	by$$$81$$$83$$$O	cyclohexenone$$$84$$$97$$$I	compounds.$$$98$$$108$$$O
WO2014135674A1
Substituted$$$0$$$11$$$O	chroman-6-yloxy-cycloalkanes$$$12$$$40$$$I	and$$$41$$$44$$$O	their$$$45$$$50$$$O	use$$$51$$$54$$$O	as$$$55$$$57$$$O	pharmaceuticals$$$58$$$73$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	substituted$$$33$$$44$$$O	chroman-6-yloxy-cycloalkanes$$$45$$$73$$$I	of$$$74$$$76$$$O	the$$$77$$$80$$$O	formula$$$81$$$88$$$O	(I)$$$89$$$92$$$O	in$$$93$$$95$$$O	which$$$96$$$101$$$O	Ar,$$$102$$$105$$$O	R1$$$106$$$108$$$O	to$$$109$$$111$$$O	R4,$$$112$$$115$$$O	p$$$116$$$117$$$O	and$$$118$$$121$$$O	q$$$122$$$123$$$O	are$$$124$$$127$$$O	as$$$128$$$130$$$O	defined$$$131$$$138$$$O	in$$$139$$$141$$$O	the$$$142$$$145$$$O	claims.$$$146$$$153$$$O	The$$$154$$$157$$$O	compounds$$$158$$$167$$$O	of$$$168$$$170$$$O	the$$$171$$$174$$$O	formula$$$175$$$182$$$O	(I)$$$183$$$186$$$O	are$$$187$$$190$$$O	inhibitors$$$191$$$201$$$O	of$$$202$$$204$$$O	the$$$205$$$208$$$O	sodium-calcium$$$209$$$223$$$I	exchanger$$$224$$$233$$$O	(NCX),$$$234$$$240$$$O	especially$$$241$$$251$$$O	of$$$252$$$254$$$O	the$$$255$$$258$$$O	sodium-calcium$$$259$$$273$$$I	exchanger$$$274$$$283$$$O	of$$$284$$$286$$$O	subtype$$$287$$$294$$$O	1$$$295$$$296$$$O	(NCX1),$$$297$$$304$$$O	and$$$305$$$308$$$O	are$$$309$$$312$$$O	suitable$$$313$$$321$$$O	for$$$322$$$325$$$O	the$$$326$$$329$$$O	treatment$$$330$$$339$$$O	of$$$340$$$342$$$O	diverse$$$343$$$350$$$O	disorders$$$351$$$360$$$O	in$$$361$$$363$$$O	which$$$364$$$369$$$O	intracellular$$$370$$$383$$$O	calcium$$$384$$$391$$$I	homeostasis$$$392$$$403$$$O	is$$$404$$$406$$$O	disturbed,$$$407$$$417$$$O	such$$$418$$$422$$$O	as$$$423$$$425$$$O	arrhythmias,$$$426$$$438$$$O	heart$$$439$$$444$$$O	failure$$$445$$$452$$$O	and$$$453$$$456$$$O	stroke.$$$457$$$464$$$O	The$$$465$$$468$$$O	invention$$$469$$$478$$$O	furthermore$$$479$$$490$$$O	relates$$$491$$$498$$$O	to$$$499$$$501$$$O	processes$$$502$$$511$$$O	for$$$512$$$515$$$O	the$$$516$$$519$$$O	preparation$$$520$$$531$$$O	of$$$532$$$534$$$O	the$$$535$$$538$$$O	compounds$$$539$$$548$$$O	of$$$549$$$551$$$O	the$$$552$$$555$$$O	formula$$$556$$$563$$$O	(I),$$$564$$$568$$$O	their$$$569$$$574$$$O	use$$$575$$$578$$$O	as$$$579$$$581$$$O	pharmaceuticals,$$$582$$$598$$$O	and$$$599$$$602$$$O	pharmaceutical$$$603$$$617$$$O	compositions$$$618$$$630$$$O	comprising$$$631$$$641$$$O	them.$$$642$$$647$$$O
EP1406616B1
Injectable$$$0$$$10$$$O	galenic$$$11$$$18$$$O	formulation$$$19$$$30$$$O	for$$$31$$$34$$$O	use$$$35$$$38$$$O	in$$$39$$$41$$$O	a$$$42$$$43$$$O	diagnosis$$$44$$$53$$$O	or$$$54$$$56$$$O	a$$$57$$$58$$$O	photodynamic$$$59$$$71$$$O	therapy$$$72$$$79$$$O	and$$$80$$$83$$$O	method$$$84$$$90$$$O	for$$$91$$$94$$$O	preparing$$$95$$$104$$$O	same$$$105$$$109$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	an$$$23$$$25$$$O	injectable$$$26$$$36$$$O	galenic$$$37$$$44$$$O	formulation$$$45$$$56$$$O	for$$$57$$$60$$$O	use$$$61$$$64$$$O	in$$$65$$$67$$$O	a$$$68$$$69$$$O	diagnosis$$$70$$$79$$$O	or$$$80$$$82$$$O	a$$$83$$$84$$$O	photodynamic$$$85$$$97$$$O	therapy$$$98$$$105$$$O	and$$$106$$$109$$$O	the$$$110$$$113$$$O	method$$$114$$$120$$$O	for$$$121$$$124$$$O	preparing$$$125$$$134$$$O	same.$$$135$$$140$$$O	The$$$141$$$144$$$O	formulation$$$145$$$156$$$O	contains:$$$157$$$166$$$O	a$$$167$$$168$$$O	compound$$$169$$$177$$$O	of$$$178$$$180$$$O	general$$$181$$$188$$$O	formula$$$189$$$196$$$O	(I),$$$197$$$201$$$O	wherein:$$$202$$$210$$$O	R2$$$211$$$213$$$O	represents$$$214$$$224$$$O	a$$$225$$$226$$$O	H,$$$227$$$229$$$I	OH$$$230$$$232$$$I	or$$$233$$$235$$$O	COOR4$$$236$$$241$$$I	group,$$$242$$$248$$$O	where$$$249$$$254$$$O	R4$$$255$$$257$$$O	is$$$258$$$260$$$O	a$$$261$$$262$$$O	hydrogen$$$263$$$271$$$I	or$$$272$$$274$$$O	an$$$275$$$277$$$O	C1-C12$$$278$$$284$$$I	alkyl$$$285$$$290$$$I	or$$$291$$$293$$$O	a$$$294$$$295$$$O	C3-C12$$$296$$$302$$$I	cycloalkyl;$$$303$$$314$$$I	R3$$$315$$$317$$$O	represents$$$318$$$328$$$O	H,$$$329$$$331$$$I	OH$$$332$$$334$$$I	or$$$335$$$337$$$O	a$$$338$$$339$$$O	C1-C12$$$340$$$346$$$I	alkyl$$$347$$$352$$$I	or$$$353$$$355$$$O	alkoxy;$$$356$$$363$$$O	and$$$364$$$367$$$O	*$$$368$$$369$$$O	represents$$$370$$$380$$$O	an$$$381$$$383$$$O	asymmetric$$$384$$$394$$$O	carbon$$$395$$$401$$$I	in$$$402$$$404$$$O	the$$$405$$$408$$$O	form$$$409$$$413$$$O	of$$$414$$$416$$$O	an$$$417$$$419$$$O	alkali$$$420$$$426$$$O	metal$$$427$$$432$$$O	salt$$$433$$$437$$$O	in$$$438$$$440$$$O	an$$$441$$$443$$$O	amount$$$444$$$450$$$O	not$$$451$$$454$$$O	exceeding$$$455$$$464$$$O	10$$$465$$$467$$$O	mg/ml,$$$468$$$474$$$O	as$$$475$$$477$$$O	photosensitizing$$$478$$$494$$$O	agent,$$$495$$$501$$$O	and$$$502$$$505$$$O	a$$$506$$$507$$$O	carrier$$$508$$$515$$$O	in$$$516$$$518$$$O	aqueous$$$519$$$526$$$O	phase$$$527$$$532$$$O	containing$$$533$$$543$$$O	at$$$544$$$546$$$O	least$$$547$$$552$$$O	a$$$553$$$554$$$O	benzyl$$$555$$$561$$$I	alcohol-ethanol$$$562$$$577$$$I	mixture$$$578$$$585$$$O	or$$$586$$$588$$$O	propylene$$$589$$$598$$$I	glycol$$$599$$$605$$$I	as$$$606$$$608$$$O	solubilizing$$$609$$$621$$$O	agent$$$622$$$627$$$O	for$$$628$$$631$$$O	the$$$632$$$635$$$O	photosensitizing$$$636$$$652$$$O	agent$$$653$$$658$$$O	and$$$659$$$662$$$O	a$$$663$$$664$$$O	surfactant$$$665$$$675$$$O	in$$$676$$$678$$$O	an$$$679$$$681$$$O	amount$$$682$$$688$$$O	not$$$689$$$692$$$O	exceeding$$$693$$$702$$$O	20$$$703$$$705$$$O	wt.$$$706$$$709$$$O	%$$$710$$$711$$$O	relative$$$712$$$720$$$O	to$$$721$$$723$$$O	the$$$724$$$727$$$O	total$$$728$$$733$$$O	weight$$$734$$$740$$$O	of$$$741$$$743$$$O	the$$$744$$$747$$$O	formulation.$$$748$$$760$$$O
CN1802947A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	liver-benefiting,$$$21$$$38$$$O	face-beautifying$$$39$$$55$$$O	milk$$$56$$$60$$$O	liquid$$$61$$$67$$$O	with$$$68$$$72$$$O	micron$$$73$$$79$$$O	pine$$$80$$$84$$$O	pollen,$$$85$$$92$$$O	pearl$$$93$$$98$$$O	powder$$$99$$$105$$$O	for$$$106$$$109$$$O	women$$$110$$$115$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	process$$$27$$$34$$$O	for$$$35$$$38$$$O	preparing$$$39$$$48$$$O	liver-benefiting$$$49$$$65$$$O	and$$$66$$$69$$$O	face-beautifying$$$70$$$86$$$O	milk$$$87$$$91$$$O	liquid,$$$92$$$99$$$O	which$$$100$$$105$$$O	is$$$106$$$108$$$O	prepared$$$109$$$117$$$O	from$$$118$$$122$$$O	various$$$123$$$130$$$O	conventional$$$131$$$143$$$O	milks$$$144$$$149$$$O	and$$$150$$$153$$$O	air$$$154$$$157$$$O	flow$$$158$$$162$$$O	super$$$163$$$168$$$O	fine$$$169$$$173$$$O	disintegrated$$$174$$$187$$$O	micrometer$$$188$$$198$$$O	pine$$$199$$$203$$$O	pollen$$$204$$$210$$$O	powder,$$$211$$$218$$$O	micron$$$219$$$225$$$O	pearl$$$226$$$231$$$O	powder,$$$232$$$239$$$O	micrometer$$$240$$$250$$$O	ligustrum$$$251$$$260$$$O	japonicum$$$261$$$270$$$O	powder,$$$271$$$278$$$O	micrometer$$$279$$$289$$$O	lotus$$$290$$$295$$$O	nut$$$296$$$299$$$O	starch,$$$300$$$307$$$O	micrometer$$$308$$$318$$$O	doddor$$$319$$$325$$$O	seed$$$326$$$330$$$O	powder,$$$331$$$338$$$O	micrometer$$$339$$$349$$$O	wolfberry$$$350$$$359$$$O	powder$$$360$$$366$$$O	and$$$367$$$370$$$O	oligosaccharide$$$371$$$386$$$I	as$$$387$$$389$$$O	raw$$$390$$$393$$$O	materials$$$394$$$403$$$O	through$$$404$$$411$$$O	combination.$$$412$$$424$$$O	The$$$425$$$428$$$O	invention$$$429$$$438$$$O	realizes$$$439$$$447$$$O	the$$$448$$$451$$$O	functions$$$452$$$461$$$O	of$$$462$$$464$$$O	liver-benefiting,$$$465$$$482$$$O	face-beautifying,$$$483$$$500$$$O	blood$$$501$$$506$$$O	circulation-promoting,$$$507$$$529$$$O	vision-improving,$$$530$$$547$$$O	fatigue-resisting,$$$548$$$566$$$O	and$$$567$$$570$$$O	human$$$571$$$576$$$O	body$$$577$$$581$$$O	immunity-improving.$$$582$$$601$$$O
US7838565
Suppresses$$$0$$$10$$$O	reduction$$$11$$$20$$$O	in$$$21$$$23$$$O	peripheral$$$24$$$34$$$O	nerve$$$35$$$40$$$O	conduction$$$41$$$51$$$O	rate$$$52$$$56$$$O	and$$$57$$$60$$$O	alleviates$$$61$$$71$$$O	hypofunction$$$72$$$84$$$O	of$$$85$$$87$$$O	bladder$$$88$$$95$$$O	so$$$96$$$98$$$O	that$$$99$$$103$$$O	it$$$104$$$106$$$O	is$$$107$$$109$$$O	useful$$$110$$$116$$$O	as$$$117$$$119$$$O	a$$$120$$$121$$$O	preventive$$$122$$$132$$$O	and/or$$$133$$$139$$$O	therapeutic$$$140$$$151$$$O	agent$$$152$$$157$$$O	for,$$$158$$$162$$$O	particularly,$$$163$$$176$$$O	diabetic$$$177$$$185$$$O	neuropathy$$$186$$$196$$$O
A$$$0$$$1$$$O	preventive$$$2$$$12$$$O	and/or$$$13$$$19$$$O	therapeutic$$$20$$$31$$$O	agent$$$32$$$37$$$O	for$$$38$$$41$$$O	diabetes$$$42$$$50$$$O	complications,$$$51$$$65$$$O	which$$$66$$$71$$$O	comprises$$$72$$$81$$$O	as$$$82$$$84$$$O	an$$$85$$$87$$$O	effective$$$88$$$97$$$O	ingredient$$$98$$$108$$$O	a$$$109$$$110$$$O	cyclohexenone$$$111$$$124$$$I	long-chain$$$125$$$135$$$O	alcoholic$$$136$$$145$$$O	derivative$$$146$$$156$$$O	represented$$$157$$$168$$$O	by$$$169$$$171$$$O	the$$$172$$$175$$$O	following$$$176$$$185$$$O	formula$$$186$$$193$$$O	(1):$$$194$$$198$$$O	wherein,$$$199$$$207$$$O	R1,$$$208$$$211$$$O	R2$$$212$$$214$$$O	and$$$215$$$218$$$O	R3$$$219$$$221$$$O	each$$$222$$$226$$$O	independently$$$227$$$240$$$O	represents$$$241$$$251$$$O	a$$$252$$$253$$$O	hydrogen$$$254$$$262$$$I	atom$$$263$$$267$$$O	or$$$268$$$270$$$O	a$$$271$$$272$$$O	methyl$$$273$$$279$$$I	group$$$280$$$285$$$O	and$$$286$$$289$$$O	X$$$290$$$291$$$O	represents$$$292$$$302$$$O	a$$$303$$$304$$$O	linear$$$305$$$311$$$O	or$$$312$$$314$$$O	branched$$$315$$$323$$$O	C10-28$$$324$$$330$$$I	alkylene$$$331$$$339$$$I	or$$$340$$$342$$$O	alkenylene$$$343$$$353$$$I	group.$$$354$$$360$$$O	The$$$361$$$364$$$O	cyclohexenone$$$365$$$378$$$I	long-chain$$$379$$$389$$$O	alcoholic$$$390$$$399$$$O	derivative$$$400$$$410$$$O	of$$$411$$$413$$$O	the$$$414$$$417$$$O	present$$$418$$$425$$$O	invention$$$426$$$435$$$O	significantly$$$436$$$449$$$O	suppresses$$$450$$$460$$$O	a$$$461$$$462$$$O	reduction$$$463$$$472$$$O	in$$$473$$$475$$$O	a$$$476$$$477$$$O	peripheral$$$478$$$488$$$O	nerve$$$489$$$494$$$O	conduction$$$495$$$505$$$O	rate$$$506$$$510$$$O	and$$$511$$$514$$$O	alleviates$$$515$$$525$$$O	the$$$526$$$529$$$O	hypofunction$$$530$$$542$$$O	of$$$543$$$545$$$O	the$$$546$$$549$$$O	bladder$$$550$$$557$$$O	so$$$558$$$560$$$O	that$$$561$$$565$$$O	it$$$566$$$568$$$O	is$$$569$$$571$$$O	useful$$$572$$$578$$$O	as$$$579$$$581$$$O	a$$$582$$$583$$$O	preventive$$$584$$$594$$$O	and/or$$$595$$$601$$$O	therapeutic$$$602$$$613$$$O	agent$$$614$$$619$$$O	for$$$620$$$623$$$O	diabetes$$$624$$$632$$$O	complications,$$$633$$$647$$$O	particularly,$$$648$$$661$$$O	for$$$662$$$665$$$O	diabetic$$$666$$$674$$$O	neuropathy.$$$675$$$686$$$O
WO2006031556A3
Amidine$$$0$$$7$$$I	substituted$$$8$$$19$$$I	aryl$$$20$$$24$$$I	aniline$$$25$$$32$$$I	compounds$$$33$$$42$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	novel$$$23$$$28$$$O	Ã2$$$29$$$32$$$O	adrenergic$$$33$$$43$$$O	receptor$$$44$$$52$$$O	agonist$$$53$$$60$$$O	compounds.$$$61$$$71$$$O	The$$$72$$$75$$$O	invention$$$76$$$85$$$O	also$$$86$$$90$$$O	provides$$$91$$$99$$$O	pharmaceutical$$$100$$$114$$$O	compositions$$$115$$$127$$$O	comprising$$$128$$$138$$$O	such$$$139$$$143$$$O	compounds,$$$144$$$154$$$O	methods$$$155$$$162$$$O	of$$$163$$$165$$$O	using$$$166$$$171$$$O	such$$$172$$$176$$$O	compounds$$$177$$$186$$$O	to$$$187$$$189$$$O	treat$$$190$$$195$$$O	diseases$$$196$$$204$$$O	associated$$$205$$$215$$$O	with$$$216$$$220$$$O	Ã2adrenergic$$$221$$$234$$$O	receptor$$$235$$$243$$$O	activity,$$$244$$$253$$$O	and$$$254$$$257$$$O	processes$$$258$$$267$$$O	and$$$268$$$271$$$O	intermediates$$$272$$$285$$$O	useful$$$286$$$292$$$O	for$$$293$$$296$$$O	preparing$$$297$$$306$$$O	such$$$307$$$311$$$O	compounds.$$$312$$$322$$$O
CN1823805A
Ground$$$0$$$6$$$O	erythromycin$$$7$$$19$$$I	enteric$$$20$$$27$$$O	micropill$$$28$$$37$$$O	and$$$38$$$41$$$O	its$$$42$$$45$$$O	preparation$$$46$$$57$$$O	method$$$58$$$64$$$O
An$$$0$$$2$$$O	enteric$$$3$$$10$$$O	micropill$$$11$$$20$$$O	of$$$21$$$23$$$O	dirithromycin$$$24$$$37$$$I	is$$$38$$$40$$$O	composed$$$41$$$49$$$O	of$$$50$$$52$$$O	a$$$53$$$54$$$O	micropill$$$55$$$64$$$O	prepared$$$65$$$73$$$O	from$$$74$$$78$$$O	dirithromycin$$$79$$$92$$$I	and$$$93$$$96$$$O	one$$$97$$$100$$$O	or$$$101$$$103$$$O	more$$$104$$$108$$$O	medicinal$$$109$$$118$$$O	excipients,$$$119$$$130$$$O	an$$$131$$$133$$$O	isolating$$$134$$$143$$$O	layer$$$144$$$149$$$O	prepared$$$150$$$158$$$O	from$$$159$$$163$$$O	hydroxypropylmethyl$$$164$$$183$$$O	cellulose$$$184$$$193$$$O	and$$$194$$$197$$$O	medicinal$$$198$$$207$$$O	excipient,$$$208$$$218$$$O	and$$$219$$$222$$$O	an$$$223$$$225$$$O	enteric$$$226$$$233$$$O	layer$$$234$$$239$$$O	prepared$$$240$$$248$$$O	from$$$249$$$253$$$O	one$$$254$$$257$$$O	or$$$258$$$260$$$O	more$$$261$$$265$$$O	medicinal$$$266$$$275$$$O	excipients.$$$276$$$287$$$O	Its$$$288$$$291$$$O	preparing$$$292$$$301$$$O	process$$$302$$$309$$$O	is$$$310$$$312$$$O	also$$$313$$$317$$$O	disclosed.$$$318$$$328$$$O
US20110129512
Antimicrobial$$$0$$$13$$$O	Releasing$$$14$$$23$$$O	Polymers$$$24$$$32$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	is$$$23$$$25$$$O	directed$$$26$$$34$$$O	to$$$35$$$37$$$O	polymers$$$38$$$46$$$O	having$$$47$$$53$$$O	hydroxyl$$$54$$$62$$$I	containing$$$63$$$73$$$O	bioactive$$$74$$$83$$$O	agents$$$84$$$90$$$O	incorporated$$$91$$$103$$$O	into$$$104$$$108$$$O	the$$$109$$$112$$$O	backbone$$$113$$$121$$$O	of$$$122$$$124$$$O	the$$$125$$$128$$$O	polymer$$$129$$$136$$$O	or$$$137$$$139$$$O	attached$$$140$$$148$$$O	thereto$$$149$$$156$$$O	by$$$157$$$159$$$O	pendant$$$160$$$167$$$O	linkages.$$$168$$$177$$$O	Hydroxyl$$$178$$$186$$$I	containing$$$187$$$197$$$O	bioactive$$$198$$$207$$$O	agents$$$208$$$214$$$O	which$$$215$$$220$$$O	may$$$221$$$224$$$O	be$$$225$$$227$$$O	attached$$$228$$$236$$$O	to$$$237$$$239$$$O	these$$$240$$$245$$$O	polymers$$$246$$$254$$$O	include$$$255$$$262$$$O	antimicrobial$$$263$$$276$$$O	agents$$$277$$$283$$$O	such$$$284$$$288$$$O	as$$$289$$$291$$$O	triclosan.$$$292$$$302$$$O	The$$$303$$$306$$$O	polymers$$$307$$$315$$$O	may$$$316$$$319$$$O	be$$$320$$$322$$$O	utilized$$$323$$$331$$$O	to$$$332$$$334$$$O	form$$$335$$$339$$$O	medical$$$340$$$347$$$O	devices$$$348$$$355$$$O	or$$$356$$$358$$$O	coatings$$$359$$$367$$$O	for$$$368$$$371$$$O	such$$$372$$$376$$$O	devices.$$$377$$$385$$$O	The$$$386$$$389$$$O	hydroxyl$$$390$$$398$$$I	containing$$$399$$$409$$$O	bioactive$$$410$$$419$$$O	agent$$$420$$$425$$$O	may$$$426$$$429$$$O	be$$$430$$$432$$$O	released$$$433$$$441$$$O	from$$$442$$$446$$$O	the$$$447$$$450$$$O	polymer$$$451$$$458$$$O	upon$$$459$$$463$$$O	hydrolysis$$$464$$$474$$$O	of$$$475$$$477$$$O	the$$$478$$$481$$$O	polymeric$$$482$$$491$$$O	backbone$$$492$$$500$$$O	or$$$501$$$503$$$O	pendant$$$504$$$511$$$O	linkage$$$512$$$519$$$O	in$$$520$$$522$$$O	vivo.$$$523$$$528$$$O
CN102659687A
Benzimidazolamines$$$0$$$18$$$I	compounds$$$19$$$28$$$O	as$$$29$$$31$$$O	well$$$32$$$36$$$O	as$$$37$$$39$$$O	preparation$$$40$$$51$$$O	method$$$52$$$58$$$O	and$$$59$$$62$$$O	application$$$63$$$74$$$O	thereof$$$75$$$82$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	benzimidazolamines$$$24$$$42$$$I	compounds$$$43$$$52$$$O	shown$$$53$$$58$$$O	by$$$59$$$61$$$O	general$$$62$$$69$$$O	formulas$$$70$$$78$$$O	I-V,$$$79$$$83$$$O	medical$$$84$$$91$$$O	salt$$$92$$$96$$$O	of$$$97$$$99$$$O	the$$$100$$$103$$$O	benzimidazolamines$$$104$$$122$$$I	compounds,$$$123$$$133$$$O	and$$$134$$$137$$$O	a$$$138$$$139$$$O	preparation$$$140$$$151$$$O	method$$$152$$$158$$$O	of$$$159$$$161$$$O	the$$$162$$$165$$$O	benzimidazolamines$$$166$$$184$$$I	compounds;$$$185$$$195$$$O	the$$$196$$$199$$$O	preparation$$$200$$$211$$$O	method$$$212$$$218$$$O	comprises$$$219$$$228$$$O	the$$$229$$$232$$$O	following$$$233$$$242$$$O	steps$$$243$$$248$$$O	of:$$$249$$$252$$$O	stirring$$$253$$$261$$$O	2-chloromethyl-1H-benzimidazole$$$262$$$293$$$I	and$$$294$$$297$$$O	a$$$298$$$299$$$O	compound$$$300$$$308$$$O	shown$$$309$$$314$$$O	by$$$315$$$317$$$O	a$$$318$$$319$$$O	general$$$320$$$327$$$O	formula$$$328$$$335$$$O	VII$$$336$$$339$$$O	in$$$340$$$342$$$O	an$$$343$$$345$$$O	organic$$$346$$$353$$$O	solvent$$$354$$$361$$$O	for$$$362$$$365$$$O	reaction,$$$366$$$375$$$O	and$$$376$$$379$$$O	controlling$$$380$$$391$$$O	the$$$392$$$395$$$O	temperature$$$396$$$407$$$O	to$$$408$$$410$$$O	be$$$411$$$413$$$O	within$$$414$$$420$$$O	the$$$421$$$424$$$O	range$$$425$$$430$$$O	of$$$431$$$433$$$O	75-90$$$434$$$439$$$O	DEG$$$440$$$443$$$O	C;$$$444$$$446$$$O	then,$$$447$$$452$$$O	adding$$$453$$$459$$$O	an$$$460$$$462$$$O	alkali$$$463$$$469$$$O	reagent$$$470$$$477$$$O	under$$$478$$$483$$$O	the$$$484$$$487$$$O	stirring$$$488$$$496$$$O	condition,$$$497$$$507$$$O	controlling$$$508$$$519$$$O	the$$$520$$$523$$$O	temperature$$$524$$$535$$$O	to$$$536$$$538$$$O	be$$$539$$$541$$$O	within$$$542$$$548$$$O	the$$$549$$$552$$$O	range$$$553$$$558$$$O	of$$$559$$$561$$$O	10-60$$$562$$$567$$$O	DEG$$$568$$$571$$$O	C,$$$572$$$574$$$O	and$$$575$$$578$$$O	stirring$$$579$$$587$$$O	for$$$588$$$591$$$O	reaction,$$$592$$$601$$$O	thus$$$602$$$606$$$O	obtaining$$$607$$$616$$$O	the$$$617$$$620$$$O	benzimidazolamines$$$621$$$639$$$I	compound$$$640$$$648$$$O	shown$$$649$$$654$$$O	in$$$655$$$657$$$O	the$$$658$$$661$$$O	general$$$662$$$669$$$O	formula$$$670$$$677$$$O	I;$$$678$$$680$$$O	stirring$$$681$$$689$$$O	the$$$690$$$693$$$O	benzimidazolamines$$$694$$$712$$$I	compound$$$713$$$721$$$O	shown$$$722$$$727$$$O	in$$$728$$$730$$$O	the$$$731$$$734$$$O	general$$$735$$$742$$$O	formula$$$743$$$750$$$O	I$$$751$$$752$$$O	and$$$753$$$756$$$O	compound$$$757$$$765$$$O	shown$$$766$$$771$$$O	in$$$772$$$774$$$O	the$$$775$$$778$$$O	general$$$779$$$786$$$O	formula$$$787$$$794$$$O	VIII,$$$795$$$800$$$O	IX,$$$801$$$804$$$O	X$$$805$$$806$$$O	or$$$807$$$809$$$O	XI$$$810$$$812$$$O	in$$$813$$$815$$$O	an$$$816$$$818$$$O	organic$$$819$$$826$$$O	solvent$$$827$$$834$$$O	for$$$835$$$838$$$O	reaction,$$$839$$$848$$$O	and$$$849$$$852$$$O	controlling$$$853$$$864$$$O	the$$$865$$$868$$$O	temperature$$$869$$$880$$$O	to$$$881$$$883$$$O	be$$$884$$$886$$$O	within$$$887$$$893$$$O	the$$$894$$$897$$$O	range$$$898$$$903$$$O	of$$$904$$$906$$$O	50-70$$$907$$$912$$$O	DEG$$$913$$$916$$$O	C;$$$917$$$919$$$O	and$$$920$$$923$$$O	after$$$924$$$929$$$O	the$$$930$$$933$$$O	system$$$934$$$940$$$O	is$$$941$$$943$$$O	acidic,$$$944$$$951$$$O	adding$$$952$$$958$$$O	the$$$959$$$962$$$O	alkali$$$963$$$969$$$O	reagent,$$$970$$$978$$$O	controlling$$$979$$$990$$$O	the$$$991$$$994$$$O	temperature$$$995$$$1006$$$O	to$$$1007$$$1009$$$O	be$$$1010$$$1012$$$O	within$$$1013$$$1019$$$O	the$$$1020$$$1023$$$O	range$$$1024$$$1029$$$O	of$$$1030$$$1032$$$O	50-70$$$1033$$$1038$$$O	DEG$$$1039$$$1042$$$O	C,$$$1043$$$1045$$$O	and$$$1046$$$1049$$$O	stirring$$$1050$$$1058$$$O	for$$$1059$$$1062$$$O	reaction,$$$1063$$$1072$$$O	thus$$$1073$$$1077$$$O	obtaining$$$1078$$$1087$$$O	the$$$1088$$$1091$$$O	compound$$$1092$$$1100$$$O	shown$$$1101$$$1106$$$O	in$$$1107$$$1109$$$O	the$$$1110$$$1113$$$O	general$$$1114$$$1121$$$O	formula$$$1122$$$1129$$$O	II,$$$1130$$$1133$$$O	III,$$$1134$$$1138$$$O	IV$$$1139$$$1141$$$O	or$$$1142$$$1144$$$O	V.$$$1145$$$1147$$$O	The$$$1148$$$1151$$$O	benzimidazolamines$$$1152$$$1170$$$I	compounds$$$1171$$$1180$$$O	and$$$1181$$$1184$$$O	the$$$1185$$$1188$$$O	medical$$$1189$$$1196$$$O	salt$$$1197$$$1201$$$O	of$$$1202$$$1204$$$O	the$$$1205$$$1208$$$O	benzimidazolamines$$$1209$$$1227$$$I	compounds$$$1228$$$1237$$$O	have$$$1238$$$1242$$$O	certain$$$1243$$$1250$$$O	inhibitory$$$1251$$$1261$$$O	activity$$$1262$$$1270$$$O	for$$$1271$$$1274$$$O	gram-positive$$$1275$$$1288$$$O	bacteria,$$$1289$$$1298$$$O	gram-negative$$$1299$$$1312$$$O	bacteria$$$1313$$$1321$$$O	and$$$1322$$$1325$$$O	fungi,$$$1326$$$1332$$$O	thus$$$1333$$$1337$$$O	being$$$1338$$$1343$$$O	used$$$1344$$$1348$$$O	for$$$1349$$$1352$$$O	preparing$$$1353$$$1362$$$O	medicines$$$1363$$$1372$$$O	for$$$1373$$$1376$$$O	resisting$$$1377$$$1386$$$O	bacteria$$$1387$$$1395$$$O	and/$$$1396$$$1400$$$O	or$$$1401$$$1403$$$O	fungi.$$$1404$$$1410$$$O
US20110172197
Dosace$$$0$$$6$$$O	Form$$$7$$$11$$$O	For$$$12$$$15$$$O	Hormonal$$$16$$$24$$$O	Contraceptive$$$25$$$38$$$O
A$$$0$$$1$$$O	dosage$$$2$$$8$$$O	form$$$9$$$13$$$O	for$$$14$$$17$$$O	hormonal$$$18$$$26$$$O	contraception$$$27$$$40$$$O	containing$$$41$$$51$$$O	a$$$52$$$53$$$O	given$$$54$$$59$$$O	number$$$60$$$66$$$O	of$$$67$$$69$$$O	hormone-containing$$$70$$$88$$$O	daily$$$89$$$94$$$O	units$$$95$$$100$$$O	and$$$101$$$104$$$O	a$$$105$$$106$$$O	given$$$107$$$112$$$O	number$$$113$$$119$$$O	of$$$120$$$122$$$O	hormone-free$$$123$$$135$$$O	daily$$$136$$$141$$$O	units$$$142$$$147$$$O	for$$$148$$$151$$$O	daily,$$$152$$$158$$$O	oral$$$159$$$163$$$O	administration,$$$164$$$179$$$O	where$$$180$$$185$$$O	the$$$186$$$189$$$O	hormone-containing$$$190$$$208$$$O	daily$$$209$$$214$$$O	units$$$215$$$220$$$O	each$$$221$$$225$$$O	contain$$$226$$$233$$$O	at$$$234$$$236$$$O	most$$$237$$$241$$$O	the$$$242$$$245$$$O	minimum$$$246$$$253$$$O	effective$$$254$$$263$$$O	daily$$$264$$$269$$$O	amount$$$270$$$276$$$O	of$$$277$$$279$$$O	folic$$$280$$$285$$$I	acid$$$286$$$290$$$I	for$$$291$$$294$$$O	women$$$295$$$300$$$O	and$$$301$$$304$$$O	the$$$305$$$308$$$O	hormone-free$$$309$$$321$$$O	daily$$$322$$$327$$$O	units$$$328$$$333$$$O	contain$$$334$$$341$$$O	at$$$342$$$344$$$O	least$$$345$$$350$$$O	a$$$351$$$352$$$O	multiple$$$353$$$361$$$O	of$$$362$$$364$$$O	this$$$365$$$369$$$O	amount$$$370$$$376$$$O	up$$$377$$$379$$$O	to$$$380$$$382$$$O	the$$$383$$$386$$$O	maximum$$$387$$$394$$$O	permissible$$$395$$$406$$$O	amount$$$407$$$413$$$O	of$$$414$$$416$$$O	folic$$$417$$$422$$$I	acid$$$423$$$427$$$I	for$$$428$$$431$$$O	women.$$$432$$$438$$$O
US20080214586
2-Amino-4-Phenylquinazoline$$$0$$$27$$$I	Derivatives$$$28$$$39$$$O	and$$$40$$$43$$$O	the$$$44$$$47$$$O	Use$$$48$$$51$$$O	Thereof$$$52$$$59$$$O	as$$$60$$$62$$$O	Hsp90$$$63$$$68$$$O	Modulators$$$69$$$79$$$O
Novel$$$0$$$5$$$O	phenylquinazoline$$$6$$$23$$$I	derivatives$$$24$$$35$$$O	of$$$36$$$38$$$O	the$$$39$$$42$$$O	formula$$$43$$$50$$$O	(I),$$$51$$$55$$$O	in$$$56$$$58$$$O	which$$$59$$$64$$$O	R1,$$$65$$$68$$$O	R2,$$$69$$$72$$$O	R3,$$$73$$$76$$$O	R4$$$77$$$79$$$O	and$$$80$$$83$$$O	R5$$$84$$$86$$$O	have$$$87$$$91$$$O	the$$$92$$$95$$$O	meanings$$$96$$$104$$$O	indicated$$$105$$$114$$$O	in$$$115$$$117$$$O	Claim$$$118$$$123$$$O	1,$$$124$$$126$$$O	are$$$127$$$130$$$O	HSP90$$$131$$$136$$$O	inhibitors$$$137$$$147$$$O	and$$$148$$$151$$$O	can$$$152$$$155$$$O	be$$$156$$$158$$$O	used$$$159$$$163$$$O	for$$$164$$$167$$$O	the$$$168$$$171$$$O	preparation$$$172$$$183$$$O	of$$$184$$$186$$$O	a$$$187$$$188$$$O	medicament$$$189$$$199$$$O	for$$$200$$$203$$$O	the$$$204$$$207$$$O	treatment$$$208$$$217$$$O	of$$$218$$$220$$$O	diseases$$$221$$$229$$$O	in$$$230$$$232$$$O	which$$$233$$$238$$$O	the$$$239$$$242$$$O	inhibition,$$$243$$$254$$$O	regulation$$$255$$$265$$$O	and/or$$$266$$$272$$$O	modulation$$$273$$$283$$$O	of$$$284$$$286$$$O	HSP90$$$287$$$292$$$O	plays$$$293$$$298$$$O	a$$$299$$$300$$$O	role.$$$301$$$306$$$O
US20110130444
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	targeted$$$29$$$37$$$O	delivery$$$38$$$46$$$O	of$$$47$$$49$$$O	gene$$$50$$$54$$$O	therapeutic$$$55$$$66$$$O	vectors$$$67$$$74$$$O
Embodiments$$$0$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	present$$$19$$$26$$$O	invention$$$27$$$36$$$O	relate$$$37$$$43$$$O	to$$$44$$$46$$$O	methods$$$47$$$54$$$O	and$$$55$$$58$$$O	compositions$$$59$$$71$$$O	for$$$72$$$75$$$O	tissue-$$$76$$$83$$$O	specific$$$84$$$92$$$O	delivery$$$93$$$101$$$O	of$$$102$$$104$$$O	a$$$105$$$106$$$O	gene$$$107$$$111$$$O	therapeutic,$$$112$$$124$$$O	transgenic$$$125$$$135$$$O	nucleic$$$136$$$143$$$O	acid$$$144$$$148$$$O	in$$$149$$$151$$$O	mammals.$$$152$$$160$$$O	Methods$$$161$$$168$$$O	and$$$169$$$172$$$O	compositions$$$173$$$185$$$O	of$$$186$$$188$$$O	the$$$189$$$192$$$O	invention$$$193$$$202$$$O	include$$$203$$$210$$$O	the$$$211$$$214$$$O	steps$$$215$$$220$$$O	of$$$221$$$223$$$O	providing$$$224$$$233$$$O	a$$$234$$$235$$$O	nucleic$$$236$$$243$$$O	acid$$$244$$$248$$$O	comprising$$$249$$$259$$$O	a$$$260$$$261$$$O	transgene$$$262$$$271$$$O	flanked$$$272$$$279$$$O	by$$$280$$$282$$$O	two$$$283$$$286$$$O	terminal$$$287$$$295$$$O	repeats$$$296$$$303$$$O	and,$$$304$$$308$$$O	within$$$309$$$315$$$O	the$$$316$$$319$$$O	same$$$320$$$324$$$O	or$$$325$$$327$$$O	on$$$328$$$330$$$O	a$$$331$$$332$$$O	separate$$$333$$$341$$$O	nucleic$$$342$$$349$$$O	acid,$$$350$$$355$$$O	a$$$356$$$357$$$O	nucleotide$$$358$$$368$$$O	sequence$$$369$$$377$$$O	encoding$$$378$$$386$$$O	a$$$387$$$388$$$O	transposase,$$$389$$$401$$$O	wherein$$$402$$$409$$$O	the$$$410$$$413$$$O	transgene$$$414$$$423$$$O	comprises$$$424$$$433$$$O	a$$$434$$$435$$$O	biotherapeutic$$$436$$$450$$$O	gene,$$$451$$$456$$$O	contacting$$$457$$$467$$$O	the$$$468$$$471$$$O	nucleic$$$472$$$479$$$O	acid$$$480$$$484$$$O	with$$$485$$$489$$$O	perfluorocarbon$$$490$$$505$$$O	gas-filled$$$506$$$516$$$O	microbubbles$$$517$$$529$$$O	to$$$530$$$532$$$O	form$$$533$$$537$$$O	a$$$538$$$539$$$O	mixture,$$$540$$$548$$$O	introducing$$$549$$$560$$$O	the$$$561$$$564$$$O	mixture$$$565$$$572$$$O	into$$$573$$$577$$$O	the$$$578$$$581$$$O	bloodstream$$$582$$$593$$$O	of$$$594$$$596$$$O	a$$$597$$$598$$$O	mammal,$$$599$$$606$$$O	and$$$607$$$610$$$O	focusing$$$611$$$619$$$O	ultrasound$$$620$$$630$$$O	pulses$$$631$$$637$$$O	on$$$638$$$640$$$O	a$$$641$$$642$$$O	specific$$$643$$$651$$$O	tissue$$$652$$$658$$$O	of$$$659$$$661$$$O	said$$$662$$$666$$$O	mammal,$$$667$$$674$$$O	wherein$$$675$$$682$$$O	said$$$683$$$687$$$O	pulses$$$688$$$694$$$O	disrupt$$$695$$$702$$$O	said$$$703$$$707$$$O	microbubbles$$$708$$$720$$$O	of$$$721$$$723$$$O	said$$$724$$$728$$$O	mixture$$$729$$$736$$$O	and$$$737$$$740$$$O	release$$$741$$$748$$$O	said$$$749$$$753$$$O	nucleic$$$754$$$761$$$O	acid$$$762$$$766$$$O	into$$$767$$$771$$$O	the$$$772$$$775$$$O	bloodstream$$$776$$$787$$$O	within$$$788$$$794$$$O	the$$$795$$$798$$$O	target$$$799$$$805$$$O	tissue,$$$806$$$813$$$O	thereby$$$814$$$821$$$O	enabling$$$822$$$830$$$O	uptake$$$831$$$837$$$O	of$$$838$$$840$$$O	the$$$841$$$844$$$O	transgenic$$$845$$$855$$$O	nucleic$$$856$$$863$$$O	acid$$$864$$$868$$$O	into$$$869$$$873$$$O	the$$$874$$$877$$$O	cells$$$878$$$883$$$O	of$$$884$$$886$$$O	said$$$887$$$891$$$O	target$$$892$$$898$$$O	tissue.$$$899$$$906$$$O
CN101343078A
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	preparing$$$10$$$19$$$O	aluminum$$$20$$$28$$$I	magnesium$$$29$$$38$$$I	carbonate$$$39$$$48$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	novel$$$27$$$32$$$O	preparation$$$33$$$44$$$O	method$$$45$$$51$$$O	of$$$52$$$54$$$O	a$$$55$$$56$$$O	useful$$$57$$$63$$$O	decisive$$$64$$$72$$$O	compound$$$73$$$81$$$O	of$$$82$$$84$$$O	Aluminum$$$85$$$93$$$I	Magnesium$$$94$$$103$$$I	hydroxy$$$104$$$111$$$I	Carbonate$$$112$$$121$$$I	serving$$$122$$$129$$$O	as$$$130$$$132$$$O	a$$$133$$$134$$$O	therapeutic$$$135$$$146$$$O	agent$$$147$$$152$$$O	of$$$153$$$155$$$O	gastrointestinal$$$156$$$172$$$O	diseases$$$173$$$181$$$O	as$$$182$$$184$$$O	shown$$$185$$$190$$$O	in$$$191$$$193$$$O	chemical$$$194$$$202$$$O	formula$$$203$$$210$$$O	1.$$$211$$$213$$$O
US20110014227
Pre-or$$$0$$$6$$$O	post-exposure$$$7$$$20$$$O	treatment$$$21$$$30$$$O	for$$$31$$$34$$$O	filovirus$$$35$$$44$$$O	or$$$45$$$47$$$O	arenavirus$$$48$$$58$$$O	infection$$$59$$$68$$$O
The$$$0$$$3$$$O	compositions$$$4$$$16$$$O	and$$$17$$$20$$$O	methods$$$21$$$28$$$O	of$$$29$$$31$$$O	the$$$32$$$35$$$O	invention$$$36$$$45$$$O	described$$$46$$$55$$$O	herein$$$56$$$62$$$O	provide$$$63$$$70$$$O	pre-$$$71$$$75$$$O	or$$$76$$$78$$$O	post-exposure$$$79$$$92$$$O	treatments$$$93$$$103$$$O	against$$$104$$$111$$$O	filovirus$$$112$$$121$$$O	or$$$122$$$124$$$O	arenavirus$$$125$$$135$$$O	infection$$$136$$$145$$$O	by$$$146$$$148$$$O	expressing$$$149$$$159$$$O	one$$$160$$$163$$$O	or$$$164$$$166$$$O	more$$$167$$$171$$$O	genes$$$172$$$177$$$O	(e.g.,$$$178$$$184$$$O	two$$$185$$$188$$$O	ore$$$189$$$192$$$O	more$$$193$$$197$$$O	genes)$$$198$$$204$$$O	from$$$205$$$209$$$O	filoviruses$$$210$$$221$$$O	or$$$222$$$224$$$O	arenaviruses$$$225$$$237$$$O	in$$$238$$$240$$$O	a$$$241$$$242$$$O	delivery$$$243$$$251$$$O	vehicle$$$252$$$259$$$O	(e.g.,$$$260$$$266$$$O	a$$$267$$$268$$$O	recombinant$$$269$$$280$$$O	viral$$$281$$$286$$$O	vector$$$287$$$293$$$O	or$$$294$$$296$$$O	a$$$297$$$298$$$O	liposome).$$$299$$$309$$$O
WO2013006738A1
Compounds$$$0$$$9$$$O	for$$$10$$$13$$$O	the$$$14$$$17$$$O	treatment$$$18$$$27$$$O	of$$$28$$$30$$$O	hiv$$$31$$$34$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds$$$23$$$32$$$O	of$$$33$$$35$$$O	formula$$$36$$$43$$$O	(I):$$$44$$$48$$$O	or$$$49$$$51$$$O	a$$$52$$$53$$$O	salt$$$54$$$58$$$O	thereof$$$59$$$66$$$O	as$$$67$$$69$$$O	described$$$70$$$79$$$O	herein.$$$80$$$87$$$O	The$$$88$$$91$$$O	invention$$$92$$$101$$$O	also$$$102$$$106$$$O	provides$$$107$$$115$$$O	pharmaceutical$$$116$$$130$$$O	compositions$$$131$$$143$$$O	comprising$$$144$$$154$$$O	a$$$155$$$156$$$O	compound$$$157$$$165$$$O	of$$$166$$$168$$$O	formula$$$169$$$176$$$O	(I),$$$177$$$181$$$O	processes$$$182$$$191$$$O	for$$$192$$$195$$$O	preparing$$$196$$$205$$$O	compounds$$$206$$$215$$$O	of$$$216$$$218$$$O	formula$$$219$$$226$$$O	(I),$$$227$$$231$$$O	intermediates$$$232$$$245$$$O	useful$$$246$$$252$$$O	for$$$253$$$256$$$O	preparing$$$257$$$266$$$O	compounds$$$267$$$276$$$O	of$$$277$$$279$$$O	formula$$$280$$$287$$$O	I$$$288$$$289$$$O	and$$$290$$$293$$$O	therapeutic$$$294$$$305$$$O	methods$$$306$$$313$$$O	for$$$314$$$317$$$O	treating$$$318$$$326$$$O	a$$$327$$$328$$$O	Retroviridae$$$329$$$341$$$O	viral$$$342$$$347$$$O	infection$$$348$$$357$$$O	including$$$358$$$367$$$O	an$$$368$$$370$$$O	infection$$$371$$$380$$$O	caused$$$381$$$387$$$O	by$$$388$$$390$$$O	the$$$391$$$394$$$O	HIV$$$395$$$398$$$O	virus.$$$399$$$405$$$O
CN1810790A
Non-metal$$$0$$$9$$$O	salt$$$10$$$14$$$O	of$$$15$$$17$$$O	Glicididazole$$$18$$$31$$$I	and$$$32$$$35$$$O	its$$$36$$$39$$$O	prepn$$$40$$$45$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	non-metal$$$33$$$42$$$O	salt$$$43$$$47$$$O	compounds$$$48$$$57$$$O	of$$$58$$$60$$$O	glycididazole,$$$61$$$75$$$I	including$$$76$$$85$$$O	ammonium$$$86$$$94$$$I	salt$$$95$$$99$$$I	of$$$100$$$102$$$I	glycididazole,$$$103$$$117$$$I	diethylamine$$$118$$$130$$$I	double$$$131$$$137$$$I	salt$$$138$$$142$$$I	of$$$143$$$145$$$I	glycididazole$$$146$$$159$$$I	and$$$160$$$163$$$O	ethylene$$$164$$$172$$$I	diamine$$$173$$$180$$$I	double$$$181$$$187$$$I	salt$$$188$$$192$$$I	of$$$193$$$195$$$I	glycididazole,$$$196$$$210$$$I	and$$$211$$$214$$$O	their$$$215$$$220$$$O	preparation$$$221$$$232$$$O	process.$$$233$$$241$$$O	The$$$242$$$245$$$O	present$$$246$$$253$$$O	invention$$$254$$$263$$$O	provides$$$264$$$272$$$O	new$$$273$$$276$$$O	glycididazole$$$277$$$290$$$I	compounds$$$291$$$300$$$O	with$$$301$$$305$$$O	improved$$$306$$$314$$$O	water$$$315$$$320$$$O	solubility$$$321$$$331$$$O	and$$$332$$$335$$$O	stability$$$336$$$345$$$O	for$$$346$$$349$$$O	convenient$$$350$$$360$$$O	medicinal$$$361$$$370$$$O	application.$$$371$$$383$$$O	In$$$384$$$386$$$O	addition,$$$387$$$396$$$O	the$$$397$$$400$$$O	non-metal$$$401$$$410$$$O	salt$$$411$$$415$$$O	compounds$$$416$$$425$$$O	of$$$426$$$428$$$O	glycididazole$$$429$$$442$$$I	are$$$443$$$446$$$O	non-sodium$$$447$$$457$$$I	ion$$$458$$$461$$$I	salt$$$462$$$466$$$O	and$$$467$$$470$$$O	can$$$471$$$474$$$O	avoid$$$475$$$480$$$O	sodium$$$481$$$487$$$I	accumulation$$$488$$$500$$$O	and$$$501$$$504$$$O	other$$$505$$$510$$$O	bad$$$511$$$514$$$O	reaction$$$515$$$523$$$O	causing$$$524$$$531$$$O	electrolyte$$$532$$$543$$$O	metabolism$$$544$$$554$$$O	disorder.$$$555$$$564$$$O
EP1578897A2
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	inducing$$$12$$$20$$$O	functional$$$21$$$31$$$O	tolerance$$$32$$$41$$$O	to$$$42$$$44$$$O	gene$$$45$$$49$$$O	transfer$$$50$$$58$$$O	products$$$59$$$67$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	inducing$$$11$$$19$$$O	functional$$$20$$$30$$$O	tolerance$$$31$$$40$$$O	for$$$41$$$44$$$O	the$$$45$$$48$$$O	expression$$$49$$$59$$$O	products$$$60$$$68$$$O	of$$$69$$$71$$$O	transgenes$$$72$$$82$$$O	in$$$83$$$85$$$O	somatic$$$86$$$93$$$O	cells$$$94$$$99$$$O	are$$$100$$$103$$$O	disclosed,$$$104$$$114$$$O	which$$$115$$$120$$$O	methods$$$121$$$128$$$O	comprise$$$129$$$137$$$O	the$$$138$$$141$$$O	introduction$$$142$$$154$$$O	into$$$155$$$159$$$O	the$$$160$$$163$$$O	recipient$$$164$$$173$$$O	of$$$174$$$176$$$O	stem$$$177$$$181$$$O	cells,$$$182$$$188$$$O	such$$$189$$$193$$$O	as$$$194$$$196$$$O	hematopoietic$$$197$$$210$$$O	stem$$$211$$$215$$$O	cells,$$$216$$$222$$$O	transgenically$$$223$$$237$$$O	modified$$$238$$$246$$$O	so$$$247$$$249$$$O	as$$$250$$$252$$$O	to$$$253$$$255$$$O	express$$$256$$$263$$$O	one$$$264$$$267$$$O	or$$$268$$$270$$$O	more$$$271$$$275$$$O	neoantigens,$$$276$$$288$$$O	such$$$289$$$293$$$O	procedure$$$294$$$303$$$O	optionally$$$304$$$314$$$O	preceded$$$315$$$323$$$O	by$$$324$$$326$$$O	a$$$327$$$328$$$O	myeloreductive$$$329$$$343$$$O	procedure.$$$344$$$354$$$O	The$$$355$$$358$$$O	purpose$$$359$$$366$$$O	of$$$367$$$369$$$O	the$$$370$$$373$$$O	disclosed$$$374$$$383$$$O	methods$$$384$$$391$$$O	is$$$392$$$394$$$O	to$$$395$$$397$$$O	induce$$$398$$$404$$$O	tolerance$$$405$$$414$$$O	to$$$415$$$417$$$O	these$$$418$$$423$$$O	same$$$424$$$428$$$O	antigens$$$429$$$437$$$O	when$$$438$$$442$$$O	later$$$443$$$448$$$O	expressed$$$449$$$458$$$O	by$$$459$$$461$$$O	cells$$$462$$$467$$$O	or$$$468$$$470$$$O	vectors$$$471$$$478$$$O	to$$$479$$$481$$$O	be$$$482$$$484$$$O	introduced$$$485$$$495$$$O	as$$$496$$$498$$$O	part$$$499$$$503$$$O	of$$$504$$$506$$$O	a$$$507$$$508$$$O	gene$$$509$$$513$$$O	therapy$$$514$$$521$$$O	treatment.$$$522$$$532$$$O
WO2014002104A1
A$$$0$$$1$$$O	synergistic$$$2$$$13$$$O	pharmaceutical$$$14$$$28$$$O	composition$$$29$$$40$$$O	useful$$$41$$$47$$$O	for$$$48$$$51$$$O	the$$$52$$$55$$$O	treatment$$$56$$$65$$$O	of$$$66$$$68$$$O	lung$$$69$$$73$$$O	cancer$$$74$$$80$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	synergistic$$$35$$$46$$$O	pharmaceutical$$$47$$$61$$$O	composition$$$62$$$73$$$O	comprising$$$74$$$84$$$O	Compound$$$85$$$93$$$O	C2$$$94$$$96$$$O	(Neo-isopulegol),$$$97$$$114$$$I	C3$$$115$$$117$$$O	(Iso-pulegol)$$$118$$$131$$$I	and$$$132$$$135$$$O	C4$$$136$$$138$$$O	(Citronellol)$$$139$$$152$$$I	derived$$$153$$$160$$$O	from$$$161$$$165$$$O	herbal$$$166$$$172$$$O	seed$$$173$$$177$$$O	extract$$$178$$$185$$$O	of$$$186$$$188$$$O	Litsea$$$189$$$195$$$O	cubebp$$$196$$$202$$$O	useful$$$203$$$209$$$O	for$$$210$$$213$$$O	the$$$214$$$217$$$O	treatment$$$218$$$227$$$O	of$$$228$$$230$$$O	lung$$$231$$$235$$$O	cancer.$$$236$$$243$$$O	The$$$244$$$247$$$O	present$$$248$$$255$$$O	invention$$$256$$$265$$$O	also$$$266$$$270$$$O	relates$$$271$$$278$$$O	to$$$279$$$281$$$O	the$$$282$$$285$$$O	activity$$$286$$$294$$$O	of$$$295$$$297$$$O	compounds$$$298$$$307$$$O	C2$$$308$$$310$$$O	or$$$311$$$313$$$O	C3$$$314$$$316$$$O	or$$$317$$$319$$$O	C4$$$320$$$322$$$O	either$$$323$$$329$$$O	alone$$$330$$$335$$$O	or$$$336$$$338$$$O	in$$$339$$$341$$$O	combination$$$342$$$353$$$O	in$$$354$$$356$$$O	killing$$$357$$$364$$$O	of$$$365$$$367$$$O	A549$$$368$$$372$$$O	lung$$$373$$$377$$$O	cancer$$$378$$$384$$$O	cells.$$$385$$$391$$$O
US20110144089
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	treating$$$10$$$18$$$O	schizophrenia$$$19$$$32$$$O	and$$$33$$$36$$$O	other$$$37$$$42$$$O	disorders$$$43$$$52$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	treating$$$12$$$20$$$O	at$$$21$$$23$$$O	least$$$24$$$29$$$O	one$$$30$$$33$$$O	symptom$$$34$$$41$$$O	or$$$42$$$44$$$O	condition$$$45$$$54$$$O	associated$$$55$$$65$$$O	with$$$66$$$70$$$O	but$$$71$$$74$$$O	not$$$75$$$78$$$O	limited$$$79$$$86$$$O	to:$$$87$$$90$$$O	1)$$$91$$$93$$$O	Schizophrenia$$$94$$$107$$$O	and$$$108$$$111$$$O	other$$$112$$$117$$$O	Psychotic$$$118$$$127$$$O	Disorders$$$128$$$137$$$O	including$$$138$$$147$$$O	but$$$148$$$151$$$O	not$$$152$$$155$$$O	limited$$$156$$$163$$$O	to$$$164$$$166$$$O	Psychotic$$$167$$$176$$$O	Disorder,$$$177$$$186$$$O	Schizophreniform$$$187$$$203$$$O	Disorder,$$$204$$$213$$$O	Schizoaffective$$$214$$$229$$$O	Disorder,$$$230$$$239$$$O	Delusional$$$240$$$250$$$O	Disorder,$$$251$$$260$$$O	Brief$$$261$$$266$$$O	Psychotic$$$267$$$276$$$O	Disorder,$$$277$$$286$$$O	Shared$$$287$$$293$$$O	Psychotic$$$294$$$303$$$O	Disorder,$$$304$$$313$$$O	and$$$314$$$317$$$O	Psychotic$$$318$$$327$$$O	Disorder$$$328$$$336$$$O	Due$$$337$$$340$$$O	to$$$341$$$343$$$O	a$$$344$$$345$$$O	General$$$346$$$353$$$O	Medical$$$354$$$361$$$O	Condition$$$362$$$371$$$O	and$$$372$$$375$$$O	2)$$$376$$$378$$$O	Dementia$$$379$$$387$$$O	and$$$388$$$391$$$O	other$$$392$$$397$$$O	Cognitive$$$398$$$407$$$O	Disorders$$$408$$$417$$$O	comprising$$$418$$$428$$$O	administering$$$429$$$442$$$O	an$$$443$$$445$$$O	effective$$$446$$$455$$$O	amount$$$456$$$462$$$O	of$$$463$$$465$$$O	Formula$$$466$$$473$$$O	I$$$474$$$475$$$O	or$$$513$$$515$$$O	its$$$516$$$519$$$O	pharmaceutically$$$520$$$536$$$O	acceptable$$$537$$$547$$$O	salt.$$$548$$$553$$$O	In$$$554$$$556$$$O	another$$$557$$$564$$$O	aspect$$$565$$$571$$$O	of$$$572$$$574$$$O	the$$$575$$$578$$$O	invention$$$579$$$588$$$O	a$$$589$$$590$$$O	pharmaceutical$$$591$$$605$$$O	composition$$$606$$$617$$$O	is$$$618$$$620$$$O	provided$$$621$$$629$$$O	comprising$$$630$$$640$$$O	an$$$641$$$643$$$O	effective$$$644$$$653$$$O	amount$$$654$$$660$$$O	of$$$661$$$663$$$O	Formula$$$664$$$671$$$O	I$$$672$$$673$$$O	or$$$674$$$676$$$O	its$$$677$$$680$$$O	pharmaceutically$$$681$$$697$$$O	acceptable$$$698$$$708$$$O	salt$$$709$$$713$$$O	and$$$714$$$717$$$O	at$$$718$$$720$$$O	least$$$721$$$726$$$O	one$$$727$$$730$$$O	pharmaceutically$$$731$$$747$$$O	acceptable$$$748$$$758$$$O	carrier$$$759$$$766$$$O	or$$$767$$$769$$$O	diluent.$$$770$$$778$$$O
EP1251818B9
Galenic$$$0$$$7$$$O	formulation$$$8$$$19$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	cosmetic$$$25$$$33$$$O	or$$$34$$$36$$$O	dermatological$$$37$$$51$$$O	formulations$$$52$$$64$$$O	which$$$65$$$70$$$O	contain$$$71$$$78$$$O	one$$$79$$$82$$$O	or$$$83$$$85$$$O	more$$$86$$$90$$$O	active$$$91$$$97$$$O	substances$$$98$$$108$$$O	selected$$$109$$$117$$$O	from$$$118$$$122$$$O	phyllochinon,$$$123$$$136$$$I	2-hydroxy-5-methyllaurophenonoxime,$$$137$$$172$$$I	vitamin$$$173$$$180$$$I	A$$$181$$$182$$$I	and$$$183$$$186$$$O	derivatives$$$187$$$198$$$O	thereof,$$$199$$$207$$$O	vitamin$$$208$$$215$$$I	E$$$216$$$217$$$I	and$$$218$$$221$$$O	derivatives$$$222$$$233$$$O	thereof,$$$234$$$242$$$O	vitamin$$$243$$$250$$$I	H,$$$251$$$253$$$I	allantoin,$$$254$$$264$$$I	bisabolol,$$$265$$$275$$$I	nicotine$$$276$$$284$$$I	acid$$$285$$$289$$$I	derivatives,$$$290$$$302$$$O	caffeine$$$303$$$311$$$I	and,$$$312$$$316$$$O	optionally:$$$317$$$328$$$O	(a)$$$329$$$332$$$O	one$$$333$$$336$$$O	or$$$337$$$339$$$O	more$$$340$$$344$$$O	antioxidants$$$345$$$357$$$O	and/or;$$$358$$$365$$$O	(b)$$$366$$$369$$$O	one$$$370$$$373$$$O	or$$$374$$$376$$$O	more$$$377$$$381$$$O	UV$$$382$$$384$$$O	filters.$$$385$$$393$$$O	The$$$394$$$397$$$O	formulations$$$398$$$410$$$O	are$$$411$$$414$$$O	particularly$$$415$$$427$$$O	characterized$$$428$$$441$$$O	in$$$442$$$444$$$O	that$$$445$$$449$$$O	the$$$450$$$453$$$O	active$$$454$$$460$$$O	substances$$$461$$$471$$$O	containing$$$472$$$482$$$O	the$$$483$$$486$$$O	inventive$$$487$$$496$$$O	formulations$$$497$$$509$$$O	are$$$510$$$513$$$O	stabilized.$$$514$$$525$$$O
WO2005061454A1
Agent$$$0$$$5$$$O	or$$$6$$$8$$$O	method$$$9$$$15$$$O	for$$$16$$$19$$$O	treatment$$$20$$$29$$$O	for$$$30$$$33$$$O	severe$$$34$$$40$$$O	aphasia$$$41$$$48$$$O	in$$$49$$$51$$$O	chronic-stage$$$52$$$65$$$O	cerebrovascular$$$66$$$81$$$O	disorder$$$82$$$90$$$O
An$$$0$$$2$$$O	agent$$$3$$$8$$$O	or$$$9$$$11$$$O	method$$$12$$$18$$$O	for$$$19$$$22$$$O	treatments$$$23$$$33$$$O	for$$$34$$$37$$$O	severe$$$38$$$44$$$O	aphasia$$$45$$$52$$$O	in$$$53$$$55$$$O	chronic-stage$$$56$$$69$$$O	cerebrovascular$$$70$$$85$$$O	disorders$$$86$$$95$$$O	which$$$96$$$101$$$O	contains$$$102$$$110$$$O	or$$$111$$$113$$$O	employs$$$114$$$121$$$O	2-oxo-1-pyrrolidineacetamide$$$122$$$150$$$I	as$$$151$$$153$$$O	an$$$154$$$156$$$O	active$$$157$$$163$$$O	ingredient.$$$164$$$175$$$O
WO2009143578A1
Cancer$$$0$$$6$$$O	drug$$$7$$$11$$$O	target$$$12$$$18$$$O	and$$$19$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	diagnosis$$$34$$$43$$$O	and$$$44$$$47$$$O	therapy$$$48$$$55$$$O
A$$$0$$$1$$$O	single$$$2$$$8$$$O	nucleotide$$$9$$$19$$$O	G$$$20$$$21$$$O	>A$$$22$$$24$$$O	polymorphism$$$25$$$37$$$O	at$$$38$$$40$$$O	position$$$41$$$49$$$O	-126$$$50$$$54$$$O	in$$$55$$$57$$$O	the$$$58$$$61$$$O	promoter$$$62$$$70$$$O	of$$$71$$$73$$$O	the$$$74$$$77$$$O	human$$$78$$$83$$$O	myeloid$$$84$$$91$$$O	cell$$$92$$$96$$$O	leukemia-1$$$97$$$107$$$O	gene$$$108$$$112$$$O	is$$$113$$$115$$$O	associated$$$116$$$126$$$O	with$$$127$$$131$$$O	a$$$132$$$133$$$O	reduced$$$134$$$141$$$O	predisposition$$$142$$$156$$$O	to$$$157$$$159$$$O	cancer$$$160$$$166$$$O	and$$$167$$$170$$$O	an$$$171$$$173$$$O	increased$$$174$$$183$$$O	responsiveness$$$184$$$198$$$O	to$$$199$$$201$$$O	pro-apoptotic$$$202$$$215$$$O	cancer$$$216$$$222$$$O	therapeutic$$$223$$$234$$$O	agents.$$$235$$$242$$$O	The$$$243$$$246$$$O	G>;A$$$247$$$251$$$O	polymorphism$$$252$$$264$$$O	is$$$265$$$267$$$O	in$$$268$$$270$$$O	an$$$271$$$273$$$O	ELK4$$$274$$$278$$$O	transcription$$$279$$$292$$$O	factor$$$293$$$299$$$O	binding$$$300$$$307$$$O	site,$$$308$$$313$$$O	which$$$314$$$319$$$O	results$$$320$$$327$$$O	in$$$328$$$330$$$O	reduced$$$331$$$338$$$O	myeloid$$$339$$$346$$$O	cell$$$347$$$351$$$O	leukemia-1$$$352$$$362$$$O	gene$$$363$$$367$$$O	expression.$$$368$$$379$$$O	Elevated$$$380$$$388$$$O	levels$$$389$$$395$$$O	of$$$396$$$398$$$O	ELK4$$$399$$$403$$$O	and$$$404$$$407$$$O	Mcl-1$$$408$$$413$$$O	protein$$$414$$$421$$$O	and$$$422$$$425$$$O	nucleic$$$426$$$433$$$O	acids$$$434$$$439$$$O	are$$$440$$$443$$$O	associated$$$444$$$454$$$O	with$$$455$$$459$$$O	an$$$460$$$462$$$O	increased$$$463$$$472$$$O	predisposition$$$473$$$487$$$O	to$$$488$$$490$$$O	cancer$$$491$$$497$$$O	and$$$498$$$501$$$O	an$$$502$$$504$$$O	decreased$$$505$$$514$$$O	responsiveness$$$515$$$529$$$O	to$$$530$$$532$$$O	pro-apoptotic$$$533$$$546$$$O	agents.$$$547$$$554$$$O	Reduced$$$555$$$562$$$O	levels$$$563$$$569$$$O	of$$$570$$$572$$$O	ELK4$$$573$$$577$$$O	and$$$578$$$581$$$O	Mcl-1$$$582$$$587$$$O	protein$$$588$$$595$$$O	and$$$596$$$599$$$O	nucleic$$$600$$$607$$$O	acids$$$608$$$613$$$O	are$$$614$$$617$$$O	associated$$$618$$$628$$$O	with$$$629$$$633$$$O	less$$$634$$$638$$$O	of$$$639$$$641$$$O	a$$$642$$$643$$$O	predisposition$$$644$$$658$$$O	to$$$659$$$661$$$O	cancer$$$662$$$668$$$O	and$$$669$$$672$$$O	an$$$673$$$675$$$O	increased$$$676$$$685$$$O	responsiveness$$$686$$$700$$$O	to$$$701$$$703$$$O	pro-apoptotic$$$704$$$717$$$O	cancer$$$718$$$724$$$O	therapeutic$$$725$$$736$$$O	agents.$$$737$$$744$$$O	Methods$$$745$$$752$$$O	of$$$753$$$755$$$O	cancer$$$756$$$762$$$O	diagnosis$$$763$$$772$$$O	and/or$$$773$$$779$$$O	therapy$$$780$$$787$$$O	which$$$788$$$793$$$O	target$$$794$$$800$$$O	ELK4$$$801$$$805$$$O	and/or$$$806$$$812$$$O	Mcl-1$$$813$$$818$$$O	protein$$$819$$$826$$$O	and/or$$$827$$$833$$$O	nucleic$$$834$$$841$$$O	acids$$$842$$$847$$$O	are$$$848$$$851$$$O	particularly$$$852$$$864$$$O	applicable$$$865$$$875$$$O	to$$$876$$$878$$$O	cancers$$$879$$$886$$$O	such$$$887$$$891$$$O	as$$$892$$$894$$$O	glioma,$$$895$$$902$$$O	colon$$$903$$$908$$$O	cancer,$$$909$$$916$$$O	lung$$$917$$$921$$$O	cancer,$$$922$$$929$$$O	thyroid$$$930$$$937$$$O	cancer,$$$938$$$945$$$O	kidney$$$946$$$952$$$O	cancer$$$953$$$959$$$O	and/or$$$960$$$966$$$O	melanoma.$$$967$$$976$$$O	Such$$$977$$$981$$$O	methods$$$982$$$989$$$O	and$$$990$$$993$$$O	compositions$$$994$$$1006$$$O	may$$$1007$$$1010$$$O	sensitize$$$1011$$$1020$$$O	or$$$1021$$$1023$$$O	improve$$$1024$$$1031$$$O	responsiveness$$$1032$$$1046$$$O	of$$$1047$$$1049$$$O	cancer$$$1050$$$1056$$$O	cells$$$1057$$$1062$$$O	to$$$1063$$$1065$$$O	pro-apoptotic$$$1066$$$1079$$$O	agents.$$$1080$$$1087$$$O
US6890961
Applying$$$0$$$8$$$O	topically$$$9$$$18$$$O	to$$$19$$$21$$$O	the$$$22$$$25$$$O	leukoplakia$$$26$$$37$$$O	lesion$$$38$$$44$$$O	an$$$45$$$47$$$O	effective$$$48$$$57$$$O	amount$$$58$$$64$$$O	of$$$65$$$67$$$O	a$$$68$$$69$$$O	clear$$$70$$$75$$$O	aqueous$$$76$$$83$$$O	formulation$$$84$$$95$$$O	comprising:$$$96$$$107$$$O	water;$$$108$$$114$$$O	a$$$115$$$116$$$O	water$$$117$$$122$$$O	miscible$$$123$$$131$$$O	polyol;$$$132$$$139$$$O	unsaturated$$$140$$$151$$$I	fatty$$$152$$$157$$$I	acid$$$158$$$162$$$I	ester;$$$163$$$169$$$I	a$$$170$$$171$$$O	surfactant,$$$172$$$183$$$O	and$$$184$$$187$$$O	beta$$$188$$$192$$$O	-carotene$$$193$$$202$$$O
A$$$0$$$1$$$O	clear$$$2$$$7$$$O	aqueous$$$8$$$15$$$O	formulation$$$16$$$27$$$O	for$$$28$$$31$$$O	topical$$$32$$$39$$$O	application$$$40$$$51$$$O	in$$$52$$$54$$$O	the$$$55$$$58$$$O	oral$$$59$$$63$$$O	cavity$$$64$$$70$$$O	of$$$71$$$73$$$O	humans$$$74$$$80$$$O	to$$$81$$$83$$$O	treat$$$84$$$89$$$O	leukoplakia$$$90$$$101$$$O	contains$$$102$$$110$$$O	water,$$$111$$$117$$$O	Î²-carotene,$$$118$$$130$$$I	a$$$131$$$132$$$O	water$$$133$$$138$$$O	miscible$$$139$$$147$$$I	polyol,$$$148$$$155$$$I	an$$$156$$$158$$$I	unsaturated$$$159$$$170$$$I	fatty$$$171$$$176$$$I	acid$$$177$$$181$$$I	ester,$$$182$$$188$$$I	and$$$189$$$192$$$O	a$$$193$$$194$$$O	surfactant,$$$195$$$206$$$O	preferably$$$207$$$217$$$O	polyethoxylated$$$218$$$233$$$I	castor$$$234$$$240$$$I	oil$$$241$$$244$$$I	or$$$245$$$247$$$I	POE(20)$$$248$$$255$$$I	sorbitan$$$256$$$264$$$I	monooleate.$$$265$$$276$$$I	The$$$277$$$280$$$O	formulation$$$281$$$292$$$O	preferably$$$293$$$303$$$O	also$$$304$$$308$$$O	contains$$$309$$$317$$$O	a$$$318$$$319$$$O	pharmaceutically$$$320$$$336$$$O	acceptable$$$337$$$347$$$O	anti-oxidant,$$$348$$$361$$$O	preferably$$$362$$$372$$$I	d-alpha-tocopherol$$$373$$$391$$$I	(vitamin$$$392$$$400$$$I	E),$$$401$$$404$$$I	and$$$405$$$408$$$O	is$$$409$$$411$$$O	in$$$412$$$414$$$O	the$$$415$$$418$$$O	form$$$419$$$423$$$O	of$$$424$$$426$$$O	an$$$427$$$429$$$O	oral$$$430$$$434$$$O	rinse$$$435$$$440$$$O	or$$$441$$$443$$$O	as$$$444$$$446$$$O	a$$$447$$$448$$$O	gel$$$449$$$452$$$O	well$$$453$$$457$$$O	suited$$$458$$$464$$$O	for$$$465$$$468$$$O	spreading$$$469$$$478$$$O	on$$$479$$$481$$$O	gums$$$482$$$486$$$O	or$$$487$$$489$$$O	other$$$490$$$495$$$O	parts$$$496$$$501$$$O	of$$$502$$$504$$$O	the$$$505$$$508$$$O	oral$$$509$$$513$$$O	cavity.$$$514$$$521$$$O	The$$$522$$$525$$$O	formulation$$$526$$$537$$$O	is$$$538$$$540$$$O	applied$$$541$$$548$$$O	in$$$549$$$551$$$O	a$$$552$$$553$$$O	gel$$$554$$$557$$$O	form$$$558$$$562$$$O	on$$$563$$$565$$$O	a$$$566$$$567$$$O	substantially$$$568$$$581$$$O	regular$$$582$$$589$$$O	daily$$$590$$$595$$$O	basis$$$596$$$601$$$O	to$$$602$$$604$$$O	areas$$$605$$$610$$$O	in$$$611$$$613$$$O	the$$$614$$$617$$$O	oral$$$618$$$622$$$O	cavity$$$623$$$629$$$O	where$$$630$$$635$$$O	leukoplakia$$$636$$$647$$$O	lesions$$$648$$$655$$$O	are$$$656$$$659$$$O	present.$$$660$$$668$$$O	Persistent$$$669$$$679$$$O	application$$$680$$$691$$$O	of$$$692$$$694$$$O	the$$$695$$$698$$$O	gel$$$699$$$702$$$O	results$$$703$$$710$$$O	in$$$711$$$713$$$O	substantial$$$714$$$725$$$O	diminution$$$726$$$736$$$O	or$$$737$$$739$$$O	total$$$740$$$745$$$O	elimination$$$746$$$757$$$O	of$$$758$$$760$$$O	the$$$761$$$764$$$O	leukoplakia$$$765$$$776$$$O	lesions.$$$777$$$785$$$O
CN102349890A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	thaspine$$$15$$$23$$$I	derivative$$$24$$$34$$$O	HMQ1611$$$35$$$42$$$I	in$$$43$$$45$$$O	inhibition$$$46$$$56$$$O	of$$$57$$$59$$$O	mammary$$$60$$$67$$$O	cancer$$$68$$$74$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	application$$$25$$$36$$$O	of$$$37$$$39$$$O	thaspine$$$40$$$48$$$I	derivative$$$49$$$59$$$O	HMQ1611$$$60$$$67$$$I	in$$$68$$$70$$$O	inhibition$$$71$$$81$$$O	of$$$82$$$84$$$O	mammary$$$85$$$92$$$O	cancer.$$$93$$$100$$$O	In$$$101$$$103$$$O	an$$$104$$$106$$$O	integral$$$107$$$115$$$O	level,$$$116$$$122$$$O	a$$$123$$$124$$$O	mammary$$$125$$$132$$$O	cancer$$$133$$$139$$$O	ZR-75-30$$$140$$$148$$$O	tumor$$$149$$$154$$$O	transplantation$$$155$$$170$$$O	tumor$$$171$$$176$$$O	model$$$177$$$182$$$O	is$$$183$$$185$$$O	built$$$186$$$191$$$O	on$$$192$$$194$$$O	the$$$195$$$198$$$O	basis$$$199$$$204$$$O	of$$$205$$$207$$$O	a$$$208$$$209$$$O	nude$$$210$$$214$$$O	mouse$$$215$$$220$$$O	transplantation$$$221$$$236$$$O	tumor$$$237$$$242$$$O	model,$$$243$$$249$$$O	the$$$250$$$253$$$O	inhibition$$$254$$$264$$$O	effect$$$265$$$271$$$O	of$$$272$$$274$$$O	the$$$275$$$278$$$O	thaspine$$$279$$$287$$$I	derivative$$$288$$$298$$$O	HMQ1611$$$299$$$306$$$I	on$$$307$$$309$$$O	mammary$$$310$$$317$$$O	cancer$$$318$$$324$$$O	is$$$325$$$327$$$O	researched,$$$328$$$339$$$O	and$$$340$$$343$$$O	then$$$344$$$348$$$O	the$$$349$$$352$$$O	mammary$$$353$$$360$$$O	cancer$$$361$$$367$$$O	resistance$$$368$$$378$$$O	passageway$$$379$$$389$$$O	of$$$390$$$392$$$O	the$$$393$$$396$$$O	thaspine$$$397$$$405$$$I	derivative$$$406$$$416$$$O	HMQ1611$$$417$$$424$$$I	is$$$425$$$427$$$O	also$$$428$$$432$$$O	researched,$$$433$$$444$$$O	thus$$$445$$$449$$$O	the$$$450$$$453$$$O	inhibition$$$454$$$464$$$O	effect$$$465$$$471$$$O	of$$$472$$$474$$$O	the$$$475$$$478$$$O	thaspine$$$479$$$487$$$I	derivative$$$488$$$498$$$O	HMQ1611$$$499$$$506$$$I	on$$$507$$$509$$$O	ER$$$510$$$512$$$O	(estrogen$$$513$$$522$$$I	receptor)-dependent$$$523$$$542$$$O	mammary$$$543$$$550$$$O	cancer$$$551$$$557$$$O	is$$$558$$$560$$$O	verified,$$$561$$$570$$$O	and$$$571$$$574$$$O	the$$$575$$$578$$$O	influence$$$579$$$588$$$O	of$$$589$$$591$$$O	the$$$592$$$595$$$O	thaspine$$$596$$$604$$$I	derivative$$$605$$$615$$$O	HMQ1611$$$616$$$623$$$I	on$$$624$$$626$$$O	ER$$$627$$$629$$$O	passageway$$$630$$$640$$$O	of$$$641$$$643$$$O	mammary$$$644$$$651$$$O	cancer$$$652$$$658$$$O	cells$$$659$$$664$$$O	is$$$665$$$667$$$O	also$$$668$$$672$$$O	verified,$$$673$$$682$$$O	thereby$$$683$$$690$$$O	showing$$$691$$$698$$$O	that$$$699$$$703$$$O	the$$$704$$$707$$$O	thaspine$$$708$$$716$$$I	derivative$$$717$$$727$$$O	HMQ1611$$$728$$$735$$$I	can$$$736$$$739$$$O	truly$$$740$$$745$$$O	inhibit$$$746$$$753$$$O	mammary$$$754$$$761$$$O	cancer.$$$762$$$769$$$O
EP2094258A1
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	using$$$27$$$32$$$O	aliskiren$$$33$$$42$$$I	and$$$43$$$46$$$O	avosentan$$$47$$$56$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	and$$$62$$$65$$$O	method$$$66$$$72$$$O	of$$$73$$$75$$$O	achieving$$$76$$$85$$$O	a$$$86$$$87$$$O	therapeutic$$$88$$$99$$$O	effect$$$100$$$106$$$O	including,$$$107$$$117$$$O	but$$$118$$$121$$$O	not$$$122$$$125$$$O	limited$$$126$$$133$$$O	to,$$$134$$$137$$$O	the$$$138$$$141$$$O	treatment$$$142$$$151$$$O	of$$$152$$$154$$$O	hypertension,$$$155$$$168$$$O	kidney$$$169$$$175$$$O	or$$$176$$$178$$$O	heart$$$179$$$184$$$O	disease$$$185$$$192$$$O	in$$$193$$$195$$$O	an$$$196$$$198$$$O	animal,$$$199$$$206$$$O	preferably$$$207$$$217$$$O	a$$$218$$$219$$$O	mammal$$$220$$$226$$$O	including$$$227$$$236$$$O	a$$$237$$$238$$$O	human$$$239$$$244$$$O	subject,$$$245$$$253$$$O	using$$$254$$$259$$$O	(i)$$$260$$$263$$$O	SPP100/aliskiren$$$264$$$280$$$I	or$$$281$$$283$$$O	a$$$284$$$285$$$O	pharmaceutically$$$286$$$302$$$O	acceptable$$$303$$$313$$$O	salt$$$314$$$318$$$O	thereof$$$319$$$326$$$O	in$$$327$$$329$$$O	combination$$$330$$$341$$$O	with$$$342$$$346$$$O	(ii)$$$347$$$351$$$O	SPP301/avosentan$$$352$$$368$$$I	or$$$369$$$371$$$O	a$$$372$$$373$$$O	pharmaceutically$$$374$$$390$$$O	acceptable$$$391$$$401$$$O	salt$$$402$$$406$$$O	thereof$$$407$$$414$$$O	and$$$415$$$418$$$O	(iii)$$$419$$$424$$$O	a$$$425$$$426$$$O	pharmaceutically$$$427$$$443$$$O	acceptable$$$444$$$454$$$O	carrier.$$$455$$$463$$$O
CN103271879A
Stable$$$0$$$6$$$O	fructose$$$7$$$15$$$I	composition$$$16$$$27$$$O	preparation$$$28$$$39$$$O	and$$$40$$$43$$$O	preparation$$$44$$$55$$$O	method$$$56$$$62$$$O	thereof$$$63$$$70$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	belongs$$$25$$$32$$$O	to$$$33$$$35$$$O	the$$$36$$$39$$$O	field$$$40$$$45$$$O	of$$$46$$$48$$$O	medicament$$$49$$$59$$$O	synthesis$$$60$$$69$$$O	and$$$70$$$73$$$O	preparation$$$74$$$85$$$O	thereof,$$$86$$$94$$$O	and$$$95$$$98$$$O	relates$$$99$$$106$$$O	to$$$107$$$109$$$O	the$$$110$$$113$$$O	stable$$$114$$$120$$$O	fructose$$$121$$$129$$$I	composition$$$130$$$141$$$O	preparation$$$142$$$153$$$O	and$$$154$$$157$$$O	preparation$$$158$$$169$$$O	method$$$170$$$176$$$O	thereof.$$$177$$$185$$$O	Aseptic$$$186$$$193$$$O	beta-fructose$$$194$$$207$$$I	is$$$208$$$210$$$O	suspended$$$211$$$220$$$O	in$$$221$$$223$$$O	water,$$$224$$$230$$$O	and$$$231$$$234$$$O	aseptic$$$235$$$242$$$O	fructose$$$243$$$251$$$I	is$$$252$$$254$$$O	added$$$255$$$260$$$O	for$$$261$$$264$$$O	adjusting$$$265$$$274$$$O	pH$$$275$$$277$$$O	for$$$278$$$281$$$O	dissolving$$$282$$$292$$$O	the$$$293$$$296$$$O	aseptic$$$297$$$304$$$O	beta-fructose$$$305$$$318$$$I	totally,$$$319$$$327$$$O	and$$$328$$$331$$$O	the$$$332$$$335$$$O	aqueous$$$336$$$343$$$O	solution$$$344$$$352$$$O	of$$$353$$$355$$$O	fructose/glycerin$$$356$$$373$$$I	is$$$374$$$376$$$O	obtained,$$$377$$$386$$$O	and$$$387$$$390$$$O	hydroxypropyl-beta-cyclodextrin$$$391$$$422$$$O	(HP-beta-CD)$$$423$$$435$$$O	is$$$436$$$438$$$O	added$$$439$$$444$$$O	into$$$445$$$449$$$O	the$$$450$$$453$$$O	aqueous$$$454$$$461$$$O	solution$$$462$$$470$$$O	for$$$471$$$474$$$O	clathration,$$$475$$$487$$$I	and$$$488$$$491$$$O	after$$$492$$$497$$$O	package$$$498$$$505$$$O	and$$$506$$$509$$$O	freeze$$$510$$$516$$$O	drying,$$$517$$$524$$$O	the$$$525$$$528$$$O	fructose$$$529$$$537$$$I	powder$$$538$$$544$$$O	injection$$$545$$$554$$$O	for$$$555$$$558$$$O	injection$$$559$$$568$$$O	is$$$569$$$571$$$O	obtained.$$$572$$$581$$$O	The$$$582$$$585$$$O	preparation$$$586$$$597$$$O	method$$$598$$$604$$$O	provided$$$605$$$613$$$O	by$$$614$$$616$$$O	the$$$617$$$620$$$O	invention$$$621$$$630$$$O	is$$$631$$$633$$$O	simple,$$$634$$$641$$$O	and$$$642$$$645$$$O	the$$$646$$$649$$$O	fructose$$$650$$$658$$$I	glycerin$$$659$$$667$$$I	compound$$$668$$$676$$$O	is$$$677$$$679$$$O	clathrated$$$680$$$690$$$O	by$$$691$$$693$$$O	hydroxypropyl-beta-cyclodextrin,$$$694$$$726$$$O	thereby$$$727$$$734$$$O	the$$$735$$$738$$$O	water-solubility$$$739$$$755$$$O	and$$$756$$$759$$$O	stability$$$760$$$769$$$O	of$$$770$$$772$$$O	fructose$$$773$$$781$$$I	medicament$$$782$$$792$$$O	are$$$793$$$796$$$O	increased,$$$797$$$807$$$O	and$$$808$$$811$$$O	the$$$812$$$815$$$O	biological$$$816$$$826$$$O	availability$$$827$$$839$$$O	of$$$840$$$842$$$O	the$$$843$$$846$$$O	medicament$$$847$$$857$$$O	is$$$858$$$860$$$O	improved;$$$861$$$870$$$O	the$$$871$$$874$$$O	preparation$$$875$$$886$$$O	technology$$$887$$$897$$$O	is$$$898$$$900$$$O	simple$$$901$$$907$$$O	and$$$908$$$911$$$O	is$$$912$$$914$$$O	suitable$$$915$$$923$$$O	for$$$924$$$927$$$O	industrial$$$928$$$938$$$O	production.$$$939$$$950$$$O
WO2014146604A1
Fused$$$0$$$5$$$O	ring$$$6$$$10$$$O	compound$$$11$$$19$$$O	having$$$20$$$26$$$O	gpr40$$$27$$$32$$$O	receptor$$$33$$$41$$$O	function$$$42$$$50$$$O	regulating$$$51$$$61$$$O	action$$$62$$$68$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	fused$$$14$$$19$$$O	ring$$$20$$$24$$$O	compound$$$25$$$33$$$O	having$$$34$$$40$$$O	GPR40$$$41$$$46$$$O	receptor$$$47$$$55$$$O	function$$$56$$$64$$$O	regulating$$$65$$$75$$$O	action,$$$76$$$83$$$O	and$$$84$$$87$$$O	preparation$$$88$$$99$$$O	method$$$100$$$106$$$O	and$$$107$$$110$$$O	pharmaceutical$$$111$$$125$$$O	compositions$$$126$$$138$$$O	thereof,$$$139$$$147$$$O	and$$$148$$$151$$$O	the$$$152$$$155$$$O	use$$$156$$$159$$$O	thereof$$$160$$$167$$$O	in$$$168$$$170$$$O	drugs$$$171$$$176$$$O	for$$$177$$$180$$$O	the$$$181$$$184$$$O	treatment$$$185$$$194$$$O	and/or$$$195$$$201$$$O	prevention$$$202$$$212$$$O	of$$$213$$$215$$$O	diseases$$$216$$$224$$$O	associated$$$225$$$235$$$O	with$$$236$$$240$$$O	GPR40,$$$241$$$247$$$O	especially$$$248$$$258$$$O	diabetes.$$$259$$$268$$$O
CN101007838A
Nucleic$$$0$$$7$$$O	acid$$$8$$$12$$$O	molecule$$$13$$$21$$$O	RTN4BSR22$$$22$$$31$$$O	and$$$32$$$35$$$O	its$$$36$$$39$$$O	application$$$40$$$51$$$O	in$$$52$$$54$$$O	preparing$$$55$$$64$$$O	anticancer$$$65$$$75$$$O	medicine$$$76$$$84$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	biological$$$38$$$48$$$O	pharmacology,$$$49$$$62$$$O	and$$$63$$$66$$$O	relates$$$67$$$74$$$O	to$$$75$$$77$$$O	the$$$78$$$81$$$O	use$$$82$$$85$$$O	of$$$86$$$88$$$O	RTN4BSR22$$$89$$$98$$$O	in$$$99$$$101$$$O	preparing$$$102$$$111$$$O	antitumor$$$112$$$121$$$O	medicament,$$$122$$$133$$$O	wherein$$$134$$$141$$$O	a$$$142$$$143$$$O	nucleotide$$$144$$$154$$$I	molecule$$$155$$$163$$$O	is$$$164$$$166$$$O	provided$$$167$$$175$$$O	which$$$176$$$181$$$O	can$$$182$$$185$$$O	be$$$186$$$188$$$O	used$$$189$$$193$$$O	for$$$194$$$197$$$O	preparing$$$198$$$207$$$O	antitumor$$$208$$$217$$$O	medicaments,$$$218$$$230$$$O	wherein$$$231$$$238$$$O	the$$$239$$$242$$$O	sequence$$$243$$$251$$$O	includes$$$252$$$260$$$O	5'-AAACACCACTCCAGTCTTC-3'$$$261$$$286$$$O	or$$$287$$$289$$$O	5'-AAACACCACUCCAGUCUUC-3',$$$290$$$316$$$O	and$$$317$$$320$$$O	is$$$321$$$323$$$O	named$$$324$$$329$$$O	RTN4BSR22$$$330$$$339$$$O	in$$$340$$$342$$$O	the$$$343$$$346$$$O	present$$$347$$$354$$$O	invention.$$$355$$$365$$$O	The$$$366$$$369$$$O	nucleotide$$$370$$$380$$$I	molecule$$$381$$$389$$$O	RTN4BSR22$$$390$$$399$$$O	of$$$400$$$402$$$O	the$$$403$$$406$$$O	invention$$$407$$$416$$$O	can$$$417$$$420$$$O	be$$$421$$$423$$$O	injected$$$424$$$432$$$O	into$$$433$$$437$$$O	tumors$$$438$$$444$$$O	of$$$445$$$447$$$O	the$$$448$$$451$$$O	nude$$$452$$$456$$$O	mice,$$$457$$$462$$$O	compared$$$463$$$471$$$O	with$$$472$$$476$$$O	nude$$$477$$$481$$$O	mice$$$482$$$486$$$O	injected$$$487$$$495$$$O	with$$$496$$$500$$$O	other$$$501$$$506$$$O	nucleotide$$$507$$$517$$$I	molecule$$$518$$$526$$$O	under$$$527$$$532$$$O	the$$$533$$$536$$$O	identical$$$537$$$546$$$O	culture$$$547$$$554$$$O	conditions,$$$555$$$566$$$O	the$$$567$$$570$$$O	tumor$$$571$$$576$$$O	growth$$$577$$$583$$$O	is$$$584$$$586$$$O	inhibited$$$587$$$596$$$O	appreciably,$$$597$$$609$$$O	which$$$610$$$615$$$O	is$$$616$$$618$$$O	becoming$$$619$$$627$$$O	more$$$628$$$632$$$O	appreciable$$$633$$$644$$$O	with$$$645$$$649$$$O	lapses$$$650$$$656$$$O	of$$$657$$$659$$$O	time.$$$660$$$665$$$O	The$$$666$$$669$$$O	invention$$$670$$$679$$$O	provides$$$680$$$688$$$O	a$$$689$$$690$$$O	novel$$$691$$$696$$$O	approach$$$697$$$705$$$O	for$$$706$$$709$$$O	the$$$710$$$713$$$O	treatment$$$714$$$723$$$O	and$$$724$$$727$$$O	alleviation$$$728$$$739$$$O	of$$$740$$$742$$$O	tumor.$$$743$$$749$$$O
CN101210037A
Short$$$0$$$5$$$O	interference$$$6$$$18$$$O	ribonucleic$$$19$$$30$$$O	acid$$$31$$$35$$$O	pointed$$$36$$$43$$$O	to$$$44$$$46$$$O	human$$$47$$$52$$$O	OPN$$$53$$$56$$$O	gene$$$57$$$61$$$O	for$$$62$$$65$$$O	treating$$$66$$$74$$$O	tumor$$$75$$$80$$$O	gene$$$81$$$85$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	short$$$26$$$31$$$O	interfering$$$32$$$43$$$O	RNA$$$44$$$47$$$O	(short$$$48$$$54$$$O	interfering$$$55$$$66$$$O	RNA,$$$67$$$71$$$O	siRNA)$$$72$$$78$$$O	used$$$79$$$83$$$O	in$$$84$$$86$$$O	curing$$$87$$$93$$$O	oncogene$$$94$$$102$$$O	aiming$$$103$$$109$$$O	at$$$110$$$112$$$O	the$$$113$$$116$$$O	OPN$$$117$$$120$$$O	genes$$$121$$$126$$$O	of$$$127$$$129$$$O	human$$$130$$$135$$$O	beings.$$$136$$$143$$$O	The$$$144$$$147$$$O	siRNA$$$148$$$153$$$O	uses$$$154$$$158$$$O	RNA$$$159$$$162$$$O	interfering$$$163$$$174$$$O	technology$$$175$$$185$$$O	and$$$186$$$189$$$O	makes$$$190$$$195$$$O	use$$$196$$$199$$$O	of$$$200$$$202$$$O	double$$$203$$$209$$$O	strand$$$210$$$216$$$O	RNA$$$217$$$220$$$O	of$$$221$$$223$$$O	short$$$224$$$229$$$O	bit$$$230$$$233$$$O	to$$$234$$$236$$$O	cause$$$237$$$242$$$O	mRNA$$$243$$$247$$$O	degradation$$$248$$$259$$$O	of$$$260$$$262$$$O	specified$$$263$$$272$$$O	genes$$$273$$$278$$$O	to$$$279$$$281$$$O	differentially$$$282$$$296$$$O	interrupt$$$297$$$306$$$O	the$$$307$$$310$$$O	expressions$$$311$$$322$$$O	of$$$323$$$325$$$O	the$$$326$$$329$$$O	specified$$$330$$$339$$$O	genes$$$340$$$345$$$O	with$$$346$$$350$$$O	high$$$351$$$355$$$O	efficiency$$$356$$$366$$$O	and$$$367$$$370$$$O	lead$$$371$$$375$$$O	cells$$$376$$$381$$$O	to$$$382$$$384$$$O	show$$$385$$$389$$$O	the$$$390$$$393$$$O	silent$$$394$$$400$$$O	phenotypes$$$401$$$411$$$O	of$$$412$$$414$$$O	the$$$415$$$418$$$O	specified$$$419$$$428$$$O	genes$$$429$$$434$$$O	that$$$435$$$439$$$O	can$$$440$$$443$$$O	be$$$444$$$446$$$O	applied$$$447$$$454$$$O	in$$$455$$$457$$$O	diseases$$$458$$$466$$$O	curing$$$467$$$473$$$O	field$$$474$$$479$$$O	by$$$480$$$482$$$O	researchers.$$$483$$$495$$$O	The$$$496$$$499$$$O	OPN$$$500$$$503$$$O	genes$$$504$$$509$$$O	express$$$510$$$517$$$O	a$$$518$$$519$$$O	multi-functional$$$520$$$536$$$O	protein,$$$537$$$545$$$O	which$$$546$$$551$$$O	attends$$$552$$$559$$$O	the$$$560$$$563$$$O	production$$$564$$$574$$$O	and$$$575$$$578$$$O	diversion$$$579$$$588$$$O	of$$$589$$$591$$$O	tumours$$$592$$$599$$$O	of$$$600$$$602$$$O	human$$$603$$$608$$$O	beings.$$$609$$$616$$$O	The$$$617$$$620$$$O	invention$$$621$$$630$$$O	widely$$$631$$$637$$$O	exists$$$638$$$644$$$O	in$$$645$$$647$$$O	the$$$648$$$651$$$O	tissues$$$652$$$659$$$O	and$$$660$$$663$$$O	the$$$664$$$667$$$O	body$$$668$$$672$$$O	fluid$$$673$$$678$$$O	of$$$679$$$681$$$O	normal$$$682$$$688$$$O	adults.$$$689$$$696$$$O	Being$$$697$$$702$$$O	proved$$$703$$$709$$$O	by$$$710$$$712$$$O	the$$$713$$$716$$$O	experiment,$$$717$$$728$$$O	the$$$729$$$732$$$O	growth$$$733$$$739$$$O	of$$$740$$$742$$$O	tumour$$$743$$$749$$$O	cells$$$750$$$755$$$O	is$$$756$$$758$$$O	obviously$$$759$$$768$$$O	restricted$$$769$$$779$$$O	after$$$780$$$785$$$O	the$$$786$$$789$$$O	expression$$$790$$$800$$$O	of$$$801$$$803$$$O	the$$$804$$$807$$$O	OPN$$$808$$$811$$$O	genes$$$812$$$817$$$O	is$$$818$$$820$$$O	controlled.$$$821$$$832$$$O
CN101695502A
Lanthanum$$$0$$$9$$$I	fullerenol$$$10$$$20$$$I	and$$$21$$$24$$$O	application$$$25$$$36$$$O	in$$$37$$$39$$$O	preparing$$$40$$$49$$$O	medicaments$$$50$$$61$$$O	for$$$62$$$65$$$O	inhibiting$$$66$$$76$$$O	tumor$$$77$$$82$$$O	growth$$$83$$$89$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	lanthanum$$$25$$$34$$$I	fullerenol$$$35$$$45$$$I	and$$$46$$$49$$$O	application$$$50$$$61$$$O	in$$$62$$$64$$$O	preparing$$$65$$$74$$$O	medicaments$$$75$$$86$$$O	for$$$87$$$90$$$O	inhibiting$$$91$$$101$$$O	tumor$$$102$$$107$$$O	growth,$$$108$$$115$$$O	in$$$116$$$118$$$O	particular$$$119$$$129$$$O	to$$$130$$$132$$$O	lanthanum$$$133$$$142$$$I	fullerenol$$$143$$$153$$$I	nanoparticles$$$154$$$167$$$O	with$$$168$$$172$$$O	the$$$173$$$176$$$O	general$$$177$$$184$$$O	formula$$$185$$$192$$$O	of$$$193$$$195$$$O	M@C2m(OH)x$$$196$$$206$$$O	and$$$207$$$210$$$O	the$$$211$$$214$$$O	application$$$215$$$226$$$O	thereof$$$227$$$234$$$O	in$$$235$$$237$$$O	preparing$$$238$$$247$$$O	medicaments$$$248$$$259$$$O	for$$$260$$$263$$$O	inhibiting$$$264$$$274$$$O	tumor$$$275$$$280$$$O	growth,$$$281$$$288$$$O	wherein$$$289$$$296$$$O	M$$$297$$$298$$$O	is$$$299$$$301$$$O	La$$$302$$$304$$$O	rare$$$305$$$309$$$O	earth$$$310$$$315$$$O	metal,$$$316$$$322$$$O	m$$$323$$$324$$$O	is$$$325$$$327$$$O	equal$$$328$$$333$$$O	to$$$334$$$336$$$O	41$$$337$$$339$$$O	or$$$340$$$342$$$O	30,$$$343$$$346$$$O	and$$$347$$$350$$$O	X$$$351$$$352$$$O	is$$$353$$$355$$$O	equal$$$356$$$361$$$O	to$$$362$$$364$$$O	or$$$365$$$367$$$O	larger$$$368$$$374$$$O	than$$$375$$$379$$$O	10$$$380$$$382$$$O	and$$$383$$$386$$$O	is$$$387$$$389$$$O	less$$$390$$$394$$$O	than$$$395$$$399$$$O	50;$$$400$$$403$$$O	and$$$404$$$407$$$O	because$$$408$$$415$$$O	of$$$416$$$418$$$O	the$$$419$$$422$$$O	reorganization$$$423$$$437$$$O	of$$$438$$$440$$$O	adjacent$$$441$$$449$$$O	hydroxyl$$$450$$$458$$$I	groups,$$$459$$$466$$$O	the$$$467$$$470$$$O	quantity$$$471$$$479$$$O	of$$$480$$$482$$$O	O$$$483$$$484$$$I	on$$$485$$$487$$$O	C82$$$488$$$491$$$O	carbon$$$492$$$498$$$I	cage$$$499$$$503$$$O	is$$$504$$$506$$$O	actually$$$507$$$515$$$O	different$$$516$$$525$$$O	from$$$526$$$530$$$O	the$$$531$$$534$$$O	quantity$$$535$$$543$$$O	of$$$544$$$546$$$O	H,$$$547$$$549$$$I	and$$$550$$$553$$$O	therefore,$$$554$$$564$$$O	the$$$565$$$568$$$O	general$$$569$$$576$$$O	formula$$$577$$$584$$$O	can$$$585$$$588$$$O	be$$$589$$$591$$$O	written$$$592$$$599$$$O	in$$$600$$$602$$$O	the$$$603$$$606$$$O	form$$$607$$$611$$$O	of$$$612$$$614$$$O	M@C2mOXHY.$$$615$$$625$$$O	Compared$$$626$$$634$$$O	with$$$635$$$639$$$O	cyclophosphamide,$$$640$$$657$$$I	cis-platinum,$$$658$$$671$$$I	taxol,$$$672$$$678$$$I	and$$$679$$$682$$$O	the$$$683$$$686$$$O	like$$$687$$$691$$$O	which$$$692$$$697$$$O	are$$$698$$$701$$$O	clinically$$$702$$$712$$$O	and$$$713$$$716$$$O	widely$$$717$$$723$$$O	used,$$$724$$$729$$$O	the$$$730$$$733$$$O	lanthanum$$$734$$$743$$$I	fullerenol$$$744$$$754$$$I	M@C2m(OH)x$$$755$$$765$$$O	or$$$766$$$768$$$O	M@C2mOXHY$$$769$$$778$$$O	has$$$779$$$782$$$O	the$$$783$$$786$$$O	advantages$$$787$$$797$$$O	of$$$798$$$800$$$O	low$$$801$$$804$$$O	consumption$$$805$$$816$$$O	and$$$817$$$820$$$O	toxicity$$$821$$$829$$$O	and$$$830$$$833$$$O	high$$$834$$$838$$$O	rate$$$839$$$843$$$O	of$$$844$$$846$$$O	tumor$$$847$$$852$$$O	inhibition.$$$853$$$864$$$O
EP2134704B1
Compounds$$$0$$$9$$$O	and$$$10$$$13$$$O	compositions$$$14$$$26$$$O	as$$$27$$$29$$$O	modulators$$$30$$$40$$$O	of$$$41$$$43$$$O	gpr119$$$44$$$50$$$O	activity$$$51$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds,$$$23$$$33$$$O	pharmaceutical$$$34$$$48$$$O	compositions$$$49$$$61$$$O	comprising$$$62$$$72$$$O	such$$$73$$$77$$$O	compounds$$$78$$$87$$$O	and$$$88$$$91$$$O	methods$$$92$$$99$$$O	of$$$100$$$102$$$O	using$$$103$$$108$$$O	such$$$109$$$113$$$O	compounds$$$114$$$123$$$O	to$$$124$$$126$$$O	treat$$$127$$$132$$$O	or$$$133$$$135$$$O	prevent$$$136$$$143$$$O	diseases$$$144$$$152$$$O	or$$$153$$$155$$$O	disorders$$$156$$$165$$$O	associated$$$166$$$176$$$O	with$$$177$$$181$$$O	the$$$182$$$185$$$O	activity$$$186$$$194$$$O	of$$$195$$$197$$$O	GPR119.$$$198$$$205$$$O
WO2009049208A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	nitric$$$7$$$13$$$I	oxide$$$14$$$19$$$I	to$$$20$$$22$$$O	enhance$$$23$$$30$$$O	the$$$31$$$34$$$O	efficacy$$$35$$$43$$$O	of$$$44$$$46$$$O	silver$$$47$$$53$$$O	and$$$54$$$57$$$O	other$$$58$$$63$$$O	topical$$$64$$$71$$$O	wound$$$72$$$77$$$O	care$$$78$$$82$$$O	agents$$$83$$$89$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	compositions$$$37$$$49$$$O	comprising$$$50$$$60$$$O	at$$$61$$$63$$$O	least$$$64$$$69$$$O	one$$$70$$$73$$$O	nitric$$$74$$$80$$$I	oxide$$$81$$$86$$$I	donor$$$87$$$92$$$O	and$$$93$$$96$$$O	at$$$97$$$99$$$O	least$$$100$$$105$$$O	one$$$106$$$109$$$O	second$$$110$$$116$$$O	therapeutically$$$117$$$132$$$O	active$$$133$$$139$$$O	agent$$$140$$$145$$$O	with$$$146$$$150$$$O	antimicrobial$$$151$$$164$$$O	or$$$165$$$167$$$O	wound$$$168$$$173$$$O	healing$$$174$$$181$$$O	capability.$$$182$$$193$$$O	In$$$194$$$196$$$O	one$$$197$$$200$$$O	embodiment,$$$201$$$212$$$O	the$$$213$$$216$$$O	nitric$$$217$$$223$$$I	oxide$$$224$$$229$$$I	donor$$$230$$$235$$$O	is$$$236$$$238$$$O	a$$$239$$$240$$$O	nanoparticle$$$241$$$253$$$O	which$$$254$$$259$$$O	is$$$260$$$262$$$O	designed$$$263$$$271$$$O	to$$$272$$$274$$$O	control$$$275$$$282$$$O	for$$$283$$$286$$$O	the$$$287$$$290$$$O	amount$$$291$$$297$$$O	and$$$298$$$301$$$O	duration$$$302$$$310$$$O	of$$$311$$$313$$$O	release$$$314$$$321$$$O	of$$$322$$$324$$$O	nitric$$$325$$$331$$$I	oxide.$$$332$$$338$$$I	The$$$339$$$342$$$O	nanoparticle$$$343$$$355$$$O	may$$$356$$$359$$$O	further$$$360$$$367$$$O	comprise$$$368$$$376$$$O	the$$$377$$$380$$$O	additional$$$381$$$391$$$O	therapeutically$$$392$$$407$$$O	active$$$408$$$414$$$O	agent.$$$415$$$421$$$O	The$$$422$$$425$$$O	composition$$$426$$$437$$$O	is$$$438$$$440$$$O	useful$$$441$$$447$$$O	for$$$448$$$451$$$O	enhancing$$$452$$$461$$$O	wound$$$462$$$467$$$O	healing$$$468$$$475$$$O	and$$$476$$$479$$$O	for$$$480$$$483$$$O	treating$$$484$$$492$$$O	and$$$493$$$496$$$O	preventing$$$497$$$507$$$O	microbial$$$508$$$517$$$O	infection.$$$518$$$528$$$O	In$$$529$$$531$$$O	one$$$532$$$535$$$O	embodiment,$$$536$$$547$$$O	the$$$548$$$551$$$O	composition$$$552$$$563$$$O	is$$$564$$$566$$$O	directed$$$567$$$575$$$O	toward$$$576$$$582$$$O	reducing$$$583$$$591$$$O	oral$$$592$$$596$$$O	bacteria$$$597$$$605$$$O	or$$$606$$$608$$$O	dental$$$609$$$615$$$O	plaque.$$$616$$$623$$$O	The$$$624$$$627$$$O	combination$$$628$$$639$$$O	of$$$640$$$642$$$O	one$$$643$$$646$$$O	or$$$647$$$649$$$O	more$$$650$$$654$$$O	nitric$$$655$$$661$$$I	oxide$$$662$$$667$$$I	donors$$$668$$$674$$$O	and$$$675$$$678$$$O	one$$$679$$$682$$$O	or$$$683$$$685$$$O	more$$$686$$$690$$$O	additional$$$691$$$701$$$O	therapeutically$$$702$$$717$$$O	active$$$718$$$724$$$O	agent$$$725$$$730$$$O	results$$$731$$$738$$$O	in$$$739$$$741$$$O	unexpected$$$742$$$752$$$O	synergistic$$$753$$$764$$$O	effects,$$$765$$$773$$$O	wherein$$$774$$$781$$$O	both$$$782$$$786$$$O	the$$$787$$$790$$$O	antimicrobial$$$791$$$804$$$O	efficacy$$$805$$$813$$$O	of$$$814$$$816$$$O	the$$$817$$$820$$$O	nitric$$$821$$$827$$$I	oxide$$$828$$$833$$$I	and$$$834$$$837$$$O	the$$$838$$$841$$$O	antimicrobial$$$842$$$855$$$O	or$$$856$$$858$$$O	wound$$$859$$$864$$$O	healing$$$865$$$872$$$O	efficacy$$$873$$$881$$$O	of$$$882$$$884$$$O	the$$$885$$$888$$$O	second$$$889$$$895$$$O	therapeutically$$$896$$$911$$$O	active$$$912$$$918$$$O	agent$$$919$$$924$$$O	are$$$925$$$928$$$O	enhanced.$$$929$$$938$$$O	As$$$939$$$941$$$O	a$$$942$$$943$$$O	result,$$$944$$$951$$$O	a$$$952$$$953$$$O	patient$$$954$$$961$$$O	may$$$962$$$965$$$O	benefit$$$966$$$973$$$O	from$$$974$$$978$$$O	reduced$$$979$$$986$$$O	dosage$$$987$$$993$$$O	requirements$$$994$$$1006$$$O	and$$$1007$$$1010$$$O	a$$$1011$$$1012$$$O	reduced$$$1013$$$1020$$$O	likelihood$$$1021$$$1031$$$O	of$$$1032$$$1034$$$O	antimicrobial$$$1035$$$1048$$$O	resistance.$$$1049$$$1060$$$O	The$$$1061$$$1064$$$O	composition$$$1065$$$1076$$$O	may$$$1077$$$1080$$$O	be$$$1081$$$1083$$$O	formulated$$$1084$$$1094$$$O	for$$$1095$$$1098$$$O	local$$$1099$$$1104$$$O	or$$$1105$$$1107$$$O	systemic$$$1108$$$1116$$$O	administration,$$$1117$$$1132$$$O	for$$$1133$$$1136$$$O	topical$$$1137$$$1144$$$O	applications$$$1145$$$1157$$$O	as$$$1158$$$1160$$$O	well$$$1161$$$1165$$$O	as$$$1166$$$1168$$$O	for$$$1169$$$1172$$$O	use$$$1173$$$1176$$$O	in$$$1177$$$1179$$$O	coatings$$$1180$$$1188$$$O	for$$$1189$$$1192$$$O	medical$$$1193$$$1200$$$O	supplies$$$1201$$$1209$$$O	and$$$1210$$$1213$$$O	devices.$$$1214$$$1222$$$O
CN102302482A
Morin-7-sodium$$$0$$$14$$$I	sulfate$$$15$$$22$$$I	for$$$23$$$26$$$O	inhibiting$$$27$$$37$$$O	enzymatic$$$38$$$47$$$O	activity$$$48$$$56$$$O	of$$$57$$$59$$$O	PRL-3$$$60$$$65$$$O	(phosphatase$$$66$$$78$$$O	of$$$79$$$81$$$O	regenerating$$$82$$$94$$$O	liver-3)$$$95$$$103$$$O	and$$$104$$$107$$$O	application$$$108$$$119$$$O	of$$$120$$$122$$$O	morin-7-$$$123$$$131$$$I	sodium$$$132$$$138$$$I	sulfate$$$139$$$146$$$I	in$$$147$$$149$$$O	medicines$$$150$$$159$$$O	for$$$160$$$163$$$O	resisting$$$164$$$173$$$O	tumor$$$174$$$179$$$O	metastasis$$$180$$$190$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	morin-7-sodium$$$25$$$39$$$I	sulfate$$$40$$$47$$$I	for$$$48$$$51$$$O	inhibiting$$$52$$$62$$$O	enzymatic$$$63$$$72$$$O	activity$$$73$$$81$$$O	of$$$82$$$84$$$O	PRL-3$$$85$$$90$$$O	(phosphatase$$$91$$$103$$$O	of$$$104$$$106$$$O	regenerating$$$107$$$119$$$O	liver-3)$$$120$$$128$$$O	and$$$129$$$132$$$O	application$$$133$$$144$$$O	of$$$145$$$147$$$O	the$$$148$$$151$$$O	morin-7-$$$152$$$160$$$I	sodium$$$161$$$167$$$I	sulfate$$$168$$$175$$$I	in$$$176$$$178$$$O	medicines$$$179$$$188$$$O	for$$$189$$$192$$$O	resisting$$$193$$$202$$$O	tumor$$$203$$$208$$$O	metastasis.$$$209$$$220$$$O	Human$$$221$$$226$$$O	PRL-3$$$227$$$232$$$O	protein$$$233$$$240$$$O	with$$$241$$$245$$$O	enzymatic$$$246$$$255$$$O	activity$$$256$$$264$$$O	is$$$265$$$267$$$O	obtained$$$268$$$276$$$O	through$$$277$$$284$$$O	a$$$285$$$286$$$O	gene$$$287$$$291$$$O	engineering$$$292$$$303$$$O	technology,$$$304$$$315$$$O	the$$$316$$$319$$$O	water-soluble$$$320$$$333$$$O	morin-7-sodium$$$334$$$348$$$I	sulfate$$$349$$$356$$$I	obtained$$$357$$$365$$$O	through$$$366$$$373$$$O	screening$$$374$$$383$$$O	has$$$384$$$387$$$O	an$$$388$$$390$$$O	obvious$$$391$$$398$$$O	inhibiting$$$399$$$409$$$O	effect$$$410$$$416$$$O	for$$$417$$$420$$$O	the$$$421$$$424$$$O	enzymatic$$$425$$$434$$$O	activity$$$435$$$443$$$O	of$$$444$$$446$$$O	the$$$447$$$450$$$O	PRL-3,$$$451$$$457$$$O	the$$$458$$$461$$$O	inhibiting$$$462$$$472$$$O	effect$$$473$$$479$$$O	of$$$480$$$482$$$O	the$$$483$$$486$$$O	morin-7-sodium$$$487$$$501$$$I	sulfate$$$502$$$509$$$I	is$$$510$$$512$$$O	stronger$$$513$$$521$$$O	than$$$522$$$526$$$O	that$$$527$$$531$$$O	of$$$532$$$534$$$O	parent$$$535$$$541$$$O	morin$$$542$$$547$$$I	of$$$548$$$550$$$O	the$$$551$$$554$$$O	morin-7-sodium$$$555$$$569$$$I	sulfate$$$570$$$577$$$I	and$$$578$$$581$$$O	is$$$582$$$584$$$O	also$$$585$$$589$$$O	superior$$$590$$$598$$$O	to$$$599$$$601$$$O	the$$$602$$$605$$$O	inhibiting$$$606$$$616$$$O	effects$$$617$$$624$$$O	of$$$625$$$627$$$O	other$$$628$$$633$$$O	compounds$$$634$$$643$$$O	or$$$644$$$646$$$O	natural$$$647$$$654$$$O	products,$$$655$$$664$$$O	a$$$665$$$666$$$O	Transwell$$$667$$$676$$$O	measurement$$$677$$$688$$$O	result$$$689$$$695$$$O	shows$$$696$$$701$$$O	that$$$702$$$706$$$O	the$$$707$$$710$$$O	compound$$$711$$$719$$$O	can$$$720$$$723$$$O	obviously$$$724$$$733$$$O	inhibit$$$734$$$741$$$O	the$$$742$$$745$$$O	invitro$$$746$$$753$$$O	invasive$$$754$$$762$$$O	capability$$$763$$$773$$$O	and$$$774$$$777$$$O	the$$$778$$$781$$$O	motility$$$782$$$790$$$O	of$$$791$$$793$$$O	a$$$794$$$795$$$O	tumour$$$796$$$802$$$O	cell,$$$803$$$808$$$O	and$$$809$$$812$$$O	a$$$813$$$814$$$O	Western$$$815$$$822$$$O	blot$$$823$$$827$$$O	and$$$828$$$831$$$O	fluorescence$$$832$$$844$$$O	quantitative$$$845$$$857$$$O	PCR$$$858$$$861$$$O	(polymerase$$$862$$$873$$$O	chain$$$874$$$879$$$O	reaction)$$$880$$$889$$$O	result$$$890$$$896$$$O	shows$$$897$$$902$$$O	that$$$903$$$907$$$O	the$$$908$$$911$$$O	compound$$$912$$$920$$$O	can$$$921$$$924$$$O	specifically$$$925$$$937$$$O	inhibit$$$938$$$945$$$O	the$$$946$$$949$$$O	PRL-3$$$950$$$955$$$O	protein$$$956$$$963$$$O	and$$$964$$$967$$$O	mRNA$$$968$$$972$$$O	(Messenger$$$973$$$983$$$O	RNA)$$$984$$$988$$$O	expression$$$989$$$999$$$O	rather$$$1000$$$1006$$$O	than$$$1007$$$1011$$$O	PRL-1$$$1012$$$1017$$$O	protein$$$1018$$$1025$$$O	and$$$1026$$$1029$$$O	PRL-2$$$1030$$$1035$$$O	protein$$$1036$$$1043$$$O	(same$$$1044$$$1049$$$O	species$$$1050$$$1057$$$O	as$$$1058$$$1060$$$O	the$$$1061$$$1064$$$O	PRL-3$$$1065$$$1070$$$O	protein)$$$1071$$$1079$$$O	and$$$1080$$$1083$$$O	mRNA$$$1084$$$1088$$$O	expression.$$$1089$$$1100$$$O	The$$$1101$$$1104$$$O	compound$$$1105$$$1113$$$O	provided$$$1114$$$1122$$$O	by$$$1123$$$1125$$$O	the$$$1126$$$1129$$$O	invention$$$1130$$$1139$$$O	has$$$1140$$$1143$$$O	higher$$$1144$$$1150$$$O	application$$$1151$$$1162$$$O	value$$$1163$$$1168$$$O	in$$$1169$$$1171$$$O	researching$$$1172$$$1183$$$O	the$$$1184$$$1187$$$O	effect$$$1188$$$1194$$$O	of$$$1195$$$1197$$$O	the$$$1198$$$1201$$$O	PRL-3$$$1202$$$1207$$$O	in$$$1208$$$1210$$$O	the$$$1211$$$1214$$$O	tumor$$$1215$$$1220$$$O	metastasis$$$1221$$$1231$$$O	and$$$1232$$$1235$$$O	designing,$$$1236$$$1246$$$O	researching$$$1247$$$1258$$$O	and$$$1259$$$1262$$$O	developing$$$1263$$$1273$$$O	the$$$1274$$$1277$$$O	medicines$$$1278$$$1287$$$O	for$$$1288$$$1291$$$O	resisting$$$1292$$$1301$$$O	the$$$1302$$$1305$$$O	tumor$$$1306$$$1311$$$O	metastasis,$$$1312$$$1323$$$O	can$$$1324$$$1327$$$O	be$$$1328$$$1330$$$O	applied$$$1331$$$1338$$$O	to$$$1339$$$1341$$$O	preparing$$$1342$$$1351$$$O	a$$$1352$$$1353$$$O	positive$$$1354$$$1362$$$O	control$$$1363$$$1370$$$O	reagent$$$1371$$$1378$$$O	or$$$1379$$$1381$$$O	compound$$$1382$$$1390$$$O	of$$$1391$$$1393$$$O	a$$$1394$$$1395$$$O	PRL-3$$$1396$$$1401$$$O	enzyme$$$1402$$$1408$$$O	inhibitor,$$$1409$$$1419$$$O	and$$$1420$$$1423$$$O	is$$$1424$$$1426$$$O	used$$$1427$$$1431$$$O	as$$$1432$$$1434$$$O	one$$$1435$$$1438$$$O	component$$$1439$$$1448$$$O	or$$$1449$$$1451$$$O	precursor$$$1452$$$1461$$$O	for$$$1462$$$1465$$$O	preparing$$$1466$$$1475$$$O	the$$$1476$$$1479$$$O	medicines$$$1480$$$1489$$$O	for$$$1490$$$1493$$$O	resisting$$$1494$$$1503$$$O	the$$$1504$$$1507$$$O	tumor$$$1508$$$1513$$$O	metastasis$$$1514$$$1524$$$O	in$$$1525$$$1527$$$O	medicine$$$1528$$$1536$$$O	development.$$$1537$$$1549$$$O
WO2006085562A1
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	preventing$$$16$$$26$$$O	and/or$$$27$$$33$$$O	treating$$$34$$$42$$$O	metabolic$$$43$$$52$$$O	syndrome$$$53$$$61$$$O	and$$$62$$$65$$$O	insulin$$$66$$$73$$$O	resistance$$$74$$$84$$$O	syndrome$$$85$$$93$$$O
It$$$0$$$2$$$O	is$$$3$$$5$$$O	intended$$$6$$$14$$$O	to$$$15$$$17$$$O	conveniently$$$18$$$30$$$O	and$$$31$$$34$$$O	efficiently$$$35$$$46$$$O	provide$$$47$$$54$$$O	a$$$55$$$56$$$O	specific$$$57$$$65$$$O	compound$$$66$$$74$$$O	originating$$$75$$$86$$$O	in$$$87$$$89$$$O	a$$$90$$$91$$$O	natural$$$92$$$99$$$O	material$$$100$$$108$$$O	and$$$109$$$112$$$O	a$$$113$$$114$$$O	composition$$$115$$$126$$$O	for$$$127$$$130$$$O	preventing$$$131$$$141$$$O	and/or$$$142$$$148$$$O	treating$$$149$$$157$$$O	metabolic$$$158$$$167$$$O	syndrome$$$168$$$176$$$O	and$$$177$$$180$$$O	insulin$$$181$$$188$$$O	resistance$$$189$$$199$$$O	syndrome$$$200$$$208$$$O	characterized$$$209$$$222$$$O	by$$$223$$$225$$$O	containing$$$226$$$236$$$O	the$$$237$$$240$$$O	above$$$241$$$246$$$O	compound$$$247$$$255$$$O	as$$$256$$$258$$$O	the$$$259$$$262$$$O	active$$$263$$$269$$$O	ingredient.$$$270$$$281$$$O	Namely,$$$282$$$289$$$O	a$$$290$$$291$$$O	composition$$$292$$$303$$$O	for$$$304$$$307$$$O	preventing$$$308$$$318$$$O	and/or$$$319$$$325$$$O	treating$$$326$$$334$$$O	metabolic$$$335$$$344$$$O	syndrome$$$345$$$353$$$O	and$$$354$$$357$$$O	insulin$$$358$$$365$$$O	resistance$$$366$$$376$$$O	syndrome$$$377$$$385$$$O	which$$$386$$$391$$$O	contains,$$$392$$$401$$$O	as$$$402$$$404$$$O	the$$$405$$$408$$$O	active$$$409$$$415$$$O	ingredient,$$$416$$$427$$$O	at$$$428$$$430$$$O	least$$$431$$$436$$$O	one$$$437$$$440$$$O	compound$$$441$$$449$$$O	selected$$$450$$$458$$$O	from$$$459$$$463$$$O	among$$$464$$$469$$$O	the$$$470$$$473$$$O	compound$$$474$$$482$$$O	represented$$$483$$$494$$$O	by$$$495$$$497$$$O	the$$$498$$$501$$$O	formula$$$502$$$509$$$O	(1),$$$510$$$514$$$O	the$$$515$$$518$$$O	compound$$$519$$$527$$$O	represented$$$528$$$539$$$O	by$$$540$$$542$$$O	the$$$543$$$546$$$O	formula$$$547$$$554$$$O	(4)$$$555$$$558$$$O	and$$$559$$$562$$$O	the$$$563$$$566$$$O	compound$$$567$$$575$$$O	represented$$$576$$$587$$$O	by$$$588$$$590$$$O	the$$$591$$$594$$$O	formula$$$595$$$602$$$O	(5)$$$603$$$606$$$O	or$$$607$$$609$$$O	a$$$610$$$611$$$O	salt$$$612$$$616$$$O	or$$$617$$$619$$$O	an$$$620$$$622$$$O	ester$$$623$$$628$$$O	of$$$629$$$631$$$O	the$$$632$$$635$$$O	same.$$$636$$$641$$$O
CA2623733A1
Supplements$$$0$$$11$$$O	for$$$12$$$15$$$O	pain$$$16$$$20$$$O	management$$$21$$$31$$$O
Dietary$$$0$$$7$$$O	supplements,$$$8$$$20$$$O	compositions$$$21$$$33$$$O	and$$$34$$$37$$$O	methods$$$38$$$45$$$O	of$$$46$$$48$$$O	administering$$$49$$$62$$$O	the$$$63$$$66$$$O	supplements$$$67$$$78$$$O	to$$$79$$$81$$$O	reduce$$$82$$$88$$$O	pain,$$$89$$$94$$$O	inflammation$$$95$$$107$$$O	and$$$108$$$111$$$O	stiffness$$$112$$$121$$$O	in$$$122$$$124$$$O	said$$$125$$$129$$$O	mammal$$$130$$$136$$$O	within$$$137$$$143$$$O	a$$$144$$$145$$$O	few$$$146$$$149$$$O	hours.$$$150$$$156$$$O	The$$$157$$$160$$$O	supplements$$$161$$$172$$$O	and$$$173$$$176$$$O	compositions$$$177$$$189$$$O	can$$$190$$$193$$$O	include$$$194$$$201$$$O	a$$$202$$$203$$$O	combination$$$204$$$215$$$O	of$$$216$$$218$$$O	an$$$219$$$221$$$O	amino$$$222$$$227$$$I	acid,$$$228$$$233$$$I	vitamins,$$$234$$$243$$$O	herbs$$$244$$$249$$$O	and$$$250$$$253$$$O	enzymes.$$$254$$$262$$$O	The$$$263$$$266$$$O	composition/supplement$$$267$$$289$$$O	can$$$290$$$293$$$O	be$$$294$$$296$$$O	put$$$297$$$300$$$O	in$$$301$$$303$$$O	capsule$$$304$$$311$$$O	form$$$312$$$316$$$O	and$$$317$$$320$$$O	when$$$321$$$325$$$O	administered$$$326$$$338$$$O	to$$$339$$$341$$$O	mammals$$$342$$$349$$$O	can$$$350$$$353$$$O	reduce$$$354$$$360$$$O	these$$$361$$$366$$$O	symptoms$$$367$$$375$$$O	with$$$376$$$380$$$O	approximately$$$381$$$394$$$O	two$$$395$$$398$$$O	hours.$$$399$$$405$$$O	reducing$$$406$$$414$$$O	the$$$415$$$418$$$O	pain$$$419$$$423$$$O	and$$$424$$$427$$$O	inflammation$$$428$$$440$$$O	associated$$$441$$$451$$$O	with$$$452$$$456$$$O	chronic$$$457$$$464$$$O	joint$$$465$$$470$$$O	discomfort,$$$471$$$482$$$O	chronic$$$483$$$490$$$O	low$$$491$$$494$$$O	back$$$495$$$499$$$O	pain,$$$500$$$505$$$O	muscle$$$506$$$512$$$O	strain,$$$513$$$520$$$O	arthritis,$$$521$$$531$$$O	sports$$$532$$$538$$$O	injuries,$$$539$$$548$$$O	normal$$$549$$$555$$$O	everyday$$$556$$$564$$$O	bumps$$$565$$$570$$$O	and$$$571$$$574$$$O	bruises.$$$575$$$583$$$O	The$$$584$$$587$$$O	novel$$$588$$$593$$$O	composition$$$594$$$605$$$O	has$$$606$$$609$$$O	also$$$610$$$614$$$O	been$$$615$$$619$$$O	shown$$$620$$$625$$$O	to$$$626$$$628$$$O	be$$$629$$$631$$$O	very$$$632$$$636$$$O	effective$$$637$$$646$$$O	in$$$647$$$649$$$O	reducing$$$650$$$658$$$O	monthly$$$659$$$666$$$O	menstrual$$$667$$$676$$$O	symptoms$$$677$$$685$$$O	(PMS).$$$686$$$692$$$O	The$$$693$$$696$$$O	novel$$$697$$$702$$$O	composition$$$703$$$714$$$O	can$$$715$$$718$$$O	also$$$719$$$723$$$O	have$$$724$$$728$$$O	benefits$$$729$$$737$$$O	for$$$738$$$741$$$O	other$$$742$$$747$$$O	ailments$$$748$$$756$$$O	such$$$757$$$761$$$O	as$$$762$$$764$$$O	but$$$765$$$768$$$O	not$$$769$$$772$$$O	limited$$$773$$$780$$$O	to$$$781$$$783$$$O	Osteoarthritis,$$$784$$$799$$$O	Cardiovascular$$$800$$$814$$$O	disease,$$$815$$$823$$$O	Neurological$$$824$$$836$$$O	ailments,$$$837$$$846$$$O	Alzheimer$$$847$$$856$$$O	disease,$$$857$$$865$$$O	and$$$866$$$869$$$O	Cancer.$$$870$$$877$$$O
WO2005095369A1
Water$$$0$$$5$$$O	soluble$$$6$$$13$$$O	esters$$$14$$$20$$$I	of$$$21$$$23$$$O	[n-(4-amino-2-butynyl)]$$$24$$$47$$$I	with$$$48$$$52$$$O	anticancer$$$53$$$63$$$O	activity$$$64$$$72$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	water$$$33$$$38$$$O	soluble$$$39$$$46$$$O	esters$$$47$$$53$$$I	of$$$54$$$56$$$O	[N-(4-amino-2-butynyl)]$$$57$$$80$$$I	or$$$81$$$83$$$O	4-(N-substituted$$$84$$$100$$$I	amino)-2-butynyl-1-esters$$$101$$$126$$$I	and$$$127$$$130$$$O	methods$$$131$$$138$$$O	for$$$139$$$142$$$O	production$$$143$$$153$$$O	of$$$154$$$156$$$O	said$$$157$$$161$$$O	esters$$$162$$$168$$$I	and$$$169$$$172$$$O	the$$$173$$$176$$$O	use$$$177$$$180$$$O	of$$$181$$$183$$$O	the$$$184$$$187$$$O	esters$$$188$$$194$$$O	for$$$195$$$198$$$O	treatment$$$199$$$208$$$O	of$$$209$$$211$$$O	cancer.$$$212$$$219$$$O
US20100324078
Crystalline$$$0$$$11$$$O	Forms$$$12$$$17$$$O	of$$$18$$$20$$$O	Naltrexone$$$21$$$31$$$I	Methobromide$$$32$$$44$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	crystalline$$$39$$$50$$$O	forms$$$51$$$56$$$O	of$$$57$$$59$$$O	naltrexone$$$60$$$70$$$I	methobromide$$$71$$$83$$$I	including$$$84$$$93$$$O	hydrated$$$94$$$102$$$O	and$$$103$$$106$$$O	solvated$$$107$$$115$$$O	forms.$$$116$$$122$$$O	The$$$123$$$126$$$O	invention$$$127$$$136$$$O	also$$$137$$$141$$$O	describes$$$142$$$151$$$O	methods$$$152$$$159$$$O	of$$$160$$$162$$$O	preparing$$$163$$$172$$$O	the$$$173$$$176$$$O	various$$$177$$$184$$$O	crystalline$$$185$$$196$$$O	forms.$$$197$$$203$$$O	The$$$204$$$207$$$O	present$$$208$$$215$$$O	invention$$$216$$$225$$$O	also$$$226$$$230$$$O	relates$$$231$$$238$$$O	to$$$239$$$241$$$O	pharmaceutical$$$242$$$256$$$O	compositions$$$257$$$269$$$O	containing$$$270$$$280$$$O	crystalline$$$281$$$292$$$O	forms$$$293$$$298$$$O	of$$$299$$$301$$$O	naltrexone$$$302$$$312$$$I	methobromide,$$$313$$$326$$$I	as$$$327$$$329$$$O	well$$$330$$$334$$$O	as$$$335$$$337$$$O	methods$$$338$$$345$$$O	of$$$346$$$348$$$O	treating$$$349$$$357$$$O	or$$$358$$$360$$$O	preventing$$$361$$$371$$$O	opioid$$$372$$$378$$$O	induced$$$379$$$386$$$O	side$$$387$$$391$$$O	effects$$$392$$$399$$$O	by$$$400$$$402$$$O	administering$$$403$$$416$$$O	the$$$417$$$420$$$O	pharmaceutical$$$421$$$435$$$O	compositions.$$$436$$$449$$$O
US20120004265
Ophthalmic$$$0$$$10$$$O	Compositions$$$11$$$23$$$O	and$$$24$$$27$$$O	Methods$$$28$$$35$$$O	of$$$36$$$38$$$O	Using$$$39$$$44$$$O	the$$$45$$$48$$$O	Same$$$49$$$53$$$O
Ophthalmic$$$0$$$10$$$O	compositions$$$11$$$23$$$O	are$$$24$$$27$$$O	provided$$$28$$$36$$$O	that$$$37$$$41$$$O	comprise$$$42$$$50$$$O	or$$$51$$$53$$$O	consist$$$54$$$61$$$O	essentially$$$62$$$73$$$O	of$$$74$$$76$$$O	(a)$$$77$$$80$$$O	ketotifen$$$81$$$90$$$I	or$$$91$$$93$$$O	a$$$94$$$95$$$O	ketotifen$$$96$$$105$$$I	salt,$$$106$$$111$$$O	(b)$$$112$$$115$$$O	a$$$116$$$117$$$O	non-ionic$$$118$$$127$$$O	tonicity$$$128$$$136$$$O	agent,$$$137$$$143$$$O	and$$$144$$$147$$$O	(c)$$$148$$$151$$$O	water.$$$152$$$158$$$O	The$$$159$$$162$$$O	concentration$$$163$$$176$$$O	of$$$177$$$179$$$O	ketotifen$$$180$$$189$$$I	or$$$190$$$192$$$O	the$$$193$$$196$$$O	ketotifen$$$197$$$206$$$I	salt$$$207$$$211$$$O	is$$$212$$$214$$$O	preferably$$$215$$$225$$$O	from$$$226$$$230$$$O	0.01%$$$231$$$236$$$O	to$$$237$$$239$$$O	0.05%.$$$240$$$246$$$O	The$$$247$$$250$$$O	non-ionic$$$251$$$260$$$O	tonicity$$$261$$$269$$$O	agent$$$270$$$275$$$O	is$$$276$$$278$$$O	preferably$$$279$$$289$$$O	glycerol$$$290$$$298$$$I	and$$$299$$$302$$$O	the$$$303$$$306$$$O	concentration$$$307$$$320$$$O	of$$$321$$$323$$$O	the$$$324$$$327$$$O	glycerol$$$328$$$336$$$I	is$$$337$$$339$$$O	preferably$$$340$$$350$$$O	from$$$351$$$355$$$O	4%$$$356$$$358$$$O	to$$$359$$$361$$$O	7%.$$$362$$$365$$$O	The$$$366$$$369$$$O	compositions$$$370$$$382$$$O	preferably$$$383$$$393$$$O	have$$$394$$$398$$$O	an$$$399$$$401$$$O	osmolality$$$402$$$412$$$O	of$$$413$$$415$$$O	from$$$416$$$420$$$O	400$$$421$$$424$$$O	to$$$425$$$427$$$O	875$$$428$$$431$$$O	milliosmoles/Kg.$$$432$$$448$$$O	The$$$449$$$452$$$O	compositions$$$453$$$465$$$O	may$$$466$$$469$$$O	also$$$470$$$474$$$O	contain$$$475$$$482$$$O	an$$$483$$$485$$$O	anti-redness$$$486$$$498$$$O	agent.$$$499$$$505$$$O	Methods$$$506$$$513$$$O	of$$$514$$$516$$$O	treating$$$517$$$525$$$O	allergic$$$526$$$534$$$O	conjunctivitis$$$535$$$549$$$O	using$$$550$$$555$$$O	the$$$556$$$559$$$O	ophthalmic$$$560$$$570$$$O	compositions$$$571$$$583$$$O	and$$$584$$$587$$$O	methods$$$588$$$595$$$O	of$$$596$$$598$$$O	treating$$$599$$$607$$$O	dry$$$608$$$611$$$O	eye$$$612$$$615$$$O	disease$$$616$$$623$$$O	using$$$624$$$629$$$O	the$$$630$$$633$$$O	ophthalmic$$$634$$$644$$$O	compositions$$$645$$$657$$$O	are$$$658$$$661$$$O	also$$$662$$$666$$$O	provided.$$$667$$$676$$$O
US20090061008
Fiber/granule$$$0$$$13$$$O	complex$$$14$$$21$$$O	for$$$22$$$25$$$O	treatment$$$26$$$35$$$O	of$$$36$$$38$$$O	the$$$39$$$42$$$O	gi$$$43$$$45$$$O	tract$$$46$$$51$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	a$$$22$$$23$$$O	gastrointestinal$$$24$$$40$$$O	(GI)$$$41$$$45$$$O	tract$$$46$$$51$$$O	including$$$52$$$61$$$O	providing$$$62$$$71$$$O	a$$$72$$$73$$$O	fiber/granule$$$74$$$87$$$O	complex$$$88$$$95$$$O	made$$$96$$$100$$$O	of$$$101$$$103$$$O	non-absorbable$$$104$$$118$$$O	fibers$$$119$$$125$$$O	having$$$126$$$132$$$O	granules$$$133$$$141$$$O	attached$$$142$$$150$$$O	thereto,$$$151$$$159$$$O	and$$$160$$$163$$$O	ingesting$$$164$$$173$$$O	the$$$174$$$177$$$O	fiber/granule$$$178$$$191$$$O	complex$$$192$$$199$$$O	orally,$$$200$$$207$$$O	wherein$$$208$$$215$$$O	the$$$216$$$219$$$O	fiber/granule$$$220$$$233$$$O	complex$$$234$$$241$$$O	treats$$$242$$$248$$$O	materials$$$249$$$258$$$O	in$$$259$$$261$$$O	the$$$262$$$265$$$O	GI$$$266$$$268$$$O	tract$$$269$$$274$$$O	as$$$275$$$277$$$O	it$$$278$$$280$$$O	passes$$$281$$$287$$$O	through$$$288$$$295$$$O	the$$$296$$$299$$$O	GI$$$300$$$302$$$O	tract,$$$303$$$309$$$O	the$$$310$$$313$$$O	fiber/granule$$$314$$$327$$$O	complex$$$328$$$335$$$O	not$$$336$$$339$$$O	being$$$340$$$345$$$O	substantially$$$346$$$359$$$O	absorbed$$$360$$$368$$$O	by$$$369$$$371$$$O	the$$$372$$$375$$$O	GI$$$376$$$378$$$O	tract.$$$379$$$385$$$O
EP1978968A2
Cationic$$$0$$$8$$$O	steroid$$$9$$$16$$$I	antimicrobial$$$17$$$30$$$O	compositions$$$31$$$43$$$O	for$$$44$$$47$$$O	treating$$$48$$$56$$$O	or$$$57$$$59$$$O	preventing$$$60$$$70$$$O	hiv$$$71$$$74$$$O	infections$$$75$$$85$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	methods$$$23$$$30$$$O	for$$$31$$$34$$$O	decreasing$$$35$$$45$$$O	or$$$46$$$48$$$O	inhibiting$$$49$$$59$$$O	human$$$60$$$65$$$O	immunodeficiency$$$66$$$82$$$O	virus$$$83$$$88$$$O	(HIV)$$$89$$$94$$$O	infection$$$95$$$104$$$O	or$$$105$$$107$$$O	pathogenesis$$$108$$$120$$$O	(e.g.,$$$121$$$127$$$O	illness)$$$128$$$136$$$O	of$$$137$$$139$$$O	a$$$140$$$141$$$O	cell$$$142$$$146$$$O	in$$$147$$$149$$$O	vitro,$$$150$$$156$$$O	ex$$$157$$$159$$$O	vivo$$$160$$$164$$$O	or$$$165$$$167$$$O	in$$$168$$$170$$$O	vivo,$$$171$$$176$$$O	a$$$177$$$178$$$O	symptom$$$179$$$186$$$O	or$$$187$$$189$$$O	pathology$$$190$$$199$$$O	associated$$$200$$$210$$$O	with$$$211$$$215$$$O	human$$$216$$$221$$$O	immunodeficiency$$$222$$$238$$$O	virus$$$239$$$244$$$O	(HIV)$$$245$$$250$$$O	infection$$$251$$$260$$$O	or$$$261$$$263$$$O	pathogenesis$$$264$$$276$$$O	(e.g.,$$$277$$$283$$$O	illness)$$$284$$$292$$$O	in$$$293$$$295$$$O	vitro,$$$296$$$302$$$O	ex$$$303$$$305$$$O	vivo$$$306$$$310$$$O	or$$$311$$$313$$$O	in$$$314$$$316$$$O	vivo,$$$317$$$322$$$O	or$$$323$$$325$$$O	an$$$326$$$328$$$O	adverse$$$329$$$336$$$O	side$$$337$$$341$$$O	effect$$$342$$$348$$$O	of$$$349$$$351$$$O	human$$$352$$$357$$$O	immunodeficiency$$$358$$$374$$$O	virus$$$375$$$380$$$O	(HTV)$$$381$$$386$$$O	infection$$$387$$$396$$$O	or$$$397$$$399$$$O	pathogenesis$$$400$$$412$$$O	(e.g$$$413$$$417$$$O	,$$$418$$$419$$$O	illness)$$$420$$$428$$$O	in$$$429$$$431$$$O	vitro,$$$432$$$438$$$O	ex$$$439$$$441$$$O	vivo$$$442$$$446$$$O	or$$$447$$$449$$$O	in$$$450$$$452$$$O	vivo.$$$453$$$458$$$O	In$$$459$$$461$$$O	one$$$462$$$465$$$O	embodiment,$$$466$$$477$$$O	a$$$478$$$479$$$O	method$$$480$$$486$$$O	of$$$487$$$489$$$O	the$$$490$$$493$$$O	invention$$$494$$$503$$$O	includes$$$504$$$512$$$O	treating$$$513$$$521$$$O	a$$$522$$$523$$$O	subject$$$524$$$531$$$O	with$$$532$$$536$$$O	an$$$537$$$539$$$O	invention$$$540$$$549$$$O	compound$$$550$$$558$$$O	(e.g.,$$$559$$$565$$$O	cationic$$$566$$$574$$$O	steroid$$$575$$$582$$$I	antimicrobial$$$583$$$596$$$O	or$$$597$$$599$$$O	CSA).$$$600$$$605$$$O
WO2010135714A2
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	modulating$$$12$$$22$$$O	adipocyte$$$23$$$32$$$O	expression$$$33$$$43$$$O	using$$$44$$$49$$$O	microrna$$$50$$$58$$$O	compositions$$$59$$$71$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	compositions$$$14$$$26$$$O	and$$$27$$$30$$$O	methods$$$31$$$38$$$O	useful$$$39$$$45$$$O	for$$$46$$$49$$$O	modulating$$$50$$$60$$$O	adipocyte$$$61$$$70$$$O	differentiation$$$71$$$86$$$O	and/or$$$87$$$93$$$O	development.$$$94$$$106$$$O	Also$$$107$$$111$$$O	disclosed$$$112$$$121$$$O	are$$$122$$$125$$$O	compounds,$$$126$$$136$$$O	compositions,$$$137$$$150$$$O	and$$$151$$$154$$$O	methods$$$155$$$162$$$O	useful$$$163$$$169$$$O	for$$$170$$$173$$$O	altering$$$174$$$182$$$O	the$$$183$$$186$$$O	expression$$$187$$$197$$$O	and/or$$$198$$$204$$$O	activity$$$205$$$213$$$O	of$$$214$$$216$$$O	one$$$217$$$220$$$O	or$$$221$$$223$$$O	more$$$224$$$228$$$O	genes$$$229$$$234$$$O	involved$$$235$$$243$$$O	in$$$244$$$246$$$O	pathways$$$247$$$255$$$O	relating$$$256$$$264$$$O	to$$$265$$$267$$$O	adipogenesis$$$268$$$280$$$O	and/or$$$281$$$287$$$O	adipocyte$$$288$$$297$$$O	activity$$$298$$$306$$$O	both$$$307$$$311$$$O	in$$$312$$$314$$$O	vitro$$$315$$$320$$$O	and$$$321$$$324$$$O	in$$$325$$$327$$$O	vivo.$$$328$$$333$$$O	In$$$334$$$336$$$O	particular,$$$337$$$348$$$O	the$$$349$$$352$$$O	present$$$353$$$360$$$O	invention$$$361$$$370$$$O	provides$$$371$$$379$$$O	small$$$380$$$385$$$O	interfering$$$386$$$397$$$O	nucleic$$$398$$$405$$$O	acid$$$406$$$410$$$O	molecules,$$$411$$$421$$$O	and$$$422$$$425$$$O	in$$$426$$$428$$$O	particular,$$$429$$$440$$$O	micro-$$$441$$$447$$$O	RNA$$$448$$$451$$$O	and$$$452$$$455$$$O	miR-155-derived$$$456$$$471$$$O	molecules,$$$472$$$482$$$O	and$$$483$$$486$$$O	methods$$$487$$$494$$$O	for$$$495$$$498$$$O	their$$$499$$$504$$$O	use$$$505$$$508$$$O	in$$$509$$$511$$$O	altering$$$512$$$520$$$O	the$$$521$$$524$$$O	expression,$$$525$$$536$$$O	regulation,$$$537$$$548$$$O	or$$$549$$$551$$$O	accumulation$$$552$$$564$$$O	of$$$565$$$567$$$O	one$$$568$$$571$$$O	or$$$572$$$574$$$O	more$$$575$$$579$$$O	adipogenic$$$580$$$590$$$O	or$$$591$$$593$$$O	anti-adipogenic$$$594$$$609$$$O	genes$$$610$$$615$$$O	or$$$616$$$618$$$O	a$$$619$$$620$$$O	gene$$$621$$$625$$$O	products$$$626$$$634$$$O	in$$$635$$$637$$$O	a$$$638$$$639$$$O	mammal,$$$640$$$647$$$O
CN101045704A
An$$$0$$$2$$$O	improved$$$3$$$11$$$O	process$$$12$$$19$$$O	for$$$20$$$23$$$O	preparing$$$24$$$33$$$O	pure$$$34$$$38$$$O	ondansetron$$$39$$$50$$$I	hydrochloride$$$51$$$64$$$I	dihydrate$$$65$$$74$$$I
An$$$0$$$2$$$O	improved$$$3$$$11$$$O	method$$$12$$$18$$$O	for$$$19$$$22$$$O	preparing$$$23$$$32$$$O	dimethylamino-methyl-carbazolone$$$33$$$65$$$I	and$$$66$$$69$$$O	ondansetron$$$70$$$81$$$I	base.$$$82$$$87$$$O	A$$$88$$$89$$$O	recrystallization$$$90$$$107$$$O	process$$$108$$$115$$$O	for$$$116$$$119$$$O	preparing$$$120$$$129$$$O	pure$$$130$$$134$$$O	ondansetron$$$135$$$146$$$I	hydrochloride$$$147$$$160$$$I	dihydrate$$$161$$$170$$$I	with$$$171$$$175$$$O	a$$$176$$$177$$$O	purity$$$178$$$184$$$O	of$$$185$$$187$$$O	at$$$188$$$190$$$O	least$$$191$$$196$$$O	99.0%$$$197$$$202$$$O	is$$$203$$$205$$$O	also$$$206$$$210$$$O	disclosed.$$$211$$$221$$$O
CN1813713A
Solution$$$0$$$8$$$O	type$$$9$$$13$$$O	potassium$$$14$$$23$$$I	sodium$$$24$$$30$$$I	dehydroandroan$$$31$$$45$$$I	drographolide$$$46$$$59$$$I	succinate$$$60$$$69$$$I	injection$$$70$$$79$$$O	and$$$80$$$83$$$O	its$$$84$$$87$$$O	preparing$$$88$$$97$$$O	method$$$98$$$104$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	Yanhuning$$$36$$$45$$$O	injection$$$46$$$55$$$O	and$$$56$$$59$$$O	its$$$60$$$63$$$O	preparation$$$64$$$75$$$O	method.$$$76$$$83$$$O	Said$$$84$$$88$$$O	invention$$$89$$$98$$$O	provides$$$99$$$107$$$O	a$$$108$$$109$$$O	solution$$$110$$$118$$$O	type$$$119$$$123$$$O	Yanhuning$$$124$$$133$$$O	injection,$$$134$$$144$$$O	at$$$145$$$147$$$O	the$$$148$$$151$$$O	same$$$152$$$156$$$O	time$$$157$$$161$$$O	provides$$$162$$$170$$$O	an$$$171$$$173$$$O	Yanhuning$$$174$$$183$$$O	infusion$$$184$$$192$$$O	preparation$$$193$$$204$$$O	which$$$205$$$210$$$O	has$$$211$$$214$$$O	no$$$215$$$217$$$O	need$$$218$$$222$$$O	of$$$223$$$225$$$O	dilution$$$226$$$234$$$O	and$$$235$$$238$$$O	can$$$239$$$242$$$O	be$$$243$$$245$$$O	directly$$$246$$$254$$$O	used$$$255$$$259$$$O	for$$$260$$$263$$$O	intravenous$$$264$$$275$$$O	injection$$$276$$$285$$$O	Besides,$$$286$$$294$$$O	said$$$295$$$299$$$O	invention$$$300$$$309$$$O	also$$$310$$$314$$$O	provides$$$315$$$323$$$O	their$$$324$$$329$$$O	preparation$$$330$$$341$$$O	method.$$$342$$$349$$$O
CN102743363A
Product$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	skin$$$21$$$25$$$O	diseases$$$26$$$34$$$O	caused$$$35$$$41$$$O	by$$$42$$$44$$$O	Malassezia$$$45$$$55$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	product$$$25$$$32$$$O	for$$$33$$$36$$$O	treating$$$37$$$45$$$O	skin$$$46$$$50$$$O	diseases$$$51$$$59$$$O	caused$$$60$$$66$$$O	by$$$67$$$69$$$O	Malassezia,$$$70$$$81$$$O	and$$$82$$$85$$$O	medicines$$$86$$$95$$$O	and$$$96$$$99$$$O	daily$$$100$$$105$$$O	chemical$$$106$$$114$$$O	products$$$115$$$123$$$O	of$$$124$$$126$$$O	honokiol,$$$127$$$136$$$I	wherein$$$137$$$144$$$O	the$$$145$$$148$$$O	product$$$149$$$156$$$O	treats$$$157$$$163$$$O	honokiol$$$164$$$172$$$I	or$$$173$$$175$$$O	its$$$176$$$179$$$O	derivative$$$180$$$190$$$O	as$$$191$$$193$$$O	an$$$194$$$196$$$O	active$$$197$$$203$$$O	component;$$$204$$$214$$$O	and$$$215$$$218$$$O	the$$$219$$$222$$$O	medicines$$$223$$$232$$$O	and$$$233$$$236$$$O	the$$$237$$$240$$$O	daily$$$241$$$246$$$O	chemical$$$247$$$255$$$O	products$$$256$$$264$$$O	are$$$265$$$268$$$O	prepared$$$269$$$277$$$O	through$$$278$$$285$$$O	dispersing$$$286$$$296$$$O	the$$$297$$$300$$$O	honokiol$$$301$$$309$$$I	or$$$310$$$312$$$O	its$$$313$$$316$$$O	derivative$$$317$$$327$$$O	in$$$328$$$330$$$O	medicine$$$331$$$339$$$O	carriers.$$$340$$$349$$$O	Above$$$350$$$355$$$O	medicaments$$$356$$$367$$$O	provided$$$368$$$376$$$O	by$$$377$$$379$$$O	the$$$380$$$383$$$O	invention$$$384$$$393$$$O	can$$$394$$$397$$$O	effectively$$$398$$$409$$$O	inhibit$$$410$$$417$$$O	the$$$418$$$421$$$O	breeding$$$422$$$430$$$O	of$$$431$$$433$$$O	the$$$434$$$437$$$O	Malassezia,$$$438$$$449$$$O	have$$$450$$$454$$$O	the$$$455$$$458$$$O	advantages$$$459$$$469$$$O	of$$$470$$$472$$$O	low$$$473$$$476$$$O	toxicity$$$477$$$485$$$O	and$$$486$$$489$$$O	high$$$490$$$494$$$O	medicine$$$495$$$503$$$O	effect$$$504$$$510$$$O	efficiency,$$$511$$$522$$$O	and$$$523$$$526$$$O	have$$$527$$$531$$$O	wide$$$532$$$536$$$O	application$$$537$$$548$$$O	prospects.$$$549$$$559$$$O
CN1817153A
Preparation$$$0$$$11$$$O	of$$$12$$$14$$$O	digestive$$$15$$$24$$$O	and$$$25$$$28$$$O	Yiwei$$$29$$$34$$$O	milk$$$35$$$39$$$O	powder$$$40$$$46$$$O	with$$$47$$$51$$$O	micro-meter$$$52$$$63$$$O	Huaguoshan$$$64$$$74$$$O	and$$$75$$$78$$$O	golden$$$79$$$85$$$O	monkey$$$86$$$92$$$O	sugar$$$93$$$98$$$I
A$$$0$$$1$$$O	micron-class$$$2$$$14$$$O	milk$$$15$$$19$$$O	powder$$$20$$$26$$$O	for$$$27$$$30$$$O	helping$$$31$$$38$$$O	digestion$$$39$$$48$$$O	and$$$49$$$52$$$O	nourishing$$$53$$$63$$$O	stomach$$$64$$$71$$$O	is$$$72$$$74$$$O	prepared$$$75$$$83$$$O	from$$$84$$$88$$$O	traditional$$$89$$$100$$$O	milk$$$101$$$105$$$O	powder,$$$106$$$113$$$O	oligose$$$114$$$121$$$I	and$$$122$$$125$$$O	the$$$126$$$129$$$O	micron$$$130$$$136$$$O	class$$$137$$$142$$$O	superfine$$$143$$$152$$$O	particles$$$153$$$162$$$O	of$$$163$$$165$$$O	pine$$$166$$$170$$$O	pollen,$$$171$$$178$$$O	bee$$$179$$$182$$$O	pollen,$$$183$$$190$$$O	fig,$$$191$$$195$$$O	haw,$$$196$$$200$$$O	chickenÃ­Â»s$$$201$$$213$$$O	gizzard-skin,$$$214$$$227$$$O	hedgehog$$$228$$$236$$$O	hydnum$$$237$$$243$$$O	and$$$244$$$247$$$O	radish$$$248$$$254$$$O	seed.$$$255$$$260$$$O	Its$$$261$$$264$$$O	advantages$$$265$$$275$$$O	are$$$276$$$279$$$O	high$$$280$$$284$$$O	effect$$$285$$$291$$$O	to$$$292$$$294$$$O	relieve$$$295$$$302$$$O	fatigue$$$303$$$310$$$O	and$$$311$$$314$$$O	improve$$$315$$$322$$$O	immunity$$$323$$$331$$$O	and$$$332$$$335$$$O	rich$$$336$$$340$$$O	nutrients$$$341$$$350$$$O	including$$$351$$$360$$$O	protein,$$$361$$$369$$$I	vitamins,$$$370$$$379$$$I	minerals,$$$380$$$389$$$I	active$$$390$$$396$$$O	enzymes,$$$397$$$405$$$O	etc.$$$406$$$410$$$O
US20090137482
Biologically$$$0$$$12$$$O	active$$$13$$$19$$$O	peptide$$$20$$$27$$$O	and$$$28$$$31$$$O	agent$$$32$$$37$$$O	containing$$$38$$$48$$$O	the$$$49$$$52$$$O	same$$$53$$$57$$$O
A$$$0$$$1$$$O	peptide$$$2$$$9$$$O	having$$$10$$$16$$$O	any$$$17$$$20$$$O	one$$$21$$$24$$$O	of$$$25$$$27$$$O	the$$$28$$$31$$$O	amino$$$32$$$37$$$I	acid$$$38$$$42$$$I	sequences$$$43$$$52$$$O	of$$$53$$$55$$$O	SEQ$$$56$$$59$$$O	ID$$$60$$$62$$$O	NO:$$$63$$$66$$$O	1$$$67$$$68$$$O	or$$$69$$$71$$$O	13,$$$72$$$75$$$O	preferably$$$76$$$86$$$O	a$$$87$$$88$$$O	peptide$$$89$$$96$$$O	having$$$97$$$103$$$O	any$$$104$$$107$$$O	one$$$108$$$111$$$O	of$$$112$$$114$$$O	the$$$115$$$118$$$O	amino$$$119$$$124$$$I	acid$$$125$$$129$$$I	sequences$$$130$$$139$$$O	of$$$140$$$142$$$O	SEQ$$$143$$$146$$$O	ID$$$147$$$149$$$O	NOS:$$$150$$$154$$$O	2$$$155$$$156$$$O	to$$$157$$$159$$$O	9$$$160$$$161$$$O	or$$$162$$$164$$$O	a$$$165$$$166$$$O	peptide$$$167$$$174$$$O	having$$$175$$$181$$$O	any$$$182$$$185$$$O	one$$$186$$$189$$$O	of$$$190$$$192$$$O	the$$$193$$$196$$$O	amino$$$197$$$202$$$I	acid$$$203$$$207$$$I	sequences$$$208$$$217$$$O	of$$$218$$$220$$$O	SEQ$$$221$$$224$$$O	ID$$$225$$$227$$$O	NOS:$$$228$$$232$$$O	10$$$233$$$235$$$O	and$$$236$$$239$$$O	15$$$240$$$242$$$O	to$$$243$$$245$$$O	17,$$$246$$$249$$$O	is$$$250$$$252$$$O	used$$$253$$$257$$$O	as$$$258$$$260$$$O	an$$$261$$$263$$$O	active$$$264$$$270$$$O	ingredient$$$271$$$281$$$O	of$$$282$$$284$$$O	an$$$285$$$287$$$O	agent$$$288$$$293$$$O	for$$$294$$$297$$$O	promoting$$$298$$$307$$$O	growth$$$308$$$314$$$O	or$$$315$$$317$$$O	differentiation$$$318$$$333$$$O	of$$$334$$$336$$$O	cells$$$337$$$342$$$O	such$$$343$$$347$$$O	as$$$348$$$350$$$O	osteoblasts,$$$351$$$363$$$O	chondroblasts,$$$364$$$378$$$O	cementoblasts,$$$379$$$393$$$O	bone$$$394$$$398$$$O	marrow-derived$$$399$$$413$$$O	mesenchymal$$$414$$$425$$$O	stem$$$426$$$430$$$O	cells$$$431$$$436$$$O	and$$$437$$$440$$$O	periodontal$$$441$$$452$$$O	ligament-derived$$$453$$$469$$$O	cells.$$$470$$$476$$$O
CN101543511A
Pressed$$$0$$$7$$$O	pharmaceutical$$$8$$$22$$$O	composition$$$23$$$34$$$O	containing$$$35$$$45$$$O	medicinal$$$46$$$55$$$O	charcoal$$$56$$$64$$$O	and$$$65$$$68$$$O	polyethyleneglycol$$$69$$$87$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	pressed$$$25$$$32$$$O	pharmaceutical$$$33$$$47$$$O	composition$$$48$$$59$$$O	containing$$$60$$$70$$$O	medicinal$$$71$$$80$$$O	charcoal$$$81$$$89$$$O	and$$$90$$$93$$$O	polyethyleneglycol,$$$94$$$113$$$I	which$$$114$$$119$$$O	is$$$120$$$122$$$O	characterized$$$123$$$136$$$O	in$$$137$$$139$$$O	that$$$140$$$144$$$O	the$$$145$$$148$$$O	medicinal$$$149$$$158$$$O	charcoal$$$159$$$167$$$O	accounts$$$168$$$176$$$O	for$$$177$$$180$$$O	65$$$181$$$183$$$O	to$$$184$$$186$$$O	75$$$187$$$189$$$O	percent$$$190$$$197$$$O	of$$$198$$$200$$$O	the$$$201$$$204$$$O	composition,$$$205$$$217$$$O	and$$$218$$$221$$$O	the$$$222$$$225$$$O	polyethyleneglycol$$$226$$$244$$$I	of$$$245$$$247$$$O	which$$$248$$$253$$$O	the$$$254$$$257$$$O	molecular$$$258$$$267$$$O	weight$$$268$$$274$$$O	is$$$275$$$277$$$O	between$$$278$$$285$$$O	1,500$$$286$$$291$$$O	and$$$292$$$295$$$O	6,000$$$296$$$301$$$O	accounts$$$302$$$310$$$O	for$$$311$$$314$$$O	15$$$315$$$317$$$O	to$$$318$$$320$$$O	25$$$321$$$323$$$O	percent$$$324$$$331$$$O	of$$$332$$$334$$$O	the$$$335$$$338$$$O	composition.$$$339$$$351$$$O	The$$$352$$$355$$$O	pharmaceutical$$$356$$$370$$$O	composition$$$371$$$382$$$O	is$$$383$$$385$$$O	applied$$$386$$$393$$$O	to$$$394$$$396$$$O	correcting$$$397$$$407$$$O	a$$$408$$$409$$$O	digestive$$$410$$$419$$$O	symptom$$$420$$$427$$$O	of$$$428$$$430$$$O	intestinal$$$431$$$441$$$O	constipation$$$442$$$454$$$O	caused$$$455$$$461$$$O	by$$$462$$$464$$$O	the$$$465$$$468$$$O	medicinal$$$469$$$478$$$O	charcoal$$$479$$$487$$$O	while$$$488$$$493$$$O	being$$$494$$$499$$$O	applied$$$500$$$507$$$O	to$$$508$$$510$$$O	a$$$511$$$512$$$O	clinical$$$513$$$521$$$O	nonspecific$$$522$$$533$$$O	antidote.$$$534$$$543$$$O	People$$$544$$$550$$$O	are$$$551$$$554$$$O	surprised$$$555$$$564$$$O	to$$$565$$$567$$$O	find$$$568$$$572$$$O	that$$$573$$$577$$$O	the$$$578$$$581$$$O	composition,$$$582$$$594$$$O	such$$$595$$$599$$$O	as$$$600$$$602$$$O	solid$$$603$$$608$$$O	colored$$$609$$$616$$$O	film$$$617$$$621$$$O	coat$$$622$$$626$$$O	tablet,$$$627$$$634$$$O	has$$$635$$$638$$$O	more$$$639$$$643$$$O	acceptable$$$644$$$654$$$O	perceptive$$$655$$$665$$$O	and$$$666$$$669$$$O	clinical$$$670$$$678$$$O	curative$$$679$$$687$$$O	effects$$$688$$$695$$$O	compared$$$696$$$704$$$O	with$$$705$$$709$$$O	the$$$710$$$713$$$O	prior$$$714$$$719$$$O	medicinal$$$720$$$729$$$O	charcoal$$$730$$$738$$$O	tablet.$$$739$$$746$$$O
CN101885676A
Reduction$$$0$$$9$$$O	anthraquinone$$$10$$$23$$$I	compound$$$24$$$32$$$O	with$$$33$$$37$$$O	antibacterial$$$38$$$51$$$O	activity$$$52$$$60$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicaments.$$$48$$$60$$$O	Three$$$61$$$66$$$O	reduction$$$67$$$76$$$O	anthraquinone$$$77$$$90$$$I	antifungal$$$91$$$101$$$O	compounds,$$$102$$$112$$$O	namely$$$113$$$119$$$O	Coniothranthraquinone$$$120$$$141$$$I	one$$$142$$$145$$$O	to$$$146$$$148$$$O	three,$$$149$$$155$$$O	are$$$156$$$159$$$O	separated$$$160$$$169$$$O	from$$$170$$$174$$$O	plant$$$175$$$180$$$O	endophytic$$$181$$$191$$$O	fungi$$$192$$$197$$$O	and$$$198$$$201$$$O	have$$$202$$$206$$$O	the$$$207$$$210$$$O	chemical$$$211$$$219$$$O	structural$$$220$$$230$$$O	formulas$$$231$$$239$$$O	shown$$$240$$$245$$$O	in$$$246$$$248$$$O	the$$$249$$$252$$$O	specification.$$$253$$$267$$$O	An$$$268$$$270$$$O	in$$$271$$$273$$$O	vitro$$$274$$$279$$$O	anti-bacteria$$$280$$$293$$$O	test$$$294$$$298$$$O	shows$$$299$$$304$$$O	that:$$$305$$$310$$$O	the$$$311$$$314$$$O	Coniothranthraquinone$$$315$$$336$$$I	one$$$337$$$340$$$O	has$$$341$$$344$$$O	a$$$345$$$346$$$O	remarkable$$$347$$$357$$$O	inhibiting$$$358$$$368$$$O	effect$$$369$$$375$$$O	on$$$376$$$378$$$O	anther$$$379$$$385$$$O	smut$$$386$$$390$$$O	and$$$391$$$394$$$O	bacillus$$$395$$$403$$$O	megaterium;$$$404$$$415$$$O	and$$$416$$$419$$$O	the$$$420$$$423$$$O	Coniothranthraquinone$$$424$$$445$$$I	two$$$446$$$449$$$O	and$$$450$$$453$$$O	the$$$454$$$457$$$O	Coniothranthraquinone$$$458$$$479$$$I	three$$$480$$$485$$$O	have$$$486$$$490$$$O	a$$$491$$$492$$$O	remarkable$$$493$$$503$$$O	inhibiting$$$504$$$514$$$O	effect$$$515$$$521$$$O	on$$$522$$$524$$$O	botrytis$$$525$$$533$$$O	cinerea.$$$534$$$542$$$O	The$$$543$$$546$$$O	invention$$$547$$$556$$$O	provides$$$557$$$565$$$O	a$$$566$$$567$$$O	new$$$568$$$571$$$O	lead$$$572$$$576$$$O	compound$$$577$$$585$$$O	for$$$586$$$589$$$O	developing$$$590$$$600$$$O	antibacterial$$$601$$$614$$$O	medicaments,$$$615$$$627$$$O	and$$$628$$$631$$$O	has$$$632$$$635$$$O	very$$$636$$$640$$$O	important$$$641$$$650$$$O	significance$$$651$$$663$$$O	on$$$664$$$666$$$O	protecting$$$667$$$677$$$O	endangered$$$678$$$688$$$O	medical$$$689$$$696$$$O	plants.$$$697$$$704$$$O
US20090069305
Substituted$$$0$$$11$$$O	nitrogen-containing$$$12$$$31$$$O	heteroaryl$$$32$$$42$$$O	derivatives$$$43$$$54$$$O	useful$$$55$$$61$$$O	as$$$62$$$64$$$O	modulators$$$65$$$75$$$O	of$$$76$$$78$$$O	the$$$79$$$82$$$O	histamine$$$83$$$92$$$O	H4$$$93$$$95$$$O	receptor$$$96$$$104$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	substituted$$$33$$$44$$$O	nitrogen-containing$$$45$$$64$$$O	heteroaryl$$$65$$$75$$$O	derivatives,$$$76$$$88$$$O	pharmaceutical$$$89$$$103$$$O	compositions$$$104$$$116$$$O	containing$$$117$$$127$$$O	them,$$$128$$$133$$$O	and$$$134$$$137$$$O	methods$$$138$$$145$$$O	of$$$146$$$148$$$O	using$$$149$$$154$$$O	any$$$155$$$158$$$O	of$$$159$$$161$$$O	these$$$162$$$167$$$O	derivatives$$$168$$$179$$$O	and$$$180$$$183$$$O	compositions$$$184$$$196$$$O	for$$$197$$$200$$$O	H4$$$201$$$203$$$O	receptor$$$204$$$212$$$O	activity$$$213$$$221$$$O	modulation$$$222$$$232$$$O	and$$$233$$$236$$$O	the$$$237$$$240$$$O	treatment$$$241$$$250$$$O	of$$$251$$$253$$$O	states$$$254$$$260$$$O	mediated$$$261$$$269$$$O	by$$$270$$$272$$$O	histamine$$$273$$$282$$$O	H4$$$283$$$285$$$O	receptor$$$286$$$294$$$O	activity.$$$295$$$304$$$O
DE102007030198A1
Therapeutic$$$0$$$11$$$O	agent,$$$12$$$18$$$O	useful$$$19$$$25$$$O	for$$$26$$$29$$$O	treating$$$30$$$38$$$O	skin$$$39$$$43$$$O	disease$$$44$$$51$$$O	e.g.$$$52$$$56$$$O	atopic$$$57$$$63$$$O	dermatitis,$$$64$$$75$$$O	psoriasis,$$$76$$$86$$$O	inflammation,$$$87$$$100$$$O	zoster,$$$101$$$108$$$O	chickenpox,$$$109$$$120$$$O	acne,$$$121$$$126$$$O	dandruff$$$127$$$135$$$O	head,$$$136$$$141$$$O	itching,$$$142$$$150$$$O	herpes,$$$151$$$158$$$O	shingles,$$$159$$$168$$$O	burns,$$$169$$$175$$$O	comprises$$$176$$$185$$$O	silica$$$186$$$192$$$I	sol$$$193$$$196$$$O	containing$$$197$$$207$$$O	silicon-dioxide$$$208$$$223$$$I
Therapeutic$$$0$$$11$$$O	agent$$$12$$$17$$$O	(I)$$$18$$$21$$$O	comprises$$$22$$$31$$$O	silica$$$32$$$38$$$I	sol$$$39$$$42$$$O	containing$$$43$$$53$$$O	silicon-dioxide$$$54$$$69$$$I	with$$$70$$$74$$$O	a$$$75$$$76$$$O	particle$$$77$$$85$$$O	size$$$86$$$90$$$O	of$$$91$$$93$$$O	1-1000$$$94$$$100$$$O	nm.$$$101$$$104$$$O	-$$$105$$$106$$$O	ACTIVITY$$$107$$$115$$$O	:$$$116$$$117$$$O	Dermatological;$$$118$$$133$$$O	Antiparasitic;$$$134$$$148$$$O	Antipsoriatic;$$$149$$$163$$$O	Antiinflammatory;$$$164$$$181$$$O	Virucide;$$$182$$$191$$$O	Antiseborrheic;$$$192$$$207$$$O	Antipruritic;$$$208$$$221$$$O	Vulnerary;$$$222$$$232$$$O	Analgesic.$$$233$$$243$$$O	-$$$244$$$245$$$O	MECHANISM$$$246$$$255$$$O	OF$$$256$$$258$$$O	ACTION$$$259$$$265$$$O	:$$$266$$$267$$$O	None$$$268$$$272$$$O	given.$$$273$$$279$$$O
US7812034
Using$$$0$$$5$$$O	HIV$$$6$$$9$$$O	protease$$$10$$$18$$$O	inhibitors$$$19$$$29$$$O	(indinavir,$$$30$$$41$$$I	nelfinavir,$$$42$$$53$$$I	ritonavir,$$$54$$$64$$$I	or$$$65$$$67$$$O	saquinavir)$$$68$$$79$$$I	alone$$$80$$$85$$$O	or$$$86$$$88$$$O	in$$$89$$$91$$$O	combination$$$92$$$103$$$O	with$$$104$$$108$$$O	chemotherapy,$$$109$$$122$$$O	radiotherapy,$$$123$$$136$$$O	or$$$137$$$139$$$O	surgery$$$140$$$147$$$O
Liposarcomas$$$0$$$12$$$O	are$$$13$$$16$$$O	treated$$$17$$$24$$$O	using$$$25$$$30$$$O	HIV$$$31$$$34$$$O	protease$$$35$$$43$$$O	inhibitors,$$$44$$$55$$$O	particularly$$$56$$$68$$$O	nelfinavir.$$$69$$$80$$$I	The$$$81$$$84$$$O	protease$$$85$$$93$$$O	inhibitors$$$94$$$104$$$O	may$$$105$$$108$$$O	be$$$109$$$111$$$O	used$$$112$$$116$$$O	alone$$$117$$$122$$$O	or$$$123$$$125$$$O	in$$$126$$$128$$$O	combination$$$129$$$140$$$O	with$$$141$$$145$$$O	traditional$$$146$$$157$$$O	cancer$$$158$$$164$$$O	treatments,$$$165$$$176$$$O	such$$$177$$$181$$$O	as$$$182$$$184$$$O	chemotherapy,$$$185$$$198$$$O	radiotherapy,$$$199$$$212$$$O	or$$$213$$$215$$$O	surgery.$$$216$$$224$$$O
CN103479630A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Lycojaponicumin$$$15$$$30$$$I	A$$$31$$$32$$$I	in$$$33$$$35$$$O	preparation$$$36$$$47$$$O	of$$$48$$$50$$$O	drugs$$$51$$$56$$$O	for$$$57$$$60$$$O	treating$$$61$$$69$$$O	breast$$$70$$$76$$$O	cancer$$$77$$$83$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	Lycojaponicumin$$$39$$$54$$$I	A$$$55$$$56$$$I	in$$$57$$$59$$$O	the$$$60$$$63$$$O	preparation$$$64$$$75$$$O	of$$$76$$$78$$$O	drugs$$$79$$$84$$$O	for$$$85$$$88$$$O	treating$$$89$$$97$$$O	breast$$$98$$$104$$$O	cancer$$$105$$$111$$$O	and$$$112$$$115$$$O	belongs$$$116$$$123$$$O	to$$$124$$$126$$$O	the$$$127$$$130$$$O	technical$$$131$$$140$$$O	field$$$141$$$146$$$O	of$$$147$$$149$$$O	novel$$$150$$$155$$$O	application$$$156$$$167$$$O	of$$$168$$$170$$$O	drugs.$$$171$$$177$$$O	In$$$178$$$180$$$O	vitro$$$181$$$186$$$O	MTT$$$187$$$190$$$I	anti-tumor$$$191$$$201$$$O	activity$$$202$$$210$$$O	evaluation$$$211$$$221$$$O	shows$$$222$$$227$$$O	that$$$228$$$232$$$O	the$$$233$$$236$$$O	Lycojaponicumin$$$237$$$252$$$I	A$$$253$$$254$$$I	has$$$255$$$258$$$O	a$$$259$$$260$$$O	remarkable$$$261$$$271$$$O	inhibiting$$$272$$$282$$$O	effect$$$283$$$289$$$O	on$$$290$$$292$$$O	the$$$293$$$296$$$O	growth$$$297$$$303$$$O	of$$$304$$$306$$$O	the$$$307$$$310$$$O	human$$$311$$$316$$$O	breast$$$317$$$323$$$O	cancer$$$324$$$330$$$O	cell$$$331$$$335$$$O	strains$$$336$$$343$$$O	of$$$344$$$346$$$O	4T1,$$$347$$$351$$$O	MCF-7,$$$352$$$358$$$O	MDA-MB-231$$$359$$$369$$$O	and$$$370$$$373$$$O	MCF-7B.$$$374$$$381$$$O	Therefore,$$$382$$$392$$$O	the$$$393$$$396$$$O	Lycojaponicumin$$$397$$$412$$$I	A$$$413$$$414$$$I	can$$$415$$$418$$$O	be$$$419$$$421$$$O	used$$$422$$$426$$$O	for$$$427$$$430$$$O	preparing$$$431$$$440$$$O	the$$$441$$$444$$$O	anti-breast$$$445$$$456$$$O	cancer$$$457$$$463$$$O	drugs,$$$464$$$470$$$O	and$$$471$$$474$$$O	has$$$475$$$478$$$O	a$$$479$$$480$$$O	good$$$481$$$485$$$O	development$$$486$$$497$$$O	and$$$498$$$501$$$O	application$$$502$$$513$$$O	prospect.$$$514$$$523$$$O	The$$$524$$$527$$$O	application$$$528$$$539$$$O	of$$$540$$$542$$$O	the$$$543$$$546$$$O	Lycojaponicumin$$$547$$$562$$$I	A$$$563$$$564$$$I	in$$$565$$$567$$$O	the$$$568$$$571$$$O	preparation$$$572$$$583$$$O	of$$$584$$$586$$$O	the$$$587$$$590$$$O	drugs$$$591$$$596$$$O	for$$$597$$$600$$$O	treating$$$601$$$609$$$O	the$$$610$$$613$$$O	breast$$$614$$$620$$$O	cancer$$$621$$$627$$$O	is$$$628$$$630$$$O	disclosed$$$631$$$640$$$O	for$$$641$$$644$$$O	the$$$645$$$648$$$O	first$$$649$$$654$$$O	time.$$$655$$$660$$$O	The$$$661$$$664$$$O	Lycojaponicumin$$$665$$$680$$$I	A$$$681$$$682$$$I	has$$$683$$$686$$$O	the$$$687$$$690$$$O	advantages$$$691$$$701$$$O	that$$$702$$$706$$$O	the$$$707$$$710$$$O	skeleton$$$711$$$719$$$O	type$$$720$$$724$$$O	belongs$$$725$$$732$$$O	to$$$733$$$735$$$O	an$$$736$$$738$$$O	unprecedented$$$739$$$752$$$O	skeleton$$$753$$$761$$$O	type,$$$762$$$767$$$O	and$$$768$$$771$$$O	the$$$772$$$775$$$O	inhibitory$$$776$$$786$$$O	activity$$$787$$$795$$$O	on$$$796$$$798$$$O	breast$$$799$$$805$$$O	cancer$$$806$$$812$$$O	cells$$$813$$$818$$$O	is$$$819$$$821$$$O	unexpectedly$$$822$$$834$$$O	high.$$$835$$$840$$$O
CN101040869A
Nanometer$$$0$$$9$$$O	elemental$$$10$$$19$$$O	selenium$$$20$$$28$$$I	coupled$$$29$$$36$$$O	with$$$37$$$41$$$O	liquid$$$42$$$48$$$O	amino$$$49$$$54$$$I	acid$$$55$$$59$$$I	and$$$60$$$63$$$O	the$$$64$$$67$$$O	method$$$68$$$74$$$O	for$$$75$$$78$$$O	preparing$$$79$$$88$$$O	and$$$89$$$92$$$O	preserving$$$93$$$103$$$O	the$$$104$$$107$$$O	same$$$108$$$112$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	method$$$26$$$32$$$O	for$$$33$$$36$$$O	preparing$$$37$$$46$$$O	nanometer$$$47$$$56$$$O	monomer$$$57$$$64$$$O	selenium$$$65$$$73$$$I	via$$$74$$$77$$$O	coupling$$$78$$$86$$$O	liquid$$$87$$$93$$$O	amino$$$94$$$99$$$I	acid,$$$100$$$105$$$I	comprising$$$106$$$116$$$O	that$$$117$$$121$$$O	at$$$122$$$124$$$O	normal$$$125$$$131$$$O	temperature$$$132$$$143$$$O	and$$$144$$$147$$$O	normal$$$148$$$154$$$O	pressure,$$$155$$$164$$$O	adding$$$165$$$171$$$O	vitamin$$$172$$$179$$$I	C$$$180$$$181$$$I	solution$$$182$$$190$$$O	into$$$191$$$195$$$O	amino$$$196$$$201$$$I	acid$$$202$$$206$$$I	solution,$$$207$$$216$$$O	mixing$$$217$$$223$$$O	uniformly$$$224$$$233$$$O	and$$$234$$$237$$$O	adding$$$238$$$244$$$O	selenious$$$245$$$254$$$I	anhydride$$$255$$$264$$$I	or$$$265$$$267$$$O	selenite$$$268$$$276$$$I	solution$$$277$$$285$$$O	until$$$286$$$291$$$O	the$$$292$$$295$$$O	product$$$296$$$303$$$O	has$$$304$$$307$$$O	held$$$308$$$312$$$O	red,$$$313$$$317$$$O	to$$$318$$$320$$$O	obtain$$$321$$$327$$$O	the$$$328$$$331$$$O	liquid$$$332$$$338$$$O	coupled$$$339$$$346$$$O	product$$$347$$$354$$$O	of$$$355$$$357$$$O	amino$$$358$$$363$$$I	acid$$$364$$$368$$$I	and$$$369$$$372$$$O	nanometer$$$373$$$382$$$O	selenium.$$$383$$$392$$$I	The$$$393$$$396$$$O	nanometer$$$397$$$406$$$O	monomer$$$407$$$414$$$O	selenium$$$415$$$423$$$I	can$$$424$$$427$$$O	be$$$428$$$430$$$O	used$$$431$$$435$$$O	as$$$436$$$438$$$O	medical$$$439$$$446$$$O	health-care$$$447$$$458$$$O	product$$$459$$$466$$$O	to$$$467$$$469$$$O	display$$$470$$$477$$$O	the$$$478$$$481$$$O	cooperation$$$482$$$493$$$O	between$$$494$$$501$$$O	amino$$$502$$$507$$$I	acid$$$508$$$512$$$I	and$$$513$$$516$$$O	nanometer$$$517$$$526$$$O	selenium,$$$527$$$536$$$I	while$$$537$$$542$$$O	the$$$543$$$546$$$O	nanometer$$$547$$$556$$$O	selenium$$$557$$$565$$$I	gel$$$566$$$569$$$O	has$$$570$$$573$$$O	small$$$574$$$579$$$O	diameter,$$$580$$$589$$$O	narrow$$$590$$$596$$$O	distribution$$$597$$$609$$$O	and$$$610$$$613$$$O	liquid$$$614$$$620$$$O	storage,$$$621$$$629$$$O	to$$$630$$$632$$$O	develop$$$633$$$640$$$O	oral,$$$641$$$646$$$O	injection$$$647$$$656$$$O	or$$$657$$$659$$$O	the$$$660$$$663$$$O	like.$$$664$$$669$$$O
CN101352418B
Pirarubicin$$$0$$$11$$$I	or$$$12$$$14$$$O	pirarubicin$$$15$$$26$$$I	hydrochloride$$$27$$$40$$$I	lipid$$$41$$$46$$$O	nano$$$47$$$51$$$O	granule$$$52$$$59$$$O	and$$$60$$$63$$$O	preparation$$$64$$$75$$$O	method$$$76$$$82$$$O	thereof$$$83$$$90$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	pirarubicin$$$25$$$36$$$I	hydrochloride$$$37$$$50$$$I	or$$$51$$$53$$$O	pirarubicin$$$54$$$65$$$I	lipid$$$66$$$71$$$O	nanoparticle$$$72$$$84$$$O	which$$$85$$$90$$$O	can$$$91$$$94$$$O	be$$$95$$$97$$$O	used$$$98$$$102$$$O	for$$$103$$$106$$$O	injection$$$107$$$116$$$O	and$$$117$$$120$$$O	oral$$$121$$$125$$$O	administration$$$126$$$140$$$O	and$$$141$$$144$$$O	a$$$145$$$146$$$O	preparation$$$147$$$158$$$O	method$$$159$$$165$$$O	thereof;$$$166$$$174$$$O	the$$$175$$$178$$$O	invention$$$179$$$188$$$O	is$$$189$$$191$$$O	characterized$$$192$$$205$$$O	that$$$206$$$210$$$O	in$$$211$$$213$$$O	the$$$214$$$217$$$O	existence$$$218$$$227$$$O	of$$$228$$$230$$$O	a$$$231$$$232$$$O	surface$$$233$$$240$$$O	active$$$241$$$247$$$O	agent,$$$248$$$254$$$O	a$$$255$$$256$$$O	carrier$$$257$$$264$$$O	material$$$265$$$273$$$O	packs$$$274$$$279$$$O	the$$$280$$$283$$$O	pirarubicin$$$284$$$295$$$I	hydrochloride$$$296$$$309$$$I	or$$$310$$$312$$$O	pirarubicin$$$313$$$324$$$I	and$$$325$$$328$$$O	the$$$329$$$332$$$O	prepared$$$333$$$341$$$O	lipid$$$342$$$347$$$O	nanoparticle$$$348$$$360$$$O	has$$$361$$$364$$$O	small$$$365$$$370$$$O	particle$$$371$$$379$$$O	size,$$$380$$$385$$$O	high$$$386$$$390$$$O	entrapment$$$391$$$401$$$O	rate,$$$402$$$407$$$O	good$$$408$$$412$$$O	stability$$$413$$$422$$$O	and$$$423$$$426$$$O	low$$$427$$$430$$$O	toxicity.$$$431$$$440$$$O	The$$$441$$$444$$$O	prepared$$$445$$$453$$$O	lipid$$$454$$$459$$$O	nanoparticle$$$460$$$472$$$O	of$$$473$$$475$$$O	the$$$476$$$479$$$O	invention$$$480$$$489$$$O	can$$$490$$$493$$$O	enhance$$$494$$$501$$$O	the$$$502$$$505$$$O	targeting$$$506$$$515$$$O	function$$$516$$$524$$$O	to$$$525$$$527$$$O	cancer$$$528$$$534$$$O	cells,$$$535$$$541$$$O	improve$$$542$$$549$$$O	the$$$550$$$553$$$O	inhibiting$$$554$$$564$$$O	and$$$565$$$568$$$O	killing$$$569$$$576$$$O	function$$$577$$$585$$$O	of$$$586$$$588$$$O	the$$$589$$$592$$$O	pirarubicin$$$593$$$604$$$I	to$$$605$$$607$$$O	tumor$$$608$$$613$$$O	cells$$$614$$$619$$$O	and$$$620$$$623$$$O	improve$$$624$$$631$$$O	the$$$632$$$635$$$O	curative$$$636$$$644$$$O	effect;$$$645$$$652$$$O	the$$$653$$$656$$$O	various$$$657$$$664$$$O	preparation$$$665$$$676$$$O	method$$$677$$$683$$$O	of$$$684$$$686$$$O	the$$$687$$$690$$$O	pirarubicin$$$691$$$702$$$I	or$$$703$$$705$$$O	the$$$706$$$709$$$O	pirarubicin$$$710$$$721$$$I	hydrochloride$$$722$$$735$$$I	lipid$$$736$$$741$$$O	nanoparticle$$$742$$$754$$$O	related$$$755$$$762$$$O	by$$$763$$$765$$$O	the$$$766$$$769$$$O	invention$$$770$$$779$$$O	has$$$780$$$783$$$O	simple$$$784$$$790$$$O	preparation$$$791$$$802$$$O	technique$$$803$$$812$$$O	and$$$813$$$816$$$O	low$$$817$$$820$$$O	cost$$$821$$$825$$$O	and$$$826$$$829$$$O	is$$$830$$$832$$$O	applicable$$$833$$$843$$$O	to$$$844$$$846$$$O	industrial$$$847$$$857$$$O	production$$$858$$$868$$$O	on$$$869$$$871$$$O	a$$$872$$$873$$$O	large$$$874$$$879$$$O	scale.$$$880$$$886$$$O
CN103285002A
Compound$$$0$$$8$$$O	norfloxacin$$$9$$$20$$$I	double-layered$$$21$$$35$$$O	suppository$$$36$$$47$$$O	for$$$48$$$51$$$O	animals,$$$52$$$60$$$O	and$$$61$$$64$$$O	preparation$$$65$$$76$$$O	method$$$77$$$83$$$O	thereof$$$84$$$91$$$O
For$$$0$$$3$$$O	meeting$$$4$$$11$$$O	market$$$12$$$18$$$O	demands$$$19$$$26$$$O	for$$$27$$$30$$$O	products$$$31$$$39$$$O	for$$$40$$$43$$$O	veterinary$$$44$$$54$$$O	use,$$$55$$$59$$$O	the$$$60$$$63$$$O	invention$$$64$$$73$$$O	provides$$$74$$$82$$$O	a$$$83$$$84$$$O	compound$$$85$$$93$$$O	norfloxacin$$$94$$$105$$$I	double-layered$$$106$$$120$$$O	suppository$$$121$$$132$$$O	for$$$133$$$136$$$O	animals$$$137$$$144$$$O	for$$$145$$$148$$$O	treatment$$$149$$$158$$$O	and$$$159$$$162$$$O	prevention$$$163$$$173$$$O	of$$$174$$$176$$$O	livestock$$$177$$$186$$$O	postpartum$$$187$$$197$$$O	infection,$$$198$$$208$$$O	and$$$209$$$212$$$O	is$$$213$$$215$$$O	characterized$$$216$$$229$$$O	in$$$230$$$232$$$O	that$$$233$$$237$$$O	the$$$238$$$241$$$O	double-layered$$$242$$$256$$$O	suppository,$$$257$$$269$$$O	which$$$270$$$275$$$O	is$$$276$$$278$$$O	advanced$$$279$$$287$$$O	in$$$288$$$290$$$O	technology,$$$291$$$302$$$O	contains$$$303$$$311$$$O	a$$$312$$$313$$$O	rapid-release$$$314$$$327$$$O	part$$$328$$$332$$$O	and$$$333$$$336$$$O	a$$$337$$$338$$$O	slow-release$$$339$$$351$$$O	part,$$$352$$$357$$$O	the$$$358$$$361$$$O	unique$$$362$$$368$$$O	rapid-release$$$369$$$382$$$O	slow-release$$$383$$$395$$$O	double-layered$$$396$$$410$$$O	structure$$$411$$$420$$$O	can$$$421$$$424$$$O	help$$$425$$$429$$$O	to$$$430$$$432$$$O	control$$$433$$$440$$$O	medicament$$$441$$$451$$$O	diffusion$$$452$$$461$$$O	and$$$462$$$465$$$O	control$$$466$$$473$$$O	successive$$$474$$$484$$$O	release$$$485$$$492$$$O	of$$$493$$$495$$$O	different$$$496$$$505$$$O	medicaments,$$$506$$$518$$$O	and$$$519$$$522$$$O	therefore$$$523$$$532$$$O	the$$$533$$$536$$$O	purposes$$$537$$$545$$$O	of$$$546$$$548$$$O	quick$$$549$$$554$$$O	response,$$$555$$$564$$$O	long$$$565$$$569$$$O	acting$$$570$$$576$$$O	time$$$577$$$581$$$O	are$$$582$$$585$$$O	achieved.$$$586$$$595$$$O	Simultaneously,$$$596$$$611$$$O	the$$$612$$$615$$$O	invention$$$616$$$625$$$O	also$$$626$$$630$$$O	provided$$$631$$$639$$$O	a$$$640$$$641$$$O	preparation$$$642$$$653$$$O	method$$$654$$$660$$$O	of$$$661$$$663$$$O	the$$$664$$$667$$$O	compound$$$668$$$676$$$O	norfloxacin$$$677$$$688$$$I	double-layered$$$689$$$703$$$O	suppository$$$704$$$715$$$O	for$$$716$$$719$$$O	animals,$$$720$$$728$$$O	and$$$729$$$732$$$O	the$$$733$$$736$$$O	preparation$$$737$$$748$$$O	method$$$749$$$755$$$O	has$$$756$$$759$$$O	advantages$$$760$$$770$$$O	of$$$771$$$773$$$O	being$$$774$$$779$$$O	good$$$780$$$784$$$O	in$$$785$$$787$$$O	reappearance,$$$788$$$801$$$O	low$$$802$$$805$$$O	in$$$806$$$808$$$O	cost$$$809$$$813$$$O	and$$$814$$$817$$$O	suitable$$$818$$$826$$$O	for$$$827$$$830$$$O	industrialized$$$831$$$845$$$O	production.$$$846$$$857$$$O
WO2012009646A1
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	treating$$$11$$$19$$$O	fragile$$$20$$$27$$$O	x$$$28$$$29$$$O	syndrome,$$$30$$$39$$$O	down's$$$40$$$46$$$O	syndrome,$$$47$$$56$$$O	autism$$$57$$$63$$$O	and$$$64$$$67$$$O	related$$$68$$$75$$$O	disorders$$$76$$$85$$$O
Disclosed$$$0$$$9$$$O	herein$$$10$$$16$$$O	are$$$17$$$20$$$O	methods$$$21$$$28$$$O	of$$$29$$$31$$$O	treating$$$32$$$40$$$O	fragile$$$41$$$48$$$O	X$$$49$$$50$$$O	syndrome,$$$51$$$60$$$O	fragile$$$61$$$68$$$O	X-associated$$$69$$$81$$$O	tremor/ataxia$$$82$$$95$$$O	syndrome,$$$96$$$105$$$O	Down's$$$106$$$112$$$O	syndrome$$$113$$$121$$$O	and$$$122$$$125$$$O	other$$$126$$$131$$$O	forms$$$132$$$137$$$O	of$$$138$$$140$$$O	mental$$$141$$$147$$$O	retardation,$$$148$$$160$$$O	and/or$$$161$$$167$$$O	autism$$$168$$$174$$$O	comprising$$$175$$$185$$$O	administering$$$186$$$199$$$O	a$$$200$$$201$$$O	GABAB$$$202$$$207$$$O	agonist$$$208$$$215$$$O	prodrug$$$216$$$223$$$O	to$$$224$$$226$$$O	a$$$227$$$228$$$O	subject$$$229$$$236$$$O	suffering$$$237$$$246$$$O	therefrom.$$$247$$$257$$$O	The$$$258$$$261$$$O	GABAB$$$262$$$267$$$O	agonist$$$268$$$275$$$O	prodrugs$$$276$$$284$$$O	can$$$285$$$288$$$O	be$$$289$$$291$$$O	compounds$$$292$$$301$$$O	of$$$302$$$304$$$O	Formula$$$305$$$312$$$O	(I),$$$313$$$317$$$O	(II)$$$318$$$322$$$O	or$$$323$$$325$$$O	(III)$$$326$$$331$$$O	as$$$332$$$334$$$O	disclosed$$$335$$$344$$$O	herein.$$$345$$$352$$$O
US7084270
Pyrimido$$$0$$$8$$$I	compounds$$$9$$$18$$$O	having$$$19$$$25$$$O	antiproliferative$$$26$$$43$$$O	activity$$$44$$$52$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	novel$$$14$$$19$$$O	pyrimido$$$20$$$28$$$I	compounds$$$29$$$38$$$O	that$$$39$$$43$$$O	are$$$44$$$47$$$O	selective$$$48$$$57$$$O	inhibitors$$$58$$$68$$$O	of$$$69$$$71$$$O	both$$$72$$$76$$$O	KDR$$$77$$$80$$$O	an$$$81$$$83$$$O	FGFR$$$84$$$88$$$O	kinases$$$89$$$96$$$O	and$$$97$$$100$$$O	are$$$101$$$104$$$O	selective$$$105$$$114$$$O	against$$$115$$$122$$$O	LCK.$$$123$$$127$$$O	These$$$128$$$133$$$O	compounds$$$134$$$143$$$O	and$$$144$$$147$$$O	their$$$148$$$153$$$O	pharmaceutically$$$154$$$170$$$O	acceptable$$$171$$$181$$$O	salts$$$182$$$187$$$O	are$$$188$$$191$$$O	anti-proliferative$$$192$$$210$$$O	agents$$$211$$$217$$$O	useful$$$218$$$224$$$O	in$$$225$$$227$$$O	the$$$228$$$231$$$O	treatment$$$232$$$241$$$O	or$$$242$$$244$$$O	control$$$245$$$252$$$O	of$$$253$$$255$$$O	solid$$$256$$$261$$$O	tumors,$$$262$$$269$$$O	in$$$270$$$272$$$O	particular$$$273$$$283$$$O	breast,$$$284$$$291$$$O	colon,$$$292$$$298$$$O	lung$$$299$$$303$$$O	and$$$304$$$307$$$O	prostate$$$308$$$316$$$O	tumors.$$$317$$$324$$$O	Also$$$325$$$329$$$O	disclosed$$$330$$$339$$$O	are$$$340$$$343$$$O	pharmaceutical$$$344$$$358$$$O	compositions$$$359$$$371$$$O	containing$$$372$$$382$$$O	these$$$383$$$388$$$O	compounds$$$389$$$398$$$O	and$$$399$$$402$$$O	methods$$$403$$$410$$$O	of$$$411$$$413$$$O	treating$$$414$$$422$$$O	cancer.$$$423$$$430$$$O
WO2008036954A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	n-$$$7$$$9$$$I	[5-$$$10$$$13$$$I	[$$$14$$$15$$$I	[$$$16$$$17$$$I	[5-$$$18$$$21$$$I	(1,$$$22$$$25$$$I	1-dimethylethyl)$$$26$$$42$$$I	-2-oxazoyl]$$$43$$$54$$$I	methyl]$$$55$$$62$$$I	thio]$$$63$$$68$$$I	-2-thiazolyl]$$$69$$$82$$$I	-4-piperidinecarboxamide$$$83$$$107$$$I
The$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	N-$$$11$$$13$$$I	[5-$$$14$$$17$$$I	[$$$18$$$19$$$I	[$$$20$$$21$$$I	[5-$$$22$$$25$$$I	(1,$$$26$$$29$$$I	1-$$$30$$$32$$$I	dimethylethyl)$$$33$$$47$$$I	-2-$$$48$$$51$$$I	oxazolyl]$$$52$$$61$$$I	methyl]$$$62$$$69$$$I	thio]$$$70$$$75$$$I	-2-thiazolyl]$$$76$$$89$$$I	-4-piperidinecarboxamide$$$90$$$114$$$I	for$$$115$$$118$$$O	the$$$119$$$122$$$O	treatment$$$123$$$132$$$O	of$$$133$$$135$$$O	cancer$$$136$$$142$$$O	is$$$143$$$145$$$O	disclosed.$$$146$$$156$$$O	Also$$$157$$$161$$$O	provided$$$162$$$170$$$O	is$$$171$$$173$$$O	the$$$174$$$177$$$O	use$$$178$$$181$$$O	of$$$182$$$184$$$O	the$$$185$$$188$$$O	compound$$$189$$$197$$$O	in$$$198$$$200$$$O	combination$$$201$$$212$$$O	with$$$213$$$217$$$O	other$$$218$$$223$$$O	therapies$$$224$$$233$$$O	for$$$234$$$237$$$O	treating$$$238$$$246$$$O	cancer.$$$247$$$254$$$O	Also$$$255$$$259$$$O	provided$$$260$$$268$$$O	are$$$269$$$272$$$O	pharmaceutical$$$273$$$287$$$O	compositions$$$288$$$300$$$O	and$$$301$$$304$$$O	single$$$305$$$311$$$O	unit$$$312$$$316$$$O	dosage$$$317$$$323$$$O	forms$$$324$$$329$$$O	that$$$330$$$334$$$O	can$$$335$$$338$$$O	be$$$339$$$341$$$O	used$$$342$$$346$$$O	for$$$347$$$350$$$O	treating$$$351$$$359$$$O	cancer.$$$360$$$367$$$O
CN102319234A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	curcumin$$$15$$$23$$$I	in$$$24$$$26$$$O	preparation$$$27$$$38$$$O	of$$$39$$$41$$$O	thyroid$$$42$$$49$$$O	carcinoma$$$50$$$59$$$O	therapeutic$$$60$$$71$$$O	agent$$$72$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	application$$$27$$$38$$$O	of$$$39$$$41$$$O	curcumin$$$42$$$50$$$I	in$$$51$$$53$$$O	the$$$54$$$57$$$O	preparation$$$58$$$69$$$O	of$$$70$$$72$$$O	a$$$73$$$74$$$O	thyroid$$$75$$$82$$$O	carcinoma$$$83$$$92$$$O	therapeutic$$$93$$$104$$$O	agent,$$$105$$$111$$$O	and$$$112$$$115$$$O	belongs$$$116$$$123$$$O	to$$$124$$$126$$$O	the$$$127$$$130$$$O	technical$$$131$$$140$$$O	field$$$141$$$146$$$O	of$$$147$$$149$$$O	curcumin$$$150$$$158$$$I	pharmaceutical$$$159$$$173$$$O	application.$$$174$$$186$$$O	Curcumin$$$187$$$195$$$I	can$$$196$$$199$$$O	kill$$$200$$$204$$$O	thyroid$$$205$$$212$$$O	carcinoma$$$213$$$222$$$O	cells$$$223$$$228$$$O	specifically$$$229$$$241$$$O	and$$$242$$$245$$$O	has$$$246$$$249$$$O	little$$$250$$$256$$$O	influence$$$257$$$266$$$O	on$$$267$$$269$$$O	normal$$$270$$$276$$$O	thyroid$$$277$$$284$$$O	cells.$$$285$$$291$$$O	Curcumin$$$292$$$300$$$I	can$$$301$$$304$$$O	promote$$$305$$$312$$$O	the$$$313$$$316$$$O	apoptosis$$$317$$$326$$$O	of$$$327$$$329$$$O	thyroid$$$330$$$337$$$O	carcinoma$$$338$$$347$$$O	cells,$$$348$$$354$$$O	initiate$$$355$$$363$$$O	the$$$364$$$367$$$O	digestion$$$368$$$377$$$O	of$$$378$$$380$$$O	poly$$$381$$$385$$$O	adenosine$$$386$$$395$$$O	diphosphate-ribose$$$396$$$414$$$O	polymerase$$$415$$$425$$$O	(PARP),$$$426$$$433$$$O	and$$$434$$$437$$$O	significantly$$$438$$$451$$$O	inhibit$$$452$$$459$$$O	the$$$460$$$463$$$O	expression$$$464$$$474$$$O	of$$$475$$$477$$$O	anti-apoptotic$$$478$$$492$$$O	protein$$$493$$$500$$$O	Bcl-2;$$$501$$$507$$$O	meanwhile,$$$508$$$518$$$O	curcumin$$$519$$$527$$$I	can$$$528$$$531$$$O	also$$$532$$$536$$$O	inhibit$$$537$$$544$$$O	the$$$545$$$548$$$O	secretion$$$549$$$558$$$O	of$$$559$$$561$$$O	thyroid$$$562$$$569$$$O	carcinoma$$$570$$$579$$$O	cell$$$580$$$584$$$O	matrix$$$585$$$591$$$O	metalloproteinase-9$$$592$$$611$$$O	and$$$612$$$615$$$O	the$$$616$$$619$$$O	adhesion$$$620$$$628$$$O	to$$$629$$$631$$$O	extracellular$$$632$$$645$$$O	matrix.$$$646$$$653$$$O	Above$$$654$$$659$$$O	results$$$660$$$667$$$O	show$$$668$$$672$$$O	that$$$673$$$677$$$O	curcumin$$$678$$$686$$$I	has$$$687$$$690$$$O	good$$$691$$$695$$$O	intervention$$$696$$$708$$$O	effect$$$709$$$715$$$O	on$$$716$$$718$$$O	various$$$719$$$726$$$O	links$$$727$$$732$$$O	of$$$733$$$735$$$O	proliferation,$$$736$$$750$$$O	migration,$$$751$$$761$$$O	and$$$762$$$765$$$O	adhesion$$$766$$$774$$$O	of$$$775$$$777$$$O	thyroid$$$778$$$785$$$O	carcinoma$$$786$$$795$$$O	cells,$$$796$$$802$$$O	and$$$803$$$806$$$O	is$$$807$$$809$$$O	applicable$$$810$$$820$$$O	to$$$821$$$823$$$O	the$$$824$$$827$$$O	preparation$$$828$$$839$$$O	of$$$840$$$842$$$O	medicaments$$$843$$$854$$$O	for$$$855$$$858$$$O	treating$$$859$$$867$$$O	thyroid$$$868$$$875$$$O	carcinoma.$$$876$$$886$$$O
CA2548922A1
2-$$$0$$$2$$$I	($$$3$$$4$$$I	(2,$$$5$$$8$$$I	3-dihydroxypropyl)$$$9$$$27$$$I	aminomethyl)$$$28$$$40$$$I	chromane$$$41$$$49$$$I	derivatives$$$50$$$61$$$O	for$$$62$$$65$$$O	use$$$66$$$69$$$O	as$$$70$$$72$$$O	beta-3$$$73$$$79$$$O	adrenoreceptor$$$80$$$94$$$O	agonists$$$95$$$103$$$O	in$$$104$$$106$$$O	the$$$107$$$110$$$O	treatment$$$111$$$120$$$O	of$$$121$$$123$$$O	urological$$$124$$$134$$$O	and$$$135$$$138$$$O	inflammatory$$$139$$$151$$$O	disorders$$$152$$$161$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	chroman$$$26$$$33$$$I	derivatives$$$34$$$45$$$O	of$$$46$$$48$$$O	formula$$$49$$$56$$$O	(I)$$$57$$$60$$$O	and$$$61$$$64$$$O	salts$$$65$$$70$$$O	thereof$$$71$$$78$$$O	which$$$79$$$84$$$O	are$$$85$$$88$$$O	useful$$$89$$$95$$$O	as$$$96$$$98$$$O	active$$$99$$$105$$$O	ingredients$$$106$$$117$$$O	of$$$118$$$120$$$O	pharmaceutical$$$121$$$135$$$O	preparations.$$$136$$$149$$$O	The$$$150$$$153$$$O	chroman$$$154$$$161$$$I	derivatives$$$162$$$173$$$O	of$$$174$$$176$$$O	the$$$177$$$180$$$O	present$$$181$$$188$$$O	invention$$$189$$$198$$$O	have$$$199$$$203$$$O	an$$$204$$$206$$$O	excellent$$$207$$$216$$$O	activity$$$217$$$225$$$O	as$$$226$$$228$$$O	BETA$$$229$$$233$$$O	3$$$234$$$235$$$O	antagonists$$$236$$$247$$$O	and$$$248$$$251$$$O	are$$$252$$$255$$$O	useful$$$256$$$262$$$O	for$$$263$$$266$$$O	the$$$267$$$270$$$O	prophylaxis$$$271$$$282$$$O	and$$$283$$$286$$$O	treatment$$$287$$$296$$$O	of$$$297$$$299$$$O	diseases$$$300$$$308$$$O	associated$$$309$$$319$$$O	with$$$320$$$324$$$O	BETA$$$325$$$329$$$O	3$$$330$$$331$$$O	activity,$$$332$$$341$$$O	in$$$342$$$344$$$O	particular$$$345$$$355$$$O	for$$$356$$$359$$$O	the$$$360$$$363$$$O	treatment$$$364$$$373$$$O	of$$$374$$$376$$$O	urological$$$377$$$387$$$O	disorder$$$388$$$396$$$O	or$$$397$$$399$$$O	disease,$$$400$$$408$$$O	such$$$409$$$413$$$O	as$$$414$$$416$$$O	detrusor$$$417$$$425$$$O	overactivity$$$426$$$438$$$O	(overactive$$$439$$$450$$$O	bladder),$$$451$$$460$$$O	urinary$$$461$$$468$$$O	incontinence,$$$469$$$482$$$O	neurogenic$$$483$$$493$$$O	detrusor$$$494$$$502$$$O	overactivity$$$503$$$515$$$O	(detrusor$$$516$$$525$$$O	hyperflexia),$$$526$$$539$$$O	idiopathic$$$540$$$550$$$O	detrusor$$$551$$$559$$$O	overactivity$$$560$$$572$$$O	(detrusor$$$573$$$582$$$O	instability),$$$583$$$596$$$O	benign$$$597$$$603$$$O	prostatic$$$604$$$613$$$O	hyperplasia,$$$614$$$626$$$O	and$$$627$$$630$$$O	lower$$$631$$$636$$$O	urinary$$$637$$$644$$$O	tract$$$645$$$650$$$O	symptoms;$$$651$$$660$$$O	and$$$661$$$664$$$O	inflammatory$$$665$$$677$$$O	disorders,$$$678$$$688$$$O	such$$$689$$$693$$$O	as$$$694$$$696$$$O	asthma$$$697$$$703$$$O	and$$$704$$$707$$$O	COPD.$$$708$$$713$$$O
WO2011044504A1
Modulating$$$0$$$10$$$O	levels$$$11$$$17$$$O	of$$$18$$$20$$$O	rna-binding$$$21$$$32$$$O	proteins$$$33$$$41$$$O	for$$$42$$$45$$$O	the$$$46$$$49$$$O	treatment$$$50$$$59$$$O	of$$$60$$$62$$$O	breast$$$63$$$69$$$O	cancer$$$70$$$76$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	methods$$$33$$$40$$$O	of$$$41$$$43$$$O	using$$$44$$$49$$$O	RNA-binding$$$50$$$61$$$O	protein$$$62$$$69$$$O	modulating$$$70$$$80$$$O	agents$$$81$$$87$$$O	to$$$88$$$90$$$O	treat$$$91$$$96$$$O	of$$$97$$$99$$$O	cancer,$$$100$$$107$$$O	particularly$$$108$$$120$$$O	patients$$$121$$$129$$$O	that$$$130$$$134$$$O	are$$$135$$$138$$$O	susceptible$$$139$$$150$$$O	to$$$151$$$153$$$O	or$$$154$$$156$$$O	diagnosed$$$157$$$166$$$O	with$$$167$$$171$$$O	estrogen$$$172$$$180$$$I	receptor-negative$$$181$$$198$$$O	breast$$$199$$$205$$$O	cancer,$$$206$$$213$$$O	such$$$214$$$218$$$O	as$$$219$$$221$$$O	methods$$$222$$$229$$$O	of$$$230$$$232$$$O	inhibiting$$$233$$$243$$$O	the$$$244$$$247$$$O	growth$$$248$$$254$$$O	or$$$255$$$257$$$O	metastasis$$$258$$$268$$$O	of$$$269$$$271$$$O	cancer$$$272$$$278$$$O	cells$$$279$$$284$$$O	comprising$$$285$$$295$$$O	contacting$$$296$$$306$$$O	cells$$$307$$$312$$$O	with$$$313$$$317$$$O	a$$$318$$$319$$$O	therapeutically-effective$$$320$$$345$$$O	amount$$$346$$$352$$$O	of$$$353$$$355$$$O	an$$$356$$$358$$$O	HuR-modulating$$$359$$$373$$$O	agent.$$$374$$$380$$$O	The$$$381$$$384$$$O	invention$$$385$$$394$$$O	also$$$395$$$399$$$O	relates$$$400$$$407$$$O	to$$$408$$$410$$$O	compositions$$$411$$$423$$$O	comprising$$$424$$$434$$$O	therapeutically-effective$$$435$$$460$$$O	amounts$$$461$$$468$$$O	of$$$469$$$471$$$O	an$$$472$$$474$$$O	HuR-modulating$$$475$$$489$$$O	agent.$$$490$$$496$$$O
US20130136714
Functionalized$$$0$$$14$$$O	polymer$$$15$$$22$$$O	nanoparticles$$$23$$$36$$$O	and$$$37$$$40$$$O	the$$$41$$$44$$$O	pharmaceutical$$$45$$$59$$$O	use$$$60$$$63$$$O	thereof$$$64$$$71$$$O
PEO-PPO-PEO$$$0$$$11$$$I	polymers$$$12$$$20$$$O	and$$$21$$$24$$$O	vinyl$$$25$$$30$$$I	monomers$$$31$$$39$$$O	are$$$40$$$43$$$O	used$$$44$$$48$$$O	to$$$49$$$51$$$O	prepare$$$52$$$59$$$O	several$$$60$$$67$$$O	block$$$68$$$73$$$O	copolymers$$$74$$$84$$$O	via$$$85$$$88$$$O	consecutive$$$89$$$100$$$O	atom$$$101$$$105$$$O	transfer$$$106$$$114$$$O	radical$$$115$$$122$$$O	polymerization$$$123$$$137$$$O	(ATRP).$$$138$$$145$$$O	The$$$146$$$149$$$O	block$$$150$$$155$$$O	copolymers$$$156$$$166$$$O	provide$$$167$$$174$$$O	good$$$175$$$179$$$O	delivery$$$180$$$188$$$O	characteristics$$$189$$$204$$$O	and$$$205$$$208$$$O	can$$$209$$$212$$$O	be$$$213$$$215$$$O	used$$$216$$$220$$$O	as$$$221$$$223$$$O	a$$$224$$$225$$$O	gene/drug$$$226$$$235$$$O	delivery$$$236$$$244$$$O	carrier$$$245$$$252$$$O	for$$$253$$$256$$$O	therapy$$$257$$$264$$$O	and$$$265$$$268$$$O	diagnosis.$$$269$$$279$$$O
US20120329806
Novel$$$0$$$5$$$O	fluoroergoline$$$6$$$20$$$I	analogs$$$21$$$28$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	novel$$$20$$$25$$$O	fluoroergoline$$$26$$$40$$$I	derivatives$$$41$$$52$$$O	and$$$53$$$56$$$O	compositions$$$57$$$69$$$O	thereof.$$$70$$$78$$$O	In$$$79$$$81$$$O	other$$$82$$$87$$$O	embodiments,$$$88$$$100$$$O	provided$$$101$$$109$$$O	herein$$$110$$$116$$$O	are$$$117$$$120$$$O	methods$$$121$$$128$$$O	of$$$129$$$131$$$O	treatment,$$$132$$$142$$$O	prevention,$$$143$$$154$$$O	or$$$155$$$157$$$O	amelioration$$$158$$$170$$$O	of$$$171$$$173$$$O	a$$$174$$$175$$$O	variety$$$176$$$183$$$O	of$$$184$$$186$$$O	medical$$$187$$$194$$$O	disorders$$$195$$$204$$$O	such$$$205$$$209$$$O	as,$$$210$$$213$$$O	for$$$214$$$217$$$O	example,$$$218$$$226$$$O	migraine$$$227$$$235$$$O	using$$$236$$$241$$$O	the$$$242$$$245$$$O	compounds$$$246$$$255$$$O	and$$$256$$$259$$$O	compositions$$$260$$$272$$$O	disclosed$$$273$$$282$$$O	herein.$$$283$$$290$$$O	In$$$291$$$293$$$O	still$$$294$$$299$$$O	other$$$300$$$305$$$O	embodiments,$$$306$$$318$$$O	provided$$$319$$$327$$$O	herein$$$328$$$334$$$O	are$$$335$$$338$$$O	methods$$$339$$$346$$$O	of$$$347$$$349$$$O	agonizing$$$350$$$359$$$O	receptors$$$360$$$369$$$O	such$$$370$$$374$$$O	as,$$$375$$$378$$$O	for$$$379$$$382$$$O	example,$$$383$$$391$$$O	the$$$392$$$395$$$O	5-HT1D$$$396$$$402$$$O	and/or$$$403$$$409$$$O	the$$$410$$$413$$$O	5-HT1B$$$414$$$420$$$O	receptor,$$$421$$$430$$$O	without$$$431$$$438$$$O	agonizing$$$439$$$448$$$O	the$$$449$$$452$$$O	5-HT2B$$$453$$$459$$$O	receptor$$$460$$$468$$$O	using$$$469$$$474$$$O	the$$$475$$$478$$$O	compounds$$$479$$$488$$$O	and$$$489$$$492$$$O	compositions$$$493$$$505$$$O	disclosed$$$506$$$515$$$O	herein.$$$516$$$523$$$O	In$$$524$$$526$$$O	still$$$527$$$532$$$O	other$$$533$$$538$$$O	embodiments,$$$539$$$551$$$O	provided$$$552$$$560$$$O	herein$$$561$$$567$$$O	are$$$568$$$571$$$O	methods$$$572$$$579$$$O	of$$$580$$$582$$$O	antagonizing$$$583$$$595$$$O	or$$$596$$$598$$$O	inhibiting$$$599$$$609$$$O	activity$$$610$$$618$$$O	at$$$619$$$621$$$O	receptors$$$622$$$631$$$O	such$$$632$$$636$$$O	as,$$$637$$$640$$$O	for$$$641$$$644$$$O	example,$$$645$$$653$$$O	the$$$654$$$657$$$O	adrenergic$$$658$$$668$$$O	alpha2A$$$669$$$676$$$O	and/or$$$677$$$683$$$O	the$$$684$$$687$$$O	alpha2B$$$688$$$695$$$O	receptors$$$696$$$705$$$O	using$$$706$$$711$$$O	the$$$712$$$715$$$O	compounds$$$716$$$725$$$O	and$$$726$$$729$$$O	compositions$$$730$$$742$$$O	disclosed$$$743$$$752$$$O	herein.$$$753$$$760$$$O
CN102631388A
Protopanaxatriol$$$0$$$16$$$I	composition$$$17$$$28$$$O	and$$$29$$$32$$$O	application$$$33$$$44$$$O	thereof$$$45$$$52$$$O	to$$$53$$$55$$$O	preparation$$$56$$$67$$$O	of$$$68$$$70$$$O	Parkinson$$$71$$$80$$$O	resisting$$$81$$$90$$$O	drugs$$$91$$$96$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	panaxatriol$$$26$$$37$$$I	saponins$$$38$$$46$$$I	composition$$$47$$$58$$$O	and$$$59$$$62$$$O	application$$$63$$$74$$$O	thereof$$$75$$$82$$$O	to$$$83$$$85$$$O	preparation$$$86$$$97$$$O	of$$$98$$$100$$$O	drugs$$$101$$$106$$$O	for$$$107$$$110$$$O	strengthening$$$111$$$124$$$O	immunity.$$$125$$$134$$$O	The$$$135$$$138$$$O	panaxatriol$$$139$$$150$$$I	saponins$$$151$$$159$$$I	composition$$$160$$$171$$$O	at$$$172$$$174$$$O	least$$$175$$$180$$$O	comprises$$$181$$$190$$$O	5-60%$$$191$$$196$$$O	of$$$197$$$199$$$O	ginsenoside-Re$$$200$$$214$$$I	and$$$215$$$218$$$O	5-60%$$$219$$$224$$$O	of$$$225$$$227$$$O	ginsenoside-Rg1$$$228$$$243$$$I	by$$$244$$$246$$$O	weight$$$247$$$253$$$O	percent.$$$254$$$262$$$O	The$$$263$$$266$$$O	panaxatriol$$$267$$$278$$$I	saponins$$$279$$$287$$$I	composition$$$288$$$299$$$O	has$$$300$$$303$$$O	stronger$$$304$$$312$$$O	activity$$$313$$$321$$$O	than$$$322$$$326$$$O	the$$$327$$$330$$$O	single$$$331$$$337$$$O	ginsenoside$$$338$$$349$$$I	in$$$350$$$352$$$O	resisting$$$353$$$362$$$O	Parkinson's$$$363$$$374$$$O	diseases$$$375$$$383$$$O	and$$$384$$$387$$$O	has$$$388$$$391$$$O	high$$$392$$$396$$$O	bioavailability,$$$397$$$413$$$O	simple$$$414$$$420$$$O	preparation$$$421$$$432$$$O	method$$$433$$$439$$$O	and$$$440$$$443$$$O	low$$$444$$$447$$$O	price.$$$448$$$454$$$O
WO2004045490A3
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	inducing$$$27$$$35$$$O	cancer$$$36$$$42$$$O	cell$$$43$$$47$$$O	differentiation$$$48$$$63$$$O	and$$$64$$$67$$$O	the$$$68$$$71$$$O	use$$$72$$$75$$$O	for$$$76$$$79$$$O	treatment$$$80$$$89$$$O	and$$$90$$$93$$$O	prevention$$$94$$$104$$$O	of$$$105$$$107$$$O	cancer$$$108$$$114$$$O	thereof$$$115$$$122$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	for$$$62$$$65$$$O	the$$$66$$$69$$$O	treatment$$$70$$$79$$$O	and$$$80$$$83$$$O	prevention$$$84$$$94$$$O	of$$$95$$$97$$$O	cancer$$$98$$$104$$$O	and$$$105$$$108$$$O	the$$$109$$$112$$$O	preparation$$$113$$$124$$$O	method$$$125$$$131$$$O	thereof,$$$132$$$140$$$O	especially$$$141$$$151$$$O	to$$$152$$$154$$$O	a$$$155$$$156$$$O	cell$$$157$$$161$$$O	differentiation$$$162$$$177$$$O	agent$$$178$$$183$$$O	named$$$184$$$189$$$O	CDA-II$$$190$$$196$$$O	which$$$197$$$202$$$O	is$$$203$$$205$$$O	prepared$$$206$$$214$$$O	by$$$215$$$217$$$O	reverse$$$218$$$225$$$O	phase$$$226$$$231$$$O	chromatography$$$232$$$246$$$O	of$$$247$$$249$$$O	fresh$$$250$$$255$$$O	human$$$256$$$261$$$O	urine.$$$262$$$268$$$O	The$$$269$$$272$$$O	pharmaceutical$$$273$$$287$$$O	composition$$$288$$$299$$$O	is$$$300$$$302$$$O	effective$$$303$$$312$$$O	for$$$313$$$316$$$O	the$$$317$$$320$$$O	treatment$$$321$$$330$$$O	and$$$331$$$334$$$O	prevention$$$335$$$345$$$O	of$$$346$$$348$$$O	cancer.$$$349$$$356$$$O	The$$$357$$$360$$$O	active$$$361$$$367$$$O	components$$$368$$$378$$$O	in$$$379$$$381$$$O	CDA-II$$$382$$$388$$$O	contain$$$389$$$396$$$O	differentiation$$$397$$$412$$$O	inducers,$$$413$$$422$$$O	differentiation$$$423$$$438$$$O	helper$$$439$$$445$$$O	inducers$$$446$$$454$$$O	and$$$455$$$458$$$O	an$$$459$$$461$$$O	anticachexia$$$462$$$474$$$O	agent,$$$475$$$481$$$O	which$$$482$$$487$$$O	act$$$488$$$491$$$O	cooperatively$$$492$$$505$$$O	to$$$506$$$508$$$O	achieve$$$509$$$516$$$O	the$$$517$$$520$$$O	best$$$521$$$525$$$O	therapeutic$$$526$$$537$$$O	effect.$$$538$$$545$$$O
WO2011071684A1
Oral$$$0$$$4$$$O	rehydration$$$5$$$16$$$O	solutions$$$17$$$26$$$O	comprising$$$27$$$37$$$O	dextrose$$$38$$$46$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	is$$$23$$$25$$$O	directed$$$26$$$34$$$O	to$$$35$$$37$$$O	oral$$$38$$$42$$$O	rehydration$$$43$$$54$$$O	solutions,$$$55$$$65$$$O	and$$$66$$$69$$$O	the$$$70$$$73$$$O	use$$$74$$$77$$$O	of$$$78$$$80$$$O	these$$$81$$$86$$$O	solutions$$$87$$$96$$$O	to$$$97$$$99$$$O	prevent$$$100$$$107$$$O	dehydration$$$108$$$119$$$O	due$$$120$$$123$$$O	to$$$124$$$126$$$O	fever.$$$127$$$133$$$O	The$$$134$$$137$$$O	oral$$$138$$$142$$$O	rehydration$$$143$$$154$$$O	solutions$$$155$$$164$$$O	of$$$165$$$167$$$O	the$$$168$$$171$$$O	present$$$172$$$179$$$O	disclosure$$$180$$$190$$$O	may$$$191$$$194$$$O	be$$$195$$$197$$$O	oral$$$198$$$202$$$O	rehydration$$$203$$$214$$$O	solutions$$$215$$$224$$$O	comprising$$$225$$$235$$$O	about$$$236$$$241$$$O	12$$$242$$$244$$$O	mEq/L$$$245$$$250$$$O	to$$$251$$$253$$$O	about$$$254$$$259$$$O	18$$$260$$$262$$$O	mEq/L$$$263$$$268$$$O	of$$$269$$$271$$$O	sodium,$$$272$$$279$$$I	from$$$280$$$284$$$O	about$$$285$$$290$$$O	11$$$291$$$293$$$O	g/L$$$294$$$297$$$O	to$$$298$$$300$$$O	about$$$301$$$306$$$O	60$$$307$$$309$$$O	g/L$$$310$$$313$$$O	of$$$314$$$316$$$O	dextrose,$$$317$$$326$$$I	a$$$327$$$328$$$O	zinc$$$329$$$333$$$I	source,$$$334$$$341$$$O	and$$$342$$$345$$$O	less$$$346$$$350$$$O	than$$$351$$$355$$$O	about$$$356$$$361$$$O	25$$$362$$$364$$$O	mEq/L$$$365$$$370$$$O	of$$$371$$$373$$$O	citrates.$$$374$$$383$$$I	The$$$384$$$387$$$O	pH$$$388$$$390$$$O	of$$$391$$$393$$$O	the$$$394$$$397$$$O	oral$$$398$$$402$$$O	rehydration$$$403$$$414$$$O	solutions$$$415$$$424$$$O	can$$$425$$$428$$$O	be$$$429$$$431$$$O	controlled$$$432$$$442$$$O	by$$$443$$$445$$$O	adjusting$$$446$$$455$$$O	the$$$456$$$459$$$O	amount$$$460$$$466$$$O	of$$$467$$$469$$$O	dextrose$$$470$$$478$$$I	present$$$479$$$486$$$O	in$$$487$$$489$$$O	the$$$490$$$493$$$O	oral$$$494$$$498$$$O	rehydration$$$499$$$510$$$O	solutions,$$$511$$$521$$$O	allowing$$$522$$$530$$$O	for$$$531$$$534$$$O	formulation$$$535$$$546$$$O	of$$$547$$$549$$$O	oral$$$550$$$554$$$O	rehydration$$$555$$$566$$$O	solutions$$$567$$$576$$$O	comprising$$$577$$$587$$$O	lower$$$588$$$593$$$O	levels$$$594$$$600$$$O	of$$$601$$$603$$$O	citrates.$$$604$$$613$$$O
CN101703506B
Medicinal-composition$$$0$$$21$$$O	suspension$$$22$$$32$$$O	powder$$$33$$$39$$$O	injection$$$40$$$49$$$O	with$$$50$$$54$$$O	mezlocillin$$$55$$$66$$$I	sodium$$$67$$$73$$$I	and$$$74$$$77$$$O	sulbactam$$$78$$$87$$$I	sodium,$$$88$$$95$$$I	and$$$96$$$99$$$O	novel$$$100$$$105$$$O	application$$$106$$$117$$$O	thereof$$$118$$$125$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicine,$$$48$$$57$$$O	and$$$58$$$61$$$O	discloses$$$62$$$71$$$O	a$$$72$$$73$$$O	medicinal-composition$$$74$$$95$$$O	suspension$$$96$$$106$$$O	powder$$$107$$$113$$$O	injection$$$114$$$123$$$O	taking$$$124$$$130$$$O	mezlocillin$$$131$$$142$$$I	sodium$$$143$$$149$$$I	and$$$150$$$153$$$O	sulbactam$$$154$$$163$$$I	sodium$$$164$$$170$$$I	as$$$171$$$173$$$O	active$$$174$$$180$$$O	components.$$$181$$$192$$$O	The$$$193$$$196$$$O	injection$$$197$$$206$$$O	comprises$$$207$$$216$$$O	4$$$217$$$218$$$O	parts$$$219$$$224$$$O	of$$$225$$$227$$$O	mezlocillin$$$228$$$239$$$I	sodium,$$$240$$$247$$$I	1$$$248$$$249$$$O	part$$$250$$$254$$$O	of$$$255$$$257$$$O	sulbactam$$$258$$$267$$$I	sodium,$$$268$$$275$$$I	5$$$276$$$277$$$O	to$$$278$$$280$$$O	20$$$281$$$283$$$O	parts$$$284$$$289$$$O	of$$$290$$$292$$$O	Tween$$$293$$$298$$$O	80,$$$299$$$302$$$O	1$$$303$$$304$$$O	to$$$305$$$307$$$O	10$$$308$$$310$$$O	parts$$$311$$$316$$$O	of$$$317$$$319$$$O	cholesterol,$$$320$$$332$$$I	0.5$$$333$$$336$$$O	to$$$337$$$339$$$O	15$$$340$$$342$$$O	parts$$$343$$$348$$$O	of$$$349$$$351$$$O	deoxysodium$$$352$$$363$$$I	cholate,$$$364$$$372$$$I	and$$$373$$$376$$$O	2$$$377$$$378$$$O	to$$$379$$$381$$$O	30$$$382$$$384$$$O	parts$$$385$$$390$$$O	of$$$391$$$393$$$O	frozen-dried$$$394$$$406$$$O	supporting$$$407$$$417$$$O	agent.$$$418$$$424$$$O	The$$$425$$$428$$$O	invention$$$429$$$438$$$O	further$$$439$$$446$$$O	discloses$$$447$$$456$$$O	novel$$$457$$$462$$$O	application$$$463$$$474$$$O	of$$$475$$$477$$$O	the$$$478$$$481$$$O	injection$$$482$$$491$$$O	in$$$492$$$494$$$O	the$$$495$$$498$$$O	preparation$$$499$$$510$$$O	of$$$511$$$513$$$O	medicaments$$$514$$$525$$$O	for$$$526$$$529$$$O	preventing$$$530$$$540$$$O	postoperative$$$541$$$554$$$O	infection$$$555$$$564$$$O	of$$$565$$$567$$$O	appendicitis.$$$568$$$581$$$O
CN1846686A
Slow-released$$$0$$$13$$$O	injection$$$14$$$23$$$O	containing$$$24$$$34$$$O	taxol$$$35$$$40$$$I	and$$$41$$$44$$$O	its$$$45$$$48$$$O	synergist$$$49$$$58$$$O
The$$$0$$$3$$$O	slow$$$4$$$8$$$O	released$$$9$$$17$$$O	injection$$$18$$$27$$$O	containing$$$28$$$38$$$O	taxane$$$39$$$45$$$I	and$$$46$$$49$$$O	its$$$50$$$53$$$O	synergist$$$54$$$63$$$O	consists$$$64$$$72$$$O	of$$$73$$$75$$$O	slow$$$76$$$80$$$O	released$$$81$$$89$$$O	microballoon$$$90$$$102$$$O	and$$$103$$$106$$$O	solvent.$$$107$$$115$$$O	The$$$116$$$119$$$O	slow$$$120$$$124$$$O	released$$$125$$$133$$$O	microballoon$$$134$$$146$$$O	includes$$$147$$$155$$$O	effective$$$156$$$165$$$O	anticancer$$$166$$$176$$$O	component$$$177$$$186$$$O	and$$$187$$$190$$$O	slow$$$191$$$195$$$O	releasing$$$196$$$205$$$O	supplementary$$$206$$$219$$$O	material,$$$220$$$229$$$O	and$$$230$$$233$$$O	the$$$234$$$237$$$O	solvent$$$238$$$245$$$O	is$$$246$$$248$$$O	common$$$249$$$255$$$O	solvent$$$256$$$263$$$O	or$$$264$$$266$$$O	special$$$267$$$274$$$O	solvent$$$275$$$282$$$O	containing$$$283$$$293$$$O	suspending$$$294$$$304$$$O	agent.$$$305$$$311$$$O	The$$$312$$$315$$$O	effective$$$316$$$325$$$O	anticancer$$$326$$$336$$$O	component$$$337$$$346$$$O	is$$$347$$$349$$$O	taxane$$$350$$$356$$$I	and/or$$$357$$$363$$$O	taxane$$$364$$$370$$$I	synergist$$$371$$$380$$$O	of$$$381$$$383$$$O	topoisomerase$$$384$$$397$$$O	inhibitor,$$$398$$$408$$$O	guanine$$$409$$$416$$$I	analogue,$$$417$$$426$$$O	tetrazine$$$427$$$436$$$I	compound$$$437$$$445$$$O	and/or$$$446$$$452$$$O	platinum$$$453$$$461$$$I	compound;$$$462$$$471$$$O	the$$$472$$$475$$$O	slow$$$476$$$480$$$O	releasing$$$481$$$490$$$O	supplementary$$$491$$$504$$$O	material$$$505$$$513$$$O	is$$$514$$$516$$$O	PLA,$$$517$$$521$$$O	PLGA,$$$522$$$527$$$O	EVAc,$$$528$$$533$$$O	etc$$$534$$$537$$$O	or$$$538$$$540$$$O	their$$$541$$$546$$$O	composition;$$$547$$$559$$$O	and$$$560$$$563$$$O	the$$$564$$$567$$$O	suspending$$$568$$$578$$$O	agent$$$579$$$584$$$O	is$$$585$$$587$$$O	sodium$$$588$$$594$$$O	carboxymethyl$$$595$$$608$$$O	cellulose,$$$609$$$619$$$O	Tween-40,$$$620$$$629$$$O	Tween-80$$$630$$$638$$$O	or$$$639$$$641$$$O	their$$$642$$$647$$$O	composition.$$$648$$$660$$$O	The$$$661$$$664$$$O	slow$$$665$$$669$$$O	released$$$670$$$678$$$O	microballoon$$$679$$$691$$$O	may$$$692$$$695$$$O	be$$$696$$$698$$$O	also$$$699$$$703$$$O	prepared$$$704$$$712$$$O	into$$$713$$$717$$$O	implantation$$$718$$$730$$$O	preparation.$$$731$$$743$$$O	Implanting$$$744$$$754$$$O	or$$$755$$$757$$$O	injecting$$$758$$$767$$$O	the$$$768$$$771$$$O	slow$$$772$$$776$$$O	released$$$777$$$785$$$O	preparation$$$786$$$797$$$O	to$$$798$$$800$$$O	local$$$801$$$806$$$O	tumor$$$807$$$812$$$O	part$$$813$$$817$$$O	can$$$818$$$821$$$O	lower$$$822$$$827$$$O	the$$$828$$$831$$$O	systematic$$$832$$$842$$$O	toxic$$$843$$$848$$$O	reaction$$$849$$$857$$$O	of$$$858$$$860$$$O	the$$$861$$$864$$$O	medicine$$$865$$$873$$$O	and$$$874$$$877$$$O	raise$$$878$$$883$$$O	the$$$884$$$887$$$O	treating$$$888$$$896$$$O	effect.$$$897$$$904$$$O
US20110262537
Extended$$$0$$$8$$$O	release$$$9$$$16$$$O	dosage$$$17$$$23$$$O	form$$$24$$$28$$$O	of$$$29$$$31$$$O	ropinirole$$$32$$$42$$$I
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	an$$$18$$$20$$$O	extended$$$21$$$29$$$O	release$$$30$$$37$$$O	tablet$$$38$$$44$$$O	in$$$45$$$47$$$O	tablet$$$48$$$54$$$O	dosage$$$55$$$61$$$O	form$$$62$$$66$$$O	of$$$67$$$69$$$O	ropinirole$$$70$$$80$$$I	or$$$81$$$83$$$O	salts$$$84$$$89$$$O	thereof$$$90$$$97$$$O	comprising$$$98$$$108$$$O	a)$$$109$$$111$$$O	an$$$112$$$114$$$O	inner$$$115$$$120$$$O	tablet$$$121$$$127$$$O	of$$$128$$$130$$$O	ropinirole$$$131$$$141$$$I	or$$$142$$$144$$$O	salts$$$145$$$150$$$O	thereof$$$151$$$158$$$O	optionally$$$159$$$169$$$O	with$$$170$$$174$$$O	other$$$175$$$180$$$O	pharmaceutically$$$181$$$197$$$O	acceptable$$$198$$$208$$$O	excipients$$$209$$$219$$$O	and$$$220$$$223$$$O	b)$$$224$$$226$$$O	an$$$227$$$229$$$O	outer$$$230$$$235$$$O	tablet$$$236$$$242$$$O	of$$$243$$$245$$$O	other$$$246$$$251$$$O	pharmaceutically$$$252$$$268$$$O	acceptable$$$269$$$279$$$O	excipients.$$$280$$$291$$$O	The$$$292$$$295$$$O	invention$$$296$$$305$$$O	also$$$306$$$310$$$O	provides$$$311$$$319$$$O	an$$$320$$$322$$$O	extended$$$323$$$331$$$O	release$$$332$$$339$$$O	pharmaceutical$$$340$$$354$$$O	composition$$$355$$$366$$$O	comprising$$$367$$$377$$$O	a$$$378$$$379$$$O	core$$$380$$$384$$$O	of$$$385$$$387$$$O	ropinirole$$$388$$$398$$$I	or$$$399$$$401$$$O	salt$$$402$$$406$$$O	thereof$$$407$$$414$$$O	and$$$415$$$418$$$O	outer$$$419$$$424$$$O	mantle$$$425$$$431$$$O	coating$$$432$$$439$$$O	comprising$$$440$$$450$$$O	one$$$451$$$454$$$O	or$$$455$$$457$$$O	more$$$458$$$462$$$O	pharmaceutically$$$463$$$479$$$O	acceptable$$$480$$$490$$$O	excipients.$$$491$$$502$$$O	The$$$503$$$506$$$O	invention$$$507$$$516$$$O	also$$$517$$$521$$$O	relates$$$522$$$529$$$O	to$$$530$$$532$$$O	processes$$$533$$$542$$$O	of$$$543$$$545$$$O	preparing$$$546$$$555$$$O	such$$$556$$$560$$$O	compositions.$$$561$$$574$$$O
US7144912
drugs$$$0$$$5$$$O	such$$$6$$$10$$$O	as$$$11$$$13$$$O	(4-methoxy-5-(1H-indol-2yl-methylene)-2,2'-bi-1H-pyrrole)$$$14$$$71$$$I	used$$$72$$$76$$$O	as$$$77$$$79$$$O	anticarcinogenic$$$80$$$96$$$O	or$$$97$$$99$$$O	antitumor$$$100$$$109$$$O	agents$$$110$$$116$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	Pyrrole-Type$$$39$$$51$$$I	compounds,$$$52$$$62$$$O	compositions$$$63$$$75$$$O	comprising$$$76$$$86$$$O	Pyrrole-Type$$$87$$$99$$$I	compounds,$$$100$$$110$$$O	and$$$111$$$114$$$O	methods$$$115$$$122$$$O	useful$$$123$$$129$$$O	for$$$130$$$133$$$O	treating$$$134$$$142$$$O	or$$$143$$$145$$$O	preventing$$$146$$$156$$$O	cancer$$$157$$$163$$$O	or$$$164$$$166$$$O	a$$$167$$$168$$$O	neoplastic$$$169$$$179$$$O	disorder$$$180$$$188$$$O	comprising$$$189$$$199$$$O	administering$$$200$$$213$$$O	a$$$214$$$215$$$O	Pyrrole-Type$$$216$$$228$$$I	compound.$$$229$$$238$$$O	The$$$239$$$242$$$O	compounds,$$$243$$$253$$$O	compositions,$$$254$$$267$$$O	and$$$268$$$271$$$O	methods$$$272$$$279$$$O	of$$$280$$$282$$$O	the$$$283$$$286$$$O	invention$$$287$$$296$$$O	are$$$297$$$300$$$O	also$$$301$$$305$$$O	useful$$$306$$$312$$$O	for$$$313$$$316$$$O	inhibiting$$$317$$$327$$$O	the$$$328$$$331$$$O	growth$$$332$$$338$$$O	of$$$339$$$341$$$O	a$$$342$$$343$$$O	cancer$$$344$$$350$$$O	cell$$$351$$$355$$$O	or$$$356$$$358$$$O	neoplastic$$$359$$$369$$$O	cell.$$$370$$$375$$$O	The$$$376$$$379$$$O	present$$$380$$$387$$$O	invention$$$388$$$397$$$O	also$$$398$$$402$$$O	relates$$$403$$$410$$$O	to$$$411$$$413$$$O	novel$$$414$$$419$$$O	Pyrrole-Type$$$420$$$432$$$I	compounds,$$$433$$$443$$$O	compositions,$$$444$$$457$$$O	and$$$458$$$461$$$O	methods$$$462$$$469$$$O	useful$$$470$$$476$$$O	for$$$477$$$480$$$O	treating$$$481$$$489$$$O	or$$$490$$$492$$$O	preventing$$$493$$$503$$$O	a$$$504$$$505$$$O	viral$$$506$$$511$$$O	infection.$$$512$$$522$$$O	The$$$523$$$526$$$O	compounds,$$$527$$$537$$$O	compositions,$$$538$$$551$$$O	and$$$552$$$555$$$O	methods$$$556$$$563$$$O	of$$$564$$$566$$$O	the$$$567$$$570$$$O	invention$$$571$$$580$$$O	are$$$581$$$584$$$O	also$$$585$$$589$$$O	useful$$$590$$$596$$$O	for$$$597$$$600$$$O	inhibiting$$$601$$$611$$$O	the$$$612$$$615$$$O	replication$$$616$$$627$$$O	and/or$$$628$$$634$$$O	infectivity$$$635$$$646$$$O	of$$$647$$$649$$$O	a$$$650$$$651$$$O	virus.$$$652$$$658$$$O	The$$$659$$$662$$$O	present$$$663$$$670$$$O	invention$$$671$$$680$$$O	also$$$681$$$685$$$O	relates$$$686$$$693$$$O	to$$$694$$$696$$$O	novel$$$697$$$702$$$O	Pyrrole-Type$$$703$$$715$$$I	compounds,$$$716$$$726$$$O	compositions,$$$727$$$740$$$O	and$$$741$$$744$$$O	methods$$$745$$$752$$$O	useful$$$753$$$759$$$O	for$$$760$$$763$$$O	causing$$$764$$$771$$$O	immunosuppression.$$$772$$$790$$$O	The$$$791$$$794$$$O	present$$$795$$$802$$$O	invention$$$803$$$812$$$O	also$$$813$$$817$$$O	relates$$$818$$$825$$$O	to$$$826$$$828$$$O	novel$$$829$$$834$$$O	Pyrrole-Type$$$835$$$847$$$I	compounds,$$$848$$$858$$$O	compositions,$$$859$$$872$$$O	and$$$873$$$876$$$O	methods$$$877$$$884$$$O	useful$$$885$$$891$$$O	for$$$892$$$895$$$O	treating$$$896$$$904$$$O	or$$$905$$$907$$$O	preventing$$$908$$$918$$$O	an$$$919$$$921$$$O	autoimmune$$$922$$$932$$$O	disease.$$$933$$$941$$$O
CN103223172A
Medicine$$$0$$$8$$$O	used$$$9$$$13$$$O	for$$$14$$$17$$$O	preventing$$$18$$$28$$$O	and$$$29$$$32$$$O	treating$$$33$$$41$$$O	postmenopausal$$$42$$$56$$$O	osteoporosis$$$57$$$69$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	pharmaceutical$$$26$$$40$$$O	formulation$$$41$$$52$$$O	which$$$53$$$58$$$O	contains$$$59$$$67$$$O	alfacalcidol$$$68$$$80$$$I	and$$$81$$$84$$$O	estrogen$$$85$$$93$$$I	and$$$94$$$97$$$O	is$$$98$$$100$$$O	used$$$101$$$105$$$O	for$$$106$$$109$$$O	preventing$$$110$$$120$$$O	and$$$121$$$124$$$O	treating$$$125$$$133$$$O	premenopausal$$$134$$$147$$$O	and$$$148$$$151$$$O	postmenopausal$$$152$$$166$$$O	osteoporosis.$$$167$$$180$$$O
US20100330212
Skin$$$0$$$4$$$O	sensitizer$$$5$$$15$$$O	delivery$$$16$$$24$$$O	system$$$25$$$31$$$O
A$$$0$$$1$$$O	skin-sensitizing$$$2$$$18$$$O	formulation$$$19$$$30$$$O	is$$$31$$$33$$$O	provided$$$34$$$42$$$O	in$$$43$$$45$$$O	an$$$46$$$48$$$O	edible,$$$49$$$56$$$O	softgel$$$57$$$64$$$O	pill.$$$65$$$70$$$O	A$$$71$$$72$$$O	person$$$73$$$79$$$O	engaged$$$80$$$87$$$O	in$$$88$$$90$$$O	a$$$91$$$92$$$O	sexual$$$93$$$99$$$O	activity$$$100$$$108$$$O	bites$$$109$$$114$$$O	down$$$115$$$119$$$O	on$$$120$$$122$$$O	the$$$123$$$126$$$O	pill,$$$127$$$132$$$O	thereby$$$133$$$140$$$O	effectuating$$$141$$$153$$$O	the$$$154$$$157$$$O	oral$$$158$$$162$$$O	release$$$163$$$170$$$O	of$$$171$$$173$$$O	the$$$174$$$177$$$O	skin-sensitizing$$$178$$$194$$$O	formulation.$$$195$$$207$$$O	This$$$208$$$212$$$O	allows$$$213$$$219$$$O	the$$$220$$$223$$$O	skin-sensitizing$$$224$$$240$$$O	formulation$$$241$$$252$$$O	to$$$253$$$255$$$O	be$$$256$$$258$$$O	spread$$$259$$$265$$$O	to$$$266$$$268$$$O	a$$$269$$$270$$$O	sexual$$$271$$$277$$$O	partner,$$$278$$$286$$$O	on$$$287$$$289$$$O	any$$$290$$$293$$$O	part$$$294$$$298$$$O	of$$$299$$$301$$$O	the$$$302$$$305$$$O	skin$$$306$$$310$$$O	or$$$311$$$313$$$O	sexual$$$314$$$320$$$O	region$$$321$$$327$$$O	of$$$328$$$330$$$O	the$$$331$$$334$$$O	body$$$335$$$339$$$O	preferably$$$340$$$350$$$O	through$$$351$$$358$$$O	oral$$$359$$$363$$$O	contact$$$364$$$371$$$O	with$$$372$$$376$$$O	the$$$377$$$380$$$O	partner.$$$381$$$389$$$O	The$$$390$$$393$$$O	skin-sensitizing$$$394$$$410$$$O	substance$$$411$$$420$$$O	is$$$421$$$423$$$O	spread$$$424$$$430$$$O	to$$$431$$$433$$$O	the$$$434$$$437$$$O	partner$$$438$$$445$$$O	directly$$$446$$$454$$$O	on$$$455$$$457$$$O	the$$$458$$$461$$$O	skin$$$462$$$466$$$O	or$$$467$$$469$$$O	through$$$470$$$477$$$O	oral$$$478$$$482$$$O	contact$$$483$$$490$$$O	or$$$491$$$493$$$O	beneath$$$494$$$501$$$O	a$$$502$$$503$$$O	condom$$$504$$$510$$$O	worn$$$511$$$515$$$O	by$$$516$$$518$$$O	the$$$519$$$522$$$O	partner.$$$523$$$531$$$O	The$$$532$$$535$$$O	skin-sensitizing$$$536$$$552$$$O	formulation$$$553$$$564$$$O	may$$$565$$$568$$$O	include$$$569$$$576$$$O	an$$$577$$$579$$$O	essential$$$580$$$589$$$O	mint$$$590$$$594$$$O	oil,$$$595$$$599$$$O	analog$$$600$$$606$$$O	or$$$607$$$609$$$O	derivative,$$$610$$$621$$$O	and$$$622$$$625$$$O	may$$$626$$$629$$$O	further$$$630$$$637$$$O	includes$$$638$$$646$$$O	an$$$647$$$649$$$O	enhancer,$$$650$$$659$$$O	rubefacient,$$$660$$$672$$$O	counterirritant,$$$673$$$689$$$O	anesthetic,$$$690$$$701$$$O	K-Opoid$$$702$$$709$$$O	Receptor$$$710$$$718$$$O	activator,$$$719$$$729$$$O	or$$$730$$$732$$$O	TRPM8$$$733$$$738$$$O	activator.$$$739$$$749$$$O	Various$$$750$$$757$$$O	inactive$$$758$$$766$$$O	ingredients$$$767$$$778$$$O	are$$$779$$$782$$$O	also$$$783$$$787$$$O	disclosed.$$$788$$$798$$$O
EP1301460B1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	a$$$21$$$22$$$O	fatty$$$23$$$28$$$O	substance$$$29$$$38$$$O	ester$$$39$$$44$$$I	and$$$45$$$48$$$O	use$$$49$$$52$$$O	thereof$$$53$$$60$$$O	in$$$61$$$63$$$O	pharmaceutics,$$$64$$$78$$$O	cosmetics$$$79$$$88$$$O	or$$$89$$$91$$$O	food$$$92$$$96$$$O	industry$$$97$$$105$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	a$$$23$$$24$$$O	method$$$25$$$31$$$O	for$$$32$$$35$$$O	preparing$$$36$$$45$$$O	a$$$46$$$47$$$O	fatty$$$48$$$53$$$O	substance$$$54$$$63$$$O	ester,$$$64$$$70$$$I	characterised$$$71$$$84$$$O	in$$$85$$$87$$$O	that$$$88$$$92$$$O	it$$$93$$$95$$$O	consists$$$96$$$104$$$O	in$$$105$$$107$$$O	subjecting$$$108$$$118$$$O	to$$$119$$$121$$$O	an$$$122$$$124$$$O	esterification$$$125$$$139$$$O	reaction$$$140$$$148$$$O	at$$$149$$$151$$$O	least$$$152$$$157$$$O	a$$$158$$$159$$$O	fatty$$$160$$$165$$$O	substance$$$166$$$175$$$O	with$$$176$$$180$$$O	at$$$181$$$183$$$O	least$$$184$$$189$$$O	an$$$190$$$192$$$O	alcohol$$$193$$$200$$$I	compound$$$201$$$209$$$O	selected$$$210$$$218$$$O	from$$$219$$$223$$$O	the$$$224$$$227$$$O	group$$$228$$$233$$$O	consisting$$$234$$$244$$$O	of$$$245$$$247$$$O	sterols,$$$248$$$256$$$I	stanols,$$$257$$$265$$$I	4-methylsterols$$$266$$$281$$$I	and$$$282$$$285$$$O	their$$$286$$$291$$$O	hydrogenated$$$292$$$304$$$O	homologues,$$$305$$$316$$$O	triterpene$$$317$$$327$$$I	alcohols$$$328$$$336$$$I	and$$$337$$$340$$$O	their$$$341$$$346$$$O	hydrogenated$$$347$$$359$$$O	homologues,$$$360$$$371$$$O	and$$$372$$$375$$$O	mixtures$$$376$$$384$$$O	thereof,$$$385$$$393$$$O	in$$$394$$$396$$$O	the$$$397$$$400$$$O	presence$$$401$$$409$$$O	of$$$410$$$412$$$O	at$$$413$$$415$$$O	least$$$416$$$421$$$O	a$$$422$$$423$$$O	solid$$$424$$$429$$$O	catalyst$$$430$$$438$$$O	selected$$$439$$$447$$$O	in$$$448$$$450$$$O	the$$$451$$$454$$$O	group$$$455$$$460$$$O	consisting$$$461$$$471$$$O	of$$$472$$$474$$$O	lanthanide$$$475$$$485$$$I	oxides$$$486$$$492$$$I	and$$$493$$$496$$$O	the$$$497$$$500$$$O	mixtures$$$501$$$509$$$O	of$$$510$$$512$$$O	said$$$513$$$517$$$O	oxides.$$$518$$$525$$$I	Said$$$526$$$530$$$O	method$$$531$$$537$$$O	enables$$$538$$$545$$$O	to$$$546$$$548$$$O	obtain$$$549$$$555$$$O	products$$$556$$$564$$$O	particularly$$$565$$$577$$$O	suited$$$578$$$584$$$O	for$$$585$$$588$$$O	use$$$589$$$592$$$O	in$$$593$$$595$$$O	the$$$596$$$599$$$O	field$$$600$$$605$$$O	of$$$606$$$608$$$O	pharmaceutics,$$$609$$$623$$$O	in$$$624$$$626$$$O	particular$$$627$$$637$$$O	dermatology,$$$638$$$650$$$O	cosmetics$$$651$$$660$$$O	and$$$661$$$664$$$O	special$$$665$$$672$$$O	food$$$673$$$677$$$O	production$$$678$$$688$$$O	(functional$$$689$$$700$$$O	food$$$701$$$705$$$O	products,$$$706$$$715$$$O	medicinal$$$716$$$725$$$O	food$$$726$$$730$$$O	products$$$731$$$739$$$O	and$$$740$$$743$$$O	dietetic$$$744$$$752$$$O	food$$$753$$$757$$$O	products)$$$758$$$767$$$O
CN1927198A
Tiopronin$$$0$$$9$$$I	freeze-dried$$$10$$$22$$$O	powder$$$23$$$29$$$O	injection$$$30$$$39$$$O	with$$$40$$$44$$$O	no$$$45$$$47$$$O	need$$$48$$$52$$$O	of$$$53$$$55$$$O	special$$$56$$$63$$$O	dissolvant$$$64$$$74$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	involves$$$14$$$22$$$O	the$$$23$$$26$$$O	composition$$$27$$$38$$$O	of$$$39$$$41$$$O	tiopronin$$$42$$$51$$$I	gelsiccation$$$52$$$64$$$O	powder$$$65$$$71$$$O	styporocts$$$72$$$82$$$O	without$$$83$$$90$$$O	special$$$91$$$98$$$O	solvents$$$99$$$107$$$O	and$$$108$$$111$$$O	can$$$112$$$115$$$O	be$$$116$$$118$$$O	directly$$$119$$$127$$$O	dissolved$$$128$$$137$$$O	after$$$138$$$143$$$O	intravenous$$$144$$$155$$$O	infusion$$$156$$$164$$$O	drip$$$165$$$169$$$O	and$$$170$$$173$$$O	its$$$174$$$177$$$O	preparation.$$$178$$$190$$$O	The$$$191$$$194$$$O	invention$$$195$$$204$$$O	tiopronin$$$205$$$214$$$I	gelsiccation$$$215$$$227$$$O	powder$$$228$$$234$$$O	styporocts$$$235$$$245$$$O	contains$$$246$$$254$$$O	active$$$255$$$261$$$O	ingredients$$$262$$$273$$$O	tiopronin$$$274$$$283$$$I	and$$$284$$$287$$$O	drug$$$288$$$292$$$O	additives$$$293$$$302$$$O	arginine,$$$303$$$312$$$I	dextran$$$313$$$320$$$O	and$$$321$$$324$$$O	ethylenediaminetetraacetate$$$325$$$352$$$I	optimizing$$$353$$$363$$$O	components$$$364$$$374$$$O	is:$$$375$$$378$$$O	tiopronin,$$$379$$$389$$$I	L-arginine,$$$390$$$401$$$I	dextran$$$402$$$409$$$O	20$$$410$$$412$$$O	and$$$413$$$416$$$O	sodium$$$417$$$423$$$I	calciumedetate,$$$424$$$439$$$I	optimal$$$440$$$447$$$O	weight$$$448$$$454$$$O	ratio$$$455$$$460$$$O	of$$$461$$$463$$$O	the$$$464$$$467$$$O	four$$$468$$$472$$$O	components$$$473$$$483$$$O	is$$$484$$$486$$$O	1:1.1:1:0.002,$$$487$$$501$$$O	Preparation$$$502$$$513$$$O	method$$$514$$$520$$$O	is$$$521$$$523$$$O	to$$$524$$$526$$$O	dissolve$$$527$$$535$$$O	the$$$536$$$539$$$O	tiopronin$$$540$$$549$$$I	and$$$550$$$553$$$O	drug$$$554$$$558$$$O	additives$$$559$$$568$$$O	arginine,$$$569$$$578$$$I	dextran$$$579$$$586$$$O	and$$$587$$$590$$$O	sodium$$$591$$$597$$$I	calciumedetate$$$598$$$612$$$I	in$$$613$$$615$$$O	the$$$616$$$619$$$O	adequate$$$620$$$628$$$O	water$$$629$$$634$$$O	for$$$635$$$638$$$O	injection,$$$639$$$649$$$O	After$$$650$$$655$$$O	being$$$656$$$661$$$O	stirred$$$662$$$669$$$O	and$$$670$$$673$$$O	dissolved,$$$674$$$684$$$O	sterilization,$$$685$$$699$$$O	packaging,$$$700$$$710$$$O	freeze-dried$$$711$$$723$$$O	according$$$724$$$733$$$O	to$$$734$$$736$$$O	conventional$$$737$$$749$$$O	method.$$$750$$$757$$$O
US20080274546
Artificial$$$0$$$10$$$O	physiological$$$11$$$24$$$O	salt$$$25$$$29$$$O	solution$$$30$$$38$$$O	and$$$39$$$42$$$O	manufacturing$$$43$$$56$$$O	method$$$57$$$63$$$O	for$$$64$$$67$$$O	same$$$68$$$72$$$O
An$$$0$$$2$$$O	artificial$$$3$$$13$$$O	physiological$$$14$$$27$$$O	salt$$$28$$$32$$$O	solution,$$$33$$$42$$$O	wherein$$$43$$$50$$$O	the$$$51$$$54$$$O	active$$$55$$$61$$$O	hydrogen$$$62$$$70$$$I	reaction$$$71$$$79$$$O	value$$$80$$$85$$$O	is$$$86$$$88$$$O	0.01$$$89$$$93$$$O	to$$$94$$$96$$$O	1,$$$97$$$99$$$O	the$$$100$$$103$$$O	pH$$$104$$$106$$$O	is$$$107$$$109$$$O	4.0$$$110$$$113$$$O	to$$$114$$$116$$$O	7.9$$$117$$$120$$$O	and$$$121$$$124$$$O	the$$$125$$$128$$$O	osmotic$$$129$$$136$$$O	pressure$$$137$$$145$$$O	is$$$146$$$148$$$O	260$$$149$$$152$$$O	mOsm/L$$$153$$$159$$$O	to$$$160$$$162$$$O	2560$$$163$$$167$$$O	mOsm/L,$$$168$$$175$$$O	as$$$176$$$178$$$O	well$$$179$$$183$$$O	as$$$184$$$186$$$O	a$$$187$$$188$$$O	manufacturing$$$189$$$202$$$O	method$$$203$$$209$$$O	for$$$210$$$213$$$O	the$$$214$$$217$$$O	same$$$218$$$222$$$O	are$$$223$$$226$$$O	provided$$$227$$$235$$$O	as$$$236$$$238$$$O	a$$$239$$$240$$$O	novel$$$241$$$246$$$O	artificial$$$247$$$257$$$O	physiological$$$258$$$271$$$O	salt$$$272$$$276$$$O	solution,$$$277$$$286$$$O	which$$$287$$$292$$$O	has$$$293$$$296$$$O	active$$$297$$$303$$$O	oxygen$$$304$$$310$$$I	eliminating$$$311$$$322$$$O	activity$$$323$$$331$$$O	and$$$332$$$335$$$O	anti-inflammation$$$336$$$353$$$O	effects,$$$354$$$362$$$O	and$$$363$$$366$$$O	can$$$367$$$370$$$O	be$$$371$$$373$$$O	appropriately$$$374$$$387$$$O	used$$$388$$$392$$$O	in$$$393$$$395$$$O	a$$$396$$$397$$$O	multitude$$$398$$$407$$$O	of$$$408$$$410$$$O	applications$$$411$$$423$$$O	such$$$424$$$428$$$O	as$$$429$$$431$$$O	organ$$$432$$$437$$$O	cleaning$$$438$$$446$$$O	solutions$$$447$$$456$$$O	(cleaning$$$457$$$466$$$O	solutions$$$467$$$476$$$O	for$$$477$$$480$$$O	the$$$481$$$484$$$O	eyes,$$$485$$$490$$$O	cleaning$$$491$$$499$$$O	solutions$$$500$$$509$$$O	for$$$510$$$513$$$O	the$$$514$$$517$$$O	nose$$$518$$$522$$$O	and$$$523$$$526$$$O	the$$$527$$$530$$$O	like),$$$531$$$537$$$O	artificial$$$538$$$548$$$O	infusions,$$$549$$$559$$$O	artificial$$$560$$$570$$$O	amniotic$$$571$$$579$$$O	fluid,$$$580$$$586$$$O	protective$$$587$$$597$$$O	solutions,$$$598$$$608$$$O	cell/tissue$$$609$$$620$$$O	cultures$$$621$$$629$$$O	and$$$630$$$633$$$O	the$$$634$$$637$$$O	like,$$$638$$$643$$$O	as$$$644$$$646$$$O	well$$$647$$$651$$$O	as$$$652$$$654$$$O	a$$$655$$$656$$$O	manufacturing$$$657$$$670$$$O	method$$$671$$$677$$$O	for$$$678$$$681$$$O	the$$$682$$$685$$$O	same.$$$686$$$691$$$O
US20070274936
Oligonucleotide$$$0$$$15$$$I	and$$$16$$$19$$$O	the$$$20$$$23$$$O	Use$$$24$$$27$$$O	Thereof$$$28$$$35$$$O	for$$$36$$$39$$$O	Modulating$$$40$$$50$$$O	an$$$51$$$53$$$O	Isoform$$$54$$$61$$$O	C$$$62$$$63$$$O	Beta-1$$$64$$$70$$$O	Protein-Kinase$$$71$$$85$$$O	in$$$86$$$88$$$O	the$$$89$$$92$$$O	Form$$$93$$$97$$$O	of$$$98$$$100$$$O	a$$$101$$$102$$$O	Skin$$$103$$$107$$$O	Depigmentation$$$108$$$122$$$O	Agent$$$123$$$128$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	oligonucleotide$$$26$$$41$$$I	sequences$$$42$$$51$$$O	and$$$52$$$55$$$O	their$$$56$$$61$$$O	derivatives.$$$62$$$74$$$O	These$$$75$$$80$$$O	oligonucleotide$$$81$$$96$$$I	sequences$$$97$$$106$$$O	are$$$107$$$110$$$O	capable$$$111$$$118$$$O	of$$$119$$$121$$$O	hybridising$$$122$$$133$$$O	with$$$134$$$138$$$O	the$$$139$$$142$$$O	genes$$$143$$$148$$$O	or$$$149$$$151$$$O	with$$$152$$$156$$$O	products$$$157$$$165$$$O	of$$$166$$$168$$$O	the$$$169$$$172$$$O	genes$$$173$$$178$$$O	coding$$$179$$$185$$$O	for$$$186$$$189$$$O	the$$$190$$$193$$$O	PKC-beta$$$194$$$202$$$O	1.$$$203$$$205$$$O	This$$$206$$$210$$$O	invention$$$211$$$220$$$O	also$$$221$$$225$$$O	relates$$$226$$$233$$$O	to$$$234$$$236$$$O	the$$$237$$$240$$$O	use$$$241$$$244$$$O	of$$$245$$$247$$$O	these$$$248$$$253$$$O	oligonucleotide$$$254$$$269$$$I	sequences$$$270$$$279$$$O	as$$$280$$$282$$$O	a$$$283$$$284$$$O	depigmenting$$$285$$$297$$$O	or$$$298$$$300$$$O	bleaching$$$301$$$310$$$O	agent$$$311$$$316$$$O	for$$$317$$$320$$$O	the$$$321$$$324$$$O	skin$$$325$$$329$$$O	in$$$330$$$332$$$O	a$$$333$$$334$$$O	cosmetic$$$335$$$343$$$O	composition$$$344$$$355$$$O	or$$$356$$$358$$$O	in$$$359$$$361$$$O	a$$$362$$$363$$$O	topical$$$364$$$371$$$O	pharmaceutical$$$372$$$386$$$O	composition.$$$387$$$399$$$O
CN101416937A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	new$$$22$$$25$$$O	cephalosporin$$$26$$$39$$$I	compound$$$40$$$48$$$O	formulation$$$49$$$60$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	new$$$27$$$30$$$O	preparation$$$31$$$42$$$O	method$$$43$$$49$$$O	of$$$50$$$52$$$O	a$$$53$$$54$$$O	cephalosporin$$$55$$$68$$$I	compound.$$$69$$$78$$$O	The$$$79$$$82$$$O	formula$$$83$$$90$$$O	for$$$91$$$94$$$O	preparing$$$95$$$104$$$O	a$$$105$$$106$$$O	suspension$$$107$$$117$$$O	comprises$$$118$$$127$$$O	1g$$$128$$$130$$$O	to$$$131$$$133$$$O	10g$$$134$$$137$$$O	of$$$138$$$140$$$O	the$$$141$$$144$$$O	cephalosporin$$$145$$$158$$$I	compound$$$159$$$167$$$O	(C18H23N5O6S2),$$$168$$$183$$$I	5g$$$184$$$186$$$O	to$$$187$$$189$$$O	15g$$$190$$$193$$$O	of$$$194$$$196$$$O	acacia,$$$197$$$204$$$O	0.1g$$$205$$$209$$$O	to$$$210$$$212$$$O	1g$$$213$$$215$$$O	of$$$216$$$218$$$O	sorbic$$$219$$$225$$$I	acid,$$$226$$$231$$$I	10g$$$232$$$235$$$O	to$$$236$$$238$$$O	20g$$$239$$$242$$$O	of$$$243$$$245$$$O	poloxamer$$$246$$$255$$$I	and$$$256$$$259$$$O	a$$$260$$$261$$$O	proper$$$262$$$268$$$O	amount$$$269$$$275$$$O	of$$$276$$$278$$$O	glycerin;$$$279$$$288$$$I	the$$$289$$$292$$$O	formula$$$293$$$300$$$O	for$$$301$$$304$$$O	preparing$$$305$$$314$$$O	an$$$315$$$317$$$O	injectable$$$318$$$328$$$O	powder$$$329$$$335$$$O	injection$$$336$$$345$$$O	comprises:$$$346$$$356$$$O	700g$$$357$$$361$$$O	to$$$362$$$364$$$O	900g$$$365$$$369$$$O	of$$$370$$$372$$$O	the$$$373$$$376$$$O	cephalosporin$$$377$$$390$$$I	compound$$$391$$$399$$$O	(C18H23N5O6S2),$$$400$$$415$$$I	20g$$$416$$$419$$$O	to$$$420$$$422$$$O	40g$$$423$$$426$$$O	of$$$427$$$429$$$O	chlorobutanol,$$$430$$$444$$$I	300g$$$445$$$449$$$O	to$$$450$$$452$$$O	500g$$$453$$$457$$$O	of$$$458$$$460$$$O	ibuprofen$$$461$$$470$$$I	and$$$471$$$474$$$O	a$$$475$$$476$$$O	proper$$$477$$$483$$$O	amount$$$484$$$490$$$O	of$$$491$$$493$$$O	water$$$494$$$499$$$O	used$$$500$$$504$$$O	for$$$505$$$508$$$O	injection.$$$509$$$519$$$O	The$$$520$$$523$$$O	cephalosporin$$$524$$$537$$$I	compound$$$538$$$546$$$O	can$$$547$$$550$$$O	be$$$551$$$553$$$O	prepared$$$554$$$562$$$O	into$$$563$$$567$$$O	tablets,$$$568$$$576$$$O	capsules,$$$577$$$586$$$O	powder,$$$587$$$594$$$O	particles,$$$595$$$605$$$O	pastilles,$$$606$$$616$$$O	emulsions$$$617$$$626$$$O	or$$$627$$$629$$$O	liquid$$$630$$$636$$$O	preparations;$$$637$$$650$$$O	the$$$651$$$654$$$O	liquid$$$655$$$661$$$O	preparations$$$662$$$674$$$O	comprise$$$675$$$683$$$O	oral$$$684$$$688$$$O	or$$$689$$$691$$$O	sterile$$$692$$$699$$$O	solutions$$$700$$$709$$$O	or$$$710$$$712$$$O	suspensions$$$713$$$724$$$O	used$$$725$$$729$$$O	for$$$730$$$733$$$O	injection.$$$734$$$744$$$O	The$$$745$$$748$$$O	cephalosporin$$$749$$$762$$$I	compound$$$763$$$771$$$O	has$$$772$$$775$$$O	broad$$$776$$$781$$$O	antibiotic$$$782$$$792$$$O	spectrum,$$$793$$$802$$$O	can$$$803$$$806$$$O	be$$$807$$$809$$$O	used$$$810$$$814$$$O	for$$$815$$$818$$$O	treating$$$819$$$827$$$O	various$$$828$$$835$$$O	diseases$$$836$$$844$$$O	caused$$$845$$$851$$$O	by$$$852$$$854$$$O	bacterial$$$855$$$864$$$O	infection,$$$865$$$875$$$O	can$$$876$$$879$$$O	be$$$880$$$882$$$O	prepared$$$883$$$891$$$O	into$$$892$$$896$$$O	various$$$897$$$904$$$O	preparation$$$905$$$916$$$O	types$$$917$$$922$$$O	and$$$923$$$926$$$O	can$$$927$$$930$$$O	be$$$931$$$933$$$O	widely$$$934$$$940$$$O	used$$$941$$$945$$$O	for$$$946$$$949$$$O	treating$$$950$$$958$$$O	the$$$959$$$962$$$O	diseases$$$963$$$971$$$O	of$$$972$$$974$$$O	animals,$$$975$$$983$$$O	which$$$984$$$989$$$O	are$$$990$$$993$$$O	caused$$$994$$$1000$$$O	by$$$1001$$$1003$$$O	bacterial$$$1004$$$1013$$$O	infection,$$$1014$$$1024$$$O	especially$$$1025$$$1035$$$O	the$$$1036$$$1039$$$O	diseases$$$1040$$$1048$$$O	of$$$1049$$$1051$$$O	animals.$$$1052$$$1060$$$O
CN102319273A
Salicornia$$$0$$$10$$$O	biggelowii$$$11$$$21$$$O	Torr.$$$22$$$27$$$O	active$$$28$$$34$$$O	total$$$35$$$40$$$O	saponin$$$41$$$48$$$I	extract,$$$49$$$57$$$O	its$$$58$$$61$$$O	preparation$$$62$$$73$$$O	method$$$74$$$80$$$O	and$$$81$$$84$$$O	its$$$85$$$88$$$O	purpose$$$89$$$96$$$O	of$$$97$$$99$$$O	losing$$$100$$$106$$$O	weight$$$107$$$113$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	Salicornia$$$27$$$37$$$O	biggelowii$$$38$$$48$$$O	Torr.$$$49$$$54$$$O	active$$$55$$$61$$$O	total$$$62$$$67$$$O	saponin$$$68$$$75$$$I	(elaboration$$$76$$$88$$$O	product)$$$89$$$97$$$O	extracted$$$98$$$107$$$O	from$$$108$$$112$$$O	Salicornia$$$113$$$123$$$O	biggelowii$$$124$$$134$$$O	Torr.$$$135$$$140$$$O	plants,$$$141$$$148$$$O	its$$$149$$$152$$$O	preparation$$$153$$$164$$$O	method$$$165$$$171$$$O	and$$$172$$$175$$$O	its$$$176$$$179$$$O	purpose$$$180$$$187$$$O	of$$$188$$$190$$$O	being$$$191$$$196$$$O	as$$$197$$$199$$$O	a$$$200$$$201$$$O	medicine$$$202$$$210$$$O	for$$$211$$$214$$$O	losing$$$215$$$221$$$O	weight$$$222$$$228$$$O	or$$$229$$$231$$$O	health$$$232$$$238$$$O	food$$$239$$$243$$$O	for$$$244$$$247$$$O	losing$$$248$$$254$$$O	weight,$$$255$$$262$$$O	which$$$263$$$268$$$O	belongs$$$269$$$276$$$O	to$$$277$$$279$$$O	the$$$280$$$283$$$O	medicinal$$$284$$$293$$$O	natural$$$294$$$301$$$O	product$$$302$$$309$$$O	field$$$310$$$315$$$O	or$$$316$$$318$$$O	the$$$319$$$322$$$O	health$$$323$$$329$$$O	food$$$330$$$334$$$O	manufacturing$$$335$$$348$$$O	industry.$$$349$$$358$$$O	The$$$359$$$362$$$O	extract$$$363$$$370$$$O	is$$$371$$$373$$$O	the$$$374$$$377$$$O	alicornia$$$378$$$387$$$O	biggelowii$$$388$$$398$$$O	Torr.$$$399$$$404$$$O	active$$$405$$$411$$$O	total$$$412$$$417$$$O	saponin,$$$418$$$426$$$I	and$$$427$$$430$$$O	the$$$431$$$434$$$O	preparation$$$435$$$446$$$O	method$$$447$$$453$$$O	comprises$$$454$$$463$$$O	the$$$464$$$467$$$O	following$$$468$$$477$$$O	steps:$$$478$$$484$$$O	extracting$$$485$$$495$$$O	by$$$496$$$498$$$O	50-95%$$$499$$$505$$$O	of$$$506$$$508$$$O	ethanol,$$$509$$$517$$$I	extracting$$$518$$$528$$$O	by$$$529$$$531$$$O	a$$$532$$$533$$$O	low$$$534$$$537$$$O	polarity$$$538$$$546$$$O	solvent,$$$547$$$555$$$O	centrifuging,$$$556$$$569$$$O	absorbing$$$570$$$579$$$O	by$$$580$$$582$$$O	macroporous$$$583$$$594$$$O	resin$$$595$$$600$$$O	to$$$601$$$603$$$O	obtain$$$604$$$610$$$O	the$$$611$$$614$$$O	Salicornia$$$615$$$625$$$O	biggelowii$$$626$$$636$$$O	Torr.$$$637$$$642$$$O	active$$$643$$$649$$$O	total$$$650$$$655$$$O	saponin.$$$656$$$664$$$I	The$$$665$$$668$$$O	extraction$$$669$$$679$$$O	process$$$680$$$687$$$O	and$$$688$$$691$$$O	the$$$692$$$695$$$O	method$$$696$$$702$$$O	of$$$703$$$705$$$O	the$$$706$$$709$$$O	invention$$$710$$$719$$$O	have$$$720$$$724$$$O	high$$$725$$$729$$$O	yield$$$730$$$735$$$O	and$$$736$$$739$$$O	high$$$740$$$744$$$O	purity$$$745$$$751$$$O	of$$$752$$$754$$$O	the$$$755$$$758$$$O	active$$$759$$$765$$$O	components,$$$766$$$777$$$O	the$$$778$$$781$$$O	pharmacyological$$$782$$$798$$$O	effect$$$799$$$805$$$O	and$$$806$$$809$$$O	drug$$$810$$$814$$$O	effect$$$815$$$821$$$O	of$$$822$$$824$$$O	the$$$825$$$828$$$O	Salicornia$$$829$$$839$$$O	biggelowii$$$840$$$850$$$O	Torr.$$$851$$$856$$$O	active$$$857$$$863$$$O	total$$$864$$$869$$$O	saponin,$$$870$$$878$$$I	the$$$879$$$882$$$O	effective$$$883$$$892$$$O	components$$$893$$$903$$$O	of$$$904$$$906$$$O	Salicornia$$$907$$$917$$$O	biggelowii$$$918$$$928$$$O	Torr.$$$929$$$934$$$O	active$$$935$$$941$$$O	total$$$942$$$947$$$O	saponin$$$948$$$955$$$I	and$$$956$$$959$$$O	the$$$960$$$963$$$O	content$$$964$$$971$$$O	proportion$$$972$$$982$$$O	of$$$983$$$985$$$O	the$$$986$$$989$$$O	effective$$$990$$$999$$$O	components$$$1000$$$1010$$$O	can$$$1011$$$1014$$$O	be$$$1015$$$1017$$$O	determined,$$$1018$$$1029$$$O	the$$$1030$$$1033$$$O	content$$$1034$$$1041$$$O	of$$$1042$$$1044$$$O	a$$$1045$$$1046$$$O	nortriterpenoid$$$1047$$$1062$$$O	saponins$$$1063$$$1071$$$I	compound$$$1072$$$1080$$$O	(a$$$1081$$$1083$$$O	structural$$$1084$$$1094$$$O	general$$$1095$$$1102$$$O	formula$$$1103$$$1110$$$O	is$$$1111$$$1113$$$O	shown$$$1114$$$1119$$$O	in$$$1120$$$1122$$$O	a$$$1123$$$1124$$$O	right$$$1125$$$1130$$$O	graph)$$$1131$$$1137$$$O	is$$$1138$$$1140$$$O	not$$$1141$$$1144$$$O	less$$$1145$$$1149$$$O	than$$$1150$$$1154$$$O	20%,$$$1155$$$1159$$$O	so$$$1160$$$1162$$$O	that$$$1163$$$1167$$$O	the$$$1168$$$1171$$$O	effective$$$1172$$$1181$$$O	dosage$$$1182$$$1188$$$O	is$$$1189$$$1191$$$O	easy$$$1192$$$1196$$$O	to$$$1197$$$1199$$$O	grasp.$$$1200$$$1206$$$O	The$$$1207$$$1210$$$O	action$$$1211$$$1217$$$O	mechanism$$$1218$$$1227$$$O	of$$$1228$$$1230$$$O	alicornia$$$1231$$$1240$$$O	biggelowii$$$1241$$$1251$$$O	Torr.$$$1252$$$1257$$$O	active$$$1258$$$1264$$$O	total$$$1265$$$1270$$$O	saponin$$$1271$$$1278$$$I	for$$$1279$$$1282$$$O	losing$$$1283$$$1289$$$O	weight$$$1290$$$1296$$$O	is$$$1297$$$1299$$$O	for$$$1300$$$1303$$$O	preventing$$$1304$$$1314$$$O	the$$$1315$$$1318$$$O	absorption$$$1319$$$1329$$$O	of$$$1330$$$1332$$$O	endogenous$$$1333$$$1343$$$O	and$$$1344$$$1347$$$O	exogenous$$$1348$$$1357$$$O	cholesterol$$$1358$$$1369$$$I	in$$$1370$$$1372$$$O	gastrointestinal$$$1373$$$1389$$$O	tract,$$$1390$$$1396$$$O	promoting$$$1397$$$1406$$$O	the$$$1407$$$1410$$$O	degradation$$$1411$$$1422$$$O	of$$$1423$$$1425$$$O	cholesterol$$$1426$$$1437$$$I	to$$$1438$$$1440$$$O	cholic$$$1441$$$1447$$$I	acid$$$1448$$$1452$$$I	and$$$1453$$$1456$$$O	then$$$1457$$$1461$$$O	eliminating$$$1462$$$1473$$$O	in$$$1474$$$1476$$$O	vitro,$$$1477$$$1483$$$O	simultaneously$$$1484$$$1498$$$O	accelerating$$$1499$$$1511$$$O	the$$$1512$$$1515$$$O	catabolism$$$1516$$$1526$$$O	of$$$1527$$$1529$$$O	fat,$$$1530$$$1534$$$O	reducing$$$1535$$$1543$$$O	the$$$1544$$$1547$$$O	content$$$1548$$$1555$$$O	of$$$1556$$$1558$$$O	TC,$$$1559$$$1562$$$O	TG$$$1563$$$1565$$$I	and$$$1566$$$1569$$$O	LDL-C$$$1570$$$1575$$$O	and$$$1576$$$1579$$$O	rising$$$1580$$$1586$$$O	the$$$1587$$$1590$$$O	level$$$1591$$$1596$$$O	content$$$1597$$$1604$$$O	of$$$1605$$$1607$$$O	HDL-C,$$$1608$$$1614$$$O	so$$$1615$$$1617$$$O	that$$$1618$$$1622$$$O	the$$$1623$$$1626$$$O	normalization$$$1627$$$1640$$$O	of$$$1641$$$1643$$$O	lipoproteins$$$1644$$$1656$$$O	can$$$1657$$$1660$$$O	be$$$1661$$$1663$$$O	realized$$$1664$$$1672$$$O	and$$$1673$$$1676$$$O	the$$$1677$$$1680$$$O	purpose$$$1681$$$1688$$$O	of$$$1689$$$1691$$$O	weight$$$1692$$$1698$$$O	reduction$$$1699$$$1708$$$O	can$$$1709$$$1712$$$O	be$$$1713$$$1715$$$O	achieved.$$$1716$$$1725$$$O
CN101143138B
Paracetamol$$$0$$$11$$$I	and$$$12$$$15$$$O	pseudoephedrine$$$16$$$31$$$I	hydrochloride$$$32$$$45$$$I	tablets$$$46$$$53$$$O	made$$$54$$$58$$$O	by$$$59$$$61$$$O	dry$$$62$$$65$$$O	powder$$$66$$$72$$$O	direct$$$73$$$79$$$O	tabletting$$$80$$$90$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	antipyretic$$$28$$$39$$$O	and$$$40$$$43$$$O	analgesic$$$44$$$53$$$O	and$$$54$$$57$$$O	a$$$58$$$59$$$O	nonsteroid$$$60$$$70$$$O	anti-inflammation$$$71$$$88$$$O	analgesic$$$89$$$98$$$O	drug$$$99$$$103$$$O	and$$$104$$$107$$$O	concretely$$$108$$$118$$$O	relates$$$119$$$126$$$O	to$$$127$$$129$$$O	a$$$130$$$131$$$O	paracetamol$$$132$$$143$$$I	and$$$144$$$147$$$O	pseudoephedrine$$$148$$$163$$$I	hydrochloride$$$164$$$177$$$I	tablet,$$$178$$$185$$$O	which$$$186$$$191$$$O	is$$$192$$$194$$$O	obtained$$$195$$$203$$$O	by$$$204$$$206$$$O	directly$$$207$$$215$$$O	tablet$$$216$$$222$$$O	forming$$$223$$$230$$$O	dry$$$231$$$234$$$O	powder,$$$235$$$242$$$O	which$$$243$$$248$$$O	is$$$249$$$251$$$O	used$$$252$$$256$$$O	for$$$257$$$260$$$O	remedying$$$261$$$270$$$O	the$$$271$$$274$$$O	cold.$$$275$$$280$$$O	The$$$281$$$284$$$O	paracetamol$$$285$$$296$$$I	and$$$297$$$300$$$O	pseudoephedrine$$$301$$$316$$$I	hydrochloride$$$317$$$330$$$I	tablet$$$331$$$337$$$O	consists$$$338$$$346$$$O	of$$$347$$$349$$$O	the$$$350$$$353$$$O	components$$$354$$$364$$$O	of$$$365$$$367$$$O	the$$$368$$$371$$$O	following$$$372$$$381$$$O	weight$$$382$$$388$$$O	portions$$$389$$$397$$$O	of500$$$398$$$403$$$O	portions$$$404$$$412$$$O	of$$$413$$$415$$$O	paracetamol,$$$416$$$428$$$I	30$$$429$$$431$$$O	portions$$$432$$$440$$$O	of$$$441$$$443$$$O	pseudoephedrine,$$$444$$$460$$$I	48$$$461$$$463$$$O	portions$$$464$$$472$$$O	of$$$473$$$475$$$O	microcrystalline$$$476$$$492$$$O	cellulose,$$$493$$$503$$$O	5.3$$$504$$$507$$$O	portions$$$508$$$516$$$O	of$$$517$$$519$$$O	vapor$$$520$$$525$$$O	phase$$$526$$$531$$$O	silicon$$$532$$$539$$$I	dioxide$$$540$$$547$$$I	and$$$548$$$551$$$O	48$$$552$$$554$$$O	portions$$$555$$$563$$$O	of$$$564$$$566$$$O	pre-gelatinized$$$567$$$582$$$O	starch.$$$583$$$590$$$O	The$$$591$$$594$$$O	invention$$$595$$$604$$$O	is$$$605$$$607$$$O	fit$$$608$$$611$$$O	for$$$612$$$615$$$O	remedying$$$616$$$625$$$O	the$$$626$$$629$$$O	symptoms$$$630$$$638$$$O	caused$$$639$$$645$$$O	by$$$646$$$648$$$O	the$$$649$$$652$$$O	cold$$$653$$$657$$$O	of$$$658$$$660$$$O	fever,$$$661$$$667$$$O	headache,$$$668$$$677$$$O	the$$$678$$$681$$$O	ache$$$682$$$686$$$O	of$$$687$$$689$$$O	the$$$690$$$693$$$O	whole$$$694$$$699$$$O	body$$$700$$$704$$$O	and$$$705$$$708$$$O	limbs,$$$709$$$715$$$O	nasal$$$716$$$721$$$O	obstruction,$$$722$$$734$$$O	rhinorrhea,$$$735$$$746$$$O	sneezes$$$747$$$754$$$O	etc.$$$755$$$759$$$O
CN101863945A
American$$$0$$$8$$$O	ginseng$$$9$$$16$$$O	saponin$$$17$$$24$$$I	F6$$$25$$$27$$$I	as$$$28$$$30$$$O	well$$$31$$$35$$$O	as$$$36$$$38$$$O	extraction$$$39$$$49$$$O	method$$$50$$$56$$$O	and$$$57$$$60$$$O	medical$$$61$$$68$$$O	application$$$69$$$80$$$O	thereof$$$81$$$88$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	American$$$25$$$33$$$O	ginseng$$$34$$$41$$$O	saponin$$$42$$$49$$$I	F6$$$50$$$52$$$I	as$$$53$$$55$$$O	well$$$56$$$60$$$O	as$$$61$$$63$$$O	an$$$64$$$66$$$O	extraction$$$67$$$77$$$O	method$$$78$$$84$$$O	and$$$85$$$88$$$O	medical$$$89$$$96$$$O	application$$$97$$$108$$$O	thereof,$$$109$$$117$$$O	which$$$118$$$123$$$O	belong$$$124$$$130$$$O	to$$$131$$$133$$$O	a$$$134$$$135$$$O	new$$$136$$$139$$$O	compound$$$140$$$148$$$O	as$$$149$$$151$$$O	well$$$152$$$156$$$O	as$$$157$$$159$$$O	an$$$160$$$162$$$O	extraction$$$163$$$173$$$O	method$$$174$$$180$$$O	and$$$181$$$184$$$O	medical$$$185$$$192$$$O	application$$$193$$$204$$$O	thereof.$$$205$$$213$$$O	The$$$214$$$217$$$O	extraction$$$218$$$228$$$O	method$$$229$$$235$$$O	comprises$$$236$$$245$$$O	the$$$246$$$249$$$O	following$$$250$$$259$$$O	steps:$$$260$$$266$$$O	taking$$$267$$$273$$$O	American$$$274$$$282$$$O	ginseng$$$283$$$290$$$O	fruit$$$291$$$296$$$O	as$$$297$$$299$$$O	a$$$300$$$301$$$O	raw$$$302$$$305$$$O	material,$$$306$$$315$$$O	obtaining$$$316$$$325$$$O	the$$$326$$$329$$$O	new$$$330$$$333$$$O	compound$$$334$$$342$$$O	through$$$343$$$350$$$O	macroporous$$$351$$$362$$$O	absorbent$$$363$$$372$$$O	resin,$$$373$$$379$$$O	normal$$$380$$$386$$$O	and$$$387$$$390$$$O	reversed-phase$$$391$$$405$$$O	silica$$$406$$$412$$$I	gel$$$413$$$416$$$I	column$$$417$$$423$$$O	chromatography$$$424$$$438$$$O	and$$$439$$$442$$$O	a$$$443$$$444$$$O	recrystallization$$$445$$$462$$$O	method$$$463$$$469$$$O	of$$$470$$$472$$$O	fruit$$$473$$$478$$$O	juice,$$$479$$$485$$$O	wherein$$$486$$$493$$$O	the$$$494$$$497$$$O	new$$$498$$$501$$$O	compound$$$502$$$510$$$O	has$$$511$$$514$$$O	the$$$515$$$518$$$O	chemical$$$519$$$527$$$O	name$$$528$$$532$$$O	of$$$533$$$535$$$O	6-O-beta-D-glucopyranesyl-20-O-[alpha-L-arabinofuranosyl-(1-6)-beta-D-glucopyranosyl]-dammar-24-ene-3beta,$$$536$$$642$$$I	6alpha,12beta,$$$643$$$657$$$I	20S-tetraol$$$658$$$669$$$I	and$$$670$$$673$$$O	is$$$674$$$676$$$O	abbreviated$$$677$$$688$$$O	as$$$689$$$691$$$O	the$$$692$$$695$$$O	American$$$696$$$704$$$O	ginseng$$$705$$$712$$$O	saponin$$$713$$$720$$$I	F6,$$$721$$$724$$$I	and$$$725$$$728$$$O	the$$$729$$$732$$$O	yield$$$733$$$738$$$O	reaches$$$739$$$746$$$O	more$$$747$$$751$$$O	than$$$752$$$756$$$O	0.01%.$$$757$$$763$$$O	The$$$764$$$767$$$O	American$$$768$$$776$$$O	ginseng$$$777$$$784$$$O	saponin$$$785$$$792$$$I	F6$$$793$$$795$$$I	has$$$796$$$799$$$O	wide$$$800$$$804$$$O	application$$$805$$$816$$$O	in$$$817$$$819$$$O	preparing$$$820$$$829$$$O	antitumor$$$830$$$839$$$O	medicaments.$$$840$$$852$$$O
CN101805355A
Thienopyridone$$$0$$$14$$$I	derivative,$$$15$$$26$$$O	preparation$$$27$$$38$$$O	method$$$39$$$45$$$O	and$$$46$$$49$$$O	uses$$$50$$$54$$$O	thereof$$$55$$$62$$$O
The$$$0$$$3$$$O	invention,$$$4$$$14$$$O	belonging$$$15$$$24$$$O	to$$$25$$$27$$$O	the$$$28$$$31$$$O	technical$$$32$$$41$$$O	field$$$42$$$47$$$O	of$$$48$$$50$$$O	anti-malignant$$$51$$$65$$$O	tumor$$$66$$$71$$$O	medicines,$$$72$$$82$$$O	provides$$$83$$$91$$$O	a$$$92$$$93$$$O	thienopyridone$$$94$$$108$$$I	derivative$$$109$$$119$$$O	having$$$120$$$126$$$O	the$$$127$$$130$$$O	structure$$$131$$$140$$$O	shown$$$141$$$146$$$O	as$$$147$$$149$$$O	formula$$$150$$$157$$$O	I$$$158$$$159$$$O	and$$$160$$$163$$$O	pharmaceutically$$$164$$$180$$$O	acceptable$$$181$$$191$$$O	salts$$$192$$$197$$$O	thereof,$$$198$$$206$$$O	wherein$$$207$$$214$$$O	R1$$$215$$$217$$$O	and$$$218$$$221$$$O	R2$$$222$$$224$$$O	are$$$225$$$228$$$O	defined$$$229$$$236$$$O	as$$$237$$$239$$$O	specification.$$$240$$$254$$$O	The$$$255$$$258$$$O	invention$$$259$$$268$$$O	further$$$269$$$276$$$O	relates$$$277$$$284$$$O	a$$$285$$$286$$$O	preparation$$$287$$$298$$$O	method$$$299$$$305$$$O	of$$$306$$$308$$$O	the$$$309$$$312$$$O	compound,$$$313$$$322$$$O	and$$$323$$$326$$$O	simultaneously$$$327$$$341$$$O	discloses$$$342$$$351$$$O	pharmaceutical$$$352$$$366$$$O	compositions$$$367$$$379$$$O	with$$$380$$$384$$$O	the$$$385$$$388$$$O	compound$$$389$$$397$$$O	or$$$398$$$400$$$O	pharmaceutically$$$401$$$417$$$O	acceptable$$$418$$$428$$$O	salts$$$429$$$434$$$O	thereof$$$435$$$442$$$O	as$$$443$$$445$$$O	effective$$$446$$$455$$$O	active$$$456$$$462$$$O	ingredient$$$463$$$473$$$O	as$$$474$$$476$$$O	well$$$477$$$481$$$O	as$$$482$$$484$$$O	uses$$$485$$$489$$$O	of$$$490$$$492$$$O	the$$$493$$$496$$$O	pharmaceutical$$$497$$$511$$$O	compositions$$$512$$$524$$$O	as$$$525$$$527$$$O	anti-malignant$$$528$$$542$$$O	tumor$$$543$$$548$$$O	medicines,.$$$549$$$560$$$O
CN101401885A
Liquid$$$0$$$6$$$O	medicine$$$7$$$15$$$O	for$$$16$$$19$$$O	removing$$$20$$$28$$$O	miliaria$$$29$$$37$$$O	and$$$38$$$41$$$O	preparation$$$42$$$53$$$O	method$$$54$$$60$$$O	thereof$$$61$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	liquid$$$27$$$33$$$O	medicine$$$34$$$42$$$O	for$$$43$$$46$$$O	removing$$$47$$$55$$$O	miliaria,$$$56$$$65$$$O	and$$$66$$$69$$$O	a$$$70$$$71$$$O	preparation$$$72$$$83$$$O	method$$$84$$$90$$$O	thereof.$$$91$$$99$$$O	The$$$100$$$103$$$O	liquid$$$104$$$110$$$O	medicine$$$111$$$119$$$O	for$$$120$$$123$$$O	removing$$$124$$$132$$$O	miliaria$$$133$$$141$$$O	comprises$$$142$$$151$$$O	the$$$152$$$155$$$O	following$$$156$$$165$$$O	components:$$$166$$$177$$$O	140$$$178$$$181$$$O	to$$$182$$$184$$$O	170$$$185$$$188$$$O	grams$$$189$$$194$$$O	of$$$195$$$197$$$O	Chinese$$$198$$$205$$$O	atractylodes,$$$206$$$219$$$O	150$$$220$$$223$$$O	to$$$224$$$226$$$O	180$$$227$$$230$$$O	grams$$$231$$$236$$$O	of$$$237$$$239$$$O	tangerine$$$240$$$249$$$O	peel,$$$250$$$255$$$O	220$$$256$$$259$$$O	to$$$260$$$262$$$O	250$$$263$$$266$$$O	grams$$$267$$$272$$$O	of$$$273$$$275$$$O	magnolia$$$276$$$284$$$O	officinalis,$$$285$$$297$$$O	220$$$298$$$301$$$O	to$$$302$$$304$$$O	260$$$305$$$308$$$O	grams$$$309$$$314$$$O	of$$$315$$$317$$$O	angelica$$$318$$$326$$$O	dahurica,$$$327$$$336$$$O	220$$$337$$$340$$$O	to$$$341$$$343$$$O	250$$$344$$$347$$$O	grams$$$348$$$353$$$O	of$$$354$$$356$$$O	tuckahoe,$$$357$$$366$$$O	220$$$367$$$370$$$O	to$$$371$$$373$$$O	250$$$374$$$377$$$O	grams$$$378$$$383$$$O	of$$$384$$$386$$$O	areca$$$387$$$392$$$O	peel,$$$393$$$398$$$O	150$$$399$$$402$$$O	to$$$403$$$405$$$O	180$$$406$$$409$$$O	grams$$$410$$$415$$$O	of$$$416$$$418$$$O	raw$$$419$$$422$$$O	pinellia$$$423$$$431$$$O	tuber,$$$432$$$438$$$O	10$$$439$$$441$$$O	to$$$442$$$444$$$O	40$$$445$$$447$$$O	grams$$$448$$$453$$$O	of$$$454$$$456$$$O	liquorice$$$457$$$466$$$O	extractum,$$$467$$$477$$$O	1$$$478$$$479$$$O	to$$$480$$$482$$$O	2$$$483$$$484$$$O	milliliters$$$485$$$496$$$O	of$$$497$$$499$$$O	patchouli$$$500$$$509$$$O	oil,$$$510$$$514$$$O	0.2$$$515$$$518$$$O	to$$$519$$$521$$$O	1$$$522$$$523$$$O	milliliter$$$524$$$534$$$O	of$$$535$$$537$$$O	perilla$$$538$$$545$$$O	leaf$$$546$$$550$$$O	oil,$$$551$$$555$$$O	5$$$556$$$557$$$O	to$$$558$$$560$$$O	15$$$561$$$563$$$O	grams$$$564$$$569$$$O	of$$$570$$$572$$$O	borneol$$$573$$$580$$$O	and$$$581$$$584$$$O	180$$$585$$$588$$$O	to$$$589$$$591$$$O	210$$$592$$$595$$$O	milliliters$$$596$$$607$$$O	of$$$608$$$610$$$O	gentamycin$$$611$$$621$$$O	sulfate.$$$622$$$630$$$O	The$$$631$$$634$$$O	liquid$$$635$$$641$$$O	medicine$$$642$$$650$$$O	has$$$651$$$654$$$O	the$$$655$$$658$$$O	advantages$$$659$$$669$$$O	of$$$670$$$672$$$O	remarkable$$$673$$$683$$$O	medicine$$$684$$$692$$$O	application$$$693$$$704$$$O	effect,$$$705$$$712$$$O	allergy$$$713$$$720$$$O	resistance,$$$721$$$732$$$O	rapid$$$733$$$738$$$O	action,$$$739$$$746$$$O	fast$$$747$$$751$$$O	inflammation$$$752$$$764$$$O	elimination$$$765$$$776$$$O	and$$$777$$$780$$$O	itching$$$781$$$788$$$O	relief$$$789$$$795$$$O	and$$$796$$$799$$$O	high$$$800$$$804$$$O	cure$$$805$$$809$$$O	rate,$$$810$$$815$$$O	and$$$816$$$819$$$O	is$$$820$$$822$$$O	applicable$$$823$$$833$$$O	to$$$834$$$836$$$O	miliaria$$$837$$$845$$$O	and$$$846$$$849$$$O	various$$$850$$$857$$$O	types$$$858$$$863$$$O	of$$$864$$$866$$$O	dermatitis.$$$867$$$878$$$O
US20110071108
Beta-Cyclodextrin$$$0$$$17$$$O	Derivatives$$$18$$$29$$$O	as$$$30$$$32$$$O	Antibacterial$$$33$$$46$$$O	Agents$$$47$$$53$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	new$$$25$$$28$$$O	class$$$29$$$34$$$O	of$$$35$$$37$$$O	antibiotics$$$38$$$49$$$O	to$$$50$$$52$$$O	which$$$53$$$58$$$O	pathogenic$$$59$$$69$$$O	bacteria$$$70$$$78$$$O	have$$$79$$$83$$$O	not$$$84$$$87$$$O	been$$$88$$$92$$$O	exposed,$$$93$$$101$$$O	and$$$102$$$105$$$O	thus$$$106$$$110$$$O	should$$$111$$$117$$$O	not$$$118$$$121$$$O	have$$$122$$$126$$$O	developed$$$127$$$136$$$O	resistance.$$$137$$$148$$$O	This$$$149$$$153$$$O	new$$$154$$$157$$$O	class$$$158$$$163$$$O	of$$$164$$$166$$$O	antibiotics$$$167$$$178$$$O	are$$$179$$$182$$$O	derivatives$$$183$$$194$$$O	of$$$195$$$197$$$O	Î²-cyclodextrin$$$198$$$213$$$O	(Î²-CD),$$$214$$$222$$$O	which$$$223$$$228$$$O	is$$$229$$$231$$$O	a$$$232$$$233$$$O	cyclic$$$234$$$240$$$O	molecule$$$241$$$249$$$O	comprising$$$250$$$260$$$O	seven$$$261$$$266$$$I	D-glucose$$$267$$$276$$$I	units.$$$277$$$283$$$O
US20130029935
Mineral$$$0$$$7$$$O	amino$$$8$$$13$$$I	acid$$$14$$$18$$$I	polysaccharide$$$19$$$33$$$O	complex$$$34$$$41$$$O
This$$$0$$$4$$$O	document$$$5$$$13$$$O	provides$$$14$$$22$$$O	complexes$$$23$$$32$$$O	comprising$$$33$$$43$$$O	a$$$44$$$45$$$O	mineral-amino$$$46$$$59$$$I	acid$$$60$$$64$$$I	compound$$$65$$$73$$$O	and$$$74$$$77$$$O	a$$$78$$$79$$$O	polysaccharide.$$$80$$$95$$$O	For$$$96$$$99$$$O	example,$$$100$$$108$$$O	the$$$109$$$112$$$O	document$$$113$$$121$$$O	provides$$$122$$$130$$$O	compositions$$$131$$$143$$$O	containing$$$144$$$154$$$O	such$$$155$$$159$$$O	complexes$$$160$$$169$$$O	and$$$170$$$173$$$O	methods$$$174$$$181$$$O	of$$$182$$$184$$$O	making$$$185$$$191$$$O	and$$$192$$$195$$$O	using$$$196$$$201$$$O	such$$$202$$$206$$$O	complexes.$$$207$$$217$$$O
CN102145077A
Oral$$$0$$$4$$$O	Chinese$$$5$$$12$$$O	medical$$$13$$$20$$$O	preparation$$$21$$$32$$$O	for$$$33$$$36$$$O	treating$$$37$$$45$$$O	acute$$$46$$$51$$$O	periodontitis$$$52$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	oral$$$27$$$31$$$O	Chinese$$$32$$$39$$$O	medical$$$40$$$47$$$O	preparation$$$48$$$59$$$O	for$$$60$$$63$$$O	treating$$$64$$$72$$$O	acute$$$73$$$78$$$O	periodontitis.$$$79$$$93$$$O	The$$$94$$$97$$$O	preparation$$$98$$$109$$$O	is$$$110$$$112$$$O	prepared$$$113$$$121$$$O	from$$$122$$$126$$$O	the$$$127$$$130$$$O	following$$$131$$$140$$$O	raw$$$141$$$144$$$O	material$$$145$$$153$$$O	herbs$$$154$$$159$$$O	in$$$160$$$162$$$O	parts$$$163$$$168$$$O	by$$$169$$$171$$$O	weight:$$$172$$$179$$$O	10-20$$$180$$$185$$$O	parts$$$186$$$191$$$O	of$$$192$$$194$$$O	white$$$195$$$200$$$O	peony,$$$201$$$207$$$O	10-20$$$208$$$213$$$O	parts$$$214$$$219$$$O	of$$$220$$$222$$$O	indigo,$$$223$$$230$$$O	10-20$$$231$$$236$$$O	parts$$$237$$$242$$$O	of$$$243$$$245$$$O	root$$$246$$$250$$$O	of$$$251$$$253$$$O	red-rooted$$$254$$$264$$$O	salvia,$$$265$$$272$$$O	10-20$$$273$$$278$$$O	parts$$$279$$$284$$$O	of$$$285$$$287$$$O	drynaria$$$288$$$296$$$O	rhizome,$$$297$$$305$$$O	10-20$$$306$$$311$$$O	parts$$$312$$$317$$$O	of$$$318$$$320$$$O	pseudo-ginseng,$$$321$$$336$$$O	10-20$$$337$$$342$$$O	parts$$$343$$$348$$$O	of$$$349$$$351$$$O	radix$$$352$$$357$$$O	angelicae$$$358$$$367$$$O	formosanae,$$$368$$$379$$$O	10-20$$$380$$$385$$$O	parts$$$386$$$391$$$O	of$$$392$$$394$$$O	evodia$$$395$$$401$$$O	rutaecarpa,$$$402$$$413$$$O	10-20$$$414$$$419$$$O	parts$$$420$$$425$$$O	of$$$426$$$428$$$O	dried$$$429$$$434$$$O	rehamnnia$$$435$$$444$$$O	root,$$$445$$$450$$$O	10-20$$$451$$$456$$$O	parts$$$457$$$462$$$O	of$$$463$$$465$$$O	honeysuckle,$$$466$$$478$$$O	10-20$$$479$$$484$$$O	parts$$$485$$$490$$$O	of$$$491$$$493$$$O	dandelion,$$$494$$$504$$$O	10-20$$$505$$$510$$$O	parts$$$511$$$516$$$O	of$$$517$$$519$$$O	scutellaria$$$520$$$531$$$O	baicalensis,$$$532$$$544$$$O	10-20$$$545$$$550$$$O	parts$$$551$$$556$$$O	of$$$557$$$559$$$O	rheum$$$560$$$565$$$O	officinale,$$$566$$$577$$$O	10-20$$$578$$$583$$$O	parts$$$584$$$589$$$O	of$$$590$$$592$$$O	borneol,$$$593$$$601$$$I	10-20$$$602$$$607$$$O	parts$$$608$$$613$$$O	of$$$614$$$616$$$O	fructus$$$617$$$624$$$O	forsythiae,$$$625$$$636$$$O	10-20$$$637$$$642$$$O	parts$$$643$$$648$$$O	of$$$649$$$651$$$O	cordate$$$652$$$659$$$O	houttuynia$$$660$$$670$$$O	and$$$671$$$674$$$O	10-20$$$675$$$680$$$O	parts$$$681$$$686$$$O	of$$$687$$$689$$$O	catechu.$$$690$$$698$$$O	By$$$699$$$701$$$O	utilizing$$$702$$$711$$$O	different$$$712$$$721$$$O	Chinese$$$722$$$729$$$O	medical$$$730$$$737$$$O	characteristics,$$$738$$$754$$$O	the$$$755$$$758$$$O	invention$$$759$$$768$$$O	researches$$$769$$$779$$$O	the$$$780$$$783$$$O	Chinese$$$784$$$791$$$O	medical$$$792$$$799$$$O	preparation$$$800$$$811$$$O	which$$$812$$$817$$$O	can$$$818$$$821$$$O	clear$$$822$$$827$$$O	away$$$828$$$832$$$O	heat,$$$833$$$838$$$O	detoxify,$$$839$$$848$$$O	reduce$$$849$$$855$$$O	swelling,$$$856$$$865$$$O	alleviate$$$866$$$875$$$O	pain,$$$876$$$881$$$O	remove$$$882$$$888$$$O	necrotic$$$889$$$897$$$O	tissue,$$$898$$$905$$$O	promote$$$906$$$913$$$O	granulation$$$914$$$925$$$O	and$$$926$$$929$$$O	stop$$$930$$$934$$$O	bleeding$$$935$$$943$$$O	with$$$944$$$948$$$O	astringents$$$949$$$960$$$O	and$$$961$$$964$$$O	has$$$965$$$968$$$O	a$$$969$$$970$$$O	favorable$$$971$$$980$$$O	curative$$$981$$$989$$$O	effect$$$990$$$996$$$O	on$$$997$$$999$$$O	acute$$$1000$$$1005$$$O	periodontitis.$$$1006$$$1020$$$O	The$$$1021$$$1024$$$O	oral$$$1025$$$1029$$$O	Chinese$$$1030$$$1037$$$O	medical$$$1038$$$1045$$$O	preparation$$$1046$$$1057$$$O	for$$$1058$$$1061$$$O	treating$$$1062$$$1070$$$O	acute$$$1071$$$1076$$$O	periodontitis$$$1077$$$1090$$$O	has$$$1091$$$1094$$$O	the$$$1095$$$1098$$$O	maximum$$$1099$$$1106$$$O	advantage$$$1107$$$1116$$$O	of$$$1117$$$1119$$$O	rapidly$$$1120$$$1127$$$O	alleviating$$$1128$$$1139$$$O	pain,$$$1140$$$1145$$$O	can$$$1146$$$1149$$$O	take$$$1150$$$1154$$$O	an$$$1155$$$1157$$$O	auxiliary$$$1158$$$1167$$$O	curative$$$1168$$$1176$$$O	effect$$$1177$$$1183$$$O	on$$$1184$$$1186$$$O	patients$$$1187$$$1195$$$O	subjected$$$1196$$$1205$$$O	to$$$1206$$$1208$$$O	dental$$$1209$$$1215$$$O	operations,$$$1216$$$1227$$$O	and$$$1228$$$1231$$$O	can$$$1232$$$1235$$$O	clear$$$1236$$$1241$$$O	away$$$1242$$$1246$$$O	heat,$$$1247$$$1252$$$O	detoxify,$$$1253$$$1262$$$O	reduce$$$1263$$$1269$$$O	swelling$$$1270$$$1278$$$O	and$$$1279$$$1282$$$O	alleviate$$$1283$$$1292$$$O	pain.$$$1293$$$1298$$$O
WO2007084857A3
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	treating$$$29$$$37$$$O	cell$$$38$$$42$$$O	proliferative$$$43$$$56$$$O	disorders$$$57$$$66$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	for$$$39$$$42$$$O	treating$$$43$$$51$$$O	and$$$52$$$55$$$O	preventing$$$56$$$66$$$O	cell$$$67$$$71$$$O	proliferative$$$72$$$85$$$O	disorders$$$86$$$95$$$O	and$$$96$$$99$$$O	conditions$$$100$$$110$$$O	comprising$$$111$$$121$$$O	administering$$$122$$$135$$$O	to$$$136$$$138$$$O	a$$$139$$$140$$$O	subject$$$141$$$148$$$O	resveratrol$$$149$$$160$$$I	or$$$161$$$163$$$O	an$$$164$$$166$$$O	analog$$$167$$$173$$$O	thereof.$$$174$$$182$$$O
CN101897712A
Ursodeoxycholic$$$0$$$15$$$I	acid$$$16$$$20$$$I	phospholipid$$$21$$$33$$$O	composition$$$34$$$45$$$O	and$$$46$$$49$$$O	preparation$$$50$$$61$$$O	method$$$62$$$68$$$O	thereof$$$69$$$76$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	ursodeoxycholic$$$28$$$43$$$I	acid$$$44$$$48$$$I	phospholipid$$$49$$$61$$$O	composition,$$$62$$$74$$$O	which$$$75$$$80$$$O	consists$$$81$$$89$$$O	of$$$90$$$92$$$O	ursodeoxycholic$$$93$$$108$$$I	acid$$$109$$$113$$$I	and$$$114$$$117$$$O	phospholipid,$$$118$$$131$$$O	wherein$$$132$$$139$$$O	the$$$140$$$143$$$O	weight$$$144$$$150$$$O	ratio$$$151$$$156$$$O	of$$$157$$$159$$$O	the$$$160$$$163$$$O	ursodeoxycholic$$$164$$$179$$$I	acid$$$180$$$184$$$I	to$$$185$$$187$$$O	the$$$188$$$191$$$O	phospholipid$$$192$$$204$$$O	is$$$205$$$207$$$O	1:1-5.$$$208$$$214$$$O	The$$$215$$$218$$$O	invention$$$219$$$228$$$O	also$$$229$$$233$$$O	discloses$$$234$$$243$$$O	a$$$244$$$245$$$O	preparation$$$246$$$257$$$O	method$$$258$$$264$$$O	for$$$265$$$268$$$O	the$$$269$$$272$$$O	ursodeoxycholic$$$273$$$288$$$I	acid$$$289$$$293$$$I	phospholipid$$$294$$$306$$$O	composition.$$$307$$$319$$$O	The$$$320$$$323$$$O	method$$$324$$$330$$$O	has$$$331$$$334$$$O	simple$$$335$$$341$$$O	operation$$$342$$$351$$$O	and$$$352$$$355$$$O	low$$$356$$$359$$$O	cost.$$$360$$$365$$$O	The$$$366$$$369$$$O	ursodeoxycholic$$$370$$$385$$$I	acid$$$386$$$390$$$I	phospholipid$$$391$$$403$$$O	composition$$$404$$$415$$$O	prepared$$$416$$$424$$$O	by$$$425$$$427$$$O	using$$$428$$$433$$$O	the$$$434$$$437$$$O	method$$$438$$$444$$$O	can$$$445$$$448$$$O	remarkably$$$449$$$459$$$O	improve$$$460$$$467$$$O	the$$$468$$$471$$$O	effect$$$472$$$478$$$O	of$$$479$$$481$$$O	the$$$482$$$485$$$O	ursodeoxycholic$$$486$$$501$$$I	acid$$$502$$$506$$$I	on$$$507$$$509$$$O	the$$$510$$$513$$$O	aspects$$$514$$$521$$$O	of$$$522$$$524$$$O	protecting$$$525$$$535$$$O	the$$$536$$$539$$$O	liver$$$540$$$545$$$O	and$$$546$$$549$$$O	benefiting$$$550$$$560$$$O	the$$$561$$$564$$$O	gallbladder.$$$565$$$577$$$O	The$$$578$$$581$$$O	ursodeoxycholic$$$582$$$597$$$I	acid$$$598$$$602$$$I	phospholipid$$$603$$$615$$$O	composition$$$616$$$627$$$O	is$$$628$$$630$$$O	used$$$631$$$635$$$O	for$$$636$$$639$$$O	treating$$$640$$$648$$$O	liver$$$649$$$654$$$O	and$$$655$$$658$$$O	gallbladder$$$659$$$670$$$O	diseases$$$671$$$679$$$O	such$$$680$$$684$$$O	as$$$685$$$687$$$O	fatty$$$688$$$693$$$O	liver,$$$694$$$700$$$O	liver$$$701$$$706$$$O	cirrhosis,$$$707$$$717$$$O	gallstone$$$718$$$727$$$O	and$$$728$$$731$$$O	the$$$732$$$735$$$O	like.$$$736$$$741$$$O
US20110098266
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	administering$$$10$$$23$$$O	an$$$24$$$26$$$O	injectable$$$27$$$37$$$O	antibiotic$$$38$$$48$$$O	to$$$49$$$51$$$O	an$$$52$$$54$$$O	animal$$$55$$$61$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	administering$$$12$$$25$$$O	an$$$26$$$28$$$O	antibiotic$$$29$$$39$$$O	to$$$40$$$42$$$O	an$$$43$$$45$$$O	animal$$$46$$$52$$$O	in$$$53$$$55$$$O	need$$$56$$$60$$$O	thereof,$$$61$$$69$$$O	including$$$70$$$79$$$O	the$$$80$$$83$$$O	step$$$84$$$88$$$O	of$$$89$$$91$$$O	injecting$$$92$$$101$$$O	the$$$102$$$105$$$O	antibiotic$$$106$$$116$$$O	subcutaneously$$$117$$$131$$$O	at$$$132$$$134$$$O	the$$$135$$$138$$$O	junction$$$139$$$147$$$O	of$$$148$$$150$$$O	a$$$151$$$152$$$O	pinna$$$153$$$158$$$O	with$$$159$$$163$$$O	the$$$164$$$167$$$O	cranium$$$168$$$175$$$O	of$$$176$$$178$$$O	the$$$179$$$182$$$O	animal,$$$183$$$190$$$O	is$$$191$$$193$$$O	disclosed.$$$194$$$204$$$O
CN101342277A
Externally$$$0$$$10$$$O	used$$$11$$$15$$$O	antimicrobial$$$16$$$29$$$O	spray$$$30$$$35$$$O	for$$$36$$$39$$$O	treating$$$40$$$48$$$O	snore$$$49$$$54$$$O	and$$$55$$$58$$$O	preparation$$$59$$$70$$$O	method$$$71$$$77$$$O	thereof$$$78$$$85$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	external$$$36$$$44$$$O	antimicrobial$$$45$$$58$$$O	spraying$$$59$$$67$$$O	agent$$$68$$$73$$$O	which$$$74$$$79$$$O	is$$$80$$$82$$$O	used$$$83$$$87$$$O	for$$$88$$$91$$$O	treating$$$92$$$100$$$O	snoring,$$$101$$$109$$$O	and$$$110$$$113$$$O	is$$$114$$$116$$$O	characterized$$$117$$$130$$$O	by$$$131$$$133$$$O	adopting$$$134$$$142$$$O	the$$$143$$$146$$$O	raw$$$147$$$150$$$O	materials$$$151$$$160$$$O	of$$$161$$$163$$$O	the$$$164$$$167$$$O	following$$$168$$$177$$$O	weight$$$178$$$184$$$O	ratio:$$$185$$$191$$$O	15$$$192$$$194$$$O	to$$$195$$$197$$$O	25$$$198$$$200$$$O	portions$$$201$$$209$$$O	of$$$210$$$212$$$O	herba$$$213$$$218$$$O	gynostemae,$$$219$$$230$$$O	8$$$231$$$232$$$O	to$$$233$$$235$$$O	12$$$236$$$238$$$O	portions$$$239$$$247$$$O	of$$$248$$$250$$$O	luffa$$$251$$$256$$$O	rattan,$$$257$$$264$$$O	8$$$265$$$266$$$O	to$$$267$$$269$$$O	12$$$270$$$272$$$O	portions$$$273$$$281$$$O	of$$$282$$$284$$$O	Angelica$$$285$$$293$$$O	dahurica,$$$294$$$303$$$O	3$$$304$$$305$$$O	to$$$306$$$308$$$O	7$$$309$$$310$$$O	portions$$$311$$$319$$$O	of$$$320$$$322$$$O	honeysuckle,$$$323$$$335$$$O	3$$$336$$$337$$$O	to$$$338$$$340$$$O	7$$$341$$$342$$$O	portions$$$343$$$351$$$O	of$$$352$$$354$$$O	calculus$$$355$$$363$$$O	calamus,$$$364$$$372$$$O	0.5$$$373$$$376$$$O	to$$$377$$$379$$$O	1.5$$$380$$$383$$$O	portions$$$384$$$392$$$O	of$$$393$$$395$$$O	peppermint$$$396$$$406$$$O	cream,$$$407$$$413$$$O	and$$$414$$$417$$$O	1$$$418$$$419$$$O	to$$$420$$$422$$$O	3$$$423$$$424$$$O	portions$$$425$$$433$$$O	of$$$434$$$436$$$O	borneol.$$$437$$$445$$$I	The$$$446$$$449$$$O	present$$$450$$$457$$$O	invention$$$458$$$467$$$O	also$$$468$$$472$$$O	discloses$$$473$$$482$$$O	a$$$483$$$484$$$O	preparation$$$485$$$496$$$O	method$$$497$$$503$$$O	of$$$504$$$506$$$O	the$$$507$$$510$$$O	external$$$511$$$519$$$O	antimicrobial$$$520$$$533$$$O	spraying$$$534$$$542$$$O	agent.$$$543$$$549$$$O	The$$$550$$$553$$$O	external$$$554$$$562$$$O	antimicrobial$$$563$$$576$$$O	spraying$$$577$$$585$$$O	agent$$$586$$$591$$$O	has$$$592$$$595$$$O	the$$$596$$$599$$$O	advantages$$$600$$$610$$$O	of$$$611$$$613$$$O	simple$$$614$$$620$$$O	and$$$621$$$624$$$O	reasonable$$$625$$$635$$$O	formula,$$$636$$$644$$$O	significant$$$645$$$656$$$O	curative$$$657$$$665$$$O	effects,$$$666$$$674$$$O	convenient$$$675$$$685$$$O	use,$$$686$$$690$$$O	no$$$691$$$693$$$O	pains$$$694$$$699$$$O	to$$$700$$$702$$$O	the$$$703$$$706$$$O	patient,$$$707$$$715$$$O	and$$$716$$$719$$$O	difficult$$$720$$$729$$$O	recrudescence.$$$730$$$744$$$O
EP2494973A1
Topical$$$0$$$7$$$O	compositions$$$8$$$20$$$O	for$$$21$$$24$$$O	the$$$25$$$28$$$O	treatment$$$29$$$38$$$O	and$$$39$$$42$$$O	prevention$$$43$$$53$$$O	of$$$54$$$56$$$O	skin$$$57$$$61$$$O	diseases,$$$62$$$71$$$O	in$$$72$$$74$$$O	particular$$$75$$$85$$$O	radiation$$$86$$$95$$$O	dermatitis$$$96$$$106$$$O	caused$$$107$$$113$$$O	by$$$114$$$116$$$O	ionising$$$117$$$125$$$O	radiation$$$126$$$135$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	topical$$$33$$$40$$$O	compositions$$$41$$$53$$$O	for$$$54$$$57$$$O	the$$$58$$$61$$$O	treatment$$$62$$$71$$$O	and$$$72$$$75$$$O	prevention$$$76$$$86$$$O	of$$$87$$$89$$$O	skin$$$90$$$94$$$O	diseases,$$$95$$$104$$$O	in$$$105$$$107$$$O	particular$$$108$$$118$$$O	radiation$$$119$$$128$$$O	dermatitis$$$129$$$139$$$O	due$$$140$$$143$$$O	to$$$144$$$146$$$O	ionising$$$147$$$155$$$O	radiation$$$156$$$165$$$O	treatments.$$$166$$$177$$$O
US8501244
Chlorite$$$0$$$8$$$O	formulations$$$9$$$21$$$O	and$$$22$$$25$$$O	methods$$$26$$$33$$$O	of$$$34$$$36$$$O	preparation$$$37$$$48$$$O	and$$$49$$$52$$$O	use$$$53$$$56$$$O	thereof$$$57$$$64$$$O
Described$$$0$$$9$$$O	herein$$$10$$$16$$$O	are$$$17$$$20$$$O	chlorite$$$21$$$29$$$I	formulations$$$30$$$42$$$O	having$$$43$$$49$$$O	a$$$50$$$51$$$O	pH$$$52$$$54$$$O	between$$$55$$$62$$$O	about$$$63$$$68$$$O	7$$$69$$$70$$$O	and$$$71$$$74$$$O	about$$$75$$$80$$$O	8.5,$$$81$$$85$$$O	wherein$$$86$$$93$$$O	the$$$94$$$97$$$O	chlorite$$$98$$$106$$$I	formulations$$$107$$$119$$$O	are$$$120$$$123$$$O	substantially$$$124$$$137$$$O	free$$$138$$$142$$$O	of$$$143$$$145$$$O	deleterious$$$146$$$157$$$O	non-chlorite$$$158$$$170$$$I	components.$$$171$$$182$$$O	Described$$$183$$$192$$$O	herein$$$193$$$199$$$O	are$$$200$$$203$$$O	chlorite$$$204$$$212$$$I	formulations,$$$213$$$226$$$O	including$$$227$$$236$$$O	pharmaceutical$$$237$$$251$$$O	formulations,$$$252$$$265$$$O	which$$$266$$$271$$$O	are$$$272$$$275$$$O	formulated$$$276$$$286$$$O	for$$$287$$$290$$$O	systemic,$$$291$$$300$$$O	parenteral,$$$301$$$312$$$O	or$$$313$$$315$$$O	intravenous$$$316$$$327$$$O	administration.$$$328$$$343$$$O	Described$$$344$$$353$$$O	herein$$$354$$$360$$$O	are$$$361$$$364$$$O	methods$$$365$$$372$$$O	of$$$373$$$375$$$O	preparing$$$376$$$385$$$O	and$$$386$$$389$$$O	methods$$$390$$$397$$$O	of$$$398$$$400$$$O	using$$$401$$$406$$$O	the$$$407$$$410$$$O	chlorite$$$411$$$419$$$I	formulations$$$420$$$432$$$O	described$$$433$$$442$$$O	herein.$$$443$$$450$$$O
US20110008429
Anti-Retroviral$$$0$$$15$$$O	Combination$$$16$$$27$$$O
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	composition$$$17$$$28$$$O	comprising$$$29$$$39$$$O	a$$$40$$$41$$$O	solid$$$42$$$47$$$O	unit$$$48$$$52$$$O	dosage$$$53$$$59$$$O	form$$$60$$$64$$$O	comprising:$$$65$$$76$$$O	(i)$$$80$$$83$$$O	ritonavir$$$84$$$93$$$I	or$$$94$$$96$$$O	a$$$97$$$98$$$O	pharmaceutically$$$99$$$115$$$O	acceptable$$$116$$$126$$$O	salt$$$127$$$131$$$O	and$$$132$$$135$$$O	ester$$$136$$$141$$$O	thereof;$$$142$$$150$$$O	(ii)$$$151$$$155$$$O	darunavir$$$156$$$165$$$I	or$$$166$$$168$$$O	a$$$169$$$170$$$O	pharmaceutically$$$171$$$187$$$O	acceptable$$$188$$$198$$$O	salt$$$199$$$203$$$O	and$$$204$$$207$$$O	ester$$$208$$$213$$$O	thereof.$$$214$$$222$$$O
WO2010004433A3
Hydrophobically$$$0$$$15$$$O	enhanced$$$16$$$24$$$O	aminoglycosides$$$25$$$40$$$I
Hydrophobically$$$0$$$15$$$O	enhanced$$$16$$$24$$$O	aminoglycosides$$$25$$$40$$$I	have$$$41$$$45$$$O	been$$$46$$$50$$$O	prepared$$$51$$$59$$$O	and$$$60$$$63$$$O	shown$$$64$$$69$$$O	to$$$70$$$72$$$O	be$$$73$$$75$$$O	effective$$$76$$$85$$$O	antibacterial$$$86$$$99$$$O	agents.$$$100$$$107$$$O	These$$$108$$$113$$$O	agents$$$114$$$120$$$O	may$$$121$$$124$$$O	be$$$125$$$127$$$O	used$$$128$$$132$$$O	in$$$133$$$135$$$O	the$$$136$$$139$$$O	treatment$$$140$$$149$$$O	or$$$150$$$152$$$O	prevention$$$153$$$163$$$O	of$$$164$$$166$$$O	various$$$167$$$174$$$O	bacterial$$$175$$$184$$$O	infections.$$$185$$$196$$$O	Methods$$$197$$$204$$$O	of$$$205$$$207$$$O	preparing$$$208$$$217$$$O	these$$$218$$$223$$$O	agents$$$224$$$230$$$O	also$$$231$$$235$$$O	permit$$$236$$$242$$$O	facile$$$243$$$249$$$O	synthetic$$$250$$$259$$$O	access.$$$260$$$267$$$O	Formula$$$268$$$275$$$O	(I).$$$276$$$280$$$O
US20080299189
Controlled$$$0$$$10$$$O	release$$$11$$$18$$$O	dopamine$$$19$$$27$$$I	agonist$$$28$$$35$$$O	compositions$$$36$$$48$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	multiphase$$$35$$$45$$$O	release$$$46$$$53$$$O	oral$$$54$$$58$$$O	pharmaceutical$$$59$$$73$$$O	formulation$$$74$$$85$$$O	having$$$86$$$92$$$O	a$$$93$$$94$$$O	dopamine$$$95$$$103$$$I	agonist$$$104$$$111$$$O	as$$$112$$$114$$$O	an$$$115$$$117$$$O	active$$$118$$$124$$$O	ingredient.$$$125$$$136$$$O	The$$$137$$$140$$$O	multiphase$$$141$$$151$$$O	composition$$$152$$$163$$$O	comprises$$$164$$$173$$$O	at$$$174$$$176$$$O	least$$$177$$$182$$$O	two$$$183$$$186$$$O	different$$$187$$$196$$$O	release$$$197$$$204$$$O	components.$$$205$$$216$$$O	The$$$217$$$220$$$O	invention$$$221$$$230$$$O	relates$$$231$$$238$$$O	to$$$239$$$241$$$O	controlled$$$242$$$252$$$O	release$$$253$$$260$$$O	pharmaceutical$$$261$$$275$$$O	compositions$$$276$$$288$$$O	of$$$289$$$291$$$O	pramipexole$$$292$$$303$$$I	or$$$304$$$306$$$O	a$$$307$$$308$$$O	pharmaceutically$$$309$$$325$$$O	acceptable$$$326$$$336$$$O	salt$$$337$$$341$$$O	thereof$$$342$$$349$$$O	for$$$350$$$353$$$O	once-daily$$$354$$$364$$$O	administration.$$$365$$$380$$$O
US8809348
6-arylmethyl$$$0$$$12$$$O	substituted$$$13$$$24$$$O	pyrazolo[3,4-d]pyrimidines$$$25$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	6-arylmethyl-substituted$$$31$$$55$$$O	pyrazolopyrimidines,$$$56$$$76$$$O	process$$$77$$$84$$$O	for$$$85$$$88$$$O	their$$$89$$$94$$$O	preparation$$$95$$$106$$$O	and$$$107$$$110$$$O	their$$$111$$$116$$$O	use$$$117$$$120$$$O	for$$$121$$$124$$$O	producing$$$125$$$134$$$O	medicaments$$$135$$$146$$$O	for$$$147$$$150$$$O	improving$$$151$$$160$$$O	perception,$$$161$$$172$$$O	concentration,$$$173$$$187$$$O	learning$$$188$$$196$$$O	and/or$$$197$$$203$$$O	memory.$$$204$$$211$$$O
CN102178693A
Glucose-electrolyte$$$0$$$19$$$I	effervescent$$$20$$$32$$$O	tablets$$$33$$$40$$$O	and$$$41$$$44$$$O	preparation$$$45$$$56$$$O	method$$$57$$$63$$$O	thereof$$$64$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	glucose-electrolyte$$$24$$$43$$$I	effervescent$$$44$$$56$$$O	tablets,$$$57$$$65$$$O	which$$$66$$$71$$$O	can$$$72$$$75$$$O	disintegrate$$$76$$$88$$$O	quickly,$$$89$$$97$$$O	can$$$98$$$101$$$O	be$$$102$$$104$$$O	taken$$$105$$$110$$$O	conveniently,$$$111$$$124$$$O	are$$$125$$$128$$$O	quick$$$129$$$134$$$O	in$$$135$$$137$$$O	effectiveness$$$138$$$151$$$O	and$$$152$$$155$$$O	convenient$$$156$$$166$$$O	for$$$167$$$170$$$O	storage$$$171$$$178$$$O	and$$$179$$$182$$$O	carrying,$$$183$$$192$$$O	and$$$193$$$196$$$O	are$$$197$$$200$$$O	particularly$$$201$$$213$$$O	applicable$$$214$$$224$$$O	to$$$225$$$227$$$O	children,$$$228$$$237$$$O	old$$$238$$$241$$$O	people$$$242$$$248$$$O	and$$$249$$$252$$$O	people$$$253$$$259$$$O	having$$$260$$$266$$$O	difficulty$$$267$$$277$$$O	in$$$278$$$280$$$O	swallowing$$$281$$$291$$$O	pills.$$$292$$$298$$$O	The$$$299$$$302$$$O	glucose-electrolyte$$$303$$$322$$$I	effervescent$$$323$$$335$$$O	tablets$$$336$$$343$$$O	comprises$$$344$$$353$$$O	0$$$354$$$355$$$O	to$$$356$$$358$$$O	20$$$359$$$361$$$O	mass$$$362$$$366$$$O	percent$$$367$$$374$$$O	of$$$375$$$377$$$O	vitamin$$$378$$$385$$$I	C,$$$386$$$388$$$I	10$$$389$$$391$$$O	to$$$392$$$394$$$O	70$$$395$$$397$$$O	mass$$$398$$$402$$$O	percent$$$403$$$410$$$O	of$$$411$$$413$$$O	glucose,$$$414$$$422$$$I	3$$$423$$$424$$$O	to$$$425$$$427$$$O	20$$$428$$$430$$$O	mass$$$431$$$435$$$O	percent$$$436$$$443$$$O	of$$$444$$$446$$$O	sodium$$$447$$$453$$$I	chloride,$$$454$$$463$$$I	0$$$464$$$465$$$O	to$$$466$$$468$$$O	10$$$469$$$471$$$O	mass$$$472$$$476$$$O	percent$$$477$$$484$$$O	of$$$485$$$487$$$O	potassium$$$488$$$497$$$I	carbonate,$$$498$$$508$$$I	20$$$509$$$511$$$O	to$$$512$$$514$$$O	60$$$515$$$517$$$O	mass$$$518$$$522$$$O	percent$$$523$$$530$$$O	of$$$531$$$533$$$O	disintegrating$$$534$$$548$$$O	agent$$$549$$$554$$$O	and$$$555$$$558$$$O	0$$$559$$$560$$$O	to$$$561$$$563$$$O	30$$$564$$$566$$$O	mass$$$567$$$571$$$O	percent$$$572$$$579$$$O	of$$$580$$$582$$$O	filler,$$$583$$$590$$$O	wherein$$$591$$$598$$$O	the$$$599$$$602$$$O	disintegrating$$$603$$$617$$$O	agent$$$618$$$623$$$O	consists$$$624$$$632$$$O	of$$$633$$$635$$$O	an$$$636$$$638$$$O	alkaline$$$639$$$647$$$O	component$$$648$$$657$$$O	and$$$658$$$661$$$O	an$$$662$$$664$$$O	acid$$$665$$$669$$$O	component,$$$670$$$680$$$O	wherein$$$681$$$688$$$O	the$$$689$$$692$$$O	alkaline$$$693$$$701$$$O	component$$$702$$$711$$$O	is$$$712$$$714$$$O	one$$$715$$$718$$$O	of$$$719$$$721$$$O	sodium$$$722$$$728$$$I	carbonate$$$729$$$738$$$I	and$$$739$$$742$$$O	sodium$$$743$$$749$$$I	bicarbonate$$$750$$$761$$$I	or$$$762$$$764$$$O	the$$$765$$$768$$$O	mixture$$$769$$$776$$$O	of$$$777$$$779$$$O	the$$$780$$$783$$$O	sodium$$$784$$$790$$$I	carbonate$$$791$$$800$$$I	and$$$801$$$804$$$O	sodium$$$805$$$811$$$I	bicarbonate;$$$812$$$824$$$I	the$$$825$$$828$$$O	acid$$$829$$$833$$$O	component$$$834$$$843$$$O	is$$$844$$$846$$$O	one$$$847$$$850$$$O	of$$$851$$$853$$$O	citric$$$854$$$860$$$I	acid,$$$861$$$866$$$I	malic$$$867$$$872$$$I	acid$$$873$$$877$$$I	and$$$878$$$881$$$O	tartaric$$$882$$$890$$$I	acid$$$891$$$895$$$I	or$$$896$$$898$$$O	a$$$899$$$900$$$O	mixture$$$901$$$908$$$O	of$$$909$$$911$$$O	several$$$912$$$919$$$O	of$$$920$$$922$$$O	the$$$923$$$926$$$O	citric$$$927$$$933$$$I	acid,$$$934$$$939$$$I	malic$$$940$$$945$$$I	acid$$$946$$$950$$$I	and$$$951$$$954$$$O	tartaric$$$955$$$963$$$I	acid;$$$964$$$969$$$I	the$$$970$$$973$$$O	mass$$$974$$$978$$$O	ratio$$$979$$$984$$$O	of$$$985$$$987$$$O	the$$$988$$$991$$$O	acid$$$992$$$996$$$O	component$$$997$$$1006$$$O	to$$$1007$$$1009$$$O	the$$$1010$$$1013$$$O	alkaline$$$1014$$$1022$$$O	component$$$1023$$$1032$$$O	is$$$1033$$$1035$$$O	1$$$1036$$$1037$$$O	to$$$1038$$$1040$$$O	3;$$$1041$$$1043$$$O	and$$$1044$$$1047$$$O	the$$$1048$$$1051$$$O	filler$$$1052$$$1058$$$O	is$$$1059$$$1061$$$O	one$$$1062$$$1065$$$O	of$$$1066$$$1068$$$O	lactin,$$$1069$$$1076$$$I	sorbierite,$$$1077$$$1088$$$I	mannitol$$$1089$$$1097$$$I	and$$$1098$$$1101$$$O	starch$$$1102$$$1108$$$O	or$$$1109$$$1111$$$O	the$$$1112$$$1115$$$O	mixture$$$1116$$$1123$$$O	of$$$1124$$$1126$$$O	several$$$1127$$$1134$$$O	of$$$1135$$$1137$$$O	the$$$1138$$$1141$$$O	lactin,$$$1142$$$1149$$$I	sorbierite,$$$1150$$$1161$$$I	mannitol$$$1162$$$1170$$$I	and$$$1171$$$1174$$$O	starch.$$$1175$$$1182$$$O
CA2464309C
Combinations$$$0$$$12$$$O	comprising$$$13$$$23$$$O	a$$$24$$$25$$$O	selective$$$26$$$35$$$O	cyclooxygenase-2$$$36$$$52$$$O	inhibitor$$$53$$$62$$$O
A$$$0$$$1$$$O	combination$$$2$$$13$$$O	therapy$$$14$$$21$$$O	for$$$22$$$25$$$O	treating$$$26$$$34$$$O	patients$$$35$$$43$$$O	suffering$$$44$$$53$$$O	from$$$54$$$58$$$O	pre-malignant$$$59$$$72$$$O	colon$$$73$$$78$$$O	lesions$$$79$$$86$$$O	(e.g.$$$87$$$92$$$O	polyps)$$$93$$$100$$$O	and$$$101$$$104$$$O	colon$$$105$$$110$$$O	cancer,$$$111$$$118$$$O	as$$$119$$$121$$$O	well$$$122$$$126$$$O	as$$$127$$$129$$$O	other$$$130$$$135$$$O	malignancies,$$$136$$$149$$$O	is$$$150$$$152$$$O	disclosed.$$$153$$$163$$$O	The$$$164$$$167$$$O	patient$$$168$$$175$$$O	is$$$176$$$178$$$O	treated$$$179$$$186$$$O	concurrently$$$187$$$199$$$O	with$$$200$$$204$$$O	a$$$205$$$206$$$O	cycloocygenase-2$$$207$$$223$$$O	inhibitor$$$224$$$233$$$O	and$$$234$$$237$$$O	at$$$238$$$240$$$O	least$$$241$$$246$$$O	one$$$247$$$250$$$O	compound$$$251$$$259$$$O	selected$$$260$$$268$$$O	from$$$269$$$273$$$O	the$$$274$$$277$$$O	group$$$278$$$283$$$O	consisting$$$284$$$294$$$O	of$$$295$$$297$$$O	a$$$298$$$299$$$O	microtubule$$$300$$$311$$$O	interfering$$$312$$$323$$$O	agent,$$$324$$$330$$$O	an$$$331$$$333$$$O	epithelial$$$334$$$344$$$O	growth$$$345$$$351$$$O	factor$$$352$$$358$$$O	receptor$$$359$$$367$$$O	tyrosine$$$368$$$376$$$I	protein$$$377$$$384$$$O	kinase$$$385$$$391$$$O	inhibitor$$$392$$$401$$$O	and$$$402$$$405$$$O	a$$$406$$$407$$$O	vascular$$$408$$$416$$$O	endothelial$$$417$$$428$$$O	growth$$$429$$$435$$$O	factor$$$436$$$442$$$O	receptor$$$443$$$451$$$O	tyrosine$$$452$$$460$$$O	kinase$$$461$$$467$$$O	inhibitor.$$$468$$$478$$$O
CN102321025A
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	preparation$$$16$$$27$$$O	of$$$28$$$30$$$O	indazolyl$$$31$$$40$$$I	ureas$$$41$$$46$$$I	that$$$47$$$51$$$O	inhibit$$$52$$$59$$$O	vanilloid$$$60$$$69$$$O	subtype$$$70$$$77$$$O	1$$$78$$$79$$$O	(VR1)$$$80$$$85$$$O	receptors$$$86$$$95$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	process$$$35$$$42$$$O	of$$$43$$$45$$$O	preparing$$$46$$$55$$$O	indazolyl$$$56$$$65$$$I	ureas$$$66$$$71$$$I	that$$$72$$$76$$$O	are$$$77$$$80$$$O	useful$$$81$$$87$$$O	as$$$88$$$90$$$O	antagonists$$$91$$$102$$$O	of$$$103$$$105$$$O	the$$$106$$$109$$$O	vanilloid$$$110$$$119$$$I	receptor$$$120$$$128$$$O	subtype$$$129$$$136$$$O	1$$$137$$$138$$$O	(VR1).$$$139$$$145$$$O
US20080153781
Applying$$$0$$$8$$$O	4-(2,4-bistrimethylsilyphenylcarboxamide)$$$9$$$50$$$I	benzoic$$$51$$$58$$$I	acid;$$$59$$$64$$$I	warts,$$$65$$$71$$$O	eczema,$$$72$$$79$$$O	dandruff$$$80$$$88$$$O
A$$$0$$$1$$$O	medicament$$$2$$$12$$$O	having$$$13$$$19$$$O	an$$$20$$$22$$$O	anti-wrinkle$$$23$$$35$$$O	action,$$$36$$$43$$$O	which$$$44$$$49$$$O	comprises$$$50$$$59$$$O	as$$$60$$$62$$$O	an$$$63$$$65$$$O	active$$$66$$$72$$$O	ingredient$$$73$$$83$$$O	a$$$84$$$85$$$O	retinoid$$$86$$$94$$$I	having$$$95$$$101$$$O	a$$$102$$$103$$$O	fundamental$$$104$$$115$$$O	structure$$$116$$$125$$$O	of$$$126$$$128$$$O	a$$$129$$$130$$$O	phenyl$$$131$$$137$$$I	substituted$$$138$$$149$$$O	carbamoyl$$$150$$$159$$$I	benzoic$$$160$$$167$$$I	acid$$$168$$$172$$$I	or$$$173$$$175$$$O	a$$$176$$$177$$$O	phenyl$$$178$$$184$$$I	substituted$$$185$$$196$$$O	carboxamide$$$197$$$208$$$I	benzoic$$$209$$$216$$$I	acid$$$217$$$221$$$I	(for$$$222$$$226$$$O	example,$$$227$$$235$$$O	4-(2,4-bistrimethylsilylphenylcarboxamide)$$$236$$$278$$$I	benzoic$$$279$$$286$$$I	acid,$$$287$$$292$$$I	4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)$$$293$$$351$$$I	carbamoyl]$$$352$$$362$$$I	benzoic$$$363$$$370$$$I	acid,$$$371$$$376$$$I	or$$$377$$$379$$$O	the$$$380$$$383$$$O	like).$$$384$$$390$$$O
WO2009083444A1
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	the$$$16$$$19$$$O	treatment$$$20$$$29$$$O	of$$$30$$$32$$$O	osteoarthritis$$$33$$$47$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compositions$$$33$$$45$$$O	comprising$$$46$$$56$$$O	chondroitin$$$57$$$68$$$O	sulphate$$$69$$$77$$$I	and$$$78$$$81$$$O	mannosamine$$$82$$$93$$$I	or$$$94$$$96$$$O	a$$$97$$$98$$$O	derivative$$$99$$$109$$$O	thereof.$$$110$$$118$$$O	The$$$119$$$122$$$O	mannosamine$$$123$$$134$$$I	derivative$$$135$$$145$$$O	is$$$146$$$148$$$O	preferably$$$149$$$159$$$O	N-acetylmannosamine.$$$160$$$180$$$I	The$$$181$$$184$$$O	compositions$$$185$$$197$$$O	may$$$198$$$201$$$O	comprise$$$202$$$210$$$O	glucosamine.$$$211$$$223$$$I	Said$$$224$$$228$$$O	compositions$$$229$$$241$$$O	are$$$242$$$245$$$O	useful$$$246$$$252$$$O	in$$$253$$$255$$$O	the$$$256$$$259$$$O	treatment$$$260$$$269$$$O	or$$$270$$$272$$$O	prevention$$$273$$$283$$$O	of$$$284$$$286$$$O	degenerative$$$287$$$299$$$O	joint$$$300$$$305$$$O	diseases,$$$306$$$315$$$O	preferably$$$316$$$326$$$O	of$$$327$$$329$$$O	osteoarthritis,$$$330$$$345$$$O	in$$$346$$$348$$$O	the$$$349$$$352$$$O	treatment$$$353$$$362$$$O	or$$$363$$$365$$$O	prevention$$$366$$$376$$$O	of$$$377$$$379$$$O	tendon$$$380$$$386$$$O	or$$$387$$$389$$$O	ligament$$$390$$$398$$$O	diseases,$$$399$$$408$$$O	disorders$$$409$$$418$$$O	or$$$419$$$421$$$O	injuries$$$422$$$430$$$O	and$$$431$$$434$$$O	of$$$435$$$437$$$O	immune$$$438$$$444$$$O	system$$$445$$$451$$$O	diseases,$$$452$$$461$$$O	preferably$$$462$$$472$$$O	of$$$473$$$475$$$O	rheumatoid$$$476$$$486$$$O	arthritis.$$$487$$$497$$$O
US20110064773
pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	comprising$$$28$$$38$$$O	a$$$39$$$40$$$O	thyroid$$$41$$$48$$$O	hormon$$$49$$$55$$$O	and$$$56$$$59$$$O	their$$$60$$$65$$$O	therapeutic$$$66$$$77$$$O	use$$$78$$$81$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	comprising,$$$62$$$73$$$O	as$$$74$$$76$$$O	active$$$77$$$83$$$O	substance,$$$84$$$94$$$O	at$$$95$$$97$$$O	least$$$98$$$103$$$O	one$$$104$$$107$$$O	hormone$$$108$$$115$$$O	chosen$$$116$$$122$$$O	among$$$123$$$128$$$O	3â²,5â²,3-triiodothyronine$$$129$$$157$$$I	(rT3),$$$158$$$164$$$I	a$$$165$$$166$$$I	rT3$$$167$$$170$$$O	derived$$$171$$$178$$$O	hormone,$$$179$$$187$$$O	or$$$188$$$190$$$O	a$$$191$$$192$$$O	precursor$$$193$$$202$$$I	of$$$203$$$205$$$I	rT3,$$$206$$$210$$$O	such$$$211$$$215$$$I	as$$$216$$$218$$$I	T4$$$219$$$221$$$O	in$$$222$$$224$$$O	association$$$225$$$236$$$O	with$$$237$$$241$$$O	a$$$242$$$243$$$O	molecule$$$244$$$252$$$O	susceptible$$$253$$$264$$$O	to$$$265$$$267$$$O	promote$$$268$$$275$$$O	the$$$276$$$279$$$O	formation$$$280$$$289$$$I	of$$$290$$$292$$$I	rT3,$$$293$$$297$$$O	in$$$298$$$300$$$O	association$$$301$$$312$$$O	with$$$313$$$317$$$O	a$$$318$$$319$$$O	pharmaceutically$$$320$$$336$$$O	acceptable$$$337$$$347$$$O	vehicle.$$$348$$$356$$$O
US7101846
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	optimization$$$29$$$41$$$O	of$$$42$$$44$$$O	oxygen$$$45$$$51$$$I	transport$$$52$$$61$$$O	by$$$62$$$64$$$O	cell-free$$$65$$$74$$$O	systems$$$75$$$82$$$O
Compositions,$$$0$$$13$$$O	and$$$14$$$17$$$O	methods$$$18$$$25$$$O	of$$$26$$$28$$$O	use$$$29$$$32$$$O	thereof,$$$33$$$41$$$O	for$$$42$$$45$$$O	use$$$46$$$49$$$O	as$$$50$$$52$$$O	blood$$$53$$$58$$$O	substitute$$$59$$$69$$$O	products$$$70$$$78$$$O	comprise$$$79$$$87$$$O	aqueous$$$88$$$95$$$O	mixtures$$$96$$$104$$$O	of$$$105$$$107$$$O	oxygen-carrying$$$108$$$123$$$I	and$$$124$$$127$$$O	non-oxygen$$$128$$$138$$$I	carrying$$$139$$$147$$$O	plasma$$$148$$$154$$$O	expanders$$$155$$$164$$$O	and$$$165$$$168$$$O	methods$$$169$$$176$$$O	for$$$177$$$180$$$O	the$$$181$$$184$$$O	use$$$185$$$188$$$O	thereof.$$$189$$$197$$$O	The$$$198$$$201$$$O	oxygen-carrying$$$202$$$217$$$I	component$$$218$$$227$$$O	may$$$228$$$231$$$O	consist$$$232$$$239$$$O	of$$$240$$$242$$$O	any$$$243$$$246$$$O	hemoglobin-based$$$247$$$263$$$O	oxygen$$$264$$$270$$$I	carrier,$$$271$$$279$$$O	while$$$280$$$285$$$O	the$$$286$$$289$$$O	non-oxygen$$$290$$$300$$$I	carrying$$$301$$$309$$$O	plasma$$$310$$$316$$$O	expander$$$317$$$325$$$O	my$$$326$$$328$$$O	consist$$$329$$$336$$$O	of$$$337$$$339$$$O	any$$$340$$$343$$$O	suitable$$$344$$$352$$$O	diluent.$$$353$$$361$$$O
CN103371967A
Furosemide$$$0$$$10$$$I	injection$$$11$$$20$$$O	and$$$21$$$24$$$O	preparation$$$25$$$36$$$O	process$$$37$$$44$$$O	thereof$$$45$$$52$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	furosemide$$$25$$$35$$$I	injection$$$36$$$45$$$O	and$$$46$$$49$$$O	a$$$50$$$51$$$O	preparation$$$52$$$63$$$O	process$$$64$$$71$$$O	thereof.$$$72$$$80$$$O	Each$$$81$$$85$$$O	10000ml$$$86$$$93$$$O	of$$$94$$$96$$$O	furosemide$$$97$$$107$$$I	injection$$$108$$$117$$$O	contains$$$118$$$126$$$O	the$$$127$$$130$$$O	following$$$131$$$140$$$O	raw$$$141$$$144$$$O	materials:$$$145$$$155$$$O	100g$$$156$$$160$$$O	of$$$161$$$163$$$O	furosemide,$$$164$$$175$$$I	60-90g$$$176$$$182$$$O	of$$$183$$$185$$$O	sodium$$$186$$$192$$$I	chloride,$$$193$$$202$$$I	120-180ml$$$203$$$212$$$O	of$$$213$$$215$$$O	10%$$$216$$$219$$$O	(mass$$$220$$$225$$$O	concentration)$$$226$$$240$$$O	of$$$241$$$243$$$O	sodium$$$244$$$250$$$I	hydroxide$$$251$$$260$$$I	and$$$261$$$264$$$O	injection$$$265$$$274$$$O	water$$$275$$$280$$$O	for$$$281$$$284$$$O	supplementing$$$285$$$298$$$O	to$$$299$$$301$$$O	10000ml.$$$302$$$310$$$O	The$$$311$$$314$$$O	preparation$$$315$$$326$$$O	process$$$327$$$334$$$O	comprises$$$335$$$344$$$O	the$$$345$$$348$$$O	following$$$349$$$358$$$O	steps$$$359$$$364$$$O	of:$$$365$$$368$$$O	adding$$$369$$$375$$$O	the$$$376$$$379$$$O	injection$$$380$$$389$$$O	water$$$390$$$395$$$O	which$$$396$$$401$$$O	accounts$$$402$$$410$$$O	for$$$411$$$414$$$O	70$$$415$$$417$$$O	percent$$$418$$$425$$$O	of$$$426$$$428$$$O	the$$$429$$$432$$$O	total$$$433$$$438$$$O	amount$$$439$$$445$$$O	of$$$446$$$448$$$O	preparation$$$449$$$460$$$O	into$$$461$$$465$$$O	a$$$466$$$467$$$O	burdening$$$468$$$477$$$O	tank;$$$478$$$483$$$O	adding$$$484$$$490$$$O	the$$$491$$$494$$$O	furosemide,$$$495$$$506$$$I	the$$$507$$$510$$$O	sodium$$$511$$$517$$$I	chloride$$$518$$$526$$$I	and$$$527$$$530$$$O	the$$$531$$$534$$$O	10%$$$535$$$538$$$O	(mass$$$539$$$544$$$O	concentration)$$$545$$$559$$$O	of$$$560$$$562$$$O	sodium$$$563$$$569$$$I	hydroxide$$$570$$$579$$$I	to$$$580$$$582$$$O	the$$$583$$$586$$$O	burdening$$$587$$$596$$$O	tank;$$$597$$$602$$$O	stirring$$$603$$$611$$$O	till$$$612$$$616$$$O	the$$$617$$$620$$$O	furosemide$$$621$$$631$$$I	is$$$632$$$634$$$O	dissolved;$$$635$$$645$$$O	cooling$$$646$$$653$$$O	the$$$654$$$657$$$O	solution$$$658$$$666$$$O	to$$$667$$$669$$$O	be$$$670$$$672$$$O	below$$$673$$$678$$$O	30$$$679$$$681$$$O	DEG$$$682$$$685$$$O	C;$$$686$$$688$$$O	adjusting$$$689$$$698$$$O	the$$$699$$$702$$$O	pH$$$703$$$705$$$O	value$$$706$$$711$$$O	of$$$712$$$714$$$O	the$$$715$$$718$$$O	solution$$$719$$$727$$$O	to$$$728$$$730$$$O	9.1-9.4;$$$731$$$739$$$O	adding$$$740$$$746$$$O	the$$$747$$$750$$$O	injection$$$751$$$760$$$O	water$$$761$$$766$$$O	to$$$767$$$769$$$O	reach$$$770$$$775$$$O	total$$$776$$$781$$$O	preparation$$$782$$$793$$$O	amount$$$794$$$800$$$O	and$$$801$$$804$$$O	uniformly$$$805$$$814$$$O	stirring;$$$815$$$824$$$O	filtering$$$825$$$834$$$O	the$$$835$$$838$$$O	solution;$$$839$$$848$$$O	and$$$849$$$852$$$O	introducing$$$853$$$864$$$O	N2$$$865$$$867$$$I	to$$$868$$$870$$$O	the$$$871$$$874$$$O	filtered$$$875$$$883$$$O	solution$$$884$$$892$$$O	to$$$893$$$895$$$O	realize$$$896$$$903$$$O	encapsulation.$$$904$$$918$$$O	The$$$919$$$922$$$O	furosemide$$$923$$$933$$$I	injection$$$934$$$943$$$O	and$$$944$$$947$$$O	the$$$948$$$951$$$O	preparation$$$952$$$963$$$O	process$$$964$$$971$$$O	thereof$$$972$$$979$$$O	have$$$980$$$984$$$O	the$$$985$$$988$$$O	advantages$$$989$$$999$$$O	that$$$1000$$$1004$$$O	the$$$1005$$$1008$$$O	problem$$$1009$$$1016$$$O	that$$$1017$$$1021$$$O	related$$$1022$$$1029$$$O	substances$$$1030$$$1040$$$O	in$$$1041$$$1043$$$O	an$$$1044$$$1046$$$O	original$$$1047$$$1055$$$O	formula$$$1056$$$1063$$$O	of$$$1064$$$1066$$$O	the$$$1067$$$1070$$$O	furosemide$$$1071$$$1081$$$I	injection$$$1082$$$1091$$$O	are$$$1092$$$1095$$$O	unqualified$$$1096$$$1107$$$O	is$$$1108$$$1110$$$O	solved,$$$1111$$$1118$$$O	and$$$1119$$$1122$$$O	the$$$1123$$$1126$$$O	furosemide$$$1127$$$1137$$$I	injection$$$1138$$$1147$$$O	can$$$1148$$$1151$$$O	meet$$$1152$$$1156$$$O	the$$$1157$$$1160$$$O	quality$$$1161$$$1168$$$O	standard$$$1169$$$1177$$$O	of$$$1178$$$1180$$$O	the$$$1181$$$1184$$$O	furosemide$$$1185$$$1195$$$I	injection$$$1196$$$1205$$$O	in$$$1206$$$1208$$$O	China$$$1209$$$1214$$$O	Pharmacopoeia$$$1215$$$1228$$$O	(2010$$$1229$$$1234$$$O	Edition$$$1235$$$1242$$$O	2)$$$1243$$$1245$$$O	and$$$1246$$$1249$$$O	provision$$$1250$$$1259$$$O	of$$$1260$$$1262$$$O	notification$$$1263$$$1275$$$O	related$$$1276$$$1283$$$O	to$$$1284$$$1286$$$O	release$$$1287$$$1294$$$O	of$$$1295$$$1297$$$O	basic$$$1298$$$1303$$$O	technical$$$1304$$$1313$$$O	requirements$$$1314$$$1326$$$O	of$$$1327$$$1329$$$O	chemical$$$1330$$$1338$$$O	injection$$$1339$$$1348$$$O	and$$$1349$$$1352$$$O	multi-component$$$1353$$$1368$$$O	biochemical$$$1369$$$1380$$$O	medicine$$$1381$$$1389$$$O	injection.$$$1390$$$1400$$$O
US20100022581
Pyrrolidine-substituted$$$0$$$23$$$I	azaindole$$$24$$$33$$$I	compounds$$$34$$$43$$$O	having$$$44$$$50$$$O	5-ht6$$$51$$$56$$$O	receptor$$$57$$$65$$$O	affinity$$$66$$$74$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	provides$$$23$$$31$$$O	compounds$$$32$$$41$$$O	having$$$42$$$48$$$O	affinity$$$49$$$57$$$O	for$$$58$$$61$$$O	the$$$62$$$65$$$O	5-HT6$$$66$$$71$$$O	receptor$$$72$$$80$$$O	which$$$81$$$86$$$O	are$$$87$$$90$$$O	of$$$91$$$93$$$O	the$$$94$$$97$$$O	formula$$$98$$$105$$$O	(I):$$$106$$$110$$$O	wherein$$$148$$$155$$$O	R1,$$$156$$$159$$$O	R2,$$$160$$$163$$$O	A,$$$164$$$166$$$O	B,$$$167$$$169$$$O	D,$$$170$$$172$$$O	E,$$$173$$$175$$$O	G,$$$176$$$178$$$O	Ar,$$$179$$$182$$$O	and$$$183$$$186$$$O	n$$$187$$$188$$$O	are$$$189$$$192$$$O	as$$$193$$$195$$$O	defined$$$196$$$203$$$O	herein.$$$204$$$211$$$O	The$$$212$$$215$$$O	disclosure$$$216$$$226$$$O	also$$$227$$$231$$$O	relates$$$232$$$239$$$O	to$$$240$$$242$$$O	methods$$$243$$$250$$$O	of$$$251$$$253$$$O	preparing$$$254$$$263$$$O	such$$$264$$$268$$$O	compounds,$$$269$$$279$$$O	compositions$$$280$$$292$$$O	containing$$$293$$$303$$$O	such$$$304$$$308$$$O	compounds,$$$309$$$319$$$O	and$$$320$$$323$$$O	methods$$$324$$$331$$$O	of$$$332$$$334$$$O	use$$$335$$$338$$$O	thereof.$$$339$$$347$$$O
EP1684770A1
Oligo-beta-(1,3)-glucan$$$0$$$23$$$I	and$$$24$$$27$$$O	monoclonal$$$28$$$38$$$O	antibodies$$$39$$$49$$$O	against$$$50$$$57$$$O	cancer$$$58$$$64$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	therapeutical$$$35$$$48$$$O	method$$$49$$$55$$$O	comprising$$$56$$$66$$$O	administration$$$67$$$81$$$O	of$$$82$$$84$$$O	a$$$85$$$86$$$O	composition$$$87$$$98$$$O	comprising$$$99$$$109$$$O	a$$$110$$$111$$$O	monoclonal$$$112$$$122$$$O	antibody$$$123$$$131$$$O	with$$$132$$$136$$$O	an$$$137$$$139$$$O	oligo-Î²-(1,3)-glucan$$$140$$$161$$$I	and.$$$162$$$166$$$O	a$$$167$$$168$$$O	pharmaceutically$$$169$$$185$$$O	acceptable$$$186$$$196$$$O	carrier,$$$197$$$205$$$O	to$$$206$$$208$$$O	a$$$209$$$210$$$O	human$$$211$$$216$$$O	being$$$217$$$222$$$O	or$$$223$$$225$$$O	to$$$226$$$228$$$O	a$$$229$$$230$$$O	warm-blood$$$231$$$241$$$O	animal$$$242$$$248$$$O	suffering$$$249$$$258$$$O	from$$$259$$$263$$$O	cancer$$$264$$$270$$$O	in$$$271$$$273$$$O	an$$$274$$$276$$$O	amount$$$277$$$283$$$O	which$$$284$$$289$$$O	is$$$290$$$292$$$O	effective$$$293$$$302$$$O	to$$$303$$$305$$$O	treat$$$306$$$311$$$O	the$$$312$$$315$$$O	cancer.$$$316$$$323$$$O
US20100120799
Purine$$$0$$$6$$$I	derivatives$$$7$$$18$$$O	as$$$19$$$21$$$O	immunomodulators$$$22$$$38$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I):$$$21$$$25$$$O	wherein$$$63$$$70$$$O	R1$$$74$$$76$$$O	is$$$77$$$79$$$O	C1-8alkylamino,$$$80$$$95$$$I	C1-8alkoxy,$$$96$$$107$$$I	C3-7cycloalkylC1-6alkylamino,$$$108$$$137$$$I	C3-7cycloalkylC1-6alkoxy,$$$138$$$163$$$I	C1-3alkoxyC2-3alkoxy,$$$164$$$185$$$I	or$$$186$$$188$$$O	Hetb-C1-3alkoxy;$$$189$$$205$$$I	Hetb$$$206$$$210$$$O	is$$$211$$$213$$$O	a$$$214$$$215$$$O	5-$$$216$$$218$$$I	or$$$219$$$221$$$I	6-membered$$$222$$$232$$$I	saturated$$$233$$$242$$$I	aliphatic$$$243$$$252$$$I	heterocycle$$$253$$$264$$$I	containing$$$265$$$275$$$O	one$$$276$$$279$$$O	oxygen$$$280$$$286$$$I	atom;$$$287$$$292$$$O	R2$$$293$$$295$$$O	is$$$296$$$298$$$O	â(CH2)n-Het;$$$299$$$313$$$I	n$$$314$$$315$$$O	is$$$316$$$318$$$O	an$$$319$$$321$$$O	integer$$$322$$$329$$$O	having$$$330$$$336$$$O	a$$$337$$$338$$$O	value$$$339$$$344$$$O	of$$$345$$$347$$$O	1$$$348$$$349$$$O	to$$$350$$$352$$$O	4;$$$353$$$355$$$O	Het$$$356$$$359$$$O	is$$$360$$$362$$$O	a$$$363$$$364$$$O	5-$$$365$$$367$$$O	or$$$368$$$370$$$O	6-membered$$$371$$$381$$$O	saturated$$$382$$$391$$$I	aliphatic$$$392$$$401$$$I	heterocycle$$$402$$$413$$$I	containing$$$414$$$424$$$O	one$$$425$$$428$$$I	oxygen$$$429$$$435$$$I	heteroatom,$$$436$$$447$$$O	which$$$448$$$453$$$I	heterocycle$$$454$$$465$$$I	may$$$466$$$469$$$O	be$$$470$$$472$$$O	substituted$$$473$$$484$$$O	by$$$485$$$487$$$O	one$$$488$$$491$$$O	or$$$492$$$494$$$O	two$$$495$$$498$$$I	C1-4alkyl$$$499$$$508$$$I	groups,$$$509$$$516$$$O	and$$$517$$$520$$$O	salts$$$521$$$526$$$O	and$$$527$$$530$$$O	solvates$$$531$$$539$$$O	thereof,$$$540$$$548$$$O	are$$$549$$$552$$$O	inducers$$$553$$$561$$$O	of$$$562$$$564$$$O	human$$$565$$$570$$$O	interferon$$$571$$$581$$$O	and$$$582$$$585$$$O	may$$$586$$$589$$$O	be$$$590$$$592$$$O	useful$$$593$$$599$$$O	in$$$600$$$602$$$O	the$$$603$$$606$$$O	treatment$$$607$$$616$$$O	of$$$617$$$619$$$O	various$$$620$$$627$$$O	disorders$$$628$$$637$$$O	in$$$638$$$640$$$O	particular$$$641$$$651$$$O	infectious$$$652$$$662$$$O	diseases,$$$663$$$672$$$O	cancer,$$$673$$$680$$$O	and$$$681$$$684$$$O	allergic$$$685$$$693$$$O	diseases$$$694$$$702$$$O	and$$$703$$$706$$$O	other$$$707$$$712$$$O	inflammatory$$$713$$$725$$$O	conditions$$$726$$$736$$$O	for$$$737$$$740$$$O	example$$$741$$$748$$$O	allergic$$$749$$$757$$$O	rhinitis$$$758$$$766$$$O	and$$$767$$$770$$$O	asthma,$$$771$$$778$$$O	and$$$779$$$782$$$O	as$$$783$$$785$$$O	vaccine$$$786$$$793$$$O	adjuvants.$$$794$$$804$$$O
US7053058
For$$$0$$$3$$$O	inhibiting$$$4$$$14$$$O	growth$$$15$$$21$$$O	of$$$22$$$24$$$O	prostatic$$$25$$$34$$$O	adenocarcinoma,$$$35$$$50$$$O	stomach$$$51$$$58$$$O	cancer,$$$59$$$66$$$O	breast$$$67$$$73$$$O	cancer,$$$74$$$81$$$O	endometrial,$$$82$$$94$$$O	ovarian$$$95$$$102$$$O	or$$$103$$$105$$$O	other$$$106$$$111$$$O	cancers$$$112$$$119$$$O	of$$$120$$$122$$$O	epithelial$$$123$$$133$$$O	secretion,$$$134$$$144$$$O	or$$$145$$$147$$$O	benign$$$148$$$154$$$O	prostate$$$155$$$163$$$O	hyperplasia$$$164$$$175$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	pharmaceutical$$$23$$$37$$$O	compositions$$$38$$$50$$$O	and$$$51$$$54$$$O	method$$$55$$$61$$$O	for$$$62$$$65$$$O	inhibiting$$$66$$$76$$$O	growth$$$77$$$83$$$O	of$$$84$$$86$$$O	prostatic$$$87$$$96$$$O	adenocarcinoma,$$$97$$$112$$$O	stomach$$$113$$$120$$$O	cancer,$$$121$$$128$$$O	breast$$$129$$$135$$$O	cancer,$$$136$$$143$$$O	endometrial,$$$144$$$156$$$O	ovarian$$$157$$$164$$$O	or$$$165$$$167$$$O	other$$$168$$$173$$$O	cancers$$$174$$$181$$$O	of$$$182$$$184$$$O	epithelial$$$185$$$195$$$O	secretion,$$$196$$$206$$$O	or$$$207$$$209$$$O	benign$$$210$$$216$$$O	prostate$$$217$$$225$$$O	hyperplasia$$$226$$$237$$$O	(BPH).$$$238$$$244$$$O	In$$$245$$$247$$$O	one$$$248$$$251$$$O	embodiment$$$252$$$262$$$O	the$$$263$$$266$$$O	pharmaceutical$$$267$$$281$$$O	composition$$$282$$$293$$$O	includes$$$294$$$302$$$O	human$$$303$$$308$$$O	rHuPSP94,$$$309$$$318$$$O	antigenic$$$319$$$328$$$O	portions$$$329$$$337$$$O	thereof,$$$338$$$346$$$O	and$$$347$$$350$$$O	functionally$$$351$$$363$$$O	equivalent$$$364$$$374$$$O	polypeptides$$$375$$$387$$$O	thereof.$$$388$$$396$$$O	In$$$397$$$399$$$O	another$$$400$$$407$$$O	embodiment,$$$408$$$419$$$O	the$$$420$$$423$$$O	pharmaceutical$$$424$$$438$$$O	composition$$$439$$$450$$$O	includes$$$451$$$459$$$O	a$$$460$$$461$$$O	mixture$$$462$$$469$$$O	of$$$470$$$472$$$O	human$$$473$$$478$$$O	rHuPSP94,$$$479$$$488$$$O	antigenic$$$489$$$498$$$O	portions$$$499$$$507$$$O	thereof,$$$508$$$516$$$O	and$$$517$$$520$$$O	functionally$$$521$$$533$$$O	equivalent$$$534$$$544$$$O	polypeptides$$$545$$$557$$$O	thereof$$$558$$$565$$$O	and$$$566$$$569$$$O	an$$$570$$$572$$$O	anticancer$$$573$$$583$$$O	drug$$$584$$$588$$$O	which$$$589$$$594$$$O	may$$$595$$$598$$$O	be$$$599$$$601$$$O	administered$$$602$$$614$$$O	in$$$615$$$617$$$O	an$$$618$$$620$$$O	appropriate$$$621$$$632$$$O	dosage$$$633$$$639$$$O	form,$$$640$$$645$$$O	dosage$$$646$$$652$$$O	quantity$$$653$$$661$$$O	and$$$662$$$665$$$O	dosage$$$666$$$672$$$O	regimen$$$673$$$680$$$O	to$$$681$$$683$$$O	a$$$684$$$685$$$O	patient$$$686$$$693$$$O	suffering$$$694$$$703$$$O	from,$$$704$$$709$$$O	for$$$710$$$713$$$O	example$$$714$$$721$$$O	of$$$722$$$724$$$O	prostatic$$$725$$$734$$$O	adenocarcinoma,$$$735$$$750$$$O	stomach$$$751$$$758$$$O	cancer,$$$759$$$766$$$O	breast$$$767$$$773$$$O	cancer,$$$774$$$781$$$O	endometrial,$$$782$$$794$$$O	ovarian$$$795$$$802$$$O	or$$$803$$$805$$$O	other$$$806$$$811$$$O	cancers$$$812$$$819$$$O	of$$$820$$$822$$$O	epithelial$$$823$$$833$$$O	secretion,$$$834$$$844$$$O	benign$$$845$$$851$$$O	prostate$$$852$$$860$$$O	hyperplasia,$$$861$$$873$$$O	or$$$874$$$876$$$O	(BPH)$$$877$$$882$$$O	gastrointestinal$$$883$$$899$$$O	cancer.$$$900$$$907$$$O	The$$$908$$$911$$$O	anticancer$$$912$$$922$$$O	drug$$$923$$$927$$$O	of$$$928$$$930$$$O	the$$$931$$$934$$$O	latter$$$935$$$941$$$O	mixture$$$942$$$949$$$O	may$$$950$$$953$$$O	be$$$954$$$956$$$O	one$$$957$$$960$$$O	selected$$$961$$$969$$$O	from$$$970$$$974$$$O	the$$$975$$$978$$$O	group$$$979$$$984$$$O	of$$$985$$$987$$$O	drugs$$$988$$$993$$$O	including$$$994$$$1003$$$O	mitomycin,$$$1004$$$1014$$$I	idarubicin,$$$1015$$$1026$$$I	cisplatin,$$$1027$$$1037$$$I	5-fluoro-uracil,$$$1038$$$1054$$$I	methotrexate,$$$1055$$$1068$$$I	adriamycin,$$$1069$$$1080$$$I	daunomycin,$$$1081$$$1092$$$I	taxol,$$$1093$$$1099$$$I	taxol$$$1100$$$1105$$$I	derivative,$$$1106$$$1117$$$O	and$$$1118$$$1121$$$O	mixtures$$$1122$$$1130$$$O	thereof.$$$1131$$$1139$$$O
EP1768661A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	targeted$$$7$$$15$$$O	oxidative$$$16$$$25$$$O	therapeutic$$$26$$$37$$$O	formulation$$$38$$$49$$$O	in$$$50$$$52$$$O	treatment$$$53$$$62$$$O	of$$$63$$$65$$$O	burns$$$66$$$71$$$O
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	formulation$$$17$$$28$$$O	and$$$29$$$32$$$O	its$$$33$$$36$$$O	use.$$$37$$$41$$$O	The$$$42$$$45$$$O	pharmaceutical$$$46$$$60$$$O	formulation$$$61$$$72$$$O	contains$$$73$$$81$$$O	peroxidic$$$82$$$91$$$O	species$$$92$$$99$$$O	or$$$100$$$102$$$O	reaction$$$103$$$111$$$O	products$$$112$$$120$$$O	resulting$$$121$$$130$$$O	from$$$131$$$135$$$O	oxidation$$$136$$$145$$$O	of$$$146$$$148$$$O	an$$$149$$$151$$$O	alkene,$$$152$$$159$$$I	such$$$160$$$164$$$O	as$$$165$$$167$$$O	geraniol,$$$168$$$177$$$I	by$$$178$$$180$$$O	an$$$181$$$183$$$O	oxygen-containing$$$184$$$201$$$I	oxidizing$$$202$$$211$$$O	agent,$$$212$$$218$$$O	such$$$219$$$223$$$O	as$$$224$$$226$$$O	ozone;$$$227$$$233$$$I	a$$$234$$$235$$$O	penetrating$$$236$$$247$$$O	solvent,$$$248$$$256$$$O	such$$$257$$$261$$$O	as$$$262$$$264$$$O	dimethylsulfoxide$$$265$$$282$$$I	('DMSO');$$$283$$$292$$$I	a$$$293$$$294$$$O	dye$$$295$$$298$$$O	containing$$$299$$$309$$$O	a$$$310$$$311$$$O	chelated$$$312$$$320$$$O	metal,$$$321$$$327$$$O	such$$$328$$$332$$$O	as$$$333$$$335$$$O	hematoporphyrin;$$$336$$$352$$$I	and$$$353$$$356$$$O	an$$$357$$$359$$$O	aromatic$$$360$$$368$$$I	redox$$$369$$$374$$$O	compound,$$$375$$$384$$$O	such$$$385$$$389$$$O	as$$$390$$$392$$$O	benzoquinone.$$$393$$$406$$$I	The$$$407$$$410$$$O	pharmaceutical$$$411$$$425$$$O	formulation$$$426$$$437$$$O	is$$$438$$$440$$$O	used$$$441$$$445$$$O	to$$$446$$$448$$$O	effectively$$$449$$$460$$$O	resolve$$$461$$$468$$$O	scar$$$469$$$473$$$O	tissue,$$$474$$$481$$$O	particularly$$$482$$$494$$$O	scar$$$495$$$499$$$O	tissue$$$500$$$506$$$O	resulting$$$507$$$516$$$O	from$$$517$$$521$$$O	a$$$522$$$523$$$O	burn,$$$524$$$529$$$O	and$$$530$$$533$$$O	to$$$534$$$536$$$O	treat$$$537$$$542$$$O	patients$$$543$$$551$$$O	with$$$552$$$556$$$O	bum-related$$$557$$$568$$$O	injuries.$$$569$$$578$$$O
US20120101104
Topical$$$0$$$7$$$O	gel$$$8$$$11$$$O	compositions$$$12$$$24$$$O	and$$$25$$$28$$$O	methods$$$29$$$36$$$O	of$$$37$$$39$$$O	use$$$40$$$43$$$O
Improved$$$0$$$8$$$O	topical$$$9$$$16$$$O	gel$$$17$$$20$$$O	compositions,$$$21$$$34$$$O	such$$$35$$$39$$$O	as$$$40$$$42$$$O	those$$$43$$$48$$$O	containing$$$49$$$59$$$O	brimonidine,$$$60$$$72$$$I	for$$$73$$$76$$$O	the$$$77$$$80$$$O	treatment$$$81$$$90$$$O	of$$$91$$$93$$$O	skin$$$94$$$98$$$O	disorders$$$99$$$108$$$O	are$$$109$$$112$$$O	described.$$$113$$$123$$$O	The$$$124$$$127$$$O	gel$$$128$$$131$$$O	compositions$$$132$$$144$$$O	contain$$$145$$$152$$$O	carbomer$$$153$$$161$$$O	and$$$162$$$165$$$O	paraben,$$$166$$$174$$$O	and$$$175$$$178$$$O	are$$$179$$$182$$$O	substantially$$$183$$$196$$$O	free$$$197$$$201$$$O	of$$$202$$$204$$$O	paraben$$$205$$$212$$$O	crystalline$$$213$$$224$$$O	particles$$$225$$$234$$$O	after$$$235$$$240$$$O	an$$$241$$$243$$$O	extended$$$244$$$252$$$O	period$$$253$$$259$$$O	of$$$260$$$262$$$O	storage.$$$263$$$271$$$O
US20050250716
Immunostimulatory$$$0$$$17$$$O	oligodeoxynucleotides$$$18$$$39$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	inununostimulatory$$$36$$$54$$$O	deoxyinosine/deoxyuridine$$$55$$$80$$$O	containing$$$81$$$91$$$O	oligodeoxynucleotides$$$92$$$113$$$I	for$$$114$$$117$$$O	pharmaceutical$$$118$$$132$$$O	application,$$$133$$$145$$$O	such$$$146$$$150$$$O	as$$$151$$$153$$$O	treating$$$154$$$162$$$O	and$$$163$$$166$$$O	preventing$$$167$$$177$$$O	chronic$$$178$$$185$$$O	infectious$$$186$$$196$$$O	diseases,$$$197$$$206$$$O	acute$$$207$$$212$$$O	decrements$$$213$$$223$$$O	in$$$224$$$226$$$O	air$$$227$$$230$$$O	flow,$$$231$$$236$$$O	parasitic$$$237$$$246$$$O	infections$$$247$$$257$$$O	and$$$258$$$261$$$O	the$$$262$$$265$$$O	like.$$$266$$$271$$$O
CN102872109A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Houttuynoid$$$15$$$26$$$I	A$$$27$$$28$$$I	in$$$29$$$31$$$O	medicament$$$32$$$42$$$O	for$$$43$$$46$$$O	treating$$$47$$$55$$$O	prostate$$$56$$$64$$$O	cancer$$$65$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	Houttuynoid$$$39$$$50$$$I	A$$$51$$$52$$$I	in$$$53$$$55$$$O	preparing$$$56$$$65$$$O	a$$$66$$$67$$$O	medicament$$$68$$$78$$$O	for$$$79$$$82$$$O	treating$$$83$$$91$$$O	prostate$$$92$$$100$$$O	cancer,$$$101$$$108$$$O	and$$$109$$$112$$$O	belongs$$$113$$$120$$$O	to$$$121$$$123$$$O	the$$$124$$$127$$$O	technical$$$128$$$137$$$O	field$$$138$$$143$$$O	of$$$144$$$146$$$O	new$$$147$$$150$$$O	use$$$151$$$154$$$O	of$$$155$$$157$$$O	medicament.$$$158$$$169$$$O	Houttuynoid$$$170$$$181$$$I	A$$$182$$$183$$$I	is$$$184$$$186$$$O	found$$$187$$$192$$$O	to$$$193$$$195$$$O	have$$$196$$$200$$$O	an$$$201$$$203$$$O	obvious$$$204$$$211$$$O	inbibitional$$$212$$$224$$$O	effect$$$225$$$231$$$O	on$$$232$$$234$$$O	the$$$235$$$238$$$O	growth$$$239$$$245$$$O	of$$$246$$$248$$$O	human$$$249$$$254$$$O	prostate$$$255$$$263$$$O	cancer$$$264$$$270$$$O	cell$$$271$$$275$$$O	lines$$$276$$$281$$$O	ALVA,$$$282$$$287$$$O	gpc-1,$$$288$$$294$$$O	9L-B$$$295$$$299$$$O	and$$$300$$$303$$$O	Du145$$$304$$$309$$$O	through$$$310$$$317$$$O	MTT$$$318$$$321$$$I	(Methyl$$$322$$$329$$$I	Thiazolyl$$$330$$$339$$$I	Ternzolinm)$$$340$$$351$$$I	anticancer$$$352$$$362$$$O	activity$$$363$$$371$$$O	evaluation$$$372$$$382$$$O	in$$$383$$$385$$$O	vitro.$$$386$$$392$$$O	Therefore,$$$393$$$403$$$O	Houttuynoid$$$404$$$415$$$I	A$$$416$$$417$$$I	can$$$418$$$421$$$O	be$$$422$$$424$$$O	used$$$425$$$429$$$O	for$$$430$$$433$$$O	preparing$$$434$$$443$$$O	the$$$444$$$447$$$O	anti-prostate$$$448$$$461$$$O	cancer$$$462$$$468$$$O	medicament$$$469$$$479$$$O	and$$$480$$$483$$$O	has$$$484$$$487$$$O	excellent$$$488$$$497$$$O	prospects$$$498$$$507$$$O	in$$$508$$$510$$$O	development$$$511$$$522$$$O	and$$$523$$$526$$$O	application.$$$527$$$539$$$O	The$$$540$$$543$$$O	use$$$544$$$547$$$O	of$$$548$$$550$$$O	Houttuynoid$$$551$$$562$$$I	A$$$563$$$564$$$I	in$$$565$$$567$$$O	preparing$$$568$$$577$$$O	the$$$578$$$581$$$O	medicament$$$582$$$592$$$O	for$$$593$$$596$$$O	treating$$$597$$$605$$$O	the$$$606$$$609$$$O	prostate$$$610$$$618$$$O	cancer$$$619$$$625$$$O	involved$$$626$$$634$$$O	in$$$635$$$637$$$O	the$$$638$$$641$$$O	invention$$$642$$$651$$$O	is$$$652$$$654$$$O	disclosed$$$655$$$664$$$O	for$$$665$$$668$$$O	the$$$669$$$672$$$O	first$$$673$$$678$$$O	time;$$$679$$$684$$$O	the$$$685$$$688$$$O	framework$$$689$$$698$$$O	type$$$699$$$703$$$O	of$$$704$$$706$$$O	Houttuynoid$$$707$$$718$$$I	A$$$719$$$720$$$I	is$$$721$$$723$$$O	a$$$724$$$725$$$O	brand$$$726$$$731$$$O	new$$$732$$$735$$$O	framework$$$736$$$745$$$O	type;$$$746$$$751$$$O	and$$$752$$$755$$$O	Houttuynoid$$$756$$$767$$$I	A$$$768$$$769$$$I	has$$$770$$$773$$$O	an$$$774$$$776$$$O	unexpectedly$$$777$$$789$$$O	high$$$790$$$794$$$O	inhibition$$$795$$$805$$$O	activity$$$806$$$814$$$O	for$$$815$$$818$$$O	the$$$819$$$822$$$O	prostate$$$823$$$831$$$O	cancer$$$832$$$838$$$O	cells.$$$839$$$845$$$O
EP1998768A2
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	crf1$$$7$$$11$$$O	receptor$$$12$$$20$$$O	antagonists$$$21$$$32$$$O	for$$$33$$$36$$$O	preparing$$$37$$$46$$$O	a$$$47$$$48$$$O	drug$$$49$$$53$$$O	for$$$54$$$57$$$O	treating$$$58$$$66$$$O	metabolic$$$67$$$76$$$O	syndrome$$$77$$$85$$$O	and/or$$$86$$$92$$$O	obesity$$$93$$$100$$$O	and/or$$$101$$$107$$$O	dyslipoproteinemia$$$108$$$126$$$O
An$$$0$$$2$$$O	object$$$3$$$9$$$O	of$$$10$$$12$$$O	the$$$13$$$16$$$O	present$$$17$$$24$$$O	invention$$$25$$$34$$$O	is$$$35$$$37$$$O	the$$$38$$$41$$$O	use$$$42$$$45$$$O	of$$$46$$$48$$$O	a$$$49$$$50$$$O	compound$$$51$$$59$$$O	of$$$60$$$62$$$O	formula$$$63$$$70$$$O	(I):$$$71$$$75$$$O	or$$$76$$$78$$$O	one$$$79$$$82$$$O	of$$$83$$$85$$$O	its$$$86$$$89$$$O	pharmaceutically$$$90$$$106$$$O	acceptable$$$107$$$117$$$O	salts,$$$118$$$124$$$O	for$$$125$$$128$$$O	the$$$129$$$132$$$O	manufacture$$$133$$$144$$$O	of$$$145$$$147$$$O	a$$$148$$$149$$$O	medicament$$$150$$$160$$$O	for$$$161$$$164$$$O	the$$$165$$$168$$$O	prevention$$$169$$$179$$$O	and/or$$$180$$$186$$$O	the$$$187$$$190$$$O	treatment$$$191$$$200$$$O	of$$$201$$$203$$$O	metabolic$$$204$$$213$$$O	syndrome$$$214$$$222$$$O	and/or$$$223$$$229$$$O	obesity$$$230$$$237$$$O	and/or$$$238$$$244$$$O	dyslipoproteinemia.$$$245$$$264$$$O
WO2010007318A3
Imidazo$$$0$$$7$$$I	[1,$$$8$$$11$$$I	2-a]$$$12$$$16$$$I	pyrimidine$$$17$$$27$$$I	derivatives$$$28$$$39$$$O	method$$$40$$$46$$$O	for$$$47$$$50$$$O	the$$$51$$$54$$$O	production$$$55$$$65$$$O	thereof$$$66$$$73$$$O	application$$$74$$$85$$$O	thereof$$$86$$$93$$$O	as$$$94$$$96$$$O	medicaments$$$97$$$108$$$O	pharmaceutical$$$109$$$123$$$O	compositions$$$124$$$136$$$O	and$$$137$$$140$$$O	use$$$141$$$144$$$O	thereof$$$145$$$152$$$O	as$$$153$$$155$$$O	met$$$156$$$159$$$O	inhibitors$$$160$$$170$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	novel$$$29$$$34$$$O	products$$$35$$$43$$$O	of$$$44$$$46$$$O	formula$$$47$$$54$$$O	(I):$$$55$$$59$$$O	in$$$60$$$62$$$O	which:$$$63$$$69$$$O	n$$$70$$$71$$$O	=$$$72$$$73$$$O	0,1$$$74$$$77$$$O	or$$$78$$$80$$$O	2;$$$81$$$83$$$O	X$$$84$$$85$$$O	is$$$86$$$88$$$O	H,$$$89$$$91$$$I	Hal$$$92$$$95$$$I	or$$$96$$$98$$$O	alk;$$$99$$$103$$$I	R$$$104$$$105$$$O	is$$$106$$$108$$$O	H,$$$109$$$111$$$I	NH2,$$$112$$$116$$$I	NHalk$$$117$$$122$$$I	or$$$123$$$125$$$O	N(alk)2;$$$126$$$134$$$I	Ra$$$135$$$137$$$O	is$$$138$$$140$$$O	H,$$$141$$$143$$$I	Hal,$$$144$$$148$$$I	-O-cycloalkyl,$$$149$$$163$$$I	-O-alkyl,$$$164$$$173$$$I	-O-aryl,$$$174$$$182$$$I	-O-heteroaryl,$$$183$$$197$$$I	âNRd(cycloalkyl),$$$198$$$217$$$I	âNRd(alkyl),$$$218$$$232$$$I	-NRd(aryl),$$$233$$$244$$$I	-NRd(heteroaryl),$$$245$$$262$$$I	alkyl,$$$263$$$269$$$I	cycloalkyl,$$$270$$$281$$$I	heterocycloalkyl,$$$282$$$299$$$I	aryl$$$300$$$304$$$I	or$$$305$$$307$$$I	heteroaryl,$$$308$$$319$$$I	all$$$320$$$323$$$O	optionally$$$324$$$334$$$O	substituted;$$$335$$$347$$$O	Rb$$$348$$$350$$$I	is$$$351$$$353$$$I	H,$$$354$$$356$$$O	Rc,$$$357$$$360$$$I	-COORc-CO-Rc$$$361$$$373$$$I	or$$$374$$$376$$$I	-CO-NRcRd;$$$377$$$387$$$I	where$$$388$$$393$$$O	Rc$$$394$$$396$$$I	is$$$397$$$399$$$I	alkyl,$$$400$$$406$$$I	cycloalkyl,$$$407$$$418$$$I	heterocycloalkyl,$$$419$$$436$$$I	aryl$$$437$$$441$$$I	and$$$442$$$445$$$I	heteroaryl,$$$446$$$457$$$I	all$$$458$$$461$$$O	optionally$$$462$$$472$$$O	substituted;$$$473$$$485$$$O	Rd$$$486$$$488$$$I	is$$$489$$$491$$$I	H,$$$492$$$494$$$I	alk$$$495$$$498$$$I	or$$$499$$$501$$$I	cycloalkyl;$$$502$$$513$$$I	these$$$514$$$519$$$O	products$$$520$$$528$$$O	being$$$529$$$534$$$O	in$$$535$$$537$$$O	all$$$538$$$541$$$O	the$$$542$$$545$$$O	isomer$$$546$$$552$$$O	forms$$$553$$$558$$$O	and$$$559$$$562$$$O	the$$$563$$$566$$$O	salts,$$$567$$$573$$$O	as$$$574$$$576$$$O	medicaments,$$$577$$$589$$$O	in$$$590$$$592$$$O	particular$$$593$$$603$$$O	as$$$604$$$606$$$O	MET$$$607$$$610$$$O	inhibitors.$$$611$$$622$$$O
WO2011085216A2
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	faah$$$7$$$11$$$O	inhibitors$$$12$$$22$$$O	for$$$23$$$26$$$O	treating$$$27$$$35$$$O	parkinson's$$$36$$$47$$$O	disease$$$48$$$55$$$O	and$$$56$$$59$$$O	restless$$$60$$$68$$$O	legs$$$69$$$73$$$O	syndrome$$$74$$$82$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	relates$$$23$$$30$$$O	to$$$31$$$33$$$O	methods$$$34$$$41$$$O	of$$$42$$$44$$$O	using$$$45$$$50$$$O	fatty$$$51$$$56$$$O	acid$$$57$$$61$$$O	amide$$$62$$$67$$$O	hydrolase$$$68$$$77$$$O	(FAAH)$$$78$$$84$$$O	inhibitors$$$85$$$95$$$O	to$$$96$$$98$$$O	treat$$$99$$$104$$$O	aspects$$$105$$$112$$$O	of$$$113$$$115$$$O	Parkinson's$$$116$$$127$$$O	disease$$$128$$$135$$$O	(PD),$$$136$$$141$$$O	restless$$$142$$$150$$$O	legs$$$151$$$155$$$O	syndrome$$$156$$$164$$$O	(RLS)$$$165$$$170$$$O	and$$$171$$$174$$$O	periodic$$$175$$$183$$$O	limb$$$184$$$188$$$O	movement$$$189$$$197$$$O	disorder$$$198$$$206$$$O	(PLMD),$$$207$$$214$$$O	the$$$215$$$218$$$O	use$$$219$$$222$$$O	of$$$223$$$225$$$O	FAAH$$$226$$$230$$$O	inhibitors$$$231$$$241$$$O	for$$$242$$$245$$$O	the$$$246$$$249$$$O	manufacture$$$250$$$261$$$O	of$$$262$$$264$$$O	medicaments$$$265$$$276$$$O	for$$$277$$$280$$$O	use$$$281$$$284$$$O	in$$$285$$$287$$$O	the$$$288$$$291$$$O	treatment$$$292$$$301$$$O	of$$$302$$$304$$$O	PD,$$$305$$$308$$$O	RLS$$$309$$$312$$$O	and$$$313$$$316$$$O	PLMD,$$$317$$$322$$$O	as$$$323$$$325$$$O	well$$$326$$$330$$$O	as$$$331$$$333$$$O	pharmaceutically$$$334$$$350$$$O	acceptable$$$351$$$361$$$O	compositions$$$362$$$374$$$O	comprising$$$375$$$385$$$O	FAAH$$$386$$$390$$$O	inhibitors$$$391$$$401$$$O	for$$$402$$$405$$$O	use$$$406$$$409$$$O	in$$$410$$$412$$$O	the$$$413$$$416$$$O	treatment$$$417$$$426$$$O	of$$$427$$$429$$$O	PD,$$$430$$$433$$$O	RLS$$$434$$$437$$$O	and$$$438$$$441$$$O	PLMD.$$$442$$$447$$$O
WO2014078581A1
Stable$$$0$$$6$$$O	thermolysin$$$7$$$18$$$O	hydrogel$$$19$$$27$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	hydrogel$$$15$$$23$$$O	comprising$$$24$$$34$$$O	a$$$35$$$36$$$O	hydrophilic$$$37$$$48$$$O	gelling$$$49$$$56$$$O	agent$$$57$$$62$$$O	that$$$63$$$67$$$O	includes$$$68$$$76$$$O	a$$$77$$$78$$$O	nonionic$$$79$$$87$$$O	cellulose$$$88$$$97$$$O	ether,$$$98$$$104$$$O	and$$$105$$$108$$$O	active$$$109$$$115$$$O	thermolysin,$$$116$$$128$$$O	wherein$$$129$$$136$$$O	the$$$137$$$140$$$O	proteolytic$$$141$$$152$$$O	activity$$$153$$$161$$$O	of$$$162$$$164$$$O	the$$$165$$$168$$$O	thermolysin$$$169$$$180$$$O	does$$$181$$$185$$$O	not$$$186$$$189$$$O	decrease$$$190$$$198$$$O	by$$$199$$$201$$$O	more$$$202$$$206$$$O	than$$$207$$$211$$$O	20%$$$212$$$215$$$O	when$$$216$$$220$$$O	stored$$$221$$$227$$$O	at$$$228$$$230$$$O	room$$$231$$$235$$$O	temperature$$$236$$$247$$$O	for$$$248$$$251$$$O	6$$$252$$$253$$$O	months.$$$254$$$261$$$O
WO2012137227A3
Solid$$$0$$$5$$$O	forms$$$6$$$11$$$O	of$$$12$$$14$$$O	antiretroviral$$$15$$$29$$$O	compounds$$$30$$$39$$$O	and$$$40$$$43$$$O	anti-oxidative$$$44$$$58$$$O	acids,$$$59$$$65$$$O	processes$$$66$$$75$$$O	for$$$76$$$79$$$O	preparation$$$80$$$91$$$O	and$$$92$$$95$$$O	pharmaceutical$$$96$$$110$$$O	compositions$$$111$$$123$$$O	thereof$$$124$$$131$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	solid$$$14$$$19$$$O	forms$$$20$$$25$$$O	of$$$26$$$28$$$O	antiretroviral$$$29$$$43$$$O	compounds$$$44$$$53$$$O	and$$$54$$$57$$$O	anti-oxidative$$$58$$$72$$$O	acids,$$$73$$$79$$$O	and$$$80$$$83$$$O	processes$$$84$$$93$$$O	for$$$94$$$97$$$O	their$$$98$$$103$$$O	preparation.$$$104$$$116$$$O	Pharmaceutical$$$117$$$131$$$O	compositions$$$132$$$144$$$O	using$$$145$$$150$$$O	the$$$151$$$154$$$O	solid$$$155$$$160$$$O	forms$$$161$$$166$$$O	are$$$167$$$170$$$O	also$$$171$$$175$$$O	disclosed.$$$176$$$186$$$O
WO2008122100A1
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	supporting$$$16$$$26$$$O	restful$$$27$$$34$$$O	sleep$$$35$$$40$$$O	comprising$$$41$$$51$$$O	valerian$$$52$$$60$$$O	root$$$61$$$65$$$O	extract$$$66$$$73$$$O	and$$$74$$$77$$$O	methylcobalamim$$$78$$$93$$$I
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	promoting$$$13$$$22$$$O	and$$$23$$$26$$$O	supporting$$$27$$$37$$$O	restful,$$$38$$$46$$$O	quality$$$47$$$54$$$O	sleep$$$55$$$60$$$O	in$$$61$$$63$$$O	an$$$64$$$66$$$O	individual$$$67$$$77$$$O	comprising$$$78$$$88$$$O	the$$$89$$$92$$$O	administration$$$93$$$107$$$O	of$$$108$$$110$$$O	a$$$111$$$112$$$O	composition$$$113$$$124$$$O	comprising$$$125$$$135$$$O	Valerian$$$136$$$144$$$O	root$$$145$$$149$$$O	extract$$$150$$$157$$$O	and$$$158$$$161$$$O	Methylcobalamin.$$$162$$$178$$$I
US20120046300
Quinazoline$$$0$$$11$$$I	Derivatives$$$12$$$23$$$O	as$$$24$$$26$$$O	Angiogenesis$$$27$$$39$$$O	Inhibitors$$$40$$$50$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	the$$$46$$$49$$$O	formula$$$50$$$57$$$O	I:$$$58$$$60$$$O	wherein:$$$106$$$114$$$O	ring$$$115$$$119$$$O	C$$$120$$$121$$$O	is$$$122$$$124$$$O	an$$$125$$$127$$$O	8,$$$128$$$130$$$O	9,$$$131$$$133$$$O	10,$$$134$$$137$$$O	12$$$138$$$140$$$O	or$$$141$$$143$$$O	13-membered$$$144$$$155$$$O	bicyclic$$$156$$$164$$$I	or$$$165$$$167$$$O	tricyclic$$$168$$$177$$$I	moiety$$$178$$$184$$$O	which$$$185$$$190$$$O	moiety$$$191$$$197$$$O	may$$$198$$$201$$$O	be$$$202$$$204$$$O	saturated$$$205$$$214$$$O	or$$$215$$$217$$$O	unsaturated,$$$218$$$230$$$O	which$$$231$$$236$$$O	may$$$237$$$240$$$O	be$$$241$$$243$$$O	aromatic$$$244$$$252$$$O	or$$$253$$$255$$$O	non-aromatic,$$$256$$$269$$$O	and$$$270$$$273$$$O	which$$$274$$$279$$$O	optionally$$$280$$$290$$$O	may$$$291$$$294$$$O	contain$$$295$$$302$$$O	1-3$$$303$$$306$$$O	heteroatoms$$$307$$$318$$$O	selected$$$319$$$327$$$O	independently$$$328$$$341$$$O	from$$$342$$$346$$$O	O,$$$347$$$349$$$I	N$$$350$$$351$$$I	and$$$352$$$355$$$O	S;$$$356$$$358$$$I	is$$$359$$$361$$$O	âOâ$$$362$$$369$$$I	âNHâ$$$370$$$378$$$I	or$$$379$$$381$$$O	âSâ;$$$382$$$390$$$O	is$$$391$$$393$$$O	0,$$$394$$$396$$$O	1,$$$397$$$399$$$O	2,$$$400$$$402$$$O	3,$$$403$$$405$$$O	4$$$406$$$407$$$O	or$$$408$$$410$$$O	5;$$$411$$$413$$$O	is$$$414$$$416$$$O	0,$$$417$$$419$$$O	1,$$$420$$$422$$$O	2$$$423$$$424$$$O	or$$$425$$$427$$$O	3;$$$428$$$430$$$O	and$$$431$$$434$$$O	R2$$$435$$$437$$$O	and$$$438$$$441$$$O	R1$$$442$$$444$$$O	are$$$445$$$448$$$O	as$$$449$$$451$$$O	defined$$$452$$$459$$$O	herein;$$$460$$$467$$$O	and$$$468$$$471$$$O	salts$$$472$$$477$$$O	thereof;$$$478$$$486$$$O	their$$$487$$$492$$$O	use$$$493$$$496$$$O	in$$$497$$$499$$$O	the$$$500$$$503$$$O	manufacture$$$504$$$515$$$O	of$$$516$$$518$$$O	a$$$519$$$520$$$O	medicament$$$521$$$531$$$O	for$$$532$$$535$$$O	use$$$536$$$539$$$O	in$$$540$$$542$$$O	the$$$543$$$546$$$O	production$$$547$$$557$$$O	of$$$558$$$560$$$O	an$$$561$$$563$$$O	antiangiogenic$$$564$$$578$$$O	and/or$$$579$$$585$$$O	vascular$$$586$$$594$$$O	permeability$$$595$$$607$$$O	reducing$$$608$$$616$$$O	effect$$$617$$$623$$$O	in$$$624$$$626$$$O	warm-blooded$$$627$$$639$$$O	animals;$$$640$$$648$$$O	processes$$$649$$$658$$$O	for$$$659$$$662$$$O	the$$$663$$$666$$$O	preparation$$$667$$$678$$$O	of$$$679$$$681$$$O	such$$$682$$$686$$$O	compounds;$$$687$$$697$$$O	pharmaceutical$$$698$$$712$$$O	compositions$$$713$$$725$$$O	containing$$$726$$$736$$$O	a$$$737$$$738$$$O	compound$$$739$$$747$$$O	of$$$748$$$750$$$O	formula$$$751$$$758$$$O	I$$$759$$$760$$$O	or$$$761$$$763$$$O	a$$$764$$$765$$$O	pharmaceutically$$$766$$$782$$$O	acceptable$$$783$$$793$$$O	salt$$$794$$$798$$$O	thereof$$$799$$$806$$$O	and$$$807$$$810$$$O	methods$$$811$$$818$$$O	of$$$819$$$821$$$O	treating$$$822$$$830$$$O	disease$$$831$$$838$$$O	states$$$839$$$845$$$O	involving$$$846$$$855$$$O	angiogenesis$$$856$$$868$$$O	by$$$869$$$871$$$O	administering$$$872$$$885$$$O	a$$$886$$$887$$$O	compound$$$888$$$896$$$O	of$$$897$$$899$$$O	formula$$$900$$$907$$$O	I$$$908$$$909$$$O	or$$$910$$$912$$$O	a$$$913$$$914$$$O	pharmaceutically$$$915$$$931$$$O	acceptable$$$932$$$942$$$O	salt$$$943$$$947$$$O	thereof.$$$948$$$956$$$O	The$$$957$$$960$$$O	compounds$$$961$$$970$$$O	of$$$971$$$973$$$O	formula$$$974$$$981$$$O	I$$$982$$$983$$$O	inhibit$$$984$$$991$$$O	the$$$992$$$995$$$O	effects$$$996$$$1003$$$O	of$$$1004$$$1006$$$O	VEGF,$$$1007$$$1012$$$O	a$$$1013$$$1014$$$O	property$$$1015$$$1023$$$O	of$$$1024$$$1026$$$O	value$$$1027$$$1032$$$O	in$$$1033$$$1035$$$O	the$$$1036$$$1039$$$O	treatment$$$1040$$$1049$$$O	of$$$1050$$$1052$$$O	a$$$1053$$$1054$$$O	number$$$1055$$$1061$$$O	of$$$1062$$$1064$$$O	disease$$$1065$$$1072$$$O	states$$$1073$$$1079$$$O	including$$$1080$$$1089$$$O	cancer$$$1090$$$1096$$$O	and$$$1097$$$1100$$$O	rheumatoid$$$1101$$$1111$$$O	arthritis.$$$1112$$$1122$$$O
CN101386617B
Substituted$$$0$$$11$$$O	tetrahydroisoquinoline$$$12$$$34$$$I	derivatives,$$$35$$$47$$$O	preparation$$$48$$$59$$$O	method$$$60$$$66$$$O	thereof$$$67$$$74$$$O	and$$$75$$$78$$$O	pharmaceutical$$$79$$$93$$$O	compositions$$$94$$$106$$$O	containing$$$107$$$117$$$O	same$$$118$$$122$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	pharmacy$$$29$$$37$$$O	field,$$$38$$$44$$$O	and$$$45$$$48$$$O	discloses$$$49$$$58$$$O	a$$$59$$$60$$$O	set$$$61$$$64$$$O	of$$$65$$$67$$$O	novel$$$68$$$73$$$O	tetrahydroisoquinoline$$$74$$$96$$$I	derivatives$$$97$$$108$$$O	substituted$$$109$$$120$$$O	by$$$121$$$123$$$O	sulfonamide$$$124$$$135$$$I	with$$$136$$$140$$$O	the$$$141$$$144$$$O	general$$$145$$$152$$$O	expression$$$153$$$163$$$O	(I),$$$164$$$168$$$O	a$$$169$$$170$$$O	method$$$171$$$177$$$O	for$$$178$$$181$$$O	preparing$$$182$$$191$$$O	the$$$192$$$195$$$O	same$$$196$$$200$$$O	and$$$201$$$204$$$O	a$$$205$$$206$$$O	medicine$$$207$$$215$$$O	composite$$$216$$$225$$$O	containing$$$226$$$236$$$O	the$$$237$$$240$$$O	same.$$$241$$$246$$$O	Pharmacological$$$247$$$262$$$O	experiments$$$263$$$274$$$O	show$$$275$$$279$$$O	that$$$280$$$284$$$O	the$$$285$$$288$$$O	general$$$289$$$296$$$O	formula$$$297$$$304$$$O	(I)$$$305$$$308$$$O	compound$$$309$$$317$$$O	has$$$318$$$321$$$O	excellent$$$322$$$331$$$O	antidiabetic$$$332$$$344$$$O	effect.$$$345$$$352$$$O
US20120308593
Immunological$$$0$$$13$$$O	Compositions$$$14$$$26$$$O	for$$$27$$$30$$$O	HIV$$$31$$$34$$$O
The$$$0$$$3$$$O	disclosure$$$4$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	immunological$$$26$$$39$$$O	compositions$$$40$$$52$$$O	for$$$53$$$56$$$O	vaccinating$$$57$$$68$$$O	human$$$69$$$74$$$O	beings$$$75$$$81$$$O	against$$$82$$$89$$$O	infection$$$90$$$99$$$O	by$$$100$$$102$$$O	the$$$103$$$106$$$O	Human$$$107$$$112$$$O	Immunodeficiency$$$113$$$129$$$O	Virus$$$130$$$135$$$O	(HIV).$$$136$$$142$$$O
WO2011158388A1
Sialic$$$0$$$6$$$I	acid-containing$$$7$$$22$$$I	sugar$$$23$$$28$$$I	chain$$$29$$$34$$$O	complex$$$35$$$42$$$O	and$$$43$$$46$$$O	method$$$47$$$53$$$O	for$$$54$$$57$$$O	producing$$$58$$$67$$$O	same,$$$68$$$73$$$O	anti-influenza$$$74$$$88$$$O	virus$$$89$$$94$$$O	agent$$$95$$$100$$$O	and$$$101$$$104$$$O	filter$$$105$$$111$$$O
A$$$0$$$1$$$O	sialic$$$2$$$8$$$I	acid-containing$$$9$$$24$$$I	sugar$$$25$$$30$$$I	chain$$$31$$$36$$$O	complex$$$37$$$44$$$O	characterized$$$45$$$58$$$O	by$$$59$$$61$$$O	comprising$$$62$$$72$$$O	a$$$73$$$74$$$O	C14-18$$$75$$$81$$$I	fatty$$$82$$$87$$$I	acid,$$$88$$$93$$$I	excluding$$$94$$$103$$$O	a$$$104$$$105$$$O	sphingolipid,$$$106$$$119$$$I	that$$$120$$$124$$$O	is$$$125$$$127$$$O	bonded,$$$128$$$135$$$O	via$$$136$$$139$$$O	an$$$140$$$142$$$O	amide$$$143$$$148$$$I	bond,$$$149$$$154$$$O	to$$$155$$$157$$$O	an$$$158$$$160$$$O	end$$$161$$$164$$$O	other$$$165$$$170$$$O	than$$$171$$$175$$$O	the$$$176$$$179$$$O	sialic$$$180$$$186$$$I	acid$$$187$$$191$$$I	end$$$192$$$195$$$O	of$$$196$$$198$$$O	a$$$199$$$200$$$O	sialic$$$201$$$207$$$I	acid-containing$$$208$$$223$$$I	sugar$$$224$$$229$$$I	chain,$$$230$$$236$$$O	which$$$237$$$242$$$O	contains$$$243$$$251$$$O	sialic$$$252$$$258$$$I	acid$$$259$$$263$$$I	at$$$264$$$266$$$O	one$$$267$$$270$$$O	end,$$$271$$$275$$$O	and$$$276$$$279$$$O	having$$$280$$$286$$$O	a$$$287$$$288$$$O	molecular$$$289$$$298$$$O	weight$$$299$$$305$$$O	of$$$306$$$308$$$O	400-1,400;$$$309$$$319$$$O	an$$$320$$$322$$$O	anti-influenza$$$323$$$337$$$O	virus$$$338$$$343$$$O	agent$$$344$$$349$$$O	which$$$350$$$355$$$O	comprises$$$356$$$365$$$O	said$$$366$$$370$$$O	complex$$$371$$$378$$$O	as$$$379$$$381$$$O	the$$$382$$$385$$$O	active$$$386$$$392$$$O	ingredient;$$$393$$$404$$$O	and$$$405$$$408$$$O	a$$$409$$$410$$$O	filter$$$411$$$417$$$O	which$$$418$$$423$$$O	carries$$$424$$$431$$$O	said$$$432$$$436$$$O	anti-influenza$$$437$$$451$$$O	virus$$$452$$$457$$$O	agent.$$$458$$$464$$$O
US20120178792
Drg11-responsive$$$0$$$16$$$O	(dragon)$$$17$$$25$$$O	gene$$$26$$$30$$$O	family$$$31$$$37$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	features$$$15$$$23$$$O	methods$$$24$$$31$$$O	and$$$32$$$35$$$O	compositions$$$36$$$48$$$O	useful$$$49$$$55$$$O	for$$$56$$$59$$$O	treating$$$60$$$68$$$O	and$$$69$$$72$$$O	diagnosing$$$73$$$83$$$O	diseases$$$84$$$92$$$O	of$$$93$$$95$$$O	the$$$96$$$99$$$O	nervous$$$100$$$107$$$O	system,$$$108$$$115$$$O	retina,$$$116$$$123$$$O	skin,$$$124$$$129$$$O	muscle,$$$130$$$137$$$O	joint,$$$138$$$144$$$O	and$$$145$$$148$$$O	cartilage$$$149$$$158$$$O	using$$$159$$$164$$$O	a$$$165$$$166$$$O	Dragon$$$167$$$173$$$O	family$$$174$$$180$$$O	protein.$$$181$$$189$$$O	Protein$$$190$$$197$$$O	and$$$198$$$201$$$O	nucleic$$$202$$$209$$$O	acid$$$210$$$214$$$O	sequences$$$215$$$224$$$O	of$$$225$$$227$$$O	human,$$$228$$$234$$$O	murine,$$$235$$$242$$$O	zebrafish,$$$243$$$253$$$O	and$$$254$$$257$$$O	C.$$$258$$$260$$$O	elegans$$$261$$$268$$$O	Dragon$$$269$$$275$$$O	family$$$276$$$282$$$O	members$$$283$$$290$$$O	are$$$291$$$294$$$O	also$$$295$$$299$$$O	disclosed.$$$300$$$310$$$O
US7235658
Imidazol$$$0$$$8$$$I	derivatives$$$9$$$20$$$O	as$$$21$$$23$$$O	Raf$$$24$$$27$$$O	kinase$$$28$$$34$$$O	inhibitors$$$35$$$45$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I):$$$21$$$25$$$O	wherein$$$45$$$52$$$O	X$$$56$$$57$$$O	is$$$58$$$60$$$O	O,$$$61$$$63$$$I	CH2,$$$64$$$68$$$I	S$$$69$$$70$$$I	or$$$71$$$73$$$O	NH,$$$74$$$77$$$I	or$$$78$$$80$$$O	the$$$81$$$84$$$O	moiety$$$85$$$91$$$O	XâR1$$$92$$$98$$$O	is$$$99$$$101$$$I	hydrogen;$$$102$$$111$$$I	V$$$112$$$113$$$O	is$$$114$$$116$$$I	CH$$$117$$$119$$$I	or$$$120$$$122$$$I	N;$$$123$$$125$$$O	R1$$$126$$$128$$$O	is$$$129$$$131$$$I	hydrogen,$$$132$$$141$$$I	C1-6alkyl,$$$142$$$152$$$I	C3-7cycloalkyl,$$$153$$$168$$$I	aryl,$$$169$$$174$$$I	arylC1-6alkyl,$$$175$$$189$$$I	heterocyclyl,$$$190$$$203$$$I	heterocyclylC1-6alkyl,$$$204$$$226$$$I	heteroaryl,$$$227$$$238$$$I	or$$$239$$$241$$$I	heteroarylC1-6alkyl$$$242$$$261$$$I	any$$$262$$$265$$$O	of$$$266$$$268$$$O	which$$$269$$$274$$$O	except$$$275$$$281$$$O	for$$$282$$$285$$$I	hydrogen$$$286$$$294$$$I	may$$$295$$$298$$$O	be$$$299$$$301$$$O	optionally$$$302$$$312$$$O	substituted;$$$313$$$325$$$O	R2$$$326$$$328$$$O	and$$$329$$$332$$$O	R3$$$333$$$335$$$O	independently$$$336$$$349$$$O	represent$$$350$$$359$$$O	optionally$$$360$$$370$$$O	substituted$$$371$$$382$$$I	C1-6alkyl,$$$383$$$393$$$I	or$$$394$$$396$$$O	R2$$$397$$$399$$$O	and$$$400$$$403$$$O	R3$$$404$$$406$$$O	together$$$407$$$415$$$O	with$$$416$$$420$$$O	the$$$421$$$424$$$I	carbon$$$425$$$431$$$I	atom$$$432$$$436$$$O	to$$$437$$$439$$$O	which$$$440$$$445$$$O	they$$$446$$$450$$$O	are$$$451$$$454$$$O	attached$$$455$$$463$$$O	form$$$464$$$468$$$O	an$$$469$$$471$$$O	optionally$$$472$$$482$$$O	substituted$$$483$$$494$$$I	C3-7cycloalkyl$$$495$$$509$$$I	or$$$510$$$512$$$I	C3-7cycloalkenyl$$$513$$$529$$$I	ring;$$$530$$$535$$$O	or$$$536$$$538$$$O	R2$$$539$$$541$$$O	and$$$542$$$545$$$O	R3$$$546$$$548$$$O	together$$$549$$$557$$$O	with$$$558$$$562$$$O	the$$$563$$$566$$$I	carbon$$$567$$$573$$$I	atom$$$574$$$578$$$O	to$$$579$$$581$$$O	which$$$582$$$587$$$O	they$$$588$$$592$$$O	are$$$593$$$596$$$O	attached$$$597$$$605$$$O	form$$$606$$$610$$$O	an$$$611$$$613$$$O	optionally$$$614$$$624$$$O	substituted$$$625$$$636$$$I	5$$$637$$$638$$$I	to$$$639$$$641$$$I	7-membered$$$642$$$652$$$I	heterocyclyl$$$653$$$665$$$I	ring$$$666$$$670$$$O	containing$$$671$$$681$$$O	up$$$682$$$684$$$O	to$$$685$$$687$$$O	3$$$688$$$689$$$I	heteroatoms$$$690$$$701$$$I	selected$$$702$$$710$$$O	from$$$711$$$715$$$I	N,$$$716$$$718$$$I	O,$$$719$$$721$$$I	S.R4$$$722$$$726$$$I	and$$$727$$$730$$$O	R5$$$731$$$733$$$O	independently$$$734$$$747$$$O	represent$$$748$$$757$$$I	hydrogen,$$$758$$$767$$$I	C1-6alkyl,$$$768$$$778$$$I	C3-7cycloalkyl,$$$779$$$794$$$I	aryl,$$$795$$$800$$$I	arylC1-6alkyl,$$$801$$$815$$$I	heteroaryl,$$$816$$$827$$$I	heteroarylC1-6alkyl,$$$828$$$848$$$I	heterocyclyl,$$$849$$$862$$$I	or$$$863$$$865$$$I	heterocyclylC1-6alkyl,$$$866$$$888$$$I	any$$$889$$$892$$$O	of$$$893$$$895$$$O	which$$$896$$$901$$$O	except$$$902$$$908$$$O	for$$$909$$$912$$$I	hydrogen$$$913$$$921$$$I	may$$$922$$$925$$$O	be$$$926$$$928$$$O	optionally$$$929$$$939$$$O	substituted$$$940$$$951$$$O	or$$$952$$$954$$$O	R4$$$955$$$957$$$O	and$$$958$$$961$$$O	R5$$$962$$$964$$$O	together$$$965$$$973$$$O	with$$$974$$$978$$$O	the$$$979$$$982$$$I	nitrogen$$$983$$$991$$$I	atom$$$992$$$996$$$O	to$$$997$$$999$$$O	which$$$1000$$$1005$$$O	they$$$1006$$$1010$$$O	are$$$1011$$$1014$$$O	attached$$$1015$$$1023$$$O	form$$$1024$$$1028$$$O	4-$$$1029$$$1031$$$O	to$$$1032$$$1034$$$O	8-membered$$$1035$$$1045$$$O	ring;$$$1046$$$1051$$$I	Ar$$$1052$$$1054$$$I	is$$$1055$$$1057$$$O	an$$$1058$$$1060$$$I	aryl$$$1061$$$1065$$$I	or$$$1066$$$1068$$$I	heteroaryl$$$1069$$$1079$$$I	ring$$$1080$$$1084$$$O	either$$$1085$$$1091$$$O	of$$$1092$$$1094$$$O	which$$$1095$$$1100$$$O	may$$$1101$$$1104$$$O	be$$$1105$$$1107$$$O	optionally$$$1108$$$1118$$$O	substituted;$$$1119$$$1131$$$O	one$$$1132$$$1135$$$O	of$$$1136$$$1138$$$O	X1$$$1139$$$1141$$$O	and$$$1142$$$1145$$$O	X2$$$1146$$$1148$$$O	is$$$1149$$$1151$$$I	N$$$1152$$$1153$$$O	and$$$1154$$$1157$$$O	the$$$1158$$$1161$$$O	other$$$1162$$$1167$$$O	is$$$1168$$$1170$$$I	NR6,$$$1171$$$1175$$$I	wherein$$$1176$$$1183$$$O	R6$$$1184$$$1186$$$O	is$$$1187$$$1189$$$I	hydrogen,$$$1190$$$1199$$$I	C1-6alkyl,$$$1200$$$1210$$$I	or$$$1211$$$1213$$$I	arylC1-6alkyl$$$1214$$$1227$$$I	or$$$1228$$$1230$$$O	pharmaceutically$$$1231$$$1247$$$O	acceptable$$$1248$$$1258$$$O	salts$$$1259$$$1264$$$O	thereof,$$$1265$$$1273$$$O	their$$$1274$$$1279$$$O	use$$$1280$$$1283$$$O	as$$$1284$$$1286$$$O	inhibitors$$$1287$$$1297$$$O	of$$$1298$$$1300$$$O	Raf$$$1301$$$1304$$$O	kinases,$$$1305$$$1313$$$O	and$$$1314$$$1317$$$O	pharmaceutical$$$1318$$$1332$$$O	compositions$$$1333$$$1345$$$O	containing$$$1346$$$1356$$$O	them.$$$1357$$$1362$$$O
WO2010074647A1
Ethanamine$$$0$$$10$$$I	compounds$$$11$$$20$$$O	and$$$21$$$24$$$O	their$$$25$$$30$$$O	use$$$31$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	depression$$$48$$$58$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	ethanamine$$$33$$$43$$$I	compounds,$$$44$$$54$$$O	namely$$$55$$$61$$$O	1-$$$62$$$64$$$I	(3-f$$$65$$$69$$$I	luorophenyl)$$$70$$$82$$$I	-2-methyl-2-$$$83$$$95$$$I	(pyridine-2-yl)$$$96$$$111$$$I	propan-1-amine$$$112$$$126$$$I	and$$$127$$$130$$$O	2-methyl-l-phenyl-2-$$$131$$$151$$$I	(pyridine-2yl)$$$152$$$166$$$I	propan-1-amine,$$$167$$$182$$$I	the$$$183$$$186$$$O	enantiomers$$$187$$$198$$$O	and$$$199$$$202$$$O	salts$$$203$$$208$$$O	thereof$$$209$$$216$$$O	and$$$217$$$220$$$O	their$$$221$$$226$$$O	use$$$227$$$230$$$O	for$$$231$$$234$$$O	the$$$235$$$238$$$O	treatment$$$239$$$248$$$O	of$$$249$$$251$$$O	depression.$$$252$$$263$$$O
WO2007056593A3
Î±-HELIX$$$0$$$8$$$O	MIMETICS$$$9$$$17$$$O	AND$$$18$$$21$$$O	METHOD$$$22$$$28$$$O	RELATING$$$29$$$37$$$O	TO$$$38$$$40$$$O	THE$$$41$$$44$$$O	TREATMENT$$$45$$$54$$$O	OF$$$55$$$57$$$O	CANCER$$$58$$$64$$$O	STEM$$$65$$$69$$$O	CELLS$$$70$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	alpha$$$23$$$28$$$O	-mimetic$$$29$$$37$$$O	structure$$$38$$$47$$$O	of$$$48$$$50$$$O	formula$$$51$$$58$$$O	(I)$$$59$$$62$$$O	wherein$$$63$$$70$$$O	A$$$71$$$72$$$O	is$$$73$$$75$$$O	-(C=O)-CHR3-,$$$76$$$89$$$I	or$$$90$$$92$$$O	-(C=O),$$$93$$$100$$$I	B$$$101$$$102$$$O	is$$$103$$$105$$$O	N-R3-$$$106$$$111$$$I	or$$$112$$$114$$$O	-CHR6-,$$$115$$$122$$$I	D$$$123$$$124$$$O	is$$$125$$$127$$$O	-(C=O)-(CHR7)-$$$128$$$142$$$I	or$$$143$$$145$$$O	-$$$146$$$147$$$I	(C=O)$$$148$$$153$$$I	E$$$154$$$155$$$O	is$$$156$$$158$$$O	-(ZR8)-$$$159$$$166$$$O	or$$$167$$$169$$$O	(C=O),$$$170$$$176$$$I	G$$$177$$$178$$$O	is$$$179$$$181$$$O	-(XR9)n-,$$$182$$$191$$$O	-(CHR10)-(NR6)-,$$$192$$$208$$$I	-(C=O)-(XR12)-,$$$209$$$224$$$I	-(C=N-W-R1)-,$$$225$$$238$$$I	-(C=O)-,$$$239$$$247$$$I	X-(C=O)-R13,$$$248$$$260$$$I	X-(C=O)-NR13R14,$$$261$$$277$$$I	X-(SO2)-R13,$$$278$$$290$$$I	or$$$291$$$293$$$O	X-(C=O)-OR13,$$$294$$$307$$$I	W$$$308$$$309$$$O	is$$$310$$$312$$$O	-Y(C=O)-,$$$313$$$322$$$I	-(C=O)NH-,$$$323$$$333$$$I	-(SO2)-,$$$334$$$342$$$I	-CHR14,$$$343$$$350$$$I	(C=O)-(NR15)-,$$$351$$$365$$$I	substituted$$$366$$$377$$$O	or$$$378$$$380$$$O	unsubstituted$$$381$$$394$$$O	oxadiazole,$$$395$$$406$$$I	substituted$$$407$$$418$$$O	or$$$419$$$421$$$O	unsubstituted$$$422$$$435$$$O	triazole,$$$436$$$445$$$I	substituted$$$446$$$457$$$O	or$$$458$$$460$$$O	unsubstituted$$$461$$$474$$$O	thiadiazole,$$$475$$$487$$$I	substituted$$$488$$$499$$$O	or$$$500$$$502$$$O	unsubstituted$$$503$$$516$$$O	4,5$$$517$$$520$$$I	dihydrooxazole,$$$521$$$536$$$I	substituted$$$537$$$548$$$O	or$$$549$$$551$$$O	unsubstituted$$$552$$$565$$$O	4,5$$$566$$$569$$$I	dihydrothiazole,$$$570$$$586$$$I	substituted$$$587$$$598$$$O	or$$$599$$$601$$$O	unsubstituted$$$602$$$615$$$O	4,5$$$616$$$619$$$I	dihydroimidazole,$$$620$$$637$$$I	or$$$638$$$640$$$O	nothing,$$$641$$$649$$$O	Y$$$650$$$651$$$O	is$$$652$$$654$$$O	oxygen$$$655$$$661$$$I	or$$$662$$$664$$$O	sulfur,$$$665$$$672$$$I	X$$$673$$$674$$$O	and$$$675$$$678$$$O	Z$$$679$$$680$$$O	is$$$681$$$683$$$O	independently$$$684$$$697$$$O	nitrogen$$$698$$$706$$$I	or$$$707$$$709$$$O	CH,$$$710$$$713$$$I	n=0$$$714$$$717$$$O	or$$$718$$$720$$$O	1;$$$721$$$723$$$O	and$$$724$$$727$$$O	R1$$$728$$$730$$$O	R2,$$$731$$$734$$$O	R3,$$$735$$$738$$$O	R4,$$$739$$$742$$$O	R5,$$$743$$$746$$$O	R6,$$$747$$$750$$$O	R7,$$$751$$$754$$$O	R8,$$$755$$$758$$$O	R9$$$759$$$761$$$O	R10,$$$762$$$766$$$O	R11,$$$767$$$771$$$O	R12,$$$772$$$776$$$O	R13,$$$777$$$781$$$O	R14,$$$782$$$786$$$O	and$$$787$$$790$$$O	R15$$$791$$$794$$$O	are$$$795$$$798$$$O	the$$$799$$$802$$$O	same$$$803$$$807$$$O	or$$$808$$$810$$$O	different$$$811$$$820$$$O	and$$$821$$$824$$$O	independently$$$825$$$838$$$O	selected$$$839$$$847$$$O	from$$$848$$$852$$$O	an$$$853$$$855$$$O	amino$$$856$$$861$$$I	acid$$$862$$$866$$$I	side$$$867$$$871$$$O	chain$$$872$$$877$$$O	moiety$$$878$$$884$$$O	or$$$885$$$887$$$O	derivative$$$888$$$898$$$O	thereof,$$$899$$$907$$$O	the$$$908$$$911$$$O	remainder$$$912$$$921$$$O	of$$$922$$$924$$$O	the$$$925$$$928$$$O	molecule,$$$929$$$938$$$O	a$$$939$$$940$$$O	linker$$$941$$$947$$$O	and$$$948$$$951$$$O	a$$$952$$$953$$$O	solid$$$954$$$959$$$O	support,$$$960$$$968$$$O	and$$$969$$$972$$$O	stereoisomers,$$$973$$$987$$$O	salts,$$$988$$$994$$$O	and$$$995$$$998$$$O	prodrugs$$$999$$$1007$$$O	thereof,$$$1008$$$1016$$$O	provided$$$1017$$$1025$$$O	that$$$1026$$$1030$$$O	where$$$1031$$$1036$$$O	B$$$1037$$$1038$$$O	is$$$1039$$$1041$$$O	CHR6$$$1042$$$1046$$$I	and$$$1047$$$1050$$$O	W$$$1051$$$1052$$$O	is$$$1053$$$1055$$$O	-Y(C=O)-,$$$1056$$$1065$$$I	-(C=O)NH-,$$$1066$$$1076$$$I	-(SO2),$$$1077$$$1084$$$I	-CHR14,$$$1085$$$1092$$$I	or$$$1093$$$1095$$$O	(C=O)-(NR15)-,$$$1096$$$1110$$$I	G$$$1111$$$1112$$$O	cannot$$$1113$$$1119$$$O	be$$$1120$$$1122$$$O	CHR9,$$$1123$$$1128$$$I	NR9,$$$1129$$$1133$$$I	(C=O)-CHR12,$$$1134$$$1146$$$I	(C=O)-NR12,$$$1147$$$1158$$$I	or$$$1159$$$1161$$$O	no$$$1162$$$1164$$$O	atom$$$1165$$$1169$$$O	at$$$1170$$$1172$$$O	all.$$$1173$$$1177$$$O	Additionally,$$$1178$$$1191$$$O	the$$$1192$$$1195$$$O	invention$$$1196$$$1205$$$O	provides$$$1206$$$1214$$$O	methods$$$1215$$$1222$$$O	wherein$$$1223$$$1230$$$O	Î±-mimetic$$$1231$$$1241$$$O	compounds$$$1242$$$1251$$$O	are$$$1252$$$1255$$$O	used$$$1256$$$1260$$$O	to$$$1261$$$1263$$$O	treat$$$1264$$$1269$$$O	cancer$$$1270$$$1276$$$O	stem$$$1277$$$1281$$$O	cells$$$1282$$$1287$$$O	.$$$1288$$$1289$$$O
CN101347454A
Medicament$$$0$$$10$$$O	for$$$11$$$14$$$O	treating$$$15$$$23$$$O	chronic$$$24$$$31$$$O	renal$$$32$$$37$$$O	failure$$$38$$$45$$$O	and$$$46$$$49$$$O	production$$$50$$$60$$$O	method$$$61$$$67$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medicine$$$27$$$35$$$O	for$$$36$$$39$$$O	curing$$$40$$$46$$$O	chronic$$$47$$$54$$$O	renal$$$55$$$60$$$O	failure$$$61$$$68$$$O	and$$$69$$$72$$$O	a$$$73$$$74$$$O	production$$$75$$$85$$$O	method$$$86$$$92$$$O	thereof,$$$93$$$101$$$O	which$$$102$$$107$$$O	is$$$108$$$110$$$O	characterized$$$111$$$124$$$O	in$$$125$$$127$$$O	that$$$128$$$132$$$O	the$$$133$$$136$$$O	medicine$$$137$$$145$$$O	is$$$146$$$148$$$O	calcium-base$$$149$$$161$$$I	samoite$$$162$$$169$$$O	excluding$$$170$$$179$$$O	K+,$$$180$$$183$$$I	Na+,$$$184$$$188$$$I	Mg2+$$$189$$$193$$$I	and$$$194$$$197$$$O	other$$$198$$$203$$$O	exchangeable$$$204$$$216$$$O	cations.$$$217$$$225$$$O	The$$$226$$$229$$$O	preparation$$$230$$$241$$$O	method$$$242$$$248$$$O	includes$$$249$$$257$$$O	immersing$$$258$$$267$$$O	the$$$268$$$271$$$O	samoite$$$272$$$279$$$O	in$$$280$$$282$$$O	calcium$$$283$$$290$$$I	chloride$$$291$$$299$$$I	solution$$$300$$$308$$$O	and$$$309$$$312$$$O	then$$$313$$$317$$$O	exchanging$$$318$$$328$$$O	ions.$$$329$$$334$$$O	After$$$335$$$340$$$O	oral$$$341$$$345$$$O	administration,$$$346$$$361$$$O	toxins$$$362$$$368$$$O	in$$$369$$$371$$$O	the$$$372$$$375$$$O	alimentary$$$376$$$386$$$O	tract$$$387$$$392$$$O	of$$$393$$$395$$$O	patients$$$396$$$404$$$O	with$$$405$$$409$$$O	chronic$$$410$$$417$$$O	renal$$$418$$$423$$$O	failure$$$424$$$431$$$O	is$$$432$$$434$$$O	absorbed$$$435$$$443$$$O	by$$$444$$$446$$$O	samoite$$$447$$$454$$$O	of$$$455$$$457$$$O	the$$$458$$$461$$$O	medicine$$$462$$$470$$$O	and$$$471$$$474$$$O	then$$$475$$$479$$$O	discharged$$$480$$$490$$$O	out$$$491$$$494$$$O	of$$$495$$$497$$$O	the$$$498$$$501$$$O	body$$$502$$$506$$$O	along$$$507$$$512$$$O	with$$$513$$$517$$$O	intestinal$$$518$$$528$$$O	peristalsis,$$$529$$$541$$$O	thus$$$542$$$546$$$O	achieving$$$547$$$556$$$O	intestinal$$$557$$$567$$$O	hemodialysis.$$$568$$$581$$$O	While$$$582$$$587$$$O	absorbing$$$588$$$597$$$O	and$$$598$$$601$$$O	fixing$$$602$$$608$$$O	the$$$609$$$612$$$O	toxins$$$613$$$619$$$O	in$$$620$$$622$$$O	the$$$623$$$626$$$O	alimentary$$$627$$$637$$$O	tract,$$$638$$$644$$$O	the$$$645$$$648$$$O	calcium-base$$$649$$$661$$$I	samoite$$$662$$$669$$$O	has$$$670$$$673$$$O	no$$$674$$$676$$$O	side$$$677$$$681$$$O	effect$$$682$$$688$$$O	on$$$689$$$691$$$O	patients$$$692$$$700$$$O	of$$$701$$$703$$$O	Na$$$704$$$706$$$I	and$$$707$$$710$$$O	K$$$711$$$712$$$I	restriction$$$713$$$724$$$O	without$$$725$$$732$$$O	releasing$$$733$$$742$$$O	K+,$$$743$$$746$$$I	Na+,$$$747$$$751$$$I	Mg2+$$$752$$$756$$$I	and$$$757$$$760$$$O	other$$$761$$$766$$$O	exchangeable$$$767$$$779$$$O	cations.$$$780$$$788$$$O
US20110142880
Lentivirus-based$$$0$$$16$$$O	immunogenic$$$17$$$28$$$O	vectors$$$29$$$36$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	for$$$31$$$34$$$O	lentiviral$$$35$$$45$$$O	vectors$$$46$$$53$$$O	for$$$54$$$57$$$O	vaccine$$$58$$$65$$$O	delivery$$$66$$$74$$$O	comprising$$$75$$$85$$$O	a$$$86$$$87$$$O	5â²$$$88$$$92$$$O	long$$$93$$$97$$$O	terminal$$$98$$$106$$$O	repeat$$$107$$$113$$$O	(LTR)$$$114$$$119$$$O	and$$$120$$$123$$$O	a$$$124$$$125$$$O	3â²$$$126$$$130$$$O	LTR,$$$131$$$135$$$O	an$$$136$$$138$$$O	integrated$$$139$$$149$$$O	nucleic$$$150$$$157$$$O	acid$$$158$$$162$$$O	sequence,$$$163$$$172$$$O	wherein$$$173$$$180$$$O	the$$$181$$$184$$$O	integrated$$$185$$$195$$$O	nucleic$$$196$$$203$$$O	acid$$$204$$$208$$$O	sequence$$$209$$$217$$$O	is$$$218$$$220$$$O	expressed$$$221$$$230$$$O	by$$$231$$$233$$$O	the$$$234$$$237$$$O	5â²$$$238$$$242$$$O	LTR;$$$243$$$247$$$O	and$$$248$$$251$$$O	a$$$252$$$253$$$O	nucleic$$$254$$$261$$$O	acid$$$262$$$266$$$O	sequence$$$267$$$275$$$O	encoding$$$276$$$284$$$O	functional$$$285$$$295$$$O	REV$$$296$$$299$$$O	coding$$$300$$$306$$$O	sequence$$$307$$$315$$$O	and$$$316$$$319$$$O	a$$$320$$$321$$$O	rev$$$322$$$325$$$O	response$$$326$$$334$$$O	element$$$335$$$342$$$O	(RRE)-containing$$$343$$$359$$$O	sequence,$$$360$$$369$$$O	wherein$$$370$$$377$$$O	the$$$378$$$381$$$O	RRE-containing$$$382$$$396$$$O	sequence$$$397$$$405$$$O	is$$$406$$$408$$$O	located$$$409$$$416$$$O	upstream$$$417$$$425$$$O	of$$$426$$$428$$$O	the$$$429$$$432$$$O	REV$$$433$$$436$$$O	coding$$$437$$$443$$$O	sequence,$$$444$$$453$$$O	and$$$454$$$457$$$O	wherein$$$458$$$465$$$O	transcription$$$466$$$479$$$O	of$$$480$$$482$$$O	said$$$483$$$487$$$O	first$$$488$$$493$$$O	nucleic$$$494$$$501$$$O	acid$$$502$$$506$$$O	sequence$$$507$$$515$$$O	and$$$516$$$519$$$O	said$$$520$$$524$$$O	second$$$525$$$531$$$O	nucleic$$$532$$$539$$$O	acid$$$540$$$544$$$O	sequence$$$545$$$553$$$O	is$$$554$$$556$$$O	driven$$$557$$$563$$$O	by$$$564$$$566$$$O	said$$$567$$$571$$$O	5â²$$$572$$$576$$$O	LTR.$$$577$$$581$$$O	Also$$$582$$$586$$$O	provided$$$587$$$595$$$O	for$$$596$$$599$$$O	are$$$600$$$603$$$O	pharmaceutical$$$604$$$618$$$O	compositions,$$$619$$$632$$$O	methods$$$633$$$640$$$O	of$$$641$$$643$$$O	making$$$644$$$650$$$O	and$$$651$$$654$$$O	using$$$655$$$660$$$O	the$$$661$$$664$$$O	lentiviral$$$665$$$675$$$O	vectors$$$676$$$683$$$O	of$$$684$$$686$$$O	the$$$687$$$690$$$O	present$$$691$$$698$$$O	invention.$$$699$$$709$$$O
CN101244278A
Preparation$$$0$$$11$$$O	for$$$12$$$15$$$O	injection$$$16$$$25$$$O	of$$$26$$$28$$$O	diclofenac$$$29$$$39$$$I	sodium$$$40$$$46$$$I	capable$$$47$$$54$$$O	of$$$55$$$57$$$O	being$$$58$$$63$$$O	used$$$64$$$68$$$O	for$$$69$$$72$$$O	intravenous$$$73$$$84$$$O	injection$$$85$$$94$$$O	and$$$95$$$98$$$O	preparation$$$99$$$110$$$O	thereof$$$111$$$118$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	injection$$$26$$$35$$$O	formulation$$$36$$$47$$$O	of$$$48$$$50$$$O	diclofenac$$$51$$$61$$$I	sodium$$$62$$$68$$$I	for$$$69$$$72$$$O	intravenous$$$73$$$84$$$O	injection$$$85$$$94$$$O	and$$$95$$$98$$$O	the$$$99$$$102$$$O	preparation$$$103$$$114$$$O	method,$$$115$$$122$$$O	which$$$123$$$128$$$O	is$$$129$$$131$$$O	characterized$$$132$$$145$$$O	in$$$146$$$148$$$O	that$$$149$$$153$$$O	the$$$154$$$157$$$O	diclofenac$$$158$$$168$$$I	sodium$$$169$$$175$$$I	is$$$176$$$178$$$O	included$$$179$$$187$$$O	successfully$$$188$$$200$$$O	with$$$201$$$205$$$O	the$$$206$$$209$$$O	inclusion$$$210$$$219$$$O	material$$$220$$$228$$$O	of$$$229$$$231$$$O	propyl-Beta-cyclodextrin.$$$232$$$257$$$O	The$$$258$$$261$$$O	injection$$$262$$$271$$$O	formulation$$$272$$$283$$$O	has$$$284$$$287$$$O	the$$$288$$$291$$$O	advantages$$$292$$$302$$$O	of$$$303$$$305$$$O	improving$$$306$$$315$$$O	the$$$316$$$319$$$O	solubility$$$320$$$330$$$O	of$$$331$$$333$$$O	diclofenac$$$334$$$344$$$I	sodium$$$345$$$351$$$I	in$$$352$$$354$$$O	the$$$355$$$358$$$O	solution$$$359$$$367$$$O	and$$$368$$$371$$$O	reducing$$$372$$$380$$$O	the$$$381$$$384$$$O	adverse$$$385$$$392$$$O	reaction$$$393$$$401$$$O	in$$$402$$$404$$$O	intravenous$$$405$$$416$$$O	injection.$$$417$$$427$$$O	The$$$428$$$431$$$O	injection$$$432$$$441$$$O	formulation$$$442$$$453$$$O	exists$$$454$$$460$$$O	in$$$461$$$463$$$O	the$$$464$$$467$$$O	form$$$468$$$472$$$O	of$$$473$$$475$$$O	injection,$$$476$$$486$$$O	frozen$$$487$$$493$$$O	powder,$$$494$$$501$$$O	sterile$$$502$$$509$$$O	powder$$$510$$$516$$$O	and$$$517$$$520$$$O	large-capacity$$$521$$$535$$$O	infusion.$$$536$$$545$$$O	The$$$546$$$549$$$O	invention$$$550$$$559$$$O	also$$$560$$$564$$$O	describes$$$565$$$574$$$O	the$$$575$$$578$$$O	main$$$579$$$583$$$O	technical$$$584$$$593$$$O	parameters$$$594$$$604$$$O	of$$$605$$$607$$$O	adopting$$$608$$$616$$$O	propyl-$$$617$$$624$$$O	Beta$$$625$$$629$$$O	-cyclodextrin$$$630$$$643$$$O	to$$$644$$$646$$$O	include$$$647$$$654$$$O	the$$$655$$$658$$$O	diclofenac$$$659$$$669$$$I	sodium,$$$670$$$677$$$I	such$$$678$$$682$$$O	as$$$683$$$685$$$O	inclusion$$$686$$$695$$$O	method,$$$696$$$703$$$O	the$$$704$$$707$$$O	concentration$$$708$$$721$$$O	of$$$722$$$724$$$O	propyl-Beta-cyclodextrin,$$$725$$$750$$$O	solution$$$751$$$759$$$O	temperature$$$760$$$771$$$O	in$$$772$$$774$$$O	inclusion$$$775$$$784$$$O	and$$$785$$$788$$$O	inclusion$$$789$$$798$$$O	time.$$$799$$$804$$$O
US20080160083
Composition$$$0$$$11$$$O	and$$$12$$$15$$$O	method$$$16$$$22$$$O	for$$$23$$$26$$$O	treatment$$$27$$$36$$$O	of$$$37$$$39$$$O	premenstrual$$$40$$$52$$$O	symptoms$$$53$$$61$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	a$$$25$$$26$$$O	composition$$$27$$$38$$$O	delivering$$$39$$$49$$$O	effective$$$50$$$59$$$O	amounts$$$60$$$67$$$O	of$$$68$$$70$$$O	Chasteberry$$$71$$$82$$$O	Extract,$$$83$$$91$$$O	Pyridoxine,$$$92$$$103$$$I	and$$$104$$$107$$$O	Magnesium$$$108$$$117$$$I	in$$$118$$$120$$$O	a$$$121$$$122$$$O	single$$$123$$$129$$$O	dosage$$$130$$$136$$$O	unit$$$137$$$141$$$O	and$$$142$$$145$$$O	a$$$146$$$147$$$O	method$$$148$$$154$$$O	of$$$155$$$157$$$O	treating$$$158$$$166$$$O	PMS$$$167$$$170$$$O	and$$$171$$$174$$$O	related$$$175$$$182$$$O	disorders$$$183$$$192$$$O	with$$$193$$$197$$$O	the$$$198$$$201$$$O	composition.$$$202$$$214$$$O
US7132425
5-substituted-six-membered$$$0$$$26$$$I	heteroaromatic$$$27$$$41$$$I	glucokinase$$$42$$$53$$$O	activators$$$54$$$64$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	compound$$$33$$$41$$$O	according$$$42$$$51$$$O	to$$$52$$$54$$$O	formula$$$55$$$62$$$O	I$$$63$$$64$$$O	where$$$84$$$89$$$O	the$$$90$$$93$$$O	substituent$$$94$$$105$$$O	designations$$$106$$$118$$$O	are$$$119$$$122$$$O	provided$$$123$$$131$$$O	in$$$132$$$134$$$O	the$$$135$$$138$$$O	specification.$$$139$$$153$$$O	Pharmaceutical$$$154$$$168$$$O	compositions$$$169$$$181$$$O	comprising$$$182$$$192$$$O	a$$$193$$$194$$$O	compound$$$195$$$203$$$O	according$$$204$$$213$$$O	to$$$214$$$216$$$O	formula$$$217$$$224$$$O	I$$$225$$$226$$$O	are$$$227$$$230$$$O	also$$$231$$$235$$$O	provided.$$$236$$$245$$$O
US20100048529
New$$$0$$$3$$$O	2-Azetidinone$$$4$$$17$$$I	Derivatives$$$18$$$29$$$O	Useful$$$30$$$36$$$O	In$$$37$$$39$$$O	The$$$40$$$43$$$O	Treatment$$$44$$$53$$$O	Of$$$54$$$56$$$O	Hyperlipidaemic$$$57$$$72$$$O	Conditions$$$73$$$83$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	formula$$$38$$$45$$$O	(I)$$$46$$$49$$$O	and$$$50$$$53$$$O	pharmaceutically$$$54$$$70$$$O	acceptable$$$71$$$81$$$O	salts,$$$82$$$88$$$O	solvates,$$$89$$$98$$$O	and$$$99$$$102$$$O	prodrugs$$$103$$$111$$$O	thereof,$$$112$$$120$$$O	and$$$121$$$124$$$O	to$$$125$$$127$$$O	their$$$128$$$133$$$O	use$$$134$$$137$$$O	as$$$138$$$140$$$O	cholesterol$$$141$$$152$$$I	absorption$$$153$$$163$$$O	inhibitors$$$164$$$174$$$O	for$$$175$$$178$$$O	the$$$179$$$182$$$O	treatment$$$183$$$192$$$O	of$$$193$$$195$$$O	hyperlipidaemia.$$$196$$$212$$$O	The$$$213$$$216$$$O	invention$$$217$$$226$$$O	also$$$227$$$231$$$O	relates$$$232$$$239$$$O	to$$$240$$$242$$$O	processes$$$243$$$252$$$O	for$$$253$$$256$$$O	their$$$257$$$262$$$O	manufacture$$$263$$$274$$$O	and$$$275$$$278$$$O	pharmaceutical$$$279$$$293$$$O	compositions$$$294$$$306$$$O	containing$$$307$$$317$$$O	them.$$$318$$$323$$$O
CN103360423A
Benzyltin$$$0$$$9$$$I	aromatic$$$10$$$18$$$I	aldehyde$$$19$$$27$$$I	condensed$$$28$$$37$$$I	arylamine$$$38$$$47$$$I	Schiff$$$48$$$54$$$I	base$$$55$$$59$$$I	complex$$$60$$$67$$$O	and$$$68$$$71$$$O	its$$$72$$$75$$$O	preparation$$$76$$$87$$$O	method$$$88$$$94$$$O	and$$$95$$$98$$$O	application$$$99$$$110$$$O	thereof$$$111$$$118$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	benzyltin$$$26$$$35$$$I	aromatic$$$36$$$44$$$I	aldehyde$$$45$$$53$$$I	condensed$$$54$$$63$$$I	arylamine$$$64$$$73$$$I	Schiff$$$74$$$80$$$I	base$$$81$$$85$$$I	complex$$$86$$$93$$$O	which$$$94$$$99$$$O	is$$$100$$$102$$$O	as$$$103$$$105$$$O	shown$$$106$$$111$$$O	in$$$112$$$114$$$O	the$$$115$$$118$$$O	structural$$$119$$$129$$$O	formula$$$130$$$137$$$O	in$$$138$$$140$$$O	the$$$141$$$144$$$O	specification,$$$145$$$159$$$O	wherein$$$160$$$167$$$O	R1$$$168$$$170$$$O	is$$$171$$$173$$$O	-OCH3$$$174$$$179$$$I	or$$$180$$$182$$$O	Cl,$$$183$$$186$$$I	R2$$$187$$$189$$$O	is$$$190$$$192$$$O	-H$$$193$$$195$$$I	or$$$196$$$198$$$O	-Cl,$$$199$$$203$$$I	and$$$204$$$207$$$O	R3$$$208$$$210$$$O	is$$$211$$$213$$$O	-NO2$$$214$$$218$$$I	or$$$219$$$221$$$O	-H.$$$222$$$225$$$I	The$$$226$$$229$$$O	invention$$$230$$$239$$$O	also$$$240$$$244$$$O	discloses$$$245$$$254$$$O	a$$$255$$$256$$$O	preparation$$$257$$$268$$$O	method$$$269$$$275$$$O	of$$$276$$$278$$$O	the$$$279$$$282$$$O	benzyltin$$$283$$$292$$$I	aromatic$$$293$$$301$$$I	aldehyde$$$302$$$310$$$I	condensed$$$311$$$320$$$I	arylamine$$$321$$$330$$$I	Schiff$$$331$$$337$$$I	base$$$338$$$342$$$I	complex$$$343$$$350$$$O	and$$$351$$$354$$$O	its$$$355$$$358$$$O	application$$$359$$$370$$$O	in$$$371$$$373$$$O	drugs$$$374$$$379$$$O	for$$$380$$$383$$$O	treating$$$384$$$392$$$O	tumour.$$$393$$$400$$$O
US20080131366
Administering$$$0$$$13$$$O	folate$$$14$$$20$$$I	receptor$$$21$$$29$$$O	alpha$$$30$$$35$$$O	inducer$$$36$$$43$$$O	comprising$$$44$$$54$$$O	steroid$$$55$$$62$$$I	receptor$$$63$$$71$$$O	agent$$$72$$$77$$$O	optionally$$$78$$$88$$$O	with$$$89$$$93$$$O	one$$$94$$$97$$$O	or$$$98$$$100$$$O	more$$$101$$$105$$$O	histone$$$106$$$113$$$I	deacetylase$$$114$$$125$$$O	inhibitors$$$126$$$136$$$O	to$$$137$$$139$$$O	treat$$$140$$$145$$$O	or$$$146$$$148$$$O	diagnose$$$149$$$157$$$O	a$$$158$$$159$$$O	patient$$$160$$$167$$$O	having$$$168$$$174$$$O	a$$$175$$$176$$$O	solid$$$177$$$182$$$O	tumor;$$$183$$$189$$$O	increases$$$190$$$199$$$O	levels$$$200$$$206$$$O	of$$$207$$$209$$$O	receptors$$$210$$$219$$$O	on$$$220$$$222$$$O	cancer$$$223$$$229$$$O	cell$$$230$$$234$$$O	plasma$$$235$$$241$$$O	membranes$$$242$$$251$$$O	and$$$252$$$255$$$O	in$$$256$$$258$$$O	serum,$$$259$$$265$$$O	ascites$$$266$$$273$$$O	and$$$274$$$277$$$O	cerebrospinal$$$278$$$291$$$O	fluid$$$292$$$297$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	diagnosing$$$12$$$22$$$O	and$$$23$$$26$$$O	treating$$$27$$$35$$$O	a$$$36$$$37$$$O	patient$$$38$$$45$$$O	with$$$46$$$50$$$O	or$$$51$$$53$$$O	suspected$$$54$$$63$$$O	of$$$64$$$66$$$O	having$$$67$$$73$$$O	at$$$74$$$76$$$O	least$$$77$$$82$$$O	one$$$83$$$86$$$O	solid$$$87$$$92$$$O	tumor$$$93$$$98$$$O	that$$$99$$$103$$$O	produces$$$104$$$112$$$O	folate$$$113$$$119$$$I	receptor$$$120$$$128$$$O	type$$$129$$$133$$$O	Î±$$$134$$$136$$$O	includes$$$137$$$145$$$O	administering$$$146$$$159$$$O	a$$$160$$$161$$$O	biologically$$$162$$$174$$$O	effective$$$175$$$184$$$O	amount$$$185$$$191$$$O	of$$$192$$$194$$$O	at$$$195$$$197$$$O	least$$$198$$$203$$$O	one$$$204$$$207$$$I	folate$$$208$$$214$$$I	receptor$$$215$$$223$$$O	Î±$$$224$$$226$$$O	inducer,$$$227$$$235$$$O	specifically$$$236$$$248$$$I	steroid$$$249$$$256$$$I	receptor$$$257$$$265$$$O	ligands,$$$266$$$274$$$O	with$$$275$$$279$$$O	or$$$280$$$282$$$O	without$$$283$$$290$$$O	aid$$$291$$$294$$$O	from$$$295$$$299$$$O	at$$$300$$$302$$$O	least$$$303$$$308$$$O	one$$$309$$$312$$$I	histone$$$313$$$320$$$I	deacetylase$$$321$$$332$$$O	inhibitor,$$$333$$$343$$$O	to$$$344$$$346$$$O	increase$$$347$$$355$$$O	the$$$356$$$359$$$O	level$$$360$$$365$$$O	of$$$366$$$368$$$O	the$$$369$$$372$$$I	folate$$$373$$$379$$$I	receptor$$$380$$$388$$$O	Î±$$$389$$$391$$$O	on$$$392$$$394$$$O	the$$$395$$$398$$$O	plasma$$$399$$$405$$$O	membrane$$$406$$$414$$$O	of$$$415$$$417$$$O	cancer$$$418$$$424$$$O	cells$$$425$$$430$$$O	as$$$431$$$433$$$O	well$$$434$$$438$$$O	as$$$439$$$441$$$O	the$$$442$$$445$$$I	folate$$$446$$$452$$$I	receptor$$$453$$$461$$$O	Î±$$$462$$$464$$$O	in$$$465$$$467$$$O	at$$$468$$$470$$$O	least$$$471$$$476$$$O	one$$$477$$$480$$$O	type$$$481$$$485$$$O	of$$$486$$$488$$$O	body$$$489$$$493$$$O	fluid,$$$494$$$500$$$O	including,$$$501$$$511$$$O	for$$$512$$$515$$$O	example,$$$516$$$524$$$O	serum,$$$525$$$531$$$O	ascites$$$532$$$539$$$O	and$$$540$$$543$$$O	cerebrospinal$$$544$$$557$$$O	fluid.$$$558$$$564$$$O
CN103405412A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Chukrasone$$$15$$$25$$$I	B$$$26$$$27$$$I	in$$$28$$$30$$$O	medicine$$$31$$$39$$$O	for$$$40$$$43$$$O	treating$$$44$$$52$$$O	laryngocarcinoma$$$53$$$69$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	Chukrasone$$$39$$$49$$$I	B$$$50$$$51$$$I	in$$$52$$$54$$$O	preparation$$$55$$$66$$$O	of$$$67$$$69$$$O	a$$$70$$$71$$$O	medicine$$$72$$$80$$$O	for$$$81$$$84$$$O	treating$$$85$$$93$$$O	laryngocarcinoma,$$$94$$$111$$$O	and$$$112$$$115$$$O	belongs$$$116$$$123$$$O	to$$$124$$$126$$$O	the$$$127$$$130$$$O	technical$$$131$$$140$$$O	field$$$141$$$146$$$O	of$$$147$$$149$$$O	new$$$150$$$153$$$O	application$$$154$$$165$$$O	of$$$166$$$168$$$O	medicines.$$$169$$$179$$$O	The$$$180$$$183$$$O	in-vitro$$$184$$$192$$$O	MTT$$$193$$$196$$$O	(3-4,$$$197$$$202$$$I	5-Dimethylthiazol-2-yl)-2,$$$203$$$229$$$I	5-diphenyltetrazolium$$$230$$$251$$$I	bromide)$$$252$$$260$$$I	antitumor$$$261$$$270$$$O	activity$$$271$$$279$$$O	evaluation$$$280$$$290$$$O	shows$$$291$$$296$$$O	that$$$297$$$301$$$O	Chukrasone$$$302$$$312$$$I	B$$$313$$$314$$$I	has$$$315$$$318$$$O	remarkable$$$319$$$329$$$O	inhibition$$$330$$$340$$$O	effect$$$341$$$347$$$O	on$$$348$$$350$$$O	the$$$351$$$354$$$O	growth$$$355$$$361$$$O	of$$$362$$$364$$$O	human$$$365$$$370$$$O	laryngocarcinoma$$$371$$$387$$$O	cell$$$388$$$392$$$O	lines$$$393$$$398$$$O	HEP-2,$$$399$$$405$$$O	TU686,$$$406$$$412$$$O	M2e$$$413$$$416$$$O	and$$$417$$$420$$$O	M4e,$$$421$$$425$$$O	so$$$426$$$428$$$O	that$$$429$$$433$$$O	Chukrasone$$$434$$$444$$$I	B$$$445$$$446$$$I	has$$$447$$$450$$$O	a$$$451$$$452$$$O	good$$$453$$$457$$$O	development$$$458$$$469$$$O	and$$$470$$$473$$$O	application$$$474$$$485$$$O	prospect$$$486$$$494$$$O	and$$$495$$$498$$$O	can$$$499$$$502$$$O	be$$$503$$$505$$$O	applied$$$506$$$513$$$O	to$$$514$$$516$$$O	the$$$517$$$520$$$O	preparation$$$521$$$532$$$O	of$$$533$$$535$$$O	the$$$536$$$539$$$O	medicine$$$540$$$548$$$O	for$$$549$$$552$$$O	treating$$$553$$$561$$$O	laryngocarcinoma.$$$562$$$579$$$O	The$$$580$$$583$$$O	application$$$584$$$595$$$O	of$$$596$$$598$$$O	Chukrasone$$$599$$$609$$$I	B$$$610$$$611$$$I	in$$$612$$$614$$$O	the$$$615$$$618$$$O	preparation$$$619$$$630$$$O	of$$$631$$$633$$$O	the$$$634$$$637$$$O	medicine$$$638$$$646$$$O	for$$$647$$$650$$$O	treating$$$651$$$659$$$O	laryngocarcinoma$$$660$$$676$$$O	is$$$677$$$679$$$O	disclosed$$$680$$$689$$$O	for$$$690$$$693$$$O	the$$$694$$$697$$$O	first$$$698$$$703$$$O	time;$$$704$$$709$$$O	the$$$710$$$713$$$O	framework$$$714$$$723$$$O	type$$$724$$$728$$$O	of$$$729$$$731$$$O	Chukrasone$$$732$$$742$$$I	B$$$743$$$744$$$I	is$$$745$$$747$$$O	brand$$$748$$$753$$$O	new;$$$754$$$758$$$O	Chukrasone$$$759$$$769$$$I	B$$$770$$$771$$$I	brings$$$772$$$778$$$O	unexpected$$$779$$$789$$$O	inhibition$$$790$$$800$$$O	activity$$$801$$$809$$$O	for$$$810$$$813$$$O	laryngocarcinoma$$$814$$$830$$$O	cells.$$$831$$$837$$$O
CN103054850A
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	pinocembrin$$$7$$$18$$$I	in$$$19$$$21$$$O	preparation$$$22$$$33$$$O	of$$$34$$$36$$$O	medicines$$$37$$$46$$$O	for$$$47$$$50$$$O	treating$$$51$$$59$$$O	neurodegenerative$$$60$$$77$$$O	diseases$$$78$$$86$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	use$$$26$$$29$$$O	of$$$30$$$32$$$O	pinocembrin$$$33$$$44$$$I	(PCB)$$$45$$$50$$$I	in$$$51$$$53$$$O	the$$$54$$$57$$$O	preparation$$$58$$$69$$$O	of$$$70$$$72$$$O	medicines$$$73$$$82$$$O	for$$$83$$$86$$$O	treating$$$87$$$95$$$O	neurodegenerative$$$96$$$113$$$O	diseases,$$$114$$$123$$$O	and$$$124$$$127$$$O	belongs$$$128$$$135$$$O	to$$$136$$$138$$$O	the$$$139$$$142$$$O	medicinal$$$143$$$152$$$O	field.$$$153$$$159$$$O	Wide$$$160$$$164$$$O	researches$$$165$$$175$$$O	on$$$176$$$178$$$O	the$$$179$$$182$$$O	screening$$$183$$$192$$$O	of$$$193$$$195$$$O	oxidation$$$196$$$205$$$O	damage$$$206$$$212$$$O	resistant$$$213$$$222$$$O	medicines$$$223$$$232$$$O	prove$$$233$$$238$$$O	that$$$239$$$243$$$O	pinocembrin$$$244$$$255$$$I	has$$$256$$$259$$$O	a$$$260$$$261$$$O	nerve$$$262$$$267$$$O	protection$$$268$$$278$$$O	effect.$$$279$$$286$$$O	Concrete$$$287$$$295$$$O	researches$$$296$$$306$$$O	prove$$$307$$$312$$$O	that$$$313$$$317$$$O	pinocembrin$$$318$$$329$$$I	has$$$330$$$333$$$O	the$$$334$$$337$$$O	nerve$$$338$$$343$$$O	protection$$$344$$$354$$$O	effect$$$355$$$361$$$O	on$$$362$$$364$$$O	Alzheimer$$$365$$$374$$$O	disease$$$375$$$382$$$O	beta-amyloid$$$383$$$395$$$O	protein$$$396$$$403$$$O	(Abeta)$$$404$$$411$$$O	and$$$412$$$415$$$O	1-methyl-4-phenylpyridine$$$416$$$441$$$I	(MPP<+>)$$$442$$$450$$$I	induced$$$451$$$458$$$O	Parkinson's$$$459$$$470$$$O	disease$$$471$$$478$$$O	models,$$$479$$$486$$$O	so$$$487$$$489$$$O	pinocembrin$$$490$$$501$$$I	can$$$502$$$505$$$O	be$$$506$$$508$$$O	used$$$509$$$513$$$O	for$$$514$$$517$$$O	preparing$$$518$$$527$$$O	medicines$$$528$$$537$$$O	for$$$538$$$541$$$O	preventing$$$542$$$552$$$O	and$$$553$$$556$$$O	treating$$$557$$$565$$$O	the$$$566$$$569$$$O	neurodegenerative$$$570$$$587$$$O	diseases.$$$588$$$597$$$O	Medicines$$$598$$$607$$$O	treating$$$608$$$616$$$O	pinocembrin$$$617$$$628$$$I	as$$$629$$$631$$$O	an$$$632$$$634$$$O	active$$$635$$$641$$$O	component$$$642$$$651$$$O	will$$$652$$$656$$$O	have$$$657$$$661$$$O	substantial$$$662$$$673$$$O	curative$$$674$$$682$$$O	effects$$$683$$$690$$$O	clinically,$$$691$$$702$$$O	so$$$703$$$705$$$O	great$$$706$$$711$$$O	social$$$712$$$718$$$O	and$$$719$$$722$$$O	economic$$$723$$$731$$$O	benefits$$$732$$$740$$$O	are$$$741$$$744$$$O	generated.$$$745$$$755$$$O
US6984653
useful$$$0$$$6$$$O	as$$$7$$$9$$$O	a$$$10$$$11$$$O	growth$$$12$$$18$$$O	factor$$$19$$$25$$$O	receptor$$$26$$$34$$$O	tyrosine$$$35$$$43$$$I	kinase$$$44$$$50$$$O	HER2$$$51$$$55$$$O	(Human$$$56$$$62$$$O	epidermal$$$63$$$72$$$O	growth$$$73$$$79$$$O	factor$$$80$$$86$$$O	receptor-2)$$$87$$$98$$$O	inhibitor;$$$99$$$109$$$O	for$$$110$$$113$$$O	treating$$$114$$$122$$$O	cancer$$$123$$$129$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	a$$$24$$$25$$$O	heterocyclic$$$26$$$38$$$I	compound$$$39$$$47$$$O	having$$$48$$$54$$$O	potent$$$55$$$61$$$O	tyrosine$$$62$$$70$$$I	kinase-inhibiting$$$71$$$88$$$O	activity$$$89$$$97$$$O	represented$$$98$$$109$$$O	by$$$110$$$112$$$O	the$$$113$$$116$$$O	formula:$$$117$$$125$$$O	wherein$$$141$$$148$$$O	m$$$149$$$150$$$O	is$$$151$$$153$$$O	an$$$154$$$156$$$O	integer$$$157$$$164$$$O	of$$$165$$$167$$$O	1$$$168$$$169$$$O	to$$$170$$$172$$$O	3;$$$173$$$175$$$O	n$$$176$$$177$$$O	is$$$178$$$180$$$O	an$$$181$$$183$$$O	integer$$$184$$$191$$$O	of$$$192$$$194$$$O	1$$$195$$$196$$$O	or$$$197$$$199$$$O	2;$$$200$$$202$$$O	R1$$$203$$$205$$$O	is$$$206$$$208$$$O	a$$$209$$$210$$$O	halogen$$$211$$$218$$$I	atom$$$219$$$223$$$O	or$$$224$$$226$$$O	an$$$227$$$229$$$O	optionally$$$230$$$240$$$O	halogenated$$$241$$$252$$$O	C1-2$$$253$$$257$$$I	alkyl$$$258$$$263$$$I	group;$$$264$$$270$$$O	each$$$271$$$275$$$O	of$$$276$$$278$$$O	R2$$$279$$$281$$$O	and$$$282$$$285$$$O	R3$$$286$$$288$$$O	is,$$$289$$$292$$$O	same$$$293$$$297$$$O	or$$$298$$$300$$$O	different,$$$301$$$311$$$O	a$$$312$$$313$$$O	hydrogen$$$314$$$322$$$I	atom,$$$323$$$328$$$O	a$$$329$$$330$$$O	halogen$$$331$$$338$$$I	atom,$$$339$$$344$$$O	a$$$345$$$346$$$O	lower$$$347$$$352$$$O	alkyl$$$353$$$358$$$I	group$$$359$$$364$$$O	or$$$365$$$367$$$O	a$$$368$$$369$$$O	lower$$$370$$$375$$$O	alkoxy$$$376$$$382$$$I	group;$$$383$$$389$$$O	R4$$$390$$$392$$$O	is$$$393$$$395$$$O	a$$$396$$$397$$$O	group$$$398$$$403$$$O	represented$$$404$$$415$$$O	by$$$416$$$418$$$O	the$$$419$$$422$$$O	formula:$$$423$$$431$$$O	wherein$$$447$$$454$$$O	p$$$455$$$456$$$O	is$$$457$$$459$$$O	an$$$460$$$462$$$O	integer$$$463$$$470$$$O	of$$$471$$$473$$$O	2$$$474$$$475$$$O	to$$$476$$$478$$$O	5;$$$479$$$481$$$O	R5$$$482$$$484$$$O	is$$$485$$$487$$$O	a$$$488$$$489$$$O	C1-4$$$490$$$494$$$I	alkyl$$$495$$$500$$$I	group$$$501$$$506$$$O	substituted$$$507$$$518$$$O	by$$$519$$$521$$$O	alkoxycarbonyl$$$522$$$536$$$I	group,$$$537$$$543$$$O	carbamoyl$$$544$$$553$$$I	group,$$$554$$$560$$$O	carbamoyloxy$$$561$$$573$$$I	group,$$$574$$$580$$$O	alkylsulfonyl$$$581$$$594$$$I	group,$$$595$$$601$$$O	alkylsulfinyl$$$602$$$615$$$I	group,$$$616$$$622$$$O	sulfamoyl$$$623$$$632$$$I	group,$$$633$$$639$$$O	carbamoylamino$$$640$$$654$$$I	group,$$$655$$$661$$$O	alkylsulfonylamino$$$662$$$680$$$I	group,$$$681$$$687$$$O	acylamino$$$688$$$697$$$I	group,$$$698$$$704$$$O	and$$$705$$$708$$$O	the$$$709$$$712$$$O	like;$$$713$$$718$$$O	or$$$719$$$721$$$O	a$$$722$$$723$$$O	salt$$$724$$$728$$$O	thereof$$$729$$$736$$$O	and$$$737$$$740$$$O	a$$$741$$$742$$$O	pharmaceutical$$$743$$$757$$$O	composition$$$758$$$769$$$O	comprising$$$770$$$780$$$O	thereof.$$$781$$$789$$$O
CN102319369A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	mixed$$$15$$$20$$$O	liquor$$$21$$$27$$$O	of$$$28$$$30$$$O	anthocyanin$$$31$$$42$$$I	extract$$$43$$$50$$$O	and$$$51$$$54$$$O	corn$$$55$$$59$$$O	silk$$$60$$$64$$$O	extract$$$65$$$72$$$O	to$$$73$$$75$$$O	preparation$$$76$$$87$$$O	of$$$88$$$90$$$O	bacteriostasis$$$91$$$105$$$O	medicament$$$106$$$116$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	application$$$23$$$34$$$O	of$$$35$$$37$$$O	a$$$38$$$39$$$O	mixed$$$40$$$45$$$O	liquor$$$46$$$52$$$O	of$$$53$$$55$$$O	an$$$56$$$58$$$O	anthocyanin$$$59$$$70$$$I	extract$$$71$$$78$$$O	and$$$79$$$82$$$O	a$$$83$$$84$$$O	corn$$$85$$$89$$$O	silk$$$90$$$94$$$O	extract$$$95$$$102$$$O	to$$$103$$$105$$$O	preparation$$$106$$$117$$$O	of$$$118$$$120$$$O	a$$$121$$$122$$$O	bacteriostasis$$$123$$$137$$$O	medicament.$$$138$$$149$$$O	In$$$150$$$152$$$O	the$$$153$$$156$$$O	invention,$$$157$$$167$$$O	two$$$168$$$171$$$O	different$$$172$$$181$$$O	extracts,$$$182$$$191$$$O	i.e.,$$$192$$$197$$$O	the$$$198$$$201$$$O	anthocyanin$$$202$$$213$$$I	extract$$$214$$$221$$$O	and$$$222$$$225$$$O	the$$$226$$$229$$$O	corn$$$230$$$234$$$O	silk$$$235$$$239$$$O	extract$$$240$$$247$$$O	are$$$248$$$251$$$O	prepared$$$252$$$260$$$O	into$$$261$$$265$$$O	a$$$266$$$267$$$O	mixed$$$268$$$273$$$O	liquor.$$$274$$$281$$$O	The$$$282$$$285$$$O	mixed$$$286$$$291$$$O	liquor$$$292$$$298$$$O	has$$$299$$$302$$$O	a$$$303$$$304$$$O	remarkable$$$305$$$315$$$O	bacteriostasis$$$316$$$330$$$O	effect$$$331$$$337$$$O	positively$$$338$$$348$$$O	relevant$$$349$$$357$$$O	to$$$358$$$360$$$O	the$$$361$$$364$$$O	concentration$$$365$$$378$$$O	of$$$379$$$381$$$O	the$$$382$$$385$$$O	mixed$$$386$$$391$$$O	liquor,and$$$392$$$402$$$O	particularly$$$403$$$415$$$O	has$$$416$$$419$$$O	a$$$420$$$421$$$O	bacteriostasis$$$422$$$436$$$O	function$$$437$$$445$$$O	on$$$446$$$448$$$O	bacteria$$$449$$$457$$$O	having$$$458$$$464$$$O	high$$$465$$$469$$$O	drug$$$470$$$474$$$O	resistance$$$475$$$485$$$O	to$$$486$$$488$$$O	the$$$489$$$492$$$O	conventional$$$493$$$505$$$O	antibiotics$$$506$$$517$$$O	specific$$$518$$$526$$$O	to$$$527$$$529$$$O	urinary$$$530$$$537$$$O	system$$$538$$$544$$$O	infection.$$$545$$$555$$$O	Based$$$556$$$561$$$O	on$$$562$$$564$$$O	the$$$565$$$568$$$O	research$$$569$$$577$$$O	results$$$578$$$585$$$O	of$$$586$$$588$$$O	the$$$589$$$592$$$O	invention,$$$593$$$603$$$O	an$$$604$$$606$$$O	effective$$$607$$$616$$$O	bacteriostasis$$$617$$$631$$$O	medicament$$$632$$$642$$$O	can$$$643$$$646$$$O	be$$$647$$$649$$$O	developed.$$$650$$$660$$$O
WO2006112456A1
Perkinson$$$0$$$9$$$O	disease-related$$$10$$$25$$$O	gene$$$26$$$30$$$O	grk5$$$31$$$35$$$O	and$$$36$$$39$$$O	use$$$40$$$43$$$O	thereof$$$44$$$51$$$O
As$$$0$$$2$$$O	a$$$3$$$4$$$O	result$$$5$$$11$$$O	of$$$12$$$14$$$O	a$$$15$$$16$$$O	large$$$17$$$22$$$O	scale$$$23$$$28$$$O	SNP$$$29$$$32$$$O	analysis$$$33$$$41$$$O	on$$$42$$$44$$$O	a$$$45$$$46$$$O	group$$$47$$$52$$$O	of$$$53$$$55$$$O	Perkinson$$$56$$$65$$$O	disease$$$66$$$73$$$O	patients$$$74$$$82$$$O	and$$$83$$$86$$$O	a$$$87$$$88$$$O	control$$$89$$$96$$$O	group$$$97$$$102$$$O	of$$$103$$$105$$$O	normal$$$106$$$112$$$O	persons,$$$113$$$121$$$O	it$$$122$$$124$$$O	has$$$125$$$128$$$O	succeeded$$$129$$$138$$$O	in$$$139$$$141$$$O	the$$$142$$$145$$$O	identification$$$146$$$160$$$O	of$$$161$$$163$$$O	a$$$164$$$165$$$O	gene$$$166$$$170$$$O	involved$$$171$$$179$$$O	in$$$180$$$182$$$O	Perkinson$$$183$$$192$$$O	disease$$$193$$$200$$$O	(GRK5).$$$201$$$208$$$O	It$$$209$$$211$$$O	is$$$212$$$214$$$O	now$$$215$$$218$$$O	found$$$219$$$224$$$O	that$$$225$$$229$$$O	the$$$230$$$233$$$O	increase$$$234$$$242$$$O	in$$$243$$$245$$$O	the$$$246$$$249$$$O	expression$$$250$$$260$$$O	of$$$261$$$263$$$O	the$$$264$$$267$$$O	GRK5$$$268$$$272$$$O	gene$$$273$$$277$$$O	induces$$$278$$$285$$$O	the$$$286$$$289$$$O	enhancement$$$290$$$301$$$O	of$$$302$$$304$$$O	the$$$305$$$308$$$O	phosphorylation$$$309$$$324$$$O	of$$$325$$$327$$$O	Î±-synuclein,$$$328$$$341$$$O	which$$$342$$$347$$$O	in$$$348$$$350$$$O	turn$$$351$$$355$$$O	induces$$$356$$$363$$$O	the$$$364$$$367$$$O	enhancement$$$368$$$379$$$O	of$$$380$$$382$$$O	the$$$383$$$386$$$O	formation$$$387$$$396$$$O	of$$$397$$$399$$$O	a$$$400$$$401$$$O	soluble$$$402$$$409$$$O	Î±-synuclein$$$410$$$422$$$O	oligomer,$$$423$$$432$$$O	leading$$$433$$$440$$$O	to$$$441$$$443$$$O	the$$$444$$$447$$$O	development$$$448$$$459$$$O	of$$$460$$$462$$$O	Perkinson$$$463$$$472$$$O	disease.$$$473$$$481$$$O	It$$$482$$$484$$$O	becomes$$$485$$$492$$$O	possible$$$493$$$501$$$O	to$$$502$$$504$$$O	diagnose$$$505$$$513$$$O	Perkinson$$$514$$$523$$$O	disease$$$524$$$531$$$O	and$$$532$$$535$$$O	screen$$$536$$$542$$$O	a$$$543$$$544$$$O	therapeutic$$$545$$$556$$$O	agent$$$557$$$562$$$O	for$$$563$$$566$$$O	Perkinson$$$567$$$576$$$O	disease$$$577$$$584$$$O	by$$$585$$$587$$$O	using$$$588$$$593$$$O	the$$$594$$$597$$$O	expression$$$598$$$608$$$O	of$$$609$$$611$$$O	the$$$612$$$615$$$O	GRK5$$$616$$$620$$$O	gene.$$$621$$$626$$$O
US20060183794
Drug$$$0$$$4$$$O	composition$$$5$$$16$$$O	containing$$$17$$$27$$$O	nf-kb$$$28$$$33$$$O	inhibitor$$$34$$$43$$$O
Pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	for$$$28$$$31$$$O	improving$$$32$$$41$$$O	at$$$42$$$44$$$O	least$$$45$$$50$$$O	one$$$51$$$54$$$O	symptom$$$55$$$62$$$O	resulting$$$63$$$72$$$O	from$$$73$$$77$$$O	tumor$$$78$$$83$$$O	cells,$$$84$$$90$$$O	which$$$91$$$96$$$O	contains$$$97$$$105$$$O	a$$$106$$$107$$$O	compound$$$108$$$116$$$O	represented$$$117$$$128$$$O	by$$$129$$$131$$$O	the$$$132$$$135$$$O	following$$$136$$$145$$$O	general$$$146$$$153$$$O	formula$$$154$$$161$$$O	(1)$$$162$$$165$$$O	or$$$166$$$168$$$O	a$$$169$$$170$$$O	pharmacologically$$$171$$$188$$$O	acceptable$$$189$$$199$$$O	salt$$$200$$$204$$$O	thereof$$$205$$$212$$$O	as$$$213$$$215$$$O	an$$$216$$$218$$$O	active$$$219$$$225$$$O	ingredient.$$$226$$$237$$$O	wherein$$$254$$$261$$$O	R1$$$262$$$264$$$O	represents$$$265$$$275$$$O	a$$$276$$$277$$$O	hydrogen$$$278$$$286$$$I	atom$$$287$$$291$$$O	or$$$292$$$294$$$O	a$$$295$$$296$$$O	C2-4$$$297$$$301$$$O	alkanoyl$$$302$$$310$$$I	group$$$311$$$316$$$O	and$$$317$$$320$$$O	R2$$$321$$$323$$$O	represents$$$324$$$334$$$O	a$$$335$$$336$$$O	group$$$337$$$342$$$O	represented$$$343$$$354$$$O	by$$$355$$$357$$$O	the$$$358$$$361$$$O	following$$$362$$$371$$$O	formulae$$$372$$$380$$$O	(A),$$$381$$$385$$$O	(B),$$$386$$$390$$$O	(C),$$$391$$$395$$$O	(D),$$$396$$$400$$$O	(E),$$$401$$$405$$$O	(F)$$$406$$$409$$$O	or$$$410$$$412$$$O	(G):$$$413$$$417$$$O	wherein$$$434$$$441$$$O	R3$$$442$$$444$$$O	represents$$$445$$$455$$$O	a$$$456$$$457$$$O	C1-4$$$458$$$462$$$I	alkyl$$$463$$$468$$$I	group.$$$469$$$475$$$O
EP2112926A2
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	estrogen$$$7$$$15$$$I	receptor$$$16$$$24$$$O	beta$$$25$$$29$$$O	selective$$$30$$$39$$$O	ligands$$$40$$$47$$$O	for$$$48$$$51$$$O	treating$$$52$$$60$$$O	acute$$$61$$$66$$$O	lung$$$67$$$71$$$O	injuries$$$72$$$80$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	method$$$33$$$39$$$O	of$$$40$$$42$$$O	treating$$$43$$$51$$$O	acute$$$52$$$57$$$O	lung$$$58$$$62$$$O	injuries,$$$63$$$72$$$O	such$$$73$$$77$$$O	as$$$78$$$80$$$O	acute$$$81$$$86$$$O	lung$$$87$$$91$$$O	injury$$$92$$$98$$$O	induced$$$99$$$106$$$O	by$$$107$$$109$$$O	peritonitis$$$110$$$121$$$O	during$$$122$$$128$$$O	sepsis,$$$129$$$136$$$O	acute$$$137$$$142$$$O	lung$$$143$$$147$$$O	injury$$$148$$$154$$$O	induced$$$155$$$162$$$O	by$$$163$$$165$$$O	intravenous$$$166$$$177$$$O	bacteremia$$$178$$$188$$$O	during$$$189$$$195$$$O	sepsis,$$$196$$$203$$$O	acute$$$204$$$209$$$O	lung$$$210$$$214$$$O	injury$$$215$$$221$$$O	caused$$$222$$$228$$$O	by$$$229$$$231$$$O	smoke$$$232$$$237$$$O	inhalation,$$$238$$$249$$$O	acute$$$250$$$255$$$O	lung$$$256$$$260$$$O	injury$$$261$$$267$$$O	occurring$$$268$$$277$$$O	in$$$278$$$280$$$O	a$$$281$$$282$$$O	premature$$$283$$$292$$$O	infant$$$293$$$299$$$O	with$$$300$$$304$$$O	deficiency$$$305$$$315$$$O	of$$$316$$$318$$$O	surfactant,$$$319$$$330$$$O	acute$$$331$$$336$$$O	lung$$$337$$$341$$$O	injury$$$342$$$348$$$O	caused$$$349$$$355$$$O	by$$$356$$$358$$$O	oxygen$$$359$$$365$$$I	toxicity$$$366$$$374$$$O	or$$$375$$$377$$$O	acute$$$378$$$383$$$O	lung$$$384$$$388$$$O	injury$$$389$$$395$$$O	caused$$$396$$$402$$$O	by$$$403$$$405$$$O	barotraumas$$$406$$$417$$$O	from$$$418$$$422$$$O	mechanical$$$423$$$433$$$O	ventilation,$$$434$$$446$$$O	using$$$447$$$452$$$O	an$$$453$$$455$$$O	ERÎ²$$$456$$$460$$$O	selective$$$461$$$470$$$O	ligand$$$471$$$477$$$O	such$$$478$$$482$$$O	as$$$483$$$485$$$I	2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol$$$486$$$542$$$I	or$$$543$$$545$$$I	3-(3-fluoro-4-hydroxy-phenyl)-7-hydroxy-naphthalene-1-carbonitrile.$$$546$$$613$$$I	The$$$614$$$617$$$O	present$$$618$$$625$$$O	invention$$$626$$$635$$$O	further$$$636$$$643$$$O	relates$$$644$$$651$$$O	to$$$652$$$654$$$O	use$$$655$$$658$$$O	of$$$659$$$661$$$O	ERÎ²$$$662$$$666$$$O	selective$$$667$$$676$$$O	ligands$$$677$$$684$$$O	or$$$685$$$687$$$O	compositions$$$688$$$700$$$O	thereof$$$701$$$708$$$O	for$$$709$$$712$$$O	the$$$713$$$716$$$O	prevention$$$717$$$727$$$O	of$$$728$$$730$$$O	acute$$$731$$$736$$$O	lung$$$737$$$741$$$O	injuries$$$742$$$750$$$O	in$$$751$$$753$$$O	those$$$754$$$759$$$O	being$$$760$$$765$$$O	at$$$766$$$768$$$O	risk$$$769$$$773$$$O	thereof.$$$774$$$782$$$O
CN1923798A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	dexibuprofen$$$22$$$34$$$I	amino$$$35$$$40$$$I	acid$$$41$$$45$$$I	salt$$$46$$$50$$$I	and$$$51$$$54$$$O	application$$$55$$$66$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	nalorphine$$$26$$$36$$$I	amino$$$37$$$42$$$I	compound$$$43$$$51$$$O	and$$$52$$$55$$$O	preparing$$$56$$$65$$$O	method$$$66$$$72$$$O	with$$$73$$$77$$$O	structural$$$78$$$88$$$O	formula$$$89$$$96$$$O	as$$$97$$$99$$$O	(I),$$$100$$$104$$$O	wherein$$$105$$$112$$$O	the$$$113$$$116$$$O	amino$$$117$$$122$$$I	can$$$123$$$126$$$O	be$$$127$$$129$$$O	Arg,$$$130$$$134$$$I	Lys$$$135$$$138$$$I	or$$$139$$$141$$$O	His;$$$142$$$146$$$I	the$$$147$$$150$$$O	molecular$$$151$$$160$$$O	rate$$$161$$$165$$$O	of$$$166$$$168$$$O	nalorphine$$$169$$$179$$$I	and$$$180$$$183$$$O	amino$$$184$$$189$$$I	is$$$190$$$192$$$O	1:1-1:$$$193$$$199$$$O	5$$$200$$$201$$$O	or$$$202$$$204$$$O	5:1-1:1.$$$205$$$213$$$O
US20100316624
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	fibroses$$$13$$$21$$$O	and$$$22$$$25$$$O	liver$$$26$$$31$$$O	disorders$$$32$$$41$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	ACE2$$$33$$$37$$$O	for$$$38$$$41$$$O	the$$$42$$$45$$$O	therapeutic$$$46$$$57$$$O	treatment$$$58$$$67$$$O	or$$$68$$$70$$$O	prevention$$$71$$$81$$$O	of$$$82$$$84$$$O	a$$$85$$$86$$$O	fibrosis$$$87$$$95$$$O	or$$$96$$$98$$$O	liver$$$99$$$104$$$O	disorder.$$$105$$$114$$$O
US20100092553
anti-misuse$$$0$$$11$$$O	microparticulate$$$12$$$28$$$O	oral$$$29$$$33$$$O	pharmaceutical$$$34$$$48$$$O	form$$$49$$$53$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	solid$$$33$$$38$$$O	microparticulate$$$39$$$55$$$O	oral$$$56$$$60$$$O	pharmaceutical$$$61$$$75$$$O	forms$$$76$$$81$$$O	whose$$$82$$$87$$$O	composition$$$88$$$99$$$O	and$$$100$$$103$$$O	structure$$$104$$$113$$$O	make$$$114$$$118$$$O	it$$$119$$$121$$$O	possible$$$122$$$130$$$O	to$$$131$$$133$$$O	avoid$$$134$$$139$$$O	misuse$$$140$$$146$$$O	of$$$147$$$149$$$O	the$$$150$$$153$$$O	pharmaceutical$$$154$$$168$$$O	active$$$169$$$175$$$O	principle$$$176$$$185$$$O	(AP)$$$186$$$190$$$O	they$$$191$$$195$$$O	contain.$$$196$$$204$$$O	The$$$209$$$212$$$O	object$$$213$$$219$$$O	of$$$220$$$222$$$O	the$$$223$$$226$$$O	present$$$227$$$234$$$O	invention$$$235$$$244$$$O	is$$$245$$$247$$$O	to$$$248$$$250$$$O	prevent$$$251$$$258$$$O	solid$$$259$$$264$$$O	oral$$$265$$$269$$$O	drugs$$$270$$$275$$$O	from$$$276$$$280$$$O	being$$$281$$$286$$$O	misappropriated$$$287$$$302$$$O	for$$$303$$$306$$$O	any$$$307$$$310$$$O	use$$$311$$$314$$$O	other$$$315$$$320$$$O	than$$$321$$$325$$$O	the$$$326$$$329$$$O	therapeutic$$$330$$$341$$$O	use(s)$$$342$$$348$$$O	officially$$$349$$$359$$$O	approved$$$360$$$368$$$O	by$$$369$$$371$$$O	the$$$372$$$375$$$O	competent$$$376$$$385$$$O	public$$$386$$$392$$$O	health$$$393$$$399$$$O	authorities.$$$400$$$412$$$O	In$$$413$$$415$$$O	other$$$416$$$421$$$O	words,$$$422$$$428$$$O	the$$$429$$$432$$$O	object$$$433$$$439$$$O	is$$$440$$$442$$$O	to$$$443$$$445$$$O	avoid$$$446$$$451$$$O	the$$$452$$$455$$$O	voluntary$$$456$$$465$$$O	or$$$466$$$468$$$O	involuntary$$$469$$$480$$$O	misuse$$$481$$$487$$$O	of$$$488$$$490$$$O	solid$$$491$$$496$$$O	oral$$$497$$$501$$$O	drugs.$$$502$$$508$$$O	The$$$513$$$516$$$O	invention$$$517$$$526$$$O	relates$$$527$$$534$$$O	to$$$535$$$537$$$O	a$$$538$$$539$$$O	solid$$$540$$$545$$$O	oral$$$546$$$550$$$O	pharmaceutical$$$551$$$565$$$O	form$$$566$$$570$$$O	which$$$571$$$576$$$O	is$$$577$$$579$$$O	characterized$$$580$$$593$$$O	in$$$594$$$596$$$O	that$$$597$$$601$$$O	it$$$602$$$604$$$O	contains$$$605$$$613$$$O	anti-misuse$$$614$$$625$$$O	means,$$$626$$$632$$$O	in$$$633$$$635$$$O	that$$$636$$$640$$$O	at$$$641$$$643$$$O	least$$$644$$$649$$$O	part$$$650$$$654$$$O	of$$$655$$$657$$$O	the$$$658$$$661$$$O	AP$$$662$$$664$$$O	it$$$665$$$667$$$O	comprises$$$668$$$677$$$O	is$$$678$$$680$$$O	contained$$$681$$$690$$$O	in$$$691$$$693$$$O	coated$$$694$$$700$$$O	microparticles$$$701$$$715$$$O	for$$$716$$$719$$$O	modified$$$720$$$728$$$O	release$$$729$$$736$$$O	of$$$737$$$739$$$O	the$$$740$$$743$$$O	AP,$$$744$$$747$$$O	and$$$748$$$751$$$O	in$$$752$$$754$$$O	that$$$755$$$759$$$O	the$$$760$$$763$$$O	coated$$$764$$$770$$$O	microparticles$$$771$$$785$$$O	of$$$786$$$788$$$O	AP$$$789$$$791$$$O	have$$$792$$$796$$$O	a$$$797$$$798$$$O	coating$$$799$$$806$$$O	layer$$$807$$$812$$$O	(Ra)$$$813$$$817$$$O	which$$$818$$$823$$$O	assures$$$824$$$831$$$O	the$$$832$$$835$$$O	modified$$$836$$$844$$$O	release$$$845$$$852$$$O	of$$$853$$$855$$$O	the$$$856$$$859$$$O	AP$$$860$$$862$$$O	and$$$863$$$866$$$O	simultaneously$$$867$$$881$$$O	imparts$$$882$$$889$$$O	crushing$$$890$$$898$$$O	resistance$$$899$$$909$$$O	to$$$910$$$912$$$O	the$$$913$$$916$$$O	coated$$$917$$$923$$$O	microparticles$$$924$$$938$$$O	of$$$939$$$941$$$O	AP$$$942$$$944$$$O	so$$$945$$$947$$$O	as$$$948$$$950$$$O	to$$$951$$$953$$$O	avoid$$$954$$$959$$$O	misuse.$$$960$$$967$$$O
EP2615163A1
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	preventing$$$16$$$26$$$O	inflammations$$$27$$$40$$$O
The$$$0$$$3$$$O	purpose$$$4$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	present$$$19$$$26$$$O	invention$$$27$$$36$$$O	is$$$37$$$39$$$O	to$$$40$$$42$$$O	provide$$$43$$$50$$$O	a$$$51$$$52$$$O	probiotic(s)$$$53$$$65$$$O	which$$$66$$$71$$$O	can$$$72$$$75$$$O	activate$$$76$$$84$$$O	an$$$85$$$87$$$O	aromatic$$$88$$$96$$$I	hydrocarbon$$$97$$$108$$$I	receptor$$$109$$$117$$$O	(AhR)$$$118$$$123$$$O	and$$$124$$$127$$$O	can$$$128$$$131$$$O	consequently$$$132$$$144$$$O	prevent$$$145$$$152$$$O	inflammatory$$$153$$$165$$$O	damage$$$166$$$172$$$O	in$$$173$$$175$$$O	the$$$176$$$179$$$O	digestive$$$180$$$189$$$O	tract.$$$190$$$196$$$O	The$$$197$$$200$$$O	present$$$201$$$208$$$O	invention$$$209$$$218$$$O	relates$$$219$$$226$$$O	to;$$$227$$$230$$$O	a$$$231$$$232$$$O	probiotic$$$233$$$242$$$O	(s)$$$243$$$246$$$O	capable$$$247$$$254$$$O	of$$$255$$$257$$$O	activating$$$258$$$268$$$O	an$$$269$$$271$$$O	AhR;$$$272$$$276$$$O	an$$$277$$$279$$$O	anti-inflammatory$$$280$$$297$$$O	agent$$$298$$$303$$$O	comprising$$$304$$$314$$$O	the$$$315$$$318$$$O	probiotic(s);$$$319$$$332$$$O	an$$$333$$$335$$$O	orally$$$336$$$342$$$O	ingestible$$$343$$$353$$$O	composition$$$354$$$365$$$O	containing$$$366$$$376$$$O	the$$$377$$$380$$$O	anti-inflammatory$$$381$$$398$$$O	agent;$$$399$$$405$$$O	and$$$406$$$409$$$O	a$$$410$$$411$$$O	method$$$412$$$418$$$O	for$$$419$$$422$$$O	screening$$$423$$$432$$$O	for$$$433$$$436$$$O	the$$$437$$$440$$$O	probiotic(s).$$$441$$$454$$$O
CN103432181A
Common$$$0$$$6$$$O	pternopetalum$$$7$$$20$$$O	root$$$21$$$25$$$O	extract$$$26$$$33$$$O	and$$$34$$$37$$$O	new$$$38$$$41$$$O	use$$$42$$$45$$$O	thereof$$$46$$$53$$$O	in$$$54$$$56$$$O	pharmacy$$$57$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	new$$$27$$$30$$$O	use$$$31$$$34$$$O	of$$$35$$$37$$$O	a$$$38$$$39$$$O	common$$$40$$$46$$$O	pternopetalum$$$47$$$60$$$O	root$$$61$$$65$$$O	extract,$$$66$$$74$$$O	and$$$75$$$78$$$O	particularly$$$79$$$91$$$O	relates$$$92$$$99$$$O	to$$$100$$$102$$$O	the$$$103$$$106$$$O	use$$$107$$$110$$$O	of$$$111$$$113$$$O	the$$$114$$$117$$$O	common$$$118$$$124$$$O	pternopetalum$$$125$$$138$$$O	root$$$139$$$143$$$O	extract$$$144$$$151$$$O	in$$$152$$$154$$$O	the$$$155$$$158$$$O	field$$$159$$$164$$$O	of$$$165$$$167$$$O	pharmacy.$$$168$$$177$$$O	The$$$178$$$181$$$O	use$$$182$$$185$$$O	concretely$$$186$$$196$$$O	comprises$$$197$$$206$$$O	the$$$207$$$210$$$O	functions$$$211$$$220$$$O	of$$$221$$$223$$$O	treating$$$224$$$232$$$O	and$$$233$$$236$$$O	preventing$$$237$$$247$$$O	dysmenorrheal,$$$248$$$262$$$O	treating$$$263$$$271$$$O	and$$$272$$$275$$$O	preventing$$$276$$$286$$$O	hypertension,$$$287$$$300$$$O	treating$$$301$$$309$$$O	and$$$310$$$313$$$O	preventing$$$314$$$324$$$O	atherosclerosis,$$$325$$$341$$$O	treating$$$342$$$350$$$O	and$$$351$$$354$$$O	preventing$$$355$$$365$$$O	cerebral$$$366$$$374$$$O	thrombosis$$$375$$$385$$$O	and$$$386$$$389$$$O	the$$$390$$$393$$$O	like$$$394$$$398$$$O	caused$$$399$$$405$$$O	by$$$406$$$408$$$O	cerebral$$$409$$$417$$$O	apoplexy.$$$418$$$427$$$O	The$$$428$$$431$$$O	common$$$432$$$438$$$O	pternopetalum$$$439$$$452$$$O	root$$$453$$$457$$$O	extract$$$458$$$465$$$O	is$$$466$$$468$$$O	safe$$$469$$$473$$$O	and$$$474$$$477$$$O	non-toxic,$$$478$$$488$$$O	and$$$489$$$492$$$O	strong$$$493$$$499$$$O	in$$$500$$$502$$$O	pharmacologic$$$503$$$516$$$O	action,$$$517$$$524$$$O	and$$$525$$$528$$$O	heralds$$$529$$$536$$$O	a$$$537$$$538$$$O	good$$$539$$$543$$$O	medicinal$$$544$$$553$$$O	prospect;$$$554$$$563$$$O	meanwhile,$$$564$$$574$$$O	the$$$575$$$578$$$O	common$$$579$$$585$$$O	pternopetalum$$$586$$$599$$$O	root$$$600$$$604$$$O	extract$$$605$$$612$$$O	is$$$613$$$615$$$O	simple$$$616$$$622$$$O	in$$$623$$$625$$$O	preparation$$$626$$$637$$$O	process,$$$638$$$646$$$O	and$$$647$$$650$$$O	can$$$651$$$654$$$O	be$$$655$$$657$$$O	prepared$$$658$$$666$$$O	into$$$667$$$671$$$O	capsules,$$$672$$$681$$$O	tablets,$$$682$$$690$$$O	cream$$$691$$$696$$$O	and$$$697$$$700$$$O	oiling$$$701$$$707$$$O	agents$$$708$$$714$$$O	to$$$715$$$717$$$O	be$$$718$$$720$$$O	taken$$$721$$$726$$$O	orally$$$727$$$733$$$O	or$$$734$$$736$$$O	used$$$737$$$741$$$O	externally.$$$742$$$753$$$O
CN101003539A
Trometamol$$$0$$$10$$$I	salt$$$11$$$15$$$I	in$$$16$$$18$$$O	compound$$$19$$$27$$$O	of$$$28$$$30$$$O	cillin$$$31$$$37$$$I	category,$$$38$$$47$$$O	and$$$48$$$51$$$O	preparation$$$52$$$63$$$O	method$$$64$$$70$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	discloses$$$15$$$24$$$O	trometamol$$$25$$$35$$$I	salts$$$36$$$41$$$I	of$$$42$$$44$$$O	cillin$$$45$$$51$$$I	compounds,$$$52$$$62$$$O	or$$$63$$$65$$$O	their$$$66$$$71$$$O	hydrates$$$72$$$80$$$O	that$$$81$$$85$$$O	can$$$86$$$89$$$O	be$$$90$$$92$$$O	used$$$93$$$97$$$O	to$$$98$$$100$$$O	treat$$$101$$$106$$$O	bacillosis.$$$107$$$118$$$O	As$$$119$$$121$$$O	hown$$$122$$$126$$$O	in$$$127$$$129$$$O	formula$$$130$$$137$$$O	1,$$$138$$$140$$$O	the$$$141$$$144$$$O	salts$$$145$$$150$$$O	comprise$$$151$$$159$$$O	trometamol$$$160$$$170$$$I	salts$$$171$$$176$$$I	of$$$177$$$179$$$O	azlocillin,$$$180$$$191$$$I	amoxicillin,$$$192$$$204$$$I	ampicillin,$$$205$$$216$$$I	oxazacillin,$$$217$$$229$$$I	furbucillin,$$$230$$$242$$$I	cloxacillin,$$$243$$$255$$$I	mezlocillin,$$$256$$$268$$$I	mecillinam,$$$269$$$280$$$I	piperacillin,$$$281$$$294$$$I	ticarcillin,$$$295$$$307$$$I	floxacillin,$$$308$$$320$$$I	hetacillin,$$$321$$$332$$$I	cloxacillin$$$333$$$344$$$I	and$$$345$$$348$$$O	penicillin.$$$349$$$360$$$I	This$$$361$$$365$$$O	invention$$$366$$$375$$$O	provides$$$376$$$384$$$O	drug$$$385$$$389$$$O	compositions$$$390$$$402$$$O	with$$$403$$$407$$$O	the$$$408$$$411$$$O	salts$$$412$$$417$$$O	shown$$$418$$$423$$$O	in$$$424$$$426$$$O	formula$$$427$$$434$$$O	1$$$435$$$436$$$O	as$$$437$$$439$$$O	the$$$440$$$443$$$O	active$$$444$$$450$$$O	components,$$$451$$$462$$$O	and$$$463$$$466$$$O	their$$$467$$$472$$$O	application$$$473$$$484$$$O	in$$$485$$$487$$$O	drugs$$$488$$$493$$$O	for$$$494$$$497$$$O	treating$$$498$$$506$$$O	bacillosis.$$$507$$$518$$$O
CN102626441A
Antipyrotic$$$0$$$11$$$O	powder$$$12$$$18$$$O	for$$$19$$$22$$$O	external$$$23$$$31$$$O	use$$$32$$$35$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	antipyrotic$$$28$$$39$$$O	powder$$$40$$$46$$$O	for$$$47$$$50$$$O	external$$$51$$$59$$$O	use.$$$60$$$64$$$O	The$$$65$$$68$$$O	antipyrotic$$$69$$$80$$$O	powder$$$81$$$87$$$O	is$$$88$$$90$$$O	characterized$$$91$$$104$$$O	by$$$105$$$107$$$O	comprising$$$108$$$118$$$O	phellodendron,$$$119$$$133$$$O	radix$$$134$$$139$$$O	sophorae$$$140$$$148$$$O	flavescentis,$$$149$$$162$$$O	borneol,$$$163$$$171$$$I	scorpio,$$$172$$$180$$$O	alum$$$181$$$185$$$O	and$$$186$$$189$$$O	Senecio$$$190$$$197$$$O	scandens$$$198$$$206$$$O	with$$$207$$$211$$$O	auxiliary$$$212$$$221$$$O	materials$$$222$$$231$$$O	including$$$232$$$241$$$O	tea$$$242$$$245$$$O	oil$$$246$$$249$$$O	and$$$250$$$253$$$O	pig$$$254$$$257$$$O	bile.$$$258$$$263$$$O	A$$$264$$$265$$$O	preparation$$$266$$$277$$$O	method$$$278$$$284$$$O	of$$$285$$$287$$$O	the$$$288$$$291$$$O	antipyrotic$$$292$$$303$$$O	powder$$$304$$$310$$$O	comprises$$$311$$$320$$$O	the$$$321$$$324$$$O	following$$$325$$$334$$$O	steps$$$335$$$340$$$O	of:$$$341$$$344$$$O	weighing$$$345$$$353$$$O	the$$$354$$$357$$$O	above$$$358$$$363$$$O	various$$$364$$$371$$$O	raw$$$372$$$375$$$O	materials$$$376$$$385$$$O	according$$$386$$$395$$$O	to$$$396$$$398$$$O	a$$$399$$$400$$$O	weight$$$401$$$407$$$O	ratio,$$$408$$$414$$$O	placing$$$415$$$422$$$O	into$$$423$$$427$$$O	a$$$428$$$429$$$O	pulverizer,$$$430$$$441$$$O	stirring$$$442$$$450$$$O	and$$$451$$$454$$$O	crushing,$$$455$$$464$$$O	sieving$$$465$$$472$$$O	through$$$473$$$480$$$O	a$$$481$$$482$$$O	sieve$$$483$$$488$$$O	of$$$489$$$491$$$O	6$$$492$$$493$$$O	meshes$$$494$$$500$$$O	to$$$501$$$503$$$O	obtain$$$504$$$510$$$O	a$$$511$$$512$$$O	yellow$$$513$$$519$$$O	powder,$$$520$$$527$$$O	and$$$528$$$531$$$O	packing$$$532$$$539$$$O	by$$$540$$$542$$$O	the$$$543$$$546$$$O	use$$$547$$$550$$$O	of$$$551$$$553$$$O	aluminium$$$554$$$563$$$I	foil$$$564$$$568$$$O	with$$$569$$$573$$$O	5g$$$574$$$576$$$O	per$$$577$$$580$$$O	pack.$$$581$$$586$$$O	The$$$587$$$590$$$O	invention$$$591$$$600$$$O	has$$$601$$$604$$$O	the$$$605$$$608$$$O	following$$$609$$$618$$$O	significant$$$619$$$630$$$O	effects:$$$631$$$639$$$O	drug$$$640$$$644$$$O	properties$$$645$$$655$$$O	are$$$656$$$659$$$O	mild;$$$660$$$665$$$O	there$$$666$$$671$$$O	is$$$672$$$674$$$O	no$$$675$$$677$$$O	side$$$678$$$682$$$O	effect;$$$683$$$690$$$O	the$$$691$$$694$$$O	treatment$$$695$$$704$$$O	cost$$$705$$$709$$$O	is$$$710$$$712$$$O	low;$$$713$$$717$$$O	the$$$718$$$721$$$O	curative$$$722$$$730$$$O	effect$$$731$$$737$$$O	is$$$738$$$740$$$O	fast$$$741$$$745$$$O	with$$$746$$$750$$$O	no$$$751$$$753$$$O	ache;$$$754$$$759$$$O	and$$$760$$$763$$$O	the$$$764$$$767$$$O	total$$$768$$$773$$$O	efficiency$$$774$$$784$$$O	is$$$785$$$787$$$O	about$$$788$$$793$$$O	more$$$794$$$798$$$O	than$$$799$$$803$$$O	90%.$$$804$$$808$$$O
CN1923803A
Arginine$$$0$$$8$$$O	rosmarinate,$$$9$$$21$$$O	preparation$$$22$$$33$$$O	method,$$$34$$$41$$$O	pharmaceutical$$$42$$$56$$$O	composition$$$57$$$68$$$O	and$$$69$$$72$$$O	use$$$73$$$76$$$O	thereof$$$77$$$84$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	rosmarinic$$$26$$$36$$$O	acid$$$37$$$41$$$O	arginine$$$42$$$50$$$O	salt$$$51$$$55$$$O	and$$$56$$$59$$$O	preparing$$$60$$$69$$$O	method$$$70$$$76$$$O	and$$$77$$$80$$$O	drug$$$81$$$85$$$O	combination$$$86$$$97$$$O	as$$$98$$$100$$$O	well$$$101$$$105$$$O	as$$$106$$$108$$$O	application$$$109$$$120$$$O	in$$$121$$$123$$$O	the$$$124$$$127$$$O	cardiovascular$$$128$$$142$$$O	disease$$$143$$$150$$$O	treatment$$$151$$$160$$$O	or$$$161$$$163$$$O	prevention$$$164$$$174$$$O	drug.$$$175$$$180$$$O
CN101037415A
S-DABO$$$0$$$6$$$I	compound,$$$7$$$16$$$O	synthesizing$$$17$$$29$$$O	method$$$30$$$36$$$O	and$$$37$$$40$$$O	usage$$$41$$$46$$$O
S-DABO$$$0$$$6$$$I	composition$$$7$$$18$$$O	and$$$19$$$22$$$O	its$$$23$$$26$$$O	synthesis$$$27$$$36$$$O	method$$$37$$$43$$$O	and$$$44$$$47$$$O	function$$$48$$$56$$$O	belong$$$57$$$63$$$O	to$$$64$$$66$$$O	medicine$$$67$$$75$$$O	technical$$$76$$$85$$$O	medicine.$$$86$$$95$$$O	The$$$96$$$99$$$O	invention$$$100$$$109$$$O	relates$$$110$$$117$$$O	to$$$118$$$120$$$O	a$$$121$$$122$$$O	5-alkyl-6-phenyl-2-(substituted$$$123$$$154$$$I	arylcarbonylmethylsulfur)uracil$$$155$$$186$$$I	composition,$$$187$$$199$$$O	having$$$200$$$206$$$O	following$$$207$$$216$$$O	general$$$217$$$224$$$O	formula:$$$225$$$233$$$O	wherein,$$$234$$$242$$$O	R1$$$243$$$245$$$O	is$$$246$$$248$$$O	C1-3$$$249$$$253$$$I	alkyl;$$$254$$$260$$$I	R2=C1-6$$$261$$$268$$$I	alkyl,$$$269$$$275$$$I	substituted$$$276$$$287$$$O	furan$$$288$$$293$$$I	ring,$$$294$$$299$$$O	thiofuran$$$300$$$309$$$I	ring,$$$310$$$315$$$O	benzene$$$316$$$323$$$I	ring$$$324$$$328$$$O	(substituent$$$329$$$341$$$O	on$$$342$$$344$$$O	the$$$345$$$348$$$O	benzene$$$349$$$356$$$I	ring$$$357$$$361$$$O	is$$$362$$$364$$$O	H,$$$365$$$367$$$I	OH,$$$368$$$371$$$I	Cl3$$$372$$$375$$$I	alkoxy),$$$376$$$384$$$I	having$$$385$$$391$$$O	the$$$392$$$395$$$O	5-alkyl-6-phenylthiouracil$$$396$$$422$$$I	as$$$423$$$425$$$O	reagent,$$$426$$$434$$$O	reacting$$$435$$$443$$$O	with$$$444$$$448$$$O	alpha-halogen$$$449$$$462$$$I	ketone$$$463$$$469$$$I	to$$$470$$$472$$$O	get$$$473$$$476$$$O	the$$$477$$$480$$$O	inventive$$$481$$$490$$$O	product$$$491$$$498$$$O	which$$$499$$$504$$$O	is$$$505$$$507$$$O	catalyzed$$$508$$$517$$$O	by$$$518$$$520$$$O	K2CO3.$$$521$$$527$$$I	The$$$528$$$531$$$O	synthesis$$$532$$$541$$$O	method$$$542$$$548$$$O	is$$$549$$$551$$$O	easy$$$552$$$556$$$O	to$$$557$$$559$$$O	operate.$$$560$$$568$$$O	The$$$569$$$572$$$O	product$$$573$$$580$$$O	has$$$581$$$584$$$O	an$$$585$$$587$$$O	obvious$$$588$$$595$$$O	anti-HIV$$$596$$$604$$$O	virus$$$605$$$610$$$O	activity,$$$611$$$620$$$O	a$$$621$$$622$$$O	low$$$623$$$626$$$O	toxicity,$$$627$$$636$$$O	a$$$637$$$638$$$O	high$$$639$$$643$$$O	selectivity$$$644$$$655$$$O	index$$$656$$$661$$$O	and$$$662$$$665$$$O	can$$$666$$$669$$$O	be$$$670$$$672$$$O	an$$$673$$$675$$$O	anti-HIV$$$676$$$684$$$O	medicine$$$685$$$693$$$O	candidate.$$$694$$$704$$$O
CN102161655A
Apigenin$$$0$$$8$$$I	derivatives$$$9$$$20$$$O	and$$$21$$$24$$$O	preparation$$$25$$$36$$$O	method$$$37$$$43$$$O	and$$$44$$$47$$$O	applications$$$48$$$60$$$O	thereof$$$61$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	apigenin$$$23$$$31$$$I	derivatives$$$32$$$43$$$O	shown$$$44$$$49$$$O	in$$$50$$$52$$$O	the$$$53$$$56$$$O	structural$$$57$$$67$$$O	formula$$$68$$$75$$$O	1$$$76$$$77$$$O	and$$$78$$$81$$$O	a$$$82$$$83$$$O	preparation$$$84$$$95$$$O	method$$$96$$$102$$$O	and$$$103$$$106$$$O	applications$$$107$$$119$$$O	thereof.$$$120$$$128$$$O	The$$$129$$$132$$$O	compounds$$$133$$$142$$$O	have$$$143$$$147$$$O	good$$$148$$$152$$$O	inhibitory$$$153$$$163$$$O	activities$$$164$$$174$$$O	to$$$175$$$177$$$O	Hela$$$178$$$182$$$O	cells,$$$183$$$189$$$O	CAOV3$$$190$$$195$$$O	cells$$$196$$$201$$$O	and$$$202$$$205$$$O	the$$$206$$$209$$$O	like$$$210$$$214$$$O	and$$$215$$$218$$$O	can$$$219$$$222$$$O	be$$$223$$$225$$$O	used$$$226$$$230$$$O	to$$$231$$$233$$$O	cure$$$234$$$238$$$O	female$$$239$$$245$$$O	reproductive$$$246$$$258$$$O	tract$$$259$$$264$$$O	cancers$$$265$$$272$$$O	such$$$273$$$277$$$O	as$$$278$$$280$$$O	cervical$$$281$$$289$$$O	cancer$$$290$$$296$$$O	and$$$297$$$300$$$O	ovarian$$$301$$$308$$$O	cancer.$$$309$$$316$$$O
US6949259
Solid$$$0$$$5$$$O	preparations$$$6$$$18$$$O	for$$$19$$$22$$$O	oral$$$23$$$27$$$O	use$$$28$$$31$$$O
Solid$$$0$$$5$$$O	preparations$$$6$$$18$$$O	for$$$19$$$22$$$O	oral$$$23$$$27$$$O	use$$$28$$$31$$$O	for$$$32$$$35$$$O	facilitating$$$36$$$48$$$O	the$$$49$$$52$$$O	administration$$$53$$$67$$$O	in$$$68$$$70$$$O	a$$$71$$$72$$$O	small$$$73$$$78$$$O	dose$$$79$$$83$$$O	of$$$84$$$86$$$O	KRP-297,$$$87$$$95$$$I	which$$$96$$$101$$$O	is$$$102$$$104$$$O	a$$$105$$$106$$$O	ligand$$$107$$$113$$$O	common$$$114$$$120$$$O	to$$$121$$$123$$$O	peroxisome$$$124$$$134$$$O	proliferator-activated$$$135$$$157$$$O	receptors$$$158$$$167$$$O	PPAR$$$168$$$172$$$O	Î±$$$173$$$175$$$O	and$$$176$$$179$$$O	PPAR$$$180$$$184$$$O	Î³$$$185$$$187$$$O	(i.e.,$$$188$$$194$$$O	nuclear$$$195$$$202$$$O	receptors)$$$203$$$213$$$O	and$$$214$$$217$$$O	has$$$218$$$221$$$O	an$$$222$$$224$$$O	effect$$$225$$$231$$$O	of$$$232$$$234$$$O	ameliorating$$$235$$$247$$$O	insulin$$$248$$$255$$$O	resistance,$$$256$$$267$$$O	which$$$268$$$273$$$O	contain$$$274$$$281$$$O	the$$$282$$$285$$$O	drug$$$286$$$290$$$O	ingredient$$$291$$$301$$$O	in$$$302$$$304$$$O	a$$$305$$$306$$$O	uniform$$$307$$$314$$$O	content$$$315$$$322$$$O	and$$$323$$$326$$$O	can$$$327$$$330$$$O	be$$$331$$$333$$$O	easily$$$334$$$340$$$O	and$$$341$$$344$$$O	quantitatively$$$345$$$359$$$O	taken.$$$360$$$366$$$O	By$$$367$$$369$$$O	preparing$$$370$$$379$$$O	solid$$$380$$$385$$$O	preparations$$$386$$$398$$$O	for$$$399$$$402$$$O	oral$$$403$$$407$$$O	use$$$408$$$411$$$O	composed$$$412$$$420$$$O	of$$$421$$$423$$$O	a$$$424$$$425$$$O	trace$$$426$$$431$$$O	amount$$$432$$$438$$$O	of$$$439$$$441$$$O	the$$$442$$$445$$$O	drug$$$446$$$450$$$O	ingredient$$$451$$$461$$$O	together$$$462$$$470$$$O	with$$$471$$$475$$$O	pharmaceutical$$$476$$$490$$$O	carriers,$$$491$$$500$$$O	it$$$501$$$503$$$O	is$$$504$$$506$$$O	possible$$$507$$$515$$$O	to$$$516$$$518$$$O	provide$$$519$$$526$$$O	tablets$$$527$$$534$$$O	which$$$535$$$540$$$O	contain$$$541$$$548$$$O	the$$$549$$$552$$$O	drug$$$553$$$557$$$O	component$$$558$$$567$$$O	in$$$568$$$570$$$O	a$$$571$$$572$$$O	uniform$$$573$$$580$$$O	content$$$581$$$588$$$O	and$$$589$$$592$$$O	can$$$593$$$596$$$O	be$$$597$$$599$$$O	easily$$$600$$$606$$$O	and$$$607$$$610$$$O	quantitatively$$$611$$$625$$$O	taken.$$$626$$$632$$$O
WO2011151551A1
Xenon-based$$$0$$$11$$$O	inhalable$$$12$$$21$$$O	drug$$$22$$$26$$$O	for$$$27$$$30$$$O	preventing$$$31$$$41$$$O	addiction$$$42$$$51$$$O	relapses$$$52$$$60$$$O	in$$$61$$$63$$$O	humans$$$64$$$70$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	gas$$$27$$$30$$$O	composition$$$31$$$42$$$O	containing$$$43$$$53$$$O	xenon$$$54$$$59$$$I	gas$$$60$$$63$$$I	for$$$64$$$67$$$O	use$$$68$$$71$$$O	in$$$72$$$74$$$O	preventing$$$75$$$85$$$O	the$$$86$$$89$$$O	relapse$$$90$$$97$$$O	of$$$98$$$100$$$O	a$$$101$$$102$$$O	patient$$$103$$$110$$$O	who$$$111$$$114$$$O	has$$$115$$$118$$$O	been$$$119$$$123$$$O	weaned$$$124$$$130$$$O	from$$$131$$$135$$$O	at$$$136$$$138$$$O	least$$$139$$$144$$$O	one$$$145$$$148$$$O	psychotropic$$$149$$$161$$$O	product$$$162$$$169$$$O	which$$$170$$$175$$$O	resulted$$$176$$$184$$$O	in$$$185$$$187$$$O	said$$$188$$$192$$$O	patient$$$193$$$200$$$O	becoming$$$201$$$209$$$O	habituated,$$$210$$$221$$$O	the$$$222$$$225$$$O	xenon$$$226$$$231$$$I	being$$$232$$$237$$$O	administered$$$238$$$250$$$O	to$$$251$$$253$$$O	the$$$254$$$257$$$O	patient$$$258$$$265$$$O	by$$$266$$$268$$$O	inhalation.$$$269$$$280$$$O	The$$$281$$$284$$$O	composition$$$285$$$296$$$O	of$$$297$$$299$$$O	the$$$300$$$303$$$O	invention$$$304$$$313$$$O	contains$$$314$$$322$$$O	an$$$323$$$325$$$O	effective$$$326$$$335$$$O	volume$$$336$$$342$$$O	proportion$$$343$$$353$$$O	of$$$354$$$356$$$O	xenon,$$$357$$$363$$$I	in$$$364$$$366$$$O	particular$$$367$$$377$$$O	from$$$378$$$382$$$O	5$$$383$$$384$$$O	to$$$385$$$387$$$O	70%$$$388$$$391$$$O	by$$$392$$$394$$$O	volume$$$395$$$401$$$O	of$$$402$$$404$$$O	xenon.$$$405$$$411$$$I	DRAWING:$$$412$$$420$$$O	FIG.$$$421$$$425$$$O	5:$$$426$$$428$$$O	Nombres$$$429$$$436$$$O	de$$$437$$$439$$$O	pression$$$440$$$448$$$O	sur$$$449$$$452$$$O	le$$$453$$$455$$$O	levier/session$$$456$$$470$$$O	Number$$$471$$$477$$$O	of$$$478$$$480$$$O	presses$$$481$$$488$$$O	on$$$489$$$491$$$O	the$$$492$$$495$$$O	lever/session$$$496$$$509$$$O	Levier$$$510$$$516$$$O	respectif$$$517$$$526$$$O	inactif$$$527$$$534$$$O	Respective$$$535$$$545$$$O	inactive$$$546$$$554$$$O	lever$$$555$$$560$$$O	rechute$$$561$$$568$$$O	relapse$$$569$$$576$$$O
WO2011120040A2
Thrombin$$$0$$$8$$$O	inhibiting$$$9$$$19$$$O	compositions$$$20$$$32$$$O
Novel$$$0$$$5$$$O	compounds$$$6$$$15$$$O	and$$$16$$$19$$$O	methods$$$20$$$27$$$O	of$$$28$$$30$$$O	treating$$$31$$$39$$$O	or$$$40$$$42$$$O	preventing$$$43$$$53$$$O	thrombosis$$$54$$$64$$$O	or$$$65$$$67$$$O	a$$$68$$$69$$$O	thrombosis-associated$$$70$$$91$$$O	disease.$$$92$$$100$$$O
CA2548379C
Compositions$$$0$$$12$$$O	of$$$13$$$15$$$O	galactomannan$$$16$$$29$$$O	for$$$30$$$33$$$O	the$$$34$$$37$$$O	treatment$$$38$$$47$$$O	of$$$48$$$50$$$O	bowel$$$51$$$56$$$O	diseases$$$57$$$65$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	composition$$$35$$$46$$$O	for$$$47$$$50$$$O	preventing,$$$51$$$62$$$O	ameliorating$$$63$$$75$$$O	or$$$76$$$78$$$O	treating$$$79$$$87$$$O	a$$$88$$$89$$$O	bowel$$$90$$$95$$$O	disease,$$$96$$$104$$$O	comprising$$$105$$$115$$$O	galactomannan$$$116$$$129$$$O	and/or$$$130$$$136$$$O	arabinogalactan;$$$137$$$153$$$O	a$$$154$$$155$$$O	liquid$$$156$$$162$$$O	food$$$163$$$167$$$O	for$$$168$$$171$$$O	preventing,$$$172$$$183$$$O	ameliorating$$$184$$$196$$$O	or$$$197$$$199$$$O	treating$$$200$$$208$$$O	a$$$209$$$210$$$O	bowel$$$211$$$216$$$O	disease,$$$217$$$225$$$O	characterized$$$226$$$239$$$O	in$$$240$$$242$$$O	that$$$243$$$247$$$O	the$$$248$$$251$$$O	liquid$$$252$$$258$$$O	food$$$259$$$263$$$O	comprises$$$264$$$273$$$O	a$$$274$$$275$$$O	protein$$$276$$$283$$$O	and$$$284$$$287$$$O	galactomannan$$$288$$$301$$$O	and/or$$$302$$$308$$$O	arabinogalactan;$$$309$$$325$$$I	and$$$326$$$329$$$O	a$$$330$$$331$$$O	composition$$$332$$$343$$$O	for$$$344$$$347$$$O	preventing,$$$348$$$359$$$O	ameliorating$$$360$$$372$$$O	or$$$373$$$375$$$O	treating$$$376$$$384$$$O	an$$$385$$$387$$$O	irritable$$$388$$$397$$$O	bowel$$$398$$$403$$$O	syndrome,$$$404$$$413$$$O	comprising$$$414$$$424$$$O	degraded$$$425$$$433$$$O	galactomannan.$$$434$$$448$$$O
WO2010123766A1
DIAMIDE$$$0$$$7$$$I	COMPOUNDS$$$8$$$17$$$O	HAVING$$$18$$$24$$$O	MUSCARINIC$$$25$$$35$$$O	RECEPTOR$$$36$$$44$$$O	ANTAGONIST$$$45$$$55$$$O	AND$$$56$$$59$$$O	Î²2$$$60$$$63$$$O	ADRENERGIC$$$64$$$74$$$O	RECEPTOR$$$75$$$83$$$O	AGONIST$$$84$$$91$$$O	ACTIVITY$$$92$$$100$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	compound$$$28$$$36$$$O	of$$$37$$$39$$$O	formula$$$40$$$47$$$O	I;$$$48$$$50$$$O	or$$$51$$$53$$$O	a$$$54$$$55$$$O	pharmaceutically$$$56$$$72$$$O	acceptable$$$73$$$83$$$O	salt$$$84$$$88$$$O	thereof.$$$89$$$97$$$O	Such$$$98$$$102$$$O	compounds$$$103$$$112$$$O	possess$$$113$$$120$$$O	both$$$121$$$125$$$O	muscarinic$$$126$$$136$$$O	receptor$$$137$$$145$$$O	antagonist$$$146$$$156$$$O	and$$$157$$$160$$$O	Î²2$$$161$$$164$$$O	adrenergic$$$165$$$175$$$O	receptor$$$176$$$184$$$O	agonist$$$185$$$192$$$O	activities.$$$193$$$204$$$O	The$$$205$$$208$$$O	invention$$$209$$$218$$$O	also$$$219$$$223$$$O	relates$$$224$$$231$$$O	to$$$232$$$234$$$O	pharmaceutical$$$235$$$249$$$O	compositions$$$250$$$262$$$O	comprising$$$263$$$273$$$O	such$$$274$$$278$$$O	compounds,$$$279$$$289$$$O	processes$$$290$$$299$$$O	and$$$300$$$303$$$O	intermediates$$$304$$$317$$$O	for$$$318$$$321$$$O	preparing$$$322$$$331$$$O	such$$$332$$$336$$$O	compounds,$$$337$$$347$$$O	and$$$348$$$351$$$O	methods$$$352$$$359$$$O	of$$$360$$$362$$$O	using$$$363$$$368$$$O	such$$$369$$$373$$$O	compounds$$$374$$$383$$$O	as$$$384$$$386$$$O	bronchodilating$$$387$$$402$$$O	agents$$$403$$$409$$$O	to$$$410$$$412$$$O	treat$$$413$$$418$$$O	pulmonary$$$419$$$428$$$O	disorders.$$$429$$$439$$$O
CN102836147A
Paclitaxel-entrapped$$$0$$$20$$$I	biodegradable$$$21$$$34$$$O	nanocomposite$$$35$$$48$$$O	and$$$49$$$52$$$O	preparation$$$53$$$64$$$O	method$$$65$$$71$$$O	thereof$$$72$$$79$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	biological$$$48$$$58$$$O	medicines$$$59$$$68$$$O	and$$$69$$$72$$$O	relates$$$73$$$80$$$O	to$$$81$$$83$$$O	a$$$84$$$85$$$O	paclitaxel-entrapped$$$86$$$106$$$I	biodegradable$$$107$$$120$$$O	nanocomposite$$$121$$$134$$$O	and$$$135$$$138$$$O	a$$$139$$$140$$$O	preparation$$$141$$$152$$$O	method$$$153$$$159$$$O	thereof.$$$160$$$168$$$O	A$$$169$$$170$$$O	paclitaxel$$$171$$$181$$$I	polyethylene$$$182$$$194$$$I	glycol-poly$$$195$$$206$$$I	trimethylene$$$207$$$219$$$I	carbonate$$$220$$$229$$$I	(PEG-PTMC)$$$230$$$240$$$I	nanocomposite$$$241$$$254$$$O	is$$$255$$$257$$$O	prepared$$$258$$$266$$$O	by$$$267$$$269$$$O	adopting$$$270$$$278$$$O	an$$$279$$$281$$$O	emulsification/solvent$$$282$$$304$$$O	evaporation$$$305$$$316$$$O	method,$$$317$$$324$$$O	and$$$325$$$328$$$O	by$$$329$$$331$$$O	taking$$$332$$$338$$$O	a$$$339$$$340$$$O	PEG-PTMC$$$341$$$349$$$I	copolymer$$$350$$$359$$$O	as$$$360$$$362$$$O	a$$$363$$$364$$$O	carrier,$$$365$$$373$$$O	paclitaxel$$$374$$$384$$$I	is$$$385$$$387$$$O	entrapped$$$388$$$397$$$O	in$$$398$$$400$$$O	a$$$401$$$402$$$O	hydrophobic$$$403$$$414$$$O	core$$$415$$$419$$$O	of$$$420$$$422$$$O	PTMC.$$$423$$$428$$$I	The$$$429$$$432$$$O	solubility$$$433$$$443$$$O	of$$$444$$$446$$$O	the$$$447$$$450$$$O	paclitaxel$$$451$$$461$$$I	can$$$462$$$465$$$O	be$$$466$$$468$$$O	effectively$$$469$$$480$$$O	increased$$$481$$$490$$$O	by$$$491$$$493$$$O	the$$$494$$$497$$$O	prepared$$$498$$$506$$$O	paclitaxel$$$507$$$517$$$I	PEG-PTMC$$$518$$$526$$$I	nanocomposite,$$$527$$$541$$$O	and$$$542$$$545$$$O	a$$$546$$$547$$$O	PEG$$$548$$$551$$$I	long$$$552$$$556$$$O	chain$$$557$$$562$$$O	of$$$563$$$565$$$O	a$$$566$$$567$$$O	carrier$$$568$$$575$$$O	material$$$576$$$584$$$O	can$$$585$$$588$$$O	take$$$589$$$593$$$O	effect$$$594$$$600$$$O	of$$$601$$$603$$$O	invisibility,$$$604$$$617$$$O	and$$$618$$$621$$$O	thereby,$$$622$$$630$$$O	the$$$631$$$634$$$O	phagocytosis$$$635$$$647$$$O	of$$$648$$$650$$$O	an$$$651$$$653$$$O	in-vivo$$$654$$$661$$$O	reticulo-endothelial$$$662$$$682$$$O	system$$$683$$$689$$$O	is$$$690$$$692$$$O	avoided.$$$693$$$701$$$O	The$$$702$$$705$$$O	nanocomposite$$$706$$$719$$$O	has$$$720$$$723$$$O	a$$$724$$$725$$$O	long$$$726$$$730$$$O	circulation$$$731$$$742$$$O	effect,$$$743$$$750$$$O	and$$$751$$$754$$$O	the$$$755$$$758$$$O	half-life$$$759$$$768$$$O	period$$$769$$$775$$$O	of$$$776$$$778$$$O	the$$$779$$$782$$$O	nanocomposite$$$783$$$796$$$O	in$$$797$$$799$$$O	blood$$$800$$$805$$$O	can$$$806$$$809$$$O	be$$$810$$$812$$$O	prolonged.$$$813$$$823$$$O	Moreover,$$$824$$$833$$$O	through$$$834$$$841$$$O	controlling$$$842$$$853$$$O	the$$$854$$$857$$$O	grain$$$858$$$863$$$O	size$$$864$$$868$$$O	of$$$869$$$871$$$O	the$$$872$$$875$$$O	nanocomposite,$$$876$$$890$$$O	a$$$891$$$892$$$O	passive$$$893$$$900$$$O	targeting$$$901$$$910$$$O	effect$$$911$$$917$$$O	on$$$918$$$920$$$O	a$$$921$$$922$$$O	tumor$$$923$$$928$$$O	tissue$$$929$$$935$$$O	is$$$936$$$938$$$O	realized,$$$939$$$948$$$O	and$$$949$$$952$$$O	thereby,$$$953$$$961$$$O	a$$$962$$$963$$$O	treatment$$$964$$$973$$$O	effect$$$974$$$980$$$O	is$$$981$$$983$$$O	improved.$$$984$$$993$$$O	As$$$994$$$996$$$O	the$$$997$$$1000$$$O	nanocomposite$$$1001$$$1014$$$O	does$$$1015$$$1019$$$O	not$$$1020$$$1023$$$O	contain$$$1024$$$1031$$$O	Cremophor$$$1032$$$1041$$$O	El$$$1042$$$1044$$$O	or$$$1045$$$1047$$$O	ethanol,$$$1048$$$1056$$$I	compared$$$1057$$$1065$$$O	with$$$1066$$$1070$$$O	commercially$$$1071$$$1083$$$O	available$$$1084$$$1093$$$O	paclitaxel$$$1094$$$1104$$$I	injections,$$$1105$$$1116$$$O	the$$$1117$$$1120$$$O	toxic$$$1121$$$1126$$$O	and$$$1127$$$1130$$$O	side$$$1131$$$1135$$$O	effects$$$1136$$$1143$$$O	of$$$1144$$$1146$$$O	the$$$1147$$$1150$$$O	nanocomposite$$$1151$$$1164$$$O	can$$$1165$$$1168$$$O	be$$$1169$$$1171$$$O	reduced,$$$1172$$$1180$$$O	and$$$1181$$$1184$$$O	the$$$1185$$$1188$$$O	safety$$$1189$$$1195$$$O	of$$$1196$$$1198$$$O	the$$$1199$$$1202$$$O	nanocomposite$$$1203$$$1216$$$O	in$$$1217$$$1219$$$O	clinical$$$1220$$$1228$$$O	application$$$1229$$$1240$$$O	is$$$1241$$$1243$$$O	enhanced.$$$1244$$$1253$$$O
EP1370684B1
Polynucleotides$$$0$$$15$$$O	related$$$16$$$23$$$O	to$$$24$$$26$$$O	colon$$$27$$$32$$$O	cancer$$$33$$$39$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	based$$$25$$$30$$$O	on$$$31$$$33$$$O	the$$$34$$$37$$$O	discovery$$$38$$$47$$$O	of$$$48$$$50$$$O	polynucleotides$$$51$$$66$$$O	that$$$67$$$71$$$O	represent$$$72$$$81$$$O	genes$$$82$$$87$$$O	that$$$88$$$92$$$O	are$$$93$$$96$$$O	differentially$$$97$$$111$$$O	expressed$$$112$$$121$$$O	in$$$122$$$124$$$O	colon$$$125$$$130$$$O	cancer,$$$131$$$138$$$O	e.g.,$$$139$$$144$$$O	adenomatous$$$145$$$156$$$O	polyp,$$$157$$$163$$$O	colorectal$$$164$$$174$$$O	carcinoma,$$$175$$$185$$$O	high$$$186$$$190$$$O	metastatic$$$191$$$201$$$O	potential$$$202$$$211$$$O	colon$$$212$$$217$$$O	tumor$$$218$$$223$$$O	and$$$224$$$227$$$O	metastatic$$$228$$$238$$$O	colon$$$239$$$244$$$O	cancer.$$$245$$$252$$$O	The$$$253$$$256$$$O	invention$$$257$$$266$$$O	features$$$267$$$275$$$O	methods$$$276$$$283$$$O	of$$$284$$$286$$$O	identifying$$$287$$$298$$$O	cells$$$299$$$304$$$O	affected$$$305$$$313$$$O	by$$$314$$$316$$$O	such$$$317$$$321$$$O	colon$$$322$$$327$$$O	diseases$$$328$$$336$$$O	by$$$337$$$339$$$O	detection$$$340$$$349$$$O	of$$$350$$$352$$$O	a$$$353$$$354$$$O	gene$$$355$$$359$$$O	product$$$360$$$367$$$O	encoded$$$368$$$375$$$O	by$$$376$$$378$$$O	such$$$379$$$383$$$O	differentially$$$384$$$398$$$O	expressed$$$399$$$408$$$O	genes,$$$409$$$415$$$O	as$$$416$$$418$$$O	well$$$419$$$423$$$O	as$$$424$$$426$$$O	method$$$427$$$433$$$O	of$$$434$$$436$$$O	moduloating$$$437$$$448$$$O	expression$$$449$$$459$$$O	of$$$460$$$462$$$O	such$$$463$$$467$$$O	gene$$$468$$$472$$$O	products$$$473$$$481$$$O	to$$$482$$$484$$$O	effect$$$485$$$491$$$O	therapy$$$492$$$499$$$O	(e.g.,$$$500$$$506$$$O	to$$$507$$$509$$$O	decrease$$$510$$$518$$$O	growth$$$519$$$525$$$O	and/or$$$526$$$532$$$O	affect$$$533$$$539$$$O	abnormal$$$540$$$548$$$O	characteristics$$$549$$$564$$$O	of$$$565$$$567$$$O	cancerous$$$568$$$577$$$O	or$$$578$$$580$$$O	displastic$$$581$$$591$$$O	colon$$$592$$$597$$$O	cells).$$$598$$$605$$$O
US8524212
Prophylactic$$$0$$$12$$$O	and/or$$$13$$$19$$$O	therapeutic$$$20$$$31$$$O	drug$$$32$$$36$$$O	for$$$37$$$40$$$O	nonalcoholic$$$41$$$53$$$O	steatohepatitis$$$54$$$69$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	method$$$33$$$39$$$O	for$$$40$$$43$$$O	the$$$44$$$47$$$O	treatment$$$48$$$57$$$O	of$$$58$$$60$$$O	nonalcoholic$$$61$$$73$$$O	steatohepatitis$$$74$$$89$$$O	with$$$90$$$94$$$O	a$$$95$$$96$$$O	pharmaceutically$$$97$$$113$$$O	acceptable$$$114$$$124$$$O	anion$$$125$$$130$$$O	exchange$$$131$$$139$$$O	resin$$$140$$$145$$$O	such$$$146$$$150$$$O	as,$$$151$$$154$$$O	for$$$155$$$158$$$O	example,$$$159$$$167$$$O	colestimide.$$$168$$$180$$$I
CN102949694A
Medicinal$$$0$$$9$$$O	composition$$$10$$$21$$$O	for$$$22$$$25$$$O	oral$$$26$$$30$$$O	hygiene$$$31$$$38$$$O	and$$$39$$$42$$$O	disinfection$$$43$$$55$$$O	and$$$56$$$59$$$O	preparation$$$60$$$71$$$O	method$$$72$$$78$$$O	of$$$79$$$81$$$O	spray$$$82$$$87$$$O	of$$$88$$$90$$$O	the$$$91$$$94$$$O	medicinal$$$95$$$104$$$O	composition$$$105$$$116$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicinal$$$26$$$35$$$O	composition$$$36$$$47$$$O	for$$$48$$$51$$$O	oral$$$52$$$56$$$O	hygiene$$$57$$$64$$$O	and$$$65$$$68$$$O	disinfection$$$69$$$81$$$O	and$$$82$$$85$$$O	a$$$86$$$87$$$O	preparation$$$88$$$99$$$O	method$$$100$$$106$$$O	of$$$107$$$109$$$O	spray$$$110$$$115$$$O	of$$$116$$$118$$$O	the$$$119$$$122$$$O	medicinal$$$123$$$132$$$O	composition.$$$133$$$145$$$O	The$$$146$$$149$$$O	medicinal$$$150$$$159$$$O	composition$$$160$$$171$$$O	contains$$$172$$$180$$$O	the$$$181$$$184$$$O	following$$$185$$$194$$$O	components$$$195$$$205$$$O	in$$$206$$$208$$$O	parts$$$209$$$214$$$O	by$$$215$$$217$$$O	weight:$$$218$$$225$$$O	9$$$226$$$227$$$O	parts$$$228$$$233$$$O	of$$$234$$$236$$$O	ginger$$$237$$$243$$$O	extracting$$$244$$$254$$$O	solution,$$$255$$$264$$$O	40$$$265$$$267$$$O	parts$$$268$$$273$$$O	of$$$274$$$276$$$O	green$$$277$$$282$$$O	tea$$$283$$$286$$$O	concentrated$$$287$$$299$$$O	solution,$$$300$$$309$$$O	9$$$310$$$311$$$O	parts$$$312$$$317$$$O	of$$$318$$$320$$$O	xylitol$$$321$$$328$$$I	and$$$329$$$332$$$O	30$$$333$$$335$$$O	parts$$$336$$$341$$$O	of$$$342$$$344$$$O	ethanol.$$$345$$$353$$$I	According$$$354$$$363$$$O	to$$$364$$$366$$$O	the$$$367$$$370$$$O	invention,$$$371$$$381$$$O	the$$$382$$$385$$$O	medicinal$$$386$$$395$$$O	composition$$$396$$$407$$$O	is$$$408$$$410$$$O	expected$$$411$$$419$$$O	to$$$420$$$422$$$O	reach$$$423$$$428$$$O	the$$$429$$$432$$$O	effects$$$433$$$440$$$O	of$$$441$$$443$$$O	the$$$444$$$447$$$O	oral$$$448$$$452$$$O	hygiene$$$453$$$460$$$O	and$$$461$$$464$$$O	disinfection,$$$465$$$478$$$O	and$$$479$$$482$$$O	is$$$483$$$485$$$O	prepared$$$486$$$494$$$O	by$$$495$$$497$$$O	the$$$498$$$501$$$O	ginger$$$502$$$508$$$O	extracting$$$509$$$519$$$O	solution,$$$520$$$529$$$O	the$$$530$$$533$$$O	green$$$534$$$539$$$O	tea$$$540$$$543$$$O	concentrated$$$544$$$556$$$O	solution,$$$557$$$566$$$O	the$$$567$$$570$$$O	xylitol$$$571$$$578$$$I	and$$$579$$$582$$$O	the$$$583$$$586$$$O	ethanol$$$587$$$594$$$I	as$$$595$$$597$$$O	the$$$598$$$601$$$O	main$$$602$$$606$$$O	raw$$$607$$$610$$$O	materials$$$611$$$620$$$O	based$$$621$$$626$$$O	on$$$627$$$629$$$O	a$$$630$$$631$$$O	scientific$$$632$$$642$$$O	and$$$643$$$646$$$O	reasonable$$$647$$$657$$$O	production$$$658$$$668$$$O	technology.$$$669$$$680$$$O	The$$$681$$$684$$$O	medicinal$$$685$$$694$$$O	composition$$$695$$$706$$$O	is$$$707$$$709$$$O	definite$$$710$$$718$$$O	in$$$719$$$721$$$O	function,$$$722$$$731$$$O	controllable$$$732$$$744$$$O	in$$$745$$$747$$$O	quality$$$748$$$755$$$O	and$$$756$$$759$$$O	safe$$$760$$$764$$$O	to$$$765$$$767$$$O	take.$$$768$$$773$$$O	According$$$774$$$783$$$O	to$$$784$$$786$$$O	the$$$787$$$790$$$O	invention,$$$791$$$801$$$O	the$$$802$$$805$$$O	preparation$$$806$$$817$$$O	method$$$818$$$824$$$O	of$$$825$$$827$$$O	the$$$828$$$831$$$O	medicinal$$$832$$$841$$$O	composition$$$842$$$853$$$O	is$$$854$$$856$$$O	simple,$$$857$$$864$$$O	and$$$865$$$868$$$O	the$$$869$$$872$$$O	preparation$$$873$$$884$$$O	of$$$885$$$887$$$O	the$$$888$$$891$$$O	medicinal$$$892$$$901$$$O	composition$$$902$$$913$$$O	can$$$914$$$917$$$O	be$$$918$$$920$$$O	finished$$$921$$$929$$$O	by$$$930$$$932$$$O	conventional$$$933$$$945$$$O	equipment.$$$946$$$956$$$O
CN1957944A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	yew$$$15$$$18$$$O	amylose$$$19$$$26$$$O	in$$$27$$$29$$$O	pharmacy$$$30$$$38$$$O
An$$$0$$$2$$$O	application$$$3$$$14$$$O	of$$$15$$$17$$$O	the$$$18$$$21$$$O	polyose$$$22$$$29$$$O	extracted$$$30$$$39$$$O	from$$$40$$$44$$$O	enqlish$$$45$$$52$$$O	yew$$$53$$$56$$$O	in$$$57$$$59$$$O	preparing$$$60$$$69$$$O	the$$$70$$$73$$$O	medicines$$$74$$$83$$$O	for$$$84$$$87$$$O	improving$$$88$$$97$$$O	immunity$$$98$$$106$$$O	and$$$107$$$110$$$O	the$$$111$$$114$$$O	tolerance$$$115$$$124$$$O	of$$$125$$$127$$$O	body,$$$128$$$133$$$O	preventing$$$134$$$144$$$O	tumor,$$$145$$$151$$$O	and$$$152$$$155$$$O	treating$$$156$$$164$$$O	lung$$$165$$$169$$$O	cancer,$$$170$$$177$$$O	stomach$$$178$$$185$$$O	cancer,$$$186$$$193$$$O	colon$$$194$$$199$$$O	cancer,$$$200$$$207$$$O	breast$$$208$$$214$$$O	cancer$$$215$$$221$$$O	and$$$222$$$225$$$O	prostatic$$$226$$$235$$$O	cancer$$$236$$$242$$$O	is$$$243$$$245$$$O	disclosed.$$$246$$$256$$$O
US20080004345
Novel$$$0$$$5$$$O	Water-Soluble$$$6$$$19$$$O	Fullerene,$$$20$$$30$$$O	Process$$$31$$$38$$$O	for$$$39$$$42$$$O	Producing$$$43$$$52$$$O	the$$$53$$$56$$$O	Same$$$57$$$61$$$O	and$$$62$$$65$$$O	Active$$$66$$$72$$$O	Oxygen$$$73$$$79$$$I	Generator$$$80$$$89$$$O	Containing$$$90$$$100$$$O	the$$$101$$$104$$$O	Fullerene$$$105$$$114$$$O
A$$$0$$$1$$$O	water-soluble$$$2$$$15$$$O	fullerene$$$16$$$25$$$O	wherein$$$26$$$33$$$O	the$$$34$$$37$$$O	number$$$38$$$44$$$O	of$$$45$$$47$$$O	water-soluble$$$48$$$61$$$O	polymers$$$62$$$70$$$O	bonded$$$71$$$77$$$O	has$$$78$$$81$$$O	been$$$82$$$86$$$O	regulated$$$87$$$96$$$O	can$$$97$$$100$$$O	be$$$101$$$103$$$O	obtained$$$104$$$112$$$O	by$$$113$$$115$$$O	coupling$$$116$$$124$$$O	water-soluble$$$125$$$138$$$O	polymers$$$139$$$147$$$O	with$$$148$$$152$$$O	a$$$153$$$154$$$O	fullerene$$$155$$$164$$$O	having$$$165$$$171$$$O	functional$$$172$$$182$$$O	groups$$$183$$$189$$$O	in$$$190$$$192$$$O	its$$$193$$$196$$$O	molecule$$$197$$$205$$$O	via$$$206$$$209$$$O	the$$$210$$$213$$$O	functional$$$214$$$224$$$O	groups.$$$225$$$232$$$O	This$$$233$$$237$$$O	water-soluble$$$238$$$251$$$O	fullerene$$$252$$$261$$$O	can$$$262$$$265$$$O	be$$$266$$$268$$$O	used$$$269$$$273$$$O	in$$$274$$$276$$$O	the$$$277$$$280$$$O	photodynamic$$$281$$$293$$$O	therapy$$$294$$$301$$$O	or$$$302$$$304$$$O	supersonic$$$305$$$315$$$O	therapy$$$316$$$323$$$O	of$$$324$$$326$$$O	cancer$$$327$$$333$$$O	through$$$334$$$341$$$O	the$$$342$$$345$$$O	use$$$346$$$349$$$O	thereof$$$350$$$357$$$O	as$$$358$$$360$$$O	an$$$361$$$363$$$O	active$$$364$$$370$$$O	oxygen$$$371$$$377$$$I	generator.$$$378$$$388$$$O
WO2007012762A1
Novel$$$0$$$5$$$O	polysubstituted$$$6$$$21$$$O	1,1-pyridinyloxycyclopropanamine$$$22$$$54$$$I	compounds,$$$55$$$65$$$O	method$$$66$$$72$$$O	for$$$73$$$76$$$O	preparing$$$77$$$86$$$O	same$$$87$$$91$$$O	and$$$92$$$95$$$O	pharmaceutical$$$96$$$110$$$O	compositions$$$111$$$123$$$O	containing$$$124$$$134$$$O	same$$$135$$$139$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	compounds$$$23$$$32$$$O	of$$$33$$$35$$$O	formula$$$36$$$43$$$O	(I)$$$44$$$47$$$O	wherein:$$$48$$$56$$$O	n$$$57$$$58$$$O	represents$$$59$$$69$$$O	an$$$70$$$72$$$O	integer$$$73$$$80$$$O	between$$$81$$$88$$$O	1$$$89$$$90$$$O	and$$$91$$$94$$$O	6$$$95$$$96$$$O	inclusive;$$$97$$$107$$$O	R1$$$108$$$110$$$O	and$$$111$$$114$$$O	R2$$$115$$$117$$$O	represent$$$118$$$127$$$O	a$$$128$$$129$$$O	hydrogen$$$130$$$138$$$I	atom,$$$139$$$144$$$O	a$$$145$$$146$$$O	C1-C6$$$147$$$152$$$I	alkyl$$$153$$$158$$$I	or$$$159$$$161$$$O	C1-C6$$$162$$$167$$$I	arylalkyl$$$168$$$177$$$I	group;$$$178$$$184$$$O	R3$$$185$$$187$$$O	and$$$188$$$191$$$O	R4$$$192$$$194$$$O	represent$$$195$$$204$$$O	a$$$205$$$206$$$O	hydrogen$$$207$$$215$$$I	atom,$$$216$$$221$$$O	a$$$222$$$223$$$O	C1-C6$$$224$$$229$$$I	alkyl$$$230$$$235$$$I	group;$$$236$$$242$$$O	R5$$$243$$$245$$$O	and$$$246$$$249$$$O	R6$$$250$$$252$$$O	represent$$$253$$$262$$$O	a$$$263$$$264$$$O	hydrogen$$$265$$$273$$$I	atom,$$$274$$$279$$$O	a$$$280$$$281$$$O	C1-C6$$$282$$$287$$$I	alkyl$$$288$$$293$$$I	group,$$$294$$$300$$$O	halogen,$$$301$$$309$$$I	hydroxy,$$$310$$$318$$$I	C1-C6$$$319$$$324$$$I	alkoxy,$$$325$$$332$$$I	cyano,$$$333$$$339$$$I	nitro,$$$340$$$346$$$I	C2-C6$$$347$$$352$$$I	acyl,$$$353$$$358$$$I	C1-C6$$$359$$$364$$$I	alkoxycarbonyl,$$$365$$$380$$$I	C1-C6$$$381$$$386$$$I	trihalogenoalkyl,$$$387$$$404$$$I	C1-C6$$$405$$$410$$$I	triahalogenoalkoxy$$$411$$$429$$$I	or$$$430$$$432$$$O	amino$$$433$$$438$$$I	group$$$439$$$444$$$O	optionally$$$445$$$455$$$O	substituted.$$$456$$$468$$$O	The$$$469$$$472$$$O	invention$$$473$$$482$$$O	is$$$483$$$485$$$O	useful$$$486$$$492$$$O	for$$$493$$$496$$$O	making$$$497$$$503$$$O	drugs.$$$504$$$510$$$O
CN103263386A
Preparation$$$0$$$11$$$O	process$$$12$$$19$$$O	of$$$20$$$22$$$O	saligenin$$$23$$$32$$$I	emulsion$$$33$$$41$$$O	injection$$$42$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	process$$$38$$$45$$$O	of$$$46$$$48$$$O	saligenin$$$49$$$58$$$I	emulsion$$$59$$$67$$$O	injection.$$$68$$$78$$$O	The$$$79$$$82$$$O	preparation$$$83$$$94$$$O	process$$$95$$$102$$$O	comprises$$$103$$$112$$$O	the$$$113$$$116$$$O	specific$$$117$$$125$$$O	steps$$$126$$$131$$$O	of:$$$132$$$135$$$O	weighing$$$136$$$144$$$O	0.5g$$$145$$$149$$$O	of$$$150$$$152$$$O	sodium$$$153$$$159$$$I	sulfite$$$160$$$167$$$I	and$$$168$$$171$$$O	400ml$$$172$$$177$$$O	of$$$178$$$180$$$O	injection$$$181$$$190$$$O	water;$$$191$$$197$$$O	agitating$$$198$$$207$$$O	and$$$208$$$211$$$O	dissolving$$$212$$$222$$$O	the$$$223$$$226$$$O	sodium$$$227$$$233$$$I	sulfite$$$234$$$241$$$I	into$$$242$$$246$$$O	the$$$247$$$250$$$O	injection$$$251$$$260$$$O	water;$$$261$$$267$$$O	weighing$$$268$$$276$$$O	10.0g$$$277$$$282$$$O	of$$$283$$$285$$$O	saligenin;$$$286$$$296$$$I	agitating$$$297$$$306$$$O	and$$$307$$$310$$$O	dissolving$$$311$$$321$$$O	the$$$322$$$325$$$O	saligenin$$$326$$$335$$$I	into$$$336$$$340$$$O	the$$$341$$$344$$$O	injection$$$345$$$354$$$O	water;$$$355$$$361$$$O	heating$$$362$$$369$$$O	the$$$370$$$373$$$O	solution$$$374$$$382$$$O	to$$$383$$$385$$$O	40$$$386$$$388$$$O	DEG$$$389$$$392$$$O	C;$$$393$$$395$$$O	adding$$$396$$$402$$$O	10g$$$403$$$406$$$O	of$$$407$$$409$$$O	Tween$$$410$$$415$$$I	80,$$$416$$$419$$$I	and$$$420$$$423$$$O	agitating$$$424$$$433$$$O	and$$$434$$$437$$$O	dissolving$$$438$$$448$$$O	the$$$449$$$452$$$O	Tween$$$453$$$458$$$I	80$$$459$$$461$$$I	to$$$462$$$464$$$O	prepare$$$465$$$472$$$O	a$$$473$$$474$$$O	solution$$$475$$$483$$$O	A;$$$484$$$486$$$O	weighing$$$487$$$495$$$O	500ml$$$496$$$501$$$O	of$$$502$$$504$$$O	plant$$$505$$$510$$$O	oil$$$511$$$514$$$O	and$$$515$$$518$$$O	heating$$$519$$$526$$$O	to$$$527$$$529$$$O	50$$$530$$$532$$$O	DEG$$$533$$$536$$$O	C;$$$537$$$539$$$O	weighing$$$540$$$548$$$O	20g$$$549$$$552$$$O	of$$$553$$$555$$$O	Span$$$556$$$560$$$I	85$$$561$$$563$$$I	and$$$564$$$567$$$O	agitating$$$568$$$577$$$O	and$$$578$$$581$$$O	dissolving$$$582$$$592$$$O	the$$$593$$$596$$$O	Span$$$597$$$601$$$I	85$$$602$$$604$$$I	into$$$605$$$609$$$O	the$$$610$$$613$$$O	plant$$$614$$$619$$$O	oil$$$620$$$623$$$O	to$$$624$$$626$$$O	obtain$$$627$$$633$$$O	a$$$634$$$635$$$O	solution$$$636$$$644$$$O	B;$$$645$$$647$$$O	adding$$$648$$$654$$$O	the$$$655$$$658$$$O	solution$$$659$$$667$$$O	B$$$668$$$669$$$O	and$$$670$$$673$$$O	the$$$674$$$677$$$O	solution$$$678$$$686$$$O	A$$$687$$$688$$$O	to$$$689$$$691$$$O	obtain$$$692$$$698$$$O	a$$$699$$$700$$$O	mixed$$$701$$$706$$$O	solution;$$$707$$$716$$$O	adding$$$717$$$723$$$O	the$$$724$$$727$$$O	plant$$$728$$$733$$$O	oil$$$734$$$737$$$O	into$$$738$$$742$$$O	the$$$743$$$746$$$O	mixed$$$747$$$752$$$O	solution$$$753$$$761$$$O	until$$$762$$$767$$$O	the$$$768$$$771$$$O	volume$$$772$$$778$$$O	is$$$779$$$781$$$O	1000ml;$$$782$$$789$$$O	agitating$$$790$$$799$$$O	uniformly$$$800$$$809$$$O	and$$$810$$$813$$$O	placing$$$814$$$821$$$O	into$$$822$$$826$$$O	an$$$827$$$829$$$O	emulsifying$$$830$$$841$$$O	machine;$$$842$$$850$$$O	emulsifying$$$851$$$862$$$O	for$$$863$$$866$$$O	10min$$$867$$$872$$$O	under$$$873$$$878$$$O	the$$$879$$$882$$$O	condition$$$883$$$892$$$O	of$$$893$$$895$$$O	5000r/min;$$$896$$$906$$$O	and$$$907$$$910$$$O	packaging$$$911$$$920$$$O	to$$$921$$$923$$$O	obtain$$$924$$$930$$$O	the$$$931$$$934$$$O	saligenin$$$935$$$944$$$I	emulsion$$$945$$$953$$$O	injection.$$$954$$$964$$$O	According$$$965$$$974$$$O	to$$$975$$$977$$$O	the$$$978$$$981$$$O	preparation$$$982$$$993$$$O	process$$$994$$$1001$$$O	disclosed$$$1002$$$1011$$$O	by$$$1012$$$1014$$$O	the$$$1015$$$1018$$$O	invention,$$$1019$$$1029$$$O	an$$$1030$$$1032$$$O	emulsion$$$1033$$$1041$$$O	form$$$1042$$$1046$$$O	is$$$1047$$$1049$$$O	adopted$$$1050$$$1057$$$O	to$$$1058$$$1060$$$O	solve$$$1061$$$1066$$$O	the$$$1067$$$1070$$$O	problems$$$1071$$$1079$$$O	that$$$1080$$$1084$$$O	the$$$1085$$$1088$$$O	saligenin$$$1089$$$1098$$$I	is$$$1099$$$1101$$$O	dissolved$$$1102$$$1111$$$O	in$$$1112$$$1114$$$O	the$$$1115$$$1118$$$O	water,$$$1119$$$1125$$$O	is$$$1126$$$1128$$$O	rapidly$$$1129$$$1136$$$O	absorbed$$$1137$$$1145$$$O	by$$$1146$$$1148$$$O	animals$$$1149$$$1156$$$O	and$$$1157$$$1160$$$O	is$$$1161$$$1163$$$O	short$$$1164$$$1169$$$O	in$$$1170$$$1172$$$O	acting$$$1173$$$1179$$$O	time$$$1180$$$1184$$$O	so$$$1185$$$1187$$$O	that$$$1188$$$1192$$$O	the$$$1193$$$1196$$$O	saligenin$$$1197$$$1206$$$I	needs$$$1207$$$1212$$$O	to$$$1213$$$1215$$$O	be$$$1216$$$1218$$$O	repeatedly$$$1219$$$1229$$$O	used;$$$1230$$$1235$$$O	the$$$1236$$$1239$$$O	saligenin$$$1240$$$1249$$$I	emulsion$$$1250$$$1258$$$O	injection$$$1259$$$1268$$$O	can$$$1269$$$1272$$$O	be$$$1273$$$1275$$$O	kept$$$1276$$$1280$$$O	in$$$1281$$$1283$$$O	the$$$1284$$$1287$$$O	bodies$$$1288$$$1294$$$O	of$$$1295$$$1297$$$O	the$$$1298$$$1301$$$O	animals$$$1302$$$1309$$$O	for$$$1310$$$1313$$$O	a$$$1314$$$1315$$$O	long$$$1316$$$1320$$$O	time$$$1321$$$1325$$$O	and$$$1326$$$1329$$$O	the$$$1330$$$1333$$$O	absorption$$$1334$$$1344$$$O	speed$$$1345$$$1350$$$O	is$$$1351$$$1353$$$O	slower$$$1354$$$1360$$$O	than$$$1361$$$1365$$$O	that$$$1366$$$1370$$$O	of$$$1371$$$1373$$$O	an$$$1374$$$1376$$$O	aqueous$$$1377$$$1384$$$O	solution;$$$1385$$$1394$$$O	and$$$1395$$$1398$$$O	the$$$1399$$$1402$$$O	saligenin$$$1403$$$1412$$$I	emulsion$$$1413$$$1421$$$O	injection$$$1422$$$1431$$$O	can$$$1432$$$1435$$$O	be$$$1436$$$1438$$$O	kept$$$1439$$$1443$$$O	in$$$1444$$$1446$$$O	the$$$1447$$$1450$$$O	bodies$$$1451$$$1457$$$O	of$$$1458$$$1460$$$O	the$$$1461$$$1464$$$O	animals$$$1465$$$1472$$$O	for$$$1473$$$1476$$$O	a$$$1477$$$1478$$$O	long$$$1479$$$1483$$$O	time$$$1484$$$1488$$$O	to$$$1489$$$1491$$$O	express$$$1492$$$1499$$$O	pesticide$$$1500$$$1509$$$O	effects.$$$1510$$$1518$$$O
WO2013100585A3
Adonis$$$0$$$6$$$O	amurensis$$$7$$$16$$$O	extract$$$17$$$24$$$O	or$$$25$$$27$$$O	anti-cancer$$$28$$$39$$$O	composition$$$40$$$51$$$O	using$$$52$$$57$$$O	same$$$58$$$62$$$O	as$$$63$$$65$$$O	an$$$66$$$68$$$O	active$$$69$$$75$$$O	ingredient$$$76$$$86$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	Adonis$$$36$$$42$$$O	amurensis$$$43$$$52$$$O	extract$$$53$$$60$$$O	showing$$$61$$$68$$$O	anti-cancer$$$69$$$80$$$O	activity$$$81$$$89$$$O	in$$$90$$$92$$$O	cell$$$93$$$97$$$O	and$$$98$$$101$$$O	animal$$$102$$$108$$$O	experiments,$$$109$$$121$$$O	and$$$122$$$125$$$O	an$$$126$$$128$$$O	anti-cancer$$$129$$$140$$$O	composition$$$141$$$152$$$O	using$$$153$$$158$$$O	the$$$159$$$162$$$O	same$$$163$$$167$$$O	as$$$168$$$170$$$O	an$$$171$$$173$$$O	active$$$174$$$180$$$O	material.$$$181$$$190$$$O
CN102940632A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	FK506-A$$$15$$$22$$$I	compound$$$23$$$31$$$O	in$$$32$$$34$$$O	preparation$$$35$$$46$$$O	of$$$47$$$49$$$O	immunosuppressant$$$50$$$67$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medical$$$26$$$33$$$O	application$$$34$$$45$$$O	of$$$46$$$48$$$O	a$$$49$$$50$$$O	FK506-A$$$51$$$58$$$I	compound,$$$59$$$68$$$O	particularly$$$69$$$81$$$O	discloses$$$82$$$91$$$O	an$$$92$$$94$$$O	application$$$95$$$106$$$O	in$$$107$$$109$$$O	preparation$$$110$$$121$$$O	of$$$122$$$124$$$O	an$$$125$$$127$$$O	immunosuppressant.$$$128$$$146$$$O
CA2704882A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	amorolfine$$$7$$$17$$$I	for$$$18$$$21$$$O	treating$$$22$$$30$$$O	a$$$31$$$32$$$O	nail$$$33$$$37$$$O	disease$$$38$$$45$$$O	by$$$46$$$48$$$O	iontophoresis$$$49$$$62$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	a$$$36$$$37$$$O	composition$$$38$$$49$$$O	comprising$$$50$$$60$$$O	1$$$61$$$62$$$O	%$$$63$$$64$$$O	to$$$65$$$67$$$O	5%$$$68$$$70$$$O	by$$$71$$$73$$$O	weight$$$74$$$80$$$O	of$$$81$$$83$$$O	amorolfine$$$84$$$94$$$I	in$$$95$$$97$$$O	ionized$$$98$$$105$$$O	form$$$106$$$110$$$O	in$$$111$$$113$$$O	an$$$114$$$116$$$O	aqueous-alcoholic$$$117$$$134$$$O	solution,$$$135$$$144$$$O	at$$$145$$$147$$$O	a$$$148$$$149$$$O	pH$$$150$$$152$$$O	of$$$153$$$155$$$O	between$$$156$$$163$$$O	3$$$164$$$165$$$O	and$$$166$$$169$$$O	6,$$$170$$$172$$$O	in$$$173$$$175$$$O	the$$$176$$$179$$$O	manufacture$$$180$$$191$$$O	of$$$192$$$194$$$O	a$$$195$$$196$$$O	medicament$$$197$$$207$$$O	for$$$208$$$211$$$O	use$$$212$$$215$$$O	in$$$216$$$218$$$O	the$$$219$$$222$$$O	treatment$$$223$$$232$$$O	of$$$233$$$235$$$O	a$$$236$$$237$$$O	nail$$$238$$$242$$$O	disease,$$$243$$$251$$$O	said$$$252$$$256$$$O	composition$$$257$$$268$$$O	being$$$269$$$274$$$O	applied$$$275$$$282$$$O	to$$$283$$$285$$$O	the$$$286$$$289$$$O	nail$$$290$$$294$$$O	in$$$295$$$297$$$O	combination$$$298$$$309$$$O	with$$$310$$$314$$$O	an$$$315$$$317$$$O	iontophoretic$$$318$$$331$$$O	current,$$$332$$$340$$$O	the$$$341$$$344$$$O	intensity$$$345$$$354$$$O	of$$$355$$$357$$$O	which$$$358$$$363$$$O	is$$$364$$$366$$$O	between$$$367$$$374$$$O	0.01$$$375$$$379$$$O	and$$$380$$$383$$$O	5$$$384$$$385$$$O	mA/cm2,$$$386$$$393$$$O	for$$$394$$$397$$$O	a$$$398$$$399$$$O	period$$$400$$$406$$$O	of$$$407$$$409$$$O	time$$$410$$$414$$$O	which$$$415$$$420$$$O	is$$$421$$$423$$$O	sufficient$$$424$$$434$$$O	to$$$435$$$437$$$O	enable$$$438$$$444$$$O	the$$$445$$$448$$$O	amorolfine$$$449$$$459$$$I	to$$$460$$$462$$$O	pass$$$463$$$467$$$O	into$$$468$$$472$$$O	or$$$473$$$475$$$O	through$$$476$$$483$$$O	the$$$484$$$487$$$O	nail.$$$488$$$493$$$O
US20050256178
Novel$$$0$$$5$$$O	nutraceutical$$$6$$$19$$$O	compositions$$$20$$$32$$$O	comprising$$$33$$$43$$$O	boitin$$$44$$$50$$$O
Nutraceutical$$$0$$$13$$$O	compositions$$$14$$$26$$$O	comprise$$$27$$$35$$$O	biotin$$$36$$$42$$$I	in$$$43$$$45$$$O	an$$$46$$$48$$$O	amount$$$49$$$55$$$O	sufficient$$$56$$$66$$$O	to$$$67$$$69$$$O	administer$$$70$$$80$$$O	to$$$81$$$83$$$O	a$$$84$$$85$$$O	subject$$$86$$$93$$$O	a$$$94$$$95$$$O	daily$$$96$$$101$$$O	dosage$$$102$$$108$$$O	of$$$109$$$111$$$O	0.01$$$112$$$116$$$O	mg$$$117$$$119$$$O	per$$$120$$$123$$$O	kg$$$124$$$126$$$O	body$$$127$$$131$$$O	weight$$$132$$$138$$$O	to$$$139$$$141$$$O	about$$$142$$$147$$$O	3$$$148$$$149$$$O	mg$$$150$$$152$$$O	per$$$153$$$156$$$O	kg$$$157$$$159$$$O	body$$$160$$$164$$$O	weight$$$165$$$171$$$O	and$$$172$$$175$$$O	at$$$176$$$178$$$O	least$$$179$$$184$$$O	one$$$185$$$188$$$O	additional$$$189$$$199$$$O	component$$$200$$$209$$$O	selected$$$210$$$218$$$O	from$$$219$$$223$$$O	pantethine$$$224$$$234$$$I	or$$$235$$$237$$$O	a$$$238$$$239$$$O	metabolite$$$240$$$250$$$O	thereof,$$$251$$$259$$$O	EGCG,$$$260$$$265$$$I	phytanic$$$266$$$274$$$I	acid,$$$275$$$280$$$I	lipoic$$$281$$$287$$$I	acid$$$288$$$292$$$I	and$$$293$$$296$$$O	policosanol.$$$297$$$309$$$I	The$$$310$$$313$$$O	compositions$$$314$$$326$$$O	are$$$327$$$330$$$O	useful$$$331$$$337$$$O	for$$$338$$$341$$$O	the$$$342$$$345$$$O	treatment$$$346$$$355$$$O	of$$$356$$$358$$$O	both$$$359$$$363$$$O	type$$$364$$$368$$$O	1$$$369$$$370$$$O	and$$$371$$$374$$$O	2$$$375$$$376$$$O	diabetes,$$$377$$$386$$$O	and$$$387$$$390$$$O	for$$$391$$$394$$$O	the$$$395$$$398$$$O	prevention$$$399$$$409$$$O	of$$$410$$$412$$$O	type$$$413$$$417$$$O	2$$$418$$$419$$$O	diabetes$$$420$$$428$$$O	in$$$429$$$431$$$O	those$$$432$$$437$$$O	individuals$$$438$$$449$$$O	with$$$450$$$454$$$O	pre-diabetes,$$$455$$$468$$$O	or$$$469$$$471$$$O	impaired$$$472$$$480$$$O	glucose$$$481$$$488$$$I	tolerance$$$489$$$498$$$O	(IGT)$$$499$$$504$$$O	or$$$505$$$507$$$O	obesity.$$$508$$$516$$$O
US20110257215
Novel$$$0$$$5$$$O	co-crystal$$$6$$$16$$$O	of$$$17$$$19$$$O	tiotropium$$$20$$$30$$$I	bromide$$$31$$$38$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	new$$$27$$$30$$$O	crystalline$$$31$$$42$$$O	form$$$43$$$47$$$O	of$$$48$$$50$$$O	tiotropium$$$51$$$61$$$I	bromide,$$$62$$$70$$$I	processes$$$71$$$80$$$O	for$$$81$$$84$$$O	preparing$$$85$$$94$$$O	it$$$95$$$97$$$O	and$$$98$$$101$$$O	its$$$102$$$105$$$O	use$$$106$$$109$$$O	for$$$110$$$113$$$O	preparing$$$114$$$123$$$O	a$$$124$$$125$$$O	pharmaceutical$$$126$$$140$$$O	composition$$$141$$$152$$$O	for$$$153$$$156$$$O	the$$$157$$$160$$$O	treatment$$$161$$$170$$$O	of$$$171$$$173$$$O	respiratory$$$174$$$185$$$O	complaints,$$$186$$$197$$$O	particularly$$$198$$$210$$$O	for$$$211$$$214$$$O	the$$$215$$$218$$$O	treatment$$$219$$$228$$$O	of$$$229$$$231$$$O	COPD$$$232$$$236$$$O	(chronic$$$237$$$245$$$O	obstructive$$$246$$$257$$$O	pulmonary$$$258$$$267$$$O	disease)$$$268$$$276$$$O	and$$$277$$$280$$$O	asthma.$$$281$$$288$$$O
US20100285087
Single$$$0$$$6$$$O	phenothiazine$$$7$$$20$$$I	enantiomers$$$21$$$32$$$O	as$$$33$$$35$$$O	agents$$$36$$$42$$$O	for$$$43$$$46$$$O	the$$$47$$$50$$$O	prevention$$$51$$$61$$$O	of$$$62$$$64$$$O	bone$$$65$$$69$$$O	loss$$$70$$$74$$$O
Enantomerically$$$0$$$15$$$O	purified$$$16$$$24$$$O	phenothiazines$$$25$$$39$$$I	are$$$40$$$43$$$O	provided$$$44$$$52$$$O	as$$$53$$$55$$$O	active$$$56$$$62$$$O	ingredients$$$63$$$74$$$O	of$$$75$$$77$$$O	medicaments$$$78$$$89$$$O	to$$$90$$$92$$$O	limit$$$93$$$98$$$O	activity$$$99$$$107$$$O	of$$$108$$$110$$$O	bone$$$111$$$115$$$O	resorbing$$$116$$$125$$$O	cells$$$126$$$131$$$O	so$$$132$$$134$$$O	as$$$135$$$137$$$O	to$$$138$$$140$$$O	reduce$$$141$$$147$$$O	bone$$$148$$$152$$$O	loss.$$$153$$$158$$$O	Novel$$$159$$$164$$$O	phenothiazine$$$165$$$178$$$I	derivatives$$$179$$$190$$$O	are$$$191$$$194$$$O	provided.$$$195$$$204$$$O	A$$$205$$$206$$$O	method$$$207$$$213$$$O	of$$$214$$$216$$$O	synthesizing$$$217$$$229$$$O	enantiomerically$$$230$$$246$$$O	pure$$$247$$$251$$$O	phenothiazine$$$252$$$265$$$I	derivatives$$$266$$$277$$$O	is$$$278$$$280$$$O	provided$$$281$$$289$$$O	that$$$290$$$294$$$O	avoids$$$295$$$301$$$O	post-synthetic$$$302$$$316$$$O	enantiomeric$$$317$$$329$$$O	resolution.$$$330$$$341$$$O
US7045633
Hydrate$$$0$$$7$$$O	of$$$8$$$10$$$O	5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione$$$11$$$84$$$I	maleic$$$85$$$91$$$I	acid$$$92$$$96$$$I	salt$$$97$$$101$$$I
A$$$0$$$1$$$O	hydrate$$$2$$$9$$$O	of$$$10$$$12$$$O	5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione,$$$13$$$87$$$I	maleic$$$88$$$94$$$I	acid$$$95$$$99$$$I	salt,$$$100$$$105$$$I	characterized$$$106$$$119$$$O	in$$$120$$$122$$$O	that$$$123$$$127$$$O	it:$$$128$$$131$$$O	(i)$$$132$$$135$$$O	comprises$$$136$$$145$$$O	water$$$146$$$151$$$O	in$$$152$$$154$$$O	the$$$155$$$158$$$O	range$$$159$$$164$$$O	of$$$165$$$167$$$O	from$$$168$$$172$$$O	0.2$$$173$$$176$$$O	to$$$177$$$179$$$O	1.1%$$$180$$$184$$$O	w/w;$$$185$$$189$$$O	and$$$190$$$193$$$O	(ii)$$$194$$$198$$$O	provides$$$199$$$207$$$O	an$$$208$$$210$$$O	infrared$$$211$$$219$$$O	spectrum$$$220$$$228$$$O	containing$$$229$$$239$$$O	peaks$$$240$$$245$$$O	at$$$246$$$248$$$O	764$$$249$$$252$$$O	and$$$253$$$256$$$O	579$$$257$$$260$$$O	cmâ1;$$$261$$$268$$$O	and/or$$$269$$$275$$$O	(iii)$$$276$$$281$$$O	provides$$$282$$$290$$$O	an$$$291$$$293$$$O	X-ray$$$294$$$299$$$O	powder$$$300$$$306$$$O	diffraction$$$307$$$318$$$O	(XRPD)$$$319$$$325$$$O	pattern$$$326$$$333$$$O	substantially$$$334$$$347$$$O	as$$$348$$$350$$$O	set$$$351$$$354$$$O	out$$$355$$$358$$$O	in$$$359$$$361$$$O	FIG.$$$362$$$366$$$O	II;$$$367$$$370$$$O	a$$$371$$$372$$$O	process$$$373$$$380$$$O	for$$$381$$$384$$$O	the$$$385$$$388$$$O	preparation$$$389$$$400$$$O	of$$$401$$$403$$$O	such$$$404$$$408$$$O	a$$$409$$$410$$$O	compound,$$$411$$$420$$$O	a$$$421$$$422$$$O	pharmaceutical$$$423$$$437$$$O	composition$$$438$$$449$$$O	containing$$$450$$$460$$$O	such$$$461$$$465$$$O	a$$$466$$$467$$$O	compound$$$468$$$476$$$O	and$$$477$$$480$$$O	the$$$481$$$484$$$O	use$$$485$$$488$$$O	of$$$489$$$491$$$O	such$$$492$$$496$$$O	a$$$497$$$498$$$O	compound$$$499$$$507$$$O	or$$$508$$$510$$$O	composition$$$511$$$522$$$O	in$$$523$$$525$$$O	medicine.$$$526$$$535$$$O
WO2010106106A1
2,$$$0$$$2$$$I	5-disubstituted$$$3$$$18$$$I	tetrazole$$$19$$$28$$$I	derivatives$$$29$$$40$$$O	and$$$41$$$44$$$O	their$$$45$$$50$$$O	use$$$51$$$54$$$O	as$$$55$$$57$$$O	nicotinic$$$58$$$67$$$O	acetylcholine$$$68$$$81$$$I	receptor$$$82$$$90$$$O	modulators$$$91$$$101$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	tetrazole$$$32$$$41$$$I	derivatives$$$42$$$53$$$O	of$$$54$$$56$$$O	formula$$$57$$$64$$$O	(I),$$$65$$$69$$$O	which$$$70$$$75$$$O	are$$$76$$$79$$$O	found$$$80$$$85$$$O	to$$$86$$$88$$$O	be$$$89$$$91$$$O	modulators$$$92$$$102$$$O	of$$$103$$$105$$$O	the$$$106$$$109$$$O	nicotinic$$$110$$$119$$$O	acetylcholine$$$120$$$133$$$I	receptors.$$$134$$$144$$$O	Due$$$145$$$148$$$O	to$$$149$$$151$$$O	their$$$152$$$157$$$O	pharmacological$$$158$$$173$$$O	profile$$$174$$$181$$$O	the$$$182$$$185$$$O	compounds$$$186$$$195$$$O	of$$$196$$$198$$$O	the$$$199$$$202$$$O	invention$$$203$$$212$$$O	may$$$213$$$216$$$O	be$$$217$$$219$$$O	useful$$$220$$$226$$$O	for$$$227$$$230$$$O	the$$$231$$$234$$$O	treatment$$$235$$$244$$$O	of$$$245$$$247$$$O	diseases$$$248$$$256$$$O	or$$$257$$$259$$$O	disorders$$$260$$$269$$$O	as$$$270$$$272$$$O	diverse$$$273$$$280$$$O	as$$$281$$$283$$$O	those$$$284$$$289$$$O	related$$$290$$$297$$$O	to$$$298$$$300$$$O	the$$$301$$$304$$$O	cholinergic$$$305$$$316$$$O	system$$$317$$$323$$$O	of$$$324$$$326$$$O	the$$$327$$$330$$$O	central$$$331$$$338$$$O	nervous$$$339$$$346$$$O	system$$$347$$$353$$$O	(CNS),$$$354$$$360$$$O	the$$$361$$$364$$$O	peripheral$$$365$$$375$$$O	nervous$$$376$$$383$$$O	system$$$384$$$390$$$O	(PNS),$$$391$$$397$$$O	diseases$$$398$$$406$$$O	or$$$407$$$409$$$O	disorders$$$410$$$419$$$O	related$$$420$$$427$$$O	to$$$428$$$430$$$O	smooth$$$431$$$437$$$O	muscle$$$438$$$444$$$O	contraction,$$$445$$$457$$$O	endocrine$$$458$$$467$$$O	diseases$$$468$$$476$$$O	or$$$477$$$479$$$O	disorders,$$$480$$$490$$$O	diseases$$$491$$$499$$$O	or$$$500$$$502$$$O	disorders$$$503$$$512$$$O	related$$$513$$$520$$$O	to$$$521$$$523$$$O	neuro-$$$524$$$530$$$O	degeneration,$$$531$$$544$$$O	diseases$$$545$$$553$$$O	or$$$554$$$556$$$O	disorders$$$557$$$566$$$O	related$$$567$$$574$$$O	to$$$575$$$577$$$O	inflammation,$$$578$$$591$$$O	pain,$$$592$$$597$$$O	and$$$598$$$601$$$O	withdrawal$$$602$$$612$$$O	symptoms$$$613$$$621$$$O	caused$$$622$$$628$$$O	by$$$629$$$631$$$O	the$$$632$$$635$$$O	termination$$$636$$$647$$$O	of$$$648$$$650$$$O	abuse$$$651$$$656$$$O	of$$$657$$$659$$$O	chemical$$$660$$$668$$$O	substances.$$$669$$$680$$$O
WO2006033422A1
Quinolizinone$$$0$$$13$$$I	compound$$$14$$$22$$$O	and$$$23$$$26$$$O	use$$$27$$$30$$$O	thereof$$$31$$$38$$$O	as$$$39$$$41$$$O	hiv$$$42$$$45$$$O	integrase$$$46$$$55$$$O	inhibitor$$$56$$$65$$$O
A$$$0$$$1$$$O	drug$$$2$$$6$$$O	having$$$7$$$13$$$O	anti-HIV$$$14$$$22$$$O	activity,$$$23$$$32$$$O	especially$$$33$$$43$$$O	a$$$44$$$45$$$O	drug$$$46$$$50$$$O	having$$$51$$$57$$$O	integrase$$$58$$$67$$$O	inhibitory$$$68$$$78$$$O	activity.$$$79$$$88$$$O	Also$$$89$$$93$$$O	provided$$$94$$$102$$$O	is$$$103$$$105$$$O	a$$$106$$$107$$$O	quinolizinone$$$108$$$121$$$I	compound$$$122$$$130$$$O	represented$$$131$$$142$$$O	by$$$143$$$145$$$O	the$$$146$$$149$$$O	following$$$150$$$159$$$O	general$$$160$$$167$$$O	formula$$$168$$$175$$$O	[I]:$$$176$$$180$$$O	[I]$$$181$$$184$$$O	(wherein$$$185$$$193$$$O	the$$$194$$$197$$$O	symbols$$$198$$$205$$$O	are$$$206$$$209$$$O	the$$$210$$$213$$$O	same$$$214$$$218$$$O	as$$$219$$$221$$$O	defined$$$222$$$229$$$O	in$$$230$$$232$$$O	the$$$233$$$236$$$O	description)$$$237$$$249$$$O	or$$$250$$$252$$$O	a$$$253$$$254$$$O	pharmaceutically$$$255$$$271$$$O	acceptable$$$272$$$282$$$O	salt$$$283$$$287$$$O	thereof.$$$288$$$296$$$O	The$$$297$$$300$$$O	drug$$$301$$$305$$$O	is$$$306$$$308$$$O	an$$$309$$$311$$$O	anti-HIV$$$312$$$320$$$O	agent$$$321$$$326$$$O	containing$$$327$$$337$$$O	the$$$338$$$341$$$O	compound$$$342$$$350$$$O	or$$$351$$$353$$$O	salt$$$354$$$358$$$O	as$$$359$$$361$$$O	an$$$362$$$364$$$O	active$$$365$$$371$$$O	ingredient.$$$372$$$383$$$O	The$$$384$$$387$$$O	compound$$$388$$$396$$$O	has$$$397$$$400$$$O	the$$$401$$$404$$$O	function$$$405$$$413$$$O	of$$$414$$$416$$$O	inhibiting$$$417$$$427$$$O	HIV$$$428$$$431$$$O	integrase$$$432$$$441$$$O	activity$$$442$$$450$$$O	and$$$451$$$454$$$O	is$$$455$$$457$$$O	useful$$$458$$$464$$$O	as$$$465$$$467$$$O	an$$$468$$$470$$$O	anti-HIV$$$471$$$479$$$O	agent$$$480$$$485$$$O	for$$$486$$$489$$$O	the$$$490$$$493$$$O	treatment$$$494$$$503$$$O	or$$$504$$$506$$$O	prevention$$$507$$$517$$$O	of$$$518$$$520$$$O	AIDs.$$$521$$$526$$$O	The$$$527$$$530$$$O	anti-HIV$$$531$$$539$$$O	agent$$$540$$$545$$$O	can$$$546$$$549$$$O	be$$$550$$$552$$$O	a$$$553$$$554$$$O	more$$$555$$$559$$$O	effective$$$560$$$569$$$O	one$$$570$$$573$$$O	when$$$574$$$578$$$O	used$$$579$$$583$$$O	in$$$584$$$586$$$O	combination$$$587$$$598$$$O	with$$$599$$$603$$$O	other$$$604$$$609$$$O	anti-HIV$$$610$$$618$$$O	agent$$$619$$$624$$$O	such$$$625$$$629$$$O	as$$$630$$$632$$$O	a$$$633$$$634$$$O	protease$$$635$$$643$$$O	inhibitor$$$644$$$653$$$O	or$$$654$$$656$$$O	reverse$$$657$$$664$$$O	transcriptase$$$665$$$678$$$O	inhibitor.$$$679$$$689$$$O	The$$$690$$$693$$$O	anti-HIV$$$694$$$702$$$O	agent$$$703$$$708$$$O	has$$$709$$$712$$$O	high$$$713$$$717$$$O	inhibitory$$$718$$$728$$$O	activity$$$729$$$737$$$O	specific$$$738$$$746$$$O	for$$$747$$$750$$$O	integrases$$$751$$$761$$$O	and$$$762$$$765$$$O	can$$$766$$$769$$$O	hence$$$770$$$775$$$O	be$$$776$$$778$$$O	a$$$779$$$780$$$O	drug$$$781$$$785$$$O	safe$$$786$$$790$$$O	for$$$791$$$794$$$O	the$$$795$$$798$$$O	human$$$799$$$804$$$O	body$$$805$$$809$$$O	and$$$810$$$813$$$O	reduced$$$814$$$821$$$O	in$$$822$$$824$$$O	side$$$825$$$829$$$O	effects.$$$830$$$838$$$O
CA2366186C
Retinoid$$$0$$$8$$$I	antagonists$$$9$$$20$$$O	and$$$21$$$24$$$O	use$$$25$$$28$$$O	thereof$$$29$$$36$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	retinoid$$$39$$$47$$$I	antagonists$$$48$$$59$$$O	of$$$60$$$62$$$O	the$$$63$$$66$$$O	formula$$$67$$$74$$$O	(I)$$$75$$$78$$$O	wherein$$$79$$$86$$$O	the$$$87$$$90$$$O	dotted$$$91$$$97$$$O	bond$$$98$$$102$$$O	is$$$103$$$105$$$O	optional;$$$106$$$115$$$O	and,$$$116$$$120$$$O	when$$$121$$$125$$$O	the$$$126$$$129$$$O	dotted$$$130$$$136$$$O	bond$$$137$$$141$$$O	is$$$142$$$144$$$O	present,$$$145$$$153$$$O	R1$$$154$$$156$$$O	is$$$157$$$159$$$O	lower$$$160$$$165$$$O	alkyl$$$166$$$171$$$I	and$$$172$$$175$$$O	R2$$$176$$$178$$$O	is$$$179$$$181$$$O	hydrogen;$$$182$$$191$$$I	and,$$$192$$$196$$$O	when$$$197$$$201$$$O	the$$$202$$$205$$$O	dotted$$$206$$$212$$$O	bond$$$213$$$217$$$O	is$$$218$$$220$$$O	absent,$$$221$$$228$$$O	R1$$$229$$$231$$$O	and$$$232$$$235$$$O	R2$$$236$$$238$$$O	taken$$$239$$$244$$$O	together$$$245$$$253$$$O	are$$$254$$$257$$$O	methylene$$$258$$$267$$$I	to$$$268$$$270$$$O	form$$$271$$$275$$$O	a$$$276$$$277$$$O	cis-substituted$$$278$$$293$$$O	cyclopropyl$$$294$$$305$$$I	ring;$$$306$$$311$$$O	R3$$$312$$$314$$$O	is$$$315$$$317$$$O	hydroxy$$$318$$$325$$$I	or$$$326$$$328$$$O	lower$$$329$$$334$$$O	alkoxy;$$$335$$$342$$$I	R4$$$343$$$345$$$O	is$$$346$$$348$$$O	alkyl$$$349$$$354$$$I	or$$$355$$$357$$$O	alkoxy;$$$358$$$365$$$I	and$$$366$$$369$$$O	R5$$$370$$$372$$$O	and$$$373$$$376$$$O	R6$$$377$$$379$$$O	are,$$$380$$$384$$$O	independently,$$$385$$$399$$$O	a$$$400$$$401$$$O	C4-12$$$402$$$407$$$O	alkyl$$$408$$$413$$$I	group$$$414$$$419$$$O	or$$$420$$$422$$$O	a$$$423$$$424$$$O	mono-$$$425$$$430$$$O	or$$$431$$$433$$$O	polycyclic$$$434$$$444$$$O	C5-12-hydrocarbon$$$445$$$462$$$I	group$$$463$$$468$$$O	which$$$469$$$474$$$O	are$$$475$$$478$$$O	linked$$$479$$$485$$$O	to$$$486$$$488$$$O	the$$$489$$$492$$$O	phenyl$$$493$$$499$$$I	ring$$$500$$$504$$$O	through$$$505$$$512$$$O	a$$$513$$$514$$$O	quaternary$$$515$$$525$$$I	carbon$$$526$$$532$$$I	atom,$$$533$$$538$$$O	and$$$539$$$542$$$O	pharmaceutically$$$543$$$559$$$O	acceptable$$$560$$$570$$$O	salts$$$571$$$576$$$O	of$$$577$$$579$$$O	carboxylic$$$580$$$590$$$I	acids$$$591$$$596$$$I	of$$$597$$$599$$$O	formula$$$600$$$607$$$O	(I);$$$608$$$612$$$O	the$$$613$$$616$$$O	use$$$617$$$620$$$O	of$$$621$$$623$$$O	retinoid$$$624$$$632$$$I	antagonists,$$$633$$$645$$$O	their$$$646$$$651$$$O	pharmaceutically$$$652$$$668$$$O	acceptable$$$669$$$679$$$O	salts$$$680$$$685$$$O	or$$$686$$$688$$$O	pharmaceutically$$$689$$$705$$$O	acceptable$$$706$$$716$$$O	hydrolyzable$$$717$$$729$$$O	esters,$$$730$$$737$$$I	for$$$738$$$741$$$O	the$$$742$$$745$$$O	manufacture$$$746$$$757$$$O	of$$$758$$$760$$$O	a$$$761$$$762$$$O	medicament$$$763$$$773$$$O	for$$$774$$$777$$$O	the$$$778$$$781$$$O	treatment$$$782$$$791$$$O	of$$$792$$$794$$$O	T-helper$$$795$$$803$$$O	cell$$$804$$$808$$$O	type$$$809$$$813$$$O	2$$$814$$$815$$$O	(Th2)-mediated$$$816$$$830$$$O	immune$$$831$$$837$$$O	diseases,$$$838$$$847$$$O	for$$$848$$$851$$$O	the$$$852$$$855$$$O	manufacture$$$856$$$867$$$O	of$$$868$$$870$$$O	a$$$871$$$872$$$O	medicament$$$873$$$883$$$O	for$$$884$$$887$$$O	the$$$888$$$891$$$O	treatment$$$892$$$901$$$O	of$$$902$$$904$$$O	osteoporosis$$$905$$$917$$$O	and$$$918$$$921$$$O	for$$$922$$$925$$$O	use$$$926$$$929$$$O	in$$$930$$$932$$$O	the$$$933$$$936$$$O	treatment$$$937$$$946$$$O	of$$$947$$$949$$$O	preneoplastic$$$950$$$963$$$O	and$$$964$$$967$$$O	neoplastic$$$968$$$978$$$O	diseases.$$$979$$$988$$$O
WO2013146797A1
Heparan$$$0$$$7$$$O	sulfate$$$8$$$15$$$O	production$$$16$$$26$$$O	promoter$$$27$$$35$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	heparan$$$14$$$21$$$O	sulfate$$$22$$$29$$$O	production$$$30$$$40$$$O	promoter$$$41$$$49$$$O	comprising$$$50$$$60$$$O	a$$$61$$$62$$$O	mixture$$$63$$$70$$$O	of$$$71$$$73$$$O	an$$$74$$$76$$$O	extract$$$77$$$84$$$O	of$$$85$$$87$$$O	the$$$88$$$91$$$O	Madonna$$$92$$$99$$$O	lily$$$100$$$104$$$O	(Lilium$$$105$$$112$$$O	Candidum)$$$113$$$122$$$O	and$$$123$$$126$$$O	glucosamine.$$$127$$$139$$$O
CN1876065A
An$$$0$$$2$$$O	ointment$$$3$$$11$$$O	for$$$12$$$15$$$O	treating$$$16$$$24$$$O	burns$$$25$$$30$$$O	and$$$31$$$34$$$O	scalds$$$35$$$41$$$O	and$$$42$$$45$$$O	preparation$$$46$$$57$$$O	method$$$58$$$64$$$O	thereof$$$65$$$72$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	plaster$$$27$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	burn$$$48$$$52$$$O	and$$$53$$$56$$$O	scald,$$$57$$$63$$$O	which$$$64$$$69$$$O	is$$$70$$$72$$$O	prepared$$$73$$$81$$$O	mainly$$$82$$$88$$$O	from$$$89$$$93$$$O	mimosa-tree$$$94$$$105$$$O	bark,$$$106$$$111$$$O	subprostrate$$$112$$$124$$$O	sophora$$$125$$$132$$$O	root,$$$133$$$138$$$O	tuber$$$139$$$144$$$O	fleeceflower$$$145$$$157$$$O	stem,$$$158$$$163$$$O	gecko,$$$164$$$170$$$O	sesame$$$171$$$177$$$O	oil$$$178$$$181$$$O	and$$$182$$$185$$$O	baras$$$186$$$191$$$O	camphor.$$$192$$$200$$$I
US20110105470
Novel$$$0$$$5$$$O	Lapachone$$$6$$$15$$$I	Compounds$$$16$$$25$$$O	And$$$26$$$29$$$O	Methods$$$30$$$37$$$O	of$$$38$$$40$$$O	Use$$$41$$$44$$$O	Thereof$$$45$$$52$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	novel$$$31$$$36$$$O	tricyclic$$$37$$$46$$$I	spiro-oxathiine$$$47$$$62$$$I	naphthoquinone$$$63$$$77$$$I	derivatives,$$$78$$$90$$$O	a$$$91$$$92$$$O	synthetic$$$93$$$102$$$O	method$$$103$$$109$$$O	for$$$110$$$113$$$O	making$$$114$$$120$$$O	the$$$121$$$124$$$O	derivatives,$$$125$$$137$$$O	and$$$138$$$141$$$O	the$$$142$$$145$$$O	use$$$146$$$149$$$O	of$$$150$$$152$$$O	the$$$153$$$156$$$O	derivatives$$$157$$$168$$$O	to$$$169$$$171$$$O	induce$$$172$$$178$$$O	cell$$$179$$$183$$$O	death$$$184$$$189$$$O	and/or$$$190$$$196$$$O	to$$$197$$$199$$$O	inhibit$$$200$$$207$$$O	proliferation$$$208$$$221$$$O	of$$$222$$$224$$$O	cancer$$$225$$$231$$$O	or$$$232$$$234$$$O	precancerous$$$235$$$247$$$O	cells.$$$248$$$254$$$O	The$$$255$$$258$$$O	naphthoquinone$$$259$$$273$$$I	derivatives$$$274$$$285$$$O	of$$$286$$$288$$$O	the$$$289$$$292$$$O	present$$$293$$$300$$$O	invention$$$301$$$310$$$O	are$$$311$$$314$$$O	related$$$315$$$322$$$O	to$$$323$$$325$$$O	the$$$326$$$329$$$O	compound$$$330$$$338$$$O	known$$$339$$$344$$$O	as$$$345$$$347$$$O	Î²-lapachone$$$348$$$360$$$I	(3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).$$$361$$$421$$$I
CN101919817B
Lafutidine$$$0$$$10$$$I	gastric-retention$$$11$$$28$$$O	controlled-release$$$29$$$47$$$O	composition$$$48$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	lafutidine$$$27$$$37$$$I	gastric-retention$$$38$$$55$$$O	controlled-release$$$56$$$74$$$O	composite$$$75$$$84$$$O	belonging$$$85$$$94$$$O	to$$$95$$$97$$$O	the$$$98$$$101$$$O	field$$$102$$$107$$$O	of$$$108$$$110$$$O	pharmaceutic$$$111$$$123$$$O	preparations.$$$124$$$137$$$O	The$$$138$$$141$$$O	lafutidine$$$142$$$152$$$I	gastric-retention$$$153$$$170$$$O	controlled-release$$$171$$$189$$$O	composite$$$190$$$199$$$O	is$$$200$$$202$$$O	characterized$$$203$$$216$$$O	by$$$217$$$219$$$O	comprising$$$220$$$230$$$O	the$$$231$$$234$$$O	following$$$235$$$244$$$O	components$$$245$$$255$$$O	in$$$256$$$258$$$O	percentage$$$259$$$269$$$O	by$$$270$$$272$$$O	weight:$$$273$$$280$$$O	5%-20%$$$281$$$287$$$O	of$$$288$$$290$$$O	the$$$291$$$294$$$O	lafutidine,$$$295$$$306$$$I	10%-40%$$$307$$$314$$$O	of$$$315$$$317$$$O	framework$$$318$$$327$$$O	materials,$$$328$$$338$$$O	10%-30%$$$339$$$346$$$O	of$$$347$$$349$$$O	assistant$$$350$$$359$$$O	bleaching$$$360$$$369$$$O	agents,$$$370$$$377$$$O	5%-15%$$$378$$$384$$$O	of$$$385$$$387$$$O	foaming$$$388$$$395$$$O	agents,$$$396$$$403$$$O	5%-15%$$$404$$$410$$$O	of$$$411$$$413$$$O	filling$$$414$$$421$$$O	agents$$$422$$$428$$$O	and$$$429$$$432$$$O	0.5%-10%$$$433$$$441$$$O	of$$$442$$$444$$$O	lubricating$$$445$$$456$$$O	agents.$$$457$$$464$$$O	The$$$465$$$468$$$O	composite$$$469$$$478$$$O	has$$$479$$$482$$$O	reasonability$$$483$$$496$$$O	and$$$497$$$500$$$O	simple$$$501$$$507$$$O	preparation$$$508$$$519$$$O	process;$$$520$$$528$$$O	compared$$$529$$$537$$$O	with$$$538$$$542$$$O	same$$$543$$$547$$$O	pharmaceuticals,$$$548$$$564$$$O	the$$$565$$$568$$$O	lafutidine$$$569$$$579$$$I	gastric-retention$$$580$$$597$$$O	controlled-release$$$598$$$616$$$O	composite$$$617$$$626$$$O	has$$$627$$$630$$$O	little$$$631$$$637$$$O	dose,$$$638$$$643$$$O	good$$$644$$$648$$$O	tolerance,$$$649$$$659$$$O	little$$$660$$$666$$$O	side$$$667$$$671$$$O	effect,$$$672$$$679$$$O	and$$$680$$$683$$$O	the$$$684$$$687$$$O	like;$$$688$$$693$$$O	and$$$694$$$697$$$O	in$$$698$$$700$$$O	addition,$$$701$$$710$$$O	compared$$$711$$$719$$$O	with$$$720$$$724$$$O	the$$$725$$$728$$$O	conventional$$$729$$$741$$$O	tablets,$$$742$$$750$$$O	the$$$751$$$754$$$O	lafutidine$$$755$$$765$$$I	gastric-retention$$$766$$$783$$$O	controlled-release$$$784$$$802$$$O	composite$$$803$$$812$$$O	enhances$$$813$$$821$$$O	the$$$822$$$825$$$O	solubility$$$826$$$836$$$O	of$$$837$$$839$$$O	lafutidine,$$$840$$$851$$$I	prolongs$$$852$$$860$$$O	the$$$861$$$864$$$O	action$$$865$$$871$$$O	time$$$872$$$876$$$O	(prolonged$$$877$$$887$$$O	from$$$888$$$892$$$O	2-3$$$893$$$896$$$O	hours$$$897$$$902$$$O	to$$$903$$$905$$$O	5-6$$$906$$$909$$$O	hours)$$$910$$$916$$$O	on$$$917$$$919$$$O	the$$$920$$$923$$$O	upper$$$924$$$929$$$O	parts$$$930$$$935$$$O	of$$$936$$$938$$$O	a$$$939$$$940$$$O	stomach$$$941$$$948$$$O	and$$$949$$$952$$$O	a$$$953$$$954$$$O	small$$$955$$$960$$$O	intestine,$$$961$$$971$$$O	promotes$$$972$$$980$$$O	the$$$981$$$984$$$O	absorption,$$$985$$$996$$$O	enhances$$$997$$$1005$$$O	the$$$1006$$$1009$$$O	bioavailability,$$$1010$$$1026$$$O	reduces$$$1027$$$1034$$$O	the$$$1035$$$1038$$$O	pharmaceutical$$$1039$$$1053$$$O	usage$$$1054$$$1059$$$O	times,$$$1060$$$1066$$$O	achieves$$$1067$$$1075$$$O	the$$$1076$$$1079$$$O	maximum$$$1080$$$1087$$$O	treatment$$$1088$$$1097$$$O	effect$$$1098$$$1104$$$O	through$$$1105$$$1112$$$O	minimum$$$1113$$$1120$$$O	doses,$$$1121$$$1127$$$O	reduces$$$1128$$$1135$$$O	the$$$1136$$$1139$$$O	concentration$$$1140$$$1153$$$O	change$$$1154$$$1160$$$O	of$$$1161$$$1163$$$O	peaks$$$1164$$$1169$$$O	and$$$1170$$$1173$$$O	valleys$$$1174$$$1181$$$O	and$$$1182$$$1185$$$O	has$$$1186$$$1189$$$O	good$$$1190$$$1194$$$O	patient$$$1195$$$1202$$$O	compliance.$$$1203$$$1214$$$O
US20100076053
Sequence$$$0$$$8$$$O	of$$$9$$$11$$$O	dsrna:$$$12$$$18$$$O	atn-rna,$$$19$$$27$$$O	intervention$$$28$$$40$$$O	using$$$41$$$46$$$O	irnai,$$$47$$$53$$$O	use$$$54$$$57$$$O	of$$$58$$$60$$$O	a$$$61$$$62$$$O	sequence$$$63$$$71$$$O	of$$$72$$$74$$$O	dsrna:$$$75$$$81$$$O	atn-rna,$$$82$$$90$$$O	a$$$91$$$92$$$O	method$$$93$$$99$$$O	of$$$100$$$102$$$O	treating$$$103$$$111$$$O	and$$$112$$$115$$$O	inhibiting$$$116$$$126$$$O	a$$$127$$$128$$$O	brain$$$129$$$134$$$O	tumor,$$$135$$$141$$$O	a$$$142$$$143$$$O	kit$$$144$$$147$$$O	for$$$148$$$151$$$O	inhibiting$$$152$$$162$$$O	cancer$$$163$$$169$$$O	cell$$$170$$$174$$$O	which$$$175$$$180$$$O	expresses$$$181$$$190$$$O	tenascin,$$$191$$$200$$$O	a$$$201$$$202$$$O	method$$$203$$$209$$$O	for$$$210$$$213$$$O	a$$$214$$$215$$$O	kit$$$216$$$219$$$O	preparation$$$220$$$231$$$O	in$$$232$$$234$$$O	a$$$235$$$236$$$O	brain$$$237$$$242$$$O	tumor$$$243$$$248$$$O	therapy$$$249$$$256$$$O
The$$$0$$$3$$$O	subject$$$4$$$11$$$O	matters$$$12$$$19$$$O	of$$$20$$$22$$$O	this$$$23$$$27$$$O	invention$$$28$$$37$$$O	are$$$38$$$41$$$O	a$$$42$$$43$$$O	sequence$$$44$$$52$$$O	of$$$53$$$55$$$O	double-stranded$$$56$$$71$$$O	RNA:$$$72$$$76$$$O	ATN-RNA,$$$77$$$85$$$O	intervention$$$86$$$98$$$O	using$$$99$$$104$$$O	interference$$$105$$$117$$$O	RNA$$$118$$$121$$$O	(iRNAi),$$$122$$$130$$$O	use$$$131$$$134$$$O	of$$$135$$$137$$$O	a$$$138$$$139$$$O	sequence$$$140$$$148$$$O	of$$$149$$$151$$$O	double-stranded$$$152$$$167$$$O	RNA:$$$168$$$172$$$O	ATN-RNA,$$$173$$$181$$$O	a$$$182$$$183$$$O	method$$$184$$$190$$$O	of$$$191$$$193$$$O	treating$$$194$$$202$$$O	a$$$203$$$204$$$O	brain$$$205$$$210$$$O	tumor$$$211$$$216$$$O	and$$$217$$$220$$$O	a$$$221$$$222$$$O	method$$$223$$$229$$$O	of$$$230$$$232$$$O	inhibiting$$$233$$$243$$$O	a$$$244$$$245$$$O	brain$$$246$$$251$$$O	tumor$$$252$$$257$$$O	cells$$$258$$$263$$$O	which$$$264$$$269$$$O	express$$$270$$$277$$$O	tenascin,$$$278$$$287$$$O	a$$$288$$$289$$$O	kit$$$290$$$293$$$O	for$$$294$$$297$$$O	inhibiting$$$298$$$308$$$O	cancer$$$309$$$315$$$O	cell$$$316$$$320$$$O	which$$$321$$$326$$$O	expresses$$$327$$$336$$$O	tenascin$$$337$$$345$$$O	and$$$346$$$349$$$O	a$$$350$$$351$$$O	method$$$352$$$358$$$O	for$$$359$$$362$$$O	a$$$363$$$364$$$O	kit$$$365$$$368$$$O	preparation$$$369$$$380$$$O	in$$$381$$$383$$$O	a$$$384$$$385$$$O	brain$$$386$$$391$$$O	tumor$$$392$$$397$$$O	therapy.$$$398$$$406$$$O	Malignant$$$407$$$416$$$O	gliomas$$$417$$$424$$$O	preferentially$$$425$$$439$$$O	express$$$440$$$447$$$O	a$$$448$$$449$$$O	number$$$450$$$456$$$O	of$$$457$$$459$$$O	surface$$$460$$$467$$$O	markers$$$468$$$475$$$O	that$$$476$$$480$$$O	may$$$481$$$484$$$O	be$$$485$$$487$$$O	exploited$$$488$$$497$$$O	as$$$498$$$500$$$O	therapeutic$$$501$$$512$$$O	targets,$$$513$$$521$$$O	including$$$522$$$531$$$O	tenascin-C,$$$532$$$543$$$O	an$$$544$$$546$$$O	extracellular$$$547$$$560$$$O	matrix$$$561$$$567$$$O	glycoprotein$$$568$$$580$$$O	that$$$581$$$585$$$O	is$$$586$$$588$$$O	ubiquitously$$$589$$$601$$$O	expressed$$$602$$$611$$$O	by$$$612$$$614$$$O	malignant$$$615$$$624$$$O	gliomas$$$625$$$632$$$O	and$$$633$$$636$$$O	probably$$$637$$$645$$$O	contributes$$$646$$$657$$$O	to$$$658$$$660$$$O	tumor$$$661$$$666$$$O	cell$$$667$$$671$$$O	adhesion,$$$672$$$681$$$O	invasion,$$$682$$$691$$$O	migration$$$692$$$701$$$O	and$$$702$$$705$$$O	proliferation.$$$706$$$720$$$O	For$$$721$$$724$$$O	tenascin-C$$$725$$$735$$$O	inhibition,$$$736$$$747$$$O	RNA$$$748$$$751$$$O	interference$$$752$$$764$$$O	intervention$$$765$$$777$$$O	(iRNAi)$$$778$$$785$$$O	approach$$$786$$$794$$$O	have$$$795$$$799$$$O	been$$$800$$$804$$$O	applied.$$$805$$$813$$$O
WO2010006697A3
Powders$$$0$$$7$$$O	for$$$8$$$11$$$O	reconstitution$$$12$$$26$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	drinkable$$$26$$$35$$$O	formulations$$$36$$$48$$$O	prepared$$$49$$$57$$$O	from$$$58$$$62$$$O	powders$$$63$$$70$$$O	for$$$71$$$74$$$O	reconstitution$$$75$$$89$$$O	comprising$$$90$$$100$$$O	etravirine$$$101$$$111$$$I	(TMC125)$$$112$$$120$$$I	dispersed$$$121$$$130$$$O	in$$$131$$$133$$$O	certain$$$134$$$141$$$O	water-soluble$$$142$$$155$$$O	polymers,$$$156$$$165$$$O	which$$$166$$$171$$$O	can$$$172$$$175$$$O	be$$$176$$$178$$$O	used$$$179$$$183$$$O	in$$$184$$$186$$$O	the$$$187$$$190$$$O	treatment$$$191$$$200$$$O	of$$$201$$$203$$$O	HIV$$$204$$$207$$$O	infection.$$$208$$$218$$$O
WO2014128611A1
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	graft$$$13$$$18$$$O	versus$$$19$$$25$$$O	host$$$26$$$30$$$O	disease$$$31$$$38$$$O	in$$$39$$$41$$$O	transplant$$$42$$$52$$$O	patients$$$53$$$61$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	of$$$42$$$44$$$O	treating$$$45$$$53$$$O	patients$$$54$$$62$$$O	who$$$63$$$66$$$O	undergo$$$67$$$74$$$O	hematopoietic$$$75$$$88$$$O	stem$$$89$$$93$$$O	cell$$$94$$$98$$$O	transplantation$$$99$$$114$$$O	(HSCT)$$$115$$$121$$$O	with$$$122$$$126$$$O	peripheral$$$127$$$137$$$O	blood$$$138$$$143$$$O	mobilized$$$144$$$153$$$O	stem$$$154$$$158$$$O	cells$$$159$$$164$$$O	for$$$165$$$168$$$O	hematological$$$169$$$182$$$O	malignancies$$$183$$$195$$$O	and$$$196$$$199$$$O	for$$$200$$$203$$$O	whom$$$204$$$208$$$O	the$$$209$$$212$$$O	risk$$$213$$$217$$$O	for$$$218$$$221$$$O	severe$$$222$$$228$$$O	acute$$$229$$$234$$$O	graft$$$235$$$240$$$O	versus$$$241$$$247$$$O	host$$$248$$$252$$$O	disease$$$253$$$260$$$O	(GVHD)$$$261$$$267$$$O	is$$$268$$$270$$$O	considerable.$$$271$$$284$$$O
WO2012071221A2
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	once-daily$$$29$$$39$$$O	treatment$$$40$$$49$$$O	of$$$50$$$52$$$O	obsessive$$$53$$$62$$$O	compulsive$$$63$$$73$$$O	disorder$$$74$$$82$$$O	with$$$83$$$87$$$O	ondansetron$$$88$$$99$$$I
Compositions$$$0$$$12$$$O	for$$$13$$$16$$$O	once-daily$$$17$$$27$$$O	administration$$$28$$$42$$$O	of$$$43$$$45$$$O	ondansetron$$$46$$$57$$$O	are$$$58$$$61$$$O	described.$$$62$$$72$$$O	Compositions$$$73$$$85$$$O	include$$$86$$$93$$$O	a$$$94$$$95$$$O	core,$$$96$$$101$$$O	a$$$102$$$103$$$O	semi-permeable$$$104$$$118$$$O	membrane$$$119$$$127$$$O	disposed$$$128$$$136$$$O	generally$$$137$$$146$$$O	around$$$147$$$153$$$O	the$$$154$$$157$$$O	core,$$$158$$$163$$$O	an$$$164$$$166$$$O	orifice$$$167$$$174$$$O	in$$$175$$$177$$$O	the$$$178$$$181$$$O	semi-permeable$$$182$$$196$$$O	membrane$$$197$$$205$$$O	in$$$206$$$208$$$O	fluid$$$209$$$214$$$O	communication$$$215$$$228$$$O	with$$$229$$$233$$$O	the$$$234$$$237$$$O	core,$$$238$$$243$$$O	and$$$244$$$247$$$O	a$$$248$$$249$$$O	coating$$$250$$$257$$$O	having$$$258$$$264$$$O	a$$$265$$$266$$$O	first$$$267$$$272$$$O	therapeutically$$$273$$$288$$$O	effective$$$289$$$298$$$O	dose$$$299$$$303$$$O	of$$$304$$$306$$$O	ondansetron$$$307$$$318$$$I	or$$$319$$$321$$$O	a$$$322$$$323$$$O	pharmaceutically$$$324$$$340$$$O	acceptable$$$341$$$351$$$O	salt$$$352$$$356$$$O	disposed$$$357$$$365$$$O	generally$$$366$$$375$$$O	around$$$376$$$382$$$O	the$$$383$$$386$$$O	semi-permeable$$$387$$$401$$$O	membrane.$$$402$$$411$$$O	The$$$412$$$415$$$O	core$$$416$$$420$$$O	includes$$$421$$$429$$$O	first,$$$430$$$436$$$O	second,$$$437$$$444$$$O	and$$$445$$$448$$$O	third$$$449$$$454$$$O	layers.$$$455$$$462$$$O	The$$$463$$$466$$$O	first$$$467$$$472$$$O	layer$$$473$$$478$$$O	is$$$479$$$481$$$O	in$$$482$$$484$$$O	fluid$$$485$$$490$$$O	communication$$$491$$$504$$$O	with$$$505$$$509$$$O	the$$$510$$$513$$$O	orifice.$$$514$$$522$$$O	The$$$523$$$526$$$O	second$$$527$$$533$$$O	layer$$$534$$$539$$$O	includes$$$540$$$548$$$O	a$$$549$$$550$$$O	second$$$551$$$557$$$O	therapeutically$$$558$$$573$$$O	effective$$$574$$$583$$$O	dose$$$584$$$588$$$O	of$$$589$$$591$$$O	ondansetron$$$592$$$603$$$O	or$$$604$$$606$$$O	a$$$607$$$608$$$O	pharmaceutically$$$609$$$625$$$O	acceptable$$$626$$$636$$$O	salt$$$637$$$641$$$O	and$$$642$$$645$$$O	is$$$646$$$648$$$O	located$$$649$$$656$$$O	adjacent$$$657$$$665$$$O	to$$$666$$$668$$$O	the$$$669$$$672$$$O	first$$$673$$$678$$$O	layer.$$$679$$$685$$$O	The$$$686$$$689$$$O	third$$$690$$$695$$$O	layer$$$696$$$701$$$O	is$$$702$$$704$$$O	located$$$705$$$712$$$O	adjacent$$$713$$$721$$$O	the$$$722$$$725$$$O	second$$$726$$$732$$$O	layer.$$$733$$$739$$$O	Methods$$$740$$$747$$$O	for$$$748$$$751$$$O	treating$$$752$$$760$$$O	obsessive$$$761$$$770$$$O	compulsive$$$771$$$781$$$O	disorder$$$782$$$790$$$O	by$$$791$$$793$$$O	administering$$$794$$$807$$$O	these$$$808$$$813$$$O	compositions$$$814$$$826$$$O	are$$$827$$$830$$$O	also$$$831$$$835$$$O	described.$$$836$$$846$$$O
WO2009038057A1
Nitrogenated$$$0$$$12$$$I	fused-ring$$$13$$$23$$$I	derivative,$$$24$$$35$$$O	pharmaceutical$$$36$$$50$$$O	composition$$$51$$$62$$$O	comprising$$$63$$$73$$$O	the$$$74$$$77$$$O	same,$$$78$$$83$$$O	and$$$84$$$87$$$O	use$$$88$$$91$$$O	of$$$92$$$94$$$O	the$$$95$$$98$$$O	same$$$99$$$103$$$O	for$$$104$$$107$$$O	medical$$$108$$$115$$$O	purposes$$$116$$$124$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	compound$$$15$$$23$$$O	which$$$24$$$29$$$O	is$$$30$$$32$$$O	useful$$$33$$$39$$$O	as$$$40$$$42$$$O	a$$$43$$$44$$$O	prophylactic$$$45$$$57$$$O	or$$$58$$$60$$$O	therapeutic$$$61$$$72$$$O	agent$$$73$$$78$$$O	for$$$79$$$82$$$O	a$$$83$$$84$$$O	sex$$$85$$$88$$$O	hormone-dependent$$$89$$$106$$$O	disease$$$107$$$114$$$O	or$$$115$$$117$$$O	the$$$118$$$121$$$O	like.$$$122$$$127$$$O	Specifically$$$128$$$140$$$O	disclosed$$$141$$$150$$$O	are:$$$151$$$155$$$O	a$$$156$$$157$$$O	nitrogenated$$$158$$$170$$$O	fused-ring$$$171$$$181$$$O	derivative$$$182$$$192$$$O	which$$$193$$$198$$$O	is$$$199$$$201$$$O	represented$$$202$$$213$$$O	by$$$214$$$216$$$O	the$$$217$$$220$$$O	general$$$221$$$228$$$O	formula$$$229$$$236$$$O	(I)$$$237$$$240$$$O	and$$$241$$$244$$$O	which$$$245$$$250$$$O	has$$$251$$$254$$$O	a$$$255$$$256$$$O	GnRH$$$257$$$261$$$I	antagonistic$$$262$$$274$$$O	activity,$$$275$$$284$$$O	or$$$285$$$287$$$O	a$$$288$$$289$$$O	prodrug$$$290$$$297$$$O	or$$$298$$$300$$$O	a$$$301$$$302$$$O	pharmacologically$$$303$$$320$$$O	acceptable$$$321$$$331$$$O	salt$$$332$$$336$$$O	thereof;$$$337$$$345$$$O	a$$$346$$$347$$$O	pharmaceutical$$$348$$$362$$$O	composition$$$363$$$374$$$O	comprising$$$375$$$385$$$O	the$$$386$$$389$$$O	derivative,$$$390$$$401$$$O	the$$$402$$$405$$$O	prodrug$$$406$$$413$$$O	or$$$414$$$416$$$O	the$$$417$$$420$$$O	pharmacologically$$$421$$$438$$$O	acceptable$$$439$$$449$$$O	salt;$$$450$$$455$$$O	use$$$456$$$459$$$O	of$$$460$$$462$$$O	the$$$463$$$466$$$O	derivative,$$$467$$$478$$$O	the$$$479$$$482$$$O	prodrug$$$483$$$490$$$O	or$$$491$$$493$$$O	the$$$494$$$497$$$O	pharmacologically$$$498$$$515$$$O	acceptable$$$516$$$526$$$O	salt$$$527$$$531$$$O	for$$$532$$$535$$$O	medical$$$536$$$543$$$O	purposes;$$$544$$$553$$$O	and$$$554$$$557$$$O	others.$$$558$$$565$$$O	In$$$566$$$568$$$O	the$$$569$$$572$$$O	formula$$$573$$$580$$$O	(I),$$$581$$$585$$$O	the$$$586$$$589$$$O	rings$$$590$$$595$$$O	A$$$596$$$597$$$O	and$$$598$$$601$$$O	B$$$602$$$603$$$O	independently$$$604$$$617$$$O	represent$$$618$$$627$$$O	an$$$628$$$630$$$O	aryl$$$631$$$635$$$I	or$$$636$$$638$$$O	a$$$639$$$640$$$O	heteroaryl;$$$641$$$652$$$I	RA$$$653$$$655$$$O	and$$$656$$$659$$$O	RB$$$660$$$662$$$O	independently$$$663$$$676$$$O	represent$$$677$$$686$$$O	a$$$687$$$688$$$O	halogen,$$$689$$$697$$$I	a$$$698$$$699$$$O	nitro,$$$700$$$706$$$I	an$$$707$$$709$$$O	alkyl,$$$710$$$716$$$I	-OW1,$$$717$$$722$$$I	-COW2,$$$723$$$729$$$I	-NW3W4$$$730$$$736$$$I	or$$$737$$$739$$$O	the$$$740$$$743$$$O	like;$$$744$$$749$$$O	E$$$750$$$751$$$O	represents$$$752$$$762$$$O	an$$$763$$$765$$$O	oxygen$$$766$$$772$$$I	atom$$$773$$$777$$$O	or$$$778$$$780$$$O	the$$$781$$$784$$$O	like;$$$785$$$790$$$O	U$$$791$$$792$$$O	represents$$$793$$$803$$$O	a$$$804$$$805$$$O	single$$$806$$$812$$$O	bond$$$813$$$817$$$O	or$$$818$$$820$$$O	the$$$821$$$824$$$O	like;$$$825$$$830$$$O	and$$$831$$$834$$$O	X$$$835$$$836$$$O	represents$$$837$$$847$$$O	-SO2-Y,$$$848$$$855$$$I	-O-(alkylene)-Y$$$856$$$871$$$I	or$$$872$$$874$$$O	the$$$875$$$878$$$O	like$$$879$$$883$$$O	[wherein$$$884$$$892$$$O	Y$$$893$$$894$$$O	represents$$$895$$$905$$$O	Z,$$$906$$$908$$$O	an$$$909$$$911$$$O	amino$$$912$$$917$$$I	or$$$918$$$920$$$O	the$$$921$$$924$$$O	like;$$$925$$$930$$$O	Z$$$931$$$932$$$O	represents$$$933$$$943$$$O	a$$$944$$$945$$$O	heterocycloalkyl,$$$946$$$963$$$I	an$$$964$$$966$$$O	aryl$$$967$$$971$$$I	or$$$972$$$974$$$O	the$$$975$$$978$$$O	like].$$$979$$$985$$$O
US20100113352
Retinol$$$0$$$7$$$I	formulations$$$8$$$20$$$O	and$$$21$$$24$$$O	methods$$$25$$$32$$$O	for$$$33$$$36$$$O	their$$$37$$$42$$$O	use$$$43$$$46$$$O
A$$$0$$$1$$$O	composition$$$2$$$13$$$O	for$$$14$$$17$$$O	the$$$18$$$21$$$O	treatment$$$22$$$31$$$O	of$$$32$$$34$$$O	skin$$$35$$$39$$$O	comprises$$$40$$$49$$$O	a$$$50$$$51$$$O	non-emulsified,$$$52$$$67$$$O	aqueous$$$68$$$75$$$O	suspension$$$76$$$86$$$O	of$$$87$$$89$$$O	retinol.$$$90$$$98$$$I	The$$$99$$$102$$$O	composition$$$103$$$114$$$O	may$$$115$$$118$$$O	further$$$119$$$126$$$O	include$$$127$$$134$$$O	at$$$135$$$137$$$O	least$$$138$$$143$$$O	one$$$144$$$147$$$O	protein$$$148$$$155$$$O	species,$$$156$$$164$$$O	and$$$165$$$168$$$O	some$$$169$$$173$$$O	proteins$$$174$$$182$$$O	used$$$183$$$187$$$O	in$$$188$$$190$$$O	the$$$191$$$194$$$O	composition$$$195$$$206$$$O	include$$$207$$$214$$$O	collagen$$$215$$$223$$$O	and$$$224$$$227$$$O	elastin.$$$228$$$236$$$O	The$$$237$$$240$$$O	composition$$$241$$$252$$$O	may$$$253$$$256$$$O	also$$$257$$$261$$$O	include$$$262$$$269$$$O	hyaluronic$$$270$$$280$$$O	acid.$$$281$$$286$$$O	The$$$287$$$290$$$O	composition$$$291$$$302$$$O	may$$$303$$$306$$$O	also$$$307$$$311$$$O	include$$$312$$$319$$$O	one$$$320$$$323$$$O	or$$$324$$$326$$$O	more$$$327$$$331$$$O	of$$$332$$$334$$$O	tocopheryl$$$335$$$345$$$I	acetate,$$$346$$$354$$$I	propylene$$$355$$$364$$$I	glycol,$$$365$$$372$$$I	and$$$373$$$376$$$O	linseed$$$377$$$384$$$O	extract.$$$385$$$393$$$O	Also$$$394$$$398$$$O	disclosed$$$399$$$408$$$O	are$$$409$$$412$$$O	methods$$$413$$$420$$$O	for$$$421$$$424$$$O	making$$$425$$$431$$$O	the$$$432$$$435$$$O	composition$$$436$$$447$$$O	and$$$448$$$451$$$O	use$$$452$$$455$$$O	of$$$456$$$458$$$O	the$$$459$$$462$$$O	composition$$$463$$$474$$$O	for$$$475$$$478$$$O	the$$$479$$$482$$$O	treatment$$$483$$$492$$$O	of$$$493$$$495$$$O	skin.$$$496$$$501$$$O
CA2330128C
Food$$$0$$$4$$$O	compositions,$$$5$$$18$$$O	compositions$$$19$$$31$$$O	for$$$32$$$35$$$O	oral$$$36$$$40$$$O	cavity$$$41$$$47$$$O	and$$$48$$$51$$$O	medicinal$$$52$$$61$$$O	compositions$$$62$$$74$$$O	for$$$75$$$78$$$O	preventing$$$79$$$89$$$O	or$$$90$$$92$$$O	treating$$$93$$$101$$$O	periodontosis$$$102$$$115$$$O	and$$$116$$$119$$$O	method$$$120$$$126$$$O	for$$$127$$$130$$$O	preventing$$$131$$$141$$$O	or$$$142$$$144$$$O	treating$$$145$$$153$$$O	periodontosis$$$154$$$167$$$O
Food$$$0$$$4$$$O	compositions,$$$5$$$18$$$O	compositions$$$19$$$31$$$O	for$$$32$$$35$$$O	the$$$36$$$39$$$O	oral$$$40$$$44$$$O	cavity$$$45$$$51$$$O	and$$$52$$$55$$$O	medicinal$$$56$$$65$$$O	compositions$$$66$$$78$$$O	for$$$79$$$82$$$O	preventing$$$83$$$93$$$O	or$$$94$$$96$$$O	treating$$$97$$$105$$$O	periodontosis$$$106$$$119$$$O	which$$$120$$$125$$$O	contain$$$126$$$133$$$O	(A)$$$134$$$137$$$O	one$$$138$$$141$$$O	or$$$142$$$144$$$O	more$$$145$$$149$$$O	components$$$150$$$160$$$O	selected$$$161$$$169$$$O	from$$$170$$$174$$$O	among$$$175$$$180$$$O	natural$$$181$$$188$$$O	polyphenol-containing$$$189$$$210$$$I	extracts,$$$211$$$220$$$O	and$$$221$$$224$$$O	(B)$$$225$$$228$$$O	one$$$229$$$232$$$O	or$$$233$$$235$$$O	more$$$236$$$240$$$O	components$$$241$$$251$$$O	selected$$$252$$$260$$$O	from$$$261$$$265$$$O	the$$$266$$$269$$$O	group$$$270$$$275$$$O	consisting$$$276$$$286$$$O	of$$$287$$$289$$$O	vitamin$$$290$$$297$$$I	C,$$$298$$$300$$$I	vitamin$$$301$$$308$$$I	E,$$$309$$$311$$$I	vitamin$$$312$$$319$$$I	A$$$320$$$321$$$I	and$$$322$$$325$$$O	.beta.-carotene;$$$326$$$342$$$I	and$$$343$$$346$$$O	a$$$347$$$348$$$O	method$$$349$$$355$$$O	for$$$356$$$359$$$O	preventing$$$360$$$370$$$O	or$$$371$$$373$$$O	treating$$$374$$$382$$$O	periodontosis$$$383$$$396$$$O	with$$$397$$$401$$$O	the$$$402$$$405$$$O	use$$$406$$$409$$$O	of$$$410$$$412$$$O	these$$$413$$$418$$$O	compositions.$$$419$$$432$$$O
US20050250730
Combination$$$0$$$11$$$O	of$$$12$$$14$$$O	an$$$15$$$17$$$O	adenosine$$$18$$$27$$$O	A2A-receptor$$$28$$$40$$$O	agonist$$$41$$$48$$$O	and$$$49$$$52$$$O	tiotropium$$$53$$$63$$$I	or$$$64$$$66$$$O	a$$$67$$$68$$$O	derivative$$$69$$$79$$$O	thereof$$$80$$$87$$$O	for$$$88$$$91$$$O	treating$$$92$$$100$$$O	obstructive$$$101$$$112$$$O	airways$$$113$$$120$$$O	and$$$121$$$124$$$O	other$$$125$$$130$$$O	inflammatory$$$131$$$143$$$O	diseases$$$144$$$152$$$O
A$$$0$$$1$$$O	combination$$$2$$$13$$$O	of$$$14$$$16$$$O	therapeutic$$$17$$$28$$$O	agents$$$29$$$35$$$O	useful$$$36$$$42$$$O	in$$$43$$$45$$$O	the$$$46$$$49$$$O	treatment$$$50$$$59$$$O	of$$$60$$$62$$$O	obstructive$$$63$$$74$$$O	airways$$$75$$$82$$$O	and$$$83$$$86$$$O	other$$$87$$$92$$$O	inflammatory$$$93$$$105$$$O	diseases$$$106$$$114$$$O	comprising$$$115$$$125$$$O	(i)$$$126$$$129$$$O	an$$$130$$$132$$$O	adenosine$$$133$$$142$$$I	A2A$$$143$$$146$$$O	receptor$$$147$$$155$$$O	agonist;$$$156$$$164$$$O	and$$$165$$$168$$$O	(ii)$$$169$$$173$$$O	an$$$174$$$176$$$O	anti-cholinergic$$$177$$$193$$$O	agent,$$$194$$$200$$$O	preferably$$$201$$$211$$$O	comprising$$$212$$$222$$$O	a$$$223$$$224$$$O	member$$$225$$$231$$$O	selected$$$232$$$240$$$O	from$$$241$$$245$$$O	the$$$246$$$249$$$O	group$$$250$$$255$$$O	consisting$$$256$$$266$$$O	of$$$267$$$269$$$O	tiotropium$$$270$$$280$$$I	and$$$281$$$284$$$O	derivatives$$$285$$$296$$$O	thereof;$$$297$$$305$$$O	the$$$306$$$309$$$O	combination$$$310$$$321$$$O	being$$$322$$$327$$$O	therapeutically$$$328$$$343$$$O	effective$$$344$$$353$$$O	in$$$354$$$356$$$O	the$$$357$$$360$$$O	treatment$$$361$$$370$$$O	of$$$371$$$373$$$O	the$$$374$$$377$$$O	diseases$$$378$$$386$$$O	when$$$387$$$391$$$O	administered$$$392$$$404$$$O	by$$$405$$$407$$$O	inhalation;$$$408$$$419$$$O	as$$$420$$$422$$$O	well$$$423$$$427$$$O	as$$$428$$$430$$$O	to$$$431$$$433$$$O	a$$$434$$$435$$$O	method$$$436$$$442$$$O	of$$$443$$$445$$$O	treating$$$446$$$454$$$O	the$$$455$$$458$$$O	obstructive$$$459$$$470$$$O	airways$$$471$$$478$$$O	and$$$479$$$482$$$O	other$$$483$$$488$$$O	inflammatory$$$489$$$501$$$O	diseases$$$502$$$510$$$O	comprising$$$511$$$521$$$O	administering$$$522$$$535$$$O	separately,$$$536$$$547$$$O	simultaneously$$$548$$$562$$$O	or$$$563$$$565$$$O	sequentially$$$566$$$578$$$O	to$$$579$$$581$$$O	the$$$582$$$585$$$O	mammal$$$586$$$592$$$O	by$$$593$$$595$$$O	inhalation$$$596$$$606$$$O	a$$$607$$$608$$$O	therapeutically$$$609$$$624$$$O	effective$$$625$$$634$$$O	amount$$$635$$$641$$$O	of$$$642$$$644$$$O	the$$$645$$$648$$$O	combination$$$649$$$660$$$O	of$$$661$$$663$$$O	therapeutic$$$664$$$675$$$O	agents;$$$676$$$683$$$O	as$$$684$$$686$$$O	well$$$687$$$691$$$O	as$$$692$$$694$$$O	to$$$695$$$697$$$O	a$$$698$$$699$$$O	pharmaceutical$$$700$$$714$$$O	composition$$$715$$$726$$$O	comprising$$$727$$$737$$$O	a$$$738$$$739$$$O	pharmaceutically$$$740$$$756$$$O	acceptable$$$757$$$767$$$O	carrier$$$768$$$775$$$O	together$$$776$$$784$$$O	with$$$785$$$789$$$O	the$$$790$$$793$$$O	combination$$$794$$$805$$$O	of$$$806$$$808$$$O	therapeutic$$$809$$$820$$$O	agents;$$$821$$$828$$$O	as$$$829$$$831$$$O	well$$$832$$$836$$$O	as$$$837$$$839$$$O	to$$$840$$$842$$$O	a$$$843$$$844$$$O	product$$$845$$$852$$$O	containing$$$853$$$863$$$O	the$$$864$$$867$$$O	compounds$$$868$$$877$$$O	of$$$878$$$880$$$O	the$$$881$$$884$$$O	combination$$$885$$$896$$$O	for$$$897$$$900$$$O	separate,$$$901$$$910$$$O	simultaneous$$$911$$$923$$$O	or$$$924$$$926$$$O	sequential$$$927$$$937$$$O	administration$$$938$$$952$$$O	by$$$953$$$955$$$O	inhalation$$$956$$$966$$$O	to$$$967$$$969$$$O	a$$$970$$$971$$$O	mammal$$$972$$$978$$$O	for$$$979$$$982$$$O	the$$$983$$$986$$$O	treatment$$$987$$$996$$$O	of$$$997$$$999$$$O	obstructive$$$1000$$$1011$$$O	airways$$$1012$$$1019$$$O	and$$$1020$$$1023$$$O	other$$$1024$$$1029$$$O	inflammatory$$$1030$$$1042$$$O	diseases.$$$1043$$$1052$$$O	It$$$1053$$$1055$$$O	is$$$1056$$$1058$$$O	preferred$$$1059$$$1068$$$O	that$$$1069$$$1073$$$O	the$$$1074$$$1077$$$O	anti-cholinergic$$$1078$$$1094$$$O	agent$$$1095$$$1100$$$O	component$$$1101$$$1110$$$O	be$$$1111$$$1113$$$O	tiotropium$$$1114$$$1124$$$O	bromide.$$$1125$$$1133$$$O
US20110059923
Novel$$$0$$$5$$$O	phosphate$$$6$$$15$$$I	or$$$16$$$18$$$O	a$$$19$$$20$$$O	pharmaceutically$$$21$$$37$$$O	acceptable$$$38$$$48$$$O	salt$$$49$$$53$$$O	thereof,$$$54$$$62$$$O	a$$$63$$$64$$$O	production$$$65$$$75$$$O	method$$$76$$$82$$$O	therefor$$$83$$$91$$$O	and$$$92$$$95$$$O	a$$$96$$$97$$$O	pharmaceutical$$$98$$$112$$$O	composition$$$113$$$124$$$O	for$$$125$$$128$$$O	preventing$$$129$$$139$$$O	and$$$140$$$143$$$O	treating$$$144$$$152$$$O	central$$$153$$$160$$$O	nervous$$$161$$$168$$$O	system$$$169$$$175$$$O	disorders$$$176$$$185$$$O	containing$$$186$$$196$$$O	the$$$197$$$200$$$O	same$$$201$$$205$$$O	as$$$206$$$208$$$O	an$$$209$$$211$$$O	active$$$212$$$218$$$O	component$$$219$$$228$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	novel$$$35$$$40$$$O	{4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate$$$41$$$109$$$I	or$$$110$$$112$$$O	a$$$113$$$114$$$O	pharmaceutically$$$115$$$131$$$O	acceptable$$$132$$$142$$$O	salt$$$143$$$147$$$O	thereof,$$$148$$$156$$$O	a$$$157$$$158$$$O	production$$$159$$$169$$$O	method$$$170$$$176$$$O	therefor$$$177$$$185$$$O	and$$$186$$$189$$$O	a$$$190$$$191$$$O	pharmaceutical$$$192$$$206$$$O	composition$$$207$$$218$$$O	for$$$219$$$222$$$O	preventing$$$223$$$233$$$O	and$$$234$$$237$$$O	treating$$$238$$$246$$$O	central$$$247$$$254$$$O	nervous$$$255$$$262$$$O	system$$$263$$$269$$$O	disorders$$$270$$$279$$$O	which$$$280$$$285$$$O	contains$$$286$$$294$$$O	the$$$295$$$298$$$O	same$$$299$$$303$$$O	as$$$304$$$306$$$O	an$$$307$$$309$$$O	active$$$310$$$316$$$O	component.$$$317$$$327$$$O	The$$$328$$$331$$$O	novel$$$332$$$337$$$O	{4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate$$$338$$$406$$$I	or$$$407$$$409$$$O	a$$$410$$$411$$$O	pharmaceutically$$$412$$$428$$$O	acceptable$$$429$$$439$$$O	salt$$$440$$$444$$$O	thereof$$$445$$$452$$$O	according$$$453$$$462$$$O	to$$$463$$$465$$$O	the$$$466$$$469$$$O	present$$$470$$$477$$$O	invention$$$478$$$487$$$O	can$$$488$$$491$$$O	beneficially$$$492$$$504$$$O	be$$$505$$$507$$$O	used$$$508$$$512$$$O	to$$$513$$$515$$$O	prevent$$$516$$$523$$$O	and$$$524$$$527$$$O	treat$$$528$$$533$$$O	central$$$534$$$541$$$O	nervous$$$542$$$549$$$O	system$$$550$$$556$$$O	disorders$$$557$$$566$$$O	since$$$567$$$572$$$O	it$$$573$$$575$$$O	exhibits$$$576$$$584$$$O	an$$$585$$$587$$$O	equivalent$$$588$$$598$$$O	biological$$$599$$$609$$$O	and$$$610$$$613$$$O	pharmacological$$$614$$$629$$$O	activity$$$630$$$638$$$O	to$$$639$$$641$$$O	venlafaxine$$$642$$$653$$$O	and$$$654$$$657$$$O	salts$$$658$$$663$$$O	thereof$$$664$$$671$$$O	which$$$672$$$677$$$O	are$$$678$$$681$$$O	known$$$682$$$687$$$O	in$$$688$$$690$$$O	the$$$691$$$694$$$O	field,$$$695$$$701$$$O	it$$$702$$$704$$$O	has$$$705$$$708$$$O	very$$$709$$$713$$$O	little$$$714$$$720$$$O	toxicity,$$$721$$$730$$$O	and,$$$731$$$735$$$O	in$$$736$$$738$$$O	particular,$$$739$$$750$$$O	it$$$751$$$753$$$O	is$$$754$$$756$$$O	outstandingly$$$757$$$770$$$O	soluble$$$771$$$778$$$O	in$$$779$$$781$$$O	water$$$782$$$787$$$O	as$$$788$$$790$$$O	compared$$$791$$$799$$$O	with$$$800$$$804$$$O	prior-art$$$805$$$814$$$O	venlafaxine$$$815$$$826$$$I	derivatives.$$$827$$$839$$$O
US6994862
Comprising$$$0$$$10$$$O	9-90%$$$11$$$16$$$O	by$$$17$$$19$$$O	weight$$$20$$$26$$$O	monoglyceride$$$27$$$40$$$I	compound,$$$41$$$50$$$O	0.01-90%$$$51$$$59$$$O	by$$$60$$$62$$$O	weight$$$63$$$69$$$O	emulsifier,$$$70$$$81$$$O	0-50%$$$82$$$87$$$O	by$$$88$$$90$$$O	weight$$$91$$$97$$$O	water-insoluble$$$98$$$113$$$O	material,$$$114$$$123$$$O	0-90.9%$$$124$$$131$$$O	by$$$132$$$134$$$O	weight$$$135$$$141$$$O	of$$$142$$$144$$$O	organic$$$145$$$152$$$O	solvent;$$$153$$$161$$$O	drug$$$162$$$166$$$O	delivery$$$167$$$175$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	anhydrous$$$36$$$45$$$O	liquid$$$46$$$52$$$O	composition$$$53$$$64$$$O	wherein$$$65$$$72$$$O	monoglyceride$$$73$$$86$$$I	is$$$87$$$89$$$O	mixed$$$90$$$95$$$O	with$$$96$$$100$$$O	an$$$101$$$103$$$O	emulsifier$$$104$$$114$$$O	and$$$115$$$118$$$O	a$$$119$$$120$$$O	solvent,$$$121$$$129$$$O	and$$$130$$$133$$$O	the$$$134$$$137$$$O	manufacturing$$$138$$$151$$$O	method$$$152$$$158$$$O	thereof,$$$159$$$167$$$O	and$$$168$$$171$$$O	more$$$172$$$176$$$O	specifically,$$$177$$$190$$$O	to$$$191$$$193$$$O	an$$$194$$$196$$$O	anhydrous$$$197$$$206$$$O	liquid$$$207$$$213$$$O	composition$$$214$$$225$$$O	wherein$$$226$$$233$$$O	monoglyceride$$$234$$$247$$$I	is$$$248$$$250$$$O	mixed$$$251$$$256$$$O	with$$$257$$$261$$$O	a$$$262$$$263$$$O	water-insoluble$$$264$$$279$$$O	material,$$$280$$$289$$$O	an$$$290$$$292$$$O	emulsifier$$$293$$$303$$$O	and$$$304$$$307$$$O	a$$$308$$$309$$$O	solvent,$$$310$$$318$$$O	and$$$319$$$322$$$O	the$$$323$$$326$$$O	manufacturing$$$327$$$340$$$O	method$$$341$$$347$$$O	thereof.$$$348$$$356$$$O	Further,$$$357$$$365$$$O	the$$$366$$$369$$$O	present$$$370$$$377$$$O	invention$$$378$$$387$$$O	relates$$$388$$$395$$$O	to$$$396$$$398$$$O	a$$$399$$$400$$$O	lyophilized$$$401$$$412$$$O	powder$$$413$$$419$$$O	and$$$420$$$423$$$O	the$$$424$$$427$$$O	manufacturing$$$428$$$441$$$O	method$$$442$$$448$$$O	thereof,$$$449$$$457$$$O	wherein$$$458$$$465$$$O	the$$$466$$$469$$$O	lyophilized$$$470$$$481$$$O	powder$$$482$$$488$$$O	is$$$489$$$491$$$O	prepared$$$492$$$500$$$O	by$$$501$$$503$$$O	dissolving$$$504$$$514$$$O	the$$$515$$$518$$$O	mixed$$$519$$$524$$$O	liquid$$$525$$$531$$$O	composition$$$532$$$543$$$O	in$$$544$$$546$$$O	water,$$$547$$$553$$$O	adding$$$554$$$560$$$O	with$$$561$$$565$$$O	a$$$566$$$567$$$O	cryoprotectant$$$568$$$582$$$O	followed$$$583$$$591$$$O	by$$$592$$$594$$$O	the$$$595$$$598$$$O	lyophilization.$$$599$$$614$$$O	In$$$615$$$617$$$O	the$$$618$$$621$$$O	process$$$622$$$629$$$O	of$$$630$$$632$$$O	dispersion,$$$633$$$644$$$O	the$$$645$$$648$$$O	lyophilized$$$649$$$660$$$O	liquid$$$661$$$667$$$O	composition$$$668$$$679$$$O	and$$$680$$$683$$$O	the$$$684$$$687$$$O	powder$$$688$$$694$$$O	of$$$695$$$697$$$O	the$$$698$$$701$$$O	present$$$702$$$709$$$O	invention$$$710$$$719$$$O	can$$$720$$$723$$$O	spontaneously$$$724$$$737$$$O	generate$$$738$$$746$$$O	particles$$$747$$$756$$$O	of$$$757$$$759$$$O	200-500$$$760$$$767$$$O	nm$$$768$$$770$$$O	by$$$771$$$773$$$O	gently$$$774$$$780$$$O	shaking$$$781$$$788$$$O	with$$$789$$$793$$$O	hands$$$794$$$799$$$O	without$$$800$$$807$$$O	a$$$808$$$809$$$O	powerful$$$810$$$818$$$O	mechanical$$$819$$$829$$$O	force.$$$830$$$836$$$O	Also$$$837$$$841$$$O	the$$$842$$$845$$$O	lyophilized$$$846$$$857$$$O	liquid$$$858$$$864$$$O	composition$$$865$$$876$$$O	and$$$877$$$880$$$O	the$$$881$$$884$$$O	powder$$$885$$$891$$$O	of$$$892$$$894$$$O	the$$$895$$$898$$$O	present$$$899$$$906$$$O	invention$$$907$$$916$$$O	are$$$917$$$920$$$O	physicochemically$$$921$$$938$$$O	stable$$$939$$$945$$$O	since$$$946$$$951$$$O	they$$$952$$$956$$$O	neither$$$957$$$964$$$O	contain$$$965$$$972$$$O	water$$$973$$$978$$$O	that$$$979$$$983$$$O	causes$$$984$$$990$$$O	oxidation$$$991$$$1000$$$O	or$$$1001$$$1003$$$O	hydrolysis$$$1004$$$1014$$$O	upon$$$1015$$$1019$$$O	storage$$$1020$$$1027$$$O	nor$$$1028$$$1031$$$O	undergo$$$1032$$$1039$$$O	phase$$$1040$$$1045$$$O	separation.$$$1046$$$1057$$$O	Considering$$$1058$$$1069$$$O	all$$$1070$$$1073$$$O	the$$$1074$$$1077$$$O	raw$$$1078$$$1081$$$O	materials$$$1082$$$1091$$$O	of$$$1092$$$1094$$$O	the$$$1095$$$1098$$$O	present$$$1099$$$1106$$$O	invention$$$1107$$$1116$$$O	are$$$1117$$$1120$$$O	biocompatible,$$$1121$$$1135$$$O	the$$$1136$$$1139$$$O	present$$$1140$$$1147$$$O	invention$$$1148$$$1157$$$O	will$$$1158$$$1162$$$O	be$$$1163$$$1165$$$O	useful$$$1166$$$1172$$$O	in$$$1173$$$1175$$$O	medical$$$1176$$$1183$$$O	and$$$1184$$$1187$$$O	pharmaceutical$$$1188$$$1202$$$O	fields$$$1203$$$1209$$$O	such$$$1210$$$1214$$$O	as$$$1215$$$1217$$$O	drug$$$1218$$$1222$$$O	delivery.$$$1223$$$1232$$$O
CA2662732A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	a$$$7$$$8$$$O	pharmaceutical$$$9$$$23$$$O	composition$$$24$$$35$$$O	comprising$$$36$$$46$$$O	an$$$47$$$49$$$O	anticholinergic$$$50$$$65$$$O	for$$$66$$$69$$$O	killing$$$70$$$77$$$O	microorganisms$$$78$$$92$$$O	and$$$93$$$96$$$O	for$$$97$$$100$$$O	treating$$$101$$$109$$$O	respiratory$$$110$$$121$$$O	tract$$$122$$$127$$$O	infections$$$128$$$138$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	a$$$44$$$45$$$O	compound$$$46$$$54$$$O	of$$$55$$$57$$$O	the$$$58$$$61$$$O	formula$$$62$$$69$$$O	(1)$$$70$$$73$$$O	in$$$74$$$76$$$O	which$$$77$$$82$$$O	X-$$$83$$$85$$$O	is$$$86$$$88$$$O	a$$$89$$$90$$$O	singly$$$91$$$97$$$O	negatively$$$98$$$108$$$O	charged$$$109$$$116$$$O	anion,$$$117$$$123$$$O	R$$$124$$$125$$$O	is$$$126$$$128$$$O	H,$$$129$$$131$$$I	methyl$$$132$$$138$$$I	or$$$139$$$141$$$O	OH,$$$142$$$145$$$I	R1$$$146$$$148$$$O	and$$$149$$$152$$$O	R2$$$153$$$155$$$O	are$$$156$$$159$$$O	identical$$$160$$$169$$$O	or$$$170$$$172$$$O	different,$$$173$$$183$$$O	phenyl$$$184$$$190$$$I	or$$$191$$$193$$$O	thienyl,$$$194$$$202$$$I	for$$$203$$$206$$$O	producing$$$207$$$216$$$O	a$$$217$$$218$$$O	medicament$$$219$$$229$$$O	for$$$230$$$233$$$O	killing$$$234$$$241$$$O	microorganisms$$$242$$$256$$$O	and/or$$$257$$$263$$$O	for$$$264$$$267$$$O	producing$$$268$$$277$$$O	a$$$278$$$279$$$O	medicament$$$280$$$290$$$O	for$$$291$$$294$$$O	the$$$295$$$298$$$O	treatment$$$299$$$308$$$O	of$$$309$$$311$$$O	respiratory$$$312$$$323$$$O	tract$$$324$$$329$$$O	infections$$$330$$$340$$$O	caused$$$341$$$347$$$O	by$$$348$$$350$$$O	microorganisms.$$$351$$$366$$$O
WO2009153179A1
Pyrrolidine$$$0$$$11$$$I	derivatives$$$12$$$23$$$O	as$$$24$$$26$$$O	nk2$$$27$$$30$$$O	receptor$$$31$$$39$$$O	antagonists$$$40$$$51$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	compound$$$35$$$43$$$O	of$$$44$$$46$$$O	Formula$$$47$$$54$$$O	(I)$$$55$$$58$$$O	wherein$$$59$$$66$$$O	R1$$$67$$$69$$$O	is$$$71$$$73$$$O	hydrogen,$$$74$$$83$$$I	halogen,$$$84$$$92$$$I	cyano$$$93$$$98$$$I	or$$$99$$$101$$$O	lower$$$102$$$107$$$O	alkyl;$$$108$$$114$$$I	n$$$115$$$116$$$O	is$$$117$$$119$$$O	1,$$$120$$$122$$$O	2$$$123$$$124$$$O	or$$$125$$$127$$$O	3;$$$128$$$130$$$O	R2$$$131$$$133$$$O	is$$$134$$$136$$$O	hydrogen$$$137$$$145$$$I	or$$$146$$$148$$$O	lower$$$149$$$154$$$O	alkyl;$$$155$$$161$$$I	R3$$$162$$$164$$$O	is$$$165$$$167$$$O	an$$$168$$$170$$$O	aryl-$$$171$$$176$$$I	or$$$177$$$179$$$O	a$$$180$$$181$$$O	heteroaryl$$$182$$$192$$$I	ring,$$$193$$$198$$$O	wherein$$$199$$$206$$$O	the$$$207$$$210$$$O	rings$$$211$$$216$$$O	are$$$217$$$220$$$O	optionally$$$221$$$231$$$O	substituted$$$232$$$243$$$O	by$$$244$$$246$$$O	one$$$247$$$250$$$O	or$$$251$$$253$$$O	two$$$254$$$257$$$O	substituents$$$258$$$270$$$O	R';$$$271$$$274$$$O	R'$$$275$$$277$$$O	is$$$278$$$280$$$O	selected$$$281$$$289$$$O	from$$$290$$$294$$$O	hydrogen,$$$295$$$304$$$I	halogen,$$$305$$$313$$$I	lower$$$314$$$319$$$O	alkyl,$$$320$$$326$$$I	lower$$$327$$$332$$$O	alkoxy,$$$333$$$340$$$I	lower$$$341$$$346$$$O	alkyl$$$347$$$352$$$I	substituted$$$353$$$364$$$O	by$$$365$$$367$$$O	halogen,$$$368$$$376$$$I	lower$$$377$$$382$$$O	alkoxy$$$383$$$389$$$I	substituted$$$390$$$401$$$O	by$$$402$$$404$$$O	halogen,-S(O)2-lower$$$405$$$425$$$I	alkyl,$$$426$$$432$$$I	CN,$$$433$$$436$$$I	-NR4R5,$$$437$$$444$$$I	-C(O)-lower$$$445$$$456$$$I	alkyl,$$$457$$$463$$$I	heterocyclyl$$$464$$$476$$$I	or$$$477$$$479$$$O	heteroaryl;$$$480$$$491$$$I	R4/R5$$$492$$$497$$$O	are$$$498$$$501$$$O	independently$$$502$$$515$$$O	from$$$516$$$520$$$O	each$$$521$$$525$$$O	other$$$526$$$531$$$O	hydrogen,$$$532$$$541$$$I	-(CO)CF3$$$542$$$550$$$O	or$$$551$$$553$$$O	lower$$$554$$$559$$$O	alkyl$$$560$$$565$$$I	or$$$566$$$568$$$O	is$$$569$$$571$$$O	a$$$572$$$573$$$O	non$$$574$$$577$$$O	aromatic$$$578$$$586$$$I	heterocyclic$$$587$$$599$$$I	group$$$600$$$605$$$O	(II)$$$606$$$610$$$O	wherein$$$611$$$618$$$O	X$$$619$$$620$$$O	is$$$621$$$623$$$O	N$$$624$$$625$$$I	or$$$626$$$628$$$O	CH;$$$629$$$632$$$I	Y$$$633$$$634$$$O	is$$$635$$$637$$$O	-CH(R7)-;$$$638$$$647$$$I	-N(R7')-,$$$648$$$657$$$I	or$$$658$$$660$$$O	O$$$661$$$662$$$I	or$$$663$$$665$$$O	can$$$666$$$669$$$O	be$$$670$$$672$$$O	SO2;$$$673$$$677$$$I	R6$$$678$$$680$$$O	is$$$681$$$683$$$O	hydrogen,$$$684$$$693$$$I	lower$$$694$$$699$$$O	alkyl$$$700$$$705$$$I	or$$$706$$$708$$$O	hydroxy;$$$709$$$717$$$I	R7$$$718$$$720$$$O	is$$$721$$$723$$$O	hydrogen,$$$724$$$733$$$I	hydroxy,$$$734$$$742$$$I	=0,$$$743$$$746$$$I	lower$$$747$$$752$$$O	alkyl,$$$753$$$759$$$I	lower$$$760$$$765$$$O	alkoxy,$$$766$$$773$$$I	-S(O)2-lower$$$774$$$786$$$I	alkyl,$$$787$$$793$$$I	-C(O)-lower$$$794$$$805$$$I	alkyl,$$$806$$$812$$$I	-C(O)CH2O-lower$$$813$$$828$$$I	alkyl,$$$829$$$835$$$I	-CH2CN,$$$836$$$843$$$I	-C(O)CH2CN,$$$844$$$855$$$I	-C(O)-cycloalkyl$$$856$$$872$$$I	wherein$$$873$$$880$$$O	the$$$881$$$884$$$O	cycloalkyl$$$885$$$895$$$I	group$$$896$$$901$$$O	is$$$902$$$904$$$O	optionally$$$905$$$915$$$O	substituted$$$916$$$927$$$O	by$$$928$$$930$$$O	cyano,$$$931$$$937$$$I	lower$$$938$$$943$$$O	alkyl,$$$944$$$950$$$I	one$$$951$$$954$$$O	or$$$955$$$957$$$O	two$$$958$$$961$$$O	halogen$$$962$$$969$$$I	atoms,$$$970$$$976$$$O	=0$$$977$$$979$$$I	or$$$980$$$982$$$O	by$$$983$$$985$$$O	amino,$$$986$$$992$$$I	or$$$993$$$995$$$O	is$$$996$$$998$$$O	-C(O)O-lower$$$999$$$1011$$$I	alkyl,$$$1012$$$1018$$$I	-NH-lower$$$1019$$$1028$$$I	alkyl,$$$1029$$$1035$$$I	-NRC(O)O-lower$$$1036$$$1050$$$I	alkyl,$$$1051$$$1057$$$I	-NRC(O)-lower$$$1058$$$1071$$$I	alkyl$$$1072$$$1077$$$I	or$$$1078$$$1080$$$O	-CH2O-lower$$$1081$$$1092$$$I	alkyl;$$$1093$$$1099$$$I	and$$$1100$$$1103$$$O	R7'$$$1104$$$1107$$$O	is$$$1108$$$1110$$$O	hydrogen,$$$1111$$$1120$$$I	lower$$$1121$$$1126$$$O	alkyl,$$$1127$$$1133$$$I	-(CH2)q-S(O)2-lower$$$1134$$$1153$$$I	alkyl,$$$1154$$$1160$$$I	-(CH2)q-S(O)2-cycloalkyl,$$$1161$$$1186$$$I	-C(O)-lower$$$1187$$$1198$$$I	alkyl,$$$1199$$$1205$$$I	-(CH2)q-cycloalkyl,$$$1206$$$1225$$$I	-C(O)CH2-O-lower$$$1226$$$1242$$$I	alkyl,$$$1243$$$1249$$$I	-(CH2)qCN,$$$1250$$$1260$$$I	-C(O)CN,$$$1261$$$1269$$$I	-C(O)CH2CN,$$$1270$$$1281$$$I	lower$$$1282$$$1287$$$O	alkyl$$$1288$$$1293$$$I	substituted$$$1294$$$1305$$$O	by$$$1306$$$1308$$$O	halogen,$$$1309$$$1317$$$I	lower$$$1318$$$1323$$$O	alkenyl$$$1324$$$1331$$$I	substituted$$$1332$$$1343$$$O	by$$$1344$$$1346$$$O	halogen,$$$1347$$$1355$$$I	-C(O)-cycloalkyl$$$1356$$$1372$$$I	wherein$$$1373$$$1380$$$O	the$$$1381$$$1384$$$O	cycloalkyl$$$1385$$$1395$$$I	group$$$1396$$$1401$$$O	is$$$1402$$$1404$$$O	optionally$$$1405$$$1415$$$O	substituted$$$1416$$$1427$$$O	by$$$1428$$$1430$$$O	cyano,$$$1431$$$1437$$$I	lower$$$1438$$$1443$$$O	alkyl,$$$1444$$$1450$$$I	one$$$1451$$$1454$$$O	or$$$1455$$$1457$$$O	two$$$1458$$$1461$$$O	halogen$$$1462$$$1469$$$I	atoms,$$$1470$$$1476$$$O	=0$$$1477$$$1479$$$I	or$$$1480$$$1482$$$O	by$$$1483$$$1485$$$O	amino,$$$1486$$$1492$$$I	or$$$1493$$$1495$$$O	is$$$1496$$$1498$$$O	-C(O)O-lower$$$1499$$$1511$$$I	alkyl$$$1512$$$1517$$$I	or$$$1518$$$1520$$$O	-(CH2)qO-lower$$$1521$$$1535$$$I	alkyl$$$1536$$$1541$$$I	and$$$1542$$$1545$$$O	q$$$1546$$$1547$$$O	is$$$1548$$$1550$$$O	O$$$1551$$$1552$$$O	-$$$1553$$$1554$$$O	3;$$$1555$$$1557$$$O	or$$$1558$$$1560$$$O	R6$$$1561$$$1563$$$O	and$$$1564$$$1567$$$O	R7$$$1568$$$1570$$$O	may$$$1571$$$1574$$$O	form$$$1575$$$1579$$$O	together$$$1580$$$1588$$$O	with$$$1589$$$1593$$$O	the$$$1594$$$1597$$$O	carbon$$$1598$$$1604$$$I	atoms$$$1605$$$1610$$$O	to$$$1611$$$1613$$$O	which$$$1614$$$1619$$$O	they$$$1620$$$1624$$$O	are$$$1625$$$1628$$$O	attach$$$1629$$$1635$$$O	a$$$1636$$$1637$$$O	five$$$1638$$$1642$$$O	or$$$1643$$$1645$$$O	six-$$$1646$$$1650$$$O	membered$$$1651$$$1659$$$O	non$$$1660$$$1663$$$O	aromatic$$$1664$$$1672$$$I	ring$$$1673$$$1677$$$O	or$$$1678$$$1680$$$O	R6$$$1681$$$1683$$$O	and$$$1684$$$1687$$$O	R7$$$1688$$$1690$$$O	may$$$1691$$$1694$$$O	form$$$1695$$$1699$$$O	together$$$1700$$$1708$$$O	with$$$1709$$$1713$$$O	the$$$1714$$$1717$$$O	nitrogen$$$1718$$$1726$$$I	and$$$1727$$$1730$$$O	carbon$$$1731$$$1737$$$I	atoms$$$1738$$$1743$$$O	to$$$1744$$$1746$$$O	which$$$1747$$$1752$$$O	they$$$1753$$$1757$$$O	are$$$1758$$$1761$$$O	attach$$$1762$$$1768$$$O	a$$$1769$$$1770$$$O	five$$$1771$$$1775$$$O	or$$$1776$$$1778$$$O	six-membered$$$1779$$$1791$$$O	non$$$1792$$$1795$$$O	aromatic$$$1796$$$1804$$$I	ring;$$$1805$$$1810$$$O	p$$$1811$$$1812$$$O	is$$$1813$$$1815$$$O	0,$$$1816$$$1818$$$O	1$$$1819$$$1820$$$O	or$$$1821$$$1823$$$O	2;$$$1824$$$1826$$$O	Ar$$$1827$$$1829$$$I	is$$$1830$$$1832$$$O	aryl-$$$1833$$$1838$$$I	or$$$1839$$$1841$$$O	heteroaryl,$$$1842$$$1853$$$I	wherein$$$1854$$$1861$$$O	the$$$1862$$$1865$$$O	rings$$$1866$$$1871$$$O	are$$$1872$$$1875$$$O	optionally$$$1876$$$1886$$$O	substituted$$$1887$$$1898$$$O	by$$$1899$$$1901$$$O	one$$$1902$$$1905$$$O	or$$$1906$$$1908$$$O	two$$$1909$$$1912$$$O	substituents$$$1913$$$1925$$$O	R";$$$1926$$$1929$$$O	R'$$$1930$$$1932$$$O	'$$$1933$$$1934$$$O	is$$$1935$$$1937$$$O	selected$$$1938$$$1946$$$O	from$$$1947$$$1951$$$O	hydrogen,$$$1952$$$1961$$$I	halogen,$$$1962$$$1970$$$I	lower$$$1971$$$1976$$$O	alkyl,$$$1977$$$1983$$$I	lower$$$1984$$$1989$$$O	alkyl$$$1990$$$1995$$$I	substituted$$$1996$$$2007$$$O	by$$$2008$$$2010$$$O	halogen,$$$2011$$$2019$$$I	lower$$$2020$$$2025$$$O	alkoxy,$$$2026$$$2033$$$I	lower$$$2034$$$2039$$$O	alkoxy$$$2040$$$2046$$$I	substituted$$$2047$$$2058$$$O	by$$$2059$$$2061$$$O	halogen,$$$2062$$$2070$$$I	-O-CH2-cycloalkyl,$$$2071$$$2089$$$I	-NR4R5,$$$2090$$$2097$$$I	-CN,$$$2098$$$2102$$$I	-CH(CH3)CN,$$$2103$$$2114$$$I	-CH2O-lower$$$2115$$$2126$$$I	alkyl$$$2127$$$2132$$$I	or$$$2133$$$2135$$$O	pyrrolyl;$$$2136$$$2145$$$I	m$$$2146$$$2147$$$O	is$$$2148$$$2150$$$O	0,$$$2151$$$2153$$$O	1$$$2154$$$2155$$$O	or$$$2156$$$2158$$$O	2$$$2159$$$2160$$$O	and$$$2161$$$2164$$$O	o$$$2165$$$2166$$$O	is$$$2167$$$2169$$$O	0;$$$2170$$$2172$$$O	o$$$2173$$$2174$$$O	is$$$2175$$$2177$$$O	0,$$$2178$$$2180$$$O	1$$$2181$$$2182$$$O	or$$$2183$$$2185$$$O	2$$$2186$$$2187$$$O	and$$$2188$$$2191$$$O	m$$$2192$$$2193$$$O	is$$$2194$$$2196$$$O	1$$$2197$$$2198$$$O	or$$$2199$$$2201$$$O	pharmaceutically$$$2202$$$2218$$$O	active$$$2219$$$2225$$$O	salts,$$$2226$$$2232$$$O	racemic$$$2233$$$2240$$$O	mixtures,$$$2241$$$2250$$$O	enantiomers,$$$2251$$$2263$$$O	optical$$$2264$$$2271$$$O	isomers$$$2272$$$2279$$$O	or$$$2280$$$2282$$$O	tautomeric$$$2283$$$2293$$$O	forms$$$2294$$$2299$$$O	thereof.$$$2300$$$2308$$$O	The$$$2309$$$2312$$$O	compounds$$$2313$$$2322$$$O	may$$$2323$$$2326$$$O	be$$$2327$$$2329$$$O	used$$$2330$$$2334$$$O	for$$$2335$$$2338$$$O	the$$$2339$$$2342$$$O	treatment$$$2343$$$2352$$$O	of$$$2353$$$2355$$$O	depression,$$$2356$$$2367$$$O	anxiety$$$2368$$$2375$$$O	or$$$2376$$$2378$$$O	schizophrenia.$$$2379$$$2393$$$O
WO2014164667A1
Dengue$$$0$$$6$$$O	and$$$7$$$10$$$O	west$$$11$$$15$$$O	nile$$$16$$$20$$$O	virus$$$21$$$26$$$O	protease$$$27$$$35$$$O	inhibitors$$$36$$$46$$$O
Compounds$$$0$$$9$$$O	and$$$10$$$13$$$O	methods$$$14$$$21$$$O	of$$$22$$$24$$$O	treating$$$25$$$33$$$O	or$$$34$$$36$$$O	preventing$$$37$$$47$$$O	a$$$48$$$49$$$O	Flavivirus$$$50$$$60$$$O	infection$$$61$$$70$$$O	in$$$71$$$73$$$O	a$$$74$$$75$$$O	subject$$$76$$$83$$$O	are$$$84$$$87$$$O	provided.$$$88$$$97$$$O	The$$$98$$$101$$$O	methods$$$102$$$109$$$O	comprise$$$110$$$118$$$O	administering$$$119$$$132$$$O	to$$$133$$$135$$$O	the$$$136$$$139$$$O	subject$$$140$$$147$$$O	a$$$148$$$149$$$O	therapeutically$$$150$$$165$$$O	effective$$$166$$$175$$$O	amount$$$176$$$182$$$O	of$$$183$$$185$$$O	a$$$186$$$187$$$O	compound$$$188$$$196$$$O	as$$$197$$$199$$$O	described$$$200$$$209$$$O	herein.$$$210$$$217$$$O	The$$$218$$$221$$$O	methods$$$222$$$229$$$O	are$$$230$$$233$$$O	useful$$$234$$$240$$$O	in$$$241$$$243$$$O	treating$$$244$$$252$$$O	and/or$$$253$$$259$$$O	preventing$$$260$$$270$$$O	Flavivirus$$$271$$$281$$$O	infections$$$282$$$292$$$O	such$$$293$$$297$$$O	as,$$$298$$$301$$$O	for$$$302$$$305$$$O	example,$$$306$$$314$$$O	West$$$315$$$319$$$O	Nile$$$320$$$324$$$O	Virus,$$$325$$$331$$$O	Dengue$$$332$$$338$$$O	Virus,$$$339$$$345$$$O	and$$$346$$$349$$$O	Japanese$$$350$$$358$$$O	Encephalitis$$$359$$$371$$$O	Virus.$$$372$$$378$$$O	Methods$$$379$$$386$$$O	of$$$387$$$389$$$O	inhibiting$$$390$$$400$$$O	a$$$401$$$402$$$O	Flavivirus$$$403$$$413$$$O	protease$$$414$$$422$$$O	in$$$423$$$425$$$O	a$$$426$$$427$$$O	cell$$$428$$$432$$$O	are$$$433$$$436$$$O	also$$$437$$$441$$$O	provided.$$$442$$$451$$$O
CN101402632A
Aryl$$$0$$$4$$$I	hydrazide$$$5$$$14$$$I	compounds$$$15$$$24$$$O	with$$$25$$$29$$$O	antineoplastic$$$30$$$44$$$O	activity$$$45$$$53$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	N-tert-butyl-N-substituted$$$31$$$57$$$I	aroyl$$$58$$$63$$$I	group-N'-(5-substituted$$$64$$$87$$$I	aryl-2-furanylcarbonyl)$$$88$$$111$$$I	hydrazine$$$112$$$121$$$I	compounds,$$$122$$$132$$$O	which$$$133$$$138$$$O	have$$$139$$$143$$$O	a$$$144$$$145$$$O	general$$$146$$$153$$$O	formula$$$154$$$161$$$O	(I),$$$162$$$166$$$O	wherein$$$167$$$174$$$O	Ar1$$$175$$$178$$$O	and$$$179$$$182$$$O	Ar2$$$183$$$186$$$O	are$$$187$$$190$$$O	as$$$191$$$193$$$O	defined$$$194$$$201$$$O	in$$$202$$$204$$$O	an$$$205$$$207$$$O	instruction;$$$208$$$220$$$O	and$$$221$$$224$$$O	the$$$225$$$228$$$O	invention$$$229$$$238$$$O	also$$$239$$$243$$$O	relates$$$244$$$251$$$O	to$$$252$$$254$$$O	a$$$255$$$256$$$O	preparation$$$257$$$268$$$O	method$$$269$$$275$$$O	thereof$$$276$$$283$$$O	and$$$284$$$287$$$O	application$$$288$$$299$$$O	of$$$300$$$302$$$O	the$$$303$$$306$$$O	compounds$$$307$$$316$$$O	used$$$317$$$321$$$O	as$$$322$$$324$$$O	an$$$325$$$327$$$O	antitumor$$$328$$$337$$$O	depressor.$$$338$$$348$$$O
CN101940701A
Aloe$$$0$$$4$$$O	oculentum$$$5$$$14$$$O	and$$$15$$$18$$$O	preparation$$$19$$$30$$$O	method$$$31$$$37$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	aloe$$$25$$$29$$$O	oculentum$$$30$$$39$$$O	and$$$40$$$43$$$O	a$$$44$$$45$$$O	preparation$$$46$$$57$$$O	method,$$$58$$$65$$$O	and$$$66$$$69$$$O	belongs$$$70$$$77$$$O	to$$$78$$$80$$$O	the$$$81$$$84$$$O	technical$$$85$$$94$$$O	field$$$95$$$100$$$O	of$$$101$$$103$$$O	eyedrops.$$$104$$$113$$$O	The$$$114$$$117$$$O	aloe$$$118$$$122$$$O	oculentum$$$123$$$132$$$O	is$$$133$$$135$$$O	characterized$$$136$$$149$$$O	by$$$150$$$152$$$O	comprising$$$153$$$163$$$O	the$$$164$$$167$$$O	following$$$168$$$177$$$O	medicaments$$$178$$$189$$$O	and$$$190$$$193$$$O	raw$$$194$$$197$$$O	materials$$$198$$$207$$$O	in$$$208$$$210$$$O	part$$$211$$$215$$$O	by$$$216$$$218$$$O	weight:$$$219$$$226$$$O	80$$$227$$$229$$$O	to$$$230$$$232$$$O	90$$$233$$$235$$$O	parts$$$236$$$241$$$O	of$$$242$$$244$$$O	aloe$$$245$$$249$$$O	gel,$$$250$$$254$$$O	1$$$255$$$256$$$O	to$$$257$$$259$$$O	5$$$260$$$261$$$O	parts$$$262$$$267$$$O	of$$$268$$$270$$$O	aloin,$$$271$$$277$$$I	0.1$$$278$$$281$$$O	to$$$282$$$284$$$O	1$$$285$$$286$$$O	part$$$287$$$291$$$O	of$$$292$$$294$$$O	alomycin,$$$295$$$304$$$I	0.1$$$305$$$308$$$O	to$$$309$$$311$$$O	0.3$$$312$$$315$$$O	part$$$316$$$320$$$O	of$$$321$$$323$$$O	carbomer,$$$324$$$333$$$O	0.1$$$334$$$337$$$O	to$$$338$$$340$$$O	0.2$$$341$$$344$$$O	part$$$345$$$349$$$O	of$$$350$$$352$$$O	sodium$$$353$$$359$$$O	hyaluronate,$$$360$$$372$$$O	0.1$$$373$$$376$$$O	to$$$377$$$379$$$O	0.2$$$380$$$383$$$O	part$$$384$$$388$$$O	of$$$389$$$391$$$O	anthraquinone$$$392$$$405$$$I	compounds,$$$406$$$416$$$O	0.1$$$417$$$420$$$O	to$$$421$$$423$$$O	0.2$$$424$$$427$$$O	part$$$428$$$432$$$O	of$$$433$$$435$$$O	cinnamate$$$436$$$445$$$I	and$$$446$$$449$$$O	0.2$$$450$$$453$$$O	to$$$454$$$456$$$O	0.5$$$457$$$460$$$O	part$$$461$$$465$$$O	of$$$466$$$468$$$O	free$$$469$$$473$$$O	amino$$$474$$$479$$$I	acid.$$$480$$$485$$$I	The$$$486$$$489$$$O	preparation$$$490$$$501$$$O	method$$$502$$$508$$$O	comprises$$$509$$$518$$$O	the$$$519$$$522$$$O	following$$$523$$$532$$$O	steps$$$533$$$538$$$O	of:$$$539$$$542$$$O	extracting$$$543$$$553$$$O	the$$$554$$$557$$$O	aloe$$$558$$$562$$$O	gel$$$563$$$566$$$O	from$$$567$$$571$$$O	aloe$$$572$$$576$$$O	barbadensis$$$577$$$588$$$O	by$$$589$$$591$$$O	adopting$$$592$$$600$$$O	a$$$601$$$602$$$O	freezing$$$603$$$611$$$O	stabilization$$$612$$$625$$$O	method,$$$626$$$633$$$O	and$$$634$$$637$$$O	converting$$$638$$$648$$$O	the$$$649$$$652$$$O	aloe$$$653$$$657$$$O	gel$$$658$$$661$$$O	into$$$662$$$666$$$O	aloe$$$667$$$671$$$O	gel$$$672$$$675$$$O	powder;$$$676$$$683$$$O	and$$$684$$$687$$$O	mixing$$$688$$$694$$$O	the$$$695$$$698$$$O	aloe$$$699$$$703$$$O	gel$$$704$$$707$$$O	powder$$$708$$$714$$$O	and$$$715$$$718$$$O	water$$$719$$$724$$$O	for$$$725$$$728$$$O	injection$$$729$$$738$$$O	under$$$739$$$744$$$O	the$$$745$$$748$$$O	acidic$$$749$$$755$$$O	condition$$$756$$$765$$$O	or$$$766$$$768$$$O	neutral$$$769$$$776$$$O	condition,$$$777$$$787$$$O	of$$$788$$$790$$$O	which$$$791$$$796$$$O	the$$$797$$$800$$$O	PH$$$801$$$803$$$O	is$$$804$$$806$$$O	between$$$807$$$814$$$O	5.5$$$815$$$818$$$O	and$$$819$$$822$$$O	7.5,$$$823$$$827$$$O	mixing$$$828$$$834$$$O	the$$$835$$$838$$$O	mixture$$$839$$$846$$$O	and$$$847$$$850$$$O	the$$$851$$$854$$$O	aloin,$$$855$$$861$$$I	the$$$862$$$865$$$O	alomycin,$$$866$$$875$$$I	the$$$876$$$879$$$O	carbomer,$$$880$$$889$$$O	the$$$890$$$893$$$O	sodium$$$894$$$900$$$O	hyaluronate,$$$901$$$913$$$O	the$$$914$$$917$$$O	anthraquinone$$$918$$$931$$$I	compounds,$$$932$$$942$$$O	the$$$943$$$946$$$O	cinnamate$$$947$$$956$$$I	and$$$957$$$960$$$O	the$$$961$$$964$$$O	free$$$965$$$969$$$O	amino$$$970$$$975$$$I	acid,$$$976$$$981$$$I	stirring$$$982$$$990$$$O	uniformly,$$$991$$$1001$$$O	regulating$$$1002$$$1012$$$O	the$$$1013$$$1016$$$O	pH$$$1017$$$1019$$$O	value$$$1020$$$1025$$$O	to$$$1026$$$1028$$$O	be$$$1029$$$1031$$$O	neutral,$$$1032$$$1040$$$O	and$$$1041$$$1044$$$O	subpackaging$$$1045$$$1057$$$O	and$$$1058$$$1061$$$O	disinfecting.$$$1062$$$1075$$$O	The$$$1076$$$1079$$$O	aloe$$$1080$$$1084$$$O	oculentum$$$1085$$$1094$$$O	can$$$1095$$$1098$$$O	treat$$$1099$$$1104$$$O	eye$$$1105$$$1108$$$O	diseases$$$1109$$$1117$$$O	such$$$1118$$$1122$$$O	as$$$1123$$$1125$$$O	pterygium,$$$1126$$$1136$$$O	conjunctivochalasis,$$$1137$$$1157$$$O	corneal$$$1158$$$1165$$$O	nebula,$$$1166$$$1173$$$O	chronic$$$1174$$$1181$$$O	dacryocystitis,$$$1182$$$1197$$$O	eye$$$1198$$$1201$$$O	itching,$$$1202$$$1210$$$O	xerophthalmia$$$1211$$$1224$$$O	and$$$1225$$$1228$$$O	the$$$1229$$$1232$$$O	like.$$$1233$$$1238$$$O
CN101199527A
Lafutidine$$$0$$$10$$$I	lyophilized$$$11$$$22$$$O	powder$$$23$$$29$$$O	injection$$$30$$$39$$$O	and$$$40$$$43$$$O	preparing$$$44$$$53$$$O	method$$$54$$$60$$$O	thereof$$$61$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	lafutidine$$$25$$$35$$$I	freeze-dried$$$36$$$48$$$O	injection,$$$49$$$59$$$O	which$$$60$$$65$$$O	can$$$66$$$69$$$O	treat$$$70$$$75$$$O	gastric$$$76$$$83$$$O	ulcer,$$$84$$$90$$$O	duodenal$$$91$$$99$$$O	ulcer$$$100$$$105$$$O	and$$$106$$$109$$$O	ulcer$$$110$$$115$$$O	on$$$116$$$118$$$O	the$$$119$$$122$$$O	anastomosed$$$123$$$134$$$O	part.$$$135$$$140$$$O	The$$$141$$$144$$$O	lafutidine$$$145$$$155$$$I	freeze-dried$$$156$$$168$$$O	injection$$$169$$$178$$$O	is$$$179$$$181$$$O	composed$$$182$$$190$$$O	of$$$191$$$193$$$O	lafutidine$$$194$$$204$$$I	and$$$205$$$208$$$O	mannitol,$$$209$$$218$$$I	wherein,$$$219$$$227$$$O	the$$$228$$$231$$$O	mass$$$232$$$236$$$O	ratio$$$237$$$242$$$O	of$$$243$$$245$$$O	the$$$246$$$249$$$O	lafutidine$$$250$$$260$$$I	and$$$261$$$264$$$O	the$$$265$$$268$$$O	mannitol$$$269$$$277$$$I	is$$$278$$$280$$$O	1$$$281$$$282$$$O	:$$$283$$$284$$$O	10$$$285$$$287$$$O	to$$$288$$$290$$$O	100;$$$291$$$295$$$O	the$$$296$$$299$$$O	preferable$$$300$$$310$$$O	mass$$$311$$$315$$$O	ratio$$$316$$$321$$$O	is$$$322$$$324$$$O	1$$$325$$$326$$$O	:$$$327$$$328$$$O	20$$$329$$$331$$$O	to$$$332$$$334$$$O	50;$$$335$$$338$$$O	and$$$339$$$342$$$O	one$$$343$$$346$$$O	or$$$347$$$349$$$O	the$$$350$$$353$$$O	mixture$$$354$$$361$$$O	of$$$362$$$364$$$O	sodium$$$365$$$371$$$I	chloride$$$372$$$380$$$I	and$$$381$$$384$$$O	citrate$$$385$$$392$$$I	can$$$393$$$396$$$O	be$$$397$$$399$$$O	added$$$400$$$405$$$O	into$$$406$$$410$$$O	the$$$411$$$414$$$O	lafutidine$$$415$$$425$$$I	freeze-dried$$$426$$$438$$$O	injection$$$439$$$448$$$O	so$$$449$$$451$$$O	as$$$452$$$454$$$O	to$$$455$$$457$$$O	prevent$$$458$$$465$$$O	the$$$466$$$469$$$O	medicine$$$470$$$478$$$O	bottle$$$479$$$485$$$O	from$$$486$$$490$$$O	exploding$$$491$$$500$$$O	in$$$501$$$503$$$O	the$$$504$$$507$$$O	process$$$508$$$515$$$O	of$$$516$$$518$$$O	freeze-drying$$$519$$$532$$$O	the$$$533$$$536$$$O	lafutidine$$$537$$$547$$$I	freeze-dried$$$548$$$560$$$O	injection.$$$561$$$571$$$O	The$$$572$$$575$$$O	preparation$$$576$$$587$$$O	processes$$$588$$$597$$$O	are$$$598$$$601$$$O	as$$$602$$$604$$$O	following:$$$605$$$615$$$O	the$$$616$$$619$$$O	lafutidine$$$620$$$630$$$I	is$$$631$$$633$$$O	taken$$$634$$$639$$$O	to$$$640$$$642$$$O	be$$$643$$$645$$$O	placed$$$646$$$652$$$O	inside$$$653$$$659$$$O	the$$$660$$$663$$$O	aseptic$$$664$$$671$$$O	container,$$$672$$$682$$$O	and$$$683$$$686$$$O	then$$$687$$$691$$$O	the$$$692$$$695$$$O	water$$$696$$$701$$$O	for$$$702$$$705$$$O	injection$$$706$$$715$$$O	is$$$716$$$718$$$O	added$$$719$$$724$$$O	to$$$725$$$727$$$O	be$$$728$$$730$$$O	heated$$$731$$$737$$$O	until$$$738$$$743$$$O	the$$$744$$$747$$$O	temperature$$$748$$$759$$$O	reaches$$$760$$$767$$$O	70$$$768$$$770$$$O	DEG$$$771$$$774$$$O	C$$$775$$$776$$$O	so$$$777$$$779$$$O	that$$$780$$$784$$$O	the$$$785$$$788$$$O	lafutidine$$$789$$$799$$$I	can$$$800$$$803$$$O	be$$$804$$$806$$$O	dissolved$$$807$$$816$$$O	in$$$817$$$819$$$O	the$$$820$$$823$$$O	water$$$824$$$829$$$O	for$$$830$$$833$$$O	injection;$$$834$$$844$$$O	and$$$845$$$848$$$O	then$$$849$$$853$$$O	the$$$854$$$857$$$O	mannitol$$$858$$$866$$$I	is$$$867$$$869$$$O	added$$$870$$$875$$$O	to$$$876$$$878$$$O	be$$$879$$$881$$$O	mixed$$$882$$$887$$$O	so$$$888$$$890$$$O	that$$$891$$$895$$$O	the$$$896$$$899$$$O	mannitol$$$900$$$908$$$I	can$$$909$$$912$$$O	be$$$913$$$915$$$O	dissolved$$$916$$$925$$$O	and$$$926$$$929$$$O	is$$$930$$$932$$$O	mixed$$$933$$$938$$$O	evenly;$$$939$$$946$$$O	the$$$947$$$950$$$O	content$$$951$$$958$$$O	of$$$959$$$961$$$O	the$$$962$$$965$$$O	intermediate$$$966$$$978$$$O	is$$$979$$$981$$$O	measured;$$$982$$$991$$$O	after$$$992$$$997$$$O	the$$$998$$$1001$$$O	content$$$1002$$$1009$$$O	of$$$1010$$$1012$$$O	the$$$1013$$$1016$$$O	intermediate$$$1017$$$1029$$$O	is$$$1030$$$1032$$$O	qualified,$$$1033$$$1043$$$O	in$$$1044$$$1046$$$O	the$$$1047$$$1050$$$O	aseptic$$$1051$$$1058$$$O	condition,$$$1059$$$1069$$$O	the$$$1070$$$1073$$$O	solution$$$1074$$$1082$$$O	is$$$1083$$$1085$$$O	filtered$$$1086$$$1094$$$O	until$$$1095$$$1100$$$O	to$$$1101$$$1103$$$O	be$$$1104$$$1106$$$O	clear$$$1107$$$1112$$$O	by$$$1113$$$1115$$$O	microporous$$$1116$$$1127$$$O	membrane$$$1128$$$1136$$$O	of$$$1137$$$1139$$$O	0.22$$$1140$$$1144$$$O	microns;$$$1145$$$1153$$$O	the$$$1154$$$1157$$$O	filtrate$$$1158$$$1166$$$O	is$$$1167$$$1169$$$O	filled$$$1170$$$1176$$$O	inside$$$1177$$$1183$$$O	the$$$1184$$$1187$$$O	aseptic$$$1188$$$1195$$$O	silin$$$1196$$$1201$$$O	bottle;$$$1202$$$1209$$$O	and$$$1210$$$1213$$$O	part$$$1214$$$1218$$$O	of$$$1219$$$1221$$$O	the$$$1222$$$1225$$$O	silin$$$1226$$$1231$$$O	bottle$$$1232$$$1238$$$O	is$$$1239$$$1241$$$O	plugged$$$1242$$$1249$$$O	by$$$1250$$$1252$$$O	butyl$$$1253$$$1258$$$I	rubber$$$1259$$$1265$$$O	closure,$$$1266$$$1274$$$O	with$$$1275$$$1279$$$O	the$$$1280$$$1283$$$O	posterior$$$1284$$$1293$$$O	steps$$$1294$$$1299$$$O	of$$$1300$$$1302$$$O	tray$$$1303$$$1307$$$O	filling,$$$1308$$$1316$$$O	freeze-drying$$$1317$$$1330$$$O	in$$$1331$$$1333$$$O	the$$$1334$$$1337$$$O	freeze$$$1338$$$1344$$$O	dryer,$$$1345$$$1351$$$O	tamponing,$$$1352$$$1362$$$O	unpacking,$$$1363$$$1373$$$O	mouth$$$1374$$$1379$$$O	rolling,$$$1380$$$1388$$$O	quality$$$1389$$$1396$$$O	inspecting$$$1397$$$1407$$$O	and$$$1408$$$1411$$$O	packaging.$$$1412$$$1422$$$O
CN101396488A
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	chronic$$$22$$$29$$$O	faucitis$$$30$$$38$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	drug$$$26$$$30$$$O	for$$$31$$$34$$$O	treating$$$35$$$43$$$O	pharyngolaryngitis.$$$44$$$63$$$O	The$$$64$$$67$$$O	drug$$$68$$$72$$$O	is$$$73$$$75$$$O	made$$$76$$$80$$$O	from$$$81$$$85$$$O	oriental$$$86$$$94$$$O	wormwood,$$$95$$$104$$$O	blackberrylily$$$105$$$119$$$O	rhizome,$$$120$$$128$$$O	subprostrate$$$129$$$141$$$O	soplhor$$$142$$$149$$$O	root,$$$150$$$155$$$O	borax,$$$156$$$162$$$I	thyme$$$163$$$168$$$O	and$$$169$$$172$$$O	borneol,$$$173$$$181$$$I	menthe$$$182$$$188$$$I	camphor$$$189$$$196$$$I	by$$$197$$$199$$$O	the$$$200$$$203$$$O	steps$$$204$$$209$$$O	of$$$210$$$212$$$O	crushing,$$$213$$$222$$$O	putting$$$223$$$230$$$O	in$$$231$$$233$$$O	a$$$234$$$235$$$O	closed$$$236$$$242$$$O	container,$$$243$$$253$$$O	refining$$$254$$$262$$$O	in$$$263$$$265$$$O	vegetable$$$266$$$275$$$O	oil$$$276$$$279$$$O	by$$$280$$$282$$$O	fire$$$283$$$287$$$O	and$$$288$$$291$$$O	the$$$292$$$295$$$O	like.$$$296$$$301$$$O	The$$$302$$$305$$$O	drug$$$306$$$310$$$O	can$$$311$$$314$$$O	take$$$315$$$319$$$O	effect$$$320$$$326$$$O	on$$$327$$$329$$$O	the$$$330$$$333$$$O	throat$$$334$$$340$$$O	part$$$341$$$345$$$O	to$$$346$$$348$$$O	relieve$$$349$$$356$$$O	and$$$357$$$360$$$O	cure$$$361$$$365$$$O	discomfort$$$366$$$376$$$O	in$$$377$$$379$$$O	the$$$380$$$383$$$O	throat.$$$384$$$391$$$O
CN101756939A
Dexketoprofen$$$0$$$13$$$I	coating$$$14$$$21$$$O	sustained-release$$$22$$$39$$$O	micro-encapsulated$$$40$$$58$$$O	capsule$$$59$$$66$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	dexketoprofen$$$25$$$38$$$I	coating$$$39$$$46$$$O	sustained-release$$$47$$$64$$$O	micro-encapsulated$$$65$$$83$$$O	capsule$$$84$$$91$$$O	and$$$92$$$95$$$O	a$$$96$$$97$$$O	preparation$$$98$$$109$$$O	method$$$110$$$116$$$O	thereof,$$$117$$$125$$$O	which$$$126$$$131$$$O	belong$$$132$$$138$$$O	to$$$139$$$141$$$O	the$$$142$$$145$$$O	technical$$$146$$$155$$$O	filed$$$156$$$161$$$O	of$$$162$$$164$$$O	chemico-pharmaceutical$$$165$$$187$$$O	preparations.$$$188$$$201$$$O	The$$$202$$$205$$$O	coating$$$206$$$213$$$O	sustained-release$$$214$$$231$$$O	micro-encapsulated$$$232$$$250$$$O	capsule$$$251$$$258$$$O	consists$$$259$$$267$$$O	of$$$268$$$270$$$O	coating$$$271$$$278$$$O	sustained-release$$$279$$$296$$$O	particles$$$297$$$306$$$O	and$$$307$$$310$$$O	a$$$311$$$312$$$O	capsule$$$313$$$320$$$O	shell.$$$321$$$327$$$O	The$$$328$$$331$$$O	coating$$$332$$$339$$$O	sustained-release$$$340$$$357$$$O	particles$$$358$$$367$$$O	are$$$368$$$371$$$O	made$$$372$$$376$$$O	of$$$377$$$379$$$O	core$$$380$$$384$$$O	particles$$$385$$$394$$$O	containing$$$395$$$405$$$O	dexketoprofen$$$406$$$419$$$I	basic$$$420$$$425$$$O	remedy$$$426$$$432$$$O	through$$$433$$$440$$$O	a$$$441$$$442$$$O	coating$$$443$$$450$$$O	technique.$$$451$$$461$$$O	The$$$462$$$465$$$O	invention$$$466$$$475$$$O	can$$$476$$$479$$$O	reduce$$$480$$$486$$$O	the$$$487$$$490$$$O	stimulation$$$491$$$502$$$O	of$$$503$$$505$$$O	the$$$506$$$509$$$O	dexketoprofen$$$510$$$523$$$I	on$$$524$$$526$$$O	gastrointestinal$$$527$$$543$$$O	tract$$$544$$$549$$$O	and$$$550$$$553$$$O	taking$$$554$$$560$$$O	times,$$$561$$$567$$$O	consequently,$$$568$$$581$$$O	the$$$582$$$585$$$O	medication$$$586$$$596$$$O	compliance$$$597$$$607$$$O	of$$$608$$$610$$$O	patients$$$611$$$619$$$O	is$$$620$$$622$$$O	improved,$$$623$$$632$$$O	the$$$633$$$636$$$O	fluctuation$$$637$$$648$$$O	of$$$649$$$651$$$O	dexketoprofen$$$652$$$665$$$I	blood$$$666$$$671$$$O	concentration$$$672$$$685$$$O	is$$$686$$$688$$$O	reduced,$$$689$$$697$$$O	bioavailability$$$698$$$713$$$O	and$$$714$$$717$$$O	treatment$$$718$$$727$$$O	effect$$$728$$$734$$$O	are$$$735$$$738$$$O	improved$$$739$$$747$$$O	and$$$748$$$751$$$O	adverse$$$752$$$759$$$O	reactions$$$760$$$769$$$O	are$$$770$$$773$$$O	reduced.$$$774$$$782$$$O
WO2013052019A1
Production$$$0$$$10$$$O	method$$$11$$$17$$$O	for$$$18$$$21$$$O	effervescent$$$22$$$34$$$O	formulations$$$35$$$47$$$O	comprising$$$48$$$58$$$O	diclofenac$$$59$$$69$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	used$$$42$$$46$$$O	for$$$47$$$50$$$O	production$$$51$$$61$$$O	of$$$62$$$64$$$O	effervescent$$$65$$$77$$$O	formulations$$$78$$$90$$$O	comprising$$$91$$$101$$$O	diclofenac$$$102$$$112$$$I	or$$$113$$$115$$$O	a$$$116$$$117$$$O	pharmaceutically$$$118$$$134$$$O	acceptable$$$135$$$145$$$O	salt$$$146$$$150$$$O	thereof$$$151$$$158$$$O	and$$$159$$$162$$$O	effervescent$$$163$$$175$$$O	formulations$$$176$$$188$$$O	obtained$$$189$$$197$$$O	by$$$198$$$200$$$O	said$$$201$$$205$$$O	method.$$$206$$$213$$$O
WO2010029915A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	producing$$$11$$$20$$$O	a$$$21$$$22$$$O	composition$$$23$$$34$$$O	with$$$35$$$39$$$O	a$$$40$$$41$$$O	high$$$42$$$46$$$O	content$$$47$$$54$$$O	of$$$55$$$57$$$O	sapogenin$$$58$$$67$$$I
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	simple$$$15$$$21$$$O	method$$$22$$$28$$$O	for$$$29$$$32$$$O	producing$$$33$$$42$$$O	a$$$43$$$44$$$O	plant$$$45$$$50$$$O	containing$$$51$$$61$$$O	sapogenin,$$$62$$$72$$$I	which$$$73$$$78$$$O	contains$$$79$$$87$$$O	a$$$88$$$89$$$O	large$$$90$$$95$$$O	quantity$$$96$$$104$$$O	of$$$105$$$107$$$O	sapogenin$$$108$$$117$$$I	and$$$118$$$121$$$O	has$$$122$$$125$$$O	outstanding$$$126$$$137$$$O	taste$$$138$$$143$$$O	and$$$144$$$147$$$O	safety,$$$148$$$155$$$O	using$$$156$$$161$$$O	a$$$162$$$163$$$O	plant$$$164$$$169$$$O	containing$$$170$$$180$$$O	saponin$$$181$$$188$$$I	as$$$189$$$191$$$O	the$$$192$$$195$$$O	raw$$$196$$$199$$$O	material.$$$200$$$209$$$O	The$$$210$$$213$$$O	method$$$214$$$220$$$O	for$$$221$$$224$$$O	producing$$$225$$$234$$$O	a$$$235$$$236$$$O	plant$$$237$$$242$$$O	containing$$$243$$$253$$$O	sapogenin$$$254$$$263$$$I	is$$$264$$$266$$$O	a$$$267$$$268$$$O	method$$$269$$$275$$$O	for$$$276$$$279$$$O	producing$$$280$$$289$$$O	a$$$290$$$291$$$O	composition$$$292$$$303$$$O	with$$$304$$$308$$$O	a$$$309$$$310$$$O	high$$$311$$$315$$$O	content$$$316$$$323$$$O	of$$$324$$$326$$$O	sapogenin,$$$327$$$337$$$I	in$$$338$$$340$$$O	which$$$341$$$346$$$O	a$$$347$$$348$$$O	plant$$$349$$$354$$$O	containing$$$355$$$365$$$O	saponin$$$366$$$373$$$I	is$$$374$$$376$$$O	subjected$$$377$$$386$$$O	to$$$387$$$389$$$O	hydrolysis$$$390$$$400$$$O	treatment$$$401$$$410$$$O	by$$$411$$$413$$$O	the$$$414$$$417$$$O	action$$$418$$$424$$$O	of$$$425$$$427$$$O	an$$$428$$$430$$$O	aqueous$$$431$$$438$$$O	solution$$$439$$$447$$$O	of$$$448$$$450$$$O	a$$$451$$$452$$$O	strong$$$453$$$459$$$O	acid$$$460$$$464$$$O	with$$$465$$$469$$$O	a$$$470$$$471$$$O	concentration$$$472$$$485$$$O	of$$$486$$$488$$$O	0.01$$$489$$$493$$$O	mol/L$$$494$$$499$$$O	to$$$500$$$502$$$O	4$$$503$$$504$$$O	mol/L,$$$505$$$511$$$O	the$$$512$$$515$$$O	liquid$$$516$$$522$$$O	obtained$$$523$$$531$$$O	after$$$532$$$537$$$O	hydrolysis$$$538$$$548$$$O	treatment$$$549$$$558$$$O	is$$$559$$$561$$$O	neutralized$$$562$$$573$$$O	and$$$574$$$577$$$O	then$$$578$$$582$$$O	filtered,$$$583$$$592$$$O	and$$$593$$$596$$$O	the$$$597$$$600$$$O	residue$$$601$$$608$$$O	is$$$609$$$611$$$O	dried.$$$612$$$618$$$O	The$$$619$$$622$$$O	hydrolysis$$$623$$$633$$$O	treatment$$$634$$$643$$$O	is$$$644$$$646$$$O	preferably$$$647$$$657$$$O	carried$$$658$$$665$$$O	out,$$$666$$$670$$$O	for$$$671$$$674$$$O	example,$$$675$$$683$$$O	in$$$684$$$686$$$O	the$$$687$$$690$$$O	presence$$$691$$$699$$$O	of$$$700$$$702$$$O	a$$$703$$$704$$$O	lower$$$705$$$710$$$O	alcohol.$$$711$$$719$$$I
CN101574351A
Cefmetazole$$$0$$$11$$$I	preparation$$$12$$$23$$$O	used$$$24$$$28$$$O	for$$$29$$$32$$$O	injection$$$33$$$42$$$O	and$$$43$$$46$$$O	preparation$$$47$$$58$$$O	method$$$59$$$65$$$O	thereof$$$66$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	new$$$25$$$28$$$O	cefmetazole$$$29$$$40$$$I	preparation$$$41$$$52$$$O	used$$$53$$$57$$$O	for$$$58$$$61$$$O	injection.$$$62$$$72$$$O	The$$$73$$$76$$$O	preparation$$$77$$$88$$$O	mixes$$$89$$$94$$$O	evenly$$$95$$$101$$$O	active$$$102$$$108$$$O	ingredient$$$109$$$119$$$O	cefmetazole$$$120$$$131$$$I	acid$$$132$$$136$$$O	asepsis$$$137$$$144$$$O	powder$$$145$$$151$$$O	and$$$152$$$155$$$O	complex$$$156$$$163$$$O	solubilizer$$$164$$$175$$$O	anhydrous$$$176$$$185$$$O	sodium$$$186$$$192$$$I	carbonate$$$193$$$202$$$I	asepsis$$$203$$$210$$$O	powder$$$211$$$217$$$O	which$$$218$$$223$$$O	are$$$224$$$227$$$O	respectively$$$228$$$240$$$O	bottled$$$241$$$248$$$O	in$$$249$$$251$$$O	sterilized$$$252$$$262$$$O	amoxicillin$$$263$$$274$$$I	bottles$$$275$$$282$$$O	according$$$283$$$292$$$O	to$$$293$$$295$$$O	labeled$$$296$$$303$$$O	amount$$$304$$$310$$$O	and$$$311$$$314$$$O	are$$$315$$$318$$$O	packaged$$$319$$$327$$$O	to$$$328$$$330$$$O	obtain$$$331$$$337$$$O	the$$$338$$$341$$$O	product$$$342$$$349$$$O	of$$$350$$$352$$$O	cefmetazole$$$353$$$364$$$I	used$$$365$$$369$$$O	for$$$370$$$373$$$O	injection$$$374$$$383$$$O	after$$$384$$$389$$$O	tamponage,$$$390$$$400$$$O	rolling$$$401$$$408$$$O	of$$$409$$$411$$$O	cover$$$412$$$417$$$O	and$$$418$$$421$$$O	full$$$422$$$426$$$O	inspection;$$$427$$$438$$$O	wherein$$$439$$$446$$$O	the$$$447$$$450$$$O	weight$$$451$$$457$$$O	ratio$$$458$$$463$$$O	between$$$464$$$471$$$O	cefmetazole$$$472$$$483$$$I	acid$$$484$$$488$$$O	(pure)$$$489$$$495$$$O	and$$$496$$$499$$$O	anhydrous$$$500$$$509$$$O	sodium$$$510$$$516$$$I	carbonate$$$517$$$526$$$I	is$$$527$$$529$$$O	1:0.1$$$530$$$535$$$O	to$$$536$$$538$$$O	1:0.2$$$539$$$544$$$O	with$$$545$$$549$$$O	1:0.15$$$550$$$556$$$O	being$$$557$$$562$$$O	the$$$563$$$566$$$O	better$$$567$$$573$$$O	ratio,$$$574$$$580$$$O	namely,$$$581$$$588$$$O	1g$$$589$$$591$$$O	of$$$592$$$594$$$O	cefmetazole$$$595$$$606$$$I	acid$$$607$$$611$$$I	(pure)$$$612$$$618$$$O	asepsis$$$619$$$626$$$O	powder$$$627$$$633$$$O	is$$$634$$$636$$$O	added$$$637$$$642$$$O	into$$$643$$$647$$$O	0.1-0.2g$$$648$$$656$$$O	of$$$657$$$659$$$O	anhydrous$$$660$$$669$$$O	sodium$$$670$$$676$$$I	carbonate$$$677$$$686$$$I	asepsis$$$687$$$694$$$O	powder.$$$695$$$702$$$O	The$$$703$$$706$$$O	preparation$$$707$$$718$$$O	is$$$719$$$721$$$O	good$$$722$$$726$$$O	in$$$727$$$729$$$O	stability$$$730$$$739$$$O	and$$$740$$$743$$$O	safe$$$744$$$748$$$O	in$$$749$$$751$$$O	usage.$$$752$$$758$$$O
EP0994880B1
Crystalline$$$0$$$11$$$O	macrolides$$$12$$$22$$$I	and$$$23$$$26$$$O	process$$$27$$$34$$$O	for$$$35$$$38$$$O	their$$$39$$$44$$$O	preparation$$$45$$$56$$$O
33-Epichloro-33-desoxyascomycin$$$0$$$31$$$I	of$$$32$$$34$$$O	formula$$$35$$$42$$$O	(I)$$$43$$$46$$$O	and$$$47$$$50$$$O	various$$$51$$$58$$$O	tautomeric$$$59$$$69$$$O	or$$$70$$$72$$$O	solvated$$$73$$$81$$$O	forms$$$82$$$87$$$O	thereof,$$$88$$$96$$$O	in$$$97$$$99$$$O	crystalline$$$100$$$111$$$O	form,$$$112$$$117$$$O	such$$$118$$$122$$$O	as$$$123$$$125$$$O	Form$$$126$$$130$$$O	A$$$131$$$132$$$O	and$$$133$$$136$$$O	Form$$$137$$$141$$$O	B.$$$142$$$144$$$O	Their$$$145$$$150$$$O	preparation$$$151$$$162$$$O	involves$$$163$$$171$$$O	appropriately$$$172$$$185$$$O	converting$$$186$$$196$$$O	amorphous$$$197$$$206$$$O	compound$$$207$$$215$$$O	of$$$216$$$218$$$O	formula$$$219$$$226$$$O	(I),$$$227$$$231$$$O	or$$$232$$$234$$$O	compound$$$235$$$243$$$O	of$$$244$$$246$$$O	formula$$$247$$$254$$$O	(I)$$$255$$$258$$$O	in$$$259$$$261$$$O	other$$$262$$$267$$$O	than$$$268$$$272$$$O	Form$$$273$$$277$$$O	A,$$$278$$$280$$$O	or$$$281$$$283$$$O	compound$$$284$$$292$$$O	of$$$293$$$295$$$O	formula$$$296$$$303$$$O	(I)$$$304$$$307$$$O	in$$$308$$$310$$$O	other$$$311$$$316$$$O	than$$$317$$$321$$$O	Form$$$322$$$326$$$O	B,$$$327$$$329$$$O	respectively,$$$330$$$343$$$O	from$$$344$$$348$$$O	a$$$349$$$350$$$O	solution$$$351$$$359$$$O	thereof$$$360$$$367$$$O	under$$$368$$$373$$$O	crystallization-inducing$$$374$$$398$$$O	conditions$$$399$$$409$$$O	or$$$410$$$412$$$O	conditions$$$413$$$423$$$O	inducing$$$424$$$432$$$O	preferential$$$433$$$445$$$O	crystallization$$$446$$$461$$$O	of$$$462$$$464$$$O	Form$$$465$$$469$$$O	A$$$470$$$471$$$O	or$$$472$$$474$$$O	B,$$$475$$$477$$$O	respectively.$$$478$$$491$$$O	Such$$$492$$$496$$$O	crystals$$$497$$$505$$$O	are$$$506$$$509$$$O	particularly$$$510$$$522$$$O	indicated$$$523$$$532$$$O	for$$$533$$$536$$$O	use$$$537$$$540$$$O	in$$$541$$$543$$$O	the$$$544$$$547$$$O	preparation$$$548$$$559$$$O	of$$$560$$$562$$$O	topical$$$563$$$570$$$O	galenical$$$571$$$580$$$O	forms$$$581$$$586$$$O	of$$$587$$$589$$$O	the$$$590$$$593$$$O	compound$$$594$$$602$$$O	for$$$603$$$606$$$O	pharmaceutical$$$607$$$621$$$O	use,$$$622$$$626$$$O	e.g.$$$627$$$631$$$O	creams,$$$632$$$639$$$O	emulsions$$$640$$$649$$$O	and$$$650$$$653$$$O	ointments.$$$654$$$664$$$O
CN101703469A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	and$$$19$$$22$$$O	products$$$23$$$31$$$O	of$$$32$$$34$$$O	danofloxacin$$$35$$$47$$$I	mesylate$$$48$$$56$$$I	liposome$$$57$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	preparation$$$25$$$36$$$O	method$$$37$$$43$$$O	and$$$44$$$47$$$O	products$$$48$$$56$$$O	of$$$57$$$59$$$O	danofloxacin$$$60$$$72$$$I	mesylate$$$73$$$81$$$I	liposome.$$$82$$$91$$$O	The$$$92$$$95$$$O	preparation$$$96$$$107$$$O	method$$$108$$$114$$$O	comprises$$$115$$$124$$$O	the$$$125$$$128$$$O	following$$$129$$$138$$$O	steps:$$$139$$$145$$$O	(1)$$$146$$$149$$$O	adopting$$$150$$$158$$$O	the$$$159$$$162$$$O	ammonium$$$163$$$171$$$I	sulfate$$$172$$$179$$$I	gradient$$$180$$$188$$$O	method$$$189$$$195$$$O	to$$$196$$$198$$$O	prepare$$$199$$$206$$$O	blank$$$207$$$212$$$O	liposome;$$$213$$$222$$$O	and$$$223$$$226$$$O	(2)$$$227$$$230$$$O	adding$$$231$$$237$$$O	danofloxacin$$$238$$$250$$$I	mesylate$$$251$$$259$$$I	liquor$$$260$$$266$$$O	in$$$267$$$269$$$O	the$$$270$$$273$$$O	blank$$$274$$$279$$$O	liposome,$$$280$$$289$$$O	using$$$290$$$295$$$O	water$$$296$$$301$$$O	bath$$$302$$$306$$$O	for$$$307$$$310$$$O	incubation,$$$311$$$322$$$O	filtrating,$$$323$$$334$$$O	and$$$335$$$338$$$O	performing$$$339$$$349$$$O	repeated$$$350$$$358$$$O	freeze$$$359$$$365$$$O	thawing$$$366$$$373$$$O	to$$$374$$$376$$$O	the$$$377$$$380$$$O	filtrate$$$381$$$389$$$O	by$$$390$$$392$$$O	using$$$393$$$398$$$O	the$$$399$$$402$$$O	freeze$$$403$$$409$$$O	and$$$410$$$413$$$O	thawing$$$414$$$421$$$O	method$$$422$$$428$$$O	to$$$429$$$431$$$O	obtain$$$432$$$438$$$O	the$$$439$$$442$$$O	danofloxacin$$$443$$$455$$$I	mesylate$$$456$$$464$$$I	liposome.$$$465$$$474$$$O	The$$$475$$$478$$$O	finished$$$479$$$487$$$O	liposome$$$488$$$496$$$O	prepared$$$497$$$505$$$O	by$$$506$$$508$$$O	the$$$509$$$512$$$O	preparation$$$513$$$524$$$O	method$$$525$$$531$$$O	of$$$532$$$534$$$O	the$$$535$$$538$$$O	invention$$$539$$$548$$$O	is$$$549$$$551$$$O	milky$$$552$$$557$$$O	semitransparent$$$558$$$573$$$O	mixed$$$574$$$579$$$O	suspension$$$580$$$590$$$O	which$$$591$$$596$$$O	appears$$$597$$$604$$$O	as$$$605$$$607$$$O	spherical$$$608$$$617$$$O	or$$$618$$$620$$$O	nearly$$$621$$$627$$$O	globose$$$628$$$635$$$O	small$$$636$$$641$$$O	vesicles$$$642$$$650$$$O	with$$$651$$$655$$$O	regular$$$656$$$663$$$O	shape,$$$664$$$670$$$O	good$$$671$$$675$$$O	dispersity$$$676$$$686$$$O	and$$$687$$$690$$$O	uniform$$$691$$$698$$$O	grain$$$699$$$704$$$O	size$$$705$$$709$$$O	under$$$710$$$715$$$O	an$$$716$$$718$$$O	electron$$$719$$$727$$$O	microscope;$$$728$$$739$$$O	the$$$740$$$743$$$O	entrapment$$$744$$$754$$$O	rate$$$755$$$759$$$O	of$$$760$$$762$$$O	the$$$763$$$766$$$O	liposome$$$767$$$775$$$O	is$$$776$$$778$$$O	above$$$779$$$784$$$O	90%$$$785$$$788$$$O	and$$$789$$$792$$$O	the$$$793$$$796$$$O	liposome$$$797$$$805$$$O	has$$$806$$$809$$$O	good$$$810$$$814$$$O	stability;$$$815$$$825$$$O	the$$$826$$$829$$$O	pharmacokinetic$$$830$$$845$$$O	and$$$846$$$849$$$O	pharmacodynamic$$$850$$$865$$$O	properties$$$866$$$876$$$O	of$$$877$$$879$$$O	the$$$880$$$883$$$O	liposome$$$884$$$892$$$O	are$$$893$$$896$$$O	better$$$897$$$903$$$O	than$$$904$$$908$$$O	that$$$909$$$913$$$O	of$$$914$$$916$$$O	conventional$$$917$$$929$$$O	dosage$$$930$$$936$$$O	forms$$$937$$$942$$$O	and$$$943$$$946$$$O	the$$$947$$$950$$$O	liposome$$$951$$$959$$$O	is$$$960$$$962$$$O	characterized$$$963$$$976$$$O	by$$$977$$$979$$$O	slow$$$980$$$984$$$O	release,$$$985$$$993$$$O	long$$$994$$$998$$$O	acting$$$999$$$1005$$$O	and$$$1006$$$1009$$$O	high$$$1010$$$1014$$$O	lung-targeting.$$$1015$$$1030$$$O
EP2749641A1
Cancer$$$0$$$6$$$O	stem$$$7$$$11$$$O	cell$$$12$$$16$$$O	isolation$$$17$$$26$$$O
An$$$0$$$2$$$O	objective$$$3$$$12$$$O	of$$$13$$$15$$$O	the$$$16$$$19$$$O	present$$$20$$$27$$$O	invention$$$28$$$37$$$O	is$$$38$$$40$$$O	to$$$41$$$43$$$O	provide:$$$44$$$52$$$O	a$$$53$$$54$$$O	cancer$$$55$$$61$$$O	stem$$$62$$$66$$$O	cell$$$67$$$71$$$O	isolated$$$72$$$80$$$O	using$$$81$$$86$$$O	a$$$87$$$88$$$O	cell$$$89$$$93$$$O	marker;$$$94$$$101$$$O	a$$$102$$$103$$$O	substantively$$$104$$$117$$$O	homogeneous$$$118$$$129$$$O	cancer$$$130$$$136$$$O	stem$$$137$$$141$$$O	cell$$$142$$$146$$$O	population$$$147$$$157$$$O	including$$$158$$$167$$$O	said$$$168$$$172$$$O	cancer$$$173$$$179$$$O	stem$$$180$$$184$$$O	cell;$$$185$$$190$$$O	and$$$191$$$194$$$O	a$$$195$$$196$$$O	method$$$197$$$203$$$O	of$$$204$$$206$$$O	preparing$$$207$$$216$$$O	said$$$217$$$221$$$O	cancer$$$222$$$228$$$O	stem$$$229$$$233$$$O	cell$$$234$$$238$$$O	population.$$$239$$$250$$$O	Another$$$251$$$258$$$O	objective$$$259$$$268$$$O	of$$$269$$$271$$$O	the$$$272$$$275$$$O	present$$$276$$$283$$$O	invention$$$284$$$293$$$O	is$$$294$$$296$$$O	to$$$297$$$299$$$O	provide:$$$300$$$308$$$O	a$$$309$$$310$$$O	method$$$311$$$317$$$O	for$$$318$$$321$$$O	separating$$$322$$$332$$$O	cancer$$$333$$$339$$$O	stem$$$340$$$344$$$O	cells$$$345$$$350$$$O	with$$$351$$$355$$$O	a$$$356$$$357$$$O	high$$$358$$$362$$$O	proliferative$$$363$$$376$$$O	potential$$$377$$$386$$$O	and$$$387$$$390$$$O	those$$$391$$$396$$$O	with$$$397$$$401$$$O	a$$$402$$$403$$$O	low$$$404$$$407$$$O	proliferative$$$408$$$421$$$O	potential;$$$422$$$432$$$O	a$$$433$$$434$$$O	method$$$435$$$441$$$O	for$$$442$$$445$$$O	inducing$$$446$$$454$$$O	cancer$$$455$$$461$$$O	stem$$$462$$$466$$$O	cells$$$467$$$472$$$O	to$$$473$$$475$$$O	have$$$476$$$480$$$O	a$$$481$$$482$$$O	different$$$483$$$492$$$O	proliferative$$$493$$$506$$$O	potential;$$$507$$$517$$$O	and$$$518$$$521$$$O	cancer$$$522$$$528$$$O	stem$$$529$$$533$$$O	cells$$$534$$$539$$$O	separated$$$540$$$549$$$O	or$$$550$$$552$$$O	induced$$$553$$$560$$$O	by$$$561$$$563$$$O	these$$$564$$$569$$$O	separation$$$570$$$580$$$O	or$$$581$$$583$$$O	induction$$$584$$$593$$$O	methods.$$$594$$$602$$$O	A$$$603$$$604$$$O	further$$$605$$$612$$$O	objective$$$613$$$622$$$O	of$$$623$$$625$$$O	the$$$626$$$629$$$O	present$$$630$$$637$$$O	invention$$$638$$$647$$$O	is$$$648$$$650$$$O	to$$$651$$$653$$$O	provide:$$$654$$$662$$$O	a$$$663$$$664$$$O	method$$$665$$$671$$$O	of$$$672$$$674$$$O	screening$$$675$$$684$$$O	for$$$685$$$688$$$O	pharmaceuticals$$$689$$$704$$$O	using$$$705$$$710$$$O	said$$$711$$$715$$$O	cancer$$$716$$$722$$$O	stem$$$723$$$727$$$O	cell$$$728$$$732$$$O	or$$$733$$$735$$$O	cancer$$$736$$$742$$$O	stem$$$743$$$747$$$O	cell$$$748$$$752$$$O	population;$$$753$$$764$$$O	a$$$765$$$766$$$O	method$$$767$$$773$$$O	for$$$774$$$777$$$O	detecting$$$778$$$787$$$O	the$$$788$$$791$$$O	presence$$$792$$$800$$$O	of$$$801$$$803$$$O	said$$$804$$$808$$$O	cancer$$$809$$$815$$$O	stem$$$816$$$820$$$O	cell$$$821$$$825$$$O	or$$$826$$$828$$$O	cancer$$$829$$$835$$$O	stem$$$836$$$840$$$O	cell$$$841$$$845$$$O	population$$$846$$$856$$$O	and$$$857$$$860$$$O	for$$$861$$$864$$$O	identifying$$$865$$$876$$$O	or$$$877$$$879$$$O	quantifying$$$880$$$891$$$O	the$$$892$$$895$$$O	same.$$$896$$$901$$$O	The$$$902$$$905$$$O	present$$$906$$$913$$$O	inventors$$$914$$$923$$$O	discovered$$$924$$$934$$$O	that$$$935$$$939$$$O	highly$$$940$$$946$$$O	pure$$$947$$$951$$$O	colon$$$952$$$957$$$O	cancer$$$958$$$964$$$O	stem$$$965$$$969$$$O	cells$$$970$$$975$$$O	(CSC)$$$976$$$981$$$O	can$$$982$$$985$$$O	be$$$986$$$988$$$O	obtained$$$989$$$997$$$O	in$$$998$$$1000$$$O	a$$$1001$$$1002$$$O	large$$$1003$$$1008$$$O	quantity,$$$1009$$$1018$$$O	and$$$1019$$$1022$$$O	identified$$$1023$$$1033$$$O	two$$$1034$$$1037$$$O	types$$$1038$$$1043$$$O	of$$$1044$$$1046$$$O	states$$$1047$$$1053$$$O	of$$$1054$$$1056$$$O	colon$$$1057$$$1062$$$O	CSCs$$$1063$$$1067$$$O	distinguishable$$$1068$$$1083$$$O	through$$$1084$$$1091$$$O	Lgr5$$$1092$$$1096$$$O	expression.$$$1097$$$1108$$$O
CA2348767C
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	producing$$$11$$$20$$$O	an$$$21$$$23$$$O	antitumoral$$$24$$$35$$$O	agent$$$36$$$41$$$O	and$$$42$$$45$$$O	antitumoral$$$46$$$57$$$O	agent$$$58$$$63$$$O	thus$$$64$$$68$$$O	obtained$$$69$$$77$$$O
In$$$0$$$2$$$O	order$$$3$$$8$$$O	to$$$9$$$11$$$O	lower$$$12$$$17$$$O	the$$$18$$$21$$$O	painfulness$$$22$$$33$$$O	of$$$34$$$36$$$O	injection$$$37$$$46$$$O	of$$$47$$$49$$$O	the$$$50$$$53$$$O	remedy$$$54$$$60$$$O	containing$$$61$$$71$$$O	the$$$72$$$75$$$O	products$$$76$$$84$$$O	of$$$85$$$87$$$O	Iignin$$$88$$$94$$$O	basic$$$95$$$100$$$O	hydrolysis$$$101$$$111$$$O	and$$$112$$$115$$$O	oxidation,$$$116$$$126$$$O	pyrophosphate,$$$127$$$141$$$I	NaCl$$$142$$$146$$$I	and$$$147$$$150$$$O	water$$$151$$$156$$$O	the$$$157$$$160$$$O	value$$$161$$$166$$$O	of$$$167$$$169$$$O	pH$$$170$$$172$$$O	of$$$173$$$175$$$O	the$$$176$$$179$$$O	remedy$$$180$$$186$$$O	is$$$187$$$189$$$O	adjusted$$$190$$$198$$$O	to$$$199$$$201$$$O	a$$$202$$$203$$$O	neutral$$$204$$$211$$$O	one$$$212$$$215$$$O	by$$$216$$$218$$$O	the$$$219$$$222$$$O	addition$$$223$$$231$$$O	of$$$232$$$234$$$O	HCl.$$$235$$$239$$$I
US20130034578
Recombinant$$$0$$$11$$$O	multimeric$$$12$$$22$$$O	influenza$$$23$$$32$$$O	proteins$$$33$$$41$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	immunogenic$$$25$$$36$$$O	compositions$$$37$$$49$$$O	comprising$$$50$$$60$$$O	recombinant$$$61$$$72$$$O	multimeric$$$73$$$83$$$O	influenza$$$84$$$93$$$O	proteins$$$94$$$102$$$O	or$$$103$$$105$$$O	parts$$$106$$$111$$$O	thereof$$$112$$$119$$$O	fused$$$120$$$125$$$O	to$$$126$$$128$$$O	a$$$129$$$130$$$O	streptavidin$$$131$$$143$$$O	affinity$$$144$$$152$$$O	tag,$$$153$$$157$$$O	preferably$$$158$$$168$$$O	recombinant$$$169$$$180$$$O	trimeric$$$181$$$189$$$O	influenza$$$190$$$199$$$O	virus$$$200$$$205$$$O	hemagglutinin$$$206$$$219$$$O	and/or$$$220$$$226$$$O	recombinant$$$227$$$238$$$O	tetrameric$$$239$$$249$$$O	influenza$$$250$$$259$$$O	virus$$$260$$$265$$$O	neuraminidase,$$$266$$$280$$$O	or$$$281$$$283$$$O	vectors$$$284$$$291$$$O	comprising$$$292$$$302$$$O	nucleic$$$303$$$310$$$O	acid$$$311$$$315$$$O	sequences$$$316$$$325$$$O	encoding$$$326$$$334$$$O	such$$$335$$$339$$$O	influenza$$$340$$$349$$$O	proteins.$$$350$$$359$$$O	The$$$360$$$363$$$O	inventions$$$364$$$374$$$O	further$$$375$$$382$$$O	relate$$$383$$$389$$$O	to$$$390$$$392$$$O	methods$$$393$$$400$$$O	for$$$401$$$404$$$O	the$$$405$$$408$$$O	preparation$$$409$$$420$$$O	of$$$421$$$423$$$O	such$$$424$$$428$$$O	immunogenic$$$429$$$440$$$O	compositions$$$441$$$453$$$O	and$$$454$$$457$$$O	uses$$$458$$$462$$$O	thereof$$$463$$$470$$$O	and$$$471$$$474$$$O	methods$$$475$$$482$$$O	for$$$483$$$486$$$O	eliciting$$$487$$$496$$$O	an$$$497$$$499$$$O	immune$$$500$$$506$$$O	response$$$507$$$515$$$O	in$$$516$$$518$$$O	an$$$519$$$521$$$O	individual.$$$522$$$533$$$O
US20100113479
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	preparation$$$16$$$27$$$O	of$$$28$$$30$$$O	tri-substituted$$$31$$$46$$$I	pyridine$$$47$$$55$$$I	and$$$56$$$59$$$O	tri-substituted$$$60$$$75$$$I	pyrimidine$$$76$$$86$$$I	derivatives$$$87$$$98$$$O	useful$$$99$$$105$$$O	as$$$106$$$108$$$O	gdir$$$109$$$113$$$O	agonists$$$114$$$122$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	novel$$$37$$$42$$$O	processes$$$43$$$52$$$O	for$$$53$$$56$$$O	the$$$57$$$60$$$O	preparation$$$61$$$72$$$O	of$$$73$$$75$$$O	tri-substituted$$$76$$$91$$$I	pyridine$$$92$$$100$$$I	and$$$101$$$104$$$O	tri-substituted$$$105$$$120$$$I	pyrimidine$$$121$$$131$$$I	derivatives,$$$132$$$144$$$O	useful$$$145$$$151$$$O	as$$$152$$$154$$$O	glucose$$$155$$$162$$$I	dependent$$$163$$$172$$$O	insulinotropic$$$173$$$187$$$O	receptor$$$188$$$196$$$O	agonist,$$$197$$$205$$$O	for$$$206$$$209$$$O	the$$$210$$$213$$$O	treatment$$$214$$$223$$$O	of$$$224$$$226$$$O	metabolic-related$$$227$$$244$$$O	disorders$$$245$$$254$$$O	and$$$255$$$258$$$O	complications$$$259$$$272$$$O	thereof,$$$273$$$281$$$O	such$$$282$$$286$$$O	as,$$$287$$$290$$$O	diabetes$$$291$$$299$$$O	and$$$300$$$303$$$O	obesity.$$$304$$$312$$$O
US20110178121
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	Treating$$$12$$$20$$$O	Pain$$$21$$$25$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	methods$$$37$$$44$$$O	of$$$45$$$47$$$O	treating$$$48$$$56$$$O	pain$$$57$$$61$$$O	by$$$62$$$64$$$O	administering$$$65$$$78$$$O	a$$$79$$$80$$$O	therapeutically$$$81$$$96$$$O	effective$$$97$$$106$$$O	amount$$$107$$$113$$$O	of$$$114$$$116$$$O	an$$$117$$$119$$$O	Î±7$$$120$$$123$$$O	nAChR$$$124$$$129$$$O	ligand$$$130$$$136$$$O	or$$$137$$$139$$$O	a$$$140$$$141$$$O	pharmaceutically$$$142$$$158$$$O	acceptable$$$159$$$169$$$O	salt$$$170$$$174$$$O	thereof,$$$175$$$183$$$O	to$$$184$$$186$$$O	a$$$187$$$188$$$O	mammal$$$189$$$195$$$O	in$$$196$$$198$$$O	need$$$199$$$203$$$O	of$$$204$$$206$$$O	treatment$$$207$$$216$$$O	thereof$$$217$$$224$$$O	and$$$225$$$228$$$O	to$$$229$$$231$$$O	pharmaceutical$$$232$$$246$$$O	compositions$$$247$$$259$$$O	comprising$$$260$$$270$$$O	such$$$271$$$275$$$O	a$$$276$$$277$$$O	compound$$$278$$$286$$$O	or$$$287$$$289$$$O	salt.$$$290$$$295$$$O
CN101703522A
Medicinal$$$0$$$9$$$O	and$$$10$$$13$$$O	edible$$$14$$$20$$$O	product$$$21$$$28$$$O	for$$$29$$$32$$$O	calcium$$$33$$$40$$$I	supplement$$$41$$$51$$$O	and$$$52$$$55$$$O	preparation$$$56$$$67$$$O	method$$$68$$$74$$$O	thereof$$$75$$$82$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medicinal$$$27$$$36$$$O	and$$$37$$$40$$$O	edible$$$41$$$47$$$O	product$$$48$$$55$$$O	for$$$56$$$59$$$O	calcium$$$60$$$67$$$I	supplement$$$68$$$78$$$O	and$$$79$$$82$$$O	a$$$83$$$84$$$O	preparation$$$85$$$96$$$O	method$$$97$$$103$$$O	thereof.$$$104$$$112$$$O	The$$$113$$$116$$$O	raw$$$117$$$120$$$O	materials$$$121$$$130$$$O	of$$$131$$$133$$$O	the$$$134$$$137$$$O	product$$$138$$$145$$$O	for$$$146$$$149$$$O	calcium$$$150$$$157$$$I	supplement$$$158$$$168$$$O	are$$$169$$$172$$$O	calcium$$$173$$$180$$$I	diacetate$$$181$$$190$$$I	made$$$191$$$195$$$O	by$$$196$$$198$$$O	activating$$$199$$$209$$$O	oyster$$$210$$$216$$$O	and$$$217$$$220$$$O	seaweed.$$$221$$$229$$$O	The$$$230$$$233$$$O	preparation$$$234$$$245$$$O	method$$$246$$$252$$$O	includes$$$253$$$261$$$O	the$$$262$$$265$$$O	following$$$266$$$275$$$O	main$$$276$$$280$$$O	steps:$$$281$$$287$$$O	activating$$$288$$$298$$$O	the$$$299$$$302$$$O	wild$$$303$$$307$$$O	oyster$$$308$$$314$$$O	in$$$315$$$317$$$O	deep$$$318$$$322$$$O	sea$$$323$$$326$$$O	into$$$327$$$331$$$O	powdered$$$332$$$340$$$O	white$$$341$$$346$$$O	calcium$$$347$$$354$$$I	diacetate;$$$355$$$365$$$I	cutting$$$366$$$373$$$O	the$$$374$$$377$$$O	clean$$$378$$$383$$$O	frond$$$384$$$389$$$O	of$$$390$$$392$$$O	dried$$$393$$$398$$$O	seaweed$$$399$$$406$$$O	into$$$407$$$411$$$O	bits$$$412$$$416$$$O	or$$$417$$$419$$$O	grinding$$$420$$$428$$$O	the$$$429$$$432$$$O	clean$$$433$$$438$$$O	frond;$$$439$$$445$$$O	mixing$$$446$$$452$$$O	the$$$453$$$456$$$O	calcium$$$457$$$464$$$I	diacetate$$$465$$$474$$$I	and$$$475$$$478$$$O	the$$$479$$$482$$$O	seaweed$$$483$$$490$$$O	according$$$491$$$500$$$O	to$$$501$$$503$$$O	proportion;$$$504$$$515$$$O	and$$$516$$$519$$$O	the$$$520$$$523$$$O	mixture$$$524$$$531$$$O	into$$$532$$$536$$$O	a$$$537$$$538$$$O	tea$$$539$$$542$$$O	bag$$$543$$$546$$$O	or$$$547$$$549$$$O	capsule.$$$550$$$558$$$O	The$$$559$$$562$$$O	preparation$$$563$$$574$$$O	method$$$575$$$581$$$O	is$$$582$$$584$$$O	simple,$$$585$$$592$$$O	the$$$593$$$596$$$O	prepared$$$597$$$605$$$O	product$$$606$$$613$$$O	contains$$$614$$$622$$$O	high$$$623$$$627$$$O	content$$$628$$$635$$$O	of$$$636$$$638$$$O	calcium,$$$639$$$647$$$I	is$$$648$$$650$$$O	easy$$$651$$$655$$$O	to$$$656$$$658$$$O	be$$$659$$$661$$$O	absorbed,$$$662$$$671$$$O	and$$$672$$$675$$$O	can$$$676$$$679$$$O	effectively$$$680$$$691$$$O	promote$$$692$$$699$$$O	the$$$700$$$703$$$O	formation$$$704$$$713$$$O	of$$$714$$$716$$$O	bone$$$717$$$721$$$O	mass,$$$722$$$727$$$O	maintain$$$728$$$736$$$O	nerve$$$737$$$742$$$O	conduction,$$$743$$$754$$$O	muscle$$$755$$$761$$$O	contraction$$$762$$$773$$$O	and$$$774$$$777$$$O	the$$$778$$$781$$$O	regular$$$782$$$789$$$O	osmotic$$$790$$$797$$$O	pressure$$$798$$$806$$$O	of$$$807$$$809$$$O	blood$$$810$$$815$$$O	capillary$$$816$$$825$$$O	and$$$826$$$829$$$O	keep$$$830$$$834$$$O	the$$$835$$$838$$$O	acid$$$839$$$843$$$O	alkali$$$844$$$850$$$O	balance$$$851$$$858$$$O	of$$$859$$$861$$$O	blood.$$$862$$$868$$$O	The$$$869$$$872$$$O	medicinal$$$873$$$882$$$O	and$$$883$$$886$$$O	edible$$$887$$$893$$$O	product$$$894$$$901$$$O	has$$$902$$$905$$$O	evident$$$906$$$913$$$O	food$$$914$$$918$$$O	therapy$$$919$$$926$$$O	effect$$$927$$$933$$$O	on$$$934$$$936$$$O	osteoporosis,$$$937$$$950$$$O	hyperosteogeny,$$$951$$$966$$$O	ostealgia,$$$967$$$977$$$O	muscle$$$978$$$984$$$O	spasm,$$$985$$$991$$$O	rickets$$$992$$$999$$$O	and$$$1000$$$1003$$$O	other$$$1004$$$1009$$$O	symptoms$$$1010$$$1018$$$O	caused$$$1019$$$1025$$$O	by$$$1026$$$1028$$$O	lack$$$1029$$$1033$$$O	of$$$1034$$$1036$$$O	calcium,$$$1037$$$1045$$$I	and$$$1046$$$1049$$$O	is$$$1050$$$1052$$$O	also$$$1053$$$1057$$$O	the$$$1058$$$1061$$$O	ideal,$$$1062$$$1068$$$O	safe$$$1069$$$1073$$$O	and$$$1074$$$1077$$$O	effective$$$1078$$$1087$$$O	natural$$$1088$$$1095$$$O	calcium$$$1096$$$1103$$$I	replenisher$$$1104$$$1115$$$O	containing$$$1116$$$1126$$$O	high$$$1127$$$1131$$$O	calcium$$$1132$$$1139$$$I	for$$$1140$$$1143$$$O	children$$$1144$$$1152$$$O	and$$$1153$$$1156$$$O	adults.$$$1157$$$1164$$$O
CN102133395A
Skeleton$$$0$$$8$$$O	health-care$$$9$$$20$$$O	product$$$21$$$28$$$O	or$$$29$$$31$$$O	medicinal$$$32$$$41$$$O	composite$$$42$$$51$$$O	and$$$52$$$55$$$O	application$$$56$$$67$$$O	thereof$$$68$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	skeleton$$$27$$$35$$$O	health-care$$$36$$$47$$$O	product$$$48$$$55$$$O	or$$$56$$$58$$$O	a$$$59$$$60$$$O	medicinal$$$61$$$70$$$O	composite,$$$71$$$81$$$O	which$$$82$$$87$$$O	comprises$$$88$$$97$$$O	the$$$98$$$101$$$O	following$$$102$$$111$$$O	raw$$$112$$$115$$$O	materials$$$116$$$125$$$O	in$$$126$$$128$$$O	part$$$129$$$133$$$O	by$$$134$$$136$$$O	weight:$$$137$$$144$$$O	160,000$$$145$$$152$$$O	to$$$153$$$155$$$O	185,000$$$156$$$163$$$O	parts$$$164$$$169$$$O	of$$$170$$$172$$$O	calcium$$$173$$$180$$$I	carbonate,$$$181$$$191$$$I	1$$$192$$$193$$$O	to$$$194$$$196$$$O	2$$$197$$$198$$$O	parts$$$199$$$204$$$O	of$$$205$$$207$$$O	vitamin$$$208$$$215$$$I	D3,$$$216$$$219$$$I	11,000$$$220$$$226$$$O	to$$$227$$$229$$$O	13,000$$$230$$$236$$$O	parts$$$237$$$242$$$O	of$$$243$$$245$$$O	casein$$$246$$$252$$$O	phosphoeptide,$$$253$$$267$$$O	30,000$$$268$$$274$$$O	to$$$275$$$277$$$O	50,000$$$278$$$284$$$O	parts$$$285$$$290$$$O	of$$$291$$$293$$$O	chondroitin$$$294$$$305$$$I	sulfate,$$$306$$$314$$$I	80,000$$$315$$$321$$$O	to$$$322$$$324$$$O	100,000$$$325$$$332$$$O	parts$$$333$$$338$$$O	of$$$339$$$341$$$O	glucosamine$$$342$$$353$$$I	hydrochloride,$$$354$$$368$$$I	50,000$$$369$$$375$$$O	to$$$376$$$378$$$O	70,000$$$379$$$385$$$O	parts$$$386$$$391$$$O	of$$$392$$$394$$$O	ossein$$$395$$$401$$$O	and$$$402$$$405$$$O	1,150$$$406$$$411$$$O	to$$$412$$$414$$$O	1,500$$$415$$$420$$$O	parts$$$421$$$426$$$O	of$$$427$$$429$$$O	manganese$$$430$$$439$$$I	chloride.$$$440$$$449$$$I	The$$$450$$$453$$$O	skeleton$$$454$$$462$$$O	health-care$$$463$$$474$$$O	product$$$475$$$482$$$O	or$$$483$$$485$$$O	the$$$486$$$489$$$O	medicinal$$$490$$$499$$$O	composite$$$500$$$509$$$O	has$$$510$$$513$$$O	a$$$514$$$515$$$O	skillful$$$516$$$524$$$O	and$$$525$$$528$$$O	unique$$$529$$$535$$$O	design,$$$536$$$543$$$O	mutually-synergistic$$$544$$$564$$$O	components$$$565$$$575$$$O	and$$$576$$$579$$$O	high$$$580$$$584$$$O	bioavailability,$$$585$$$601$$$O	can$$$602$$$605$$$O	be$$$606$$$608$$$O	used$$$609$$$613$$$O	for$$$614$$$617$$$O	increasing$$$618$$$628$$$O	bone$$$629$$$633$$$O	mineral$$$634$$$641$$$O	density,$$$642$$$650$$$O	relieving$$$651$$$660$$$O	bone$$$661$$$665$$$O	pain,$$$666$$$671$$$O	restoring$$$672$$$681$$$O	bone$$$682$$$686$$$O	functions$$$687$$$696$$$O	and$$$697$$$700$$$O	improving$$$701$$$710$$$O	immunity,$$$711$$$720$$$O	treats$$$721$$$727$$$O	the$$$728$$$731$$$O	symptoms$$$732$$$740$$$O	of$$$741$$$743$$$O	osteoporosis,$$$744$$$757$$$O	bone$$$758$$$762$$$O	pain,$$$763$$$768$$$O	loss$$$769$$$773$$$O	of$$$774$$$776$$$O	bone$$$777$$$781$$$O	joint$$$782$$$787$$$O	functions$$$788$$$797$$$O	and$$$798$$$801$$$O	the$$$802$$$805$$$O	like,$$$806$$$811$$$O	can$$$812$$$815$$$O	be$$$816$$$818$$$O	prepared$$$819$$$827$$$O	into$$$828$$$832$$$O	a$$$833$$$834$$$O	compound$$$835$$$843$$$O	preparation,$$$844$$$856$$$O	does$$$857$$$861$$$O	not$$$862$$$865$$$O	have$$$866$$$870$$$O	toxic$$$871$$$876$$$O	or$$$877$$$879$$$O	side$$$880$$$884$$$O	effect,$$$885$$$892$$$O	and$$$893$$$896$$$O	is$$$897$$$899$$$O	suitable$$$900$$$908$$$O	for$$$909$$$912$$$O	large-scale$$$913$$$924$$$O	popularization$$$925$$$939$$$O	and$$$940$$$943$$$O	application.$$$944$$$956$$$O
CN100999470B
Salvia$$$0$$$6$$$O	minium$$$7$$$13$$$O	phenolic$$$14$$$22$$$I	acid$$$23$$$27$$$I	A$$$28$$$29$$$O	and$$$30$$$33$$$O	process$$$34$$$41$$$O	of$$$42$$$44$$$O	preparing$$$45$$$54$$$O	preparation$$$55$$$66$$$O	and$$$67$$$70$$$O	use$$$71$$$74$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	concerns$$$15$$$23$$$O	the$$$24$$$27$$$O	method$$$28$$$34$$$O	of$$$35$$$37$$$O	extracting$$$38$$$48$$$O	salvianolic$$$49$$$60$$$I	acid$$$61$$$65$$$I	A$$$66$$$67$$$I	from$$$68$$$72$$$O	Chinese$$$73$$$80$$$O	crude$$$81$$$86$$$O	drug:$$$87$$$92$$$O	danshen$$$93$$$100$$$O	root,$$$101$$$106$$$O	and$$$107$$$110$$$O	the$$$111$$$114$$$O	quality$$$115$$$122$$$O	control$$$123$$$130$$$O	methods$$$131$$$138$$$O	and$$$139$$$142$$$O	drug$$$143$$$147$$$O	combinations,$$$148$$$161$$$O	and$$$162$$$165$$$O	the$$$166$$$169$$$O	application$$$170$$$181$$$O	of$$$182$$$184$$$O	this$$$185$$$189$$$O	drug.$$$190$$$195$$$O	It$$$196$$$198$$$O	can$$$199$$$202$$$O	be$$$203$$$205$$$O	used$$$206$$$210$$$O	in$$$211$$$213$$$O	the$$$214$$$217$$$O	preparation$$$218$$$229$$$O	of$$$230$$$232$$$O	the$$$233$$$236$$$O	prevention$$$237$$$247$$$O	drugs$$$248$$$253$$$O	for$$$254$$$257$$$O	cardiovascular$$$258$$$272$$$O	disease,$$$273$$$281$$$O	liver$$$282$$$287$$$O	damage,$$$288$$$295$$$O	liver$$$296$$$301$$$O	fibrosis,$$$302$$$311$$$O	pulmonary$$$312$$$321$$$O	fibrosis$$$322$$$330$$$O	and$$$331$$$334$$$O	other.$$$335$$$341$$$O
CN101327267A
Compound$$$0$$$8$$$O	Houttuynia$$$9$$$19$$$O	cordata$$$20$$$27$$$O	injection$$$28$$$37$$$O	for$$$38$$$41$$$O	animals$$$42$$$49$$$O	and$$$50$$$53$$$O	preparation$$$54$$$65$$$O	method$$$66$$$72$$$O	thereof$$$73$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	livestock$$$26$$$35$$$O	used$$$36$$$40$$$O	compound$$$41$$$49$$$O	cordate$$$50$$$57$$$O	houttuynia$$$58$$$68$$$O	herba$$$69$$$74$$$O	injection$$$75$$$84$$$O	solution$$$85$$$93$$$O	and$$$94$$$97$$$O	a$$$98$$$99$$$O	preparation$$$100$$$111$$$O	method$$$112$$$118$$$O	thereof.$$$119$$$127$$$O	The$$$128$$$131$$$O	invention$$$132$$$141$$$O	aims$$$142$$$146$$$O	to$$$147$$$149$$$O	provide$$$150$$$157$$$O	the$$$158$$$161$$$O	beast$$$162$$$167$$$O	used$$$168$$$172$$$O	compound$$$173$$$181$$$O	cordate$$$182$$$189$$$O	houttuynia$$$190$$$200$$$O	herba$$$201$$$206$$$O	injection$$$207$$$216$$$O	solution$$$217$$$225$$$O	for$$$226$$$229$$$O	remedying$$$230$$$239$$$O	mastitis$$$240$$$248$$$O	and$$$249$$$252$$$O	central$$$253$$$260$$$O	prolactin$$$261$$$270$$$O	hyposecretion$$$271$$$284$$$O	which$$$285$$$290$$$O	can$$$291$$$294$$$O	cure$$$295$$$299$$$O	both$$$300$$$304$$$O	the$$$305$$$308$$$O	symptoms$$$309$$$317$$$O	and$$$318$$$321$$$O	root$$$322$$$326$$$O	cause$$$327$$$332$$$O	of$$$333$$$335$$$O	the$$$336$$$339$$$O	diseases,$$$340$$$349$$$O	and$$$350$$$353$$$O	the$$$354$$$357$$$O	preparation$$$358$$$369$$$O	method$$$370$$$376$$$O	which$$$377$$$382$$$O	has$$$383$$$386$$$O	simple$$$387$$$393$$$O	technology$$$394$$$404$$$O	and$$$405$$$408$$$O	is$$$409$$$411$$$O	easy$$$412$$$416$$$O	to$$$417$$$419$$$O	be$$$420$$$422$$$O	realized.$$$423$$$432$$$O	For$$$433$$$436$$$O	every$$$437$$$442$$$O	100L,$$$443$$$448$$$O	the$$$449$$$452$$$O	injection$$$453$$$462$$$O	solution$$$463$$$471$$$O	is$$$472$$$474$$$O	made$$$475$$$479$$$O	from$$$480$$$484$$$O	the$$$485$$$488$$$O	following$$$489$$$498$$$O	components$$$499$$$509$$$O	of$$$510$$$512$$$O	100-300kg$$$513$$$522$$$O	of$$$523$$$525$$$O	cordate$$$526$$$533$$$O	houttuynia$$$534$$$544$$$O	herba,$$$545$$$551$$$O	0.1-1kg$$$552$$$559$$$O	of$$$560$$$562$$$O	hydrochloric$$$563$$$575$$$I	acid$$$576$$$580$$$I	metoclopramide$$$581$$$595$$$I	paspertin,$$$596$$$606$$$I	0.2kg$$$607$$$612$$$O	of$$$613$$$615$$$O	hydrosulphite$$$616$$$629$$$I	of$$$630$$$632$$$O	sodium,$$$633$$$640$$$I	0.01kg$$$641$$$647$$$O	of$$$648$$$650$$$O	EDTA-2Na$$$651$$$659$$$I	and$$$660$$$663$$$O	injection$$$664$$$673$$$O	water$$$674$$$679$$$O	for$$$680$$$683$$$O	the$$$684$$$687$$$O	surplus$$$688$$$695$$$O	proportions.$$$696$$$708$$$O	The$$$709$$$712$$$O	invention$$$713$$$722$$$O	is$$$723$$$725$$$O	the$$$726$$$729$$$O	compound$$$730$$$738$$$O	preparation$$$739$$$750$$$O	of$$$751$$$753$$$O	the$$$754$$$757$$$O	cordate$$$758$$$765$$$O	houttuynia$$$766$$$776$$$O	herba$$$777$$$782$$$O	and$$$783$$$786$$$O	the$$$787$$$790$$$O	hydrochloric$$$791$$$803$$$I	acid$$$804$$$808$$$I	metoclopramide$$$809$$$823$$$I	paspertin$$$824$$$833$$$I	which$$$834$$$839$$$O	is$$$840$$$842$$$O	used$$$843$$$847$$$O	to$$$848$$$850$$$O	stimulate$$$851$$$860$$$O	the$$$861$$$864$$$O	central$$$865$$$872$$$O	prolactin$$$873$$$882$$$O	to$$$883$$$885$$$O	secrete$$$886$$$893$$$O	latex.$$$894$$$900$$$O	The$$$901$$$904$$$O	combination$$$905$$$916$$$O	use$$$917$$$920$$$O	of$$$921$$$923$$$O	the$$$924$$$927$$$O	cordate$$$928$$$935$$$O	houttuynia$$$936$$$946$$$O	herba$$$947$$$952$$$O	and$$$953$$$956$$$O	the$$$957$$$960$$$O	hydrochloric$$$961$$$973$$$I	acid$$$974$$$978$$$I	metoclopramide$$$979$$$993$$$I	paspertin$$$994$$$1003$$$I	has$$$1004$$$1007$$$O	high$$$1008$$$1012$$$O	efficiency$$$1013$$$1023$$$O	to$$$1024$$$1026$$$O	livestock$$$1027$$$1036$$$O	mastitis$$$1037$$$1045$$$O	and$$$1046$$$1049$$$O	central$$$1050$$$1057$$$O	prolactin$$$1058$$$1067$$$O	hyposecretion,$$$1068$$$1082$$$O	can$$$1083$$$1086$$$O	avoid$$$1087$$$1092$$$O	the$$$1093$$$1096$$$O	adverse$$$1097$$$1104$$$O	effect$$$1105$$$1111$$$O	to$$$1112$$$1114$$$O	pups,$$$1115$$$1120$$$O	can$$$1121$$$1124$$$O	reduce$$$1125$$$1131$$$O	the$$$1132$$$1135$$$O	incidence$$$1136$$$1145$$$O	rate$$$1146$$$1150$$$O	of$$$1151$$$1153$$$O	diseases,$$$1154$$$1163$$$O	and$$$1164$$$1167$$$O	can$$$1168$$$1171$$$O	improve$$$1172$$$1179$$$O	milkability.$$$1180$$$1192$$$O
CN103040795A
Rotundine$$$0$$$9$$$I	transdermal$$$10$$$21$$$O	patch$$$22$$$27$$$O	and$$$28$$$31$$$O	preparation$$$32$$$43$$$O	method$$$44$$$50$$$O	thereof$$$51$$$58$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	rotundine$$$26$$$35$$$I	transdermal$$$36$$$47$$$O	patch$$$48$$$53$$$O	and$$$54$$$57$$$O	a$$$58$$$59$$$O	preparation$$$60$$$71$$$O	method$$$72$$$78$$$O	thereof.$$$79$$$87$$$O	The$$$88$$$91$$$O	transdermal$$$92$$$103$$$O	patch$$$104$$$109$$$O	is$$$110$$$112$$$O	formed$$$113$$$119$$$O	by$$$120$$$122$$$O	a$$$123$$$124$$$O	lining$$$125$$$131$$$O	layer,$$$132$$$138$$$O	a$$$139$$$140$$$O	drug-containing$$$141$$$156$$$O	sticking$$$157$$$165$$$O	layer$$$166$$$171$$$O	and$$$172$$$175$$$O	a$$$176$$$177$$$O	protective$$$178$$$188$$$O	layer$$$189$$$194$$$O	which$$$195$$$200$$$O	are$$$201$$$204$$$O	sequentially$$$205$$$217$$$O	laminated,$$$218$$$228$$$O	wherein$$$229$$$236$$$O	the$$$237$$$240$$$O	drug-containing$$$241$$$256$$$O	sticking$$$257$$$265$$$O	layer$$$266$$$271$$$O	is$$$272$$$274$$$O	prepared$$$275$$$283$$$O	from$$$284$$$288$$$O	7-14$$$289$$$293$$$O	parts$$$294$$$299$$$O	of$$$300$$$302$$$O	rotundine$$$303$$$312$$$I	or$$$313$$$315$$$O	rotundine$$$316$$$325$$$I	sulphate,$$$326$$$335$$$I	1-10$$$336$$$340$$$O	parts$$$341$$$346$$$O	of$$$347$$$349$$$O	percutaneous$$$350$$$362$$$O	penetration$$$363$$$374$$$O	enhancer,$$$375$$$384$$$O	40-70$$$385$$$390$$$O	parts$$$391$$$396$$$O	of$$$397$$$399$$$O	pressure-sensitive$$$400$$$418$$$O	adhesive,$$$419$$$428$$$O	10-30$$$429$$$434$$$O	parts$$$435$$$440$$$O	of$$$441$$$443$$$O	moisturizer,$$$444$$$456$$$O	10-25$$$457$$$462$$$O	parts$$$463$$$468$$$O	of$$$469$$$471$$$O	plasticizer$$$472$$$483$$$O	and$$$484$$$487$$$O	1-3$$$488$$$491$$$O	parts$$$492$$$497$$$O	of$$$498$$$500$$$O	crosslinking$$$501$$$513$$$O	agent.$$$514$$$520$$$O	The$$$521$$$524$$$O	rotundine$$$525$$$534$$$I	transdermal$$$535$$$546$$$O	patch$$$547$$$552$$$O	disclosed$$$553$$$562$$$O	by$$$563$$$565$$$O	the$$$566$$$569$$$O	invention$$$570$$$579$$$O	is$$$580$$$582$$$O	higher$$$583$$$589$$$O	in$$$590$$$592$$$O	rotundine$$$593$$$602$$$I	accumulation$$$603$$$615$$$O	infiltration$$$616$$$628$$$O	capacity$$$629$$$637$$$O	and$$$638$$$641$$$O	can$$$642$$$645$$$O	maintain$$$646$$$654$$$O	effective$$$655$$$664$$$O	blood$$$665$$$670$$$O	concentration$$$671$$$684$$$O	for$$$685$$$688$$$O	a$$$689$$$690$$$O	longer$$$691$$$697$$$O	time,$$$698$$$703$$$O	and$$$704$$$707$$$O	experiments$$$708$$$719$$$O	adopting$$$720$$$728$$$O	a$$$729$$$730$$$O	writhing$$$731$$$739$$$O	method$$$740$$$746$$$O	and$$$747$$$750$$$O	a$$$751$$$752$$$O	hot$$$753$$$756$$$O	plate$$$757$$$762$$$O	method$$$763$$$769$$$O	show$$$770$$$774$$$O	that$$$775$$$779$$$O	the$$$780$$$783$$$O	rotundine$$$784$$$793$$$I	transdermal$$$794$$$805$$$O	patch$$$806$$$811$$$O	disclosed$$$812$$$821$$$O	by$$$822$$$824$$$O	the$$$825$$$828$$$O	invention$$$829$$$838$$$O	has$$$839$$$842$$$O	a$$$843$$$844$$$O	good$$$845$$$849$$$O	analgesic$$$850$$$859$$$O	effect.$$$860$$$867$$$O	Blood$$$868$$$873$$$O	concentration$$$874$$$887$$$O	is$$$888$$$890$$$O	still$$$891$$$896$$$O	kept$$$897$$$901$$$O	at$$$902$$$904$$$O	0.433mg/L$$$905$$$914$$$O	48$$$915$$$917$$$O	hours$$$918$$$923$$$O	after$$$924$$$929$$$O	administration,$$$930$$$945$$$O	stable$$$946$$$952$$$O	blood$$$953$$$958$$$O	concentration$$$959$$$972$$$O	is$$$973$$$975$$$O	kept$$$976$$$980$$$O	in$$$981$$$983$$$O	vivo,$$$984$$$989$$$O	and$$$990$$$993$$$O	no$$$994$$$996$$$O	peak$$$997$$$1001$$$O	phenomenon$$$1002$$$1012$$$O	is$$$1013$$$1015$$$O	caused;$$$1016$$$1023$$$O	and$$$1024$$$1027$$$O	pharmacology$$$1028$$$1040$$$O	experiments$$$1041$$$1052$$$O	prove$$$1053$$$1058$$$O	that$$$1059$$$1063$$$O	the$$$1064$$$1067$$$O	rotundine$$$1068$$$1077$$$I	transdermal$$$1078$$$1089$$$O	patch$$$1090$$$1095$$$O	disclosed$$$1096$$$1105$$$O	by$$$1106$$$1108$$$O	the$$$1109$$$1112$$$O	invention$$$1113$$$1122$$$O	has$$$1123$$$1126$$$O	an$$$1127$$$1129$$$O	obvious$$$1130$$$1137$$$O	and$$$1138$$$1141$$$O	long-lasting$$$1142$$$1154$$$O	analgesic$$$1155$$$1164$$$O	effect.$$$1165$$$1172$$$O
US20120058155
Slow-degrading$$$0$$$14$$$O	polymers$$$15$$$23$$$O	for$$$24$$$27$$$O	undelayed$$$28$$$37$$$O	and$$$38$$$41$$$O	sustained$$$42$$$51$$$O	drug$$$52$$$56$$$O	delivery$$$57$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	polymers$$$23$$$31$$$O	and$$$32$$$35$$$O	methods$$$36$$$43$$$O	for$$$44$$$47$$$O	their$$$48$$$53$$$O	use.$$$54$$$58$$$O	Certain$$$59$$$66$$$O	embodiments$$$67$$$78$$$O	of$$$79$$$81$$$O	the$$$82$$$85$$$O	invention$$$86$$$95$$$O	provide$$$96$$$103$$$O	slow$$$104$$$108$$$O	degrading$$$109$$$118$$$O	microspheres$$$119$$$131$$$O	for$$$132$$$135$$$O	undelayed$$$136$$$145$$$O	and$$$146$$$149$$$O	sustained$$$150$$$159$$$O	drug$$$160$$$164$$$O	delivery.$$$165$$$174$$$O
US8486902
Hydroxyl,$$$0$$$9$$$I	keto,$$$10$$$15$$$I	and$$$16$$$19$$$O	glucuronide$$$20$$$31$$$I	derivatives$$$32$$$43$$$O	of$$$44$$$46$$$O	3-(4-(7H-pyrrolo[2,3-d]$$$47$$$70$$$I	pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile$$$71$$$131$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	hydroxyl,$$$31$$$40$$$I	keto,$$$41$$$46$$$I	and$$$47$$$50$$$O	glucuronide$$$51$$$62$$$I	derivatives$$$63$$$74$$$O	of$$$75$$$77$$$O	3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.$$$78$$$162$$$I
CN102451272A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	ointment$$$22$$$30$$$O	for$$$31$$$34$$$O	scalds$$$35$$$41$$$O	and$$$42$$$45$$$O	burns$$$46$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	preparation$$$27$$$38$$$O	method$$$39$$$45$$$O	of$$$46$$$48$$$O	ointment$$$49$$$57$$$O	for$$$58$$$61$$$O	scalds$$$62$$$68$$$O	and$$$69$$$72$$$O	burns.$$$73$$$79$$$O	The$$$80$$$83$$$O	method$$$84$$$90$$$O	comprises:$$$91$$$101$$$O	first$$$102$$$107$$$O	putting$$$108$$$115$$$O	a$$$116$$$117$$$O	washed$$$118$$$124$$$O	rotten$$$125$$$131$$$O	orange$$$132$$$138$$$O	in$$$139$$$141$$$O	a$$$142$$$143$$$O	capped$$$144$$$150$$$O	bottle,$$$151$$$158$$$O	when$$$159$$$163$$$O	juice$$$164$$$169$$$O	exudes,$$$170$$$177$$$O	adding$$$178$$$184$$$O	ultrafine$$$185$$$194$$$O	powder$$$195$$$201$$$O	ground$$$202$$$208$$$O	from$$$209$$$213$$$O	sophora$$$214$$$221$$$O	flavescens,$$$222$$$233$$$O	forsythia,$$$234$$$244$$$O	stir-fried$$$245$$$255$$$O	sanguisorba$$$256$$$267$$$O	officinalis,$$$268$$$280$$$O	rheum$$$281$$$286$$$O	officinale,$$$287$$$298$$$O	and$$$299$$$302$$$O	phellodendron,$$$303$$$317$$$O	etc.$$$318$$$322$$$O	into$$$323$$$327$$$O	the$$$328$$$331$$$O	rotten$$$332$$$338$$$O	orange$$$339$$$345$$$O	juice$$$346$$$351$$$O	so$$$352$$$354$$$O	as$$$355$$$357$$$O	to$$$358$$$360$$$O	prepare$$$361$$$368$$$O	a$$$369$$$370$$$O	paste,$$$371$$$377$$$O	which$$$378$$$383$$$O	is$$$384$$$386$$$O	then$$$387$$$391$$$O	filled$$$392$$$398$$$O	into$$$399$$$403$$$O	a$$$404$$$405$$$O	bottle$$$406$$$412$$$O	and$$$413$$$416$$$O	can$$$417$$$420$$$O	be$$$421$$$423$$$O	applied$$$424$$$431$$$O	to$$$432$$$434$$$O	burns$$$435$$$440$$$O	and$$$441$$$444$$$O	scalds$$$445$$$451$$$O	during$$$452$$$458$$$O	usage.$$$459$$$465$$$O	The$$$466$$$469$$$O	ointment$$$470$$$478$$$O	of$$$479$$$481$$$O	the$$$482$$$485$$$O	invention$$$486$$$495$$$O	can$$$496$$$499$$$O	be$$$500$$$502$$$O	used$$$503$$$507$$$O	for$$$508$$$511$$$O	treating$$$512$$$520$$$O	various$$$521$$$528$$$O	burns$$$529$$$534$$$O	and$$$535$$$538$$$O	scalds$$$539$$$545$$$O	by$$$546$$$548$$$O	water$$$549$$$554$$$O	and$$$555$$$558$$$O	fire,$$$559$$$564$$$O	has$$$565$$$568$$$O	good$$$569$$$573$$$O	anti-inflammation$$$574$$$591$$$O	and$$$592$$$595$$$O	pain$$$596$$$600$$$O	relieving$$$601$$$610$$$O	effect,$$$611$$$618$$$O	and$$$619$$$622$$$O	can$$$623$$$626$$$O	promote$$$627$$$634$$$O	scabbing$$$635$$$643$$$O	and$$$644$$$647$$$O	recovery$$$648$$$656$$$O	wounds$$$657$$$663$$$O	without$$$664$$$671$$$O	scar,$$$672$$$677$$$O	thus$$$678$$$682$$$O	being$$$683$$$688$$$O	a$$$689$$$690$$$O	good$$$691$$$695$$$O	medicine$$$696$$$704$$$O	for$$$705$$$708$$$O	treating$$$709$$$717$$$O	burns$$$718$$$723$$$O	and$$$724$$$727$$$O	scalds.$$$728$$$735$$$O
CN103656736A
Antibacterial$$$0$$$13$$$O	finishing$$$14$$$23$$$O	agent$$$24$$$29$$$O	for$$$30$$$33$$$O	medical$$$34$$$41$$$O	dressing$$$42$$$50$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	antibacterial$$$28$$$41$$$O	finishing$$$42$$$51$$$O	agent$$$52$$$57$$$O	for$$$58$$$61$$$O	a$$$62$$$63$$$O	medical$$$64$$$71$$$O	dressing.$$$72$$$81$$$O	The$$$82$$$85$$$O	antibacterial$$$86$$$99$$$O	finishing$$$100$$$109$$$O	agent$$$110$$$115$$$O	is$$$116$$$118$$$O	prepared$$$119$$$127$$$O	through$$$128$$$135$$$O	an$$$136$$$138$$$O	antibacterial$$$139$$$152$$$O	agent,$$$153$$$159$$$O	a$$$160$$$161$$$O	hemostatic,$$$162$$$173$$$O	and$$$174$$$177$$$O	an$$$178$$$180$$$O	astringent$$$181$$$191$$$O	capable$$$192$$$199$$$O	of$$$200$$$202$$$O	promoting$$$203$$$212$$$O	wound$$$213$$$218$$$O	healing$$$219$$$226$$$O	by$$$227$$$229$$$O	virtue$$$230$$$236$$$O	of$$$237$$$239$$$O	a$$$240$$$241$$$O	special$$$242$$$249$$$O	process.$$$250$$$258$$$O	The$$$259$$$262$$$O	antibacterial$$$263$$$276$$$O	finishing$$$277$$$286$$$O	agent$$$287$$$292$$$O	is$$$293$$$295$$$O	used$$$296$$$300$$$O	for$$$301$$$304$$$O	finishing$$$305$$$314$$$O	gauze,$$$315$$$321$$$O	a$$$322$$$323$$$O	bandage,$$$324$$$332$$$O	sponge$$$333$$$339$$$O	and$$$340$$$343$$$O	other$$$344$$$349$$$O	medical$$$350$$$357$$$O	dressings,$$$358$$$368$$$O	and$$$369$$$372$$$O	has$$$373$$$376$$$O	the$$$377$$$380$$$O	characteristics$$$381$$$396$$$O	of$$$397$$$399$$$O	broad-spectrum$$$400$$$414$$$O	antibacterial$$$415$$$428$$$O	property,$$$429$$$438$$$O	blood$$$439$$$444$$$O	stopping,$$$445$$$454$$$O	healing$$$455$$$462$$$O	promoting,$$$463$$$473$$$O	safety$$$474$$$480$$$O	and$$$481$$$484$$$O	non-irritation,$$$485$$$500$$$O	and$$$501$$$504$$$O	simple$$$505$$$511$$$O	preparation$$$512$$$523$$$O	process.$$$524$$$532$$$O	The$$$533$$$536$$$O	finished$$$537$$$545$$$O	medical$$$546$$$553$$$O	dressing$$$554$$$562$$$O	has$$$563$$$566$$$O	the$$$567$$$570$$$O	effects$$$571$$$578$$$O	of$$$579$$$581$$$O	resisting$$$582$$$591$$$O	bacteria,$$$592$$$601$$$O	stopping$$$602$$$610$$$O	blooding,$$$611$$$620$$$O	diminishing$$$621$$$632$$$O	inflammation,$$$633$$$646$$$O	and$$$647$$$650$$$O	promoting$$$651$$$660$$$O	wound$$$661$$$666$$$O	healing.$$$667$$$675$$$O
US20050004177
Joint$$$0$$$5$$$O	cartilage$$$6$$$15$$$O	damage,$$$16$$$23$$$O	inflammation,$$$24$$$37$$$O	stiffness,$$$38$$$48$$$O	impaired$$$49$$$57$$$O	function$$$58$$$66$$$O	and/or$$$67$$$73$$$O	pain;$$$74$$$79$$$O	osteoarthritis,$$$80$$$95$$$O	rheumatoid$$$96$$$106$$$O	arthritis$$$107$$$116$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	combination$$$28$$$39$$$O	of$$$40$$$42$$$O	an$$$43$$$45$$$O	allosteric$$$46$$$56$$$O	inhibitor$$$57$$$66$$$O	of$$$67$$$69$$$O	matrix$$$70$$$76$$$O	metalloproteinase-13,$$$77$$$98$$$O	or$$$99$$$101$$$O	a$$$102$$$103$$$O	pharmaceutically$$$104$$$120$$$O	acceptable$$$121$$$131$$$O	salt$$$132$$$136$$$O	thereof,$$$137$$$145$$$O	and$$$146$$$149$$$O	a$$$150$$$151$$$O	ligand$$$152$$$158$$$O	to$$$159$$$161$$$O	an$$$162$$$164$$$O	alpha-2-delta$$$165$$$178$$$O	receptor,$$$179$$$188$$$O	or$$$189$$$191$$$O	a$$$192$$$193$$$O	pharmaceutically$$$194$$$210$$$O	acceptable$$$211$$$221$$$O	salt$$$222$$$226$$$O	thereof,$$$227$$$235$$$O	a$$$236$$$237$$$O	pharmaceutical$$$238$$$252$$$O	composition$$$253$$$264$$$O	comprising$$$265$$$275$$$O	the$$$276$$$279$$$O	combination,$$$280$$$292$$$O	and$$$293$$$296$$$O	a$$$297$$$298$$$O	method$$$299$$$305$$$O	of$$$306$$$308$$$O	using$$$309$$$314$$$O	the$$$315$$$318$$$O	combination$$$319$$$330$$$O	to$$$331$$$333$$$O	treat$$$334$$$339$$$O	a$$$340$$$341$$$O	disease$$$342$$$349$$$O	or$$$350$$$352$$$O	disorder$$$353$$$361$$$O	in$$$362$$$364$$$O	a$$$365$$$366$$$O	mammal$$$367$$$373$$$O	suffering$$$374$$$383$$$O	therefrom,$$$384$$$394$$$O	wherein$$$395$$$402$$$O	the$$$403$$$406$$$O	disease$$$407$$$414$$$O	or$$$415$$$417$$$O	disorder$$$418$$$426$$$O	is$$$427$$$429$$$O	responsive$$$430$$$440$$$O	to$$$441$$$443$$$O	treatment$$$444$$$453$$$O	in$$$454$$$456$$$O	one$$$457$$$460$$$O	aspect$$$461$$$467$$$O	by$$$468$$$470$$$O	an$$$471$$$473$$$O	allosteric$$$474$$$484$$$O	inhibitor$$$485$$$494$$$O	of$$$495$$$497$$$O	MMP-13$$$498$$$504$$$O	and$$$505$$$508$$$O	in$$$509$$$511$$$O	the$$$512$$$515$$$O	same$$$516$$$520$$$O	or$$$521$$$523$$$O	a$$$524$$$525$$$O	different$$$526$$$535$$$O	aspect$$$536$$$542$$$O	by$$$543$$$545$$$O	a$$$546$$$547$$$O	ligand$$$548$$$554$$$O	to$$$555$$$557$$$O	an$$$558$$$560$$$O	alpha-2-delta$$$561$$$574$$$O	receptor.$$$575$$$584$$$O
US20080159984
Compositions$$$0$$$12$$$O	Capable$$$13$$$20$$$O	of$$$21$$$23$$$O	Facilitating$$$24$$$36$$$O	Penetration$$$37$$$48$$$O	Across$$$49$$$55$$$O	a$$$56$$$57$$$O	Biological$$$58$$$68$$$O	Barrier$$$69$$$76$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	penetrating$$$32$$$43$$$O	compositions$$$44$$$56$$$O	including$$$57$$$66$$$O	one$$$67$$$70$$$O	or$$$71$$$73$$$O	more$$$74$$$78$$$O	effectors$$$79$$$88$$$O	included$$$89$$$97$$$O	within$$$98$$$104$$$O	a$$$105$$$106$$$O	water$$$107$$$112$$$O	soluble$$$113$$$120$$$O	composition,$$$121$$$133$$$O	immersed$$$134$$$142$$$O	in$$$143$$$145$$$O	a$$$146$$$147$$$O	hydrophobic$$$148$$$159$$$O	medium$$$160$$$166$$$O	The$$$167$$$170$$$O	invention$$$171$$$180$$$O	also$$$181$$$185$$$O	relates$$$186$$$193$$$O	to$$$194$$$196$$$O	methods$$$197$$$204$$$O	of$$$205$$$207$$$O	treating$$$208$$$216$$$O	or$$$217$$$219$$$O	preventing$$$220$$$230$$$O	diseases$$$231$$$239$$$O	by$$$240$$$242$$$O	administering$$$243$$$256$$$O	such$$$257$$$261$$$O	penetrating$$$262$$$273$$$O	compositions$$$274$$$286$$$O	to$$$287$$$289$$$O	affected$$$290$$$298$$$O	subjects.$$$299$$$308$$$O
WO2013106410A3
Improved$$$0$$$8$$$O	sock$$$9$$$13$$$O	for$$$14$$$17$$$O	treatment$$$18$$$27$$$O	of$$$28$$$30$$$O	foot$$$31$$$35$$$O	and$$$36$$$39$$$O	leg$$$40$$$43$$$O	wounds,$$$44$$$51$$$O	methods$$$52$$$59$$$O	of$$$60$$$62$$$O	use$$$63$$$66$$$O	and$$$67$$$70$$$O	manufacture$$$71$$$82$$$O
The$$$0$$$3$$$O	Improved$$$4$$$12$$$O	Sock$$$13$$$17$$$O	is$$$18$$$20$$$O	made$$$21$$$25$$$O	of$$$26$$$28$$$O	yarns$$$29$$$34$$$O	knitted$$$35$$$42$$$O	into$$$43$$$47$$$O	a$$$48$$$49$$$O	foot$$$50$$$54$$$O	and$$$55$$$58$$$O	calf,$$$59$$$64$$$O	with$$$65$$$69$$$O	graduated$$$70$$$79$$$O	compression$$$80$$$91$$$O	on$$$92$$$94$$$O	an$$$95$$$97$$$O	individual's$$$98$$$110$$$O	foot$$$111$$$115$$$O	from$$$116$$$120$$$O	the$$$121$$$124$$$O	foot$$$125$$$129$$$O	to$$$130$$$132$$$O	the$$$133$$$136$$$O	calf.$$$137$$$142$$$O	The$$$143$$$146$$$O	yarns$$$147$$$152$$$O	can$$$153$$$156$$$O	include$$$157$$$164$$$O	wool$$$165$$$169$$$O	and$$$170$$$173$$$O	alpaca$$$174$$$180$$$O	fibers.$$$181$$$188$$$O	A$$$189$$$190$$$O	substantial$$$191$$$202$$$O	proportion$$$203$$$213$$$O	of$$$214$$$216$$$O	wool$$$217$$$221$$$O	and/or$$$222$$$228$$$O	alpaca$$$229$$$235$$$O	are$$$236$$$239$$$O	on$$$240$$$242$$$O	the$$$243$$$246$$$O	inside$$$247$$$253$$$O	of$$$254$$$256$$$O	the$$$257$$$260$$$O	sock$$$261$$$265$$$O	so$$$266$$$268$$$O	as$$$269$$$271$$$O	to$$$272$$$274$$$O	be$$$275$$$277$$$O	in$$$278$$$280$$$O	direct$$$281$$$287$$$O	contact$$$288$$$295$$$O	with$$$296$$$300$$$O	the$$$301$$$304$$$O	skin$$$305$$$309$$$O	and$$$310$$$313$$$O	wound.$$$314$$$320$$$O	The$$$321$$$324$$$O	Improved$$$325$$$333$$$O	Sock$$$334$$$338$$$O	provides$$$339$$$347$$$O	absorption$$$348$$$358$$$O	and$$$359$$$362$$$O	wicking$$$363$$$370$$$O	of$$$371$$$373$$$O	inflammatory$$$374$$$386$$$O	mediators,$$$387$$$397$$$O	bacteria$$$398$$$406$$$O	and$$$407$$$410$$$O	biofilm$$$411$$$418$$$O	and$$$419$$$422$$$O	necrotic$$$423$$$431$$$O	exudate$$$432$$$439$$$O	from$$$440$$$444$$$O	the$$$445$$$448$$$O	foot$$$449$$$453$$$O	and$$$454$$$457$$$O	leg.$$$458$$$462$$$O	The$$$463$$$466$$$O	Improved$$$467$$$475$$$O	Sock$$$476$$$480$$$O	has$$$481$$$484$$$O	AgNP$$$485$$$489$$$O	shapes$$$490$$$496$$$O	electrostatically$$$497$$$514$$$O	bonded$$$515$$$521$$$O	to$$$522$$$524$$$O	the$$$525$$$528$$$O	yarn.$$$529$$$534$$$O	At$$$535$$$537$$$O	least$$$538$$$543$$$O	30%$$$544$$$547$$$O	of$$$548$$$550$$$O	the$$$551$$$554$$$O	mass$$$555$$$559$$$O	of$$$560$$$562$$$O	the$$$563$$$566$$$O	AgNP$$$567$$$571$$$O	shapes$$$572$$$578$$$O	attached$$$579$$$587$$$O	to$$$588$$$590$$$O	the$$$591$$$594$$$O	fibers$$$595$$$601$$$O	have$$$602$$$606$$$O	a$$$607$$$608$$$O	shape$$$609$$$614$$$O	selected$$$615$$$623$$$O	from$$$624$$$628$$$O	the$$$629$$$632$$$O	group$$$633$$$638$$$O	consisting$$$639$$$649$$$O	of$$$650$$$652$$$O	truncated$$$653$$$662$$$O	triangular$$$663$$$673$$$O	plates$$$674$$$680$$$O	(a$$$681$$$683$$$O	triangle$$$684$$$692$$$O	with$$$693$$$697$$$O	the$$$698$$$701$$$O	corners$$$702$$$709$$$O	rounded$$$710$$$717$$$O	off),$$$718$$$723$$$O	triangular$$$724$$$734$$$O	prisms,$$$735$$$742$$$O	discs$$$743$$$748$$$O	and$$$749$$$752$$$O	combinations$$$753$$$765$$$O	of$$$766$$$768$$$O	two$$$769$$$772$$$O	or$$$773$$$775$$$O	more$$$776$$$780$$$O	of$$$781$$$783$$$O	them.$$$784$$$789$$$O	The$$$790$$$793$$$O	Improved$$$794$$$802$$$O	Sock$$$803$$$807$$$O	functions$$$808$$$817$$$O	as$$$818$$$820$$$O	a$$$821$$$822$$$O	unique$$$823$$$829$$$O	wound$$$830$$$835$$$O	dressing$$$836$$$844$$$O	with$$$845$$$849$$$O	the$$$850$$$853$$$O	sock$$$854$$$858$$$O	in$$$859$$$861$$$O	direct$$$862$$$868$$$O	contact$$$869$$$876$$$O	with$$$877$$$881$$$O	the$$$882$$$885$$$O	wound.$$$886$$$892$$$O
CN101812063A
Alpha-naphthalenesulfonamide$$$0$$$28$$$I	base$$$29$$$33$$$O	quintuple$$$34$$$43$$$O	heterocyclic$$$44$$$56$$$O	compound$$$57$$$65$$$O	and$$$66$$$69$$$O	anti-tumor$$$70$$$80$$$O	activity$$$81$$$89$$$O	thereof$$$90$$$97$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	alpha-naphthalenesulfonamide$$$28$$$56$$$I	base$$$57$$$61$$$O	quintuple$$$62$$$71$$$O	heterocyclic$$$72$$$84$$$O	compound$$$85$$$93$$$O	and$$$94$$$97$$$O	application$$$98$$$109$$$O	thereof$$$110$$$117$$$O	in$$$118$$$120$$$O	anti-tumor$$$121$$$131$$$O	treatment.$$$132$$$142$$$O	Shown$$$143$$$148$$$O	as$$$149$$$151$$$O	research$$$152$$$160$$$O	results,$$$161$$$169$$$O	the$$$170$$$173$$$O	alpha-naphthalenesulfonamide$$$174$$$202$$$I	base$$$203$$$207$$$O	quintuple$$$208$$$217$$$O	heterocyclic$$$218$$$230$$$O	compound,$$$231$$$240$$$O	an$$$241$$$243$$$O	isomer$$$244$$$250$$$O	thereof,$$$251$$$259$$$O	a$$$260$$$261$$$O	stereomer$$$262$$$271$$$O	or$$$272$$$274$$$O	a$$$275$$$276$$$O	mixture$$$277$$$284$$$O	of$$$285$$$287$$$O	the$$$288$$$291$$$O	stereomer$$$292$$$301$$$O	and$$$302$$$305$$$O	a$$$306$$$307$$$O	pharmaceutically$$$308$$$324$$$O	acceptable$$$325$$$335$$$O	salt$$$336$$$340$$$O	or$$$341$$$343$$$O	a$$$344$$$345$$$O	precursor$$$346$$$355$$$O	all$$$356$$$359$$$O	have$$$360$$$364$$$O	suppression$$$365$$$376$$$O	effects$$$377$$$384$$$O	on$$$385$$$387$$$O	tumor$$$388$$$393$$$O	cells,$$$394$$$400$$$O	wherein$$$401$$$408$$$O	the$$$409$$$412$$$O	suppression$$$413$$$424$$$O	ratios$$$425$$$431$$$O	of$$$432$$$434$$$O	about$$$435$$$440$$$O	half$$$441$$$445$$$O	compounds$$$446$$$455$$$O	on$$$456$$$458$$$O	the$$$459$$$462$$$O	cell$$$463$$$467$$$O	level$$$468$$$473$$$O	are$$$474$$$477$$$O	superior$$$478$$$486$$$O	to$$$487$$$489$$$O	that$$$490$$$494$$$O	of$$$495$$$497$$$O	ML-7$$$498$$$502$$$O	positive$$$503$$$511$$$O	control$$$512$$$519$$$O	medicine.$$$520$$$529$$$O	The$$$530$$$533$$$O	invention$$$534$$$543$$$O	is$$$544$$$546$$$O	expected$$$547$$$555$$$O	to$$$556$$$558$$$O	lay$$$559$$$562$$$O	the$$$563$$$566$$$O	foundation$$$567$$$577$$$O	for$$$578$$$581$$$O	developing$$$582$$$592$$$O	anti-tumor$$$593$$$603$$$O	medicaments.$$$604$$$616$$$O
US7504434
3-(acetylamino)-4-{[amino(imino)methyl]amino}-6-carboxy-3,4-dihydro-2H-pyran-2-yl)-dimer;$$$0$$$89$$$O	viricide;$$$90$$$99$$$O	influenza$$$100$$$109$$$O	A$$$110$$$111$$$O	or$$$112$$$114$$$O	B$$$115$$$116$$$O	infection,$$$117$$$127$$$O	parainfluenza,$$$128$$$142$$$O	mumps$$$143$$$148$$$O	or$$$149$$$151$$$O	Newcastle$$$152$$$161$$$O	disease,$$$162$$$170$$$O	myxovirus$$$171$$$180$$$O	infections;$$$181$$$192$$$O	stability;$$$193$$$203$$$O	long$$$204$$$208$$$O	time$$$209$$$213$$$O	in$$$214$$$216$$$O	lungs$$$217$$$222$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	general$$$38$$$45$$$O	formula$$$46$$$53$$$O	(I),$$$54$$$58$$$O	in$$$59$$$61$$$O	which:$$$62$$$68$$$O	R$$$69$$$70$$$O	is$$$71$$$73$$$O	an$$$74$$$76$$$O	amino$$$77$$$82$$$O	or$$$83$$$85$$$O	guanidino$$$86$$$95$$$O	group;$$$96$$$102$$$O	R2$$$103$$$105$$$O	is$$$106$$$108$$$O	acetyl$$$109$$$115$$$O	or$$$116$$$118$$$O	trifluoroacetyl;$$$119$$$135$$$O	n$$$136$$$137$$$O	and$$$138$$$141$$$O	q$$$142$$$143$$$O	are$$$144$$$147$$$O	either$$$148$$$154$$$O	the$$$155$$$158$$$O	same$$$159$$$163$$$O	or$$$164$$$166$$$O	different$$$167$$$176$$$O	and$$$177$$$180$$$O	selected$$$181$$$189$$$O	from$$$190$$$194$$$O	0,$$$195$$$197$$$O	1$$$198$$$199$$$O	or$$$200$$$202$$$O	2;$$$203$$$205$$$O	and$$$206$$$209$$$O	X$$$210$$$211$$$O	is$$$212$$$214$$$O	an$$$215$$$217$$$O	optionally$$$218$$$228$$$O	substituted$$$229$$$240$$$O	phenyl,$$$241$$$248$$$O	optionally$$$249$$$259$$$O	substituted$$$260$$$271$$$O	naphthyl$$$272$$$280$$$O	or$$$281$$$283$$$O	optionally$$$284$$$294$$$O	substituted$$$295$$$306$$$O	phenyl-Y-optionally$$$307$$$326$$$O	substituted$$$327$$$338$$$O	phenyl$$$339$$$345$$$O	in$$$346$$$348$$$O	which$$$349$$$354$$$O	Y$$$355$$$356$$$O	is$$$357$$$359$$$O	selected$$$360$$$368$$$O	from$$$369$$$373$$$O	a$$$374$$$375$$$O	covalent$$$376$$$384$$$O	bond,$$$385$$$390$$$O	CH2,$$$391$$$395$$$O	CH2CH2,$$$396$$$403$$$O	O$$$404$$$405$$$O	or$$$406$$$408$$$O	SO2,$$$409$$$413$$$O	or$$$414$$$416$$$O	a$$$417$$$418$$$O	pharmaceutically$$$419$$$435$$$O	acceptable$$$436$$$446$$$O	derivative$$$447$$$457$$$O	thereof,$$$458$$$466$$$O	with$$$467$$$471$$$O	the$$$472$$$475$$$O	proviso$$$476$$$483$$$O	that$$$484$$$488$$$O	when$$$489$$$493$$$O	X$$$494$$$495$$$O	is$$$496$$$498$$$O	phenyl$$$499$$$505$$$O	or$$$506$$$508$$$O	naphthyl,$$$509$$$518$$$O	n$$$519$$$520$$$O	and$$$521$$$524$$$O	q$$$525$$$526$$$O	are$$$527$$$530$$$O	both$$$531$$$535$$$O	2$$$536$$$537$$$O	and$$$538$$$541$$$O	when$$$542$$$546$$$O	X$$$547$$$548$$$O	is$$$549$$$551$$$O	phenyl-Y-phenyl$$$552$$$567$$$O	in$$$568$$$570$$$O	which$$$571$$$576$$$O	Y$$$577$$$578$$$O	is$$$579$$$581$$$O	a$$$582$$$583$$$O	covalent$$$584$$$592$$$O	bond,$$$593$$$598$$$O	then$$$599$$$603$$$O	n$$$604$$$605$$$O	and$$$606$$$609$$$O	q$$$610$$$611$$$O	are$$$612$$$615$$$O	not$$$616$$$619$$$O	both$$$620$$$624$$$O	0,$$$625$$$627$$$O	methods$$$628$$$635$$$O	for$$$636$$$639$$$O	their$$$640$$$645$$$O	preparation,$$$646$$$658$$$O	pharmaceutical$$$659$$$673$$$O	formulations$$$674$$$686$$$O	containing$$$687$$$697$$$O	them$$$698$$$702$$$O	or$$$703$$$705$$$O	their$$$706$$$711$$$O	use$$$712$$$715$$$O	in$$$716$$$718$$$O	the$$$719$$$722$$$O	prevention$$$723$$$733$$$O	or$$$734$$$736$$$O	treatment$$$737$$$746$$$O	of$$$747$$$749$$$O	a$$$750$$$751$$$O	viral$$$752$$$757$$$O	infection.$$$758$$$768$$$O
US8080565
Substituted$$$0$$$11$$$O	4-amino-benzylpiperidine$$$12$$$36$$$I	compounds$$$37$$$46$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	4-amino-1-benzylpiperidine$$$24$$$50$$$I	and$$$51$$$54$$$O	related$$$55$$$62$$$O	compounds$$$63$$$72$$$O	and$$$73$$$76$$$O	pharmaceutically$$$77$$$93$$$O	acceptable$$$94$$$104$$$O	salts$$$105$$$110$$$O	thereof$$$111$$$118$$$O	which$$$119$$$124$$$O	are$$$125$$$128$$$O	useful$$$129$$$135$$$O	as$$$136$$$138$$$O	muscarinic$$$139$$$149$$$O	receptor$$$150$$$158$$$O	antagonists.$$$159$$$171$$$O	This$$$172$$$176$$$O	invention$$$177$$$186$$$O	also$$$187$$$191$$$O	provides$$$192$$$200$$$O	pharmaceutical$$$201$$$215$$$O	compositions$$$216$$$228$$$O	containing$$$229$$$239$$$O	such$$$240$$$244$$$O	compounds;$$$245$$$255$$$O	processes$$$256$$$265$$$O	and$$$266$$$269$$$O	intermediates$$$270$$$283$$$O	useful$$$284$$$290$$$O	for$$$291$$$294$$$O	preparing$$$295$$$304$$$O	such$$$305$$$309$$$O	compounds;$$$310$$$320$$$O	and$$$321$$$324$$$O	methods$$$325$$$332$$$O	for$$$333$$$336$$$O	treating$$$337$$$345$$$O	disease$$$346$$$353$$$O	conditions$$$354$$$364$$$O	mediated$$$365$$$373$$$O	by$$$374$$$376$$$O	muscarinic$$$377$$$387$$$O	receptors,$$$388$$$398$$$O	such$$$399$$$403$$$O	as$$$404$$$406$$$O	overactive$$$407$$$417$$$O	bladder,$$$418$$$426$$$O	irritable$$$427$$$436$$$O	bowel$$$437$$$442$$$O	syndrome,$$$443$$$452$$$O	asthma$$$453$$$459$$$O	and$$$460$$$463$$$O	chronic$$$464$$$471$$$O	obstructive$$$472$$$483$$$O	pulmonary$$$484$$$493$$$O	disease,$$$494$$$502$$$O	using$$$503$$$508$$$O	such$$$509$$$513$$$O	compounds.$$$514$$$524$$$O
US20110269745
6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES$$$0$$$55$$$I	AS$$$56$$$58$$$O	5-HT2C$$$59$$$65$$$O	RECEPTOR$$$66$$$74$$$O	AGONISTS$$$75$$$83$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	6-substituted$$$31$$$44$$$I	2,3,4,5-tetrahydro-1H-benzo[d]azepines$$$45$$$83$$$I	of$$$84$$$86$$$O	Formula$$$87$$$94$$$O	(I)$$$95$$$98$$$O	as$$$99$$$101$$$O	selective$$$102$$$111$$$O	5-HT2c$$$112$$$118$$$O	receptor$$$119$$$127$$$O	agonists$$$128$$$136$$$O	for$$$137$$$140$$$O	the$$$141$$$144$$$O	treatment$$$145$$$154$$$O	of$$$155$$$157$$$O	5-HT2c$$$158$$$164$$$O	associated$$$165$$$175$$$O	disorders$$$176$$$185$$$O	including$$$186$$$195$$$O	obesity,$$$196$$$204$$$O	obsessive/compulsive$$$205$$$225$$$O	disorder,$$$226$$$235$$$O	depression,$$$236$$$247$$$O	and$$$248$$$251$$$O	anxiety,$$$252$$$260$$$O	where,$$$261$$$267$$$O	R6$$$268$$$270$$$O	is$$$271$$$273$$$O	âNR10R11,$$$274$$$285$$$I	where$$$286$$$291$$$O	R10$$$292$$$295$$$O	is$$$296$$$298$$$O	substituted$$$299$$$310$$$I	phenylalkyl$$$311$$$322$$$I	or$$$323$$$325$$$O	substituted$$$326$$$337$$$I	pyridylalkyl$$$338$$$350$$$I	and$$$351$$$354$$$O	other$$$355$$$360$$$O	substituents$$$361$$$373$$$O	are$$$374$$$377$$$O	as$$$378$$$380$$$O	defined$$$381$$$388$$$O	in$$$389$$$391$$$O	the$$$392$$$395$$$O	specification.$$$396$$$410$$$O
WO2013077446A1
Single-stranded$$$0$$$15$$$O	nucleic$$$16$$$23$$$O	acid$$$24$$$28$$$O	molecule$$$29$$$37$$$O	for$$$38$$$41$$$O	regulating$$$42$$$52$$$O	expression$$$53$$$63$$$O	of$$$64$$$66$$$O	gene$$$67$$$71$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	novel$$$14$$$19$$$O	nucleic$$$20$$$27$$$O	acid$$$28$$$32$$$O	molecule$$$33$$$41$$$O	capable$$$42$$$49$$$O	of$$$50$$$52$$$O	suppressing$$$53$$$64$$$O	the$$$65$$$68$$$O	expression$$$69$$$79$$$O	of$$$80$$$82$$$O	a$$$83$$$84$$$O	gene.$$$85$$$90$$$O	A$$$91$$$92$$$O	single-stranded$$$93$$$108$$$O	nucleic$$$109$$$116$$$O	acid$$$117$$$121$$$O	molecule$$$122$$$130$$$O	containing$$$131$$$141$$$O	an$$$142$$$144$$$O	expression-suppressing$$$145$$$167$$$O	sequence$$$168$$$176$$$O	for$$$177$$$180$$$O	a$$$181$$$182$$$O	target$$$183$$$189$$$O	gene$$$190$$$194$$$O	and$$$195$$$198$$$O	a$$$199$$$200$$$O	complementary$$$201$$$214$$$O	sequence$$$215$$$223$$$O	having$$$224$$$230$$$O	a$$$231$$$232$$$O	mismatch$$$233$$$241$$$O	with$$$242$$$246$$$O	the$$$247$$$250$$$O	expression-suppressing$$$251$$$273$$$O	sequence,$$$274$$$283$$$O	wherein$$$284$$$291$$$O	a$$$292$$$293$$$O	5'-side$$$294$$$301$$$O	region$$$302$$$308$$$O	(Xc),$$$309$$$314$$$O	an$$$315$$$317$$$O	internal$$$318$$$326$$$O	region$$$327$$$333$$$O	(Z)$$$334$$$337$$$O	and$$$338$$$341$$$O	a$$$342$$$343$$$O	3'-side$$$344$$$351$$$O	region$$$352$$$358$$$O	(Yc)$$$359$$$363$$$O	are$$$364$$$367$$$O	contained$$$368$$$377$$$O	in$$$378$$$380$$$O	this$$$381$$$385$$$O	order$$$386$$$391$$$O	from$$$392$$$396$$$O	the$$$397$$$400$$$O	5'-side$$$401$$$408$$$O	toward$$$409$$$415$$$O	the$$$416$$$419$$$O	3'-side,$$$420$$$428$$$O	the$$$429$$$432$$$O	region$$$433$$$439$$$O	(Z)$$$440$$$443$$$O	is$$$444$$$446$$$O	formed$$$447$$$453$$$O	by$$$454$$$456$$$O	linking$$$457$$$464$$$O	an$$$465$$$467$$$O	internal$$$468$$$476$$$O	5'-side$$$477$$$484$$$O	region$$$485$$$491$$$O	(X)$$$492$$$495$$$O	to$$$496$$$498$$$O	an$$$499$$$501$$$O	internal$$$502$$$510$$$O	3'-side$$$511$$$518$$$O	region$$$519$$$525$$$O	(Y),$$$526$$$530$$$O	the$$$531$$$534$$$O	region$$$535$$$541$$$O	(Xc)$$$542$$$546$$$O	is$$$547$$$549$$$O	complementary$$$550$$$563$$$O	to$$$564$$$566$$$O	the$$$567$$$570$$$O	region$$$571$$$577$$$O	(X),$$$578$$$582$$$O	the$$$583$$$586$$$O	region$$$587$$$593$$$O	(Yc)$$$594$$$598$$$O	is$$$599$$$601$$$O	complementary$$$602$$$615$$$O	to$$$616$$$618$$$O	the$$$619$$$622$$$O	region$$$623$$$629$$$O	(Y),$$$630$$$634$$$O	at$$$635$$$637$$$O	least$$$638$$$643$$$O	one$$$644$$$647$$$O	of$$$648$$$650$$$O	the$$$651$$$654$$$O	region$$$655$$$661$$$O	(Z),$$$662$$$666$$$O	the$$$667$$$670$$$O	region$$$671$$$677$$$O	(Xc)$$$678$$$682$$$O	and$$$683$$$686$$$O	the$$$687$$$690$$$O	region$$$691$$$697$$$O	(Yc)$$$698$$$702$$$O	contains$$$703$$$711$$$O	the$$$712$$$715$$$O	expression-suppressing$$$716$$$738$$$O	sequence,$$$739$$$748$$$O	a$$$749$$$750$$$O	region$$$751$$$757$$$O	complementary$$$758$$$771$$$O	to$$$772$$$774$$$O	the$$$775$$$778$$$O	region$$$779$$$785$$$O	containing$$$786$$$796$$$O	the$$$797$$$800$$$O	expression-suppressing$$$801$$$823$$$O	sequence$$$824$$$832$$$O	contains$$$833$$$841$$$O	the$$$842$$$845$$$O	complementary$$$846$$$859$$$O	sequence,$$$860$$$869$$$O	and$$$870$$$873$$$O	a$$$874$$$875$$$O	5'-terminal$$$876$$$887$$$O	nucleotide$$$888$$$898$$$I	and$$$899$$$902$$$O	a$$$903$$$904$$$O	3'-terminal$$$905$$$916$$$O	nucleotide$$$917$$$927$$$I	in$$$928$$$930$$$O	the$$$931$$$934$$$O	single-stranded$$$935$$$950$$$O	nucleic$$$951$$$958$$$O	acid$$$959$$$963$$$O	molecule$$$964$$$972$$$O	are$$$973$$$976$$$O	not$$$977$$$980$$$O	bound$$$981$$$986$$$O	to$$$987$$$989$$$O	each$$$990$$$994$$$O	other.$$$995$$$1001$$$O	The$$$1002$$$1005$$$O	single-stranded$$$1006$$$1021$$$O	nucleic$$$1022$$$1029$$$O	acid$$$1030$$$1034$$$O	molecule$$$1035$$$1043$$$O	can$$$1044$$$1047$$$O	suppress$$$1048$$$1056$$$O	the$$$1057$$$1060$$$O	expression$$$1061$$$1071$$$O	of$$$1072$$$1074$$$O	the$$$1075$$$1078$$$O	target$$$1079$$$1085$$$O	gene.$$$1086$$$1091$$$O
US20110129530
Compressible-Coated$$$0$$$19$$$O	Pharmaceutical$$$20$$$34$$$O	Compositions$$$35$$$47$$$O	and$$$48$$$51$$$O	Tablets$$$52$$$59$$$O	and$$$60$$$63$$$O	Methods$$$64$$$71$$$O	of$$$72$$$74$$$O	Manufacture$$$75$$$86$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	a$$$18$$$19$$$O	method$$$20$$$26$$$O	for$$$27$$$30$$$O	preparing$$$31$$$40$$$O	a$$$41$$$42$$$O	pharmaceutical$$$43$$$57$$$O	composition$$$58$$$69$$$O	comprising$$$70$$$80$$$O	compressible$$$81$$$93$$$O	coated,$$$94$$$101$$$O	taste-masked$$$102$$$114$$$O	and/or$$$115$$$121$$$O	controlled-release$$$122$$$140$$$O	coated$$$141$$$147$$$O	drug-containing$$$148$$$163$$$O	particles,$$$164$$$174$$$O	rapidly-dispersing$$$175$$$193$$$O	microgranules$$$194$$$207$$$O	comprising$$$208$$$218$$$O	a$$$219$$$220$$$O	disintegrant$$$221$$$233$$$O	and$$$234$$$237$$$O	a$$$238$$$239$$$O	sugar$$$240$$$245$$$I	alcohol,$$$246$$$254$$$I	a$$$255$$$256$$$O	saccharide,$$$257$$$268$$$I	or$$$269$$$271$$$O	a$$$272$$$273$$$O	mixture$$$274$$$281$$$O	thereof,$$$282$$$290$$$O	and$$$291$$$294$$$O	other$$$295$$$300$$$O	optional,$$$301$$$310$$$O	pharmaceutically$$$311$$$327$$$O	acceptable$$$328$$$338$$$O	excipients$$$339$$$349$$$O	wherein$$$350$$$357$$$O	the$$$358$$$361$$$O	orally$$$362$$$368$$$O	disintegrating$$$369$$$383$$$O	tablet$$$384$$$390$$$O	(ODT)$$$391$$$396$$$O	or$$$397$$$399$$$O	rapidly$$$400$$$407$$$O	dispersing$$$408$$$418$$$O	tablet$$$419$$$425$$$O	(RDT)$$$426$$$431$$$O	composition$$$432$$$443$$$O	having$$$444$$$450$$$O	acceptable$$$451$$$461$$$O	tableting,$$$462$$$472$$$O	organoleptic,$$$473$$$486$$$O	and$$$487$$$490$$$O	pharmacokinetic$$$491$$$506$$$O	properties.$$$507$$$518$$$O
US20090203144
Hiv-gag$$$0$$$7$$$O	codon-optimised$$$8$$$23$$$O	dna$$$24$$$27$$$O	vaccines$$$28$$$36$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	nucleotide$$$25$$$35$$$O	sequence$$$36$$$44$$$O	that$$$45$$$49$$$O	encodes$$$50$$$57$$$O	an$$$58$$$60$$$O	HIV-1$$$61$$$66$$$O	gag$$$67$$$70$$$O	protein$$$71$$$78$$$O	or$$$79$$$81$$$O	fragment$$$82$$$90$$$O	thereof$$$91$$$98$$$O	containing$$$99$$$109$$$O	a$$$110$$$111$$$O	gag$$$112$$$115$$$O	epitope$$$116$$$123$$$O	and$$$124$$$127$$$O	a$$$128$$$129$$$O	second$$$130$$$136$$$O	HIV$$$137$$$140$$$O	antigen$$$141$$$148$$$O	or$$$149$$$151$$$O	a$$$152$$$153$$$O	fragment$$$154$$$162$$$O	encoding$$$163$$$171$$$O	an$$$172$$$174$$$O	epitope$$$175$$$182$$$O	of$$$183$$$185$$$O	said$$$186$$$190$$$O	second$$$191$$$197$$$O	HIV$$$198$$$201$$$O	antigen,$$$202$$$210$$$O	operably$$$211$$$219$$$O	linked$$$220$$$226$$$O	to$$$227$$$229$$$O	a$$$230$$$231$$$O	heterologous$$$232$$$244$$$O	promoter.$$$245$$$254$$$O	Preferred$$$255$$$264$$$O	polynucleotide$$$265$$$279$$$O	sequences$$$280$$$289$$$O	further$$$290$$$297$$$O	encodes$$$298$$$305$$$O	nef$$$306$$$309$$$O	or$$$310$$$312$$$O	a$$$313$$$314$$$O	fragment$$$315$$$323$$$O	thereof$$$324$$$331$$$O	and$$$332$$$335$$$O	RT$$$336$$$338$$$O	or$$$339$$$341$$$O	a$$$342$$$343$$$O	fragment$$$344$$$352$$$O	thereof.$$$353$$$361$$$O
WO2006048248A3
Novel$$$0$$$5$$$O	anthranilamide$$$6$$$20$$$I	pyridinureas$$$21$$$33$$$I	as$$$34$$$36$$$O	vegf$$$37$$$41$$$O	receptor$$$42$$$50$$$O	kinase$$$51$$$57$$$O	imhibitors$$$58$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	anthranilamide$$$31$$$45$$$I	pyridinureas$$$46$$$58$$$I	as$$$59$$$61$$$O	VEGF$$$62$$$66$$$O	receptor$$$67$$$75$$$O	kinase$$$76$$$82$$$O	inhibitors,$$$83$$$94$$$O	their$$$95$$$100$$$O	production$$$101$$$111$$$O	and$$$112$$$115$$$O	use$$$116$$$119$$$O	as$$$120$$$122$$$O	pharmaceutical$$$123$$$137$$$O	agents$$$138$$$144$$$O	for$$$145$$$148$$$O	preventing$$$149$$$159$$$O	or$$$160$$$162$$$O	treating$$$163$$$171$$$O	diseases$$$172$$$180$$$O	that$$$181$$$185$$$O	are$$$186$$$189$$$O	triggered$$$190$$$199$$$O	by$$$200$$$202$$$O	persistent$$$203$$$213$$$O	angiogenesis.$$$214$$$227$$$O
CN101955459A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	blonanserin$$$21$$$32$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	for$$$34$$$37$$$O	preparing$$$38$$$47$$$O	a$$$48$$$49$$$O	compound$$$50$$$58$$$O	blonanserin$$$59$$$70$$$I	in$$$71$$$73$$$O	a$$$74$$$75$$$O	formula$$$76$$$83$$$O	(I),$$$84$$$88$$$O	which$$$89$$$94$$$O	comprises$$$95$$$104$$$O	a$$$105$$$106$$$O	step$$$107$$$111$$$O	of$$$112$$$114$$$O	transforming$$$115$$$127$$$O	a$$$128$$$129$$$O	compound$$$130$$$138$$$O	in$$$139$$$141$$$O	a$$$142$$$143$$$O	formula$$$144$$$151$$$O	(II)$$$152$$$156$$$O	and$$$157$$$160$$$O	N-ethylpiperazine$$$161$$$178$$$I	under$$$179$$$184$$$O	the$$$185$$$188$$$O	catalysis$$$189$$$198$$$O	of$$$199$$$201$$$O	base$$$202$$$206$$$O	into$$$207$$$211$$$O	the$$$212$$$215$$$O	compound$$$216$$$224$$$O	blonanserin$$$225$$$236$$$I	in$$$237$$$239$$$O	the$$$240$$$243$$$O	formula$$$244$$$251$$$O	(I).$$$252$$$256$$$O	The$$$257$$$260$$$O	blonanserin$$$261$$$272$$$I	has$$$273$$$276$$$O	extremely$$$277$$$286$$$O	valuable$$$287$$$295$$$O	pharmacodynamic$$$296$$$311$$$O	and$$$312$$$315$$$O	treatment$$$316$$$325$$$O	properties$$$326$$$336$$$O	in$$$337$$$339$$$O	the$$$340$$$343$$$O	aspect$$$344$$$350$$$O	of$$$351$$$353$$$O	treating$$$354$$$362$$$O	schizophrenia.$$$363$$$377$$$O
WO2009123575A8
A$$$0$$$1$$$O	photosensitising$$$2$$$18$$$O	composition$$$19$$$30$$$O	and$$$31$$$34$$$O	its$$$35$$$38$$$O	uses$$$39$$$43$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	photosensitising$$$33$$$49$$$O	composition$$$50$$$61$$$O	comprising$$$62$$$72$$$O	a$$$73$$$74$$$O	mixture$$$75$$$82$$$O	of$$$83$$$85$$$O	at$$$86$$$88$$$O	least$$$89$$$94$$$O	one$$$95$$$98$$$O	oxygen$$$99$$$105$$$I	carrier,$$$106$$$114$$$O	at$$$115$$$117$$$O	least$$$118$$$123$$$O	one$$$124$$$127$$$O	oxidising$$$128$$$137$$$O	agent$$$138$$$143$$$O	and$$$144$$$147$$$O	at$$$148$$$150$$$O	least$$$151$$$156$$$O	one$$$157$$$160$$$O	surfactant,$$$161$$$172$$$O	and$$$173$$$176$$$O	its$$$177$$$180$$$O	uses.$$$181$$$186$$$O	The$$$187$$$190$$$O	ratio$$$191$$$196$$$O	of$$$197$$$199$$$O	the$$$200$$$203$$$O	at$$$204$$$206$$$O	least$$$207$$$212$$$O	one$$$213$$$216$$$O	oxygen$$$217$$$223$$$I	carrier$$$224$$$231$$$O	to$$$232$$$234$$$O	the$$$235$$$238$$$O	at$$$239$$$241$$$O	least$$$242$$$247$$$O	one$$$248$$$251$$$O	oxidising$$$252$$$261$$$O	agent$$$262$$$267$$$O	to$$$268$$$270$$$O	the$$$271$$$274$$$O	at$$$275$$$277$$$O	least$$$278$$$283$$$O	one$$$284$$$287$$$O	surfactant$$$288$$$298$$$O	may$$$299$$$302$$$O	be$$$303$$$305$$$O	in$$$306$$$308$$$O	the$$$309$$$312$$$O	range$$$313$$$318$$$O	of$$$319$$$321$$$O	50:40:10$$$322$$$330$$$O	to$$$331$$$333$$$O	80:19.8:0.2.$$$334$$$346$$$O	The$$$347$$$350$$$O	photosensitising$$$351$$$367$$$O	composition$$$368$$$379$$$O	may$$$380$$$383$$$O	be$$$384$$$386$$$O	used$$$387$$$391$$$O	for$$$392$$$395$$$O	treating$$$396$$$404$$$O	and/or$$$405$$$411$$$O	preventing$$$412$$$422$$$O	conditions$$$423$$$433$$$O	caused$$$434$$$440$$$O	by$$$441$$$443$$$O	microorganisms.$$$444$$$459$$$O
CN101928328A
RGD$$$0$$$3$$$O	peptide-epimedium$$$4$$$21$$$O	flavone$$$22$$$29$$$I	combination,$$$30$$$42$$$O	preparation$$$43$$$54$$$O	method$$$55$$$61$$$O	and$$$62$$$65$$$O	application$$$66$$$77$$$O	thereof$$$78$$$85$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	RGD$$$26$$$29$$$O	peptide-epimedium$$$30$$$47$$$O	flavone$$$48$$$55$$$I	combination$$$56$$$67$$$O	synthesized$$$68$$$79$$$O	by$$$80$$$82$$$O	combining$$$83$$$92$$$O	two$$$93$$$96$$$O	structural$$$97$$$107$$$O	units$$$108$$$113$$$O	of$$$114$$$116$$$O	RGD$$$117$$$120$$$O	peptides$$$121$$$129$$$O	and$$$130$$$133$$$O	epimedium$$$134$$$143$$$O	flavone$$$144$$$151$$$I	which$$$152$$$157$$$O	have$$$158$$$162$$$O	pharmacological$$$163$$$178$$$O	activities$$$179$$$189$$$O	of$$$190$$$192$$$O	different$$$193$$$202$$$O	action$$$203$$$209$$$O	mechanisms$$$210$$$220$$$O	on$$$221$$$223$$$O	osseous$$$224$$$231$$$O	metabolic$$$232$$$241$$$O	diseases,$$$242$$$251$$$O	and$$$252$$$255$$$O	also$$$256$$$260$$$O	provides$$$261$$$269$$$O	a$$$270$$$271$$$O	synthesis$$$272$$$281$$$O	method$$$282$$$288$$$O	thereof.$$$289$$$297$$$O	The$$$298$$$301$$$O	compound$$$302$$$310$$$O	of$$$311$$$313$$$O	the$$$314$$$317$$$O	invention$$$318$$$327$$$O	has$$$328$$$331$$$O	two$$$332$$$335$$$O	receptor$$$336$$$344$$$O	combining$$$345$$$354$$$O	sites$$$355$$$360$$$O	and$$$361$$$364$$$O	simultaneously$$$365$$$379$$$O	has$$$380$$$383$$$O	the$$$384$$$387$$$O	capability$$$388$$$398$$$O	of$$$399$$$401$$$O	combining$$$402$$$411$$$O	estrogen$$$412$$$420$$$I	receptors$$$421$$$430$$$O	of$$$431$$$433$$$O	icaritin$$$434$$$442$$$I	and$$$443$$$446$$$O	the$$$447$$$450$$$O	capability$$$451$$$461$$$O	of$$$462$$$464$$$O	combining$$$465$$$474$$$O	integrins$$$475$$$484$$$O	alphaVbeta3$$$485$$$496$$$O	of$$$497$$$499$$$O	RGD,$$$500$$$504$$$O	and$$$505$$$508$$$O	the$$$509$$$512$$$O	capabilities$$$513$$$525$$$O	of$$$526$$$528$$$O	combining$$$529$$$538$$$O	the$$$539$$$542$$$O	two$$$543$$$546$$$O	different$$$547$$$556$$$O	receptors$$$557$$$566$$$O	can$$$567$$$570$$$O	produce$$$571$$$578$$$O	a$$$579$$$580$$$O	synergistic$$$581$$$592$$$O	effect$$$593$$$599$$$O	to$$$600$$$602$$$O	greatly$$$603$$$610$$$O	improve$$$611$$$618$$$O	the$$$619$$$622$$$O	curative$$$623$$$631$$$O	activity$$$632$$$640$$$O	of$$$641$$$643$$$O	the$$$644$$$647$$$O	medicament$$$648$$$658$$$O	on$$$659$$$661$$$O	osteoporosis$$$662$$$674$$$O	and$$$675$$$678$$$O	osseous$$$679$$$686$$$O	metabolic$$$687$$$696$$$O	diseases.$$$697$$$706$$$O	The$$$707$$$710$$$O	synthesis$$$711$$$720$$$O	method$$$721$$$727$$$O	has$$$728$$$731$$$O	the$$$732$$$735$$$O	advantages$$$736$$$746$$$O	of$$$747$$$749$$$O	high$$$750$$$754$$$O	yield,$$$755$$$761$$$O	high$$$762$$$766$$$O	synthesis$$$767$$$776$$$O	speed$$$777$$$782$$$O	and$$$783$$$786$$$O	easy$$$787$$$791$$$O	purification$$$792$$$804$$$O	of$$$805$$$807$$$O	products.$$$808$$$817$$$O
CN101019863A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	2-phenyl-1,$$$15$$$26$$$I	2-benzoisoselenazole-3(2H)-tone$$$27$$$58$$$I	in$$$59$$$61$$$O	preparing$$$62$$$71$$$O	medicine$$$72$$$80$$$O	for$$$81$$$84$$$O	resisting$$$85$$$94$$$O	sports$$$95$$$101$$$O	fatigue$$$102$$$109$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	application$$$25$$$36$$$O	of$$$37$$$39$$$O	2-phenyl-1,$$$40$$$51$$$I	2-benzoisoselenazole-3(2H)-tone$$$52$$$83$$$I	in$$$84$$$86$$$O	preparing$$$87$$$96$$$O	medicine$$$97$$$105$$$O	for$$$106$$$109$$$O	resisting$$$110$$$119$$$O	sports$$$120$$$126$$$O	fatigue.$$$127$$$135$$$O	Pharmacological$$$136$$$151$$$O	experiment$$$152$$$162$$$O	proves$$$163$$$169$$$O	that$$$170$$$174$$$O	active$$$175$$$181$$$O	component$$$182$$$191$$$O	2-phenyl-1,$$$192$$$203$$$I	2-benzoisoselenazole-3(2H)-tone$$$204$$$235$$$I	has$$$236$$$239$$$O	the$$$240$$$243$$$O	effects$$$244$$$251$$$O	of$$$252$$$254$$$O	resisting$$$255$$$264$$$O	the$$$265$$$268$$$O	overoxidation$$$269$$$282$$$O	of$$$283$$$285$$$O	lipid,$$$286$$$292$$$O	eliminating$$$293$$$304$$$O	free$$$305$$$309$$$O	radical$$$310$$$317$$$O	caused$$$318$$$324$$$O	in$$$325$$$327$$$O	overtraining,$$$328$$$341$$$O	inhibiting$$$342$$$352$$$O	apoptosis$$$353$$$362$$$O	during$$$363$$$369$$$O	sports$$$370$$$376$$$O	and$$$377$$$380$$$O	maintaining$$$381$$$392$$$O	the$$$393$$$396$$$O	normal$$$397$$$403$$$O	morphological$$$404$$$417$$$O	structure$$$418$$$427$$$O	and$$$428$$$431$$$O	function$$$432$$$440$$$O	of$$$441$$$443$$$O	locomotive$$$444$$$454$$$O	organs,$$$455$$$462$$$O	delaying$$$463$$$471$$$O	sports$$$472$$$478$$$O	fatigue$$$479$$$486$$$O	and$$$487$$$490$$$O	raising$$$491$$$498$$$O	sport$$$499$$$504$$$O	capacity$$$505$$$513$$$O	of$$$514$$$516$$$O	rat.$$$517$$$521$$$O
US20080254010
Controlling$$$0$$$11$$$O	Clostridium$$$12$$$23$$$O	difficile-Associated$$$24$$$44$$$O	Disease$$$45$$$52$$$O	in$$$53$$$55$$$O	the$$$56$$$59$$$O	Gastrointestinal$$$60$$$76$$$O	Tract$$$77$$$82$$$O
This$$$0$$$4$$$O	document$$$5$$$13$$$O	provide$$$14$$$21$$$O	materials$$$22$$$31$$$O	and$$$32$$$35$$$O	methods$$$36$$$43$$$O	for$$$44$$$47$$$O	treating$$$48$$$56$$$O	patients$$$57$$$65$$$O	infected$$$66$$$74$$$O	with$$$75$$$79$$$O	a$$$80$$$81$$$O	spore-forming$$$82$$$95$$$O	bacteria$$$96$$$104$$$O	and$$$105$$$108$$$O	materials$$$109$$$118$$$O	and$$$119$$$122$$$O	methods$$$123$$$130$$$O	for$$$131$$$134$$$O	preventing$$$135$$$145$$$O	development$$$146$$$157$$$O	of$$$158$$$160$$$O	Clostridium$$$161$$$172$$$O	difficile-associated$$$173$$$193$$$O	disease.$$$194$$$202$$$O
WO2012143624A2
Acadesine$$$0$$$9$$$I	derivatives,$$$10$$$22$$$O	products$$$23$$$31$$$O	and$$$32$$$35$$$O	compositions$$$36$$$48$$$O	including$$$49$$$58$$$O	same,$$$59$$$64$$$O	therapeutic$$$65$$$76$$$O	uses$$$77$$$81$$$O	thereof,$$$82$$$90$$$O	and$$$91$$$94$$$O	methods$$$95$$$102$$$O	for$$$103$$$106$$$O	synthesizing$$$107$$$119$$$O	same$$$120$$$124$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	acadesine$$$25$$$34$$$I	derivatives$$$35$$$46$$$O	as$$$47$$$49$$$O	a$$$50$$$51$$$O	drug,$$$52$$$57$$$O	as$$$58$$$60$$$O	well$$$61$$$65$$$O	as$$$66$$$68$$$O	to$$$69$$$71$$$O	said$$$72$$$76$$$O	derivatives$$$77$$$88$$$O	for$$$89$$$92$$$O	the$$$93$$$96$$$O	treatment$$$97$$$106$$$O	of$$$107$$$109$$$O	cancer$$$110$$$116$$$O	and$$$117$$$120$$$O	particularly$$$121$$$133$$$O	for$$$134$$$137$$$O	the$$$138$$$141$$$O	treatment$$$142$$$151$$$O	of$$$152$$$154$$$O	chronic$$$155$$$162$$$O	myeloid$$$163$$$170$$$O	leukemia$$$171$$$179$$$O	(CML).$$$180$$$186$$$O	The$$$187$$$190$$$O	invention$$$191$$$200$$$O	further$$$201$$$208$$$O	relates$$$209$$$216$$$O	to$$$217$$$219$$$O	a$$$220$$$221$$$O	product$$$222$$$229$$$O	containing$$$230$$$240$$$O	said$$$241$$$245$$$O	derivatives$$$246$$$257$$$O	and$$$258$$$261$$$O	at$$$262$$$264$$$O	least$$$265$$$270$$$O	one$$$271$$$274$$$O	second$$$275$$$281$$$O	active$$$282$$$288$$$O	ingredient$$$289$$$299$$$O	as$$$300$$$302$$$O	a$$$303$$$304$$$O	combination$$$305$$$316$$$O	product$$$317$$$324$$$O	to$$$325$$$327$$$O	be$$$328$$$330$$$O	simultaneously$$$331$$$345$$$O	or$$$346$$$348$$$O	separately$$$349$$$359$$$O	administered,$$$360$$$373$$$O	or$$$374$$$376$$$O	administered$$$377$$$389$$$O	over$$$390$$$394$$$O	time,$$$395$$$400$$$O	in$$$401$$$403$$$O	the$$$404$$$407$$$O	treatment$$$408$$$417$$$O	of$$$418$$$420$$$O	cancer,$$$421$$$428$$$O	as$$$429$$$431$$$O	well$$$432$$$436$$$O	as$$$437$$$439$$$O	to$$$440$$$442$$$O	a$$$443$$$444$$$O	pharmaceutical$$$445$$$459$$$O	composition$$$460$$$471$$$O	including$$$472$$$481$$$O	said$$$482$$$486$$$O	derivatives$$$487$$$498$$$O	and$$$499$$$502$$$O	a$$$503$$$504$$$O	pharmaceutically$$$505$$$521$$$O	acceptable$$$522$$$532$$$O	carrier.$$$533$$$541$$$O	Finally,$$$542$$$550$$$O	the$$$551$$$554$$$O	invention$$$555$$$564$$$O	relates$$$565$$$572$$$O	to$$$573$$$575$$$O	a$$$576$$$577$$$O	method$$$578$$$584$$$O	for$$$585$$$588$$$O	the$$$589$$$592$$$O	in$$$593$$$595$$$O	vitro$$$596$$$601$$$O	inhibition$$$602$$$612$$$O	of$$$613$$$615$$$O	the$$$616$$$619$$$O	proliferation$$$620$$$633$$$O	of$$$634$$$636$$$O	cells,$$$637$$$643$$$O	including$$$644$$$653$$$O	contacting$$$654$$$664$$$O	a$$$665$$$666$$$O	cell$$$667$$$671$$$O	with$$$672$$$676$$$O	said$$$677$$$681$$$O	derivatives$$$682$$$693$$$O	in$$$694$$$696$$$O	vitro,$$$697$$$703$$$O	and$$$704$$$707$$$O	to$$$708$$$710$$$O	methods$$$711$$$718$$$O	for$$$719$$$722$$$O	synthesizing$$$723$$$735$$$O	said$$$736$$$740$$$O	derivatives.$$$741$$$753$$$O
CN102342951A
Chickweed$$$0$$$9$$$O	flavonoid$$$10$$$19$$$I	glycoside$$$20$$$29$$$I	extract,$$$30$$$38$$$O	its$$$39$$$42$$$O	preparation$$$43$$$54$$$O	method$$$55$$$61$$$O	and$$$62$$$65$$$O	pharmaceutical$$$66$$$80$$$O	application$$$81$$$92$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	chickweed$$$27$$$36$$$O	flavonoid$$$37$$$46$$$I	glycoside$$$47$$$56$$$I	extract,$$$57$$$65$$$O	comprising$$$66$$$76$$$O	18.69-28.03$$$77$$$88$$$O	w/w%$$$89$$$93$$$O	of$$$94$$$96$$$O	apigenin-6-C-beta-D-galactose-8-C-alfa-L-arabinoside$$$97$$$149$$$I	and$$$150$$$153$$$O	apigenin-6-C-alfa-L-arabinose-8-C-beta-D-galactoside$$$154$$$206$$$I	measured$$$207$$$215$$$O	as$$$216$$$218$$$O	the$$$219$$$222$$$O	weight$$$223$$$229$$$O	of$$$230$$$232$$$O	the$$$233$$$236$$$O	extract.$$$237$$$245$$$O	The$$$246$$$249$$$O	invention$$$250$$$259$$$O	also$$$260$$$264$$$O	relates$$$265$$$272$$$O	to$$$273$$$275$$$O	an$$$276$$$278$$$O	extraction$$$279$$$289$$$O	method$$$290$$$296$$$O	of$$$297$$$299$$$O	the$$$300$$$303$$$O	chickweed$$$304$$$313$$$O	flavonoid$$$314$$$323$$$I	glycoside$$$324$$$333$$$I	extract,$$$334$$$342$$$O	a$$$343$$$344$$$O	pharmaceutical$$$345$$$359$$$O	composition$$$360$$$371$$$O	containing$$$372$$$382$$$O	the$$$383$$$386$$$O	extract,$$$387$$$395$$$O	and$$$396$$$399$$$O	an$$$400$$$402$$$O	application$$$403$$$414$$$O	of$$$415$$$417$$$O	the$$$418$$$421$$$O	extract$$$422$$$429$$$O	for$$$430$$$433$$$O	preparing$$$434$$$443$$$O	drugs$$$444$$$449$$$O	for$$$450$$$453$$$O	lowering$$$454$$$462$$$O	blood$$$463$$$468$$$O	fat.$$$469$$$473$$$O
EP1913945A2
Composition$$$0$$$11$$$O	based$$$12$$$17$$$O	on$$$18$$$20$$$O	a$$$21$$$22$$$O	thiazolidinedione$$$23$$$40$$$I	and$$$41$$$44$$$O	metformin$$$45$$$54$$$I	and$$$55$$$58$$$O	its$$$59$$$62$$$O	use$$$63$$$66$$$O
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	composition,$$$17$$$29$$$O	comprising$$$30$$$40$$$O	a$$$41$$$42$$$O	thiazolidinedione,$$$43$$$61$$$I	such$$$62$$$66$$$O	as$$$67$$$69$$$O	Compound$$$70$$$78$$$O	(I),$$$79$$$83$$$O	metformin$$$84$$$93$$$I	hydrochloride$$$94$$$107$$$I	and$$$108$$$111$$$O	a$$$112$$$113$$$O	pharmaceutically$$$114$$$130$$$O	acceptable$$$131$$$141$$$O	carrier,$$$142$$$150$$$O	wherein$$$151$$$158$$$O	the$$$159$$$162$$$O	thiazolidinedione$$$163$$$180$$$I	and$$$181$$$184$$$O	metformin$$$185$$$194$$$I	hydrochloride$$$195$$$208$$$I	are$$$209$$$212$$$O	each$$$213$$$217$$$O	dispersed$$$218$$$227$$$O	within$$$228$$$234$$$O	its$$$235$$$238$$$O	own$$$239$$$242$$$O	pharmaceutically$$$243$$$259$$$O	acceptable$$$260$$$270$$$O	carrier$$$271$$$278$$$O	in$$$279$$$281$$$O	the$$$282$$$285$$$O	pharmaceutical$$$286$$$300$$$O	composition$$$301$$$312$$$O	for$$$313$$$316$$$O	use$$$317$$$320$$$O	in$$$321$$$323$$$O	the$$$324$$$327$$$O	treatment$$$328$$$337$$$O	of$$$338$$$340$$$O	conditions$$$341$$$351$$$O	associated$$$352$$$362$$$O	with$$$363$$$367$$$O	the$$$368$$$371$$$O	pre-diabetic$$$372$$$384$$$O	state.$$$385$$$391$$$O
US20050192237
Antisense$$$0$$$9$$$O	antibacterial$$$10$$$23$$$O	cell$$$24$$$28$$$O	division$$$29$$$37$$$O	composition$$$38$$$49$$$O	and$$$50$$$53$$$O	method$$$54$$$60$$$O
Antisense$$$0$$$9$$$O	oligomers$$$10$$$19$$$I	directed$$$20$$$28$$$O	to$$$29$$$31$$$O	bacterial$$$32$$$41$$$O	cell$$$42$$$46$$$O	division$$$47$$$55$$$O	and$$$56$$$59$$$O	cell$$$60$$$64$$$O	cycle-encoding$$$65$$$79$$$O	nucleic$$$80$$$87$$$O	acids$$$88$$$93$$$O	are$$$94$$$97$$$O	capable$$$98$$$105$$$O	of$$$106$$$108$$$O	selectively$$$109$$$120$$$O	modulating$$$121$$$131$$$O	the$$$132$$$135$$$O	biological$$$136$$$146$$$O	activity$$$147$$$155$$$O	thereof,$$$156$$$164$$$O	and$$$165$$$168$$$O	are$$$169$$$172$$$O	useful$$$173$$$179$$$O	in$$$180$$$182$$$O	treatment$$$183$$$192$$$O	and$$$193$$$196$$$O	prevention$$$197$$$207$$$O	of$$$208$$$210$$$O	bacterial$$$211$$$220$$$O	infection.$$$221$$$231$$$O	The$$$232$$$235$$$O	antisense$$$236$$$245$$$O	oligomers$$$246$$$255$$$I	are$$$256$$$259$$$O	substantially$$$260$$$273$$$O	uncharged,$$$274$$$284$$$O	and$$$285$$$288$$$O	contain$$$289$$$296$$$O	from$$$297$$$301$$$O	8$$$302$$$303$$$O	to$$$304$$$306$$$O	40$$$307$$$309$$$O	nucleotide$$$310$$$320$$$O	subunits,$$$321$$$330$$$O	including$$$331$$$340$$$O	a$$$341$$$342$$$O	targeting$$$343$$$352$$$O	nucleic$$$353$$$360$$$O	acid$$$361$$$365$$$O	sequence$$$366$$$374$$$O	at$$$375$$$377$$$O	least$$$378$$$383$$$O	10$$$384$$$386$$$O	nucleotides$$$387$$$398$$$O	in$$$399$$$401$$$O	length$$$402$$$408$$$O	which$$$409$$$414$$$O	is$$$415$$$417$$$O	effective$$$418$$$427$$$O	to$$$428$$$430$$$O	hybridize$$$431$$$440$$$O	to$$$441$$$443$$$O	(i)$$$444$$$447$$$O	a$$$448$$$449$$$O	bacterial$$$450$$$459$$$O	tRNA$$$460$$$464$$$O	or$$$465$$$467$$$O	(ii)$$$468$$$472$$$O	a$$$473$$$474$$$O	target$$$475$$$481$$$O	sequence,$$$482$$$491$$$O	containing$$$492$$$502$$$O	a$$$503$$$504$$$O	translational$$$505$$$518$$$O	start$$$519$$$524$$$O	codon,$$$525$$$531$$$O	within$$$532$$$538$$$O	a$$$539$$$540$$$O	bacterial$$$541$$$550$$$O	nucleic$$$551$$$558$$$O	acid$$$559$$$563$$$O	which$$$564$$$569$$$O	encodes$$$570$$$577$$$O	a$$$578$$$579$$$O	protein$$$580$$$587$$$O	associated$$$588$$$598$$$O	with$$$599$$$603$$$O	cell$$$604$$$608$$$O	division$$$609$$$617$$$O	or$$$618$$$620$$$O	the$$$621$$$624$$$O	cell$$$625$$$629$$$O	cycle.$$$630$$$636$$$O	Such$$$637$$$641$$$O	proteins$$$642$$$650$$$O	include$$$651$$$658$$$O	zipA,$$$659$$$664$$$O	sulA,$$$665$$$670$$$O	secA,$$$671$$$676$$$O	dicA,$$$677$$$682$$$O	dicB,$$$683$$$688$$$O	diCc,$$$689$$$694$$$O	dicF,$$$695$$$700$$$O	ftsA,$$$701$$$706$$$O	ftsl,ftsN,$$$707$$$717$$$O	ftsK,$$$718$$$723$$$O	ftsL,$$$724$$$729$$$O	ftsQ,$$$730$$$735$$$O	ftsw,$$$736$$$741$$$O	ftsZ,$$$742$$$747$$$O	murC,$$$748$$$753$$$O	murD,$$$754$$$759$$$O	murE,$$$760$$$765$$$O	murF,$$$766$$$771$$$O	murg,$$$772$$$777$$$O	minC,$$$778$$$783$$$O	minD,$$$784$$$789$$$O	minE,$$$790$$$795$$$O	mraY,$$$796$$$801$$$O	mraW,$$$802$$$807$$$O	mraZ,$$$808$$$813$$$O	seqA,$$$814$$$819$$$O	ddlB,$$$820$$$825$$$O	carbamate$$$826$$$835$$$O	kinase,$$$836$$$843$$$O	D-ala$$$844$$$849$$$I	D-ala$$$850$$$855$$$I	ligase,$$$856$$$863$$$O	topoisomerase,$$$864$$$878$$$O	alkyl$$$879$$$884$$$I	hydroperoxide$$$885$$$898$$$I	reductase,$$$899$$$909$$$O	thioredoxin$$$910$$$921$$$O	reductase,$$$922$$$932$$$O	dihydrofolate$$$933$$$946$$$I	reductase,$$$947$$$957$$$O	and$$$958$$$961$$$O	cell$$$962$$$966$$$O	wall$$$967$$$971$$$O	enzyme.$$$972$$$979$$$O
WO2009005613A2
Stable$$$0$$$6$$$O	non-disintegrating$$$7$$$25$$$O	dosage$$$26$$$32$$$O	forms$$$33$$$38$$$O	and$$$39$$$42$$$O	method$$$43$$$49$$$O	of$$$50$$$52$$$O	making$$$53$$$59$$$O	same$$$60$$$64$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	a$$$25$$$26$$$O	stable,$$$27$$$34$$$O	non-disintegrable$$$35$$$52$$$O	dosage$$$53$$$59$$$O	form$$$60$$$64$$$O	which$$$65$$$70$$$O	combines$$$71$$$79$$$O	the$$$80$$$83$$$O	benefits$$$84$$$92$$$O	of$$$93$$$95$$$O	a$$$96$$$97$$$O	microencapsulated$$$98$$$115$$$O	substrate$$$116$$$125$$$O	with$$$126$$$130$$$O	the$$$131$$$134$$$O	convenience$$$135$$$146$$$O	of$$$147$$$149$$$O	direct$$$150$$$156$$$O	compression.$$$157$$$169$$$O	The$$$170$$$173$$$O	present$$$174$$$181$$$O	invention$$$182$$$191$$$O	is$$$192$$$194$$$O	also$$$195$$$199$$$O	directed$$$200$$$208$$$O	to$$$209$$$211$$$O	methods$$$212$$$219$$$O	for$$$220$$$223$$$O	producing$$$224$$$233$$$O	directly$$$234$$$242$$$O	compressed$$$243$$$253$$$O	microencapsulated$$$254$$$271$$$O	dosage$$$272$$$278$$$O	forms$$$279$$$284$$$O	to$$$285$$$287$$$O	provide$$$288$$$295$$$O	modified$$$296$$$304$$$O	release$$$305$$$312$$$O	and$$$313$$$316$$$O	dosage$$$317$$$323$$$O	form$$$324$$$328$$$O	stability.$$$329$$$339$$$O	The$$$340$$$343$$$O	dosage$$$344$$$350$$$O	unit$$$351$$$355$$$O	can$$$356$$$359$$$O	have$$$360$$$364$$$O	a$$$365$$$366$$$O	high$$$367$$$371$$$O	active$$$372$$$378$$$O	load.$$$379$$$384$$$O
EP1372627B1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	breakers$$$7$$$15$$$O	of$$$16$$$18$$$O	advanced$$$19$$$27$$$O	glycation$$$28$$$37$$$O	endproducts$$$38$$$49$$$O	for$$$50$$$53$$$O	treating$$$54$$$62$$$O	deleterious$$$63$$$74$$$O	effects$$$75$$$82$$$O	of$$$83$$$85$$$O	aging$$$86$$$91$$$O	and$$$92$$$95$$$O	debilitating$$$96$$$108$$$O	diseases$$$109$$$117$$$O
Advanced$$$0$$$8$$$O	glycation$$$9$$$18$$$O	endproducts$$$19$$$30$$$O	(AGEs)$$$31$$$37$$$O	have$$$38$$$42$$$O	been$$$43$$$47$$$O	implicated$$$48$$$58$$$O	in$$$59$$$61$$$O	the$$$62$$$65$$$O	pathogenesis$$$66$$$78$$$O	of$$$79$$$81$$$O	a$$$82$$$83$$$O	variety$$$84$$$91$$$O	of$$$92$$$94$$$O	debilitating$$$95$$$107$$$O	diseases$$$108$$$116$$$O	such$$$117$$$121$$$O	as$$$122$$$124$$$O	diabetes,$$$125$$$134$$$O	atherosclerosis,$$$135$$$151$$$O	Alzheimer's$$$152$$$163$$$O	and$$$164$$$167$$$O	rheumatoid$$$168$$$178$$$O	arthritis,$$$179$$$189$$$O	as$$$190$$$192$$$O	well$$$193$$$197$$$O	as$$$198$$$200$$$O	in$$$201$$$203$$$O	the$$$204$$$207$$$O	normal$$$208$$$214$$$O	aging$$$215$$$220$$$O	process.$$$221$$$229$$$O	Seven$$$230$$$235$$$O	compounds$$$236$$$245$$$O	are$$$246$$$249$$$O	here$$$250$$$254$$$O	reported$$$255$$$263$$$O	to$$$264$$$266$$$O	be$$$267$$$269$$$O	active$$$270$$$276$$$O	in$$$277$$$279$$$O	breaking$$$280$$$288$$$O	AGE-protein$$$289$$$300$$$O	cross-links.$$$301$$$313$$$O	These$$$314$$$319$$$O	compounds$$$320$$$329$$$O	are$$$330$$$333$$$O	1,4-benzene-bis[4-methyleneamino-phenoxyisobutyric$$$334$$$384$$$I	acid]$$$385$$$390$$$I	(LR102);$$$391$$$399$$$I	4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic$$$400$$$461$$$I	acid$$$462$$$466$$$I	(LR99);$$$467$$$474$$$I	L-bis-[4-(4-chlorobenzamidophenoxyisobutyryl)cystine]$$$475$$$528$$$I	(LR20);$$$529$$$536$$$I	4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amidocyclohexane-1-carboxylic$$$537$$$614$$$I	acid$$$615$$$619$$$I	(LR23);$$$620$$$627$$$I	methylene$$$628$$$637$$$I	bis$$$638$$$641$$$I	[4,4'-(2-chlorophenylureidophenoxyisobutyric$$$642$$$686$$$I	acid)]$$$687$$$693$$$I	(LR90);$$$694$$$701$$$I	5-aminosalicylic$$$702$$$718$$$I	acid$$$719$$$723$$$I	(5-ASA);$$$724$$$732$$$I	and$$$733$$$736$$$O	metformin.$$$737$$$747$$$I	These$$$748$$$753$$$O	compounds$$$754$$$763$$$O	may$$$764$$$767$$$O	be$$$768$$$770$$$O	used$$$771$$$775$$$O	to$$$776$$$778$$$O	reverse$$$779$$$786$$$O	the$$$787$$$790$$$O	debilitating$$$791$$$803$$$O	effects$$$804$$$811$$$O	of$$$812$$$814$$$O	those$$$815$$$820$$$O	diseases$$$821$$$829$$$O	in$$$830$$$832$$$O	which$$$833$$$838$$$O	AGEs$$$839$$$843$$$O	are$$$844$$$847$$$O	formed.$$$848$$$855$$$O
US8246930
Multicomponent$$$0$$$14$$$O	assemblies$$$15$$$25$$$O	having$$$26$$$32$$$O	enhanced$$$33$$$41$$$O	binding$$$42$$$49$$$O	properties$$$50$$$60$$$O	for$$$61$$$64$$$O	diagnosis$$$65$$$74$$$O	and$$$75$$$78$$$O	therapy$$$79$$$86$$$O
An$$$0$$$2$$$O	organized$$$3$$$12$$$O	mobile$$$13$$$19$$$O	multicomponent$$$20$$$34$$$O	conjugate$$$35$$$44$$$O	(OMMC)$$$45$$$51$$$O	and$$$52$$$55$$$O	method$$$56$$$62$$$O	of$$$63$$$65$$$O	using$$$66$$$71$$$O	to$$$72$$$74$$$O	enhance$$$75$$$82$$$O	binding$$$83$$$90$$$O	of$$$91$$$93$$$O	weakly$$$94$$$100$$$O	binding$$$101$$$108$$$O	compounds$$$109$$$118$$$O	to$$$119$$$121$$$O	a$$$122$$$123$$$O	target.$$$124$$$131$$$O	A$$$132$$$133$$$O	lamellar$$$134$$$142$$$O	structure$$$143$$$152$$$O	containing$$$153$$$163$$$O	at$$$164$$$166$$$O	least$$$167$$$172$$$O	two$$$173$$$176$$$O	binding$$$177$$$184$$$O	compounds$$$185$$$194$$$O	is$$$195$$$197$$$O	assembled$$$198$$$207$$$O	under$$$208$$$213$$$O	conditions$$$214$$$224$$$O	in$$$225$$$227$$$O	which$$$228$$$233$$$O	the$$$234$$$237$$$O	binding$$$238$$$245$$$O	compounds$$$246$$$255$$$O	self-regulate$$$256$$$269$$$O	in$$$270$$$272$$$O	or$$$273$$$275$$$O	on$$$276$$$278$$$O	the$$$279$$$282$$$O	lamellar$$$283$$$291$$$O	structure,$$$292$$$302$$$O	forming$$$303$$$310$$$O	a$$$311$$$312$$$O	cooperative$$$313$$$324$$$O	ensemble$$$325$$$333$$$O	that$$$334$$$338$$$O	is$$$339$$$341$$$O	capable$$$342$$$349$$$O	of$$$350$$$352$$$O	binding$$$353$$$360$$$O	with$$$361$$$365$$$O	enhanced$$$366$$$374$$$O	affinity$$$375$$$383$$$O	to$$$384$$$386$$$O	a$$$387$$$388$$$O	complementary$$$389$$$402$$$O	affinity$$$403$$$411$$$O	site$$$412$$$416$$$O	on$$$417$$$419$$$O	a$$$420$$$421$$$O	target.$$$422$$$429$$$O	Each$$$430$$$434$$$O	binding$$$435$$$442$$$O	compound$$$443$$$451$$$O	is$$$452$$$454$$$O	bound$$$455$$$460$$$O	to$$$461$$$463$$$O	the$$$464$$$467$$$O	lamellar$$$468$$$476$$$O	surface,$$$477$$$485$$$O	and$$$486$$$489$$$O	may$$$490$$$493$$$O	be$$$494$$$496$$$O	connected$$$497$$$506$$$O	by$$$507$$$509$$$O	a$$$510$$$511$$$O	linker.$$$512$$$519$$$O	The$$$520$$$523$$$O	OMMC$$$524$$$528$$$O	may$$$529$$$532$$$O	contain$$$533$$$540$$$O	an$$$541$$$543$$$O	effector$$$544$$$552$$$O	molecule,$$$553$$$562$$$O	such$$$563$$$567$$$O	as$$$568$$$570$$$O	a$$$571$$$572$$$O	diagnostic$$$573$$$583$$$O	or$$$584$$$586$$$O	therapeutic$$$587$$$598$$$O	agent,$$$599$$$605$$$O	for$$$606$$$609$$$O	administration$$$610$$$624$$$O	to$$$625$$$627$$$O	a$$$628$$$629$$$O	patent$$$630$$$636$$$O	who$$$637$$$640$$$O	is$$$641$$$643$$$O	then$$$644$$$648$$$O	diagnosed$$$649$$$658$$$O	or$$$659$$$661$$$O	treated$$$662$$$669$$$O	using$$$670$$$675$$$O	the$$$676$$$679$$$O	effector$$$680$$$688$$$O	molecule.$$$689$$$698$$$O
EP2730577A1
Crystal$$$0$$$7$$$O	modification$$$8$$$20$$$O	of$$$21$$$23$$$O	a$$$24$$$25$$$O	para-methoxyanilide$$$26$$$45$$$I	of$$$46$$$48$$$I	6-hydroxy-4-oxo-2,4,dihydro-1h-pyrrolo[3,2,1-ij]-quinoline-5-carboxylic$$$49$$$120$$$I	acid$$$121$$$125$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	organic$$$25$$$32$$$O	chemistry,$$$33$$$43$$$O	in$$$44$$$46$$$O	particular,$$$47$$$58$$$O	to$$$59$$$61$$$O	a$$$62$$$63$$$O	novel$$$64$$$69$$$O	crystal$$$70$$$77$$$O	modification$$$78$$$90$$$O	of$$$91$$$93$$$O	6-hydroxy-4-oxo-2,4-dihydro-1H-pyrrolo[3,2,1-ij]-quinoline-5-carboxylic$$$94$$$165$$$I	acid$$$166$$$170$$$I	para-metoxyanilide$$$171$$$189$$$I	with$$$190$$$194$$$O	a$$$195$$$196$$$O	diuretic$$$197$$$205$$$O	effect,$$$206$$$213$$$O	which$$$214$$$219$$$O	can$$$220$$$223$$$O	be$$$224$$$226$$$O	used$$$227$$$231$$$O	in$$$232$$$234$$$O	the$$$235$$$238$$$O	chemical-pharmaceutical$$$239$$$262$$$O	industry$$$263$$$271$$$O	and$$$272$$$275$$$O	medicine.$$$276$$$285$$$O	The$$$286$$$289$$$O	objective$$$290$$$299$$$O	of$$$300$$$302$$$O	the$$$303$$$306$$$O	present$$$307$$$314$$$O	invention$$$315$$$324$$$O	Is$$$325$$$327$$$O	to$$$328$$$330$$$O	prepare$$$331$$$338$$$O	a$$$339$$$340$$$O	novel$$$341$$$346$$$O	crystal$$$347$$$354$$$O	modification$$$355$$$367$$$O	of$$$368$$$370$$$O	6-hydroxy-4-oxo-2,4-dihydro-1H-pyrrolo[3,2,1-ij]-quinoline-5-carboxylic$$$371$$$442$$$I	acid$$$443$$$447$$$I	para-metoxyanilide$$$448$$$466$$$I	with$$$467$$$471$$$O	more$$$472$$$476$$$O	advantageous$$$477$$$489$$$O	pharmaceutical$$$490$$$504$$$O	and$$$505$$$508$$$O	biological$$$509$$$519$$$O	properties.$$$520$$$531$$$O	Said$$$532$$$536$$$O	objective$$$537$$$546$$$O	is$$$547$$$549$$$O	achieved$$$550$$$558$$$O	by$$$559$$$561$$$O	the$$$562$$$565$$$O	preparation$$$566$$$577$$$O	of$$$578$$$580$$$O	a$$$581$$$582$$$O	novel$$$583$$$588$$$O	crystal$$$589$$$596$$$O	modification$$$597$$$609$$$O	of$$$610$$$612$$$O	6-hydroxy-4-oxo-2,4-dihydro-1H-pyrrolo[3,2,1-ij]-quinoline-5-carboxylic$$$613$$$684$$$I	acid$$$685$$$689$$$I	para-metoxyanilide$$$690$$$708$$$I	(Î²-form)$$$709$$$718$$$O	characterized$$$719$$$732$$$O	by$$$733$$$735$$$O	the$$$736$$$739$$$O	following$$$740$$$749$$$O	interplanar$$$750$$$761$$$O	spacings$$$762$$$770$$$O	(d)$$$771$$$774$$$O	and$$$775$$$778$$$O	relative$$$779$$$787$$$O	intensities$$$788$$$799$$$O	of$$$800$$$802$$$O	the$$$803$$$806$$$O	reflections$$$807$$$818$$$O	(Irel)$$$819$$$825$$$O	exhibiting$$$826$$$836$$$O	an$$$837$$$839$$$O	added$$$840$$$845$$$O	enhanced$$$846$$$854$$$O	diuretic$$$855$$$863$$$O	effect.$$$864$$$871$$$O
US7045546
Stabilized$$$0$$$10$$$O	derivatives$$$11$$$22$$$O	of$$$23$$$25$$$O	ascorbic$$$26$$$34$$$I	acid-3-phosphate$$$35$$$51$$$I
Novel$$$0$$$5$$$O	derivatives$$$6$$$17$$$O	of$$$18$$$20$$$O	ascorbic$$$21$$$29$$$I	acid$$$30$$$34$$$I	and$$$35$$$38$$$O	compositions$$$39$$$51$$$O	comprising$$$52$$$62$$$O	them$$$63$$$67$$$O	are$$$68$$$71$$$O	provided.$$$72$$$81$$$O	The$$$82$$$85$$$O	novel$$$86$$$91$$$O	derivatives$$$92$$$103$$$O	are$$$104$$$107$$$O	of$$$108$$$110$$$O	the$$$111$$$114$$$O	following$$$115$$$124$$$O	general$$$125$$$132$$$O	formula$$$133$$$140$$$O	(I):$$$141$$$145$$$O	where$$$146$$$151$$$O	R1$$$152$$$154$$$O	is$$$155$$$157$$$O	a$$$158$$$159$$$O	C2âC22$$$160$$$168$$$O	saturated$$$169$$$178$$$O	or$$$179$$$181$$$O	unsaturated$$$182$$$193$$$I	fatty$$$194$$$199$$$I	acid$$$200$$$204$$$I	residues,$$$205$$$214$$$I	amino$$$215$$$220$$$I	acid$$$221$$$225$$$I	residues,$$$226$$$235$$$O	or$$$236$$$238$$$O	a$$$239$$$240$$$I	C1âC17$$$241$$$249$$$I	alkyl$$$250$$$255$$$I	;$$$256$$$257$$$O	R2$$$258$$$260$$$O	is$$$261$$$263$$$O	a$$$264$$$265$$$O	group$$$266$$$271$$$O	of$$$272$$$274$$$O	the$$$275$$$278$$$O	following$$$279$$$288$$$O	formula$$$289$$$296$$$O	(II)$$$297$$$301$$$O	wherein$$$302$$$309$$$O	R5$$$310$$$312$$$O	or$$$313$$$315$$$O	R6$$$316$$$318$$$O	are$$$319$$$322$$$O	the$$$323$$$326$$$O	same$$$327$$$331$$$O	or$$$332$$$334$$$O	different$$$335$$$344$$$O	and$$$345$$$348$$$O	represent$$$349$$$358$$$I	hydrogen,$$$359$$$368$$$I	a$$$369$$$370$$$I	C1âC4$$$371$$$378$$$I	alkyl,$$$379$$$385$$$O	or$$$386$$$388$$$O	R5$$$389$$$391$$$I	is$$$392$$$394$$$I	C1âC4$$$395$$$402$$$I	alkyl$$$403$$$408$$$O	group$$$409$$$414$$$O	and$$$415$$$418$$$O	R6$$$419$$$421$$$O	is$$$422$$$424$$$O	a$$$425$$$426$$$O	metal$$$427$$$432$$$O	cation$$$433$$$439$$$I	or$$$440$$$442$$$I	ammonium$$$443$$$451$$$I	cation;$$$452$$$459$$$O	R3$$$460$$$462$$$O	or$$$463$$$465$$$O	R4$$$466$$$468$$$O	are$$$469$$$472$$$O	the$$$473$$$476$$$O	same$$$477$$$481$$$O	or$$$482$$$484$$$O	different$$$485$$$494$$$O	and$$$495$$$498$$$O	represent$$$499$$$508$$$I	hydrogen,$$$509$$$518$$$I	C2âC22$$$519$$$527$$$O	saturated$$$528$$$537$$$O	or$$$538$$$540$$$O	unsaturated$$$541$$$552$$$I	fatty$$$553$$$558$$$I	acid$$$559$$$563$$$O	residues,$$$564$$$573$$$I	amino$$$574$$$579$$$I	acid$$$580$$$584$$$O	residues,$$$585$$$594$$$I	or$$$595$$$597$$$I	a$$$598$$$599$$$I	C1âC17$$$600$$$608$$$I	alkyl.$$$609$$$615$$$O
CN101062118A
Chewing$$$0$$$7$$$O	gum$$$8$$$11$$$O	having$$$12$$$18$$$O	functions$$$19$$$28$$$O	of$$$29$$$31$$$O	preventing$$$32$$$42$$$O	and$$$43$$$46$$$O	treating$$$47$$$55$$$O	decayed$$$56$$$63$$$O	tooth$$$64$$$69$$$O	and$$$70$$$73$$$O	the$$$74$$$77$$$O	preparing$$$78$$$87$$$O	method$$$88$$$94$$$O	thereof$$$95$$$102$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	chewing$$$27$$$34$$$O	gum$$$35$$$38$$$O	for$$$39$$$42$$$O	preventing$$$43$$$53$$$O	caries$$$54$$$60$$$O	and$$$61$$$64$$$O	process$$$65$$$72$$$O	for$$$73$$$76$$$O	preparation,$$$77$$$89$$$O	wherein$$$90$$$97$$$O	the$$$98$$$101$$$O	chewing$$$102$$$109$$$O	gum$$$110$$$113$$$O	is$$$114$$$116$$$O	prepared$$$117$$$125$$$O	from$$$126$$$130$$$O	green$$$131$$$136$$$O	tea$$$137$$$140$$$O	polyphenols,$$$141$$$153$$$I	powder$$$154$$$160$$$O	of$$$161$$$163$$$O	honeysuckle$$$164$$$175$$$O	flower,$$$176$$$183$$$O	giant$$$184$$$189$$$O	knotweed$$$190$$$198$$$O	rhizome$$$199$$$206$$$O	powder,$$$207$$$214$$$O	vitamin$$$215$$$222$$$I	C,$$$223$$$225$$$I	phosphatide,$$$226$$$238$$$I	xylitol,$$$239$$$247$$$I	glue$$$248$$$252$$$O	base$$$253$$$257$$$O	and$$$258$$$261$$$O	flavoring$$$262$$$271$$$O	essence$$$272$$$279$$$O	through$$$280$$$287$$$O	mixing$$$288$$$294$$$O	homogeneously.$$$295$$$309$$$O
CN102091310A
Muscle$$$0$$$6$$$O	and$$$7$$$10$$$O	bone$$$11$$$15$$$O	paste$$$16$$$21$$$O	and$$$22$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	thereof$$$45$$$52$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	muscle$$$26$$$32$$$O	and$$$33$$$36$$$O	bone$$$37$$$41$$$O	paste$$$42$$$47$$$O	and$$$48$$$51$$$O	a$$$52$$$53$$$O	preparation$$$54$$$65$$$O	method$$$66$$$72$$$O	thereof.$$$73$$$81$$$O	On$$$82$$$84$$$O	the$$$85$$$88$$$O	one$$$89$$$92$$$O	hand,$$$93$$$98$$$O	the$$$99$$$102$$$O	muscle$$$103$$$109$$$O	and$$$110$$$113$$$O	bone$$$114$$$118$$$O	paste$$$119$$$124$$$O	comprises$$$125$$$134$$$O	56$$$135$$$137$$$O	medicaments$$$138$$$149$$$O	such$$$150$$$154$$$O	as$$$155$$$157$$$O	vine$$$158$$$162$$$O	root,$$$163$$$168$$$O	East$$$169$$$173$$$O	Asian$$$174$$$179$$$O	tree$$$180$$$184$$$O	fern$$$185$$$189$$$O	rhizome,$$$190$$$198$$$O	heracleum,$$$199$$$209$$$O	divaricate$$$210$$$220$$$O	saposhnikovia$$$221$$$234$$$O	root,$$$235$$$240$$$O	prepared$$$241$$$249$$$O	common$$$250$$$256$$$O	monkshood$$$257$$$266$$$O	daughter$$$267$$$275$$$O	root,$$$276$$$281$$$O	ephedra$$$282$$$289$$$O	herb,$$$290$$$295$$$O	dragon's$$$296$$$304$$$O	blood$$$305$$$310$$$O	and$$$311$$$314$$$O	the$$$315$$$318$$$O	like;$$$319$$$324$$$O	and$$$325$$$328$$$O	on$$$329$$$331$$$O	the$$$332$$$335$$$O	other$$$336$$$341$$$O	hand,$$$342$$$347$$$O	the$$$348$$$351$$$O	preparation$$$352$$$363$$$O	method$$$364$$$370$$$O	of$$$371$$$373$$$O	the$$$374$$$377$$$O	muscle$$$378$$$384$$$O	and$$$385$$$388$$$O	bone$$$389$$$393$$$O	paste$$$394$$$399$$$O	comprises$$$400$$$409$$$O	the$$$410$$$413$$$O	following$$$414$$$423$$$O	steps$$$424$$$429$$$O	of:$$$430$$$433$$$O	crushing$$$434$$$442$$$O	the$$$443$$$446$$$O	dragon's$$$447$$$455$$$O	blood$$$456$$$461$$$O	in$$$462$$$464$$$O	the$$$465$$$468$$$O	muscle$$$469$$$475$$$O	and$$$476$$$479$$$O	bone$$$480$$$484$$$O	paste$$$485$$$490$$$O	into$$$491$$$495$$$O	fine$$$496$$$500$$$O	powder;$$$501$$$508$$$O	fragmenting$$$509$$$520$$$O	other$$$521$$$526$$$O	55$$$527$$$529$$$O	medicaments$$$530$$$541$$$O	except$$$542$$$548$$$O	the$$$549$$$552$$$O	dragon's$$$553$$$561$$$O	blood$$$562$$$567$$$O	in$$$568$$$570$$$O	the$$$571$$$574$$$O	muscle$$$575$$$581$$$O	and$$$582$$$585$$$O	bone$$$586$$$590$$$O	paste;$$$591$$$597$$$O	mixing$$$598$$$604$$$O	the$$$605$$$608$$$O	medicaments$$$609$$$620$$$O	with$$$621$$$625$$$O	4,000$$$626$$$631$$$O	to$$$632$$$634$$$O	6,000g$$$635$$$641$$$O	of$$$642$$$644$$$O	edible$$$645$$$651$$$O	oil,$$$652$$$656$$$O	and$$$657$$$660$$$O	frying$$$661$$$667$$$O	until$$$668$$$673$$$O	the$$$674$$$677$$$O	medicaments$$$678$$$689$$$O	are$$$690$$$693$$$O	dry;$$$694$$$698$$$O	refining$$$699$$$707$$$O	until$$$708$$$713$$$O	drips$$$714$$$719$$$O	are$$$720$$$723$$$O	formed$$$724$$$730$$$O	into$$$731$$$735$$$O	beads;$$$736$$$742$$$O	filtering$$$743$$$752$$$O	and$$$753$$$756$$$O	deslagging$$$757$$$767$$$O	to$$$768$$$770$$$O	obtain$$$771$$$777$$$O	mixed$$$778$$$783$$$O	liquor$$$784$$$790$$$O	A;$$$791$$$793$$$O	adding$$$794$$$800$$$O	2,000$$$801$$$806$$$O	to$$$807$$$809$$$O	2,500g$$$810$$$816$$$O	of$$$817$$$819$$$O	red$$$820$$$823$$$O	lead$$$824$$$828$$$O	into$$$829$$$833$$$O	the$$$834$$$837$$$O	mixed$$$838$$$843$$$O	liquor$$$844$$$850$$$O	A;$$$851$$$853$$$O	stirring$$$854$$$862$$$O	to$$$863$$$865$$$O	obtain$$$866$$$872$$$O	paste,$$$873$$$879$$$O	and$$$880$$$883$$$O	collecting$$$884$$$894$$$O	the$$$895$$$898$$$O	paste;$$$899$$$905$$$O	and$$$906$$$909$$$O	melting$$$910$$$917$$$O	with$$$918$$$922$$$O	soft$$$923$$$927$$$O	fire,$$$928$$$933$$$O	adding$$$934$$$940$$$O	the$$$941$$$944$$$O	dragon's$$$945$$$953$$$O	blood$$$954$$$959$$$O	powder,$$$960$$$967$$$O	stirring$$$968$$$976$$$O	uniformly,$$$977$$$987$$$O	and$$$988$$$991$$$O	spreading$$$992$$$1001$$$O	on$$$1002$$$1004$$$O	cloth.$$$1005$$$1011$$$O	The$$$1012$$$1015$$$O	muscle$$$1016$$$1022$$$O	and$$$1023$$$1026$$$O	bone$$$1027$$$1031$$$O	paste$$$1032$$$1037$$$O	has$$$1038$$$1041$$$O	effects$$$1042$$$1049$$$O	of$$$1050$$$1052$$$O	activating$$$1053$$$1063$$$O	blood$$$1064$$$1069$$$O	and$$$1070$$$1073$$$O	dissolving$$$1074$$$1084$$$O	stasis,$$$1085$$$1092$$$O	clearing$$$1093$$$1101$$$O	away$$$1102$$$1106$$$O	heat$$$1107$$$1111$$$O	and$$$1112$$$1115$$$O	toxic$$$1116$$$1121$$$O	materials,$$$1122$$$1132$$$O	diminishing$$$1133$$$1144$$$O	swelling$$$1145$$$1153$$$O	and$$$1154$$$1157$$$O	relieving$$$1158$$$1167$$$O	pain,$$$1168$$$1173$$$O	activating$$$1174$$$1184$$$O	collateral$$$1185$$$1195$$$O	flows$$$1196$$$1201$$$O	and$$$1202$$$1205$$$O	has$$$1206$$$1209$$$O	good$$$1210$$$1214$$$O	effects$$$1215$$$1222$$$O	of$$$1223$$$1225$$$O	treating$$$1226$$$1234$$$O	cervical$$$1235$$$1243$$$O	spondylosis,$$$1244$$$1256$$$O	protrusion$$$1257$$$1267$$$O	of$$$1268$$$1270$$$O	lumbar$$$1271$$$1277$$$O	vertebral$$$1278$$$1287$$$O	discs,$$$1288$$$1294$$$O	rheumatoid$$$1295$$$1305$$$O	arthritis$$$1306$$$1315$$$O	and$$$1316$$$1319$$$O	the$$$1320$$$1323$$$O	like$$$1324$$$1328$$$O	caused$$$1329$$$1335$$$O	by$$$1336$$$1338$$$O	accumulated$$$1339$$$1350$$$O	heat$$$1351$$$1355$$$O	skin$$$1356$$$1360$$$O	and$$$1361$$$1364$$$O	joints,$$$1365$$$1372$$$O	traumatic$$$1373$$$1382$$$O	injuries,$$$1383$$$1392$$$O	sacrodynia$$$1393$$$1403$$$O	and$$$1404$$$1407$$$O	hyperosteogeny.$$$1408$$$1423$$$O
WO2007074089A1
Aryl-isoxazol-4-yl-imidazo[1,$$$0$$$29$$$I	5-a]pyridine$$$30$$$42$$$I	derivatives$$$43$$$54$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	concerned$$$25$$$34$$$O	with$$$35$$$39$$$O	aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine$$$40$$$81$$$I	derivatives$$$82$$$93$$$O	of$$$94$$$96$$$O	formula$$$97$$$104$$$O	(I)$$$105$$$108$$$O	wherein:$$$109$$$117$$$O	R1$$$118$$$120$$$O	is$$$121$$$123$$$O	hydrogen,$$$124$$$133$$$I	halogen,$$$134$$$142$$$I	hydroxy,$$$143$$$151$$$I	lower$$$152$$$157$$$O	alkyl,$$$158$$$164$$$I	benzyloxy$$$165$$$174$$$I	or$$$175$$$177$$$O	-O-(CH2)-(CO)-5$$$178$$$193$$$I	or$$$194$$$196$$$O	6$$$197$$$198$$$O	membered$$$199$$$207$$$O	heteroaryl$$$208$$$218$$$I	optionally$$$219$$$229$$$O	substituted$$$230$$$241$$$O	by$$$242$$$244$$$O	aryl$$$245$$$249$$$I	and$$$250$$$253$$$O	lower$$$254$$$259$$$O	alkyl;$$$260$$$266$$$I	R2$$$267$$$269$$$O	is$$$270$$$272$$$O	hydrogen,$$$273$$$282$$$I	lower$$$283$$$288$$$O	alkyl,$$$289$$$295$$$I	or$$$296$$$298$$$O	-(CO)-Ra;$$$299$$$308$$$I	R3$$$309$$$311$$$O	is$$$312$$$314$$$O	hydrogen,$$$315$$$324$$$I	halogen,$$$325$$$333$$$I	cyano,$$$334$$$340$$$I	lower$$$341$$$346$$$O	alkyl,$$$347$$$353$$$I	or$$$354$$$356$$$O	-(CO)-Ra;$$$357$$$366$$$I	Ra$$$367$$$369$$$O	is$$$370$$$372$$$O	hydroxy,$$$373$$$381$$$I	lower$$$382$$$387$$$O	alkoxy,$$$388$$$395$$$I	NR'R'',$$$396$$$403$$$I	wherein$$$404$$$411$$$O	R'$$$412$$$414$$$O	and$$$415$$$418$$$O	R''$$$419$$$422$$$O	are$$$423$$$426$$$O	each$$$427$$$431$$$O	independently$$$432$$$445$$$O	hydrogen,$$$446$$$455$$$I	cycloalkyl,$$$456$$$467$$$I	5$$$468$$$469$$$O	or$$$470$$$472$$$O	6-membered$$$473$$$483$$$O	heterocycloalkyl$$$484$$$500$$$I	or$$$501$$$503$$$O	lower$$$504$$$509$$$O	alkyl$$$510$$$515$$$I	optionally$$$516$$$526$$$O	substituted$$$527$$$538$$$O	by$$$539$$$541$$$O	cycloalkyl,$$$542$$$553$$$I	cyano,$$$554$$$560$$$I	5$$$561$$$562$$$O	or$$$563$$$565$$$O	6-membered$$$566$$$576$$$O	heterocycloalkyl$$$577$$$593$$$I	or$$$594$$$596$$$O	5$$$597$$$598$$$O	or$$$599$$$601$$$O	6-membered$$$602$$$612$$$O	heteroaryl;$$$613$$$624$$$I	as$$$625$$$627$$$O	well$$$628$$$632$$$O	as$$$633$$$635$$$O	pharmaceutically$$$636$$$652$$$O	acceptable$$$653$$$663$$$O	acid$$$664$$$668$$$O	addition$$$669$$$677$$$O	salts$$$678$$$683$$$O	thereof.$$$684$$$692$$$O	It$$$693$$$695$$$O	has$$$696$$$699$$$O	been$$$700$$$704$$$O	found$$$705$$$710$$$O	that$$$711$$$715$$$O	this$$$716$$$720$$$O	class$$$721$$$726$$$O	of$$$727$$$729$$$O	compounds$$$730$$$739$$$O	show$$$740$$$744$$$O	high$$$745$$$749$$$O	affinity$$$750$$$758$$$O	and$$$759$$$762$$$O	selectivity$$$763$$$774$$$O	for$$$775$$$778$$$O	GABA$$$779$$$783$$$O	A$$$784$$$785$$$O	Î±5$$$786$$$789$$$O	receptor$$$790$$$798$$$O	binding$$$799$$$806$$$O	sites$$$807$$$812$$$O	and$$$813$$$816$$$O	might$$$817$$$822$$$O	be$$$823$$$825$$$O	useful$$$826$$$832$$$O	as$$$833$$$835$$$O	cognitive$$$836$$$845$$$O	enhancer$$$846$$$854$$$O	or$$$855$$$857$$$O	for$$$858$$$861$$$O	the$$$862$$$865$$$O	treatment$$$866$$$875$$$O	of$$$876$$$878$$$O	cognitive$$$879$$$888$$$O	disorders$$$889$$$898$$$O	like$$$899$$$903$$$O	Alzheimer's$$$904$$$915$$$O	disease.$$$916$$$924$$$O
US20090197853
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	of$$$25$$$27$$$O	treating$$$28$$$36$$$O	cancer$$$37$$$43$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	involves$$$23$$$31$$$O	the$$$32$$$35$$$O	use$$$36$$$39$$$O	of$$$40$$$42$$$O	metal-containing$$$43$$$59$$$O	texaphyrins$$$60$$$71$$$I	and$$$72$$$75$$$O	zinc$$$76$$$80$$$I	(II)$$$81$$$85$$$I	reagents$$$86$$$94$$$O	for$$$95$$$98$$$O	the$$$99$$$102$$$O	treatment$$$103$$$112$$$O	of$$$113$$$115$$$O	tumors,$$$116$$$123$$$O	atheromas$$$124$$$133$$$O	and$$$134$$$137$$$O	other$$$138$$$143$$$O	neoplastic$$$144$$$154$$$O	tissue.$$$155$$$162$$$O	The$$$163$$$166$$$O	present$$$167$$$174$$$O	application$$$175$$$186$$$O	demonstrates$$$187$$$199$$$O	increased$$$200$$$209$$$O	oxidative$$$210$$$219$$$O	stress,$$$220$$$227$$$O	alterations$$$228$$$239$$$O	in$$$240$$$242$$$O	zinc$$$243$$$247$$$I	homeostasis,$$$248$$$260$$$O	cell$$$261$$$265$$$O	cycle$$$266$$$271$$$O	arrest,$$$272$$$279$$$O	and$$$280$$$283$$$O	apoptosis$$$284$$$293$$$O	of$$$294$$$296$$$O	cancer$$$297$$$303$$$O	cells$$$304$$$309$$$O	in$$$310$$$312$$$O	the$$$313$$$316$$$O	presence$$$317$$$325$$$O	of$$$326$$$328$$$O	texaphyrins$$$329$$$340$$$I	and/or$$$341$$$347$$$O	zinc.$$$348$$$353$$$I	One$$$354$$$357$$$O	aspect$$$358$$$364$$$O	is$$$365$$$367$$$O	to$$$368$$$370$$$O	monitor$$$371$$$378$$$O	oxidative$$$379$$$388$$$O	stress$$$389$$$395$$$O	and/or$$$396$$$402$$$O	alterations$$$403$$$414$$$O	in$$$415$$$417$$$O	zinc$$$418$$$422$$$I	homeostasis$$$423$$$434$$$O	in$$$435$$$437$$$O	target$$$438$$$444$$$O	cells$$$445$$$450$$$O	prior$$$451$$$456$$$O	to$$$457$$$459$$$O	and/or$$$460$$$466$$$O	after$$$467$$$472$$$O	treatment$$$473$$$482$$$O	with$$$483$$$487$$$O	metal-containing$$$488$$$504$$$O	texaphyrins$$$505$$$516$$$I	and/or$$$517$$$523$$$O	zinc$$$524$$$528$$$I	(II)$$$529$$$533$$$I	reagents$$$534$$$542$$$O	as$$$543$$$545$$$O	a$$$546$$$547$$$O	predictor$$$548$$$557$$$O	for$$$558$$$561$$$O	treatment$$$562$$$571$$$O	efficacy.$$$572$$$581$$$O	The$$$582$$$585$$$O	present$$$586$$$593$$$O	disclosure$$$594$$$604$$$O	provides$$$605$$$613$$$O	molecular$$$614$$$623$$$O	basis$$$624$$$629$$$O	for$$$630$$$633$$$O	the$$$634$$$637$$$O	cell$$$638$$$642$$$O	cycle$$$643$$$648$$$O	arrest$$$649$$$655$$$O	and$$$656$$$659$$$O	apoptosis$$$660$$$669$$$O	on$$$670$$$672$$$O	cancer$$$673$$$679$$$O	cells$$$680$$$685$$$O	in$$$686$$$688$$$O	the$$$689$$$692$$$O	presence$$$693$$$701$$$O	of$$$702$$$704$$$O	texaphyrins$$$705$$$716$$$I	and$$$717$$$720$$$O	zinc.$$$721$$$726$$$I	Another$$$727$$$734$$$O	aspect$$$735$$$741$$$O	is$$$742$$$744$$$O	to$$$745$$$747$$$O	monitor$$$748$$$755$$$O	different$$$756$$$765$$$O	genes$$$766$$$771$$$O	involved$$$772$$$780$$$O	in$$$781$$$783$$$O	response$$$784$$$792$$$O	to$$$793$$$795$$$O	treatment$$$796$$$805$$$O	with$$$806$$$810$$$O	texaphyrins$$$811$$$822$$$I	and$$$823$$$826$$$O	zinc$$$827$$$831$$$I	prior$$$832$$$837$$$O	to$$$838$$$840$$$O	and/or$$$841$$$847$$$O	after$$$848$$$853$$$O	treatment$$$854$$$863$$$O	as$$$864$$$866$$$O	predictors$$$867$$$877$$$O	for$$$878$$$881$$$O	treatment$$$882$$$891$$$O	efficacy.$$$892$$$901$$$O
US20090041751
Sepsis$$$0$$$6$$$O	Prevention$$$7$$$17$$$O	Through$$$18$$$25$$$O	Adenosine$$$26$$$35$$$I	Receptor$$$36$$$44$$$O	Modulation$$$45$$$55$$$O
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	sepsis$$$21$$$27$$$O	or$$$28$$$30$$$O	septic$$$31$$$37$$$O	shock$$$38$$$43$$$O	in$$$44$$$46$$$O	a$$$47$$$48$$$O	patient$$$49$$$56$$$O	comprising$$$57$$$67$$$O	administering$$$68$$$81$$$O	to$$$82$$$84$$$O	said$$$85$$$89$$$O	patient$$$90$$$97$$$O	a$$$98$$$99$$$O	therapeutically$$$100$$$115$$$O	effective$$$116$$$125$$$O	amount$$$126$$$132$$$O	of$$$133$$$135$$$O	a$$$136$$$137$$$O	composition$$$138$$$149$$$O	containing$$$150$$$160$$$O	an$$$161$$$163$$$O	adenosine$$$164$$$173$$$I	A2a$$$174$$$177$$$O	receptor$$$178$$$186$$$O	antagonist.$$$187$$$198$$$O
CN102976974A
Phenyl$$$0$$$6$$$I	benzyl$$$7$$$13$$$I	propionyl-N-methyloxyxamic$$$14$$$40$$$I	urease$$$41$$$47$$$O	inhibitor$$$48$$$57$$$O	and$$$58$$$61$$$O	synthesis$$$62$$$71$$$O	and$$$72$$$75$$$O	use$$$76$$$79$$$O	thereof$$$80$$$87$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	phenyl$$$26$$$32$$$I	benzyl$$$33$$$39$$$I	propionyl-N-methyloxyxamic$$$40$$$66$$$I	compound$$$67$$$75$$$O	of$$$76$$$78$$$O	which$$$79$$$84$$$O	the$$$85$$$88$$$O	structural$$$89$$$99$$$O	general$$$100$$$107$$$O	formula$$$108$$$115$$$O	is$$$116$$$118$$$O	figured$$$119$$$126$$$O	as$$$127$$$129$$$O	follows.$$$130$$$138$$$O	The$$$139$$$142$$$O	compound$$$143$$$151$$$O	has$$$152$$$155$$$O	a$$$156$$$157$$$O	good$$$158$$$162$$$O	inhibition$$$163$$$173$$$O	effect$$$174$$$180$$$O	on$$$181$$$183$$$O	urease,$$$184$$$191$$$O	and$$$192$$$195$$$O	can$$$196$$$199$$$O	be$$$200$$$202$$$O	used$$$203$$$207$$$O	for$$$208$$$211$$$O	preparing$$$212$$$221$$$O	a$$$222$$$223$$$O	medicament,$$$224$$$235$$$O	such$$$236$$$240$$$O	as$$$241$$$243$$$O	an$$$244$$$246$$$O	anti-gastritis$$$247$$$261$$$O	medicament,$$$262$$$273$$$O	an$$$274$$$276$$$O	anti-gastric$$$277$$$289$$$O	ulcer$$$290$$$295$$$O	medicament$$$296$$$306$$$O	and$$$307$$$310$$$O	an$$$311$$$313$$$O	anti-lithangiuria$$$314$$$331$$$O	medicament.$$$332$$$343$$$O	The$$$344$$$347$$$O	invention$$$348$$$357$$$O	further$$$358$$$365$$$O	discloses$$$366$$$375$$$O	a$$$376$$$377$$$O	method$$$378$$$384$$$O	for$$$385$$$388$$$O	preparing$$$389$$$398$$$O	the$$$399$$$402$$$O	compound.$$$403$$$412$$$O
US20090170197
Nucleic$$$0$$$7$$$O	Acid-Mediated$$$8$$$21$$$O	Treatment$$$22$$$31$$$O	of$$$32$$$34$$$O	Diseases$$$35$$$43$$$O	or$$$44$$$46$$$O	Conditions$$$47$$$57$$$O	Related$$$58$$$65$$$O	to$$$66$$$68$$$O	Levels$$$69$$$75$$$O	of$$$76$$$78$$$O	Vascular$$$79$$$87$$$O	Endothelial$$$88$$$99$$$O	Growth$$$100$$$106$$$O	Factor$$$107$$$113$$$O	Receptor$$$114$$$122$$$O	(VEGF-R)$$$123$$$131$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	nucleic$$$33$$$40$$$O	acid$$$41$$$45$$$O	molecules$$$46$$$55$$$O	such$$$56$$$60$$$O	as$$$61$$$63$$$O	ribozymes,$$$64$$$74$$$O	DNAzymes,$$$75$$$84$$$O	short$$$85$$$90$$$O	interfering$$$91$$$102$$$O	RNA$$$103$$$106$$$O	(siRNA),$$$107$$$115$$$O	short$$$116$$$121$$$O	interfering$$$122$$$133$$$O	nucleic$$$134$$$141$$$O	acid$$$142$$$146$$$O	(siNA),$$$147$$$154$$$O	and$$$155$$$158$$$O	antisense$$$159$$$168$$$O	which$$$169$$$174$$$O	modulate$$$175$$$183$$$O	the$$$184$$$187$$$O	synthesis,$$$188$$$198$$$O	expression$$$199$$$209$$$O	and/or$$$210$$$216$$$O	stability$$$217$$$226$$$O	of$$$227$$$229$$$O	an$$$230$$$232$$$O	mRNA$$$233$$$237$$$O	encoding$$$238$$$246$$$O	one$$$247$$$250$$$O	or$$$251$$$253$$$O	more$$$254$$$258$$$O	receptors$$$259$$$268$$$O	of$$$269$$$271$$$O	vascular$$$272$$$280$$$O	endothelial$$$281$$$292$$$O	growth$$$293$$$299$$$O	factor,$$$300$$$307$$$O	such$$$308$$$312$$$O	as$$$313$$$315$$$O	flt-1$$$316$$$321$$$O	(VEGFR1)$$$322$$$330$$$O	and/or$$$331$$$337$$$O	KDR$$$338$$$341$$$O	(VEGFR2).$$$342$$$351$$$O	Nucleic$$$352$$$359$$$O	acid$$$360$$$364$$$O	molecules$$$365$$$374$$$O	and$$$375$$$378$$$O	methods$$$379$$$386$$$O	for$$$387$$$390$$$O	the$$$391$$$394$$$O	inhibition$$$395$$$405$$$O	of$$$406$$$408$$$O	angiogenesis$$$409$$$421$$$O	and$$$422$$$425$$$O	treatment$$$426$$$435$$$O	of$$$436$$$438$$$O	cancer$$$439$$$445$$$O	and$$$446$$$449$$$O	other$$$450$$$455$$$O	conditions$$$456$$$466$$$O	associated$$$467$$$477$$$O	with$$$478$$$482$$$O	VEGF-R$$$483$$$489$$$O	are$$$490$$$493$$$O	provided,$$$494$$$503$$$O	optionally$$$504$$$514$$$O	in$$$515$$$517$$$O	conjunction$$$518$$$529$$$O	with$$$530$$$534$$$O	other$$$535$$$540$$$O	therapeutic$$$541$$$552$$$O	agents$$$553$$$559$$$O	such$$$560$$$564$$$O	as$$$565$$$567$$$O	interferons.$$$568$$$580$$$O
CN101036654B
Stable$$$0$$$6$$$O	cefoperazone$$$7$$$19$$$I	sulbactam$$$20$$$29$$$I	medicine$$$30$$$38$$$O	compound$$$39$$$47$$$O	preparation$$$48$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	stable$$$26$$$32$$$O	compound$$$33$$$41$$$O	preparation$$$42$$$53$$$O	of$$$54$$$56$$$O	cefoperazone-sulbactam$$$57$$$79$$$I	drug,$$$80$$$85$$$O	which$$$86$$$91$$$O	is$$$92$$$94$$$O	comprised$$$95$$$104$$$O	by$$$105$$$107$$$O	cefoperazone$$$108$$$120$$$I	acid,$$$121$$$126$$$I	sulbactam$$$127$$$136$$$I	and$$$137$$$140$$$O	latent$$$141$$$147$$$O	solvent,$$$148$$$156$$$O	which$$$157$$$162$$$O	weight$$$163$$$169$$$O	ratio$$$170$$$175$$$O	is$$$176$$$178$$$O	8~1:1:6~0.06.$$$179$$$192$$$O	The$$$193$$$196$$$O	latent$$$197$$$203$$$O	solvent$$$204$$$211$$$O	is$$$212$$$214$$$O	preferred$$$215$$$224$$$O	selected$$$225$$$233$$$O	from$$$234$$$238$$$O	sodium$$$239$$$245$$$I	carbonate$$$246$$$255$$$I	and$$$256$$$259$$$O	sodium$$$260$$$266$$$I	bicarbonate.$$$267$$$279$$$I	Related$$$280$$$287$$$O	substances$$$288$$$298$$$O	of$$$299$$$301$$$O	the$$$302$$$305$$$O	compound$$$306$$$314$$$O	preparation$$$315$$$326$$$O	in$$$327$$$329$$$O	the$$$330$$$333$$$O	invention$$$334$$$343$$$O	are$$$344$$$347$$$O	lower$$$348$$$353$$$O	than$$$354$$$358$$$O	standard$$$359$$$367$$$O	of$$$368$$$370$$$O	Chinese$$$371$$$378$$$O	pharmacopoeia$$$379$$$392$$$O	(2005$$$393$$$398$$$O	edition)$$$399$$$407$$$O	in$$$408$$$410$$$O	influencing$$$411$$$422$$$O	factor$$$423$$$429$$$O	and$$$430$$$433$$$O	accelerated$$$434$$$445$$$O	test$$$446$$$450$$$O	in$$$451$$$453$$$O	40$$$454$$$456$$$O	DEG$$$457$$$460$$$O	C,$$$461$$$463$$$O	labelled$$$464$$$472$$$O	content$$$473$$$480$$$O	accords$$$481$$$488$$$O	with$$$489$$$493$$$O	the$$$494$$$497$$$O	standard$$$498$$$506$$$O	of$$$507$$$509$$$O	the$$$510$$$513$$$O	pharmacopoeia$$$514$$$527$$$O	and$$$528$$$531$$$O	changes$$$532$$$539$$$O	very$$$540$$$544$$$O	little$$$545$$$551$$$O	in$$$552$$$554$$$O	the$$$555$$$558$$$O	experiment,$$$559$$$570$$$O	and$$$571$$$574$$$O	the$$$575$$$578$$$O	product$$$579$$$586$$$O	quality$$$587$$$594$$$O	is$$$595$$$597$$$O	more$$$598$$$602$$$O	stable$$$603$$$609$$$O	than$$$610$$$614$$$O	cefoperazone$$$615$$$627$$$I	sodium$$$628$$$634$$$I	and$$$635$$$638$$$O	sulbac$$$639$$$645$$$O	during$$$646$$$652$$$O	period$$$653$$$659$$$O	of$$$660$$$662$$$O	validity.$$$663$$$672$$$O
CN101219100A
Medicine$$$0$$$8$$$O	film$$$9$$$13$$$O	for$$$14$$$17$$$O	eyes$$$18$$$22$$$O	and$$$23$$$26$$$O	production$$$27$$$37$$$O	method$$$38$$$44$$$O	thereof$$$45$$$52$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pilocarpine$$$27$$$38$$$I	nitrate$$$39$$$46$$$I	emulsion$$$47$$$55$$$O	for$$$56$$$59$$$O	eye$$$60$$$63$$$O	use,$$$64$$$68$$$O	constituents$$$69$$$81$$$O	and$$$82$$$85$$$O	respective$$$86$$$96$$$O	weight$$$97$$$103$$$O	proportion$$$104$$$114$$$O	of$$$115$$$117$$$O	which$$$118$$$123$$$O	are$$$124$$$127$$$O	as$$$128$$$130$$$O	follows:$$$131$$$139$$$O	pilocarpine$$$140$$$151$$$I	nitrate:$$$152$$$160$$$I	sodium$$$161$$$167$$$I	hyaluronate$$$168$$$179$$$I	:$$$180$$$181$$$O	edetate$$$182$$$189$$$I	disodium:$$$190$$$199$$$I	sodium$$$200$$$206$$$I	chloride:$$$207$$$216$$$I	ethylparaben$$$217$$$229$$$I	is$$$230$$$232$$$O	equal$$$233$$$238$$$O	to$$$239$$$241$$$O	1-8$$$242$$$245$$$O	:$$$246$$$247$$$O	8.0$$$248$$$251$$$O	:$$$252$$$253$$$O	0.1$$$254$$$257$$$O	:$$$258$$$259$$$O	1.3$$$260$$$263$$$O	:$$$264$$$265$$$O	0.1;$$$266$$$270$$$O	the$$$271$$$274$$$O	preparation$$$275$$$286$$$O	method$$$287$$$293$$$O	of$$$294$$$296$$$O	the$$$297$$$300$$$O	emulsion$$$301$$$309$$$O	is$$$310$$$312$$$O	that:$$$313$$$318$$$O	1.pilocarpine$$$319$$$332$$$I	nitrate$$$333$$$340$$$I	is$$$341$$$343$$$O	mixed$$$344$$$349$$$O	with$$$350$$$354$$$O	a$$$355$$$356$$$O	proper$$$357$$$363$$$O	amount$$$364$$$370$$$O	of$$$371$$$373$$$O	water$$$374$$$379$$$O	for$$$380$$$383$$$O	injection$$$384$$$393$$$O	under$$$394$$$399$$$O	acidic$$$400$$$406$$$O	condition$$$407$$$416$$$O	(pH$$$417$$$420$$$O	value$$$421$$$426$$$O	is$$$427$$$429$$$O	equal$$$430$$$435$$$O	to$$$436$$$438$$$O	5.5-6.5),$$$439$$$448$$$O	sodium$$$449$$$455$$$I	chloride,$$$456$$$465$$$I	ethylparaben$$$466$$$478$$$I	and$$$479$$$482$$$O	edetate$$$483$$$490$$$I	disodium,$$$491$$$500$$$I	heated$$$501$$$507$$$O	and$$$508$$$511$$$O	dissolved$$$512$$$521$$$O	at$$$522$$$524$$$O	the$$$525$$$528$$$O	temperature$$$529$$$540$$$O	of$$$541$$$543$$$O	60-90$$$544$$$549$$$O	DEG$$$550$$$553$$$O	C;$$$554$$$556$$$O	2.$$$557$$$559$$$O	acquired$$$560$$$568$$$O	material$$$569$$$577$$$O	is$$$578$$$580$$$O	cooled$$$581$$$587$$$O	to$$$588$$$590$$$O	room$$$591$$$595$$$O	temperature,$$$596$$$608$$$O	added$$$609$$$614$$$O	with$$$615$$$619$$$O	sodium$$$620$$$626$$$I	hyaluronate$$$627$$$638$$$I	and$$$639$$$642$$$O	stirred$$$643$$$650$$$O	fully$$$651$$$656$$$O	till$$$657$$$661$$$O	the$$$662$$$665$$$O	material$$$666$$$674$$$O	turns$$$675$$$680$$$O	transparent;$$$681$$$693$$$O	3.$$$694$$$696$$$O	acquired$$$697$$$705$$$O	material$$$706$$$714$$$O	is$$$715$$$717$$$O	sterilized$$$718$$$728$$$O	with$$$729$$$733$$$O	100$$$734$$$737$$$O	percent$$$738$$$745$$$O	flow-steam,$$$746$$$757$$$O	scored,$$$758$$$765$$$O	mesh$$$766$$$770$$$O	divided$$$771$$$778$$$O	and$$$779$$$782$$$O	put$$$783$$$786$$$O	into$$$787$$$791$$$O	a$$$792$$$793$$$O	refrigerator$$$794$$$806$$$O	to$$$807$$$809$$$O	be$$$810$$$812$$$O	frozen$$$813$$$819$$$O	and$$$820$$$823$$$O	dried;$$$824$$$830$$$O	after$$$831$$$836$$$O	membrane$$$837$$$845$$$O	is$$$846$$$848$$$O	formed,$$$849$$$856$$$O	the$$$857$$$860$$$O	material$$$861$$$869$$$O	is$$$870$$$872$$$O	stripped$$$873$$$881$$$O	and$$$882$$$885$$$O	the$$$886$$$889$$$O	emulsion$$$890$$$898$$$O	is$$$899$$$901$$$O	acquired.$$$902$$$911$$$O	The$$$912$$$915$$$O	emulsion$$$916$$$924$$$O	of$$$925$$$927$$$O	the$$$928$$$931$$$O	invention$$$932$$$941$$$O	is$$$942$$$944$$$O	planted$$$945$$$952$$$O	into$$$953$$$957$$$O	conjunctival$$$958$$$970$$$O	sac$$$971$$$974$$$O	in$$$975$$$977$$$O	external$$$978$$$986$$$O	lower$$$987$$$992$$$O	border$$$993$$$999$$$O	of$$$1000$$$1002$$$O	eyes,$$$1003$$$1008$$$O	and$$$1009$$$1012$$$O	medicine$$$1013$$$1021$$$O	is$$$1022$$$1024$$$O	released$$$1025$$$1033$$$O	in$$$1034$$$1036$$$O	the$$$1037$$$1040$$$O	pilocarpine$$$1041$$$1052$$$I	nitrate$$$1053$$$1060$$$I	and$$$1061$$$1064$$$O	retention$$$1065$$$1074$$$O	time$$$1075$$$1079$$$O	of$$$1080$$$1082$$$O	pilocarpine$$$1083$$$1094$$$I	nitrate$$$1095$$$1102$$$I	is$$$1103$$$1105$$$O	prolonged.$$$1106$$$1116$$$O
CN101117340A
Ruthenium-anthraquinone$$$0$$$23$$$I	conjugates,$$$24$$$35$$$O	preparation$$$36$$$47$$$O	method$$$48$$$54$$$O	thereof$$$55$$$62$$$O	and$$$63$$$66$$$O	application$$$67$$$78$$$O	for$$$79$$$82$$$O	optical$$$83$$$90$$$O	power$$$91$$$96$$$O	therapeutic$$$97$$$108$$$O	photosensitizer$$$109$$$124$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	ruthenium-anthraquinone$$$26$$$49$$$I	conjugate,$$$50$$$60$$$O	the$$$61$$$64$$$O	preparation$$$65$$$76$$$O	process$$$77$$$84$$$O	thereof$$$85$$$92$$$O	and$$$93$$$96$$$O	the$$$97$$$100$$$O	application$$$101$$$112$$$O	as$$$113$$$115$$$O	a$$$116$$$117$$$O	photo-dynamic$$$118$$$131$$$O	therapy$$$132$$$139$$$O	photosensitizer.$$$140$$$156$$$O	The$$$157$$$160$$$O	general$$$161$$$168$$$O	formula$$$169$$$176$$$O	of$$$177$$$179$$$O	the$$$180$$$183$$$O	ruthenium-anthraquinone$$$184$$$207$$$I	conjugate$$$208$$$217$$$O	of$$$218$$$220$$$O	the$$$221$$$224$$$O	invention$$$225$$$234$$$O	is$$$235$$$237$$$O	[Ru(L)2HAIP].(PF6)2,$$$238$$$258$$$I	the$$$259$$$262$$$O	general$$$263$$$270$$$O	formula$$$271$$$278$$$O	of$$$279$$$281$$$O	the$$$282$$$285$$$O	HAIP$$$286$$$290$$$I	is$$$291$$$293$$$O	1,8-$$$294$$$298$$$I	dihydroxy$$$299$$$308$$$I	-9,10-$$$309$$$315$$$I	anthraquinoneimidazole$$$316$$$338$$$I	[4,5-f][1,10]$$$339$$$352$$$I	phenanthroline,$$$353$$$368$$$I	the$$$369$$$372$$$O	general$$$373$$$380$$$O	of$$$381$$$383$$$O	the$$$384$$$387$$$O	L$$$388$$$389$$$O	is$$$390$$$392$$$O	bpy$$$393$$$396$$$I	or$$$397$$$399$$$O	phen.$$$400$$$405$$$I	The$$$406$$$409$$$O	preparation$$$410$$$421$$$O	process$$$422$$$429$$$O	for$$$430$$$433$$$O	the$$$434$$$437$$$O	ruthenium-anthraquinone$$$438$$$461$$$I	conjugate$$$462$$$471$$$O	comprises$$$472$$$481$$$O	the$$$482$$$485$$$O	following$$$486$$$495$$$O	procedures:$$$496$$$507$$$O	1.$$$508$$$510$$$O	the$$$511$$$514$$$O	synthesis$$$515$$$524$$$O	of$$$525$$$527$$$O	the$$$528$$$531$$$O	HAIP:$$$532$$$537$$$I	1,8-$$$538$$$542$$$I	dihydroxy$$$543$$$552$$$I	-9,10-$$$553$$$559$$$I	anthraquinone-3-aldehyde$$$560$$$584$$$I	is$$$585$$$587$$$O	reacted$$$588$$$595$$$O	with$$$596$$$600$$$O	the$$$601$$$604$$$O	phenanthroline5,6-diketone$$$605$$$631$$$I	to$$$632$$$634$$$O	produce$$$635$$$642$$$O	the$$$643$$$646$$$O	HAIP;$$$647$$$652$$$I	2.$$$653$$$655$$$O	Ru(L)2Cl2$$$656$$$665$$$I	is$$$666$$$668$$$O	reacted$$$669$$$676$$$O	with$$$677$$$681$$$O	HAIP$$$682$$$686$$$I	and$$$687$$$690$$$O	NH4PF6$$$691$$$697$$$I	to$$$698$$$700$$$O	produce$$$701$$$708$$$O	the$$$709$$$712$$$O	[Ru(L)2HAIP].(PF6)2.$$$713$$$733$$$I	The$$$734$$$737$$$O	invention$$$738$$$747$$$O	takes$$$748$$$753$$$O	the$$$754$$$757$$$O	aloe-emodin$$$758$$$769$$$I	as$$$770$$$772$$$O	the$$$773$$$776$$$O	raw$$$777$$$780$$$O	material$$$781$$$789$$$O	and$$$790$$$793$$$O	the$$$794$$$797$$$O	ruthenium$$$798$$$807$$$I	polypyridyl$$$808$$$819$$$I	complex$$$820$$$827$$$O	has$$$828$$$831$$$O	single$$$832$$$838$$$O	chemical$$$839$$$847$$$O	composition;$$$848$$$860$$$O	the$$$861$$$864$$$O	synthesis$$$865$$$874$$$O	route$$$875$$$880$$$O	is$$$881$$$883$$$O	simple$$$884$$$890$$$O	and$$$891$$$894$$$O	the$$$895$$$898$$$O	yields$$$899$$$905$$$O	are$$$906$$$909$$$O	higher;$$$910$$$917$$$O	during$$$918$$$924$$$O	the$$$925$$$928$$$O	experiment,$$$929$$$940$$$O	the$$$941$$$944$$$O	compound$$$945$$$953$$$O	shows$$$954$$$959$$$O	the$$$960$$$963$$$O	light$$$964$$$969$$$O	suppression$$$970$$$981$$$O	to$$$982$$$984$$$O	the$$$985$$$988$$$O	growth$$$989$$$995$$$O	of$$$996$$$998$$$O	cancer$$$999$$$1005$$$O	cells.$$$1006$$$1012$$$O
CN102850344A
Medicinal$$$0$$$9$$$O	application$$$10$$$21$$$O	of$$$22$$$24$$$O	penehyclidine$$$25$$$38$$$I	optical$$$39$$$46$$$O	isomer$$$47$$$53$$$O	derivative$$$54$$$64$$$O	in$$$65$$$67$$$O	anti-tumor$$$68$$$78$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	penehyclidine$$$25$$$38$$$I	optical$$$39$$$46$$$O	isomer$$$47$$$53$$$O	derivative$$$54$$$64$$$O	with$$$65$$$69$$$O	anti-tumor$$$70$$$80$$$O	effect,$$$81$$$88$$$O	its$$$89$$$92$$$O	nontoxic$$$93$$$101$$$O	pharmaceutically-available$$$102$$$128$$$O	salts,$$$129$$$135$$$O	pharmaceutical$$$136$$$150$$$O	composition$$$151$$$162$$$O	containing$$$163$$$173$$$O	these$$$174$$$179$$$O	compounds$$$180$$$189$$$O	as$$$190$$$192$$$O	active$$$193$$$199$$$O	components,$$$200$$$211$$$O	and$$$212$$$215$$$O	its$$$216$$$219$$$O	application$$$220$$$231$$$O	of$$$232$$$234$$$O	anti-tumor$$$235$$$245$$$O	effect.$$$246$$$253$$$O
CN102178691B
Starch$$$0$$$6$$$O	stypticum$$$7$$$16$$$O	and$$$17$$$20$$$O	preparation$$$21$$$32$$$O	method$$$33$$$39$$$O	thereof$$$40$$$47$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	starch$$$26$$$32$$$O	stypticum$$$33$$$42$$$O	and$$$43$$$46$$$O	a$$$47$$$48$$$O	preparation$$$49$$$60$$$O	method$$$61$$$67$$$O	thereof,$$$68$$$76$$$O	belonging$$$77$$$86$$$O	to$$$87$$$89$$$O	the$$$90$$$93$$$O	field$$$94$$$99$$$O	of$$$100$$$102$$$O	medical$$$103$$$110$$$O	preparations.$$$111$$$124$$$O	The$$$125$$$128$$$O	preparation$$$129$$$140$$$O	method$$$141$$$147$$$O	comprises$$$148$$$157$$$O	the$$$158$$$161$$$O	following$$$162$$$171$$$O	steps:$$$172$$$178$$$O	refining$$$179$$$187$$$O	waxy$$$188$$$192$$$O	maize$$$193$$$198$$$O	starch$$$199$$$205$$$O	to$$$206$$$208$$$O	4,000$$$209$$$214$$$O	to$$$215$$$217$$$O	10,000$$$218$$$224$$$O	meshes;$$$225$$$232$$$O	centrifugally$$$233$$$246$$$O	filtering$$$247$$$256$$$O	after$$$257$$$262$$$O	crosslinking,$$$263$$$276$$$O	acidolysis$$$277$$$287$$$O	and$$$288$$$291$$$O	enzymolysis$$$292$$$303$$$O	are$$$304$$$307$$$O	completed;$$$308$$$318$$$O	cleaning$$$319$$$327$$$O	with$$$328$$$332$$$O	distilled$$$333$$$342$$$O	water;$$$343$$$349$$$O	blasting$$$350$$$358$$$O	and$$$359$$$362$$$O	drying$$$363$$$369$$$O	at$$$370$$$372$$$O	constant$$$373$$$381$$$O	temperature$$$382$$$393$$$O	untilthe$$$394$$$402$$$O	weight$$$403$$$409$$$O	is$$$410$$$412$$$O	constant;$$$413$$$422$$$O	crushing,$$$423$$$432$$$O	and$$$433$$$436$$$O	screening$$$437$$$446$$$O	through$$$447$$$454$$$O	a$$$455$$$456$$$O	200-mesh$$$457$$$465$$$O	screen;$$$466$$$473$$$O	radiating$$$474$$$483$$$O	by$$$484$$$486$$$O	Co60$$$487$$$491$$$O	to$$$492$$$494$$$O	disinfect$$$495$$$504$$$O	to$$$505$$$507$$$O	prepare$$$508$$$515$$$O	the$$$516$$$519$$$O	starch$$$520$$$526$$$O	stypticum.$$$527$$$537$$$O	The$$$538$$$541$$$O	water$$$542$$$547$$$O	absorption$$$548$$$558$$$O	rate$$$559$$$563$$$O	of$$$564$$$566$$$O	the$$$567$$$570$$$O	starch$$$571$$$577$$$O	stypticum$$$578$$$587$$$O	prepared$$$588$$$596$$$O	by$$$597$$$599$$$O	adopting$$$600$$$608$$$O	the$$$609$$$612$$$O	method$$$613$$$619$$$O	is$$$620$$$622$$$O	2$$$623$$$624$$$O	to$$$625$$$627$$$O	3$$$628$$$629$$$O	times$$$630$$$635$$$O	that$$$636$$$640$$$O	of$$$641$$$643$$$O	the$$$644$$$647$$$O	conventional$$$648$$$660$$$O	styptic$$$661$$$668$$$O	materials,$$$669$$$679$$$O	the$$$680$$$683$$$O	starch$$$684$$$690$$$O	stypticum$$$691$$$700$$$O	can$$$701$$$704$$$O	quickly$$$705$$$712$$$O	stop$$$713$$$717$$$O	bleeding$$$718$$$726$$$O	in$$$727$$$729$$$O	actual$$$730$$$736$$$O	application,$$$737$$$749$$$O	has$$$750$$$753$$$O	quick$$$754$$$759$$$O	styptic$$$760$$$767$$$O	function$$$768$$$776$$$O	in$$$777$$$779$$$O	great$$$780$$$785$$$O	vessel$$$786$$$792$$$O	hemorrhage,$$$793$$$804$$$O	even$$$805$$$809$$$O	massive$$$810$$$817$$$O	bleeding$$$818$$$826$$$O	wound$$$827$$$832$$$O	surface,$$$833$$$841$$$O	and$$$842$$$845$$$O	can$$$846$$$849$$$O	be$$$850$$$852$$$O	widely$$$853$$$859$$$O	applied$$$860$$$867$$$O	to$$$868$$$870$$$O	surgeries$$$871$$$880$$$O	of$$$881$$$883$$$O	cardiothoracic$$$884$$$898$$$O	and$$$899$$$902$$$O	vascular$$$903$$$911$$$O	surgery$$$912$$$919$$$O	department,$$$920$$$931$$$O	hepatobiliary$$$932$$$945$$$O	surgery$$$946$$$953$$$O	department,$$$954$$$965$$$O	orthopedics$$$966$$$977$$$O	department,$$$978$$$989$$$O	general$$$990$$$997$$$O	surgery$$$998$$$1005$$$O	department,$$$1006$$$1017$$$O	obstetrics$$$1018$$$1028$$$O	and$$$1029$$$1032$$$O	gynecology$$$1033$$$1043$$$O	department,$$$1044$$$1055$$$O	urology$$$1056$$$1063$$$O	surgery$$$1064$$$1071$$$O	department$$$1072$$$1082$$$O	and$$$1083$$$1086$$$O	ear-nose-throat$$$1087$$$1102$$$O	department$$$1103$$$1113$$$O	and$$$1114$$$1117$$$O	the$$$1118$$$1121$$$O	like.$$$1122$$$1127$$$O
WO2010028542A1
Pleuromutilin$$$0$$$13$$$I	phosphate,$$$14$$$24$$$I	its$$$25$$$28$$$O	pharmaceutical$$$29$$$43$$$O	composition,$$$44$$$56$$$O	preparation$$$57$$$68$$$O	method$$$69$$$75$$$O	and$$$76$$$79$$$O	uses$$$80$$$84$$$O	thereof$$$85$$$92$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	in$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	pharmaceutical$$$38$$$52$$$O	chemistry$$$53$$$62$$$O	provides$$$63$$$71$$$O	a$$$72$$$73$$$O	type$$$74$$$78$$$O	of$$$79$$$81$$$O	pleuromutilin$$$82$$$95$$$I	phosphate$$$96$$$105$$$I	according$$$106$$$115$$$O	to$$$116$$$118$$$O	formula$$$119$$$126$$$O	(I),$$$127$$$131$$$O	its$$$132$$$135$$$O	pharmaceutical$$$136$$$150$$$O	composition,$$$151$$$163$$$O	its$$$164$$$167$$$O	preparation$$$168$$$179$$$O	method$$$180$$$186$$$O	and$$$187$$$190$$$O	uses$$$191$$$195$$$O	thereof.$$$196$$$204$$$O	The$$$205$$$208$$$O	pleuromutilin$$$209$$$222$$$I	phosphate$$$223$$$232$$$I	of$$$233$$$235$$$O	the$$$236$$$239$$$O	present$$$240$$$247$$$O	invention$$$248$$$257$$$O	has$$$258$$$261$$$O	good$$$262$$$266$$$O	water-solubility,$$$267$$$284$$$O	releases$$$285$$$293$$$O	the$$$294$$$297$$$O	parent$$$298$$$304$$$O	drug$$$305$$$309$$$O	quickly$$$310$$$317$$$O	after$$$318$$$323$$$O	intravenous$$$324$$$335$$$O	injection,$$$336$$$346$$$O	can$$$347$$$350$$$O	achieve$$$351$$$358$$$O	a$$$359$$$360$$$O	very$$$361$$$365$$$O	high$$$366$$$370$$$O	plasma$$$371$$$377$$$O	concentration,$$$378$$$392$$$O	and$$$393$$$396$$$O	has$$$397$$$400$$$O	excellent$$$401$$$410$$$O	anti-infectious$$$411$$$426$$$O	activity.$$$427$$$436$$$O	The$$$437$$$440$$$O	medicine$$$441$$$449$$$O	can$$$450$$$453$$$O	be$$$454$$$456$$$O	used$$$457$$$461$$$O	for$$$462$$$465$$$O	the$$$466$$$469$$$O	treatment$$$470$$$479$$$O	of$$$480$$$482$$$O	infectious$$$483$$$493$$$O	diseases,$$$494$$$503$$$O	especially$$$504$$$514$$$O	infectious$$$515$$$525$$$O	diseases$$$526$$$534$$$O	caused$$$535$$$541$$$O	by$$$542$$$544$$$O	multidrug-resistant$$$545$$$564$$$O	bacteria.$$$565$$$574$$$O
CN102688257A
Liquid$$$0$$$6$$$O	molecular$$$7$$$16$$$O	iodine$$$17$$$23$$$I	disinfectant,$$$24$$$37$$$O	preparation$$$38$$$49$$$O	method$$$50$$$56$$$O	and$$$57$$$60$$$O	used$$$61$$$65$$$O	container$$$66$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	liquid$$$26$$$32$$$O	molecular$$$33$$$42$$$O	iodine$$$43$$$49$$$I	disinfectant,$$$50$$$63$$$O	which$$$64$$$69$$$O	comprises$$$70$$$79$$$O	an$$$80$$$82$$$O	iodide,$$$83$$$90$$$I	an$$$91$$$93$$$O	oxidant$$$94$$$101$$$O	and$$$102$$$105$$$O	an$$$106$$$108$$$O	acidity$$$109$$$116$$$O	pH$$$117$$$119$$$O	regulator,$$$120$$$130$$$O	wherein$$$131$$$138$$$O	the$$$139$$$142$$$O	oxidant$$$143$$$150$$$O	can$$$151$$$154$$$O	be$$$155$$$157$$$O	used$$$158$$$162$$$O	for$$$163$$$166$$$O	oxidizing$$$167$$$176$$$O	the$$$177$$$180$$$O	iodide$$$181$$$187$$$I	to$$$188$$$190$$$O	generate$$$191$$$199$$$O	iodine$$$200$$$206$$$I	molecules,$$$207$$$217$$$O	and$$$218$$$221$$$O	the$$$222$$$225$$$O	acidity$$$226$$$233$$$O	pH$$$234$$$236$$$O	regulator$$$237$$$246$$$O	is$$$247$$$249$$$O	used$$$250$$$254$$$O	for$$$255$$$258$$$O	regulating$$$259$$$269$$$O	a$$$270$$$271$$$O	mixture$$$272$$$279$$$O	of$$$280$$$282$$$O	the$$$283$$$286$$$O	iodide$$$287$$$293$$$I	and$$$294$$$297$$$O	the$$$298$$$301$$$O	oxidant$$$302$$$309$$$O	to$$$310$$$312$$$O	be$$$313$$$315$$$O	acid.$$$316$$$321$$$O	The$$$322$$$325$$$O	disinfectant$$$326$$$338$$$O	consists$$$339$$$347$$$O	of$$$348$$$350$$$O	a$$$351$$$352$$$O	composition$$$353$$$364$$$O	of$$$365$$$367$$$O	a$$$368$$$369$$$O	preparation$$$370$$$381$$$O	1$$$382$$$383$$$O	containing$$$384$$$394$$$O	the$$$395$$$398$$$O	iodide$$$399$$$405$$$I	and$$$406$$$409$$$O	the$$$410$$$413$$$O	oxidant$$$414$$$421$$$O	and$$$422$$$425$$$O	a$$$426$$$427$$$O	preparation$$$428$$$439$$$O	2$$$440$$$441$$$O	containing$$$442$$$452$$$O	the$$$453$$$456$$$O	acidity$$$457$$$464$$$O	pH$$$465$$$467$$$O	regulator;$$$468$$$478$$$O	the$$$479$$$482$$$O	preparation$$$483$$$494$$$O	1$$$495$$$496$$$O	and$$$497$$$500$$$O	the$$$501$$$504$$$O	preparation$$$505$$$516$$$O	2$$$517$$$518$$$O	are$$$519$$$522$$$O	in$$$523$$$525$$$O	a$$$526$$$527$$$O	liquid$$$528$$$534$$$O	state$$$535$$$540$$$O	respectively;$$$541$$$554$$$O	and$$$555$$$558$$$O	the$$$559$$$562$$$O	pH$$$563$$$565$$$O	value$$$566$$$571$$$O	of$$$572$$$574$$$O	the$$$575$$$578$$$O	preparation$$$579$$$590$$$O	I$$$591$$$592$$$O	is$$$593$$$595$$$O	greater$$$596$$$603$$$O	than$$$604$$$608$$$O	6.5.$$$609$$$613$$$O	The$$$614$$$617$$$O	liquid$$$618$$$624$$$O	molecular$$$625$$$634$$$O	iodine$$$635$$$641$$$I	disinfectant$$$642$$$654$$$O	disclosed$$$655$$$664$$$O	by$$$665$$$667$$$O	the$$$668$$$671$$$O	invention$$$672$$$681$$$O	not$$$682$$$685$$$O	only$$$686$$$690$$$O	is$$$691$$$693$$$O	high$$$694$$$698$$$O	in$$$699$$$701$$$O	stability,$$$702$$$712$$$O	can$$$713$$$716$$$O	be$$$717$$$719$$$O	stored$$$720$$$726$$$O	for$$$727$$$730$$$O	a$$$731$$$732$$$O	long$$$733$$$737$$$O	time,$$$738$$$743$$$O	is$$$744$$$746$$$O	light$$$747$$$752$$$O	in$$$753$$$755$$$O	irritation$$$756$$$766$$$O	to$$$767$$$769$$$O	skins,$$$770$$$776$$$O	rapid$$$777$$$782$$$O	in$$$783$$$785$$$O	penetration$$$786$$$797$$$O	and$$$798$$$801$$$O	volatilization,$$$802$$$817$$$O	light$$$818$$$823$$$O	in$$$824$$$826$$$O	coloring$$$827$$$835$$$O	and$$$836$$$839$$$O	obvious$$$840$$$847$$$O	in$$$848$$$850$$$O	sterilizing$$$851$$$862$$$O	effect$$$863$$$869$$$O	and$$$870$$$873$$$O	does$$$874$$$878$$$O	not$$$879$$$882$$$O	need$$$883$$$887$$$O	to$$$888$$$890$$$O	be$$$891$$$893$$$O	de-iodinated$$$894$$$906$$$O	but$$$907$$$910$$$O	also$$$911$$$915$$$O	is$$$916$$$918$$$O	safe$$$919$$$923$$$O	and$$$924$$$927$$$O	convenient$$$928$$$938$$$O	in$$$939$$$941$$$O	use$$$942$$$945$$$O	and$$$946$$$949$$$O	carrying.$$$950$$$959$$$O	The$$$960$$$963$$$O	liquid$$$964$$$970$$$O	molecular$$$971$$$980$$$O	iodine$$$981$$$987$$$I	disinfectant$$$988$$$1000$$$O	disclosed$$$1001$$$1010$$$O	by$$$1011$$$1013$$$O	the$$$1014$$$1017$$$O	invention$$$1018$$$1027$$$O	has$$$1028$$$1031$$$O	a$$$1032$$$1033$$$O	broad-spectrum$$$1034$$$1048$$$O	sterilizing$$$1049$$$1060$$$O	effect$$$1061$$$1067$$$O	and$$$1068$$$1071$$$O	is$$$1072$$$1074$$$O	light$$$1075$$$1080$$$O	in$$$1081$$$1083$$$O	irritation$$$1084$$$1094$$$O	to$$$1095$$$1097$$$O	skin$$$1098$$$1102$$$O	mucosae$$$1103$$$1110$$$O	and$$$1111$$$1114$$$O	can$$$1115$$$1118$$$O	be$$$1119$$$1121$$$O	used$$$1122$$$1126$$$O	for$$$1127$$$1130$$$O	various$$$1131$$$1138$$$O	skin$$$1139$$$1143$$$O	diseases$$$1144$$$1152$$$O	caused$$$1153$$$1159$$$O	by$$$1160$$$1162$$$O	bacteria,$$$1163$$$1172$$$O	fungi$$$1173$$$1178$$$O	and$$$1179$$$1182$$$O	viruses.$$$1183$$$1191$$$O
WO2007040238A1
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	production$$$12$$$22$$$O	of$$$23$$$25$$$O	optically$$$26$$$35$$$O	active$$$36$$$42$$$O	4-hydroxy-1,2,3,4$$$43$$$60$$$I	-tetrahydroquinolines$$$61$$$82$$$I
A$$$0$$$1$$$O	process$$$2$$$9$$$O	for$$$10$$$13$$$O	the$$$14$$$17$$$O	production$$$18$$$28$$$O	of$$$29$$$31$$$O	optically$$$32$$$41$$$O	active$$$42$$$48$$$O	4-hydroxy$$$49$$$58$$$I	-1,2,3,4-tetrahydroquinolines$$$59$$$88$$$I	[I]$$$89$$$92$$$O	which$$$93$$$98$$$O	comprises$$$99$$$108$$$O	treating$$$109$$$117$$$O	a$$$118$$$119$$$O	racemic$$$120$$$127$$$I	mixture$$$128$$$135$$$I	of$$$136$$$138$$$I	a$$$139$$$140$$$I	4-hydroxy-1,2,3,4-tetrahydroquinoline$$$141$$$178$$$I	represented$$$179$$$190$$$O	by$$$191$$$193$$$O	the$$$194$$$197$$$O	general$$$198$$$205$$$O	formula$$$206$$$213$$$O	[I]$$$214$$$217$$$O	with$$$218$$$222$$$O	an$$$223$$$225$$$O	enzyme$$$226$$$232$$$O	having$$$233$$$239$$$O	the$$$240$$$243$$$O	ability$$$244$$$251$$$O	to$$$252$$$254$$$O	acylate$$$255$$$262$$$O	one$$$263$$$266$$$O	antipode$$$267$$$275$$$O	of$$$276$$$278$$$O	the$$$279$$$282$$$O	racemic$$$283$$$290$$$O	mixture$$$291$$$298$$$O	selectively$$$299$$$310$$$O	or$$$311$$$313$$$O	preferentially$$$314$$$328$$$O	in$$$329$$$331$$$O	the$$$332$$$335$$$O	presence$$$336$$$344$$$O	of$$$345$$$347$$$O	an$$$348$$$350$$$O	acyl$$$351$$$355$$$I	donor$$$356$$$361$$$O	and,$$$362$$$366$$$O	if$$$367$$$369$$$O	necessary,$$$370$$$380$$$O	subjecting$$$381$$$391$$$O	the$$$392$$$395$$$O	obtained$$$396$$$404$$$O	product$$$405$$$412$$$O	to$$$413$$$415$$$O	solvolysis:$$$416$$$427$$$O	[I]$$$428$$$431$$$O	wherein$$$432$$$439$$$O	R1$$$440$$$442$$$O	is$$$443$$$445$$$O	hydrogen$$$446$$$454$$$I	or$$$455$$$457$$$O	an$$$458$$$460$$$O	amino-protecting$$$461$$$477$$$I	group.$$$478$$$484$$$O
CN102145172B
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	improving$$$16$$$25$$$O	absorbance$$$26$$$36$$$O	of$$$37$$$39$$$O	aminoglycoside$$$40$$$54$$$I	drug$$$55$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	composition$$$25$$$36$$$O	for$$$37$$$40$$$O	improving$$$41$$$50$$$O	the$$$51$$$54$$$O	absorbance$$$55$$$65$$$O	of$$$66$$$68$$$O	aminoglycoside$$$69$$$83$$$I	drug,$$$84$$$89$$$O	which$$$90$$$95$$$O	has$$$96$$$99$$$O	greatly-improved$$$100$$$116$$$O	absorbance$$$117$$$127$$$O	in$$$128$$$130$$$O	organisms$$$131$$$140$$$O	and$$$141$$$144$$$O	exhibits$$$145$$$153$$$O	effective$$$154$$$163$$$O	pharmacological$$$164$$$179$$$O	action.$$$180$$$187$$$O	The$$$188$$$191$$$O	composition$$$192$$$203$$$O	contains$$$204$$$212$$$O	0.1$$$213$$$216$$$O	to$$$217$$$219$$$O	5%$$$220$$$222$$$O	absorption$$$223$$$233$$$O	enhancer,$$$234$$$243$$$O	which$$$244$$$249$$$O	is$$$250$$$252$$$O	one$$$253$$$256$$$O	or$$$257$$$259$$$O	more$$$260$$$264$$$O	of$$$265$$$267$$$O	medium$$$268$$$274$$$O	chain$$$275$$$280$$$O	sodium$$$281$$$287$$$I	aliphatate$$$288$$$298$$$I	salt$$$299$$$303$$$O	and$$$304$$$307$$$O	cholic$$$308$$$314$$$I	acid$$$315$$$319$$$I	salts;$$$320$$$326$$$O	5$$$327$$$328$$$O	to$$$329$$$331$$$O	20%$$$332$$$335$$$O	of$$$336$$$338$$$O	aminoglycoside$$$339$$$353$$$I	drug,$$$354$$$359$$$O	and$$$360$$$363$$$O	the$$$364$$$367$$$O	balance$$$368$$$375$$$O	of$$$376$$$378$$$O	pharmaceutically$$$379$$$395$$$O	acceptable$$$396$$$406$$$O	auxiliaries.$$$407$$$419$$$O	Oral$$$420$$$424$$$O	administration$$$425$$$439$$$O	of$$$440$$$442$$$O	the$$$443$$$446$$$O	aminoglycoside$$$447$$$461$$$I	drug$$$462$$$466$$$O	results$$$467$$$474$$$O	in$$$475$$$477$$$O	quite$$$478$$$483$$$O	little$$$484$$$490$$$O	absorption$$$491$$$501$$$O	of$$$502$$$504$$$O	the$$$505$$$508$$$O	aminoglycoside$$$509$$$523$$$I	drug,$$$524$$$529$$$O	and$$$530$$$533$$$O	clinical$$$534$$$542$$$O	oral$$$543$$$547$$$O	drug$$$548$$$552$$$O	is$$$553$$$555$$$O	used$$$556$$$560$$$O	only$$$561$$$565$$$O	as$$$566$$$568$$$O	the$$$569$$$572$$$O	drug$$$573$$$577$$$O	for$$$578$$$581$$$O	enteric$$$582$$$589$$$O	infection.$$$590$$$600$$$O	According$$$601$$$610$$$O	to$$$611$$$613$$$O	the$$$614$$$617$$$O	invention,$$$618$$$628$$$O	as$$$629$$$631$$$O	the$$$632$$$635$$$O	absorption$$$636$$$646$$$O	enhancer$$$647$$$655$$$O	is$$$656$$$658$$$O	added,$$$659$$$665$$$O	the$$$666$$$669$$$O	applicable$$$670$$$680$$$O	scope$$$681$$$686$$$O	of$$$687$$$689$$$O	the$$$690$$$693$$$O	aminoglycoside$$$694$$$708$$$I	drug$$$709$$$713$$$O	is$$$714$$$716$$$O	widened,$$$717$$$725$$$O	and$$$726$$$729$$$O	oral$$$730$$$734$$$O	administration$$$735$$$749$$$O	can$$$750$$$753$$$O	reach$$$754$$$759$$$O	the$$$760$$$763$$$O	purpose$$$764$$$771$$$O	of$$$772$$$774$$$O	treating$$$775$$$783$$$O	general$$$784$$$791$$$O	infection.$$$792$$$802$$$O
CN102362880A
Macaranga$$$0$$$9$$$O	tanarius$$$10$$$18$$$O	extract$$$19$$$26$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	macaranga$$$27$$$36$$$O	tanarius$$$37$$$45$$$O	extract,$$$46$$$54$$$O	which$$$55$$$60$$$O	contains$$$61$$$69$$$O	20$$$70$$$72$$$O	to$$$73$$$75$$$O	25$$$76$$$78$$$O	percent$$$79$$$86$$$O	of$$$87$$$89$$$O	deoxypodophyllotoxin.$$$90$$$111$$$I	The$$$112$$$115$$$O	macaranga$$$116$$$125$$$O	tanarius$$$126$$$134$$$O	extract$$$135$$$142$$$O	is$$$143$$$145$$$O	prepared$$$146$$$154$$$O	by$$$155$$$157$$$O	a$$$158$$$159$$$O	method$$$160$$$166$$$O	which$$$167$$$172$$$O	comprises:$$$173$$$183$$$O	crushing$$$184$$$192$$$O	hernandia$$$193$$$202$$$O	sonora$$$203$$$209$$$O	seeds,$$$210$$$216$$$O	adding$$$217$$$223$$$O	the$$$224$$$227$$$O	crushed$$$228$$$235$$$O	material$$$236$$$244$$$O	into$$$245$$$249$$$O	a$$$250$$$251$$$O	CO2$$$252$$$255$$$I	supercritical$$$256$$$269$$$O	extractor,$$$270$$$280$$$O	extracting$$$281$$$291$$$O	for$$$292$$$295$$$O	150$$$296$$$299$$$O	minutes$$$300$$$307$$$O	by$$$308$$$310$$$O	using$$$311$$$316$$$O	ethanol$$$317$$$324$$$I	as$$$325$$$327$$$O	an$$$328$$$330$$$O	entrainer$$$331$$$340$$$O	which$$$341$$$346$$$O	accounts$$$347$$$355$$$O	for$$$356$$$359$$$O	1$$$360$$$361$$$O	percent$$$362$$$369$$$O	of$$$370$$$372$$$O	the$$$373$$$376$$$O	volume$$$377$$$383$$$O	of$$$384$$$386$$$O	the$$$387$$$390$$$O	total$$$391$$$396$$$O	extract$$$397$$$404$$$O	solution$$$405$$$413$$$O	and$$$414$$$417$$$O	under$$$418$$$423$$$O	conditions$$$424$$$434$$$O	of$$$435$$$437$$$O	an$$$438$$$440$$$O	extraction$$$441$$$451$$$O	pressure$$$452$$$460$$$O	of$$$461$$$463$$$O	20MPa,$$$464$$$470$$$O	a$$$471$$$472$$$O	temperature$$$473$$$484$$$O	of$$$485$$$487$$$O	45$$$488$$$490$$$O	DEG$$$491$$$494$$$O	C$$$495$$$496$$$O	and$$$497$$$500$$$O	a$$$501$$$502$$$O	CO2$$$503$$$506$$$I	flow$$$507$$$511$$$O	rate$$$512$$$516$$$O	per$$$517$$$520$$$O	gram$$$521$$$525$$$O	of$$$526$$$528$$$O	raw$$$529$$$532$$$O	medicine$$$533$$$541$$$O	per$$$542$$$545$$$O	minute$$$546$$$552$$$O	of$$$553$$$555$$$O	2ml,$$$556$$$560$$$O	obtaining$$$561$$$570$$$O	the$$$571$$$574$$$O	extract,$$$575$$$583$$$O	adding$$$584$$$590$$$O	the$$$591$$$594$$$O	extract$$$595$$$602$$$O	onto$$$603$$$607$$$O	a$$$608$$$609$$$O	D101$$$610$$$614$$$O	macroporous$$$615$$$626$$$O	adsorption$$$627$$$637$$$O	resin$$$638$$$643$$$O	column$$$644$$$650$$$O	for$$$651$$$654$$$O	absorption,$$$655$$$666$$$O	eluting$$$667$$$674$$$O	with$$$675$$$679$$$O	35-percent$$$680$$$690$$$O	ethanol,$$$691$$$699$$$I	collecting$$$700$$$710$$$O	eluent$$$711$$$717$$$O	in$$$718$$$720$$$O	an$$$721$$$723$$$O	amount$$$724$$$730$$$O	which$$$731$$$736$$$O	is$$$737$$$739$$$O	5$$$740$$$741$$$O	times$$$742$$$747$$$O	of$$$748$$$750$$$O	column$$$751$$$757$$$O	volume,$$$758$$$765$$$O	recovering$$$766$$$776$$$O	ethanol$$$777$$$784$$$I	under$$$785$$$790$$$O	reduced$$$791$$$798$$$O	pressure,$$$799$$$808$$$O	concentrating$$$809$$$822$$$O	the$$$823$$$826$$$O	eluent,$$$827$$$834$$$O	spray-drying$$$835$$$847$$$O	and$$$848$$$851$$$O	thus,$$$852$$$857$$$O	obtaining$$$858$$$867$$$O	the$$$868$$$871$$$O	macaranga$$$872$$$881$$$O	tanarius$$$882$$$890$$$O	extract.$$$891$$$899$$$O	The$$$900$$$903$$$O	extract$$$904$$$911$$$O	provided$$$912$$$920$$$O	by$$$921$$$923$$$O	the$$$924$$$927$$$O	invention$$$928$$$937$$$O	has$$$938$$$941$$$O	high$$$942$$$946$$$O	active$$$947$$$953$$$O	ingredient$$$954$$$964$$$O	content$$$965$$$972$$$O	and$$$973$$$976$$$O	high$$$977$$$981$$$O	pharmacological$$$982$$$997$$$O	activity.$$$998$$$1007$$$O
CN1559612A
Medicinal$$$0$$$9$$$O	mixture$$$10$$$17$$$O	for$$$18$$$21$$$O	treating$$$22$$$30$$$O	digestire$$$31$$$40$$$O	system$$$41$$$47$$$O	anabrosis$$$48$$$57$$$O
A$$$0$$$1$$$O	medicinal$$$2$$$11$$$O	mixture$$$12$$$19$$$O	for$$$20$$$23$$$O	treating$$$24$$$32$$$O	the$$$33$$$36$$$O	ulcer$$$37$$$42$$$O	in$$$43$$$45$$$O	digestive$$$46$$$55$$$O	system$$$56$$$62$$$O	contains$$$63$$$71$$$O	at$$$72$$$74$$$O	least$$$75$$$80$$$O	one$$$81$$$84$$$O	histamine$$$85$$$94$$$I	receptor$$$95$$$103$$$O	antagon$$$104$$$111$$$O	chosen$$$112$$$118$$$O	from$$$119$$$123$$$O	cimetidine,$$$124$$$135$$$I	ranitidine,$$$136$$$147$$$I	famotidine,$$$148$$$159$$$I	etc$$$160$$$163$$$O	and$$$164$$$167$$$O	at$$$168$$$170$$$O	least$$$171$$$176$$$O	one$$$177$$$180$$$O	H/K-ATP$$$181$$$188$$$O	enzyme$$$189$$$195$$$O	(proton$$$196$$$203$$$O	pump)$$$204$$$209$$$O	inhibitor$$$210$$$219$$$O	chosen$$$220$$$226$$$O	from$$$227$$$231$$$O	omeprazole,$$$232$$$243$$$I	lansoprazole,$$$244$$$257$$$I	etc.$$$258$$$262$$$O
US20100280069
Controlled$$$0$$$10$$$O	release$$$11$$$18$$$O	local$$$19$$$24$$$O	anesthetic$$$25$$$35$$$O	for$$$36$$$39$$$O	post$$$40$$$44$$$O	dental$$$45$$$51$$$O	surgery$$$52$$$59$$$O	and$$$60$$$63$$$O	method$$$64$$$70$$$O	of$$$71$$$73$$$O	use$$$74$$$77$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	of$$$42$$$44$$$O	delivering$$$45$$$55$$$O	local$$$56$$$61$$$O	anesthetic$$$62$$$72$$$O	after$$$73$$$78$$$O	dental$$$79$$$85$$$O	extraction$$$86$$$96$$$O	surgery.$$$97$$$105$$$O	The$$$106$$$109$$$O	present$$$110$$$117$$$O	invention$$$118$$$127$$$O	relates$$$128$$$135$$$O	to$$$136$$$138$$$O	packing$$$139$$$146$$$O	the$$$147$$$150$$$O	tooth$$$151$$$156$$$O	socket$$$157$$$163$$$O	with$$$164$$$168$$$O	a$$$169$$$170$$$O	tinned$$$171$$$177$$$O	release$$$178$$$185$$$O	local$$$186$$$191$$$O	anesthetic$$$192$$$202$$$O	which$$$203$$$208$$$O	is$$$209$$$211$$$O	coordinated$$$212$$$223$$$O	with$$$224$$$228$$$O	an$$$229$$$231$$$O	initial$$$232$$$239$$$O	local$$$240$$$245$$$O	anesthetic$$$246$$$256$$$O	and$$$257$$$260$$$O	which$$$261$$$266$$$O	lasts$$$267$$$272$$$O	up$$$273$$$275$$$O	to$$$276$$$278$$$O	5$$$279$$$280$$$O	days.$$$281$$$286$$$O	The$$$287$$$290$$$O	socket$$$291$$$297$$$O	can$$$298$$$301$$$O	be$$$302$$$304$$$O	surgically$$$305$$$315$$$O	sealed$$$316$$$322$$$O	or$$$323$$$325$$$O	the$$$326$$$329$$$O	implant$$$330$$$337$$$O	can$$$338$$$341$$$O	act$$$342$$$345$$$O	as$$$346$$$348$$$O	the$$$349$$$352$$$O	sealing$$$353$$$360$$$O	means.$$$361$$$367$$$O
CN103169757A
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	mastitis$$$22$$$30$$$O	in$$$31$$$33$$$O	dairy$$$34$$$39$$$O	cattle$$$40$$$46$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicine$$$26$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	mastitis$$$48$$$56$$$O	in$$$57$$$59$$$O	dairy$$$60$$$65$$$O	cattle.$$$66$$$73$$$O	The$$$74$$$77$$$O	medicine$$$78$$$86$$$O	is$$$87$$$89$$$O	prepared$$$90$$$98$$$O	from$$$99$$$103$$$O	radix$$$104$$$109$$$O	astragali,$$$110$$$120$$$O	taraxacum$$$121$$$130$$$O	and$$$131$$$134$$$O	prodigiosin.$$$135$$$147$$$O	The$$$148$$$151$$$O	medicine$$$152$$$160$$$O	is$$$161$$$163$$$O	effective$$$164$$$173$$$O	for$$$174$$$177$$$O	mastitis$$$178$$$186$$$O	in$$$187$$$189$$$O	dairy$$$190$$$195$$$O	cattle,$$$196$$$203$$$O	including$$$204$$$213$$$O	acute$$$214$$$219$$$O	mastitis$$$220$$$228$$$O	in$$$229$$$231$$$O	dairy$$$232$$$237$$$O	cattle,$$$238$$$245$$$O	chronic$$$246$$$253$$$O	mastitis$$$254$$$262$$$O	in$$$263$$$265$$$O	dairy$$$266$$$271$$$O	cattle,$$$272$$$279$$$O	suppurative$$$280$$$291$$$O	mastitis$$$292$$$300$$$O	in$$$301$$$303$$$O	dairy$$$304$$$309$$$O	cattle$$$310$$$316$$$O	and$$$317$$$320$$$O	the$$$321$$$324$$$O	like.$$$325$$$330$$$O	The$$$331$$$334$$$O	effective$$$335$$$344$$$O	rate$$$345$$$349$$$O	can$$$350$$$353$$$O	reach$$$354$$$359$$$O	98.7%,$$$360$$$366$$$O	and$$$367$$$370$$$O	the$$$371$$$374$$$O	cure$$$375$$$379$$$O	rate$$$380$$$384$$$O	is$$$385$$$387$$$O	93.7%$$$388$$$393$$$O	or$$$394$$$396$$$O	so.$$$397$$$400$$$O	The$$$401$$$404$$$O	medicine$$$405$$$413$$$O	disclosed$$$414$$$423$$$O	by$$$424$$$426$$$O	the$$$427$$$430$$$O	invention$$$431$$$440$$$O	has$$$441$$$444$$$O	high$$$445$$$449$$$O	cure$$$450$$$454$$$O	rate$$$455$$$459$$$O	for$$$460$$$463$$$O	mastitis$$$464$$$472$$$O	in$$$473$$$475$$$O	dairy$$$476$$$481$$$O	cattle,$$$482$$$489$$$O	saves$$$490$$$495$$$O	raw$$$496$$$499$$$O	materials,$$$500$$$510$$$O	and$$$511$$$514$$$O	thus,$$$515$$$520$$$O	is$$$521$$$523$$$O	an$$$524$$$526$$$O	ideal$$$527$$$532$$$O	medicine$$$533$$$541$$$O	for$$$542$$$545$$$O	treating$$$546$$$554$$$O	mastitis$$$555$$$563$$$O	in$$$564$$$566$$$O	dairy$$$567$$$572$$$O	cattle.$$$573$$$580$$$O
US20110184033
Selective$$$0$$$9$$$O	Ligands$$$10$$$17$$$O	for$$$18$$$21$$$O	the$$$22$$$25$$$O	Dopamine$$$26$$$34$$$I	3$$$35$$$36$$$O	(D3)$$$37$$$41$$$O	Receptor$$$45$$$53$$$O	and$$$54$$$57$$$O	Methods$$$58$$$65$$$O	of$$$66$$$68$$$O	using$$$69$$$74$$$O	the$$$75$$$78$$$O	Same$$$79$$$83$$$O
Potent$$$0$$$6$$$O	and$$$7$$$10$$$O	selective$$$11$$$20$$$O	ligands$$$21$$$28$$$O	for$$$29$$$32$$$O	the$$$33$$$36$$$O	dopamine$$$37$$$45$$$I	3$$$46$$$47$$$O	(D3)$$$48$$$52$$$O	receptor$$$53$$$61$$$O	are$$$62$$$65$$$O	disclosed.$$$66$$$76$$$O	The$$$77$$$80$$$O	D3$$$81$$$83$$$O	receptor$$$84$$$92$$$O	ligands$$$93$$$100$$$O	have$$$101$$$105$$$O	a$$$106$$$107$$$O	structural$$$108$$$118$$$O	formula$$$119$$$126$$$O	(I)$$$127$$$130$$$O	wherein$$$131$$$138$$$O	X$$$139$$$140$$$O	is$$$141$$$143$$$O	CâO$$$144$$$149$$$I	or$$$150$$$152$$$I	SO2,$$$153$$$157$$$I	R1$$$158$$$160$$$O	is$$$161$$$163$$$I	C1-6$$$164$$$168$$$I	alkyl,$$$169$$$175$$$I	R2$$$176$$$178$$$O	is$$$179$$$181$$$I	aryl,$$$182$$$187$$$I	heteroaryl,$$$188$$$199$$$I	aryl,$$$200$$$205$$$I	â(CH2)1-3aryl,$$$206$$$222$$$I	or$$$223$$$225$$$I	â(CH2)1-3heteroaryl,$$$226$$$248$$$I	and$$$249$$$252$$$O	n$$$253$$$254$$$O	is$$$255$$$257$$$O	0$$$258$$$259$$$O	or$$$260$$$262$$$O	1.$$$263$$$265$$$O	Methods$$$266$$$273$$$O	of$$$274$$$276$$$O	using$$$277$$$282$$$O	the$$$283$$$286$$$O	D3$$$287$$$289$$$O	receptor$$$290$$$298$$$O	ligands$$$299$$$306$$$O	in$$$307$$$309$$$O	the$$$310$$$313$$$O	treatment$$$314$$$323$$$O	of$$$324$$$326$$$O	diseases$$$327$$$335$$$O	and$$$336$$$339$$$O	conditions$$$340$$$350$$$O	wherein$$$351$$$358$$$O	modulation$$$359$$$369$$$O	of$$$370$$$372$$$O	the$$$373$$$376$$$O	D3$$$377$$$379$$$O	receptor$$$380$$$388$$$O	provides$$$389$$$397$$$O	a$$$398$$$399$$$O	benefit$$$400$$$407$$$O	also$$$408$$$412$$$O	are$$$413$$$416$$$O	disclosed.$$$417$$$427$$$O
CN102215844A
Folate$$$0$$$6$$$I	receptor$$$7$$$15$$$O	binding$$$16$$$23$$$O	conjugates$$$24$$$34$$$O	of$$$35$$$37$$$O	antifolates$$$38$$$49$$$O
Conjugates$$$0$$$10$$$O	of$$$11$$$13$$$O	antifolates,$$$14$$$26$$$O	releasable$$$27$$$37$$$O	linkers,$$$38$$$46$$$O	and$$$47$$$50$$$O	drugs,$$$51$$$57$$$O	and$$$58$$$61$$$O	pharmaceutical$$$62$$$76$$$O	compositions$$$77$$$89$$$O	containing$$$90$$$100$$$O	them$$$101$$$105$$$O	are$$$106$$$109$$$O	described.$$$110$$$120$$$O	The$$$121$$$124$$$O	conjugates$$$125$$$135$$$O	are$$$136$$$139$$$O	useful$$$140$$$146$$$O	for$$$147$$$150$$$O	treating$$$151$$$159$$$O	diseases$$$160$$$168$$$O	arising$$$169$$$176$$$O	from$$$177$$$181$$$O	pathogenic$$$182$$$192$$$O	cell$$$193$$$197$$$O	populations.$$$198$$$210$$$O	Methods$$$211$$$218$$$O	for$$$219$$$222$$$O	treating$$$223$$$231$$$O	such$$$232$$$236$$$O	diseases$$$237$$$245$$$O	are$$$246$$$249$$$O	also$$$250$$$254$$$O	described.$$$255$$$265$$$O
CN103479785A
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	herpes$$$22$$$28$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	medicine$$$25$$$33$$$O	for$$$34$$$37$$$O	treating$$$38$$$46$$$O	herpes,$$$47$$$54$$$O	relating$$$55$$$63$$$O	to$$$64$$$66$$$O	medicines$$$67$$$76$$$O	for$$$77$$$80$$$O	treating$$$81$$$89$$$O	herpes.$$$90$$$97$$$O	The$$$98$$$101$$$O	medicine$$$102$$$110$$$O	is$$$111$$$113$$$O	prepared$$$114$$$122$$$O	from$$$123$$$127$$$O	the$$$128$$$131$$$O	following$$$132$$$141$$$O	selected$$$142$$$150$$$O	raw$$$151$$$154$$$O	materials$$$155$$$164$$$O	by$$$165$$$167$$$O	weight:$$$168$$$175$$$O	12-18g$$$176$$$182$$$O	of$$$183$$$185$$$O	dried$$$186$$$191$$$O	rehmannia$$$192$$$201$$$O	root,$$$202$$$207$$$O	12-18g$$$208$$$214$$$O	of$$$215$$$217$$$O	prepared$$$218$$$226$$$O	rehmannia$$$227$$$236$$$O	root,$$$237$$$242$$$O	12-18g$$$243$$$249$$$O	of$$$250$$$252$$$O	Chinese$$$253$$$260$$$O	angelica,$$$261$$$270$$$O	3-7g$$$271$$$275$$$O	of$$$276$$$278$$$O	root$$$279$$$283$$$O	of$$$284$$$286$$$O	sharpspur$$$287$$$296$$$O	corydalis,$$$297$$$307$$$O	8-12g$$$308$$$313$$$O	of$$$314$$$316$$$O	borneol,$$$317$$$325$$$I	8-12g$$$326$$$331$$$O	of$$$332$$$334$$$O	beewax$$$335$$$341$$$O	and$$$342$$$345$$$O	700-800g$$$346$$$354$$$O	of$$$355$$$357$$$O	sesame$$$358$$$364$$$O	oil;$$$365$$$369$$$O	the$$$370$$$373$$$O	medicine$$$374$$$382$$$O	is$$$383$$$385$$$O	prepared$$$386$$$394$$$O	by$$$395$$$397$$$O	the$$$398$$$401$$$O	following$$$402$$$411$$$O	steps$$$412$$$417$$$O	of$$$418$$$420$$$O	putting$$$421$$$428$$$O	the$$$429$$$432$$$O	sesame$$$433$$$439$$$O	oil$$$440$$$443$$$O	into$$$444$$$448$$$O	a$$$449$$$450$$$O	pot,$$$451$$$455$$$O	heating$$$456$$$463$$$O	until$$$464$$$469$$$O	smoke$$$470$$$475$$$O	appears,$$$476$$$484$$$O	cutting$$$485$$$492$$$O	dried$$$493$$$498$$$O	rehmannia$$$499$$$508$$$O	root,$$$509$$$514$$$O	prepared$$$515$$$523$$$O	rehmannia$$$524$$$533$$$O	root,$$$534$$$539$$$O	Chinese$$$540$$$547$$$O	angelica$$$548$$$556$$$O	and$$$557$$$560$$$O	root$$$561$$$565$$$O	of$$$566$$$568$$$O	sharpspur$$$569$$$578$$$O	corydalis$$$579$$$588$$$O	into$$$589$$$593$$$O	pieces$$$594$$$600$$$O	or$$$601$$$603$$$O	strips,$$$604$$$611$$$O	putting$$$612$$$619$$$O	into$$$620$$$624$$$O	the$$$625$$$628$$$O	sesame$$$629$$$635$$$O	oil,$$$636$$$640$$$O	frying$$$641$$$647$$$O	until$$$648$$$653$$$O	the$$$654$$$657$$$O	pieces$$$658$$$664$$$O	or$$$665$$$667$$$O	strips$$$668$$$674$$$O	are$$$675$$$678$$$O	slightly$$$679$$$687$$$O	brown,$$$688$$$694$$$O	fishing$$$695$$$702$$$O	the$$$703$$$706$$$O	pieces$$$707$$$713$$$O	or$$$714$$$716$$$O	strips$$$717$$$723$$$O	out$$$724$$$727$$$O	and$$$728$$$731$$$O	then$$$732$$$736$$$O	adding$$$737$$$743$$$O	borneol$$$744$$$751$$$I	and$$$752$$$755$$$O	beewax$$$756$$$762$$$O	to$$$763$$$765$$$O	prepare$$$766$$$773$$$O	paste.$$$774$$$780$$$O	The$$$781$$$784$$$O	medicine$$$785$$$793$$$O	has$$$794$$$797$$$O	the$$$798$$$801$$$O	beneficial$$$802$$$812$$$O	effects$$$813$$$820$$$O	that$$$821$$$825$$$O	the$$$826$$$829$$$O	medicine$$$830$$$838$$$O	is$$$839$$$841$$$O	used$$$842$$$846$$$O	externally,$$$847$$$858$$$O	takes$$$859$$$864$$$O	effect$$$865$$$871$$$O	quickly,$$$872$$$880$$$O	is$$$881$$$883$$$O	safe$$$884$$$888$$$O	and$$$889$$$892$$$O	reliable$$$893$$$901$$$O	and$$$902$$$905$$$O	has$$$906$$$909$$$O	good$$$910$$$914$$$O	curative$$$915$$$923$$$O	effects;$$$924$$$932$$$O	47$$$933$$$935$$$O	clinical$$$936$$$944$$$O	tests$$$945$$$950$$$O	show$$$951$$$955$$$O	that$$$956$$$960$$$O	the$$$961$$$964$$$O	effective$$$965$$$974$$$O	rate$$$975$$$979$$$O	is$$$980$$$982$$$O	100%.$$$983$$$988$$$O
EP2655312A1
3-acyl-ingenols$$$0$$$15$$$I	ii$$$16$$$18$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	general$$$38$$$45$$$O	formula$$$46$$$53$$$O	I,$$$54$$$56$$$O	(I),$$$57$$$61$$$O	wherein$$$62$$$69$$$O	R$$$70$$$71$$$O	is$$$72$$$74$$$O	wherein$$$75$$$82$$$O	R$$$83$$$84$$$O	is$$$85$$$87$$$O	aryl$$$88$$$92$$$I	substituted$$$93$$$104$$$O	by$$$105$$$107$$$O	R3;$$$108$$$111$$$O	or$$$112$$$114$$$O	R$$$115$$$116$$$O	is$$$117$$$119$$$O	(C3-Ci3)-cycloalkyl,$$$120$$$140$$$I	(C3-Ci3)-cycloalkenyl$$$141$$$162$$$I	or$$$163$$$165$$$O	(C7-Ci3)-cycloalkynyl$$$166$$$187$$$I	optionally$$$188$$$198$$$O	substituted$$$199$$$210$$$O	by$$$211$$$213$$$O	R4;$$$214$$$217$$$O	and$$$218$$$221$$$O	pharmaceutically$$$222$$$238$$$O	acceptable$$$239$$$249$$$O	salts,$$$250$$$256$$$O	hydrates,$$$257$$$266$$$O	or$$$267$$$269$$$O	solvates$$$270$$$278$$$O	thereof,$$$279$$$287$$$O	for$$$288$$$291$$$O	use-alone$$$292$$$301$$$O	or$$$302$$$304$$$O	in$$$305$$$307$$$O	combination$$$308$$$319$$$O	with$$$320$$$324$$$O	one$$$325$$$328$$$O	or$$$329$$$331$$$O	more$$$332$$$336$$$O	other$$$337$$$342$$$O	pharmaceutically$$$343$$$359$$$O	active$$$360$$$366$$$O	compounds-in$$$367$$$379$$$O	therapy,$$$380$$$388$$$O	for$$$389$$$392$$$O	preventing,$$$393$$$404$$$O	treating$$$405$$$413$$$O	or$$$414$$$416$$$O	ameliorating$$$417$$$429$$$O	diseases$$$430$$$438$$$O	or$$$439$$$441$$$O	conditions$$$442$$$452$$$O	responsive$$$453$$$463$$$O	to$$$464$$$466$$$O	stimulation$$$467$$$478$$$O	of$$$479$$$481$$$O	neutrophil$$$482$$$492$$$O	oxidative$$$493$$$502$$$O	burst,$$$503$$$509$$$O	responsive$$$510$$$520$$$O	to$$$521$$$523$$$O	stimulation$$$524$$$535$$$O	of$$$536$$$538$$$O	keratinocyte$$$539$$$551$$$O	IL-8$$$552$$$556$$$O	release$$$557$$$564$$$O	or$$$565$$$567$$$O	responsive$$$568$$$578$$$O	to$$$579$$$581$$$O	induction$$$582$$$591$$$O	of$$$592$$$594$$$O	necrosis.$$$595$$$604$$$O
CN101653449B
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	ADDA$$$15$$$19$$$I	and/or$$$20$$$26$$$O	DMTA$$$27$$$31$$$I	in$$$32$$$34$$$O	preparing$$$35$$$44$$$O	medicine$$$45$$$53$$$O	for$$$54$$$57$$$O	improving$$$58$$$67$$$O	expression$$$68$$$78$$$O	level$$$79$$$84$$$O	of$$$85$$$87$$$O	gamma-globin$$$88$$$100$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	biological$$$48$$$58$$$O	medicine,$$$59$$$68$$$O	discloses$$$69$$$78$$$O	an$$$79$$$81$$$O	application$$$82$$$93$$$O	of$$$94$$$96$$$O	ADDA$$$97$$$101$$$I	and/or$$$102$$$108$$$O	DMTA$$$109$$$113$$$I	in$$$114$$$116$$$O	preparing$$$117$$$126$$$O	medicine$$$127$$$135$$$O	for$$$136$$$139$$$O	improving$$$140$$$149$$$O	expression$$$150$$$160$$$O	level$$$161$$$166$$$O	of$$$167$$$169$$$O	gamma-globin,$$$170$$$183$$$O	and$$$184$$$187$$$O	provides$$$188$$$196$$$O	a$$$197$$$198$$$O	candidate$$$199$$$208$$$O	drug$$$209$$$213$$$O	for$$$214$$$217$$$O	curing$$$218$$$224$$$O	anemia$$$225$$$231$$$O	caused$$$232$$$238$$$O	by$$$239$$$241$$$O	beta-thalassemia,$$$242$$$259$$$O	sickle-cell$$$260$$$271$$$O	anemia,$$$272$$$279$$$O	hematopoietic$$$280$$$293$$$O	system$$$294$$$300$$$O	tumor$$$301$$$306$$$O	and$$$307$$$310$$$O	hematopoietic$$$311$$$324$$$O	dysfunction.$$$325$$$337$$$O
EP0800397B1
Bone$$$0$$$4$$$O	mass$$$5$$$9$$$O	anabolic$$$10$$$18$$$O	composition$$$19$$$30$$$O	comprising$$$31$$$41$$$O	olpadronate$$$42$$$53$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	for$$$39$$$42$$$O	bone$$$43$$$47$$$O	mass$$$48$$$52$$$O	anabolic$$$53$$$61$$$O	preservation$$$62$$$74$$$O	or$$$75$$$77$$$O	augmentation$$$78$$$90$$$O	in$$$91$$$93$$$O	human$$$94$$$99$$$O	or$$$100$$$102$$$O	other$$$103$$$108$$$O	animal$$$109$$$115$$$O	subjects$$$116$$$124$$$O	affected$$$125$$$133$$$O	by$$$134$$$136$$$O	osteoporosis$$$137$$$149$$$O	or$$$150$$$152$$$O	other$$$153$$$158$$$O	metabolic$$$159$$$168$$$O	bone$$$169$$$173$$$O	disorder$$$174$$$182$$$O	characterized$$$183$$$196$$$O	by$$$197$$$199$$$O	systemic$$$200$$$208$$$O	or$$$209$$$211$$$O	regional$$$212$$$220$$$O	bone$$$221$$$225$$$O	loss,$$$226$$$231$$$O	using$$$232$$$237$$$O	bisphosphonates$$$238$$$253$$$I	formulations,$$$254$$$267$$$O	wherein$$$268$$$275$$$O	the$$$276$$$279$$$O	bone$$$280$$$284$$$O	mass$$$285$$$289$$$O	anabolic$$$290$$$298$$$O	composition$$$299$$$310$$$O	contains$$$311$$$319$$$O	effective$$$320$$$329$$$O	non-toxic$$$330$$$339$$$O	doses$$$340$$$345$$$O	of$$$346$$$348$$$O	[3-(N,N-dimethylamine)-1-hydroxypropylidene]-bisphosphonic$$$349$$$407$$$I	acid$$$408$$$412$$$I	or$$$413$$$415$$$O	olpadronate$$$416$$$427$$$I	or$$$428$$$430$$$O	the$$$431$$$434$$$O	monosodium$$$435$$$445$$$I	or$$$446$$$448$$$O	other$$$449$$$454$$$O	pharmaceutically$$$455$$$471$$$O	acceptable$$$472$$$482$$$O	salt$$$483$$$487$$$O	thereof.$$$488$$$496$$$O
WO2012045363A1
Antidiabetic$$$0$$$12$$$O	enolic$$$13$$$19$$$O	glucoside$$$20$$$29$$$I	of$$$30$$$32$$$O	phenylpyruvic$$$33$$$46$$$I	acid$$$47$$$51$$$I
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	an$$$18$$$20$$$O	antidiabetic$$$21$$$33$$$O	enolic$$$34$$$40$$$O	glucoside$$$41$$$50$$$I	of$$$51$$$53$$$O	phenylpyruvic$$$54$$$67$$$I	acid$$$68$$$72$$$I	and$$$73$$$76$$$O	derivatives$$$77$$$88$$$O	thereof$$$89$$$96$$$O	for$$$97$$$100$$$O	use$$$101$$$104$$$O	as$$$105$$$107$$$O	medicaments,$$$108$$$120$$$O	especially$$$121$$$131$$$O	normoglycemic$$$132$$$145$$$O	agents,$$$146$$$153$$$O	i.e.$$$154$$$158$$$O	for$$$159$$$162$$$O	lowering$$$163$$$171$$$O	blood$$$172$$$177$$$O	glucose$$$178$$$185$$$I	levels$$$186$$$192$$$O	to$$$193$$$195$$$O	normal$$$196$$$202$$$O	levels$$$203$$$209$$$O	in$$$210$$$212$$$O	mammals$$$213$$$220$$$O	that$$$221$$$225$$$O	are$$$226$$$229$$$O	obese,$$$230$$$236$$$O	pre-diabetic$$$237$$$249$$$O	or$$$250$$$252$$$O	have$$$253$$$257$$$O	diabetes,$$$258$$$267$$$O	obesity$$$268$$$275$$$O	and/or$$$276$$$282$$$O	syndrome$$$283$$$291$$$O	X.Hence$$$292$$$299$$$O	the$$$300$$$303$$$O	compounds$$$304$$$313$$$O	of$$$314$$$316$$$O	the$$$317$$$320$$$O	present$$$321$$$328$$$O	invention$$$329$$$338$$$O	help$$$339$$$343$$$O	to$$$344$$$346$$$O	manage$$$347$$$353$$$O	blood$$$354$$$359$$$O	sugar$$$360$$$365$$$I	levels,$$$366$$$373$$$O	i.e.$$$374$$$378$$$O	helping$$$379$$$386$$$O	the$$$387$$$390$$$O	body$$$391$$$395$$$O	by$$$396$$$398$$$O	balancing$$$399$$$408$$$O	the$$$409$$$412$$$O	blood$$$413$$$418$$$O	sugar$$$419$$$424$$$I	levels;$$$425$$$432$$$O	helping$$$433$$$440$$$O	to$$$441$$$443$$$O	keep$$$444$$$448$$$O	balanced$$$449$$$457$$$O	blood$$$458$$$463$$$O	glucose$$$464$$$471$$$I	levels,$$$472$$$479$$$O	particularly$$$480$$$492$$$O	in$$$493$$$495$$$O	humans$$$496$$$502$$$O	with$$$503$$$507$$$O	diabetes;$$$508$$$517$$$O	aiding$$$518$$$524$$$O	by$$$525$$$527$$$O	enhancing$$$528$$$537$$$O	the$$$538$$$541$$$O	glucose$$$542$$$549$$$I	uptake$$$550$$$556$$$O	by$$$557$$$559$$$O	the$$$560$$$563$$$O	cells$$$564$$$569$$$O	and$$$570$$$573$$$O	by$$$574$$$576$$$O	reducing$$$577$$$585$$$O	sugar$$$586$$$591$$$I	levels,$$$592$$$599$$$O	thus$$$600$$$604$$$O	improving$$$605$$$614$$$O	or$$$615$$$617$$$O	restoring$$$618$$$627$$$O	the$$$628$$$631$$$O	glucose$$$632$$$639$$$I	tolerance;$$$640$$$650$$$O	optimizing$$$651$$$661$$$O	the$$$662$$$665$$$O	glycemic$$$666$$$674$$$O	response;$$$675$$$684$$$O	normalizing$$$685$$$696$$$O	the$$$697$$$700$$$O	glucose$$$701$$$708$$$O	tolerance.$$$709$$$719$$$O
US20070148197
Treating$$$0$$$8$$$O	inflammation$$$9$$$21$$$O	with$$$22$$$26$$$O	ondansetron$$$27$$$38$$$I	and$$$39$$$42$$$O	pharmaceutical$$$43$$$57$$$O	compositions$$$58$$$70$$$O	comprised$$$71$$$80$$$O	thereof$$$81$$$88$$$O
Inflammatory$$$0$$$12$$$O	skin$$$13$$$17$$$O	disorders$$$18$$$27$$$O	such$$$28$$$32$$$O	as$$$33$$$35$$$O	rosacea,$$$36$$$44$$$O	including$$$45$$$54$$$O	a$$$55$$$56$$$O	variety$$$57$$$64$$$O	of$$$65$$$67$$$O	skin$$$68$$$72$$$O	diseases,$$$73$$$82$$$O	whether$$$83$$$90$$$O	or$$$91$$$93$$$O	not$$$94$$$97$$$O	accompanied$$$98$$$109$$$O	by$$$110$$$112$$$O	dermatosis,$$$113$$$124$$$O	are$$$125$$$128$$$O	treated$$$129$$$136$$$O	by$$$137$$$139$$$O	topically$$$140$$$149$$$O	applying$$$150$$$158$$$O	onto$$$159$$$163$$$O	the$$$164$$$167$$$O	affected$$$168$$$176$$$O	skin$$$177$$$181$$$O	area,$$$182$$$187$$$O	a$$$188$$$189$$$O	thus$$$190$$$194$$$O	effective$$$195$$$204$$$O	amount$$$205$$$211$$$O	of$$$212$$$214$$$O	Ondansetron,$$$215$$$227$$$I	or$$$228$$$230$$$O	salt$$$231$$$235$$$O	or$$$236$$$238$$$O	base$$$239$$$243$$$O	thereof.$$$244$$$252$$$O
DE102008005498A1
Adherent,$$$0$$$9$$$O	sperm$$$10$$$15$$$O	blocking$$$16$$$24$$$O	drug$$$25$$$29$$$O	combination$$$30$$$41$$$O	with$$$42$$$46$$$O	contraceptive$$$47$$$60$$$O	effect,$$$61$$$68$$$O	useful$$$69$$$75$$$O	as$$$76$$$78$$$O	contraceptive,$$$79$$$93$$$O	comprises$$$94$$$103$$$O	deionized$$$104$$$113$$$O	water,$$$114$$$120$$$O	polysaccharide-gum,$$$121$$$140$$$O	and$$$141$$$144$$$O	alcohol$$$145$$$152$$$I	as$$$153$$$155$$$O	lubricant,$$$156$$$166$$$O	where$$$167$$$172$$$O	composition$$$173$$$184$$$O	has$$$185$$$188$$$O	specific$$$189$$$197$$$O	total$$$198$$$203$$$O	viscosity$$$204$$$213$$$O
Adherent,$$$0$$$9$$$O	sperm$$$10$$$15$$$O	blocking$$$16$$$24$$$O	drug$$$25$$$29$$$O	combination$$$30$$$41$$$O	with$$$42$$$46$$$O	contraceptive$$$47$$$60$$$O	effect,$$$61$$$68$$$O	comprises:$$$69$$$79$$$O	pure$$$80$$$84$$$O	deionized$$$85$$$94$$$O	water;$$$95$$$101$$$O	0.3-10$$$102$$$108$$$O	wt.%$$$109$$$113$$$O	of$$$114$$$116$$$O	a$$$117$$$118$$$O	polysaccharide-gum$$$119$$$137$$$O	from$$$138$$$142$$$O	cellulose$$$143$$$152$$$O	and$$$153$$$156$$$O	its$$$157$$$160$$$O	derivatives,$$$161$$$173$$$O	hemicellulose,$$$174$$$188$$$O	fibers,$$$189$$$196$$$O	starch$$$197$$$203$$$O	and$$$204$$$207$$$O	its$$$208$$$211$$$O	derivatives,$$$212$$$224$$$O	polydextran$$$225$$$236$$$O	and$$$237$$$240$$$O	its$$$241$$$244$$$O	derivatives,$$$245$$$257$$$O	pectin$$$258$$$264$$$O	and$$$265$$$268$$$O	its$$$269$$$272$$$O	derivatives,$$$273$$$285$$$O	seaweed-saccharide$$$286$$$304$$$O	and$$$305$$$308$$$O	its$$$309$$$312$$$O	derivatives$$$313$$$324$$$O	and$$$325$$$328$$$O	salts$$$329$$$334$$$O	or$$$335$$$337$$$O	natural$$$338$$$345$$$O	gums;$$$346$$$351$$$O	and$$$352$$$355$$$O	0.5-10$$$356$$$362$$$O	wt.%$$$363$$$367$$$O	of$$$368$$$370$$$O	alcohol$$$371$$$378$$$I	as$$$379$$$381$$$O	a$$$382$$$383$$$O	lubricant.$$$384$$$394$$$O	Adherent,$$$395$$$404$$$O	sperm$$$405$$$410$$$O	blocking$$$411$$$419$$$O	drug$$$420$$$424$$$O	combination$$$425$$$436$$$O	with$$$437$$$441$$$O	contraceptive$$$442$$$455$$$O	effect,$$$456$$$463$$$O	comprises:$$$464$$$474$$$O	pure$$$475$$$479$$$O	deionized$$$480$$$489$$$O	water;$$$490$$$496$$$O	0.3-10$$$497$$$503$$$O	wt.%$$$504$$$508$$$O	of$$$509$$$511$$$O	a$$$512$$$513$$$O	polysaccharide-gum$$$514$$$532$$$O	from$$$533$$$537$$$O	cellulose$$$538$$$547$$$O	and$$$548$$$551$$$O	its$$$552$$$555$$$O	derivatives,$$$556$$$568$$$O	hemicellulose,$$$569$$$583$$$O	fibers,$$$584$$$591$$$O	starch$$$592$$$598$$$O	and$$$599$$$602$$$O	its$$$603$$$606$$$O	derivatives,$$$607$$$619$$$O	polydextran$$$620$$$631$$$O	and$$$632$$$635$$$O	its$$$636$$$639$$$O	derivatives,$$$640$$$652$$$O	pectin$$$653$$$659$$$O	and$$$660$$$663$$$O	its$$$664$$$667$$$O	derivatives,$$$668$$$680$$$O	seaweed-saccharide$$$681$$$699$$$O	and$$$700$$$703$$$O	its$$$704$$$707$$$O	derivatives$$$708$$$719$$$O	and$$$720$$$723$$$O	salts$$$724$$$729$$$O	or$$$730$$$732$$$O	natural$$$733$$$740$$$O	gums;$$$741$$$746$$$O	and$$$747$$$750$$$O	0.5-10$$$751$$$757$$$O	wt.%$$$758$$$762$$$O	of$$$763$$$765$$$O	alcohol$$$766$$$773$$$I	as$$$774$$$776$$$O	a$$$777$$$778$$$O	lubricant,$$$779$$$789$$$O	where$$$790$$$795$$$O	the$$$796$$$799$$$O	alcohol$$$800$$$807$$$I	is$$$808$$$810$$$O	at$$$811$$$813$$$O	least$$$814$$$819$$$O	a$$$820$$$821$$$O	polyethylene$$$822$$$834$$$I	glycol$$$835$$$841$$$I	with$$$842$$$846$$$O	a$$$847$$$848$$$O	molecular$$$849$$$858$$$O	weight$$$859$$$865$$$O	of$$$866$$$868$$$O	greater$$$869$$$876$$$O	than$$$877$$$881$$$O	200,$$$882$$$886$$$O	polypropylene$$$887$$$900$$$I	glycol$$$901$$$907$$$I	with$$$908$$$912$$$O	a$$$913$$$914$$$O	molecular$$$915$$$924$$$O	weight,$$$925$$$932$$$O	poly(ethylene$$$933$$$946$$$I	oxide)-polymer$$$947$$$961$$$I	and$$$962$$$965$$$O	glycerin,$$$966$$$975$$$I	and$$$976$$$979$$$O	the$$$980$$$983$$$O	total$$$984$$$989$$$O	viscosity$$$990$$$999$$$O	of$$$1000$$$1002$$$O	the$$$1003$$$1006$$$O	composition$$$1007$$$1018$$$O	is$$$1019$$$1021$$$O	9000$$$1022$$$1026$$$O	cst.$$$1027$$$1031$$$O	-$$$1032$$$1033$$$O	ACTIVITY$$$1034$$$1042$$$O	:$$$1043$$$1044$$$O	Contraceptive.$$$1045$$$1059$$$O	-$$$1060$$$1061$$$O	MECHANISM$$$1062$$$1071$$$O	OF$$$1072$$$1074$$$O	ACTION$$$1075$$$1081$$$O	:$$$1082$$$1083$$$O	None$$$1084$$$1088$$$O	given.$$$1089$$$1095$$$O
CN103432114A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	epigallocatechin$$$15$$$31$$$I	gallate$$$32$$$39$$$I	to$$$40$$$42$$$O	preparation$$$43$$$54$$$O	of$$$55$$$57$$$O	drugs$$$58$$$63$$$O	for$$$64$$$67$$$O	promoting$$$68$$$77$$$O	epidermal$$$78$$$87$$$O	repair$$$88$$$94$$$O	and$$$95$$$98$$$O	regeneration$$$99$$$111$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	effect$$$26$$$32$$$O	of$$$33$$$35$$$O	activating$$$36$$$46$$$O	serine,$$$47$$$54$$$I	threonine$$$55$$$64$$$I	and$$$65$$$68$$$O	tyrosine$$$69$$$77$$$I	phosphorylation$$$78$$$93$$$O	of$$$94$$$96$$$O	an$$$97$$$99$$$O	epidermal$$$100$$$109$$$O	growth$$$110$$$116$$$O	factor$$$117$$$123$$$O	receptor$$$124$$$132$$$O	(EGFR)$$$133$$$139$$$O	by$$$140$$$142$$$O	epigallocatechin$$$143$$$159$$$I	gallate$$$160$$$167$$$I	(EGCG),$$$168$$$175$$$I	and$$$176$$$179$$$O	the$$$180$$$183$$$O	effect$$$184$$$190$$$O	is$$$191$$$193$$$O	similar$$$194$$$201$$$O	to$$$202$$$204$$$O	an$$$205$$$207$$$O	epidermal$$$208$$$217$$$O	growth$$$218$$$224$$$O	factor$$$225$$$231$$$O	(EGF),$$$232$$$238$$$O	that$$$239$$$243$$$O	is,$$$244$$$247$$$O	the$$$248$$$251$$$O	EGCG$$$252$$$256$$$I	can$$$257$$$260$$$O	serve$$$261$$$266$$$O	as$$$267$$$269$$$O	the$$$270$$$273$$$O	EGF$$$274$$$277$$$O	of$$$278$$$280$$$O	a$$$281$$$282$$$O	plant$$$283$$$288$$$O	origin$$$289$$$295$$$O	to$$$296$$$298$$$O	be$$$299$$$301$$$O	applied$$$302$$$309$$$O	to$$$310$$$312$$$O	promotion$$$313$$$322$$$O	of$$$323$$$325$$$O	epidermal$$$326$$$335$$$O	repair$$$336$$$342$$$O	and$$$343$$$346$$$O	regeneration.$$$347$$$360$$$O	The$$$361$$$364$$$O	invention$$$365$$$374$$$O	provides$$$375$$$383$$$O	application$$$384$$$395$$$O	of$$$396$$$398$$$O	the$$$399$$$402$$$O	EGCG$$$403$$$407$$$O	to$$$408$$$410$$$O	preparation$$$411$$$422$$$O	of$$$423$$$425$$$O	drugs$$$426$$$431$$$O	and$$$432$$$435$$$O	cosmetics$$$436$$$445$$$O	for$$$446$$$449$$$O	promoting$$$450$$$459$$$O	epidermal$$$460$$$469$$$O	repair$$$470$$$476$$$O	and$$$477$$$480$$$O	regeneration.$$$481$$$494$$$O	The$$$495$$$498$$$O	invention$$$499$$$508$$$O	further$$$509$$$516$$$O	provides$$$517$$$525$$$O	the$$$526$$$529$$$O	EGCG$$$530$$$534$$$I	serving$$$535$$$542$$$O	as$$$543$$$545$$$O	the$$$546$$$549$$$O	epidermal$$$550$$$559$$$O	growth$$$560$$$566$$$O	factor,$$$567$$$574$$$O	an$$$575$$$577$$$O	epidermal$$$578$$$587$$$O	growth$$$588$$$594$$$O	factor$$$595$$$601$$$O	receptor$$$602$$$610$$$O	activator$$$611$$$620$$$O	and$$$621$$$624$$$O	an$$$625$$$627$$$O	epidermal$$$628$$$637$$$O	growth$$$638$$$644$$$O	factor$$$645$$$651$$$O	receptor$$$652$$$660$$$O	signal$$$661$$$667$$$O	channel$$$668$$$675$$$O	promoter.$$$676$$$685$$$O
US20110269737
7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic$$$0$$$47$$$I	Acid$$$48$$$52$$$I	(Phenyl)-Amide$$$53$$$67$$$I	Derivatives$$$68$$$79$$$O	and$$$80$$$83$$$O	Allied$$$84$$$90$$$O	Compounds$$$91$$$100$$$O	as$$$101$$$103$$$O	P38$$$104$$$107$$$O	Map$$$108$$$111$$$O	Kinase$$$112$$$118$$$O	Inhibitors$$$119$$$129$$$O	for$$$130$$$133$$$O	the$$$134$$$137$$$O	Treatment$$$138$$$147$$$O	of$$$148$$$150$$$O	Respiratory$$$151$$$162$$$O	Diseases$$$163$$$171$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	compounds$$$31$$$40$$$O	according$$$41$$$50$$$O	to$$$51$$$53$$$O	general$$$54$$$61$$$O	formula$$$62$$$69$$$O	(I)$$$70$$$73$$$O	which$$$111$$$116$$$O	are$$$117$$$120$$$O	proposed$$$121$$$129$$$O	for$$$130$$$133$$$O	the$$$134$$$137$$$O	treatment$$$138$$$147$$$O	of$$$148$$$150$$$O	respiratory$$$151$$$162$$$O	complaints,$$$163$$$174$$$O	particularly$$$175$$$187$$$O	asthma$$$188$$$194$$$O	and$$$195$$$198$$$O	COPD.$$$199$$$204$$$O
EP2603096A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	treating$$$11$$$19$$$O	fatty$$$20$$$25$$$O	liver$$$26$$$31$$$O	diseases,$$$32$$$41$$$O	in$$$42$$$44$$$O	particular$$$45$$$55$$$O	non-alcoholic$$$56$$$69$$$O	steatohepatitis.$$$70$$$86$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	in$$$17$$$19$$$O	the$$$20$$$23$$$O	field$$$24$$$29$$$O	of$$$30$$$32$$$O	medical$$$33$$$40$$$O	treatments$$$41$$$51$$$O	of$$$52$$$54$$$O	liver$$$55$$$60$$$O	disease,$$$61$$$69$$$O	in$$$70$$$72$$$O	particular$$$73$$$83$$$O	non-alcoholic$$$84$$$97$$$O	fatty$$$98$$$103$$$O	liver$$$104$$$109$$$O	diseases,$$$110$$$119$$$O	such$$$120$$$124$$$O	as$$$125$$$127$$$O	non-alcoholic$$$128$$$141$$$O	steatohepatitis.$$$142$$$158$$$O	The$$$159$$$162$$$O	invention$$$163$$$172$$$O	provides$$$173$$$181$$$O	a$$$182$$$183$$$O	composition$$$184$$$195$$$O	comprising$$$196$$$206$$$O	an$$$207$$$209$$$O	effective$$$210$$$219$$$O	amount$$$220$$$226$$$O	of$$$227$$$229$$$O	a$$$230$$$231$$$O	compound$$$232$$$240$$$O	capable$$$241$$$248$$$O	of$$$249$$$251$$$O	increasing$$$252$$$262$$$O	the$$$263$$$266$$$O	intracellular$$$267$$$280$$$O	level$$$281$$$286$$$O	of$$$287$$$289$$$O	27-hydroxycholesterol$$$290$$$311$$$I	for$$$312$$$315$$$O	the$$$316$$$319$$$O	treatment$$$320$$$329$$$O	of$$$330$$$332$$$O	liver$$$333$$$338$$$O	inflammation$$$339$$$351$$$O	in$$$352$$$354$$$O	fatty$$$355$$$360$$$O	liver$$$361$$$366$$$O	disease.$$$367$$$375$$$O	It$$$376$$$378$$$O	also$$$379$$$383$$$O	provides$$$384$$$392$$$O	a$$$393$$$394$$$O	method$$$395$$$401$$$O	of$$$402$$$404$$$O	reducing$$$405$$$413$$$O	liver$$$414$$$419$$$O	inflammation$$$420$$$432$$$O	in$$$433$$$435$$$O	a$$$436$$$437$$$O	patient$$$438$$$445$$$O	with$$$446$$$450$$$O	non-alcoholic$$$451$$$464$$$O	fatty$$$465$$$470$$$O	liver$$$471$$$476$$$O	disease$$$477$$$484$$$O	by$$$485$$$487$$$O	administering$$$488$$$501$$$O	an$$$502$$$504$$$O	effective$$$505$$$514$$$O	amount$$$515$$$521$$$O	of$$$522$$$524$$$O	27-hydroxycholesterol.$$$525$$$547$$$I
CN101757374A
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	curing$$$13$$$19$$$O	burns$$$20$$$25$$$O	and$$$26$$$29$$$O	scalds$$$30$$$36$$$O	and$$$37$$$40$$$O	preparation$$$41$$$52$$$O	method$$$53$$$59$$$O	thereof$$$60$$$67$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	for$$$34$$$37$$$O	preparing$$$38$$$47$$$O	a$$$48$$$49$$$O	medicine$$$50$$$58$$$O	for$$$59$$$62$$$O	curing$$$63$$$69$$$O	burns$$$70$$$75$$$O	and$$$76$$$79$$$O	scalds,$$$80$$$87$$$O	which$$$88$$$93$$$O	comprises$$$94$$$103$$$O	the$$$104$$$107$$$O	following$$$108$$$117$$$O	steps$$$118$$$123$$$O	of:$$$124$$$127$$$O	using$$$128$$$133$$$O	rhubarb,$$$134$$$142$$$O	coptis$$$143$$$149$$$O	roots,$$$150$$$156$$$O	phellodendron,$$$157$$$171$$$O	dragon's$$$172$$$180$$$O	blood,$$$181$$$187$$$O	calcined$$$188$$$196$$$O	calamine,$$$197$$$206$$$O	calcined$$$207$$$215$$$O	gypsum,$$$216$$$223$$$I	alum$$$224$$$228$$$O	and$$$229$$$232$$$O	pig$$$233$$$236$$$O	gall$$$237$$$241$$$O	powder,$$$242$$$249$$$O	wherein$$$250$$$257$$$O	rhubarb,$$$258$$$266$$$O	coptis$$$267$$$273$$$O	roots$$$274$$$279$$$O	and$$$280$$$283$$$O	phellodendron$$$284$$$297$$$O	are$$$298$$$301$$$O	reflux$$$302$$$308$$$O	extracted$$$309$$$318$$$O	by$$$319$$$321$$$O	60-90%v/v$$$322$$$331$$$O	alcohol;$$$332$$$340$$$O	mixing$$$341$$$347$$$O	and$$$348$$$351$$$O	crushing$$$352$$$360$$$O	dragon's$$$361$$$369$$$O	blood,$$$370$$$376$$$O	calcined$$$377$$$385$$$O	calamine,$$$386$$$395$$$O	calcined$$$396$$$404$$$O	gypsum,$$$405$$$412$$$I	alum$$$413$$$417$$$O	and$$$418$$$421$$$O	pig$$$422$$$425$$$O	gall$$$426$$$430$$$O	powder,$$$431$$$438$$$O	and$$$439$$$442$$$O	screening$$$443$$$452$$$O	the$$$453$$$456$$$O	powder$$$457$$$463$$$O	with$$$464$$$468$$$O	a$$$469$$$470$$$O	sieve$$$471$$$476$$$O	of$$$477$$$479$$$O	20-100$$$480$$$486$$$O	meshes;$$$487$$$494$$$O	uniformly$$$495$$$504$$$O	mixing,$$$505$$$512$$$O	drying,$$$513$$$520$$$O	screening$$$521$$$530$$$O	by$$$531$$$533$$$O	using$$$534$$$539$$$O	a$$$540$$$541$$$O	40-mesh$$$542$$$549$$$O	sieve,$$$550$$$556$$$O	mixing$$$557$$$563$$$O	the$$$564$$$567$$$O	material$$$568$$$576$$$O	with$$$577$$$581$$$O	water$$$582$$$587$$$O	in$$$588$$$590$$$O	the$$$591$$$594$$$O	weight$$$595$$$601$$$O	ratio$$$602$$$607$$$O	of$$$608$$$610$$$O	1:(0.4-5),$$$611$$$621$$$O	micronizing$$$622$$$633$$$O	the$$$634$$$637$$$O	mixture$$$638$$$645$$$O	for$$$646$$$649$$$O	7-10$$$650$$$654$$$O	min,$$$655$$$659$$$O	and$$$660$$$663$$$O	adding$$$664$$$670$$$O	pharmaceutically$$$671$$$687$$$O	acceptable$$$688$$$698$$$O	auxiliary$$$699$$$708$$$O	materials$$$709$$$718$$$O	or$$$719$$$721$$$O	auxiliary$$$722$$$731$$$O	ingredients$$$732$$$743$$$O	to$$$744$$$746$$$O	prepare$$$747$$$754$$$O	the$$$755$$$758$$$O	externally$$$759$$$769$$$O	applied$$$770$$$777$$$O	preparation$$$778$$$789$$$O	which$$$790$$$795$$$O	is$$$796$$$798$$$O	commonly$$$799$$$807$$$O	used$$$808$$$812$$$O	in$$$813$$$815$$$O	pharmacy.$$$816$$$825$$$O	The$$$826$$$829$$$O	medicine$$$830$$$838$$$O	prepared$$$839$$$847$$$O	by$$$848$$$850$$$O	the$$$851$$$854$$$O	method$$$855$$$861$$$O	has$$$862$$$865$$$O	dosage$$$866$$$872$$$O	saving$$$873$$$879$$$O	for$$$880$$$883$$$O	each$$$884$$$888$$$O	application,$$$889$$$901$$$O	better$$$902$$$908$$$O	curative$$$909$$$917$$$O	effect,$$$918$$$925$$$O	wide$$$926$$$930$$$O	application$$$931$$$942$$$O	range$$$943$$$948$$$O	and$$$949$$$952$$$O	obvious$$$953$$$960$$$O	effect$$$961$$$967$$$O	for$$$968$$$971$$$O	curing$$$972$$$978$$$O	burns$$$979$$$984$$$O	and$$$985$$$988$$$O	scalds.$$$989$$$996$$$O
US7157491
Hydroxy-phenyl)-aryl-carbaldehyde$$$0$$$33$$$I	oxime$$$34$$$39$$$I	derivatives;$$$40$$$52$$$O	estrogen$$$53$$$61$$$O	receptor$$$62$$$70$$$O	modulators,$$$71$$$82$$$O	treating$$$83$$$91$$$O	inflammatory$$$92$$$104$$$O	bowel$$$105$$$110$$$O	diseases,$$$111$$$120$$$O	Crohn's$$$121$$$128$$$O	disease$$$129$$$136$$$O	and$$$137$$$140$$$O	colitis$$$141$$$148$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	estrogen$$$24$$$32$$$O	receptor$$$33$$$41$$$O	modulators$$$42$$$52$$$O	having$$$53$$$59$$$O	the$$$60$$$63$$$O	structure$$$64$$$73$$$O	where$$$93$$$98$$$O	R1âR5$$$99$$$106$$$O	are$$$107$$$110$$$O	as$$$111$$$113$$$O	defined$$$114$$$121$$$O	in$$$122$$$124$$$O	the$$$125$$$128$$$O	specification;$$$129$$$143$$$O	or$$$144$$$146$$$O	a$$$147$$$148$$$O	pharmaceutically$$$149$$$165$$$O	acceptable$$$166$$$176$$$O	salt$$$177$$$181$$$O	thereof.$$$182$$$190$$$O
EP2668168A1
COMPOUNDS$$$0$$$9$$$O	FOR$$$10$$$13$$$O	THE$$$14$$$17$$$O	REDUCTION$$$18$$$27$$$O	OF$$$28$$$30$$$O	Ã-AMYLOID$$$31$$$41$$$O	PRODUCTION$$$42$$$52$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	provides$$$23$$$31$$$O	a$$$32$$$33$$$O	series$$$34$$$40$$$O	of$$$41$$$43$$$O	compounds$$$44$$$53$$$O	of$$$54$$$56$$$O	the$$$57$$$60$$$O	formula$$$61$$$68$$$O	(I)$$$69$$$72$$$O	which$$$73$$$78$$$O	modulate$$$79$$$87$$$O	&bgr;-amyloid$$$88$$$101$$$O	peptide$$$102$$$109$$$O	(&bgr;-AP)$$$110$$$120$$$O	production$$$121$$$131$$$O	and$$$132$$$135$$$O	are$$$136$$$139$$$O	useful$$$140$$$146$$$O	in$$$147$$$149$$$O	the$$$150$$$153$$$O	treatment$$$154$$$163$$$O	of$$$164$$$166$$$O	Alzheimer's$$$167$$$178$$$O	Disease$$$179$$$186$$$O	and$$$187$$$190$$$O	other$$$191$$$196$$$O	conditions$$$197$$$207$$$O	affected$$$208$$$216$$$O	by$$$217$$$219$$$O	&bgr;-amyloid$$$220$$$233$$$O	peptide$$$234$$$241$$$O	(&bgr;-AP)$$$242$$$252$$$O	production.$$$253$$$264$$$O
WO2008061399A1
Fatty$$$0$$$5$$$I	acid$$$6$$$10$$$I	synthase$$$11$$$19$$$O	inhibitor$$$20$$$29$$$O	and$$$30$$$33$$$O	its$$$34$$$37$$$O	use$$$38$$$41$$$O
Formula$$$0$$$7$$$O	(I)$$$8$$$11$$$O	or$$$12$$$14$$$O	its$$$15$$$18$$$O	pharmaceutically$$$19$$$35$$$O	acceptable$$$36$$$46$$$O	salt$$$47$$$51$$$O	or$$$52$$$54$$$O	hydrate$$$55$$$62$$$O	possessing$$$63$$$73$$$O	inhibiting$$$74$$$84$$$O	fatty$$$85$$$90$$$I	acid$$$91$$$95$$$I	synthase$$$96$$$104$$$O	FabH$$$105$$$109$$$O	effect,$$$110$$$117$$$O	its$$$118$$$121$$$O	preparation,$$$122$$$134$$$O	pharmaceutical$$$135$$$149$$$O	composition$$$150$$$161$$$O	and$$$162$$$165$$$O	use$$$166$$$169$$$O	of$$$170$$$172$$$O	such$$$173$$$177$$$O	compound$$$178$$$186$$$O	in$$$187$$$189$$$O	preparation$$$190$$$201$$$O	of$$$202$$$204$$$O	a$$$205$$$206$$$O	medicament$$$207$$$217$$$O	for$$$218$$$221$$$O	the$$$222$$$225$$$O	treatment$$$226$$$235$$$O	of$$$236$$$238$$$O	bacterial$$$239$$$248$$$O	infections.$$$249$$$260$$$O
WO2013121449A1
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	the$$$29$$$32$$$O	modulation$$$33$$$43$$$O	of$$$44$$$46$$$O	specific$$$47$$$55$$$O	amidases$$$56$$$64$$$O	for$$$65$$$68$$$O	n-acylethanolamines$$$69$$$88$$$I	for$$$89$$$92$$$O	use$$$93$$$96$$$O	in$$$97$$$99$$$O	the$$$100$$$103$$$O	therapy$$$104$$$111$$$O	of$$$112$$$114$$$O	inflammatory$$$115$$$127$$$O	diseases$$$128$$$136$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	regards$$$22$$$29$$$O	compositions$$$30$$$42$$$O	and$$$43$$$46$$$O	methods$$$47$$$54$$$O	for$$$55$$$58$$$O	the$$$59$$$62$$$O	modulation$$$63$$$73$$$O	of$$$74$$$76$$$O	amidases$$$77$$$85$$$O	capable$$$86$$$93$$$O	of$$$94$$$96$$$O	hydrolysing$$$97$$$108$$$O	N-acylethanolamines$$$109$$$128$$$I	useable$$$129$$$136$$$O	in$$$137$$$139$$$O	the$$$140$$$143$$$O	therapy$$$144$$$151$$$O	of$$$152$$$154$$$O	inflammatory$$$155$$$167$$$O	diseases.$$$168$$$177$$$O	In$$$178$$$180$$$O	particular,$$$181$$$192$$$O	the$$$193$$$196$$$O	present$$$197$$$204$$$O	invention$$$205$$$214$$$O	regards$$$215$$$222$$$O	a$$$223$$$224$$$O	compound$$$225$$$233$$$O	of$$$234$$$236$$$O	general$$$237$$$244$$$O	formula$$$245$$$252$$$O	(I):$$$253$$$257$$$O	enantiomers,$$$258$$$270$$$O	diastereoisomers,$$$271$$$288$$$O	racemes$$$289$$$296$$$O	and$$$297$$$300$$$O	mixtures,$$$301$$$310$$$O	polymorphs,$$$311$$$322$$$O	salts,$$$323$$$329$$$O	solvates$$$330$$$338$$$O	thereof,$$$339$$$347$$$O	wherein:$$$348$$$356$$$O	(a)$$$357$$$360$$$O	R$$$361$$$362$$$O	is$$$363$$$365$$$O	a$$$366$$$367$$$O	linear$$$368$$$374$$$O	alkyl$$$375$$$380$$$I	radical$$$381$$$388$$$O	having$$$389$$$395$$$O	13$$$396$$$398$$$O	to$$$399$$$401$$$O	19$$$402$$$404$$$O	carbon$$$405$$$411$$$I	atoms$$$412$$$417$$$O	or$$$418$$$420$$$O	alkenyl$$$421$$$428$$$I	radical$$$429$$$436$$$O	having$$$437$$$443$$$O	13$$$444$$$446$$$O	to$$$447$$$449$$$O	19$$$450$$$452$$$O	carbon$$$453$$$459$$$I	atoms$$$460$$$465$$$O	carrying$$$466$$$474$$$O	a$$$475$$$476$$$O	double$$$477$$$483$$$O	bond;$$$484$$$489$$$O	(b)$$$490$$$493$$$O	X$$$494$$$495$$$O	is$$$496$$$498$$$O	0$$$499$$$500$$$I	or$$$501$$$503$$$O	S;$$$504$$$506$$$I	(c)$$$507$$$510$$$O	Y$$$511$$$512$$$O	is$$$513$$$515$$$O	a$$$516$$$517$$$O	2$$$518$$$519$$$O	or$$$520$$$522$$$O	3$$$523$$$524$$$O	carbon$$$525$$$531$$$I	atom$$$532$$$536$$$O	alkylene$$$537$$$545$$$I	residue,$$$546$$$554$$$O	optionally$$$555$$$565$$$O	substituted$$$566$$$577$$$O	with$$$578$$$582$$$O	one$$$583$$$586$$$O	or$$$587$$$589$$$O	two$$$590$$$593$$$O	groups$$$594$$$600$$$O	equal$$$601$$$606$$$O	or$$$607$$$609$$$O	different$$$610$$$619$$$O	from$$$620$$$624$$$O	each$$$625$$$629$$$O	other$$$630$$$635$$$O	and$$$636$$$639$$$O	selected$$$640$$$648$$$O	from$$$649$$$653$$$O	among$$$654$$$659$$$O	the$$$660$$$663$$$O	group$$$664$$$669$$$O	consisting$$$670$$$680$$$O	of:$$$681$$$684$$$O	-CH3,$$$685$$$690$$$I	-CH2OH,$$$691$$$698$$$I	-COOCH3,$$$699$$$707$$$I	-COOH.$$$708$$$714$$$I	Y$$$715$$$716$$$O	may$$$717$$$720$$$O	preferably$$$721$$$731$$$O	be:$$$732$$$735$$$O	-CH2-CH2-,$$$736$$$746$$$I	-CH2-CH2-CH2-,$$$747$$$761$$$I	CH$$$762$$$764$$$I	(CH3)$$$765$$$770$$$I	-CH2-,$$$771$$$777$$$I	-CH2-CH$$$778$$$785$$$I	(CH3)$$$786$$$791$$$I	-,$$$792$$$794$$$I	-CH2-C$$$795$$$801$$$I	(CH3)$$$802$$$807$$$I	2-,$$$808$$$811$$$I	-CH2-CH$$$812$$$819$$$I	(CH2OH)$$$820$$$827$$$I	-,$$$828$$$830$$$I	-CH2-C$$$831$$$837$$$I	($$$838$$$839$$$I	(CH2OH)$$$840$$$847$$$I	2)$$$848$$$850$$$I	-,$$$851$$$853$$$I	-CH=CH-,$$$854$$$862$$$I	-CH2-CH$$$863$$$870$$$I	(COOCH3)$$$871$$$879$$$I	-,$$$880$$$882$$$I	-CH2-CH$$$883$$$890$$$I	(COOH)$$$891$$$897$$$I	-,$$$898$$$900$$$I	for$$$901$$$904$$$O	use$$$905$$$908$$$O	as$$$909$$$911$$$O	a$$$912$$$913$$$O	medicine.$$$914$$$923$$$O
CN103536527A
Dextromethorphan$$$0$$$16$$$I	hydrobromide$$$17$$$29$$$I	injection$$$30$$$39$$$O	and$$$40$$$43$$$O	preparation$$$44$$$55$$$O	method$$$56$$$62$$$O	thereof$$$63$$$70$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	dextromethorphan$$$27$$$43$$$I	hydrobromide$$$44$$$56$$$I	injection$$$57$$$66$$$O	prepared$$$67$$$75$$$O	from$$$76$$$80$$$O	the$$$81$$$84$$$O	following$$$85$$$94$$$O	raw$$$95$$$98$$$O	materials:$$$99$$$109$$$O	15g$$$110$$$113$$$O	of$$$114$$$116$$$O	dextromethorphan$$$117$$$133$$$I	hydrobromide,$$$134$$$147$$$I	13g$$$148$$$151$$$O	of$$$152$$$154$$$O	lactic$$$155$$$161$$$I	acid,$$$162$$$167$$$I	7g$$$168$$$170$$$O	of$$$171$$$173$$$O	sorbic$$$174$$$180$$$I	acid,$$$181$$$186$$$I	42g$$$187$$$190$$$O	of$$$191$$$193$$$O	polyethylene$$$194$$$206$$$I	glycol$$$207$$$213$$$I	2000$$$214$$$218$$$I	and$$$219$$$222$$$O	2000ml$$$223$$$229$$$O	of$$$230$$$232$$$O	water$$$233$$$238$$$O	for$$$239$$$242$$$O	injection$$$243$$$252$$$O	through$$$253$$$260$$$O	adjusting$$$261$$$270$$$O	the$$$271$$$274$$$O	pH$$$275$$$277$$$O	value$$$278$$$283$$$O	to$$$284$$$286$$$O	3.4-3.5.$$$287$$$295$$$O
CN101278976A
Quality$$$0$$$7$$$O	control$$$8$$$15$$$O	method$$$16$$$22$$$O	of$$$23$$$25$$$O	Shangke$$$26$$$33$$$O	bone-knitting$$$34$$$47$$$O	medicine$$$48$$$56$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	quality$$$26$$$33$$$O	control$$$34$$$41$$$O	method$$$42$$$48$$$O	for$$$49$$$52$$$O	orthopedics-traumatology$$$53$$$77$$$O	coaptation.$$$78$$$89$$$O	The$$$90$$$93$$$O	method$$$94$$$100$$$O	adopts$$$101$$$107$$$O	TLC$$$108$$$111$$$O	to$$$112$$$114$$$O	carry$$$115$$$120$$$O	out$$$121$$$124$$$O	qualitative$$$125$$$136$$$O	identification$$$137$$$151$$$O	for$$$152$$$155$$$O	notoginseng,$$$156$$$168$$$O	borneol,$$$169$$$177$$$I	safflower$$$178$$$187$$$O	and$$$188$$$191$$$O	Nux$$$192$$$195$$$O	vomica$$$196$$$202$$$O	powder$$$203$$$209$$$O	and$$$210$$$213$$$O	uses$$$214$$$218$$$O	electrophoresis$$$219$$$234$$$O	for$$$235$$$238$$$O	carrying$$$239$$$247$$$O	out$$$248$$$251$$$O	qualitative$$$252$$$263$$$O	identification$$$264$$$278$$$O	for$$$279$$$282$$$O	starfish.$$$283$$$292$$$O	HPLC$$$293$$$297$$$O	and$$$298$$$301$$$O	GC$$$302$$$304$$$O	are$$$305$$$308$$$O	respectively$$$309$$$321$$$O	adopted$$$322$$$329$$$O	to$$$330$$$332$$$O	carry$$$333$$$338$$$O	out$$$339$$$342$$$O	quantitative$$$343$$$355$$$O	identification$$$356$$$370$$$O	for$$$371$$$374$$$O	strychnine$$$375$$$385$$$I	and$$$386$$$389$$$O	the$$$390$$$393$$$O	borneol.$$$394$$$402$$$I	Chemical$$$403$$$411$$$O	titration$$$412$$$421$$$O	is$$$422$$$424$$$O	adopted$$$425$$$432$$$O	to$$$433$$$435$$$O	carry$$$436$$$441$$$O	out$$$442$$$445$$$O	quantitative$$$446$$$458$$$O	identification$$$459$$$473$$$O	for$$$474$$$477$$$O	mercury$$$478$$$485$$$I	sulfide.$$$486$$$494$$$I	Therefore,$$$495$$$505$$$O	the$$$506$$$509$$$O	quality$$$510$$$517$$$O	control$$$518$$$525$$$O	scope$$$526$$$531$$$O	of$$$532$$$534$$$O	the$$$535$$$538$$$O	orthopedics-traumatology$$$539$$$563$$$O	coaptation$$$564$$$574$$$O	is$$$575$$$577$$$O	enlarged.$$$578$$$587$$$O	The$$$588$$$591$$$O	quality$$$592$$$599$$$O	control$$$600$$$607$$$O	method$$$608$$$614$$$O	for$$$615$$$618$$$O	orthopedics-traumatology$$$619$$$643$$$O	coaptation$$$644$$$654$$$O	is$$$655$$$657$$$O	easy$$$658$$$662$$$O	to$$$663$$$665$$$O	be$$$666$$$668$$$O	practiced$$$669$$$678$$$O	and$$$679$$$682$$$O	has$$$683$$$686$$$O	strong$$$687$$$693$$$O	specialization.$$$694$$$709$$$O	In$$$710$$$712$$$O	addition,$$$713$$$722$$$O	the$$$723$$$726$$$O	quantitative$$$727$$$739$$$O	identification$$$740$$$754$$$O	has$$$755$$$758$$$O	high$$$759$$$763$$$O	precision$$$764$$$773$$$O	and$$$774$$$777$$$O	good$$$778$$$782$$$O	repeatability,$$$783$$$797$$$O	thus$$$798$$$802$$$O	ensuring$$$803$$$811$$$O	that$$$812$$$816$$$O	the$$$817$$$820$$$O	quality$$$821$$$828$$$O	of$$$829$$$831$$$O	compound$$$832$$$840$$$O	medicine$$$841$$$849$$$O	is$$$850$$$852$$$O	uniform,$$$853$$$861$$$O	stable,$$$862$$$869$$$O	effective$$$870$$$879$$$O	and$$$880$$$883$$$O	controllable.$$$884$$$897$$$O
US8592420
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	treating$$$10$$$18$$$O	an$$$19$$$21$$$O	anxiety$$$22$$$29$$$O	disorder$$$30$$$38$$$O
Anxiety$$$0$$$7$$$O	disorders,$$$8$$$18$$$O	such$$$19$$$23$$$O	as$$$24$$$26$$$O	panic$$$27$$$32$$$O	disorder,$$$33$$$42$$$O	agoraphobia,$$$43$$$55$$$O	obsessive-compulsive$$$56$$$76$$$O	disorder,$$$77$$$86$$$O	social$$$87$$$93$$$O	phobia,$$$94$$$101$$$O	post-traumatic$$$102$$$116$$$O	stress$$$117$$$123$$$O	disorder,$$$124$$$133$$$O	generalized$$$134$$$145$$$O	anxiety$$$146$$$153$$$O	disorder,$$$154$$$163$$$O	specific$$$164$$$172$$$O	phobia,$$$173$$$180$$$O	or$$$181$$$183$$$O	the$$$184$$$187$$$O	like,$$$188$$$193$$$O	are$$$194$$$197$$$O	treated$$$198$$$205$$$O	by$$$206$$$208$$$O	administering$$$209$$$222$$$O	an$$$223$$$225$$$O	effective$$$226$$$235$$$O	amount$$$236$$$242$$$O	of$$$243$$$245$$$O	at$$$246$$$248$$$O	least$$$249$$$254$$$O	one$$$255$$$258$$$O	adenosine$$$259$$$268$$$I	A2A$$$269$$$272$$$O	receptor$$$273$$$281$$$O	antagonist$$$282$$$292$$$O	to$$$293$$$295$$$O	a$$$296$$$297$$$O	patient$$$298$$$305$$$O	in$$$306$$$308$$$O	need$$$309$$$313$$$O	thereof,$$$314$$$322$$$O	optionally$$$323$$$333$$$O	in$$$334$$$336$$$O	combination$$$337$$$348$$$O	with$$$349$$$353$$$O	an$$$354$$$356$$$O	anxiolytic(s)$$$357$$$370$$$O	other$$$371$$$376$$$O	than$$$377$$$381$$$O	the$$$382$$$385$$$O	adenosine$$$386$$$395$$$I	A2A$$$396$$$399$$$O	receptor$$$400$$$408$$$O	antagonist.$$$409$$$420$$$O
WO2008004117A1
Selective$$$0$$$9$$$O	azole$$$10$$$15$$$I	pde10a$$$16$$$22$$$O	inhibitor$$$23$$$32$$$O	compounds$$$33$$$42$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	pertains$$$14$$$22$$$O	to$$$23$$$25$$$O	heteroaromatic$$$26$$$40$$$I	compounds$$$41$$$50$$$O	of$$$51$$$53$$$O	the$$$54$$$57$$$O	formula$$$58$$$65$$$O	I,$$$66$$$68$$$O	as$$$69$$$71$$$O	defined$$$72$$$79$$$O	herein,$$$80$$$87$$$O	that$$$88$$$92$$$O	serve$$$93$$$98$$$O	as$$$99$$$101$$$O	effective$$$102$$$111$$$O	phosphodiesterase$$$112$$$129$$$O	(PDE)$$$130$$$135$$$O	inhibitors.$$$136$$$147$$$O	In$$$148$$$150$$$O	particular,$$$151$$$162$$$O	the$$$163$$$166$$$O	invention$$$167$$$176$$$O	relates$$$177$$$184$$$O	to$$$185$$$187$$$O	said$$$188$$$192$$$O	compounds$$$193$$$202$$$O	which$$$203$$$208$$$O	are$$$209$$$212$$$O	selective$$$213$$$222$$$O	inhibitors$$$223$$$233$$$O	of$$$234$$$236$$$O	PDE10.$$$237$$$243$$$O	The$$$244$$$247$$$O	invention$$$248$$$257$$$O	also$$$258$$$262$$$O	relates$$$263$$$270$$$O	to$$$271$$$273$$$O	pharmaceutical$$$274$$$288$$$O	compositions$$$289$$$301$$$O	comprising$$$302$$$312$$$O	said$$$313$$$317$$$O	compounds;$$$318$$$328$$$O	and$$$329$$$332$$$O	the$$$333$$$336$$$O	use$$$337$$$340$$$O	of$$$341$$$343$$$O	said$$$344$$$348$$$O	compounds$$$349$$$358$$$O	in$$$359$$$361$$$O	a$$$362$$$363$$$O	method$$$364$$$370$$$O	for$$$371$$$374$$$O	treating$$$375$$$383$$$O	certain$$$384$$$391$$$O	central$$$392$$$399$$$O	nervous$$$400$$$407$$$O	system$$$408$$$414$$$O	(CNS)$$$415$$$420$$$O	or$$$421$$$423$$$O	other$$$424$$$429$$$O	disorders.$$$430$$$440$$$O
WO2006097323A1
TETRAHYDRO-ISOQUINOLIN-l-ONES$$$0$$$29$$$I	FOR$$$30$$$33$$$O	THE$$$34$$$37$$$O	TREATMENT$$$38$$$47$$$O	OF$$$48$$$50$$$O	CANCER$$$51$$$57$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	compound$$$33$$$41$$$O	selected$$$42$$$50$$$O	from$$$51$$$55$$$O	compounds$$$56$$$65$$$O	of$$$66$$$68$$$O	formula$$$69$$$76$$$O	I$$$77$$$78$$$O	as$$$79$$$81$$$O	ligand$$$82$$$88$$$O	binding$$$89$$$96$$$O	to$$$97$$$99$$$O	the$$$100$$$103$$$O	HDM2$$$104$$$108$$$O	protein,$$$109$$$117$$$O	inducing$$$118$$$126$$$O	apoptosis$$$127$$$136$$$O	and$$$137$$$140$$$O	inhibiting$$$141$$$151$$$O	proliferation,and$$$152$$$169$$$O	having$$$170$$$176$$$O	therapeutic$$$177$$$188$$$O	utility$$$189$$$196$$$O	in$$$197$$$199$$$O	cancer$$$200$$$206$$$O	therapy.$$$207$$$215$$$O	Compounds$$$216$$$225$$$O	of$$$226$$$228$$$O	formula$$$229$$$236$$$O	(I)$$$237$$$240$$$O	can$$$241$$$244$$$O	be$$$245$$$247$$$O	used$$$248$$$252$$$O	as$$$253$$$255$$$O	therapeutics$$$256$$$268$$$O	for$$$269$$$272$$$O	treating$$$273$$$281$$$O	stroke,$$$282$$$289$$$O	myocardial$$$290$$$300$$$O	infarction,$$$301$$$312$$$O	ischemia,$$$313$$$322$$$O	multi-organ$$$323$$$334$$$O	failure,$$$335$$$343$$$O	spinal$$$344$$$350$$$O	cord$$$351$$$355$$$O	injury,$$$356$$$363$$$O	Alzheimer's$$$364$$$375$$$O	Disease,$$$376$$$384$$$O	injury$$$385$$$391$$$O	from$$$392$$$396$$$O	ischemic$$$397$$$405$$$O	events,$$$406$$$413$$$O	heart$$$414$$$419$$$O	valvular$$$420$$$428$$$O	degenerative$$$429$$$441$$$O	disease$$$442$$$449$$$O	Moreover,$$$450$$$459$$$O	compounds$$$460$$$469$$$O	of$$$470$$$472$$$O	formula$$$473$$$480$$$O	(I)$$$481$$$484$$$O	can$$$485$$$488$$$O	be$$$489$$$491$$$O	used$$$492$$$496$$$O	to$$$497$$$499$$$O	decrease$$$500$$$508$$$O	the$$$509$$$512$$$O	side$$$513$$$517$$$O	effects$$$518$$$525$$$O	from$$$526$$$530$$$O	cytotoxic$$$531$$$540$$$O	cancer$$$541$$$547$$$O	agents$$$548$$$554$$$O	and$$$555$$$558$$$O	to$$$559$$$561$$$O	treat$$$562$$$567$$$O	viral$$$568$$$573$$$O	infections$$$574$$$584$$$O	.$$$585$$$586$$$O
EP1732897A1
Quinolone$$$0$$$9$$$I	carboxylic$$$10$$$20$$$I	acid$$$21$$$25$$$I	derivatives$$$26$$$37$$$O	for$$$38$$$41$$$O	treatment$$$42$$$51$$$O	of$$$52$$$54$$$O	hyperproliferative$$$55$$$73$$$O	conditions$$$74$$$84$$$O
Quinolone$$$0$$$9$$$I	carboxylic$$$10$$$20$$$I	acid$$$21$$$25$$$I	derivatives$$$26$$$37$$$O	of$$$38$$$40$$$O	formula$$$41$$$48$$$O	(I)$$$49$$$52$$$O	wherein$$$53$$$60$$$O	Ar$$$61$$$63$$$I	is$$$64$$$66$$$O	an$$$67$$$69$$$O	optionally$$$70$$$80$$$O	substituted$$$81$$$92$$$O	phenyl,$$$93$$$100$$$I	pyridyl,$$$101$$$109$$$I	or$$$110$$$112$$$O	pyrimidinyl$$$113$$$124$$$I	group$$$125$$$130$$$O	and$$$131$$$134$$$O	the$$$135$$$138$$$O	substituent$$$139$$$150$$$O	groups$$$151$$$157$$$O	R1,$$$158$$$161$$$O	R4,$$$162$$$165$$$O	R10,$$$166$$$170$$$O	R11,$$$171$$$175$$$O	R19,$$$176$$$180$$$O	and$$$181$$$184$$$O	R20$$$185$$$188$$$O	are$$$189$$$192$$$O	as$$$193$$$195$$$O	defined$$$196$$$203$$$O	in$$$204$$$206$$$O	the$$$207$$$210$$$O	specification,$$$211$$$225$$$O	pharmaceutical$$$226$$$240$$$O	compositions$$$241$$$253$$$O	containing$$$254$$$264$$$O	them,$$$265$$$270$$$O	and$$$271$$$274$$$O	methods$$$275$$$282$$$O	of$$$283$$$285$$$O	using$$$286$$$291$$$O	them$$$292$$$296$$$O	in$$$297$$$299$$$O	treatment$$$300$$$309$$$O	of$$$310$$$312$$$O	hyperproliferative$$$313$$$331$$$O	diseases$$$332$$$340$$$O	such$$$341$$$345$$$O	as$$$346$$$348$$$O	cancer$$$349$$$355$$$O	are$$$356$$$359$$$O	disclosed$$$360$$$369$$$O	and$$$370$$$373$$$O	claimed.$$$374$$$382$$$O
CN101108172A
Oral$$$0$$$4$$$O	sticking$$$5$$$13$$$O	tablet$$$14$$$20$$$O	and$$$21$$$24$$$O	method$$$25$$$31$$$O	of$$$32$$$34$$$O	preparing$$$35$$$44$$$O	the$$$45$$$48$$$O	same$$$49$$$53$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	oral$$$28$$$32$$$O	cavity$$$33$$$39$$$O	plaster,$$$40$$$48$$$O	which$$$49$$$54$$$O	has$$$55$$$58$$$O	effective$$$59$$$68$$$O	dosage$$$69$$$75$$$O	of$$$76$$$78$$$O	active$$$79$$$85$$$O	drug$$$86$$$90$$$O	ingredient,$$$91$$$102$$$O	1$$$103$$$104$$$O	per$$$105$$$108$$$O	cent$$$109$$$113$$$O	to$$$114$$$116$$$O	40$$$117$$$119$$$O	per$$$120$$$123$$$O	cent$$$124$$$128$$$O	bioadhesion$$$129$$$140$$$O	ingredient,$$$141$$$152$$$O	0$$$153$$$154$$$O	per$$$155$$$158$$$O	cent$$$159$$$163$$$O	to$$$164$$$166$$$O	85$$$167$$$169$$$O	per$$$170$$$173$$$O	cent$$$174$$$178$$$O	(w/w)$$$179$$$184$$$O	diluted$$$185$$$192$$$O	filling$$$193$$$200$$$O	ingredient,$$$201$$$212$$$O	0$$$213$$$214$$$O	per$$$215$$$218$$$O	cent$$$219$$$223$$$O	to$$$224$$$226$$$O	5$$$227$$$228$$$O	per$$$229$$$232$$$O	cent$$$233$$$237$$$O	(w/w)$$$238$$$243$$$O	lubricant$$$244$$$253$$$O	glidant$$$254$$$261$$$O	ingredient$$$262$$$272$$$O	and$$$273$$$276$$$O	0.5$$$277$$$280$$$O	per$$$281$$$284$$$O	cent$$$285$$$289$$$O	to$$$290$$$292$$$O	89$$$293$$$295$$$O	per$$$296$$$299$$$O	cent$$$300$$$304$$$O	(w/w)$$$305$$$310$$$O	water$$$311$$$316$$$O	absorption$$$317$$$327$$$O	carrier$$$328$$$335$$$O	ingredient.$$$336$$$347$$$O	Wherein,$$$348$$$356$$$O	the$$$357$$$360$$$O	active$$$361$$$367$$$O	drug$$$368$$$372$$$O	ingredient$$$373$$$383$$$O	comprises$$$384$$$393$$$O	fluconazole,$$$394$$$406$$$I	itraconazole,$$$407$$$420$$$I	clotrimazole$$$421$$$433$$$I	or$$$434$$$436$$$O	Nystatin.$$$437$$$446$$$I	Therefore,$$$447$$$457$$$O	the$$$458$$$461$$$O	oral$$$462$$$466$$$O	cavity$$$467$$$473$$$O	plaster$$$474$$$481$$$O	in$$$482$$$484$$$O	the$$$485$$$488$$$O	invention$$$489$$$498$$$O	can$$$499$$$502$$$O	be$$$503$$$505$$$O	adhered$$$506$$$513$$$O	to$$$514$$$516$$$O	the$$$517$$$520$$$O	medication$$$521$$$531$$$O	position,$$$532$$$541$$$O	is$$$542$$$544$$$O	able$$$545$$$549$$$O	to$$$550$$$552$$$O	continuously$$$553$$$565$$$O	and$$$566$$$569$$$O	stably$$$570$$$576$$$O	release$$$577$$$584$$$O	drug$$$585$$$589$$$O	in$$$590$$$592$$$O	during$$$593$$$599$$$O	a$$$600$$$601$$$O	long$$$602$$$606$$$O	time$$$607$$$611$$$O	(within$$$612$$$619$$$O	9$$$620$$$621$$$O	hours)$$$622$$$628$$$O	as$$$629$$$631$$$O	well$$$632$$$636$$$O	as$$$637$$$639$$$O	maintain$$$640$$$648$$$O	effective$$$649$$$658$$$O	and$$$659$$$662$$$O	safe$$$663$$$667$$$O	drug$$$668$$$672$$$O	concentration$$$673$$$686$$$O	and$$$687$$$690$$$O	prevent$$$691$$$698$$$O	the$$$699$$$702$$$O	impact$$$703$$$709$$$O	on$$$710$$$712$$$O	medication$$$713$$$723$$$O	resulted$$$724$$$732$$$O	from$$$733$$$737$$$O	eating,$$$738$$$745$$$O	drinking$$$746$$$754$$$O	and$$$755$$$758$$$O	swallow$$$759$$$766$$$O	action$$$767$$$773$$$O	of$$$774$$$776$$$O	oral$$$777$$$781$$$O	cavity.$$$782$$$789$$$O
EP1714652A2
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	thiazolidinediones$$$7$$$25$$$I	to$$$26$$$28$$$O	prevent$$$29$$$36$$$O	or$$$37$$$39$$$O	delay$$$40$$$45$$$O	onset$$$46$$$51$$$O	of$$$52$$$54$$$O	niddm$$$55$$$60$$$O
A$$$0$$$1$$$O	novel$$$2$$$7$$$O	method$$$8$$$14$$$O	of$$$15$$$17$$$O	using$$$18$$$23$$$O	thiazolidinedione$$$24$$$41$$$I	derivatives$$$42$$$53$$$O	and$$$54$$$57$$$O	related$$$58$$$65$$$O	antihyperglycemic$$$66$$$83$$$O	agents$$$84$$$90$$$O	to$$$91$$$93$$$O	treat$$$94$$$99$$$O	populations$$$100$$$111$$$O	experiencing$$$112$$$124$$$O	impaired$$$125$$$133$$$O	glucose$$$134$$$141$$$I	tolerance$$$142$$$151$$$O	in$$$152$$$154$$$O	order$$$155$$$160$$$O	to$$$161$$$163$$$O	prevent$$$164$$$171$$$O	or$$$172$$$174$$$O	delay$$$175$$$180$$$O	the$$$181$$$184$$$O	onset$$$185$$$190$$$O	of$$$191$$$193$$$O	noninsulin-dependent$$$194$$$214$$$O	diabetes$$$215$$$223$$$O	mellitus$$$224$$$232$$$O	(NIDDM)$$$233$$$240$$$O	and$$$241$$$244$$$O	complications$$$245$$$258$$$O	arising$$$259$$$266$$$O	therefrom$$$267$$$276$$$O	is$$$277$$$279$$$O	disclosed.$$$280$$$290$$$O
US20130059917
Modified$$$0$$$8$$$O	release$$$9$$$16$$$O	dosage$$$17$$$23$$$O	form$$$24$$$28$$$O	comprising$$$29$$$39$$$O	desvenlafaxine$$$40$$$54$$$I	or$$$55$$$57$$$O	salts$$$58$$$63$$$O	thereof$$$64$$$71$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	refers$$$22$$$28$$$O	to$$$29$$$31$$$O	a$$$32$$$33$$$O	modified$$$34$$$42$$$O	release$$$43$$$50$$$O	pharmaceutical$$$51$$$65$$$O	composition$$$66$$$77$$$O	comprising$$$78$$$88$$$O	desvenlafaxine$$$89$$$103$$$I	or$$$104$$$106$$$O	salts$$$107$$$112$$$O	thereof,$$$113$$$121$$$O	a$$$122$$$123$$$O	release$$$124$$$131$$$O	rate$$$132$$$136$$$O	modifying$$$137$$$146$$$O	system$$$147$$$153$$$O	that$$$154$$$158$$$O	controls$$$159$$$167$$$O	the$$$168$$$171$$$O	release$$$172$$$179$$$O	of$$$180$$$182$$$O	active$$$183$$$189$$$O	agent(s)$$$190$$$198$$$O	in$$$199$$$201$$$O	both$$$202$$$206$$$O	acidic$$$207$$$213$$$O	and$$$214$$$217$$$O	basic$$$218$$$223$$$O	environments.$$$224$$$237$$$O	A$$$238$$$239$$$O	process$$$240$$$247$$$O	of$$$248$$$250$$$O	making$$$251$$$257$$$O	and$$$258$$$261$$$O	method$$$262$$$268$$$O	of$$$269$$$271$$$O	using$$$272$$$277$$$O	the$$$278$$$281$$$O	above-described$$$282$$$297$$$O	composition$$$298$$$309$$$O	is$$$310$$$312$$$O	also$$$313$$$317$$$O	disclosed.$$$318$$$328$$$O
CN101766689A
Soft$$$0$$$4$$$O	capsule$$$5$$$12$$$O	for$$$13$$$16$$$O	preventing$$$17$$$27$$$O	and$$$28$$$31$$$O	treating$$$32$$$40$$$O	climacteric$$$41$$$52$$$O	syndrome$$$53$$$61$$$O	and$$$62$$$65$$$O	preparation$$$66$$$77$$$O	method$$$78$$$84$$$O	thereof$$$85$$$92$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	soft$$$27$$$31$$$O	capsule$$$32$$$39$$$O	for$$$40$$$43$$$O	preventing$$$44$$$54$$$O	and$$$55$$$58$$$O	treating$$$59$$$67$$$O	climacteric$$$68$$$79$$$O	syndrome$$$80$$$88$$$O	and$$$89$$$92$$$O	a$$$93$$$94$$$O	preparation$$$95$$$106$$$O	method$$$107$$$113$$$O	thereof.$$$114$$$122$$$O	The$$$123$$$126$$$O	soft$$$127$$$131$$$O	capsule$$$132$$$139$$$O	for$$$140$$$143$$$O	preventing$$$144$$$154$$$O	and$$$155$$$158$$$O	treating$$$159$$$167$$$O	climacteric$$$168$$$179$$$O	syndrome$$$180$$$188$$$O	comprises$$$189$$$198$$$O	the$$$199$$$202$$$O	raw$$$203$$$206$$$O	materials$$$207$$$216$$$O	by$$$217$$$219$$$O	weight$$$220$$$226$$$O	portion:$$$227$$$235$$$O	10-100$$$236$$$242$$$O	portions$$$243$$$251$$$O	of$$$252$$$254$$$O	soybean$$$255$$$262$$$O	isoflavone,$$$263$$$274$$$I	50-200$$$275$$$281$$$O	portions$$$282$$$290$$$O	of$$$291$$$293$$$O	acanthopanacis$$$294$$$308$$$O	senticosi$$$309$$$318$$$O	extractum,$$$319$$$329$$$O	20-100$$$330$$$336$$$O	portions$$$337$$$345$$$O	of$$$346$$$348$$$O	fructus$$$349$$$356$$$O	schizandrae$$$357$$$368$$$O	extractum,$$$369$$$379$$$O	20-200$$$380$$$386$$$O	portions$$$387$$$395$$$O	of$$$396$$$398$$$O	vitamin$$$399$$$406$$$I	E,$$$407$$$409$$$I	20-100$$$410$$$416$$$O	portions$$$417$$$425$$$O	of$$$426$$$428$$$O	sodium$$$429$$$435$$$I	glycerophosphate,$$$436$$$453$$$I	food$$$454$$$458$$$O	oil$$$459$$$462$$$O	and$$$463$$$466$$$O	dried$$$467$$$472$$$O	extract$$$473$$$480$$$O	mixed$$$481$$$486$$$O	powder,$$$487$$$494$$$O	wherein$$$495$$$502$$$O	the$$$503$$$506$$$O	dried$$$507$$$512$$$O	extract$$$513$$$520$$$O	mixed$$$521$$$526$$$O	powder$$$527$$$533$$$O	is$$$534$$$536$$$O	20-50%$$$537$$$543$$$O	of$$$544$$$546$$$O	the$$$547$$$550$$$O	oil-based$$$551$$$560$$$O	quality$$$561$$$568$$$O	of$$$569$$$571$$$O	the$$$572$$$575$$$O	food$$$576$$$580$$$O	oil$$$581$$$584$$$O	in$$$585$$$587$$$O	the$$$588$$$591$$$O	soft$$$592$$$596$$$O	capsule.$$$597$$$605$$$O	The$$$606$$$609$$$O	soft$$$610$$$614$$$O	capsule$$$615$$$622$$$O	is$$$623$$$625$$$O	used$$$626$$$630$$$O	for$$$631$$$634$$$O	preventing$$$635$$$645$$$O	and$$$646$$$649$$$O	treating$$$650$$$658$$$O	climacteric$$$659$$$670$$$O	syndrome$$$671$$$679$$$O	of$$$680$$$682$$$O	women.$$$683$$$689$$$O
CN103142567A
Softening$$$0$$$9$$$O	and$$$10$$$13$$$O	dissolving$$$14$$$24$$$O	method$$$25$$$31$$$O	of$$$32$$$34$$$O	ossific$$$35$$$42$$$O	mass$$$43$$$47$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	softening$$$26$$$35$$$O	and$$$36$$$39$$$O	dissolving$$$40$$$50$$$O	method$$$51$$$57$$$O	of$$$58$$$60$$$O	an$$$61$$$63$$$O	ossific$$$64$$$71$$$O	mass,$$$72$$$77$$$O	which$$$78$$$83$$$O	comprises$$$84$$$93$$$O	the$$$94$$$97$$$O	following$$$98$$$107$$$O	steps:$$$108$$$114$$$O	A.$$$115$$$117$$$O	adding$$$118$$$124$$$O	pure$$$125$$$129$$$O	water$$$130$$$135$$$O	into$$$136$$$140$$$O	100%$$$141$$$145$$$O	glacial$$$146$$$153$$$I	acetic$$$154$$$160$$$I	acid$$$161$$$165$$$I	to$$$166$$$168$$$O	prepare$$$169$$$176$$$O	an$$$177$$$179$$$O	18-20%$$$180$$$186$$$O	solution,$$$187$$$196$$$O	and$$$197$$$200$$$O	adding$$$201$$$207$$$O	1/1000$$$208$$$214$$$O	deodorant$$$215$$$224$$$O	to$$$225$$$227$$$O	obtain$$$228$$$234$$$O	a$$$235$$$236$$$O	mixed$$$237$$$242$$$O	liquid;$$$243$$$250$$$O	B.$$$251$$$253$$$O	taking$$$254$$$260$$$O	a$$$261$$$262$$$O	common$$$263$$$269$$$O	towel,$$$270$$$276$$$O	folding$$$277$$$284$$$O	into$$$285$$$289$$$O	4-6$$$290$$$293$$$O	layers,$$$294$$$301$$$O	pouring$$$302$$$309$$$O	20$$$310$$$312$$$O	ml$$$313$$$315$$$O	of$$$316$$$318$$$O	the$$$319$$$322$$$O	mixed$$$323$$$328$$$O	liquid$$$329$$$335$$$O	obtained$$$336$$$344$$$O	in$$$345$$$347$$$O	the$$$348$$$351$$$O	step$$$352$$$356$$$O	A$$$357$$$358$$$O	to$$$359$$$361$$$O	the$$$362$$$365$$$O	middle$$$366$$$372$$$O	part$$$373$$$377$$$O	of$$$378$$$380$$$O	the$$$381$$$384$$$O	towel,$$$385$$$391$$$O	and$$$392$$$395$$$O	applying$$$396$$$404$$$O	the$$$405$$$408$$$O	towel$$$409$$$414$$$O	on$$$415$$$417$$$O	the$$$418$$$421$$$O	ossific$$$422$$$429$$$O	mass$$$430$$$434$$$O	part;$$$435$$$440$$$O	and$$$441$$$444$$$O	C.$$$445$$$447$$$O	putting$$$448$$$455$$$O	a$$$456$$$457$$$O	heating$$$458$$$465$$$O	unit$$$466$$$470$$$O	on$$$471$$$473$$$O	the$$$474$$$477$$$O	towel$$$478$$$483$$$O	until$$$484$$$489$$$O	the$$$490$$$493$$$O	temperature$$$494$$$505$$$O	reaches$$$506$$$513$$$O	50$$$514$$$516$$$O	DEG$$$517$$$520$$$O	C,$$$521$$$523$$$O	and$$$524$$$527$$$O	carrying$$$528$$$536$$$O	out$$$537$$$540$$$O	hot$$$541$$$544$$$O	compress$$$545$$$553$$$O	for$$$554$$$557$$$O	30$$$558$$$560$$$O	minutes$$$561$$$568$$$O	so$$$569$$$571$$$O	that$$$572$$$576$$$O	the$$$577$$$580$$$O	mixed$$$581$$$586$$$O	liquid$$$587$$$593$$$O	obtained$$$594$$$602$$$O	in$$$603$$$605$$$O	the$$$606$$$609$$$O	step$$$610$$$614$$$O	A$$$615$$$616$$$O	becomes$$$617$$$624$$$O	gas$$$625$$$628$$$O	and$$$629$$$632$$$O	permeates$$$633$$$642$$$O	into$$$643$$$647$$$O	the$$$648$$$651$$$O	ossific$$$652$$$659$$$O	mass$$$660$$$664$$$O	part$$$665$$$669$$$O	via$$$670$$$673$$$O	the$$$674$$$677$$$O	skin.$$$678$$$683$$$O	Compared$$$684$$$692$$$O	with$$$693$$$697$$$O	the$$$698$$$701$$$O	prior$$$702$$$707$$$O	art,$$$708$$$712$$$O	the$$$713$$$716$$$O	method$$$717$$$723$$$O	disclosed$$$724$$$733$$$O	by$$$734$$$736$$$O	the$$$737$$$740$$$O	invention$$$741$$$750$$$O	can$$$751$$$754$$$O	effectively$$$755$$$766$$$O	soften$$$767$$$773$$$O	and$$$774$$$777$$$O	dissolve$$$778$$$786$$$O	the$$$787$$$790$$$O	ossific$$$791$$$798$$$O	mass,$$$799$$$804$$$O	relieve$$$805$$$812$$$O	the$$$813$$$816$$$O	pain$$$817$$$821$$$O	of$$$822$$$824$$$O	the$$$825$$$828$$$O	patient,$$$829$$$837$$$O	avoid$$$838$$$843$$$O	the$$$844$$$847$$$O	danger$$$848$$$854$$$O	of$$$855$$$857$$$O	operative$$$858$$$867$$$O	treatment,$$$868$$$878$$$O	and$$$879$$$882$$$O	perform$$$883$$$890$$$O	the$$$891$$$894$$$O	function$$$895$$$903$$$O	of$$$904$$$906$$$O	radical$$$907$$$914$$$O	cure;$$$915$$$920$$$O	and$$$921$$$924$$$O	the$$$925$$$928$$$O	method$$$929$$$935$$$O	disclosed$$$936$$$945$$$O	by$$$946$$$948$$$O	the$$$949$$$952$$$O	invention$$$953$$$962$$$O	is$$$963$$$965$$$O	low$$$966$$$969$$$O	in$$$970$$$972$$$O	cost$$$973$$$977$$$O	and$$$978$$$981$$$O	simple$$$982$$$988$$$O	to$$$989$$$991$$$O	operate.$$$992$$$1000$$$O
US20080020969
36$$$0$$$2$$$O	Human$$$3$$$8$$$O	Secreted$$$9$$$17$$$O	Proteins$$$18$$$26$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	36$$$33$$$35$$$O	novel$$$36$$$41$$$O	human$$$42$$$47$$$O	secreted$$$48$$$56$$$O	proteins$$$57$$$65$$$O	and$$$66$$$69$$$O	isolated$$$70$$$78$$$O	nucleic$$$79$$$86$$$O	acids$$$87$$$92$$$O	containing$$$93$$$103$$$O	the$$$104$$$107$$$O	coding$$$108$$$114$$$O	regions$$$115$$$122$$$O	of$$$123$$$125$$$O	the$$$126$$$129$$$O	genes$$$130$$$135$$$O	encoding$$$136$$$144$$$O	such$$$145$$$149$$$O	proteins.$$$150$$$159$$$O	Also$$$160$$$164$$$O	provided$$$165$$$173$$$O	are$$$174$$$177$$$O	vectors,$$$178$$$186$$$O	host$$$187$$$191$$$O	cells,$$$192$$$198$$$O	antibodies,$$$199$$$210$$$O	and$$$211$$$214$$$O	recombinant$$$215$$$226$$$O	methods$$$227$$$234$$$O	for$$$235$$$238$$$O	producing$$$239$$$248$$$O	human$$$249$$$254$$$O	secreted$$$255$$$263$$$O	proteins.$$$264$$$273$$$O	The$$$274$$$277$$$O	invention$$$278$$$287$$$O	further$$$288$$$295$$$O	relates$$$296$$$303$$$O	to$$$304$$$306$$$O	diagnostic$$$307$$$317$$$O	and$$$318$$$321$$$O	therapeutic$$$322$$$333$$$O	methods$$$334$$$341$$$O	useful$$$342$$$348$$$O	for$$$349$$$352$$$O	diagnosing$$$353$$$363$$$O	and$$$364$$$367$$$O	treating$$$368$$$376$$$O	disorders$$$377$$$386$$$O	related$$$387$$$394$$$O	to$$$395$$$397$$$O	these$$$398$$$403$$$O	novel$$$404$$$409$$$O	human$$$410$$$415$$$O	secreted$$$416$$$424$$$O	proteins.$$$425$$$434$$$O
US20100189771
Fixed$$$0$$$5$$$O	ratio$$$6$$$11$$$O	drug$$$12$$$16$$$O	combination$$$17$$$28$$$O	treatments$$$29$$$39$$$O	for$$$40$$$43$$$O	solid$$$44$$$49$$$O	tumors$$$50$$$56$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	methods$$$20$$$27$$$O	for$$$28$$$31$$$O	treating$$$32$$$40$$$O	cancer$$$41$$$47$$$O	by$$$48$$$50$$$O	administering$$$51$$$64$$$O	a$$$65$$$66$$$O	pharmaceutical$$$67$$$81$$$O	composition$$$82$$$93$$$O	comprising$$$94$$$104$$$O	a$$$105$$$106$$$O	fixed,$$$107$$$113$$$O	non-antagonistic$$$114$$$130$$$O	molar$$$131$$$136$$$O	ratio$$$137$$$142$$$O	of$$$143$$$145$$$O	irinotecan$$$146$$$156$$$I	and$$$157$$$160$$$O	floxuridine.$$$161$$$173$$$I	Such$$$174$$$178$$$O	methods$$$179$$$186$$$O	are$$$187$$$190$$$O	particularly$$$191$$$203$$$O	useful$$$204$$$210$$$O	in$$$211$$$213$$$O	the$$$214$$$217$$$O	treatment$$$218$$$227$$$O	of$$$228$$$230$$$O	cancer$$$231$$$237$$$O	patients$$$238$$$246$$$O	with$$$247$$$251$$$O	advanced$$$252$$$260$$$O	solid$$$261$$$266$$$O	tumors.$$$267$$$274$$$O
US8071631
An$$$0$$$2$$$O	enzyme$$$3$$$9$$$O	in$$$10$$$12$$$O	the$$$13$$$16$$$O	tryptophan$$$17$$$27$$$I	degradation$$$28$$$39$$$O	pathway,$$$40$$$48$$$O	used$$$49$$$53$$$O	to$$$54$$$56$$$O	treat$$$57$$$62$$$O	neurodegenerative$$$63$$$80$$$O	disorders,$$$81$$$91$$$O	certain$$$92$$$99$$$O	cancers,$$$100$$$108$$$O	drug$$$109$$$113$$$O	addiction;$$$114$$$124$$$O	arylsulfonamides$$$125$$$141$$$I	such$$$142$$$146$$$O	as$$$147$$$149$$$O	3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide$$$150$$$227$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	Formula$$$46$$$53$$$O	I$$$54$$$55$$$O	below$$$56$$$61$$$O	and$$$62$$$65$$$O	their$$$66$$$71$$$O	tautomers$$$72$$$81$$$O	or$$$82$$$84$$$O	pharmaceutically$$$85$$$101$$$O	acceptable$$$102$$$112$$$O	salts,$$$113$$$119$$$O	compositions$$$120$$$132$$$O	and$$$133$$$136$$$O	methods$$$137$$$144$$$O	of$$$145$$$147$$$O	uses$$$148$$$152$$$O	thereof:$$$153$$$161$$$O
CN102512462A
Ointment$$$0$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	rhinitis$$$22$$$30$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	an$$$32$$$34$$$O	ointment$$$35$$$43$$$O	for$$$44$$$47$$$O	treating$$$48$$$56$$$O	rhinitis.$$$57$$$66$$$O	The$$$67$$$70$$$O	ointment$$$71$$$79$$$O	comprises$$$80$$$89$$$O	the$$$90$$$93$$$O	following$$$94$$$103$$$O	components:$$$104$$$115$$$O	0.02$$$116$$$120$$$O	to$$$121$$$123$$$O	0.05g$$$124$$$129$$$O	artificial$$$130$$$140$$$O	bezoar,$$$141$$$148$$$O	0.25$$$149$$$153$$$O	to$$$154$$$156$$$O	0.75g$$$157$$$162$$$O	concha$$$163$$$169$$$O	arcae,$$$170$$$176$$$O	0.1$$$177$$$180$$$O	to$$$181$$$183$$$O	0.3g$$$184$$$188$$$O	borneol,$$$189$$$197$$$I	0.1$$$198$$$201$$$O	to$$$202$$$204$$$O	0.5g$$$205$$$209$$$O	dried$$$210$$$215$$$O	portulaca$$$216$$$225$$$O	oleracea$$$226$$$234$$$O	L,$$$235$$$237$$$O	0.1$$$238$$$241$$$O	to$$$242$$$244$$$O	0.3g$$$245$$$249$$$O	cooling$$$250$$$257$$$O	oil$$$258$$$261$$$O	and$$$262$$$265$$$O	0.25$$$266$$$270$$$O	to$$$271$$$273$$$O	0.75g$$$274$$$279$$$O	vaseline;$$$280$$$289$$$O	a$$$290$$$291$$$O	production$$$292$$$302$$$O	process$$$303$$$310$$$O	comprises$$$311$$$320$$$O	the$$$321$$$324$$$O	following$$$325$$$334$$$O	steps:$$$335$$$341$$$O	cleaning$$$342$$$350$$$O	artificial$$$351$$$361$$$O	bezoar,$$$362$$$369$$$O	drying$$$370$$$376$$$O	and$$$377$$$380$$$O	crushing$$$381$$$389$$$O	into$$$390$$$394$$$O	fine$$$395$$$399$$$O	powder$$$400$$$406$$$O	capable$$$407$$$414$$$O	of$$$415$$$417$$$O	passing$$$418$$$425$$$O	through$$$426$$$433$$$O	a$$$434$$$435$$$O	sieve$$$436$$$441$$$O	with$$$442$$$446$$$O	270$$$447$$$450$$$O	meshes,$$$451$$$458$$$O	drying$$$459$$$465$$$O	dried$$$466$$$471$$$O	portulaca$$$472$$$481$$$O	oleracea$$$482$$$490$$$O	L$$$491$$$492$$$O	and$$$493$$$496$$$O	crushing$$$497$$$505$$$O	into$$$506$$$510$$$O	fine$$$511$$$515$$$O	powder$$$516$$$522$$$O	capable$$$523$$$530$$$O	of$$$531$$$533$$$O	passing$$$534$$$541$$$O	through$$$542$$$549$$$O	a$$$550$$$551$$$O	sieve$$$552$$$557$$$O	with$$$558$$$562$$$O	270$$$563$$$566$$$O	meshes,$$$567$$$574$$$O	then$$$575$$$579$$$O	taking$$$580$$$586$$$O	artificial$$$587$$$597$$$O	bezoar,$$$598$$$605$$$O	concha$$$606$$$612$$$O	arcae,$$$613$$$619$$$O	borneol$$$620$$$627$$$I	powder$$$628$$$634$$$O	and$$$635$$$638$$$O	dried$$$639$$$644$$$O	portulaca$$$645$$$654$$$O	oleracea$$$655$$$663$$$O	L$$$664$$$665$$$O	with$$$666$$$670$$$O	the$$$671$$$674$$$O	above$$$675$$$680$$$O	ratio,$$$681$$$687$$$O	and$$$688$$$691$$$O	finally$$$692$$$699$$$O	adding$$$700$$$706$$$O	cooling$$$707$$$714$$$O	oil$$$715$$$718$$$O	and$$$719$$$722$$$O	vaseline$$$723$$$731$$$O	with$$$732$$$736$$$O	the$$$737$$$740$$$O	proportion,$$$741$$$752$$$O	uniformly$$$753$$$762$$$O	mixing$$$763$$$769$$$O	and$$$770$$$773$$$O	packaging.$$$774$$$784$$$O	The$$$785$$$788$$$O	ointment$$$789$$$797$$$O	for$$$798$$$801$$$O	treating$$$802$$$810$$$O	rhinitis$$$811$$$819$$$O	has$$$820$$$823$$$O	the$$$824$$$827$$$O	advantages$$$828$$$838$$$O	of$$$839$$$841$$$O	easy$$$842$$$846$$$O	usage,$$$847$$$853$$$O	and$$$854$$$857$$$O	no$$$858$$$860$$$O	toxic$$$861$$$866$$$O	and$$$867$$$870$$$O	side$$$871$$$875$$$O	effect,$$$876$$$883$$$O	and$$$884$$$887$$$O	the$$$888$$$891$$$O	clinical$$$892$$$900$$$O	tests$$$901$$$906$$$O	of$$$907$$$909$$$O	500$$$910$$$913$$$O	patients$$$914$$$922$$$O	show$$$923$$$927$$$O	that$$$928$$$932$$$O	the$$$933$$$936$$$O	cure$$$937$$$941$$$O	rate$$$942$$$946$$$O	is$$$947$$$949$$$O	100%.$$$950$$$955$$$O
US20090124675
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	anti-apoptotic$$$14$$$28$$$O	proteins$$$29$$$37$$$O
Various$$$0$$$7$$$O	compounds$$$8$$$17$$$O	comprising$$$18$$$28$$$O	a$$$29$$$30$$$O	thiazolidine$$$31$$$43$$$I	ring$$$44$$$48$$$O	are$$$49$$$52$$$O	described$$$53$$$62$$$O	as$$$63$$$65$$$O	well$$$66$$$70$$$O	as$$$71$$$73$$$O	the$$$74$$$77$$$O	use$$$78$$$81$$$O	of$$$82$$$84$$$O	such$$$85$$$89$$$O	compounds$$$90$$$99$$$O	to$$$100$$$102$$$O	inhibit$$$103$$$110$$$O	at$$$111$$$113$$$O	least$$$114$$$119$$$O	one$$$120$$$123$$$O	BCL-2$$$124$$$129$$$O	protein$$$130$$$137$$$O	family$$$138$$$144$$$O	member.$$$145$$$152$$$O	One$$$153$$$156$$$O	of$$$157$$$159$$$O	the$$$160$$$163$$$O	compounds$$$164$$$173$$$O	described$$$174$$$183$$$O	has$$$184$$$187$$$O	the$$$188$$$191$$$O	structure$$$192$$$201$$$O	the$$$202$$$205$$$O	structure$$$206$$$215$$$O	A,$$$216$$$218$$$O	wherein$$$256$$$263$$$O	each$$$264$$$268$$$O	of$$$269$$$271$$$O	R1,$$$272$$$275$$$O	and$$$276$$$279$$$O	R2$$$280$$$282$$$O	comprises$$$283$$$292$$$O	hydrogen,$$$293$$$302$$$I	a$$$303$$$304$$$O	substituted$$$305$$$316$$$I	or$$$317$$$319$$$I	unsubstituted$$$320$$$333$$$I	straight-chained$$$334$$$350$$$I	aliphatic$$$351$$$360$$$I	group,$$$361$$$367$$$I	a$$$368$$$369$$$O	halogen,$$$370$$$378$$$I	an$$$379$$$381$$$O	alkoxyl,$$$382$$$390$$$I	a$$$391$$$392$$$O	halogen-substituted$$$393$$$412$$$I	alkyl,$$$413$$$419$$$I	a$$$420$$$421$$$O	halogen-substituted$$$422$$$441$$$I	alkoxyl,$$$442$$$450$$$I	hydroxyl,$$$451$$$460$$$I	carboxyl,$$$461$$$470$$$I	cyano$$$471$$$476$$$I	group,$$$477$$$483$$$O	an$$$484$$$486$$$O	amido$$$487$$$492$$$I	group,$$$493$$$499$$$O	a$$$500$$$501$$$O	substituted$$$502$$$513$$$I	or$$$514$$$516$$$I	unsubstituted$$$517$$$530$$$I	cycloaliphatic$$$531$$$545$$$I	group,$$$546$$$552$$$I	a$$$553$$$554$$$I	substituted$$$555$$$566$$$I	or$$$567$$$569$$$I	unsubstituted$$$570$$$583$$$I	aromatic$$$584$$$592$$$I	group,$$$593$$$599$$$I	or$$$600$$$602$$$O	a$$$603$$$604$$$O	substituted$$$605$$$616$$$I	or$$$617$$$619$$$I	unsubstituted$$$620$$$633$$$I	heterocyclic$$$634$$$646$$$I	group;$$$647$$$653$$$I	X$$$654$$$655$$$O	comprises$$$656$$$665$$$O	oxygen,$$$666$$$673$$$I	sulfur,$$$674$$$681$$$I	or$$$682$$$684$$$O	imino$$$685$$$690$$$I	group;$$$691$$$697$$$O	and$$$698$$$701$$$O	Z$$$702$$$703$$$O	comprises$$$704$$$713$$$O	a$$$714$$$715$$$O	moiety$$$716$$$722$$$O	such$$$723$$$727$$$O	as$$$728$$$730$$$O	naphthaline$$$731$$$742$$$I	or$$$743$$$745$$$O	dehydronaphthaline,$$$746$$$765$$$I	among$$$766$$$771$$$O	others.$$$772$$$779$$$O
US20110311461
Alkaloid$$$0$$$8$$$I	aminoester$$$9$$$19$$$I	derivatives$$$20$$$31$$$O	and$$$32$$$35$$$O	medicinal$$$36$$$45$$$O	composition$$$46$$$57$$$O	thereof$$$58$$$65$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	alkaloid$$$33$$$41$$$I	aminoester$$$42$$$52$$$I	compounds$$$53$$$62$$$O	which$$$63$$$68$$$O	act$$$69$$$72$$$O	as$$$73$$$75$$$O	muscarinic$$$76$$$86$$$O	receptor$$$87$$$95$$$O	antagonists,$$$96$$$108$$$O	processes$$$109$$$118$$$O	for$$$119$$$122$$$O	their$$$123$$$128$$$O	preparation,$$$129$$$141$$$O	compositions$$$142$$$154$$$O	comprising$$$155$$$165$$$O	them,$$$166$$$171$$$O	and$$$172$$$175$$$O	therapeutic$$$176$$$187$$$O	uses$$$188$$$192$$$O	thereof.$$$193$$$201$$$O
US20080207756
Dispensing$$$0$$$10$$$O	liquid$$$11$$$17$$$O	for$$$18$$$21$$$O	coating$$$22$$$29$$$O	interior$$$30$$$38$$$O	body$$$39$$$43$$$O	tissue;$$$44$$$51$$$O	prevent$$$52$$$59$$$O	tissue$$$60$$$66$$$O	dessciation$$$67$$$78$$$O	during$$$79$$$85$$$O	surgery$$$86$$$93$$$O
Exemplary$$$0$$$9$$$O	embodiments$$$10$$$21$$$O	of$$$22$$$24$$$O	the$$$25$$$28$$$O	invention$$$29$$$38$$$O	provide$$$39$$$46$$$O	a$$$47$$$48$$$O	dispersing$$$49$$$59$$$O	liquid$$$60$$$66$$$O	for$$$67$$$70$$$O	coating$$$71$$$78$$$O	internal$$$79$$$87$$$O	body$$$88$$$92$$$O	tissues$$$93$$$100$$$O	with$$$101$$$105$$$O	a$$$106$$$107$$$O	bio-absorbable$$$108$$$122$$$O	oil,$$$123$$$127$$$O	a$$$128$$$129$$$O	method$$$130$$$136$$$O	of$$$137$$$139$$$O	making$$$140$$$146$$$O	the$$$147$$$150$$$O	dispersing$$$151$$$161$$$O	liquid,$$$162$$$169$$$O	methods$$$170$$$177$$$O	of$$$178$$$180$$$O	using$$$181$$$186$$$O	the$$$187$$$190$$$O	dispersing$$$191$$$201$$$O	liquid$$$202$$$208$$$O	and$$$209$$$212$$$O	a$$$213$$$214$$$O	kit$$$215$$$218$$$O	for$$$219$$$222$$$O	coating$$$223$$$230$$$O	internal$$$231$$$239$$$O	body$$$240$$$244$$$O	tissues$$$245$$$252$$$O	using$$$253$$$258$$$O	the$$$259$$$262$$$O	dispersing$$$263$$$273$$$O	liquid.$$$274$$$281$$$O	The$$$282$$$285$$$O	dispersing$$$286$$$296$$$O	liquid$$$297$$$303$$$O	includes$$$304$$$312$$$O	a$$$313$$$314$$$O	suspension$$$315$$$325$$$O	of$$$326$$$328$$$O	a$$$329$$$330$$$O	bio-absorbable$$$331$$$345$$$O	oil$$$346$$$349$$$O	suspended$$$350$$$359$$$O	in$$$360$$$362$$$O	a$$$363$$$364$$$O	liquid$$$365$$$371$$$O	carrier.$$$372$$$380$$$O	The$$$381$$$384$$$O	invention$$$385$$$394$$$O	results$$$395$$$402$$$O	in$$$403$$$405$$$O	a$$$406$$$407$$$O	uniform$$$408$$$415$$$O	thin$$$416$$$420$$$O	coating$$$421$$$428$$$O	of$$$429$$$431$$$O	bio-absorbable$$$432$$$446$$$O	oil$$$447$$$450$$$O	on$$$451$$$453$$$O	internal$$$454$$$462$$$O	body$$$463$$$467$$$O	tissues.$$$468$$$476$$$O
US20110217247
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	protection$$$29$$$39$$$O	of$$$40$$$42$$$O	skin$$$43$$$47$$$O	against$$$48$$$55$$$O	thermal$$$56$$$63$$$O	insult$$$64$$$70$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	novel$$$31$$$36$$$O	topically-applied$$$37$$$54$$$O	skin$$$55$$$59$$$O	and$$$60$$$63$$$O	face$$$64$$$68$$$O	coating$$$69$$$76$$$O	and$$$77$$$80$$$O	paint$$$81$$$86$$$O	compositions$$$87$$$99$$$O	comprising$$$100$$$110$$$O	near$$$111$$$115$$$O	infrared$$$116$$$124$$$O	reflecting$$$125$$$135$$$O	pigments$$$136$$$144$$$O	and$$$145$$$148$$$O	hydrogels$$$149$$$158$$$O	swollen$$$159$$$166$$$O	with$$$167$$$171$$$O	aqueous$$$172$$$179$$$O	solution$$$180$$$188$$$O	and/or$$$189$$$195$$$O	with$$$196$$$200$$$O	simulated$$$201$$$210$$$O	sweat.$$$211$$$217$$$O	The$$$218$$$221$$$O	invention$$$222$$$231$$$O	further$$$232$$$239$$$O	provides$$$240$$$248$$$O	methods$$$249$$$256$$$O	of$$$257$$$259$$$O	making$$$260$$$266$$$O	and$$$267$$$270$$$O	using$$$271$$$276$$$O	the$$$277$$$280$$$O	compositions.$$$281$$$294$$$O	The$$$295$$$298$$$O	novel$$$299$$$304$$$O	compositions$$$305$$$317$$$O	protect$$$318$$$325$$$O	the$$$326$$$329$$$O	skin$$$330$$$334$$$O	of$$$335$$$337$$$O	the$$$338$$$341$$$O	wearer$$$342$$$348$$$O	from$$$349$$$353$$$O	damage$$$354$$$360$$$O	due$$$361$$$364$$$O	to$$$365$$$367$$$O	intense$$$368$$$375$$$O	external$$$376$$$384$$$O	heat$$$385$$$389$$$O	or$$$390$$$392$$$O	thermal$$$393$$$400$$$O	flux$$$401$$$405$$$O	and$$$406$$$409$$$O	simultaneously$$$410$$$424$$$O	divert$$$425$$$431$$$O	thermal$$$432$$$439$$$O	energy$$$440$$$446$$$O	to$$$447$$$449$$$O	a$$$450$$$451$$$O	complementary$$$452$$$465$$$O	evaporative$$$466$$$477$$$O	cooling$$$478$$$485$$$O	mechanism.$$$486$$$496$$$O	The$$$497$$$500$$$O	compositions$$$501$$$513$$$O	protect$$$514$$$521$$$O	skin$$$522$$$526$$$O	from$$$527$$$531$$$O	external$$$532$$$540$$$O	thermal$$$541$$$548$$$O	fluxes,$$$549$$$556$$$O	conform$$$557$$$564$$$O	to$$$565$$$567$$$O	skin$$$568$$$572$$$O	chemistry,$$$573$$$583$$$O	and$$$584$$$587$$$O	are$$$588$$$591$$$O	easy$$$592$$$596$$$O	to$$$597$$$599$$$O	apply$$$600$$$605$$$O	and$$$606$$$609$$$O	remove.$$$610$$$617$$$O
US20100144786
Quinoline$$$0$$$9$$$I	derivatives$$$10$$$21$$$O	as$$$22$$$24$$$O	crth2$$$25$$$30$$$O	receptor$$$31$$$39$$$O	ligands$$$40$$$47$$$O
Specific$$$0$$$8$$$O	quinoline$$$9$$$18$$$I	derivatives$$$19$$$30$$$O	are$$$31$$$34$$$O	CRTH2$$$35$$$40$$$O	antagonists,$$$41$$$53$$$O	useful$$$54$$$60$$$O	in$$$61$$$63$$$O	the$$$64$$$67$$$O	treatment$$$68$$$77$$$O	of$$$78$$$80$$$O	conditions$$$81$$$91$$$O	having$$$92$$$98$$$O	an$$$99$$$101$$$O	inflammatory$$$102$$$114$$$O	component.$$$115$$$125$$$O
WO2008026046A1
Morpholine$$$0$$$10$$$I	d3$$$11$$$13$$$O	dopamine$$$14$$$22$$$I	antagonists$$$23$$$34$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	the$$$46$$$49$$$O	formula$$$50$$$57$$$O	(I)$$$58$$$61$$$O	wherein$$$62$$$69$$$O	R1,$$$70$$$73$$$O	R2,$$$74$$$77$$$O	R3,$$$78$$$81$$$O	R4,$$$82$$$85$$$O	R5$$$86$$$88$$$O	and$$$89$$$92$$$O	R6$$$93$$$95$$$O	are$$$96$$$99$$$O	as$$$100$$$102$$$O	defined$$$103$$$110$$$O	in$$$111$$$113$$$O	the$$$114$$$117$$$O	specification,$$$118$$$132$$$O	to$$$133$$$135$$$O	intermediates$$$136$$$149$$$O	for$$$150$$$153$$$O	their$$$154$$$159$$$O	preparation,$$$160$$$172$$$O	to$$$173$$$175$$$O	pharmaceutical$$$176$$$190$$$O	compositions$$$191$$$203$$$O	containing$$$204$$$214$$$O	them$$$215$$$219$$$O	and$$$220$$$223$$$O	to$$$224$$$226$$$O	their$$$227$$$232$$$O	medicinal$$$233$$$242$$$O	use$$$243$$$246$$$O	as$$$247$$$249$$$O	modulators$$$250$$$260$$$O	of$$$261$$$263$$$O	the$$$264$$$267$$$O	dopamine$$$268$$$276$$$I	D3$$$277$$$279$$$O	receptor,$$$280$$$289$$$O	particularly$$$290$$$302$$$O	as$$$303$$$305$$$O	psychotherapeutic$$$306$$$323$$$O	agents.$$$324$$$331$$$O
US20130041002
Denibulin$$$0$$$9$$$I	di-hydrochloride$$$10$$$26$$$I
MN-029$$$0$$$6$$$I	di-hydrochloride$$$7$$$23$$$I	(MN-029.2HCl,$$$24$$$37$$$I	Formula$$$38$$$45$$$O	2)$$$46$$$48$$$O	is$$$49$$$51$$$O	a$$$52$$$53$$$O	potent$$$54$$$60$$$O	vascular$$$61$$$69$$$O	targeting$$$70$$$79$$$O	agent.$$$80$$$86$$$O	The$$$124$$$127$$$O	present$$$128$$$135$$$O	invention$$$136$$$145$$$O	focuses$$$146$$$153$$$O	on$$$154$$$156$$$O	the$$$157$$$160$$$O	synthesis$$$161$$$170$$$O	and$$$171$$$174$$$O	characterization$$$175$$$191$$$O	of$$$192$$$194$$$O	the$$$195$$$198$$$O	di-hydrochloride$$$199$$$215$$$I	salt$$$216$$$220$$$I	MN-029$$$221$$$227$$$I	and$$$228$$$231$$$O	the$$$232$$$235$$$O	preparation$$$236$$$247$$$O	of$$$248$$$250$$$O	pharmaceutically$$$251$$$267$$$O	acceptable$$$268$$$278$$$O	formulations$$$279$$$291$$$O	thereof.$$$292$$$300$$$O	Methods$$$301$$$308$$$O	are$$$309$$$312$$$O	disclosed$$$313$$$322$$$O	of$$$323$$$325$$$O	using$$$326$$$331$$$O	the$$$332$$$335$$$O	compound$$$336$$$344$$$O	and$$$345$$$348$$$O	formulations$$$349$$$361$$$O	thereof$$$362$$$369$$$O	in$$$370$$$372$$$O	the$$$373$$$376$$$O	treatment$$$377$$$386$$$O	of$$$387$$$389$$$O	diseases$$$390$$$398$$$O	that$$$399$$$403$$$O	rely$$$404$$$408$$$O	on$$$409$$$411$$$O	the$$$412$$$415$$$O	generation$$$416$$$426$$$O	of$$$427$$$429$$$O	neovasculature$$$430$$$444$$$O	by$$$445$$$447$$$O	angiogenesis$$$448$$$460$$$O	for$$$461$$$464$$$O	disease$$$465$$$472$$$O	progression.$$$473$$$485$$$O
CN103191104A
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	Aphanamixoid$$$7$$$19$$$I	A$$$20$$$21$$$I	in$$$22$$$24$$$O	drug$$$25$$$29$$$O	for$$$30$$$33$$$O	treating$$$34$$$42$$$O	Alzheimer's$$$43$$$54$$$O	disease$$$55$$$62$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	novel$$$27$$$32$$$O	use$$$33$$$36$$$O	of$$$37$$$39$$$O	Aphanamixoid$$$40$$$52$$$I	A$$$53$$$54$$$I	and$$$55$$$58$$$O	especially$$$59$$$69$$$O	relates$$$70$$$77$$$O	to$$$78$$$80$$$O	a$$$81$$$82$$$O	use$$$83$$$86$$$O	of$$$87$$$89$$$O	Aphanamixoid$$$90$$$102$$$I	A$$$103$$$104$$$I	in$$$105$$$107$$$O	a$$$108$$$109$$$O	drug$$$110$$$114$$$O	for$$$115$$$118$$$O	treating$$$119$$$127$$$O	the$$$128$$$131$$$O	Alzheimer's$$$132$$$143$$$O	disease.$$$144$$$152$$$O	Aphanamixoid$$$153$$$165$$$I	A$$$166$$$167$$$I	has$$$168$$$171$$$O	an$$$172$$$174$$$O	acetylcholinesterase$$$175$$$195$$$O	inhibitory$$$196$$$206$$$O	activity$$$207$$$215$$$O	and$$$216$$$219$$$O	a$$$220$$$221$$$O	nerve$$$222$$$227$$$O	cell$$$228$$$232$$$O	protection$$$233$$$243$$$O	effect$$$244$$$250$$$O	and$$$251$$$254$$$O	can$$$255$$$258$$$O	be$$$259$$$261$$$O	used$$$262$$$266$$$O	as$$$267$$$269$$$O	a$$$270$$$271$$$O	multi-effect$$$272$$$284$$$O	target$$$285$$$291$$$O	compound$$$292$$$300$$$O	for$$$301$$$304$$$O	preparation$$$305$$$316$$$O	of$$$317$$$319$$$O	an$$$320$$$322$$$O	Alzheimer's$$$323$$$334$$$O	disease-resistant$$$335$$$352$$$O	drug.$$$353$$$358$$$O	The$$$359$$$362$$$O	invention$$$363$$$372$$$O	discloses$$$373$$$382$$$O	the$$$383$$$386$$$O	use$$$387$$$390$$$O	of$$$391$$$393$$$O	Aphanamixoid$$$394$$$406$$$I	A$$$407$$$408$$$I	in$$$409$$$411$$$O	a$$$412$$$413$$$O	drug$$$414$$$418$$$O	for$$$419$$$422$$$O	treating$$$423$$$431$$$O	Alzheimer's$$$432$$$443$$$O	disease$$$444$$$451$$$O	first.$$$452$$$458$$$O	Aphanamixoid$$$459$$$471$$$I	A$$$472$$$473$$$I	has$$$474$$$477$$$O	a$$$478$$$479$$$O	novel$$$480$$$485$$$O	skeleton$$$486$$$494$$$O	type,$$$495$$$500$$$O	a$$$501$$$502$$$O	strong$$$503$$$509$$$O	acetylcholinesterase$$$510$$$530$$$O	inhibitory$$$531$$$541$$$O	activity,$$$542$$$551$$$O	and$$$552$$$555$$$O	outstanding$$$556$$$567$$$O	and$$$568$$$571$$$O	substantive$$$572$$$583$$$O	features,$$$584$$$593$$$O	is$$$594$$$596$$$O	not$$$597$$$600$$$O	prompted$$$601$$$609$$$O	by$$$610$$$612$$$O	other$$$613$$$618$$$O	compounds,$$$619$$$629$$$O	and$$$630$$$633$$$O	obviously$$$634$$$643$$$O	improves$$$644$$$652$$$O	effects$$$653$$$660$$$O	of$$$661$$$663$$$O	preventing$$$664$$$674$$$O	and$$$675$$$678$$$O	treating$$$679$$$687$$$O	the$$$688$$$691$$$O	Alzheimer's$$$692$$$703$$$O	disease.$$$704$$$712$$$O
EP0961612B2
Protein$$$0$$$7$$$O	stabilized$$$8$$$18$$$O	pharmacologically$$$19$$$36$$$O	active$$$37$$$43$$$O	agents$$$44$$$50$$$O	and$$$51$$$54$$$O	their$$$55$$$60$$$O	use$$$61$$$64$$$O
In$$$0$$$2$$$O	accordance$$$3$$$13$$$O	with$$$14$$$18$$$O	the$$$19$$$22$$$O	present$$$23$$$30$$$O	invention,$$$31$$$41$$$O	there$$$42$$$47$$$O	are$$$48$$$51$$$O	provided$$$52$$$60$$$O	compositions$$$61$$$73$$$O	and$$$74$$$77$$$O	methods$$$78$$$85$$$O	useful$$$86$$$92$$$O	for$$$93$$$96$$$O	the$$$97$$$100$$$O	in$$$101$$$103$$$O	vivo$$$104$$$108$$$O	delivery$$$109$$$117$$$O	of$$$118$$$120$$$O	substantially$$$121$$$134$$$O	water-insoluble$$$135$$$150$$$O	pharmacologically$$$151$$$168$$$O	active$$$169$$$175$$$O	agents$$$176$$$182$$$O	(such$$$183$$$188$$$O	as$$$189$$$191$$$O	the$$$192$$$195$$$O	anticancer$$$196$$$206$$$O	drug$$$207$$$211$$$O	paclitaxel)$$$212$$$223$$$I	in$$$224$$$226$$$O	which$$$227$$$232$$$O	the$$$233$$$236$$$O	pharmacologically$$$237$$$254$$$O	active$$$255$$$261$$$O	agent$$$262$$$267$$$O	is$$$268$$$270$$$O	delivered$$$271$$$280$$$O	in$$$281$$$283$$$O	the$$$284$$$287$$$O	form$$$288$$$292$$$O	of$$$293$$$295$$$O	suspended$$$296$$$305$$$O	particles$$$306$$$315$$$O	coated$$$316$$$322$$$O	with$$$323$$$327$$$O	protein$$$328$$$335$$$O	(which$$$336$$$342$$$O	acts$$$343$$$347$$$O	as$$$348$$$350$$$O	a$$$351$$$352$$$O	stabilizing$$$353$$$364$$$O	agent).$$$365$$$372$$$O	In$$$373$$$375$$$O	particular,$$$376$$$387$$$O	protein$$$388$$$395$$$O	and$$$396$$$399$$$O	pharmacologically$$$400$$$417$$$O	active$$$418$$$424$$$O	agent$$$425$$$430$$$O	in$$$431$$$433$$$O	a$$$434$$$435$$$O	biocompatible$$$436$$$449$$$O	dispersing$$$450$$$460$$$O	medium$$$461$$$467$$$O	are$$$468$$$471$$$O	subjected$$$472$$$481$$$O	to$$$482$$$484$$$O	high$$$485$$$489$$$O	shear,$$$490$$$496$$$O	in$$$497$$$499$$$O	the$$$500$$$503$$$O	absence$$$504$$$511$$$O	of$$$512$$$514$$$O	any$$$515$$$518$$$O	conventional$$$519$$$531$$$O	surfactants,$$$532$$$544$$$O	and$$$545$$$548$$$O	also$$$549$$$553$$$O	in$$$554$$$556$$$O	the$$$557$$$560$$$O	absence$$$561$$$568$$$O	of$$$569$$$571$$$O	any$$$572$$$575$$$O	polymeric$$$576$$$585$$$O	core$$$586$$$590$$$O	material$$$591$$$599$$$O	for$$$600$$$603$$$O	the$$$604$$$607$$$O	particles.$$$608$$$618$$$O	The$$$619$$$622$$$O	procedure$$$623$$$632$$$O	yields$$$633$$$639$$$O	particles$$$640$$$649$$$O	with$$$650$$$654$$$O	a$$$655$$$656$$$O	diameter$$$657$$$665$$$O	of$$$666$$$668$$$O	less$$$669$$$673$$$O	than$$$674$$$678$$$O	about$$$679$$$684$$$O	1$$$685$$$686$$$O	micron.$$$687$$$694$$$O	The$$$695$$$698$$$O	use$$$699$$$702$$$O	of$$$703$$$705$$$O	specific$$$706$$$714$$$O	composition$$$715$$$726$$$O	and$$$727$$$730$$$O	preparation$$$731$$$742$$$O	conditions$$$743$$$753$$$O	(e.g.,$$$754$$$760$$$O	addition$$$761$$$769$$$O	of$$$770$$$772$$$O	a$$$773$$$774$$$O	polar$$$775$$$780$$$O	solvent$$$781$$$788$$$O	to$$$789$$$791$$$O	the$$$792$$$795$$$O	organic$$$796$$$803$$$O	phase),$$$804$$$811$$$O	and$$$812$$$815$$$O	careful$$$816$$$823$$$O	selection$$$824$$$833$$$O	of$$$834$$$836$$$O	the$$$837$$$840$$$O	proper$$$841$$$847$$$O	organic$$$848$$$855$$$O	phase$$$856$$$861$$$O	and$$$862$$$865$$$O	phase$$$866$$$871$$$O	fraction,$$$872$$$881$$$O	enables$$$882$$$889$$$O	the$$$890$$$893$$$O	reproducible$$$894$$$906$$$O	production$$$907$$$917$$$O	of$$$918$$$920$$$O	unusually$$$921$$$930$$$O	small$$$931$$$936$$$O	nanoparticles$$$937$$$950$$$O	of$$$951$$$953$$$O	less$$$954$$$958$$$O	than$$$959$$$963$$$O	200$$$964$$$967$$$O	nm$$$968$$$970$$$O	diameter,$$$971$$$980$$$O	which$$$981$$$986$$$O	can$$$987$$$990$$$O	be$$$991$$$993$$$O	sterile-filtered.$$$994$$$1011$$$O	The$$$1012$$$1015$$$O	particulate$$$1016$$$1027$$$O	system$$$1028$$$1034$$$O	produced$$$1035$$$1043$$$O	according$$$1044$$$1053$$$O	to$$$1054$$$1056$$$O	the$$$1057$$$1060$$$O	invention$$$1061$$$1070$$$O	can$$$1071$$$1074$$$O	be$$$1075$$$1077$$$O	converted$$$1078$$$1087$$$O	into$$$1088$$$1092$$$O	a$$$1093$$$1094$$$O	redispersible$$$1095$$$1108$$$O	dry$$$1109$$$1112$$$O	power$$$1113$$$1118$$$O	comprising$$$1119$$$1129$$$O	nanoparticles$$$1130$$$1143$$$O	of$$$1144$$$1146$$$O	water-insoluble$$$1147$$$1162$$$O	drug$$$1163$$$1167$$$O	coated$$$1168$$$1174$$$O	with$$$1175$$$1179$$$O	a$$$1180$$$1181$$$O	protein,$$$1182$$$1190$$$O	and$$$1191$$$1194$$$O	free$$$1195$$$1199$$$O	protein$$$1200$$$1207$$$O	to$$$1208$$$1210$$$O	which$$$1211$$$1216$$$O	molecules$$$1217$$$1226$$$O	of$$$1227$$$1229$$$O	the$$$1230$$$1233$$$O	pharmacological$$$1234$$$1249$$$O	agent$$$1250$$$1255$$$O	are$$$1256$$$1259$$$O	bound.$$$1260$$$1266$$$O	This$$$1267$$$1271$$$O	results$$$1272$$$1279$$$O	in$$$1280$$$1282$$$O	a$$$1283$$$1284$$$O	unique$$$1285$$$1291$$$O	delivery$$$1292$$$1300$$$O	system,$$$1301$$$1308$$$O	in$$$1309$$$1311$$$O	which$$$1312$$$1317$$$O	part$$$1318$$$1322$$$O	of$$$1323$$$1325$$$O	the$$$1326$$$1329$$$O	pharmacologically$$$1330$$$1347$$$O	active$$$1348$$$1354$$$O	agent$$$1355$$$1360$$$O	is$$$1361$$$1363$$$O	readily$$$1364$$$1371$$$O	bioavailable$$$1372$$$1384$$$O	(in$$$1385$$$1388$$$O	the$$$1389$$$1392$$$O	form$$$1393$$$1397$$$O	of$$$1398$$$1400$$$O	molecules$$$1401$$$1410$$$O	bound$$$1411$$$1416$$$O	to$$$1417$$$1419$$$O	the$$$1420$$$1423$$$O	protein),$$$1424$$$1433$$$O	and$$$1434$$$1437$$$O	part$$$1438$$$1442$$$O	of$$$1443$$$1445$$$O	the$$$1446$$$1449$$$O	agent$$$1450$$$1455$$$O	is$$$1456$$$1458$$$O	present$$$1459$$$1466$$$O	within$$$1467$$$1473$$$O	particles$$$1474$$$1483$$$O	without$$$1484$$$1491$$$O	any$$$1492$$$1495$$$O	polymeric$$$1496$$$1505$$$O	matrix$$$1506$$$1512$$$O	therein.$$$1513$$$1521$$$O
US20090105317
VEGF$$$0$$$4$$$O	Inhibition$$$5$$$15$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	for$$$39$$$42$$$O	inhibiting$$$43$$$53$$$O	VEGF$$$54$$$58$$$O	production$$$59$$$69$$$O	or$$$70$$$72$$$O	secretion$$$73$$$82$$$O	in$$$83$$$85$$$O	a$$$86$$$87$$$O	subject$$$88$$$95$$$O	comprising$$$96$$$106$$$O	administering$$$107$$$120$$$O	to$$$121$$$123$$$O	the$$$124$$$127$$$O	subject$$$128$$$135$$$O	an$$$136$$$138$$$O	effective$$$139$$$148$$$O	amount$$$149$$$155$$$O	of$$$156$$$158$$$O	a$$$159$$$160$$$O	compound$$$161$$$169$$$O	of$$$170$$$172$$$O	Formula$$$173$$$180$$$O	I.$$$181$$$183$$$O	The$$$184$$$187$$$O	invention$$$188$$$197$$$O	also$$$198$$$202$$$O	provides$$$203$$$211$$$O	methods$$$212$$$219$$$O	for$$$220$$$223$$$O	the$$$224$$$227$$$O	treatment$$$228$$$237$$$O	or$$$238$$$240$$$O	prevention$$$241$$$251$$$O	of$$$252$$$254$$$O	conditions$$$255$$$265$$$O	associated$$$266$$$276$$$O	with$$$277$$$281$$$O	abnormal$$$282$$$290$$$O	levels$$$291$$$297$$$O	of$$$298$$$300$$$O	VEGF$$$301$$$305$$$O	production$$$306$$$316$$$O	or$$$317$$$319$$$O	secretion.$$$320$$$330$$$O
EP2501669A2
Novel$$$0$$$5$$$O	arylated$$$6$$$14$$$I	camphenes,$$$15$$$25$$$I	processes$$$26$$$35$$$O	for$$$36$$$39$$$O	their$$$40$$$45$$$O	preparation$$$46$$$57$$$O	and$$$58$$$61$$$O	uses$$$62$$$66$$$O	thereof$$$67$$$74$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	arylated$$$33$$$41$$$I	camphenes,$$$42$$$52$$$I	processes$$$53$$$62$$$O	for$$$63$$$66$$$O	their$$$67$$$72$$$O	preparation$$$73$$$84$$$O	and$$$85$$$88$$$O	uses$$$89$$$93$$$O	thereof$$$94$$$101$$$O	for$$$102$$$105$$$O	the$$$106$$$109$$$O	manufacture$$$110$$$121$$$O	of$$$122$$$124$$$O	medicaments$$$125$$$136$$$O	for$$$137$$$140$$$O	the$$$141$$$144$$$O	treatment$$$145$$$154$$$O	of$$$155$$$157$$$O	diseases,$$$158$$$167$$$O	disorders$$$168$$$177$$$O	or$$$178$$$180$$$O	conditions$$$181$$$191$$$O	associated$$$192$$$202$$$O	with,$$$203$$$208$$$O	or$$$209$$$211$$$O	benefiting$$$212$$$222$$$O	from$$$223$$$227$$$O	stimulation$$$228$$$239$$$O	of$$$240$$$242$$$O	CB2$$$243$$$246$$$O	receptors.$$$247$$$257$$$O
WO2008043243A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	hydrochloric$$$7$$$19$$$I	acid$$$20$$$24$$$I	in$$$25$$$27$$$O	manufacture$$$28$$$39$$$O	of$$$40$$$42$$$O	medicament$$$43$$$53$$$O	for$$$54$$$57$$$O	treating$$$58$$$66$$$O	disease$$$67$$$74$$$O	caused$$$75$$$81$$$O	by$$$82$$$84$$$O	fouling$$$85$$$92$$$O	of$$$93$$$95$$$O	transport$$$96$$$105$$$O	tract$$$106$$$111$$$O
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	hydrochloric$$$7$$$19$$$I	acid$$$20$$$24$$$I	in$$$25$$$27$$$O	the$$$28$$$31$$$O	manufacture$$$32$$$43$$$O	of$$$44$$$46$$$O	a$$$47$$$48$$$O	medicament$$$49$$$59$$$O	for$$$60$$$63$$$O	treating$$$64$$$72$$$O	the$$$73$$$76$$$O	disease$$$77$$$84$$$O	caused$$$85$$$91$$$O	by$$$92$$$94$$$O	fouling$$$95$$$102$$$O	of$$$103$$$105$$$O	transport$$$106$$$115$$$O	tract,$$$116$$$122$$$O	wherein$$$123$$$130$$$O	the$$$131$$$134$$$O	disease$$$135$$$142$$$O	comprises$$$143$$$152$$$O	diabetes$$$153$$$161$$$O	and$$$162$$$165$$$O	prostate$$$166$$$174$$$O	disease.$$$175$$$183$$$O
WO2013098588A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	calcilytic$$$7$$$17$$$O	drugs$$$18$$$23$$$O	as$$$24$$$26$$$O	a$$$27$$$28$$$O	pharmacological$$$29$$$44$$$O	approach$$$45$$$53$$$O	to$$$54$$$56$$$O	the$$$57$$$60$$$O	treatment$$$61$$$70$$$O	and$$$71$$$74$$$O	prevention$$$75$$$85$$$O	of$$$86$$$88$$$O	alzheimer's$$$89$$$100$$$O	disease,$$$101$$$109$$$O	alzheimer's$$$110$$$121$$$O	disease-related$$$122$$$137$$$O	disorders,$$$138$$$148$$$O	and$$$149$$$152$$$O	down's$$$153$$$159$$$O	syndrome$$$160$$$168$$$O	neuropathies$$$169$$$181$$$O
A$$$0$$$1$$$O	pharmacological$$$2$$$17$$$O	treatment$$$18$$$27$$$O	of$$$28$$$30$$$O	both$$$31$$$35$$$O	familial$$$36$$$44$$$O	early$$$45$$$50$$$O	onset$$$51$$$56$$$O	and$$$57$$$60$$$O	sporadic$$$61$$$69$$$O	late$$$70$$$74$$$O	onset$$$75$$$80$$$O	Alzheimer's$$$81$$$92$$$O	disease$$$93$$$100$$$O	(AD),$$$101$$$106$$$O	AD-related$$$107$$$117$$$O	disorders$$$118$$$127$$$O	and$$$128$$$131$$$O	Down's$$$132$$$138$$$O	syndrome-coupled$$$139$$$155$$$O	neuropathies$$$156$$$168$$$O	involves$$$169$$$177$$$O	the$$$178$$$181$$$O	use$$$182$$$185$$$O	of$$$186$$$188$$$O	a$$$189$$$190$$$O	class$$$191$$$196$$$O	of$$$197$$$199$$$O	drugs,$$$200$$$206$$$O	the$$$207$$$210$$$O	calcilytics,$$$211$$$223$$$O	which$$$224$$$229$$$O	by$$$230$$$232$$$O	inhibiting$$$233$$$243$$$O	the$$$244$$$247$$$O	calcium-sensing$$$248$$$263$$$O	receptor$$$264$$$272$$$O	(CaSR)signaling$$$273$$$288$$$O	in$$$289$$$291$$$O	all$$$292$$$295$$$O	types$$$296$$$301$$$O	of$$$302$$$304$$$O	brain$$$305$$$310$$$O	cells$$$311$$$316$$$O	prevent:$$$317$$$325$$$O	(i)$$$326$$$329$$$O	the$$$330$$$333$$$O	overproduction$$$334$$$348$$$O	of$$$349$$$351$$$O	cell-harming$$$352$$$364$$$O	nitric$$$365$$$371$$$I	oxide$$$372$$$377$$$I	(NO)$$$378$$$382$$$I	and$$$383$$$386$$$O	peroxynitrite$$$387$$$400$$$I	(ONOO-),$$$401$$$409$$$I	and$$$410$$$413$$$O	most$$$414$$$418$$$O	importantly$$$419$$$430$$$O	(ii)$$$431$$$435$$$O	the$$$436$$$439$$$O	intracellular$$$440$$$453$$$O	overproduction,$$$454$$$469$$$O	accumulation,$$$470$$$483$$$O	and$$$484$$$487$$$O	secretion$$$488$$$497$$$O	of$$$498$$$500$$$O	Amyloid$$$501$$$508$$$O	Î²$$$509$$$511$$$O	(AÎ²)$$$512$$$517$$$O	peptides$$$518$$$526$$$O	in$$$527$$$529$$$O	response$$$530$$$538$$$O	to$$$539$$$541$$$O	the$$$542$$$545$$$O	extracellular$$$546$$$559$$$O	presence$$$560$$$568$$$O	of$$$569$$$571$$$O	exogenous$$$572$$$581$$$O	AÎ²peptides$$$582$$$593$$$O	and/or$$$594$$$600$$$O	proinflammatory$$$601$$$616$$$O	cytokines,$$$617$$$627$$$O	and$$$628$$$631$$$O	(iii)$$$632$$$637$$$O	the$$$638$$$641$$$O	AÎ²$$$642$$$645$$$O	peptide-related$$$646$$$661$$$O	hyperphosphorylation$$$662$$$682$$$O	of$$$683$$$685$$$O	the$$$686$$$689$$$O	Tau$$$690$$$693$$$O	(Ï)$$$694$$$698$$$O	protein$$$699$$$706$$$O	on$$$707$$$709$$$O	the$$$710$$$713$$$O	part$$$714$$$718$$$O	of$$$719$$$721$$$O	an$$$722$$$724$$$O	AÎ²/Ca$$$725$$$731$$$O	SR-signaling$$$732$$$744$$$O	activated$$$745$$$754$$$O	glycogen$$$755$$$763$$$O	synthase$$$764$$$772$$$O	kinase-(GSK)-3Î²$$$773$$$789$$$O	w$$$790$$$791$$$O	i$$$792$$$793$$$O	t$$$794$$$795$$$O	h$$$796$$$797$$$O	the$$$798$$$801$$$O	resulting$$$802$$$811$$$O	formation$$$812$$$821$$$O	of$$$822$$$824$$$O	neurofibrillary$$$825$$$840$$$O	tangles$$$841$$$848$$$O	(NTFs),$$$849$$$856$$$O	the$$$857$$$860$$$O	latter$$$861$$$867$$$O	known$$$868$$$873$$$O	to$$$874$$$876$$$O	cause$$$877$$$882$$$O	such$$$883$$$887$$$O	severe$$$888$$$894$$$O	dysfunctioning$$$895$$$909$$$O	of$$$910$$$912$$$O	the$$$913$$$916$$$O	microtubular$$$917$$$929$$$O	cytoskeleton$$$930$$$942$$$O	as$$$943$$$945$$$O	to$$$946$$$948$$$O	eventually$$$949$$$959$$$O	favor$$$960$$$965$$$O	(iv)$$$966$$$970$$$O	the$$$971$$$974$$$O	death$$$975$$$980$$$O	of$$$981$$$983$$$O	human$$$984$$$989$$$O	cerebral$$$990$$$998$$$O	cortex$$$999$$$1005$$$O	neurons.$$$1006$$$1014$$$O
EP1931636B1
Isoquinolines$$$0$$$13$$$I	as$$$14$$$16$$$O	igf-1r$$$17$$$23$$$O	inhibitors$$$24$$$34$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	the$$$13$$$16$$$O	formula$$$17$$$24$$$O	(I)$$$25$$$28$$$O	were$$$29$$$33$$$O	synthesized.$$$34$$$46$$$O	They$$$47$$$51$$$O	were$$$52$$$56$$$O	found$$$57$$$62$$$O	to$$$63$$$65$$$O	down-$$$66$$$71$$$O	regulate$$$72$$$80$$$O	or$$$81$$$83$$$O	inhibit$$$84$$$91$$$O	the$$$92$$$95$$$O	expression$$$96$$$106$$$O	or$$$107$$$109$$$O	function$$$110$$$118$$$O	of$$$119$$$121$$$O	the$$$122$$$125$$$O	IGF-I$$$126$$$131$$$O	receptor.$$$132$$$141$$$O
WO2008133192A1
Fused$$$0$$$5$$$I	imidazole$$$6$$$15$$$I	compound$$$16$$$24$$$O	and$$$25$$$28$$$O	use$$$29$$$32$$$O	thereof$$$33$$$40$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	compound$$$15$$$23$$$O	represented$$$24$$$35$$$O	by$$$36$$$38$$$O	the$$$39$$$42$$$O	formula$$$43$$$50$$$O	(I)$$$51$$$54$$$O	below$$$55$$$60$$$O	or$$$61$$$63$$$O	a$$$64$$$65$$$O	salt$$$66$$$70$$$O	thereof.$$$71$$$79$$$O	The$$$80$$$83$$$O	compound$$$84$$$92$$$O	is$$$93$$$95$$$O	useful$$$96$$$102$$$O	as$$$103$$$105$$$O	a$$$106$$$107$$$O	p38$$$108$$$111$$$O	MAPK$$$112$$$116$$$O	inhibitor$$$117$$$126$$$O	and/or$$$127$$$133$$$O	a$$$134$$$135$$$O	TNF-Î±$$$136$$$142$$$O	production$$$143$$$153$$$O	inhibitor.$$$154$$$164$$$O	(In$$$165$$$168$$$O	the$$$169$$$172$$$O	formula,$$$173$$$181$$$O	Xa,$$$182$$$185$$$O	Xb$$$186$$$188$$$O	and$$$189$$$192$$$O	Xc$$$193$$$195$$$O	may$$$196$$$199$$$O	be$$$200$$$202$$$O	the$$$203$$$206$$$O	same$$$207$$$211$$$O	or$$$212$$$214$$$O	different$$$215$$$224$$$O	and$$$225$$$228$$$O	each$$$229$$$233$$$O	represents$$$234$$$244$$$O	an$$$245$$$247$$$O	optionally$$$248$$$258$$$O	substituted$$$259$$$270$$$I	CH$$$271$$$273$$$I	or$$$274$$$276$$$O	a$$$277$$$278$$$I	nitrogen$$$279$$$287$$$I	atom,$$$288$$$293$$$O	and$$$294$$$297$$$O	either$$$298$$$304$$$O	one$$$305$$$308$$$O	of$$$309$$$311$$$O	them$$$312$$$316$$$O	represents$$$317$$$327$$$O	a$$$328$$$329$$$I	nitrogen$$$330$$$338$$$I	atom;$$$339$$$344$$$O	Xd$$$345$$$347$$$O	represents$$$348$$$358$$$O	an$$$359$$$361$$$O	optionally$$$362$$$372$$$O	substituted$$$373$$$384$$$I	CH;$$$385$$$388$$$I	Ra$$$389$$$391$$$O	represents$$$392$$$402$$$O	an$$$403$$$405$$$O	optionally$$$406$$$416$$$O	substituted$$$417$$$428$$$I	phenyl$$$429$$$435$$$I	or$$$436$$$438$$$O	an$$$439$$$441$$$O	optionally$$$442$$$452$$$O	substituted$$$453$$$464$$$I	heterocyclic$$$465$$$477$$$I	group;$$$478$$$484$$$O	Rb$$$485$$$487$$$O	represents$$$488$$$498$$$O	a$$$499$$$500$$$I	hydrogen$$$501$$$509$$$I	atom;$$$510$$$515$$$O	Rc$$$516$$$518$$$O	represents$$$519$$$529$$$O	an$$$530$$$532$$$O	optionally$$$533$$$543$$$O	substituted$$$544$$$555$$$I	nitrogen-containing$$$556$$$575$$$I	heterocyclic$$$576$$$588$$$I	N-oxide,$$$589$$$597$$$I	an$$$598$$$600$$$O	N-(optionally$$$601$$$614$$$O	substituted$$$615$$$626$$$I	nitrogen-containing$$$627$$$646$$$I	heterocyclic$$$647$$$659$$$I	N-oxide-C1-6-alkyl)amino$$$660$$$684$$$I	or$$$685$$$687$$$O	an$$$688$$$690$$$O	optionally$$$691$$$701$$$O	substituted$$$702$$$713$$$I	nitrogen-containing$$$714$$$733$$$I	heterocyclic$$$734$$$746$$$I	N-oxide-carbonylamino-C1-6-$$$747$$$774$$$I	alkyl.)$$$775$$$782$$$I
CA2616222C
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	producing$$$11$$$20$$$O	tiotropium$$$21$$$31$$$I	salts$$$32$$$37$$$O	comprising$$$38$$$48$$$O	an$$$49$$$51$$$O	esterification$$$52$$$66$$$O	reaction$$$67$$$75$$$O	of$$$76$$$78$$$O	methylscopinium$$$79$$$94$$$I	and$$$95$$$98$$$O	a$$$99$$$100$$$O	dithienyl$$$101$$$110$$$I	derivative$$$111$$$121$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	process$$$25$$$32$$$O	for$$$33$$$36$$$O	preparation$$$37$$$48$$$O	of$$$49$$$51$$$O	tiotropium$$$52$$$62$$$I	salts$$$63$$$68$$$O	of$$$69$$$71$$$O	Formula$$$72$$$79$$$O	1$$$80$$$81$$$O	(see$$$82$$$86$$$O	formula$$$87$$$94$$$O	1)$$$95$$$97$$$O	wherein$$$98$$$105$$$O	a$$$106$$$107$$$O	compound$$$108$$$116$$$O	of$$$117$$$119$$$O	Formula$$$120$$$127$$$O	2$$$128$$$129$$$O	(see$$$130$$$134$$$O	formula$$$135$$$142$$$O	2)$$$143$$$145$$$O	is$$$146$$$148$$$O	reacted$$$149$$$156$$$O	in$$$157$$$159$$$O	one$$$160$$$163$$$O	step$$$164$$$168$$$O	with$$$169$$$173$$$O	a$$$174$$$175$$$O	compound$$$176$$$184$$$O	of$$$185$$$187$$$O	Formula$$$188$$$195$$$O	3$$$196$$$197$$$O	(see$$$198$$$202$$$O	formula$$$203$$$210$$$O	3)$$$211$$$213$$$O	in$$$214$$$216$$$O	the$$$217$$$220$$$O	presence$$$221$$$229$$$O	of$$$230$$$232$$$O	a$$$233$$$234$$$O	solvent$$$235$$$242$$$O	and$$$243$$$246$$$O	a$$$247$$$248$$$O	catalyst$$$249$$$257$$$O	selected$$$258$$$266$$$O	from$$$267$$$271$$$O	the$$$272$$$275$$$O	group$$$276$$$281$$$O	consisting$$$282$$$292$$$O	of$$$293$$$295$$$O	zeolites,$$$296$$$305$$$I	alkoxides,$$$306$$$316$$$I	lipases$$$317$$$324$$$O	and$$$325$$$328$$$O	tertiary$$$329$$$337$$$I	amines$$$338$$$344$$$I	to$$$345$$$347$$$O	obtain$$$348$$$354$$$O	a$$$355$$$356$$$O	compound$$$357$$$365$$$O	of$$$366$$$368$$$O	Formula$$$369$$$376$$$O	4$$$377$$$378$$$O	(see$$$379$$$383$$$O	formula$$$384$$$391$$$O	4)$$$392$$$394$$$O	and$$$395$$$398$$$O	without$$$399$$$406$$$O	being$$$407$$$412$$$O	isolated,$$$413$$$422$$$O	the$$$423$$$426$$$O	compound$$$427$$$435$$$O	of$$$436$$$438$$$O	Formula$$$439$$$446$$$O	4$$$447$$$448$$$O	is$$$449$$$451$$$O	converted$$$452$$$461$$$O	to$$$462$$$464$$$O	the$$$465$$$468$$$O	compound$$$469$$$477$$$O	of$$$478$$$480$$$O	Formula$$$481$$$488$$$O	1$$$489$$$490$$$O	with$$$491$$$495$$$O	a$$$496$$$497$$$O	salt$$$498$$$502$$$O	of$$$503$$$505$$$O	Formula$$$506$$$513$$$O	cat+X-.$$$514$$$521$$$O
CN101601799A
Medicament$$$0$$$10$$$O	for$$$11$$$14$$$O	treating$$$15$$$23$$$O	scalding$$$24$$$32$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicament$$$26$$$36$$$O	for$$$37$$$40$$$O	treating$$$41$$$49$$$O	scalding,$$$50$$$59$$$O	which$$$60$$$65$$$O	consists$$$66$$$74$$$O	of$$$75$$$77$$$O	the$$$78$$$81$$$O	following$$$82$$$91$$$O	raw$$$92$$$95$$$O	materials$$$96$$$105$$$O	in$$$106$$$108$$$O	portion$$$109$$$116$$$O	by$$$117$$$119$$$O	weight:$$$120$$$127$$$O	20$$$128$$$130$$$O	to$$$131$$$133$$$O	30$$$134$$$136$$$O	portions$$$137$$$145$$$O	of$$$146$$$148$$$O	aloe,$$$149$$$154$$$O	10$$$155$$$157$$$O	to$$$158$$$160$$$O	20$$$161$$$163$$$O	portions$$$164$$$172$$$O	of$$$173$$$175$$$O	pumpkin,$$$176$$$184$$$O	20$$$185$$$187$$$O	to$$$188$$$190$$$O	25$$$191$$$193$$$O	portions$$$194$$$202$$$O	of$$$203$$$205$$$O	peanut$$$206$$$212$$$O	oil,$$$213$$$217$$$O	5$$$218$$$219$$$O	to$$$220$$$222$$$O	10$$$223$$$225$$$O	portions$$$226$$$234$$$O	of$$$235$$$237$$$O	salt,$$$238$$$243$$$O	5$$$244$$$245$$$O	to$$$246$$$248$$$O	10$$$249$$$251$$$O	portions$$$252$$$260$$$O	of$$$261$$$263$$$O	egg$$$264$$$267$$$O	white,$$$268$$$274$$$O	1$$$275$$$276$$$O	to$$$277$$$279$$$O	5$$$280$$$281$$$O	portions$$$282$$$290$$$O	of$$$291$$$293$$$O	eucalyptus$$$294$$$304$$$O	oil$$$305$$$308$$$O	and$$$309$$$312$$$O	1$$$313$$$314$$$O	to$$$315$$$317$$$O	5$$$318$$$319$$$O	portions$$$320$$$328$$$O	of$$$329$$$331$$$O	peppermint.$$$332$$$343$$$O	The$$$344$$$347$$$O	formula$$$348$$$355$$$O	of$$$356$$$358$$$O	the$$$359$$$362$$$O	medicament$$$363$$$373$$$O	adopts$$$374$$$380$$$O	compositions$$$381$$$393$$$O	such$$$394$$$398$$$O	as$$$399$$$401$$$O	the$$$402$$$405$$$O	aloe,$$$406$$$411$$$O	the$$$412$$$415$$$O	pumpkin,$$$416$$$424$$$O	the$$$425$$$428$$$O	peanut$$$429$$$435$$$O	oil,$$$436$$$440$$$O	the$$$441$$$444$$$O	salt,$$$445$$$450$$$O	the$$$451$$$454$$$O	egg$$$455$$$458$$$O	white,$$$459$$$465$$$O	the$$$466$$$469$$$O	eucalyptus$$$470$$$480$$$O	oil$$$481$$$484$$$O	and$$$485$$$488$$$O	the$$$489$$$492$$$O	peppermint,$$$493$$$504$$$O	and$$$505$$$508$$$O	has$$$509$$$512$$$O	effects$$$513$$$520$$$O	of$$$521$$$523$$$O	diminishing$$$524$$$535$$$O	inflammation$$$536$$$548$$$O	and$$$549$$$552$$$O	relieving$$$553$$$562$$$O	pain;$$$563$$$568$$$O	after$$$569$$$574$$$O	the$$$575$$$578$$$O	medicament$$$579$$$589$$$O	with$$$590$$$594$$$O	the$$$595$$$598$$$O	formula$$$599$$$606$$$O	is$$$607$$$609$$$O	used,$$$610$$$615$$$O	a$$$616$$$617$$$O	wound$$$618$$$623$$$O	is$$$624$$$626$$$O	not$$$627$$$630$$$O	itching$$$631$$$638$$$O	and$$$639$$$642$$$O	does$$$643$$$647$$$O	not$$$648$$$651$$$O	form$$$652$$$656$$$O	pustule$$$657$$$664$$$O	and$$$665$$$668$$$O	the$$$669$$$672$$$O	like,$$$673$$$678$$$O	and$$$679$$$682$$$O	a$$$683$$$684$$$O	growing$$$685$$$692$$$O	scar$$$693$$$697$$$O	cannot$$$698$$$704$$$O	appear$$$705$$$711$$$O	after$$$712$$$717$$$O	the$$$718$$$721$$$O	wound$$$722$$$727$$$O	is$$$728$$$730$$$O	healed;$$$731$$$738$$$O	and$$$739$$$742$$$O	the$$$743$$$746$$$O	formula$$$747$$$754$$$O	is$$$755$$$757$$$O	effectively$$$758$$$769$$$O	used$$$770$$$774$$$O	for$$$775$$$778$$$O	treating$$$779$$$787$$$O	the$$$788$$$791$$$O	scalding,$$$792$$$801$$$O	and$$$802$$$805$$$O	has$$$806$$$809$$$O	skillful$$$810$$$818$$$O	concept,$$$819$$$827$$$O	high$$$828$$$832$$$O	utility$$$833$$$840$$$O	value$$$841$$$846$$$O	and$$$847$$$850$$$O	great$$$851$$$856$$$O	market$$$857$$$863$$$O	prospect.$$$864$$$873$$$O
WO2007085718A1
Sulfonamide$$$0$$$11$$$I	derivatives,$$$12$$$24$$$O	preparation$$$25$$$36$$$O	thereof$$$37$$$44$$$O	and$$$45$$$48$$$O	therapeutic$$$49$$$60$$$O	use$$$61$$$64$$$O	thereof$$$65$$$72$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	sulphonamide$$$33$$$45$$$I	derivatives$$$46$$$57$$$O	corresponding$$$58$$$71$$$O	to$$$72$$$74$$$O	the$$$75$$$78$$$O	general$$$79$$$86$$$O	formula$$$87$$$94$$$O	(I),$$$95$$$99$$$O	in$$$100$$$102$$$O	which$$$103$$$108$$$O	Ar1$$$109$$$112$$$O	represents$$$113$$$123$$$O	an$$$124$$$126$$$O	aryl$$$127$$$131$$$O	optionally$$$132$$$142$$$O	substituted$$$143$$$154$$$O	with$$$155$$$159$$$O	one$$$160$$$163$$$O	or$$$164$$$166$$$O	more$$$167$$$171$$$O	groups,$$$172$$$179$$$O	or$$$180$$$182$$$O	an$$$183$$$185$$$O	optionally$$$186$$$196$$$O	substituted$$$197$$$208$$$O	heterocyclyl$$$209$$$221$$$I	group;$$$222$$$228$$$O	T$$$229$$$230$$$O	represents$$$231$$$241$$$O	a$$$242$$$243$$$O	-(CH2)n-$$$244$$$252$$$I	or$$$253$$$255$$$O	a$$$256$$$257$$$O	group$$$258$$$263$$$O	(II),$$$264$$$269$$$O	Ar2$$$270$$$273$$$O	represents$$$274$$$284$$$O	an$$$285$$$287$$$O	aryl$$$288$$$292$$$I	as$$$293$$$295$$$O	optionally$$$296$$$306$$$O	substituted$$$307$$$318$$$O	with$$$319$$$323$$$O	one$$$324$$$327$$$O	or$$$328$$$330$$$O	more$$$331$$$335$$$O	groups,$$$336$$$343$$$O	or$$$344$$$346$$$O	an$$$347$$$349$$$O	optionally$$$350$$$360$$$O	substituted$$$361$$$372$$$O	heterocyclyl$$$373$$$385$$$I	group;$$$386$$$392$$$O	Ar3$$$393$$$396$$$O	represents$$$397$$$407$$$O	an$$$408$$$410$$$O	aryl$$$411$$$415$$$I	optionally$$$416$$$426$$$O	substituted$$$427$$$438$$$O	with$$$439$$$443$$$O	one$$$444$$$447$$$O	or$$$448$$$450$$$O	more$$$451$$$455$$$O	groups,$$$456$$$463$$$O	or$$$464$$$466$$$O	else$$$467$$$471$$$O	an$$$472$$$474$$$O	optionally$$$475$$$485$$$O	substituted$$$486$$$497$$$O	heterocyclyl,$$$498$$$511$$$I	R1$$$512$$$514$$$O	represents$$$515$$$525$$$O	a$$$526$$$527$$$O	group$$$528$$$533$$$O	of$$$534$$$536$$$O	formula$$$537$$$544$$$O	(A)$$$545$$$548$$$O	or$$$549$$$551$$$O	(B):$$$552$$$556$$$O	(A)$$$557$$$560$$$O	(B)$$$561$$$564$$$O	in$$$565$$$567$$$O	the$$$568$$$571$$$O	form$$$572$$$576$$$O	of$$$577$$$579$$$O	a$$$580$$$581$$$O	base,$$$582$$$587$$$O	an$$$588$$$590$$$O	addition$$$591$$$599$$$O	salt$$$600$$$604$$$O	with$$$605$$$609$$$O	an$$$610$$$612$$$O	acid,$$$613$$$618$$$O	a$$$619$$$620$$$O	hydrate$$$621$$$628$$$O	or$$$629$$$631$$$O	a$$$632$$$633$$$O	solvate,$$$634$$$642$$$O	in$$$643$$$645$$$O	the$$$646$$$649$$$O	form$$$650$$$654$$$O	of$$$655$$$657$$$O	enantiomers,$$$658$$$670$$$O	diastereoisomers,$$$671$$$688$$$O	rotamers$$$689$$$697$$$O	or$$$698$$$700$$$O	atropoisomers,$$$701$$$715$$$O	or$$$716$$$718$$$O	mixtures$$$719$$$727$$$O	thereof.$$$728$$$736$$$O	It$$$737$$$739$$$O	also$$$740$$$744$$$O	relates$$$745$$$752$$$O	to$$$753$$$755$$$O	the$$$756$$$759$$$O	process$$$760$$$767$$$O	for$$$768$$$771$$$O	the$$$772$$$775$$$O	preparation$$$776$$$787$$$O	and$$$788$$$791$$$O	also$$$792$$$796$$$O	the$$$797$$$800$$$O	therapeutic$$$801$$$812$$$O	use$$$813$$$816$$$O	of$$$817$$$819$$$O	the$$$820$$$823$$$O	compounds$$$824$$$833$$$O	of$$$834$$$836$$$O	formula$$$837$$$844$$$O	(I).$$$845$$$849$$$O
CN1810803B
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	high$$$11$$$15$$$O	enantiomer$$$16$$$26$$$O	selection$$$27$$$36$$$O	preparation$$$37$$$48$$$O	of$$$49$$$51$$$O	(S)-Omeprazole$$$52$$$66$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	antimer$$$33$$$40$$$O	selective$$$41$$$50$$$O	catalytic$$$51$$$60$$$O	oxidation$$$61$$$70$$$O	process$$$71$$$78$$$O	for$$$79$$$82$$$O	preparing$$$83$$$92$$$O	optical$$$93$$$100$$$O	active$$$101$$$107$$$O	antimer$$$108$$$115$$$O	or$$$116$$$118$$$O	optically$$$119$$$128$$$O	pure$$$129$$$133$$$O	antimer$$$134$$$141$$$O	(S)-omeprazole.$$$142$$$157$$$I	In$$$158$$$160$$$O	the$$$161$$$164$$$O	presence$$$165$$$173$$$O	of$$$174$$$176$$$O	the$$$177$$$180$$$O	titanium$$$181$$$189$$$O	containing$$$190$$$200$$$O	catalyst$$$201$$$209$$$O	in-situ$$$210$$$217$$$O	created$$$218$$$225$$$O	with$$$226$$$230$$$O	metal$$$231$$$236$$$O	titanium$$$237$$$245$$$O	reagent$$$246$$$253$$$O	and$$$254$$$257$$$O	chiral$$$258$$$264$$$O	glycol$$$265$$$271$$$O	ligand$$$272$$$278$$$O	and$$$279$$$282$$$O	the$$$283$$$286$$$O	oxidant,$$$287$$$295$$$O	omeprazole$$$296$$$306$$$I	sulfide$$$307$$$314$$$I	is$$$315$$$317$$$O	catalytically$$$318$$$331$$$O	oxidized$$$332$$$340$$$O	with$$$341$$$345$$$O	antimer.$$$346$$$354$$$O	Compared$$$355$$$363$$$O	with$$$364$$$368$$$O	the$$$369$$$372$$$O	process$$$373$$$380$$$O	utilizing$$$381$$$390$$$O	tetraisopropanol$$$391$$$407$$$I	titanium-diethyl$$$408$$$424$$$I	tartrate$$$425$$$433$$$I	system,$$$434$$$441$$$O	the$$$442$$$445$$$O	process$$$446$$$453$$$O	of$$$454$$$456$$$O	the$$$457$$$460$$$O	present$$$461$$$468$$$O	invention$$$469$$$478$$$O	has$$$479$$$482$$$O	the$$$483$$$486$$$O	advantages$$$487$$$497$$$O	of$$$498$$$500$$$O	cheap$$$501$$$506$$$O	material,$$$507$$$516$$$O	high$$$517$$$521$$$O	antimer$$$522$$$529$$$O	selectivity$$$530$$$541$$$O	and$$$542$$$545$$$O	high$$$546$$$550$$$O	yield.$$$551$$$557$$$O	The$$$558$$$561$$$O	present$$$562$$$569$$$O	invention$$$570$$$579$$$O	also$$$580$$$584$$$O	relates$$$585$$$592$$$O	to$$$593$$$595$$$O	thepreparation$$$596$$$610$$$O	of$$$611$$$613$$$O	(S)-omeprazole$$$614$$$628$$$I	in$$$629$$$631$$$O	neutralized$$$632$$$643$$$O	state,$$$644$$$650$$$O	partial$$$651$$$658$$$O	crystallized$$$659$$$671$$$O	state$$$672$$$677$$$O	or$$$678$$$680$$$O	completely$$$681$$$691$$$O	crystallized$$$692$$$704$$$O	state.$$$705$$$711$$$O
CN103041227A
Liver$$$0$$$5$$$O	benefiting$$$6$$$16$$$O	powder$$$17$$$23$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicine,$$$48$$$57$$$O	and$$$58$$$61$$$O	particularly$$$62$$$74$$$O	relates$$$75$$$82$$$O	to$$$83$$$85$$$O	a$$$86$$$87$$$O	compound$$$88$$$96$$$O	Chinese$$$97$$$104$$$O	patent$$$105$$$111$$$O	drug$$$112$$$116$$$O	for$$$117$$$120$$$O	treating$$$121$$$129$$$O	a$$$130$$$131$$$O	primary$$$132$$$139$$$O	liver$$$140$$$145$$$O	cancer,$$$146$$$153$$$O	and$$$154$$$157$$$O	an$$$158$$$160$$$O	administration$$$161$$$175$$$O	method$$$176$$$182$$$O	of$$$183$$$185$$$O	the$$$186$$$189$$$O	compound$$$190$$$198$$$O	Chinese$$$199$$$206$$$O	patent$$$207$$$213$$$O	drug.$$$214$$$219$$$O	The$$$220$$$223$$$O	primary$$$224$$$231$$$O	liver$$$232$$$237$$$O	cancer$$$238$$$244$$$O	is$$$245$$$247$$$O	one$$$248$$$251$$$O	of$$$252$$$254$$$O	the$$$255$$$258$$$O	common$$$259$$$265$$$O	malignant$$$266$$$275$$$O	tumors$$$276$$$282$$$O	in$$$283$$$285$$$O	China.$$$286$$$292$$$O	The$$$293$$$296$$$O	compound$$$297$$$305$$$O	Chinese$$$306$$$313$$$O	patent$$$314$$$320$$$O	drug$$$321$$$325$$$O	adopts$$$326$$$332$$$O	13$$$333$$$335$$$O	medicinal$$$336$$$345$$$O	materials$$$346$$$355$$$O	for$$$356$$$359$$$O	compounding,$$$360$$$372$$$O	can$$$373$$$376$$$O	eliminate$$$377$$$386$$$O	pathogens,$$$387$$$397$$$O	strengthen$$$398$$$408$$$O	body$$$409$$$413$$$O	resistance,$$$414$$$425$$$O	promote$$$426$$$433$$$O	blood$$$434$$$439$$$O	circulation,$$$440$$$452$$$O	stop$$$453$$$457$$$O	bleeding$$$458$$$466$$$O	and$$$467$$$470$$$O	treat$$$471$$$476$$$O	a$$$477$$$478$$$O	liver$$$479$$$484$$$O	and$$$485$$$488$$$O	a$$$489$$$490$$$O	spleen,$$$491$$$498$$$O	and$$$499$$$502$$$O	treats$$$503$$$509$$$O	the$$$510$$$513$$$O	primary$$$514$$$521$$$O	liver$$$522$$$527$$$O	cancer$$$528$$$534$$$O	by$$$535$$$537$$$O	integrating$$$538$$$549$$$O	external$$$550$$$558$$$O	treatment$$$559$$$568$$$O	and$$$569$$$572$$$O	internal$$$573$$$581$$$O	treatment.$$$582$$$592$$$O	The$$$593$$$596$$$O	compound$$$597$$$605$$$O	Chinese$$$606$$$613$$$O	patent$$$614$$$620$$$O	drug$$$621$$$625$$$O	adopts$$$626$$$632$$$O	the$$$633$$$636$$$O	technical$$$637$$$646$$$O	scheme$$$647$$$653$$$O	that$$$654$$$658$$$O	the$$$659$$$662$$$O	following$$$663$$$672$$$O	medicinal$$$673$$$682$$$O	materials$$$683$$$692$$$O	and$$$693$$$696$$$O	matching$$$697$$$705$$$O	ratio$$$706$$$711$$$O	are$$$712$$$715$$$O	adopted,$$$716$$$724$$$O	and$$$725$$$728$$$O	the$$$729$$$732$$$O	13$$$733$$$735$$$O	medicinal$$$736$$$745$$$O	materials$$$746$$$755$$$O	are$$$756$$$759$$$O	porphyrized$$$760$$$771$$$O	and$$$772$$$775$$$O	uniformly$$$776$$$785$$$O	mixed$$$786$$$791$$$O	into$$$792$$$796$$$O	powder$$$797$$$803$$$O	according$$$804$$$813$$$O	to$$$814$$$816$$$O	the$$$817$$$820$$$O	matching$$$821$$$829$$$O	ratio.$$$830$$$836$$$O	The$$$837$$$840$$$O	1.5-2g$$$841$$$847$$$O	liver$$$848$$$853$$$O	benefiting$$$854$$$864$$$O	powder$$$865$$$871$$$O	is$$$872$$$874$$$O	taken$$$875$$$880$$$O	directly$$$881$$$889$$$O	with$$$890$$$894$$$O	warm$$$895$$$899$$$O	water$$$900$$$905$$$O	at$$$906$$$908$$$O	each$$$909$$$913$$$O	time$$$914$$$918$$$O	for$$$919$$$922$$$O	2-3$$$923$$$926$$$O	times$$$927$$$932$$$O	per$$$933$$$936$$$O	day.$$$937$$$941$$$O	External$$$942$$$950$$$O	application$$$951$$$962$$$O	treatment$$$963$$$972$$$O	is$$$973$$$975$$$O	conducted$$$976$$$985$$$O	as$$$986$$$988$$$O	follows:$$$989$$$997$$$O	realgar$$$998$$$1005$$$O	is$$$1006$$$1008$$$O	placed$$$1009$$$1015$$$O	in$$$1016$$$1018$$$O	an$$$1019$$$1021$$$O	abdomen$$$1022$$$1029$$$O	of$$$1030$$$1032$$$O	a$$$1033$$$1034$$$O	live$$$1035$$$1039$$$O	toad$$$1040$$$1044$$$O	(with$$$1045$$$1050$$$O	viscera$$$1051$$$1058$$$O	being$$$1059$$$1064$$$O	removed),$$$1065$$$1074$$$O	warm$$$1075$$$1079$$$O	water$$$1080$$$1085$$$O	is$$$1086$$$1088$$$O	added$$$1089$$$1094$$$O	to$$$1095$$$1097$$$O	prepare$$$1098$$$1105$$$O	paste,$$$1106$$$1112$$$O	and$$$1113$$$1116$$$O	then$$$1117$$$1121$$$O	the$$$1122$$$1125$$$O	toad$$$1126$$$1130$$$O	is$$$1131$$$1133$$$O	externally$$$1134$$$1144$$$O	applied$$$1145$$$1152$$$O	at$$$1153$$$1155$$$O	a$$$1156$$$1157$$$O	hepatic$$$1158$$$1165$$$O	region$$$1166$$$1172$$$O	for$$$1173$$$1176$$$O	twice$$$1177$$$1182$$$O	per$$$1183$$$1186$$$O	day.$$$1187$$$1191$$$O
US20110097343
Diagnosis$$$0$$$9$$$O	and$$$10$$$13$$$O	therapy$$$14$$$21$$$O	of$$$22$$$24$$$O	hematological$$$25$$$38$$$O	malignancies$$$39$$$51$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	field$$$37$$$42$$$O	of$$$43$$$45$$$O	diagnosis$$$46$$$55$$$O	and$$$56$$$59$$$O	therapy$$$60$$$67$$$O	of$$$68$$$70$$$O	hematological$$$71$$$84$$$O	malignancies$$$85$$$97$$$O	based$$$98$$$103$$$O	on$$$104$$$106$$$O	the$$$107$$$110$$$O	tumor$$$111$$$116$$$O	antigen$$$117$$$124$$$O	FMR1NB$$$125$$$131$$$O	(also$$$132$$$137$$$O	called$$$138$$$144$$$O	NY-SAR-35,$$$145$$$155$$$O	Cancer/testis$$$156$$$169$$$O	antigen$$$170$$$177$$$O	37$$$178$$$180$$$O	or$$$181$$$183$$$O	Fragile$$$184$$$191$$$O	X$$$192$$$193$$$O	mental$$$194$$$200$$$O	retardation$$$201$$$212$$$O	1$$$213$$$214$$$O	neighbor$$$215$$$223$$$O	protein)$$$224$$$232$$$O	and$$$233$$$236$$$O	agents$$$237$$$243$$$O	specifically$$$244$$$256$$$O	targeting$$$257$$$266$$$O	this$$$267$$$271$$$O	antigen$$$272$$$279$$$O	or$$$280$$$282$$$O	cells$$$283$$$288$$$O	expressing$$$289$$$299$$$O	the$$$300$$$303$$$O	same,$$$304$$$309$$$O	e.g.,$$$310$$$315$$$O	antibodies.$$$316$$$327$$$O	The$$$328$$$331$$$O	inventors$$$332$$$341$$$O	were$$$342$$$346$$$O	able$$$347$$$351$$$O	to$$$352$$$354$$$O	prove$$$355$$$360$$$O	that$$$361$$$365$$$O	the$$$366$$$369$$$O	molecule$$$370$$$378$$$O	is$$$379$$$381$$$O	expressed$$$382$$$391$$$O	on$$$392$$$394$$$O	the$$$395$$$398$$$O	cell$$$399$$$403$$$O	surface$$$404$$$411$$$O	and$$$412$$$415$$$O	thus$$$416$$$420$$$O	represents$$$421$$$431$$$O	a$$$432$$$433$$$O	particularly$$$434$$$446$$$O	advantageous$$$447$$$459$$$O	target$$$460$$$466$$$O	in$$$467$$$469$$$O	cancer$$$470$$$476$$$O	therapy$$$477$$$484$$$O	and$$$485$$$488$$$O	vaccination.$$$489$$$501$$$O	Surprisingly,$$$502$$$515$$$O	FMR1NB$$$516$$$522$$$O	was$$$523$$$526$$$O	found$$$527$$$532$$$O	to$$$533$$$535$$$O	be$$$536$$$538$$$O	associated$$$539$$$549$$$O	with$$$550$$$554$$$O	hematological$$$555$$$568$$$O	malignancies,$$$569$$$582$$$O	e.g.$$$583$$$587$$$O	acute$$$588$$$593$$$O	myeloid$$$594$$$601$$$O	leukemia$$$602$$$610$$$O	(AML)$$$611$$$616$$$O	or$$$617$$$619$$$O	chronic$$$620$$$627$$$O	myeloid$$$628$$$635$$$O	leukemia$$$636$$$644$$$O	(CML).$$$645$$$651$$$O
CN103181901A
Dihydroartemisinin$$$0$$$18$$$I	controlled-release$$$19$$$37$$$O	preparation$$$38$$$49$$$O	used$$$50$$$54$$$O	for$$$55$$$58$$$O	treating$$$59$$$67$$$O	lupus$$$68$$$73$$$O	erythematosus$$$74$$$87$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	dihydroartemisinin$$$26$$$44$$$I	controlled-release$$$45$$$63$$$O	preparation$$$64$$$75$$$O	used$$$76$$$80$$$O	for$$$81$$$84$$$O	treating$$$85$$$93$$$O	lupus$$$94$$$99$$$O	erythematosus.$$$100$$$114$$$O	The$$$115$$$118$$$O	controlled-release$$$119$$$137$$$O	preparation$$$138$$$149$$$O	shows$$$150$$$155$$$O	at$$$156$$$158$$$O	least$$$159$$$164$$$O	one$$$165$$$168$$$O	property$$$169$$$177$$$O	of$$$178$$$180$$$O	the$$$181$$$184$$$O	following:$$$185$$$195$$$O	(1)$$$196$$$199$$$O	according$$$200$$$209$$$O	to$$$210$$$212$$$O	an$$$213$$$215$$$O	in-vitro$$$216$$$224$$$O	release$$$225$$$232$$$O	curve,$$$233$$$239$$$O	when$$$240$$$244$$$O	the$$$245$$$248$$$O	preparation$$$249$$$260$$$O	is$$$261$$$263$$$O	placed$$$264$$$270$$$O	for$$$271$$$274$$$O	0.5h$$$275$$$279$$$O	according$$$280$$$289$$$O	to$$$290$$$292$$$O	a$$$293$$$294$$$O	standard$$$295$$$303$$$O	dissolution$$$304$$$315$$$O	test,$$$316$$$321$$$O	an$$$322$$$324$$$O	accumulative$$$325$$$337$$$O	release$$$338$$$345$$$O	rate$$$346$$$350$$$O	of$$$351$$$353$$$O	dihydroartemisinin$$$354$$$372$$$I	is$$$373$$$375$$$O	10-25%;$$$376$$$383$$$O	and$$$384$$$387$$$O	(2)$$$388$$$391$$$O	according$$$392$$$401$$$O	to$$$402$$$404$$$O	a$$$405$$$406$$$O	healthy$$$407$$$414$$$O	adult$$$415$$$420$$$O	single-dose$$$421$$$432$$$O	oral$$$433$$$437$$$O	administration$$$438$$$452$$$O	dihydroartemisinin$$$453$$$471$$$I	in-vivo$$$472$$$479$$$O	absorption$$$480$$$490$$$O	curve,$$$491$$$497$$$O	an$$$498$$$500$$$O	average$$$501$$$508$$$O	time$$$509$$$513$$$O	for$$$514$$$517$$$O	40%$$$518$$$521$$$O	absorption$$$522$$$532$$$O	is$$$533$$$535$$$O	longer$$$536$$$542$$$O	than$$$543$$$547$$$O	approximately$$$548$$$561$$$O	2h,$$$562$$$565$$$O	and/or$$$566$$$572$$$O	an$$$573$$$575$$$O	average$$$576$$$583$$$O	time$$$584$$$588$$$O	for$$$589$$$592$$$O	70%$$$593$$$596$$$O	absorption$$$597$$$607$$$O	is$$$608$$$610$$$O	longer$$$611$$$617$$$O	than$$$618$$$622$$$O	approximately$$$623$$$636$$$O	6h.$$$637$$$640$$$O	With$$$641$$$645$$$O	the$$$646$$$649$$$O	preparation,$$$650$$$662$$$O	dihydroartemisinin$$$663$$$681$$$I	in-vivo$$$682$$$689$$$O	release$$$690$$$697$$$O	speed$$$698$$$703$$$O	can$$$704$$$707$$$O	be$$$708$$$710$$$O	controlled.$$$711$$$722$$$O	The$$$723$$$726$$$O	preparation$$$727$$$738$$$O	can$$$739$$$742$$$O	be$$$743$$$745$$$O	taken$$$746$$$751$$$O	only$$$752$$$756$$$O	once$$$757$$$761$$$O	every$$$762$$$767$$$O	day,$$$768$$$772$$$O	and$$$773$$$776$$$O	long-time$$$777$$$786$$$O	effective$$$787$$$796$$$O	blood$$$797$$$802$$$O	concentration$$$803$$$816$$$O	can$$$817$$$820$$$O	be$$$821$$$823$$$O	maintained,$$$824$$$835$$$O	such$$$836$$$840$$$O	that$$$841$$$845$$$O	medication$$$846$$$856$$$O	is$$$857$$$859$$$O	more$$$860$$$864$$$O	convenient.$$$865$$$876$$$O	The$$$877$$$880$$$O	preparation$$$881$$$892$$$O	has$$$893$$$896$$$O	stable$$$897$$$903$$$O	performance,$$$904$$$916$$$O	and$$$917$$$920$$$O	low$$$921$$$924$$$O	toxic$$$925$$$930$$$O	and$$$931$$$934$$$O	side$$$935$$$939$$$O	effect.$$$940$$$947$$$O	Because$$$948$$$955$$$O	the$$$956$$$959$$$O	preparation$$$960$$$971$$$O	only$$$972$$$976$$$O	needs$$$977$$$982$$$O	to$$$983$$$985$$$O	be$$$986$$$988$$$O	taken$$$989$$$994$$$O	once$$$995$$$999$$$O	a$$$1000$$$1001$$$O	day,$$$1002$$$1006$$$O	treatment$$$1007$$$1016$$$O	cost$$$1017$$$1021$$$O	is$$$1022$$$1024$$$O	reduced.$$$1025$$$1033$$$O
US6893641
Ganoderma$$$0$$$9$$$O	lucidum$$$10$$$17$$$O	spores$$$18$$$24$$$O	for$$$25$$$28$$$O	treatment$$$29$$$38$$$O	of$$$39$$$41$$$O	autoimmune$$$42$$$52$$$O	diseases$$$53$$$61$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	method$$$33$$$39$$$O	for$$$40$$$43$$$O	treating$$$44$$$52$$$O	a$$$53$$$54$$$O	mammal$$$55$$$61$$$O	with$$$62$$$66$$$O	immunological$$$67$$$80$$$O	disorders,$$$81$$$91$$$O	particularly$$$92$$$104$$$O	autoimmune$$$105$$$115$$$O	disease,$$$116$$$124$$$O	and$$$125$$$128$$$O	most$$$129$$$133$$$O	preferably$$$134$$$144$$$O	systemic$$$145$$$153$$$O	lupus$$$154$$$159$$$O	erythematosus$$$160$$$173$$$O	(SLE).$$$174$$$180$$$O	The$$$181$$$184$$$O	method$$$185$$$191$$$O	includes$$$192$$$200$$$O	oral$$$201$$$205$$$O	administration$$$206$$$220$$$O	of$$$221$$$223$$$O	germination$$$224$$$235$$$O	activated$$$236$$$245$$$O	Ganoderma$$$246$$$255$$$O	lucidum$$$256$$$263$$$O	spores$$$264$$$270$$$O	(âGLSsâ)$$$271$$$283$$$O	to$$$284$$$286$$$O	the$$$287$$$290$$$O	mammal.$$$291$$$298$$$O	Additionally,$$$299$$$312$$$I	a$$$313$$$314$$$I	corticosteroid,$$$315$$$330$$$I	such$$$331$$$335$$$I	as$$$336$$$338$$$I	prednisolone,$$$339$$$352$$$I	can$$$353$$$356$$$O	be$$$357$$$359$$$O	co-administered$$$360$$$375$$$O	with$$$376$$$380$$$O	the$$$381$$$384$$$O	GLSs$$$385$$$389$$$O	to$$$390$$$392$$$O	the$$$393$$$396$$$O	mammal$$$397$$$403$$$O	to$$$404$$$406$$$O	achieve$$$407$$$414$$$O	synergistic$$$415$$$426$$$O	effect$$$427$$$433$$$O	of$$$434$$$436$$$O	treatment.$$$437$$$447$$$O
CN103191068A
Catechin$$$0$$$8$$$I	lozenge$$$9$$$16$$$O	and$$$17$$$20$$$O	its$$$21$$$24$$$O	making$$$25$$$31$$$O	method$$$32$$$38$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	catechin$$$26$$$34$$$I	lozenge$$$35$$$42$$$O	and$$$43$$$46$$$O	its$$$47$$$50$$$O	making$$$51$$$57$$$O	method.$$$58$$$65$$$O	The$$$66$$$69$$$O	making$$$70$$$76$$$O	of$$$77$$$79$$$O	the$$$80$$$83$$$O	catechin$$$84$$$92$$$I	lozenge$$$93$$$100$$$O	through$$$101$$$108$$$O	the$$$109$$$112$$$O	method$$$113$$$119$$$O	is$$$120$$$122$$$O	in$$$123$$$125$$$O	favor$$$126$$$131$$$O	of$$$132$$$134$$$O	obtaining$$$135$$$144$$$O	a$$$145$$$146$$$O	lozenge$$$147$$$154$$$O	having$$$155$$$161$$$O	high$$$162$$$166$$$O	ester$$$167$$$172$$$I	catechin-tea$$$173$$$185$$$I	flavones,$$$186$$$195$$$I	and$$$196$$$199$$$O	guaranteeing$$$200$$$212$$$O	the$$$213$$$216$$$O	high$$$217$$$221$$$O	biological$$$222$$$232$$$O	activities$$$233$$$243$$$O	of$$$244$$$246$$$O	the$$$247$$$250$$$O	high$$$251$$$255$$$O	ester$$$256$$$261$$$I	catechin-tea$$$262$$$274$$$I	flavones,$$$275$$$284$$$I	so$$$285$$$287$$$O	the$$$288$$$291$$$O	antibacterial$$$292$$$305$$$O	antiviral$$$306$$$315$$$O	capabilities$$$316$$$328$$$O	are$$$329$$$332$$$O	possessed.$$$333$$$343$$$O	The$$$344$$$347$$$O	catechin$$$348$$$356$$$I	lozenge$$$357$$$364$$$O	made$$$365$$$369$$$O	through$$$370$$$377$$$O	the$$$378$$$381$$$O	method$$$382$$$388$$$O	mainly$$$389$$$395$$$O	comprises$$$396$$$405$$$O	a$$$406$$$407$$$O	microencapsulated$$$408$$$425$$$O	lipidosome$$$426$$$436$$$O	and$$$437$$$440$$$O	the$$$441$$$444$$$O	high$$$445$$$449$$$O	ester$$$450$$$455$$$I	catechin-tea$$$456$$$468$$$I	flavones$$$469$$$477$$$I	wrapped$$$478$$$485$$$O	by$$$486$$$488$$$O	the$$$489$$$492$$$O	microencapsulated$$$493$$$510$$$O	lipidosome.$$$511$$$522$$$O	According$$$523$$$532$$$O	to$$$533$$$535$$$O	the$$$536$$$539$$$O	invention,$$$540$$$550$$$O	the$$$551$$$554$$$O	making$$$555$$$561$$$O	method$$$562$$$568$$$O	of$$$569$$$571$$$O	the$$$572$$$575$$$O	catechin$$$576$$$584$$$I	lozenge$$$585$$$592$$$O	is$$$593$$$595$$$O	in$$$596$$$598$$$O	favor$$$599$$$604$$$O	of$$$605$$$607$$$O	obtaining$$$608$$$617$$$O	the$$$618$$$621$$$O	catechin$$$622$$$630$$$I	lozenge$$$631$$$638$$$O	having$$$639$$$645$$$O	the$$$646$$$649$$$O	high$$$650$$$654$$$O	ester$$$655$$$660$$$I	catechin-tea$$$661$$$673$$$I	flavones,$$$674$$$683$$$I	preventing$$$684$$$694$$$O	catechins$$$695$$$704$$$I	in$$$705$$$707$$$O	the$$$708$$$711$$$O	lozenge$$$712$$$719$$$O	from$$$720$$$724$$$O	oxidizing,$$$725$$$735$$$O	storing$$$736$$$743$$$O	the$$$744$$$747$$$O	lozenge$$$748$$$755$$$O	for$$$756$$$759$$$O	a$$$760$$$761$$$O	long$$$762$$$766$$$O	term,$$$767$$$772$$$O	and$$$773$$$776$$$O	guaranteeing$$$777$$$789$$$O	the$$$790$$$793$$$O	quality$$$794$$$801$$$O	and$$$802$$$805$$$O	the$$$806$$$809$$$O	curative$$$810$$$818$$$O	effects$$$819$$$826$$$O	of$$$827$$$829$$$O	the$$$830$$$833$$$O	lozenge;$$$834$$$842$$$O	and$$$843$$$846$$$O	catechin$$$847$$$855$$$I	lozenge$$$856$$$863$$$O	obtained$$$864$$$872$$$O	through$$$873$$$880$$$O	the$$$881$$$884$$$O	method$$$885$$$891$$$O	has$$$892$$$895$$$O	the$$$896$$$899$$$O	advantages$$$900$$$910$$$O	of$$$911$$$913$$$O	good$$$914$$$918$$$O	quality$$$919$$$926$$$O	and$$$927$$$930$$$O	curative$$$931$$$939$$$O	effects,$$$940$$$948$$$O	antibiosis,$$$949$$$960$$$O	antivirus,$$$961$$$971$$$O	and$$$972$$$975$$$O	high$$$976$$$980$$$O	biological$$$981$$$991$$$O	activities.$$$992$$$1003$$$O
CA2320288C
Oligodeoxyribonucleotides$$$0$$$25$$$I	comprising$$$26$$$36$$$O	o6-benzylguanine$$$37$$$53$$$I	and$$$54$$$57$$$O	their$$$58$$$63$$$O	use$$$64$$$67$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	single-stranded$$$33$$$48$$$O	oligodeoxyribonucleotide,$$$49$$$74$$$I	which$$$75$$$80$$$O	(i)$$$81$$$84$$$O	comprises$$$85$$$94$$$O	from$$$95$$$99$$$O	about$$$100$$$105$$$O	5$$$106$$$107$$$O	to$$$108$$$110$$$O	11$$$111$$$113$$$O	bases,$$$114$$$120$$$O	at$$$121$$$123$$$O	least$$$124$$$129$$$O	one$$$130$$$133$$$O	of$$$134$$$136$$$O	which$$$137$$$142$$$O	is$$$143$$$145$$$O	a$$$146$$$147$$$O	substituted$$$148$$$159$$$O	or$$$160$$$162$$$O	an$$$163$$$165$$$O	unsubstituted$$$166$$$179$$$O	O6-benzylguanine,$$$180$$$197$$$I	and$$$198$$$201$$$O	(ii)$$$202$$$206$$$O	inactivates$$$207$$$218$$$O	human$$$219$$$224$$$O	AGT.$$$225$$$229$$$O	The$$$230$$$233$$$O	present$$$234$$$241$$$O	invention$$$242$$$251$$$O	also$$$252$$$256$$$O	provides$$$257$$$265$$$O	a$$$266$$$267$$$O	single-stranded$$$268$$$283$$$O	oligodeoxyribonucleotide,$$$284$$$309$$$I	which$$$310$$$315$$$O	can$$$316$$$319$$$O	inactivate$$$320$$$330$$$O	a$$$331$$$332$$$O	mutant$$$333$$$339$$$O	human$$$340$$$345$$$O	AGT,$$$346$$$350$$$O	which$$$351$$$356$$$O	either$$$357$$$363$$$O	is$$$364$$$366$$$O	not$$$367$$$370$$$O	inactivated$$$371$$$382$$$O	by$$$383$$$385$$$O	O6-benzylguanine$$$386$$$402$$$I	or$$$403$$$405$$$O	is$$$406$$$408$$$O	less$$$409$$$413$$$O	inactivated$$$414$$$425$$$O	by$$$426$$$428$$$O	O6-benzylguanine$$$429$$$445$$$I	than$$$446$$$450$$$O	by$$$451$$$453$$$O	said$$$454$$$458$$$O	single-stranded$$$459$$$474$$$O	oligodeoxyribonucleotide.$$$475$$$500$$$I	A$$$501$$$502$$$O	phosphate$$$503$$$512$$$O	of$$$513$$$515$$$O	the$$$516$$$519$$$O	single-stranded$$$520$$$535$$$O	oligodeoxyribonucleotide$$$536$$$560$$$I	can$$$561$$$564$$$O	be$$$565$$$567$$$O	replaced$$$568$$$576$$$O	by$$$577$$$579$$$O	a$$$580$$$581$$$O	methylphosphonate$$$582$$$599$$$I	or$$$600$$$602$$$O	a$$$603$$$604$$$O	phosphorothioate.$$$605$$$622$$$I	The$$$623$$$626$$$O	present$$$627$$$634$$$O	invention$$$635$$$644$$$O	also$$$645$$$649$$$O	provides$$$650$$$658$$$O	a$$$659$$$660$$$O	composition$$$661$$$672$$$O	comprising$$$673$$$683$$$O	such$$$684$$$688$$$O	an$$$689$$$691$$$O	oligodeoxyribonucleotide.$$$692$$$717$$$I	In$$$718$$$720$$$O	addition,$$$721$$$730$$$O	the$$$731$$$734$$$O	present$$$735$$$742$$$O	invention$$$743$$$752$$$O	provides$$$753$$$761$$$O	a$$$762$$$763$$$O	method$$$764$$$770$$$O	of$$$771$$$773$$$O	enhancing$$$774$$$783$$$O	the$$$784$$$787$$$O	effect$$$788$$$794$$$O	of$$$795$$$797$$$O	an$$$798$$$800$$$O	antineoplastic$$$801$$$815$$$O	alkylating$$$816$$$826$$$O	agent,$$$827$$$833$$$O	which$$$834$$$839$$$O	alkylates$$$840$$$849$$$O	the$$$850$$$853$$$O	O6$$$854$$$856$$$O	position$$$857$$$865$$$O	of$$$866$$$868$$$O	guanine$$$869$$$876$$$I	residues$$$877$$$885$$$O	in$$$886$$$888$$$O	DNA,$$$889$$$893$$$O	in$$$894$$$896$$$O	the$$$897$$$900$$$O	chemotherapeutic$$$901$$$917$$$O	treatment$$$918$$$927$$$O	of$$$928$$$930$$$O	cancer$$$931$$$937$$$O	in$$$938$$$940$$$O	a$$$941$$$942$$$O	mammal,$$$943$$$950$$$O	which$$$951$$$956$$$O	method$$$957$$$963$$$O	comprises$$$964$$$973$$$O	the$$$974$$$977$$$O	co-administration$$$978$$$995$$$O	to$$$996$$$998$$$O	the$$$999$$$1002$$$O	mammal$$$1003$$$1009$$$O	of$$$1010$$$1012$$$O	a$$$1013$$$1014$$$O	cancer-treatment$$$1015$$$1031$$$O	effective$$$1032$$$1041$$$O	amount$$$1042$$$1048$$$O	of$$$1049$$$1051$$$O	an$$$1052$$$1054$$$O	antineoplastic$$$1055$$$1069$$$O	alkylating$$$1070$$$1080$$$O	agent$$$1081$$$1086$$$O	and$$$1087$$$1090$$$O	a$$$1091$$$1092$$$O	chemotherapeutic$$$1093$$$1109$$$O	treatment-enhancing$$$1110$$$1129$$$O	amount$$$1130$$$1136$$$O	of$$$1137$$$1139$$$O	a$$$1140$$$1141$$$O	present$$$1142$$$1149$$$O	inventive$$$1150$$$1159$$$O	oligodeoxyribonucleotide$$$1160$$$1184$$$I	or$$$1185$$$1187$$$O	composition$$$1188$$$1199$$$O	thereof.$$$1200$$$1208$$$O
CN102370639A
Compound$$$0$$$8$$$O	preparation$$$9$$$20$$$O	of$$$21$$$23$$$O	naproxen$$$24$$$32$$$I	and$$$33$$$36$$$O	sumatriptan$$$37$$$48$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	compound$$$25$$$33$$$O	preparation$$$34$$$45$$$O	of$$$46$$$48$$$O	naproxen$$$49$$$57$$$I	and$$$58$$$61$$$O	sumatriptan.$$$62$$$74$$$I	The$$$75$$$78$$$O	compound$$$79$$$87$$$O	preparation$$$88$$$99$$$O	comprises$$$100$$$109$$$O	active$$$110$$$116$$$O	components$$$117$$$127$$$O	of$$$128$$$130$$$O	naproxen$$$131$$$139$$$I	and$$$140$$$143$$$O	sumatriptan$$$144$$$155$$$I	and$$$156$$$159$$$O	pharmaceutic$$$160$$$172$$$O	adjuvants.$$$173$$$183$$$O	A$$$184$$$185$$$O	single$$$186$$$192$$$O	dose$$$193$$$197$$$O	preparation$$$198$$$209$$$O	comprises$$$210$$$219$$$O	200-800mg$$$220$$$229$$$O	of$$$230$$$232$$$O	naproxen$$$233$$$241$$$I	and$$$242$$$245$$$O	20-200$$$246$$$252$$$O	mg$$$253$$$255$$$O	of$$$256$$$258$$$O	sumatriptan.$$$259$$$271$$$I	The$$$272$$$275$$$O	compound$$$276$$$284$$$O	preparation$$$285$$$296$$$O	of$$$297$$$299$$$O	the$$$300$$$303$$$O	invention$$$304$$$313$$$O	combines$$$314$$$322$$$O	two$$$323$$$326$$$O	effect$$$327$$$333$$$O	mechanisms$$$334$$$344$$$O	of$$$345$$$347$$$O	inflammatory$$$348$$$360$$$O	resistance$$$361$$$371$$$O	and$$$372$$$375$$$O	blood$$$376$$$381$$$O	vessel$$$382$$$388$$$O	diastole$$$389$$$397$$$O	into$$$398$$$402$$$O	a$$$403$$$404$$$O	whole,$$$405$$$411$$$O	can$$$412$$$415$$$O	be$$$416$$$418$$$O	used$$$419$$$423$$$O	for$$$424$$$427$$$O	treating$$$428$$$436$$$O	acute$$$437$$$442$$$O	attack$$$443$$$449$$$O	of$$$450$$$452$$$O	adult$$$453$$$458$$$O	tendency$$$459$$$467$$$O	or$$$468$$$470$$$O	non-tendency$$$471$$$483$$$O	migraine$$$484$$$492$$$O	and$$$493$$$496$$$O	has$$$497$$$500$$$O	curative$$$501$$$509$$$O	effect$$$510$$$516$$$O	better$$$517$$$523$$$O	than$$$524$$$528$$$O	individual$$$529$$$539$$$O	usage$$$540$$$545$$$O	of$$$546$$$548$$$O	naproxen$$$549$$$557$$$I	or$$$558$$$560$$$O	sumatriptan$$$561$$$572$$$I	and$$$573$$$576$$$O	good$$$577$$$581$$$O	clinic$$$582$$$588$$$O	application$$$589$$$600$$$O	value.$$$601$$$607$$$O
EP1003777B1
PGC-1,$$$0$$$6$$$O	A$$$7$$$8$$$O	NOVEL$$$9$$$14$$$O	BROWN$$$15$$$20$$$O	FAT$$$21$$$24$$$O	PPARgamma$$$25$$$34$$$O	COACTIVATOR$$$35$$$46$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	isolated$$$23$$$31$$$O	nucleic$$$32$$$39$$$O	acids$$$40$$$45$$$O	molecules,$$$46$$$56$$$O	designated$$$57$$$67$$$O	PGC-1$$$68$$$73$$$O	nucleic$$$74$$$81$$$O	acid$$$82$$$86$$$O	molecules,$$$87$$$97$$$O	which$$$98$$$103$$$O	encode$$$104$$$110$$$O	proteins$$$111$$$119$$$O	which$$$120$$$125$$$O	can$$$126$$$129$$$O	modulate$$$130$$$138$$$O	various$$$139$$$146$$$O	adipocyte-associated$$$147$$$167$$$O	activities$$$168$$$178$$$O	including,$$$179$$$189$$$O	for$$$190$$$193$$$O	example,$$$194$$$202$$$O	thermogenesis$$$203$$$216$$$O	in$$$217$$$219$$$O	adipocytes,$$$220$$$231$$$O	e.g.,$$$232$$$237$$$O	brown$$$238$$$243$$$O	adipocytes,$$$244$$$255$$$O	and$$$256$$$259$$$O	adipogenesis.$$$260$$$273$$$O	The$$$274$$$277$$$O	invention$$$278$$$287$$$O	also$$$288$$$292$$$O	provides$$$293$$$301$$$O	antisense$$$302$$$311$$$O	nucleic$$$312$$$319$$$O	acid$$$320$$$324$$$O	molecules,$$$325$$$335$$$O	recombinant$$$336$$$347$$$O	expression$$$348$$$358$$$O	vectors$$$359$$$366$$$O	containing$$$367$$$377$$$O	PGC-1$$$378$$$383$$$O	nucleic$$$384$$$391$$$O	acid$$$392$$$396$$$O	molecules,$$$397$$$407$$$O	host$$$408$$$412$$$O	cells$$$413$$$418$$$O	into$$$419$$$423$$$O	which$$$424$$$429$$$O	the$$$430$$$433$$$O	expression$$$434$$$444$$$O	vectors$$$445$$$452$$$O	have$$$453$$$457$$$O	been$$$458$$$462$$$O	introduced,$$$463$$$474$$$O	and$$$475$$$478$$$O	nonhuman$$$479$$$487$$$O	transgenic$$$488$$$498$$$O	animals$$$499$$$506$$$O	in$$$507$$$509$$$O	which$$$510$$$515$$$O	a$$$516$$$517$$$O	PGC-1$$$518$$$523$$$O	gene$$$524$$$528$$$O	has$$$529$$$532$$$O	been$$$533$$$537$$$O	introduced$$$538$$$548$$$O	or$$$549$$$551$$$O	disrupted.$$$552$$$562$$$O	The$$$563$$$566$$$O	invention$$$567$$$576$$$O	still$$$577$$$582$$$O	further$$$583$$$590$$$O	provides$$$591$$$599$$$O	isolated$$$600$$$608$$$O	PGC-1$$$609$$$614$$$O	proteins,$$$615$$$624$$$O	fusion$$$625$$$631$$$O	proteins,$$$632$$$641$$$O	antigenic$$$642$$$651$$$O	peptides$$$652$$$660$$$O	and$$$661$$$664$$$O	anti-PGC-1$$$665$$$675$$$O	antibodies.$$$676$$$687$$$O	Diagnostic,$$$688$$$699$$$O	screening,$$$700$$$710$$$O	and$$$711$$$714$$$O	therapeutic$$$715$$$726$$$O	methods$$$727$$$734$$$O	utilizing$$$735$$$744$$$O	compositions$$$745$$$757$$$O	of$$$758$$$760$$$O	the$$$761$$$764$$$O	invention$$$765$$$774$$$O	are$$$775$$$778$$$O	also$$$779$$$783$$$O	provided.$$$784$$$793$$$O
WO2010141427A1
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	ophthalmologic$$$13$$$27$$$O	disorders$$$28$$$37$$$O	mediated$$$38$$$46$$$O	by$$$47$$$49$$$O	albha-carbonic$$$50$$$64$$$O	anhydrase$$$65$$$74$$$O	isoforms$$$75$$$83$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	pertains$$$22$$$30$$$O	to$$$31$$$33$$$O	4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide$$$34$$$134$$$I	or$$$135$$$137$$$O	a$$$138$$$139$$$O	pharmaceutically$$$140$$$156$$$O	acceptable$$$157$$$167$$$O	salt$$$168$$$172$$$O	thereof,$$$173$$$181$$$O	or$$$182$$$184$$$O	4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Î/-[5-(4-methyl-1$$$185$$$253$$$I	H-imidazol-1-yl)-3-(trifluoro-$$$254$$$284$$$I	methyl)phenyl]$$$285$$$299$$$I	benzamide$$$300$$$309$$$I	or$$$310$$$312$$$O	a$$$313$$$314$$$O	pharmaceutically$$$315$$$331$$$O	acceptable$$$332$$$342$$$O	salt$$$343$$$347$$$O	thereof,$$$348$$$356$$$O	for$$$357$$$360$$$O	the$$$361$$$364$$$O	treatment$$$365$$$374$$$O	of$$$375$$$377$$$O	ophthalmologic$$$378$$$392$$$O	disorders$$$393$$$402$$$O	mediated$$$403$$$411$$$O	by$$$412$$$414$$$O	alpha-carbonic$$$415$$$429$$$O	anhydrase$$$430$$$439$$$O	isoforms.$$$440$$$449$$$O
EP1902017A1
Antiviral$$$0$$$9$$$O	compounds$$$10$$$19$$$O	and$$$20$$$23$$$O	methods$$$24$$$31$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	compounds$$$39$$$48$$$O	and$$$49$$$52$$$O	compositions$$$53$$$65$$$O	having$$$66$$$72$$$O	antiviral$$$73$$$82$$$O	activity.$$$83$$$92$$$O	The$$$93$$$96$$$O	invention$$$97$$$106$$$O	also$$$107$$$111$$$O	relates$$$112$$$119$$$O	to$$$120$$$122$$$O	methods$$$123$$$130$$$O	for$$$131$$$134$$$O	the$$$135$$$138$$$O	therapeutic$$$139$$$150$$$O	or$$$151$$$153$$$O	prophylactic$$$154$$$166$$$O	treatment$$$167$$$176$$$O	of$$$177$$$179$$$O	viral$$$180$$$185$$$O	infections$$$186$$$196$$$O	in$$$197$$$199$$$O	mammals.$$$200$$$208$$$O
CN102020623B
Butterbur$$$0$$$9$$$O	extract$$$10$$$17$$$O	as$$$18$$$20$$$O	well$$$21$$$25$$$O	as$$$26$$$28$$$O	preparation$$$29$$$40$$$O	method$$$41$$$47$$$O	and$$$48$$$51$$$O	application$$$52$$$63$$$O	thereof$$$64$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicines,$$$48$$$58$$$O	in$$$59$$$61$$$O	particular$$$62$$$72$$$O	to$$$73$$$75$$$O	a$$$76$$$77$$$O	butterbur$$$78$$$87$$$O	extract,$$$88$$$96$$$O	a$$$97$$$98$$$O	butterbur$$$99$$$108$$$O	lactone$$$109$$$116$$$I	VIa$$$117$$$120$$$O	which$$$121$$$126$$$O	is$$$127$$$129$$$O	a$$$130$$$131$$$O	new$$$132$$$135$$$O	sesquiterpene$$$136$$$149$$$I	lactone$$$150$$$157$$$I	compound$$$158$$$166$$$O	separated$$$167$$$176$$$O	from$$$177$$$181$$$O	the$$$182$$$185$$$O	butterbur$$$186$$$195$$$O	extract,$$$196$$$204$$$O	and$$$205$$$208$$$O	the$$$209$$$212$$$O	application$$$213$$$224$$$O	of$$$225$$$227$$$O	the$$$228$$$231$$$O	butterbur$$$232$$$241$$$O	extract$$$242$$$249$$$O	and$$$250$$$253$$$O	the$$$254$$$257$$$O	butterbur$$$258$$$267$$$O	lactone$$$268$$$275$$$I	VIa.$$$276$$$280$$$O	The$$$281$$$284$$$O	chemical$$$285$$$293$$$O	structural$$$294$$$304$$$O	formula$$$305$$$312$$$O	of$$$313$$$315$$$O	the$$$316$$$319$$$O	butterbur$$$320$$$329$$$O	lactone$$$330$$$337$$$I	VIa$$$338$$$341$$$O	is$$$342$$$344$$$O	shown$$$345$$$350$$$O	as$$$351$$$353$$$O	in$$$354$$$356$$$O	the$$$357$$$360$$$O	specification.$$$361$$$375$$$O	The$$$376$$$379$$$O	butterbur$$$380$$$389$$$O	extract$$$390$$$397$$$O	and$$$398$$$401$$$O	the$$$402$$$405$$$O	butterbur$$$406$$$415$$$O	lactone$$$416$$$423$$$I	VIa$$$424$$$427$$$O	in$$$428$$$430$$$O	the$$$431$$$434$$$O	invention$$$435$$$444$$$O	have$$$445$$$449$$$O	the$$$450$$$453$$$O	advantages$$$454$$$464$$$O	of$$$465$$$467$$$O	simple$$$468$$$474$$$O	preparation$$$475$$$486$$$O	method$$$487$$$493$$$O	and$$$494$$$497$$$O	low$$$498$$$501$$$O	cost;$$$502$$$507$$$O	proved$$$508$$$514$$$O	by$$$515$$$517$$$O	animal$$$518$$$524$$$O	experiments$$$525$$$536$$$O	and$$$537$$$540$$$O	in$$$541$$$543$$$O	vitro$$$544$$$549$$$O	experiments,$$$550$$$562$$$O	the$$$563$$$566$$$O	butterbur$$$567$$$576$$$O	extract$$$577$$$584$$$O	or$$$585$$$587$$$O	the$$$588$$$591$$$O	butterbur$$$592$$$601$$$O	lactone$$$602$$$609$$$I	VIa$$$610$$$613$$$O	has$$$614$$$617$$$O	the$$$618$$$621$$$O	activity$$$622$$$630$$$O	of$$$631$$$633$$$O	preventing$$$634$$$644$$$O	and$$$645$$$648$$$O	treating$$$649$$$657$$$O	cerebral$$$658$$$666$$$O	ischemia,$$$667$$$676$$$O	myocardial$$$677$$$687$$$O	ischemia,$$$688$$$697$$$O	allergic$$$698$$$706$$$O	rhinitis,$$$707$$$716$$$O	tumors,$$$717$$$724$$$O	memory$$$725$$$731$$$O	impairment$$$732$$$742$$$O	and$$$743$$$746$$$O	the$$$747$$$750$$$O	like,$$$751$$$756$$$O	and$$$757$$$760$$$O	therefore,$$$761$$$771$$$O	the$$$772$$$775$$$O	butterbur$$$776$$$785$$$O	extract$$$786$$$793$$$O	or$$$794$$$796$$$O	the$$$797$$$800$$$O	butterbur$$$801$$$810$$$O	lactone$$$811$$$818$$$I	VIa$$$819$$$822$$$O	can$$$823$$$826$$$O	be$$$827$$$829$$$O	used$$$830$$$834$$$O	for$$$835$$$838$$$O	preparing$$$839$$$848$$$O	drugs$$$849$$$854$$$O	for$$$855$$$858$$$O	preventing$$$859$$$869$$$O	and$$$870$$$873$$$O	treating$$$874$$$882$$$O	cardiovascular$$$883$$$897$$$O	and$$$898$$$901$$$O	cerebrovascular$$$902$$$917$$$O	diseases,$$$918$$$927$$$O	allergic$$$928$$$936$$$O	rhinitis,$$$937$$$946$$$O	tumors,$$$947$$$954$$$O	senile$$$955$$$961$$$O	dementia,$$$962$$$971$$$O	depression,$$$972$$$983$$$O	diseases$$$984$$$992$$$O	related$$$993$$$1000$$$O	to$$$1001$$$1003$$$O	histamine$$$1004$$$1013$$$I	and/or$$$1014$$$1020$$$O	leukotriene$$$1021$$$1032$$$I	compositions.$$$1033$$$1046$$$O
CN103497192A
Modulators$$$0$$$10$$$O	of$$$11$$$13$$$O	TOLL-like$$$14$$$23$$$O	receptors$$$24$$$33$$$O
Provided$$$0$$$8$$$O	are$$$9$$$12$$$O	modulators$$$13$$$23$$$O	of$$$24$$$26$$$O	TLRs$$$27$$$31$$$O	of$$$32$$$34$$$O	Formula$$$35$$$42$$$O	II,$$$43$$$46$$$O	pharmaceutically$$$47$$$63$$$O	acceptable$$$64$$$74$$$O	salts$$$75$$$80$$$O	thereof,$$$81$$$89$$$O	compositions$$$90$$$102$$$O	containing$$$103$$$113$$$O	such$$$114$$$118$$$O	compounds,$$$119$$$129$$$O	and$$$130$$$133$$$O	therapeutic$$$134$$$145$$$O	methods$$$146$$$153$$$O	that$$$154$$$158$$$O	include$$$159$$$166$$$O	the$$$167$$$170$$$O	administration$$$171$$$185$$$O	of$$$186$$$188$$$O	such$$$189$$$193$$$O	compounds.$$$194$$$204$$$O
US6890911
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	the$$$11$$$14$$$O	treatment$$$15$$$24$$$O	of$$$25$$$27$$$O	inflammation$$$28$$$40$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	mycobacterial$$$35$$$48$$$O	deoxyribonucleic$$$49$$$65$$$O	acid$$$66$$$70$$$O	(B-DNA)$$$71$$$78$$$O	preserved$$$79$$$88$$$O	and$$$89$$$92$$$O	complexed$$$93$$$102$$$O	on$$$103$$$105$$$O	the$$$106$$$109$$$O	mycobacterial$$$110$$$123$$$O	cell$$$124$$$128$$$O	wall$$$129$$$133$$$O	(BCC)$$$134$$$139$$$O	and$$$140$$$143$$$O	a$$$144$$$145$$$O	pharmaceutically$$$146$$$162$$$O	acceptable$$$163$$$173$$$O	carrier,$$$174$$$182$$$O	wherein$$$183$$$190$$$O	the$$$191$$$194$$$O	BCC$$$195$$$198$$$O	is$$$199$$$201$$$O	effective$$$202$$$211$$$O	in$$$212$$$214$$$O	treating$$$215$$$223$$$O	an$$$224$$$226$$$O	inflammation$$$227$$$239$$$O	in$$$240$$$242$$$O	an$$$243$$$245$$$O	animal$$$246$$$252$$$O	having$$$253$$$259$$$O	an$$$260$$$262$$$O	inflammation.$$$263$$$276$$$O	More$$$277$$$281$$$O	particularly,$$$282$$$295$$$O	the$$$296$$$299$$$O	present$$$300$$$307$$$O	invention$$$308$$$317$$$O	relates$$$318$$$325$$$O	to$$$326$$$328$$$O	a$$$329$$$330$$$O	Mycobacterium$$$331$$$344$$$O	phlei$$$345$$$350$$$O	deoxyribonucleic$$$351$$$367$$$O	acid$$$368$$$372$$$O	(M-DNA)$$$373$$$380$$$O	preserved$$$381$$$390$$$O	and$$$391$$$394$$$O	complexed$$$395$$$404$$$O	on$$$405$$$407$$$O	Mycobacterium$$$408$$$421$$$O	phlei$$$422$$$427$$$O	cell$$$428$$$432$$$O	wall$$$433$$$437$$$O	(MCC)$$$438$$$443$$$O	and$$$444$$$447$$$O	a$$$448$$$449$$$O	pharmaceutically$$$450$$$466$$$O	acceptable$$$467$$$477$$$O	carrier,$$$478$$$486$$$O	wherein$$$487$$$494$$$O	the$$$495$$$498$$$O	MCC$$$499$$$502$$$O	is$$$503$$$505$$$O	effective$$$506$$$515$$$O	in$$$516$$$518$$$O	treating$$$519$$$527$$$O	an$$$528$$$530$$$O	inflammation$$$531$$$543$$$O	in$$$544$$$546$$$O	an$$$547$$$549$$$O	animal$$$550$$$556$$$O	having$$$557$$$563$$$O	an$$$564$$$566$$$O	inflammation.$$$567$$$580$$$O
US20080275018
Antibacterial$$$0$$$13$$$O	amide-macrocycles$$$14$$$31$$$O	v$$$32$$$33$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	antibacterial$$$25$$$38$$$O	amide-macrocycles$$$39$$$56$$$O	of$$$57$$$59$$$O	formula$$$60$$$67$$$O	(I),$$$68$$$72$$$O	in$$$73$$$75$$$O	which$$$76$$$81$$$O	R26$$$82$$$85$$$O	represents$$$86$$$96$$$O	hydrogen,$$$97$$$106$$$I	halogen,$$$107$$$115$$$I	amino$$$116$$$121$$$I	or$$$122$$$124$$$O	methyl,$$$125$$$132$$$I	R7$$$133$$$135$$$O	represents$$$136$$$146$$$O	a$$$147$$$148$$$O	group$$$149$$$154$$$O	of$$$155$$$157$$$O	formula$$$158$$$165$$$O	(II),$$$166$$$171$$$O	(III),$$$172$$$178$$$O	(IV)$$$179$$$183$$$O	or$$$184$$$186$$$O	(V),$$$187$$$191$$$O	whereby$$$192$$$199$$$O	R1$$$200$$$202$$$O	represents$$$203$$$213$$$O	hydrogen$$$214$$$222$$$I	or$$$223$$$225$$$O	hydroxy$$$226$$$233$$$I	and$$$234$$$237$$$O	*$$$238$$$239$$$O	is$$$240$$$242$$$O	the$$$243$$$246$$$O	linkage$$$247$$$254$$$O	site$$$255$$$259$$$O	to$$$260$$$262$$$O	the$$$263$$$266$$$O	carbon$$$267$$$273$$$I	atom,$$$274$$$279$$$O	R2$$$280$$$282$$$O	represents$$$283$$$293$$$O	hydrogen$$$294$$$302$$$I	or$$$303$$$305$$$O	methyl$$$306$$$312$$$I	and$$$313$$$316$$$O	methods$$$317$$$324$$$O	for$$$325$$$328$$$O	their$$$329$$$334$$$O	production,$$$335$$$346$$$O	their$$$347$$$352$$$O	use$$$353$$$356$$$O	for$$$357$$$360$$$O	the$$$361$$$364$$$O	treatment$$$365$$$374$$$O	and/or$$$375$$$381$$$O	prophylaxis$$$382$$$393$$$O	of$$$394$$$396$$$O	diseases$$$397$$$405$$$O	as$$$406$$$408$$$O	well$$$409$$$413$$$O	as$$$414$$$416$$$O	their$$$417$$$422$$$O	use$$$423$$$426$$$O	for$$$427$$$430$$$O	the$$$431$$$434$$$O	production$$$435$$$445$$$O	of$$$446$$$448$$$O	medicaments$$$449$$$460$$$O	for$$$461$$$464$$$O	the$$$465$$$468$$$O	treatment$$$469$$$478$$$O	and/or$$$479$$$485$$$O	prophylaxis$$$486$$$497$$$O	of$$$498$$$500$$$O	diseases,$$$501$$$510$$$O	in$$$511$$$513$$$O	particular$$$514$$$524$$$O	of$$$525$$$527$$$O	bacterial$$$528$$$537$$$O	infections.$$$538$$$549$$$O
US20070275887
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	Inhibiting$$$10$$$20$$$O	Secretase$$$21$$$30$$$O	Activity$$$31$$$39$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	method$$$33$$$39$$$O	for$$$40$$$43$$$O	inhibiting$$$44$$$54$$$O	secretase$$$55$$$64$$$O	activity.$$$65$$$74$$$O	A$$$75$$$76$$$O	method$$$77$$$83$$$O	for$$$84$$$87$$$O	promoting$$$88$$$97$$$O	the$$$98$$$101$$$O	sensitivity$$$102$$$113$$$O	of$$$114$$$116$$$O	a$$$117$$$118$$$O	secretase$$$119$$$128$$$O	inhibitor,$$$129$$$139$$$O	a$$$140$$$141$$$O	method$$$142$$$148$$$O	for$$$149$$$152$$$O	binding$$$153$$$160$$$O	synoviolin$$$161$$$171$$$O	to$$$172$$$174$$$O	Herp$$$175$$$179$$$O	(homocysteine-inducible$$$180$$$203$$$I	endoplasmic$$$204$$$215$$$O	reticulum$$$216$$$225$$$O	stress-inducible$$$226$$$242$$$O	ubiquitin-like$$$243$$$257$$$O	domain$$$258$$$264$$$O	member$$$265$$$271$$$O	1),$$$272$$$275$$$O	or$$$276$$$278$$$O	the$$$279$$$282$$$O	like$$$283$$$287$$$O	is$$$288$$$290$$$O	employed$$$291$$$299$$$O	to$$$300$$$302$$$O	inhibit$$$303$$$310$$$O	secretase$$$311$$$320$$$O	activity.$$$321$$$330$$$O
US20120195870
Preparations$$$0$$$12$$$O	with$$$13$$$17$$$O	wood$$$18$$$22$$$O	extracts$$$23$$$31$$$O	of$$$32$$$34$$$O	locust$$$35$$$41$$$O	trees$$$42$$$47$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	primarily$$$30$$$39$$$O	to$$$40$$$42$$$O	the$$$43$$$46$$$O	use$$$47$$$50$$$O	of$$$51$$$53$$$O	locust$$$54$$$60$$$O	tree$$$61$$$65$$$O	(Gleditsia)$$$66$$$77$$$O	wood$$$78$$$82$$$O	or$$$83$$$85$$$O	heartwood$$$86$$$95$$$O	extracts$$$96$$$104$$$O	as$$$105$$$107$$$O	anti-cellulite$$$108$$$122$$$O	active$$$123$$$129$$$O	substances.$$$130$$$141$$$O	The$$$142$$$145$$$O	present$$$146$$$153$$$O	invention$$$154$$$163$$$O	further$$$164$$$171$$$O	relates$$$172$$$179$$$O	to$$$180$$$182$$$O	certain$$$183$$$190$$$O	locust-tree$$$191$$$202$$$O	wood$$$203$$$207$$$O	extracts$$$208$$$216$$$O	and$$$217$$$220$$$O	mixtures$$$221$$$229$$$O	containing$$$230$$$240$$$O	locust-tree$$$241$$$252$$$O	wood$$$253$$$257$$$O	extracts$$$258$$$266$$$O	and$$$267$$$270$$$O	corresponding$$$271$$$284$$$O	cosmetic,$$$285$$$294$$$O	dermatological$$$295$$$309$$$O	or$$$310$$$312$$$O	pharmaceutical$$$313$$$327$$$O	preparations,$$$328$$$341$$$O	which$$$342$$$347$$$O	are$$$348$$$351$$$O	suitable$$$352$$$360$$$O	in$$$361$$$363$$$O	particular$$$364$$$374$$$O	for$$$375$$$378$$$O	the$$$379$$$382$$$O	prevention$$$383$$$393$$$O	and$$$394$$$397$$$O	treatment$$$398$$$407$$$O	of$$$408$$$410$$$O	cellulite$$$411$$$420$$$O	in$$$421$$$423$$$O	humans.$$$424$$$431$$$O
WO2014085489A1
Inhibitor$$$0$$$9$$$O	of$$$10$$$12$$$O	apoptosis$$$13$$$22$$$O	protein$$$23$$$30$$$O	(iap)$$$31$$$36$$$O	antagonists$$$37$$$48$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	compounds$$$20$$$29$$$O	that$$$30$$$34$$$O	modulate$$$35$$$43$$$O	the$$$44$$$47$$$O	activity$$$48$$$56$$$O	of$$$57$$$59$$$O	inhibitor$$$60$$$69$$$O	of$$$70$$$72$$$O	apoptosis$$$73$$$82$$$O	proteins$$$83$$$91$$$O	(IAPs),$$$92$$$99$$$O	compositions$$$100$$$112$$$O	comprising$$$113$$$123$$$O	the$$$124$$$127$$$O	compounds,$$$128$$$138$$$O	and$$$139$$$142$$$O	methods$$$143$$$150$$$O	of$$$151$$$153$$$O	using$$$154$$$159$$$O	the$$$160$$$163$$$O	compounds$$$164$$$173$$$O	and$$$174$$$177$$$O	compositions$$$178$$$190$$$O	comprising$$$191$$$201$$$O	the$$$202$$$205$$$O	compounds.$$$206$$$216$$$O
US20130059007
Modified$$$0$$$8$$$O	Release$$$9$$$16$$$O	Formulations$$$17$$$29$$$O	Containing$$$30$$$40$$$O	Drug-Ion$$$41$$$49$$$O	Exchange$$$50$$$58$$$O	Resin$$$59$$$64$$$O	Complexes$$$65$$$74$$$O
A$$$0$$$1$$$O	coated$$$2$$$8$$$O	drug-ion$$$9$$$17$$$O	exchange$$$18$$$26$$$O	resin$$$27$$$32$$$O	complex$$$33$$$40$$$O	comprising$$$41$$$51$$$O	a$$$52$$$53$$$O	core$$$54$$$58$$$O	composed$$$59$$$67$$$O	of$$$68$$$70$$$O	a$$$71$$$72$$$O	drug$$$73$$$77$$$O	complexed$$$78$$$87$$$O	with$$$88$$$92$$$O	a$$$93$$$94$$$O	pharmaceutically$$$95$$$111$$$O	acceptable$$$112$$$122$$$O	ion-exchange$$$123$$$135$$$O	resin$$$136$$$141$$$O	is$$$142$$$144$$$O	provided.$$$145$$$154$$$O	The$$$155$$$158$$$O	drug-ion$$$159$$$167$$$O	exchange$$$168$$$176$$$O	resin$$$177$$$182$$$O	complex$$$183$$$190$$$O	is$$$191$$$193$$$O	in$$$194$$$196$$$O	admixture$$$197$$$206$$$O	with$$$207$$$211$$$O	a$$$212$$$213$$$O	release$$$214$$$221$$$O	retardant.$$$222$$$232$$$O	The$$$233$$$236$$$O	coating$$$237$$$244$$$O	is$$$245$$$247$$$O	a$$$248$$$249$$$O	polyvinyl$$$250$$$259$$$I	acetate$$$260$$$267$$$I	polymer$$$268$$$275$$$O	and$$$276$$$279$$$O	a$$$280$$$281$$$O	plasticizer.$$$282$$$294$$$O	Methods$$$295$$$302$$$O	of$$$303$$$305$$$O	making$$$306$$$312$$$O	and$$$313$$$316$$$O	products$$$317$$$325$$$O	containing$$$326$$$336$$$O	this$$$337$$$341$$$O	coated$$$342$$$348$$$O	complex$$$349$$$356$$$O	are$$$357$$$360$$$O	described.$$$361$$$371$$$O
EP1864658A1
Agent$$$0$$$5$$$O	for$$$6$$$9$$$O	alleviating$$$10$$$21$$$O	vascular$$$22$$$30$$$O	insufficiency$$$31$$$44$$$O
[Object]$$$0$$$8$$$O	In$$$9$$$11$$$O	recent$$$12$$$18$$$O	years,$$$19$$$25$$$O	life$$$26$$$30$$$O	style-related$$$31$$$44$$$O	diseases,$$$45$$$54$$$O	particularly$$$55$$$67$$$O	circulatory$$$68$$$79$$$O	system$$$80$$$86$$$O	diseases$$$87$$$95$$$O	caused$$$96$$$102$$$O	by$$$103$$$105$$$O	the$$$106$$$109$$$O	tendency$$$110$$$118$$$O	toward$$$119$$$125$$$O	high$$$126$$$130$$$O	caloric$$$131$$$138$$$O	diet,$$$139$$$144$$$O	the$$$145$$$148$$$O	change$$$149$$$155$$$O	in$$$156$$$158$$$O	life$$$159$$$163$$$O	style,$$$164$$$170$$$O	lack$$$171$$$175$$$O	of$$$176$$$178$$$O	exercise,$$$179$$$188$$$O	stress$$$189$$$195$$$O	and$$$196$$$199$$$O	so$$$200$$$202$$$O	on$$$203$$$205$$$O	increased$$$206$$$215$$$O	and$$$216$$$219$$$O	have$$$220$$$224$$$O	became$$$225$$$231$$$O	a$$$232$$$233$$$O	serious$$$234$$$241$$$O	social$$$242$$$248$$$O	problem.$$$249$$$257$$$O	These$$$258$$$263$$$O	diseases$$$264$$$272$$$O	are$$$273$$$276$$$O	caused$$$277$$$283$$$O	mainly$$$284$$$290$$$O	by$$$291$$$293$$$O	injures$$$294$$$301$$$O	in$$$302$$$304$$$O	blood$$$305$$$310$$$O	vessels.$$$311$$$319$$$O	To$$$320$$$322$$$O	prevent$$$323$$$330$$$O	injures$$$331$$$338$$$O	in$$$339$$$341$$$O	blood$$$342$$$347$$$O	vessels,$$$348$$$356$$$O	there$$$357$$$362$$$O	has$$$363$$$366$$$O	been$$$367$$$371$$$O	required$$$372$$$380$$$O	a$$$381$$$382$$$O	vascular$$$383$$$391$$$O	endothelial$$$392$$$403$$$O	cell-protecting$$$404$$$419$$$O	agent$$$420$$$425$$$O	and$$$426$$$429$$$O	a$$$430$$$431$$$O	food$$$432$$$436$$$O	having$$$437$$$443$$$O	an$$$444$$$446$$$O	effect$$$447$$$453$$$O	of$$$454$$$456$$$O	protecting$$$457$$$467$$$O	vascular$$$468$$$476$$$O	endothelial$$$477$$$488$$$O	cells.$$$489$$$495$$$O	[Means$$$500$$$506$$$O	to$$$507$$$509$$$O	solve]$$$510$$$516$$$O	It$$$517$$$519$$$O	is$$$520$$$522$$$O	possible$$$523$$$531$$$O	to$$$532$$$534$$$O	provide$$$535$$$542$$$O	an$$$543$$$545$$$O	agent$$$546$$$551$$$O	for$$$552$$$555$$$O	alleviating,$$$556$$$568$$$O	treating$$$569$$$577$$$O	and$$$578$$$581$$$O	preventing$$$582$$$592$$$O	vascular$$$593$$$601$$$O	failure$$$602$$$609$$$O	and$$$610$$$613$$$O	a$$$614$$$615$$$O	vascular$$$616$$$624$$$O	endothelial$$$625$$$636$$$O	cell-protecting$$$637$$$652$$$O	agent$$$653$$$658$$$O	characterized$$$659$$$672$$$O	by$$$673$$$675$$$O	containing,$$$676$$$687$$$O	as$$$688$$$690$$$O	an$$$691$$$693$$$O	effective$$$694$$$703$$$O	ingredient,$$$704$$$715$$$O	at$$$716$$$718$$$O	least$$$719$$$724$$$O	one$$$725$$$728$$$O	active$$$729$$$735$$$O	oxygen$$$736$$$742$$$I	scavenger$$$743$$$752$$$O	such$$$753$$$757$$$O	as$$$758$$$760$$$O	astaxanthin$$$761$$$772$$$I	and$$$773$$$776$$$O	tocotrienols;$$$777$$$790$$$I	and$$$791$$$794$$$O	a$$$795$$$796$$$O	food,$$$797$$$802$$$O	a$$$803$$$804$$$O	drink$$$805$$$810$$$O	and$$$811$$$814$$$O	an$$$815$$$817$$$O	animal$$$818$$$824$$$O	feed$$$825$$$829$$$O	each$$$830$$$834$$$O	having$$$835$$$841$$$O	an$$$842$$$844$$$O	effect$$$845$$$851$$$O	of$$$852$$$854$$$O	alleviating,$$$855$$$867$$$O	treating$$$868$$$876$$$O	and$$$877$$$880$$$O	preventing$$$881$$$891$$$O	vascular$$$892$$$900$$$O	failure$$$901$$$908$$$O	and$$$909$$$912$$$O	an$$$913$$$915$$$O	effect$$$916$$$922$$$O	of$$$923$$$925$$$O	protecting$$$926$$$936$$$O	vascular$$$937$$$945$$$O	endothelial$$$946$$$957$$$O	cells$$$958$$$963$$$O	characterized$$$964$$$977$$$O	by$$$978$$$980$$$O	containing,$$$981$$$992$$$O	as$$$993$$$995$$$O	the$$$996$$$999$$$O	effective$$$1000$$$1009$$$O	ingredient,$$$1010$$$1021$$$O	at$$$1022$$$1024$$$O	least$$$1025$$$1030$$$O	one$$$1031$$$1034$$$O	active$$$1035$$$1041$$$O	oxygen$$$1042$$$1048$$$I	scavenger$$$1049$$$1058$$$O	such$$$1059$$$1063$$$O	as$$$1064$$$1066$$$O	astaxanthin$$$1067$$$1078$$$O	and$$$1079$$$1082$$$O	tocotrienols.$$$1083$$$1096$$$O
WO2009004873A1
Prostaglandin$$$0$$$13$$$I	derivative-containing$$$14$$$35$$$O	aqueous$$$36$$$43$$$O	liquid$$$44$$$50$$$O	agent$$$51$$$56$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	an$$$13$$$15$$$O	aqueous$$$16$$$23$$$O	liquid$$$24$$$30$$$O	agent$$$31$$$36$$$O	characterized$$$37$$$50$$$O	by$$$51$$$53$$$O	containing$$$54$$$64$$$O	(a)$$$65$$$68$$$O	a$$$69$$$70$$$O	prostaglandin$$$71$$$84$$$I	derivative$$$85$$$95$$$O	represented$$$96$$$107$$$O	by$$$108$$$110$$$O	the$$$111$$$114$$$O	formula$$$115$$$122$$$O	(I)$$$123$$$126$$$O	below,$$$127$$$133$$$O	a$$$134$$$135$$$O	pharmaceutically$$$136$$$152$$$O	acceptable$$$153$$$163$$$O	salt$$$164$$$168$$$O	thereof$$$169$$$176$$$O	or$$$177$$$179$$$O	a$$$180$$$181$$$O	hydrate$$$182$$$189$$$I	of$$$190$$$192$$$O	any$$$193$$$196$$$O	of$$$197$$$199$$$O	them,$$$200$$$205$$$O	and$$$206$$$209$$$O	(b)$$$210$$$213$$$O	at$$$214$$$216$$$O	least$$$217$$$222$$$O	one$$$223$$$226$$$O	polyhydric$$$227$$$237$$$I	alcohol$$$238$$$245$$$I	selected$$$246$$$254$$$O	from$$$255$$$259$$$O	glycerin,$$$260$$$269$$$I	propylene$$$270$$$279$$$I	glycol,$$$280$$$287$$$I	dipropylene$$$288$$$299$$$I	glycol$$$300$$$306$$$I	and$$$307$$$310$$$O	1,3-butylene$$$311$$$323$$$I	glycol.$$$324$$$331$$$I
WO2012018069A1
Preparation$$$0$$$11$$$O	for$$$12$$$15$$$O	treatment$$$16$$$25$$$O	of$$$26$$$28$$$O	spinal$$$29$$$35$$$O	cord$$$36$$$40$$$O	injury$$$41$$$47$$$O
A$$$0$$$1$$$O	sustained$$$2$$$11$$$O	release$$$12$$$19$$$O	preparation$$$20$$$31$$$O	containing$$$32$$$42$$$O	a$$$43$$$44$$$O	semaphorin$$$45$$$55$$$O	3A$$$56$$$58$$$O	inhibitor$$$59$$$68$$$O	as$$$69$$$71$$$O	an$$$72$$$74$$$O	active$$$75$$$81$$$O	ingredient,$$$82$$$93$$$O	which$$$94$$$99$$$O	is$$$100$$$102$$$O	a$$$103$$$104$$$O	solid$$$105$$$110$$$O	preparation$$$111$$$122$$$O	that$$$123$$$127$$$O	comprises$$$128$$$137$$$O	the$$$138$$$141$$$O	semaphorin$$$142$$$152$$$O	3A$$$153$$$155$$$O	inhibitor$$$156$$$165$$$O	and$$$166$$$169$$$O	a$$$170$$$171$$$O	carrier$$$172$$$179$$$O	comprising$$$180$$$190$$$O	a$$$191$$$192$$$O	silicone$$$193$$$201$$$I	containing$$$202$$$212$$$O	a$$$213$$$214$$$O	pharmaceutically$$$215$$$231$$$O	acceptable$$$232$$$242$$$O	poorly$$$243$$$249$$$O	water-soluble$$$250$$$263$$$O	solid$$$264$$$269$$$O	substance.$$$270$$$280$$$O
CN103230407A
Compound$$$0$$$8$$$O	glycyrrhizin$$$9$$$21$$$I	capsule$$$22$$$29$$$O	composition$$$30$$$41$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	compound$$$26$$$34$$$O	glycyrrhizin$$$35$$$47$$$I	capsule$$$48$$$55$$$O	composition.$$$56$$$68$$$O	The$$$69$$$72$$$O	compound$$$73$$$81$$$O	glycyrrhizin$$$82$$$94$$$I	capsule$$$95$$$102$$$O	composition$$$103$$$114$$$O	is$$$115$$$117$$$O	characterized$$$118$$$131$$$O	in$$$132$$$134$$$O	that$$$135$$$139$$$O	the$$$140$$$143$$$O	formula$$$144$$$151$$$O	of$$$152$$$154$$$O	each$$$155$$$159$$$O	1000$$$160$$$164$$$O	particles$$$165$$$174$$$O	of$$$175$$$177$$$O	capsules$$$178$$$186$$$O	comprises$$$187$$$196$$$O	the$$$197$$$200$$$O	components$$$201$$$211$$$O	shown$$$212$$$217$$$O	in$$$218$$$220$$$O	the$$$221$$$224$$$O	specification.$$$225$$$239$$$O
WO2007096251A1
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	cpt$$$14$$$17$$$O	in$$$18$$$20$$$O	the$$$21$$$24$$$O	central$$$25$$$32$$$O	nervous$$$33$$$40$$$O	system$$$41$$$47$$$O	as$$$48$$$50$$$O	antidiabetic$$$51$$$63$$$O	and/or$$$64$$$70$$$O	anti-obesity$$$71$$$83$$$O	drugs$$$84$$$89$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	new$$$27$$$30$$$O	class$$$31$$$36$$$O	of$$$37$$$39$$$O	compounds$$$40$$$49$$$O	with$$$50$$$54$$$O	inhibitory$$$55$$$65$$$O	action$$$66$$$72$$$O	on$$$73$$$75$$$O	carnitine$$$76$$$85$$$O	palmitoyl$$$86$$$95$$$O	transferase$$$96$$$107$$$O	(CPT)$$$108$$$113$$$O	in$$$114$$$116$$$O	the$$$117$$$120$$$O	central$$$121$$$128$$$O	nervous$$$129$$$136$$$O	system$$$137$$$143$$$O	(SNC),$$$144$$$150$$$O	derived$$$151$$$158$$$O	from$$$159$$$163$$$O	trimetazidine$$$164$$$177$$$I	and$$$178$$$181$$$O	perhexiline,$$$182$$$194$$$I	preferentially$$$195$$$209$$$O	selective$$$210$$$219$$$O	for$$$220$$$223$$$O	the$$$224$$$227$$$O	hepatic$$$228$$$235$$$O	form$$$236$$$240$$$O	of$$$241$$$243$$$O	CPT1$$$244$$$248$$$O	(CPT1L),$$$249$$$257$$$O	pharmaceutical$$$258$$$272$$$O	compounds$$$273$$$282$$$O	which$$$283$$$288$$$O	contain$$$289$$$296$$$O	at$$$297$$$299$$$O	least$$$300$$$305$$$O	one$$$306$$$309$$$O	new$$$310$$$313$$$O	compound$$$314$$$322$$$O	according$$$323$$$332$$$O	to$$$333$$$335$$$O	the$$$336$$$339$$$O	invention,$$$340$$$350$$$O	and$$$351$$$354$$$O	their$$$355$$$360$$$O	therapeutic$$$361$$$372$$$O	use$$$373$$$376$$$O	in$$$377$$$379$$$O	the$$$380$$$383$$$O	treatment$$$384$$$393$$$O	and/or$$$394$$$400$$$O	in$$$401$$$403$$$O	the$$$404$$$407$$$O	prevention$$$408$$$418$$$O	of$$$419$$$421$$$O	obesity,$$$422$$$430$$$O	hyperglycaemia,$$$431$$$446$$$O	diabetes$$$447$$$455$$$O	and$$$456$$$459$$$O	disorders$$$460$$$469$$$O	associated$$$470$$$480$$$O	with$$$481$$$485$$$O	them,$$$486$$$491$$$O	such$$$492$$$496$$$O	as,$$$497$$$500$$$O	for$$$501$$$504$$$O	example,$$$505$$$513$$$O	diabetic$$$514$$$522$$$O	retinopathy,$$$523$$$535$$$O	diabetic$$$536$$$544$$$O	neuropathy$$$545$$$555$$$O	and$$$556$$$559$$$O	cardiovascular$$$560$$$574$$$O	disorders.$$$575$$$585$$$O	The$$$586$$$589$$$O	compounds$$$590$$$599$$$O	of$$$600$$$602$$$O	the$$$603$$$606$$$O	present$$$607$$$614$$$O	invention$$$615$$$624$$$O	are$$$625$$$628$$$O	also$$$629$$$633$$$O	used$$$634$$$638$$$O	in$$$639$$$641$$$O	the$$$642$$$645$$$O	prevention$$$646$$$656$$$O	and/or$$$657$$$663$$$O	treatment$$$664$$$673$$$O	of$$$674$$$676$$$O	heart$$$677$$$682$$$O	disorders$$$683$$$692$$$O	such$$$693$$$697$$$O	as$$$698$$$700$$$O	CHF$$$701$$$704$$$O	(congestive$$$705$$$716$$$O	heart$$$717$$$722$$$O	failure).$$$723$$$732$$$O
EP2571541A2
Gaseous$$$0$$$7$$$O	nitric$$$8$$$14$$$I	oxide-sequestering$$$15$$$33$$$I	products$$$34$$$42$$$O	and$$$43$$$46$$$O	processes$$$47$$$56$$$O	of$$$57$$$59$$$O	preparing$$$60$$$69$$$O	same$$$70$$$74$$$O
A$$$0$$$1$$$O	process$$$2$$$9$$$O	of$$$10$$$12$$$O	preparing$$$13$$$22$$$O	articles$$$23$$$31$$$O	having$$$32$$$38$$$O	gaseous$$$39$$$46$$$O	NO$$$47$$$49$$$I	sequestered$$$50$$$61$$$O	therein$$$62$$$69$$$O	is$$$70$$$72$$$O	disclosed,$$$73$$$83$$$O	as$$$84$$$86$$$O	well$$$87$$$91$$$O	as$$$92$$$94$$$O	articles$$$95$$$103$$$O	prepared$$$104$$$112$$$O	thereby.$$$113$$$121$$$O	Also$$$122$$$126$$$O	disclosed$$$127$$$136$$$O	are$$$137$$$140$$$O	articles$$$141$$$149$$$O	having$$$150$$$156$$$O	gaseous$$$157$$$164$$$O	NO$$$165$$$167$$$I	sequestered$$$168$$$179$$$O	therewithin$$$180$$$191$$$O	and$$$192$$$195$$$O	having$$$196$$$202$$$O	reduced$$$203$$$210$$$O	amount$$$211$$$217$$$O	of$$$218$$$220$$$O	oxygen-containing$$$221$$$238$$$I	and/or$$$239$$$245$$$O	nitrogen-containing$$$246$$$265$$$I	reactive$$$266$$$274$$$O	species.$$$275$$$283$$$O	Also$$$284$$$288$$$O	disclosed$$$289$$$298$$$O	are$$$299$$$302$$$O	processes$$$303$$$312$$$O	of$$$313$$$315$$$O	preparing$$$316$$$325$$$O	packaged$$$326$$$334$$$O	articles$$$335$$$343$$$O	having$$$344$$$350$$$O	a$$$351$$$352$$$O	non-gas$$$353$$$360$$$O	permeable$$$361$$$370$$$O	package$$$371$$$378$$$O	that$$$379$$$383$$$O	comprises$$$384$$$393$$$O	gaseous$$$394$$$401$$$O	NO$$$402$$$404$$$I	therein$$$405$$$412$$$O	and$$$413$$$416$$$O	packaged$$$417$$$425$$$O	articles$$$426$$$434$$$O	made$$$435$$$439$$$O	therefrom.$$$440$$$450$$$O	Also$$$451$$$455$$$O	disclosed$$$456$$$465$$$O	are$$$466$$$469$$$O	charging$$$470$$$478$$$O	devices$$$479$$$486$$$O	which$$$487$$$492$$$O	can$$$493$$$496$$$O	be$$$497$$$499$$$O	utilized$$$500$$$508$$$O	in$$$509$$$511$$$O	the$$$512$$$515$$$O	above-described$$$516$$$531$$$O	processes.$$$532$$$542$$$O	The$$$543$$$546$$$O	articles$$$547$$$555$$$O	prepared$$$556$$$564$$$O	by$$$565$$$567$$$O	the$$$568$$$571$$$O	above-described$$$572$$$587$$$O	processes$$$588$$$597$$$O	are$$$598$$$601$$$O	preferably$$$602$$$612$$$O	medical$$$613$$$620$$$O	devices$$$621$$$628$$$O	such$$$629$$$633$$$O	as$$$634$$$636$$$O	indwelling$$$637$$$647$$$O	catheters,$$$648$$$658$$$O	intubation$$$659$$$669$$$O	devices$$$670$$$677$$$O	and$$$678$$$681$$$O	tampons.$$$682$$$690$$$O	Tampons$$$691$$$698$$$O	having$$$699$$$705$$$O	sequestered$$$706$$$717$$$O	therein$$$718$$$725$$$O	gaseous$$$726$$$733$$$O	NO,$$$734$$$737$$$I	uses$$$738$$$742$$$O	thereof$$$743$$$750$$$O	and$$$751$$$754$$$O	processes$$$755$$$764$$$O	of$$$765$$$767$$$O	preparing$$$768$$$777$$$O	same$$$778$$$782$$$O	are$$$783$$$786$$$O	also$$$787$$$791$$$O	disclosed.$$$792$$$802$$$O
US20110071115
Pharmaceutically$$$0$$$16$$$O	useful$$$17$$$23$$$O	heterocycle-substituted$$$24$$$47$$$I	lactams$$$48$$$55$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds$$$23$$$32$$$O	that$$$33$$$37$$$O	inhibit$$$38$$$45$$$O	CK2$$$46$$$49$$$O	and/or$$$50$$$56$$$O	Pim$$$57$$$60$$$O	kinases$$$61$$$68$$$O	and$$$69$$$72$$$O	compositions$$$73$$$85$$$O	containing$$$86$$$96$$$O	such$$$97$$$101$$$O	compounds.$$$102$$$112$$$O	These$$$113$$$118$$$O	compounds$$$119$$$128$$$O	and$$$129$$$132$$$O	compositions$$$133$$$145$$$O	are$$$146$$$149$$$O	useful$$$150$$$156$$$O	for$$$157$$$160$$$O	treating$$$161$$$169$$$O	proliferative$$$170$$$183$$$O	disorders$$$184$$$193$$$O	such$$$194$$$198$$$O	as$$$199$$$201$$$O	cancer,$$$202$$$209$$$O	as$$$210$$$212$$$O	well$$$213$$$217$$$O	as$$$218$$$220$$$O	other$$$221$$$226$$$O	kinase-associated$$$227$$$244$$$O	conditions$$$245$$$255$$$O	including$$$256$$$265$$$O	inflammation,$$$266$$$279$$$O	pain,$$$280$$$285$$$O	infections,$$$286$$$297$$$O	and$$$298$$$301$$$O	certain$$$302$$$309$$$O	immunological$$$310$$$323$$$O	disorders.$$$324$$$334$$$O
CN101385833A
Eucalyptus$$$0$$$10$$$O	leaf$$$11$$$15$$$O	cough$$$16$$$21$$$O	syrup$$$22$$$27$$$O	and$$$28$$$31$$$O	preparation$$$32$$$43$$$O	method$$$44$$$50$$$O	thereof$$$51$$$58$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	folium$$$25$$$31$$$O	eucalypti$$$32$$$41$$$O	linctus$$$42$$$49$$$O	and$$$50$$$53$$$O	a$$$54$$$55$$$O	preparation$$$56$$$67$$$O	method$$$68$$$74$$$O	thereof.$$$75$$$83$$$O	According$$$84$$$93$$$O	to$$$94$$$96$$$O	parts$$$97$$$102$$$O	by$$$103$$$105$$$O	weight,$$$106$$$113$$$O	the$$$114$$$117$$$O	linctus$$$118$$$125$$$O	mainly$$$126$$$132$$$O	consists$$$133$$$141$$$O	of$$$142$$$144$$$O	50-3500$$$145$$$152$$$O	parts$$$153$$$158$$$O	of$$$159$$$161$$$O	folium$$$162$$$168$$$O	eucalypti,$$$169$$$179$$$O	1000-4500$$$180$$$189$$$O	parts$$$190$$$195$$$O	of$$$196$$$198$$$O	baikal$$$199$$$205$$$O	skullcap$$$206$$$214$$$O	root,$$$215$$$220$$$O	300-800$$$221$$$228$$$O	parts$$$229$$$234$$$O	of$$$235$$$237$$$O	radix$$$238$$$243$$$O	stemonae$$$244$$$252$$$O	and$$$253$$$256$$$O	2-7$$$257$$$260$$$O	parts$$$261$$$266$$$O	of$$$267$$$269$$$O	ephedrine$$$270$$$279$$$I	hydrochloride,$$$280$$$294$$$I	wherein,$$$295$$$303$$$O	the$$$304$$$307$$$O	adopted$$$308$$$315$$$O	folium$$$316$$$322$$$O	eucalypti$$$323$$$332$$$O	has$$$333$$$336$$$O	antibacterial$$$337$$$350$$$O	and$$$351$$$354$$$O	antivirus$$$355$$$364$$$O	functions,$$$365$$$375$$$O	the$$$376$$$379$$$O	baikal$$$380$$$386$$$O	skullcap$$$387$$$395$$$O	root$$$396$$$400$$$O	has$$$401$$$404$$$O	such$$$405$$$409$$$O	broad$$$410$$$415$$$O	pharmacological$$$416$$$431$$$O	effects$$$432$$$439$$$O	as$$$440$$$442$$$O	oxidation$$$443$$$452$$$O	resistance,$$$453$$$464$$$O	inflammation$$$465$$$477$$$O	resistance,$$$478$$$489$$$O	antianaphylaxis,$$$490$$$506$$$O	antibiosis$$$507$$$517$$$O	(broad-spectrum$$$518$$$533$$$O	and$$$534$$$537$$$O	strong$$$538$$$544$$$O	antibacterial$$$545$$$558$$$O	function$$$559$$$567$$$O	on$$$568$$$570$$$O	pneumococci,$$$571$$$583$$$O	haemolytic$$$584$$$594$$$O	streptococcus$$$595$$$608$$$O	and$$$609$$$612$$$O	the$$$613$$$616$$$O	like),$$$617$$$623$$$O	as$$$624$$$626$$$O	well$$$627$$$631$$$O	as$$$632$$$634$$$O	antivirus$$$635$$$644$$$O	and$$$645$$$648$$$O	anti-tumor$$$649$$$659$$$O	properties,$$$660$$$671$$$O	the$$$672$$$675$$$O	radix$$$676$$$681$$$O	stemonae$$$682$$$690$$$O	has$$$691$$$694$$$O	the$$$695$$$698$$$O	actions$$$699$$$706$$$O	of$$$707$$$709$$$O	fungus$$$710$$$716$$$O	resistance,$$$717$$$728$$$O	relieving$$$729$$$738$$$O	cough$$$739$$$744$$$O	and$$$745$$$748$$$O	asthma,$$$749$$$756$$$O	eliminating$$$757$$$768$$$O	phlegm$$$769$$$775$$$O	and$$$776$$$779$$$O	reducing$$$780$$$788$$$O	asthma$$$789$$$795$$$O	and$$$796$$$799$$$O	the$$$800$$$803$$$O	ephedrine$$$804$$$813$$$I	hydrochloride$$$814$$$827$$$I	has$$$828$$$831$$$O	the$$$832$$$835$$$O	functions$$$836$$$845$$$O	of$$$846$$$848$$$O	contracting$$$849$$$860$$$O	vein,$$$861$$$866$$$O	relieving$$$867$$$876$$$O	asthma,$$$877$$$884$$$O	exciting$$$885$$$893$$$O	nerve$$$894$$$899$$$O	centre,$$$900$$$907$$$O	allaying$$$908$$$916$$$O	a$$$917$$$918$$$O	fever,$$$919$$$925$$$O	resisting$$$926$$$935$$$O	virus,$$$936$$$942$$$O	etc.$$$943$$$947$$$O	Compared$$$948$$$956$$$O	with$$$957$$$961$$$O	the$$$962$$$965$$$O	prior$$$966$$$971$$$O	art,$$$972$$$976$$$O	the$$$977$$$980$$$O	folium$$$981$$$987$$$O	eucalypti$$$988$$$997$$$O	linctus$$$998$$$1005$$$O	has$$$1006$$$1009$$$O	the$$$1010$$$1013$$$O	advantages$$$1014$$$1024$$$O	of$$$1025$$$1027$$$O	low$$$1028$$$1031$$$O	treatment$$$1032$$$1041$$$O	cost,$$$1042$$$1047$$$O	good$$$1048$$$1052$$$O	effect$$$1053$$$1059$$$O	and$$$1060$$$1063$$$O	few$$$1064$$$1067$$$O	side$$$1068$$$1072$$$O	effects,$$$1073$$$1081$$$O	etc.$$$1082$$$1086$$$O
CN101143146A
Cefoperazone$$$0$$$12$$$I	sodium$$$13$$$19$$$I	and$$$20$$$23$$$O	sulbactam$$$24$$$33$$$I	sodium$$$34$$$40$$$I	composition$$$41$$$52$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	combination$$$25$$$36$$$O	of$$$37$$$39$$$O	cefoperazone$$$40$$$52$$$I	sodium$$$53$$$59$$$I	and$$$60$$$63$$$O	sulbactam$$$64$$$73$$$I	sodium.$$$74$$$81$$$I	The$$$82$$$85$$$O	combination$$$86$$$97$$$O	consists$$$98$$$106$$$O	of$$$107$$$109$$$O	the$$$110$$$113$$$O	cefoperazone$$$114$$$126$$$I	sodium$$$127$$$133$$$I	and$$$134$$$137$$$O	the$$$138$$$141$$$O	sulbactam$$$142$$$151$$$I	sodium,$$$152$$$159$$$I	and$$$160$$$163$$$O	the$$$164$$$167$$$O	weight$$$168$$$174$$$O	ratio$$$175$$$180$$$O	of$$$181$$$183$$$O	which$$$184$$$189$$$O	is$$$190$$$192$$$O	3$$$193$$$194$$$O	to$$$195$$$197$$$O	1.$$$198$$$200$$$O	The$$$201$$$204$$$O	combination$$$205$$$216$$$O	of$$$217$$$219$$$O	cefoperazone$$$220$$$232$$$I	sodium$$$233$$$239$$$I	and$$$240$$$243$$$O	sulbactam$$$244$$$253$$$I	sodium$$$254$$$260$$$I	of$$$261$$$263$$$O	the$$$264$$$267$$$O	invention$$$268$$$277$$$O	has$$$278$$$281$$$O	the$$$282$$$285$$$O	comparative$$$286$$$297$$$O	curative$$$298$$$306$$$O	effect$$$307$$$313$$$O	at$$$314$$$316$$$O	the$$$317$$$320$$$O	aspect$$$321$$$327$$$O	of$$$328$$$330$$$O	antibacterial$$$331$$$344$$$O	effect$$$345$$$351$$$O	with$$$352$$$356$$$O	a$$$357$$$358$$$O	compound$$$359$$$367$$$O	preparation$$$368$$$379$$$O	of$$$380$$$382$$$O	1$$$383$$$384$$$O	to$$$385$$$387$$$O	1$$$388$$$389$$$O	or$$$390$$$392$$$O	2$$$393$$$394$$$O	to$$$395$$$397$$$O	1$$$398$$$399$$$O	of$$$400$$$402$$$O	the$$$403$$$406$$$O	cefoperazone$$$407$$$419$$$I	sodium/the$$$420$$$430$$$I	sulbactam$$$431$$$440$$$I	sodium$$$441$$$447$$$I	in$$$448$$$450$$$O	markets.$$$451$$$459$$$O	The$$$460$$$463$$$O	invention$$$464$$$473$$$O	reduces$$$474$$$481$$$O	the$$$482$$$485$$$O	corresponding$$$486$$$499$$$O	content$$$500$$$507$$$O	of$$$508$$$510$$$O	the$$$511$$$514$$$O	sulbactam$$$515$$$524$$$I	sodium$$$525$$$531$$$I	in$$$532$$$534$$$O	the$$$535$$$538$$$O	combination,$$$539$$$551$$$O	so$$$552$$$554$$$O	the$$$555$$$558$$$O	invention$$$559$$$568$$$O	has$$$569$$$572$$$O	wider$$$573$$$578$$$O	clinical$$$579$$$587$$$O	application$$$588$$$599$$$O	range$$$600$$$605$$$O	and$$$606$$$609$$$O	can$$$610$$$613$$$O	reduce$$$614$$$620$$$O	the$$$621$$$624$$$O	production$$$625$$$635$$$O	cost$$$636$$$640$$$O	of$$$641$$$643$$$O	the$$$644$$$647$$$O	drug.$$$648$$$653$$$O	Compared$$$654$$$662$$$O	with$$$663$$$667$$$O	the$$$668$$$671$$$O	prior$$$672$$$677$$$O	compound$$$678$$$686$$$O	preparation$$$687$$$698$$$O	of$$$699$$$701$$$O	the$$$702$$$705$$$O	cefoperazone$$$706$$$718$$$I	sodium/the$$$719$$$729$$$I	sulbactam$$$730$$$739$$$I	sodium,$$$740$$$747$$$I	the$$$748$$$751$$$O	invention$$$752$$$761$$$O	is$$$762$$$764$$$O	characterized$$$765$$$778$$$O	by$$$779$$$781$$$O	being$$$782$$$787$$$O	fit$$$788$$$791$$$O	for$$$792$$$795$$$O	the$$$796$$$799$$$O	anti-infection$$$800$$$814$$$O	remedy$$$815$$$821$$$O	of$$$822$$$824$$$O	the$$$825$$$828$$$O	patient$$$829$$$836$$$O	with$$$837$$$841$$$O	the$$$842$$$845$$$O	renal$$$846$$$851$$$O	dysfunction$$$852$$$863$$$O	and$$$864$$$867$$$O	the$$$868$$$871$$$O	remedy$$$872$$$878$$$O	of$$$879$$$881$$$O	the$$$882$$$885$$$O	seriously$$$886$$$895$$$O	infected$$$896$$$904$$$O	patient.$$$905$$$913$$$O
US7632808
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	MP52$$$7$$$11$$$O	or$$$12$$$14$$$O	MP121$$$15$$$20$$$O	for$$$21$$$24$$$O	the$$$25$$$28$$$O	treatment$$$29$$$38$$$O	and$$$39$$$42$$$O	prevention$$$43$$$53$$$O	of$$$54$$$56$$$O	diseases$$$57$$$65$$$O	of$$$66$$$68$$$O	the$$$69$$$72$$$O	nervous$$$73$$$80$$$O	system$$$81$$$87$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	concerns$$$22$$$30$$$O	the$$$31$$$34$$$O	use$$$35$$$38$$$O	of$$$39$$$41$$$O	biologically$$$42$$$54$$$O	active$$$55$$$61$$$O	MP52$$$62$$$66$$$O	or/and$$$67$$$73$$$O	MP121$$$74$$$79$$$O	for$$$80$$$83$$$O	the$$$84$$$87$$$O	treatment$$$88$$$97$$$O	and$$$98$$$101$$$O	prevention$$$102$$$112$$$O	of$$$113$$$115$$$O	diseases$$$116$$$124$$$O	of$$$125$$$127$$$O	the$$$128$$$131$$$O	nervous$$$132$$$139$$$O	system$$$140$$$146$$$O	or/and$$$147$$$153$$$O	for$$$154$$$157$$$O	the$$$158$$$161$$$O	treatment$$$162$$$171$$$O	of$$$172$$$174$$$O	neuropathological$$$175$$$192$$$O	situations$$$193$$$203$$$O	which$$$204$$$209$$$O	are$$$210$$$213$$$O	caused$$$214$$$220$$$O	by$$$221$$$223$$$O	ageing$$$224$$$230$$$O	of$$$231$$$233$$$O	the$$$234$$$237$$$O	nervous$$$238$$$245$$$O	system.$$$246$$$253$$$O	A$$$254$$$255$$$O	pharmaceutical$$$256$$$270$$$O	agent$$$271$$$276$$$O	according$$$277$$$286$$$O	to$$$287$$$289$$$O	the$$$290$$$293$$$O	invention$$$294$$$303$$$O	for$$$304$$$307$$$O	the$$$308$$$311$$$O	treatment$$$312$$$321$$$O	and$$$322$$$325$$$O	prevention$$$326$$$336$$$O	of$$$337$$$339$$$O	diseases$$$340$$$348$$$O	of$$$349$$$351$$$O	the$$$352$$$355$$$O	nervous$$$356$$$363$$$O	system$$$364$$$370$$$O	or/and$$$371$$$377$$$O	for$$$378$$$381$$$O	treating$$$382$$$390$$$O	neuropathological$$$391$$$408$$$O	situations$$$409$$$419$$$O	which$$$420$$$425$$$O	are$$$426$$$429$$$O	caused$$$430$$$436$$$O	by$$$437$$$439$$$O	ageing$$$440$$$446$$$O	of$$$447$$$449$$$O	the$$$450$$$453$$$O	nervous$$$454$$$461$$$O	system$$$462$$$468$$$O	therefore$$$469$$$478$$$O	contains$$$479$$$487$$$O	biologically$$$488$$$500$$$O	active$$$501$$$507$$$O	MP52$$$508$$$512$$$O	or/and$$$513$$$519$$$O	MP121$$$520$$$525$$$O	as$$$526$$$528$$$O	the$$$529$$$532$$$O	active$$$533$$$539$$$O	substance.$$$540$$$550$$$O
CN102772378A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	for$$$19$$$22$$$O	cyclodextrin$$$23$$$35$$$O	inclusion$$$36$$$45$$$O	levonorgestral$$$46$$$60$$$I	tablets$$$61$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	preparation$$$25$$$36$$$O	method$$$37$$$43$$$O	for$$$44$$$47$$$O	cyclodextrin$$$48$$$60$$$O	inclusion$$$61$$$70$$$O	levonorgestral$$$71$$$85$$$I	tablets.$$$86$$$94$$$O	The$$$95$$$98$$$O	preparation$$$99$$$110$$$O	method$$$111$$$117$$$O	comprises$$$118$$$127$$$O	stirring$$$128$$$136$$$O	beta-cyclodextrin$$$137$$$154$$$O	and$$$155$$$158$$$O	levonorgestrel$$$159$$$173$$$I	in$$$174$$$176$$$O	an$$$177$$$179$$$O	appropriate$$$180$$$191$$$O	solvent$$$192$$$199$$$O	for$$$200$$$203$$$O	some$$$204$$$208$$$O	time;$$$209$$$214$$$O	and$$$215$$$218$$$O	mixing$$$219$$$225$$$O	and$$$226$$$229$$$O	tabletting$$$230$$$240$$$O	with$$$241$$$245$$$O	appropriate$$$246$$$257$$$O	accessories.$$$258$$$270$$$O	Compared$$$271$$$279$$$O	with$$$280$$$284$$$O	common$$$285$$$291$$$O	levonorgestrel$$$292$$$306$$$I	tablets$$$307$$$314$$$O	obtained$$$315$$$323$$$O	by$$$324$$$326$$$O	directly$$$327$$$335$$$O	tabletting,$$$336$$$347$$$O	the$$$348$$$351$$$O	levonorgestrel$$$352$$$366$$$I	tablets$$$367$$$374$$$O	of$$$375$$$377$$$O	the$$$378$$$381$$$O	invention$$$382$$$391$$$O	are$$$392$$$395$$$O	significantly$$$396$$$409$$$O	increased$$$410$$$419$$$O	in$$$420$$$422$$$O	dissolution$$$423$$$434$$$O	rate,$$$435$$$440$$$O	so$$$441$$$443$$$O	that$$$444$$$448$$$O	the$$$449$$$452$$$O	levonorgestrel$$$453$$$467$$$I	tablets$$$468$$$475$$$O	prepared$$$476$$$484$$$O	by$$$485$$$487$$$O	the$$$488$$$491$$$O	method$$$492$$$498$$$O	of$$$499$$$501$$$O	the$$$502$$$505$$$O	invention$$$506$$$515$$$O	are$$$516$$$519$$$O	convenient$$$520$$$530$$$O	to$$$531$$$533$$$O	take,$$$534$$$539$$$O	fast$$$540$$$544$$$O	in$$$545$$$547$$$O	absorption,$$$548$$$559$$$O	high$$$560$$$564$$$O	in$$$565$$$567$$$O	bioavailability,$$$568$$$584$$$O	and$$$585$$$588$$$O	the$$$589$$$592$$$O	like,$$$593$$$598$$$O	and$$$599$$$602$$$O	can$$$603$$$606$$$O	improve$$$607$$$614$$$O	patient$$$615$$$622$$$O	adaptability$$$623$$$635$$$O	and$$$636$$$639$$$O	increase$$$640$$$648$$$O	choices$$$649$$$656$$$O	of$$$657$$$659$$$O	clinical$$$660$$$668$$$O	medication$$$669$$$679$$$O	for$$$680$$$683$$$O	doctors$$$684$$$691$$$O	and$$$692$$$695$$$O	patients.$$$696$$$705$$$O
US7393526
Systemic$$$0$$$8$$$O	gene$$$9$$$13$$$O	delivery$$$14$$$22$$$O	vehicles$$$23$$$31$$$O	for$$$32$$$35$$$O	the$$$36$$$39$$$O	treatment$$$40$$$49$$$O	of$$$50$$$52$$$O	tumors$$$53$$$59$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	field$$$37$$$42$$$O	of$$$43$$$45$$$O	cellular$$$46$$$54$$$O	and$$$55$$$58$$$O	molecular$$$59$$$68$$$O	therapy$$$69$$$76$$$O	with$$$77$$$81$$$O	modified$$$82$$$90$$$O	(genetically$$$91$$$103$$$O	or$$$104$$$106$$$O	growth$$$107$$$113$$$O	factor$$$114$$$120$$$O	engineered)$$$121$$$132$$$O	and$$$133$$$136$$$O	unmodified$$$137$$$147$$$O	stem$$$148$$$152$$$O	cells$$$153$$$158$$$O	(SCs).$$$159$$$165$$$O	More$$$166$$$170$$$O	particularly,$$$171$$$184$$$O	the$$$185$$$188$$$O	invention$$$189$$$198$$$O	relates$$$199$$$206$$$O	to$$$207$$$209$$$O	a$$$210$$$211$$$O	method$$$212$$$218$$$O	of$$$219$$$221$$$O	systemic$$$222$$$230$$$O	treatment$$$231$$$240$$$O	of$$$241$$$243$$$O	central$$$244$$$251$$$O	nervous$$$252$$$259$$$O	system$$$260$$$266$$$O	(CNS)$$$267$$$272$$$O	and$$$273$$$276$$$O	other$$$277$$$282$$$O	tumors$$$283$$$289$$$O	in$$$290$$$292$$$O	both$$$293$$$297$$$O	intracranial/intraspinal$$$298$$$322$$$O	and$$$323$$$326$$$O	extracranial/extraspinal$$$327$$$351$$$O	sites,$$$352$$$358$$$O	using$$$359$$$364$$$O	neural$$$365$$$371$$$O	stem$$$372$$$376$$$O	cells$$$377$$$382$$$O	(NSCs),$$$383$$$390$$$O	a$$$391$$$392$$$O	prototype$$$393$$$402$$$O	for$$$403$$$406$$$O	solid$$$407$$$412$$$O	organ,$$$413$$$419$$$O	non-hematopoietic$$$420$$$437$$$O	stem$$$438$$$442$$$O	cells.$$$443$$$449$$$O
CN103739549A
Preparation$$$0$$$11$$$O	and$$$12$$$15$$$O	application$$$16$$$27$$$O	of$$$28$$$30$$$O	naphthalimide-amino$$$31$$$50$$$I	acid$$$51$$$55$$$I	compound$$$56$$$64$$$O	and$$$65$$$68$$$O	modified$$$69$$$77$$$O	quantum$$$78$$$85$$$O	dot$$$86$$$89$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	pharmaceutical$$$29$$$43$$$O	chemistry$$$44$$$53$$$O	field,$$$54$$$60$$$O	and$$$61$$$64$$$O	concretely$$$65$$$75$$$O	relates$$$76$$$83$$$O	to$$$84$$$86$$$O	a$$$87$$$88$$$O	naphthalimide-amino$$$89$$$108$$$I	acid$$$109$$$113$$$I	compound,$$$114$$$123$$$O	its$$$124$$$127$$$O	preparation$$$128$$$139$$$O	method$$$140$$$146$$$O	and$$$147$$$150$$$O	an$$$151$$$153$$$O	application,$$$154$$$166$$$O	and$$$167$$$170$$$O	simultaneously$$$171$$$185$$$O	relates$$$186$$$193$$$O	to$$$194$$$196$$$O	a$$$197$$$198$$$O	quantum$$$199$$$206$$$O	dot$$$207$$$210$$$O	modified$$$211$$$219$$$O	by$$$220$$$222$$$O	the$$$223$$$226$$$O	naphthalimide-amino$$$227$$$246$$$I	acid$$$247$$$251$$$I	compound$$$252$$$260$$$O	and$$$261$$$264$$$O	its$$$265$$$268$$$O	application.$$$269$$$281$$$O	The$$$282$$$285$$$O	naphthalimide-amino$$$286$$$305$$$I	acid$$$306$$$310$$$I	compound$$$311$$$319$$$O	has$$$320$$$323$$$O	a$$$324$$$325$$$O	general$$$326$$$333$$$O	formula$$$334$$$341$$$O	of$$$342$$$344$$$O	(img$$$345$$$349$$$O	file='2013106912783100004dest_path_image002.$$$350$$$394$$$O	TIF'$$$395$$$399$$$O	wi='261'$$$400$$$408$$$O	he='86'/).$$$409$$$419$$$O	The$$$420$$$423$$$O	provided$$$424$$$432$$$O	naphthalimide-amino$$$433$$$452$$$I	acid$$$453$$$457$$$I	compound$$$458$$$466$$$O	and$$$467$$$470$$$O	its$$$471$$$474$$$O	modified$$$475$$$483$$$O	quantum$$$484$$$491$$$O	dot$$$492$$$495$$$O	is$$$496$$$498$$$O	the$$$499$$$502$$$O	nano-material$$$503$$$516$$$O	with$$$517$$$521$$$O	high$$$522$$$526$$$O	biology$$$527$$$534$$$O	targeting$$$535$$$544$$$O	and$$$545$$$548$$$O	singularity,$$$549$$$561$$$O	can$$$562$$$565$$$O	realize$$$566$$$573$$$O	anti-tumour$$$574$$$585$$$O	targeting$$$586$$$595$$$O	effect,$$$596$$$603$$$O	and$$$604$$$607$$$O	make$$$608$$$612$$$O	the$$$613$$$616$$$O	contribution$$$617$$$629$$$O	for$$$630$$$633$$$O	the$$$634$$$637$$$O	development$$$638$$$649$$$O	of$$$650$$$652$$$O	new$$$653$$$656$$$O	drugs.$$$657$$$663$$$O
US20100029710
COMPOUNDS$$$0$$$9$$$O	HAVING$$$10$$$16$$$O	BOTH$$$17$$$21$$$O	ANGIOTENSIN$$$22$$$33$$$I	II$$$34$$$36$$$I	RECEPTOR$$$37$$$45$$$O	ANTAGONISM$$$46$$$56$$$O	AND$$$57$$$60$$$O	PPARy$$$61$$$66$$$O	ACTIVATING$$$67$$$77$$$O	ACTIVITIES$$$78$$$88$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	following$$$13$$$22$$$O	formula$$$23$$$30$$$O	(I)$$$31$$$34$$$O	are$$$35$$$38$$$O	provided$$$39$$$47$$$O	that$$$48$$$52$$$O	have$$$53$$$57$$$O	both$$$58$$$62$$$O	angiotensin$$$63$$$74$$$I	II$$$75$$$77$$$I	receptor$$$78$$$86$$$O	antagonist$$$87$$$97$$$O	activity$$$98$$$106$$$O	and$$$107$$$110$$$O	PPARy$$$111$$$116$$$O	agonist$$$117$$$124$$$O	activity.$$$125$$$134$$$O	Also$$$135$$$139$$$O	provided$$$140$$$148$$$O	are$$$149$$$152$$$O	pharmaceutical$$$153$$$167$$$O	compositions$$$168$$$180$$$O	comprising$$$181$$$191$$$O	the$$$192$$$195$$$O	compounds$$$196$$$205$$$O	and$$$206$$$209$$$O	methods$$$210$$$217$$$O	of$$$218$$$220$$$O	treatment$$$221$$$230$$$O	of$$$231$$$233$$$O	diseases$$$234$$$242$$$O	with$$$243$$$247$$$O	the$$$248$$$251$$$O	compounds$$$252$$$261$$$O	including$$$262$$$271$$$O	type$$$272$$$276$$$O	2$$$277$$$278$$$O	diabetes,$$$279$$$288$$$O	insulin$$$289$$$296$$$O	resistance,$$$297$$$308$$$O	hyperinsulinemia,$$$309$$$326$$$O	hyperlipidemia,$$$327$$$342$$$O	hypertriglyceridemia,$$$343$$$364$$$O	metabolic$$$365$$$374$$$O	syndrome,$$$375$$$384$$$O	congestive$$$385$$$395$$$O	heart$$$396$$$401$$$O	failure,$$$402$$$410$$$O	and$$$411$$$414$$$O	hypertension.$$$415$$$428$$$O
US7820818
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	cathepsin$$$14$$$23$$$O	K;$$$24$$$26$$$O	inflammation,$$$28$$$41$$$O	rheumatoid$$$42$$$52$$$O	arthritis,$$$53$$$63$$$O	osteoarthritis,$$$64$$$79$$$O	osteoporosis$$$80$$$92$$$O	and$$$93$$$96$$$O	tumors;$$$97$$$104$$$O	4-Cyclopentylamino-5-(4-phenyl-but-1-ynyl)-pyrimidine-2-carbonitrile;$$$105$$$174$$$I	5-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)-prop-1-ynyl]-4-(2,2-dimethyl-propylamino)-pyrimidine-2-carbonitrile$$$175$$$281$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds$$$23$$$32$$$O	of$$$33$$$35$$$O	formula$$$36$$$43$$$O	I$$$44$$$45$$$O	or$$$46$$$48$$$O	a$$$49$$$50$$$O	pharmaceutically$$$51$$$67$$$O	acceptable$$$68$$$78$$$O	salt$$$79$$$83$$$O	or$$$84$$$86$$$O	ester$$$87$$$92$$$I	thereof$$$93$$$100$$$O	wherein$$$120$$$127$$$O	the$$$128$$$131$$$O	symbols$$$132$$$139$$$O	have$$$140$$$144$$$O	meaning$$$145$$$152$$$O	as$$$153$$$155$$$O	defined,$$$156$$$164$$$O	which$$$165$$$170$$$O	are$$$171$$$174$$$O	inhibitors$$$175$$$185$$$O	of$$$186$$$188$$$O	cathepsin$$$189$$$198$$$O	K$$$199$$$200$$$O	and$$$201$$$204$$$O	find$$$205$$$209$$$O	use$$$210$$$213$$$O	pharmaceutically$$$214$$$230$$$O	for$$$231$$$234$$$O	treatment$$$235$$$244$$$O	of$$$245$$$247$$$O	diseases$$$248$$$256$$$O	and$$$257$$$260$$$O	medical$$$261$$$268$$$O	conditions$$$269$$$279$$$O	in$$$280$$$282$$$O	which$$$283$$$288$$$O	cathepsin$$$289$$$298$$$O	K$$$299$$$300$$$O	is$$$301$$$303$$$O	implicated,$$$304$$$315$$$O	e.g.$$$316$$$320$$$O	various$$$321$$$328$$$O	disorders$$$329$$$338$$$O	including$$$339$$$348$$$O	inflammation,$$$349$$$362$$$O	rheumatoid$$$363$$$373$$$O	arthritis,$$$374$$$384$$$O	osteoarthritis,$$$385$$$400$$$O	osteoporosis$$$401$$$413$$$O	and$$$414$$$417$$$O	tumors.$$$418$$$425$$$O
EP1909769A2
Alcohol$$$0$$$7$$$I	resistant$$$8$$$17$$$O	pharmaceutical$$$18$$$32$$$O	formulations$$$33$$$45$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	alcohol$$$31$$$38$$$I	resistant$$$39$$$48$$$O	oral$$$49$$$53$$$O	dosage$$$54$$$60$$$O	pharmaceutical$$$61$$$75$$$O	forms$$$76$$$81$$$O	and$$$82$$$85$$$O	methods$$$86$$$93$$$O	of$$$94$$$96$$$O	using$$$97$$$102$$$O	such$$$103$$$107$$$O	oral$$$108$$$112$$$O	dosage$$$113$$$119$$$O	forms$$$120$$$125$$$O	to$$$126$$$128$$$O	avoid$$$129$$$134$$$O	dose$$$135$$$139$$$O	dumping$$$140$$$147$$$O	if$$$148$$$150$$$O	the$$$151$$$154$$$O	dosage$$$155$$$161$$$O	form$$$162$$$166$$$O	is$$$167$$$169$$$O	taken$$$170$$$175$$$O	together$$$176$$$184$$$O	with$$$185$$$189$$$O	alcohol.$$$190$$$198$$$I
US7576067
Pulsatile$$$0$$$9$$$O	release$$$10$$$17$$$O	compositions$$$18$$$30$$$O	and$$$31$$$34$$$O	methods$$$35$$$42$$$O	for$$$43$$$46$$$O	enhanced$$$47$$$55$$$O	intestinal$$$56$$$66$$$O	oligonucleotide$$$67$$$82$$$I	drug$$$83$$$87$$$O	absorption$$$88$$$98$$$O
Delayed$$$0$$$7$$$O	release$$$8$$$15$$$O	oral$$$16$$$20$$$O	pharmaceutical$$$21$$$35$$$O	formulations$$$36$$$48$$$O	and$$$49$$$52$$$O	methods$$$53$$$60$$$O	for$$$61$$$64$$$O	enhanced$$$65$$$73$$$O	intestinal$$$74$$$84$$$O	drug$$$85$$$89$$$O	absorption.$$$90$$$101$$$O	The$$$102$$$105$$$O	formulation$$$106$$$117$$$O	comprises$$$118$$$127$$$O	a$$$128$$$129$$$O	first$$$130$$$135$$$O	population$$$136$$$146$$$O	of$$$147$$$149$$$O	carrier$$$150$$$157$$$O	particles$$$158$$$167$$$O	comprising$$$168$$$178$$$O	a$$$179$$$180$$$O	drug$$$181$$$185$$$O	and$$$186$$$189$$$O	a$$$190$$$191$$$O	penetration$$$192$$$203$$$O	enhancer$$$204$$$212$$$O	which$$$213$$$218$$$O	are$$$219$$$222$$$O	released$$$223$$$231$$$O	at$$$232$$$234$$$O	a$$$235$$$236$$$O	first$$$237$$$242$$$O	location$$$243$$$251$$$O	in$$$252$$$254$$$O	the$$$255$$$258$$$O	intestine,$$$259$$$269$$$O	and$$$270$$$273$$$O	a$$$274$$$275$$$O	second$$$276$$$282$$$O	population$$$283$$$293$$$O	of$$$294$$$296$$$O	carrier$$$297$$$304$$$O	particles$$$305$$$314$$$O	comprising$$$315$$$325$$$O	a$$$326$$$327$$$O	penetration$$$328$$$339$$$O	enhancer$$$340$$$348$$$O	and$$$349$$$352$$$O	a$$$353$$$354$$$O	delayed$$$355$$$362$$$O	release$$$363$$$370$$$O	coating$$$371$$$378$$$O	or$$$379$$$381$$$O	matrix.$$$382$$$389$$$O	This$$$390$$$394$$$O	penetration$$$395$$$406$$$O	enhancer$$$407$$$415$$$O	is$$$416$$$418$$$O	released$$$419$$$427$$$O	at$$$428$$$430$$$O	a$$$431$$$432$$$O	second$$$433$$$439$$$O	location$$$440$$$448$$$O	in$$$449$$$451$$$O	the$$$452$$$455$$$O	intestine$$$456$$$465$$$O	downstream$$$466$$$476$$$O	from$$$477$$$481$$$O	the$$$482$$$485$$$O	first$$$486$$$491$$$O	location$$$492$$$500$$$O	and$$$501$$$504$$$O	enhances$$$505$$$513$$$O	absorption$$$514$$$524$$$O	of$$$525$$$527$$$O	the$$$528$$$531$$$O	drug$$$532$$$536$$$O	when$$$537$$$541$$$O	it$$$542$$$544$$$O	reaches$$$545$$$552$$$O	the$$$553$$$556$$$O	second$$$557$$$563$$$O	location.$$$564$$$573$$$O
US7208491
N-monoacylated$$$0$$$14$$$I	o-phenylenediamines$$$15$$$34$$$I
Mono-acylated$$$0$$$13$$$I	o-phenylendiamines$$$14$$$32$$$I	derivatives$$$33$$$44$$$O	of$$$45$$$47$$$O	formula$$$48$$$55$$$O	I$$$56$$$57$$$O	wherein$$$77$$$84$$$O	X$$$85$$$86$$$O	and$$$87$$$90$$$O	R$$$91$$$92$$$O	are$$$93$$$96$$$O	as$$$97$$$99$$$O	described$$$100$$$109$$$O	herein,$$$110$$$117$$$O	have$$$118$$$122$$$O	been$$$123$$$127$$$O	found$$$128$$$133$$$O	useful$$$134$$$140$$$O	for$$$141$$$144$$$O	the$$$145$$$148$$$O	treatment$$$149$$$158$$$O	of$$$159$$$161$$$O	diseases$$$162$$$170$$$O	mediated$$$171$$$179$$$O	by$$$180$$$182$$$O	the$$$183$$$186$$$O	inhibition$$$187$$$197$$$O	of$$$198$$$200$$$O	histone$$$201$$$208$$$O	deacetylase,$$$209$$$221$$$O	such$$$222$$$226$$$O	as$$$227$$$229$$$O	cancer.$$$230$$$237$$$O
WO2013171729A3
Aryl$$$0$$$4$$$I	and$$$5$$$8$$$O	heteroaryl$$$9$$$19$$$I	amide$$$20$$$25$$$I	compounds$$$26$$$35$$$O	as$$$36$$$38$$$O	ror$$$39$$$42$$$O	gamma$$$43$$$48$$$O	t$$$49$$$50$$$O	modulator$$$51$$$60$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	is$$$23$$$25$$$O	directed$$$26$$$34$$$O	to$$$35$$$37$$$O	compounds$$$38$$$47$$$O	of$$$48$$$50$$$O	Formula$$$51$$$58$$$O	(I),$$$59$$$63$$$O	and$$$64$$$67$$$O	pharmaceutically$$$68$$$84$$$O	acceptable$$$85$$$95$$$O	salts$$$96$$$101$$$O	thereof,$$$102$$$110$$$O	as$$$111$$$113$$$O	modulator$$$114$$$123$$$O	of$$$124$$$126$$$O	retinoid-related$$$127$$$143$$$I	orphan$$$144$$$150$$$O	receptor$$$151$$$159$$$O	gamma$$$160$$$165$$$O	t$$$166$$$167$$$O	(RORÏt).$$$168$$$177$$$O	These$$$178$$$183$$$O	compounds$$$184$$$193$$$O	prevent,$$$194$$$202$$$O	inhibit,$$$203$$$211$$$O	or$$$212$$$214$$$O	suppress$$$215$$$223$$$O	the$$$224$$$227$$$O	action$$$228$$$234$$$O	of$$$235$$$237$$$O	RORÏt$$$238$$$244$$$O	and$$$245$$$248$$$O	are$$$249$$$252$$$O	therefore$$$253$$$262$$$O	useful$$$263$$$269$$$O	in$$$270$$$272$$$O	the$$$273$$$276$$$O	treatment$$$277$$$286$$$O	of$$$287$$$289$$$O	RORÏt$$$290$$$296$$$O	mediated$$$297$$$305$$$O	disease,$$$306$$$314$$$O	disorder,$$$315$$$324$$$O	syndrome$$$325$$$333$$$O	or$$$334$$$336$$$O	condition$$$337$$$346$$$O	such$$$347$$$351$$$O	as$$$352$$$354$$$O	pain,$$$355$$$360$$$O	inflammation,$$$361$$$374$$$O	COPD,$$$375$$$380$$$O	asthma,$$$381$$$388$$$O	rheumatoid$$$389$$$399$$$O	arthritis,$$$400$$$410$$$O	colitis,$$$411$$$419$$$O	multiple$$$420$$$428$$$O	sclerosis,$$$429$$$439$$$O	neurodegenerative$$$440$$$457$$$O	diseases$$$458$$$466$$$O	or$$$467$$$469$$$O	cancer.$$$470$$$477$$$O
US20100261681
Alpha-chloro$$$0$$$12$$$I	and$$$13$$$16$$$I	alpha-bromo$$$17$$$28$$$I	phosphonate$$$29$$$40$$$I	analogs$$$41$$$48$$$O	of$$$49$$$51$$$O	lysophosphatidic$$$52$$$68$$$I	acid$$$69$$$73$$$I	and$$$74$$$77$$$O	methods$$$78$$$85$$$O	of$$$86$$$88$$$O	making$$$89$$$95$$$O	and$$$96$$$99$$$O	using$$$100$$$105$$$O	thereof$$$106$$$113$$$O
Described$$$0$$$9$$$O	herein$$$10$$$16$$$O	is$$$17$$$19$$$O	the$$$20$$$23$$$O	synthesis$$$24$$$33$$$O	and$$$34$$$37$$$O	pharmacology$$$38$$$50$$$O	of$$$51$$$53$$$O	a$$$54$$$55$$$O	series$$$56$$$62$$$O	of$$$63$$$65$$$O	Î±-substituted$$$66$$$80$$$I	methylene$$$81$$$90$$$I	phosphonate$$$91$$$102$$$I	analogs,$$$103$$$111$$$O	in$$$112$$$114$$$O	which$$$115$$$120$$$O	the$$$121$$$124$$$I	Î±-CH2$$$125$$$131$$$I	moiety$$$132$$$138$$$O	is$$$139$$$141$$$O	replaced$$$142$$$150$$$O	with$$$151$$$155$$$I	CHCl$$$156$$$160$$$I	or$$$161$$$163$$$I	CHBr.$$$164$$$169$$$I
CN103127085A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Eryngiolide$$$15$$$26$$$I	A$$$27$$$28$$$I	in$$$29$$$31$$$O	medicines$$$32$$$41$$$O	treating$$$42$$$50$$$O	chronic$$$51$$$58$$$O	obstructive$$$59$$$70$$$O	pulmonary$$$71$$$80$$$O	disease$$$81$$$88$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	novel$$$24$$$29$$$O	application$$$30$$$41$$$O	of$$$42$$$44$$$O	Eryngiolide$$$45$$$56$$$I	A$$$57$$$58$$$I	in$$$59$$$61$$$O	preparing$$$62$$$71$$$O	medicines$$$72$$$81$$$O	preventing$$$82$$$92$$$O	and$$$93$$$96$$$O	treating$$$97$$$105$$$O	chronic$$$106$$$113$$$O	obstructive$$$114$$$125$$$O	pulmonary$$$126$$$135$$$O	disease.$$$136$$$144$$$O	The$$$145$$$148$$$O	application$$$149$$$160$$$O	of$$$161$$$163$$$O	the$$$164$$$167$$$O	Eryngiolide$$$168$$$179$$$I	A$$$180$$$181$$$I	in$$$182$$$184$$$O	preparing$$$185$$$194$$$O	medicines$$$195$$$204$$$O	treating$$$205$$$213$$$O	chronic$$$214$$$221$$$O	obstructive$$$222$$$233$$$O	pulmonary$$$234$$$243$$$O	disease$$$244$$$251$$$O	is$$$252$$$254$$$O	made$$$255$$$259$$$O	public$$$260$$$266$$$O	for$$$267$$$270$$$O	the$$$271$$$274$$$O	first$$$275$$$280$$$O	time,$$$281$$$286$$$O	due$$$287$$$290$$$O	to$$$291$$$293$$$O	the$$$294$$$297$$$O	fact$$$298$$$302$$$O	that$$$303$$$307$$$O	matrix$$$308$$$314$$$O	type$$$315$$$319$$$O	is$$$320$$$322$$$O	brand$$$323$$$328$$$O	novel,$$$329$$$335$$$O	besides,$$$336$$$344$$$O	the$$$345$$$348$$$O	Eryngiolide$$$349$$$360$$$I	A$$$361$$$362$$$I	has$$$363$$$366$$$O	an$$$367$$$369$$$O	unexpectedly$$$370$$$382$$$O	high$$$383$$$387$$$O	chronic$$$388$$$395$$$O	obstructive$$$396$$$407$$$O	pulmonary$$$408$$$417$$$O	disease$$$418$$$425$$$O	inhibitory$$$426$$$436$$$O	activity,$$$437$$$446$$$O	the$$$447$$$450$$$O	possibility$$$451$$$462$$$O	that$$$463$$$467$$$O	inspiration$$$468$$$479$$$O	is$$$480$$$482$$$O	obtained$$$483$$$491$$$O	from$$$492$$$496$$$O	other$$$497$$$502$$$O	compounds$$$503$$$512$$$O	does$$$513$$$517$$$O	not$$$518$$$521$$$O	exist,$$$522$$$528$$$O	and$$$529$$$532$$$O	the$$$533$$$536$$$O	Eryngiolide$$$537$$$548$$$I	A$$$549$$$550$$$I	possesses$$$551$$$560$$$O	outstanding$$$561$$$572$$$O	substantial$$$573$$$584$$$O	characteristics,$$$585$$$601$$$O	meanwhile,$$$602$$$612$$$O	significant$$$613$$$624$$$O	progress$$$625$$$633$$$O	is$$$634$$$636$$$O	obviously$$$637$$$646$$$O	achieved$$$647$$$655$$$O	by$$$656$$$658$$$O	the$$$659$$$662$$$O	application$$$663$$$674$$$O	of$$$675$$$677$$$O	the$$$678$$$681$$$O	Eryngiolide$$$682$$$693$$$I	A$$$694$$$695$$$I	in$$$696$$$698$$$O	resisting$$$699$$$708$$$O	chronic$$$709$$$716$$$O	obstructive$$$717$$$728$$$O	pulmonary$$$729$$$738$$$O	disease.$$$739$$$747$$$O
CN101716222A
Anti-alcohol$$$0$$$12$$$O	vinegar$$$13$$$20$$$O	and$$$21$$$24$$$O	preparation$$$25$$$36$$$O	method$$$37$$$43$$$O	thereof$$$44$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	anti-alcohol$$$24$$$36$$$O	vinegar,$$$37$$$45$$$O	which$$$46$$$51$$$O	consists$$$52$$$60$$$O	of$$$61$$$63$$$O	the$$$64$$$67$$$O	following$$$68$$$77$$$O	components$$$78$$$88$$$O	in$$$89$$$91$$$O	part$$$92$$$96$$$O	by$$$97$$$99$$$O	weight:$$$100$$$107$$$O	18$$$108$$$110$$$O	to$$$111$$$113$$$O	22$$$114$$$116$$$O	parts$$$117$$$122$$$O	of$$$123$$$125$$$O	vinegar,$$$126$$$134$$$O	2$$$135$$$136$$$O	to$$$137$$$139$$$O	3$$$140$$$141$$$O	parts$$$142$$$147$$$O	of$$$148$$$150$$$O	honey$$$151$$$156$$$O	and$$$157$$$160$$$O	9$$$161$$$162$$$O	to$$$163$$$165$$$O	12$$$166$$$168$$$O	parts$$$169$$$174$$$O	of$$$175$$$177$$$O	kudzuvine$$$178$$$187$$$O	root$$$188$$$192$$$O	decoct,$$$193$$$200$$$O	wherein$$$201$$$208$$$O	each$$$209$$$213$$$O	liter$$$214$$$219$$$O	of$$$220$$$222$$$O	the$$$223$$$226$$$O	kudzuvine$$$227$$$236$$$O	root$$$237$$$241$$$O	decoction$$$242$$$251$$$O	is$$$252$$$254$$$O	prepared$$$255$$$263$$$O	from$$$264$$$268$$$O	1g$$$269$$$271$$$O	of$$$272$$$274$$$O	kudzuvine$$$275$$$284$$$O	root.$$$285$$$290$$$O	A$$$291$$$292$$$O	preparation$$$293$$$304$$$O	method$$$305$$$311$$$O	for$$$312$$$315$$$O	the$$$316$$$319$$$O	anti-alcohol$$$320$$$332$$$O	vinegar$$$333$$$340$$$O	comprises$$$341$$$350$$$O	the$$$351$$$354$$$O	following$$$355$$$364$$$O	steps:$$$365$$$371$$$O	decocting$$$372$$$381$$$O	kudzuvine$$$382$$$391$$$O	root$$$392$$$396$$$O	in$$$397$$$399$$$O	proportion$$$400$$$410$$$O	by$$$411$$$413$$$O	adding$$$414$$$420$$$O	water$$$421$$$426$$$O	until$$$427$$$432$$$O	the$$$433$$$436$$$O	decoction$$$437$$$446$$$O	is$$$447$$$449$$$O	condensed$$$450$$$459$$$O	to$$$460$$$462$$$O	one$$$463$$$466$$$O	third$$$467$$$472$$$O	of$$$473$$$475$$$O	the$$$476$$$479$$$O	volume$$$480$$$486$$$O	of$$$487$$$489$$$O	the$$$490$$$493$$$O	added$$$494$$$499$$$O	water,$$$500$$$506$$$O	and$$$507$$$510$$$O	separating$$$511$$$521$$$O	out$$$522$$$525$$$O	the$$$526$$$529$$$O	kudzuvine$$$530$$$539$$$O	root$$$540$$$544$$$O	decoction$$$545$$$554$$$O	and$$$555$$$558$$$O	kudzuvine$$$559$$$568$$$O	root;$$$569$$$574$$$O	taking$$$575$$$581$$$O	the$$$582$$$585$$$O	filtered$$$586$$$594$$$O	kudzuvine$$$595$$$604$$$O	root,$$$605$$$610$$$O	decocting$$$611$$$620$$$O	the$$$621$$$624$$$O	kudzuvine$$$625$$$634$$$O	root$$$635$$$639$$$O	by$$$640$$$642$$$O	adding$$$643$$$649$$$O	water$$$650$$$655$$$O	in$$$656$$$658$$$O	proportion$$$659$$$669$$$O	until$$$670$$$675$$$O	the$$$676$$$679$$$O	decoction$$$680$$$689$$$O	is$$$690$$$692$$$O	condensed$$$693$$$702$$$O	to$$$703$$$705$$$O	half$$$706$$$710$$$O	of$$$711$$$713$$$O	the$$$714$$$717$$$O	volume$$$718$$$724$$$O	of$$$725$$$727$$$O	the$$$728$$$731$$$O	added$$$732$$$737$$$O	water,$$$738$$$744$$$O	and$$$745$$$748$$$O	filtering$$$749$$$758$$$O	out$$$759$$$762$$$O	the$$$763$$$766$$$O	kudzuvine$$$767$$$776$$$O	root$$$777$$$781$$$O	decoction;$$$782$$$792$$$O	and$$$793$$$796$$$O	combining$$$797$$$806$$$O	the$$$807$$$810$$$O	decoction$$$811$$$820$$$O	of$$$821$$$823$$$O	the$$$824$$$827$$$O	two$$$828$$$831$$$O	times,$$$832$$$838$$$O	heating$$$839$$$846$$$O	and$$$847$$$850$$$O	decocting,$$$851$$$861$$$O	condensing$$$862$$$872$$$O	to$$$873$$$875$$$O	one$$$876$$$879$$$O	fourth,$$$880$$$887$$$O	cooling,$$$888$$$896$$$O	adding$$$897$$$903$$$O	rice$$$904$$$908$$$O	vinegar$$$909$$$916$$$O	of$$$917$$$919$$$O	which$$$920$$$925$$$O	the$$$926$$$929$$$O	volume$$$930$$$936$$$O	is$$$937$$$939$$$O	1.5$$$940$$$943$$$O	to$$$944$$$946$$$O	2.45$$$947$$$951$$$O	times$$$952$$$957$$$O	that$$$958$$$962$$$O	of$$$963$$$965$$$O	the$$$966$$$969$$$O	decoction,$$$970$$$980$$$O	and$$$981$$$984$$$O	adding$$$985$$$991$$$O	the$$$992$$$995$$$O	honey$$$996$$$1001$$$O	in$$$1002$$$1004$$$O	an$$$1005$$$1007$$$O	amount$$$1008$$$1014$$$O	which$$$1015$$$1020$$$O	is$$$1021$$$1023$$$O	one$$$1024$$$1027$$$O	thirds$$$1028$$$1034$$$O	to$$$1035$$$1037$$$O	one$$$1038$$$1041$$$O	sixth$$$1042$$$1047$$$O	volume$$$1048$$$1054$$$O	of$$$1055$$$1057$$$O	the$$$1058$$$1061$$$O	decoction$$$1062$$$1071$$$O	in$$$1072$$$1074$$$O	the$$$1075$$$1078$$$O	heating$$$1079$$$1086$$$O	process,$$$1087$$$1095$$$O	stirring$$$1096$$$1104$$$O	uniformly,$$$1105$$$1115$$$O	boiling,$$$1116$$$1124$$$O	eliminating$$$1125$$$1136$$$O	fire$$$1137$$$1141$$$O	and$$$1142$$$1145$$$O	cooling$$$1146$$$1153$$$O	to$$$1154$$$1156$$$O	obtain$$$1157$$$1163$$$O	the$$$1164$$$1167$$$O	anti-alcohol$$$1168$$$1180$$$O	vinegar.$$$1181$$$1189$$$O	Under$$$1190$$$1195$$$O	the$$$1196$$$1199$$$O	combined$$$1200$$$1208$$$O	action$$$1209$$$1215$$$O	of$$$1216$$$1218$$$O	the$$$1219$$$1222$$$O	rice$$$1223$$$1227$$$O	vinegar,$$$1228$$$1236$$$O	the$$$1237$$$1240$$$O	kudzuvine$$$1241$$$1250$$$O	root$$$1251$$$1255$$$O	and$$$1256$$$1259$$$O	the$$$1260$$$1263$$$O	honey,$$$1264$$$1270$$$O	the$$$1271$$$1274$$$O	alcohol$$$1275$$$1282$$$O	in$$$1283$$$1285$$$O	the$$$1286$$$1289$$$O	body$$$1290$$$1294$$$O	is$$$1295$$$1297$$$O	quickly$$$1298$$$1305$$$O	decomposed$$$1306$$$1316$$$O	and$$$1317$$$1320$$$O	metabolized$$$1321$$$1332$$$O	so$$$1333$$$1335$$$O	as$$$1336$$$1338$$$O	to$$$1339$$$1341$$$O	achieve$$$1342$$$1349$$$O	the$$$1350$$$1353$$$O	anti-alcohol$$$1354$$$1366$$$O	effect.$$$1367$$$1374$$$O
US20110092565
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	treating$$$10$$$18$$$O	neurodegenerative$$$19$$$36$$$O	disease$$$37$$$44$$$O
Aspects$$$0$$$7$$$O	featured$$$8$$$16$$$O	in$$$17$$$19$$$O	the$$$20$$$23$$$O	invention$$$24$$$33$$$O	relate$$$34$$$40$$$O	to$$$41$$$43$$$O	compositions$$$44$$$56$$$O	and$$$57$$$60$$$O	methods$$$61$$$68$$$O	for$$$69$$$72$$$O	inhibiting$$$73$$$83$$$O	alpha-synuclein$$$84$$$99$$$O	(SNCA)$$$100$$$106$$$O	gene$$$107$$$111$$$O	expression,$$$112$$$123$$$O	such$$$124$$$128$$$O	as$$$129$$$131$$$O	for$$$132$$$135$$$O	the$$$136$$$139$$$O	treatment$$$140$$$149$$$O	of$$$150$$$152$$$O	neurodegenerative$$$153$$$170$$$O	disorders.$$$171$$$181$$$O	An$$$182$$$184$$$O	anti-SNCA$$$185$$$194$$$O	agent$$$195$$$200$$$O	featured$$$201$$$209$$$O	herein$$$210$$$216$$$O	that$$$217$$$221$$$O	targets$$$222$$$229$$$O	the$$$230$$$233$$$O	SNCA$$$234$$$238$$$O	gene$$$239$$$243$$$O	can$$$244$$$247$$$O	have$$$248$$$252$$$O	been$$$253$$$257$$$O	modified$$$258$$$266$$$O	to$$$267$$$269$$$O	alter$$$270$$$275$$$O	distribution$$$276$$$288$$$O	in$$$289$$$291$$$O	favor$$$292$$$297$$$O	of$$$298$$$300$$$O	neural$$$301$$$307$$$O	cells.$$$308$$$314$$$O
DE102004027685A1
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	composition$$$11$$$22$$$O	useful$$$23$$$29$$$O	e.g.$$$30$$$34$$$O	to$$$35$$$37$$$O	improve$$$38$$$45$$$O	the$$$46$$$49$$$O	symptoms$$$50$$$58$$$O	of$$$59$$$61$$$O	hypersensitive$$$62$$$76$$$O	teeth$$$77$$$82$$$O	or$$$83$$$85$$$O	toothache$$$86$$$95$$$O	comprises$$$96$$$105$$$O	applying$$$106$$$114$$$O	topical$$$115$$$122$$$O	formulation$$$123$$$134$$$O	comprising$$$135$$$145$$$O	sodium-channel$$$146$$$160$$$I	blockers$$$161$$$169$$$O	(e.g.$$$170$$$175$$$O	tetracaine$$$176$$$186$$$I	or$$$187$$$189$$$O	bupivacaine)$$$190$$$202$$$I	and$$$203$$$206$$$O	additives$$$207$$$216$$$O	on$$$217$$$219$$$O	the$$$220$$$223$$$O	tooth$$$224$$$229$$$O	surface$$$230$$$237$$$O
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	composition$$$11$$$22$$$O	(A)$$$23$$$26$$$O	for$$$27$$$30$$$O	topical$$$31$$$38$$$O	treatment$$$39$$$48$$$O	to$$$49$$$51$$$O	improve$$$52$$$59$$$O	the$$$60$$$63$$$O	symptoms$$$64$$$72$$$O	of$$$73$$$75$$$O	hypersensitive$$$76$$$90$$$O	teeth$$$91$$$96$$$O	or$$$97$$$99$$$O	toothache$$$100$$$109$$$O	comprises$$$110$$$119$$$O	applying$$$120$$$128$$$O	(A)$$$129$$$132$$$O	(comprising$$$133$$$144$$$O	a$$$145$$$146$$$O	dosage$$$147$$$153$$$O	of$$$154$$$156$$$O	sodium$$$157$$$163$$$I	channel$$$164$$$171$$$O	blockers$$$172$$$180$$$O	(local$$$181$$$187$$$O	anesthetic$$$188$$$198$$$O	of$$$199$$$201$$$O	ester$$$202$$$207$$$I	or$$$208$$$210$$$O	amide$$$211$$$216$$$I	type)$$$217$$$222$$$O	(B),$$$223$$$227$$$O	which$$$228$$$233$$$O	influences$$$234$$$244$$$O	the$$$245$$$248$$$O	hypersensitive$$$249$$$263$$$O	irritated$$$264$$$273$$$O	terminal$$$274$$$282$$$O	nerves$$$283$$$289$$$O	for$$$290$$$293$$$O	tooth$$$294$$$299$$$O	normalizing)$$$300$$$312$$$O	on$$$313$$$315$$$O	one$$$316$$$319$$$O	or$$$320$$$322$$$O	more$$$323$$$327$$$O	tooth$$$328$$$333$$$O	surface$$$334$$$341$$$O	in$$$342$$$344$$$O	a$$$345$$$346$$$O	mechanical$$$347$$$357$$$O	order.$$$358$$$364$$$O	-$$$365$$$366$$$O	ACTIVITY$$$367$$$375$$$O	:$$$376$$$377$$$O	Analgesic.$$$378$$$388$$$O	-$$$389$$$390$$$O	MECHANISM$$$391$$$400$$$O	OF$$$401$$$403$$$O	ACTION$$$404$$$410$$$O	:$$$411$$$412$$$O	Sodium$$$413$$$419$$$I	channel$$$420$$$427$$$O	blocker.$$$428$$$436$$$O
CN101352503A
Plaster$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	joint$$$21$$$26$$$O	ache$$$27$$$31$$$O	and$$$32$$$35$$$O	preparation$$$36$$$47$$$O	method$$$48$$$54$$$O	thereof$$$55$$$62$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	plaster$$$25$$$32$$$O	for$$$33$$$36$$$O	treating$$$37$$$45$$$O	arthralgia,$$$46$$$57$$$O	which$$$58$$$63$$$O	is$$$64$$$66$$$O	made$$$67$$$71$$$O	from$$$72$$$76$$$O	mulberry$$$77$$$85$$$O	twig,$$$86$$$91$$$O	speranskia$$$92$$$102$$$O	herb,$$$103$$$108$$$O	angelica,$$$109$$$118$$$O	pyrite,$$$119$$$126$$$I	dragons$$$127$$$134$$$O	blood,$$$135$$$141$$$O	myrrh,$$$142$$$148$$$O	hemlock$$$149$$$156$$$O	parsley,$$$157$$$165$$$O	red$$$166$$$169$$$O	peony$$$170$$$175$$$O	root,$$$176$$$181$$$O	safflower,$$$182$$$192$$$O	cyathula$$$193$$$201$$$O	root,$$$202$$$207$$$O	acanthopanax$$$208$$$220$$$O	bark,$$$221$$$226$$$O	grassleaved$$$227$$$238$$$O	sweetflag$$$239$$$248$$$O	rhizome,$$$249$$$257$$$O	atractylodes$$$258$$$270$$$O	rhizome,$$$271$$$279$$$O	aucklandia$$$280$$$290$$$O	root,$$$291$$$296$$$O	large-leaf$$$297$$$307$$$O	gentian$$$308$$$315$$$O	root,$$$316$$$321$$$O	aconite$$$322$$$329$$$O	root,$$$330$$$335$$$O	musk,$$$336$$$341$$$O	frankincense,$$$342$$$355$$$O	dried$$$356$$$361$$$O	body$$$362$$$366$$$O	of$$$367$$$369$$$O	ground$$$370$$$376$$$O	beetle,$$$377$$$384$$$O	dipsacus$$$385$$$393$$$O	root,$$$394$$$399$$$O	pangolin$$$400$$$408$$$O	scale,$$$409$$$415$$$O	scorpion,$$$416$$$425$$$O	earthworm,$$$426$$$436$$$O	long-noded$$$437$$$447$$$O	pit$$$448$$$451$$$O	viper,$$$452$$$458$$$O	buck$$$459$$$463$$$O	grass,$$$464$$$470$$$O	cibot$$$471$$$476$$$O	rhizome$$$477$$$484$$$O	and$$$485$$$488$$$O	rhizoma$$$489$$$496$$$O	drynariae$$$497$$$506$$$O	serving$$$507$$$514$$$O	as$$$515$$$517$$$O	bulk$$$518$$$522$$$O	drugs.$$$523$$$529$$$O	The$$$530$$$533$$$O	plaster$$$534$$$541$$$O	has$$$542$$$545$$$O	a$$$546$$$547$$$O	proper$$$548$$$554$$$O	compatibility$$$555$$$568$$$O	of$$$569$$$571$$$O	all$$$572$$$575$$$O	bulk$$$576$$$580$$$O	drugs,$$$581$$$587$$$O	achieves$$$588$$$596$$$O	the$$$597$$$600$$$O	efficacies$$$601$$$611$$$O	of$$$612$$$614$$$O	expelling$$$615$$$624$$$O	wind$$$625$$$629$$$O	and$$$630$$$633$$$O	removing$$$634$$$642$$$O	dampness,$$$643$$$652$$$O	eliminating$$$653$$$664$$$O	cold,$$$665$$$670$$$O	reducing$$$671$$$679$$$O	swelling,$$$680$$$689$$$O	regulating$$$690$$$700$$$O	the$$$701$$$704$$$O	meridians,$$$705$$$715$$$O	promoting$$$716$$$725$$$O	blood$$$726$$$731$$$O	flow,$$$732$$$737$$$O	eliminating$$$738$$$749$$$O	stasis,$$$750$$$757$$$O	relieving$$$758$$$767$$$O	pain$$$768$$$772$$$O	as$$$773$$$775$$$O	well$$$776$$$780$$$O	as$$$781$$$783$$$O	strengthening$$$784$$$797$$$O	the$$$798$$$801$$$O	muscles$$$802$$$809$$$O	and$$$810$$$813$$$O	bones.$$$814$$$820$$$O	The$$$821$$$824$$$O	plaster$$$825$$$832$$$O	can$$$833$$$836$$$O	treat$$$837$$$842$$$O	pain$$$843$$$847$$$O	caused$$$848$$$854$$$O	by$$$855$$$857$$$O	rheumatism,$$$858$$$869$$$O	rheumatoid$$$870$$$880$$$O	disease$$$881$$$888$$$O	and$$$889$$$892$$$O	osteoarthropathy,$$$893$$$910$$$O	and$$$911$$$914$$$O	further$$$915$$$922$$$O	treat$$$923$$$928$$$O	pain$$$929$$$933$$$O	in$$$934$$$936$$$O	shoulder,$$$937$$$946$$$O	neck,$$$947$$$952$$$O	waist$$$953$$$958$$$O	and$$$959$$$962$$$O	leg$$$963$$$966$$$O	caused$$$967$$$973$$$O	by$$$974$$$976$$$O	hyperosteogeny,$$$977$$$992$$$O	bony$$$993$$$997$$$O	spur$$$998$$$1002$$$O	and$$$1003$$$1006$$$O	lumbar$$$1007$$$1013$$$O	disc$$$1014$$$1018$$$O	protrusion.$$$1019$$$1030$$$O	The$$$1031$$$1034$$$O	plaster$$$1035$$$1042$$$O	has$$$1043$$$1046$$$O	simple$$$1047$$$1053$$$O	preparation$$$1054$$$1065$$$O	process.$$$1066$$$1074$$$O
US20090176886
Polymorphic$$$0$$$11$$$O	Forms$$$12$$$17$$$O	of$$$18$$$20$$$O	Oseltamivir$$$21$$$32$$$I	Phosphate$$$33$$$42$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	polymorphic$$$33$$$44$$$O	forms$$$45$$$50$$$O	of$$$51$$$53$$$O	(3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic$$$54$$$132$$$I	acid$$$133$$$137$$$I	ethyl$$$138$$$143$$$I	ester$$$144$$$149$$$I	phosphate,$$$150$$$160$$$I	which$$$161$$$166$$$O	is$$$167$$$169$$$O	a$$$170$$$171$$$O	potent$$$172$$$178$$$O	inhibitor$$$179$$$188$$$O	of$$$189$$$191$$$O	viral$$$192$$$197$$$O	neuraminidase.$$$198$$$212$$$O
CN102085192A
Rosuvastatin$$$0$$$12$$$I	calcium$$$13$$$20$$$I	oral$$$21$$$25$$$O	disintegrating$$$26$$$40$$$O	tablet$$$41$$$47$$$O	and$$$48$$$51$$$O	preparation$$$52$$$63$$$O	method$$$64$$$70$$$O	thereof$$$71$$$78$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	rosuvastatin$$$25$$$37$$$O	calcium$$$38$$$45$$$O	oral$$$46$$$50$$$O	disintegrating$$$51$$$65$$$O	tablet$$$66$$$72$$$O	and$$$73$$$76$$$O	a$$$77$$$78$$$O	preparation$$$79$$$90$$$O	method$$$91$$$97$$$O	thereof.$$$98$$$106$$$O	The$$$107$$$110$$$O	rosuvastatin$$$111$$$123$$$I	calcium$$$124$$$131$$$I	oral$$$132$$$136$$$O	disintegrating$$$137$$$151$$$O	tablet$$$152$$$158$$$O	contains$$$159$$$167$$$O	a$$$168$$$169$$$O	main$$$170$$$174$$$O	constituent$$$175$$$186$$$O	of$$$187$$$189$$$O	rosuvastatin$$$190$$$202$$$I	calcium$$$203$$$210$$$I	and$$$211$$$214$$$O	auxiliary$$$215$$$224$$$O	constituents$$$225$$$237$$$O	of$$$238$$$240$$$O	a$$$241$$$242$$$O	disintegrating$$$243$$$257$$$O	agent,$$$258$$$264$$$O	filler,$$$265$$$272$$$O	a$$$273$$$274$$$O	flavoring$$$275$$$284$$$O	agent$$$285$$$290$$$O	and$$$291$$$294$$$O	the$$$295$$$298$$$O	like.$$$299$$$304$$$O	The$$$305$$$308$$$O	rosuvastatin$$$309$$$321$$$I	calcium$$$322$$$329$$$I	is$$$330$$$332$$$O	clinically$$$333$$$343$$$O	used$$$344$$$348$$$O	for$$$349$$$352$$$O	treating$$$353$$$361$$$O	primary$$$362$$$369$$$O	hypercholesterolemia,$$$370$$$391$$$O	and$$$392$$$395$$$O	the$$$396$$$399$$$O	clinical$$$400$$$408$$$O	patients$$$409$$$417$$$O	are$$$418$$$421$$$O	mostly$$$422$$$428$$$O	old-age$$$429$$$436$$$O	people.$$$437$$$444$$$O	The$$$445$$$448$$$O	oral$$$449$$$453$$$O	disintegrating$$$454$$$468$$$O	tablet$$$469$$$475$$$O	has$$$476$$$479$$$O	the$$$480$$$483$$$O	advantages$$$484$$$494$$$O	of$$$495$$$497$$$O	being$$$498$$$503$$$O	disintegrated$$$504$$$517$$$O	or$$$518$$$520$$$O	dissolved$$$521$$$530$$$O	in$$$531$$$533$$$O	the$$$534$$$537$$$O	oral$$$538$$$542$$$O	cavity$$$543$$$549$$$O	without$$$550$$$557$$$O	water,$$$558$$$564$$$O	entering$$$565$$$573$$$O	the$$$574$$$577$$$O	digestive$$$578$$$587$$$O	tract$$$588$$$593$$$O	along$$$594$$$599$$$O	with$$$600$$$604$$$O	a$$$605$$$606$$$O	deglutition$$$607$$$618$$$O	action$$$619$$$625$$$O	and$$$626$$$629$$$O	having$$$630$$$636$$$O	consistent$$$637$$$647$$$O	in-vivo$$$648$$$655$$$O	behaviors$$$656$$$665$$$O	with$$$666$$$670$$$O	common$$$671$$$677$$$O	tablets,$$$678$$$686$$$O	has$$$687$$$690$$$O	the$$$691$$$694$$$O	characteristics$$$695$$$710$$$O	of$$$711$$$713$$$O	convenience$$$714$$$725$$$O	for$$$726$$$729$$$O	taking,$$$730$$$737$$$O	rapidness$$$738$$$747$$$O	in$$$748$$$750$$$O	absorption,$$$751$$$762$$$O	high$$$763$$$767$$$O	bioavailability$$$768$$$783$$$O	and$$$784$$$787$$$O	the$$$788$$$791$$$O	like,$$$792$$$797$$$O	and$$$798$$$801$$$O	is$$$802$$$804$$$O	particularly$$$805$$$817$$$O	suitable$$$818$$$826$$$O	for$$$827$$$830$$$O	the$$$831$$$834$$$O	old-age$$$835$$$842$$$O	people.$$$843$$$850$$$O
WO2009131947A2
Compounds,$$$0$$$10$$$O	compositions$$$11$$$23$$$O	and$$$24$$$27$$$O	methods$$$28$$$35$$$O	comprising$$$36$$$46$$$O	pyridazine$$$47$$$57$$$I	derivatives$$$58$$$69$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compositions$$$33$$$45$$$O	and$$$46$$$49$$$O	methods$$$50$$$57$$$O	for$$$58$$$61$$$O	treating$$$62$$$70$$$O	a$$$71$$$72$$$O	disease$$$73$$$80$$$O	in$$$81$$$83$$$O	an$$$84$$$86$$$O	animal,$$$87$$$94$$$O	which$$$95$$$100$$$O	disease$$$101$$$108$$$O	is$$$109$$$111$$$O	responsive$$$112$$$122$$$O	to$$$123$$$125$$$O	inhibiting$$$126$$$136$$$O	of$$$137$$$139$$$O	functional$$$140$$$150$$$O	cystic$$$151$$$157$$$O	fibrosis$$$158$$$166$$$O	transmembrane$$$167$$$180$$$O	conductance$$$181$$$192$$$O	regulator$$$193$$$202$$$O	(CFTR)$$$203$$$209$$$O	polypeptide$$$210$$$221$$$O	by$$$222$$$224$$$O	administering$$$225$$$238$$$O	to$$$239$$$241$$$O	a$$$242$$$243$$$O	mammal$$$244$$$250$$$O	in$$$251$$$253$$$O	need$$$254$$$258$$$O	thereof$$$259$$$266$$$O	an$$$267$$$269$$$O	effective$$$270$$$279$$$O	amount$$$280$$$286$$$O	of$$$287$$$289$$$O	a$$$290$$$291$$$O	compound$$$292$$$300$$$O	defined$$$301$$$308$$$O	herein$$$309$$$315$$$O	(including$$$316$$$326$$$O	those$$$327$$$332$$$O	compounds$$$333$$$342$$$O	set$$$343$$$346$$$O	forth$$$347$$$352$$$O	in$$$353$$$355$$$O	Table$$$356$$$361$$$O	1$$$362$$$363$$$O	or$$$364$$$366$$$O	encompassed$$$367$$$378$$$O	by$$$379$$$381$$$O	formula$$$382$$$389$$$O	I)$$$390$$$392$$$O	or$$$393$$$395$$$O	compositions$$$396$$$408$$$O	thereof,$$$409$$$417$$$O	thereby$$$418$$$425$$$O	treating$$$426$$$434$$$O	the$$$435$$$438$$$O	disease.$$$439$$$447$$$O	The$$$449$$$452$$$O	present$$$453$$$460$$$O	invention$$$461$$$470$$$O	particularly,$$$471$$$484$$$O	relates$$$485$$$492$$$O	to$$$493$$$495$$$O	a$$$496$$$497$$$O	method$$$498$$$504$$$O	of$$$505$$$507$$$O	treating$$$508$$$516$$$O	diarrhea$$$517$$$525$$$O	and$$$526$$$529$$$O	polycystic$$$530$$$540$$$O	kidney$$$541$$$547$$$O	disease.$$$548$$$556$$$O
CN101606907A
Fotemustine$$$0$$$11$$$I	solid$$$12$$$17$$$O	lipid$$$18$$$23$$$O	nanoparticle$$$24$$$36$$$O	and$$$37$$$40$$$O	preparation$$$41$$$52$$$O	method$$$53$$$59$$$O	thereof$$$60$$$67$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	fotemustine$$$25$$$36$$$I	solid$$$37$$$42$$$O	lipid$$$43$$$48$$$O	nanoparticle$$$49$$$61$$$O	for$$$62$$$65$$$O	injection$$$66$$$75$$$O	and$$$76$$$79$$$O	oral$$$80$$$84$$$O	administration.$$$85$$$100$$$O	The$$$101$$$104$$$O	nanoparticle$$$105$$$117$$$O	is$$$118$$$120$$$O	characterized$$$121$$$134$$$O	in$$$135$$$137$$$O	that$$$138$$$142$$$O	a$$$143$$$144$$$O	lipid$$$145$$$150$$$O	material$$$151$$$159$$$O	and$$$160$$$163$$$O	an$$$164$$$166$$$O	emulsifier$$$167$$$177$$$O	are$$$178$$$181$$$O	used$$$182$$$186$$$O	to$$$187$$$189$$$O	encapsulate$$$190$$$201$$$O	the$$$202$$$205$$$O	fotemustine$$$206$$$217$$$I	to$$$218$$$220$$$O	prepare$$$221$$$228$$$O	the$$$229$$$232$$$O	fotemustine$$$233$$$244$$$I	solid$$$245$$$250$$$O	lipid$$$251$$$256$$$O	nanoparticle$$$257$$$269$$$O	with$$$270$$$274$$$O	small$$$275$$$280$$$O	particle$$$281$$$289$$$O	diameter,$$$290$$$299$$$O	high$$$300$$$304$$$O	encapsulation$$$305$$$318$$$O	rate,$$$319$$$324$$$O	good$$$325$$$329$$$O	stability$$$330$$$339$$$O	and$$$340$$$343$$$O	low$$$344$$$347$$$O	toxicity.$$$348$$$357$$$O	The$$$358$$$361$$$O	prepared$$$362$$$370$$$O	fotemustine$$$371$$$382$$$I	solid$$$383$$$388$$$O	lipid$$$389$$$394$$$O	nanoparticle$$$395$$$407$$$O	improves$$$408$$$416$$$O	the$$$417$$$420$$$O	solubility$$$421$$$431$$$O	and$$$432$$$435$$$O	the$$$436$$$439$$$O	stability$$$440$$$449$$$O	of$$$450$$$452$$$O	the$$$453$$$456$$$O	fotemustine,$$$457$$$469$$$I	reduces$$$470$$$477$$$O	vascular$$$478$$$486$$$O	stimulation$$$487$$$498$$$O	of$$$499$$$501$$$O	the$$$502$$$505$$$O	fotemustine,$$$506$$$518$$$I	and$$$519$$$522$$$O	prolongs$$$523$$$531$$$O	the$$$532$$$535$$$O	circulating$$$536$$$547$$$O	time$$$548$$$552$$$O	of$$$553$$$555$$$O	the$$$556$$$559$$$O	medicament$$$560$$$570$$$O	in$$$571$$$573$$$O	blood,$$$574$$$580$$$O	thereby$$$581$$$588$$$O	improving$$$589$$$598$$$O	the$$$599$$$602$$$O	curative$$$603$$$611$$$O	effect$$$612$$$618$$$O	of$$$619$$$621$$$O	medicaments,$$$622$$$634$$$O	and$$$635$$$638$$$O	ensuring$$$639$$$647$$$O	that$$$648$$$652$$$O	preparations$$$653$$$665$$$O	made$$$666$$$670$$$O	of$$$671$$$673$$$O	the$$$674$$$677$$$O	solid$$$678$$$683$$$O	lipid$$$684$$$689$$$O	nanoparticle$$$690$$$702$$$O	have$$$703$$$707$$$O	the$$$708$$$711$$$O	characteristics$$$712$$$727$$$O	of$$$728$$$730$$$O	low$$$731$$$734$$$O	toxicity,$$$735$$$744$$$O	low$$$745$$$748$$$O	fotemustine$$$749$$$760$$$I	solid$$$761$$$766$$$O	lipid$$$767$$$772$$$O	nanoparticle$$$773$$$785$$$O	with$$$786$$$790$$$O	low$$$791$$$794$$$O	stimulation$$$795$$$806$$$O	and$$$807$$$810$$$O	high$$$811$$$815$$$O	efficiency.$$$816$$$827$$$O	The$$$828$$$831$$$O	invention$$$832$$$841$$$O	also$$$842$$$846$$$O	relates$$$847$$$854$$$O	to$$$855$$$857$$$O	a$$$858$$$859$$$O	method$$$860$$$866$$$O	for$$$867$$$870$$$O	preparing$$$871$$$880$$$O	the$$$881$$$884$$$O	fotemustine$$$885$$$896$$$I	solid$$$897$$$902$$$O	lipid$$$903$$$908$$$O	nanoparticle,$$$909$$$922$$$O	which$$$923$$$928$$$O	has$$$929$$$932$$$O	simple$$$933$$$939$$$O	preparation$$$940$$$951$$$O	process$$$952$$$959$$$O	and$$$960$$$963$$$O	low$$$964$$$967$$$O	cost,$$$968$$$973$$$O	and$$$974$$$977$$$O	is$$$978$$$980$$$O	applicable$$$981$$$991$$$O	to$$$992$$$994$$$O	industrial$$$995$$$1005$$$O	production.$$$1006$$$1017$$$O
US8778990
Betulinic$$$0$$$9$$$I	acid$$$10$$$14$$$I	derivatives$$$15$$$26$$$O	and$$$27$$$30$$$O	methods$$$31$$$38$$$O	of$$$39$$$41$$$O	use$$$42$$$45$$$O	thereof$$$46$$$53$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	features$$$15$$$23$$$O	betulinic$$$24$$$33$$$I	acid$$$34$$$38$$$I	derivatives$$$39$$$50$$$O	having$$$51$$$57$$$O	the$$$58$$$61$$$O	formula:$$$62$$$70$$$O	wherein$$$71$$$78$$$O	the$$$79$$$82$$$O	variables$$$83$$$92$$$O	are$$$93$$$96$$$O	defined$$$97$$$104$$$O	herein.$$$105$$$112$$$O	The$$$113$$$116$$$O	invention$$$117$$$126$$$O	also$$$127$$$131$$$O	provides$$$132$$$140$$$O	related$$$141$$$148$$$O	compounds$$$149$$$158$$$O	and$$$159$$$162$$$O	intermediates$$$163$$$176$$$O	thereof,$$$177$$$185$$$O	as$$$186$$$188$$$O	well$$$189$$$193$$$O	as$$$194$$$196$$$O	pharmaceutical$$$197$$$211$$$O	compositions,$$$212$$$225$$$O	kits,$$$226$$$231$$$O	and$$$232$$$235$$$O	articles$$$236$$$244$$$O	of$$$245$$$247$$$O	manufacture$$$248$$$259$$$O	comprising$$$260$$$270$$$O	such$$$271$$$275$$$O	compounds.$$$276$$$286$$$O	Treatment$$$287$$$296$$$O	methods$$$297$$$304$$$O	and$$$305$$$308$$$O	methods$$$309$$$316$$$O	of$$$317$$$319$$$O	manufacture$$$320$$$331$$$O	are$$$332$$$335$$$O	also$$$336$$$340$$$O	provided.$$$341$$$350$$$O
WO2006005844A1
Pressurized$$$0$$$11$$$O	foaming$$$12$$$19$$$O	composition$$$20$$$31$$$O	for$$$32$$$35$$$O	topical$$$36$$$43$$$O	treatment$$$44$$$53$$$O	of$$$54$$$56$$$O	psoriasis$$$57$$$66$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	a$$$23$$$24$$$O	stable$$$25$$$31$$$O	foaming$$$32$$$39$$$O	pharmaceutical$$$40$$$54$$$O	composition$$$55$$$66$$$O	for$$$67$$$70$$$O	topical$$$71$$$78$$$O	use$$$79$$$82$$$O	for$$$83$$$86$$$O	treating$$$87$$$95$$$O	psoriasis,$$$96$$$106$$$O	comprising$$$107$$$117$$$O	a$$$118$$$119$$$O	hydrophilic$$$120$$$131$$$O	phase,$$$132$$$138$$$O	at$$$139$$$141$$$O	least$$$142$$$147$$$O	one$$$148$$$151$$$O	hydrophobic$$$152$$$163$$$O	phase,$$$164$$$170$$$O	a$$$171$$$172$$$O	surfactant,$$$173$$$184$$$O	and$$$185$$$188$$$O	as$$$189$$$191$$$O	active$$$192$$$198$$$O	principle$$$199$$$208$$$O	a$$$209$$$210$$$O	combination$$$211$$$222$$$O	of$$$223$$$225$$$O	vitamin$$$226$$$233$$$I	D$$$234$$$235$$$I	analogue$$$236$$$244$$$O	and$$$245$$$248$$$O	corticosteroid$$$249$$$263$$$I	and$$$264$$$267$$$O	at$$$268$$$270$$$O	least$$$271$$$276$$$O	one$$$277$$$280$$$O	propellant$$$281$$$291$$$O	gas.$$$292$$$296$$$O
CN102232920A
Breviscapine$$$0$$$12$$$I	ethosome$$$13$$$21$$$O	gel$$$22$$$25$$$O	preparation$$$26$$$37$$$O	and$$$38$$$41$$$O	preparation$$$42$$$53$$$O	method$$$54$$$60$$$O	thereof$$$61$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	breviscapine$$$27$$$39$$$I	ethosome$$$40$$$48$$$O	gel$$$49$$$52$$$O	preparation$$$53$$$64$$$O	and$$$65$$$68$$$O	a$$$69$$$70$$$O	preparation$$$71$$$82$$$O	method$$$83$$$89$$$O	thereof,$$$90$$$98$$$O	belonging$$$99$$$108$$$O	to$$$109$$$111$$$O	the$$$112$$$115$$$O	technical$$$116$$$125$$$O	field$$$126$$$131$$$O	of$$$132$$$134$$$O	medicine.$$$135$$$144$$$O	The$$$145$$$148$$$O	breviscapine$$$149$$$161$$$I	ethosome$$$162$$$170$$$O	gel$$$171$$$174$$$O	preparation$$$175$$$186$$$O	disclosed$$$187$$$196$$$O	by$$$197$$$199$$$O	the$$$200$$$203$$$O	invention$$$204$$$213$$$O	is$$$214$$$216$$$O	composed$$$217$$$225$$$O	of$$$226$$$228$$$O	breviscapine$$$229$$$241$$$I	ethosome$$$242$$$250$$$O	(A),$$$251$$$255$$$O	a$$$256$$$257$$$O	penetration$$$258$$$269$$$O	enhancer$$$270$$$278$$$O	(B)$$$279$$$282$$$O	and$$$283$$$286$$$O	a$$$287$$$288$$$O	gel$$$289$$$292$$$O	substrate,$$$293$$$303$$$O	and$$$304$$$307$$$O	can$$$308$$$311$$$O	be$$$312$$$314$$$O	used$$$315$$$319$$$O	for$$$320$$$323$$$O	transdermal$$$324$$$335$$$O	administration.$$$336$$$351$$$O	The$$$352$$$355$$$O	breviscapine$$$356$$$368$$$I	ethosome$$$369$$$377$$$O	gel$$$378$$$381$$$O	preparation$$$382$$$393$$$O	uses$$$394$$$398$$$O	a$$$399$$$400$$$O	novel$$$401$$$406$$$O	ethosome$$$407$$$415$$$O	administration$$$416$$$430$$$O	carrier,$$$431$$$439$$$O	obviously$$$440$$$449$$$O	improves$$$450$$$458$$$O	the$$$459$$$462$$$O	transdermal$$$463$$$474$$$O	penetrating$$$475$$$486$$$O	quality$$$487$$$494$$$O	of$$$495$$$497$$$O	the$$$498$$$501$$$O	breviscapine,$$$502$$$515$$$I	controls$$$516$$$524$$$O	the$$$525$$$528$$$O	drug$$$529$$$533$$$O	release,$$$534$$$542$$$O	improves$$$543$$$551$$$O	the$$$552$$$555$$$O	compliance$$$556$$$566$$$O	of$$$567$$$569$$$O	patients$$$570$$$578$$$O	and$$$579$$$582$$$O	also$$$583$$$587$$$O	reduces$$$588$$$595$$$O	the$$$596$$$599$$$O	administration$$$600$$$614$$$O	frequency$$$615$$$624$$$O	and$$$625$$$628$$$O	administration$$$629$$$643$$$O	dosage.$$$644$$$651$$$O
US20110301111
Cyclic$$$0$$$6$$$I	adenosine$$$7$$$16$$$I	monophosphates$$$17$$$31$$$I	for$$$32$$$35$$$O	reducing$$$36$$$44$$$O	the$$$45$$$48$$$O	formation$$$49$$$58$$$O	of$$$59$$$61$$$O	adhesions$$$62$$$71$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	methods$$$20$$$27$$$O	of$$$28$$$30$$$O	reducing$$$31$$$39$$$O	adhesion$$$40$$$48$$$O	formation$$$49$$$58$$$O	in$$$59$$$61$$$O	a$$$62$$$63$$$O	subject,$$$64$$$72$$$O	for$$$73$$$76$$$O	example,$$$77$$$85$$$O	post-surgical$$$86$$$99$$$O	abdominal$$$100$$$109$$$O	and$$$110$$$113$$$O	pelvic$$$114$$$120$$$O	adhesions.$$$121$$$131$$$O	The$$$132$$$135$$$O	methods$$$136$$$143$$$O	comprise$$$144$$$152$$$O	administering$$$153$$$166$$$O	to$$$167$$$169$$$O	the$$$170$$$173$$$O	subject$$$174$$$181$$$O	a$$$182$$$183$$$O	compound$$$184$$$192$$$O	chosen$$$193$$$199$$$O	from$$$200$$$204$$$O	one$$$205$$$208$$$O	or$$$209$$$211$$$O	both$$$212$$$216$$$O	of$$$217$$$219$$$O	2â²,3â²$$$220$$$229$$$I	cyclic$$$230$$$236$$$I	adenosine$$$237$$$246$$$I	monophosphate,$$$247$$$261$$$I	or$$$262$$$264$$$O	an$$$265$$$267$$$O	analogue$$$268$$$276$$$O	or$$$277$$$279$$$O	pharmaceutically$$$280$$$296$$$O	acceptable$$$297$$$307$$$O	salt$$$308$$$312$$$O	thereof,$$$313$$$321$$$O	able$$$322$$$326$$$O	to$$$327$$$329$$$O	reduce$$$330$$$336$$$O	the$$$337$$$340$$$O	formation$$$341$$$350$$$O	of$$$351$$$353$$$O	adhesions$$$354$$$363$$$O	in$$$364$$$366$$$O	a$$$367$$$368$$$O	subject$$$369$$$376$$$O	as$$$377$$$379$$$O	compared$$$380$$$388$$$I	to$$$389$$$391$$$I	adenosine$$$392$$$401$$$I	monophosphate,$$$402$$$416$$$I	wherein$$$417$$$424$$$O	the$$$425$$$428$$$I	2â²,3â²$$$429$$$438$$$I	cyclic$$$439$$$445$$$I	adenosine$$$446$$$455$$$I	monophosphate,$$$456$$$470$$$I	or$$$471$$$473$$$O	analogue$$$474$$$482$$$O	or$$$483$$$485$$$O	pharmaceutically$$$486$$$502$$$O	acceptable$$$503$$$513$$$O	salt$$$514$$$518$$$O	thereof,$$$519$$$527$$$O	is$$$528$$$530$$$O	administered$$$531$$$543$$$O	to$$$544$$$546$$$O	the$$$547$$$550$$$O	subject$$$551$$$558$$$O	in$$$559$$$561$$$O	an$$$562$$$564$$$O	amount$$$565$$$571$$$O	effective$$$572$$$581$$$O	to$$$582$$$584$$$O	reduce$$$585$$$591$$$O	adhesions$$$592$$$601$$$O	in$$$602$$$604$$$O	the$$$605$$$608$$$O	subject.$$$609$$$617$$$O
WO2009016855A1
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	preventing$$$10$$$20$$$O	hair$$$21$$$25$$$O	loss$$$26$$$30$$$O	and$$$31$$$34$$$O	method$$$35$$$41$$$O	of$$$42$$$44$$$O	preventing$$$45$$$55$$$O	hair$$$56$$$60$$$O	depigmentation$$$61$$$75$$$O
It$$$0$$$2$$$O	is$$$3$$$5$$$O	intended$$$6$$$14$$$O	to$$$15$$$17$$$O	provide$$$18$$$25$$$O	a$$$26$$$27$$$O	hair$$$28$$$32$$$O	loss-preventing$$$33$$$48$$$O	agent$$$49$$$54$$$O	and$$$55$$$58$$$O	a$$$59$$$60$$$O	hair$$$61$$$65$$$O	depigmentation-preventing$$$66$$$91$$$O	agent.$$$92$$$98$$$O	Hair$$$99$$$103$$$O	loss$$$104$$$108$$$O	or$$$109$$$111$$$O	hair$$$112$$$116$$$O	depigmentation$$$117$$$131$$$O	can$$$132$$$135$$$O	be$$$136$$$138$$$O	prevented$$$139$$$148$$$O	by$$$149$$$151$$$O	type$$$152$$$156$$$O	XVII$$$157$$$161$$$O	collagen.$$$162$$$171$$$O
CN102049051A
Medicinal$$$0$$$9$$$O	composition$$$10$$$21$$$O	for$$$22$$$25$$$O	stabilizing$$$26$$$37$$$O	pholcodine$$$38$$$48$$$I	granules$$$49$$$57$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicinal$$$26$$$35$$$O	composition$$$36$$$47$$$O	for$$$48$$$51$$$O	stabilizing$$$52$$$63$$$O	pholcodine$$$64$$$74$$$I	granules,$$$75$$$84$$$O	which$$$85$$$90$$$O	consists$$$91$$$99$$$O	of$$$100$$$102$$$O	pholcodine$$$103$$$113$$$I	serving$$$114$$$121$$$O	as$$$122$$$124$$$O	an$$$125$$$127$$$O	active$$$128$$$134$$$O	ingredient,$$$135$$$146$$$O	a$$$147$$$148$$$O	stabilizing$$$149$$$160$$$O	agent$$$161$$$166$$$O	and$$$167$$$170$$$O	a$$$171$$$172$$$O	pharmaceutically-acceptable$$$173$$$200$$$O	soluble$$$201$$$208$$$O	auxiliary$$$209$$$218$$$O	material$$$219$$$227$$$O	in$$$228$$$230$$$O	a$$$231$$$232$$$O	weight$$$233$$$239$$$O	ratio$$$240$$$245$$$O	of$$$246$$$248$$$O	1:0.01-1:15-50,$$$249$$$264$$$O	preferably$$$265$$$275$$$O	1:0.05-0.2:15-30.$$$276$$$293$$$O	The$$$294$$$297$$$O	medicinal$$$298$$$307$$$O	composition$$$308$$$319$$$O	solves$$$320$$$326$$$O	the$$$327$$$330$$$O	problem$$$331$$$338$$$O	of$$$339$$$341$$$O	unstable$$$342$$$350$$$O	phenomenon$$$351$$$361$$$O	of$$$362$$$364$$$O	brown$$$365$$$370$$$O	agglomeration$$$371$$$384$$$O	formed$$$385$$$391$$$O	by$$$392$$$394$$$O	a$$$395$$$396$$$O	chemical$$$397$$$405$$$O	pickup$$$406$$$412$$$O	reaction$$$413$$$421$$$O	of$$$422$$$424$$$O	the$$$425$$$428$$$O	pholcodine$$$429$$$439$$$I	and$$$440$$$443$$$O	monosaccharide$$$444$$$458$$$I	or$$$459$$$461$$$O	polysaccharide$$$462$$$476$$$O	and$$$477$$$480$$$O	even$$$481$$$485$$$O	lactose$$$486$$$493$$$I	which$$$494$$$499$$$O	is$$$500$$$502$$$O	mixed$$$503$$$508$$$O	with$$$509$$$513$$$O	the$$$514$$$517$$$O	pholcodine.$$$518$$$529$$$I	In$$$530$$$532$$$O	addition$$$533$$$541$$$O	the$$$542$$$545$$$O	operation$$$546$$$555$$$O	is$$$556$$$558$$$O	simple$$$559$$$565$$$O	and$$$566$$$569$$$O	convenient,$$$570$$$581$$$O	and$$$582$$$585$$$O	the$$$586$$$589$$$O	cost$$$590$$$594$$$O	is$$$595$$$597$$$O	saved,$$$598$$$604$$$O	so$$$605$$$607$$$O	the$$$608$$$611$$$O	medicinal$$$612$$$621$$$O	composition$$$622$$$633$$$O	is$$$634$$$636$$$O	suitable$$$637$$$645$$$O	for$$$646$$$649$$$O	large-scale$$$650$$$661$$$O	industrial$$$662$$$672$$$O	production.$$$673$$$684$$$O
US20120045522
Synergistic$$$0$$$11$$$O	fungicidal$$$12$$$22$$$O	and$$$23$$$26$$$O	algicidal$$$27$$$36$$$O	compositions$$$37$$$49$$$O	including$$$50$$$59$$$O	7-hydroxy-indanone$$$60$$$78$$$I	benzoylhydrazones$$$79$$$96$$$I	and$$$97$$$100$$$O	copper$$$101$$$107$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	mixtures$$$44$$$52$$$O	containing$$$53$$$63$$$O	7-hydroxy-indanone$$$64$$$82$$$I	benzoylhydrazone$$$83$$$99$$$I	compounds$$$100$$$109$$$O	and$$$110$$$113$$$O	copper$$$114$$$120$$$O	for$$$121$$$124$$$O	controlling$$$125$$$136$$$O	the$$$137$$$140$$$O	growth$$$141$$$147$$$O	of$$$148$$$150$$$O	fungi$$$151$$$156$$$O	and$$$157$$$160$$$O	algae.$$$161$$$167$$$O
US20130072499
PIPERAZINE$$$0$$$10$$$I	DERIVATIVES$$$11$$$22$$$O	FOR$$$23$$$26$$$O	BLOCKING$$$27$$$35$$$O	Cav2.2$$$36$$$42$$$O	CALCIUM$$$43$$$50$$$I	CHANNELS$$$51$$$59$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	piperazine$$$39$$$49$$$I	compounds;$$$50$$$60$$$O	to$$$61$$$63$$$O	pharmaceutical$$$64$$$78$$$O	compositions$$$79$$$91$$$O	containing$$$92$$$102$$$O	the$$$103$$$106$$$O	compounds;$$$107$$$117$$$O	and$$$118$$$121$$$O	to$$$122$$$124$$$O	the$$$125$$$128$$$O	use$$$129$$$132$$$O	of$$$133$$$135$$$O	the$$$136$$$139$$$O	compounds$$$140$$$149$$$O	in$$$150$$$152$$$O	therapy$$$153$$$160$$$O	to$$$161$$$163$$$O	treat$$$164$$$169$$$O	diseases$$$170$$$178$$$O	for$$$179$$$182$$$O	which$$$183$$$188$$$O	blocking$$$189$$$197$$$O	the$$$198$$$201$$$O	Cav2.2$$$202$$$208$$$O	calcium$$$209$$$216$$$I	channels$$$217$$$225$$$O	is$$$226$$$228$$$O	beneficial$$$229$$$239$$$O	and$$$240$$$243$$$O	to$$$244$$$246$$$O	treat$$$247$$$252$$$O	diseases$$$253$$$261$$$O	for$$$262$$$265$$$O	which$$$266$$$271$$$O	blocking$$$272$$$280$$$O	the$$$281$$$284$$$O	Cav2.2$$$285$$$291$$$O	and$$$292$$$295$$$O	Cav3.2$$$296$$$302$$$O	calcium$$$303$$$310$$$I	channels$$$311$$$319$$$O	is$$$320$$$322$$$O	beneficial,$$$323$$$334$$$O	e.g.$$$335$$$339$$$O	to$$$340$$$342$$$O	treat$$$343$$$348$$$O	pain.$$$349$$$354$$$O
US20110250297
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	Hyperproliferative$$$13$$$31$$$O	Disorders$$$32$$$41$$$O	Using$$$42$$$47$$$O	Cardiac$$$48$$$55$$$O	Glycosides$$$56$$$66$$$I
Provided$$$0$$$8$$$O	are$$$9$$$12$$$O	methods$$$13$$$20$$$O	and$$$21$$$24$$$O	compositions$$$25$$$37$$$O	for$$$38$$$41$$$O	treating$$$42$$$50$$$O	and$$$51$$$54$$$O	preventing$$$55$$$65$$$O	hyperproliferative$$$66$$$84$$$O	disorders$$$85$$$94$$$O	such$$$95$$$99$$$O	as$$$100$$$102$$$O	psoriasis$$$103$$$112$$$O	by$$$113$$$115$$$O	administration$$$116$$$130$$$O	of$$$131$$$133$$$O	a$$$134$$$135$$$O	cardiac$$$136$$$143$$$O	glycoside$$$144$$$153$$$I	alone$$$154$$$159$$$O	or$$$160$$$162$$$O	in$$$163$$$165$$$O	combination$$$166$$$177$$$O	locally$$$178$$$185$$$O	or$$$186$$$188$$$O	systemically$$$189$$$201$$$O	with$$$202$$$206$$$O	a$$$207$$$208$$$O	calciotropic$$$209$$$221$$$O	agents$$$222$$$228$$$O	and/or$$$229$$$235$$$O	a$$$236$$$237$$$O	diffusion-limiting$$$238$$$256$$$O	component,$$$257$$$267$$$O	such$$$268$$$272$$$O	a$$$273$$$274$$$O	vasoconstrictor$$$275$$$290$$$O	or$$$291$$$293$$$O	collagen$$$294$$$302$$$O	barrier.$$$303$$$311$$$O
WO2007033137A1
5-oxo-5,8-dihydro-pyrido-pyrimidines$$$0$$$36$$$I	as$$$37$$$39$$$O	inhibitors$$$40$$$50$$$O	of$$$51$$$53$$$O	c-fms$$$54$$$59$$$O	kinase$$$60$$$66$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	addresses$$$14$$$23$$$O	the$$$24$$$27$$$O	current$$$28$$$35$$$O	need$$$36$$$40$$$O	for$$$41$$$44$$$O	selective$$$45$$$54$$$O	and$$$55$$$58$$$O	potent$$$59$$$65$$$O	protein$$$66$$$73$$$O	tyrosine$$$74$$$82$$$I	kinase$$$83$$$89$$$O	inhibitors$$$90$$$100$$$O	by$$$101$$$103$$$O	providing$$$104$$$113$$$O	potent$$$114$$$120$$$O	inhibitors$$$121$$$131$$$O	of$$$132$$$134$$$O	c-fms$$$135$$$140$$$O	kinase.$$$141$$$148$$$O	The$$$149$$$152$$$O	invention$$$153$$$162$$$O	is$$$163$$$165$$$O	directed$$$166$$$174$$$O	to$$$175$$$177$$$O	the$$$178$$$181$$$O	novel$$$182$$$187$$$O	compounds$$$188$$$197$$$O	of$$$198$$$200$$$O	Formula$$$201$$$208$$$O	I:$$$209$$$211$$$O	or$$$212$$$214$$$O	a$$$215$$$216$$$O	solvate,$$$217$$$225$$$O	hydrate,$$$226$$$234$$$O	tautomer$$$235$$$243$$$O	or$$$244$$$246$$$O	pharmaceutically$$$247$$$263$$$O	acceptable$$$264$$$274$$$O	salt$$$275$$$279$$$O	thereof,$$$280$$$288$$$O	wherein:W,$$$289$$$299$$$O	A,$$$300$$$302$$$O	Y,$$$303$$$305$$$O	n,$$$306$$$308$$$O	Z,$$$309$$$311$$$O	and$$$312$$$315$$$O	R102$$$316$$$320$$$O	are$$$321$$$324$$$O	described$$$325$$$334$$$O	in$$$335$$$337$$$O	the$$$338$$$341$$$O	specification.$$$342$$$356$$$O
US20090062270
Spiro$$$0$$$5$$$I	2,4$$$6$$$9$$$I	pyrimidinediamine$$$10$$$27$$$I	compounds$$$28$$$37$$$O	and$$$38$$$41$$$O	their$$$42$$$47$$$O	uses$$$48$$$52$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	of$$$39$$$41$$$O	treating$$$42$$$50$$$O	or$$$51$$$53$$$O	preventing$$$54$$$64$$$O	autoimmune$$$65$$$75$$$O	diseases$$$76$$$84$$$O	with$$$85$$$89$$$O	spiro$$$90$$$95$$$I	2,4-pyrimidinediamine$$$96$$$117$$$I	compounds,$$$118$$$128$$$O	as$$$129$$$131$$$O	well$$$132$$$136$$$O	as$$$137$$$139$$$O	methods$$$140$$$147$$$O	of$$$148$$$150$$$O	treating,$$$151$$$160$$$O	preventing$$$161$$$171$$$O	or$$$172$$$174$$$O	ameliorating$$$175$$$187$$$O	symptoms$$$188$$$196$$$O	associated$$$197$$$207$$$O	with$$$208$$$212$$$O	such$$$213$$$217$$$O	diseases.$$$218$$$227$$$O	Specific$$$228$$$236$$$O	examples$$$237$$$245$$$O	of$$$246$$$248$$$O	autoimmune$$$249$$$259$$$O	diseases$$$260$$$268$$$O	that$$$269$$$273$$$O	can$$$274$$$277$$$O	be$$$278$$$280$$$O	treated$$$281$$$288$$$O	or$$$289$$$291$$$O	prevented$$$292$$$301$$$O	with$$$302$$$306$$$O	the$$$307$$$310$$$O	compounds$$$311$$$320$$$O	include$$$321$$$328$$$O	rheumatoid$$$329$$$339$$$O	arthritis$$$340$$$349$$$O	and/or$$$350$$$356$$$O	its$$$357$$$360$$$O	associated$$$361$$$371$$$O	symptoms,$$$372$$$381$$$O	systemic$$$382$$$390$$$O	lupus$$$391$$$396$$$O	erythematosis$$$397$$$410$$$O	and/or$$$411$$$417$$$O	its$$$418$$$421$$$O	associated$$$422$$$432$$$O	symptoms$$$433$$$441$$$O	and$$$442$$$445$$$O	multiple$$$446$$$454$$$O	sclerosis$$$455$$$464$$$O	and/or$$$465$$$471$$$O	its$$$472$$$475$$$O	associated$$$476$$$486$$$O	symptoms.$$$487$$$496$$$O
US20080125387
Administering$$$0$$$13$$$O	vector$$$14$$$20$$$O	system$$$21$$$27$$$O	that$$$28$$$32$$$O	directs$$$33$$$40$$$O	regulated$$$41$$$50$$$O	erythropoietin$$$51$$$65$$$O	(Epo)$$$66$$$71$$$O	gene$$$72$$$76$$$O	therapy$$$77$$$84$$$O	in$$$85$$$87$$$O	a$$$88$$$89$$$O	manner$$$90$$$96$$$O	that$$$97$$$101$$$O	physiologically$$$102$$$117$$$O	corrects$$$118$$$126$$$O	the$$$127$$$130$$$O	hematocrit$$$131$$$141$$$O	levels$$$142$$$148$$$O	in$$$149$$$151$$$O	a$$$152$$$153$$$O	patient$$$154$$$161$$$O	in$$$162$$$164$$$O	need$$$165$$$169$$$O	of$$$170$$$172$$$O	anemia$$$173$$$179$$$O	treatment$$$180$$$189$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	viral$$$15$$$20$$$O	vector$$$21$$$27$$$O	containing$$$28$$$38$$$O	a$$$39$$$40$$$O	nucleic$$$41$$$48$$$O	acid$$$49$$$53$$$O	sequence$$$54$$$62$$$O	encoding$$$63$$$71$$$O	erythropoietin$$$72$$$86$$$O	(Epo),$$$87$$$93$$$O	in$$$94$$$96$$$O	operable$$$97$$$105$$$O	linkage$$$106$$$113$$$O	with$$$114$$$118$$$O	an$$$119$$$121$$$O	HRE$$$122$$$125$$$O	expression$$$126$$$136$$$O	control$$$137$$$144$$$O	sequence,$$$145$$$154$$$O	as$$$155$$$157$$$O	well$$$158$$$162$$$O	as$$$163$$$165$$$O	uses$$$166$$$170$$$O	of$$$171$$$173$$$O	the$$$174$$$177$$$O	vector;$$$178$$$185$$$O	for$$$186$$$189$$$O	instance,$$$190$$$199$$$O	in$$$200$$$202$$$O	preparing$$$203$$$212$$$O	a$$$213$$$214$$$O	medicament.$$$215$$$226$$$O	Also$$$227$$$231$$$O	provided$$$232$$$240$$$O	are$$$241$$$244$$$O	methods$$$245$$$252$$$O	for$$$253$$$256$$$O	treating$$$257$$$265$$$O	anemia,$$$266$$$273$$$O	can$$$274$$$277$$$O	involve$$$278$$$285$$$O	administering$$$286$$$299$$$O	the$$$300$$$303$$$O	vector$$$304$$$310$$$O	to$$$311$$$313$$$O	a$$$314$$$315$$$O	patient,$$$316$$$324$$$O	wherein$$$325$$$332$$$O	expression$$$333$$$343$$$O	of$$$344$$$346$$$O	Epo$$$347$$$350$$$O	is$$$351$$$353$$$O	physiologically$$$354$$$369$$$O	regulated$$$370$$$379$$$O	such$$$380$$$384$$$O	that$$$385$$$389$$$O	hematocrit$$$390$$$400$$$O	levels$$$401$$$407$$$O	of$$$408$$$410$$$O	the$$$411$$$414$$$O	patient$$$415$$$422$$$O	are$$$423$$$426$$$O	corrected$$$427$$$436$$$O	and$$$437$$$440$$$O	maintained.$$$441$$$452$$$O
CN1923177A
Chlorhydric$$$0$$$11$$$I	acid$$$12$$$16$$$I	tranditerol$$$17$$$28$$$I	aerosol$$$29$$$36$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	Tranditerol$$$25$$$36$$$I	Hydrochloride$$$37$$$50$$$I	aerosol,$$$51$$$59$$$O	which$$$60$$$65$$$O	comprises$$$66$$$75$$$O	(by$$$76$$$79$$$O	weight$$$80$$$86$$$O	ratio)$$$87$$$93$$$O	Tranditerol$$$94$$$105$$$I	Hydrochloride$$$106$$$119$$$I	0.005-0.01$$$120$$$130$$$O	part,$$$131$$$136$$$O	double$$$137$$$143$$$O	solvent$$$144$$$151$$$O	5-10$$$152$$$156$$$O	parts,$$$157$$$163$$$O	and$$$164$$$167$$$O	propellant$$$168$$$178$$$O	90-95$$$179$$$184$$$O	parts.$$$185$$$191$$$O
WO2007052013A1
A$$$0$$$1$$$O	combination$$$2$$$13$$$O	of$$$14$$$16$$$O	cannabinoids$$$17$$$29$$$I	for$$$30$$$33$$$O	the$$$34$$$37$$$O	treatment$$$38$$$47$$$O	of$$$48$$$50$$$O	peripheral$$$51$$$61$$$O	neurophatic$$$62$$$73$$$O	pain$$$74$$$78$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	a$$$44$$$45$$$O	combination$$$46$$$57$$$O	of$$$58$$$60$$$O	cannabinoids$$$61$$$73$$$I	in$$$74$$$76$$$O	the$$$77$$$80$$$O	treatment$$$81$$$90$$$O	of$$$91$$$93$$$O	neuropathic$$$94$$$105$$$O	pain,$$$106$$$111$$$O	in$$$112$$$114$$$O	particular$$$115$$$125$$$O	peripheral$$$126$$$136$$$O	neuropathic$$$137$$$148$$$O	pain.$$$149$$$154$$$O	A$$$155$$$156$$$O	combination$$$157$$$168$$$O	of$$$169$$$171$$$O	cannabidiol$$$172$$$183$$$I	(CBD)$$$184$$$189$$$I	and$$$190$$$193$$$O	delta-9-tetrahydrocannabinol$$$194$$$222$$$I	(THC)$$$223$$$228$$$I	may$$$229$$$232$$$O	be$$$233$$$235$$$O	used,$$$236$$$241$$$O	wherein$$$242$$$249$$$O	the$$$250$$$253$$$O	ratio$$$254$$$259$$$O	of$$$260$$$262$$$O	CBD:THC$$$263$$$270$$$I	by$$$271$$$273$$$O	weight$$$274$$$280$$$O	is$$$281$$$283$$$O	between$$$284$$$291$$$O	10:1$$$292$$$296$$$O	and$$$297$$$300$$$O	1:10.$$$301$$$306$$$O
EP1694335A4
Osteoclastogenesis$$$0$$$18$$$O	inhibitors$$$19$$$29$$$O	and$$$30$$$33$$$O	uses$$$34$$$38$$$O	thereof$$$39$$$46$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	method$$$33$$$39$$$O	of$$$40$$$42$$$O	reducing$$$43$$$51$$$O	or$$$52$$$54$$$O	inhibiting$$$55$$$65$$$O	osteoclast$$$66$$$76$$$O	development$$$77$$$88$$$O	Induced$$$89$$$96$$$O	by$$$97$$$99$$$O	the$$$100$$$103$$$O	receptor$$$104$$$112$$$O	for$$$113$$$116$$$O	activation$$$117$$$127$$$O	of$$$128$$$130$$$O	nuclear$$$131$$$138$$$O	factor$$$139$$$145$$$O	kappa$$$146$$$151$$$O	B$$$152$$$153$$$O	ligand$$$154$$$160$$$O	(RANKL),$$$161$$$169$$$O	comprising$$$170$$$180$$$O	the$$$181$$$184$$$O	step$$$185$$$189$$$O	of$$$190$$$192$$$O	contacting$$$193$$$203$$$O	said$$$204$$$208$$$O	osteoclast,$$$209$$$220$$$O	or$$$221$$$223$$$O	a$$$224$$$225$$$O	precursor$$$226$$$235$$$O	of$$$236$$$238$$$O	the$$$239$$$242$$$O	osteoclast,$$$243$$$254$$$O	with$$$255$$$259$$$O	a$$$260$$$261$$$O	pharmacologically$$$262$$$279$$$O	effective$$$280$$$289$$$O	dose$$$290$$$294$$$O	of$$$295$$$297$$$O	compounds$$$298$$$307$$$O	such$$$308$$$312$$$O	as$$$313$$$315$$$O	diferuloylmethane,$$$316$$$334$$$I	guggulsterone,$$$335$$$349$$$I	1'Â­-Acetoxychavicol$$$350$$$370$$$I	or$$$371$$$373$$$O	analogues$$$374$$$383$$$O	thereof.$$$384$$$392$$$O
CN101095658A
Policresulen$$$0$$$12$$$I	gelling$$$13$$$20$$$O	agent,$$$21$$$27$$$O	method$$$28$$$34$$$O	for$$$35$$$38$$$O	preparation$$$39$$$50$$$O	the$$$51$$$54$$$O	same$$$55$$$59$$$O	and$$$60$$$63$$$O	the$$$64$$$67$$$O	pharmaceutical$$$68$$$82$$$O	use$$$83$$$86$$$O	thereof$$$87$$$94$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	policresulen$$$27$$$39$$$I	gel$$$40$$$43$$$O	product,$$$44$$$52$$$O	which$$$53$$$58$$$O	comprises$$$59$$$68$$$O	policresulen$$$69$$$81$$$I	solution$$$82$$$90$$$O	with$$$91$$$95$$$O	its$$$96$$$99$$$O	concentration$$$100$$$113$$$O	being$$$114$$$119$$$O	45-55%$$$120$$$126$$$O	and$$$127$$$130$$$O	proportion$$$131$$$141$$$O	being$$$142$$$147$$$O	2.0-6.0%,$$$148$$$157$$$O	sodium$$$158$$$164$$$O	carboxymethyl$$$165$$$178$$$O	cellulose$$$179$$$188$$$O	(CMC-Na)with$$$189$$$201$$$O	proportion$$$202$$$212$$$O	being$$$213$$$218$$$O	2.0-6.0%$$$219$$$227$$$O	and$$$228$$$231$$$O	glycerin$$$232$$$240$$$I	with$$$241$$$245$$$O	proportion$$$246$$$256$$$O	being$$$257$$$262$$$O	10-15%.$$$263$$$270$$$O	The$$$271$$$274$$$O	invention$$$275$$$284$$$O	also$$$285$$$289$$$O	provides$$$290$$$298$$$O	a$$$299$$$300$$$O	method$$$301$$$307$$$O	for$$$308$$$311$$$O	preparing$$$312$$$321$$$O	said$$$322$$$326$$$O	gel$$$327$$$330$$$O	product,$$$331$$$339$$$O	which$$$340$$$345$$$O	comprises$$$346$$$355$$$O	steps$$$356$$$361$$$O	of$$$362$$$364$$$O	adding$$$365$$$371$$$O	CMC-Na$$$372$$$378$$$O	into$$$379$$$383$$$O	hot$$$384$$$387$$$O	purified$$$388$$$396$$$O	water$$$397$$$402$$$O	for$$$403$$$406$$$O	swelling$$$407$$$415$$$O	for$$$416$$$419$$$O	12$$$420$$$422$$$O	hours,$$$423$$$429$$$O	adding$$$430$$$436$$$O	glycerin$$$437$$$445$$$I	and$$$446$$$449$$$O	stirring$$$450$$$458$$$O	evenly,$$$459$$$466$$$O	adding$$$467$$$473$$$O	policresulen$$$474$$$486$$$I	into$$$487$$$491$$$O	CMC-Na$$$492$$$498$$$O	solution,$$$499$$$508$$$O	or$$$509$$$511$$$O	adding$$$512$$$518$$$O	some$$$519$$$523$$$O	preservative$$$524$$$536$$$O	agent,$$$537$$$543$$$O	stirring$$$544$$$552$$$O	and$$$553$$$556$$$O	adding$$$557$$$563$$$O	more$$$564$$$568$$$O	purified$$$569$$$577$$$O	water,$$$578$$$584$$$O	and$$$585$$$588$$$O	getting$$$589$$$596$$$O	policresulen$$$597$$$609$$$I	gel$$$610$$$613$$$O	product.$$$614$$$622$$$O	The$$$623$$$626$$$O	gel$$$627$$$630$$$O	product$$$631$$$638$$$O	is$$$639$$$641$$$O	characterized$$$642$$$655$$$O	by$$$656$$$658$$$O	stable$$$659$$$665$$$O	property,$$$666$$$675$$$O	strong$$$676$$$682$$$O	adhesive$$$683$$$691$$$O	ability$$$692$$$699$$$O	to$$$700$$$702$$$O	mucosa$$$703$$$709$$$O	and$$$710$$$713$$$O	good$$$714$$$718$$$O	skin$$$719$$$723$$$O	accidental$$$724$$$734$$$O	union$$$735$$$740$$$O	effect,$$$741$$$748$$$O	prolonged$$$749$$$758$$$O	retention$$$759$$$768$$$O	time$$$769$$$773$$$O	for$$$774$$$777$$$O	policresulen$$$778$$$790$$$I	in$$$791$$$793$$$O	vaginal$$$794$$$801$$$O	and$$$802$$$805$$$O	improved$$$806$$$814$$$O	medicine$$$815$$$823$$$O	absorption,$$$824$$$835$$$O	increased$$$836$$$845$$$O	biological$$$846$$$856$$$O	utilization$$$857$$$868$$$O	rate$$$869$$$873$$$O	and$$$874$$$877$$$O	curative$$$878$$$886$$$O	effect,$$$887$$$894$$$O	favor$$$895$$$900$$$O	for$$$901$$$904$$$O	water$$$905$$$910$$$O	soluble$$$911$$$918$$$O	medicine$$$919$$$927$$$O	release,$$$928$$$936$$$O	and$$$937$$$940$$$O	clinical$$$941$$$949$$$O	practicability.$$$950$$$965$$$O
CN103638008A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Artoxanthochromane$$$15$$$33$$$I	in$$$34$$$36$$$O	skin$$$37$$$41$$$O	cancer$$$42$$$48$$$O	treatment$$$49$$$58$$$O	drugs$$$59$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	application$$$27$$$38$$$O	of$$$39$$$41$$$O	Artoxanthochromane$$$42$$$60$$$I	in$$$61$$$63$$$O	preparation$$$64$$$75$$$O	of$$$76$$$78$$$O	skin$$$79$$$83$$$O	cancer$$$84$$$90$$$O	treatment$$$91$$$100$$$O	drugs,$$$101$$$107$$$O	belonging$$$108$$$117$$$O	to$$$118$$$120$$$O	the$$$121$$$124$$$O	technical$$$125$$$134$$$O	field$$$135$$$140$$$O	of$$$141$$$143$$$O	a$$$144$$$145$$$O	new$$$146$$$149$$$O	application$$$150$$$161$$$O	of$$$162$$$164$$$O	drugs.$$$165$$$171$$$O	According$$$172$$$181$$$O	to$$$182$$$184$$$O	in-vitro$$$185$$$193$$$O	MTT$$$194$$$197$$$O	antitumor$$$198$$$207$$$O	activity$$$208$$$216$$$O	evaluation,$$$217$$$228$$$O	the$$$229$$$232$$$O	Artoxanthochromane$$$233$$$251$$$I	has$$$252$$$255$$$O	a$$$256$$$257$$$O	remarkable$$$258$$$268$$$O	inhibitory$$$269$$$279$$$O	effect$$$280$$$286$$$O	on$$$287$$$289$$$O	the$$$290$$$293$$$O	growth$$$294$$$300$$$O	of$$$301$$$303$$$O	human$$$304$$$309$$$O	skin$$$310$$$314$$$O	cancer$$$315$$$321$$$O	cell$$$322$$$326$$$O	strains$$$327$$$334$$$O	A431,$$$335$$$340$$$O	HME1,$$$341$$$346$$$O	A375$$$347$$$351$$$O	and$$$352$$$355$$$O	SK23.$$$356$$$361$$$O	Therefore,$$$362$$$372$$$O	the$$$373$$$376$$$O	Artoxanthochromane$$$377$$$395$$$I	can$$$396$$$399$$$O	be$$$400$$$402$$$O	used$$$403$$$407$$$O	for$$$408$$$411$$$O	preparing$$$412$$$421$$$O	anti-skin$$$422$$$431$$$O	cancer$$$432$$$438$$$O	drugs$$$439$$$444$$$O	and$$$445$$$448$$$O	has$$$449$$$452$$$O	a$$$453$$$454$$$O	good$$$455$$$459$$$O	prospect$$$460$$$468$$$O	in$$$469$$$471$$$O	development$$$472$$$483$$$O	and$$$484$$$487$$$O	application.$$$488$$$500$$$O	The$$$501$$$504$$$O	application$$$505$$$516$$$O	of$$$517$$$519$$$O	Artoxanthochromane$$$520$$$538$$$I	in$$$539$$$541$$$O	preparation$$$542$$$553$$$O	of$$$554$$$556$$$O	skin$$$557$$$561$$$O	cancer$$$562$$$568$$$O	treatment$$$569$$$578$$$O	drugs$$$579$$$584$$$O	is$$$585$$$587$$$O	disclosed$$$588$$$597$$$O	for$$$598$$$601$$$O	the$$$602$$$605$$$O	first$$$606$$$611$$$O	time;$$$612$$$617$$$O	the$$$618$$$621$$$O	Artoxanthochromane$$$622$$$640$$$I	has$$$641$$$644$$$O	strong$$$645$$$651$$$O	inhibitory$$$652$$$662$$$O	activity$$$663$$$671$$$O	on$$$672$$$674$$$O	the$$$675$$$678$$$O	skin$$$679$$$683$$$O	cancer$$$684$$$690$$$O	cells,$$$691$$$697$$$O	and$$$698$$$701$$$O	a$$$702$$$703$$$O	remarkable$$$704$$$714$$$O	progress$$$715$$$723$$$O	is$$$724$$$726$$$O	realized.$$$727$$$736$$$O
EP1996180B1
Benzamide$$$0$$$9$$$I	and$$$10$$$13$$$O	pyridylamide$$$14$$$26$$$I	derivatives$$$27$$$38$$$O	as$$$39$$$41$$$O	antibacterial$$$42$$$55$$$O	agents$$$56$$$62$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I)$$$21$$$24$$$O	have$$$25$$$29$$$O	antibacterial$$$30$$$43$$$O	activity$$$44$$$52$$$O	wherein$$$53$$$60$$$O	R$$$61$$$62$$$O	represents$$$63$$$73$$$O	hydrogen$$$74$$$82$$$I	or$$$83$$$85$$$O	1,$$$86$$$88$$$O	2$$$89$$$90$$$O	or$$$91$$$93$$$O	3$$$94$$$95$$$O	optional$$$96$$$104$$$O	substituents;$$$105$$$118$$$O	W$$$119$$$120$$$O	is$$$121$$$123$$$O	=C(R1)-$$$124$$$131$$$I	or$$$132$$$134$$$O	=N-;$$$135$$$139$$$I	R1$$$140$$$142$$$O	is$$$143$$$145$$$O	hydrogen$$$146$$$154$$$I	or$$$155$$$157$$$O	an$$$158$$$160$$$O	optional$$$161$$$169$$$O	substituent$$$170$$$181$$$O	and$$$182$$$185$$$O	R2$$$186$$$188$$$O	is$$$189$$$191$$$O	hydrogen,$$$192$$$201$$$I	methyl,$$$202$$$209$$$I	or$$$210$$$212$$$O	fluorine;$$$213$$$222$$$I	or$$$223$$$225$$$O	R1$$$226$$$228$$$O	and$$$229$$$232$$$O	R2$$$233$$$235$$$O	taken$$$236$$$241$$$O	together$$$242$$$250$$$O	are$$$251$$$254$$$O	-CH2-,$$$255$$$261$$$I	-CH2CH2-,$$$262$$$271$$$I	-O-,$$$272$$$276$$$I	or,$$$277$$$280$$$O	in$$$281$$$283$$$O	either$$$284$$$290$$$O	orientation,$$$291$$$303$$$O	-O-$$$304$$$307$$$I	CH2-$$$308$$$312$$$I	Or$$$313$$$315$$$O	-OCH2CH2-;$$$316$$$326$$$I	R3$$$327$$$329$$$O	is$$$330$$$332$$$O	a$$$333$$$334$$$O	radical$$$335$$$342$$$O	of$$$343$$$345$$$O	formula$$$346$$$353$$$O	-(Alk1)m-(Z)p-(Alk2)n-Q$$$354$$$377$$$I	wherein$$$378$$$385$$$O	m,$$$386$$$388$$$O	p$$$389$$$390$$$O	and$$$391$$$394$$$O	n$$$395$$$396$$$O	are$$$397$$$400$$$O	independently$$$401$$$414$$$O	0$$$415$$$416$$$O	or$$$417$$$419$$$O	1,$$$420$$$422$$$O	provided$$$423$$$431$$$O	that$$$432$$$436$$$O	at$$$437$$$439$$$O	least$$$440$$$445$$$O	one$$$446$$$449$$$O	of$$$450$$$452$$$O	m,$$$453$$$455$$$O	p$$$456$$$457$$$O	and$$$458$$$461$$$O	n$$$462$$$463$$$O	is$$$464$$$466$$$O	1,$$$467$$$469$$$O	Z$$$470$$$471$$$O	is$$$472$$$474$$$O	-O-,$$$475$$$479$$$I	-S-,$$$480$$$484$$$I	-S(O)-,$$$485$$$492$$$I	-S(O2)-,$$$493$$$501$$$I	-NH-,$$$502$$$507$$$I	-N(CH3)-,$$$508$$$517$$$I	-N(CH2CH3)-,$$$518$$$530$$$I	-C(=O)-,$$$531$$$539$$$I	-O-(C=O)-,$$$540$$$550$$$I	-C(=O)-O-,$$$551$$$561$$$I	or$$$562$$$564$$$O	an$$$565$$$567$$$O	optionally$$$568$$$578$$$O	substituted$$$579$$$590$$$O	divalent$$$591$$$599$$$O	monocyclic$$$600$$$610$$$I	carbocyclic$$$611$$$622$$$I	or$$$623$$$625$$$O	heterocyclic$$$626$$$638$$$I	radical$$$639$$$646$$$O	having$$$647$$$653$$$O	3$$$654$$$655$$$O	to$$$656$$$658$$$O	6$$$659$$$660$$$O	ring$$$661$$$665$$$O	atoms;$$$666$$$672$$$O	or$$$673$$$675$$$O	an$$$676$$$678$$$O	optionally$$$679$$$689$$$O	substituted$$$690$$$701$$$O	divalent$$$702$$$710$$$O	bicyclic$$$711$$$719$$$I	heterocyclic$$$720$$$732$$$I	radical$$$733$$$740$$$O	having$$$741$$$747$$$O	5$$$748$$$749$$$O	to$$$750$$$752$$$O	10$$$753$$$755$$$O	ring$$$756$$$760$$$O	atoms;$$$761$$$767$$$O	Alk1$$$768$$$772$$$O	and$$$773$$$776$$$O	Alk2$$$777$$$781$$$O	are$$$782$$$785$$$O	optionally$$$786$$$796$$$O	substituted$$$797$$$808$$$O	C1C6$$$809$$$813$$$I	alkylene,$$$814$$$823$$$I	C2-C6$$$824$$$829$$$I	alkenylene,$$$830$$$841$$$I	or$$$842$$$844$$$O	C2-C6$$$845$$$850$$$I	alkynylene$$$851$$$861$$$I	radicals,$$$862$$$871$$$O	which$$$872$$$877$$$O	may$$$878$$$881$$$O	optionally$$$882$$$892$$$O	terminate$$$893$$$902$$$O	with$$$903$$$907$$$O	or$$$908$$$910$$$O	be$$$911$$$913$$$O	interrupted$$$914$$$925$$$O	by$$$926$$$928$$$O	-O-,$$$929$$$933$$$I	-S-,$$$934$$$938$$$I	-S(O)-,$$$939$$$946$$$I	-S(O2)-,$$$947$$$955$$$I	-NH-,$$$956$$$961$$$I	-N(CH3)-,$$$962$$$971$$$I	or$$$972$$$974$$$O	-N(CH2CH3)-;$$$975$$$987$$$I	and$$$988$$$991$$$O	Q$$$992$$$993$$$O	is$$$994$$$996$$$O	hydrogen,$$$997$$$1006$$$I	halogen,$$$1007$$$1015$$$I	nitrile,$$$1016$$$1024$$$I	or$$$1025$$$1027$$$O	hydroxyl$$$1028$$$1036$$$I	or$$$1037$$$1039$$$O	an$$$1040$$$1042$$$O	optionally$$$1043$$$1053$$$O	substituted$$$1054$$$1065$$$O	monocyclic$$$1066$$$1076$$$I	carbocyclic$$$1077$$$1088$$$I	or$$$1089$$$1091$$$O	heterocyclic$$$1092$$$1104$$$I	radical$$$1105$$$1112$$$O	having$$$1113$$$1119$$$O	3$$$1120$$$1121$$$O	to$$$1122$$$1124$$$O	6$$$1125$$$1126$$$O	ring$$$1127$$$1131$$$O	atoms;$$$1132$$$1138$$$O	or$$$1139$$$1141$$$O	an$$$1142$$$1144$$$O	optionally$$$1145$$$1155$$$O	substituted$$$1156$$$1167$$$O	bicyclic$$$1168$$$1176$$$I	heterocyclic$$$1177$$$1189$$$I	radical$$$1190$$$1197$$$O	having$$$1198$$$1204$$$O	5$$$1205$$$1206$$$O	to$$$1207$$$1209$$$O	10$$$1210$$$1212$$$O	ring$$$1213$$$1217$$$O	atoms.$$$1218$$$1224$$$O
CN1989952A
Acne$$$0$$$4$$$O	lotion$$$5$$$11$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	lotion$$$27$$$33$$$O	for$$$34$$$37$$$O	dispelling$$$38$$$48$$$O	acne,$$$49$$$54$$$O	wherein$$$55$$$62$$$O	the$$$63$$$66$$$O	lotion$$$67$$$73$$$O	is$$$74$$$76$$$O	prepared$$$77$$$85$$$O	mainly$$$86$$$92$$$O	from$$$93$$$97$$$O	dimethyl$$$98$$$106$$$I	carbinol,$$$107$$$116$$$I	distilled$$$117$$$126$$$O	water,$$$127$$$133$$$O	glycerin,$$$134$$$143$$$I	triethanolamine$$$144$$$159$$$I	and$$$160$$$163$$$O	ethanol$$$164$$$171$$$I	through$$$172$$$179$$$O	specific$$$180$$$188$$$O	processes.$$$189$$$199$$$O	The$$$200$$$203$$$O	medicament$$$204$$$214$$$O	provided$$$215$$$223$$$O	by$$$224$$$226$$$O	the$$$227$$$230$$$O	invention$$$231$$$240$$$O	has$$$241$$$244$$$O	good$$$245$$$249$$$O	treatment$$$250$$$259$$$O	action$$$260$$$266$$$O	for$$$267$$$270$$$O	acne$$$271$$$275$$$O	with$$$276$$$280$$$O	simple$$$281$$$287$$$O	process$$$288$$$295$$$O	of$$$296$$$298$$$O	production$$$299$$$309$$$O	and$$$310$$$313$$$O	method$$$314$$$320$$$O	of$$$321$$$323$$$O	use.$$$324$$$328$$$O
CN102824630A
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	for$$$27$$$30$$$O	treating$$$31$$$39$$$O	chicken$$$40$$$47$$$O	proventriculitis$$$48$$$64$$$O	and$$$65$$$68$$$O	preparation$$$69$$$80$$$O	method$$$81$$$87$$$O	of$$$88$$$90$$$O	pharmaceutical$$$91$$$105$$$O	composition$$$106$$$117$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	pharmaceutical$$$26$$$40$$$O	composition$$$41$$$52$$$O	for$$$53$$$56$$$O	treating$$$57$$$65$$$O	chicken$$$66$$$73$$$O	proventriculitis$$$74$$$90$$$O	and$$$91$$$94$$$O	a$$$95$$$96$$$O	preparation$$$97$$$108$$$O	method$$$109$$$115$$$O	of$$$116$$$118$$$O	the$$$119$$$122$$$O	pharmaceutical$$$123$$$137$$$O	composition.$$$138$$$150$$$O	The$$$151$$$154$$$O	pharmaceutical$$$155$$$169$$$O	composition$$$170$$$181$$$O	comprises$$$182$$$191$$$O	pharmacodynamic$$$192$$$207$$$O	raw$$$208$$$211$$$O	materials$$$212$$$221$$$O	in$$$222$$$224$$$O	weight$$$225$$$231$$$O	ratio:$$$232$$$238$$$O	5-20$$$239$$$243$$$O	of$$$244$$$246$$$O	pepsase,$$$247$$$255$$$O	20-50$$$256$$$261$$$O	of$$$262$$$264$$$O	vitamin$$$265$$$272$$$I	B1,$$$273$$$276$$$I	60-200$$$277$$$283$$$O	of$$$284$$$286$$$O	astragalus$$$287$$$297$$$O	mongholicus,$$$298$$$310$$$O	10-50$$$311$$$316$$$O	of$$$317$$$319$$$O	umbellate$$$320$$$329$$$O	pore$$$330$$$334$$$O	fungus,$$$335$$$342$$$O	100-200$$$343$$$350$$$O	of$$$351$$$353$$$O	processed$$$354$$$363$$$O	bighead$$$364$$$371$$$O	atractylodes$$$372$$$384$$$O	rhizome$$$385$$$392$$$O	and$$$393$$$396$$$O	40-100$$$397$$$403$$$O	of$$$404$$$406$$$O	dried$$$407$$$412$$$O	tangerine$$$413$$$422$$$O	or$$$423$$$425$$$O	orange$$$426$$$432$$$O	peel.$$$433$$$438$$$O	The$$$439$$$442$$$O	preparation$$$443$$$454$$$O	method$$$455$$$461$$$O	comprises$$$462$$$471$$$O	the$$$472$$$475$$$O	following$$$476$$$485$$$O	steps$$$486$$$491$$$O	of:$$$492$$$495$$$O	A,$$$496$$$498$$$O	weighing$$$499$$$507$$$O	each$$$508$$$512$$$O	pharmacodynamic$$$513$$$528$$$O	raw$$$529$$$532$$$O	material;$$$533$$$542$$$O	B,$$$543$$$545$$$O	flatly$$$546$$$552$$$O	paving$$$553$$$559$$$O	the$$$560$$$563$$$O	pepsase$$$564$$$571$$$O	in$$$572$$$574$$$O	water,$$$575$$$581$$$O	adjusting$$$582$$$591$$$O	the$$$592$$$595$$$O	pH$$$596$$$598$$$O	value$$$599$$$604$$$O	to$$$605$$$607$$$O	1-5$$$608$$$611$$$O	by$$$612$$$614$$$O	hydrochloric$$$615$$$627$$$I	acid,$$$628$$$633$$$I	adding$$$634$$$640$$$O	vitamin$$$641$$$648$$$I	B1,$$$649$$$652$$$I	stirring$$$653$$$661$$$O	and$$$662$$$665$$$O	dissolving$$$666$$$676$$$O	for$$$677$$$680$$$O	later$$$681$$$686$$$O	use;$$$687$$$691$$$O	C,$$$692$$$694$$$O	smashing$$$695$$$703$$$O	and$$$704$$$707$$$O	mixing$$$708$$$714$$$O	the$$$715$$$718$$$O	other$$$719$$$724$$$O	medicaments$$$725$$$736$$$O	in$$$737$$$739$$$O	the$$$740$$$743$$$O	prescription$$$744$$$756$$$O	except$$$757$$$763$$$O	the$$$764$$$767$$$O	pepsase$$$768$$$775$$$O	and$$$776$$$779$$$O	the$$$780$$$783$$$O	vitamin$$$784$$$791$$$I	B1,$$$792$$$795$$$I	decocting$$$796$$$805$$$O	in$$$806$$$808$$$O	a$$$809$$$810$$$O	heating$$$811$$$818$$$O	way,$$$819$$$823$$$O	concentrating,$$$824$$$838$$$O	putting,$$$839$$$847$$$O	and$$$848$$$851$$$O	taking$$$852$$$858$$$O	liquid$$$859$$$865$$$O	supernatant;$$$866$$$878$$$O	D,$$$879$$$881$$$O	concentrating$$$882$$$895$$$O	the$$$896$$$899$$$O	liquid$$$900$$$906$$$O	supernatant$$$907$$$918$$$O	to$$$919$$$921$$$O	be$$$922$$$924$$$O	free$$$925$$$929$$$O	from$$$930$$$934$$$O	alcohol$$$935$$$942$$$O	smell,$$$943$$$949$$$O	adjusting$$$950$$$959$$$O	the$$$960$$$963$$$O	pH$$$964$$$966$$$O	value$$$967$$$972$$$O	to$$$973$$$975$$$O	1-5$$$976$$$979$$$O	by$$$980$$$982$$$O	hydrochloric$$$983$$$995$$$I	acid,$$$996$$$1001$$$I	and$$$1002$$$1005$$$O	filtering;$$$1006$$$1016$$$O	and$$$1017$$$1020$$$O	E,$$$1021$$$1023$$$O	evenly$$$1024$$$1030$$$O	mixing$$$1031$$$1037$$$O	the$$$1038$$$1041$$$O	filter$$$1042$$$1048$$$O	liquor$$$1049$$$1055$$$O	obtained$$$1056$$$1064$$$O	by$$$1065$$$1067$$$O	the$$$1068$$$1071$$$O	step$$$1072$$$1076$$$O	D$$$1077$$$1078$$$O	with$$$1079$$$1083$$$O	the$$$1084$$$1087$$$O	solution$$$1088$$$1096$$$O	prepared$$$1097$$$1105$$$O	by$$$1106$$$1108$$$O	the$$$1109$$$1112$$$O	step$$$1113$$$1117$$$O	B,$$$1118$$$1120$$$O	sterilizing,$$$1121$$$1133$$$O	and$$$1134$$$1137$$$O	subpackaging,$$$1138$$$1151$$$O	so$$$1152$$$1154$$$O	that$$$1155$$$1159$$$O	the$$$1160$$$1163$$$O	pharmaceutical$$$1164$$$1178$$$O	composite$$$1179$$$1188$$$O	can$$$1189$$$1192$$$O	be$$$1193$$$1195$$$O	prepared.$$$1196$$$1205$$$O	In$$$1206$$$1208$$$O	combination$$$1209$$$1220$$$O	with$$$1221$$$1225$$$O	the$$$1226$$$1229$$$O	dietary$$$1230$$$1237$$$O	characteristics$$$1238$$$1253$$$O	of$$$1254$$$1256$$$O	poultry,$$$1257$$$1265$$$O	the$$$1266$$$1269$$$O	pharmaceutical$$$1270$$$1284$$$O	composition$$$1285$$$1296$$$O	is$$$1297$$$1299$$$O	optimally$$$1300$$$1309$$$O	designed,$$$1310$$$1319$$$O	not$$$1320$$$1323$$$O	only$$$1324$$$1328$$$O	can$$$1329$$$1332$$$O	make$$$1333$$$1337$$$O	up$$$1338$$$1340$$$O	the$$$1341$$$1344$$$O	defects$$$1345$$$1352$$$O	of$$$1353$$$1355$$$O	the$$$1356$$$1359$$$O	antibiotic$$$1360$$$1370$$$O	therapy,$$$1371$$$1379$$$O	but$$$1380$$$1383$$$O	also$$$1384$$$1388$$$O	has$$$1389$$$1392$$$O	the$$$1393$$$1396$$$O	characteristics$$$1397$$$1412$$$O	of$$$1413$$$1415$$$O	simple$$$1416$$$1422$$$O	prescription$$$1423$$$1435$$$O	and$$$1436$$$1439$$$O	low$$$1440$$$1443$$$O	price,$$$1444$$$1450$$$O	is$$$1451$$$1453$$$O	suitable$$$1454$$$1462$$$O	for$$$1463$$$1466$$$O	the$$$1467$$$1470$$$O	large-scale$$$1471$$$1482$$$O	production,$$$1483$$$1494$$$O	and$$$1495$$$1498$$$O	is$$$1499$$$1501$$$O	good$$$1502$$$1506$$$O	in$$$1507$$$1509$$$O	curative$$$1510$$$1518$$$O	effect.$$$1519$$$1526$$$O
WO2014062658A8
Methylene$$$0$$$9$$$O	linked$$$10$$$16$$$O	quinolinyl$$$17$$$27$$$O	modulators$$$28$$$38$$$O	of$$$39$$$41$$$O	ror-gamma-t$$$42$$$53$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	comprises$$$22$$$31$$$O	compounds$$$32$$$41$$$O	of$$$42$$$44$$$O	Formula$$$45$$$52$$$O	(I),$$$53$$$57$$$O	wherein:$$$58$$$66$$$O	R1,$$$67$$$70$$$O	R2,$$$71$$$74$$$O	R3,$$$75$$$78$$$O	R4,$$$79$$$82$$$O	R5,$$$83$$$86$$$O	R6,$$$87$$$90$$$O	R7,$$$91$$$94$$$O	R8,$$$95$$$98$$$O	and$$$99$$$102$$$O	R9$$$103$$$105$$$O	are$$$106$$$109$$$O	defined$$$110$$$117$$$O	in$$$118$$$120$$$O	the$$$121$$$124$$$O	specification.$$$125$$$139$$$O	The$$$140$$$143$$$O	invention$$$144$$$153$$$O	also$$$154$$$158$$$O	comprises$$$159$$$168$$$O	a$$$169$$$170$$$O	method$$$171$$$177$$$O	of$$$178$$$180$$$O	treating$$$181$$$189$$$O	or$$$190$$$192$$$O	ameliorating$$$193$$$205$$$O	a$$$206$$$207$$$O	syndrome,$$$208$$$217$$$O	disorder$$$218$$$226$$$O	or$$$227$$$229$$$O	disease,$$$230$$$238$$$O	wherein$$$239$$$246$$$O	said$$$247$$$251$$$O	syndrome,$$$252$$$261$$$O	disorder$$$262$$$270$$$O	or$$$271$$$273$$$O	disease$$$274$$$281$$$O	is$$$282$$$284$$$O	rheumatoid$$$285$$$295$$$O	arthritis$$$296$$$305$$$O	or$$$306$$$308$$$O	psoriasis.$$$309$$$319$$$O	The$$$320$$$323$$$O	invention$$$324$$$333$$$O	also$$$334$$$338$$$O	comprises$$$339$$$348$$$O	a$$$349$$$350$$$O	method$$$351$$$357$$$O	of$$$358$$$360$$$O	modulating$$$361$$$371$$$O	RORÎ³t$$$372$$$378$$$O	activity$$$379$$$387$$$O	in$$$388$$$390$$$O	a$$$391$$$392$$$O	mammal$$$393$$$399$$$O	by$$$400$$$402$$$O	administration$$$403$$$417$$$O	of$$$418$$$420$$$O	a$$$421$$$422$$$O	therapeutically$$$423$$$438$$$O	effective$$$439$$$448$$$O	amount$$$449$$$455$$$O	of$$$456$$$458$$$O	at$$$459$$$461$$$O	least$$$462$$$467$$$O	one$$$468$$$471$$$O	compound$$$472$$$480$$$O	of$$$481$$$483$$$O	claim$$$484$$$489$$$O	1.$$$490$$$492$$$O
US20080139535
1-(2-naphthylsulfonyl)-4-(5-hydroxyaminocarbonylthiazol-2-yl)piperazine;$$$0$$$72$$$I	antiproliferative$$$73$$$90$$$O	agent;$$$91$$$97$$$O	cell$$$98$$$102$$$O	cycle$$$103$$$108$$$O	arrest,$$$109$$$116$$$O	cellular$$$117$$$125$$$O	differentiation,$$$126$$$142$$$O	apoptosis$$$143$$$152$$$O	and$$$153$$$156$$$O	reversal$$$157$$$165$$$O	of$$$166$$$168$$$O	the$$$169$$$172$$$O	transformed$$$173$$$184$$$O	phenotype;$$$185$$$195$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	compounds$$$14$$$23$$$O	which$$$24$$$29$$$O	inhibit$$$30$$$37$$$O	histone$$$38$$$45$$$O	deacetylase$$$46$$$57$$$O	(HDAC)$$$58$$$64$$$O	enzymatic$$$65$$$74$$$O	activity.$$$75$$$84$$$O	Also$$$85$$$89$$$O	disclosed$$$90$$$99$$$O	are$$$100$$$103$$$O	pharmaceutical$$$104$$$118$$$O	compositions$$$119$$$131$$$O	comprising$$$132$$$142$$$O	such$$$143$$$147$$$O	compounds$$$148$$$157$$$O	as$$$158$$$160$$$O	well$$$161$$$165$$$O	as$$$166$$$168$$$O	methods$$$169$$$176$$$O	to$$$177$$$179$$$O	treat$$$180$$$185$$$O	conditions,$$$186$$$197$$$O	particularly$$$198$$$210$$$O	proliferative$$$211$$$224$$$O	conditions,$$$225$$$236$$$O	mediated$$$237$$$245$$$O	at$$$246$$$248$$$O	least$$$249$$$254$$$O	in$$$255$$$257$$$O	part$$$258$$$262$$$O	by$$$263$$$265$$$O	HDAC.$$$266$$$271$$$O
US20110274739
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	governing$$$12$$$21$$$O	tissue$$$22$$$28$$$O	growth$$$29$$$35$$$O
Resorbable$$$0$$$10$$$O	polymer$$$11$$$18$$$O	barrier$$$19$$$26$$$O	membranes$$$27$$$36$$$O	and$$$37$$$40$$$O	methods$$$41$$$48$$$O	of$$$49$$$51$$$O	their$$$52$$$57$$$O	applications$$$58$$$70$$$O	are$$$71$$$74$$$O	disclosed.$$$75$$$85$$$O	In$$$86$$$88$$$O	a$$$89$$$90$$$O	broad$$$91$$$96$$$O	embodiment,$$$97$$$108$$$O	methods$$$109$$$116$$$O	of$$$117$$$119$$$O	governing$$$120$$$129$$$O	tissue$$$130$$$136$$$O	growth,$$$137$$$144$$$O	or$$$145$$$147$$$O	preventing$$$148$$$158$$$O	tissue$$$159$$$165$$$O	growth$$$166$$$172$$$O	into$$$173$$$177$$$O	a$$$178$$$179$$$O	certain$$$180$$$187$$$O	spatial$$$188$$$195$$$O	area,$$$196$$$201$$$O	includes$$$202$$$210$$$O	the$$$211$$$214$$$O	step$$$215$$$219$$$O	of$$$220$$$222$$$O	forming$$$223$$$230$$$O	a$$$231$$$232$$$O	spatial$$$233$$$240$$$O	barrier$$$241$$$248$$$O	with$$$249$$$253$$$O	the$$$254$$$257$$$O	present$$$258$$$265$$$O	resorbable$$$266$$$276$$$O	barrier$$$277$$$284$$$O	membrane.$$$285$$$294$$$O	The$$$295$$$298$$$O	barrier$$$299$$$306$$$O	membrane$$$307$$$315$$$O	separates$$$316$$$325$$$O	a$$$326$$$327$$$O	tissue-growth$$$328$$$341$$$O	area$$$342$$$346$$$O	and$$$347$$$350$$$O	a$$$351$$$352$$$O	non-bone-growth$$$353$$$368$$$O	area,$$$369$$$374$$$O	and$$$375$$$378$$$O	prevents$$$379$$$387$$$O	tissue$$$388$$$394$$$O	from$$$395$$$399$$$O	growing$$$400$$$407$$$O	into$$$408$$$412$$$O	the$$$413$$$416$$$O	non-growth$$$417$$$427$$$O	area.$$$428$$$433$$$O
US20120041007
Cdk$$$0$$$3$$$O	inhibitor$$$4$$$13$$$O	salts$$$14$$$19$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	crystalline$$$39$$$50$$$O	form(s)$$$51$$$58$$$O	of$$$59$$$61$$$O	water-soluble$$$62$$$75$$$O	salts$$$76$$$81$$$O	and$$$82$$$85$$$O	of$$$86$$$88$$$O	free$$$89$$$93$$$O	base$$$94$$$98$$$O	of$$$99$$$101$$$O	a$$$102$$$103$$$O	cdk$$$104$$$107$$$O	inhibitor.$$$108$$$118$$$O	Such$$$119$$$123$$$O	crystal$$$124$$$131$$$O	salts$$$132$$$137$$$O	are$$$138$$$141$$$O	for$$$142$$$145$$$O	example$$$146$$$153$$$O	fumarate,$$$154$$$163$$$I	L-malate,$$$164$$$173$$$I	maleate,$$$174$$$182$$$I	succinate,$$$183$$$193$$$I	adipate,$$$194$$$202$$$I	malonate,$$$203$$$212$$$I	glycolate,$$$213$$$223$$$I	phosphate,$$$224$$$234$$$I	mesylate,$$$235$$$244$$$I	L-lactate,$$$245$$$255$$$I	hydrochloride,$$$256$$$270$$$I	di-hydrochloride,$$$271$$$288$$$I	tri-hydrochloride.$$$289$$$307$$$I	Hydrates$$$308$$$316$$$I	and$$$317$$$320$$$O	polymorphs$$$321$$$331$$$O	of$$$332$$$334$$$O	such$$$335$$$339$$$O	new$$$340$$$343$$$O	salt$$$344$$$348$$$O	forms,$$$349$$$355$$$O	a$$$356$$$357$$$O	process$$$358$$$365$$$O	for$$$366$$$369$$$O	their$$$370$$$375$$$O	preparation,$$$376$$$388$$$O	their$$$389$$$394$$$O	utility$$$395$$$402$$$O	in$$$403$$$405$$$O	therapy$$$406$$$413$$$O	and$$$414$$$417$$$O	to$$$418$$$420$$$O	the$$$421$$$424$$$O	pharmaceutical$$$425$$$439$$$O	compositions$$$440$$$452$$$O	containing$$$453$$$463$$$O	them$$$464$$$468$$$O	are$$$469$$$472$$$O	also$$$473$$$477$$$O	claimed$$$478$$$485$$$O	and$$$486$$$489$$$O	described$$$490$$$499$$$O	in$$$500$$$502$$$O	the$$$503$$$506$$$O	present$$$507$$$514$$$O	application.$$$515$$$527$$$O
CN102172355A
Absorption-promoting$$$0$$$20$$$O	pharmaceutical$$$21$$$35$$$O	composition$$$36$$$47$$$O	ointment$$$48$$$56$$$O	for$$$57$$$60$$$O	treating$$$61$$$69$$$O	skin$$$70$$$74$$$O	diseases$$$75$$$83$$$O	and$$$84$$$87$$$O	preparation$$$88$$$99$$$O	method$$$100$$$106$$$O	thereof$$$107$$$114$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	of$$$45$$$47$$$O	a$$$48$$$49$$$O	pharmaceutical$$$50$$$64$$$O	composition$$$65$$$76$$$O	ointment$$$77$$$85$$$O	for$$$86$$$89$$$O	treating$$$90$$$98$$$O	skin$$$99$$$103$$$O	diseases.$$$104$$$113$$$O	The$$$114$$$117$$$O	pharmaceutical$$$118$$$132$$$O	composition$$$133$$$144$$$O	contains$$$145$$$153$$$O	the$$$154$$$157$$$O	following$$$158$$$167$$$O	components$$$168$$$178$$$O	in$$$179$$$181$$$O	proportion$$$182$$$192$$$O	by$$$193$$$195$$$O	weight:$$$196$$$203$$$O	0.05-0.08%$$$204$$$214$$$O	of$$$215$$$217$$$O	betamethasone$$$218$$$231$$$I	valerate,$$$232$$$241$$$I	0.08-0.12%$$$242$$$252$$$O	of$$$253$$$255$$$O	chlorocresol$$$256$$$268$$$I	and$$$269$$$272$$$O	0.08-0.12%$$$273$$$283$$$O	of$$$284$$$286$$$O	gentamicin$$$287$$$297$$$I	sulfate.$$$298$$$306$$$I	The$$$307$$$310$$$O	pharmaceutical$$$311$$$325$$$O	composition$$$326$$$337$$$O	ointment$$$338$$$346$$$O	is$$$347$$$349$$$O	mainly$$$350$$$356$$$O	used$$$357$$$361$$$O	for$$$362$$$365$$$O	treating$$$366$$$374$$$O	dermatitis,$$$375$$$386$$$O	eczema,$$$387$$$394$$$O	contact$$$395$$$402$$$O	dermatitis,$$$403$$$414$$$O	seborrheic$$$415$$$425$$$O	dermatitis,$$$426$$$437$$$O	photodermatitis,$$$438$$$454$$$O	neurodermatitis,$$$455$$$471$$$O	intertrigo,$$$472$$$483$$$O	exfoliative$$$484$$$495$$$O	dermatitis,$$$496$$$507$$$O	skin$$$508$$$512$$$O	itch,$$$513$$$518$$$O	psoriasis,$$$519$$$529$$$O	first-degree$$$530$$$542$$$O	burn$$$543$$$547$$$O	and$$$548$$$551$$$O	the$$$552$$$555$$$O	like.$$$556$$$561$$$O	The$$$562$$$565$$$O	pharmaceutical$$$566$$$580$$$O	composition$$$581$$$592$$$O	ointment$$$593$$$601$$$O	has$$$602$$$605$$$O	the$$$606$$$609$$$O	characteristics$$$610$$$625$$$O	of$$$626$$$628$$$O	jointly$$$629$$$636$$$O	applying$$$637$$$645$$$O	pharmaceutical$$$646$$$660$$$O	components$$$661$$$671$$$O	with$$$672$$$676$$$O	anti-inflammatory,$$$677$$$695$$$O	antifungal$$$696$$$706$$$O	and$$$707$$$710$$$O	antibacterial$$$711$$$724$$$O	curative$$$725$$$733$$$O	effects,$$$734$$$742$$$O	playing$$$743$$$750$$$O	the$$$751$$$754$$$O	curative$$$755$$$763$$$O	effects$$$764$$$771$$$O	in$$$772$$$774$$$O	multiple$$$775$$$783$$$O	aspects,$$$784$$$792$$$O	overcoming$$$793$$$803$$$O	the$$$804$$$807$$$O	defect$$$808$$$814$$$O	that$$$815$$$819$$$O	an$$$820$$$822$$$O	individual$$$823$$$833$$$O	component$$$834$$$843$$$O	can$$$844$$$847$$$O	not$$$848$$$851$$$O	more$$$852$$$856$$$O	effectively$$$857$$$868$$$O	treat$$$869$$$874$$$O	skin$$$875$$$879$$$O	mycotic$$$880$$$887$$$O	infection,$$$888$$$898$$$O	skin$$$899$$$903$$$O	allergy,$$$904$$$912$$$O	dermatitis,$$$913$$$924$$$O	eczema$$$925$$$931$$$O	and$$$932$$$935$$$O	the$$$936$$$939$$$O	like,$$$940$$$945$$$O	or$$$946$$$948$$$O	concurrence$$$949$$$960$$$O	of$$$961$$$963$$$O	mycotic$$$964$$$971$$$O	infection,$$$972$$$982$$$O	skin$$$983$$$987$$$O	allergy,$$$988$$$996$$$O	dermatitis,$$$997$$$1008$$$O	eczema$$$1009$$$1015$$$O	and$$$1016$$$1019$$$O	the$$$1020$$$1023$$$O	like,$$$1024$$$1029$$$O	and$$$1030$$$1033$$$O	relieving$$$1034$$$1043$$$O	the$$$1044$$$1047$$$O	serious$$$1048$$$1055$$$O	side$$$1056$$$1060$$$O	effects$$$1061$$$1068$$$O	caused$$$1069$$$1075$$$O	by$$$1076$$$1078$$$O	singly$$$1079$$$1085$$$O	using$$$1086$$$1091$$$O	a$$$1092$$$1093$$$O	big$$$1094$$$1097$$$O	amount$$$1098$$$1104$$$O	of$$$1105$$$1107$$$O	hormone$$$1108$$$1115$$$O	for$$$1116$$$1119$$$O	treating$$$1120$$$1128$$$O	dermatitis,$$$1129$$$1140$$$O	eczema$$$1141$$$1147$$$O	and$$$1148$$$1151$$$O	the$$$1152$$$1155$$$O	like;$$$1156$$$1161$$$O	and$$$1162$$$1165$$$O	a$$$1166$$$1167$$$O	component$$$1168$$$1177$$$O	for$$$1178$$$1181$$$O	promoting$$$1182$$$1191$$$O	percutaneous$$$1192$$$1204$$$O	absorption$$$1205$$$1215$$$O	is$$$1216$$$1218$$$O	added$$$1219$$$1224$$$O	to$$$1225$$$1227$$$O	auxiliary$$$1228$$$1237$$$O	materials$$$1238$$$1247$$$O	to$$$1248$$$1250$$$O	enhance$$$1251$$$1258$$$O	the$$$1259$$$1262$$$O	pharmaceutical$$$1263$$$1277$$$O	curative$$$1278$$$1286$$$O	effect$$$1287$$$1293$$$O	and$$$1294$$$1297$$$O	promote$$$1298$$$1305$$$O	absorption.$$$1306$$$1317$$$O	The$$$1318$$$1321$$$O	ointment$$$1322$$$1330$$$O	disclosed$$$1331$$$1340$$$O	by$$$1341$$$1343$$$O	the$$$1344$$$1347$$$O	invention$$$1348$$$1357$$$O	has$$$1358$$$1361$$$O	the$$$1362$$$1365$$$O	advantages$$$1366$$$1376$$$O	of$$$1377$$$1379$$$O	exact$$$1380$$$1385$$$O	efficacy,$$$1386$$$1395$$$O	strong$$$1396$$$1402$$$O	local$$$1403$$$1408$$$O	pertinence,$$$1409$$$1420$$$O	no$$$1421$$$1423$$$O	irritation$$$1424$$$1434$$$O	on$$$1435$$$1437$$$O	skin,$$$1438$$$1443$$$O	and$$$1444$$$1447$$$O	the$$$1448$$$1451$$$O	like,$$$1452$$$1457$$$O	and$$$1458$$$1461$$$O	the$$$1462$$$1465$$$O	preparation$$$1466$$$1477$$$O	method$$$1478$$$1484$$$O	of$$$1485$$$1487$$$O	the$$$1488$$$1491$$$O	ointment$$$1492$$$1500$$$O	is$$$1501$$$1503$$$O	suitable$$$1504$$$1512$$$O	for$$$1513$$$1516$$$O	industrial$$$1517$$$1527$$$O	production.$$$1528$$$1539$$$O
CN101323600A
Triadimefon$$$0$$$11$$$I	and$$$12$$$15$$$O	triadimenol$$$16$$$27$$$I	compounds$$$28$$$37$$$O	having$$$38$$$44$$$O	antimicrobial$$$45$$$58$$$O	activity,$$$59$$$68$$$O	salts,$$$69$$$75$$$O	synthetic$$$76$$$85$$$O	methods$$$86$$$93$$$O	and$$$94$$$97$$$O	uses$$$98$$$102$$$O	thereof$$$103$$$110$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	for$$$34$$$37$$$O	synthesizing$$$38$$$50$$$O	a$$$51$$$52$$$O	novel$$$53$$$58$$$O	triazolone$$$59$$$69$$$I	and$$$70$$$73$$$O	a$$$74$$$75$$$O	triadimenol$$$76$$$87$$$I	compound,$$$88$$$97$$$O	namely,$$$98$$$105$$$O	benzene$$$106$$$113$$$I	or$$$114$$$116$$$O	substituted$$$117$$$128$$$O	benzene$$$129$$$136$$$I	is$$$137$$$139$$$O	used$$$140$$$144$$$O	as$$$145$$$147$$$O	a$$$148$$$149$$$O	raw$$$150$$$153$$$O	material$$$154$$$162$$$O	and$$$163$$$166$$$O	subjected$$$167$$$176$$$O	to$$$177$$$179$$$O	Friedel-Crafts$$$180$$$194$$$O	acylation,$$$195$$$205$$$O	Tolyltriazole$$$206$$$219$$$I	alkylation$$$220$$$230$$$O	and$$$231$$$234$$$O	halogenous-benzylation$$$235$$$257$$$O	to$$$258$$$260$$$O	obtain$$$261$$$267$$$O	the$$$268$$$271$$$O	novel$$$272$$$277$$$O	triazolone$$$278$$$288$$$I	compound;$$$289$$$298$$$O	then$$$299$$$303$$$O	carbonyl$$$304$$$312$$$I	reduction$$$313$$$322$$$O	is$$$323$$$325$$$O	carried$$$326$$$333$$$O	out$$$334$$$337$$$O	to$$$338$$$340$$$O	obtain$$$341$$$347$$$O	the$$$348$$$351$$$O	novel$$$352$$$357$$$O	triadimenol$$$358$$$369$$$I	compound.$$$370$$$379$$$O	The$$$380$$$383$$$O	invention$$$384$$$393$$$O	also$$$394$$$398$$$O	relates$$$399$$$406$$$O	to$$$407$$$409$$$O	medical$$$410$$$417$$$O	and$$$418$$$421$$$O	pesticide$$$422$$$431$$$O	applications$$$432$$$444$$$O	of$$$445$$$447$$$O	the$$$448$$$451$$$O	novel$$$452$$$457$$$O	triazolone$$$458$$$468$$$I	and$$$469$$$472$$$O	triadimenol$$$473$$$484$$$I	compounds.$$$485$$$495$$$O
US20080039410
Inositol$$$0$$$8$$$I	1,4,5-Trisphosphate$$$9$$$28$$$I	Receptor$$$29$$$37$$$O	Mutants$$$38$$$45$$$O	and$$$46$$$49$$$O	Uses$$$50$$$54$$$O	Thereof$$$55$$$62$$$O
Disclosed$$$0$$$9$$$O	herein$$$10$$$16$$$O	are$$$17$$$20$$$O	compositions$$$21$$$33$$$O	and$$$34$$$37$$$O	methods$$$38$$$45$$$O	for$$$46$$$49$$$O	treating$$$50$$$58$$$O	subjects$$$59$$$67$$$O	with$$$68$$$72$$$O	conditions$$$73$$$83$$$O	related$$$84$$$91$$$O	to$$$92$$$94$$$O	Inositol$$$95$$$103$$$I	1,4,5-trisphosphate$$$104$$$123$$$I	receptor$$$124$$$132$$$O	(InsP3R).$$$133$$$142$$$O	Described$$$143$$$152$$$O	herein$$$153$$$159$$$O	are$$$160$$$163$$$O	mutants$$$164$$$171$$$O	of$$$172$$$174$$$O	InsP3R,$$$175$$$182$$$O	methods$$$183$$$190$$$O	of$$$191$$$193$$$O	making$$$194$$$200$$$O	mutants,$$$201$$$209$$$O	and$$$210$$$213$$$O	methods$$$214$$$221$$$O	of$$$222$$$224$$$O	using$$$225$$$230$$$O	InsP3R$$$231$$$237$$$O	mutants$$$238$$$245$$$O	for$$$246$$$249$$$O	the$$$250$$$253$$$O	treatment$$$254$$$263$$$O	of$$$264$$$266$$$O	a$$$267$$$268$$$O	disease$$$269$$$276$$$O	or$$$277$$$279$$$O	condition.$$$280$$$290$$$O
WO2007003594A1
Screening$$$0$$$9$$$O	methods$$$10$$$17$$$O	for$$$18$$$21$$$O	inhibitors$$$22$$$32$$$O	of$$$33$$$35$$$O	the$$$36$$$39$$$O	metalloprotease$$$40$$$55$$$O	meprin$$$56$$$62$$$O
Compounds$$$0$$$9$$$O	that$$$10$$$14$$$O	regulate$$$15$$$23$$$O	the$$$24$$$27$$$O	zinc$$$28$$$32$$$I	metalloprotease$$$33$$$48$$$O	meprin$$$49$$$55$$$O	can$$$56$$$59$$$O	play$$$60$$$64$$$O	a$$$65$$$66$$$O	role$$$67$$$71$$$O	in$$$72$$$74$$$O	preventing,$$$75$$$86$$$O	ameliorating,$$$87$$$100$$$O	or$$$101$$$103$$$O	correcting$$$104$$$114$$$O	dysfunctions$$$115$$$127$$$O	or$$$128$$$130$$$O	diseases$$$131$$$139$$$O	including$$$140$$$149$$$O	cardiovascular$$$150$$$164$$$O	and$$$165$$$168$$$O	renal$$$169$$$174$$$O	disorders.$$$175$$$185$$$O	The$$$186$$$189$$$O	invention$$$190$$$199$$$O	provides$$$200$$$208$$$O	assays$$$209$$$215$$$O	for$$$216$$$219$$$O	the$$$220$$$223$$$O	identification$$$224$$$238$$$O	of$$$239$$$241$$$O	such$$$242$$$246$$$O	compounds.$$$247$$$257$$$O
CN103239466A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	punicalin$$$15$$$24$$$I	in$$$25$$$27$$$O	preparation$$$28$$$39$$$O	of$$$40$$$42$$$O	medicine$$$43$$$51$$$O	for$$$52$$$55$$$O	treating$$$56$$$64$$$O	or$$$65$$$67$$$O	preventing$$$68$$$78$$$O	hepatitis$$$79$$$88$$$O	C$$$89$$$90$$$O	virus$$$91$$$96$$$O	infection$$$97$$$106$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	punicalin$$$39$$$48$$$I	in$$$49$$$51$$$O	preparation$$$52$$$63$$$O	of$$$64$$$66$$$O	medicine$$$67$$$75$$$O	for$$$76$$$79$$$O	treating$$$80$$$88$$$O	or$$$89$$$91$$$O	preventing$$$92$$$102$$$O	hepatitis$$$103$$$112$$$O	C$$$113$$$114$$$O	virus$$$115$$$120$$$O	infection.$$$121$$$131$$$O	An$$$132$$$134$$$O	antivirus$$$135$$$144$$$O	test$$$145$$$149$$$O	is$$$150$$$152$$$O	performed$$$153$$$162$$$O	by$$$163$$$165$$$O	selecting$$$166$$$175$$$O	basically$$$176$$$185$$$O	non-toxic$$$186$$$195$$$O	medicine$$$196$$$204$$$O	concentration,$$$205$$$219$$$O	the$$$220$$$223$$$O	influence$$$224$$$233$$$O	of$$$234$$$236$$$O	punicalin$$$237$$$246$$$I	on$$$247$$$249$$$O	copy$$$250$$$254$$$O	of$$$255$$$257$$$O	hepatitis$$$258$$$267$$$O	C$$$268$$$269$$$O	virus$$$270$$$275$$$O	is$$$276$$$278$$$O	detected,$$$279$$$288$$$O	and$$$289$$$292$$$O	the$$$293$$$296$$$O	compound$$$297$$$305$$$O	has$$$306$$$309$$$O	obvious$$$310$$$317$$$O	hepatitis$$$318$$$327$$$O	C$$$328$$$329$$$O	virus$$$330$$$335$$$O	resistant$$$336$$$345$$$O	activity$$$346$$$354$$$O	and$$$355$$$358$$$O	has$$$359$$$362$$$O	a$$$363$$$364$$$O	dose-dependent$$$365$$$379$$$O	effect.$$$380$$$387$$$O	The$$$388$$$391$$$O	further$$$392$$$399$$$O	experiment$$$400$$$410$$$O	proves$$$411$$$417$$$O	that$$$418$$$422$$$O	the$$$423$$$426$$$O	punicalin$$$427$$$436$$$I	can$$$437$$$440$$$O	prevent$$$441$$$448$$$O	HCV$$$449$$$452$$$O	from$$$453$$$457$$$O	being$$$458$$$463$$$O	adsorbed$$$464$$$472$$$O	and$$$473$$$476$$$O	invading$$$477$$$485$$$O	the$$$486$$$489$$$O	target$$$490$$$496$$$O	cells,$$$497$$$503$$$O	so$$$504$$$506$$$O	that$$$507$$$511$$$O	the$$$512$$$515$$$O	entrance$$$516$$$524$$$O	and$$$525$$$528$$$O	reinfection$$$529$$$540$$$O	of$$$541$$$543$$$O	HCV$$$544$$$547$$$O	are$$$548$$$551$$$O	inhibited;$$$552$$$562$$$O	and$$$563$$$566$$$O	meanwhile,$$$567$$$577$$$O	the$$$578$$$581$$$O	compound$$$582$$$590$$$O	also$$$591$$$595$$$O	can$$$596$$$599$$$O	obviously$$$600$$$609$$$O	reduce$$$610$$$616$$$O	the$$$617$$$620$$$O	activity$$$621$$$629$$$O	of$$$630$$$632$$$O	HCVNS3$$$633$$$639$$$O	serine$$$640$$$646$$$O	protease.$$$647$$$656$$$O	Thus,$$$657$$$662$$$O	when$$$663$$$667$$$O	being$$$668$$$673$$$O	independently$$$674$$$687$$$O	used$$$688$$$692$$$O	or$$$693$$$695$$$O	combined$$$696$$$704$$$O	with$$$705$$$709$$$O	other$$$710$$$715$$$O	anti-HCV$$$716$$$724$$$O	medicines,$$$725$$$735$$$O	the$$$736$$$739$$$O	punicalin$$$740$$$749$$$I	can$$$750$$$753$$$O	play$$$754$$$758$$$O	an$$$759$$$761$$$O	important$$$762$$$771$$$O	role$$$772$$$776$$$O	in$$$777$$$779$$$O	the$$$780$$$783$$$O	process$$$784$$$791$$$O	of$$$792$$$794$$$O	preventing$$$795$$$805$$$O	or$$$806$$$808$$$O	treating$$$809$$$817$$$O	hepatitis$$$818$$$827$$$O	C$$$828$$$829$$$O	virus$$$830$$$835$$$O	infection.$$$836$$$846$$$O
EP1280777B1
Tetrahydroisoquinoline$$$0$$$22$$$I	analogs$$$23$$$30$$$O	useful$$$31$$$37$$$O	as$$$38$$$40$$$O	growth$$$41$$$47$$$O	hormone$$$48$$$55$$$O	secretagogues$$$56$$$69$$$O
Tetrahydroisoquinoline$$$0$$$22$$$I	analogs$$$23$$$30$$$O	are$$$31$$$34$$$O	provided$$$35$$$43$$$O	which$$$44$$$49$$$O	are$$$50$$$53$$$O	useful$$$54$$$60$$$O	in$$$61$$$63$$$O	stimulating$$$64$$$75$$$O	endogenous$$$76$$$86$$$O	production$$$87$$$97$$$O	or$$$98$$$100$$$O	release$$$101$$$108$$$O	of$$$109$$$111$$$O	growth$$$112$$$118$$$O	hormone$$$119$$$126$$$O	and$$$127$$$130$$$O	in$$$131$$$133$$$O	treating$$$134$$$142$$$O	obesity,$$$143$$$151$$$O	osteoporosis$$$152$$$164$$$O	(improving$$$165$$$175$$$O	bone$$$176$$$180$$$O	density)$$$181$$$189$$$O	and$$$190$$$193$$$O	in$$$194$$$196$$$O	improving$$$197$$$206$$$O	muscle$$$207$$$213$$$O	mass$$$214$$$218$$$O	and$$$219$$$222$$$O	muscle$$$223$$$229$$$O	strength.$$$230$$$239$$$O	The$$$240$$$243$$$O	tetrahydroisoquinoline$$$244$$$266$$$I	analogs$$$267$$$274$$$O	thereof$$$275$$$282$$$O	have$$$283$$$287$$$O	the$$$288$$$291$$$O	structure$$$292$$$301$$$O	(I)$$$302$$$305$$$O	wherein$$$306$$$313$$$O	R1,$$$314$$$317$$$O	R2,$$$318$$$321$$$O	R3,$$$322$$$325$$$O	R3a,$$$326$$$330$$$O	X1,$$$331$$$334$$$O	X2,$$$335$$$338$$$O	X3,$$$339$$$342$$$O	X4,$$$343$$$346$$$O	m$$$347$$$348$$$O	and$$$349$$$352$$$O	n$$$353$$$354$$$O	are$$$355$$$358$$$O	as$$$359$$$361$$$O	described$$$362$$$371$$$O	herein.$$$372$$$379$$$O
US20090022737
Aldos$$$0$$$5$$$O	as$$$6$$$8$$$O	modifiers$$$9$$$18$$$O	of$$$19$$$21$$$O	the$$$22$$$25$$$O	igf$$$26$$$29$$$O	pathway$$$30$$$37$$$O	and$$$38$$$41$$$O	methods$$$42$$$49$$$O	of$$$50$$$52$$$O	use$$$53$$$56$$$O
Human$$$0$$$5$$$O	ALDO$$$6$$$10$$$O	genes$$$11$$$16$$$O	are$$$17$$$20$$$O	identified$$$21$$$31$$$O	as$$$32$$$34$$$O	modulators$$$35$$$45$$$O	of$$$46$$$48$$$O	the$$$49$$$52$$$O	IGF$$$53$$$56$$$O	pathway,$$$57$$$65$$$O	and$$$66$$$69$$$O	thus$$$70$$$74$$$O	are$$$75$$$78$$$O	therapeutic$$$79$$$90$$$O	targets$$$91$$$98$$$O	for$$$99$$$102$$$O	disorders$$$103$$$112$$$O	associated$$$113$$$123$$$O	with$$$124$$$128$$$O	defective$$$129$$$138$$$O	IGF$$$139$$$142$$$O	function.$$$143$$$152$$$O	Methods$$$153$$$160$$$O	for$$$161$$$164$$$O	identifying$$$165$$$176$$$O	modulators$$$177$$$187$$$O	of$$$188$$$190$$$O	IGF,$$$191$$$195$$$O	comprising$$$196$$$206$$$O	screening$$$207$$$216$$$O	for$$$217$$$220$$$O	agents$$$221$$$227$$$O	that$$$228$$$232$$$O	modulate$$$233$$$241$$$O	the$$$242$$$245$$$O	activity$$$246$$$254$$$O	of$$$255$$$257$$$O	ALDO$$$258$$$262$$$O	are$$$263$$$266$$$O	provided.$$$267$$$276$$$O
US20120076832
Synthesis$$$0$$$9$$$O	and$$$10$$$13$$$O	use$$$14$$$17$$$O	of$$$18$$$20$$$O	therapeutic$$$21$$$32$$$O	metal$$$33$$$38$$$O	ion$$$39$$$42$$$O	containing$$$43$$$53$$$O	polymeric$$$54$$$63$$$O	particles$$$64$$$73$$$O
Therapeutic$$$0$$$11$$$O	particles$$$12$$$21$$$O	contain$$$22$$$29$$$O	metal$$$30$$$35$$$O	ions$$$36$$$40$$$O	and$$$41$$$44$$$O	are$$$45$$$48$$$O	characterized$$$49$$$62$$$O	by$$$63$$$65$$$O	the$$$66$$$69$$$O	use$$$70$$$73$$$O	of$$$74$$$76$$$O	unique$$$77$$$83$$$O	ligand$$$84$$$90$$$O	sets$$$91$$$95$$$O	capable$$$96$$$103$$$O	of$$$104$$$106$$$O	making$$$107$$$113$$$O	the$$$114$$$117$$$O	metal$$$118$$$123$$$O	ion$$$124$$$127$$$O	complex$$$128$$$135$$$O	soluble$$$136$$$143$$$O	in$$$144$$$146$$$O	biological$$$147$$$157$$$O	media$$$158$$$163$$$O	to$$$164$$$166$$$O	induce$$$167$$$173$$$O	selective$$$174$$$183$$$O	toxicity$$$184$$$192$$$O	in$$$193$$$195$$$O	diseased$$$196$$$204$$$O	cells.$$$205$$$211$$$O	The$$$212$$$215$$$O	particles$$$216$$$225$$$O	may$$$226$$$229$$$O	comprise$$$230$$$238$$$O	a$$$239$$$240$$$O	polymeric$$$241$$$250$$$O	base$$$251$$$255$$$O	particle,$$$256$$$265$$$O	at$$$266$$$268$$$O	least$$$269$$$274$$$O	one$$$275$$$278$$$O	pharmaceutically$$$279$$$295$$$O	active$$$296$$$302$$$O	metal$$$303$$$308$$$O	ion,$$$309$$$313$$$O	including$$$314$$$323$$$O	metal$$$324$$$329$$$O	ions$$$330$$$334$$$O	from$$$335$$$339$$$O	more$$$340$$$344$$$O	than$$$345$$$349$$$O	one$$$350$$$353$$$O	metal$$$354$$$359$$$O	element,$$$360$$$368$$$O	a$$$369$$$370$$$O	ligand$$$371$$$377$$$O	that$$$378$$$382$$$O	is$$$383$$$385$$$O	covalently$$$386$$$396$$$O	attached$$$397$$$405$$$O	to$$$406$$$408$$$O	the$$$409$$$412$$$O	polymeric$$$413$$$422$$$O	base$$$423$$$427$$$O	particle$$$428$$$436$$$O	and$$$437$$$440$$$O	attached$$$441$$$449$$$O	to$$$450$$$452$$$O	the$$$453$$$456$$$O	metal$$$457$$$462$$$O	ion$$$463$$$466$$$O	via$$$467$$$470$$$O	a$$$471$$$472$$$O	stimuli-responsive$$$473$$$491$$$O	bond,$$$492$$$497$$$O	and$$$498$$$501$$$O	a$$$502$$$503$$$O	cell$$$504$$$508$$$O	targeting$$$509$$$518$$$O	component.$$$519$$$529$$$O	When$$$530$$$534$$$O	the$$$535$$$538$$$O	metal$$$539$$$544$$$O	ion-containing$$$545$$$559$$$O	particle$$$560$$$568$$$O	enters$$$569$$$575$$$O	a$$$576$$$577$$$O	pre-defined$$$578$$$589$$$O	environment,$$$590$$$602$$$O	the$$$603$$$606$$$O	ligands$$$607$$$614$$$O	binding$$$615$$$622$$$O	the$$$623$$$626$$$O	metal$$$627$$$632$$$O	to$$$633$$$635$$$O	the$$$636$$$639$$$O	particle$$$640$$$648$$$O	are$$$649$$$652$$$O	broken,$$$653$$$660$$$O	triggering$$$661$$$671$$$O	release$$$672$$$679$$$O	of$$$680$$$682$$$O	the$$$683$$$686$$$O	free$$$687$$$691$$$O	metal$$$692$$$697$$$O	ion$$$698$$$701$$$O	while$$$702$$$707$$$O	the$$$708$$$711$$$O	original$$$712$$$720$$$O	ligands$$$721$$$728$$$O	remain$$$729$$$735$$$O	covalently$$$736$$$746$$$O	bound$$$747$$$752$$$O	to$$$753$$$755$$$O	the$$$756$$$759$$$O	particle.$$$760$$$769$$$O
US20120009132
Transparent$$$0$$$11$$$O	Xyloglucan/Chitosan$$$12$$$31$$$O	Gel$$$32$$$35$$$O	and$$$36$$$39$$$O	a$$$40$$$41$$$O	Process$$$42$$$49$$$O	for$$$50$$$53$$$O	the$$$54$$$57$$$O	Preparation$$$58$$$69$$$O	Thereof$$$70$$$77$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	transparent$$$33$$$44$$$O	Xyloglucan/Chitosan$$$45$$$64$$$O	gel$$$65$$$68$$$O	and$$$69$$$72$$$O	a$$$73$$$74$$$O	process$$$75$$$82$$$O	to$$$83$$$85$$$O	prepare$$$86$$$93$$$O	the$$$94$$$97$$$O	same$$$98$$$102$$$O	which$$$103$$$108$$$O	comprises$$$109$$$118$$$O	of$$$119$$$121$$$O	extracting$$$122$$$132$$$O	the$$$133$$$136$$$O	xyloglucan$$$137$$$147$$$O	from$$$148$$$152$$$O	tamarind$$$153$$$161$$$O	seed$$$162$$$166$$$O	powder$$$167$$$173$$$O	by$$$174$$$176$$$O	a$$$177$$$178$$$O	suitable$$$179$$$187$$$O	solvent$$$188$$$195$$$O	at$$$196$$$198$$$O	a$$$199$$$200$$$O	high$$$201$$$205$$$O	temperature$$$206$$$217$$$O	and$$$218$$$221$$$O	precipitating$$$222$$$235$$$O	the$$$236$$$239$$$O	xyloglucan$$$240$$$250$$$O	by$$$251$$$253$$$O	alcohol$$$254$$$261$$$O	and$$$262$$$265$$$O	then$$$266$$$270$$$O	modifying$$$271$$$280$$$O	the$$$281$$$284$$$O	xyloglucan$$$285$$$295$$$O	to$$$296$$$298$$$O	form$$$299$$$303$$$O	dialdehyde$$$304$$$314$$$I	and$$$315$$$318$$$O	making$$$319$$$325$$$O	a$$$326$$$327$$$O	co-polymer$$$328$$$338$$$O	with$$$339$$$343$$$O	chitosan$$$344$$$352$$$O	to$$$353$$$355$$$O	form$$$356$$$360$$$O	a$$$361$$$362$$$O	thermo$$$363$$$369$$$O	stable$$$370$$$376$$$O	crystal$$$377$$$384$$$O	clear,$$$385$$$391$$$O	colourless$$$392$$$402$$$O	gel$$$403$$$406$$$O	which$$$407$$$412$$$O	is$$$413$$$415$$$O	stable$$$416$$$422$$$O	at$$$423$$$425$$$O	temperature$$$426$$$437$$$O	â20$$$438$$$443$$$O	to$$$444$$$446$$$O	90.$$$447$$$450$$$O	A$$$451$$$452$$$O	transparent$$$453$$$464$$$O	chitam$$$465$$$471$$$O	gel$$$472$$$475$$$O	and$$$476$$$479$$$O	a$$$480$$$481$$$O	process$$$482$$$489$$$O	for$$$490$$$493$$$O	the$$$494$$$497$$$O	preparation$$$498$$$509$$$O	thereof$$$510$$$517$$$O	C$$$518$$$519$$$O	and$$$520$$$523$$$O	pH$$$524$$$526$$$O	3-7,$$$527$$$531$$$O	having$$$532$$$538$$$O	an$$$539$$$541$$$O	average$$$542$$$549$$$O	molecular$$$550$$$559$$$O	weight$$$560$$$566$$$O	of$$$567$$$569$$$O	4730$$$570$$$574$$$O	KDa$$$575$$$578$$$O	and$$$579$$$582$$$O	a$$$583$$$584$$$O	viscosity$$$585$$$594$$$O	of$$$595$$$597$$$O	4100$$$598$$$602$$$O	centi$$$603$$$608$$$O	Poises$$$609$$$615$$$O	at$$$616$$$618$$$O	28Â±2Â°$$$619$$$626$$$O	C.,$$$627$$$630$$$O	not$$$631$$$634$$$O	digested$$$635$$$643$$$O	by$$$644$$$646$$$O	digestive$$$647$$$656$$$O	enzymes$$$657$$$664$$$O	in$$$665$$$667$$$O	humans$$$668$$$674$$$O	and$$$675$$$678$$$O	does$$$679$$$683$$$O	not$$$684$$$687$$$O	contribute$$$688$$$698$$$O	to$$$699$$$701$$$O	calorie$$$702$$$709$$$O	intake$$$710$$$716$$$O	can$$$717$$$720$$$O	be$$$721$$$723$$$O	used$$$724$$$728$$$O	as$$$729$$$731$$$O	a$$$732$$$733$$$O	food$$$734$$$738$$$O	ingredient,$$$739$$$750$$$O	and$$$751$$$754$$$O	supplement$$$755$$$765$$$O	functional$$$766$$$776$$$O	foods$$$777$$$782$$$O	(nutritional$$$783$$$795$$$O	care).$$$796$$$802$$$O	This$$$803$$$807$$$O	Xyloglucan/Chitosan$$$808$$$827$$$O	gel$$$828$$$831$$$O	has$$$832$$$835$$$O	applications$$$836$$$848$$$O	in$$$849$$$851$$$O	the$$$852$$$855$$$O	area$$$856$$$860$$$O	of$$$861$$$863$$$O	cosmetic$$$864$$$872$$$O	and$$$873$$$876$$$O	personal$$$877$$$885$$$O	care$$$886$$$890$$$O	products,$$$891$$$900$$$O	as$$$901$$$903$$$O	an$$$904$$$906$$$O	ultraviolet$$$907$$$918$$$O	protective$$$919$$$929$$$O	agent$$$930$$$935$$$O	or$$$936$$$938$$$O	as$$$939$$$941$$$O	a$$$942$$$943$$$O	tissue$$$944$$$950$$$O	adhesive$$$951$$$959$$$O	which$$$960$$$965$$$O	can$$$966$$$969$$$O	be$$$970$$$972$$$O	used,$$$973$$$978$$$O	including$$$979$$$988$$$O	haemostasis,$$$989$$$1001$$$O	wound$$$1002$$$1007$$$O	sealing,$$$1008$$$1016$$$O	tissue$$$1017$$$1023$$$O	engineering$$$1024$$$1035$$$O	or$$$1036$$$1038$$$O	localised$$$1039$$$1048$$$O	drug$$$1049$$$1053$$$O	delivery$$$1054$$$1062$$$O	as$$$1063$$$1065$$$O	capsules$$$1066$$$1074$$$O	&$$$1075$$$1076$$$O	tablets.$$$1077$$$1085$$$O
WO2008150260A1
8-oxy-2-aminopyrido$$$0$$$19$$$I	(2,$$$20$$$23$$$I	3-d)$$$24$$$28$$$I	pyrimidin-7-one$$$29$$$44$$$I	derivatives$$$45$$$56$$$O	as$$$57$$$59$$$O	kinase$$$60$$$66$$$O	inhibitors$$$67$$$77$$$O	and$$$78$$$81$$$O	anticancer$$$82$$$92$$$O	agents$$$93$$$99$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	derivatives$$$31$$$42$$$O	of$$$43$$$45$$$O	pyrido$$$46$$$52$$$I	[2,$$$53$$$56$$$I	3-d]$$$57$$$61$$$I	pyrimidin-7-one.$$$62$$$78$$$I	These$$$79$$$84$$$O	compounds$$$85$$$94$$$O	are$$$95$$$98$$$O	kinase$$$99$$$105$$$O	inhibitors,$$$106$$$117$$$O	including$$$118$$$127$$$O	compounds$$$128$$$137$$$O	that$$$138$$$142$$$O	show$$$143$$$147$$$O	anti-proliferative$$$148$$$166$$$O	activity,$$$167$$$176$$$O	including$$$177$$$186$$$O	against$$$187$$$194$$$O	tumor$$$195$$$200$$$O	cells,$$$201$$$207$$$O	and$$$208$$$211$$$O	are$$$212$$$215$$$O	useful$$$216$$$222$$$O	in$$$223$$$225$$$O	the$$$226$$$229$$$O	treatment$$$230$$$239$$$O	of$$$240$$$242$$$O	diseases$$$243$$$251$$$O	including$$$252$$$261$$$O	cancer.$$$262$$$269$$$O
US7317018
The$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	adenosine-5'-triphosphate-2',3'-dialdehyde$$$11$$$53$$$I	(oATP)$$$54$$$60$$$I	as$$$61$$$63$$$O	a$$$64$$$65$$$O	medicament$$$66$$$76$$$O	useful$$$77$$$83$$$O	for$$$84$$$87$$$O	the$$$88$$$91$$$O	treatment$$$92$$$101$$$O	of$$$102$$$104$$$O	inflammatory$$$105$$$117$$$O	conditions$$$118$$$128$$$O
The$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	adenosine-5â²-triphosphate-2â²,3â²-dialdehyde$$$11$$$59$$$I	(oATP)$$$60$$$66$$$O	as$$$67$$$69$$$O	a$$$70$$$71$$$O	medicament$$$72$$$82$$$O	useful$$$83$$$89$$$O	for$$$90$$$93$$$O	the$$$94$$$97$$$O	treatment$$$98$$$107$$$O	of$$$108$$$110$$$O	inflammatory$$$111$$$123$$$O	conditions$$$124$$$134$$$O	is$$$135$$$137$$$O	disclosed.$$$138$$$148$$$O
CN101112396A
Extract$$$0$$$7$$$O	of$$$8$$$10$$$O	sparassis$$$11$$$20$$$O	crispa$$$21$$$27$$$O	MH-3$$$28$$$32$$$O	bacterial$$$33$$$42$$$O	strain$$$43$$$49$$$O	and$$$50$$$53$$$O	method$$$54$$$60$$$O	for$$$61$$$64$$$O	preparing$$$65$$$74$$$O	the$$$75$$$78$$$O	same$$$79$$$83$$$O	and$$$84$$$87$$$O	use$$$88$$$91$$$O	thereof$$$92$$$99$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	an$$$32$$$34$$$O	extract$$$35$$$42$$$O	of$$$43$$$45$$$O	Sparassis$$$46$$$55$$$O	Crispa$$$56$$$62$$$O	MH-3$$$63$$$67$$$O	strain$$$68$$$74$$$O	NIBH$$$75$$$79$$$O	FERM$$$80$$$84$$$O	P-17221,$$$85$$$93$$$O	which$$$94$$$99$$$O	takes$$$100$$$105$$$O	the$$$106$$$109$$$O	Beta-1,$$$110$$$117$$$O	3-glucan$$$118$$$126$$$O	as$$$127$$$129$$$O	the$$$130$$$133$$$O	main$$$134$$$138$$$O	ingredient.$$$139$$$150$$$O	The$$$151$$$154$$$O	present$$$155$$$162$$$O	invention$$$163$$$172$$$O	also$$$173$$$177$$$O	discloses$$$178$$$187$$$O	a$$$188$$$189$$$O	preparation$$$190$$$201$$$O	method$$$202$$$208$$$O	of$$$209$$$211$$$O	the$$$212$$$215$$$O	extract$$$216$$$223$$$O	of$$$224$$$226$$$O	sparassis$$$227$$$236$$$O	crispa$$$237$$$243$$$O	MH-3$$$244$$$248$$$O	strain.$$$249$$$256$$$O	In$$$257$$$259$$$O	addition,$$$260$$$269$$$O	the$$$270$$$273$$$O	present$$$274$$$281$$$O	invention$$$282$$$291$$$O	also$$$292$$$296$$$O	discloses$$$297$$$306$$$O	the$$$307$$$310$$$O	application$$$311$$$322$$$O	of$$$323$$$325$$$O	the$$$326$$$329$$$O	extract$$$330$$$337$$$O	of$$$338$$$340$$$O	sparassis$$$341$$$350$$$O	crispa$$$351$$$357$$$O	MH-3$$$358$$$362$$$O	strain$$$363$$$369$$$O	in$$$370$$$372$$$O	the$$$373$$$376$$$O	preparation$$$377$$$388$$$O	of$$$389$$$391$$$O	foods,$$$392$$$398$$$O	beverages$$$399$$$408$$$O	and$$$409$$$412$$$O	health$$$413$$$419$$$O	care$$$420$$$424$$$O	products$$$425$$$433$$$O	and$$$434$$$437$$$O	the$$$438$$$441$$$O	application$$$442$$$453$$$O	of$$$454$$$456$$$O	which$$$457$$$462$$$O	in$$$463$$$465$$$O	the$$$466$$$469$$$O	preparation$$$470$$$481$$$O	of$$$482$$$484$$$O	anti-tumor$$$485$$$495$$$O	drugs.$$$496$$$502$$$O
CN101318946A
Dimeric$$$0$$$7$$$O	ainsliaea$$$8$$$17$$$O	terpene$$$18$$$25$$$I	A,$$$26$$$28$$$O	preparation$$$29$$$40$$$O	and$$$41$$$44$$$O	application$$$45$$$56$$$O	thereof$$$57$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	medicine$$$29$$$37$$$O	technical$$$38$$$47$$$O	field,$$$48$$$54$$$O	in$$$55$$$57$$$O	particular$$$58$$$68$$$O	to$$$69$$$71$$$O	a$$$72$$$73$$$O	compound$$$74$$$82$$$O	Ainsliaidimer$$$83$$$96$$$I	A,$$$97$$$99$$$I	a$$$100$$$101$$$O	preparation$$$102$$$113$$$O	method$$$114$$$120$$$O	and$$$121$$$124$$$O	an$$$125$$$127$$$O	application$$$128$$$139$$$O	thereof.$$$140$$$148$$$O	The$$$149$$$152$$$O	compound$$$153$$$161$$$O	Ainsliaidimer$$$162$$$175$$$I	A$$$176$$$177$$$I	is$$$178$$$180$$$O	obtained$$$181$$$189$$$O	through$$$190$$$197$$$O	extracting$$$198$$$208$$$O	and$$$209$$$212$$$O	separating$$$213$$$223$$$O	Ainsliaiea$$$224$$$234$$$O	macrocephala,$$$235$$$248$$$O	and$$$249$$$252$$$O	is$$$253$$$255$$$O	a$$$256$$$257$$$O	colorless$$$258$$$267$$$O	prismatic$$$268$$$277$$$O	crystal$$$278$$$285$$$O	with$$$286$$$290$$$O	a$$$291$$$292$$$O	molecular$$$293$$$302$$$O	formula$$$303$$$310$$$O	C30H34O7.$$$311$$$320$$$I	Experiments$$$321$$$332$$$O	show$$$333$$$337$$$O	that$$$338$$$342$$$O	the$$$343$$$346$$$O	compound$$$347$$$355$$$O	has$$$356$$$359$$$O	obvious$$$360$$$367$$$O	functions$$$368$$$377$$$O	in$$$378$$$380$$$O	inhibiting$$$381$$$391$$$O	tumor$$$392$$$397$$$O	and$$$398$$$401$$$O	inflammations,$$$402$$$416$$$O	so$$$417$$$419$$$O	the$$$420$$$423$$$O	compound$$$424$$$432$$$O	can$$$433$$$436$$$O	be$$$437$$$439$$$O	used$$$440$$$444$$$O	for$$$445$$$448$$$O	preparing$$$449$$$458$$$O	anti-tumor$$$459$$$469$$$O	drugs$$$470$$$475$$$O	and$$$476$$$479$$$O	anti-inflammatory$$$480$$$497$$$O	drugs.$$$498$$$504$$$O
CN101766608A
Compound$$$0$$$8$$$O	pseudoephedrine$$$9$$$24$$$I	hydrochloride$$$25$$$38$$$I	slow$$$39$$$43$$$O	release$$$44$$$51$$$O	preparation$$$52$$$63$$$O	and$$$64$$$67$$$O	preparing$$$68$$$77$$$O	method$$$78$$$84$$$O	thereof$$$85$$$92$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	slow$$$27$$$31$$$O	release$$$32$$$39$$$O	preparation$$$40$$$51$$$O	which$$$52$$$57$$$O	uses$$$58$$$62$$$O	pseudoephedrine$$$63$$$78$$$I	or$$$79$$$81$$$O	physiologically$$$82$$$97$$$O	acceptable$$$98$$$108$$$O	salts$$$109$$$114$$$O	and$$$115$$$118$$$O	chlorpheniramine$$$119$$$135$$$I	or$$$136$$$138$$$O	physiologically$$$139$$$154$$$O	acceptable$$$155$$$165$$$O	salts$$$166$$$171$$$O	as$$$172$$$174$$$O	active$$$175$$$181$$$O	ingredients.$$$182$$$194$$$O	The$$$195$$$198$$$O	preparation$$$199$$$210$$$O	is$$$211$$$213$$$O	characterized$$$214$$$227$$$O	in$$$228$$$230$$$O	that$$$231$$$235$$$O	the$$$236$$$239$$$O	slow$$$240$$$244$$$O	release$$$245$$$252$$$O	system$$$253$$$259$$$O	comprises$$$260$$$269$$$O	a$$$270$$$271$$$O	pill$$$272$$$276$$$O	core$$$277$$$281$$$O	and/or$$$282$$$288$$$O	a$$$289$$$290$$$O	coating$$$291$$$298$$$O	which$$$299$$$304$$$O	enable$$$305$$$311$$$O	drugs$$$312$$$317$$$O	to$$$318$$$320$$$O	slowly$$$321$$$327$$$O	release;$$$328$$$336$$$O	and$$$337$$$340$$$O	all$$$341$$$344$$$O	active$$$345$$$351$$$O	ingredients$$$352$$$363$$$O	are$$$364$$$367$$$O	stored$$$368$$$374$$$O	in$$$375$$$377$$$O	the$$$378$$$381$$$O	pill$$$382$$$386$$$O	core.$$$387$$$392$$$O	The$$$393$$$396$$$O	slow$$$397$$$401$$$O	release$$$402$$$409$$$O	preparation$$$410$$$421$$$O	can$$$422$$$425$$$O	not$$$426$$$429$$$O	only$$$430$$$434$$$O	fully$$$435$$$440$$$O	overcome$$$441$$$449$$$O	the$$$450$$$453$$$O	symptoms$$$454$$$462$$$O	related$$$463$$$470$$$O	to$$$471$$$473$$$O	colds$$$474$$$479$$$O	and$$$480$$$483$$$O	play$$$484$$$488$$$O	the$$$489$$$492$$$O	synergic$$$493$$$501$$$O	effect$$$502$$$508$$$O	of$$$509$$$511$$$O	the$$$512$$$515$$$O	compound$$$516$$$524$$$O	drugs,$$$525$$$531$$$O	but$$$532$$$535$$$O	also$$$536$$$540$$$O	realize$$$541$$$548$$$O	synchronization$$$549$$$564$$$O	of$$$565$$$567$$$O	release$$$568$$$575$$$O	and$$$576$$$579$$$O	absorption$$$580$$$590$$$O	of$$$591$$$593$$$O	threeactive$$$594$$$605$$$O	ingredients$$$606$$$617$$$O	and$$$618$$$621$$$O	achieve$$$622$$$629$$$O	the$$$630$$$633$$$O	expected$$$634$$$642$$$O	drug$$$643$$$647$$$O	releasing$$$648$$$657$$$O	activity$$$658$$$666$$$O	inside$$$667$$$673$$$O	or$$$674$$$676$$$O	outside$$$677$$$684$$$O	the$$$685$$$688$$$O	body.$$$689$$$694$$$O	The$$$695$$$698$$$O	administration$$$699$$$713$$$O	times$$$714$$$719$$$O	can$$$720$$$723$$$O	be$$$724$$$726$$$O	reduced$$$727$$$734$$$O	by$$$735$$$737$$$O	the$$$738$$$741$$$O	drug$$$742$$$746$$$O	releasing$$$747$$$756$$$O	activity$$$757$$$765$$$O	(from$$$766$$$771$$$O	four$$$772$$$776$$$O	times$$$777$$$782$$$O	one$$$783$$$786$$$O	day$$$787$$$790$$$O	to$$$791$$$793$$$O	twice$$$794$$$799$$$O	one$$$800$$$803$$$O	day,$$$804$$$808$$$O	i.e.$$$809$$$813$$$O	taking$$$814$$$820$$$O	once$$$821$$$825$$$O	respectively$$$826$$$838$$$O	on$$$839$$$841$$$O	morning$$$842$$$849$$$O	and$$$850$$$853$$$O	at$$$854$$$856$$$O	night).$$$857$$$864$$$O	The$$$865$$$868$$$O	invention$$$869$$$878$$$O	has$$$879$$$882$$$O	the$$$883$$$886$$$O	advantages$$$887$$$897$$$O	of$$$898$$$900$$$O	few$$$901$$$904$$$O	drug$$$905$$$909$$$O	taking$$$910$$$916$$$O	times,$$$917$$$923$$$O	slow$$$924$$$928$$$O	release$$$929$$$936$$$O	of$$$937$$$939$$$O	the$$$940$$$943$$$O	drugs$$$944$$$949$$$O	in$$$950$$$952$$$O	the$$$953$$$956$$$O	body,$$$957$$$962$$$O	stable$$$963$$$969$$$O	blood$$$970$$$975$$$O	and$$$976$$$979$$$O	drug$$$980$$$984$$$O	concentration,$$$985$$$999$$$O	small$$$1000$$$1005$$$O	fluctuation,$$$1006$$$1018$$$O	high$$$1019$$$1023$$$O	biological$$$1024$$$1034$$$O	utilization$$$1035$$$1046$$$O	degree$$$1047$$$1053$$$O	and$$$1054$$$1057$$$O	high$$$1058$$$1062$$$O	safety.$$$1063$$$1070$$$O
EP2654763A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	marihuana$$$7$$$16$$$O	and$$$17$$$20$$$O	compounds$$$21$$$30$$$O	therein$$$31$$$38$$$O	for$$$39$$$42$$$O	treating$$$43$$$51$$$O	obesity$$$52$$$59$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	or$$$22$$$24$$$O	preventing$$$25$$$35$$$O	obesity$$$36$$$43$$$O	or$$$44$$$46$$$O	to$$$47$$$49$$$O	facilitate$$$50$$$60$$$O	weight$$$61$$$67$$$O	loss,$$$68$$$73$$$O	particularly$$$74$$$86$$$O	in$$$87$$$89$$$O	overweight$$$90$$$100$$$O	individuals$$$101$$$112$$$O	with$$$113$$$117$$$O	a$$$118$$$119$$$O	body$$$120$$$124$$$O	mass$$$125$$$129$$$O	index$$$130$$$135$$$O	(BMI)$$$136$$$141$$$O	of$$$142$$$144$$$O	about$$$145$$$150$$$O	25$$$151$$$153$$$O	or$$$154$$$156$$$O	greater$$$157$$$164$$$O	or$$$165$$$167$$$O	in$$$168$$$170$$$O	obese$$$171$$$176$$$O	individuals$$$177$$$188$$$O	with$$$189$$$193$$$O	a$$$194$$$195$$$O	BMI$$$196$$$199$$$O	of$$$200$$$202$$$O	about$$$203$$$208$$$O	25$$$209$$$211$$$O	or$$$212$$$214$$$O	greater,$$$215$$$223$$$O	as$$$224$$$226$$$O	well$$$227$$$231$$$O	as$$$232$$$234$$$O	nutraceutical$$$235$$$248$$$O	or$$$249$$$251$$$O	pharmaceutical$$$252$$$266$$$O	compositions$$$267$$$279$$$O	and$$$280$$$283$$$O	supplements$$$284$$$295$$$O	therefor.$$$296$$$305$$$O	The$$$306$$$309$$$O	methods$$$310$$$317$$$O	involve$$$318$$$325$$$O	administering$$$326$$$339$$$O	to$$$340$$$342$$$O	a$$$343$$$344$$$O	subject$$$345$$$352$$$O	in$$$353$$$355$$$O	need$$$356$$$360$$$O	thereof$$$361$$$368$$$O	a$$$369$$$370$$$O	therapeutically$$$371$$$386$$$O	effective$$$387$$$396$$$O	amount$$$397$$$403$$$O	of$$$404$$$406$$$O	cannabis,$$$407$$$416$$$O	at$$$417$$$419$$$O	least$$$420$$$425$$$O	one$$$426$$$429$$$O	cannabinoid$$$430$$$441$$$I	or$$$442$$$444$$$O	derivative$$$445$$$455$$$O	thereof,$$$456$$$464$$$O	an$$$465$$$467$$$O	extract$$$468$$$475$$$O	prepared$$$476$$$484$$$O	from$$$485$$$489$$$O	at$$$490$$$492$$$O	least$$$493$$$498$$$O	one$$$499$$$502$$$O	cannabis$$$503$$$511$$$O	plant,$$$512$$$518$$$O	or$$$519$$$521$$$O	a$$$522$$$523$$$O	combination$$$524$$$535$$$O	thereof.$$$536$$$544$$$O
US20120294822
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	anti-cgrp$$$7$$$16$$$O	antibodies$$$17$$$27$$$O	and$$$28$$$31$$$O	antibody$$$32$$$40$$$O	fragments$$$41$$$50$$$O	to$$$51$$$53$$$O	treat$$$54$$$59$$$O	diarrhea$$$60$$$68$$$O	in$$$69$$$71$$$O	subjects$$$72$$$80$$$O	with$$$81$$$85$$$O	diseases$$$86$$$94$$$O	or$$$95$$$97$$$O	treatments$$$98$$$108$$$O	that$$$109$$$113$$$O	result$$$114$$$120$$$O	in$$$121$$$123$$$O	elevated$$$124$$$132$$$O	cgrp$$$133$$$137$$$O	levels$$$138$$$144$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	methods$$$37$$$44$$$O	for$$$45$$$48$$$O	treating$$$49$$$57$$$O	diarrhea,$$$58$$$67$$$O	both$$$68$$$72$$$O	chronic$$$73$$$80$$$O	or$$$81$$$83$$$O	acute$$$84$$$89$$$O	forms,$$$90$$$96$$$O	by$$$97$$$99$$$O	the$$$100$$$103$$$O	administration$$$104$$$118$$$O	of$$$119$$$121$$$O	a$$$122$$$123$$$O	therapeutically$$$124$$$139$$$O	or$$$140$$$142$$$O	prophylactically$$$143$$$159$$$O	effective$$$160$$$169$$$O	amount$$$170$$$176$$$O	of$$$177$$$179$$$O	antibodies$$$180$$$190$$$O	and$$$191$$$194$$$O	fragments$$$195$$$204$$$O	thereof$$$205$$$212$$$O	having$$$213$$$219$$$O	binding$$$220$$$227$$$O	specificity$$$228$$$239$$$O	for$$$240$$$243$$$O	CGRP.$$$244$$$249$$$O	In$$$250$$$252$$$O	particular$$$253$$$263$$$O	the$$$264$$$267$$$O	methods$$$268$$$275$$$O	prevent$$$276$$$283$$$O	or$$$284$$$286$$$O	reduce$$$287$$$293$$$O	diarrhea$$$294$$$302$$$O	in$$$303$$$305$$$O	conditions$$$306$$$316$$$O	or$$$317$$$319$$$O	treatments$$$320$$$330$$$O	resulting$$$331$$$340$$$O	in$$$341$$$343$$$O	elevated$$$344$$$352$$$O	CGRP$$$353$$$357$$$O	levels,$$$358$$$365$$$O	e.g.,$$$366$$$371$$$O	in$$$372$$$374$$$O	the$$$375$$$378$$$O	GI$$$379$$$381$$$O	tract$$$382$$$387$$$O	(colon)$$$388$$$395$$$O	that$$$396$$$400$$$O	are$$$401$$$404$$$O	associated$$$405$$$415$$$O	with$$$416$$$420$$$O	diarrhea$$$421$$$429$$$O	and/or$$$430$$$436$$$O	improper$$$437$$$445$$$O	electrolyte$$$446$$$457$$$O	and$$$458$$$461$$$O	fluid$$$462$$$467$$$O	excretion$$$468$$$477$$$O	from$$$478$$$482$$$O	the$$$483$$$486$$$O	bowel$$$487$$$492$$$O	or$$$493$$$495$$$O	urinary$$$496$$$503$$$O	system.$$$504$$$511$$$O	More$$$512$$$516$$$O	specifically,$$$517$$$530$$$O	this$$$531$$$535$$$O	invention$$$536$$$545$$$O	relates$$$546$$$553$$$O	to$$$554$$$556$$$O	treatments$$$557$$$567$$$O	using$$$568$$$573$$$O	the$$$574$$$577$$$O	anti-CGRP$$$578$$$587$$$O	antibodies$$$588$$$598$$$O	and$$$599$$$602$$$O	fragments$$$603$$$612$$$O	described$$$613$$$622$$$O	herein,$$$623$$$630$$$O	and$$$631$$$634$$$O	binding$$$635$$$642$$$O	fragments$$$643$$$652$$$O	thereof.$$$653$$$661$$$O
WO2010144043A1
A$$$0$$$1$$$O	novel$$$2$$$7$$$O	4-methylbenzenesulphonate$$$8$$$33$$$I	salt$$$34$$$38$$$O	and$$$39$$$42$$$O	a$$$43$$$44$$$O	process$$$45$$$52$$$O	for$$$53$$$56$$$O	preparing$$$57$$$66$$$O	a$$$67$$$68$$$O	pharmaceutical$$$69$$$83$$$O	composition$$$84$$$95$$$O	comprising$$$96$$$106$$$O	the$$$107$$$110$$$O	salt$$$111$$$115$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	4-methylbenzenesulphonate$$$25$$$50$$$I	salt$$$51$$$55$$$O	of$$$56$$$58$$$O	the$$$59$$$62$$$O	muscarinic$$$63$$$73$$$O	antagonist$$$74$$$84$$$O	(R)-$$$85$$$89$$$I	1-(4-fluorophenethyl)-3-((S)-2-phenyl-2-(piperidin-1$$$90$$$142$$$I	-yl)propanoyloxy)-1-$$$143$$$163$$$I	azoniabicyclo[2.2.2]octane$$$164$$$190$$$I	and$$$191$$$194$$$O	its$$$195$$$198$$$O	use$$$199$$$202$$$O	in$$$203$$$205$$$O	therapy,as$$$206$$$216$$$O	well$$$217$$$221$$$O	as$$$222$$$224$$$O	a$$$225$$$226$$$O	process$$$227$$$234$$$O	for$$$235$$$238$$$O	preparing$$$239$$$248$$$O	a$$$249$$$250$$$O	pharmaceutical$$$251$$$265$$$O	composition$$$266$$$277$$$O	comprising$$$278$$$288$$$O	the$$$289$$$292$$$O	salt$$$293$$$297$$$O	and$$$298$$$301$$$O	its$$$302$$$305$$$O	use$$$306$$$309$$$O	in$$$310$$$312$$$O	therapy.$$$313$$$321$$$O
WO2011106334A1
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	dermatological$$$13$$$27$$$O	allergic$$$28$$$36$$$O	conditions$$$37$$$47$$$O
A$$$0$$$1$$$O	treatment$$$2$$$11$$$O	for$$$12$$$15$$$O	a$$$16$$$17$$$O	dermatological$$$18$$$32$$$O	allergic$$$33$$$41$$$O	condition$$$42$$$51$$$O	is$$$52$$$54$$$O	disclosed,$$$55$$$65$$$O	using$$$66$$$71$$$O	a$$$72$$$73$$$O	compound:$$$74$$$83$$$O	as$$$84$$$86$$$O	[4-(5-Aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone.$$$87$$$208$$$I
CN102626386A
Bacilli$$$0$$$7$$$O	calmette-gurin$$$8$$$22$$$O	polysaccharide$$$23$$$37$$$O	nucleic$$$38$$$45$$$O	acid$$$46$$$50$$$O	inhalation$$$51$$$61$$$O	aerosol$$$62$$$69$$$O	and$$$70$$$73$$$O	preparation$$$74$$$85$$$O	method$$$86$$$92$$$O	and$$$93$$$96$$$O	application$$$97$$$108$$$O	thereof$$$109$$$116$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	bacilli$$$26$$$33$$$O	calmette-gurin$$$34$$$48$$$O	polysaccharide$$$49$$$63$$$O	nucleic$$$64$$$71$$$O	acid$$$72$$$76$$$O	inhalation$$$77$$$87$$$O	aerosol$$$88$$$95$$$O	and$$$96$$$99$$$O	a$$$100$$$101$$$O	preparation$$$102$$$113$$$O	method$$$114$$$120$$$O	and$$$121$$$124$$$O	an$$$125$$$127$$$O	application$$$128$$$139$$$O	thereof.$$$140$$$148$$$O	The$$$149$$$152$$$O	aerosol$$$153$$$160$$$O	consists$$$161$$$169$$$O	of$$$170$$$172$$$O	bacilli$$$173$$$180$$$O	calmette-gurin$$$181$$$195$$$O	polysaccharide$$$196$$$210$$$O	nucleic$$$211$$$218$$$O	acid,$$$219$$$224$$$O	a$$$225$$$226$$$O	propellant,$$$227$$$238$$$O	a$$$239$$$240$$$O	cosolvent,$$$241$$$251$$$O	a$$$252$$$253$$$O	surfactant$$$254$$$264$$$O	and$$$265$$$268$$$O	a$$$269$$$270$$$O	preservative,$$$271$$$284$$$O	wherein$$$285$$$292$$$O	the$$$293$$$296$$$O	propellant$$$297$$$307$$$O	is$$$308$$$310$$$O	prepared$$$311$$$319$$$O	from$$$320$$$324$$$O	1,1,1,2-tetrafluoroethane$$$325$$$350$$$I	and$$$351$$$354$$$O	1,1,1,2,3,3,3-heptafluoropropane.$$$355$$$388$$$I	The$$$389$$$392$$$O	aerosol$$$393$$$400$$$O	is$$$401$$$403$$$O	prepared$$$404$$$412$$$O	with$$$413$$$417$$$O	a$$$418$$$419$$$O	pressure$$$420$$$428$$$O	filling$$$429$$$436$$$O	method$$$437$$$443$$$O	or$$$444$$$446$$$O	a$$$447$$$448$$$O	cover$$$449$$$454$$$O	filling$$$455$$$462$$$O	method$$$463$$$469$$$O	and$$$470$$$473$$$O	the$$$474$$$477$$$O	like;$$$478$$$483$$$O	and$$$484$$$487$$$O	an$$$488$$$490$$$O	aerosol$$$491$$$498$$$O	tank$$$499$$$503$$$O	is$$$504$$$506$$$O	provided$$$507$$$515$$$O	with$$$516$$$520$$$O	a$$$521$$$522$$$O	quantifying$$$523$$$534$$$O	valve$$$535$$$540$$$O	which$$$541$$$546$$$O	can$$$547$$$550$$$O	be$$$551$$$553$$$O	used$$$554$$$558$$$O	for$$$559$$$562$$$O	quantitatively$$$563$$$577$$$O	releasing$$$578$$$587$$$O	a$$$588$$$589$$$O	medicament.$$$590$$$601$$$O	Due$$$602$$$605$$$O	to$$$606$$$608$$$O	the$$$609$$$612$$$O	adoption$$$613$$$621$$$O	of$$$622$$$624$$$O	the$$$625$$$628$$$O	bacilli$$$629$$$636$$$O	calmette-gurin$$$637$$$651$$$O	polysaccharide$$$652$$$666$$$O	nucleic$$$667$$$674$$$O	acid$$$675$$$679$$$O	inhalation$$$680$$$690$$$O	aerosol$$$691$$$698$$$O	provided$$$699$$$707$$$O	by$$$708$$$710$$$O	the$$$711$$$714$$$O	invention,$$$715$$$725$$$O	the$$$726$$$729$$$O	bacilli$$$730$$$737$$$O	calmette-gurin$$$738$$$752$$$O	polysaccharide$$$753$$$767$$$O	nucleic$$$768$$$775$$$O	acid$$$776$$$780$$$O	can$$$781$$$784$$$O	be$$$785$$$787$$$O	directly$$$788$$$796$$$O	distributed$$$797$$$808$$$O	into$$$809$$$813$$$O	nasal$$$814$$$819$$$O	cavities,$$$820$$$829$$$O	trachea,$$$830$$$838$$$O	bronchus$$$839$$$847$$$O	and$$$848$$$851$$$O	lungs,$$$852$$$858$$$O	and$$$859$$$862$$$O	is$$$863$$$865$$$O	taken$$$866$$$871$$$O	as$$$872$$$874$$$O	a$$$875$$$876$$$O	medicament$$$877$$$887$$$O	for$$$888$$$891$$$O	treating$$$892$$$900$$$O	allergic$$$901$$$909$$$O	asthma/or$$$910$$$919$$$O	allergic$$$920$$$928$$$O	rhinitis.$$$929$$$938$$$O
US20090258951
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	vanillyl$$$7$$$15$$$I	alcohol$$$16$$$23$$$I	for$$$24$$$27$$$O	the$$$28$$$31$$$O	treatment$$$32$$$41$$$O	of$$$42$$$44$$$O	Parkinson's$$$45$$$56$$$O	disease$$$57$$$64$$$O
A$$$0$$$1$$$O	use$$$2$$$5$$$O	of$$$6$$$8$$$O	Vanillyl$$$9$$$17$$$I	alcohol$$$18$$$25$$$I	for$$$26$$$29$$$O	treatment$$$30$$$39$$$O	of$$$40$$$42$$$O	Parkinson's$$$43$$$54$$$O	disease$$$55$$$62$$$O	is$$$63$$$65$$$O	disclosed$$$66$$$75$$$O	in$$$76$$$78$$$O	accordance$$$79$$$89$$$O	with$$$90$$$94$$$O	the$$$95$$$98$$$O	present$$$99$$$106$$$O	invention.$$$107$$$117$$$O	The$$$118$$$121$$$O	Vanillyl$$$122$$$130$$$I	alcohol's$$$131$$$140$$$I	formula$$$141$$$148$$$O	is$$$149$$$151$$$O	4-hydroxy-3-methoxy-benzyl$$$152$$$178$$$I	alcohol$$$179$$$186$$$I	and$$$187$$$190$$$O	similitude$$$191$$$201$$$O	with$$$202$$$206$$$O	the$$$207$$$210$$$O	human$$$211$$$216$$$O	neurotransmitter$$$217$$$233$$$O	dopamine.$$$234$$$243$$$I	The$$$244$$$247$$$O	Vanillyl$$$248$$$256$$$I	alcohol$$$257$$$264$$$I	has$$$265$$$268$$$O	dopamine$$$269$$$277$$$I	receptor$$$278$$$286$$$O	stimulant$$$287$$$296$$$O	and$$$297$$$300$$$O	which$$$301$$$306$$$O	is$$$307$$$309$$$O	applied$$$310$$$317$$$O	for$$$318$$$321$$$O	pharmaceutical$$$322$$$336$$$O	preparation$$$337$$$348$$$O	of$$$349$$$351$$$O	treating$$$352$$$360$$$O	Parkinson's$$$361$$$372$$$O	disease.$$$373$$$381$$$O
US20090297644
Herbal$$$0$$$6$$$O	compositions$$$7$$$19$$$O	for$$$20$$$23$$$O	the$$$24$$$27$$$O	treatment$$$28$$$37$$$O	of$$$38$$$40$$$O	diseases$$$41$$$49$$$O	of$$$50$$$52$$$O	the$$$53$$$56$$$O	oral$$$57$$$61$$$O	cavity$$$62$$$68$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	bioadhesive$$$33$$$44$$$O	compositions$$$45$$$57$$$O	for$$$58$$$61$$$O	oral$$$62$$$66$$$O	application,$$$67$$$79$$$O	which$$$80$$$85$$$O	comprise$$$86$$$94$$$O	a$$$95$$$96$$$O	curcuminoid$$$97$$$108$$$I	substance$$$109$$$118$$$O	as$$$119$$$121$$$O	an$$$122$$$124$$$O	active$$$125$$$131$$$O	ingredient.$$$132$$$143$$$O	The$$$144$$$147$$$O	present$$$148$$$155$$$O	invention$$$156$$$165$$$O	also$$$166$$$170$$$O	relates$$$171$$$178$$$O	to$$$179$$$181$$$O	method$$$182$$$188$$$O	of$$$189$$$191$$$O	using$$$192$$$197$$$O	said$$$198$$$202$$$O	bioadhesive$$$203$$$214$$$O	composition$$$215$$$226$$$O	for$$$227$$$230$$$O	the$$$231$$$234$$$O	prevention$$$235$$$245$$$O	and$$$246$$$249$$$O	treatment$$$250$$$259$$$O	of$$$260$$$262$$$O	periodontal$$$263$$$274$$$O	diseases$$$275$$$283$$$O	such$$$284$$$288$$$O	as$$$289$$$291$$$O	gingivitis$$$292$$$302$$$O	and$$$303$$$306$$$O	other$$$307$$$312$$$O	periodontal$$$313$$$324$$$O	diseases.$$$325$$$334$$$O
CN103127512A
Novel$$$0$$$5$$$O	drug$$$6$$$10$$$O	composition$$$11$$$22$$$O	for$$$23$$$26$$$O	curing$$$27$$$33$$$O	hepatitis$$$34$$$43$$$O	B$$$44$$$45$$$O	virus$$$46$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	novel$$$27$$$32$$$O	antiviral$$$33$$$42$$$O	drug$$$43$$$47$$$O	composition$$$48$$$59$$$O	and$$$60$$$63$$$O	a$$$64$$$65$$$O	method$$$66$$$72$$$O	for$$$73$$$76$$$O	curing$$$77$$$83$$$O	hepatitis$$$84$$$93$$$O	B$$$94$$$95$$$O	virus$$$96$$$101$$$O	(HBV)$$$102$$$107$$$O	infection$$$108$$$117$$$O	by$$$118$$$120$$$O	using$$$121$$$126$$$O	the$$$127$$$130$$$O	novel$$$131$$$136$$$O	antiviral$$$137$$$146$$$O	drug$$$147$$$151$$$O	composition.$$$152$$$164$$$O	The$$$165$$$168$$$O	novel$$$169$$$174$$$O	type$$$175$$$179$$$O	antiviral$$$180$$$189$$$O	drug$$$190$$$194$$$O	composition$$$195$$$206$$$O	comprises$$$207$$$216$$$O	1$$$217$$$218$$$I	-$$$219$$$220$$$I	(4$$$221$$$223$$$I	-$$$224$$$225$$$I	fluorine$$$226$$$234$$$I	phenyl)$$$235$$$242$$$I	-$$$243$$$244$$$I	(3R)$$$245$$$249$$$I	-$$$250$$$251$$$I	[3$$$252$$$254$$$I	-$$$255$$$256$$$I	(4$$$257$$$259$$$I	-$$$260$$$261$$$I	fluorine$$$262$$$270$$$I	phenyl)$$$271$$$278$$$I	-$$$279$$$280$$$I	(3S)$$$281$$$285$$$I	-$$$286$$$287$$$I	hydroxypropyl]$$$288$$$302$$$I	-$$$303$$$304$$$I	(4S)$$$305$$$309$$$I	-$$$310$$$311$$$I	(4$$$312$$$314$$$I	-$$$315$$$316$$$I	hydroxypropyl)$$$317$$$331$$$I	-$$$332$$$333$$$I	2$$$334$$$335$$$I	-$$$336$$$337$$$I	acrylic$$$338$$$345$$$I	amide$$$346$$$351$$$I	(ezetimibe,$$$352$$$363$$$I	structural$$$364$$$374$$$O	formula$$$375$$$382$$$O	presented$$$383$$$392$$$O	as$$$393$$$395$$$O	graph$$$396$$$401$$$O	1)$$$402$$$404$$$O	or$$$405$$$407$$$O	acceptable$$$408$$$418$$$O	derivatives$$$419$$$430$$$O	in$$$431$$$433$$$O	pharmaceutic$$$434$$$446$$$O	preparation$$$447$$$458$$$O	thereof,$$$459$$$467$$$O	and$$$468$$$471$$$O	a$$$472$$$473$$$O	HCV$$$474$$$477$$$O	copy$$$478$$$482$$$O	inhibitor.$$$483$$$493$$$O
US7718665
10-(o-Hydroxyphenyl)--3a,4,9,10-tetrahydro-2-alkyl-2,9,10a-triazacyclopenty[b]fluorene-1,3-diones$$$0$$$97$$$I	or$$$98$$$100$$$O	the$$$101$$$104$$$O	corresponding$$$105$$$118$$$O	2,10a-diaza-9$$$119$$$132$$$I	oxafluorenediones$$$133$$$150$$$I	or$$$151$$$153$$$I	1,10a-diaza-9-thiafluorenediones;$$$154$$$187$$$I	antiproliferative,$$$188$$$206$$$O	apoptosis-inducing$$$207$$$225$$$O	agents;$$$226$$$233$$$O	treating$$$234$$$242$$$O	color$$$243$$$248$$$O	cancer$$$249$$$255$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	the$$$13$$$16$$$O	formula$$$17$$$24$$$O	(1)$$$25$$$28$$$O	in$$$48$$$50$$$O	which$$$51$$$56$$$O	R1,$$$57$$$60$$$O	R2,$$$61$$$64$$$O	R3,$$$65$$$68$$$O	R4$$$69$$$71$$$O	and$$$72$$$75$$$O	X$$$76$$$77$$$O	have$$$78$$$82$$$O	the$$$83$$$86$$$O	meanings$$$87$$$95$$$O	indicated$$$96$$$105$$$O	in$$$106$$$108$$$O	the$$$109$$$112$$$O	description,$$$113$$$125$$$O	are$$$126$$$129$$$O	novel$$$130$$$135$$$O	effective$$$136$$$145$$$O	compounds$$$146$$$155$$$O	with$$$156$$$160$$$O	Eg5$$$161$$$164$$$O	inhibitory,$$$165$$$176$$$O	anti-proliferative$$$177$$$195$$$O	and/or$$$196$$$202$$$O	apoptosis$$$203$$$212$$$O	inducing$$$213$$$221$$$O	activity.$$$222$$$231$$$O
CN101439039B
Fortifier$$$0$$$9$$$O
An$$$0$$$2$$$O	agent$$$3$$$8$$$O	for$$$9$$$12$$$O	enhancing$$$13$$$22$$$O	therapeutic$$$23$$$34$$$O	or$$$35$$$37$$$O	prophylactic$$$38$$$50$$$O	effect$$$51$$$57$$$O	of$$$58$$$60$$$O	administering$$$61$$$74$$$O	an$$$75$$$77$$$O	inhibitor$$$78$$$87$$$O	of$$$88$$$90$$$O	renin-angiotensin$$$91$$$108$$$O	system,$$$109$$$116$$$O	such$$$117$$$121$$$O	as$$$122$$$124$$$O	candesartan$$$125$$$136$$$I	cilexetil,$$$137$$$147$$$I	on$$$148$$$150$$$O	renal$$$151$$$156$$$O	diseases$$$157$$$165$$$O	is$$$166$$$168$$$O	disclosed.$$$169$$$179$$$O	The$$$180$$$183$$$O	agent$$$184$$$189$$$O	comprises$$$190$$$199$$$O	a$$$200$$$201$$$O	specific$$$202$$$210$$$O	prostaglandin$$$211$$$224$$$O	I$$$225$$$226$$$O	derivative$$$227$$$237$$$O	such$$$238$$$242$$$O	as$$$243$$$245$$$O	beraprost$$$246$$$255$$$I	sodium$$$256$$$262$$$I	as$$$263$$$265$$$O	an$$$266$$$268$$$O	effective$$$269$$$278$$$O	ingredient.$$$279$$$290$$$O
US20130022593
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	diagnosing$$$11$$$21$$$O	endometriosis$$$22$$$35$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	biomarkers$$$31$$$41$$$O	for$$$42$$$45$$$O	the$$$46$$$49$$$O	diagnosis$$$50$$$59$$$O	and$$$60$$$63$$$O	prognosis$$$64$$$73$$$O	of$$$74$$$76$$$O	endometriosis.$$$77$$$91$$$O	Generally,$$$92$$$102$$$O	the$$$103$$$106$$$O	methods$$$107$$$114$$$O	of$$$115$$$117$$$O	this$$$118$$$122$$$O	invention$$$123$$$132$$$O	find$$$133$$$137$$$O	use$$$138$$$141$$$O	in$$$142$$$144$$$O	diagnosing$$$145$$$155$$$O	or$$$156$$$158$$$O	for$$$159$$$162$$$O	providing$$$163$$$172$$$O	a$$$173$$$174$$$O	prognosis$$$175$$$184$$$O	for$$$185$$$188$$$O	endometriosis$$$189$$$202$$$O	by$$$203$$$205$$$O	detecting$$$206$$$215$$$O	the$$$216$$$219$$$O	expression$$$220$$$230$$$O	levels$$$231$$$237$$$O	of$$$238$$$240$$$O	biomarkers,$$$241$$$252$$$O	which$$$253$$$258$$$O	are$$$259$$$262$$$O	differentially$$$263$$$277$$$O	expressed$$$278$$$287$$$O	(up-$$$288$$$292$$$O	or$$$293$$$295$$$O	down-regulated)$$$296$$$311$$$O	in$$$312$$$314$$$O	endometrial$$$315$$$326$$$O	cells$$$327$$$332$$$O	from$$$333$$$337$$$O	a$$$338$$$339$$$O	patient$$$340$$$347$$$O	with$$$348$$$352$$$O	endometriosis.$$$353$$$367$$$O	Similarly,$$$368$$$378$$$O	these$$$379$$$384$$$O	markers$$$385$$$392$$$O	can$$$393$$$396$$$O	be$$$397$$$399$$$O	used$$$400$$$404$$$O	to$$$405$$$407$$$O	diagnose$$$408$$$416$$$O	reduced$$$417$$$424$$$O	fertility$$$425$$$434$$$O	in$$$435$$$437$$$O	a$$$438$$$439$$$O	patient$$$440$$$447$$$O	with$$$448$$$452$$$O	endometriosis$$$453$$$466$$$O	or$$$467$$$469$$$O	to$$$470$$$472$$$O	provide$$$473$$$480$$$O	a$$$481$$$482$$$O	prognosis$$$483$$$492$$$O	for$$$493$$$496$$$O	a$$$497$$$498$$$O	fertility$$$499$$$508$$$O	trial$$$509$$$514$$$O	in$$$515$$$517$$$O	a$$$518$$$519$$$O	patient$$$520$$$527$$$O	suffering$$$528$$$537$$$O	from$$$538$$$542$$$O	endometriosis.$$$543$$$557$$$O	The$$$558$$$561$$$O	present$$$562$$$569$$$O	invention$$$570$$$579$$$O	also$$$580$$$584$$$O	provides$$$585$$$593$$$O	methods$$$594$$$601$$$O	of$$$602$$$604$$$O	identifying$$$605$$$616$$$O	a$$$617$$$618$$$O	compound$$$619$$$627$$$O	for$$$628$$$631$$$O	treating$$$632$$$640$$$O	or$$$641$$$643$$$O	preventing$$$644$$$654$$$O	endometriosis.$$$655$$$669$$$O	Finally,$$$670$$$678$$$O	the$$$679$$$682$$$O	present$$$683$$$690$$$O	invention$$$691$$$700$$$O	provides$$$701$$$709$$$O	kits$$$710$$$714$$$O	for$$$715$$$718$$$O	the$$$719$$$722$$$O	diagnosis$$$723$$$732$$$O	or$$$733$$$735$$$O	prognosis$$$736$$$745$$$O	of$$$746$$$748$$$O	endometriosis.$$$749$$$763$$$O
US20120220610
Inhibitions$$$0$$$11$$$O	of$$$12$$$14$$$O	glutaminase$$$15$$$26$$$O	c$$$27$$$28$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	of$$$42$$$44$$$O	reducing$$$45$$$53$$$O	the$$$54$$$57$$$O	production$$$58$$$68$$$O	of$$$69$$$71$$$O	glutamate$$$72$$$81$$$I	from$$$82$$$86$$$O	glutamine$$$87$$$96$$$I	by$$$97$$$99$$$O	glutaminase$$$100$$$111$$$O	C$$$112$$$113$$$O	in$$$114$$$116$$$O	a$$$117$$$118$$$O	cell$$$119$$$123$$$O	or$$$124$$$126$$$O	tissue.$$$127$$$134$$$O	The$$$135$$$138$$$O	method$$$139$$$145$$$O	involves$$$146$$$154$$$O	inhibiting$$$155$$$165$$$O	glutaminase$$$166$$$177$$$O	C$$$178$$$179$$$O	activity$$$180$$$188$$$O	in$$$189$$$191$$$O	the$$$192$$$195$$$O	cell$$$196$$$200$$$O	or$$$201$$$203$$$O	tissue$$$204$$$210$$$O	under$$$211$$$216$$$O	conditions$$$217$$$227$$$O	effective$$$228$$$237$$$O	to$$$238$$$240$$$O	reduce$$$241$$$247$$$O	production$$$248$$$258$$$O	of$$$259$$$261$$$O	glutamate$$$262$$$271$$$I	from$$$272$$$276$$$O	glutamine.$$$277$$$287$$$I	Compounds$$$288$$$297$$$O	for$$$298$$$301$$$O	carrying$$$302$$$310$$$O	out$$$311$$$314$$$O	this$$$315$$$319$$$O	method$$$320$$$326$$$O	are$$$327$$$330$$$O	also$$$331$$$335$$$O	disclosed.$$$336$$$346$$$O
CN1915230A
Injection$$$0$$$9$$$O	in$$$10$$$12$$$O	large$$$13$$$18$$$O	capacity$$$19$$$27$$$O	of$$$28$$$30$$$O	sodium$$$31$$$37$$$I	sulfonate$$$38$$$47$$$I	containing$$$48$$$58$$$O	tanshinone$$$59$$$69$$$I	Ã³ÃA$$$70$$$75$$$I	and$$$76$$$79$$$O	preparation$$$80$$$91$$$O	method$$$92$$$98$$$O
A$$$0$$$1$$$O	high-capacity$$$2$$$15$$$O	injection$$$16$$$25$$$O	contains$$$26$$$34$$$O	tanshinone$$$35$$$45$$$I	IIA-sodium$$$46$$$56$$$I	sulfonate$$$57$$$66$$$I	and$$$67$$$70$$$O	pharmacologically$$$71$$$88$$$O	acceptable$$$89$$$99$$$O	additive.$$$100$$$109$$$O	Its$$$110$$$113$$$O	preparing$$$114$$$123$$$O	process$$$124$$$131$$$O	is$$$132$$$134$$$O	also$$$135$$$139$$$O	disclosed.$$$140$$$150$$$O
CA2603199A1
Shigella$$$0$$$8$$$O	ipad$$$9$$$13$$$O	protein$$$14$$$21$$$O	and$$$22$$$25$$$O	its$$$26$$$29$$$O	use$$$30$$$33$$$O	as$$$34$$$36$$$O	a$$$37$$$38$$$O	vaccine$$$39$$$46$$$O	against$$$47$$$54$$$O	shigella$$$55$$$63$$$O	infection$$$64$$$73$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compositions$$$33$$$45$$$O	and$$$46$$$49$$$O	methods$$$50$$$57$$$O	for$$$58$$$61$$$O	blocking$$$62$$$70$$$O	entry$$$71$$$76$$$O	of$$$77$$$79$$$O	Shigella$$$80$$$88$$$O	into$$$89$$$93$$$O	a$$$94$$$95$$$O	cell$$$96$$$100$$$O	of$$$101$$$103$$$O	an$$$104$$$106$$$O	animal,$$$107$$$114$$$O	to$$$115$$$117$$$O	therefore$$$118$$$127$$$O	providing$$$128$$$137$$$O	protection$$$138$$$148$$$O	against,$$$149$$$157$$$O	or$$$158$$$160$$$O	reduce$$$161$$$167$$$O	the$$$168$$$171$$$O	severity$$$172$$$180$$$O	of$$$181$$$183$$$O	Shigella$$$184$$$192$$$O	infections.$$$193$$$204$$$O	More$$$205$$$209$$$O	particularly$$$210$$$222$$$O	it$$$223$$$225$$$O	relates$$$226$$$233$$$O	to$$$234$$$236$$$O	the$$$237$$$240$$$O	use$$$241$$$244$$$O	of$$$245$$$247$$$O	the$$$248$$$251$$$O	IpaD$$$252$$$256$$$O	protein$$$257$$$264$$$O	obtained$$$265$$$273$$$O	from$$$274$$$278$$$O	natural$$$279$$$286$$$O	sources$$$287$$$294$$$O	and/or$$$295$$$301$$$O	through$$$302$$$309$$$O	synthesis$$$310$$$319$$$O	or$$$320$$$322$$$O	recombinant$$$323$$$334$$$O	technology,$$$335$$$346$$$O	and$$$347$$$350$$$O	conjugates$$$351$$$361$$$O	thereof$$$362$$$369$$$O	to$$$370$$$372$$$O	induce$$$373$$$379$$$O	neutralizing$$$380$$$392$$$O	antibodies$$$393$$$403$$$O	having$$$404$$$410$$$O	protective$$$411$$$421$$$O	activity$$$422$$$430$$$O	against$$$431$$$438$$$O	several$$$439$$$446$$$O	serotypes$$$447$$$456$$$O	of$$$457$$$459$$$O	Shigella,$$$460$$$469$$$O	in$$$470$$$472$$$O	particular$$$473$$$483$$$O	S.$$$484$$$486$$$O	flexneri.$$$487$$$496$$$O	The$$$497$$$500$$$O	composition$$$501$$$512$$$O	of$$$513$$$515$$$O	the$$$516$$$519$$$O	invention$$$520$$$529$$$O	is$$$530$$$532$$$O	useful$$$533$$$539$$$O	to$$$540$$$542$$$O	prevent$$$543$$$550$$$O	and/or$$$551$$$557$$$O	treat$$$558$$$563$$$O	shigellosis$$$564$$$575$$$O	caused$$$576$$$582$$$O	by$$$583$$$585$$$O	a$$$586$$$587$$$O	bacterium$$$588$$$597$$$O	of$$$598$$$600$$$O	the$$$601$$$604$$$O	Shigella$$$605$$$613$$$O	family.$$$614$$$621$$$O
WO2013081087A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	optically$$$21$$$30$$$O	active$$$31$$$37$$$O	compound$$$38$$$46$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	preparing$$$13$$$22$$$O	trans-{4-[({2-[({1-[3,5-bis(tri-$$$23$$$55$$$I	fluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]-$$$56$$$112$$$I	pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}-$$$113$$$169$$$I	(ethyl)amino)methyl]cyclohexyl}acetic$$$170$$$207$$$I	acid$$$208$$$212$$$I	having$$$213$$$219$$$O	a$$$220$$$221$$$O	high$$$222$$$226$$$O	optical$$$227$$$234$$$O	purity$$$235$$$241$$$O	from$$$242$$$246$$$O	trans-{4-[({2-[({1-[3,5-bis(trifluoro-$$$247$$$285$$$I	methyl)phenyl]ethyl}$$$286$$$306$$$I	{5-[2-(methylthio)ethoxy]pyrimidin-2-$$$307$$$344$$$I	yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)-$$$345$$$402$$$I	methyl]cyclohexyl}acetic$$$403$$$427$$$I	acid$$$428$$$432$$$I	having$$$433$$$439$$$O	a$$$440$$$441$$$O	low$$$442$$$445$$$O	optical$$$446$$$453$$$O	purity,$$$454$$$461$$$O	including$$$462$$$471$$$O	a$$$472$$$473$$$O	step$$$474$$$478$$$O	of$$$479$$$481$$$O	subjecting$$$482$$$492$$$O	a$$$493$$$494$$$O	salt$$$495$$$499$$$O	of$$$500$$$502$$$O	the$$$503$$$506$$$O	starting$$$507$$$515$$$O	(latter)$$$516$$$524$$$O	substance$$$525$$$534$$$O	with$$$535$$$539$$$O	an$$$540$$$542$$$O	optically$$$543$$$552$$$O	inactive$$$553$$$561$$$O	acid$$$562$$$566$$$O	to$$$567$$$569$$$O	crystallization$$$570$$$585$$$O	in$$$586$$$588$$$O	a$$$589$$$590$$$O	solvent$$$591$$$598$$$O	and$$$599$$$602$$$O	then$$$603$$$607$$$O	isolating$$$608$$$617$$$O	the$$$618$$$621$$$O	resulting$$$622$$$631$$$O	crystals.$$$632$$$641$$$O
EP2711372A1
The$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	pregnane$$$11$$$19$$$I	and$$$20$$$23$$$O	androstane$$$24$$$34$$$I	steroids$$$35$$$43$$$I	for$$$44$$$47$$$O	the$$$48$$$51$$$O	manufacture$$$52$$$63$$$O	of$$$64$$$66$$$O	a$$$67$$$68$$$O	pharmaceutical$$$69$$$83$$$O	composition$$$84$$$95$$$O	for$$$96$$$99$$$O	the$$$100$$$103$$$O	treatment$$$104$$$113$$$O	of$$$114$$$116$$$O	CNS$$$117$$$120$$$O	disorders$$$121$$$130$$$O
Steroid$$$0$$$7$$$I	compounds$$$8$$$17$$$O	having$$$18$$$24$$$O	increased$$$25$$$34$$$O	resistance$$$35$$$45$$$O	against$$$46$$$53$$$O	metabolism$$$54$$$64$$$O	and$$$65$$$68$$$O	increased$$$69$$$78$$$O	water$$$79$$$84$$$O	solubility$$$85$$$95$$$O	are$$$96$$$99$$$O	disclosed,$$$100$$$110$$$O	together$$$111$$$119$$$O	with$$$120$$$124$$$O	methods$$$125$$$132$$$O	for$$$133$$$136$$$O	their$$$137$$$142$$$O	production.$$$143$$$154$$$O	These$$$155$$$160$$$O	substances$$$161$$$171$$$O	are$$$172$$$175$$$O	suitable$$$176$$$184$$$O	for$$$185$$$188$$$O	the$$$189$$$192$$$O	manufacture$$$193$$$204$$$O	of$$$205$$$207$$$O	pharmaceuticals$$$208$$$223$$$O	for$$$224$$$227$$$O	the$$$228$$$231$$$O	treatment$$$232$$$241$$$O	of$$$242$$$244$$$O	steroid$$$245$$$252$$$I	related$$$253$$$260$$$O	or$$$261$$$263$$$O	steroid$$$264$$$271$$$I	induced$$$272$$$279$$$O	CNS$$$280$$$283$$$O	disorders$$$284$$$293$$$O	and$$$294$$$297$$$O	for$$$298$$$301$$$O	use$$$302$$$305$$$O	in$$$306$$$308$$$O	methods$$$309$$$316$$$O	of$$$317$$$319$$$O	prevention,$$$320$$$331$$$O	alleviation$$$332$$$343$$$O	or$$$344$$$346$$$O	treatment$$$347$$$356$$$O	of$$$357$$$359$$$O	such$$$360$$$364$$$O	disorders.$$$365$$$375$$$O
CA2153849C
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	improving$$$11$$$20$$$O	breeding$$$21$$$29$$$O	activity$$$30$$$38$$$O	of$$$39$$$41$$$O	boars$$$42$$$47$$$O	by$$$48$$$50$$$O	using$$$51$$$56$$$O	feed$$$57$$$61$$$O	for$$$62$$$65$$$O	the$$$66$$$69$$$O	breeding$$$70$$$78$$$O	boars$$$79$$$84$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	aims$$$15$$$19$$$O	at$$$20$$$22$$$O	improving$$$23$$$32$$$O	the$$$33$$$36$$$O	breeding$$$37$$$45$$$O	activity$$$46$$$54$$$O	of$$$55$$$57$$$O	boars,$$$58$$$64$$$O	especially$$$65$$$75$$$O	at$$$76$$$78$$$O	preventing$$$79$$$89$$$O	the$$$90$$$93$$$O	reduction$$$94$$$103$$$O	of$$$104$$$106$$$O	fertilization$$$107$$$120$$$O	capacity$$$121$$$129$$$O	in$$$130$$$132$$$O	the$$$133$$$136$$$O	hot$$$137$$$140$$$O	season,$$$141$$$148$$$O	more$$$149$$$153$$$O	particularly,$$$154$$$167$$$O	this$$$168$$$172$$$O	invention$$$173$$$182$$$O	provides$$$183$$$191$$$O	a$$$192$$$193$$$O	method$$$194$$$200$$$O	for$$$201$$$204$$$O	improving$$$205$$$214$$$O	the$$$215$$$218$$$O	breeding$$$219$$$227$$$O	activity$$$228$$$236$$$O	of$$$237$$$239$$$O	boars$$$240$$$245$$$O	with$$$246$$$250$$$O	the$$$251$$$254$$$O	use$$$255$$$258$$$O	of$$$259$$$261$$$O	a$$$262$$$263$$$O	feed$$$264$$$268$$$O	for$$$269$$$272$$$O	breeding$$$273$$$281$$$O	boars$$$282$$$287$$$O	which$$$288$$$293$$$O	contains$$$294$$$302$$$O	saccharides$$$303$$$314$$$O	mainly$$$315$$$321$$$O	composed$$$322$$$330$$$O	of$$$331$$$333$$$O	oligosaccharides.$$$334$$$351$$$O
CN102796040A
1,4-disubstituted$$$0$$$17$$$I	piperazine$$$18$$$28$$$I	derivatives$$$29$$$40$$$O	and$$$41$$$44$$$O	their$$$45$$$50$$$O	preparation$$$51$$$62$$$O	method$$$63$$$69$$$O	and$$$70$$$73$$$O	use$$$74$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	antiplatelet$$$48$$$60$$$O	drugs$$$61$$$66$$$O	and$$$67$$$70$$$O	provides$$$71$$$79$$$O	1,4-disubstituted$$$80$$$97$$$I	piperazine$$$98$$$108$$$I	derivatives$$$109$$$120$$$O	and$$$121$$$124$$$O	pharmaceutically$$$125$$$141$$$O	acceptable$$$142$$$152$$$O	salts$$$153$$$158$$$O	thereof.$$$159$$$167$$$O	The$$$168$$$171$$$O	1,4-disubstituted$$$172$$$189$$$I	piperazine$$$190$$$200$$$I	derivatives$$$201$$$212$$$O	have$$$213$$$217$$$O	a$$$218$$$219$$$O	general$$$220$$$227$$$O	structural$$$228$$$238$$$O	formula$$$239$$$246$$$O	I.$$$247$$$249$$$O	In$$$250$$$252$$$O	the$$$253$$$256$$$O	general$$$257$$$264$$$O	structural$$$265$$$275$$$O	formula$$$276$$$283$$$O	I,$$$284$$$286$$$O	x,$$$287$$$289$$$O	y,$$$290$$$292$$$O	m,$$$293$$$295$$$O	R1,$$$296$$$299$$$O	R2,$$$300$$$303$$$O	R3$$$304$$$306$$$O	and$$$307$$$310$$$O	R4$$$311$$$313$$$O	are$$$314$$$317$$$O	defined$$$318$$$325$$$O	in$$$326$$$328$$$O	the$$$329$$$332$$$O	patent$$$333$$$339$$$O	specification.$$$340$$$354$$$O	The$$$355$$$358$$$O	invention$$$359$$$368$$$O	relates$$$369$$$376$$$O	to$$$377$$$379$$$O	a$$$380$$$381$$$O	preparation$$$382$$$393$$$O	method$$$394$$$400$$$O	of$$$401$$$403$$$O	the$$$404$$$407$$$O	1,4-disubstituted$$$408$$$425$$$I	piperazine$$$426$$$436$$$I	derivatives,$$$437$$$449$$$O	discloses$$$450$$$459$$$O	a$$$460$$$461$$$O	drug$$$462$$$466$$$O	composition$$$467$$$478$$$O	containing$$$479$$$489$$$O	the$$$490$$$493$$$O	1,4-disubstituted$$$494$$$511$$$I	piperazine$$$512$$$522$$$I	derivatives$$$523$$$534$$$O	or$$$535$$$537$$$O	their$$$538$$$543$$$O	pharmaceutically$$$544$$$560$$$O	acceptable$$$561$$$571$$$O	salts$$$572$$$577$$$O	as$$$578$$$580$$$O	active$$$581$$$587$$$O	ingredients,$$$588$$$600$$$O	and$$$601$$$604$$$O	also$$$605$$$609$$$O	discloses$$$610$$$619$$$O	a$$$620$$$621$$$O	use$$$622$$$625$$$O	of$$$626$$$628$$$O	the$$$629$$$632$$$O	1,4-disubstituted$$$633$$$650$$$I	piperazine$$$651$$$661$$$I	derivatives$$$662$$$673$$$O	and$$$674$$$677$$$O	their$$$678$$$683$$$O	pharmaceutically$$$684$$$700$$$O	acceptable$$$701$$$711$$$O	salts$$$712$$$717$$$O	in$$$718$$$720$$$O	antiplatelet$$$721$$$733$$$O	drugs.$$$734$$$740$$$O
US20110182849
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	treating$$$29$$$37$$$O	an$$$38$$$40$$$O	intervertebral$$$41$$$55$$$O	disc$$$56$$$60$$$O	using$$$61$$$66$$$O	bulking$$$67$$$74$$$O	agents$$$75$$$81$$$O	or$$$82$$$84$$$O	sealing$$$85$$$92$$$O	agents$$$93$$$99$$$O
Effective$$$0$$$9$$$O	compositions$$$10$$$22$$$O	and$$$23$$$26$$$O	methods$$$27$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	an$$$48$$$50$$$O	intervertebral$$$51$$$65$$$O	disc$$$66$$$70$$$O	are$$$71$$$74$$$O	provided.$$$75$$$84$$$O	The$$$85$$$88$$$O	compositions$$$89$$$101$$$O	and$$$102$$$105$$$O	methods$$$106$$$113$$$O	comprise$$$114$$$122$$$O	a$$$123$$$124$$$O	bulking$$$125$$$132$$$O	agent$$$133$$$138$$$O	or$$$139$$$141$$$O	sealing$$$142$$$149$$$O	agent,$$$150$$$156$$$O	the$$$157$$$160$$$O	bulking$$$161$$$168$$$O	agent$$$169$$$174$$$O	or$$$175$$$177$$$O	sealing$$$178$$$185$$$O	agent$$$186$$$191$$$O	adapted$$$192$$$199$$$O	to$$$200$$$202$$$O	be$$$203$$$205$$$O	administered$$$206$$$218$$$O	at$$$219$$$221$$$O	or$$$222$$$224$$$O	within$$$225$$$231$$$O	the$$$232$$$235$$$O	intervertebral$$$236$$$250$$$O	disc,$$$251$$$256$$$O	the$$$257$$$260$$$O	bulking$$$261$$$268$$$O	or$$$269$$$271$$$O	sealing$$$272$$$279$$$O	agent$$$280$$$285$$$O	having$$$286$$$292$$$O	a$$$293$$$294$$$O	drug$$$295$$$299$$$O	depot$$$300$$$305$$$O	comprising$$$306$$$316$$$O	an$$$317$$$319$$$O	effective$$$320$$$329$$$O	amount$$$330$$$336$$$O	of$$$337$$$339$$$O	a$$$340$$$341$$$O	therapeutic$$$342$$$353$$$O	agent$$$354$$$359$$$O	disposed$$$360$$$368$$$O	therein,$$$369$$$377$$$O	wherein$$$378$$$385$$$O	the$$$386$$$389$$$O	drug$$$390$$$394$$$O	depot$$$395$$$400$$$O	is$$$401$$$403$$$O	capable$$$404$$$411$$$O	of$$$412$$$414$$$O	releasing$$$415$$$424$$$O	an$$$425$$$427$$$O	effective$$$428$$$437$$$O	amount$$$438$$$444$$$O	of$$$445$$$447$$$O	the$$$448$$$451$$$O	therapeutic$$$452$$$463$$$O	agent$$$464$$$469$$$O	over$$$470$$$474$$$O	a$$$475$$$476$$$O	period$$$477$$$483$$$O	of$$$484$$$486$$$O	at$$$487$$$489$$$O	least$$$490$$$495$$$O	one$$$496$$$499$$$O	day.$$$500$$$504$$$O
WO2010131718A1
Anti-hyperglycemic$$$0$$$18$$$O	and/or$$$19$$$25$$$O	anti-hyperlipidemic$$$26$$$45$$$O	agent$$$46$$$51$$$O	comprising$$$52$$$62$$$O	material$$$63$$$71$$$O	containing$$$72$$$82$$$O	avian$$$83$$$88$$$O	skin-derived$$$89$$$101$$$O	sphingomyelin$$$102$$$115$$$I	as$$$116$$$118$$$O	active$$$119$$$125$$$O	ingredient$$$126$$$136$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	sphingomyelin-containing$$$15$$$39$$$I	material$$$40$$$48$$$O	which$$$49$$$54$$$O	can$$$55$$$58$$$O	be$$$59$$$61$$$O	produced$$$62$$$70$$$O	in$$$71$$$73$$$O	a$$$74$$$75$$$O	large$$$76$$$81$$$O	quantity$$$82$$$90$$$O	at$$$91$$$93$$$O	low$$$94$$$97$$$O	cost.$$$98$$$103$$$O	Also$$$104$$$108$$$O	disclosed$$$109$$$118$$$O	is$$$119$$$121$$$O	an$$$122$$$124$$$O	useful$$$125$$$131$$$O	use$$$132$$$135$$$O	application$$$136$$$147$$$O	of$$$148$$$150$$$O	a$$$151$$$152$$$O	sphingomyelin-containing$$$153$$$177$$$I	material.$$$178$$$187$$$O	Specifically$$$188$$$200$$$O	disclosed$$$201$$$210$$$O	is$$$211$$$213$$$O	an$$$214$$$216$$$O	anti-hyperglycemic$$$217$$$235$$$O	and/or$$$236$$$242$$$O	anti-hyperlipidemic$$$243$$$262$$$O	agent$$$263$$$268$$$O	comprising$$$269$$$279$$$O	a$$$280$$$281$$$O	material$$$282$$$290$$$O	containing$$$291$$$301$$$O	a$$$302$$$303$$$O	sphingomyelin$$$304$$$317$$$I	derived$$$318$$$325$$$O	from$$$326$$$330$$$O	an$$$331$$$333$$$O	avain$$$334$$$339$$$O	skin$$$340$$$344$$$O	as$$$345$$$347$$$O	an$$$348$$$350$$$O	active$$$351$$$357$$$O	ingredient.$$$358$$$369$$$O
US7240785
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	apparatus$$$11$$$20$$$O	for$$$21$$$24$$$O	transferring$$$25$$$37$$$O	substrates$$$38$$$48$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	a$$$37$$$38$$$O	method$$$39$$$45$$$O	for$$$46$$$49$$$O	transferring$$$50$$$62$$$O	substrates$$$63$$$73$$$O	by$$$74$$$76$$$O	receiving$$$77$$$86$$$O	a$$$87$$$88$$$O	first$$$89$$$94$$$O	substrate$$$95$$$104$$$O	at$$$105$$$107$$$O	a$$$108$$$109$$$O	first$$$110$$$115$$$O	substrate$$$116$$$125$$$O	receiving$$$126$$$135$$$O	station$$$136$$$143$$$O	in$$$144$$$146$$$O	a$$$147$$$148$$$O	first$$$149$$$154$$$O	transfer$$$155$$$163$$$O	unit$$$164$$$168$$$O	capable$$$169$$$176$$$O	of$$$177$$$179$$$O	holding$$$180$$$187$$$O	at$$$188$$$190$$$O	least$$$191$$$196$$$O	two$$$197$$$200$$$O	substrates,$$$201$$$212$$$O	moving$$$213$$$219$$$O	the$$$220$$$223$$$O	first$$$224$$$229$$$O	transfer$$$230$$$238$$$O	unit$$$239$$$243$$$O	containing$$$244$$$254$$$O	only$$$255$$$259$$$O	the$$$260$$$263$$$O	first$$$264$$$269$$$O	substrate$$$270$$$279$$$O	along$$$280$$$285$$$O	a$$$286$$$287$$$O	conveying$$$288$$$297$$$O	line$$$298$$$302$$$O	to$$$303$$$305$$$O	a$$$306$$$307$$$O	second$$$308$$$314$$$O	substrate$$$315$$$324$$$O	receiving$$$325$$$334$$$O	station,$$$335$$$343$$$O	causing$$$344$$$351$$$O	the$$$352$$$355$$$O	first$$$356$$$361$$$O	transfer$$$362$$$370$$$O	unit$$$371$$$375$$$O	to$$$376$$$378$$$O	receive$$$379$$$386$$$O	a$$$387$$$388$$$O	second$$$389$$$395$$$O	substrate$$$396$$$405$$$O	at$$$406$$$408$$$O	the$$$409$$$412$$$O	second$$$413$$$419$$$O	substrate$$$420$$$429$$$O	receiving$$$430$$$439$$$O	station;$$$440$$$448$$$O	and$$$449$$$452$$$O	transferring$$$453$$$465$$$O	the$$$466$$$469$$$O	first$$$470$$$475$$$O	and$$$476$$$479$$$O	second$$$480$$$486$$$O	substrates$$$487$$$497$$$O	simultaneously$$$498$$$512$$$O	to$$$513$$$515$$$O	a$$$516$$$517$$$O	substrate$$$518$$$527$$$O	transfer$$$528$$$536$$$O	station.$$$537$$$545$$$O
CN102643186A
Anthraquinone$$$0$$$13$$$I	dimer$$$14$$$19$$$I	derivative$$$20$$$30$$$O	and$$$31$$$34$$$O	preparation$$$35$$$46$$$O	method$$$47$$$53$$$O	and$$$54$$$57$$$O	application$$$58$$$69$$$O	thereof$$$70$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	anthraquinone$$$25$$$38$$$I	dimer$$$39$$$44$$$I	derivatives$$$45$$$56$$$O	and$$$57$$$60$$$O	a$$$61$$$62$$$O	preparation$$$63$$$74$$$O	method$$$75$$$81$$$O	and$$$82$$$85$$$O	application$$$86$$$97$$$O	thereof.$$$98$$$106$$$O	The$$$107$$$110$$$O	preparation$$$111$$$122$$$O	method$$$123$$$129$$$O	comprises$$$130$$$139$$$O	the$$$140$$$143$$$O	steps$$$144$$$149$$$O	of$$$150$$$152$$$O	firstly$$$153$$$160$$$O	conducting$$$161$$$171$$$O	strain$$$172$$$178$$$O	culture$$$179$$$186$$$O	of$$$187$$$189$$$O	an$$$190$$$192$$$O	endophytic$$$193$$$203$$$O	fungus$$$204$$$210$$$O	Alternaria$$$211$$$221$$$O	sp.$$$222$$$225$$$O	(ZJ-2008003)$$$226$$$238$$$O	coming$$$239$$$245$$$O	from$$$246$$$250$$$O	South$$$251$$$256$$$O	China$$$257$$$262$$$O	Sea$$$263$$$266$$$O	soft$$$267$$$271$$$O	coral$$$272$$$277$$$O	Sarcophyton$$$278$$$289$$$O	Sp.$$$290$$$293$$$O	in$$$294$$$296$$$O	a$$$297$$$298$$$O	strain$$$299$$$305$$$O	culture$$$306$$$313$$$O	medium,$$$314$$$321$$$O	conducting$$$322$$$332$$$O	fermentation$$$333$$$345$$$O	culture$$$346$$$353$$$O	in$$$354$$$356$$$O	a$$$357$$$358$$$O	fermentation$$$359$$$371$$$O	culture$$$372$$$379$$$O	medium,$$$380$$$387$$$O	filtering$$$388$$$397$$$O	the$$$398$$$401$$$O	obtained$$$402$$$410$$$O	fermentation$$$411$$$423$$$O	liquid,$$$424$$$431$$$O	removing$$$432$$$440$$$O	filtrate$$$441$$$449$$$O	to$$$450$$$452$$$O	obtain$$$453$$$459$$$O	thalli,$$$460$$$467$$$O	extracting$$$468$$$478$$$O	the$$$479$$$482$$$O	thalli$$$483$$$489$$$O	by$$$490$$$492$$$O	using$$$493$$$498$$$O	methanol,$$$499$$$508$$$I	concentrating$$$509$$$522$$$O	the$$$523$$$526$$$O	extract,$$$527$$$535$$$O	conducting$$$536$$$546$$$O	silica$$$547$$$553$$$O	gel$$$554$$$557$$$O	column$$$558$$$564$$$O	chromatography,$$$565$$$580$$$O	Sephadex$$$581$$$589$$$O	LH-20$$$590$$$595$$$O	gel$$$596$$$599$$$O	column$$$600$$$606$$$O	chromatography$$$607$$$621$$$O	and$$$622$$$625$$$O	high-performance$$$626$$$642$$$O	liquid$$$643$$$649$$$O	chromatographic$$$650$$$665$$$O	preparation,$$$666$$$678$$$O	concentrating$$$679$$$692$$$O	the$$$693$$$696$$$O	eluent$$$697$$$703$$$O	to$$$704$$$706$$$O	obtain$$$707$$$713$$$O	red$$$714$$$717$$$O	powder,$$$718$$$725$$$O	which$$$726$$$731$$$O	is$$$732$$$734$$$O	the$$$735$$$738$$$O	anthraquinone$$$739$$$752$$$I	dimer$$$753$$$758$$$I	derivatives$$$759$$$770$$$O	alterporriol$$$771$$$783$$$I	Q$$$784$$$785$$$I	and$$$786$$$789$$$O	alterporriol$$$790$$$802$$$I	R.$$$803$$$805$$$I	The$$$806$$$809$$$O	anthraquinone$$$810$$$823$$$I	dimmer$$$824$$$830$$$I	derivatives$$$831$$$842$$$O	coming$$$843$$$849$$$O	from$$$850$$$854$$$O	marine$$$855$$$861$$$O	fungi$$$862$$$867$$$O	have$$$868$$$872$$$O	a$$$873$$$874$$$O	strong$$$875$$$881$$$O	antiviral$$$882$$$891$$$O	effect,$$$892$$$899$$$O	can$$$900$$$903$$$O	effectively$$$904$$$915$$$O	inhibit$$$916$$$923$$$O	porcine$$$924$$$931$$$O	reproductive$$$932$$$944$$$O	and$$$945$$$948$$$O	respiratory$$$949$$$960$$$O	syndrome$$$961$$$969$$$O	viruses$$$970$$$977$$$O	(PRRSV)$$$978$$$985$$$O	and$$$986$$$989$$$O	can$$$990$$$993$$$O	be$$$994$$$996$$$O	used$$$997$$$1001$$$O	as$$$1002$$$1004$$$O	antiviral$$$1005$$$1014$$$O	drugs,$$$1015$$$1021$$$O	raw$$$1022$$$1025$$$O	materials$$$1026$$$1035$$$O	can$$$1036$$$1039$$$O	be$$$1040$$$1042$$$O	produced$$$1043$$$1051$$$O	in$$$1052$$$1054$$$O	a$$$1055$$$1056$$$O	large$$$1057$$$1062$$$O	scale$$$1063$$$1068$$$O	and$$$1069$$$1072$$$O	the$$$1073$$$1076$$$O	application$$$1077$$$1088$$$O	prospect$$$1089$$$1097$$$O	is$$$1098$$$1100$$$O	wide.$$$1101$$$1106$$$O
US20050166911
preparing$$$0$$$9$$$O	raw$$$10$$$13$$$O	material$$$14$$$22$$$O	liquid$$$23$$$29$$$O	so$$$30$$$32$$$O	that$$$33$$$37$$$O	lactulose$$$38$$$47$$$I	content$$$48$$$55$$$O	within$$$56$$$62$$$O	powder$$$63$$$69$$$O	produced$$$70$$$78$$$O	following$$$79$$$88$$$O	spray$$$89$$$94$$$O	drying$$$95$$$101$$$O	is$$$102$$$104$$$O	10$$$105$$$107$$$O	to$$$108$$$110$$$O	50%$$$111$$$114$$$O	by$$$115$$$117$$$O	weight,$$$118$$$125$$$O	protein$$$126$$$133$$$O	content$$$134$$$141$$$O	is$$$142$$$144$$$O	0.2$$$145$$$148$$$O	to$$$149$$$151$$$O	9.0$$$152$$$155$$$O	parts$$$156$$$161$$$O	by$$$162$$$164$$$O	weight$$$165$$$171$$$O	per$$$172$$$175$$$O	1$$$176$$$177$$$O	part$$$178$$$182$$$O	by$$$183$$$185$$$O	weight$$$186$$$192$$$O	of$$$193$$$195$$$O	lactulose,$$$196$$$206$$$I	and$$$207$$$210$$$O	chlorine$$$211$$$219$$$I	content$$$220$$$227$$$O	is$$$228$$$230$$$O	no$$$231$$$233$$$O	more$$$234$$$238$$$O	than$$$239$$$243$$$O	0.08$$$244$$$248$$$O	parts$$$249$$$254$$$O	by$$$255$$$257$$$O	weight$$$258$$$264$$$O	per$$$265$$$268$$$O	1$$$269$$$270$$$O	part$$$271$$$275$$$O	by$$$276$$$278$$$O	weight$$$279$$$285$$$O	of$$$286$$$288$$$O	protein,$$$289$$$297$$$O	drying$$$298$$$304$$$O
A$$$0$$$1$$$O	lactulose-containing$$$2$$$22$$$I	powder$$$23$$$29$$$O	composition$$$30$$$41$$$O	is$$$42$$$44$$$O	produced$$$45$$$53$$$O	by$$$54$$$56$$$O	preparing$$$57$$$66$$$O	a$$$67$$$68$$$O	raw$$$69$$$72$$$O	material$$$73$$$81$$$O	liquid$$$82$$$88$$$O	so$$$89$$$91$$$O	that$$$92$$$96$$$O	a$$$97$$$98$$$O	lactulose$$$99$$$108$$$I	content$$$109$$$116$$$O	within$$$117$$$123$$$O	a$$$124$$$125$$$O	powder$$$126$$$132$$$O	produced$$$133$$$141$$$O	following$$$142$$$151$$$O	spray$$$152$$$157$$$O	drying$$$158$$$164$$$O	is$$$165$$$167$$$O	10$$$168$$$170$$$O	to$$$171$$$173$$$O	50%$$$174$$$177$$$O	by$$$178$$$180$$$O	weight,$$$181$$$188$$$O	a$$$189$$$190$$$O	protein$$$191$$$198$$$O	content$$$199$$$206$$$O	is$$$207$$$209$$$O	0.2$$$210$$$213$$$O	to$$$214$$$216$$$O	9.0$$$217$$$220$$$O	parts$$$221$$$226$$$O	by$$$227$$$229$$$O	weight$$$230$$$236$$$O	per$$$237$$$240$$$O	1$$$241$$$242$$$O	part$$$243$$$247$$$O	by$$$248$$$250$$$O	weight$$$251$$$257$$$O	of$$$258$$$260$$$O	lactulose,$$$261$$$271$$$I	and$$$272$$$275$$$O	a$$$276$$$277$$$O	chlorine$$$278$$$286$$$O	content$$$287$$$294$$$O	is$$$295$$$297$$$O	no$$$298$$$300$$$O	more$$$301$$$305$$$O	than$$$306$$$310$$$O	0.08$$$311$$$315$$$O	parts$$$316$$$321$$$O	by$$$322$$$324$$$O	weight$$$325$$$331$$$O	per$$$332$$$335$$$O	1$$$336$$$337$$$O	part$$$338$$$342$$$O	by$$$343$$$345$$$O	weight$$$346$$$352$$$O	of$$$353$$$355$$$O	protein,$$$356$$$364$$$O	and$$$365$$$368$$$O	subsequently$$$369$$$381$$$O	subjecting$$$382$$$392$$$O	this$$$393$$$397$$$O	raw$$$398$$$401$$$O	material$$$402$$$410$$$O	liquid$$$411$$$417$$$O	to$$$418$$$420$$$O	spray$$$421$$$426$$$O	drying.$$$427$$$434$$$O
US6849624
Headaches;$$$0$$$10$$$O	antiarthritic$$$11$$$24$$$O	agents;$$$25$$$32$$$O	respiratory$$$33$$$44$$$O	system$$$45$$$51$$$O	disorders;$$$52$$$62$$$O	psychological$$$63$$$76$$$O	disorders$$$77$$$86$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	the$$$17$$$20$$$O	compounds$$$21$$$30$$$O	2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1Î»6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide$$$32$$$154$$$I	and$$$155$$$158$$$I	2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1Î»6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.$$$159$$$301$$$I	Compounds$$$303$$$312$$$O	of$$$313$$$315$$$O	the$$$316$$$319$$$O	invention$$$320$$$329$$$O	are$$$330$$$333$$$O	useful$$$334$$$340$$$O	in$$$341$$$343$$$O	pharmaceutical$$$344$$$358$$$O	compositions$$$359$$$371$$$O	for$$$372$$$375$$$O	the$$$376$$$379$$$O	treatment$$$380$$$389$$$O	of$$$390$$$392$$$O	migraine,$$$393$$$402$$$O	rheumatoid$$$403$$$413$$$O	arthritis,$$$414$$$424$$$O	asthma,$$$425$$$432$$$O	bronchial$$$433$$$442$$$O	hyperreactivity,$$$443$$$459$$$O	inflammatory$$$460$$$472$$$O	bowel$$$473$$$478$$$O	disease$$$479$$$486$$$O	or$$$487$$$489$$$O	for$$$490$$$493$$$O	the$$$494$$$497$$$O	treatment$$$498$$$507$$$O	of$$$508$$$510$$$O	disorders$$$511$$$520$$$O	including$$$521$$$530$$$O	Parkinson's$$$531$$$542$$$O	disease,$$$543$$$551$$$O	anxiety,$$$552$$$560$$$O	depression,$$$561$$$572$$$O	pain,$$$573$$$578$$$O	headache,$$$579$$$588$$$O	Alzheimer's$$$589$$$600$$$O	disease,$$$601$$$609$$$O	multiple$$$610$$$618$$$O	sclerosis,$$$619$$$629$$$O	edema,$$$630$$$636$$$O	allergic$$$637$$$645$$$O	rhinitis,$$$646$$$655$$$O	Crohn's$$$656$$$663$$$O	disease,$$$664$$$672$$$O	ocular$$$673$$$679$$$O	injury,$$$680$$$687$$$O	ocular$$$688$$$694$$$O	inflammatory$$$695$$$707$$$O	diseases,$$$708$$$717$$$O	psychosis,$$$718$$$728$$$O	motion$$$729$$$735$$$O	sickness,$$$736$$$745$$$O	induced$$$746$$$753$$$O	vomiting,$$$754$$$763$$$O	emesis,$$$764$$$771$$$O	urinary$$$772$$$779$$$O	incontinence,$$$780$$$793$$$O	psychoimmunologic$$$794$$$811$$$O	or$$$812$$$814$$$O	psychosomatic$$$815$$$828$$$O	disorders,$$$829$$$839$$$O	cancer,$$$840$$$847$$$O	withdrawal$$$848$$$858$$$O	symptoms$$$859$$$867$$$O	of$$$868$$$870$$$O	addictive$$$871$$$880$$$O	drugs$$$881$$$886$$$O	from$$$887$$$891$$$O	opiates$$$892$$$899$$$O	or$$$900$$$902$$$I	nicotine,$$$903$$$912$$$I	traumatic$$$913$$$922$$$O	brain$$$923$$$928$$$O	injury$$$929$$$935$$$O	or$$$936$$$938$$$O	benign$$$939$$$945$$$O	prostatic$$$946$$$955$$$O	hyperplasia.$$$956$$$968$$$O
US8673347
Polymer$$$0$$$7$$$O	conjugates$$$8$$$18$$$O	of$$$19$$$21$$$O	K-252A$$$22$$$28$$$I	and$$$29$$$32$$$O	derivatives$$$33$$$44$$$O	thereof$$$45$$$52$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	polymer$$$39$$$46$$$O	conjugates$$$47$$$57$$$O	of$$$58$$$60$$$O	K-252a$$$61$$$67$$$I	and$$$68$$$71$$$O	derivatives$$$72$$$83$$$O	thereof$$$84$$$91$$$O	and$$$92$$$95$$$O	to$$$96$$$98$$$O	their$$$99$$$104$$$O	use$$$105$$$108$$$O	for$$$109$$$112$$$O	the$$$113$$$116$$$O	preparation$$$117$$$128$$$O	of$$$129$$$131$$$O	a$$$132$$$133$$$O	pharmaceutical$$$134$$$148$$$O	composition$$$149$$$160$$$O	useful$$$161$$$167$$$O	for$$$168$$$171$$$O	the$$$172$$$175$$$O	prevention,$$$176$$$187$$$O	alleviation$$$188$$$199$$$O	and$$$200$$$203$$$O	treatment$$$204$$$213$$$O	of$$$214$$$216$$$O	kinase-associated$$$217$$$234$$$O	pathologies.$$$235$$$247$$$O	In$$$248$$$250$$$O	particular,$$$251$$$262$$$O	the$$$263$$$266$$$O	present$$$267$$$274$$$O	invention$$$275$$$284$$$O	relates$$$285$$$292$$$O	to$$$293$$$295$$$O	the$$$296$$$299$$$O	prevention,$$$300$$$311$$$O	alleviation$$$312$$$323$$$O	and$$$324$$$327$$$O	treatment$$$328$$$337$$$O	of$$$338$$$340$$$O	HMGB1-associated$$$341$$$357$$$O	pathologies.$$$358$$$370$$$O	The$$$371$$$374$$$O	invention$$$375$$$384$$$O	relates$$$385$$$392$$$O	to$$$393$$$395$$$O	the$$$396$$$399$$$O	use$$$400$$$403$$$O	of$$$404$$$406$$$O	the$$$407$$$410$$$O	novel$$$411$$$416$$$O	polymer$$$417$$$424$$$O	conjugates$$$425$$$435$$$O	of$$$436$$$438$$$O	K-252a$$$439$$$445$$$I	and$$$446$$$449$$$O	derivatives$$$450$$$461$$$O	thereof$$$462$$$469$$$O	in$$$470$$$472$$$O	the$$$473$$$476$$$O	preparation$$$477$$$488$$$O	of$$$489$$$491$$$O	a$$$492$$$493$$$O	pharmaceutical$$$494$$$508$$$O	composition$$$509$$$520$$$O	useful$$$521$$$527$$$O	for$$$528$$$531$$$O	the$$$532$$$535$$$O	prevention,$$$536$$$547$$$O	alleviation$$$548$$$559$$$O	and$$$560$$$563$$$O	treatment$$$564$$$573$$$O	of$$$574$$$576$$$O	a)$$$577$$$579$$$O	neurological$$$580$$$592$$$O	disorders,$$$593$$$603$$$O	neuropathies$$$604$$$616$$$O	and$$$617$$$620$$$O	neurodegenerative$$$621$$$638$$$O	disorders$$$639$$$648$$$O	of$$$649$$$651$$$O	the$$$652$$$655$$$O	central$$$656$$$663$$$O	and$$$664$$$667$$$O	peripheral$$$668$$$678$$$O	nervous$$$679$$$686$$$O	system;$$$687$$$694$$$O	b)$$$695$$$697$$$O	dermal$$$698$$$704$$$O	pathologies,$$$705$$$717$$$O	in$$$718$$$720$$$O	particular$$$721$$$731$$$O	dermal$$$732$$$738$$$O	pathologies$$$739$$$750$$$O	associated$$$751$$$761$$$O	with$$$762$$$766$$$O	an$$$767$$$769$$$O	excessive$$$770$$$779$$$O	keratinocyte$$$780$$$792$$$O	proliferation,$$$793$$$807$$$O	in$$$808$$$810$$$O	particular$$$811$$$821$$$O	psoriasis;$$$822$$$832$$$O	and$$$833$$$836$$$O	c)$$$837$$$839$$$O	NGF-related$$$840$$$851$$$O	pain.$$$852$$$857$$$O	More$$$858$$$862$$$O	specifically,$$$863$$$876$$$O	the$$$877$$$880$$$O	present$$$881$$$888$$$O	invention$$$889$$$898$$$O	relates$$$899$$$906$$$O	to$$$907$$$909$$$O	a$$$910$$$911$$$O	polymer$$$912$$$919$$$O	conjugate$$$920$$$929$$$O	of$$$930$$$932$$$O	K-252a$$$933$$$939$$$I	and$$$940$$$943$$$O	derivatives$$$944$$$955$$$O	thereof,$$$956$$$964$$$O	wherein$$$965$$$972$$$O	the$$$973$$$976$$$O	polymer$$$977$$$984$$$O	is$$$985$$$987$$$O	polyethylene$$$988$$$1000$$$I	glycol$$$1001$$$1007$$$I	or$$$1008$$$1010$$$O	methoxy-polyethylene$$$1011$$$1031$$$I	glycol$$$1032$$$1038$$$I	formula$$$1039$$$1046$$$O	(I).$$$1047$$$1051$$$O
WO2009122983A1
Ketone$$$0$$$6$$$I	accumulation$$$7$$$19$$$O	inhibitor$$$20$$$29$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	ketone$$$15$$$21$$$I	accumulation$$$22$$$34$$$O	inhibitor$$$35$$$44$$$O	which$$$45$$$50$$$O	can$$$51$$$54$$$O	inhibit$$$55$$$62$$$O	the$$$63$$$66$$$O	accumulation$$$67$$$79$$$O	of$$$80$$$82$$$O	ketones$$$83$$$90$$$I	which$$$91$$$96$$$O	is$$$97$$$99$$$O	caused$$$100$$$106$$$O	by$$$107$$$109$$$O	exercising.$$$110$$$121$$$O	The$$$123$$$126$$$O	ketone$$$127$$$133$$$I	accumulation$$$134$$$146$$$O	inhibitor$$$147$$$156$$$O	comprises$$$157$$$166$$$O	isomaltulose$$$167$$$179$$$O	as$$$180$$$182$$$O	an$$$183$$$185$$$O	active$$$186$$$192$$$O	ingredient.$$$193$$$204$$$O
CN101406457A
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	manufacture$$$16$$$27$$$O	of$$$28$$$30$$$O	a$$$31$$$32$$$O	pharmaceutical$$$33$$$47$$$O	product$$$48$$$55$$$O
A$$$0$$$1$$$O	process$$$2$$$9$$$O	for$$$10$$$13$$$O	the$$$14$$$17$$$O	preparation$$$18$$$29$$$O	of$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	comprising$$$62$$$72$$$O	a$$$73$$$74$$$O	homogeneous$$$75$$$86$$$O	or$$$87$$$89$$$O	substantially$$$90$$$103$$$O	homogeneous$$$104$$$115$$$O	mixture$$$116$$$123$$$O	of$$$124$$$126$$$O	citric$$$127$$$133$$$I	acid,$$$134$$$139$$$I	magnesium$$$140$$$149$$$I	oxide,$$$150$$$156$$$I	potassium$$$157$$$166$$$I	bicarbonate$$$167$$$178$$$I	and$$$179$$$182$$$O	sodium$$$183$$$189$$$I	picosulphate$$$190$$$202$$$I	and,$$$203$$$207$$$O	optionally,$$$208$$$219$$$O	saccharin$$$220$$$229$$$I	sodium$$$230$$$236$$$I	and/or$$$237$$$243$$$O	orange$$$244$$$250$$$O	flavour;$$$251$$$259$$$O	products,$$$260$$$269$$$O	intermediate$$$270$$$282$$$O	products,$$$283$$$292$$$O	and$$$293$$$296$$$O	uses$$$297$$$301$$$O	thereof.$$$302$$$310$$$O
US8821920
Therapeutic$$$0$$$11$$$O	patch$$$12$$$17$$$O	for$$$18$$$21$$$O	transdermal$$$22$$$33$$$O	delivery$$$34$$$42$$$O	of$$$43$$$45$$$O	capsaicin$$$46$$$55$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	topical$$$27$$$34$$$O	patch$$$35$$$40$$$O	comprising$$$41$$$51$$$O	a$$$52$$$53$$$O	therapeutic$$$54$$$65$$$O	compound-impermeable$$$66$$$86$$$O	backing$$$87$$$94$$$O	layer,$$$95$$$101$$$O	a$$$102$$$103$$$O	self-adhesive$$$104$$$117$$$O	matrix$$$118$$$124$$$O	based$$$125$$$130$$$O	on$$$131$$$133$$$O	polysiloxanes$$$134$$$147$$$O	and$$$148$$$151$$$O	containing$$$152$$$162$$$O	capsaicin$$$163$$$172$$$I	or$$$173$$$175$$$O	a$$$176$$$177$$$O	therapeutic$$$178$$$189$$$O	compound$$$190$$$198$$$O	analogous$$$199$$$208$$$O	to$$$209$$$211$$$O	capsaicin,$$$212$$$222$$$I	and$$$223$$$226$$$O	a$$$227$$$228$$$O	protective$$$229$$$239$$$O	film$$$240$$$244$$$O	to$$$245$$$247$$$O	be$$$248$$$250$$$O	removed$$$251$$$258$$$O	before$$$259$$$265$$$O	use,$$$266$$$270$$$O	in$$$271$$$273$$$O	which$$$274$$$279$$$O	the$$$280$$$283$$$O	matrix$$$284$$$290$$$O	contains$$$291$$$299$$$O	liquid$$$300$$$306$$$O	microreservoirs$$$307$$$322$$$O	based$$$323$$$328$$$O	on$$$329$$$331$$$O	an$$$332$$$334$$$O	amphiphilic$$$335$$$346$$$O	solvent,$$$347$$$355$$$O	in$$$356$$$358$$$O	which$$$359$$$364$$$O	the$$$365$$$368$$$O	therapeutic$$$369$$$380$$$O	compound$$$381$$$389$$$O	is$$$390$$$392$$$O	present$$$393$$$400$$$O	in$$$401$$$403$$$O	completely$$$404$$$414$$$O	dissolved$$$415$$$424$$$O	form$$$425$$$429$$$O	and$$$430$$$433$$$O	the$$$434$$$437$$$O	concentration$$$438$$$451$$$O	of$$$452$$$454$$$O	the$$$455$$$458$$$O	therapeutic$$$459$$$470$$$O	compound$$$471$$$479$$$O	in$$$480$$$482$$$O	the$$$483$$$486$$$O	microreservoir$$$487$$$501$$$O	droplets$$$502$$$510$$$O	is$$$511$$$513$$$O	below$$$514$$$519$$$O	the$$$520$$$523$$$O	saturation$$$524$$$534$$$O	concentration.$$$535$$$549$$$O	The$$$550$$$553$$$O	invention$$$554$$$563$$$O	furthermore$$$564$$$575$$$O	relates$$$576$$$583$$$O	to$$$584$$$586$$$O	a$$$587$$$588$$$O	process$$$589$$$596$$$O	for$$$597$$$600$$$O	its$$$601$$$604$$$O	production$$$605$$$615$$$O	and$$$616$$$619$$$O	its$$$620$$$623$$$O	use$$$624$$$627$$$O	in$$$628$$$630$$$O	the$$$631$$$634$$$O	treatment$$$635$$$644$$$O	of$$$645$$$647$$$O	neuropathic$$$648$$$659$$$O	pain.$$$660$$$665$$$O
EP0944311B1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	antagonizing$$$11$$$23$$$O	HEREGUlin$$$24$$$33$$$O	or$$$34$$$36$$$O	its$$$37$$$40$$$O	receptor$$$41$$$49$$$O	and$$$50$$$53$$$O	use$$$54$$$57$$$O	for$$$58$$$61$$$O	the$$$62$$$65$$$O	inhibition$$$66$$$76$$$O	of$$$77$$$79$$$O	cancer$$$80$$$86$$$O	cells$$$87$$$92$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	method$$$25$$$31$$$O	of$$$32$$$34$$$O	inhibiting$$$35$$$45$$$O	cancer$$$46$$$52$$$O	cell$$$53$$$57$$$O	growth,$$$58$$$65$$$O	and$$$66$$$69$$$O	thereby$$$70$$$77$$$O	of$$$78$$$80$$$O	treating$$$81$$$89$$$O	cancer$$$90$$$96$$$O	comprising$$$97$$$107$$$O	administering$$$108$$$121$$$O	to$$$122$$$124$$$O	a$$$125$$$126$$$O	mammal$$$127$$$133$$$O	afflicted$$$134$$$143$$$O	with$$$144$$$148$$$O	cancer$$$149$$$155$$$O	an$$$156$$$158$$$O	effective$$$159$$$168$$$O	amount$$$169$$$175$$$O	of$$$176$$$178$$$O	the$$$179$$$182$$$O	compound$$$183$$$191$$$O	of$$$192$$$194$$$O	formula$$$195$$$202$$$O	(I),$$$203$$$207$$$O	wherein$$$208$$$215$$$O	the$$$216$$$219$$$O	variables$$$220$$$229$$$O	of$$$230$$$232$$$O	R1+and$$$233$$$239$$$O	R2$$$240$$$242$$$O	have$$$243$$$247$$$O	the$$$248$$$251$$$O	meanings$$$252$$$260$$$O	defined$$$261$$$268$$$O	in$$$269$$$271$$$O	the$$$272$$$275$$$O	specification.$$$276$$$290$$$O	The$$$291$$$294$$$O	present$$$295$$$302$$$O	invention$$$303$$$312$$$O	also$$$313$$$317$$$O	provides$$$318$$$326$$$O	novel$$$327$$$332$$$O	compounds$$$333$$$342$$$O	of$$$343$$$345$$$O	formula$$$346$$$353$$$O	(I)$$$354$$$357$$$O	as$$$358$$$360$$$O	well$$$361$$$365$$$O	as$$$366$$$368$$$O	novel$$$369$$$374$$$O	pharmaceutical$$$375$$$389$$$O	compositions$$$390$$$402$$$O	and$$$403$$$406$$$O	intermediates$$$407$$$420$$$O	useful$$$421$$$427$$$O	for$$$428$$$431$$$O	preparing$$$432$$$441$$$O	compounds$$$442$$$451$$$O	of$$$452$$$454$$$O	formula$$$455$$$462$$$O	(I).$$$463$$$467$$$O	The$$$468$$$471$$$O	figure$$$472$$$478$$$O	illustrates$$$479$$$490$$$O	the$$$491$$$494$$$O	structure$$$495$$$504$$$O	and$$$505$$$508$$$O	binding$$$509$$$516$$$O	activity$$$517$$$525$$$O	of$$$526$$$528$$$O	compounds$$$529$$$538$$$O	of$$$539$$$541$$$O	the$$$542$$$545$$$O	invention$$$546$$$555$$$O	and$$$556$$$559$$$O	some$$$560$$$564$$$O	of$$$565$$$567$$$O	the$$$568$$$571$$$O	rifamycin$$$572$$$581$$$I	analogs.$$$582$$$590$$$O
US6903203
Immunoglobulin$$$0$$$14$$$O	for$$$15$$$18$$$O	use$$$19$$$22$$$O	in$$$23$$$25$$$O	the$$$26$$$29$$$O	diagnosis$$$30$$$39$$$O	and$$$40$$$43$$$O	therapy$$$44$$$51$$$O	of$$$52$$$54$$$O	cancer$$$55$$$61$$$O
An$$$0$$$2$$$O	anti-CEA$$$3$$$11$$$O	monoclonal$$$12$$$22$$$O	antibody,$$$23$$$32$$$O	designated$$$33$$$43$$$O	806.077,$$$44$$$52$$$O	of$$$53$$$55$$$O	murine$$$56$$$62$$$O	origin$$$63$$$69$$$O	is$$$70$$$72$$$O	useful$$$73$$$79$$$O	for$$$80$$$83$$$O	the$$$84$$$87$$$O	diagnosis$$$88$$$97$$$O	and$$$98$$$101$$$O	therapy$$$102$$$109$$$O	of$$$110$$$112$$$O	cancer.$$$113$$$120$$$O	The$$$121$$$124$$$O	antibody$$$125$$$133$$$O	complementarity$$$134$$$149$$$O	determining$$$150$$$161$$$O	regions$$$162$$$169$$$O	have$$$170$$$174$$$O	the$$$175$$$178$$$O	following$$$179$$$188$$$O	sequences:$$$189$$$199$$$O	heavy$$$200$$$205$$$O	chain$$$206$$$211$$$O	CDR1$$$212$$$216$$$O	DBYMH$$$217$$$222$$$I	CDR2$$$223$$$227$$$O	WIDPENGDTE$$$228$$$238$$$O	YAPKFRG,$$$239$$$247$$$O	CDR3$$$248$$$252$$$O	LIYAGYLAMD$$$253$$$263$$$I	Y;$$$264$$$266$$$I	and$$$267$$$270$$$O	light$$$271$$$276$$$O	chain$$$277$$$282$$$O	CDR1$$$283$$$287$$$O	SASSSVTYMH,$$$288$$$299$$$I	CDR2$$$300$$$304$$$O	STSNLAS,$$$305$$$313$$$I	CDR3$$$314$$$318$$$O	QQRSTYPLT.$$$319$$$329$$$I	The$$$330$$$333$$$O	antibody$$$334$$$342$$$O	optionally$$$343$$$353$$$O	is$$$354$$$356$$$O	humanized$$$357$$$366$$$O	and$$$367$$$370$$$O	can$$$371$$$374$$$O	be$$$375$$$377$$$O	in$$$378$$$380$$$O	the$$$381$$$384$$$O	form$$$385$$$389$$$O	of$$$390$$$392$$$O	a$$$393$$$394$$$O	conjugate$$$395$$$404$$$O	with$$$405$$$409$$$O	either$$$410$$$416$$$O	an$$$417$$$419$$$O	enzyme,$$$420$$$427$$$O	such$$$428$$$432$$$O	as$$$433$$$435$$$O	carboxypeptidase,$$$436$$$453$$$O	or$$$454$$$456$$$O	a$$$457$$$458$$$O	co-stimulatory$$$459$$$473$$$O	molecule$$$474$$$482$$$O	such$$$483$$$487$$$O	as$$$488$$$490$$$O	the$$$491$$$494$$$O	extracellular$$$495$$$508$$$O	domain$$$509$$$515$$$O	of$$$516$$$518$$$O	human$$$519$$$524$$$O	B7.1.$$$525$$$530$$$O
US20120276039
Aptamer-modified$$$0$$$16$$$O	polymeric$$$17$$$26$$$O	materials$$$27$$$36$$$O	for$$$37$$$40$$$O	the$$$41$$$44$$$O	binding$$$45$$$52$$$O	of$$$53$$$55$$$O	factors$$$56$$$63$$$O	in$$$64$$$66$$$O	a$$$67$$$68$$$O	wound$$$69$$$74$$$O	environment$$$75$$$86$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	aptamer-modified$$$31$$$47$$$O	polymers$$$48$$$56$$$O	and$$$57$$$60$$$O	materials$$$61$$$70$$$O	thereof,$$$71$$$79$$$O	which$$$80$$$85$$$O	may$$$86$$$89$$$O	be$$$90$$$92$$$O	used$$$93$$$97$$$O	for$$$98$$$101$$$O	the$$$102$$$105$$$O	binding$$$106$$$113$$$O	of$$$114$$$116$$$O	factors$$$117$$$124$$$O	in$$$125$$$127$$$O	a$$$128$$$129$$$O	wound$$$130$$$135$$$O	bed.$$$136$$$140$$$O	For$$$141$$$144$$$O	example,$$$145$$$153$$$O	the$$$154$$$157$$$O	aptamer-modified$$$158$$$174$$$O	materials$$$175$$$184$$$O	can$$$185$$$188$$$O	be$$$189$$$191$$$O	polypeptides$$$192$$$204$$$O	conjugated$$$205$$$215$$$O	to$$$216$$$218$$$O	polymer$$$219$$$226$$$O	foam$$$227$$$231$$$O	materials.$$$232$$$242$$$O	Such$$$243$$$247$$$O	materials$$$248$$$257$$$O	may$$$258$$$261$$$O	be$$$262$$$264$$$O	used,$$$265$$$270$$$O	for$$$271$$$274$$$O	example,$$$275$$$283$$$O	for$$$284$$$287$$$O	dressings,$$$288$$$298$$$O	wound$$$299$$$304$$$O	inserts,$$$305$$$313$$$O	or$$$314$$$316$$$O	pads.$$$317$$$322$$$O
EP2772253A1
Topical$$$0$$$7$$$O	formulations$$$8$$$20$$$O	useful$$$21$$$27$$$O	for$$$28$$$31$$$O	treating$$$32$$$40$$$O	gagging$$$41$$$48$$$O	reflex$$$49$$$55$$$O
New$$$0$$$3$$$O	formulations$$$4$$$16$$$O	are$$$17$$$20$$$O	disclosed,$$$21$$$31$$$O	based$$$32$$$37$$$O	on$$$38$$$40$$$O	highly$$$41$$$47$$$O	concentrated$$$48$$$60$$$O	benzocain$$$61$$$70$$$I	in$$$71$$$73$$$O	a$$$74$$$75$$$O	semisolid$$$76$$$85$$$O	system,$$$86$$$93$$$O	suitable$$$94$$$102$$$O	for$$$103$$$106$$$O	topical$$$107$$$114$$$O	administration$$$115$$$129$$$O	within$$$130$$$136$$$O	selected$$$137$$$145$$$O	areas$$$146$$$151$$$O	of$$$152$$$154$$$O	the$$$155$$$158$$$O	mouth,$$$159$$$165$$$O	having$$$166$$$172$$$O	a$$$173$$$174$$$O	strong$$$175$$$181$$$O	and$$$182$$$185$$$O	consistent$$$186$$$196$$$O	efficacy$$$197$$$205$$$O	in$$$206$$$208$$$O	reducing/eliminating$$$209$$$229$$$O	the$$$230$$$233$$$O	gagging$$$234$$$241$$$O	reflex$$$242$$$248$$$O	in$$$249$$$251$$$O	patients$$$252$$$260$$$O	exposed$$$261$$$268$$$O	to$$$269$$$271$$$O	it,$$$272$$$275$$$O	especially$$$276$$$286$$$O	those$$$287$$$292$$$O	undergoing$$$293$$$303$$$O	dental$$$304$$$310$$$O	manipulations.$$$311$$$325$$$O
US20120148689
Film$$$0$$$4$$$O	comprising$$$5$$$15$$$O	active$$$16$$$22$$$O	drugs$$$23$$$28$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	related$$$25$$$32$$$O	to$$$33$$$35$$$O	the$$$36$$$39$$$O	composition$$$40$$$51$$$O	and$$$52$$$55$$$O	methods$$$56$$$63$$$O	of$$$64$$$66$$$O	manufacture$$$67$$$78$$$O	of$$$79$$$81$$$O	orally-dissolvable,$$$82$$$101$$$O	edible$$$102$$$108$$$O	films$$$109$$$114$$$O	as$$$115$$$117$$$O	a$$$118$$$119$$$O	vehicle$$$120$$$127$$$O	for$$$128$$$131$$$O	the$$$132$$$135$$$O	non-invasive$$$136$$$148$$$O	administration$$$149$$$163$$$O	of$$$164$$$166$$$O	active$$$167$$$173$$$O	drugs$$$174$$$179$$$O	through$$$180$$$187$$$O	the$$$188$$$191$$$O	mucosal$$$192$$$199$$$O	tissues$$$200$$$207$$$O	of$$$208$$$210$$$O	the$$$211$$$214$$$O	oral$$$215$$$219$$$O	cavity.$$$220$$$227$$$O	The$$$228$$$231$$$O	films$$$232$$$237$$$O	include$$$238$$$245$$$O	a$$$246$$$247$$$O	water$$$248$$$253$$$O	soluble$$$254$$$261$$$O	film-forming$$$262$$$274$$$O	polymer$$$275$$$282$$$O	such$$$283$$$287$$$O	as$$$288$$$290$$$O	pullulan.$$$291$$$300$$$O	Methods$$$301$$$308$$$O	for$$$309$$$312$$$O	producing$$$313$$$322$$$O	the$$$323$$$326$$$O	films$$$327$$$332$$$O	are$$$333$$$336$$$O	also$$$337$$$341$$$O	disclosed.$$$342$$$352$$$O
CA2379003C
Therapy$$$0$$$7$$$O	of$$$8$$$10$$$O	respiratory$$$11$$$22$$$O	influenza$$$23$$$32$$$O	virus$$$33$$$38$$$O	infection$$$39$$$48$$$O	using$$$49$$$54$$$O	free$$$55$$$59$$$O	and$$$60$$$63$$$O	liposome-encapsulated$$$64$$$85$$$O	ribonucleotides$$$86$$$101$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	ribonucleotide$$$39$$$53$$$O	oligonucleotides$$$54$$$70$$$O	(RNOs)$$$71$$$77$$$O	that$$$78$$$82$$$O	are$$$83$$$86$$$O	specifically$$$87$$$99$$$O	designed$$$100$$$108$$$O	to$$$109$$$111$$$O	inhibit$$$112$$$119$$$O	viral$$$120$$$125$$$O	replication.$$$126$$$138$$$O	The$$$139$$$142$$$O	RNOs$$$143$$$147$$$O	are$$$148$$$151$$$O	capable$$$152$$$159$$$O	of$$$160$$$162$$$O	binding$$$163$$$170$$$O	to$$$171$$$173$$$O	both$$$174$$$178$$$O	the$$$179$$$182$$$O	negative$$$183$$$191$$$O	and$$$192$$$195$$$O	positive$$$196$$$204$$$O	strands$$$205$$$212$$$O	of$$$213$$$215$$$O	influenza$$$216$$$225$$$O	RNA$$$226$$$229$$$O	segments,$$$230$$$239$$$O	thereby$$$240$$$247$$$O	inhibiting$$$248$$$258$$$O	the$$$259$$$262$$$O	virus'$$$263$$$269$$$O	ability$$$270$$$277$$$O	to$$$278$$$280$$$O	produce$$$281$$$288$$$O	various$$$289$$$296$$$O	viral$$$297$$$302$$$O	components,$$$303$$$314$$$O	thus$$$315$$$319$$$O	inhibiting$$$320$$$330$$$O	viral$$$331$$$336$$$O	propagation,$$$337$$$349$$$O	and$$$350$$$353$$$O	effectively$$$354$$$365$$$O	killing$$$366$$$373$$$O	the$$$374$$$377$$$O	virus$$$378$$$383$$$O	at$$$384$$$386$$$O	the$$$387$$$390$$$O	intracellular$$$391$$$404$$$O	sites$$$405$$$410$$$O	of$$$411$$$413$$$O	infection$$$414$$$423$$$O	in$$$424$$$426$$$O	the$$$427$$$430$$$O	respiratory$$$431$$$442$$$O	tract.$$$443$$$449$$$O	The$$$450$$$453$$$O	RNOs$$$454$$$458$$$O	provided$$$459$$$467$$$O	may$$$468$$$471$$$O	act$$$472$$$475$$$O	independently,$$$476$$$490$$$O	or$$$491$$$493$$$O	in$$$494$$$496$$$O	combination$$$497$$$508$$$O	to$$$509$$$511$$$O	optimize$$$512$$$520$$$O	their$$$521$$$526$$$O	antiviral$$$527$$$536$$$O	activity.$$$537$$$546$$$O	In$$$547$$$549$$$O	addition,$$$550$$$559$$$O	the$$$560$$$563$$$O	RNOs$$$564$$$568$$$O	provided$$$569$$$577$$$O	may$$$578$$$581$$$O	be$$$582$$$584$$$O	formulated$$$585$$$595$$$O	in$$$596$$$598$$$O	liposomes,$$$599$$$609$$$O	which$$$610$$$615$$$O	facilitate$$$616$$$626$$$O	their$$$627$$$632$$$O	therapeutic$$$633$$$644$$$O	delivery$$$645$$$653$$$O	to$$$654$$$656$$$O	intracellular$$$657$$$670$$$O	sites$$$671$$$676$$$O	of$$$677$$$679$$$O	infection,$$$680$$$690$$$O	and$$$691$$$694$$$O	additionally$$$695$$$707$$$O	increase$$$708$$$716$$$O	antiviral$$$717$$$726$$$O	efficacies.$$$727$$$738$$$O
US7396660
Expression$$$0$$$10$$$O	vector$$$11$$$17$$$O	comprising$$$18$$$28$$$O	nucleotide$$$29$$$39$$$I	sequences$$$40$$$49$$$O	coding$$$50$$$56$$$O	polyketide$$$57$$$67$$$I	synthase$$$68$$$76$$$O	for$$$77$$$80$$$O	use$$$81$$$84$$$O	in$$$85$$$87$$$O	transformation,$$$88$$$103$$$O	and$$$104$$$107$$$O	propagation$$$108$$$119$$$O	of$$$120$$$122$$$O	streptomyces$$$123$$$135$$$O	cells$$$136$$$141$$$O	capable$$$142$$$149$$$O	of$$$150$$$152$$$O	producing$$$153$$$162$$$O	moxidectin;$$$163$$$174$$$I	bactericides;$$$175$$$188$$$O	nematocide$$$189$$$199$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	complete$$$37$$$45$$$O	biosynthetic$$$46$$$58$$$O	pathway$$$59$$$66$$$O	for$$$67$$$70$$$O	the$$$71$$$74$$$O	formation$$$75$$$84$$$O	of$$$85$$$87$$$O	the$$$88$$$91$$$O	LL-F28249$$$92$$$101$$$I	compounds$$$102$$$111$$$O	and,$$$112$$$116$$$O	most$$$117$$$121$$$O	importantly,$$$122$$$134$$$O	the$$$135$$$138$$$O	major$$$139$$$144$$$O	component$$$145$$$154$$$O	LL-F28249Î±.$$$155$$$167$$$I	The$$$168$$$171$$$O	purified$$$172$$$180$$$O	and$$$181$$$184$$$O	isolated$$$185$$$193$$$O	nucleic$$$194$$$201$$$O	acid$$$202$$$206$$$O	molecule$$$207$$$215$$$O	encoding$$$216$$$224$$$O	the$$$225$$$228$$$O	proteins$$$229$$$237$$$O	of$$$238$$$240$$$O	the$$$241$$$244$$$O	biosynthetic$$$245$$$257$$$O	pathway,$$$258$$$266$$$O	which$$$267$$$272$$$O	is$$$273$$$275$$$O	isolated$$$276$$$284$$$O	from$$$285$$$289$$$O	a$$$290$$$291$$$O	wild-type$$$292$$$301$$$O	or$$$302$$$304$$$O	mutant$$$305$$$311$$$O	Streptomyces,$$$312$$$325$$$O	is$$$326$$$328$$$O	fully$$$329$$$334$$$O	described$$$335$$$344$$$O	in$$$345$$$347$$$O	FIG.$$$348$$$352$$$O	6$$$353$$$354$$$O	to$$$355$$$357$$$O	FIG.$$$358$$$362$$$O	6-39$$$363$$$367$$$O	and$$$368$$$371$$$O	SEQ$$$372$$$375$$$O	ID$$$376$$$378$$$O	NO:1.$$$379$$$384$$$O	The$$$385$$$388$$$O	DNA$$$389$$$392$$$O	gene$$$393$$$397$$$O	cluster$$$398$$$405$$$O	and$$$406$$$409$$$O	its$$$410$$$413$$$O	expression$$$414$$$424$$$O	in$$$425$$$427$$$O	a$$$428$$$429$$$O	suitable$$$430$$$438$$$O	host$$$439$$$443$$$O	enable$$$444$$$450$$$O	the$$$451$$$454$$$O	efficient$$$455$$$464$$$O	production$$$465$$$475$$$O	of$$$476$$$478$$$O	the$$$479$$$482$$$O	highly$$$483$$$489$$$O	active$$$490$$$496$$$O	natural$$$497$$$504$$$O	metabolites$$$505$$$516$$$O	and$$$517$$$520$$$O	semisynthetic$$$521$$$534$$$O	derivatives.$$$535$$$547$$$O	The$$$548$$$551$$$O	invention$$$552$$$561$$$O	further$$$562$$$569$$$O	concerns$$$570$$$578$$$O	plasmids,$$$579$$$588$$$O	vectors$$$589$$$596$$$O	and$$$597$$$600$$$O	host$$$601$$$605$$$O	cells$$$606$$$611$$$O	that$$$612$$$616$$$O	contain$$$617$$$624$$$O	and$$$625$$$628$$$O	express$$$629$$$636$$$O	the$$$637$$$640$$$O	novel$$$641$$$646$$$O	nucleic$$$647$$$654$$$O	acid$$$655$$$659$$$O	molecule.$$$660$$$669$$$O	Of$$$670$$$672$$$O	particular$$$673$$$683$$$O	interest,$$$684$$$693$$$O	the$$$694$$$697$$$O	entire$$$698$$$704$$$O	biosynthetic$$$705$$$717$$$O	pathway$$$718$$$725$$$O	fits$$$726$$$730$$$O	compactly$$$731$$$740$$$O	in$$$741$$$743$$$O	three$$$744$$$749$$$O	plasmids,$$$750$$$759$$$O	Cos11,$$$760$$$766$$$O	Cos36$$$767$$$772$$$O	and$$$773$$$776$$$O	Cos40.$$$777$$$783$$$O	The$$$784$$$787$$$O	invention$$$788$$$797$$$O	also$$$798$$$802$$$O	concerns$$$803$$$811$$$O	the$$$812$$$815$$$O	purified$$$816$$$824$$$O	and$$$825$$$828$$$O	isolated$$$829$$$837$$$O	biosynthesis$$$838$$$850$$$O	proteins$$$851$$$859$$$O	that$$$860$$$864$$$O	are$$$865$$$868$$$O	encoded$$$869$$$876$$$O	by$$$877$$$879$$$O	the$$$880$$$883$$$O	whole$$$884$$$889$$$O	DNA$$$890$$$893$$$O	gene$$$894$$$898$$$O	cluster.$$$899$$$907$$$O	Additionally,$$$908$$$921$$$O	the$$$922$$$925$$$O	invention$$$926$$$935$$$O	involves$$$936$$$944$$$O	a$$$945$$$946$$$O	new$$$947$$$950$$$O	efficient,$$$951$$$961$$$O	biochemical$$$962$$$973$$$O	method$$$974$$$980$$$O	of$$$981$$$983$$$O	preparing$$$984$$$993$$$I	moxidectin.$$$994$$$1005$$$I
WO2011054315A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	cyr61$$$7$$$12$$$O	protein$$$13$$$20$$$O	for$$$21$$$24$$$O	preparing$$$25$$$34$$$O	medicine$$$35$$$43$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	the$$$31$$$34$$$O	use$$$35$$$38$$$O	of$$$39$$$41$$$O	CYR61$$$42$$$47$$$O	protein$$$48$$$55$$$O	and$$$56$$$59$$$O	inhibitors$$$60$$$70$$$O	thereof$$$71$$$78$$$O	for$$$79$$$82$$$O	preparing$$$83$$$92$$$O	medicine$$$93$$$101$$$O	for$$$102$$$105$$$O	treating$$$106$$$114$$$O	rheumatic$$$115$$$124$$$O	disease,$$$125$$$133$$$O	wherein$$$134$$$141$$$O	the$$$142$$$145$$$O	inhibitors$$$146$$$156$$$O	are$$$157$$$160$$$O	selected$$$161$$$169$$$O	from$$$170$$$174$$$O	anti-CYR61$$$175$$$185$$$O	antibody$$$186$$$194$$$O	or$$$195$$$197$$$O	interfering$$$198$$$209$$$O	RNA$$$210$$$213$$$O	of$$$214$$$216$$$O	CYR61$$$217$$$222$$$O	gene.$$$223$$$228$$$O
US20050085513
Baccatin$$$0$$$8$$$I	III$$$9$$$12$$$I	analog$$$13$$$19$$$O	conjugated$$$20$$$30$$$O	to$$$31$$$33$$$O	cell$$$34$$$38$$$O	binding$$$39$$$46$$$O	agent$$$47$$$52$$$O	such$$$53$$$57$$$O	as$$$58$$$60$$$O	monoclonal$$$61$$$71$$$O	antibody$$$72$$$80$$$O	through$$$81$$$88$$$O	a$$$89$$$90$$$O	link$$$91$$$95$$$O	from$$$96$$$100$$$O	the$$$101$$$104$$$O	oxygen$$$105$$$111$$$I	atom$$$112$$$116$$$O	at$$$117$$$119$$$O	the$$$120$$$123$$$O	C-7$$$124$$$127$$$I	position;$$$128$$$137$$$O	treating$$$138$$$146$$$O	cancer,$$$147$$$154$$$O	rheumatoid$$$155$$$165$$$O	arthritis,$$$166$$$176$$$O	transplant$$$177$$$187$$$O	rejection,$$$188$$$198$$$O	viral$$$199$$$204$$$O	and$$$205$$$208$$$O	parasite$$$209$$$217$$$O	infections$$$218$$$228$$$O
Included$$$0$$$8$$$O	within$$$9$$$15$$$O	the$$$16$$$19$$$O	scope$$$20$$$25$$$O	of$$$26$$$28$$$O	the$$$29$$$32$$$O	present$$$33$$$40$$$O	invention$$$41$$$50$$$O	are$$$51$$$54$$$O	potent$$$55$$$61$$$O	taxanes$$$62$$$69$$$I	and$$$70$$$73$$$O	taxanes$$$74$$$81$$$I	containing$$$82$$$92$$$O	a$$$93$$$94$$$O	linking$$$95$$$102$$$O	group.$$$103$$$109$$$O	Also$$$110$$$114$$$O	included$$$115$$$123$$$O	is$$$124$$$126$$$O	a$$$127$$$128$$$O	cytotoxic$$$129$$$138$$$O	agent$$$139$$$144$$$O	comprising$$$145$$$155$$$O	one$$$156$$$159$$$O	or$$$160$$$162$$$O	more$$$163$$$167$$$O	taxanes$$$168$$$175$$$I	linked$$$176$$$182$$$O	to$$$183$$$185$$$O	a$$$186$$$187$$$O	cell$$$188$$$192$$$O	binding$$$193$$$200$$$O	agent.$$$201$$$207$$$O	A$$$208$$$209$$$O	therapeutic$$$210$$$221$$$O	composition$$$222$$$233$$$O	for$$$234$$$237$$$O	inducing$$$238$$$246$$$O	cell$$$247$$$251$$$O	death$$$252$$$257$$$O	in$$$258$$$260$$$O	selected$$$261$$$269$$$O	cell$$$270$$$274$$$O	populations$$$275$$$286$$$O	comprising:$$$287$$$298$$$O	(A)$$$299$$$302$$$O	a$$$303$$$304$$$O	cytotoxic$$$305$$$314$$$O	amount$$$315$$$321$$$O	of$$$322$$$324$$$O	one$$$325$$$328$$$O	or$$$329$$$331$$$O	more$$$332$$$336$$$O	taxanes$$$337$$$344$$$I	covalently$$$345$$$355$$$O	bonded$$$356$$$362$$$O	to$$$363$$$365$$$O	a$$$366$$$367$$$O	cell$$$368$$$372$$$O	binding$$$373$$$380$$$O	agent$$$381$$$386$$$O	through$$$387$$$394$$$O	a$$$395$$$396$$$O	link,$$$397$$$402$$$O	and$$$403$$$406$$$O	(B)$$$407$$$410$$$O	a$$$411$$$412$$$O	pharmaceutically$$$413$$$429$$$O	acceptable$$$430$$$440$$$O	carrier,$$$441$$$449$$$O	diluent$$$450$$$457$$$O	or$$$458$$$460$$$O	excipient$$$461$$$470$$$O	is$$$471$$$473$$$O	also$$$474$$$478$$$O	included.$$$479$$$488$$$O	A$$$489$$$490$$$O	method$$$491$$$497$$$O	for$$$498$$$501$$$O	inducing$$$502$$$510$$$O	cell$$$511$$$515$$$O	death$$$516$$$521$$$O	in$$$522$$$524$$$O	selected$$$525$$$533$$$O	cell$$$534$$$538$$$O	populations$$$539$$$550$$$O	comprising$$$551$$$561$$$O	contacting$$$562$$$572$$$O	target$$$573$$$579$$$O	cells$$$580$$$585$$$O	or$$$586$$$588$$$O	tissue$$$589$$$595$$$O	containing$$$596$$$606$$$O	target$$$607$$$613$$$O	cells$$$614$$$619$$$O	with$$$620$$$624$$$O	an$$$625$$$627$$$O	effective$$$628$$$637$$$O	amount$$$638$$$644$$$O	of$$$645$$$647$$$O	a$$$648$$$649$$$O	cytotoxic$$$650$$$659$$$O	agent$$$660$$$665$$$O	comprising$$$666$$$676$$$O	one$$$677$$$680$$$O	or$$$681$$$683$$$O	more$$$684$$$688$$$O	taxanes$$$689$$$696$$$I	linked$$$697$$$703$$$O	to$$$704$$$706$$$O	a$$$707$$$708$$$O	cell$$$709$$$713$$$O	binding$$$714$$$721$$$O	agent$$$722$$$727$$$O	is$$$728$$$730$$$O	included$$$731$$$739$$$O	as$$$740$$$742$$$O	well.$$$743$$$748$$$O
US20090269404
Crosslinked$$$0$$$11$$$O	Gelatin$$$12$$$19$$$O	Gel,$$$20$$$24$$$O	Multilayered$$$25$$$37$$$O	Structure,$$$38$$$48$$$O	Carrier$$$49$$$56$$$O	for$$$57$$$60$$$O	Bioactive$$$61$$$70$$$O	Factor,$$$71$$$78$$$O	Preparation$$$79$$$90$$$O	for$$$91$$$94$$$O	Release$$$95$$$102$$$O	of$$$103$$$105$$$O	Bioactive$$$106$$$115$$$O	Factor,$$$116$$$123$$$O	and$$$124$$$127$$$O	Their$$$128$$$133$$$O	Production$$$134$$$144$$$O	Methods$$$145$$$152$$$O
A$$$0$$$1$$$O	multi-layer$$$2$$$13$$$O	crosslinked$$$14$$$25$$$O	gelatin$$$26$$$33$$$O	gel$$$34$$$37$$$O	structure$$$38$$$47$$$O	having$$$48$$$54$$$O	a$$$55$$$56$$$O	layer$$$57$$$62$$$O	structure$$$63$$$72$$$O	that$$$73$$$77$$$O	plural$$$78$$$84$$$O	layers$$$85$$$91$$$O	of$$$92$$$94$$$O	crosslinked$$$95$$$106$$$O	gelatin$$$107$$$114$$$O	gel$$$115$$$118$$$O	crosslinked$$$119$$$130$$$O	by$$$131$$$133$$$O	irradiating$$$134$$$145$$$O	gelatin$$$146$$$153$$$O	or$$$154$$$156$$$O	a$$$157$$$158$$$O	gelatin$$$159$$$166$$$O	derivative$$$167$$$177$$$O	with$$$178$$$182$$$O	electron$$$183$$$191$$$O	beam$$$192$$$196$$$O	under$$$197$$$202$$$O	an$$$203$$$205$$$O	oxygen-containing$$$206$$$223$$$I	atmosphere$$$224$$$234$$$O	are$$$235$$$238$$$O	arranged$$$239$$$247$$$O	adjoiningly$$$248$$$259$$$O	to$$$260$$$262$$$O	each$$$263$$$267$$$O	other,$$$268$$$274$$$O	a$$$275$$$276$$$O	preparation$$$277$$$288$$$O	for$$$289$$$292$$$O	release$$$293$$$300$$$O	of$$$301$$$303$$$O	a$$$304$$$305$$$O	bioactive$$$306$$$315$$$O	factor$$$316$$$322$$$O	with$$$323$$$327$$$O	the$$$328$$$331$$$O	bioactive$$$332$$$341$$$O	factor$$$342$$$348$$$O	contained$$$349$$$358$$$O	in$$$359$$$361$$$O	the$$$362$$$365$$$O	multi-layer$$$366$$$377$$$O	crosslinked$$$378$$$389$$$O	gelatin$$$390$$$397$$$O	gel$$$398$$$401$$$O	structure,$$$402$$$412$$$O	and$$$413$$$416$$$O	production$$$417$$$427$$$O	processes$$$428$$$437$$$O	thereof.$$$438$$$446$$$O
WO2010044686A1
Akr1c3$$$0$$$6$$$O	as$$$7$$$9$$$O	a$$$10$$$11$$$O	biomarker,$$$12$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	selecting$$$34$$$43$$$O	and$$$44$$$47$$$O	treating$$$48$$$56$$$O	patients$$$57$$$65$$$O	based$$$66$$$71$$$O	upon$$$72$$$76$$$O	an$$$77$$$79$$$O	akr1c3$$$80$$$86$$$O	profile$$$87$$$94$$$O	and$$$95$$$98$$$O	compounds$$$99$$$108$$$O	for$$$109$$$112$$$O	use$$$113$$$116$$$O	therein$$$117$$$124$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	based$$$17$$$22$$$O	on$$$23$$$25$$$O	the$$$26$$$29$$$O	finding$$$30$$$37$$$O	that$$$38$$$42$$$O	the$$$43$$$46$$$O	enzyme$$$47$$$53$$$O	AKR1C3$$$54$$$60$$$O	is$$$61$$$63$$$O	capable$$$64$$$71$$$O	of$$$72$$$74$$$O	exhibiting$$$75$$$85$$$O	nitroreductase$$$86$$$100$$$O	activity$$$101$$$109$$$O	and$$$110$$$113$$$O	activating$$$114$$$124$$$O	nitroaromatic$$$125$$$138$$$O	prodrugs$$$139$$$147$$$O	to$$$148$$$150$$$O	release$$$151$$$158$$$O	the$$$159$$$162$$$O	cytotoxic$$$163$$$172$$$O	effector.$$$173$$$182$$$O	AKR1C3-activated$$$183$$$199$$$O	nitroaromatic$$$200$$$213$$$I	prodrugs$$$214$$$222$$$O	include$$$223$$$230$$$O	dinitrobenzamide$$$231$$$247$$$I	mustards$$$248$$$256$$$O	such$$$257$$$261$$$O	as$$$262$$$264$$$O	2-((2-bromoethyl)-2-{[(2-hydroxyethyl)amino]carbonyl}-4,6-dinitroanilino)ethyl$$$265$$$343$$$I	methanesulfonate$$$344$$$360$$$I	(PR-104A),$$$361$$$371$$$I	and$$$372$$$375$$$O	the$$$376$$$379$$$O	corresponding$$$380$$$393$$$O	pre-prodrug$$$394$$$405$$$O	2-[(2-(bromoethyl)-2,4-dinitro-6-[[[2-$$$406$$$444$$$I	(phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl$$$445$$$493$$$I	methanesulfonate$$$494$$$510$$$I	(PR-104).$$$511$$$520$$$I	The$$$521$$$524$$$O	invention$$$525$$$534$$$O	provides$$$535$$$543$$$O	methods$$$544$$$551$$$O	and$$$552$$$555$$$O	procedures$$$556$$$566$$$O	to$$$567$$$569$$$O	determine$$$570$$$579$$$O	drug$$$580$$$584$$$O	sensitivity$$$585$$$596$$$O	in$$$597$$$599$$$O	patients$$$600$$$608$$$O	to$$$609$$$611$$$O	allow$$$612$$$617$$$O	the$$$618$$$621$$$O	identification$$$622$$$636$$$O	of$$$637$$$639$$$O	individualized$$$640$$$654$$$O	patient$$$655$$$662$$$O	profiles$$$663$$$671$$$O	which$$$672$$$677$$$O	will$$$678$$$682$$$O	aid$$$683$$$686$$$O	in$$$687$$$689$$$O	treating$$$690$$$698$$$O	diseases$$$699$$$707$$$O	and$$$708$$$711$$$O	disorders,$$$712$$$722$$$O	such$$$723$$$727$$$O	as$$$728$$$730$$$O	cancer.$$$731$$$738$$$O	The$$$739$$$742$$$O	invention$$$743$$$752$$$O	also$$$753$$$757$$$O	provides$$$758$$$766$$$O	methods$$$767$$$774$$$O	of$$$775$$$777$$$O	treatment$$$778$$$787$$$O	which$$$788$$$793$$$O	are$$$794$$$797$$$O	based$$$798$$$803$$$O	upon$$$804$$$808$$$O	such$$$809$$$813$$$O	biomarker-related$$$814$$$831$$$O	profiles,$$$832$$$841$$$O	as$$$842$$$844$$$O	well$$$845$$$849$$$O	as$$$850$$$852$$$O	compounds$$$853$$$862$$$O	suitable$$$863$$$871$$$O	for$$$872$$$875$$$O	use$$$876$$$879$$$O	in$$$880$$$882$$$O	such$$$883$$$887$$$O	methods$$$888$$$895$$$O	and$$$896$$$899$$$O	compositions$$$900$$$912$$$O	comprising$$$913$$$923$$$O	"such$$$924$$$929$$$O	compounds.$$$930$$$940$$$O
CN1965846A
Neomycin$$$0$$$8$$$I	sulphate$$$9$$$17$$$I	solution$$$18$$$26$$$O	containing$$$27$$$37$$$O	clustered$$$38$$$47$$$O	water$$$48$$$53$$$O	used$$$54$$$58$$$O	for$$$59$$$62$$$O	animal$$$63$$$69$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	for$$$34$$$37$$$O	using$$$38$$$43$$$O	bykomycin$$$44$$$53$$$I	Hydrochloride$$$54$$$67$$$I	to$$$68$$$70$$$O	prepare$$$71$$$78$$$O	wide-spectrum$$$79$$$92$$$O	antibiosis$$$93$$$103$$$O	solution,$$$104$$$113$$$O	wherein$$$114$$$121$$$O	it$$$122$$$124$$$O	uses$$$125$$$129$$$O	hexacyclic$$$130$$$140$$$O	ring$$$141$$$145$$$O	water$$$146$$$151$$$O	as$$$152$$$154$$$O	carrier$$$155$$$162$$$O	that$$$163$$$167$$$O	adds$$$168$$$172$$$O	frozen$$$173$$$179$$$O	hexacyclic$$$180$$$190$$$O	ring$$$191$$$195$$$O	water$$$196$$$201$$$O	into$$$202$$$206$$$O	bykomycin$$$207$$$216$$$I	Hydrochloride$$$217$$$230$$$I	solution,$$$231$$$240$$$O	to$$$241$$$243$$$O	reduce$$$244$$$250$$$O	the$$$251$$$254$$$O	volume$$$255$$$261$$$O	of$$$262$$$264$$$O	hydrone$$$265$$$272$$$I	group,$$$273$$$279$$$O	the$$$280$$$283$$$O	viscosity$$$284$$$293$$$O	and$$$294$$$297$$$O	surface$$$298$$$305$$$O	tension,$$$306$$$314$$$O	to$$$315$$$317$$$O	reduce$$$318$$$324$$$O	the$$$325$$$328$$$O	expand$$$329$$$335$$$O	resistance$$$336$$$346$$$O	and$$$347$$$350$$$O	accelerate$$$351$$$361$$$O	the$$$362$$$365$$$O	drug$$$366$$$370$$$O	release.$$$371$$$379$$$O	The$$$380$$$383$$$O	hexacyclic$$$384$$$394$$$O	ring$$$395$$$399$$$O	water$$$400$$$405$$$O	has$$$406$$$409$$$O	strong$$$410$$$416$$$O	affinity$$$417$$$425$$$O	with$$$426$$$430$$$O	cell,$$$431$$$436$$$O	to$$$437$$$439$$$O	improve$$$440$$$447$$$O	the$$$448$$$451$$$O	treatment$$$452$$$461$$$O	effect$$$462$$$468$$$O	on$$$469$$$471$$$O	animal$$$472$$$478$$$O	bacterial$$$479$$$488$$$O	and$$$489$$$492$$$O	mycoplasma$$$493$$$503$$$O	affection.$$$504$$$514$$$O
CA2314326C
Transdermal$$$0$$$11$$$O	therapeutic$$$12$$$23$$$O	device$$$24$$$30$$$O	and$$$31$$$34$$$O	method$$$35$$$41$$$O	with$$$42$$$46$$$O	capsaicin$$$47$$$56$$$I	and$$$57$$$60$$$O	capsaicin$$$61$$$70$$$I	analogs$$$71$$$78$$$O
Transdermal$$$0$$$11$$$O	application$$$12$$$23$$$O	of$$$24$$$26$$$O	capsaicin$$$27$$$36$$$I	(or$$$37$$$40$$$O	a$$$41$$$42$$$O	capsaicin$$$43$$$52$$$I	analog)$$$53$$$60$$$O	in$$$61$$$63$$$O	a$$$64$$$65$$$O	concentration$$$66$$$79$$$O	from$$$80$$$84$$$O	greater$$$85$$$92$$$O	than$$$93$$$97$$$O	about$$$98$$$103$$$O	5$$$104$$$105$$$O	%$$$106$$$107$$$O	to$$$108$$$110$$$O	about$$$111$$$116$$$O	10$$$117$$$119$$$O	%$$$120$$$121$$$O	by$$$122$$$124$$$O	weight$$$125$$$131$$$O	has$$$132$$$135$$$O	been$$$136$$$140$$$O	discovered$$$141$$$151$$$O	to$$$152$$$154$$$O	be$$$155$$$157$$$O	an$$$158$$$160$$$O	extremely$$$161$$$170$$$O	effective$$$171$$$180$$$O	therapy$$$181$$$188$$$O	for$$$189$$$192$$$O	treating$$$193$$$201$$$O	neuropathic$$$202$$$213$$$O	pain,$$$214$$$219$$$O	so$$$220$$$222$$$O	long$$$223$$$227$$$O	as$$$228$$$230$$$O	an$$$231$$$233$$$O	anesthetic,$$$234$$$245$$$O	preferably$$$246$$$256$$$O	by$$$257$$$259$$$O	means$$$260$$$265$$$O	of$$$266$$$268$$$O	a$$$269$$$270$$$O	transdermal$$$271$$$282$$$O	patch,$$$283$$$289$$$O	is$$$290$$$292$$$O	administered$$$293$$$305$$$O	initially$$$306$$$315$$$O	to$$$316$$$318$$$O	the$$$319$$$322$$$O	affected$$$323$$$331$$$O	area$$$332$$$336$$$O	to$$$337$$$339$$$O	minimize$$$340$$$348$$$O	the$$$349$$$352$$$O	expected$$$353$$$361$$$O	side$$$362$$$366$$$O	effects$$$367$$$374$$$O	from$$$375$$$379$$$O	subsequent$$$380$$$390$$$O	capsaicin$$$391$$$400$$$I	application.$$$401$$$413$$$O
US7341712
Synergistic$$$0$$$11$$$O	effect$$$12$$$18$$$O	protecting$$$19$$$29$$$O	the$$$30$$$33$$$O	skin$$$34$$$38$$$O	against$$$39$$$46$$$O	light;$$$47$$$53$$$O	use$$$54$$$57$$$O	for$$$58$$$61$$$O	skin$$$62$$$66$$$O	tanning;$$$67$$$75$$$O	impregnated$$$76$$$87$$$O	wipes$$$88$$$93$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	a$$$17$$$18$$$O	light-protective$$$19$$$35$$$O	cosmetic$$$36$$$44$$$O	or$$$45$$$47$$$O	dermatological$$$48$$$62$$$O	preparation,$$$63$$$75$$$O	comprising$$$76$$$86$$$O	(a)$$$87$$$90$$$O	at$$$91$$$93$$$O	least$$$94$$$99$$$O	hydroxybenzophenone$$$100$$$119$$$I	and$$$120$$$123$$$O	(b)$$$124$$$127$$$O	at$$$128$$$130$$$O	least$$$131$$$136$$$O	one$$$137$$$140$$$O	benzoxazole$$$141$$$152$$$I	derivative.$$$153$$$164$$$O	The$$$165$$$168$$$O	invention$$$169$$$178$$$O	is$$$179$$$181$$$O	also$$$182$$$186$$$O	a$$$187$$$188$$$O	cosmetic$$$189$$$197$$$O	or$$$198$$$200$$$O	dermatological$$$201$$$215$$$O	preparation$$$216$$$227$$$O	comprising$$$228$$$238$$$O	at$$$239$$$241$$$O	least$$$242$$$247$$$O	one$$$248$$$251$$$O	hydroxybenzophenone$$$252$$$271$$$I	of$$$272$$$274$$$O	a$$$275$$$276$$$O	specified$$$277$$$286$$$O	chemical$$$287$$$295$$$O	structure$$$296$$$305$$$O	and$$$306$$$309$$$O	at$$$310$$$312$$$O	least$$$313$$$318$$$O	one$$$319$$$322$$$O	benzoxazole$$$323$$$334$$$I	derivative.$$$335$$$346$$$O	The$$$347$$$350$$$O	invention$$$351$$$360$$$O	is$$$361$$$363$$$O	also$$$364$$$368$$$O	a$$$369$$$370$$$O	method$$$371$$$377$$$O	of$$$378$$$380$$$O	treating$$$381$$$389$$$O	or$$$390$$$392$$$O	preventing$$$393$$$403$$$O	cosmetic$$$404$$$412$$$O	or$$$413$$$415$$$O	dermatological$$$416$$$430$$$O	changes$$$431$$$438$$$O	in$$$439$$$441$$$O	the$$$442$$$445$$$O	skin,$$$446$$$451$$$O	a$$$452$$$453$$$O	method$$$454$$$460$$$O	of$$$461$$$463$$$O	tanning$$$464$$$471$$$O	or$$$472$$$474$$$O	accelerating$$$475$$$487$$$O	tanning$$$488$$$495$$$O	of$$$496$$$498$$$O	the$$$499$$$502$$$O	skin,$$$503$$$508$$$O	and$$$509$$$512$$$O	a$$$513$$$514$$$O	method$$$515$$$521$$$O	of$$$522$$$524$$$O	protecting$$$525$$$535$$$O	the$$$536$$$539$$$O	skin$$$540$$$544$$$O	against$$$545$$$552$$$O	light-induced$$$553$$$566$$$O	aging,$$$567$$$573$$$O	each$$$574$$$578$$$O	comprising$$$579$$$589$$$O	applying$$$590$$$598$$$O	the$$$599$$$602$$$O	preparation$$$603$$$614$$$O	to$$$615$$$617$$$O	the$$$618$$$621$$$O	skin.$$$622$$$627$$$O	The$$$628$$$631$$$O	invention$$$632$$$641$$$O	also$$$642$$$646$$$O	includes$$$647$$$655$$$O	a$$$656$$$657$$$O	wipe$$$658$$$662$$$O	impregnated$$$663$$$674$$$O	with$$$675$$$679$$$O	the$$$680$$$683$$$O	preparation.$$$684$$$696$$$O
CN201182672Y
Novel$$$0$$$5$$$O	nano$$$6$$$10$$$O	memory$$$11$$$17$$$O	alloy$$$18$$$23$$$O	intrauterine$$$24$$$36$$$O	device$$$37$$$43$$$O
the$$$0$$$3$$$O	utility$$$4$$$11$$$O	model$$$12$$$17$$$O	relates$$$18$$$25$$$O	to$$$26$$$28$$$O	a$$$29$$$30$$$O	novel$$$31$$$36$$$O	nano$$$37$$$41$$$O	memory$$$42$$$48$$$O	alloy$$$49$$$54$$$O	inner$$$55$$$60$$$O	uterus$$$61$$$67$$$O	contraceptive$$$68$$$81$$$O	device$$$82$$$88$$$O	which$$$89$$$94$$$O	is$$$95$$$97$$$O	characterized$$$98$$$111$$$O	in$$$112$$$114$$$O	that$$$115$$$119$$$O	the$$$120$$$123$$$O	titanium$$$124$$$132$$$I	and$$$133$$$136$$$O	nickel$$$137$$$143$$$I	memory$$$144$$$150$$$O	alloy$$$151$$$156$$$O	material$$$157$$$165$$$O	is$$$166$$$168$$$O	adopted$$$169$$$176$$$O	to$$$177$$$179$$$O	make$$$180$$$184$$$O	a$$$185$$$186$$$O	V-shaped$$$187$$$195$$$O	support,$$$196$$$204$$$O	a$$$205$$$206$$$O	composite$$$207$$$216$$$O	material$$$217$$$225$$$O	body$$$226$$$230$$$O	and$$$231$$$234$$$O	connecting$$$235$$$245$$$O	lines;$$$246$$$252$$$O	the$$$253$$$256$$$O	composite$$$257$$$266$$$O	material$$$267$$$275$$$O	body$$$276$$$280$$$O	is$$$281$$$283$$$O	fixed$$$284$$$289$$$O	on$$$290$$$292$$$O	the$$$293$$$296$$$O	V-shaped$$$297$$$305$$$O	support,$$$306$$$314$$$O	or$$$315$$$317$$$O	part$$$318$$$322$$$O	of$$$323$$$325$$$O	the$$$326$$$329$$$O	composite$$$330$$$339$$$O	material$$$340$$$348$$$O	body$$$349$$$353$$$O	is$$$354$$$356$$$O	fixed$$$357$$$362$$$O	on$$$363$$$365$$$O	the$$$366$$$369$$$O	V-shaped$$$370$$$378$$$O	support$$$379$$$386$$$O	with$$$387$$$391$$$O	the$$$392$$$395$$$O	other$$$396$$$401$$$O	part$$$402$$$406$$$O	tied$$$407$$$411$$$O	to$$$412$$$414$$$O	the$$$415$$$418$$$O	V-shaped$$$419$$$427$$$O	support;$$$428$$$436$$$O	the$$$437$$$440$$$O	V-shaped$$$441$$$449$$$O	support$$$450$$$457$$$O	is$$$458$$$460$$$O	provided$$$461$$$469$$$O	with$$$470$$$474$$$O	1-15$$$475$$$479$$$O	bending$$$480$$$487$$$O	parts.$$$488$$$494$$$O	The$$$495$$$498$$$O	volume$$$499$$$505$$$O	of$$$506$$$508$$$O	the$$$509$$$512$$$O	composite$$$513$$$522$$$O	material$$$523$$$531$$$O	body$$$532$$$536$$$O	is$$$537$$$539$$$O	0.1-400$$$540$$$547$$$O	mm<3>$$$548$$$553$$$O	and$$$554$$$557$$$O	is$$$558$$$560$$$O	indicated$$$561$$$570$$$O	in$$$571$$$573$$$O	1-20$$$574$$$578$$$O	segments;$$$579$$$588$$$O	the$$$589$$$592$$$O	segments$$$593$$$601$$$O	can$$$602$$$605$$$O	have$$$606$$$610$$$O	different$$$611$$$620$$$O	shapes$$$621$$$627$$$O	and$$$628$$$631$$$O	specifications;$$$632$$$647$$$O	the$$$648$$$651$$$O	surface$$$652$$$659$$$O	of$$$660$$$662$$$O	each$$$663$$$667$$$O	segment$$$668$$$675$$$O	can$$$676$$$679$$$O	be$$$680$$$682$$$O	coated$$$683$$$689$$$O	with$$$690$$$694$$$O	medicine$$$695$$$703$$$O	film$$$704$$$708$$$O	or$$$709$$$711$$$O	not$$$712$$$715$$$O	be$$$716$$$718$$$O	coated$$$719$$$725$$$O	with$$$726$$$730$$$O	medicine$$$731$$$739$$$O	film.$$$740$$$745$$$O	The$$$746$$$749$$$O	novel$$$750$$$755$$$O	nano$$$756$$$760$$$O	memory$$$761$$$767$$$O	alloy$$$768$$$773$$$O	inner$$$774$$$779$$$O	uterus$$$780$$$786$$$O	contraceptive$$$787$$$800$$$O	device$$$801$$$807$$$O	adopts$$$808$$$814$$$O	the$$$815$$$818$$$O	memory$$$819$$$825$$$O	alloy$$$826$$$831$$$O	to$$$832$$$834$$$O	make$$$835$$$839$$$O	the$$$840$$$843$$$O	support;$$$844$$$852$$$O	the$$$853$$$856$$$O	composite$$$857$$$866$$$O	material$$$867$$$875$$$O	is$$$876$$$878$$$O	attached$$$879$$$887$$$O	to$$$888$$$890$$$O	the$$$891$$$894$$$O	support$$$895$$$902$$$O	to$$$903$$$905$$$O	deliver$$$906$$$913$$$O	copper$$$914$$$920$$$I	to$$$921$$$923$$$O	the$$$924$$$927$$$O	highest$$$928$$$935$$$O	part$$$936$$$940$$$O	for$$$941$$$944$$$O	being$$$945$$$950$$$O	distributed$$$951$$$962$$$O	on$$$963$$$965$$$O	the$$$966$$$969$$$O	middle$$$970$$$976$$$O	part$$$977$$$981$$$O	of$$$982$$$984$$$O	the$$$985$$$988$$$O	uterus$$$989$$$995$$$O	and$$$996$$$999$$$O	the$$$1000$$$1003$$$O	uterus$$$1004$$$1010$$$O	orifice;$$$1011$$$1019$$$O	the$$$1020$$$1023$$$O	contraception$$$1024$$$1037$$$O	effect$$$1038$$$1044$$$O	of$$$1045$$$1047$$$O	the$$$1048$$$1051$$$O	contraceptive$$$1052$$$1065$$$O	device$$$1066$$$1072$$$O	is$$$1073$$$1075$$$O	improved$$$1076$$$1084$$$O	while$$$1085$$$1090$$$O	the$$$1091$$$1094$$$O	original$$$1095$$$1103$$$O	performance$$$1104$$$1115$$$O	of$$$1116$$$1118$$$O	the$$$1119$$$1122$$$O	memory$$$1123$$$1129$$$O	alloy$$$1130$$$1135$$$O	is$$$1136$$$1138$$$O	not$$$1139$$$1142$$$O	influenced;$$$1143$$$1154$$$O	the$$$1155$$$1158$$$O	defects$$$1159$$$1166$$$O	of$$$1167$$$1169$$$O	traditional$$$1170$$$1181$$$O	IUD$$$1182$$$1185$$$O	support$$$1186$$$1193$$$O	material$$$1194$$$1202$$$O	and$$$1203$$$1206$$$O	the$$$1207$$$1210$$$O	naked$$$1211$$$1216$$$O	copper$$$1217$$$1223$$$I	are$$$1224$$$1227$$$O	overcome;$$$1228$$$1237$$$O	the$$$1238$$$1241$$$O	medicine$$$1242$$$1250$$$O	film$$$1251$$$1255$$$O	coated$$$1256$$$1262$$$O	on$$$1263$$$1265$$$O	the$$$1266$$$1269$$$O	surface$$$1270$$$1277$$$O	releases$$$1278$$$1286$$$O	the$$$1287$$$1290$$$O	medicine$$$1291$$$1299$$$O	in$$$1300$$$1302$$$O	the$$$1303$$$1306$$$O	implantation$$$1307$$$1319$$$O	initial$$$1320$$$1327$$$O	stage$$$1328$$$1333$$$O	of$$$1334$$$1336$$$O	the$$$1337$$$1340$$$O	IUD;$$$1341$$$1345$$$O	the$$$1346$$$1349$$$O	side$$$1350$$$1354$$$O	reaction$$$1355$$$1363$$$O	caused$$$1364$$$1370$$$O	by$$$1371$$$1373$$$O	the$$$1374$$$1377$$$O	mechanical$$$1378$$$1388$$$O	stimulation$$$1389$$$1400$$$O	is$$$1401$$$1403$$$O	relieved.$$$1404$$$1413$$$O
US20100305113
Substituted$$$0$$$11$$$O	Imidazopyridazines$$$12$$$30$$$I	as$$$31$$$33$$$O	Lipid$$$34$$$39$$$O	Kinase$$$40$$$46$$$O	Inhibitors$$$47$$$57$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	compounds$$$31$$$40$$$O	of$$$41$$$43$$$O	the$$$44$$$47$$$O	formula$$$48$$$55$$$O	I,$$$56$$$58$$$O	as$$$96$$$98$$$O	well$$$99$$$103$$$O	as$$$104$$$106$$$O	other$$$107$$$112$$$O	invention$$$113$$$122$$$O	embodiments$$$123$$$134$$$O	related$$$135$$$142$$$O	to$$$143$$$145$$$O	these$$$146$$$151$$$O	compounds.$$$152$$$162$$$O	The$$$163$$$166$$$O	compounds$$$167$$$176$$$O	are$$$177$$$180$$$O	e.g.$$$181$$$185$$$O	useful$$$186$$$192$$$O	in$$$193$$$195$$$O	the$$$196$$$199$$$O	treatment$$$200$$$209$$$O	of$$$210$$$212$$$O	the$$$213$$$216$$$O	animal$$$217$$$223$$$O	or$$$224$$$226$$$O	human$$$227$$$232$$$O	body$$$233$$$237$$$O	in$$$238$$$240$$$O	view$$$241$$$245$$$O	of$$$246$$$248$$$O	their$$$249$$$254$$$O	ability$$$255$$$262$$$O	to$$$263$$$265$$$O	inhibit$$$266$$$273$$$O	protein$$$274$$$281$$$O	kinases$$$282$$$289$$$O	such$$$290$$$294$$$O	as$$$295$$$297$$$O	especially$$$298$$$308$$$O	PI3$$$309$$$312$$$O	kinase.$$$313$$$320$$$O
US20080200548
N-Acetylcysteine$$$0$$$16$$$I	Amide$$$17$$$22$$$I	(Nac$$$23$$$27$$$I	Amide)$$$28$$$34$$$I	for$$$35$$$38$$$O	Treatment$$$39$$$48$$$O	of$$$49$$$51$$$O	Oxidative$$$52$$$61$$$O	Stress$$$62$$$68$$$O	Associated$$$69$$$79$$$O	with$$$80$$$84$$$O	Infertility$$$85$$$96$$$O
An$$$0$$$2$$$O	in$$$3$$$5$$$O	vitro$$$6$$$11$$$O	culture$$$12$$$19$$$O	and/or$$$20$$$26$$$O	fertilization$$$27$$$40$$$O	medium$$$41$$$47$$$O	containing$$$48$$$58$$$O	N-acetylcysteine$$$59$$$75$$$I	amide$$$76$$$81$$$I	(NAC$$$82$$$86$$$I	amide)$$$87$$$93$$$I	reduces$$$94$$$101$$$O	or$$$102$$$104$$$O	prevents$$$105$$$113$$$O	oxidative$$$114$$$123$$$O	stress$$$124$$$130$$$O	and$$$131$$$134$$$O	free$$$135$$$139$$$O	radical$$$140$$$147$$$O	formation$$$148$$$157$$$O	that$$$158$$$162$$$O	contribute$$$163$$$173$$$O	to$$$174$$$176$$$O	the$$$177$$$180$$$O	cellular$$$181$$$189$$$O	damage$$$190$$$196$$$O	and$$$197$$$200$$$O	eventual$$$201$$$209$$$O	demise$$$210$$$216$$$O	of$$$217$$$219$$$O	sperm,$$$220$$$226$$$O	oocytes$$$227$$$234$$$O	and$$$235$$$238$$$O	embryos$$$239$$$246$$$O	that$$$247$$$251$$$O	are$$$252$$$255$$$O	cultured,$$$256$$$265$$$O	fertilized$$$266$$$276$$$O	and$$$277$$$280$$$O	maintained$$$281$$$291$$$O	in$$$292$$$294$$$O	vitro.$$$295$$$301$$$O	The$$$302$$$305$$$O	NAC$$$306$$$309$$$I	amide-containing$$$310$$$326$$$I	medium$$$327$$$333$$$O	composition$$$334$$$345$$$O	for$$$346$$$349$$$O	in$$$350$$$352$$$O	vitro$$$353$$$358$$$O	culture$$$359$$$366$$$O	and$$$367$$$370$$$O	fertilization$$$371$$$384$$$O	is$$$385$$$387$$$O	suitable$$$388$$$396$$$O	for$$$397$$$400$$$O	use$$$401$$$404$$$O	in$$$405$$$407$$$O	the$$$408$$$411$$$O	culture$$$412$$$419$$$O	of$$$420$$$422$$$O	oocytes,$$$423$$$431$$$O	in$$$432$$$434$$$O	the$$$435$$$438$$$O	culture$$$439$$$446$$$O	and$$$447$$$450$$$O	development$$$451$$$462$$$O	of$$$463$$$465$$$O	early$$$466$$$471$$$O	embryos,$$$472$$$480$$$O	in$$$481$$$483$$$O	the$$$484$$$487$$$O	preparation$$$488$$$499$$$O	or$$$500$$$502$$$O	culture$$$503$$$510$$$O	of$$$511$$$513$$$O	sperm,$$$514$$$520$$$O	and$$$521$$$524$$$O	in$$$525$$$527$$$O	the$$$528$$$531$$$O	pre-treatment$$$532$$$545$$$O	of$$$546$$$548$$$O	oocytes$$$549$$$556$$$O	or$$$557$$$559$$$O	sperm.$$$560$$$566$$$O	The$$$567$$$570$$$O	NAC$$$571$$$574$$$I	amide-containing$$$575$$$591$$$I	composition$$$592$$$603$$$O	supports$$$604$$$612$$$O	the$$$613$$$616$$$O	growth$$$617$$$623$$$O	of$$$624$$$626$$$O	viable$$$627$$$633$$$O	embryos$$$634$$$641$$$O	until$$$642$$$647$$$O	blastocyst$$$648$$$658$$$O	stage.$$$659$$$665$$$O
WO2013024427A1
Novel$$$0$$$5$$$O	urea$$$6$$$10$$$I	derivatives$$$11$$$22$$$O	as$$$23$$$25$$$O	tec$$$26$$$29$$$O	kinase$$$30$$$36$$$O	inhibitors$$$37$$$47$$$O	and$$$48$$$51$$$O	uses$$$52$$$56$$$O	thereof$$$57$$$64$$$O
Provided$$$0$$$8$$$O	are$$$9$$$12$$$O	urea$$$13$$$17$$$I	compounds$$$18$$$27$$$O	of$$$28$$$30$$$O	formula$$$31$$$38$$$O	(I)$$$39$$$42$$$O	as$$$43$$$45$$$O	Tec$$$46$$$49$$$O	kinase$$$50$$$56$$$O	inhibitors,$$$57$$$68$$$O	in$$$69$$$71$$$O	particular$$$72$$$82$$$O	ITK$$$83$$$86$$$O	(interleukin-2$$$87$$$101$$$O	inducible$$$102$$$111$$$O	tyrosine$$$112$$$120$$$I	kinase)$$$121$$$128$$$O	inhibitors.$$$129$$$140$$$O	Also$$$141$$$145$$$O	provided$$$146$$$154$$$O	herein$$$155$$$161$$$O	are$$$162$$$165$$$O	processes$$$166$$$175$$$O	for$$$176$$$179$$$O	preparing$$$180$$$189$$$O	compounds$$$190$$$199$$$O	described$$$200$$$209$$$O	herein,$$$210$$$217$$$O	intermediates$$$218$$$231$$$O	used$$$232$$$236$$$O	in$$$237$$$239$$$O	their$$$240$$$245$$$O	synthesis,$$$246$$$256$$$O	pharmaceutical$$$257$$$271$$$O	compositions$$$272$$$284$$$O	thereof,$$$285$$$293$$$O	and$$$294$$$297$$$O	methods$$$298$$$305$$$O	for$$$306$$$309$$$O	treating$$$310$$$318$$$O	or$$$319$$$321$$$O	preventing$$$322$$$332$$$O	diseases,$$$333$$$342$$$O	conditions$$$343$$$353$$$O	and/or$$$354$$$360$$$O	disorders$$$361$$$370$$$O	mediated$$$371$$$379$$$O	by$$$380$$$382$$$O	ITK.$$$383$$$387$$$O
US20090018209
Curcumin$$$0$$$8$$$I	and$$$9$$$12$$$O	curcuminoid$$$13$$$24$$$I	inhibition$$$25$$$35$$$O	of$$$36$$$38$$$O	angiogenesis$$$39$$$51$$$O
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	diseases$$$21$$$29$$$O	or$$$30$$$32$$$O	disorders$$$33$$$42$$$O	of$$$43$$$45$$$O	the$$$46$$$49$$$O	skin$$$50$$$54$$$O	which$$$55$$$60$$$O	are$$$61$$$64$$$O	characterized$$$65$$$78$$$O	by$$$79$$$81$$$O	angiogenesis$$$82$$$94$$$O	have$$$95$$$99$$$O	been$$$100$$$104$$$O	developed$$$105$$$114$$$O	using$$$115$$$120$$$O	curcumin$$$121$$$129$$$I	and$$$130$$$133$$$O	curcumin$$$134$$$142$$$I	analogs.$$$143$$$151$$$O	Based$$$152$$$157$$$O	on$$$158$$$160$$$O	the$$$161$$$164$$$O	results$$$165$$$172$$$O	obtained$$$173$$$181$$$O	with$$$182$$$186$$$O	curcumin,$$$187$$$196$$$I	it$$$197$$$199$$$O	has$$$200$$$203$$$O	been$$$204$$$208$$$O	determined$$$209$$$219$$$O	that$$$220$$$224$$$O	other$$$225$$$230$$$O	angiogenesis$$$231$$$243$$$O	inhibitors$$$244$$$254$$$O	can$$$255$$$258$$$O	also$$$259$$$263$$$O	be$$$264$$$266$$$O	used$$$267$$$271$$$O	to$$$272$$$274$$$O	treat$$$275$$$280$$$O	these$$$281$$$286$$$O	skin$$$287$$$291$$$O	disorders.$$$292$$$302$$$O	It$$$303$$$305$$$O	has$$$306$$$309$$$O	further$$$310$$$317$$$O	been$$$318$$$322$$$O	discovered$$$323$$$333$$$O	that$$$334$$$338$$$O	curcumin$$$339$$$347$$$I	acts$$$348$$$352$$$O	to$$$353$$$355$$$O	inhibit$$$356$$$363$$$O	angiogenesis$$$364$$$376$$$O	in$$$377$$$379$$$O	part$$$380$$$384$$$O	by$$$385$$$387$$$O	inhibition$$$388$$$398$$$O	of$$$399$$$401$$$O	basic$$$402$$$407$$$O	fibroblast$$$408$$$418$$$O	growth$$$419$$$425$$$O	factor$$$426$$$432$$$O	(bFGF),$$$433$$$440$$$O	and$$$441$$$444$$$O	thereby$$$445$$$452$$$O	provides$$$453$$$461$$$O	a$$$462$$$463$$$O	means$$$464$$$469$$$O	for$$$470$$$473$$$O	treating$$$474$$$482$$$O	other$$$483$$$488$$$O	disorders$$$489$$$498$$$O	characterized$$$499$$$512$$$O	by$$$513$$$515$$$O	elevated$$$516$$$524$$$O	levels$$$525$$$531$$$O	of$$$532$$$534$$$O	bFGF,$$$535$$$540$$$O	such$$$541$$$545$$$O	as$$$546$$$548$$$O	bladder$$$549$$$556$$$O	cancer,$$$557$$$564$$$O	using$$$565$$$570$$$O	curcumin$$$571$$$579$$$I	and$$$580$$$583$$$O	other$$$584$$$589$$$O	analogues$$$590$$$599$$$O	which$$$600$$$605$$$O	also$$$606$$$610$$$O	inhibit$$$611$$$618$$$O	bFGF.$$$619$$$624$$$O	Representative$$$625$$$639$$$O	skin$$$640$$$644$$$O	disorders$$$645$$$654$$$O	to$$$655$$$657$$$O	be$$$658$$$660$$$O	treated$$$661$$$668$$$O	include$$$669$$$676$$$O	the$$$677$$$680$$$O	malignant$$$681$$$690$$$O	diseases$$$691$$$699$$$O	angiosarcoma,$$$700$$$713$$$O	hemangioendothelioma,$$$714$$$735$$$O	basal$$$736$$$741$$$O	cell$$$742$$$746$$$O	carcinoma,$$$747$$$757$$$O	squamous$$$758$$$766$$$O	cell$$$767$$$771$$$O	carcinoma,$$$772$$$782$$$O	malignant$$$783$$$792$$$O	melanoma$$$793$$$801$$$O	and$$$802$$$805$$$O	Karposi's$$$806$$$815$$$O	sarcoma,$$$816$$$824$$$O	and$$$825$$$828$$$O	the$$$829$$$832$$$O	non-malignant$$$833$$$846$$$O	diseases$$$847$$$855$$$O	or$$$856$$$858$$$O	conditions$$$859$$$869$$$O	including$$$870$$$879$$$O	psoriasis,$$$880$$$890$$$O	lymphangiogenesis,$$$891$$$909$$$O	hemangioma$$$910$$$920$$$O	of$$$921$$$923$$$O	childhood,$$$924$$$934$$$O	Sturge-Weber$$$935$$$947$$$O	syndrome,$$$948$$$957$$$O	verruca$$$958$$$965$$$O	vulgaris,$$$966$$$975$$$O	neurofibromatosis,$$$976$$$994$$$O	tuberous$$$995$$$1003$$$O	sclerosis,$$$1004$$$1014$$$O	pyogenic$$$1015$$$1023$$$O	granulomas,$$$1024$$$1035$$$O	recessive$$$1036$$$1045$$$O	dystrophic$$$1046$$$1056$$$O	epidermolysis$$$1057$$$1070$$$O	bullosa,$$$1071$$$1079$$$O	venous$$$1080$$$1086$$$O	ulcers,$$$1087$$$1094$$$O	acne,$$$1095$$$1100$$$O	rosacea,$$$1101$$$1109$$$O	eczema,$$$1110$$$1117$$$O	molluscum$$$1118$$$1127$$$O	contagious,$$$1128$$$1139$$$O	seborrheic$$$1140$$$1150$$$O	keratosis,$$$1151$$$1161$$$O	and$$$1162$$$1165$$$O	actinic$$$1166$$$1173$$$O	keratosis.$$$1174$$$1184$$$O
CN101940549A
Flurbiprofen$$$0$$$12$$$I	axetil$$$13$$$19$$$I	medium-chain$$$20$$$32$$$O	and$$$33$$$36$$$O	long-chain$$$37$$$47$$$O	fat$$$48$$$51$$$O	emulsion$$$52$$$60$$$O	and$$$61$$$64$$$O	preparation$$$65$$$76$$$O	method$$$77$$$83$$$O	thereof$$$84$$$91$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	flurbiprofen$$$27$$$39$$$I	axetil$$$40$$$46$$$I	medium-chain$$$47$$$59$$$O	and$$$60$$$63$$$O	long-chain$$$64$$$74$$$O	fat$$$75$$$78$$$O	emulsion$$$79$$$87$$$O	and$$$88$$$91$$$O	a$$$92$$$93$$$O	preparation$$$94$$$105$$$O	method$$$106$$$112$$$O	thereof.$$$113$$$121$$$O	The$$$122$$$125$$$O	fat$$$126$$$129$$$O	emulsion$$$130$$$138$$$O	comprises$$$139$$$148$$$O	flurbiprofen$$$149$$$161$$$I	axetil,$$$162$$$169$$$I	long-chain$$$170$$$180$$$O	oil$$$181$$$184$$$O	for$$$185$$$188$$$O	injection,$$$189$$$199$$$O	medium-chain$$$200$$$212$$$O	oil$$$213$$$216$$$O	for$$$217$$$220$$$O	injection,$$$221$$$231$$$O	emulsifier,$$$232$$$243$$$O	isotonic$$$244$$$252$$$O	agent,$$$253$$$259$$$O	pH$$$260$$$262$$$O	regulator$$$263$$$272$$$O	and$$$273$$$276$$$O	water$$$277$$$282$$$O	for$$$283$$$286$$$O	injection,$$$287$$$297$$$O	wherein$$$298$$$305$$$O	the$$$306$$$309$$$O	weight-volume$$$310$$$323$$$O	percentage$$$324$$$334$$$O	of$$$335$$$337$$$O	the$$$338$$$341$$$O	flurbiprofen$$$342$$$354$$$I	axetil$$$355$$$361$$$I	is$$$362$$$364$$$O	0.5-5%(w/v),$$$365$$$377$$$O	the$$$378$$$381$$$O	weight-volume$$$382$$$395$$$O	percentage$$$396$$$406$$$O	of$$$407$$$409$$$O	the$$$410$$$413$$$O	long-chain$$$414$$$424$$$O	oil$$$425$$$428$$$O	for$$$429$$$432$$$O	injection$$$433$$$442$$$O	is$$$443$$$445$$$O	5-10%(w/v),$$$446$$$457$$$O	the$$$458$$$461$$$O	weight-volume$$$462$$$475$$$O	percentage$$$476$$$486$$$O	of$$$487$$$489$$$O	the$$$490$$$493$$$O	medium-chain$$$494$$$506$$$O	oil$$$507$$$510$$$O	for$$$511$$$514$$$O	injection$$$515$$$524$$$O	is$$$525$$$527$$$O	5-10%(w/v),$$$528$$$539$$$O	and$$$540$$$543$$$O	the$$$544$$$547$$$O	weight-volume$$$548$$$561$$$O	percentage$$$562$$$572$$$O	of$$$573$$$575$$$O	the$$$576$$$579$$$O	isotonic$$$580$$$588$$$O	agent$$$589$$$594$$$O	is$$$595$$$597$$$O	1-5%(w/v).$$$598$$$608$$$O
US20120189678
Liposome$$$0$$$8$$$O	and$$$9$$$12$$$O	Personal$$$13$$$21$$$O	Care$$$22$$$26$$$O	Composition$$$27$$$38$$$O	Comprising$$$39$$$49$$$O	Thereof$$$50$$$57$$$O
A$$$0$$$1$$$O	liposome$$$2$$$10$$$O	comprising$$$11$$$21$$$O	a$$$22$$$23$$$O	phospholipid,$$$24$$$37$$$O	a$$$38$$$39$$$O	hydrophobic$$$40$$$51$$$O	active$$$52$$$58$$$O	comprising$$$59$$$69$$$O	a$$$70$$$71$$$O	carboxylate$$$72$$$83$$$I	group,$$$84$$$90$$$O	and$$$91$$$94$$$O	a$$$95$$$96$$$O	component$$$97$$$106$$$O	selected$$$107$$$115$$$O	from$$$116$$$120$$$O	a$$$121$$$122$$$O	group$$$123$$$128$$$O	consisting$$$129$$$139$$$O	of:$$$140$$$143$$$O	a$$$144$$$145$$$O	hydrophilic$$$146$$$157$$$O	adjuvant$$$158$$$166$$$O	comprising$$$167$$$177$$$O	a$$$178$$$179$$$O	positively$$$180$$$190$$$O	charged$$$191$$$198$$$O	group,$$$199$$$205$$$O	a$$$206$$$207$$$O	complex$$$208$$$215$$$O	of$$$216$$$218$$$O	said$$$219$$$223$$$O	hydrophobic$$$224$$$235$$$O	active$$$236$$$242$$$O	with$$$243$$$247$$$O	said$$$248$$$252$$$O	hydrophilic$$$253$$$264$$$O	adjuvant,$$$265$$$274$$$O	and$$$275$$$278$$$O	combinations$$$279$$$291$$$O	thereof.$$$292$$$300$$$O	An$$$301$$$303$$$O	aqueous$$$304$$$311$$$O	liposome$$$312$$$320$$$O	dispersion$$$321$$$331$$$O	comprising$$$332$$$342$$$O	the$$$343$$$346$$$O	liposome,$$$347$$$356$$$O	and$$$357$$$360$$$O	a$$$361$$$362$$$O	personal$$$363$$$371$$$O	care$$$372$$$376$$$O	composition$$$377$$$388$$$O	comprising$$$389$$$399$$$O	the$$$400$$$403$$$O	liposome.$$$404$$$413$$$O	A$$$414$$$415$$$O	process$$$416$$$423$$$O	of$$$424$$$426$$$O	preparing$$$427$$$436$$$O	the$$$437$$$440$$$O	liposome,$$$441$$$450$$$O	comprising$$$451$$$461$$$O	the$$$462$$$465$$$O	steps$$$466$$$471$$$O	of:$$$472$$$475$$$O	forming$$$476$$$483$$$O	a$$$484$$$485$$$O	premix$$$486$$$492$$$O	by$$$493$$$495$$$O	dissolving$$$496$$$506$$$O	a$$$507$$$508$$$O	phospholipid,$$$509$$$522$$$O	a$$$523$$$524$$$O	hydrophobic$$$525$$$536$$$O	active$$$537$$$543$$$O	comprising$$$544$$$554$$$O	a$$$555$$$556$$$O	carboxylate$$$557$$$568$$$I	group$$$569$$$574$$$O	in$$$575$$$577$$$O	an$$$578$$$580$$$O	organic$$$581$$$588$$$O	solvent;$$$589$$$597$$$O	evaporating$$$598$$$609$$$O	off$$$610$$$613$$$O	said$$$614$$$618$$$O	organic$$$619$$$626$$$O	solvent$$$627$$$634$$$O	from$$$635$$$639$$$O	the$$$640$$$643$$$O	premix$$$644$$$650$$$O	to$$$651$$$653$$$O	form$$$654$$$658$$$O	a$$$659$$$660$$$O	phospholipid$$$661$$$673$$$O	film;$$$674$$$679$$$O	and$$$680$$$683$$$O	hydrating$$$684$$$693$$$O	said$$$694$$$698$$$O	lipid$$$699$$$704$$$O	film$$$705$$$709$$$O	with$$$710$$$714$$$O	a$$$715$$$716$$$O	hydration$$$717$$$726$$$O	medium$$$727$$$733$$$O	comprising$$$734$$$744$$$O	a$$$745$$$746$$$O	hydrophilic$$$747$$$758$$$O	adjuvant$$$759$$$767$$$O	comprising$$$768$$$778$$$O	a$$$779$$$780$$$O	positively$$$781$$$791$$$O	charged$$$792$$$799$$$O	group$$$800$$$805$$$O	and$$$806$$$809$$$O	homogenize$$$810$$$820$$$O	the$$$821$$$824$$$O	medium$$$825$$$831$$$O	to$$$832$$$834$$$O	form$$$835$$$839$$$O	an$$$840$$$842$$$O	aqueous$$$843$$$850$$$O	liposome$$$851$$$859$$$O	dispersion.$$$860$$$871$$$O
US20110177098
Tm4sf4$$$0$$$6$$$O	and$$$7$$$10$$$O	modulators$$$11$$$21$$$O	thereof$$$22$$$29$$$O	and$$$30$$$33$$$O	methods$$$34$$$41$$$O	for$$$42$$$45$$$O	their$$$46$$$51$$$O	use$$$52$$$55$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	methods$$$33$$$40$$$O	for$$$41$$$44$$$O	modulating$$$45$$$55$$$O	a$$$56$$$57$$$O	Î²-cell$$$58$$$65$$$O	population$$$66$$$76$$$O	using$$$77$$$82$$$O	a$$$83$$$84$$$O	TM4SF4$$$85$$$91$$$O	modulator$$$92$$$101$$$O	or$$$102$$$104$$$O	a$$$105$$$106$$$O	modulator$$$107$$$116$$$O	of$$$117$$$119$$$O	a$$$120$$$121$$$O	TM4SF4$$$122$$$128$$$O	homolog.$$$129$$$137$$$O	More$$$138$$$142$$$O	particularly,$$$143$$$156$$$O	the$$$157$$$160$$$O	invention$$$161$$$170$$$O	relates,$$$171$$$179$$$O	inter$$$180$$$185$$$O	alia,$$$186$$$191$$$O	to$$$192$$$194$$$O	methods$$$195$$$202$$$O	and$$$203$$$206$$$O	compositions$$$207$$$219$$$O	for$$$220$$$223$$$O	generating,$$$224$$$235$$$O	expanding,$$$236$$$246$$$O	and$$$247$$$250$$$O	maintaining$$$251$$$262$$$O	a$$$263$$$264$$$O	Î²-cell$$$265$$$272$$$O	population$$$273$$$283$$$O	and$$$284$$$287$$$O	treatment$$$288$$$297$$$O	of$$$298$$$300$$$O	diseases$$$301$$$309$$$O	associated$$$310$$$320$$$O	with$$$321$$$325$$$O	the$$$326$$$329$$$O	loss$$$330$$$334$$$O	of$$$335$$$337$$$O	Î²-cells$$$338$$$346$$$O	using$$$347$$$352$$$O	a$$$353$$$354$$$O	TM4SF4$$$355$$$361$$$O	modulator$$$362$$$371$$$O	or$$$372$$$374$$$O	a$$$375$$$376$$$O	modulator$$$377$$$386$$$O	of$$$387$$$389$$$O	a$$$390$$$391$$$O	TM4SF4$$$392$$$398$$$O	homolog.$$$399$$$407$$$O
CN1931329A
Stomatocase$$$0$$$11$$$O	treating$$$12$$$20$$$O	medicine$$$21$$$29$$$O
The$$$0$$$3$$$O	stomatocase$$$4$$$15$$$O	treating$$$16$$$24$$$O	medicine$$$25$$$33$$$O	is$$$34$$$36$$$O	prepared$$$37$$$45$$$O	with$$$46$$$50$$$O	five$$$51$$$55$$$O	kinds$$$56$$$61$$$O	of$$$62$$$64$$$O	main$$$65$$$69$$$O	materials,$$$70$$$80$$$O	including$$$81$$$90$$$O	gypsum,$$$91$$$98$$$O	cape$$$99$$$103$$$O	jasmine,$$$104$$$112$$$O	reed$$$113$$$117$$$O	rhizome,$$$118$$$126$$$O	mint$$$127$$$131$$$O	and$$$132$$$135$$$O	anemarrhena$$$136$$$147$$$O	rhizome,$$$148$$$156$$$O	and$$$157$$$160$$$O	six$$$161$$$164$$$O	kinds$$$165$$$170$$$O	of$$$171$$$173$$$O	supplementary$$$174$$$187$$$O	medicine$$$188$$$196$$$O	materials,$$$197$$$207$$$O	including$$$208$$$217$$$O	rehmannia$$$218$$$227$$$O	root,$$$228$$$233$$$O	skullcap$$$234$$$242$$$O	root,$$$243$$$248$$$O	etc.$$$249$$$253$$$O	The$$$254$$$257$$$O	present$$$258$$$265$$$O	invention$$$266$$$275$$$O	has$$$276$$$279$$$O	unique$$$280$$$286$$$O	recipe,$$$287$$$294$$$O	obvious$$$295$$$302$$$O	treating$$$303$$$311$$$O	effect$$$312$$$318$$$O	and$$$319$$$322$$$O	fast$$$323$$$327$$$O	acting.$$$328$$$335$$$O
EP1496900A2
New$$$0$$$3$$$O	pharmaceutical$$$4$$$18$$$O	compositions$$$19$$$31$$$O	based$$$32$$$37$$$O	on$$$38$$$40$$$O	anticholinergics$$$41$$$57$$$O	and$$$58$$$61$$$O	p38$$$62$$$65$$$O	kinase$$$66$$$72$$$O	inhibitors$$$73$$$83$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	pharmaceutical$$$39$$$53$$$O	compositions$$$54$$$66$$$O	based$$$67$$$72$$$O	on$$$73$$$75$$$O	anticholinergics$$$76$$$92$$$O	and$$$93$$$96$$$O	p38$$$97$$$100$$$O	kinase$$$101$$$107$$$O	inhibitors,$$$108$$$119$$$O	processes$$$120$$$129$$$O	for$$$130$$$133$$$O	preparing$$$134$$$143$$$O	them$$$144$$$148$$$O	and$$$149$$$152$$$O	their$$$153$$$158$$$O	use$$$159$$$162$$$O	in$$$163$$$165$$$O	the$$$166$$$169$$$O	treatment$$$170$$$179$$$O	of$$$180$$$182$$$O	respiratory$$$183$$$194$$$O	diseases.$$$195$$$204$$$O
WO2010068605A1
Novel$$$0$$$5$$$O	polymorphic$$$6$$$17$$$O	forms$$$18$$$23$$$O	of$$$24$$$26$$$O	4-[(4-methoxyphenyl)methyl]-5-(trifluoromethyl)-1h-pyrazole-3-yl]4-deoxy-4-fluoro-beta-d-glucopyranoside$$$27$$$131$$$I	including$$$132$$$141$$$O	hydrates$$$142$$$150$$$I	thereof$$$151$$$158$$$O	and$$$159$$$162$$$O	the$$$163$$$166$$$O	preparations$$$167$$$179$$$O	thereof$$$180$$$187$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	stable$$$37$$$43$$$O	polymorphic$$$44$$$55$$$O	forms$$$56$$$61$$$O	of$$$62$$$64$$$O	the$$$65$$$68$$$O	compound$$$69$$$77$$$O	of$$$78$$$80$$$O	formula$$$81$$$88$$$O	Il$$$89$$$91$$$O	and$$$92$$$95$$$O	hydrates$$$96$$$104$$$I	thereof:$$$105$$$113$$$O	i.$$$114$$$116$$$O	e.,$$$117$$$120$$$O	a$$$121$$$122$$$O	solvent$$$123$$$130$$$O	free$$$131$$$135$$$O	polymorph$$$136$$$145$$$O	"C"$$$146$$$149$$$O	of$$$150$$$152$$$O	4-[(4-methoxyphenyl)methyl]-5-(trifluoromethyl)-$$$153$$$201$$$I	1H-pyrazole-3-yl]-4-deoxy-4-fluoro-beta-D-glucopyranoside;$$$202$$$260$$$I	a$$$261$$$262$$$O	monohydrate$$$263$$$274$$$I	form$$$275$$$279$$$O	"D";$$$280$$$284$$$O	and$$$285$$$288$$$O	a$$$289$$$290$$$O	dihydrate$$$291$$$300$$$I	form$$$301$$$305$$$O	"B",$$$306$$$310$$$O	each$$$311$$$315$$$O	substantially$$$316$$$329$$$O	free$$$330$$$334$$$O	of$$$335$$$337$$$O	residual$$$338$$$346$$$O	organic$$$347$$$354$$$O	solvent$$$355$$$362$$$O	contaminants$$$363$$$375$$$O	and$$$376$$$379$$$O	impurities.$$$380$$$391$$$O
US20080171781
Administering$$$0$$$13$$$O	an$$$14$$$16$$$O	extract$$$17$$$24$$$O	of$$$25$$$27$$$O	safflower$$$28$$$37$$$O	seeds,$$$38$$$44$$$O	p-coumaroyl,$$$45$$$57$$$I	feruloyl$$$58$$$66$$$I	or$$$67$$$69$$$O	caffoyl$$$70$$$77$$$I	serotonin,$$$78$$$88$$$I	to$$$89$$$91$$$O	suppress$$$92$$$100$$$O	an$$$101$$$103$$$O	increase$$$104$$$112$$$O	of$$$113$$$115$$$O	the$$$116$$$119$$$O	pulse$$$120$$$125$$$O	wave$$$126$$$130$$$O	velocity$$$131$$$139$$$O	and$$$140$$$143$$$O	Augmentation$$$144$$$156$$$O	Index,$$$157$$$163$$$O	and$$$164$$$167$$$O	decrease$$$168$$$176$$$O	the$$$177$$$180$$$O	systolic$$$181$$$189$$$O	and$$$190$$$193$$$O	mean$$$194$$$198$$$O	blood$$$199$$$204$$$O	pressure$$$205$$$213$$$O	and$$$214$$$217$$$O	pulse$$$218$$$223$$$O	pressure;$$$224$$$233$$$O	vascular$$$234$$$242$$$O	ageing$$$243$$$249$$$O	resistance;$$$250$$$261$$$O	atherosclerosis;$$$262$$$278$$$O	oral$$$279$$$283$$$O	dosage;$$$284$$$291$$$O	food$$$292$$$296$$$O	additive$$$297$$$305$$$O
Agents$$$0$$$6$$$O	which$$$7$$$12$$$O	contains$$$13$$$21$$$O	a$$$22$$$23$$$O	serotonin$$$24$$$33$$$O	derivative$$$34$$$44$$$O	as$$$45$$$47$$$O	an$$$48$$$50$$$O	active$$$51$$$57$$$O	ingredient$$$58$$$68$$$O	are$$$69$$$72$$$O	effective$$$73$$$82$$$O	for$$$83$$$86$$$O	improving$$$87$$$96$$$O	hemodynamics$$$97$$$109$$$O	and$$$110$$$113$$$O	for$$$114$$$117$$$O	preventing$$$118$$$128$$$O	or$$$129$$$131$$$O	improving$$$132$$$141$$$O	deterioration$$$142$$$155$$$O	of$$$156$$$158$$$O	hemodynamics$$$159$$$171$$$O	associated$$$172$$$182$$$O	with$$$183$$$187$$$O	aging$$$188$$$193$$$O	and$$$194$$$197$$$O	progression$$$198$$$209$$$O	of$$$210$$$212$$$O	cardiovascular$$$213$$$227$$$O	diseases.$$$228$$$237$$$O
US20110021462
Substituted$$$0$$$11$$$O	tetrahydro-2h-isoquinolin-1-one$$$12$$$43$$$I	derivatives,$$$44$$$56$$$O	and$$$57$$$60$$$O	methods$$$61$$$68$$$O	for$$$69$$$72$$$O	the$$$73$$$76$$$O	production$$$77$$$87$$$O	and$$$88$$$91$$$O	use$$$92$$$95$$$O	thereof$$$96$$$103$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	compounds$$$26$$$35$$$O	according$$$36$$$45$$$O	to$$$46$$$48$$$O	the$$$49$$$52$$$O	general$$$53$$$60$$$O	formula$$$61$$$68$$$O	(I),$$$69$$$73$$$O	where$$$74$$$79$$$O	the$$$80$$$83$$$O	definitions$$$84$$$95$$$O	of$$$96$$$98$$$O	the$$$99$$$102$$$O	substituents$$$103$$$115$$$O	R1,$$$116$$$119$$$O	R2,$$$120$$$123$$$O	Ar$$$124$$$126$$$I	and$$$127$$$130$$$O	X$$$131$$$132$$$O	are$$$133$$$136$$$O	as$$$137$$$139$$$O	specified$$$140$$$149$$$O	in$$$150$$$152$$$O	the$$$153$$$156$$$O	description,$$$157$$$169$$$O	and$$$170$$$173$$$O	to$$$174$$$176$$$O	their$$$177$$$182$$$O	physiologically$$$183$$$198$$$O	tolerated$$$199$$$208$$$O	salts,$$$209$$$215$$$O	methods$$$216$$$223$$$O	for$$$224$$$227$$$O	the$$$228$$$231$$$O	preparation$$$232$$$243$$$O	of$$$244$$$246$$$O	these$$$247$$$252$$$O	compounds$$$253$$$262$$$O	and$$$263$$$266$$$O	their$$$267$$$272$$$O	use$$$273$$$276$$$O	as$$$277$$$279$$$O	medicaments.$$$280$$$292$$$O	These$$$330$$$335$$$O	compounds$$$336$$$345$$$O	are$$$346$$$349$$$O	poly(ADP-ribose)$$$350$$$366$$$O	polymerase$$$367$$$377$$$O	(PARP)$$$378$$$384$$$O	inhibitors.$$$385$$$396$$$O
US20100215646
Immunostimulatory$$$0$$$17$$$O	activity$$$18$$$26$$$O	of$$$27$$$29$$$O	palindromic$$$30$$$41$$$O	immune$$$42$$$48$$$O	modulatory$$$49$$$59$$$O	oligonucleotides$$$60$$$76$$$O	(imo)$$$77$$$82$$$O	containing$$$83$$$93$$$O	different$$$94$$$103$$$O	lengths$$$104$$$111$$$O	of$$$112$$$114$$$O	palindromic$$$115$$$126$$$O	segments$$$127$$$135$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	palindromic$$$25$$$36$$$O	immune$$$37$$$43$$$O	modulatory$$$44$$$54$$$O	nucleic$$$55$$$62$$$O	acid.$$$63$$$68$$$O	The$$$69$$$72$$$O	invention$$$73$$$82$$$O	also$$$83$$$87$$$O	provides$$$88$$$96$$$O	methods$$$97$$$104$$$O	for$$$105$$$108$$$O	generating,$$$109$$$120$$$O	enhancing$$$121$$$130$$$O	and$$$131$$$134$$$O	modifying$$$135$$$144$$$O	the$$$145$$$148$$$O	immune$$$149$$$155$$$O	response$$$156$$$164$$$O	caused$$$165$$$171$$$O	by$$$172$$$174$$$O	palindromic$$$175$$$186$$$O	immune$$$187$$$193$$$O	modulatory$$$194$$$204$$$O	compounds$$$205$$$214$$$O	used$$$215$$$219$$$O	for$$$220$$$223$$$O	immunotherapy$$$224$$$237$$$O	applications$$$238$$$250$$$O
CN102886014A
Anticancer$$$0$$$10$$$O	drug$$$11$$$15$$$O	capable$$$16$$$23$$$O	of$$$24$$$26$$$O	clearing$$$27$$$35$$$O	blood$$$36$$$41$$$O	and$$$42$$$45$$$O	diminishing$$$46$$$57$$$O	inflammation$$$58$$$70$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	anticancer$$$27$$$37$$$O	drug$$$38$$$42$$$O	capable$$$43$$$50$$$O	of$$$51$$$53$$$O	clearing$$$54$$$62$$$O	blood$$$63$$$68$$$O	and$$$69$$$72$$$O	diminishing$$$73$$$84$$$O	inflammation.$$$85$$$98$$$O	The$$$99$$$102$$$O	drug$$$103$$$107$$$O	comprises$$$108$$$117$$$O	components:$$$118$$$129$$$O	48$$$130$$$132$$$O	grams?of$$$133$$$141$$$O	Leptopyrum$$$142$$$152$$$O	fumarioides,$$$153$$$165$$$O	36$$$166$$$168$$$O	grams$$$169$$$174$$$O	of$$$175$$$177$$$O	sulphur,$$$178$$$186$$$I	36$$$187$$$189$$$O	grams$$$190$$$195$$$O	of$$$196$$$198$$$O	arsaparilla$$$199$$$210$$$O	root,$$$211$$$216$$$O	18$$$217$$$219$$$O	grams$$$220$$$225$$$O	of$$$226$$$228$$$O	Terminalia,$$$229$$$240$$$O	18$$$241$$$243$$$O	grams$$$244$$$249$$$O	of$$$250$$$252$$$O	Chinese$$$253$$$260$$$O	olive,$$$261$$$267$$$O	24$$$268$$$270$$$O	grams$$$271$$$276$$$O	of$$$277$$$279$$$O	semen$$$280$$$285$$$O	cuscutae,$$$286$$$295$$$O	36$$$296$$$298$$$O	grams$$$299$$$304$$$O	of$$$305$$$307$$$O	yellow$$$308$$$314$$$O	Terminalia,$$$315$$$326$$$O	33$$$327$$$329$$$O	grams$$$330$$$335$$$O	of$$$336$$$338$$$O	red$$$339$$$342$$$O	rose,$$$343$$$348$$$O	24$$$349$$$351$$$O	grams$$$352$$$357$$$O	of$$$358$$$360$$$O	common$$$361$$$367$$$O	fennel$$$368$$$374$$$O	fruit,$$$375$$$381$$$O	24$$$382$$$384$$$O	grams$$$385$$$390$$$O	of$$$391$$$393$$$O	common$$$394$$$400$$$O	polydiaceae,$$$401$$$413$$$O	48$$$414$$$416$$$O	grams$$$417$$$422$$$O	of$$$423$$$425$$$O	Poria$$$426$$$431$$$O	cocos,$$$432$$$438$$$O	48$$$439$$$441$$$O	grams$$$442$$$447$$$O	of$$$448$$$450$$$O	Rhizoma$$$451$$$458$$$O	Smilacis$$$459$$$467$$$O	Glabrae,$$$468$$$476$$$O	24$$$477$$$479$$$O	grams$$$480$$$485$$$O	of$$$486$$$488$$$O	agkistrodon,$$$489$$$501$$$O	12$$$502$$$504$$$O	grams$$$505$$$510$$$O	of$$$511$$$513$$$O	lavender,$$$514$$$523$$$O	250$$$524$$$527$$$O	grams$$$528$$$533$$$O	of$$$534$$$536$$$O	realgar,$$$537$$$545$$$O	12$$$546$$$548$$$O	grams$$$549$$$554$$$O	of$$$555$$$557$$$O	gekko,$$$558$$$564$$$O	18$$$565$$$567$$$O	grams$$$568$$$573$$$O	of$$$574$$$576$$$O	flying$$$577$$$583$$$O	frog,$$$584$$$589$$$O	24$$$590$$$592$$$O	grams$$$593$$$598$$$O	of$$$599$$$601$$$O	nutgall,$$$602$$$610$$$O	600$$$611$$$614$$$O	grams$$$615$$$620$$$O	of$$$621$$$623$$$O	mercury,$$$624$$$632$$$O	800$$$633$$$636$$$O	grams$$$637$$$642$$$O	of$$$643$$$645$$$O	peganum$$$646$$$653$$$O	harmala$$$654$$$661$$$O	seed,$$$662$$$667$$$O	900$$$668$$$671$$$O	grams$$$672$$$677$$$O	of$$$678$$$680$$$O	Rome$$$681$$$685$$$O	pyrethrum$$$686$$$695$$$O	root,$$$696$$$701$$$O	600$$$702$$$705$$$O	grams$$$706$$$711$$$O	of$$$712$$$714$$$O	pepper,$$$715$$$722$$$O	12$$$723$$$725$$$O	grams$$$726$$$731$$$O	of$$$732$$$734$$$O	turmeric,$$$735$$$744$$$O	600$$$745$$$748$$$O	grams$$$749$$$754$$$O	of$$$755$$$757$$$O	catechu,$$$758$$$766$$$O	250$$$767$$$770$$$O	grams$$$771$$$776$$$O	of$$$777$$$779$$$O	scorpion,$$$780$$$789$$$O	24$$$790$$$792$$$O	grams$$$793$$$798$$$O	of$$$799$$$801$$$O	franchet$$$802$$$810$$$O	groundcherry$$$811$$$823$$$O	fruit,$$$824$$$830$$$O	3$$$831$$$832$$$O	grams$$$833$$$838$$$O	of$$$839$$$841$$$O	cinnabar$$$842$$$850$$$O	and$$$851$$$854$$$O	3$$$855$$$856$$$O	grams$$$857$$$862$$$O	of$$$863$$$865$$$O	coral$$$866$$$871$$$O	root.$$$872$$$877$$$O	wherein$$$878$$$885$$$O	the$$$886$$$889$$$O	realgar$$$890$$$897$$$O	is$$$898$$$900$$$O	put$$$901$$$904$$$O	in$$$905$$$907$$$O	a$$$908$$$909$$$O	sealed$$$910$$$916$$$O	argil$$$917$$$922$$$O	crock$$$923$$$928$$$O	to$$$929$$$931$$$O	bake$$$932$$$936$$$O	for$$$937$$$940$$$O	3$$$941$$$942$$$O	hours,$$$943$$$949$$$O	the$$$950$$$953$$$O	mercury$$$954$$$961$$$O	is$$$962$$$964$$$O	put$$$965$$$968$$$O	in$$$969$$$971$$$O	a$$$972$$$973$$$O	hollowed$$$974$$$982$$$O	white$$$983$$$988$$$O	turnip$$$989$$$995$$$O	wrapped$$$996$$$1003$$$O	with$$$1004$$$1008$$$O	mud$$$1009$$$1012$$$O	to$$$1013$$$1015$$$O	bake$$$1016$$$1020$$$O	for$$$1021$$$1024$$$O	3$$$1025$$$1026$$$O	hours,$$$1027$$$1033$$$O	the$$$1034$$$1037$$$O	scorpion$$$1038$$$1046$$$O	is$$$1047$$$1049$$$O	wrapped$$$1050$$$1057$$$O	inside$$$1058$$$1064$$$O	a$$$1065$$$1066$$$O	dough$$$1067$$$1072$$$O	to$$$1073$$$1075$$$O	bake$$$1076$$$1080$$$O	for$$$1081$$$1084$$$O	1$$$1085$$$1086$$$O	hour,$$$1087$$$1092$$$O	and$$$1093$$$1096$$$O	the$$$1097$$$1100$$$O	cinnabar$$$1101$$$1109$$$O	is$$$1110$$$1112$$$O	put$$$1113$$$1116$$$O	in$$$1117$$$1119$$$O	a$$$1120$$$1121$$$O	container$$$1122$$$1131$$$O	with$$$1132$$$1136$$$O	yoghourt,$$$1137$$$1146$$$O	and$$$1147$$$1150$$$O	then$$$1151$$$1155$$$O	is$$$1156$$$1158$$$O	stirred$$$1159$$$1166$$$O	and$$$1167$$$1170$$$O	heated$$$1171$$$1177$$$O	for$$$1178$$$1181$$$O	3$$$1182$$$1183$$$O	hours.$$$1184$$$1190$$$O	Each$$$1191$$$1195$$$O	component$$$1196$$$1205$$$O	is$$$1206$$$1208$$$O	processed$$$1209$$$1218$$$O	into$$$1219$$$1223$$$O	powder$$$1224$$$1230$$$O	and$$$1231$$$1234$$$O	then$$$1235$$$1239$$$O	uniformly$$$1240$$$1249$$$O	mixed$$$1250$$$1255$$$O	to$$$1256$$$1258$$$O	prepare$$$1259$$$1266$$$O	the$$$1267$$$1270$$$O	drug.$$$1271$$$1276$$$O
US20120270849
Combinations$$$0$$$12$$$O	of$$$13$$$15$$$O	niacin,$$$16$$$23$$$O	omega-3$$$24$$$31$$$O	and$$$32$$$35$$$O	plant$$$36$$$41$$$O	sterols/stanols$$$42$$$57$$$O	for$$$58$$$61$$$O	prevention$$$62$$$72$$$O	cholesterol$$$73$$$84$$$O	treatment$$$85$$$94$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	nutritional$$$20$$$31$$$O	compositions,$$$32$$$45$$$O	regimens$$$46$$$54$$$O	and$$$55$$$58$$$O	methods$$$59$$$66$$$O	for$$$67$$$70$$$O	the$$$71$$$74$$$O	prevention,$$$75$$$86$$$O	mitigation,$$$87$$$98$$$O	and$$$99$$$102$$$O	treatment$$$103$$$112$$$O	of$$$113$$$115$$$O	a$$$116$$$117$$$O	cholesterol$$$118$$$129$$$O	abnormality.$$$130$$$142$$$O	In$$$143$$$145$$$O	some$$$146$$$150$$$O	embodiments,$$$151$$$163$$$O	the$$$164$$$167$$$O	invention$$$168$$$177$$$O	comprises$$$178$$$187$$$O	combinations$$$188$$$200$$$O	of$$$201$$$203$$$O	niacin$$$204$$$210$$$O	(precursor),$$$211$$$223$$$O	and$$$224$$$227$$$O	at$$$228$$$230$$$O	least$$$231$$$236$$$O	one$$$237$$$240$$$O	ingredient$$$241$$$251$$$O	selected$$$252$$$260$$$O	from$$$261$$$265$$$O	the$$$266$$$269$$$O	group$$$270$$$275$$$O	consisting$$$276$$$286$$$O	of:$$$287$$$290$$$O	an$$$291$$$293$$$O	Omega-3$$$294$$$301$$$O	fatty$$$302$$$307$$$O	acid,$$$308$$$313$$$O	Omega-3$$$314$$$321$$$O	fatty$$$322$$$327$$$O	acid$$$328$$$332$$$O	precursor,$$$333$$$343$$$O	or$$$344$$$346$$$O	Omega-3$$$347$$$354$$$O	fatty$$$355$$$360$$$O	acid$$$361$$$365$$$O	derivative,$$$366$$$377$$$O	and:$$$378$$$382$$$O	a$$$383$$$384$$$O	plant$$$385$$$390$$$O	sterol,$$$391$$$398$$$O	a$$$399$$$400$$$O	plant$$$401$$$406$$$O	sterol$$$407$$$413$$$O	precursor,$$$414$$$424$$$O	or$$$425$$$427$$$O	a$$$428$$$429$$$O	plant$$$430$$$435$$$O	sterol$$$436$$$442$$$O	derivative.$$$443$$$454$$$O	In$$$455$$$457$$$O	other$$$458$$$463$$$O	embodiments,$$$464$$$476$$$O	the$$$477$$$480$$$O	combination$$$481$$$492$$$O	includes$$$493$$$501$$$O	all$$$502$$$505$$$O	three$$$506$$$511$$$O	of$$$512$$$514$$$O	those$$$515$$$520$$$O	ingredients.$$$521$$$533$$$O
WO2014027658A1
INTERMEDIATE$$$0$$$12$$$O	FOR$$$13$$$16$$$O	SYNTHESIS$$$17$$$26$$$O	OF$$$27$$$29$$$O	1-(2-DEOXY-2-FLUORO-4-THIO-Î²-D-ARABINOFURANOSYL)$$$30$$$79$$$I	CYTOSINE,$$$80$$$89$$$I	INTERMEDIATE$$$90$$$102$$$O	FOR$$$103$$$106$$$O	SYNTHESIS$$$107$$$116$$$O	OF$$$117$$$119$$$I	THIONUCLEOSIDE,$$$120$$$135$$$I	AND$$$136$$$139$$$O	METHODS$$$140$$$147$$$O	FOR$$$148$$$151$$$O	PRODUCING$$$152$$$161$$$O	THESE$$$162$$$167$$$O	INTERMEDIATES$$$168$$$181$$$O
A$$$0$$$1$$$O	compound$$$2$$$10$$$O	represented$$$11$$$22$$$O	by$$$23$$$25$$$O	general$$$26$$$33$$$O	formula$$$34$$$41$$$O	[1D]$$$42$$$46$$$O	(in$$$47$$$50$$$O	the$$$51$$$54$$$O	formula,$$$55$$$63$$$O	R1A,$$$64$$$68$$$O	R1B,$$$69$$$73$$$O	R2A,$$$74$$$78$$$O	R2B,$$$79$$$83$$$O	R3A$$$84$$$87$$$O	and$$$88$$$91$$$O	R3B$$$92$$$95$$$O	each$$$96$$$100$$$O	denote$$$101$$$107$$$O	a$$$108$$$109$$$O	hydrogen$$$110$$$118$$$I	atom,$$$119$$$124$$$O	an$$$125$$$127$$$O	optionally$$$128$$$138$$$O	substituted$$$139$$$150$$$O	C1-6$$$151$$$155$$$I	alkyl$$$156$$$161$$$I	group,$$$162$$$168$$$O	and$$$169$$$172$$$O	the$$$173$$$176$$$O	like)$$$177$$$182$$$O	is$$$183$$$185$$$O	useful$$$186$$$192$$$O	as$$$193$$$195$$$O	an$$$196$$$198$$$O	intermediate$$$199$$$211$$$O	for$$$212$$$215$$$O	producing$$$216$$$225$$$O	a$$$226$$$227$$$O	thionucleoside,$$$228$$$243$$$I	and$$$244$$$247$$$O	this$$$248$$$252$$$O	production$$$253$$$263$$$O	method$$$264$$$270$$$O	is$$$271$$$273$$$O	useful$$$274$$$280$$$O	as$$$281$$$283$$$O	a$$$284$$$285$$$O	method$$$286$$$292$$$O	for$$$293$$$296$$$O	producing$$$297$$$306$$$O	a$$$307$$$308$$$O	thionucleoside.$$$309$$$324$$$I
US20120263730
Receptors$$$0$$$9$$$O	of$$$10$$$12$$$O	rspo2$$$13$$$18$$$O	and$$$19$$$22$$$O	rspo3$$$23$$$28$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	finding$$$37$$$44$$$O	that$$$45$$$49$$$O	Syndecans$$$50$$$59$$$O	(Sdc)$$$60$$$65$$$O	are$$$66$$$69$$$O	receptors$$$70$$$79$$$O	of$$$80$$$82$$$O	Rspondin-2$$$83$$$93$$$O	(Rspo2)$$$94$$$101$$$O	and$$$102$$$105$$$O	Rspondin-3$$$106$$$116$$$O	(Rspo3).$$$117$$$125$$$O	Thus,$$$126$$$131$$$O	the$$$132$$$135$$$O	present$$$136$$$143$$$O	invention$$$144$$$153$$$O	relates$$$154$$$161$$$O	to$$$162$$$164$$$O	the$$$165$$$168$$$O	identification$$$169$$$183$$$O	of$$$184$$$186$$$O	Rspo2,$$$187$$$193$$$O	Rspo3$$$194$$$199$$$O	and/or$$$200$$$206$$$O	Sdc$$$207$$$210$$$O	activity$$$211$$$219$$$O	modulators$$$220$$$230$$$O	by$$$231$$$233$$$O	determining$$$234$$$245$$$O	if$$$246$$$248$$$O	a$$$249$$$250$$$O	test$$$251$$$255$$$O	compound$$$256$$$264$$$O	has$$$265$$$268$$$O	the$$$269$$$272$$$O	ability$$$273$$$280$$$O	to$$$281$$$283$$$O	modulate$$$284$$$292$$$O	the$$$293$$$296$$$O	binding$$$297$$$304$$$O	of$$$305$$$307$$$O	an$$$308$$$310$$$O	Rspo2$$$311$$$316$$$O	and/or$$$317$$$323$$$O	Rspo3$$$324$$$329$$$O	polypeptide$$$330$$$341$$$O	to$$$342$$$344$$$O	an$$$345$$$347$$$O	Sdc$$$348$$$351$$$O	polypeptide.$$$352$$$364$$$O	Further,$$$365$$$373$$$O	the$$$374$$$377$$$O	invention$$$378$$$387$$$O	refers$$$388$$$394$$$O	to$$$395$$$397$$$O	novel$$$398$$$403$$$O	uses$$$404$$$408$$$O	for$$$409$$$412$$$O	antagonists$$$413$$$424$$$O	of$$$425$$$427$$$O	Rspo2$$$428$$$433$$$O	and/or$$$434$$$440$$$O	Rspo3$$$441$$$446$$$O	in$$$447$$$449$$$O	the$$$450$$$453$$$O	treatment$$$454$$$463$$$O	of$$$464$$$466$$$O	Sdc-associated$$$467$$$481$$$O	disorders$$$482$$$491$$$O	and$$$492$$$495$$$O	for$$$496$$$499$$$O	Sdc$$$500$$$503$$$O	antagonists$$$504$$$515$$$O	in$$$516$$$518$$$O	the$$$519$$$522$$$O	treatment$$$523$$$532$$$O	of$$$533$$$535$$$O	Rspo2-$$$536$$$542$$$O	and/or$$$543$$$549$$$O	Rspo3-associated$$$550$$$566$$$O	disorders.$$$567$$$577$$$O
US7625872
a$$$0$$$1$$$O	branch-point$$$2$$$14$$$O	nucleoside$$$15$$$25$$$O	to$$$26$$$28$$$O	which$$$29$$$34$$$O	three$$$35$$$40$$$O	core$$$41$$$45$$$O	nucleic$$$46$$$53$$$O	acid$$$54$$$58$$$O	moieties$$$59$$$67$$$O	are$$$68$$$71$$$O	covalently$$$72$$$82$$$O	coupled;$$$83$$$91$$$O	therapy$$$92$$$99$$$O	for$$$100$$$103$$$O	cancer$$$104$$$110$$$O	and$$$111$$$114$$$O	Th2-type$$$115$$$123$$$O	immune$$$124$$$130$$$O	response$$$131$$$139$$$O	(e.g.,$$$140$$$146$$$O	an$$$147$$$149$$$O	allergy$$$150$$$157$$$O	or$$$158$$$160$$$O	allergy-induced$$$161$$$176$$$O	asthma)$$$177$$$184$$$O	by$$$185$$$187$$$O	increasing$$$188$$$198$$$O	the$$$199$$$202$$$O	secretion$$$203$$$212$$$O	of$$$213$$$215$$$O	interferon-gamma$$$216$$$232$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	immunomodulatory$$$23$$$39$$$O	compounds$$$40$$$49$$$O	and$$$50$$$53$$$O	methods$$$54$$$61$$$O	for$$$62$$$65$$$O	immunomodulation$$$66$$$82$$$O	of$$$83$$$85$$$O	cells$$$86$$$91$$$O	and$$$92$$$95$$$O	individuals$$$96$$$107$$$O	using$$$108$$$113$$$O	the$$$114$$$117$$$O	immunomodulatory$$$118$$$134$$$O	compounds.$$$135$$$145$$$O
US20100099722
2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl)$$$0$$$46$$$I	acetamide$$$47$$$56$$$I	derivatives$$$57$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	2-(benzimidazol-1-yl)-N-(4-phenylthiazol-2-yl)$$$22$$$68$$$I	acetamide$$$69$$$78$$$I	derivatives$$$79$$$90$$$O	having$$$91$$$97$$$O	the$$$98$$$101$$$O	general$$$102$$$109$$$O	Formula$$$110$$$117$$$O	I$$$118$$$119$$$O	wherein$$$157$$$164$$$O	R1$$$165$$$167$$$O	is$$$168$$$170$$$O	H,$$$171$$$173$$$I	(C1-4)alkyl,$$$174$$$186$$$I	(C1-4)alkyloxy$$$187$$$201$$$I	or$$$202$$$204$$$O	halogen;$$$205$$$213$$$I	R2$$$214$$$216$$$O	represents$$$217$$$227$$$O	1-3$$$228$$$231$$$O	substituents$$$232$$$244$$$O	selected$$$245$$$253$$$O	from$$$254$$$258$$$O	H,$$$259$$$261$$$I	(C1-4)alkyl$$$262$$$273$$$I	(optionally$$$274$$$285$$$O	substituted$$$286$$$297$$$O	with$$$298$$$302$$$O	1$$$303$$$304$$$O	or$$$305$$$307$$$O	more$$$308$$$312$$$O	halogens),$$$313$$$323$$$I	(C1-4)alkyl-oxy$$$324$$$339$$$I	(optionally$$$340$$$351$$$O	substituted$$$352$$$363$$$O	with$$$364$$$368$$$O	1$$$369$$$370$$$O	or$$$371$$$373$$$O	more$$$374$$$378$$$O	halogens),$$$379$$$389$$$I	halogen,$$$390$$$398$$$I	CF3$$$399$$$402$$$I	or$$$403$$$405$$$O	cyano;$$$406$$$412$$$I	or$$$413$$$415$$$O	a$$$416$$$417$$$O	pharmaceutically$$$418$$$434$$$O	acceptable$$$435$$$445$$$O	salt$$$446$$$450$$$O	thereof;$$$451$$$459$$$O	to$$$460$$$462$$$O	pharmaceutical$$$463$$$477$$$O	compositions$$$478$$$490$$$O	comprising$$$491$$$501$$$O	the$$$502$$$505$$$O	same$$$506$$$510$$$O	and$$$511$$$514$$$O	to$$$515$$$517$$$O	the$$$518$$$521$$$O	use$$$522$$$525$$$O	of$$$526$$$528$$$O	said$$$529$$$533$$$O	2-(benzimidazol-1-yl)-N-(4-phenylthiazol-2-yl)acetamide$$$534$$$589$$$I	derivatives$$$590$$$601$$$O	in$$$602$$$604$$$O	the$$$605$$$608$$$O	treatment$$$609$$$618$$$O	of$$$619$$$621$$$O	TRPV1$$$622$$$627$$$O	mediated$$$628$$$636$$$O	disorders.$$$637$$$647$$$O
US6869975
Linked$$$0$$$6$$$O	biaryl$$$7$$$13$$$I	compounds$$$14$$$23$$$O
Compounds,$$$0$$$10$$$O	compositions$$$11$$$23$$$O	and$$$24$$$27$$$O	methods$$$28$$$35$$$O	that$$$36$$$40$$$O	are$$$41$$$44$$$O	useful$$$45$$$51$$$O	for$$$52$$$55$$$O	the$$$56$$$59$$$O	treatment$$$60$$$69$$$O	of$$$70$$$72$$$O	metabolic$$$73$$$82$$$O	disorders,$$$83$$$93$$$O	inflammatory$$$94$$$106$$$O	diseases$$$107$$$115$$$O	and$$$116$$$119$$$O	cancer$$$120$$$126$$$O	are$$$127$$$130$$$O	provided$$$131$$$139$$$O	herein.$$$140$$$147$$$O	In$$$148$$$150$$$O	particular,$$$151$$$162$$$O	the$$$163$$$166$$$O	invention$$$167$$$176$$$O	provides$$$177$$$185$$$O	compounds$$$186$$$195$$$O	which$$$196$$$201$$$O	modulate$$$202$$$210$$$O	the$$$211$$$214$$$O	expression$$$215$$$225$$$O	and/or$$$226$$$232$$$O	function$$$233$$$241$$$O	of$$$242$$$244$$$O	proteins$$$245$$$253$$$O	involved$$$254$$$262$$$O	in$$$263$$$265$$$O	lipid$$$266$$$271$$$O	metabolism,$$$272$$$283$$$O	inflammation$$$284$$$296$$$O	and$$$297$$$300$$$O	cell$$$301$$$305$$$O	proliferation.$$$306$$$320$$$O	The$$$321$$$324$$$O	subject$$$325$$$332$$$O	compounds$$$333$$$342$$$O	are$$$343$$$346$$$O	linked$$$347$$$353$$$O	biaryl$$$354$$$360$$$I	compounds.$$$361$$$371$$$O
US20140093502
Immunosuppressive$$$0$$$17$$$O	Combination$$$18$$$29$$$O	and$$$30$$$33$$$O	Its$$$34$$$37$$$O	Use$$$38$$$41$$$O	in$$$42$$$44$$$O	the$$$45$$$48$$$O	Treatment$$$49$$$58$$$O	or$$$59$$$61$$$O	Prophylaxis$$$62$$$73$$$O	of$$$74$$$76$$$O	Insulin-producing$$$77$$$94$$$O	Cell$$$95$$$99$$$O	Graft$$$100$$$105$$$O	Rejection$$$106$$$115$$$O
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	combination$$$17$$$28$$$O	comprising$$$29$$$39$$$O	an$$$40$$$42$$$O	accelerated$$$43$$$54$$$O	lymphocyte$$$55$$$65$$$O	homing$$$66$$$72$$$O	agent$$$73$$$78$$$O	in$$$79$$$81$$$O	free$$$82$$$86$$$O	form$$$87$$$91$$$O	or$$$92$$$94$$$O	in$$$95$$$97$$$O	pharmaceutically$$$98$$$114$$$O	acceptable$$$115$$$125$$$O	salt$$$126$$$130$$$O	form,$$$131$$$136$$$O	and$$$137$$$140$$$O	one$$$141$$$144$$$O	or$$$145$$$147$$$O	more$$$148$$$152$$$O	compounds$$$153$$$162$$$O	selected$$$163$$$171$$$O	from$$$172$$$176$$$O	the$$$177$$$180$$$O	group$$$181$$$186$$$O	consisting$$$187$$$197$$$O	of$$$198$$$200$$$O	an$$$201$$$203$$$O	antibody$$$204$$$212$$$O	to$$$213$$$215$$$O	the$$$216$$$219$$$O	IL-2$$$220$$$224$$$O	receptor,$$$225$$$234$$$O	an$$$235$$$237$$$O	immunosuppressive$$$238$$$255$$$O	macrocyclic$$$256$$$267$$$I	lactone$$$268$$$275$$$I	and$$$276$$$279$$$O	a$$$280$$$281$$$O	soluble$$$282$$$289$$$O	human$$$290$$$295$$$O	complement$$$296$$$306$$$O	inhibitor$$$307$$$316$$$O	is$$$317$$$319$$$O	used$$$320$$$324$$$O	to$$$325$$$327$$$O	treat$$$328$$$333$$$O	or$$$334$$$336$$$O	prevent$$$337$$$344$$$O	insulin-producing$$$345$$$362$$$O	cell$$$363$$$367$$$O	graft$$$368$$$373$$$O	rejection.$$$374$$$384$$$O
EP2582674A1
Gpr120$$$0$$$6$$$O	receptor$$$7$$$15$$$O	agonists$$$16$$$24$$$O	and$$$25$$$28$$$O	uses$$$29$$$33$$$O	thereof$$$34$$$41$$$O
GPR120$$$0$$$6$$$O	agonists$$$7$$$15$$$O	are$$$16$$$19$$$O	provided.$$$20$$$29$$$O	These$$$30$$$35$$$O	compounds$$$36$$$45$$$O	are$$$46$$$49$$$O	useful$$$50$$$56$$$O	for$$$57$$$60$$$O	the$$$61$$$64$$$O	treatment$$$65$$$74$$$O	of$$$75$$$77$$$O	metabolic$$$78$$$87$$$O	diseases,$$$88$$$97$$$O	including$$$98$$$107$$$O	Type$$$108$$$112$$$O	II$$$113$$$115$$$O	diabetes$$$116$$$124$$$O	and$$$125$$$128$$$O	diseases$$$129$$$137$$$O	associated$$$138$$$148$$$O	with$$$149$$$153$$$O	poor$$$154$$$158$$$O	glycemic$$$159$$$167$$$O	control.$$$168$$$176$$$O
WO2010084458A1
A$$$0$$$1$$$O	novel$$$2$$$7$$$O	dermaceutical$$$8$$$21$$$O	cream$$$22$$$27$$$O	made$$$28$$$32$$$O	using$$$33$$$38$$$O	sodium$$$39$$$45$$$I	fusidate,$$$46$$$55$$$I	antifungals$$$56$$$67$$$O	and$$$68$$$71$$$O	steroids$$$72$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	dermaceutical$$$26$$$39$$$O	cream$$$40$$$45$$$O	containing$$$46$$$56$$$O	antifungal$$$57$$$67$$$O	agents,$$$68$$$75$$$O	steroids$$$76$$$84$$$I	and$$$85$$$88$$$O	an$$$89$$$91$$$O	antibacterial$$$92$$$105$$$O	agent$$$106$$$111$$$O	in$$$112$$$114$$$O	the$$$115$$$118$$$O	form$$$119$$$123$$$O	of$$$124$$$126$$$O	Fusidic$$$127$$$134$$$I	acid,$$$135$$$140$$$I	which$$$141$$$146$$$O	Fusidic$$$147$$$154$$$I	acid$$$155$$$159$$$I	is$$$160$$$162$$$O	formed$$$163$$$169$$$O	in$$$170$$$172$$$O	situ$$$173$$$177$$$O	from$$$178$$$182$$$O	Sodium$$$183$$$189$$$I	Fusidate$$$190$$$198$$$I	as$$$199$$$201$$$O	the$$$202$$$205$$$O	starting$$$206$$$214$$$O	raw$$$215$$$218$$$O	material,$$$219$$$228$$$O	wherein$$$229$$$236$$$O	Sodium$$$237$$$243$$$I	Fusidate$$$244$$$252$$$I	is$$$253$$$255$$$O	converted$$$256$$$265$$$O	into$$$266$$$270$$$O	Fusidic$$$271$$$278$$$I	acid$$$279$$$283$$$I	under$$$284$$$289$$$O	oxygen-free$$$290$$$301$$$I	environment.$$$302$$$314$$$O	The$$$315$$$318$$$O	cream$$$319$$$324$$$O	of$$$325$$$327$$$O	the$$$328$$$331$$$O	present$$$332$$$339$$$O	invention$$$340$$$349$$$O	has$$$350$$$353$$$O	greater$$$354$$$361$$$O	shelf-life$$$362$$$372$$$O	stability$$$373$$$382$$$O	and$$$383$$$386$$$O	the$$$387$$$390$$$O	finer$$$391$$$396$$$O	particle$$$397$$$405$$$O	size$$$406$$$410$$$O	of$$$411$$$413$$$O	the$$$414$$$417$$$O	API$$$418$$$421$$$O	than$$$422$$$426$$$O	the$$$427$$$430$$$O	conventional$$$431$$$443$$$O	creams$$$444$$$450$$$O	containing$$$451$$$461$$$O	Fusidic$$$462$$$469$$$I	acid.$$$470$$$475$$$I	The$$$476$$$479$$$O	cream$$$480$$$485$$$O	of$$$486$$$488$$$O	the$$$489$$$492$$$O	present$$$493$$$500$$$O	invention$$$501$$$510$$$O	contains$$$511$$$519$$$O	Fusidic$$$520$$$527$$$I	acid$$$528$$$532$$$I	as$$$533$$$535$$$O	the$$$536$$$539$$$O	API$$$540$$$543$$$O	that$$$544$$$548$$$O	has$$$549$$$552$$$O	been$$$553$$$557$$$O	formed$$$558$$$564$$$O	in$$$565$$$567$$$O	situ$$$568$$$572$$$O	from$$$573$$$577$$$O	Sodium$$$578$$$584$$$I	Fusidate,$$$585$$$594$$$I	and$$$595$$$598$$$O	steroids$$$599$$$607$$$I	in$$$608$$$610$$$O	a$$$611$$$612$$$O	cream$$$613$$$618$$$O	base$$$619$$$623$$$O	comprising$$$624$$$634$$$O	an$$$635$$$637$$$O	acid,$$$638$$$643$$$O	a$$$644$$$645$$$O	co-solvent,$$$646$$$657$$$O	an$$$658$$$660$$$O	emulsifier$$$661$$$671$$$O	and$$$672$$$675$$$O	a$$$676$$$677$$$O	waxy$$$678$$$682$$$O	material$$$683$$$691$$$O	along$$$692$$$697$$$O	with$$$698$$$702$$$O	water,$$$703$$$709$$$O	preferably$$$710$$$720$$$O	purified$$$721$$$729$$$O	water.$$$730$$$736$$$O
US8012991
3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic$$$0$$$90$$$I	acid;$$$91$$$96$$$I	gamma-aminobutyric$$$97$$$115$$$I	acid$$$116$$$120$$$I	modulator;$$$121$$$131$$$O	anticarcinogenic,$$$132$$$149$$$O	antitumor,$$$150$$$160$$$O	antiproliferative$$$161$$$178$$$O	agent;$$$179$$$185$$$O	amidating$$$186$$$195$$$O	a$$$196$$$197$$$O	2-aminoindole$$$198$$$211$$$I	with$$$212$$$216$$$O	an$$$217$$$219$$$O	alpha-substituted-beta-hydroxy-alkyl$$$220$$$256$$$I	acrylate$$$257$$$265$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	relates$$$23$$$30$$$O	to$$$31$$$33$$$O	pyridoindolone$$$34$$$48$$$I	derivatives$$$49$$$60$$$O	of$$$61$$$63$$$O	general$$$64$$$71$$$O	formula$$$72$$$79$$$O	(I):$$$80$$$84$$$O	to$$$104$$$106$$$O	processes$$$107$$$116$$$O	for$$$117$$$120$$$O	preparing$$$121$$$130$$$O	the$$$131$$$134$$$O	same$$$135$$$139$$$O	and$$$140$$$143$$$O	to$$$144$$$146$$$O	their$$$147$$$152$$$O	use$$$153$$$156$$$O	in$$$157$$$159$$$O	therapeutics.$$$160$$$173$$$O
WO2014017689A1
Anti-obesity$$$0$$$12$$$O	composition$$$13$$$24$$$O	comprising$$$25$$$35$$$O	mineral$$$36$$$43$$$O	extract$$$44$$$51$$$O	of$$$52$$$54$$$O	deep$$$55$$$59$$$O	sea$$$60$$$63$$$O	water$$$64$$$69$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	novel$$$35$$$40$$$O	application$$$41$$$52$$$O	of$$$53$$$55$$$O	mineral$$$56$$$63$$$O	extract$$$64$$$71$$$O	of$$$72$$$74$$$O	deep$$$75$$$79$$$O	sea$$$80$$$83$$$O	water$$$84$$$89$$$O	having$$$90$$$96$$$O	inhibition$$$97$$$107$$$O	of$$$108$$$110$$$O	adipocyte$$$111$$$120$$$O	differentiation$$$121$$$136$$$O	and$$$137$$$140$$$O	lipid$$$141$$$146$$$O	metabolism$$$147$$$157$$$O	and$$$158$$$161$$$O	decrease$$$162$$$170$$$O	of$$$171$$$173$$$O	triglyceride$$$174$$$186$$$I	content,$$$187$$$195$$$O	which$$$196$$$201$$$O	has$$$202$$$205$$$O	an$$$206$$$208$$$O	effect$$$209$$$215$$$O	on$$$216$$$218$$$O	providing$$$219$$$228$$$O	anti-obesity$$$229$$$241$$$O	composition.$$$242$$$254$$$O
EP1893206A2
Synergistic$$$0$$$11$$$O	modulation$$$12$$$22$$$O	of$$$23$$$25$$$O	flt3$$$26$$$30$$$O	kinase$$$31$$$37$$$O	using$$$38$$$43$$$O	aminoquinoline$$$44$$$58$$$I	and$$$59$$$62$$$O	aminoquinazoline$$$63$$$79$$$I	kinase$$$80$$$86$$$O	modulators$$$87$$$97$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	directed$$$17$$$25$$$O	to$$$26$$$28$$$O	a$$$29$$$30$$$O	method$$$31$$$37$$$O	of$$$38$$$40$$$O	inhibiting$$$41$$$51$$$O	FLT3$$$52$$$56$$$O	tyrosine$$$57$$$65$$$I	kinase$$$66$$$72$$$O	activity$$$73$$$81$$$O	or$$$82$$$84$$$O	expression$$$85$$$95$$$O	or$$$96$$$98$$$O	reducing$$$99$$$107$$$O	FLT3$$$108$$$112$$$O	kinase$$$113$$$119$$$O	activity$$$120$$$128$$$O	or$$$129$$$131$$$O	expression$$$132$$$142$$$O	in$$$143$$$145$$$O	a$$$146$$$147$$$O	cell$$$148$$$152$$$O	or$$$153$$$155$$$O	a$$$156$$$157$$$O	subject$$$158$$$165$$$O	comprising$$$166$$$176$$$O	the$$$177$$$180$$$O	administration$$$181$$$195$$$O	of$$$196$$$198$$$O	a$$$199$$$200$$$O	farnesyl$$$201$$$209$$$I	transferase$$$210$$$221$$$O	inhibitor$$$222$$$231$$$O	and$$$232$$$235$$$O	a$$$236$$$237$$$O	FLT3$$$238$$$242$$$O	kinase$$$243$$$249$$$O	inhibitor$$$250$$$259$$$O	selected$$$260$$$268$$$O	from$$$269$$$273$$$O	aminoquinoline$$$274$$$288$$$I	and$$$289$$$292$$$O	aminoquinazoline$$$293$$$309$$$I	compounds$$$310$$$319$$$O	of$$$320$$$322$$$O	Formula$$$323$$$330$$$O	(Iâ)$$$331$$$337$$$O	:$$$338$$$339$$$O	where$$$340$$$345$$$O	R1,$$$346$$$349$$$O	R2,$$$350$$$353$$$O	R3,$$$354$$$357$$$O	B,$$$358$$$360$$$O	Z,$$$361$$$363$$$O	Q,$$$364$$$366$$$O	p,$$$367$$$369$$$O	q$$$370$$$371$$$O	and$$$372$$$375$$$O	X$$$376$$$377$$$O	are$$$378$$$381$$$O	as$$$382$$$384$$$O	defined$$$385$$$392$$$O	herein.$$$393$$$400$$$O	Included$$$401$$$409$$$O	within$$$410$$$416$$$O	the$$$417$$$420$$$O	present$$$421$$$428$$$O	invention$$$429$$$438$$$O	is$$$439$$$441$$$O	both$$$442$$$446$$$O	prophylactic$$$447$$$459$$$O	and$$$460$$$463$$$O	therapeutic$$$464$$$475$$$O	methods$$$476$$$483$$$O	for$$$484$$$487$$$O	treating$$$488$$$496$$$O	a$$$497$$$498$$$O	subject$$$499$$$506$$$O	at$$$507$$$509$$$O	risk$$$510$$$514$$$O	of$$$515$$$517$$$O	(or$$$518$$$521$$$O	susceptible$$$522$$$533$$$O	to)$$$534$$$537$$$O	developing$$$538$$$548$$$O	a$$$549$$$550$$$O	cell$$$551$$$555$$$O	proliferative$$$556$$$569$$$O	disorder$$$570$$$578$$$O	or$$$579$$$581$$$O	a$$$582$$$583$$$O	disorder$$$584$$$592$$$O	related$$$593$$$600$$$O	to$$$601$$$603$$$O	FLT3.$$$604$$$609$$$O
US20120316177
Extended$$$0$$$8$$$O	release$$$9$$$16$$$O	preparation$$$17$$$28$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	sustained$$$15$$$24$$$O	release$$$25$$$32$$$O	preparation$$$33$$$44$$$O	which$$$45$$$50$$$O	releases$$$51$$$59$$$O	a$$$60$$$61$$$O	poorly$$$62$$$68$$$O	soluble$$$69$$$76$$$O	medicinal$$$77$$$86$$$O	agent$$$87$$$92$$$O	in$$$93$$$95$$$O	a$$$96$$$97$$$O	pH-independent$$$98$$$112$$$O	manner.$$$113$$$120$$$O	Also$$$121$$$125$$$O	disclosed$$$126$$$135$$$O	is$$$136$$$138$$$O	a$$$139$$$140$$$O	sustained$$$141$$$150$$$O	release$$$151$$$158$$$O	preparation$$$159$$$170$$$O	which$$$171$$$176$$$O	is$$$177$$$179$$$O	capable$$$180$$$187$$$O	of$$$188$$$190$$$O	controlling$$$191$$$202$$$O	the$$$203$$$206$$$O	Cmax$$$207$$$211$$$O	of$$$212$$$214$$$O	a$$$215$$$216$$$O	medicinal$$$217$$$226$$$O	agent$$$227$$$232$$$O	to$$$233$$$235$$$O	an$$$236$$$238$$$O	adequate$$$239$$$247$$$O	amount$$$248$$$254$$$O	and$$$255$$$258$$$O	is$$$259$$$261$$$O	thus$$$262$$$266$$$O	capable$$$267$$$274$$$O	of$$$275$$$277$$$O	maintaining$$$278$$$289$$$O	the$$$290$$$293$$$O	level$$$294$$$299$$$O	of$$$300$$$302$$$O	the$$$303$$$306$$$O	medicinal$$$307$$$316$$$O	agent$$$317$$$322$$$O	in$$$323$$$325$$$O	the$$$326$$$329$$$O	blood$$$330$$$335$$$O	to$$$336$$$338$$$O	a$$$339$$$340$$$O	level$$$341$$$346$$$O	at$$$347$$$349$$$O	which$$$350$$$355$$$O	medicinal$$$356$$$365$$$O	effects$$$366$$$373$$$O	can$$$374$$$377$$$O	be$$$378$$$380$$$O	expected$$$381$$$389$$$O	for$$$390$$$393$$$O	a$$$394$$$395$$$O	long$$$396$$$400$$$O	period$$$401$$$407$$$O	of$$$408$$$410$$$O	time.$$$411$$$416$$$O	Specifically$$$417$$$429$$$O	disclosed$$$430$$$439$$$O	is$$$440$$$442$$$O	a$$$443$$$444$$$O	sustained$$$445$$$454$$$O	release$$$455$$$462$$$O	preparation$$$463$$$474$$$O	which$$$475$$$480$$$O	is$$$481$$$483$$$O	characterized$$$484$$$497$$$O	by$$$498$$$500$$$O	containing$$$501$$$511$$$O	a$$$512$$$513$$$O	pharmaceutically$$$514$$$530$$$O	acceptable$$$531$$$541$$$O	salt$$$542$$$546$$$O	of$$$547$$$549$$$O	4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone,$$$550$$$632$$$I	and$$$633$$$636$$$O	hypromellose.$$$637$$$650$$$O	An$$$651$$$653$$$O	organic$$$654$$$661$$$O	acid$$$662$$$666$$$O	is$$$667$$$669$$$O	blended$$$670$$$677$$$O	in$$$678$$$680$$$O	the$$$681$$$684$$$O	sustained$$$685$$$694$$$O	release$$$695$$$702$$$O	preparation$$$703$$$714$$$O	in$$$715$$$717$$$O	an$$$718$$$720$$$O	amount$$$721$$$727$$$O	of$$$728$$$730$$$O	less$$$731$$$735$$$O	than$$$736$$$740$$$O	1%$$$741$$$743$$$O	by$$$744$$$746$$$O	mass.$$$747$$$752$$$O
CN103202804A
Vidarabine$$$0$$$10$$$I	monophosphate$$$11$$$24$$$I	injection$$$25$$$34$$$O	and$$$35$$$38$$$O	preparation$$$39$$$50$$$O	method$$$51$$$57$$$O	thereof$$$58$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	vidarabine$$$25$$$35$$$I	monophosphate$$$36$$$49$$$I	injection$$$50$$$59$$$O	and$$$60$$$63$$$O	a$$$64$$$65$$$O	preparation$$$66$$$77$$$O	method$$$78$$$84$$$O	thereof.$$$85$$$93$$$O	The$$$94$$$97$$$O	injection$$$98$$$107$$$O	is$$$108$$$110$$$O	prepared$$$111$$$119$$$O	from$$$120$$$124$$$O	the$$$125$$$128$$$O	following$$$129$$$138$$$O	raw$$$139$$$142$$$O	materials$$$143$$$152$$$O	by$$$153$$$155$$$O	weight:$$$156$$$163$$$O	50-200$$$164$$$170$$$O	parts$$$171$$$176$$$O	of$$$177$$$179$$$O	vidarabine$$$180$$$190$$$I	monophosphate,$$$191$$$205$$$I	0.015-0.05$$$206$$$216$$$O	part$$$217$$$221$$$O	of$$$222$$$224$$$O	a$$$225$$$226$$$O	pH$$$227$$$229$$$O	regulator$$$230$$$239$$$O	and$$$240$$$243$$$O	2000$$$244$$$248$$$O	parts$$$249$$$254$$$O	of$$$255$$$257$$$O	water$$$258$$$263$$$O	for$$$264$$$267$$$O	injection.$$$268$$$278$$$O	A$$$279$$$280$$$O	finished$$$281$$$289$$$O	product$$$290$$$297$$$O	prepared$$$298$$$306$$$O	by$$$307$$$309$$$O	the$$$310$$$313$$$O	method$$$314$$$320$$$O	provided$$$321$$$329$$$O	by$$$330$$$332$$$O	the$$$333$$$336$$$O	invention$$$337$$$346$$$O	has$$$347$$$350$$$O	low$$$351$$$354$$$O	impurity$$$355$$$363$$$O	content,$$$364$$$372$$$O	good$$$373$$$377$$$O	homogeneity$$$378$$$389$$$O	and$$$390$$$393$$$O	good$$$394$$$398$$$O	stability.$$$399$$$409$$$O	A$$$410$$$411$$$O	water$$$412$$$417$$$O	injection$$$418$$$427$$$O	is$$$428$$$430$$$O	subjected$$$431$$$440$$$O	to$$$441$$$443$$$O	terminal$$$444$$$452$$$O	sterilization$$$453$$$466$$$O	to$$$467$$$469$$$O	ensure$$$470$$$476$$$O	the$$$477$$$480$$$O	safety$$$481$$$487$$$O	of$$$488$$$490$$$O	the$$$491$$$494$$$O	product.$$$495$$$503$$$O	The$$$504$$$507$$$O	water$$$508$$$513$$$O	injection$$$514$$$523$$$O	is$$$524$$$526$$$O	convenient$$$527$$$537$$$O	to$$$538$$$540$$$O	use,$$$541$$$545$$$O	and$$$546$$$549$$$O	does$$$550$$$554$$$O	not$$$555$$$558$$$O	need$$$559$$$563$$$O	to$$$564$$$566$$$O	be$$$567$$$569$$$O	prepared$$$570$$$578$$$O	before$$$579$$$585$$$O	clinical$$$586$$$594$$$O	application,$$$595$$$607$$$O	so$$$608$$$610$$$O	as$$$611$$$613$$$O	to$$$614$$$616$$$O	reduce$$$617$$$623$$$O	the$$$624$$$627$$$O	potential$$$628$$$637$$$O	safety$$$638$$$644$$$O	hazard$$$645$$$651$$$O	caused$$$652$$$658$$$O	by$$$659$$$661$$$O	operation$$$662$$$671$$$O	and$$$672$$$675$$$O	provide$$$676$$$683$$$O	a$$$684$$$685$$$O	new$$$686$$$689$$$O	choice$$$690$$$696$$$O	of$$$697$$$699$$$O	medication$$$700$$$710$$$O	for$$$711$$$714$$$O	clinical$$$715$$$723$$$O	use.$$$724$$$728$$$O
US20120135094
Oregano$$$0$$$7$$$O	and$$$8$$$11$$$O	mint$$$12$$$16$$$O	anti-inflammatory$$$17$$$34$$$O	compositions$$$35$$$47$$$O	and$$$48$$$51$$$O	methods$$$52$$$59$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	bioactivity-guided$$$33$$$51$$$O	isolation$$$52$$$61$$$O	and$$$62$$$65$$$O	identification$$$66$$$80$$$O	of$$$81$$$83$$$O	bioactive$$$84$$$93$$$O	compounds$$$94$$$103$$$O	from$$$104$$$108$$$O	oregano$$$109$$$116$$$O	and$$$117$$$120$$$O	mint$$$121$$$125$$$O	plants,$$$126$$$133$$$O	in$$$134$$$136$$$O	particular,$$$137$$$148$$$O	rosmarinic$$$149$$$159$$$I	acid,$$$160$$$165$$$I	oleanolic$$$166$$$175$$$I	acid$$$176$$$180$$$I	and$$$181$$$184$$$O	ursolic$$$185$$$192$$$I	acid,$$$193$$$198$$$I	and$$$199$$$202$$$O	use$$$203$$$206$$$O	of$$$207$$$209$$$O	these$$$210$$$215$$$O	compounds$$$216$$$225$$$O	or$$$226$$$228$$$O	combinations$$$229$$$241$$$O	thereof$$$242$$$249$$$O	as$$$250$$$252$$$O	anti-inflammatory$$$253$$$270$$$O	agents$$$271$$$277$$$O	for$$$278$$$281$$$O	the$$$282$$$285$$$O	treatment$$$286$$$295$$$O	of$$$296$$$298$$$O	conditions$$$299$$$309$$$O	related$$$310$$$317$$$O	to$$$318$$$320$$$O	pain$$$321$$$325$$$O	and$$$326$$$329$$$O	inflammation$$$330$$$342$$$O	and/or$$$343$$$349$$$O	as$$$350$$$352$$$O	ingredients$$$353$$$364$$$O	of$$$365$$$367$$$O	dietary$$$368$$$375$$$O	supplements.$$$376$$$388$$$O	The$$$389$$$392$$$O	invention$$$393$$$402$$$O	also$$$403$$$407$$$O	relates$$$408$$$415$$$O	to$$$416$$$418$$$O	optimization$$$419$$$431$$$O	of$$$432$$$434$$$O	the$$$435$$$438$$$O	methods$$$439$$$446$$$O	for$$$447$$$450$$$O	qualitative$$$451$$$462$$$O	and$$$463$$$466$$$O	quantitative$$$467$$$479$$$O	analysis$$$480$$$488$$$O	of$$$489$$$491$$$O	the$$$492$$$495$$$O	bioactive$$$496$$$505$$$O	compounds$$$506$$$515$$$O	in$$$516$$$518$$$O	oregano$$$519$$$526$$$O	and$$$527$$$530$$$O	mint$$$531$$$535$$$O	plants.$$$536$$$543$$$O	In$$$544$$$546$$$O	particular,$$$547$$$558$$$O	this$$$559$$$563$$$O	invention$$$564$$$573$$$O	introduces$$$574$$$584$$$O	an$$$585$$$587$$$O	LC/MS$$$588$$$593$$$O	(SIM$$$594$$$598$$$O	mode)$$$599$$$604$$$O	method$$$605$$$611$$$O	to$$$612$$$614$$$O	achieve$$$615$$$622$$$O	co-quantitation$$$623$$$638$$$O	of$$$639$$$641$$$O	the$$$642$$$645$$$O	three$$$646$$$651$$$O	organic$$$652$$$659$$$O	acids$$$660$$$665$$$O	using$$$666$$$671$$$O	a$$$672$$$673$$$O	unique$$$674$$$680$$$O	tandem$$$681$$$687$$$O	column$$$688$$$694$$$O	system.$$$695$$$702$$$O	In$$$703$$$705$$$O	addition,$$$706$$$715$$$O	the$$$716$$$719$$$O	invention$$$720$$$729$$$O	also$$$730$$$734$$$O	relates$$$735$$$742$$$O	to$$$743$$$745$$$O	the$$$746$$$749$$$O	methods$$$750$$$757$$$O	for$$$758$$$761$$$O	recovering$$$762$$$772$$$O	various$$$773$$$780$$$O	water-soluble$$$781$$$794$$$O	polyphenols$$$795$$$806$$$I	and$$$807$$$810$$$O	triterpenes$$$811$$$822$$$I	from$$$823$$$827$$$O	aromatic$$$828$$$836$$$O	plants.$$$837$$$844$$$O
US20110144040
Acteoside$$$0$$$9$$$I	and$$$10$$$13$$$O	acteoside-rich$$$14$$$28$$$I	plant$$$29$$$34$$$O	extracts$$$35$$$43$$$O	for$$$44$$$47$$$O	increasing$$$48$$$58$$$O	athletic$$$59$$$67$$$O	performance$$$68$$$79$$$O	in$$$80$$$82$$$O	humans$$$83$$$89$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	increasing$$$33$$$43$$$O	the$$$44$$$47$$$O	athletic$$$48$$$56$$$O	performance$$$57$$$68$$$O	of$$$69$$$71$$$O	humans$$$72$$$78$$$O	using$$$79$$$84$$$O	acteoside.$$$85$$$95$$$I	This$$$96$$$100$$$O	may$$$101$$$104$$$O	be$$$105$$$107$$$O	in$$$108$$$110$$$O	the$$$111$$$114$$$O	form$$$115$$$119$$$O	of$$$120$$$122$$$O	a$$$123$$$124$$$O	pure$$$125$$$129$$$O	compound,$$$130$$$139$$$O	or$$$140$$$142$$$O	plant$$$143$$$148$$$O	extracts$$$149$$$157$$$O	containing$$$158$$$168$$$O	at$$$169$$$171$$$O	least$$$172$$$177$$$O	10%$$$178$$$181$$$O	acteoside$$$182$$$191$$$I	by$$$192$$$194$$$O	weight.$$$195$$$202$$$O	Application$$$203$$$214$$$O	of$$$215$$$217$$$O	this$$$218$$$222$$$O	invention$$$223$$$232$$$O	provides$$$233$$$241$$$O	increased$$$242$$$251$$$O	strength,$$$252$$$261$$$O	muscle$$$262$$$268$$$O	power,$$$269$$$275$$$O	endurance,$$$276$$$286$$$O	muscle$$$287$$$293$$$O	protein$$$294$$$301$$$O	content,$$$302$$$310$$$O	and$$$311$$$314$$$O	reduced$$$315$$$322$$$O	fatigue.$$$323$$$331$$$O
WO2009134637A1
Piperazine-based$$$0$$$16$$$I	ccr5$$$17$$$21$$$O	antagonist$$$22$$$32$$$O	tablet$$$33$$$39$$$O	dosage$$$40$$$46$$$O	form$$$47$$$51$$$O
Tablets$$$0$$$7$$$O	containing$$$8$$$18$$$O	1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-[4-(trifluoromethyl)phenyl]ethyl]-3-(S)-methyl-1-piperazinyl]-4-methyl-piperi$$$19$$$158$$$I	dine$$$159$$$163$$$I	or$$$164$$$166$$$O	a$$$167$$$168$$$O	pharmaceutically$$$169$$$185$$$O	acceptable$$$186$$$196$$$O	salt$$$197$$$201$$$O	thereof$$$202$$$209$$$O	are$$$210$$$213$$$O	disclosed.$$$214$$$224$$$O	Methods$$$225$$$232$$$O	of$$$233$$$235$$$O	making$$$236$$$242$$$O	such$$$243$$$247$$$O	tablets$$$248$$$255$$$O	with$$$256$$$260$$$O	satisfactory$$$261$$$273$$$O	processability$$$274$$$288$$$O	are$$$289$$$292$$$O	also$$$293$$$297$$$O	disclosed.$$$298$$$308$$$O	In$$$309$$$311$$$O	addition,$$$312$$$321$$$O	methods$$$322$$$329$$$O	for$$$330$$$333$$$O	treating$$$334$$$342$$$O	HIV$$$343$$$346$$$O	as$$$347$$$349$$$O	well$$$350$$$354$$$O	as$$$355$$$357$$$O	inflammatory$$$358$$$370$$$O	diseases$$$371$$$379$$$O	with$$$380$$$384$$$O	an$$$385$$$387$$$O	antagonist$$$388$$$398$$$O	of$$$399$$$401$$$O	chemokine$$$402$$$411$$$O	(C-C$$$412$$$416$$$O	motif)$$$417$$$423$$$O	receptor$$$424$$$432$$$O	5$$$433$$$434$$$O	(CCR5)$$$435$$$441$$$O	are$$$442$$$445$$$O	disclosed.$$$446$$$456$$$O
US20120065147
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	the$$$7$$$10$$$O	gtpase$$$11$$$17$$$O	rab27b$$$18$$$24$$$O	to$$$25$$$27$$$O	diagnose$$$28$$$36$$$O	and$$$37$$$40$$$O	treat$$$41$$$46$$$O	poor$$$47$$$51$$$O	prognosis$$$52$$$61$$$O	estrogen-receptor-positive$$$62$$$88$$$I	breast$$$89$$$95$$$O	cancer$$$96$$$102$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	evaluating$$$33$$$43$$$O	the$$$44$$$47$$$O	prognosis$$$48$$$57$$$O	of$$$58$$$60$$$O	patients$$$61$$$69$$$O	with$$$70$$$74$$$O	estrogen$$$75$$$83$$$I	receptor-positive$$$84$$$101$$$O	breast$$$102$$$108$$$O	cancer$$$109$$$115$$$O	on$$$116$$$118$$$O	the$$$119$$$122$$$O	basis$$$123$$$128$$$O	of$$$129$$$131$$$O	Rab27B$$$132$$$138$$$O	expression.$$$139$$$150$$$O	The$$$151$$$154$$$O	invention$$$155$$$164$$$O	further$$$165$$$172$$$O	relates$$$173$$$180$$$O	to$$$181$$$183$$$O	a$$$184$$$185$$$O	kit$$$186$$$189$$$O	comprising$$$190$$$200$$$O	an$$$201$$$203$$$O	assay$$$204$$$209$$$O	for$$$210$$$213$$$O	measuring$$$214$$$223$$$O	Rab27B$$$224$$$230$$$O	levels$$$231$$$237$$$O	in$$$238$$$240$$$O	said$$$241$$$245$$$O	patients$$$246$$$254$$$O	and$$$255$$$258$$$O	to$$$259$$$261$$$O	the$$$262$$$265$$$O	usage$$$266$$$271$$$O	of$$$272$$$274$$$O	Rab27B$$$275$$$281$$$O	as$$$282$$$284$$$O	a$$$285$$$286$$$O	target$$$287$$$293$$$O	to$$$294$$$296$$$O	screen$$$297$$$303$$$O	for$$$304$$$307$$$O	drugs$$$308$$$313$$$O	capable$$$314$$$321$$$O	of$$$322$$$324$$$O	inhibiting$$$325$$$335$$$O	or$$$336$$$338$$$O	diminishing$$$339$$$350$$$O	metastasis$$$351$$$361$$$O	of$$$362$$$364$$$O	said$$$365$$$369$$$O	cancer.$$$370$$$377$$$O	Furthermore,$$$378$$$390$$$O	the$$$391$$$394$$$O	invention$$$395$$$404$$$O	discloses$$$405$$$414$$$O	compounds$$$415$$$424$$$O	which$$$425$$$430$$$O	can$$$431$$$434$$$O	be$$$435$$$437$$$O	used$$$438$$$442$$$O	to$$$443$$$445$$$O	treat$$$446$$$451$$$O	estrogen$$$452$$$460$$$I	receptor-positive$$$461$$$478$$$O	breast$$$479$$$485$$$O	cancer.$$$486$$$493$$$O
WO2012175747A1
Production$$$0$$$10$$$O	method$$$11$$$17$$$O	and$$$18$$$21$$$O	dosage$$$22$$$28$$$O	form$$$29$$$33$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	production$$$27$$$37$$$O	method$$$38$$$44$$$O	for$$$45$$$48$$$O	dosage$$$49$$$55$$$O	forms.$$$56$$$62$$$O	The$$$63$$$66$$$O	production$$$67$$$77$$$O	method$$$78$$$84$$$O	makes$$$85$$$90$$$O	dosage$$$91$$$97$$$O	forms$$$98$$$103$$$O	accessible$$$104$$$114$$$O	that$$$115$$$119$$$O	help$$$120$$$124$$$O	even$$$125$$$129$$$O	active$$$130$$$136$$$O	ingredients$$$137$$$148$$$O	that$$$149$$$153$$$O	are$$$154$$$157$$$O	poorly$$$158$$$164$$$O	soluble$$$165$$$172$$$O	to$$$173$$$175$$$O	be$$$176$$$178$$$O	highly$$$179$$$185$$$O	bioavailable$$$186$$$198$$$O	when$$$199$$$203$$$O	taken$$$204$$$209$$$O	orally.$$$210$$$217$$$O	Another$$$218$$$225$$$O	important$$$226$$$235$$$O	advantage$$$236$$$245$$$O	of$$$246$$$248$$$O	the$$$249$$$252$$$O	method$$$253$$$259$$$O	is$$$260$$$262$$$O	that$$$263$$$267$$$O	the$$$268$$$271$$$O	dosage$$$272$$$278$$$O	forms$$$279$$$284$$$O	produced$$$285$$$293$$$O	in$$$294$$$296$$$O	such$$$297$$$301$$$O	a$$$302$$$303$$$O	manner$$$304$$$310$$$O	have$$$311$$$315$$$O	good$$$316$$$320$$$O	storage$$$321$$$328$$$O	stability.$$$329$$$339$$$O	The$$$340$$$343$$$O	dosage$$$344$$$350$$$O	forms$$$351$$$356$$$O	produced$$$357$$$365$$$O	in$$$366$$$368$$$O	such$$$369$$$373$$$O	a$$$374$$$375$$$O	manner$$$376$$$382$$$O	comprise$$$383$$$391$$$O	several$$$392$$$399$$$O	subunits.$$$400$$$409$$$O	The$$$410$$$413$$$O	invention$$$414$$$423$$$O	further$$$424$$$431$$$O	relates$$$432$$$439$$$O	to$$$440$$$442$$$O	the$$$443$$$446$$$O	dosage$$$447$$$453$$$O	forms$$$454$$$459$$$O	and$$$460$$$463$$$O	to$$$464$$$466$$$O	uses$$$467$$$471$$$O	of$$$472$$$474$$$O	the$$$475$$$478$$$O	dosage$$$479$$$485$$$O	forms.$$$486$$$492$$$O	In$$$493$$$495$$$O	particular,$$$496$$$507$$$O	the$$$508$$$511$$$O	invention$$$512$$$521$$$O	relates$$$522$$$529$$$O	to$$$530$$$532$$$O	layered$$$533$$$540$$$O	tablets$$$541$$$548$$$O	and$$$549$$$552$$$O	to$$$553$$$555$$$O	capsules$$$556$$$564$$$O	that$$$565$$$569$$$O	contain$$$570$$$577$$$O	powder$$$578$$$584$$$O	and$$$585$$$588$$$O	coated$$$589$$$595$$$O	microtablets.$$$596$$$609$$$O	Examples$$$610$$$618$$$O	of$$$619$$$621$$$O	active$$$622$$$628$$$O	ingredients$$$629$$$640$$$O	are$$$641$$$644$$$O	cinnarizine$$$645$$$656$$$I	and$$$657$$$660$$$O	dimenhydrinate.$$$661$$$676$$$I
US20090137575
Fused$$$0$$$5$$$I	Tetracyclic$$$6$$$17$$$I	mGluR1$$$18$$$24$$$O	Antagonists$$$25$$$36$$$O	as$$$37$$$39$$$O	Therapeutic$$$40$$$51$$$O	Agents$$$52$$$58$$$O
In$$$0$$$2$$$O	its$$$3$$$6$$$O	many$$$7$$$11$$$O	embodiments,$$$12$$$24$$$O	the$$$25$$$28$$$O	present$$$29$$$36$$$O	invention$$$37$$$46$$$O	provides$$$47$$$55$$$O	tetracyclic$$$56$$$67$$$I	compounds$$$68$$$77$$$O	of$$$78$$$80$$$O	formula$$$81$$$88$$$O	I$$$89$$$90$$$O	or$$$91$$$93$$$O	formula$$$94$$$101$$$O	II$$$102$$$104$$$O	(wherein$$$105$$$113$$$O	the$$$114$$$117$$$O	various$$$118$$$125$$$O	moieties$$$126$$$134$$$O	are$$$135$$$138$$$O	as$$$139$$$141$$$O	defined$$$142$$$149$$$O	herein)$$$150$$$157$$$O	useful$$$158$$$164$$$O	as$$$165$$$167$$$O	metabotropic$$$168$$$180$$$O	glutamate$$$181$$$190$$$I	receptor$$$191$$$199$$$O	(mGluR)$$$200$$$207$$$O	antagonists,$$$208$$$220$$$O	particularly$$$221$$$233$$$O	as$$$234$$$236$$$O	selective$$$237$$$246$$$O	metabotropic$$$247$$$259$$$O	glutamate$$$260$$$269$$$I	receptor$$$270$$$278$$$O	1$$$279$$$280$$$O	antagonists,$$$281$$$293$$$O	pharmaceutical$$$294$$$308$$$O	compositions$$$309$$$321$$$O	containing$$$322$$$332$$$O	the$$$333$$$336$$$O	compounds,$$$337$$$347$$$O	and$$$348$$$351$$$O	methods$$$352$$$359$$$O	of$$$360$$$362$$$O	treatment$$$363$$$372$$$O	using$$$373$$$378$$$O	the$$$379$$$382$$$O	compounds$$$383$$$392$$$O	and$$$393$$$396$$$O	compositions$$$397$$$409$$$O	to$$$410$$$412$$$O	treat$$$413$$$418$$$O	diseases$$$419$$$427$$$O	associated$$$428$$$438$$$O	with$$$439$$$443$$$O	metabotropic$$$444$$$456$$$O	glutamate$$$457$$$466$$$I	receptor$$$467$$$475$$$O	(e.g.,$$$476$$$482$$$O	mGluR1)$$$483$$$490$$$O	such$$$491$$$495$$$O	as,$$$496$$$499$$$O	for$$$500$$$503$$$O	example,$$$504$$$512$$$O	pain,$$$513$$$518$$$O	migraine,$$$519$$$528$$$O	anxiety,$$$529$$$537$$$O	urinary$$$538$$$545$$$O	incontinence$$$546$$$558$$$O	and$$$559$$$562$$$O	neurodegenerative$$$563$$$580$$$O	diseases$$$581$$$589$$$O	such$$$590$$$594$$$O	Alzheimer's$$$595$$$606$$$O	disease.$$$607$$$615$$$O
WO2009117540A1
Bridged$$$0$$$7$$$O	heterocycles$$$8$$$20$$$O	as$$$21$$$23$$$O	hiv$$$24$$$27$$$O	integrase$$$28$$$37$$$O	inhibitors$$$38$$$48$$$O
The$$$0$$$3$$$O	disclosure$$$4$$$14$$$O	generally$$$15$$$24$$$O	relates$$$25$$$32$$$O	to$$$33$$$35$$$O	the$$$36$$$39$$$O	novel$$$40$$$45$$$O	compounds$$$46$$$55$$$O	of$$$56$$$58$$$O	formula$$$59$$$66$$$O	I,$$$67$$$69$$$O	including$$$70$$$79$$$O	their$$$80$$$85$$$O	salts,$$$86$$$92$$$O	which$$$93$$$98$$$O	inhibit$$$99$$$106$$$O	HIV$$$107$$$110$$$O	integrase$$$111$$$120$$$O	and$$$121$$$124$$$O	prevent$$$125$$$132$$$O	viral$$$133$$$138$$$O	integration$$$139$$$150$$$O	into$$$151$$$155$$$O	human$$$156$$$161$$$O	DNA.$$$162$$$166$$$O	This$$$167$$$171$$$O	action$$$172$$$178$$$O	makes$$$179$$$184$$$O	the$$$185$$$188$$$O	compounds$$$189$$$198$$$O	useful$$$199$$$205$$$O	for$$$206$$$209$$$O	treating$$$210$$$218$$$O	HIV$$$219$$$222$$$O	infection$$$223$$$232$$$O	and$$$233$$$236$$$O	AIDS.$$$237$$$242$$$O	The$$$243$$$246$$$O	invention$$$247$$$256$$$O	also$$$257$$$261$$$O	encompasses$$$262$$$273$$$O	pharmaceutical$$$274$$$288$$$O	compositions$$$289$$$301$$$O	and$$$302$$$305$$$O	methods$$$306$$$313$$$O	for$$$314$$$317$$$O	treating$$$318$$$326$$$O	those$$$327$$$332$$$O	infected$$$333$$$341$$$O	with$$$342$$$346$$$O	HIV.$$$347$$$351$$$O	Formule$$$352$$$359$$$O	(I).$$$360$$$364$$$O
CA2106819C
Oligoribonucleotide$$$0$$$19$$$I	and$$$20$$$23$$$O	ribozyme$$$24$$$32$$$O	analogs$$$33$$$40$$$O	with$$$41$$$45$$$O	terminal$$$46$$$54$$$O	3'-3'$$$55$$$60$$$O	and/or$$$61$$$67$$$O	5'-5'$$$68$$$73$$$O	linkages$$$74$$$82$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	oligoribonucleotide$$$25$$$44$$$I	analogs$$$45$$$52$$$O	with$$$53$$$57$$$O	terminal$$$58$$$66$$$O	3'-3'$$$67$$$72$$$O	and/or$$$73$$$79$$$O	5'-5'$$$80$$$85$$$O	internucleotide$$$86$$$101$$$O	linkages.$$$102$$$111$$$O	This$$$116$$$120$$$O	modification$$$121$$$133$$$O	stabilizes$$$134$$$144$$$O	the$$$145$$$148$$$O	molecules$$$149$$$158$$$O	altered$$$159$$$166$$$O	in$$$167$$$169$$$O	this$$$170$$$174$$$O	way,$$$175$$$179$$$O	including$$$180$$$189$$$O	ribozymes,$$$190$$$200$$$O	without$$$201$$$208$$$O	adversely$$$209$$$218$$$O	altering$$$219$$$227$$$O	their$$$228$$$233$$$O	properties,$$$234$$$245$$$O	including,$$$246$$$256$$$O	where$$$257$$$262$$$O	appropriate,$$$263$$$275$$$O	catalytic$$$276$$$285$$$O	activities.$$$286$$$297$$$O
US6994842
Aerogel$$$0$$$7$$$O	powder$$$8$$$14$$$O	therapeutic$$$15$$$26$$$O	agents$$$27$$$33$$$O
Drugs$$$0$$$5$$$O	in$$$6$$$8$$$O	the$$$9$$$12$$$O	form$$$13$$$17$$$O	of$$$18$$$20$$$O	very$$$21$$$25$$$O	fine$$$26$$$30$$$O	highly$$$31$$$37$$$O	porous$$$38$$$44$$$O	aerogel$$$45$$$52$$$O	particles$$$53$$$62$$$O	are$$$63$$$66$$$O	delivered$$$67$$$76$$$O	to$$$77$$$79$$$O	a$$$80$$$81$$$O	patient$$$82$$$89$$$O	via$$$90$$$93$$$O	inhalation.$$$94$$$105$$$O	The$$$106$$$109$$$O	aerogel$$$110$$$117$$$O	particles$$$118$$$127$$$O	are$$$128$$$131$$$O	either$$$132$$$138$$$O	an$$$139$$$141$$$O	aerogelized$$$142$$$153$$$O	form$$$154$$$158$$$O	of$$$159$$$161$$$O	a$$$162$$$163$$$O	pharmaceutical$$$164$$$178$$$O	or$$$179$$$181$$$O	deposited$$$182$$$191$$$O	upon$$$192$$$196$$$O	aerogel$$$197$$$204$$$O	particles$$$205$$$214$$$O	produced$$$215$$$223$$$O	from$$$224$$$228$$$O	a$$$229$$$230$$$O	non-inorganic$$$231$$$244$$$O	oxide$$$245$$$250$$$O	carrier$$$251$$$258$$$O	matrix$$$259$$$265$$$O	material,$$$266$$$275$$$O	e.g.$$$276$$$280$$$O	a$$$281$$$282$$$O	sugar$$$283$$$288$$$O	or$$$289$$$291$$$O	carbohydrate.$$$292$$$305$$$I	The$$$306$$$309$$$O	aerogel$$$310$$$317$$$O	particles$$$318$$$327$$$O	are$$$328$$$331$$$O	readily$$$332$$$339$$$O	dissolvable$$$340$$$351$$$O	by$$$352$$$354$$$O	the$$$355$$$358$$$O	pulmonary$$$359$$$368$$$O	surfactant$$$369$$$379$$$O	present$$$380$$$387$$$O	in$$$388$$$390$$$O	the$$$391$$$394$$$O	lungs$$$395$$$400$$$O	of$$$401$$$403$$$O	a$$$404$$$405$$$O	mammal.$$$406$$$413$$$O
US20130034503
Preventing$$$0$$$10$$$O	or$$$11$$$13$$$O	reducing$$$14$$$22$$$O	drug$$$23$$$27$$$O	abuse$$$28$$$33$$$O	and$$$34$$$37$$$O	overdose$$$38$$$46$$$O	events$$$47$$$53$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	and$$$9$$$12$$$O	compositions$$$13$$$25$$$O	for$$$26$$$29$$$O	treating$$$30$$$38$$$O	a$$$39$$$40$$$O	patient$$$41$$$48$$$O	that$$$49$$$53$$$O	prevent$$$54$$$61$$$O	or$$$62$$$64$$$O	reduce$$$65$$$71$$$O	drug$$$72$$$76$$$O	abuse$$$77$$$82$$$O	and$$$83$$$86$$$O	overdose$$$87$$$95$$$O	events.$$$96$$$103$$$O
US6906091
Inhibiting$$$0$$$10$$$O	metastasis$$$11$$$21$$$O	with$$$22$$$26$$$O	a$$$27$$$28$$$O	2-(alkoxycarbonylamino)benzimidazole$$$29$$$65$$$I	prodrug$$$66$$$73$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	treating$$$11$$$19$$$O	and$$$20$$$23$$$O	inhibiting$$$24$$$34$$$O	cancer$$$35$$$41$$$O	in$$$42$$$44$$$O	animals$$$45$$$52$$$O	by$$$53$$$55$$$O	administering$$$56$$$69$$$O	a$$$70$$$71$$$O	therapeutically$$$72$$$87$$$O	effective$$$88$$$97$$$O	amount$$$98$$$104$$$O	of$$$105$$$107$$$O	a$$$108$$$109$$$O	pharmaceutical$$$110$$$124$$$O	composition$$$125$$$136$$$O	having$$$137$$$143$$$O	benzimidazole$$$144$$$157$$$I	of$$$158$$$160$$$O	the$$$161$$$164$$$O	general$$$165$$$172$$$O	formula:$$$173$$$181$$$O	wherein$$$197$$$204$$$O	X$$$205$$$206$$$O	is$$$207$$$209$$$O	hydrogen,$$$210$$$219$$$I	halogen,$$$220$$$228$$$I	alkyl$$$229$$$234$$$I	of$$$235$$$237$$$O	less$$$238$$$242$$$O	than$$$243$$$247$$$O	7$$$248$$$249$$$O	carbon$$$250$$$256$$$I	atoms$$$257$$$262$$$O	or$$$263$$$265$$$O	alkoxy$$$266$$$272$$$I	of$$$273$$$275$$$O	less$$$276$$$280$$$O	than$$$281$$$285$$$O	7$$$286$$$287$$$O	carbon$$$288$$$294$$$I	atoms;$$$295$$$301$$$O	n$$$302$$$303$$$O	is$$$304$$$306$$$O	a$$$307$$$308$$$O	positive$$$309$$$317$$$O	integer$$$318$$$325$$$O	of$$$326$$$328$$$O	less$$$329$$$333$$$O	than$$$334$$$338$$$O	4;$$$339$$$341$$$O	Y$$$342$$$343$$$O	is$$$344$$$346$$$O	hydrogen,$$$347$$$356$$$I	chlorine,$$$357$$$366$$$I	oxychloro,$$$367$$$377$$$I	nitro,$$$378$$$384$$$I	methyl$$$385$$$391$$$I	or$$$392$$$394$$$O	ethyl;$$$395$$$401$$$I	and$$$402$$$405$$$O	R$$$406$$$407$$$O	is$$$408$$$410$$$O	hydrogen,$$$411$$$420$$$I	or$$$421$$$423$$$O	an$$$424$$$426$$$O	alkyl$$$427$$$432$$$I	group$$$433$$$438$$$O	of$$$439$$$441$$$O	from$$$442$$$446$$$O	1$$$447$$$448$$$O	to$$$449$$$451$$$O	8$$$452$$$453$$$O	carbon$$$454$$$460$$$I	atoms$$$461$$$466$$$O	and$$$467$$$470$$$O	R2$$$471$$$473$$$O	is$$$474$$$476$$$O	NHCOOR1$$$477$$$484$$$I	wherein$$$485$$$492$$$O	R1$$$493$$$495$$$O	is$$$496$$$498$$$O	aliphatic$$$499$$$508$$$I	hydrocarbon$$$509$$$520$$$I	of$$$521$$$523$$$O	less$$$524$$$528$$$O	than$$$529$$$533$$$O	7$$$534$$$535$$$O	carbon$$$536$$$542$$$I	atoms,$$$543$$$549$$$O	and$$$550$$$553$$$O	preferably$$$554$$$564$$$O	an$$$565$$$567$$$O	alkyl$$$568$$$573$$$I	group$$$574$$$579$$$O	of$$$580$$$582$$$O	less$$$583$$$587$$$O	than$$$588$$$592$$$O	7$$$593$$$594$$$O	carbon$$$595$$$601$$$I	atoms$$$602$$$607$$$O	and$$$608$$$611$$$O	pharmaceutically$$$612$$$628$$$O	acceptable$$$629$$$639$$$O	derivatives$$$640$$$651$$$O	alone,$$$652$$$658$$$O	or$$$659$$$661$$$O	in$$$662$$$664$$$O	combination,$$$665$$$677$$$O	or$$$678$$$680$$$O	in$$$681$$$683$$$O	conduction$$$684$$$694$$$O	with$$$695$$$699$$$O	other$$$700$$$705$$$O	therapeutic$$$706$$$717$$$O	agents$$$718$$$724$$$O	such$$$725$$$729$$$O	as$$$730$$$732$$$O	other$$$733$$$738$$$O	cancer$$$739$$$745$$$O	inhibiting$$$746$$$756$$$O	compounds,$$$757$$$767$$$O	and$$$768$$$771$$$O	operative$$$772$$$781$$$O	combinations$$$782$$$794$$$O	thereof.$$$795$$$803$$$O
CN101822651A
Chewable$$$0$$$8$$$O	capsule$$$9$$$16$$$O	and$$$17$$$20$$$O	preparation$$$21$$$32$$$O	method$$$33$$$39$$$O	thereof$$$40$$$47$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	chewable$$$25$$$33$$$O	capsule$$$34$$$41$$$O	and$$$42$$$45$$$O	a$$$46$$$47$$$O	preparation$$$48$$$59$$$O	method$$$60$$$66$$$O	thereof.$$$67$$$75$$$O	The$$$76$$$79$$$O	chewable$$$80$$$88$$$O	capsule$$$89$$$96$$$O	comprises$$$97$$$106$$$O	a$$$107$$$108$$$O	capsule$$$109$$$116$$$O	skin$$$117$$$121$$$O	and$$$122$$$125$$$O	content,$$$126$$$134$$$O	wherein$$$135$$$142$$$O	the$$$143$$$146$$$O	content$$$147$$$154$$$O	contains$$$155$$$163$$$O	omega-3$$$164$$$171$$$I	polyunsaturated$$$172$$$187$$$I	fatty$$$188$$$193$$$I	acid$$$194$$$198$$$I	or$$$199$$$201$$$O	derivative$$$202$$$212$$$O	thereof,$$$213$$$221$$$O	and$$$222$$$225$$$O	is$$$226$$$228$$$O	taken$$$229$$$234$$$O	as$$$235$$$237$$$O	active$$$238$$$244$$$O	ingredient$$$245$$$255$$$O	with$$$256$$$260$$$O	medical$$$261$$$268$$$O	health$$$269$$$275$$$O	protection$$$276$$$286$$$O	function.$$$287$$$296$$$O	The$$$297$$$300$$$O	chewable$$$301$$$309$$$O	capsule$$$310$$$317$$$O	also$$$318$$$322$$$O	can$$$323$$$326$$$O	contain$$$327$$$334$$$O	peppermint$$$335$$$345$$$O	oil$$$346$$$349$$$O	and/or$$$350$$$356$$$O	xylitol.$$$357$$$365$$$O
WO2008112241A1
Methods$$$0$$$7$$$O	an$$$8$$$10$$$O	compositions$$$11$$$23$$$O	for$$$24$$$27$$$O	treatment$$$28$$$37$$$O	of$$$38$$$40$$$O	an$$$41$$$43$$$O	interstitial$$$44$$$56$$$O	lung$$$57$$$61$$$O	disease$$$62$$$69$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	methods$$$20$$$27$$$O	of$$$28$$$30$$$O	treatment$$$31$$$40$$$O	of$$$41$$$43$$$O	an$$$44$$$46$$$O	interstitial$$$47$$$59$$$O	lung$$$60$$$64$$$O	disease$$$65$$$72$$$O	(ILD)$$$73$$$78$$$O	by$$$79$$$81$$$O	administering$$$82$$$95$$$O	an$$$96$$$98$$$O	endothelin$$$99$$$109$$$O	antagonist,$$$110$$$121$$$O	such$$$122$$$126$$$O	as$$$127$$$129$$$O	sitaxsentan$$$130$$$141$$$I	or$$$142$$$144$$$O	a$$$145$$$146$$$O	pharmaceutically$$$147$$$163$$$O	acceptable$$$164$$$174$$$O	salt$$$175$$$179$$$O	thereof.$$$180$$$188$$$O
US7026359
e.g.,$$$0$$$5$$$O	tridecafluoro-4,4-dimethyl-1-heptene$$$6$$$42$$$I	trimer$$$43$$$49$$$O	or$$$50$$$52$$$O	1H,$$$53$$$56$$$I	1H,$$$57$$$60$$$I	2H-perfluoro-1-octane$$$61$$$82$$$I	trimer;$$$83$$$90$$$O	causes$$$91$$$97$$$O	little$$$98$$$104$$$O	or$$$105$$$107$$$O	no$$$108$$$110$$$O	damage$$$111$$$117$$$O	to$$$118$$$120$$$O	the$$$121$$$124$$$O	retina$$$125$$$131$$$O	even$$$132$$$136$$$O	when$$$137$$$141$$$O	used$$$142$$$146$$$O	over$$$147$$$151$$$O	a$$$152$$$153$$$O	long$$$154$$$158$$$O	period.$$$159$$$166$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	utilization$$$29$$$40$$$O	of$$$41$$$43$$$O	a$$$44$$$45$$$O	highly$$$46$$$52$$$O	fluorinated$$$53$$$64$$$O	oligomeric$$$65$$$75$$$O	alkane$$$76$$$82$$$I	as$$$83$$$85$$$O	a$$$86$$$87$$$O	therapeutic$$$88$$$99$$$O	agent$$$100$$$105$$$O	in$$$106$$$108$$$O	ophthalmology,$$$109$$$123$$$O	the$$$124$$$127$$$O	alkane$$$128$$$134$$$I	having$$$135$$$141$$$O	the$$$142$$$145$$$O	general$$$146$$$153$$$O	formula$$$154$$$161$$$O	[âRF(CH2)nCR1âCR2â]x,$$$162$$$189$$$I	wherein$$$190$$$197$$$I	RF$$$198$$$200$$$O	is$$$201$$$203$$$O	a$$$204$$$205$$$O	linear$$$206$$$212$$$O	or$$$213$$$215$$$O	branched$$$216$$$224$$$O	perfluorinated$$$225$$$239$$$I	alkyl$$$240$$$245$$$O	chain$$$246$$$251$$$I	C2F5$$$252$$$256$$$I	to$$$257$$$259$$$I	C12F23,$$$260$$$267$$$I	R1$$$268$$$270$$$O	and$$$271$$$274$$$O	R2$$$275$$$277$$$O	are$$$278$$$281$$$O	independently$$$282$$$295$$$O	selected$$$296$$$304$$$O	from$$$305$$$309$$$O	the$$$310$$$313$$$O	group$$$314$$$319$$$O	consisting$$$320$$$330$$$I	of$$$331$$$333$$$I	H,$$$334$$$336$$$I	CH3,$$$337$$$341$$$I	C2H5$$$342$$$346$$$I	and$$$347$$$350$$$I	C3H7,$$$351$$$356$$$O	n$$$357$$$358$$$O	is$$$359$$$361$$$O	selected$$$362$$$370$$$O	from$$$371$$$375$$$O	the$$$376$$$379$$$O	numbers$$$380$$$387$$$O	0,$$$388$$$390$$$O	1$$$391$$$392$$$O	and$$$393$$$396$$$O	2,$$$397$$$399$$$O	and$$$400$$$403$$$O	x$$$404$$$405$$$O	is$$$406$$$408$$$O	a$$$409$$$410$$$O	number$$$411$$$417$$$O	between$$$418$$$425$$$O	2$$$426$$$427$$$O	and$$$428$$$431$$$O	6,$$$432$$$434$$$O	with$$$435$$$439$$$O	a$$$440$$$441$$$O	molar$$$442$$$447$$$O	mass$$$448$$$452$$$O	of$$$453$$$455$$$O	at$$$456$$$458$$$O	least$$$459$$$464$$$O	750.$$$465$$$469$$$O	According$$$470$$$479$$$O	to$$$480$$$482$$$O	the$$$483$$$486$$$O	invention,$$$487$$$497$$$O	a$$$498$$$499$$$O	pharmacological$$$500$$$515$$$O	agent$$$516$$$521$$$O	is$$$522$$$524$$$O	provided$$$525$$$533$$$O	that$$$534$$$538$$$O	is$$$539$$$541$$$O	used$$$542$$$546$$$O	in$$$547$$$549$$$O	ophthalmology$$$550$$$563$$$O	and$$$564$$$567$$$O	that$$$568$$$572$$$O	causes$$$573$$$579$$$O	little$$$580$$$586$$$O	or$$$587$$$589$$$O	no$$$590$$$592$$$O	damage$$$593$$$599$$$O	to$$$600$$$602$$$O	the$$$603$$$606$$$O	retina$$$607$$$613$$$O	even$$$614$$$618$$$O	when$$$619$$$623$$$O	used$$$624$$$628$$$O	over$$$629$$$633$$$O	a$$$634$$$635$$$O	long$$$636$$$640$$$O	period.$$$641$$$648$$$O
CN101348509A
2-aryl-6-arylÃ­Â»-glucoside$$$0$$$27$$$I	compound,$$$28$$$37$$$O	and$$$38$$$41$$$O	preparation$$$42$$$53$$$O	and$$$54$$$57$$$O	use$$$58$$$61$$$O	thereof$$$62$$$69$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	compound$$$26$$$34$$$O	of$$$35$$$37$$$O	2-aryl-6-aryl'-glucoside$$$38$$$62$$$I	as$$$63$$$65$$$O	well$$$66$$$70$$$O	as$$$71$$$73$$$O	a$$$74$$$75$$$O	preparation$$$76$$$87$$$O	method$$$88$$$94$$$O	and$$$95$$$98$$$O	an$$$99$$$101$$$O	application$$$102$$$113$$$O	thereof.$$$114$$$122$$$O	The$$$123$$$126$$$O	compound$$$127$$$135$$$O	having$$$136$$$142$$$O	the$$$143$$$146$$$O	following$$$147$$$156$$$O	structural$$$157$$$167$$$O	formula$$$168$$$175$$$O	is$$$176$$$178$$$O	used$$$179$$$183$$$O	for$$$184$$$187$$$O	preparation$$$188$$$199$$$O	of$$$200$$$202$$$O	a$$$203$$$204$$$O	small-molecular$$$205$$$220$$$O	inhibitor/anti-neoplasm$$$221$$$244$$$O	drug$$$245$$$249$$$O	belonging$$$250$$$259$$$O	to$$$260$$$262$$$O	the$$$263$$$266$$$O	bcl-2$$$267$$$272$$$O	protein$$$273$$$280$$$O	family.$$$281$$$288$$$O	The$$$289$$$292$$$O	preparation$$$293$$$304$$$O	method$$$305$$$311$$$O	of$$$312$$$314$$$O	the$$$315$$$318$$$O	compound$$$319$$$327$$$O	comprises$$$328$$$337$$$O	the$$$338$$$341$$$O	following$$$342$$$351$$$O	steps$$$352$$$357$$$O	that:$$$358$$$363$$$O	1)$$$364$$$366$$$O	an$$$367$$$369$$$O	epoxidation$$$370$$$381$$$O	of$$$382$$$384$$$O	2-$$$385$$$387$$$I	iodoglucose-1,6-inner$$$388$$$409$$$I	ether$$$410$$$415$$$I	is$$$416$$$418$$$O	carried$$$419$$$426$$$O	out;$$$427$$$431$$$O	2)$$$432$$$434$$$O	a$$$435$$$436$$$O	ring$$$437$$$441$$$O	opening$$$442$$$449$$$O	reaction$$$450$$$458$$$O	of$$$459$$$461$$$O	a$$$462$$$463$$$O	compound$$$464$$$472$$$O	obtained$$$473$$$481$$$O	from$$$482$$$486$$$O	the$$$487$$$490$$$O	epoxidation$$$491$$$502$$$O	and$$$503$$$506$$$O	a$$$507$$$508$$$O	phenol$$$509$$$515$$$I	is$$$516$$$518$$$O	carried$$$519$$$526$$$O	out$$$527$$$530$$$O	under$$$531$$$536$$$O	alkali$$$537$$$543$$$O	condition;$$$544$$$554$$$O	3)$$$555$$$557$$$O	the$$$558$$$561$$$O	product$$$562$$$569$$$O	of$$$570$$$572$$$O	the$$$573$$$576$$$O	ring$$$577$$$581$$$O	opening$$$582$$$589$$$O	reaction$$$590$$$598$$$O	undergoes$$$599$$$608$$$O	benzyl$$$609$$$615$$$I	protection,$$$616$$$627$$$O	and$$$628$$$631$$$O	then$$$632$$$636$$$O	a$$$637$$$638$$$O	ring$$$639$$$643$$$O	opening$$$644$$$651$$$O	reaction$$$652$$$660$$$O	of$$$661$$$663$$$O	1,6-inner$$$664$$$673$$$O	ether$$$674$$$679$$$O	is$$$680$$$682$$$O	carried$$$683$$$690$$$O	out;$$$691$$$695$$$O	4)$$$696$$$698$$$O	the$$$699$$$702$$$O	product$$$703$$$710$$$O	obtained$$$711$$$719$$$O	from$$$720$$$724$$$O	the$$$725$$$728$$$O	ring$$$729$$$733$$$O	opening$$$734$$$741$$$O	reaction$$$742$$$750$$$O	of$$$751$$$753$$$O	step$$$754$$$758$$$O	3)$$$759$$$761$$$O	undergoes$$$762$$$771$$$O	benzyl$$$772$$$778$$$I	protection$$$779$$$789$$$O	and$$$790$$$793$$$O	then$$$794$$$798$$$O	undergoes$$$799$$$808$$$O	a$$$809$$$810$$$O	substitution$$$811$$$823$$$O	reaction$$$824$$$832$$$O	with$$$833$$$837$$$O	a$$$838$$$839$$$O	phenol$$$840$$$846$$$I	or$$$847$$$849$$$O	an$$$850$$$852$$$O	alcohol$$$853$$$860$$$I	under$$$861$$$866$$$O	alkali$$$867$$$873$$$O	condition;$$$874$$$884$$$O	and$$$885$$$888$$$O	5)$$$889$$$891$$$O	the$$$892$$$895$$$O	product$$$896$$$903$$$O	obtained$$$904$$$912$$$O	from$$$913$$$917$$$O	the$$$918$$$921$$$O	substitution$$$922$$$934$$$O	undergoes$$$935$$$944$$$O	Pd/C$$$945$$$949$$$I	deoxidization$$$950$$$963$$$O	to$$$964$$$966$$$O	eliminate$$$967$$$976$$$O	the$$$977$$$980$$$O	benzyl$$$981$$$987$$$I	protecting$$$988$$$998$$$O	group$$$999$$$1004$$$O	to$$$1005$$$1007$$$O	obtain$$$1008$$$1014$$$O	the$$$1015$$$1018$$$O	compound$$$1019$$$1027$$$O	of$$$1028$$$1030$$$O	2-aryl-6-aryl'-glucoside.$$$1031$$$1056$$$I
CN101220044A
Telomerase$$$0$$$10$$$O	inhibitor,$$$11$$$21$$$O	preparation$$$22$$$33$$$O	method$$$34$$$40$$$O	and$$$41$$$44$$$O	application$$$45$$$56$$$O	thereof$$$57$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	pharmaceutical$$$38$$$52$$$O	chemistry,$$$53$$$63$$$O	in$$$64$$$66$$$O	particular$$$67$$$77$$$O	to$$$78$$$80$$$O	a$$$81$$$82$$$O	thiazole$$$83$$$91$$$I	[5,$$$92$$$95$$$I	4-b]$$$96$$$100$$$I	pyrimidine$$$101$$$111$$$I	compounds$$$112$$$121$$$O	(I),$$$122$$$126$$$O	preparation$$$127$$$138$$$O	methods$$$139$$$146$$$O	thereof$$$147$$$154$$$O	and$$$155$$$158$$$O	also$$$159$$$163$$$O	to$$$164$$$166$$$O	pharmaceutical$$$167$$$181$$$O	composites$$$182$$$192$$$O	containing$$$193$$$203$$$O	the$$$204$$$207$$$O	compounds$$$208$$$217$$$O	and$$$218$$$221$$$O	medical$$$222$$$229$$$O	purposes$$$230$$$238$$$O	thereof,$$$239$$$247$$$O	in$$$248$$$250$$$O	particular$$$251$$$261$$$O	to$$$262$$$264$$$O	telomerase$$$265$$$275$$$O	inhibitors.$$$276$$$287$$$O
CN101143143A
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	gastroesophageal$$$22$$$38$$$O	reflux$$$39$$$45$$$O	disease$$$46$$$53$$$O	and$$$54$$$57$$$O	functional$$$58$$$68$$$O	dyspepsia$$$69$$$78$$$O
A$$$0$$$1$$$O	combination$$$2$$$13$$$O	preparation$$$14$$$25$$$O	for$$$26$$$29$$$O	remedying$$$30$$$39$$$O	the$$$40$$$43$$$O	gastroesophageal$$$44$$$60$$$O	reflux$$$61$$$67$$$O	disease$$$68$$$75$$$O	(GERD)$$$76$$$82$$$O	and$$$83$$$86$$$O	the$$$87$$$90$$$O	functional$$$91$$$101$$$O	dyspepsia$$$102$$$111$$$O	is$$$112$$$114$$$O	characterized$$$115$$$128$$$O	in$$$129$$$131$$$O	that$$$132$$$136$$$O	the$$$137$$$140$$$O	prescription$$$141$$$153$$$O	of$$$154$$$156$$$O	the$$$157$$$160$$$O	combination$$$161$$$172$$$O	preparation$$$173$$$184$$$O	consists$$$185$$$193$$$O	of$$$194$$$196$$$O	a$$$197$$$198$$$O	proton$$$199$$$205$$$O	pump$$$206$$$210$$$O	depressor$$$211$$$220$$$O	and$$$221$$$224$$$O	a$$$225$$$226$$$O	gastrointestinal$$$227$$$243$$$O	power$$$244$$$249$$$O	drug$$$250$$$254$$$O	of$$$255$$$257$$$O	itopride;$$$258$$$267$$$I	the$$$268$$$271$$$O	proton$$$272$$$278$$$O	pump$$$279$$$283$$$O	depressor$$$284$$$293$$$O	is$$$294$$$296$$$O	selected$$$297$$$305$$$O	from$$$306$$$310$$$O	one$$$311$$$314$$$O	of$$$315$$$317$$$O	a$$$318$$$319$$$O	Pantoprazole,$$$320$$$333$$$I	a$$$334$$$335$$$O	Omeprazole,$$$336$$$347$$$I	a$$$348$$$349$$$O	Esomeprazole,$$$350$$$363$$$I	a$$$364$$$365$$$O	Lansoprazole,$$$366$$$379$$$I	a$$$380$$$381$$$O	Rabeprazole,$$$382$$$394$$$I	a$$$395$$$396$$$O	Tenatoprazole$$$397$$$410$$$I	and$$$411$$$414$$$O	a$$$415$$$416$$$O	Leminorazole,$$$417$$$430$$$I	wherein$$$431$$$438$$$O	the$$$439$$$442$$$O	Pantoprazole$$$443$$$455$$$I	is$$$456$$$458$$$O	preferential,$$$459$$$472$$$O	and$$$473$$$476$$$O	at$$$477$$$479$$$O	the$$$480$$$483$$$O	same$$$484$$$488$$$O	time$$$489$$$493$$$O	the$$$494$$$497$$$O	neutral$$$498$$$505$$$O	form$$$506$$$510$$$O	of$$$511$$$513$$$O	the$$$514$$$517$$$O	basic$$$518$$$523$$$O	salt$$$524$$$528$$$O	of$$$529$$$531$$$O	the$$$532$$$535$$$O	proton$$$536$$$542$$$O	pump$$$543$$$547$$$O	depressor$$$548$$$557$$$O	is$$$558$$$560$$$O	also$$$561$$$565$$$O	included,$$$566$$$575$$$O	such$$$576$$$580$$$O	as$$$581$$$583$$$O	Naplus,$$$584$$$591$$$I	Mg2plus,$$$592$$$600$$$I	Ca2plus,$$$601$$$609$$$I	Kplus$$$610$$$615$$$I	or$$$616$$$618$$$O	Li$$$619$$$621$$$I	plus$$$622$$$626$$$I	salt$$$627$$$631$$$O	and$$$632$$$635$$$O	a$$$636$$$637$$$O	pure$$$638$$$642$$$O	optical$$$643$$$650$$$O	stereoisomer$$$651$$$663$$$O	of$$$664$$$666$$$O	the$$$667$$$670$$$O	proton$$$671$$$677$$$O	pump$$$678$$$682$$$O	depressor$$$683$$$692$$$O	or$$$693$$$695$$$O	an$$$696$$$698$$$O	active$$$699$$$705$$$O	metabolite$$$706$$$716$$$O	of$$$717$$$719$$$O	the$$$720$$$723$$$O	proton$$$724$$$730$$$O	pump$$$731$$$735$$$O	depressor;$$$736$$$746$$$O	the$$$747$$$750$$$O	gastrointestinal$$$751$$$767$$$O	power$$$768$$$773$$$O	drug$$$774$$$778$$$O	is$$$779$$$781$$$O	the$$$782$$$785$$$O	itopride$$$786$$$794$$$I	and$$$795$$$798$$$O	a$$$799$$$800$$$O	ramification$$$801$$$813$$$O	of$$$814$$$816$$$O	the$$$817$$$820$$$O	itopride$$$821$$$829$$$I	or$$$830$$$832$$$O	one$$$833$$$836$$$O	of$$$837$$$839$$$O	the$$$840$$$843$$$O	medicinal$$$844$$$853$$$O	salts$$$854$$$859$$$O	of$$$860$$$862$$$O	the$$$863$$$866$$$O	itopride;$$$867$$$876$$$I	in$$$877$$$879$$$O	the$$$880$$$883$$$O	combination$$$884$$$895$$$O	preparation,$$$896$$$908$$$O	the$$$909$$$912$$$O	weight$$$913$$$919$$$O	ratio$$$920$$$925$$$O	of$$$926$$$928$$$O	the$$$929$$$932$$$O	Pantoprazole$$$933$$$945$$$I	and$$$946$$$949$$$O	the$$$950$$$953$$$O	itopride$$$954$$$962$$$I	is$$$963$$$965$$$O	2$$$966$$$967$$$O	to$$$968$$$970$$$O	5$$$971$$$972$$$O	to$$$973$$$975$$$O	2$$$976$$$977$$$O	to$$$978$$$980$$$O	7.$$$981$$$983$$$O	The$$$984$$$987$$$O	invention$$$988$$$997$$$O	has$$$998$$$1001$$$O	important$$$1002$$$1011$$$O	affect$$$1012$$$1018$$$O	for$$$1019$$$1022$$$O	remedying$$$1023$$$1032$$$O	the$$$1033$$$1036$$$O	gastroesophageal$$$1037$$$1053$$$O	reflux$$$1054$$$1060$$$O	disease$$$1061$$$1068$$$O	and$$$1069$$$1072$$$O	the$$$1073$$$1076$$$O	functional$$$1077$$$1087$$$O	dyspepsia,$$$1088$$$1098$$$O	and$$$1099$$$1102$$$O	the$$$1103$$$1106$$$O	preparation$$$1107$$$1118$$$O	method$$$1119$$$1125$$$O	of$$$1126$$$1128$$$O	the$$$1129$$$1132$$$O	invention$$$1133$$$1142$$$O	is$$$1143$$$1145$$$O	simple$$$1146$$$1152$$$O	and$$$1153$$$1156$$$O	convenient;$$$1157$$$1168$$$O	the$$$1169$$$1172$$$O	cost$$$1173$$$1177$$$O	is$$$1178$$$1180$$$O	low;$$$1181$$$1185$$$O	the$$$1186$$$1189$$$O	invention$$$1190$$$1199$$$O	is$$$1200$$$1202$$$O	fit$$$1203$$$1206$$$O	for$$$1207$$$1210$$$O	being$$$1211$$$1216$$$O	orally$$$1217$$$1223$$$O	taken$$$1224$$$1229$$$O	by$$$1230$$$1232$$$O	the$$$1233$$$1236$$$O	patient;$$$1237$$$1245$$$O	the$$$1246$$$1249$$$O	invention$$$1250$$$1259$$$O	has$$$1260$$$1263$$$O	good$$$1264$$$1268$$$O	conformance$$$1269$$$1280$$$O	performance,$$$1281$$$1293$$$O	high$$$1294$$$1298$$$O	curative$$$1299$$$1307$$$O	effect,$$$1308$$$1315$$$O	low$$$1316$$$1319$$$O	recrudescence$$$1320$$$1333$$$O	rate$$$1334$$$1338$$$O	and$$$1339$$$1342$$$O	little$$$1343$$$1349$$$O	adverse$$$1350$$$1357$$$O	reaction.$$$1358$$$1367$$$O
US20100204339
Orally$$$0$$$6$$$O	Bioavailable$$$7$$$19$$$O	Stilbenoids-$$$20$$$32$$$I	Compositions$$$33$$$45$$$O	and$$$46$$$49$$$O	Therapeutic$$$50$$$61$$$O	Applications$$$62$$$74$$$O	Thereof$$$75$$$82$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	novel$$$15$$$20$$$O	sirtuin$$$21$$$28$$$O	modulating$$$29$$$39$$$O	composition$$$40$$$51$$$O	comprising$$$52$$$62$$$O	an$$$63$$$65$$$O	orally$$$66$$$72$$$O	bioavailable$$$73$$$85$$$O	SIRT-1$$$86$$$92$$$O	enhancing$$$93$$$102$$$O	compound$$$103$$$111$$$O	3,5-dimethoxy-3,4â²-dihydroxystilbene$$$112$$$150$$$I	represented$$$151$$$162$$$O	by$$$163$$$165$$$O	STR#I.$$$166$$$172$$$O	Also$$$173$$$177$$$O	disclosed$$$178$$$187$$$O	is$$$188$$$190$$$O	an$$$191$$$193$$$O	anti-acne$$$194$$$203$$$O	composition$$$204$$$215$$$O	comprising$$$216$$$226$$$I	3,5-dimethoxy-$$$227$$$241$$$I	3,4â²-dihydroxystilbenes$$$242$$$267$$$I	represented$$$268$$$279$$$O	by$$$280$$$282$$$O	STR#I.$$$283$$$289$$$O	Further,$$$290$$$298$$$O	a$$$299$$$300$$$O	novel$$$301$$$306$$$O	sirtuin$$$307$$$314$$$O	modulating$$$315$$$325$$$O	composition$$$326$$$337$$$O	comprising$$$338$$$348$$$O	an$$$349$$$351$$$O	orally$$$352$$$358$$$O	bioavailable$$$359$$$371$$$O	SIRT-1$$$372$$$378$$$O	enhancing$$$379$$$388$$$O	compound$$$389$$$397$$$I	2,3â²,5â²,$$$398$$$410$$$I	6-tetrahydroxy-trans-stilbene$$$411$$$440$$$I	represented$$$441$$$452$$$O	by$$$453$$$455$$$O	STR#II$$$456$$$462$$$O	is$$$463$$$465$$$O	also$$$466$$$470$$$O	disclosed.$$$471$$$481$$$O
US20080214544
N-(4-(6-(1-methyl-6-oxo-2-(phenylamino)-1,6-dihydropyrimidin-5-yl)pyridin-3-yloxy)pyridin-2-yl)pyrrolidine-1-carboxamide;$$$0$$$121$$$I	anticarcinogenics,$$$122$$$140$$$O	antiproliferatives,$$$141$$$160$$$O	angiogenesis$$$161$$$173$$$O	inhibitors;$$$174$$$185$$$O	hepatocyte$$$186$$$196$$$O	growth$$$197$$$203$$$O	factor$$$204$$$210$$$O	mediated$$$211$$$219$$$O	diseases$$$220$$$228$$$O
Selected$$$0$$$8$$$O	compounds$$$9$$$18$$$O	are$$$19$$$22$$$O	effective$$$23$$$32$$$O	for$$$33$$$36$$$O	prophylaxis$$$37$$$48$$$O	and$$$49$$$52$$$O	treatment$$$53$$$62$$$O	of$$$63$$$65$$$O	diseases,$$$66$$$75$$$O	such$$$76$$$80$$$O	as$$$81$$$83$$$O	c-met$$$84$$$89$$$O	mediated$$$90$$$98$$$O	diseases$$$99$$$107$$$O	and/or$$$108$$$114$$$O	HGF$$$115$$$118$$$O	mediated$$$119$$$127$$$O	diseases.$$$128$$$137$$$O	The$$$138$$$141$$$O	invention$$$142$$$151$$$O	encompasses$$$152$$$163$$$O	novel$$$164$$$169$$$O	compounds,$$$170$$$180$$$O	analogs,$$$181$$$189$$$O	prodrugs$$$190$$$198$$$O	and$$$199$$$202$$$O	pharmaceutically$$$203$$$219$$$O	acceptable$$$220$$$230$$$O	salts$$$231$$$236$$$O	thereof,$$$237$$$245$$$O	pharmaceutical$$$246$$$260$$$O	compositions$$$261$$$273$$$O	and$$$274$$$277$$$O	methods$$$278$$$285$$$O	for$$$286$$$289$$$O	prophylaxis$$$290$$$301$$$O	and$$$302$$$305$$$O	treatment$$$306$$$315$$$O	of$$$316$$$318$$$O	diseases$$$319$$$327$$$O	and$$$328$$$331$$$O	other$$$332$$$337$$$O	maladies$$$338$$$346$$$O	or$$$347$$$349$$$O	conditions$$$350$$$360$$$O	involving,$$$361$$$371$$$O	cancer$$$372$$$378$$$O	and$$$379$$$382$$$O	the$$$383$$$386$$$O	like.$$$387$$$392$$$O	The$$$393$$$396$$$O	subject$$$397$$$404$$$O	invention$$$405$$$414$$$O	also$$$415$$$419$$$O	relates$$$420$$$427$$$O	to$$$428$$$430$$$O	processes$$$431$$$440$$$O	for$$$441$$$444$$$O	making$$$445$$$451$$$O	such$$$452$$$456$$$O	compounds$$$457$$$466$$$O	as$$$467$$$469$$$O	well$$$470$$$474$$$O	as$$$475$$$477$$$O	to$$$478$$$480$$$O	intermediates$$$481$$$494$$$O	useful$$$495$$$501$$$O	in$$$502$$$504$$$O	such$$$505$$$509$$$O	processes.$$$510$$$520$$$O
US20080044468
Processes$$$0$$$9$$$O	For$$$10$$$13$$$O	The$$$14$$$17$$$O	Preparation$$$18$$$29$$$O	Of$$$30$$$32$$$O	Oral$$$33$$$37$$$O	Dosage$$$38$$$44$$$O	Formulations$$$45$$$57$$$O	Of$$$58$$$60$$$O	Modafinil$$$61$$$70$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	for$$$42$$$45$$$O	the$$$46$$$49$$$O	preparation$$$50$$$61$$$O	of$$$62$$$64$$$O	bioavailable$$$65$$$77$$$O	dosage$$$78$$$84$$$O	form$$$85$$$89$$$O	of$$$90$$$92$$$O	modafinil.$$$93$$$103$$$I
EP2308591A1
Adsorbent,$$$0$$$10$$$O	cleansing$$$11$$$20$$$O	agent,$$$21$$$27$$$O	remedy$$$28$$$34$$$O	for$$$35$$$38$$$O	kidney$$$39$$$45$$$O	disease$$$46$$$53$$$O	and$$$54$$$57$$$O	functional$$$58$$$68$$$O	food$$$69$$$73$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	an$$$13$$$15$$$O	adsorbent$$$16$$$25$$$O	including$$$26$$$35$$$O	a$$$36$$$37$$$O	porous$$$38$$$44$$$O	carbon$$$45$$$51$$$O	material$$$52$$$60$$$O	which$$$61$$$66$$$O	is$$$67$$$69$$$O	produced$$$70$$$78$$$O	from$$$79$$$83$$$O	a$$$84$$$85$$$O	plant-derived$$$86$$$99$$$O	material$$$100$$$108$$$O	having$$$109$$$115$$$O	a$$$116$$$117$$$O	silicon$$$118$$$125$$$O	(Si)$$$126$$$130$$$O	content$$$131$$$138$$$O	of$$$139$$$141$$$O	not$$$142$$$145$$$O	less$$$146$$$150$$$O	than$$$151$$$155$$$O	5$$$156$$$157$$$O	wt.%$$$158$$$162$$$O	and$$$163$$$166$$$O	which$$$167$$$172$$$O	has$$$173$$$176$$$O	a$$$177$$$178$$$O	value$$$179$$$184$$$O	of$$$185$$$187$$$O	specific$$$188$$$196$$$O	surface$$$197$$$204$$$O	area$$$205$$$209$$$O	determined$$$210$$$220$$$O	by$$$221$$$223$$$O	the$$$224$$$227$$$O	nitrogen$$$228$$$236$$$O	BET$$$237$$$240$$$O	method$$$241$$$247$$$O	of$$$248$$$250$$$O	not$$$251$$$254$$$O	less$$$255$$$259$$$O	than$$$260$$$264$$$O	10$$$265$$$267$$$O	m2/g,$$$268$$$273$$$O	a$$$274$$$275$$$O	silicon$$$276$$$283$$$O	content$$$284$$$291$$$O	of$$$292$$$294$$$O	not$$$295$$$298$$$O	more$$$299$$$303$$$O	than$$$304$$$308$$$O	1$$$309$$$310$$$O	wt.%,$$$311$$$316$$$O	and$$$317$$$320$$$O	pore$$$321$$$325$$$O	volumes$$$326$$$333$$$O	determined$$$334$$$344$$$O	by$$$345$$$347$$$O	the$$$348$$$351$$$O	BJH$$$352$$$355$$$O	method$$$356$$$362$$$O	and$$$363$$$366$$$O	the$$$367$$$370$$$O	MP$$$371$$$373$$$O	method$$$374$$$380$$$O	of$$$381$$$383$$$O	not$$$384$$$387$$$O	less$$$388$$$392$$$O	than$$$393$$$397$$$O	0.1$$$398$$$401$$$O	cm3/g.$$$402$$$408$$$O	The$$$409$$$412$$$O	adsorbent$$$413$$$422$$$O	adsorbs$$$423$$$430$$$O	indole,$$$431$$$438$$$O	uric$$$439$$$443$$$O	acid,$$$444$$$449$$$O	adenosine,$$$450$$$460$$$O	Î±-amylase,$$$461$$$472$$$O	3-methylindole,$$$473$$$488$$$O	tryptophan,$$$489$$$500$$$O	indicant,$$$501$$$510$$$O	theophylline,$$$511$$$524$$$O	inosine$$$525$$$532$$$O	5-monophosphate$$$533$$$548$$$O	disodium$$$549$$$557$$$O	salt,$$$558$$$563$$$O	adenosine$$$564$$$573$$$O	5-triphosphate$$$574$$$588$$$O	disodium$$$589$$$597$$$O	salt,$$$598$$$603$$$O	a$$$604$$$605$$$O	fatty$$$606$$$611$$$O	acid,$$$612$$$617$$$O	a$$$618$$$619$$$O	coloring$$$620$$$628$$$O	matter,$$$629$$$636$$$O	hydrophobic$$$637$$$648$$$O	molecules,$$$649$$$659$$$O	or$$$660$$$662$$$O	an$$$663$$$665$$$O	organic$$$666$$$673$$$O	matter$$$674$$$680$$$O	(for$$$681$$$685$$$O	example,$$$686$$$694$$$O	organic$$$695$$$702$$$O	molecules$$$703$$$712$$$O	or$$$713$$$715$$$O	a$$$716$$$717$$$O	protein)$$$718$$$726$$$O	having$$$727$$$733$$$O	a$$$734$$$735$$$O	number$$$736$$$742$$$O	average$$$743$$$750$$$O	molecular$$$751$$$760$$$O	weight$$$761$$$767$$$O	of$$$768$$$770$$$O	not$$$771$$$774$$$O	less$$$775$$$779$$$O	than$$$780$$$784$$$O	1$$$785$$$786$$$O	Ã$$$787$$$789$$$O	102$$$790$$$793$$$O	and$$$794$$$797$$$O	less$$$798$$$802$$$O	than$$$803$$$807$$$O	5$$$808$$$809$$$O	Ã$$$810$$$812$$$O	102$$$813$$$816$$$O	.$$$817$$$818$$$O
EP2091523A1
Anandamide$$$0$$$10$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	describes$$$22$$$31$$$O	provides$$$32$$$40$$$O	the$$$41$$$44$$$O	use$$$45$$$48$$$O	of$$$49$$$51$$$O	anandamide$$$52$$$62$$$I	for$$$63$$$66$$$O	the$$$67$$$70$$$O	manufacture$$$71$$$82$$$O	of$$$83$$$85$$$O	a$$$86$$$87$$$O	nutraceutical$$$88$$$101$$$O	for$$$102$$$105$$$O	oral$$$106$$$110$$$O	intake$$$111$$$117$$$O	preferably$$$118$$$128$$$O	a$$$129$$$130$$$O	medicament$$$131$$$141$$$O	for$$$142$$$145$$$O	reducing$$$146$$$154$$$O	appetite,$$$155$$$164$$$O	giving$$$165$$$171$$$O	a$$$172$$$173$$$O	satiety$$$174$$$181$$$O	effect,$$$182$$$189$$$O	preventing$$$190$$$200$$$O	or$$$201$$$203$$$O	reducing$$$204$$$212$$$O	inflammatory$$$213$$$225$$$O	bowel$$$226$$$231$$$O	disease$$$232$$$239$$$O	or$$$240$$$242$$$O	preventing$$$243$$$253$$$O	or$$$254$$$256$$$O	reducing$$$257$$$265$$$O	irritable$$$266$$$275$$$O	bowel$$$276$$$281$$$O	syndrome.$$$282$$$291$$$O
CN1861082A
Medicine$$$0$$$8$$$O	prepn.$$$9$$$15$$$O	of$$$16$$$18$$$O	compounding$$$19$$$30$$$O	deoxypregnene$$$31$$$44$$$I	contg.$$$45$$$51$$$O	non-ionic$$$52$$$61$$$O	surfactant$$$62$$$72$$$O
A$$$0$$$1$$$O	compound$$$2$$$10$$$O	desogestrel$$$11$$$22$$$I	in$$$23$$$25$$$O	the$$$26$$$29$$$O	form$$$30$$$34$$$O	of$$$35$$$37$$$O	dripping$$$38$$$46$$$O	pill,$$$47$$$52$$$O	capsule$$$53$$$60$$$O	or$$$61$$$63$$$O	soft$$$64$$$68$$$O	capsule$$$69$$$76$$$O	is$$$77$$$79$$$O	prepared$$$80$$$88$$$O	from$$$89$$$93$$$O	desogestrel$$$94$$$105$$$I	and$$$106$$$109$$$O	ethinyl$$$110$$$117$$$I	estradiol$$$118$$$127$$$I	through$$$128$$$135$$$O	proportional$$$136$$$148$$$O	mixing$$$149$$$155$$$O	or$$$156$$$158$$$O	dissolving$$$159$$$169$$$O	(or$$$170$$$173$$$O	dispersing)$$$174$$$185$$$O	in$$$186$$$188$$$O	the$$$189$$$192$$$O	hydrophilic$$$193$$$204$$$O	high-molecular$$$205$$$219$$$O	carrier$$$220$$$227$$$O	containing$$$228$$$238$$$O	non-ionic$$$239$$$248$$$O	surfactant,$$$249$$$260$$$O	and$$$261$$$264$$$O	shaping.$$$265$$$273$$$O
CN101258156A
Amorphous$$$0$$$9$$$O	and$$$10$$$13$$$O	crystalline$$$14$$$25$$$O	forms$$$26$$$31$$$O	of$$$32$$$34$$$O	dorzolamide$$$35$$$46$$$I	hydrochloride$$$47$$$60$$$I	and$$$61$$$64$$$O	processes$$$65$$$74$$$O	of$$$75$$$77$$$O	making$$$78$$$84$$$O	same$$$85$$$89$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	amorphous$$$26$$$35$$$O	form$$$36$$$40$$$O	of$$$41$$$43$$$O	Dorzolamide$$$44$$$55$$$I	hydrochloride,$$$56$$$70$$$I	processes$$$71$$$80$$$O	for$$$81$$$84$$$O	the$$$85$$$88$$$O	preparation$$$89$$$100$$$O	of$$$101$$$103$$$O	amorphous$$$104$$$113$$$O	Dorzolamide$$$114$$$125$$$I	hydrochloride,$$$126$$$140$$$I	processes$$$141$$$150$$$O	for$$$151$$$154$$$O	making$$$155$$$161$$$O	Form$$$162$$$166$$$O	II$$$167$$$169$$$O	from$$$170$$$174$$$O	amorphous$$$175$$$184$$$O	Dorzolamide$$$185$$$196$$$I	HCl5$$$197$$$201$$$I	a$$$202$$$203$$$O	crystalline$$$204$$$215$$$O	form$$$216$$$220$$$O	of$$$221$$$223$$$O	Dorzolamide$$$224$$$235$$$I	hydrochloride,$$$236$$$250$$$I	Form$$$251$$$255$$$O	IV,$$$256$$$259$$$O	process$$$260$$$267$$$O	for$$$268$$$271$$$O	making$$$272$$$278$$$O	Form$$$279$$$283$$$O	IV,$$$284$$$287$$$O	and$$$288$$$291$$$O	pharmaceutical$$$292$$$306$$$O	compositions$$$307$$$319$$$O	of$$$320$$$322$$$O	amorphous$$$323$$$332$$$O	Dorzolamide$$$333$$$344$$$I	hydrochloride,$$$345$$$359$$$I	Dorzolamide$$$360$$$371$$$I	hydrochloride$$$372$$$385$$$I	Form$$$386$$$390$$$O	II$$$391$$$393$$$O	and$$$394$$$397$$$O	Dorzolamide$$$398$$$409$$$I	hydrochloride$$$410$$$423$$$I	Form$$$424$$$428$$$O	IV.$$$429$$$432$$$O
US7189718
viricides;$$$0$$$10$$$O	polymerase$$$11$$$21$$$O	inhibitor;$$$22$$$32$$$O	therapy$$$33$$$40$$$O	for$$$41$$$44$$$O	genetic$$$45$$$52$$$O	engineered$$$53$$$63$$$O	viruses$$$64$$$71$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	pyridazinone$$$32$$$44$$$I	derivatives$$$45$$$56$$$O	of$$$57$$$59$$$O	formula$$$60$$$67$$$O	I$$$68$$$69$$$O	wherein$$$70$$$77$$$O	R1âR4,$$$78$$$86$$$O	R7,$$$87$$$90$$$O	R8$$$91$$$93$$$O	and$$$94$$$97$$$O	X1$$$98$$$100$$$O	are$$$101$$$104$$$O	as$$$105$$$107$$$O	defined$$$108$$$115$$$O	in$$$116$$$118$$$O	the$$$119$$$122$$$O	summary$$$123$$$130$$$O	and$$$131$$$134$$$O	pharmaceutically$$$135$$$151$$$O	acceptable$$$152$$$162$$$O	salts$$$163$$$168$$$O	and$$$169$$$172$$$O	solvates$$$173$$$181$$$O	thereof,$$$182$$$190$$$O	methods$$$191$$$198$$$O	to$$$199$$$201$$$O	inhibit$$$202$$$209$$$O	or$$$210$$$212$$$O	modulate$$$213$$$221$$$O	Human$$$222$$$227$$$O	Immunodeficiency$$$228$$$244$$$O	Virus$$$245$$$250$$$O	(HIV)$$$251$$$256$$$O	reverse$$$257$$$264$$$O	transcriptase$$$265$$$278$$$O	with$$$279$$$283$$$O	compounds$$$284$$$293$$$O	of$$$294$$$296$$$O	formula$$$297$$$304$$$O	I,$$$305$$$307$$$O	pharmaceutical$$$308$$$322$$$O	compositions$$$323$$$335$$$O	containing$$$336$$$346$$$O	of$$$347$$$349$$$O	formula$$$350$$$357$$$O	I$$$358$$$359$$$O	admixed$$$360$$$367$$$O	with$$$368$$$372$$$O	at$$$373$$$375$$$O	least$$$376$$$381$$$O	one$$$382$$$385$$$O	solvent,$$$386$$$394$$$O	carrier$$$395$$$402$$$O	or$$$403$$$405$$$O	excipient$$$406$$$415$$$O	and$$$416$$$419$$$O	processes$$$420$$$429$$$O	to$$$430$$$432$$$O	prepare$$$433$$$440$$$O	compounds$$$441$$$450$$$O	of$$$451$$$453$$$O	formula$$$454$$$461$$$O	I.$$$462$$$464$$$O	The$$$465$$$468$$$O	compounds$$$469$$$478$$$O	are$$$479$$$482$$$O	useful$$$483$$$489$$$O	for$$$490$$$493$$$O	treating$$$494$$$502$$$O	disorders$$$503$$$512$$$O	in$$$513$$$515$$$O	which$$$516$$$521$$$O	HIV$$$522$$$525$$$O	and$$$526$$$529$$$O	genetically$$$530$$$541$$$O	related$$$542$$$549$$$O	viruses$$$550$$$557$$$O	are$$$558$$$561$$$O	implicated$$$562$$$572$$$O
WO2008069262A1
Film-coated$$$0$$$11$$$O	preparation$$$12$$$23$$$O	having$$$24$$$30$$$O	improved$$$31$$$39$$$O	stability$$$40$$$49$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	pharmaceutical$$$15$$$29$$$O	composition$$$30$$$41$$$O	containing$$$42$$$52$$$O	a$$$53$$$54$$$O	compound$$$55$$$63$$$O	represented$$$64$$$75$$$O	by$$$76$$$78$$$O	the$$$79$$$82$$$O	general$$$83$$$90$$$O	formula$$$91$$$98$$$O	(I)$$$99$$$102$$$O	below,$$$103$$$109$$$O	while$$$110$$$115$$$O	having$$$116$$$122$$$O	improved$$$123$$$131$$$O	storage$$$132$$$139$$$O	stability.$$$140$$$150$$$O	Specifically$$$151$$$163$$$O	disclosed$$$164$$$173$$$O	is$$$174$$$176$$$O	a$$$177$$$178$$$O	film-coated$$$179$$$190$$$O	preparation$$$191$$$202$$$O	having$$$203$$$209$$$O	excellent$$$210$$$219$$$O	storage$$$220$$$227$$$O	stability,$$$228$$$238$$$O	which$$$239$$$244$$$O	contains$$$245$$$253$$$O	a$$$254$$$255$$$O	compound$$$256$$$264$$$O	represented$$$265$$$276$$$O	by$$$277$$$279$$$O	the$$$280$$$283$$$O	general$$$284$$$291$$$O	formula$$$292$$$299$$$O	(I)$$$300$$$303$$$O	below$$$304$$$309$$$O	or$$$310$$$312$$$O	a$$$313$$$314$$$O	pharmacologically$$$315$$$332$$$O	acceptable$$$333$$$343$$$O	salt$$$344$$$348$$$O	thereof,$$$349$$$357$$$O	while$$$358$$$363$$$O	having$$$364$$$370$$$O	a$$$371$$$372$$$O	film$$$373$$$377$$$O	layer$$$378$$$383$$$O	containing$$$384$$$394$$$O	one$$$395$$$398$$$O	or$$$399$$$401$$$O	more$$$402$$$406$$$O	film$$$407$$$411$$$O	coating$$$412$$$419$$$O	base$$$420$$$424$$$O	agents$$$425$$$431$$$O	selected$$$432$$$440$$$O	from$$$441$$$445$$$O	polyvinyl$$$446$$$455$$$I	alcohols,$$$456$$$465$$$I	sodium$$$466$$$472$$$O	carboxymethylcelluloses$$$473$$$496$$$O	and$$$497$$$500$$$O	pullulans.$$$501$$$511$$$O	[chemical$$$512$$$521$$$O	formula$$$522$$$529$$$O	1]$$$530$$$532$$$O	(I)$$$533$$$536$$$O
CN103284043A
Health$$$0$$$6$$$O	care$$$7$$$11$$$O	product$$$12$$$19$$$O	with$$$20$$$24$$$O	efficacy$$$25$$$33$$$O	of$$$34$$$36$$$O	losing$$$37$$$43$$$O	weight$$$44$$$50$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	health$$$26$$$32$$$O	care$$$33$$$37$$$O	product$$$38$$$45$$$O	with$$$46$$$50$$$O	an$$$51$$$53$$$O	efficacy$$$54$$$62$$$O	of$$$63$$$65$$$O	losing$$$66$$$72$$$O	weight.$$$73$$$80$$$O	The$$$81$$$84$$$O	health$$$85$$$91$$$O	care$$$92$$$96$$$O	product$$$97$$$104$$$O	can$$$105$$$108$$$O	be$$$109$$$111$$$O	prepared$$$112$$$120$$$O	into$$$121$$$125$$$O	dosage$$$126$$$132$$$O	forms$$$133$$$138$$$O	such$$$139$$$143$$$O	as$$$144$$$146$$$O	capsules$$$147$$$155$$$O	by$$$156$$$158$$$O	taking$$$159$$$165$$$O	l-carnitine$$$166$$$177$$$I	tartrate,$$$178$$$187$$$I	konjac$$$188$$$194$$$O	powder,$$$195$$$202$$$O	tea$$$203$$$206$$$O	polyphenols,$$$207$$$219$$$I	fructooligosaccharides,$$$220$$$243$$$I	red$$$244$$$247$$$O	kojic$$$248$$$253$$$O	rice$$$254$$$258$$$O	powder,$$$259$$$266$$$O	chromium$$$267$$$275$$$I	picolinate$$$276$$$286$$$I	and$$$287$$$290$$$O	senna$$$291$$$296$$$O	whole$$$297$$$302$$$O	leaf$$$303$$$307$$$O	dry$$$308$$$311$$$O	powder$$$312$$$318$$$O	as$$$319$$$321$$$O	raw$$$322$$$325$$$O	materials$$$326$$$335$$$O	in$$$336$$$338$$$O	proportion.$$$339$$$350$$$O	The$$$351$$$354$$$O	health$$$355$$$361$$$O	care$$$362$$$366$$$O	product$$$367$$$374$$$O	is$$$375$$$377$$$O	reasonable$$$378$$$388$$$O	in$$$389$$$391$$$O	formula,$$$392$$$400$$$O	unique$$$401$$$407$$$O	in$$$408$$$410$$$O	preparation$$$411$$$422$$$O	method,$$$423$$$430$$$O	and$$$431$$$434$$$O	has$$$435$$$438$$$O	the$$$439$$$442$$$O	efficacy$$$443$$$451$$$O	of$$$452$$$454$$$O	losing$$$455$$$461$$$O	weight.$$$462$$$469$$$O
US20070259826
Chimeric$$$0$$$8$$$O	(Double)$$$9$$$17$$$O	Decoy$$$18$$$23$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	prophylactic,$$$33$$$46$$$O	ameliorative$$$47$$$59$$$O	or$$$60$$$62$$$O	therapeutic$$$63$$$74$$$O	medicament$$$75$$$85$$$O	for$$$86$$$89$$$O	vascular$$$90$$$98$$$O	restenosis,$$$99$$$110$$$O	ischemic$$$111$$$119$$$O	disease,$$$120$$$128$$$O	allergic$$$129$$$137$$$O	disease,$$$138$$$146$$$O	inflammatory$$$147$$$159$$$O	disease,$$$160$$$168$$$O	autoimmune$$$169$$$179$$$O	disease,$$$180$$$188$$$O	or$$$189$$$191$$$O	cancer$$$192$$$198$$$O	metastasis,$$$199$$$210$$$O	invasion$$$211$$$219$$$O	(cancer$$$220$$$227$$$O	metastasis/invasion)$$$228$$$248$$$O	or$$$249$$$251$$$O	cachexia$$$252$$$260$$$O	based$$$261$$$266$$$O	on$$$267$$$269$$$O	the$$$270$$$273$$$O	inhibitory$$$274$$$284$$$O	action$$$285$$$291$$$O	on$$$292$$$294$$$O	a$$$295$$$296$$$O	plural$$$297$$$303$$$O	of$$$304$$$306$$$O	transcriptional$$$307$$$322$$$O	regulatory$$$323$$$333$$$O	factor.$$$334$$$341$$$O	A$$$342$$$343$$$O	chimera$$$344$$$351$$$O	(double)$$$352$$$360$$$O	decoy$$$361$$$366$$$O	of$$$367$$$369$$$O	the$$$370$$$373$$$O	present$$$374$$$381$$$O	invention$$$382$$$391$$$O	has$$$392$$$395$$$O	plural$$$396$$$402$$$O	transcriptional$$$403$$$418$$$O	regulatory$$$419$$$429$$$O	factor$$$430$$$436$$$O	binding$$$437$$$444$$$O	sequences$$$445$$$454$$$O	in$$$455$$$457$$$O	a$$$458$$$459$$$O	single$$$460$$$466$$$O	molecule$$$467$$$475$$$O	thereof.$$$476$$$484$$$O	Thus,$$$485$$$490$$$O	it$$$491$$$493$$$O	is$$$494$$$496$$$O	able$$$497$$$501$$$O	to$$$502$$$504$$$O	inhibit$$$505$$$512$$$O	the$$$513$$$516$$$O	activity$$$517$$$525$$$O	of$$$526$$$528$$$O	plural$$$529$$$535$$$O	transcriptional$$$536$$$551$$$O	regulatory$$$552$$$562$$$O	factors$$$563$$$570$$$O	with$$$571$$$575$$$O	a$$$576$$$577$$$O	single$$$578$$$584$$$O	molecule.$$$585$$$594$$$O	For$$$595$$$598$$$O	example,$$$599$$$607$$$O	stenosis$$$608$$$616$$$O	of$$$617$$$619$$$O	an$$$620$$$622$$$O	anastomosed$$$623$$$634$$$O	site$$$635$$$639$$$O	of$$$640$$$642$$$O	an$$$643$$$645$$$O	artificial$$$646$$$656$$$O	blood$$$657$$$662$$$O	vessel$$$663$$$669$$$O	is$$$670$$$672$$$O	caused$$$673$$$679$$$O	by$$$680$$$682$$$O	thickening$$$683$$$693$$$O	of$$$694$$$696$$$O	the$$$697$$$700$$$O	vascular$$$701$$$709$$$O	intima,$$$710$$$717$$$O	and$$$718$$$721$$$O	this$$$722$$$726$$$O	is$$$727$$$729$$$O	mainly$$$730$$$736$$$O	caused$$$737$$$743$$$O	by$$$744$$$746$$$O	activation$$$747$$$757$$$O	of$$$758$$$760$$$O	cell$$$761$$$765$$$O	proliferation$$$766$$$779$$$O	by$$$780$$$782$$$O	an$$$783$$$785$$$O	inflammatory$$$786$$$798$$$O	reaction$$$799$$$807$$$O	occurring$$$808$$$817$$$O	at$$$818$$$820$$$O	the$$$821$$$824$$$O	anastomosed$$$825$$$836$$$O	site.$$$837$$$842$$$O	Thus,$$$843$$$848$$$O	thickening$$$849$$$859$$$O	of$$$860$$$862$$$O	vessel$$$863$$$869$$$O	walls$$$870$$$875$$$O	can$$$876$$$879$$$O	be$$$880$$$882$$$O	inhibited$$$883$$$892$$$O	by$$$893$$$895$$$O	simultaneously$$$896$$$910$$$O	inhibiting$$$911$$$921$$$O	two$$$922$$$925$$$O	transcriptional$$$926$$$941$$$O	regulatory$$$942$$$952$$$O	factors$$$953$$$960$$$O	involved$$$961$$$969$$$O	in$$$970$$$972$$$O	inflammation$$$973$$$985$$$O	and$$$986$$$989$$$O	cell$$$990$$$994$$$O	proliferation$$$995$$$1008$$$O	by$$$1009$$$1011$$$O	using$$$1012$$$1017$$$O	the$$$1018$$$1021$$$O	chimera$$$1022$$$1029$$$O	decoy$$$1030$$$1035$$$O	of$$$1036$$$1038$$$O	the$$$1039$$$1042$$$O	present$$$1043$$$1050$$$O	invention.$$$1051$$$1061$$$O
US20080021021
Preventive$$$0$$$10$$$O	And/Or$$$11$$$17$$$O	Remedy$$$18$$$24$$$O	For$$$25$$$28$$$O	Lower$$$29$$$34$$$O	Urinary$$$35$$$42$$$O	Tract$$$43$$$48$$$O	Diseases$$$49$$$57$$$O	Containing$$$58$$$68$$$O	Ep4$$$69$$$72$$$O	Agonist$$$73$$$80$$$O
(1)$$$0$$$3$$$O	A$$$4$$$5$$$O	preventive$$$6$$$16$$$O	and/or$$$17$$$23$$$O	a$$$24$$$25$$$O	remedy$$$26$$$32$$$O	for$$$33$$$36$$$O	lower$$$37$$$42$$$O	urinary$$$43$$$50$$$O	tract$$$51$$$56$$$O	diseases$$$57$$$65$$$O	such$$$66$$$70$$$O	as$$$71$$$73$$$O	inflammation$$$74$$$86$$$O	in$$$87$$$89$$$O	the$$$90$$$93$$$O	lower$$$94$$$99$$$O	urinary$$$100$$$107$$$O	tract,$$$108$$$114$$$O	cystitis$$$115$$$123$$$O	(interstitial$$$124$$$137$$$O	cystitis,$$$138$$$147$$$O	etc.)$$$148$$$153$$$O	and$$$154$$$157$$$O	urethritis;$$$158$$$169$$$O	(2)$$$170$$$173$$$O	an$$$174$$$176$$$O	agent$$$177$$$182$$$O	for$$$183$$$186$$$O	improving$$$187$$$196$$$O	bladder$$$197$$$204$$$O	compliance$$$205$$$215$$$O	and/or$$$216$$$222$$$O	bladder$$$223$$$230$$$O	capacity;$$$231$$$240$$$O	and$$$241$$$244$$$O	(3)$$$245$$$248$$$O	an$$$249$$$251$$$O	agent$$$252$$$257$$$O	for$$$258$$$261$$$O	protecting$$$262$$$272$$$O	bladder$$$273$$$280$$$O	mucosa$$$281$$$287$$$O	and/or$$$288$$$294$$$O	bladder$$$295$$$302$$$O	epithelial$$$303$$$313$$$O	cells$$$314$$$319$$$O	and/or$$$320$$$326$$$O	promoting$$$327$$$336$$$O	the$$$337$$$340$$$O	regeneration$$$341$$$353$$$O	thereof;$$$354$$$362$$$O	each$$$363$$$367$$$O	containing$$$368$$$378$$$O	an$$$379$$$381$$$O	EP4$$$382$$$385$$$O	agonist.$$$386$$$394$$$O	An$$$400$$$402$$$O	EP4$$$403$$$406$$$O	agonist$$$407$$$414$$$O	is$$$415$$$417$$$O	useful$$$418$$$424$$$O	in$$$425$$$427$$$O	ameliorating$$$428$$$440$$$O	symptoms$$$441$$$449$$$O	of$$$450$$$452$$$O	lower$$$453$$$458$$$O	urinary$$$459$$$466$$$O	tract$$$467$$$472$$$O	diseases$$$473$$$481$$$O	such$$$482$$$486$$$O	as$$$487$$$489$$$O	(1)$$$490$$$493$$$O	frequent$$$494$$$502$$$O	urination,$$$503$$$513$$$O	(2)$$$514$$$517$$$O	urgency$$$518$$$525$$$O	of$$$526$$$528$$$O	urination,$$$529$$$539$$$O	(3)$$$540$$$543$$$O	pain$$$544$$$548$$$O	in$$$549$$$551$$$O	the$$$552$$$555$$$O	reproductive$$$556$$$568$$$O	organs$$$569$$$575$$$O	and/or$$$576$$$582$$$O	lower$$$583$$$588$$$O	urinary$$$589$$$596$$$O	tract$$$597$$$602$$$O	(for$$$603$$$607$$$O	example,$$$608$$$616$$$O	bladder$$$617$$$624$$$O	pain,$$$625$$$630$$$O	urinary$$$631$$$638$$$O	tract$$$639$$$644$$$O	pain,$$$645$$$650$$$O	vulvar$$$651$$$657$$$O	pain,$$$658$$$663$$$O	vaginal$$$664$$$671$$$O	pain,$$$672$$$677$$$O	scrotal$$$678$$$685$$$O	pain,$$$686$$$691$$$O	perineal$$$692$$$700$$$O	pain,$$$701$$$706$$$O	pelvic$$$707$$$713$$$O	pain,$$$714$$$719$$$O	etc.)$$$720$$$725$$$O	and/or$$$726$$$732$$$O	(4)$$$733$$$736$$$O	discomfort$$$737$$$747$$$O	in$$$748$$$750$$$O	the$$$751$$$754$$$O	reproductive$$$755$$$767$$$O	organs$$$768$$$774$$$O	and/or$$$775$$$781$$$O	lower$$$782$$$787$$$O	urinary$$$788$$$795$$$O	tract.$$$796$$$802$$$O	Among$$$803$$$808$$$O	all,$$$809$$$813$$$O	a$$$814$$$815$$$O	selective$$$816$$$825$$$O	EP4$$$826$$$829$$$O	agonist$$$830$$$837$$$O	is$$$838$$$840$$$O	useful$$$841$$$847$$$O	as$$$848$$$850$$$O	a$$$851$$$852$$$O	preventive$$$853$$$863$$$O	and/or$$$864$$$870$$$O	remedy$$$871$$$877$$$O	for$$$878$$$881$$$O	lower$$$882$$$887$$$O	urinary$$$888$$$895$$$O	tract$$$896$$$901$$$O	diseases$$$902$$$910$$$O	having$$$911$$$917$$$O	no$$$918$$$920$$$O	side$$$921$$$925$$$O	effect.$$$926$$$933$$$O
CA2173839C
Transferrin$$$0$$$11$$$O	compositions$$$12$$$24$$$O	to$$$25$$$27$$$O	alleviate$$$28$$$37$$$O	the$$$38$$$41$$$O	side$$$42$$$46$$$O	effects$$$47$$$54$$$O	of$$$55$$$57$$$O	cytotoxic$$$58$$$67$$$O	drugs$$$68$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	pertains$$$14$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	eutrophic$$$28$$$37$$$O	drug$$$38$$$42$$$O	composition$$$43$$$54$$$O	containing$$$55$$$65$$$O	transferrins,$$$66$$$79$$$O	particularly$$$80$$$92$$$O	human$$$93$$$98$$$O	transferrin.$$$99$$$111$$$O	It$$$112$$$114$$$O	allows$$$115$$$121$$$O	the$$$122$$$125$$$O	toxic$$$126$$$131$$$O	effects$$$132$$$139$$$O	of$$$140$$$142$$$O	cytotoxic$$$143$$$152$$$O	drugs$$$153$$$158$$$O	when$$$159$$$163$$$O	used$$$164$$$168$$$O	at$$$169$$$171$$$O	high$$$172$$$176$$$O	dosages$$$177$$$184$$$O	or$$$185$$$187$$$O	over$$$188$$$192$$$O	prolonged$$$193$$$202$$$O	times,$$$203$$$209$$$O	e.g.,$$$210$$$215$$$O	cyclosporin,$$$216$$$228$$$I	to$$$229$$$231$$$O	be$$$232$$$234$$$O	alleviated$$$235$$$245$$$O	or$$$246$$$248$$$O	even$$$249$$$253$$$O	suppressed.$$$254$$$265$$$O
CN1891225A
Adefovir$$$0$$$8$$$I	dipivoxil$$$9$$$18$$$I	self-emulsifiable$$$19$$$36$$$O	preparation$$$37$$$48$$$O	and$$$49$$$52$$$O	its$$$53$$$56$$$O	preparing$$$57$$$66$$$O	method$$$67$$$73$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	an$$$32$$$34$$$O	adefovir$$$35$$$43$$$I	ester$$$44$$$49$$$I	self-emulsification$$$50$$$69$$$O	preparation$$$70$$$81$$$O	and$$$82$$$85$$$O	its$$$86$$$89$$$O	preparation$$$90$$$101$$$O	method.$$$102$$$109$$$O	Its$$$110$$$113$$$O	composition$$$114$$$125$$$O	includes$$$126$$$134$$$O	0.5-5$$$135$$$140$$$O	portions$$$141$$$149$$$O	of$$$150$$$152$$$O	adefovir$$$153$$$161$$$I	ester.$$$162$$$168$$$I	50-85$$$169$$$174$$$O	portions$$$175$$$183$$$O	of$$$184$$$186$$$O	midchain$$$187$$$195$$$O	oil$$$196$$$199$$$O	and$$$200$$$203$$$O	10-45$$$204$$$209$$$O	portions$$$210$$$218$$$O	of$$$219$$$221$$$O	emulsifying$$$222$$$233$$$O	agent,$$$234$$$240$$$O	all$$$241$$$244$$$O	the$$$245$$$248$$$O	above-mentioned$$$249$$$264$$$O	materials$$$265$$$274$$$O	are$$$275$$$278$$$O	uniformly$$$279$$$288$$$O	mixed,$$$289$$$295$$$O	heated$$$296$$$302$$$O	to$$$303$$$305$$$O	obtain$$$306$$$312$$$O	transparent$$$313$$$324$$$O	solution,$$$325$$$334$$$O	then$$$335$$$339$$$O	cooled$$$340$$$346$$$O	at$$$347$$$349$$$O	normal$$$350$$$356$$$O	temperature$$$357$$$368$$$O	and$$$369$$$372$$$O	made$$$373$$$377$$$O	into$$$378$$$382$$$O	soft$$$383$$$387$$$O	capsule.$$$388$$$396$$$O
CN101317918A
Kidney$$$0$$$6$$$O	tonifying$$$7$$$16$$$O	plaster$$$17$$$24$$$O	medicine$$$25$$$33$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	kidney$$$35$$$41$$$O	reinforcing$$$42$$$53$$$O	plaster.$$$54$$$62$$$O	The$$$63$$$66$$$O	present$$$67$$$74$$$O	invention$$$75$$$84$$$O	is$$$85$$$87$$$O	characterized$$$88$$$101$$$O	by$$$102$$$104$$$O	extracting$$$105$$$115$$$O	concentrated$$$116$$$128$$$O	solution$$$129$$$137$$$O	from$$$138$$$142$$$O	cistanche,$$$143$$$153$$$O	truestar$$$154$$$162$$$O	anisetree,$$$163$$$173$$$O	prepared$$$174$$$182$$$O	rehmannia$$$183$$$192$$$O	rhizome,$$$193$$$201$$$O	malaytea$$$202$$$210$$$O	scurfpea$$$211$$$219$$$O	fruit,$$$220$$$226$$$O	common$$$227$$$233$$$O	cnidum$$$234$$$240$$$O	fruit,$$$241$$$247$$$O	bidentate$$$248$$$257$$$O	achyranthes,$$$258$$$270$$$O	himalayan$$$271$$$280$$$O	teasel$$$281$$$287$$$O	root,$$$288$$$293$$$O	common$$$294$$$300$$$O	fenugreek$$$301$$$310$$$O	seed,$$$311$$$316$$$O	liquorice,$$$317$$$327$$$O	cortex$$$328$$$334$$$O	eucommiae,$$$335$$$345$$$O	dodder$$$346$$$352$$$O	seed,$$$353$$$358$$$O	plantain$$$359$$$367$$$O	seed,$$$368$$$373$$$O	aconite$$$374$$$381$$$O	root,$$$382$$$387$$$O	Chinese$$$388$$$395$$$O	magnoliavine$$$396$$$408$$$O	fruit,$$$409$$$415$$$O	tokay$$$416$$$421$$$O	and$$$422$$$425$$$O	clove;$$$426$$$432$$$O	preparing$$$433$$$442$$$O	extract$$$443$$$450$$$O	powder$$$451$$$457$$$O	to$$$458$$$460$$$O	be$$$461$$$463$$$O	mixed$$$464$$$469$$$O	with$$$470$$$474$$$O	camphor,$$$475$$$483$$$I	borneol$$$484$$$491$$$I	and$$$492$$$495$$$O	menthol;$$$496$$$504$$$I	then$$$505$$$509$$$O	mixing$$$510$$$516$$$O	with$$$517$$$521$$$O	matrigel$$$522$$$530$$$O	and$$$531$$$534$$$O	coating,$$$535$$$543$$$O	thus$$$544$$$548$$$O	obtaining$$$549$$$558$$$O	the$$$559$$$562$$$O	kidney$$$563$$$569$$$O	reinforcing$$$570$$$581$$$O	plaster.$$$582$$$590$$$O
WO2007139464A1
Isoindole$$$0$$$9$$$I	derivatives$$$10$$$21$$$O	useful$$$22$$$28$$$O	for$$$29$$$32$$$O	treating$$$33$$$41$$$O	pain,$$$42$$$47$$$O	gastrointestinal$$$48$$$64$$$O	diseases$$$65$$$73$$$O	and$$$74$$$77$$$O	cancer$$$78$$$84$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	I$$$21$$$22$$$O	or$$$23$$$25$$$O	pharmaceutically$$$26$$$42$$$O	acceptable$$$43$$$53$$$O	salts$$$54$$$59$$$O	thereof:$$$60$$$68$$$O	[Chemical$$$69$$$78$$$O	formula$$$79$$$86$$$O	should$$$87$$$93$$$O	be$$$94$$$96$$$O	inserted$$$97$$$105$$$O	here.$$$106$$$111$$$O	Please$$$112$$$118$$$O	see$$$119$$$122$$$O	paper$$$123$$$128$$$O	copy]$$$129$$$134$$$O	I$$$135$$$136$$$O	wherein$$$137$$$144$$$O	X,$$$145$$$147$$$O	R1,$$$148$$$151$$$O	R2,$$$152$$$155$$$O	R3,$$$156$$$159$$$O	m$$$160$$$161$$$O	and$$$162$$$165$$$O	n$$$166$$$167$$$O	are$$$168$$$171$$$O	as$$$172$$$174$$$O	defined$$$175$$$182$$$O	in$$$183$$$185$$$O	the$$$186$$$189$$$O	specification$$$190$$$203$$$O	as$$$204$$$206$$$O	well$$$207$$$211$$$O	as$$$212$$$214$$$O	salts$$$215$$$220$$$O	and$$$221$$$224$$$O	pharmaceutical$$$225$$$239$$$O	compositions$$$240$$$252$$$O	including$$$253$$$262$$$O	the$$$263$$$266$$$O	compounds$$$267$$$276$$$O	are$$$277$$$280$$$O	prepared.$$$281$$$290$$$O	They$$$291$$$295$$$O	are$$$296$$$299$$$O	useful$$$300$$$306$$$O	in$$$307$$$309$$$O	therapy,$$$310$$$318$$$O	in$$$319$$$321$$$O	particular$$$322$$$332$$$O	in$$$333$$$335$$$O	the$$$336$$$339$$$O	management$$$340$$$350$$$O	of$$$351$$$353$$$O	pain.$$$354$$$359$$$O
EP2063883A2
Binding$$$0$$$7$$$O	interaction$$$8$$$19$$$O	of$$$20$$$22$$$O	proanthocyanidins$$$23$$$40$$$I	with$$$41$$$45$$$O	bacteria$$$46$$$54$$$O	and$$$55$$$58$$$O	bacterial$$$59$$$68$$$O	components$$$69$$$79$$$O
A$$$0$$$1$$$O	composition$$$2$$$13$$$O	having:$$$14$$$21$$$O	a$$$22$$$23$$$O	proanthocyanidin:$$$24$$$41$$$I	and$$$42$$$45$$$O	a$$$46$$$47$$$O	macromolecule,$$$48$$$62$$$O	an$$$63$$$65$$$O	assembly$$$66$$$74$$$O	of$$$75$$$77$$$O	macromolecules,$$$78$$$93$$$O	a$$$94$$$95$$$O	semi-solid,$$$96$$$107$$$O	or$$$108$$$110$$$O	a$$$111$$$112$$$O	solid$$$113$$$118$$$O	surface$$$119$$$126$$$O	to$$$127$$$129$$$O	which$$$130$$$135$$$O	the$$$136$$$139$$$O	proanthocyanidin$$$140$$$156$$$I	is$$$157$$$159$$$O	immobilized.$$$160$$$172$$$O	A$$$173$$$174$$$O	composition$$$175$$$186$$$O	having$$$187$$$193$$$O	proanthocyanidin$$$194$$$210$$$I	compounds$$$211$$$220$$$O	having$$$221$$$227$$$O	an$$$228$$$230$$$O	average$$$231$$$238$$$O	degree$$$239$$$245$$$O	of$$$246$$$248$$$O	polymerization$$$249$$$263$$$O	of$$$264$$$266$$$O	at$$$267$$$269$$$O	least$$$270$$$275$$$O	about$$$276$$$281$$$O	6.$$$282$$$284$$$O	A$$$285$$$286$$$O	method$$$287$$$293$$$O	of$$$294$$$296$$$O	administering$$$297$$$310$$$O	to$$$311$$$313$$$O	an$$$314$$$316$$$O	immunosuppressed$$$317$$$333$$$O	patient$$$334$$$341$$$O	or$$$342$$$344$$$O	a$$$345$$$346$$$O	patient$$$347$$$354$$$O	diagnosed$$$355$$$364$$$O	with$$$365$$$369$$$O	sepsis$$$370$$$376$$$O	or$$$377$$$379$$$O	septic$$$380$$$386$$$O	shock$$$387$$$392$$$O	a$$$393$$$394$$$O	composition$$$395$$$406$$$O	having$$$407$$$413$$$O	a$$$414$$$415$$$O	proanthocyanidin.$$$416$$$433$$$I	A$$$434$$$435$$$O	method$$$436$$$442$$$O	of$$$443$$$445$$$O	administering$$$446$$$459$$$O	to$$$460$$$462$$$O	a$$$463$$$464$$$O	patient$$$465$$$472$$$O	diagnosed$$$473$$$482$$$O	with$$$483$$$487$$$O	a$$$488$$$489$$$O	gram$$$490$$$494$$$O	negative$$$495$$$503$$$O	bacterial$$$504$$$513$$$O	infection$$$514$$$523$$$O	a$$$524$$$525$$$O	composition$$$526$$$537$$$O	having$$$538$$$544$$$O	proanthocyanidin$$$545$$$561$$$I	compounds$$$562$$$571$$$O	having$$$572$$$578$$$O	an$$$579$$$581$$$O	average$$$582$$$589$$$O	degree$$$590$$$596$$$O	of$$$597$$$599$$$O	polymerization$$$600$$$614$$$O	of$$$615$$$617$$$O	at$$$618$$$620$$$O	least$$$621$$$626$$$O	about$$$627$$$632$$$O	6.$$$633$$$635$$$O
EP1408950B1
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	treating$$$11$$$19$$$O	cytokine$$$20$$$28$$$O	mediated$$$29$$$37$$$O	diseases$$$38$$$46$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	methods$$$14$$$21$$$O	of$$$22$$$24$$$O	treating$$$25$$$33$$$O	certain$$$34$$$41$$$O	cytokine$$$42$$$50$$$O	mediated$$$51$$$59$$$O	diseases$$$60$$$68$$$O	or$$$69$$$71$$$O	conditionsusing$$$72$$$87$$$O	novel$$$88$$$93$$$O	aromatic$$$94$$$102$$$I	heterocyclic$$$103$$$115$$$I	compounds$$$116$$$125$$$O	of$$$126$$$128$$$O	the$$$129$$$132$$$O	formula$$$133$$$140$$$O	(I)$$$141$$$144$$$O	wherein$$$145$$$152$$$O	Ar1,$$$153$$$157$$$O	Ar2,$$$158$$$162$$$O	L,$$$163$$$165$$$O	Q$$$166$$$167$$$O	and$$$168$$$171$$$O	X$$$172$$$173$$$O	are$$$174$$$177$$$O	described$$$178$$$187$$$O	herein.$$$188$$$195$$$O
WO2008035757A1
Jelly-like$$$0$$$10$$$O	food$$$11$$$15$$$O	containing$$$16$$$26$$$O	ubiquinol$$$27$$$36$$$O
A$$$0$$$1$$$O	jelly-like$$$2$$$12$$$O	food$$$13$$$17$$$O	containing$$$18$$$28$$$O	ubiquinol.$$$29$$$39$$$O	It$$$41$$$43$$$O	is$$$44$$$46$$$O	found$$$47$$$52$$$O	out$$$53$$$56$$$O	that$$$57$$$61$$$O	ubiquinol$$$62$$$71$$$O	can$$$72$$$75$$$O	be$$$76$$$78$$$O	stably$$$79$$$85$$$O	and$$$86$$$89$$$O	homogeneously$$$90$$$103$$$O	dispersed$$$104$$$113$$$O	by$$$114$$$116$$$O	using$$$117$$$122$$$O	a$$$123$$$124$$$O	gelling$$$125$$$132$$$O	agent$$$133$$$138$$$O	as$$$139$$$141$$$O	a$$$142$$$143$$$O	substitute$$$144$$$154$$$O	for$$$155$$$158$$$O	a$$$159$$$160$$$O	fat$$$161$$$164$$$O	or$$$165$$$167$$$O	the$$$168$$$171$$$O	like.$$$172$$$177$$$O	Thus,$$$179$$$184$$$O	it$$$185$$$187$$$O	becomes$$$188$$$195$$$O	possible$$$196$$$204$$$O	to$$$205$$$207$$$O	easily$$$208$$$214$$$O	and$$$215$$$218$$$O	efficiently$$$219$$$230$$$O	supply$$$231$$$237$$$O	ubiquinol,$$$238$$$248$$$O	which$$$249$$$254$$$O	is$$$255$$$257$$$O	essentially$$$258$$$269$$$O	required$$$270$$$278$$$O	by$$$279$$$281$$$O	living$$$282$$$288$$$O	bodies$$$289$$$295$$$O	but$$$296$$$299$$$O	frequently$$$300$$$310$$$O	shows$$$311$$$316$$$O	a$$$317$$$318$$$O	tendency$$$319$$$327$$$O	to$$$328$$$330$$$O	decrease$$$331$$$339$$$O	or$$$340$$$342$$$O	shortage,$$$343$$$352$$$O	not$$$353$$$356$$$O	only$$$357$$$361$$$O	to$$$362$$$364$$$O	normal$$$365$$$371$$$O	people$$$372$$$378$$$O	but$$$379$$$382$$$O	also$$$383$$$387$$$O	to$$$388$$$390$$$O	those$$$391$$$396$$$O	having$$$397$$$403$$$O	disorders$$$404$$$413$$$O	in$$$414$$$416$$$O	swallowing$$$417$$$427$$$O	ability$$$428$$$435$$$O	such$$$436$$$440$$$O	as$$$441$$$443$$$O	aged$$$444$$$448$$$O	persons$$$449$$$456$$$O	and$$$457$$$460$$$O	ill$$$461$$$464$$$O	persons.$$$465$$$473$$$O	Because$$$475$$$482$$$O	of$$$483$$$485$$$O	having$$$486$$$492$$$O	a$$$493$$$494$$$O	low$$$495$$$498$$$O	fat$$$499$$$502$$$O	content,$$$503$$$511$$$O	the$$$512$$$515$$$O	above-described$$$516$$$531$$$O	jelly-like$$$532$$$542$$$O	food$$$543$$$547$$$O	is$$$548$$$550$$$O	advantageous$$$551$$$563$$$O	for$$$564$$$567$$$O	modern$$$568$$$574$$$O	people$$$575$$$581$$$O	with$$$582$$$586$$$O	a$$$587$$$588$$$O	tendency$$$589$$$597$$$O	to$$$598$$$600$$$O	take$$$601$$$605$$$O	too$$$606$$$609$$$O	much$$$610$$$614$$$O	energy.$$$615$$$622$$$O
CN102614292A
Radix$$$0$$$5$$$O	angelicae$$$6$$$15$$$O	antiphlogosis$$$16$$$29$$$O	powder$$$30$$$36$$$O
Radix$$$0$$$5$$$O	angelicae$$$6$$$15$$$O	antiphlogosis$$$16$$$29$$$O	powder$$$30$$$36$$$O	is$$$37$$$39$$$O	a$$$40$$$41$$$O	new$$$42$$$45$$$O	technique$$$46$$$55$$$O	in$$$56$$$58$$$O	treating$$$59$$$67$$$O	tonsillitis.$$$68$$$80$$$O	The$$$81$$$84$$$O	formula$$$85$$$92$$$O	includes:$$$93$$$102$$$O	10g$$$103$$$106$$$O	of$$$107$$$109$$$O	burdock,$$$110$$$118$$$O	10g$$$119$$$122$$$O	of$$$123$$$125$$$O	Gardenia$$$126$$$134$$$O	jasminoides$$$135$$$146$$$O	Ellis,$$$147$$$153$$$O	10g$$$154$$$157$$$O	of$$$158$$$160$$$O	sodium$$$161$$$167$$$I	borate,$$$168$$$175$$$I	10g$$$176$$$179$$$O	of$$$180$$$182$$$O	Platycodon$$$183$$$193$$$O	grandiflorum,$$$194$$$207$$$O	10g$$$208$$$211$$$O	of$$$212$$$214$$$O	Mentha$$$215$$$221$$$O	haplocalyx,$$$222$$$233$$$O	10g$$$234$$$237$$$O	radix$$$238$$$243$$$O	angelicae,$$$244$$$254$$$O	10g$$$255$$$258$$$O	of$$$259$$$261$$$O	Coptis$$$262$$$268$$$O	chinensis,$$$269$$$279$$$O	10g$$$280$$$283$$$O	of$$$284$$$286$$$O	borneol,$$$287$$$295$$$I	10g$$$296$$$299$$$O	of$$$300$$$302$$$O	Artemisia$$$303$$$312$$$O	apiacea,$$$313$$$321$$$O	10g$$$322$$$325$$$O	of$$$326$$$328$$$O	mentholum,$$$329$$$339$$$O	10g$$$340$$$343$$$O	of$$$344$$$346$$$O	camphor,$$$347$$$355$$$I	10g$$$356$$$359$$$O	of$$$360$$$362$$$O	Asarum$$$363$$$369$$$O	sieboldi$$$370$$$378$$$O	Mig,$$$379$$$383$$$O	10g$$$384$$$387$$$O	of$$$388$$$390$$$O	Scutellaria$$$391$$$402$$$O	baicalensis,$$$403$$$415$$$O	10g$$$416$$$419$$$O	of$$$420$$$422$$$O	pepper$$$423$$$429$$$O	and$$$430$$$433$$$O	10g$$$434$$$437$$$O	of$$$438$$$440$$$O	liquorice.$$$441$$$451$$$O	The$$$452$$$455$$$O	pharmacologic$$$456$$$469$$$O	action$$$470$$$476$$$O	of$$$477$$$479$$$O	the$$$480$$$483$$$O	formula$$$484$$$491$$$O	includesis$$$492$$$502$$$O	that:$$$503$$$508$$$O	clearing$$$509$$$517$$$O	away$$$518$$$522$$$O	heat$$$523$$$527$$$O	and$$$528$$$531$$$O	toxic$$$532$$$537$$$O	materials,$$$538$$$548$$$O	relieving$$$549$$$558$$$O	swelling$$$559$$$567$$$O	and$$$568$$$571$$$O	pain,$$$572$$$577$$$O	purging$$$578$$$585$$$O	intense$$$586$$$593$$$O	heat$$$594$$$598$$$O	and$$$599$$$602$$$O	dissolving$$$603$$$613$$$O	phlegm,$$$614$$$621$$$O	eliminating$$$622$$$633$$$O	phlegm$$$634$$$640$$$O	and$$$641$$$644$$$O	discharging$$$645$$$656$$$O	pus,$$$657$$$661$$$O	clearing$$$662$$$670$$$O	heat$$$671$$$675$$$O	and$$$676$$$679$$$O	purging$$$680$$$687$$$O	intense$$$688$$$695$$$O	heat,$$$696$$$701$$$O	relieving$$$702$$$711$$$O	exterior$$$712$$$720$$$O	syndrome$$$721$$$729$$$O	and$$$730$$$733$$$O	eliminating$$$734$$$745$$$O	dampness,$$$746$$$755$$$O	evacuating$$$756$$$766$$$O	wind$$$767$$$771$$$O	heat,$$$772$$$777$$$O	relieving$$$778$$$787$$$O	exterior$$$788$$$796$$$O	syndrome$$$797$$$805$$$O	and$$$806$$$809$$$O	dispelling$$$810$$$820$$$O	wind,$$$821$$$826$$$O	moistening$$$827$$$837$$$O	lung$$$838$$$842$$$O	and$$$843$$$846$$$O	reducing$$$847$$$855$$$O	phlegm,$$$856$$$863$$$O	expelling$$$864$$$873$$$O	phlegm$$$874$$$880$$$O	to$$$881$$$883$$$O	arrest$$$884$$$890$$$O	coughing,$$$891$$$900$$$O	dissolving$$$901$$$911$$$O	phlegm$$$912$$$918$$$O	and$$$919$$$922$$$O	breaking$$$923$$$931$$$O	deposit,$$$932$$$940$$$O	removing$$$941$$$949$$$O	nebula$$$950$$$956$$$O	and$$$957$$$960$$$O	relieving$$$961$$$970$$$O	pain,$$$971$$$976$$$O	breaking$$$977$$$985$$$O	deposit$$$986$$$993$$$O	and$$$994$$$997$$$O	relieving$$$998$$$1007$$$O	pain$$$1008$$$1012$$$O	and$$$1013$$$1016$$$O	eliminating$$$1017$$$1028$$$O	throat$$$1029$$$1035$$$O	pain$$$1036$$$1040$$$O	and$$$1041$$$1044$$$O	ulcerative$$$1045$$$1055$$$O	carbuncle$$$1056$$$1065$$$O	and$$$1066$$$1069$$$O	sore-toxin.$$$1070$$$1081$$$O	Patients$$$1082$$$1090$$$O	taking$$$1091$$$1097$$$O	the$$$1098$$$1101$$$O	radix$$$1102$$$1107$$$O	angelicae$$$1108$$$1117$$$O	antiphlogosis$$$1118$$$1131$$$O	powder$$$1132$$$1138$$$O	can$$$1139$$$1142$$$O	fast$$$1143$$$1147$$$O	eliminate$$$1148$$$1157$$$O	pain$$$1158$$$1162$$$O	and$$$1163$$$1166$$$O	can$$$1167$$$1170$$$O	be$$$1171$$$1173$$$O	healed$$$1174$$$1180$$$O	with$$$1181$$$1185$$$O	no$$$1186$$$1188$$$O	undesirable$$$1189$$$1200$$$O	effects,$$$1201$$$1209$$$O	and$$$1210$$$1213$$$O	tonsillitis$$$1214$$$1225$$$O	of$$$1226$$$1228$$$O	the$$$1229$$$1232$$$O	cured$$$1233$$$1238$$$O	patients$$$1239$$$1247$$$O	does$$$1248$$$1252$$$O	not$$$1253$$$1256$$$O	reappear.$$$1257$$$1266$$$O	Proved$$$1267$$$1273$$$O	by$$$1274$$$1276$$$O	cured$$$1277$$$1282$$$O	cases,$$$1283$$$1289$$$O	the$$$1290$$$1293$$$O	radix$$$1294$$$1299$$$O	angelicae$$$1300$$$1309$$$O	antiphlogosis$$$1310$$$1323$$$O	powder$$$1324$$$1330$$$O	is$$$1331$$$1333$$$O	the$$$1334$$$1337$$$O	only$$$1338$$$1342$$$O	effective$$$1343$$$1352$$$O	new$$$1353$$$1356$$$O	technique$$$1357$$$1366$$$O	for$$$1367$$$1370$$$O	treating$$$1371$$$1379$$$O	the$$$1380$$$1383$$$O	tonsillitis$$$1384$$$1395$$$O	and$$$1396$$$1399$$$O	solves$$$1400$$$1406$$$O	the$$$1407$$$1410$$$O	puzzle$$$1411$$$1417$$$O	that$$$1418$$$1422$$$O	the$$$1423$$$1426$$$O	tonsillitis$$$1427$$$1438$$$O	cannot$$$1439$$$1445$$$O	be$$$1446$$$1448$$$O	thoroughly$$$1449$$$1459$$$O	cured$$$1460$$$1465$$$O	by$$$1466$$$1468$$$O	western$$$1469$$$1476$$$O	medicine$$$1477$$$1485$$$O	and$$$1486$$$1489$$$O	other$$$1490$$$1495$$$O	drugs$$$1496$$$1501$$$O	in$$$1502$$$1504$$$O	a$$$1505$$$1506$$$O	long$$$1507$$$1511$$$O	period.$$$1512$$$1519$$$O
WO2013124701A3
Homo-$$$0$$$5$$$O	and$$$6$$$9$$$O	heterodimeric$$$10$$$23$$$O	smac$$$24$$$28$$$O	mimetic$$$29$$$36$$$O	compounds$$$37$$$46$$$O	as$$$47$$$49$$$O	apoptosis$$$50$$$59$$$O	inducers$$$60$$$68$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	conformationally$$$33$$$49$$$O	constrained$$$50$$$61$$$O	homo-$$$62$$$67$$$O	and$$$68$$$71$$$O	heterodimeric$$$72$$$85$$$O	mimetics$$$86$$$94$$$O	of$$$95$$$97$$$O	Smac$$$98$$$102$$$O	with$$$103$$$107$$$O	function$$$108$$$116$$$O	as$$$117$$$119$$$O	inhibitors$$$120$$$130$$$O	of$$$131$$$133$$$O	Inhibitor$$$134$$$143$$$O	of$$$144$$$146$$$O	Apoptosis$$$147$$$156$$$O	Proteins$$$157$$$165$$$O	(IAPs),$$$166$$$173$$$O	the$$$174$$$177$$$O	invention$$$178$$$187$$$O	also$$$188$$$192$$$O	relates$$$193$$$200$$$O	to$$$201$$$203$$$O	the$$$204$$$207$$$O	use$$$208$$$211$$$O	of$$$212$$$214$$$O	these$$$215$$$220$$$O	compounds$$$221$$$230$$$O	in$$$231$$$233$$$O	therapy,$$$234$$$242$$$O	wherein$$$243$$$250$$$O	the$$$251$$$254$$$O	induction$$$255$$$264$$$O	of$$$265$$$267$$$O	apoptotic$$$268$$$277$$$O	cell$$$278$$$282$$$O	death$$$283$$$288$$$O	is$$$289$$$291$$$O	beneficial,$$$292$$$303$$$O	especially$$$304$$$314$$$O	in$$$315$$$317$$$O	the$$$318$$$321$$$O	treatment$$$322$$$331$$$O	of$$$332$$$334$$$O	cancer,$$$335$$$342$$$O	alone$$$343$$$348$$$O	or$$$349$$$351$$$O	in$$$352$$$354$$$O	combination$$$355$$$366$$$O	with$$$367$$$371$$$O	other$$$372$$$377$$$O	active$$$378$$$384$$$O	ingredients.$$$385$$$397$$$O
CN102861039A
Medicinal$$$0$$$9$$$O	formulation$$$10$$$21$$$O	for$$$22$$$25$$$O	treating$$$26$$$34$$$O	beriberi$$$35$$$43$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medicinal$$$27$$$36$$$O	formulation$$$37$$$48$$$O	for$$$49$$$52$$$O	treating$$$53$$$61$$$O	beriberi,$$$62$$$71$$$O	which$$$72$$$77$$$O	is$$$78$$$80$$$O	obtained$$$81$$$89$$$O	by$$$90$$$92$$$O	mixing$$$93$$$99$$$O	alcohol,$$$100$$$108$$$I	salicylic$$$109$$$118$$$I	acid,$$$119$$$124$$$I	benzoic$$$125$$$132$$$I	acid,$$$133$$$138$$$I	penicillin$$$139$$$149$$$I	and$$$150$$$153$$$O	rivanol.$$$154$$$162$$$I	The$$$163$$$166$$$O	medicinal$$$167$$$176$$$O	formulation$$$177$$$188$$$O	provided$$$189$$$197$$$O	by$$$198$$$200$$$O	the$$$201$$$204$$$O	invention$$$205$$$214$$$O	is$$$215$$$217$$$O	short$$$218$$$223$$$O	in$$$224$$$226$$$O	course$$$227$$$233$$$O	of$$$234$$$236$$$O	treatment$$$237$$$246$$$O	which$$$247$$$252$$$O	lasts$$$253$$$258$$$O	for$$$259$$$262$$$O	3$$$263$$$264$$$O	to$$$265$$$267$$$O	5$$$268$$$269$$$O	days.$$$270$$$275$$$O	The$$$276$$$279$$$O	medicine$$$280$$$288$$$O	can$$$289$$$292$$$O	be$$$293$$$295$$$O	externally$$$296$$$306$$$O	applied$$$307$$$314$$$O	and$$$315$$$318$$$O	is$$$319$$$321$$$O	applied$$$322$$$329$$$O	to$$$330$$$332$$$O	the$$$333$$$336$$$O	affected$$$337$$$345$$$O	parts$$$346$$$351$$$O	for$$$352$$$355$$$O	one$$$356$$$359$$$O	to$$$360$$$362$$$O	two$$$363$$$366$$$O	courses$$$367$$$374$$$O	of$$$375$$$377$$$O	treatment,$$$378$$$388$$$O	and$$$389$$$392$$$O	the$$$393$$$396$$$O	cure$$$397$$$401$$$O	rate$$$402$$$406$$$O	is$$$407$$$409$$$O	above$$$410$$$415$$$O	90%$$$416$$$419$$$O	and$$$420$$$423$$$O	the$$$424$$$427$$$O	radical$$$428$$$435$$$O	treatment$$$436$$$445$$$O	persons$$$446$$$453$$$O	reach$$$454$$$459$$$O	up$$$460$$$462$$$O	to$$$463$$$465$$$O	85%;$$$466$$$470$$$O	and$$$471$$$474$$$O	the$$$475$$$478$$$O	medicine$$$479$$$487$$$O	is$$$488$$$490$$$O	safe$$$491$$$495$$$O	to$$$496$$$498$$$O	use$$$499$$$502$$$O	and$$$503$$$506$$$O	free$$$507$$$511$$$O	from$$$512$$$516$$$O	toxic$$$517$$$522$$$O	and$$$523$$$526$$$O	side$$$527$$$531$$$O	effects.$$$532$$$540$$$O
US20100247659
Phenylphthalimide$$$0$$$17$$$I	analogs$$$18$$$25$$$O	for$$$26$$$29$$$O	treating$$$30$$$38$$$O	diabetic$$$39$$$47$$$O	macular$$$48$$$55$$$O	edema$$$56$$$61$$$O
Novel$$$0$$$5$$$O	methods$$$6$$$13$$$O	are$$$14$$$17$$$O	provided$$$18$$$26$$$O	to$$$27$$$29$$$O	prevent$$$30$$$37$$$O	blindness$$$38$$$47$$$O	associated$$$48$$$58$$$O	with$$$59$$$63$$$O	diabetic$$$64$$$72$$$O	macular$$$73$$$80$$$O	edema$$$81$$$86$$$O	by$$$87$$$89$$$O	administration$$$90$$$104$$$O	of$$$105$$$107$$$O	a$$$108$$$109$$$O	phenylphthalimide$$$110$$$127$$$I	analog.$$$128$$$135$$$O	Additionally,$$$136$$$149$$$O	sustainability$$$150$$$164$$$O	of$$$165$$$167$$$O	the$$$168$$$171$$$O	effect$$$172$$$178$$$O	of$$$179$$$181$$$O	administration$$$182$$$196$$$O	of$$$197$$$199$$$O	the$$$200$$$203$$$O	phenylphthalimide$$$204$$$221$$$I	analog$$$222$$$228$$$O	is$$$229$$$231$$$O	improved$$$232$$$240$$$O	via$$$241$$$244$$$O	encapsulation$$$245$$$258$$$O	with$$$259$$$263$$$O	poly(lactic-co-glycolic$$$264$$$287$$$I	acid)$$$288$$$293$$$I	nanoparticles.$$$294$$$308$$$O	Finally,$$$309$$$317$$$O	a$$$318$$$319$$$O	novel$$$320$$$325$$$O	method$$$326$$$332$$$O	for$$$333$$$336$$$O	synthesizing$$$337$$$349$$$O	(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione$$$350$$$404$$$I	is$$$405$$$407$$$O	disclosed.$$$408$$$418$$$O
US20120100218
Intralymphatic$$$0$$$14$$$O	Chemotherapy$$$15$$$27$$$O	Drug$$$28$$$32$$$O	Carriers$$$33$$$41$$$O
A$$$0$$$1$$$O	chemotherapeutic$$$2$$$18$$$O	composition$$$19$$$30$$$O	can$$$31$$$34$$$O	be$$$35$$$37$$$O	configured$$$38$$$48$$$O	for$$$49$$$52$$$O	subcutaneous$$$53$$$65$$$O	administration$$$66$$$80$$$O	for$$$81$$$84$$$O	preferential$$$85$$$97$$$O	intralymphatic$$$98$$$112$$$O	accumulation$$$113$$$125$$$O	while$$$126$$$131$$$O	also$$$132$$$136$$$O	providing$$$137$$$146$$$O	a$$$147$$$148$$$O	therapeutic$$$149$$$160$$$O	systemic$$$161$$$169$$$O	concentration$$$170$$$183$$$O	that$$$184$$$188$$$O	is$$$189$$$191$$$O	not$$$192$$$195$$$O	toxic.$$$196$$$202$$$O	The$$$203$$$206$$$O	composition$$$207$$$218$$$O	can$$$219$$$222$$$O	include$$$223$$$230$$$O	a$$$231$$$232$$$O	pharmaceutically$$$233$$$249$$$O	acceptable$$$250$$$260$$$O	carrier,$$$261$$$269$$$O	and$$$270$$$273$$$O	a$$$274$$$275$$$O	nanoconjugate$$$276$$$289$$$O	configured$$$290$$$300$$$O	for$$$301$$$304$$$O	preferential$$$305$$$317$$$O	intralymphatic$$$318$$$332$$$O	accumulation$$$333$$$345$$$O	after$$$346$$$351$$$O	subcutaneous$$$352$$$364$$$O	administration.$$$365$$$380$$$O	The$$$381$$$384$$$O	nanoconjugate$$$385$$$398$$$O	can$$$399$$$402$$$O	include$$$403$$$410$$$O	a$$$411$$$412$$$O	nanocarrier$$$413$$$424$$$O	configured$$$425$$$435$$$O	for$$$436$$$439$$$O	preferential$$$440$$$452$$$O	intralymphatic$$$453$$$467$$$O	accumulation$$$468$$$480$$$O	after$$$481$$$486$$$O	subcutaneous$$$487$$$499$$$O	or$$$500$$$502$$$O	interstitial$$$503$$$515$$$O	administration,$$$516$$$531$$$O	and$$$532$$$535$$$O	a$$$536$$$537$$$O	plurality$$$538$$$547$$$O	of$$$548$$$550$$$O	chemotherapeutic$$$551$$$567$$$O	agents$$$568$$$574$$$O	coupled$$$575$$$582$$$O	to$$$583$$$585$$$O	the$$$586$$$589$$$O	nanocarrier.$$$590$$$602$$$O	The$$$603$$$606$$$O	nanoconjugate$$$607$$$620$$$O	can$$$621$$$624$$$O	have$$$625$$$629$$$O	a$$$630$$$631$$$O	dimension$$$632$$$641$$$O	of$$$642$$$644$$$O	about$$$645$$$650$$$O	10$$$651$$$653$$$O	nm$$$654$$$656$$$O	to$$$657$$$659$$$O	about$$$660$$$665$$$O	5$$$666$$$667$$$O	nm.$$$668$$$671$$$O	Also,$$$672$$$677$$$O	the$$$678$$$681$$$O	nanoconjugate$$$682$$$695$$$O	can$$$696$$$699$$$O	be$$$700$$$702$$$O	loaded$$$703$$$709$$$O	with$$$710$$$714$$$O	the$$$715$$$718$$$O	chemotherapeutic$$$719$$$735$$$O	agents$$$736$$$742$$$O	from$$$743$$$747$$$O	about$$$748$$$753$$$O	10%$$$754$$$757$$$O	to$$$758$$$760$$$O	about$$$761$$$766$$$O	50%$$$767$$$770$$$O	w/w.$$$771$$$775$$$O	The$$$776$$$779$$$O	nanocarrier$$$780$$$791$$$O	can$$$792$$$795$$$O	be$$$796$$$798$$$O	a$$$799$$$800$$$O	hyaluronan$$$801$$$811$$$O	polymer$$$812$$$819$$$O	of$$$820$$$822$$$O	about$$$823$$$828$$$O	3$$$829$$$830$$$O	kDa$$$831$$$834$$$O	to$$$835$$$837$$$O	about$$$838$$$843$$$O	50$$$844$$$846$$$O	kDa.$$$847$$$851$$$O	Alternatively,$$$852$$$866$$$O	the$$$867$$$870$$$O	nanocarrier$$$871$$$882$$$O	can$$$883$$$886$$$O	be$$$887$$$889$$$O	a$$$890$$$891$$$O	dendrimer.$$$892$$$902$$$O
CN101390854A
Medical$$$0$$$7$$$O	composition$$$8$$$19$$$O	containing$$$20$$$30$$$O	riluzole$$$31$$$39$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	stable$$$26$$$32$$$O	medicinal$$$33$$$42$$$O	combination$$$43$$$54$$$O	which$$$55$$$60$$$O	contains$$$61$$$69$$$O	active$$$70$$$76$$$O	ingredient$$$77$$$87$$$O	riluzole$$$88$$$96$$$I	and$$$97$$$100$$$O	pharmaceutical$$$101$$$115$$$O	auxiliary$$$116$$$125$$$O	material.$$$126$$$135$$$O	The$$$136$$$139$$$O	medicine$$$140$$$148$$$O	combination$$$149$$$160$$$O	is$$$161$$$163$$$O	mainly$$$164$$$170$$$O	used$$$171$$$175$$$O	for$$$176$$$179$$$O	the$$$180$$$183$$$O	clinical$$$184$$$192$$$O	treatment$$$193$$$202$$$O	of$$$203$$$205$$$O	amyotrophic$$$206$$$217$$$O	lateral$$$218$$$225$$$O	sclerosis.$$$226$$$236$$$O
CA2284863C
Active$$$0$$$6$$$O	substance$$$7$$$16$$$O	and$$$17$$$20$$$O	composition$$$21$$$32$$$O	inhibiting$$$33$$$43$$$O	tumorous$$$44$$$52$$$O	proliferation$$$53$$$66$$$O	in$$$67$$$69$$$O	ectoderm$$$70$$$78$$$O	derived$$$79$$$86$$$O	tissues$$$87$$$94$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	substance$$$27$$$36$$$O	inhibiting$$$37$$$47$$$O	tumorous$$$48$$$56$$$O	proliferation$$$57$$$70$$$O	in$$$71$$$73$$$O	ectoderm$$$74$$$82$$$O	derived$$$83$$$90$$$O	tissues$$$91$$$98$$$O	and$$$99$$$102$$$O	to$$$103$$$105$$$O	a$$$106$$$107$$$O	composition$$$108$$$119$$$O	containing$$$120$$$130$$$O	such$$$131$$$135$$$O	substance.$$$136$$$146$$$O	The$$$147$$$150$$$O	active$$$151$$$157$$$O	substance$$$158$$$167$$$O	and$$$168$$$171$$$O	composition$$$172$$$183$$$O	according$$$184$$$193$$$O	to$$$194$$$196$$$O	the$$$197$$$200$$$O	invention$$$201$$$210$$$O	are$$$211$$$214$$$O	characterized$$$215$$$228$$$O	in$$$229$$$231$$$O	that$$$232$$$236$$$O	human$$$237$$$242$$$O	or$$$243$$$245$$$O	animal$$$246$$$252$$$O	derived$$$253$$$260$$$O	fertilized$$$261$$$271$$$O	ovum,$$$272$$$277$$$O	preferably$$$278$$$288$$$O	derived$$$289$$$296$$$O	from$$$297$$$301$$$O	sea$$$302$$$305$$$O	water$$$306$$$311$$$O	fish$$$312$$$316$$$O	or$$$317$$$319$$$O	fresh$$$320$$$325$$$O	water$$$326$$$331$$$O	fish$$$332$$$336$$$O	or$$$337$$$339$$$O	amphibian$$$340$$$349$$$O	is$$$350$$$352$$$O	subjected$$$353$$$362$$$O	to$$$363$$$365$$$O	cell$$$366$$$370$$$O	wall$$$371$$$375$$$O	destruction$$$376$$$387$$$O	after$$$388$$$393$$$O	24$$$394$$$396$$$O	hours$$$397$$$402$$$O	at$$$403$$$405$$$O	most,$$$406$$$411$$$O	preferably$$$412$$$422$$$O	after$$$423$$$428$$$O	14-16$$$429$$$434$$$O	hours$$$435$$$440$$$O	after$$$441$$$446$$$O	fertilization,$$$447$$$461$$$O	then$$$462$$$466$$$O	the$$$467$$$470$$$O	material$$$471$$$479$$$O	is$$$480$$$482$$$O	ultracentrifuged,$$$483$$$500$$$O	the$$$501$$$504$$$O	supernatant$$$505$$$516$$$O	is$$$517$$$519$$$O	separated,$$$520$$$530$$$O	the$$$531$$$534$$$O	sediment$$$535$$$543$$$O	is$$$544$$$546$$$O	homogenized,$$$547$$$559$$$O	then$$$560$$$564$$$O	ultracentrifuged$$$565$$$581$$$O	several$$$582$$$589$$$O	times,$$$590$$$596$$$O	and$$$597$$$600$$$O	each$$$601$$$605$$$O	time$$$606$$$610$$$O	the$$$611$$$614$$$O	supernatant$$$615$$$626$$$O	and$$$627$$$630$$$O	the$$$631$$$634$$$O	sediment$$$635$$$643$$$O	are$$$644$$$647$$$O	separated,$$$648$$$658$$$O	thereafter$$$659$$$669$$$O	all$$$670$$$673$$$O	supernatant$$$674$$$685$$$O	fractions$$$686$$$695$$$O	are$$$696$$$699$$$O	combined$$$700$$$708$$$O	and$$$709$$$712$$$O	centrifuged$$$713$$$724$$$O	preferably$$$725$$$735$$$O	at$$$736$$$738$$$O	8,000-15,000$$$739$$$751$$$O	rpm,$$$752$$$756$$$O	the$$$757$$$760$$$O	supernatant$$$761$$$772$$$O	obtained$$$773$$$781$$$O	is$$$782$$$784$$$O	separated$$$785$$$794$$$O	and$$$795$$$798$$$O	diluted$$$799$$$806$$$O	with$$$807$$$811$$$O	physiological$$$812$$$825$$$O	solution,$$$826$$$835$$$O	preferable$$$836$$$846$$$O	in$$$847$$$849$$$O	1:2$$$850$$$853$$$O	ratio$$$854$$$859$$$O	by$$$860$$$862$$$O	weight,$$$863$$$870$$$O	the$$$871$$$874$$$O	material$$$875$$$883$$$O	is$$$884$$$886$$$O	subjected$$$887$$$896$$$O	to$$$897$$$899$$$O	a$$$900$$$901$$$O	series$$$902$$$908$$$O	of$$$909$$$911$$$O	gel$$$912$$$915$$$O	filtration$$$916$$$926$$$O	at$$$927$$$929$$$O	least$$$930$$$935$$$O	twice,$$$936$$$942$$$O	then$$$943$$$947$$$O	the$$$948$$$951$$$O	filtered$$$952$$$960$$$O	substance$$$961$$$970$$$O	is$$$971$$$973$$$O	lyophilized$$$974$$$985$$$O	or$$$986$$$988$$$O	optionally$$$989$$$999$$$O	diluted$$$1000$$$1007$$$O	with$$$1008$$$1012$$$O	a$$$1013$$$1014$$$O	diluent,$$$1015$$$1023$$$O	preferably$$$1024$$$1034$$$O	with$$$1035$$$1039$$$O	physiological$$$1040$$$1053$$$O	saline$$$1054$$$1060$$$O	solution$$$1061$$$1069$$$O	or$$$1070$$$1072$$$O	dextrose$$$1073$$$1081$$$I	solution$$$1082$$$1090$$$O	or$$$1091$$$1093$$$O	sterile$$$1094$$$1101$$$O	distilled$$$1102$$$1111$$$O	water,$$$1112$$$1118$$$O	preferably$$$1119$$$1129$$$O	in$$$1130$$$1132$$$O	1:2$$$1133$$$1136$$$O	ratio$$$1137$$$1142$$$O	by$$$1143$$$1145$$$O	weight.$$$1146$$$1153$$$O
CN103356663A
Sulfamonomethoxine-ciprofloxacin-fosfomycin$$$0$$$43$$$I	combined$$$44$$$52$$$O	injection$$$53$$$62$$$O	for$$$63$$$66$$$O	veterinary$$$67$$$77$$$O	use$$$78$$$81$$$O	and$$$82$$$85$$$O	preparation$$$86$$$97$$$O	method$$$98$$$104$$$O	thereof$$$105$$$112$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	sulfamonomethoxine-ciprofloxacin-fosfomycin$$$26$$$69$$$I	combined$$$70$$$78$$$O	injection$$$79$$$88$$$O	for$$$89$$$92$$$O	veterinary$$$93$$$103$$$O	use$$$104$$$107$$$O	and$$$108$$$111$$$O	a$$$112$$$113$$$O	preparation$$$114$$$125$$$O	method$$$126$$$132$$$O	thereof.$$$133$$$141$$$O	Every$$$142$$$147$$$O	100mL$$$148$$$153$$$O	of$$$154$$$156$$$O	the$$$157$$$160$$$O	sulfamonomethoxine-ciprofloxacin-fosfomycin$$$161$$$204$$$I	combined$$$205$$$213$$$O	injection$$$214$$$223$$$O	for$$$224$$$227$$$O	veterinary$$$228$$$238$$$O	use$$$239$$$242$$$O	comprises$$$243$$$252$$$O	the$$$253$$$256$$$O	following$$$257$$$266$$$O	components$$$267$$$277$$$O	by$$$278$$$280$$$O	weight:$$$281$$$288$$$O	5-15g$$$289$$$294$$$O	of$$$295$$$297$$$O	sulfamonomethoxine$$$298$$$316$$$I	sodium,$$$317$$$324$$$I	1-5g$$$325$$$329$$$O	of$$$330$$$332$$$O	ciprofloxacin,$$$333$$$347$$$I	0.1-0.5g$$$348$$$356$$$O	of$$$357$$$359$$$O	fosfomycin$$$360$$$370$$$I	sodium,$$$371$$$378$$$I	0.5-1.5g$$$379$$$387$$$O	of$$$388$$$390$$$O	an$$$391$$$393$$$O	analgesic,$$$394$$$404$$$O	0.1-0.2g$$$405$$$413$$$O	of$$$414$$$416$$$O	an$$$417$$$419$$$O	antioxidant,$$$420$$$432$$$O	5-20g$$$433$$$438$$$O	of$$$439$$$441$$$O	a$$$442$$$443$$$O	cosolvent,$$$444$$$454$$$O	0.01-0.05g$$$455$$$465$$$O	of$$$466$$$468$$$O	ethylenediamine$$$469$$$484$$$I	tetraacetic$$$485$$$496$$$I	acid$$$497$$$501$$$I	disodium$$$502$$$510$$$I	salt,$$$511$$$516$$$I	an$$$517$$$519$$$O	appropriate$$$520$$$531$$$O	amount$$$532$$$538$$$O	of$$$539$$$541$$$O	a$$$542$$$543$$$O	pH$$$544$$$546$$$O	regulator,$$$547$$$557$$$O	and$$$558$$$561$$$O	the$$$562$$$565$$$O	balance$$$566$$$573$$$O	of$$$574$$$576$$$O	water$$$577$$$582$$$O	for$$$583$$$586$$$O	injection.$$$587$$$597$$$O	The$$$598$$$601$$$O	preparation$$$602$$$613$$$O	method$$$614$$$620$$$O	of$$$621$$$623$$$O	the$$$624$$$627$$$O	sulfamonomethoxine-ciprofloxacin-fosfomycin$$$628$$$671$$$I	combined$$$672$$$680$$$O	injection$$$681$$$690$$$O	mainly$$$691$$$697$$$O	comprises$$$698$$$707$$$O	the$$$708$$$711$$$O	steps$$$712$$$717$$$O	of$$$718$$$720$$$O	liquid$$$721$$$727$$$O	preparation,$$$728$$$740$$$O	filtration,$$$741$$$752$$$O	packaging$$$753$$$762$$$O	and$$$763$$$766$$$O	sterilization.$$$767$$$781$$$O	According$$$782$$$791$$$O	to$$$792$$$794$$$O	the$$$795$$$798$$$O	injection,$$$799$$$809$$$O	three$$$810$$$815$$$O	types$$$816$$$821$$$O	of$$$822$$$824$$$O	drugs$$$825$$$830$$$O	are$$$831$$$834$$$O	in$$$835$$$837$$$O	reasonable$$$838$$$848$$$O	compatibility,$$$849$$$863$$$O	and$$$864$$$867$$$O	different$$$868$$$877$$$O	antibacterial$$$878$$$891$$$O	mechanisms$$$892$$$902$$$O	of$$$903$$$905$$$O	the$$$906$$$909$$$O	three$$$910$$$915$$$O	drugs$$$916$$$921$$$O	are$$$922$$$925$$$O	used$$$926$$$930$$$O	for$$$931$$$934$$$O	inhibiting$$$935$$$945$$$O	and$$$946$$$949$$$O	killing$$$950$$$957$$$O	pathogenic$$$958$$$968$$$O	bacteria$$$969$$$977$$$O	in$$$978$$$980$$$O	various$$$981$$$988$$$O	ways,$$$989$$$994$$$O	so$$$995$$$997$$$O	that$$$998$$$1002$$$O	the$$$1003$$$1006$$$O	injection$$$1007$$$1016$$$O	has$$$1017$$$1020$$$O	broad-spectrum$$$1021$$$1035$$$O	antibacterial$$$1036$$$1049$$$O	activity$$$1050$$$1058$$$O	and$$$1059$$$1062$$$O	can$$$1063$$$1066$$$O	not$$$1067$$$1070$$$O	generate$$$1071$$$1079$$$O	drug$$$1080$$$1084$$$O	tolerance$$$1085$$$1094$$$O	easily,$$$1095$$$1102$$$O	the$$$1103$$$1106$$$O	dosage$$$1107$$$1113$$$O	is$$$1114$$$1116$$$O	reduced,$$$1117$$$1125$$$O	harms$$$1126$$$1131$$$O	caused$$$1132$$$1138$$$O	by$$$1139$$$1141$$$O	residual$$$1142$$$1150$$$O	antibiotics$$$1151$$$1162$$$O	are$$$1163$$$1166$$$O	lowered,$$$1167$$$1175$$$O	and$$$1176$$$1179$$$O	the$$$1180$$$1183$$$O	safety$$$1184$$$1190$$$O	of$$$1191$$$1193$$$O	livestock$$$1194$$$1203$$$O	and$$$1204$$$1207$$$O	poultry$$$1208$$$1215$$$O	products$$$1216$$$1224$$$O	is$$$1225$$$1227$$$O	ensured$$$1228$$$1235$$$O	favorably.$$$1236$$$1246$$$O
US20080255101
spiro[2H-1,2,4-benzothiadiazine-3,4'-piperidin]-1'-yloxy,7-(aminosulfonyl)-6-chloro-2',2',6',6'-tetramethyl-1,1-dioxide;$$$0$$$120$$$I	antidiabetic$$$121$$$133$$$O	agent;$$$134$$$140$$$O	electrolyte$$$141$$$152$$$O	retention;$$$153$$$163$$$O	cardiovascular$$$164$$$178$$$O	diseases;$$$179$$$188$$$O	renovascular$$$189$$$201$$$O	diseases;$$$202$$$211$$$O	oxidative$$$212$$$221$$$O	stress;$$$222$$$229$$$O	endothelial$$$230$$$241$$$O	dysfunctions;$$$242$$$255$$$O	endothelial$$$256$$$267$$$O	dysfunctions;$$$268$$$281$$$O	cirrhosis;$$$282$$$292$$$O	osteoporosis$$$293$$$305$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	describes$$$14$$$23$$$O	novel$$$24$$$29$$$O	compositions$$$30$$$42$$$O	and$$$43$$$46$$$O	kits$$$47$$$51$$$O	comprising$$$52$$$62$$$O	at$$$63$$$65$$$O	least$$$66$$$71$$$O	one$$$72$$$75$$$O	nitric$$$76$$$82$$$I	oxide$$$83$$$88$$$I	enhancing$$$89$$$98$$$O	diuretic$$$99$$$107$$$O	compound,$$$108$$$117$$$O	or$$$118$$$120$$$O	pharmaceutically$$$121$$$137$$$O	acceptable$$$138$$$148$$$O	salts$$$149$$$154$$$O	thereof,$$$155$$$163$$$O	and,$$$164$$$168$$$O	optionally,$$$169$$$180$$$O	at$$$181$$$183$$$O	least$$$184$$$189$$$O	one$$$190$$$193$$$O	nitric$$$194$$$200$$$I	oxide$$$201$$$206$$$I	enhancing$$$207$$$216$$$O	compound$$$217$$$225$$$O	and/or$$$226$$$232$$$O	at$$$233$$$235$$$O	least$$$236$$$241$$$O	one$$$242$$$245$$$O	therapeutic$$$246$$$257$$$O	agent.$$$258$$$264$$$O	The$$$265$$$268$$$O	invention$$$269$$$278$$$O	also$$$279$$$283$$$O	provides$$$284$$$292$$$O	methods$$$293$$$300$$$O	for$$$301$$$304$$$O	(a)$$$305$$$308$$$O	treating$$$309$$$317$$$O	conditions$$$318$$$328$$$O	resulting$$$329$$$338$$$O	from$$$339$$$343$$$O	excessive$$$344$$$353$$$O	water$$$354$$$359$$$O	and/or$$$360$$$366$$$O	electrolyte$$$367$$$378$$$O	retention;$$$379$$$389$$$O	(b)$$$390$$$393$$$O	treating$$$394$$$402$$$O	cardiovascular$$$403$$$417$$$O	diseases;$$$418$$$427$$$O	(c)$$$428$$$431$$$O	treating$$$432$$$440$$$O	renovascular$$$441$$$453$$$O	diseases;$$$454$$$463$$$O	(d)$$$464$$$467$$$O	treating$$$468$$$476$$$O	diabetes;$$$477$$$486$$$O	(e)$$$487$$$490$$$O	treating$$$491$$$499$$$O	diseases$$$500$$$508$$$O	resulting$$$509$$$518$$$O	from$$$519$$$523$$$O	oxidative$$$524$$$533$$$O	stress;$$$534$$$541$$$O	(f)$$$542$$$545$$$O	treating$$$546$$$554$$$O	endothelial$$$555$$$566$$$O	dysfunctions;$$$567$$$580$$$O	(g)$$$581$$$584$$$O	treating$$$585$$$593$$$O	diseases$$$594$$$602$$$O	caused$$$603$$$609$$$O	by$$$610$$$612$$$O	endothelial$$$613$$$624$$$O	dysfunctions;$$$625$$$638$$$O	(h)$$$639$$$642$$$O	treating$$$643$$$651$$$O	cirrhosis;$$$652$$$662$$$O	(j)$$$663$$$666$$$O	treating$$$667$$$675$$$O	pre-eclampsia;$$$676$$$690$$$O	(k)$$$691$$$694$$$O	treating$$$695$$$703$$$O	osteoporosis;$$$704$$$717$$$O	(l)$$$718$$$721$$$O	treating$$$722$$$730$$$O	nephropathy;$$$731$$$743$$$O	(m)$$$744$$$747$$$O	treating$$$748$$$756$$$O	peripheral$$$757$$$767$$$O	vascular$$$768$$$776$$$O	diseases;$$$777$$$786$$$O	(n)$$$787$$$790$$$O	treating$$$791$$$799$$$O	portal$$$800$$$806$$$O	hypertension;$$$807$$$820$$$O	(o)$$$821$$$824$$$O	treating$$$825$$$833$$$O	central$$$834$$$841$$$O	nervous$$$842$$$849$$$O	system$$$850$$$856$$$O	disorders;$$$857$$$867$$$O	(p)$$$868$$$871$$$O	treating$$$872$$$880$$$O	metabolic$$$881$$$890$$$O	syndrome;$$$891$$$900$$$O	(q)$$$901$$$904$$$O	treating$$$905$$$913$$$O	sexual$$$914$$$920$$$O	dysfunctions;$$$921$$$934$$$O	and$$$935$$$938$$$O	(r)$$$939$$$942$$$O	hyperlipidemia.$$$943$$$958$$$O	The$$$959$$$962$$$O	nitric$$$963$$$969$$$I	oxide$$$970$$$975$$$I	enhancing$$$976$$$985$$$O	diuretic$$$986$$$994$$$O	compounds$$$995$$$1004$$$O	comprise$$$1005$$$1013$$$O	at$$$1014$$$1016$$$O	least$$$1017$$$1022$$$O	one$$$1023$$$1026$$$O	nitric$$$1027$$$1033$$$I	oxide$$$1034$$$1039$$$I	enhancing$$$1040$$$1049$$$O	group$$$1050$$$1055$$$O	linked$$$1056$$$1062$$$O	to$$$1063$$$1065$$$O	the$$$1066$$$1069$$$O	diuretic$$$1070$$$1078$$$O	compound$$$1079$$$1087$$$O	through$$$1088$$$1095$$$O	one$$$1096$$$1099$$$O	or$$$1100$$$1102$$$O	more$$$1103$$$1107$$$O	sites$$$1108$$$1113$$$O	such$$$1114$$$1118$$$O	as$$$1119$$$1121$$$O	carbon,$$$1122$$$1129$$$I	oxygen$$$1130$$$1136$$$I	and/or$$$1137$$$1143$$$O	nitrogen$$$1144$$$1152$$$I	via$$$1153$$$1156$$$O	a$$$1157$$$1158$$$O	bond$$$1159$$$1163$$$O	or$$$1164$$$1166$$$O	moiety$$$1167$$$1173$$$O	that$$$1174$$$1178$$$O	cannot$$$1179$$$1185$$$O	be$$$1186$$$1188$$$O	hydrolyzed.$$$1189$$$1200$$$O
EP2780326A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	inhibition$$$11$$$21$$$O	of$$$22$$$24$$$O	deubiquitinating$$$25$$$41$$$O	activity$$$42$$$50$$$O
A$$$0$$$1$$$O	compound$$$2$$$10$$$O	of$$$11$$$13$$$O	the$$$14$$$17$$$O	general$$$18$$$25$$$O	structure$$$26$$$35$$$O	(I)$$$36$$$39$$$O	is$$$40$$$42$$$O	capable$$$43$$$50$$$O	of$$$51$$$53$$$O	abrogating$$$54$$$64$$$O	the$$$65$$$68$$$O	deubiquitinating$$$69$$$85$$$O	(DUB)$$$86$$$91$$$O	activity$$$92$$$100$$$O	of$$$101$$$103$$$O	the$$$104$$$107$$$O	19S$$$108$$$111$$$O	RP$$$112$$$114$$$O	DUBs.$$$115$$$120$$$O	The$$$121$$$124$$$O	compound$$$125$$$133$$$O	can$$$134$$$137$$$O	be$$$138$$$140$$$O	used$$$141$$$145$$$O	for$$$146$$$149$$$O	treating$$$150$$$158$$$O	cancer,$$$159$$$166$$$O	in$$$167$$$169$$$O	particular$$$170$$$180$$$O	of$$$181$$$183$$$O	cancer$$$184$$$190$$$O	refractory$$$191$$$201$$$O	to$$$202$$$204$$$O	treatment$$$205$$$214$$$O	by$$$215$$$217$$$O	state-of-the-art$$$218$$$234$$$O	chemotherapy.$$$235$$$248$$$O	Also$$$249$$$253$$$O	disclosed$$$254$$$263$$$O	are$$$264$$$267$$$O	corresponding$$$268$$$281$$$O	methods$$$282$$$289$$$O	of$$$290$$$292$$$O	treatment$$$293$$$302$$$O	and$$$303$$$306$$$O	a$$$307$$$308$$$O	pharmaceutical$$$309$$$323$$$O	composition$$$324$$$335$$$O	comprising$$$336$$$346$$$O	the$$$347$$$350$$$O	compound.$$$351$$$360$$$O
CN103356479A
Moxifloxacin$$$0$$$12$$$I	hydrochloride$$$13$$$26$$$I	injection$$$27$$$36$$$O	aqua$$$37$$$41$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	moxifloxacin$$$27$$$39$$$I	hydrochloride$$$40$$$53$$$I	injection$$$54$$$63$$$O	aqua.$$$64$$$69$$$O	The$$$70$$$73$$$O	moxifloxacin$$$74$$$86$$$I	hydrochloride$$$87$$$100$$$I	injection$$$101$$$110$$$O	aqua$$$111$$$115$$$O	is$$$116$$$118$$$O	characterized$$$119$$$132$$$O	in$$$133$$$135$$$O	that$$$136$$$140$$$O	the$$$141$$$144$$$O	moxifloxacin$$$145$$$157$$$I	hydrochloride$$$158$$$171$$$I	injection$$$172$$$181$$$O	aqua$$$182$$$186$$$O	is$$$187$$$189$$$O	formed$$$190$$$196$$$O	by$$$197$$$199$$$O	using$$$200$$$205$$$O	a$$$206$$$207$$$O	sodium$$$208$$$214$$$I	carbonate$$$215$$$224$$$I	solution$$$225$$$233$$$O	as$$$234$$$236$$$O	a$$$237$$$238$$$O	pH$$$239$$$241$$$O	adjusting$$$242$$$251$$$O	agent,$$$252$$$258$$$O	and$$$259$$$262$$$O	the$$$263$$$266$$$O	pH$$$267$$$269$$$O	value$$$270$$$275$$$O	of$$$276$$$278$$$O	the$$$279$$$282$$$O	above$$$283$$$288$$$O	preparation$$$289$$$300$$$O	is$$$301$$$303$$$O	7.1-8.0.$$$304$$$312$$$O	The$$$313$$$316$$$O	preparation$$$317$$$328$$$O	method$$$329$$$335$$$O	of$$$336$$$338$$$O	the$$$339$$$342$$$O	preparation$$$343$$$354$$$O	is$$$355$$$357$$$O	characterized$$$358$$$371$$$O	in$$$372$$$374$$$O	that$$$375$$$379$$$O	water$$$380$$$385$$$O	accounting$$$386$$$396$$$O	for$$$397$$$400$$$O	50-80%$$$401$$$407$$$O	of$$$408$$$410$$$O	the$$$411$$$414$$$O	total$$$415$$$420$$$O	water$$$421$$$426$$$O	consumption$$$427$$$438$$$O	is$$$439$$$441$$$O	preferably$$$442$$$452$$$O	used$$$453$$$457$$$O	for$$$458$$$461$$$O	dissolving$$$462$$$472$$$O	moxifloxacin$$$473$$$485$$$I	hydrochloride,$$$486$$$500$$$I	and$$$501$$$504$$$O	water$$$505$$$510$$$O	accounting$$$511$$$521$$$O	for$$$522$$$525$$$O	15-35%$$$526$$$532$$$O	the$$$533$$$536$$$O	total$$$537$$$542$$$O	water$$$543$$$548$$$O	consumption$$$549$$$560$$$O	is$$$561$$$563$$$O	introduced$$$564$$$574$$$O	in$$$575$$$577$$$O	a$$$578$$$579$$$O	sodium$$$580$$$586$$$I	carbonate$$$587$$$596$$$I	solution$$$597$$$605$$$O	manner,$$$606$$$613$$$O	and$$$614$$$617$$$O	standing$$$618$$$626$$$O	or$$$627$$$629$$$O	weak$$$630$$$634$$$O	stirring$$$635$$$643$$$O	for$$$644$$$647$$$O	a$$$648$$$649$$$O	period$$$650$$$656$$$O	of$$$657$$$659$$$O	time$$$660$$$664$$$O	is$$$665$$$667$$$O	carried$$$668$$$675$$$O	out$$$676$$$679$$$O	at$$$680$$$682$$$O	room$$$683$$$687$$$O	temperature$$$688$$$699$$$O	after$$$700$$$705$$$O	the$$$706$$$709$$$O	adjustment$$$710$$$720$$$O	of$$$721$$$723$$$O	the$$$724$$$727$$$O	pH$$$728$$$730$$$O	value$$$731$$$736$$$O	to$$$737$$$739$$$O	make$$$740$$$744$$$O	the$$$745$$$748$$$O	pH$$$749$$$751$$$O	value$$$752$$$757$$$O	constant.$$$758$$$767$$$O	The$$$768$$$771$$$O	preparation$$$772$$$783$$$O	obtained$$$784$$$792$$$O	in$$$793$$$795$$$O	the$$$796$$$799$$$O	invention$$$800$$$809$$$O	has$$$810$$$813$$$O	a$$$814$$$815$$$O	high$$$816$$$820$$$O	effective$$$821$$$830$$$O	concentration$$$831$$$844$$$O	and$$$845$$$848$$$O	a$$$849$$$850$$$O	good$$$851$$$855$$$O	storage$$$856$$$863$$$O	stability.$$$864$$$874$$$O
CN102028666A
Sustained$$$0$$$9$$$O	release$$$10$$$17$$$O	tablet$$$18$$$24$$$O	containing$$$25$$$35$$$O	famciclovir$$$36$$$47$$$I	and$$$48$$$51$$$O	preparation$$$52$$$63$$$O	method$$$64$$$70$$$O	thereof$$$71$$$78$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	sustained$$$26$$$35$$$O	release$$$36$$$43$$$O	tablet$$$44$$$50$$$O	containing$$$51$$$61$$$O	famciclovir,$$$62$$$74$$$I	which$$$75$$$80$$$O	comprises$$$81$$$90$$$O	famciclovir$$$91$$$102$$$I	as$$$103$$$105$$$O	an$$$106$$$108$$$O	active$$$109$$$115$$$O	component$$$116$$$125$$$O	,$$$126$$$127$$$O	sustained$$$128$$$137$$$O	release$$$138$$$145$$$O	material$$$146$$$154$$$O	and$$$155$$$158$$$O	other$$$159$$$164$$$O	auxiliary$$$165$$$174$$$O	materials,$$$175$$$185$$$O	wherein$$$186$$$193$$$O	the$$$194$$$197$$$O	weight$$$198$$$204$$$O	ratio$$$205$$$210$$$O	of$$$211$$$213$$$O	the$$$214$$$217$$$O	Famciclovir$$$218$$$229$$$I	to$$$230$$$232$$$O	the$$$233$$$236$$$O	sustained$$$237$$$246$$$O	release$$$247$$$254$$$O	material$$$255$$$263$$$O	to$$$264$$$266$$$O	common$$$267$$$273$$$O	auxiliary$$$274$$$283$$$O	materials$$$284$$$293$$$O	is$$$294$$$296$$$O	1:0.2-20:10-200,$$$297$$$313$$$O	preferably$$$314$$$324$$$O	1:0.5-10:20-100.$$$325$$$341$$$O	The$$$342$$$345$$$O	sustained$$$346$$$355$$$O	release$$$356$$$363$$$O	tablet$$$364$$$370$$$O	drug$$$371$$$375$$$O	containing$$$376$$$386$$$O	famciclovir$$$387$$$398$$$I	is$$$399$$$401$$$O	stable$$$402$$$408$$$O	to$$$409$$$411$$$O	release$$$412$$$419$$$O	and$$$420$$$423$$$O	is$$$424$$$426$$$O	favorable$$$427$$$436$$$O	for$$$437$$$440$$$O	lowering$$$441$$$449$$$O	in$$$450$$$452$$$O	vivo$$$453$$$457$$$O	drug$$$458$$$462$$$O	fluctuation$$$463$$$474$$$O	so$$$475$$$477$$$O	as$$$478$$$480$$$O	to$$$481$$$483$$$O	stably$$$484$$$490$$$O	lower$$$491$$$496$$$O	pressure.$$$497$$$506$$$O	Thus,$$$507$$$512$$$O	the$$$513$$$516$$$O	sustained$$$517$$$526$$$O	release$$$527$$$534$$$O	tablet$$$535$$$541$$$O	is$$$542$$$544$$$O	more$$$545$$$549$$$O	suitable$$$550$$$558$$$O	for$$$559$$$562$$$O	patients$$$563$$$571$$$O	with$$$572$$$576$$$O	hypertension.$$$577$$$590$$$O
US20070249715
treating$$$0$$$8$$$O	schizophrenia$$$9$$$22$$$O	in$$$23$$$25$$$O	a$$$26$$$27$$$O	patient$$$28$$$35$$$O	by$$$36$$$38$$$O	administering$$$39$$$52$$$O	an$$$53$$$55$$$O	effective$$$56$$$65$$$O	amount$$$66$$$72$$$O	of$$$73$$$75$$$O	4,4-dimethylcyclohexylamine$$$76$$$103$$$I
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	neboglamine,$$$7$$$19$$$I	(S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic$$$20$$$66$$$I	acid$$$67$$$71$$$I	(CR$$$72$$$75$$$I	2249)$$$76$$$81$$$I	(CAS$$$82$$$86$$$O	Registry$$$87$$$95$$$O	Number$$$96$$$102$$$O	163000-63-3),$$$103$$$116$$$I	of$$$117$$$119$$$O	the$$$120$$$123$$$O	racemate$$$124$$$132$$$O	thereof$$$133$$$140$$$O	or$$$141$$$143$$$O	of$$$144$$$146$$$O	a$$$147$$$148$$$O	pharmaceutically$$$149$$$165$$$O	acceptable$$$166$$$176$$$O	salt$$$177$$$181$$$O	thereof$$$182$$$189$$$O	for$$$190$$$193$$$O	the$$$194$$$197$$$O	preparation$$$198$$$209$$$O	of$$$210$$$212$$$O	a$$$213$$$214$$$O	medicament$$$215$$$225$$$O	for$$$226$$$229$$$O	the$$$230$$$233$$$O	treatment$$$234$$$243$$$O	of$$$244$$$246$$$O	schizophrenia.$$$247$$$261$$$O
CN103405387A
Novel$$$0$$$5$$$O	cefixime$$$6$$$14$$$I	dry$$$15$$$18$$$O	suspension$$$19$$$29$$$O	and$$$30$$$33$$$O	preparation$$$34$$$45$$$O	method$$$46$$$52$$$O	thereof$$$53$$$60$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	cefixime$$$26$$$34$$$I	dry$$$35$$$38$$$O	suspension$$$39$$$49$$$O	and$$$50$$$53$$$O	a$$$54$$$55$$$O	pellet$$$56$$$62$$$O	dressing$$$63$$$71$$$O	preparation$$$72$$$83$$$O	method$$$84$$$90$$$O	thereof,$$$91$$$99$$$O	belongs$$$100$$$107$$$O	to$$$108$$$110$$$O	the$$$111$$$114$$$O	technical$$$115$$$124$$$O	field$$$125$$$130$$$O	of$$$131$$$133$$$O	preparation,$$$134$$$146$$$O	and$$$147$$$150$$$O	specifically$$$151$$$163$$$O	relates$$$164$$$171$$$O	to$$$172$$$174$$$O	a$$$175$$$176$$$O	dry$$$177$$$180$$$O	suspension$$$181$$$191$$$O	containing$$$192$$$202$$$O	cefixime$$$203$$$211$$$I	and$$$212$$$215$$$O	a$$$216$$$217$$$O	preparation$$$218$$$229$$$O	method$$$230$$$236$$$O	thereof.$$$237$$$245$$$O	The$$$246$$$249$$$O	dry$$$250$$$253$$$O	suspension$$$254$$$264$$$O	contains$$$265$$$273$$$O	25-250$$$274$$$280$$$O	milligram$$$281$$$290$$$O	of$$$291$$$293$$$O	cefixime$$$294$$$302$$$I	and$$$303$$$306$$$O	pharmaceutically$$$307$$$323$$$O	acceptable$$$324$$$334$$$O	suspending$$$335$$$345$$$O	agent,$$$346$$$352$$$O	filler,$$$353$$$360$$$O	adhesive,$$$361$$$370$$$O	disintegrating$$$371$$$385$$$O	agent,$$$386$$$392$$$O	lubricant,$$$393$$$403$$$O	sweetener$$$404$$$413$$$O	and$$$414$$$417$$$O	flavouring.$$$418$$$429$$$O	The$$$430$$$433$$$O	preparation$$$434$$$445$$$O	method$$$446$$$452$$$O	comprises$$$453$$$462$$$O	steps$$$463$$$468$$$O	of:$$$469$$$472$$$O	evenly$$$473$$$479$$$O	mixing$$$480$$$486$$$O	suspending$$$487$$$497$$$O	agent,$$$498$$$504$$$O	lactose,$$$505$$$513$$$I	tartrate$$$514$$$522$$$I	and$$$523$$$526$$$O	cefixime;$$$527$$$536$$$I	preparing$$$537$$$546$$$O	the$$$547$$$550$$$O	mixture$$$551$$$558$$$O	into$$$559$$$563$$$O	pellets$$$564$$$571$$$O	by$$$572$$$574$$$O	using$$$575$$$580$$$O	85%$$$581$$$584$$$O	ethanol$$$585$$$592$$$I	solution$$$593$$$601$$$O	containing$$$602$$$612$$$O	a$$$613$$$614$$$O	pigment$$$615$$$622$$$O	and$$$623$$$626$$$O	a$$$627$$$628$$$O	sweetener;$$$629$$$639$$$O	and$$$640$$$643$$$O	finally$$$644$$$651$$$O	adding$$$652$$$658$$$O	essence$$$659$$$666$$$O	and$$$667$$$670$$$O	mixing$$$671$$$677$$$O	uniformly$$$678$$$687$$$O	to$$$688$$$690$$$O	prepare$$$691$$$698$$$O	the$$$699$$$702$$$O	cefixime$$$703$$$711$$$I	dry$$$712$$$715$$$O	suspension.$$$716$$$727$$$O	Compared$$$728$$$736$$$O	with$$$737$$$741$$$O	other$$$742$$$747$$$O	commercial$$$748$$$758$$$O	common$$$759$$$765$$$O	particulate$$$766$$$777$$$O	agent$$$778$$$783$$$O	medicaments,$$$784$$$796$$$O	the$$$797$$$800$$$O	cefixime$$$801$$$809$$$I	dry$$$810$$$813$$$O	suspension$$$814$$$824$$$O	provided$$$825$$$833$$$O	by$$$834$$$836$$$O	the$$$837$$$840$$$O	invention$$$841$$$850$$$O	has$$$851$$$854$$$O	characteristics$$$855$$$870$$$O	of$$$871$$$873$$$O	high$$$874$$$878$$$O	effect$$$879$$$885$$$O	speed,$$$886$$$892$$$O	novel$$$893$$$898$$$O	appearance$$$899$$$909$$$O	and$$$910$$$913$$$O	excellent$$$914$$$923$$$O	mouthfeel;$$$924$$$934$$$O	and$$$935$$$938$$$O	due$$$939$$$942$$$O	to$$$943$$$945$$$O	its$$$946$$$949$$$O	excellent$$$950$$$959$$$O	mouthfeel,$$$960$$$970$$$O	the$$$971$$$974$$$O	dry$$$975$$$978$$$O	suspension$$$979$$$989$$$O	is$$$990$$$992$$$O	especially$$$993$$$1003$$$O	suitable$$$1004$$$1012$$$O	for$$$1013$$$1016$$$O	usage$$$1017$$$1022$$$O	by$$$1023$$$1025$$$O	children,$$$1026$$$1035$$$O	the$$$1036$$$1039$$$O	elderly$$$1040$$$1047$$$O	and$$$1048$$$1051$$$O	patients$$$1052$$$1060$$$O	with$$$1061$$$1065$$$O	sensitive$$$1066$$$1075$$$O	sense$$$1076$$$1081$$$O	of$$$1082$$$1084$$$O	taste.$$$1085$$$1091$$$O
WO2011024004A1
Heterocyclic$$$0$$$12$$$I	urea$$$13$$$17$$$I	derivatives$$$18$$$29$$$O	useful$$$30$$$36$$$O	for$$$37$$$40$$$O	treatment$$$41$$$50$$$O	of$$$51$$$53$$$O	bacterial$$$54$$$63$$$O	infection$$$64$$$73$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I)$$$21$$$24$$$O	and$$$25$$$28$$$O	their$$$29$$$34$$$O	pharmaceutically$$$35$$$51$$$O	acceptable$$$52$$$62$$$O	salts$$$63$$$68$$$O	are$$$69$$$72$$$O	described.$$$73$$$83$$$O	Processes$$$84$$$93$$$O	for$$$94$$$97$$$O	their$$$98$$$103$$$O	preparation,$$$104$$$116$$$O	pharmaceutical$$$117$$$131$$$O	compositions$$$132$$$144$$$O	containing$$$145$$$155$$$O	them,$$$156$$$161$$$O	their$$$162$$$167$$$O	use$$$168$$$171$$$O	as$$$172$$$174$$$O	medicaments$$$175$$$186$$$O	and$$$187$$$190$$$O	their$$$191$$$196$$$O	use$$$197$$$200$$$O	in$$$201$$$203$$$O	the$$$204$$$207$$$O	treatment$$$208$$$217$$$O	of$$$218$$$220$$$O	bacterial$$$221$$$230$$$O	infections$$$231$$$241$$$O	are$$$242$$$245$$$O	also$$$246$$$250$$$O	described.$$$251$$$261$$$O
CN101249062A
Fibraurea$$$0$$$9$$$O	stem$$$10$$$14$$$O	element$$$15$$$22$$$O	jelly$$$23$$$28$$$O	glue$$$29$$$33$$$O	preparations$$$34$$$46$$$O	and$$$47$$$50$$$O	preparation$$$51$$$62$$$O	technique$$$63$$$72$$$O	thereof$$$73$$$80$$$O
A$$$0$$$1$$$O	fibrauretine$$$2$$$14$$$O	gel$$$15$$$18$$$O	preparation$$$19$$$30$$$O	and$$$31$$$34$$$O	a$$$35$$$36$$$O	preparation$$$37$$$48$$$O	method$$$49$$$55$$$O	thereof$$$56$$$63$$$O	are$$$64$$$67$$$O	provided.$$$68$$$77$$$O	The$$$78$$$81$$$O	preparation$$$82$$$93$$$O	contains$$$94$$$102$$$O	0.25-5wt%$$$103$$$112$$$O	of$$$113$$$115$$$O	fibrauretine,$$$116$$$129$$$I	0.5-5wt%$$$130$$$138$$$O	of$$$139$$$141$$$O	gel$$$142$$$145$$$O	matrix,$$$146$$$153$$$O	0.01-1wt%$$$154$$$163$$$O	of$$$164$$$166$$$O	pH$$$167$$$169$$$O	regulator,$$$170$$$180$$$O	0.05-0.15wt%$$$181$$$193$$$O	of$$$194$$$196$$$O	antiseptics$$$197$$$208$$$O	and$$$209$$$212$$$O	distilled$$$213$$$222$$$O	water$$$223$$$228$$$O	in$$$229$$$231$$$O	balance.$$$232$$$240$$$O	The$$$241$$$244$$$O	preparation$$$245$$$256$$$O	method$$$257$$$263$$$O	doesn't$$$264$$$271$$$O	use$$$272$$$275$$$O	any$$$276$$$279$$$O	stabilizer$$$280$$$290$$$O	and$$$291$$$294$$$O	employs$$$295$$$302$$$O	heating$$$303$$$310$$$O	process$$$311$$$318$$$O	to$$$319$$$321$$$O	completely$$$322$$$332$$$O	swell$$$333$$$338$$$O	the$$$339$$$342$$$O	gel$$$343$$$346$$$O	substrate$$$347$$$356$$$O	during$$$357$$$363$$$O	a$$$364$$$365$$$O	short$$$366$$$371$$$O	period$$$372$$$378$$$O	of$$$379$$$381$$$O	time.$$$382$$$387$$$O	The$$$388$$$391$$$O	production$$$392$$$402$$$O	cycle$$$403$$$408$$$O	is$$$409$$$411$$$O	short$$$412$$$417$$$O	and$$$418$$$421$$$O	suitable$$$422$$$430$$$O	for$$$431$$$434$$$O	industrialized$$$435$$$449$$$O	production.$$$450$$$461$$$O	The$$$462$$$465$$$O	fibrauretine$$$466$$$478$$$I	gel$$$479$$$482$$$O	has$$$483$$$486$$$O	uniform$$$487$$$494$$$O	and$$$495$$$498$$$O	fine$$$499$$$503$$$O	texture$$$504$$$511$$$O	and$$$512$$$515$$$O	good$$$516$$$520$$$O	effect$$$521$$$527$$$O	of$$$528$$$530$$$O	coupling$$$531$$$539$$$O	and$$$540$$$543$$$O	hydration$$$544$$$553$$$O	to$$$554$$$556$$$O	mucosa,$$$557$$$564$$$O	and$$$565$$$568$$$O	also$$$569$$$573$$$O	has$$$574$$$577$$$O	the$$$578$$$581$$$O	advantages$$$582$$$592$$$O	of$$$593$$$595$$$O	remarkable$$$596$$$606$$$O	curative$$$607$$$615$$$O	effect,$$$616$$$623$$$O	convenient$$$624$$$634$$$O	adminstraiton,$$$635$$$649$$$O	long$$$650$$$654$$$O	retention$$$655$$$664$$$O	time$$$665$$$669$$$O	in$$$670$$$672$$$O	vagina,$$$673$$$680$$$O	long-lasting$$$681$$$693$$$O	action,$$$694$$$701$$$O	complete$$$702$$$710$$$O	release$$$711$$$718$$$O	of$$$719$$$721$$$O	active$$$722$$$728$$$O	components,$$$729$$$740$$$O	no$$$741$$$743$$$O	foreign$$$744$$$751$$$O	body$$$752$$$756$$$O	sensation$$$757$$$766$$$O	of$$$767$$$769$$$O	vagina,$$$770$$$777$$$O	no$$$778$$$780$$$O	damage$$$781$$$787$$$O	to$$$788$$$790$$$O	vagina,$$$791$$$798$$$O	no$$$799$$$801$$$O	deformation,$$$802$$$814$$$O	storage$$$815$$$822$$$O	stability$$$823$$$832$$$O	and$$$833$$$836$$$O	no$$$837$$$839$$$O	contamination$$$840$$$853$$$O	to$$$854$$$856$$$O	clothing.$$$857$$$866$$$O
EP1858887A1
Piperidinyl$$$0$$$11$$$I	piperazine$$$12$$$22$$$I	derivatives$$$23$$$34$$$O	useful$$$35$$$41$$$O	as$$$42$$$44$$$O	inhibitors$$$45$$$55$$$O	of$$$56$$$58$$$O	chemokine$$$59$$$68$$$O	receptors$$$69$$$78$$$O
In$$$0$$$2$$$O	its$$$3$$$6$$$O	many$$$7$$$11$$$O	embodiments,$$$12$$$24$$$O	the$$$25$$$28$$$O	present$$$29$$$36$$$O	invention$$$37$$$46$$$O	provides$$$47$$$55$$$O	a$$$56$$$57$$$O	novel$$$58$$$63$$$O	class$$$64$$$69$$$O	of$$$70$$$72$$$O	compounds$$$73$$$82$$$O	of$$$83$$$85$$$O	structural$$$86$$$96$$$O	formula$$$97$$$104$$$O	IA$$$105$$$107$$$O	or$$$108$$$110$$$O	IB$$$111$$$113$$$O	where$$$114$$$119$$$O	R1-R8$$$120$$$125$$$O	are$$$126$$$129$$$O	as$$$130$$$132$$$O	disclosed$$$133$$$142$$$O	herein$$$143$$$149$$$O	Formula$$$150$$$157$$$O	(IA)$$$158$$$162$$$O	or$$$163$$$165$$$O	(IB)$$$166$$$170$$$O	as$$$171$$$173$$$O	inhibitors$$$174$$$184$$$O	of$$$185$$$187$$$O	the$$$188$$$191$$$O	CCR5$$$192$$$196$$$O	receptors,$$$197$$$207$$$O	methods$$$208$$$215$$$O	of$$$216$$$218$$$O	preparing$$$219$$$228$$$O	such$$$229$$$233$$$O	compounds,$$$234$$$244$$$O	pharmaceutical$$$245$$$259$$$O	compositions$$$260$$$272$$$O	containing$$$273$$$283$$$O	one$$$284$$$287$$$O	or$$$288$$$290$$$O	more$$$291$$$295$$$O	such$$$296$$$300$$$O	compounds,$$$301$$$311$$$O	methods$$$312$$$319$$$O	of$$$320$$$322$$$O	preparing$$$323$$$332$$$O	pharmaceutical$$$333$$$347$$$O	formulations$$$348$$$360$$$O	comprising$$$361$$$371$$$O	one$$$372$$$375$$$O	or$$$376$$$378$$$O	more$$$379$$$383$$$O	such$$$384$$$388$$$O	compounds,$$$389$$$399$$$O	and$$$400$$$403$$$O	methods$$$404$$$411$$$O	of$$$412$$$414$$$O	treatment,$$$415$$$425$$$O	prevention,$$$426$$$437$$$O	inhibition,$$$438$$$449$$$O	or$$$450$$$452$$$O	amelioration$$$453$$$465$$$O	of$$$466$$$468$$$O	one$$$469$$$472$$$O	or$$$473$$$475$$$O	more$$$476$$$480$$$O	diseases$$$481$$$489$$$O	associated$$$490$$$500$$$O	with$$$501$$$505$$$O	CCR5$$$506$$$510$$$O	using$$$511$$$516$$$O	such$$$517$$$521$$$O	compounds$$$522$$$531$$$O	or$$$532$$$534$$$O	pharmaceutical$$$535$$$549$$$O	compositions.$$$550$$$563$$$O	The$$$564$$$567$$$O	invention$$$568$$$577$$$O	also$$$578$$$582$$$O	relates$$$583$$$590$$$O	to$$$591$$$593$$$O	the$$$594$$$597$$$O	use$$$598$$$601$$$O	of$$$602$$$604$$$O	a$$$605$$$606$$$O	combination$$$607$$$618$$$O	of$$$619$$$621$$$O	a$$$622$$$623$$$O	compound$$$624$$$632$$$O	of$$$633$$$635$$$O	this$$$636$$$640$$$O	invention$$$641$$$650$$$O	and$$$651$$$654$$$O	one$$$655$$$658$$$O	or$$$659$$$661$$$O	more$$$662$$$666$$$O	antiviral$$$667$$$676$$$O	or$$$677$$$679$$$O	other$$$680$$$685$$$O	agents$$$686$$$692$$$O	useful$$$693$$$699$$$O	in$$$700$$$702$$$O	the$$$703$$$706$$$O	treatment$$$707$$$716$$$O	of$$$717$$$719$$$O	Human$$$720$$$725$$$O	Immunodeficiency$$$726$$$742$$$O	Virus$$$743$$$748$$$O	(HIV).$$$749$$$755$$$O	The$$$756$$$759$$$O	invention$$$760$$$769$$$O	further$$$770$$$777$$$O	relates$$$778$$$785$$$O	to$$$786$$$788$$$O	the$$$789$$$792$$$O	use$$$793$$$796$$$O	of$$$797$$$799$$$O	a$$$800$$$801$$$O	compound$$$802$$$810$$$O	of$$$811$$$813$$$O	this$$$814$$$818$$$O	invention,$$$819$$$829$$$O	alone$$$830$$$835$$$O	or$$$836$$$838$$$O	in$$$839$$$841$$$O	combination$$$842$$$853$$$O	with$$$854$$$858$$$O	another$$$859$$$866$$$O	agent,$$$867$$$873$$$O	in$$$874$$$876$$$O	the$$$877$$$880$$$O	treatment$$$881$$$890$$$O	of$$$891$$$893$$$O	solid$$$894$$$899$$$O	organ$$$900$$$905$$$O	transplant$$$906$$$916$$$O	rejection,$$$917$$$927$$$O	graft$$$928$$$933$$$O	v.$$$934$$$936$$$O	host$$$937$$$941$$$O	disease,$$$942$$$950$$$O	arthritis,$$$951$$$961$$$O	rheumatoid$$$962$$$972$$$O	arthritis,$$$973$$$983$$$O	inflammatory$$$984$$$996$$$O	bowel$$$997$$$1002$$$O	disease,$$$1003$$$1011$$$O	atopic$$$1012$$$1018$$$O	dermatitis,$$$1019$$$1030$$$O	psoriasis,$$$1031$$$1041$$$O	asthma,$$$1042$$$1049$$$O	allergies$$$1050$$$1059$$$O	or$$$1060$$$1062$$$O	multiple$$$1063$$$1071$$$O	sclerosis.$$$1072$$$1082$$$O
WO2013090634A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	polymeric$$$7$$$16$$$O	excipients$$$17$$$27$$$O	for$$$28$$$31$$$O	lyophilization$$$32$$$46$$$O	or$$$47$$$49$$$O	freezing$$$50$$$58$$$O	of$$$59$$$61$$$O	particles$$$62$$$71$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	use$$$20$$$23$$$O	of$$$24$$$26$$$O	polymeric$$$27$$$36$$$O	excipients,$$$37$$$48$$$O	specifically$$$49$$$61$$$O	polyvinyl$$$62$$$71$$$I	alcohols,$$$72$$$81$$$I	optionally$$$82$$$92$$$O	in$$$93$$$95$$$O	conjunction$$$96$$$107$$$O	with$$$108$$$112$$$O	sugars,$$$113$$$120$$$I	as$$$121$$$123$$$O	cryoprotectants$$$124$$$139$$$O	to$$$140$$$142$$$O	prevent$$$143$$$150$$$O	aggregation$$$151$$$162$$$O	of$$$163$$$165$$$O	PEG-$$$166$$$170$$$I	containing$$$171$$$181$$$O	particles.$$$182$$$192$$$O	Also$$$193$$$197$$$O	provided$$$198$$$206$$$O	are$$$207$$$210$$$O	PEG-containing$$$211$$$225$$$I	particles$$$226$$$235$$$O	comprising$$$236$$$246$$$O	such$$$247$$$251$$$O	polymeric$$$252$$$261$$$O	excipients.$$$262$$$273$$$O
WO2004091597A3
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	treating$$$10$$$18$$$O	irritable$$$19$$$28$$$O	bowel$$$29$$$34$$$O	syndrome$$$35$$$43$$$O	(ibs)$$$44$$$49$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	features$$$14$$$22$$$O	a$$$23$$$24$$$O	method$$$25$$$31$$$O	of$$$32$$$34$$$O	treating$$$35$$$43$$$O	irritable$$$44$$$53$$$O	bowel$$$54$$$59$$$O	syndrome$$$60$$$68$$$O	(IBS)$$$69$$$74$$$O	by$$$75$$$77$$$O	administering$$$78$$$91$$$O	quarternary$$$92$$$103$$$I	ammonium$$$104$$$112$$$I	compounds$$$113$$$122$$$O	of$$$123$$$125$$$O	formulae$$$126$$$134$$$O	I-V,$$$135$$$139$$$O	described$$$140$$$149$$$O	herein.$$$150$$$157$$$O
WO2012053003A1
A$$$0$$$1$$$O	novel$$$2$$$7$$$O	herbal$$$8$$$14$$$O	oil$$$15$$$18$$$O	for$$$19$$$22$$$O	controlling$$$23$$$34$$$O	blood$$$35$$$40$$$O	sugar$$$41$$$46$$$I	without$$$47$$$54$$$O	risk$$$55$$$59$$$O	of$$$60$$$62$$$O	hypoglycemea$$$63$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	herbal$$$27$$$33$$$O	oil,$$$34$$$38$$$O	for$$$39$$$42$$$O	controlling$$$43$$$54$$$O	blood$$$55$$$60$$$O	sugar$$$61$$$66$$$I	without$$$67$$$74$$$O	risk$$$75$$$79$$$O	of$$$80$$$82$$$O	hypoglycemia,$$$83$$$96$$$O	comprising$$$97$$$107$$$O	of$$$108$$$110$$$O	the$$$111$$$114$$$O	step$$$115$$$119$$$O	of$$$120$$$122$$$O	(i)$$$123$$$126$$$O	fractional$$$127$$$137$$$O	distillation$$$138$$$150$$$O	of$$$151$$$153$$$O	essential$$$154$$$163$$$O	oils$$$164$$$168$$$O	comprising$$$169$$$179$$$O	of$$$180$$$182$$$O	turpentine$$$183$$$193$$$O	oil,$$$194$$$198$$$O	jasmine$$$199$$$206$$$O	oil,$$$207$$$211$$$O	rose$$$212$$$216$$$O	oil,$$$217$$$221$$$O	eucalyptus$$$222$$$232$$$O	oil,$$$233$$$237$$$O	sandal$$$238$$$244$$$O	wood$$$245$$$249$$$O	oil$$$250$$$253$$$O	and$$$254$$$257$$$O	water$$$258$$$263$$$O	green$$$264$$$269$$$O	oil$$$270$$$273$$$O	to$$$274$$$276$$$O	obtain$$$277$$$283$$$O	hydroxyl$$$284$$$292$$$I	compounds$$$293$$$302$$$O	Î±-terpinol,$$$303$$$315$$$I	linalool,$$$316$$$325$$$I	Gereneol,$$$326$$$335$$$I	Citroneoll,$$$336$$$347$$$I	Î±-Santalol,$$$348$$$360$$$I	Methyl$$$361$$$367$$$I	salicylate$$$368$$$378$$$I	and$$$379$$$382$$$O	other$$$383$$$388$$$I	alcoholic$$$389$$$398$$$I	terpenoils$$$399$$$409$$$I	and$$$410$$$413$$$O	(ii)$$$414$$$418$$$O	dilution$$$419$$$427$$$O	with$$$428$$$432$$$O	fat$$$433$$$436$$$O	oil$$$437$$$440$$$O	so$$$441$$$443$$$O	as$$$444$$$446$$$O	to$$$447$$$449$$$O	have$$$450$$$454$$$O	approximate$$$455$$$466$$$O	weight$$$467$$$473$$$O	percentage$$$474$$$484$$$O	of$$$485$$$487$$$I	Î±-terpinol$$$488$$$499$$$I	50%,$$$500$$$504$$$I	linalool$$$505$$$513$$$I	6%,$$$514$$$517$$$I	Gereneol$$$518$$$526$$$I	4%,$$$527$$$530$$$I	Citroneoll$$$531$$$541$$$I	3.5%,$$$542$$$547$$$I	Î±-Santalol$$$548$$$559$$$I	2.7%,$$$560$$$565$$$I	Methyl$$$566$$$572$$$I	salicylate$$$573$$$583$$$I	2%,$$$584$$$587$$$O	other$$$588$$$593$$$I	alcoholic$$$594$$$603$$$I	terpenoils$$$604$$$614$$$I	and$$$615$$$618$$$O	fat$$$619$$$622$$$O	oil$$$623$$$626$$$O	31.8%.$$$627$$$633$$$O
WO2008143637A2
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	making$$$29$$$35$$$O	therapies$$$36$$$45$$$O	delivered$$$46$$$55$$$O	by$$$56$$$58$$$O	viral$$$59$$$64$$$O	vectors$$$65$$$72$$$O	reversible$$$73$$$83$$$O	for$$$84$$$87$$$O	safety$$$88$$$94$$$O	or$$$95$$$97$$$O	allele-specificity$$$98$$$116$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	compositions$$$37$$$49$$$O	methods$$$50$$$57$$$O	and$$$58$$$61$$$O	kits$$$62$$$66$$$O	for$$$67$$$70$$$O	regulation$$$71$$$81$$$O	of$$$82$$$84$$$O	gene$$$85$$$89$$$O	therapies,$$$90$$$100$$$O	including,$$$101$$$111$$$O	without$$$112$$$119$$$O	limitation,$$$120$$$131$$$O	reversible$$$132$$$142$$$O	gene$$$143$$$147$$$O	therapies$$$148$$$157$$$O	and$$$158$$$161$$$O	allele-$$$162$$$169$$$O	specific$$$170$$$178$$$O	therapies.$$$179$$$189$$$O
CN101926765A
Fluticasone$$$0$$$11$$$I	propionate$$$12$$$22$$$I	foaming$$$23$$$30$$$O	agent$$$31$$$36$$$O	composition$$$37$$$48$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	fluticasone$$$26$$$37$$$I	propionate$$$38$$$48$$$I	foaming$$$49$$$56$$$O	agent$$$57$$$62$$$O	composition,$$$63$$$75$$$O	which$$$76$$$81$$$O	contains$$$82$$$90$$$O	fluticasone$$$91$$$102$$$I	propionate$$$103$$$113$$$I	serving$$$114$$$121$$$O	as$$$122$$$124$$$O	an$$$125$$$127$$$O	active$$$128$$$134$$$O	ingredient$$$135$$$145$$$O	and$$$146$$$149$$$O	one$$$150$$$153$$$O	or$$$154$$$156$$$O	more$$$157$$$161$$$O	pharmaceutically$$$162$$$178$$$O	acceptable$$$179$$$189$$$O	auxiliary$$$190$$$199$$$O	materials$$$200$$$209$$$O	for$$$210$$$213$$$O	a$$$214$$$215$$$O	foaming$$$216$$$223$$$O	agent,$$$224$$$230$$$O	wherein$$$231$$$238$$$O	the$$$239$$$242$$$O	content$$$243$$$250$$$O	of$$$251$$$253$$$O	the$$$254$$$257$$$O	fluticasone$$$258$$$269$$$I	propionate$$$270$$$280$$$I	serving$$$281$$$288$$$O	as$$$289$$$291$$$O	the$$$292$$$295$$$O	active$$$296$$$302$$$O	ingredient$$$303$$$313$$$O	is$$$314$$$316$$$O	0.05$$$317$$$321$$$O	to$$$322$$$324$$$O	0.2$$$325$$$328$$$O	percent$$$329$$$336$$$O	(weight/weight),$$$337$$$353$$$O	and$$$354$$$357$$$O	the$$$358$$$361$$$O	volume$$$362$$$368$$$O	expansion$$$369$$$378$$$O	ratio$$$379$$$384$$$O	of$$$385$$$387$$$O	the$$$388$$$391$$$O	foaming$$$392$$$399$$$O	agent$$$400$$$405$$$O	composition$$$406$$$417$$$O	is$$$418$$$420$$$O	25$$$421$$$423$$$O	to$$$424$$$426$$$O	50.$$$427$$$430$$$O
US7465553
Psoriasin$$$0$$$9$$$O	expression$$$10$$$20$$$O	by$$$21$$$23$$$O	breast$$$24$$$30$$$O	epithelial$$$31$$$41$$$O	cells$$$42$$$47$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	features$$$14$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	diagnosing$$$34$$$44$$$O	high$$$45$$$49$$$O	grade$$$50$$$55$$$O	ductal$$$56$$$62$$$O	carcinoma$$$63$$$72$$$O	in$$$73$$$75$$$O	situ$$$76$$$80$$$O	(DCIS)$$$81$$$87$$$O	These$$$88$$$93$$$O	methods$$$94$$$101$$$O	involve$$$102$$$109$$$O	measuring:$$$110$$$120$$$O	(1)$$$121$$$124$$$O	the$$$125$$$128$$$O	level$$$129$$$134$$$O	of$$$135$$$137$$$O	HID-5$$$138$$$143$$$O	in$$$144$$$146$$$O	a$$$147$$$148$$$O	body$$$149$$$153$$$O	fluid$$$154$$$159$$$O	(e.g.,$$$160$$$166$$$O	blood$$$167$$$172$$$O	or$$$173$$$175$$$O	urine)$$$176$$$182$$$O	of$$$183$$$185$$$O	a$$$186$$$187$$$O	subject$$$188$$$195$$$O	suspected$$$196$$$205$$$O	of$$$206$$$208$$$O	having,$$$209$$$216$$$O	or$$$217$$$219$$$O	at$$$220$$$222$$$O	risk$$$223$$$227$$$O	of$$$228$$$230$$$O	having,$$$231$$$238$$$O	high$$$239$$$243$$$O	grade$$$244$$$249$$$O	DCIS;$$$250$$$255$$$O	or$$$256$$$258$$$O	(2)$$$259$$$262$$$O	the$$$263$$$266$$$O	level$$$267$$$272$$$O	of$$$273$$$275$$$O	HID-5$$$276$$$281$$$O	gene$$$282$$$286$$$O	expression$$$287$$$297$$$O	in$$$298$$$300$$$O	breast$$$301$$$307$$$O	tissue$$$308$$$314$$$O	from$$$315$$$319$$$O	a$$$320$$$321$$$O	subject$$$322$$$329$$$O	suspected$$$330$$$339$$$O	of$$$340$$$342$$$O	having,$$$343$$$350$$$O	or$$$351$$$353$$$O	at$$$354$$$356$$$O	risk$$$357$$$361$$$O	of$$$362$$$364$$$O	having,$$$365$$$372$$$O	high$$$373$$$377$$$O	grade$$$378$$$383$$$O	DCIS.$$$384$$$389$$$O	The$$$390$$$393$$$O	invention$$$394$$$403$$$O	also$$$404$$$408$$$O	embodies$$$409$$$417$$$O	a$$$418$$$419$$$O	method$$$420$$$426$$$O	of$$$427$$$429$$$O	inhibiting$$$430$$$440$$$O	expression$$$441$$$451$$$O	of$$$452$$$454$$$O	HID-5$$$455$$$460$$$O	protein$$$461$$$468$$$O	in$$$469$$$471$$$O	DCIS$$$472$$$476$$$O	cells$$$477$$$482$$$O	and$$$483$$$486$$$O	methods$$$487$$$494$$$O	of$$$495$$$497$$$O	treating$$$498$$$506$$$O	a$$$507$$$508$$$O	subject$$$509$$$516$$$O	suspected$$$517$$$526$$$O	of$$$527$$$529$$$O	having,$$$530$$$537$$$O	or$$$538$$$540$$$O	at$$$541$$$543$$$O	risk$$$544$$$548$$$O	of$$$549$$$551$$$O	having,$$$552$$$559$$$O	high$$$560$$$564$$$O	grade$$$565$$$570$$$O	DCIS.$$$571$$$576$$$O
WO2013068967A2
Cosmetic$$$0$$$8$$$O	composition$$$9$$$20$$$O	comprising$$$21$$$31$$$O	an$$$32$$$34$$$O	alpha-alkoxysilane$$$35$$$53$$$I	obtained$$$54$$$62$$$O	from$$$63$$$67$$$O	an$$$68$$$70$$$O	acrylate$$$71$$$79$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	cosmetic$$$27$$$35$$$O	composition,$$$36$$$48$$$O	in$$$49$$$51$$$O	particular$$$52$$$62$$$O	a$$$63$$$64$$$O	composition$$$65$$$76$$$O	for$$$77$$$80$$$O	making$$$81$$$87$$$O	up$$$88$$$90$$$O	and/or$$$91$$$97$$$O	caring$$$98$$$104$$$O	for$$$105$$$108$$$O	keratin$$$109$$$116$$$O	materials,$$$117$$$127$$$O	preferably$$$128$$$138$$$O	a$$$139$$$140$$$O	nail$$$141$$$145$$$O	makeup,$$$146$$$153$$$O	comprising$$$154$$$164$$$O	the$$$165$$$168$$$O	compound$$$169$$$177$$$O	of$$$178$$$180$$$O	chemical$$$181$$$189$$$O	formula$$$190$$$197$$$O	(I)$$$198$$$201$$$O	below:$$$202$$$208$$$O	(I)$$$209$$$212$$$O	in$$$213$$$215$$$O	which:$$$216$$$222$$$O	n$$$223$$$224$$$O	is$$$225$$$227$$$O	between$$$228$$$235$$$O	1$$$236$$$237$$$O	and$$$238$$$241$$$O	8,$$$242$$$244$$$O	m$$$245$$$246$$$O	is$$$247$$$249$$$O	between$$$250$$$257$$$O	1$$$258$$$259$$$O	and$$$260$$$263$$$O	20,$$$264$$$267$$$O	m'$$$268$$$270$$$O	is$$$271$$$273$$$O	equal$$$274$$$279$$$O	to$$$280$$$282$$$O	0$$$283$$$284$$$O	or$$$285$$$287$$$O	1,$$$288$$$290$$$O	R1$$$291$$$293$$$O	represents$$$294$$$304$$$O	a$$$305$$$306$$$O	hydrogen$$$307$$$315$$$I	atom$$$316$$$320$$$O	or$$$321$$$323$$$O	a$$$324$$$325$$$O	methyl$$$326$$$332$$$I	group,$$$333$$$339$$$O	R2$$$340$$$342$$$O	and$$$343$$$346$$$O	R2'$$$347$$$350$$$O	independently$$$351$$$364$$$O	represent$$$365$$$374$$$O	a$$$375$$$376$$$O	hydrogen$$$377$$$385$$$I	atom$$$386$$$390$$$O	or$$$391$$$393$$$O	a$$$394$$$395$$$O	group$$$396$$$401$$$O	(C1-C20)alkyl$$$402$$$415$$$I	or$$$416$$$418$$$O	an$$$419$$$421$$$O	aryl$$$422$$$426$$$I	group,$$$427$$$433$$$O	or$$$434$$$436$$$O	alternatively$$$437$$$450$$$O	R2$$$451$$$453$$$O	and$$$454$$$457$$$O	R2'$$$458$$$461$$$O	are$$$462$$$465$$$O	linked$$$466$$$472$$$O	to$$$473$$$475$$$O	form$$$476$$$480$$$O	a$$$481$$$482$$$O	(C1-C6)$$$483$$$490$$$I	alkylene$$$491$$$499$$$I	chain,$$$500$$$506$$$O	R3$$$507$$$509$$$O	and$$$510$$$513$$$O	R4$$$514$$$516$$$O	independently$$$517$$$530$$$O	represent$$$531$$$540$$$O	an$$$541$$$543$$$O	ethoxy$$$544$$$550$$$I	group,$$$551$$$557$$$O	a$$$558$$$559$$$O	group$$$560$$$565$$$O	(C1-C20)alkyl$$$566$$$579$$$I	or$$$580$$$582$$$O	a$$$583$$$584$$$O	(C1-C4)aminoalkyl$$$585$$$602$$$I	group,$$$603$$$609$$$O	Y$$$610$$$611$$$O	represents$$$612$$$622$$$O	a$$$623$$$624$$$O	polyether$$$625$$$634$$$I	or$$$635$$$637$$$O	a$$$638$$$639$$$O	polyester$$$640$$$649$$$I	or$$$650$$$652$$$O	a$$$653$$$654$$$O	polyurethane$$$655$$$667$$$I	or$$$668$$$670$$$O	a$$$671$$$672$$$O	polyurea,$$$673$$$682$$$I	or$$$683$$$685$$$O	alternatively$$$686$$$699$$$O	a$$$700$$$701$$$O	hydrocarbon-based$$$702$$$719$$$I	group$$$720$$$725$$$O	comprising$$$726$$$736$$$O	from$$$737$$$741$$$O	2$$$742$$$743$$$O	to$$$744$$$746$$$O	1500$$$747$$$751$$$O	carbon$$$752$$$758$$$I	atoms.$$$759$$$765$$$O	The$$$766$$$769$$$O	invention$$$770$$$779$$$O	also$$$780$$$784$$$O	relates$$$785$$$792$$$O	to$$$793$$$795$$$O	a$$$796$$$797$$$O	cosmetic$$$798$$$806$$$O	process,$$$807$$$815$$$O	in$$$816$$$818$$$O	particular$$$819$$$829$$$O	a$$$830$$$831$$$O	makeup$$$832$$$838$$$O	or$$$839$$$841$$$O	hair$$$842$$$846$$$O	shaping$$$847$$$854$$$O	process,$$$855$$$863$$$O	preferably$$$864$$$874$$$O	a$$$875$$$876$$$O	process$$$877$$$884$$$O	for$$$885$$$888$$$O	making$$$889$$$895$$$O	up$$$896$$$898$$$O	keratin$$$899$$$906$$$O	materials,$$$907$$$917$$$O	in$$$918$$$920$$$O	particular$$$921$$$931$$$O	the$$$932$$$935$$$O	nails$$$936$$$941$$$O	and/or$$$942$$$948$$$O	the$$$949$$$952$$$O	hair,$$$953$$$958$$$O	characterized$$$959$$$972$$$O	in$$$973$$$975$$$O	that$$$976$$$980$$$O	it$$$981$$$983$$$O	comprises$$$984$$$993$$$O	at$$$994$$$996$$$O	least$$$997$$$1002$$$O	one$$$1003$$$1006$$$O	step$$$1007$$$1011$$$O	which$$$1012$$$1017$$$O	consists$$$1018$$$1026$$$O	in$$$1027$$$1029$$$O	applying$$$1030$$$1038$$$O	a$$$1039$$$1040$$$O	cosmetic$$$1041$$$1049$$$O	composition$$$1050$$$1061$$$O	as$$$1062$$$1064$$$O	above$$$1065$$$1070$$$O	defined$$$1071$$$1078$$$O	to$$$1079$$$1081$$$O	keratin$$$1082$$$1089$$$O	materials.$$$1090$$$1100$$$O
CN101732292A
Novel$$$0$$$5$$$O	application$$$6$$$17$$$O	of$$$18$$$20$$$O	tetrahydrocurcumin$$$21$$$39$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	application$$$23$$$34$$$O	of$$$35$$$37$$$O	tetrahydrocurcumin$$$38$$$56$$$I	in$$$57$$$59$$$O	preparing$$$60$$$69$$$O	a$$$70$$$71$$$O	medicament$$$72$$$82$$$O	for$$$83$$$86$$$O	preventing$$$87$$$97$$$O	or/and$$$98$$$104$$$O	treating$$$105$$$113$$$O	a$$$114$$$115$$$O	set$$$116$$$119$$$O	of$$$120$$$122$$$O	clinical$$$123$$$131$$$O	syndromes$$$132$$$141$$$O	which$$$142$$$147$$$O	are$$$148$$$151$$$O	characterized$$$152$$$165$$$O	by$$$166$$$168$$$O	aggregating$$$169$$$180$$$O	a$$$181$$$182$$$O	variety$$$183$$$190$$$O	of$$$191$$$193$$$O	metabolic$$$194$$$203$$$O	disturbances$$$204$$$216$$$O	in$$$217$$$219$$$O	an$$$220$$$222$$$O	individual,$$$223$$$234$$$O	such$$$235$$$239$$$O	as$$$240$$$242$$$O	obesity,$$$243$$$251$$$O	hypertension,$$$252$$$265$$$O	abnormal$$$266$$$274$$$O	blood$$$275$$$280$$$O	fat,$$$281$$$285$$$O	abnormal$$$286$$$294$$$O	saccharometabolism,$$$295$$$314$$$O	has$$$315$$$318$$$O	specific$$$319$$$327$$$O	medicinal$$$328$$$337$$$O	effect,$$$338$$$345$$$O	and$$$346$$$349$$$O	is$$$350$$$352$$$O	a$$$353$$$354$$$O	new$$$355$$$358$$$O	treatment$$$359$$$368$$$O	medicament$$$369$$$379$$$O	which$$$380$$$385$$$O	can$$$386$$$389$$$O	simultaneously$$$390$$$404$$$O	and$$$405$$$408$$$O	effectively$$$409$$$420$$$O	correct$$$421$$$428$$$O	a$$$429$$$430$$$O	variety$$$431$$$438$$$O	of$$$439$$$441$$$O	clinical$$$442$$$450$$$O	disturbance$$$451$$$462$$$O	factors$$$463$$$470$$$O	of$$$471$$$473$$$O	MS$$$474$$$476$$$O	clinically.$$$477$$$488$$$O
CN103211809A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	terpenoid$$$15$$$24$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	application$$$26$$$37$$$O	of$$$38$$$40$$$O	a$$$41$$$42$$$O	terpenoid$$$43$$$52$$$I	to$$$53$$$55$$$O	preparation$$$56$$$67$$$O	of$$$68$$$70$$$O	an$$$71$$$73$$$O	anticoagulation$$$74$$$89$$$O	drug.$$$90$$$95$$$O	The$$$96$$$99$$$O	terpenoid$$$100$$$109$$$I	has$$$110$$$113$$$O	a$$$114$$$115$$$O	structural$$$116$$$126$$$O	formula$$$127$$$134$$$O	I$$$135$$$136$$$O	which$$$137$$$142$$$O	is$$$143$$$145$$$O	as$$$146$$$148$$$O	shown$$$149$$$154$$$O	in$$$155$$$157$$$O	the$$$158$$$161$$$O	description,$$$162$$$174$$$O	wherein$$$175$$$182$$$O	R1$$$183$$$185$$$O	represents$$$186$$$196$$$O	H,$$$197$$$199$$$I	C1-C5$$$200$$$205$$$O	linear$$$206$$$212$$$O	alkyl,$$$213$$$219$$$I	glycosyl$$$220$$$228$$$I	or$$$229$$$231$$$O	a$$$232$$$233$$$O	formula$$$234$$$241$$$O	which$$$242$$$247$$$O	is$$$248$$$250$$$O	as$$$251$$$253$$$O	shown$$$254$$$259$$$O	in$$$260$$$262$$$O	the$$$263$$$266$$$O	description,$$$267$$$279$$$O	and$$$280$$$283$$$O	R2$$$284$$$286$$$O	is$$$287$$$289$$$O	selected$$$290$$$298$$$O	from$$$299$$$303$$$O	C1-C4$$$304$$$309$$$O	linear$$$310$$$316$$$O	alkyl.$$$317$$$323$$$I	According$$$324$$$333$$$O	to$$$334$$$336$$$O	the$$$337$$$340$$$O	application$$$341$$$352$$$O	of$$$353$$$355$$$O	the$$$356$$$359$$$O	terpenoid,$$$360$$$370$$$I	an$$$371$$$373$$$O	ionane$$$374$$$380$$$O	type$$$381$$$385$$$O	sesquiterpene$$$386$$$399$$$I	compound$$$400$$$408$$$O	separated$$$409$$$418$$$O	and$$$419$$$422$$$O	obtained$$$423$$$431$$$O	from$$$432$$$436$$$O	leonurus$$$437$$$445$$$O	for$$$446$$$449$$$O	the$$$450$$$453$$$O	first$$$454$$$459$$$O	time$$$460$$$464$$$O	can$$$465$$$468$$$O	obviously$$$469$$$478$$$O	inhibit$$$479$$$486$$$O	the$$$487$$$490$$$O	platelet$$$491$$$499$$$O	aggregation$$$500$$$511$$$O	in$$$512$$$514$$$O	vitro$$$515$$$520$$$O	and$$$521$$$524$$$O	has$$$525$$$528$$$O	extension$$$529$$$538$$$O	tendencies$$$539$$$549$$$O	to$$$550$$$552$$$O	prothrombin$$$553$$$564$$$O	time$$$565$$$569$$$O	(PT),$$$570$$$575$$$O	activated$$$576$$$585$$$O	partial$$$586$$$593$$$O	thromboplastin$$$594$$$608$$$O	time$$$609$$$613$$$O	(APTT)$$$614$$$620$$$O	and$$$621$$$624$$$O	thrombin$$$625$$$633$$$O	time$$$634$$$638$$$O	(TT)$$$639$$$643$$$O	and$$$644$$$647$$$O	has$$$648$$$651$$$O	a$$$652$$$653$$$O	certain$$$654$$$661$$$O	anticoagulation$$$662$$$677$$$O	activity,$$$678$$$687$$$O	so$$$688$$$690$$$O	that$$$691$$$695$$$O	a$$$696$$$697$$$O	new$$$698$$$701$$$O	choice$$$702$$$708$$$O	is$$$709$$$711$$$O	provided$$$712$$$720$$$O	for$$$721$$$724$$$O	the$$$725$$$728$$$O	development$$$729$$$740$$$O	of$$$741$$$743$$$O	natural$$$744$$$751$$$O	anti-thrombus$$$752$$$765$$$O	drugs.$$$766$$$772$$$O
WO2007009704A3
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	substituted$$$7$$$18$$$O	pyrazoline$$$19$$$29$$$I	compounds$$$30$$$39$$$O	for$$$40$$$43$$$O	the$$$44$$$47$$$O	treatment$$$48$$$57$$$O	of$$$58$$$60$$$O	food$$$61$$$65$$$O	disorders,$$$66$$$76$$$O	including$$$77$$$86$$$O	obesity$$$87$$$94$$$O	or$$$95$$$97$$$O	metabolic$$$98$$$107$$$O	syndrome$$$108$$$116$$$O	in$$$117$$$119$$$O	patients$$$120$$$128$$$O	with$$$129$$$133$$$O	developed$$$134$$$143$$$O	diabetes$$$144$$$152$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	substituted$$$44$$$55$$$O	pyrazoline$$$56$$$66$$$I	compounds$$$67$$$76$$$O	for$$$77$$$80$$$O	the$$$81$$$84$$$O	treatment$$$85$$$94$$$O	of$$$95$$$97$$$O	food$$$98$$$102$$$O	disorders,$$$103$$$113$$$O	including$$$114$$$123$$$O	obesity$$$124$$$131$$$O	or$$$132$$$134$$$O	metabolic$$$135$$$144$$$O	syndrome$$$145$$$153$$$O	in$$$154$$$156$$$O	patients$$$157$$$165$$$O	with$$$166$$$170$$$O	developed$$$171$$$180$$$O	diabetes.$$$181$$$190$$$O
CN103462960A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Incarviatone$$$15$$$27$$$I	A$$$28$$$29$$$I	in$$$30$$$32$$$O	medicaments$$$33$$$44$$$O	for$$$45$$$48$$$O	treating$$$49$$$57$$$O	prostatic$$$58$$$67$$$O	cancer$$$68$$$74$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	application$$$27$$$38$$$O	of$$$39$$$41$$$O	Incarviatone$$$42$$$54$$$I	A$$$55$$$56$$$I	in$$$57$$$59$$$O	preparation$$$60$$$71$$$O	of$$$72$$$74$$$O	medicaments$$$75$$$86$$$O	for$$$87$$$90$$$O	treating$$$91$$$99$$$O	prostatic$$$100$$$109$$$O	cancer,$$$110$$$117$$$O	and$$$118$$$121$$$O	belongs$$$122$$$129$$$O	to$$$130$$$132$$$O	the$$$133$$$136$$$O	technical$$$137$$$146$$$O	field$$$147$$$152$$$O	of$$$153$$$155$$$O	a$$$156$$$157$$$O	new$$$158$$$161$$$O	application$$$162$$$173$$$O	of$$$174$$$176$$$O	medicaments.$$$177$$$189$$$O	In-vitro$$$190$$$198$$$O	methyl$$$199$$$205$$$I	thiazolyl$$$206$$$215$$$I	tetrazolium$$$216$$$227$$$I	(MTT)$$$228$$$233$$$I	anti-tumor$$$234$$$244$$$O	activity$$$245$$$253$$$O	evaluation$$$254$$$264$$$O	discovers$$$265$$$274$$$O	that$$$275$$$279$$$O	the$$$280$$$283$$$O	Incarviatone$$$284$$$296$$$O	A$$$297$$$298$$$O	has$$$299$$$302$$$O	a$$$303$$$304$$$O	prominent$$$305$$$314$$$O	inhibiting$$$315$$$325$$$O	effect$$$326$$$332$$$O	on$$$333$$$335$$$O	growth$$$336$$$342$$$O	of$$$343$$$345$$$O	human$$$346$$$351$$$O	prostatic$$$352$$$361$$$O	cancer$$$362$$$368$$$O	cell$$$369$$$373$$$O	strains$$$374$$$381$$$O	ALVA,$$$382$$$387$$$O	gpc-1,$$$388$$$394$$$O	9L-B$$$395$$$399$$$O	and$$$400$$$403$$$O	Du145.$$$404$$$410$$$O	Therefore,$$$411$$$421$$$O	the$$$422$$$425$$$O	Incarviatone$$$426$$$438$$$I	A$$$439$$$440$$$I	can$$$441$$$444$$$O	be$$$445$$$447$$$O	used$$$448$$$452$$$O	for$$$453$$$456$$$O	preparing$$$457$$$466$$$O	anti-prostatic$$$467$$$481$$$O	cancer$$$482$$$488$$$O	medicaments,$$$489$$$501$$$O	and$$$502$$$505$$$O	has$$$506$$$509$$$O	a$$$510$$$511$$$O	good$$$512$$$516$$$O	development$$$517$$$528$$$O	and$$$529$$$532$$$O	application$$$533$$$544$$$O	prospect.$$$545$$$554$$$O	The$$$555$$$558$$$O	application$$$559$$$570$$$O	of$$$571$$$573$$$O	the$$$574$$$577$$$O	Incarviatone$$$578$$$590$$$I	A$$$591$$$592$$$I	in$$$593$$$595$$$O	preparation$$$596$$$607$$$O	of$$$608$$$610$$$O	the$$$611$$$614$$$O	medicaments$$$615$$$626$$$O	for$$$627$$$630$$$O	treating$$$631$$$639$$$O	the$$$640$$$643$$$O	prostatic$$$644$$$653$$$O	cancer$$$654$$$660$$$O	is$$$661$$$663$$$O	made$$$664$$$668$$$O	public$$$669$$$675$$$O	for$$$676$$$679$$$O	the$$$680$$$683$$$O	first$$$684$$$689$$$O	time,$$$690$$$695$$$O	the$$$696$$$699$$$O	skeleton$$$700$$$708$$$O	type$$$709$$$713$$$O	is$$$714$$$716$$$O	completely$$$717$$$727$$$O	novel,$$$728$$$734$$$O	and$$$735$$$738$$$O	the$$$739$$$742$$$O	Incarviatone$$$743$$$755$$$I	A$$$756$$$757$$$I	has$$$758$$$761$$$O	an$$$762$$$764$$$O	unexpectedly$$$765$$$777$$$O	strong$$$778$$$784$$$O	prostatic$$$785$$$794$$$O	cancer$$$795$$$801$$$O	cell$$$802$$$806$$$O	inhibiting$$$807$$$817$$$O	activity.$$$818$$$827$$$O
US20100316708
Novel$$$0$$$5$$$O	Pharmaceutical$$$6$$$20$$$O	Formulation$$$21$$$32$$$O	Containing$$$33$$$43$$$O	A$$$44$$$45$$$O	Biguanide$$$46$$$55$$$I	and$$$56$$$59$$$O	a$$$60$$$61$$$O	Thiazolidinedione$$$62$$$79$$$I	Derivative$$$80$$$90$$$O
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	dosage$$$17$$$23$$$O	form$$$24$$$28$$$O	comprising$$$29$$$39$$$O	a$$$40$$$41$$$O	controlled$$$42$$$52$$$O	release$$$53$$$60$$$O	component$$$61$$$70$$$O	comprising$$$71$$$81$$$O	an$$$82$$$84$$$O	antihyperglycemic$$$85$$$102$$$O	drug$$$103$$$107$$$O	in$$$108$$$110$$$O	combination$$$111$$$122$$$O	with$$$123$$$127$$$O	a$$$128$$$129$$$O	second$$$130$$$136$$$O	component$$$137$$$146$$$O	comprising$$$147$$$157$$$O	a$$$158$$$159$$$O	thiazolidinedione$$$160$$$177$$$I	derivative$$$178$$$188$$$O	is$$$189$$$191$$$O	herein$$$192$$$198$$$O	disclosed$$$199$$$208$$$O	and$$$209$$$212$$$O	described.$$$213$$$223$$$O
US6962941
such$$$0$$$4$$$O	as$$$5$$$7$$$O	1,4-Bis-{N-[3-(3-aminomethylphenylproplonyl)-2-methoxycarbonylpyrrolidin-4-yl]aminocarbonyloxy}-2-butyne$$$8$$$112$$$I	dihydrochloride;$$$113$$$129$$$I	for$$$130$$$133$$$O	treatment$$$134$$$143$$$O	of$$$144$$$146$$$O	asthma,$$$147$$$154$$$O	allergic$$$155$$$163$$$O	conjunctivitis,$$$164$$$179$$$O	allergic$$$180$$$188$$$O	rhinitis,$$$189$$$198$$$O	psoriasis,$$$199$$$209$$$O	and$$$210$$$213$$$O	ulcerative$$$214$$$224$$$O	colitis$$$225$$$232$$$O
The$$$0$$$3$$$O	compounds$$$4$$$13$$$O	of$$$14$$$16$$$O	formula$$$17$$$24$$$O	I$$$25$$$26$$$O	in$$$42$$$44$$$O	which$$$45$$$50$$$O	M,$$$51$$$53$$$O	B1,$$$54$$$57$$$O	B2,$$$58$$$61$$$O	R1,$$$62$$$65$$$O	R2,$$$66$$$69$$$O	R6,$$$70$$$73$$$O	R7,$$$74$$$77$$$O	K1$$$78$$$80$$$O	and$$$81$$$84$$$O	K2$$$85$$$87$$$O	have$$$88$$$92$$$O	the$$$93$$$96$$$O	meanings$$$97$$$105$$$O	as$$$106$$$108$$$O	indicated$$$109$$$118$$$O	in$$$119$$$121$$$O	the$$$122$$$125$$$O	description$$$126$$$137$$$O	are$$$138$$$141$$$O	novel$$$142$$$147$$$O	active$$$148$$$154$$$O	tryptase$$$155$$$163$$$O	inhibitors.$$$164$$$175$$$O
US20120045505
Fixed$$$0$$$5$$$O	dose$$$6$$$10$$$O	drug$$$11$$$15$$$O	combination$$$16$$$27$$$O	formulations$$$28$$$40$$$O
Pharmaceutical$$$0$$$14$$$O	formulations$$$15$$$27$$$O	comprising$$$28$$$38$$$O	multiple$$$39$$$47$$$O	drugs,$$$48$$$54$$$O	for$$$55$$$58$$$O	treating$$$59$$$67$$$O	or$$$68$$$70$$$O	preventing$$$71$$$81$$$O	cardiovascular$$$82$$$96$$$O	disease.$$$97$$$105$$$O	Embodiments$$$106$$$117$$$O	are$$$118$$$121$$$O	capsules$$$122$$$130$$$O	containing$$$131$$$141$$$O	individual$$$142$$$152$$$O	drugs,$$$153$$$159$$$O	or$$$160$$$162$$$O	combinations$$$163$$$175$$$O	of$$$176$$$178$$$O	drugs,$$$179$$$185$$$O	in$$$186$$$188$$$O	the$$$189$$$192$$$O	form$$$193$$$197$$$O	of$$$198$$$200$$$O	small$$$201$$$206$$$O	tablets.$$$207$$$215$$$O
US20110097409
Particles$$$0$$$9$$$O	comprising$$$10$$$20$$$O	a$$$21$$$22$$$O	salt$$$23$$$27$$$O	of$$$28$$$30$$$O	8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone$$$31$$$114$$$I	having$$$115$$$121$$$O	improved$$$122$$$130$$$O	adhesion$$$131$$$139$$$O	properties$$$140$$$150$$$O	for$$$151$$$154$$$O	powder$$$155$$$161$$$O	formulations$$$162$$$174$$$O	for$$$175$$$178$$$O	inhalation$$$179$$$189$$$O
Powder$$$0$$$6$$$O	particles$$$7$$$16$$$O	comprising$$$17$$$27$$$O	a$$$28$$$29$$$O	pharmaceutically$$$30$$$46$$$O	acceptable$$$47$$$57$$$O	salt$$$58$$$62$$$O	of$$$63$$$65$$$O	8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone$$$66$$$167$$$I	(carmoterol)$$$168$$$180$$$I	having$$$181$$$187$$$O	a$$$188$$$189$$$O	specific$$$190$$$198$$$O	properties$$$199$$$209$$$O	exhibit$$$210$$$217$$$O	improved$$$218$$$226$$$O	adhesion$$$227$$$235$$$O	properties$$$236$$$246$$$O	for$$$247$$$250$$$O	dry$$$251$$$254$$$O	powder$$$255$$$261$$$O	formulations$$$262$$$274$$$O	for$$$275$$$278$$$O	inhalation.$$$279$$$290$$$O	Such$$$291$$$295$$$O	particles$$$296$$$305$$$O	are$$$306$$$309$$$O	useful$$$310$$$316$$$O	for$$$317$$$320$$$O	formulations$$$321$$$333$$$O	in$$$334$$$336$$$O	the$$$337$$$340$$$O	form$$$341$$$345$$$O	of$$$346$$$348$$$O	powders$$$349$$$356$$$O	for$$$357$$$360$$$O	inhalation$$$361$$$371$$$O	and$$$372$$$375$$$O	the$$$376$$$379$$$O	treatment$$$380$$$389$$$O	of$$$390$$$392$$$O	certain$$$393$$$400$$$O	conditions$$$401$$$411$$$O	and$$$412$$$415$$$O	diseases.$$$416$$$425$$$O
WO2010033444A1
Crystalline$$$0$$$11$$$O	forms$$$12$$$17$$$O	of$$$18$$$20$$$O	a$$$21$$$22$$$O	2-thiazolyl-$$$23$$$35$$$I	4-quinolinyl-oxy$$$36$$$52$$$I	derivative,$$$53$$$64$$$O	a$$$65$$$66$$$O	potent$$$67$$$73$$$O	hcv$$$74$$$77$$$O	inhibitor$$$78$$$87$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	crystalline$$$32$$$43$$$O	forms$$$44$$$49$$$O	of$$$50$$$52$$$O	the$$$53$$$56$$$O	following$$$57$$$66$$$O	Compound$$$67$$$75$$$O	(1),$$$76$$$80$$$O	and$$$81$$$84$$$O	the$$$85$$$88$$$O	sodium$$$89$$$95$$$O	salt$$$96$$$100$$$O	thereof,$$$101$$$109$$$O	and$$$110$$$113$$$O	methods$$$114$$$121$$$O	for$$$122$$$125$$$O	the$$$126$$$129$$$O	preparation$$$130$$$141$$$O	thereof,$$$142$$$150$$$O	pharmaceutical$$$151$$$165$$$O	compositions$$$166$$$178$$$O	thereof,$$$179$$$187$$$O	and$$$188$$$191$$$O	their$$$192$$$197$$$O	use$$$198$$$201$$$O	in$$$202$$$204$$$O	the$$$205$$$208$$$O	treatment$$$209$$$218$$$O	of$$$219$$$221$$$O	Hepatitis$$$222$$$231$$$O	C$$$232$$$233$$$O	Viral$$$234$$$239$$$O	(HCV)$$$240$$$245$$$O	infection.$$$246$$$256$$$O
WO2009058801A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	cfms$$$7$$$11$$$O	inhibitor$$$12$$$21$$$O	for$$$22$$$25$$$O	treating$$$26$$$34$$$O	or$$$35$$$37$$$O	preventing$$$38$$$48$$$O	bone$$$49$$$53$$$O	cancer$$$54$$$60$$$O	and$$$61$$$64$$$O	the$$$65$$$68$$$O	bone$$$69$$$73$$$O	loss$$$74$$$78$$$O	and$$$79$$$82$$$O	bone$$$83$$$87$$$O	pain$$$88$$$92$$$O	associated$$$93$$$103$$$O	with$$$104$$$108$$$O	bone$$$109$$$113$$$O	cancer$$$114$$$120$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	therapeutic$$$31$$$42$$$O	methods$$$43$$$50$$$O	for$$$51$$$54$$$O	treating$$$55$$$63$$$O	a$$$64$$$65$$$O	subject$$$66$$$73$$$O	having,$$$74$$$81$$$O	and$$$82$$$85$$$O	prophylactic$$$86$$$98$$$O	methods$$$99$$$106$$$O	for$$$107$$$110$$$O	preventing$$$111$$$121$$$O	in$$$122$$$124$$$O	a$$$125$$$126$$$O	subject$$$127$$$134$$$O	at$$$135$$$137$$$O	risk$$$138$$$142$$$O	of$$$143$$$145$$$O	(or$$$146$$$149$$$O	susceptible$$$150$$$161$$$O	to$$$162$$$164$$$O	)$$$165$$$166$$$O	developing,$$$167$$$178$$$O	bone$$$179$$$183$$$O	cancer$$$184$$$190$$$O	and$$$191$$$194$$$O	the$$$195$$$198$$$O	bone$$$199$$$203$$$O	loss$$$204$$$208$$$O	and$$$209$$$212$$$O	bone$$$213$$$217$$$O	pain$$$218$$$222$$$O	associtated$$$223$$$234$$$O	with$$$235$$$239$$$O	bone$$$240$$$244$$$O	cancer,$$$245$$$252$$$O	said$$$253$$$257$$$O	method$$$258$$$264$$$O	comprising$$$265$$$275$$$O	the$$$276$$$279$$$O	administration$$$280$$$294$$$O	of$$$295$$$297$$$O	a$$$298$$$299$$$O	compound$$$300$$$308$$$O	of$$$309$$$311$$$O	Formula$$$312$$$319$$$O	(I),$$$320$$$324$$$O	or$$$325$$$327$$$O	a$$$328$$$329$$$O	solvate,$$$330$$$338$$$O	hydrate,$$$339$$$347$$$I	tautomer$$$348$$$356$$$O	or$$$357$$$359$$$O	pharmaceutically$$$360$$$376$$$O	acceptable$$$377$$$387$$$O	salt$$$388$$$392$$$O	thereof.$$$393$$$401$$$O
EP1140930B1
DIBENZO$$$0$$$7$$$I	a,g]QUINOLIZINIUM$$$8$$$25$$$I	DERIVATIVES$$$26$$$37$$$O	AND$$$38$$$41$$$O	THE$$$42$$$45$$$O	SALTS$$$46$$$51$$$O	THEREOF$$$52$$$59$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	5,6-dihydrodibenzo[a,g]quinolizinium$$$33$$$69$$$I	derivative$$$70$$$80$$$O	and$$$81$$$84$$$O	the$$$85$$$88$$$O	salts$$$89$$$94$$$O	thereof$$$95$$$102$$$O	of$$$103$$$105$$$O	formula$$$106$$$113$$$O	(I)$$$114$$$117$$$O	which$$$118$$$123$$$O	specifically$$$124$$$136$$$O	inhibits$$$137$$$145$$$O	the$$$146$$$149$$$O	sterol$$$150$$$156$$$I	14-reductase$$$157$$$169$$$O	which$$$170$$$175$$$O	is$$$176$$$178$$$O	involved$$$179$$$187$$$O	in$$$188$$$190$$$O	the$$$191$$$194$$$O	distal$$$195$$$201$$$O	pathway$$$202$$$209$$$O	of$$$210$$$212$$$O	cholesterol$$$213$$$224$$$I	biosynthesis,$$$225$$$238$$$O	and$$$239$$$242$$$O	the$$$243$$$246$$$O	use$$$247$$$250$$$O	of$$$251$$$253$$$O	the$$$254$$$257$$$O	compound$$$258$$$266$$$O	of$$$267$$$269$$$O	formula$$$270$$$277$$$O	(I)$$$278$$$281$$$O	for$$$282$$$285$$$O	treating$$$286$$$294$$$O	hypercholesterolaemia$$$295$$$316$$$O	or$$$317$$$319$$$O	hyperlipidaemia,$$$320$$$336$$$O	wherein$$$337$$$344$$$O	R?1,$$$345$$$349$$$O	R2,$$$350$$$353$$$O	R3,$$$354$$$357$$$O	R4Â¿,$$$358$$$363$$$O	X$$$364$$$365$$$O	and$$$366$$$369$$$O	2$$$370$$$371$$$O	are$$$372$$$375$$$O	defined$$$376$$$383$$$O	in$$$384$$$386$$$O	the$$$387$$$390$$$O	claims.$$$391$$$398$$$O
CN102382014A
Aminopeptidase$$$0$$$14$$$O	N$$$15$$$16$$$O	inhibitor,$$$17$$$27$$$O	preparation$$$28$$$39$$$O	method$$$40$$$46$$$O	and$$$47$$$50$$$O	application$$$51$$$62$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	drugs,$$$48$$$54$$$O	and$$$55$$$58$$$O	particularly$$$59$$$71$$$O	relates$$$72$$$79$$$O	to$$$80$$$82$$$O	aminopeptidase$$$83$$$97$$$O	N$$$98$$$99$$$O	inhibitor,$$$100$$$110$$$O	a$$$111$$$112$$$O	preparation$$$113$$$124$$$O	method$$$125$$$131$$$O	and$$$132$$$135$$$O	application$$$136$$$147$$$O	to$$$148$$$150$$$O	tumor$$$151$$$156$$$O	resistance.$$$157$$$168$$$O	The$$$169$$$172$$$O	technical$$$173$$$182$$$O	scheme$$$183$$$189$$$O	includes$$$190$$$198$$$O	that$$$199$$$203$$$O	the$$$204$$$207$$$O	aminopeptidase$$$208$$$222$$$O	N$$$223$$$224$$$O	inhibitor$$$225$$$234$$$O	is$$$235$$$237$$$O	chemically$$$238$$$248$$$O	named$$$249$$$254$$$O	as$$$255$$$257$$$O	(S)-4-methyl-2-(3-naphthyl-1-ylmethyl-ureido)-valeryl$$$258$$$311$$$I	group$$$312$$$317$$$O	hydroxylamine.$$$318$$$332$$$I	The$$$333$$$336$$$O	constitutional$$$337$$$351$$$O	formula$$$352$$$359$$$O	(I)$$$360$$$363$$$O	of$$$364$$$366$$$O	the$$$367$$$370$$$O	aminopeptidase$$$371$$$385$$$O	N$$$386$$$387$$$O	inhibitor$$$388$$$397$$$O	is$$$398$$$400$$$O	shown$$$401$$$406$$$O	here.$$$407$$$412$$$O	The$$$413$$$416$$$O	pharmacodynamic$$$417$$$432$$$O	effect$$$433$$$439$$$O	of$$$440$$$442$$$O	the$$$443$$$446$$$O	aminopeptidase$$$447$$$461$$$O	N$$$462$$$463$$$O	inhibitor$$$464$$$473$$$O	is$$$474$$$476$$$O	evaluated$$$477$$$486$$$O	by$$$487$$$489$$$O	in-vitro$$$490$$$498$$$O	APN$$$499$$$502$$$O	(adiponectin)$$$503$$$516$$$O	inhibitory$$$517$$$527$$$O	experiments,$$$528$$$540$$$O	in-vitro$$$541$$$549$$$O	resistance$$$550$$$560$$$O	to$$$561$$$563$$$O	tumor$$$564$$$569$$$O	cell$$$570$$$574$$$O	invasion,$$$575$$$584$$$O	antiangiogenesis$$$585$$$601$$$O	and$$$602$$$605$$$O	mouse$$$606$$$611$$$O	in-vivo$$$612$$$619$$$O	resistance$$$620$$$630$$$O	to$$$631$$$633$$$O	melanoma$$$634$$$642$$$O	manual$$$643$$$649$$$O	transfer$$$650$$$658$$$O	and$$$659$$$662$$$O	antiangiogenesis$$$663$$$679$$$O	experiments.$$$680$$$692$$$O
CN102125530A
Gefarnate$$$0$$$9$$$I	sustained$$$10$$$19$$$O	release$$$20$$$27$$$O	preparation$$$28$$$39$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	gefarnate$$$25$$$34$$$I	sustained$$$35$$$44$$$O	release$$$45$$$52$$$O	preparation,$$$53$$$65$$$O	wherein$$$66$$$73$$$O	the$$$74$$$77$$$O	gefarnate$$$78$$$87$$$I	is$$$88$$$90$$$O	dispersed$$$91$$$100$$$O	in$$$101$$$103$$$O	a$$$104$$$105$$$O	sustained-release$$$106$$$123$$$O	skeletal$$$124$$$132$$$O	material.$$$133$$$142$$$O	Skeletal$$$143$$$151$$$O	materials$$$152$$$161$$$O	applicable$$$162$$$172$$$O	to$$$173$$$175$$$O	the$$$176$$$179$$$O	invention$$$180$$$189$$$O	are$$$190$$$193$$$O	selected$$$194$$$202$$$O	from$$$203$$$207$$$O	cellulose$$$208$$$217$$$O	derivatives,$$$218$$$230$$$O	acrylic$$$231$$$238$$$I	resins,$$$239$$$246$$$O	vinyl$$$247$$$252$$$I	polymers$$$253$$$261$$$O	and$$$262$$$265$$$O	other$$$266$$$271$$$O	types$$$272$$$277$$$O	of$$$278$$$280$$$O	skeletal$$$281$$$289$$$O	materials.$$$290$$$300$$$O	The$$$301$$$304$$$O	cellulose$$$305$$$314$$$O	derivative$$$315$$$325$$$O	is$$$326$$$328$$$O	selected$$$329$$$337$$$O	from$$$338$$$342$$$O	one$$$343$$$346$$$O	or$$$347$$$349$$$O	more$$$350$$$354$$$O	than$$$355$$$359$$$O	one$$$360$$$363$$$O	of$$$364$$$366$$$O	ethyl$$$367$$$372$$$O	cellulose,$$$373$$$383$$$O	methyl$$$384$$$390$$$O	cellulose,$$$391$$$401$$$O	hydroxypropyl$$$402$$$415$$$O	methylcellulose,$$$416$$$432$$$O	hydroxypropyl$$$433$$$446$$$O	cellulose,$$$447$$$457$$$O	and$$$458$$$461$$$O	sodium$$$462$$$468$$$O	carboxymethylcellulose.$$$469$$$492$$$O	The$$$493$$$496$$$O	acrylic$$$497$$$504$$$I	resin$$$505$$$510$$$O	is$$$511$$$513$$$O	selected$$$514$$$522$$$O	from$$$523$$$527$$$O	acrylic$$$528$$$535$$$I	resin$$$536$$$541$$$O	No.$$$542$$$545$$$O	II$$$546$$$548$$$O	and/or$$$549$$$555$$$O	acrylic$$$556$$$563$$$I	resin$$$564$$$569$$$O	No.$$$570$$$573$$$O	III.$$$574$$$578$$$O	The$$$579$$$582$$$O	vinyl$$$583$$$588$$$I	polymer$$$589$$$596$$$O	is$$$597$$$599$$$O	selected$$$600$$$608$$$O	from$$$609$$$613$$$O	one$$$614$$$617$$$O	or$$$618$$$620$$$O	more$$$621$$$625$$$O	than$$$626$$$630$$$O	one$$$631$$$634$$$O	of$$$635$$$637$$$O	polyvinylpyrrolidone,$$$638$$$659$$$I	polyvinyl$$$660$$$669$$$I	alcohol,$$$670$$$678$$$I	polystyrene,$$$679$$$691$$$I	and$$$692$$$695$$$O	polyvinyl$$$696$$$705$$$I	chloride.$$$706$$$715$$$I	A$$$716$$$717$$$O	unit$$$718$$$722$$$O	preparation$$$723$$$734$$$O	of$$$735$$$737$$$O	the$$$738$$$741$$$O	gefarnate$$$742$$$751$$$I	sustained$$$752$$$761$$$O	release$$$762$$$769$$$O	preparation$$$770$$$781$$$O	of$$$782$$$784$$$O	the$$$785$$$788$$$O	invention$$$789$$$798$$$O	contains$$$799$$$807$$$O	150-300$$$808$$$815$$$O	mg$$$816$$$818$$$O	gefarnate,$$$819$$$829$$$I	and$$$830$$$833$$$O	the$$$834$$$837$$$O	dosage$$$838$$$844$$$O	form$$$845$$$849$$$O	can$$$850$$$853$$$O	be$$$854$$$856$$$O	tablets,$$$857$$$865$$$O	pills$$$866$$$871$$$O	or$$$872$$$874$$$O	granules.$$$875$$$884$$$O	The$$$885$$$888$$$O	gefarnate$$$889$$$898$$$I	sustained$$$899$$$908$$$O	release$$$909$$$916$$$O	preparation$$$917$$$928$$$O	of$$$929$$$931$$$O	the$$$932$$$935$$$O	invention$$$936$$$945$$$O	reduces$$$946$$$953$$$O	the$$$954$$$957$$$O	times$$$958$$$963$$$O	of$$$964$$$966$$$O	administration$$$967$$$981$$$O	when$$$982$$$986$$$O	compared$$$987$$$995$$$O	with$$$996$$$1000$$$O	routine$$$1001$$$1008$$$O	preparations.$$$1009$$$1022$$$O
US20050101632
Treating$$$0$$$8$$$O	inflammation$$$9$$$21$$$O	of$$$22$$$24$$$O	the$$$25$$$28$$$O	skin$$$29$$$33$$$O	or$$$34$$$36$$$O	mucous$$$37$$$43$$$O	membrane$$$44$$$52$$$O	by$$$53$$$55$$$O	topical$$$56$$$63$$$O	administration$$$64$$$78$$$O	of$$$79$$$81$$$O	an$$$82$$$84$$$O	anti-inflammatory$$$85$$$102$$$O	amount$$$103$$$109$$$O	of$$$110$$$112$$$O	dimethicone$$$113$$$124$$$O	in$$$125$$$127$$$O	the$$$128$$$131$$$O	absence$$$132$$$139$$$O	of$$$140$$$142$$$O	any$$$143$$$146$$$O	other$$$147$$$152$$$O	anti-inflammatory$$$153$$$170$$$O	agent$$$171$$$176$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	treating,$$$13$$$22$$$O	eliminating$$$23$$$34$$$O	and$$$35$$$38$$$O	preventing$$$39$$$49$$$O	an$$$50$$$52$$$O	inflammation$$$53$$$65$$$O	of$$$66$$$68$$$O	the$$$69$$$72$$$O	skin$$$73$$$77$$$O	or$$$78$$$80$$$O	mucous$$$81$$$87$$$O	membrane$$$88$$$96$$$O	of$$$97$$$99$$$O	a$$$100$$$101$$$O	mammal,$$$102$$$109$$$O	including$$$110$$$119$$$O	a$$$120$$$121$$$O	human,$$$122$$$128$$$O	by$$$129$$$131$$$O	administering$$$132$$$145$$$O	to$$$146$$$148$$$O	the$$$149$$$152$$$O	skin$$$153$$$157$$$O	or$$$158$$$160$$$O	mucous$$$161$$$167$$$O	membrane$$$168$$$176$$$O	a$$$177$$$178$$$O	composition$$$179$$$190$$$O	containing$$$191$$$201$$$O	dimethicone$$$202$$$213$$$O	and$$$214$$$217$$$O	a$$$218$$$219$$$O	pharmaceutically$$$220$$$236$$$O	acceptable$$$237$$$247$$$O	carrier.$$$248$$$256$$$O	The$$$257$$$260$$$O	dimethicone$$$261$$$272$$$O	composition$$$273$$$284$$$O	is$$$285$$$287$$$O	applied$$$288$$$295$$$O	to$$$296$$$298$$$O	the$$$299$$$302$$$O	skin$$$303$$$307$$$O	or$$$308$$$310$$$O	mucous$$$311$$$317$$$O	membrane$$$318$$$326$$$O	in$$$327$$$329$$$O	an$$$330$$$332$$$O	amount$$$333$$$339$$$O	effective$$$340$$$349$$$O	to$$$350$$$352$$$O	treat,$$$353$$$359$$$O	eliminate$$$360$$$369$$$O	or$$$370$$$372$$$O	prevent$$$373$$$380$$$O	the$$$381$$$384$$$O	inflammation.$$$385$$$398$$$O
WO2012008565A1
Imidazoline$$$0$$$11$$$I	derivatives$$$12$$$23$$$O
Imidazoline$$$0$$$11$$$I	derivatives$$$12$$$23$$$O	represented$$$24$$$35$$$O	by$$$36$$$38$$$O	general$$$39$$$46$$$O	formula$$$47$$$54$$$O	(I)$$$55$$$58$$$O	or$$$59$$$61$$$O	pharmacologically$$$62$$$79$$$O	acceptable$$$80$$$90$$$O	salts$$$91$$$96$$$O	thereof,$$$97$$$105$$$O	which$$$106$$$111$$$O	exhibit$$$112$$$119$$$O	high$$$120$$$124$$$O	selectivity$$$125$$$136$$$O	for$$$137$$$140$$$O	Î±1L$$$141$$$145$$$O	and$$$146$$$149$$$O	are$$$150$$$153$$$O	useful$$$154$$$160$$$O	as$$$161$$$163$$$O	drugs$$$164$$$169$$$O	for$$$170$$$173$$$O	the$$$174$$$177$$$O	treatment$$$178$$$187$$$O	of$$$188$$$190$$$O	urinary$$$191$$$198$$$O	incontinence.$$$199$$$212$$$O	In$$$213$$$215$$$O	general$$$216$$$223$$$O	formula$$$224$$$231$$$O	(I),$$$232$$$236$$$O	either$$$237$$$243$$$O	X$$$244$$$245$$$O	or$$$246$$$248$$$O	Y$$$249$$$250$$$O	is$$$251$$$253$$$I	hydrogen,$$$254$$$263$$$I	and$$$264$$$267$$$O	the$$$268$$$271$$$O	other$$$272$$$277$$$O	is$$$278$$$280$$$I	NR1R2;$$$281$$$287$$$I	R1$$$288$$$290$$$O	and$$$291$$$294$$$O	R2$$$295$$$297$$$O	may$$$298$$$301$$$O	be$$$302$$$304$$$O	the$$$305$$$308$$$O	same$$$309$$$313$$$O	or$$$314$$$316$$$O	different$$$317$$$326$$$O	and$$$327$$$330$$$O	are$$$331$$$334$$$O	each$$$335$$$339$$$I	hydrogen$$$340$$$348$$$I	or$$$349$$$351$$$I	methyl;$$$352$$$359$$$I	and$$$360$$$363$$$O	Z$$$364$$$365$$$O	is$$$366$$$368$$$I	chloro$$$369$$$375$$$I	or$$$376$$$378$$$I	methyl.$$$379$$$386$$$I
CN101087777B
Pyrrolidinium$$$0$$$13$$$O	derivatives$$$14$$$25$$$O	as$$$26$$$28$$$O	M3$$$29$$$31$$$O	muscarinic$$$32$$$42$$$O	receptors$$$43$$$52$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I)$$$21$$$24$$$O	in$$$25$$$27$$$O	salt$$$28$$$32$$$O	or$$$33$$$35$$$O	zwitterionic$$$36$$$48$$$O	form,$$$49$$$54$$$O	wherein$$$55$$$62$$$O	R<1>,$$$63$$$68$$$O	R<2>,$$$69$$$74$$$O	R<3>,$$$75$$$80$$$O	R<4>$$$81$$$85$$$O	and$$$86$$$89$$$O	R<5>$$$90$$$94$$$O	have$$$95$$$99$$$O	the$$$100$$$103$$$O	meanings$$$104$$$112$$$O	as$$$113$$$115$$$O	indicated$$$116$$$125$$$O	in$$$126$$$128$$$O	the$$$129$$$132$$$O	specification,$$$133$$$147$$$O	are$$$148$$$151$$$O	useful$$$152$$$158$$$O	for$$$159$$$162$$$O	treating$$$163$$$171$$$O	conditions$$$172$$$182$$$O	that$$$183$$$187$$$O	are$$$188$$$191$$$O	mediated$$$192$$$200$$$O	by$$$201$$$203$$$O	the$$$204$$$207$$$O	muscarinic$$$208$$$218$$$O	M3$$$219$$$221$$$O	receptor.$$$222$$$231$$$O	Pharmaceutical$$$232$$$246$$$O	compositions$$$247$$$259$$$O	that$$$260$$$264$$$O	contain$$$265$$$272$$$O	the$$$273$$$276$$$O	compounds$$$277$$$286$$$O	and$$$287$$$290$$$O	a$$$291$$$292$$$O	process$$$293$$$300$$$O	for$$$301$$$304$$$O	preparing$$$305$$$314$$$O	the$$$315$$$318$$$O	compounds$$$319$$$328$$$O	are$$$329$$$332$$$O	also$$$333$$$337$$$O	described.$$$338$$$348$$$O
US8258132
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	of$$$27$$$29$$$O	a$$$30$$$31$$$O	tachykinin$$$32$$$42$$$O	receptor$$$43$$$51$$$O	antagonist$$$52$$$62$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	novel$$$37$$$42$$$O	pharmaceutical$$$43$$$57$$$O	compositions$$$58$$$70$$$O	of$$$71$$$73$$$O	the$$$74$$$77$$$O	compound$$$78$$$86$$$O	2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine.$$$87$$$213$$$I	The$$$214$$$217$$$O	pharmaceutical$$$218$$$232$$$O	compositions$$$233$$$245$$$O	of$$$246$$$248$$$O	this$$$249$$$253$$$O	invention$$$254$$$263$$$O	useful$$$264$$$270$$$O	in$$$271$$$273$$$O	the$$$274$$$277$$$O	treatment$$$278$$$287$$$O	or$$$288$$$290$$$O	prevention$$$291$$$301$$$O	of$$$302$$$304$$$O	disorders$$$305$$$314$$$O	such$$$315$$$319$$$O	as$$$320$$$322$$$O	psychiatric$$$323$$$334$$$O	disorders$$$335$$$344$$$O	including$$$345$$$354$$$O	depression$$$355$$$365$$$O	and$$$366$$$369$$$O	anxiety,$$$370$$$378$$$O	inflammatory$$$379$$$391$$$O	diseases$$$392$$$400$$$O	and$$$401$$$404$$$O	emesis.$$$405$$$412$$$O
US20090169595
Controlled$$$0$$$10$$$O	Release$$$11$$$18$$$O	Polymeric$$$19$$$28$$$O	Compositions$$$29$$$41$$$O	of$$$42$$$44$$$O	Bone$$$45$$$49$$$O	Growth$$$50$$$56$$$O	Promoting$$$57$$$66$$$O	Compounds$$$67$$$76$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	an$$$37$$$39$$$O	improved$$$40$$$48$$$O	system$$$49$$$55$$$O	for$$$56$$$59$$$O	controlled$$$60$$$70$$$O	release$$$71$$$78$$$O	of$$$79$$$81$$$O	a$$$82$$$83$$$O	bone$$$84$$$88$$$O	growth$$$89$$$95$$$O	promoting$$$96$$$105$$$O	compound$$$106$$$114$$$O	and$$$115$$$118$$$O	to$$$119$$$121$$$O	a$$$122$$$123$$$O	flowable$$$124$$$132$$$O	composition$$$133$$$144$$$O	for$$$145$$$148$$$O	its$$$149$$$152$$$O	formation.$$$153$$$163$$$O	The$$$164$$$167$$$O	flowable$$$168$$$176$$$O	composition$$$177$$$188$$$O	is$$$189$$$191$$$O	composed$$$192$$$200$$$O	of$$$201$$$203$$$O	a$$$204$$$205$$$O	bone$$$206$$$210$$$O	growth$$$211$$$217$$$O	promoting$$$218$$$227$$$O	compound,$$$228$$$237$$$O	a$$$238$$$239$$$O	thermoplastic$$$240$$$253$$$O	polymer$$$254$$$261$$$O	and$$$262$$$265$$$O	an$$$266$$$268$$$O	organic$$$269$$$276$$$O	solvent.$$$277$$$285$$$O	The$$$286$$$289$$$O	flowable$$$290$$$298$$$O	composition$$$299$$$310$$$O	is$$$311$$$313$$$O	capable$$$314$$$321$$$O	of$$$322$$$324$$$O	forming$$$325$$$332$$$O	a$$$333$$$334$$$O	biodegradable$$$335$$$348$$$O	and/or$$$349$$$355$$$O	bioerodible$$$356$$$367$$$O	microporous,$$$368$$$380$$$O	solid$$$381$$$386$$$O	polymer$$$387$$$394$$$O	matrix.$$$395$$$402$$$O	The$$$403$$$406$$$O	matrix$$$407$$$413$$$O	is$$$414$$$416$$$O	useful$$$417$$$423$$$O	as$$$424$$$426$$$O	an$$$427$$$429$$$O	implant$$$430$$$437$$$O	in$$$438$$$440$$$O	patients$$$441$$$449$$$O	(humans$$$450$$$457$$$O	and$$$458$$$461$$$O	animals)$$$462$$$470$$$O	for$$$471$$$474$$$O	delivery$$$475$$$483$$$O	of$$$484$$$486$$$O	a$$$487$$$488$$$O	bone$$$489$$$493$$$O	growth$$$494$$$500$$$O	promoting$$$501$$$510$$$O	compound$$$511$$$519$$$O	to$$$520$$$522$$$O	certain$$$523$$$530$$$O	tissues.$$$531$$$539$$$O
CN103172587A
Benzisothiazole-3-ketone-2-amide$$$0$$$32$$$I	compound$$$33$$$41$$$O	with$$$42$$$46$$$O	Caspase-3$$$47$$$56$$$O	inhibiting$$$57$$$67$$$O	activity$$$68$$$76$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	benzisothiazole-3-ketone-2-amide$$$27$$$59$$$I	compound$$$60$$$68$$$O	with$$$69$$$73$$$O	Caspase-3$$$74$$$83$$$O	inhibiting$$$84$$$94$$$O	activity.$$$95$$$104$$$O	The$$$105$$$108$$$O	benzisothiazole-3-ketone-2-amide$$$109$$$141$$$I	compound$$$142$$$150$$$O	has$$$151$$$154$$$O	the$$$155$$$158$$$O	Caspase-3$$$159$$$168$$$O	inhibiting$$$169$$$179$$$O	activity,$$$180$$$189$$$O	can$$$190$$$193$$$O	be$$$194$$$196$$$O	used$$$197$$$201$$$O	for$$$202$$$205$$$O	treating$$$206$$$214$$$O	diseases$$$215$$$223$$$O	mediated$$$224$$$232$$$O	by$$$233$$$235$$$O	Caspase-3,$$$236$$$246$$$O	belongs$$$247$$$254$$$O	to$$$255$$$257$$$O	the$$$258$$$261$$$O	field$$$262$$$267$$$O	of$$$268$$$270$$$O	pharmaceutical$$$271$$$285$$$O	chemistry,$$$286$$$296$$$O	and$$$297$$$300$$$O	has$$$301$$$304$$$O	a$$$305$$$306$$$O	structural$$$307$$$317$$$O	formula$$$318$$$325$$$O	(I)$$$326$$$329$$$O	as$$$330$$$332$$$O	shown$$$333$$$338$$$O	in$$$339$$$341$$$O	the$$$342$$$345$$$O	specification.$$$346$$$360$$$O
US20080292681
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	Dha,$$$7$$$11$$$I	Epa$$$12$$$15$$$I	or$$$16$$$18$$$O	Dha-Derived$$$19$$$30$$$I	Epa$$$31$$$34$$$I	for$$$35$$$38$$$O	Treating$$$39$$$47$$$O	a$$$48$$$49$$$O	Pathology$$$50$$$59$$$O	Associated$$$60$$$70$$$O	with$$$71$$$75$$$O	Cellular$$$76$$$84$$$O	Oxidative$$$85$$$94$$$O	Damage$$$95$$$101$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	an$$$44$$$46$$$O	acid$$$47$$$51$$$O	enriched$$$52$$$60$$$O	in$$$61$$$63$$$O	docosahexaenoic$$$64$$$79$$$I	acid$$$80$$$84$$$I	(DHA)$$$85$$$90$$$I	or$$$91$$$93$$$O	eicosapentaenoic$$$94$$$110$$$I	acid$$$111$$$115$$$I	(EPA)$$$116$$$121$$$I	or$$$122$$$124$$$O	DHA-derived$$$125$$$136$$$I	EPA$$$137$$$140$$$I	for$$$141$$$144$$$O	manufacturing$$$145$$$158$$$O	a$$$159$$$160$$$O	drug$$$161$$$165$$$O	for$$$166$$$169$$$O	the$$$170$$$173$$$O	treatment$$$174$$$183$$$O	of$$$184$$$186$$$O	processes$$$187$$$196$$$O	that$$$197$$$201$$$O	involve$$$202$$$209$$$O	associated$$$210$$$220$$$O	oxidative$$$221$$$230$$$O	damage.$$$231$$$238$$$O	In$$$239$$$241$$$O	particular,$$$242$$$253$$$O	it$$$254$$$256$$$O	is$$$257$$$259$$$O	for$$$260$$$263$$$O	the$$$264$$$267$$$O	treatment$$$268$$$277$$$O	of$$$278$$$280$$$O	processes$$$281$$$290$$$O	associated$$$291$$$301$$$O	with$$$302$$$306$$$O	neurodegenerative,$$$307$$$325$$$O	ocular,$$$326$$$333$$$O	ischaemic$$$334$$$343$$$O	and$$$344$$$347$$$O	inflammatory$$$348$$$360$$$O	pathology,$$$361$$$371$$$O	atherosclerosis,$$$372$$$388$$$O	with$$$389$$$393$$$O	oxidative$$$394$$$403$$$O	damage$$$404$$$410$$$O	to$$$411$$$413$$$O	DNA$$$414$$$417$$$O	and$$$418$$$421$$$O	with$$$422$$$426$$$O	physical$$$427$$$435$$$O	exercise.$$$436$$$445$$$O
US20060173014
Useful$$$0$$$6$$$O	for$$$7$$$10$$$O	the$$$11$$$14$$$O	prevention$$$15$$$25$$$O	and/or$$$26$$$32$$$O	treatment$$$33$$$42$$$O	of$$$43$$$45$$$O	cognitive$$$46$$$55$$$O	disorders;$$$56$$$66$$$O	3-Amino-N-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide,$$$67$$$153$$$I	for$$$154$$$157$$$O	example$$$158$$$165$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	new$$$33$$$36$$$O	compounds,$$$37$$$47$$$O	a$$$48$$$49$$$O	process$$$50$$$57$$$O	for$$$58$$$61$$$O	their$$$62$$$67$$$O	preparation$$$68$$$79$$$O	and$$$80$$$83$$$O	new$$$84$$$87$$$O	intermediates$$$88$$$101$$$O	used$$$102$$$106$$$O	therein,$$$107$$$115$$$O	pharmaceutical$$$116$$$130$$$O	formulations$$$131$$$143$$$O	containing$$$144$$$154$$$O	said$$$155$$$159$$$O	therapeutically$$$160$$$175$$$O	active$$$176$$$182$$$O	compounds$$$183$$$192$$$O	and$$$193$$$196$$$O	to$$$197$$$199$$$O	the$$$200$$$203$$$O	use$$$204$$$207$$$O	of$$$208$$$210$$$O	said$$$211$$$215$$$O	active$$$216$$$222$$$O	compounds$$$223$$$232$$$O	in$$$233$$$235$$$O	therapy,$$$236$$$244$$$O	such$$$245$$$249$$$O	as$$$250$$$252$$$O	provide$$$253$$$260$$$O	compounds$$$261$$$270$$$O	having$$$271$$$277$$$O	a$$$278$$$279$$$O	selective$$$280$$$289$$$O	inhibiting$$$290$$$300$$$O	effect$$$301$$$307$$$O	at$$$308$$$310$$$O	GSK3.$$$311$$$316$$$O
CN101502486A
Antineoplastic$$$0$$$14$$$O	2-methoxyestradiol$$$15$$$33$$$I	injection$$$34$$$43$$$O	containing$$$44$$$54$$$O	cyclodextrin$$$55$$$67$$$O	or$$$68$$$70$$$O	cyclodextrin$$$71$$$83$$$O	derivates$$$84$$$93$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	2-methoxyestradiol$$$25$$$43$$$I	injection,$$$44$$$54$$$O	an$$$55$$$57$$$O	anti-tumor$$$58$$$68$$$O	drug$$$69$$$73$$$O	containing$$$74$$$84$$$O	cyclodextrin$$$85$$$97$$$O	or$$$98$$$100$$$O	cyclodextrin$$$101$$$113$$$O	derivatives,$$$114$$$126$$$O	and$$$127$$$130$$$O	solves$$$131$$$137$$$O	the$$$138$$$141$$$O	problem$$$142$$$149$$$O	that$$$150$$$154$$$O	2-methoxyestradiol$$$155$$$173$$$I	is$$$174$$$176$$$O	hard$$$177$$$181$$$O	to$$$182$$$184$$$O	be$$$185$$$187$$$O	dissolved$$$188$$$197$$$O	in$$$198$$$200$$$O	water.$$$201$$$207$$$O	The$$$208$$$211$$$O	technical$$$212$$$221$$$O	scheme$$$222$$$228$$$O	to$$$229$$$231$$$O	be$$$232$$$234$$$O	solved$$$235$$$241$$$O	is$$$242$$$244$$$O	as$$$245$$$247$$$O	follows:$$$248$$$256$$$O	the$$$257$$$260$$$O	anti-tumor$$$261$$$271$$$O	drug,$$$272$$$277$$$O	that$$$278$$$282$$$O	is,$$$283$$$286$$$O	the$$$287$$$290$$$O	2-methoxyestradiol$$$291$$$309$$$I	injection$$$310$$$319$$$O	containing$$$320$$$330$$$O	cyclodextrin$$$331$$$343$$$O	or$$$344$$$346$$$O	cyclodextrin$$$347$$$359$$$O	derivatives,$$$360$$$372$$$O	is$$$373$$$375$$$O	prepared$$$376$$$384$$$O	from$$$385$$$389$$$O	2-methoxyestradiol$$$390$$$408$$$I	and$$$409$$$412$$$O	cyclodextrin$$$413$$$425$$$O	or$$$426$$$428$$$O	cyclodextrin$$$429$$$441$$$O	derivatives$$$442$$$453$$$O	with$$$454$$$458$$$O	the$$$459$$$462$$$O	mole$$$463$$$467$$$O	ratio$$$468$$$473$$$O	being$$$474$$$479$$$O	1:(2-10);$$$480$$$489$$$O	and$$$490$$$493$$$O	the$$$494$$$497$$$O	mass$$$498$$$502$$$O	concentration$$$503$$$516$$$O	of$$$517$$$519$$$O	2-methoxyestradiol$$$520$$$538$$$I	in$$$539$$$541$$$O	the$$$542$$$545$$$O	final$$$546$$$551$$$O	water$$$552$$$557$$$O	solution$$$558$$$566$$$O	of$$$567$$$569$$$O	the$$$570$$$573$$$O	2-methoxyestradiol$$$574$$$592$$$I	injection$$$593$$$602$$$O	is$$$603$$$605$$$O	0.1mg/ml$$$606$$$614$$$O	to$$$615$$$617$$$O	25mg/ml.$$$618$$$626$$$O	The$$$627$$$630$$$O	invention$$$631$$$640$$$O	is$$$641$$$643$$$O	prepared$$$644$$$652$$$O	by$$$653$$$655$$$O	mixing$$$656$$$662$$$O	2-methoxyestradiol$$$663$$$681$$$I	and$$$682$$$685$$$O	cyclodextrin$$$686$$$698$$$O	or$$$699$$$701$$$O	cyclodextrin$$$702$$$714$$$O	derivatives$$$715$$$726$$$O	having$$$727$$$733$$$O	good$$$734$$$738$$$O	water$$$739$$$744$$$O	solubility$$$745$$$755$$$O	and$$$756$$$759$$$O	biocompatibility,$$$760$$$777$$$O	thereby$$$778$$$785$$$O	effectively$$$786$$$797$$$O	solving$$$798$$$805$$$O	the$$$806$$$809$$$O	problem$$$810$$$817$$$O	that$$$818$$$822$$$O	2-methoxyestradiol$$$823$$$841$$$I	is$$$842$$$844$$$O	hard$$$845$$$849$$$O	to$$$850$$$852$$$O	be$$$853$$$855$$$O	dissolved$$$856$$$865$$$O	in$$$866$$$868$$$O	water,$$$869$$$875$$$O	avoiding$$$876$$$884$$$O	the$$$885$$$888$$$O	allergic$$$889$$$897$$$O	reaction,$$$898$$$907$$$O	greatly$$$908$$$915$$$O	reducing$$$916$$$924$$$O	the$$$925$$$928$$$O	hemolytic$$$929$$$938$$$O	activity$$$939$$$947$$$O	and$$$948$$$951$$$O	ensuring$$$952$$$960$$$O	good$$$961$$$965$$$O	cell$$$966$$$970$$$O	inhibitory$$$971$$$981$$$O	activity$$$982$$$990$$$O	and$$$991$$$994$$$O	high$$$995$$$999$$$O	stability.$$$1000$$$1010$$$O	The$$$1011$$$1014$$$O	invention$$$1015$$$1024$$$O	is$$$1025$$$1027$$$O	an$$$1028$$$1030$$$O	innovation$$$1031$$$1041$$$O	in$$$1042$$$1044$$$O	the$$$1045$$$1048$$$O	field$$$1049$$$1054$$$O	of$$$1055$$$1057$$$O	medicine.$$$1058$$$1067$$$O
WO2008084081A2
2-substituted$$$0$$$13$$$I	5-phenylpyrimidines$$$14$$$33$$$I	for$$$34$$$37$$$O	the$$$38$$$41$$$O	treatment$$$42$$$51$$$O	of$$$52$$$54$$$O	proliferative$$$55$$$68$$$O	disorders$$$69$$$78$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	2-substituted$$$44$$$57$$$I	pyridines$$$58$$$67$$$I	of$$$68$$$70$$$O	the$$$71$$$74$$$O	formulaI$$$75$$$83$$$O	and$$$84$$$87$$$O	the$$$88$$$91$$$O	pharmaceutically$$$92$$$108$$$O	acceptable$$$109$$$119$$$O	salts$$$120$$$125$$$O	of$$$126$$$128$$$O	the$$$129$$$132$$$O	2-substituted$$$133$$$146$$$I	pyridines$$$147$$$156$$$I	of$$$157$$$159$$$O	formula$$$160$$$167$$$O	I$$$168$$$169$$$O	in$$$170$$$172$$$O	therapy,$$$173$$$181$$$O	in$$$182$$$184$$$O	particular$$$185$$$195$$$O	in$$$196$$$198$$$O	therapy$$$199$$$206$$$O	or$$$207$$$209$$$O	treatment$$$210$$$219$$$O	of$$$220$$$222$$$O	cancerous$$$223$$$232$$$O	diseases:$$$233$$$242$$$O	in$$$243$$$245$$$O	which$$$246$$$251$$$O	the$$$252$$$255$$$O	indices$$$256$$$263$$$O	and$$$264$$$267$$$O	the$$$268$$$271$$$O	substituents$$$272$$$284$$$O	are$$$285$$$288$$$O	as$$$289$$$291$$$O	defined$$$292$$$299$$$O	in$$$300$$$302$$$O	the$$$303$$$306$$$O	claims$$$307$$$313$$$O	and$$$314$$$317$$$O	the$$$318$$$321$$$O	specification.$$$322$$$336$$$O
CN103360310A
Sitafloxacin$$$0$$$12$$$I	intermediate,$$$13$$$26$$$O	preparation$$$27$$$38$$$O	method$$$39$$$45$$$O	of$$$46$$$48$$$O	sitafloxacin$$$49$$$61$$$I	and$$$62$$$65$$$O	sitafloxacin$$$66$$$78$$$I	pharmaceutical$$$79$$$93$$$O	composition$$$94$$$105$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	sitafloxacin$$$26$$$38$$$I	intermediate,$$$39$$$52$$$O	a$$$53$$$54$$$O	preparation$$$55$$$66$$$O	method$$$67$$$73$$$O	of$$$74$$$76$$$O	sitafloxacin$$$77$$$89$$$I	and$$$90$$$93$$$O	a$$$94$$$95$$$O	sitafloxacin$$$96$$$108$$$I	pharmaceutical$$$109$$$123$$$O	composition.$$$124$$$136$$$O	The$$$137$$$140$$$O	preparation$$$141$$$152$$$O	method$$$153$$$159$$$O	can$$$160$$$163$$$O	be$$$164$$$166$$$O	used$$$167$$$171$$$O	for$$$172$$$175$$$O	solving$$$176$$$183$$$O	the$$$184$$$187$$$O	problems$$$188$$$196$$$O	of$$$197$$$199$$$O	low$$$200$$$203$$$O	yield,$$$204$$$210$$$O	troublesome$$$211$$$222$$$O	aftertreatment,$$$223$$$238$$$O	poor$$$239$$$243$$$O	safety$$$244$$$250$$$O	and$$$251$$$254$$$O	higher$$$255$$$261$$$O	cost$$$262$$$266$$$O	in$$$267$$$269$$$O	the$$$270$$$273$$$O	existing$$$274$$$282$$$O	sitafloxacin$$$283$$$295$$$I	preparation.$$$296$$$308$$$O	The$$$309$$$312$$$O	preparation$$$313$$$324$$$O	method$$$325$$$331$$$O	disclosed$$$332$$$341$$$O	by$$$342$$$344$$$O	the$$$345$$$348$$$O	invention$$$349$$$358$$$O	is$$$359$$$361$$$O	simple$$$362$$$368$$$O	in$$$369$$$371$$$O	process,$$$372$$$380$$$O	easily$$$381$$$387$$$O	available$$$388$$$397$$$O	in$$$398$$$400$$$O	raw$$$401$$$404$$$O	materials,$$$405$$$415$$$O	lower$$$416$$$421$$$O	in$$$422$$$424$$$O	cost,$$$425$$$430$$$O	the$$$431$$$434$$$O	solvent$$$435$$$442$$$O	after$$$443$$$448$$$O	reaction$$$449$$$457$$$O	is$$$458$$$460$$$O	easy$$$461$$$465$$$O	to$$$466$$$468$$$O	treat,$$$469$$$475$$$O	high$$$476$$$480$$$O	yield$$$481$$$486$$$O	and$$$487$$$490$$$O	quite$$$491$$$496$$$O	suitable$$$497$$$505$$$O	for$$$506$$$509$$$O	large-scale$$$510$$$521$$$O	industrial$$$522$$$532$$$O	production.$$$533$$$544$$$O	The$$$545$$$548$$$O	sitafloxacin$$$549$$$561$$$I	pharmaceutical$$$562$$$576$$$O	composition$$$577$$$588$$$O	obtained$$$589$$$597$$$O	by$$$598$$$600$$$O	virtue$$$601$$$607$$$O	of$$$608$$$610$$$O	the$$$611$$$614$$$O	preparation$$$615$$$626$$$O	method$$$627$$$633$$$O	provided$$$634$$$642$$$O	by$$$643$$$645$$$O	the$$$646$$$649$$$O	invention$$$650$$$659$$$O	can$$$660$$$663$$$O	be$$$664$$$666$$$O	used$$$667$$$671$$$O	for$$$672$$$675$$$O	further$$$676$$$683$$$O	improving$$$684$$$693$$$O	the$$$694$$$697$$$O	product$$$698$$$705$$$O	dissolution$$$706$$$717$$$O	effect,$$$718$$$725$$$O	improving$$$726$$$735$$$O	the$$$736$$$739$$$O	in-vivo$$$740$$$747$$$O	bioavailability$$$748$$$763$$$O	of$$$764$$$766$$$O	the$$$767$$$770$$$O	sitafloxacin$$$771$$$783$$$I	and$$$784$$$787$$$O	enhancing$$$788$$$797$$$O	the$$$798$$$801$$$O	exertion$$$802$$$810$$$O	of$$$811$$$813$$$O	medical$$$814$$$821$$$O	effect.$$$822$$$829$$$O
EP2582660A1
New$$$0$$$3$$$O	cathepsin$$$4$$$13$$$O	s$$$14$$$15$$$O	protease$$$16$$$24$$$O	inhibitors,$$$25$$$36$$$O	useful$$$37$$$43$$$O	in$$$44$$$46$$$O	the$$$47$$$50$$$O	treatment$$$51$$$60$$$O	of$$$61$$$63$$$O	e.g.$$$64$$$68$$$O	autoimmune$$$69$$$79$$$O	disorders,$$$80$$$90$$$O	allergy$$$91$$$98$$$O	and$$$99$$$102$$$O	chronic$$$103$$$110$$$O	pain$$$111$$$115$$$O	conditions$$$116$$$126$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	the$$$13$$$16$$$O	formula$$$17$$$24$$$O	(I)$$$25$$$28$$$O	wherein$$$29$$$36$$$O	R2a$$$37$$$40$$$O	and$$$41$$$44$$$O	R2b$$$45$$$48$$$O	are$$$49$$$52$$$O	independently$$$53$$$66$$$O	H,$$$67$$$69$$$I	halo,$$$70$$$75$$$I	C1-C4alkyl,$$$76$$$87$$$I	C1-C4haloalkyl$$$88$$$102$$$I	or$$$103$$$105$$$O	C1-C4alkoxy,$$$106$$$118$$$I	or$$$119$$$121$$$O	R2a$$$122$$$125$$$O	and$$$126$$$129$$$O	R2b$$$130$$$133$$$O	together$$$134$$$142$$$O	with$$$143$$$147$$$O	the$$$148$$$151$$$O	carbon$$$152$$$158$$$I	atom$$$159$$$163$$$O	to$$$164$$$166$$$O	which$$$167$$$172$$$O	they$$$173$$$177$$$O	are$$$178$$$181$$$O	attached$$$182$$$190$$$O	form$$$191$$$195$$$O	a$$$196$$$197$$$O	C3-C6cycloalkyl;$$$198$$$214$$$I	R3$$$215$$$217$$$O	is$$$218$$$220$$$O	a$$$221$$$222$$$O	C5-C10$$$223$$$229$$$I	alkyl,$$$230$$$236$$$I	optionally$$$237$$$247$$$O	substituted$$$248$$$259$$$O	with$$$260$$$264$$$O	1-3$$$265$$$268$$$O	substituents$$$269$$$281$$$O	independently$$$282$$$295$$$O	selected$$$296$$$304$$$O	from$$$305$$$309$$$O	halo,$$$310$$$315$$$I	C1-C4haloalkyl,$$$316$$$331$$$I	C1-C4alkoxy,$$$332$$$344$$$I	C1-C4haloalkoxy;$$$345$$$361$$$I	or$$$362$$$364$$$O	R3$$$365$$$367$$$O	is$$$368$$$370$$$O	a$$$371$$$372$$$O	C2-C4alkyl$$$373$$$383$$$I	chain$$$384$$$389$$$O	with$$$390$$$394$$$O	at$$$395$$$397$$$O	least$$$398$$$403$$$O	2$$$404$$$405$$$O	chloro$$$406$$$412$$$I	or$$$413$$$415$$$O	3$$$416$$$417$$$O	fluoro$$$418$$$424$$$I	substituents;$$$425$$$438$$$O	or$$$439$$$441$$$O	R3$$$442$$$444$$$O	is$$$445$$$447$$$O	C3-C7cycloalkylmethyl,$$$448$$$470$$$I	optionally$$$471$$$481$$$O	substituted$$$482$$$493$$$O	with$$$494$$$498$$$O	1-3$$$499$$$502$$$O	substituents$$$503$$$515$$$O	independently$$$516$$$529$$$O	selected$$$530$$$538$$$O	from$$$539$$$543$$$O	C1-C4alkyl,$$$544$$$555$$$I	halo,$$$556$$$561$$$I	C1-C4haloalkyl,$$$562$$$577$$$I	C1-C4alkoxy,$$$578$$$590$$$I	C1-C4haloalkoxy;$$$591$$$607$$$I	R4$$$608$$$610$$$O	is$$$611$$$613$$$O	C1-C6alkyl,$$$614$$$625$$$I	C1-C6haloalkyl,$$$626$$$641$$$I	C1-C6alkoxy,$$$642$$$654$$$I	C1-C6haloalkoxy,$$$655$$$671$$$I	C1-C6alkylamino,$$$672$$$688$$$I	C1-$$$689$$$692$$$I	C6dialkylamino$$$693$$$707$$$I	or;$$$708$$$711$$$O	R4$$$712$$$714$$$O	is$$$715$$$717$$$O	Het$$$718$$$721$$$I	or$$$722$$$724$$$O	Carbocyclyl,$$$725$$$737$$$I	either$$$738$$$744$$$O	of$$$745$$$747$$$O	which$$$748$$$753$$$O	is$$$754$$$756$$$O	optionally$$$757$$$767$$$O	substituted$$$768$$$779$$$O	with$$$780$$$784$$$O	1-3$$$785$$$788$$$O	substituents;$$$789$$$802$$$O	n$$$803$$$804$$$O	is$$$805$$$807$$$O	1,$$$808$$$810$$$O	2$$$811$$$812$$$O	or$$$813$$$815$$$O	3;$$$816$$$818$$$O	for$$$819$$$822$$$O	the$$$823$$$826$$$O	use$$$827$$$830$$$O	in$$$831$$$833$$$O	the$$$834$$$837$$$O	prophylaxis$$$838$$$849$$$O	or$$$850$$$852$$$O	treatment$$$853$$$862$$$O	of$$$863$$$865$$$O	a$$$866$$$867$$$O	disorder$$$868$$$876$$$O	characterised$$$877$$$890$$$O	by$$$891$$$893$$$O	inappropriate$$$894$$$907$$$O	expression$$$908$$$918$$$O	or$$$919$$$921$$$O	activation$$$922$$$932$$$O	of$$$933$$$935$$$O	cathepsin$$$936$$$945$$$O	S.$$$946$$$948$$$O
CN103724445A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	and$$$19$$$22$$$O	blood$$$23$$$28$$$O	sugar$$$29$$$34$$$I	lowering$$$35$$$43$$$O	function$$$44$$$52$$$O	of$$$53$$$55$$$O	Grifola$$$56$$$63$$$O	frondosa$$$64$$$72$$$O	polysaccharide$$$73$$$87$$$O	F2$$$88$$$90$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	Grifola$$$26$$$33$$$O	frondosa$$$34$$$42$$$O	polysaccharide$$$43$$$57$$$O	F2$$$58$$$60$$$O	with$$$61$$$65$$$O	blood$$$66$$$71$$$O	sugar$$$72$$$77$$$I	lowering$$$78$$$86$$$O	function,$$$87$$$96$$$O	and$$$97$$$100$$$O	a$$$101$$$102$$$O	preparation$$$103$$$114$$$O	method$$$115$$$121$$$O	and$$$122$$$125$$$O	application$$$126$$$137$$$O	thereof.$$$138$$$146$$$O	The$$$147$$$150$$$O	preparation$$$151$$$162$$$O	method$$$163$$$169$$$O	comprises$$$170$$$179$$$O	the$$$180$$$183$$$O	following$$$184$$$193$$$O	steps:$$$194$$$200$$$O	taking$$$201$$$207$$$O	Grifola$$$208$$$215$$$O	frondosa$$$216$$$224$$$O	sporophores,$$$225$$$237$$$O	pulverizing,$$$238$$$250$$$O	extracting$$$251$$$261$$$O	with$$$262$$$266$$$O	hot$$$267$$$270$$$O	water,$$$271$$$277$$$O	filtering,$$$278$$$288$$$O	adding$$$289$$$295$$$O	ethanol$$$296$$$303$$$I	into$$$304$$$308$$$O	the$$$309$$$312$$$O	filtrate$$$313$$$321$$$O	to$$$322$$$324$$$O	precipitate,$$$325$$$337$$$O	and$$$338$$$341$$$O	separating$$$342$$$352$$$O	the$$$353$$$356$$$O	precipitate;$$$357$$$369$$$O	passing$$$370$$$377$$$O	the$$$378$$$381$$$O	precipitate$$$382$$$393$$$O	through$$$394$$$401$$$O	a$$$402$$$403$$$O	DEAE$$$404$$$408$$$I	(diethylaminoethanol)$$$409$$$430$$$I	Sepharose$$$431$$$440$$$O	Fast$$$441$$$445$$$O	Flow$$$446$$$450$$$O	chromatographic$$$451$$$466$$$O	column,$$$467$$$474$$$O	balancing$$$475$$$484$$$O	with$$$485$$$489$$$O	Tris-HCl$$$490$$$498$$$I	(10mM,$$$499$$$505$$$O	pH=8.0),$$$506$$$514$$$O	and$$$515$$$518$$$O	collecting$$$519$$$529$$$O	to$$$530$$$532$$$O	obtain$$$533$$$539$$$O	a$$$540$$$541$$$O	fraction$$$542$$$550$$$O	F1;$$$551$$$554$$$O	and$$$555$$$558$$$O	eluting$$$559$$$566$$$O	with$$$567$$$571$$$O	Tris-HCl$$$572$$$580$$$I	(10mM,$$$581$$$587$$$O	pH=8.0)$$$588$$$595$$$O	containing$$$596$$$606$$$O	0.1M$$$607$$$611$$$O	NaCl$$$612$$$616$$$I	to$$$617$$$619$$$O	obtain$$$620$$$626$$$O	a$$$627$$$628$$$O	fraction$$$629$$$637$$$O	F2,$$$638$$$641$$$O	concentrating$$$642$$$655$$$O	the$$$656$$$659$$$O	F2$$$660$$$662$$$O	under$$$663$$$668$$$O	reduced$$$669$$$676$$$O	pressure,$$$677$$$686$$$O	dialyzing,$$$687$$$697$$$O	and$$$698$$$701$$$O	drying$$$702$$$708$$$O	to$$$709$$$711$$$O	obtain$$$712$$$718$$$O	the$$$719$$$722$$$O	Grifola$$$723$$$730$$$O	frondosa$$$731$$$739$$$O	polysaccharide$$$740$$$754$$$O	F2.$$$755$$$758$$$O	The$$$759$$$762$$$O	new$$$763$$$766$$$O	Grifola$$$767$$$774$$$O	frondosa$$$775$$$783$$$O	polysaccharide$$$784$$$798$$$O	F2$$$799$$$801$$$O	separated$$$802$$$811$$$O	from$$$812$$$816$$$O	the$$$817$$$820$$$O	Grifola$$$821$$$828$$$O	frondosa$$$829$$$837$$$O	sporophores$$$838$$$849$$$O	has$$$850$$$853$$$O	blood$$$854$$$859$$$O	sugar$$$860$$$865$$$I	lowering$$$866$$$874$$$O	activity,$$$875$$$884$$$O	can$$$885$$$888$$$O	be$$$889$$$891$$$O	used$$$892$$$896$$$O	for$$$897$$$900$$$O	preparing$$$901$$$910$$$O	medicines$$$911$$$920$$$O	for$$$921$$$924$$$O	treating$$$925$$$933$$$O	diabetes,$$$934$$$943$$$O	and$$$944$$$947$$$O	lays$$$948$$$952$$$O	foundation$$$953$$$963$$$O	for$$$964$$$967$$$O	developing$$$968$$$978$$$O	new$$$979$$$982$$$O	medicines$$$983$$$992$$$O	for$$$993$$$996$$$O	treating$$$997$$$1005$$$O	diabetes.$$$1006$$$1015$$$O
US20110206775
Preparation$$$0$$$11$$$O	of$$$12$$$14$$$O	inert$$$15$$$20$$$O	pharmaceutical$$$21$$$35$$$O	excipients$$$36$$$46$$$O	for$$$47$$$50$$$O	stabilizing$$$51$$$62$$$O	unstable$$$63$$$71$$$O	pharmaceutical$$$72$$$86$$$O	ingredients$$$87$$$98$$$O
In$$$0$$$2$$$O	a$$$3$$$4$$$O	method$$$5$$$11$$$O	of$$$12$$$14$$$O	treating$$$15$$$23$$$O	a$$$24$$$25$$$O	pharmaceutical$$$26$$$40$$$O	component,$$$41$$$51$$$O	a$$$52$$$53$$$O	reducing$$$54$$$62$$$O	substance$$$63$$$72$$$O	is$$$73$$$75$$$O	added$$$76$$$81$$$O	to$$$82$$$84$$$O	a$$$85$$$86$$$O	solution$$$87$$$95$$$O	of$$$96$$$98$$$O	water$$$99$$$104$$$O	and$$$105$$$108$$$O	a$$$109$$$110$$$O	pharmaceutical$$$111$$$125$$$O	excipient$$$126$$$135$$$O	having$$$136$$$142$$$O	at$$$143$$$145$$$O	least$$$146$$$151$$$O	one$$$152$$$155$$$O	residual$$$156$$$164$$$O	reactive$$$165$$$173$$$O	impurity.$$$174$$$183$$$O	The$$$184$$$187$$$O	reducing$$$188$$$196$$$O	substance$$$197$$$206$$$O	is$$$207$$$209$$$O	allowed$$$210$$$217$$$O	to$$$218$$$220$$$O	react$$$221$$$226$$$O	with$$$227$$$231$$$O	the$$$232$$$235$$$O	residual$$$236$$$244$$$O	reactive$$$245$$$253$$$O	impurity,$$$254$$$263$$$O	thereby$$$264$$$271$$$O	generating$$$272$$$282$$$O	an$$$283$$$285$$$O	inert$$$286$$$291$$$O	reaction$$$292$$$300$$$O	product.$$$301$$$309$$$O	The$$$310$$$313$$$O	any$$$314$$$317$$$O	remaining$$$318$$$327$$$O	amount$$$328$$$334$$$O	of$$$335$$$337$$$O	the$$$338$$$341$$$O	reducing$$$342$$$350$$$O	substance$$$351$$$360$$$O	is$$$361$$$363$$$O	removed$$$364$$$371$$$O	from$$$372$$$376$$$O	the$$$377$$$380$$$O	pharmaceutical$$$381$$$395$$$O	excipient.$$$396$$$406$$$O	The$$$407$$$410$$$O	pharmaceutical$$$411$$$425$$$O	excipient$$$426$$$435$$$O	is$$$436$$$438$$$O	dried$$$439$$$444$$$O	after$$$445$$$450$$$O	the$$$451$$$454$$$O	removing$$$455$$$463$$$O	step.$$$464$$$469$$$O
WO2014142290A1
Pyrazole-amide$$$0$$$14$$$O	compound$$$15$$$23$$$O	and$$$24$$$27$$$O	medicinal$$$28$$$37$$$O	uses$$$38$$$42$$$O	therefor$$$43$$$51$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	compound$$$14$$$22$$$O	as$$$23$$$25$$$O	represented$$$26$$$37$$$O	by$$$38$$$40$$$O	formula$$$41$$$48$$$O	[I]$$$49$$$52$$$O	[in$$$53$$$56$$$O	which$$$57$$$62$$$O	n$$$63$$$64$$$O	indicates$$$65$$$74$$$O	1$$$75$$$76$$$O	or$$$77$$$79$$$O	2],$$$80$$$83$$$O	formula$$$84$$$91$$$O	[II]$$$92$$$96$$$O	or$$$97$$$99$$$O	[IIh],$$$100$$$106$$$O	or$$$107$$$109$$$O	formula$$$110$$$117$$$O	[III],$$$118$$$124$$$O	or$$$125$$$127$$$O	a$$$128$$$129$$$O	pharmaceutically$$$130$$$146$$$O	acceptable$$$147$$$157$$$O	salt$$$158$$$162$$$O	thereof.$$$163$$$171$$$O	Also$$$172$$$176$$$O	provided$$$177$$$185$$$O	are$$$186$$$189$$$O	medicinal$$$190$$$199$$$O	uses$$$200$$$204$$$O	for$$$205$$$208$$$O	the$$$209$$$212$$$O	compound$$$213$$$221$$$O	or$$$222$$$224$$$O	the$$$225$$$228$$$O	salt$$$229$$$233$$$O	thereof.$$$234$$$242$$$O
CN101244079A
Iron$$$0$$$4$$$I	supplement$$$5$$$15$$$O	composition,$$$16$$$28$$$O	its$$$29$$$32$$$O	preparing$$$33$$$42$$$O	method$$$43$$$49$$$O	and$$$50$$$53$$$O	application$$$54$$$65$$$O	of$$$66$$$68$$$O	the$$$69$$$72$$$O	same$$$73$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	drug$$$26$$$30$$$O	combination$$$31$$$42$$$O	as$$$43$$$45$$$O	iron$$$46$$$50$$$I	supplementary$$$51$$$64$$$O	agent$$$65$$$70$$$O	which$$$71$$$76$$$O	is$$$77$$$79$$$O	characterized$$$80$$$93$$$O	in$$$94$$$96$$$O	that$$$97$$$101$$$O	the$$$102$$$105$$$O	drug$$$106$$$110$$$O	combination$$$111$$$122$$$O	has$$$123$$$126$$$O	carbonyl$$$127$$$135$$$I	iron$$$136$$$140$$$I	and$$$141$$$144$$$O	natural$$$145$$$152$$$O	anti-oxidant$$$153$$$165$$$O	components$$$166$$$176$$$O	which$$$177$$$182$$$O	have$$$183$$$187$$$O	the$$$188$$$191$$$O	drug$$$192$$$196$$$O	activity;$$$197$$$206$$$O	the$$$207$$$210$$$O	drug$$$211$$$215$$$O	combination$$$216$$$227$$$O	can$$$228$$$231$$$O	also$$$232$$$236$$$O	have$$$237$$$241$$$O	pharmaceutical$$$242$$$256$$$O	carrier.$$$257$$$265$$$O	The$$$266$$$269$$$O	invention$$$270$$$279$$$O	also$$$280$$$284$$$O	disclosed$$$285$$$294$$$O	the$$$295$$$298$$$O	preparation,$$$299$$$311$$$O	comprising$$$312$$$322$$$O	the$$$323$$$326$$$O	drug$$$327$$$331$$$O	combination,$$$332$$$344$$$O	the$$$345$$$348$$$O	preparation$$$349$$$360$$$O	method$$$361$$$367$$$O	of$$$368$$$370$$$O	the$$$371$$$374$$$O	combination$$$375$$$386$$$O	and$$$387$$$390$$$O	the$$$391$$$394$$$O	preparation,$$$395$$$407$$$O	and$$$408$$$411$$$O	the$$$412$$$415$$$O	function$$$416$$$424$$$O	of$$$425$$$427$$$O	preventing$$$428$$$438$$$O	and$$$439$$$442$$$O	curing$$$443$$$449$$$O	iron$$$450$$$454$$$O	deficiency$$$455$$$465$$$O	of$$$466$$$468$$$O	the$$$469$$$472$$$O	drug$$$473$$$477$$$O	combination.$$$478$$$490$$$O	The$$$491$$$494$$$O	drug$$$495$$$499$$$O	combination$$$500$$$511$$$O	has$$$512$$$515$$$O	the$$$516$$$519$$$O	advantages$$$520$$$530$$$O	that$$$531$$$535$$$O	the$$$536$$$539$$$O	iron$$$540$$$544$$$O	deficiency$$$545$$$555$$$O	anemia$$$556$$$562$$$O	is$$$563$$$565$$$O	treated$$$566$$$573$$$O	effectively;$$$574$$$586$$$O	the$$$587$$$590$$$O	production$$$591$$$601$$$O	of$$$602$$$604$$$O	free$$$605$$$609$$$O	radical$$$610$$$617$$$O	in$$$618$$$620$$$O	human$$$621$$$626$$$O	body$$$627$$$631$$$O	is$$$632$$$634$$$O	inhibited;$$$635$$$645$$$O	the$$$646$$$649$$$O	oxygen$$$650$$$656$$$I	metabolism$$$657$$$667$$$O	balance$$$668$$$675$$$O	in$$$676$$$678$$$O	human$$$679$$$684$$$O	body$$$685$$$689$$$O	is$$$690$$$692$$$O	maintained;$$$693$$$704$$$O	the$$$705$$$708$$$O	physical$$$709$$$717$$$O	quality$$$718$$$725$$$O	of$$$726$$$728$$$O	the$$$729$$$732$$$O	patient$$$733$$$740$$$O	is$$$741$$$743$$$O	enhanced;$$$744$$$753$$$O	and$$$754$$$757$$$O	the$$$758$$$761$$$O	immunity$$$762$$$770$$$O	of$$$771$$$773$$$O	body$$$774$$$778$$$O	is$$$779$$$781$$$O	improved.$$$782$$$791$$$O
CN103372002A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Chukrasone$$$15$$$25$$$I	B$$$26$$$27$$$I	in$$$28$$$30$$$O	preparation$$$31$$$42$$$O	of$$$43$$$45$$$O	medicines$$$46$$$55$$$O	for$$$56$$$59$$$O	increasing$$$60$$$70$$$O	red$$$71$$$74$$$O	blood$$$75$$$80$$$O	cells$$$81$$$86$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	new$$$27$$$30$$$O	application$$$31$$$42$$$O	of$$$43$$$45$$$O	a$$$46$$$47$$$O	Chukrasone$$$48$$$58$$$I	B$$$59$$$60$$$I	compound$$$61$$$69$$$O	in$$$70$$$72$$$O	the$$$73$$$76$$$O	pharmaceutical$$$77$$$91$$$O	field,$$$92$$$98$$$O	and$$$99$$$102$$$O	particularly$$$103$$$115$$$O	relates$$$116$$$123$$$O	to$$$124$$$126$$$O	an$$$127$$$129$$$O	application$$$130$$$141$$$O	of$$$142$$$144$$$O	the$$$145$$$148$$$O	Chukrasone$$$149$$$159$$$I	B$$$160$$$161$$$I	in$$$162$$$164$$$O	the$$$165$$$168$$$O	preparation$$$169$$$180$$$O	of$$$181$$$183$$$O	medicines$$$184$$$193$$$O	for$$$194$$$197$$$O	increasing$$$198$$$208$$$O	red$$$209$$$212$$$O	blood$$$213$$$218$$$O	cells.$$$219$$$225$$$O	The$$$226$$$229$$$O	application$$$230$$$241$$$O	of$$$242$$$244$$$O	the$$$245$$$248$$$O	Chukrasone$$$249$$$259$$$I	B$$$260$$$261$$$I	in$$$262$$$264$$$O	the$$$265$$$268$$$O	preparation$$$269$$$280$$$O	of$$$281$$$283$$$O	the$$$284$$$287$$$O	medicines$$$288$$$297$$$O	for$$$298$$$301$$$O	treating$$$302$$$310$$$O	the$$$311$$$314$$$O	reduction$$$315$$$324$$$O	of$$$325$$$327$$$O	red$$$328$$$331$$$O	blood$$$332$$$337$$$O	cells$$$338$$$343$$$O	is$$$344$$$346$$$O	disclosed$$$347$$$356$$$O	for$$$357$$$360$$$O	the$$$361$$$364$$$O	first$$$365$$$370$$$O	time.$$$371$$$376$$$O	As$$$377$$$379$$$O	the$$$380$$$383$$$O	skeleton$$$384$$$392$$$O	type$$$393$$$397$$$O	of$$$398$$$400$$$O	the$$$401$$$404$$$O	Chukrasone$$$405$$$415$$$I	B$$$416$$$417$$$I	belongs$$$418$$$425$$$O	to$$$426$$$428$$$O	a$$$429$$$430$$$O	bran-new$$$431$$$439$$$O	skeleton$$$440$$$448$$$O	type$$$449$$$453$$$O	and$$$454$$$457$$$O	the$$$458$$$461$$$O	Chukrasone$$$462$$$472$$$I	B$$$473$$$474$$$I	has$$$475$$$478$$$O	unexpected$$$479$$$489$$$O	strong$$$490$$$496$$$O	inhibitory$$$497$$$507$$$O	activity$$$508$$$516$$$O	on$$$517$$$519$$$O	the$$$520$$$523$$$O	reduction$$$524$$$533$$$O	of$$$534$$$536$$$O	the$$$537$$$540$$$O	red$$$541$$$544$$$O	blood$$$545$$$550$$$O	cells,$$$551$$$557$$$O	the$$$558$$$561$$$O	possibility$$$562$$$573$$$O	that$$$574$$$578$$$O	other$$$579$$$584$$$O	compounds$$$585$$$594$$$O	provide$$$595$$$602$$$O	revelation$$$603$$$613$$$O	does$$$614$$$618$$$O	not$$$619$$$622$$$O	exist.$$$623$$$629$$$O	The$$$630$$$633$$$O	Chukrasone$$$634$$$644$$$I	B$$$645$$$646$$$I	has$$$647$$$650$$$O	prominently$$$651$$$662$$$O	substantial$$$663$$$674$$$O	characteristics$$$675$$$690$$$O	and$$$691$$$694$$$O	meanwhile$$$695$$$704$$$O	has$$$705$$$708$$$O	remarkably$$$709$$$719$$$O	progressive$$$720$$$731$$$O	significance$$$732$$$744$$$O	when$$$745$$$749$$$O	being$$$750$$$755$$$O	used$$$756$$$760$$$O	for$$$761$$$764$$$O	preventing$$$765$$$775$$$O	and$$$776$$$779$$$O	treating$$$780$$$788$$$O	the$$$789$$$792$$$O	reduction$$$793$$$802$$$O	of$$$803$$$805$$$O	the$$$806$$$809$$$O	red$$$810$$$813$$$O	blood$$$814$$$819$$$O	cells.$$$820$$$826$$$O
CN103432155A
Production$$$0$$$10$$$O	technology$$$11$$$21$$$O	of$$$22$$$24$$$O	particle$$$25$$$33$$$O	comprising$$$34$$$44$$$O	ten$$$45$$$48$$$O	vitamins$$$49$$$57$$$O	for$$$58$$$61$$$O	children$$$62$$$70$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	production$$$25$$$35$$$O	technology$$$36$$$46$$$O	of$$$47$$$49$$$O	a$$$50$$$51$$$O	particle$$$52$$$60$$$O	comprising$$$61$$$71$$$O	ten$$$72$$$75$$$O	vitamins$$$76$$$84$$$O	for$$$85$$$88$$$O	children.$$$89$$$98$$$O	The$$$99$$$102$$$O	production$$$103$$$113$$$O	technology$$$114$$$124$$$O	comprises$$$125$$$134$$$O	the$$$135$$$138$$$O	steps$$$139$$$144$$$O	of$$$145$$$147$$$O	firstly$$$148$$$155$$$O	reasonably$$$156$$$166$$$O	grouping$$$167$$$175$$$O	the$$$176$$$179$$$O	vitamins,$$$180$$$189$$$O	choosing$$$190$$$198$$$O	a$$$199$$$200$$$O	centrifugal$$$201$$$212$$$O	pelletizer$$$213$$$223$$$O	for$$$224$$$227$$$O	pelletizing$$$228$$$239$$$O	while$$$240$$$245$$$O	controlling$$$246$$$257$$$O	the$$$258$$$261$$$O	temperature$$$262$$$273$$$O	and$$$274$$$277$$$O	humidity$$$278$$$286$$$O	of$$$287$$$289$$$O	the$$$290$$$293$$$O	environment$$$294$$$305$$$O	and$$$306$$$309$$$O	operating$$$310$$$319$$$O	in$$$320$$$322$$$O	a$$$323$$$324$$$O	dark$$$325$$$329$$$O	place,$$$330$$$336$$$O	drying$$$337$$$343$$$O	by$$$344$$$346$$$O	decompression$$$347$$$360$$$O	drying$$$361$$$367$$$O	equipment,$$$368$$$378$$$O	introducing$$$379$$$390$$$O	nitrogen,$$$391$$$400$$$I	filtering$$$401$$$410$$$O	out$$$411$$$414$$$O	ultraviolet$$$415$$$426$$$O	lights$$$427$$$433$$$O	and$$$434$$$437$$$O	packing.$$$438$$$446$$$O	According$$$447$$$456$$$O	to$$$457$$$459$$$O	the$$$460$$$463$$$O	production$$$464$$$474$$$O	technology,$$$475$$$486$$$O	mutual$$$487$$$493$$$O	interference$$$494$$$506$$$O	and$$$507$$$510$$$O	interaction$$$511$$$522$$$O	of$$$523$$$525$$$O	the$$$526$$$529$$$O	vitamins$$$530$$$538$$$O	in$$$539$$$541$$$O	the$$$542$$$545$$$O	particle$$$546$$$554$$$O	are$$$555$$$558$$$O	reduced,$$$559$$$567$$$O	and$$$568$$$571$$$O	the$$$572$$$575$$$O	problem$$$576$$$583$$$O	that$$$584$$$588$$$O	the$$$589$$$592$$$O	vitamins$$$593$$$601$$$O	are$$$602$$$605$$$O	easy$$$606$$$610$$$O	to$$$611$$$613$$$O	degrade$$$614$$$621$$$O	and$$$622$$$625$$$O	are$$$626$$$629$$$O	sensitive$$$630$$$639$$$O	to$$$640$$$642$$$O	light,$$$643$$$649$$$O	heat,$$$650$$$655$$$O	acid$$$656$$$660$$$O	and$$$661$$$664$$$O	alkali,$$$665$$$672$$$O	humidity$$$673$$$681$$$O	and$$$682$$$685$$$O	temperature$$$686$$$697$$$O	is$$$698$$$700$$$O	solved.$$$701$$$708$$$O	Therefore,$$$709$$$719$$$O	the$$$720$$$723$$$O	particle$$$724$$$732$$$O	comprising$$$733$$$743$$$O	ten$$$744$$$747$$$O	vitamins$$$748$$$756$$$O	for$$$757$$$760$$$O	children$$$761$$$769$$$O	prepared$$$770$$$778$$$O	by$$$779$$$781$$$O	the$$$782$$$785$$$O	production$$$786$$$796$$$O	technology$$$797$$$807$$$O	has$$$808$$$811$$$O	the$$$812$$$815$$$O	beneficial$$$816$$$826$$$O	effects$$$827$$$834$$$O	that$$$835$$$839$$$O	the$$$840$$$843$$$O	effective$$$844$$$853$$$O	ingredient$$$854$$$864$$$O	content$$$865$$$872$$$O	is$$$873$$$875$$$O	high$$$876$$$880$$$O	and$$$881$$$884$$$O	the$$$885$$$888$$$O	effective$$$889$$$898$$$O	ingredients$$$899$$$910$$$O	are$$$911$$$914$$$O	stable.$$$915$$$922$$$O
WO2010005851A1
Combination$$$0$$$11$$$O	therapy$$$12$$$19$$$O	for$$$20$$$23$$$O	treating$$$24$$$32$$$O	iron$$$33$$$37$$$O	disorders$$$38$$$47$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	is$$$15$$$17$$$O	directed$$$18$$$26$$$O	to$$$27$$$29$$$O	combination$$$30$$$41$$$O	therapies$$$42$$$51$$$O	to$$$52$$$54$$$O	treat$$$55$$$60$$$O	iron$$$61$$$65$$$I	overload$$$66$$$74$$$O	disorders$$$75$$$84$$$O	utilizing$$$85$$$94$$$O	inhibitors$$$95$$$105$$$O	of$$$106$$$108$$$O	divalent$$$109$$$117$$$O	metal$$$118$$$123$$$O	transporter-1$$$124$$$137$$$O	(DMT1$$$138$$$143$$$O	),$$$144$$$146$$$O	proton$$$147$$$153$$$O	pump$$$154$$$158$$$O	inhibitors$$$159$$$169$$$O	(PPIs),$$$170$$$177$$$O	calcium$$$178$$$185$$$I	channel$$$186$$$193$$$O	blockers$$$194$$$202$$$O	and$$$203$$$206$$$O	iron$$$207$$$211$$$I	chelators.$$$212$$$222$$$O
US7670601
Using$$$0$$$5$$$O	uterine$$$6$$$13$$$O	tumor$$$14$$$19$$$O	specific$$$20$$$28$$$O	marker$$$29$$$35$$$O	as$$$36$$$38$$$O	diagnostic$$$39$$$49$$$O	tool$$$50$$$54$$$O	in$$$55$$$57$$$O	detection$$$58$$$67$$$O	of$$$68$$$70$$$O	urogenital$$$71$$$81$$$O	specific$$$82$$$90$$$O	cell$$$91$$$95$$$O	proliferative$$$96$$$109$$$O	disorders$$$110$$$119$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	is$$$9$$$11$$$O	described$$$12$$$21$$$O	for$$$22$$$25$$$O	the$$$26$$$29$$$O	diagnosis$$$30$$$39$$$O	of$$$40$$$42$$$O	an$$$43$$$45$$$O	ovarian$$$46$$$53$$$O	or$$$54$$$56$$$O	endometrial$$$57$$$68$$$O	tumor$$$69$$$74$$$O	or$$$75$$$77$$$O	for$$$78$$$81$$$O	a$$$82$$$83$$$O	prognosis,$$$84$$$94$$$O	characterized$$$95$$$108$$$O	in$$$109$$$111$$$O	that$$$112$$$116$$$O	the$$$117$$$120$$$O	L1$$$121$$$123$$$O	level$$$124$$$129$$$O	is$$$130$$$132$$$O	determined$$$133$$$143$$$O	in$$$144$$$146$$$O	a$$$147$$$148$$$O	patient$$$149$$$156$$$O	sample,$$$157$$$164$$$O	preferably$$$165$$$175$$$O	via$$$176$$$179$$$O	an$$$180$$$182$$$O	anti$$$183$$$187$$$O	L1$$$188$$$190$$$O	antibody,$$$191$$$200$$$O	the$$$201$$$204$$$O	presence$$$205$$$213$$$O	of$$$214$$$216$$$O	L1$$$217$$$219$$$O	being$$$220$$$225$$$O	an$$$226$$$228$$$O	indication$$$229$$$239$$$O	of$$$240$$$242$$$O	the$$$243$$$246$$$O	presence$$$247$$$255$$$O	of$$$256$$$258$$$O	an$$$259$$$261$$$O	ovarian$$$262$$$269$$$O	or$$$270$$$272$$$O	endometrial$$$273$$$284$$$O	tumor$$$285$$$290$$$O	or$$$291$$$293$$$O	a$$$294$$$295$$$O	predisposition$$$296$$$310$$$O	for$$$311$$$314$$$O	such$$$315$$$319$$$O	a$$$320$$$321$$$O	tumor.$$$322$$$328$$$O	Furthermore,$$$329$$$341$$$O	methods$$$342$$$349$$$O	for$$$350$$$353$$$O	treating$$$354$$$362$$$O	of$$$363$$$365$$$O	ovarian$$$366$$$373$$$O	or$$$374$$$376$$$O	endometrial$$$377$$$388$$$O	tumors$$$389$$$395$$$O	are$$$396$$$399$$$O	provided.$$$400$$$409$$$O
WO2008044691A1
Antidepressant$$$0$$$14$$$O	agent$$$15$$$20$$$O
An$$$0$$$2$$$O	antidepressant$$$3$$$17$$$O	agent$$$18$$$23$$$O	comprising$$$24$$$34$$$O	at$$$35$$$37$$$O	least$$$38$$$43$$$O	one$$$44$$$47$$$O	compound$$$48$$$56$$$O	selected$$$57$$$65$$$O	from$$$66$$$70$$$O	a$$$71$$$72$$$O	branched$$$73$$$81$$$O	amino$$$82$$$87$$$I	acid,$$$88$$$93$$$I	a$$$94$$$95$$$O	pharmacologically$$$96$$$113$$$O	acceptable$$$114$$$124$$$O	salt$$$125$$$129$$$O	thereof$$$130$$$137$$$O	and$$$138$$$141$$$O	a$$$142$$$143$$$O	derivative$$$144$$$154$$$O	thereof$$$155$$$162$$$O	as$$$163$$$165$$$O	an$$$166$$$168$$$O	active$$$169$$$175$$$O	ingredient.$$$176$$$187$$$O
CN101380320B
The$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	cholinesterase$$$11$$$25$$$O	inhibitors$$$26$$$36$$$O	in$$$37$$$39$$$O	pharmacy$$$40$$$48$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	use$$$27$$$30$$$O	of$$$31$$$33$$$O	cholinesterase$$$34$$$48$$$O	inhibitor$$$49$$$58$$$O	in$$$59$$$61$$$O	the$$$62$$$65$$$O	treatment$$$66$$$75$$$O	of$$$76$$$78$$$O	xerostomia,$$$79$$$90$$$O	in$$$91$$$93$$$O	particular$$$94$$$104$$$O	a$$$105$$$106$$$O	use$$$107$$$110$$$O	of$$$111$$$113$$$O	cholinesterase$$$114$$$128$$$O	inhibitor$$$129$$$138$$$O	together$$$139$$$147$$$O	with$$$148$$$152$$$O	topical$$$153$$$160$$$O	delivery$$$161$$$169$$$O	in$$$170$$$172$$$O	the$$$173$$$176$$$O	treatment$$$177$$$186$$$O	of$$$187$$$189$$$O	xerostomia.$$$190$$$201$$$O	The$$$202$$$205$$$O	invention$$$206$$$215$$$O	also$$$216$$$220$$$O	provides$$$221$$$229$$$O	a$$$230$$$231$$$O	use$$$232$$$235$$$O	of$$$236$$$238$$$O	cholinesterase$$$239$$$253$$$O	inhibitor$$$254$$$263$$$O	in$$$264$$$266$$$O	the$$$267$$$270$$$O	treatment$$$271$$$280$$$O	of$$$281$$$283$$$O	xerostomia$$$284$$$294$$$O	for$$$295$$$298$$$O	topical$$$299$$$306$$$O	delivery$$$307$$$315$$$O	to$$$316$$$318$$$O	the$$$319$$$322$$$O	oral$$$323$$$327$$$O	mucosa.$$$328$$$335$$$O
CN102078325A
Nasal$$$0$$$5$$$O	composition$$$6$$$17$$$O	containing$$$18$$$28$$$O	povidone$$$29$$$37$$$I	iodine$$$38$$$44$$$I	and$$$45$$$48$$$O	cyclodextrin$$$49$$$61$$$O	inclusion$$$62$$$71$$$O	of$$$72$$$74$$$O	glucocorticoid$$$75$$$89$$$I
A$$$0$$$1$$$O	nasal$$$2$$$7$$$O	composition$$$8$$$19$$$O	containing$$$20$$$30$$$O	povidone$$$31$$$39$$$I	iodine$$$40$$$46$$$I	and$$$47$$$50$$$O	cyclodextrin$$$51$$$63$$$O	inclusion$$$64$$$73$$$O	of$$$74$$$76$$$O	glucocorticoid$$$77$$$91$$$I	comprises$$$92$$$101$$$O	povidone$$$102$$$110$$$I	iodine$$$111$$$117$$$I	and$$$118$$$121$$$O	glucocorticoid$$$122$$$136$$$I	as$$$137$$$139$$$O	active$$$140$$$146$$$O	components,$$$147$$$158$$$O	and$$$159$$$162$$$O	one$$$163$$$166$$$O	or$$$167$$$169$$$O	several$$$170$$$177$$$O	accessories$$$178$$$189$$$O	which$$$190$$$195$$$O	are$$$196$$$199$$$O	suitable$$$200$$$208$$$O	for$$$209$$$212$$$O	nasal$$$213$$$218$$$O	drug$$$219$$$223$$$O	administration.$$$224$$$239$$$O	The$$$240$$$243$$$O	nasal$$$244$$$249$$$O	composition$$$250$$$261$$$O	is$$$262$$$264$$$O	characterized$$$265$$$278$$$O	in$$$279$$$281$$$O	that$$$282$$$286$$$O	the$$$287$$$290$$$O	glucocorticoid$$$291$$$305$$$I	is$$$306$$$308$$$O	included$$$309$$$317$$$O	by$$$318$$$320$$$O	beta-cyclodextrin$$$321$$$338$$$O	or$$$339$$$341$$$O	its$$$342$$$345$$$O	derivatives,$$$346$$$358$$$O	and$$$359$$$362$$$O	the$$$363$$$366$$$O	povidone$$$367$$$375$$$I	iodine$$$376$$$382$$$I	content$$$383$$$390$$$O	in$$$391$$$393$$$O	the$$$394$$$397$$$O	nasal$$$398$$$403$$$O	composition$$$404$$$415$$$O	is$$$416$$$418$$$O	0.5%-5%.$$$419$$$427$$$O
CN101130083B
Ophthalmic$$$0$$$10$$$O	composition,$$$11$$$23$$$O	producing$$$24$$$33$$$O	method$$$34$$$40$$$O	and$$$41$$$44$$$O	use$$$45$$$48$$$O	of$$$49$$$51$$$O	the$$$52$$$55$$$O	same$$$56$$$60$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	eye$$$27$$$30$$$O	composition$$$31$$$42$$$O	and$$$43$$$46$$$O	making$$$47$$$53$$$O	method$$$54$$$60$$$O	and$$$61$$$64$$$O	application$$$65$$$76$$$O	with$$$77$$$81$$$O	antibiotic$$$82$$$92$$$O	antiphlogistic$$$93$$$107$$$O	activity,$$$108$$$117$$$O	which$$$118$$$123$$$O	consists$$$124$$$132$$$O	of$$$133$$$135$$$O	(a)$$$136$$$139$$$O	one$$$140$$$143$$$O	or$$$144$$$146$$$O	more$$$147$$$151$$$O	antibiotics$$$152$$$163$$$O	or$$$164$$$166$$$O	carbostyrile$$$167$$$179$$$I	antibacterial$$$180$$$193$$$O	drugsand$$$194$$$202$$$O	(b)$$$203$$$206$$$O	glycyrrhizic$$$207$$$219$$$I	acid$$$220$$$224$$$I	activator.$$$225$$$235$$$O	The$$$236$$$239$$$O	making$$$240$$$246$$$O	method$$$247$$$253$$$O	comprises$$$254$$$263$$$O	the$$$264$$$267$$$O	following$$$268$$$277$$$O	steps:$$$278$$$284$$$O	transmitting$$$285$$$297$$$O	the$$$298$$$301$$$O	composition$$$302$$$313$$$O	and$$$314$$$317$$$O	at$$$318$$$320$$$O	least$$$321$$$326$$$O	one$$$327$$$330$$$O	liquid$$$331$$$337$$$O	or$$$338$$$340$$$O	semi-liquid$$$341$$$352$$$O	carrier$$$353$$$360$$$O	or$$$361$$$363$$$O	adjuvant$$$364$$$372$$$O	into$$$373$$$377$$$O	eye$$$378$$$381$$$O	agent$$$382$$$387$$$O	to$$$388$$$390$$$O	treat$$$391$$$396$$$O	opthalmitis$$$397$$$408$$$O	and$$$409$$$412$$$O	bacterial$$$413$$$422$$$O	infection.$$$423$$$433$$$O	The$$$434$$$437$$$O	invention$$$438$$$447$$$O	can$$$448$$$451$$$O	reduce$$$452$$$458$$$O	side$$$459$$$463$$$O	effect$$$464$$$470$$$O	greatly.$$$471$$$479$$$O
CN101466683B
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	AKT$$$14$$$17$$$O	(protein$$$18$$$26$$$O	kinase$$$27$$$33$$$O	B)$$$34$$$36$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	4-[5-(2-Amino-ethanesulfonyl)-isoquinolin-7-yl]-phenol$$$33$$$87$$$I	or$$$88$$$90$$$O	a$$$91$$$92$$$O	pharmaceutically$$$93$$$109$$$O	acceptable$$$110$$$120$$$O	salt$$$121$$$125$$$O	thereof$$$126$$$133$$$O	or$$$134$$$136$$$O	a$$$137$$$138$$$O	hydrate$$$139$$$146$$$I	of$$$147$$$149$$$O	the$$$150$$$153$$$O	compound$$$154$$$162$$$O	or$$$163$$$165$$$O	the$$$166$$$169$$$O	salt$$$170$$$174$$$O	thereof$$$175$$$182$$$O	as$$$183$$$185$$$O	Akt$$$186$$$189$$$O	inhibitors$$$190$$$200$$$O	ceptable$$$201$$$209$$$O	salt$$$210$$$214$$$O	thereof$$$215$$$222$$$O	or$$$223$$$225$$$O	a$$$226$$$227$$$O	hydrate$$$228$$$235$$$I	of$$$236$$$238$$$O	the$$$239$$$242$$$O	compound$$$243$$$251$$$O	or$$$252$$$254$$$O	the$$$255$$$258$$$O	salt$$$259$$$263$$$O	thereof$$$264$$$271$$$O	as$$$272$$$274$$$O	Akt$$$275$$$278$$$O	inhibitors$$$279$$$289$$$O	that$$$290$$$294$$$O	are$$$295$$$298$$$O	antineoplastic$$$299$$$313$$$O	and/or$$$314$$$320$$$O	antiviral$$$321$$$330$$$O	agents.$$$331$$$338$$$O	The$$$339$$$342$$$O	invention$$$343$$$352$$$O	also$$$353$$$357$$$O	relates$$$358$$$365$$$O	to$$$366$$$368$$$O	the$$$369$$$372$$$O	composition$$$373$$$384$$$O	comprising$$$385$$$395$$$O	these$$$396$$$401$$$O	compounds$$$402$$$411$$$O	and$$$412$$$415$$$O	methods$$$416$$$423$$$O	for$$$424$$$427$$$O	applying$$$428$$$436$$$O	these$$$437$$$442$$$O	compounds.$$$443$$$453$$$O
US20100105777
Amide$$$0$$$5$$$I	or$$$6$$$8$$$O	thioamide$$$9$$$18$$$I	derivatives$$$19$$$30$$$O	and$$$31$$$34$$$O	their$$$35$$$40$$$O	use$$$41$$$44$$$O	in$$$45$$$47$$$O	the$$$48$$$51$$$O	treatment$$$52$$$61$$$O	of$$$62$$$64$$$O	pain$$$65$$$69$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	compounds,$$$39$$$49$$$O	pharmaceutical$$$50$$$64$$$O	compositions$$$65$$$77$$$O	comprising$$$78$$$88$$$O	the$$$89$$$92$$$O	same,$$$93$$$98$$$O	use$$$99$$$102$$$O	of$$$103$$$105$$$O	said$$$106$$$110$$$O	compounds$$$111$$$120$$$O	for$$$121$$$124$$$O	the$$$125$$$128$$$O	manufacture$$$129$$$140$$$O	of$$$141$$$143$$$O	a$$$144$$$145$$$O	medicament$$$146$$$156$$$O	for$$$157$$$160$$$O	treatment$$$161$$$170$$$O	of$$$171$$$173$$$O	pain$$$174$$$178$$$O	and$$$179$$$182$$$O	disorders$$$183$$$192$$$O	related$$$193$$$200$$$O	thereto$$$201$$$208$$$O	as$$$209$$$211$$$O	well$$$212$$$216$$$O	as$$$217$$$219$$$O	a$$$220$$$221$$$O	method$$$222$$$228$$$O	for$$$229$$$232$$$O	treatment$$$233$$$242$$$O	of$$$243$$$245$$$O	pain$$$246$$$250$$$O	and$$$251$$$254$$$O	disorders$$$255$$$264$$$O	related$$$265$$$272$$$O	thereto,$$$273$$$281$$$O	wherein$$$282$$$289$$$O	said$$$290$$$294$$$O	compounds$$$295$$$304$$$O	are$$$305$$$308$$$O	administered.$$$309$$$322$$$O	The$$$323$$$326$$$O	compounds$$$327$$$336$$$O	are$$$337$$$340$$$O	represented$$$341$$$352$$$O	by$$$353$$$355$$$O	the$$$356$$$359$$$O	general$$$360$$$367$$$O	formula$$$368$$$375$$$O	(I),$$$376$$$380$$$O	as$$$381$$$383$$$O	further$$$384$$$391$$$O	defined$$$392$$$399$$$O	in$$$400$$$402$$$O	the$$$403$$$406$$$O	specification.$$$407$$$421$$$O
CN102617672A
Camellia$$$0$$$8$$$O	nitidissima$$$9$$$20$$$O	flavonoid$$$21$$$30$$$I	glycoside,$$$31$$$41$$$I	and$$$42$$$45$$$O	preparation$$$46$$$57$$$O	method$$$58$$$64$$$O	and$$$65$$$68$$$O	application$$$69$$$80$$$O	thereof$$$81$$$88$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	anticancer$$$28$$$38$$$O	compound$$$39$$$47$$$O	camellia$$$48$$$56$$$O	nitidissima$$$57$$$68$$$O	flavonoid$$$69$$$78$$$I	glycoside$$$79$$$88$$$I	A$$$89$$$90$$$I	separated$$$91$$$100$$$O	from$$$101$$$105$$$O	camellia$$$106$$$114$$$O	nitidissima,$$$115$$$127$$$O	and$$$128$$$131$$$O	a$$$132$$$133$$$O	preparation$$$134$$$145$$$O	method$$$146$$$152$$$O	and$$$153$$$156$$$O	application$$$157$$$168$$$O	thereof.$$$169$$$177$$$O	By$$$178$$$180$$$O	qualitative$$$181$$$192$$$O	and$$$193$$$196$$$O	quantitative$$$197$$$209$$$O	determination,$$$210$$$224$$$O	a$$$225$$$226$$$O	monomeric$$$227$$$236$$$O	compound$$$237$$$245$$$O	and$$$246$$$249$$$O	fraction$$$250$$$258$$$O	which$$$259$$$264$$$O	are$$$265$$$268$$$O	obtained$$$269$$$277$$$O	by$$$278$$$280$$$O	separation$$$281$$$291$$$O	from$$$292$$$296$$$O	an$$$297$$$299$$$O	ethyl$$$300$$$305$$$I	acetate$$$306$$$313$$$I	extract$$$314$$$321$$$O	of$$$322$$$324$$$O	a$$$325$$$326$$$O	95%$$$327$$$330$$$O	ethanol$$$331$$$338$$$I	extract$$$339$$$346$$$O	of$$$347$$$349$$$O	the$$$350$$$353$$$O	camellia$$$354$$$362$$$O	nitidissima$$$363$$$374$$$O	are$$$375$$$378$$$O	mainly$$$379$$$385$$$O	flavonoid$$$386$$$395$$$I	components.$$$396$$$407$$$O	The$$$408$$$411$$$O	chemical$$$412$$$420$$$O	structure$$$421$$$430$$$O	of$$$431$$$433$$$O	the$$$434$$$437$$$O	compound$$$438$$$446$$$O	is$$$447$$$449$$$O	determined$$$450$$$460$$$O	by$$$461$$$463$$$O	analysis$$$464$$$472$$$O	of$$$473$$$475$$$O	a$$$476$$$477$$$O	modern$$$478$$$484$$$O	spectrum$$$485$$$493$$$O	technology,$$$494$$$505$$$O	and$$$506$$$509$$$O	the$$$510$$$513$$$O	chemical$$$514$$$522$$$O	name$$$523$$$527$$$O	is$$$528$$$530$$$O	quercetin-7-O-(6''-O-E-$$$531$$$554$$$I	dicaffeoyl$$$555$$$565$$$I	group)-beta-D-glucoside.$$$566$$$590$$$I	An$$$591$$$593$$$O	in$$$594$$$596$$$O	vitro$$$597$$$602$$$O	anti-tumor$$$603$$$613$$$O	experiment$$$614$$$624$$$O	proves$$$625$$$631$$$O	that$$$632$$$636$$$O	the$$$637$$$640$$$O	compound$$$641$$$649$$$O	can$$$650$$$653$$$O	remarkably$$$654$$$664$$$O	restrain$$$665$$$673$$$O	proliferation$$$674$$$687$$$O	of$$$688$$$690$$$O	tumor$$$691$$$696$$$O	cells$$$697$$$702$$$O	and$$$703$$$706$$$O	has$$$707$$$710$$$O	activity$$$711$$$719$$$O	of$$$720$$$722$$$O	inducing$$$723$$$731$$$O	apoptosis$$$732$$$741$$$O	of$$$742$$$744$$$O	the$$$745$$$748$$$O	tumor$$$749$$$754$$$O	cells.$$$755$$$761$$$O	An$$$762$$$764$$$O	anticancer$$$765$$$775$$$O	compound$$$776$$$784$$$O	camellia$$$785$$$793$$$O	nitidissima$$$794$$$805$$$O	flavonoid$$$806$$$815$$$I	glycoside$$$816$$$825$$$I	A$$$826$$$827$$$I	product$$$828$$$835$$$O	has$$$836$$$839$$$O	the$$$840$$$843$$$O	developing$$$844$$$854$$$O	potential$$$855$$$864$$$O	of$$$865$$$867$$$O	antitumor$$$868$$$877$$$O	medicines.$$$878$$$888$$$O
CN1561991A
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	producing$$$12$$$21$$$O	medicine$$$22$$$30$$$O	grade$$$31$$$36$$$O	natural$$$37$$$44$$$O	vitamin$$$45$$$52$$$I	E$$$53$$$54$$$I	raw$$$55$$$58$$$O	oil$$$59$$$62$$$O
A$$$0$$$1$$$O	medicine-class$$$2$$$16$$$O	raw$$$17$$$20$$$O	VE$$$21$$$23$$$I	oil$$$24$$$27$$$O	is$$$28$$$30$$$O	prepared$$$31$$$39$$$O	through$$$40$$$47$$$O	proportional$$$48$$$60$$$O	acetate$$$61$$$68$$$I	reaction$$$69$$$77$$$O	of$$$78$$$80$$$O	d-alpha-VE,$$$81$$$92$$$I	solvent,$$$93$$$101$$$O	catalyst$$$102$$$110$$$O	and$$$111$$$114$$$O	dewatering$$$115$$$125$$$O	agent,$$$126$$$132$$$O	cooling,$$$133$$$141$$$O	washing$$$142$$$149$$$O	with$$$150$$$154$$$O	clean$$$155$$$160$$$O	water,$$$161$$$167$$$O	laying$$$168$$$174$$$O	aside,$$$175$$$181$$$O	distilling$$$182$$$192$$$O	to$$$193$$$195$$$O	remove$$$196$$$202$$$O	solvnet$$$203$$$210$$$O	and$$$211$$$214$$$O	obtain$$$215$$$221$$$O	d-alpha-VE$$$222$$$232$$$I	acetate,$$$233$$$241$$$I	and$$$242$$$245$$$O	purifying$$$246$$$255$$$O	by$$$256$$$258$$$O	molecular$$$259$$$268$$$O	distilling.$$$269$$$280$$$O
CN101693038B
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	for$$$27$$$30$$$O	treating$$$31$$$39$$$O	skin$$$40$$$44$$$O	(A)$$$45$$$48$$$O	disease$$$49$$$56$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pharmaceutical$$$27$$$41$$$O	composition$$$42$$$53$$$O	for$$$54$$$57$$$O	treating$$$58$$$66$$$O	skin$$$67$$$71$$$O	(A)$$$72$$$75$$$O	disease,$$$76$$$84$$$O	having$$$85$$$91$$$O	the$$$92$$$95$$$O	strong$$$96$$$102$$$O	eliminating$$$103$$$114$$$O	function$$$115$$$123$$$O	on$$$124$$$126$$$O	bacteria,$$$127$$$136$$$O	epiphyte$$$137$$$145$$$O	and$$$146$$$149$$$O	viruses$$$150$$$157$$$O	and$$$158$$$161$$$O	has$$$162$$$165$$$O	the$$$166$$$169$$$O	obvious$$$170$$$177$$$O	effect$$$178$$$184$$$O	on$$$185$$$187$$$O	tinea$$$188$$$193$$$O	of$$$194$$$196$$$O	feet$$$197$$$201$$$O	and$$$202$$$205$$$O	hands,$$$206$$$212$$$O	onychomycosis,$$$213$$$227$$$O	tinea$$$228$$$233$$$O	cruris,$$$234$$$241$$$O	scald$$$242$$$247$$$O	head,$$$248$$$253$$$O	furuncle,$$$254$$$263$$$O	mosquito$$$264$$$272$$$O	bite$$$273$$$277$$$O	and$$$278$$$281$$$O	acrohyperhidrosis.$$$282$$$300$$$O	The$$$301$$$304$$$O	high-molecule$$$305$$$318$$$O	material$$$319$$$327$$$O	and$$$328$$$331$$$O	recipe$$$332$$$338$$$O	composition$$$339$$$350$$$O	of$$$351$$$353$$$O	the$$$354$$$357$$$O	pharmaceutical$$$358$$$372$$$O	composition$$$373$$$384$$$O	has$$$385$$$388$$$O	no$$$389$$$391$$$O	poison$$$392$$$398$$$O	and$$$399$$$402$$$O	little$$$403$$$409$$$O	stimulation$$$410$$$421$$$O	on$$$422$$$424$$$O	skin,$$$425$$$430$$$O	has$$$431$$$434$$$O	long$$$435$$$439$$$O	action$$$440$$$446$$$O	time$$$447$$$451$$$O	and$$$452$$$455$$$O	presents$$$456$$$464$$$O	the$$$465$$$468$$$O	actions$$$469$$$476$$$O	of$$$477$$$479$$$O	controlled$$$480$$$490$$$O	release$$$491$$$498$$$O	and$$$499$$$502$$$O	stability.$$$503$$$513$$$O	The$$$514$$$517$$$O	quality$$$518$$$525$$$O	can$$$526$$$529$$$O	be$$$530$$$532$$$O	kept$$$533$$$537$$$O	to$$$538$$$540$$$O	be$$$541$$$543$$$O	stable$$$544$$$550$$$O	when$$$551$$$555$$$O	the$$$556$$$559$$$O	composition$$$560$$$571$$$O	is$$$572$$$574$$$O	stored$$$575$$$581$$$O	at$$$582$$$584$$$O	normal$$$585$$$591$$$O	temperature,$$$592$$$604$$$O	and$$$605$$$608$$$O	thereby,$$$609$$$617$$$O	the$$$618$$$621$$$O	composition$$$622$$$633$$$O	is$$$634$$$636$$$O	safe$$$637$$$641$$$O	and$$$642$$$645$$$O	effective.$$$646$$$656$$$O	The$$$657$$$660$$$O	composition$$$661$$$672$$$O	contains$$$673$$$681$$$O	the$$$682$$$685$$$O	main$$$686$$$690$$$O	constituents$$$691$$$703$$$O	of$$$704$$$706$$$O	povidone$$$707$$$715$$$I	iodine,$$$716$$$723$$$I	acetylsalicylic$$$724$$$739$$$I	acid,$$$740$$$745$$$I	polyethylene$$$746$$$758$$$I	glycol,$$$759$$$766$$$I	potash$$$767$$$773$$$I	iodate,$$$774$$$781$$$I	phenol$$$782$$$788$$$I	and$$$789$$$792$$$O	high-molecule$$$793$$$806$$$O	material.$$$807$$$816$$$O
CN101138564A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	alkaloids$$$15$$$24$$$I	compounds$$$25$$$34$$$O	in$$$35$$$37$$$O	the$$$38$$$41$$$O	preparation$$$42$$$53$$$O	of$$$54$$$56$$$O	antineoplastic$$$57$$$71$$$O	medicament$$$72$$$82$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	pertains$$$22$$$30$$$O	to$$$31$$$33$$$O	the$$$34$$$37$$$O	art$$$38$$$41$$$O	of$$$42$$$44$$$O	medical$$$45$$$52$$$O	technology,$$$53$$$64$$$O	in$$$65$$$67$$$O	particular$$$68$$$78$$$O	to$$$79$$$81$$$O	an$$$82$$$84$$$O	application$$$85$$$96$$$O	of$$$97$$$99$$$O	an$$$100$$$102$$$O	alkaloid$$$103$$$111$$$I	compound$$$112$$$120$$$O	in$$$121$$$123$$$O	the$$$124$$$127$$$O	preparation$$$128$$$139$$$O	of$$$140$$$142$$$O	antitumor$$$143$$$152$$$O	drugs.$$$153$$$159$$$O	The$$$160$$$163$$$O	alkaloid$$$164$$$172$$$I	compound$$$173$$$181$$$O	consists$$$182$$$190$$$O	of$$$191$$$193$$$O	a$$$194$$$195$$$O	Lycoris$$$196$$$203$$$O	lactone,$$$204$$$212$$$O	a$$$213$$$214$$$O	narciprimine$$$215$$$227$$$I	and$$$228$$$231$$$O	a$$$232$$$233$$$O	7-dehydroxyl$$$234$$$246$$$I	narciprimine$$$247$$$259$$$I	and$$$260$$$263$$$O	the$$$264$$$267$$$O	molecular$$$268$$$277$$$O	formula$$$278$$$285$$$O	of$$$286$$$288$$$O	the$$$289$$$292$$$O	alkaloid$$$293$$$301$$$I	compound$$$302$$$310$$$O	is$$$311$$$313$$$O	C17H19NO5,$$$314$$$324$$$I	C14H9NO5,$$$325$$$334$$$I	C14H9NO4.$$$335$$$344$$$I	Animal$$$345$$$351$$$O	experiments$$$352$$$363$$$O	prove$$$364$$$369$$$O	that$$$370$$$374$$$O	the$$$375$$$378$$$O	compounds$$$379$$$388$$$O	have$$$389$$$393$$$O	better$$$394$$$400$$$O	inhibited$$$401$$$410$$$O	activity$$$411$$$419$$$O	on$$$420$$$422$$$O	a$$$423$$$424$$$O	variety$$$425$$$432$$$O	of$$$433$$$435$$$O	tumors.$$$436$$$443$$$O	The$$$444$$$447$$$O	invention$$$448$$$457$$$O	also$$$458$$$462$$$O	includes$$$463$$$471$$$O	one$$$472$$$475$$$O	or$$$476$$$478$$$O	more$$$479$$$483$$$O	than$$$484$$$488$$$O	one$$$489$$$492$$$O	types$$$493$$$498$$$O	of$$$499$$$501$$$O	three$$$502$$$507$$$O	compounds$$$508$$$517$$$O	with$$$518$$$522$$$O	effective$$$523$$$532$$$O	treatment,$$$533$$$543$$$O	or$$$544$$$546$$$O	includes$$$547$$$555$$$O	medicine$$$556$$$564$$$O	combinations$$$565$$$577$$$O	of$$$578$$$580$$$O	the$$$581$$$584$$$O	pharmaceutical$$$585$$$599$$$O	acceptable$$$600$$$610$$$O	carrier.$$$611$$$619$$$O
WO2011119649A3
Pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	containing$$$28$$$38$$$O	berberine$$$39$$$48$$$I	for$$$49$$$52$$$O	treatment$$$53$$$62$$$O	or$$$63$$$65$$$O	prevention$$$66$$$76$$$O	of$$$77$$$79$$$O	weight$$$80$$$86$$$O	gain$$$87$$$91$$$O	and$$$92$$$95$$$O	obesity$$$96$$$103$$$O	associated$$$104$$$114$$$O	with$$$115$$$119$$$O	anti-psychotic$$$120$$$134$$$O	drugs$$$135$$$140$$$O
The$$$0$$$3$$$O	compositions$$$4$$$16$$$O	and$$$17$$$20$$$O	methods$$$21$$$28$$$O	disclosed$$$29$$$38$$$O	herein$$$39$$$45$$$O	are$$$46$$$49$$$O	of$$$50$$$52$$$O	use$$$53$$$56$$$O	for$$$57$$$60$$$O	the$$$61$$$64$$$O	treatment$$$65$$$74$$$O	and$$$75$$$78$$$O	prevention$$$79$$$89$$$O	of$$$90$$$92$$$O	weight$$$93$$$99$$$O	gain$$$100$$$104$$$O	and$$$105$$$108$$$O	obesity.$$$109$$$117$$$O	In$$$118$$$120$$$O	particular,$$$121$$$132$$$O	the$$$133$$$136$$$O	compositions$$$137$$$149$$$O	and$$$150$$$153$$$O	methods$$$154$$$161$$$O	include$$$162$$$169$$$O	treatment$$$170$$$179$$$O	of$$$180$$$182$$$O	weight$$$183$$$189$$$O	gain$$$190$$$194$$$O	and$$$195$$$198$$$O	obesity$$$199$$$206$$$O	with$$$207$$$211$$$O	berberine$$$212$$$221$$$I	and/or$$$222$$$228$$$O	berberine$$$229$$$238$$$I	analogs$$$239$$$246$$$O	alone$$$247$$$252$$$O	or$$$253$$$255$$$O	in$$$256$$$258$$$O	combination$$$259$$$270$$$O	thereof$$$271$$$278$$$O	to$$$279$$$281$$$O	cause$$$282$$$287$$$O	a$$$288$$$289$$$O	reduction$$$290$$$299$$$O	in$$$300$$$302$$$O	an$$$303$$$305$$$O	individual's$$$306$$$318$$$O	weight$$$319$$$325$$$O	or$$$326$$$328$$$O	prevent$$$329$$$336$$$O	weight$$$337$$$343$$$O	gain$$$344$$$348$$$O	or$$$349$$$351$$$O	obesity.$$$352$$$360$$$O	In$$$361$$$363$$$O	certain$$$364$$$371$$$O	embodiments,$$$372$$$384$$$O	the$$$385$$$388$$$O	weight$$$389$$$395$$$O	gain$$$396$$$400$$$O	and$$$401$$$404$$$O	obesity$$$405$$$412$$$O	are$$$413$$$416$$$O	associated$$$417$$$427$$$O	with$$$428$$$432$$$O	administration$$$433$$$447$$$O	of$$$448$$$450$$$O	anti-psychotic$$$451$$$465$$$O	drugs.$$$466$$$472$$$O	In$$$473$$$475$$$O	an$$$476$$$478$$$O	alternative$$$479$$$490$$$O	embodiment,$$$491$$$502$$$O	the$$$503$$$506$$$O	compositions$$$507$$$519$$$O	and$$$520$$$523$$$O	methods$$$524$$$531$$$O	provide$$$532$$$539$$$O	berberine$$$540$$$549$$$O	or$$$550$$$552$$$O	berberine$$$553$$$562$$$I	analogs$$$563$$$570$$$O	alone$$$571$$$576$$$O	or$$$577$$$579$$$O	for$$$580$$$583$$$O	coadministration$$$584$$$600$$$O	with$$$601$$$605$$$O	an$$$606$$$608$$$O	anti-psychotic$$$609$$$623$$$O	agent.$$$624$$$630$$$O	In$$$631$$$633$$$O	an$$$634$$$636$$$O	additional$$$637$$$647$$$O	embodiment,$$$648$$$659$$$O	the$$$660$$$663$$$O	compositions$$$664$$$676$$$O	and$$$677$$$680$$$O	methods$$$681$$$688$$$O	further$$$689$$$696$$$O	include$$$697$$$704$$$O	a$$$705$$$706$$$O	natural$$$707$$$714$$$O	product.$$$715$$$723$$$O	The$$$724$$$727$$$O	usefulness$$$728$$$738$$$O	of$$$739$$$741$$$O	the$$$742$$$745$$$O	present$$$746$$$753$$$O	invention$$$754$$$763$$$O	is$$$764$$$766$$$O	that$$$767$$$771$$$O	berberine$$$772$$$781$$$I	and$$$782$$$785$$$O	berberine$$$786$$$795$$$I	analogs$$$796$$$803$$$O	do$$$804$$$806$$$O	not$$$807$$$810$$$O	have$$$811$$$815$$$O	synergistic$$$816$$$827$$$O	effects$$$828$$$835$$$O	with$$$836$$$840$$$O	other$$$841$$$846$$$O	drugs$$$847$$$852$$$O	and$$$853$$$856$$$O	administration$$$857$$$871$$$O	results$$$872$$$879$$$O	in$$$880$$$882$$$O	few$$$883$$$886$$$O	side$$$887$$$891$$$O	effects.$$$892$$$900$$$O	Such$$$901$$$905$$$O	characteristics$$$906$$$921$$$O	of$$$922$$$924$$$O	berberine$$$925$$$934$$$I	or$$$935$$$937$$$O	berberine$$$938$$$947$$$I	analogs$$$948$$$955$$$O	are$$$956$$$959$$$O	a$$$960$$$961$$$O	great$$$962$$$967$$$O	improvement$$$968$$$979$$$O	able$$$980$$$984$$$O	to$$$985$$$987$$$O	support$$$988$$$995$$$O	the$$$996$$$999$$$O	widespread$$$1000$$$1010$$$O	use$$$1011$$$1014$$$O	of$$$1015$$$1017$$$O	the$$$1018$$$1021$$$O	compositions$$$1022$$$1034$$$O	and$$$1035$$$1038$$$O	methods$$$1039$$$1046$$$O	of$$$1047$$$1049$$$O	the$$$1050$$$1053$$$O	present$$$1054$$$1061$$$O	invention$$$1062$$$1071$$$O	as$$$1072$$$1074$$$O	therapeutics$$$1075$$$1087$$$O	for$$$1088$$$1091$$$O	the$$$1092$$$1095$$$O	treatment$$$1096$$$1105$$$O	and$$$1106$$$1109$$$O	prevention$$$1110$$$1120$$$O	of$$$1121$$$1123$$$O	weight$$$1124$$$1130$$$O	gain$$$1131$$$1135$$$O	and$$$1136$$$1139$$$O	obesity.$$$1140$$$1148$$$O
US8617539
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	administration$$$10$$$24$$$O	of$$$25$$$27$$$O	platelet-rich$$$28$$$41$$$O	plasma$$$42$$$48$$$O	to$$$49$$$51$$$O	treat$$$52$$$57$$$O	an$$$58$$$60$$$O	acute$$$61$$$66$$$O	cardiac$$$67$$$74$$$O	dysfunction$$$75$$$86$$$O
Methods$$$0$$$7$$$O	are$$$8$$$11$$$O	described$$$12$$$21$$$O	for$$$22$$$25$$$O	using$$$26$$$31$$$O	compositions$$$32$$$44$$$O	containing$$$45$$$55$$$O	platelet-rich$$$56$$$69$$$O	plasma$$$70$$$76$$$O	for$$$77$$$80$$$O	the$$$81$$$84$$$O	treatment$$$85$$$94$$$O	of$$$95$$$97$$$O	acute$$$98$$$103$$$O	or$$$104$$$106$$$O	chronic$$$107$$$114$$$O	dysfunction$$$115$$$126$$$O	of$$$127$$$129$$$O	cardiac$$$130$$$137$$$O	muscle.$$$138$$$145$$$O	The$$$146$$$149$$$O	method$$$150$$$156$$$O	may$$$157$$$160$$$O	employ$$$161$$$167$$$O	a$$$168$$$169$$$O	kit$$$170$$$173$$$O	which$$$174$$$179$$$O	includes$$$180$$$188$$$O	a$$$189$$$190$$$O	platelet-rich$$$191$$$204$$$O	plasma$$$205$$$211$$$O	composition$$$212$$$223$$$O	and$$$224$$$227$$$O	a$$$228$$$229$$$O	pH$$$230$$$232$$$O	adjusting$$$233$$$242$$$O	agent$$$243$$$248$$$O	and$$$249$$$252$$$O	a$$$253$$$254$$$O	catheter$$$255$$$263$$$O	or$$$264$$$266$$$O	syringe$$$267$$$274$$$O	for$$$275$$$278$$$O	delivery$$$279$$$287$$$O	of$$$288$$$290$$$O	the$$$291$$$294$$$O	platelet-rich$$$295$$$308$$$O	plasma$$$309$$$315$$$O	composition$$$316$$$327$$$O	to$$$328$$$330$$$O	dysfunctional$$$331$$$344$$$O	cardiac$$$345$$$352$$$O	muscle.$$$353$$$360$$$O	The$$$361$$$364$$$O	kit$$$365$$$368$$$O	may$$$369$$$372$$$O	also$$$373$$$377$$$O	include$$$378$$$385$$$O	a$$$386$$$387$$$O	syringe$$$388$$$395$$$O	for$$$396$$$399$$$O	withdrawing$$$400$$$411$$$O	blood$$$412$$$417$$$O	from$$$418$$$422$$$O	a$$$423$$$424$$$O	patient$$$425$$$432$$$O	and$$$433$$$436$$$O	a$$$437$$$438$$$O	centrifuge$$$439$$$449$$$O	device$$$450$$$456$$$O	means$$$457$$$462$$$O	to$$$463$$$465$$$O	obtain$$$466$$$472$$$O	platelet-rich$$$473$$$486$$$O	plasma.$$$487$$$494$$$O
US20110009426
5,6-bisaryl-2-pyridine-carboxamide$$$0$$$34$$$I	derivatives,$$$35$$$47$$$O	preparation$$$48$$$59$$$O	thereof$$$60$$$67$$$O	and$$$68$$$71$$$O	therapeutic$$$72$$$83$$$O	application$$$84$$$95$$$O	thereof$$$96$$$103$$$O	as$$$104$$$106$$$O	urotensin$$$107$$$116$$$O	ii$$$117$$$119$$$O	receptor$$$120$$$128$$$O	antagonists$$$129$$$140$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	5,6-bisaryl-2-pyridinecarboxamides,$$$33$$$68$$$I	to$$$69$$$71$$$O	their$$$72$$$77$$$O	preparation$$$78$$$89$$$O	and$$$90$$$93$$$O	to$$$94$$$96$$$O	their$$$97$$$102$$$O	therapeutic$$$103$$$114$$$O	use$$$115$$$118$$$O	as$$$119$$$121$$$O	urotensin$$$122$$$131$$$O	II$$$132$$$134$$$O	receptor$$$135$$$143$$$O	antagonists.$$$144$$$156$$$O
CN103316030A
Medicament$$$0$$$10$$$O	for$$$11$$$14$$$O	treating$$$15$$$23$$$O	nasal$$$24$$$29$$$O	obstruction$$$30$$$41$$$O	when$$$42$$$46$$$O	catching$$$47$$$55$$$O	a$$$56$$$57$$$O	cold$$$58$$$62$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medicament$$$27$$$37$$$O	for$$$38$$$41$$$O	treating$$$42$$$50$$$O	nasal$$$51$$$56$$$O	obstruction$$$57$$$68$$$O	when$$$69$$$73$$$O	catching$$$74$$$82$$$O	a$$$83$$$84$$$O	cold,$$$85$$$90$$$O	and$$$91$$$94$$$O	relates$$$95$$$102$$$O	to$$$103$$$105$$$O	a$$$106$$$107$$$O	new$$$108$$$111$$$O	medical$$$112$$$119$$$O	application$$$120$$$131$$$O	of$$$132$$$134$$$O	chloramphenicol.$$$135$$$151$$$I	In$$$152$$$154$$$O	the$$$155$$$158$$$O	prior$$$159$$$164$$$O	art,$$$165$$$169$$$O	chloramphenicol$$$170$$$185$$$I	can$$$186$$$189$$$O	be$$$190$$$192$$$O	prepared$$$193$$$201$$$O	to$$$202$$$204$$$O	be$$$205$$$207$$$O	nasal$$$208$$$213$$$O	drops,$$$214$$$220$$$O	which$$$221$$$226$$$O	can$$$227$$$230$$$O	be$$$231$$$233$$$O	dropped$$$234$$$241$$$O	into$$$242$$$246$$$O	nasal$$$247$$$252$$$O	cavities$$$253$$$261$$$O	for$$$262$$$265$$$O	1-2$$$266$$$269$$$O	droplets$$$270$$$278$$$O	each$$$279$$$283$$$O	time$$$284$$$288$$$O	when$$$289$$$293$$$O	nasal$$$294$$$299$$$O	obstruction,$$$300$$$312$$$O	and$$$313$$$316$$$O	makes$$$317$$$322$$$O	an$$$323$$$325$$$O	immediate$$$326$$$335$$$O	effect.$$$336$$$343$$$O
EP1730126A1
Novel$$$0$$$5$$$O	benzoxazinone$$$6$$$19$$$I	derivatives$$$20$$$31$$$O	used$$$32$$$36$$$O	as$$$37$$$39$$$O	long-acting$$$40$$$51$$$O	betamimetics$$$52$$$64$$$O	for$$$65$$$68$$$O	treating$$$69$$$77$$$O	respiratory$$$78$$$89$$$O	illnesses$$$90$$$99$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	general$$$38$$$45$$$O	formula$$$46$$$53$$$O	(I)$$$54$$$57$$$O	in$$$58$$$60$$$O	which$$$61$$$66$$$O	radicals$$$67$$$75$$$O	R,$$$76$$$78$$$O	R1,$$$79$$$82$$$O	R2,$$$83$$$86$$$O	R3$$$87$$$89$$$O	and$$$90$$$93$$$O	A$$$94$$$95$$$O	can$$$96$$$99$$$O	have$$$100$$$104$$$O	the$$$105$$$108$$$O	meanings$$$109$$$117$$$O	as$$$118$$$120$$$O	cited$$$121$$$126$$$O	in$$$127$$$129$$$O	the$$$130$$$133$$$O	claims$$$134$$$140$$$O	and$$$141$$$144$$$O	in$$$145$$$147$$$O	the$$$148$$$151$$$O	description,$$$152$$$164$$$O	to$$$165$$$167$$$O	methods$$$168$$$175$$$O	for$$$176$$$179$$$O	the$$$180$$$183$$$O	production$$$184$$$194$$$O	thereof,$$$195$$$203$$$O	and$$$204$$$207$$$O	to$$$208$$$210$$$O	their$$$211$$$216$$$O	use$$$217$$$220$$$O	as$$$221$$$223$$$O	medicaments,$$$224$$$236$$$O	particularly$$$237$$$249$$$O	for$$$250$$$253$$$O	treating$$$254$$$262$$$O	inflammatory$$$263$$$275$$$O	and$$$276$$$279$$$O	obstructive$$$280$$$291$$$O	respiratory$$$292$$$303$$$O	illnesses.$$$304$$$314$$$O
CN1988887A
Injectable$$$0$$$10$$$O	pharmaceutical$$$11$$$25$$$O	suspension$$$26$$$36$$$O	comprising$$$37$$$47$$$O	posaconazole$$$48$$$60$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	formulations$$$31$$$43$$$O	useful$$$44$$$50$$$O	for$$$51$$$54$$$O	treating$$$55$$$63$$$O	infections,$$$64$$$75$$$O	in$$$76$$$78$$$O	particular,$$$79$$$90$$$O	formulations$$$91$$$103$$$O	that$$$104$$$108$$$O	include$$$109$$$116$$$O	the$$$117$$$120$$$O	active$$$121$$$127$$$O	pharmaceutical$$$128$$$142$$$O	ingredient$$$143$$$153$$$O	posaconazole$$$154$$$166$$$I	in$$$167$$$169$$$O	an$$$170$$$172$$$O	injectable$$$173$$$183$$$O	suspension$$$184$$$194$$$O	that$$$195$$$199$$$O	is$$$200$$$202$$$O	stable$$$203$$$209$$$O	when$$$210$$$214$$$O	subjected$$$215$$$224$$$O	to$$$225$$$227$$$O	terminal$$$228$$$236$$$O	steam$$$237$$$242$$$O	sterilization.$$$243$$$257$$$O
US20120040917
Splice$$$0$$$6$$$O	Switching$$$7$$$16$$$O	Oligomers$$$17$$$26$$$O	for$$$27$$$30$$$O	TNF$$$31$$$34$$$O	Superfamily$$$35$$$46$$$O	Receptors$$$47$$$56$$$O	and$$$57$$$60$$$O	Their$$$61$$$66$$$O	Use$$$67$$$70$$$O	in$$$71$$$73$$$O	Treatment$$$74$$$83$$$O	of$$$84$$$86$$$O	Disease$$$87$$$94$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compositions$$$33$$$45$$$O	and$$$46$$$49$$$O	methods$$$50$$$57$$$O	for$$$58$$$61$$$O	preparing$$$62$$$71$$$O	splice$$$72$$$78$$$O	variants$$$79$$$87$$$O	of$$$88$$$90$$$O	TNFalpha$$$91$$$99$$$O	receptor$$$100$$$108$$$O	(TNFR)$$$109$$$115$$$O	in$$$116$$$118$$$O	vivo$$$119$$$123$$$O	or$$$124$$$126$$$O	in$$$127$$$129$$$O	vitro,$$$130$$$136$$$O	and$$$137$$$140$$$O	the$$$141$$$144$$$O	resulting$$$145$$$154$$$O	TNFR$$$155$$$159$$$O	protein$$$160$$$167$$$O	variants.$$$168$$$177$$$O	Such$$$178$$$182$$$O	variants$$$183$$$191$$$O	may$$$192$$$195$$$O	be$$$196$$$198$$$O	prepared$$$199$$$207$$$O	by$$$208$$$210$$$O	controlling$$$211$$$222$$$O	the$$$223$$$226$$$O	splicing$$$227$$$235$$$O	of$$$236$$$238$$$O	pre-mRNA$$$239$$$247$$$O	molecules$$$248$$$257$$$O	and$$$258$$$261$$$O	regulating$$$262$$$272$$$O	protein$$$273$$$280$$$O	expression$$$281$$$291$$$O	with$$$292$$$296$$$O	splice$$$297$$$303$$$O	switching$$$304$$$313$$$O	oligonucleotides$$$314$$$330$$$O	or$$$331$$$333$$$O	splice$$$334$$$340$$$O	switching$$$341$$$350$$$O	oligomers$$$351$$$360$$$O	(SSOs).$$$361$$$368$$$O	The$$$369$$$372$$$O	preferred$$$373$$$382$$$O	SSOs$$$383$$$387$$$O	according$$$388$$$397$$$O	to$$$398$$$400$$$O	the$$$401$$$404$$$O	invention$$$405$$$414$$$O	target$$$415$$$421$$$O	exon$$$422$$$426$$$O	7$$$427$$$428$$$O	or$$$429$$$431$$$O	8$$$432$$$433$$$O	of$$$434$$$436$$$O	TNFR1$$$437$$$442$$$O	(TNFRSF1A)$$$443$$$453$$$O	or$$$454$$$456$$$O	TNFR2$$$457$$$462$$$O	(TNFRSF1A)$$$463$$$473$$$O	pre-mRNA,$$$474$$$483$$$O	typically$$$484$$$493$$$O	resulting$$$494$$$503$$$O	in$$$504$$$506$$$O	the$$$507$$$510$$$O	production$$$511$$$521$$$O	of$$$522$$$524$$$O	TNFR$$$525$$$529$$$O	variants$$$530$$$538$$$O	which$$$539$$$544$$$O	comprise$$$545$$$553$$$O	a$$$554$$$555$$$O	deletion$$$556$$$564$$$O	in$$$565$$$567$$$O	part$$$568$$$572$$$O	or$$$573$$$575$$$O	the$$$576$$$579$$$O	entire$$$580$$$586$$$O	exon$$$587$$$591$$$O	7$$$592$$$593$$$O	or$$$594$$$596$$$O	8$$$597$$$598$$$O	respectfully.$$$599$$$612$$$O	SSOs$$$613$$$617$$$O	targeting$$$618$$$627$$$O	exon$$$628$$$632$$$O	7$$$633$$$634$$$O	are$$$635$$$638$$$O	found$$$639$$$644$$$O	to$$$645$$$647$$$O	result$$$648$$$654$$$O	in$$$655$$$657$$$O	a$$$658$$$659$$$O	soluble$$$660$$$667$$$O	form$$$668$$$672$$$O	of$$$673$$$675$$$O	the$$$676$$$679$$$O	TNFR,$$$680$$$685$$$O	which$$$686$$$691$$$O	has$$$692$$$695$$$O	therapeutic$$$696$$$707$$$O	benefit$$$708$$$715$$$O	for$$$716$$$719$$$O	treatment$$$720$$$729$$$O	of$$$730$$$732$$$O	inflammatory$$$733$$$745$$$O	diseases.$$$746$$$755$$$O	The$$$756$$$759$$$O	SSO's$$$760$$$765$$$O	are$$$766$$$769$$$O	characterized$$$770$$$783$$$O	in$$$784$$$786$$$O	that$$$787$$$791$$$O	they$$$792$$$796$$$O	are$$$797$$$800$$$O	substantially$$$801$$$814$$$O	incapable$$$815$$$824$$$O	or$$$825$$$827$$$O	incapable$$$828$$$837$$$O	of$$$838$$$840$$$O	recruiting$$$841$$$851$$$O	RNaseH.$$$852$$$859$$$O
WO2011128445A1
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	the$$$14$$$17$$$O	accumulation$$$18$$$30$$$O	of$$$31$$$33$$$O	sprd$$$34$$$38$$$O	transcripts$$$39$$$50$$$O	in$$$51$$$53$$$O	s.$$$54$$$56$$$O	aureus$$$57$$$63$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	in$$$22$$$24$$$O	particular$$$25$$$35$$$O	to$$$36$$$38$$$O	an$$$39$$$41$$$O	inhibitor$$$42$$$51$$$O	of$$$52$$$54$$$O	the$$$55$$$58$$$O	accumulation$$$59$$$71$$$O	of$$$72$$$74$$$O	sprD$$$75$$$79$$$O	transcripts$$$80$$$91$$$O	and/or$$$92$$$98$$$O	of$$$99$$$101$$$O	the$$$102$$$105$$$O	transcription$$$106$$$119$$$O	of$$$120$$$122$$$O	the$$$123$$$126$$$O	sprD$$$127$$$131$$$O	gene$$$132$$$136$$$O	and$$$137$$$140$$$O	to$$$141$$$143$$$O	a$$$144$$$145$$$O	method$$$146$$$152$$$O	for$$$153$$$156$$$O	the$$$157$$$160$$$O	in$$$161$$$163$$$O	vitro$$$164$$$169$$$O	or$$$170$$$172$$$O	ex$$$173$$$175$$$O	vivo$$$176$$$180$$$O	selection$$$181$$$190$$$O	or$$$191$$$193$$$O	identification$$$194$$$208$$$O	of$$$209$$$211$$$O	compounds$$$212$$$221$$$O	for$$$222$$$225$$$O	preventing$$$226$$$236$$$O	and/or$$$237$$$243$$$O	treating$$$244$$$252$$$O	a$$$253$$$254$$$O	staphylococcus$$$255$$$269$$$O	infection.$$$270$$$280$$$O
EP0934412B1
HUMAN$$$0$$$5$$$O	THYMOSIN$$$6$$$14$$$O	beta$$$15$$$19$$$O	15$$$20$$$22$$$O	GENE,$$$23$$$28$$$O	PROTEIN$$$29$$$36$$$O	AND$$$37$$$40$$$O	USES$$$41$$$45$$$O	THEREOF$$$46$$$53$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	inventors$$$12$$$21$$$O	have$$$22$$$26$$$O	now$$$27$$$30$$$O	discovered$$$31$$$41$$$O	that$$$42$$$46$$$O	humans$$$47$$$53$$$O	have$$$54$$$58$$$O	a$$$59$$$60$$$O	gene$$$61$$$65$$$O	that$$$66$$$70$$$O	encodes$$$71$$$78$$$O	a$$$79$$$80$$$O	novel$$$81$$$86$$$O	protein$$$87$$$94$$$O	of$$$95$$$97$$$O	the$$$98$$$101$$$O	thymosin$$$102$$$110$$$O	beta$$$112$$$116$$$O	family.$$$118$$$125$$$O	This$$$126$$$130$$$O	novel$$$131$$$136$$$O	protein,$$$137$$$145$$$O	herein$$$146$$$152$$$O	referred$$$153$$$161$$$O	to$$$162$$$164$$$O	as$$$165$$$167$$$O	thymosin$$$168$$$176$$$O	beta$$$178$$$182$$$O	15,$$$183$$$186$$$O	has$$$187$$$190$$$O	the$$$191$$$194$$$O	ability$$$195$$$202$$$O	to$$$203$$$205$$$O	bind$$$206$$$210$$$O	and$$$211$$$214$$$O	sequester$$$215$$$224$$$O	G-actin,$$$225$$$233$$$O	like$$$234$$$238$$$O	other$$$239$$$244$$$O	members$$$245$$$252$$$O	of$$$253$$$255$$$O	the$$$256$$$259$$$O	thymosin$$$260$$$268$$$O	beta$$$270$$$274$$$O	family,$$$276$$$283$$$O	but$$$284$$$287$$$O	unlike$$$288$$$294$$$O	what$$$295$$$299$$$O	is$$$300$$$302$$$O	known$$$303$$$308$$$O	about$$$309$$$314$$$O	other$$$315$$$320$$$O	members$$$321$$$328$$$O	it$$$329$$$331$$$O	also$$$332$$$336$$$O	directly$$$337$$$345$$$O	regulates$$$346$$$355$$$O	cell$$$356$$$360$$$O	motility$$$361$$$369$$$O	in$$$370$$$372$$$O	prostatic$$$373$$$382$$$O	carcinoma$$$383$$$392$$$O	cells.$$$393$$$399$$$O	The$$$400$$$403$$$O	present$$$404$$$411$$$O	invention$$$412$$$421$$$O	is$$$422$$$424$$$O	directed$$$425$$$433$$$O	to$$$434$$$436$$$O	an$$$437$$$439$$$O	isolated$$$440$$$448$$$O	cDNA$$$449$$$453$$$O	encoding$$$454$$$462$$$O	the$$$463$$$466$$$O	human$$$467$$$472$$$O	thymosin$$$473$$$481$$$O	beta$$$483$$$487$$$O	15$$$488$$$490$$$O	gene$$$491$$$495$$$O	(SEQ$$$496$$$500$$$O	ID$$$501$$$503$$$O	NO:$$$504$$$507$$$O	1)$$$508$$$510$$$O	and$$$511$$$514$$$O	have$$$515$$$519$$$O	deduced$$$520$$$527$$$O	the$$$528$$$531$$$O	amino$$$532$$$537$$$I	acid$$$538$$$542$$$I	sequence$$$543$$$551$$$O	(SEQ$$$552$$$556$$$O	ID$$$557$$$559$$$O	NO:$$$560$$$563$$$O	2).$$$564$$$567$$$O
EP1216228B1
BENZAMIDES$$$0$$$10$$$I	AND$$$11$$$14$$$O	RELATED$$$15$$$22$$$O	INHIBITORS$$$23$$$33$$$O	OF$$$34$$$36$$$O	FACTOR$$$37$$$43$$$O	Xa$$$44$$$46$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	the$$$13$$$16$$$O	formula$$$17$$$24$$$O	A$$$25$$$26$$$O	-$$$27$$$28$$$O	Q$$$29$$$30$$$O	-$$$31$$$32$$$O	D$$$33$$$34$$$O	-$$$35$$$36$$$O	E$$$37$$$38$$$O	-$$$39$$$40$$$O	G$$$41$$$42$$$O	-$$$43$$$44$$$O	J$$$45$$$46$$$O	-$$$47$$$48$$$O	X$$$49$$$50$$$O	in$$$51$$$53$$$O	which$$$54$$$59$$$O	D$$$60$$$61$$$O	is$$$62$$$64$$$O	a$$$65$$$66$$$O	direct$$$67$$$73$$$O	link,$$$74$$$79$$$O	a$$$80$$$81$$$O	substituted$$$82$$$93$$$O	or$$$94$$$96$$$O	unsubstituted$$$97$$$110$$$O	phenyl$$$111$$$117$$$I	or$$$118$$$120$$$O	naphthyl$$$121$$$129$$$I	group$$$130$$$135$$$O	or$$$136$$$138$$$O	a$$$139$$$140$$$O	heterocyclic$$$141$$$153$$$I	ring$$$154$$$158$$$O	system;$$$159$$$166$$$O	X$$$167$$$168$$$O	is$$$169$$$171$$$O	a$$$172$$$173$$$O	substituted$$$174$$$185$$$O	or$$$186$$$188$$$O	unsubstituted$$$189$$$202$$$O	phenyl$$$203$$$209$$$I	or$$$210$$$212$$$O	naphthyl$$$213$$$221$$$I	group$$$222$$$227$$$O	or$$$228$$$230$$$O	a$$$231$$$232$$$O	heterocyclic$$$233$$$245$$$I	system;$$$246$$$253$$$O	and$$$254$$$257$$$O	the$$$258$$$261$$$O	other$$$262$$$267$$$O	variables$$$268$$$277$$$O	are$$$278$$$281$$$O	as$$$282$$$284$$$O	defined$$$285$$$292$$$O	in$$$293$$$295$$$O	the$$$296$$$299$$$O	claims,$$$300$$$307$$$O	their$$$308$$$313$$$O	salts$$$314$$$319$$$O	and$$$320$$$323$$$O	compositions$$$324$$$336$$$O	related$$$337$$$344$$$O	thereto$$$345$$$352$$$O	having$$$353$$$359$$$O	activity$$$360$$$368$$$O	against$$$369$$$376$$$O	mammalian$$$377$$$386$$$O	factor$$$387$$$393$$$O	Xa$$$394$$$396$$$O	are$$$397$$$400$$$O	disclosed.$$$401$$$411$$$O	The$$$412$$$415$$$O	compounds$$$416$$$425$$$O	are$$$426$$$429$$$O	useful$$$430$$$436$$$O	in$$$437$$$439$$$O	vitro$$$440$$$445$$$O	or$$$446$$$448$$$O	in$$$449$$$451$$$O	vivo$$$452$$$456$$$O	for$$$457$$$460$$$O	preventing$$$461$$$471$$$O	or$$$472$$$474$$$O	treating$$$475$$$483$$$O	coagulation$$$484$$$495$$$O	disorders.$$$496$$$506$$$O
EP0890105B1
Methods$$$0$$$7$$$O	related$$$8$$$15$$$O	to$$$16$$$18$$$O	Alzheimer's$$$19$$$30$$$O	disease$$$31$$$38$$$O	for$$$39$$$42$$$O	diagnosis,$$$43$$$53$$$O	manufacture$$$54$$$65$$$O	of$$$66$$$68$$$O	medicaments$$$69$$$80$$$O	and$$$81$$$84$$$O	screening$$$85$$$94$$$O	of$$$95$$$97$$$O	substances$$$98$$$108$$$O	and$$$109$$$112$$$O	beta-amyloid$$$113$$$125$$$O	related$$$126$$$133$$$O	peptides$$$134$$$142$$$O
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	evaluating$$$12$$$22$$$O	the$$$23$$$26$$$O	risk$$$27$$$31$$$O	of$$$32$$$34$$$O	an$$$35$$$37$$$O	individual$$$38$$$48$$$O	to$$$49$$$51$$$O	develop$$$52$$$59$$$O	Alzheimer's$$$60$$$71$$$O	disease$$$72$$$79$$$O	using$$$80$$$85$$$O	cultured$$$86$$$94$$$O	neural$$$95$$$101$$$O	crest-derived$$$102$$$115$$$O	melanocytes$$$116$$$127$$$O	are$$$128$$$131$$$O	described.$$$132$$$142$$$O	Also$$$143$$$147$$$O	described$$$148$$$157$$$O	are$$$158$$$161$$$O	methods$$$162$$$169$$$O	of$$$170$$$172$$$O	therapy$$$173$$$180$$$O	for$$$181$$$184$$$O	Alzheimer's$$$185$$$196$$$O	disease$$$197$$$204$$$O	using$$$205$$$210$$$O	peptides$$$211$$$219$$$O	that$$$220$$$224$$$O	bind$$$225$$$229$$$O	to$$$230$$$232$$$O	the$$$233$$$236$$$O	neurotrophin$$$237$$$249$$$O	receptor$$$250$$$258$$$O	(p75<NTR>)$$$259$$$269$$$O	and$$$270$$$273$$$O	competitively$$$274$$$287$$$O	inhibit$$$288$$$295$$$O	the$$$296$$$299$$$O	binding$$$300$$$307$$$O	of$$$308$$$310$$$O	beta$$$312$$$316$$$O	-amyloid$$$317$$$325$$$O	to$$$326$$$328$$$O	the$$$329$$$332$$$O	p75<NTR>.$$$333$$$342$$$O
US6855732
Containing$$$0$$$10$$$O	one$$$11$$$14$$$O	or$$$15$$$17$$$O	more$$$18$$$22$$$O	optionally$$$23$$$33$$$O	hydrogenated$$$34$$$46$$$O	substituted$$$47$$$58$$$O	styryl$$$59$$$65$$$I	groups;$$$66$$$73$$$O	especially$$$74$$$84$$$O	3-(3,5-dimethoxyphenyl)-2-(p-(p-(2,2-bis(methoxycarbonyl)-viny$$$85$$$147$$$I	l)phenoxy)phenyl)acrylic$$$148$$$172$$$I	acid$$$173$$$177$$$I
Compounds$$$0$$$9$$$O	are$$$10$$$13$$$O	provided$$$14$$$22$$$O	that$$$23$$$27$$$O	lower$$$28$$$33$$$O	blood$$$34$$$39$$$O	glucose$$$40$$$47$$$I	concentrations,$$$48$$$63$$$O	lower$$$64$$$69$$$O	serum$$$70$$$75$$$O	triglyceride$$$76$$$88$$$I	concentrations,$$$89$$$104$$$O	lower$$$105$$$110$$$O	systolic$$$111$$$119$$$O	blood$$$120$$$125$$$O	pressure,$$$126$$$135$$$O	and$$$136$$$139$$$O	increase$$$140$$$148$$$O	glucose$$$149$$$156$$$I	uptake$$$157$$$163$$$O	by$$$164$$$166$$$O	adipose$$$167$$$174$$$O	tissue,$$$175$$$182$$$O	but$$$183$$$186$$$O	do$$$187$$$189$$$O	not$$$190$$$193$$$O	affect$$$194$$$200$$$O	the$$$201$$$204$$$O	expression$$$205$$$215$$$O	of$$$216$$$218$$$O	PPAR-Î³$$$219$$$226$$$O	by$$$227$$$229$$$O	adipose$$$230$$$237$$$O	tissue.$$$238$$$245$$$O
US20110129422
Viscous$$$0$$$7$$$O	Terpolymers$$$8$$$19$$$O	as$$$20$$$22$$$O	Drug$$$23$$$27$$$O	Delivery$$$28$$$36$$$O	Platform$$$37$$$45$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	terpolymer$$$14$$$24$$$O	compositions$$$25$$$37$$$O	of$$$38$$$40$$$O	lactide,$$$41$$$49$$$I	glycolide,$$$50$$$60$$$I	and$$$61$$$64$$$O	caprolactone$$$65$$$77$$$I	and$$$78$$$81$$$O	methods$$$82$$$89$$$O	of$$$90$$$92$$$O	making$$$93$$$99$$$O	such$$$100$$$104$$$O	polymers$$$105$$$113$$$O	with$$$114$$$118$$$O	an$$$119$$$121$$$O	initiator.$$$122$$$132$$$O	Methods$$$133$$$140$$$O	of$$$141$$$143$$$O	using$$$144$$$149$$$O	the$$$150$$$153$$$O	terpolymers$$$154$$$165$$$O	as$$$166$$$168$$$O	a$$$169$$$170$$$O	drug$$$171$$$175$$$O	delivery$$$176$$$184$$$O	platform$$$185$$$193$$$O	are$$$194$$$197$$$O	also$$$198$$$202$$$O	disclosed.$$$203$$$213$$$O
EP1144609B1
Chimeric$$$0$$$8$$$O	antisense$$$9$$$18$$$O	oligonucleotides$$$19$$$35$$$I	and$$$36$$$39$$$O	cell$$$40$$$44$$$O	transfecting$$$45$$$57$$$O	formulations$$$58$$$70$$$O	thereof$$$71$$$78$$$O
Chimeric$$$0$$$8$$$O	oligonucleotide$$$9$$$24$$$I	of$$$25$$$27$$$O	the$$$28$$$31$$$O	formula$$$32$$$39$$$O	5'-W-X1-Y-X2-Z-3',$$$40$$$58$$$O	where$$$59$$$64$$$O	W$$$65$$$66$$$O	represents$$$67$$$77$$$O	a$$$78$$$79$$$O	5'-O-alkyl$$$80$$$90$$$I	nucleotide,$$$91$$$102$$$I	each$$$103$$$107$$$O	of$$$108$$$110$$$O	X?1$$$111$$$114$$$O	and$$$115$$$118$$$O	X2Â¿$$$119$$$123$$$O	represented$$$124$$$135$$$O	a$$$136$$$137$$$O	block$$$138$$$143$$$O	of$$$144$$$146$$$O	seven$$$147$$$152$$$O	to$$$153$$$155$$$O	twelve$$$156$$$162$$$I	phosphodiester-linked$$$163$$$184$$$I	2'-O-alkyl$$$185$$$195$$$I	ribonucleotides,$$$196$$$212$$$I	Y$$$213$$$214$$$O	represents$$$215$$$225$$$O	a$$$226$$$227$$$O	block$$$228$$$233$$$O	of$$$234$$$236$$$O	five$$$237$$$241$$$O	to$$$242$$$244$$$O	twelve$$$245$$$251$$$O	phosphorothioate-linked$$$252$$$275$$$O	deoxyribonucleotides,$$$276$$$297$$$O	and$$$298$$$301$$$O	Z$$$302$$$303$$$O	represents$$$304$$$314$$$O	a$$$315$$$316$$$O	blocking$$$317$$$325$$$O	group$$$326$$$331$$$O	effective$$$332$$$341$$$O	to$$$342$$$344$$$O	block$$$345$$$350$$$O	nuclease$$$351$$$359$$$O	activity$$$360$$$368$$$O	at$$$369$$$371$$$O	the$$$372$$$375$$$O	3'$$$376$$$378$$$O	end$$$379$$$382$$$O	of$$$383$$$385$$$O	the$$$386$$$389$$$O	oligonucleotide,$$$390$$$406$$$O	are$$$407$$$410$$$O	described.$$$411$$$421$$$O	These$$$422$$$427$$$O	compounds$$$428$$$437$$$O	exhibit$$$438$$$445$$$O	high$$$446$$$450$$$O	resistance$$$451$$$461$$$O	to$$$462$$$464$$$O	endo-$$$465$$$470$$$O	and$$$471$$$474$$$O	exonucleases,$$$475$$$488$$$O	high$$$489$$$493$$$O	sequence$$$494$$$502$$$O	specificity,$$$503$$$515$$$O	and$$$516$$$519$$$O	the$$$520$$$523$$$O	ability$$$524$$$531$$$O	to$$$532$$$534$$$O	activate$$$535$$$543$$$O	RNAse$$$544$$$549$$$O	H,$$$550$$$552$$$O	as$$$553$$$555$$$O	evidenced$$$556$$$565$$$O	by$$$566$$$568$$$O	efficient$$$569$$$578$$$O	and$$$579$$$582$$$O	long-lasting$$$583$$$595$$$O	suppression$$$596$$$607$$$O	of$$$608$$$610$$$O	target$$$611$$$617$$$O	mRNA.$$$618$$$623$$$O	The$$$624$$$627$$$O	oligonucleotides$$$628$$$644$$$O	are$$$645$$$648$$$O	preferably$$$649$$$659$$$O	transfected$$$660$$$671$$$O	into$$$672$$$676$$$O	cells$$$677$$$682$$$O	in$$$683$$$685$$$O	formulations$$$686$$$698$$$O	containing$$$699$$$709$$$O	a$$$710$$$711$$$O	lipid-peptoid$$$712$$$725$$$O	conjugate$$$726$$$735$$$O	carrier$$$736$$$743$$$O	molecule$$$744$$$752$$$O	of$$$753$$$755$$$O	the$$$756$$$759$$$O	formula$$$760$$$767$$$O	L-linker-[N(CHÂ¿2?CH2NH2)CH2(C=O)-N(CH2CH2R)CH2(C=O)-N(CH2CH2R)CH2(C=O)]3-NH2,$$$768$$$846$$$I	where$$$847$$$852$$$O	L$$$853$$$854$$$O	is$$$855$$$857$$$O	a$$$858$$$859$$$O	lipid$$$860$$$865$$$O	moiety,$$$866$$$873$$$O	including$$$874$$$883$$$O	a$$$884$$$885$$$I	steroid,$$$886$$$894$$$I	and$$$895$$$898$$$O	each$$$899$$$903$$$O	group$$$904$$$909$$$O	R$$$910$$$911$$$O	is$$$912$$$914$$$O	independently$$$915$$$928$$$O	selected$$$929$$$937$$$O	from$$$938$$$942$$$I	alkyl,$$$943$$$949$$$I	aminoalkyl,$$$950$$$961$$$I	and$$$962$$$965$$$I	aralkyl.$$$966$$$974$$$I
WO2008141239A1
Imidazol$$$0$$$8$$$I	[1,2-a]$$$9$$$16$$$I	pyridines$$$17$$$26$$$I	and$$$27$$$30$$$O	related$$$31$$$38$$$O	compounds$$$39$$$48$$$O	with$$$49$$$53$$$O	activity$$$54$$$62$$$O	at$$$63$$$65$$$O	cannabinoid$$$66$$$77$$$I	cb2$$$78$$$81$$$O	receptors$$$82$$$91$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	compounds$$$14$$$23$$$O	of$$$24$$$26$$$O	Formula$$$27$$$34$$$O	(I)$$$35$$$38$$$O	or$$$39$$$41$$$O	Formula$$$42$$$49$$$O	(II)$$$50$$$54$$$O	or$$$55$$$57$$$O	a$$$58$$$59$$$O	pharmaceutically$$$60$$$76$$$O	acceptable$$$77$$$87$$$O	salt,$$$88$$$93$$$O	ester,$$$94$$$100$$$I	amide,$$$101$$$107$$$I	or$$$108$$$110$$$O	prodrug$$$111$$$118$$$O	thereof;$$$119$$$127$$$O	and$$$128$$$131$$$O	methods$$$132$$$139$$$O	of$$$140$$$142$$$O	modulating$$$143$$$153$$$O	the$$$154$$$157$$$O	activity$$$158$$$166$$$O	of$$$167$$$169$$$O	a$$$170$$$171$$$O	cannabinoid$$$172$$$183$$$I	CB2$$$184$$$187$$$O	receptor$$$188$$$196$$$O	comprising$$$197$$$207$$$O	contacting$$$208$$$218$$$O	a$$$219$$$220$$$O	compound$$$221$$$229$$$O	of$$$230$$$232$$$O	Formula$$$233$$$240$$$O	(I)$$$241$$$244$$$O	or$$$245$$$247$$$O	Formula$$$248$$$255$$$O	(II)$$$256$$$260$$$O	with$$$261$$$265$$$O	the$$$266$$$269$$$O	cannabinoid$$$270$$$281$$$I	CB2$$$282$$$285$$$O	receptor.$$$286$$$295$$$O	Said$$$296$$$300$$$O	compounds$$$301$$$310$$$O	are$$$311$$$314$$$O	useful$$$315$$$321$$$O	in$$$322$$$324$$$O	the$$$325$$$328$$$O	treatment$$$329$$$338$$$O	of$$$339$$$341$$$O	various$$$342$$$349$$$O	condition$$$350$$$359$$$O	and$$$360$$$363$$$O	disorders$$$364$$$373$$$O	such$$$374$$$378$$$O	as$$$379$$$381$$$O	pain,$$$382$$$387$$$O	and$$$388$$$391$$$O	neurodegenerative$$$392$$$409$$$O	disorders.$$$410$$$420$$$O
WO2014025890A1
Drug$$$0$$$4$$$O	delivery$$$5$$$13$$$O	vehicle$$$14$$$21$$$O	comprising$$$22$$$32$$$O	conjugates$$$33$$$43$$$O	between$$$44$$$51$$$O	targeting$$$52$$$61$$$O	polyamino$$$62$$$71$$$I	acids$$$72$$$77$$$I	and$$$78$$$81$$$O	fatty$$$82$$$87$$$I	acids$$$88$$$93$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provide$$$14$$$21$$$O	herein$$$22$$$28$$$O	provides$$$29$$$37$$$O	for$$$38$$$41$$$O	a$$$42$$$43$$$O	targeted$$$44$$$52$$$O	drug$$$53$$$57$$$O	delivery$$$58$$$66$$$O	vehicle$$$67$$$74$$$O	compositions,$$$75$$$88$$$O	methods$$$89$$$96$$$O	of$$$97$$$99$$$O	manufacture,$$$100$$$112$$$O	and$$$113$$$116$$$O	methods$$$117$$$124$$$O	of$$$125$$$127$$$O	treatment$$$128$$$137$$$O	for$$$138$$$141$$$O	therapeutic$$$142$$$153$$$O	applications.$$$154$$$167$$$O
US20080279764
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	composition$$$11$$$22$$$O	for$$$23$$$26$$$O	treating$$$27$$$35$$$O	cancer$$$36$$$42$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	cancer,$$$22$$$29$$$O	preventing$$$30$$$40$$$O	cancer$$$41$$$47$$$O	or$$$48$$$50$$$O	delaying$$$51$$$59$$$O	the$$$60$$$63$$$O	progression$$$64$$$75$$$O	of$$$76$$$78$$$O	a$$$79$$$80$$$O	cancer$$$81$$$87$$$O	in$$$88$$$90$$$O	an$$$91$$$93$$$O	animal$$$94$$$100$$$O	or$$$101$$$103$$$O	a$$$104$$$105$$$O	human$$$106$$$111$$$O	comprising$$$112$$$122$$$O	the$$$123$$$126$$$O	step$$$127$$$131$$$O	of:$$$132$$$135$$$O	administering$$$136$$$149$$$O	to$$$150$$$152$$$O	the$$$153$$$156$$$O	animal$$$157$$$163$$$O	or$$$164$$$166$$$O	the$$$167$$$170$$$O	human$$$171$$$176$$$O	having$$$177$$$183$$$O	a$$$184$$$185$$$O	cancer$$$186$$$192$$$O	a$$$193$$$194$$$O	composition$$$195$$$206$$$O	in$$$207$$$209$$$O	an$$$210$$$212$$$O	amount$$$213$$$219$$$O	effective$$$220$$$229$$$O	to$$$230$$$232$$$O	treat$$$233$$$238$$$O	cancer,$$$239$$$246$$$O	prevent$$$247$$$254$$$O	cancer$$$255$$$261$$$O	or$$$262$$$264$$$O	delay$$$265$$$270$$$O	the$$$271$$$274$$$O	progression$$$275$$$286$$$O	of$$$287$$$289$$$O	cancer$$$290$$$296$$$O	in$$$297$$$299$$$O	the$$$300$$$303$$$O	animal$$$304$$$310$$$O	or$$$311$$$313$$$O	the$$$314$$$317$$$O	human.$$$318$$$324$$$O	The$$$325$$$328$$$O	composition$$$329$$$340$$$O	comprises$$$341$$$350$$$O	a$$$351$$$352$$$O	pharmaceutically$$$353$$$369$$$O	acceptable$$$370$$$380$$$O	excipient,$$$381$$$391$$$O	and$$$392$$$395$$$O	ascorbate$$$396$$$405$$$O	which$$$406$$$411$$$O	is$$$412$$$414$$$O	joined$$$415$$$421$$$O	to$$$422$$$424$$$O	a$$$425$$$426$$$O	carrier$$$427$$$434$$$O	structure$$$435$$$444$$$O	containing$$$445$$$455$$$O	an$$$456$$$458$$$O	anti-cancer$$$459$$$470$$$O	active$$$471$$$477$$$O	agent,$$$478$$$484$$$O	said$$$485$$$489$$$O	carrier$$$490$$$497$$$O	structure$$$498$$$507$$$O	being$$$508$$$513$$$O	capable$$$514$$$521$$$O	of$$$522$$$524$$$O	releasing$$$525$$$534$$$O	the$$$535$$$538$$$O	anti-cancer$$$539$$$550$$$O	agent$$$551$$$556$$$O	in$$$557$$$559$$$O	the$$$560$$$563$$$O	presence$$$564$$$572$$$O	of$$$573$$$575$$$O	a$$$576$$$577$$$O	reactive$$$578$$$586$$$O	oxygen$$$587$$$593$$$I	species.$$$594$$$602$$$O
WO2008120766A1
Analgesic$$$0$$$9$$$O	composition$$$10$$$21$$$O
[PROBLEMS]$$$0$$$10$$$O	To$$$11$$$13$$$O	provide$$$14$$$21$$$O	an$$$22$$$24$$$O	analgesic$$$25$$$34$$$O	composition$$$35$$$46$$$O	which$$$47$$$52$$$O	is$$$53$$$55$$$O	more$$$56$$$60$$$O	safe$$$61$$$65$$$O	compared$$$66$$$74$$$O	to$$$75$$$77$$$O	a$$$78$$$79$$$O	conventional$$$80$$$92$$$O	analgesic$$$93$$$102$$$O	agent$$$103$$$108$$$O	and$$$109$$$112$$$O	exhibits$$$113$$$121$$$O	an$$$122$$$124$$$O	analgesic$$$125$$$134$$$O	activity$$$135$$$143$$$O	at$$$144$$$146$$$O	the$$$147$$$150$$$O	same$$$151$$$155$$$O	or$$$156$$$158$$$O	higher$$$159$$$165$$$O	level$$$166$$$171$$$O	compared$$$172$$$180$$$O	to$$$181$$$183$$$O	a$$$184$$$185$$$O	conventional$$$186$$$198$$$O	analgesic$$$199$$$208$$$O	agent.$$$209$$$215$$$O	[MEANS$$$216$$$222$$$O	FOR$$$223$$$226$$$O	SOLVING$$$227$$$234$$$O	PROBLEMS]$$$235$$$244$$$O	Disclosed$$$245$$$254$$$O	is$$$255$$$257$$$O	an$$$258$$$260$$$O	analgesic$$$261$$$270$$$O	composition$$$271$$$282$$$O	comprising$$$283$$$293$$$O	vitamin$$$294$$$301$$$I	B12$$$302$$$305$$$I	as$$$306$$$308$$$O	an$$$309$$$311$$$O	active$$$312$$$318$$$O	ingredient.$$$319$$$330$$$O	Preferably,$$$331$$$342$$$O	the$$$343$$$346$$$O	analgesic$$$347$$$356$$$O	composition$$$357$$$368$$$O	additionally$$$369$$$381$$$O	contains$$$382$$$390$$$O	folic$$$391$$$396$$$I	acid.$$$397$$$402$$$I
CA2585967A1
Substituted$$$0$$$11$$$O	indolizines$$$12$$$23$$$I	and$$$24$$$27$$$O	derivatives$$$28$$$39$$$O	as$$$40$$$42$$$O	cns$$$43$$$46$$$O	agents$$$47$$$53$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I)$$$21$$$24$$$O	of$$$25$$$27$$$O	pharmaceutically$$$28$$$44$$$O	acceptable$$$45$$$55$$$O	salts$$$56$$$61$$$O	thereof$$$62$$$69$$$O	are$$$70$$$73$$$O	provided:$$$74$$$83$$$O	formula$$$84$$$91$$$O	(I),$$$92$$$96$$$O	which$$$97$$$102$$$O	are$$$103$$$106$$$O	agonists$$$107$$$115$$$O	or$$$116$$$118$$$O	partial$$$119$$$126$$$O	agonists$$$127$$$135$$$O	of$$$136$$$138$$$O	the$$$139$$$142$$$O	2C$$$143$$$145$$$O	subtype$$$146$$$153$$$O	of$$$154$$$156$$$O	brain$$$157$$$162$$$O	serotonin$$$163$$$172$$$I	receptors.$$$173$$$183$$$O	The$$$184$$$187$$$O	compounds,$$$188$$$198$$$O	and$$$199$$$202$$$O	compositions$$$203$$$215$$$O	containing$$$216$$$226$$$O	the$$$227$$$230$$$O	compounds,$$$231$$$241$$$O	can$$$242$$$245$$$O	be$$$246$$$248$$$O	used$$$249$$$253$$$O	to$$$254$$$256$$$O	treat$$$257$$$262$$$O	a$$$263$$$264$$$O	variety$$$265$$$272$$$O	of$$$273$$$275$$$O	central$$$276$$$283$$$O	nervous$$$284$$$291$$$O	system$$$292$$$298$$$O	disorders$$$299$$$308$$$O	such$$$309$$$313$$$O	as$$$314$$$316$$$O	schizophrenia.$$$317$$$331$$$O
CN103463009A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	racemosins$$$15$$$25$$$I	A$$$26$$$27$$$I	in$$$28$$$30$$$O	preparation$$$31$$$42$$$O	of$$$43$$$45$$$O	medicine$$$46$$$54$$$O	treating$$$55$$$63$$$O	acute$$$64$$$69$$$O	renal$$$70$$$75$$$O	failure$$$76$$$83$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	new$$$25$$$28$$$O	medical$$$29$$$36$$$O	application$$$37$$$48$$$O	of$$$49$$$51$$$O	racemosins$$$52$$$62$$$I	A,$$$63$$$65$$$I	in$$$66$$$68$$$O	particular$$$69$$$79$$$O	to$$$80$$$82$$$O	the$$$83$$$86$$$O	application$$$87$$$98$$$O	of$$$99$$$101$$$O	the$$$102$$$105$$$O	racemosins$$$106$$$116$$$I	A$$$117$$$118$$$I	in$$$119$$$121$$$O	preparation$$$122$$$133$$$O	of$$$134$$$136$$$O	the$$$137$$$140$$$O	medicine$$$141$$$149$$$O	treating$$$150$$$158$$$O	the$$$159$$$162$$$O	acute$$$163$$$168$$$O	renal$$$169$$$174$$$O	failure.$$$175$$$183$$$O	The$$$184$$$187$$$O	application$$$188$$$199$$$O	of$$$200$$$202$$$O	the$$$203$$$206$$$O	racemosins$$$207$$$217$$$I	A$$$218$$$219$$$I	in$$$220$$$222$$$O	preparation$$$223$$$234$$$O	of$$$235$$$237$$$O	the$$$238$$$241$$$O	medicine$$$242$$$250$$$O	treating$$$251$$$259$$$O	the$$$260$$$263$$$O	acute$$$264$$$269$$$O	renal$$$270$$$275$$$O	failure$$$276$$$283$$$O	is$$$284$$$286$$$O	disclosed$$$287$$$296$$$O	for$$$297$$$300$$$O	the$$$301$$$304$$$O	first$$$305$$$310$$$O	time.$$$311$$$316$$$O	The$$$317$$$320$$$O	matrix$$$321$$$327$$$O	type$$$328$$$332$$$O	of$$$333$$$335$$$O	the$$$336$$$339$$$O	racemosins$$$340$$$350$$$I	A$$$351$$$352$$$I	belongs$$$353$$$360$$$O	to$$$361$$$363$$$O	a$$$364$$$365$$$O	brand$$$366$$$371$$$O	new$$$372$$$375$$$O	matrix$$$376$$$382$$$O	type.$$$383$$$388$$$O	The$$$389$$$392$$$O	racemosins$$$393$$$403$$$I	A$$$404$$$405$$$I	has$$$406$$$409$$$O	the$$$410$$$413$$$O	advantages$$$414$$$424$$$O	of$$$425$$$427$$$O	being$$$428$$$433$$$O	high$$$434$$$438$$$O	in$$$439$$$441$$$O	inhibitory$$$442$$$452$$$O	activity$$$453$$$461$$$O	for$$$462$$$465$$$O	the$$$466$$$469$$$O	acute$$$470$$$475$$$O	renal$$$476$$$481$$$O	failure$$$482$$$489$$$O	and$$$490$$$493$$$O	prominent$$$494$$$503$$$O	in$$$504$$$506$$$O	substantive$$$507$$$518$$$O	features,$$$519$$$528$$$O	and$$$529$$$532$$$O	makes$$$533$$$538$$$O	remarkable$$$539$$$549$$$O	progress$$$550$$$558$$$O	in$$$559$$$561$$$O	preventing$$$562$$$572$$$O	the$$$573$$$576$$$O	acute$$$577$$$582$$$O	renal$$$583$$$588$$$O	failure.$$$589$$$597$$$O
US20140199394
Controlled$$$0$$$10$$$O	release$$$11$$$18$$$O	hydrocodone$$$19$$$30$$$I
A$$$0$$$1$$$O	solid$$$2$$$7$$$O	oral$$$8$$$12$$$O	controlled-release$$$13$$$31$$$O	dosage$$$32$$$38$$$O	form$$$39$$$43$$$O	of$$$44$$$46$$$O	hydrocodone$$$47$$$58$$$I	is$$$59$$$61$$$O	disclosed,$$$62$$$72$$$O	the$$$73$$$76$$$O	dosage$$$77$$$83$$$O	form$$$84$$$88$$$O	comprising$$$89$$$99$$$O	an$$$100$$$102$$$O	analgesically$$$103$$$116$$$O	effective$$$117$$$126$$$O	amount$$$127$$$133$$$O	of$$$134$$$136$$$O	hydrocodone$$$137$$$148$$$I	or$$$149$$$151$$$O	a$$$152$$$153$$$O	pharmaceutically$$$154$$$170$$$O	acceptable$$$171$$$181$$$O	salt$$$182$$$186$$$O	thereof,$$$187$$$195$$$O	and$$$196$$$199$$$O	controlled$$$200$$$210$$$O	release$$$211$$$218$$$O	material.$$$219$$$228$$$O
WO2010060742A1
Combination$$$0$$$11$$$O	of$$$12$$$14$$$O	bifeprunox$$$15$$$25$$$I	and$$$26$$$29$$$O	an$$$30$$$32$$$O	antipsychotic$$$33$$$46$$$O	drug$$$47$$$51$$$O	with$$$52$$$56$$$O	d2/5-ht2a$$$57$$$66$$$O	receptor$$$67$$$75$$$O	antagonistic$$$76$$$88$$$O	activity$$$89$$$97$$$O	for$$$98$$$101$$$O	treating$$$102$$$110$$$O	cns$$$111$$$114$$$O	disorders$$$115$$$124$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	(a$$$33$$$35$$$O	pharmaceutical$$$36$$$50$$$O	composition$$$51$$$62$$$O	comprising)$$$63$$$74$$$O	a$$$75$$$76$$$O	combination$$$77$$$88$$$O	of$$$89$$$91$$$O	bifeprunox$$$92$$$102$$$I	(a$$$103$$$105$$$O	D2/5-HT1A$$$106$$$115$$$O	receptor$$$116$$$124$$$O	ligand)$$$125$$$132$$$O	and$$$133$$$136$$$O	at$$$137$$$139$$$O	least$$$140$$$145$$$O	one$$$146$$$149$$$O	D2/5-HT2A$$$150$$$159$$$O	receptor$$$160$$$168$$$O	antagonistic$$$169$$$181$$$O	ligand$$$182$$$188$$$O	and$$$189$$$192$$$O	pharmaceutically$$$193$$$209$$$O	acceptable$$$210$$$220$$$O	auxiliaries$$$221$$$232$$$O	for$$$233$$$236$$$O	use$$$237$$$240$$$O	in$$$241$$$243$$$O	the$$$244$$$247$$$O	treatment$$$248$$$257$$$O	of$$$258$$$260$$$O	various$$$261$$$268$$$O	CNS$$$269$$$272$$$O	disorders,$$$273$$$283$$$O	particularly$$$284$$$296$$$O	psychotic$$$297$$$306$$$O	disorders$$$307$$$316$$$O	like$$$317$$$321$$$O	schizophrenia$$$322$$$335$$$O	and$$$336$$$339$$$O	related$$$340$$$347$$$O	psychiatric$$$348$$$359$$$O	conditions,$$$360$$$371$$$O	including$$$372$$$381$$$O	bipolar$$$382$$$389$$$O	disorder,$$$390$$$399$$$O	bipolar$$$400$$$407$$$O	depression,$$$408$$$419$$$O	mania$$$420$$$425$$$O	and$$$426$$$429$$$O	atypical$$$430$$$438$$$O	depression.$$$439$$$450$$$O
WO2008043180A1
Immunostimulatory$$$0$$$17$$$O	composition$$$18$$$29$$$O	comprising$$$30$$$40$$$O	recombinant$$$41$$$52$$$O	bcg$$$53$$$56$$$O	mycobacterium$$$57$$$70$$$O	expressing$$$71$$$81$$$O	mammalian$$$82$$$91$$$O	cysteine$$$92$$$100$$$I	protease$$$101$$$109$$$O
A$$$0$$$1$$$O	nucleic$$$2$$$9$$$O	acid$$$10$$$14$$$O	molecule$$$15$$$23$$$O	comprising$$$24$$$34$$$O	a$$$35$$$36$$$O	nucleotide$$$37$$$47$$$I	sequence$$$48$$$56$$$O	configured$$$57$$$67$$$O	for$$$68$$$71$$$O	controllable$$$72$$$84$$$O	expression$$$85$$$95$$$O	of$$$96$$$98$$$O	a$$$99$$$100$$$O	mammalian$$$101$$$110$$$O	cysteine$$$111$$$119$$$I	protease$$$120$$$128$$$O	suitable$$$129$$$137$$$O	for$$$138$$$141$$$O	enhancing$$$142$$$151$$$O	an$$$152$$$154$$$O	immune$$$155$$$161$$$O	response$$$162$$$170$$$O	directed$$$171$$$179$$$O	against$$$180$$$187$$$O	Mycobacterium$$$188$$$201$$$I	A$$$202$$$203$$$I	recombinant$$$204$$$215$$$O	Mycobacterium$$$216$$$229$$$O	Bacille$$$230$$$237$$$O	Calmette-Guerm$$$238$$$252$$$O	(BCG)$$$253$$$258$$$O	provided$$$259$$$267$$$O	with$$$268$$$272$$$O	the$$$273$$$276$$$O	nucleic$$$277$$$284$$$O	acid$$$285$$$289$$$O	molecule$$$290$$$298$$$O	and$$$299$$$302$$$O	pharmaceutical$$$303$$$317$$$O	compositions$$$318$$$330$$$O	comprising$$$331$$$341$$$O	the$$$342$$$345$$$O	recombinant$$$346$$$357$$$O	BCG$$$358$$$361$$$O	are$$$362$$$365$$$O	suitable$$$366$$$374$$$O	for$$$375$$$378$$$O	use$$$379$$$382$$$O	in$$$383$$$385$$$O	immunotherapy$$$386$$$399$$$O	and$$$400$$$403$$$O	in$$$404$$$406$$$O	vaccinations$$$407$$$419$$$O	against$$$420$$$427$$$O	tuberculosis$$$428$$$440$$$O
CA2347387C
Vitamin$$$0$$$7$$$I	k2$$$8$$$10$$$I	containing$$$11$$$21$$$O	food$$$22$$$26$$$O	product$$$27$$$34$$$O
A$$$0$$$1$$$O	food$$$2$$$6$$$O	product$$$7$$$14$$$O	comprising$$$15$$$25$$$O	menaquinone$$$26$$$37$$$I	at$$$38$$$40$$$O	a$$$41$$$42$$$O	level$$$43$$$48$$$O	of$$$49$$$51$$$O	50$$$52$$$54$$$O	to$$$55$$$57$$$O	5,000$$$58$$$63$$$O	Âµg$$$64$$$67$$$O	per$$$68$$$71$$$O	100$$$72$$$75$$$O	g$$$76$$$77$$$O	of$$$78$$$80$$$O	product.$$$81$$$89$$$O
WO2014165057A1
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	treating$$$29$$$37$$$O	infectious$$$38$$$48$$$O	disease$$$49$$$56$$$O
Provided$$$0$$$8$$$O	are$$$9$$$12$$$O	cyanogenic$$$13$$$23$$$O	compositions$$$24$$$36$$$O	for$$$37$$$40$$$O	treating$$$41$$$49$$$O	infectious$$$50$$$60$$$O	diseases.$$$61$$$70$$$O
WO2012112230A3
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	multi-step$$$17$$$27$$$O	methods$$$28$$$35$$$O	of$$$36$$$38$$$O	using$$$39$$$44$$$O	the$$$45$$$48$$$O	same$$$49$$$53$$$O	for$$$54$$$57$$$O	the$$$58$$$61$$$O	treatment$$$62$$$71$$$O	of$$$72$$$74$$$O	jellyfish$$$75$$$84$$$O	stings$$$85$$$91$$$O
Embodiments$$$0$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	invention$$$19$$$28$$$O	relate$$$29$$$35$$$O	to$$$36$$$38$$$O	a$$$39$$$40$$$O	composition$$$41$$$52$$$O	containing$$$53$$$63$$$O	zinc$$$64$$$68$$$I	and$$$69$$$72$$$O	copper$$$73$$$79$$$I	and$$$80$$$83$$$O	methods$$$84$$$91$$$O	of$$$92$$$94$$$O	using$$$95$$$100$$$O	the$$$101$$$104$$$O	same$$$105$$$109$$$O	in$$$110$$$112$$$O	treatment$$$113$$$122$$$O	of$$$123$$$125$$$O	exposure$$$126$$$134$$$O	to$$$135$$$137$$$O	a$$$138$$$139$$$O	pore-forming$$$140$$$152$$$O	toxin$$$153$$$158$$$O	(PFT)$$$159$$$164$$$O	in$$$165$$$167$$$O	a$$$168$$$169$$$O	subject$$$170$$$177$$$O	or$$$178$$$180$$$O	membrane$$$181$$$189$$$O	perturbant$$$190$$$200$$$O	(MP).$$$201$$$206$$$O
CA2158610C
17-deoxycorticosteroid-21-/o/-carboxylic$$$0$$$40$$$I	esters,$$$41$$$48$$$I	processes$$$49$$$58$$$O	for$$$59$$$62$$$O	their$$$63$$$68$$$O	preparation$$$69$$$80$$$O	and$$$81$$$84$$$O	pharmaceuticals$$$85$$$100$$$O	containing$$$101$$$111$$$O	these$$$112$$$117$$$O	compounds$$$118$$$127$$$O
17-Deoxycorticoid-21-carboxylic$$$0$$$31$$$I	esters$$$32$$$38$$$I	of$$$39$$$41$$$O	the$$$42$$$45$$$O	formula$$$46$$$53$$$O	I$$$54$$$55$$$O	(see$$$56$$$60$$$O	Formula$$$61$$$68$$$O	I)$$$69$$$71$$$O	are$$$72$$$75$$$O	described,$$$76$$$86$$$O	in$$$87$$$89$$$O	which$$$90$$$95$$$O	A$$$96$$$97$$$O	is$$$98$$$100$$$O	CHOH$$$101$$$105$$$I	and$$$106$$$109$$$O	CHCl,$$$110$$$115$$$I	CH2,$$$116$$$120$$$I	C=O$$$121$$$124$$$I	or$$$125$$$127$$$O	9(11)$$$128$$$133$$$O	double$$$134$$$140$$$O	bond;$$$141$$$146$$$O	Y$$$147$$$148$$$O	is$$$149$$$151$$$O	H,$$$152$$$154$$$I	F$$$155$$$156$$$I	or$$$157$$$159$$$O	Cl;$$$160$$$163$$$I	Z$$$164$$$165$$$O	is$$$166$$$168$$$O	H,$$$169$$$171$$$I	F$$$172$$$173$$$I	or$$$174$$$176$$$O	CH3;$$$177$$$181$$$I	R(1)$$$182$$$186$$$O	is$$$187$$$189$$$O	aryl$$$190$$$194$$$I	or$$$195$$$197$$$O	hetaryl$$$198$$$205$$$I	and$$$206$$$209$$$O	R(2)$$$210$$$214$$$O	is$$$215$$$217$$$O	H$$$218$$$219$$$I	or$$$220$$$222$$$O	methyl.$$$223$$$230$$$I	They$$$231$$$235$$$O	are$$$236$$$239$$$O	obtained$$$240$$$248$$$O	by$$$249$$$251$$$O	reacting$$$252$$$260$$$O	a$$$261$$$262$$$O	compound$$$263$$$271$$$O	of$$$272$$$274$$$O	the$$$275$$$278$$$O	formula$$$279$$$286$$$O	II,$$$287$$$290$$$O	(see$$$291$$$295$$$O	formula$$$296$$$303$$$O	II)$$$304$$$307$$$O	in$$$308$$$310$$$O	which$$$311$$$316$$$O	R(4)$$$317$$$321$$$O	is$$$322$$$324$$$O	OH,$$$325$$$328$$$I	with$$$329$$$333$$$O	an$$$334$$$336$$$O	activated$$$337$$$346$$$O	carboxylic$$$347$$$357$$$I	acid$$$358$$$362$$$I	of$$$363$$$365$$$O	the$$$366$$$369$$$O	formula$$$370$$$377$$$O	III,$$$378$$$382$$$O	R(5)-CO-[(C1-C4)-alkyl]-R(1)$$$383$$$411$$$I	III.$$$412$$$416$$$O	The$$$417$$$420$$$O	compounds$$$421$$$430$$$O	I$$$431$$$432$$$O	possess$$$433$$$440$$$O	very$$$441$$$445$$$O	strong$$$446$$$452$$$O	local$$$453$$$458$$$O	and$$$459$$$462$$$O	topical$$$463$$$470$$$O	antiinflammatory$$$471$$$487$$$O	activity$$$488$$$496$$$O	and$$$497$$$500$$$O	exhibit$$$501$$$508$$$O	a$$$509$$$510$$$O	very$$$511$$$515$$$O	good$$$516$$$520$$$O	ratio$$$521$$$526$$$O	of$$$527$$$529$$$O	local$$$530$$$535$$$O	to$$$536$$$538$$$O	systemic$$$539$$$547$$$O	antiinflammatory$$$548$$$564$$$O	effect,$$$565$$$572$$$O	which$$$573$$$578$$$O	ratio$$$579$$$584$$$O	is$$$585$$$587$$$O	often$$$588$$$593$$$O	clearly$$$594$$$601$$$O	superior$$$602$$$610$$$O	to$$$611$$$613$$$O	that$$$614$$$618$$$O	of$$$619$$$621$$$O	structurally$$$622$$$634$$$O	related$$$635$$$642$$$O	corticoid$$$643$$$652$$$I	21-esters$$$653$$$662$$$I	which$$$663$$$668$$$O	do$$$669$$$671$$$O	not$$$672$$$675$$$O	carry$$$676$$$681$$$O	any$$$682$$$685$$$O	aryl$$$686$$$690$$$I	or$$$691$$$693$$$I	hetaryl$$$694$$$701$$$I	group$$$702$$$707$$$O	in$$$708$$$710$$$O	the$$$711$$$714$$$O	21-ester$$$715$$$723$$$I	residue$$$724$$$731$$$O	or$$$732$$$734$$$O	to$$$735$$$737$$$O	that$$$738$$$742$$$O	of$$$743$$$745$$$O	analogous$$$746$$$755$$$O	17-deoxycorticoids$$$756$$$774$$$I	having$$$775$$$781$$$O	an$$$782$$$784$$$O	unesterified,$$$785$$$798$$$O	that$$$799$$$803$$$O	is$$$804$$$806$$$O	a$$$807$$$808$$$O	free,$$$809$$$814$$$O	21-hydroxyl$$$815$$$826$$$I	group.$$$827$$$833$$$O
US6953808
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	treating$$$11$$$19$$$O	gastric$$$20$$$27$$$O	disorders$$$28$$$37$$$O	using$$$38$$$43$$$O	optically$$$44$$$53$$$O	pure$$$54$$$58$$$O	(â)$$$59$$$64$$$I	pantoprazole$$$65$$$77$$$I
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	are$$$25$$$28$$$O	disclosed$$$29$$$38$$$O	utilizing$$$39$$$48$$$O	optically$$$49$$$58$$$O	pure$$$59$$$63$$$O	(â)$$$64$$$69$$$I	pantoprazole$$$70$$$82$$$I	for$$$83$$$86$$$O	the$$$87$$$90$$$O	treatment$$$91$$$100$$$O	of$$$101$$$103$$$O	ulcers$$$104$$$110$$$O	in$$$111$$$113$$$O	humans$$$114$$$120$$$O	while$$$121$$$126$$$O	substantially$$$127$$$140$$$O	reducing$$$141$$$149$$$O	the$$$150$$$153$$$O	concomitant$$$154$$$165$$$O	liability$$$166$$$175$$$O	of$$$176$$$178$$$O	adverse$$$179$$$186$$$O	effects$$$187$$$194$$$O	associated$$$195$$$205$$$O	with$$$206$$$210$$$O	the$$$211$$$214$$$O	racemic$$$215$$$222$$$O	mixture$$$223$$$230$$$O	of$$$231$$$233$$$I	pantoprazole.$$$234$$$247$$$I	The$$$248$$$251$$$O	optically$$$252$$$261$$$O	pure$$$262$$$266$$$O	(â)$$$267$$$272$$$O	isomer$$$273$$$279$$$O	is$$$280$$$282$$$O	also$$$283$$$287$$$O	useful$$$288$$$294$$$O	for$$$295$$$298$$$O	the$$$299$$$302$$$O	treatment$$$303$$$312$$$O	of$$$313$$$315$$$O	gastroesophageal$$$316$$$332$$$O	reflux.$$$333$$$340$$$I	(â)$$$341$$$346$$$I	Pantoprazole$$$347$$$359$$$I	is$$$360$$$362$$$O	an$$$363$$$365$$$O	inhibitor$$$366$$$375$$$O	of$$$376$$$378$$$O	H+$$$379$$$381$$$O	release$$$382$$$389$$$O	and$$$390$$$393$$$O	is$$$394$$$396$$$O	therefore$$$397$$$406$$$O	useful$$$407$$$413$$$O	in$$$414$$$416$$$O	the$$$417$$$420$$$O	treatment$$$421$$$430$$$O	of$$$431$$$433$$$O	other$$$434$$$439$$$O	conditions$$$440$$$450$$$O	related$$$451$$$458$$$O	to$$$459$$$461$$$O	gastric$$$462$$$469$$$O	hypersecretion$$$470$$$484$$$O	such$$$485$$$489$$$O	as$$$490$$$492$$$O	Zollinger-Ellison$$$493$$$510$$$O	Syndrome.$$$511$$$520$$$O
CN103272042A
Smoked$$$0$$$6$$$O	lotion$$$7$$$13$$$O	for$$$14$$$17$$$O	treating$$$18$$$26$$$O	hemorrhoids$$$27$$$38$$$O	and$$$39$$$42$$$O	fistula$$$43$$$50$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	fuming$$$27$$$33$$$O	and$$$34$$$37$$$O	washing$$$38$$$45$$$O	drug$$$46$$$50$$$O	for$$$51$$$54$$$O	treating$$$55$$$63$$$O	an$$$64$$$66$$$O	anorectal$$$67$$$76$$$O	disease,$$$77$$$85$$$O	and$$$86$$$89$$$O	particularly$$$90$$$102$$$O	relates$$$103$$$110$$$O	to$$$111$$$113$$$O	smoked$$$114$$$120$$$O	lotion$$$121$$$127$$$O	for$$$128$$$131$$$O	treating$$$132$$$140$$$O	hemorrhoids$$$141$$$152$$$O	and$$$153$$$156$$$O	fistula.$$$157$$$165$$$O	The$$$166$$$169$$$O	smoked$$$170$$$176$$$O	lotion$$$177$$$183$$$O	is$$$184$$$186$$$O	prepared$$$187$$$195$$$O	from$$$196$$$200$$$O	compound$$$201$$$209$$$O	of$$$210$$$212$$$O	salt$$$213$$$217$$$O	and$$$218$$$221$$$O	liquorice,$$$222$$$232$$$O	gypsum$$$233$$$239$$$O	rubrum,$$$240$$$247$$$O	realgar,$$$248$$$256$$$O	white$$$257$$$262$$$O	alum,$$$263$$$268$$$O	borax,$$$269$$$275$$$O	ossa$$$276$$$280$$$O	draconis,$$$281$$$290$$$O	borneol$$$291$$$298$$$I	and$$$299$$$302$$$O	fructus$$$303$$$310$$$O	zanthoxyli$$$311$$$321$$$O	in$$$322$$$324$$$O	a$$$325$$$326$$$O	processing$$$327$$$337$$$O	manner$$$338$$$344$$$O	according$$$345$$$354$$$O	to$$$355$$$357$$$O	certain$$$358$$$365$$$O	parts$$$366$$$371$$$O	by$$$372$$$374$$$O	weight.$$$375$$$382$$$O	Each$$$383$$$387$$$O	component$$$388$$$397$$$O	drug$$$398$$$402$$$O	of$$$403$$$405$$$O	the$$$406$$$409$$$O	smoked$$$410$$$416$$$O	lotion$$$417$$$423$$$O	is$$$424$$$426$$$O	reasonable$$$427$$$437$$$O	in$$$438$$$440$$$O	compatibility,$$$441$$$455$$$O	so$$$456$$$458$$$O	that$$$459$$$463$$$O	the$$$464$$$467$$$O	effects$$$468$$$475$$$O	of$$$476$$$478$$$O	clearing$$$479$$$487$$$O	away$$$488$$$492$$$O	heat$$$493$$$497$$$O	and$$$498$$$501$$$O	drying$$$502$$$508$$$O	dampness,$$$509$$$518$$$O	detoxifying$$$519$$$530$$$O	and$$$531$$$534$$$O	diminishing$$$535$$$546$$$O	inflammation,$$$547$$$560$$$O	removing$$$561$$$569$$$O	dampness$$$570$$$578$$$O	to$$$579$$$581$$$O	relieve$$$582$$$589$$$O	itching,$$$590$$$598$$$O	activating$$$599$$$609$$$O	meridians$$$610$$$619$$$O	to$$$620$$$622$$$O	stop$$$623$$$627$$$O	pain,$$$628$$$633$$$O	removing$$$634$$$642$$$O	swelling$$$643$$$651$$$O	and$$$652$$$655$$$O	lump,$$$656$$$661$$$O	promoting$$$662$$$671$$$O	blood$$$672$$$677$$$O	circulation$$$678$$$689$$$O	to$$$690$$$692$$$O	remove$$$693$$$699$$$O	blood$$$700$$$705$$$O	stasis,$$$706$$$713$$$O	stopping$$$714$$$722$$$O	bleeding$$$723$$$731$$$O	and$$$732$$$735$$$O	astringing$$$736$$$746$$$O	intestine$$$747$$$756$$$O	to$$$757$$$759$$$O	stop$$$760$$$764$$$O	diarrhea,$$$765$$$774$$$O	regenerating$$$775$$$787$$$O	tissue$$$788$$$794$$$O	to$$$795$$$797$$$O	heal$$$798$$$802$$$O	wound$$$803$$$808$$$O	and$$$809$$$812$$$O	the$$$813$$$816$$$O	like$$$817$$$821$$$O	are$$$822$$$825$$$O	achieved;$$$826$$$835$$$O	and$$$836$$$839$$$O	the$$$840$$$843$$$O	smoked$$$844$$$850$$$O	lotion$$$851$$$857$$$O	has$$$858$$$861$$$O	good$$$862$$$866$$$O	restraining$$$867$$$878$$$O	and$$$879$$$882$$$O	killing$$$883$$$890$$$O	roles$$$891$$$896$$$O	on$$$897$$$899$$$O	failing$$$900$$$907$$$O	to$$$908$$$910$$$O	close$$$911$$$916$$$O	of$$$917$$$919$$$O	ulcer$$$920$$$925$$$O	and$$$926$$$929$$$O	pathogenic$$$930$$$940$$$O	bacteria$$$941$$$949$$$O	after$$$950$$$955$$$O	the$$$956$$$959$$$O	hemorrhoids$$$960$$$971$$$O	and$$$972$$$975$$$O	fistula$$$976$$$983$$$O	operation,$$$984$$$994$$$O	can$$$995$$$998$$$O	be$$$999$$$1001$$$O	used$$$1002$$$1006$$$O	for$$$1007$$$1010$$$O	rapidly$$$1011$$$1018$$$O	relieving$$$1019$$$1028$$$O	the$$$1029$$$1032$$$O	symptoms$$$1033$$$1041$$$O	of$$$1042$$$1044$$$O	inflammatory$$$1045$$$1057$$$O	external$$$1058$$$1066$$$O	hemorrhoids,$$$1067$$$1079$$$O	earlier$$$1080$$$1087$$$O	anal$$$1088$$$1092$$$O	fissure,$$$1093$$$1101$$$O	incarceration$$$1102$$$1115$$$O	of$$$1116$$$1118$$$O	internal$$$1119$$$1127$$$O	hemorrhoid,$$$1128$$$1139$$$O	acute$$$1140$$$1145$$$O	infection$$$1146$$$1155$$$O	of$$$1156$$$1158$$$O	anal$$$1159$$$1163$$$O	fistula,$$$1164$$$1172$$$O	perianal$$$1173$$$1181$$$O	abscess$$$1182$$$1189$$$O	and$$$1190$$$1193$$$O	the$$$1194$$$1197$$$O	like,$$$1198$$$1203$$$O	preventing$$$1204$$$1214$$$O	and$$$1215$$$1218$$$O	treating$$$1219$$$1227$$$O	wound$$$1228$$$1233$$$O	infection$$$1234$$$1243$$$O	after$$$1244$$$1249$$$O	the$$$1250$$$1253$$$O	hemorrhoids$$$1254$$$1265$$$O	and$$$1266$$$1269$$$O	fistula$$$1270$$$1277$$$O	operation$$$1278$$$1287$$$O	and$$$1288$$$1291$$$O	accelerating$$$1292$$$1304$$$O	wound$$$1305$$$1310$$$O	healing,$$$1311$$$1319$$$O	has$$$1320$$$1323$$$O	important$$$1324$$$1333$$$O	clinical$$$1334$$$1342$$$O	significance,$$$1343$$$1356$$$O	and$$$1357$$$1360$$$O	is$$$1361$$$1363$$$O	good$$$1364$$$1368$$$O	in$$$1369$$$1371$$$O	curative$$$1372$$$1380$$$O	effect,$$$1381$$$1388$$$O	fast$$$1389$$$1393$$$O	to$$$1394$$$1396$$$O	become$$$1397$$$1403$$$O	effective,$$$1404$$$1414$$$O	small$$$1415$$$1420$$$O	in$$$1421$$$1423$$$O	toxic$$$1424$$$1429$$$O	and$$$1430$$$1433$$$O	side$$$1434$$$1438$$$O	effects,$$$1439$$$1447$$$O	and$$$1448$$$1451$$$O	convenient$$$1452$$$1462$$$O	to$$$1463$$$1465$$$O	store,$$$1466$$$1472$$$O	carry$$$1473$$$1478$$$O	and$$$1479$$$1482$$$O	use.$$$1483$$$1487$$$O
EP0979080B9
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	modulating$$$12$$$22$$$O	an$$$23$$$25$$$O	immune$$$26$$$32$$$O	response$$$33$$$41$$$O	in$$$42$$$44$$$O	an$$$45$$$47$$$O	infected$$$48$$$56$$$O	mammal$$$57$$$63$$$O	by$$$64$$$66$$$O	transmucosal$$$67$$$79$$$O	administration$$$80$$$94$$$O	of$$$95$$$97$$$O	modulating$$$98$$$108$$$O	agent$$$109$$$114$$$O
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	modulating$$$29$$$39$$$O	an$$$40$$$42$$$O	immune$$$43$$$49$$$O	response$$$50$$$58$$$O	in$$$59$$$61$$$O	a$$$62$$$63$$$O	mammal$$$64$$$70$$$O	infected$$$71$$$79$$$O	with$$$80$$$84$$$O	a$$$85$$$86$$$O	bacterium,$$$87$$$97$$$O	a$$$98$$$99$$$O	virus,$$$100$$$106$$$O	or$$$107$$$109$$$O	a$$$110$$$111$$$O	parasite$$$112$$$120$$$O	are$$$121$$$124$$$O	provided.$$$125$$$134$$$O	The$$$135$$$138$$$O	methods$$$139$$$146$$$O	and$$$147$$$150$$$O	compositions$$$151$$$163$$$O	are$$$164$$$167$$$O	useful$$$168$$$174$$$O	in$$$175$$$177$$$O	mammals$$$178$$$185$$$O	experiencing$$$186$$$198$$$O	an$$$199$$$201$$$O	acute$$$202$$$207$$$O	infection$$$208$$$217$$$O	and$$$218$$$221$$$O	in$$$222$$$224$$$O	mammals$$$225$$$232$$$O	experiencing$$$233$$$245$$$O	a$$$246$$$247$$$O	chronic$$$248$$$255$$$O	infection.$$$256$$$266$$$O	The$$$267$$$270$$$O	methods$$$271$$$278$$$O	and$$$279$$$282$$$O	compositions$$$283$$$295$$$O	may$$$296$$$299$$$O	be$$$300$$$302$$$O	used$$$303$$$307$$$O	in$$$308$$$310$$$O	conjunction$$$311$$$322$$$O	with$$$323$$$327$$$O	a$$$328$$$329$$$O	known$$$330$$$335$$$O	treatment$$$336$$$345$$$O	for$$$346$$$349$$$O	infection$$$350$$$359$$$O	of$$$360$$$362$$$O	a$$$363$$$364$$$O	mammal$$$365$$$371$$$O	by$$$372$$$374$$$O	an$$$375$$$377$$$O	infectious$$$378$$$388$$$O	agent.$$$389$$$395$$$O	Methods$$$396$$$403$$$O	and$$$404$$$407$$$O	compositions$$$408$$$420$$$O	for$$$421$$$424$$$O	transmucosal$$$425$$$437$$$O	delivery$$$438$$$446$$$O	of$$$447$$$449$$$O	a$$$450$$$451$$$O	molecule$$$452$$$460$$$O	comprising$$$461$$$471$$$O	an$$$472$$$474$$$O	epitope$$$475$$$482$$$O	located$$$483$$$490$$$O	in$$$491$$$493$$$O	close$$$494$$$499$$$O	proximity$$$500$$$509$$$O	to$$$510$$$512$$$O	the$$$513$$$516$$$O	immune$$$517$$$523$$$O	response$$$524$$$532$$$O	are$$$533$$$536$$$O	provided.$$$537$$$546$$$O
WO2011030868A1
Substituted$$$0$$$11$$$O	carbonyl$$$12$$$20$$$I	compounds$$$21$$$30$$$O
Novel$$$0$$$5$$$O	substituted$$$6$$$17$$$O	carbonyl$$$18$$$26$$$I	compounds$$$27$$$36$$$O	represented$$$37$$$48$$$O	by$$$49$$$51$$$O	general$$$52$$$59$$$O	formula$$$60$$$67$$$O	(I)$$$68$$$71$$$O	or$$$72$$$74$$$O	salts$$$75$$$80$$$O	thereof,$$$81$$$89$$$O	which$$$90$$$95$$$O	exhibit$$$96$$$103$$$O	excellent$$$104$$$113$$$O	bronchodilating$$$114$$$129$$$O	effect$$$130$$$136$$$O	that$$$137$$$141$$$O	relies$$$142$$$148$$$O	on$$$149$$$151$$$O	potent$$$152$$$158$$$O	EP2$$$159$$$162$$$O	agonist$$$163$$$170$$$O	activity$$$171$$$179$$$O	and$$$180$$$183$$$O	which$$$184$$$189$$$O	are$$$190$$$193$$$O	useful$$$194$$$200$$$O	in$$$201$$$203$$$O	the$$$204$$$207$$$O	treatment$$$208$$$217$$$O	of$$$218$$$220$$$O	respiratory$$$221$$$232$$$O	diseases.$$$233$$$242$$$O	In$$$243$$$245$$$O	general$$$246$$$253$$$O	formula$$$254$$$261$$$O	(I),$$$262$$$266$$$O	R1$$$267$$$269$$$O	is$$$270$$$272$$$O	-OR5,$$$273$$$278$$$I	-O(CH2CH2O)mR6$$$279$$$293$$$I	or$$$294$$$296$$$O	-NR7R8$$$297$$$303$$$I	(wherein$$$304$$$312$$$O	R5$$$313$$$315$$$O	is$$$316$$$318$$$O	C7-22$$$319$$$324$$$I	alkyl$$$325$$$330$$$I	or$$$331$$$333$$$O	the$$$334$$$337$$$O	like;$$$338$$$343$$$O	R6$$$344$$$346$$$O	is$$$347$$$349$$$O	H$$$350$$$351$$$I	or$$$352$$$354$$$O	benzyl;$$$355$$$362$$$I	m$$$363$$$364$$$O	is$$$365$$$367$$$O	1$$$368$$$369$$$O	to$$$370$$$372$$$O	4;$$$373$$$375$$$O	and$$$376$$$379$$$O	R7$$$380$$$382$$$O	and$$$383$$$386$$$O	R8$$$387$$$389$$$O	are$$$390$$$393$$$O	each$$$394$$$398$$$O	H,$$$399$$$401$$$I	C1-12$$$402$$$407$$$I	alkyl,$$$408$$$414$$$I	or$$$415$$$417$$$O	the$$$418$$$421$$$O	like);$$$422$$$428$$$O	R2$$$429$$$431$$$O	and$$$432$$$435$$$O	R3$$$436$$$438$$$O	are$$$439$$$442$$$O	each$$$443$$$447$$$O	H$$$448$$$449$$$I	or$$$450$$$452$$$O	C1-6$$$453$$$457$$$I	alkyl;$$$458$$$464$$$I	Y$$$465$$$466$$$O	is$$$467$$$469$$$O	a$$$470$$$471$$$O	(substituted)$$$472$$$485$$$O	bicyclic$$$486$$$494$$$I	heteroaromatic$$$495$$$509$$$I	ring,$$$510$$$515$$$O	-Q1-Q2,$$$516$$$523$$$O	or$$$524$$$526$$$O	the$$$527$$$530$$$O	like$$$531$$$535$$$O	(wherein$$$536$$$544$$$O	Q1$$$545$$$547$$$O	is$$$548$$$550$$$O	arylene$$$551$$$558$$$I	or$$$559$$$561$$$O	the$$$562$$$565$$$O	like;$$$566$$$571$$$O	and$$$572$$$575$$$O	Q2$$$576$$$578$$$O	is$$$579$$$581$$$O	a$$$582$$$583$$$O	(substituted)$$$584$$$597$$$O	5-$$$598$$$600$$$O	or$$$601$$$603$$$O	6-memebred$$$604$$$614$$$O	heterocycle,$$$615$$$627$$$I	or$$$628$$$630$$$O	the$$$631$$$634$$$O	like);$$$635$$$641$$$O	and$$$642$$$645$$$O	Z$$$646$$$647$$$O	is$$$648$$$650$$$O	(substituted)$$$651$$$664$$$O	aryl$$$665$$$669$$$I	or$$$670$$$672$$$O	a$$$673$$$674$$$O	(substituted)$$$675$$$688$$$O	5-$$$689$$$691$$$O	or$$$692$$$694$$$O	6-memeberd$$$695$$$705$$$O	heteroaromatic$$$706$$$720$$$I	ring.$$$721$$$726$$$O
US20110189127
Tricyclic$$$0$$$9$$$I	indole$$$10$$$16$$$I	derivatives$$$17$$$28$$$O	and$$$29$$$32$$$O	methods$$$33$$$40$$$O	of$$$41$$$43$$$O	use$$$44$$$47$$$O	thereof$$$48$$$55$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	Tricyclic$$$33$$$42$$$I	Indole$$$43$$$49$$$I	Derivatives,$$$50$$$62$$$O	compositions$$$63$$$75$$$O	comprising$$$76$$$86$$$O	at$$$87$$$89$$$O	least$$$90$$$95$$$O	one$$$96$$$99$$$O	Tricyclic$$$100$$$109$$$I	Indole$$$110$$$116$$$I	Derivatives,$$$117$$$129$$$O	and$$$130$$$133$$$O	methods$$$134$$$141$$$O	of$$$142$$$144$$$O	using$$$145$$$150$$$O	the$$$151$$$154$$$O	Tricyclic$$$155$$$164$$$I	Indole$$$165$$$171$$$I	Derivatives$$$172$$$183$$$O	for$$$184$$$187$$$O	treating$$$188$$$196$$$O	or$$$197$$$199$$$O	preventing$$$200$$$210$$$O	a$$$211$$$212$$$O	viral$$$213$$$218$$$O	infection$$$219$$$228$$$O	or$$$229$$$231$$$O	a$$$232$$$233$$$O	virus-related$$$234$$$247$$$O	disorder$$$248$$$256$$$O	in$$$257$$$259$$$O	a$$$260$$$261$$$O	patient.$$$262$$$270$$$O
CN101591316A
Homoisoflavone,$$$0$$$15$$$I	dihydrohomoisoflavone$$$16$$$37$$$I	and$$$38$$$41$$$O	homoisoflavane$$$42$$$56$$$I	derivatives$$$57$$$68$$$O	and$$$69$$$72$$$O	application$$$73$$$84$$$O	thereof$$$85$$$92$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicaments,$$$48$$$60$$$O	and$$$61$$$64$$$O	relates$$$65$$$72$$$O	to$$$73$$$75$$$O	homoisoflavone,$$$76$$$91$$$I	dihydrohomoisoflavone$$$92$$$113$$$I	and$$$114$$$117$$$O	homoisoflavane$$$118$$$132$$$I	derivatives.$$$133$$$145$$$O	A$$$146$$$147$$$O	structure$$$148$$$157$$$O	of$$$158$$$160$$$O	the$$$161$$$164$$$O	derivatives$$$165$$$176$$$O	is$$$177$$$179$$$O	shown$$$180$$$185$$$O	in$$$186$$$188$$$O	(I),$$$189$$$193$$$O	wherein$$$194$$$201$$$O	X1$$$202$$$204$$$O	and$$$205$$$208$$$O	X2$$$209$$$211$$$O	co-represent$$$212$$$224$$$O	oxygen,$$$225$$$232$$$I	or$$$233$$$235$$$O	the$$$236$$$239$$$O	X1$$$240$$$242$$$O	and$$$243$$$246$$$O	the$$$247$$$250$$$O	X2$$$251$$$253$$$O	simultaneously$$$254$$$268$$$O	represent$$$269$$$278$$$O	hydrogen$$$279$$$287$$$I	respectively;$$$288$$$301$$$O	Z-Y$$$302$$$305$$$O	is$$$306$$$308$$$O	-CH=C-$$$309$$$315$$$I	or$$$316$$$318$$$O	-CH2CH-;$$$319$$$327$$$I	R1$$$328$$$330$$$O	is$$$331$$$333$$$O	the$$$334$$$337$$$O	hydrogen$$$338$$$346$$$I	or$$$347$$$349$$$O	a$$$350$$$351$$$O	haloid$$$352$$$358$$$I	atom;$$$359$$$364$$$O	R2,$$$365$$$368$$$O	R5,$$$369$$$372$$$O	R6,$$$373$$$376$$$O	R7$$$377$$$379$$$O	and$$$380$$$383$$$O	R8$$$384$$$386$$$O	are$$$387$$$390$$$O	independently$$$391$$$404$$$O	the$$$405$$$408$$$O	hydrogen,$$$409$$$418$$$I	methoxy,$$$419$$$427$$$I	hydroxy,$$$428$$$436$$$I	the$$$437$$$440$$$O	haloid$$$441$$$447$$$I	atom$$$448$$$452$$$O	and$$$453$$$456$$$O	amino$$$457$$$462$$$I	respectively;$$$463$$$476$$$O	or$$$477$$$479$$$O	two$$$480$$$483$$$O	adjacent$$$484$$$492$$$O	substitutional$$$493$$$507$$$O	groups$$$508$$$514$$$O	can$$$515$$$518$$$O	be$$$519$$$521$$$O	-OCH2O-,$$$522$$$530$$$I	thereby$$$531$$$538$$$O	forming$$$539$$$546$$$O	a$$$547$$$548$$$O	five-membered$$$549$$$562$$$O	ring;$$$563$$$568$$$O	and$$$569$$$572$$$O	R3$$$573$$$575$$$O	and$$$576$$$579$$$O	R4$$$580$$$582$$$O	are$$$583$$$586$$$O	independently$$$587$$$600$$$O	the$$$601$$$604$$$O	hydrogen,$$$605$$$614$$$I	and$$$615$$$618$$$O	C1,$$$619$$$622$$$O	C2$$$623$$$625$$$O	and$$$626$$$629$$$O	C3$$$630$$$632$$$O	are$$$633$$$636$$$O	alkyl$$$637$$$642$$$I	or$$$643$$$645$$$O	-OCH2O-,$$$646$$$654$$$I	thereby$$$655$$$662$$$O	forming$$$663$$$670$$$O	the$$$671$$$674$$$O	five-membered$$$675$$$688$$$O	ring.$$$689$$$694$$$O	The$$$695$$$698$$$O	invention$$$699$$$708$$$O	also$$$709$$$713$$$O	provides$$$714$$$722$$$O	pharmaceutically$$$723$$$739$$$O	acceptable$$$740$$$750$$$O	nontoxic$$$751$$$759$$$O	salts$$$760$$$765$$$O	formed$$$766$$$772$$$O	by$$$773$$$775$$$O	the$$$776$$$779$$$O	derivatives$$$780$$$791$$$O	shown$$$792$$$797$$$O	in$$$798$$$800$$$O	the$$$801$$$804$$$O	structural$$$805$$$815$$$O	formula$$$816$$$823$$$O	and$$$824$$$827$$$O	hydrates$$$828$$$836$$$O	thereof,$$$837$$$845$$$O	wherein$$$846$$$853$$$O	the$$$854$$$857$$$O	pharmaceutically$$$858$$$874$$$O	acceptable$$$875$$$885$$$O	nontoxic$$$886$$$894$$$O	salts$$$895$$$900$$$O	comprise$$$901$$$909$$$O	salts$$$910$$$915$$$O	formed$$$916$$$922$$$O	by$$$923$$$925$$$O	the$$$926$$$929$$$O	derivatives$$$930$$$941$$$O	and$$$942$$$945$$$O	acids.$$$946$$$952$$$O	Pharmacological$$$953$$$968$$$O	activity$$$969$$$977$$$O	experiment$$$978$$$988$$$O	results$$$989$$$996$$$O	show$$$997$$$1001$$$O	that$$$1002$$$1006$$$O	the$$$1007$$$1010$$$O	derivatives$$$1011$$$1022$$$O	have$$$1023$$$1027$$$O	better$$$1028$$$1034$$$O	tumor$$$1035$$$1040$$$O	inhibition$$$1041$$$1051$$$O	activity,$$$1052$$$1061$$$O	and$$$1062$$$1065$$$O	can$$$1066$$$1069$$$O	be$$$1070$$$1072$$$O	used$$$1073$$$1077$$$O	for$$$1078$$$1081$$$O	the$$$1082$$$1085$$$O	application$$$1086$$$1097$$$O	of$$$1098$$$1100$$$O	a$$$1101$$$1102$$$O	tumor$$$1103$$$1108$$$O	cell$$$1109$$$1113$$$O	proliferation$$$1114$$$1127$$$O	inhibitor$$$1128$$$1137$$$O	in$$$1138$$$1140$$$O	preparing$$$1141$$$1150$$$O	antitumor$$$1151$$$1160$$$O	medicaments.$$$1161$$$1173$$$O
CN102161710A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	tremellan$$$21$$$30$$$O	with$$$31$$$35$$$O	low$$$36$$$39$$$O	molecular$$$40$$$49$$$O	weight$$$50$$$56$$$O	and$$$57$$$60$$$O	novel$$$61$$$66$$$O	medicinal$$$67$$$76$$$O	application$$$77$$$88$$$O	thereof$$$89$$$96$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	method$$$26$$$32$$$O	for$$$33$$$36$$$O	preparing$$$37$$$46$$$O	tremellan$$$47$$$56$$$O	with$$$57$$$61$$$O	low$$$62$$$65$$$O	molecular$$$66$$$75$$$O	weight$$$76$$$82$$$O	from$$$83$$$87$$$O	Tremella$$$88$$$96$$$O	fueiformis$$$97$$$107$$$O	Berk$$$108$$$112$$$O	and$$$113$$$116$$$O	application$$$117$$$128$$$O	of$$$129$$$131$$$O	the$$$132$$$135$$$O	tremellan$$$136$$$145$$$O	with$$$146$$$150$$$O	low$$$151$$$154$$$O	molecular$$$155$$$164$$$O	weight$$$165$$$171$$$O	in$$$172$$$174$$$O	treatment$$$175$$$184$$$O	for$$$185$$$188$$$O	chronic$$$189$$$196$$$O	atrophic$$$197$$$205$$$O	gastritis$$$206$$$215$$$O	and$$$216$$$219$$$O	serving$$$220$$$227$$$O	as$$$228$$$230$$$O	an$$$231$$$233$$$O	adjuvant$$$234$$$242$$$O	medicament$$$243$$$253$$$O	in$$$254$$$256$$$O	tumor$$$257$$$262$$$O	therapy.$$$263$$$271$$$O	The$$$272$$$275$$$O	method$$$276$$$282$$$O	for$$$283$$$286$$$O	preparing$$$287$$$296$$$O	the$$$297$$$300$$$O	tremellan$$$301$$$310$$$O	with$$$311$$$315$$$O	low$$$316$$$319$$$O	molecular$$$320$$$329$$$O	weight$$$330$$$336$$$O	comprises$$$337$$$346$$$O	the$$$347$$$350$$$O	following$$$351$$$360$$$O	steps$$$361$$$366$$$O	of:$$$367$$$370$$$O	cleaning$$$371$$$379$$$O	the$$$380$$$383$$$O	Tremella$$$384$$$392$$$O	fueiformis$$$393$$$403$$$O	Berk,$$$404$$$409$$$O	homogenating,$$$410$$$423$$$O	adding$$$424$$$430$$$O	solution$$$431$$$439$$$O	of$$$440$$$442$$$O	acid$$$443$$$447$$$O	water,$$$448$$$454$$$O	extracting$$$455$$$465$$$O	for$$$466$$$469$$$O	1$$$470$$$471$$$O	to$$$472$$$474$$$O	3$$$475$$$476$$$O	hours$$$477$$$482$$$O	by$$$483$$$485$$$O	using$$$486$$$491$$$O	the$$$492$$$495$$$O	acid$$$496$$$500$$$O	water$$$501$$$506$$$O	at$$$507$$$509$$$O	certain$$$510$$$517$$$O	temperature$$$518$$$529$$$O	and$$$530$$$533$$$O	under$$$534$$$539$$$O	certain$$$540$$$547$$$O	pressure,$$$548$$$557$$$O	neutralizing$$$558$$$570$$$O	extracting$$$571$$$581$$$O	solution$$$582$$$590$$$O	of$$$591$$$593$$$O	the$$$594$$$597$$$O	acid$$$598$$$602$$$O	water$$$603$$$608$$$O	until$$$609$$$614$$$O	the$$$615$$$618$$$O	extracting$$$619$$$629$$$O	solution$$$630$$$638$$$O	is$$$639$$$641$$$O	neutral$$$642$$$649$$$O	by$$$650$$$652$$$O	using$$$653$$$658$$$O	alkaline$$$659$$$667$$$O	water,$$$668$$$674$$$O	centrifuging,$$$675$$$688$$$O	concentrating$$$689$$$702$$$O	supernatant$$$703$$$714$$$O	to$$$715$$$717$$$O	an$$$718$$$720$$$O	appropriate$$$721$$$732$$$O	volume,$$$733$$$740$$$O	and$$$741$$$744$$$O	preparing$$$745$$$754$$$O	the$$$755$$$758$$$O	tremellan$$$759$$$768$$$O	through$$$769$$$776$$$O	ultrafiltration$$$777$$$792$$$O	membranes$$$793$$$802$$$O	with$$$803$$$807$$$O	different$$$808$$$817$$$O	molecular$$$818$$$827$$$O	weight$$$828$$$834$$$O	cutoffs$$$835$$$842$$$O	or$$$843$$$845$$$O	an$$$846$$$848$$$O	ethanol$$$849$$$856$$$I	fractional$$$857$$$867$$$O	precipitation$$$868$$$881$$$O	method.$$$882$$$889$$$O	The$$$890$$$893$$$O	tremellan$$$894$$$903$$$O	with$$$904$$$908$$$O	low$$$909$$$912$$$O	molecular$$$913$$$922$$$O	weight$$$923$$$929$$$O	prepared$$$930$$$938$$$O	by$$$939$$$941$$$O	the$$$942$$$945$$$O	method$$$946$$$952$$$O	is$$$953$$$955$$$O	used$$$956$$$960$$$O	for$$$961$$$964$$$O	treating$$$965$$$973$$$O	chronic$$$974$$$981$$$O	atrophic$$$982$$$990$$$O	gastritis$$$991$$$1000$$$O	and$$$1001$$$1004$$$O	carrying$$$1005$$$1013$$$O	out$$$1014$$$1017$$$O	pharmacodynamics$$$1018$$$1034$$$O	research$$$1035$$$1043$$$O	of$$$1044$$$1046$$$O	adjuvant$$$1047$$$1055$$$O	medicaments$$$1056$$$1067$$$O	in$$$1068$$$1070$$$O	tumor$$$1071$$$1076$$$O	therapy,$$$1077$$$1085$$$O	and$$$1086$$$1089$$$O	the$$$1090$$$1093$$$O	medicinal$$$1094$$$1103$$$O	effect$$$1104$$$1110$$$O	is$$$1111$$$1113$$$O	high.$$$1114$$$1119$$$O
CN1900094A
Organic$$$0$$$7$$$O	platinum$$$8$$$16$$$I	new$$$17$$$20$$$O	complex$$$21$$$28$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	a$$$25$$$26$$$O	kind$$$27$$$31$$$O	of$$$32$$$34$$$O	norcantharidimde$$$35$$$51$$$I	complex$$$52$$$59$$$O	of$$$60$$$62$$$O	organic$$$63$$$70$$$O	plantinum,$$$71$$$81$$$I	and$$$82$$$85$$$O	the$$$86$$$89$$$O	norcantharidimde$$$90$$$106$$$O	complex$$$107$$$114$$$O	includes$$$115$$$123$$$O	four$$$124$$$128$$$O	kinds$$$129$$$134$$$O	of$$$135$$$137$$$O	compounds.$$$138$$$148$$$O	The$$$149$$$152$$$O	norcantharidimde$$$153$$$169$$$I	complex$$$170$$$177$$$O	possesses$$$178$$$187$$$O	anticancer$$$188$$$198$$$O	effect,$$$199$$$206$$$O	and$$$207$$$210$$$O	the$$$211$$$214$$$O	medicinal$$$215$$$224$$$O	composition$$$225$$$236$$$O	containing$$$237$$$247$$$O	the$$$248$$$251$$$O	norcantharidimde$$$252$$$268$$$I	complex$$$269$$$276$$$O	may$$$277$$$280$$$O	be$$$281$$$283$$$O	used$$$284$$$288$$$O	in$$$289$$$291$$$O	treating$$$292$$$300$$$O	lung$$$301$$$305$$$O	cancer,$$$306$$$313$$$O	liver$$$314$$$319$$$O	cancer,$$$320$$$327$$$O	mammary$$$328$$$335$$$O	cancer,$$$336$$$343$$$O	colon$$$344$$$349$$$O	cancer,$$$350$$$357$$$O	leukemia,$$$358$$$367$$$O	etc$$$368$$$371$$$O	and$$$372$$$375$$$O	may$$$376$$$379$$$O	be$$$380$$$382$$$O	prepared$$$383$$$391$$$O	into$$$392$$$396$$$O	different$$$397$$$406$$$O	preparation$$$407$$$418$$$O	forms,$$$419$$$425$$$O	such$$$426$$$430$$$O	as$$$431$$$433$$$O	tablet,$$$434$$$441$$$O	granule,$$$442$$$450$$$O	injection,$$$451$$$461$$$O	etc.$$$462$$$466$$$O
EP1365768B1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	er-beta$$$7$$$14$$$O	selective$$$15$$$24$$$O	antagonists$$$25$$$36$$$O	as$$$37$$$39$$$O	contraceptives$$$40$$$54$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	the$$$32$$$35$$$O	use$$$36$$$39$$$O	of$$$40$$$42$$$O	ERSS-selective$$$43$$$57$$$O	ligands$$$58$$$65$$$O	for$$$66$$$69$$$O	production$$$70$$$80$$$O	of$$$81$$$83$$$O	medicaments$$$84$$$95$$$O	for$$$96$$$99$$$O	regulating$$$100$$$110$$$O	fertility$$$111$$$120$$$O	without$$$121$$$128$$$O	additional$$$129$$$139$$$O	use$$$140$$$143$$$O	of$$$144$$$146$$$O	a$$$147$$$148$$$O	progestin.$$$149$$$159$$$O	ERSS-agonists$$$161$$$174$$$O	are$$$175$$$178$$$O	used$$$179$$$183$$$O	for$$$184$$$187$$$O	treatment$$$188$$$197$$$O	of$$$198$$$200$$$O	infertility$$$201$$$212$$$O	and$$$213$$$216$$$O	ERSS-antagonists$$$217$$$233$$$O	for$$$234$$$237$$$O	contraception.$$$238$$$252$$$O
CN1615865A
Cepharanthine$$$0$$$13$$$I	dripping$$$14$$$22$$$O	pill$$$23$$$27$$$O	and$$$28$$$31$$$O	preparing$$$32$$$41$$$O	process$$$42$$$49$$$O
The$$$0$$$3$$$O	cepharanthine$$$4$$$17$$$O	dripping$$$18$$$26$$$O	pill$$$27$$$31$$$O	containing$$$32$$$42$$$O	cepharanthine$$$43$$$56$$$I	1-10$$$57$$$61$$$O	mg$$$62$$$64$$$O	and$$$65$$$68$$$O	proper$$$69$$$75$$$O	amount$$$76$$$82$$$O	of$$$83$$$85$$$O	dripping$$$86$$$94$$$O	pill$$$95$$$99$$$O	medium$$$100$$$106$$$O	in$$$107$$$109$$$O	each$$$110$$$114$$$O	pill.$$$115$$$120$$$O	The$$$121$$$124$$$O	dripping$$$125$$$133$$$O	pill$$$134$$$138$$$O	medium$$$139$$$145$$$O	is$$$146$$$148$$$O	one$$$149$$$152$$$O	or$$$153$$$155$$$O	two$$$156$$$159$$$O	of$$$160$$$162$$$O	polyglycol-6000,$$$163$$$179$$$I	polyglycol-4000,$$$180$$$196$$$I	polyoxyethylene$$$197$$$212$$$I	monostearate,$$$213$$$226$$$I	sodium$$$227$$$233$$$I	stearate,$$$234$$$243$$$I	glycerin,$$$244$$$253$$$I	gelatin,$$$254$$$262$$$O	poloxamer,$$$263$$$273$$$O	stearic$$$274$$$281$$$I	acid,$$$282$$$287$$$I	glycerin$$$288$$$296$$$I	monostearate$$$297$$$309$$$I	and$$$310$$$313$$$O	insect$$$314$$$320$$$O	wax.$$$321$$$325$$$O	The$$$326$$$329$$$O	preparation$$$330$$$341$$$O	process$$$342$$$349$$$O	of$$$350$$$352$$$O	the$$$353$$$356$$$O	cepharanthine$$$357$$$370$$$I	dripping$$$371$$$379$$$O	pill$$$380$$$384$$$O	includes$$$385$$$393$$$O	melting$$$394$$$401$$$O	and$$$402$$$405$$$O	mixing$$$406$$$412$$$O	cepharanthine$$$413$$$426$$$I	and$$$427$$$430$$$O	dripping$$$431$$$439$$$O	pill$$$440$$$444$$$O	medium,$$$445$$$452$$$O	dropping$$$453$$$461$$$O	at$$$462$$$464$$$O	60-100$$$465$$$471$$$O	deg.c$$$472$$$477$$$O	into$$$478$$$482$$$O	condensating$$$483$$$495$$$O	agent,$$$496$$$502$$$O	and$$$503$$$506$$$O	eliminating$$$507$$$518$$$O	condensating$$$519$$$531$$$O	agent.$$$532$$$538$$$O	The$$$539$$$542$$$O	condensating$$$543$$$555$$$O	agent$$$556$$$561$$$O	is$$$562$$$564$$$O	one$$$565$$$568$$$O	or$$$569$$$571$$$O	two$$$572$$$575$$$O	of$$$576$$$578$$$O	dimethyl$$$579$$$587$$$I	silicon$$$588$$$595$$$I	oil,$$$596$$$600$$$O	liquid$$$601$$$607$$$O	paraffin,$$$608$$$617$$$I	tea$$$618$$$621$$$O	seed$$$622$$$626$$$O	oil$$$627$$$630$$$O	and$$$631$$$634$$$O	rape$$$635$$$639$$$O	seed$$$640$$$644$$$O	oil.$$$645$$$649$$$O	The$$$650$$$653$$$O	cepharanthine$$$654$$$667$$$I	dripping$$$668$$$676$$$O	pill$$$677$$$681$$$O	is$$$682$$$684$$$O	white$$$685$$$690$$$O	or$$$691$$$693$$$O	slight$$$694$$$700$$$O	yellow$$$701$$$707$$$O	and$$$708$$$711$$$O	bitter.$$$712$$$719$$$O	The$$$720$$$723$$$O	cepharanthine$$$724$$$737$$$I	dripping$$$738$$$746$$$O	pill$$$747$$$751$$$O	is$$$752$$$754$$$O	used$$$755$$$759$$$O	in$$$760$$$762$$$O	treating$$$763$$$771$$$O	chemotherapy$$$772$$$784$$$O	caused$$$785$$$791$$$O	leucopenia,$$$792$$$803$$$O	and$$$804$$$807$$$O	has$$$808$$$811$$$O	the$$$812$$$815$$$O	features$$$816$$$824$$$O	of$$$825$$$827$$$O	less$$$828$$$832$$$O	side$$$833$$$837$$$O	effect,$$$838$$$845$$$O	low$$$846$$$849$$$O	dosage,$$$850$$$857$$$O	high$$$858$$$862$$$O	medicinal$$$863$$$872$$$O	effect,$$$873$$$880$$$O	etc.$$$881$$$885$$$O
CN103520099A
Long-acting$$$0$$$11$$$O	injection$$$12$$$21$$$O	agent$$$22$$$27$$$O	containing$$$28$$$38$$$O	valnemulin$$$39$$$49$$$I	serving$$$50$$$57$$$O	as$$$58$$$60$$$O	effective$$$61$$$70$$$O	component$$$71$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technology$$$29$$$39$$$O	that$$$40$$$44$$$O	sucrose$$$45$$$52$$$I	acetate$$$53$$$60$$$I	isobutyrate$$$61$$$72$$$I	is$$$73$$$75$$$O	applied$$$76$$$83$$$O	to$$$84$$$86$$$O	preparation$$$87$$$98$$$O	of$$$99$$$101$$$O	an$$$102$$$104$$$O	oily$$$105$$$109$$$O	injection$$$110$$$119$$$O	agent$$$120$$$125$$$O	for$$$126$$$129$$$O	animals,$$$130$$$138$$$O	in$$$139$$$141$$$O	particular$$$142$$$152$$$O	to$$$153$$$155$$$O	the$$$156$$$159$$$O	technology$$$160$$$170$$$O	which$$$171$$$176$$$O	combines$$$177$$$185$$$O	the$$$186$$$189$$$O	sucrose$$$190$$$197$$$I	acetate$$$198$$$205$$$I	isobutyrate$$$206$$$217$$$I	with$$$218$$$222$$$O	hydrogenated$$$223$$$235$$$O	castor$$$236$$$242$$$O	oil$$$243$$$246$$$O	or$$$247$$$249$$$O	aluminium$$$250$$$259$$$I	stearate$$$260$$$268$$$I	and$$$269$$$272$$$O	is$$$273$$$275$$$O	used$$$276$$$280$$$O	for$$$281$$$284$$$O	preparing$$$285$$$294$$$O	a$$$295$$$296$$$O	long-acting$$$297$$$308$$$O	injection$$$309$$$318$$$O	agent$$$319$$$324$$$O	containing$$$325$$$335$$$O	valnemulin.$$$336$$$347$$$I	A$$$348$$$349$$$O	dispersion$$$350$$$360$$$O	medium$$$361$$$367$$$O	of$$$368$$$370$$$O	the$$$371$$$374$$$O	long-acting$$$375$$$386$$$O	injection$$$387$$$396$$$O	agent$$$397$$$402$$$O	is$$$403$$$405$$$O	isopropyl$$$406$$$415$$$I	myristate$$$416$$$425$$$I	or$$$426$$$428$$$O	benzyl$$$429$$$435$$$I	benzoate$$$436$$$444$$$I	or$$$445$$$447$$$O	ethyl$$$448$$$453$$$I	oleate$$$454$$$460$$$I	or$$$461$$$463$$$O	a$$$464$$$465$$$O	mixture$$$466$$$473$$$O	mixing$$$474$$$480$$$O	more$$$481$$$485$$$O	than$$$486$$$490$$$O	one$$$491$$$494$$$O	of$$$495$$$497$$$O	isopropyl$$$498$$$507$$$I	myristate,$$$508$$$518$$$I	benzyl$$$519$$$525$$$I	benzoate$$$526$$$534$$$I	and$$$535$$$538$$$O	ethyl$$$539$$$544$$$I	oleate.$$$545$$$552$$$I	The$$$553$$$556$$$O	injection$$$557$$$566$$$O	agent$$$567$$$572$$$O	is$$$573$$$575$$$O	good$$$576$$$580$$$O	in$$$581$$$583$$$O	sustained$$$584$$$593$$$O	release$$$594$$$601$$$O	effect,$$$602$$$609$$$O	stable$$$610$$$616$$$O	in$$$617$$$619$$$O	character,$$$620$$$630$$$O	good$$$631$$$635$$$O	in$$$636$$$638$$$O	histocompatibility$$$639$$$657$$$O	and$$$658$$$661$$$O	easy$$$662$$$666$$$O	to$$$667$$$669$$$O	prepare.$$$670$$$678$$$O
US20080108596
Antiserotonine$$$0$$$14$$$O	agents;$$$15$$$22$$$O	psycholgical$$$23$$$35$$$O	disorders;$$$36$$$46$$$O	headaches;$$$47$$$57$$$O	kits$$$58$$$62$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	combination$$$35$$$46$$$O	comprising$$$47$$$57$$$O	quetiapine$$$58$$$68$$$O	or$$$69$$$71$$$O	a$$$72$$$73$$$O	pharmaceutically$$$74$$$90$$$O	acceptable$$$91$$$101$$$O	salt$$$102$$$106$$$O	thereof$$$107$$$114$$$O	and$$$115$$$118$$$O	zolmitriptan$$$119$$$131$$$I	or$$$132$$$134$$$O	a$$$135$$$136$$$O	pharmaceutically$$$137$$$153$$$O	acceptable$$$154$$$164$$$O	salt$$$165$$$169$$$O	thereof,$$$170$$$178$$$O	pharmaceutical$$$179$$$193$$$O	compositions,$$$194$$$207$$$O	processes$$$208$$$217$$$O	for$$$218$$$221$$$O	its$$$222$$$225$$$O	preparation,$$$226$$$238$$$O	the$$$239$$$242$$$O	use$$$243$$$246$$$O	thereof$$$247$$$254$$$O	in$$$255$$$257$$$O	the$$$258$$$261$$$O	manufacture$$$262$$$273$$$O	of$$$274$$$276$$$O	a$$$277$$$278$$$O	medicament$$$279$$$289$$$O	and$$$290$$$293$$$O	a$$$294$$$295$$$O	method$$$296$$$302$$$O	of$$$303$$$305$$$O	treatment$$$306$$$315$$$O	of$$$316$$$318$$$O	disease$$$319$$$326$$$O	and$$$327$$$330$$$O	more$$$331$$$335$$$O	particularly$$$336$$$348$$$O	to$$$349$$$351$$$O	a$$$352$$$353$$$O	method$$$354$$$360$$$O	of$$$361$$$363$$$O	treatment$$$364$$$373$$$O	of$$$374$$$376$$$O	diseases$$$377$$$385$$$O	typically$$$386$$$395$$$O	treated$$$396$$$403$$$O	with$$$404$$$408$$$O	5-HT1D$$$409$$$415$$$O	agonists$$$416$$$424$$$O	and/or$$$425$$$431$$$O	atypical$$$432$$$440$$$O	antipsychotics,$$$441$$$456$$$O	in$$$457$$$459$$$O	particularly,$$$460$$$473$$$O	migraine,$$$474$$$483$$$O	related$$$484$$$491$$$O	conditions$$$492$$$502$$$O	and$$$503$$$506$$$O	for$$$507$$$510$$$O	reducing$$$511$$$519$$$O	or$$$520$$$522$$$O	eliminating$$$523$$$534$$$O	of$$$535$$$537$$$O	migraine$$$538$$$546$$$O	recurrence.$$$547$$$558$$$O
CN101225070A
Antineoplastic$$$0$$$14$$$O	medicament$$$15$$$25$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	drug$$$26$$$30$$$O	used$$$31$$$35$$$O	for$$$36$$$39$$$O	antitumor,$$$40$$$50$$$O	belonging$$$51$$$60$$$O	to$$$61$$$63$$$O	technical$$$64$$$73$$$O	field$$$74$$$79$$$O	of$$$80$$$82$$$O	medication$$$83$$$93$$$O	chemistry,$$$94$$$104$$$O	which$$$105$$$110$$$O	is$$$111$$$113$$$O	characterized$$$114$$$127$$$O	in$$$128$$$130$$$O	that:$$$131$$$136$$$O	2-substituted-3-hydroxy-2,$$$137$$$163$$$I	3-xylylenimine-1-ketone$$$164$$$187$$$I	(I),$$$188$$$192$$$O	6-substituted-5-hydroxy-5,$$$193$$$219$$$I	6-dihydropyrrolo$$$220$$$236$$$I	[3,$$$237$$$240$$$I	4-b]pyridine-7-ketone$$$241$$$262$$$I	(II),$$$263$$$268$$$O	6-substituted-5,$$$269$$$285$$$I	6-dihydropyrrolo$$$286$$$302$$$I	[3,$$$303$$$306$$$I	4-b]pyridine-7-ketone$$$307$$$328$$$I	(III),$$$329$$$335$$$O	6-substituted-5,$$$336$$$352$$$I	6-dihydropyrrolo$$$353$$$369$$$I	[3,$$$370$$$373$$$I	4-d]$$$374$$$378$$$I	pyrimidine$$$379$$$389$$$I	-7-ketone$$$390$$$399$$$I	(IV);$$$400$$$405$$$O	the$$$406$$$409$$$O	general$$$410$$$417$$$O	formula$$$418$$$425$$$O	of$$$426$$$428$$$O	the$$$429$$$432$$$O	structure$$$433$$$442$$$O	is$$$443$$$445$$$O	as$$$446$$$448$$$O	above.$$$449$$$455$$$O	The$$$456$$$459$$$O	drug$$$460$$$464$$$O	used$$$465$$$469$$$O	for$$$470$$$473$$$O	antitumor$$$474$$$483$$$O	has$$$484$$$487$$$O	the$$$488$$$491$$$O	advantages$$$492$$$502$$$O	of$$$503$$$505$$$O	having$$$506$$$512$$$O	higher$$$513$$$519$$$O	protein$$$520$$$527$$$O	kinase$$$528$$$534$$$O	inhibitory$$$535$$$545$$$O	activity,$$$546$$$555$$$O	easily$$$556$$$562$$$O	preparing,$$$563$$$573$$$O	conveniently$$$574$$$586$$$O	getting$$$587$$$594$$$O	raw$$$595$$$598$$$O	material,$$$599$$$608$$$O	easily$$$609$$$615$$$O	realizing$$$616$$$625$$$O	industrialization$$$626$$$643$$$O	and$$$644$$$647$$$O	meeting$$$648$$$655$$$O	requirements$$$656$$$668$$$O	of$$$669$$$671$$$O	preparing$$$672$$$681$$$O	drugs$$$682$$$687$$$O	treating$$$688$$$696$$$O	cancers$$$697$$$704$$$O	clinically.$$$705$$$716$$$O
WO2012075849A1
4',5-dihydroxy-7-[4-(n,$$$0$$$23$$$I	n-diethylamino)$$$24$$$39$$$I	butoxy]$$$40$$$47$$$I	isoflavones,$$$48$$$60$$$I	and$$$61$$$64$$$O	preparation$$$65$$$76$$$O	method$$$77$$$83$$$O	and$$$84$$$87$$$O	application$$$88$$$99$$$O	thereof$$$100$$$107$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	genistein$$$15$$$24$$$I	derivative,$$$25$$$36$$$O	4',5-dihydroxy-7-[4-(N,$$$37$$$60$$$I	N-diethylamino)$$$61$$$76$$$I	butoxy]$$$77$$$84$$$I	isoflavones,$$$85$$$97$$$I	and$$$98$$$101$$$O	a$$$102$$$103$$$O	preparation$$$104$$$115$$$O	method$$$116$$$122$$$O	and$$$123$$$126$$$O	application$$$127$$$138$$$O	thereof.$$$139$$$147$$$O	The$$$148$$$151$$$O	4',5-dihydroxy-7-[4-(N,$$$152$$$175$$$I	N-diethylamino)$$$176$$$191$$$I	butoxy]$$$192$$$199$$$I	isoflavones$$$200$$$211$$$I	is$$$212$$$214$$$O	acquired$$$215$$$223$$$O	via$$$224$$$227$$$O	chemical$$$228$$$236$$$O	modification$$$237$$$249$$$O	of$$$250$$$252$$$O	genistein,$$$253$$$263$$$I	has$$$264$$$267$$$O	acetylcholinesterase$$$268$$$288$$$O	inhibiting$$$289$$$299$$$O	activity,$$$300$$$309$$$O	and$$$310$$$313$$$O	estrogenic$$$314$$$324$$$O	activity,$$$325$$$334$$$O	and$$$335$$$338$$$O	offers$$$339$$$345$$$O	protection$$$346$$$356$$$O	for$$$357$$$360$$$O	nerve$$$361$$$366$$$O	cells.$$$367$$$373$$$O	As$$$374$$$376$$$O	a$$$377$$$378$$$O	compound$$$379$$$387$$$O	having$$$388$$$394$$$O	multiple$$$395$$$403$$$O	active$$$404$$$410$$$O	target$$$411$$$417$$$O	sites,$$$418$$$424$$$O	the$$$425$$$428$$$O	compound$$$429$$$437$$$O	can$$$438$$$441$$$O	be$$$442$$$444$$$O	used$$$445$$$449$$$O	for$$$450$$$453$$$O	the$$$454$$$457$$$O	preparation$$$458$$$469$$$O	of$$$470$$$472$$$O	an$$$473$$$475$$$O	anti-Alzheimer$$$476$$$490$$$O	disease$$$491$$$498$$$O	medicament.$$$499$$$510$$$O
CN101856385A
Composition$$$0$$$11$$$O	containing$$$12$$$22$$$O	echinacea$$$23$$$32$$$O	extract$$$33$$$40$$$O	and$$$41$$$44$$$O	preparation$$$45$$$56$$$O	method$$$57$$$63$$$O	thereof$$$64$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	composition$$$26$$$37$$$O	containing$$$38$$$48$$$O	an$$$49$$$51$$$O	echinacea$$$52$$$61$$$O	extract$$$62$$$69$$$O	and$$$70$$$73$$$O	a$$$74$$$75$$$O	preparation$$$76$$$87$$$O	method$$$88$$$94$$$O	thereof.$$$95$$$103$$$O	The$$$104$$$107$$$O	composition$$$108$$$119$$$O	mainly$$$120$$$126$$$O	comprises$$$127$$$136$$$O	the$$$137$$$140$$$O	following$$$141$$$150$$$O	components$$$151$$$161$$$O	in$$$162$$$164$$$O	parts$$$165$$$170$$$O	by$$$171$$$173$$$O	weight:$$$174$$$181$$$O	1$$$182$$$183$$$O	part$$$184$$$188$$$O	of$$$189$$$191$$$O	echinacea$$$192$$$201$$$O	extract,$$$202$$$210$$$O	2$$$211$$$212$$$O	parts$$$213$$$218$$$O	of$$$219$$$221$$$O	astragalus$$$222$$$232$$$O	membranaceus$$$233$$$245$$$O	extract$$$246$$$253$$$O	and$$$254$$$257$$$O	a$$$258$$$259$$$O	little$$$260$$$266$$$O	quantity$$$267$$$275$$$O	of$$$276$$$278$$$O	lutein.$$$279$$$286$$$I	The$$$287$$$290$$$O	preparation$$$291$$$302$$$O	method$$$303$$$309$$$O	comprises$$$310$$$319$$$O	the$$$320$$$323$$$O	following$$$324$$$333$$$O	steps$$$334$$$339$$$O	of:$$$340$$$343$$$O	crushing$$$344$$$352$$$O	echinacea$$$353$$$362$$$O	raw$$$363$$$366$$$O	materials,$$$367$$$377$$$O	removing$$$378$$$386$$$O	impurity,$$$387$$$396$$$O	extracting$$$397$$$407$$$O	with$$$408$$$412$$$O	ethanol,$$$413$$$421$$$I	filtering$$$422$$$431$$$O	the$$$432$$$435$$$O	extracting$$$436$$$446$$$O	solution,$$$447$$$456$$$O	concentrating,$$$457$$$471$$$O	drying$$$472$$$478$$$O	and$$$479$$$482$$$O	crushing$$$483$$$491$$$O	to$$$492$$$494$$$O	obtain$$$495$$$501$$$O	the$$$502$$$505$$$O	echinacea$$$506$$$515$$$O	extract;$$$516$$$524$$$O	crushing$$$525$$$533$$$O	astragalus$$$534$$$544$$$O	membranaceus$$$545$$$557$$$O	raw$$$558$$$561$$$O	materials$$$562$$$571$$$O	,$$$572$$$573$$$O	decocting$$$574$$$583$$$O	with$$$584$$$588$$$O	water$$$589$$$594$$$O	to$$$595$$$597$$$O	obtain$$$598$$$604$$$O	an$$$605$$$607$$$O	extractive,$$$608$$$619$$$O	carrying$$$620$$$628$$$O	out$$$629$$$632$$$O	alcohol$$$633$$$640$$$O	precipitation$$$641$$$654$$$O	on$$$655$$$657$$$O	the$$$658$$$661$$$O	extractive$$$662$$$672$$$O	with$$$673$$$677$$$O	the$$$678$$$681$$$O	ethanol,$$$682$$$690$$$I	drying$$$691$$$697$$$O	the$$$698$$$701$$$O	precipitate$$$702$$$713$$$O	and$$$714$$$717$$$O	crushing$$$718$$$726$$$O	to$$$727$$$729$$$O	obtain$$$730$$$736$$$O	an$$$737$$$739$$$O	astragalus$$$740$$$750$$$O	membranaceus$$$751$$$763$$$O	extract;$$$764$$$772$$$O	and$$$773$$$776$$$O	weighing$$$777$$$785$$$O	the$$$786$$$789$$$O	extracts$$$790$$$798$$$O	by$$$799$$$801$$$O	the$$$802$$$805$$$O	parts,$$$806$$$812$$$O	adding$$$813$$$819$$$O	the$$$820$$$823$$$O	lutein,$$$824$$$831$$$I	and$$$832$$$835$$$O	mixing$$$836$$$842$$$O	to$$$843$$$845$$$O	prepare$$$846$$$853$$$O	a$$$854$$$855$$$O	preparation$$$856$$$867$$$O	of$$$868$$$870$$$O	the$$$871$$$874$$$O	combination$$$875$$$886$$$O	containing$$$887$$$897$$$O	the$$$898$$$901$$$O	echinacea$$$902$$$911$$$O	extract$$$912$$$919$$$O	which$$$920$$$925$$$O	can$$$926$$$929$$$O	accepted$$$930$$$938$$$O	by$$$939$$$941$$$O	a$$$942$$$943$$$O	human$$$944$$$949$$$O	body.$$$950$$$955$$$O	The$$$956$$$959$$$O	composition$$$960$$$971$$$O	has$$$972$$$975$$$O	favorable$$$976$$$985$$$O	function$$$986$$$994$$$O	on$$$995$$$997$$$O	enhancing$$$998$$$1007$$$O	the$$$1008$$$1011$$$O	human$$$1012$$$1017$$$O	immunity,$$$1018$$$1027$$$O	improves$$$1028$$$1036$$$O	the$$$1037$$$1040$$$O	taste$$$1041$$$1046$$$O	and$$$1047$$$1050$$$O	the$$$1051$$$1054$$$O	smell$$$1055$$$1060$$$O	of$$$1061$$$1063$$$O	the$$$1064$$$1067$$$O	echinacea$$$1068$$$1077$$$O	extract$$$1078$$$1085$$$O	and$$$1086$$$1089$$$O	is$$$1090$$$1092$$$O	more$$$1093$$$1097$$$O	convenient$$$1098$$$1108$$$O	to$$$1109$$$1111$$$O	take.$$$1112$$$1117$$$O
US8389484
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	targeting$$$12$$$21$$$O	RNA$$$22$$$25$$$O	molecules$$$26$$$35$$$O
Described$$$0$$$9$$$O	are$$$10$$$13$$$O	methods$$$14$$$21$$$O	for$$$22$$$25$$$O	identifying$$$26$$$37$$$O	targets$$$38$$$45$$$O	in$$$46$$$48$$$O	RNA$$$49$$$52$$$O	molecules$$$53$$$62$$$O	based$$$63$$$68$$$O	on$$$69$$$71$$$O	differences$$$72$$$83$$$O	in$$$84$$$86$$$O	RNA$$$87$$$90$$$O	secondary$$$91$$$100$$$O	structure$$$101$$$110$$$O	related$$$111$$$118$$$O	to$$$119$$$121$$$O	sequence$$$122$$$130$$$O	variances$$$131$$$140$$$O	between$$$141$$$148$$$O	different$$$149$$$158$$$O	allelic$$$159$$$166$$$O	forms.$$$167$$$173$$$O	Also$$$174$$$178$$$O	described$$$179$$$188$$$O	are$$$189$$$192$$$O	methods$$$193$$$200$$$O	for$$$201$$$204$$$O	identifying$$$205$$$216$$$O	or$$$217$$$219$$$O	developing$$$220$$$230$$$O	small$$$231$$$236$$$O	molecules$$$237$$$246$$$O	which$$$247$$$252$$$O	can$$$253$$$256$$$O	be$$$257$$$259$$$O	used$$$260$$$264$$$O	to$$$265$$$267$$$O	modulate$$$268$$$276$$$O	a$$$277$$$278$$$O	target$$$279$$$285$$$O	RNA$$$286$$$289$$$O	by$$$290$$$292$$$O	creation$$$293$$$301$$$O	of$$$302$$$304$$$O	protein-small-molecule-RNA$$$305$$$331$$$O	complexes,$$$332$$$342$$$O	as$$$343$$$345$$$O	well$$$346$$$350$$$O	as$$$351$$$353$$$O	compositions$$$354$$$366$$$O	which$$$367$$$372$$$O	include$$$373$$$380$$$O	such$$$381$$$385$$$O	small$$$386$$$391$$$O	molecules$$$392$$$401$$$O	and$$$402$$$405$$$O	methods$$$406$$$413$$$O	of$$$414$$$416$$$O	using$$$417$$$422$$$O	those$$$423$$$428$$$O	small$$$429$$$434$$$O	molecules$$$435$$$444$$$O	and$$$445$$$448$$$O	compositions.$$$449$$$462$$$O
US7223397
Administering$$$0$$$13$$$O	an$$$14$$$16$$$O	agent$$$17$$$22$$$O	which$$$23$$$28$$$O	upregulates$$$29$$$40$$$O	the$$$41$$$44$$$O	expression$$$45$$$55$$$O	of$$$56$$$58$$$O	a$$$59$$$60$$$O	cellular$$$61$$$69$$$O	target;$$$70$$$77$$$O	administering$$$78$$$91$$$O	a$$$92$$$93$$$O	dose$$$94$$$98$$$O	of$$$99$$$101$$$O	an$$$102$$$104$$$O	immunotoxin$$$105$$$116$$$O	directed$$$117$$$125$$$O	against$$$126$$$133$$$O	the$$$134$$$137$$$O	upregulated$$$138$$$149$$$O	cellular$$$150$$$158$$$O	target$$$159$$$165$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	the$$$37$$$40$$$O	use$$$41$$$44$$$O	of$$$45$$$47$$$O	agents$$$48$$$54$$$O	that$$$55$$$59$$$O	induce$$$60$$$66$$$O	high$$$67$$$71$$$O	levels$$$72$$$78$$$O	of$$$79$$$81$$$O	cell$$$82$$$86$$$O	surface$$$87$$$94$$$O	molecules$$$95$$$104$$$O	to$$$105$$$107$$$O	provide$$$108$$$115$$$O	targets$$$116$$$123$$$O	for$$$124$$$127$$$O	immunotoxins$$$128$$$140$$$O	directed$$$141$$$149$$$O	against$$$150$$$157$$$O	the$$$158$$$161$$$O	same$$$162$$$166$$$O	cell$$$167$$$171$$$O	surface$$$172$$$179$$$O	molecules.$$$180$$$190$$$O	A$$$191$$$192$$$O	specific$$$193$$$201$$$O	example$$$202$$$209$$$O	is$$$210$$$212$$$O	given$$$213$$$218$$$O	in$$$219$$$221$$$O	which$$$222$$$227$$$O	all-trans-retinoic$$$228$$$246$$$I	acid$$$247$$$251$$$I	(RA)$$$252$$$256$$$I	is$$$257$$$259$$$O	used$$$260$$$264$$$O	to$$$265$$$267$$$O	induce$$$268$$$274$$$O	high$$$275$$$279$$$O	levels$$$280$$$286$$$O	of$$$287$$$289$$$O	CD38$$$290$$$294$$$O	cell$$$295$$$299$$$O	surface$$$300$$$307$$$O	antigen$$$308$$$315$$$O	expression$$$316$$$326$$$O	in$$$327$$$329$$$O	several$$$330$$$337$$$O	myeloid$$$338$$$345$$$O	and$$$346$$$349$$$O	lymphoid$$$350$$$358$$$O	leukemia$$$359$$$367$$$O	cells.$$$368$$$374$$$O	CD38$$$375$$$379$$$O	was$$$380$$$383$$$O	then$$$384$$$388$$$O	used$$$389$$$393$$$O	as$$$394$$$396$$$O	target$$$397$$$403$$$O	for$$$404$$$407$$$O	delivering$$$408$$$418$$$O	plant$$$419$$$424$$$O	toxin$$$425$$$430$$$O	(gelonin)$$$431$$$440$$$O	to$$$441$$$443$$$O	leukemia$$$444$$$452$$$O	cells.$$$453$$$459$$$O	Treatment$$$460$$$469$$$O	of$$$470$$$472$$$O	leukemia$$$473$$$481$$$O	cells$$$482$$$487$$$O	with$$$488$$$492$$$O	RA$$$493$$$495$$$O	induced$$$496$$$503$$$O	high$$$504$$$508$$$O	levels$$$509$$$515$$$O	of$$$516$$$518$$$O	CD38$$$519$$$523$$$O	in$$$524$$$526$$$O	those$$$527$$$532$$$O	cells$$$533$$$538$$$O	that$$$539$$$543$$$O	otherwise$$$544$$$553$$$O	had$$$554$$$557$$$O	low$$$558$$$561$$$O	CD38$$$562$$$566$$$O	expression.$$$567$$$578$$$O	The$$$579$$$582$$$O	RA-induced$$$583$$$593$$$O	leukemia$$$594$$$602$$$O	cells$$$603$$$608$$$O	then$$$609$$$613$$$O	became$$$614$$$620$$$O	exquisitely$$$621$$$632$$$O	sensitive$$$633$$$642$$$O	to$$$643$$$645$$$O	an$$$646$$$648$$$O	immunotoxin$$$649$$$660$$$O	constructed$$$661$$$672$$$O	from$$$673$$$677$$$O	an$$$678$$$680$$$O	anti-CD38$$$681$$$690$$$O	monoclonal$$$691$$$701$$$O	antibody$$$702$$$710$$$O	conjugated$$$711$$$721$$$O	to$$$722$$$724$$$O	the$$$725$$$728$$$O	plant$$$729$$$734$$$O	toxin$$$735$$$740$$$O	gelonin.$$$741$$$749$$$O
CN102451351A
Recipe$$$0$$$6$$$O	for$$$7$$$10$$$O	immunity$$$11$$$19$$$O	regulation$$$20$$$30$$$O	medicine$$$31$$$39$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	recipe$$$25$$$31$$$O	for$$$32$$$35$$$O	immunity$$$36$$$44$$$O	regulation$$$45$$$55$$$O	medicine,$$$56$$$65$$$O	which$$$66$$$71$$$O	relates$$$72$$$79$$$O	to$$$80$$$82$$$O	the$$$83$$$86$$$O	field$$$87$$$92$$$O	of$$$93$$$95$$$O	medicine.$$$96$$$105$$$O	The$$$106$$$109$$$O	recipe$$$110$$$116$$$O	is$$$117$$$119$$$O	prepared$$$120$$$128$$$O	from$$$129$$$133$$$O	85.3g$$$134$$$139$$$O	to$$$140$$$142$$$O	95.8g$$$143$$$148$$$O	of$$$149$$$151$$$O	garlic$$$152$$$158$$$O	chive$$$159$$$164$$$O	extracts,$$$165$$$174$$$O	70g$$$175$$$178$$$O	to$$$179$$$181$$$O	85g$$$182$$$185$$$O	of$$$186$$$188$$$O	ginseng$$$189$$$196$$$O	extracts,$$$197$$$206$$$O	105g$$$207$$$211$$$O	to$$$212$$$214$$$O	120g$$$215$$$219$$$O	of$$$220$$$222$$$O	epimedium$$$223$$$232$$$O	extracts,$$$233$$$242$$$O	70g$$$243$$$246$$$O	to$$$247$$$249$$$O	85g$$$250$$$253$$$O	of$$$254$$$256$$$O	arginine,$$$257$$$266$$$O	130g$$$267$$$271$$$O	to$$$272$$$274$$$O	145g$$$275$$$279$$$O	of$$$280$$$282$$$O	beta-cyclodextrin,$$$283$$$301$$$O	185g$$$302$$$306$$$O	to$$$307$$$309$$$O	200g$$$310$$$314$$$O	of$$$315$$$317$$$O	sorbitol$$$318$$$326$$$I	and$$$327$$$330$$$O	4.5g$$$331$$$335$$$O	to$$$336$$$338$$$O	6.5g$$$339$$$343$$$O	of$$$344$$$346$$$O	magnesium$$$347$$$356$$$I	stearate.$$$357$$$366$$$I	The$$$367$$$370$$$O	recipe$$$371$$$377$$$O	has$$$378$$$381$$$O	a$$$382$$$383$$$O	good$$$384$$$388$$$O	effect$$$389$$$395$$$O	on$$$396$$$398$$$O	enhancing$$$399$$$408$$$O	the$$$409$$$412$$$O	immunity$$$413$$$421$$$O	of$$$422$$$424$$$O	human$$$425$$$430$$$O	bodies$$$431$$$437$$$O	and$$$438$$$441$$$O	has$$$442$$$445$$$O	a$$$446$$$447$$$O	cold$$$448$$$452$$$O	and$$$453$$$456$$$O	heat$$$457$$$461$$$O	stress$$$462$$$468$$$O	resistance$$$469$$$479$$$O	effect$$$480$$$486$$$O	on$$$487$$$489$$$O	treating$$$490$$$498$$$O	symptoms$$$499$$$507$$$O	such$$$508$$$512$$$O	as$$$513$$$515$$$O	immunity$$$516$$$524$$$O	hypofunction$$$525$$$537$$$O	and$$$538$$$541$$$O	the$$$542$$$545$$$O	like$$$546$$$550$$$O	of$$$551$$$553$$$O	cancer$$$554$$$560$$$O	patients,$$$561$$$570$$$O	caused$$$571$$$577$$$O	by$$$578$$$580$$$O	radiation$$$581$$$590$$$O	treatment$$$591$$$600$$$O	and$$$601$$$604$$$O	chemo-treatment,$$$605$$$621$$$O	and$$$622$$$625$$$O	simultaneously,$$$626$$$641$$$O	the$$$642$$$645$$$O	effects$$$646$$$653$$$O	of$$$654$$$656$$$O	inhabiting$$$657$$$667$$$O	the$$$668$$$671$$$O	senescence$$$672$$$682$$$O	and$$$683$$$686$$$O	enhancing$$$687$$$696$$$O	the$$$697$$$700$$$O	activity$$$701$$$709$$$O	of$$$710$$$712$$$O	superficial$$$713$$$724$$$O	cells$$$725$$$730$$$O	of$$$731$$$733$$$O	the$$$734$$$737$$$O	human$$$738$$$743$$$O	bodies$$$744$$$750$$$O	are$$$751$$$754$$$O	realized.$$$755$$$764$$$O
CN1718244A
Activated$$$0$$$9$$$O	carbon$$$10$$$16$$$I	external$$$17$$$25$$$O	application$$$26$$$37$$$O	antiphlogistine,$$$38$$$54$$$O	and$$$55$$$58$$$O	its$$$59$$$62$$$O	prepn.$$$63$$$69$$$O	method$$$70$$$76$$$O
An$$$0$$$2$$$O	exterior-applied$$$3$$$19$$$O	anti-inflammatory$$$20$$$37$$$O	ointment$$$38$$$46$$$O	for$$$47$$$50$$$O	treating$$$51$$$59$$$O	the$$$60$$$63$$$O	inflammatory$$$64$$$76$$$O	wound$$$77$$$82$$$O	is$$$83$$$85$$$O	prepared$$$86$$$94$$$O	from$$$95$$$99$$$O	granular$$$100$$$108$$$O	activated$$$109$$$118$$$O	carbon$$$119$$$125$$$I	(10-80%),$$$126$$$135$$$O	antibacterial$$$136$$$149$$$O	and$$$150$$$153$$$O	anti-inflammatory$$$154$$$171$$$O	medicine$$$172$$$180$$$O	(5-20%)$$$181$$$188$$$O	and$$$189$$$192$$$O	matrix$$$193$$$199$$$O	(10-80%)$$$200$$$208$$$O	through$$$209$$$216$$$O	sequential$$$217$$$227$$$O	mixing$$$228$$$234$$$O	and$$$235$$$238$$$O	stirring.$$$239$$$248$$$O
EP0941093B1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	nk-1$$$7$$$11$$$O	receptor$$$12$$$20$$$O	antagonists$$$21$$$32$$$O	for$$$33$$$36$$$O	treating$$$37$$$45$$$O	major$$$46$$$51$$$O	depressive$$$52$$$62$$$O	disorders$$$63$$$72$$$O	with$$$73$$$77$$$O	anxiety$$$78$$$85$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	the$$$31$$$34$$$O	use$$$35$$$38$$$O	of$$$39$$$41$$$O	an$$$42$$$44$$$O	orally$$$45$$$51$$$O	active,$$$52$$$59$$$O	long$$$60$$$64$$$O	acting,$$$65$$$72$$$O	CNS-penetrant$$$73$$$86$$$O	NK-1$$$87$$$91$$$O	receptor$$$92$$$100$$$O	antagonist$$$101$$$111$$$O	for$$$112$$$115$$$O	the$$$116$$$119$$$O	manufacture$$$120$$$131$$$O	of$$$132$$$134$$$O	a$$$135$$$136$$$O	medicament$$$137$$$147$$$O	adapted$$$148$$$155$$$O	for$$$156$$$159$$$O	oral$$$160$$$164$$$O	administration$$$165$$$179$$$O	for$$$180$$$183$$$O	the$$$184$$$187$$$O	treatment$$$188$$$197$$$O	or$$$198$$$200$$$O	prevention$$$201$$$211$$$O	of$$$212$$$214$$$O	major$$$215$$$220$$$O	depressive$$$221$$$231$$$O	disorder$$$232$$$240$$$O	with$$$241$$$245$$$O	anxiety$$$246$$$253$$$O	without$$$254$$$261$$$O	concomitant$$$262$$$273$$$O	therapy$$$274$$$281$$$O	with$$$282$$$286$$$O	other$$$287$$$292$$$O	anti-depressant$$$293$$$308$$$O	or$$$309$$$311$$$O	anti-anxiety$$$312$$$324$$$O	agents,$$$325$$$332$$$O	methods$$$333$$$340$$$O	of$$$341$$$343$$$O	treatment$$$344$$$353$$$O	using$$$354$$$359$$$O	such$$$360$$$364$$$O	a$$$365$$$366$$$O	NK-1$$$367$$$371$$$O	receptor$$$372$$$380$$$O	antagonist$$$381$$$391$$$O	and$$$392$$$395$$$O	pharmaceutical$$$396$$$410$$$O	compositions$$$411$$$423$$$O	comprising$$$424$$$434$$$O	the$$$435$$$438$$$O	same.$$$439$$$444$$$O
CN102144988A
Chitosan$$$0$$$8$$$O	cervix$$$9$$$15$$$O	uteri$$$16$$$21$$$O	anti-microbial$$$22$$$36$$$O	membrane$$$37$$$45$$$O	and$$$46$$$49$$$O	preparation$$$50$$$61$$$O	method$$$62$$$68$$$O	thereof$$$69$$$76$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	chitosan$$$26$$$34$$$O	cervix$$$35$$$41$$$O	uteri$$$42$$$47$$$O	anti-microbial$$$48$$$62$$$O	membrane$$$63$$$71$$$O	and$$$72$$$75$$$O	a$$$76$$$77$$$O	preparation$$$78$$$89$$$O	method$$$90$$$96$$$O	thereof.$$$97$$$105$$$O	The$$$106$$$109$$$O	chitosan$$$110$$$118$$$O	cervix$$$119$$$125$$$O	uteri$$$126$$$131$$$O	anti-microbial$$$132$$$146$$$O	membrane$$$147$$$155$$$O	has$$$156$$$159$$$O	a$$$160$$$161$$$O	structure$$$162$$$171$$$O	of$$$172$$$174$$$O	a$$$175$$$176$$$O	circular$$$177$$$185$$$O	plate,$$$186$$$192$$$O	bulged$$$193$$$199$$$O	flangings$$$200$$$209$$$O	are$$$210$$$213$$$O	formed$$$214$$$220$$$O	at$$$221$$$223$$$O	the$$$224$$$227$$$O	periphery$$$228$$$237$$$O	of$$$238$$$240$$$O	the$$$241$$$244$$$O	circular$$$245$$$253$$$O	plate,$$$254$$$260$$$O	and$$$261$$$264$$$O	a$$$265$$$266$$$O	convex$$$267$$$273$$$O	body$$$274$$$278$$$O	is$$$279$$$281$$$O	arranged$$$282$$$290$$$O	in$$$291$$$293$$$O	the$$$294$$$297$$$O	center$$$298$$$304$$$O	of$$$305$$$307$$$O	the$$$308$$$311$$$O	reverse$$$312$$$319$$$O	side$$$320$$$324$$$O	of$$$325$$$327$$$O	the$$$328$$$331$$$O	circular$$$332$$$340$$$O	plate.$$$341$$$347$$$O	The$$$348$$$351$$$O	chitosan$$$352$$$360$$$O	cervix$$$361$$$367$$$O	uteri$$$368$$$373$$$O	anti-microbial$$$374$$$388$$$O	membrane$$$389$$$397$$$O	is$$$398$$$400$$$O	prepared$$$401$$$409$$$O	from$$$410$$$414$$$O	the$$$415$$$418$$$O	following$$$419$$$428$$$O	raw$$$429$$$432$$$O	materials$$$433$$$442$$$O	in$$$443$$$445$$$O	percentage$$$446$$$456$$$O	by$$$457$$$459$$$O	mass:$$$460$$$465$$$O	0.5$$$466$$$469$$$O	to$$$470$$$472$$$O	5.0$$$473$$$476$$$O	percent$$$477$$$484$$$O	of$$$485$$$487$$$O	chitosan$$$488$$$496$$$O	iodine,$$$497$$$504$$$O	2.0$$$505$$$508$$$O	to$$$509$$$511$$$O	10.0$$$512$$$516$$$O	percent$$$517$$$524$$$O	of$$$525$$$527$$$O	polysorbate-20,$$$528$$$543$$$I	0.1$$$544$$$547$$$O	to$$$548$$$550$$$O	2.0$$$551$$$554$$$O	percent$$$555$$$562$$$O	of$$$563$$$565$$$O	acetic$$$566$$$572$$$I	acid,$$$573$$$578$$$I	0.1$$$579$$$582$$$O	to$$$583$$$585$$$O	5.0$$$586$$$589$$$O	percent$$$590$$$597$$$O	of$$$598$$$600$$$O	hydroxypropyl$$$601$$$614$$$O	methyl$$$615$$$621$$$O	cellulose,$$$622$$$632$$$O	1.0$$$633$$$636$$$O	to$$$637$$$639$$$O	10.0$$$640$$$644$$$O	percent$$$645$$$652$$$O	of$$$653$$$655$$$O	gelatin,$$$656$$$664$$$I	1.0$$$665$$$668$$$O	to$$$669$$$671$$$O	10.0$$$672$$$676$$$O	percent$$$677$$$684$$$O	of$$$685$$$687$$$O	glycerol$$$688$$$696$$$I	and$$$697$$$700$$$O	the$$$701$$$704$$$O	balance$$$705$$$712$$$O	of$$$713$$$715$$$O	purified$$$716$$$724$$$O	water.$$$725$$$731$$$O	The$$$732$$$735$$$O	chitosan$$$736$$$744$$$O	cervix$$$745$$$751$$$O	uteri$$$752$$$757$$$O	anti-microbial$$$758$$$772$$$O	membrane$$$773$$$781$$$O	is$$$782$$$784$$$O	prepared$$$785$$$793$$$O	from$$$794$$$798$$$O	novel$$$799$$$804$$$O	biological$$$805$$$815$$$O	materials$$$816$$$825$$$O	synthesized$$$826$$$837$$$O	by$$$838$$$840$$$O	the$$$841$$$844$$$O	chitosan$$$845$$$853$$$I	and$$$854$$$857$$$O	derivatives$$$858$$$869$$$O	thereof$$$870$$$877$$$O	by$$$878$$$880$$$O	processes$$$881$$$890$$$O	of$$$891$$$893$$$O	freezing,$$$894$$$903$$$O	vacuum$$$904$$$910$$$O	drying$$$911$$$917$$$O	and$$$918$$$921$$$O	the$$$922$$$925$$$O	like$$$926$$$930$$$O	according$$$931$$$940$$$O	to$$$941$$$943$$$O	characteristics$$$944$$$959$$$O	of$$$960$$$962$$$O	human$$$963$$$968$$$O	anatomy,$$$969$$$977$$$O	pathology,$$$978$$$988$$$O	physiology$$$989$$$999$$$O	and$$$1000$$$1003$$$O	the$$$1004$$$1007$$$O	like,$$$1008$$$1013$$$O	has$$$1014$$$1017$$$O	a$$$1018$$$1019$$$O	shape$$$1020$$$1025$$$O	of$$$1026$$$1028$$$O	a$$$1029$$$1030$$$O	thin$$$1031$$$1035$$$O	curved$$$1036$$$1042$$$O	surface,$$$1043$$$1051$$$O	and$$$1052$$$1055$$$O	can$$$1056$$$1059$$$O	be$$$1060$$$1062$$$O	in$$$1063$$$1065$$$O	full$$$1066$$$1070$$$O	fit$$$1071$$$1074$$$O	with$$$1075$$$1079$$$O	pathological$$$1080$$$1092$$$O	tissue,$$$1093$$$1100$$$O	absorb$$$1101$$$1107$$$O	wound$$$1108$$$1113$$$O	exudate$$$1114$$$1121$$$O	and$$$1122$$$1125$$$O	eliminate$$$1126$$$1135$$$O	necrotic$$$1136$$$1144$$$O	tissue$$$1145$$$1151$$$O	by$$$1152$$$1154$$$O	being$$$1155$$$1160$$$O	attached$$$1161$$$1169$$$O	to$$$1170$$$1172$$$O	cervix$$$1173$$$1179$$$O	uteri$$$1180$$$1185$$$O	surfaces$$$1186$$$1194$$$O	outside$$$1195$$$1202$$$O	uterine$$$1203$$$1210$$$O	cavities,$$$1211$$$1220$$$O	so$$$1221$$$1223$$$O	that$$$1224$$$1228$$$O	wounds$$$1229$$$1235$$$O	are$$$1236$$$1239$$$O	drained$$$1240$$$1247$$$O	fully;$$$1248$$$1254$$$O	and$$$1255$$$1258$$$O	sterilizing$$$1259$$$1270$$$O	inflammation-diminishing$$$1271$$$1295$$$O	active$$$1296$$$1302$$$O	factors$$$1303$$$1310$$$O	are$$$1311$$$1314$$$O	released$$$1315$$$1323$$$O	in$$$1324$$$1326$$$O	a$$$1327$$$1328$$$O	sustained$$$1329$$$1338$$$O	way$$$1339$$$1342$$$O	at$$$1343$$$1345$$$O	the$$$1346$$$1349$$$O	targeting$$$1350$$$1359$$$O	position$$$1360$$$1368$$$O	to$$$1369$$$1371$$$O	promote$$$1372$$$1379$$$O	wound$$$1380$$$1385$$$O	union$$$1386$$$1391$$$O	effectively.$$$1392$$$1404$$$O	The$$$1405$$$1408$$$O	chitosan$$$1409$$$1417$$$O	cervix$$$1418$$$1424$$$O	uteri$$$1425$$$1430$$$O	anti-microbial$$$1431$$$1445$$$O	membrane$$$1446$$$1454$$$O	is$$$1455$$$1457$$$O	suitable$$$1458$$$1466$$$O	for$$$1467$$$1470$$$O	patients$$$1471$$$1479$$$O	who$$$1480$$$1483$$$O	suffer$$$1484$$$1490$$$O	from$$$1491$$$1495$$$O	gynecological$$$1496$$$1509$$$O	cervical$$$1510$$$1518$$$O	diseases.$$$1519$$$1528$$$O
WO2008099874A1
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	comprising$$$27$$$37$$$O	pyrazine$$$38$$$46$$$I	derivative,$$$47$$$58$$$O	and$$$59$$$62$$$O	method$$$63$$$69$$$O	of$$$70$$$72$$$O	using$$$73$$$78$$$O	pyrazine$$$79$$$87$$$I	derivative$$$88$$$98$$$O	in$$$99$$$101$$$O	combination$$$102$$$113$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	pharmaceutical$$$15$$$29$$$O	composition$$$30$$$41$$$O	comprising$$$42$$$52$$$O	a$$$53$$$54$$$O	pyrazine$$$55$$$63$$$I	derivative$$$64$$$74$$$O	represented$$$75$$$86$$$O	by$$$87$$$89$$$O	the$$$90$$$93$$$O	general$$$94$$$101$$$O	formula:$$$102$$$110$$$O	[wherein$$$114$$$122$$$O	R1$$$123$$$125$$$O	and$$$126$$$129$$$O	R2$$$130$$$132$$$O	independently$$$133$$$146$$$O	represent$$$147$$$156$$$O	a$$$157$$$158$$$O	hydrogen$$$159$$$167$$$I	atom$$$168$$$172$$$O	or$$$173$$$175$$$O	a$$$176$$$177$$$O	halogen$$$178$$$185$$$I	atom;$$$186$$$191$$$O	and$$$192$$$195$$$O	R3$$$196$$$198$$$O	represents$$$199$$$209$$$O	a$$$210$$$211$$$O	hydrogen$$$212$$$220$$$I	atom$$$221$$$225$$$O	or$$$226$$$228$$$O	an$$$229$$$231$$$O	amino-protecting$$$232$$$248$$$I	group]$$$249$$$255$$$O	or$$$256$$$258$$$O	a$$$259$$$260$$$O	salt$$$261$$$265$$$O	thereof$$$266$$$273$$$O	and$$$274$$$277$$$O	at$$$278$$$280$$$O	least$$$281$$$286$$$O	one$$$287$$$290$$$O	neuraminidase$$$291$$$304$$$O	inhibitor.$$$305$$$315$$$O	The$$$317$$$320$$$O	pharmaceutical$$$321$$$335$$$O	composition$$$336$$$347$$$O	is$$$348$$$350$$$O	useful$$$351$$$357$$$O	for$$$358$$$361$$$O	a$$$362$$$363$$$O	treatment$$$364$$$373$$$O	including$$$374$$$383$$$O	the$$$384$$$387$$$O	treatment$$$388$$$397$$$O	or$$$398$$$400$$$O	prevention$$$401$$$411$$$O	of$$$412$$$414$$$O	influenza.$$$415$$$425$$$O	Also$$$427$$$431$$$O	disclosed$$$432$$$441$$$O	is$$$442$$$444$$$O	a$$$445$$$446$$$O	method$$$447$$$453$$$O	of$$$454$$$456$$$O	using$$$457$$$462$$$O	these$$$463$$$468$$$O	components$$$469$$$479$$$O	in$$$480$$$482$$$O	combination.$$$483$$$495$$$O	The$$$497$$$500$$$O	method$$$501$$$507$$$O	is$$$508$$$510$$$O	useful$$$511$$$517$$$O	for$$$518$$$521$$$O	a$$$522$$$523$$$O	treatment$$$524$$$533$$$O	including$$$534$$$543$$$O	the$$$544$$$547$$$O	treatment$$$548$$$557$$$O	or$$$558$$$560$$$O	prevention$$$561$$$571$$$O	of$$$572$$$574$$$O	influenza.$$$575$$$585$$$O
CN103705523A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	prostacyclin$$$15$$$27$$$I	and$$$28$$$31$$$O	analogues$$$32$$$41$$$O	in$$$42$$$44$$$O	in-vitro$$$45$$$53$$$O	inhibition$$$54$$$64$$$O	of$$$65$$$67$$$O	proliferation$$$68$$$81$$$O	of$$$82$$$84$$$O	cardiac$$$85$$$92$$$O	fibroblasts$$$93$$$104$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	application$$$27$$$38$$$O	of$$$39$$$41$$$O	prostacyclin$$$42$$$54$$$I	and$$$55$$$58$$$O	analogues$$$59$$$68$$$O	in$$$69$$$71$$$O	in-vitro$$$72$$$80$$$O	inhibition$$$81$$$91$$$O	of$$$92$$$94$$$O	proliferation$$$95$$$108$$$O	of$$$109$$$111$$$O	cardiac$$$112$$$119$$$O	fibroblasts.$$$120$$$132$$$O	The$$$133$$$136$$$O	invention$$$137$$$146$$$O	explores$$$147$$$155$$$O	novel$$$156$$$161$$$O	medical$$$162$$$169$$$O	uses$$$170$$$174$$$O	of$$$175$$$177$$$O	prostacyclin$$$178$$$190$$$I	and$$$191$$$194$$$O	analogues$$$195$$$204$$$O	thereof$$$205$$$212$$$O	and$$$213$$$216$$$O	exploits$$$217$$$225$$$O	a$$$226$$$227$$$O	novel$$$228$$$233$$$O	application$$$234$$$245$$$O	field,$$$246$$$252$$$O	and$$$253$$$256$$$O	provides$$$257$$$265$$$O	significative$$$266$$$279$$$O	reference$$$280$$$289$$$O	for$$$290$$$293$$$O	inhibiting$$$294$$$304$$$O	proliferation$$$305$$$318$$$O	of$$$319$$$321$$$O	cardiac$$$322$$$329$$$O	muscle$$$330$$$336$$$O	fibers$$$337$$$343$$$O	and$$$344$$$347$$$O	improving$$$348$$$357$$$O	myocardial$$$358$$$368$$$O	remodeling.$$$369$$$380$$$O
CA2741984A1
Novel$$$0$$$5$$$O	and$$$6$$$9$$$O	potent$$$10$$$16$$$O	tapentadol$$$17$$$27$$$I	dosage$$$28$$$34$$$O	forms$$$35$$$40$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	dosage$$$33$$$39$$$O	form$$$40$$$44$$$O	comprising$$$45$$$55$$$O	at$$$56$$$58$$$O	least$$$59$$$64$$$O	one$$$65$$$68$$$O	form$$$69$$$73$$$O	of$$$74$$$76$$$O	tapentadol,$$$77$$$88$$$I	with$$$89$$$93$$$O	or$$$94$$$96$$$O	without$$$97$$$104$$$O	a$$$105$$$106$$$O	second$$$107$$$113$$$O	analgesic,$$$114$$$124$$$O	and$$$125$$$128$$$O	at$$$129$$$131$$$O	least$$$132$$$137$$$O	one$$$138$$$141$$$O	opioid$$$142$$$148$$$O	antagonist,$$$149$$$160$$$O	wherein$$$161$$$168$$$O	tapentadol$$$169$$$179$$$I	is$$$180$$$182$$$O	present$$$183$$$190$$$O	in$$$191$$$193$$$O	an$$$194$$$196$$$O	optimal$$$197$$$204$$$O	or$$$205$$$207$$$O	suboptimal$$$208$$$218$$$O	amount$$$219$$$225$$$O	and$$$226$$$229$$$O	the$$$230$$$233$$$O	said$$$234$$$238$$$O	antagonist$$$239$$$249$$$O	is$$$250$$$252$$$O	present$$$253$$$260$$$O	in$$$261$$$263$$$O	an$$$264$$$266$$$O	amount$$$267$$$273$$$O	effective$$$274$$$283$$$O	to$$$284$$$286$$$O	improve$$$287$$$294$$$O	the$$$295$$$298$$$O	efficacy$$$299$$$307$$$O	and$$$308$$$311$$$O	or$$$312$$$314$$$O	reduce$$$315$$$321$$$O	the$$$322$$$325$$$O	side$$$326$$$330$$$O	effects$$$331$$$338$$$O	of$$$339$$$341$$$O	tapentadol.$$$342$$$353$$$O	The$$$354$$$357$$$O	present$$$358$$$365$$$O	invention$$$366$$$375$$$O	further$$$376$$$383$$$O	provides$$$384$$$392$$$O	a$$$393$$$394$$$O	method$$$395$$$401$$$O	of$$$402$$$404$$$O	treating$$$405$$$413$$$O	pain$$$414$$$418$$$O	and$$$419$$$422$$$O	pain$$$423$$$427$$$O	related$$$428$$$435$$$O	conditions$$$436$$$446$$$O	by$$$447$$$449$$$O	administering$$$450$$$463$$$O	to$$$464$$$466$$$O	a$$$467$$$468$$$O	patient$$$469$$$476$$$O	in$$$477$$$479$$$O	need$$$480$$$484$$$O	thereof,$$$485$$$493$$$O	a$$$494$$$495$$$O	dosage$$$496$$$502$$$O	form$$$503$$$507$$$O	comprising$$$508$$$518$$$O	at$$$519$$$521$$$O	least$$$522$$$527$$$O	one$$$528$$$531$$$O	form$$$532$$$536$$$O	of$$$537$$$539$$$O	tapentadol,$$$540$$$551$$$I	with$$$552$$$556$$$O	or$$$557$$$559$$$O	without$$$560$$$567$$$O	a$$$568$$$569$$$O	second$$$570$$$576$$$O	analgesic,$$$577$$$587$$$O	and$$$588$$$591$$$O	at$$$592$$$594$$$O	least$$$595$$$600$$$O	one$$$601$$$604$$$O	opioid$$$605$$$611$$$O	antagonist,$$$612$$$623$$$O	wherein$$$624$$$631$$$O	tapentadol$$$632$$$642$$$I	is$$$643$$$645$$$O	present$$$646$$$653$$$O	in$$$654$$$656$$$O	an$$$657$$$659$$$O	optimal$$$660$$$667$$$O	or$$$668$$$670$$$O	suboptimal$$$671$$$681$$$O	amount$$$682$$$688$$$O	and$$$689$$$692$$$O	the$$$693$$$696$$$O	said$$$697$$$701$$$O	antagonist$$$702$$$712$$$O	is$$$713$$$715$$$O	present$$$716$$$723$$$O	in$$$724$$$726$$$O	an$$$727$$$729$$$O	amount$$$730$$$736$$$O	effective$$$737$$$746$$$O	to$$$747$$$749$$$O	improve$$$750$$$757$$$O	the$$$758$$$761$$$O	efficacy$$$762$$$770$$$O	and$$$771$$$774$$$O	or$$$775$$$777$$$O	reduce$$$778$$$784$$$O	the$$$785$$$788$$$O	side$$$789$$$793$$$O	effects$$$794$$$801$$$O	of$$$802$$$804$$$O	tapentadol.$$$805$$$816$$$I
US20100125096
Acetam$$$0$$$6$$$I	Derivatives$$$7$$$18$$$O	for$$$19$$$22$$$O	Pain$$$23$$$27$$$O	Relief$$$28$$$34$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	method$$$33$$$39$$$O	of$$$40$$$42$$$O	treatment,$$$43$$$53$$$O	prevention$$$54$$$64$$$O	and/or$$$65$$$71$$$O	delay$$$72$$$77$$$O	of$$$78$$$80$$$O	progression$$$81$$$92$$$O	of$$$93$$$95$$$O	neuropathic$$$96$$$107$$$O	pain$$$108$$$112$$$O	by$$$113$$$115$$$O	a$$$116$$$117$$$O	specific$$$118$$$126$$$O	dosing$$$127$$$133$$$O	regime$$$134$$$140$$$O	of$$$141$$$143$$$O	acetam$$$144$$$150$$$I	derivatives.$$$151$$$163$$$O
CN103494875A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	cyclocarya$$$15$$$25$$$O	paliurus$$$26$$$34$$$O	extract$$$35$$$42$$$O	in$$$43$$$45$$$O	preparation$$$46$$$57$$$O	of$$$58$$$60$$$O	medicament$$$61$$$71$$$O	for$$$72$$$75$$$O	preventing$$$76$$$86$$$O	and$$$87$$$90$$$O	treating$$$91$$$99$$$O	leukemia$$$100$$$108$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	the$$$24$$$27$$$O	application$$$28$$$39$$$O	of$$$40$$$42$$$O	cyclocarya$$$43$$$53$$$O	paliurus$$$54$$$62$$$O	extract$$$63$$$70$$$O	in$$$71$$$73$$$O	the$$$74$$$77$$$O	preparation$$$78$$$89$$$O	of$$$90$$$92$$$O	a$$$93$$$94$$$O	medicament$$$95$$$105$$$O	for$$$106$$$109$$$O	preventing$$$110$$$120$$$O	and$$$121$$$124$$$O	treating$$$125$$$133$$$O	leukemia.$$$134$$$143$$$O	High-content$$$144$$$156$$$O	cyclocarya$$$157$$$167$$$O	paliurus$$$168$$$176$$$O	extract$$$177$$$184$$$O	is$$$185$$$187$$$O	obtained$$$188$$$196$$$O	by$$$197$$$199$$$O	performing$$$200$$$210$$$O	the$$$211$$$214$$$O	purification$$$215$$$227$$$O	treatment$$$228$$$237$$$O	combined$$$238$$$246$$$O	of$$$247$$$249$$$O	water$$$250$$$255$$$O	extraction,$$$256$$$267$$$O	ethanol$$$268$$$275$$$I	extraction,$$$276$$$287$$$O	membrane$$$288$$$296$$$O	dialysis,$$$297$$$306$$$O	and$$$307$$$310$$$O	gel$$$311$$$314$$$O	chromatographic$$$315$$$330$$$O	column$$$331$$$337$$$O	on$$$338$$$340$$$O	cyclocarya$$$341$$$351$$$O	paliurus$$$352$$$360$$$O	leaves.$$$361$$$368$$$O	The$$$369$$$372$$$O	cyclocarya$$$373$$$383$$$O	paliurus$$$384$$$392$$$O	extract$$$393$$$400$$$O	contains$$$401$$$409$$$O	90$$$410$$$412$$$O	to$$$413$$$415$$$O	98$$$416$$$418$$$O	percent$$$419$$$426$$$O	of$$$427$$$429$$$O	polysaccharide;$$$430$$$445$$$O	killing$$$446$$$453$$$O	activity$$$454$$$462$$$O	detection$$$463$$$472$$$O	experiments$$$473$$$484$$$O	show$$$485$$$489$$$O	that$$$490$$$494$$$O	the$$$495$$$498$$$O	cyclocarya$$$499$$$509$$$O	paliurus$$$510$$$518$$$O	extract$$$519$$$526$$$O	can$$$527$$$530$$$O	be$$$531$$$533$$$O	used$$$534$$$538$$$O	for$$$539$$$542$$$O	improving$$$543$$$552$$$O	the$$$553$$$556$$$O	activity$$$557$$$565$$$O	of$$$566$$$568$$$O	the$$$569$$$572$$$O	splenocytes$$$573$$$584$$$O	for$$$585$$$588$$$O	killing$$$589$$$596$$$O	human$$$597$$$602$$$O	leukemia$$$603$$$611$$$O	cells$$$612$$$617$$$O	K652$$$618$$$622$$$O	in$$$623$$$625$$$O	vitro;$$$626$$$632$$$O	the$$$633$$$636$$$O	killing$$$637$$$644$$$O	multiples$$$645$$$654$$$O	can$$$655$$$658$$$O	reach$$$659$$$664$$$O	2.47$$$665$$$669$$$O	to$$$670$$$672$$$O	the$$$673$$$676$$$O	maximum.$$$677$$$685$$$O	After$$$686$$$691$$$O	granules,$$$692$$$701$$$O	tablets,$$$702$$$710$$$O	buccal$$$711$$$717$$$O	tablets,$$$718$$$726$$$O	capsules,$$$727$$$736$$$O	pills,$$$737$$$743$$$O	powder$$$744$$$750$$$O	injection$$$751$$$760$$$O	or$$$761$$$763$$$O	oral$$$764$$$768$$$O	liquid$$$769$$$775$$$O	prepared$$$776$$$784$$$O	by$$$785$$$787$$$O	adding$$$788$$$794$$$O	certain$$$795$$$802$$$O	additives$$$803$$$812$$$O	into$$$813$$$817$$$O	the$$$818$$$821$$$O	cyclocarya$$$822$$$832$$$O	paliurus$$$833$$$841$$$O	extract$$$842$$$849$$$O	disclosed$$$850$$$859$$$O	by$$$860$$$862$$$O	the$$$863$$$866$$$O	invention$$$867$$$876$$$O	are$$$877$$$880$$$O	orally$$$881$$$887$$$O	taken,$$$888$$$894$$$O	the$$$895$$$898$$$O	effects$$$899$$$906$$$O	of$$$907$$$909$$$O	preventing$$$910$$$920$$$O	and$$$921$$$924$$$O	treating$$$925$$$933$$$O	the$$$934$$$937$$$O	leukemia$$$938$$$946$$$O	can$$$947$$$950$$$O	be$$$951$$$953$$$O	achieved.$$$954$$$963$$$O
EP1291016B1
New$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	modafinil$$$11$$$20$$$I	and$$$21$$$24$$$O	the$$$25$$$28$$$O	d/l$$$29$$$32$$$O	enantiomer$$$33$$$43$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	new$$$37$$$40$$$O	use$$$41$$$44$$$O	of$$$45$$$47$$$O	modafinil$$$48$$$57$$$I	and$$$58$$$61$$$O	the$$$62$$$65$$$O	D/L$$$66$$$69$$$O	enantiomer$$$70$$$80$$$O	thereof$$$81$$$88$$$O	in$$$89$$$91$$$O	manufacture$$$92$$$103$$$O	of$$$104$$$106$$$O	medicine.$$$107$$$116$$$O	Especially,$$$117$$$128$$$O	the$$$129$$$132$$$O	present$$$133$$$140$$$O	invention$$$141$$$150$$$O	provides$$$151$$$159$$$O	the$$$160$$$163$$$O	use$$$164$$$167$$$O	of$$$168$$$170$$$O	modafinil$$$171$$$180$$$I	in$$$181$$$183$$$O	manufacture$$$184$$$195$$$O	of$$$196$$$198$$$O	medicine$$$199$$$207$$$O	for$$$208$$$211$$$O	increasing$$$212$$$222$$$O	the$$$223$$$226$$$O	amount$$$227$$$233$$$O	and$$$234$$$237$$$O	the$$$238$$$241$$$O	quality$$$242$$$249$$$O	of$$$250$$$252$$$O	sperm$$$253$$$258$$$O	in$$$259$$$261$$$O	male$$$262$$$266$$$O	mammal,$$$267$$$274$$$O	improving$$$275$$$284$$$O	the$$$285$$$288$$$O	androlepsis$$$289$$$300$$$O	of$$$301$$$303$$$O	uterus$$$304$$$310$$$O	of$$$311$$$313$$$O	female$$$314$$$320$$$O	mammal,$$$321$$$328$$$O	treating$$$329$$$337$$$O	aphoria$$$338$$$345$$$O	or$$$346$$$348$$$O	low$$$349$$$352$$$O	rate$$$353$$$357$$$O	of$$$358$$$360$$$O	procreation$$$361$$$372$$$O	in$$$373$$$375$$$O	male$$$376$$$380$$$O	mammal$$$381$$$387$$$O	and$$$388$$$391$$$O	aciesis$$$392$$$399$$$O	or$$$400$$$402$$$O	low$$$403$$$406$$$O	rate$$$407$$$411$$$O	of$$$412$$$414$$$O	pregnancy$$$415$$$424$$$O	in$$$425$$$427$$$O	female$$$428$$$434$$$O	mammal,$$$435$$$442$$$O	and$$$443$$$446$$$O	improving$$$447$$$456$$$O	the$$$457$$$460$$$O	sex$$$461$$$464$$$O	function.$$$465$$$474$$$O
CN102846566A
A$$$0$$$1$$$O	duloxetine$$$2$$$12$$$I	enteric-coated$$$13$$$27$$$O	tablet$$$28$$$34$$$O	and$$$35$$$38$$$O	its$$$39$$$42$$$O	preparation$$$43$$$54$$$O	method$$$55$$$61$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	duloxetine$$$26$$$36$$$I	enteric-coated$$$37$$$51$$$O	tablet,$$$52$$$59$$$O	comprising$$$60$$$70$$$O	duloxetine$$$71$$$81$$$I	and/or$$$82$$$88$$$O	pharmaceutically$$$89$$$105$$$O	acceptable$$$106$$$116$$$O	salt$$$117$$$121$$$O	thereof$$$122$$$129$$$O	and$$$130$$$133$$$O	adjuvants,$$$134$$$144$$$O	the$$$145$$$148$$$O	adjuvants$$$149$$$158$$$O	including$$$159$$$168$$$O	pH$$$169$$$171$$$O	regulator$$$172$$$181$$$O	and/or$$$182$$$188$$$O	buffer$$$189$$$195$$$O	pair$$$196$$$200$$$O	and$$$201$$$204$$$O	stabilizer.$$$205$$$216$$$O	The$$$217$$$220$$$O	pH$$$221$$$223$$$O	regulator$$$224$$$233$$$O	is$$$234$$$236$$$O	selected$$$237$$$245$$$O	from$$$246$$$250$$$O	one$$$251$$$254$$$O	or$$$255$$$257$$$O	more$$$258$$$262$$$O	of$$$263$$$265$$$O	sodium$$$266$$$272$$$I	citrate,$$$273$$$281$$$I	sodium$$$282$$$288$$$I	bisulfite,$$$289$$$299$$$I	cysteine,$$$300$$$309$$$I	sodium$$$310$$$316$$$I	hydroxide,$$$317$$$327$$$I	hydrochloric$$$328$$$340$$$I	acid.$$$341$$$346$$$I	The$$$347$$$350$$$O	invention$$$351$$$360$$$O	also$$$361$$$365$$$O	discloses$$$366$$$375$$$O	a$$$376$$$377$$$O	preparation$$$378$$$389$$$O	method$$$390$$$396$$$O	for$$$397$$$400$$$O	the$$$401$$$404$$$O	duloxetine$$$405$$$415$$$I	enteric-coated$$$416$$$430$$$O	preparation.$$$431$$$443$$$O	The$$$444$$$447$$$O	duloxetine$$$448$$$458$$$I	enteric-coated$$$459$$$473$$$O	preparation$$$474$$$485$$$O	prepared$$$486$$$494$$$O	by$$$495$$$497$$$O	the$$$498$$$501$$$O	preparation$$$502$$$513$$$O	method$$$514$$$520$$$O	can$$$521$$$524$$$O	maintain$$$525$$$533$$$O	the$$$534$$$537$$$O	related$$$538$$$545$$$O	substrates$$$546$$$556$$$O	in$$$557$$$559$$$O	a$$$560$$$561$$$O	low$$$562$$$565$$$O	level$$$566$$$571$$$O	during$$$572$$$578$$$O	long-term$$$579$$$588$$$O	storage,$$$589$$$597$$$O	and$$$598$$$601$$$O	has$$$602$$$605$$$O	good$$$606$$$610$$$O	dissolution$$$611$$$622$$$O	property$$$623$$$631$$$O	and$$$632$$$635$$$O	stability$$$636$$$645$$$O	and$$$646$$$649$$$O	high$$$650$$$654$$$O	bioavailability.$$$655$$$671$$$O
WO2012068412A2
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	compositions$$$11$$$23$$$O	for$$$24$$$27$$$O	treatment$$$28$$$37$$$O	of$$$38$$$40$$$O	stat3-responsive$$$41$$$57$$$O	cancers$$$58$$$65$$$O	and/or$$$66$$$72$$$O	renal$$$73$$$78$$$O	cancer$$$79$$$85$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	compounds$$$44$$$53$$$O	of$$$54$$$56$$$O	Formula$$$57$$$64$$$O	A$$$65$$$66$$$O	for$$$67$$$70$$$O	the$$$71$$$74$$$O	treatment$$$75$$$84$$$O	of$$$85$$$87$$$O	neoplasia$$$88$$$97$$$O	with$$$98$$$102$$$O	inducibly$$$103$$$112$$$O	expressed$$$113$$$122$$$O	STAT3.$$$123$$$129$$$O	Further,$$$130$$$138$$$O	the$$$139$$$142$$$O	present$$$143$$$150$$$O	invention$$$151$$$160$$$O	relates$$$161$$$168$$$O	to$$$169$$$171$$$O	determining$$$172$$$183$$$O	treatment$$$184$$$193$$$O	regimens$$$194$$$202$$$O	and$$$203$$$206$$$O	therapeutic$$$207$$$218$$$O	efficacy$$$219$$$227$$$O	with$$$228$$$232$$$O	respect$$$233$$$240$$$O	to$$$241$$$243$$$O	treatment$$$244$$$253$$$O	of$$$254$$$256$$$O	neoplasia$$$257$$$266$$$O	with$$$267$$$271$$$O	inducibly$$$272$$$281$$$O	expressed$$$282$$$291$$$O	STAT3.$$$292$$$298$$$O
US20100247677
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	Methods$$$17$$$24$$$O	for$$$25$$$28$$$O	Preferential$$$29$$$41$$$O	Distribution$$$42$$$54$$$O	of$$$55$$$57$$$O	Active$$$58$$$64$$$O	Agents$$$65$$$71$$$O	to$$$72$$$74$$$O	Injury$$$75$$$81$$$O	Sites$$$82$$$87$$$O
Compositions$$$0$$$12$$$O	are$$$13$$$16$$$O	provided$$$17$$$25$$$O	for$$$26$$$29$$$O	preferential$$$30$$$42$$$O	distribution$$$43$$$55$$$O	of$$$56$$$58$$$O	active$$$59$$$65$$$O	agents$$$66$$$72$$$O	to$$$73$$$75$$$O	injury$$$76$$$82$$$O	sites.$$$83$$$89$$$O	Such$$$90$$$94$$$O	compositions$$$95$$$107$$$O	may$$$108$$$111$$$O	comprise$$$112$$$120$$$O	a$$$121$$$122$$$O	ligand$$$123$$$129$$$O	with$$$130$$$134$$$O	hydrophilic$$$135$$$146$$$O	properties$$$147$$$157$$$O	and$$$158$$$161$$$O	one$$$162$$$165$$$O	or$$$166$$$168$$$O	more$$$169$$$173$$$O	active$$$174$$$180$$$O	agents,$$$181$$$188$$$O	such$$$189$$$193$$$O	as$$$194$$$196$$$O	compounds$$$197$$$206$$$O	comprising$$$207$$$217$$$O	hydrophilic$$$218$$$229$$$O	metal$$$230$$$235$$$O	ions.$$$236$$$241$$$O	Because$$$242$$$249$$$O	the$$$250$$$253$$$O	delivery$$$254$$$262$$$O	ligand$$$263$$$269$$$O	and$$$270$$$273$$$O	the$$$274$$$277$$$O	active$$$278$$$284$$$O	agent$$$285$$$290$$$O	are$$$291$$$294$$$O	specifically$$$295$$$307$$$O	selected$$$308$$$316$$$O	so$$$317$$$319$$$O	the$$$320$$$323$$$O	interactions$$$324$$$336$$$O	between$$$337$$$344$$$O	them$$$345$$$349$$$O	are$$$350$$$353$$$O	mainly$$$354$$$360$$$O	of$$$361$$$363$$$O	an$$$364$$$366$$$O	ionic$$$367$$$372$$$O	nature$$$373$$$379$$$O	so$$$380$$$382$$$O	that$$$383$$$387$$$O	binding$$$388$$$395$$$O	of$$$396$$$398$$$O	the$$$399$$$402$$$O	active$$$403$$$409$$$O	agent$$$410$$$415$$$O	to$$$416$$$418$$$O	the$$$419$$$422$$$O	delivery$$$423$$$431$$$O	ligand$$$432$$$438$$$O	and$$$439$$$442$$$O	release$$$443$$$450$$$O	of$$$451$$$453$$$O	the$$$454$$$457$$$O	active$$$458$$$464$$$O	agent$$$465$$$470$$$O	into$$$471$$$475$$$O	the$$$476$$$479$$$O	target$$$480$$$486$$$O	site$$$487$$$491$$$O	are$$$492$$$495$$$O	not$$$496$$$499$$$O	dependent$$$500$$$509$$$O	on$$$510$$$512$$$O	enzymatic$$$513$$$522$$$O	activity.$$$523$$$532$$$O	Methods$$$533$$$540$$$O	of$$$541$$$543$$$O	using$$$544$$$549$$$O	such$$$550$$$554$$$O	compositions$$$555$$$567$$$O	are$$$568$$$571$$$O	also$$$572$$$576$$$O	disclosed.$$$577$$$587$$$O
CA2240721C
Implantable$$$0$$$11$$$O	acrylamide$$$12$$$22$$$I	copolymer$$$23$$$32$$$O	hydrogel$$$33$$$41$$$O	for$$$42$$$45$$$O	therapeutic$$$46$$$57$$$O	uses$$$58$$$62$$$O
The$$$0$$$3$$$O	hydrogel$$$4$$$12$$$O	is$$$13$$$15$$$O	a$$$16$$$17$$$O	copolymer$$$18$$$27$$$O	of$$$28$$$30$$$O	an$$$31$$$33$$$O	N-substituted$$$34$$$47$$$I	methacrylamide$$$48$$$62$$$I	or$$$63$$$65$$$O	acrylamide,$$$66$$$77$$$I	a$$$78$$$79$$$O	cross-linking$$$80$$$93$$$O	agent$$$94$$$99$$$O	and$$$100$$$103$$$O	a$$$104$$$105$$$O	complex$$$106$$$113$$$O	sugar$$$114$$$119$$$I	or$$$120$$$122$$$O	derivative,$$$123$$$134$$$O	a$$$135$$$136$$$O	tissue$$$137$$$143$$$O	adhesion$$$144$$$152$$$O	peptide$$$153$$$160$$$O	or$$$161$$$163$$$O	a$$$164$$$165$$$O	polymer$$$166$$$173$$$O	conjugate$$$174$$$183$$$O	with$$$184$$$188$$$O	antibodies,$$$189$$$200$$$O	the$$$201$$$204$$$O	polymer$$$205$$$212$$$O	being$$$213$$$218$$$O	heterogeneous,$$$219$$$233$$$O	elastically$$$234$$$245$$$O	deformable$$$246$$$256$$$O	and$$$257$$$260$$$O	having$$$261$$$267$$$O	an$$$268$$$270$$$O	equilibrium$$$271$$$282$$$O	water$$$283$$$288$$$O	content$$$289$$$296$$$O	of$$$297$$$299$$$O	at$$$300$$$302$$$O	least$$$303$$$308$$$O	about$$$309$$$314$$$O	80%.$$$315$$$319$$$O	It$$$320$$$322$$$O	can$$$323$$$326$$$O	be$$$327$$$329$$$O	used$$$330$$$334$$$O	for$$$335$$$338$$$O	tissue$$$339$$$345$$$O	regeneration$$$346$$$358$$$O	and$$$359$$$362$$$O	for$$$363$$$366$$$O	organ$$$367$$$372$$$O	repair,$$$373$$$380$$$O	for$$$381$$$384$$$O	example,$$$385$$$393$$$O	in$$$394$$$396$$$O	the$$$397$$$400$$$O	developing$$$401$$$411$$$O	and$$$412$$$415$$$O	adult$$$416$$$421$$$O	nervous$$$422$$$429$$$O	system.$$$430$$$437$$$O
US20070225260
Amino-Propanol$$$0$$$14$$$I	Derivatives$$$15$$$26$$$O
A$$$0$$$1$$$O	compound$$$2$$$10$$$O	of$$$11$$$13$$$O	formula$$$14$$$21$$$O	(I)$$$22$$$25$$$O	wherein$$$26$$$33$$$O	R1,$$$34$$$37$$$O	R2,$$$38$$$41$$$O	R3,$$$42$$$45$$$O	R4$$$46$$$48$$$O	and$$$49$$$52$$$O	R5$$$53$$$55$$$O	are$$$56$$$59$$$O	as$$$60$$$62$$$O	defined$$$63$$$70$$$O	in$$$71$$$73$$$O	the$$$74$$$77$$$O	specification,$$$78$$$92$$$O	processes$$$93$$$102$$$O	for$$$103$$$106$$$O	their$$$107$$$112$$$O	production,$$$113$$$124$$$O	their$$$125$$$130$$$O	uses,$$$131$$$136$$$O	in$$$137$$$139$$$O	particular$$$140$$$150$$$O	in$$$151$$$153$$$O	transplantation,$$$154$$$170$$$O	and$$$171$$$174$$$O	pharmaceutical$$$175$$$189$$$O	compositions$$$190$$$202$$$O	containing$$$203$$$213$$$O	them.$$$214$$$219$$$O
CN101439046B
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Bingpeng$$$15$$$23$$$O	San$$$24$$$27$$$O	or$$$28$$$30$$$O	pseudo-ginseng$$$31$$$45$$$O	Bingpeng$$$46$$$54$$$O	San$$$55$$$58$$$O	combined$$$59$$$67$$$O	with$$$68$$$72$$$O	zinc$$$73$$$77$$$I	selenium$$$78$$$86$$$I	treasure$$$87$$$95$$$O	tablet$$$96$$$102$$$O	in$$$103$$$105$$$O	preparing$$$106$$$115$$$O	medicament$$$116$$$126$$$O	for$$$127$$$130$$$O	treating$$$131$$$139$$$O	cervical$$$140$$$148$$$O	erosion$$$149$$$156$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	application$$$28$$$39$$$O	of$$$40$$$42$$$O	Bingpeng$$$43$$$51$$$O	San$$$52$$$55$$$O	together$$$56$$$64$$$O	with$$$65$$$69$$$O	zinc$$$70$$$74$$$I	and$$$75$$$78$$$O	selenium$$$79$$$87$$$I	tablet$$$88$$$94$$$O	in$$$95$$$97$$$O	the$$$98$$$101$$$O	preparation$$$102$$$113$$$O	of$$$114$$$116$$$O	a$$$117$$$118$$$O	drug$$$119$$$123$$$O	for$$$124$$$127$$$O	curing$$$128$$$134$$$O	cervical$$$135$$$143$$$O	erosion,$$$144$$$152$$$O	and$$$153$$$156$$$O	an$$$157$$$159$$$O	application$$$160$$$171$$$O	of$$$172$$$174$$$O	notoginseng$$$175$$$186$$$O	Bingpeng$$$187$$$195$$$O	San$$$196$$$199$$$O	together$$$200$$$208$$$O	with$$$209$$$213$$$O	zinc$$$214$$$218$$$I	and$$$219$$$222$$$O	selenium$$$223$$$231$$$I	tablet$$$232$$$238$$$O	in$$$239$$$241$$$O	the$$$242$$$245$$$O	preparation$$$246$$$257$$$O	of$$$258$$$260$$$O	a$$$261$$$262$$$O	drug$$$263$$$267$$$O	for$$$268$$$271$$$O	curing$$$272$$$278$$$O	cervical$$$279$$$287$$$O	erosion.$$$288$$$296$$$O	The$$$297$$$300$$$O	proposal,$$$301$$$310$$$O	from$$$311$$$315$$$O	the$$$316$$$319$$$O	whole$$$320$$$325$$$O	to$$$326$$$328$$$O	the$$$329$$$332$$$O	part,$$$333$$$338$$$O	not$$$339$$$342$$$O	only$$$343$$$347$$$O	achieves$$$348$$$356$$$O	a$$$357$$$358$$$O	good$$$359$$$363$$$O	effect$$$364$$$370$$$O	in$$$371$$$373$$$O	curing$$$374$$$380$$$O	erosion$$$381$$$388$$$O	but$$$389$$$392$$$O	also$$$393$$$397$$$O	effectively$$$398$$$409$$$O	prevents$$$410$$$418$$$O	relapse.$$$419$$$427$$$O	The$$$428$$$431$$$O	proposal$$$432$$$440$$$O	is$$$441$$$443$$$O	easy$$$444$$$448$$$O	to$$$449$$$451$$$O	be$$$452$$$454$$$O	generalized$$$455$$$466$$$O	in$$$467$$$469$$$O	application$$$470$$$481$$$O	and$$$482$$$485$$$O	has$$$486$$$489$$$O	great$$$490$$$495$$$O	value$$$496$$$501$$$O	of$$$502$$$504$$$O	practical$$$505$$$514$$$O	application$$$515$$$526$$$O	and$$$527$$$530$$$O	great$$$531$$$536$$$O	academic$$$537$$$545$$$O	theory$$$546$$$552$$$O	significance,$$$553$$$566$$$O	and$$$567$$$570$$$O	the$$$571$$$574$$$O	operation$$$575$$$584$$$O	of$$$585$$$587$$$O	the$$$588$$$591$$$O	proposal$$$592$$$600$$$O	is$$$601$$$603$$$O	simple,$$$604$$$611$$$O	easy,$$$612$$$617$$$O	convenient$$$618$$$628$$$O	and$$$629$$$632$$$O	reliable$$$633$$$641$$$O	and$$$642$$$645$$$O	causes$$$646$$$652$$$O	little$$$653$$$659$$$O	pain.$$$660$$$665$$$O	The$$$666$$$669$$$O	proposal$$$670$$$678$$$O	has$$$679$$$682$$$O	the$$$683$$$686$$$O	advantages$$$687$$$697$$$O	of$$$698$$$700$$$O	low$$$701$$$704$$$O	cost,$$$705$$$710$$$O	little$$$711$$$717$$$O	pain$$$718$$$722$$$O	and$$$723$$$726$$$O	no$$$727$$$729$$$O	scar$$$730$$$734$$$O	formation$$$735$$$744$$$O	and$$$745$$$748$$$O	can$$$749$$$752$$$O	satisfy$$$753$$$760$$$O	the$$$761$$$764$$$O	natural$$$765$$$772$$$O	childbirth$$$773$$$783$$$O	requirement$$$784$$$795$$$O	of$$$796$$$798$$$O	part$$$799$$$803$$$O	of$$$804$$$806$$$O	the$$$807$$$810$$$O	sufferers.$$$811$$$821$$$O
WO2011042497A1
Pyrrolo$$$0$$$7$$$I	[3,2$$$8$$$12$$$I	-e]$$$13$$$16$$$I	[1,2,4]$$$17$$$24$$$I	triazolo$$$25$$$33$$$I	[1,5-a]$$$34$$$41$$$I	pyrimidines$$$42$$$53$$$I	derivatives$$$54$$$65$$$O	as$$$66$$$68$$$O	inhibitors$$$69$$$79$$$O	of$$$80$$$82$$$O	microglia$$$83$$$92$$$O	activation$$$93$$$103$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	compounds$$$31$$$40$$$O	useful$$$41$$$47$$$O	in$$$48$$$50$$$O	the$$$51$$$54$$$O	treatment$$$55$$$64$$$O	and$$$65$$$68$$$O	prophylaxis$$$69$$$80$$$O	of$$$81$$$83$$$O	disease.$$$84$$$92$$$O	Compounds$$$93$$$102$$$O	of$$$103$$$105$$$O	the$$$106$$$109$$$O	formula$$$110$$$117$$$O	(I),$$$118$$$122$$$O	wherein$$$123$$$130$$$O	X$$$131$$$132$$$O	is$$$133$$$135$$$O	halogen,$$$136$$$144$$$I	independently$$$145$$$158$$$O	selected$$$159$$$167$$$O	form$$$168$$$172$$$O	chlorine$$$173$$$181$$$I	and$$$182$$$185$$$O	fluorine$$$186$$$194$$$I	and$$$195$$$198$$$O	their$$$199$$$204$$$O	pharmaceutically$$$205$$$221$$$O	acceptable$$$222$$$232$$$O	salts$$$233$$$238$$$O	are$$$239$$$242$$$O	useful$$$243$$$249$$$O	in$$$250$$$252$$$O	the$$$253$$$256$$$O	treatment$$$257$$$266$$$O	and$$$267$$$270$$$O	prophylaxis$$$271$$$282$$$O	of$$$283$$$285$$$O	diseases$$$286$$$294$$$O	caused$$$295$$$301$$$O	by$$$302$$$304$$$O	activation$$$305$$$315$$$O	of$$$316$$$318$$$O	microglia,$$$319$$$329$$$O	particularly$$$330$$$342$$$O	Alzheimer's$$$343$$$354$$$O	disease.$$$355$$$363$$$O
CN103315958A
2-(1-methylethyl)-5-[(E)-2-phenylethenyl]benzene-1,3-diol$$$0$$$57$$$I	nanoemulsion$$$58$$$70$$$O	and$$$71$$$74$$$O	its$$$75$$$78$$$O	preparation$$$79$$$90$$$O	method$$$91$$$97$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	2-(1-methylethyl)-5-[(E)-2-phenylethenyl]benzene-1,3-diol$$$26$$$83$$$I	nanoemulsion$$$84$$$96$$$O	and$$$97$$$100$$$O	its$$$101$$$104$$$O	preparation$$$105$$$116$$$O	method.$$$117$$$124$$$O	According$$$125$$$134$$$O	to$$$135$$$137$$$O	the$$$138$$$141$$$O	invention,$$$142$$$152$$$O	a$$$153$$$154$$$O	compound$$$155$$$163$$$O	surfactant$$$164$$$174$$$O	is$$$175$$$177$$$O	adopted$$$178$$$185$$$O	to$$$186$$$188$$$O	adjust$$$189$$$195$$$O	HLB$$$196$$$199$$$O	value$$$200$$$205$$$O	to$$$206$$$208$$$O	13-14$$$209$$$214$$$O	and$$$215$$$218$$$O	stipulate$$$219$$$228$$$O	to$$$229$$$231$$$O	a$$$232$$$233$$$O	specific$$$234$$$242$$$O	HLB$$$243$$$246$$$O	point$$$247$$$252$$$O	value.$$$253$$$259$$$O	The$$$260$$$263$$$O	particle$$$264$$$272$$$O	size$$$273$$$277$$$O	range$$$278$$$283$$$O	of$$$284$$$286$$$O	the$$$287$$$290$$$O	prepared$$$291$$$299$$$O	nanoemulsion$$$300$$$312$$$O	is$$$313$$$315$$$O	10-50nm,$$$316$$$324$$$O	the$$$325$$$328$$$O	particles$$$329$$$338$$$O	are$$$339$$$342$$$O	uniform,$$$343$$$351$$$O	and$$$352$$$355$$$O	the$$$356$$$359$$$O	nanoemulsion$$$360$$$372$$$O	has$$$373$$$376$$$O	characteristics$$$377$$$392$$$O	of$$$393$$$395$$$O	increased$$$396$$$405$$$O	drug$$$406$$$410$$$O	loading$$$411$$$418$$$O	capacity$$$419$$$427$$$O	and$$$428$$$431$$$O	stronger$$$432$$$440$$$O	stability.$$$441$$$451$$$O	0.5-4h$$$452$$$458$$$O	transmitance$$$459$$$471$$$O	of$$$472$$$474$$$O	the$$$475$$$478$$$O	nanoemulsion$$$479$$$491$$$O	is$$$492$$$494$$$O	9$$$495$$$496$$$O	times$$$497$$$502$$$O	greater$$$503$$$510$$$O	than$$$511$$$515$$$O	a$$$516$$$517$$$O	single$$$518$$$524$$$O	surfactant$$$525$$$535$$$O	and$$$536$$$539$$$O	45$$$540$$$542$$$O	times$$$543$$$548$$$O	greater$$$549$$$556$$$O	than$$$557$$$561$$$O	an$$$562$$$564$$$O	original$$$565$$$573$$$O	medicine.$$$574$$$583$$$O	The$$$584$$$587$$$O	preparation$$$588$$$599$$$O	method$$$600$$$606$$$O	provided$$$607$$$615$$$O	by$$$616$$$618$$$O	the$$$619$$$622$$$O	invention$$$623$$$632$$$O	is$$$633$$$635$$$O	suitable$$$636$$$644$$$O	for$$$645$$$648$$$O	preparation$$$649$$$660$$$O	of$$$661$$$663$$$O	the$$$664$$$667$$$O	2-(1-methylethyl)-5-[(E)-2-phenylethenyl]benzene-1,3-diol$$$668$$$725$$$I	nanoemulsion,$$$726$$$739$$$O	and$$$740$$$743$$$O	further$$$744$$$751$$$O	can$$$752$$$755$$$O	be$$$756$$$758$$$O	adopted$$$759$$$766$$$O	to$$$767$$$769$$$O	treat$$$770$$$775$$$O	diseases$$$776$$$784$$$O	such$$$785$$$789$$$O	as$$$790$$$792$$$O	intractable$$$793$$$804$$$O	psoriasis$$$805$$$814$$$O	and$$$815$$$818$$$O	the$$$819$$$822$$$O	like.$$$823$$$828$$$O
CN1775227A
Ointment$$$0$$$8$$$O	medicine$$$9$$$17$$$O	for$$$18$$$21$$$O	treating$$$22$$$30$$$O	bedsore$$$31$$$38$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	an$$$32$$$34$$$O	ointment$$$35$$$43$$$O	medicine$$$44$$$52$$$O	preparation$$$53$$$64$$$O	for$$$65$$$68$$$O	curing$$$69$$$75$$$O	bed$$$76$$$79$$$O	sore$$$80$$$84$$$O	with$$$85$$$89$$$O	obvious$$$90$$$97$$$O	therapeutic$$$98$$$109$$$O	effect.$$$110$$$117$$$O	Its$$$118$$$121$$$O	raw$$$122$$$125$$$O	material$$$126$$$134$$$O	composition$$$135$$$146$$$O	includes$$$147$$$155$$$O	(by$$$156$$$159$$$O	weight$$$160$$$166$$$O	portion)$$$167$$$175$$$O	0.1-5$$$176$$$181$$$O	portions$$$182$$$190$$$O	of$$$191$$$193$$$O	berberine,$$$194$$$204$$$I	20-40$$$205$$$210$$$O	portions$$$211$$$219$$$O	of$$$220$$$222$$$O	fluocinonide$$$223$$$235$$$I	ointment,$$$236$$$245$$$O	0.1-5$$$246$$$251$$$O	portions$$$252$$$260$$$O	of$$$261$$$263$$$O	Yunnan$$$264$$$270$$$O	white$$$271$$$276$$$O	medicine$$$277$$$285$$$O	and$$$286$$$289$$$O	0.1-5$$$290$$$295$$$O	portions$$$296$$$304$$$O	of$$$305$$$307$$$O	sulfonamides$$$308$$$320$$$I	anti-inflammatory$$$321$$$338$$$O	powder.$$$339$$$346$$$O
CN103099814A
Chick$$$0$$$5$$$O	bacterial$$$6$$$15$$$O	disease$$$16$$$23$$$O	preventing$$$24$$$34$$$O	and$$$35$$$38$$$O	treating$$$39$$$47$$$O	composition$$$48$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	chick$$$27$$$32$$$O	bacterial$$$33$$$42$$$O	disease$$$43$$$50$$$O	preventing$$$51$$$61$$$O	and$$$62$$$65$$$O	treating$$$66$$$74$$$O	composition$$$75$$$86$$$O	in$$$87$$$89$$$O	veterinary$$$90$$$100$$$O	drugs.$$$101$$$107$$$O	The$$$108$$$111$$$O	chick$$$112$$$117$$$O	bacterial$$$118$$$127$$$O	disease$$$128$$$135$$$O	preventing$$$136$$$146$$$O	and$$$147$$$150$$$O	treating$$$151$$$159$$$O	composition$$$160$$$171$$$O	is$$$172$$$174$$$O	mainly$$$175$$$181$$$O	composed$$$182$$$190$$$O	of$$$191$$$193$$$O	the$$$194$$$197$$$O	effective$$$198$$$207$$$O	component$$$208$$$217$$$O	by$$$218$$$220$$$O	weight:$$$221$$$228$$$O	1%$$$229$$$231$$$O	of$$$232$$$234$$$O	norfloxacin,$$$235$$$247$$$I	2%$$$248$$$250$$$O	of$$$251$$$253$$$O	vitamin$$$254$$$261$$$I	C,$$$262$$$264$$$I	17%$$$265$$$268$$$O	of$$$269$$$271$$$O	sodium$$$272$$$278$$$I	chloride$$$279$$$287$$$I	and$$$288$$$291$$$O	80%$$$292$$$295$$$O	of$$$296$$$298$$$O	glucose.$$$299$$$307$$$I	The$$$308$$$311$$$O	composition$$$312$$$323$$$O	is$$$324$$$326$$$O	used$$$327$$$331$$$O	for$$$332$$$335$$$O	prevention$$$336$$$346$$$O	and$$$347$$$350$$$O	treatment$$$351$$$360$$$O	of$$$361$$$363$$$O	the$$$364$$$367$$$O	bacterial$$$368$$$377$$$O	diseases$$$378$$$386$$$O	of$$$387$$$389$$$O	1-15-day-old$$$390$$$402$$$O	chicks,$$$403$$$410$$$O	and$$$411$$$414$$$O	the$$$415$$$418$$$O	prevention$$$419$$$429$$$O	and$$$430$$$433$$$O	treatment$$$434$$$443$$$O	rate$$$444$$$448$$$O	and$$$449$$$452$$$O	the$$$453$$$456$$$O	cure$$$457$$$461$$$O	rate$$$462$$$466$$$O	both$$$467$$$471$$$O	are$$$472$$$475$$$O	higher$$$476$$$482$$$O	than$$$483$$$487$$$O	96%.$$$488$$$492$$$O	The$$$493$$$496$$$O	process$$$497$$$504$$$O	for$$$505$$$508$$$O	processing$$$509$$$519$$$O	the$$$520$$$523$$$O	composition$$$524$$$535$$$O	comprises$$$536$$$545$$$O	accurately$$$546$$$556$$$O	weighing$$$557$$$565$$$O	all$$$566$$$569$$$O	of$$$570$$$572$$$O	the$$$573$$$576$$$O	effective$$$577$$$586$$$O	components$$$587$$$597$$$O	dried$$$598$$$603$$$O	previously,$$$604$$$615$$$O	mixing,$$$616$$$623$$$O	weighing$$$624$$$632$$$O	and$$$633$$$636$$$O	packaging,$$$637$$$647$$$O	testing$$$648$$$655$$$O	quality$$$656$$$663$$$O	and$$$664$$$667$$$O	warehousing.$$$668$$$680$$$O	The$$$681$$$684$$$O	method$$$685$$$691$$$O	of$$$692$$$694$$$O	using$$$695$$$700$$$O	the$$$701$$$704$$$O	composition$$$705$$$716$$$O	comprises$$$717$$$726$$$O	mixing$$$727$$$733$$$O	the$$$734$$$737$$$O	composition$$$738$$$749$$$O	with$$$750$$$754$$$O	other$$$755$$$760$$$O	materials$$$761$$$770$$$O	by$$$771$$$773$$$O	the$$$774$$$777$$$O	proportion$$$778$$$788$$$O	of$$$789$$$791$$$O	1.6%,$$$792$$$797$$$O	or$$$798$$$800$$$O	mixing$$$801$$$807$$$O	the$$$808$$$811$$$O	composition$$$812$$$823$$$O	with$$$824$$$828$$$O	drinking$$$829$$$837$$$O	water$$$838$$$843$$$O	by$$$844$$$846$$$O	the$$$847$$$850$$$O	proportion$$$851$$$861$$$O	of$$$862$$$864$$$O	0.8%.$$$865$$$870$$$O
CN103110578A
Self-microemulsion$$$0$$$18$$$O	composition$$$19$$$30$$$O	of$$$31$$$33$$$O	breviscapine$$$34$$$46$$$I	phytosome$$$47$$$56$$$O	and$$$57$$$60$$$O	preparation$$$61$$$72$$$O	method$$$73$$$79$$$O	of$$$80$$$82$$$O	composition$$$83$$$94$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	self-microemulsion$$$26$$$44$$$O	composition$$$45$$$56$$$O	of$$$57$$$59$$$O	a$$$60$$$61$$$O	breviscapine$$$62$$$74$$$I	phytosome$$$75$$$84$$$O	and$$$85$$$88$$$O	a$$$89$$$90$$$O	preparation$$$91$$$102$$$O	method$$$103$$$109$$$O	of$$$110$$$112$$$O	the$$$113$$$116$$$O	composition.$$$117$$$129$$$O	The$$$130$$$133$$$O	composition$$$134$$$145$$$O	is$$$146$$$148$$$O	prepared$$$149$$$157$$$O	by$$$158$$$160$$$O	the$$$161$$$164$$$O	following$$$165$$$174$$$O	steps$$$175$$$180$$$O	of:$$$181$$$184$$$O	firstly,$$$185$$$193$$$O	preparing$$$194$$$203$$$O	the$$$204$$$207$$$O	breviscapine$$$208$$$220$$$I	phytosome$$$221$$$230$$$O	from$$$231$$$235$$$O	breviscapine$$$236$$$248$$$I	and$$$249$$$252$$$O	phospholipid;$$$253$$$266$$$I	then,$$$267$$$272$$$O	dissolving$$$273$$$283$$$O	the$$$284$$$287$$$O	breviscapine$$$288$$$300$$$I	phytosome$$$301$$$310$$$O	in$$$311$$$313$$$O	an$$$314$$$316$$$O	appropriate$$$317$$$328$$$O	amount$$$329$$$335$$$O	of$$$336$$$338$$$O	a$$$339$$$340$$$O	low-boiling-point$$$341$$$358$$$O	organic$$$359$$$366$$$O	solvent;$$$367$$$375$$$O	adding$$$376$$$382$$$O	an$$$383$$$385$$$O	oil$$$386$$$389$$$O	phase,$$$390$$$396$$$O	an$$$397$$$399$$$O	emulsifier$$$400$$$410$$$O	and$$$411$$$414$$$O	a$$$415$$$416$$$O	co-emulsifier$$$417$$$430$$$O	to$$$431$$$433$$$O	the$$$434$$$437$$$O	solvent,$$$438$$$446$$$O	carrying$$$447$$$455$$$O	out$$$456$$$459$$$O	circulating$$$460$$$471$$$O	homogenizing$$$472$$$484$$$O	for$$$485$$$488$$$O	2-10$$$489$$$493$$$O	times$$$494$$$499$$$O	through$$$500$$$507$$$O	magnetic$$$508$$$516$$$O	stirring$$$517$$$525$$$O	or$$$526$$$528$$$O	ultrasound$$$529$$$539$$$O	or$$$540$$$542$$$O	through$$$543$$$550$$$O	a$$$551$$$552$$$O	high-pressure$$$553$$$566$$$O	homogenizer$$$567$$$578$$$O	or$$$579$$$581$$$O	a$$$582$$$583$$$O	micro-jet$$$584$$$593$$$O	homogenizer,$$$594$$$606$$$O	and$$$607$$$610$$$O	performing$$$611$$$621$$$O	decompression$$$622$$$635$$$O	and$$$636$$$639$$$O	condensation$$$640$$$652$$$O	after$$$653$$$658$$$O	the$$$659$$$662$$$O	mixture$$$663$$$670$$$O	is$$$671$$$673$$$O	uniformly$$$674$$$683$$$O	blended,$$$684$$$692$$$O	thus$$$693$$$697$$$O	obtaining$$$698$$$707$$$O	the$$$708$$$711$$$O	composition.$$$712$$$724$$$O	The$$$725$$$728$$$O	composition$$$729$$$740$$$O	overcomes$$$741$$$750$$$O	the$$$751$$$754$$$O	problems$$$755$$$763$$$O	of$$$764$$$766$$$O	low$$$767$$$770$$$O	solubility,$$$771$$$782$$$O	low$$$783$$$786$$$O	bioavailability,$$$787$$$803$$$O	low$$$804$$$807$$$O	drug$$$808$$$812$$$O	loading$$$813$$$820$$$O	capacity$$$821$$$829$$$O	and$$$830$$$833$$$O	the$$$834$$$837$$$O	like$$$838$$$842$$$O	of$$$843$$$845$$$O	the$$$846$$$849$$$O	water$$$850$$$855$$$O	insoluble$$$856$$$865$$$O	and$$$866$$$869$$$O	oil$$$870$$$873$$$O	insoluble$$$874$$$883$$$O	breviscapine,$$$884$$$897$$$I	and$$$898$$$901$$$O	the$$$902$$$905$$$O	drug$$$906$$$910$$$O	stability$$$911$$$920$$$O	is$$$921$$$923$$$O	greatly$$$924$$$931$$$O	improved.$$$932$$$941$$$O	The$$$942$$$945$$$O	preparation$$$946$$$957$$$O	method$$$958$$$964$$$O	is$$$965$$$967$$$O	simple,$$$968$$$975$$$O	mature$$$976$$$982$$$O	in$$$983$$$985$$$O	process,$$$986$$$994$$$O	and$$$995$$$998$$$O	suitable$$$999$$$1007$$$O	for$$$1008$$$1011$$$O	industrial$$$1012$$$1022$$$O	production.$$$1023$$$1034$$$O
WO2010043787A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	4-(3-[hexahydrocyclopenta[c]pyrrol-i(1h)-yl]propoxy}benzamide$$$7$$$68$$$I	for$$$69$$$72$$$O	making$$$73$$$79$$$O	drugs$$$80$$$85$$$O	for$$$86$$$89$$$O	treating$$$90$$$98$$$O	sleep$$$99$$$104$$$O	disorders$$$105$$$114$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	4-{3-[hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide$$$36$$$97$$$I	for$$$98$$$101$$$O	making$$$102$$$108$$$O	drugs$$$109$$$114$$$O	for$$$115$$$118$$$O	treating$$$119$$$127$$$O	sleep$$$128$$$133$$$O	disorders.$$$134$$$144$$$O
US20100087374
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	Treatment$$$12$$$21$$$O	and$$$22$$$25$$$O	Diagnosis$$$26$$$35$$$O	of$$$36$$$38$$$O	Pulmonary$$$39$$$48$$$O	Diseases$$$49$$$57$$$O	Based$$$58$$$63$$$O	on$$$64$$$66$$$O	the$$$67$$$70$$$O	Expression$$$71$$$81$$$O	of$$$82$$$84$$$O	SERCA2$$$85$$$91$$$O	Protein$$$92$$$99$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	methods$$$37$$$44$$$O	of$$$45$$$47$$$O	treatment$$$48$$$57$$$O	of$$$58$$$60$$$O	cystic$$$61$$$67$$$O	fibrosis.$$$68$$$77$$$O	The$$$78$$$81$$$O	invention$$$82$$$91$$$O	includes$$$92$$$100$$$O	a$$$101$$$102$$$O	method$$$103$$$109$$$O	for$$$110$$$113$$$O	treatment$$$114$$$123$$$O	of$$$124$$$126$$$O	cystic$$$127$$$133$$$O	fibrosis$$$134$$$142$$$O	in$$$143$$$145$$$O	a$$$146$$$147$$$O	patient$$$148$$$155$$$O	by$$$156$$$158$$$O	increasing$$$159$$$169$$$O	the$$$170$$$173$$$O	activity$$$174$$$182$$$O	of$$$183$$$185$$$O	sarcoendoplasmic$$$186$$$202$$$O	reticulum$$$203$$$212$$$O	calcium$$$213$$$220$$$I	ATPase$$$221$$$227$$$O	(SERCA)$$$228$$$235$$$O	in$$$236$$$238$$$O	a$$$239$$$240$$$O	patient.$$$241$$$249$$$O	More$$$250$$$254$$$O	specifically,$$$255$$$268$$$O	the$$$269$$$272$$$O	step$$$273$$$277$$$O	of$$$278$$$280$$$O	increasing$$$281$$$291$$$O	SERCA$$$292$$$297$$$O	activity$$$298$$$306$$$O	can$$$307$$$310$$$O	include$$$311$$$318$$$O	but$$$319$$$322$$$O	is$$$323$$$325$$$O	not$$$326$$$329$$$O	limited$$$330$$$337$$$O	to,$$$338$$$341$$$O	administration$$$342$$$356$$$O	of$$$357$$$359$$$O	SERCA$$$360$$$365$$$O	protein$$$366$$$373$$$O	or$$$374$$$376$$$O	its$$$377$$$380$$$O	homologues,$$$381$$$392$$$O	gene$$$393$$$397$$$O	therapy$$$398$$$405$$$O	to$$$406$$$408$$$O	restore$$$409$$$416$$$O	or$$$417$$$419$$$O	enhance$$$420$$$427$$$O	SERCA$$$428$$$433$$$O	activity,$$$434$$$443$$$O	or$$$444$$$446$$$O	the$$$447$$$450$$$O	administration$$$451$$$465$$$O	of$$$466$$$468$$$O	compounds$$$469$$$478$$$O	stimulating$$$479$$$490$$$O	the$$$491$$$494$$$O	activity$$$495$$$503$$$O	of$$$504$$$506$$$O	endogenous$$$507$$$517$$$O	SERCA.$$$518$$$524$$$O	Reference$$$525$$$534$$$O	herein$$$535$$$541$$$O	to$$$542$$$544$$$O	SERCA,$$$545$$$551$$$O	can$$$552$$$555$$$O	include$$$556$$$563$$$O	in$$$564$$$566$$$O	preferred$$$567$$$576$$$O	embodiments,$$$577$$$589$$$O	the$$$590$$$593$$$O	isoform$$$594$$$601$$$O	SERCA2,$$$602$$$609$$$O	which$$$610$$$615$$$O	is$$$616$$$618$$$O	the$$$619$$$622$$$O	principal$$$623$$$632$$$O	lung$$$633$$$637$$$O	isoform$$$638$$$645$$$O	of$$$646$$$648$$$O	SERCA.$$$649$$$655$$$O	The$$$656$$$659$$$O	present$$$660$$$667$$$O	invention$$$668$$$677$$$O	is$$$678$$$680$$$O	based$$$681$$$686$$$O	on$$$687$$$689$$$O	the$$$690$$$693$$$O	finding$$$694$$$701$$$O	that$$$702$$$706$$$O	SERCA2$$$707$$$713$$$O	(a$$$714$$$716$$$O	calcium$$$717$$$724$$$I	pump)$$$725$$$730$$$O	is$$$731$$$733$$$O	deficient$$$734$$$743$$$O	(not$$$744$$$748$$$O	100%)$$$749$$$754$$$O	in$$$755$$$757$$$O	the$$$758$$$761$$$O	lung$$$762$$$766$$$O	epithelial$$$767$$$777$$$O	cells$$$778$$$783$$$O	of$$$784$$$786$$$O	cystic$$$787$$$793$$$O	fibrosis$$$794$$$802$$$O	samples.$$$803$$$811$$$O
US20110052723
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	compounds$$$7$$$16$$$O	binding$$$17$$$24$$$O	to$$$25$$$27$$$O	the$$$28$$$31$$$O	sigma$$$32$$$37$$$O	receptor$$$38$$$46$$$O	ligands$$$47$$$54$$$O	for$$$55$$$58$$$O	the$$$59$$$62$$$O	treatment$$$63$$$72$$$O	of$$$73$$$75$$$O	neuropathic$$$76$$$87$$$O	pain$$$88$$$92$$$O	developing$$$93$$$103$$$O	as$$$104$$$106$$$O	a$$$107$$$108$$$O	consequence$$$109$$$120$$$O	of$$$121$$$123$$$O	chemotherapy$$$124$$$136$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	refers$$$22$$$28$$$O	to$$$29$$$31$$$O	the$$$32$$$35$$$O	use$$$36$$$39$$$O	of$$$40$$$42$$$O	compounds$$$43$$$52$$$O	binding$$$53$$$60$$$O	to$$$61$$$63$$$O	the$$$64$$$67$$$O	sigma$$$68$$$73$$$O	receptor$$$74$$$82$$$O	for$$$83$$$86$$$O	the$$$87$$$90$$$O	treatment$$$91$$$100$$$O	or$$$101$$$103$$$O	prevention$$$104$$$114$$$O	of$$$115$$$117$$$O	neuropathic$$$118$$$129$$$O	pain$$$130$$$134$$$O	resulting$$$135$$$144$$$O	from$$$145$$$149$$$O	chemotherapy.$$$150$$$163$$$O
EP1536840B1
Formulation$$$0$$$11$$$O	for$$$12$$$15$$$O	inwardly$$$16$$$24$$$O	transferring$$$25$$$37$$$O	nucleic$$$38$$$45$$$O	acids$$$46$$$51$$$O	into$$$52$$$56$$$O	eucaryotic$$$57$$$67$$$O	cells$$$68$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pharmaceutical$$$27$$$41$$$O	formulation$$$42$$$53$$$O	for$$$54$$$57$$$O	inwardly$$$58$$$66$$$O	transferring$$$67$$$79$$$O	nucleic$$$80$$$87$$$O	acids$$$88$$$93$$$O	into$$$94$$$98$$$O	eucaryotic$$$99$$$109$$$O	cells,$$$110$$$116$$$O	characterized$$$117$$$130$$$O	in$$$131$$$133$$$O	that$$$134$$$138$$$O	the$$$139$$$142$$$O	formulation$$$143$$$154$$$O	has$$$155$$$158$$$O	a$$$159$$$160$$$O	pH$$$161$$$163$$$O	value$$$164$$$169$$$O	of$$$170$$$172$$$O	6.0$$$173$$$176$$$O	-$$$177$$$178$$$O	pH$$$179$$$181$$$O	7,4,$$$182$$$186$$$O	and/or$$$187$$$193$$$O	an$$$194$$$196$$$O	anion$$$197$$$202$$$O	concentration$$$203$$$216$$$O	of$$$217$$$219$$$O	5$$$220$$$221$$$O	-$$$222$$$223$$$O	100$$$224$$$227$$$O	mmol/l$$$228$$$234$$$O	and/or$$$235$$$241$$$O	a$$$242$$$243$$$O	concentration$$$244$$$257$$$O	of$$$258$$$260$$$O	10$$$261$$$263$$$O	-$$$264$$$265$$$O	500$$$266$$$269$$$O	Ã±mol/l$$$270$$$277$$$O	of$$$278$$$280$$$O	nonsteroidal$$$281$$$293$$$O	antiphlogistics.$$$294$$$310$$$O
CN102973494A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	lidocaine$$$22$$$31$$$I	carbonate$$$32$$$41$$$I	injection$$$42$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	of$$$45$$$47$$$O	a$$$48$$$49$$$O	lidocaine$$$50$$$59$$$I	carbonate$$$60$$$69$$$I	injection.$$$70$$$80$$$O	The$$$81$$$84$$$O	preparation$$$85$$$96$$$O	method$$$97$$$103$$$O	comprises$$$104$$$113$$$O	the$$$114$$$117$$$O	following$$$118$$$127$$$O	processes$$$128$$$137$$$O	of$$$138$$$140$$$O	solution$$$141$$$149$$$O	preparation,$$$150$$$162$$$O	pH$$$163$$$165$$$O	adjustment,$$$166$$$177$$$O	filtration$$$178$$$188$$$O	and$$$189$$$192$$$O	disinfection.$$$193$$$206$$$O	The$$$207$$$210$$$O	preparation$$$211$$$222$$$O	method$$$223$$$229$$$O	is$$$230$$$232$$$O	characterized$$$233$$$246$$$O	in$$$247$$$249$$$O	that$$$250$$$254$$$O	the$$$255$$$258$$$O	filtration$$$259$$$269$$$O	process$$$270$$$277$$$O	comprises$$$278$$$287$$$O	filtering$$$288$$$297$$$O	a$$$298$$$299$$$O	solution$$$300$$$308$$$O	subjected$$$309$$$318$$$O	to$$$319$$$321$$$O	pH$$$322$$$324$$$O	adjustment$$$325$$$335$$$O	by$$$336$$$338$$$O	a$$$339$$$340$$$O	cellulose$$$341$$$350$$$O	acetate$$$351$$$358$$$O	microfiltration$$$359$$$374$$$O	membrane$$$375$$$383$$$O	having$$$384$$$390$$$O	an$$$391$$$393$$$O	aperture$$$394$$$402$$$O	size$$$403$$$407$$$O	of$$$408$$$410$$$O	0.22$$$411$$$415$$$O	micrometers,$$$416$$$428$$$O	filtering$$$429$$$438$$$O	the$$$439$$$442$$$O	solution$$$443$$$451$$$O	by$$$452$$$454$$$O	a$$$455$$$456$$$O	PVDF$$$457$$$461$$$I	microfiltration$$$462$$$477$$$O	membrane$$$478$$$486$$$O	having$$$487$$$493$$$O	an$$$494$$$496$$$O	aperture$$$497$$$505$$$O	size$$$506$$$510$$$O	of$$$511$$$513$$$O	0.22$$$514$$$518$$$O	micrometers$$$519$$$530$$$O	until$$$531$$$536$$$O	clarification,$$$537$$$551$$$O	filling$$$552$$$559$$$O	the$$$560$$$563$$$O	filtered$$$564$$$572$$$O	solution$$$573$$$581$$$O	in$$$582$$$584$$$O	an$$$585$$$587$$$O	ampoule,$$$588$$$596$$$O	and$$$597$$$600$$$O	carrying$$$601$$$609$$$O	out$$$610$$$613$$$O	sealing.$$$614$$$622$$$O	The$$$623$$$626$$$O	solution$$$627$$$635$$$O	subjected$$$636$$$645$$$O	to$$$646$$$648$$$O	pH$$$649$$$651$$$O	adjustment$$$652$$$662$$$O	is$$$663$$$665$$$O	filtered$$$666$$$674$$$O	by$$$675$$$677$$$O	the$$$678$$$681$$$O	cellulose$$$682$$$691$$$O	acetate$$$692$$$699$$$O	microfiltration$$$700$$$715$$$O	membrane$$$716$$$724$$$O	having$$$725$$$731$$$O	an$$$732$$$734$$$O	aperture$$$735$$$743$$$O	size$$$744$$$748$$$O	of$$$749$$$751$$$O	0.22$$$752$$$756$$$O	micrometers,$$$757$$$769$$$O	then$$$770$$$774$$$O	is$$$775$$$777$$$O	filtered$$$778$$$786$$$O	by$$$787$$$789$$$O	the$$$790$$$793$$$O	PVDF$$$794$$$798$$$I	microfiltration$$$799$$$814$$$O	membrane,$$$815$$$824$$$O	and$$$825$$$828$$$O	is$$$829$$$831$$$O	subjected$$$832$$$841$$$O	to$$$842$$$844$$$O	high-pressure$$$845$$$858$$$O	steam$$$859$$$864$$$O	sterilization$$$865$$$878$$$O	at$$$879$$$881$$$O	a$$$882$$$883$$$O	high$$$884$$$888$$$O	temperature$$$889$$$900$$$O	of$$$901$$$903$$$O	121$$$904$$$907$$$O	DEG$$$908$$$911$$$O	C$$$912$$$913$$$O	so$$$914$$$916$$$O	that$$$917$$$921$$$O	impurities$$$922$$$932$$$O	and$$$933$$$936$$$O	bacteria$$$937$$$945$$$O	in$$$946$$$948$$$O	the$$$949$$$952$$$O	solution$$$953$$$961$$$O	are$$$962$$$965$$$O	removed$$$966$$$973$$$O	thoroughly$$$974$$$984$$$O	and$$$985$$$988$$$O	preparation$$$989$$$1000$$$O	bioavailability$$$1001$$$1016$$$O	and$$$1017$$$1020$$$O	absorption$$$1021$$$1031$$$O	effects$$$1032$$$1039$$$O	are$$$1040$$$1043$$$O	improved.$$$1044$$$1053$$$O	The$$$1054$$$1057$$$O	preparation$$$1058$$$1069$$$O	method$$$1070$$$1076$$$O	has$$$1077$$$1080$$$O	simple$$$1081$$$1087$$$O	processes$$$1088$$$1097$$$O	and$$$1098$$$1101$$$O	is$$$1102$$$1104$$$O	convenient$$$1105$$$1115$$$O	for$$$1116$$$1119$$$O	operation.$$$1120$$$1130$$$O	The$$$1131$$$1134$$$O	lidocaine$$$1135$$$1144$$$I	carbonate$$$1145$$$1154$$$I	injection$$$1155$$$1164$$$O	obtained$$$1165$$$1173$$$O	by$$$1174$$$1176$$$O	the$$$1177$$$1180$$$O	preparation$$$1181$$$1192$$$O	method$$$1193$$$1199$$$O	is$$$1200$$$1202$$$O	safe$$$1203$$$1207$$$O	and$$$1208$$$1211$$$O	effective$$$1212$$$1221$$$O	in$$$1222$$$1224$$$O	clinical$$$1225$$$1233$$$O	use$$$1234$$$1237$$$O	and$$$1238$$$1241$$$O	has$$$1242$$$1245$$$O	small$$$1246$$$1251$$$O	side-effects.$$$1252$$$1265$$$O	Compared$$$1266$$$1274$$$O	with$$$1275$$$1279$$$O	the$$$1280$$$1283$$$O	existing$$$1284$$$1292$$$O	lidocaine$$$1293$$$1302$$$I	carbonate$$$1303$$$1312$$$I	injection,$$$1313$$$1323$$$O	the$$$1324$$$1327$$$O	lidocaine$$$1328$$$1337$$$I	carbonate$$$1338$$$1347$$$I	injection$$$1348$$$1357$$$O	obtained$$$1358$$$1366$$$O	by$$$1367$$$1369$$$O	the$$$1370$$$1373$$$O	preparation$$$1374$$$1385$$$O	method$$$1386$$$1392$$$O	obviously$$$1393$$$1402$$$O	shortens$$$1403$$$1411$$$O	onset$$$1412$$$1417$$$O	time$$$1418$$$1422$$$O	and$$$1423$$$1426$$$O	pain$$$1427$$$1431$$$O	sensation$$$1432$$$1441$$$O	disappearance$$$1442$$$1455$$$O	time$$$1456$$$1460$$$O	and$$$1461$$$1464$$$O	prolongs$$$1465$$$1473$$$O	anaesthesia$$$1474$$$1485$$$O	duration$$$1486$$$1494$$$O	time.$$$1495$$$1500$$$O
EP2492267A1
Indole$$$0$$$6$$$I	derivatives$$$7$$$18$$$O	as$$$19$$$21$$$O	CRTH2$$$22$$$27$$$O	receptor$$$28$$$36$$$O	antagonists$$$37$$$48$$$O	in$$$49$$$51$$$O	combination$$$52$$$63$$$O	with$$$64$$$68$$$O	a$$$69$$$70$$$O	second$$$71$$$77$$$O	active$$$78$$$84$$$O	ingredient$$$85$$$95$$$O
Compound$$$0$$$8$$$O	of$$$9$$$11$$$O	formula$$$12$$$19$$$O	I$$$20$$$21$$$O	are$$$22$$$25$$$O	antagonists$$$26$$$37$$$O	of$$$38$$$40$$$O	the$$$41$$$44$$$O	PGD2$$$45$$$49$$$I	receptor,$$$50$$$59$$$O	CRTH2,$$$60$$$66$$$O	and$$$67$$$70$$$O	as$$$71$$$73$$$O	such$$$74$$$78$$$O	are$$$79$$$82$$$O	useful$$$83$$$89$$$O	in$$$90$$$92$$$O	the$$$93$$$96$$$O	treatment$$$97$$$106$$$O	and/or$$$107$$$113$$$O	prevention$$$114$$$124$$$O	of$$$125$$$127$$$O	CRTH2-mediated$$$128$$$142$$$O	diseases$$$143$$$151$$$O	such$$$152$$$156$$$O	as$$$157$$$159$$$O	asthma$$$160$$$166$$$O	in$$$167$$$169$$$O	combination$$$170$$$181$$$O	with$$$182$$$186$$$O	a$$$187$$$188$$$O	second$$$189$$$195$$$O	active$$$196$$$202$$$O	ingredient$$$203$$$213$$$O	such$$$214$$$218$$$O	as$$$219$$$221$$$O	a$$$222$$$223$$$O	leukotriene$$$224$$$235$$$I	antagonist.$$$236$$$247$$$O
US20110160132
Lymphangiogenesis-promoting$$$0$$$27$$$O	agents$$$28$$$34$$$O
Described$$$0$$$9$$$O	herein$$$10$$$16$$$O	is$$$17$$$19$$$O	the$$$20$$$23$$$O	discovery$$$24$$$33$$$O	that$$$34$$$38$$$O	HGFs$$$39$$$43$$$O	activate$$$44$$$52$$$O	the$$$53$$$56$$$O	growth$$$57$$$63$$$O	and$$$64$$$67$$$O	migration$$$68$$$77$$$O	of$$$78$$$80$$$O	lymphatic$$$81$$$90$$$O	endothelial$$$91$$$102$$$O	cells$$$103$$$108$$$O	and$$$109$$$112$$$O	thereby$$$113$$$120$$$O	promote$$$121$$$128$$$O	lymphangiogenesis.$$$129$$$147$$$O	The$$$148$$$151$$$O	present$$$152$$$159$$$O	invention$$$160$$$169$$$O	is$$$170$$$172$$$O	based$$$173$$$178$$$O	on$$$179$$$181$$$O	this$$$182$$$186$$$O	finding,$$$187$$$195$$$O	and$$$196$$$199$$$O	provides$$$200$$$208$$$O	lymphangiogenesis-promoting$$$209$$$236$$$O	agents$$$237$$$243$$$O	comprising$$$244$$$254$$$O	as$$$255$$$257$$$O	active$$$258$$$264$$$O	ingredients$$$265$$$276$$$O	HGFs,$$$277$$$282$$$O	or$$$283$$$285$$$O	proteins$$$286$$$294$$$O	or$$$295$$$297$$$O	compounds$$$298$$$307$$$O	functionally$$$308$$$320$$$O	equivalent$$$321$$$331$$$O	thereto.$$$332$$$340$$$O	Based$$$341$$$346$$$O	on$$$347$$$349$$$O	the$$$350$$$353$$$O	finding$$$354$$$361$$$O	described$$$362$$$371$$$O	above,$$$372$$$378$$$O	the$$$379$$$382$$$O	present$$$383$$$390$$$O	invention$$$391$$$400$$$O	also$$$401$$$405$$$O	provides$$$406$$$414$$$O	methods$$$415$$$422$$$O	for$$$423$$$426$$$O	promoting$$$427$$$436$$$O	lymphangiogenesis$$$437$$$454$$$O	which$$$455$$$460$$$O	comprise$$$461$$$469$$$O	the$$$470$$$473$$$O	step$$$474$$$478$$$O	of$$$479$$$481$$$O	locally$$$482$$$489$$$O	administering$$$490$$$503$$$O	HGFs$$$504$$$508$$$O	or$$$509$$$511$$$O	proteins$$$512$$$520$$$O	functionally$$$521$$$533$$$O	equivalent$$$534$$$544$$$O	thereto$$$545$$$552$$$O	to$$$553$$$555$$$O	affected$$$556$$$564$$$O	areas$$$565$$$570$$$O	in$$$571$$$573$$$O	patients$$$574$$$582$$$O	with$$$583$$$587$$$O	lymphedema.$$$588$$$599$$$O
CN102911180A
8H-benzopyran[2,3-f]-4-ketone$$$0$$$29$$$I	derivatives$$$30$$$41$$$O	and$$$42$$$45$$$O	preparation$$$46$$$57$$$O	method$$$58$$$64$$$O	and$$$65$$$68$$$O	application$$$69$$$80$$$O	thereof$$$81$$$88$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	chemical$$$48$$$56$$$O	medicaments,$$$57$$$69$$$O	and$$$70$$$73$$$O	in$$$74$$$76$$$O	particular$$$77$$$87$$$O	relates$$$88$$$95$$$O	to$$$96$$$98$$$O	8H-benzopyran[2,3-f]-4-ketone$$$99$$$128$$$I	derivatives$$$129$$$140$$$O	and$$$141$$$144$$$O	a$$$145$$$146$$$O	preparation$$$147$$$158$$$O	method$$$159$$$165$$$O	and$$$166$$$169$$$O	application$$$170$$$181$$$O	of$$$182$$$184$$$O	the$$$185$$$188$$$O	derivatives.$$$189$$$201$$$O	The$$$202$$$205$$$O	first$$$206$$$211$$$O	technical$$$212$$$221$$$O	problem$$$222$$$229$$$O	to$$$230$$$232$$$O	be$$$233$$$235$$$O	solved$$$236$$$242$$$O	by$$$243$$$245$$$O	the$$$246$$$249$$$O	invention$$$250$$$259$$$O	is$$$260$$$262$$$O	to$$$263$$$265$$$O	provide$$$266$$$273$$$O	8,8-dimethyl-3-(2,4,5-trimethoxy$$$274$$$306$$$I	phenyl)-8H-benzopyran[2,3-f]-4-ketone$$$307$$$344$$$I	and$$$345$$$348$$$O	analogs$$$349$$$356$$$O	thereof,$$$357$$$365$$$O	the$$$366$$$369$$$O	structure$$$370$$$379$$$O	of$$$380$$$382$$$O	which$$$383$$$388$$$O	is$$$389$$$391$$$O	shown$$$392$$$397$$$O	in$$$398$$$400$$$O	formula$$$401$$$408$$$O	I$$$409$$$410$$$O	in$$$411$$$413$$$O	the$$$414$$$417$$$O	specification.$$$418$$$432$$$O	8H-benzopyran[2,3-f]-4-ketone$$$433$$$462$$$I	derivatives$$$463$$$474$$$O	obtained$$$475$$$483$$$O	on$$$484$$$486$$$O	the$$$487$$$490$$$O	basis$$$491$$$496$$$O	of$$$497$$$499$$$O	a$$$500$$$501$$$O	great$$$502$$$507$$$O	deal$$$508$$$512$$$O	of$$$513$$$515$$$O	screening$$$516$$$525$$$O	have$$$526$$$530$$$O	antitumor$$$531$$$540$$$O	activity,$$$541$$$550$$$O	so$$$551$$$553$$$O	that$$$554$$$558$$$O	a$$$559$$$560$$$O	new$$$561$$$564$$$O	choice$$$565$$$571$$$O	is$$$572$$$574$$$O	provided$$$575$$$583$$$O	for$$$584$$$587$$$O	development$$$588$$$599$$$O	and$$$600$$$603$$$O	application$$$604$$$615$$$O	of$$$616$$$618$$$O	antitumor$$$619$$$628$$$O	medicaments.$$$629$$$641$$$O
US7772392
prostaglandin$$$0$$$13$$$I	receptor$$$14$$$22$$$O	agonists;$$$23$$$32$$$O	for$$$33$$$36$$$O	treating$$$37$$$45$$$O	various$$$46$$$53$$$O	ocular$$$54$$$60$$$O	hypertensive$$$61$$$73$$$O	conditions$$$74$$$84$$$O	such$$$85$$$89$$$O	as$$$90$$$92$$$O	post-surgical$$$93$$$106$$$O	and$$$107$$$110$$$O	post-laser$$$111$$$121$$$O	trabeculectomy$$$122$$$136$$$O	ocular$$$137$$$143$$$O	hypertensive$$$144$$$156$$$O	episodes,$$$157$$$166$$$O	glaucoma,$$$167$$$176$$$O	and$$$177$$$180$$$O	as$$$181$$$183$$$O	presurgical$$$184$$$195$$$O	adjuncts$$$196$$$204$$$O
Compounds$$$0$$$9$$$O	comprising$$$10$$$20$$$O	or$$$134$$$136$$$O	a$$$137$$$138$$$O	pharmaceutically$$$139$$$155$$$O	acceptable$$$156$$$166$$$O	salt$$$167$$$171$$$O	or$$$172$$$174$$$O	a$$$175$$$176$$$O	prodrug$$$177$$$184$$$O	thereof;$$$185$$$193$$$O	wherein$$$206$$$213$$$O	a$$$214$$$215$$$O	dashed$$$216$$$222$$$O	line$$$223$$$227$$$O	indicates$$$228$$$237$$$O	the$$$238$$$241$$$O	presence$$$242$$$250$$$O	or$$$251$$$253$$$O	absence$$$254$$$261$$$O	of$$$262$$$264$$$O	a$$$265$$$266$$$O	bond;$$$267$$$272$$$O	Y$$$285$$$286$$$O	is$$$287$$$289$$$O	an$$$290$$$292$$$O	organic$$$293$$$300$$$O	acid$$$301$$$305$$$O	group,$$$306$$$312$$$O	or$$$313$$$315$$$O	an$$$316$$$318$$$O	amide$$$319$$$324$$$I	or$$$325$$$327$$$O	ester$$$328$$$333$$$I	thereof$$$334$$$341$$$O	comprising$$$342$$$352$$$O	from$$$353$$$357$$$O	1$$$358$$$359$$$O	to$$$360$$$362$$$O	12$$$363$$$365$$$O	carbon$$$366$$$372$$$I	atoms;$$$373$$$379$$$O	or$$$380$$$382$$$O	Y$$$383$$$384$$$O	is$$$385$$$387$$$O	hydroxymethyl$$$388$$$401$$$I	or$$$402$$$404$$$O	an$$$405$$$407$$$O	ether$$$408$$$413$$$I	thereof$$$414$$$421$$$O	comprising$$$422$$$432$$$O	from$$$433$$$437$$$O	1$$$438$$$439$$$O	to$$$440$$$442$$$O	12$$$443$$$445$$$O	carbon$$$446$$$452$$$I	atoms;$$$453$$$459$$$O	or$$$472$$$474$$$O	Y$$$475$$$476$$$O	is$$$477$$$479$$$O	a$$$480$$$481$$$O	tetrazolyl$$$482$$$492$$$I	group;$$$493$$$499$$$O	A$$$512$$$513$$$O	is$$$514$$$516$$$O	â(CH2)6â,$$$517$$$530$$$I	cis$$$531$$$534$$$I	âCH2CHâCHâ(CH2)3â,$$$535$$$561$$$I	or$$$562$$$564$$$I	âCH2Câ¡Câ(CH2)3â,$$$565$$$589$$$I	wherein$$$590$$$597$$$I	1$$$598$$$599$$$O	or$$$600$$$602$$$O	2$$$603$$$604$$$O	carbon$$$605$$$611$$$O	atoms$$$612$$$617$$$O	may$$$618$$$621$$$O	be$$$622$$$624$$$I	substituted$$$625$$$636$$$I	with$$$637$$$641$$$I	S$$$642$$$643$$$I	or$$$644$$$646$$$I	O;$$$647$$$649$$$I	or$$$650$$$652$$$I	A$$$653$$$654$$$I	is$$$655$$$657$$$I	â(CH2)mâArâ(CH2)oâ$$$658$$$684$$$I	wherein$$$685$$$692$$$O	Ar$$$693$$$695$$$O	is$$$696$$$698$$$O	interarylene$$$699$$$711$$$O	or$$$712$$$714$$$O	heterointerarylene,$$$715$$$734$$$O	the$$$735$$$738$$$O	sum$$$739$$$742$$$O	of$$$743$$$745$$$O	m$$$746$$$747$$$O	and$$$748$$$751$$$O	o$$$752$$$753$$$O	is$$$754$$$756$$$O	from$$$757$$$761$$$I	1$$$762$$$763$$$O	to$$$764$$$766$$$O	4,$$$767$$$769$$$O	and$$$770$$$773$$$O	wherein$$$774$$$781$$$O	one$$$782$$$785$$$I	CH2$$$786$$$789$$$I	may$$$790$$$793$$$O	be$$$794$$$796$$$O	replaced$$$797$$$805$$$O	with$$$806$$$810$$$I	S$$$811$$$812$$$I	or$$$813$$$815$$$I	O;$$$816$$$818$$$I	J$$$831$$$832$$$I	is$$$833$$$835$$$I	CHOH,$$$836$$$841$$$I	CâO,$$$842$$$848$$$O	CH2CHOH,$$$849$$$857$$$I	or$$$858$$$860$$$O	CH2CâO;$$$861$$$870$$$I	and$$$871$$$874$$$I	Ar1$$$887$$$890$$$I	is$$$891$$$893$$$I	aryl,$$$894$$$899$$$I	heteroaryl,$$$900$$$911$$$I	CH2-aryl,$$$912$$$921$$$I	CH2-heteroaryl,$$$922$$$937$$$I	O-aryl,$$$938$$$945$$$I	O-heteroaryl,$$$946$$$959$$$I	S-aryl,$$$960$$$967$$$O	or$$$968$$$970$$$O	S-heteroaryl.$$$971$$$984$$$O
EP2714712A1
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	production$$$16$$$26$$$O	of$$$27$$$29$$$O	estetrol$$$30$$$38$$$I	intermediates$$$39$$$52$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	process$$$35$$$42$$$O	for$$$43$$$46$$$O	the$$$47$$$50$$$O	preparation$$$51$$$62$$$O	of$$$63$$$65$$$O	a$$$66$$$67$$$O	compound$$$68$$$76$$$O	of$$$77$$$79$$$O	formula$$$80$$$87$$$O	(I)$$$88$$$91$$$O	comprising$$$92$$$102$$$O	the$$$103$$$106$$$O	steps$$$107$$$112$$$O	of$$$113$$$115$$$O	a)$$$116$$$118$$$O	reacting$$$119$$$127$$$O	a$$$128$$$129$$$O	compound$$$130$$$138$$$O	of$$$139$$$141$$$O	formula$$$142$$$149$$$O	(II)$$$150$$$154$$$O	with$$$155$$$159$$$O	a$$$160$$$161$$$O	silylating$$$162$$$172$$$O	or$$$173$$$175$$$O	an$$$176$$$178$$$O	acylating$$$179$$$188$$$O	agent$$$189$$$194$$$O	to$$$195$$$197$$$O	produce$$$198$$$205$$$O	compound$$$206$$$214$$$O	of$$$215$$$217$$$O	formula$$$218$$$225$$$O	(III),$$$226$$$232$$$O	wherein$$$233$$$240$$$O	P1$$$241$$$243$$$O	is$$$244$$$246$$$O	a$$$247$$$248$$$O	protecting$$$249$$$259$$$O	group$$$260$$$265$$$O	selected$$$266$$$274$$$O	from$$$275$$$279$$$O	R2-Si-R3R4$$$280$$$290$$$I	or$$$291$$$293$$$O	R1CO-,$$$294$$$300$$$I	R1$$$301$$$303$$$O	is$$$304$$$306$$$O	a$$$307$$$308$$$O	group$$$309$$$314$$$O	selected$$$315$$$323$$$O	from$$$324$$$328$$$O	C1-6alkyl$$$329$$$338$$$I	or$$$339$$$341$$$O	C3-6cycloalkyl,$$$342$$$357$$$I	each$$$358$$$362$$$O	group$$$363$$$368$$$O	being$$$369$$$374$$$O	optionally$$$375$$$385$$$O	substituted$$$386$$$397$$$O	by$$$398$$$400$$$O	one$$$401$$$404$$$O	or$$$405$$$407$$$O	more$$$408$$$412$$$O	substituents$$$413$$$425$$$O	independently$$$426$$$439$$$O	selected$$$440$$$448$$$O	from$$$449$$$453$$$O	fluoro$$$454$$$460$$$I	or$$$461$$$463$$$O	C1-4alkyl;$$$464$$$474$$$I	R2,$$$475$$$478$$$O	R3$$$479$$$481$$$O	and$$$482$$$485$$$O	R4$$$486$$$488$$$O	are$$$489$$$492$$$O	each$$$493$$$497$$$O	independently$$$498$$$511$$$O	a$$$512$$$513$$$O	group$$$514$$$519$$$O	selected$$$520$$$528$$$O	from$$$529$$$533$$$O	C1-6alkyl$$$534$$$543$$$I	or$$$544$$$546$$$O	phenyl,$$$547$$$554$$$I	each$$$555$$$559$$$O	group$$$560$$$565$$$O	being$$$566$$$571$$$O	optionally$$$572$$$582$$$O	substituted$$$583$$$594$$$O	by$$$595$$$597$$$O	one$$$598$$$601$$$O	or$$$602$$$604$$$O	more$$$605$$$609$$$O	substituents$$$610$$$622$$$O	independently$$$623$$$636$$$O	selected$$$637$$$645$$$O	from$$$646$$$650$$$O	fluoro$$$651$$$657$$$I	or$$$658$$$660$$$O	C1-4alkyl;$$$661$$$671$$$I	b)$$$672$$$674$$$O	halogenation$$$675$$$687$$$O	or$$$688$$$690$$$O	sulfinylation$$$691$$$704$$$O	of$$$705$$$707$$$O	the$$$708$$$711$$$O	compound$$$712$$$720$$$O	of$$$721$$$723$$$O	formula$$$724$$$731$$$O	(III)$$$732$$$737$$$O	to$$$738$$$740$$$O	produce$$$741$$$748$$$O	a$$$749$$$750$$$O	compound$$$751$$$759$$$O	of$$$760$$$762$$$O	formula$$$763$$$770$$$O	(IV);$$$771$$$776$$$O	wherein$$$777$$$784$$$O	X$$$785$$$786$$$O	is$$$787$$$789$$$O	halo,$$$790$$$795$$$I	or$$$796$$$798$$$O	-O-SO-R5,$$$799$$$808$$$I	and$$$809$$$812$$$O	R5$$$813$$$815$$$O	is$$$816$$$818$$$O	a$$$819$$$820$$$O	group$$$821$$$826$$$O	selected$$$827$$$835$$$O	from$$$836$$$840$$$O	C6-10aryl$$$841$$$850$$$I	or$$$851$$$853$$$O	heteroaryl,$$$854$$$865$$$I	each$$$866$$$870$$$O	group$$$871$$$876$$$O	being$$$877$$$882$$$O	optionally$$$883$$$893$$$O	substituted$$$894$$$905$$$O	by$$$906$$$908$$$O	one$$$909$$$912$$$O	or$$$913$$$915$$$O	more$$$916$$$920$$$O	substituents$$$921$$$933$$$O	independently$$$934$$$947$$$O	selected$$$948$$$956$$$O	from$$$957$$$961$$$O	chloro$$$962$$$968$$$I	or$$$969$$$971$$$O	C1-4alkyl;$$$972$$$982$$$I	c)$$$983$$$985$$$O	dehalogenation$$$986$$$1000$$$O	or$$$1001$$$1003$$$O	desulfinylation$$$1004$$$1019$$$O	of$$$1020$$$1022$$$O	the$$$1023$$$1026$$$O	compound$$$1027$$$1035$$$O	of$$$1036$$$1038$$$O	formula$$$1039$$$1046$$$O	(IV)$$$1047$$$1051$$$O	to$$$1052$$$1054$$$O	produce$$$1055$$$1062$$$O	compound$$$1063$$$1071$$$O	of$$$1072$$$1074$$$O	formula$$$1075$$$1082$$$O	(V);$$$1083$$$1087$$$O	and$$$1088$$$1091$$$O	d)$$$1092$$$1094$$$O	reacting$$$1095$$$1103$$$O	the$$$1104$$$1107$$$O	compound$$$1108$$$1116$$$O	of$$$1117$$$1119$$$O	formula$$$1120$$$1127$$$O	(V)$$$1128$$$1131$$$O	with$$$1132$$$1136$$$O	a$$$1137$$$1138$$$O	reducing$$$1139$$$1147$$$O	agent$$$1148$$$1153$$$O	to$$$1154$$$1156$$$O	produce$$$1157$$$1164$$$O	compound$$$1165$$$1173$$$O	of$$$1174$$$1176$$$O	formula$$$1177$$$1184$$$O	(I).$$$1185$$$1189$$$O
CN102973578A
Compound$$$0$$$8$$$O	preparation$$$9$$$20$$$O	used$$$21$$$25$$$O	for$$$26$$$29$$$O	controlling$$$30$$$41$$$O	avian$$$42$$$47$$$O	mycoplasma$$$48$$$58$$$O	and$$$59$$$62$$$O	Escherichia$$$63$$$74$$$O	coli$$$75$$$79$$$O	mixed$$$80$$$85$$$O	infection,$$$86$$$96$$$O	and$$$97$$$100$$$O	preparation$$$101$$$112$$$O	method$$$113$$$119$$$O	thereof$$$120$$$127$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	veterinary$$$27$$$37$$$O	drug$$$38$$$42$$$O	solution$$$43$$$51$$$O	preparation$$$52$$$63$$$O	used$$$64$$$68$$$O	for$$$69$$$72$$$O	controlling$$$73$$$84$$$O	avian$$$85$$$90$$$O	mycoplasma$$$91$$$101$$$O	and$$$102$$$105$$$O	Escherichia$$$106$$$117$$$O	coli$$$118$$$122$$$O	mixed$$$123$$$128$$$O	infection.$$$129$$$139$$$O	The$$$140$$$143$$$O	solution$$$144$$$152$$$O	is$$$153$$$155$$$O	composed$$$156$$$164$$$O	of$$$165$$$167$$$O	three$$$168$$$173$$$O	main$$$174$$$178$$$O	medicine$$$179$$$187$$$O	components$$$188$$$198$$$O	which$$$199$$$204$$$O	are$$$205$$$208$$$O	florfenicol,$$$209$$$221$$$I	doxycycline$$$222$$$233$$$I	hydrochloride,$$$234$$$248$$$I	and$$$249$$$252$$$O	indomethacin,$$$253$$$266$$$I	and$$$267$$$270$$$O	added$$$271$$$276$$$O	materials$$$277$$$286$$$O	of$$$287$$$289$$$O	a$$$290$$$291$$$O	solvent,$$$292$$$300$$$O	an$$$301$$$303$$$O	auxiliary$$$304$$$313$$$O	solvent,$$$314$$$322$$$O	and$$$323$$$326$$$O	a$$$327$$$328$$$O	pH-regulating$$$329$$$342$$$O	agent.$$$343$$$349$$$O	The$$$350$$$353$$$O	solution$$$354$$$362$$$O	comprises$$$363$$$372$$$O	5-10%$$$373$$$378$$$O	(W/V)$$$379$$$384$$$O	of$$$385$$$387$$$O	florfenicol,$$$388$$$400$$$I	5-6%$$$401$$$405$$$O	(W/V)$$$406$$$411$$$O	of$$$412$$$414$$$O	doxycycline$$$415$$$426$$$I	hydrochloride,$$$427$$$441$$$I	0.5-1.0%$$$442$$$450$$$O	(W/V)$$$451$$$456$$$O	of$$$457$$$459$$$O	indomethacin,$$$460$$$473$$$I	and$$$474$$$477$$$O	balance$$$478$$$485$$$O	of$$$486$$$488$$$O	the$$$489$$$492$$$O	solvent,$$$493$$$501$$$O	the$$$502$$$505$$$O	auxiliary$$$506$$$515$$$O	solvent,$$$516$$$524$$$O	and$$$525$$$528$$$O	the$$$529$$$532$$$O	pH-regulating$$$533$$$546$$$O	agent.$$$547$$$553$$$O	Florfenicol$$$554$$$565$$$I	and$$$566$$$569$$$O	doxycycline$$$570$$$581$$$I	hydrochloride$$$582$$$595$$$I	both$$$596$$$600$$$O	have$$$601$$$605$$$O	broad-spectrum$$$606$$$620$$$O	antibacterial$$$621$$$634$$$O	effects,$$$635$$$643$$$O	and$$$644$$$647$$$O	has$$$648$$$651$$$O	a$$$652$$$653$$$O	certain$$$654$$$661$$$O	controlling$$$662$$$673$$$O	effect$$$674$$$680$$$O	against$$$681$$$688$$$O	mycoplasma$$$689$$$699$$$O	and$$$700$$$703$$$O	Escherichia$$$704$$$715$$$O	coli.$$$716$$$721$$$O	The$$$722$$$725$$$O	effect$$$726$$$732$$$O	of$$$733$$$735$$$O	florfenicol$$$736$$$747$$$O	against$$$748$$$755$$$O	Escherichia$$$756$$$767$$$O	coli$$$768$$$772$$$O	is$$$773$$$775$$$O	better$$$776$$$782$$$O	than$$$783$$$787$$$O	that$$$788$$$792$$$O	against$$$793$$$800$$$O	mycoplasma,$$$801$$$812$$$O	and$$$813$$$816$$$O	the$$$817$$$820$$$O	effect$$$821$$$827$$$O	of$$$828$$$830$$$O	doxycycline$$$831$$$842$$$I	hydrochloride$$$843$$$856$$$I	against$$$857$$$864$$$O	mycoplasma$$$865$$$875$$$O	is$$$876$$$878$$$O	better$$$879$$$885$$$O	than$$$886$$$890$$$O	that$$$891$$$895$$$O	against$$$896$$$903$$$O	Escherichia$$$904$$$915$$$O	coli.$$$916$$$921$$$O	In$$$922$$$924$$$O	addition,$$$925$$$934$$$O	the$$$935$$$938$$$O	inflammation-inhibiting$$$939$$$962$$$O	heat-clearing$$$963$$$976$$$O	medicine$$$977$$$985$$$O	indomethacin$$$986$$$998$$$I	is$$$999$$$1001$$$O	added,$$$1002$$$1008$$$O	such$$$1009$$$1013$$$O	that$$$1014$$$1018$$$O	inflammations$$$1019$$$1032$$$O	caused$$$1033$$$1039$$$O	by$$$1040$$$1042$$$O	mycoplasma$$$1043$$$1053$$$O	and$$$1054$$$1057$$$O	Escherichia$$$1058$$$1069$$$O	coli$$$1070$$$1074$$$O	can$$$1075$$$1078$$$O	be$$$1079$$$1081$$$O	substantially$$$1082$$$1095$$$O	relieved.$$$1096$$$1105$$$O	Therefore,$$$1106$$$1116$$$O	both$$$1117$$$1121$$$O	symptoms$$$1122$$$1130$$$O	and$$$1131$$$1134$$$O	root$$$1135$$$1139$$$O	causes$$$1140$$$1146$$$O	are$$$1147$$$1150$$$O	treated,$$$1151$$$1159$$$O	a$$$1160$$$1161$$$O	treatment$$$1162$$$1171$$$O	effect$$$1172$$$1178$$$O	is$$$1179$$$1181$$$O	enhanced,$$$1182$$$1191$$$O	and$$$1192$$$1195$$$O	pathogenic$$$1196$$$1206$$$O	microorganism$$$1207$$$1220$$$O	inhibiting$$$1221$$$1231$$$O	range$$$1232$$$1237$$$O	is$$$1238$$$1240$$$O	enlarged.$$$1241$$$1250$$$O	The$$$1251$$$1254$$$O	preparation$$$1255$$$1266$$$O	is$$$1267$$$1269$$$O	safe$$$1270$$$1274$$$O	and$$$1275$$$1278$$$O	effective,$$$1279$$$1289$$$O	and$$$1290$$$1293$$$O	caused$$$1294$$$1300$$$O	no$$$1301$$$1303$$$O	drug$$$1304$$$1308$$$O	resistance.$$$1309$$$1320$$$O	The$$$1321$$$1324$$$O	preparation$$$1325$$$1336$$$O	method$$$1337$$$1343$$$O	of$$$1344$$$1346$$$O	the$$$1347$$$1350$$$O	composition$$$1351$$$1362$$$O	comprises$$$1363$$$1372$$$O	the$$$1373$$$1376$$$O	steps$$$1377$$$1382$$$O	that:$$$1383$$$1388$$$O	florfenicol$$$1389$$$1400$$$I	and$$$1401$$$1404$$$O	doxycycline$$$1405$$$1416$$$I	hydrochloride$$$1417$$$1430$$$I	are$$$1431$$$1434$$$O	dissolved$$$1435$$$1444$$$O	in$$$1445$$$1447$$$O	dimethyl$$$1448$$$1456$$$I	acetamide,$$$1457$$$1467$$$I	and$$$1468$$$1471$$$O	are$$$1472$$$1475$$$O	stirred$$$1476$$$1483$$$O	for$$$1484$$$1487$$$O	10min$$$1488$$$1493$$$O	for$$$1494$$$1497$$$O	dissolving;$$$1498$$$1509$$$O	indomethacin$$$1510$$$1522$$$I	is$$$1523$$$1525$$$O	stirred$$$1526$$$1533$$$O	and$$$1534$$$1537$$$O	dissolved$$$1538$$$1547$$$O	by$$$1548$$$1550$$$O	using$$$1551$$$1556$$$O	propylene$$$1557$$$1566$$$I	glycol;$$$1567$$$1574$$$I	the$$$1575$$$1578$$$O	solution$$$1579$$$1587$$$O	is$$$1588$$$1590$$$O	added$$$1591$$$1596$$$O	into$$$1597$$$1601$$$O	the$$$1602$$$1605$$$O	mixed$$$1606$$$1611$$$O	liquid,$$$1612$$$1619$$$O	and$$$1620$$$1623$$$O	the$$$1624$$$1627$$$O	mixture$$$1628$$$1635$$$O	is$$$1636$$$1638$$$O	well$$$1639$$$1643$$$O	mixed$$$1644$$$1649$$$O	by$$$1650$$$1652$$$O	stirring$$$1653$$$1661$$$O	for$$$1662$$$1665$$$O	15min;$$$1666$$$1672$$$O	anhydrous$$$1673$$$1682$$$O	ethanol$$$1683$$$1690$$$I	is$$$1691$$$1693$$$O	added$$$1694$$$1699$$$O	for$$$1700$$$1703$$$O	metering$$$1704$$$1712$$$O	the$$$1713$$$1716$$$O	volume$$$1717$$$1723$$$O	to$$$1724$$$1726$$$O	1000ml;$$$1727$$$1734$$$O	a$$$1735$$$1736$$$O	pH$$$1737$$$1739$$$O	value$$$1740$$$1745$$$O	is$$$1746$$$1748$$$O	reduced$$$1749$$$1756$$$O	to$$$1757$$$1759$$$O	3.0-4.0$$$1760$$$1767$$$O	by$$$1768$$$1770$$$O	using$$$1771$$$1776$$$O	a$$$1777$$$1778$$$O	proper$$$1779$$$1785$$$O	amount$$$1786$$$1792$$$O	of$$$1793$$$1795$$$O	lactic$$$1796$$$1802$$$I	acid;$$$1803$$$1808$$$I	and$$$1809$$$1812$$$O	the$$$1813$$$1816$$$O	mixture$$$1817$$$1824$$$O	is$$$1825$$$1827$$$O	filtered$$$1828$$$1836$$$O	and$$$1837$$$1840$$$O	sub-packaged,$$$1841$$$1854$$$O	such$$$1855$$$1859$$$O	that$$$1860$$$1864$$$O	the$$$1865$$$1868$$$O	product$$$1869$$$1876$$$O	is$$$1877$$$1879$$$O	obtained.$$$1880$$$1889$$$O	When$$$1890$$$1894$$$O	the$$$1895$$$1898$$$O	product$$$1899$$$1906$$$O	is$$$1907$$$1909$$$O	prepared$$$1910$$$1918$$$O	into$$$1919$$$1923$$$O	a$$$1924$$$1925$$$O	solution$$$1926$$$1934$$$O	preparation,$$$1935$$$1947$$$O	the$$$1948$$$1951$$$O	product$$$1952$$$1959$$$O	can$$$1960$$$1963$$$O	easily$$$1964$$$1970$$$O	be$$$1971$$$1973$$$O	dissolved$$$1974$$$1983$$$O	in$$$1984$$$1986$$$O	water,$$$1987$$$1993$$$O	and$$$1994$$$1997$$$O	is$$$1998$$$2000$$$O	convenient$$$2001$$$2011$$$O	to$$$2012$$$2014$$$O	use.$$$2015$$$2019$$$O	Therefore,$$$2020$$$2030$$$O	an$$$2031$$$2033$$$O	administration$$$2034$$$2048$$$O	problem,$$$2049$$$2057$$$O	that$$$2058$$$2062$$$O	poultry$$$2063$$$2070$$$O	takes$$$2071$$$2076$$$O	only$$$2077$$$2081$$$O	water$$$2082$$$2087$$$O	but$$$2088$$$2091$$$O	no$$$2092$$$2094$$$O	feedstuff$$$2095$$$2104$$$O	after$$$2105$$$2110$$$O	illness,$$$2111$$$2119$$$O	is$$$2120$$$2122$$$O	solved.$$$2123$$$2130$$$O	The$$$2131$$$2134$$$O	preparation$$$2135$$$2146$$$O	has$$$2147$$$2150$$$O	a$$$2151$$$2152$$$O	substantial$$$2153$$$2164$$$O	effect.$$$2165$$$2172$$$O	The$$$2173$$$2176$$$O	preparation$$$2177$$$2188$$$O	has$$$2189$$$2192$$$O	the$$$2193$$$2196$$$O	advantages$$$2197$$$2207$$$O	of$$$2208$$$2210$$$O	high$$$2211$$$2215$$$O	sensitivity$$$2216$$$2227$$$O	against$$$2228$$$2235$$$O	avian$$$2236$$$2241$$$O	mycoplasma$$$2242$$$2252$$$O	and$$$2253$$$2256$$$O	Escherichia$$$2257$$$2268$$$O	coli$$$2269$$$2273$$$O	mixed$$$2274$$$2279$$$O	infection$$$2280$$$2289$$$O	diseases,$$$2290$$$2299$$$O	good$$$2300$$$2304$$$O	effect,$$$2305$$$2312$$$O	low$$$2313$$$2316$$$O	drug$$$2317$$$2321$$$O	resistance,$$$2322$$$2333$$$O	convenient$$$2334$$$2344$$$O	application,$$$2345$$$2357$$$O	and$$$2358$$$2361$$$O	good$$$2362$$$2366$$$O	popularization$$$2367$$$2381$$$O	and$$$2382$$$2385$$$O	application$$$2386$$$2397$$$O	values.$$$2398$$$2405$$$O
CN101260075B
Aralkylpiperidine$$$0$$$17$$$I	derivative$$$18$$$28$$$O	and$$$29$$$32$$$O	application$$$33$$$44$$$O	thereof$$$45$$$52$$$O	in$$$53$$$55$$$O	preparing$$$56$$$65$$$O	analgesic$$$66$$$75$$$O	and$$$76$$$79$$$O	sedative$$$80$$$88$$$O	medicament$$$89$$$99$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	aralkyl$$$25$$$32$$$I	piperidine$$$33$$$43$$$I	derivatives,$$$44$$$56$$$O	a$$$57$$$58$$$O	compound$$$59$$$67$$$O	thereof$$$68$$$75$$$O	and$$$76$$$79$$$O	an$$$80$$$82$$$O	application$$$83$$$94$$$O	in$$$95$$$97$$$O	the$$$98$$$101$$$O	preparation$$$102$$$113$$$O	of$$$114$$$116$$$O	a$$$117$$$118$$$O	novel$$$119$$$124$$$O	analgesic$$$125$$$134$$$O	and$$$135$$$138$$$O	sedative$$$139$$$147$$$O	drug.$$$148$$$153$$$O	The$$$154$$$157$$$O	derivatives$$$158$$$169$$$O	of$$$170$$$172$$$O	the$$$173$$$176$$$O	invention$$$177$$$186$$$O	are$$$187$$$190$$$O	free$$$191$$$195$$$O	alkali$$$196$$$202$$$O	or$$$203$$$205$$$O	salt$$$206$$$210$$$O	of$$$211$$$213$$$O	the$$$214$$$217$$$O	general$$$218$$$225$$$O	formula$$$226$$$233$$$O	compound.$$$234$$$243$$$O	The$$$244$$$247$$$O	pharmacological$$$248$$$263$$$O	test$$$264$$$268$$$O	shows$$$269$$$274$$$O	that$$$275$$$279$$$O	the$$$280$$$283$$$O	compound$$$284$$$292$$$O	of$$$293$$$295$$$O	the$$$296$$$299$$$O	invention$$$300$$$309$$$O	has$$$310$$$313$$$O	good$$$314$$$318$$$O	analgesic$$$319$$$328$$$O	and$$$329$$$332$$$O	sedative$$$333$$$341$$$O	activity$$$342$$$350$$$O	and$$$351$$$354$$$O	extremely$$$355$$$364$$$O	small$$$365$$$370$$$O	side$$$371$$$375$$$O	effect.$$$376$$$383$$$O
EP2609914A1
Novel$$$0$$$5$$$O	methods$$$6$$$13$$$O	for$$$14$$$17$$$O	treating$$$18$$$26$$$O	or$$$27$$$29$$$O	preventing$$$30$$$40$$$O	neurodegeneration$$$41$$$58$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	compound$$$27$$$35$$$O	which$$$36$$$41$$$O	is$$$42$$$44$$$O	effective$$$45$$$54$$$O	in$$$55$$$57$$$O	inhibiting$$$58$$$68$$$O	the$$$69$$$72$$$O	function$$$73$$$81$$$O	of$$$82$$$84$$$O	the$$$85$$$88$$$O	TRPM4$$$89$$$94$$$O	ion$$$95$$$98$$$O	channel$$$99$$$106$$$O	and$$$107$$$110$$$O	the$$$111$$$114$$$O	use$$$115$$$118$$$O	of$$$119$$$121$$$O	such$$$122$$$126$$$O	compound$$$127$$$135$$$O	in$$$136$$$138$$$O	treating$$$139$$$147$$$O	or$$$148$$$150$$$O	preventing$$$151$$$161$$$O	a$$$162$$$163$$$O	neurodegenerative$$$164$$$181$$$O	disease,$$$182$$$190$$$O	such$$$191$$$195$$$O	as$$$196$$$198$$$O	Multiple$$$199$$$207$$$O	Sclerosis,$$$208$$$218$$$O	Parkinson's$$$219$$$230$$$O	disease,$$$231$$$239$$$O	Alzheimer's$$$240$$$251$$$O	disease,$$$252$$$260$$$O	or$$$261$$$263$$$O	amyotrophic$$$264$$$275$$$O	lateral$$$276$$$283$$$O	sclerosis,$$$284$$$294$$$O	in$$$295$$$297$$$O	a$$$298$$$299$$$O	subject.$$$300$$$308$$$O	The$$$309$$$312$$$O	invention$$$313$$$322$$$O	also$$$323$$$327$$$O	provides$$$328$$$336$$$O	a$$$337$$$338$$$O	pharmaceutical$$$339$$$353$$$O	composition$$$354$$$365$$$O	comprising$$$366$$$376$$$O	a$$$377$$$378$$$O	TRPM4$$$379$$$384$$$O	inhibitory$$$385$$$395$$$O	compound.$$$396$$$405$$$O	The$$$406$$$409$$$O	invention$$$410$$$419$$$O	further$$$420$$$427$$$O	relates$$$428$$$435$$$O	to$$$436$$$438$$$O	in$$$439$$$441$$$O	vitro$$$442$$$447$$$O	methods$$$448$$$455$$$O	for$$$456$$$459$$$O	identifying$$$460$$$471$$$O	pharmaceutically$$$472$$$488$$$O	active$$$489$$$495$$$O	compounds$$$496$$$505$$$O	that$$$506$$$510$$$O	are$$$511$$$514$$$O	useful$$$515$$$521$$$O	for$$$522$$$525$$$O	treating$$$526$$$534$$$O	or$$$535$$$537$$$O	preventing$$$538$$$548$$$O	a$$$549$$$550$$$O	neurodegenerative$$$551$$$568$$$O	disease.$$$569$$$577$$$O
EP2688565A1
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	proliferative$$$13$$$26$$$O	disorders$$$27$$$36$$$O	with$$$37$$$41$$$O	a$$$42$$$43$$$O	chemiluminescent$$$44$$$60$$$O	agent$$$61$$$66$$$O
Methods$$$0$$$7$$$O	employing$$$8$$$17$$$O	chemiluminescent$$$18$$$34$$$O	agents$$$35$$$41$$$O	as$$$42$$$44$$$O	therapeutically$$$45$$$60$$$O	active$$$61$$$67$$$O	agents$$$68$$$74$$$O	in$$$75$$$77$$$O	the$$$78$$$81$$$O	treatment$$$82$$$91$$$O	of$$$92$$$94$$$O	proliferative$$$95$$$108$$$O	disorders$$$109$$$118$$$O	are$$$119$$$122$$$O	disclosed.$$$123$$$133$$$O	The$$$134$$$137$$$O	chemiluminiscent$$$138$$$154$$$O	agents$$$155$$$161$$$O	are$$$162$$$165$$$O	used$$$166$$$170$$$O	in$$$171$$$173$$$O	the$$$174$$$177$$$O	disclosed$$$178$$$187$$$O	method$$$188$$$194$$$O	without$$$195$$$202$$$O	a$$$203$$$204$$$O	therapeutically$$$205$$$220$$$O	effective$$$221$$$230$$$O	amount$$$231$$$237$$$O	of$$$238$$$240$$$O	a$$$241$$$242$$$O	photosensitizer.$$$243$$$259$$$O	Novel$$$260$$$265$$$O	chemiluminescent$$$266$$$282$$$O	agents$$$283$$$289$$$O	having$$$290$$$296$$$O	the$$$297$$$300$$$O	general$$$301$$$308$$$O	formula:$$$309$$$317$$$O	are$$$318$$$321$$$O	also$$$322$$$326$$$O	disclosed,$$$327$$$337$$$O	wherein$$$338$$$345$$$O	X,$$$346$$$348$$$O	Y,$$$349$$$351$$$O	Z,$$$352$$$354$$$O	R3$$$355$$$357$$$O	and$$$358$$$361$$$O	R5-R9$$$362$$$367$$$O	are$$$368$$$371$$$O	as$$$372$$$374$$$O	defined$$$375$$$382$$$O	herein.$$$383$$$390$$$O
CN101703500A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	isofraxidin$$$15$$$26$$$I	in$$$27$$$29$$$O	preparing$$$30$$$39$$$O	medicament$$$40$$$50$$$O	for$$$51$$$54$$$O	treating$$$55$$$63$$$O	osteoporosis$$$64$$$76$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	application$$$28$$$39$$$O	method$$$40$$$46$$$O	of$$$47$$$49$$$O	isofraxidin$$$50$$$61$$$I	in$$$62$$$64$$$O	preparing$$$65$$$74$$$O	a$$$75$$$76$$$O	medicament$$$77$$$87$$$O	for$$$88$$$91$$$O	treating$$$92$$$100$$$O	osteoporosis.$$$101$$$114$$$O	The$$$115$$$118$$$O	medicament$$$119$$$129$$$O	prepared$$$130$$$138$$$O	from$$$139$$$143$$$O	the$$$144$$$147$$$O	isofraxidin$$$148$$$159$$$I	and$$$160$$$163$$$O	used$$$164$$$168$$$O	for$$$169$$$172$$$O	treating$$$173$$$181$$$O	the$$$182$$$185$$$O	osteoporosis$$$186$$$198$$$O	can$$$199$$$202$$$O	obviously$$$203$$$212$$$O	increase$$$213$$$221$$$O	the$$$222$$$225$$$O	bone$$$226$$$230$$$O	mineral$$$231$$$238$$$O	density$$$239$$$246$$$O	and$$$247$$$250$$$O	improve$$$251$$$258$$$O	indexes$$$259$$$266$$$O	of$$$267$$$269$$$O	osseous$$$270$$$277$$$O	biomechanics,$$$278$$$291$$$O	and$$$292$$$295$$$O	improve$$$296$$$303$$$O	the$$$304$$$307$$$O	concentration$$$308$$$321$$$O	of$$$322$$$324$$$O	blood-serum$$$325$$$336$$$O	estradiol$$$337$$$346$$$I	(E2),$$$347$$$352$$$I	and$$$353$$$356$$$O	has$$$357$$$360$$$O	an$$$361$$$363$$$O	obvious$$$364$$$371$$$O	effect.$$$372$$$379$$$O
CN102038652A
Melphalan$$$0$$$9$$$I	multi-targeted$$$10$$$24$$$O	drug$$$25$$$29$$$O	carrying$$$30$$$38$$$O	system,$$$39$$$46$$$O	and$$$47$$$50$$$O	preparation$$$51$$$62$$$O	method$$$63$$$69$$$O	and$$$70$$$73$$$O	application$$$74$$$85$$$O	thereof$$$86$$$93$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	tumor$$$27$$$32$$$O	cell$$$33$$$37$$$O	multi-targeted$$$38$$$52$$$O	drug$$$53$$$57$$$O	carrying$$$58$$$66$$$O	system,$$$67$$$74$$$O	and$$$75$$$78$$$O	a$$$79$$$80$$$O	preparation$$$81$$$92$$$O	method$$$93$$$99$$$O	of$$$100$$$102$$$O	the$$$103$$$106$$$O	drug$$$107$$$111$$$O	carrying$$$112$$$120$$$O	system$$$121$$$127$$$O	and$$$128$$$131$$$O	application$$$132$$$143$$$O	of$$$144$$$146$$$O	the$$$147$$$150$$$O	drug$$$151$$$155$$$O	carrying$$$156$$$164$$$O	system$$$165$$$171$$$O	in$$$172$$$174$$$O	the$$$175$$$178$$$O	aspect$$$179$$$185$$$O	of$$$186$$$188$$$O	antitumor$$$189$$$198$$$O	drugs.$$$199$$$205$$$O	The$$$206$$$209$$$O	drug$$$210$$$214$$$O	carrying$$$215$$$223$$$O	system$$$224$$$230$$$O	is$$$231$$$233$$$O	prepared$$$234$$$242$$$O	by$$$243$$$245$$$O	mixing$$$246$$$252$$$O	a$$$253$$$254$$$O	PEG$$$255$$$258$$$I	(Polyethylene$$$259$$$272$$$I	Glycol)-HA$$$273$$$283$$$I	(Hyaluronic$$$284$$$295$$$I	Acid)-MEL$$$296$$$305$$$I	(Melamine)$$$306$$$316$$$I	component$$$317$$$326$$$O	and$$$327$$$330$$$O	a$$$331$$$332$$$O	Fe3O4$$$333$$$338$$$I	magnetic$$$339$$$347$$$O	fluid$$$348$$$353$$$O	component$$$354$$$363$$$O	according$$$364$$$373$$$O	to$$$374$$$376$$$O	a$$$377$$$378$$$O	weight$$$379$$$385$$$O	ratio$$$386$$$391$$$O	of$$$392$$$394$$$O	1:1-5,$$$395$$$401$$$O	wherein$$$402$$$409$$$O	the$$$410$$$413$$$O	PEG-HA-MEL$$$414$$$424$$$I	component$$$425$$$434$$$O	comprises$$$435$$$444$$$O	the$$$445$$$448$$$O	following$$$449$$$458$$$O	components$$$459$$$469$$$O	in$$$470$$$472$$$O	parts$$$473$$$478$$$O	by$$$479$$$481$$$O	weight:$$$482$$$489$$$O	20-100$$$490$$$496$$$O	parts$$$497$$$502$$$O	of$$$503$$$505$$$O	melphalan,$$$506$$$516$$$I	500-1500$$$517$$$525$$$O	parts$$$526$$$531$$$O	of$$$532$$$534$$$O	PEG,$$$535$$$539$$$I	100-500$$$540$$$547$$$O	parts$$$548$$$553$$$O	of$$$554$$$556$$$O	HA,$$$557$$$560$$$I	10-50$$$561$$$566$$$O	parts$$$567$$$572$$$O	of$$$573$$$575$$$O	DCC$$$576$$$579$$$I	(dicyclohexylcarbodiimide),$$$580$$$607$$$I	1-10$$$608$$$612$$$O	parts$$$613$$$618$$$O	of$$$619$$$621$$$O	DMAP$$$622$$$626$$$I	(Dimethylamino$$$627$$$641$$$I	Pyridine),$$$642$$$652$$$I	100-500$$$653$$$660$$$O	parts$$$661$$$666$$$O	of$$$667$$$669$$$O	succinic$$$670$$$678$$$I	anhydride,$$$679$$$689$$$I	10-50$$$690$$$695$$$O	parts$$$696$$$701$$$O	of$$$702$$$704$$$O	EDC$$$705$$$708$$$I	(ethylene$$$709$$$718$$$I	dichloride)$$$719$$$730$$$I	and$$$731$$$734$$$O	20-100$$$735$$$741$$$O	parts$$$742$$$747$$$O	of$$$748$$$750$$$O	sodium$$$751$$$757$$$I	hydrogensulfite.$$$758$$$774$$$I	The$$$775$$$778$$$O	invention$$$779$$$788$$$O	has$$$789$$$792$$$O	the$$$793$$$796$$$O	advantages$$$797$$$807$$$O	of$$$808$$$810$$$O	drug$$$811$$$815$$$O	release$$$816$$$823$$$O	intelligence$$$824$$$836$$$O	of$$$837$$$839$$$O	the$$$840$$$843$$$O	system,$$$844$$$851$$$O	multi-targeted$$$852$$$866$$$O	property$$$867$$$875$$$O	and$$$876$$$879$$$O	good$$$880$$$884$$$O	reverse$$$885$$$892$$$O	drug$$$893$$$897$$$O	resistance$$$898$$$908$$$O	action$$$909$$$915$$$O	of$$$916$$$918$$$O	the$$$919$$$922$$$O	system,$$$923$$$930$$$O	drug$$$931$$$935$$$O	release$$$936$$$943$$$O	control$$$944$$$951$$$O	of$$$952$$$954$$$O	the$$$955$$$958$$$O	system,$$$959$$$966$$$O	good$$$967$$$971$$$O	blood$$$972$$$977$$$O	circulation$$$978$$$989$$$O	stability$$$990$$$999$$$O	of$$$1000$$$1002$$$O	the$$$1003$$$1006$$$O	system,$$$1007$$$1014$$$O	good$$$1015$$$1019$$$O	invisibility$$$1020$$$1032$$$O	of$$$1033$$$1035$$$O	the$$$1036$$$1039$$$O	system,$$$1040$$$1047$$$O	and$$$1048$$$1051$$$O	wide$$$1052$$$1056$$$O	applicability$$$1057$$$1070$$$O	of$$$1071$$$1073$$$O	the$$$1074$$$1077$$$O	system.$$$1078$$$1085$$$O
US20110257270
Drug$$$0$$$4$$$O	for$$$5$$$8$$$O	treatment$$$9$$$18$$$O	of$$$19$$$21$$$O	colon$$$22$$$27$$$O	cancer$$$28$$$34$$$O
A$$$0$$$1$$$O	first$$$2$$$7$$$O	aspect$$$8$$$14$$$O	of$$$15$$$17$$$O	the$$$18$$$21$$$O	invention$$$22$$$31$$$O	provides$$$32$$$40$$$O	a$$$41$$$42$$$O	method$$$43$$$49$$$O	for$$$50$$$53$$$O	treating,$$$54$$$63$$$O	preventing$$$64$$$74$$$O	or$$$75$$$77$$$O	ameliorating$$$78$$$90$$$O	a$$$91$$$92$$$O	hyperproliferative$$$93$$$111$$$O	disease$$$112$$$119$$$O	and/or$$$120$$$126$$$O	disorder$$$127$$$135$$$O	in$$$136$$$138$$$O	a$$$139$$$140$$$O	mammal$$$141$$$147$$$O	comprising$$$148$$$158$$$O	administering$$$159$$$172$$$O	to$$$173$$$175$$$O	the$$$176$$$179$$$O	mammal$$$180$$$186$$$O	a$$$187$$$188$$$O	therapeutically$$$189$$$204$$$O	effective$$$205$$$214$$$O	amount$$$215$$$221$$$O	of$$$222$$$224$$$O	one$$$225$$$228$$$O	or$$$229$$$231$$$O	more$$$232$$$236$$$O	compounds$$$237$$$246$$$O	selected$$$247$$$255$$$O	from$$$256$$$260$$$O	the$$$261$$$264$$$O	group$$$265$$$270$$$O	consisting$$$271$$$281$$$O	of$$$282$$$284$$$O	compounds$$$285$$$294$$$O	of$$$295$$$297$$$O	Formula$$$298$$$305$$$O	(1),$$$306$$$310$$$O	(2),$$$311$$$315$$$O	or$$$316$$$318$$$O	a$$$319$$$320$$$O	pharmaceutically$$$321$$$337$$$O	acceptable$$$338$$$348$$$O	salt$$$349$$$353$$$O	or$$$354$$$356$$$O	metabolite$$$357$$$367$$$O	thereof.$$$368$$$376$$$O
WO2008003378A1
Sulfamate$$$0$$$9$$$I	benzothiophene$$$10$$$24$$$I	derivatives$$$25$$$36$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	compounds$$$31$$$40$$$O	of$$$41$$$43$$$O	general$$$44$$$51$$$O	formula$$$52$$$59$$$O	(I),$$$60$$$64$$$O	in$$$65$$$67$$$O	which$$$68$$$73$$$O	R$$$74$$$75$$$O	is$$$76$$$78$$$O	defined$$$79$$$86$$$O	as$$$87$$$89$$$O	cited$$$90$$$95$$$O	in$$$96$$$98$$$O	claim$$$99$$$104$$$O	1,$$$105$$$107$$$O	to$$$108$$$110$$$O	the$$$111$$$114$$$O	production$$$115$$$125$$$O	thereof$$$126$$$133$$$O	and$$$134$$$137$$$O	to$$$138$$$140$$$O	the$$$141$$$144$$$O	use$$$145$$$148$$$O	of$$$149$$$151$$$O	said$$$152$$$156$$$O	compounds$$$157$$$166$$$O	as$$$167$$$169$$$O	medicaments.$$$170$$$182$$$O	The$$$183$$$186$$$O	compounds$$$187$$$196$$$O	(I)$$$197$$$200$$$O	are$$$201$$$204$$$O	inhibitors$$$205$$$215$$$O	of$$$216$$$218$$$O	steroid$$$219$$$226$$$I	sulfatase$$$227$$$236$$$O	and$$$237$$$240$$$O	are$$$241$$$244$$$O	used$$$245$$$249$$$O	to$$$250$$$252$$$O	treat$$$253$$$258$$$O	cancer.$$$259$$$266$$$O
US7824717
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	licochalcone$$$7$$$19$$$I	A$$$20$$$21$$$I	against$$$22$$$29$$$O	rosacea$$$30$$$37$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	licochalcone$$$44$$$56$$$I	A$$$57$$$58$$$I	for$$$59$$$62$$$O	the$$$63$$$66$$$O	treatment$$$67$$$76$$$O	of$$$77$$$79$$$O	rosacea.$$$80$$$88$$$O
CN103040849A
Tannic$$$0$$$6$$$I	acid$$$7$$$11$$$I	preparation$$$12$$$23$$$O	for$$$24$$$27$$$O	treating$$$28$$$36$$$O	burn,$$$37$$$42$$$O	bedsore$$$43$$$50$$$O	and$$$51$$$54$$$O	diaper$$$55$$$61$$$O	dermatitis$$$62$$$72$$$O	and$$$73$$$76$$$O	preparation$$$77$$$88$$$O	method$$$89$$$95$$$O	thereof$$$96$$$103$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	tannic$$$27$$$33$$$I	acid$$$34$$$38$$$I	preparation$$$39$$$50$$$O	and$$$51$$$54$$$O	a$$$55$$$56$$$O	preparation$$$57$$$68$$$O	method,$$$69$$$76$$$O	and$$$77$$$80$$$O	the$$$81$$$84$$$O	tannic$$$85$$$91$$$I	acid$$$92$$$96$$$I	preparation$$$97$$$108$$$O	is$$$109$$$111$$$O	characterized$$$112$$$125$$$O	by$$$126$$$128$$$O	comprising,$$$129$$$140$$$O	by$$$141$$$143$$$O	weight,$$$144$$$151$$$O	2-30%$$$152$$$157$$$O	of$$$158$$$160$$$O	tannic$$$161$$$167$$$I	acid,$$$168$$$173$$$I	40-75%$$$174$$$180$$$O	of$$$181$$$183$$$O	pharmaceutical$$$184$$$198$$$O	adjuvants,$$$199$$$209$$$O	and$$$210$$$213$$$O	20-50%$$$214$$$220$$$O	of$$$221$$$223$$$O	water.$$$224$$$230$$$O	The$$$231$$$234$$$O	pharmaceutical$$$235$$$249$$$O	adjuvants$$$250$$$259$$$O	used$$$260$$$264$$$O	in$$$265$$$267$$$O	the$$$268$$$271$$$O	preparation$$$272$$$283$$$O	comprise$$$284$$$292$$$O	glycerin,$$$293$$$302$$$I	monoglyceride$$$303$$$316$$$I	stearate,$$$317$$$326$$$I	beeswax,$$$327$$$335$$$O	Vaseline,$$$336$$$345$$$O	paraffin,$$$346$$$355$$$I	tween,$$$356$$$362$$$I	span,$$$363$$$368$$$I	sodium$$$369$$$375$$$I	bisulfate,$$$376$$$386$$$I	ethylparaben,$$$387$$$400$$$I	etc.$$$401$$$405$$$O	The$$$406$$$409$$$O	preparation$$$410$$$421$$$O	method$$$422$$$428$$$O	comprises$$$429$$$438$$$O	the$$$439$$$442$$$O	following$$$443$$$452$$$O	steps:$$$453$$$459$$$O	dissolving$$$460$$$470$$$O	tannic$$$471$$$477$$$I	acid$$$478$$$482$$$I	by$$$483$$$485$$$O	a$$$486$$$487$$$O	little$$$488$$$494$$$O	water$$$495$$$500$$$O	or$$$501$$$503$$$O	ethanol,$$$504$$$512$$$I	heating$$$513$$$520$$$O	to$$$521$$$523$$$O	55-85$$$524$$$529$$$O	DEG$$$530$$$533$$$O	C$$$534$$$535$$$O	to$$$536$$$538$$$O	prepare$$$539$$$546$$$O	an$$$547$$$549$$$O	oil$$$550$$$553$$$O	phase$$$554$$$559$$$O	and$$$560$$$563$$$O	a$$$564$$$565$$$O	water$$$566$$$571$$$O	phase,$$$572$$$578$$$O	finally$$$579$$$586$$$O	adding$$$587$$$593$$$O	the$$$594$$$597$$$O	water$$$598$$$603$$$O	phase$$$604$$$609$$$O	into$$$610$$$614$$$O	the$$$615$$$618$$$O	oil$$$619$$$622$$$O	phase$$$623$$$628$$$O	under$$$629$$$634$$$O	uniform$$$635$$$642$$$O	stirring,$$$643$$$652$$$O	and$$$653$$$656$$$O	performing$$$657$$$667$$$O	condensation$$$668$$$680$$$O	and$$$681$$$684$$$O	split$$$685$$$690$$$O	charging$$$691$$$699$$$O	to$$$700$$$702$$$O	obtain$$$703$$$709$$$O	the$$$710$$$713$$$O	tannic$$$714$$$720$$$I	acid$$$721$$$725$$$I	preparation.$$$726$$$738$$$O	The$$$739$$$742$$$O	preparation$$$743$$$754$$$O	comprises$$$755$$$764$$$O	paste$$$765$$$770$$$O	agents$$$771$$$777$$$O	(ointment,$$$778$$$788$$$O	plaster),$$$789$$$798$$$O	cream,$$$799$$$805$$$O	emulsion,$$$806$$$815$$$O	oil$$$816$$$819$$$O	agents,$$$820$$$827$$$O	water$$$828$$$833$$$O	aqua,$$$834$$$839$$$O	and$$$840$$$843$$$O	the$$$844$$$847$$$O	like,$$$848$$$853$$$O	and$$$854$$$857$$$O	the$$$858$$$861$$$O	tannic$$$862$$$868$$$I	acid$$$869$$$873$$$I	content$$$874$$$881$$$O	can$$$882$$$885$$$O	be$$$886$$$888$$$O	determined$$$889$$$899$$$O	by$$$900$$$902$$$O	a$$$903$$$904$$$O	spectrophotometric$$$905$$$923$$$O	method.$$$924$$$931$$$O	The$$$932$$$935$$$O	prepared$$$936$$$944$$$O	tannic$$$945$$$951$$$I	acid$$$952$$$956$$$I	preparation$$$957$$$968$$$O	conforms$$$969$$$977$$$O	with$$$978$$$982$$$O	medicine$$$983$$$991$$$O	standards,$$$992$$$1002$$$O	and$$$1003$$$1006$$$O	is$$$1007$$$1009$$$O	suitable$$$1010$$$1018$$$O	for$$$1019$$$1022$$$O	the$$$1023$$$1026$$$O	treatment$$$1027$$$1036$$$O	of$$$1037$$$1039$$$O	burn,$$$1040$$$1045$$$O	bedsore$$$1046$$$1053$$$O	and$$$1054$$$1057$$$O	diaper$$$1058$$$1064$$$O	dermatitis$$$1065$$$1075$$$O	(neonatal$$$1076$$$1085$$$O	red$$$1086$$$1089$$$O	buttock)$$$1090$$$1098$$$O	and$$$1099$$$1102$$$O	the$$$1103$$$1106$$$O	like.$$$1107$$$1112$$$O
CN101850087A
Medicinal$$$0$$$9$$$O	composition$$$10$$$21$$$O	used$$$22$$$26$$$O	for$$$27$$$30$$$O	alleviating$$$31$$$42$$$O	pains$$$43$$$48$$$O	and$$$49$$$52$$$O	preparation$$$53$$$64$$$O	method$$$65$$$71$$$O	and$$$72$$$75$$$O	application$$$76$$$87$$$O	thereof$$$88$$$95$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	medicaments,$$$38$$$50$$$O	and$$$51$$$54$$$O	particularly$$$55$$$67$$$O	relates$$$68$$$75$$$O	to$$$76$$$78$$$O	a$$$79$$$80$$$O	medicinal$$$81$$$90$$$O	composition$$$91$$$102$$$O	used$$$103$$$107$$$O	for$$$108$$$111$$$O	alleviating$$$112$$$123$$$O	pains$$$124$$$129$$$O	and$$$130$$$133$$$O	a$$$134$$$135$$$O	preparation$$$136$$$147$$$O	method$$$148$$$154$$$O	and$$$155$$$158$$$O	application$$$159$$$170$$$O	thereof.$$$171$$$179$$$O	The$$$180$$$183$$$O	invention$$$184$$$193$$$O	provides$$$194$$$202$$$O	a$$$203$$$204$$$O	brand-new$$$205$$$214$$$O	medicinal$$$215$$$224$$$O	composition$$$225$$$236$$$O	used$$$237$$$241$$$O	for$$$242$$$245$$$O	alleviating$$$246$$$257$$$O	the$$$258$$$261$$$O	pains.$$$262$$$268$$$O	The$$$269$$$272$$$O	medicinal$$$273$$$282$$$O	composition$$$283$$$294$$$O	is$$$295$$$297$$$O	prepared$$$298$$$306$$$O	from$$$307$$$311$$$O	the$$$312$$$315$$$O	following$$$316$$$325$$$O	raw$$$326$$$329$$$O	medicinal$$$330$$$339$$$O	materials$$$340$$$349$$$O	in$$$350$$$352$$$O	part$$$353$$$357$$$O	by$$$358$$$360$$$O	weight:$$$361$$$368$$$O	5$$$369$$$370$$$O	to$$$371$$$373$$$O	9$$$374$$$375$$$O	parts$$$376$$$381$$$O	of$$$382$$$384$$$O	rhizoma$$$385$$$392$$$O	corydalis,$$$393$$$403$$$O	3$$$404$$$405$$$O	to$$$406$$$408$$$O	5$$$409$$$410$$$O	parts$$$411$$$416$$$O	of$$$417$$$419$$$O	hiraute$$$420$$$427$$$O	shiny$$$428$$$433$$$O	bugleweed$$$434$$$443$$$O	herb,$$$444$$$449$$$O	3$$$450$$$451$$$O	to$$$452$$$454$$$O	5$$$455$$$456$$$O	parts$$$457$$$462$$$O	of$$$463$$$465$$$O	pyrite,$$$466$$$473$$$O	2$$$474$$$475$$$O	to$$$476$$$478$$$O	5$$$479$$$480$$$O	parts$$$481$$$486$$$O	of$$$487$$$489$$$O	henbane$$$490$$$497$$$O	seed,$$$498$$$503$$$O	3$$$504$$$505$$$O	to$$$506$$$508$$$O	5$$$509$$$510$$$O	parts$$$511$$$516$$$O	of$$$517$$$519$$$O	dragon's$$$520$$$528$$$O	blood,$$$529$$$535$$$O	5$$$536$$$537$$$O	to$$$538$$$540$$$O	7$$$541$$$542$$$O	parts$$$543$$$548$$$O	of$$$549$$$551$$$O	frankincense,$$$552$$$565$$$O	5$$$566$$$567$$$O	to$$$568$$$570$$$O	7$$$571$$$572$$$O	parts$$$573$$$578$$$O	of$$$579$$$581$$$O	myrrh,$$$582$$$588$$$O	3$$$589$$$590$$$O	to$$$591$$$593$$$O	5$$$594$$$595$$$O	parts$$$596$$$601$$$O	of$$$602$$$604$$$O	zedoary,$$$605$$$613$$$O	3$$$614$$$615$$$O	to$$$616$$$618$$$O	5$$$619$$$620$$$O	parts$$$621$$$626$$$O	of$$$627$$$629$$$O	common$$$630$$$636$$$O	burreed$$$637$$$644$$$O	rhizome,$$$645$$$653$$$O	5$$$654$$$655$$$O	to$$$656$$$658$$$O	7$$$659$$$660$$$O	parts$$$661$$$666$$$O	of$$$667$$$669$$$O	safflower,$$$670$$$680$$$O	5$$$681$$$682$$$O	to$$$683$$$685$$$O	9$$$686$$$687$$$O	parts$$$688$$$693$$$O	of$$$694$$$696$$$O	Chinese$$$697$$$704$$$O	angelica,$$$705$$$714$$$O	3$$$715$$$716$$$O	to$$$717$$$719$$$O	7$$$720$$$721$$$O	parts$$$722$$$727$$$O	of$$$728$$$730$$$O	rhubarb,$$$731$$$739$$$O	and$$$740$$$743$$$O	3$$$744$$$745$$$O	to$$$746$$$748$$$O	7$$$749$$$750$$$O	parts$$$751$$$756$$$O	of$$$757$$$759$$$O	combined$$$760$$$768$$$O	spicebush$$$769$$$778$$$O	root.$$$779$$$784$$$O	For$$$785$$$788$$$O	external$$$789$$$797$$$O	use,$$$798$$$802$$$O	the$$$803$$$806$$$O	medicinal$$$807$$$816$$$O	composition$$$817$$$828$$$O	can$$$829$$$832$$$O	be$$$833$$$835$$$O	used$$$836$$$840$$$O	for$$$841$$$844$$$O	treating$$$845$$$853$$$O	various$$$854$$$861$$$O	pains$$$862$$$867$$$O	caused$$$868$$$874$$$O	by$$$875$$$877$$$O	acute$$$878$$$883$$$O	soft$$$884$$$888$$$O	tissue$$$889$$$895$$$O	sprain$$$896$$$902$$$O	and$$$903$$$906$$$O	contusion,$$$907$$$917$$$O	chronic$$$918$$$925$$$O	appendicitis,$$$926$$$939$$$O	traumatic$$$940$$$949$$$O	hematoma,$$$950$$$959$$$O	hyperosteogeny$$$960$$$974$$$O	of$$$975$$$977$$$O	cervical$$$978$$$986$$$O	vertebra$$$987$$$995$$$O	and$$$996$$$999$$$O	lumbar$$$1000$$$1006$$$O	vertebrae,$$$1007$$$1017$$$O	protrusion$$$1018$$$1028$$$O	of$$$1029$$$1031$$$O	intervertebral$$$1032$$$1046$$$O	disc,$$$1047$$$1052$$$O	scapulohumeral$$$1053$$$1067$$$O	periarthritis,$$$1068$$$1082$$$O	ischiatitis,$$$1083$$$1095$$$O	cancerous$$$1096$$$1105$$$O	protuberances,$$$1106$$$1120$$$O	dysmenorrhea,$$$1121$$$1134$$$O	healing$$$1135$$$1142$$$O	after$$$1143$$$1148$$$O	fracture$$$1149$$$1157$$$O	and$$$1158$$$1161$$$O	the$$$1162$$$1165$$$O	like,$$$1166$$$1171$$$O	and$$$1172$$$1175$$$O	has$$$1176$$$1179$$$O	an$$$1180$$$1182$$$O	obvious$$$1183$$$1190$$$O	effect$$$1191$$$1197$$$O	of$$$1198$$$1200$$$O	alleviating$$$1201$$$1212$$$O	the$$$1213$$$1216$$$O	pains.$$$1217$$$1223$$$O
US6869956
Such$$$0$$$4$$$O	as$$$5$$$7$$$O	4-(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)$$$8$$$57$$$I	quinoxaline;$$$58$$$70$$$I	kits;$$$71$$$76$$$O	treating$$$77$$$85$$$O	arthritis,$$$86$$$96$$$O	psoriasis,$$$97$$$107$$$O	inflammatory$$$108$$$120$$$O	bowel$$$121$$$126$$$O	disease,$$$127$$$135$$$O	autoimmune$$$136$$$146$$$O	diseases$$$147$$$155$$$O	and$$$156$$$159$$$O	neurodegenerative$$$160$$$177$$$O	diseases$$$178$$$186$$$O	among$$$187$$$192$$$O	others$$$193$$$199$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	describes$$$22$$$31$$$O	methods$$$32$$$39$$$O	of$$$40$$$42$$$O	preventing$$$43$$$53$$$O	and$$$54$$$57$$$O	treating$$$58$$$66$$$O	inflammatory$$$67$$$79$$$O	and$$$80$$$83$$$O	immune-related$$$84$$$98$$$O	diseases$$$99$$$107$$$O	or$$$108$$$110$$$O	disorders$$$111$$$120$$$O	using$$$121$$$126$$$O	inhibitors$$$127$$$137$$$O	of$$$138$$$140$$$O	IÎºB$$$141$$$145$$$O	kinase$$$146$$$152$$$O	(IKK).$$$153$$$159$$$O	Also$$$160$$$164$$$O	described$$$165$$$174$$$O	are$$$175$$$178$$$O	IKK$$$179$$$182$$$O	inhibitors$$$183$$$193$$$O	effective$$$194$$$203$$$O	for$$$204$$$207$$$O	the$$$208$$$211$$$O	prevention$$$212$$$222$$$O	and$$$223$$$226$$$O	treatment$$$227$$$236$$$O	of$$$237$$$239$$$O	inflammatory$$$240$$$252$$$O	and$$$253$$$256$$$O	immune-related$$$257$$$271$$$O	diseases$$$272$$$280$$$O	or$$$281$$$283$$$O	disorders,$$$284$$$294$$$O	as$$$295$$$297$$$O	demonstrated$$$298$$$310$$$O	in$$$311$$$313$$$O	vivo.$$$314$$$319$$$O	Further$$$320$$$327$$$O	embodiments$$$328$$$339$$$O	of$$$340$$$342$$$O	the$$$343$$$346$$$O	present$$$347$$$354$$$O	invention$$$355$$$364$$$O	relate$$$365$$$371$$$O	to$$$372$$$374$$$O	a$$$375$$$376$$$O	specific$$$377$$$385$$$O	IKK$$$386$$$389$$$O	inhibitors,$$$390$$$401$$$I	4(2â²-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)$$$402$$$452$$$I	quinoxaline$$$453$$$464$$$I	and$$$465$$$468$$$O	compounds$$$469$$$478$$$O	of$$$479$$$481$$$O	formula$$$482$$$489$$$O	(I),$$$490$$$494$$$O	salts$$$495$$$500$$$O	thereof,$$$501$$$509$$$O	and$$$510$$$513$$$O	pharmaceutical$$$514$$$528$$$O	compositions.$$$529$$$542$$$O
CN102973528A
Calcitriol$$$0$$$10$$$I	solid$$$11$$$16$$$O	lipidic$$$17$$$24$$$O	dispersion$$$25$$$35$$$O	and$$$36$$$39$$$O	preparation$$$40$$$51$$$O	method$$$52$$$58$$$O	thereof$$$59$$$66$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	calcitriol$$$26$$$36$$$I	solid$$$37$$$42$$$O	lipidic$$$43$$$50$$$O	dispersion$$$51$$$61$$$O	and$$$62$$$65$$$O	a$$$66$$$67$$$O	preparation$$$68$$$79$$$O	method$$$80$$$86$$$O	thereof.$$$87$$$95$$$O	Raw$$$96$$$99$$$O	materials$$$100$$$109$$$O	of$$$110$$$112$$$O	the$$$113$$$116$$$O	calcitriol$$$117$$$127$$$I	solid$$$128$$$133$$$O	lipidic$$$134$$$141$$$O	dispersion$$$142$$$152$$$O	comprise$$$153$$$161$$$O	calcitriol,$$$162$$$173$$$I	one$$$174$$$177$$$O	or$$$178$$$180$$$O	more$$$181$$$185$$$O	lipidic$$$186$$$193$$$O	carriers$$$194$$$202$$$O	and$$$203$$$206$$$O	solid$$$207$$$212$$$O	carriers,$$$213$$$222$$$O	wherein$$$223$$$230$$$O	a$$$231$$$232$$$O	mass$$$233$$$237$$$O	ratio$$$238$$$243$$$O	of$$$244$$$246$$$O	calcitriol$$$247$$$257$$$I	to$$$258$$$260$$$O	the$$$261$$$264$$$O	one$$$265$$$268$$$O	or$$$269$$$271$$$O	more$$$272$$$276$$$O	lipidic$$$277$$$284$$$O	carriers$$$285$$$293$$$O	is$$$294$$$296$$$O	1:$$$297$$$299$$$O	(90-200000);$$$300$$$312$$$O	a$$$313$$$314$$$O	mass$$$315$$$319$$$O	ratio$$$320$$$325$$$O	of$$$326$$$328$$$O	the$$$329$$$332$$$O	one$$$333$$$336$$$O	or$$$337$$$339$$$O	more$$$340$$$344$$$O	lipidic$$$345$$$352$$$O	carriers$$$353$$$361$$$O	to$$$362$$$364$$$O	the$$$365$$$368$$$O	solid$$$369$$$374$$$O	carriers$$$375$$$383$$$O	is$$$384$$$386$$$O	(1-2):$$$387$$$393$$$O	1;$$$394$$$396$$$O	and$$$397$$$400$$$O	the$$$401$$$404$$$O	one$$$405$$$408$$$O	or$$$409$$$411$$$O	more$$$412$$$416$$$O	lipidic$$$417$$$424$$$O	carriers$$$425$$$433$$$O	are$$$434$$$437$$$O	selected$$$438$$$446$$$O	from$$$447$$$451$$$O	caprylic$$$452$$$460$$$I	triglyceride,$$$461$$$474$$$I	capric$$$475$$$481$$$I	triglyceride,$$$482$$$495$$$I	caprylic/capric$$$496$$$511$$$I	triglyceride,$$$512$$$525$$$I	laurin,$$$526$$$533$$$I	caprylic$$$534$$$542$$$I	dilaurin,$$$543$$$552$$$I	capric$$$553$$$559$$$I	dilaurin,$$$560$$$569$$$I	vitamin$$$570$$$577$$$I	E,$$$578$$$580$$$I	vitamin$$$581$$$588$$$I	E$$$589$$$590$$$I	succinate,$$$591$$$601$$$I	vitamin$$$602$$$609$$$I	E$$$610$$$611$$$I	polyethylene$$$612$$$624$$$I	glycol$$$625$$$631$$$I	succinate$$$632$$$641$$$I	and$$$642$$$645$$$O	vitamin$$$646$$$653$$$I	E$$$654$$$655$$$I	acetate.$$$656$$$664$$$I	The$$$665$$$668$$$O	calcitriol$$$669$$$679$$$I	solid$$$680$$$685$$$O	lipidic$$$686$$$693$$$O	dispersion$$$694$$$704$$$O	has$$$705$$$708$$$O	high$$$709$$$713$$$O	drug$$$714$$$718$$$O	stability$$$719$$$728$$$O	and$$$729$$$732$$$O	can$$$733$$$736$$$O	keep$$$737$$$741$$$O	a$$$742$$$743$$$O	constant$$$744$$$752$$$O	treatment$$$753$$$762$$$O	level.$$$763$$$769$$$O	The$$$770$$$773$$$O	preparation$$$774$$$785$$$O	method$$$786$$$792$$$O	does$$$793$$$797$$$O	not$$$798$$$801$$$O	adopt$$$802$$$807$$$O	an$$$808$$$810$$$O	inorganic$$$811$$$820$$$O	solvent,$$$821$$$829$$$O	is$$$830$$$832$$$O	suitable$$$833$$$841$$$O	for$$$842$$$845$$$O	industrial$$$846$$$856$$$O	production$$$857$$$867$$$O	and$$$868$$$871$$$O	is$$$872$$$874$$$O	conducive$$$875$$$884$$$O	to$$$885$$$887$$$O	storage$$$888$$$895$$$O	and$$$896$$$899$$$O	taking.$$$900$$$907$$$O	An$$$908$$$910$$$O	experiment$$$911$$$921$$$O	proves$$$922$$$928$$$O	that$$$929$$$933$$$O	the$$$934$$$937$$$O	calcitriol$$$938$$$948$$$I	solid$$$949$$$954$$$O	lipidic$$$955$$$962$$$O	dispersion$$$963$$$973$$$O	has$$$974$$$977$$$O	good$$$978$$$982$$$O	stability$$$983$$$992$$$O	and$$$993$$$996$$$O	dispersion$$$997$$$1007$$$O	uniformity$$$1008$$$1018$$$O	satisfying$$$1019$$$1029$$$O	requirements.$$$1030$$$1043$$$O
WO2009101199A3
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	acne$$$13$$$17$$$O	vulgaris;$$$18$$$27$$$O	rosacea$$$28$$$35$$$O	and$$$36$$$39$$$O	rhinophym$$$40$$$49$$$O
A$$$0$$$1$$$O	composition$$$2$$$13$$$O	for$$$14$$$17$$$O	the$$$18$$$21$$$O	treatment$$$22$$$31$$$O	of$$$32$$$34$$$O	acne$$$35$$$39$$$O	vulgaris,$$$40$$$49$$$O	rosacea$$$50$$$57$$$O	and/or$$$58$$$64$$$O	rhinophym$$$65$$$74$$$O	comprising$$$75$$$85$$$O	at$$$86$$$88$$$O	least$$$89$$$94$$$O	one$$$95$$$98$$$O	inhibitor$$$99$$$108$$$O	of$$$109$$$111$$$O	the$$$112$$$115$$$O	FGFR2$$$116$$$121$$$O	signal$$$122$$$128$$$O	pathway$$$129$$$136$$$O	and/or$$$137$$$143$$$O	IGFR1$$$144$$$149$$$O	signal$$$150$$$156$$$O	pathway.$$$157$$$165$$$O
CN101559063A
External$$$0$$$8$$$O	medicament$$$9$$$19$$$O	for$$$20$$$23$$$O	curing$$$24$$$30$$$O	herpes$$$31$$$37$$$O	zoster$$$38$$$44$$$O	and$$$45$$$48$$$O	preparation$$$49$$$60$$$O	method$$$61$$$67$$$O	thereof$$$68$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicament$$$26$$$36$$$O	for$$$37$$$40$$$O	curing$$$41$$$47$$$O	herpes$$$48$$$54$$$O	zoster,$$$55$$$62$$$O	which$$$63$$$68$$$O	is$$$69$$$71$$$O	mainly$$$72$$$78$$$O	prepared$$$79$$$87$$$O	from$$$88$$$92$$$O	moroxydine,$$$93$$$104$$$I	vitamins,$$$105$$$114$$$O	dexamethasone$$$115$$$128$$$O	and$$$129$$$132$$$O	vaseline$$$133$$$141$$$O	as$$$142$$$144$$$O	auxiliary$$$145$$$154$$$O	material$$$155$$$163$$$O	according$$$164$$$173$$$O	to$$$174$$$176$$$O	certain$$$177$$$184$$$O	proportion$$$185$$$195$$$O	by$$$196$$$198$$$O	parts.$$$199$$$205$$$O	The$$$206$$$209$$$O	medicament$$$210$$$220$$$O	has$$$221$$$224$$$O	the$$$225$$$228$$$O	advantages$$$229$$$239$$$O	of$$$240$$$242$$$O	acesodyne,$$$243$$$253$$$O	anti-inflammatory,$$$254$$$272$$$O	toxin$$$273$$$278$$$O	expulsion,$$$279$$$289$$$O	sarcogenic$$$290$$$300$$$O	convergence,$$$301$$$313$$$O	ulceration$$$314$$$324$$$O	healing$$$325$$$332$$$O	promotion,$$$333$$$343$$$O	and$$$344$$$347$$$O	the$$$348$$$351$$$O	like$$$352$$$356$$$O	and$$$357$$$360$$$O	also$$$361$$$365$$$O	has$$$366$$$369$$$O	quick$$$370$$$375$$$O	effect,$$$376$$$383$$$O	high$$$384$$$388$$$O	cure$$$389$$$393$$$O	rate$$$394$$$398$$$O	and$$$399$$$402$$$O	no$$$403$$$405$$$O	toxic$$$406$$$411$$$O	side$$$412$$$416$$$O	effect$$$417$$$423$$$O	and$$$424$$$427$$$O	pain$$$428$$$432$$$O	on$$$433$$$435$$$O	curing$$$436$$$442$$$O	the$$$443$$$446$$$O	toxic$$$447$$$452$$$O	side$$$453$$$457$$$O	effect$$$458$$$464$$$O	for$$$465$$$468$$$O	curing$$$469$$$475$$$O	herpes$$$476$$$482$$$O	zoster.$$$483$$$490$$$O	In$$$491$$$493$$$O	addition,$$$494$$$503$$$O	the$$$504$$$507$$$O	medicament$$$508$$$518$$$O	is$$$519$$$521$$$O	mainly$$$522$$$528$$$O	prepared$$$529$$$537$$$O	from$$$538$$$542$$$O	6-12$$$543$$$547$$$O	portions$$$548$$$556$$$O	of$$$557$$$559$$$O	the$$$560$$$563$$$O	moroxydine,$$$564$$$575$$$I	3-6$$$576$$$579$$$O	portions$$$580$$$588$$$O	of$$$589$$$591$$$O	vitamin$$$592$$$599$$$I	C,$$$600$$$602$$$I	3-6$$$603$$$606$$$O	portions$$$607$$$615$$$O	of$$$616$$$618$$$O	the$$$619$$$622$$$O	dexamethasone$$$623$$$636$$$I	and$$$637$$$640$$$O	the$$$641$$$644$$$O	Vaseline$$$645$$$653$$$O	as$$$654$$$656$$$O	theauxiliary$$$657$$$669$$$O	material.$$$670$$$679$$$O
EP1005485B1
Therapeutic$$$0$$$11$$$O	pulmonary$$$12$$$21$$$O	lavage$$$22$$$28$$$O	with$$$29$$$33$$$O	diluted$$$34$$$41$$$O	surfactants$$$42$$$53$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	useful$$$32$$$38$$$O	surfactant$$$39$$$49$$$O	molecules$$$50$$$59$$$O	including$$$60$$$69$$$O	polypeptides,$$$70$$$83$$$O	proteins,$$$84$$$93$$$O	and$$$94$$$97$$$O	a$$$98$$$99$$$O	variety$$$100$$$107$$$O	of$$$108$$$110$$$O	other$$$111$$$116$$$O	organic$$$117$$$124$$$O	molecules,$$$125$$$135$$$O	as$$$136$$$138$$$O	well$$$139$$$143$$$O	as$$$144$$$146$$$O	methods$$$147$$$154$$$O	of$$$155$$$157$$$O	making$$$158$$$164$$$O	and$$$165$$$168$$$O	using$$$169$$$174$$$O	same.$$$175$$$180$$$O	Surfactant$$$181$$$191$$$O	compositions,$$$192$$$205$$$O	including$$$206$$$215$$$O	liposomal$$$216$$$225$$$O	surfactant$$$226$$$236$$$O	compositions,$$$237$$$250$$$O	are$$$251$$$254$$$O	also$$$255$$$259$$$O	disclosed.$$$260$$$270$$$O	Use$$$271$$$274$$$O	of$$$275$$$277$$$O	the$$$278$$$281$$$O	surfactant$$$282$$$292$$$O	molecules$$$293$$$302$$$O	of$$$303$$$305$$$O	the$$$306$$$309$$$O	present$$$310$$$317$$$O	invention$$$318$$$327$$$O	in$$$328$$$330$$$O	pulmonary$$$331$$$340$$$O	lavage$$$341$$$347$$$O	procedures$$$348$$$358$$$O	for$$$359$$$362$$$O	a$$$363$$$364$$$O	variety$$$365$$$372$$$O	of$$$373$$$375$$$O	therapeutic$$$376$$$387$$$O	applications$$$388$$$400$$$O	is$$$401$$$403$$$O	also$$$404$$$408$$$O	disclosed,$$$409$$$419$$$O	including$$$420$$$429$$$O	the$$$430$$$433$$$O	treatment$$$434$$$443$$$O	of$$$444$$$446$$$O	respiratory$$$447$$$458$$$O	distress$$$459$$$467$$$O	syndrome;$$$468$$$477$$$O	the$$$478$$$481$$$O	removal$$$482$$$489$$$O	of$$$490$$$492$$$O	inflammatory$$$493$$$505$$$O	exudate$$$506$$$513$$$O	from$$$514$$$518$$$O	inflamed$$$519$$$527$$$O	lung$$$528$$$532$$$O	tissues;$$$533$$$541$$$O	and$$$542$$$545$$$O	the$$$546$$$549$$$O	treatment$$$550$$$559$$$O	of$$$560$$$562$$$O	meconium$$$563$$$571$$$O	aspiration$$$572$$$582$$$O	syndrome$$$583$$$591$$$O	in$$$592$$$594$$$O	infants.$$$595$$$603$$$O
WO2006044524A1
Benzothienoâ2,3-d!$$$0$$$20$$$I	pyrimidine$$$21$$$31$$$I	compounds$$$32$$$41$$$O	as$$$42$$$44$$$O	inhibitors$$$45$$$55$$$O	of$$$56$$$58$$$I	tyrosine$$$59$$$67$$$I	kinase$$$68$$$74$$$O	activities$$$75$$$85$$$O	of$$$86$$$88$$$O	the$$$89$$$92$$$O	epidermal$$$93$$$102$$$O	growth$$$103$$$109$$$O	factor$$$110$$$116$$$O	receptors$$$117$$$126$$$O	(egfrs)$$$127$$$134$$$O	for$$$135$$$138$$$O	the$$$139$$$142$$$O	treatment$$$143$$$152$$$O	of$$$153$$$155$$$O	hyperproliferative$$$156$$$174$$$O	diseases$$$175$$$183$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	compounds$$$32$$$41$$$O	of$$$42$$$44$$$O	formula$$$45$$$52$$$O	(I)$$$53$$$56$$$O	and$$$57$$$60$$$O	processes$$$61$$$70$$$O	for$$$71$$$74$$$O	their$$$75$$$80$$$O	preparation,$$$81$$$93$$$O	their$$$94$$$99$$$O	use$$$100$$$103$$$O	for$$$104$$$107$$$O	of$$$108$$$110$$$O	treating$$$111$$$119$$$O	diseases,$$$120$$$129$$$O	particularly$$$130$$$142$$$O	hyperproliferative$$$143$$$161$$$O	diseases$$$162$$$170$$$O	such$$$171$$$175$$$O	as$$$176$$$178$$$O	cancer,$$$179$$$186$$$O	and$$$187$$$190$$$O	methods$$$191$$$198$$$O	of$$$199$$$201$$$O	making$$$202$$$208$$$O	pharmaceutical$$$209$$$223$$$O	compositions$$$224$$$236$$$O	for$$$237$$$240$$$O	the$$$241$$$244$$$O	treatment$$$245$$$254$$$O	or$$$255$$$257$$$O	prevention$$$258$$$268$$$O	of$$$269$$$271$$$O	disorders,$$$272$$$282$$$O	particularly$$$283$$$295$$$O	hyperproliferative$$$296$$$314$$$O	diseases$$$315$$$323$$$O	such$$$324$$$328$$$O	as$$$329$$$331$$$O	cancer.$$$332$$$339$$$O	Wherein$$$340$$$347$$$O	m$$$348$$$349$$$O	is$$$350$$$352$$$O	0,$$$353$$$355$$$O	1$$$356$$$357$$$O	or$$$358$$$360$$$O	2;$$$361$$$363$$$O	R3$$$364$$$366$$$O	is$$$367$$$369$$$O	*-O(CH2)n$$$370$$$379$$$I	AR,$$$380$$$383$$$I	wherein$$$384$$$391$$$O	Ar$$$392$$$394$$$I	is$$$395$$$397$$$O	phenyl,$$$398$$$405$$$I	thienyl,$$$406$$$414$$$I	furyl,$$$415$$$421$$$I	pyrrolyl,$$$422$$$431$$$I	thiazolyl,$$$432$$$442$$$I	oxazolyl,$$$443$$$452$$$I	imidazolyl,$$$453$$$464$$$I	pyridyl,$$$465$$$473$$$I	pyrimidyl$$$474$$$483$$$I	od$$$484$$$486$$$O	pyridazinyl,$$$487$$$499$$$I	wherein$$$500$$$507$$$O	Ar$$$508$$$510$$$I	can$$$511$$$514$$$O	optionally$$$515$$$525$$$O	be$$$526$$$528$$$O	substituted.$$$529$$$541$$$O
WO2007150063A2
Compositions$$$0$$$12$$$O	for$$$13$$$16$$$O	lowering$$$17$$$25$$$O	blood$$$26$$$31$$$O	serum$$$32$$$37$$$O	cholesterol$$$38$$$49$$$I	and$$$50$$$53$$$O	use$$$54$$$57$$$O	in$$$58$$$60$$$O	foods,$$$61$$$67$$$O	beverages,$$$68$$$78$$$O	and$$$79$$$82$$$O	health$$$83$$$89$$$O	supplements$$$90$$$101$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	disclosed$$$9$$$18$$$O	a$$$19$$$20$$$O	composition$$$21$$$32$$$O	comprising$$$33$$$43$$$O	at$$$44$$$46$$$O	least$$$47$$$52$$$O	one$$$53$$$56$$$O	of$$$57$$$59$$$O	a$$$60$$$61$$$O	compound$$$62$$$70$$$O	selected$$$71$$$79$$$O	from$$$80$$$84$$$O	the$$$85$$$88$$$O	group$$$89$$$94$$$O	consisting$$$95$$$105$$$O	of$$$106$$$108$$$O	a$$$109$$$110$$$O	bioflavonoid,$$$111$$$124$$$O	a$$$125$$$126$$$O	beta-1,3-beta-1,4-polymer$$$127$$$152$$$O	of$$$153$$$155$$$O	glucose$$$156$$$163$$$I	having$$$164$$$170$$$O	a$$$171$$$172$$$O	weight$$$173$$$179$$$O	average$$$180$$$187$$$O	molecular$$$188$$$197$$$O	weight$$$198$$$204$$$O	(MW)$$$205$$$209$$$O	of$$$210$$$212$$$O	not$$$213$$$216$$$O	greater$$$217$$$224$$$O	than$$$225$$$229$$$O	1000$$$230$$$234$$$O	kDa,$$$235$$$239$$$O	and$$$240$$$243$$$O	a$$$244$$$245$$$O	sterol.$$$246$$$253$$$I	Moreover,$$$254$$$263$$$O	there$$$264$$$269$$$O	is$$$270$$$272$$$O	disclosed$$$273$$$282$$$O	a$$$283$$$284$$$O	food$$$285$$$289$$$O	or$$$290$$$292$$$O	beverage$$$293$$$301$$$O	or$$$302$$$304$$$O	health$$$305$$$311$$$O	supplement$$$312$$$322$$$O	product$$$323$$$330$$$O	comprising$$$331$$$341$$$O	the$$$342$$$345$$$O	disclosed$$$346$$$355$$$O	composition.$$$356$$$368$$$O	Further,$$$369$$$377$$$O	there$$$378$$$383$$$O	is$$$384$$$386$$$O	disclosed$$$387$$$396$$$O	a$$$397$$$398$$$O	method$$$399$$$405$$$O	of$$$406$$$408$$$O	lowering$$$409$$$417$$$O	blood$$$418$$$423$$$O	serum$$$424$$$429$$$O	cholesterol$$$430$$$441$$$I	levels$$$442$$$448$$$O	comprising$$$449$$$459$$$O	administering$$$460$$$473$$$O	to$$$474$$$476$$$O	a$$$477$$$478$$$O	patient$$$479$$$486$$$O	in$$$487$$$489$$$O	need$$$490$$$494$$$O	thereof$$$495$$$502$$$O	an$$$503$$$505$$$O	effective$$$506$$$515$$$O	amount$$$516$$$522$$$O	of$$$523$$$525$$$O	the$$$526$$$529$$$O	disclosed$$$530$$$539$$$O	composition.$$$540$$$552$$$O
CN101602707B
Naphthaline$$$0$$$11$$$I	lactam$$$12$$$18$$$I	derivative$$$19$$$29$$$O	and$$$30$$$33$$$O	application$$$34$$$45$$$O	thereof$$$46$$$53$$$O	in$$$54$$$56$$$O	propagation$$$57$$$68$$$O	suppression$$$69$$$80$$$O	of$$$81$$$83$$$O	tumor$$$84$$$89$$$O	cells$$$90$$$95$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	naphthaline$$$27$$$38$$$I	lactam$$$39$$$45$$$I	derivative$$$46$$$56$$$O	and$$$57$$$60$$$O	application$$$61$$$72$$$O	thereof$$$73$$$80$$$O	in$$$81$$$83$$$O	the$$$84$$$87$$$O	propagation$$$88$$$99$$$O	suppression$$$100$$$111$$$O	of$$$112$$$114$$$O	tumor$$$115$$$120$$$O	cells,$$$121$$$127$$$O	belonging$$$128$$$137$$$O	to$$$138$$$140$$$O	the$$$141$$$144$$$O	technical$$$145$$$154$$$O	field$$$155$$$160$$$O	of$$$161$$$163$$$O	pharmaceutical$$$164$$$178$$$O	chemistry.$$$179$$$189$$$O	N$$$190$$$191$$$I	aphthaline$$$192$$$202$$$I	lactam$$$203$$$209$$$I	is$$$210$$$212$$$O	taken$$$213$$$218$$$O	as$$$219$$$221$$$O	a$$$222$$$223$$$O	parent$$$224$$$230$$$O	for$$$231$$$234$$$O	the$$$235$$$238$$$O	naphthaline$$$239$$$250$$$I	lactam$$$251$$$257$$$I	derivative$$$258$$$268$$$O	takes,$$$269$$$275$$$O	and$$$276$$$279$$$O	a$$$280$$$281$$$O	derivative$$$282$$$292$$$O	with$$$293$$$297$$$O	high$$$298$$$302$$$O	biological$$$303$$$313$$$O	activity$$$314$$$322$$$O	base$$$323$$$327$$$O	groups,$$$328$$$335$$$O	such$$$336$$$340$$$O	as$$$341$$$343$$$O	acetylene$$$344$$$353$$$I	bonds,$$$354$$$360$$$O	nitrile$$$361$$$368$$$I	groups,$$$369$$$376$$$O	amine$$$377$$$382$$$I	groups$$$383$$$389$$$O	or$$$390$$$392$$$O	acylamide$$$393$$$402$$$I	structures,$$$403$$$414$$$O	and$$$415$$$418$$$O	the$$$419$$$422$$$O	like$$$423$$$427$$$O	is$$$428$$$430$$$O	obtained$$$431$$$439$$$O	respectively$$$440$$$452$$$O	by$$$453$$$455$$$O	synthetic$$$456$$$465$$$O	methods$$$466$$$473$$$O	of$$$474$$$476$$$O	firstly$$$477$$$484$$$O	using$$$485$$$490$$$O	different$$$491$$$500$$$O	alkylogen$$$501$$$510$$$I	hydrocarbon$$$511$$$522$$$I	to$$$523$$$525$$$O	carry$$$526$$$531$$$O	out$$$532$$$535$$$O	dehydrogenating$$$536$$$551$$$O	condensation$$$552$$$564$$$O	to$$$565$$$567$$$O	two-position$$$568$$$580$$$O	carbonyl$$$581$$$589$$$I	and$$$590$$$593$$$O	a$$$594$$$595$$$O	compound$$$596$$$604$$$O	with$$$605$$$609$$$O	active$$$610$$$616$$$O	methylene,$$$617$$$627$$$I	introducing$$$628$$$639$$$O	different$$$640$$$649$$$O	electrophilic$$$650$$$663$$$O	substitution$$$664$$$676$$$O	base$$$677$$$681$$$O	groups$$$682$$$688$$$O	by$$$689$$$691$$$O	six$$$692$$$695$$$O	positions$$$696$$$705$$$O	and$$$706$$$709$$$O	then$$$710$$$714$$$O	carrying$$$715$$$723$$$O	out$$$724$$$727$$$O	substitution$$$728$$$740$$$O	to$$$741$$$743$$$O	the$$$744$$$747$$$O	active$$$748$$$754$$$O	hydrogen$$$755$$$763$$$I	of$$$764$$$766$$$O	one-position$$$767$$$779$$$O	imine.$$$780$$$786$$$I	An$$$787$$$789$$$O	experiment$$$790$$$800$$$O	of$$$801$$$803$$$O	the$$$804$$$807$$$O	naphthaline$$$808$$$819$$$I	lactam$$$820$$$826$$$I	derivative$$$827$$$837$$$O	for$$$838$$$841$$$O	the$$$842$$$845$$$O	propagation$$$846$$$857$$$O	suppression$$$858$$$869$$$O	of$$$870$$$872$$$O	tumor$$$873$$$878$$$O	cells$$$879$$$884$$$O	selects$$$885$$$892$$$O	a$$$893$$$894$$$O	tetrazolium$$$895$$$906$$$I	reduction$$$907$$$916$$$O	method$$$917$$$923$$$O	and$$$924$$$927$$$O	is$$$928$$$930$$$O	carried$$$931$$$938$$$O	out$$$939$$$942$$$O	aiming$$$943$$$949$$$O	at$$$950$$$952$$$O	7721$$$953$$$957$$$O	human$$$958$$$963$$$O	body$$$964$$$968$$$O	liver$$$969$$$974$$$O	cancer$$$975$$$981$$$O	cells,$$$982$$$988$$$O	MCF-7$$$989$$$994$$$O	human$$$995$$$1000$$$O	body$$$1001$$$1005$$$O	mammarycancer$$$1006$$$1019$$$O	cells,$$$1020$$$1026$$$O	Hela$$$1027$$$1031$$$O	human$$$1032$$$1037$$$O	body$$$1038$$$1042$$$O	cervical$$$1043$$$1051$$$O	carcinoma$$$1052$$$1061$$$O	cells$$$1062$$$1067$$$O	or$$$1068$$$1070$$$O	BGC-823$$$1071$$$1078$$$O	human$$$1079$$$1084$$$O	body$$$1085$$$1089$$$O	stomach$$$1090$$$1097$$$O	cancer$$$1098$$$1104$$$O	cells;$$$1105$$$1111$$$O	and$$$1112$$$1115$$$O	a$$$1116$$$1117$$$O	result$$$1118$$$1124$$$O	indicates$$$1125$$$1134$$$O	that$$$1135$$$1139$$$O	the$$$1140$$$1143$$$O	naphthaline$$$1144$$$1155$$$I	lactam$$$1156$$$1162$$$I	derivative$$$1163$$$1173$$$O	has$$$1174$$$1177$$$O	favorable$$$1178$$$1187$$$O	activity$$$1188$$$1196$$$O	and$$$1197$$$1200$$$O	selectivity$$$1201$$$1212$$$O	in$$$1213$$$1215$$$O	the$$$1216$$$1219$$$O	propagation$$$1220$$$1231$$$O	suppression$$$1232$$$1243$$$O	of$$$1244$$$1246$$$O	the$$$1247$$$1250$$$O	tumor$$$1251$$$1256$$$O	cells.$$$1257$$$1263$$$O
WO2008092465A1
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	device$$$11$$$17$$$O	for$$$18$$$21$$$O	obtaining$$$22$$$31$$$O	a$$$32$$$33$$$O	salt$$$34$$$38$$$O	aerosol$$$39$$$46$$$O	of$$$47$$$49$$$O	adjustable$$$50$$$60$$$O	concentration$$$61$$$74$$$O	and$$$75$$$78$$$O	personal$$$79$$$87$$$O	halotheraphy$$$88$$$100$$$O	assembly$$$101$$$109$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	belongs$$$15$$$22$$$O	to$$$23$$$25$$$O	the$$$26$$$29$$$O	field$$$30$$$35$$$O	of$$$36$$$38$$$O	medical$$$39$$$46$$$O	technology$$$47$$$57$$$O	and$$$58$$$61$$$O	it$$$62$$$64$$$O	can$$$65$$$68$$$O	be$$$69$$$71$$$O	used$$$72$$$76$$$O	to$$$77$$$79$$$O	perform$$$80$$$87$$$O	personal$$$88$$$96$$$O	halotherapy$$$97$$$108$$$O	at$$$109$$$111$$$O	room$$$112$$$116$$$O	temperature$$$117$$$128$$$O	in$$$129$$$131$$$O	personal$$$132$$$140$$$O	halotherapy$$$141$$$152$$$O	assembly$$$153$$$161$$$O	or$$$162$$$164$$$O	in$$$165$$$167$$$O	salt$$$168$$$172$$$O	chamber$$$173$$$180$$$O	in$$$181$$$183$$$O	the$$$184$$$187$$$O	treatment$$$188$$$197$$$O	and$$$198$$$201$$$O	prophylaxis$$$202$$$213$$$O	of$$$214$$$216$$$O	respiratory$$$217$$$228$$$O	tract$$$229$$$234$$$O	diseases,$$$235$$$244$$$O	allergies$$$245$$$254$$$O	and$$$255$$$258$$$O	psoriasis,$$$259$$$269$$$O	carried$$$270$$$277$$$O	out$$$278$$$281$$$O	in$$$282$$$284$$$O	spas,$$$285$$$290$$$O	health$$$291$$$297$$$O	centres,$$$298$$$306$$$O	sanatoria,$$$307$$$317$$$O	hotels$$$318$$$324$$$O	as$$$325$$$327$$$O	well$$$328$$$332$$$O	as$$$333$$$335$$$O	at$$$336$$$338$$$O	home$$$339$$$343$$$O	or$$$344$$$346$$$O	in$$$347$$$349$$$O	outpatient$$$350$$$360$$$O	health$$$361$$$367$$$O	institutions.$$$368$$$381$$$O	The$$$382$$$385$$$O	salt$$$386$$$390$$$O	aerosol$$$391$$$398$$$O	in$$$399$$$401$$$O	the$$$402$$$405$$$O	salt$$$406$$$410$$$O	chamber$$$411$$$418$$$O	is$$$419$$$421$$$O	mixed$$$422$$$427$$$O	in$$$428$$$430$$$O	a$$$431$$$432$$$O	continuous$$$433$$$443$$$O	process$$$444$$$451$$$O	with$$$452$$$456$$$O	freshly$$$457$$$464$$$O	crushed$$$465$$$472$$$O	salt$$$473$$$477$$$O	crystals,$$$478$$$487$$$O	thus$$$488$$$492$$$O	saturating$$$493$$$503$$$O	the$$$504$$$507$$$O	salt$$$508$$$512$$$O	aerosol$$$513$$$520$$$O	with$$$521$$$525$$$O	salt$$$526$$$530$$$O	particles$$$531$$$540$$$O	activated$$$541$$$550$$$O	with$$$551$$$555$$$O	kinetic$$$556$$$563$$$O	energy.$$$564$$$571$$$O	The$$$572$$$575$$$O	therapy$$$576$$$583$$$O	mode$$$584$$$588$$$O	is$$$589$$$591$$$O	adjusted$$$592$$$600$$$O	in$$$601$$$603$$$O	real-time$$$604$$$613$$$O	in$$$614$$$616$$$O	the$$$617$$$620$$$O	course$$$621$$$627$$$O	of$$$628$$$630$$$O	the$$$631$$$634$$$O	therapy$$$635$$$642$$$O	process$$$643$$$650$$$O	in$$$651$$$653$$$O	the$$$654$$$657$$$O	salt$$$658$$$662$$$O	chamber$$$663$$$670$$$O	by$$$671$$$673$$$O	the$$$674$$$677$$$O	operator$$$678$$$686$$$O	or$$$687$$$689$$$O	the$$$690$$$693$$$O	patient$$$694$$$701$$$O	with$$$702$$$706$$$O	the$$$707$$$710$$$O	help$$$711$$$715$$$O	of$$$716$$$718$$$O	the$$$719$$$722$$$O	control$$$723$$$730$$$O	desk.$$$731$$$736$$$O	The$$$737$$$740$$$O	personal$$$741$$$749$$$O	halotherapy$$$750$$$761$$$O	assembly$$$762$$$770$$$O	is$$$771$$$773$$$O	a$$$774$$$775$$$O	small$$$776$$$781$$$O	hermetically$$$782$$$794$$$O	sealed$$$795$$$801$$$O	salt$$$802$$$806$$$O	chamber$$$807$$$814$$$O	or$$$815$$$817$$$O	salt$$$818$$$822$$$O	capsule$$$823$$$830$$$O	and$$$831$$$834$$$O	is$$$835$$$837$$$O	intended$$$838$$$846$$$O	for$$$847$$$850$$$O	one$$$851$$$854$$$O	person$$$855$$$861$$$O	or$$$862$$$864$$$O	an$$$865$$$867$$$O	adult$$$868$$$873$$$O	along$$$874$$$879$$$O	with$$$880$$$884$$$O	a$$$885$$$886$$$O	child.$$$887$$$893$$$O	The$$$894$$$897$$$O	whole$$$898$$$903$$$O	dry$$$904$$$907$$$O	salt$$$908$$$912$$$O	aerosol$$$913$$$920$$$O	saturation$$$921$$$931$$$O	device$$$932$$$938$$$O	along$$$939$$$944$$$O	with$$$945$$$949$$$O	the$$$950$$$953$$$O	patient$$$954$$$961$$$O	is$$$962$$$964$$$O	in$$$965$$$967$$$O	a$$$968$$$969$$$O	hermetically$$$970$$$982$$$O	sealed$$$983$$$989$$$O	capsule$$$990$$$997$$$O	ensures$$$998$$$1005$$$O	an$$$1006$$$1008$$$O	individually$$$1009$$$1021$$$O	prescribed$$$1022$$$1032$$$O	and$$$1033$$$1036$$$O	uniformly$$$1037$$$1046$$$O	distributed$$$1047$$$1058$$$O	environment$$$1059$$$1070$$$O	of$$$1071$$$1073$$$O	a$$$1074$$$1075$$$O	salt$$$1076$$$1080$$$O	aerosol,$$$1081$$$1089$$$O	consisting$$$1090$$$1100$$$O	of$$$1101$$$1103$$$O	freshly$$$1104$$$1111$$$O	ground$$$1112$$$1118$$$O	dry$$$1119$$$1122$$$O	salt$$$1123$$$1127$$$O	crystals$$$1128$$$1136$$$O	of$$$1137$$$1139$$$O	NaCl$$$1140$$$1144$$$O	with$$$1145$$$1149$$$O	a$$$1150$$$1151$$$O	size$$$1152$$$1156$$$O	of$$$1157$$$1159$$$O	0,5-5$$$1160$$$1165$$$O	Î¼m$$$1166$$$1169$$$O	at$$$1170$$$1172$$$O	a$$$1173$$$1174$$$O	concentration$$$1175$$$1188$$$O	of$$$1189$$$1191$$$O	0,5-80$$$1192$$$1198$$$O	mg/m3,$$$1199$$$1205$$$O	around$$$1206$$$1212$$$O	the$$$1213$$$1216$$$O	body$$$1217$$$1221$$$O	of$$$1222$$$1224$$$O	the$$$1225$$$1228$$$O	patient$$$1229$$$1236$$$O	during$$$1237$$$1243$$$O	a$$$1244$$$1245$$$O	10$$$1246$$$1248$$$O	to$$$1249$$$1251$$$O	45$$$1252$$$1254$$$O	minute$$$1255$$$1261$$$O	salt$$$1262$$$1266$$$O	procedure.$$$1267$$$1277$$$O	During$$$1278$$$1284$$$O	the$$$1285$$$1288$$$O	performance$$$1289$$$1300$$$O	of$$$1301$$$1303$$$O	a$$$1304$$$1305$$$O	salt$$$1306$$$1310$$$O	procedure,$$$1311$$$1321$$$O	the$$$1322$$$1325$$$O	salt$$$1326$$$1330$$$O	capsule$$$1331$$$1338$$$O	is$$$1339$$$1341$$$O	hermetically$$$1342$$$1354$$$O	isolated$$$1355$$$1363$$$O	from$$$1364$$$1368$$$O	the$$$1369$$$1372$$$O	surrounding$$$1373$$$1384$$$O	environment$$$1385$$$1396$$$O	and$$$1397$$$1400$$$O	the$$$1401$$$1404$$$O	saturation$$$1405$$$1415$$$O	of$$$1416$$$1418$$$O	the$$$1419$$$1422$$$O	salt$$$1423$$$1427$$$O	aerosol$$$1428$$$1435$$$O	is$$$1436$$$1438$$$O	carried$$$1439$$$1446$$$O	out$$$1447$$$1450$$$O	autonomously.$$$1451$$$1464$$$O	The$$$1465$$$1468$$$O	control$$$1469$$$1476$$$O	desk$$$1477$$$1481$$$O	(5)is$$$1482$$$1487$$$O	duplicated$$$1488$$$1498$$$O	to$$$1499$$$1501$$$O	the$$$1502$$$1505$$$O	lower$$$1506$$$1511$$$O	part$$$1512$$$1516$$$O	(A)$$$1517$$$1520$$$O	of$$$1521$$$1523$$$O	the$$$1524$$$1527$$$O	personal$$$1528$$$1536$$$O	therapy$$$1537$$$1544$$$O	assembly$$$1545$$$1553$$$O	as$$$1554$$$1556$$$O	well$$$1557$$$1561$$$O	as$$$1562$$$1564$$$O	to$$$1565$$$1567$$$O	the$$$1568$$$1571$$$O	personal$$$1572$$$1580$$$O	console$$$1581$$$1588$$$O	of$$$1589$$$1591$$$O	the$$$1592$$$1595$$$O	patient$$$1596$$$1603$$$O	in$$$1604$$$1606$$$O	the$$$1607$$$1610$$$O	salt$$$1611$$$1615$$$O	therapy$$$1616$$$1623$$$O	room$$$1624$$$1628$$$O	(C).$$$1629$$$1633$$$O	The$$$1634$$$1637$$$O	personal$$$1638$$$1646$$$O	halotherapy$$$1647$$$1658$$$O	assembly$$$1659$$$1667$$$O	may$$$1668$$$1671$$$O	be$$$1672$$$1674$$$O	equipped$$$1675$$$1683$$$O	with$$$1684$$$1688$$$O	wheels$$$1689$$$1695$$$O	that$$$1696$$$1700$$$O	make$$$1701$$$1705$$$O	it$$$1706$$$1708$$$O	easy$$$1709$$$1713$$$O	to$$$1714$$$1716$$$O	transport.$$$1717$$$1727$$$O
CN101224265A
Plaster$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	fracture$$$21$$$29$$$O	dialocation$$$30$$$41$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	plaster$$$26$$$33$$$O	used$$$34$$$38$$$O	for$$$39$$$42$$$O	treating$$$43$$$51$$$O	fracture$$$52$$$60$$$O	dislocation,$$$61$$$73$$$O	which$$$74$$$79$$$O	is$$$80$$$82$$$O	prepared$$$83$$$91$$$O	by$$$92$$$94$$$O	the$$$95$$$98$$$O	following$$$99$$$108$$$O	raw$$$109$$$112$$$O	materials$$$113$$$122$$$O	by$$$123$$$125$$$O	weight$$$126$$$132$$$O	proportion:$$$133$$$144$$$O	0.9-1.1$$$145$$$152$$$O	parts$$$153$$$158$$$O	of$$$159$$$161$$$O	safflower,$$$162$$$172$$$O	0.45-0.55$$$173$$$182$$$O	part$$$183$$$187$$$O	of$$$188$$$190$$$O	sapanwood,$$$191$$$201$$$O	0.45-0.55$$$202$$$211$$$O	part$$$212$$$216$$$O	of$$$217$$$219$$$O	rhizoma$$$220$$$227$$$O	drynariae,$$$228$$$238$$$O	0.45-0.55$$$239$$$248$$$O	part$$$249$$$253$$$O	of$$$254$$$256$$$O	angelica,$$$257$$$266$$$O	0.90-1.05$$$267$$$276$$$O	parts$$$277$$$282$$$O	of$$$283$$$285$$$O	catechu,$$$286$$$294$$$O	0.45-0.55$$$295$$$304$$$O	part$$$305$$$309$$$O	of$$$310$$$312$$$O	dragon's$$$313$$$321$$$O	blood,$$$322$$$328$$$O	0.45-0.55$$$329$$$338$$$O	part$$$339$$$343$$$O	of$$$344$$$346$$$O	frankincense,$$$347$$$360$$$O	0.9-1.0$$$361$$$368$$$O	part$$$369$$$373$$$O	of$$$374$$$376$$$O	rhubarb,$$$377$$$385$$$O	18-21$$$386$$$391$$$O	parts$$$392$$$397$$$O	of$$$398$$$400$$$O	red$$$401$$$404$$$O	lead$$$405$$$409$$$I	and$$$410$$$413$$$O	48-51$$$414$$$419$$$O	parts$$$420$$$425$$$O	of$$$426$$$428$$$O	vegetable$$$429$$$438$$$O	oil.$$$439$$$443$$$O	The$$$444$$$447$$$O	invention$$$448$$$457$$$O	also$$$458$$$462$$$O	discloses$$$463$$$472$$$O	the$$$473$$$476$$$O	preparation$$$477$$$488$$$O	method$$$489$$$495$$$O	of$$$496$$$498$$$O	the$$$499$$$502$$$O	plaster.$$$503$$$511$$$O	The$$$512$$$515$$$O	plaster$$$516$$$523$$$O	has$$$524$$$527$$$O	the$$$528$$$531$$$O	efficacies$$$532$$$542$$$O	of$$$543$$$545$$$O	activating$$$546$$$556$$$O	blood$$$557$$$562$$$O	circulation,$$$563$$$575$$$O	eliminating$$$576$$$587$$$O	swelling,$$$588$$$597$$$O	rejoining$$$598$$$607$$$O	fractured$$$608$$$617$$$O	bones,$$$618$$$624$$$O	alleviating$$$625$$$636$$$O	pains,$$$637$$$643$$$O	penetrating$$$644$$$655$$$O	bones,$$$656$$$662$$$O	relieving$$$663$$$672$$$O	rigidity$$$673$$$681$$$O	of$$$682$$$684$$$O	muscles$$$685$$$692$$$O	and$$$693$$$696$$$O	activating$$$697$$$707$$$O	collaterals$$$708$$$719$$$O	as$$$720$$$722$$$O	well$$$723$$$727$$$O	as$$$728$$$730$$$O	the$$$731$$$734$$$O	advantages$$$735$$$745$$$O	of$$$746$$$748$$$O	short$$$749$$$754$$$O	curing$$$755$$$761$$$O	time$$$762$$$766$$$O	and$$$767$$$770$$$O	high$$$771$$$775$$$O	cure$$$776$$$780$$$O	rate.$$$781$$$786$$$O	.$$$787$$$788$$$O
CN101555266A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	Tibifuding$$$22$$$32$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	new$$$26$$$29$$$O	preparation$$$30$$$41$$$O	method$$$42$$$48$$$O	of$$$49$$$51$$$O	Tibifuding$$$52$$$62$$$I	which$$$63$$$68$$$O	comprises$$$69$$$78$$$O	the$$$79$$$82$$$O	steps$$$83$$$88$$$O	as$$$89$$$91$$$O	follows:$$$92$$$100$$$O	2'-deoxidated-2'-halo-3',5'-bi-O-$$$101$$$134$$$I	alkanoyl-5-methyl-beta-L-uridine$$$135$$$167$$$I	is$$$168$$$170$$$O	used$$$171$$$175$$$O	as$$$176$$$178$$$O	raw$$$179$$$182$$$O	material$$$183$$$191$$$O	to$$$192$$$194$$$O	react$$$195$$$200$$$O	with$$$201$$$205$$$O	ortho$$$206$$$211$$$I	phosphorous$$$212$$$223$$$I	acid$$$224$$$228$$$I	or$$$229$$$231$$$O	hypophosphite$$$232$$$245$$$I	and$$$246$$$249$$$O	alkali$$$250$$$256$$$O	under$$$257$$$262$$$O	effect$$$263$$$269$$$O	of$$$270$$$272$$$O	radical$$$273$$$280$$$O	initiator$$$281$$$290$$$O	in$$$291$$$293$$$O	latent$$$294$$$300$$$O	solvent,$$$301$$$309$$$O	thereby$$$310$$$317$$$O	preparing$$$318$$$327$$$O	Tibifuding.$$$328$$$339$$$I	The$$$340$$$343$$$O	preparation$$$344$$$355$$$O	method$$$356$$$362$$$O	of$$$363$$$365$$$O	Tibifuding$$$366$$$376$$$I	is$$$377$$$379$$$O	free$$$380$$$384$$$O	of$$$385$$$387$$$O	metal$$$388$$$393$$$O	catalyst$$$394$$$402$$$O	in$$$403$$$405$$$O	reaction;$$$406$$$415$$$O	therefore,$$$416$$$426$$$O	the$$$427$$$430$$$O	preparation$$$431$$$442$$$O	method$$$443$$$449$$$O	of$$$450$$$452$$$O	Tibifuding$$$453$$$463$$$I	has$$$464$$$467$$$O	mild$$$468$$$472$$$O	reaction$$$473$$$481$$$O	condition,$$$482$$$492$$$O	higher$$$493$$$499$$$O	yield,$$$500$$$506$$$O	economical$$$507$$$517$$$O	and$$$518$$$521$$$O	effective$$$522$$$531$$$O	application$$$532$$$543$$$O	which$$$544$$$549$$$O	is$$$550$$$552$$$O	applicable$$$553$$$563$$$O	to$$$564$$$566$$$O	mass$$$567$$$571$$$O	industrial$$$572$$$582$$$O	production.$$$583$$$594$$$O
WO2008097317A1
Solvating$$$0$$$9$$$O	system$$$10$$$16$$$O	and$$$17$$$20$$$O	sealant$$$21$$$28$$$O	for$$$29$$$32$$$O	medical$$$33$$$40$$$O	use$$$41$$$44$$$O
Chronic$$$0$$$7$$$O	Otitis$$$8$$$14$$$O	Media$$$15$$$20$$$O	with$$$21$$$25$$$O	Effusion$$$26$$$34$$$O	(COME),$$$35$$$42$$$O	Recurrent$$$43$$$52$$$O	Acute$$$53$$$58$$$O	Otitis$$$59$$$65$$$O	Media$$$66$$$71$$$O	(RAOM),$$$72$$$79$$$O	cholesteatoma,$$$80$$$94$$$O	chronic$$$95$$$102$$$O	rhinosinusitis$$$103$$$117$$$O	and$$$118$$$121$$$O	other$$$122$$$127$$$O	bacterial$$$128$$$137$$$O	ear,$$$138$$$142$$$O	nose$$$143$$$147$$$O	or$$$148$$$150$$$O	throat$$$151$$$157$$$O	conditions$$$158$$$168$$$O	may$$$169$$$172$$$O	be$$$173$$$175$$$O	treated$$$176$$$183$$$O	by$$$184$$$186$$$O	applying$$$187$$$195$$$O	a$$$196$$$197$$$O	solvating$$$198$$$207$$$O	system$$$208$$$214$$$O	to$$$215$$$217$$$O	a$$$218$$$219$$$O	bacterial$$$220$$$229$$$O	biofilm$$$230$$$237$$$O	attached$$$238$$$246$$$O	or$$$247$$$249$$$O	adhered$$$250$$$257$$$O	to$$$258$$$260$$$O	the$$$261$$$264$$$O	treatment$$$265$$$274$$$O	site.$$$275$$$280$$$O	The$$$281$$$284$$$O	biofilm$$$285$$$292$$$O	is$$$293$$$295$$$O	disrupted$$$296$$$305$$$O	and$$$306$$$309$$$O	a$$$310$$$311$$$O	protective$$$312$$$322$$$O	layer$$$323$$$328$$$O	of$$$329$$$331$$$O	a$$$332$$$333$$$O	polymeric$$$334$$$343$$$O	film-forming$$$344$$$356$$$O	medical$$$357$$$364$$$O	sealant$$$365$$$372$$$O	is$$$373$$$375$$$O	applied$$$376$$$383$$$O	to$$$384$$$386$$$O	the$$$387$$$390$$$O	treatment$$$391$$$400$$$O	site.$$$401$$$406$$$O
CN102335179A
Alprostadil$$$0$$$11$$$I	composite$$$12$$$21$$$O	medicine,$$$22$$$31$$$O	preparation$$$32$$$43$$$O	method$$$44$$$50$$$O	thereof,$$$51$$$59$$$O	quality$$$60$$$67$$$O	controlling$$$68$$$79$$$O	method$$$80$$$86$$$O	thereof,$$$87$$$95$$$O	and$$$96$$$99$$$O	purpose$$$100$$$107$$$O	thereof$$$108$$$115$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	alprostadil$$$28$$$39$$$I	composite$$$40$$$49$$$O	medicine$$$50$$$58$$$O	comprising$$$59$$$69$$$O	high-purity$$$70$$$81$$$O	alprostadil$$$82$$$93$$$I	and$$$94$$$97$$$O	a$$$98$$$99$$$O	mixture$$$100$$$107$$$O	of$$$108$$$110$$$O	aspirin-DL-lysine$$$111$$$128$$$I	and$$$129$$$132$$$O	sodium$$$133$$$139$$$I	salicylate,$$$140$$$151$$$I	wherein$$$152$$$159$$$O	a$$$160$$$161$$$O	weight$$$162$$$168$$$O	ratio$$$169$$$174$$$O	of$$$175$$$177$$$O	aspirin-DL-lysine$$$178$$$195$$$I	to$$$196$$$198$$$O	sodium$$$199$$$205$$$I	salicylate$$$206$$$216$$$I	is$$$217$$$219$$$O	90-95:5-10.$$$220$$$231$$$O	The$$$232$$$235$$$O	invention$$$236$$$245$$$O	also$$$246$$$250$$$O	provides$$$251$$$259$$$O	a$$$260$$$261$$$O	weight$$$262$$$268$$$O	ratio$$$269$$$274$$$O	of$$$275$$$277$$$O	the$$$278$$$281$$$O	raw$$$282$$$285$$$O	materials$$$286$$$295$$$O	of$$$296$$$298$$$O	the$$$299$$$302$$$O	composite$$$303$$$312$$$O	medicine.$$$313$$$322$$$O	The$$$323$$$326$$$O	invention$$$327$$$336$$$O	also$$$337$$$341$$$O	provides$$$342$$$350$$$O	a$$$351$$$352$$$O	preparation$$$353$$$364$$$O	method$$$365$$$371$$$O	of$$$372$$$374$$$O	the$$$375$$$378$$$O	alprostadil$$$379$$$390$$$I	composite$$$391$$$400$$$O	medicine,$$$401$$$410$$$O	and$$$411$$$414$$$O	a$$$415$$$416$$$O	quality$$$417$$$424$$$O	controlling$$$425$$$436$$$O	method$$$437$$$443$$$O	of$$$444$$$446$$$O	the$$$447$$$450$$$O	alprostadil$$$451$$$462$$$I	composite$$$463$$$472$$$O	medicine.$$$473$$$482$$$O	With$$$483$$$487$$$O	a$$$488$$$489$$$O	pharmaceutically$$$490$$$506$$$O	acceptable$$$507$$$517$$$O	alprostadil$$$518$$$529$$$I	composite$$$530$$$539$$$O	medicine$$$540$$$548$$$O	dosage,$$$549$$$556$$$O	the$$$557$$$560$$$O	medicine$$$561$$$569$$$O	can$$$570$$$573$$$O	be$$$574$$$576$$$O	prepared$$$577$$$585$$$O	into$$$586$$$590$$$O	lyophilized$$$591$$$602$$$O	injections,$$$603$$$614$$$O	oral$$$615$$$619$$$O	preparations,$$$620$$$633$$$O	aerosols,$$$634$$$643$$$O	suppositories,$$$644$$$658$$$O	or$$$659$$$661$$$O	enemas$$$662$$$668$$$O	of$$$669$$$671$$$O	the$$$672$$$675$$$O	acceptable$$$676$$$686$$$O	alprostadil$$$687$$$698$$$I	composite$$$699$$$708$$$O	medicine.$$$709$$$718$$$O	The$$$719$$$722$$$O	invention$$$723$$$732$$$O	discloses$$$733$$$742$$$O	chromatographic$$$743$$$758$$$O	conditions$$$759$$$769$$$O	for$$$770$$$773$$$O	determining$$$774$$$785$$$O	the$$$786$$$789$$$O	contents$$$790$$$798$$$O	of$$$799$$$801$$$O	alprostadil,$$$802$$$814$$$I	prostaglandin$$$815$$$828$$$I	A1$$$829$$$831$$$I	and$$$832$$$835$$$O	prostaglandin$$$836$$$849$$$I	B1.$$$850$$$853$$$I	Three$$$854$$$859$$$O	peaks$$$860$$$865$$$O	before$$$866$$$872$$$O	an$$$873$$$875$$$O	alprostadil$$$876$$$887$$$I	peak$$$888$$$892$$$O	are$$$893$$$896$$$O	characteristic$$$897$$$911$$$O	peaks$$$912$$$917$$$O	of$$$918$$$920$$$O	alprostadil$$$921$$$932$$$I	composite$$$933$$$942$$$O	medicine$$$943$$$951$$$O	auxiliary$$$952$$$961$$$O	materials.$$$962$$$972$$$O	The$$$973$$$976$$$O	alprostadil$$$977$$$988$$$I	composite$$$989$$$998$$$O	medicine$$$999$$$1007$$$O	is$$$1008$$$1010$$$O	used$$$1011$$$1015$$$O	for$$$1016$$$1019$$$O	treating$$$1020$$$1028$$$O	and$$$1029$$$1032$$$O	preventing$$$1033$$$1043$$$O	diseases$$$1044$$$1052$$$O	such$$$1053$$$1057$$$O	as$$$1058$$$1060$$$O	coronary$$$1061$$$1069$$$O	heart$$$1070$$$1075$$$O	disease,$$$1076$$$1084$$$O	myocardial$$$1085$$$1095$$$O	infarction,$$$1096$$$1107$$$O	brain$$$1108$$$1113$$$O	infarction,$$$1114$$$1125$$$O	hypertension,$$$1126$$$1139$$$O	hyperlipemia,$$$1140$$$1153$$$O	atherosclerosis,$$$1154$$$1170$$$O	angiitis,$$$1171$$$1180$$$O	tumour,$$$1181$$$1188$$$O	hepatitis,$$$1189$$$1199$$$O	diabetic$$$1200$$$1208$$$O	angiopathies,$$$1209$$$1222$$$O	kidney$$$1223$$$1229$$$O	insufficiency,$$$1230$$$1244$$$O	bronchial$$$1245$$$1254$$$O	asthma,$$$1255$$$1262$$$O	pancreatitis,$$$1263$$$1276$$$O	gastric$$$1277$$$1284$$$O	ulcer,$$$1285$$$1291$$$O	and$$$1292$$$1295$$$O	vertebrobasilar$$$1296$$$1311$$$O	insufficiency.$$$1312$$$1326$$$O
CN1955163A
Cyclooxygenase-2$$$0$$$16$$$O	selection$$$17$$$26$$$O	inhibitor$$$27$$$36$$$O	and$$$37$$$40$$$O	its$$$41$$$44$$$O	medicine$$$45$$$53$$$O	use$$$54$$$57$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	cyclooxygenase$$$28$$$42$$$O	[b]symphyso-pyrrole$$$43$$$62$$$I	derivate$$$63$$$71$$$O	of$$$72$$$74$$$O	formula$$$75$$$82$$$O	I$$$83$$$84$$$O	that$$$85$$$89$$$O	possesses$$$90$$$99$$$O	selective$$$100$$$109$$$O	restraining$$$110$$$121$$$O	activity$$$122$$$130$$$O	for$$$131$$$134$$$O	cyclooxygenase-2,$$$135$$$152$$$O	containing$$$153$$$163$$$O	medicine$$$164$$$172$$$O	combination$$$173$$$184$$$O	of$$$185$$$187$$$O	mentioned$$$188$$$197$$$O	compound,$$$198$$$207$$$O	and$$$208$$$211$$$O	the$$$212$$$215$$$O	usage$$$216$$$221$$$O	of$$$222$$$224$$$O	mentioned$$$225$$$234$$$O	compound$$$235$$$243$$$O	which$$$244$$$249$$$O	is$$$250$$$252$$$O	used$$$253$$$257$$$O	for$$$258$$$261$$$O	preparing$$$262$$$271$$$O	medicine$$$272$$$280$$$O	to$$$281$$$283$$$O	cure$$$284$$$288$$$O	inflammation$$$289$$$301$$$O	such$$$302$$$306$$$O	as$$$307$$$309$$$O	rheumatic$$$310$$$319$$$O	arthritis,$$$320$$$330$$$O	osteoarthritis,$$$331$$$346$$$O	pain$$$347$$$351$$$O	and$$$352$$$355$$$O	tumor,$$$356$$$362$$$O	among$$$363$$$368$$$O	them,$$$369$$$374$$$O	n$$$375$$$376$$$O	is$$$377$$$379$$$O	1$$$380$$$381$$$O	or$$$382$$$384$$$O	2;$$$385$$$387$$$O	R1$$$388$$$390$$$O	is$$$391$$$393$$$O	methyl$$$394$$$400$$$I	or$$$401$$$403$$$O	amino$$$404$$$409$$$I	group;$$$410$$$416$$$O	R2$$$417$$$419$$$O	is$$$420$$$422$$$O	C4-C7$$$423$$$428$$$I	saturation$$$429$$$439$$$I	cyclane$$$440$$$447$$$I	group,$$$448$$$454$$$O	aromatic$$$455$$$463$$$I	heterocycle$$$464$$$475$$$I	or$$$476$$$478$$$O	benzene$$$479$$$486$$$I	ring$$$487$$$491$$$O	which$$$492$$$497$$$O	is$$$498$$$500$$$O	substituted$$$501$$$512$$$O	by$$$513$$$515$$$O	1,2$$$516$$$519$$$O	or$$$520$$$522$$$O	more$$$523$$$527$$$O	substituted$$$528$$$539$$$O	group,$$$540$$$546$$$O	mentioned$$$547$$$556$$$O	substituted$$$557$$$568$$$O	group$$$569$$$574$$$O	is$$$575$$$577$$$O	respectively$$$578$$$590$$$O	selected$$$591$$$599$$$O	from$$$600$$$604$$$O	halogen,$$$605$$$613$$$I	methyl,$$$614$$$621$$$I	methoxy$$$622$$$629$$$I	group$$$630$$$635$$$O	or$$$636$$$638$$$O	methylthio.$$$639$$$650$$$I
CN101015524B
Coenzyme$$$0$$$8$$$O	Q10$$$9$$$12$$$O	oral$$$13$$$17$$$O	emulsion$$$18$$$26$$$O	and$$$27$$$30$$$O	preparing$$$31$$$40$$$O	process$$$41$$$48$$$O	thereof$$$49$$$56$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	coenzyme$$$27$$$35$$$O	Q10$$$36$$$39$$$O	oral$$$40$$$44$$$O	emulsion$$$45$$$53$$$O	and$$$54$$$57$$$O	its$$$58$$$61$$$O	preparation$$$62$$$73$$$O	method,$$$74$$$81$$$O	wherein$$$82$$$89$$$O	the$$$90$$$93$$$O	constituents$$$94$$$106$$$O	include$$$107$$$114$$$O	coenzyme$$$115$$$123$$$O	Q10$$$124$$$127$$$O	0.1-80%,$$$128$$$136$$$O	medicinal$$$137$$$146$$$O	oil$$$147$$$150$$$O	1-95%,$$$151$$$157$$$O	emulsifying$$$158$$$169$$$O	agent$$$170$$$175$$$O	0.5-30%,$$$176$$$184$$$O	auxiliary$$$185$$$194$$$O	emulsifying$$$195$$$206$$$O	agent$$$207$$$212$$$O	0-10%,$$$213$$$219$$$O	anti-oxidant$$$220$$$232$$$O	0.001-15%,$$$233$$$243$$$O	and$$$244$$$247$$$O	balancing$$$248$$$257$$$O	purified$$$258$$$266$$$O	water.$$$267$$$273$$$O	The$$$274$$$277$$$O	emulsion$$$278$$$286$$$O	can$$$287$$$290$$$O	be$$$291$$$293$$$O	prepared$$$294$$$302$$$O	through$$$303$$$310$$$O	inversion$$$311$$$320$$$O	phase$$$321$$$326$$$O	emulsification$$$327$$$341$$$O	method,$$$342$$$349$$$O	PIT$$$350$$$353$$$O	emulsification$$$354$$$368$$$O	method,$$$369$$$376$$$O	alternative$$$377$$$388$$$O	liquid$$$389$$$395$$$O	feeding$$$396$$$403$$$O	emulsification$$$404$$$418$$$O	method,$$$419$$$426$$$O	or$$$427$$$429$$$O	continuous$$$430$$$440$$$O	emulsification$$$441$$$455$$$O	method.$$$456$$$463$$$O
CA2604161A1
Purine$$$0$$$6$$$I	and$$$7$$$10$$$O	imidazopyridine$$$11$$$26$$$I	derivatives$$$27$$$38$$$O	for$$$39$$$42$$$O	immunosuppression$$$43$$$60$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	novel$$$31$$$36$$$O	purine$$$37$$$43$$$I	and$$$44$$$47$$$O	imidazopyridine$$$48$$$63$$$I	derivatives$$$64$$$75$$$O	useful$$$76$$$82$$$O	for$$$83$$$86$$$O	the$$$87$$$90$$$O	prevention$$$91$$$101$$$O	and$$$102$$$105$$$O	treatment$$$106$$$115$$$O	of$$$116$$$118$$$O	autoimmune$$$119$$$129$$$O	diseases,$$$130$$$139$$$O	inflammatory$$$140$$$152$$$O	disease,$$$153$$$161$$$O	mast$$$162$$$166$$$O	cell$$$167$$$171$$$O	mediated$$$172$$$180$$$O	disease$$$181$$$188$$$O	and$$$189$$$192$$$O	transplant$$$193$$$203$$$O	rejection.$$$204$$$214$$$O	The$$$215$$$218$$$O	compounds$$$219$$$228$$$O	are$$$229$$$232$$$O	of$$$233$$$235$$$O	the$$$236$$$239$$$O	general$$$240$$$247$$$O	formulas$$$248$$$256$$$O	($$$257$$$258$$$O	I$$$259$$$260$$$O	)$$$261$$$262$$$O	and$$$263$$$266$$$O	($$$267$$$268$$$O	II$$$269$$$271$$$O	).$$$272$$$274$$$O
WO2007135122A1
Novel$$$0$$$5$$$O	1,4-diaza-bicyclo[3.2.2]nonane$$$6$$$36$$$I	derivatives$$$37$$$48$$$O	and$$$49$$$52$$$O	their$$$53$$$58$$$O	medical$$$59$$$66$$$O	use$$$67$$$70$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	1,4-diaza-bicyclo[3.2.2]nonane$$$32$$$62$$$I	derivatives,$$$63$$$75$$$O	which$$$76$$$81$$$O	are$$$82$$$85$$$O	found$$$86$$$91$$$O	to$$$92$$$94$$$O	be$$$95$$$97$$$O	cholinergic$$$98$$$109$$$O	ligands$$$110$$$117$$$O	at$$$118$$$120$$$O	the$$$121$$$124$$$O	nicotinic$$$125$$$134$$$O	acetylcholine$$$135$$$148$$$I	receptors$$$149$$$158$$$O	and$$$159$$$162$$$O	modulators$$$163$$$173$$$O	of$$$174$$$176$$$O	the$$$177$$$180$$$O	monoamine$$$181$$$190$$$I	receptors$$$191$$$200$$$O	and$$$201$$$204$$$O	transporters.$$$205$$$218$$$O	Due$$$219$$$222$$$O	to$$$223$$$225$$$O	their$$$226$$$231$$$O	pharmacological$$$232$$$247$$$O	profile$$$248$$$255$$$O	the$$$256$$$259$$$O	compounds$$$260$$$269$$$O	of$$$270$$$272$$$O	the$$$273$$$276$$$O	invention$$$277$$$286$$$O	may$$$287$$$290$$$O	be$$$291$$$293$$$O	useful$$$294$$$300$$$O	for$$$301$$$304$$$O	the$$$305$$$308$$$O	treatment$$$309$$$318$$$O	of$$$319$$$321$$$O	diseases$$$322$$$330$$$O	or$$$331$$$333$$$O	disorders$$$334$$$343$$$O	as$$$344$$$346$$$O	diverse$$$347$$$354$$$O	as$$$355$$$357$$$O	those$$$358$$$363$$$O	related$$$364$$$371$$$O	to$$$372$$$374$$$O	the$$$375$$$378$$$O	cholinergic$$$379$$$390$$$O	system$$$391$$$397$$$O	of$$$398$$$400$$$O	the$$$401$$$404$$$O	central$$$405$$$412$$$O	nervous$$$413$$$420$$$O	system$$$421$$$427$$$O	(CNS),$$$428$$$434$$$O	the$$$435$$$438$$$O	peripheral$$$439$$$449$$$O	nervous$$$450$$$457$$$O	system$$$458$$$464$$$O	(PNS),$$$465$$$471$$$O	diseases$$$472$$$480$$$O	or$$$481$$$483$$$O	disorders$$$484$$$493$$$O	related$$$494$$$501$$$O	to$$$502$$$504$$$O	smooth$$$505$$$511$$$O	muscle$$$512$$$518$$$O	contraction,$$$519$$$531$$$O	endocrine$$$532$$$541$$$O	diseases$$$542$$$550$$$O	or$$$551$$$553$$$O	disorders,$$$554$$$564$$$O	diseases$$$565$$$573$$$O	or$$$574$$$576$$$O	disorders$$$577$$$586$$$O	related$$$587$$$594$$$O	to$$$595$$$597$$$O	neuro-degeneration,$$$598$$$617$$$O	diseases$$$618$$$626$$$O	or$$$627$$$629$$$O	disorders$$$630$$$639$$$O	related$$$640$$$647$$$O	to$$$648$$$650$$$O	inflammation,$$$651$$$664$$$O	pain,$$$665$$$670$$$O	and$$$671$$$674$$$O	withdrawal$$$675$$$685$$$O	symptoms$$$686$$$694$$$O	caused$$$695$$$701$$$O	by$$$702$$$704$$$O	the$$$705$$$708$$$O	termination$$$709$$$720$$$O	of$$$721$$$723$$$O	abuse$$$724$$$729$$$O	of$$$730$$$732$$$O	chemical$$$733$$$741$$$O	substances.$$$742$$$753$$$O
CN103524533A
Cefprozil$$$0$$$9$$$I	compound,$$$10$$$19$$$O	and$$$20$$$23$$$O	dispersible$$$24$$$35$$$O	tablets,$$$36$$$44$$$O	dry$$$45$$$48$$$O	suspension$$$49$$$59$$$O	and$$$60$$$63$$$O	preparation$$$64$$$75$$$O	method$$$76$$$82$$$O	thereof$$$83$$$90$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	medicine,$$$38$$$47$$$O	and$$$48$$$51$$$O	in$$$52$$$54$$$O	particular$$$55$$$65$$$O	relates$$$66$$$73$$$O	to$$$74$$$76$$$O	a$$$77$$$78$$$O	cefprozil$$$79$$$88$$$I	compound,$$$89$$$98$$$O	and$$$99$$$102$$$O	dispersible$$$103$$$114$$$O	tablets,$$$115$$$123$$$O	a$$$124$$$125$$$O	dry$$$126$$$129$$$O	suspension$$$130$$$140$$$O	and$$$141$$$144$$$O	a$$$145$$$146$$$O	preparation$$$147$$$158$$$O	method$$$159$$$165$$$O	thereof.$$$166$$$174$$$O	The$$$175$$$178$$$O	cefprozil$$$179$$$188$$$I	compound$$$189$$$197$$$O	is$$$198$$$200$$$O	a$$$201$$$202$$$O	crystal,$$$203$$$211$$$O	and$$$212$$$215$$$O	an$$$216$$$218$$$O	X-ray$$$219$$$224$$$O	powder$$$225$$$231$$$O	diffraction$$$232$$$243$$$O	diagram$$$244$$$251$$$O	obtained$$$252$$$260$$$O	by$$$261$$$263$$$O	Cu-K$$$264$$$268$$$I	alpha$$$269$$$274$$$O	ray$$$275$$$278$$$O	measurement$$$279$$$290$$$O	is$$$291$$$293$$$O	shown$$$294$$$299$$$O	in$$$300$$$302$$$O	figure$$$303$$$309$$$O	1.$$$310$$$312$$$O	Through$$$313$$$320$$$O	experimental$$$321$$$333$$$O	detection,$$$334$$$344$$$O	the$$$345$$$348$$$O	cefprozil$$$349$$$358$$$I	dispersible$$$359$$$370$$$O	tablets$$$371$$$378$$$O	and$$$379$$$382$$$O	the$$$383$$$386$$$O	dry$$$387$$$390$$$O	suspension$$$391$$$401$$$O	have$$$402$$$406$$$O	the$$$407$$$410$$$O	advantages$$$411$$$421$$$O	of$$$422$$$424$$$O	superior$$$425$$$433$$$O	stability$$$434$$$443$$$O	and$$$444$$$447$$$O	quite$$$448$$$453$$$O	good$$$454$$$458$$$O	smell$$$459$$$464$$$O	and$$$465$$$468$$$O	taste,$$$469$$$475$$$O	and$$$476$$$479$$$O	are$$$480$$$483$$$O	quite$$$484$$$489$$$O	suitable$$$490$$$498$$$O	for$$$499$$$502$$$O	clinical$$$503$$$511$$$O	application.$$$512$$$524$$$O
WO2009031709A1
Coumarin$$$0$$$8$$$I	compound$$$9$$$17$$$O	and$$$18$$$21$$$O	use$$$22$$$25$$$O	thereof$$$26$$$33$$$O
Disclosed$$$0$$$9$$$O	are:$$$10$$$14$$$O	a$$$15$$$16$$$O	type-3$$$17$$$23$$$O	17Î²-hydroxysteroid$$$24$$$43$$$I	dehydrogenase-inhibiting$$$44$$$68$$$O	composition$$$69$$$80$$$O	which$$$81$$$86$$$O	is$$$87$$$89$$$O	characterized$$$90$$$103$$$O	by$$$104$$$106$$$O	comprising$$$107$$$117$$$O	a$$$118$$$119$$$I	coumarin$$$120$$$128$$$I	compound$$$129$$$137$$$O	represented$$$138$$$149$$$O	by$$$150$$$152$$$O	the$$$153$$$156$$$O	formula$$$157$$$164$$$O	(A)$$$165$$$168$$$O	or$$$169$$$171$$$O	the$$$172$$$175$$$O	like$$$176$$$180$$$O	and$$$181$$$184$$$O	an$$$185$$$187$$$O	inert$$$188$$$193$$$O	carrier;$$$194$$$202$$$O	and$$$203$$$206$$$O	others.$$$207$$$214$$$O
EP2451453A1
Substituted$$$0$$$11$$$O	pyrrolidinone$$$12$$$25$$$I	as$$$26$$$28$$$O	inhibitors$$$29$$$39$$$O	of$$$40$$$42$$$O	hepatitis$$$43$$$52$$$O	c$$$53$$$54$$$O	ns5b$$$55$$$59$$$O	polymerase,$$$60$$$71$$$O	the$$$72$$$75$$$O	pharmaceutical$$$76$$$90$$$O	composition$$$91$$$102$$$O	thereof$$$103$$$110$$$O	and$$$111$$$114$$$O	their$$$115$$$120$$$O	therapeutic$$$121$$$132$$$O	use$$$133$$$136$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	concerns$$$22$$$30$$$O	a$$$31$$$32$$$O	substituted$$$33$$$44$$$O	pyrrolidinone$$$45$$$58$$$I	of$$$59$$$61$$$O	the$$$62$$$65$$$O	following$$$66$$$75$$$O	formula$$$76$$$83$$$O	I$$$84$$$85$$$O	or$$$86$$$88$$$O	a$$$89$$$90$$$O	salt,$$$91$$$96$$$O	solvate,$$$97$$$105$$$O	tautomer,$$$106$$$115$$$O	isotope,$$$116$$$124$$$O	enantiomer,$$$125$$$136$$$O	diastereoisomer$$$137$$$152$$$O	or$$$153$$$155$$$O	racemic$$$156$$$163$$$O	mixture$$$164$$$171$$$O	thereof:$$$172$$$180$$$O	(I),$$$181$$$185$$$O	for$$$186$$$189$$$O	the$$$190$$$193$$$O	treatment$$$194$$$203$$$O	of$$$204$$$206$$$O	hepatitis$$$207$$$216$$$O	C.$$$217$$$219$$$O
US20080213407
Topical$$$0$$$7$$$O	application$$$8$$$19$$$O	of$$$20$$$22$$$O	L-arginine$$$23$$$33$$$I	and$$$34$$$37$$$O	menthol$$$38$$$45$$$I	to$$$46$$$48$$$O	increase$$$49$$$57$$$O	penis$$$58$$$63$$$O	size$$$64$$$68$$$O
A$$$0$$$1$$$O	manual$$$2$$$8$$$O	application$$$9$$$20$$$O	of$$$21$$$23$$$O	a$$$24$$$25$$$O	topical$$$26$$$33$$$O	penis$$$34$$$39$$$O	sensitizing$$$40$$$51$$$O	compound$$$52$$$60$$$O	combination$$$61$$$72$$$O	consisting$$$73$$$83$$$O	of$$$84$$$86$$$O	L-arginine$$$87$$$97$$$I	and$$$98$$$101$$$O	a$$$102$$$103$$$O	cooling$$$104$$$111$$$O	agent$$$112$$$117$$$O	comprised$$$118$$$127$$$O	of$$$128$$$130$$$O	Menthol$$$131$$$138$$$I	or$$$139$$$141$$$O	menthol$$$142$$$149$$$I	derivative$$$150$$$160$$$O	or$$$161$$$163$$$O	menthol$$$164$$$171$$$I	analog,$$$172$$$179$$$O	wherein$$$180$$$187$$$O	the$$$188$$$191$$$O	combination$$$192$$$203$$$O	is$$$204$$$206$$$O	applicable$$$207$$$217$$$O	manually$$$218$$$226$$$O	to$$$227$$$229$$$O	the$$$230$$$233$$$O	penis.$$$234$$$240$$$O
US20100216736
2'-cyanopyrimidine$$$0$$$18$$$I	nucleoside$$$19$$$29$$$O	compound$$$30$$$38$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	pyrimidine$$$33$$$43$$$I	nucleoside$$$44$$$54$$$O	compound$$$55$$$63$$$O	represented$$$64$$$75$$$O	by$$$76$$$78$$$O	the$$$79$$$82$$$O	following$$$83$$$92$$$O	formula$$$93$$$100$$$O	(1):$$$101$$$105$$$O	[wherein$$$122$$$130$$$O	one$$$131$$$134$$$O	of$$$135$$$137$$$O	X$$$138$$$139$$$O	and$$$140$$$143$$$O	Y$$$144$$$145$$$O	is$$$146$$$148$$$O	cyano$$$149$$$154$$$I	and$$$155$$$158$$$O	the$$$159$$$162$$$O	other$$$163$$$168$$$O	is$$$169$$$171$$$O	hydrogen;$$$172$$$181$$$I	and$$$182$$$185$$$O	i)$$$186$$$188$$$O	R1$$$189$$$191$$$O	is$$$192$$$194$$$O	hydrogen,$$$195$$$204$$$I	and$$$205$$$208$$$O	R2$$$209$$$211$$$O	is$$$212$$$214$$$O	alkyloxycarbonyl$$$215$$$231$$$I	wherein$$$232$$$239$$$O	the$$$240$$$243$$$O	alkyl$$$244$$$249$$$I	moiety$$$250$$$256$$$O	is$$$257$$$259$$$O	straight$$$260$$$268$$$O	or$$$269$$$271$$$O	branched$$$272$$$280$$$O	C5-12$$$281$$$286$$$I	alkyl$$$287$$$292$$$I	(the$$$293$$$297$$$O	alkyl$$$298$$$303$$$I	may$$$304$$$307$$$O	be$$$308$$$310$$$O	substituted),$$$311$$$324$$$O	or$$$325$$$327$$$O	alternatively,$$$328$$$342$$$O	ii)$$$343$$$346$$$O	R1$$$347$$$349$$$O	is$$$350$$$352$$$O	alkyloxycarbonyl$$$353$$$369$$$I	wherein$$$370$$$377$$$O	the$$$378$$$381$$$O	alkyl$$$382$$$387$$$I	moiety$$$388$$$394$$$O	is$$$395$$$397$$$O	straight$$$398$$$406$$$O	or$$$407$$$409$$$O	branched$$$410$$$418$$$O	C9$$$419$$$421$$$I	alkyl$$$422$$$427$$$I	or$$$428$$$430$$$O	alkenyloxycarbonyl$$$431$$$449$$$I	wherein$$$450$$$457$$$O	the$$$458$$$461$$$O	alkenyl$$$462$$$469$$$I	moiety$$$470$$$476$$$O	is$$$477$$$479$$$O	straight$$$480$$$488$$$O	or$$$489$$$491$$$O	branched$$$492$$$500$$$O	C9$$$501$$$503$$$I	alkenyl,$$$504$$$512$$$I	and$$$513$$$516$$$O	R2$$$517$$$519$$$O	is$$$520$$$522$$$O	hydrogen]$$$523$$$532$$$I	or$$$533$$$535$$$O	a$$$536$$$537$$$O	salt$$$538$$$542$$$O	thereof.$$$543$$$551$$$O	The$$$552$$$555$$$O	pyrimidine$$$556$$$566$$$I	nucleoside$$$567$$$577$$$O	compound$$$578$$$586$$$O	or$$$587$$$589$$$O	a$$$590$$$591$$$O	salt$$$592$$$596$$$O	thereof$$$597$$$604$$$O	of$$$605$$$607$$$O	the$$$608$$$611$$$O	present$$$612$$$619$$$O	invention$$$620$$$629$$$O	shows$$$630$$$635$$$O	a$$$636$$$637$$$O	higher$$$638$$$644$$$O	antitumor$$$645$$$654$$$O	effect$$$655$$$661$$$O	than$$$662$$$666$$$O	existing$$$667$$$675$$$O	pyrimidine$$$676$$$686$$$I	nucleoside$$$687$$$697$$$O	compounds.$$$698$$$708$$$O
US20130102567
3-Desoxy-2-Methylene-Vitamin$$$0$$$28$$$I	D$$$29$$$30$$$I	Analogs$$$31$$$38$$$O	and$$$39$$$42$$$O	Their$$$43$$$48$$$O	Uses$$$49$$$53$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	discloses$$$15$$$24$$$O	3-desoxy-2-methylene-vitamin$$$25$$$53$$$I	D$$$54$$$55$$$I	analogs,$$$56$$$64$$$O	and$$$65$$$68$$$O	specifically$$$69$$$81$$$O	(20S)-3-desoxy-1Î±,25-dihydroxy-2-methylene-vitamin$$$82$$$133$$$I	D3$$$134$$$136$$$I	and$$$137$$$140$$$I	(20R)-3-desoxy-1Î±,$$$141$$$160$$$I	25-dihydroxy-2-methylene-vitamin$$$161$$$193$$$I	D3$$$194$$$196$$$I	as$$$197$$$199$$$O	well$$$200$$$204$$$O	as$$$205$$$207$$$O	pharmaceutical$$$208$$$222$$$O	uses$$$223$$$227$$$O	therefor.$$$228$$$237$$$O	These$$$238$$$243$$$O	compounds$$$244$$$253$$$O	exhibit$$$254$$$261$$$O	relatively$$$262$$$272$$$O	high$$$273$$$277$$$O	binding$$$278$$$285$$$O	activity$$$286$$$294$$$O	and$$$295$$$298$$$O	pronounced$$$299$$$309$$$O	activity$$$310$$$318$$$O	in$$$319$$$321$$$O	arresting$$$322$$$331$$$O	the$$$332$$$335$$$O	proliferation$$$336$$$349$$$O	of$$$350$$$352$$$O	undifferentiated$$$353$$$369$$$O	cells$$$370$$$375$$$O	and$$$376$$$379$$$O	inducing$$$380$$$388$$$O	their$$$389$$$394$$$O	differentiation$$$395$$$410$$$O	to$$$411$$$413$$$O	monocytes$$$414$$$423$$$O	thus$$$424$$$428$$$O	evidencing$$$429$$$439$$$O	use$$$440$$$443$$$O	as$$$444$$$446$$$O	anti-cancer$$$447$$$458$$$O	agents$$$459$$$465$$$O	especially$$$466$$$476$$$O	for$$$477$$$480$$$O	the$$$481$$$484$$$O	treatment$$$485$$$494$$$O	or$$$495$$$497$$$O	prevention$$$498$$$508$$$O	of$$$509$$$511$$$O	osteosarcoma,$$$512$$$525$$$O	leukemia,$$$526$$$535$$$O	colon$$$536$$$541$$$O	cancer,$$$542$$$549$$$O	breast$$$550$$$556$$$O	cancer,$$$557$$$564$$$O	skin$$$565$$$569$$$O	cancer$$$570$$$576$$$O	or$$$577$$$579$$$O	prostate$$$580$$$588$$$O	cancer.$$$589$$$596$$$O	These$$$597$$$602$$$O	compounds$$$603$$$612$$$O	also$$$613$$$617$$$O	exhibit$$$618$$$625$$$O	relatively$$$626$$$636$$$O	high$$$637$$$641$$$O	calcemic$$$642$$$650$$$O	activity$$$651$$$659$$$O	evidencing$$$660$$$670$$$O	use$$$671$$$674$$$O	in$$$675$$$677$$$O	the$$$678$$$681$$$O	treatment$$$682$$$691$$$O	of$$$692$$$694$$$O	bone$$$695$$$699$$$O	diseases.$$$700$$$709$$$O
WO2014165482A1
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	using$$$25$$$30$$$O	4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione$$$31$$$90$$$I	for$$$91$$$94$$$O	treatment$$$95$$$104$$$O	and$$$105$$$108$$$O	management$$$109$$$119$$$O	of$$$120$$$122$$$O	central$$$123$$$130$$$O	nervous$$$131$$$138$$$O	system$$$139$$$145$$$O	cancers$$$146$$$153$$$O
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	treating,$$$29$$$38$$$O	preventing$$$39$$$49$$$O	or$$$50$$$52$$$O	managing$$$53$$$61$$$O	central$$$62$$$69$$$O	nervous$$$70$$$77$$$O	system$$$78$$$84$$$O	cancers$$$85$$$92$$$O	are$$$93$$$96$$$O	disclosed.$$$97$$$107$$$O	The$$$108$$$111$$$O	methods$$$112$$$119$$$O	encompass$$$120$$$129$$$O	the$$$130$$$133$$$O	administration$$$134$$$148$$$O	of$$$149$$$151$$$O	4-amino-2-$$$152$$$162$$$I	(2,6-dioxo-piperidine-3-yl)-isoindoline-l,3-dione,$$$163$$$213$$$I	also$$$214$$$218$$$O	known$$$219$$$224$$$O	as$$$225$$$227$$$O	Pomalidomide.$$$228$$$241$$$I	Furthermore,$$$242$$$254$$$O	provided$$$255$$$263$$$O	herein$$$264$$$270$$$O	are$$$271$$$274$$$O	methods$$$275$$$282$$$O	of$$$283$$$285$$$O	treatment$$$286$$$295$$$O	using$$$296$$$301$$$O	this$$$302$$$306$$$O	compound$$$307$$$315$$$O	with$$$316$$$320$$$O	chemotherapy,$$$321$$$334$$$O	radiation$$$335$$$344$$$O	therapy,$$$345$$$353$$$O	hormonal$$$354$$$362$$$O	therapy,$$$363$$$371$$$O	biological$$$372$$$382$$$O	therapy$$$383$$$390$$$O	or$$$391$$$393$$$O	immunotherapy.$$$394$$$408$$$O	Pharmaceutical$$$409$$$423$$$O	compositions$$$424$$$436$$$O	and$$$437$$$440$$$O	single$$$441$$$447$$$O	unit$$$448$$$452$$$O	dosage$$$453$$$459$$$O	forms$$$460$$$465$$$O	suitable$$$466$$$474$$$O	for$$$475$$$478$$$O	use$$$479$$$482$$$O	in$$$483$$$485$$$O	the$$$486$$$489$$$O	methods$$$490$$$497$$$O	provided$$$498$$$506$$$O	herein$$$507$$$513$$$O	are$$$514$$$517$$$O	also$$$518$$$522$$$O	disclosed.$$$523$$$533$$$O
CN201586232U
Vitamin$$$0$$$7$$$I	C$$$8$$$9$$$I	fructus$$$10$$$17$$$O	forsythiae$$$18$$$28$$$O	soft$$$29$$$33$$$O	capsule$$$34$$$41$$$O
The$$$0$$$3$$$O	utility$$$4$$$11$$$O	model$$$12$$$17$$$O	relates$$$18$$$25$$$O	to$$$26$$$28$$$O	a$$$29$$$30$$$O	vitamin$$$31$$$38$$$I	C$$$39$$$40$$$I	fructus$$$41$$$48$$$O	forsythiae$$$49$$$59$$$O	soft$$$60$$$64$$$O	capsule,$$$65$$$73$$$O	which$$$74$$$79$$$O	comprises$$$80$$$89$$$O	medicaments$$$90$$$101$$$O	in$$$102$$$104$$$O	liquid$$$105$$$111$$$O	form$$$112$$$116$$$O	or$$$117$$$119$$$O	suspension$$$120$$$130$$$O	liquid$$$131$$$137$$$O	form$$$138$$$142$$$O	or$$$143$$$145$$$O	paste$$$146$$$151$$$O	form.$$$152$$$157$$$O	The$$$158$$$161$$$O	medicaments$$$162$$$173$$$O	are$$$174$$$177$$$O	closely$$$178$$$185$$$O	disposed$$$186$$$194$$$O	inside$$$195$$$201$$$O	a$$$202$$$203$$$O	capsule$$$204$$$211$$$O	outer$$$212$$$217$$$O	casing$$$218$$$224$$$O	in$$$225$$$227$$$O	shape$$$228$$$233$$$O	of$$$234$$$236$$$O	an$$$237$$$239$$$O	ellipse$$$240$$$247$$$O	or$$$248$$$250$$$O	ball$$$251$$$255$$$O	or$$$256$$$258$$$O	rugby$$$259$$$264$$$O	or$$$265$$$267$$$O	water$$$268$$$273$$$O	drop.$$$274$$$279$$$O	Thickness$$$280$$$289$$$O	of$$$290$$$292$$$O	the$$$293$$$296$$$O	capsule$$$297$$$304$$$O	outer$$$305$$$310$$$O	casing$$$311$$$317$$$O	is$$$318$$$320$$$O	0.7-0.8mm.$$$321$$$331$$$O	The$$$332$$$335$$$O	vitamin$$$336$$$343$$$I	C$$$344$$$345$$$I	fructus$$$346$$$353$$$O	forsythiae$$$354$$$364$$$O	soft$$$365$$$369$$$O	capsule$$$370$$$377$$$O	has$$$378$$$381$$$O	high$$$382$$$386$$$O	bioavailability,$$$387$$$403$$$O	good$$$404$$$408$$$O	tightness,$$$409$$$419$$$O	fine$$$420$$$424$$$O	uniformity,$$$425$$$436$$$O	stable$$$437$$$443$$$O	content,$$$444$$$452$$$O	beautiful$$$453$$$462$$$O	appearance$$$463$$$473$$$O	and$$$474$$$477$$$O	the$$$478$$$481$$$O	like.$$$482$$$487$$$O
CN102309461A
Pyridostigmine$$$0$$$14$$$I	bromide$$$15$$$22$$$I	odor$$$23$$$27$$$O	masking$$$28$$$35$$$O	dispersible$$$36$$$47$$$O	tablets$$$48$$$55$$$O	and$$$56$$$59$$$O	preparation$$$60$$$71$$$O	method$$$72$$$78$$$O	thereof$$$79$$$86$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	pyridostigmine$$$23$$$37$$$I	bromide$$$38$$$45$$$I	odor$$$46$$$50$$$O	masking$$$51$$$58$$$O	dispersible$$$59$$$70$$$O	tablets$$$71$$$78$$$O	and$$$79$$$82$$$O	a$$$83$$$84$$$O	preparation$$$85$$$96$$$O	method$$$97$$$103$$$O	thereof.$$$104$$$112$$$O	Each$$$113$$$117$$$O	pyridostigmine$$$118$$$132$$$I	bromide$$$133$$$140$$$I	odor$$$141$$$145$$$O	masking$$$146$$$153$$$O	dispersible$$$154$$$165$$$O	tablet$$$166$$$172$$$O	comprises$$$173$$$182$$$O	an$$$183$$$185$$$O	effective$$$186$$$195$$$O	dose$$$196$$$200$$$O	of$$$201$$$203$$$O	pyridostigmine$$$204$$$218$$$I	bromide$$$219$$$226$$$I	and$$$227$$$230$$$O	pharmaceutical$$$231$$$245$$$O	auxiliary$$$246$$$255$$$O	materials,$$$256$$$266$$$O	and$$$267$$$270$$$O	is$$$271$$$273$$$O	characterized$$$274$$$287$$$O	by$$$288$$$290$$$O	being$$$291$$$296$$$O	prepared$$$297$$$305$$$O	by$$$306$$$308$$$O	performing$$$309$$$319$$$O	odor$$$320$$$324$$$O	masking$$$325$$$332$$$O	treatment$$$333$$$342$$$O	on$$$343$$$345$$$O	the$$$346$$$349$$$O	pyridostigmine$$$350$$$364$$$I	bromide$$$365$$$372$$$I	and$$$373$$$376$$$O	mixing$$$377$$$383$$$O	the$$$384$$$387$$$O	pyridostigmine$$$388$$$402$$$I	bromide$$$403$$$410$$$I	and$$$411$$$414$$$O	the$$$415$$$418$$$O	pharmaceutically-acceptable$$$419$$$446$$$O	auxiliary$$$447$$$456$$$O	materials.$$$457$$$467$$$O	The$$$468$$$471$$$O	pyridostigmine$$$472$$$486$$$I	bromide$$$487$$$494$$$I	odor$$$495$$$499$$$O	masking$$$500$$$507$$$O	dispersible$$$508$$$519$$$O	tablets$$$520$$$527$$$O	obtained$$$528$$$536$$$O	by$$$537$$$539$$$O	the$$$540$$$543$$$O	method$$$544$$$550$$$O	do$$$551$$$553$$$O	not$$$554$$$557$$$O	have$$$558$$$562$$$O	bitter$$$563$$$569$$$O	taste,$$$570$$$576$$$O	the$$$577$$$580$$$O	disintegration$$$581$$$595$$$O	time$$$596$$$600$$$O	limit$$$601$$$606$$$O	of$$$607$$$609$$$O	a$$$610$$$611$$$O	prescription$$$612$$$624$$$O	is$$$625$$$627$$$O	within$$$628$$$634$$$O	2$$$635$$$636$$$O	minutes,$$$637$$$645$$$O	and$$$646$$$649$$$O	the$$$650$$$653$$$O	dissolution$$$654$$$665$$$O	rate$$$666$$$670$$$O	of$$$671$$$673$$$O	the$$$674$$$677$$$O	dispersible$$$678$$$689$$$O	tablets$$$690$$$697$$$O	within$$$698$$$704$$$O	45$$$705$$$707$$$O	minutes$$$708$$$715$$$O	is$$$716$$$718$$$O	more$$$719$$$723$$$O	than$$$724$$$728$$$O	85$$$729$$$731$$$O	percent.$$$732$$$740$$$O	The$$$741$$$744$$$O	pyridostigmine$$$745$$$759$$$I	bromide$$$760$$$767$$$I	odor$$$768$$$772$$$O	masking$$$773$$$780$$$O	dispersible$$$781$$$792$$$O	tablets$$$793$$$800$$$O	have$$$801$$$805$$$O	a$$$806$$$807$$$O	simple$$$808$$$814$$$O	and$$$815$$$818$$$O	convenient$$$819$$$829$$$O	preparation$$$830$$$841$$$O	method,$$$842$$$849$$$O	controllable$$$850$$$862$$$O	quality,$$$863$$$871$$$O	wide$$$872$$$876$$$O	sources$$$877$$$884$$$O	of$$$885$$$887$$$O	an$$$888$$$890$$$O	odor$$$891$$$895$$$O	masking$$$896$$$903$$$O	agent$$$904$$$909$$$O	and$$$910$$$913$$$O	low$$$914$$$917$$$O	energy$$$918$$$924$$$O	consumption$$$925$$$936$$$O	and$$$937$$$940$$$O	are$$$941$$$944$$$O	easy$$$945$$$949$$$O	to$$$950$$$952$$$O	be$$$953$$$955$$$O	produce$$$956$$$963$$$O	industrially.$$$964$$$977$$$O
US20110135724
Ondansetron$$$0$$$11$$$I	Orally$$$12$$$18$$$O	Disintegrating$$$19$$$33$$$O	Tablet$$$34$$$40$$$O	Compositions$$$41$$$53$$$O	for$$$54$$$57$$$O	Prevention$$$58$$$68$$$O	of$$$69$$$71$$$O	Nausea$$$72$$$78$$$O	and$$$79$$$82$$$O	Vomiting$$$83$$$91$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	is$$$15$$$17$$$O	related$$$18$$$25$$$O	to$$$26$$$28$$$O	a$$$29$$$30$$$O	pharmaceutical$$$31$$$45$$$O	composition$$$46$$$57$$$O	in$$$58$$$60$$$O	the$$$61$$$64$$$O	patient-friendly$$$65$$$81$$$O	orally$$$82$$$88$$$O	disintegrating$$$89$$$103$$$O	tablet$$$104$$$110$$$O	form$$$111$$$115$$$O	comprising$$$116$$$126$$$O	a$$$127$$$128$$$O	weakly$$$129$$$135$$$O	basic,$$$136$$$142$$$O	selective$$$143$$$152$$$O	serotonin$$$153$$$162$$$I	5-HT3$$$163$$$168$$$O	blocking$$$169$$$177$$$O	agent$$$178$$$183$$$O	for$$$184$$$187$$$O	the$$$188$$$191$$$O	prevention$$$192$$$202$$$O	of$$$203$$$205$$$O	nausea$$$206$$$212$$$O	and/or$$$213$$$219$$$O	vomiting$$$220$$$228$$$O	for$$$229$$$232$$$O	up$$$233$$$235$$$O	to$$$236$$$238$$$O	24$$$239$$$241$$$O	hrs$$$242$$$245$$$O	postdosing$$$246$$$256$$$O	in$$$257$$$259$$$O	cancer$$$260$$$266$$$O	patients$$$267$$$275$$$O	prior$$$276$$$281$$$O	to$$$282$$$284$$$O	undergoing$$$285$$$295$$$O	moderately$$$296$$$306$$$O	emetogenic$$$307$$$317$$$O	chemotherapy$$$318$$$330$$$O	or$$$331$$$333$$$O	partial$$$334$$$341$$$O	or$$$342$$$344$$$O	whole$$$345$$$350$$$O	body$$$351$$$355$$$O	radiotherapy$$$356$$$368$$$O	or$$$369$$$371$$$O	in$$$372$$$374$$$O	subjects$$$375$$$383$$$O	at$$$384$$$386$$$O	moderate$$$387$$$395$$$O	to$$$396$$$398$$$O	high$$$399$$$403$$$O	risk$$$404$$$408$$$O	of$$$409$$$411$$$O	postoperative$$$412$$$425$$$O	or$$$426$$$428$$$O	postdischarge$$$429$$$442$$$O	nausea$$$443$$$449$$$O	and/or$$$450$$$456$$$O	vomiting$$$457$$$465$$$O	prior$$$466$$$471$$$O	to$$$472$$$474$$$O	inpatient$$$475$$$484$$$O	or$$$485$$$487$$$O	outpatient$$$488$$$498$$$O	ambulatory$$$499$$$509$$$O	surgery.$$$510$$$518$$$O	The$$$519$$$522$$$O	unit$$$523$$$527$$$O	dosage$$$528$$$534$$$O	form$$$535$$$539$$$O	comprising$$$540$$$550$$$O	a$$$551$$$552$$$O	multitude$$$553$$$562$$$O	of$$$563$$$565$$$O	immediate-release$$$566$$$583$$$O	drug$$$584$$$588$$$O	particles$$$589$$$598$$$O	providing$$$599$$$608$$$O	dissolution$$$609$$$620$$$O	profiles$$$621$$$629$$$O	similar$$$630$$$637$$$O	to$$$638$$$640$$$O	that$$$641$$$645$$$O	of$$$646$$$648$$$O	reference$$$649$$$658$$$O	drug$$$659$$$663$$$O	product,$$$664$$$672$$$O	and$$$673$$$676$$$O	one$$$677$$$680$$$O	or$$$681$$$683$$$O	more$$$684$$$688$$$O	timed,$$$689$$$695$$$O	pulsatile-release$$$696$$$713$$$O	bead$$$714$$$718$$$O	populations,$$$719$$$731$$$O	comprising$$$732$$$742$$$O	at$$$743$$$745$$$O	least$$$746$$$751$$$O	one$$$752$$$755$$$O	organic$$$756$$$763$$$O	acid,$$$764$$$769$$$O	which$$$770$$$775$$$O	solubilizes$$$776$$$787$$$O	said$$$788$$$792$$$O	weakly$$$793$$$799$$$O	basic$$$800$$$805$$$O	selective$$$806$$$815$$$O	serotonin$$$816$$$825$$$I	5-HT3$$$826$$$831$$$O	blocking$$$832$$$840$$$O	agent$$$841$$$846$$$O	prior$$$847$$$852$$$O	to$$$853$$$855$$$O	releasing$$$856$$$865$$$O	it$$$866$$$868$$$O	into$$$869$$$873$$$O	the$$$874$$$877$$$O	hostile$$$878$$$885$$$O	intestinal$$$886$$$896$$$O	environment,$$$897$$$909$$$O	wherein$$$910$$$917$$$O	the$$$918$$$921$$$O	blocking$$$922$$$930$$$O	agent$$$931$$$936$$$O	is$$$937$$$939$$$O	practically$$$940$$$951$$$O	insoluble,$$$952$$$962$$$O	is$$$963$$$965$$$O	capable$$$966$$$973$$$O	of$$$974$$$976$$$O	delivering$$$977$$$987$$$O	said$$$988$$$992$$$O	antiemetic$$$993$$$1003$$$O	agent$$$1004$$$1009$$$O	in$$$1010$$$1012$$$O	patients$$$1013$$$1021$$$O	in$$$1022$$$1024$$$O	need$$$1025$$$1029$$$O	thereof$$$1030$$$1037$$$O	in$$$1038$$$1040$$$O	a$$$1041$$$1042$$$O	sustained-released$$$1043$$$1061$$$O	fashion$$$1062$$$1069$$$O	to$$$1070$$$1072$$$O	be$$$1073$$$1075$$$O	suitable$$$1076$$$1084$$$O	for$$$1085$$$1088$$$O	a$$$1089$$$1090$$$O	once-daily$$$1091$$$1101$$$O	dosing$$$1102$$$1108$$$O	regimen.$$$1109$$$1117$$$O
WO2010011653A1
Tricyclic$$$0$$$9$$$I	heterocycle$$$10$$$21$$$I	derivatives$$$22$$$33$$$O	as$$$34$$$36$$$O	histamine$$$37$$$46$$$I	h3$$$47$$$49$$$O	antagonists$$$50$$$61$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	Tricyclic$$$39$$$48$$$I	Heterocylce$$$49$$$60$$$I	Derivatives,$$$61$$$73$$$O	pharmaceutical$$$74$$$88$$$O	compositions$$$89$$$101$$$O	comprising$$$102$$$112$$$O	the$$$113$$$116$$$O	Tricyclic$$$117$$$126$$$I	Heterocycle$$$127$$$138$$$I	Derivatives$$$139$$$150$$$O	and$$$151$$$154$$$O	the$$$155$$$158$$$O	use$$$159$$$162$$$O	of$$$163$$$165$$$O	these$$$166$$$171$$$O	compounds$$$172$$$181$$$O	for$$$182$$$185$$$O	treating$$$186$$$194$$$O	or$$$195$$$197$$$O	preventing$$$198$$$208$$$O	allergy,$$$209$$$217$$$O	an$$$218$$$220$$$O	allergy-induced$$$221$$$236$$$O	airway$$$237$$$243$$$O	response,$$$244$$$253$$$O	congestion,$$$254$$$265$$$O	a$$$266$$$267$$$O	cardiovascular$$$268$$$282$$$O	disease,$$$283$$$291$$$O	an$$$292$$$294$$$O	inflammatory$$$295$$$307$$$O	disease,$$$308$$$316$$$O	a$$$317$$$318$$$O	gastrointestinal$$$319$$$335$$$O	disorder,$$$336$$$345$$$O	a$$$346$$$347$$$O	neurological$$$348$$$360$$$O	disorder,$$$361$$$370$$$O	a$$$371$$$372$$$O	metabolic$$$373$$$382$$$O	disorder,$$$383$$$392$$$O	obesity$$$393$$$400$$$O	or$$$401$$$403$$$O	an$$$404$$$406$$$O	obesity-related$$$407$$$422$$$O	disorder,$$$423$$$432$$$O	diabetes,$$$433$$$442$$$O	a$$$443$$$444$$$O	diabetic$$$445$$$453$$$O	complication,$$$454$$$467$$$O	impaired$$$468$$$476$$$O	glucose$$$477$$$484$$$I	tolerance$$$485$$$494$$$O	or$$$495$$$497$$$O	impaired$$$498$$$506$$$O	fasting$$$507$$$514$$$O	glucose.$$$515$$$523$$$I	R1$$$524$$$526$$$O	is$$$527$$$529$$$O	formula$$$530$$$537$$$O	(Ia),$$$538$$$543$$$O	(Ib)$$$544$$$548$$$O	or$$$549$$$551$$$O	(Ic);$$$552$$$557$$$O	R2$$$558$$$560$$$O	is$$$561$$$563$$$O	alkvl,$$$564$$$570$$$I	alkenyl,$$$571$$$579$$$I	alkynyl,$$$580$$$588$$$I	aryl,$$$589$$$594$$$I	heteroaryl,$$$595$$$606$$$I	cycloalkyl$$$607$$$617$$$I	or$$$618$$$620$$$O	heterocycloalkyl.$$$621$$$638$$$I	any$$$639$$$642$$$O	of$$$643$$$645$$$O	which$$$646$$$651$$$O	can$$$652$$$655$$$O	be$$$656$$$658$$$O	optionally$$$659$$$669$$$O	substituted$$$670$$$681$$$O	with$$$682$$$686$$$O	R11;$$$687$$$691$$$O	M1$$$692$$$694$$$O	is$$$695$$$697$$$O	-CH-.$$$698$$$703$$$I	-C(halo)-$$$704$$$713$$$I	or$$$714$$$716$$$O	-N-;$$$717$$$721$$$I	Y$$$722$$$723$$$O	is$$$724$$$726$$$O	-C(O)-,$$$727$$$734$$$I	-S-.$$$735$$$739$$$I	-S(O)-,$$$740$$$747$$$I	-S(O)2-,$$$748$$$756$$$I	-CH2-$$$757$$$762$$$I	or$$$763$$$765$$$O	-O-,$$$766$$$770$$$I	such$$$771$$$775$$$O	that$$$776$$$780$$$O	Y$$$781$$$782$$$O	is$$$783$$$785$$$O	not$$$786$$$789$$$O	-O-$$$790$$$793$$$I	when$$$794$$$798$$$O	an$$$799$$$801$$$O	adjacent$$$802$$$810$$$O	atom$$$811$$$815$$$O	is$$$816$$$818$$$O	N.$$$819$$$821$$$I
EP1251871B1
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	for$$$27$$$30$$$O	immunomodulation$$$31$$$47$$$O	and$$$48$$$51$$$O	preparation$$$52$$$63$$$O	of$$$64$$$66$$$O	vaccines$$$67$$$75$$$O	comprising$$$76$$$86$$$O	an$$$87$$$89$$$O	antigen$$$90$$$97$$$O	and$$$98$$$101$$$O	as$$$103$$$105$$$O	adjuvants$$$106$$$115$$$O	an$$$116$$$118$$$O	immunogenic$$$119$$$130$$$O	oligodeoxynucleotide$$$131$$$151$$$I	and$$$152$$$155$$$O	a$$$156$$$157$$$O	polycationic$$$158$$$170$$$O	polypeptide$$$171$$$182$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	pharmaceutical$$$26$$$40$$$O	composition$$$41$$$52$$$O	comprising$$$53$$$63$$$O	an$$$64$$$66$$$O	antigen,$$$67$$$75$$$O	an$$$76$$$78$$$O	immunogenic$$$79$$$90$$$O	CpG-ODN$$$91$$$98$$$O	and$$$99$$$102$$$O	a$$$103$$$104$$$O	polycationic$$$105$$$117$$$O	polymer.$$$118$$$126$$$O
US20110182997
Suspension$$$0$$$10$$$O	formulations$$$11$$$23$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	suspension$$$33$$$43$$$O	formulations,$$$44$$$57$$$O	especially$$$58$$$68$$$O	those$$$69$$$74$$$O	for$$$75$$$78$$$O	delivering$$$79$$$89$$$O	a$$$90$$$91$$$O	pharmaceutically$$$92$$$108$$$O	active$$$109$$$115$$$O	agent$$$116$$$121$$$O	in$$$122$$$124$$$O	aerosol$$$125$$$132$$$O	form$$$133$$$137$$$O	using$$$138$$$143$$$O	a$$$144$$$145$$$O	spray$$$146$$$151$$$O	or$$$152$$$154$$$O	aerosol$$$155$$$162$$$O	device,$$$163$$$170$$$O	such$$$171$$$175$$$O	as$$$176$$$178$$$O	a$$$179$$$180$$$O	pressurised$$$181$$$192$$$O	metered$$$193$$$200$$$O	dose$$$201$$$205$$$O	inhaler$$$206$$$213$$$O	(pMDI).$$$214$$$221$$$O	The$$$222$$$225$$$O	formulations$$$226$$$238$$$O	may$$$239$$$242$$$O	be$$$243$$$245$$$O	for$$$246$$$249$$$O	pulmonary,$$$250$$$260$$$O	nasal,$$$261$$$267$$$O	buccal$$$268$$$274$$$O	or$$$275$$$277$$$O	topical$$$278$$$285$$$O	administration,$$$286$$$301$$$O	but$$$302$$$305$$$O	are$$$306$$$309$$$O	preferably$$$310$$$320$$$O	for$$$321$$$324$$$O	pulmonary$$$325$$$334$$$O	inhalation.$$$335$$$346$$$O
US6858612
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	tetrahydropteridine$$$7$$$26$$$I	derivatives$$$27$$$38$$$O	as$$$39$$$41$$$O	no$$$42$$$44$$$O	synthase$$$45$$$53$$$O	inhibitors$$$54$$$64$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	pteridine$$$44$$$53$$$I	derivatives$$$54$$$65$$$O	of$$$66$$$68$$$O	the$$$69$$$72$$$O	formula$$$73$$$80$$$O	I$$$81$$$82$$$O	in$$$98$$$100$$$O	which$$$101$$$106$$$O	X$$$107$$$108$$$O	is$$$109$$$111$$$O	O$$$112$$$113$$$I	or$$$114$$$116$$$O	NH$$$117$$$119$$$I	and$$$120$$$123$$$O	R4,$$$124$$$127$$$O	for$$$128$$$131$$$O	example,$$$132$$$140$$$O	is$$$141$$$143$$$O	hydrogen,$$$144$$$153$$$I	phenyl$$$154$$$160$$$I	or$$$161$$$163$$$O	the$$$164$$$167$$$O	radical$$$168$$$175$$$O	R4aâCH2â$$$176$$$188$$$I	and$$$189$$$192$$$O	R4a,$$$193$$$197$$$O	for$$$198$$$201$$$O	example,$$$202$$$210$$$I	is$$$211$$$213$$$I	hydrogen,$$$214$$$223$$$I	(C1-C4)-alkylmercapto,$$$224$$$246$$$I	the$$$247$$$250$$$O	radical$$$251$$$258$$$I	âNR11R12$$$259$$$269$$$I	or$$$270$$$272$$$O	the$$$273$$$276$$$O	radical$$$277$$$284$$$I	âOR13,$$$285$$$293$$$O	and$$$294$$$297$$$O	in$$$298$$$300$$$O	which$$$301$$$306$$$O	R1,$$$307$$$310$$$O	R2,$$$311$$$314$$$O	R3,$$$315$$$318$$$O	R5,$$$319$$$322$$$O	R6,$$$323$$$326$$$O	R7,$$$327$$$330$$$O	R11,$$$331$$$335$$$O	R12$$$336$$$339$$$O	and$$$340$$$343$$$O	R13$$$344$$$347$$$O	have$$$348$$$352$$$O	the$$$353$$$356$$$O	meanings$$$357$$$365$$$O	given$$$366$$$371$$$O	in$$$372$$$374$$$O	claim$$$375$$$380$$$O	1,$$$381$$$383$$$O	which$$$384$$$389$$$I	are$$$390$$$393$$$I	nitric$$$394$$$400$$$I	oxide$$$401$$$406$$$O	synthase$$$407$$$415$$$O	inhibitors,$$$416$$$427$$$O	for$$$428$$$431$$$O	the$$$432$$$435$$$O	treatment$$$436$$$445$$$O	of$$$446$$$448$$$O	diseases$$$449$$$457$$$O	which$$$458$$$463$$$O	are$$$464$$$467$$$O	caused$$$468$$$474$$$O	by$$$475$$$477$$$O	an$$$478$$$480$$$O	increased$$$481$$$490$$$O	nitric$$$491$$$497$$$O	oxide$$$498$$$503$$$O	level.$$$504$$$510$$$O
CN1846783A
Compound$$$0$$$8$$$O	piracetam-cerebral$$$9$$$27$$$I	protein$$$28$$$35$$$O	hydrolysate$$$36$$$47$$$O	capsule$$$48$$$55$$$O	and$$$56$$$59$$$O	its$$$60$$$63$$$O	prepn$$$64$$$69$$$O
The$$$0$$$3$$$O	compound$$$4$$$12$$$O	piracetam-cerebral$$$13$$$31$$$I	protolysate$$$32$$$43$$$O	capsule$$$44$$$51$$$O	is$$$52$$$54$$$O	prepared$$$55$$$63$$$O	with$$$64$$$68$$$O	piracetam,$$$69$$$79$$$O	cerebral$$$80$$$88$$$O	protolysate,$$$89$$$101$$$O	glutamic$$$102$$$110$$$I	acid,$$$111$$$116$$$I	chondrotin$$$117$$$127$$$I	sulfate,$$$128$$$136$$$I	vitamin$$$137$$$144$$$I	B1,$$$145$$$148$$$I	vitamin$$$149$$$156$$$I	B2,$$$157$$$160$$$I	vitamin$$$161$$$168$$$I	B6$$$169$$$171$$$I	and$$$172$$$175$$$O	vitamin$$$176$$$183$$$I	E$$$184$$$185$$$I	in$$$186$$$188$$$O	certain$$$189$$$196$$$O	weight$$$197$$$203$$$O	proportion$$$204$$$214$$$O	as$$$215$$$217$$$O	main$$$218$$$222$$$O	components,$$$223$$$234$$$O	and$$$235$$$238$$$O	PVP$$$239$$$242$$$O	as$$$243$$$245$$$O	supplementary$$$246$$$259$$$O	material.$$$260$$$269$$$O	Its$$$270$$$273$$$O	preparation$$$274$$$285$$$O	process$$$286$$$293$$$O	includes$$$294$$$302$$$O	the$$$303$$$306$$$O	steps$$$307$$$312$$$O	of$$$313$$$315$$$O	preparing$$$316$$$325$$$O	soft$$$326$$$330$$$O	material,$$$331$$$340$$$O	preparing$$$341$$$350$$$O	wet$$$351$$$354$$$O	pellet,$$$355$$$362$$$O	stoving$$$363$$$370$$$O	at$$$371$$$373$$$O	20-50$$$374$$$379$$$O	deg.c,$$$380$$$386$$$O	finishing,$$$387$$$397$$$O	and$$$398$$$401$$$O	encapsulating.$$$402$$$416$$$O	The$$$417$$$420$$$O	present$$$421$$$428$$$O	invention$$$429$$$438$$$O	has$$$439$$$442$$$O	high$$$443$$$447$$$O	bioavailability,$$$448$$$464$$$O	simple$$$465$$$471$$$O	preparation$$$472$$$483$$$O	process$$$484$$$491$$$O	and$$$492$$$495$$$O	other$$$496$$$501$$$O	advantages.$$$502$$$513$$$O
CN103040827A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	antagonist$$$15$$$25$$$O	SR140333$$$26$$$34$$$I	of$$$35$$$37$$$O	neurokinin$$$38$$$48$$$O	receptor$$$49$$$57$$$O	in$$$58$$$60$$$O	hepatoma$$$61$$$69$$$O	treatment$$$70$$$79$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	anti-hepatoma$$$28$$$41$$$O	effect$$$42$$$48$$$O	of$$$49$$$51$$$O	an$$$52$$$54$$$O	antagonist$$$55$$$65$$$O	SR140333$$$66$$$74$$$I	of$$$75$$$77$$$O	a$$$78$$$79$$$O	neurokinin$$$80$$$90$$$O	receptor$$$91$$$99$$$O	1,$$$100$$$102$$$O	in$$$103$$$105$$$O	particular$$$106$$$116$$$O	to$$$117$$$119$$$O	a$$$120$$$121$$$O	method$$$122$$$128$$$O	for$$$129$$$132$$$O	treating$$$133$$$141$$$O	hepatoma$$$142$$$150$$$O	of$$$151$$$153$$$O	a$$$154$$$155$$$O	subject,$$$156$$$164$$$O	relieving$$$165$$$174$$$O	a$$$175$$$176$$$O	hepatoma$$$177$$$185$$$O	symptom$$$186$$$193$$$O	of$$$194$$$196$$$O	the$$$197$$$200$$$O	subject$$$201$$$208$$$O	or$$$209$$$211$$$O	inhibiting$$$212$$$222$$$O	hepatoma$$$223$$$231$$$O	cell$$$232$$$236$$$O	proliferation,$$$237$$$251$$$O	an$$$252$$$254$$$O	application$$$255$$$266$$$O	of$$$267$$$269$$$O	the$$$270$$$273$$$O	antagonist$$$274$$$284$$$O	of$$$285$$$287$$$O	the$$$288$$$291$$$O	neurokinin$$$292$$$302$$$O	receptor$$$303$$$311$$$O	1$$$312$$$313$$$O	in$$$314$$$316$$$O	preparing$$$317$$$326$$$O	medicine,$$$327$$$336$$$O	an$$$337$$$339$$$O	reagent$$$340$$$347$$$O	or$$$348$$$350$$$O	a$$$351$$$352$$$O	medicine$$$353$$$361$$$O	composition$$$362$$$373$$$O	for$$$374$$$377$$$O	treating$$$378$$$386$$$O	the$$$387$$$390$$$O	hepatoma,$$$391$$$400$$$O	relieving$$$401$$$410$$$O	the$$$411$$$414$$$O	hepatoma$$$415$$$423$$$O	symptom$$$424$$$431$$$O	or$$$432$$$434$$$O	inhibiting$$$435$$$445$$$O	the$$$446$$$449$$$O	hepatoma$$$450$$$458$$$O	cell$$$459$$$463$$$O	proliferation,$$$464$$$478$$$O	and$$$479$$$482$$$O	a$$$483$$$484$$$O	pharmaceutical$$$485$$$499$$$O	product.$$$500$$$508$$$O	The$$$509$$$512$$$O	pharmaceutical$$$513$$$527$$$O	product$$$528$$$535$$$O	comprises$$$536$$$545$$$O	the$$$546$$$549$$$O	antagonist$$$550$$$560$$$O	SR140333$$$561$$$569$$$I	of$$$570$$$572$$$O	the$$$573$$$576$$$O	neurokinin$$$577$$$587$$$O	receptor$$$588$$$596$$$O	1$$$597$$$598$$$O	as$$$599$$$601$$$O	an$$$602$$$604$$$O	active$$$605$$$611$$$O	ingredient$$$612$$$622$$$O	and$$$623$$$626$$$O	a$$$627$$$628$$$O	specification$$$629$$$642$$$O	of$$$643$$$645$$$O	the$$$646$$$649$$$O	pharmaceutical$$$650$$$664$$$O	product.$$$665$$$673$$$O
EP2005968A9
Nanocomposite$$$0$$$13$$$O	particle$$$14$$$22$$$O
Nanocomposite$$$0$$$13$$$O	particles$$$14$$$23$$$O	having$$$24$$$30$$$O	good$$$31$$$35$$$O	solubility$$$36$$$46$$$O	and$$$47$$$50$$$O	redispersibility$$$51$$$67$$$O	in$$$68$$$70$$$O	water$$$71$$$76$$$O	are$$$77$$$80$$$O	provided.$$$81$$$90$$$O	The$$$91$$$94$$$O	nanocomposite$$$95$$$108$$$O	particles$$$109$$$118$$$O	include$$$119$$$126$$$O	a$$$127$$$128$$$O	sugar$$$129$$$134$$$I	material$$$135$$$143$$$O	and$$$144$$$147$$$O	nanoparticles$$$148$$$161$$$O	containing$$$162$$$172$$$O	a$$$173$$$174$$$O	drug$$$175$$$179$$$O	to$$$180$$$182$$$O	be$$$183$$$185$$$O	delivered$$$186$$$195$$$O	and$$$196$$$199$$$O	a$$$200$$$201$$$O	biodegradable$$$202$$$215$$$O	polymer,$$$216$$$224$$$O	the$$$225$$$228$$$O	sugar$$$229$$$234$$$I	material$$$235$$$243$$$O	being$$$244$$$249$$$O	disaccharide,$$$250$$$263$$$I	and$$$264$$$267$$$O	a$$$268$$$269$$$O	mass$$$270$$$274$$$O	ratio$$$275$$$280$$$O	of$$$281$$$283$$$O	the$$$284$$$287$$$O	nanoparticles$$$288$$$301$$$O	to$$$302$$$304$$$O	the$$$305$$$308$$$O	disaccharide$$$309$$$321$$$I	being$$$322$$$327$$$O	within$$$328$$$334$$$O	the$$$335$$$338$$$O	range$$$339$$$344$$$O	of$$$345$$$347$$$O	from$$$348$$$352$$$O	40:60$$$353$$$358$$$O	to$$$359$$$361$$$O	60:40.$$$362$$$368$$$O
WO2009036754A1
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	the$$$14$$$17$$$O	myelin-associated$$$18$$$35$$$O	glycoprotein$$$36$$$48$$$O	(mag)$$$49$$$54$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	composition$$$27$$$38$$$O	having$$$39$$$45$$$O	the$$$46$$$49$$$O	general$$$50$$$57$$$O	structure$$$58$$$67$$$O	(formula),$$$68$$$78$$$O	wherein$$$79$$$86$$$O	R1$$$87$$$89$$$O	is$$$90$$$92$$$O	a$$$93$$$94$$$O	hydrophobic$$$95$$$106$$$O	group,$$$107$$$113$$$O	R2$$$114$$$116$$$O	is$$$117$$$119$$$O	hydrogen$$$120$$$128$$$I	(H),$$$129$$$133$$$I	a$$$134$$$135$$$O	cation$$$136$$$142$$$O	or$$$143$$$145$$$O	an$$$146$$$148$$$O	alkyl$$$149$$$154$$$I	ester,$$$155$$$161$$$I	R3$$$162$$$164$$$O	is$$$165$$$167$$$O	hydrogen$$$168$$$176$$$I	(H)$$$177$$$180$$$I	or$$$181$$$183$$$O	a$$$184$$$185$$$O	group$$$186$$$191$$$O	that$$$192$$$196$$$O	can$$$197$$$200$$$O	be$$$201$$$203$$$O	converted$$$204$$$213$$$O	into$$$214$$$218$$$O	the$$$219$$$222$$$O	hydroxy$$$223$$$230$$$I	group$$$231$$$236$$$O	under$$$237$$$242$$$O	physiological$$$243$$$256$$$O	conditions,$$$257$$$268$$$O	R4$$$269$$$271$$$O	is$$$272$$$274$$$O	a$$$275$$$276$$$O	hydrophobic$$$277$$$288$$$O	group,$$$289$$$295$$$O	R5$$$296$$$298$$$O	is$$$299$$$301$$$O	hydrogen$$$302$$$310$$$I	(H)$$$311$$$314$$$I	or$$$315$$$317$$$O	an$$$318$$$320$$$O	alkyl$$$321$$$326$$$I	group,$$$327$$$333$$$O	an$$$334$$$336$$$O	amino$$$337$$$342$$$I	acid$$$343$$$347$$$I	residue$$$348$$$355$$$O	or$$$356$$$358$$$O	a$$$359$$$360$$$O	peptidyl$$$361$$$369$$$O	residue,$$$370$$$378$$$O	R6$$$379$$$381$$$O	is$$$382$$$384$$$O	hydrogen$$$385$$$393$$$I	(H),$$$394$$$398$$$I	a$$$399$$$400$$$O	cation,$$$401$$$408$$$O	a$$$409$$$410$$$O	hydrolyzable$$$411$$$423$$$O	group,$$$424$$$430$$$O	an$$$431$$$433$$$O	amino$$$434$$$439$$$I	acid$$$440$$$444$$$I	residue,$$$445$$$453$$$O	or$$$454$$$456$$$O	a$$$457$$$458$$$O	peptide$$$459$$$466$$$O	group,$$$467$$$473$$$O	and$$$474$$$477$$$O	X$$$478$$$479$$$O	is$$$480$$$482$$$O	an$$$483$$$485$$$O	oxygen$$$486$$$492$$$I	atom$$$493$$$497$$$O	(O)$$$498$$$501$$$I	or$$$502$$$504$$$O	an$$$505$$$507$$$O	NH$$$508$$$510$$$I	group.$$$511$$$517$$$O	The$$$518$$$521$$$O	invention$$$522$$$531$$$O	further$$$532$$$539$$$O	relates$$$540$$$547$$$O	to$$$548$$$550$$$O	a$$$551$$$552$$$O	method$$$553$$$559$$$O	for$$$560$$$563$$$O	producing$$$564$$$573$$$O	said$$$574$$$578$$$O	composition.$$$579$$$591$$$O
EP2738156A1
9-aminomethyl$$$0$$$13$$$I	substituted$$$14$$$25$$$I	tetracycline$$$26$$$38$$$I	compound$$$39$$$47$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	9-aminomethyl$$$33$$$46$$$I	substituted$$$47$$$58$$$I	tetracycline$$$59$$$71$$$I	compounds$$$72$$$81$$$O	represented$$$82$$$93$$$O	by$$$94$$$96$$$O	formula$$$97$$$104$$$O	(I),$$$105$$$109$$$O	or$$$110$$$112$$$O	pharmaceutically$$$113$$$129$$$O	acceptable$$$130$$$140$$$O	salt,$$$141$$$146$$$O	prodrug,$$$147$$$155$$$O	solvate$$$156$$$163$$$O	or$$$164$$$166$$$O	isomer$$$167$$$173$$$O	thereof,$$$174$$$182$$$O	as$$$183$$$185$$$O	well$$$186$$$190$$$O	as$$$191$$$193$$$O	a$$$194$$$195$$$O	method$$$196$$$202$$$O	for$$$203$$$206$$$O	preparing$$$207$$$216$$$O	these$$$217$$$222$$$O	compounds$$$223$$$232$$$O	and$$$233$$$236$$$O	a$$$237$$$238$$$O	pharmaceutical$$$239$$$253$$$O	composition$$$254$$$265$$$O	comprising$$$266$$$276$$$O	the$$$277$$$280$$$O	same.$$$281$$$286$$$O	The$$$287$$$290$$$O	present$$$291$$$298$$$O	invention$$$299$$$308$$$O	relates$$$309$$$316$$$O	also$$$317$$$321$$$O	to$$$322$$$324$$$O	a$$$325$$$326$$$O	use$$$327$$$330$$$O	of$$$331$$$333$$$O	these$$$334$$$339$$$O	compounds$$$340$$$349$$$O	in$$$350$$$352$$$O	the$$$353$$$356$$$O	preparation$$$357$$$368$$$O	of$$$369$$$371$$$O	a$$$372$$$373$$$O	medicament$$$374$$$384$$$O	for$$$385$$$388$$$O	the$$$389$$$392$$$O	treatment$$$393$$$402$$$O	and/or$$$403$$$409$$$O	prophylaxis$$$410$$$421$$$O	of$$$422$$$424$$$O	tetracycline$$$425$$$437$$$I	drug-sensitive$$$438$$$452$$$O	disease.$$$453$$$461$$$O	wherein,$$$469$$$477$$$O	R2a,$$$478$$$482$$$O	R2b,$$$483$$$487$$$O	R3,$$$488$$$491$$$O	R4a,$$$492$$$496$$$O	R4b,$$$497$$$501$$$O	R5,$$$502$$$505$$$O	R6a,$$$506$$$510$$$O	R6b,$$$511$$$515$$$O	R7,$$$516$$$519$$$O	R8,$$$520$$$523$$$O	R9a,$$$524$$$528$$$O	R9b,$$$529$$$533$$$O	R10,$$$534$$$538$$$O	R11,$$$539$$$543$$$O	R12,$$$544$$$548$$$O	R13a$$$549$$$553$$$O	and$$$554$$$557$$$O	R13b$$$558$$$562$$$O	are$$$563$$$566$$$O	each$$$567$$$571$$$O	independently$$$572$$$585$$$O	as$$$586$$$588$$$O	defined$$$589$$$596$$$O	in$$$597$$$599$$$O	the$$$600$$$603$$$O	description.$$$604$$$616$$$O
CN101274054A
Compound$$$0$$$8$$$O	formulation$$$9$$$20$$$O	of$$$21$$$23$$$O	mouth$$$24$$$29$$$O	ulcer$$$30$$$35$$$O	tablets$$$36$$$43$$$O	and$$$44$$$47$$$O	producing$$$48$$$57$$$O	process$$$58$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	combination$$$27$$$38$$$O	method$$$39$$$45$$$O	of$$$46$$$48$$$O	a$$$49$$$50$$$O	tablet$$$51$$$57$$$O	for$$$58$$$61$$$O	curing$$$62$$$68$$$O	mouth$$$69$$$74$$$O	ulcer$$$75$$$80$$$O	and$$$81$$$84$$$O	a$$$85$$$86$$$O	preparation$$$87$$$98$$$O	method$$$99$$$105$$$O	thereof.$$$106$$$114$$$O	The$$$115$$$118$$$O	preparation$$$119$$$130$$$O	method$$$131$$$137$$$O	comprises$$$138$$$147$$$O	the$$$148$$$151$$$O	steps$$$152$$$157$$$O	of:$$$158$$$161$$$O	80$$$162$$$164$$$O	percent$$$165$$$172$$$O	to$$$173$$$175$$$O	95$$$176$$$178$$$O	percent$$$179$$$186$$$O	of$$$187$$$189$$$O	tea,$$$190$$$194$$$O	0.5$$$195$$$198$$$O	percent$$$199$$$206$$$O	to$$$207$$$209$$$O	1$$$210$$$211$$$O	percent$$$212$$$219$$$O	of$$$220$$$222$$$O	salt,$$$223$$$228$$$O	and$$$229$$$232$$$O	welsh-onion$$$233$$$244$$$O	stalk$$$245$$$250$$$O	are$$$251$$$254$$$O	taken$$$255$$$260$$$O	as$$$261$$$263$$$O	raw$$$264$$$267$$$O	materials,$$$268$$$278$$$O	50$$$279$$$281$$$O	percent$$$282$$$289$$$O	of$$$290$$$292$$$O	formula$$$293$$$300$$$O	ratio$$$301$$$306$$$O	of$$$307$$$309$$$O	which$$$310$$$315$$$O	are$$$316$$$319$$$O	washed,$$$320$$$327$$$O	put$$$328$$$331$$$O	in$$$332$$$334$$$O	a$$$335$$$336$$$O	stainless$$$337$$$346$$$O	steel$$$347$$$352$$$O	extraction$$$353$$$363$$$O	kettle,$$$364$$$371$$$O	added$$$372$$$377$$$O	with$$$378$$$382$$$O	tap-water$$$383$$$392$$$O	with$$$393$$$397$$$O	moderate$$$398$$$406$$$O	amount,$$$407$$$414$$$O	and$$$415$$$418$$$O	after$$$419$$$424$$$O	three-time$$$425$$$435$$$O	extractions,$$$436$$$448$$$O	added$$$449$$$454$$$O	with$$$455$$$459$$$O	moderate$$$460$$$468$$$O	amount$$$469$$$475$$$O	of$$$476$$$478$$$O	magnesium$$$479$$$488$$$I	stearate,$$$489$$$498$$$I	pelletized$$$499$$$509$$$O	and$$$510$$$513$$$O	tabletted$$$514$$$523$$$O	to$$$524$$$526$$$O	form$$$527$$$531$$$O	finished$$$532$$$540$$$O	products.$$$541$$$550$$$O	The$$$551$$$554$$$O	tablet$$$555$$$561$$$O	of$$$562$$$564$$$O	the$$$565$$$568$$$O	invention$$$569$$$578$$$O	has$$$579$$$582$$$O	the$$$583$$$586$$$O	functions$$$587$$$596$$$O	of$$$597$$$599$$$O	enriching$$$600$$$609$$$O	yin,$$$610$$$614$$$O	boosting$$$615$$$623$$$O	qi$$$624$$$626$$$O	(vital$$$627$$$633$$$O	energy)$$$634$$$641$$$O	and$$$642$$$645$$$O	nourishing$$$646$$$656$$$O	skin,$$$657$$$662$$$O	which$$$663$$$668$$$O	can$$$669$$$672$$$O	not$$$673$$$676$$$O	only$$$677$$$681$$$O	effectively$$$682$$$693$$$O	remove$$$694$$$700$$$O	mouth$$$701$$$706$$$O	ulcer,$$$707$$$713$$$O	but$$$714$$$717$$$O	also$$$718$$$722$$$O	improve$$$723$$$730$$$O	immunity,$$$731$$$740$$$O	promote$$$741$$$748$$$O	metabolism$$$749$$$759$$$O	and$$$760$$$763$$$O	delay$$$764$$$769$$$O	the$$$770$$$773$$$O	process$$$774$$$781$$$O	of$$$782$$$784$$$O	aging$$$785$$$790$$$O	after$$$791$$$796$$$O	long-term$$$797$$$806$$$O	usage.$$$807$$$813$$$O	Besides,$$$814$$$822$$$O	the$$$823$$$826$$$O	combination$$$827$$$838$$$O	method$$$839$$$845$$$O	has$$$846$$$849$$$O	simple$$$850$$$856$$$O	making$$$857$$$863$$$O	technique$$$864$$$873$$$O	and$$$874$$$877$$$O	low$$$878$$$881$$$O	cost.$$$882$$$887$$$O
WO2008124878A1
Non-steroidal$$$0$$$13$$$O	compounds$$$14$$$23$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	non-steroidal$$$33$$$46$$$O	compounds$$$47$$$56$$$O	useful$$$57$$$63$$$O	in$$$64$$$66$$$O	the$$$67$$$70$$$O	treatment$$$71$$$80$$$O	of$$$81$$$83$$$O	inflammatory$$$84$$$96$$$O	conditions$$$97$$$107$$$O	and$$$108$$$111$$$O	pharmaceutical$$$112$$$126$$$O	compositions$$$127$$$139$$$O	comprising$$$140$$$150$$$O	them.$$$151$$$156$$$O	A$$$157$$$158$$$O	representative$$$159$$$173$$$O	example$$$174$$$181$$$O	of$$$182$$$184$$$O	these$$$185$$$190$$$O	compounds$$$191$$$200$$$O	is$$$201$$$203$$$O	formula$$$204$$$211$$$O	(III).$$$212$$$218$$$O
US20080312249
Kmup-1$$$0$$$6$$$O	capable$$$7$$$14$$$O	of$$$15$$$17$$$O	treating$$$18$$$26$$$O	hypertension$$$27$$$39$$$O
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	composition$$$17$$$28$$$O	for$$$29$$$32$$$O	treating$$$33$$$41$$$O	the$$$42$$$45$$$O	hypertension$$$46$$$58$$$O	is$$$59$$$61$$$O	provided.$$$62$$$71$$$O	The$$$72$$$75$$$O	pharmaceutical$$$76$$$90$$$O	composition$$$91$$$102$$$O	comprises$$$103$$$112$$$O	a$$$113$$$114$$$O	chemical$$$115$$$123$$$O	compound$$$124$$$132$$$O	of$$$133$$$135$$$O	7-[2-[4-(2-Chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl$$$136$$$192$$$I	xanthine$$$193$$$201$$$I	and$$$202$$$205$$$O	one$$$206$$$209$$$O	of$$$210$$$212$$$O	a$$$213$$$214$$$O	pharmaceutical$$$215$$$229$$$O	acceptable$$$230$$$240$$$O	salt$$$241$$$245$$$O	thereof$$$246$$$253$$$O	and$$$254$$$257$$$O	a$$$258$$$259$$$O	solvate$$$260$$$267$$$O	thereof,$$$268$$$276$$$O	wherein$$$277$$$284$$$O	the$$$285$$$288$$$O	chemical$$$289$$$297$$$O	compound$$$298$$$306$$$O	treats$$$307$$$313$$$O	the$$$314$$$317$$$O	hypertension$$$318$$$330$$$O	by$$$331$$$333$$$O	cGMP-dependent$$$334$$$348$$$O	inhibition$$$349$$$359$$$O	on$$$360$$$362$$$O	Rho$$$363$$$366$$$O	kinase.$$$367$$$374$$$O
CN1864697A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	non-adenine$$$15$$$26$$$I	in$$$27$$$29$$$O	preparation$$$30$$$41$$$O	of$$$42$$$44$$$O	drug$$$45$$$49$$$O	for$$$50$$$53$$$O	promoting$$$54$$$63$$$O	wound$$$64$$$69$$$O	healing$$$70$$$77$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	application$$$37$$$48$$$O	of$$$49$$$51$$$O	nonglandular$$$52$$$64$$$O	purine$$$65$$$71$$$I	in$$$72$$$74$$$O	promoting$$$75$$$84$$$O	wound$$$85$$$90$$$O	healing,$$$91$$$99$$$O	and$$$100$$$103$$$O	nonglandular$$$104$$$116$$$O	purine,$$$117$$$124$$$I	such$$$125$$$129$$$O	as$$$130$$$132$$$O	guanosine,$$$133$$$143$$$I	guanine$$$144$$$151$$$I	and$$$152$$$155$$$O	inosine,$$$156$$$164$$$I	may$$$165$$$168$$$O	be$$$169$$$171$$$O	used$$$172$$$176$$$O	in$$$177$$$179$$$O	treating$$$180$$$188$$$O	wound$$$189$$$194$$$O	and$$$195$$$198$$$O	promoting$$$199$$$208$$$O	wound$$$209$$$214$$$O	healing.$$$215$$$223$$$O	The$$$224$$$227$$$O	nonglandular$$$228$$$240$$$O	purine$$$241$$$247$$$I	can$$$248$$$251$$$O	promote$$$252$$$259$$$O	the$$$260$$$263$$$O	healing$$$264$$$271$$$O	of$$$272$$$274$$$O	damaged$$$275$$$282$$$O	skin$$$283$$$287$$$O	of$$$288$$$290$$$O	white$$$291$$$296$$$O	mouse,$$$297$$$303$$$O	health$$$304$$$310$$$O	and$$$311$$$314$$$O	suffering$$$315$$$324$$$O	from$$$325$$$329$$$O	congenital$$$330$$$340$$$O	diabetes.$$$341$$$350$$$O	During$$$351$$$357$$$O	promoting$$$358$$$367$$$O	wound$$$368$$$373$$$O	healing,$$$374$$$382$$$O	the$$$383$$$386$$$O	nonglandular$$$387$$$399$$$O	purine$$$400$$$406$$$I	acts$$$407$$$411$$$O	via$$$412$$$415$$$O	activating$$$416$$$426$$$O	the$$$427$$$430$$$O	intracellular$$$431$$$444$$$O	biological$$$445$$$455$$$O	enzyme$$$456$$$462$$$O	while$$$463$$$468$$$O	the$$$469$$$472$$$O	natto$$$473$$$478$$$O	kinase$$$479$$$485$$$O	inhibitor$$$486$$$495$$$O	inhibits$$$496$$$504$$$O	the$$$505$$$508$$$O	biological$$$509$$$519$$$O	effect$$$520$$$526$$$O	of$$$527$$$529$$$O	the$$$530$$$533$$$O	compound.$$$534$$$543$$$O
CN101773496A
New$$$0$$$3$$$O	application$$$4$$$15$$$O	of$$$16$$$18$$$O	cimetidine$$$19$$$29$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	new$$$27$$$30$$$O	application$$$31$$$42$$$O	of$$$43$$$45$$$O	cimetidine$$$46$$$56$$$I	for$$$57$$$60$$$O	trauma$$$61$$$67$$$O	hemostasis$$$68$$$78$$$O	and$$$79$$$82$$$O	for$$$83$$$86$$$O	treating$$$87$$$95$$$O	periodontitis.$$$96$$$110$$$O	The$$$111$$$114$$$O	method$$$115$$$121$$$O	for$$$122$$$125$$$O	trauma$$$126$$$132$$$O	hemostasis$$$133$$$143$$$O	comprises$$$144$$$153$$$O	the$$$154$$$157$$$O	following$$$158$$$167$$$O	steps:$$$168$$$174$$$O	cimetidine$$$175$$$185$$$I	is$$$186$$$188$$$O	coated$$$189$$$195$$$O	on$$$196$$$198$$$O	the$$$199$$$202$$$O	bleeding$$$203$$$211$$$O	wound$$$212$$$217$$$O	surface$$$218$$$225$$$O	twice$$$226$$$231$$$O	each$$$232$$$236$$$O	day$$$237$$$240$$$O	with$$$241$$$245$$$O	dosage$$$246$$$252$$$O	thereof$$$253$$$260$$$O	being$$$261$$$266$$$O	approximately$$$267$$$280$$$O	200mg$$$281$$$286$$$O	and$$$287$$$290$$$O	the$$$291$$$294$$$O	wound$$$295$$$300$$$O	can$$$301$$$304$$$O	be$$$305$$$307$$$O	cured$$$308$$$313$$$O	two$$$314$$$317$$$O	days$$$318$$$322$$$O	later;$$$323$$$329$$$O	the$$$330$$$333$$$O	method$$$334$$$340$$$O	for$$$341$$$344$$$O	treating$$$345$$$353$$$O	periodontitis:$$$354$$$368$$$O	one$$$369$$$372$$$O	tablet$$$373$$$379$$$O	of$$$380$$$382$$$O	cimetidine$$$383$$$393$$$I	weighing$$$394$$$402$$$O	200mg$$$403$$$408$$$O	is$$$409$$$411$$$O	put$$$412$$$415$$$O	into$$$416$$$420$$$O	the$$$421$$$424$$$O	mouth$$$425$$$430$$$O	and$$$431$$$434$$$O	the$$$435$$$438$$$O	disease$$$439$$$446$$$O	can$$$447$$$450$$$O	be$$$451$$$453$$$O	cured$$$454$$$459$$$O	by$$$460$$$462$$$O	taking$$$463$$$469$$$O	the$$$470$$$473$$$O	medicine$$$474$$$482$$$O	once$$$483$$$487$$$O	a$$$488$$$489$$$O	day.$$$490$$$494$$$O	The$$$495$$$498$$$O	medicine$$$499$$$507$$$O	of$$$508$$$510$$$O	the$$$511$$$514$$$O	invention$$$515$$$524$$$O	features$$$525$$$533$$$O	rapid$$$534$$$539$$$O	treatment$$$540$$$549$$$O	speed,$$$550$$$556$$$O	good$$$557$$$561$$$O	curative$$$562$$$570$$$O	effect$$$571$$$577$$$O	and$$$578$$$581$$$O	radical$$$582$$$589$$$O	treatment,$$$590$$$600$$$O	thus$$$601$$$605$$$O	being$$$606$$$611$$$O	widely$$$612$$$618$$$O	applied$$$619$$$626$$$O	to$$$627$$$629$$$O	various$$$630$$$637$$$O	groups$$$638$$$644$$$O	of$$$645$$$647$$$O	people$$$648$$$654$$$O	for$$$655$$$658$$$O	treating$$$659$$$667$$$O	trauma$$$668$$$674$$$O	hemostasis$$$675$$$685$$$O	and$$$686$$$689$$$O	periodontitis.$$$690$$$704$$$O
EP2470176A1
Composition$$$0$$$11$$$O	and$$$12$$$15$$$O	method$$$16$$$22$$$O	for$$$23$$$26$$$O	treating$$$27$$$35$$$O	cognitive$$$36$$$45$$$O	impairments$$$46$$$57$$$O	in$$$58$$$60$$$O	down$$$61$$$65$$$O	syndrom$$$66$$$73$$$O	subjects$$$74$$$82$$$O
This$$$0$$$4$$$O	application$$$5$$$16$$$O	relates$$$17$$$24$$$O	to$$$25$$$27$$$O	compounds$$$28$$$37$$$O	having$$$38$$$44$$$O	inverse$$$45$$$52$$$O	agonist$$$53$$$60$$$O	functional$$$61$$$71$$$O	selectivity$$$72$$$83$$$O	for$$$84$$$87$$$O	GABA$$$88$$$92$$$I	A$$$93$$$94$$$O	receptors$$$95$$$104$$$O	containing$$$105$$$115$$$O	the$$$116$$$119$$$O	Î±5$$$120$$$123$$$O	subunit$$$124$$$131$$$O	for$$$132$$$135$$$O	use$$$136$$$139$$$O	as$$$140$$$142$$$O	a$$$143$$$144$$$O	medicament$$$145$$$155$$$O	in$$$156$$$158$$$O	the$$$159$$$162$$$O	treatment$$$163$$$172$$$O	of$$$173$$$175$$$O	cognitive$$$176$$$185$$$O	impairments$$$186$$$197$$$O	in$$$198$$$200$$$O	subjects$$$201$$$209$$$O	suffering$$$210$$$219$$$O	from$$$220$$$224$$$O	Down$$$225$$$229$$$O	syndrome.$$$230$$$239$$$O	The$$$240$$$243$$$O	present$$$244$$$251$$$O	application$$$252$$$263$$$O	also$$$264$$$268$$$O	relates$$$269$$$276$$$O	to$$$277$$$279$$$O	the$$$280$$$283$$$O	use$$$284$$$287$$$O	of$$$288$$$290$$$O	compounds$$$291$$$300$$$O	having$$$301$$$307$$$O	inverse$$$308$$$315$$$O	agonist$$$316$$$323$$$O	functional$$$324$$$334$$$O	selectivity$$$335$$$346$$$O	for$$$347$$$350$$$I	GABA$$$351$$$355$$$I	A$$$356$$$357$$$O	receptors$$$358$$$367$$$O	containing$$$368$$$378$$$O	the$$$379$$$382$$$O	Î±5$$$383$$$386$$$O	subunit$$$387$$$394$$$O	for$$$395$$$398$$$O	the$$$399$$$402$$$O	preparation$$$403$$$414$$$O	of$$$415$$$417$$$O	a$$$418$$$419$$$O	medicament$$$420$$$430$$$O	in$$$431$$$433$$$O	the$$$434$$$437$$$O	treatment$$$438$$$447$$$O	of$$$448$$$450$$$O	cognitive$$$451$$$460$$$O	impairments$$$461$$$472$$$O	in$$$473$$$475$$$O	subjects$$$476$$$484$$$O	suffering$$$485$$$494$$$O	from$$$495$$$499$$$O	Down$$$500$$$504$$$O	syndrome.$$$505$$$514$$$O	The$$$515$$$518$$$O	application$$$519$$$530$$$O	further$$$531$$$538$$$O	relates$$$539$$$546$$$O	to$$$547$$$549$$$O	pharmaceutical$$$550$$$564$$$O	compositions$$$565$$$577$$$O	for$$$578$$$581$$$O	treating$$$582$$$590$$$O	cognitive$$$591$$$600$$$O	impairments$$$601$$$612$$$O	in$$$613$$$615$$$O	subjects$$$616$$$624$$$O	suffering$$$625$$$634$$$O	from$$$635$$$639$$$O	Down$$$640$$$644$$$O	syndrome$$$645$$$653$$$O	comprising$$$654$$$664$$$O	a$$$665$$$666$$$O	compound$$$667$$$675$$$O	having$$$676$$$682$$$O	inverse$$$683$$$690$$$O	agonist$$$691$$$698$$$O	functional$$$699$$$709$$$O	selectivity$$$710$$$721$$$O	for$$$722$$$725$$$I	GABA$$$726$$$730$$$I	A$$$731$$$732$$$O	receptors$$$733$$$742$$$O	containing$$$743$$$753$$$O	the$$$754$$$757$$$O	Î±5$$$758$$$761$$$O	subunit,$$$762$$$770$$$O	or$$$771$$$773$$$O	suitable$$$774$$$782$$$O	pharmaceutically$$$783$$$799$$$O	acceptable$$$800$$$810$$$O	salt$$$811$$$815$$$O	thereof,$$$816$$$824$$$I	a$$$825$$$826$$$I	polyethoxylated$$$827$$$842$$$I	castor$$$843$$$849$$$I	oil$$$850$$$853$$$I	and$$$854$$$857$$$I	dimethyl$$$858$$$866$$$I	sulfoxide$$$867$$$876$$$I	(DMSO).$$$877$$$884$$$I	The$$$885$$$888$$$O	present$$$889$$$896$$$O	application$$$897$$$908$$$O	also$$$909$$$913$$$O	describes$$$914$$$923$$$O	methods$$$924$$$931$$$O	for$$$932$$$935$$$O	enhancing$$$936$$$945$$$O	cognitive$$$946$$$955$$$O	function,$$$956$$$965$$$O	or$$$966$$$968$$$O	treating$$$969$$$977$$$O	or$$$978$$$980$$$O	lessening$$$981$$$990$$$O	the$$$991$$$994$$$O	severity$$$995$$$1003$$$O	of$$$1004$$$1006$$$O	cognitive$$$1007$$$1016$$$O	impairments,$$$1017$$$1029$$$O	in$$$1030$$$1032$$$O	subjects$$$1033$$$1041$$$O	suffering$$$1042$$$1051$$$O	from$$$1052$$$1056$$$O	Down$$$1057$$$1061$$$O	syndrome$$$1062$$$1070$$$O	by$$$1071$$$1073$$$O	administering$$$1074$$$1087$$$O	to$$$1088$$$1090$$$O	a$$$1091$$$1092$$$O	subject$$$1093$$$1100$$$O	in$$$1101$$$1103$$$O	need$$$1104$$$1108$$$O	thereof$$$1109$$$1116$$$O	a$$$1117$$$1118$$$O	pharmaceutically$$$1119$$$1135$$$O	effective$$$1136$$$1145$$$O	amount$$$1146$$$1152$$$O	of$$$1153$$$1155$$$O	one$$$1156$$$1159$$$O	or$$$1160$$$1162$$$O	more$$$1163$$$1167$$$O	compounds$$$1168$$$1177$$$O	having$$$1178$$$1184$$$O	inverse$$$1185$$$1192$$$O	agonist$$$1193$$$1200$$$O	functional$$$1201$$$1211$$$O	selectivity$$$1212$$$1223$$$O	for$$$1224$$$1227$$$I	GABA$$$1228$$$1232$$$I	A$$$1233$$$1234$$$O	receptors$$$1235$$$1244$$$O	containing$$$1245$$$1255$$$O	the$$$1256$$$1259$$$O	Î±5$$$1260$$$1263$$$O	subunit.$$$1264$$$1272$$$O	More$$$1273$$$1277$$$O	particularly,$$$1278$$$1291$$$O	the$$$1292$$$1295$$$O	present$$$1296$$$1303$$$O	application$$$1304$$$1315$$$O	is$$$1316$$$1318$$$O	concerned$$$1319$$$1328$$$O	with$$$1329$$$1333$$$O	the$$$1334$$$1337$$$O	treatment$$$1338$$$1347$$$O	of$$$1348$$$1350$$$O	cognitive$$$1351$$$1360$$$O	impairments,$$$1361$$$1373$$$O	such$$$1374$$$1378$$$O	as$$$1379$$$1381$$$O	impairment$$$1382$$$1392$$$O	in$$$1393$$$1395$$$O	memory,$$$1396$$$1403$$$O	learning$$$1404$$$1412$$$O	capacity$$$1413$$$1421$$$O	or$$$1422$$$1424$$$O	both,$$$1425$$$1430$$$O	in$$$1431$$$1433$$$O	subjects$$$1434$$$1442$$$O	suffering$$$1443$$$1452$$$O	from$$$1453$$$1457$$$O	Down$$$1458$$$1462$$$O	syndrome.$$$1463$$$1472$$$O
CN101798558A
Ant$$$0$$$3$$$O	and$$$4$$$7$$$O	ginseng$$$8$$$15$$$O	wine$$$16$$$20$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	wine,$$$48$$$53$$$O	in$$$54$$$56$$$O	particular$$$57$$$67$$$O	to$$$68$$$70$$$O	ant$$$71$$$74$$$O	and$$$75$$$78$$$O	ginseng$$$79$$$86$$$O	wine.$$$87$$$92$$$O	The$$$93$$$96$$$O	invention$$$97$$$106$$$O	has$$$107$$$110$$$O	the$$$111$$$114$$$O	main$$$115$$$119$$$O	technical$$$120$$$129$$$O	scheme$$$130$$$136$$$O	that$$$137$$$141$$$O	1000g$$$142$$$147$$$O	of$$$148$$$150$$$O	wine$$$151$$$155$$$O	comprises$$$156$$$165$$$O	1$$$166$$$167$$$O	to$$$168$$$170$$$O	5g$$$171$$$173$$$O	of$$$174$$$176$$$O	ginseng,$$$177$$$185$$$O	1$$$186$$$187$$$O	to$$$188$$$190$$$O	5g$$$191$$$193$$$O	of$$$194$$$196$$$O	lucid$$$197$$$202$$$O	ganoderma,$$$203$$$213$$$O	1$$$214$$$215$$$O	to$$$216$$$218$$$O	5g$$$219$$$221$$$O	of$$$222$$$224$$$O	polyrhachis$$$225$$$236$$$O	vicina,$$$237$$$244$$$O	0.01$$$245$$$249$$$O	to$$$250$$$252$$$O	0.1g$$$253$$$257$$$O	of$$$258$$$260$$$O	stevioside$$$261$$$271$$$I	and$$$272$$$275$$$O	0.1$$$276$$$279$$$O	to$$$280$$$282$$$O	1g$$$283$$$285$$$O	of$$$286$$$288$$$O	flavouring$$$289$$$299$$$O	agents.$$$300$$$307$$$O	The$$$308$$$311$$$O	invention$$$312$$$321$$$O	gives$$$322$$$327$$$O	full$$$328$$$332$$$O	play$$$333$$$337$$$O	to$$$338$$$340$$$O	the$$$341$$$344$$$O	medical$$$345$$$352$$$O	value$$$353$$$358$$$O	of$$$359$$$361$$$O	the$$$362$$$365$$$O	ginseng,$$$366$$$374$$$O	the$$$375$$$378$$$O	lucid$$$379$$$384$$$O	ganoderma$$$385$$$394$$$O	and$$$395$$$398$$$O	the$$$399$$$402$$$O	polyrhachis$$$403$$$414$$$O	vicina$$$415$$$421$$$O	per$$$422$$$425$$$O	se,$$$426$$$429$$$O	so$$$430$$$432$$$O	the$$$433$$$436$$$O	ginseng,$$$437$$$445$$$O	the$$$446$$$449$$$O	lucid$$$450$$$455$$$O	ganoderma$$$456$$$465$$$O	and$$$466$$$469$$$O	the$$$470$$$473$$$O	polyrhachis$$$474$$$485$$$O	vicina$$$486$$$492$$$O	have$$$493$$$497$$$O	the$$$498$$$501$$$O	pharmacodynamic$$$502$$$517$$$O	effects,$$$518$$$526$$$O	and$$$527$$$530$$$O	in$$$531$$$533$$$O	addition,$$$534$$$543$$$O	the$$$544$$$547$$$O	wine$$$548$$$552$$$O	has$$$553$$$556$$$O	the$$$557$$$560$$$O	effects$$$561$$$568$$$O	of$$$569$$$571$$$O	clearing$$$572$$$580$$$O	and$$$581$$$584$$$O	activating$$$585$$$595$$$O	the$$$596$$$599$$$O	channels$$$600$$$608$$$O	and$$$609$$$612$$$O	collaterals,$$$613$$$625$$$O	nourishing$$$626$$$636$$$O	qi,$$$637$$$640$$$O	activating$$$641$$$651$$$O	blood$$$652$$$657$$$O	and$$$658$$$661$$$O	regulating$$$662$$$672$$$O	the$$$673$$$676$$$O	immunity$$$677$$$685$$$O	in$$$686$$$688$$$O	two$$$689$$$692$$$O	ways.$$$693$$$698$$$O	Particularly,$$$699$$$712$$$O	the$$$713$$$716$$$O	wine$$$717$$$721$$$O	of$$$722$$$724$$$O	the$$$725$$$728$$$O	invention$$$729$$$738$$$O	is$$$739$$$741$$$O	sweet,$$$742$$$748$$$O	contains$$$749$$$757$$$O	no$$$758$$$760$$$O	sugar,$$$761$$$767$$$O	does$$$768$$$772$$$O	not$$$773$$$776$$$O	have$$$777$$$781$$$O	medicine$$$782$$$790$$$O	flavor,$$$791$$$798$$$O	and$$$799$$$802$$$O	is$$$803$$$805$$$O	applicable$$$806$$$816$$$O	to$$$817$$$819$$$O	wide$$$820$$$824$$$O	range$$$825$$$830$$$O	of$$$831$$$833$$$O	people.$$$834$$$841$$$O
CN101543504A
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	for$$$27$$$30$$$O	resisting$$$31$$$40$$$O	osteoporosis$$$41$$$53$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicaments,$$$48$$$60$$$O	in$$$61$$$63$$$O	particular$$$64$$$74$$$O	to$$$75$$$77$$$O	a$$$78$$$79$$$O	pharmaceutical$$$80$$$94$$$O	composition$$$95$$$106$$$O	for$$$107$$$110$$$O	resisting$$$111$$$120$$$O	osteoporosis,$$$121$$$134$$$O	which$$$135$$$140$$$O	consists$$$141$$$149$$$O	of$$$150$$$152$$$O	any$$$153$$$156$$$O	two,$$$157$$$161$$$O	three$$$162$$$167$$$O	or$$$168$$$170$$$O	four$$$171$$$175$$$O	components$$$176$$$186$$$O	of$$$187$$$189$$$O	icariin,$$$190$$$198$$$I	timosaponin-B$$$199$$$212$$$I	II,$$$213$$$216$$$I	curculigoside$$$217$$$230$$$I	B$$$231$$$232$$$I	and$$$233$$$236$$$O	berberine$$$237$$$246$$$I	respectively$$$247$$$259$$$O	and$$$260$$$263$$$O	is$$$264$$$266$$$O	characterized$$$267$$$280$$$O	in$$$281$$$283$$$O	that$$$284$$$288$$$O	the$$$289$$$292$$$O	composition$$$293$$$304$$$O	consists$$$305$$$313$$$O	of$$$314$$$316$$$O	the$$$317$$$320$$$O	following$$$321$$$330$$$O	components$$$331$$$341$$$O	by$$$342$$$344$$$O	weight$$$345$$$351$$$O	portion:$$$352$$$360$$$O	0$$$361$$$362$$$O	to$$$363$$$365$$$O	135$$$366$$$369$$$O	portions$$$370$$$378$$$O	of$$$379$$$381$$$O	the$$$382$$$385$$$O	icariin,$$$386$$$394$$$I	0$$$395$$$396$$$O	to$$$397$$$399$$$O	450$$$400$$$403$$$O	portions$$$404$$$412$$$O	of$$$413$$$415$$$O	the$$$416$$$419$$$O	timosaponin-B$$$420$$$433$$$I	II,$$$434$$$437$$$I	0$$$438$$$439$$$O	to$$$440$$$442$$$O	63$$$443$$$445$$$O	portions$$$446$$$454$$$O	of$$$455$$$457$$$O	the$$$458$$$461$$$O	curculigoside$$$462$$$475$$$I	B,$$$476$$$478$$$I	and$$$479$$$482$$$O	0$$$483$$$484$$$O	to$$$485$$$487$$$O	1,350$$$488$$$493$$$O	portions$$$494$$$502$$$O	of$$$503$$$505$$$O	the$$$506$$$509$$$O	berberine.$$$510$$$520$$$I	The$$$521$$$524$$$O	composition$$$525$$$536$$$O	can$$$537$$$540$$$O	promote$$$541$$$548$$$O	the$$$549$$$552$$$O	formation$$$553$$$562$$$O	of$$$563$$$565$$$O	osteoblasts$$$566$$$577$$$O	synergistically$$$578$$$593$$$O	and$$$594$$$597$$$O	inhibit$$$598$$$605$$$O	the$$$606$$$609$$$O	bone$$$610$$$614$$$O	resorption$$$615$$$625$$$O	of$$$626$$$628$$$O	osteoclasts,$$$629$$$641$$$O	and$$$642$$$645$$$O	can$$$646$$$649$$$O	reinforce$$$650$$$659$$$O	the$$$660$$$663$$$O	function$$$664$$$672$$$O	of$$$673$$$675$$$O	resisting$$$676$$$685$$$O	the$$$686$$$689$$$O	osteoporosis$$$690$$$702$$$O	through$$$703$$$710$$$O	synergistic$$$711$$$722$$$O	adjustment$$$723$$$733$$$O	of$$$734$$$736$$$O	a$$$737$$$738$$$O	plurality$$$739$$$748$$$O	of$$$749$$$751$$$O	correlative$$$752$$$763$$$O	indexes$$$764$$$771$$$O	of$$$772$$$774$$$O	bone$$$775$$$779$$$O	metabolism$$$780$$$790$$$O	to$$$791$$$793$$$O	achieve$$$794$$$801$$$O	the$$$802$$$805$$$O	aim$$$806$$$809$$$O	of$$$810$$$812$$$O	preventing$$$813$$$823$$$O	and$$$824$$$827$$$O	treating$$$828$$$836$$$O	the$$$837$$$840$$$O	osteoporosis,$$$841$$$854$$$O	thus$$$855$$$859$$$O	the$$$860$$$863$$$O	composition$$$864$$$875$$$O	can$$$876$$$879$$$O	be$$$880$$$882$$$O	applied$$$883$$$890$$$O	to$$$891$$$893$$$O	preparing$$$894$$$903$$$O	medicaments$$$904$$$915$$$O	for$$$916$$$919$$$O	preventing$$$920$$$930$$$O	the$$$931$$$934$$$O	osteoporosis.$$$935$$$948$$$O
CN102228451A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	tamsulosin$$$21$$$31$$$I	hydrochloride$$$32$$$45$$$I	sustained$$$46$$$55$$$O	release$$$56$$$63$$$O	preparation$$$64$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	for$$$34$$$37$$$O	preparing$$$38$$$47$$$O	a$$$48$$$49$$$O	tamsulosin$$$50$$$60$$$I	hydrochloride$$$61$$$74$$$I	sustained$$$75$$$84$$$O	release$$$85$$$92$$$O	preparation.$$$93$$$105$$$O	The$$$106$$$109$$$O	method$$$110$$$116$$$O	comprises$$$117$$$126$$$O	the$$$127$$$130$$$O	following$$$131$$$140$$$O	steps$$$141$$$146$$$O	of:$$$147$$$150$$$O	dispersing$$$151$$$161$$$O	components$$$162$$$172$$$O	of$$$173$$$175$$$O	a$$$176$$$177$$$O	main$$$178$$$182$$$O	medicament$$$183$$$193$$$O	into$$$194$$$198$$$O	a$$$199$$$200$$$O	solvent,$$$201$$$209$$$O	wherein$$$210$$$217$$$O	the$$$218$$$221$$$O	single$$$222$$$228$$$O	excipient$$$229$$$238$$$O	and$$$239$$$242$$$O	the$$$243$$$246$$$O	components$$$247$$$257$$$O	of$$$258$$$260$$$O	the$$$261$$$264$$$O	main$$$265$$$269$$$O	medicament$$$270$$$280$$$O	are$$$281$$$284$$$O	uniformly$$$285$$$294$$$O	mixed$$$295$$$300$$$O	in$$$301$$$303$$$O	two$$$304$$$307$$$O	steps;$$$308$$$314$$$O	putting$$$315$$$322$$$O	one$$$323$$$326$$$O	part$$$327$$$331$$$O	of$$$332$$$334$$$O	the$$$335$$$338$$$O	obtained$$$339$$$347$$$O	mixture$$$348$$$355$$$O	into$$$356$$$360$$$O	a$$$361$$$362$$$O	centrifugal$$$363$$$374$$$O	granulator$$$375$$$385$$$O	and$$$386$$$389$$$O	preparingparent$$$390$$$405$$$O	nucleuses;$$$406$$$416$$$O	preparing$$$417$$$426$$$O	medicament-containing$$$427$$$448$$$O	pill$$$449$$$453$$$O	cores$$$454$$$459$$$O	by$$$460$$$462$$$O	taking$$$463$$$469$$$O	the$$$470$$$473$$$O	residual$$$474$$$482$$$O	mixture$$$483$$$490$$$O	as$$$491$$$493$$$O	supplied$$$494$$$502$$$O	powder$$$503$$$509$$$O	by$$$510$$$512$$$O	a$$$513$$$514$$$O	granulation$$$515$$$526$$$O	method;$$$527$$$534$$$O	and$$$535$$$538$$$O	preparing$$$539$$$548$$$O	coating$$$549$$$556$$$O	fluid$$$557$$$562$$$O	by$$$563$$$565$$$O	a$$$566$$$567$$$O	method$$$568$$$574$$$O	of$$$575$$$577$$$O	mixing$$$578$$$584$$$O	two$$$585$$$588$$$O	coating$$$589$$$596$$$O	materials,$$$597$$$607$$$O	and$$$608$$$611$$$O	coating$$$612$$$619$$$O	the$$$620$$$623$$$O	medicament-containing$$$624$$$645$$$O	pill$$$646$$$650$$$O	cores.$$$651$$$657$$$O	The$$$658$$$661$$$O	method$$$662$$$668$$$O	for$$$669$$$672$$$O	preparing$$$673$$$682$$$O	the$$$683$$$686$$$O	tamsulosin$$$687$$$697$$$I	hydrochloride$$$698$$$711$$$I	sustained$$$712$$$721$$$O	release$$$722$$$729$$$O	preparation$$$730$$$741$$$O	is$$$742$$$744$$$O	simple$$$745$$$751$$$O	and$$$752$$$755$$$O	easy$$$756$$$760$$$O	to$$$761$$$763$$$O	operate,$$$764$$$772$$$O	the$$$773$$$776$$$O	problem$$$777$$$784$$$O	that$$$785$$$789$$$O	a$$$790$$$791$$$O	trace$$$792$$$797$$$O	amount$$$798$$$804$$$O	of$$$805$$$807$$$O	main$$$808$$$812$$$O	medicament$$$813$$$823$$$O	of$$$824$$$826$$$O	the$$$827$$$830$$$O	preparation$$$831$$$842$$$O	and$$$843$$$846$$$O	the$$$847$$$850$$$O	excipient$$$851$$$860$$$O	are$$$861$$$864$$$O	difficult$$$865$$$874$$$O	to$$$875$$$877$$$O	fully$$$878$$$883$$$O	and$$$884$$$887$$$O	uniformly$$$888$$$897$$$O	mix$$$898$$$901$$$O	is$$$902$$$904$$$O	solved,$$$905$$$912$$$O	the$$$913$$$916$$$O	release$$$917$$$924$$$O	of$$$925$$$927$$$O	the$$$928$$$931$$$O	medicament$$$932$$$942$$$O	is$$$943$$$945$$$O	stable,$$$946$$$953$$$O	and$$$954$$$957$$$O	the$$$958$$$961$$$O	requirements$$$962$$$974$$$O	of$$$975$$$977$$$O	quality$$$978$$$985$$$O	standard$$$986$$$994$$$O	aremet.$$$995$$$1002$$$O
CN102199163A
2-hydroxy$$$0$$$9$$$I	tetrahydrothiophene$$$10$$$29$$$I	derivative,$$$30$$$41$$$O	preparation$$$42$$$53$$$O	method$$$54$$$60$$$O	thereof$$$61$$$68$$$O	and$$$69$$$72$$$O	application$$$73$$$84$$$O	thereof$$$85$$$92$$$O	in$$$93$$$95$$$O	pharmacy$$$96$$$104$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	series$$$26$$$32$$$O	of$$$33$$$35$$$O	2-hydroxy$$$36$$$45$$$I	tetrahydrothiophene$$$46$$$65$$$I	derivatives,$$$66$$$78$$$O	a$$$79$$$80$$$O	preparation$$$81$$$92$$$O	method$$$93$$$99$$$O	thereof$$$100$$$107$$$O	and$$$108$$$111$$$O	application$$$112$$$123$$$O	thereof$$$124$$$131$$$O	in$$$132$$$134$$$O	pharmacy;$$$135$$$144$$$O	and$$$145$$$148$$$O	the$$$149$$$152$$$O	derivatives$$$153$$$164$$$O	are$$$165$$$168$$$O	compounds$$$169$$$178$$$O	shown$$$179$$$184$$$O	in$$$185$$$187$$$O	the$$$188$$$191$$$O	formula$$$192$$$199$$$O	I.$$$200$$$202$$$O	The$$$203$$$206$$$O	experimental$$$207$$$219$$$O	results$$$220$$$227$$$O	of$$$228$$$230$$$O	pharmacodynamics$$$231$$$247$$$O	show$$$248$$$252$$$O	that$$$253$$$257$$$O	the$$$258$$$261$$$O	compounds$$$262$$$271$$$O	I$$$272$$$273$$$O	in$$$274$$$276$$$O	the$$$277$$$280$$$O	formula$$$281$$$288$$$O	I$$$289$$$290$$$O	have$$$291$$$295$$$O	obvious$$$296$$$303$$$O	effect$$$304$$$310$$$O	of$$$311$$$313$$$O	inhibiting$$$314$$$324$$$O	the$$$325$$$328$$$O	congregation$$$329$$$341$$$O	of$$$342$$$344$$$O	blood$$$345$$$350$$$O	platelets;$$$351$$$361$$$O	the$$$362$$$365$$$O	aggregation$$$366$$$377$$$O	effect$$$378$$$384$$$O	of$$$385$$$387$$$O	blood$$$388$$$393$$$O	platelet$$$394$$$402$$$O	resistance$$$403$$$413$$$O	of$$$414$$$416$$$O	most$$$417$$$421$$$O	of$$$422$$$424$$$O	compounds$$$425$$$434$$$O	is$$$435$$$437$$$O	obviously$$$438$$$447$$$O	better$$$448$$$454$$$O	than$$$455$$$459$$$O	that$$$460$$$464$$$O	of$$$465$$$467$$$O	clopidogrel;$$$468$$$480$$$I	and$$$481$$$484$$$O	the$$$485$$$488$$$O	activity$$$489$$$497$$$O	of$$$498$$$500$$$O	individual$$$501$$$511$$$O	compound$$$512$$$520$$$O	is$$$521$$$523$$$O	stronger$$$524$$$532$$$O	than$$$533$$$537$$$O	prasugrel.$$$538$$$548$$$I	The$$$549$$$552$$$O	compounds$$$553$$$562$$$O	in$$$563$$$565$$$O	the$$$566$$$569$$$O	formula$$$570$$$577$$$O	I$$$578$$$579$$$O	can$$$580$$$583$$$O	be$$$584$$$586$$$O	used$$$587$$$591$$$O	for$$$592$$$595$$$O	preparing$$$596$$$605$$$O	medicines$$$606$$$615$$$O	for$$$616$$$619$$$O	preventing$$$620$$$630$$$O	or$$$631$$$633$$$O	treating$$$634$$$642$$$O	related$$$643$$$650$$$O	diseases$$$651$$$659$$$O	such$$$660$$$664$$$O	as$$$665$$$667$$$O	thrombus$$$668$$$676$$$O	and$$$677$$$680$$$O	embolism.$$$681$$$690$$$O	The$$$691$$$694$$$O	invention$$$695$$$704$$$O	also$$$705$$$709$$$O	provides$$$710$$$718$$$O	a$$$719$$$720$$$O	preparation$$$721$$$732$$$O	method$$$733$$$739$$$O	of$$$740$$$742$$$O	the$$$743$$$746$$$O	compounds$$$747$$$756$$$O	in$$$757$$$759$$$O	the$$$760$$$763$$$O	formula$$$764$$$771$$$O	I.$$$772$$$774$$$O
US20130011461
Nicotine-containing$$$0$$$19$$$I	chewing$$$20$$$27$$$O	gum$$$28$$$31$$$O	piece$$$32$$$37$$$O	packed$$$38$$$44$$$O	in$$$45$$$47$$$O	a$$$48$$$49$$$O	wrapping$$$50$$$58$$$O	of$$$59$$$61$$$O	laminate$$$62$$$70$$$O
A$$$0$$$1$$$O	nicotine-containing$$$2$$$21$$$O	chewing$$$22$$$29$$$O	gum$$$30$$$33$$$O	piece$$$34$$$39$$$O	packed$$$40$$$46$$$O	in$$$47$$$49$$$O	a$$$50$$$51$$$O	wrapping$$$52$$$60$$$O	of$$$61$$$63$$$O	laminate,$$$64$$$73$$$O	where$$$74$$$79$$$O	the$$$80$$$83$$$O	laminate$$$84$$$92$$$O	comprises$$$93$$$102$$$O	at$$$103$$$105$$$O	least$$$106$$$111$$$O	an$$$112$$$114$$$O	inner$$$115$$$120$$$O	layer$$$121$$$126$$$O	facing$$$127$$$133$$$O	the$$$134$$$137$$$O	chewing$$$138$$$145$$$O	gum$$$146$$$149$$$O	and$$$150$$$153$$$O	a$$$154$$$155$$$O	nicotine$$$156$$$164$$$I	degradation$$$165$$$176$$$O	agent$$$177$$$182$$$O	barrier$$$183$$$190$$$O	layer$$$191$$$196$$$O	of$$$197$$$199$$$O	a$$$200$$$201$$$O	metal$$$202$$$207$$$O	foil.$$$208$$$213$$$O	The$$$214$$$217$$$O	nicotine-containing$$$218$$$237$$$I	chewing$$$238$$$245$$$O	gum$$$246$$$249$$$O	piece$$$250$$$255$$$O	is$$$256$$$258$$$O	shaped$$$259$$$265$$$O	as$$$266$$$268$$$O	an$$$269$$$271$$$O	elongate$$$272$$$280$$$O	plate$$$281$$$286$$$O	having$$$287$$$293$$$O	two$$$294$$$297$$$O	ends$$$298$$$302$$$O	and$$$303$$$306$$$O	a$$$307$$$308$$$O	thickness$$$309$$$318$$$O	and$$$319$$$322$$$O	a$$$323$$$324$$$O	length,$$$325$$$332$$$O	where$$$333$$$338$$$O	the$$$339$$$342$$$O	length$$$343$$$349$$$O	is$$$350$$$352$$$O	in$$$353$$$355$$$O	the$$$356$$$359$$$O	range$$$360$$$365$$$O	of$$$366$$$368$$$O	8$$$369$$$370$$$O	to$$$371$$$373$$$O	20$$$374$$$376$$$O	times$$$377$$$382$$$O	the$$$383$$$386$$$O	thickness.$$$387$$$397$$$O	The$$$398$$$401$$$O	wrapping$$$402$$$410$$$O	has$$$411$$$414$$$O	two$$$415$$$418$$$O	elongate$$$419$$$427$$$O	edges$$$428$$$433$$$O	sealed$$$434$$$440$$$O	to$$$441$$$443$$$O	one$$$444$$$447$$$O	another$$$448$$$455$$$O	in$$$456$$$458$$$O	a$$$459$$$460$$$O	fin$$$461$$$464$$$O	area$$$465$$$469$$$O	extending$$$470$$$479$$$O	along$$$480$$$485$$$O	the$$$486$$$489$$$O	length$$$490$$$496$$$O	of$$$497$$$499$$$O	the$$$500$$$503$$$O	chewing$$$504$$$511$$$O	gum$$$512$$$515$$$O	piece$$$516$$$521$$$O	and$$$522$$$525$$$O	two$$$526$$$529$$$O	sealed$$$530$$$536$$$O	end$$$537$$$540$$$O	areas$$$541$$$546$$$O	extending$$$547$$$556$$$O	beyond$$$557$$$563$$$O	the$$$564$$$567$$$O	ends$$$568$$$572$$$O	of$$$573$$$575$$$O	the$$$576$$$579$$$O	chewing$$$580$$$587$$$O	gum$$$588$$$591$$$O	piece.$$$592$$$598$$$O
US20100292189
Oligonucleotide$$$0$$$15$$$I	analog$$$16$$$22$$$O	and$$$23$$$26$$$O	method$$$27$$$33$$$O	for$$$34$$$37$$$O	treating$$$38$$$46$$$O	flavivirus$$$47$$$57$$$O	infections$$$58$$$68$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	inhibiting$$$12$$$22$$$O	replication$$$23$$$34$$$O	of$$$35$$$37$$$O	a$$$38$$$39$$$O	flavivirus$$$40$$$50$$$O	in$$$51$$$53$$$O	animal$$$54$$$60$$$O	cells,$$$61$$$67$$$O	and$$$68$$$71$$$O	an$$$72$$$74$$$O	oligonucleotide$$$75$$$90$$$I	compound$$$91$$$99$$$O	for$$$100$$$103$$$O	use$$$104$$$107$$$O	in$$$108$$$110$$$O	the$$$111$$$114$$$O	method$$$115$$$121$$$O	are$$$122$$$125$$$O	disclosed.$$$126$$$136$$$O	The$$$137$$$140$$$O	oligonucleotide$$$141$$$156$$$I	analog$$$157$$$163$$$O	(i)$$$164$$$167$$$O	has$$$168$$$171$$$O	a$$$172$$$173$$$O	nuclease-resistant$$$174$$$192$$$O	backbone,$$$193$$$202$$$O	(ii)$$$203$$$207$$$O	is$$$208$$$210$$$O	capable$$$211$$$218$$$O	of$$$219$$$221$$$O	uptake$$$222$$$228$$$O	by$$$229$$$231$$$O	the$$$232$$$235$$$O	cells,$$$236$$$242$$$O	(iii)$$$243$$$248$$$O	contains$$$249$$$257$$$O	between$$$258$$$265$$$O	8-40$$$266$$$270$$$O	nucleotide$$$271$$$281$$$O	bases,$$$282$$$288$$$O	and$$$289$$$292$$$O	(iv)$$$293$$$297$$$O	has$$$298$$$301$$$O	a$$$302$$$303$$$O	sequence$$$304$$$312$$$O	of$$$313$$$315$$$O	at$$$316$$$318$$$O	least$$$319$$$324$$$O	8$$$325$$$326$$$O	bases$$$327$$$332$$$O	complementary$$$333$$$346$$$O	to$$$347$$$349$$$O	a$$$350$$$351$$$O	region$$$352$$$358$$$O	of$$$359$$$361$$$O	the$$$362$$$365$$$O	virus'$$$366$$$372$$$O	positive$$$373$$$381$$$O	strand$$$382$$$388$$$O	RNA$$$389$$$392$$$O	genome$$$393$$$399$$$O	that$$$400$$$404$$$O	includes$$$405$$$413$$$O	at$$$414$$$416$$$O	least$$$417$$$422$$$O	a$$$423$$$424$$$O	portion$$$425$$$432$$$O	of$$$433$$$435$$$O	SEQ$$$436$$$439$$$O	ID$$$440$$$442$$$O	NOS:1-4.$$$443$$$451$$$O	Exposure$$$452$$$460$$$O	of$$$461$$$463$$$O	cells$$$464$$$469$$$O	infected$$$470$$$478$$$O	with$$$479$$$483$$$O	a$$$484$$$485$$$O	flavivirus$$$486$$$496$$$O	to$$$497$$$499$$$O	the$$$500$$$503$$$O	analog$$$504$$$510$$$O	is$$$511$$$513$$$O	effective$$$514$$$523$$$O	to$$$524$$$526$$$O	form$$$527$$$531$$$O	within$$$532$$$538$$$O	the$$$539$$$542$$$O	cells,$$$543$$$549$$$O	a$$$550$$$551$$$O	heteroduplex$$$552$$$564$$$O	structure$$$565$$$574$$$O	composed$$$575$$$583$$$O	of$$$584$$$586$$$O	the$$$587$$$590$$$O	virus$$$591$$$596$$$O	ssRNA$$$597$$$602$$$O	and$$$603$$$606$$$O	the$$$607$$$610$$$O	oligonucleotide,$$$611$$$627$$$I	characterized$$$628$$$641$$$O	by$$$642$$$644$$$O	a$$$645$$$646$$$O	Tm$$$647$$$649$$$O	of$$$650$$$652$$$O	dissociation$$$653$$$665$$$O	of$$$666$$$668$$$O	at$$$669$$$671$$$O	least$$$672$$$677$$$O	45Â°$$$678$$$682$$$O	C.,$$$683$$$686$$$O	and$$$687$$$690$$$O	having$$$691$$$697$$$O	disrupted$$$698$$$707$$$O	base$$$708$$$712$$$O	pairing$$$713$$$720$$$O	between$$$721$$$728$$$O	the$$$729$$$732$$$O	virus'$$$733$$$739$$$O	5â²$$$740$$$744$$$O	and$$$745$$$748$$$O	3â²$$$749$$$753$$$O	cyclization$$$754$$$765$$$O	sequences.$$$766$$$776$$$O
CA2729582A1
Particles$$$0$$$9$$$O	containing$$$10$$$20$$$O	an$$$21$$$23$$$O	opioid$$$24$$$30$$$I	receptor$$$31$$$39$$$O	antagonist$$$40$$$50$$$O	and$$$51$$$54$$$O	methods$$$55$$$62$$$O	of$$$63$$$65$$$O	use$$$66$$$69$$$O
Particles$$$0$$$9$$$O	comprising$$$10$$$20$$$O	an$$$21$$$23$$$O	opioid$$$24$$$30$$$I	receptor$$$31$$$39$$$O	antagonist$$$40$$$50$$$O	as$$$51$$$53$$$O	well$$$54$$$58$$$O	as$$$59$$$61$$$O	methods$$$62$$$69$$$O	of$$$70$$$72$$$O	their$$$73$$$78$$$O	use$$$79$$$82$$$O	and$$$83$$$86$$$O	methods$$$87$$$94$$$O	of$$$95$$$97$$$O	their$$$98$$$103$$$O	preparation$$$104$$$115$$$O	are$$$116$$$119$$$O	provided$$$120$$$128$$$O	herein$$$129$$$135$$$O	Such$$$136$$$140$$$O	particles$$$141$$$150$$$O	may$$$151$$$154$$$O	be$$$155$$$157$$$O	used$$$158$$$162$$$O	for$$$163$$$166$$$O	treating$$$167$$$175$$$O	and$$$176$$$179$$$O	preventing$$$180$$$190$$$O	opioid-induced$$$191$$$205$$$I	side$$$206$$$210$$$O	effects$$$211$$$218$$$O	in$$$219$$$221$$$O	patients,$$$222$$$231$$$O	and$$$232$$$235$$$O	may$$$236$$$239$$$O	be$$$240$$$242$$$O	provided$$$243$$$251$$$O	to$$$252$$$254$$$O	chronic$$$255$$$262$$$O	opioid$$$263$$$269$$$I	users$$$270$$$275$$$O	as$$$276$$$278$$$O	well$$$279$$$283$$$O
US7994219
Approach$$$0$$$8$$$O	to$$$9$$$11$$$O	anti-microbial$$$12$$$26$$$O	host$$$27$$$31$$$O	defense$$$32$$$39$$$O	with$$$40$$$44$$$O	molecular$$$45$$$54$$$O	shields$$$55$$$62$$$O	with$$$63$$$67$$$O	lipoxin$$$68$$$75$$$I	compounds$$$76$$$85$$$O
Methods$$$0$$$7$$$O	to$$$8$$$10$$$O	cause$$$11$$$16$$$O	tissue,$$$17$$$24$$$O	such$$$25$$$29$$$O	as$$$30$$$32$$$O	mucosal$$$33$$$40$$$O	cells,$$$41$$$47$$$O	to$$$48$$$50$$$O	express$$$51$$$58$$$O	increased$$$59$$$68$$$O	amounts$$$69$$$76$$$O	of$$$77$$$79$$$O	bactericidal$$$80$$$92$$$O	permeability$$$93$$$105$$$O	increasing$$$106$$$116$$$O	protein$$$117$$$124$$$O	(BPI)$$$125$$$130$$$O	are$$$131$$$134$$$O	described.$$$135$$$145$$$O	The$$$146$$$149$$$O	BPI$$$150$$$153$$$O	inducing$$$154$$$162$$$O	agents$$$163$$$169$$$O	include,$$$170$$$178$$$O	for$$$179$$$182$$$O	example,$$$183$$$191$$$O	lipoxin$$$192$$$199$$$I	compounds.$$$200$$$210$$$O
CN102114168B
Pulvis$$$0$$$6$$$O	for$$$7$$$10$$$O	topical$$$11$$$18$$$O	application$$$19$$$30$$$O	for$$$31$$$34$$$O	treating$$$35$$$43$$$O	acne$$$44$$$48$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medicinal$$$27$$$36$$$O	composition$$$37$$$48$$$O	prepared$$$49$$$57$$$O	by$$$58$$$60$$$O	using$$$61$$$66$$$O	plants$$$67$$$73$$$O	and$$$74$$$77$$$O	minerals$$$78$$$86$$$O	as$$$87$$$89$$$O	raw$$$90$$$93$$$O	materials,$$$94$$$104$$$O	in$$$105$$$107$$$O	particular$$$108$$$118$$$O	to$$$119$$$121$$$O	pulvis$$$122$$$128$$$O	for$$$129$$$132$$$O	topical$$$133$$$140$$$O	application$$$141$$$152$$$O	for$$$153$$$156$$$O	treating$$$157$$$165$$$O	acne.$$$166$$$171$$$O	The$$$172$$$175$$$O	externally$$$176$$$186$$$O	used$$$187$$$191$$$O	powder$$$192$$$198$$$O	comprises$$$199$$$208$$$O	the$$$209$$$212$$$O	following$$$213$$$222$$$O	raw$$$223$$$226$$$O	medicinal$$$227$$$236$$$O	materials$$$237$$$246$$$O	in$$$247$$$249$$$O	percentage$$$250$$$260$$$O	by$$$261$$$263$$$O	weight:$$$264$$$271$$$O	19-30%$$$272$$$278$$$O	of$$$279$$$281$$$O	Chinese$$$282$$$289$$$O	rhubarb,$$$290$$$298$$$O	19-30%$$$299$$$305$$$O	of$$$306$$$308$$$O	sulphur,$$$309$$$317$$$I	19-30%$$$318$$$324$$$O	of$$$325$$$327$$$O	coptis,$$$328$$$335$$$O	19-30%$$$336$$$342$$$O	of$$$343$$$345$$$O	aloe,$$$346$$$351$$$O	and$$$352$$$355$$$O	1-4%$$$356$$$360$$$O	of$$$361$$$363$$$O	calomel.$$$364$$$372$$$I	In$$$373$$$375$$$O	the$$$376$$$379$$$O	invention,$$$380$$$390$$$O	all$$$391$$$394$$$O	the$$$395$$$398$$$O	medicines$$$399$$$408$$$O	are$$$409$$$412$$$O	reasonably$$$413$$$423$$$O	mixed$$$424$$$429$$$O	to$$$430$$$432$$$O	achieve$$$433$$$440$$$O	the$$$441$$$444$$$O	efficacies$$$445$$$455$$$O	of$$$456$$$458$$$O	purging$$$459$$$466$$$O	intense$$$467$$$474$$$O	heat$$$475$$$479$$$O	and$$$480$$$483$$$O	detoxicating,$$$484$$$497$$$O	removing$$$498$$$506$$$O	swelling$$$507$$$515$$$O	and$$$516$$$519$$$O	masses,$$$520$$$527$$$O	killing$$$528$$$535$$$O	the$$$536$$$539$$$O	parasites$$$540$$$549$$$O	and$$$550$$$553$$$O	relieving$$$554$$$563$$$O	itching,$$$564$$$572$$$O	and$$$573$$$576$$$O	protecting$$$577$$$587$$$O	the$$$588$$$591$$$O	skin$$$592$$$596$$$O	and$$$597$$$600$$$O	beautifying$$$601$$$612$$$O	the$$$613$$$616$$$O	face.$$$617$$$622$$$O	The$$$623$$$626$$$O	invention$$$627$$$636$$$O	has$$$637$$$640$$$O	good$$$641$$$645$$$O	restoration$$$646$$$657$$$O	effect$$$658$$$664$$$O	on$$$665$$$667$$$O	pockmarks$$$668$$$677$$$O	and$$$678$$$681$$$O	scars.$$$682$$$688$$$O
CN103356500A
Calcium$$$0$$$7$$$I	rosuvastatin$$$8$$$20$$$I	and$$$21$$$24$$$O	fenofibric$$$25$$$35$$$I	acid$$$36$$$40$$$I	choline$$$41$$$48$$$I	salt$$$49$$$53$$$I	time-selecting$$$54$$$68$$$O	osmotic$$$69$$$76$$$O	pump$$$77$$$81$$$O	controlled$$$82$$$92$$$O	release$$$93$$$100$$$O	tablet$$$101$$$107$$$O	and$$$108$$$111$$$O	preparation$$$112$$$123$$$O	method$$$124$$$130$$$O	thereof$$$131$$$138$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	compound$$$25$$$33$$$O	preparation$$$34$$$45$$$O	consisting$$$46$$$56$$$O	of$$$57$$$59$$$O	calcium$$$60$$$67$$$I	rosuvastatin$$$68$$$80$$$I	and$$$81$$$84$$$O	a$$$85$$$86$$$O	fenofibric$$$87$$$97$$$I	acid$$$98$$$102$$$I	choline$$$103$$$110$$$I	salt$$$111$$$115$$$I	time-selecting$$$116$$$130$$$O	osmotic$$$131$$$138$$$O	pump$$$139$$$143$$$O	controlled$$$144$$$154$$$O	release$$$155$$$162$$$O	tablet$$$163$$$169$$$O	and$$$170$$$173$$$O	a$$$174$$$175$$$O	preparation$$$176$$$187$$$O	method$$$188$$$194$$$O	thereof.$$$195$$$203$$$O	The$$$204$$$207$$$O	compound$$$208$$$216$$$O	preparation$$$217$$$228$$$O	structurally$$$229$$$241$$$O	comprises$$$242$$$251$$$O	the$$$252$$$255$$$O	following$$$256$$$265$$$O	components$$$266$$$276$$$O	from$$$277$$$281$$$O	inside$$$282$$$288$$$O	to$$$289$$$291$$$O	outside$$$292$$$299$$$O	in$$$300$$$302$$$O	sequence:$$$303$$$312$$$O	a$$$313$$$314$$$O	tablet$$$315$$$321$$$O	chip$$$322$$$326$$$O	consisting$$$327$$$337$$$O	of$$$338$$$340$$$O	a$$$341$$$342$$$O	medicine$$$343$$$351$$$O	containing$$$352$$$362$$$O	layer$$$363$$$368$$$O	and$$$369$$$372$$$O	a$$$373$$$374$$$O	boosting$$$375$$$383$$$O	layer,$$$384$$$390$$$O	a$$$391$$$392$$$O	controlled$$$393$$$403$$$O	release$$$404$$$411$$$O	coating$$$412$$$419$$$O	for$$$420$$$423$$$O	a$$$424$$$425$$$O	medicine$$$426$$$434$$$O	release$$$435$$$442$$$O	hole,$$$443$$$448$$$O	a$$$449$$$450$$$O	calcium$$$451$$$458$$$I	rosuvastatin$$$459$$$471$$$I	quick$$$472$$$477$$$O	release$$$478$$$485$$$O	layer$$$486$$$491$$$O	and$$$492$$$495$$$O	a$$$496$$$497$$$O	protective$$$498$$$508$$$O	gastric$$$509$$$516$$$O	soluble$$$517$$$524$$$O	thin$$$525$$$529$$$O	film$$$530$$$534$$$O	coating.$$$535$$$543$$$O	The$$$544$$$547$$$O	preparation$$$548$$$559$$$O	method$$$560$$$566$$$O	comprises$$$567$$$576$$$O	the$$$577$$$580$$$O	following$$$581$$$590$$$O	steps$$$591$$$596$$$O	of:$$$597$$$600$$$O	(1)$$$601$$$604$$$O	preparing$$$605$$$614$$$O	the$$$615$$$618$$$O	medicine$$$619$$$627$$$O	containing$$$628$$$638$$$O	layer;$$$639$$$645$$$O	(2)$$$646$$$649$$$O	preparing$$$650$$$659$$$O	the$$$660$$$663$$$O	boosting$$$664$$$672$$$O	layer;$$$673$$$679$$$O	(3)$$$680$$$683$$$O	pressing$$$684$$$692$$$O	the$$$693$$$696$$$O	tablet$$$697$$$703$$$O	chip;$$$704$$$709$$$O	(5)$$$710$$$713$$$O	coating$$$714$$$721$$$O	a$$$722$$$723$$$O	control$$$724$$$731$$$O	release$$$732$$$739$$$O	coating;$$$740$$$748$$$O	(6)$$$749$$$752$$$O	punching$$$753$$$761$$$O	the$$$762$$$765$$$O	coating$$$766$$$773$$$O	tablet;$$$774$$$781$$$O	(6)$$$782$$$785$$$O	coating$$$786$$$793$$$O	the$$$794$$$797$$$O	calcium$$$798$$$805$$$I	rosuvastatin$$$806$$$818$$$I	quick$$$819$$$824$$$O	release$$$825$$$832$$$O	layer;$$$833$$$839$$$O	and$$$840$$$843$$$O	(7)$$$844$$$847$$$O	coating$$$848$$$855$$$O	the$$$856$$$859$$$O	protective$$$860$$$870$$$O	gastric$$$871$$$878$$$O	soluble$$$879$$$886$$$O	thin$$$887$$$891$$$O	film$$$892$$$896$$$O	coating.$$$897$$$905$$$O
CN103360276A
Crystal$$$0$$$7$$$O	form,$$$8$$$13$$$O	preparation$$$14$$$25$$$O	method$$$26$$$32$$$O	and$$$33$$$36$$$O	application$$$37$$$48$$$O	of$$$49$$$51$$$O	agomelatine,$$$52$$$64$$$I	as$$$65$$$67$$$O	well$$$68$$$72$$$O	as$$$73$$$75$$$O	medicine$$$76$$$84$$$O	composition$$$85$$$96$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	crystal$$$25$$$32$$$O	form,$$$33$$$38$$$O	a$$$39$$$40$$$O	preparation$$$41$$$52$$$O	method$$$53$$$59$$$O	and$$$60$$$63$$$O	an$$$64$$$66$$$O	application$$$67$$$78$$$O	of$$$79$$$81$$$O	agomelatine,$$$82$$$94$$$I	as$$$95$$$97$$$O	well$$$98$$$102$$$O	as$$$103$$$105$$$O	a$$$106$$$107$$$O	medicine$$$108$$$116$$$O	composition.$$$117$$$129$$$O	Compared$$$130$$$138$$$O	with$$$139$$$143$$$O	the$$$144$$$147$$$O	prior$$$148$$$153$$$O	art,$$$154$$$158$$$O	the$$$159$$$162$$$O	crystal$$$163$$$170$$$O	form$$$171$$$175$$$O	provided$$$176$$$184$$$O	by$$$185$$$187$$$O	the$$$188$$$191$$$O	invention$$$192$$$201$$$O	has$$$202$$$205$$$O	the$$$206$$$209$$$O	following$$$210$$$219$$$O	advantages$$$220$$$230$$$O	and$$$231$$$234$$$O	positive$$$235$$$243$$$O	effects$$$244$$$251$$$O	that$$$252$$$256$$$O	the$$$257$$$260$$$O	new$$$261$$$264$$$O	crystal$$$265$$$272$$$O	form$$$273$$$277$$$O	of$$$278$$$280$$$O	the$$$281$$$284$$$O	agomelatine$$$285$$$296$$$I	obtained$$$297$$$305$$$O	by$$$306$$$308$$$O	the$$$309$$$312$$$O	preparation$$$313$$$324$$$O	method$$$325$$$331$$$O	provided$$$332$$$340$$$O	by$$$341$$$343$$$O	the$$$344$$$347$$$O	invention$$$348$$$357$$$O	is$$$358$$$360$$$O	high$$$361$$$365$$$O	in$$$366$$$368$$$O	purity,$$$369$$$376$$$O	stable,$$$377$$$384$$$O	good$$$385$$$389$$$O	in$$$390$$$392$$$O	repeatability,$$$393$$$407$$$O	better$$$408$$$414$$$O	than$$$415$$$419$$$O	a$$$420$$$421$$$O	plurality$$$422$$$431$$$O	of$$$432$$$434$$$O	existing$$$435$$$443$$$O	crystal$$$444$$$451$$$O	forms$$$452$$$457$$$O	in$$$458$$$460$$$O	purity$$$461$$$467$$$O	and$$$468$$$471$$$O	stability,$$$472$$$482$$$O	and$$$483$$$486$$$O	suitable$$$487$$$495$$$O	for$$$496$$$499$$$O	preparing$$$500$$$509$$$O	medicament$$$510$$$520$$$O	preparations.$$$521$$$534$$$O	The$$$535$$$538$$$O	preparation$$$539$$$550$$$O	method$$$551$$$557$$$O	of$$$558$$$560$$$O	the$$$561$$$564$$$O	new$$$565$$$568$$$O	crystal$$$569$$$576$$$O	form$$$577$$$581$$$O	of$$$582$$$584$$$O	the$$$585$$$588$$$O	agomelatine$$$589$$$600$$$I	provided$$$601$$$609$$$O	by$$$610$$$612$$$O	the$$$613$$$616$$$O	invention$$$617$$$626$$$O	is$$$627$$$629$$$O	simpler$$$630$$$637$$$O	and$$$638$$$641$$$O	more$$$642$$$646$$$O	convenient$$$647$$$657$$$O	than$$$658$$$662$$$O	the$$$663$$$666$$$O	existing$$$667$$$675$$$O	crystal$$$676$$$683$$$O	form,$$$684$$$689$$$O	is$$$690$$$692$$$O	also$$$693$$$697$$$O	moderate$$$698$$$706$$$O	in$$$707$$$709$$$O	condition,$$$710$$$720$$$O	easy$$$721$$$725$$$O	to$$$726$$$728$$$O	be$$$729$$$731$$$O	applied$$$732$$$739$$$O	in$$$740$$$742$$$O	actual$$$743$$$749$$$O	production$$$750$$$760$$$O	and$$$761$$$764$$$O	low$$$765$$$768$$$O	in$$$769$$$771$$$O	cost,$$$772$$$777$$$O	and$$$778$$$781$$$O	satisfies$$$782$$$791$$$O	the$$$792$$$795$$$O	requirements$$$796$$$808$$$O	of$$$809$$$811$$$O	industrial$$$812$$$822$$$O	production.$$$823$$$834$$$O
US20110070318
skin$$$0$$$4$$$O	dressings$$$5$$$14$$$O
A$$$0$$$1$$$O	skin$$$2$$$6$$$O	dressing$$$7$$$15$$$O	is$$$16$$$18$$$O	provided$$$19$$$27$$$O	comprising$$$28$$$38$$$O	a$$$39$$$40$$$O	first$$$41$$$46$$$O	component$$$47$$$56$$$O	comprising$$$57$$$67$$$O	a$$$68$$$69$$$O	source$$$70$$$76$$$O	of$$$77$$$79$$$O	protons,$$$80$$$88$$$O	a$$$89$$$90$$$O	second$$$91$$$97$$$O	component$$$98$$$107$$$O	comprising$$$108$$$118$$$O	a$$$119$$$120$$$O	nitrite$$$121$$$128$$$I	salt,$$$129$$$134$$$I	the$$$135$$$138$$$O	dressing$$$139$$$147$$$O	comprising$$$148$$$158$$$O	a$$$159$$$160$$$O	non-thiol$$$161$$$170$$$O	reductant,$$$171$$$181$$$O	such$$$182$$$186$$$O	that,$$$187$$$192$$$O	when$$$193$$$197$$$O	the$$$198$$$201$$$O	first$$$202$$$207$$$O	and$$$208$$$211$$$O	second$$$212$$$218$$$O	components$$$219$$$229$$$O	are$$$230$$$233$$$O	brought$$$234$$$241$$$O	together$$$242$$$250$$$O	and$$$251$$$254$$$O	applied$$$255$$$262$$$O	to$$$263$$$265$$$O	a$$$266$$$267$$$O	skin$$$268$$$272$$$O	site$$$273$$$277$$$O	the$$$278$$$281$$$O	nitrite$$$282$$$289$$$I	reacts$$$290$$$296$$$O	to$$$297$$$299$$$O	generate$$$300$$$308$$$O	nitric$$$309$$$315$$$I	oxide,$$$316$$$322$$$I	increasing$$$323$$$333$$$O	the$$$334$$$337$$$O	pH$$$338$$$340$$$O	of$$$341$$$343$$$O	the$$$344$$$347$$$O	dressing$$$348$$$356$$$O	in$$$357$$$359$$$O	contact$$$360$$$367$$$O	with$$$368$$$372$$$O	the$$$373$$$376$$$O	skin$$$377$$$381$$$O	from$$$382$$$386$$$O	an$$$387$$$389$$$O	acidic$$$390$$$396$$$O	value$$$397$$$402$$$O	to$$$403$$$405$$$O	a$$$406$$$407$$$O	more$$$408$$$412$$$O	neutral$$$413$$$420$$$O	value.$$$421$$$427$$$O
WO2014071480A1
Pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	containing$$$28$$$38$$$O	a$$$39$$$40$$$O	fraction$$$41$$$49$$$O	obtained$$$50$$$58$$$O	from$$$59$$$63$$$O	rhizophora$$$64$$$74$$$O	mangle$$$75$$$81$$$O	extract$$$82$$$89$$$O	and$$$90$$$93$$$O	use$$$94$$$97$$$O	thereof$$$98$$$105$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	describes$$$22$$$31$$$O	a$$$32$$$33$$$O	method$$$34$$$40$$$O	for$$$41$$$44$$$O	fractionating$$$45$$$58$$$O	an$$$59$$$61$$$O	R.$$$62$$$64$$$O	mangle$$$65$$$71$$$O	extract,$$$72$$$80$$$O	by$$$81$$$83$$$O	means$$$84$$$89$$$O	of$$$90$$$92$$$O	which$$$93$$$98$$$O	it$$$99$$$101$$$O	is$$$102$$$104$$$O	possible$$$105$$$113$$$O	to$$$114$$$116$$$O	efficiently$$$117$$$128$$$O	concentrate$$$129$$$140$$$O	a$$$141$$$142$$$O	significant$$$143$$$154$$$O	quantity$$$155$$$163$$$O	of$$$164$$$166$$$O	complex$$$167$$$174$$$O	tannins.$$$175$$$183$$$O	The$$$184$$$187$$$O	fraction$$$188$$$196$$$O	obtained$$$197$$$205$$$O	by$$$206$$$208$$$O	means$$$209$$$214$$$O	of$$$215$$$217$$$O	the$$$218$$$221$$$O	proposed$$$222$$$230$$$O	method$$$231$$$237$$$O	has$$$238$$$241$$$O	a$$$242$$$243$$$O	surprising$$$244$$$254$$$O	effect$$$255$$$261$$$O	in$$$262$$$264$$$O	the$$$265$$$268$$$O	treatment$$$269$$$278$$$O	of$$$279$$$281$$$O	ulcers$$$282$$$288$$$O	and$$$289$$$292$$$O	gastrointestinal$$$293$$$309$$$O	injuries,$$$310$$$319$$$O	compared$$$320$$$328$$$O	to$$$329$$$331$$$O	the$$$332$$$335$$$O	drug$$$336$$$340$$$O	that$$$341$$$345$$$O	is$$$346$$$348$$$O	currently$$$349$$$358$$$O	used$$$359$$$363$$$O	for$$$364$$$367$$$O	this$$$368$$$372$$$O	purpose,$$$373$$$381$$$O	since$$$382$$$387$$$O	a$$$388$$$389$$$O	dose$$$390$$$394$$$O	up$$$395$$$397$$$O	to$$$398$$$400$$$O	60$$$401$$$403$$$O	times$$$404$$$409$$$O	lower$$$410$$$415$$$O	than$$$416$$$420$$$O	that$$$421$$$425$$$O	of$$$426$$$428$$$O	the$$$429$$$432$$$O	currently$$$433$$$442$$$O	used$$$443$$$447$$$O	drug$$$448$$$452$$$O	can$$$453$$$456$$$O	be$$$457$$$459$$$O	used$$$460$$$464$$$O	and$$$465$$$468$$$O	is$$$469$$$471$$$O	as$$$472$$$474$$$O	effective.$$$475$$$485$$$O	Therefore,$$$486$$$496$$$O	pharmaceutical$$$497$$$511$$$O	or$$$512$$$514$$$O	medicinal$$$515$$$524$$$O	compositions$$$525$$$537$$$O	involving$$$538$$$547$$$O	the$$$548$$$551$$$O	butanol$$$552$$$559$$$I	fraction$$$560$$$568$$$O	obtained$$$569$$$577$$$O	are$$$578$$$581$$$O	described$$$582$$$591$$$O	in$$$592$$$594$$$O	the$$$595$$$598$$$O	present$$$599$$$606$$$O	invention,$$$607$$$617$$$O	as$$$618$$$620$$$O	well$$$621$$$625$$$O	as$$$626$$$628$$$O	the$$$629$$$632$$$O	proposal$$$633$$$641$$$O	of$$$642$$$644$$$O	the$$$645$$$648$$$O	compounds$$$649$$$658$$$O	contained$$$659$$$668$$$O	in$$$669$$$671$$$O	said$$$672$$$676$$$O	fraction.$$$677$$$686$$$O
CN103040930A
Anti-inflammatory$$$0$$$17$$$O	and$$$18$$$21$$$O	antiallergic$$$22$$$34$$$O	cream$$$35$$$40$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	anti-inflammatory$$$28$$$45$$$O	and$$$46$$$49$$$O	antiallergic$$$50$$$62$$$O	cream$$$63$$$68$$$O	which$$$69$$$74$$$O	is$$$75$$$77$$$O	prepared$$$78$$$86$$$O	from$$$87$$$91$$$O	the$$$92$$$95$$$O	following$$$96$$$105$$$O	components:$$$106$$$117$$$O	borneol,$$$118$$$126$$$I	glycerin$$$127$$$135$$$I	stearate,$$$136$$$145$$$I	propylene$$$146$$$155$$$I	glycol,$$$156$$$163$$$I	metronidazole,$$$164$$$178$$$I	deionized$$$179$$$188$$$O	water,$$$189$$$195$$$O	vitamin$$$196$$$203$$$I	E$$$204$$$205$$$I	and$$$206$$$209$$$O	labender$$$210$$$218$$$O	essential$$$219$$$228$$$O	oil$$$229$$$232$$$O	through$$$233$$$240$$$O	an$$$241$$$243$$$O	emulsification$$$244$$$258$$$O	process.$$$259$$$267$$$O	The$$$268$$$271$$$O	anti-inflammatory$$$272$$$289$$$O	and$$$290$$$293$$$O	antiallergic$$$294$$$306$$$O	cream$$$307$$$312$$$O	provided$$$313$$$321$$$O	by$$$322$$$324$$$O	the$$$325$$$328$$$O	invention$$$329$$$338$$$O	has$$$339$$$342$$$O	favorable$$$343$$$352$$$O	healing$$$353$$$360$$$O	and$$$361$$$364$$$O	repairing$$$365$$$374$$$O	effects$$$375$$$382$$$O	on$$$383$$$385$$$O	fungal$$$386$$$392$$$O	infection$$$393$$$402$$$O	and$$$403$$$406$$$O	skin$$$407$$$411$$$O	infection$$$412$$$421$$$O	caused$$$422$$$428$$$O	by$$$429$$$431$$$O	various$$$432$$$439$$$O	strains$$$440$$$447$$$O	such$$$448$$$452$$$O	as$$$453$$$455$$$O	propionibacterium$$$456$$$473$$$O	acnes$$$474$$$479$$$O	and$$$480$$$483$$$O	the$$$484$$$487$$$O	like,$$$488$$$493$$$O	also$$$494$$$498$$$O	has$$$499$$$502$$$O	a$$$503$$$504$$$O	certain$$$505$$$512$$$O	effects$$$513$$$520$$$O	of$$$521$$$523$$$O	fading$$$524$$$530$$$O	and$$$531$$$534$$$O	eliminating$$$535$$$546$$$O	acne$$$547$$$551$$$O	marks$$$552$$$557$$$O	remained$$$558$$$566$$$O	for$$$567$$$570$$$O	a$$$571$$$572$$$O	long$$$573$$$577$$$O	term$$$578$$$582$$$O	and$$$583$$$586$$$O	particularly$$$587$$$599$$$O	has$$$600$$$603$$$O	ideal$$$604$$$609$$$O	relieving$$$610$$$619$$$O	and$$$620$$$623$$$O	healing$$$624$$$631$$$O	effects$$$632$$$639$$$O	on$$$640$$$642$$$O	sensitive$$$643$$$652$$$O	and$$$653$$$656$$$O	allergic$$$657$$$665$$$O	dermatitis.$$$666$$$677$$$O	The$$$678$$$681$$$O	anti-inflammatory$$$682$$$699$$$O	and$$$700$$$703$$$O	antiallergic$$$704$$$716$$$O	cream$$$717$$$722$$$O	is$$$723$$$725$$$O	free$$$726$$$730$$$O	of$$$731$$$733$$$O	any$$$734$$$737$$$O	side$$$738$$$742$$$O	effect,$$$743$$$750$$$O	is$$$751$$$753$$$O	low$$$754$$$757$$$O	in$$$758$$$760$$$O	reoccurrence$$$761$$$773$$$O	rate$$$774$$$778$$$O	after$$$779$$$784$$$O	being$$$785$$$790$$$O	used,$$$791$$$796$$$O	safe$$$797$$$801$$$O	to$$$802$$$804$$$O	use,$$$805$$$809$$$O	free$$$810$$$814$$$O	of$$$815$$$817$$$O	damage$$$818$$$824$$$O	to$$$825$$$827$$$O	the$$$828$$$831$$$O	skin,$$$832$$$837$$$O	non-toxic$$$838$$$847$$$O	and$$$848$$$851$$$O	capable$$$852$$$859$$$O	of$$$860$$$862$$$O	improving$$$863$$$872$$$O	the$$$873$$$876$$$O	skin$$$877$$$881$$$O	and$$$882$$$885$$$O	has$$$886$$$889$$$O	certain$$$890$$$897$$$O	nourishing$$$898$$$908$$$O	and$$$909$$$912$$$O	moistening$$$913$$$923$$$O	effects.$$$924$$$932$$$O
CN102924322A
Novel$$$0$$$5$$$O	crystal$$$6$$$13$$$O	form$$$14$$$18$$$O	of$$$19$$$21$$$O	tigecycline$$$22$$$33$$$I	and$$$34$$$37$$$O	preparation$$$38$$$49$$$O	method$$$50$$$56$$$O	thereof$$$57$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicines$$$48$$$57$$$O	and$$$58$$$61$$$O	relates$$$62$$$69$$$O	to$$$70$$$72$$$O	a$$$73$$$74$$$O	novel$$$75$$$80$$$O	crystal$$$81$$$88$$$O	form$$$89$$$93$$$O	of$$$94$$$96$$$O	tigecycline$$$97$$$108$$$I	and$$$109$$$112$$$O	a$$$113$$$114$$$O	preparation$$$115$$$126$$$O	method$$$127$$$133$$$O	thereof.$$$134$$$142$$$O	The$$$143$$$146$$$O	novel$$$147$$$152$$$O	crystal$$$153$$$160$$$O	form$$$161$$$165$$$O	of$$$166$$$168$$$O	tigecycline$$$169$$$180$$$I	has$$$181$$$184$$$O	the$$$185$$$188$$$O	following$$$189$$$198$$$O	diffraction$$$199$$$210$$$O	peaks$$$211$$$216$$$O	on$$$217$$$219$$$O	an$$$220$$$222$$$O	X-ray$$$223$$$228$$$O	powder$$$229$$$235$$$O	diffraction$$$236$$$247$$$O	pattern:$$$248$$$256$$$O	4.6,$$$257$$$261$$$O	6.2,$$$262$$$266$$$O	6.6,$$$267$$$271$$$O	8.8,$$$272$$$276$$$O	9.3,$$$277$$$281$$$O	9.6,$$$282$$$286$$$O	12.0,$$$287$$$292$$$O	12.4,$$$293$$$298$$$O	13.6,$$$299$$$304$$$O	17.6,$$$305$$$310$$$O	18.0,$$$311$$$316$$$O	20.0,$$$317$$$322$$$O	21.4,$$$323$$$328$$$O	23.2$$$329$$$333$$$O	and$$$334$$$337$$$O	26.6.$$$338$$$343$$$O	Deviation$$$344$$$353$$$O	values$$$354$$$360$$$O	of$$$361$$$363$$$O	the$$$364$$$367$$$O	diffraction$$$368$$$379$$$O	peaks$$$380$$$385$$$O	are$$$386$$$389$$$O	+/-0.2$$$390$$$396$$$O	degrees.$$$397$$$405$$$O
WO2005082459A2
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	decreasing$$$10$$$20$$$O	blood$$$21$$$26$$$O	cells$$$27$$$32$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	method$$$25$$$31$$$O	of$$$32$$$34$$$O	decreasing$$$35$$$45$$$O	the$$$46$$$49$$$O	number$$$50$$$56$$$O	of$$$57$$$59$$$O	blood$$$60$$$65$$$O	cells$$$66$$$71$$$O	in$$$72$$$74$$$O	a$$$75$$$76$$$O	subject$$$77$$$84$$$O	in$$$85$$$87$$$O	need$$$88$$$92$$$O	thereof$$$93$$$100$$$O	comprising$$$101$$$111$$$O	administering$$$112$$$125$$$O	a$$$126$$$127$$$O	compound$$$128$$$136$$$O	of$$$137$$$139$$$O	Formula$$$140$$$147$$$O	(I)$$$148$$$151$$$O	to$$$152$$$154$$$O	a$$$155$$$156$$$O	subject.$$$157$$$165$$$O
CA2695844A1
Treatments$$$0$$$10$$$O	and$$$11$$$14$$$O	prevention$$$15$$$25$$$O	of$$$26$$$28$$$O	hydrocephalus$$$29$$$42$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	prevention$$$37$$$47$$$O	or$$$48$$$50$$$O	treatment$$$51$$$60$$$O	of$$$61$$$63$$$O	hydrocephalus.$$$64$$$78$$$O	In$$$79$$$81$$$O	one$$$82$$$85$$$O	embodiment,$$$86$$$97$$$O	the$$$98$$$101$$$O	invention$$$102$$$111$$$O	includes$$$112$$$120$$$O	the$$$121$$$124$$$O	use$$$125$$$128$$$O	of$$$129$$$131$$$O	one$$$132$$$135$$$O	or$$$136$$$138$$$O	more$$$139$$$143$$$O	bioavailable$$$144$$$156$$$O	folate$$$157$$$163$$$I	derivatives,$$$164$$$176$$$O	or$$$177$$$179$$$O	salts$$$180$$$185$$$O	thereof,$$$186$$$194$$$O	for$$$195$$$198$$$O	the$$$199$$$202$$$O	prevention$$$203$$$213$$$O	or$$$214$$$216$$$O	treatment$$$217$$$226$$$O	of$$$227$$$229$$$O	hydrocephalus.$$$230$$$244$$$O	Examples$$$245$$$253$$$O	of$$$254$$$256$$$O	more$$$257$$$261$$$O	bioavailable$$$262$$$274$$$O	folate$$$275$$$281$$$I	derivatives$$$282$$$293$$$O	that$$$294$$$298$$$O	may$$$299$$$302$$$O	be$$$303$$$305$$$O	used$$$306$$$310$$$O	include$$$311$$$318$$$O	any$$$319$$$322$$$O	combination$$$323$$$334$$$O	of:$$$335$$$338$$$O	folinic$$$339$$$346$$$I	acid,$$$347$$$352$$$I	tetrahydrofolate,$$$353$$$370$$$I	thymidine,$$$371$$$381$$$I	10-formyltetrahydrofolate$$$382$$$407$$$I	or$$$408$$$410$$$O	methyltetrahydrofolate,$$$411$$$434$$$I	or$$$435$$$437$$$O	salts$$$438$$$443$$$O	thereof.$$$444$$$452$$$O	The$$$453$$$456$$$O	invention$$$457$$$466$$$O	also$$$467$$$471$$$O	relates$$$472$$$479$$$O	to$$$480$$$482$$$O	a$$$483$$$484$$$O	composition$$$485$$$496$$$O	comprising$$$497$$$507$$$O	two$$$508$$$511$$$O	or$$$512$$$514$$$O	more$$$515$$$519$$$O	bioavailable$$$520$$$532$$$O	folate$$$533$$$539$$$O	derivative(s);$$$540$$$554$$$O	for$$$555$$$558$$$O	example,$$$559$$$567$$$O	folinic$$$568$$$575$$$I	acid$$$576$$$580$$$I	and$$$581$$$584$$$O	tetrahydrofolate.$$$585$$$602$$$I
WO2009067607A2
Combinations$$$0$$$12$$$O	of$$$13$$$15$$$O	pde4$$$16$$$20$$$O	inhibitors$$$21$$$31$$$O	and$$$32$$$35$$$O	antipsychotics$$$36$$$50$$$O	for$$$51$$$54$$$O	the$$$55$$$58$$$O	treatment$$$59$$$68$$$O	of$$$69$$$71$$$O	psychotic$$$72$$$81$$$O	disorders$$$82$$$91$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	methods$$$25$$$32$$$O	and$$$33$$$36$$$O	compositions$$$37$$$49$$$O	for$$$50$$$53$$$O	treating$$$54$$$62$$$O	a$$$63$$$64$$$O	psychotic$$$65$$$74$$$O	disorder$$$75$$$83$$$O	or$$$84$$$86$$$O	condition,$$$87$$$97$$$O	associated$$$98$$$108$$$O	with$$$109$$$113$$$O	cognitive$$$114$$$123$$$O	impairment.$$$124$$$135$$$O	The$$$136$$$139$$$O	pharmaceutical$$$140$$$154$$$O	composition$$$155$$$166$$$O	comprises:$$$167$$$177$$$O	(a)$$$178$$$181$$$O	an$$$182$$$184$$$O	amount$$$185$$$191$$$O	of$$$192$$$194$$$O	an$$$195$$$197$$$O	antipsychotic$$$198$$$211$$$O	agent$$$212$$$217$$$O	and$$$218$$$221$$$O	(b)$$$222$$$225$$$O	an$$$226$$$228$$$O	amount$$$229$$$235$$$O	of$$$236$$$238$$$O	a$$$239$$$240$$$O	PDE4$$$241$$$245$$$O	inhibitor$$$246$$$255$$$O	compound,$$$256$$$265$$$O	wherein$$$266$$$273$$$O	the$$$274$$$277$$$O	amounts$$$278$$$285$$$O	of$$$286$$$288$$$O	(a)$$$289$$$292$$$O	and$$$293$$$296$$$O	(b)$$$297$$$300$$$O	are$$$301$$$304$$$O	together$$$305$$$313$$$O	effective$$$314$$$323$$$O	in$$$324$$$326$$$O	treating$$$327$$$335$$$O	the$$$336$$$339$$$O	cognitive$$$340$$$349$$$O	impairment$$$350$$$360$$$O	or$$$361$$$363$$$O	psychotic$$$364$$$373$$$O	disorder$$$374$$$382$$$O	such$$$383$$$387$$$O	as$$$388$$$390$$$O	schizophrenia.$$$391$$$405$$$O	The$$$406$$$409$$$O	method$$$410$$$416$$$O	of$$$417$$$419$$$O	treatment$$$420$$$429$$$O	comprises$$$430$$$439$$$O	administering$$$440$$$453$$$O	to$$$454$$$456$$$O	a$$$457$$$458$$$O	patient$$$459$$$466$$$O	(a)$$$467$$$470$$$O	an$$$471$$$473$$$O	amount$$$474$$$480$$$O	of$$$481$$$483$$$O	a$$$484$$$485$$$O	antipsychotic$$$486$$$499$$$O	agent$$$500$$$505$$$O	and$$$506$$$509$$$O	(b)$$$510$$$513$$$O	an$$$514$$$516$$$O	amount$$$517$$$523$$$O	of$$$524$$$526$$$O	a$$$527$$$528$$$O	PDE4$$$529$$$533$$$O	inhibitor$$$534$$$543$$$O	compound,$$$544$$$553$$$O	wherein$$$554$$$561$$$O	the$$$562$$$565$$$O	amounts$$$566$$$573$$$O	of$$$574$$$576$$$O	(a)$$$577$$$580$$$O	and$$$581$$$584$$$O	(b)$$$585$$$588$$$O	are$$$589$$$592$$$O	together$$$593$$$601$$$O	effective$$$602$$$611$$$O	in$$$612$$$614$$$O	treating$$$615$$$623$$$O	the$$$624$$$627$$$O	psychotic$$$628$$$637$$$O	disorder$$$638$$$646$$$O	such$$$647$$$651$$$O	as$$$652$$$654$$$O	schizophrenia.$$$655$$$669$$$O
WO2006131303A3
Peptide$$$0$$$7$$$O	deformylase$$$8$$$19$$$O	(pdf)$$$20$$$25$$$O	inhibitors$$$26$$$36$$$O	4$$$37$$$38$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	formula$$$46$$$53$$$O	(I).$$$54$$$58$$$O	These$$$59$$$64$$$O	compounds$$$65$$$74$$$O	are$$$75$$$78$$$O	a$$$79$$$80$$$O	novel$$$81$$$86$$$O	type$$$87$$$91$$$O	of$$$92$$$94$$$O	peptide$$$95$$$102$$$O	deformylase$$$103$$$114$$$O	(PDF)$$$115$$$120$$$O	inhibitors,$$$121$$$132$$$O	and$$$133$$$136$$$O	are$$$137$$$140$$$O	therefore$$$141$$$150$$$O	of$$$151$$$153$$$O	great$$$154$$$159$$$O	interest$$$160$$$168$$$O	especially$$$169$$$179$$$O	as$$$180$$$182$$$O	new$$$183$$$186$$$O	antibiotics.$$$187$$$199$$$O
CN102675252A
Cembrane$$$0$$$8$$$O	type$$$9$$$13$$$O	diterpenoids$$$14$$$26$$$I	with$$$27$$$31$$$O	anti-tumor$$$32$$$42$$$O	activities$$$43$$$53$$$O	and$$$54$$$57$$$O	application$$$58$$$69$$$O	thereof$$$70$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	novel$$$24$$$29$$$O	Cembrane$$$30$$$38$$$O	type$$$39$$$43$$$O	diterpenoids$$$44$$$56$$$I	with$$$57$$$61$$$O	anti-tumor$$$62$$$72$$$O	activities.$$$73$$$84$$$O	In$$$85$$$87$$$O	vitro$$$88$$$93$$$O	anti-tumor$$$94$$$104$$$O	activity$$$105$$$113$$$O	study$$$114$$$119$$$O	shows$$$120$$$125$$$O	that$$$126$$$130$$$O	the$$$131$$$134$$$O	Cembrane$$$135$$$143$$$O	type$$$144$$$148$$$O	diterpenoids$$$149$$$161$$$I	have$$$162$$$166$$$O	strong$$$167$$$173$$$O	anti-tumor$$$174$$$184$$$O	activities$$$185$$$195$$$O	on$$$196$$$198$$$O	a$$$199$$$200$$$O	plurality$$$201$$$210$$$O	of$$$211$$$213$$$O	kinds$$$214$$$219$$$O	of$$$220$$$222$$$O	tumor$$$223$$$228$$$O	cells$$$229$$$234$$$O	including$$$235$$$244$$$O	gastric$$$245$$$252$$$O	cancer,$$$253$$$260$$$O	colon$$$261$$$266$$$O	cancer,$$$267$$$274$$$O	liver$$$275$$$280$$$O	cancer$$$281$$$287$$$O	or$$$288$$$290$$$O	renal$$$291$$$296$$$O	carcinoma$$$297$$$306$$$O	and$$$307$$$310$$$O	the$$$311$$$314$$$O	like,$$$315$$$320$$$O	and$$$321$$$324$$$O	toxicity$$$325$$$333$$$O	test$$$334$$$338$$$O	study$$$339$$$344$$$O	shows$$$345$$$350$$$O	that$$$351$$$355$$$O	the$$$356$$$359$$$O	Cembrane$$$360$$$368$$$O	type$$$369$$$373$$$O	diterpenoids$$$374$$$386$$$I	with$$$387$$$391$$$O	anti-tumor$$$392$$$402$$$O	activities$$$403$$$413$$$O	have$$$414$$$418$$$O	low$$$419$$$422$$$O	toxicity$$$423$$$431$$$O	and$$$432$$$435$$$O	can$$$436$$$439$$$O	be$$$440$$$442$$$O	expected$$$443$$$451$$$O	to$$$452$$$454$$$O	be$$$455$$$457$$$O	developed$$$458$$$467$$$O	into$$$468$$$472$$$O	novel$$$473$$$478$$$O	antitumor$$$479$$$488$$$O	drugs.$$$489$$$495$$$O
CN102557972A
Polycrystal$$$0$$$11$$$O	substance$$$12$$$21$$$O	of$$$22$$$24$$$O	acetyl$$$25$$$31$$$I	chloride$$$32$$$40$$$I	levocarnitine$$$41$$$54$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	new$$$23$$$26$$$O	crystal$$$27$$$34$$$O	solid$$$35$$$40$$$O	forms$$$41$$$46$$$O	of$$$47$$$49$$$O	acetyl$$$50$$$56$$$I	chloride$$$57$$$65$$$I	levocarnitine,$$$66$$$80$$$I	namely$$$81$$$87$$$O	acetyl$$$88$$$94$$$I	chloride$$$95$$$103$$$I	levocarnitine$$$104$$$117$$$I	of$$$118$$$120$$$O	type$$$121$$$125$$$O	II$$$126$$$128$$$O	and$$$129$$$132$$$O	type$$$133$$$137$$$O	III,$$$138$$$142$$$O	and$$$143$$$146$$$O	a$$$147$$$148$$$O	composition$$$149$$$160$$$O	comprising$$$161$$$171$$$O	the$$$172$$$175$$$O	crystal$$$176$$$183$$$O	solid$$$184$$$189$$$O	forms$$$190$$$195$$$O	and$$$196$$$199$$$O	a$$$200$$$201$$$O	method$$$202$$$208$$$O	for$$$209$$$212$$$O	preparing$$$213$$$222$$$O	the$$$223$$$226$$$O	crystal$$$227$$$234$$$O	solid$$$235$$$240$$$O	forms.$$$241$$$247$$$O
WO2013164337A9
Pyrimidine$$$0$$$10$$$I	derivatives$$$11$$$22$$$O	for$$$23$$$26$$$O	the$$$27$$$30$$$O	treatment$$$31$$$40$$$O	of$$$41$$$43$$$O	bacterial$$$44$$$53$$$O	diseases$$$54$$$62$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	compounds$$$39$$$48$$$O	of$$$49$$$51$$$O	formula$$$52$$$59$$$O	(I)$$$60$$$63$$$O	or$$$64$$$66$$$O	a$$$67$$$68$$$O	pharmaceutically$$$69$$$85$$$O	acceptable$$$86$$$96$$$O	salt$$$97$$$101$$$O	thereof,$$$102$$$110$$$O	wherein$$$111$$$118$$$O	the$$$119$$$122$$$O	integers$$$123$$$131$$$O	are$$$132$$$135$$$O	as$$$136$$$138$$$O	defined$$$139$$$146$$$O	in$$$147$$$149$$$O	the$$$150$$$153$$$O	description.$$$154$$$166$$$O	The$$$167$$$170$$$O	claimed$$$171$$$178$$$O	compounds$$$179$$$188$$$O	are$$$189$$$192$$$O	useful$$$193$$$199$$$O	for$$$200$$$203$$$O	the$$$204$$$207$$$O	treatment$$$208$$$217$$$O	of$$$218$$$220$$$O	a$$$221$$$222$$$O	bacterial$$$223$$$232$$$O	infection.$$$233$$$243$$$O	Also$$$244$$$248$$$O	claimed$$$249$$$256$$$O	is$$$257$$$259$$$O	a$$$260$$$261$$$O	composition$$$262$$$273$$$O	comprising$$$274$$$284$$$O	a$$$285$$$286$$$O	pharmaceutically$$$287$$$303$$$O	acceptable$$$304$$$314$$$O	carrier$$$315$$$322$$$O	and,$$$323$$$327$$$O	as$$$328$$$330$$$O	active$$$331$$$337$$$O	ingredient,$$$338$$$349$$$O	a$$$350$$$351$$$O	therapeutically$$$352$$$367$$$O	effective$$$368$$$377$$$O	amount$$$378$$$384$$$O	of$$$385$$$387$$$O	the$$$388$$$391$$$O	claimed$$$392$$$399$$$O	compounds,$$$400$$$410$$$O	the$$$411$$$414$$$O	use$$$415$$$418$$$O	of$$$419$$$421$$$O	the$$$422$$$425$$$O	claimed$$$426$$$433$$$O	compounds$$$434$$$443$$$O	or$$$444$$$446$$$O	compositions$$$447$$$459$$$O	for$$$460$$$463$$$O	the$$$464$$$467$$$O	manufacture$$$468$$$479$$$O	of$$$480$$$482$$$O	a$$$483$$$484$$$O	medicament$$$485$$$495$$$O	for$$$496$$$499$$$O	the$$$500$$$503$$$O	treatment$$$504$$$513$$$O	of$$$514$$$516$$$O	a$$$517$$$518$$$O	bacterial$$$519$$$528$$$O	infection$$$529$$$538$$$O	and$$$539$$$542$$$O	a$$$543$$$544$$$O	process$$$545$$$552$$$O	for$$$553$$$556$$$O	preparing$$$557$$$566$$$O	the$$$567$$$570$$$O	claimed$$$571$$$578$$$O	compounds.$$$579$$$589$$$O
CN1883683A
Mind$$$0$$$4$$$O	tranquilizing$$$5$$$18$$$O	tablet$$$19$$$25$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	tablets$$$25$$$32$$$O	for$$$33$$$36$$$O	benefiting$$$37$$$47$$$O	heart$$$48$$$53$$$O	and$$$54$$$57$$$O	tranquillizing$$$58$$$72$$$O	spirit,$$$73$$$80$$$O	wherein$$$81$$$88$$$O	the$$$89$$$92$$$O	raw$$$93$$$96$$$O	materials$$$97$$$106$$$O	include$$$107$$$114$$$O	areca-nut$$$115$$$124$$$O	40-70g,$$$125$$$132$$$O	ligumaloes$$$133$$$143$$$O	25-55g,$$$144$$$151$$$O	clove,$$$152$$$158$$$O	long$$$159$$$163$$$O	pepper,$$$164$$$171$$$O	black$$$172$$$177$$$O	pepper,$$$178$$$185$$$O	iron$$$186$$$190$$$O	wooden$$$191$$$197$$$O	club$$$198$$$202$$$O	each$$$203$$$207$$$O	10-25g,$$$208$$$215$$$O	mace$$$216$$$220$$$O	nutmeg$$$221$$$227$$$O	10-20g,$$$228$$$235$$$O	banksia$$$236$$$243$$$O	rose,$$$244$$$249$$$O	brown$$$250$$$255$$$O	sugar$$$256$$$261$$$O	15-35g,$$$262$$$269$$$O	Guangzao$$$270$$$278$$$O	10-35g,$$$279$$$286$$$O	purpurea$$$287$$$295$$$O	halituim$$$296$$$304$$$O	5-20g,$$$305$$$311$$$O	rabbit$$$312$$$318$$$O	heart,$$$319$$$325$$$O	mossback$$$326$$$334$$$O	heart$$$335$$$340$$$O	5-15g,$$$341$$$347$$$O	gum$$$348$$$351$$$O	asafetida$$$352$$$361$$$O	and$$$362$$$365$$$O	and$$$366$$$369$$$O	magnesium$$$370$$$379$$$I	stearate$$$380$$$388$$$I	3-10.$$$389$$$394$$$O
US20120115926
Antisense$$$0$$$9$$$O	modulation$$$10$$$20$$$O	of$$$21$$$23$$$O	apolipoprotein$$$24$$$38$$$O	b$$$39$$$40$$$O	expression$$$41$$$51$$$O
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	rapid$$$16$$$21$$$O	and$$$22$$$25$$$O	long-term$$$26$$$35$$$O	lowering$$$36$$$44$$$O	of$$$45$$$47$$$O	lipid$$$48$$$53$$$O	levels$$$54$$$60$$$O	in$$$61$$$63$$$O	human$$$64$$$69$$$O	subjects$$$70$$$78$$$O	and$$$79$$$82$$$O	for$$$83$$$86$$$O	the$$$87$$$90$$$O	treatment$$$91$$$100$$$O	of$$$101$$$103$$$O	conditions$$$104$$$114$$$O	associated$$$115$$$125$$$O	with$$$126$$$130$$$O	elevated$$$131$$$139$$$O	LDL-cholesterol$$$140$$$155$$$I	and$$$156$$$159$$$O	elevated$$$160$$$168$$$O	apolipoprotein$$$169$$$183$$$O	B$$$184$$$185$$$O	are$$$186$$$189$$$O	provided.$$$190$$$199$$$O
CN102846538A
Sedative$$$0$$$8$$$O	hypnotic$$$9$$$17$$$O	pharmaceutical$$$18$$$32$$$O	preparation$$$33$$$44$$$O	and$$$45$$$48$$$O	its$$$49$$$52$$$O	preparation$$$53$$$64$$$O	method$$$65$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	of$$$45$$$47$$$O	a$$$48$$$49$$$O	sedative$$$50$$$58$$$O	hypnotic$$$59$$$67$$$O	pharmaceutical$$$68$$$82$$$O	preparation.$$$83$$$95$$$O	The$$$96$$$99$$$O	preparation$$$100$$$111$$$O	method$$$112$$$118$$$O	includes$$$119$$$127$$$O	the$$$128$$$131$$$O	steps$$$132$$$137$$$O	of$$$138$$$140$$$O	dissolving$$$141$$$151$$$O	active$$$152$$$158$$$O	ingredient$$$159$$$169$$$O	dexzopiclone$$$170$$$182$$$I	or$$$183$$$185$$$O	zopiclone$$$186$$$195$$$I	in$$$196$$$198$$$O	acidifier-containing$$$199$$$219$$$O	acidic$$$220$$$226$$$O	solution$$$227$$$235$$$O	to$$$236$$$238$$$O	give$$$239$$$243$$$O	drug-containing$$$244$$$259$$$O	acidic$$$260$$$266$$$O	solution,$$$267$$$276$$$O	and$$$277$$$280$$$O	then$$$281$$$285$$$O	performing$$$286$$$296$$$O	wet$$$297$$$300$$$O	granulation$$$301$$$312$$$O	with$$$313$$$317$$$O	the$$$318$$$321$$$O	obtained$$$322$$$330$$$O	drug-containing$$$331$$$346$$$O	acidic$$$347$$$353$$$O	solution,$$$354$$$363$$$O	basifier$$$364$$$372$$$O	and$$$373$$$376$$$O	adjuvant.$$$377$$$386$$$O	The$$$387$$$390$$$O	acidifier$$$391$$$400$$$O	is$$$401$$$403$$$O	hydrochloric$$$404$$$416$$$I	acid,$$$417$$$422$$$I	and$$$423$$$426$$$O	the$$$427$$$430$$$O	basifier$$$431$$$439$$$O	is$$$440$$$442$$$O	sodium$$$443$$$449$$$I	hydroxide.$$$450$$$460$$$I	One$$$461$$$464$$$O	or$$$465$$$467$$$O	more$$$468$$$472$$$O	of$$$473$$$475$$$O	organic$$$476$$$483$$$O	weak$$$484$$$488$$$O	acid,$$$489$$$494$$$O	acid$$$495$$$499$$$O	salt$$$500$$$504$$$O	and$$$505$$$508$$$O	conjugate$$$509$$$518$$$O	base$$$519$$$523$$$O	of$$$524$$$526$$$O	organic$$$527$$$534$$$O	weak$$$535$$$539$$$O	acid$$$540$$$544$$$O	are$$$545$$$548$$$O	added$$$549$$$554$$$O	before$$$555$$$561$$$O	or$$$562$$$564$$$O	during$$$565$$$571$$$O	the$$$572$$$575$$$O	addition$$$576$$$584$$$O	of$$$585$$$587$$$O	the$$$588$$$591$$$O	basifier.$$$592$$$601$$$O	The$$$602$$$605$$$O	invention$$$606$$$615$$$O	also$$$616$$$620$$$O	discloses$$$621$$$630$$$O	the$$$631$$$634$$$O	sedative$$$635$$$643$$$O	hypnotic$$$644$$$652$$$O	pharmaceutical$$$653$$$667$$$O	preparation$$$668$$$679$$$O	prepared$$$680$$$688$$$O	by$$$689$$$691$$$O	the$$$692$$$695$$$O	method.$$$696$$$703$$$O	The$$$704$$$707$$$O	inventive$$$708$$$717$$$O	preparation$$$718$$$729$$$O	method$$$730$$$736$$$O	has$$$737$$$740$$$O	no$$$741$$$743$$$O	potential$$$744$$$753$$$O	safety$$$754$$$760$$$O	hazard,$$$761$$$768$$$O	simple$$$769$$$775$$$O	and$$$776$$$779$$$O	convenient$$$780$$$790$$$O	operation,$$$791$$$801$$$O	low$$$802$$$805$$$O	pollution$$$806$$$815$$$O	and$$$816$$$819$$$O	loss,$$$820$$$825$$$O	low$$$826$$$829$$$O	cost,$$$830$$$835$$$O	and$$$836$$$839$$$O	good$$$840$$$844$$$O	process$$$845$$$852$$$O	controllability.$$$853$$$869$$$O	The$$$870$$$873$$$O	obtained$$$874$$$882$$$O	pharmaceutical$$$883$$$897$$$O	preparation$$$898$$$909$$$O	has$$$910$$$913$$$O	excellent$$$914$$$923$$$O	dissolution$$$924$$$935$$$O	and$$$936$$$939$$$O	stability,$$$940$$$950$$$O	and$$$951$$$954$$$O	lower$$$955$$$960$$$O	related$$$961$$$968$$$O	substance$$$969$$$978$$$O	content.$$$979$$$987$$$O
CN101693034A
Diffractive-ring$$$0$$$16$$$O	mangiferin$$$17$$$27$$$I	A$$$28$$$29$$$I	in$$$30$$$32$$$O	mango$$$33$$$38$$$O	leaves$$$39$$$45$$$O	and$$$46$$$49$$$O	new$$$50$$$53$$$O	application$$$54$$$65$$$O	of$$$66$$$68$$$O	mango$$$69$$$74$$$O	leaf$$$75$$$79$$$O	extractives$$$80$$$91$$$O	containing$$$92$$$102$$$O	diffractive-ring$$$103$$$119$$$O	mangiferin$$$120$$$130$$$I	A$$$131$$$132$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	diffractive-ring$$$23$$$39$$$O	mangiferin$$$40$$$50$$$I	A$$$51$$$52$$$I	in$$$53$$$55$$$O	mango$$$56$$$61$$$O	leaves$$$62$$$68$$$O	and$$$69$$$72$$$O	new$$$73$$$76$$$O	application$$$77$$$88$$$O	of$$$89$$$91$$$O	mango$$$92$$$97$$$O	leaf$$$98$$$102$$$O	extractives$$$103$$$114$$$O	containing$$$115$$$125$$$O	the$$$126$$$129$$$O	diffractive-ring$$$130$$$146$$$O	mangiferin$$$147$$$157$$$I	A$$$158$$$159$$$I	in$$$160$$$162$$$O	activity$$$163$$$171$$$O	inhibition$$$172$$$182$$$O	of$$$183$$$185$$$O	alaph-glucosaccharase,$$$186$$$208$$$O	which$$$209$$$214$$$O	further$$$215$$$222$$$O	shows$$$223$$$228$$$O	the$$$229$$$232$$$O	application$$$233$$$244$$$O	of$$$245$$$247$$$O	the$$$248$$$251$$$O	mango$$$252$$$257$$$O	leaf$$$258$$$262$$$O	extractives$$$263$$$274$$$O	in$$$275$$$277$$$O	the$$$278$$$281$$$O	preparation$$$282$$$293$$$O	of$$$294$$$296$$$O	medicines$$$297$$$306$$$O	for$$$307$$$310$$$O	treating$$$311$$$319$$$O	diabetes$$$320$$$328$$$O	and$$$329$$$332$$$O	realizes$$$333$$$341$$$O	a$$$342$$$343$$$O	composition$$$344$$$355$$$O	for$$$356$$$359$$$O	treating$$$360$$$368$$$O	diabetes,$$$369$$$378$$$O	wherein$$$379$$$386$$$O	the$$$387$$$390$$$O	composition$$$391$$$402$$$O	contains$$$403$$$411$$$O	an$$$412$$$414$$$O	effective$$$415$$$424$$$O	amount$$$425$$$431$$$O	of$$$432$$$434$$$O	diffractive-ring$$$435$$$451$$$O	mangiferin$$$452$$$462$$$I	A,$$$463$$$465$$$I	and$$$466$$$469$$$O	one$$$470$$$473$$$O	or$$$474$$$476$$$O	any$$$477$$$480$$$O	combination$$$481$$$492$$$O	of$$$493$$$495$$$O	mango$$$496$$$501$$$O	leaf$$$502$$$506$$$O	extractives$$$507$$$518$$$O	containing$$$519$$$529$$$O	the$$$530$$$533$$$O	diffractive-ring$$$534$$$550$$$O	mangiferin$$$551$$$561$$$I	A$$$562$$$563$$$I	and$$$564$$$567$$$O	as$$$568$$$570$$$O	well$$$571$$$575$$$O	as$$$576$$$578$$$O	any$$$579$$$582$$$O	excipient$$$583$$$592$$$O	acceptable$$$593$$$603$$$O	in$$$604$$$606$$$O	pharmacy.$$$607$$$616$$$O
CN101444491B
Ozagrel$$$0$$$7$$$I	sodium$$$8$$$14$$$I	microballoon$$$15$$$27$$$O	lyophilized$$$28$$$39$$$O	preparation$$$40$$$51$$$O	and$$$52$$$55$$$O	preparation$$$56$$$67$$$O	method$$$68$$$74$$$O	thereof$$$75$$$82$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	ozagrel$$$28$$$35$$$I	sodium$$$36$$$42$$$I	microballoon$$$43$$$55$$$O	lyophilized$$$56$$$67$$$O	preparation$$$68$$$79$$$O	and$$$80$$$83$$$O	a$$$84$$$85$$$O	preparation$$$86$$$97$$$O	method$$$98$$$104$$$O	thereof.$$$105$$$113$$$O	The$$$114$$$117$$$O	ozagrel$$$118$$$125$$$I	sodium$$$126$$$132$$$I	microballoon$$$133$$$145$$$O	lyophilized$$$146$$$157$$$O	preparation$$$158$$$169$$$O	of$$$170$$$172$$$O	the$$$173$$$176$$$O	invention$$$177$$$186$$$O	mainly$$$187$$$193$$$O	includes$$$194$$$202$$$O	the$$$203$$$206$$$O	following$$$207$$$216$$$O	components$$$217$$$227$$$O	by$$$228$$$230$$$O	weight$$$231$$$237$$$O	part:$$$238$$$243$$$O	20-80$$$244$$$249$$$O	parts$$$250$$$255$$$O	of$$$256$$$258$$$O	ozagrel$$$259$$$266$$$I	sodium,$$$267$$$274$$$I	50-150$$$275$$$281$$$O	parts$$$282$$$287$$$O	of$$$288$$$290$$$O	chitosan,$$$291$$$300$$$O	40-100$$$301$$$307$$$O	parts$$$308$$$313$$$O	of$$$314$$$316$$$O	polyvinyl$$$317$$$326$$$I	alcohol,$$$327$$$335$$$I	and$$$336$$$339$$$O	50-300$$$340$$$346$$$O	parts$$$347$$$352$$$O	of$$$353$$$355$$$O	lyophilization$$$356$$$370$$$O	protective$$$371$$$381$$$O	agent.$$$382$$$388$$$O	The$$$389$$$392$$$O	ozagrelsodium$$$393$$$406$$$I	microballoon$$$407$$$419$$$O	lyophilized$$$420$$$431$$$O	preparation$$$432$$$443$$$O	of$$$444$$$446$$$O	the$$$447$$$450$$$O	invention$$$451$$$460$$$O	has$$$461$$$464$$$O	the$$$465$$$468$$$O	advantages$$$469$$$479$$$O	of$$$480$$$482$$$O	good$$$483$$$487$$$O	stability$$$488$$$497$$$O	and$$$498$$$501$$$O	solubility,$$$502$$$513$$$O	small$$$514$$$519$$$O	grain$$$520$$$525$$$O	diameter$$$526$$$534$$$O	of$$$535$$$537$$$O	lipidosome$$$538$$$548$$$O	after$$$549$$$554$$$O	hydration,$$$555$$$565$$$O	strong$$$566$$$572$$$O	targeting$$$573$$$582$$$O	property,$$$583$$$592$$$O	low$$$593$$$596$$$O	production$$$597$$$607$$$O	cost$$$608$$$612$$$O	and$$$613$$$616$$$O	the$$$617$$$620$$$O	like.$$$621$$$626$$$O
US6987106
Nootropic$$$0$$$9$$$O	agents;$$$10$$$17$$$O	Alzheimer's$$$18$$$29$$$O	Disease,$$$30$$$38$$$O	Schizophrenia;$$$39$$$53$$$O	ligands$$$54$$$61$$$O	for$$$62$$$65$$$O	the$$$66$$$69$$$O	a7$$$70$$$72$$$O	subunits$$$73$$$81$$$O	of$$$82$$$84$$$O	the$$$85$$$88$$$O	nicotinic$$$89$$$98$$$O	receptor;$$$99$$$108$$$O	4-Bromophenyl-1,4-diazabicyclo[3.2.2]nonane-4-carboxylate$$$109$$$166$$$I
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	general$$$13$$$20$$$O	formula$$$21$$$28$$$O	in$$$43$$$45$$$O	which$$$46$$$51$$$O	X$$$52$$$53$$$O	represents$$$54$$$64$$$O	an$$$65$$$67$$$O	oxygen$$$68$$$74$$$I	atom$$$75$$$79$$$O	or$$$80$$$82$$$O	a$$$83$$$84$$$O	group$$$85$$$90$$$O	of$$$91$$$93$$$O	formula$$$94$$$101$$$O	NZ$$$102$$$104$$$O	in$$$105$$$107$$$O	which$$$108$$$113$$$O	Z$$$114$$$115$$$O	represents$$$116$$$126$$$O	a$$$127$$$128$$$O	hydrogen$$$129$$$137$$$I	atom$$$138$$$142$$$O	or$$$143$$$145$$$O	an$$$146$$$148$$$O	alkyl$$$149$$$154$$$I	group,$$$155$$$161$$$O	n$$$162$$$163$$$O	represents$$$164$$$174$$$O	a$$$175$$$176$$$O	number$$$177$$$183$$$O	0,$$$184$$$186$$$O	1$$$187$$$188$$$O	or$$$189$$$191$$$O	2,$$$192$$$194$$$O	and$$$195$$$198$$$O	R1,$$$199$$$202$$$O	R2,$$$203$$$206$$$O	R3,$$$207$$$210$$$O	R4$$$211$$$213$$$O	and$$$214$$$217$$$O	R5$$$218$$$220$$$O	each$$$221$$$225$$$O	represent$$$226$$$235$$$O	a$$$236$$$237$$$O	hydrogen$$$238$$$246$$$I	or$$$247$$$249$$$O	halogen$$$250$$$257$$$I	atom$$$258$$$262$$$O	or$$$263$$$265$$$O	a$$$266$$$267$$$O	trifluoromethyl,$$$268$$$284$$$I	trifluoromethoxy,$$$285$$$302$$$I	cyano,$$$303$$$309$$$I	hydroxyl,$$$310$$$319$$$I	alkyl,$$$320$$$326$$$I	alkoxy,$$$327$$$334$$$I	phenoxy$$$335$$$342$$$I	or$$$343$$$345$$$O	phenyl$$$346$$$352$$$I	group$$$353$$$358$$$O	optionally$$$359$$$369$$$O	substituted$$$370$$$381$$$O	with$$$382$$$386$$$O	a$$$387$$$388$$$O	halogen$$$389$$$396$$$I	atom$$$397$$$401$$$O	or$$$402$$$404$$$O	a$$$405$$$406$$$O	trifluoromethyl,$$$407$$$423$$$I	cyano,$$$424$$$430$$$I	hydroxyl,$$$431$$$440$$$I	alkyl$$$441$$$446$$$I	or$$$447$$$449$$$O	alkoxy$$$450$$$456$$$I	group,$$$457$$$463$$$O	or$$$464$$$466$$$O	alternatively$$$467$$$480$$$O	R2$$$481$$$483$$$O	and$$$484$$$487$$$O	R3$$$488$$$490$$$O	together$$$491$$$499$$$O	form$$$500$$$504$$$O	a$$$505$$$506$$$O	group$$$507$$$512$$$O	of$$$513$$$515$$$O	formula$$$516$$$523$$$O	âOCH2Oâ$$$524$$$535$$$I	or$$$536$$$538$$$I	âCH2CH2CH2CH2â.$$$539$$$558$$$I	Application$$$560$$$571$$$O	in$$$572$$$574$$$O	therapy.$$$575$$$583$$$O
CN1683369A
S-omeprazole$$$0$$$12$$$I	zinc$$$13$$$17$$$I	salt$$$18$$$22$$$O	and$$$23$$$26$$$O	its$$$27$$$30$$$O	preparing$$$31$$$40$$$O	method$$$41$$$47$$$O	and$$$48$$$51$$$O	use$$$52$$$55$$$O
The$$$0$$$3$$$O	;present$$$4$$$12$$$O	invention$$$13$$$22$$$O	discloses$$$23$$$32$$$O	S-omeprazole$$$33$$$45$$$I	zinc$$$46$$$50$$$I	and$$$51$$$54$$$O	its$$$55$$$58$$$O	preparation$$$59$$$70$$$O	process$$$71$$$78$$$O	and$$$79$$$82$$$O	application$$$83$$$94$$$O	in$$$95$$$97$$$O	preparing$$$98$$$107$$$O	medicine$$$108$$$116$$$O	for$$$117$$$120$$$O	treating$$$121$$$129$$$O	gastric$$$130$$$137$$$O	acid$$$138$$$142$$$O	relevant$$$143$$$151$$$O	diseases.$$$152$$$161$$$O	The$$$162$$$165$$$O	S-omeprazole$$$166$$$178$$$I	zinc$$$179$$$183$$$I	of$$$184$$$186$$$O	the$$$187$$$190$$$O	present$$$191$$$198$$$O	invention$$$199$$$208$$$O	is$$$209$$$211$$$O	used$$$212$$$216$$$O	in$$$217$$$219$$$O	treating$$$220$$$228$$$O	gastric$$$229$$$236$$$O	acid$$$237$$$241$$$O	relevant$$$242$$$250$$$O	diseases$$$251$$$259$$$O	and$$$260$$$263$$$O	has$$$264$$$267$$$O	the$$$268$$$271$$$O	advantages$$$272$$$282$$$O	of$$$283$$$285$$$O	fast$$$286$$$290$$$O	curative$$$291$$$299$$$O	effect$$$300$$$306$$$O	and$$$307$$$310$$$O	less$$$311$$$315$$$O	side$$$316$$$320$$$O	effect.$$$321$$$328$$$O	The$$$329$$$332$$$O	preparation$$$333$$$344$$$O	process$$$345$$$352$$$O	is$$$353$$$355$$$O	simple,$$$356$$$363$$$O	easy$$$364$$$368$$$O	to$$$369$$$371$$$O	operate$$$372$$$379$$$O	and$$$380$$$383$$$O	suitable$$$384$$$392$$$O	for$$$393$$$396$$$O	industrial$$$397$$$407$$$O	production.$$$408$$$419$$$O
CN103751531A
Medicinal$$$0$$$9$$$O	liquor$$$10$$$16$$$O	for$$$17$$$20$$$O	rheumatism$$$21$$$31$$$O	and$$$32$$$35$$$O	traumatic$$$36$$$45$$$O	injury$$$46$$$52$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicinal$$$26$$$35$$$O	liquor$$$36$$$42$$$O	for$$$43$$$46$$$O	rheumatism$$$47$$$57$$$O	and$$$58$$$61$$$O	traumatic$$$62$$$71$$$O	injury.$$$72$$$79$$$O	The$$$80$$$83$$$O	medicinal$$$84$$$93$$$O	liquor$$$94$$$100$$$O	is$$$101$$$103$$$O	prepared$$$104$$$112$$$O	from$$$113$$$117$$$O	various$$$118$$$125$$$O	materials$$$126$$$135$$$O	according$$$136$$$145$$$O	to$$$146$$$148$$$O	a$$$149$$$150$$$O	certain$$$151$$$158$$$O	weight$$$159$$$165$$$O	ratio,$$$166$$$172$$$O	and$$$173$$$176$$$O	is$$$177$$$179$$$O	low$$$180$$$183$$$O	in$$$184$$$186$$$O	cost,$$$187$$$192$$$O	reasonable$$$193$$$203$$$O	in$$$204$$$206$$$O	formula,$$$207$$$215$$$O	simple$$$216$$$222$$$O	for$$$223$$$226$$$O	preparation$$$227$$$238$$$O	and$$$239$$$242$$$O	convenient$$$243$$$253$$$O	for$$$254$$$257$$$O	drinking.$$$258$$$267$$$O	The$$$268$$$271$$$O	medicines$$$272$$$281$$$O	are$$$282$$$285$$$O	combined$$$286$$$294$$$O	to$$$295$$$297$$$O	perform$$$298$$$305$$$O	synergistic$$$306$$$317$$$O	effect$$$318$$$324$$$O	of$$$325$$$327$$$O	individual$$$328$$$338$$$O	effect,$$$339$$$346$$$O	so$$$347$$$349$$$O	as$$$350$$$352$$$O	to$$$353$$$355$$$O	realize$$$356$$$363$$$O	disease$$$364$$$371$$$O	exact$$$372$$$377$$$O	curative$$$378$$$386$$$O	effect,$$$387$$$394$$$O	short$$$395$$$400$$$O	course$$$401$$$407$$$O	of$$$408$$$410$$$O	treatment$$$411$$$420$$$O	and$$$421$$$424$$$O	good$$$425$$$429$$$O	curative$$$430$$$438$$$O	effect$$$439$$$445$$$O	on$$$446$$$448$$$O	rheumatic$$$449$$$458$$$O	pain,$$$459$$$464$$$O	cold$$$465$$$469$$$O	sores,$$$470$$$476$$$O	traumatic$$$477$$$486$$$O	injury,$$$487$$$494$$$O	rheumatoid$$$495$$$505$$$O	arthritis$$$506$$$515$$$O	pain,$$$516$$$521$$$O	rheumatic$$$522$$$531$$$O	ostealgia$$$532$$$541$$$O	pain,$$$542$$$547$$$O	rheumatic$$$548$$$557$$$O	arthritis,$$$558$$$568$$$O	arthralgia$$$569$$$579$$$O	and$$$580$$$583$$$O	myalgia,$$$584$$$592$$$O	hemiplegia,$$$593$$$604$$$O	lumbago$$$605$$$612$$$O	leg$$$613$$$616$$$O	pain$$$617$$$621$$$O	and$$$622$$$625$$$O	ostealgia$$$626$$$635$$$O	caused$$$636$$$642$$$O	by$$$643$$$645$$$O	rheumatism$$$646$$$656$$$O	and$$$657$$$660$$$O	rheumatoid$$$661$$$671$$$O	arthritis.$$$672$$$682$$$O	The$$$683$$$686$$$O	formula$$$687$$$694$$$O	is$$$695$$$697$$$O	as$$$698$$$700$$$O	below:$$$701$$$707$$$O	orangeeye$$$708$$$717$$$O	butterflybush$$$718$$$731$$$O	branchlet$$$732$$$741$$$O	and$$$742$$$745$$$O	leaf$$$746$$$750$$$O	or$$$751$$$753$$$O	root-bark,$$$754$$$764$$$O	anderson$$$765$$$773$$$O	cirrhopetalum$$$774$$$787$$$O	herb,$$$788$$$793$$$O	flatstem$$$794$$$802$$$O	rockvine$$$803$$$811$$$O	stem$$$812$$$816$$$O	and$$$817$$$820$$$O	root,$$$821$$$826$$$O	threeleaf$$$827$$$836$$$O	loosestrife$$$837$$$848$$$O	herb,$$$849$$$854$$$O	henry$$$855$$$860$$$O	steudnera$$$861$$$870$$$O	tuber$$$871$$$876$$$O	and$$$877$$$880$$$O	liquor$$$881$$$887$$$O	(higher$$$888$$$895$$$O	than$$$896$$$900$$$O	60$$$901$$$903$$$O	DEG).$$$904$$$909$$$O
US20060178426
Kappa$$$0$$$5$$$O	agonists,$$$6$$$15$$$O	especialy$$$16$$$25$$$O	for$$$26$$$29$$$O	the$$$30$$$33$$$O	treatment$$$34$$$43$$$O	and/or$$$44$$$50$$$O	prophylaxis$$$51$$$62$$$O	of$$$63$$$65$$$O	irritable$$$66$$$75$$$O	bowel$$$76$$$81$$$O	syndrome$$$82$$$90$$$O
Compound$$$0$$$8$$$O	of$$$9$$$11$$$O	the$$$12$$$15$$$O	formula$$$16$$$23$$$O	(I),$$$24$$$28$$$O	in$$$29$$$31$$$O	which$$$32$$$37$$$O	A,$$$38$$$40$$$O	R1,$$$41$$$44$$$O	R2,$$$45$$$48$$$O	R3,$$$49$$$52$$$O	X,$$$53$$$55$$$O	Y,$$$56$$$58$$$O	m$$$59$$$60$$$O	and$$$61$$$64$$$O	n$$$65$$$66$$$O	have$$$67$$$71$$$O	the$$$72$$$75$$$O	meaning$$$76$$$83$$$O	indicated,$$$84$$$94$$$O	are$$$95$$$98$$$O	suitable$$$99$$$107$$$O	as$$$108$$$110$$$O	for$$$111$$$114$$$O	the$$$115$$$118$$$O	treatment$$$119$$$128$$$O	of$$$129$$$131$$$O	irritable$$$132$$$141$$$O	bowel$$$142$$$147$$$O	syndrome.$$$148$$$157$$$O
US20090018103
Diaminoalkane$$$0$$$13$$$I	Aspartic$$$14$$$22$$$O	Protease$$$23$$$31$$$O	Inhibitors$$$32$$$42$$$O
Diaminoalkanes$$$0$$$14$$$I	of$$$15$$$17$$$O	Formula$$$18$$$25$$$O	I$$$26$$$27$$$O	have$$$28$$$32$$$O	now$$$33$$$36$$$O	been$$$37$$$41$$$O	found$$$42$$$47$$$O	which$$$48$$$53$$$O	are$$$54$$$57$$$O	orally$$$58$$$64$$$O	active$$$65$$$71$$$O	and$$$72$$$75$$$O	bind$$$76$$$80$$$O	to$$$81$$$83$$$O	aspartic$$$84$$$92$$$O	proteases$$$93$$$102$$$O	to$$$103$$$105$$$O	inhibit$$$106$$$113$$$O	their$$$114$$$119$$$O	activity.$$$120$$$129$$$O	They$$$130$$$134$$$O	are$$$135$$$138$$$O	useful$$$139$$$145$$$O	in$$$146$$$148$$$O	the$$$149$$$152$$$O	treatment$$$153$$$162$$$O	or$$$163$$$165$$$O	amelioration$$$166$$$178$$$O	of$$$179$$$181$$$O	diseases$$$182$$$190$$$O	associated$$$191$$$201$$$O	with$$$202$$$206$$$O	elevated$$$207$$$215$$$O	levels$$$216$$$222$$$O	of$$$223$$$225$$$O	aspartic$$$226$$$234$$$O	protease$$$235$$$243$$$O	activity.$$$244$$$253$$$O	The$$$254$$$257$$$O	invention$$$258$$$267$$$O	also$$$268$$$272$$$O	relates$$$273$$$280$$$O	to$$$281$$$283$$$O	a$$$284$$$285$$$O	method$$$286$$$292$$$O	for$$$293$$$296$$$O	the$$$297$$$300$$$O	use$$$301$$$304$$$O	of$$$305$$$307$$$O	the$$$308$$$311$$$O	compounds$$$312$$$321$$$O	of$$$322$$$324$$$O	Formula$$$325$$$332$$$O	I$$$333$$$334$$$O	in$$$335$$$337$$$O	ameliorating$$$338$$$350$$$O	or$$$351$$$353$$$O	treating$$$354$$$362$$$O	aspartic$$$363$$$371$$$O	protease$$$372$$$380$$$O	related$$$381$$$388$$$O	disorders$$$389$$$398$$$O	in$$$399$$$401$$$O	a$$$402$$$403$$$O	subject$$$404$$$411$$$O	in$$$412$$$414$$$O	need$$$415$$$419$$$O	thereof$$$420$$$427$$$O	comprising$$$428$$$438$$$O	administering$$$439$$$452$$$O	to$$$453$$$455$$$O	said$$$456$$$460$$$O	subject$$$461$$$468$$$O	an$$$469$$$471$$$O	effective$$$472$$$481$$$O	amount$$$482$$$488$$$O	of$$$489$$$491$$$O	a$$$492$$$493$$$O	compound$$$494$$$502$$$O	of$$$503$$$505$$$O	Formula$$$506$$$513$$$O	I.$$$514$$$516$$$O
WO2014100431A1
Deuterated$$$0$$$10$$$O	alk$$$11$$$14$$$O	inhibitors$$$15$$$25$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	ALK$$$32$$$35$$$O	inhibitors$$$36$$$46$$$O	of$$$47$$$49$$$O	Formula$$$50$$$57$$$O	I:$$$58$$$60$$$O	as$$$61$$$63$$$O	defined$$$64$$$71$$$O	in$$$72$$$74$$$O	the$$$75$$$78$$$O	specification,$$$79$$$93$$$O	and$$$94$$$97$$$O	pharmaceutically$$$98$$$114$$$O	acceptable$$$115$$$125$$$O	salts$$$126$$$131$$$O	thereof.$$$132$$$140$$$O	This$$$141$$$145$$$O	invention$$$146$$$155$$$O	also$$$156$$$160$$$O	provides$$$161$$$169$$$O	compositions$$$170$$$182$$$O	comprising$$$183$$$193$$$O	a$$$194$$$195$$$O	compound$$$196$$$204$$$O	of$$$205$$$207$$$O	this$$$208$$$212$$$O	invention$$$213$$$222$$$O	and$$$223$$$226$$$O	the$$$227$$$230$$$O	use$$$231$$$234$$$O	of$$$235$$$237$$$O	such$$$238$$$242$$$O	compositions$$$243$$$255$$$O	in$$$256$$$258$$$O	methods$$$259$$$266$$$O	of$$$267$$$269$$$O	treating$$$270$$$278$$$O	diseases$$$279$$$287$$$O	and$$$288$$$291$$$O	conditions$$$292$$$302$$$O	that$$$303$$$307$$$O	are$$$308$$$311$$$O	beneficially$$$312$$$324$$$O	treated$$$325$$$332$$$O	by$$$333$$$335$$$O	administering$$$336$$$349$$$O	ALK$$$350$$$353$$$O	inhibitors.$$$354$$$365$$$O
CN101899013B
2-(2-substituted$$$0$$$16$$$I	aryl-2H-1,2,4-triazole-3-sulfydryl)$$$17$$$52$$$I	acetamide$$$53$$$62$$$I	derivative$$$63$$$73$$$O	and$$$74$$$77$$$O	preparation$$$78$$$89$$$O	method$$$90$$$96$$$O	and$$$97$$$100$$$O	application$$$101$$$112$$$O	thereof$$$113$$$120$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicines,$$$48$$$58$$$O	in$$$59$$$61$$$O	particular$$$62$$$72$$$O	to$$$73$$$75$$$O	a$$$76$$$77$$$O	2-(2-substituted$$$78$$$94$$$I	aryl-2H-1,2,4-triazole-3-sulfydryl)$$$95$$$130$$$I	acetamide$$$131$$$140$$$I	derivative$$$141$$$151$$$O	shown$$$152$$$157$$$O	in$$$158$$$160$$$O	a$$$161$$$162$$$O	general$$$163$$$170$$$O	formula$$$171$$$178$$$O	I,$$$179$$$181$$$O	an$$$182$$$184$$$O	N-oxide,$$$185$$$193$$$I	a$$$194$$$195$$$O	stereomeride$$$196$$$208$$$O	form$$$209$$$213$$$O	and$$$214$$$217$$$O	a$$$218$$$219$$$O	stereomeride$$$220$$$232$$$O	mixture$$$233$$$240$$$O	thereof,$$$241$$$249$$$O	pharmaceutically$$$250$$$266$$$O	acceptable$$$267$$$277$$$O	salt,$$$278$$$283$$$O	a$$$284$$$285$$$O	hydrate$$$286$$$293$$$I	and$$$294$$$297$$$O	a$$$298$$$299$$$O	solvate$$$300$$$307$$$O	thereof,$$$308$$$316$$$O	polycrystal$$$317$$$328$$$O	and$$$329$$$332$$$O	eutecticum$$$333$$$343$$$O	thereof,$$$344$$$352$$$O	a$$$353$$$354$$$O	precursor$$$355$$$364$$$O	with$$$365$$$369$$$O	the$$$370$$$373$$$O	same$$$374$$$378$$$O	biological$$$379$$$389$$$O	function$$$390$$$398$$$O	and$$$399$$$402$$$O	a$$$403$$$404$$$O	derivative$$$405$$$415$$$O	thereof,$$$416$$$424$$$O	a$$$425$$$426$$$O	preparation$$$427$$$438$$$O	method$$$439$$$445$$$O	thereof$$$446$$$453$$$O	and$$$454$$$457$$$O	the$$$458$$$461$$$O	application$$$462$$$473$$$O	of$$$474$$$476$$$O	a$$$477$$$478$$$O	composite$$$479$$$488$$$O	containing$$$489$$$499$$$O	one$$$500$$$503$$$O	or$$$504$$$506$$$O	more$$$507$$$511$$$O	than$$$512$$$516$$$O	one$$$517$$$520$$$O	such$$$521$$$525$$$O	compound$$$526$$$534$$$O	in$$$535$$$537$$$O	medicines$$$538$$$547$$$O	of$$$548$$$550$$$O	treating$$$551$$$559$$$O	and$$$560$$$563$$$O	preventing$$$564$$$574$$$O	human$$$575$$$580$$$O	immunodeficiency$$$581$$$597$$$O	virus$$$598$$$603$$$O	(HIV)$$$604$$$609$$$O	infection.$$$610$$$620$$$O
EP1292332B1
ADJUVANTS$$$0$$$9$$$O	AND$$$10$$$13$$$O	PROCESSES$$$14$$$23$$$O	TO$$$24$$$26$$$O	INDUCE$$$27$$$33$$$O	A$$$34$$$35$$$O	Th2$$$36$$$39$$$O	IMMUNE$$$40$$$46$$$O	RESPONSE$$$47$$$55$$$O
Porphyromanas$$$0$$$13$$$O	gingivalis$$$14$$$24$$$O	LPS$$$25$$$28$$$O	elicits$$$29$$$36$$$O	a$$$37$$$38$$$O	Th2$$$39$$$42$$$O	immune$$$43$$$49$$$O	response.$$$50$$$59$$$O	P.$$$60$$$62$$$O	gingivalis$$$63$$$73$$$O	LPS,$$$74$$$78$$$O	detoxified$$$79$$$89$$$O	P.$$$90$$$92$$$O	gingivalis$$$93$$$103$$$O	LPS,$$$104$$$108$$$O	derivatives$$$109$$$120$$$O	of$$$121$$$123$$$O	P.gingivalis$$$124$$$136$$$O	LPS,$$$137$$$141$$$O	derivatives$$$142$$$153$$$O	of$$$154$$$156$$$O	detoxified$$$157$$$167$$$O	P.$$$168$$$170$$$O	gingivalis$$$171$$$181$$$O	LPS,$$$182$$$186$$$O	P.$$$187$$$189$$$O	gingivalis$$$190$$$200$$$O	Lipid$$$201$$$206$$$O	A,$$$207$$$209$$$O	detoxified$$$210$$$220$$$O	P.$$$221$$$223$$$O	gingivalis$$$224$$$234$$$O	Lipid$$$235$$$240$$$O	A,$$$241$$$243$$$O	derivatives$$$244$$$255$$$O	of$$$256$$$258$$$O	P.$$$259$$$261$$$O	gingivalis$$$262$$$272$$$O	Lipid$$$273$$$278$$$O	A,$$$279$$$281$$$O	derivatives$$$282$$$293$$$O	of$$$294$$$296$$$O	detoxified$$$297$$$307$$$O	P.$$$308$$$310$$$O	gingivalis$$$311$$$321$$$O	Lipid$$$322$$$327$$$O	A,$$$328$$$330$$$O	or$$$331$$$333$$$O	mimetics$$$334$$$342$$$O	thereof,$$$343$$$351$$$O	can$$$352$$$355$$$O	be$$$356$$$358$$$O	used$$$359$$$363$$$O	as$$$364$$$366$$$O	adjuvants$$$367$$$376$$$O	to$$$377$$$379$$$O	elicit$$$380$$$386$$$O	a$$$387$$$388$$$O	Th2$$$389$$$392$$$O	immune$$$393$$$399$$$O	response,$$$400$$$409$$$O	increase$$$410$$$418$$$O	the$$$419$$$422$$$O	efficacy$$$423$$$431$$$O	of$$$432$$$434$$$O	vaccinations$$$435$$$447$$$O	in$$$448$$$450$$$O	infectious$$$451$$$461$$$O	diseases,$$$462$$$471$$$O	decrease$$$472$$$480$$$O	the$$$481$$$484$$$O	severity$$$485$$$493$$$O	of$$$494$$$496$$$O	autoimmune$$$497$$$507$$$O	responses,$$$508$$$518$$$O	boost$$$519$$$524$$$O	the$$$525$$$528$$$O	Th2$$$529$$$532$$$O	immune$$$533$$$539$$$O	response$$$540$$$548$$$O	when$$$549$$$553$$$O	needed$$$554$$$560$$$O	in$$$561$$$563$$$O	combination$$$564$$$575$$$O	with$$$576$$$580$$$O	the$$$581$$$584$$$O	Th1$$$585$$$588$$$O	immune$$$589$$$595$$$O	response,$$$596$$$605$$$O	facilitate$$$606$$$616$$$O	the$$$617$$$620$$$O	industrial$$$621$$$631$$$O	production$$$632$$$642$$$O	of$$$643$$$645$$$O	antibodies$$$646$$$656$$$O	when$$$657$$$661$$$O	used$$$662$$$666$$$O	in$$$667$$$669$$$O	animals,$$$670$$$678$$$O	and$$$679$$$682$$$O	study$$$683$$$688$$$O	the$$$689$$$692$$$O	Th2$$$693$$$696$$$O	immune$$$697$$$703$$$O	response$$$704$$$712$$$O	in$$$713$$$715$$$O	laboratory$$$716$$$726$$$O	research.$$$727$$$736$$$O
WO2013137844A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	isolating$$$11$$$20$$$O	flavonoid$$$21$$$30$$$I	dihydroquercetin$$$31$$$47$$$I	(taxifolin)$$$48$$$59$$$I	from$$$60$$$64$$$O	conifer$$$65$$$72$$$O	wood$$$73$$$77$$$O	species$$$78$$$85$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	isolating$$$13$$$22$$$O	flavonoid$$$23$$$32$$$I	Dihydroquercetin$$$33$$$49$$$I	(taxifolin)$$$50$$$61$$$I	from$$$62$$$66$$$O	wood$$$67$$$71$$$O	parts$$$72$$$77$$$O	including$$$78$$$87$$$O	lower$$$88$$$93$$$O	portions$$$94$$$102$$$O	of$$$103$$$105$$$O	the$$$106$$$109$$$O	trunk,$$$110$$$116$$$O	referred$$$117$$$125$$$O	to$$$126$$$128$$$O	as$$$129$$$131$$$O	butt$$$132$$$136$$$O	logs,$$$137$$$142$$$O	bark$$$143$$$147$$$O	and$$$148$$$151$$$O	roots.$$$152$$$158$$$O	The$$$159$$$162$$$O	method$$$163$$$169$$$O	includes$$$170$$$178$$$O	extracting$$$179$$$189$$$O	either$$$190$$$196$$$O	the$$$197$$$200$$$O	particle-reduced$$$201$$$217$$$O	chip$$$218$$$222$$$O	fraction$$$223$$$231$$$O	obtained$$$232$$$240$$$O	by$$$241$$$243$$$O	chipping$$$244$$$252$$$O	or$$$253$$$255$$$O	subdividing$$$256$$$267$$$O	into$$$268$$$272$$$O	chips$$$273$$$278$$$O	the$$$279$$$282$$$O	butt$$$283$$$287$$$O	logs$$$288$$$292$$$O	and$$$293$$$296$$$O	roots,$$$297$$$303$$$O	or$$$304$$$306$$$O	dry$$$307$$$310$$$O	cork$$$311$$$315$$$O	fraction$$$316$$$324$$$O	of$$$325$$$327$$$O	the$$$328$$$331$$$O	bark$$$332$$$336$$$O	or$$$337$$$339$$$O	powdered$$$340$$$348$$$O	bark$$$349$$$353$$$O	obtained$$$354$$$362$$$O	as$$$363$$$365$$$O	a$$$366$$$367$$$O	residue$$$368$$$375$$$O	in$$$376$$$378$$$O	finishing$$$379$$$388$$$O	of$$$389$$$391$$$O	mechanical$$$392$$$402$$$O	wood$$$403$$$407$$$O	products$$$408$$$416$$$O	with$$$417$$$421$$$O	a$$$422$$$423$$$O	polar$$$424$$$429$$$O	solvent.$$$430$$$438$$$O	The$$$439$$$442$$$O	method$$$443$$$449$$$O	further$$$450$$$457$$$O	includes$$$458$$$466$$$O	recovering$$$467$$$477$$$O	the$$$478$$$481$$$O	extract.$$$482$$$490$$$O	The$$$491$$$494$$$O	wood$$$495$$$499$$$O	used$$$500$$$504$$$O	in$$$505$$$507$$$O	the$$$508$$$511$$$O	method$$$512$$$518$$$O	is$$$519$$$521$$$O	a$$$522$$$523$$$O	hardwood$$$524$$$532$$$O	or$$$533$$$535$$$O	a$$$536$$$537$$$O	coniferous$$$538$$$548$$$O	wood$$$549$$$553$$$O	selected$$$554$$$562$$$O	from$$$563$$$567$$$O	wood$$$568$$$572$$$O	of$$$573$$$575$$$O	Larix$$$576$$$581$$$O	genus,$$$582$$$588$$$O	spruce$$$589$$$595$$$O	wood$$$596$$$600$$$O	of$$$601$$$603$$$O	the$$$604$$$607$$$O	genus$$$608$$$613$$$O	Picea,$$$614$$$620$$$O	fir$$$621$$$624$$$O	wood$$$625$$$629$$$O	of$$$630$$$632$$$O	the$$$633$$$636$$$O	genus$$$637$$$642$$$O	Abies,$$$643$$$649$$$O	pine$$$650$$$654$$$O	wood$$$655$$$659$$$O	of$$$660$$$662$$$O	the$$$663$$$666$$$O	genus$$$667$$$672$$$O	Pinus,$$$673$$$679$$$O	and$$$680$$$683$$$O	wood$$$684$$$688$$$O	of$$$689$$$691$$$O	Pseudotsuga$$$692$$$703$$$O	genus.$$$704$$$710$$$O	The$$$711$$$714$$$O	isolated$$$715$$$723$$$O	prime$$$724$$$729$$$O	substance$$$730$$$739$$$O	from$$$740$$$744$$$O	all$$$745$$$748$$$O	of$$$749$$$751$$$O	the$$$752$$$755$$$O	above$$$756$$$761$$$O	genus$$$762$$$767$$$O	is$$$768$$$770$$$O	a$$$771$$$772$$$O	flavonoid$$$773$$$782$$$I	such$$$783$$$787$$$O	as$$$788$$$790$$$O	Dihydroquercetin$$$791$$$807$$$I	(taxifolin).$$$808$$$820$$$I
EP2343074A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	purine$$$7$$$13$$$I	analogues$$$14$$$23$$$O	for$$$24$$$27$$$O	treating$$$28$$$36$$$O	airway$$$37$$$43$$$O	diseases$$$44$$$52$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	treatment$$$37$$$46$$$O	and$$$47$$$50$$$O	prophylaxis$$$51$$$62$$$O	of$$$63$$$65$$$O	asthma$$$66$$$72$$$O	and$$$73$$$76$$$O	other$$$77$$$82$$$O	airway$$$83$$$89$$$O	dysfunctions,$$$90$$$103$$$O	diseases$$$104$$$112$$$O	and/or$$$113$$$119$$$O	symptoms$$$120$$$128$$$O	thereof,$$$129$$$137$$$O	more$$$138$$$142$$$O	particularly$$$143$$$155$$$O	the$$$156$$$159$$$O	present$$$160$$$167$$$O	invention$$$168$$$177$$$O	relates$$$178$$$185$$$O	to$$$186$$$188$$$O	the$$$189$$$192$$$O	use$$$193$$$196$$$O	of$$$197$$$199$$$O	cytostatic$$$200$$$210$$$O	and/or$$$211$$$217$$$O	cytotoxic$$$218$$$227$$$O	purine$$$228$$$234$$$I	analogues$$$235$$$244$$$O	for$$$245$$$248$$$O	such$$$249$$$253$$$O	treatment$$$254$$$263$$$O	and$$$264$$$267$$$O	prophylaxis.$$$268$$$280$$$O
WO2006053379A1
Improved$$$0$$$8$$$O	nutraceutical$$$9$$$22$$$O	composition$$$23$$$34$$$O
A$$$0$$$1$$$O	nutraceutical$$$2$$$15$$$O	composition$$$16$$$27$$$O	including$$$28$$$37$$$O	one$$$38$$$41$$$O	or$$$42$$$44$$$O	more$$$45$$$49$$$O	extracts$$$50$$$58$$$O	of$$$59$$$61$$$O	one$$$62$$$65$$$O	or$$$66$$$68$$$O	more$$$69$$$73$$$O	plant$$$74$$$79$$$O	components,$$$80$$$91$$$O	the$$$92$$$95$$$O	one$$$96$$$99$$$O	or$$$100$$$102$$$O	more$$$103$$$107$$$O	extracts$$$108$$$116$$$O	providing$$$117$$$126$$$O	a$$$127$$$128$$$O	combination$$$129$$$140$$$O	of$$$141$$$143$$$O	phytonutrient$$$144$$$157$$$O	materials,$$$158$$$168$$$O	the$$$169$$$172$$$O	type$$$173$$$177$$$O	and$$$178$$$181$$$O	amount$$$182$$$188$$$O	of$$$189$$$191$$$O	which$$$192$$$197$$$O	are$$$198$$$201$$$O	in$$$202$$$204$$$O	excess$$$205$$$211$$$O	of$$$212$$$214$$$O	a$$$215$$$216$$$O	minimum$$$217$$$224$$$O	value$$$225$$$230$$$O	predetermined$$$231$$$244$$$O	to$$$245$$$247$$$O	provide$$$248$$$255$$$O	a$$$256$$$257$$$O	therapeutically$$$258$$$273$$$O	or$$$274$$$276$$$O	prophylactically$$$277$$$293$$$O	desirable$$$294$$$303$$$O	effect.$$$304$$$311$$$O
WO2008124931A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	cyclohexanehexol$$$7$$$23$$$I	derivatives$$$24$$$35$$$O	in$$$36$$$38$$$O	the$$$39$$$42$$$O	treatment$$$43$$$52$$$O	of$$$53$$$55$$$O	amyotrophic$$$56$$$67$$$O	lateral$$$68$$$75$$$O	sclerosis$$$76$$$85$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	methods$$$33$$$40$$$O	for$$$41$$$44$$$O	modulating,$$$45$$$56$$$O	disrupting$$$57$$$67$$$O	or$$$68$$$70$$$O	enhancing$$$71$$$80$$$O	the$$$81$$$84$$$O	clearance$$$85$$$94$$$O	of$$$95$$$97$$$O	copper/zinc$$$98$$$109$$$I	superoxide$$$110$$$120$$$I	dismutase$$$121$$$130$$$O	1(SOD1)$$$131$$$138$$$O	aggregates$$$139$$$149$$$O	in$$$150$$$152$$$O	astrocytes$$$153$$$163$$$O	or$$$164$$$166$$$O	motor$$$167$$$172$$$O	neurons$$$173$$$180$$$O	in$$$181$$$183$$$O	a$$$184$$$185$$$O	subject,$$$186$$$194$$$O	by$$$195$$$197$$$O	administering$$$198$$$211$$$O	a$$$212$$$213$$$O	medicament$$$214$$$224$$$O	comprising$$$225$$$235$$$O	a$$$236$$$237$$$O	therapeutically$$$238$$$253$$$O	effective$$$254$$$263$$$O	amount$$$264$$$270$$$O	of$$$271$$$273$$$O	a$$$274$$$275$$$O	cyclohexanehexol$$$276$$$292$$$I	derivative.$$$293$$$304$$$O	In$$$305$$$307$$$O	another$$$308$$$315$$$O	aspect,$$$316$$$323$$$O	the$$$324$$$327$$$O	invention$$$328$$$337$$$O	provides$$$338$$$346$$$O	a$$$347$$$348$$$O	medicament$$$349$$$359$$$O	comprising$$$360$$$370$$$O	at$$$371$$$373$$$O	least$$$374$$$379$$$O	one$$$380$$$383$$$O	cyclohexanehexol$$$384$$$400$$$I	derivative$$$401$$$411$$$O	of$$$412$$$414$$$O	formula$$$415$$$422$$$O	III$$$423$$$426$$$O	or$$$427$$$429$$$O	IV$$$430$$$432$$$O	useful$$$433$$$439$$$O	in$$$440$$$442$$$O	preventing$$$443$$$453$$$O	or$$$454$$$456$$$O	treating$$$457$$$465$$$O	amyothropic$$$466$$$477$$$O	lateral$$$478$$$485$$$O	sclerosis$$$486$$$495$$$O	(ALS),$$$496$$$502$$$O	improving$$$503$$$512$$$O	motor$$$513$$$518$$$O	neuron$$$519$$$525$$$O	function$$$526$$$534$$$O	and$$$535$$$538$$$O	slowing$$$539$$$546$$$O	the$$$547$$$550$$$O	degeneration$$$551$$$563$$$O	or$$$564$$$566$$$O	death$$$567$$$572$$$O	of$$$573$$$575$$$O	motor$$$576$$$581$$$O	neurons$$$582$$$589$$$O	in$$$590$$$592$$$O	brain$$$593$$$598$$$O	stem,$$$599$$$604$$$O	spinal$$$605$$$611$$$O	cord$$$612$$$616$$$O	or$$$617$$$619$$$O	motor$$$620$$$625$$$O	cortex.$$$626$$$633$$$O	These$$$634$$$639$$$O	medicaments$$$640$$$651$$$O	may$$$652$$$655$$$O	be$$$656$$$658$$$O	administered$$$659$$$671$$$O	orally,$$$672$$$679$$$O	intravenously,$$$680$$$694$$$O	intraperitoneal,$$$695$$$711$$$O	subcutaneous,$$$712$$$725$$$O	intramuscular,$$$726$$$740$$$O	intranasal$$$741$$$751$$$O	or$$$752$$$754$$$O	transdermal.$$$755$$$767$$$O
CN102078319A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	dehydrocorydaline$$$15$$$32$$$I	and$$$33$$$36$$$O	scoulerine$$$37$$$47$$$I	to$$$48$$$50$$$O	medicament$$$51$$$61$$$O	production$$$62$$$72$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	dehydrocorydaline$$$39$$$56$$$I	and$$$57$$$60$$$O	scoulerine$$$61$$$71$$$I	to$$$72$$$74$$$O	medicament$$$75$$$85$$$O	production.$$$86$$$97$$$O	In$$$98$$$100$$$O	the$$$101$$$104$$$O	invention,$$$105$$$115$$$O	a$$$116$$$117$$$O	diagnostic$$$118$$$128$$$O	kit$$$129$$$132$$$O	for$$$133$$$136$$$O	hepatitis$$$137$$$146$$$O	B$$$147$$$148$$$O	virus$$$149$$$154$$$O	surface$$$155$$$162$$$O	antigen$$$163$$$170$$$O	and$$$171$$$174$$$O	a$$$175$$$176$$$O	diagnostic$$$177$$$187$$$O	kit$$$188$$$191$$$O	for$$$192$$$195$$$O	hepatitis$$$196$$$205$$$O	B$$$206$$$207$$$O	virus$$$208$$$213$$$O	e$$$214$$$215$$$O	antigen$$$216$$$223$$$O	are$$$224$$$227$$$O	adopted$$$228$$$235$$$O	to$$$236$$$238$$$O	perform$$$239$$$246$$$O	tests$$$247$$$252$$$O	of$$$253$$$255$$$O	resisting$$$256$$$265$$$O	hepatitis$$$266$$$275$$$O	B$$$276$$$277$$$O	surface$$$278$$$285$$$O	antigen$$$286$$$293$$$O	and$$$294$$$297$$$O	hepatitis$$$298$$$307$$$O	B$$$308$$$309$$$O	e$$$310$$$311$$$O	antigen$$$312$$$319$$$O	on$$$320$$$322$$$O	protoberberine$$$323$$$337$$$I	alkaloids$$$338$$$347$$$I	scoulerine$$$348$$$358$$$I	and$$$359$$$362$$$O	dehydrocorydaline$$$363$$$380$$$I	respectively.$$$381$$$394$$$O	Results$$$395$$$402$$$O	prove$$$403$$$408$$$O	that$$$409$$$413$$$O	the$$$414$$$417$$$O	dehydrocorydaline$$$418$$$435$$$I	and$$$436$$$439$$$O	the$$$440$$$443$$$O	scoulerine$$$444$$$454$$$I	have$$$455$$$459$$$O	remarkable$$$460$$$470$$$O	hepatitis$$$471$$$480$$$O	B$$$481$$$482$$$O	virus$$$483$$$488$$$O	resisting$$$489$$$498$$$O	activity,$$$499$$$508$$$O	and$$$509$$$512$$$O	can$$$513$$$516$$$O	be$$$517$$$519$$$O	used$$$520$$$524$$$O	for$$$525$$$528$$$O	preparing$$$529$$$538$$$O	hepatitis$$$539$$$548$$$O	B$$$549$$$550$$$O	virus$$$551$$$556$$$O	resistant$$$557$$$566$$$O	medicament.$$$567$$$578$$$O
CN101352504B
Bedsore$$$0$$$7$$$O	plaster$$$8$$$15$$$O	and$$$16$$$19$$$O	method$$$20$$$26$$$O	for$$$27$$$30$$$O	producing$$$31$$$40$$$O	the$$$41$$$44$$$O	same$$$45$$$49$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	bedsore$$$26$$$33$$$O	plaster$$$34$$$41$$$O	which$$$42$$$47$$$O	is$$$48$$$50$$$O	prepared$$$51$$$59$$$O	from$$$60$$$64$$$O	the$$$65$$$68$$$O	following$$$69$$$78$$$O	bulk$$$79$$$83$$$O	drugs$$$84$$$89$$$O	in$$$90$$$92$$$O	part$$$93$$$97$$$O	by$$$98$$$100$$$O	weight:$$$101$$$108$$$O	5$$$109$$$110$$$O	to$$$111$$$113$$$O	15$$$114$$$116$$$O	parts$$$117$$$122$$$O	of$$$123$$$125$$$O	dried$$$126$$$131$$$O	rehmannia$$$132$$$141$$$O	root,$$$142$$$147$$$O	5$$$148$$$149$$$O	to$$$150$$$152$$$O	15$$$153$$$155$$$O	parts$$$156$$$161$$$O	of$$$162$$$164$$$O	achyranthes$$$165$$$176$$$O	root,$$$177$$$182$$$O	10$$$183$$$185$$$O	to$$$186$$$188$$$O	20$$$189$$$191$$$O	parts$$$192$$$197$$$O	of$$$198$$$200$$$O	angelica,$$$201$$$210$$$O	5$$$211$$$212$$$O	to$$$213$$$215$$$O	20$$$216$$$218$$$O	parts$$$219$$$224$$$O	of$$$225$$$227$$$O	corydalis$$$228$$$237$$$O	tuber,$$$238$$$244$$$O	5$$$245$$$246$$$O	to$$$247$$$249$$$O	15$$$250$$$252$$$O	parts$$$253$$$258$$$O	of$$$259$$$261$$$O	frankincense,$$$262$$$275$$$O	2$$$276$$$277$$$O	to$$$278$$$280$$$O	10$$$281$$$283$$$O	parts$$$284$$$289$$$O	of$$$290$$$292$$$O	safflower,$$$293$$$303$$$O	5$$$304$$$305$$$O	to$$$306$$$308$$$O	20$$$309$$$311$$$O	parts$$$312$$$317$$$O	of$$$318$$$320$$$O	scutellaria$$$321$$$332$$$O	root,$$$333$$$338$$$O	5$$$339$$$340$$$O	to$$$341$$$343$$$O	20$$$344$$$346$$$O	parts$$$347$$$352$$$O	of$$$353$$$355$$$O	corktree$$$356$$$364$$$O	bark,$$$365$$$370$$$O	5$$$371$$$372$$$O	to$$$373$$$375$$$O	20$$$376$$$378$$$O	parts$$$379$$$384$$$O	of$$$385$$$387$$$O	atractylodes$$$388$$$400$$$O	rhizome,$$$401$$$409$$$O	1$$$410$$$411$$$O	to$$$412$$$414$$$O	5$$$415$$$416$$$O	parts$$$417$$$422$$$O	of$$$423$$$425$$$O	dragons$$$426$$$433$$$O	blood,$$$434$$$440$$$O	0.5$$$441$$$444$$$O	to$$$445$$$447$$$O	5$$$448$$$449$$$O	parts$$$450$$$455$$$O	of$$$456$$$458$$$O	borneol,$$$459$$$467$$$O	1$$$468$$$469$$$O	to$$$470$$$472$$$O	15$$$473$$$475$$$O	parts$$$476$$$481$$$O	of$$$482$$$484$$$O	notoginseng,$$$485$$$497$$$O	0.1$$$498$$$501$$$O	to$$$502$$$504$$$O	2$$$505$$$506$$$O	parts$$$507$$$512$$$O	of$$$513$$$515$$$O	Qingfen,$$$516$$$524$$$O	100$$$525$$$528$$$O	to$$$529$$$531$$$O	150$$$532$$$535$$$O	parts$$$536$$$541$$$O	of$$$542$$$544$$$O	beeswax,$$$545$$$553$$$O	and$$$554$$$557$$$O	800$$$558$$$561$$$O	to$$$562$$$564$$$O	1500$$$565$$$569$$$O	parts$$$570$$$575$$$O	of$$$576$$$578$$$O	sesame$$$579$$$585$$$O	oil.$$$586$$$590$$$O	The$$$591$$$594$$$O	production$$$595$$$605$$$O	method$$$606$$$612$$$O	of$$$613$$$615$$$O	the$$$616$$$619$$$O	bedsore$$$620$$$627$$$O	plaster$$$628$$$635$$$O	comprises$$$636$$$645$$$O	the$$$646$$$649$$$O	steps:$$$650$$$656$$$O	materials$$$657$$$666$$$O	are$$$667$$$670$$$O	selected,$$$671$$$680$$$O	purified$$$681$$$689$$$O	and$$$690$$$693$$$O	processed,$$$694$$$704$$$O	and$$$705$$$708$$$O	the$$$709$$$712$$$O	sesame$$$713$$$719$$$O	oil$$$720$$$723$$$O	is$$$724$$$726$$$O	heated$$$727$$$733$$$O	for$$$734$$$737$$$O	20$$$738$$$740$$$O	to$$$741$$$743$$$O	30$$$744$$$746$$$O	minutes;$$$747$$$755$$$O	the$$$756$$$759$$$O	dried$$$760$$$765$$$O	rehmannia$$$766$$$775$$$O	root,$$$776$$$781$$$O	the$$$782$$$785$$$O	achyranthes$$$786$$$797$$$O	root,$$$798$$$803$$$O	the$$$804$$$807$$$O	angelica,$$$808$$$817$$$O	the$$$818$$$821$$$O	corydalis$$$822$$$831$$$O	tuber,$$$832$$$838$$$O	the$$$839$$$842$$$O	frankincense,$$$843$$$856$$$O	the$$$857$$$860$$$O	safflower,$$$861$$$871$$$O	the$$$872$$$875$$$O	scutellaria$$$876$$$887$$$O	root,$$$888$$$893$$$O	the$$$894$$$897$$$O	corktree$$$898$$$906$$$O	bark$$$907$$$911$$$O	and$$$912$$$915$$$O	the$$$916$$$919$$$O	atractylodes$$$920$$$932$$$O	rhizome$$$933$$$940$$$O	are$$$941$$$944$$$O	put$$$945$$$948$$$O	into$$$949$$$953$$$O	a$$$954$$$955$$$O	container$$$956$$$965$$$O	and$$$966$$$969$$$O	heated$$$970$$$976$$$O	for$$$977$$$980$$$O	20$$$981$$$983$$$O	to$$$984$$$986$$$O	30$$$987$$$989$$$O	minutes,$$$990$$$998$$$O	purified$$$999$$$1007$$$O	and$$$1008$$$1011$$$O	filtered$$$1012$$$1020$$$O	to$$$1021$$$1023$$$O	obtain$$$1024$$$1030$$$O	filtrate;$$$1031$$$1040$$$O	the$$$1041$$$1044$$$O	beeswax$$$1045$$$1052$$$O	and$$$1053$$$1056$$$O	the$$$1057$$$1060$$$O	notoginseng$$$1061$$$1072$$$O	powder$$$1073$$$1079$$$O	are$$$1080$$$1083$$$O	added$$$1084$$$1089$$$O	into$$$1090$$$1094$$$O	the$$$1095$$$1098$$$O	filtrate$$$1099$$$1107$$$O	when$$$1108$$$1112$$$O	the$$$1113$$$1116$$$O	filtrate$$$1117$$$1125$$$O	is$$$1126$$$1128$$$O	cooled$$$1129$$$1135$$$O	down$$$1136$$$1140$$$O	to$$$1141$$$1143$$$O	a$$$1144$$$1145$$$O	temperature$$$1146$$$1157$$$O	ranging$$$1158$$$1165$$$O	from$$$1166$$$1170$$$O	120$$$1171$$$1174$$$O	to$$$1175$$$1177$$$O	180$$$1178$$$1181$$$O	DEG$$$1182$$$1185$$$O	C;$$$1186$$$1188$$$O	the$$$1189$$$1192$$$O	borneol,$$$1193$$$1201$$$I	the$$$1202$$$1205$$$O	dragons$$$1206$$$1213$$$O	blood$$$1214$$$1219$$$O	and$$$1220$$$1223$$$O	Qingfen$$$1224$$$1231$$$O	are$$$1232$$$1235$$$O	added$$$1236$$$1241$$$O	to$$$1242$$$1244$$$O	the$$$1245$$$1248$$$O	filtrate$$$1249$$$1257$$$O	when$$$1258$$$1262$$$O	the$$$1263$$$1266$$$O	temperature$$$1267$$$1278$$$O	of$$$1279$$$1281$$$O	the$$$1282$$$1285$$$O	filtrate$$$1286$$$1294$$$O	drops$$$1295$$$1300$$$O	to$$$1301$$$1303$$$O	70$$$1304$$$1306$$$O	to$$$1307$$$1309$$$O	90$$$1310$$$1312$$$O	DEG$$$1313$$$1316$$$O	C;$$$1317$$$1319$$$O	after$$$1320$$$1325$$$O	materials$$$1326$$$1335$$$O	are$$$1336$$$1339$$$O	dissolved,$$$1340$$$1350$$$O	the$$$1351$$$1354$$$O	solution$$$1355$$$1363$$$O	is$$$1364$$$1366$$$O	hermetically$$$1367$$$1379$$$O	sealed,$$$1380$$$1387$$$O	cooled$$$1388$$$1394$$$O	and$$$1395$$$1398$$$O	caned$$$1399$$$1404$$$O	to$$$1405$$$1407$$$O	obtain$$$1408$$$1414$$$O	the$$$1415$$$1418$$$O	bedsore$$$1419$$$1426$$$O	plaster$$$1427$$$1434$$$O	of$$$1435$$$1437$$$O	the$$$1438$$$1441$$$O	invention.$$$1442$$$1452$$$O	The$$$1453$$$1456$$$O	bedsore$$$1457$$$1464$$$O	paste$$$1465$$$1470$$$O	has$$$1471$$$1474$$$O	the$$$1475$$$1478$$$O	advantage$$$1479$$$1488$$$O	of$$$1489$$$1491$$$O	good$$$1492$$$1496$$$O	curative$$$1497$$$1505$$$O	effect,$$$1506$$$1513$$$O	the$$$1514$$$1517$$$O	effective$$$1518$$$1527$$$O	rate$$$1528$$$1532$$$O	is$$$1533$$$1535$$$O	up$$$1536$$$1538$$$O	to$$$1539$$$1541$$$O	96$$$1542$$$1544$$$O	percent$$$1545$$$1552$$$O	and$$$1553$$$1556$$$O	the$$$1557$$$1560$$$O	curative$$$1561$$$1569$$$O	ratio$$$1570$$$1575$$$O	is$$$1576$$$1578$$$O	up$$$1579$$$1581$$$O	to$$$1582$$$1584$$$O	98$$$1585$$$1587$$$O	percent.$$$1588$$$1596$$$O
US20070117842
Polymorph$$$0$$$9$$$O	of$$$10$$$12$$$O	4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-$$$13$$$79$$$I	quinolinecarboxamide$$$80$$$100$$$I	and$$$101$$$104$$$O	a$$$105$$$106$$$O	process$$$107$$$114$$$O	for$$$115$$$118$$$O	the$$$119$$$122$$$O	preparation$$$123$$$134$$$O	of$$$135$$$137$$$O	the$$$138$$$141$$$O	same$$$142$$$146$$$O
A$$$0$$$1$$$O	polymorph$$$2$$$11$$$O	(A)$$$12$$$15$$$O	of$$$16$$$18$$$O	4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,$$$19$$$106$$$I	having$$$107$$$113$$$O	a$$$114$$$115$$$O	diffraction$$$116$$$127$$$O	peak$$$128$$$132$$$O	at$$$133$$$135$$$O	a$$$136$$$137$$$O	diffraction$$$138$$$149$$$O	angle$$$150$$$155$$$O	(2Î¸Â±0.2Â°)$$$156$$$168$$$O	of$$$169$$$171$$$O	15.75Â°$$$172$$$179$$$O	in$$$180$$$182$$$O	a$$$183$$$184$$$O	powder$$$185$$$191$$$O	X-ray$$$192$$$197$$$O	diffraction;$$$198$$$210$$$O	and$$$211$$$214$$$O	a$$$215$$$216$$$O	polymorph$$$217$$$226$$$O	(B)$$$227$$$230$$$I	of$$$231$$$233$$$I	4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide,$$$234$$$321$$$I	having$$$322$$$328$$$O	a$$$329$$$330$$$O	diffraction$$$331$$$342$$$O	peak$$$343$$$347$$$O	at$$$348$$$350$$$O	a$$$351$$$352$$$O	diffraction$$$353$$$364$$$O	angle$$$365$$$370$$$O	(2Î¸Â±0.2Â°)$$$371$$$383$$$O	of$$$384$$$386$$$O	21.75Â°$$$387$$$394$$$O	in$$$395$$$397$$$O	a$$$398$$$399$$$O	powder$$$400$$$406$$$O	X-ray$$$407$$$412$$$O	diffraction.$$$413$$$425$$$O
US8338641
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	treating$$$11$$$19$$$O	atypical$$$20$$$28$$$O	facial$$$29$$$35$$$O	pain$$$36$$$40$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	the$$$37$$$40$$$O	use$$$41$$$44$$$O	of$$$45$$$47$$$O	a$$$48$$$49$$$O	class$$$50$$$55$$$O	of$$$56$$$58$$$O	peptide$$$59$$$66$$$O	compounds$$$67$$$76$$$O	for$$$77$$$80$$$O	treating$$$81$$$89$$$O	pain$$$90$$$94$$$O	in$$$95$$$97$$$O	trigeminal$$$98$$$108$$$O	neuralgia.$$$109$$$119$$$O
US20090110749
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	apparatus$$$11$$$20$$$O	for$$$21$$$24$$$O	producing$$$25$$$34$$$O	a$$$35$$$36$$$O	stabilized$$$37$$$47$$$O	antimicrobial$$$48$$$61$$$O	non-toxic$$$62$$$71$$$O	electrolyzed$$$72$$$84$$$O	saline$$$85$$$91$$$O	solution$$$92$$$100$$$O	exhibiting$$$101$$$111$$$O	potential$$$112$$$121$$$O	as$$$122$$$124$$$O	a$$$125$$$126$$$O	therapeutic$$$127$$$138$$$O
An$$$0$$$2$$$O	improved$$$3$$$11$$$O	method$$$12$$$18$$$O	and$$$19$$$22$$$O	apparatus$$$23$$$32$$$O	is$$$33$$$35$$$O	disclosed$$$36$$$45$$$O	for$$$46$$$49$$$O	producing$$$50$$$59$$$O	a$$$60$$$61$$$O	stable,$$$62$$$69$$$O	non-toxic,$$$70$$$80$$$O	antimicrobial$$$81$$$94$$$O	electrolyzed$$$95$$$107$$$O	saline$$$108$$$114$$$O	solution$$$115$$$123$$$O	with$$$124$$$128$$$O	a$$$129$$$130$$$O	broad$$$131$$$136$$$O	range$$$137$$$142$$$O	of$$$143$$$145$$$O	anti-infective$$$146$$$160$$$O	and$$$161$$$164$$$O	therapeutic$$$165$$$176$$$O	applications.$$$177$$$190$$$O	The$$$191$$$194$$$O	resulting$$$195$$$204$$$O	solution$$$205$$$213$$$O	is$$$214$$$216$$$O	balanced$$$217$$$225$$$O	to$$$226$$$228$$$O	normal$$$229$$$235$$$O	and$$$236$$$239$$$O	hypertonic$$$240$$$250$$$O	saline$$$251$$$257$$$O	and$$$258$$$261$$$O	has$$$262$$$265$$$O	been$$$266$$$270$$$O	shown$$$271$$$276$$$O	to$$$277$$$279$$$O	exhibit$$$280$$$287$$$O	remarkable$$$288$$$298$$$O	antimicrobial,$$$299$$$313$$$O	antiviral$$$314$$$323$$$O	and$$$324$$$327$$$O	therapeutic$$$328$$$339$$$O	characteristics.$$$340$$$356$$$O	The$$$357$$$360$$$O	nature$$$361$$$367$$$O	of$$$368$$$370$$$O	this$$$371$$$375$$$O	solution$$$376$$$384$$$O	makes$$$385$$$390$$$O	it$$$391$$$393$$$O	suitable$$$394$$$402$$$O	for$$$403$$$406$$$O	applications$$$407$$$419$$$O	in$$$420$$$422$$$O	food$$$423$$$427$$$O	safety,$$$428$$$435$$$O	animal$$$436$$$442$$$O	health,$$$443$$$450$$$O	agriculture$$$451$$$462$$$O	and$$$463$$$466$$$O	sterilization.$$$467$$$481$$$O	The$$$482$$$485$$$O	solution$$$486$$$494$$$O	also$$$495$$$499$$$O	exhibits$$$500$$$508$$$O	a$$$509$$$510$$$O	marked$$$511$$$517$$$O	lack$$$518$$$522$$$O	of$$$523$$$525$$$O	toxicity$$$526$$$534$$$O	upon$$$535$$$539$$$O	intravenous,$$$540$$$552$$$O	aspired,$$$553$$$561$$$O	oral$$$562$$$566$$$O	or$$$567$$$569$$$O	topical$$$570$$$577$$$O	application$$$578$$$589$$$O	in$$$590$$$592$$$O	mammals.$$$593$$$601$$$O	The$$$602$$$605$$$O	therapeutic$$$606$$$617$$$O	applications$$$618$$$630$$$O	represent$$$631$$$640$$$O	a$$$641$$$642$$$O	broad$$$643$$$648$$$O	platform,$$$649$$$658$$$O	possibly$$$659$$$667$$$O	covering$$$668$$$676$$$O	a$$$677$$$678$$$O	variety$$$679$$$686$$$O	of$$$687$$$689$$$O	potential$$$690$$$699$$$O	areas$$$700$$$705$$$O	of$$$706$$$708$$$O	use,$$$709$$$713$$$O	including$$$714$$$723$$$O	topical$$$724$$$731$$$O	disinfection,$$$732$$$745$$$O	antimicrobial$$$746$$$759$$$O	application,$$$760$$$772$$$O	wound$$$773$$$778$$$O	treatment,$$$779$$$789$$$O	oxidative$$$790$$$799$$$O	stress$$$800$$$806$$$O	reduction$$$807$$$816$$$O	and$$$817$$$820$$$O	enhancement$$$821$$$832$$$O	of$$$833$$$835$$$O	immune$$$836$$$842$$$O	function$$$843$$$851$$$O	to$$$852$$$854$$$O	better$$$855$$$861$$$O	detect$$$862$$$868$$$O	malfunctioning$$$869$$$883$$$O	cells.$$$884$$$890$$$O
US20090042988
Pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	containing$$$28$$$38$$$O	a$$$39$$$40$$$O	meglitinide$$$41$$$52$$$I	compound$$$53$$$61$$$O	for$$$62$$$65$$$O	preventing$$$66$$$76$$$O	hepatic$$$77$$$84$$$O	fibrosis$$$85$$$93$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	pharmaceutical$$$32$$$46$$$O	compositions$$$47$$$59$$$O	for$$$60$$$63$$$O	preventing,$$$64$$$75$$$O	improving$$$76$$$85$$$O	or$$$86$$$88$$$O	treating$$$89$$$97$$$O	hepatic$$$98$$$105$$$O	fibrosis,$$$106$$$115$$$O	hepatocellular$$$116$$$130$$$O	degeneration$$$131$$$143$$$O	or$$$144$$$146$$$O	cirrhosis,$$$147$$$157$$$O	which$$$158$$$163$$$O	contain$$$164$$$171$$$O	a$$$172$$$173$$$O	meglitinide$$$174$$$185$$$I	compound$$$186$$$194$$$O	such$$$195$$$199$$$O	as$$$200$$$202$$$O	nateglinide.$$$203$$$215$$$I
US20080057098
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	Bcl$$$7$$$10$$$O	inhibitors$$$11$$$21$$$O	For$$$22$$$25$$$O	The$$$26$$$29$$$O	Prevention$$$30$$$40$$$O	Of$$$41$$$43$$$O	Fibroproliferative$$$44$$$62$$$O	Reclosure$$$63$$$72$$$O	Of$$$73$$$75$$$O	Dilated$$$76$$$83$$$O	Blood$$$84$$$89$$$O	Vessels$$$90$$$97$$$O	And$$$98$$$101$$$O	Other$$$102$$$107$$$O	Iatrogenic$$$108$$$118$$$O	Fibroproliferative$$$119$$$137$$$O	Disorders$$$138$$$147$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	new$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	inhibitors$$$44$$$54$$$O	of$$$55$$$57$$$O	bcl-2/bcl-XI$$$58$$$70$$$O	family$$$71$$$77$$$O	of$$$78$$$80$$$O	anti-apoptotic$$$81$$$95$$$O	compounds$$$96$$$105$$$O	for$$$106$$$109$$$O	the$$$110$$$113$$$O	treatment$$$114$$$123$$$O	of$$$124$$$126$$$O	post-angioplasty$$$127$$$143$$$O	restenosis$$$144$$$154$$$O	and$$$155$$$158$$$O	in-stent$$$159$$$167$$$O	restenosis.$$$168$$$179$$$O	Small$$$180$$$185$$$O	molecules$$$186$$$195$$$O	of$$$196$$$198$$$O	Bcl$$$199$$$202$$$O	inhibitors$$$203$$$213$$$O	are$$$214$$$217$$$O	incorporated$$$218$$$230$$$O	into$$$231$$$235$$$O	a$$$236$$$237$$$O	stent,$$$238$$$244$$$O	typically$$$245$$$254$$$O	by$$$255$$$257$$$O	a$$$258$$$259$$$O	fine$$$260$$$264$$$O	polymeric$$$265$$$274$$$O	coating$$$275$$$282$$$O	over$$$283$$$287$$$O	the$$$288$$$291$$$O	metal,$$$292$$$298$$$O	which$$$299$$$304$$$O	would$$$305$$$310$$$O	be$$$311$$$313$$$O	placed$$$314$$$320$$$O	during$$$321$$$327$$$O	angioplasty$$$328$$$339$$$O	of$$$340$$$342$$$O	occluded$$$343$$$351$$$O	blood$$$352$$$357$$$O	vessels,$$$358$$$366$$$O	to$$$367$$$369$$$O	act$$$370$$$373$$$O	on$$$374$$$376$$$O	fibroproliferative$$$377$$$395$$$O	in-growth.$$$396$$$406$$$O	Hollow$$$407$$$413$$$O	organs$$$414$$$420$$$O	such$$$421$$$425$$$O	as$$$426$$$428$$$O	urethras,$$$429$$$438$$$O	Fallopian$$$439$$$448$$$O	tubes$$$449$$$454$$$O	and$$$455$$$458$$$O	vascular$$$459$$$467$$$O	access$$$468$$$474$$$O	grafts$$$475$$$481$$$O	could$$$482$$$487$$$O	be$$$488$$$490$$$O	treated$$$491$$$498$$$O	in$$$499$$$501$$$O	a$$$502$$$503$$$O	similar$$$504$$$511$$$O	manner$$$512$$$518$$$O	to$$$519$$$521$$$O	prevent$$$522$$$529$$$O	their$$$530$$$535$$$O	closure$$$536$$$543$$$O	due$$$544$$$547$$$O	to$$$548$$$550$$$O	fibrosis.$$$551$$$560$$$O	Other$$$561$$$566$$$O	iatrogenic$$$567$$$577$$$O	fibrosis$$$578$$$586$$$O	such$$$587$$$591$$$O	as$$$592$$$594$$$O	adhesions$$$595$$$604$$$O	after$$$605$$$610$$$O	surgery$$$611$$$618$$$O	could$$$619$$$624$$$O	also$$$625$$$629$$$O	be$$$630$$$632$$$O	blocked$$$633$$$640$$$O	by$$$641$$$643$$$O	this$$$644$$$648$$$O	therapy.$$$649$$$657$$$O
EP2407164A1
Copper$$$0$$$6$$$I	II$$$7$$$9$$$I	complexes$$$10$$$19$$$O	of$$$20$$$22$$$O	phenanthroline$$$23$$$37$$$I	and$$$38$$$41$$$O	their$$$42$$$47$$$O	use$$$48$$$51$$$O	in$$$52$$$54$$$O	cancer$$$55$$$61$$$O	treatment$$$62$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	CuII$$$27$$$31$$$I	complex$$$32$$$39$$$O	in$$$40$$$42$$$O	which$$$43$$$48$$$O	the$$$49$$$52$$$O	copper$$$53$$$59$$$I	ion$$$60$$$63$$$O	is$$$64$$$66$$$O	coordinated$$$67$$$78$$$O	to$$$79$$$81$$$O	an$$$82$$$84$$$O	aromatic,$$$85$$$94$$$I	non-aromatic$$$95$$$107$$$I	or$$$108$$$110$$$O	aliphatic$$$111$$$120$$$I	dicarboxylate$$$121$$$134$$$I	ligand$$$135$$$141$$$O	via$$$142$$$145$$$O	an$$$146$$$148$$$O	oxygen$$$149$$$155$$$I	atom$$$156$$$160$$$O	of$$$161$$$163$$$O	one$$$164$$$167$$$O	of$$$168$$$170$$$O	the$$$171$$$174$$$O	carboxylate$$$175$$$186$$$I	groups,$$$187$$$194$$$O	and$$$195$$$198$$$O	two$$$199$$$202$$$O	phenanthroline,$$$203$$$218$$$I	or$$$219$$$221$$$O	phenanthroline$$$222$$$236$$$I	derivative,$$$237$$$248$$$O	ligands,$$$249$$$257$$$O	and$$$258$$$261$$$O	the$$$262$$$265$$$O	use$$$266$$$269$$$O	of$$$270$$$272$$$O	the$$$273$$$276$$$O	metal$$$277$$$282$$$O	complexes$$$283$$$292$$$O	as$$$293$$$295$$$O	self-activating$$$296$$$311$$$O	nucleases$$$312$$$321$$$O	to$$$322$$$324$$$O	treat$$$325$$$330$$$O	cancer$$$331$$$337$$$O	and$$$338$$$341$$$O	other$$$342$$$347$$$O	proliferative$$$348$$$361$$$O	disorders.$$$362$$$372$$$O	In$$$373$$$375$$$O	one$$$376$$$379$$$O	embodiment,$$$380$$$391$$$O	the$$$392$$$395$$$O	CuII$$$396$$$400$$$I	complex$$$401$$$408$$$O	is$$$409$$$411$$$O	a$$$412$$$413$$$O	dinuclear$$$414$$$423$$$O	complex$$$424$$$431$$$O	comprising$$$432$$$442$$$O	two$$$443$$$446$$$O	CuII$$$447$$$451$$$I	ions,$$$452$$$457$$$O	in$$$458$$$460$$$O	which$$$461$$$466$$$O	the$$$467$$$470$$$O	aromatic,$$$471$$$480$$$I	non-aromatic$$$481$$$493$$$I	or$$$494$$$496$$$O	aliphatic$$$497$$$506$$$I	dicarboxylate$$$507$$$520$$$I	ligand$$$521$$$527$$$O	is$$$528$$$530$$$O	a$$$531$$$532$$$O	bridging$$$533$$$541$$$O	ligand,$$$542$$$549$$$O	and$$$550$$$553$$$O	in$$$554$$$556$$$O	which$$$557$$$562$$$O	each$$$563$$$567$$$O	copper$$$568$$$574$$$I	is$$$575$$$577$$$O	coordinated$$$578$$$589$$$O	to$$$590$$$592$$$O	the$$$593$$$596$$$O	bridging$$$597$$$605$$$O	ligand$$$606$$$612$$$O	via$$$613$$$616$$$O	the$$$617$$$620$$$O	carboxylate$$$621$$$632$$$I	groups.$$$633$$$640$$$O
US20070281036
System$$$0$$$6$$$O	and$$$7$$$10$$$O	method$$$11$$$17$$$O	of$$$18$$$20$$$O	delivering$$$21$$$31$$$O	a$$$32$$$33$$$O	desired$$$34$$$41$$$O	material$$$42$$$50$$$O	to$$$51$$$53$$$O	a$$$54$$$55$$$O	cell$$$56$$$60$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compositions$$$25$$$37$$$O	of$$$38$$$40$$$O	mesoporous$$$41$$$51$$$O	inorganic$$$52$$$61$$$O	oxide$$$62$$$67$$$O	particles$$$68$$$77$$$O	and$$$78$$$81$$$O	methods$$$82$$$89$$$O	of$$$90$$$92$$$O	use.$$$93$$$97$$$O	The$$$98$$$101$$$O	particles$$$102$$$111$$$O	may$$$112$$$115$$$O	be$$$116$$$118$$$O	coated$$$119$$$125$$$O	with$$$126$$$130$$$O	a$$$131$$$132$$$O	polyethylene$$$133$$$145$$$I	glycol$$$146$$$152$$$I	group.$$$153$$$159$$$O	The$$$160$$$163$$$O	compositions$$$164$$$176$$$O	of$$$177$$$179$$$O	the$$$180$$$183$$$O	invention$$$184$$$193$$$O	are$$$194$$$197$$$O	useful$$$198$$$204$$$O	for$$$205$$$208$$$O	delivering$$$209$$$219$$$O	therapeutic$$$220$$$231$$$O	and$$$232$$$235$$$O	diagnostic$$$236$$$246$$$O	materials$$$247$$$256$$$O	to$$$257$$$259$$$O	an$$$260$$$262$$$O	organism.$$$263$$$272$$$O
CN103735473A
Herbal$$$0$$$6$$$O	mouthwash$$$7$$$16$$$O	and$$$17$$$20$$$O	preparation$$$21$$$32$$$O	method$$$33$$$39$$$O	thereof$$$40$$$47$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	daily$$$48$$$53$$$O	health$$$54$$$60$$$O	care,$$$61$$$66$$$O	and$$$67$$$70$$$O	particularly$$$71$$$83$$$O	relates$$$84$$$91$$$O	to$$$92$$$94$$$O	herbal$$$95$$$101$$$O	mouthwash$$$102$$$111$$$O	and$$$112$$$115$$$O	a$$$116$$$117$$$O	preparation$$$118$$$129$$$O	method$$$130$$$136$$$O	thereof,$$$137$$$145$$$O	the$$$146$$$149$$$O	herbal$$$150$$$156$$$O	mouthwash$$$157$$$166$$$O	comprises$$$167$$$176$$$O	the$$$177$$$180$$$O	following$$$181$$$190$$$O	components:$$$191$$$202$$$O	by$$$203$$$205$$$O	mass,$$$206$$$211$$$O	3-9$$$212$$$215$$$O	parts$$$216$$$221$$$O	of$$$222$$$224$$$O	green$$$225$$$230$$$O	tea,$$$231$$$235$$$O	5-10$$$236$$$240$$$O	parts$$$241$$$246$$$O	of$$$247$$$249$$$O	stevia$$$250$$$256$$$O	rebaudianum,$$$257$$$269$$$O	2-6$$$270$$$273$$$O	parts$$$274$$$279$$$O	of$$$280$$$282$$$O	borneol,$$$283$$$291$$$I	5-13$$$292$$$296$$$O	parts$$$297$$$302$$$O	of$$$303$$$305$$$O	honeysuckle,$$$306$$$318$$$O	10-15$$$319$$$324$$$O	parts$$$325$$$330$$$O	of$$$331$$$333$$$O	mulberry$$$334$$$342$$$O	leaf,$$$343$$$348$$$O	4-9$$$349$$$352$$$O	parts$$$353$$$358$$$O	of$$$359$$$361$$$O	hemianthus$$$362$$$372$$$O	micranthemoides,$$$373$$$389$$$O	10-25$$$390$$$395$$$O	parts$$$396$$$401$$$O	of$$$402$$$404$$$O	gallnut$$$405$$$412$$$O	and$$$413$$$416$$$O	500-1000$$$417$$$425$$$O	parts$$$426$$$431$$$O	of$$$432$$$434$$$O	water.$$$435$$$441$$$O	The$$$442$$$445$$$O	herbal$$$446$$$452$$$O	mouthwash$$$453$$$462$$$O	can$$$463$$$466$$$O	eliminate$$$467$$$476$$$O	bad$$$477$$$480$$$O	breath,$$$481$$$488$$$O	clear$$$489$$$494$$$O	the$$$495$$$498$$$O	mouth$$$499$$$504$$$O	filth,$$$505$$$511$$$O	sterilize,$$$512$$$522$$$O	remove$$$523$$$529$$$O	dental$$$530$$$536$$$O	plaque,$$$537$$$544$$$O	prevent$$$545$$$552$$$O	or$$$553$$$555$$$O	inhibit$$$556$$$563$$$O	various$$$564$$$571$$$O	oral$$$572$$$576$$$O	diseases,$$$577$$$586$$$O	prevent$$$587$$$594$$$O	tooth$$$595$$$600$$$O	decay,$$$601$$$607$$$O	improve$$$608$$$615$$$O	periodontal$$$616$$$627$$$O	diseases,$$$628$$$637$$$O	and$$$638$$$641$$$O	clean$$$642$$$647$$$O	the$$$648$$$651$$$O	oral$$$652$$$656$$$O	cavity.$$$657$$$664$$$O
CA2850955A1
Pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	of$$$28$$$30$$$O	hydrophobic$$$31$$$42$$$O	camptothecin$$$43$$$55$$$I	derivatives$$$56$$$67$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	pharmaceutical$$$33$$$47$$$O	composition$$$48$$$59$$$O	comprising$$$60$$$70$$$O	at$$$71$$$73$$$O	least$$$74$$$79$$$O	one$$$80$$$83$$$O	hydrophobic$$$84$$$95$$$O	camptothecin$$$96$$$108$$$I	derivative$$$109$$$119$$$O	or$$$120$$$122$$$O	a$$$123$$$124$$$O	pharmaceutically$$$125$$$141$$$O	acceptable$$$142$$$152$$$O	salt$$$153$$$157$$$O	of$$$158$$$160$$$O	said$$$161$$$165$$$O	derivative$$$166$$$176$$$O	and$$$177$$$180$$$O	a$$$181$$$182$$$O	polyethylene$$$183$$$195$$$I	glycol$$$196$$$202$$$I	(PEG)$$$203$$$208$$$I	conjugated$$$209$$$219$$$O	phospholipid.$$$220$$$233$$$I	Also$$$234$$$238$$$O	provided$$$239$$$247$$$O	is$$$248$$$250$$$O	a$$$251$$$252$$$O	method$$$253$$$259$$$O	to$$$260$$$262$$$O	inhibit$$$263$$$270$$$O	cancer$$$271$$$277$$$O	cells$$$278$$$283$$$O	in$$$284$$$286$$$O	a$$$287$$$288$$$O	subject$$$289$$$296$$$O	in$$$297$$$299$$$O	need$$$300$$$304$$$O	thereof$$$305$$$312$$$O	by$$$313$$$315$$$O	administering$$$316$$$329$$$O	the$$$330$$$333$$$O	pharmaceutical$$$334$$$348$$$O	composition$$$349$$$360$$$O	of$$$361$$$363$$$O	the$$$364$$$367$$$O	present$$$368$$$375$$$O	invention.$$$376$$$386$$$O
US20060046992
Heterobicyclic$$$0$$$14$$$I	compounds$$$15$$$24$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	compound$$$33$$$41$$$O	represented$$$42$$$53$$$O	by$$$54$$$56$$$O	formula$$$57$$$64$$$O	(I):$$$65$$$69$$$O	[wherein$$$86$$$94$$$O	XâY-Z$$$95$$$102$$$O	represents$$$103$$$113$$$I	R5NâCâO$$$114$$$125$$$I	(wherein$$$126$$$134$$$O	R5$$$135$$$137$$$O	represents$$$138$$$148$$$I	a$$$149$$$150$$$I	hydrogen$$$151$$$159$$$I	atom,$$$160$$$165$$$O	substituted$$$166$$$177$$$O	or$$$178$$$180$$$O	unsubstituted$$$181$$$194$$$O	lower$$$195$$$200$$$I	alkyl,$$$201$$$207$$$O	substituted$$$208$$$219$$$O	or$$$220$$$222$$$O	unsubstituted$$$223$$$236$$$I	aralkyl,$$$237$$$245$$$I	substituted$$$246$$$257$$$O	or$$$258$$$260$$$O	unsubstituted$$$261$$$274$$$O	lower$$$275$$$280$$$I	alkenyl,$$$281$$$289$$$I	or$$$290$$$292$$$O	substituted$$$293$$$304$$$O	or$$$305$$$307$$$O	unsubstituted$$$308$$$321$$$O	lower$$$322$$$327$$$I	alkynyl),$$$328$$$337$$$I	etc;$$$338$$$342$$$O	R1$$$343$$$345$$$O	and$$$346$$$349$$$O	R2$$$350$$$352$$$O	may$$$353$$$356$$$O	be$$$357$$$359$$$O	the$$$360$$$363$$$O	same$$$364$$$368$$$O	or$$$369$$$371$$$O	different$$$372$$$381$$$O	and$$$382$$$385$$$O	each$$$386$$$390$$$O	represents$$$391$$$401$$$I	a$$$402$$$403$$$I	hydrogen$$$404$$$412$$$I	atom,$$$413$$$418$$$O	substituted$$$419$$$430$$$O	or$$$431$$$433$$$O	unsubstituted$$$434$$$447$$$O	lower$$$448$$$453$$$I	alkyl,$$$454$$$460$$$O	etc;$$$461$$$465$$$O	and$$$466$$$469$$$O	R3$$$470$$$472$$$O	and$$$473$$$476$$$O	R4$$$477$$$479$$$O	may$$$480$$$483$$$O	be$$$484$$$486$$$O	the$$$487$$$490$$$O	same$$$491$$$495$$$O	or$$$496$$$498$$$O	different$$$499$$$508$$$O	and$$$509$$$512$$$O	each$$$513$$$517$$$O	represents$$$518$$$528$$$I	a$$$529$$$530$$$I	hydrogen$$$531$$$539$$$I	atom,$$$540$$$545$$$O	substituted$$$546$$$557$$$O	or$$$558$$$560$$$O	unsubstituted$$$561$$$574$$$O	lower$$$575$$$580$$$I	alkyl,$$$581$$$587$$$O	etc],$$$588$$$593$$$O	or$$$594$$$596$$$O	a$$$597$$$598$$$O	pharmaceutically$$$599$$$615$$$O	acceptable$$$616$$$626$$$O	salt$$$627$$$631$$$O	thereof.$$$632$$$640$$$O
CN1651453A
Japanese$$$0$$$8$$$O	polygala$$$9$$$17$$$O	saponin$$$18$$$25$$$I	kind$$$26$$$30$$$O	compound$$$31$$$39$$$O	and$$$40$$$43$$$O	aglucon,$$$44$$$52$$$O	total$$$53$$$58$$$O	saponin$$$59$$$66$$$I	and$$$67$$$70$$$O	total$$$71$$$76$$$O	aglucon$$$77$$$84$$$O	and$$$85$$$88$$$O	its$$$89$$$92$$$O	application$$$93$$$104$$$O	in$$$105$$$107$$$O	medicine$$$108$$$116$$$O
A$$$0$$$1$$$O	polygalae$$$2$$$11$$$O	saponin$$$12$$$19$$$I	compound$$$20$$$28$$$O	series$$$29$$$35$$$O	prepaed$$$36$$$43$$$O	from$$$44$$$48$$$O	Japanese$$$49$$$57$$$O	milkwort$$$58$$$66$$$O	is$$$67$$$69$$$O	composed$$$70$$$78$$$O	of$$$79$$$81$$$O	general$$$82$$$89$$$O	polygalasaponin$$$90$$$105$$$I	and$$$106$$$109$$$O	general$$$110$$$117$$$O	polygalaglycone,$$$118$$$134$$$I	that$$$135$$$139$$$O	is,$$$140$$$143$$$O	4$$$144$$$145$$$O	saponin$$$146$$$153$$$O	compounds$$$154$$$163$$$O	(polygalasaponin$$$164$$$180$$$I	V,$$$181$$$183$$$I	polygala$$$184$$$192$$$I	saponin$$$193$$$200$$$I	E,$$$201$$$203$$$I	polygalasaponin$$$204$$$219$$$I	F$$$220$$$221$$$I	and$$$222$$$225$$$O	2$$$226$$$227$$$I	beta-27-bihydroxy-23-carboxy-oleanolic$$$228$$$266$$$I	acid$$$267$$$271$$$I	-3$$$272$$$274$$$I	beta-O-glucoside)$$$275$$$292$$$I	and$$$293$$$296$$$O	3$$$297$$$298$$$O	aglycones.$$$299$$$309$$$O	It$$$310$$$312$$$O	can$$$313$$$316$$$O	be$$$317$$$319$$$O	used$$$320$$$324$$$O	in$$$325$$$327$$$O	preparing$$$328$$$337$$$O	medicine$$$338$$$346$$$O	for$$$347$$$350$$$O	treating$$$351$$$359$$$O	depression,$$$360$$$371$$$O	anxiety,$$$372$$$380$$$O	senile$$$381$$$387$$$O	dementia$$$388$$$396$$$O	and$$$397$$$400$$$O	insomnia.$$$401$$$410$$$O
EP2305257A1
Amonafide$$$0$$$9$$$I	salts$$$10$$$15$$$O	and$$$16$$$19$$$O	compositions$$$20$$$32$$$O	comprising$$$33$$$43$$$O	same$$$44$$$48$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	concerns$$$22$$$30$$$O	novel$$$31$$$36$$$O	methods$$$37$$$44$$$O	for$$$45$$$48$$$O	the$$$49$$$52$$$O	synthesis$$$53$$$62$$$O	of$$$63$$$65$$$O	napthalimides$$$66$$$79$$$I	and$$$80$$$83$$$O	mitonafide$$$84$$$94$$$I	analogs,$$$95$$$103$$$O	as$$$104$$$106$$$O	well$$$107$$$111$$$O	as$$$112$$$114$$$O	salts$$$115$$$120$$$O	thereof.$$$121$$$129$$$O	Also$$$130$$$134$$$O	included$$$135$$$143$$$O	are$$$144$$$147$$$O	novel$$$148$$$153$$$O	compositions,$$$154$$$167$$$O	including$$$168$$$177$$$O	napthalimides$$$178$$$191$$$I	and$$$192$$$195$$$O	napthalimide$$$196$$$208$$$I	salts,$$$209$$$215$$$O	analogs$$$216$$$223$$$O	thereof,$$$224$$$232$$$O	as$$$233$$$235$$$O	well$$$236$$$240$$$O	as$$$241$$$243$$$O	stable$$$244$$$250$$$O	liquid$$$251$$$257$$$O	dosage$$$258$$$264$$$O	forms$$$265$$$270$$$O	thereof.$$$271$$$279$$$O
CN102574825A
Thiazoles$$$0$$$9$$$I	as$$$10$$$12$$$O	cannabinoid$$$13$$$24$$$I	receptor$$$25$$$33$$$O	ligands$$$34$$$41$$$O
Disclosed$$$0$$$9$$$O	herein$$$10$$$16$$$O	are$$$17$$$20$$$O	cannabinoid$$$21$$$32$$$I	receptor$$$33$$$41$$$O	ligands$$$42$$$49$$$O	of$$$50$$$52$$$O	formula$$$53$$$60$$$O	(I)$$$61$$$64$$$O	wherein$$$65$$$72$$$O	L1,$$$73$$$76$$$O	A1,$$$77$$$80$$$O	R1g,$$$81$$$85$$$O	z,$$$86$$$88$$$O	R2,$$$89$$$92$$$O	R3,$$$93$$$96$$$O	and$$$97$$$100$$$O	R4$$$101$$$103$$$O	are$$$104$$$107$$$O	as$$$108$$$110$$$O	defined$$$111$$$118$$$O	in$$$119$$$121$$$O	the$$$122$$$125$$$O	specification.$$$126$$$140$$$O	Compositions$$$141$$$153$$$O	comprising$$$154$$$164$$$O	such$$$165$$$169$$$O	compounds$$$170$$$179$$$O	and$$$180$$$183$$$O	methods$$$184$$$191$$$O	for$$$192$$$195$$$O	treating$$$196$$$204$$$O	conditions$$$205$$$215$$$O	and$$$216$$$219$$$O	disorders$$$220$$$229$$$O	using$$$230$$$235$$$O	such$$$236$$$240$$$O	compounds$$$241$$$250$$$O	and$$$251$$$254$$$O	compositions$$$255$$$267$$$O	are$$$268$$$271$$$O	also$$$272$$$276$$$O	presented.$$$277$$$287$$$O
WO2012012385A2
Compositions$$$0$$$12$$$O	comprising$$$13$$$23$$$O	derivatives$$$24$$$35$$$O	of$$$36$$$38$$$O	essential$$$39$$$48$$$O	oil$$$49$$$52$$$O	compounds$$$53$$$62$$$O	and$$$63$$$66$$$O	use$$$67$$$70$$$O	in$$$71$$$73$$$O	personal$$$74$$$82$$$O	care$$$83$$$87$$$O	products$$$88$$$96$$$O
Compositions$$$0$$$12$$$O	containing$$$13$$$23$$$O	one$$$24$$$27$$$O	or$$$28$$$30$$$O	more$$$31$$$35$$$O	derivatives$$$36$$$47$$$O	of$$$48$$$50$$$O	essential$$$51$$$60$$$O	oil$$$61$$$64$$$O	compounds$$$65$$$74$$$O	for$$$75$$$78$$$O	use$$$79$$$82$$$O	in$$$83$$$85$$$O	personal$$$86$$$94$$$O	care$$$95$$$99$$$O	compositions,$$$100$$$113$$$O	such$$$114$$$118$$$O	as$$$119$$$121$$$O	compositions$$$122$$$134$$$O	for$$$135$$$138$$$O	oral,$$$139$$$144$$$O	throat$$$145$$$151$$$O	and$$$152$$$155$$$O	skin$$$156$$$160$$$O	care$$$161$$$165$$$O	are$$$166$$$169$$$O	disclosed.$$$170$$$180$$$O	These$$$181$$$186$$$O	derivatives$$$187$$$198$$$O	include$$$199$$$206$$$O	acetals$$$207$$$214$$$I	of$$$215$$$217$$$O	parent$$$218$$$224$$$O	essential$$$225$$$234$$$O	oil$$$235$$$238$$$O	aldehydes$$$239$$$248$$$I	and$$$249$$$252$$$O	ketones;$$$253$$$261$$$I	esters$$$262$$$268$$$I	or$$$269$$$271$$$O	ethers$$$272$$$278$$$I	of$$$279$$$281$$$O	parent$$$282$$$288$$$O	essential$$$289$$$298$$$O	oil$$$299$$$302$$$O	alcohols$$$303$$$311$$$I	and$$$312$$$315$$$O	phenolics;$$$316$$$326$$$O	and$$$327$$$330$$$O	esters$$$331$$$337$$$I	of$$$338$$$340$$$O	parent$$$341$$$347$$$O	essential$$$348$$$357$$$O	oil$$$358$$$361$$$O	acids.$$$362$$$368$$$O	Examples$$$369$$$377$$$O	of$$$378$$$380$$$O	parent$$$381$$$387$$$O	essential$$$388$$$397$$$O	oil$$$398$$$401$$$O	aldehydes$$$402$$$411$$$I	and$$$412$$$415$$$O	ketones$$$416$$$423$$$I	include$$$424$$$431$$$O	citral,$$$432$$$439$$$O	cinnamic$$$440$$$448$$$I	aldehyde,$$$449$$$458$$$I	Ï-anisaldehyde,$$$459$$$475$$$I	vanillin,$$$476$$$485$$$I	ethyl$$$486$$$491$$$I	vanillin,$$$492$$$501$$$I	heliotropin,$$$502$$$514$$$I	carvone,$$$515$$$523$$$I	and$$$524$$$527$$$I	menthone.$$$528$$$537$$$I	Examples$$$538$$$546$$$O	of$$$547$$$549$$$O	parent$$$550$$$556$$$O	essential$$$557$$$566$$$O	oil$$$567$$$570$$$I	alcohols$$$571$$$579$$$I	and$$$580$$$583$$$O	phenolics$$$584$$$593$$$O	include$$$594$$$601$$$I	thymol,$$$602$$$609$$$I	eugenol,$$$610$$$618$$$I	isoeugenol,$$$619$$$630$$$I	dihydroeugenol,$$$631$$$646$$$I	carvacrol,$$$647$$$657$$$I	carveol,$$$658$$$666$$$I	geraniol,$$$667$$$676$$$I	nerol,$$$677$$$683$$$I	vanillyl$$$684$$$692$$$I	alcohol,$$$693$$$701$$$I	heliotropyl$$$702$$$713$$$I	alcohol,$$$714$$$722$$$I	Ï-anisyl$$$723$$$732$$$I	alcohol,$$$733$$$741$$$I	cinnamyl$$$742$$$750$$$I	alcohol$$$751$$$758$$$I	and$$$759$$$762$$$I	Î²-ionol.$$$763$$$772$$$I	Examples$$$773$$$781$$$O	of$$$782$$$784$$$O	parent$$$785$$$791$$$O	essential$$$792$$$801$$$O	oil$$$802$$$805$$$O	acids$$$806$$$811$$$O	include$$$812$$$819$$$I	Ï-anisic$$$820$$$829$$$I	acid,$$$830$$$835$$$I	cinnamic$$$836$$$844$$$I	acid,$$$845$$$850$$$I	vanillic$$$851$$$859$$$I	acid$$$860$$$864$$$I	and$$$865$$$868$$$I	geranic$$$869$$$876$$$I	acid.$$$877$$$882$$$I	The$$$883$$$886$$$O	present$$$887$$$894$$$O	compositions$$$895$$$907$$$O	comprising$$$908$$$918$$$O	essential$$$919$$$928$$$O	oil$$$929$$$932$$$O	derivatives$$$933$$$944$$$O	are$$$945$$$948$$$O	useful$$$949$$$955$$$O	as$$$956$$$958$$$O	base$$$959$$$963$$$O	flavor$$$964$$$970$$$O	or$$$971$$$973$$$O	base$$$974$$$978$$$O	perfume$$$979$$$986$$$O	for$$$987$$$990$$$O	incorporation$$$991$$$1004$$$O	into$$$1005$$$1009$$$O	personal$$$1010$$$1018$$$O	care$$$1019$$$1023$$$O	products$$$1024$$$1032$$$O	and$$$1033$$$1036$$$O	to$$$1037$$$1039$$$O	provide$$$1040$$$1047$$$O	other$$$1048$$$1053$$$O	benefits$$$1054$$$1062$$$O	including$$$1063$$$1072$$$O	antimicrobial$$$1073$$$1086$$$O	efficacy.$$$1087$$$1096$$$O	Optionally$$$1097$$$1107$$$O	the$$$1108$$$1111$$$O	compositions$$$1112$$$1124$$$O	will$$$1125$$$1129$$$O	contain$$$1130$$$1137$$$O	additional$$$1138$$$1148$$$O	antimicrobially-$$$1149$$$1165$$$O	or$$$1166$$$1168$$$O	anti-inflammatory-effective$$$1169$$$1196$$$O	components$$$1197$$$1207$$$O	including$$$1208$$$1217$$$O	those$$$1218$$$1223$$$O	also$$$1224$$$1228$$$O	derived$$$1229$$$1236$$$O	from$$$1237$$$1241$$$O	plant$$$1242$$$1247$$$O	essential$$$1248$$$1257$$$O	oils$$$1258$$$1262$$$O	or$$$1263$$$1265$$$O	synthetic$$$1266$$$1275$$$O	versions$$$1276$$$1284$$$O	thereof.$$$1285$$$1293$$$O
WO2012013595A1
Three-phase$$$0$$$11$$$O	controlled-release$$$12$$$30$$$O	tablet$$$31$$$37$$$O	comprising$$$38$$$48$$$O	melatonin$$$49$$$58$$$I	and$$$59$$$62$$$O	process$$$63$$$70$$$O	of$$$71$$$73$$$O	preparation$$$74$$$85$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates,$$$14$$$22$$$O	in$$$23$$$25$$$O	one$$$26$$$29$$$O	aspect,$$$30$$$37$$$O	to$$$38$$$40$$$O	a$$$41$$$42$$$O	tablet$$$43$$$49$$$O	having$$$50$$$56$$$O	an$$$57$$$59$$$O	internal$$$60$$$68$$$O	core$$$69$$$73$$$O	and$$$74$$$77$$$O	external$$$78$$$86$$$O	coating,$$$87$$$95$$$O	both$$$96$$$100$$$O	comprising$$$101$$$111$$$O	melatonin$$$112$$$121$$$I	and$$$122$$$125$$$O	separated$$$126$$$135$$$O	by$$$136$$$138$$$O	an$$$139$$$141$$$O	internal$$$142$$$150$$$O	coating$$$151$$$158$$$O	which$$$159$$$164$$$O	does$$$165$$$169$$$O	not$$$170$$$173$$$O	comprise$$$174$$$182$$$O	melatonin.$$$183$$$193$$$I	The$$$194$$$197$$$O	tablet$$$198$$$204$$$O	is$$$205$$$207$$$O	useful$$$208$$$214$$$O	as$$$215$$$217$$$O	a$$$218$$$219$$$O	medicinal$$$220$$$229$$$O	product,$$$230$$$238$$$O	dietetic$$$239$$$247$$$O	or$$$248$$$250$$$O	food$$$251$$$255$$$O	supplements$$$256$$$267$$$O	for$$$268$$$271$$$O	the$$$272$$$275$$$O	treatment$$$276$$$285$$$O	or$$$286$$$288$$$O	as$$$289$$$291$$$O	adjunctive$$$292$$$302$$$O	therapy$$$303$$$310$$$O	in$$$311$$$313$$$O	sleep$$$314$$$319$$$O	disorders.$$$320$$$330$$$O
CN103626769A
Substituted$$$0$$$11$$$O	sulfydryl$$$12$$$21$$$I	hexahydric$$$22$$$32$$$I	heteroaromatic$$$33$$$47$$$I	imidazole$$$48$$$57$$$I	derivative$$$58$$$68$$$O	and$$$69$$$72$$$O	preparation$$$73$$$84$$$O	method$$$85$$$91$$$O	and$$$92$$$95$$$O	application$$$96$$$107$$$O	thereof$$$108$$$115$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	substituted$$$27$$$38$$$O	sulfydryl$$$39$$$48$$$I	hexahydric$$$49$$$59$$$I	heteroaromatic$$$60$$$74$$$I	imidazole$$$75$$$84$$$I	derivative$$$85$$$95$$$O	shown$$$96$$$101$$$O	in$$$102$$$104$$$O	formula$$$105$$$112$$$O	I$$$113$$$114$$$O	or$$$115$$$117$$$O	II$$$118$$$120$$$O	or$$$121$$$123$$$O	a$$$124$$$125$$$O	pharmaceutically$$$126$$$142$$$O	acceptable$$$143$$$153$$$O	salt$$$154$$$158$$$O	thereof$$$159$$$166$$$O	and$$$167$$$170$$$O	also$$$171$$$175$$$O	relates$$$176$$$183$$$O	to$$$184$$$186$$$O	a$$$187$$$188$$$O	preparation$$$189$$$200$$$O	method$$$201$$$207$$$O	of$$$208$$$210$$$O	the$$$211$$$214$$$O	compound$$$215$$$223$$$O	as$$$224$$$226$$$O	shown$$$227$$$232$$$O	in$$$233$$$235$$$O	the$$$236$$$239$$$O	formula$$$240$$$247$$$O	I$$$248$$$249$$$O	or$$$250$$$252$$$O	II,$$$253$$$256$$$O	a$$$257$$$258$$$O	pharmaceutical$$$259$$$273$$$O	composition$$$274$$$285$$$O	containing$$$286$$$296$$$O	the$$$297$$$300$$$O	compound,$$$301$$$310$$$O	and$$$311$$$314$$$O	application$$$315$$$326$$$O	of$$$327$$$329$$$O	the$$$330$$$333$$$O	compound$$$334$$$342$$$O	in$$$343$$$345$$$O	preparation$$$346$$$357$$$O	of$$$358$$$360$$$O	an$$$361$$$363$$$O	antineoplastic$$$364$$$378$$$O	drug.$$$379$$$384$$$O
CN101475615B
Amino$$$0$$$5$$$I	acid$$$6$$$10$$$I	glucide$$$11$$$18$$$I	compound$$$19$$$27$$$O	and$$$28$$$31$$$O	its$$$32$$$35$$$O	use$$$36$$$39$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	amino$$$28$$$33$$$I	acid$$$34$$$38$$$I	saccharide$$$39$$$49$$$I	compound$$$50$$$58$$$O	and$$$59$$$62$$$O	application$$$63$$$74$$$O	thereof.$$$75$$$83$$$O	The$$$84$$$87$$$O	design$$$88$$$94$$$O	of$$$95$$$97$$$O	the$$$98$$$101$$$O	amino$$$102$$$107$$$I	acid$$$108$$$112$$$I	saccharide$$$113$$$123$$$I	compound$$$124$$$132$$$O	is$$$133$$$135$$$O	based$$$136$$$141$$$O	on$$$142$$$144$$$O	a$$$145$$$146$$$O	PTP-1B$$$147$$$153$$$O	double$$$154$$$160$$$O	binding$$$161$$$168$$$O	site,$$$169$$$174$$$O	and$$$175$$$178$$$O	the$$$179$$$182$$$O	amino$$$183$$$188$$$I	acid$$$189$$$193$$$I	saccharide$$$194$$$204$$$I	compound$$$205$$$213$$$O	is$$$214$$$216$$$O	obtained$$$217$$$225$$$O	by$$$226$$$228$$$O	modifying$$$229$$$238$$$O	small$$$239$$$244$$$O	molecular$$$245$$$254$$$O	monosaccharides.$$$255$$$271$$$I	An$$$272$$$274$$$O	in$$$275$$$277$$$O	vitro$$$278$$$283$$$O	bioactivity$$$284$$$295$$$O	test$$$296$$$300$$$O	shows$$$301$$$306$$$O	that$$$307$$$311$$$O	the$$$312$$$315$$$O	amino$$$316$$$321$$$I	acid$$$322$$$326$$$I	saccharide$$$327$$$337$$$I	compound$$$338$$$346$$$O	has$$$347$$$350$$$O	good$$$351$$$355$$$O	activity$$$356$$$364$$$O	of$$$365$$$367$$$O	inhibiting$$$368$$$378$$$O	PTP-1B$$$379$$$385$$$O	and$$$386$$$389$$$O	anti-tumor$$$390$$$400$$$O	activity.$$$401$$$410$$$O	Therefore,$$$411$$$421$$$O	the$$$422$$$425$$$O	designed$$$426$$$434$$$O	and$$$435$$$438$$$O	synthesized$$$439$$$450$$$O	amino$$$451$$$456$$$I	acid$$$457$$$461$$$I	saccharide$$$462$$$472$$$I	compound$$$473$$$481$$$O	has$$$482$$$485$$$O	development$$$486$$$497$$$O	prospect$$$498$$$506$$$O	on$$$507$$$509$$$O	novel$$$510$$$515$$$O	medicines$$$516$$$525$$$O	for$$$526$$$529$$$O	treating$$$530$$$538$$$O	diabetes$$$539$$$547$$$O	and$$$548$$$551$$$O	resisting$$$552$$$561$$$O	tumor.$$$562$$$568$$$O
US20130040000
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	reducing$$$11$$$19$$$O	the$$$20$$$23$$$O	risk$$$24$$$28$$$O	of$$$29$$$31$$$O	occurrence$$$32$$$42$$$O	of$$$43$$$45$$$O	pulmonary$$$46$$$55$$$O	edema$$$56$$$61$$$O	associated$$$62$$$72$$$O	with$$$73$$$77$$$O	inhalation$$$78$$$88$$$O	of$$$89$$$91$$$O	nitric$$$92$$$98$$$I	oxide$$$99$$$104$$$I	gas$$$105$$$108$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	methods$$$14$$$21$$$O	of$$$22$$$24$$$O	reducing$$$25$$$33$$$O	the$$$34$$$37$$$O	risk$$$38$$$42$$$O	of$$$43$$$45$$$O	occurrence$$$46$$$56$$$O	of$$$57$$$59$$$O	pulmonary$$$60$$$69$$$O	edema$$$70$$$75$$$O	associated$$$76$$$86$$$O	with$$$87$$$91$$$O	a$$$92$$$93$$$O	medical$$$94$$$101$$$O	treatment$$$102$$$111$$$O	comprising$$$112$$$122$$$O	inhalation$$$123$$$133$$$O	of$$$134$$$136$$$O	nitric$$$137$$$143$$$I	oxide$$$144$$$149$$$I	gas.$$$150$$$154$$$O
CN102697753A
Roxithromycin$$$0$$$13$$$I	compound$$$14$$$22$$$O	and$$$23$$$26$$$O	soft$$$27$$$31$$$O	capsule$$$32$$$39$$$O	preparation$$$40$$$51$$$O	thereof$$$52$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	roxithromycin$$$27$$$40$$$I	compound$$$41$$$49$$$O	preparation,$$$50$$$62$$$O	in$$$63$$$65$$$O	particular$$$66$$$76$$$O	to$$$77$$$79$$$O	a$$$80$$$81$$$O	soft$$$82$$$86$$$O	capsule$$$87$$$94$$$O	preparation$$$95$$$106$$$O	of$$$107$$$109$$$O	a$$$110$$$111$$$O	roxithromycin$$$112$$$125$$$I	compound.$$$126$$$135$$$O	A$$$136$$$137$$$O	preparation$$$138$$$149$$$O	method$$$150$$$156$$$O	for$$$157$$$160$$$O	soft$$$161$$$165$$$O	roxithromycin$$$166$$$179$$$I	capsules$$$180$$$188$$$O	comprises$$$189$$$198$$$O	the$$$199$$$202$$$O	following$$$203$$$212$$$O	steps$$$213$$$218$$$O	of:$$$219$$$222$$$O	adding$$$223$$$229$$$O	150$$$230$$$233$$$O	weight$$$234$$$240$$$O	parts$$$241$$$246$$$O	of$$$247$$$249$$$O	roxithromycin$$$250$$$263$$$I	and$$$264$$$267$$$O	100$$$268$$$271$$$O	to$$$272$$$274$$$O	150$$$275$$$278$$$O	weight$$$279$$$285$$$O	parts$$$286$$$291$$$O	of$$$292$$$294$$$O	oily$$$295$$$299$$$O	matrix$$$300$$$306$$$O	into$$$307$$$311$$$O	a$$$312$$$313$$$O	solution$$$314$$$322$$$O	preparation$$$323$$$334$$$O	tank,$$$335$$$340$$$O	mixing$$$341$$$347$$$O	uniformly,$$$348$$$358$$$O	and$$$359$$$362$$$O	grinding$$$363$$$371$$$O	with$$$372$$$376$$$O	a$$$377$$$378$$$O	colloid$$$379$$$386$$$O	grinder;$$$387$$$395$$$O	freezing$$$396$$$404$$$O	the$$$405$$$408$$$O	mixture$$$409$$$416$$$O	of$$$417$$$419$$$O	the$$$420$$$423$$$O	roxithromycin$$$424$$$437$$$I	and$$$438$$$441$$$O	the$$$442$$$445$$$O	oily$$$446$$$450$$$O	matrix$$$451$$$457$$$O	to$$$458$$$460$$$O	the$$$461$$$464$$$O	temperature$$$465$$$476$$$O	of$$$477$$$479$$$O	between$$$480$$$487$$$O	25$$$488$$$490$$$O	DEG$$$491$$$494$$$O	C$$$495$$$496$$$O	below$$$497$$$502$$$O	zero$$$503$$$507$$$O	and$$$508$$$511$$$O	40$$$512$$$514$$$O	DEG$$$515$$$518$$$O	C$$$519$$$520$$$O	below$$$521$$$526$$$O	zero$$$527$$$531$$$O	at$$$532$$$534$$$O	the$$$535$$$538$$$O	cooling$$$539$$$546$$$O	rate$$$547$$$551$$$O	of$$$552$$$554$$$O	2$$$555$$$556$$$O	to$$$557$$$559$$$O	15$$$560$$$562$$$O	DEG$$$563$$$566$$$O	C$$$567$$$568$$$O	per$$$569$$$572$$$O	minute;$$$573$$$580$$$O	vacuumizing,$$$581$$$593$$$O	and$$$594$$$597$$$O	heating$$$598$$$605$$$O	to$$$606$$$608$$$O	the$$$609$$$612$$$O	temperature$$$613$$$624$$$O	of$$$625$$$627$$$O	between$$$628$$$635$$$O	15$$$636$$$638$$$O	and$$$639$$$642$$$O	25$$$643$$$645$$$O	DEG$$$646$$$649$$$O	C$$$650$$$651$$$O	in$$$652$$$654$$$O	2$$$655$$$656$$$O	to$$$657$$$659$$$O	6$$$660$$$661$$$O	hours;$$$662$$$668$$$O	treating$$$669$$$677$$$O	for$$$678$$$681$$$O	5$$$682$$$683$$$O	to$$$684$$$686$$$O	15$$$687$$$689$$$O	minutes$$$690$$$697$$$O	in$$$698$$$700$$$O	an$$$701$$$703$$$O	ultrasonic$$$704$$$714$$$O	emulsifier$$$715$$$725$$$O	of$$$726$$$728$$$O	which$$$729$$$734$$$O	the$$$735$$$738$$$O	frequency$$$739$$$748$$$O	is$$$749$$$751$$$O	20$$$752$$$754$$$O	to$$$755$$$757$$$O	30KHz$$$758$$$763$$$O	and$$$764$$$767$$$O	the$$$768$$$771$$$O	power$$$772$$$777$$$O	is$$$778$$$780$$$O	20$$$781$$$783$$$O	to$$$784$$$786$$$O	500W;$$$787$$$792$$$O	and$$$793$$$796$$$O	preparing$$$797$$$806$$$O	capsule$$$807$$$814$$$O	wrappers$$$815$$$823$$$O	of$$$824$$$826$$$O	the$$$827$$$830$$$O	soft$$$831$$$835$$$O	roxithromycin$$$836$$$849$$$I	capsules,$$$850$$$859$$$O	injecting$$$860$$$869$$$O	medicinal$$$870$$$879$$$O	liquid,$$$880$$$887$$$O	pelleting,$$$888$$$898$$$O	sizing,$$$899$$$906$$$O	wiping$$$907$$$913$$$O	the$$$914$$$917$$$O	capsules,$$$918$$$927$$$O	and$$$928$$$931$$$O	drying.$$$932$$$939$$$O	The$$$940$$$943$$$O	soft$$$944$$$948$$$O	roxithromycin$$$949$$$962$$$I	capsules$$$963$$$971$$$O	are$$$972$$$975$$$O	low$$$976$$$979$$$O	in$$$980$$$982$$$O	consumption$$$983$$$994$$$O	of$$$995$$$997$$$O	the$$$998$$$1001$$$O	oily$$$1002$$$1006$$$O	matrix$$$1007$$$1013$$$O	and$$$1014$$$1017$$$O	high$$$1018$$$1022$$$O	in$$$1023$$$1025$$$O	stability.$$$1026$$$1036$$$O
CN103285381A
A$$$0$$$1$$$O	combination$$$2$$$13$$$O	of$$$14$$$16$$$O	ribonucleases$$$17$$$30$$$O	and$$$31$$$34$$$O	cantharidin$$$35$$$46$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	combination$$$27$$$38$$$O	of$$$39$$$41$$$O	ribonucleases$$$42$$$55$$$O	and$$$56$$$59$$$O	cantharidin.$$$60$$$72$$$I	Specifically,$$$73$$$86$$$O	the$$$87$$$90$$$O	invention$$$91$$$100$$$O	discloses$$$101$$$110$$$O	a$$$111$$$112$$$O	pharmaceutical$$$113$$$127$$$O	composition$$$128$$$139$$$O	comprising:$$$140$$$151$$$O	ribonucleases$$$152$$$165$$$O	as$$$166$$$168$$$O	an$$$169$$$171$$$O	active$$$172$$$178$$$O	component$$$179$$$188$$$O	(a);$$$189$$$193$$$O	cantharidin$$$194$$$205$$$I	or$$$206$$$208$$$O	derivatives$$$209$$$220$$$O	or$$$221$$$223$$$O	pharmaceutical$$$224$$$238$$$O	acceptable$$$239$$$249$$$O	salts$$$250$$$255$$$O	of$$$256$$$258$$$O	the$$$259$$$262$$$O	cantharidin$$$263$$$274$$$I	as$$$275$$$277$$$O	an$$$278$$$280$$$O	active$$$281$$$287$$$O	component$$$288$$$297$$$O	(b);$$$298$$$302$$$O	and$$$303$$$306$$$O	pharmaceutical$$$307$$$321$$$O	acceptable$$$322$$$332$$$O	carriers$$$333$$$341$$$O	as$$$342$$$344$$$O	active$$$345$$$351$$$O	components$$$352$$$362$$$O	(c).$$$363$$$367$$$O	The$$$368$$$371$$$O	pharmaceutical$$$372$$$386$$$O	composition$$$387$$$398$$$O	of$$$399$$$401$$$O	the$$$402$$$405$$$O	invention$$$406$$$415$$$O	maycooperatively$$$416$$$432$$$O	and$$$433$$$436$$$O	effectively$$$437$$$448$$$O	increase$$$449$$$457$$$O	inhibition$$$458$$$468$$$O	effects$$$469$$$476$$$O	on$$$477$$$479$$$O	the$$$480$$$483$$$O	growth$$$484$$$490$$$O	of$$$491$$$493$$$O	tumor$$$494$$$499$$$O	cells.$$$500$$$506$$$O
CN103127127A
Cefoperazone$$$0$$$12$$$I	sodium$$$13$$$19$$$I	pharmaceutical$$$20$$$34$$$O	composition$$$35$$$46$$$O	and$$$47$$$50$$$O	preparation$$$51$$$62$$$O	method$$$63$$$69$$$O	thereof$$$70$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	cefoperazone$$$25$$$37$$$I	sodium$$$38$$$44$$$I	pharmaceutical$$$45$$$59$$$O	composition$$$60$$$71$$$O	and$$$72$$$75$$$O	a$$$76$$$77$$$O	preparation$$$78$$$89$$$O	method$$$90$$$96$$$O	thereof,$$$97$$$105$$$O	relating$$$106$$$114$$$O	to$$$115$$$117$$$O	the$$$118$$$121$$$O	field$$$122$$$127$$$O	of$$$128$$$130$$$O	a$$$131$$$132$$$O	pharmaceutical$$$133$$$147$$$O	preparation$$$148$$$159$$$O	and$$$160$$$163$$$O	a$$$164$$$165$$$O	preparation$$$166$$$177$$$O	method$$$178$$$184$$$O	thereof.$$$185$$$193$$$O	The$$$194$$$197$$$O	invention$$$198$$$207$$$O	mainly$$$208$$$214$$$O	solves$$$215$$$221$$$O	the$$$222$$$225$$$O	problems$$$226$$$234$$$O	of$$$235$$$237$$$O	high$$$238$$$242$$$O	dosage$$$243$$$249$$$O	of$$$250$$$252$$$O	single$$$253$$$259$$$O	cefoperazone$$$260$$$272$$$I	sodium$$$273$$$279$$$I	and$$$280$$$283$$$O	metronidazole$$$284$$$297$$$I	preparation,$$$298$$$310$$$O	poor$$$311$$$315$$$O	treatment$$$316$$$325$$$O	effect$$$326$$$332$$$O	after$$$333$$$338$$$O	combination,$$$339$$$351$$$O	and$$$352$$$355$$$O	great$$$356$$$361$$$O	side$$$362$$$366$$$O	effect$$$367$$$373$$$O	in$$$374$$$376$$$O	the$$$377$$$380$$$O	prior$$$381$$$386$$$O	art.$$$387$$$391$$$O	The$$$392$$$395$$$O	pharmaceutical$$$396$$$410$$$O	composition$$$411$$$422$$$O	comprises$$$423$$$432$$$O	cefoperazone$$$433$$$445$$$I	sodium$$$446$$$452$$$I	and$$$453$$$456$$$O	metronidazole$$$457$$$470$$$I	lipid$$$471$$$476$$$O	microspheres$$$477$$$489$$$O	in$$$490$$$492$$$O	a$$$493$$$494$$$O	weight$$$495$$$501$$$O	ratio$$$502$$$507$$$O	of$$$508$$$510$$$O	100:3-100:10,$$$511$$$524$$$O	wherein$$$525$$$532$$$O	the$$$533$$$536$$$O	weight$$$537$$$543$$$O	of$$$544$$$546$$$O	the$$$547$$$550$$$O	metronidazole$$$551$$$564$$$I	lipid$$$565$$$570$$$O	microspheres$$$571$$$583$$$O	is$$$584$$$586$$$O	metered$$$587$$$594$$$O	on$$$595$$$597$$$O	the$$$598$$$601$$$O	basis$$$602$$$607$$$O	of$$$608$$$610$$$O	on$$$611$$$613$$$O	metronidazole;$$$614$$$628$$$I	and$$$629$$$632$$$O	when$$$633$$$637$$$O	the$$$638$$$641$$$O	pharmaceutical$$$642$$$656$$$O	composition$$$657$$$668$$$O	is$$$669$$$671$$$O	prepared$$$672$$$680$$$O	into$$$681$$$685$$$O	a$$$686$$$687$$$O	powder$$$688$$$694$$$O	injection,$$$695$$$705$$$O	the$$$706$$$709$$$O	pH$$$710$$$712$$$O	value$$$713$$$718$$$O	of$$$719$$$721$$$O	the$$$722$$$725$$$O	water$$$726$$$731$$$O	solution$$$732$$$740$$$O	of$$$741$$$743$$$O	the$$$744$$$747$$$O	pharmaceutical$$$748$$$762$$$O	composition$$$763$$$774$$$O	is$$$775$$$777$$$O	6.5-7.0.$$$778$$$786$$$O	The$$$787$$$790$$$O	pharmaceutical$$$791$$$805$$$O	composition$$$806$$$817$$$O	powder$$$818$$$824$$$O	injection$$$825$$$834$$$O	provided$$$835$$$843$$$O	by$$$844$$$846$$$O	the$$$847$$$850$$$O	invention$$$851$$$860$$$O	has$$$861$$$864$$$O	high$$$865$$$869$$$O	curative$$$870$$$878$$$O	effect,$$$879$$$886$$$O	and$$$887$$$890$$$O	can$$$891$$$894$$$O	reduce$$$895$$$901$$$O	the$$$902$$$905$$$O	consumption$$$906$$$917$$$O	of$$$918$$$920$$$O	the$$$921$$$924$$$O	metronidazole$$$925$$$938$$$I	by$$$939$$$941$$$O	more$$$942$$$946$$$O	than$$$947$$$951$$$O	80%,$$$952$$$956$$$O	thereby$$$957$$$964$$$O	greatly$$$965$$$972$$$O	relieving$$$973$$$982$$$O	or$$$983$$$985$$$O	avoiding$$$986$$$994$$$O	the$$$995$$$998$$$O	toxic$$$999$$$1004$$$O	and$$$1005$$$1008$$$O	side$$$1009$$$1013$$$O	effects$$$1014$$$1021$$$O	of$$$1022$$$1024$$$O	the$$$1025$$$1028$$$O	metronidazole,$$$1029$$$1043$$$I	especially$$$1044$$$1054$$$O	digestive$$$1055$$$1064$$$O	tract$$$1065$$$1070$$$O	reactions,$$$1071$$$1081$$$O	including$$$1082$$$1091$$$O	nausea,$$$1092$$$1099$$$O	vomit,$$$1100$$$1106$$$O	inappetence,$$$1107$$$1119$$$O	abdominal$$$1120$$$1129$$$O	colic$$$1130$$$1135$$$O	and$$$1136$$$1139$$$O	neurotoxicity,$$$1140$$$1154$$$O	and$$$1155$$$1158$$$O	lowering$$$1159$$$1167$$$O	the$$$1168$$$1171$$$O	incidence$$$1172$$$1181$$$O	rate$$$1182$$$1186$$$O	of$$$1187$$$1189$$$O	adverse$$$1190$$$1197$$$O	reactions.$$$1198$$$1208$$$O
CN1907291A
Injectio$$$0$$$8$$$O	for$$$9$$$12$$$O	nanometer$$$13$$$22$$$O	notoginsenoside$$$23$$$38$$$I	and$$$39$$$42$$$O	its$$$43$$$46$$$O	preparing$$$47$$$56$$$O	method$$$57$$$63$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	nanometer$$$26$$$35$$$O	aescin$$$36$$$42$$$I	injection$$$43$$$52$$$O	and$$$53$$$56$$$O	preparing$$$57$$$66$$$O	method,$$$67$$$74$$$O	which$$$75$$$80$$$O	is$$$81$$$83$$$O	characterized$$$84$$$97$$$O	by$$$98$$$100$$$O	the$$$101$$$104$$$O	following:$$$105$$$115$$$O	extracting$$$116$$$126$$$O	from$$$127$$$131$$$O	effective$$$132$$$141$$$O	position$$$142$$$150$$$O	from$$$151$$$155$$$O	aescin$$$156$$$162$$$I	to$$$163$$$165$$$O	prepare$$$166$$$173$$$O	nanometer$$$174$$$183$$$O	aescin$$$184$$$190$$$I	with$$$191$$$195$$$O	medical$$$196$$$203$$$O	carrier;$$$204$$$212$$$O	blending$$$213$$$221$$$O	with$$$222$$$226$$$O	drug$$$227$$$231$$$O	auxiliary$$$232$$$241$$$O	material$$$242$$$250$$$O	to$$$251$$$253$$$O	prepare$$$254$$$261$$$O	water$$$262$$$267$$$O	injection,$$$268$$$278$$$O	transfusion$$$279$$$290$$$O	agent$$$291$$$296$$$O	and$$$297$$$300$$$O	powder$$$301$$$307$$$O	injection;$$$308$$$318$$$O	controlling$$$319$$$330$$$O	the$$$331$$$334$$$O	content$$$335$$$342$$$O	of$$$343$$$345$$$O	beta-aescin$$$346$$$357$$$I	at$$$358$$$360$$$O	50-85%.$$$361$$$368$$$O
WO2012129220A1
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	improving$$$12$$$21$$$O	bone$$$22$$$26$$$O	health$$$27$$$33$$$O	in$$$34$$$36$$$O	infants$$$37$$$44$$$O	using$$$45$$$50$$$O	prebiotics$$$51$$$61$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	methods$$$14$$$21$$$O	for$$$22$$$25$$$O	improving$$$26$$$35$$$O	bone$$$36$$$40$$$O	health,$$$41$$$48$$$O	strength$$$49$$$57$$$O	and$$$58$$$61$$$O	formation$$$62$$$71$$$O	in$$$72$$$74$$$O	an$$$75$$$77$$$O	infant$$$78$$$84$$$O	who$$$85$$$88$$$O	may$$$89$$$92$$$O	be$$$93$$$95$$$O	susceptible$$$96$$$107$$$O	to$$$108$$$110$$$O	developing$$$111$$$121$$$O	bone$$$122$$$126$$$O	health$$$127$$$133$$$O	issues$$$134$$$140$$$O	from$$$141$$$145$$$O	conception$$$146$$$156$$$O	through$$$157$$$164$$$O	adolescence.$$$165$$$177$$$O	The$$$178$$$181$$$O	methods$$$182$$$189$$$O	include$$$190$$$197$$$O	administration$$$198$$$212$$$O	of$$$213$$$215$$$O	a$$$216$$$217$$$O	nutritional$$$218$$$229$$$O	formulation$$$230$$$241$$$O	including$$$242$$$251$$$O	a$$$252$$$253$$$O	prebiotic$$$254$$$263$$$O	to$$$264$$$266$$$O	a$$$267$$$268$$$O	woman$$$269$$$274$$$O	during$$$275$$$281$$$O	pregnancy$$$282$$$291$$$O	and$$$292$$$295$$$O	optionally$$$296$$$306$$$O	during$$$307$$$313$$$O	lactation$$$314$$$323$$$O	and$$$324$$$327$$$O	breastfeeding$$$328$$$341$$$O	of$$$342$$$344$$$O	an$$$345$$$347$$$O	infant.$$$348$$$355$$$O
CN1788719A
Leucogen$$$0$$$8$$$I	slow$$$9$$$13$$$O	release$$$14$$$21$$$O	composition$$$22$$$33$$$O	and$$$34$$$37$$$O	preparation$$$38$$$49$$$O	process$$$50$$$57$$$O	thereof$$$58$$$65$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	slow$$$32$$$36$$$O	released$$$37$$$45$$$O	Leucogen$$$46$$$54$$$I	composition$$$55$$$66$$$O	and$$$67$$$70$$$O	its$$$71$$$74$$$O	preparation$$$75$$$86$$$O	process.$$$87$$$95$$$O	The$$$96$$$99$$$O	slow$$$100$$$104$$$O	released$$$105$$$113$$$O	Leucogen$$$114$$$122$$$I	composition$$$123$$$134$$$O	consists$$$135$$$143$$$O	of$$$144$$$146$$$O	Leucogen$$$147$$$155$$$I	10-80$$$156$$$161$$$O	wt%,$$$162$$$166$$$O	slow$$$167$$$171$$$O	releasing$$$172$$$181$$$O	retardant$$$182$$$191$$$O	5-60$$$192$$$196$$$O	wt%$$$197$$$200$$$O	and$$$201$$$204$$$O	other$$$205$$$210$$$O	medicinal$$$211$$$220$$$O	supplementary$$$221$$$234$$$O	material$$$235$$$243$$$O	15-80$$$244$$$249$$$O	wt%.$$$250$$$254$$$O	The$$$255$$$258$$$O	slow$$$259$$$263$$$O	releasing$$$264$$$273$$$O	retardant$$$274$$$283$$$O	is$$$284$$$286$$$O	selected$$$287$$$295$$$O	from$$$296$$$300$$$O	filming$$$301$$$308$$$O	material,$$$309$$$318$$$O	dissolving$$$319$$$329$$$O	skeleton$$$330$$$338$$$O	material,$$$339$$$348$$$O	insoluble$$$349$$$358$$$O	skeleton$$$359$$$367$$$O	material$$$368$$$376$$$O	and$$$377$$$380$$$O	hydrophilic$$$381$$$392$$$O	skeleton$$$393$$$401$$$O	material;$$$402$$$411$$$O	and$$$412$$$415$$$O	the$$$416$$$419$$$O	other$$$420$$$425$$$O	medicinal$$$426$$$435$$$O	supplementary$$$436$$$449$$$O	material$$$450$$$458$$$O	includes$$$459$$$467$$$O	diluent,$$$468$$$476$$$O	adhesive$$$477$$$485$$$O	and$$$486$$$489$$$O	lubricant.$$$490$$$500$$$O	The$$$501$$$504$$$O	slow$$$505$$$509$$$O	released$$$510$$$518$$$O	composition$$$519$$$530$$$O	is$$$531$$$533$$$O	tablet$$$534$$$540$$$O	or$$$541$$$543$$$O	capsule$$$544$$$551$$$O	preferably.$$$552$$$563$$$O	The$$$564$$$567$$$O	present$$$568$$$575$$$O	invention$$$576$$$585$$$O	aims$$$586$$$590$$$O	at$$$591$$$593$$$O	providing$$$594$$$603$$$O	the$$$604$$$607$$$O	preparation$$$608$$$619$$$O	superior$$$620$$$628$$$O	to$$$629$$$631$$$O	available$$$632$$$641$$$O	tablet,$$$642$$$649$$$O	and$$$650$$$653$$$O	the$$$654$$$657$$$O	slow$$$658$$$662$$$O	released$$$663$$$671$$$O	composition$$$672$$$683$$$O	has$$$684$$$687$$$O	the$$$688$$$691$$$O	advantages$$$692$$$702$$$O	of$$$703$$$705$$$O	slow$$$706$$$710$$$O	release$$$711$$$718$$$O	of$$$719$$$721$$$O	main$$$722$$$726$$$O	medicinal$$$727$$$736$$$O	components,$$$737$$$748$$$O	less$$$749$$$753$$$O	blood$$$754$$$759$$$O	medicine$$$760$$$768$$$O	concentration$$$769$$$782$$$O	fluctuation,$$$783$$$795$$$O	prolonged$$$796$$$805$$$O	effective$$$806$$$815$$$O	blood$$$816$$$821$$$O	medicine$$$822$$$830$$$O	concentration$$$831$$$844$$$O	maintaining$$$845$$$856$$$O	period,$$$857$$$864$$$O	reduced$$$865$$$872$$$O	toxic$$$873$$$878$$$O	side$$$879$$$883$$$O	effect,$$$884$$$891$$$O	etc.$$$892$$$896$$$O
DE102006028284A1
Agent,$$$0$$$6$$$O	useful$$$7$$$13$$$O	for$$$14$$$17$$$O	the$$$18$$$21$$$O	prevention$$$22$$$32$$$O	and$$$33$$$36$$$O	treatment$$$37$$$46$$$O	of$$$47$$$49$$$O	hyperammonemia,$$$50$$$65$$$O	comprises$$$66$$$75$$$O	cobalamine,$$$76$$$87$$$I	folic$$$88$$$93$$$I	acid,$$$94$$$99$$$I	vitamin$$$100$$$107$$$I	B6,$$$108$$$111$$$I	betaine,$$$112$$$120$$$I	L-arginine,$$$121$$$132$$$I	L-ornithine,$$$133$$$145$$$I	L-citrulline,$$$146$$$159$$$I	L-valine,$$$160$$$169$$$I	L-threonine,$$$170$$$182$$$I	L-leucine,$$$183$$$193$$$I	L-isoleucine,$$$194$$$207$$$I	carnitine$$$208$$$217$$$I	and$$$218$$$221$$$O	phosphocreatine$$$222$$$237$$$I
Agent$$$0$$$5$$$O	(I)$$$6$$$9$$$O	for$$$10$$$13$$$O	the$$$14$$$17$$$O	prevention$$$18$$$28$$$O	and$$$29$$$32$$$O	treatment$$$33$$$42$$$O	of$$$43$$$45$$$O	hyperammonemia$$$46$$$60$$$O	comprises$$$61$$$70$$$O	cobalamine.$$$71$$$82$$$O	-$$$83$$$84$$$O	ACTIVITY$$$85$$$93$$$O	:$$$94$$$95$$$O	None$$$96$$$100$$$O	given.$$$101$$$107$$$O	-$$$108$$$109$$$O	MECHANISM$$$110$$$119$$$O	OF$$$120$$$122$$$O	ACTION$$$123$$$129$$$O	:$$$130$$$131$$$O	None$$$132$$$136$$$O	given.$$$137$$$143$$$O
EP1390041B1
Drug$$$0$$$4$$$O	delivery$$$5$$$13$$$O	system$$$14$$$20$$$O	comprising$$$21$$$31$$$O	a$$$32$$$33$$$O	tetrahydroxylated$$$34$$$51$$$I	estrogen$$$52$$$60$$$I	for$$$61$$$64$$$O	use$$$65$$$68$$$O	in$$$69$$$71$$$O	hormonal$$$72$$$80$$$O	contraception$$$81$$$94$$$O
One$$$0$$$3$$$O	aspect$$$4$$$10$$$O	of$$$11$$$13$$$O	the$$$14$$$17$$$O	present$$$18$$$25$$$O	invention$$$26$$$35$$$O	relates$$$36$$$43$$$O	to$$$44$$$46$$$O	a$$$47$$$48$$$O	method$$$49$$$55$$$O	of$$$56$$$58$$$O	contraception$$$59$$$72$$$O	in$$$73$$$75$$$O	mammalian$$$76$$$85$$$O	females,$$$86$$$94$$$O	which$$$95$$$100$$$O	method$$$101$$$107$$$O	comprises$$$108$$$117$$$O	the$$$118$$$121$$$O	parenteral$$$122$$$132$$$O	or$$$133$$$135$$$O	rectal$$$136$$$142$$$O	administration$$$143$$$157$$$O	of$$$158$$$160$$$O	an$$$161$$$163$$$O	estrogenic$$$164$$$174$$$O	component$$$175$$$184$$$O	and$$$185$$$188$$$O	a$$$189$$$190$$$O	progestogenic$$$191$$$204$$$O	component$$$205$$$214$$$O	to$$$215$$$217$$$O	a$$$218$$$219$$$O	female$$$220$$$226$$$O	of$$$227$$$229$$$O	childbearing$$$230$$$242$$$O	capability$$$243$$$253$$$O	in$$$254$$$256$$$O	an$$$257$$$259$$$O	amount$$$260$$$266$$$O	effective$$$267$$$276$$$O	to$$$277$$$279$$$O	inhibit$$$280$$$287$$$O	ovulation,$$$288$$$298$$$O	wherein$$$299$$$306$$$O	the$$$307$$$310$$$O	estrogenic$$$311$$$321$$$O	component$$$322$$$331$$$O	is$$$332$$$334$$$O	selected$$$335$$$343$$$O	from$$$344$$$348$$$O	the$$$349$$$352$$$O	group$$$353$$$358$$$O	consisting$$$359$$$369$$$O	of:$$$370$$$373$$$O	substances$$$374$$$384$$$O	represented$$$385$$$396$$$O	by$$$397$$$399$$$O	the$$$400$$$403$$$O	formula$$$404$$$411$$$O	(I)$$$412$$$415$$$O	in$$$416$$$418$$$O	which$$$419$$$424$$$O	formula$$$425$$$432$$$O	R1,$$$433$$$436$$$O	R2,$$$437$$$440$$$O	R3,$$$441$$$444$$$O	R4$$$445$$$447$$$O	independently$$$448$$$461$$$O	are$$$462$$$465$$$O	a$$$466$$$467$$$O	hydrogen$$$468$$$476$$$I	atom,$$$477$$$482$$$O	a$$$483$$$484$$$O	hydroxyl$$$485$$$493$$$I	group$$$494$$$499$$$O	or$$$500$$$502$$$O	an$$$503$$$505$$$O	alokxy$$$506$$$512$$$I	group$$$513$$$518$$$O	with$$$519$$$523$$$O	1-5$$$524$$$527$$$O	carbon$$$528$$$534$$$I	atoms;$$$535$$$541$$$O	each$$$542$$$546$$$O	of$$$547$$$549$$$O	R5,$$$550$$$553$$$O	R6,$$$554$$$557$$$O	R7,$$$558$$$561$$$O	is$$$562$$$564$$$O	a$$$565$$$566$$$O	hydroxyl$$$567$$$575$$$I	group;$$$576$$$582$$$O	and$$$583$$$586$$$O	no$$$587$$$589$$$O	more$$$590$$$594$$$O	than$$$595$$$599$$$O	3$$$600$$$601$$$O	of$$$602$$$604$$$O	R1,$$$605$$$608$$$O	R2,$$$609$$$612$$$O	R3,$$$613$$$616$$$O	R4$$$617$$$619$$$O	are$$$620$$$623$$$O	hydrogen$$$624$$$632$$$I	atoms;$$$633$$$639$$$O	precursors$$$640$$$650$$$O	capable$$$651$$$658$$$O	of$$$659$$$661$$$O	liberating$$$662$$$672$$$O	a$$$673$$$674$$$O	substance$$$675$$$684$$$O	according$$$685$$$694$$$O	to$$$695$$$697$$$O	the$$$698$$$701$$$O	aforementioned$$$702$$$716$$$O	formula$$$717$$$724$$$O	when$$$725$$$729$$$O	used$$$730$$$734$$$O	in$$$735$$$737$$$O	the$$$738$$$741$$$O	present$$$742$$$749$$$O	method;$$$750$$$757$$$O	and$$$758$$$761$$$O	mixtures$$$762$$$770$$$O	of$$$771$$$773$$$O	one$$$774$$$777$$$O	or$$$778$$$780$$$O	more$$$781$$$785$$$O	of$$$786$$$788$$$O	the$$$789$$$792$$$O	aforementioned$$$793$$$807$$$O	substances$$$808$$$818$$$O	and/or$$$819$$$825$$$O	precursors.$$$826$$$837$$$O	Another$$$838$$$845$$$O	aspect$$$846$$$852$$$O	of$$$853$$$855$$$O	the$$$856$$$859$$$O	invention$$$860$$$869$$$O	concerns$$$870$$$878$$$O	a$$$879$$$880$$$O	drug$$$881$$$885$$$O	delivery$$$886$$$894$$$O	system$$$895$$$901$$$O	for$$$902$$$905$$$O	parenteral$$$906$$$916$$$O	or$$$917$$$919$$$O	rectal$$$920$$$926$$$O	administration$$$927$$$941$$$O	that$$$942$$$946$$$O	contains$$$947$$$955$$$O	the$$$956$$$959$$$O	aforementioned$$$960$$$974$$$O	estrogenic$$$975$$$985$$$O	component$$$986$$$995$$$O	and$$$996$$$999$$$O	a$$$1000$$$1001$$$O	progestogenic$$$1002$$$1015$$$O	component,$$$1016$$$1026$$$O	said$$$1027$$$1031$$$O	drug$$$1032$$$1036$$$O	delivery$$$1037$$$1045$$$O	system$$$1046$$$1052$$$O	being$$$1053$$$1058$$$O	selected$$$1059$$$1067$$$O	from$$$1068$$$1072$$$O	the$$$1073$$$1076$$$O	group$$$1077$$$1082$$$O	consisting$$$1083$$$1093$$$O	of$$$1094$$$1096$$$O	suppositories,$$$1097$$$1111$$$O	systems$$$1112$$$1119$$$O	for$$$1120$$$1123$$$O	intravaginal$$$1124$$$1136$$$O	delivery,$$$1137$$$1146$$$O	inhalers,$$$1147$$$1156$$$O	nasal$$$1157$$$1162$$$O	sprays$$$1163$$$1169$$$O	and$$$1170$$$1173$$$O	transdermal$$$1174$$$1185$$$O	delivery$$$1186$$$1194$$$O	systems.$$$1195$$$1203$$$O
CN101961329A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Silibinin$$$15$$$24$$$I	in$$$25$$$27$$$O	preparing$$$28$$$37$$$O	anti-male$$$38$$$47$$$O	hormone$$$48$$$55$$$O	medicaments$$$56$$$67$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	Silibinin$$$39$$$48$$$I	in$$$49$$$51$$$O	preparing$$$52$$$61$$$O	anti-male$$$62$$$71$$$O	hormone$$$72$$$79$$$O	medicaments.$$$80$$$92$$$O	Experiments$$$93$$$104$$$O	show$$$105$$$109$$$O	that$$$110$$$114$$$O	the$$$115$$$118$$$O	Silibinin$$$119$$$128$$$I	extracted$$$129$$$138$$$O	from$$$139$$$143$$$O	seeds$$$144$$$149$$$O	of$$$150$$$152$$$O	a$$$153$$$154$$$O	feverfew$$$155$$$163$$$O	purple$$$164$$$170$$$O	flower$$$171$$$177$$$O	Herba$$$178$$$183$$$O	Silybi$$$184$$$190$$$O	has$$$191$$$194$$$O	the$$$195$$$198$$$O	pharmacological$$$199$$$214$$$O	effect$$$215$$$221$$$O	of$$$222$$$224$$$O	reducing$$$225$$$233$$$O	male$$$234$$$238$$$O	hormone,$$$239$$$247$$$O	has$$$248$$$251$$$O	the$$$252$$$255$$$O	advantages$$$256$$$266$$$O	of$$$267$$$269$$$O	safe$$$270$$$274$$$O	clinical$$$275$$$283$$$O	application$$$284$$$295$$$O	and$$$296$$$299$$$O	small$$$300$$$305$$$O	side$$$306$$$310$$$O	effect,$$$311$$$318$$$O	and$$$319$$$322$$$O	can$$$323$$$326$$$O	be$$$327$$$329$$$O	clinically$$$330$$$340$$$O	used$$$341$$$345$$$O	as$$$346$$$348$$$O	an$$$349$$$351$$$O	anti-male$$$352$$$361$$$O	hormone$$$362$$$369$$$O	medicament.$$$370$$$381$$$O
US20120034266
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	improving$$$29$$$38$$$O	immune$$$39$$$45$$$O	response$$$46$$$54$$$O	by$$$55$$$57$$$O	a$$$58$$$59$$$O	nutraceutical$$$60$$$73$$$O	antioxidant$$$74$$$85$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	new$$$33$$$36$$$O	means$$$37$$$42$$$O	of$$$43$$$45$$$O	restoring$$$46$$$55$$$O	the$$$56$$$59$$$O	immune$$$60$$$66$$$O	system$$$67$$$73$$$O	in$$$74$$$76$$$O	aging$$$77$$$82$$$O	and$$$83$$$86$$$O	immunocompromised$$$87$$$104$$$O	individuals$$$105$$$116$$$O	using$$$117$$$122$$$O	an$$$123$$$125$$$O	antioxidant$$$126$$$137$$$O	nutraceutical.$$$138$$$152$$$O	The$$$153$$$156$$$O	nutraceutical$$$157$$$170$$$O	stimulates$$$171$$$181$$$O	the$$$182$$$185$$$O	aging$$$186$$$191$$$O	immune$$$192$$$198$$$O	system$$$199$$$205$$$O	through$$$206$$$213$$$O	the$$$214$$$217$$$O	Nrf2$$$218$$$222$$$O	master$$$223$$$229$$$O	gene$$$230$$$234$$$O	regulatory$$$235$$$245$$$O	pathway.$$$246$$$254$$$O	The$$$255$$$258$$$O	invention$$$259$$$268$$$O	is$$$269$$$271$$$O	based$$$272$$$277$$$O	in$$$278$$$280$$$O	part$$$281$$$285$$$O	on$$$286$$$288$$$O	the$$$289$$$292$$$O	discovery$$$293$$$302$$$O	that$$$303$$$307$$$O	the$$$308$$$311$$$O	Nrf2$$$312$$$316$$$O	has$$$317$$$320$$$O	antioxidant$$$321$$$332$$$O	and$$$333$$$336$$$O	immune$$$337$$$343$$$O	restorative$$$344$$$355$$$O	activity.$$$356$$$365$$$O	The$$$366$$$369$$$O	nutraceutical$$$370$$$383$$$O	improves$$$384$$$392$$$O	function$$$393$$$401$$$O	of$$$402$$$404$$$O	both$$$405$$$409$$$O	the$$$410$$$413$$$O	innate$$$414$$$420$$$O	and$$$421$$$424$$$O	adaptive$$$425$$$433$$$O	immune$$$434$$$440$$$O	systems.$$$441$$$449$$$O
DE102010014411A1
New$$$0$$$3$$$O	iron$$$4$$$8$$$I	complexes,$$$9$$$19$$$O	useful$$$20$$$26$$$O	as$$$27$$$29$$$O	carbon$$$30$$$36$$$I	monoxide$$$37$$$45$$$I	and$$$46$$$49$$$O	iron$$$50$$$54$$$I	releasing$$$55$$$64$$$O	molecules$$$65$$$74$$$O	for$$$75$$$78$$$O	treating$$$79$$$87$$$O	e.g.$$$88$$$92$$$O	high$$$93$$$97$$$O	blood$$$98$$$103$$$O	pressure,$$$104$$$113$$$O	cancer,$$$114$$$121$$$O	tissue$$$122$$$128$$$O	damage$$$129$$$135$$$O	by$$$136$$$138$$$O	irradiation,$$$139$$$151$$$O	post-ischemic$$$152$$$165$$$O	injury,$$$166$$$173$$$O	atherosclerosis,$$$174$$$190$$$O	sepsis,$$$191$$$198$$$O	angina$$$199$$$205$$$O	and$$$206$$$209$$$O	myocardial$$$210$$$220$$$O	infarction$$$221$$$231$$$O
Iron$$$0$$$4$$$I	complexes$$$5$$$14$$$O	having$$$15$$$21$$$O	a$$$22$$$23$$$O	structure$$$24$$$33$$$O	(I)$$$34$$$37$$$O	are$$$38$$$41$$$O	new.$$$42$$$46$$$O	Iron$$$47$$$51$$$I	complexes$$$52$$$61$$$O	having$$$62$$$68$$$O	a$$$69$$$70$$$O	structure$$$71$$$80$$$O	of$$$81$$$83$$$O	formula$$$84$$$91$$$O	(I)$$$92$$$95$$$O	are$$$96$$$99$$$O	new.$$$100$$$104$$$O	R$$$105$$$106$$$O	:$$$107$$$108$$$O	H,$$$109$$$111$$$I	aryl-,$$$112$$$118$$$I	acyl-,$$$119$$$125$$$I	sugar-residue,$$$126$$$140$$$O	amino$$$141$$$146$$$I	acid,$$$147$$$152$$$I	peptide$$$153$$$160$$$O	sequence,$$$161$$$170$$$O	heterocycle,$$$171$$$183$$$I	alkyl$$$184$$$189$$$I	or$$$190$$$192$$$O	acyl;$$$193$$$198$$$I	and$$$199$$$202$$$O	R1a,$$$203$$$207$$$O	R2a$$$208$$$211$$$O	:$$$212$$$213$$$O	H,$$$214$$$216$$$I	alkyl,$$$217$$$223$$$I	acyl,$$$224$$$229$$$I	peptide$$$230$$$237$$$O	sequence,$$$238$$$247$$$O	amine$$$248$$$253$$$I	derivative,$$$254$$$265$$$O	ether$$$266$$$271$$$I	derivative,$$$272$$$283$$$O	carboxylic$$$284$$$294$$$I	acid$$$295$$$299$$$I	derivative,$$$300$$$311$$$O	thioether$$$312$$$321$$$I	derivative,$$$322$$$333$$$O	OH,$$$334$$$337$$$I	NH$$$338$$$340$$$I	2or$$$341$$$344$$$I	sulfonic$$$345$$$353$$$I	acid$$$354$$$358$$$I	derivative.$$$359$$$370$$$O	Where$$$371$$$376$$$O	(I)$$$377$$$380$$$O	exclude:$$$381$$$389$$$O	when$$$390$$$394$$$O	R$$$395$$$396$$$O	and$$$397$$$400$$$O	R2a$$$401$$$404$$$O	are$$$405$$$408$$$O	H$$$409$$$410$$$I	and$$$411$$$414$$$O	R1a$$$415$$$418$$$O	is$$$419$$$421$$$O	COOH;$$$422$$$427$$$I	and$$$428$$$431$$$O	when$$$432$$$436$$$O	R$$$437$$$438$$$O	is$$$439$$$441$$$O	H,$$$442$$$444$$$I	R1a$$$445$$$448$$$O	is$$$449$$$451$$$O	COO-alkyl,$$$452$$$462$$$I	and$$$463$$$466$$$O	R2a$$$467$$$470$$$O	is$$$471$$$473$$$O	H.$$$474$$$476$$$I	An$$$477$$$479$$$O	independent$$$480$$$491$$$O	claim$$$492$$$497$$$O	is$$$498$$$500$$$O	included$$$501$$$509$$$O	for$$$510$$$513$$$O	the$$$514$$$517$$$O	preparation$$$518$$$529$$$O	of$$$530$$$532$$$O	(I).$$$533$$$537$$$O	-$$$538$$$539$$$O	ACTIVITY$$$540$$$548$$$O	:$$$549$$$550$$$O	Hypotensive;$$$551$$$563$$$O	Cytostatic;$$$564$$$575$$$O	Immunosuppressive;$$$576$$$594$$$O	Vulnerary;$$$595$$$605$$$O	Antiarteriosclerotic;$$$606$$$627$$$O	Antibacterial;$$$628$$$642$$$O	Antianginal;$$$643$$$655$$$O	Cardiant;$$$656$$$665$$$O	Vasotropic;$$$666$$$677$$$O	Antiinflammatory.$$$678$$$695$$$O	-$$$696$$$697$$$O	MECHANISM$$$698$$$707$$$O	OF$$$708$$$710$$$O	ACTION$$$711$$$717$$$O	:$$$718$$$719$$$O	None$$$720$$$724$$$O	given.$$$725$$$731$$$O
CN103735500A
Tapentadol$$$0$$$10$$$I	hydrochloride$$$11$$$24$$$I	injection$$$25$$$34$$$O	and$$$35$$$38$$$O	preparation$$$39$$$50$$$O	method$$$51$$$57$$$O	thereof$$$58$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	new$$$25$$$28$$$O	tapentadol$$$29$$$39$$$I	hydrochloride$$$40$$$53$$$I	injection,$$$54$$$64$$$O	particularly$$$65$$$77$$$O	a$$$78$$$79$$$O	small-capacity$$$80$$$94$$$O	injection$$$95$$$104$$$O	and$$$105$$$108$$$O	a$$$109$$$110$$$O	preparation$$$111$$$122$$$O	method$$$123$$$129$$$O	thereof.$$$130$$$138$$$O	The$$$139$$$142$$$O	injection$$$143$$$152$$$O	is$$$153$$$155$$$O	composed$$$156$$$164$$$O	of$$$165$$$167$$$O	tapentadol$$$168$$$178$$$I	hydrochloride$$$179$$$192$$$I	or$$$193$$$195$$$O	tapentadol$$$196$$$206$$$I	alkali$$$207$$$213$$$O	with$$$214$$$218$$$O	active$$$219$$$225$$$O	ingredients,$$$226$$$238$$$O	and$$$239$$$242$$$O	medicinal$$$243$$$252$$$O	carriers.$$$253$$$262$$$O	The$$$263$$$266$$$O	tapentadol$$$267$$$277$$$I	hydrochloride$$$278$$$291$$$I	injection$$$292$$$301$$$O	can$$$302$$$305$$$O	be$$$306$$$308$$$O	suitable$$$309$$$317$$$O	for$$$318$$$321$$$O	small-capacity$$$322$$$336$$$O	injections$$$337$$$347$$$O	with$$$348$$$352$$$O	various$$$353$$$360$$$O	sizes.$$$361$$$367$$$O	Compared$$$368$$$376$$$O	with$$$377$$$381$$$O	the$$$382$$$385$$$O	conventional$$$386$$$398$$$O	oral$$$399$$$403$$$O	preparations,$$$404$$$417$$$O	the$$$418$$$421$$$O	tapentadol$$$422$$$432$$$I	hydrochloride$$$433$$$446$$$I	injection$$$447$$$456$$$O	has$$$457$$$460$$$O	the$$$461$$$464$$$O	advantages$$$465$$$475$$$O	of$$$476$$$478$$$O	high$$$479$$$483$$$O	bioavailability,$$$484$$$500$$$O	good$$$501$$$505$$$O	absorption$$$506$$$516$$$O	effect$$$517$$$523$$$O	of$$$524$$$526$$$O	medicine,$$$527$$$536$$$O	fast$$$537$$$541$$$O	distribution,$$$542$$$555$$$O	good$$$556$$$560$$$O	treatment$$$561$$$570$$$O	effect$$$571$$$577$$$O	and$$$578$$$581$$$O	the$$$582$$$585$$$O	like.$$$586$$$591$$$O	The$$$592$$$595$$$O	medicinal$$$596$$$605$$$O	occasion$$$606$$$614$$$O	of$$$615$$$617$$$O	the$$$618$$$621$$$O	tapentadol$$$622$$$632$$$I	hydrochloride$$$633$$$646$$$I	is$$$647$$$649$$$O	enlarged,$$$650$$$659$$$O	and$$$660$$$663$$$O	the$$$664$$$667$$$O	clinical$$$668$$$676$$$O	medication$$$677$$$687$$$O	level$$$688$$$693$$$O	of$$$694$$$696$$$O	the$$$697$$$700$$$O	tapentadol$$$701$$$711$$$I	hydrochloride$$$712$$$725$$$I	is$$$726$$$728$$$O	improved.$$$729$$$738$$$O
US6897315
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	producing$$$11$$$20$$$O	8-methoxy-quinolinecarboxylic$$$21$$$50$$$I	acids$$$51$$$56$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	novel$$$35$$$40$$$O	process$$$41$$$48$$$O	for$$$49$$$52$$$O	preparing$$$53$$$62$$$O	8-methoxy-3-quinolonecarboxylic$$$63$$$94$$$I	acids$$$95$$$100$$$I	which$$$101$$$106$$$O	are$$$107$$$110$$$O	antibiotics$$$111$$$122$$$O	having$$$123$$$129$$$O	potent$$$130$$$136$$$O	antibacterial$$$137$$$150$$$O	action.$$$151$$$158$$$O
CN103396436A
Monobutyltin$$$0$$$12$$$I	trichloride$$$13$$$24$$$I	substituted$$$25$$$36$$$I	salicylidenedimine$$$37$$$55$$$I	Schiff$$$56$$$62$$$I	base$$$63$$$67$$$I	complex$$$68$$$75$$$O	as$$$76$$$78$$$O	well$$$79$$$83$$$O	as$$$84$$$86$$$O	preparation$$$87$$$98$$$O	method$$$99$$$105$$$O	and$$$106$$$109$$$O	applications$$$110$$$122$$$O	thereof$$$123$$$130$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	monobutyltin$$$26$$$38$$$I	trichloride$$$39$$$50$$$I	substituted$$$51$$$62$$$I	salicylidenedimine$$$63$$$81$$$I	Schiff$$$82$$$88$$$I	base$$$89$$$93$$$I	complex$$$94$$$101$$$O	which$$$102$$$107$$$O	is$$$108$$$110$$$O	a$$$111$$$112$$$O	complex$$$113$$$120$$$O	with$$$121$$$125$$$O	the$$$126$$$129$$$O	following$$$130$$$139$$$O	structural$$$140$$$150$$$O	formula$$$151$$$158$$$O	(I),$$$159$$$163$$$O	wherein$$$164$$$171$$$O	Bu$$$172$$$174$$$I	represents$$$175$$$185$$$O	n-butyl,$$$186$$$194$$$I	R1$$$195$$$197$$$O	is$$$198$$$200$$$O	-H,$$$201$$$204$$$I	-Cl$$$205$$$208$$$I	or$$$209$$$211$$$O	-Br,$$$212$$$216$$$I	R2$$$217$$$219$$$O	is$$$220$$$222$$$O	-H$$$223$$$225$$$I	or$$$226$$$228$$$O	-N(CH2CH3)2,$$$229$$$241$$$I	R3$$$242$$$244$$$O	is$$$245$$$247$$$O	-H,$$$248$$$251$$$I	-Cl$$$252$$$255$$$I	or$$$256$$$258$$$O	-Br,$$$259$$$263$$$I	and$$$264$$$267$$$O	R4$$$268$$$270$$$O	is$$$271$$$273$$$O	-H,$$$274$$$277$$$I	-Cl,$$$278$$$282$$$I	-NO2$$$283$$$287$$$I	or$$$288$$$290$$$O	-Me.$$$291$$$295$$$I	The$$$296$$$299$$$O	invention$$$300$$$309$$$O	further$$$310$$$317$$$O	discloses$$$318$$$327$$$O	a$$$328$$$329$$$O	preparation$$$330$$$341$$$O	method$$$342$$$348$$$O	of$$$349$$$351$$$O	the$$$352$$$355$$$O	monobutyltin$$$356$$$368$$$I	trichloride$$$369$$$380$$$I	substituted$$$381$$$392$$$I	salicylidenedimine$$$393$$$411$$$I	Schiff$$$412$$$418$$$I	base$$$419$$$423$$$I	complex,$$$424$$$432$$$O	and$$$433$$$436$$$O	applications$$$437$$$449$$$O	of$$$450$$$452$$$O	the$$$453$$$456$$$O	monobutyltin$$$457$$$469$$$I	trichloride$$$470$$$481$$$I	substituted$$$482$$$493$$$I	salicylidenedimine$$$494$$$512$$$I	Schiff$$$513$$$519$$$I	base$$$520$$$524$$$I	complex$$$525$$$532$$$O	in$$$533$$$535$$$O	drugs$$$536$$$541$$$O	for$$$542$$$545$$$O	treating$$$546$$$554$$$O	tumor.$$$555$$$561$$$O
WO2011123691A1
Perifosine$$$0$$$10$$$I	and$$$11$$$14$$$O	capecitabine$$$15$$$27$$$I	as$$$28$$$30$$$O	a$$$31$$$32$$$O	combined$$$33$$$41$$$O	treatment$$$42$$$51$$$O	for$$$52$$$55$$$O	cancer$$$56$$$62$$$O
Treatment$$$0$$$9$$$O	regimens$$$10$$$18$$$O	comprising$$$19$$$29$$$O	co-treatment$$$30$$$42$$$O	of$$$43$$$45$$$O	cancer$$$46$$$52$$$O	with$$$53$$$57$$$O	perifosine$$$58$$$68$$$I	and$$$69$$$72$$$O	capecitabine$$$73$$$85$$$I	are$$$86$$$89$$$O	disclosed$$$90$$$99$$$O	herein,$$$100$$$107$$$O	as$$$108$$$110$$$O	well$$$111$$$115$$$O	as$$$116$$$118$$$O	pharmaceutical$$$119$$$133$$$O	compositions$$$134$$$146$$$O	and$$$147$$$150$$$O	unit$$$151$$$155$$$O	dosage$$$156$$$162$$$O	forms$$$163$$$168$$$O	thereof$$$169$$$176$$$O	formulated$$$177$$$187$$$O	to$$$188$$$190$$$O	be$$$191$$$193$$$O	suitable$$$194$$$202$$$O	for$$$203$$$206$$$O	use$$$207$$$210$$$O	in$$$211$$$213$$$O	said$$$214$$$218$$$O	treatment$$$219$$$228$$$O	regimens.$$$229$$$238$$$O
CN101836965A
Orally$$$0$$$6$$$O	disintegrating$$$7$$$21$$$O	tablet$$$22$$$28$$$O	containing$$$29$$$39$$$O	fexofenadine$$$40$$$52$$$I	or$$$53$$$55$$$O	salts$$$56$$$61$$$O	of$$$62$$$64$$$O	fexofenadine,$$$65$$$78$$$I	and$$$79$$$82$$$O	preparation$$$83$$$94$$$O	method$$$95$$$101$$$O	thereof$$$102$$$109$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	orally$$$26$$$32$$$O	disintegrating$$$33$$$47$$$O	tablet$$$48$$$54$$$O	containing$$$55$$$65$$$O	fexofenadine$$$66$$$78$$$I	or$$$79$$$81$$$O	salts$$$82$$$87$$$O	of$$$88$$$90$$$O	fexofenadine,$$$91$$$104$$$I	which$$$105$$$110$$$O	is$$$111$$$113$$$O	prepared$$$114$$$122$$$O	by$$$123$$$125$$$O	the$$$126$$$129$$$O	inclusion$$$130$$$139$$$O	technology.$$$140$$$151$$$O	When$$$152$$$156$$$O	main$$$157$$$161$$$O	drugs$$$162$$$167$$$O	and$$$168$$$171$$$O	inclusions$$$172$$$182$$$O	exist$$$183$$$188$$$O	at$$$189$$$191$$$O	a$$$192$$$193$$$O	specific$$$194$$$202$$$O	ratio,$$$203$$$209$$$O	the$$$210$$$213$$$O	tablet$$$214$$$220$$$O	can$$$221$$$224$$$O	effectively$$$225$$$236$$$O	solve$$$237$$$242$$$O	the$$$243$$$246$$$O	problems$$$247$$$255$$$O	of$$$256$$$258$$$O	the$$$259$$$262$$$O	taste$$$263$$$268$$$O	and$$$269$$$272$$$O	disintegration$$$273$$$287$$$O	of$$$288$$$290$$$O	the$$$291$$$294$$$O	main$$$295$$$299$$$O	drugs,$$$300$$$306$$$O	is$$$307$$$309$$$O	convenient$$$310$$$320$$$O	for$$$321$$$324$$$O	operating,$$$325$$$335$$$O	transporting$$$336$$$348$$$O	and$$$349$$$352$$$O	storing,$$$353$$$361$$$O	has$$$362$$$365$$$O	wide$$$366$$$370$$$O	application$$$371$$$382$$$O	range$$$383$$$388$$$O	and$$$389$$$392$$$O	is$$$393$$$395$$$O	suitable$$$396$$$404$$$O	for$$$405$$$408$$$O	large-scale$$$409$$$420$$$O	production.$$$421$$$432$$$O
WO2014155332A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	25-hydroxyvitamin$$$7$$$24$$$I	d3$$$25$$$27$$$I	to$$$28$$$30$$$O	enhance$$$31$$$38$$$O	executive$$$39$$$48$$$O	functions$$$49$$$58$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	the$$$26$$$29$$$O	use$$$30$$$33$$$O	of$$$34$$$36$$$O	25-hydroxyvitamin$$$37$$$54$$$I	D3$$$55$$$57$$$I	(25-OH$$$58$$$64$$$I	D3)$$$65$$$68$$$I	to$$$69$$$71$$$O	increase$$$72$$$80$$$O	or$$$81$$$83$$$O	maintain$$$84$$$92$$$O	or$$$93$$$95$$$O	alternatively,$$$96$$$110$$$O	to$$$111$$$113$$$O	lessen$$$114$$$120$$$O	the$$$121$$$124$$$O	decrease$$$125$$$133$$$O	of$$$134$$$136$$$O	the$$$137$$$140$$$O	cognitive$$$141$$$150$$$O	element$$$151$$$158$$$O	known$$$159$$$164$$$O	as$$$165$$$167$$$O	executive$$$168$$$177$$$O	functioning$$$178$$$189$$$O	in$$$190$$$192$$$O	healthy$$$193$$$200$$$O	individuals.$$$201$$$213$$$O	Optionally,$$$214$$$225$$$O	25-OH$$$226$$$231$$$I	D3$$$232$$$234$$$I	may$$$235$$$238$$$O	be$$$239$$$241$$$O	administered$$$242$$$254$$$O	in$$$255$$$257$$$O	combination$$$258$$$269$$$O	with$$$270$$$274$$$O	Vitamin$$$275$$$282$$$I	D$$$283$$$284$$$I	or$$$285$$$287$$$O	other$$$288$$$293$$$O	ingredients.$$$294$$$306$$$O
US20060106067
Androgen$$$0$$$8$$$O	receptor$$$9$$$17$$$O	agonist;$$$18$$$26$$$O	prostate$$$27$$$35$$$O	cancer,$$$36$$$43$$$O	hypogonadism;$$$44$$$57$$$O	4-[4-(hydroxymethyl)-1-piperidinyl]-1-naphthonitrile;$$$58$$$111$$$I	4-(4-hydroxy-2-methyl-1-pyrrolidinyl-1-benzothiophene-7-carbonitrile$$$112$$$180$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	compound$$$33$$$41$$$O	represented$$$42$$$53$$$O	by$$$54$$$56$$$O	the$$$57$$$60$$$O	general$$$61$$$68$$$O	formula:$$$69$$$77$$$O	[wherein$$$94$$$102$$$O	Ring$$$103$$$107$$$O	A$$$108$$$109$$$O	represents$$$110$$$120$$$O	an$$$121$$$123$$$O	optionally$$$124$$$134$$$O	substituted$$$135$$$146$$$O	5-$$$147$$$149$$$I	to$$$150$$$152$$$I	8-membered$$$153$$$163$$$I	ring,$$$164$$$169$$$I	Ring$$$170$$$174$$$O	B$$$175$$$176$$$O	represents$$$177$$$187$$$O	a$$$188$$$189$$$O	further$$$190$$$197$$$O	optionally$$$198$$$208$$$O	substituted$$$209$$$220$$$O	4-$$$221$$$223$$$I	to$$$224$$$226$$$I	10-membered$$$227$$$238$$$I	ring,$$$239$$$244$$$I	Ring$$$245$$$249$$$O	C$$$250$$$251$$$O	represents$$$252$$$262$$$O	a$$$263$$$264$$$O	further$$$265$$$272$$$O	optionally$$$273$$$283$$$O	substituted$$$284$$$295$$$O	benzene$$$296$$$303$$$I	ring,$$$304$$$309$$$O	X1$$$310$$$312$$$O	represents$$$313$$$323$$$O	carbon$$$324$$$330$$$I	atom,$$$331$$$336$$$O	X2$$$337$$$339$$$O	represents$$$340$$$350$$$O	a$$$351$$$352$$$O	carbon$$$353$$$359$$$I	atom,$$$360$$$365$$$O	an$$$366$$$368$$$O	oxygen$$$369$$$375$$$I	atom,$$$376$$$381$$$O	etc.,$$$382$$$387$$$O	W$$$388$$$389$$$O	represents$$$390$$$400$$$O	a$$$401$$$402$$$O	nitrogen$$$403$$$411$$$I	atom,$$$412$$$417$$$O	etc.,$$$418$$$423$$$O	Y11$$$424$$$427$$$O	represents$$$428$$$438$$$O	a$$$439$$$440$$$O	group$$$441$$$446$$$O	represented$$$447$$$458$$$O	by$$$459$$$461$$$O	the$$$462$$$465$$$O	formula$$$466$$$473$$$O	CR2R3â²$$$474$$$482$$$I	(wherein$$$483$$$491$$$O	R2$$$492$$$494$$$O	represents$$$495$$$505$$$O	a$$$506$$$507$$$I	hydrogen$$$508$$$516$$$I	atom,$$$517$$$522$$$O	a$$$523$$$524$$$I	cyano$$$525$$$530$$$I	group,$$$531$$$537$$$O	a$$$538$$$539$$$I	nitro$$$540$$$545$$$I	group,$$$546$$$552$$$O	etc.,$$$553$$$558$$$O	and$$$559$$$562$$$O	R3â²$$$563$$$568$$$O	represents$$$569$$$579$$$I	a$$$580$$$581$$$I	hydrogen$$$582$$$590$$$I	atom,$$$591$$$596$$$I	a$$$597$$$598$$$I	cyano$$$599$$$604$$$I	group,$$$605$$$611$$$I	a$$$612$$$613$$$I	nitro$$$614$$$619$$$I	group,$$$620$$$626$$$O	etc.,$$$627$$$632$$$O	respectively),$$$633$$$647$$$O	Y21$$$648$$$651$$$O	represents$$$652$$$662$$$O	a$$$663$$$664$$$O	group$$$665$$$670$$$O	represented$$$671$$$682$$$O	by$$$683$$$685$$$O	the$$$686$$$689$$$O	formula$$$690$$$697$$$I	CR4R5â²$$$698$$$706$$$I	(wherein$$$707$$$715$$$O	R4$$$716$$$718$$$O	represents$$$719$$$729$$$I	a$$$730$$$731$$$I	hydrogen$$$732$$$740$$$I	atom,$$$741$$$746$$$I	a$$$747$$$748$$$I	cyano$$$749$$$754$$$O	group,$$$755$$$761$$$I	a$$$762$$$763$$$I	nitro$$$764$$$769$$$O	group,$$$770$$$776$$$O	etc.,$$$777$$$782$$$O	and$$$783$$$786$$$O	R5â²$$$787$$$792$$$O	represents$$$793$$$803$$$I	a$$$804$$$805$$$I	hydrogen$$$806$$$814$$$I	atom,$$$815$$$820$$$I	a$$$821$$$822$$$O	cyano$$$823$$$828$$$O	group,$$$829$$$835$$$I	a$$$836$$$837$$$O	nitro$$$838$$$843$$$O	group,$$$844$$$850$$$O	etc.,$$$851$$$856$$$O	respectively),$$$857$$$871$$$O	etc.,$$$872$$$877$$$O	and$$$878$$$881$$$O	R1$$$882$$$884$$$O	represents$$$885$$$895$$$O	an$$$896$$$898$$$O	electron-withdrawing$$$899$$$919$$$O	group,$$$920$$$926$$$O	respectively.$$$927$$$940$$$O	The$$$941$$$944$$$O	formula$$$945$$$952$$$O	represents$$$960$$$970$$$O	a$$$971$$$972$$$O	single$$$973$$$979$$$O	bond$$$980$$$984$$$O	or$$$985$$$987$$$O	a$$$988$$$989$$$O	double$$$990$$$996$$$O	bond]$$$997$$$1002$$$O	or$$$1003$$$1005$$$O	a$$$1006$$$1007$$$O	salt$$$1008$$$1012$$$O	thereof,$$$1013$$$1021$$$O	which$$$1022$$$1027$$$O	is$$$1028$$$1030$$$O	useful$$$1031$$$1037$$$O	as$$$1038$$$1040$$$O	an$$$1041$$$1043$$$O	androgen$$$1044$$$1052$$$O	receptor$$$1053$$$1061$$$O	modulator.$$$1062$$$1072$$$O
US20110118297
Tivozanib$$$0$$$9$$$I	and$$$10$$$13$$$O	Temsirolimus$$$14$$$26$$$I	in$$$27$$$29$$$O	Combination$$$30$$$41$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	treating$$$12$$$20$$$O	a$$$21$$$22$$$O	tumor$$$23$$$28$$$O	in$$$29$$$31$$$O	a$$$32$$$33$$$O	human$$$34$$$39$$$O	patient$$$40$$$47$$$O	is$$$48$$$50$$$O	disclosed.$$$51$$$61$$$O	The$$$62$$$65$$$O	method$$$66$$$72$$$O	comprises$$$73$$$82$$$O	co-administering$$$83$$$99$$$O	to$$$100$$$102$$$O	the$$$103$$$106$$$O	patient:$$$107$$$115$$$O	(a)$$$116$$$119$$$O	a$$$120$$$121$$$O	dose$$$122$$$126$$$O	of$$$127$$$129$$$O	1.5$$$130$$$133$$$O	mg$$$134$$$136$$$O	tivozanib$$$137$$$146$$$I	per$$$147$$$150$$$O	day;$$$151$$$155$$$O	and$$$156$$$159$$$O	(b)$$$160$$$163$$$O	a$$$164$$$165$$$O	dose$$$166$$$170$$$O	of$$$171$$$173$$$O	25$$$174$$$176$$$O	mg$$$177$$$179$$$O	temsirolimus$$$180$$$192$$$I	per$$$193$$$196$$$O	week.$$$197$$$202$$$O	In$$$203$$$205$$$O	some$$$206$$$210$$$O	embodiments$$$211$$$222$$$O	of$$$223$$$225$$$O	the$$$226$$$229$$$O	invention,$$$230$$$240$$$O	the$$$241$$$244$$$O	tivozanib$$$245$$$254$$$I	is$$$255$$$257$$$O	administered$$$258$$$270$$$O	on$$$271$$$273$$$O	a$$$274$$$275$$$O	repeating$$$276$$$285$$$O	schedule$$$286$$$294$$$O	of$$$295$$$297$$$O	one$$$298$$$301$$$O	dose$$$302$$$306$$$O	per$$$307$$$310$$$O	day$$$311$$$314$$$O	for$$$315$$$318$$$O	three$$$319$$$324$$$O	weeks,$$$325$$$331$$$O	followed$$$332$$$340$$$O	by$$$341$$$343$$$O	one$$$344$$$347$$$O	week$$$348$$$352$$$O	without$$$353$$$360$$$O	tivozanib$$$361$$$370$$$I	administration.$$$371$$$386$$$O	The$$$387$$$390$$$O	disclosed$$$391$$$400$$$O	method$$$401$$$407$$$O	is$$$408$$$410$$$O	particularly$$$411$$$423$$$O	suitable$$$424$$$432$$$O	for$$$433$$$436$$$O	treatment$$$437$$$446$$$O	of$$$447$$$449$$$O	renal$$$450$$$455$$$O	cell$$$456$$$460$$$O	carcinoma.$$$461$$$471$$$O
EP1946753A1
Preparation$$$0$$$11$$$O	for$$$12$$$15$$$O	external$$$16$$$24$$$O	application$$$25$$$36$$$O	comprising$$$37$$$47$$$O	salt$$$48$$$52$$$O	of$$$53$$$55$$$O	mast$$$56$$$60$$$O	cell$$$61$$$65$$$O	degranulation$$$66$$$79$$$O	inhibitor$$$80$$$89$$$O	having$$$90$$$96$$$O	carboxyl$$$97$$$105$$$I	group$$$106$$$111$$$O	with$$$112$$$116$$$O	organic$$$117$$$124$$$O	amine$$$125$$$130$$$I
Mast$$$0$$$4$$$O	cell$$$5$$$9$$$O	degranulation$$$10$$$23$$$O	inhibitors$$$24$$$34$$$O	having$$$35$$$41$$$O	a$$$42$$$43$$$O	carboxyl$$$44$$$52$$$I	group$$$53$$$58$$$O	have$$$59$$$63$$$O	not$$$64$$$67$$$O	been$$$68$$$72$$$O	developed$$$73$$$82$$$O	as$$$83$$$85$$$O	external$$$86$$$94$$$O	preparations$$$95$$$107$$$O	due$$$108$$$111$$$O	to$$$112$$$114$$$O	the$$$115$$$118$$$O	low$$$119$$$122$$$O	transdermal$$$123$$$134$$$O	permeability$$$135$$$147$$$O	thereof.$$$148$$$156$$$O	By$$$157$$$159$$$O	formulating$$$160$$$171$$$O	external$$$172$$$180$$$O	preparations$$$181$$$193$$$O	thereof,$$$194$$$202$$$O	side$$$203$$$207$$$O	effects$$$208$$$215$$$O	on$$$216$$$218$$$O	the$$$219$$$222$$$O	internal$$$223$$$231$$$O	organs$$$232$$$238$$$O	by$$$239$$$241$$$O	oral$$$242$$$246$$$O	administration$$$247$$$261$$$O	can$$$262$$$265$$$O	be$$$266$$$268$$$O	avoided.$$$269$$$277$$$O	Some$$$278$$$282$$$O	of$$$283$$$285$$$O	the$$$286$$$289$$$O	mast$$$290$$$294$$$O	cell$$$295$$$299$$$O	degranulation$$$300$$$313$$$O	inhibitors$$$314$$$324$$$O	show$$$325$$$329$$$O	drastically$$$330$$$341$$$O	inferior$$$342$$$350$$$O	photostability,$$$351$$$366$$$O	which$$$367$$$372$$$O	is$$$373$$$375$$$O	also$$$376$$$380$$$O	one$$$381$$$384$$$O	cause$$$385$$$390$$$O	of$$$391$$$393$$$O	suppressed$$$394$$$404$$$O	development$$$405$$$416$$$O	of$$$417$$$419$$$O	the$$$420$$$423$$$O	drug$$$424$$$428$$$O	as$$$429$$$431$$$O	an$$$432$$$434$$$O	external$$$435$$$443$$$O	preparation.$$$444$$$456$$$O	The$$$461$$$464$$$O	present$$$465$$$472$$$O	invention$$$473$$$482$$$O	aims$$$483$$$487$$$O	at$$$488$$$490$$$O	improving$$$491$$$500$$$O	the$$$501$$$504$$$O	transdermal$$$505$$$516$$$O	permeability$$$517$$$529$$$O	and$$$530$$$533$$$O	photostability$$$534$$$548$$$O	of$$$549$$$551$$$O	mast$$$552$$$556$$$O	cell$$$557$$$561$$$O	degranulation$$$562$$$575$$$O	inhibitors$$$576$$$586$$$O	by$$$587$$$589$$$O	forming$$$590$$$597$$$O	a$$$598$$$599$$$O	salt$$$600$$$604$$$O	of$$$605$$$607$$$O	the$$$608$$$611$$$O	mast$$$612$$$616$$$O	cell$$$617$$$621$$$O	degranulation$$$622$$$635$$$O	inhibitor$$$636$$$645$$$O	with$$$646$$$650$$$O	an$$$651$$$653$$$O	organic$$$654$$$661$$$O	amine.$$$662$$$668$$$I	Consequently,$$$669$$$682$$$O	an$$$683$$$685$$$O	external$$$686$$$694$$$O	preparation$$$695$$$706$$$O	of$$$707$$$709$$$O	a$$$710$$$711$$$O	mast$$$712$$$716$$$O	cell$$$717$$$721$$$O	degranulation$$$722$$$735$$$O	inhibitor$$$736$$$745$$$O	can$$$746$$$749$$$O	be$$$750$$$752$$$O	provided$$$753$$$761$$$O	and$$$762$$$765$$$O	the$$$766$$$769$$$O	photostability$$$770$$$784$$$O	of$$$785$$$787$$$O	the$$$788$$$791$$$O	mast$$$792$$$796$$$O	cell$$$797$$$801$$$O	degranulation$$$802$$$815$$$O	inhibitor$$$816$$$825$$$O	itself,$$$826$$$833$$$O	and$$$834$$$837$$$O	a$$$838$$$839$$$O	preparation$$$840$$$851$$$O	containing$$$852$$$862$$$O	same$$$863$$$867$$$O	can$$$868$$$871$$$O	be$$$872$$$874$$$O	improved.$$$875$$$884$$$O
WO2014152843A1
Deuterium-enriched$$$0$$$18$$$I	2,4-thiazolidinediones$$$19$$$41$$$I	and$$$42$$$45$$$O	methods$$$46$$$53$$$O	of$$$54$$$56$$$O	treatment$$$57$$$66$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	5$$$23$$$24$$$I	-deuterium-enriched$$$25$$$44$$$I	2,4-thiazolidinediones$$$45$$$67$$$I	(e.g.,$$$68$$$74$$$O	5-[4-[2-(5-$$$75$$$86$$$I	ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione),$$$87$$$158$$$I	deuterated$$$159$$$169$$$O	derivatives$$$170$$$181$$$O	thereof,$$$182$$$190$$$O	stereoisomers$$$191$$$204$$$O	thereof,$$$205$$$213$$$O	pharmaceutically$$$214$$$230$$$O	acceptable$$$231$$$241$$$O	salt$$$242$$$246$$$O	forms$$$247$$$252$$$O	thereof,$$$253$$$261$$$O	and$$$262$$$265$$$O	methods$$$266$$$273$$$O	of$$$274$$$276$$$O	treatment$$$277$$$286$$$O	using$$$287$$$292$$$O	the$$$293$$$296$$$O	same.$$$297$$$302$$$O
WO2014116973A1
Compounds$$$0$$$9$$$O	and$$$10$$$13$$$O	methods$$$14$$$21$$$O	for$$$22$$$25$$$O	treating$$$26$$$34$$$O	inflammatory$$$35$$$47$$$O	bowel$$$48$$$53$$$O	diseases$$$54$$$62$$$O
Compounds$$$0$$$9$$$O	and$$$10$$$13$$$O	embodiments$$$14$$$25$$$O	of$$$26$$$28$$$O	a$$$29$$$30$$$O	method$$$31$$$37$$$O	for$$$38$$$41$$$O	treating$$$42$$$50$$$O	and/or$$$51$$$57$$$O	preventing$$$58$$$68$$$O	autoimmune$$$69$$$79$$$O	diseases$$$80$$$88$$$O	are$$$89$$$92$$$O	disclosed.$$$93$$$103$$$O	The$$$104$$$107$$$O	method$$$108$$$114$$$O	includes$$$115$$$123$$$O	administering$$$124$$$137$$$O	to$$$138$$$140$$$O	a$$$141$$$142$$$O	subject$$$143$$$150$$$O	having$$$151$$$157$$$O	an$$$158$$$160$$$O	autoimmune$$$161$$$171$$$O	disease,$$$172$$$180$$$O	such$$$181$$$185$$$O	as$$$186$$$188$$$O	an$$$189$$$191$$$O	inflammatory$$$192$$$204$$$O	bowel$$$205$$$210$$$O	disease,$$$211$$$219$$$O	a$$$220$$$221$$$O	therapeutically$$$222$$$237$$$O	effective$$$238$$$247$$$O	amount$$$248$$$254$$$O	of$$$255$$$257$$$O	a$$$258$$$259$$$O	compound$$$260$$$268$$$O	according$$$269$$$278$$$O	to$$$279$$$281$$$O	formula$$$282$$$289$$$O	I$$$290$$$291$$$O	wherein$$$292$$$299$$$O	X$$$300$$$301$$$O	and$$$302$$$305$$$O	Y$$$306$$$307$$$O	independently$$$308$$$321$$$O	are$$$322$$$325$$$O	O$$$326$$$327$$$I	or$$$328$$$330$$$O	NR1;$$$331$$$335$$$I	each$$$336$$$340$$$O	R1$$$341$$$343$$$O	is$$$344$$$346$$$O	independently$$$347$$$360$$$O	H$$$361$$$362$$$I	or$$$363$$$365$$$O	C1-C6$$$366$$$371$$$I	alkyl;$$$372$$$378$$$I	ring$$$379$$$383$$$O	A$$$384$$$385$$$O	is$$$386$$$388$$$O	aryl;$$$389$$$394$$$I	each$$$395$$$399$$$O	R2$$$400$$$402$$$O	independently$$$403$$$416$$$O	is$$$417$$$419$$$O	H,$$$420$$$422$$$I	alkyl,$$$423$$$429$$$I	alkoxy,$$$430$$$437$$$I	amide,$$$438$$$444$$$I	cyano,$$$445$$$451$$$I	halo,$$$452$$$457$$$I	haloalkyl,$$$458$$$468$$$I	hydroxyalkyl,$$$469$$$482$$$I	heteroalkyl,$$$483$$$495$$$I	heterocyclyl,$$$496$$$509$$$I	sulfonyl,$$$510$$$519$$$I	sulfonamide,$$$520$$$532$$$I	or$$$533$$$535$$$O	two$$$536$$$539$$$O	R2$$$540$$$542$$$O	groups,$$$543$$$550$$$O	taken$$$551$$$556$$$O	together$$$557$$$565$$$O	with$$$566$$$570$$$O	the$$$571$$$574$$$O	atom$$$575$$$579$$$O	or$$$580$$$582$$$O	atoms$$$583$$$588$$$O	to$$$589$$$591$$$O	which$$$592$$$597$$$O	they$$$598$$$602$$$O	are$$$603$$$606$$$O	attached,$$$607$$$616$$$O	combine$$$617$$$624$$$O	to$$$625$$$627$$$O	form$$$628$$$632$$$O	a$$$633$$$634$$$O	4-10$$$635$$$639$$$I	membered$$$640$$$648$$$I	ring$$$649$$$653$$$I	system;$$$654$$$661$$$O	p$$$662$$$663$$$O	is$$$664$$$666$$$O	0,$$$667$$$669$$$O	1,$$$670$$$672$$$O	2,$$$673$$$675$$$O	3,$$$676$$$678$$$O	or$$$679$$$681$$$O	4;$$$682$$$684$$$O	R3$$$685$$$687$$$O	and$$$688$$$691$$$O	R4$$$692$$$694$$$O	independently$$$695$$$708$$$O	are$$$709$$$712$$$O	H$$$713$$$714$$$I	or$$$715$$$717$$$O	C1-C6$$$718$$$723$$$I	alkyl;$$$724$$$730$$$I	and$$$731$$$734$$$O	R5$$$735$$$737$$$O	is$$$738$$$740$$$O	halo,$$$741$$$746$$$I	cyano,$$$747$$$753$$$I	or$$$754$$$756$$$O	C1-C6$$$757$$$762$$$I	alkyl.$$$763$$$769$$$I
EP2004618A1
Telomerase$$$0$$$10$$$O	inhibitors$$$11$$$21$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	metal$$$33$$$38$$$O	complexes$$$39$$$48$$$O	of$$$49$$$51$$$O	formulae$$$52$$$60$$$O	(I),$$$61$$$65$$$O	(IIa)$$$66$$$71$$$O	or$$$72$$$74$$$O	(IIb)$$$75$$$80$$$O	which$$$81$$$86$$$O	interaction$$$87$$$98$$$O	with$$$99$$$103$$$O	quadruplex$$$104$$$114$$$O	DNA$$$115$$$118$$$O	and$$$119$$$122$$$O	act$$$123$$$126$$$O	as$$$127$$$129$$$O	inhibitors$$$130$$$140$$$O	of$$$141$$$143$$$O	telomerase$$$144$$$154$$$O	activity,$$$155$$$164$$$O	the$$$165$$$168$$$O	synthesis$$$169$$$178$$$O	of$$$179$$$181$$$O	these$$$182$$$187$$$O	complexes$$$188$$$197$$$O	and$$$198$$$201$$$O	their$$$202$$$207$$$O	use$$$208$$$211$$$O	in$$$212$$$214$$$O	the$$$215$$$218$$$O	treatment$$$219$$$228$$$O	of$$$229$$$231$$$O	cancer.$$$232$$$239$$$O
CN103735565A
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	for$$$27$$$30$$$O	preventing$$$31$$$41$$$O	primary$$$42$$$49$$$O	hypertension$$$50$$$62$$$O	and$$$63$$$66$$$O	application$$$67$$$78$$$O	thereof$$$79$$$86$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicines$$$48$$$57$$$O	and$$$58$$$61$$$O	specifically$$$62$$$74$$$O	relates$$$75$$$82$$$O	to$$$83$$$85$$$O	a$$$86$$$87$$$O	pharmaceutical$$$88$$$102$$$O	composition$$$103$$$114$$$O	for$$$115$$$118$$$O	preventing$$$119$$$129$$$O	primary$$$130$$$137$$$O	hypertension$$$138$$$150$$$O	and$$$151$$$154$$$O	an$$$155$$$157$$$O	application$$$158$$$169$$$O	thereof.$$$170$$$178$$$O	The$$$179$$$182$$$O	pharmaceutical$$$183$$$197$$$O	composition$$$198$$$209$$$O	is$$$210$$$212$$$O	prepared$$$213$$$221$$$O	from$$$222$$$226$$$O	friedelan-3beta-ol,$$$227$$$246$$$I	astragalus$$$247$$$257$$$O	polysaccharide$$$258$$$272$$$O	component$$$273$$$282$$$O	A3,$$$283$$$286$$$O	forsythin,$$$287$$$297$$$I	resveratrol$$$298$$$309$$$I	and$$$310$$$313$$$O	ajugol$$$314$$$320$$$I	A.$$$321$$$323$$$I	The$$$324$$$327$$$O	pharmaceutical$$$328$$$342$$$O	composition$$$343$$$354$$$O	has$$$355$$$358$$$O	the$$$359$$$362$$$O	advantages$$$363$$$373$$$O	of$$$374$$$376$$$O	being$$$377$$$382$$$O	obvious$$$383$$$390$$$O	in$$$391$$$393$$$O	the$$$394$$$397$$$O	effects$$$398$$$405$$$O	of$$$406$$$408$$$O	suppressing$$$409$$$420$$$O	the$$$421$$$424$$$O	clinical$$$425$$$433$$$O	symptoms$$$434$$$442$$$O	of$$$443$$$445$$$O	the$$$446$$$449$$$O	primary$$$450$$$457$$$O	hypertension,$$$458$$$471$$$O	stable$$$472$$$478$$$O	in$$$479$$$481$$$O	quality$$$482$$$489$$$O	control,$$$490$$$498$$$O	natural$$$499$$$506$$$O	and$$$507$$$510$$$O	non-toxic,$$$511$$$521$$$O	and$$$522$$$525$$$O	suitable$$$526$$$534$$$O	for$$$535$$$538$$$O	long-term$$$539$$$548$$$O	use.$$$549$$$553$$$O
US20100190830
(3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic$$$0$$$52$$$I	Acid$$$53$$$57$$$I	Derivatives$$$58$$$69$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	(3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic$$$33$$$85$$$I	acid$$$86$$$90$$$I	derivatives$$$91$$$102$$$O	of$$$103$$$105$$$O	Formula$$$106$$$113$$$O	(I)$$$114$$$117$$$O	wherein$$$118$$$125$$$O	R1,$$$126$$$129$$$O	R2,$$$130$$$133$$$O	R3,$$$134$$$137$$$O	R4,$$$138$$$141$$$O	R5$$$142$$$144$$$O	and$$$145$$$148$$$O	R6$$$149$$$151$$$O	are$$$152$$$155$$$O	as$$$156$$$158$$$O	described$$$159$$$168$$$O	in$$$169$$$171$$$O	the$$$172$$$175$$$O	description$$$176$$$187$$$O	and$$$188$$$191$$$O	their$$$192$$$197$$$O	use$$$198$$$201$$$O	as$$$202$$$204$$$O	prostaglandin$$$205$$$218$$$I	receptor$$$219$$$227$$$O	modulators,$$$228$$$239$$$O	most$$$240$$$244$$$O	particularly$$$245$$$257$$$O	as$$$258$$$260$$$O	prostaglandin$$$261$$$274$$$I	D2$$$275$$$277$$$I	receptor$$$278$$$286$$$O	modulators,$$$287$$$298$$$O	in$$$299$$$301$$$O	the$$$302$$$305$$$O	treatment$$$306$$$315$$$O	of$$$316$$$318$$$O	various$$$319$$$326$$$O	prostaglandin-mediated$$$327$$$349$$$I	diseases$$$350$$$358$$$O	and$$$359$$$362$$$O	disorders,$$$363$$$373$$$O	to$$$374$$$376$$$O	pharmaceutical$$$377$$$391$$$O	compositions$$$392$$$404$$$O	containing$$$405$$$415$$$O	these$$$416$$$421$$$O	compounds$$$422$$$431$$$O	and$$$432$$$435$$$O	to$$$436$$$438$$$O	processes$$$439$$$448$$$O	for$$$449$$$452$$$O	their$$$453$$$458$$$O	preparation.$$$459$$$471$$$O
US20080051330
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	serine$$$14$$$20$$$I	protease$$$21$$$29$$$O	activity,$$$30$$$39$$$O	methods$$$40$$$47$$$O	and$$$48$$$51$$$O	compositions$$$52$$$64$$$O	for$$$65$$$68$$$O	treatment$$$69$$$78$$$O	of$$$79$$$81$$$O	herpes$$$82$$$88$$$O	viruses$$$89$$$96$$$O
Novel$$$0$$$5$$$O	compositions$$$6$$$18$$$O	and$$$19$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	treating$$$34$$$42$$$O	and$$$43$$$46$$$O	preventing$$$47$$$57$$$O	a$$$58$$$59$$$O	viral$$$60$$$65$$$O	infection$$$66$$$75$$$O	are$$$76$$$79$$$O	provided.$$$80$$$89$$$O	A$$$90$$$91$$$O	method$$$92$$$98$$$O	of$$$99$$$101$$$O	blocking$$$102$$$110$$$O	a$$$111$$$112$$$O	viral$$$113$$$118$$$O	infection$$$119$$$128$$$O	facilitated$$$129$$$140$$$O	by$$$141$$$143$$$O	a$$$144$$$145$$$O	serine$$$146$$$152$$$I	proteolytic$$$153$$$164$$$O	(SP)$$$165$$$169$$$O	activity$$$170$$$178$$$O	is$$$179$$$181$$$O	disclosed,$$$182$$$192$$$O	which$$$193$$$198$$$O	involves$$$199$$$207$$$O	administering$$$208$$$221$$$O	to$$$222$$$224$$$O	a$$$225$$$226$$$O	subject$$$227$$$234$$$O	suffering$$$235$$$244$$$O	or$$$245$$$247$$$O	about$$$248$$$253$$$O	to$$$254$$$256$$$O	suffer$$$257$$$263$$$O	from$$$264$$$268$$$O	a$$$269$$$270$$$O	viral$$$271$$$276$$$O	infection$$$277$$$286$$$O	a$$$287$$$288$$$O	therapeutically$$$289$$$304$$$O	effective$$$305$$$314$$$O	amount$$$315$$$321$$$O	of$$$322$$$324$$$O	a$$$325$$$326$$$O	substance$$$327$$$336$$$O	having$$$337$$$343$$$O	serine$$$344$$$350$$$I	protease$$$351$$$359$$$O	inhibitory$$$360$$$370$$$O	activity$$$371$$$379$$$O	or$$$380$$$382$$$O	serpin$$$383$$$389$$$O	activity.$$$390$$$399$$$O	Among$$$400$$$405$$$O	the$$$406$$$409$$$O	substances$$$410$$$420$$$O	found$$$421$$$426$$$O	to$$$427$$$429$$$O	be$$$430$$$432$$$O	useful$$$433$$$439$$$O	are$$$440$$$443$$$O	Î±1-antitrypsin$$$444$$$459$$$O	(AAT),$$$460$$$466$$$O	peptide$$$467$$$474$$$O	derivatives$$$475$$$486$$$O	from$$$487$$$491$$$O	the$$$492$$$495$$$I	carboxy$$$496$$$503$$$I	terminal$$$504$$$512$$$O	end$$$513$$$516$$$O	of$$$517$$$519$$$O	AAT$$$520$$$523$$$O	and$$$524$$$527$$$O	synthetic$$$528$$$537$$$O	drugs$$$538$$$543$$$O	mimicking$$$544$$$553$$$O	the$$$554$$$557$$$O	action$$$558$$$564$$$O	of$$$565$$$567$$$O	such$$$568$$$572$$$O	substances.$$$573$$$584$$$O	The$$$585$$$588$$$O	invention$$$589$$$598$$$O	is$$$599$$$601$$$O	particularly$$$602$$$614$$$O	well$$$615$$$619$$$O	suited$$$620$$$626$$$O	for$$$627$$$630$$$O	checking$$$631$$$639$$$O	a$$$640$$$641$$$O	viral$$$642$$$647$$$O	infection$$$648$$$657$$$O	mediated$$$658$$$666$$$O	by$$$667$$$669$$$O	members$$$670$$$677$$$O	of$$$678$$$680$$$O	herpesviridae$$$681$$$694$$$O	family.$$$695$$$702$$$O
US20050054582
Para-amino$$$0$$$10$$$I	benzoic$$$11$$$18$$$I	acids$$$19$$$24$$$I	as$$$25$$$27$$$O	integrin$$$28$$$36$$$O	antagonists$$$37$$$48$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	the$$$46$$$49$$$O	general$$$50$$$57$$$O	formula$$$58$$$65$$$O	(I),$$$66$$$70$$$O	their$$$71$$$76$$$O	preparation$$$77$$$88$$$O	and$$$89$$$92$$$O	use$$$93$$$96$$$O	as$$$97$$$99$$$O	pharmaceutical$$$100$$$114$$$O	compositions$$$115$$$127$$$O	asintegrin$$$128$$$138$$$O	antagonists,$$$139$$$151$$$O	especially$$$152$$$162$$$O	as$$$163$$$165$$$O	Î±4Î²$$$166$$$171$$$O	and/or$$$172$$$178$$$O	Î±4Î²$$$179$$$184$$$O	7$$$185$$$186$$$O	?and/or$$$187$$$194$$$O	Î±9Î²1$$$195$$$201$$$O	intergrin$$$202$$$211$$$O	antagonists$$$212$$$223$$$O	and$$$224$$$227$$$O	in$$$228$$$230$$$O	particular$$$231$$$241$$$O	for$$$242$$$245$$$O	the$$$246$$$249$$$O	production$$$250$$$260$$$O	of$$$261$$$263$$$O	pharmaceutical$$$264$$$278$$$O	compositions$$$279$$$291$$$O	suitable$$$292$$$300$$$O	for$$$301$$$304$$$O	the$$$305$$$308$$$O	inhibition$$$309$$$319$$$O	or$$$320$$$322$$$O	the$$$323$$$326$$$O	prevention$$$327$$$337$$$O	of$$$338$$$340$$$O	cell$$$341$$$345$$$O	adhesion$$$346$$$354$$$O	and$$$355$$$358$$$O	cell-adhesion$$$359$$$372$$$O	mediated$$$373$$$381$$$O	disorders.$$$382$$$392$$$O	Examples$$$393$$$401$$$O	are$$$402$$$405$$$O	the$$$406$$$409$$$O	treatment$$$410$$$419$$$O	and$$$420$$$423$$$O	the$$$424$$$427$$$O	prophylaxis$$$428$$$439$$$O	of$$$440$$$442$$$O	atherosclerosis,$$$443$$$459$$$O	asthma,$$$460$$$467$$$O	chronic$$$468$$$475$$$O	obstructive$$$476$$$487$$$O	pulmonary$$$488$$$497$$$O	disease$$$498$$$505$$$O	(COPD),$$$506$$$513$$$O	allergies,$$$514$$$524$$$O	diabetes,$$$525$$$534$$$O	inflammatory$$$535$$$547$$$O	bowel$$$548$$$553$$$O	disease,$$$554$$$562$$$O	multiple$$$563$$$571$$$O	sclerosis,$$$572$$$582$$$O	myocardial$$$583$$$593$$$O	ischemia,$$$594$$$603$$$O	rheumatoid$$$604$$$614$$$O	arthritis,$$$615$$$625$$$O	transplant$$$626$$$636$$$O	rejection$$$637$$$646$$$O	and$$$647$$$650$$$O	other$$$651$$$656$$$O	inflammatory,$$$657$$$670$$$O	autoimmune$$$671$$$681$$$O	and$$$682$$$685$$$O	immune$$$686$$$692$$$O	disorders.$$$693$$$703$$$O
CN103054828A
Ranitidine$$$0$$$10$$$I	bismuth$$$11$$$18$$$I	citrate$$$19$$$26$$$I	intra-gastric$$$27$$$40$$$O	floating$$$41$$$49$$$O	sustained-release$$$50$$$67$$$O	tablet$$$68$$$74$$$O	and$$$75$$$78$$$O	preparation$$$79$$$90$$$O	method$$$91$$$97$$$O	thereof$$$98$$$105$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	ranitidine$$$27$$$37$$$I	bismuth$$$38$$$45$$$I	citrate$$$46$$$53$$$I	intra-gastric$$$54$$$67$$$O	floating$$$68$$$76$$$O	sustained-release$$$77$$$94$$$O	tablet$$$95$$$101$$$O	which$$$102$$$107$$$O	is$$$108$$$110$$$O	composed$$$111$$$119$$$O	of$$$120$$$122$$$O	a$$$123$$$124$$$O	tablet$$$125$$$131$$$O	core$$$132$$$136$$$O	containing$$$137$$$147$$$O	ranitidine$$$148$$$158$$$I	bismuth$$$159$$$166$$$I	citrate$$$167$$$174$$$I	and$$$175$$$178$$$O	a$$$179$$$180$$$O	coating$$$181$$$188$$$O	film$$$189$$$193$$$O	wrapped$$$194$$$201$$$O	over$$$202$$$206$$$O	the$$$207$$$210$$$O	tablet$$$211$$$217$$$O	core.$$$218$$$223$$$O	The$$$224$$$227$$$O	tablet$$$228$$$234$$$O	core$$$235$$$239$$$O	is$$$240$$$242$$$O	prepared$$$243$$$251$$$O	from$$$252$$$256$$$O	raw$$$257$$$260$$$O	materials$$$261$$$270$$$O	at$$$271$$$273$$$O	least$$$274$$$279$$$O	containing,$$$280$$$291$$$O	by$$$292$$$294$$$O	weight,$$$295$$$302$$$O	110$$$303$$$306$$$O	to$$$307$$$309$$$O	120$$$310$$$313$$$O	parts$$$314$$$319$$$O	of$$$320$$$322$$$O	ranitidine$$$323$$$333$$$I	bismuth$$$334$$$341$$$I	citrate,$$$342$$$350$$$I	30$$$351$$$353$$$O	to$$$354$$$356$$$O	60$$$357$$$359$$$O	parts$$$360$$$365$$$O	of$$$366$$$368$$$O	a$$$369$$$370$$$O	skeletal$$$371$$$379$$$O	material,$$$380$$$389$$$O	5$$$390$$$391$$$O	to$$$392$$$394$$$O	20$$$395$$$397$$$O	parts$$$398$$$403$$$O	of$$$404$$$406$$$O	a$$$407$$$408$$$O	foaming$$$409$$$416$$$O	agent$$$417$$$422$$$O	and$$$423$$$426$$$O	45$$$427$$$429$$$O	to$$$430$$$432$$$O	130$$$433$$$436$$$O	parts$$$437$$$442$$$O	of$$$443$$$445$$$O	a$$$446$$$447$$$O	bleaching$$$448$$$457$$$O	assistant.$$$458$$$468$$$O	The$$$469$$$472$$$O	coating$$$473$$$480$$$O	film$$$481$$$485$$$O	accounts$$$486$$$494$$$O	for$$$495$$$498$$$O	1$$$499$$$500$$$O	to$$$501$$$503$$$O	5%$$$504$$$506$$$O	of$$$507$$$509$$$O	the$$$510$$$513$$$O	weight$$$514$$$520$$$O	of$$$521$$$523$$$O	the$$$524$$$527$$$O	tablet.$$$528$$$535$$$O	The$$$536$$$539$$$O	tablet$$$540$$$546$$$O	provided$$$547$$$555$$$O	by$$$556$$$558$$$O	the$$$559$$$562$$$O	invention$$$563$$$572$$$O	can$$$573$$$576$$$O	effectively$$$577$$$588$$$O	adjust$$$589$$$595$$$O	the$$$596$$$599$$$O	rate$$$600$$$604$$$O	of$$$605$$$607$$$O	constant$$$608$$$616$$$O	speed$$$617$$$622$$$O	release$$$623$$$630$$$O	of$$$631$$$633$$$O	the$$$634$$$637$$$O	drug$$$638$$$642$$$O	ranitidine$$$643$$$653$$$I	bismuth$$$654$$$661$$$I	citrate$$$662$$$669$$$I	and$$$670$$$673$$$O	enables$$$674$$$681$$$O	a$$$682$$$683$$$O	steady$$$684$$$690$$$O	and$$$691$$$694$$$O	lasting$$$695$$$702$$$O	effective$$$703$$$712$$$O	plasma$$$713$$$719$$$O	concentration$$$720$$$733$$$O	to$$$734$$$736$$$O	be$$$737$$$739$$$O	obtained,$$$740$$$749$$$O	so$$$750$$$752$$$O	side$$$753$$$757$$$O	effects$$$758$$$765$$$O	of$$$766$$$768$$$O	the$$$769$$$772$$$O	drug,$$$773$$$778$$$O	frequency$$$779$$$788$$$O	of$$$789$$$791$$$O	administration$$$792$$$806$$$O	and$$$807$$$810$$$O	influence$$$811$$$820$$$O	of$$$821$$$823$$$O	the$$$824$$$827$$$O	drug$$$828$$$832$$$O	on$$$833$$$835$$$O	an$$$836$$$838$$$O	in-vivo$$$839$$$846$$$O	environment$$$847$$$858$$$O	are$$$859$$$862$$$O	reduced,$$$863$$$871$$$O	and$$$872$$$875$$$O	compliance$$$876$$$886$$$O	of$$$887$$$889$$$O	a$$$890$$$891$$$O	patient$$$892$$$899$$$O	is$$$900$$$902$$$O	improved.$$$903$$$912$$$O
US20080200432
Fiber-Treating$$$0$$$14$$$O	Agent$$$15$$$20$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	fiber-treating$$$35$$$49$$$O	agent$$$50$$$55$$$O	having$$$56$$$62$$$O	a$$$63$$$64$$$O	pH$$$65$$$67$$$O	value$$$68$$$73$$$O	of$$$74$$$76$$$O	2$$$77$$$78$$$O	to$$$79$$$81$$$O	5$$$82$$$83$$$O	at$$$84$$$86$$$O	20Â°$$$87$$$91$$$O	C.$$$92$$$94$$$O	and$$$95$$$98$$$O	containing$$$99$$$109$$$O	an$$$110$$$112$$$I	alkoxysilane$$$113$$$125$$$I	(a),$$$126$$$130$$$O	an$$$131$$$133$$$O	organic$$$134$$$141$$$O	acid$$$142$$$146$$$O	(b)$$$147$$$150$$$O	and$$$151$$$154$$$O	water$$$155$$$160$$$O	(c),$$$161$$$165$$$O	wherein$$$166$$$173$$$O	50%$$$174$$$177$$$O	or$$$178$$$180$$$O	more$$$181$$$185$$$O	by$$$186$$$188$$$O	weight$$$189$$$195$$$O	of$$$196$$$198$$$O	the$$$199$$$202$$$O	component$$$203$$$212$$$O	(a)$$$213$$$216$$$O	is$$$217$$$219$$$O	an$$$220$$$222$$$I	alkoxysilane$$$223$$$235$$$I	represented$$$236$$$247$$$O	by$$$248$$$250$$$O	the$$$251$$$254$$$O	following$$$255$$$264$$$O	formula$$$265$$$272$$$O	(1):$$$273$$$277$$$O	R1$$$278$$$280$$$O	pSi$$$281$$$284$$$O	(OR2)4-p$$$285$$$293$$$O	(1)$$$294$$$297$$$O	wherein$$$298$$$305$$$O	R1$$$306$$$308$$$O	represents$$$309$$$319$$$O	a$$$320$$$321$$$I	C1$$$322$$$324$$$I	to$$$325$$$327$$$I	C6$$$328$$$330$$$I	alkyl$$$331$$$336$$$I	group,$$$337$$$343$$$O	a$$$344$$$345$$$I	phenyl$$$346$$$352$$$I	group,$$$353$$$359$$$O	or$$$360$$$362$$$O	a$$$363$$$364$$$I	C2$$$365$$$367$$$I	to$$$368$$$370$$$I	C6$$$371$$$373$$$I	alkenyl$$$374$$$381$$$I	group,$$$382$$$388$$$O	R2$$$389$$$391$$$O	represents$$$392$$$402$$$O	a$$$403$$$404$$$I	C1$$$405$$$407$$$I	to$$$408$$$410$$$I	C6$$$411$$$413$$$I	alkyl$$$414$$$419$$$I	group,$$$420$$$426$$$O	and$$$427$$$430$$$O	p$$$431$$$432$$$O	is$$$433$$$435$$$O	an$$$436$$$438$$$O	integer$$$439$$$446$$$O	of$$$447$$$449$$$O	1$$$450$$$451$$$O	to$$$452$$$454$$$O	3,$$$455$$$457$$$O	and$$$458$$$461$$$O	the$$$462$$$465$$$O	number$$$466$$$472$$$O	of$$$473$$$475$$$O	moles$$$476$$$481$$$O	of$$$482$$$484$$$O	the$$$485$$$488$$$O	component$$$489$$$498$$$O	(c)$$$499$$$502$$$O	is$$$503$$$505$$$O	3$$$506$$$507$$$O	times$$$508$$$513$$$O	or$$$514$$$516$$$O	more$$$517$$$521$$$O	as$$$522$$$524$$$O	large$$$525$$$530$$$O	as$$$531$$$533$$$O	that$$$534$$$538$$$O	of$$$539$$$541$$$O	the$$$542$$$545$$$O	component$$$546$$$555$$$O	(a),$$$556$$$560$$$O	as$$$561$$$563$$$O	well$$$564$$$568$$$O	as$$$569$$$571$$$O	a$$$572$$$573$$$O	method$$$574$$$580$$$O	of$$$581$$$583$$$O	treating$$$584$$$592$$$O	fibers$$$593$$$599$$$O	with$$$600$$$604$$$O	the$$$605$$$608$$$O	fiber-treating$$$609$$$623$$$O	agent,$$$624$$$630$$$O	and$$$631$$$634$$$O	fibers$$$635$$$641$$$O	treated$$$642$$$649$$$O	by$$$650$$$652$$$O	this$$$653$$$657$$$O	method.$$$658$$$665$$$O
US20130344166
Topical$$$0$$$7$$$O	mixture$$$8$$$15$$$O	and$$$16$$$19$$$O	method$$$20$$$26$$$O	for$$$27$$$30$$$O	dermal$$$31$$$37$$$O	application$$$38$$$49$$$O	to$$$50$$$52$$$O	remove$$$53$$$59$$$O	excess$$$60$$$66$$$O	iron$$$67$$$71$$$I	and$$$72$$$75$$$O	other$$$76$$$81$$$O	heavy$$$82$$$87$$$O	metals$$$88$$$94$$$O	from$$$95$$$99$$$O	cellular$$$100$$$108$$$O	tissue$$$109$$$115$$$O
A$$$0$$$1$$$O	topical$$$2$$$9$$$O	mixture$$$10$$$17$$$O	intended$$$18$$$26$$$O	to$$$27$$$29$$$O	reduce$$$30$$$36$$$O	undesirable$$$37$$$48$$$O	Iron$$$49$$$53$$$I	levels$$$54$$$60$$$O	in$$$61$$$63$$$O	the$$$64$$$67$$$O	cells$$$68$$$73$$$O	to$$$74$$$76$$$O	optimize$$$77$$$85$$$O	Mitochondrial$$$86$$$99$$$O	functioning.$$$100$$$112$$$O	A$$$113$$$114$$$O	method$$$115$$$121$$$O	of$$$122$$$124$$$O	reducing$$$125$$$133$$$O	undesirable$$$134$$$145$$$O	levels$$$146$$$152$$$O	of$$$153$$$155$$$O	Iron$$$156$$$160$$$I	in$$$161$$$163$$$O	the$$$164$$$167$$$O	cells$$$168$$$173$$$O	to$$$174$$$176$$$O	optimize$$$177$$$185$$$O	Mitochondrial$$$186$$$199$$$O	functioning.$$$200$$$212$$$O
US20120245087
Novel$$$0$$$5$$$O	tissue$$$6$$$12$$$O	protective$$$13$$$23$$$O	erythropoietin$$$24$$$38$$$O	receptor$$$39$$$47$$$O	(nepor)$$$48$$$55$$$O	and$$$56$$$59$$$O	methods$$$60$$$67$$$O	of$$$68$$$70$$$O	use$$$71$$$74$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	disclosed$$$9$$$18$$$O	a$$$19$$$20$$$O	molecular$$$21$$$30$$$O	composition(s)$$$31$$$45$$$O	of$$$46$$$48$$$O	a$$$49$$$50$$$O	novel$$$51$$$56$$$O	tissue$$$57$$$63$$$O	protective$$$64$$$74$$$O	erythropoietin$$$75$$$89$$$O	(EPO)$$$90$$$95$$$O	binding$$$96$$$103$$$O	receptor$$$104$$$112$$$O	protein$$$113$$$120$$$O	complex,$$$121$$$129$$$O	termed$$$130$$$136$$$O	NEPOR.$$$137$$$143$$$O	Presence$$$144$$$152$$$O	of$$$153$$$155$$$O	NEPOR$$$156$$$161$$$O	components$$$162$$$172$$$O	on$$$173$$$175$$$O	a$$$176$$$177$$$O	tumour$$$178$$$184$$$O	allows$$$185$$$191$$$O	EPO$$$192$$$195$$$O	to$$$196$$$198$$$O	impinge$$$199$$$206$$$O	on$$$207$$$209$$$O	the$$$210$$$213$$$O	survival$$$214$$$222$$$O	of$$$223$$$225$$$O	associated$$$226$$$236$$$O	cells$$$237$$$242$$$O	thereby$$$243$$$250$$$O	enhancing$$$251$$$260$$$O	tumour$$$261$$$267$$$O	progression$$$268$$$279$$$O	and$$$280$$$283$$$O	negatively$$$284$$$294$$$O	effecting$$$295$$$304$$$O	patient$$$305$$$312$$$O	survival.$$$313$$$322$$$O	Presence$$$323$$$331$$$O	of$$$332$$$334$$$O	NEPOR$$$335$$$340$$$O	represents$$$341$$$351$$$O	a$$$352$$$353$$$O	prognostic$$$354$$$364$$$O	biomarker$$$365$$$374$$$O	for$$$375$$$378$$$O	poorer$$$379$$$385$$$O	patient$$$386$$$393$$$O	outcome.$$$394$$$402$$$O	Thus,$$$403$$$408$$$O	methods$$$409$$$416$$$O	are$$$417$$$420$$$O	provided$$$421$$$429$$$O	for$$$430$$$433$$$O	stratifying$$$434$$$445$$$O	patients$$$446$$$454$$$O	having$$$455$$$461$$$O	a$$$462$$$463$$$O	tumour$$$464$$$470$$$O	as$$$471$$$473$$$O	suitable$$$474$$$482$$$O	(i.e.$$$483$$$488$$$O	NEPOR$$$489$$$494$$$O	not$$$495$$$498$$$O	present)$$$499$$$507$$$O	or$$$508$$$510$$$O	non-suitable$$$511$$$523$$$O	(i.e.,$$$524$$$530$$$O	NEPOR$$$531$$$536$$$O	present)$$$537$$$545$$$O	for$$$546$$$549$$$O	EPO$$$550$$$553$$$O	treatment,$$$554$$$564$$$O	comprising:$$$565$$$576$$$O	(a)$$$577$$$580$$$O	isolating$$$581$$$590$$$O	a$$$591$$$592$$$O	tissue$$$593$$$599$$$O	sample$$$600$$$606$$$O	from$$$607$$$611$$$O	an$$$612$$$614$$$O	individual$$$615$$$625$$$O	who$$$626$$$629$$$O	is$$$630$$$632$$$O	receiving$$$633$$$642$$$O	or$$$643$$$645$$$O	is$$$646$$$648$$$O	a$$$649$$$650$$$O	candidate$$$651$$$660$$$O	for$$$661$$$664$$$O	receiving$$$665$$$674$$$O	erythropoietin,$$$675$$$690$$$O	(b)$$$691$$$694$$$O	determining$$$695$$$706$$$O	the$$$707$$$710$$$O	level$$$711$$$716$$$O	of$$$717$$$719$$$O	expression$$$720$$$730$$$O	of$$$731$$$733$$$O	the$$$734$$$737$$$O	NEPOR$$$738$$$743$$$O	gene(s)$$$744$$$751$$$O	(mRNA)$$$752$$$758$$$O	and/or$$$759$$$765$$$O	the$$$766$$$769$$$O	presence$$$770$$$778$$$O	of$$$779$$$781$$$O	the$$$782$$$785$$$O	NEPOR$$$786$$$791$$$O	gene$$$792$$$796$$$O	product$$$797$$$804$$$O	(protein)$$$805$$$814$$$O	from$$$815$$$819$$$O	the$$$820$$$823$$$O	isolated$$$824$$$832$$$O	tissue,$$$833$$$840$$$O	and$$$841$$$844$$$O	(c)$$$845$$$848$$$O	correlating$$$849$$$860$$$O	the$$$861$$$864$$$O	presence$$$865$$$873$$$O	of$$$874$$$876$$$O	an$$$877$$$879$$$O	NEPOR$$$880$$$885$$$O	gene$$$886$$$890$$$O	expression$$$891$$$901$$$O	product$$$902$$$909$$$O	or$$$910$$$912$$$O	the$$$913$$$916$$$O	presence$$$917$$$925$$$O	of$$$926$$$928$$$O	NEPOR$$$929$$$934$$$O	protein$$$935$$$942$$$O	to$$$943$$$945$$$O	a$$$946$$$947$$$O	physiological$$$948$$$961$$$O	response$$$962$$$970$$$O	to$$$971$$$973$$$O	the$$$974$$$977$$$O	treatment$$$978$$$987$$$O	with$$$988$$$992$$$O	erythropoietin.$$$993$$$1008$$$O	Furthermore,$$$1009$$$1021$$$O	by$$$1022$$$1024$$$O	disclosing$$$1025$$$1035$$$O	the$$$1036$$$1039$$$O	molecular$$$1040$$$1049$$$O	compositions$$$1050$$$1062$$$O	of$$$1063$$$1065$$$O	NEPOR$$$1066$$$1071$$$O	species,$$$1072$$$1080$$$O	there$$$1081$$$1086$$$O	are$$$1087$$$1090$$$O	disclosed$$$1091$$$1100$$$O	methods$$$1101$$$1108$$$O	for$$$1109$$$1112$$$O	rationally$$$1113$$$1123$$$O	identifying/designing$$$1124$$$1145$$$O	NEPOR$$$1146$$$1151$$$O	modulating$$$1152$$$1162$$$O	therapeutics.$$$1163$$$1176$$$O	Methods$$$1177$$$1184$$$O	also$$$1185$$$1189$$$O	are$$$1190$$$1193$$$O	provided$$$1194$$$1202$$$O	for$$$1203$$$1206$$$O	treating$$$1207$$$1215$$$O	neurological$$$1216$$$1228$$$O	insults$$$1229$$$1236$$$O	such$$$1237$$$1241$$$O	as$$$1242$$$1244$$$O	stroke$$$1245$$$1251$$$O	(via$$$1252$$$1256$$$O	enhancement$$$1257$$$1268$$$O	of$$$1269$$$1271$$$O	NEPOR$$$1272$$$1277$$$O	activity)$$$1278$$$1287$$$O	and$$$1288$$$1291$$$O	cancer$$$1292$$$1298$$$O	(via$$$1299$$$1303$$$O	down-regulation$$$1304$$$1319$$$O	of$$$1320$$$1322$$$O	cyto-protective$$$1323$$$1338$$$O	signaling$$$1339$$$1348$$$O	from$$$1349$$$1353$$$O	NEPOR).$$$1354$$$1361$$$O
US20090053307
Immediate-release$$$0$$$17$$$O	therapeutic$$$18$$$29$$$O	systems$$$30$$$37$$$O	for$$$38$$$41$$$O	improved$$$42$$$50$$$O	oral$$$51$$$55$$$O	absorption$$$56$$$66$$$O	of$$$67$$$69$$$O	7-[(e)]-t-buty-loxyminomethyl]$$$70$$$100$$$I	camptothecin$$$101$$$113$$$I
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	composition$$$17$$$28$$$O	comprising$$$29$$$39$$$O	a$$$40$$$41$$$O	camptothecin$$$42$$$54$$$I	as$$$55$$$57$$$O	active$$$58$$$64$$$O	ingredient$$$65$$$75$$$O	is$$$76$$$78$$$O	herein$$$79$$$85$$$O	described.$$$86$$$96$$$O	In$$$97$$$99$$$O	particular$$$100$$$110$$$O	immediate-release$$$111$$$128$$$O	therapeutic$$$129$$$140$$$O	systems$$$141$$$148$$$O	are$$$149$$$152$$$O	described$$$153$$$162$$$O	for$$$163$$$166$$$O	the$$$167$$$170$$$O	improved$$$171$$$179$$$O	oral$$$180$$$184$$$O	absorption$$$185$$$195$$$O	of$$$196$$$198$$$O	7-[(E)-t-butyloxyminomethyl]$$$199$$$227$$$I	camptothecin,$$$228$$$241$$$I	comprising$$$242$$$252$$$O	a$$$253$$$254$$$O	matrix$$$255$$$261$$$O	consisting$$$262$$$272$$$O	of$$$273$$$275$$$O	liquid$$$276$$$282$$$O	amphiphilic$$$283$$$294$$$O	substances$$$295$$$305$$$O	or$$$306$$$308$$$O	having$$$309$$$315$$$O	a$$$316$$$317$$$O	melting$$$318$$$325$$$O	point$$$326$$$331$$$O	lower$$$332$$$337$$$O	than$$$338$$$342$$$O	60Â°$$$343$$$347$$$O	C.,$$$348$$$351$$$O	in$$$352$$$354$$$O	which$$$355$$$360$$$O	the$$$361$$$364$$$O	active$$$365$$$371$$$O	principle$$$372$$$381$$$O	is$$$382$$$384$$$O	at$$$385$$$387$$$O	least$$$388$$$393$$$O	partially$$$394$$$403$$$O	dissolved$$$404$$$413$$$O	and/or$$$414$$$420$$$O	dispersed$$$421$$$430$$$O	and/or$$$431$$$437$$$O	inglobated.$$$438$$$449$$$O
CN103316343A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	biguanide$$$15$$$24$$$I	based$$$25$$$30$$$O	medicament$$$31$$$41$$$O	in$$$42$$$44$$$O	medicaments$$$45$$$56$$$O	for$$$57$$$60$$$O	delaying$$$61$$$69$$$O	or$$$70$$$72$$$O	reversing$$$73$$$82$$$O	acquired$$$83$$$91$$$O	drug-resistance$$$92$$$107$$$O	of$$$108$$$110$$$O	NSELC$$$111$$$116$$$O	treated$$$117$$$124$$$O	by$$$125$$$127$$$O	EGFR-TKI$$$128$$$136$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	application$$$28$$$39$$$O	of$$$40$$$42$$$O	a$$$43$$$44$$$O	biguanide$$$45$$$54$$$I	based$$$55$$$60$$$O	medicament$$$61$$$71$$$O	in$$$72$$$74$$$O	medicaments$$$75$$$86$$$O	for$$$87$$$90$$$O	delaying$$$91$$$99$$$O	or$$$100$$$102$$$O	reversing$$$103$$$112$$$O	acquired$$$113$$$121$$$O	drug-resistance$$$122$$$137$$$O	of$$$138$$$140$$$O	NSELC$$$141$$$146$$$O	treated$$$147$$$154$$$O	by$$$155$$$157$$$O	EGFR-TKI,$$$158$$$167$$$O	wherein$$$168$$$175$$$O	the$$$176$$$179$$$O	biguanide$$$180$$$189$$$I	based$$$190$$$195$$$O	medicament$$$196$$$206$$$O	and$$$207$$$210$$$O	EGFR-TKI$$$211$$$219$$$O	are$$$220$$$223$$$O	taken$$$224$$$229$$$O	simultaneously$$$230$$$244$$$O	or$$$245$$$247$$$O	intervally.$$$248$$$259$$$O	A$$$260$$$261$$$O	new$$$262$$$265$$$O	application$$$266$$$277$$$O	of$$$278$$$280$$$O	the$$$281$$$284$$$O	biguanide$$$285$$$294$$$I	based$$$295$$$300$$$O	medicament$$$301$$$311$$$O	is$$$312$$$314$$$O	discovered.$$$315$$$326$$$O	The$$$327$$$330$$$O	biguanide$$$331$$$340$$$I	based$$$341$$$346$$$O	medicament$$$347$$$357$$$O	is$$$358$$$360$$$O	used$$$361$$$365$$$O	to$$$366$$$368$$$O	delay$$$369$$$374$$$O	or$$$375$$$377$$$O	reverse$$$378$$$385$$$O	generation$$$386$$$396$$$O	of$$$397$$$399$$$O	EGFR-TKI$$$400$$$408$$$O	acquired$$$409$$$417$$$O	drug-resistance,$$$418$$$434$$$O	and$$$435$$$438$$$O	performs$$$439$$$447$$$O	varying-degree$$$448$$$462$$$O	inhibition$$$463$$$473$$$O	effects$$$474$$$481$$$O	on$$$482$$$484$$$O	main$$$485$$$489$$$O	mechanisms$$$490$$$500$$$O	of$$$501$$$503$$$O	EGFR-TKI$$$504$$$512$$$O	acquired$$$513$$$521$$$O	drug-resistance$$$522$$$537$$$O	of$$$538$$$540$$$O	NSCLC$$$541$$$546$$$O	patients,$$$547$$$556$$$O	and$$$557$$$560$$$O	thus$$$561$$$565$$$O	the$$$566$$$569$$$O	sensibility$$$570$$$581$$$O	of$$$582$$$584$$$O	the$$$585$$$588$$$O	lung-cancer$$$589$$$600$$$O	patients$$$601$$$609$$$O	to$$$610$$$612$$$O	EGFR-TKI$$$613$$$621$$$O	is$$$622$$$624$$$O	increased,$$$625$$$635$$$O	the$$$636$$$639$$$O	disadvantage$$$640$$$652$$$O	that$$$653$$$657$$$O	EGFR-TKI$$$658$$$666$$$O	is$$$667$$$669$$$O	easy$$$670$$$674$$$O	to$$$675$$$677$$$O	resist$$$678$$$684$$$O	drugs$$$685$$$690$$$O	is$$$691$$$693$$$O	overcome,$$$694$$$703$$$O	and$$$704$$$707$$$O	the$$$708$$$711$$$O	curative$$$712$$$720$$$O	effect$$$721$$$727$$$O	of$$$728$$$730$$$O	EGFR-TKI$$$731$$$739$$$O	is$$$740$$$742$$$O	improved.$$$743$$$752$$$O
EP2688595A2
Lin28-mediated$$$0$$$14$$$O	control$$$15$$$22$$$O	of$$$23$$$25$$$O	let-7$$$26$$$31$$$O	biogenesis$$$32$$$42$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	embodiments$$$12$$$23$$$O	provide$$$24$$$31$$$O	for$$$32$$$35$$$O	compositions$$$36$$$48$$$O	and$$$49$$$52$$$O	methods$$$53$$$60$$$O	that$$$61$$$65$$$O	regulate$$$66$$$74$$$O	microRNA-binding$$$75$$$91$$$O	protein-mediated$$$92$$$108$$$O	miRNA$$$109$$$114$$$O	biogenesis;$$$115$$$126$$$O	for$$$127$$$130$$$O	example$$$131$$$138$$$O	Lin28-mediated$$$139$$$153$$$O	biogenesis$$$154$$$164$$$O	of$$$165$$$167$$$O	let-7;$$$168$$$174$$$O	and$$$175$$$178$$$O	in$$$179$$$181$$$O	particular$$$182$$$192$$$O	Lin28A-recruited$$$193$$$209$$$O	3'$$$210$$$212$$$O	terminal$$$213$$$221$$$O	uridylyl$$$222$$$230$$$O	transferase$$$231$$$242$$$O	(TUTase)$$$243$$$251$$$O	uridylation$$$252$$$263$$$O	of$$$264$$$266$$$O	pre-let-7.$$$267$$$277$$$O	A$$$278$$$279$$$O	particular$$$280$$$290$$$O	embodiment$$$291$$$301$$$O	provides$$$302$$$310$$$O	compositions$$$311$$$323$$$O	and$$$324$$$327$$$O	methods$$$328$$$335$$$O	for$$$336$$$339$$$O	screening$$$340$$$349$$$O	for$$$350$$$353$$$O	agents$$$354$$$360$$$O	that$$$361$$$365$$$O	inhibit$$$366$$$373$$$O	TUTase-dependent$$$374$$$390$$$O	Lin28A-mediated$$$391$$$406$$$O	repression$$$407$$$417$$$O	of$$$418$$$420$$$O	let-7$$$421$$$426$$$O	miRNA.$$$427$$$433$$$O
WO2004096195A3
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	ppar-gamma$$$7$$$17$$$O	agonists$$$18$$$26$$$O	as$$$27$$$29$$$O	anti-infective$$$30$$$44$$$O	agents$$$45$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	of$$$34$$$36$$$O	producing$$$37$$$46$$$O	a$$$47$$$48$$$O	therapeutic$$$49$$$60$$$O	composition$$$61$$$72$$$O	that$$$73$$$77$$$O	stimulates$$$78$$$88$$$O	the$$$89$$$92$$$O	innate$$$93$$$99$$$O	immune$$$100$$$106$$$O	response$$$107$$$115$$$O	by$$$116$$$118$$$O	induction$$$119$$$128$$$O	and/or$$$129$$$135$$$O	amplification$$$136$$$149$$$O	of$$$150$$$152$$$O	the$$$153$$$156$$$O	expression$$$157$$$167$$$O	of$$$168$$$170$$$O	macrophage$$$171$$$181$$$O	mannose$$$182$$$189$$$O	receptors.$$$190$$$200$$$O	Advantageously,$$$201$$$216$$$O	the$$$217$$$220$$$O	invention$$$221$$$230$$$O	is$$$231$$$233$$$O	applicable$$$234$$$244$$$O	for$$$245$$$248$$$O	preventive$$$249$$$259$$$O	or$$$260$$$262$$$O	curative$$$263$$$271$$$O	treatments$$$272$$$282$$$O	for$$$283$$$286$$$O	infectious$$$287$$$297$$$O	diseases$$$298$$$306$$$O	of$$$307$$$309$$$O	bacterial,$$$310$$$320$$$O	fungal,$$$321$$$328$$$O	protozoan,$$$329$$$339$$$O	etc.$$$340$$$344$$$O	origin$$$345$$$351$$$O	and$$$352$$$355$$$O	is$$$356$$$358$$$O	of$$$359$$$361$$$O	particular$$$362$$$372$$$O	interest$$$373$$$381$$$O	in$$$382$$$384$$$O	the$$$385$$$388$$$O	treatment$$$389$$$398$$$O	of$$$399$$$401$$$O	immunodepressed$$$402$$$417$$$O	patients.$$$418$$$427$$$O	According$$$428$$$437$$$O	to$$$438$$$440$$$O	the$$$441$$$444$$$O	invention,$$$445$$$455$$$O	in$$$456$$$458$$$O	order$$$459$$$464$$$O	to$$$465$$$467$$$O	induce$$$468$$$474$$$O	and/or$$$475$$$481$$$O	amplify$$$482$$$489$$$O	the$$$490$$$493$$$O	expression$$$494$$$504$$$O	of$$$505$$$507$$$O	the$$$508$$$511$$$O	macrophage$$$512$$$522$$$O	mannose$$$523$$$530$$$O	receptor,$$$531$$$540$$$O	the$$$541$$$544$$$O	aforementioned$$$545$$$559$$$O	macrophages$$$560$$$571$$$O	are$$$572$$$575$$$O	brought$$$576$$$583$$$O	into$$$584$$$588$$$O	contact$$$589$$$596$$$O	with$$$597$$$601$$$O	an$$$602$$$604$$$O	effective$$$605$$$614$$$O	quantity$$$615$$$623$$$O	of$$$624$$$626$$$O	at$$$627$$$629$$$O	least$$$630$$$635$$$O	one$$$636$$$639$$$O	agonist$$$640$$$647$$$O	ligand$$$648$$$654$$$O	of$$$655$$$657$$$O	the$$$658$$$661$$$O	PPARÏ$$$662$$$668$$$O	nuclear$$$669$$$676$$$O	receptor.$$$677$$$686$$$O
EP2483277A1
Benzoxepin$$$0$$$10$$$O	pi3k$$$11$$$15$$$O	inhibitor$$$16$$$25$$$O	compounds$$$26$$$35$$$O	and$$$36$$$39$$$O	methods$$$40$$$47$$$O	of$$$48$$$50$$$O	use$$$51$$$54$$$O
Benzoxepin$$$0$$$10$$$I	compounds$$$11$$$20$$$O	of$$$21$$$23$$$O	Formula$$$24$$$31$$$O	I,$$$32$$$34$$$O	and$$$35$$$38$$$O	including$$$39$$$48$$$O	stereoisomers,$$$49$$$63$$$O	geometric$$$64$$$73$$$O	isomers,$$$74$$$82$$$O	tautomers,$$$83$$$93$$$O	solvates,$$$94$$$103$$$O	metabolites$$$104$$$115$$$O	and$$$116$$$119$$$O	pharmaceutically$$$120$$$136$$$O	acceptable$$$137$$$147$$$O	salts$$$148$$$153$$$O	thereof,$$$154$$$162$$$O	wherein:$$$163$$$171$$$O	Z1$$$172$$$174$$$O	is$$$175$$$177$$$O	CR1$$$178$$$181$$$I	or$$$182$$$184$$$O	N;$$$185$$$187$$$I	Z2$$$188$$$190$$$O	is$$$191$$$193$$$O	CR2$$$194$$$197$$$I	or$$$198$$$200$$$O	N;$$$201$$$203$$$I	Z3$$$204$$$206$$$O	is$$$207$$$209$$$O	CR3$$$210$$$213$$$I	or$$$214$$$216$$$O	N;$$$217$$$219$$$I	Z4$$$220$$$222$$$O	is$$$223$$$225$$$O	CR4$$$226$$$229$$$I	or$$$230$$$232$$$O	N;$$$233$$$235$$$I	and$$$236$$$239$$$O	where$$$240$$$245$$$O	(i)$$$246$$$249$$$O	X1$$$250$$$252$$$O	is$$$253$$$255$$$O	N$$$256$$$257$$$I	and$$$258$$$261$$$O	X2$$$262$$$264$$$O	is$$$265$$$267$$$O	S,$$$268$$$270$$$I	(ii)$$$271$$$275$$$O	X1$$$276$$$278$$$O	is$$$279$$$281$$$O	S$$$282$$$283$$$I	and$$$284$$$287$$$O	X2$$$288$$$290$$$O	is$$$291$$$293$$$O	N,$$$294$$$296$$$I	(iii)$$$297$$$302$$$O	X1$$$303$$$305$$$O	is$$$306$$$308$$$O	CR7$$$309$$$312$$$I	and$$$313$$$316$$$O	X2$$$317$$$319$$$O	is$$$320$$$322$$$O	S,$$$323$$$325$$$I	(iv)$$$326$$$330$$$O	X1$$$331$$$333$$$O	is$$$334$$$336$$$O	S$$$337$$$338$$$I	and$$$339$$$342$$$O	X2$$$343$$$345$$$O	is$$$346$$$348$$$O	CR7;$$$349$$$353$$$I	(v)$$$354$$$357$$$O	X1$$$358$$$360$$$O	is$$$361$$$363$$$O	NR8$$$364$$$367$$$I	and$$$368$$$371$$$O	X2$$$372$$$374$$$O	is$$$375$$$377$$$O	N,$$$378$$$380$$$I	(vi)$$$381$$$385$$$O	X1$$$386$$$388$$$O	is$$$389$$$391$$$O	N$$$392$$$393$$$I	and$$$394$$$397$$$O	X2$$$398$$$400$$$O	is$$$401$$$403$$$O	NR8,$$$404$$$408$$$I	(vii)$$$409$$$414$$$O	X1$$$415$$$417$$$O	is$$$418$$$420$$$O	CR7$$$421$$$424$$$I	and$$$425$$$428$$$O	X2$$$429$$$431$$$O	is$$$432$$$434$$$O	O,$$$435$$$437$$$I	(viii)$$$438$$$444$$$O	X1$$$445$$$447$$$O	is$$$448$$$450$$$O	O$$$451$$$452$$$I	and$$$453$$$456$$$O	X2$$$457$$$459$$$O	is$$$460$$$462$$$O	CR7,$$$463$$$467$$$I	(ix)$$$468$$$472$$$O	X1$$$473$$$475$$$O	is$$$476$$$478$$$O	CR7$$$479$$$482$$$I	and$$$483$$$486$$$O	X2$$$487$$$489$$$O	is$$$490$$$492$$$O	C(R7)2,$$$493$$$500$$$I	(x)$$$501$$$504$$$O	X1$$$505$$$507$$$O	is$$$508$$$510$$$O	C(R7)2$$$511$$$517$$$I	and$$$518$$$521$$$O	X2$$$522$$$524$$$O	is$$$525$$$527$$$O	CR7;$$$528$$$532$$$I	(xi)$$$533$$$537$$$O	X1$$$538$$$540$$$O	is$$$541$$$543$$$O	N$$$544$$$545$$$I	and$$$546$$$549$$$O	X2$$$550$$$552$$$O	is$$$553$$$555$$$O	O,$$$556$$$558$$$I	or$$$559$$$561$$$O	(xii)$$$562$$$567$$$O	X1$$$568$$$570$$$O	is$$$571$$$573$$$O	O$$$574$$$575$$$I	and$$$576$$$579$$$O	X2$$$580$$$582$$$O	is$$$583$$$585$$$O	N,$$$586$$$588$$$I	are$$$589$$$592$$$O	useful$$$593$$$599$$$O	for$$$600$$$603$$$O	inhibiting$$$604$$$614$$$O	lipid$$$615$$$620$$$O	kinases$$$621$$$628$$$O	including$$$629$$$638$$$O	p110$$$639$$$643$$$O	alpha$$$644$$$649$$$O	and$$$650$$$653$$$O	other$$$654$$$659$$$O	isoforms$$$660$$$668$$$O	of$$$669$$$671$$$O	P13K,$$$672$$$677$$$O	and$$$678$$$681$$$O	for$$$682$$$685$$$O	treating$$$686$$$694$$$O	disorders$$$695$$$704$$$O	such$$$705$$$709$$$O	as$$$710$$$712$$$O	cancer$$$713$$$719$$$O	mediated$$$720$$$728$$$O	by$$$729$$$731$$$O	lipid$$$732$$$737$$$O	kinases.$$$738$$$746$$$O	Methods$$$747$$$754$$$O	of$$$755$$$757$$$O	using$$$758$$$763$$$O	compounds$$$764$$$773$$$O	of$$$774$$$776$$$O	Formula$$$777$$$784$$$O	I$$$785$$$786$$$O	for$$$787$$$790$$$O	in$$$791$$$793$$$O	vitro,$$$794$$$800$$$O	in$$$801$$$803$$$O	situ,$$$804$$$809$$$O	and$$$810$$$813$$$O	in$$$814$$$816$$$O	vivo$$$817$$$821$$$O	diagnosis,$$$822$$$832$$$O	prevention$$$833$$$843$$$O	or$$$844$$$846$$$O	treatment$$$847$$$856$$$O	of$$$857$$$859$$$O	such$$$860$$$864$$$O	disorders$$$865$$$874$$$O	in$$$875$$$877$$$O	mammalian$$$878$$$887$$$O	cells,$$$888$$$894$$$O	or$$$895$$$897$$$O	associated$$$898$$$908$$$O	pathological$$$909$$$921$$$O	conditions,$$$922$$$933$$$O	are$$$934$$$937$$$O	disclosed.$$$938$$$948$$$O
CN101786976A
Selenium$$$0$$$8$$$I	thioxo$$$9$$$15$$$I	cysteine$$$16$$$24$$$I	benzamide$$$25$$$34$$$I	compound$$$35$$$43$$$O	and$$$44$$$47$$$O	preparation$$$48$$$59$$$O	method$$$60$$$66$$$O	and$$$67$$$70$$$O	application$$$71$$$82$$$O	thereof$$$83$$$90$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	selenium$$$26$$$34$$$I	thioxo$$$35$$$41$$$I	cysteine$$$42$$$50$$$I	benzamide$$$51$$$60$$$I	compound$$$61$$$69$$$O	and$$$70$$$73$$$O	a$$$74$$$75$$$O	pharmaceutically$$$76$$$92$$$O	acceptable$$$93$$$103$$$O	salt$$$104$$$108$$$O	thereof.$$$109$$$117$$$O	Compared$$$118$$$126$$$O	with$$$127$$$131$$$O	the$$$132$$$135$$$O	dissolvability$$$136$$$150$$$O	of$$$151$$$153$$$O	ethaselen$$$154$$$163$$$I	and$$$164$$$167$$$O	derivatives$$$168$$$179$$$O	thereof,$$$180$$$188$$$O	the$$$189$$$192$$$O	dissolvability$$$193$$$207$$$O	of$$$208$$$210$$$O	the$$$211$$$214$$$O	selenium$$$215$$$223$$$I	thioxo$$$224$$$230$$$I	cysteine$$$231$$$239$$$I	benzamide$$$240$$$249$$$I	compound$$$250$$$258$$$O	is$$$259$$$261$$$O	improved,$$$262$$$271$$$O	thus$$$272$$$276$$$O	the$$$277$$$280$$$O	selenium$$$281$$$289$$$I	thioxo$$$290$$$296$$$I	cysteine$$$297$$$305$$$I	benzamide$$$306$$$315$$$I	compound$$$316$$$324$$$O	has$$$325$$$328$$$O	excellent$$$329$$$338$$$O	anti-tumor$$$339$$$349$$$O	effect$$$350$$$356$$$O	and$$$357$$$360$$$O	more$$$361$$$365$$$O	wide$$$366$$$370$$$O	medicinal$$$371$$$380$$$O	application.$$$381$$$393$$$O
WO2005120435A2
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	sustained$$$21$$$30$$$O	release$$$31$$$38$$$O	compositions$$$39$$$51$$$O	and$$$52$$$55$$$O	the$$$56$$$59$$$O	use$$$60$$$63$$$O	of$$$64$$$66$$$O	said$$$67$$$71$$$O	compositions$$$72$$$84$$$O	for$$$85$$$88$$$O	treating$$$89$$$97$$$O	chronic$$$98$$$105$$$O	diseases$$$106$$$114$$$O	of$$$115$$$117$$$O	central$$$118$$$125$$$O	nervous$$$126$$$133$$$O	system$$$134$$$140$$$O	(cns)$$$141$$$146$$$O
The$$$0$$$3$$$O	inventive$$$4$$$13$$$O	method$$$14$$$20$$$O	for$$$21$$$24$$$O	preparing$$$25$$$34$$$O	microspheres$$$35$$$47$$$O	comprising$$$48$$$58$$$O	poly$$$59$$$63$$$I	(D,L-lactide-co-glycolide),$$$64$$$91$$$I	poly(D,L-lactide$$$92$$$108$$$I	(PLAGA$$$109$$$115$$$I	or$$$116$$$118$$$I	PLA))$$$119$$$124$$$I	or$$$125$$$127$$$O	the$$$128$$$131$$$O	mixtures$$$132$$$140$$$O	thereof$$$141$$$148$$$O	which$$$149$$$154$$$O	are$$$155$$$158$$$O	ethyl$$$159$$$164$$$I	acetate$$$165$$$172$$$I	soluble$$$173$$$180$$$O	and$$$181$$$184$$$O	encapsulate$$$185$$$196$$$O	at$$$197$$$199$$$O	least$$$200$$$205$$$O	one$$$206$$$209$$$O	type$$$210$$$214$$$O	of$$$215$$$217$$$O	ethyl$$$218$$$223$$$I	acetate$$$224$$$231$$$I	non-soluble$$$232$$$243$$$O	active$$$244$$$250$$$O	substance.$$$251$$$261$$$O	Compositions$$$262$$$274$$$O	containing$$$275$$$285$$$O	microspheres$$$286$$$298$$$O	homogeneously$$$299$$$312$$$O	dispersed$$$313$$$322$$$O	in$$$323$$$325$$$O	a$$$326$$$327$$$O	biocompatible$$$328$$$341$$$O	polymer$$$342$$$349$$$O	solution$$$350$$$358$$$O	capable$$$359$$$366$$$O	to$$$367$$$369$$$O	form$$$370$$$374$$$O	a$$$375$$$376$$$O	gel$$$377$$$380$$$O	in$$$381$$$383$$$O	situ$$$384$$$388$$$O	after$$$389$$$394$$$O	administration$$$395$$$409$$$O	through$$$410$$$417$$$O	a$$$418$$$419$$$O	haemo-meningeal$$$420$$$435$$$O	barrier$$$436$$$443$$$O	(HMB)$$$444$$$449$$$O	for$$$450$$$453$$$O	treating$$$454$$$462$$$O	CNS$$$463$$$466$$$O	chronic$$$467$$$474$$$O	diseases$$$475$$$483$$$O	are$$$484$$$487$$$O	also$$$488$$$492$$$O	disclosed.$$$493$$$503$$$O
US20080318904
Deuterium-enriched$$$0$$$18$$$I	tenofovir$$$19$$$28$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	application$$$12$$$23$$$O	describes$$$24$$$33$$$O	deuterium-enriched$$$34$$$52$$$I	tenofovir,$$$53$$$63$$$I	pharmaceutically$$$64$$$80$$$O	acceptable$$$81$$$91$$$O	salt$$$92$$$96$$$O	forms$$$97$$$102$$$O	thereof,$$$103$$$111$$$O	and$$$112$$$115$$$O	methods$$$116$$$123$$$O	of$$$124$$$126$$$O	treating$$$127$$$135$$$O	using$$$136$$$141$$$O	the$$$142$$$145$$$O	same.$$$146$$$151$$$O
CN103751176A
Trigoxyphin$$$0$$$11$$$I	K$$$12$$$13$$$I	application$$$14$$$25$$$O	in$$$26$$$28$$$O	acute$$$29$$$34$$$O	heart$$$35$$$40$$$O	failure$$$41$$$48$$$O	treatment$$$49$$$58$$$O	or$$$59$$$61$$$O	prevention$$$62$$$72$$$O	drugs$$$73$$$78$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	Trigoxyphin$$$23$$$34$$$I	K$$$35$$$36$$$I	application$$$37$$$48$$$O	in$$$49$$$51$$$O	preparation$$$52$$$63$$$O	of$$$64$$$66$$$O	acute$$$67$$$72$$$O	heart$$$73$$$78$$$O	failure$$$79$$$86$$$O	treatment$$$87$$$96$$$O	or$$$97$$$99$$$O	prevention$$$100$$$110$$$O	drugs.$$$111$$$117$$$O	The$$$118$$$121$$$O	Trigoxyphin$$$122$$$133$$$I	K$$$134$$$135$$$I	application$$$136$$$147$$$O	in$$$148$$$150$$$O	preparation$$$151$$$162$$$O	of$$$163$$$165$$$O	the$$$166$$$169$$$O	acute$$$170$$$175$$$O	heart$$$176$$$181$$$O	failure$$$182$$$189$$$O	treatment$$$190$$$199$$$O	drugs$$$200$$$205$$$O	is$$$206$$$208$$$O	initially$$$209$$$218$$$O	public,$$$219$$$226$$$O	because$$$227$$$234$$$O	the$$$235$$$238$$$O	skeleton$$$239$$$247$$$O	type$$$248$$$252$$$O	belongs$$$253$$$260$$$O	to$$$261$$$263$$$O	a$$$264$$$265$$$O	new$$$266$$$269$$$O	skeleton$$$270$$$278$$$O	type,$$$279$$$284$$$O	and$$$285$$$288$$$O	the$$$289$$$292$$$O	acute$$$293$$$298$$$O	heart$$$299$$$304$$$O	failure$$$305$$$312$$$O	treatment$$$313$$$322$$$O	activity$$$323$$$331$$$O	is$$$332$$$334$$$O	strong,$$$335$$$342$$$O	the$$$343$$$346$$$O	Trigoxyphin$$$347$$$358$$$I	K$$$359$$$360$$$I	has$$$361$$$364$$$O	prominent$$$365$$$374$$$O	substantive$$$375$$$386$$$O	features,$$$387$$$396$$$O	and$$$397$$$400$$$O	at$$$401$$$403$$$O	the$$$404$$$407$$$O	same$$$408$$$412$$$O	time$$$413$$$417$$$O	obviously$$$418$$$427$$$O	has$$$428$$$431$$$O	significant$$$432$$$443$$$O	progresses$$$444$$$454$$$O	in$$$455$$$457$$$O	application$$$458$$$469$$$O	in$$$470$$$472$$$O	acute$$$473$$$478$$$O	heart$$$479$$$484$$$O	failure$$$485$$$492$$$O	treatment.$$$493$$$503$$$O
CN101229169B
Sustained$$$0$$$9$$$O	release$$$10$$$17$$$O	formulations$$$18$$$30$$$O	comprising$$$31$$$41$$$O	lamotrigine$$$42$$$53$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	of$$$34$$$36$$$O	treating$$$37$$$45$$$O	a$$$46$$$47$$$O	CNS$$$48$$$51$$$O	disorder$$$52$$$60$$$O	which$$$61$$$66$$$O	comprises$$$67$$$76$$$O	orally$$$77$$$83$$$O	administering$$$84$$$97$$$O	to$$$98$$$100$$$O	a$$$101$$$102$$$O	patient$$$103$$$110$$$O	a$$$111$$$112$$$O	therapeutically$$$113$$$128$$$O	effective$$$129$$$138$$$O	amount$$$139$$$145$$$O	of$$$146$$$148$$$O	lamotrigine$$$149$$$160$$$I	or$$$161$$$163$$$O	a$$$164$$$165$$$O	pharmaceutically$$$166$$$182$$$O	acceptable$$$183$$$193$$$O	derivative$$$194$$$204$$$O	thereof$$$205$$$212$$$O	in$$$213$$$215$$$O	the$$$216$$$219$$$O	form$$$220$$$224$$$O	of$$$225$$$227$$$O	a$$$228$$$229$$$O	sustained$$$230$$$239$$$O	release$$$240$$$247$$$O	formulation.$$$248$$$260$$$O	The$$$261$$$264$$$O	invention$$$265$$$274$$$O	also$$$275$$$279$$$O	relates$$$280$$$287$$$O	to$$$288$$$290$$$O	a$$$291$$$292$$$O	method$$$293$$$299$$$O	of$$$300$$$302$$$O	reducing$$$303$$$311$$$O	the$$$312$$$315$$$O	incidence$$$316$$$325$$$O	of$$$326$$$328$$$O	at$$$329$$$331$$$O	least$$$332$$$337$$$O	one$$$338$$$341$$$O	adverse$$$342$$$349$$$O	event,$$$350$$$356$$$O	a$$$357$$$358$$$O	sustained$$$359$$$368$$$O	release$$$369$$$376$$$O	formulation$$$377$$$388$$$O	of$$$389$$$391$$$O	lamotrigine$$$392$$$403$$$I	or$$$404$$$406$$$O	a$$$407$$$408$$$O	pharmaceutically$$$409$$$425$$$O	acceptable$$$426$$$436$$$O	derivative$$$437$$$447$$$O	thereof$$$448$$$455$$$O	and$$$456$$$459$$$O	methods$$$460$$$467$$$O	of$$$468$$$470$$$O	treatment$$$471$$$480$$$O	and$$$481$$$484$$$O	uses$$$485$$$489$$$O	thereof,$$$490$$$498$$$O	and$$$499$$$502$$$O	a$$$503$$$504$$$O	method$$$505$$$511$$$O	for$$$512$$$515$$$O	obtaining$$$516$$$525$$$O	serum$$$526$$$531$$$O	concentration.$$$532$$$546$$$O
WO2011084459A1
Ppar-sparing$$$0$$$12$$$O	thiazolidinediones$$$13$$$31$$$I	and$$$32$$$35$$$O	combinations$$$36$$$48$$$O	for$$$49$$$52$$$O	the$$$53$$$56$$$O	treatment$$$57$$$66$$$O	of$$$67$$$69$$$O	obesity$$$70$$$77$$$O	and$$$78$$$81$$$O	other$$$82$$$87$$$O	metabolic$$$88$$$97$$$O	diseases$$$98$$$106$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	thiazolidinedione$$$33$$$50$$$I	analogues$$$51$$$60$$$O	of$$$61$$$63$$$O	formula$$$64$$$71$$$O	I$$$72$$$73$$$O	and$$$74$$$77$$$O	pharmaceutical$$$78$$$92$$$O	compositions$$$93$$$105$$$O	that$$$106$$$110$$$O	are$$$111$$$114$$$O	useful$$$115$$$121$$$O	for$$$122$$$125$$$O	treating$$$126$$$134$$$O	and/or$$$135$$$141$$$O	preventing$$$142$$$152$$$O	obesity$$$153$$$160$$$O	or$$$161$$$163$$$O	diabetes,$$$164$$$173$$$O	optionally$$$174$$$184$$$O	in$$$185$$$187$$$O	combination$$$188$$$199$$$O	with$$$200$$$204$$$O	a$$$205$$$206$$$O	second$$$207$$$213$$$O	treatment$$$214$$$223$$$O	therapy$$$224$$$231$$$O	such$$$232$$$236$$$O	a$$$237$$$238$$$O	diet$$$239$$$243$$$O	restriction$$$244$$$255$$$O	or$$$256$$$258$$$O	an$$$259$$$261$$$O	increase$$$262$$$270$$$O	in$$$271$$$273$$$O	duration$$$274$$$282$$$O	or$$$283$$$285$$$O	exertion$$$286$$$294$$$O	in$$$295$$$297$$$O	physical$$$298$$$306$$$O	activity.$$$307$$$316$$$O
WO2005025583A2
Tlr7$$$0$$$4$$$O	ligands$$$5$$$12$$$O	for$$$13$$$16$$$O	the$$$17$$$20$$$O	treatment$$$21$$$30$$$O	of$$$31$$$33$$$O	hepatitis$$$34$$$43$$$O	c$$$44$$$45$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	methods$$$26$$$33$$$O	for$$$34$$$37$$$O	treating$$$38$$$46$$$O	or$$$47$$$49$$$O	preventing$$$50$$$60$$$O	hepatitis$$$61$$$70$$$O	C$$$71$$$72$$$O	virus$$$73$$$78$$$O	infections$$$79$$$89$$$O	in$$$90$$$92$$$O	mammals$$$93$$$100$$$O	using$$$101$$$106$$$O	Toll-Like$$$107$$$116$$$O	Receptor$$$117$$$125$$$O	(TLR)7$$$126$$$132$$$O	ligands$$$133$$$140$$$O	and$$$141$$$144$$$O	prodrugs$$$145$$$153$$$O	thereof.$$$154$$$162$$$O	More$$$163$$$167$$$O	particularly,$$$168$$$181$$$O	this$$$182$$$186$$$O	invention$$$187$$$196$$$O	relates$$$197$$$204$$$O	to$$$205$$$207$$$O	methods$$$208$$$215$$$O	of$$$216$$$218$$$O	orally$$$219$$$225$$$O	administering$$$226$$$239$$$O	a$$$240$$$241$$$O	therapeutically$$$242$$$257$$$O	effective$$$258$$$267$$$O	amount$$$268$$$274$$$O	of$$$275$$$277$$$O	one$$$278$$$281$$$O	or$$$282$$$284$$$O	more$$$285$$$289$$$O	prodrugs$$$290$$$298$$$O	of$$$299$$$301$$$O	TLR7$$$302$$$306$$$O	ligands$$$307$$$314$$$O	for$$$315$$$318$$$O	the$$$319$$$322$$$O	treatment$$$323$$$332$$$O	or$$$333$$$335$$$O	prevention$$$336$$$346$$$O	of$$$347$$$349$$$O	hepatitis$$$350$$$359$$$O	C$$$360$$$361$$$O	viral$$$362$$$367$$$O	infection.$$$368$$$378$$$O	Oral$$$379$$$383$$$O	administration$$$384$$$398$$$O	of$$$399$$$401$$$O	these$$$402$$$407$$$O	TLR7$$$408$$$412$$$O	immunomodulating$$$413$$$429$$$O	ligands$$$430$$$437$$$O	and$$$438$$$441$$$O	prodrugs$$$442$$$450$$$O	thereof$$$451$$$458$$$O	to$$$459$$$461$$$O	a$$$462$$$463$$$O	mammal$$$464$$$470$$$O	provides$$$471$$$479$$$O	therapeutically$$$480$$$495$$$O	effective$$$496$$$505$$$O	amounts$$$506$$$513$$$O	and$$$514$$$517$$$O	reduced$$$518$$$525$$$O	undesirable$$$526$$$537$$$O	side$$$538$$$542$$$O	effects.$$$543$$$551$$$O
WO2007147646A1
OXO-SUBSTITUTED$$$0$$$15$$$I	IMIDAZO[1,2b]PYRIDAZINES,$$$16$$$41$$$I	PRODUCTION$$$42$$$52$$$O	AND$$$53$$$56$$$O	USE$$$57$$$60$$$O	THEREOF$$$61$$$68$$$O	AS$$$69$$$71$$$O	DRUGS$$$72$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	kinase$$$31$$$37$$$O	inhibitors$$$38$$$48$$$O	of$$$49$$$51$$$O	general$$$52$$$59$$$O	formula$$$60$$$67$$$O	(I),$$$68$$$72$$$O	wherein$$$73$$$80$$$O	Q$$$81$$$82$$$O	and$$$83$$$86$$$O	R1$$$87$$$89$$$O	are$$$90$$$93$$$O	defined$$$94$$$101$$$O	as$$$102$$$104$$$O	in$$$105$$$107$$$O	the$$$108$$$111$$$O	claims.$$$112$$$119$$$O	The$$$120$$$123$$$O	invention$$$124$$$133$$$O	also$$$134$$$138$$$O	relates$$$139$$$146$$$O	to$$$147$$$149$$$O	methods$$$150$$$157$$$O	for$$$158$$$161$$$O	producing$$$162$$$171$$$O	said$$$172$$$176$$$O	inhibitors,$$$177$$$188$$$O	to$$$189$$$191$$$O	intermediates$$$192$$$205$$$O	for$$$206$$$209$$$O	producing$$$210$$$219$$$O	the$$$220$$$223$$$O	same$$$224$$$228$$$O	and$$$229$$$232$$$O	to$$$233$$$235$$$O	uses$$$236$$$240$$$O	thereof.$$$241$$$249$$$O
CN101428005A
Pantoprazole$$$0$$$12$$$I	and$$$13$$$16$$$O	its$$$17$$$20$$$O	sodium$$$21$$$27$$$I	salt$$$28$$$32$$$I	enteric$$$33$$$40$$$O	sustained-release$$$41$$$58$$$O	pellet$$$59$$$65$$$O	preparation$$$66$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	pantoprazole$$$24$$$36$$$I	and$$$37$$$40$$$O	the$$$41$$$44$$$O	sodium$$$45$$$51$$$I	salt$$$52$$$56$$$I	enteric$$$57$$$64$$$O	sustained-release$$$65$$$82$$$O	micropill$$$83$$$92$$$O	preparation$$$93$$$104$$$O	thereof.$$$105$$$113$$$O	The$$$114$$$117$$$O	preparation$$$118$$$129$$$O	comprises$$$130$$$139$$$O	pantoprazole-containing$$$140$$$163$$$I	micropills,$$$164$$$175$$$O	an$$$176$$$178$$$O	isolation$$$179$$$188$$$O	layer,$$$189$$$195$$$O	a$$$196$$$197$$$O	sustained-release$$$198$$$215$$$O	layer,$$$216$$$222$$$O	another$$$223$$$230$$$O	isolation$$$231$$$240$$$O	layer$$$241$$$246$$$O	and$$$247$$$250$$$O	an$$$251$$$253$$$O	enteric$$$254$$$261$$$O	layer$$$262$$$267$$$O	from$$$268$$$272$$$O	inside$$$273$$$279$$$O	to$$$280$$$282$$$O	outside$$$283$$$290$$$O	in$$$291$$$293$$$O	sequence;$$$294$$$303$$$O	the$$$304$$$307$$$O	weight$$$308$$$314$$$O	of$$$315$$$317$$$O	the$$$318$$$321$$$O	first$$$322$$$327$$$O	isolation$$$328$$$337$$$O	layer$$$338$$$343$$$O	is$$$344$$$346$$$O	0.5%$$$347$$$351$$$O	to$$$352$$$354$$$O	40%$$$355$$$358$$$O	of$$$359$$$361$$$O	that$$$362$$$366$$$O	of$$$367$$$369$$$O	the$$$370$$$373$$$O	pantoprazole-containing$$$374$$$397$$$I	micropills,$$$398$$$409$$$O	the$$$410$$$413$$$O	weight$$$414$$$420$$$O	of$$$421$$$423$$$O	the$$$424$$$427$$$O	sustained-release$$$428$$$445$$$O	layer$$$446$$$451$$$O	is$$$452$$$454$$$O	5%$$$455$$$457$$$O	to$$$458$$$460$$$O	100%$$$461$$$465$$$O	of$$$466$$$468$$$O	that$$$469$$$473$$$O	of$$$474$$$476$$$O	the$$$477$$$480$$$O	pantoprazole-containing$$$481$$$504$$$I	micropills,$$$505$$$516$$$O	the$$$517$$$520$$$O	weight$$$521$$$527$$$O	of$$$528$$$530$$$O	the$$$531$$$534$$$O	second$$$535$$$541$$$O	isolation$$$542$$$551$$$O	layer$$$552$$$557$$$O	is$$$558$$$560$$$O	0.5%$$$561$$$565$$$O	to$$$566$$$568$$$O	40%$$$569$$$572$$$O	of$$$573$$$575$$$O	that$$$576$$$580$$$O	of$$$581$$$583$$$O	the$$$584$$$587$$$O	pantoprazole-containing$$$588$$$611$$$I	micropills,$$$612$$$623$$$O	and$$$624$$$627$$$O	the$$$628$$$631$$$O	weight$$$632$$$638$$$O	of$$$639$$$641$$$O	the$$$642$$$645$$$O	enteric$$$646$$$653$$$O	layer$$$654$$$659$$$O	is$$$660$$$662$$$O	20%$$$663$$$666$$$O	to$$$667$$$669$$$O	200%$$$670$$$674$$$O	of$$$675$$$677$$$O	that$$$678$$$682$$$O	of$$$683$$$685$$$O	the$$$686$$$689$$$O	pantoprazole-containing$$$690$$$713$$$I	micropills.$$$714$$$725$$$O	The$$$726$$$729$$$O	pantoprazole$$$730$$$742$$$I	enteric$$$743$$$750$$$O	sustained-release$$$751$$$768$$$O	micropills$$$769$$$779$$$O	can$$$780$$$783$$$O	stably$$$784$$$790$$$O	release$$$791$$$798$$$O	the$$$799$$$802$$$O	drug.$$$803$$$808$$$O
EP1524980A1
Phenylalanine$$$0$$$13$$$I	enamide$$$14$$$21$$$I	derivatives$$$22$$$33$$$O	containing$$$34$$$44$$$O	a$$$45$$$46$$$O	spiro[3.5]non-1-ene$$$47$$$66$$$I	ring$$$67$$$71$$$O	for$$$72$$$75$$$O	use$$$76$$$79$$$O	as$$$80$$$82$$$O	integrin$$$83$$$91$$$O	inhibitors$$$92$$$102$$$O
Phenylalanine$$$0$$$13$$$I	enamide$$$14$$$21$$$I	derivatives$$$22$$$33$$$O	of$$$34$$$36$$$O	formula$$$37$$$44$$$O	(1)$$$45$$$48$$$O	are$$$49$$$52$$$O	described:$$$53$$$63$$$O	wherein$$$64$$$71$$$O	R1$$$72$$$74$$$O	is$$$75$$$77$$$O	a$$$78$$$79$$$O	-CH3,$$$80$$$85$$$I	-(CH2)3CH3,$$$86$$$97$$$I	-CH2CH20H,$$$98$$$108$$$I	-CH2CH20CH3,$$$109$$$121$$$I	-CH2CH20CH2CH20H,$$$122$$$139$$$I	-CH2CH20CH2CH20CH3,$$$140$$$159$$$I	Formula$$$160$$$167$$$O	(II)$$$168$$$172$$$O	group;$$$173$$$179$$$O	and$$$180$$$183$$$O	the$$$184$$$187$$$O	salts,$$$188$$$194$$$O	solvates$$$195$$$203$$$O	and$$$204$$$207$$$O	N-oxides$$$208$$$216$$$I	thereof.$$$217$$$225$$$O	Compounds$$$226$$$235$$$O	according$$$236$$$245$$$O	to$$$246$$$248$$$O	the$$$249$$$252$$$O	invention$$$253$$$262$$$O	are$$$263$$$266$$$O	potent$$$267$$$273$$$O	and$$$274$$$277$$$O	selective$$$278$$$287$$$O	inhibitors$$$288$$$298$$$O	of$$$299$$$301$$$O	oA$$$302$$$304$$$O	integrins.$$$305$$$315$$$O	The$$$316$$$319$$$O	compounds$$$320$$$329$$$O	are$$$330$$$333$$$O	of$$$334$$$336$$$O	use$$$337$$$340$$$O	in$$$341$$$343$$$O	modulating$$$344$$$354$$$O	cell$$$355$$$359$$$O	adhesion$$$360$$$368$$$O	and$$$369$$$372$$$O	in$$$373$$$375$$$O	particular$$$376$$$386$$$O	are$$$387$$$390$$$O	of$$$391$$$393$$$O	use$$$394$$$397$$$O	in$$$398$$$400$$$O	the$$$401$$$404$$$O	prophylaxis$$$405$$$416$$$O	and$$$417$$$420$$$O	treatment$$$421$$$430$$$O	of$$$431$$$433$$$O	diseases$$$434$$$442$$$O	or$$$443$$$445$$$O	disorders$$$446$$$455$$$O	including$$$456$$$465$$$O	inflammation$$$466$$$478$$$O	in$$$479$$$481$$$O	which$$$482$$$487$$$O	the$$$488$$$491$$$O	extravasation$$$492$$$505$$$O	of$$$506$$$508$$$O	leukocytes$$$509$$$519$$$O	plays$$$520$$$525$$$O	a$$$526$$$527$$$O	role$$$528$$$532$$$O	and$$$533$$$536$$$O	the$$$537$$$540$$$O	invention$$$541$$$550$$$O	extends$$$551$$$558$$$O	to$$$559$$$561$$$O	such$$$562$$$566$$$O	a$$$567$$$568$$$O	use$$$569$$$572$$$O	and$$$573$$$576$$$O	to$$$577$$$579$$$O	the$$$580$$$583$$$O	use$$$584$$$587$$$O	of$$$588$$$590$$$O	the$$$591$$$594$$$O	compounds$$$595$$$604$$$O	for$$$605$$$608$$$O	the$$$609$$$612$$$O	manufacture$$$613$$$624$$$O	of$$$625$$$627$$$O	a$$$628$$$629$$$O	medicament$$$630$$$640$$$O	for$$$641$$$644$$$O	treating$$$645$$$653$$$O	such$$$654$$$658$$$O	diseases$$$659$$$667$$$O	or$$$668$$$670$$$O	disorders.$$$671$$$681$$$O
US20110275673
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	sphingosine$$$14$$$25$$$I	kinase$$$26$$$32$$$O	1$$$33$$$34$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	Formula$$$38$$$45$$$O	(I).$$$46$$$50$$$O	Compounds$$$51$$$60$$$O	of$$$61$$$63$$$O	the$$$64$$$67$$$O	present$$$68$$$75$$$O	invention$$$76$$$85$$$O	are$$$86$$$89$$$O	inhibitors$$$90$$$100$$$O	of$$$101$$$103$$$O	sphingosine$$$104$$$115$$$I	kinase$$$116$$$122$$$O	3,$$$123$$$125$$$O	and$$$126$$$129$$$O	are$$$130$$$133$$$O	useful$$$134$$$140$$$O	in$$$141$$$143$$$O	the$$$144$$$147$$$O	treatment$$$148$$$157$$$O	of$$$158$$$160$$$O	various$$$161$$$168$$$O	disorders$$$169$$$178$$$O	and$$$179$$$182$$$O	conditions,$$$183$$$194$$$O	such$$$195$$$199$$$O	as$$$200$$$202$$$O	inflammatory$$$203$$$215$$$O	disorders.$$$216$$$226$$$O
US7071195
Especially$$$0$$$10$$$O	amino-$$$11$$$17$$$I	or$$$18$$$20$$$O	amido-ethyltetralin$$$21$$$40$$$I	derivatives$$$41$$$52$$$O
Amine$$$0$$$5$$$I	and$$$6$$$9$$$O	amide$$$10$$$15$$$I	derivatives$$$16$$$27$$$O	of$$$28$$$30$$$O	the$$$31$$$34$$$O	formula:$$$35$$$43$$$O	which$$$63$$$68$$$O	are$$$69$$$72$$$O	ligands$$$73$$$80$$$O	for$$$81$$$84$$$O	the$$$85$$$88$$$O	neuropeptide$$$89$$$101$$$O	Y$$$102$$$103$$$O	Y5$$$104$$$106$$$O	(NPY5)$$$107$$$113$$$O	receptor,$$$114$$$123$$$O	methods$$$124$$$131$$$O	of$$$132$$$134$$$O	preparation$$$135$$$146$$$O	and$$$147$$$150$$$O	pharmaceutical$$$151$$$165$$$O	compositions$$$166$$$178$$$O	containing$$$179$$$189$$$O	amines$$$190$$$196$$$I	and$$$197$$$200$$$O	amides$$$201$$$207$$$I	of$$$208$$$210$$$O	formula$$$211$$$218$$$O	A$$$219$$$220$$$O	as$$$221$$$223$$$O	the$$$224$$$227$$$O	active$$$228$$$234$$$O	ingredient$$$235$$$245$$$O	are$$$246$$$249$$$O	described.$$$250$$$260$$$O	The$$$261$$$264$$$O	amines$$$265$$$271$$$I	and$$$272$$$275$$$O	amides$$$276$$$282$$$I	of$$$283$$$285$$$O	formula$$$286$$$293$$$O	A$$$294$$$295$$$O	are$$$296$$$299$$$O	useful$$$300$$$306$$$O	in$$$307$$$309$$$O	the$$$310$$$313$$$O	treatment$$$314$$$323$$$O	of$$$324$$$326$$$O	disorders$$$327$$$336$$$O	and$$$337$$$340$$$O	diseases$$$341$$$349$$$O	associated$$$350$$$360$$$O	with$$$361$$$365$$$O	NPY$$$366$$$369$$$O	receptor$$$370$$$378$$$O	subtype$$$379$$$386$$$O	Y5.$$$387$$$390$$$O
US20050261496
3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide;$$$0$$$72$$$O	inhibiting,$$$73$$$84$$$O	modulating$$$85$$$95$$$O	and/or$$$96$$$102$$$O	regulating$$$103$$$113$$$O	signal$$$114$$$120$$$O	transduction$$$121$$$133$$$O	of$$$134$$$136$$$O	both$$$137$$$141$$$O	receptor$$$142$$$150$$$O	and$$$151$$$154$$$O	non-receptor$$$155$$$167$$$O	tyrosine$$$168$$$176$$$I	kinases;$$$177$$$185$$$O	anticarcinogenic,$$$186$$$203$$$O	-diabetic,$$$204$$$214$$$O	-arhtritic,$$$215$$$226$$$O	-inflammatory$$$227$$$240$$$O	agents;$$$241$$$248$$$O	psoriasis;$$$249$$$259$$$O	angiogenesisinhibitors;$$$260$$$283$$$O	liver$$$284$$$289$$$O	cirrhosis$$$290$$$299$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	that$$$43$$$47$$$O	are$$$48$$$51$$$O	capable$$$52$$$59$$$O	of$$$60$$$62$$$O	inhibiting,$$$63$$$74$$$O	modulating$$$75$$$85$$$O	and/or$$$86$$$92$$$O	regulating$$$93$$$103$$$O	signal$$$104$$$110$$$O	transduction$$$111$$$123$$$O	of$$$124$$$126$$$O	both$$$127$$$131$$$O	receptor-type$$$132$$$145$$$O	and$$$146$$$149$$$O	non-receptor$$$150$$$162$$$O	type$$$163$$$167$$$O	tyrosine$$$168$$$176$$$I	kinases.$$$177$$$185$$$O	The$$$186$$$189$$$O	compounds$$$190$$$199$$$O	of$$$200$$$202$$$O	the$$$203$$$206$$$O	instant$$$207$$$214$$$O	invention$$$215$$$224$$$O	possess$$$225$$$232$$$O	a$$$233$$$234$$$O	core$$$235$$$239$$$O	structure$$$240$$$249$$$O	that$$$250$$$254$$$O	comprises$$$255$$$264$$$O	a$$$265$$$266$$$O	sulfonyl$$$267$$$275$$$I	indole$$$276$$$282$$$I	moiety.$$$283$$$290$$$O	The$$$291$$$294$$$O	present$$$295$$$302$$$O	invention$$$303$$$312$$$O	is$$$313$$$315$$$O	also$$$316$$$320$$$O	related$$$321$$$328$$$O	to$$$329$$$331$$$O	the$$$332$$$335$$$O	pharmaceutically$$$336$$$352$$$O	acceptable$$$353$$$363$$$O	salts,$$$364$$$370$$$O	hydrates$$$371$$$379$$$I	and$$$380$$$383$$$O	stereoisomers$$$384$$$397$$$O	of$$$398$$$400$$$O	these$$$401$$$406$$$O	compounds.$$$407$$$417$$$O
CN102746309A
1-N-ethyl-4-N-2'-substituted$$$0$$$28$$$I	acylhydrazine-1H-pyrazol$$$29$$$53$$$I	[3,$$$54$$$57$$$I	4-d]$$$58$$$62$$$I	miazines$$$63$$$71$$$I	derivative$$$72$$$82$$$O	as$$$83$$$85$$$O	well$$$86$$$90$$$O	as$$$91$$$93$$$O	preparation$$$94$$$105$$$O	method$$$106$$$112$$$O	and$$$113$$$116$$$O	application$$$117$$$128$$$O	thereof$$$129$$$136$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	allopurinol$$$26$$$37$$$I	derivative$$$38$$$48$$$O	shown$$$49$$$54$$$O	in$$$55$$$57$$$O	a$$$58$$$59$$$O	formula$$$60$$$67$$$O	I$$$68$$$69$$$O	and$$$70$$$73$$$O	a$$$74$$$75$$$O	method$$$76$$$82$$$O	for$$$83$$$86$$$O	preparing$$$87$$$96$$$O	the$$$97$$$100$$$O	same.$$$101$$$106$$$O	The$$$107$$$110$$$O	allopurinol$$$111$$$122$$$I	derivative$$$123$$$133$$$O	can$$$134$$$137$$$O	effectively$$$138$$$149$$$O	inhibit$$$150$$$157$$$O	tumor$$$158$$$163$$$O	growth,$$$164$$$171$$$O	and$$$172$$$175$$$O	has$$$176$$$179$$$O	a$$$180$$$181$$$O	good$$$182$$$186$$$O	antitumor$$$187$$$196$$$O	effect;$$$197$$$204$$$O	the$$$205$$$208$$$O	allopurinol$$$209$$$220$$$I	derivative$$$221$$$231$$$O	can$$$232$$$235$$$O	also$$$236$$$240$$$O	effectively$$$241$$$252$$$O	inhibit$$$253$$$260$$$O	xanthine$$$261$$$269$$$I	oxidase$$$270$$$277$$$O	activity,$$$278$$$287$$$O	can$$$288$$$291$$$O	be$$$292$$$294$$$O	used$$$295$$$299$$$O	for$$$300$$$303$$$O	gout$$$304$$$308$$$O	treatment,$$$309$$$319$$$O	and$$$320$$$323$$$O	provides$$$324$$$332$$$O	a$$$333$$$334$$$O	new$$$335$$$338$$$O	pharmaceutical$$$339$$$353$$$O	option$$$354$$$360$$$O	for$$$361$$$364$$$O	clinically$$$365$$$375$$$O	treating$$$376$$$384$$$O	cancer$$$385$$$391$$$O	and$$$392$$$395$$$O	gout;$$$396$$$401$$$O	and$$$402$$$405$$$O	moreover,$$$406$$$415$$$O	the$$$416$$$419$$$O	preparation$$$420$$$431$$$O	method$$$432$$$438$$$O	of$$$439$$$441$$$O	the$$$442$$$445$$$O	compound$$$446$$$454$$$O	is$$$455$$$457$$$O	simple,$$$458$$$465$$$O	is$$$466$$$468$$$O	lower$$$469$$$474$$$O	in$$$475$$$477$$$O	cost,$$$478$$$483$$$O	and$$$484$$$487$$$O	has$$$488$$$491$$$O	high$$$492$$$496$$$O	yield$$$497$$$502$$$O	and$$$503$$$506$$$O	a$$$507$$$508$$$O	good$$$509$$$513$$$O	industrial$$$514$$$524$$$O	application$$$525$$$536$$$O	prospect.$$$537$$$546$$$O
EP1718645A1
2-(pyridin-3-ylamino)-pyrido$$$0$$$28$$$I	2,3-d$$$29$$$34$$$I	pyrimidin-7-ones$$$35$$$51$$$I
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	compounds$$$24$$$33$$$O	of$$$34$$$36$$$O	formula$$$37$$$44$$$O	I:R1$$$45$$$49$$$O	wherein$$$50$$$57$$$O	R',$$$58$$$61$$$O	R2,$$$62$$$65$$$O	R3,$$$66$$$69$$$O	R4,$$$70$$$73$$$O	and$$$74$$$77$$$O	X1$$$78$$$80$$$O	are$$$81$$$84$$$O	as$$$85$$$87$$$O	defined$$$88$$$95$$$O	in$$$96$$$98$$$O	the$$$99$$$102$$$O	specification.$$$103$$$117$$$O	The$$$118$$$121$$$O	2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-one$$$122$$$172$$$I	compounds$$$173$$$182$$$O	of$$$183$$$185$$$O	formula$$$186$$$193$$$O	I,$$$194$$$196$$$O	which$$$197$$$202$$$O	are$$$203$$$206$$$O	inhibitors$$$207$$$217$$$O	of$$$218$$$220$$$O	cyclin-dependent$$$221$$$237$$$O	kinases$$$238$$$245$$$O	2$$$246$$$247$$$O	and$$$248$$$251$$$O	4$$$252$$$253$$$O	(Cdk2$$$254$$$259$$$O	and$$$260$$$263$$$O	Cdk4),$$$264$$$270$$$O	are$$$271$$$274$$$O	useful$$$275$$$281$$$O	in$$$282$$$284$$$O	treating$$$285$$$293$$$O	cell$$$294$$$298$$$O	proliferative$$$299$$$312$$$O	disorders.$$$313$$$323$$$O
WO2006105222A3
Carboxamide$$$0$$$11$$$I	inhibitors$$$12$$$22$$$O	of$$$23$$$25$$$O	tgfb$$$26$$$30$$$O
Pyrimidine$$$0$$$10$$$I	having$$$11$$$17$$$O	a$$$18$$$19$$$O	pyridylamine$$$20$$$32$$$I	group$$$33$$$38$$$O	at$$$39$$$41$$$O	C-$$$42$$$44$$$I	4$$$45$$$46$$$O	of$$$47$$$49$$$O	the$$$50$$$53$$$O	pyrimidine$$$54$$$64$$$I	and$$$65$$$68$$$O	an$$$69$$$71$$$O	amide$$$72$$$77$$$I	group$$$78$$$83$$$O	on$$$84$$$86$$$O	the$$$87$$$90$$$O	pyridine$$$91$$$99$$$I	ring$$$100$$$104$$$O	(compounds$$$105$$$115$$$O	of$$$116$$$118$$$O	formula$$$119$$$126$$$O	I)$$$127$$$129$$$O	are$$$130$$$133$$$O	useful$$$134$$$140$$$O	in$$$141$$$143$$$O	the$$$144$$$147$$$O	treatment$$$148$$$157$$$O	of$$$158$$$160$$$O	conditions$$$161$$$171$$$O	associated$$$172$$$182$$$O	with$$$183$$$187$$$O	excessive$$$188$$$197$$$O	TGFB$$$198$$$202$$$O	activity.$$$203$$$212$$$O
USRE39072
2-aminopropane-1,3-diol$$$0$$$23$$$I	compounds,$$$24$$$34$$$O	medicinal$$$35$$$44$$$O	use$$$45$$$48$$$O	thereof,$$$49$$$57$$$O	and$$$58$$$61$$$O	intermediates$$$62$$$75$$$O	in$$$76$$$78$$$O	synthesizing$$$79$$$91$$$O	the$$$92$$$95$$$O	same$$$96$$$100$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	compound$$$35$$$43$$$O	of$$$44$$$46$$$O	the$$$47$$$50$$$O	general$$$51$$$58$$$O	formula$$$59$$$66$$$O	wherein$$$82$$$89$$$O	R1,$$$90$$$93$$$O	R2,$$$94$$$97$$$O	R3$$$98$$$100$$$O	and$$$101$$$104$$$O	R4$$$105$$$107$$$O	are$$$108$$$111$$$O	each$$$112$$$116$$$O	a$$$117$$$118$$$O	hydrogen$$$119$$$127$$$I	or$$$128$$$130$$$O	an$$$131$$$133$$$O	acyl,$$$134$$$139$$$I	a$$$140$$$141$$$O	pharmaceutically$$$142$$$158$$$O	acceptable$$$159$$$169$$$O	acid$$$170$$$174$$$O	addition$$$175$$$183$$$O	salt$$$184$$$188$$$O	thereof$$$189$$$196$$$O	or$$$197$$$199$$$O	a$$$200$$$201$$$O	hydrate$$$202$$$209$$$I	thereof;$$$210$$$218$$$O	a$$$219$$$220$$$O	pharmaceutical$$$221$$$235$$$O	comprising$$$236$$$246$$$O	this$$$247$$$251$$$O	compound;$$$252$$$261$$$O	a$$$262$$$263$$$O	pharmaceutical$$$264$$$278$$$O	composition$$$279$$$290$$$O	comprising$$$291$$$301$$$O	this$$$302$$$306$$$O	compound$$$307$$$315$$$O	and$$$316$$$319$$$O	a$$$320$$$321$$$O	pharmaceutically$$$322$$$338$$$O	acceptable$$$339$$$349$$$O	carrier;$$$350$$$358$$$O	and$$$359$$$362$$$O	2-amino-2-(2-(4-(1-hydroxy-5-phenylpentyl)phenyl)ethyl)propane-1,3-diol$$$363$$$434$$$I	or$$$435$$$437$$$O	2-amino-2-(2-(4-formylphenyl)ethyl)propane-1,3-diol,$$$438$$$490$$$I	the$$$491$$$494$$$O	derivatives$$$495$$$506$$$O	of$$$507$$$509$$$O	the$$$510$$$513$$$O	two$$$514$$$517$$$O	compounds$$$518$$$527$$$O	whose$$$528$$$533$$$O	amino$$$534$$$539$$$I	group$$$540$$$545$$$O	and/or$$$546$$$552$$$O	hydroxy$$$553$$$560$$$I	group$$$561$$$566$$$O	are(is)$$$567$$$574$$$O	protected$$$575$$$584$$$O	or$$$585$$$587$$$O	a$$$588$$$589$$$O	salt$$$590$$$594$$$O	thereof.$$$595$$$603$$$O	The$$$604$$$607$$$O	compound$$$608$$$616$$$O	of$$$617$$$619$$$O	the$$$620$$$623$$$O	present$$$624$$$631$$$O	invention$$$632$$$641$$$O	shows$$$642$$$647$$$O	superior$$$648$$$656$$$O	immunosuppressive$$$657$$$674$$$O	action$$$675$$$681$$$O	with$$$682$$$686$$$O	less$$$687$$$691$$$O	toxicity$$$692$$$700$$$O	and$$$701$$$704$$$O	higher$$$705$$$711$$$O	safety,$$$712$$$719$$$O	and$$$720$$$723$$$O	is$$$724$$$726$$$O	useful$$$727$$$733$$$O	as$$$734$$$736$$$O	a$$$737$$$738$$$O	drug$$$739$$$743$$$O	for$$$744$$$747$$$O	prevention$$$748$$$758$$$O	or$$$759$$$761$$$O	suppression$$$762$$$773$$$O	of$$$774$$$776$$$O	rejection$$$777$$$786$$$O	of$$$787$$$789$$$O	organs$$$790$$$796$$$O	or$$$797$$$799$$$O	bone$$$800$$$804$$$O	marrow$$$805$$$811$$$O	transplantation,$$$812$$$828$$$O	or$$$829$$$831$$$O	as$$$832$$$834$$$O	a$$$835$$$836$$$O	drug$$$837$$$841$$$O	for$$$842$$$845$$$O	prevention$$$846$$$856$$$O	or$$$857$$$859$$$O	treatment$$$860$$$869$$$O	of$$$870$$$872$$$O	various$$$873$$$880$$$O	autoimmune$$$881$$$891$$$O	diseases$$$892$$$900$$$O	or$$$901$$$903$$$O	allergic$$$904$$$912$$$O	diseases.$$$913$$$922$$$O
US20130012497
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	detecting$$$12$$$21$$$O	adhd$$$22$$$26$$$O	susceptibility$$$27$$$41$$$O	and$$$42$$$45$$$O	predicting$$$46$$$56$$$O	severity$$$57$$$65$$$O	and$$$66$$$69$$$O	long$$$70$$$74$$$O	term$$$75$$$79$$$O	outcome$$$80$$$87$$$O	of$$$88$$$90$$$O	adhd$$$91$$$95$$$O	symptoms$$$96$$$104$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	determining$$$34$$$45$$$O	an$$$46$$$48$$$O	altered$$$49$$$56$$$O	susceptibility$$$57$$$71$$$O	to$$$72$$$74$$$O	develop$$$75$$$82$$$O	ADHD,$$$83$$$88$$$O	methods$$$89$$$96$$$O	of$$$97$$$99$$$O	predicting$$$100$$$110$$$O	or$$$111$$$113$$$O	determining$$$114$$$125$$$O	the$$$126$$$129$$$O	severity$$$130$$$138$$$O	of$$$139$$$141$$$O	symptoms$$$142$$$150$$$O	of$$$151$$$153$$$O	ADHD$$$154$$$158$$$O	and$$$159$$$162$$$O	associated$$$163$$$173$$$O	disorders,$$$174$$$184$$$O	and$$$185$$$188$$$O	methods$$$189$$$196$$$O	of$$$197$$$199$$$O	treatment$$$200$$$209$$$O	based$$$210$$$215$$$O	on$$$216$$$218$$$O	the$$$219$$$222$$$O	presence$$$223$$$231$$$O	or$$$232$$$234$$$O	absence$$$235$$$242$$$O	of$$$243$$$245$$$O	one$$$246$$$249$$$O	or$$$250$$$252$$$O	more$$$253$$$257$$$O	alleles$$$258$$$265$$$O	of$$$266$$$268$$$O	single$$$269$$$275$$$O	nucleotide$$$276$$$286$$$I	polymorphism$$$287$$$299$$$O	(SNP)$$$300$$$305$$$O	markers.$$$306$$$314$$$O
CN102793883A
Plaster$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	intervertebral$$$21$$$35$$$O	disc$$$36$$$40$$$O	protrusion,$$$41$$$52$$$O	cervical$$$53$$$61$$$O	spondylosis$$$62$$$73$$$O	and$$$74$$$77$$$O	osteoproliferation$$$78$$$96$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	plaster$$$27$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	intervertebral$$$48$$$62$$$O	disc$$$63$$$67$$$O	protrusion,$$$68$$$79$$$O	cervical$$$80$$$88$$$O	spondylosis$$$89$$$100$$$O	and$$$101$$$104$$$O	osteoproliferation,$$$105$$$124$$$O	which$$$125$$$130$$$O	is$$$131$$$133$$$O	formed$$$134$$$140$$$O	by$$$141$$$143$$$O	processing$$$144$$$154$$$O	Chinese$$$155$$$162$$$O	angelica,$$$163$$$172$$$O	ligusticum$$$173$$$183$$$O	wallichii,$$$184$$$194$$$O	radix$$$195$$$200$$$O	achyranthis$$$201$$$212$$$O	bidentatae,$$$213$$$224$$$O	peach$$$225$$$230$$$O	kernel,$$$231$$$238$$$O	unprocessed$$$239$$$250$$$O	radix$$$251$$$256$$$O	aconite,$$$257$$$265$$$O	euphorbia$$$266$$$275$$$O	pekinensis,$$$276$$$287$$$O	rhizoma$$$288$$$295$$$O	gastrodiae,$$$296$$$307$$$O	radix$$$308$$$313$$$O	angelicae$$$314$$$323$$$O	pubescentis,$$$324$$$336$$$O	pangolin,$$$337$$$346$$$O	asarum,$$$347$$$354$$$O	radix$$$355$$$360$$$O	linderae,$$$361$$$370$$$O	angelica$$$371$$$379$$$O	dahurica,$$$380$$$389$$$O	galangal,$$$390$$$399$$$O	notopterygium$$$400$$$413$$$O	root,$$$414$$$419$$$O	red$$$420$$$423$$$O	paeony$$$424$$$430$$$O	root,$$$431$$$436$$$O	caulis$$$437$$$443$$$O	sinomenii,$$$444$$$454$$$O	safflower,$$$455$$$465$$$O	earthworm,$$$466$$$476$$$O	hematoxylon,$$$477$$$489$$$O	rhizoma$$$490$$$497$$$O	cyperi,$$$498$$$505$$$O	cortex$$$506$$$512$$$O	eucommiae,$$$513$$$523$$$O	radix$$$524$$$529$$$O	clematidis,$$$530$$$541$$$O	prepared$$$542$$$550$$$O	rehmannia$$$551$$$560$$$O	root,$$$561$$$566$$$O	unprocessed$$$567$$$578$$$O	radix$$$579$$$584$$$O	aconite,$$$585$$$593$$$O	dipsacus$$$594$$$602$$$O	root,$$$603$$$608$$$O	cortex$$$609$$$615$$$O	acanthopanacis,$$$616$$$631$$$O	cinnamon,$$$632$$$641$$$O	fleece-flower$$$642$$$655$$$O	root,$$$656$$$661$$$O	ledebouriella$$$662$$$675$$$O	root,$$$676$$$681$$$O	croton,$$$682$$$689$$$O	rhizoma$$$690$$$697$$$O	atractylodis,$$$698$$$711$$$O	ephedra,$$$712$$$720$$$O	liquorice,$$$721$$$731$$$O	frankincense,$$$732$$$745$$$O	myrrh,$$$746$$$752$$$O	sangusis$$$753$$$761$$$O	draconis,$$$762$$$771$$$O	borneol$$$772$$$779$$$I	and$$$780$$$783$$$O	rhizoma$$$784$$$791$$$O	anemones$$$792$$$800$$$O	raddeanae.$$$801$$$811$$$O	The$$$812$$$815$$$O	process$$$816$$$823$$$O	of$$$824$$$826$$$O	the$$$827$$$830$$$O	plaster$$$831$$$838$$$O	comprises$$$839$$$848$$$O	the$$$849$$$852$$$O	following$$$853$$$862$$$O	steps$$$863$$$868$$$O	of:$$$869$$$872$$$O	putting$$$873$$$880$$$O	the$$$881$$$884$$$O	above$$$885$$$890$$$O	raw$$$891$$$894$$$O	material$$$895$$$903$$$O	drugs$$$904$$$909$$$O	(excluding$$$910$$$920$$$O	the$$$921$$$924$$$O	olibanum,$$$925$$$934$$$O	the$$$935$$$938$$$O	myrrh,$$$939$$$945$$$O	the$$$946$$$949$$$O	sangusis$$$950$$$958$$$O	draconis$$$959$$$967$$$O	and$$$968$$$971$$$O	the$$$972$$$975$$$O	borneol)$$$976$$$984$$$O	into$$$985$$$989$$$O	an$$$990$$$992$$$O	iron$$$993$$$997$$$I	pan,$$$998$$$1002$$$O	adding$$$1003$$$1009$$$O	a$$$1010$$$1011$$$O	proper$$$1012$$$1018$$$O	amount$$$1019$$$1025$$$O	of$$$1026$$$1028$$$O	pure$$$1029$$$1033$$$O	sesame$$$1034$$$1040$$$O	oil$$$1041$$$1044$$$O	into$$$1045$$$1049$$$O	the$$$1050$$$1053$$$O	pan,$$$1054$$$1058$$$O	soaking$$$1059$$$1066$$$O	for$$$1067$$$1070$$$O	3-7$$$1071$$$1074$$$O	days,$$$1075$$$1080$$$O	decocting$$$1081$$$1090$$$O	with$$$1091$$$1095$$$O	soft$$$1096$$$1100$$$O	fire$$$1101$$$1105$$$O	till$$$1106$$$1110$$$O	medicine$$$1111$$$1119$$$O	dregs$$$1120$$$1125$$$O	become$$$1126$$$1132$$$O	black,$$$1133$$$1139$$$O	filtering$$$1140$$$1149$$$O	the$$$1150$$$1153$$$O	dregs,$$$1154$$$1160$$$O	continuously$$$1161$$$1173$$$O	decocting$$$1174$$$1183$$$O	till$$$1184$$$1188$$$O	when$$$1189$$$1193$$$O	dripping$$$1194$$$1202$$$O	into$$$1203$$$1207$$$O	water,$$$1208$$$1214$$$O	oil$$$1215$$$1218$$$O	can$$$1219$$$1222$$$O	not$$$1223$$$1226$$$O	disperse,$$$1227$$$1236$$$O	adding$$$1237$$$1243$$$O	yellow$$$1244$$$1250$$$O	lead,$$$1251$$$1256$$$O	decocting$$$1257$$$1266$$$O	till$$$1267$$$1271$$$O	smoking,$$$1272$$$1280$$$O	slightly$$$1281$$$1289$$$O	cooling,$$$1290$$$1298$$$O	adding$$$1299$$$1305$$$O	the$$$1306$$$1309$$$O	olibanum,$$$1310$$$1319$$$O	the$$$1320$$$1323$$$O	myrrh,$$$1324$$$1330$$$O	the$$$1331$$$1334$$$O	sangusis$$$1335$$$1343$$$O	draconis$$$1344$$$1352$$$O	and$$$1353$$$1356$$$O	the$$$1357$$$1360$$$O	borneol,$$$1361$$$1369$$$I	uniformly$$$1370$$$1379$$$O	agitating$$$1380$$$1389$$$O	and$$$1390$$$1393$$$O	removing$$$1394$$$1402$$$O	fire$$$1403$$$1407$$$O	toxin.$$$1408$$$1414$$$O	Cloth$$$1415$$$1420$$$O	is$$$1421$$$1423$$$O	spread$$$1424$$$1430$$$O	out,$$$1431$$$1435$$$O	and$$$1436$$$1439$$$O	the$$$1440$$$1443$$$O	weight$$$1444$$$1450$$$O	of$$$1451$$$1453$$$O	each$$$1454$$$1458$$$O	plaster$$$1459$$$1466$$$O	is$$$1467$$$1469$$$O	50g.$$$1470$$$1474$$$O	The$$$1475$$$1478$$$O	plaster$$$1479$$$1486$$$O	has$$$1487$$$1490$$$O	the$$$1491$$$1494$$$O	advantages$$$1495$$$1505$$$O	of$$$1506$$$1508$$$O	convenience$$$1509$$$1520$$$O	in$$$1521$$$1523$$$O	use,$$$1524$$$1528$$$O	low$$$1529$$$1532$$$O	cost$$$1533$$$1537$$$O	and$$$1538$$$1541$$$O	small$$$1542$$$1547$$$O	toxic$$$1548$$$1553$$$O	and$$$1554$$$1557$$$O	side$$$1558$$$1562$$$O	effects.$$$1563$$$1571$$$O
WO2006123246A3
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	identifying$$$12$$$23$$$O	chemotherapeutic$$$24$$$40$$$O	resistance$$$41$$$51$$$O	in$$$52$$$54$$$O	non-hematopoietic$$$55$$$72$$$O	tumors$$$73$$$79$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	methods$$$14$$$21$$$O	for$$$22$$$25$$$O	detecting$$$26$$$35$$$O	adriamycin$$$36$$$46$$$I	resistance$$$47$$$57$$$O	in$$$58$$$60$$$O	a$$$61$$$62$$$O	test$$$63$$$67$$$O	neoplastic$$$68$$$78$$$O	cell$$$79$$$83$$$O	from$$$84$$$88$$$O	a$$$89$$$90$$$O	non-hematological$$$91$$$108$$$O	cancer.$$$109$$$116$$$O	The$$$117$$$120$$$O	methods$$$121$$$128$$$O	include$$$129$$$136$$$O	detecting$$$137$$$146$$$O	a$$$147$$$148$$$O	level$$$149$$$154$$$O	of$$$155$$$157$$$O	pl6$$$158$$$161$$$O	expression$$$162$$$172$$$O	in$$$173$$$175$$$O	the$$$176$$$179$$$O	test$$$180$$$184$$$O	neoplastic$$$185$$$195$$$O	cell$$$196$$$200$$$O	of$$$201$$$203$$$O	a$$$204$$$205$$$O	given$$$206$$$211$$$O	origin$$$212$$$218$$$O	or$$$219$$$221$$$O	cell$$$222$$$226$$$O	type,$$$227$$$232$$$O	and$$$233$$$236$$$O	comparing$$$237$$$246$$$O	the$$$247$$$250$$$O	level$$$251$$$256$$$O	of$$$257$$$259$$$O	pl6$$$260$$$263$$$O	expression$$$264$$$274$$$O	detected$$$275$$$283$$$O	in$$$284$$$286$$$O	the$$$287$$$290$$$O	test$$$291$$$295$$$O	neoplastic$$$296$$$306$$$O	cell$$$307$$$311$$$O	to$$$312$$$314$$$O	the$$$315$$$318$$$O	level$$$319$$$324$$$O	of$$$325$$$327$$$O	pl6$$$328$$$331$$$O	expression$$$332$$$342$$$O	in$$$343$$$345$$$O	a$$$346$$$347$$$O	nonresistant$$$348$$$360$$$O	neoplastic$$$361$$$371$$$O	cell$$$372$$$376$$$O	of$$$377$$$379$$$O	the$$$380$$$383$$$O	same$$$384$$$388$$$O	origin$$$389$$$395$$$O	or$$$396$$$398$$$O	cell$$$399$$$403$$$O	type,$$$404$$$409$$$O	wherein$$$410$$$417$$$O	the$$$418$$$421$$$O	test$$$422$$$426$$$O	neoplastic$$$427$$$437$$$O	cell$$$438$$$442$$$O	is$$$443$$$445$$$O	adriamycin$$$446$$$456$$$I	resistant$$$457$$$466$$$O	if$$$467$$$469$$$O	the$$$470$$$473$$$O	level$$$474$$$479$$$O	of$$$480$$$482$$$O	pl6$$$483$$$486$$$O	expression$$$487$$$497$$$O	is$$$498$$$500$$$O	greater$$$501$$$508$$$O	than$$$509$$$513$$$O	the$$$514$$$517$$$O	level$$$518$$$523$$$O	of$$$524$$$526$$$O	pl6$$$527$$$530$$$O	expression$$$531$$$541$$$O	in$$$542$$$544$$$O	the$$$545$$$548$$$O	nonresistant$$$549$$$561$$$O	neoplastic$$$562$$$572$$$O	cell$$$573$$$577$$$O	of$$$578$$$580$$$O	the$$$581$$$584$$$O	same$$$585$$$589$$$O	origin$$$590$$$596$$$O	or$$$597$$$599$$$O	cell$$$600$$$604$$$O	type.$$$605$$$610$$$O	Also$$$611$$$615$$$O	disclosed$$$616$$$625$$$O	are$$$626$$$629$$$O	therapeutic$$$630$$$641$$$O	compositions$$$642$$$654$$$O	comprising$$$655$$$665$$$O	an$$$666$$$668$$$O	agent$$$669$$$674$$$O	that$$$675$$$679$$$O	inhibits$$$680$$$688$$$O	pl6$$$689$$$692$$$O	and$$$693$$$696$$$O	a$$$697$$$698$$$O	pharmaceutically$$$699$$$715$$$O	acceptable$$$716$$$726$$$O	carrier.$$$727$$$735$$$O
US20100227891
Threshold$$$0$$$9$$$O	blood$$$10$$$15$$$O	omeprazole$$$16$$$26$$$I	concentration$$$27$$$40$$$O	is$$$41$$$43$$$O	50$$$44$$$46$$$O	ng/ml$$$47$$$52$$$O	for$$$53$$$56$$$O	the$$$57$$$60$$$O	maintenance$$$61$$$72$$$O	of$$$73$$$75$$$O	intragastric$$$76$$$88$$$O	ph$$$89$$$91$$$O	of$$$92$$$94$$$O	at$$$95$$$97$$$O	least$$$98$$$103$$$O	4.0$$$104$$$107$$$O	after$$$108$$$113$$$O	oral$$$114$$$118$$$O	dosing$$$119$$$125$$$O	with$$$126$$$130$$$O	cma-omeprazole,$$$131$$$146$$$I	agn$$$147$$$150$$$I	201904-z$$$151$$$159$$$I
Dosage$$$0$$$6$$$O	forms$$$7$$$12$$$O	of$$$13$$$15$$$O	sodium$$$16$$$22$$$I	{4-[5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-benzoimidazole-1-sulfonyl]-phenoxy}-acetate,$$$23$$$136$$$I	and$$$137$$$140$$$O	methods$$$141$$$148$$$O	of$$$149$$$151$$$O	use$$$152$$$155$$$O	of$$$156$$$158$$$O	the$$$159$$$162$$$O	dosage$$$163$$$169$$$O	forms$$$170$$$175$$$O	are$$$176$$$179$$$O	disclosed$$$180$$$189$$$O	herein.$$$190$$$197$$$O
US20080025986
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	Treating$$$11$$$19$$$O	Tnf-Mediated$$$20$$$32$$$O	Disorders$$$33$$$42$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	of$$$39$$$41$$$O	treating$$$42$$$50$$$O	TNF-Î±-mediated$$$51$$$66$$$O	disorders,$$$67$$$77$$$O	the$$$78$$$81$$$O	methods$$$82$$$89$$$O	generally$$$90$$$99$$$O	involving$$$100$$$109$$$O	administering$$$110$$$123$$$O	to$$$124$$$126$$$O	an$$$127$$$129$$$O	individual$$$130$$$140$$$O	in$$$141$$$143$$$O	need$$$144$$$148$$$O	thereof$$$149$$$156$$$O	effective$$$157$$$166$$$O	amounts$$$167$$$174$$$O	of$$$175$$$177$$$I	pirfenidone$$$178$$$189$$$I	or$$$190$$$192$$$O	a$$$193$$$194$$$I	pirfenidone$$$195$$$206$$$I	analog$$$207$$$213$$$O	and$$$214$$$217$$$O	a$$$218$$$219$$$O	second$$$220$$$226$$$O	therapeutic$$$227$$$238$$$O	agent$$$239$$$244$$$O	that$$$245$$$249$$$O	reduces$$$250$$$257$$$O	TNF-Î±$$$258$$$264$$$O	synthesis$$$265$$$274$$$O	or$$$275$$$277$$$O	that$$$278$$$282$$$O	reduces$$$283$$$290$$$O	TNF-Î±$$$291$$$297$$$O	binding$$$298$$$305$$$O	to$$$306$$$308$$$O	a$$$309$$$310$$$O	TNF$$$311$$$314$$$O	receptor.$$$315$$$324$$$O	The$$$325$$$328$$$O	present$$$329$$$336$$$O	invention$$$337$$$346$$$O	further$$$347$$$354$$$O	provides$$$355$$$363$$$O	methods$$$364$$$371$$$O	for$$$372$$$375$$$O	treating$$$376$$$384$$$O	non-alcoholic$$$385$$$398$$$O	steatohepatitis,$$$399$$$415$$$O	the$$$416$$$419$$$O	method$$$420$$$426$$$O	generally$$$427$$$436$$$O	involving$$$437$$$446$$$O	administering$$$447$$$460$$$O	to$$$461$$$463$$$O	an$$$464$$$466$$$O	individual$$$467$$$477$$$O	in$$$478$$$480$$$O	need$$$481$$$485$$$O	thereof$$$486$$$493$$$O	an$$$494$$$496$$$O	effective$$$497$$$506$$$O	amount$$$507$$$513$$$O	of$$$514$$$516$$$I	pirfenidone.$$$517$$$529$$$I	The$$$530$$$533$$$O	present$$$534$$$541$$$O	invention$$$542$$$551$$$O	further$$$552$$$559$$$O	provides$$$560$$$568$$$O	methods$$$569$$$576$$$O	of$$$577$$$579$$$O	treating$$$580$$$588$$$O	end-stage$$$589$$$598$$$O	or$$$599$$$601$$$O	advanced$$$602$$$610$$$O	Type$$$611$$$615$$$O	II$$$616$$$618$$$O	diabetes,$$$619$$$628$$$O	the$$$629$$$632$$$O	methods$$$633$$$640$$$O	generally$$$641$$$650$$$O	involving$$$651$$$660$$$O	administering$$$661$$$674$$$O	to$$$675$$$677$$$O	an$$$678$$$680$$$O	individual$$$681$$$691$$$O	in$$$692$$$694$$$O	need$$$695$$$699$$$O	thereof$$$700$$$707$$$O	effective$$$708$$$717$$$O	amounts$$$718$$$725$$$O	of$$$726$$$728$$$I	pirfenidone$$$729$$$740$$$I	and$$$741$$$744$$$O	insulin.$$$745$$$753$$$O
US20100158946
Secretory$$$0$$$9$$$O	IgA$$$10$$$13$$$O	and$$$14$$$17$$$O	IgG$$$18$$$21$$$O	Antibody$$$22$$$30$$$O	Inducer$$$31$$$38$$$O
A$$$0$$$1$$$O	nasal$$$2$$$7$$$O	vaccine$$$8$$$15$$$O	is$$$16$$$18$$$O	provided$$$19$$$27$$$O	which$$$28$$$33$$$O	induces$$$34$$$41$$$O	the$$$42$$$45$$$O	production$$$46$$$56$$$O	of$$$57$$$59$$$O	secretory$$$60$$$69$$$O	IgA$$$70$$$73$$$O	and$$$74$$$77$$$O	IgG$$$78$$$81$$$O	antibodies$$$82$$$92$$$O	specific$$$93$$$101$$$O	for$$$102$$$105$$$O	flaviviruses,$$$106$$$119$$$O	including$$$120$$$129$$$O	hantaviruses.$$$130$$$143$$$O	Furthermore,$$$144$$$156$$$O	a$$$157$$$158$$$O	method$$$159$$$165$$$O	for$$$166$$$169$$$O	providing$$$170$$$179$$$O	protection$$$180$$$190$$$O	against$$$191$$$198$$$O	infection$$$199$$$208$$$O	with$$$209$$$213$$$O	flaviviruses$$$214$$$226$$$O	by$$$227$$$229$$$O	induces$$$230$$$237$$$O	of$$$238$$$240$$$O	the$$$241$$$244$$$O	secretory$$$245$$$254$$$O	IgA$$$255$$$258$$$O	and$$$259$$$262$$$O	IgG$$$263$$$266$$$O	antibodies$$$267$$$277$$$O	is$$$278$$$280$$$O	also$$$281$$$285$$$O	provided.$$$286$$$295$$$O	The$$$296$$$299$$$O	nasal$$$300$$$305$$$O	vaccine$$$306$$$313$$$O	includes$$$314$$$322$$$O	an$$$323$$$325$$$O	inactivated$$$326$$$337$$$O	antigen$$$338$$$345$$$O	of$$$346$$$348$$$O	a$$$349$$$350$$$O	flavivirus$$$351$$$361$$$O	and$$$362$$$365$$$O	poly(I:C)$$$366$$$375$$$O	or$$$376$$$378$$$O	a$$$379$$$380$$$O	ceramified$$$381$$$391$$$O	powder$$$392$$$398$$$O	of$$$399$$$401$$$O	surf$$$402$$$406$$$O	clam$$$407$$$411$$$O	shells$$$412$$$418$$$O	as$$$419$$$421$$$O	an$$$422$$$424$$$O	adjuvant.$$$425$$$434$$$O	The$$$435$$$438$$$O	vaccine$$$439$$$446$$$O	effectively$$$447$$$458$$$O	induces$$$459$$$466$$$O	secretion$$$467$$$476$$$O	of$$$477$$$479$$$O	IgA$$$480$$$483$$$O	antibodies$$$484$$$494$$$O	in$$$495$$$497$$$O	the$$$498$$$501$$$O	nasal$$$502$$$507$$$O	mucosa$$$508$$$514$$$O	and$$$515$$$518$$$O	serum$$$519$$$524$$$O	IgG$$$525$$$528$$$O	antibody$$$529$$$537$$$O	responses.$$$538$$$548$$$O	Also$$$549$$$553$$$O	provided$$$554$$$562$$$O	is$$$563$$$565$$$O	a$$$566$$$567$$$O	method$$$568$$$574$$$O	for$$$575$$$578$$$O	inducing$$$579$$$587$$$O	flavivirus-specific$$$588$$$607$$$O	IgA$$$608$$$611$$$O	and$$$612$$$615$$$O	IgG$$$616$$$619$$$O	antibodies,$$$620$$$631$$$O	including$$$632$$$641$$$O	administering$$$642$$$655$$$O	an$$$656$$$658$$$O	inactivated$$$659$$$670$$$O	antigen$$$671$$$678$$$O	of$$$679$$$681$$$O	a$$$682$$$683$$$O	flavivirus$$$684$$$694$$$O	and$$$695$$$698$$$O	poly(I:C)$$$699$$$708$$$O	or$$$709$$$711$$$O	a$$$712$$$713$$$O	ceramified$$$714$$$724$$$O	powder$$$725$$$731$$$O	of$$$732$$$734$$$O	surf$$$735$$$739$$$O	clam$$$740$$$744$$$O	shells$$$745$$$751$$$O	as$$$752$$$754$$$O	an$$$755$$$757$$$O	adjuvant$$$758$$$766$$$O	to$$$767$$$769$$$O	the$$$770$$$773$$$O	mucosa$$$774$$$780$$$O	of$$$781$$$783$$$O	a$$$784$$$785$$$O	respiratory$$$786$$$797$$$O	tract.$$$798$$$804$$$O
CN101332203A
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	preventing$$$13$$$23$$$O	and$$$24$$$27$$$O	curing$$$28$$$34$$$O	porcine$$$35$$$42$$$O	diarrhea$$$43$$$51$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	a$$$32$$$33$$$O	medicine$$$34$$$42$$$O	for$$$43$$$46$$$O	preventing$$$47$$$57$$$O	and$$$58$$$61$$$O	treating$$$62$$$70$$$O	diarrhea$$$71$$$79$$$O	of$$$80$$$82$$$O	pigs,$$$83$$$88$$$O	which$$$89$$$94$$$O	contains$$$95$$$103$$$O	vitriol$$$104$$$111$$$O	neomycin,$$$112$$$121$$$I	sodium$$$122$$$128$$$I	bicarbonate/zein$$$129$$$145$$$I	powder,$$$146$$$153$$$O	lactic$$$154$$$160$$$I	ethyl$$$161$$$166$$$I	ester$$$167$$$172$$$I	and$$$173$$$176$$$O	acetic$$$177$$$183$$$I	acid.$$$184$$$189$$$I	The$$$190$$$193$$$O	medicine$$$194$$$202$$$O	can$$$203$$$206$$$O	promote$$$207$$$214$$$O	piglet$$$215$$$221$$$O	feeding$$$222$$$229$$$O	and$$$230$$$233$$$O	improve$$$234$$$241$$$O	self$$$242$$$246$$$O	immunity,$$$247$$$256$$$O	which$$$257$$$262$$$O	is$$$263$$$265$$$O	convenient$$$266$$$276$$$O	for$$$277$$$280$$$O	use.$$$281$$$285$$$O
WO2007008045A1
Pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	containing$$$28$$$38$$$O	clopidogrel$$$39$$$50$$$I	bisulfate$$$51$$$60$$$I
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	pharmaceutical$$$14$$$28$$$O	composition$$$29$$$40$$$O	including$$$41$$$50$$$O	clopidogrel$$$51$$$62$$$I	bisulfate$$$63$$$72$$$I	and$$$73$$$76$$$O	a$$$77$$$78$$$O	pregelatinized$$$79$$$93$$$O	starch.$$$94$$$101$$$O	The$$$102$$$105$$$O	pharmaceutical$$$106$$$120$$$O	composition$$$121$$$132$$$O	in$$$133$$$135$$$O	which$$$136$$$141$$$O	the$$$142$$$145$$$O	stability$$$146$$$155$$$O	of$$$156$$$158$$$O	clopido$$$159$$$166$$$I	grel$$$167$$$171$$$I	bisulfate$$$172$$$181$$$I	is$$$182$$$184$$$O	significantly$$$185$$$198$$$O	enhanced$$$199$$$207$$$O	can$$$208$$$211$$$O	be$$$212$$$214$$$O	obtained$$$215$$$223$$$O	by$$$224$$$226$$$O	mixing$$$227$$$233$$$O	clopidogrel$$$234$$$245$$$I	bisulfate$$$246$$$255$$$I	w$$$256$$$257$$$O	ith$$$258$$$261$$$O	the$$$262$$$265$$$O	pregelatinized$$$266$$$280$$$O	starch.$$$281$$$288$$$O
US7202242
Substituted$$$0$$$11$$$O	1$$$12$$$13$$$I	and$$$14$$$17$$$I	2-naphthol$$$18$$$28$$$I	Mannich$$$29$$$36$$$I	bases$$$37$$$42$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	substituted$$$25$$$36$$$O	1$$$37$$$38$$$I	and$$$39$$$42$$$I	2$$$43$$$44$$$I	naphthol$$$45$$$53$$$I	Mannich$$$54$$$61$$$I	bases,$$$62$$$68$$$I	a$$$69$$$70$$$O	method$$$71$$$77$$$O	for$$$78$$$81$$$O	the$$$82$$$85$$$O	production$$$86$$$96$$$O	thereof,$$$97$$$105$$$O	medicaments$$$106$$$117$$$O	containing$$$118$$$128$$$O	said$$$129$$$133$$$O	compounds$$$134$$$143$$$O	and$$$144$$$147$$$O	the$$$148$$$151$$$O	use$$$152$$$155$$$O	of$$$156$$$158$$$O	said$$$159$$$163$$$O	compounds$$$164$$$173$$$O	in$$$174$$$176$$$O	the$$$177$$$180$$$O	production$$$181$$$191$$$O	of$$$192$$$194$$$O	medicaments.$$$195$$$207$$$O
EP2684861A2
Spiro$$$0$$$5$$$O	compounds$$$6$$$15$$$O	and$$$16$$$19$$$O	pharmaceutical$$$20$$$34$$$O	use$$$35$$$38$$$O	thereof$$$39$$$46$$$O
The$$$0$$$3$$$O	spiro$$$4$$$9$$$O	compound$$$10$$$18$$$O	represented$$$19$$$30$$$O	by$$$31$$$33$$$O	the$$$34$$$37$$$O	following$$$38$$$47$$$O	general$$$48$$$55$$$O	formula$$$56$$$63$$$O	[Ia],$$$64$$$69$$$O	its$$$70$$$73$$$O	pharmaceumatically$$$74$$$92$$$O	acceptable$$$93$$$103$$$O	salt$$$104$$$108$$$O	or$$$109$$$111$$$O	a$$$112$$$113$$$O	solvate$$$114$$$121$$$O	thereof$$$122$$$129$$$O
US7273928
Nucleic$$$0$$$7$$$O	acid$$$8$$$12$$$O	molecule$$$13$$$21$$$O	comprising$$$22$$$32$$$O	a$$$33$$$34$$$O	nucleic$$$35$$$42$$$O	acid$$$43$$$47$$$O	sequence$$$48$$$56$$$O	coding$$$57$$$63$$$O	for$$$64$$$67$$$O	a$$$68$$$69$$$O	haemocyanin$$$70$$$81$$$O
A$$$0$$$1$$$O	nucleic$$$2$$$9$$$O	acid$$$10$$$14$$$O	molecule$$$15$$$23$$$O	or$$$24$$$26$$$O	construct$$$27$$$36$$$O	alone$$$37$$$42$$$O	or$$$43$$$45$$$O	with$$$46$$$50$$$O	a$$$51$$$52$$$O	promoter$$$53$$$61$$$O	suitable$$$62$$$70$$$O	for$$$71$$$74$$$O	expression$$$75$$$85$$$O	control$$$86$$$93$$$O	is$$$94$$$96$$$O	contemplated$$$97$$$109$$$O	that$$$110$$$114$$$O	codes$$$115$$$120$$$O	for$$$121$$$124$$$O	a$$$125$$$126$$$O	HLH2$$$127$$$131$$$O	haemocyanin$$$132$$$143$$$O	polypeptide$$$144$$$155$$$O	and$$$156$$$159$$$O	comprises$$$160$$$169$$$O	at$$$170$$$172$$$O	least$$$173$$$178$$$O	one$$$179$$$182$$$O	intron$$$183$$$189$$$O	sequence,$$$190$$$199$$$O	as$$$200$$$202$$$O	well$$$203$$$207$$$O	as$$$208$$$210$$$O	haemocyanin$$$211$$$222$$$O	fusion$$$223$$$229$$$O	proteins.$$$230$$$239$$$O	The$$$240$$$243$$$O	construct$$$244$$$253$$$O	further$$$254$$$261$$$O	can$$$262$$$265$$$O	comprise$$$266$$$274$$$O	a$$$275$$$276$$$O	nucleic$$$277$$$284$$$O	acid$$$285$$$289$$$O	sequence$$$290$$$298$$$O	that$$$299$$$303$$$O	codes$$$304$$$309$$$O	for$$$310$$$313$$$O	an$$$314$$$316$$$O	antigen.$$$317$$$325$$$O	Host$$$326$$$330$$$O	cells$$$331$$$336$$$O	are$$$337$$$340$$$O	also$$$341$$$345$$$O	contemplated$$$346$$$358$$$O	that$$$359$$$363$$$O	contain$$$364$$$371$$$O	the$$$372$$$375$$$O	nucleic$$$376$$$383$$$O	acid$$$384$$$388$$$O	molecules$$$389$$$398$$$O	or$$$399$$$401$$$O	construct$$$402$$$411$$$O	and$$$412$$$415$$$O	recombinant$$$416$$$427$$$O	expression$$$428$$$438$$$O	product$$$439$$$446$$$O	thereof.$$$447$$$455$$$O	The$$$456$$$459$$$O	invention$$$460$$$469$$$O	further$$$470$$$477$$$O	relates$$$478$$$485$$$O	to$$$486$$$488$$$O	a$$$489$$$490$$$O	pharmaceutical$$$491$$$505$$$O	composition$$$506$$$517$$$O	that$$$518$$$522$$$O	comprises$$$523$$$532$$$O	the$$$533$$$536$$$O	expression$$$537$$$547$$$O	product$$$548$$$555$$$O	of$$$556$$$558$$$O	that$$$559$$$563$$$O	nucleic$$$564$$$571$$$O	acid$$$572$$$576$$$O	and$$$577$$$580$$$O	antibodies$$$581$$$591$$$O	obtainable$$$592$$$602$$$O	by$$$603$$$605$$$O	immunization$$$606$$$618$$$O	of$$$619$$$621$$$O	an$$$622$$$624$$$O	animal$$$625$$$631$$$O	therewith,$$$632$$$642$$$O	as$$$643$$$645$$$O	well$$$646$$$650$$$O	as$$$651$$$653$$$O	use$$$654$$$657$$$O	of$$$658$$$660$$$O	the$$$661$$$664$$$O	antibodies$$$665$$$675$$$O	in$$$676$$$678$$$O	screening$$$679$$$688$$$O	methods$$$689$$$696$$$O	for$$$697$$$700$$$O	the$$$701$$$704$$$O	identification$$$705$$$719$$$O	of$$$720$$$722$$$O	tumors.$$$723$$$730$$$O
CN1650851A
Injection$$$0$$$9$$$O	liquid$$$10$$$16$$$O	capable$$$17$$$24$$$O	of$$$25$$$27$$$O	direct$$$28$$$34$$$O	venoclysis$$$35$$$45$$$O
An$$$0$$$2$$$O	injection$$$3$$$12$$$O	of$$$13$$$15$$$O	sodium$$$16$$$22$$$I	neohouttuyfonate$$$23$$$39$$$I	for$$$40$$$43$$$O	venous$$$44$$$50$$$O	transfusion$$$51$$$62$$$O	contains$$$63$$$71$$$O	proportionally$$$72$$$86$$$O	sodium$$$87$$$93$$$I	neohouttuyfonate,$$$94$$$111$$$I	tween-80,$$$112$$$121$$$I	osmosis$$$122$$$129$$$O	regulator$$$130$$$139$$$O	and$$$140$$$143$$$O	the$$$144$$$147$$$O	water$$$148$$$153$$$O	for$$$154$$$157$$$O	injection.$$$158$$$168$$$O	Its$$$169$$$172$$$O	advantages$$$173$$$183$$$O	are$$$184$$$187$$$O	high$$$188$$$192$$$O	stability$$$193$$$202$$$O	and$$$203$$$206$$$O	high$$$207$$$211$$$O	biologic$$$212$$$220$$$O	safety.$$$221$$$228$$$O
US7112584
Antiinflammatory$$$0$$$16$$$O	agents;$$$17$$$24$$$O	antiarthritic$$$25$$$38$$$O	agents;$$$39$$$46$$$O	antiallergens;$$$47$$$61$$$O	antiinflammatory$$$62$$$78$$$O	agents$$$79$$$85$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	general$$$38$$$45$$$O	formula$$$46$$$53$$$O	I$$$54$$$55$$$O	and$$$75$$$78$$$O	their$$$79$$$84$$$O	use$$$85$$$88$$$O	for$$$89$$$92$$$O	the$$$93$$$96$$$O	production$$$97$$$107$$$O	of$$$108$$$110$$$O	pharmaceutical$$$111$$$125$$$O	agents$$$126$$$132$$$O	for$$$133$$$136$$$O	treatment$$$137$$$146$$$O	and$$$147$$$150$$$O	prophylaxis$$$151$$$162$$$O	of$$$163$$$165$$$O	diseases$$$166$$$174$$$O	that$$$175$$$179$$$O	coincide$$$180$$$188$$$O	with$$$189$$$193$$$O	inflammatory,$$$194$$$207$$$O	allergic$$$208$$$216$$$O	and/or$$$217$$$223$$$O	proliferative$$$224$$$237$$$O	processes.$$$238$$$248$$$O
CN101406573A
Health-care$$$0$$$11$$$O	product$$$12$$$19$$$O	with$$$20$$$24$$$O	toxin-expelling$$$25$$$40$$$O	and$$$41$$$44$$$O	health-preserving$$$45$$$62$$$O	efficacy$$$63$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	health$$$26$$$32$$$O	care$$$33$$$37$$$O	product$$$38$$$45$$$O	with$$$46$$$50$$$O	efficacies$$$51$$$61$$$O	of$$$62$$$64$$$O	expelling$$$65$$$74$$$O	toxin$$$75$$$80$$$O	and$$$81$$$84$$$O	preserving$$$85$$$95$$$O	health,$$$96$$$103$$$O	which$$$104$$$109$$$O	is$$$110$$$112$$$O	produced$$$113$$$121$$$O	from$$$122$$$126$$$O	the$$$127$$$130$$$O	following$$$131$$$140$$$O	raw$$$141$$$144$$$O	materials$$$145$$$154$$$O	in$$$155$$$157$$$O	weight$$$158$$$164$$$O	portion:$$$165$$$173$$$O	3$$$174$$$175$$$O	portions$$$176$$$184$$$O	of$$$185$$$187$$$O	honeysuckle,$$$188$$$200$$$O	2$$$201$$$202$$$O	portions$$$203$$$211$$$O	of$$$212$$$214$$$O	liquorice,$$$215$$$225$$$O	2$$$226$$$227$$$O	portions$$$228$$$236$$$O	of$$$237$$$239$$$O	propolis,$$$240$$$249$$$O	1.5$$$250$$$253$$$O	portions$$$254$$$262$$$O	of$$$263$$$265$$$O	wild$$$266$$$270$$$O	chrysanthemum$$$271$$$284$$$O	flower,$$$285$$$292$$$O	1.5$$$293$$$296$$$O	portions$$$297$$$305$$$O	of$$$306$$$308$$$O	dandelion,$$$309$$$319$$$O	1.2$$$320$$$323$$$O	portions$$$324$$$332$$$O	of$$$333$$$335$$$O	Chinese$$$336$$$343$$$O	violet,$$$344$$$351$$$O	and$$$352$$$355$$$O	1.2$$$356$$$359$$$O	portions$$$360$$$368$$$O	of$$$369$$$371$$$O	radix$$$372$$$377$$$O	semiaquilegiae.$$$378$$$393$$$O	When$$$394$$$398$$$O	the$$$399$$$402$$$O	health$$$403$$$409$$$O	care$$$410$$$414$$$O	product$$$415$$$422$$$O	is$$$423$$$425$$$O	produced,$$$426$$$435$$$O	the$$$436$$$439$$$O	raw$$$440$$$443$$$O	materials$$$444$$$453$$$O	are$$$454$$$457$$$O	ground$$$458$$$464$$$O	into$$$465$$$469$$$O	fine$$$470$$$474$$$O	powder$$$475$$$481$$$O	and$$$482$$$485$$$O	then$$$486$$$490$$$O	are$$$491$$$494$$$O	mixed$$$495$$$500$$$O	according$$$501$$$510$$$O	to$$$511$$$513$$$O	the$$$514$$$517$$$O	proportion.$$$518$$$529$$$O	The$$$530$$$533$$$O	health$$$534$$$540$$$O	care$$$541$$$545$$$O	product$$$546$$$553$$$O	with$$$554$$$558$$$O	the$$$559$$$562$$$O	efficacies$$$563$$$573$$$O	of$$$574$$$576$$$O	expelling$$$577$$$586$$$O	toxin$$$587$$$592$$$O	and$$$593$$$596$$$O	preserving$$$597$$$607$$$O	health$$$608$$$614$$$O	has$$$615$$$618$$$O	cheap$$$619$$$624$$$O	and$$$625$$$628$$$O	easily-obtained$$$629$$$644$$$O	raw$$$645$$$648$$$O	materials,$$$649$$$659$$$O	can$$$660$$$663$$$O	be$$$664$$$666$$$O	produced$$$667$$$675$$$O	into$$$676$$$680$$$O	a$$$681$$$682$$$O	plurality$$$683$$$692$$$O	of$$$693$$$695$$$O	health$$$696$$$702$$$O	care$$$703$$$707$$$O	products$$$708$$$716$$$O	such$$$717$$$721$$$O	as$$$722$$$724$$$O	health$$$725$$$731$$$O	care$$$732$$$736$$$O	wine,$$$737$$$742$$$O	health$$$743$$$749$$$O	care$$$750$$$754$$$O	tea,$$$755$$$759$$$O	health$$$760$$$766$$$O	care$$$767$$$771$$$O	pillows$$$772$$$779$$$O	and$$$780$$$783$$$O	health$$$784$$$790$$$O	care$$$791$$$795$$$O	perplex$$$796$$$803$$$O	incense,$$$804$$$812$$$O	can$$$813$$$816$$$O	ensure$$$817$$$823$$$O	that$$$824$$$828$$$O	people$$$829$$$835$$$O	can$$$836$$$839$$$O	use$$$840$$$843$$$O	anywhere$$$844$$$852$$$O	at$$$853$$$855$$$O	any$$$856$$$859$$$O	time$$$860$$$864$$$O	in$$$865$$$867$$$O	daily$$$868$$$873$$$O	life,$$$874$$$879$$$O	can$$$880$$$883$$$O	be$$$884$$$886$$$O	taken$$$887$$$892$$$O	orally$$$893$$$899$$$O	for$$$900$$$903$$$O	conditioning,$$$904$$$917$$$O	and$$$918$$$921$$$O	make$$$922$$$926$$$O	the$$$927$$$930$$$O	drug$$$931$$$935$$$O	effect$$$936$$$942$$$O	act$$$943$$$946$$$O	on$$$947$$$949$$$O	human$$$950$$$955$$$O	bodies$$$956$$$962$$$O	for$$$963$$$966$$$O	a$$$967$$$968$$$O	long$$$969$$$973$$$O	time$$$974$$$978$$$O	by$$$979$$$981$$$O	methods$$$982$$$989$$$O	such$$$990$$$994$$$O	as$$$995$$$997$$$O	external$$$998$$$1006$$$O	application,$$$1007$$$1019$$$O	medical$$$1020$$$1027$$$O	lavender$$$1028$$$1036$$$O	or$$$1037$$$1039$$$O	moxibustion,$$$1040$$$1052$$$O	thus$$$1053$$$1057$$$O	the$$$1058$$$1061$$$O	long-term$$$1062$$$1071$$$O	use$$$1072$$$1075$$$O	of$$$1076$$$1078$$$O	the$$$1079$$$1082$$$O	product$$$1083$$$1090$$$O	by$$$1091$$$1093$$$O	people$$$1094$$$1100$$$O	can$$$1101$$$1104$$$O	be$$$1105$$$1107$$$O	assured;$$$1108$$$1116$$$O	and$$$1117$$$1120$$$O	the$$$1121$$$1124$$$O	selected$$$1125$$$1133$$$O	raw$$$1134$$$1137$$$O	materials$$$1138$$$1147$$$O	focus$$$1148$$$1153$$$O	on$$$1154$$$1156$$$O	the$$$1157$$$1160$$$O	toxin$$$1161$$$1166$$$O	expelling$$$1167$$$1176$$$O	and$$$1177$$$1180$$$O	also$$$1181$$$1185$$$O	emphasize$$$1186$$$1195$$$O	the$$$1196$$$1199$$$O	nourishing$$$1200$$$1210$$$O	at$$$1211$$$1213$$$O	the$$$1214$$$1217$$$O	same$$$1218$$$1222$$$O	time,$$$1223$$$1228$$$O	so$$$1229$$$1231$$$O	no$$$1232$$$1234$$$O	side$$$1235$$$1239$$$O	effect$$$1240$$$1246$$$O	can$$$1247$$$1250$$$O	be$$$1251$$$1253$$$O	produced.$$$1254$$$1263$$$O
CN101166732A
Cyanopyridine$$$0$$$13$$$I	derivative$$$14$$$24$$$O	and$$$25$$$28$$$O	use$$$29$$$32$$$O	thereof$$$33$$$40$$$O	as$$$41$$$43$$$O	medicine$$$44$$$52$$$O
It$$$0$$$2$$$O	is$$$3$$$5$$$O	possible$$$6$$$14$$$O	to$$$15$$$17$$$O	provide$$$18$$$25$$$O	a$$$26$$$27$$$O	remedy$$$28$$$34$$$O	for$$$35$$$38$$$O	cancer$$$39$$$45$$$O	which$$$46$$$51$$$O	contains,$$$52$$$61$$$O	as$$$62$$$64$$$O	the$$$65$$$68$$$O	active$$$69$$$75$$$O	ingredient,$$$76$$$87$$$O	a$$$88$$$89$$$O	substance$$$90$$$99$$$O	selected$$$100$$$108$$$O	from$$$109$$$113$$$O	the$$$114$$$117$$$O	group$$$118$$$123$$$O	consisting$$$124$$$134$$$O	of$$$135$$$137$$$O	a$$$138$$$139$$$O	novel$$$140$$$145$$$O	cyanopyridine$$$146$$$159$$$I	derivative,$$$160$$$171$$$O	a$$$172$$$173$$$O	pharmaceutically$$$174$$$190$$$O	acceptable$$$191$$$201$$$O	salt$$$202$$$206$$$O	thereof,$$$207$$$215$$$O	a$$$216$$$217$$$O	hydrate,$$$218$$$226$$$I	a$$$227$$$228$$$O	water$$$229$$$234$$$O	adduct$$$235$$$241$$$O	and$$$242$$$245$$$O	a$$$246$$$247$$$O	solvate$$$248$$$255$$$O	thereof.$$$256$$$264$$$O
WO2014106612A1
Aminopyridine$$$0$$$13$$$I	derived$$$14$$$21$$$O	compounds$$$22$$$31$$$O	as$$$32$$$34$$$O	lrrk2$$$35$$$40$$$O	inhibitors$$$41$$$51$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	aminopyridine$$$37$$$50$$$I	derived$$$51$$$58$$$O	compounds$$$59$$$68$$$O	of$$$69$$$71$$$O	formula$$$72$$$79$$$O	(A).$$$80$$$84$$$O	The$$$85$$$88$$$O	compounds$$$89$$$98$$$O	are$$$99$$$102$$$O	considered$$$103$$$113$$$O	useful$$$114$$$120$$$O	for$$$121$$$124$$$O	the$$$125$$$128$$$O	treatment$$$129$$$138$$$O	of$$$139$$$141$$$O	diseases$$$142$$$150$$$O	associated$$$151$$$161$$$O	with$$$162$$$166$$$O	LRRK2$$$167$$$172$$$O	such$$$173$$$177$$$O	a$$$178$$$179$$$O	Lewy$$$180$$$184$$$O	body$$$185$$$189$$$O	dementia,$$$190$$$199$$$O	Parkinson's$$$200$$$211$$$O	disease$$$212$$$219$$$O	or$$$220$$$222$$$O	cancer.$$$223$$$230$$$O
US20070173537
Indazole$$$0$$$8$$$I	compound$$$9$$$17$$$O	and$$$18$$$21$$$O	pharmaceutical$$$22$$$36$$$O	use$$$37$$$40$$$O	thereof$$$41$$$48$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	can$$$22$$$25$$$O	provide$$$26$$$33$$$O	a$$$34$$$35$$$O	cancer$$$36$$$42$$$O	treatment$$$43$$$52$$$O	drug$$$53$$$57$$$O	containing,$$$58$$$69$$$O	as$$$70$$$72$$$O	an$$$73$$$75$$$O	active$$$76$$$82$$$O	ingredient,$$$83$$$94$$$O	a$$$95$$$96$$$O	substance$$$97$$$106$$$O	selected$$$107$$$115$$$O	from$$$116$$$120$$$O	the$$$121$$$124$$$O	group$$$125$$$130$$$O	consisting$$$131$$$141$$$O	of$$$142$$$144$$$O	an$$$145$$$147$$$O	indazole$$$148$$$156$$$I	compound$$$157$$$165$$$O	of$$$166$$$168$$$O	the$$$169$$$172$$$O	following$$$173$$$182$$$O	formula$$$183$$$190$$$O	(I),$$$191$$$195$$$O	a$$$196$$$197$$$O	pharmaceutically$$$198$$$214$$$O	acceptable$$$215$$$225$$$O	salt,$$$226$$$231$$$O	a$$$232$$$233$$$O	hydrate,$$$234$$$242$$$O	a$$$243$$$244$$$O	water$$$245$$$250$$$O	adduct$$$251$$$257$$$O	and$$$258$$$261$$$O	a$$$262$$$263$$$O	solvate:$$$264$$$272$$$O
CN102716140A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	liquiritin$$$15$$$25$$$I	to$$$26$$$28$$$O	preparation$$$29$$$40$$$O	of$$$41$$$43$$$O	drugs$$$44$$$49$$$O	for$$$50$$$53$$$O	preventing$$$54$$$64$$$O	and$$$65$$$68$$$O	treating$$$69$$$77$$$O	cerebral$$$78$$$86$$$O	thrombosis$$$87$$$97$$$O	disease$$$98$$$105$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	medical$$$38$$$45$$$O	technology,$$$46$$$57$$$O	and$$$58$$$61$$$O	specifically$$$62$$$74$$$O	relates$$$75$$$82$$$O	to$$$83$$$85$$$O	the$$$86$$$89$$$O	application$$$90$$$101$$$O	of$$$102$$$104$$$O	liquiritin$$$105$$$115$$$I	to$$$116$$$118$$$O	preparation$$$119$$$130$$$O	of$$$131$$$133$$$O	drugs$$$134$$$139$$$O	for$$$140$$$143$$$O	preventing$$$144$$$154$$$O	and$$$155$$$158$$$O	treating$$$159$$$167$$$O	cardiovascular$$$168$$$182$$$O	and$$$183$$$186$$$O	cerebrovascular$$$187$$$202$$$O	diseases,$$$203$$$212$$$O	particularly$$$213$$$225$$$O	the$$$226$$$229$$$O	application$$$230$$$241$$$O	of$$$242$$$244$$$O	liquiritin$$$245$$$255$$$I	to$$$256$$$258$$$O	preparation$$$259$$$270$$$O	of$$$271$$$273$$$O	drugs$$$274$$$279$$$O	for$$$280$$$283$$$O	preventing$$$284$$$294$$$O	and$$$295$$$298$$$O	treating$$$299$$$307$$$O	cerebral$$$308$$$316$$$O	vascular$$$317$$$325$$$O	diseases.$$$326$$$335$$$O	Pharmacological$$$336$$$351$$$O	experiment$$$352$$$362$$$O	results$$$363$$$370$$$O	of$$$371$$$373$$$O	the$$$374$$$377$$$O	present$$$378$$$385$$$O	invention$$$386$$$395$$$O	show$$$396$$$400$$$O	that$$$401$$$405$$$O	liquiritin$$$406$$$416$$$I	has$$$417$$$420$$$O	significant$$$421$$$432$$$O	effects$$$433$$$440$$$O	on$$$441$$$443$$$O	resisting$$$444$$$453$$$O	cerebral$$$454$$$462$$$O	ischemia,$$$463$$$472$$$O	cerebral$$$473$$$481$$$O	anoxia$$$482$$$488$$$O	and$$$489$$$492$$$O	cerebral$$$493$$$501$$$O	thrombosis,$$$502$$$513$$$O	and$$$514$$$517$$$O	improving$$$518$$$527$$$O	memory,$$$528$$$535$$$O	and$$$536$$$539$$$O	has$$$540$$$543$$$O	low$$$544$$$547$$$O	dosage,$$$548$$$555$$$O	high$$$556$$$560$$$O	security$$$561$$$569$$$O	and$$$570$$$573$$$O	broad$$$574$$$579$$$O	application$$$580$$$591$$$O	prospects.$$$592$$$602$$$O
WO2012062210A1
Compound$$$0$$$8$$$O	for$$$9$$$12$$$O	increasing$$$13$$$23$$$O	kinase$$$24$$$30$$$O	active$$$31$$$37$$$O	and$$$38$$$41$$$O	application$$$42$$$53$$$O	thereof$$$54$$$61$$$O
The$$$0$$$3$$$O	compound$$$4$$$12$$$O	of$$$13$$$15$$$O	formula$$$16$$$23$$$O	(I),$$$24$$$28$$$O	pharmaceutically$$$29$$$45$$$O	acceptable$$$46$$$56$$$O	salts$$$57$$$62$$$O	thereof,$$$63$$$71$$$O	solvates$$$72$$$80$$$O	thereof,$$$81$$$89$$$O	chelates$$$90$$$98$$$O	thereof,$$$99$$$107$$$O	non-covalent$$$108$$$120$$$O	complex$$$121$$$128$$$O	thereof$$$129$$$136$$$O	or$$$137$$$139$$$O	produgs$$$140$$$147$$$O	of$$$148$$$150$$$O	compounds$$$151$$$160$$$O	mentioned$$$161$$$170$$$O	above$$$171$$$176$$$O	or$$$177$$$179$$$O	the$$$180$$$183$$$O	mixture$$$184$$$191$$$O	of$$$192$$$194$$$O	any$$$195$$$198$$$O	form$$$199$$$203$$$O	above$$$204$$$209$$$O	mentioned$$$210$$$219$$$O	are$$$220$$$223$$$O	provided.$$$224$$$233$$$O	The$$$234$$$237$$$O	use$$$238$$$241$$$O	of$$$242$$$244$$$O	the$$$245$$$248$$$O	compounds$$$249$$$258$$$O	in$$$259$$$261$$$O	manufacturing$$$262$$$275$$$O	a$$$276$$$277$$$O	medicament$$$278$$$288$$$O	for$$$289$$$292$$$O	the$$$293$$$296$$$O	treatment$$$297$$$306$$$O	and/or$$$307$$$313$$$O	prevention$$$314$$$324$$$O	of$$$325$$$327$$$O	diabetes,$$$328$$$337$$$O	obesity$$$338$$$345$$$O	and$$$346$$$349$$$O	related$$$350$$$357$$$O	disorders.$$$358$$$368$$$O
CN1729978A
Freeze$$$0$$$6$$$O	dry$$$7$$$10$$$O	powdered$$$11$$$19$$$O	injection$$$20$$$29$$$O	of$$$30$$$32$$$O	moxlfloxacin$$$33$$$45$$$I	or$$$46$$$48$$$O	its$$$49$$$52$$$O	salts$$$53$$$58$$$O	and$$$59$$$62$$$O	preparation$$$63$$$74$$$O	process$$$75$$$82$$$O	thereof$$$83$$$90$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	moxfloxacin$$$25$$$36$$$I	for$$$37$$$40$$$O	injection$$$41$$$50$$$O	or$$$51$$$53$$$O	freeze$$$54$$$60$$$O	dried$$$61$$$66$$$O	powder$$$67$$$73$$$O	injection$$$74$$$83$$$O	of$$$84$$$86$$$O	its$$$87$$$90$$$O	salts,$$$91$$$97$$$O	and$$$98$$$101$$$O	its$$$102$$$105$$$O	preparation$$$106$$$117$$$O	process,$$$118$$$126$$$O	which$$$127$$$132$$$O	is$$$133$$$135$$$O	prepared$$$136$$$144$$$O	from$$$145$$$149$$$O	moxifloxacin$$$150$$$162$$$I	or$$$163$$$165$$$O	its$$$166$$$169$$$O	salts,$$$170$$$176$$$O	excipient,$$$177$$$187$$$O	pH$$$188$$$190$$$O	modifier$$$191$$$199$$$O	and$$$200$$$203$$$O	water$$$204$$$209$$$O	for$$$210$$$213$$$O	injection$$$214$$$223$$$O	through$$$224$$$231$$$O	freeze$$$232$$$238$$$O	drying.$$$239$$$246$$$O
WO2013146539A1
Ppars$$$0$$$5$$$O	agonist$$$6$$$13$$$O	activity$$$14$$$22$$$O	enhancing$$$23$$$32$$$O	drug$$$33$$$37$$$O
According$$$0$$$9$$$O	to$$$10$$$12$$$O	the$$$13$$$16$$$O	present$$$17$$$24$$$O	invention,$$$25$$$35$$$O	PPARs$$$36$$$41$$$O	agonist$$$42$$$49$$$O	activity$$$50$$$58$$$O	is$$$59$$$61$$$O	enhanced$$$62$$$70$$$O	in$$$71$$$73$$$O	order$$$74$$$79$$$O	to$$$80$$$82$$$O	improve$$$83$$$90$$$O	metabolic$$$91$$$100$$$O	syndrome,$$$101$$$110$$$O	hyperlipidemia,$$$111$$$126$$$O	and$$$127$$$130$$$O	diabetes.$$$131$$$140$$$O	Provided$$$141$$$149$$$O	is$$$150$$$152$$$O	a$$$153$$$154$$$O	compound$$$155$$$163$$$O	having$$$164$$$170$$$O	a$$$171$$$172$$$O	lactone$$$173$$$180$$$I	structure$$$181$$$190$$$O	comprising$$$191$$$201$$$O	formula$$$202$$$209$$$O	(9).$$$210$$$214$$$O
CN103120664A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Eryngiolide$$$15$$$26$$$I	A$$$27$$$28$$$I	in$$$29$$$31$$$O	medicine$$$32$$$40$$$O	for$$$41$$$44$$$O	resisting$$$45$$$54$$$O	hypoxia$$$55$$$62$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	application$$$27$$$38$$$O	of$$$39$$$41$$$O	Eryngiolide$$$42$$$53$$$I	A$$$54$$$55$$$I	in$$$56$$$58$$$O	preparing$$$59$$$68$$$O	a$$$69$$$70$$$O	medicine$$$71$$$79$$$O	for$$$80$$$83$$$O	resisting$$$84$$$93$$$O	hypoxia.$$$94$$$102$$$O	The$$$103$$$106$$$O	hypoxia$$$107$$$114$$$O	resistant$$$115$$$124$$$O	action$$$125$$$131$$$O	of$$$132$$$134$$$O	the$$$135$$$138$$$O	Eryngiolide$$$139$$$150$$$I	A$$$151$$$152$$$I	is$$$153$$$155$$$O	integrally$$$156$$$166$$$O	observed$$$167$$$175$$$O	through$$$176$$$183$$$O	a$$$184$$$185$$$O	cellular$$$186$$$194$$$O	level$$$195$$$200$$$O	hypoxia$$$201$$$208$$$O	model,$$$209$$$215$$$O	and$$$216$$$219$$$O	a$$$220$$$221$$$O	result$$$222$$$228$$$O	indicates$$$229$$$238$$$O	that$$$239$$$243$$$O	the$$$244$$$247$$$O	Eryngiolide$$$248$$$259$$$I	A$$$260$$$261$$$I	can$$$262$$$265$$$O	outstandingly$$$266$$$279$$$O	enhance$$$280$$$287$$$O	and$$$288$$$291$$$O	prolong$$$292$$$299$$$O	the$$$300$$$303$$$O	survival$$$304$$$312$$$O	rate$$$313$$$317$$$O	and$$$318$$$321$$$O	survival$$$322$$$330$$$O	time$$$331$$$335$$$O	of$$$336$$$338$$$O	mice$$$339$$$343$$$O	with$$$344$$$348$$$O	suffocation$$$349$$$360$$$O	hypoxia$$$361$$$368$$$O	and$$$369$$$372$$$O	acute$$$373$$$378$$$O	decompression$$$379$$$392$$$O	hypoxia,$$$393$$$401$$$O	reduces$$$402$$$409$$$O	the$$$410$$$413$$$O	myocardial$$$414$$$424$$$O	damage$$$425$$$431$$$O	of$$$432$$$434$$$O	the$$$435$$$438$$$O	mice$$$439$$$443$$$O	with$$$444$$$448$$$O	medicine$$$449$$$457$$$O	specificity$$$458$$$469$$$O	hypoxia$$$470$$$477$$$O	and$$$478$$$481$$$O	has$$$482$$$485$$$O	outstanding$$$486$$$497$$$O	protective$$$498$$$508$$$O	effect$$$509$$$515$$$O	on$$$516$$$518$$$O	the$$$519$$$522$$$O	hypoxia$$$523$$$530$$$O	damage$$$531$$$537$$$O	of$$$538$$$540$$$O	the$$$541$$$544$$$O	myocardial$$$545$$$555$$$O	cells$$$556$$$561$$$O	and$$$562$$$565$$$O	neural$$$566$$$572$$$O	cells$$$573$$$578$$$O	of$$$579$$$581$$$O	neonatal$$$582$$$590$$$O	rats$$$591$$$595$$$O	cultured$$$596$$$604$$$O	in$$$605$$$607$$$O	vitro.$$$608$$$614$$$O	The$$$615$$$618$$$O	invention$$$619$$$628$$$O	discloses$$$629$$$638$$$O	the$$$639$$$642$$$O	application$$$643$$$654$$$O	of$$$655$$$657$$$O	the$$$658$$$661$$$O	Eryngiolide$$$662$$$673$$$I	A$$$674$$$675$$$I	in$$$676$$$678$$$O	preparation$$$679$$$690$$$O	of$$$691$$$693$$$O	the$$$694$$$697$$$O	medicine$$$698$$$706$$$O	for$$$707$$$710$$$O	resisting$$$711$$$720$$$O	the$$$721$$$724$$$O	hypoxia.$$$725$$$733$$$O
CN101234107A
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	containing$$$27$$$37$$$O	(3S,$$$38$$$42$$$I	2Ã­Â»S)-3-(2Ã­Â»-hydroxy-2Ã­Â»-cyclopentyl-2Ã­Â»-phenylethoxy)$$$43$$$105$$$I	quinuclidine$$$106$$$118$$$I	hydrochloride$$$119$$$132$$$I	and$$$133$$$136$$$O	uses$$$137$$$141$$$O	thereof$$$142$$$149$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	medical$$$24$$$31$$$O	composition$$$32$$$43$$$O	containing$$$44$$$54$$$O	active$$$55$$$61$$$O	component$$$62$$$71$$$O	of$$$72$$$74$$$O	(3S,$$$75$$$79$$$I	2'$$$80$$$82$$$I	S)-3-(2'-hydroxyl-2'-cyclopentyl-2'-phenylethoxy)$$$83$$$132$$$I	quinine$$$133$$$140$$$I	quinuclidine$$$141$$$153$$$I	chloride$$$154$$$162$$$I	and$$$163$$$166$$$O	application$$$167$$$178$$$O	of$$$179$$$181$$$O	the$$$182$$$185$$$O	medical$$$186$$$193$$$O	composition$$$194$$$205$$$O	in$$$206$$$208$$$O	preparing$$$209$$$218$$$O	drugs$$$219$$$224$$$O	for$$$225$$$228$$$O	treating$$$229$$$237$$$O	chronic$$$238$$$245$$$O	obstructive$$$246$$$257$$$O	lung$$$258$$$262$$$O	disease,$$$263$$$271$$$O	incontinentia$$$272$$$285$$$O	urinae,$$$286$$$293$$$O	diversified$$$294$$$305$$$O	shock$$$306$$$311$$$O	diseases$$$312$$$320$$$O	and$$$321$$$324$$$O	preparing$$$325$$$334$$$O	adjuvant$$$335$$$343$$$O	drugs$$$344$$$349$$$O	used$$$350$$$354$$$O	before$$$355$$$361$$$O	anaesthesia.$$$362$$$374$$$O	The$$$375$$$378$$$O	active$$$379$$$385$$$O	component$$$386$$$395$$$O	of$$$396$$$398$$$O	the$$$399$$$402$$$O	medical$$$403$$$410$$$O	composition$$$411$$$422$$$O	of$$$423$$$425$$$O	the$$$426$$$429$$$O	invention$$$430$$$439$$$O	has$$$440$$$443$$$O	high$$$444$$$448$$$O	optical$$$449$$$456$$$O	purity,$$$457$$$464$$$O	strong$$$465$$$471$$$O	stereoselectivity$$$472$$$489$$$O	in$$$490$$$492$$$O	vivo$$$493$$$497$$$O	process,$$$498$$$506$$$O	definite$$$507$$$515$$$O	curative$$$516$$$524$$$O	effects$$$525$$$532$$$O	and$$$533$$$536$$$O	high$$$537$$$541$$$O	pertinency$$$542$$$552$$$O	to$$$553$$$555$$$O	the$$$556$$$559$$$O	disease,$$$560$$$568$$$O	thus$$$569$$$573$$$O	effectively$$$574$$$585$$$O	avoiding$$$586$$$594$$$O	generation$$$595$$$605$$$O	of$$$606$$$608$$$O	toxic$$$609$$$614$$$O	and$$$615$$$618$$$O	side$$$619$$$623$$$O	effects.$$$624$$$632$$$O
CN101766606A
Medical$$$0$$$7$$$O	composition$$$8$$$19$$$O	containing$$$20$$$30$$$O	amoxicillin$$$31$$$42$$$I	and$$$43$$$46$$$O	dicloxacillin$$$47$$$60$$$I	sodium$$$61$$$67$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medical$$$26$$$33$$$O	composition$$$34$$$45$$$O	containing$$$46$$$56$$$O	amoxicillin$$$57$$$68$$$I	and$$$69$$$72$$$O	dicloxacillin$$$73$$$86$$$I	sodium,$$$87$$$94$$$I	wherein,$$$95$$$103$$$O	the$$$104$$$107$$$O	amoxicillin$$$108$$$119$$$I	and$$$120$$$123$$$O	the$$$124$$$127$$$O	dicloxacillin$$$128$$$141$$$I	sodium$$$142$$$148$$$I	in$$$149$$$151$$$O	the$$$152$$$155$$$O	medical$$$156$$$163$$$O	composition$$$164$$$175$$$O	are$$$176$$$179$$$O	dispersed$$$180$$$189$$$O	on$$$190$$$192$$$O	respective$$$193$$$203$$$O	pharmaceutically$$$204$$$220$$$O	acceptable$$$221$$$231$$$O	carrier.$$$232$$$240$$$O	The$$$241$$$244$$$O	composition$$$245$$$256$$$O	has$$$257$$$260$$$O	good$$$261$$$265$$$O	stability$$$266$$$275$$$O	and$$$276$$$279$$$O	broad$$$280$$$285$$$O	spectrum$$$286$$$294$$$O	antibacterial$$$295$$$308$$$O	function.$$$309$$$318$$$O
US20110183960
Thiophene-2-carboxamide$$$0$$$23$$$I	derivatives,$$$24$$$36$$$O	preparation$$$37$$$48$$$O	thereof$$$49$$$56$$$O	and$$$57$$$60$$$O	therapeutic$$$61$$$72$$$O	use$$$73$$$76$$$O	thereof$$$77$$$84$$$O
The$$$0$$$3$$$O	subject$$$4$$$11$$$O	matter$$$12$$$18$$$O	of$$$19$$$21$$$O	the$$$22$$$25$$$O	invention$$$26$$$35$$$O	is$$$36$$$38$$$O	compounds$$$39$$$48$$$O	corresponding$$$49$$$62$$$O	to$$$63$$$65$$$O	formula$$$66$$$73$$$O	(I),$$$74$$$78$$$O	in$$$79$$$81$$$O	which:$$$82$$$88$$$O	R1$$$89$$$91$$$O	and$$$92$$$95$$$O	R2,$$$96$$$99$$$O	together$$$100$$$108$$$O	with$$$109$$$113$$$O	the$$$114$$$117$$$O	nitrogen$$$118$$$126$$$I	atom$$$127$$$131$$$O	to$$$132$$$134$$$O	which$$$135$$$140$$$O	they$$$141$$$145$$$O	are$$$146$$$149$$$O	attached,$$$150$$$159$$$O	constitute$$$160$$$170$$$O	a$$$171$$$172$$$O	saturated$$$173$$$182$$$O	heterocyclic$$$183$$$195$$$I	radical$$$196$$$203$$$I	containing$$$204$$$214$$$O	from$$$215$$$219$$$O	4$$$220$$$221$$$O	to$$$222$$$224$$$O	7$$$225$$$226$$$O	atoms,$$$227$$$233$$$O	which$$$234$$$239$$$O	is$$$240$$$242$$$O	preferably$$$243$$$253$$$O	substituted;$$$254$$$266$$$O	one$$$267$$$270$$$O	of$$$271$$$273$$$O	the$$$274$$$277$$$O	two$$$278$$$281$$$O	substituents$$$282$$$294$$$O	R3$$$295$$$297$$$O	and$$$298$$$301$$$O	R6$$$302$$$304$$$O	is$$$305$$$307$$$O	a$$$308$$$309$$$O	group$$$310$$$315$$$O	Y-A-R9;$$$316$$$323$$$O	Y$$$324$$$325$$$O	is$$$326$$$328$$$O	an$$$329$$$331$$$O	oxygen$$$332$$$338$$$I	atom$$$339$$$343$$$O	or$$$344$$$346$$$O	an$$$347$$$349$$$O	âS(O)nâ²â,$$$350$$$365$$$I	or$$$366$$$368$$$I	âOSO2$$$369$$$376$$$O	group;$$$377$$$383$$$O	A$$$384$$$385$$$O	is$$$386$$$388$$$O	an$$$389$$$391$$$O	unsubstituted$$$392$$$405$$$I	(C1-C4)$$$406$$$413$$$I	alkylene$$$414$$$422$$$I	group;$$$423$$$429$$$O	R9$$$430$$$432$$$I	is$$$433$$$435$$$I	an$$$436$$$438$$$I	âOR19,$$$439$$$447$$$I	âCH3,$$$448$$$455$$$I	âNR19R20,$$$456$$$467$$$I	âCONR19R20,$$$468$$$481$$$I	âNR15COR19,$$$482$$$495$$$I	âS(O)nR21,$$$496$$$508$$$I	or$$$509$$$511$$$O	âNR13SO2R21$$$512$$$525$$$I	group;$$$526$$$532$$$I	âR10$$$533$$$539$$$O	is$$$540$$$542$$$I	a$$$543$$$544$$$I	hydrogen$$$545$$$553$$$I	atom$$$554$$$558$$$O	or$$$559$$$561$$$O	a$$$562$$$563$$$O	(C1-C4)$$$564$$$571$$$O	alkyl$$$572$$$577$$$O	group.$$$578$$$584$$$O	The$$$585$$$588$$$O	present$$$589$$$596$$$O	invention$$$597$$$606$$$O	also$$$607$$$611$$$O	relates$$$612$$$619$$$O	to$$$620$$$622$$$O	the$$$623$$$626$$$O	methods$$$627$$$634$$$O	of$$$635$$$637$$$O	preparation$$$638$$$649$$$O	and$$$650$$$653$$$O	the$$$654$$$657$$$O	therapeutic$$$658$$$669$$$O	uses$$$670$$$674$$$O	of$$$675$$$677$$$O	the$$$678$$$681$$$O	compounds$$$682$$$691$$$O	of$$$692$$$694$$$O	formula$$$695$$$702$$$O	(I).$$$703$$$707$$$O
WO2014022923A1
Antibacterial$$$0$$$13$$$O	inhibitors$$$14$$$24$$$O
Anti-bacterial$$$0$$$14$$$O	compounds$$$15$$$24$$$O	have$$$25$$$29$$$O	been$$$30$$$34$$$O	identified$$$35$$$45$$$O	having$$$46$$$52$$$O	the$$$53$$$56$$$O	general$$$57$$$64$$$O	structures$$$65$$$75$$$O	defined$$$76$$$83$$$O	by$$$84$$$86$$$O	Formula$$$87$$$94$$$O	(I),$$$95$$$99$$$O	Formula$$$100$$$107$$$O	(II),$$$108$$$113$$$O	and$$$114$$$117$$$O	Formula$$$118$$$125$$$O	(III).$$$126$$$132$$$O
CN102071461B
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	titanium$$$21$$$29$$$I	dioxide$$$30$$$37$$$I	nanometer$$$38$$$47$$$O	tubes$$$48$$$53$$$O	and$$$54$$$57$$$O	titanium$$$58$$$66$$$I	dioxide$$$67$$$74$$$I	nanometer$$$75$$$84$$$O	tube$$$85$$$89$$$O	preparation$$$90$$$101$$$O	for$$$102$$$105$$$O	loading$$$106$$$113$$$O	enrofloxacin$$$114$$$126$$$I	animal$$$127$$$133$$$O	remedy$$$134$$$140$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	method$$$26$$$32$$$O	for$$$33$$$36$$$O	preparing$$$37$$$46$$$O	titanium$$$47$$$55$$$I	dioxide$$$56$$$63$$$I	nanometer$$$64$$$73$$$O	tubes$$$74$$$79$$$O	and$$$80$$$83$$$O	a$$$84$$$85$$$O	titanium$$$86$$$94$$$I	dioxide$$$95$$$102$$$I	nanometer$$$103$$$112$$$O	tube$$$113$$$117$$$O	preparation$$$118$$$129$$$O	for$$$130$$$133$$$O	loading$$$134$$$141$$$O	enrofloxacin$$$142$$$154$$$I	animal$$$155$$$161$$$O	remedy.$$$162$$$169$$$O	The$$$170$$$173$$$O	titanium$$$174$$$182$$$I	dioxide$$$183$$$190$$$I	nanometer$$$191$$$200$$$O	tubes$$$201$$$206$$$O	are$$$207$$$210$$$O	prepared$$$211$$$219$$$O	through$$$220$$$227$$$O	a$$$228$$$229$$$O	hydro-thermal$$$230$$$243$$$O	synthesis$$$244$$$253$$$O	technology,$$$254$$$265$$$O	and$$$266$$$269$$$O	the$$$270$$$273$$$O	titanium$$$274$$$282$$$I	dioxide$$$283$$$290$$$I	nanometer$$$291$$$300$$$O	tube$$$301$$$305$$$O	preparation$$$306$$$317$$$O	for$$$318$$$321$$$O	loading$$$322$$$329$$$O	the$$$330$$$333$$$O	enrofloxacin$$$334$$$346$$$I	animal$$$347$$$353$$$O	remedy$$$354$$$360$$$O	comprises$$$361$$$370$$$O	1$$$371$$$372$$$O	to$$$373$$$375$$$O	5$$$376$$$377$$$O	weight$$$378$$$384$$$O	parts$$$385$$$390$$$O	of$$$391$$$393$$$O	enrofloxacin$$$394$$$406$$$I	powder,$$$407$$$414$$$O	10$$$415$$$417$$$O	to$$$418$$$420$$$O	30$$$421$$$423$$$O	weight$$$424$$$430$$$O	parts$$$431$$$436$$$O	of$$$437$$$439$$$O	de-ionized$$$440$$$450$$$O	water$$$451$$$456$$$O	and$$$457$$$460$$$O	1$$$461$$$462$$$O	to$$$463$$$465$$$O	5$$$466$$$467$$$O	weight$$$468$$$474$$$O	parts$$$475$$$480$$$O	of$$$481$$$483$$$O	titanium$$$484$$$492$$$I	dioxide$$$493$$$500$$$I	nanometer$$$501$$$510$$$O	tubes.$$$511$$$517$$$O	Equipment$$$518$$$527$$$O	required$$$528$$$536$$$O	by$$$537$$$539$$$O	the$$$540$$$543$$$O	preparation$$$544$$$555$$$O	and$$$556$$$559$$$O	the$$$560$$$563$$$O	technical$$$564$$$573$$$O	flow$$$574$$$578$$$O	process$$$579$$$586$$$O	are$$$587$$$590$$$O	simple,$$$591$$$598$$$O	the$$$599$$$602$$$O	medicine$$$603$$$611$$$O	loading$$$612$$$619$$$O	rate$$$620$$$624$$$O	is$$$625$$$627$$$O	higher,$$$628$$$635$$$O	in$$$636$$$638$$$O	addition,$$$639$$$648$$$O	the$$$649$$$652$$$O	medicine$$$653$$$661$$$O	release$$$662$$$669$$$O	speed$$$670$$$675$$$O	can$$$676$$$679$$$O	be$$$680$$$682$$$O	controlled$$$683$$$693$$$O	through$$$694$$$701$$$O	technical$$$702$$$711$$$O	conditions,$$$712$$$723$$$O	the$$$724$$$727$$$O	stability$$$728$$$737$$$O	of$$$738$$$740$$$O	the$$$741$$$744$$$O	medicine$$$745$$$753$$$O	of$$$754$$$756$$$O	the$$$757$$$760$$$O	animal$$$761$$$767$$$O	remedy$$$768$$$774$$$O	can$$$775$$$778$$$O	be$$$779$$$781$$$O	enhanced$$$782$$$790$$$O	by$$$791$$$793$$$O	the$$$794$$$797$$$O	preparation,$$$798$$$810$$$O	the$$$811$$$814$$$O	toxic$$$815$$$820$$$O	or$$$821$$$823$$$O	side$$$824$$$828$$$O	effect$$$829$$$835$$$O	of$$$836$$$838$$$O	the$$$839$$$842$$$O	medicine$$$843$$$851$$$O	can$$$852$$$855$$$O	be$$$856$$$858$$$O	reduced,$$$859$$$867$$$O	the$$$868$$$871$$$O	acting$$$872$$$878$$$O	time$$$879$$$883$$$O	of$$$884$$$886$$$O	the$$$887$$$890$$$O	medicine$$$891$$$899$$$O	is$$$900$$$902$$$O	prolonged,$$$903$$$913$$$O	and$$$914$$$917$$$O	the$$$918$$$921$$$O	curative$$$922$$$930$$$O	effect$$$931$$$937$$$O	of$$$938$$$940$$$O	the$$$941$$$944$$$O	medicine$$$945$$$953$$$O	is$$$954$$$956$$$O	improved.$$$957$$$966$$$O
CN102872126A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Houttuynoid$$$15$$$26$$$I	E$$$27$$$28$$$I	in$$$29$$$31$$$O	medicament$$$32$$$42$$$O	for$$$43$$$46$$$O	preventing$$$47$$$57$$$O	or$$$58$$$60$$$O	treating$$$61$$$69$$$O	pancreatic$$$70$$$80$$$O	fibrosis$$$81$$$89$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	Houttuynoid$$$39$$$50$$$I	E$$$51$$$52$$$I	in$$$53$$$55$$$O	preparing$$$56$$$65$$$O	a$$$66$$$67$$$O	medicament$$$68$$$78$$$O	for$$$79$$$82$$$O	preventing$$$83$$$93$$$O	or$$$94$$$96$$$O	treating$$$97$$$105$$$O	pancreatic$$$106$$$116$$$O	fibrosis.$$$117$$$126$$$O	The$$$127$$$130$$$O	use$$$131$$$134$$$O	of$$$135$$$137$$$O	Houttuynoid$$$138$$$149$$$I	E$$$150$$$151$$$I	in$$$152$$$154$$$O	preparing$$$155$$$164$$$O	the$$$165$$$168$$$O	anti-pancreatic$$$169$$$184$$$O	fibrosis$$$185$$$193$$$O	medicament$$$194$$$204$$$O	involved$$$205$$$213$$$O	in$$$214$$$216$$$O	the$$$217$$$220$$$O	invention$$$221$$$230$$$O	is$$$231$$$233$$$O	disclosed$$$234$$$243$$$O	for$$$244$$$247$$$O	the$$$248$$$251$$$O	first$$$252$$$257$$$O	time;$$$258$$$263$$$O	as$$$264$$$266$$$O	the$$$267$$$270$$$O	framework$$$271$$$280$$$O	type$$$281$$$285$$$O	of$$$286$$$288$$$O	Houttuynoid$$$289$$$300$$$I	E$$$301$$$302$$$I	is$$$303$$$305$$$O	a$$$306$$$307$$$O	brand$$$308$$$313$$$O	new$$$314$$$317$$$O	framework$$$318$$$327$$$O	type$$$328$$$332$$$O	and$$$333$$$336$$$O	Houttuynoid$$$337$$$348$$$I	E$$$349$$$350$$$I	has$$$351$$$354$$$O	an$$$355$$$357$$$O	unexpectedly$$$358$$$370$$$O	high$$$371$$$375$$$O	inhibition$$$376$$$386$$$O	activity$$$387$$$395$$$O	for$$$396$$$399$$$O	the$$$400$$$403$$$O	pancreatic$$$404$$$414$$$O	fibrosis$$$415$$$423$$$O	without$$$424$$$431$$$O	possibility$$$432$$$443$$$O	of$$$444$$$446$$$O	giving$$$447$$$453$$$O	any$$$454$$$457$$$O	implication$$$458$$$469$$$O	by$$$470$$$472$$$O	other$$$473$$$478$$$O	compounds,$$$479$$$489$$$O	Houttuynoid$$$490$$$501$$$I	E$$$502$$$503$$$I	has$$$504$$$507$$$O	outstanding$$$508$$$519$$$O	substantive$$$520$$$531$$$O	features;$$$532$$$541$$$O	and$$$542$$$545$$$O	simultaneously,$$$546$$$561$$$O	the$$$562$$$565$$$O	application$$$566$$$577$$$O	of$$$578$$$580$$$O	Houttuynoid$$$581$$$592$$$I	E$$$593$$$594$$$I	for$$$595$$$598$$$O	preventing$$$599$$$609$$$O	the$$$610$$$613$$$O	pancreatic$$$614$$$624$$$O	fibrosis$$$625$$$633$$$O	apparently$$$634$$$644$$$O	has$$$645$$$648$$$O	obvious$$$649$$$656$$$O	progress.$$$657$$$666$$$O
CN101961378A
Formula$$$0$$$7$$$O	of$$$8$$$10$$$O	health-care$$$11$$$22$$$O	product$$$23$$$30$$$O	for$$$31$$$34$$$O	resisting$$$35$$$44$$$O	oxidation$$$45$$$54$$$O	and$$$55$$$58$$$O	enhancing$$$59$$$68$$$O	immunity$$$69$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	soft$$$26$$$30$$$O	capsule$$$31$$$38$$$O	health-care$$$39$$$50$$$O	product$$$51$$$58$$$O	for$$$59$$$62$$$O	resisting$$$63$$$72$$$O	oxidation$$$73$$$82$$$O	and$$$83$$$86$$$O	enhancing$$$87$$$96$$$O	immunity.$$$97$$$106$$$O	The$$$107$$$110$$$O	product$$$111$$$118$$$O	is$$$119$$$121$$$O	researched$$$122$$$132$$$O	and$$$133$$$136$$$O	prepared$$$137$$$145$$$O	for$$$146$$$149$$$O	aged$$$150$$$154$$$O	and$$$155$$$158$$$O	elderly$$$159$$$166$$$O	people,$$$167$$$174$$$O	people$$$175$$$181$$$O	of$$$182$$$184$$$O	low$$$185$$$188$$$O	immunity$$$189$$$197$$$O	and$$$198$$$201$$$O	radiation$$$202$$$211$$$O	damage$$$212$$$218$$$O	suffers.$$$219$$$227$$$O	Seabuckthorn$$$228$$$240$$$O	seed$$$241$$$245$$$O	proanthocyanidin$$$246$$$262$$$I	extract,$$$263$$$271$$$O	seabuckthorn$$$272$$$284$$$O	seed$$$285$$$289$$$O	oil$$$290$$$293$$$O	or$$$294$$$296$$$O	seabuckthorn$$$297$$$309$$$O	berry$$$310$$$315$$$O	oil$$$316$$$319$$$O	and$$$320$$$323$$$O	perilla$$$324$$$331$$$O	herb$$$332$$$336$$$O	oil$$$337$$$340$$$O	into$$$341$$$345$$$O	first$$$346$$$351$$$O	formula$$$352$$$359$$$O	and$$$360$$$363$$$O	second$$$364$$$370$$$O	formula,$$$371$$$379$$$O	and$$$380$$$383$$$O	soft$$$384$$$388$$$O	capsules$$$389$$$397$$$O	are$$$398$$$401$$$O	prepared$$$402$$$410$$$O	according$$$411$$$420$$$O	to$$$421$$$423$$$O	the$$$424$$$427$$$O	first$$$428$$$433$$$O	formula$$$434$$$441$$$O	and$$$442$$$445$$$O	second$$$446$$$452$$$O	formula;$$$453$$$461$$$O	and$$$462$$$465$$$O	the$$$466$$$469$$$O	product$$$470$$$477$$$O	has$$$478$$$481$$$O	an$$$482$$$484$$$O	obvious$$$485$$$492$$$O	function$$$493$$$501$$$O	of$$$502$$$504$$$O	resisting$$$505$$$514$$$O	oxidation$$$515$$$524$$$O	and$$$525$$$528$$$O	enhancing$$$529$$$538$$$O	immunity.$$$539$$$548$$$O	The$$$549$$$552$$$O	product$$$553$$$560$$$O	is$$$561$$$563$$$O	used$$$564$$$568$$$O	for$$$569$$$572$$$O	the$$$573$$$576$$$O	aged$$$577$$$581$$$O	and$$$582$$$585$$$O	elderly$$$586$$$593$$$O	people,$$$594$$$601$$$O	the$$$602$$$605$$$O	people$$$606$$$612$$$O	of$$$613$$$615$$$O	low$$$616$$$619$$$O	immunity$$$620$$$628$$$O	and$$$629$$$632$$$O	the$$$633$$$636$$$O	radiation$$$637$$$646$$$O	damage$$$647$$$653$$$O	suffers$$$654$$$661$$$O	for$$$662$$$665$$$O	replenishing$$$666$$$678$$$O	anti-oxidation$$$679$$$693$$$O	nutriment$$$694$$$703$$$O	extracted$$$704$$$713$$$O	from$$$714$$$718$$$O	a$$$719$$$720$$$O	medicinal$$$721$$$730$$$O	and$$$731$$$734$$$O	edible$$$735$$$741$$$O	variety,$$$742$$$750$$$O	so$$$751$$$753$$$O	that$$$754$$$758$$$O	the$$$759$$$762$$$O	anti-oxidation$$$763$$$777$$$O	function$$$778$$$786$$$O	is$$$787$$$789$$$O	improved$$$790$$$798$$$O	and$$$799$$$802$$$O	the$$$803$$$806$$$O	immunity$$$807$$$815$$$O	is$$$816$$$818$$$O	enhanced,$$$819$$$828$$$O	and$$$829$$$832$$$O	various$$$833$$$840$$$O	diseases$$$841$$$849$$$O	are$$$850$$$853$$$O	prevented$$$854$$$863$$$O	from$$$864$$$868$$$O	occurring$$$869$$$878$$$O	and$$$879$$$882$$$O	worsening.$$$883$$$893$$$O	As$$$894$$$896$$$O	proved$$$897$$$903$$$O	by$$$904$$$906$$$O	animal$$$907$$$913$$$O	tests$$$914$$$919$$$O	and$$$920$$$923$$$O	human$$$924$$$929$$$O	test-meals,$$$930$$$941$$$O	the$$$942$$$945$$$O	seabuckthorn$$$946$$$958$$$O	seed$$$959$$$963$$$O	proanthocyanidin$$$964$$$980$$$I	soft$$$981$$$985$$$O	capsules$$$986$$$994$$$O	prepared$$$995$$$1003$$$O	in$$$1004$$$1006$$$O	the$$$1007$$$1010$$$O	invention$$$1011$$$1020$$$O	have$$$1021$$$1025$$$O	the$$$1026$$$1029$$$O	obvious$$$1030$$$1037$$$O	health-care$$$1038$$$1049$$$O	function$$$1050$$$1058$$$O	of$$$1059$$$1061$$$O	resisting$$$1062$$$1071$$$O	oxidation$$$1072$$$1081$$$O	and$$$1082$$$1085$$$O	enhancing$$$1086$$$1095$$$O	immunity.$$$1096$$$1105$$$O
CN102048706A
Darifenacin$$$0$$$11$$$I	hydrobromide$$$12$$$24$$$I	sustained-release$$$25$$$42$$$O	tablet$$$43$$$49$$$O	and$$$50$$$53$$$O	preparation$$$54$$$65$$$O	method$$$66$$$72$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	new$$$38$$$41$$$O	medicament$$$42$$$52$$$O	technologies,$$$53$$$66$$$O	and$$$67$$$70$$$O	in$$$71$$$73$$$O	particular$$$74$$$84$$$O	relates$$$85$$$92$$$O	to$$$93$$$95$$$O	a$$$96$$$97$$$O	darifenacin$$$98$$$109$$$I	hydrobromide$$$110$$$122$$$I	sustained-release$$$123$$$140$$$O	tablet$$$141$$$147$$$O	and$$$148$$$151$$$O	a$$$152$$$153$$$O	preparation$$$154$$$165$$$O	method.$$$166$$$173$$$O	The$$$174$$$177$$$O	darifenacin$$$178$$$189$$$I	hydrobromide$$$190$$$202$$$I	sustained-release$$$203$$$220$$$O	tablet$$$221$$$227$$$O	adopts$$$228$$$234$$$O	carbomer$$$235$$$243$$$O	as$$$244$$$246$$$O	a$$$247$$$248$$$O	new$$$249$$$252$$$O	retardant,$$$253$$$263$$$O	and$$$264$$$267$$$O	the$$$268$$$271$$$O	dosage$$$272$$$278$$$O	of$$$279$$$281$$$O	the$$$282$$$285$$$O	carbomer$$$286$$$294$$$O	is$$$295$$$297$$$O	1-5%$$$298$$$302$$$O	by$$$303$$$305$$$O	weight$$$306$$$312$$$O	of$$$313$$$315$$$O	the$$$316$$$319$$$O	preparation$$$320$$$331$$$O	and$$$332$$$335$$$O	can$$$336$$$339$$$O	reach$$$340$$$345$$$O	considerable$$$346$$$358$$$O	vitro$$$359$$$364$$$O	release$$$365$$$372$$$O	and$$$373$$$376$$$O	bioavailability$$$377$$$392$$$O	compared$$$393$$$401$$$O	with$$$402$$$406$$$O	the$$$407$$$410$$$O	dosage$$$411$$$417$$$O	of$$$418$$$420$$$O	the$$$421$$$424$$$O	retardant$$$425$$$434$$$O	in$$$435$$$437$$$O	the$$$438$$$441$$$O	prior$$$442$$$447$$$O	art,$$$448$$$452$$$O	which$$$453$$$458$$$O	is$$$459$$$461$$$O	more$$$462$$$466$$$O	than$$$467$$$471$$$O	half$$$472$$$476$$$O	of$$$477$$$479$$$O	the$$$480$$$483$$$O	dosage$$$484$$$490$$$O	of$$$491$$$493$$$O	a$$$494$$$495$$$O	prescription.$$$496$$$509$$$O	The$$$510$$$513$$$O	dosage$$$514$$$520$$$O	of$$$521$$$523$$$O	the$$$524$$$527$$$O	retardant$$$528$$$537$$$O	in$$$538$$$540$$$O	the$$$541$$$544$$$O	new$$$545$$$548$$$O	method$$$549$$$555$$$O	is$$$556$$$558$$$O	greatly$$$559$$$566$$$O	reduced$$$567$$$574$$$O	so$$$575$$$577$$$O	that$$$578$$$582$$$O	the$$$583$$$586$$$O	consumption$$$587$$$598$$$O	of$$$599$$$601$$$O	materials$$$602$$$611$$$O	can$$$612$$$615$$$O	be$$$616$$$618$$$O	greatly$$$619$$$626$$$O	reduced,$$$627$$$635$$$O	the$$$636$$$639$$$O	process$$$640$$$647$$$O	is$$$648$$$650$$$O	simpler,$$$651$$$659$$$O	the$$$660$$$663$$$O	controllability$$$664$$$679$$$O	is$$$680$$$682$$$O	better,$$$683$$$690$$$O	the$$$691$$$694$$$O	efficiency$$$695$$$705$$$O	is$$$706$$$708$$$O	improved,$$$709$$$718$$$O	and$$$719$$$722$$$O	the$$$723$$$726$$$O	production$$$727$$$737$$$O	cost$$$738$$$742$$$O	is$$$743$$$745$$$O	greatly$$$746$$$753$$$O	reduced.$$$754$$$762$$$O
US20090270371
Quinoline$$$0$$$9$$$I	derivatives$$$10$$$21$$$O	useful$$$22$$$28$$$O	in$$$29$$$31$$$O	the$$$32$$$35$$$O	treatment$$$36$$$45$$$O	of$$$46$$$48$$$O	mglur5$$$49$$$55$$$O	receptor-mediated$$$56$$$73$$$O	disorders$$$74$$$83$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I):$$$21$$$25$$$O	and/or$$$26$$$32$$$O	enantiomers$$$33$$$44$$$O	and/or$$$45$$$51$$$O	racemates$$$52$$$61$$$O	and/or$$$62$$$68$$$O	diastereomers$$$69$$$82$$$O	and/or$$$83$$$89$$$O	pharmaceutically$$$90$$$106$$$O	acceptable$$$107$$$117$$$O	salts$$$118$$$123$$$O	thereof$$$124$$$131$$$O	formed$$$132$$$138$$$O	with$$$139$$$143$$$O	acids$$$144$$$149$$$O	or$$$150$$$152$$$O	bases,$$$153$$$159$$$O	to$$$160$$$162$$$O	the$$$163$$$166$$$O	process$$$167$$$174$$$O	for$$$175$$$178$$$O	their$$$179$$$184$$$O	preparation,$$$185$$$197$$$O	to$$$198$$$200$$$O	the$$$201$$$204$$$O	intermediates$$$205$$$218$$$O	of$$$219$$$221$$$O	the$$$222$$$225$$$O	preparation$$$226$$$237$$$O	process,$$$238$$$246$$$O	to$$$247$$$249$$$O	the$$$250$$$253$$$O	pharmaceutical$$$254$$$268$$$O	formulations$$$269$$$281$$$O	containing$$$282$$$292$$$O	these$$$293$$$298$$$O	compounds$$$299$$$308$$$O	and$$$309$$$312$$$O	to$$$313$$$315$$$O	their$$$316$$$321$$$O	use$$$322$$$325$$$O	in$$$326$$$328$$$O	the$$$329$$$332$$$O	prevention$$$333$$$343$$$O	and/or$$$344$$$350$$$O	treatment$$$351$$$360$$$O	of$$$361$$$363$$$O	mGluR5$$$364$$$370$$$O	receptor-mediated$$$371$$$388$$$O	disorders.$$$389$$$399$$$O
US20120157450
Anhydrate$$$0$$$9$$$O	Forms$$$10$$$15$$$O	Of$$$16$$$18$$$O	A$$$19$$$20$$$O	Pyridine$$$21$$$29$$$I	Derivative$$$30$$$40$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	compound$$$29$$$37$$$O	of$$$38$$$40$$$O	formula$$$41$$$48$$$O	(I)$$$49$$$52$$$O	in$$$53$$$55$$$O	a$$$56$$$57$$$O	crystalline$$$58$$$69$$$O	anhydrate$$$70$$$79$$$O	form,$$$80$$$85$$$O	pharmaceutical$$$123$$$137$$$O	formulations$$$138$$$150$$$O	containing$$$151$$$161$$$O	them,$$$162$$$167$$$O	their$$$168$$$173$$$O	use$$$174$$$177$$$O	in$$$178$$$180$$$O	therapy$$$181$$$188$$$O	and$$$189$$$192$$$O	processes$$$193$$$202$$$O	for$$$203$$$206$$$O	preparing$$$207$$$216$$$O	the$$$217$$$220$$$O	same.$$$221$$$226$$$O
US20080038247
Diagnostics$$$0$$$11$$$O	and$$$12$$$15$$$O	Therapeutics$$$16$$$28$$$O	for$$$29$$$32$$$O	Diseases$$$33$$$41$$$O	Associated$$$42$$$52$$$O	With$$$53$$$57$$$O	G-Protein-Coupled$$$58$$$75$$$O	Receptor$$$76$$$84$$$O	Gpr39$$$85$$$90$$$O	(Gpr39)$$$91$$$98$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	human$$$25$$$30$$$O	GPR39$$$31$$$36$$$O	which$$$37$$$42$$$O	is$$$43$$$45$$$O	associated$$$46$$$56$$$O	with$$$57$$$61$$$O	the$$$62$$$65$$$O	cardiovascular$$$66$$$80$$$O	disorders,$$$81$$$91$$$O	endocrine$$$92$$$101$$$O	system$$$102$$$108$$$O	and$$$109$$$112$$$O	hormone$$$113$$$120$$$O	disorders,$$$121$$$131$$$O	cancer$$$132$$$138$$$O	disorders,$$$139$$$149$$$O	metabolic$$$150$$$159$$$O	diseases,$$$160$$$169$$$O	gastrointestinal$$$170$$$186$$$O	and$$$187$$$190$$$O	liver$$$191$$$196$$$O	diseases,$$$197$$$206$$$O	hematological$$$207$$$220$$$O	disorders,$$$221$$$231$$$O	neurological$$$232$$$244$$$O	disorders$$$245$$$254$$$O	and$$$255$$$258$$$O	respiratory$$$259$$$270$$$O	diseases.$$$271$$$280$$$O	The$$$281$$$284$$$O	invention$$$285$$$294$$$O	also$$$295$$$299$$$O	provides$$$300$$$308$$$O	assays$$$309$$$315$$$O	for$$$316$$$319$$$O	the$$$320$$$323$$$O	identification$$$324$$$338$$$O	of$$$339$$$341$$$O	compounds$$$342$$$351$$$O	useful$$$352$$$358$$$O	in$$$359$$$361$$$O	the$$$362$$$365$$$O	treatment$$$366$$$375$$$O	or$$$376$$$378$$$O	prevention$$$379$$$389$$$O	of$$$390$$$392$$$O	cardiovascular$$$393$$$407$$$O	disorders,$$$408$$$418$$$O	endocrine$$$419$$$428$$$O	system$$$429$$$435$$$O	and$$$436$$$439$$$O	hormone$$$440$$$447$$$O	disorders,$$$448$$$458$$$O	cancer$$$459$$$465$$$O	disorders,$$$466$$$476$$$O	metabolic$$$477$$$486$$$O	diseases,$$$487$$$496$$$O	gastrointestinal$$$497$$$513$$$O	and$$$514$$$517$$$O	liver$$$518$$$523$$$O	diseases,$$$524$$$533$$$O	hematological$$$534$$$547$$$O	disorders,$$$548$$$558$$$O	neurological$$$559$$$571$$$O	disorders$$$572$$$581$$$O	and$$$582$$$585$$$O	respiratory$$$586$$$597$$$O	diseases.$$$598$$$607$$$O	The$$$608$$$611$$$O	invention$$$612$$$621$$$O	also$$$622$$$626$$$O	features$$$627$$$635$$$O	compounds$$$636$$$645$$$O	which$$$646$$$651$$$O	bind$$$652$$$656$$$O	to$$$657$$$659$$$O	and/or$$$660$$$666$$$O	activate$$$667$$$675$$$O	or$$$676$$$678$$$O	inhibit$$$679$$$686$$$O	the$$$687$$$690$$$O	activity$$$691$$$699$$$O	of$$$700$$$702$$$O	GPR39$$$703$$$708$$$O	as$$$709$$$711$$$O	well$$$712$$$716$$$O	as$$$717$$$719$$$O	pharmaceutical$$$720$$$734$$$O	compositions$$$735$$$747$$$O	comprising$$$748$$$758$$$O	such$$$759$$$763$$$O	compounds.$$$764$$$774$$$O
CN101249088A
Applications$$$0$$$12$$$O	of$$$13$$$15$$$O	compensating$$$16$$$28$$$O	bone$$$29$$$33$$$O	fat$$$34$$$37$$$O	flavanone$$$38$$$47$$$I	methyl$$$48$$$54$$$I	ether$$$55$$$60$$$I	for$$$61$$$64$$$O	preparing$$$65$$$74$$$O	antineoplastic,$$$75$$$90$$$O	osteoporosis$$$91$$$103$$$O	and$$$104$$$107$$$O	senile$$$108$$$114$$$O	dementia$$$115$$$123$$$O	medicamentÃ$$$124$$$136$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	bavachinin$$$36$$$46$$$I	in$$$47$$$49$$$O	preparing$$$50$$$59$$$O	drugs$$$60$$$65$$$O	against$$$66$$$73$$$O	tumors,$$$74$$$81$$$O	osteoporosis$$$82$$$94$$$O	and$$$95$$$98$$$O	senile$$$99$$$105$$$O	dementia,$$$106$$$115$$$O	which$$$116$$$121$$$O	belongs$$$122$$$129$$$O	to$$$130$$$132$$$O	the$$$133$$$136$$$O	field$$$137$$$142$$$O	of$$$143$$$145$$$O	natural$$$146$$$153$$$O	medicines.$$$154$$$164$$$O	Bavachinin$$$165$$$175$$$I	has$$$176$$$179$$$O	the$$$180$$$183$$$O	structural$$$184$$$194$$$O	formula$$$195$$$202$$$O	shown$$$203$$$208$$$O	as$$$209$$$211$$$O	the$$$212$$$215$$$O	figure$$$216$$$222$$$O	(I).$$$223$$$227$$$O	Experimental$$$228$$$240$$$O	studies$$$241$$$248$$$O	shows$$$249$$$254$$$O	that$$$255$$$259$$$O	the$$$260$$$263$$$O	compound$$$264$$$272$$$O	of$$$273$$$275$$$O	formula$$$276$$$283$$$O	(I),$$$284$$$288$$$O	in$$$289$$$291$$$O	low$$$292$$$295$$$O	concentration,$$$296$$$310$$$O	doesn't$$$311$$$318$$$O	change$$$319$$$325$$$O	the$$$326$$$329$$$O	expressions$$$330$$$341$$$O	of$$$342$$$344$$$O	ERalpha66,$$$345$$$355$$$O	ERalpha46$$$356$$$365$$$O	and$$$366$$$369$$$O	ERalpha36,$$$370$$$380$$$O	but$$$381$$$384$$$O	in$$$385$$$387$$$O	high$$$388$$$392$$$O	concentration,$$$393$$$407$$$O	inhibits$$$408$$$416$$$O	the$$$417$$$420$$$O	expressions$$$421$$$432$$$O	thereof.$$$433$$$441$$$O	Furthermore,$$$442$$$454$$$O	the$$$455$$$458$$$O	compound$$$459$$$467$$$O	(I)$$$468$$$471$$$O	can$$$472$$$475$$$O	kill$$$476$$$480$$$O	breast$$$481$$$487$$$O	cancer$$$488$$$494$$$O	cell$$$495$$$499$$$O	line$$$500$$$504$$$O	MCF7$$$505$$$509$$$O	that$$$510$$$514$$$O	expresses$$$515$$$524$$$O	ERalpha66,$$$525$$$535$$$O	ERalpha46$$$536$$$545$$$O	and$$$546$$$549$$$O	ERalpha36.$$$550$$$560$$$O	The$$$561$$$564$$$O	compound$$$565$$$573$$$O	(I)$$$574$$$577$$$O	can$$$578$$$581$$$O	also$$$582$$$586$$$O	be$$$587$$$589$$$O	used$$$590$$$594$$$O	as$$$595$$$597$$$O	regulator$$$598$$$607$$$O	of$$$608$$$610$$$O	estrogen$$$611$$$619$$$O	receptor$$$620$$$628$$$O	ERalpha36$$$629$$$638$$$O	to$$$639$$$641$$$O	treat$$$642$$$647$$$O	diseases$$$648$$$656$$$O	caused$$$657$$$663$$$O	by$$$664$$$666$$$O	abnormal$$$667$$$675$$$O	expression$$$676$$$686$$$O	of$$$687$$$689$$$O	estrogen$$$690$$$698$$$I	receptor$$$699$$$707$$$O	ERalpha36,$$$708$$$718$$$O	such$$$719$$$723$$$O	as$$$724$$$726$$$O	tumors,$$$727$$$734$$$O	osteoporosis,$$$735$$$748$$$O	asthma,$$$749$$$756$$$O	heart$$$757$$$762$$$O	diseases$$$763$$$771$$$O	and$$$772$$$775$$$O	senile$$$776$$$782$$$O	dementia.$$$783$$$792$$$O
CN101235030A
1-substituted-5-trifluoromethyl-2-(1H)pyridone$$$0$$$46$$$I	compound,$$$47$$$56$$$O	preparation$$$57$$$68$$$O	method$$$69$$$75$$$O	and$$$76$$$79$$$O	use$$$80$$$83$$$O	thereof$$$84$$$91$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	1-substituted-5-trifluoromethyl-2-(1H)$$$27$$$65$$$I	pyridine$$$66$$$74$$$I	compound,$$$75$$$84$$$O	a$$$85$$$86$$$O	relative$$$87$$$95$$$O	preparation$$$96$$$107$$$O	method$$$108$$$114$$$O	and$$$115$$$118$$$O	a$$$119$$$120$$$O	pharmaceutical$$$121$$$135$$$O	application$$$136$$$147$$$O	of$$$148$$$150$$$O	the$$$151$$$154$$$O	compound,$$$155$$$164$$$O	wherein$$$165$$$172$$$O	the$$$173$$$176$$$O	compound$$$177$$$185$$$O	is$$$186$$$188$$$O	represented$$$189$$$200$$$O	as$$$201$$$203$$$O	formula$$$204$$$211$$$O	(X),$$$212$$$216$$$O	with$$$217$$$221$$$O	anti-fibrosis$$$222$$$235$$$O	function.$$$236$$$245$$$O
CN102716098A
Cefditoren$$$0$$$10$$$I	pivoxil$$$11$$$18$$$I	liposome$$$19$$$27$$$O	solid$$$28$$$33$$$O	preparation$$$34$$$45$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	cefditoren$$$26$$$36$$$I	pivoxil$$$37$$$44$$$I	liposome$$$45$$$53$$$O	solid$$$54$$$59$$$O	preparation$$$60$$$71$$$O	and$$$72$$$75$$$O	a$$$76$$$77$$$O	method$$$78$$$84$$$O	for$$$85$$$88$$$O	preparing$$$89$$$98$$$O	the$$$99$$$102$$$O	same.$$$103$$$108$$$O	The$$$109$$$112$$$O	active$$$113$$$119$$$O	ingredient$$$120$$$130$$$O	namely$$$131$$$137$$$O	cefditoren$$$138$$$148$$$I	pivoxil$$$149$$$156$$$I	and$$$157$$$160$$$O	a$$$161$$$162$$$O	specific$$$163$$$171$$$O	combination$$$172$$$183$$$O	of$$$184$$$186$$$O	soybean$$$187$$$194$$$O	phosphatidylserine,$$$195$$$214$$$O	cholesterol,$$$215$$$227$$$I	and$$$228$$$231$$$O	polyoxyethylene$$$232$$$247$$$I	alkylamine$$$248$$$258$$$I	are$$$259$$$262$$$O	prepared$$$263$$$271$$$O	into$$$272$$$276$$$O	liposome,$$$277$$$286$$$O	so$$$287$$$289$$$O	the$$$290$$$293$$$O	stability,$$$294$$$304$$$O	dissolution$$$305$$$316$$$O	property$$$317$$$325$$$O	and$$$326$$$329$$$O	bioavailability$$$330$$$345$$$O	of$$$346$$$348$$$O	the$$$349$$$352$$$O	preparation$$$353$$$364$$$O	are$$$365$$$368$$$O	greatly$$$369$$$376$$$O	improved,$$$377$$$386$$$O	and$$$387$$$390$$$O	moreover,$$$391$$$400$$$O	the$$$401$$$404$$$O	preparation$$$405$$$416$$$O	has$$$417$$$420$$$O	a$$$421$$$422$$$O	stable$$$423$$$429$$$O	and$$$430$$$433$$$O	lasting$$$434$$$441$$$O	effect,$$$442$$$449$$$O	small$$$450$$$455$$$O	side$$$456$$$460$$$O	effects$$$461$$$468$$$O	and$$$469$$$472$$$O	obvious$$$473$$$480$$$O	efficacy.$$$481$$$490$$$O
CN1853714A
Wuren$$$0$$$5$$$O	alcohol$$$6$$$13$$$I	soft$$$14$$$18$$$O	capasule$$$19$$$27$$$O	and$$$28$$$31$$$O	preparation$$$32$$$43$$$O	thereof$$$44$$$51$$$O
A$$$0$$$1$$$O	five-kernel$$$2$$$13$$$O	extract$$$14$$$21$$$O	softgel$$$22$$$29$$$O	is$$$30$$$32$$$O	composed$$$33$$$41$$$O	of$$$42$$$44$$$O	a$$$45$$$46$$$O	liquid$$$47$$$53$$$O	medicine$$$54$$$62$$$O	as$$$63$$$65$$$O	filler$$$66$$$72$$$O	prepared$$$73$$$81$$$O	from$$$82$$$86$$$O	the$$$87$$$90$$$O	alcohol$$$91$$$98$$$I	extract$$$99$$$106$$$O	of$$$107$$$109$$$O	5$$$110$$$111$$$O	kernels,$$$112$$$120$$$O	plant$$$121$$$126$$$O	oil$$$127$$$130$$$O	and$$$131$$$134$$$O	suspending$$$135$$$145$$$O	aid$$$146$$$149$$$O	and$$$150$$$153$$$O	a$$$154$$$155$$$O	shell$$$156$$$161$$$O	prepared$$$162$$$170$$$O	from$$$171$$$175$$$O	gelatin,$$$176$$$184$$$O	glycerin$$$185$$$193$$$I	and$$$194$$$197$$$O	water.$$$198$$$204$$$O	Its$$$205$$$208$$$O	preparing$$$209$$$218$$$O	process$$$219$$$226$$$O	includes$$$227$$$235$$$O	such$$$236$$$240$$$O	steps$$$241$$$246$$$O	as$$$247$$$249$$$O	respective$$$250$$$260$$$O	pre-treating$$$261$$$273$$$O	of$$$274$$$276$$$O	raw$$$277$$$280$$$O	material,$$$281$$$290$$$O	mixing$$$291$$$297$$$O	and$$$298$$$301$$$O	die$$$302$$$305$$$O	pressing.$$$306$$$315$$$O
US20110311651
Cardenolides$$$0$$$12$$$I	for$$$13$$$16$$$O	the$$$17$$$20$$$O	treatment$$$21$$$30$$$O	of$$$31$$$33$$$O	ocular$$$34$$$40$$$O	cancer$$$41$$$47$$$O
The$$$0$$$3$$$O	instant$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	of$$$39$$$41$$$O	using$$$42$$$47$$$O	a$$$48$$$49$$$O	class$$$50$$$55$$$O	of$$$56$$$58$$$O	compounds$$$59$$$68$$$O	known$$$69$$$74$$$O	as$$$75$$$77$$$O	cardenolides$$$78$$$90$$$I	in$$$91$$$93$$$O	the$$$94$$$97$$$O	treatment$$$98$$$107$$$O	of$$$108$$$110$$$O	proliferative$$$111$$$124$$$O	diseases$$$125$$$133$$$O	such$$$134$$$138$$$O	as$$$139$$$141$$$O	cancer.$$$142$$$149$$$O	In$$$150$$$152$$$O	particular,$$$153$$$164$$$O	the$$$165$$$168$$$O	instant$$$169$$$176$$$O	invention$$$177$$$186$$$O	provides$$$187$$$195$$$O	methods$$$196$$$203$$$O	of$$$204$$$206$$$O	treating$$$207$$$215$$$O	ocular$$$216$$$222$$$O	cancer$$$223$$$229$$$O	{e.g.,$$$230$$$236$$$O	retinoblastoma)$$$237$$$252$$$O	using$$$253$$$258$$$O	intraarterial$$$259$$$272$$$O	infusion$$$273$$$281$$$O	to$$$282$$$284$$$O	administer$$$285$$$295$$$O	cardenolides$$$296$$$308$$$I	locally$$$309$$$316$$$O	to$$$317$$$319$$$O	the$$$320$$$323$$$O	eye$$$324$$$327$$$O	of$$$328$$$330$$$O	a$$$331$$$332$$$O	subject$$$333$$$340$$$O	with$$$341$$$345$$$O	an$$$346$$$348$$$O	ocular$$$349$$$355$$$O	cancer.$$$356$$$363$$$O
US20080119549
Phenyl$$$0$$$6$$$I	esters$$$7$$$13$$$I	of$$$14$$$16$$$I	alkylcarbamic$$$17$$$30$$$I	acids;$$$31$$$37$$$I	analgesics$$$38$$$48$$$O
Pharmacological$$$0$$$15$$$O	inhibition$$$16$$$26$$$O	of$$$27$$$29$$$O	fatty$$$30$$$35$$$I	acid$$$36$$$40$$$I	amide$$$41$$$46$$$O	hydrolase$$$47$$$56$$$O	(FAAH)$$$57$$$63$$$O	activity$$$64$$$72$$$O	leads$$$73$$$78$$$O	to$$$79$$$81$$$O	increased$$$82$$$91$$$O	levels$$$92$$$98$$$O	of$$$99$$$101$$$O	fatty$$$102$$$107$$$I	acid$$$108$$$112$$$I	amides.$$$113$$$120$$$I	Esters$$$121$$$127$$$I	of$$$128$$$130$$$I	alkylcarbamic$$$131$$$144$$$I	acids$$$145$$$150$$$I	are$$$151$$$154$$$O	disclosed$$$155$$$164$$$O	that$$$165$$$169$$$O	are$$$170$$$173$$$O	inhibitors$$$174$$$184$$$O	of$$$185$$$187$$$O	FAAH$$$188$$$192$$$O	activity.$$$193$$$202$$$O	Compounds$$$203$$$212$$$O	disclosed$$$213$$$222$$$O	herein$$$223$$$229$$$O	inhibit$$$230$$$237$$$O	FAAH$$$238$$$242$$$O	activity.$$$243$$$252$$$O	Described$$$253$$$262$$$O	herein$$$263$$$269$$$O	are$$$270$$$273$$$O	processes$$$274$$$283$$$O	for$$$284$$$287$$$O	the$$$288$$$291$$$O	preparation$$$292$$$303$$$O	of$$$304$$$306$$$O	esters$$$307$$$313$$$I	of$$$314$$$316$$$I	alkylcarbamic$$$317$$$330$$$I	acid$$$331$$$335$$$I	compounds,$$$336$$$346$$$O	compositions$$$347$$$359$$$O	that$$$360$$$364$$$O	include$$$365$$$372$$$O	them,$$$373$$$378$$$O	and$$$379$$$382$$$O	methods$$$383$$$390$$$O	of$$$391$$$393$$$O	use$$$394$$$397$$$O	thereof.$$$398$$$406$$$O
CN101219113A
Compound$$$0$$$8$$$O	anticancer$$$9$$$19$$$O	sustained-release$$$20$$$37$$$O	injection$$$38$$$47$$$O	containing$$$48$$$58$$$O	bendamustine$$$59$$$71$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	compound$$$25$$$33$$$O	anticancer$$$34$$$44$$$O	drug$$$45$$$49$$$O	sustained$$$50$$$59$$$O	release$$$60$$$67$$$O	agent$$$68$$$73$$$O	containing$$$74$$$84$$$O	bendamustine,$$$85$$$98$$$I	which$$$99$$$104$$$O	is$$$105$$$107$$$O	a$$$108$$$109$$$O	sustained$$$110$$$119$$$O	release$$$120$$$127$$$O	injection$$$128$$$137$$$O	consisting$$$138$$$148$$$O	of$$$149$$$151$$$O	sustained$$$152$$$161$$$O	release$$$162$$$169$$$O	microspheres$$$170$$$182$$$O	and$$$183$$$186$$$O	solvent,$$$187$$$195$$$O	wherein,$$$196$$$204$$$O	the$$$205$$$208$$$O	sustained$$$209$$$218$$$O	release$$$219$$$226$$$O	microspheres$$$227$$$239$$$O	comprise$$$240$$$248$$$O	effective$$$249$$$258$$$O	anticancer$$$259$$$269$$$O	components$$$270$$$280$$$O	and$$$281$$$284$$$O	sustained-release$$$285$$$302$$$O	excipient,$$$303$$$313$$$O	and$$$314$$$317$$$O	the$$$318$$$321$$$O	solvent$$$322$$$329$$$O	is$$$330$$$332$$$O	a$$$333$$$334$$$O	special$$$335$$$342$$$O	solvent$$$343$$$350$$$O	containing$$$351$$$361$$$O	a$$$362$$$363$$$O	suspending$$$364$$$374$$$O	agent.$$$375$$$381$$$O	The$$$382$$$385$$$O	effective$$$386$$$395$$$O	anticancer$$$396$$$406$$$O	components$$$407$$$417$$$O	are$$$418$$$421$$$O	bendamustine$$$422$$$434$$$I	and$$$435$$$438$$$O	the$$$439$$$442$$$O	combination$$$443$$$454$$$O	of$$$455$$$457$$$O	bendamustine$$$458$$$470$$$I	synergist$$$471$$$480$$$O	chosen$$$481$$$487$$$O	from$$$488$$$492$$$O	alkylating$$$493$$$503$$$O	agent$$$504$$$509$$$O	and/or$$$510$$$516$$$O	hormone$$$517$$$524$$$O	anticarcinogen.$$$525$$$540$$$O	The$$$541$$$544$$$O	sustained-release$$$545$$$562$$$O	excipient$$$563$$$572$$$O	is$$$573$$$575$$$O	chosen$$$576$$$582$$$O	from$$$583$$$587$$$O	one$$$588$$$591$$$O	of$$$592$$$594$$$O	or$$$595$$$597$$$O	the$$$598$$$601$$$O	combination$$$602$$$613$$$O	of$$$614$$$616$$$O	polylactic$$$617$$$627$$$I	acid,$$$628$$$633$$$I	copolymer$$$634$$$643$$$O	thereof,$$$644$$$652$$$O	monomethyl$$$653$$$663$$$I	polyethylene$$$664$$$676$$$I	glycol,$$$677$$$684$$$I	polyethylene$$$685$$$697$$$I	glycol,$$$698$$$705$$$I	carboxyl$$$706$$$714$$$I	end$$$715$$$718$$$O	polylactide$$$719$$$730$$$O	copolymer,$$$731$$$741$$$O	dual$$$742$$$746$$$O	fatty$$$747$$$752$$$I	acid,$$$753$$$758$$$I	sebacie$$$759$$$766$$$I	acid$$$767$$$771$$$I	copolymer,$$$772$$$782$$$O	poly$$$783$$$787$$$I	(erucic$$$788$$$795$$$I	dimer-$$$796$$$802$$$I	sebacie$$$803$$$810$$$I	acid),$$$811$$$817$$$I	poly$$$818$$$822$$$I	(fumarate-$$$823$$$833$$$I	sebacie$$$834$$$841$$$I	acid),$$$842$$$848$$$I	Polifeprosan,$$$849$$$862$$$I	polylactide$$$863$$$874$$$O	copolymer$$$875$$$884$$$O	or$$$885$$$887$$$O	mixture$$$888$$$895$$$O	and$$$896$$$899$$$O	EVAc.$$$900$$$905$$$O	The$$$906$$$909$$$O	suspending$$$910$$$920$$$O	agent$$$921$$$926$$$O	is$$$927$$$929$$$O	chosen$$$930$$$936$$$O	from$$$937$$$941$$$O	carboxymethyl$$$942$$$955$$$O	cellulose,$$$956$$$966$$$O	etc.,$$$967$$$972$$$O	and$$$973$$$976$$$O	the$$$977$$$980$$$O	viscosity$$$981$$$990$$$O	of$$$991$$$993$$$O	the$$$994$$$997$$$O	suspending$$$998$$$1008$$$O	agent$$$1009$$$1014$$$O	is$$$1015$$$1017$$$O	80cp-3000cp$$$1018$$$1029$$$O	(in$$$1030$$$1033$$$O	the$$$1034$$$1037$$$O	temperature$$$1038$$$1049$$$O	of$$$1050$$$1052$$$O	20$$$1053$$$1055$$$O	DEG$$$1056$$$1059$$$O	C-30$$$1060$$$1064$$$O	DEG$$$1065$$$1068$$$O	C).$$$1069$$$1072$$$O	The$$$1073$$$1076$$$O	sustained$$$1077$$$1086$$$O	release$$$1087$$$1094$$$O	microspheres$$$1095$$$1107$$$O	can$$$1108$$$1111$$$O	also$$$1112$$$1116$$$O	be$$$1117$$$1119$$$O	produced$$$1120$$$1128$$$O	into$$$1129$$$1133$$$O	a$$$1134$$$1135$$$O	sustained-release$$$1136$$$1153$$$O	implant.$$$1154$$$1162$$$O	The$$$1163$$$1166$$$O	sustained-release$$$1167$$$1184$$$O	implant$$$1185$$$1192$$$O	and$$$1193$$$1196$$$O	the$$$1197$$$1200$$$O	sustained$$$1201$$$1210$$$O	release$$$1211$$$1218$$$O	injection$$$1219$$$1228$$$O	is$$$1229$$$1231$$$O	arranged$$$1232$$$1240$$$O	around$$$1241$$$1247$$$O	the$$$1248$$$1251$$$O	tumor$$$1252$$$1257$$$O	or$$$1258$$$1260$$$O	injected$$$1261$$$1269$$$O	in$$$1270$$$1272$$$O	the$$$1273$$$1276$$$O	tumor,$$$1277$$$1283$$$O	which$$$1284$$$1289$$$O	can$$$1290$$$1293$$$O	obviously$$$1294$$$1303$$$O	improve$$$1304$$$1311$$$O	the$$$1312$$$1315$$$O	curative$$$1316$$$1324$$$O	effect$$$1325$$$1331$$$O	if$$$1332$$$1334$$$O	being$$$1335$$$1340$$$O	applied$$$1341$$$1348$$$O	independently$$$1349$$$1362$$$O	or$$$1363$$$1365$$$O	combined$$$1366$$$1374$$$O	with$$$1375$$$1379$$$O	chemotherapeutics$$$1380$$$1397$$$O	and/or$$$1398$$$1404$$$O	radiotherapeutics$$$1405$$$1422$$$O	and$$$1423$$$1426$$$O	other$$$1427$$$1432$$$O	non-operative$$$1433$$$1446$$$O	treatment.$$$1447$$$1457$$$O
US20100298425
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	Tocotrienols$$$7$$$19$$$I	for$$$20$$$23$$$O	Elevating$$$24$$$33$$$O	IKBKAP$$$34$$$40$$$O	Gene$$$41$$$45$$$O	Expression$$$46$$$56$$$O	and$$$57$$$60$$$O	Treating$$$61$$$69$$$O	Familial$$$70$$$78$$$O	Dysautonomia$$$79$$$91$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	for$$$39$$$42$$$O	elevating$$$43$$$52$$$O	IKBKAP$$$53$$$59$$$O	gene$$$60$$$64$$$O	expression$$$65$$$75$$$O	and$$$76$$$79$$$O	the$$$80$$$83$$$O	level$$$84$$$89$$$O	of$$$90$$$92$$$O	functional$$$93$$$103$$$O	IKAP$$$104$$$108$$$O	protein$$$109$$$116$$$O	in$$$117$$$119$$$O	cells,$$$120$$$126$$$O	which$$$127$$$132$$$O	are$$$133$$$136$$$O	beneficial$$$137$$$147$$$O	to$$$148$$$150$$$O	human$$$151$$$156$$$O	individual,$$$157$$$168$$$O	such$$$169$$$173$$$O	as$$$174$$$176$$$O	an$$$177$$$179$$$O	individual$$$180$$$190$$$O	suffering$$$191$$$200$$$O	from$$$201$$$205$$$O	Familial$$$206$$$214$$$O	Dysautonomia,$$$215$$$228$$$O	by$$$229$$$231$$$O	providing$$$232$$$241$$$O	one$$$242$$$245$$$O	or$$$246$$$248$$$O	more$$$249$$$253$$$O	tocotrienols$$$254$$$266$$$I	alone$$$267$$$272$$$O	or$$$273$$$275$$$O	in$$$276$$$278$$$O	combination$$$279$$$290$$$O	with$$$291$$$295$$$O	one$$$296$$$299$$$O	or$$$300$$$302$$$O	more$$$303$$$307$$$O	tocopherols$$$308$$$319$$$I	to$$$320$$$322$$$O	the$$$323$$$326$$$O	cells.$$$327$$$333$$$O	The$$$334$$$337$$$O	present$$$338$$$345$$$O	invention$$$346$$$355$$$O	also$$$356$$$360$$$O	provides$$$361$$$369$$$O	methods$$$370$$$377$$$O	for$$$378$$$381$$$O	treating$$$382$$$390$$$O	Familial$$$391$$$399$$$O	Dysautonomia$$$400$$$412$$$O	by$$$413$$$415$$$O	providing$$$416$$$425$$$O	tocotrienols$$$426$$$438$$$I	alone$$$439$$$444$$$O	or$$$445$$$447$$$O	in$$$448$$$450$$$O	combination$$$451$$$462$$$O	with$$$463$$$467$$$O	one$$$468$$$471$$$O	or$$$472$$$474$$$O	more$$$475$$$479$$$O	tocopherols$$$480$$$491$$$I	to$$$492$$$494$$$O	a$$$495$$$496$$$O	patient$$$497$$$504$$$O	having$$$505$$$511$$$O	Familial$$$512$$$520$$$O	Dysautonomia.$$$521$$$534$$$O	Related$$$535$$$542$$$O	therapeutic$$$543$$$554$$$O	kits$$$555$$$559$$$O	are$$$560$$$563$$$O	also$$$564$$$568$$$O	provided.$$$569$$$578$$$O
US20100151007
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	selective$$$29$$$38$$$O	inhibition$$$39$$$49$$$O	of$$$50$$$52$$$O	vegf$$$53$$$57$$$O
Disclosed$$$0$$$9$$$O	herein$$$10$$$16$$$O	are$$$17$$$20$$$O	siRNA$$$21$$$26$$$O	compositions$$$27$$$39$$$O	and$$$40$$$43$$$O	methods$$$44$$$51$$$O	useful$$$52$$$58$$$O	for$$$59$$$62$$$O	inhibiting$$$63$$$73$$$O	expression$$$74$$$84$$$O	of$$$85$$$87$$$O	vascular$$$88$$$96$$$O	endothelial$$$97$$$108$$$O	growth$$$109$$$115$$$O	factor$$$116$$$122$$$O	(VEGF)$$$123$$$129$$$O	isoforms.$$$130$$$139$$$O	Such$$$140$$$144$$$O	compositions$$$145$$$157$$$O	and$$$158$$$161$$$O	methods$$$162$$$169$$$O	further$$$170$$$177$$$O	involve$$$178$$$185$$$O	siRNA$$$186$$$191$$$O	capable$$$192$$$199$$$O	of$$$200$$$202$$$O	selectively$$$203$$$214$$$O	targeting$$$215$$$224$$$O	angiogenic$$$225$$$235$$$O	VEGF$$$236$$$240$$$O	isoforms$$$241$$$249$$$O	while$$$250$$$255$$$O	selectively$$$256$$$267$$$O	sparing$$$268$$$275$$$O	anti-angiogenic$$$276$$$291$$$O	isoforms.$$$292$$$301$$$O	Diseases$$$302$$$310$$$O	which$$$311$$$316$$$O	involve$$$317$$$324$$$O	angiogenesis$$$325$$$337$$$O	stimulated$$$338$$$348$$$O	by$$$349$$$351$$$O	overexpression$$$352$$$366$$$O	of$$$367$$$369$$$O	VEGF,$$$370$$$375$$$O	such$$$376$$$380$$$O	as$$$381$$$383$$$O	diabetic$$$384$$$392$$$O	retinopathy,$$$393$$$405$$$O	age$$$406$$$409$$$O	related$$$410$$$417$$$O	macular$$$418$$$425$$$O	degeneration$$$426$$$438$$$O	and$$$439$$$442$$$O	many$$$443$$$447$$$O	types$$$448$$$453$$$O	of$$$454$$$456$$$O	cancer,$$$457$$$464$$$O	can$$$465$$$468$$$O	be$$$469$$$471$$$O	treated$$$472$$$479$$$O	by$$$480$$$482$$$O	administering$$$483$$$496$$$O	small$$$497$$$502$$$O	interfering$$$503$$$514$$$O	RNAs$$$515$$$519$$$O	as$$$520$$$522$$$O	disclosed.$$$523$$$533$$$O
US20070249701
Cyclic$$$0$$$6$$$O	amine$$$7$$$12$$$O	CCR5$$$13$$$17$$$O	receptor$$$18$$$26$$$O	antagonists$$$27$$$38$$$O
Remedies$$$0$$$8$$$O	or$$$9$$$11$$$O	prophylactics$$$12$$$25$$$O	for$$$26$$$29$$$O	diseases$$$30$$$38$$$O	in$$$39$$$41$$$O	association$$$42$$$53$$$O	with$$$54$$$58$$$O	CCR5$$$59$$$63$$$O	such$$$64$$$68$$$O	as$$$69$$$71$$$O	AIDS,$$$72$$$77$$$O	rheumatoid$$$78$$$88$$$O	arthritis$$$89$$$98$$$O	or$$$99$$$101$$$O	nephritis$$$102$$$111$$$O	comprising$$$112$$$122$$$O	a$$$123$$$124$$$O	cyclic$$$125$$$131$$$O	amine$$$132$$$137$$$O	compound$$$138$$$146$$$O	represented$$$147$$$158$$$O	by$$$159$$$161$$$O	the$$$162$$$165$$$O	following$$$166$$$175$$$O	formula$$$176$$$183$$$O	(I),$$$184$$$188$$$O	a$$$189$$$190$$$O	pharmaceutically$$$191$$$207$$$O	acceptable$$$208$$$218$$$O	acid$$$219$$$223$$$O	addition$$$224$$$232$$$O	salt$$$233$$$237$$$O	thereof$$$238$$$245$$$O	or$$$246$$$248$$$O	a$$$249$$$250$$$O	pharmaceutically$$$251$$$267$$$O	acceptable$$$268$$$278$$$O	C1-C6$$$279$$$284$$$I	alkyl$$$285$$$290$$$I	addition$$$291$$$299$$$O	salt$$$300$$$304$$$O	thereof,$$$305$$$313$$$O	as$$$314$$$316$$$O	an$$$317$$$319$$$O	active$$$320$$$326$$$O	ingredient.$$$327$$$338$$$O
CN101195799A
SOD$$$0$$$3$$$O	distillate$$$4$$$14$$$O	spirits$$$15$$$22$$$O	and$$$23$$$26$$$O	manufacturing$$$27$$$40$$$O	method$$$41$$$47$$$O	thereof$$$48$$$55$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	SOD$$$25$$$28$$$O	health$$$29$$$35$$$O	protecting$$$36$$$46$$$O	Huoliwang$$$47$$$56$$$O	wine,$$$57$$$62$$$O	which$$$63$$$68$$$O	is$$$69$$$71$$$O	suitable$$$72$$$80$$$O	for$$$81$$$84$$$O	men$$$85$$$88$$$O	and$$$89$$$92$$$O	women.$$$93$$$99$$$O	The$$$100$$$103$$$O	wine$$$104$$$108$$$O	is$$$109$$$111$$$O	prepared$$$112$$$120$$$O	from$$$121$$$125$$$O	the$$$126$$$129$$$O	main$$$130$$$134$$$O	composition$$$135$$$146$$$O	of$$$147$$$149$$$O	SOD$$$150$$$153$$$O	and$$$154$$$157$$$O	a$$$158$$$159$$$O	proper$$$160$$$166$$$O	amount$$$167$$$173$$$O	of$$$174$$$176$$$O	high$$$177$$$181$$$O	quality$$$182$$$189$$$O	five$$$190$$$194$$$O	grain$$$195$$$200$$$O	type$$$201$$$205$$$O	wine.$$$206$$$211$$$O	The$$$212$$$215$$$O	invention$$$216$$$225$$$O	is$$$226$$$228$$$O	characterized$$$229$$$242$$$O	in$$$243$$$245$$$O	that$$$246$$$250$$$O	active$$$251$$$257$$$O	ingredient$$$258$$$268$$$O	of$$$269$$$271$$$O	SOD,$$$272$$$276$$$O	ginseng$$$277$$$284$$$O	extracts,$$$285$$$294$$$O	worm$$$295$$$299$$$O	grass$$$300$$$305$$$O	extracts,$$$306$$$315$$$O	microelement,$$$316$$$329$$$O	mineral$$$330$$$337$$$O	matter$$$338$$$344$$$O	is$$$345$$$347$$$O	included$$$348$$$356$$$O	in$$$357$$$359$$$O	every$$$360$$$365$$$O	500$$$366$$$369$$$O	ml$$$370$$$372$$$O	high$$$373$$$377$$$O	quality$$$378$$$385$$$O	five$$$386$$$390$$$O	grain$$$391$$$396$$$O	type$$$397$$$401$$$O	wine.$$$402$$$407$$$O	The$$$408$$$411$$$O	invention$$$412$$$421$$$O	aims$$$422$$$426$$$O	at$$$427$$$429$$$O	providing$$$430$$$439$$$O	SOD$$$440$$$443$$$O	health$$$444$$$450$$$O	protecting$$$451$$$461$$$O	Huoliwang$$$462$$$471$$$O	wine$$$472$$$476$$$O	which$$$477$$$482$$$O	is$$$483$$$485$$$O	healthy,$$$486$$$494$$$O	does$$$495$$$499$$$O	not$$$500$$$503$$$O	include$$$504$$$511$$$O	the$$$512$$$515$$$O	objectionable$$$516$$$529$$$O	constituent$$$530$$$541$$$O	of$$$542$$$544$$$O	irritant,$$$545$$$554$$$O	stimulant,$$$555$$$565$$$O	hormone$$$566$$$573$$$O	and$$$574$$$577$$$O	other$$$578$$$583$$$O	objectionable$$$584$$$597$$$O	constituent$$$598$$$609$$$O	which$$$610$$$615$$$O	are$$$616$$$619$$$O	forbidden$$$620$$$629$$$O	by$$$630$$$632$$$O	the$$$633$$$636$$$O	International$$$637$$$650$$$O	Olympic$$$651$$$658$$$O	Committee,$$$659$$$669$$$O	and$$$670$$$673$$$O	has$$$674$$$677$$$O	the$$$678$$$681$$$O	functions$$$682$$$691$$$O	of$$$692$$$694$$$O	antiaging,$$$695$$$705$$$O	cell$$$706$$$710$$$O	healing$$$711$$$718$$$O	and$$$719$$$722$$$O	the$$$723$$$726$$$O	fully$$$727$$$732$$$O	adjusting$$$733$$$742$$$O	of$$$743$$$745$$$O	the$$$746$$$749$$$O	balance$$$750$$$757$$$O	of$$$758$$$760$$$O	the$$$761$$$764$$$O	human$$$765$$$770$$$O	body.$$$771$$$776$$$O
CN101947207A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	tylosin$$$22$$$29$$$I	tartrate$$$30$$$38$$$I	microspheres$$$39$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	of$$$45$$$47$$$O	tylosin$$$48$$$55$$$I	tartrate$$$56$$$64$$$I	microspheres.$$$65$$$78$$$O	The$$$79$$$82$$$O	method$$$83$$$89$$$O	uses$$$90$$$94$$$O	gelatin$$$95$$$102$$$O	as$$$103$$$105$$$O	the$$$106$$$109$$$O	carrier,$$$110$$$118$$$O	liquid$$$119$$$125$$$O	paraffin$$$126$$$134$$$O	and$$$135$$$138$$$O	Span-80$$$139$$$146$$$I	as$$$147$$$149$$$O	the$$$150$$$153$$$O	oil$$$154$$$157$$$O	phase,$$$158$$$164$$$O	and$$$165$$$168$$$O	glutaraldehyde$$$169$$$183$$$I	as$$$184$$$186$$$O	the$$$187$$$190$$$O	crosslinking$$$191$$$203$$$O	agent$$$204$$$209$$$O	to$$$210$$$212$$$O	prepare$$$213$$$220$$$O	tylosin$$$221$$$228$$$I	tartrate$$$229$$$237$$$I	microspheres.$$$238$$$251$$$O	The$$$252$$$255$$$O	tylosin$$$256$$$263$$$I	tartrate$$$264$$$272$$$I	microspheres$$$273$$$285$$$O	prepared$$$286$$$294$$$O	by$$$295$$$297$$$O	the$$$298$$$301$$$O	invention$$$302$$$311$$$O	use$$$312$$$315$$$O	gelatin$$$316$$$323$$$O	as$$$324$$$326$$$O	the$$$327$$$330$$$O	carrier$$$331$$$338$$$O	material,$$$339$$$348$$$O	have$$$349$$$353$$$O	no$$$354$$$356$$$O	adverse$$$357$$$364$$$O	reactions$$$365$$$374$$$O	and$$$375$$$378$$$O	no$$$379$$$381$$$O	immunogenicity,$$$382$$$397$$$O	have$$$398$$$402$$$O	biodegradability$$$403$$$419$$$O	and$$$420$$$423$$$O	wide$$$424$$$428$$$O	application$$$429$$$440$$$O	range$$$441$$$446$$$O	and$$$447$$$450$$$O	can$$$451$$$454$$$O	be$$$455$$$457$$$O	taken$$$458$$$463$$$O	by$$$464$$$466$$$O	mouth$$$467$$$472$$$O	or$$$473$$$475$$$O	through$$$476$$$483$$$O	injection.$$$484$$$494$$$O	liquid$$$495$$$501$$$O	paraffin$$$502$$$510$$$O	and$$$511$$$514$$$O	Span-80$$$515$$$522$$$I	are$$$523$$$526$$$O	used$$$527$$$531$$$O	as$$$532$$$534$$$O	the$$$535$$$538$$$O	oil$$$539$$$542$$$O	phase,$$$543$$$549$$$O	thus$$$550$$$554$$$O	increasing$$$555$$$565$$$O	the$$$566$$$569$$$O	drug-loading$$$570$$$582$$$O	rate$$$583$$$587$$$O	and$$$588$$$591$$$O	the$$$592$$$595$$$O	encapsulation$$$596$$$609$$$O	rate,$$$610$$$615$$$O	facilitating$$$616$$$628$$$O	the$$$629$$$632$$$O	crosslinking$$$633$$$645$$$O	and$$$646$$$649$$$O	curing$$$650$$$656$$$O	of$$$657$$$659$$$O	glutaraldehyde,$$$660$$$675$$$I	prolonging$$$676$$$686$$$O	the$$$687$$$690$$$O	elimination$$$691$$$702$$$O	half$$$703$$$707$$$O	life$$$708$$$712$$$O	of$$$713$$$715$$$O	the$$$716$$$719$$$O	microsphere$$$720$$$731$$$O	medicine$$$732$$$740$$$O	and$$$741$$$744$$$O	performing$$$745$$$755$$$O	drug$$$756$$$760$$$O	controlled$$$761$$$771$$$O	release$$$772$$$779$$$O	in$$$780$$$782$$$O	animals.$$$783$$$791$$$O	In$$$792$$$794$$$O	addition,$$$795$$$804$$$O	the$$$805$$$808$$$O	preparation$$$809$$$820$$$O	method$$$821$$$827$$$O	of$$$828$$$830$$$O	the$$$831$$$834$$$O	invention$$$835$$$844$$$O	has$$$845$$$848$$$O	simple$$$849$$$855$$$O	operation,$$$856$$$866$$$O	the$$$867$$$870$$$O	adopted$$$871$$$878$$$O	reagent$$$879$$$886$$$O	is$$$887$$$889$$$O	common,$$$890$$$897$$$O	the$$$898$$$901$$$O	preparation$$$902$$$913$$$O	cost$$$914$$$918$$$O	is$$$919$$$921$$$O	lower$$$922$$$927$$$O	and$$$928$$$931$$$O	the$$$932$$$935$$$O	method$$$936$$$942$$$O	is$$$943$$$945$$$O	easy$$$946$$$950$$$O	to$$$951$$$953$$$O	popularize$$$954$$$964$$$O	and$$$965$$$968$$$O	apply.$$$969$$$975$$$O
CN102366484A
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	for$$$27$$$30$$$O	treating$$$31$$$39$$$O	herpes$$$40$$$46$$$O	zoster$$$47$$$53$$$O	and$$$54$$$57$$$O	preparation$$$58$$$69$$$O	method$$$70$$$76$$$O	thereof$$$77$$$84$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	pharmaceutical$$$26$$$40$$$O	composition$$$41$$$52$$$O	for$$$53$$$56$$$O	treating$$$57$$$65$$$O	herpes$$$66$$$72$$$O	zoster$$$73$$$79$$$O	and$$$80$$$83$$$O	a$$$84$$$85$$$O	preparation$$$86$$$97$$$O	method$$$98$$$104$$$O	thereof.$$$105$$$113$$$O	The$$$114$$$117$$$O	pharmaceutical$$$118$$$132$$$O	composition$$$133$$$144$$$O	for$$$145$$$148$$$O	treating$$$149$$$157$$$O	herpes$$$158$$$164$$$O	zoster$$$165$$$171$$$O	comprises$$$172$$$181$$$O	an$$$182$$$184$$$O	oral$$$185$$$189$$$O	medicine$$$190$$$198$$$O	and$$$199$$$202$$$O	an$$$203$$$205$$$O	external$$$206$$$214$$$O	medicine,$$$215$$$224$$$O	wherein$$$225$$$232$$$O	the$$$233$$$236$$$O	oral$$$237$$$241$$$O	medicine$$$242$$$250$$$O	comprises$$$251$$$260$$$O	honeysuckle$$$261$$$272$$$O	flower,$$$273$$$280$$$O	taraxacum,$$$281$$$291$$$O	Plantain$$$292$$$300$$$O	seed,$$$301$$$306$$$O	fiveleaf$$$307$$$315$$$O	akebia,$$$316$$$323$$$O	radix$$$324$$$329$$$O	rehmanniae,$$$330$$$341$$$O	radix$$$342$$$347$$$O	bupleuri,$$$348$$$357$$$O	gentian,$$$358$$$366$$$O	isatis$$$367$$$373$$$O	leaf,$$$374$$$379$$$O	Eurya$$$380$$$385$$$O	chinensis$$$386$$$395$$$O	root$$$396$$$400$$$O	and$$$401$$$404$$$O	the$$$405$$$408$$$O	like;$$$409$$$414$$$O	and$$$415$$$418$$$O	the$$$419$$$422$$$O	external$$$423$$$431$$$O	medicine$$$432$$$440$$$O	comprises$$$441$$$450$$$O	Eurya$$$451$$$456$$$O	chinensis$$$457$$$466$$$O	root,$$$467$$$472$$$O	white$$$473$$$478$$$O	alum,$$$479$$$484$$$O	taraxacum,$$$485$$$495$$$O	centipede$$$496$$$505$$$O	and$$$506$$$509$$$O	the$$$510$$$513$$$O	like.$$$514$$$519$$$O	The$$$520$$$523$$$O	preparation$$$524$$$535$$$O	method$$$536$$$542$$$O	is$$$543$$$545$$$O	implemented$$$546$$$557$$$O	by$$$558$$$560$$$O	decocting$$$561$$$570$$$O	with$$$571$$$575$$$O	water$$$576$$$581$$$O	to$$$582$$$584$$$O	obtain$$$585$$$591$$$O	a$$$592$$$593$$$O	pastyointment.$$$594$$$608$$$O	The$$$609$$$612$$$O	pharmaceutical$$$613$$$627$$$O	composition$$$628$$$639$$$O	has$$$640$$$643$$$O	the$$$644$$$647$$$O	main$$$648$$$652$$$O	functions$$$653$$$662$$$O	of$$$663$$$665$$$O	clearing$$$666$$$674$$$O	away$$$675$$$679$$$O	the$$$680$$$683$$$O	liver-fire$$$684$$$694$$$O	and$$$695$$$698$$$O	removing$$$699$$$707$$$O	dampness$$$708$$$716$$$O	by$$$717$$$719$$$O	diuresis,$$$720$$$729$$$O	and$$$730$$$733$$$O	can$$$734$$$737$$$O	completely$$$738$$$748$$$O	cure$$$749$$$753$$$O	herpes$$$754$$$760$$$O	zoster$$$761$$$767$$$O	without$$$768$$$775$$$O	relapse;$$$776$$$784$$$O	the$$$785$$$788$$$O	healed$$$789$$$795$$$O	patient$$$796$$$803$$$O	does$$$804$$$808$$$O	not$$$809$$$812$$$O	have$$$813$$$817$$$O	the$$$818$$$821$$$O	pain$$$822$$$826$$$O	symptom;$$$827$$$835$$$O	and$$$836$$$839$$$O	thus,$$$840$$$845$$$O	the$$$846$$$849$$$O	pharmaceutical$$$850$$$864$$$O	composition$$$865$$$876$$$O	can$$$877$$$880$$$O	treat$$$881$$$886$$$O	both$$$887$$$891$$$O	the$$$892$$$895$$$O	symptoms$$$896$$$904$$$O	and$$$905$$$908$$$O	root$$$909$$$913$$$O	causes$$$914$$$920$$$O	of$$$921$$$923$$$O	herpes$$$924$$$930$$$O	zoster,$$$931$$$938$$$O	thereby$$$939$$$946$$$O	achieving$$$947$$$956$$$O	the$$$957$$$960$$$O	goal$$$961$$$965$$$O	of$$$966$$$968$$$O	complete$$$969$$$977$$$O	cure$$$978$$$982$$$O	and$$$983$$$986$$$O	obvious$$$987$$$994$$$O	effect.$$$995$$$1002$$$O	The$$$1003$$$1006$$$O	cure$$$1007$$$1011$$$O	rate$$$1012$$$1016$$$O	is$$$1017$$$1019$$$O	up$$$1020$$$1022$$$O	to$$$1023$$$1025$$$O	higher$$$1026$$$1032$$$O	than$$$1033$$$1037$$$O	90%.$$$1038$$$1042$$$O	The$$$1043$$$1046$$$O	preparation$$$1047$$$1058$$$O	method$$$1059$$$1065$$$O	is$$$1066$$$1068$$$O	simple$$$1069$$$1075$$$O	and$$$1076$$$1079$$$O	easy$$$1080$$$1084$$$O	to$$$1085$$$1087$$$O	implement.$$$1088$$$1098$$$O
CN1739655B
Quality$$$0$$$7$$$O	control$$$8$$$15$$$O	method$$$16$$$22$$$O	of$$$23$$$25$$$O	Qingkailing$$$26$$$37$$$O	injection$$$38$$$47$$$O	preparation$$$48$$$59$$$O
The$$$0$$$3$$$O	quality$$$4$$$11$$$O	control$$$12$$$19$$$O	method$$$20$$$26$$$O	for$$$27$$$30$$$O	Qingkailing$$$31$$$42$$$O	injection$$$43$$$52$$$O	preparation$$$53$$$64$$$O	includes$$$65$$$73$$$O	character$$$74$$$83$$$O	identification,$$$84$$$99$$$O	inspection$$$100$$$110$$$O	and$$$111$$$114$$$O	content$$$115$$$122$$$O	measurement.$$$123$$$135$$$O	The$$$136$$$139$$$O	character$$$140$$$149$$$O	identification$$$150$$$164$$$O	adopts$$$165$$$171$$$O	silicone$$$172$$$180$$$O	gel$$$181$$$184$$$O	G$$$185$$$186$$$O	thin-layer$$$187$$$197$$$O	plate$$$198$$$203$$$O	and$$$204$$$207$$$O	ethyl$$$208$$$213$$$I	acetate,$$$214$$$222$$$I	acetone,$$$223$$$231$$$I	formic$$$232$$$238$$$I	acid$$$239$$$243$$$I	and$$$244$$$247$$$O	water$$$248$$$253$$$O	as$$$254$$$256$$$O	developing$$$257$$$267$$$O	solvent.$$$268$$$276$$$O	The$$$277$$$280$$$O	jasminoidin$$$281$$$292$$$I	content$$$293$$$300$$$O	measurement$$$301$$$312$$$O	has$$$313$$$316$$$O	the$$$317$$$320$$$O	contrast$$$321$$$329$$$O	dissolved$$$330$$$339$$$O	in$$$340$$$342$$$O	methanol;$$$343$$$352$$$O	the$$$353$$$356$$$O	cholic$$$357$$$363$$$I	acid$$$364$$$368$$$I	and$$$369$$$372$$$O	hyodesoxycholic$$$373$$$388$$$I	acid$$$389$$$393$$$I	content$$$394$$$401$$$O	measurement$$$402$$$413$$$O	is$$$414$$$416$$$O	in$$$417$$$419$$$O	efficient$$$420$$$429$$$O	liquid$$$430$$$436$$$O	phase$$$437$$$442$$$O	chromatographic$$$443$$$458$$$O	process$$$459$$$466$$$O	with$$$467$$$471$$$O	evaporating$$$472$$$483$$$O	dispersion$$$484$$$494$$$O	detector$$$495$$$503$$$O	to$$$504$$$506$$$O	obtain$$$507$$$513$$$O	accurate$$$514$$$522$$$O	result;$$$523$$$530$$$O	and$$$531$$$534$$$O	the$$$535$$$538$$$O	nitrogen$$$539$$$547$$$I	content,$$$548$$$556$$$O	insoluble$$$557$$$566$$$O	particle,$$$567$$$576$$$O	etc.$$$577$$$581$$$O	are$$$582$$$585$$$O	also$$$586$$$590$$$O	detectedto$$$591$$$601$$$O	avoid$$$602$$$607$$$O	negative$$$608$$$616$$$O	reaction.$$$617$$$626$$$O	The$$$627$$$630$$$O	quality$$$631$$$638$$$O	control$$$639$$$646$$$O	method$$$647$$$653$$$O	for$$$654$$$657$$$O	Qingkailing$$$658$$$669$$$O	injection$$$670$$$679$$$O	preparation$$$680$$$691$$$O	can$$$692$$$695$$$O	ensure$$$696$$$702$$$O	the$$$703$$$706$$$O	curative$$$707$$$715$$$O	effect$$$716$$$722$$$O	of$$$723$$$725$$$O	the$$$726$$$729$$$O	medicine$$$730$$$738$$$O	preparation$$$739$$$750$$$O	and$$$751$$$754$$$O	reach$$$755$$$760$$$O	effective$$$761$$$770$$$O	control$$$771$$$778$$$O	of$$$779$$$781$$$O	the$$$782$$$785$$$O	medicine$$$786$$$794$$$O	preparation$$$795$$$806$$$O	quality.$$$807$$$815$$$O
US7205295
such$$$0$$$4$$$O	as$$$5$$$7$$$O	4-(4-tert-Butyl-benzyl)-6-(4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-4H-1,4-benzoxazin-3-one;$$$8$$$103$$$I	phosphoinositide-3-kinases$$$104$$$130$$$O	(PI3Ks);$$$131$$$139$$$O	for$$$140$$$143$$$O	treatment/prevention$$$144$$$164$$$O	of$$$165$$$167$$$O	inflammatory$$$168$$$180$$$O	diseases,$$$181$$$190$$$O	cardiovascular$$$191$$$205$$$O	diseases,$$$206$$$215$$$O	and$$$216$$$219$$$O	cancers$$$220$$$227$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	compounds$$$31$$$40$$$O	of$$$41$$$43$$$O	Formula$$$44$$$51$$$O	I$$$52$$$53$$$O	wherein$$$73$$$80$$$O	W,$$$81$$$83$$$O	Q,$$$84$$$86$$$O	E,$$$87$$$89$$$O	D,$$$90$$$92$$$O	R6,$$$93$$$96$$$O	R7,$$$97$$$100$$$O	R8,$$$101$$$104$$$O	Y,$$$105$$$107$$$O	K,$$$108$$$110$$$O	R9,$$$111$$$114$$$O	R10,$$$115$$$119$$$O	R12,$$$120$$$124$$$O	G,$$$125$$$127$$$O	and$$$128$$$131$$$O	the$$$132$$$135$$$O	double$$$136$$$142$$$O	bond$$$143$$$147$$$O	denoted$$$148$$$155$$$O	â*â$$$156$$$163$$$O	have$$$164$$$168$$$O	any$$$169$$$172$$$O	of$$$173$$$175$$$O	the$$$176$$$179$$$O	values$$$180$$$186$$$O	defined$$$187$$$194$$$O	therefore$$$195$$$204$$$O	in$$$205$$$207$$$O	the$$$208$$$211$$$O	specification,$$$212$$$226$$$O	and$$$227$$$230$$$O	pharmaceutically$$$231$$$247$$$O	acceptable$$$248$$$258$$$O	salts$$$259$$$264$$$O	thereof,$$$265$$$273$$$O	that$$$274$$$278$$$O	are$$$279$$$282$$$O	useful$$$283$$$289$$$O	as$$$290$$$292$$$O	agents$$$293$$$299$$$O	in$$$300$$$302$$$O	the$$$303$$$306$$$O	treatment$$$307$$$316$$$O	of$$$317$$$319$$$O	diseases$$$320$$$328$$$O	and$$$329$$$332$$$O	conditions,$$$333$$$344$$$O	including$$$345$$$354$$$O	inflammatory$$$355$$$367$$$O	diseases,$$$368$$$377$$$O	cardiovascular$$$378$$$392$$$O	diseases,$$$393$$$402$$$O	and$$$403$$$406$$$O	cancers.$$$407$$$415$$$O	Also$$$416$$$420$$$O	provided$$$421$$$429$$$O	are$$$430$$$433$$$O	pharmaceutical$$$434$$$448$$$O	compositions$$$449$$$461$$$O	comprising$$$462$$$472$$$O	one$$$473$$$476$$$O	or$$$477$$$479$$$O	more$$$480$$$484$$$O	compounds$$$485$$$494$$$O	of$$$495$$$497$$$O	Formula$$$498$$$505$$$O	I.$$$506$$$508$$$O
EP2222636A2
Selective$$$0$$$9$$$O	androgen$$$10$$$18$$$O	receptor$$$19$$$27$$$O	modulators$$$28$$$38$$$O	(sarms)$$$39$$$46$$$O	and$$$47$$$50$$$O	uses$$$51$$$55$$$O	thereof$$$56$$$63$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	compounds$$$20$$$29$$$O	of$$$30$$$32$$$O	formulae$$$33$$$41$$$O	I$$$42$$$43$$$O	to$$$44$$$46$$$O	II$$$47$$$49$$$O	that$$$50$$$54$$$O	bind$$$55$$$59$$$O	to$$$60$$$62$$$O	androgen$$$63$$$71$$$O	receptors$$$72$$$81$$$O	and/or$$$82$$$88$$$O	modulate$$$89$$$97$$$O	activity$$$98$$$106$$$O	of$$$107$$$109$$$O	androgen$$$110$$$118$$$O	receptors;$$$119$$$129$$$O	and$$$130$$$133$$$O	to$$$134$$$136$$$O	methods$$$137$$$144$$$O	for$$$145$$$148$$$O	making$$$149$$$155$$$O	and$$$156$$$159$$$O	using$$$160$$$165$$$O	such$$$166$$$170$$$O	compounds.$$$171$$$181$$$O	Also$$$182$$$186$$$O	provided$$$187$$$195$$$O	are$$$196$$$199$$$O	compositions$$$200$$$212$$$O	including$$$213$$$222$$$O	such$$$223$$$227$$$O	compounds$$$228$$$237$$$O	and$$$238$$$241$$$O	methods$$$242$$$249$$$O	for$$$250$$$253$$$O	making$$$254$$$260$$$O	and$$$261$$$264$$$O	using$$$265$$$270$$$O	such$$$271$$$275$$$O	compositions.$$$276$$$289$$$O
CN101062936A
Novel$$$0$$$5$$$O	betulic$$$6$$$13$$$I	acid$$$14$$$18$$$I	type$$$19$$$23$$$O	triterpenoid$$$24$$$36$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	betulic$$$26$$$33$$$I	acid$$$34$$$38$$$I	type$$$39$$$43$$$O	triterpenoid,$$$44$$$57$$$I	which$$$58$$$63$$$O	is$$$64$$$66$$$O	characterized$$$67$$$80$$$O	by$$$81$$$83$$$O	the$$$84$$$87$$$O	following:$$$88$$$98$$$O	making$$$99$$$105$$$O	the$$$106$$$109$$$O	chemical$$$110$$$118$$$O	structural$$$119$$$129$$$O	formula$$$130$$$137$$$O	as$$$138$$$140$$$O	picture;$$$141$$$149$$$O	possessing$$$150$$$160$$$O	strong$$$161$$$167$$$O	against$$$168$$$175$$$O	HIV$$$176$$$179$$$O	active$$$180$$$186$$$O	with$$$187$$$191$$$O	EC50$$$192$$$196$$$O	less$$$197$$$201$$$O	than$$$202$$$206$$$O	0.$$$207$$$209$$$O	064mug/ml,$$$210$$$220$$$O	CC50$$$221$$$225$$$O	as$$$226$$$228$$$O	98.$$$229$$$232$$$O	43$$$233$$$235$$$O	mug/ml$$$236$$$242$$$O	and$$$243$$$246$$$O	Ti$$$247$$$249$$$O	as$$$250$$$252$$$O	1538;$$$253$$$258$$$O	overcoming$$$259$$$269$$$O	the$$$270$$$273$$$O	problem$$$274$$$281$$$O	of$$$282$$$284$$$O	easy$$$285$$$289$$$O	to$$$290$$$292$$$O	generate$$$293$$$301$$$O	drug$$$302$$$306$$$O	tolerance.$$$307$$$317$$$O	This$$$318$$$322$$$O	invention$$$323$$$332$$$O	is$$$333$$$335$$$O	preparing$$$336$$$345$$$O	clinical$$$346$$$354$$$O	test,$$$355$$$360$$$O	which$$$361$$$366$$$O	will$$$367$$$371$$$O	possess$$$372$$$379$$$O	important$$$380$$$389$$$O	meaning$$$390$$$397$$$O	for$$$398$$$401$$$O	against$$$402$$$409$$$O	HIV$$$410$$$413$$$O	new$$$414$$$417$$$O	medicine$$$418$$$426$$$O	exploitation.$$$427$$$440$$$O
CN101434601A
2-furyl-1H-benzimidazole-4-acidamide$$$0$$$36$$$I	type$$$37$$$41$$$O	derivative$$$42$$$52$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	derivative$$$26$$$36$$$O	of$$$37$$$39$$$O	2-furyl-1H-benzimidazole-4-amide$$$40$$$72$$$I	with$$$73$$$77$$$O	the$$$78$$$81$$$O	chemical$$$82$$$90$$$O	structural$$$91$$$101$$$O	formula$$$102$$$109$$$O	shown$$$110$$$115$$$O	on$$$116$$$118$$$O	the$$$119$$$122$$$O	lower$$$123$$$128$$$O	right.$$$129$$$135$$$O	The$$$136$$$139$$$O	derivative$$$140$$$150$$$O	has$$$151$$$154$$$O	good$$$155$$$159$$$O	effect$$$160$$$166$$$O	on$$$167$$$169$$$O	resistance$$$170$$$180$$$O	to$$$181$$$183$$$O	coxsackie$$$184$$$193$$$O	B3$$$194$$$196$$$O	virus$$$197$$$202$$$O	and$$$203$$$206$$$O	can$$$207$$$210$$$O	be$$$211$$$213$$$O	prepared$$$214$$$222$$$O	into$$$223$$$227$$$O	new$$$228$$$231$$$O	anti-virus$$$232$$$242$$$O	medicaments.$$$243$$$255$$$O
US7943627
2,4-diaminopyrimidine$$$0$$$21$$$I	derivatives$$$22$$$33$$$O
There$$$0$$$5$$$O	are$$$6$$$9$$$O	provided$$$10$$$18$$$O	compounds$$$19$$$28$$$O	of$$$29$$$31$$$O	formula$$$32$$$39$$$O	I$$$40$$$41$$$O	wherein$$$61$$$68$$$O	X,$$$69$$$71$$$O	R1,$$$72$$$75$$$O	R2,$$$76$$$79$$$O	R3,$$$80$$$83$$$O	R4,$$$84$$$87$$$O	R5,$$$88$$$91$$$O	R6,$$$92$$$95$$$O	R7,$$$96$$$99$$$O	R8$$$100$$$102$$$O	and$$$103$$$106$$$O	R9$$$107$$$109$$$O	are$$$110$$$113$$$O	as$$$114$$$116$$$O	indicated$$$117$$$126$$$O	in$$$127$$$129$$$O	claim$$$130$$$135$$$O	1,$$$136$$$138$$$O	useful$$$139$$$145$$$O	in$$$146$$$148$$$O	disorders$$$149$$$158$$$O	where$$$159$$$164$$$O	ZAP-70$$$165$$$171$$$O	and/or$$$172$$$178$$$O	Syk$$$179$$$182$$$O	inhibition$$$183$$$193$$$O	plays$$$194$$$199$$$O	a$$$200$$$201$$$O	role$$$202$$$206$$$O	or$$$207$$$209$$$O	caused$$$210$$$216$$$O	by$$$217$$$219$$$O	a$$$220$$$221$$$O	malfunction$$$222$$$233$$$O	of$$$234$$$236$$$O	signal$$$237$$$243$$$O	cascades$$$244$$$252$$$O	connected$$$253$$$262$$$O	with$$$263$$$267$$$O	FAK.$$$268$$$272$$$O
US7951795
Constrained$$$0$$$11$$$O	spirocyclic$$$12$$$23$$$O	compounds$$$24$$$33$$$O	as$$$34$$$36$$$O	CGRP$$$37$$$41$$$O	receptor$$$42$$$50$$$O	antagonists$$$51$$$62$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	I:$$$21$$$23$$$O	(wherein$$$43$$$51$$$O	variables$$$52$$$61$$$O	A1,$$$62$$$65$$$O	A2,$$$66$$$69$$$O	A3,$$$70$$$73$$$O	G1,$$$74$$$77$$$O	G2,$$$78$$$81$$$O	G3,$$$82$$$85$$$O	J,$$$86$$$88$$$O	m,$$$89$$$91$$$O	n,$$$92$$$94$$$O	p,$$$95$$$97$$$O	R1,$$$98$$$101$$$O	R2,$$$102$$$105$$$O	R3,$$$106$$$109$$$O	R4$$$110$$$112$$$O	and$$$113$$$116$$$O	Y$$$117$$$118$$$O	are$$$119$$$122$$$O	as$$$123$$$125$$$O	described$$$126$$$135$$$O	herein)$$$136$$$143$$$O	which$$$144$$$149$$$O	are$$$150$$$153$$$O	antagonists$$$154$$$165$$$O	of$$$166$$$168$$$O	CGRP$$$169$$$173$$$O	receptors$$$174$$$183$$$O	and$$$184$$$187$$$O	which$$$188$$$193$$$O	are$$$194$$$197$$$O	useful$$$198$$$204$$$O	in$$$205$$$207$$$O	the$$$208$$$211$$$O	treatment$$$212$$$221$$$O	or$$$222$$$224$$$O	prevention$$$225$$$235$$$O	of$$$236$$$238$$$O	diseases$$$239$$$247$$$O	in$$$248$$$250$$$O	which$$$251$$$256$$$O	the$$$257$$$260$$$O	CGRP$$$261$$$265$$$O	is$$$266$$$268$$$O	involved,$$$269$$$278$$$O	such$$$279$$$283$$$O	as$$$284$$$286$$$O	migraine.$$$287$$$296$$$O	The$$$297$$$300$$$O	invention$$$301$$$310$$$O	is$$$311$$$313$$$O	also$$$314$$$318$$$O	directed$$$319$$$327$$$O	to$$$328$$$330$$$O	pharmaceutical$$$331$$$345$$$O	compositions$$$346$$$358$$$O	comprising$$$359$$$369$$$O	these$$$370$$$375$$$O	compounds$$$376$$$385$$$O	and$$$386$$$389$$$O	the$$$390$$$393$$$O	use$$$394$$$397$$$O	of$$$398$$$400$$$O	these$$$401$$$406$$$O	compounds$$$407$$$416$$$O	and$$$417$$$420$$$O	compositions$$$421$$$433$$$O	in$$$434$$$436$$$O	the$$$437$$$440$$$O	prevention$$$441$$$451$$$O	or$$$452$$$454$$$O	treatment$$$455$$$464$$$O	of$$$465$$$467$$$O	such$$$468$$$472$$$O	diseases$$$473$$$481$$$O	in$$$482$$$484$$$O	which$$$485$$$490$$$O	CGRP$$$491$$$495$$$O	is$$$496$$$498$$$O	involved.$$$499$$$508$$$O
CN102920237A
Antibacterial$$$0$$$13$$$O	health-care$$$14$$$25$$$O	pillow$$$26$$$32$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	antibacterial$$$27$$$40$$$O	health-care$$$41$$$52$$$O	pillow$$$53$$$59$$$O	which$$$60$$$65$$$O	is$$$66$$$68$$$O	characterized$$$69$$$82$$$O	by$$$83$$$85$$$O	comprising$$$86$$$96$$$O	a$$$97$$$98$$$O	core$$$99$$$103$$$O	layer,$$$104$$$110$$$O	a$$$111$$$112$$$O	health-care$$$113$$$124$$$O	cover$$$125$$$130$$$O	layer$$$131$$$136$$$O	and$$$137$$$140$$$O	a$$$141$$$142$$$O	health-care$$$143$$$154$$$O	material$$$155$$$163$$$O	layer$$$164$$$169$$$O	arranged$$$170$$$178$$$O	between$$$179$$$186$$$O	the$$$187$$$190$$$O	core$$$191$$$195$$$O	layer$$$196$$$201$$$O	and$$$202$$$205$$$O	the$$$206$$$209$$$O	health-care$$$210$$$221$$$O	cover$$$222$$$227$$$O	layer.$$$228$$$234$$$O	An$$$235$$$237$$$O	antibacterial$$$238$$$251$$$O	layer$$$252$$$257$$$O	is$$$258$$$260$$$O	further$$$261$$$268$$$O	arranged$$$269$$$277$$$O	between$$$278$$$285$$$O	the$$$286$$$289$$$O	health-care$$$290$$$301$$$O	material$$$302$$$310$$$O	layer$$$311$$$316$$$O	and$$$317$$$320$$$O	the$$$321$$$324$$$O	health-care$$$325$$$336$$$O	cover$$$337$$$342$$$O	layer,$$$343$$$349$$$O	the$$$350$$$353$$$O	core$$$354$$$358$$$O	layer$$$359$$$364$$$O	is$$$365$$$367$$$O	made$$$368$$$372$$$O	of$$$373$$$375$$$O	latex,$$$376$$$382$$$O	the$$$383$$$386$$$O	health-care$$$387$$$398$$$O	material$$$399$$$407$$$O	layer$$$408$$$413$$$O	is$$$414$$$416$$$O	formed$$$417$$$423$$$O	by$$$424$$$426$$$O	mixing$$$427$$$433$$$O	borneol,$$$434$$$442$$$I	asarum$$$443$$$449$$$O	and$$$450$$$453$$$O	musk,$$$454$$$459$$$O	and$$$460$$$463$$$O	the$$$464$$$467$$$O	antibacterial$$$468$$$481$$$O	layer$$$482$$$487$$$O	is$$$488$$$490$$$O	made$$$491$$$495$$$O	of$$$496$$$498$$$O	chitosan$$$499$$$507$$$O	fiber$$$508$$$513$$$O	non-woven$$$514$$$523$$$O	fabrics.$$$524$$$532$$$O	The$$$533$$$536$$$O	antibacterial$$$537$$$550$$$O	health-care$$$551$$$562$$$O	pillow$$$563$$$569$$$O	has$$$570$$$573$$$O	good$$$574$$$578$$$O	effects$$$579$$$586$$$O	on$$$587$$$589$$$O	heart-fire$$$590$$$600$$$O	clearing,$$$601$$$610$$$O	eyesight$$$611$$$619$$$O	improving,$$$620$$$630$$$O	fungi$$$631$$$636$$$O	prevention$$$637$$$647$$$O	and$$$648$$$651$$$O	mite$$$652$$$656$$$O	removal,$$$657$$$665$$$O	has$$$666$$$669$$$O	good$$$670$$$674$$$O	comfort,$$$675$$$683$$$O	and$$$684$$$687$$$O	has$$$688$$$691$$$O	good$$$692$$$696$$$O	market$$$697$$$703$$$O	prospect$$$704$$$712$$$O	in$$$713$$$715$$$O	the$$$716$$$719$$$O	field$$$720$$$725$$$O	of$$$726$$$728$$$O	high-end$$$729$$$737$$$O	pillows.$$$738$$$746$$$O
CN101199544A
Policresulen$$$0$$$12$$$O	foam$$$13$$$17$$$O	preparation$$$18$$$29$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	a$$$14$$$15$$$O	policresulen$$$16$$$28$$$O	foam$$$29$$$33$$$O	agent$$$34$$$39$$$O	and$$$40$$$43$$$O	a$$$44$$$45$$$O	preparation$$$46$$$57$$$O	method,$$$58$$$65$$$O	which$$$66$$$71$$$O	is$$$72$$$74$$$O	characterized$$$75$$$88$$$O	in$$$89$$$91$$$O	that$$$92$$$96$$$O	raw$$$97$$$100$$$O	material$$$101$$$109$$$O	and$$$110$$$113$$$O	excipient$$$114$$$123$$$O	such$$$124$$$128$$$O	as$$$129$$$131$$$O	policresulen,$$$132$$$145$$$O	etc.$$$146$$$150$$$O	are$$$151$$$154$$$O	filled$$$155$$$161$$$O	into$$$162$$$166$$$O	a$$$167$$$168$$$O	container;$$$169$$$179$$$O	a$$$180$$$181$$$O	foam$$$182$$$186$$$O	emulsion$$$187$$$195$$$O	pump$$$196$$$200$$$O	(or$$$201$$$204$$$O	called$$$205$$$211$$$O	foam$$$212$$$216$$$O	pump$$$217$$$221$$$O	or$$$222$$$224$$$O	manual$$$225$$$231$$$O	foam$$$232$$$236$$$O	generating$$$237$$$247$$$O	device)$$$248$$$255$$$O	is$$$256$$$258$$$O	screwed$$$259$$$266$$$O	on$$$267$$$269$$$O	the$$$270$$$273$$$O	container;$$$274$$$284$$$O	and$$$285$$$288$$$O	when$$$289$$$293$$$O	the$$$294$$$297$$$O	emulsion$$$298$$$306$$$O	pump$$$307$$$311$$$O	is$$$312$$$314$$$O	pressed$$$315$$$322$$$O	by$$$323$$$325$$$O	hand,$$$326$$$331$$$O	the$$$332$$$335$$$O	foams$$$336$$$341$$$O	are$$$342$$$345$$$O	produced.$$$346$$$355$$$O	The$$$356$$$359$$$O	preparation$$$360$$$371$$$O	method$$$372$$$378$$$O	is$$$379$$$381$$$O	as$$$382$$$384$$$O	following:$$$385$$$395$$$O	the$$$396$$$399$$$O	policresulen$$$400$$$412$$$O	is$$$413$$$415$$$O	added$$$416$$$421$$$O	into$$$422$$$426$$$O	water$$$427$$$432$$$O	to$$$433$$$435$$$O	be$$$436$$$438$$$O	dissolved,$$$439$$$449$$$O	and$$$450$$$453$$$O	then$$$454$$$458$$$O	polysorbate-80,$$$459$$$474$$$O	sodium$$$475$$$481$$$O	dodecyl$$$482$$$489$$$O	sulfate$$$490$$$497$$$O	and$$$498$$$501$$$O	glycerol$$$502$$$510$$$O	,$$$511$$$512$$$O	etc.$$$513$$$517$$$O	are$$$518$$$521$$$O	added$$$522$$$527$$$O	into$$$528$$$532$$$O	the$$$533$$$536$$$O	water;$$$537$$$543$$$O	the$$$544$$$547$$$O	mixture$$$548$$$555$$$O	is$$$556$$$558$$$O	well$$$559$$$563$$$O	mixed;$$$564$$$570$$$O	and$$$571$$$574$$$O	then$$$575$$$579$$$O	distilled$$$580$$$589$$$O	water$$$590$$$595$$$O	is$$$596$$$598$$$O	added$$$599$$$604$$$O	into$$$605$$$609$$$O	the$$$610$$$613$$$O	mixture$$$614$$$621$$$O	to$$$622$$$624$$$O	the$$$625$$$628$$$O	total$$$629$$$634$$$O	amount;$$$635$$$642$$$O	all$$$643$$$646$$$O	the$$$647$$$650$$$O	components$$$651$$$661$$$O	are$$$662$$$665$$$O	well$$$666$$$670$$$O	mixed;$$$671$$$677$$$O	the$$$678$$$681$$$O	pH$$$682$$$684$$$O	value$$$685$$$690$$$O	is$$$691$$$693$$$O	adjusted;$$$694$$$703$$$O	the$$$704$$$707$$$O	mixture$$$708$$$715$$$O	is$$$716$$$718$$$O	filled$$$719$$$725$$$O	into$$$726$$$730$$$O	the$$$731$$$734$$$O	container;$$$735$$$745$$$O	the$$$746$$$749$$$O	foam$$$750$$$754$$$O	emulsion$$$755$$$763$$$O	pump$$$764$$$768$$$O	(or$$$769$$$772$$$O	called$$$773$$$779$$$O	foam$$$780$$$784$$$O	pump$$$785$$$789$$$O	or$$$790$$$792$$$O	manual$$$793$$$799$$$O	foam$$$800$$$804$$$O	generating$$$805$$$815$$$O	device)$$$816$$$823$$$O	is$$$824$$$826$$$O	screwed$$$827$$$834$$$O	on$$$835$$$837$$$O	the$$$838$$$841$$$O	container;$$$842$$$852$$$O	and$$$853$$$856$$$O	when$$$857$$$861$$$O	the$$$862$$$865$$$O	emulsion$$$866$$$874$$$O	pump$$$875$$$879$$$O	is$$$880$$$882$$$O	pressed$$$883$$$890$$$O	by$$$891$$$893$$$O	hand,$$$894$$$899$$$O	the$$$900$$$903$$$O	foams$$$904$$$909$$$O	are$$$910$$$913$$$O	produced.$$$914$$$923$$$O	The$$$924$$$927$$$O	invention$$$928$$$937$$$O	adopts$$$938$$$944$$$O	drugs,$$$945$$$951$$$O	emulsifier$$$952$$$962$$$O	and$$$963$$$966$$$O	the$$$967$$$970$$$O	foam$$$971$$$975$$$O	emulsion$$$976$$$984$$$O	pump,$$$985$$$990$$$O	and$$$991$$$994$$$O	the$$$995$$$998$$$O	foams$$$999$$$1004$$$O	are$$$1005$$$1008$$$O	produced$$$1009$$$1017$$$O	when$$$1018$$$1022$$$O	the$$$1023$$$1026$$$O	emulsion$$$1027$$$1035$$$O	pump$$$1036$$$1040$$$O	is$$$1041$$$1043$$$O	pressed$$$1044$$$1051$$$O	by$$$1052$$$1054$$$O	hand,$$$1055$$$1060$$$O	so$$$1061$$$1063$$$O	the$$$1064$$$1067$$$O	cost$$$1068$$$1072$$$O	can$$$1073$$$1076$$$O	be$$$1077$$$1079$$$O	saved;$$$1080$$$1086$$$O	environmental$$$1087$$$1100$$$O	pollution$$$1101$$$1110$$$O	caused$$$1111$$$1117$$$O	by$$$1118$$$1120$$$O	propellent$$$1121$$$1131$$$O	can$$$1132$$$1135$$$O	be$$$1136$$$1138$$$O	eliminated;$$$1139$$$1150$$$O	and$$$1151$$$1154$$$O	at$$$1155$$$1157$$$O	the$$$1158$$$1161$$$O	same$$$1162$$$1166$$$O	time,$$$1167$$$1172$$$O	the$$$1173$$$1176$$$O	possibilities$$$1177$$$1190$$$O	of$$$1191$$$1193$$$O	explosiveness$$$1194$$$1207$$$O	of$$$1208$$$1210$$$O	the$$$1211$$$1214$$$O	pressure$$$1215$$$1223$$$O	container$$$1224$$$1233$$$O	are$$$1234$$$1237$$$O	reduced,$$$1238$$$1246$$$O	thereby$$$1247$$$1254$$$O	making$$$1255$$$1261$$$O	the$$$1262$$$1265$$$O	pressure$$$1266$$$1274$$$O	container$$$1275$$$1284$$$O	safer.$$$1285$$$1291$$$O	Therefore,$$$1292$$$1302$$$O	the$$$1303$$$1306$$$O	invention$$$1307$$$1316$$$O	is$$$1317$$$1319$$$O	a$$$1320$$$1321$$$O	novel$$$1322$$$1327$$$O	foam$$$1328$$$1332$$$O	agent$$$1333$$$1338$$$O	with$$$1339$$$1343$$$O	simple$$$1344$$$1350$$$O	preparation$$$1351$$$1362$$$O	method,$$$1363$$$1370$$$O	low$$$1371$$$1374$$$O	price,$$$1375$$$1381$$$O	safety$$$1382$$$1388$$$O	and$$$1389$$$1392$$$O	environmental$$$1393$$$1406$$$O	protection.$$$1407$$$1418$$$O	The$$$1419$$$1422$$$O	policresulen$$$1423$$$1435$$$O	foam$$$1436$$$1440$$$O	agent$$$1441$$$1446$$$O	can$$$1447$$$1450$$$O	make$$$1451$$$1455$$$O	the$$$1456$$$1459$$$O	drugs$$$1460$$$1465$$$O	be$$$1466$$$1468$$$O	distributed$$$1469$$$1480$$$O	evenly$$$1481$$$1487$$$O	inside$$$1488$$$1494$$$O	the$$$1495$$$1498$$$O	vaginal$$$1499$$$1506$$$O	canal$$$1507$$$1512$$$O	and$$$1513$$$1516$$$O	on$$$1517$$$1519$$$O	the$$$1520$$$1523$$$O	surface$$$1524$$$1531$$$O	of$$$1532$$$1534$$$O	skin$$$1535$$$1539$$$O	with$$$1540$$$1544$$$O	wide$$$1545$$$1549$$$O	coating$$$1550$$$1557$$$O	area,$$$1558$$$1563$$$O	and$$$1564$$$1567$$$O	can$$$1568$$$1571$$$O	infiltrate$$$1572$$$1582$$$O	into$$$1583$$$1587$$$O	the$$$1588$$$1591$$$O	mucosa$$$1592$$$1598$$$O	wrinkled$$$1599$$$1607$$$O	wall$$$1608$$$1612$$$O	of$$$1613$$$1615$$$O	the$$$1616$$$1619$$$O	vaginal$$$1620$$$1627$$$O	fast$$$1628$$$1632$$$O	and$$$1633$$$1636$$$O	effectively$$$1637$$$1648$$$O	with$$$1649$$$1653$$$O	characteristics$$$1654$$$1669$$$O	of$$$1670$$$1672$$$O	exerting$$$1673$$$1681$$$O	therapeutic$$$1682$$$1693$$$O	effects$$$1694$$$1701$$$O	fully$$$1702$$$1707$$$O	and$$$1708$$$1711$$$O	fast,$$$1712$$$1717$$$O	good$$$1718$$$1722$$$O	therapeutic$$$1723$$$1734$$$O	effects,$$$1735$$$1743$$$O	safety,$$$1744$$$1751$$$O	sanitation$$$1752$$$1762$$$O	and$$$1763$$$1766$$$O	convenience.$$$1767$$$1779$$$O	Thus,$$$1780$$$1785$$$O	the$$$1786$$$1789$$$O	policresulen$$$1790$$$1802$$$O	foam$$$1803$$$1807$$$O	agent$$$1808$$$1813$$$O	is$$$1814$$$1816$$$O	a$$$1817$$$1818$$$O	good$$$1819$$$1823$$$O	drug$$$1824$$$1828$$$O	for$$$1829$$$1832$$$O	treating$$$1833$$$1841$$$O	gynecologic$$$1842$$$1853$$$O	diseases.$$$1854$$$1863$$$O
DE102009008851A1
Transdermal$$$0$$$11$$$O	system,$$$12$$$19$$$O	useful$$$20$$$26$$$O	for$$$27$$$30$$$O	treating$$$31$$$39$$$O	multiple$$$40$$$48$$$O	sclerosis$$$49$$$58$$$O	and$$$59$$$62$$$O	Crohn's$$$63$$$70$$$O	disease,$$$71$$$79$$$O	comprises$$$80$$$89$$$O	an$$$90$$$92$$$O	immunomodulator$$$93$$$108$$$O	comprising$$$109$$$119$$$O	e.g.$$$120$$$124$$$O	quinoline,$$$125$$$135$$$I	active$$$136$$$142$$$O	agent$$$143$$$148$$$O	impermeable$$$149$$$160$$$O	protective$$$161$$$171$$$O	layer,$$$172$$$178$$$O	active$$$179$$$185$$$O	agent$$$186$$$191$$$O	reservoir$$$192$$$201$$$O	and$$$202$$$205$$$O	a$$$206$$$207$$$O	carrier$$$208$$$215$$$O
Transdermal$$$0$$$11$$$O	system$$$12$$$18$$$O	comprises:$$$19$$$29$$$O	at$$$30$$$32$$$O	least$$$33$$$38$$$O	an$$$39$$$41$$$O	immunomodulator,$$$42$$$58$$$O	as$$$59$$$61$$$O	active$$$62$$$68$$$O	agent,$$$69$$$75$$$O	comprising$$$76$$$86$$$O	quinoline,$$$87$$$97$$$I	isoxazoles,$$$98$$$109$$$I	fumaric$$$110$$$117$$$I	acid$$$118$$$122$$$I	derivatives$$$123$$$134$$$O	or$$$135$$$137$$$O	sphingosine-1-phosphatase$$$138$$$163$$$O	receptor$$$164$$$172$$$O	modulators$$$173$$$183$$$O	or$$$184$$$186$$$O	their$$$187$$$192$$$O	salts$$$193$$$198$$$O	and$$$199$$$202$$$O	metabolites;$$$203$$$215$$$O	an$$$216$$$218$$$O	active$$$219$$$225$$$O	agent$$$226$$$231$$$O	impermeable$$$232$$$243$$$O	protective$$$244$$$254$$$O	layer;$$$255$$$261$$$O	an$$$262$$$264$$$O	active$$$265$$$271$$$O	agent$$$272$$$277$$$O	reservoir;$$$278$$$288$$$O	and$$$289$$$292$$$O	a$$$293$$$294$$$O	carrier$$$295$$$302$$$O	for$$$303$$$306$$$O	the$$$307$$$310$$$O	active$$$311$$$317$$$O	agent$$$318$$$323$$$O	reservoir.$$$324$$$334$$$O	-$$$335$$$336$$$O	ACTIVITY$$$337$$$345$$$O	:$$$346$$$347$$$O	Neuroprotective;$$$348$$$364$$$O	Antiinflammatory;$$$365$$$382$$$O	Gastrointestinal-Gen.$$$383$$$404$$$O	-$$$405$$$406$$$O	MECHANISM$$$407$$$416$$$O	OF$$$417$$$419$$$O	ACTION$$$420$$$426$$$O	:$$$427$$$428$$$O	None$$$429$$$433$$$O	given.$$$434$$$440$$$O
EP1971588B1
Tiglien-3-one$$$0$$$13$$$I	derivatives$$$14$$$25$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	tiglien-3-one$$$33$$$46$$$I	compounds$$$47$$$56$$$O	and$$$57$$$60$$$O	their$$$61$$$66$$$O	use$$$67$$$70$$$O	in$$$71$$$73$$$O	methods$$$74$$$81$$$O	of$$$82$$$84$$$O	treating$$$85$$$93$$$O	or$$$94$$$96$$$O	preventing$$$97$$$107$$$O	protozoal$$$108$$$117$$$O	infections,$$$118$$$129$$$O	bacterial$$$130$$$139$$$O	infections,$$$140$$$151$$$O	parasitic$$$152$$$161$$$O	infections$$$162$$$172$$$O	and$$$173$$$176$$$O	cell$$$177$$$181$$$O	proliferative$$$182$$$195$$$O	disorders.$$$196$$$206$$$O	The$$$207$$$210$$$O	tiglien-3-one$$$211$$$224$$$I	compounds$$$225$$$234$$$O	are$$$235$$$238$$$O	also$$$239$$$243$$$O	used$$$244$$$248$$$O	in$$$249$$$251$$$O	methods$$$252$$$259$$$O	of$$$260$$$262$$$O	controlling$$$263$$$274$$$O	pests$$$275$$$280$$$O	in$$$281$$$283$$$O	humans,$$$284$$$291$$$O	animals,$$$292$$$300$$$O	plants$$$301$$$307$$$O	and$$$308$$$311$$$O	the$$$312$$$315$$$O	environment.$$$316$$$328$$$O
US20080102085
Vaccines$$$0$$$8$$$O	for$$$9$$$12$$$O	treatment$$$13$$$22$$$O	of$$$23$$$25$$$O	Aids;$$$26$$$31$$$O	protein$$$32$$$39$$$O	or$$$40$$$42$$$O	polynucleotide$$$43$$$57$$$O	is$$$58$$$60$$$O	delivered$$$61$$$70$$$O	via$$$71$$$74$$$O	a$$$75$$$76$$$O	bombardment$$$77$$$88$$$O	approach$$$89$$$97$$$O
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	a)$$$7$$$9$$$O	an$$$10$$$12$$$O	HIV$$$13$$$16$$$O	Tat$$$17$$$20$$$O	protein$$$21$$$28$$$O	or$$$29$$$31$$$O	polynucleotide;$$$32$$$47$$$O	or$$$48$$$50$$$O	b)$$$51$$$53$$$O	an$$$54$$$56$$$O	HIV$$$57$$$60$$$O	Nef$$$61$$$64$$$O	protein$$$65$$$72$$$O	or$$$73$$$75$$$O	polynucleotide;$$$76$$$91$$$O	or$$$92$$$94$$$O	c)$$$95$$$97$$$O	an$$$98$$$100$$$O	HIV$$$101$$$104$$$O	Tat$$$105$$$108$$$O	protein$$$109$$$116$$$O	or$$$117$$$119$$$O	polynucleotide$$$120$$$134$$$O	linked$$$135$$$141$$$O	to$$$142$$$144$$$O	an$$$145$$$147$$$O	HIV$$$148$$$151$$$O	Nef$$$152$$$155$$$O	protein$$$156$$$163$$$O	or$$$164$$$166$$$O	polynucleotide;$$$167$$$182$$$O	and$$$183$$$186$$$O	an$$$187$$$189$$$O	HIV$$$190$$$193$$$O	gp120$$$194$$$199$$$O	protein$$$200$$$207$$$O	or$$$208$$$210$$$O	polynucleotide$$$211$$$225$$$O	in$$$226$$$228$$$O	the$$$229$$$232$$$O	manufacture$$$233$$$244$$$O	of$$$245$$$247$$$O	a$$$248$$$249$$$O	vaccine$$$250$$$257$$$O	suitable$$$258$$$266$$$O	for$$$267$$$270$$$O	a$$$271$$$272$$$O	prime-boost$$$273$$$284$$$O	delivery$$$285$$$293$$$O	for$$$294$$$297$$$O	the$$$298$$$301$$$O	prophylactic$$$302$$$314$$$O	or$$$315$$$317$$$O	therapeutic$$$318$$$329$$$O	immunisation$$$330$$$342$$$O	of$$$343$$$345$$$O	humans$$$346$$$352$$$O	against$$$353$$$360$$$O	HIV,$$$361$$$365$$$O	wherein$$$366$$$373$$$O	the$$$374$$$377$$$O	protein$$$378$$$385$$$O	or$$$386$$$388$$$O	polynucleotide$$$389$$$403$$$O	is$$$404$$$406$$$O	delivered$$$407$$$416$$$O	via$$$417$$$420$$$O	a$$$421$$$422$$$O	bombardment$$$423$$$434$$$O	approach.$$$435$$$444$$$O
CN103357022A
Bifunctional$$$0$$$12$$$O	polyethylene$$$13$$$25$$$I	glycol$$$26$$$32$$$I	and$$$33$$$36$$$O	adriamycin$$$37$$$47$$$I	conjugate$$$48$$$57$$$O	and$$$58$$$61$$$O	preparation$$$62$$$73$$$O	method$$$74$$$80$$$O	thereof$$$81$$$88$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	bifunctional$$$27$$$39$$$O	polyethylene$$$40$$$52$$$I	glycol$$$53$$$59$$$I	and$$$60$$$63$$$O	adriamycin$$$64$$$74$$$I	conjugate$$$75$$$84$$$O	and$$$85$$$88$$$O	a$$$89$$$90$$$O	preparation$$$91$$$102$$$O	method$$$103$$$109$$$O	thereof.$$$110$$$118$$$O	The$$$119$$$122$$$O	bifunctional$$$123$$$135$$$O	polyethylene$$$136$$$148$$$I	glycol$$$149$$$155$$$I	and$$$156$$$159$$$O	adriamycin$$$160$$$170$$$I	conjugate$$$171$$$180$$$O	is$$$181$$$183$$$O	prepared$$$184$$$192$$$O	in$$$193$$$195$$$O	the$$$196$$$199$$$O	following$$$200$$$209$$$O	steps:$$$210$$$216$$$O	modifying$$$217$$$226$$$O	methoxy$$$227$$$234$$$I	polyethylene$$$235$$$247$$$I	glycol$$$248$$$254$$$I	which$$$255$$$260$$$O	serves$$$261$$$267$$$O	as$$$268$$$270$$$O	a$$$271$$$272$$$O	raw$$$273$$$276$$$O	material$$$277$$$285$$$O	through$$$286$$$293$$$O	hydroformylation,$$$294$$$311$$$O	carrying$$$312$$$320$$$O	out$$$321$$$324$$$O	a$$$325$$$326$$$O	reductive$$$327$$$336$$$O	amination$$$337$$$346$$$O	reaction$$$347$$$355$$$O	on$$$356$$$358$$$O	the$$$359$$$362$$$O	modified$$$363$$$371$$$O	methoxy$$$372$$$379$$$I	polyethylene$$$380$$$392$$$I	glycol$$$393$$$399$$$I	and$$$400$$$403$$$O	disulfide-bond$$$404$$$418$$$I	containing$$$419$$$429$$$O	dihydrazide$$$430$$$441$$$I	to$$$442$$$444$$$O	generate$$$445$$$453$$$O	terminal-hydrazide$$$454$$$472$$$I	polyethylene$$$473$$$485$$$I	glycol,$$$486$$$493$$$I	and$$$494$$$497$$$O	carrying$$$498$$$506$$$O	out$$$507$$$510$$$O	a$$$511$$$512$$$O	reaction$$$513$$$521$$$O	on$$$522$$$524$$$O	the$$$525$$$528$$$O	terminal$$$529$$$537$$$O	hydrazide$$$538$$$547$$$I	of$$$548$$$550$$$O	the$$$551$$$554$$$O	terminal-hydrazide$$$555$$$573$$$I	polyethylene$$$574$$$586$$$I	glycol$$$587$$$593$$$I	and$$$594$$$597$$$O	the$$$598$$$601$$$O	ketone$$$602$$$608$$$O	carbonyl$$$609$$$617$$$O	of$$$618$$$620$$$O	the$$$621$$$624$$$O	adriamycin$$$625$$$635$$$O	to$$$636$$$638$$$O	generate$$$639$$$647$$$O	a$$$648$$$649$$$O	hydrazone$$$650$$$659$$$O	bond$$$660$$$664$$$O	to$$$665$$$667$$$O	obtain$$$668$$$674$$$O	the$$$675$$$678$$$O	bifunctional$$$679$$$691$$$O	polyethylene$$$692$$$704$$$O	glycol$$$705$$$711$$$O	and$$$712$$$715$$$O	adriamycin$$$716$$$726$$$O	conjugate.$$$727$$$737$$$O	The$$$738$$$741$$$O	bifunctional$$$742$$$754$$$O	polyethylene$$$755$$$767$$$I	glycol$$$768$$$774$$$I	and$$$775$$$778$$$O	adriamycin$$$779$$$789$$$I	conjugate$$$790$$$799$$$O	provided$$$800$$$808$$$O	by$$$809$$$811$$$O	the$$$812$$$815$$$O	invention$$$816$$$825$$$O	can$$$826$$$829$$$O	adapt$$$830$$$835$$$O	to$$$836$$$838$$$O	the$$$839$$$842$$$O	reductive$$$843$$$852$$$O	acidic$$$853$$$859$$$O	environment$$$860$$$871$$$O	in$$$872$$$874$$$O	a$$$875$$$876$$$O	cancer$$$877$$$883$$$O	cell$$$884$$$888$$$O	to$$$889$$$891$$$O	release$$$892$$$899$$$O	drugs$$$900$$$905$$$O	rapidly$$$906$$$913$$$O	to$$$914$$$916$$$O	improve$$$917$$$924$$$O	the$$$925$$$928$$$O	cancer$$$929$$$935$$$O	treatment$$$936$$$945$$$O	effect$$$946$$$952$$$O	and$$$953$$$956$$$O	reduce$$$957$$$963$$$O	the$$$964$$$967$$$O	drug$$$968$$$972$$$O	resisting$$$973$$$982$$$O	possibility$$$983$$$994$$$O	of$$$995$$$997$$$O	the$$$998$$$1001$$$O	cancer$$$1002$$$1008$$$O	cell,$$$1009$$$1014$$$O	and$$$1015$$$1018$$$O	in$$$1019$$$1021$$$O	addition,$$$1022$$$1031$$$O	the$$$1032$$$1035$$$O	bifunctional$$$1036$$$1048$$$O	polyethylene$$$1049$$$1061$$$I	glycol$$$1062$$$1068$$$I	and$$$1069$$$1072$$$O	adriamycin$$$1073$$$1083$$$I	conjugate$$$1084$$$1093$$$O	can$$$1094$$$1097$$$O	be$$$1098$$$1100$$$O	self-assembled$$$1101$$$1115$$$O	into$$$1116$$$1120$$$O	a$$$1121$$$1122$$$O	nano$$$1123$$$1127$$$O	particle$$$1128$$$1136$$$O	in$$$1137$$$1139$$$O	a$$$1140$$$1141$$$O	water$$$1142$$$1147$$$O	phase$$$1148$$$1153$$$O	to$$$1154$$$1156$$$O	be$$$1157$$$1159$$$O	able$$$1160$$$1164$$$O	to$$$1165$$$1167$$$O	circulate$$$1168$$$1177$$$O	for$$$1178$$$1181$$$O	a$$$1182$$$1183$$$O	long$$$1184$$$1188$$$O	time$$$1189$$$1193$$$O	in$$$1194$$$1196$$$O	blood$$$1197$$$1202$$$O	to$$$1203$$$1205$$$O	improve$$$1206$$$1213$$$O	the$$$1214$$$1217$$$O	pharmacokinetics$$$1218$$$1234$$$O	of$$$1235$$$1237$$$O	the$$$1238$$$1241$$$O	doxorubicin.$$$1242$$$1254$$$I	The$$$1255$$$1258$$$O	method$$$1259$$$1265$$$O	for$$$1266$$$1269$$$O	preparing$$$1270$$$1279$$$O	the$$$1280$$$1283$$$O	bifunctional$$$1284$$$1296$$$O	polyethylene$$$1297$$$1309$$$I	glycol$$$1310$$$1316$$$I	and$$$1317$$$1320$$$O	adriamycin$$$1321$$$1331$$$I	conjugate$$$1332$$$1341$$$O	has$$$1342$$$1345$$$O	the$$$1346$$$1349$$$O	advantages$$$1350$$$1360$$$O	of$$$1361$$$1363$$$O	simple$$$1364$$$1370$$$O	process,$$$1371$$$1379$$$O	mild$$$1380$$$1384$$$O	reaction$$$1385$$$1393$$$O	conditions,$$$1394$$$1405$$$O	high$$$1406$$$1410$$$O	drug$$$1411$$$1415$$$O	carrying$$$1416$$$1424$$$O	rate$$$1425$$$1429$$$O	and$$$1430$$$1433$$$O	low$$$1434$$$1437$$$O	cost,$$$1438$$$1443$$$O	and$$$1444$$$1447$$$O	the$$$1448$$$1451$$$O	raw$$$1452$$$1455$$$O	materials$$$1456$$$1465$$$O	are$$$1466$$$1469$$$O	easy$$$1470$$$1474$$$O	to$$$1475$$$1477$$$O	obtain.$$$1478$$$1485$$$O	The$$$1486$$$1489$$$O	bifunctional$$$1490$$$1502$$$O	polyethylene$$$1503$$$1515$$$I	glycol$$$1516$$$1522$$$I	and$$$1523$$$1526$$$O	adriamycin$$$1527$$$1537$$$I	conjugate$$$1538$$$1547$$$O	has$$$1548$$$1551$$$O	potential$$$1552$$$1561$$$O	application$$$1562$$$1573$$$O	values$$$1574$$$1580$$$O	in$$$1581$$$1583$$$O	the$$$1584$$$1587$$$O	aspects$$$1588$$$1595$$$O	of$$$1596$$$1598$$$O	targeted$$$1599$$$1607$$$O	delivery$$$1608$$$1616$$$O	of$$$1617$$$1619$$$O	drugs,$$$1620$$$1626$$$O	controlled$$$1627$$$1637$$$O	release$$$1638$$$1645$$$O	of$$$1646$$$1648$$$O	drugs$$$1649$$$1654$$$O	and$$$1655$$$1658$$$O	improvement$$$1659$$$1670$$$O	of$$$1671$$$1673$$$O	clinical$$$1674$$$1682$$$O	cancer$$$1683$$$1689$$$O	resisting$$$1690$$$1699$$$O	and$$$1700$$$1703$$$O	treating$$$1704$$$1712$$$O	effects.$$$1713$$$1721$$$O
CN103381143A
Polymer-coated$$$0$$$14$$$O	oleanolic$$$15$$$24$$$I	acid$$$25$$$29$$$I	liposome$$$30$$$38$$$O	and$$$39$$$42$$$O	preparation$$$43$$$54$$$O	method$$$55$$$61$$$O	thereof$$$62$$$69$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicine$$$48$$$56$$$O	and$$$57$$$60$$$O	relates$$$61$$$68$$$O	to$$$69$$$71$$$O	a$$$72$$$73$$$O	polymer-coated$$$74$$$88$$$O	oleanolic$$$89$$$98$$$I	acid$$$99$$$103$$$I	liposome$$$104$$$112$$$O	and$$$113$$$116$$$O	a$$$117$$$118$$$O	preparation$$$119$$$130$$$O	method$$$131$$$137$$$O	thereof.$$$138$$$146$$$O	The$$$147$$$150$$$O	preparation$$$151$$$162$$$O	method$$$163$$$169$$$O	comprises$$$170$$$179$$$O	the$$$180$$$183$$$O	following$$$184$$$193$$$O	steps$$$194$$$199$$$O	of$$$200$$$202$$$O	preparing$$$203$$$212$$$O	an$$$213$$$215$$$O	oleanolic$$$216$$$225$$$I	acid$$$226$$$230$$$I	liposome$$$231$$$239$$$O	suspension,$$$240$$$251$$$O	adding$$$252$$$258$$$O	a$$$259$$$260$$$O	polymer$$$261$$$268$$$O	into$$$269$$$273$$$O	the$$$274$$$277$$$O	oleanolic$$$278$$$287$$$I	acid$$$288$$$292$$$I	liposome$$$293$$$301$$$O	suspension,$$$302$$$313$$$O	carrying$$$314$$$322$$$O	out$$$323$$$326$$$O	coating$$$327$$$334$$$O	to$$$335$$$337$$$O	obtain$$$338$$$344$$$O	a$$$345$$$346$$$O	polymer-coated$$$347$$$361$$$O	oleanolic$$$362$$$371$$$I	acid$$$372$$$376$$$I	liposome$$$377$$$385$$$O	suspension,$$$386$$$397$$$O	and$$$398$$$401$$$O	carrying$$$402$$$410$$$O	out$$$411$$$414$$$O	spray$$$415$$$420$$$O	drying$$$421$$$427$$$O	or$$$428$$$430$$$O	freeze$$$431$$$437$$$O	drying$$$438$$$444$$$O	to$$$445$$$447$$$O	obtain$$$448$$$454$$$O	polymer-coated$$$455$$$469$$$O	oleanolic$$$470$$$479$$$I	acid$$$480$$$484$$$I	liposome$$$485$$$493$$$O	powder,$$$494$$$501$$$O	wherein$$$502$$$509$$$O	before$$$510$$$516$$$O	use,$$$517$$$521$$$O	hydration$$$522$$$531$$$O	reconstruction$$$532$$$546$$$O	is$$$547$$$549$$$O	carried$$$550$$$557$$$O	out$$$558$$$561$$$O	according$$$562$$$571$$$O	to$$$572$$$574$$$O	requirements.$$$575$$$588$$$O	The$$$589$$$592$$$O	polymer-coated$$$593$$$607$$$O	oleanolic$$$608$$$617$$$I	acid$$$618$$$622$$$I	liposome$$$623$$$631$$$O	utilizes$$$632$$$640$$$O	long-circulating$$$641$$$657$$$O	characteristics,$$$658$$$674$$$O	biological$$$675$$$685$$$O	adhesion$$$686$$$694$$$O	and$$$695$$$698$$$O	penetration$$$699$$$710$$$O	promotion$$$711$$$720$$$O	of$$$721$$$723$$$O	the$$$724$$$727$$$O	coating$$$728$$$735$$$O	material,$$$736$$$745$$$O	improves$$$746$$$754$$$O	drug$$$755$$$759$$$O	encapsulation$$$760$$$773$$$O	efficiency$$$774$$$784$$$O	and$$$785$$$788$$$O	liposome$$$789$$$797$$$O	stability,$$$798$$$808$$$O	prolongs$$$809$$$817$$$O	in-vivo$$$818$$$825$$$O	residence$$$826$$$835$$$O	and$$$836$$$839$$$O	cycle$$$840$$$845$$$O	time$$$846$$$850$$$O	of$$$851$$$853$$$O	particulates,$$$854$$$867$$$O	promotes$$$868$$$876$$$O	intercellular$$$877$$$890$$$O	transmembrane$$$891$$$904$$$O	transport$$$905$$$914$$$O	of$$$915$$$917$$$O	the$$$918$$$921$$$O	particulates,$$$922$$$935$$$O	improves$$$936$$$944$$$O	oral$$$945$$$949$$$O	bioavailability$$$950$$$965$$$O	of$$$966$$$968$$$O	oleanolic$$$969$$$978$$$I	acid,$$$979$$$984$$$I	is$$$985$$$987$$$O	processed$$$988$$$997$$$O	into$$$998$$$1002$$$O	solid$$$1003$$$1008$$$O	powder,$$$1009$$$1016$$$O	and$$$1017$$$1020$$$O	is$$$1021$$$1023$$$O	convenient$$$1024$$$1034$$$O	for$$$1035$$$1038$$$O	package,$$$1039$$$1047$$$O	storage,$$$1048$$$1056$$$O	transport$$$1057$$$1066$$$O	and$$$1067$$$1070$$$O	use.$$$1071$$$1075$$$O
US20100183721
Enhanced$$$0$$$8$$$O	delivery$$$9$$$17$$$O	of$$$18$$$20$$$O	immunosuppressive$$$21$$$38$$$O	drug$$$39$$$43$$$O	compositions$$$44$$$56$$$O	for$$$57$$$60$$$O	pulmonary$$$61$$$70$$$O	delivery$$$71$$$79$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	includes$$$22$$$30$$$O	compositions$$$31$$$43$$$O	and$$$44$$$47$$$O	methods$$$48$$$55$$$O	for$$$56$$$59$$$O	making$$$60$$$66$$$O	and$$$67$$$70$$$O	using$$$71$$$76$$$O	a$$$77$$$78$$$O	rapid$$$79$$$84$$$O	dissolving,$$$85$$$96$$$O	high$$$97$$$101$$$O	potency,$$$102$$$110$$$O	substantially$$$111$$$124$$$O	amorphous$$$125$$$134$$$O	nanostructured$$$135$$$149$$$O	aggregate$$$150$$$159$$$O	for$$$160$$$163$$$O	pulmonary$$$164$$$173$$$O	delivery$$$174$$$182$$$O	of$$$183$$$185$$$O	tacrolimus$$$186$$$196$$$I	and$$$197$$$200$$$O	a$$$201$$$202$$$O	stabilizer$$$203$$$213$$$O	matrix$$$214$$$220$$$O	comprising,$$$221$$$232$$$O	optionally,$$$233$$$244$$$O	a$$$245$$$246$$$O	polymeric$$$247$$$256$$$O	or$$$257$$$259$$$O	non-polymeric$$$260$$$273$$$O	surfactant,$$$274$$$285$$$O	a$$$286$$$287$$$O	polymeric$$$288$$$297$$$O	or$$$298$$$300$$$O	non-polymeric$$$301$$$314$$$O	saccharide$$$315$$$325$$$O	or$$$326$$$328$$$O	both,$$$329$$$334$$$O	wherein$$$335$$$342$$$O	the$$$343$$$346$$$O	aggregate$$$347$$$356$$$O	comprises$$$357$$$366$$$O	a$$$367$$$368$$$O	surface$$$369$$$376$$$O	area$$$377$$$381$$$O	greater$$$382$$$389$$$O	than$$$390$$$394$$$O	5$$$395$$$396$$$O	m2/g$$$397$$$401$$$O	as$$$402$$$404$$$O	measured$$$405$$$413$$$O	by$$$414$$$416$$$O	BET$$$417$$$420$$$O	analysis$$$421$$$429$$$O	and$$$430$$$433$$$O	exhibiting$$$434$$$444$$$O	supersaturation$$$445$$$460$$$O	for$$$461$$$464$$$O	at$$$465$$$467$$$O	least$$$468$$$473$$$O	0.5$$$474$$$477$$$O	hours$$$478$$$483$$$O	when$$$484$$$488$$$O	11-15-times$$$489$$$500$$$O	the$$$501$$$504$$$O	aqueous$$$505$$$512$$$O	crystalline$$$513$$$524$$$O	solubility$$$525$$$535$$$O	of$$$536$$$538$$$O	tacrolimus$$$539$$$549$$$O	is$$$550$$$552$$$O	added$$$553$$$558$$$O	to$$$559$$$561$$$O	simulated$$$562$$$571$$$O	lung$$$572$$$576$$$O	fluid.$$$577$$$583$$$O
US7115556
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	anti-prolactin$$$7$$$21$$$O	agents$$$22$$$28$$$O	to$$$29$$$31$$$O	treat$$$32$$$37$$$O	proliferative$$$38$$$51$$$O	conditions$$$52$$$62$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	variant$$$33$$$40$$$O	forms$$$41$$$46$$$O	of$$$47$$$49$$$O	human$$$50$$$55$$$O	prolactin$$$56$$$65$$$O	which$$$66$$$71$$$O	act$$$72$$$75$$$O	as$$$76$$$78$$$O	antagonists$$$79$$$90$$$O	at$$$91$$$93$$$O	the$$$94$$$97$$$O	prolactin$$$98$$$107$$$O	receptor,$$$108$$$117$$$O	and$$$118$$$121$$$O	to$$$122$$$124$$$O	the$$$125$$$128$$$O	use$$$129$$$132$$$O	of$$$133$$$135$$$O	such$$$136$$$140$$$O	variants$$$141$$$149$$$O	in$$$150$$$152$$$O	the$$$153$$$156$$$O	treatment$$$157$$$166$$$O	of$$$167$$$169$$$O	human$$$170$$$175$$$O	cancers$$$176$$$183$$$O	and$$$184$$$187$$$O	proliferative$$$188$$$201$$$O	disorders,$$$202$$$212$$$O	including$$$213$$$222$$$O	both$$$223$$$227$$$O	benign$$$228$$$234$$$O	and$$$235$$$238$$$O	malignant$$$239$$$248$$$O	diseases$$$249$$$257$$$O	of$$$258$$$260$$$O	the$$$261$$$264$$$O	breast$$$265$$$271$$$O	and$$$272$$$275$$$O	prostate.$$$276$$$285$$$O
WO2014057180A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	an$$$7$$$9$$$O	argon/xenon$$$10$$$21$$$I	mixture$$$22$$$29$$$O	to$$$30$$$32$$$O	prevent$$$33$$$40$$$O	or$$$41$$$43$$$O	treat$$$44$$$49$$$O	the$$$50$$$53$$$O	neurological$$$54$$$66$$$O	consequences$$$67$$$79$$$O	of$$$80$$$82$$$O	a$$$83$$$84$$$O	septic$$$85$$$91$$$O	shock$$$92$$$97$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	a$$$23$$$24$$$O	gaseous$$$25$$$32$$$O	composition$$$33$$$44$$$O	containing$$$45$$$55$$$O	a$$$56$$$57$$$O	mixture$$$58$$$65$$$O	of$$$66$$$68$$$O	gaseous$$$69$$$76$$$O	xenon$$$77$$$82$$$I	and$$$83$$$86$$$O	argon$$$87$$$92$$$I	for$$$93$$$96$$$O	use$$$97$$$100$$$O	by$$$101$$$103$$$O	inhalation$$$104$$$114$$$O	in$$$115$$$117$$$O	order$$$118$$$123$$$O	to$$$124$$$126$$$O	prevent$$$127$$$134$$$O	or$$$135$$$137$$$O	treat$$$138$$$143$$$O	at$$$144$$$146$$$O	least$$$147$$$152$$$O	one$$$153$$$156$$$O	neurological$$$157$$$169$$$O	consequence$$$170$$$181$$$O	secondary$$$182$$$191$$$O	to$$$192$$$194$$$O	a$$$195$$$196$$$O	septic$$$197$$$203$$$O	shock$$$204$$$209$$$O	in$$$210$$$212$$$O	a$$$213$$$214$$$O	patient.$$$215$$$223$$$O
CN102786576A
Triptolide$$$0$$$10$$$I	derivatives,$$$11$$$23$$$O	and$$$24$$$27$$$O	preparation$$$28$$$39$$$O	methods,$$$40$$$48$$$O	medicinal$$$49$$$58$$$O	composition$$$59$$$70$$$O	and$$$71$$$74$$$O	uses$$$75$$$79$$$O	thereof$$$80$$$87$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	fifteen$$$24$$$31$$$O	new$$$32$$$35$$$O	triptolide$$$36$$$46$$$I	derivatives,$$$47$$$59$$$O	a$$$60$$$61$$$O	medicinal$$$62$$$71$$$O	composition$$$72$$$83$$$O	containing$$$84$$$94$$$O	one$$$95$$$98$$$O	or$$$99$$$101$$$O	more$$$102$$$106$$$O	of$$$107$$$109$$$O	the$$$110$$$113$$$O	derivatives,$$$114$$$126$$$O	and$$$127$$$130$$$O	uses$$$131$$$135$$$O	of$$$136$$$138$$$O	the$$$139$$$142$$$O	derivatives$$$143$$$154$$$O	in$$$155$$$157$$$O	the$$$158$$$161$$$O	inhibition$$$162$$$172$$$O	of$$$173$$$175$$$O	the$$$176$$$179$$$O	generation$$$180$$$190$$$O	of$$$191$$$193$$$O	NO$$$194$$$196$$$I	by$$$197$$$199$$$O	macrophages,$$$200$$$212$$$O	especially$$$213$$$223$$$O	anti-inflammation$$$224$$$241$$$O	and$$$242$$$245$$$O	immunological$$$246$$$259$$$O	suppression,$$$260$$$272$$$O	as$$$273$$$275$$$O	medicines.$$$276$$$286$$$O	The$$$287$$$290$$$O	above$$$291$$$296$$$O	compounds$$$297$$$306$$$O	treat$$$307$$$312$$$O	triptolide$$$313$$$323$$$I	as$$$324$$$326$$$O	a$$$327$$$328$$$O	raw$$$329$$$332$$$O	material,$$$333$$$342$$$O	the$$$343$$$346$$$O	fourteenth$$$347$$$357$$$O	hydroxy$$$358$$$365$$$I	group$$$366$$$371$$$O	of$$$372$$$374$$$O	triptolide$$$375$$$385$$$I	and$$$386$$$389$$$O	aromatic$$$390$$$398$$$I	groups$$$399$$$405$$$O	comprising$$$406$$$416$$$O	benzoic$$$417$$$424$$$I	acid,$$$425$$$430$$$I	cinnamic$$$431$$$439$$$I	acid$$$440$$$444$$$I	and$$$445$$$448$$$O	benzene$$$449$$$456$$$I	sulfonic$$$457$$$465$$$I	acid$$$466$$$470$$$I	analogs$$$471$$$478$$$O	are$$$479$$$482$$$O	acylated$$$483$$$491$$$O	to$$$492$$$494$$$O	form$$$495$$$499$$$O	ester$$$500$$$505$$$O	derivatives.$$$506$$$518$$$O	Active$$$519$$$525$$$O	evaluation$$$526$$$536$$$O	shows$$$537$$$542$$$O	that$$$543$$$547$$$O	the$$$548$$$551$$$O	compounds$$$552$$$561$$$O	have$$$562$$$566$$$O	substantial$$$567$$$578$$$O	inhibition$$$579$$$589$$$O	activities$$$590$$$600$$$O	on$$$601$$$603$$$O	the$$$604$$$607$$$O	generation$$$608$$$618$$$O	of$$$619$$$621$$$O	the$$$622$$$625$$$O	inflammation$$$626$$$638$$$O	factor$$$639$$$645$$$O	NO$$$646$$$648$$$I	by$$$649$$$651$$$O	the$$$652$$$655$$$O	macrophages.$$$656$$$668$$$O
CN103694211A
Pharmaceutical$$$0$$$14$$$O	use$$$15$$$18$$$O	of$$$19$$$21$$$O	2,$$$22$$$24$$$I	2-dimethyl$$$25$$$35$$$I	chromanone$$$36$$$46$$$I	type$$$47$$$51$$$O	compound$$$52$$$60$$$O	and$$$61$$$64$$$O	analogs$$$65$$$72$$$O	thereof$$$73$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	medicines$$$48$$$57$$$O	and$$$58$$$61$$$O	relates$$$62$$$69$$$O	to$$$70$$$72$$$O	a$$$73$$$74$$$O	pharmaceutical$$$75$$$89$$$O	use$$$90$$$93$$$O	of$$$94$$$96$$$O	a$$$97$$$98$$$O	2,$$$99$$$101$$$I	2-dimethyl$$$102$$$112$$$I	chromanone$$$113$$$123$$$I	type$$$124$$$128$$$O	compound$$$129$$$137$$$O	and$$$138$$$141$$$O	analogs$$$142$$$149$$$O	thereof.$$$150$$$158$$$O	The$$$159$$$162$$$O	structural$$$163$$$173$$$O	general$$$174$$$181$$$O	formula$$$182$$$189$$$O	is$$$190$$$192$$$O	as$$$193$$$195$$$O	follows,$$$196$$$204$$$O	wherein$$$205$$$212$$$O	X$$$213$$$214$$$O	can$$$215$$$218$$$O	be$$$219$$$221$$$O	selected$$$222$$$230$$$O	from$$$231$$$235$$$O	CH2$$$236$$$239$$$I	or$$$240$$$242$$$O	C=O;$$$243$$$247$$$I	and$$$248$$$251$$$O	R$$$252$$$253$$$O	and$$$254$$$257$$$O	R'$$$258$$$260$$$O	are$$$261$$$264$$$O	as$$$265$$$267$$$O	described$$$268$$$277$$$O	in$$$278$$$280$$$O	the$$$281$$$284$$$O	description.$$$285$$$297$$$O	The$$$298$$$301$$$O	new$$$302$$$305$$$O	compound$$$306$$$314$$$O	provided$$$315$$$323$$$O	by$$$324$$$326$$$O	the$$$327$$$330$$$O	invention$$$331$$$340$$$O	can$$$341$$$344$$$O	be$$$345$$$347$$$O	used$$$348$$$352$$$O	as$$$353$$$355$$$O	an$$$356$$$358$$$O	effective$$$359$$$368$$$O	anti-platelet$$$369$$$382$$$O	medicament,$$$383$$$394$$$O	can$$$395$$$398$$$O	be$$$399$$$401$$$O	particularly$$$402$$$414$$$O	applied$$$415$$$422$$$O	to$$$423$$$425$$$O	the$$$426$$$429$$$O	preparation$$$430$$$441$$$O	of$$$442$$$444$$$O	medicaments$$$445$$$456$$$O	for$$$457$$$460$$$O	preventing$$$461$$$471$$$O	or$$$472$$$474$$$O	treating$$$475$$$483$$$O	coronary$$$484$$$492$$$O	syndrome,$$$493$$$502$$$O	myocardial$$$503$$$513$$$O	infarction,$$$514$$$525$$$O	myocardial$$$526$$$536$$$O	ischemia$$$537$$$545$$$O	and$$$546$$$549$$$O	cardiovascular$$$550$$$564$$$O	and$$$565$$$568$$$O	cerebrovascular$$$569$$$584$$$O	diseases$$$585$$$593$$$O	caused$$$594$$$600$$$O	by$$$601$$$603$$$O	platelet$$$604$$$612$$$O	aggregation$$$613$$$624$$$O	and$$$625$$$628$$$O	can$$$629$$$632$$$O	further$$$633$$$640$$$O	treat$$$641$$$646$$$O	thrombus$$$647$$$655$$$O	formation,$$$656$$$666$$$O	ischemia,$$$667$$$676$$$O	stroke,$$$677$$$684$$$O	restenosis$$$685$$$695$$$O	or$$$696$$$698$$$O	inflammation.$$$699$$$712$$$O
US20080286806
Ligand$$$0$$$6$$$O	for$$$7$$$10$$$O	G-protein$$$11$$$20$$$O	coupled$$$21$$$28$$$O	receptor$$$29$$$37$$$O	GPR43$$$38$$$43$$$O	and$$$44$$$47$$$O	uses$$$48$$$52$$$O	thereof$$$53$$$60$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	related$$$25$$$32$$$O	to$$$33$$$35$$$O	the$$$36$$$39$$$O	G-protein$$$40$$$49$$$O	coupled$$$50$$$57$$$O	orphan$$$58$$$64$$$O	receptor$$$65$$$73$$$O	GPR43$$$74$$$79$$$O	and$$$80$$$83$$$O	the$$$84$$$87$$$O	identification$$$88$$$102$$$O	of$$$103$$$105$$$O	short$$$106$$$111$$$O	chain$$$112$$$117$$$O	fatty$$$118$$$123$$$O	acids$$$124$$$129$$$O	as$$$130$$$132$$$O	natural$$$133$$$140$$$O	ligands$$$141$$$148$$$O	of$$$149$$$151$$$O	the$$$152$$$155$$$O	receptor.$$$156$$$165$$$O	The$$$166$$$169$$$O	invention$$$170$$$179$$$O	further$$$180$$$187$$$O	relates$$$188$$$195$$$O	to$$$196$$$198$$$O	assays$$$199$$$205$$$O	for$$$206$$$209$$$O	the$$$210$$$213$$$O	identification$$$214$$$228$$$O	of$$$229$$$231$$$O	agents$$$232$$$238$$$O	that$$$239$$$243$$$O	modulate$$$244$$$252$$$O	GPR43$$$253$$$258$$$O	ligand$$$259$$$265$$$O	binding$$$266$$$273$$$O	and$$$274$$$277$$$O	signalling$$$278$$$288$$$O	activity,$$$289$$$298$$$O	as$$$299$$$301$$$O	well$$$302$$$306$$$O	as$$$307$$$309$$$O	compositions$$$310$$$322$$$O	consisting$$$323$$$333$$$O	essentially$$$334$$$345$$$O	of$$$346$$$348$$$O	an$$$349$$$351$$$O	isolated$$$352$$$360$$$O	GPR43$$$361$$$366$$$O	polypeptide$$$367$$$378$$$O	and$$$379$$$382$$$O	an$$$383$$$385$$$O	isolated$$$386$$$394$$$O	short$$$395$$$400$$$O	chain$$$401$$$406$$$O	fatty$$$407$$$412$$$I	acid.$$$413$$$418$$$I	The$$$419$$$422$$$O	invention$$$423$$$432$$$O	also$$$433$$$437$$$O	relates$$$438$$$445$$$O	to$$$446$$$448$$$O	diagnostic$$$449$$$459$$$O	methods$$$460$$$467$$$O	and$$$468$$$471$$$O	kits$$$472$$$476$$$O	that$$$477$$$481$$$O	take$$$482$$$486$$$O	advantage$$$487$$$496$$$O	of$$$497$$$499$$$O	the$$$500$$$503$$$O	novel$$$504$$$509$$$O	interaction$$$510$$$521$$$O	of$$$522$$$524$$$O	GPR43$$$525$$$530$$$O	with$$$531$$$535$$$O	short$$$536$$$541$$$O	chain$$$542$$$547$$$O	fatty$$$548$$$553$$$I	acids.$$$554$$$560$$$I
WO2009062874A3
Benzimidazole$$$0$$$13$$$I	derivatives$$$14$$$25$$$O	and$$$26$$$29$$$O	their$$$30$$$35$$$O	use$$$36$$$39$$$O	as$$$40$$$42$$$O	fxr$$$43$$$46$$$O	agonists$$$47$$$55$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	concerned$$$17$$$26$$$O	with$$$27$$$31$$$O	novel$$$32$$$37$$$O	substituted$$$38$$$49$$$O	benzimidazole$$$50$$$63$$$I	derivatives$$$64$$$75$$$O	of$$$76$$$78$$$O	formula$$$79$$$86$$$O	(I)$$$87$$$90$$$O	wherein$$$91$$$98$$$O	R1$$$99$$$101$$$O	to$$$102$$$104$$$O	R10$$$105$$$108$$$O	are$$$109$$$112$$$O	as$$$113$$$115$$$O	defined$$$116$$$123$$$O	in$$$124$$$126$$$O	the$$$127$$$130$$$O	description$$$131$$$142$$$O	and$$$143$$$146$$$O	in$$$147$$$149$$$O	the$$$150$$$153$$$O	claims,$$$154$$$161$$$O	as$$$162$$$164$$$O	well$$$165$$$169$$$O	as$$$170$$$172$$$O	physiologically$$$173$$$188$$$O	acceptable$$$189$$$199$$$O	salts$$$200$$$205$$$O	and$$$206$$$209$$$O	esters$$$210$$$216$$$O	thereof.$$$217$$$225$$$O	These$$$226$$$231$$$O	compounds$$$232$$$241$$$O	can$$$242$$$245$$$O	be$$$246$$$248$$$O	used$$$249$$$253$$$O	as$$$254$$$256$$$O	medicaments.$$$257$$$269$$$O
WO2005105998A1
HUMAN$$$0$$$5$$$O	ANTIAMYLOID$$$6$$$17$$$O	Î²$$$18$$$20$$$O	PEPTIDE$$$21$$$28$$$O	ANTIBODY$$$29$$$37$$$O	AND$$$38$$$41$$$O	ANTIBODY$$$42$$$50$$$O	FRAGMENT$$$51$$$59$$$O	THEREOF$$$60$$$67$$$O
It$$$0$$$2$$$O	is$$$3$$$5$$$O	intended$$$6$$$14$$$O	to$$$15$$$17$$$O	provide$$$18$$$25$$$O	a$$$26$$$27$$$O	human$$$28$$$33$$$O	amyloid$$$34$$$41$$$O	Î²$$$42$$$44$$$O	peptide$$$45$$$52$$$O	(hereinafter$$$53$$$65$$$O	referred$$$66$$$74$$$O	to$$$75$$$77$$$O	as$$$78$$$80$$$O	AÎ²)$$$81$$$85$$$O	antibody$$$86$$$94$$$O	which$$$95$$$100$$$O	binds$$$101$$$106$$$O	to$$$107$$$109$$$O	AÎ²$$$110$$$113$$$O	and$$$114$$$117$$$O	inhibits$$$118$$$126$$$O	the$$$127$$$130$$$O	aggregation$$$131$$$142$$$O	of$$$143$$$145$$$O	AÎ²$$$146$$$149$$$O	molecules,$$$150$$$160$$$O	and$$$161$$$164$$$O	its$$$165$$$168$$$O	antibody$$$169$$$177$$$O	fragment.$$$178$$$187$$$O	The$$$188$$$191$$$O	above-described$$$192$$$207$$$O	antibody$$$208$$$216$$$O	or$$$217$$$219$$$O	its$$$220$$$223$$$O	antibody$$$224$$$232$$$O	fragment$$$233$$$241$$$O	has$$$242$$$245$$$O	the$$$246$$$249$$$O	variable$$$250$$$258$$$O	region$$$259$$$265$$$O	of$$$266$$$268$$$O	human$$$269$$$274$$$O	anti-AÎ²$$$275$$$283$$$O	antibody$$$284$$$292$$$O	and$$$293$$$296$$$O	strongly$$$297$$$305$$$O	reacts$$$306$$$312$$$O	with$$$313$$$317$$$O	AÎ²$$$318$$$321$$$O	to$$$322$$$324$$$O	thereby$$$325$$$332$$$O	exert$$$333$$$338$$$O	an$$$339$$$341$$$O	effect$$$342$$$348$$$O	of$$$349$$$351$$$O	inhibiting$$$352$$$362$$$O	the$$$363$$$366$$$O	aggregation$$$367$$$378$$$O	thereof.$$$379$$$387$$$O	The$$$388$$$391$$$O	above$$$392$$$397$$$O	antibody$$$398$$$406$$$O	and$$$407$$$410$$$O	its$$$411$$$414$$$O	antibody$$$415$$$423$$$O	fragment$$$424$$$432$$$O	are$$$433$$$436$$$O	usable$$$437$$$443$$$O	as$$$444$$$446$$$O	AÎ²$$$447$$$450$$$O	detection$$$451$$$460$$$O	reagents,$$$461$$$470$$$O	preventives/remedies$$$471$$$491$$$O	for$$$492$$$495$$$O	Alzheimerâs$$$496$$$509$$$O	disease$$$510$$$517$$$O	or$$$518$$$520$$$O	diagnostics$$$521$$$532$$$O	therefor.$$$533$$$542$$$O
EP2263671A1
Amide$$$0$$$5$$$I	derivative-containing$$$6$$$27$$$O	pharmaceutical$$$28$$$42$$$O	composition$$$43$$$54$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	containing$$$62$$$72$$$O	a$$$73$$$74$$$O	solid$$$75$$$80$$$O	dispersion$$$81$$$91$$$O	comprising$$$92$$$102$$$O	an$$$103$$$105$$$O	amide$$$106$$$111$$$I	derivative$$$112$$$122$$$O	or$$$123$$$125$$$O	a$$$126$$$127$$$O	salt$$$128$$$132$$$O	thereof$$$133$$$140$$$O	and$$$141$$$144$$$O	a$$$145$$$146$$$O	water-soluble$$$147$$$160$$$O	polymer,$$$161$$$169$$$O	wherein$$$170$$$177$$$O	the$$$178$$$181$$$O	pharmaceutical$$$182$$$196$$$O	composition$$$197$$$208$$$O	is$$$209$$$211$$$O	not$$$212$$$215$$$O	prepared$$$216$$$224$$$O	by$$$225$$$227$$$O	a$$$228$$$229$$$O	melting$$$230$$$237$$$O	method.$$$238$$$245$$$O	The$$$246$$$249$$$O	pharmaceutical$$$250$$$264$$$O	composition$$$265$$$276$$$O	contains$$$277$$$285$$$O	the$$$286$$$289$$$O	solid$$$290$$$295$$$O	dispersion$$$296$$$306$$$O	having$$$307$$$313$$$O	an$$$314$$$316$$$O	improved$$$317$$$325$$$O	oral$$$326$$$330$$$O	absorption,$$$331$$$342$$$O	properties$$$343$$$353$$$O	suitable$$$354$$$362$$$O	for$$$363$$$366$$$O	formulation,$$$367$$$379$$$O	and$$$380$$$383$$$O	an$$$384$$$386$$$O	excellent$$$387$$$396$$$O	stability.$$$397$$$407$$$O
US7074405
antibody$$$0$$$8$$$O	binds$$$9$$$14$$$O	target$$$15$$$21$$$O	tissue$$$22$$$28$$$O	and$$$29$$$32$$$O	conjugate$$$33$$$42$$$O	carrying$$$43$$$51$$$O	epitope$$$52$$$59$$$O	(haptens)$$$60$$$69$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	bi-specific$$$35$$$46$$$O	antibody$$$47$$$55$$$O	or$$$56$$$58$$$O	antibody$$$59$$$67$$$O	fragment$$$68$$$76$$$O	having$$$77$$$83$$$O	at$$$84$$$86$$$O	least$$$87$$$92$$$O	one$$$93$$$96$$$O	arm$$$97$$$100$$$O	that$$$101$$$105$$$O	specifically$$$106$$$118$$$O	binds$$$119$$$124$$$O	a$$$125$$$126$$$O	targeted$$$127$$$135$$$O	tissue$$$136$$$142$$$O	and$$$143$$$146$$$O	at$$$147$$$149$$$O	least$$$150$$$155$$$O	one$$$156$$$159$$$O	other$$$160$$$165$$$O	arm$$$166$$$169$$$O	that$$$170$$$174$$$O	specifically$$$175$$$187$$$O	binds$$$188$$$193$$$O	a$$$194$$$195$$$O	targetable$$$196$$$206$$$O	conjugate.$$$207$$$217$$$O	The$$$218$$$221$$$O	targetable$$$222$$$232$$$O	conjugate$$$233$$$242$$$O	comprises$$$243$$$252$$$O	a$$$253$$$254$$$O	carrier$$$255$$$262$$$O	portion$$$263$$$270$$$O	which$$$271$$$276$$$O	comprises$$$277$$$286$$$O	or$$$287$$$289$$$O	bears$$$290$$$295$$$O	at$$$296$$$298$$$O	least$$$299$$$304$$$O	one$$$305$$$308$$$O	epitope$$$309$$$316$$$O	recognizable$$$317$$$329$$$O	by$$$330$$$332$$$O	at$$$333$$$335$$$O	least$$$336$$$341$$$O	one$$$342$$$345$$$O	arm$$$346$$$349$$$O	of$$$350$$$352$$$O	said$$$353$$$357$$$O	bi-specific$$$358$$$369$$$O	antibody$$$370$$$378$$$O	or$$$379$$$381$$$O	antibody$$$382$$$390$$$O	fragment.$$$391$$$400$$$O	The$$$401$$$404$$$O	targetable$$$405$$$415$$$O	conjugate$$$416$$$425$$$O	further$$$426$$$433$$$O	comprises$$$434$$$443$$$O	one$$$444$$$447$$$O	or$$$448$$$450$$$O	more$$$451$$$455$$$O	therapeutic$$$456$$$467$$$O	or$$$468$$$470$$$O	diagnostic$$$471$$$481$$$O	agents$$$482$$$488$$$O	or$$$489$$$491$$$O	enzymes.$$$492$$$500$$$O	The$$$501$$$504$$$O	invention$$$505$$$514$$$O	provides$$$515$$$523$$$O	constructs$$$524$$$534$$$O	and$$$535$$$538$$$O	methods$$$539$$$546$$$O	for$$$547$$$550$$$O	producing$$$551$$$560$$$O	the$$$561$$$564$$$O	bi-specific$$$565$$$576$$$O	antibodies$$$577$$$587$$$O	or$$$588$$$590$$$O	antibody$$$591$$$599$$$O	fragments,$$$600$$$610$$$O	as$$$611$$$613$$$O	well$$$614$$$618$$$O	as$$$619$$$621$$$O	methods$$$622$$$629$$$O	for$$$630$$$633$$$O	using$$$634$$$639$$$O	them.$$$640$$$645$$$O
US20090076150
Deuterium-enriched$$$0$$$18$$$I	bromfenac$$$19$$$28$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	application$$$12$$$23$$$O	describes$$$24$$$33$$$O	deuterium-enriched$$$34$$$52$$$I	bromfenac,$$$53$$$63$$$I	pharmaceutically$$$64$$$80$$$O	acceptable$$$81$$$91$$$O	salt$$$92$$$96$$$O	forms$$$97$$$102$$$O	thereof,$$$103$$$111$$$O	and$$$112$$$115$$$O	methods$$$116$$$123$$$O	of$$$124$$$126$$$O	treating$$$127$$$135$$$O	using$$$136$$$141$$$O	the$$$142$$$145$$$O	same.$$$146$$$151$$$O
WO2006120557A1
Anticancer$$$0$$$10$$$O	combination$$$11$$$22$$$O	therapy$$$23$$$30$$$O	using$$$31$$$36$$$O	sunitinib$$$37$$$46$$$I	malate$$$47$$$53$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	treating$$$34$$$42$$$O	cancer$$$43$$$49$$$O	using$$$50$$$55$$$O	a$$$56$$$57$$$O	compound$$$58$$$66$$$O	of$$$67$$$69$$$O	formula$$$70$$$77$$$O	(1)$$$78$$$81$$$O	or$$$82$$$84$$$O	a$$$85$$$86$$$O	pharmaceutically$$$87$$$103$$$O	acceptable$$$104$$$114$$$O	salt$$$115$$$119$$$O	thereof,$$$120$$$128$$$O	particularly$$$129$$$141$$$O	a$$$142$$$143$$$O	malate$$$144$$$150$$$I	salt,$$$151$$$156$$$I	in$$$157$$$159$$$O	combination$$$160$$$171$$$O	with$$$172$$$176$$$O	various$$$177$$$184$$$O	additional$$$185$$$195$$$O	therapeutic$$$196$$$207$$$O	agents.$$$208$$$215$$$O	The$$$216$$$219$$$O	invention$$$220$$$229$$$O	also$$$230$$$234$$$O	provides$$$235$$$243$$$O	therapeutic$$$244$$$255$$$O	dosing$$$256$$$262$$$O	regimens,$$$263$$$272$$$O	using$$$273$$$278$$$O	the$$$279$$$282$$$O	compound$$$283$$$291$$$O	of$$$292$$$294$$$O	formula$$$295$$$302$$$O	(1)$$$303$$$306$$$O	and$$$307$$$310$$$O	an$$$311$$$313$$$O	additional$$$314$$$324$$$O	therapeutic$$$325$$$336$$$O	agent.$$$337$$$343$$$O
WO2011151731A3
Surgical$$$0$$$8$$$O	adjuvant$$$9$$$17$$$O	composition$$$18$$$29$$$O	and$$$30$$$33$$$O	associated$$$34$$$44$$$O	methods$$$45$$$52$$$O	of$$$53$$$55$$$O	use$$$56$$$59$$$O
Disclosed$$$0$$$9$$$O	herein$$$10$$$16$$$O	are$$$17$$$20$$$O	surgical$$$21$$$29$$$O	adjuvant$$$30$$$38$$$O	compositions$$$39$$$51$$$O	comprising$$$52$$$62$$$O	isotonic$$$63$$$71$$$O	phosphate$$$72$$$81$$$I	buffered$$$82$$$90$$$O	saline,$$$91$$$98$$$O	high$$$99$$$103$$$O	molecular$$$104$$$113$$$O	weight$$$114$$$120$$$O	dextran,$$$121$$$129$$$O	ascorbate,$$$130$$$140$$$I	transferrin$$$141$$$152$$$O	and$$$153$$$156$$$O	poloxamer$$$157$$$166$$$O	surfactant$$$167$$$177$$$O	P188.$$$178$$$183$$$O	Also$$$184$$$188$$$O	described$$$189$$$198$$$O	are$$$199$$$202$$$O	surgical$$$203$$$211$$$O	methods$$$212$$$219$$$O	which$$$220$$$225$$$O	include$$$226$$$233$$$O	the$$$234$$$237$$$O	use$$$238$$$241$$$O	of$$$242$$$244$$$O	the$$$245$$$248$$$O	adjuvant$$$249$$$257$$$O	composition$$$258$$$269$$$O	to$$$270$$$272$$$O	reduce$$$273$$$279$$$O	tissure$$$280$$$287$$$O	and$$$288$$$291$$$O	cellular$$$292$$$300$$$O	damage$$$301$$$307$$$O	such$$$308$$$312$$$O	as$$$313$$$315$$$O	necrosis$$$316$$$324$$$O	and/or$$$325$$$331$$$O	apoptosis.$$$332$$$342$$$O
WO2013010018A3
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	inhibiting$$$29$$$39$$$O	proteases$$$40$$$49$$$O
In$$$0$$$2$$$O	particular,$$$3$$$14$$$O	in$$$15$$$17$$$O	alternative$$$18$$$29$$$O	embodiments,$$$30$$$42$$$O	the$$$43$$$46$$$O	invention$$$47$$$56$$$O	provides$$$57$$$65$$$O	pharmaceutical$$$66$$$80$$$O	compounds$$$81$$$90$$$O	and$$$91$$$94$$$O	formulations$$$95$$$107$$$O	comprising$$$108$$$118$$$O	a$$$119$$$120$$$O	family$$$121$$$127$$$O	of$$$128$$$130$$$O	epoxyketone$$$131$$$142$$$I	compounds,$$$143$$$153$$$O	which$$$154$$$159$$$O	include$$$160$$$167$$$O	racemic$$$168$$$175$$$O	mixtures$$$176$$$184$$$O	or$$$185$$$187$$$O	racemates,$$$188$$$198$$$O	isomers,$$$199$$$207$$$O	stereoisomers,$$$208$$$222$$$O	diastereoisomers,$$$223$$$240$$$O	derivatives$$$241$$$252$$$O	and$$$253$$$256$$$O	analogs,$$$257$$$265$$$O	and$$$266$$$269$$$O	methods$$$270$$$277$$$O	for$$$278$$$281$$$O	making$$$282$$$288$$$O	and$$$289$$$292$$$O	using$$$293$$$298$$$O	them.$$$299$$$304$$$O	In$$$305$$$307$$$O	alternative$$$308$$$319$$$O	embodiments,$$$320$$$332$$$O	pharmaceutical$$$333$$$347$$$O	compositions$$$348$$$360$$$O	and$$$361$$$364$$$O	formulations$$$365$$$377$$$O	of$$$378$$$380$$$O	the$$$381$$$384$$$O	invention$$$385$$$394$$$O	are$$$395$$$398$$$O	administered$$$399$$$411$$$O	to$$$412$$$414$$$O	an$$$415$$$417$$$O	individual$$$418$$$428$$$O	in$$$429$$$431$$$O	need$$$432$$$436$$$O	thereof$$$437$$$444$$$O	in$$$445$$$447$$$O	an$$$448$$$450$$$O	amount$$$451$$$457$$$O	sufficient$$$458$$$468$$$O	to$$$469$$$471$$$O	treat,$$$472$$$478$$$O	prevent,$$$479$$$487$$$O	reverse$$$488$$$495$$$O	and/or$$$496$$$502$$$O	ameliorate$$$503$$$513$$$O	an$$$514$$$516$$$O	infection,$$$517$$$527$$$O	disease$$$528$$$535$$$O	or$$$536$$$538$$$O	condition$$$539$$$548$$$O	that$$$549$$$553$$$O	can$$$554$$$557$$$O	be$$$558$$$560$$$O	ameliorated,$$$561$$$573$$$O	treated,$$$574$$$582$$$O	prevented$$$583$$$592$$$O	or$$$593$$$595$$$O	reversed$$$596$$$604$$$O	by$$$605$$$607$$$O	partially$$$608$$$617$$$O	or$$$618$$$620$$$O	completely$$$621$$$631$$$O	inhibiting$$$632$$$642$$$O	a$$$643$$$644$$$O	chymotrypsin-like$$$645$$$662$$$O	protease$$$663$$$671$$$O	or$$$672$$$674$$$O	a$$$675$$$676$$$O	proteasome$$$677$$$687$$$O	activity,$$$688$$$697$$$O	including$$$698$$$707$$$O	e.g.,$$$708$$$713$$$O	a$$$714$$$715$$$O	retroviral$$$716$$$726$$$O	infection$$$727$$$736$$$O	such$$$737$$$741$$$O	as$$$742$$$744$$$O	human$$$745$$$750$$$O	immunodeficiency$$$751$$$767$$$O	virus-1$$$768$$$775$$$O	(HIV-1)$$$776$$$783$$$O	infection,$$$784$$$794$$$O	an$$$795$$$797$$$O	immune$$$798$$$804$$$O	disorder,$$$805$$$814$$$O	a$$$815$$$816$$$O	neurodegenerative$$$817$$$834$$$O	disease$$$835$$$842$$$O	or$$$843$$$845$$$O	condition,$$$846$$$856$$$O	or$$$857$$$859$$$O	a$$$860$$$861$$$O	cancer$$$862$$$868$$$O	such$$$869$$$873$$$O	as$$$874$$$876$$$O	a$$$877$$$878$$$O	myeloma$$$879$$$886$$$O	or$$$887$$$889$$$O	multiple$$$890$$$898$$$O	myeloma,$$$899$$$907$$$O	an$$$908$$$910$$$O	adenocarcinoma$$$911$$$925$$$O	such$$$926$$$930$$$O	as$$$931$$$933$$$O	a$$$934$$$935$$$O	lung$$$936$$$940$$$O	adenocarcinoma,$$$941$$$956$$$O	a$$$957$$$958$$$O	pancreatic$$$959$$$969$$$O	cancer,$$$970$$$977$$$O	a$$$978$$$979$$$O	B-cell$$$980$$$986$$$O	related$$$987$$$994$$$O	cancer,$$$995$$$1002$$$O	and$$$1003$$$1006$$$O	lymphomas$$$1007$$$1016$$$O	such$$$1017$$$1021$$$O	as$$$1022$$$1024$$$O	non-Hodgkin's$$$1025$$$1038$$$O	lymphoma.$$$1039$$$1048$$$O
US20100152125
Compositions$$$0$$$12$$$O	And$$$13$$$16$$$O	Methods$$$17$$$24$$$O	For$$$25$$$28$$$O	The$$$29$$$32$$$O	Diagnosis,$$$33$$$43$$$O	Treatment,$$$44$$$54$$$O	And$$$55$$$58$$$O	Prevention$$$59$$$69$$$O	Of$$$70$$$72$$$O	Amyotrophic$$$73$$$84$$$O	Lateral$$$85$$$92$$$O	Sclerosis$$$93$$$102$$$O	And$$$103$$$106$$$O	Related$$$107$$$114$$$O	Neurological$$$115$$$127$$$O	Diseases$$$128$$$136$$$O
One$$$0$$$3$$$O	aspect$$$4$$$10$$$O	of$$$11$$$13$$$O	the$$$14$$$17$$$O	invention$$$18$$$27$$$O	relates$$$28$$$35$$$O	to$$$36$$$38$$$O	a$$$39$$$40$$$O	method$$$41$$$47$$$O	of$$$48$$$50$$$O	treating$$$51$$$59$$$O	or$$$60$$$62$$$O	preventing$$$63$$$73$$$O	a$$$74$$$75$$$O	neurodegenerative$$$76$$$93$$$O	disease,$$$94$$$102$$$O	comprising$$$103$$$113$$$O	the$$$114$$$117$$$O	step$$$118$$$122$$$O	of$$$123$$$125$$$O	administering$$$126$$$139$$$O	to$$$140$$$142$$$O	a$$$143$$$144$$$O	patient$$$145$$$152$$$O	in$$$153$$$155$$$O	need$$$156$$$160$$$O	thereof$$$161$$$168$$$O	a$$$169$$$170$$$O	therapeutically$$$171$$$186$$$O	effective$$$187$$$196$$$O	amount$$$197$$$203$$$O	of$$$204$$$206$$$O	an$$$207$$$209$$$O	inhibitor$$$210$$$219$$$O	of$$$220$$$222$$$O	the$$$223$$$226$$$O	formation$$$227$$$236$$$O	of$$$237$$$239$$$O	advanced$$$240$$$248$$$O	glycation$$$249$$$258$$$O	end$$$259$$$262$$$O	products.$$$263$$$272$$$O	Another$$$273$$$280$$$O	aspect$$$281$$$287$$$O	of$$$288$$$290$$$O	the$$$291$$$294$$$O	invention$$$295$$$304$$$O	relates$$$305$$$312$$$O	to$$$313$$$315$$$O	a$$$316$$$317$$$O	proteasome$$$318$$$328$$$O	activity-based$$$329$$$343$$$O	screening$$$344$$$353$$$O	assay$$$354$$$359$$$O	to$$$360$$$362$$$O	select$$$363$$$369$$$O	compounds$$$370$$$379$$$O	which$$$380$$$385$$$O	may$$$386$$$389$$$O	be$$$390$$$392$$$O	useful$$$393$$$399$$$O	for$$$400$$$403$$$O	treating$$$404$$$412$$$O	or$$$413$$$415$$$O	preventing$$$416$$$426$$$O	a$$$427$$$428$$$O	neurodegenerative$$$429$$$446$$$O	disease,$$$447$$$455$$$O	and$$$456$$$459$$$O	the$$$460$$$463$$$O	materials$$$464$$$473$$$O	used$$$474$$$478$$$O	therein.$$$479$$$487$$$O	Yet$$$488$$$491$$$O	another$$$492$$$499$$$O	aspect$$$500$$$506$$$O	of$$$507$$$509$$$O	the$$$510$$$513$$$O	invention$$$514$$$523$$$O	relates$$$524$$$531$$$O	to$$$532$$$534$$$O	molecules,$$$535$$$545$$$O	and$$$546$$$549$$$O	methods$$$550$$$557$$$O	of$$$558$$$560$$$O	use$$$561$$$564$$$O	thereof,$$$565$$$573$$$O	which$$$574$$$579$$$O	bind$$$580$$$584$$$O	at$$$585$$$587$$$O	or$$$588$$$590$$$O	adjacent$$$591$$$599$$$O	to$$$600$$$602$$$O	SOD-I$$$603$$$608$$$O	Trp32,$$$609$$$615$$$I	including$$$616$$$625$$$O	molecules$$$626$$$635$$$O	that$$$636$$$640$$$O	bind$$$641$$$645$$$O	in$$$646$$$648$$$O	a$$$649$$$650$$$O	site$$$651$$$655$$$O	adjacent$$$656$$$664$$$O	to$$$665$$$667$$$O	SOD-I$$$668$$$673$$$O	Trp32$$$674$$$679$$$I	whether$$$680$$$687$$$O	or$$$688$$$690$$$O	not$$$691$$$694$$$O	it$$$695$$$697$$$O	is$$$698$$$700$$$O	oxidized,$$$701$$$710$$$O	for$$$711$$$714$$$O	treating$$$715$$$723$$$O	or$$$724$$$726$$$O	preventing$$$727$$$737$$$O	neurodegenerative$$$738$$$755$$$O	disease.$$$756$$$764$$$O
CN101302510A
Nucleic$$$0$$$7$$$O	acid$$$8$$$12$$$O	molecule$$$13$$$21$$$O	and$$$22$$$25$$$O	use$$$26$$$29$$$O	thereof$$$30$$$37$$$O	in$$$38$$$40$$$O	anti-cancer$$$41$$$52$$$O	medicine$$$53$$$61$$$O	preparation$$$62$$$73$$$O
The$$$0$$$3$$$O	method$$$4$$$10$$$O	belongs$$$11$$$18$$$O	to$$$19$$$21$$$O	the$$$22$$$25$$$O	biomedical$$$26$$$36$$$O	field,$$$37$$$43$$$O	relating$$$44$$$52$$$O	to$$$53$$$55$$$O	NRN1SR3$$$56$$$63$$$I	and$$$64$$$67$$$O	an$$$68$$$70$$$O	application$$$71$$$82$$$O	of$$$83$$$85$$$O	NRN1SR3$$$86$$$93$$$I	in$$$94$$$96$$$O	making$$$97$$$103$$$O	an$$$104$$$106$$$O	antitumor$$$107$$$116$$$O	drug.$$$117$$$122$$$O	As$$$123$$$125$$$O	health$$$126$$$132$$$O	of$$$133$$$135$$$O	human$$$136$$$141$$$O	is$$$142$$$144$$$O	threatened$$$145$$$155$$$O	heavily$$$156$$$163$$$O	by$$$164$$$166$$$O	tumors,$$$167$$$174$$$O	the$$$175$$$178$$$O	invention$$$179$$$188$$$O	provides$$$189$$$197$$$O	nucleotide$$$198$$$208$$$I	molecule$$$209$$$217$$$O	NRN1SR3$$$218$$$225$$$I	for$$$226$$$229$$$O	making$$$230$$$236$$$O	an$$$237$$$239$$$O	antitumor$$$240$$$249$$$O	drug.$$$250$$$255$$$O	The$$$256$$$259$$$O	sequence$$$260$$$268$$$O	of$$$269$$$271$$$O	the$$$272$$$275$$$O	nucleotide$$$276$$$286$$$I	molecule$$$287$$$295$$$O	comprises$$$296$$$305$$$O	5'-TGGTCTGCGGTCGCAAATGGTTCAAGAGA-3'$$$306$$$341$$$O	or$$$342$$$344$$$O	5'-UGGUCUGCGGUCGCAAAUGGUUCAAGAGA-3'.$$$345$$$381$$$O	Compared$$$382$$$390$$$O	nude$$$391$$$395$$$O	mice$$$396$$$400$$$O	containing$$$401$$$411$$$O	NRN1SR3$$$412$$$419$$$I	with$$$420$$$424$$$O	nude$$$425$$$429$$$O	mice$$$430$$$434$$$O	containing$$$435$$$445$$$O	no-NRN1SR3$$$446$$$456$$$I	under$$$457$$$462$$$O	the$$$463$$$466$$$O	same$$$467$$$471$$$O	culture$$$472$$$479$$$O	condition,$$$480$$$490$$$O	growth$$$491$$$497$$$O	of$$$498$$$500$$$O	the$$$501$$$504$$$O	tumor$$$505$$$510$$$O	body$$$511$$$515$$$O	is$$$516$$$518$$$O	obviously$$$519$$$528$$$O	inhibited$$$529$$$538$$$O	and$$$539$$$542$$$O	such$$$543$$$547$$$O	a$$$548$$$549$$$O	phenomenon$$$550$$$560$$$O	is$$$561$$$563$$$O	increasingly$$$564$$$576$$$O	obvious$$$577$$$584$$$O	as$$$585$$$587$$$O	time$$$588$$$592$$$O	goes$$$593$$$597$$$O	on.$$$598$$$601$$$O	The$$$602$$$605$$$O	nucleotide$$$606$$$616$$$I	molecule$$$617$$$625$$$O	NRN1SR3$$$626$$$633$$$I	for$$$634$$$637$$$O	making$$$638$$$644$$$O	the$$$645$$$648$$$O	antitumor$$$649$$$658$$$O	drug$$$659$$$663$$$O	provides$$$664$$$672$$$O	a$$$673$$$674$$$O	new$$$675$$$678$$$O	way$$$679$$$682$$$O	and$$$683$$$686$$$O	a$$$687$$$688$$$O	new$$$689$$$692$$$O	means$$$693$$$698$$$O	for$$$699$$$702$$$O	the$$$703$$$706$$$O	treatment$$$707$$$716$$$O	and$$$717$$$720$$$O	release$$$721$$$728$$$O	of$$$729$$$731$$$O	the$$$732$$$735$$$O	tumor.$$$736$$$742$$$O
US6953595
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	apoptosis$$$14$$$23$$$O	of$$$24$$$26$$$O	nerve$$$27$$$32$$$O	cells$$$33$$$38$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	refers$$$15$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	preparation$$$29$$$40$$$O	for$$$41$$$44$$$O	elimination$$$45$$$56$$$O	of$$$57$$$59$$$O	neuropathies$$$60$$$72$$$O	in$$$73$$$75$$$O	diabetes.$$$76$$$85$$$O	The$$$86$$$89$$$O	preparation$$$90$$$101$$$O	contains$$$102$$$110$$$O	a$$$111$$$112$$$O	combination$$$113$$$124$$$O	of$$$125$$$127$$$O	minerals$$$128$$$136$$$O	and$$$137$$$140$$$O	plant$$$141$$$146$$$O	extracts.$$$147$$$156$$$O	By$$$157$$$159$$$O	its$$$160$$$163$$$O	ionic$$$164$$$169$$$O	exchange,$$$170$$$179$$$O	the$$$180$$$183$$$O	invention$$$184$$$193$$$O	reduces$$$194$$$201$$$O	considerably$$$202$$$214$$$O	the$$$215$$$218$$$O	process$$$219$$$226$$$O	of$$$227$$$229$$$O	apoptosis$$$230$$$239$$$O	of$$$240$$$242$$$O	nerve-cells,$$$243$$$255$$$O	eliminates$$$256$$$266$$$O	the$$$267$$$270$$$O	process$$$271$$$278$$$O	of$$$279$$$281$$$O	activation$$$282$$$292$$$O	of$$$293$$$295$$$O	the$$$296$$$299$$$O	immunologic$$$300$$$311$$$O	system,$$$312$$$319$$$O	and$$$320$$$323$$$O	stops$$$324$$$329$$$O	the$$$330$$$333$$$O	immunologic$$$334$$$345$$$O	reaction$$$346$$$354$$$O	of$$$355$$$357$$$O	auto-destruction$$$358$$$374$$$O	of$$$375$$$377$$$O	nerve-cells.$$$378$$$390$$$O	Depositing$$$391$$$401$$$O	of$$$402$$$404$$$O	immunoglobulin$$$405$$$419$$$O	on$$$420$$$422$$$O	axons$$$423$$$428$$$O	is$$$429$$$431$$$O	absent,$$$432$$$439$$$O	and$$$440$$$443$$$O	neuropathic$$$444$$$455$$$O	pain$$$456$$$460$$$O	disappears.$$$461$$$472$$$O	Furthermore,$$$473$$$485$$$O	the$$$486$$$489$$$O	preparation$$$490$$$501$$$O	reduces$$$502$$$509$$$O	the$$$510$$$513$$$O	activity$$$514$$$522$$$O	of$$$523$$$525$$$O	free$$$526$$$530$$$O	radicals,$$$531$$$540$$$O	improves$$$541$$$549$$$O	the$$$550$$$553$$$O	regulation$$$554$$$564$$$O	of$$$565$$$567$$$O	glycemia$$$568$$$576$$$O	and$$$577$$$580$$$O	improves$$$581$$$589$$$O	the$$$590$$$593$$$O	recovery$$$594$$$602$$$O	of$$$603$$$605$$$O	axons$$$606$$$611$$$O	which$$$612$$$617$$$O	are$$$618$$$621$$$O	already$$$622$$$629$$$O	damaged.$$$630$$$638$$$O
WO2012050370A3
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	preventing$$$16$$$26$$$O	or$$$27$$$29$$$O	treating$$$30$$$38$$$O	rheumatoid$$$39$$$49$$$O	arthritis$$$50$$$59$$$O	containing$$$60$$$70$$$O	a$$$71$$$72$$$O	gamma$$$73$$$78$$$O	secretase$$$79$$$88$$$O	inhibitor$$$89$$$98$$$O	as$$$99$$$101$$$O	an$$$102$$$104$$$O	active$$$105$$$111$$$O	ingredient$$$112$$$122$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	composition$$$35$$$46$$$O	for$$$47$$$50$$$O	preventing$$$51$$$61$$$O	or$$$62$$$64$$$O	treating$$$65$$$73$$$O	rheumatoid$$$74$$$84$$$O	arthritis$$$85$$$94$$$O	containing$$$95$$$105$$$O	a$$$106$$$107$$$O	gamma$$$108$$$113$$$O	secretase$$$114$$$123$$$O	inhibitor$$$124$$$133$$$O	as$$$134$$$136$$$O	an$$$137$$$139$$$O	active$$$140$$$146$$$O	ingredient.$$$147$$$158$$$O	The$$$159$$$162$$$O	gamma$$$163$$$168$$$O	secretase$$$169$$$178$$$O	inhibitor$$$179$$$188$$$O	according$$$189$$$198$$$O	to$$$199$$$201$$$O	the$$$202$$$205$$$O	present$$$206$$$213$$$O	invention$$$214$$$223$$$O	reduces$$$224$$$231$$$O	the$$$232$$$235$$$O	extent$$$236$$$242$$$O	of$$$243$$$245$$$O	arthritis$$$246$$$255$$$O	induction$$$256$$$265$$$O	and$$$266$$$269$$$O	reduces$$$270$$$277$$$O	the$$$278$$$281$$$O	inflow$$$282$$$288$$$O	of$$$289$$$291$$$O	inflammatory$$$292$$$304$$$O	cells$$$305$$$310$$$O	into$$$311$$$315$$$O	the$$$316$$$319$$$O	knee$$$320$$$324$$$O	joint,$$$325$$$331$$$O	in$$$332$$$334$$$O	a$$$335$$$336$$$O	dose-dependent$$$337$$$351$$$O	fashion,$$$352$$$360$$$O	and$$$361$$$364$$$O	also$$$365$$$369$$$O	reduces$$$370$$$377$$$O	the$$$378$$$381$$$O	amount$$$382$$$388$$$O	of$$$389$$$391$$$O	cytokines$$$392$$$401$$$O	and$$$402$$$405$$$O	chemokines,$$$406$$$417$$$O	and$$$418$$$421$$$O	reduces$$$422$$$429$$$O	the$$$430$$$433$$$O	amount$$$434$$$440$$$O	of$$$441$$$443$$$O	expression$$$444$$$454$$$O	of$$$455$$$457$$$O	NICD$$$458$$$462$$$O	(notch$$$463$$$469$$$O	intracellular$$$470$$$483$$$O	domain).$$$484$$$492$$$O	Consequently,$$$493$$$506$$$O	the$$$507$$$510$$$O	gamma$$$511$$$516$$$O	secretase$$$517$$$526$$$O	inhibitor$$$527$$$536$$$O	according$$$537$$$546$$$O	to$$$547$$$549$$$O	the$$$550$$$553$$$O	present$$$554$$$561$$$O	invention$$$562$$$571$$$O	can$$$572$$$575$$$O	be$$$576$$$578$$$O	used$$$579$$$583$$$O	as$$$584$$$586$$$O	a$$$587$$$588$$$O	medicinal$$$589$$$598$$$O	product$$$599$$$606$$$O	and$$$607$$$610$$$O	a$$$611$$$612$$$O	functional$$$613$$$623$$$O	health$$$624$$$630$$$O	food$$$631$$$635$$$O	which$$$636$$$641$$$O	is$$$642$$$644$$$O	useful$$$645$$$651$$$O	in$$$652$$$654$$$O	the$$$655$$$658$$$O	prevention$$$659$$$669$$$O	or$$$670$$$672$$$O	treatment$$$673$$$682$$$O	of$$$683$$$685$$$O	rheumatoid$$$686$$$696$$$O	arthritis,$$$697$$$707$$$O	since$$$708$$$713$$$O	it$$$714$$$716$$$O	regulates$$$717$$$726$$$O	the$$$727$$$730$$$O	activation,$$$731$$$742$$$O	differentiation$$$743$$$758$$$O	and$$$759$$$762$$$O	growth$$$763$$$769$$$O	of$$$770$$$772$$$O	immune$$$773$$$779$$$O	cells$$$780$$$785$$$O	and$$$786$$$789$$$O	hence$$$790$$$795$$$O	has$$$796$$$799$$$O	an$$$800$$$802$$$O	outstanding$$$803$$$814$$$O	effect$$$815$$$821$$$O	in$$$822$$$824$$$O	suppressing$$$825$$$836$$$O	the$$$837$$$840$$$O	production$$$841$$$851$$$O	of$$$852$$$854$$$O	NICD$$$855$$$859$$$O	which$$$860$$$865$$$O	plays$$$866$$$871$$$O	a$$$872$$$873$$$O	highly$$$874$$$880$$$O	important$$$881$$$890$$$O	role$$$891$$$895$$$O	in$$$896$$$898$$$O	notch$$$899$$$904$$$O	signal$$$905$$$911$$$O	transmission$$$912$$$924$$$O	whereby$$$925$$$932$$$O	inflammatory$$$933$$$945$$$O	reactions$$$946$$$955$$$O	occur.$$$956$$$962$$$O
US20110281935
Combination$$$0$$$11$$$O	Therapy$$$12$$$19$$$O	Based$$$20$$$25$$$O	on$$$26$$$28$$$O	SRC$$$29$$$32$$$O	and$$$33$$$36$$$O	Aurora$$$37$$$43$$$O	Kinase$$$44$$$50$$$O	Inhibition$$$51$$$61$$$O	for$$$62$$$65$$$O	the$$$66$$$69$$$O	Treatment$$$70$$$79$$$O	of$$$80$$$82$$$O	Cancer$$$83$$$89$$$O
Compositions$$$0$$$12$$$O	which$$$13$$$18$$$O	act$$$19$$$22$$$O	synergistically$$$23$$$38$$$O	to$$$39$$$41$$$O	inhibit$$$42$$$49$$$O	the$$$50$$$53$$$O	growth$$$54$$$60$$$O	of$$$61$$$63$$$O	cancer$$$64$$$70$$$O	cells$$$71$$$76$$$O	and$$$77$$$80$$$O	methods$$$81$$$88$$$O	of$$$89$$$91$$$O	use$$$92$$$95$$$O	thereof$$$96$$$103$$$O	are$$$104$$$107$$$O	disclosed.$$$108$$$118$$$O
CN103446081A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	Scopariusins$$$15$$$27$$$I	in$$$28$$$30$$$O	preparation$$$31$$$42$$$O	of$$$43$$$45$$$O	anti-hypoxic$$$46$$$58$$$O	drug$$$59$$$63$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	Scopariusins$$$39$$$51$$$I	in$$$52$$$54$$$O	preparation$$$55$$$66$$$O	of$$$67$$$69$$$O	an$$$70$$$72$$$O	anti-hypoxic$$$73$$$85$$$O	drug.$$$86$$$91$$$O	The$$$92$$$95$$$O	anti-hypoxic$$$96$$$108$$$O	effect$$$109$$$115$$$O	of$$$116$$$118$$$O	the$$$119$$$122$$$O	Scopariusins$$$123$$$135$$$I	is$$$136$$$138$$$O	observed$$$139$$$147$$$O	through$$$148$$$155$$$O	a$$$156$$$157$$$O	whole$$$158$$$163$$$O	ad$$$164$$$166$$$O	a$$$167$$$168$$$O	cellular$$$169$$$177$$$O	level$$$178$$$183$$$O	hypoxia$$$184$$$191$$$O	model,$$$192$$$198$$$O	and$$$199$$$202$$$O	a$$$203$$$204$$$O	result$$$205$$$211$$$O	shows$$$212$$$217$$$O	that$$$218$$$222$$$O	the$$$223$$$226$$$O	Scopariusins$$$227$$$239$$$I	can$$$240$$$243$$$O	remarkably$$$244$$$254$$$O	improve$$$255$$$262$$$O	the$$$263$$$266$$$O	survival$$$267$$$275$$$O	rate$$$276$$$280$$$O	and$$$281$$$284$$$O	survival$$$285$$$293$$$O	time$$$294$$$298$$$O	of$$$299$$$301$$$O	asphyxiant$$$302$$$312$$$O	hypoxa$$$313$$$319$$$O	and$$$320$$$323$$$O	acute$$$324$$$329$$$O	decompression$$$330$$$343$$$O	hypoxia$$$344$$$351$$$O	rats,$$$352$$$357$$$O	reduce$$$358$$$364$$$O	myocardial$$$365$$$375$$$O	damage$$$376$$$382$$$O	caused$$$383$$$389$$$O	by$$$390$$$392$$$O	drug$$$393$$$397$$$O	specificity$$$398$$$409$$$O	to$$$410$$$412$$$O	the$$$413$$$416$$$O	rats,$$$417$$$422$$$O	also$$$423$$$427$$$O	has$$$428$$$431$$$O	remarkable$$$432$$$442$$$O	protecting$$$443$$$453$$$O	effect$$$454$$$460$$$O	on$$$461$$$463$$$O	cardiac$$$464$$$471$$$O	myocytes$$$472$$$480$$$O	and$$$481$$$484$$$O	nerve$$$485$$$490$$$O	cell$$$491$$$495$$$O	hypoxia$$$496$$$503$$$O	damage$$$504$$$510$$$O	of$$$511$$$513$$$O	in-vitro$$$514$$$522$$$O	cultured$$$523$$$531$$$O	neonatal$$$532$$$540$$$O	rats$$$541$$$545$$$O	and$$$546$$$549$$$O	is$$$550$$$552$$$O	applied$$$553$$$560$$$O	to$$$561$$$563$$$O	the$$$564$$$567$$$O	preparation$$$568$$$579$$$O	of$$$580$$$582$$$O	the$$$583$$$586$$$O	anti-hypoxic$$$587$$$599$$$O	drug.$$$600$$$605$$$O
WO2012007632A9
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	edg2$$$7$$$11$$$O	inhibitors$$$12$$$22$$$O	for$$$23$$$26$$$O	treating$$$27$$$35$$$O	rheumatoid$$$36$$$46$$$O	arthritis$$$47$$$56$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	novel$$$37$$$42$$$O	use$$$43$$$46$$$O	of$$$47$$$49$$$O	EDG2$$$50$$$54$$$O	inhibitors$$$55$$$65$$$O	for$$$66$$$69$$$O	treating$$$70$$$78$$$O	rheumatoid$$$79$$$89$$$O	arthritis,$$$90$$$100$$$O	particularly$$$101$$$113$$$O	in$$$114$$$116$$$O	those$$$117$$$122$$$O	patients$$$123$$$131$$$O	exhibiting$$$132$$$142$$$O	elevated$$$143$$$151$$$O	levels$$$152$$$158$$$O	of$$$159$$$161$$$O	pro-inflammatory$$$162$$$178$$$O	molecules$$$179$$$188$$$O	despite$$$189$$$196$$$O	having$$$197$$$203$$$O	been$$$204$$$208$$$O	treated$$$209$$$216$$$O	with$$$217$$$221$$$O	anti-inflammatories,$$$222$$$242$$$O	i.e.$$$243$$$247$$$O	patients$$$248$$$256$$$O	not$$$257$$$260$$$O	responding$$$261$$$271$$$O	to$$$272$$$274$$$O	said$$$275$$$279$$$O	treatments.$$$280$$$291$$$O
US7161009
Antiinflammatory$$$0$$$16$$$O	agents;$$$17$$$24$$$O	skin$$$25$$$29$$$O	disorders;$$$30$$$40$$$O	central$$$41$$$48$$$O	nervous$$$49$$$56$$$O	system$$$57$$$63$$$O	disorders$$$64$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	new$$$25$$$28$$$O	hydroxyindoles$$$29$$$43$$$I	of$$$44$$$46$$$O	the$$$47$$$50$$$O	Formula,$$$51$$$59$$$O	their$$$79$$$84$$$O	use$$$85$$$88$$$O	as$$$89$$$91$$$O	inhibitors$$$92$$$102$$$O	of$$$103$$$105$$$O	phosphodiesterase$$$106$$$123$$$O	4$$$124$$$125$$$O	and$$$126$$$129$$$O	processes$$$130$$$139$$$O	for$$$140$$$143$$$O	their$$$144$$$149$$$O	preparation.$$$150$$$162$$$O
US20070232636
schizophrenia,$$$0$$$14$$$O	emesis,$$$15$$$22$$$O	anxiety$$$23$$$30$$$O	and$$$31$$$34$$$O	depression,$$$35$$$46$$$O	irritable$$$47$$$56$$$O	bowel$$$57$$$62$$$O	syndrome$$$63$$$71$$$O	(IBS),$$$72$$$78$$$O	circadian$$$79$$$88$$$O	rhythm$$$89$$$95$$$O	disturbances,$$$96$$$109$$$O	pre-eclampsia,$$$110$$$124$$$O	nociception,$$$125$$$137$$$O	visceral$$$138$$$146$$$O	and$$$147$$$150$$$O	neuropathic$$$151$$$162$$$O	pain,$$$163$$$168$$$O	pancreatitis,$$$169$$$182$$$O	neurogenic$$$183$$$193$$$O	inflammation,$$$194$$$207$$$O	asthma,$$$208$$$215$$$O	COPD$$$216$$$220$$$O	and$$$221$$$224$$$O	micturition$$$225$$$236$$$O	disorders$$$237$$$246$$$O	such$$$247$$$251$$$O	as$$$252$$$254$$$O	urinary$$$255$$$262$$$O	incontinence$$$263$$$275$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	concerns$$$15$$$23$$$O	substituted$$$24$$$35$$$O	diaza-spiro-[5.5]-undecane$$$36$$$62$$$I	derivatives$$$63$$$74$$$O	having$$$75$$$81$$$O	neurokinin$$$82$$$92$$$I	antagonistic$$$93$$$105$$$O	activity,$$$106$$$115$$$O	in$$$116$$$118$$$O	particular$$$119$$$129$$$O	NK1$$$130$$$133$$$O	antagonistic$$$134$$$146$$$O	activity,$$$147$$$156$$$O	a$$$157$$$158$$$O	combined$$$159$$$167$$$O	NK1/NK2$$$168$$$175$$$O	antagonistic$$$176$$$188$$$O	activity,$$$189$$$198$$$O	a$$$199$$$200$$$O	combined$$$201$$$209$$$O	NK1/NK3$$$210$$$217$$$O	antagonistic$$$218$$$230$$$O	activity$$$231$$$239$$$O	and$$$240$$$243$$$O	a$$$244$$$245$$$O	combined$$$246$$$254$$$O	NK1/NK2/NK3$$$255$$$266$$$O	antagonistic$$$267$$$279$$$O	activity,$$$280$$$289$$$O	their$$$290$$$295$$$O	preparation,$$$296$$$308$$$O	compositions$$$309$$$321$$$O	comprising$$$322$$$332$$$O	them$$$333$$$337$$$O	and$$$338$$$341$$$O	their$$$342$$$347$$$O	use$$$348$$$351$$$O	as$$$352$$$354$$$O	a$$$355$$$356$$$O	medicine,$$$357$$$366$$$O	in$$$367$$$369$$$O	particular$$$370$$$380$$$O	for$$$381$$$384$$$O	the$$$385$$$388$$$O	treatment$$$389$$$398$$$O	and/or$$$399$$$405$$$O	prophylaxis$$$406$$$417$$$O	of$$$418$$$420$$$O	schizophrenia,$$$421$$$435$$$O	emesis,$$$436$$$443$$$O	anxiety$$$444$$$451$$$O	and$$$452$$$455$$$O	depression,$$$456$$$467$$$O	irritable$$$468$$$477$$$O	bowel$$$478$$$483$$$O	syndrome$$$484$$$492$$$O	(IBS),$$$493$$$499$$$O	circadian$$$500$$$509$$$O	rhythm$$$510$$$516$$$O	disturbances,$$$517$$$530$$$O	pre-eclampsia,$$$531$$$545$$$O	nociception,$$$546$$$558$$$O	pain,$$$559$$$564$$$O	in$$$565$$$567$$$O	particular$$$568$$$578$$$O	visceral$$$579$$$587$$$O	and$$$588$$$591$$$O	neuropathic$$$592$$$603$$$O	pain,$$$604$$$609$$$O	pancreatitis,$$$610$$$623$$$O	neurogenic$$$624$$$634$$$O	inflammation,$$$635$$$648$$$O	asthma,$$$649$$$656$$$O	COPD$$$657$$$661$$$O	and$$$662$$$665$$$O	micturition$$$666$$$677$$$O	disorders$$$678$$$687$$$O	such$$$688$$$692$$$O	as$$$693$$$695$$$O	urinary$$$696$$$703$$$O	incontinence.$$$704$$$717$$$O	The$$$720$$$723$$$O	compounds$$$724$$$733$$$O	according$$$734$$$743$$$O	to$$$744$$$746$$$O	the$$$747$$$750$$$O	invention$$$751$$$760$$$O	can$$$761$$$764$$$O	be$$$765$$$767$$$O	represented$$$768$$$779$$$O	by$$$780$$$782$$$O	general$$$783$$$790$$$O	Formula$$$791$$$798$$$O	(I)$$$799$$$802$$$O	and$$$818$$$821$$$O	comprises$$$822$$$831$$$O	also$$$832$$$836$$$O	the$$$837$$$840$$$O	pharmaceutically$$$841$$$857$$$O	acceptable$$$858$$$868$$$O	acid$$$869$$$873$$$O	or$$$874$$$876$$$O	base$$$877$$$881$$$O	addition$$$882$$$890$$$O	salts$$$891$$$896$$$O	thereof,$$$897$$$905$$$O	the$$$906$$$909$$$O	stereochemically$$$910$$$926$$$O	isomeric$$$927$$$935$$$O	forms$$$936$$$941$$$O	thereof,$$$942$$$950$$$O	the$$$951$$$954$$$O	N-oxide$$$955$$$962$$$I	form$$$963$$$967$$$O	thereof$$$968$$$975$$$O	and$$$976$$$979$$$O	prodrugs$$$980$$$988$$$O	thereof,$$$989$$$997$$$O	wherein$$$998$$$1005$$$O	all$$$1006$$$1009$$$O	substituents$$$1010$$$1022$$$O	are$$$1023$$$1026$$$O	defined$$$1027$$$1034$$$O	as$$$1035$$$1037$$$O	in$$$1038$$$1040$$$O	Claim$$$1041$$$1046$$$O	1.$$$1047$$$1049$$$O
US7598294
Antiproliferative$$$0$$$17$$$O	agents;$$$18$$$25$$$O	antiinflammatory$$$26$$$42$$$O	agents;$$$43$$$50$$$O	anticancer$$$51$$$61$$$O	agents;$$$62$$$69$$$O	diagnosis,$$$70$$$80$$$O	therapy$$$81$$$88$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	pertains$$$22$$$30$$$O	to$$$31$$$33$$$O	the$$$34$$$37$$$O	use$$$38$$$41$$$O	of$$$42$$$44$$$O	a$$$45$$$46$$$O	compounds$$$47$$$56$$$O	for$$$57$$$60$$$O	the$$$61$$$64$$$O	manufacture$$$65$$$76$$$O	of$$$77$$$79$$$O	a$$$80$$$81$$$O	medicament$$$82$$$92$$$O	for$$$93$$$96$$$O	use$$$97$$$100$$$O	in$$$101$$$103$$$O	the$$$104$$$107$$$O	treatment$$$108$$$117$$$O	of$$$118$$$120$$$O	a$$$121$$$122$$$O	proliferative$$$123$$$136$$$O	condition,$$$137$$$147$$$O	wherein$$$148$$$155$$$O	the$$$156$$$159$$$O	compounds$$$160$$$169$$$O	have$$$170$$$174$$$O	the$$$175$$$178$$$O	following$$$179$$$188$$$O	formula:$$$189$$$197$$$O	wherein:$$$217$$$225$$$O	each$$$226$$$230$$$O	of$$$231$$$233$$$O	RB2,$$$234$$$238$$$O	RB3,$$$239$$$243$$$O	RB4,$$$244$$$248$$$O	and$$$249$$$252$$$O	RB5$$$253$$$256$$$O	is$$$257$$$259$$$O	independently$$$260$$$273$$$O	âH,$$$274$$$279$$$I	âOH,$$$280$$$286$$$I	or$$$287$$$289$$$I	âOMe;$$$290$$$297$$$I	each$$$298$$$302$$$O	of$$$303$$$305$$$O	R1$$$306$$$308$$$O	and$$$309$$$312$$$O	R2$$$313$$$315$$$O	is$$$316$$$318$$$O	independently:$$$319$$$333$$$I	âH,$$$334$$$339$$$O	optionally$$$340$$$350$$$O	substituted$$$351$$$362$$$I	C1-4alkyl,$$$363$$$373$$$I	or$$$374$$$376$$$O	optionally$$$377$$$387$$$O	substituted$$$388$$$399$$$I	C5-20aryl;$$$400$$$410$$$I	RA3$$$411$$$414$$$I	is$$$415$$$417$$$I	âH,$$$418$$$423$$$I	âOH,$$$424$$$430$$$I	âOC(âO)RE,$$$431$$$445$$$I	âOS(âO)2OH,$$$446$$$461$$$I	or$$$462$$$464$$$O	âOP(âO)(OH)2;$$$465$$$482$$$I	RE$$$483$$$485$$$O	is:$$$486$$$489$$$O	âH,$$$490$$$495$$$I	optionally$$$496$$$506$$$I	substituted$$$507$$$518$$$O	C1-6alkyl,$$$519$$$529$$$I	optionally$$$530$$$540$$$I	substituted$$$541$$$552$$$I	C3-20$$$553$$$558$$$O	heterocyclyl,$$$559$$$572$$$O	or$$$573$$$575$$$I	optionally$$$576$$$586$$$I	substituted$$$587$$$598$$$O	C5-20aryl;$$$599$$$609$$$O	or$$$610$$$612$$$O	a$$$613$$$614$$$O	pharmaceutically$$$615$$$631$$$O	acceptable$$$632$$$642$$$I	salt,$$$643$$$648$$$I	solvate,$$$649$$$657$$$I	amide,$$$658$$$664$$$O	ester,$$$665$$$671$$$O	ether,$$$672$$$678$$$O	chemically$$$679$$$689$$$O	protected$$$690$$$699$$$O	form,$$$700$$$705$$$O	or$$$706$$$708$$$O	prodrug$$$709$$$716$$$O	thereof.$$$717$$$725$$$O	The$$$726$$$729$$$O	present$$$730$$$737$$$O	invention$$$738$$$747$$$O	also$$$748$$$752$$$O	pertains$$$753$$$761$$$O	to$$$762$$$764$$$O	such$$$765$$$769$$$O	compounds,$$$770$$$780$$$O	pharmaceutical$$$781$$$795$$$O	compositions$$$796$$$808$$$O	comprising$$$809$$$819$$$O	such$$$820$$$824$$$O	compounds,$$$825$$$835$$$O	and$$$836$$$839$$$O	the$$$840$$$843$$$O	use$$$844$$$847$$$O	of$$$848$$$850$$$O	such$$$851$$$855$$$O	compounds$$$856$$$865$$$O	and$$$866$$$869$$$O	compositions,$$$870$$$883$$$O	both$$$884$$$888$$$O	in$$$889$$$891$$$O	vitro$$$892$$$897$$$O	and$$$898$$$901$$$O	in$$$902$$$904$$$O	vivo,$$$905$$$910$$$O	for$$$911$$$914$$$O	both$$$915$$$919$$$O	diagnosis$$$920$$$929$$$O	and$$$930$$$933$$$O	treatment$$$934$$$943$$$O	of,$$$944$$$947$$$O	for$$$948$$$951$$$O	example,$$$952$$$960$$$O	proliferative$$$961$$$974$$$O	conditions,$$$975$$$986$$$O	such$$$987$$$991$$$O	as$$$992$$$994$$$O	cancer,$$$995$$$1002$$$O	and$$$1003$$$1006$$$O	inflammatory$$$1007$$$1019$$$O	conditions.$$$1020$$$1031$$$O
WO2009066138A2
Stabilization$$$0$$$13$$$O	of$$$14$$$16$$$O	vitamin$$$17$$$24$$$I	b$$$25$$$26$$$I	complex$$$27$$$34$$$O	and$$$35$$$38$$$O	lidocaine$$$39$$$48$$$I	hydrochloride$$$49$$$62$$$I	injection$$$63$$$72$$$O
The$$$0$$$3$$$O	Present$$$4$$$11$$$O	Invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	stable$$$33$$$39$$$O	parenteral$$$40$$$50$$$O	composition$$$51$$$62$$$O	of$$$63$$$65$$$O	Vitamin$$$66$$$73$$$I	B$$$74$$$75$$$I	Complex$$$76$$$83$$$O	&$$$84$$$85$$$O	Lidocaine$$$86$$$95$$$I	Hydrochloride$$$96$$$109$$$I	which$$$110$$$115$$$O	is$$$116$$$118$$$O	stabilized$$$119$$$129$$$O	by$$$130$$$132$$$O	synergistic$$$133$$$144$$$O	combination$$$145$$$156$$$O	of$$$157$$$159$$$O	stabilizers$$$160$$$171$$$O	such$$$172$$$176$$$O	as$$$177$$$179$$$O	DL-malic$$$180$$$188$$$I	acid,$$$189$$$194$$$I	Disodium$$$195$$$203$$$I	Edetate$$$204$$$211$$$I	and$$$212$$$215$$$O	Potassium$$$216$$$225$$$I	Hexacyanoferrate$$$226$$$242$$$I	III$$$243$$$246$$$I	and$$$247$$$250$$$O	process$$$251$$$258$$$O	thereof.$$$259$$$267$$$O
CN101293876A
Benzoxazole$$$0$$$11$$$I	ketones$$$12$$$19$$$I	derivative$$$20$$$30$$$O	and$$$31$$$34$$$O	preparation$$$35$$$46$$$O	method$$$47$$$53$$$O	thereof$$$54$$$61$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	series$$$27$$$33$$$O	of$$$34$$$36$$$O	novel$$$37$$$42$$$O	compounds$$$43$$$52$$$O	and$$$53$$$56$$$O	a$$$57$$$58$$$O	preparation$$$59$$$70$$$O	method$$$71$$$77$$$O	thereof,$$$78$$$86$$$O	particularly$$$87$$$99$$$O	to$$$100$$$102$$$O	a$$$103$$$104$$$O	series$$$105$$$111$$$O	of$$$112$$$114$$$O	benzoxazolone$$$115$$$128$$$I	derivatives$$$129$$$140$$$O	and$$$141$$$144$$$O	a$$$145$$$146$$$O	preparation$$$147$$$158$$$O	method$$$159$$$165$$$O	thereof,$$$166$$$174$$$O	and$$$175$$$178$$$O	solves$$$179$$$185$$$O	the$$$186$$$189$$$O	problem$$$190$$$197$$$O	that$$$198$$$202$$$O	the$$$203$$$206$$$O	prior$$$207$$$212$$$O	benzoxazolone$$$213$$$226$$$I	compounds$$$227$$$236$$$O	have$$$237$$$241$$$O	no$$$242$$$244$$$O	4-substituted$$$245$$$258$$$O	derivatives$$$259$$$270$$$O	and$$$271$$$274$$$O	have$$$275$$$279$$$O	anti-HBV$$$280$$$288$$$O	activity$$$289$$$297$$$O	and$$$298$$$301$$$O	anti-HIV$$$302$$$310$$$O	activity.$$$311$$$320$$$O	The$$$321$$$324$$$O	general$$$325$$$332$$$O	structural$$$333$$$343$$$O	formula$$$344$$$351$$$O	of$$$352$$$354$$$O	the$$$355$$$358$$$O	derivatives$$$359$$$370$$$O	is$$$371$$$373$$$O	shown$$$374$$$379$$$O	in$$$380$$$382$$$O	the$$$383$$$386$$$O	figure,$$$387$$$394$$$O	wherein$$$395$$$402$$$O	R$$$403$$$404$$$O	is$$$405$$$407$$$O	C3-C6$$$408$$$413$$$O	fatty$$$414$$$419$$$I	acid$$$420$$$424$$$I	ester$$$425$$$430$$$I	group,$$$431$$$437$$$O	benzoate$$$438$$$446$$$I	group/substituted$$$447$$$464$$$O	benzoate$$$465$$$473$$$I	group,$$$474$$$480$$$O	benzene$$$481$$$488$$$I	sulfonate$$$489$$$498$$$I	group/substituted$$$499$$$516$$$O	benzene$$$517$$$524$$$I	sulfonate$$$525$$$534$$$I	group,$$$535$$$541$$$O	amino$$$542$$$547$$$I	acid$$$548$$$552$$$I	ester$$$553$$$558$$$I	group,$$$559$$$565$$$O	or$$$566$$$568$$$O	heterocyclic$$$569$$$581$$$I	acid$$$582$$$586$$$I	ester$$$587$$$592$$$I	group/substituted$$$593$$$610$$$O	heterocyclic$$$611$$$623$$$I	acid$$$624$$$628$$$I	ester$$$629$$$634$$$I	group.$$$635$$$641$$$O	The$$$642$$$645$$$O	invention$$$646$$$655$$$O	obtains$$$656$$$663$$$O	a$$$664$$$665$$$O	series$$$666$$$672$$$O	of$$$673$$$675$$$O	4-substituted$$$676$$$689$$$O	benzoxazolone$$$690$$$703$$$I	derivatives$$$704$$$715$$$O	with$$$716$$$720$$$O	proven$$$721$$$727$$$O	anti-HBV$$$728$$$736$$$O	activity$$$737$$$745$$$O	and$$$746$$$749$$$O	anti-HIV$$$750$$$758$$$O	activity,$$$759$$$768$$$O	opens$$$769$$$774$$$O	new$$$775$$$778$$$O	preparation$$$779$$$790$$$O	paths$$$791$$$796$$$O	of$$$797$$$799$$$O	the$$$800$$$803$$$O	above$$$804$$$809$$$O	three$$$810$$$815$$$O	drugs,$$$816$$$822$$$O	and$$$823$$$826$$$O	brings$$$827$$$833$$$O	new$$$834$$$837$$$O	breakthrough$$$838$$$850$$$O	in$$$851$$$853$$$O	pharmaceutical$$$854$$$868$$$O	and$$$869$$$872$$$O	pesticide$$$873$$$882$$$O	fields.$$$883$$$890$$$O	In$$$891$$$893$$$O	addition,$$$894$$$903$$$O	the$$$904$$$907$$$O	synthetic$$$908$$$917$$$O	method$$$918$$$924$$$O	has$$$925$$$928$$$O	the$$$929$$$932$$$O	advantages$$$933$$$943$$$O	of$$$944$$$946$$$O	easy$$$947$$$951$$$O	operation,$$$952$$$962$$$O	mild$$$963$$$967$$$O	reaction$$$968$$$976$$$O	conditions,$$$977$$$988$$$O	single$$$989$$$995$$$O	reaction$$$996$$$1004$$$O	product,$$$1005$$$1013$$$O	and$$$1014$$$1017$$$O	applicability$$$1018$$$1031$$$O	to$$$1032$$$1034$$$O	large$$$1035$$$1040$$$O	scale$$$1041$$$1046$$$O	production.$$$1047$$$1058$$$O
US7294720
N3-(hydroxy-$$$0$$$12$$$I	or$$$13$$$15$$$I	alkoxyphenyl)$$$16$$$29$$$I	amidrazone,$$$30$$$41$$$I	e.g.,$$$42$$$47$$$O	N3-[3-Methoxyphenyl]-p-tert-butyl-benzamidrazone,$$$48$$$97$$$I	are$$$98$$$101$$$O	intermediates$$$102$$$115$$$O	for$$$116$$$119$$$O	preparing$$$120$$$129$$$O	phenyl-1,2,4-triazoles,$$$130$$$153$$$I	e.g.,$$$154$$$159$$$O	1-{3-[4-(tert-Butyl)phenyl]-(1,2,4-triazol-4-yl)}-3-methoxybenzene$$$160$$$226$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds$$$23$$$32$$$O	of$$$33$$$35$$$O	formula$$$36$$$43$$$O	I:$$$44$$$46$$$O	wherein$$$66$$$73$$$O	R1$$$74$$$76$$$O	to$$$77$$$79$$$O	R4$$$80$$$82$$$O	and$$$83$$$86$$$O	n$$$87$$$88$$$O	have$$$89$$$93$$$O	any$$$94$$$97$$$O	of$$$98$$$100$$$O	the$$$101$$$104$$$O	meanings$$$105$$$113$$$O	defined$$$114$$$121$$$O	in$$$122$$$124$$$O	the$$$125$$$128$$$O	specification$$$129$$$142$$$O	and$$$143$$$146$$$O	their$$$147$$$152$$$O	pharmaceutically$$$153$$$169$$$O	acceptable$$$170$$$180$$$O	salts.$$$181$$$187$$$O	The$$$188$$$191$$$O	invention$$$192$$$201$$$O	also$$$202$$$206$$$O	provides$$$207$$$215$$$O	pharmaceutical$$$216$$$230$$$O	compositions$$$231$$$243$$$O	comprising$$$244$$$254$$$O	a$$$255$$$256$$$O	compound$$$257$$$265$$$O	of$$$266$$$268$$$O	formula$$$269$$$276$$$O	I,$$$277$$$279$$$O	processes$$$280$$$289$$$O	for$$$290$$$293$$$O	preparing$$$294$$$303$$$O	compounds$$$304$$$313$$$O	of$$$314$$$316$$$O	formula$$$317$$$324$$$O	I,$$$325$$$327$$$O	intermediates$$$328$$$341$$$O	useful$$$342$$$348$$$O	for$$$349$$$352$$$O	preparing$$$353$$$362$$$O	compounds$$$363$$$372$$$O	of$$$373$$$375$$$O	formula$$$376$$$383$$$O	I,$$$384$$$386$$$O	and$$$387$$$390$$$O	therapeutic$$$391$$$402$$$O	methods$$$403$$$410$$$O	for$$$411$$$414$$$O	treating$$$415$$$423$$$O	pain$$$424$$$428$$$O	and$$$429$$$432$$$O	treating$$$433$$$441$$$O	other$$$442$$$447$$$O	conditions$$$448$$$458$$$O	which$$$459$$$464$$$O	involve,$$$465$$$473$$$O	for$$$474$$$477$$$O	example,$$$478$$$486$$$O	binding$$$487$$$494$$$O	opioid$$$495$$$501$$$O	receptors$$$502$$$511$$$O	using$$$512$$$517$$$O	compounds$$$518$$$527$$$O	of$$$528$$$530$$$O	formula$$$531$$$538$$$O	I.$$$539$$$541$$$O
US20110015176
Substituted$$$0$$$11$$$O	heteroarylamide$$$12$$$27$$$I	oxazepinopyrimidone$$$28$$$47$$$I	derivatives$$$48$$$59$$$O
The$$$0$$$3$$$O	disclosure$$$4$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	series$$$28$$$34$$$O	pyrimidone$$$35$$$45$$$I	derivatives$$$46$$$57$$$O	represented$$$58$$$69$$$O	by$$$70$$$72$$$O	formula$$$73$$$80$$$O	(I)$$$81$$$84$$$O	or$$$85$$$87$$$O	a$$$88$$$89$$$O	salt$$$90$$$94$$$O	thereof,$$$95$$$103$$$O	or$$$104$$$106$$$O	a$$$107$$$108$$$O	solvate$$$109$$$116$$$O	thereof$$$117$$$124$$$O	or$$$125$$$127$$$O	a$$$128$$$129$$$O	hydrate$$$130$$$137$$$I	thereof:$$$138$$$146$$$O	wherein:$$$184$$$192$$$O	Y,$$$194$$$196$$$O	Z,$$$197$$$199$$$O	R1,$$$200$$$203$$$O	R2,$$$204$$$207$$$O	R3,$$$208$$$211$$$O	R4$$$212$$$214$$$O	and$$$215$$$218$$$O	n$$$219$$$220$$$O	are$$$221$$$224$$$O	as$$$225$$$227$$$O	defined$$$228$$$235$$$O	in$$$236$$$238$$$O	the$$$239$$$242$$$O	disclosure.$$$243$$$254$$$O	Also$$$255$$$259$$$O	disclosed$$$260$$$269$$$O	are$$$270$$$273$$$O	methods$$$274$$$281$$$O	of$$$282$$$284$$$O	preparing$$$285$$$294$$$O	the$$$295$$$298$$$O	compounds$$$299$$$308$$$O	of$$$309$$$311$$$O	formula$$$312$$$319$$$O	(I),$$$320$$$324$$$O	intermediates$$$325$$$338$$$O	therefor$$$339$$$347$$$O	and$$$348$$$351$$$O	their$$$352$$$357$$$O	utility$$$358$$$365$$$O	in$$$366$$$368$$$O	treating$$$369$$$377$$$O	a$$$378$$$379$$$O	variety$$$380$$$387$$$O	of$$$388$$$390$$$O	disease$$$391$$$398$$$O	conditions.$$$399$$$410$$$O
US20110071225
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	obtaining$$$11$$$20$$$O	a$$$21$$$22$$$O	sequoyitol-containing$$$23$$$44$$$O	extract$$$45$$$52$$$O	from$$$53$$$57$$$O	genus$$$58$$$63$$$O	nephrolepis$$$64$$$75$$$O	and$$$76$$$79$$$O	uses$$$80$$$84$$$O	thereof$$$85$$$92$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	obtaining$$$13$$$22$$$O	a$$$23$$$24$$$O	sequoyitol-containing$$$25$$$46$$$O	extract$$$47$$$54$$$O	from$$$55$$$59$$$O	a$$$60$$$61$$$O	plant$$$62$$$67$$$O	of$$$68$$$70$$$O	genus$$$71$$$76$$$O	Nephrolepis,$$$77$$$89$$$O	comprising$$$90$$$100$$$O	extracting$$$101$$$111$$$O	with$$$112$$$116$$$O	a$$$117$$$118$$$O	solvent,$$$119$$$127$$$O	recovering$$$128$$$138$$$O	the$$$139$$$142$$$O	solvent$$$143$$$150$$$O	to$$$151$$$153$$$O	give$$$154$$$158$$$O	an$$$159$$$161$$$O	extractum,$$$162$$$172$$$O	subjecting$$$173$$$183$$$O	the$$$184$$$187$$$O	extractum$$$188$$$197$$$O	to$$$198$$$200$$$O	two-phase$$$201$$$210$$$O	extraction$$$211$$$221$$$O	and$$$222$$$225$$$O	column$$$226$$$232$$$O	chromatography,$$$233$$$248$$$O	collecting$$$249$$$259$$$O	the$$$260$$$263$$$O	fractions$$$264$$$273$$$O	containing$$$274$$$284$$$O	sequoyitol,$$$285$$$296$$$I	concentrating,$$$297$$$311$$$O	filtration$$$312$$$322$$$O	and$$$323$$$326$$$O	drying.$$$327$$$334$$$O	The$$$335$$$338$$$O	main$$$339$$$343$$$O	active$$$344$$$350$$$O	ingredient$$$351$$$361$$$O	of$$$362$$$364$$$O	the$$$365$$$368$$$O	extract$$$369$$$376$$$O	obtained$$$377$$$385$$$O	is$$$386$$$388$$$O	sequoyitol,$$$389$$$400$$$I	which$$$401$$$406$$$O	can$$$407$$$410$$$O	be$$$411$$$413$$$O	used$$$414$$$418$$$O	for$$$419$$$422$$$O	treating$$$423$$$431$$$O	diabetes$$$432$$$440$$$O	and$$$441$$$444$$$O	its$$$445$$$448$$$O	complications.$$$449$$$463$$$O
CN1565432A
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	gossypol$$$7$$$15$$$I	and$$$16$$$19$$$O	its$$$20$$$23$$$O	derivative$$$24$$$34$$$O	in$$$35$$$37$$$O	preparation$$$38$$$49$$$O	of$$$50$$$52$$$O	drug$$$53$$$57$$$O	for$$$58$$$61$$$O	leukemia$$$62$$$70$$$O	/$$$71$$$72$$$O	bone$$$73$$$77$$$O	marrow$$$78$$$84$$$O	cancer$$$85$$$91$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	gossypol$$$36$$$44$$$I	and$$$45$$$48$$$O	its$$$49$$$52$$$O	derivative$$$53$$$63$$$O	in$$$64$$$66$$$O	preparation$$$67$$$78$$$O	of$$$79$$$81$$$O	drug$$$82$$$86$$$O	for$$$87$$$90$$$O	leukemia$$$91$$$99$$$O	/$$$100$$$101$$$O	bone$$$102$$$106$$$O	marrow$$$107$$$113$$$O	cancer,$$$114$$$121$$$O	wherein$$$122$$$129$$$O	the$$$130$$$133$$$O	gossypol$$$134$$$142$$$I	has$$$143$$$146$$$O	the$$$147$$$150$$$O	constitutional$$$151$$$165$$$O	formula$$$166$$$173$$$O	disclosed$$$174$$$183$$$O	in$$$184$$$186$$$O	the$$$187$$$190$$$O	specification,$$$191$$$205$$$O	the$$$206$$$209$$$O	gossypol$$$210$$$218$$$I	derivative$$$219$$$229$$$O	is$$$230$$$232$$$O	gossypol$$$233$$$241$$$I	acetate$$$242$$$249$$$I	or$$$250$$$252$$$O	formic$$$253$$$259$$$I	acid$$$260$$$264$$$I	gossypol.$$$265$$$274$$$I
US20050065107
Plasmids$$$0$$$8$$$O	suitable$$$9$$$17$$$O	for$$$18$$$21$$$O	IL-2$$$22$$$26$$$O	expression$$$27$$$37$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	plasmids$$$33$$$41$$$O	suitable$$$42$$$50$$$O	for$$$51$$$54$$$O	IL-2$$$55$$$59$$$O	expression,$$$60$$$71$$$O	particularly,$$$72$$$85$$$O	human$$$86$$$91$$$O	IL-2$$$92$$$96$$$O	expression,$$$97$$$108$$$O	and$$$109$$$112$$$O	related$$$113$$$120$$$O	methods.$$$121$$$129$$$O
US20080070916
Treating$$$0$$$8$$$O	disorders$$$9$$$18$$$O	such$$$19$$$23$$$O	as$$$24$$$26$$$O	proliferative$$$27$$$40$$$O	diseases,$$$41$$$50$$$O	and$$$51$$$54$$$O	cancer;$$$55$$$62$$$O	compounds$$$63$$$72$$$O	can$$$73$$$76$$$O	act$$$77$$$80$$$O	as$$$81$$$83$$$O	probes$$$84$$$90$$$O	of$$$91$$$93$$$O	biological$$$94$$$104$$$O	function;$$$105$$$114$$$O	libraries;$$$115$$$125$$$O	for$$$126$$$129$$$O	example,$$$130$$$138$$$O	2-ethoxy-3-(2-hydroxyethoxyethoxyethyl)-4-(1-acetylindol-3-yl)-6-(morpholinocarbonyl)-2H-3,4-dihydropyran$$$139$$$244$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	novel$$$31$$$36$$$O	dihydropyrancarboxamide$$$37$$$60$$$I	compounds$$$61$$$70$$$O	of$$$71$$$73$$$O	formula$$$74$$$81$$$O	(I):$$$82$$$86$$$O	and$$$105$$$108$$$O	collections$$$109$$$120$$$O	of$$$121$$$123$$$O	these$$$124$$$129$$$O	compounds,$$$130$$$140$$$O	and$$$141$$$144$$$O	provides$$$145$$$153$$$O	methods$$$154$$$161$$$O	for$$$162$$$165$$$O	the$$$166$$$169$$$O	synthesis$$$170$$$179$$$O	of$$$180$$$182$$$O	these$$$183$$$188$$$O	compounds;$$$189$$$199$$$O	wherein$$$200$$$207$$$O	R1-R6$$$208$$$213$$$O	are$$$214$$$217$$$O	as$$$218$$$220$$$O	defined$$$221$$$228$$$O	herein.$$$229$$$236$$$O	Additionally,$$$237$$$250$$$O	the$$$251$$$254$$$O	present$$$255$$$262$$$O	invention$$$263$$$272$$$O	provides$$$273$$$281$$$O	pharmaceutical$$$282$$$296$$$O	compositions$$$297$$$309$$$O	and$$$310$$$313$$$O	methods$$$314$$$321$$$O	for$$$322$$$325$$$O	treating$$$326$$$334$$$O	disorders$$$335$$$344$$$O	such$$$345$$$349$$$O	as$$$350$$$352$$$O	proliferative$$$353$$$366$$$O	diseases,$$$367$$$376$$$O	and$$$377$$$380$$$O	cancer,$$$381$$$388$$$O	to$$$389$$$391$$$O	name$$$392$$$396$$$O	a$$$397$$$398$$$O	few.$$$399$$$403$$$O
CN101019843A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	hypericin$$$15$$$24$$$I	in$$$25$$$27$$$O	preventing$$$28$$$38$$$O	and$$$39$$$42$$$O	treating$$$43$$$51$$$O	swine$$$52$$$57$$$O	PC$$$58$$$60$$$O	and$$$61$$$64$$$O	PRRS$$$65$$$69$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	the$$$25$$$28$$$O	application$$$29$$$40$$$O	of$$$41$$$43$$$O	hypericin$$$44$$$53$$$I	in$$$54$$$56$$$O	preventing$$$57$$$67$$$O	and$$$68$$$71$$$O	treating$$$72$$$80$$$O	swine$$$81$$$86$$$O	PC$$$87$$$89$$$O	and$$$90$$$93$$$O	PRRS,$$$94$$$99$$$O	and$$$100$$$103$$$O	relates$$$104$$$111$$$O	to$$$112$$$114$$$O	veterinary$$$115$$$125$$$O	medicine$$$126$$$134$$$O	technology.$$$135$$$146$$$O	Up$$$147$$$149$$$O	to$$$150$$$152$$$O	now,$$$153$$$157$$$O	there$$$158$$$163$$$O	are$$$164$$$167$$$O	no$$$168$$$170$$$O	commercial$$$171$$$181$$$O	vaccine$$$182$$$189$$$O	and$$$190$$$193$$$O	medicine$$$194$$$202$$$O	for$$$203$$$206$$$O	preventing$$$207$$$217$$$O	and$$$218$$$221$$$O	treating$$$222$$$230$$$O	swine$$$231$$$236$$$O	PC$$$237$$$239$$$O	and$$$240$$$243$$$O	PRRS.$$$244$$$249$$$O	Research$$$250$$$258$$$O	shows$$$259$$$264$$$O	that$$$265$$$269$$$O	hypericin$$$270$$$279$$$I	in$$$280$$$282$$$O	the$$$283$$$286$$$O	effective$$$287$$$296$$$O	dosage$$$297$$$303$$$O	of$$$304$$$306$$$O	10-40$$$307$$$312$$$O	mcg/ml$$$313$$$319$$$O	can$$$320$$$323$$$O	kill$$$324$$$328$$$O	PC$$$329$$$331$$$O	and$$$332$$$335$$$O	PRRS$$$336$$$340$$$O	virus$$$341$$$346$$$O	directly,$$$347$$$356$$$O	and$$$357$$$360$$$O	hypericin$$$361$$$370$$$I	in$$$371$$$373$$$O	the$$$374$$$377$$$O	effective$$$378$$$387$$$O	dosage$$$388$$$394$$$O	of$$$395$$$397$$$O	0.005-0.009$$$398$$$409$$$O	g/kg$$$410$$$414$$$O	swine$$$415$$$420$$$O	weight$$$421$$$427$$$O	is$$$428$$$430$$$O	used$$$431$$$435$$$O	in$$$436$$$438$$$O	preventing$$$439$$$449$$$O	and$$$450$$$453$$$O	treating$$$454$$$462$$$O	swine$$$463$$$468$$$O	PC$$$469$$$471$$$O	and$$$472$$$475$$$O	PRRS.$$$476$$$481$$$O	The$$$482$$$485$$$O	present$$$486$$$493$$$O	invention$$$494$$$503$$$O	has$$$504$$$507$$$O	obvious$$$508$$$515$$$O	effect$$$516$$$522$$$O	and$$$523$$$526$$$O	simple$$$527$$$533$$$O	preparation$$$534$$$545$$$O	process.$$$546$$$554$$$O
WO2011073160A1
Pyrrolidine$$$0$$$11$$$I	derivatives$$$12$$$23$$$O	as$$$24$$$26$$$O	nk$$$27$$$29$$$O	-$$$30$$$31$$$O	3$$$32$$$33$$$O	receptor$$$34$$$42$$$O	antagonists$$$43$$$54$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	application$$$12$$$23$$$O	relates$$$24$$$31$$$O	to$$$32$$$34$$$O	compounds$$$35$$$44$$$O	of$$$45$$$47$$$O	formula$$$48$$$55$$$O	(I)$$$56$$$59$$$O	wherein$$$60$$$67$$$O	R1$$$68$$$70$$$O	is$$$71$$$73$$$O	hydrogen,$$$74$$$83$$$I	halogen,$$$84$$$92$$$I	cyano,$$$93$$$99$$$I	lower$$$100$$$105$$$O	alkyl$$$106$$$111$$$I	or$$$112$$$114$$$O	lower$$$115$$$120$$$O	alkyl$$$121$$$126$$$I	substituted$$$127$$$138$$$O	by$$$139$$$141$$$O	halogen;$$$142$$$150$$$I	n$$$151$$$152$$$O	is$$$153$$$155$$$O	1,$$$156$$$158$$$O	2$$$159$$$160$$$O	or$$$161$$$163$$$O	3,$$$164$$$166$$$O	if$$$167$$$169$$$O	n$$$170$$$171$$$O	is$$$172$$$174$$$O	2$$$175$$$176$$$O	or$$$177$$$179$$$O	3,$$$180$$$182$$$O	R1$$$183$$$185$$$O	can$$$186$$$189$$$O	be$$$190$$$192$$$O	different;$$$193$$$203$$$O	R2$$$204$$$206$$$O	is$$$207$$$209$$$O	C2-7-alkyl$$$210$$$220$$$I	or$$$221$$$223$$$O	C3-6-cycloalkyl;$$$224$$$240$$$I	R3$$$241$$$243$$$O	is$$$244$$$246$$$O	the$$$247$$$250$$$O	group$$$251$$$256$$$O	(II)$$$257$$$261$$$O	wherein$$$262$$$269$$$O	X$$$270$$$271$$$O	is$$$272$$$274$$$O	CH$$$275$$$277$$$I	or$$$278$$$280$$$O	N;$$$281$$$283$$$I	R5$$$284$$$286$$$O	is$$$287$$$289$$$O	hydrogen,$$$290$$$299$$$I	-C(O)-lower$$$300$$$311$$$I	alkyl,$$$312$$$318$$$I	-C(O)O-lower$$$319$$$331$$$I	alkyl,$$$332$$$338$$$I	S(O)2-lower$$$339$$$350$$$I	alkyl,$$$351$$$357$$$I	-C(O)CH2O-lower$$$358$$$373$$$I	alkyl,$$$374$$$380$$$I	-C(O)-CH2-CN,$$$381$$$394$$$I	or$$$395$$$397$$$O	is$$$398$$$400$$$O	-$$$401$$$402$$$O	or$$$403$$$405$$$O	-C(O)-cycloalkyl,$$$406$$$423$$$I	cycloalkyl,$$$424$$$435$$$I	or$$$436$$$438$$$O	-CH2-cycloalkyl,$$$439$$$455$$$I	wherein$$$456$$$463$$$O	the$$$464$$$467$$$O	cycloalkyl$$$468$$$478$$$I	groups$$$479$$$485$$$O	are$$$486$$$489$$$O	optionally$$$490$$$500$$$O	substituted$$$501$$$512$$$O	by$$$513$$$515$$$O	lower$$$516$$$521$$$O	alkyl,$$$522$$$528$$$I	-CH2-O-Iower$$$529$$$541$$$I	alkyl,$$$542$$$548$$$I	lower$$$549$$$554$$$O	alkoxy,$$$555$$$562$$$I	CF3,$$$563$$$567$$$I	halogen$$$568$$$575$$$I	or$$$576$$$578$$$O	cyano,$$$579$$$585$$$I	or$$$586$$$588$$$O	is$$$589$$$591$$$O	-C(O)-heterocycloalkyl$$$592$$$614$$$I	or$$$615$$$617$$$O	heterocycloalkyl,$$$618$$$635$$$I	or$$$636$$$638$$$O	is$$$639$$$641$$$O	-C(O)-heteroaryl$$$642$$$658$$$I	or$$$659$$$661$$$O	is$$$662$$$664$$$O	heteroaryl$$$665$$$675$$$I	or$$$676$$$678$$$O	is$$$679$$$681$$$O	-C(O)-aryl$$$682$$$692$$$I	or$$$693$$$695$$$O	aryl,$$$696$$$701$$$I	which$$$702$$$707$$$O	heterocycloalkyl,$$$708$$$725$$$I	heteroaryl$$$726$$$736$$$I	or$$$737$$$739$$$O	aryl$$$740$$$744$$$I	groups$$$745$$$751$$$O	are$$$752$$$755$$$O	optionally$$$756$$$766$$$O	substituted$$$767$$$778$$$O	by$$$779$$$781$$$O	halogen,$$$782$$$790$$$I	lower$$$791$$$796$$$O	alkyl,$$$797$$$803$$$I	=O,$$$804$$$807$$$I	lower$$$808$$$813$$$O	alkoxy,$$$814$$$821$$$I	lower$$$822$$$827$$$O	alkyl$$$828$$$833$$$I	substituted$$$834$$$845$$$O	by$$$846$$$848$$$O	halogen,$$$849$$$857$$$I	lower$$$858$$$863$$$O	alkyl$$$864$$$869$$$I	substituted$$$870$$$881$$$O	by$$$882$$$884$$$O	hydroxy,$$$885$$$893$$$I	-C(O)-CH2-N(di-lower$$$894$$$914$$$I	alkyl),$$$915$$$922$$$I	C(O)NH-lower$$$923$$$935$$$I	alkyl,$$$936$$$942$$$I	C(O)NH2,$$$943$$$951$$$I	-O-C(O)-$$$952$$$960$$$I	lower$$$961$$$966$$$O	alkyl,$$$967$$$973$$$I	C(O)-lower$$$974$$$984$$$I	alkyl,$$$985$$$991$$$I	S(O)2-lower$$$992$$$1003$$$I	alkyl$$$1004$$$1009$$$I	or$$$1010$$$1012$$$O	cyano;$$$1013$$$1019$$$I	R4$$$1020$$$1022$$$O	is$$$1023$$$1025$$$O	aryl,$$$1026$$$1031$$$I	which$$$1032$$$1037$$$O	is$$$1038$$$1040$$$O	optionally$$$1041$$$1051$$$O	substituted$$$1052$$$1063$$$O	by$$$1064$$$1066$$$O	halogen,$$$1067$$$1075$$$I	hydroxy,$$$1076$$$1084$$$I	lower$$$1085$$$1090$$$O	alkyl,$$$1091$$$1097$$$I	lower$$$1098$$$1103$$$O	alkyl$$$1104$$$1109$$$I	substituted$$$1110$$$1121$$$O	by$$$1122$$$1124$$$O	halogen,$$$1125$$$1133$$$I	S(O)2-lower$$$1134$$$1145$$$I	alkyl,$$$1146$$$1152$$$I	cyano$$$1153$$$1158$$$I	or$$$1159$$$1161$$$O	by$$$1162$$$1164$$$O	lower$$$1165$$$1170$$$O	alkoxy;$$$1171$$$1178$$$I	or$$$1179$$$1181$$$O	to$$$1182$$$1184$$$O	a$$$1185$$$1186$$$O	pharmaceutically$$$1187$$$1203$$$O	active$$$1204$$$1210$$$O	salt$$$1211$$$1215$$$O	thereof.$$$1216$$$1224$$$O	It$$$1225$$$1227$$$O	has$$$1228$$$1231$$$O	been$$$1232$$$1236$$$O	found$$$1237$$$1242$$$O	that$$$1243$$$1247$$$O	the$$$1248$$$1251$$$O	present$$$1252$$$1259$$$O	compounds$$$1260$$$1269$$$O	are$$$1270$$$1273$$$O	high$$$1274$$$1278$$$O	potential$$$1279$$$1288$$$O	NK-3$$$1289$$$1293$$$O	receptor$$$1294$$$1302$$$O	antagonists$$$1303$$$1314$$$O	for$$$1315$$$1318$$$O	the$$$1319$$$1322$$$O	treatment$$$1323$$$1332$$$O	of$$$1333$$$1335$$$O	depression,$$$1336$$$1347$$$O	pain,$$$1348$$$1353$$$O	psychosis,$$$1354$$$1364$$$O	Parkinson's$$$1365$$$1376$$$O	disease,$$$1377$$$1385$$$O	schizophrenia,$$$1386$$$1400$$$O	anxiety$$$1401$$$1408$$$O	and$$$1409$$$1412$$$O	attention$$$1413$$$1422$$$O	deficit$$$1423$$$1430$$$O	hyperactivity$$$1431$$$1444$$$O	disorder$$$1445$$$1453$$$O	(ADHD).$$$1454$$$1461$$$O
CA2525524C
Combination$$$0$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	analeptic$$$19$$$28$$$O	modafinil$$$29$$$38$$$I	and$$$39$$$42$$$O	an$$$43$$$45$$$O	antidepressant$$$46$$$60$$$O	for$$$61$$$64$$$O	the$$$65$$$68$$$O	treatment$$$69$$$78$$$O	of$$$79$$$81$$$O	depression$$$82$$$92$$$O
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	treatment$$$29$$$38$$$O	of$$$39$$$41$$$O	depressive$$$42$$$52$$$O	disorders$$$53$$$62$$$O	through$$$63$$$70$$$O	the$$$71$$$74$$$O	administration$$$75$$$89$$$O	of$$$90$$$92$$$O	modafinil$$$93$$$102$$$I	with$$$103$$$107$$$O	antidepressants.$$$108$$$124$$$O
US8697880
Compounds$$$0$$$9$$$O	useful$$$10$$$16$$$O	for$$$17$$$20$$$O	the$$$21$$$24$$$O	synthesis$$$25$$$34$$$O	of$$$35$$$37$$$O	S-$$$38$$$40$$$I	and$$$41$$$44$$$I	R-omeprazole$$$45$$$57$$$I	and$$$58$$$61$$$O	a$$$62$$$63$$$O	process$$$64$$$71$$$O	for$$$72$$$75$$$O	their$$$76$$$81$$$O	preparation$$$82$$$93$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	improved$$$36$$$44$$$O	method$$$45$$$51$$$O	for$$$52$$$55$$$O	the$$$56$$$59$$$O	synthesis$$$60$$$69$$$O	of$$$70$$$72$$$O	the$$$73$$$76$$$O	(S)-$$$77$$$81$$$I	or$$$82$$$84$$$I	(R)-enantiomer$$$85$$$99$$$I	of$$$100$$$102$$$I	omeprazole,$$$103$$$114$$$I	characterized$$$115$$$128$$$O	in$$$129$$$131$$$O	that$$$132$$$136$$$O	2-[[(4-X-3,5-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole$$$137$$$210$$$I	or$$$211$$$213$$$I	2-[[(4-X-3,5-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole,$$$214$$$296$$$I	wherein$$$297$$$304$$$O	X$$$305$$$306$$$O	is$$$307$$$309$$$O	a$$$310$$$311$$$O	leaving$$$312$$$319$$$O	group,$$$320$$$326$$$O	is$$$327$$$329$$$O	oxidized$$$330$$$338$$$O	into$$$339$$$343$$$O	the$$$344$$$347$$$O	corresponding$$$348$$$361$$$O	sulphoxide$$$362$$$372$$$I	which$$$373$$$378$$$O	is$$$379$$$381$$$O	obtained$$$382$$$390$$$O	as$$$391$$$393$$$O	a$$$394$$$395$$$O	crystalline$$$396$$$407$$$O	compound.$$$408$$$417$$$O	Recrystallization$$$418$$$435$$$O	of$$$436$$$438$$$O	the$$$439$$$442$$$O	thus$$$443$$$447$$$O	obtained$$$448$$$456$$$O	sulphoxide$$$457$$$467$$$I	results$$$468$$$475$$$O	in$$$476$$$478$$$O	a$$$479$$$480$$$O	compound$$$481$$$489$$$O	of$$$490$$$492$$$O	enhanced$$$493$$$501$$$O	chemical$$$502$$$510$$$O	and$$$511$$$514$$$O	optical$$$515$$$522$$$O	purity,$$$523$$$530$$$O	which$$$531$$$536$$$O	is$$$537$$$539$$$O	subsequently$$$540$$$552$$$O	transformed$$$553$$$564$$$O	into$$$565$$$569$$$O	the$$$570$$$573$$$O	(S)-$$$574$$$578$$$I	or$$$579$$$581$$$I	(R)-enantiomer$$$582$$$596$$$I	of$$$597$$$599$$$I	omeprazole.$$$600$$$611$$$I
EP2533787A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	isorhamnetin$$$7$$$19$$$I	triglycosides$$$20$$$33$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	isorhamnetin$$$36$$$48$$$I	triglycosides$$$49$$$62$$$I	and$$$63$$$66$$$O	of$$$67$$$69$$$O	extracts$$$70$$$78$$$O	containing$$$79$$$89$$$O	same$$$90$$$94$$$O	for$$$95$$$98$$$O	the$$$99$$$102$$$O	treatment$$$103$$$112$$$O	or$$$113$$$115$$$O	prophylaxis$$$116$$$127$$$O	of$$$128$$$130$$$O	neurological$$$131$$$143$$$O	and$$$144$$$147$$$O	mental$$$148$$$154$$$O	illnesses$$$155$$$164$$$O	which$$$165$$$170$$$O	are$$$171$$$174$$$O	associated$$$175$$$185$$$O	with$$$186$$$190$$$O	a$$$191$$$192$$$O	reduction$$$193$$$202$$$O	in$$$203$$$205$$$O	everyday$$$206$$$214$$$O	activity$$$215$$$223$$$O	and/or$$$224$$$230$$$O	with$$$231$$$235$$$O	a$$$236$$$237$$$O	disorder$$$238$$$246$$$O	of$$$247$$$249$$$O	mental$$$250$$$256$$$O	functions$$$257$$$266$$$O	which$$$267$$$272$$$O	affect$$$273$$$279$$$O	everyday$$$280$$$288$$$O	activities,$$$289$$$300$$$O	and/or$$$301$$$307$$$O	of$$$308$$$310$$$O	inattentiveness$$$311$$$326$$$O	and$$$327$$$330$$$O	states$$$331$$$337$$$O	of$$$338$$$340$$$O	restlessness$$$341$$$353$$$O	and$$$354$$$357$$$O	for$$$358$$$361$$$O	improving$$$362$$$371$$$O	memory$$$372$$$378$$$O	functions.$$$379$$$389$$$O	The$$$390$$$393$$$O	invention$$$394$$$403$$$O	further$$$404$$$411$$$O	relates$$$412$$$419$$$O	to$$$420$$$422$$$O	isorhamnetin$$$423$$$435$$$I	triglycoside$$$436$$$448$$$I	2$$$449$$$450$$$O	and$$$451$$$454$$$O	plant$$$455$$$460$$$O	extracts$$$461$$$469$$$O	containing$$$470$$$480$$$O	said$$$481$$$485$$$O	glycoside.$$$486$$$496$$$I
EP2694053A2
Selective$$$0$$$9$$$O	androgen$$$10$$$18$$$I	receptor$$$19$$$27$$$O	modulators$$$28$$$38$$$O	for$$$39$$$42$$$O	treating$$$43$$$51$$$O	diabetes$$$52$$$60$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	use$$$24$$$27$$$O	of$$$28$$$30$$$O	a$$$31$$$32$$$O	SARM$$$33$$$37$$$O	compound$$$38$$$46$$$O	or$$$47$$$49$$$O	a$$$50$$$51$$$O	composition$$$52$$$63$$$O	comprising$$$64$$$74$$$O	the$$$75$$$78$$$O	same$$$79$$$83$$$O	in$$$84$$$86$$$O	treating$$$87$$$95$$$O	and$$$96$$$99$$$O	preventing$$$100$$$110$$$O	muscle$$$111$$$117$$$O	wasting$$$118$$$125$$$O	in$$$126$$$128$$$O	patients$$$129$$$137$$$O	with$$$138$$$142$$$O	non-small$$$143$$$152$$$O	cell$$$153$$$157$$$O	lung$$$158$$$162$$$O	cancer$$$163$$$169$$$O	(NSCLC);$$$170$$$178$$$O	treating$$$179$$$187$$$O	pre-cachexia$$$188$$$200$$$O	or$$$201$$$203$$$O	early$$$204$$$209$$$O	cachexia$$$210$$$218$$$O	(preventing$$$219$$$230$$$O	muscle$$$231$$$237$$$O	wasting$$$238$$$245$$$O	in$$$246$$$248$$$O	a$$$249$$$250$$$O	cancer$$$251$$$257$$$O	patient);$$$258$$$267$$$O	treating$$$268$$$276$$$O	and$$$277$$$280$$$O	preventing$$$281$$$291$$$O	loss$$$292$$$296$$$O	of$$$297$$$299$$$O	physical$$$300$$$308$$$O	function$$$309$$$317$$$O	due$$$318$$$321$$$O	to$$$322$$$324$$$O	cancer$$$325$$$331$$$O	or$$$332$$$334$$$O	cancer$$$335$$$341$$$O	therapy;$$$342$$$350$$$O	increase$$$351$$$359$$$O	of$$$360$$$362$$$O	physical$$$363$$$371$$$O	function;$$$372$$$381$$$O	and$$$382$$$385$$$O	increasing$$$386$$$396$$$O	survival$$$397$$$405$$$O	in$$$406$$$408$$$O	a$$$409$$$410$$$O	patient$$$411$$$418$$$O	with$$$419$$$423$$$O	NSCLC.$$$424$$$430$$$O
US20120101095
Alkoxy-thienopyrimidines$$$0$$$24$$$I	as$$$25$$$27$$$O	tgf-beta$$$28$$$36$$$O	receptor$$$37$$$45$$$O	kinase$$$46$$$52$$$O	modulators$$$53$$$63$$$O
Novel$$$0$$$5$$$O	alkoxy-thienopyrimidine$$$6$$$29$$$I	derivatives$$$30$$$41$$$O	of$$$42$$$44$$$O	formula$$$45$$$52$$$O	(I)$$$53$$$56$$$O	wherein$$$94$$$101$$$O	R1$$$102$$$104$$$O	and$$$105$$$108$$$O	R2$$$109$$$111$$$O	have$$$112$$$116$$$O	the$$$117$$$120$$$O	meaning$$$121$$$128$$$O	according$$$129$$$138$$$O	to$$$139$$$141$$$O	claim$$$142$$$147$$$O	1,$$$148$$$150$$$O	are$$$153$$$156$$$O	inhibitors$$$157$$$167$$$O	of$$$168$$$170$$$O	TGF-beta$$$171$$$179$$$O	receptor$$$180$$$188$$$O	I$$$189$$$190$$$O	kinase,$$$191$$$198$$$O	and$$$199$$$202$$$O	can$$$203$$$206$$$O	be$$$207$$$209$$$O	employed,$$$210$$$219$$$O	inter$$$220$$$225$$$O	alia,$$$226$$$231$$$O	for$$$232$$$235$$$O	the$$$236$$$239$$$O	treatment$$$240$$$249$$$O	of$$$250$$$252$$$O	tumors.$$$253$$$260$$$O
CN101757026A
Dermatitis$$$0$$$10$$$O	curative$$$11$$$19$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	novel$$$26$$$31$$$O	external$$$32$$$40$$$O	application$$$41$$$52$$$O	drug$$$53$$$57$$$O	for$$$58$$$61$$$O	treating$$$62$$$70$$$O	skin$$$71$$$75$$$O	diseases,$$$76$$$85$$$O	which$$$86$$$91$$$O	uses$$$92$$$96$$$O	nine$$$97$$$101$$$O	Chinese$$$102$$$109$$$O	and$$$110$$$113$$$O	western$$$114$$$121$$$O	medicine$$$122$$$130$$$O	as$$$131$$$133$$$O	raw$$$134$$$137$$$O	materials,$$$138$$$148$$$O	such$$$149$$$153$$$O	as$$$154$$$156$$$O	realgar.$$$157$$$165$$$O	The$$$166$$$169$$$O	drug$$$170$$$174$$$O	is$$$175$$$177$$$O	mainly$$$178$$$184$$$O	used$$$185$$$189$$$O	for$$$190$$$193$$$O	treating$$$194$$$202$$$O	various$$$203$$$210$$$O	skin$$$211$$$215$$$O	diseases,$$$216$$$225$$$O	such$$$226$$$230$$$O	as$$$231$$$233$$$O	pruritus$$$234$$$242$$$O	and$$$243$$$246$$$O	scabies.$$$247$$$255$$$O	The$$$256$$$259$$$O	invention$$$260$$$269$$$O	has$$$270$$$273$$$O	the$$$274$$$277$$$O	advantages$$$278$$$288$$$O	of$$$289$$$291$$$O	scientific$$$292$$$302$$$O	and$$$303$$$306$$$O	unique$$$307$$$313$$$O	prescription$$$314$$$326$$$O	and$$$327$$$330$$$O	good$$$331$$$335$$$O	curing$$$336$$$342$$$O	effect.$$$343$$$350$$$O
WO2011029279A1
Fused$$$0$$$5$$$I	heteroaryl$$$6$$$16$$$I	compounds,$$$17$$$27$$$O	preparation$$$28$$$39$$$O	method$$$40$$$46$$$O	and$$$47$$$50$$$O	use$$$51$$$54$$$O	thereof$$$55$$$62$$$O
Fused$$$0$$$5$$$I	heteroaryl$$$6$$$16$$$I	compounds$$$17$$$26$$$O	represented$$$27$$$38$$$O	by$$$39$$$41$$$O	general$$$42$$$49$$$O	formula$$$50$$$57$$$O	(I),$$$58$$$62$$$O	wherein$$$63$$$70$$$O	X,$$$71$$$73$$$O	R1,$$$74$$$77$$$O	R2$$$78$$$80$$$O	and$$$81$$$84$$$O	R3$$$85$$$87$$$O	are$$$88$$$91$$$O	defined$$$92$$$99$$$O	as$$$100$$$102$$$O	in$$$103$$$105$$$O	the$$$106$$$109$$$O	description$$$110$$$121$$$O	are$$$122$$$125$$$O	disclosed.$$$126$$$136$$$O	The$$$137$$$140$$$O	method$$$141$$$147$$$O	for$$$148$$$151$$$O	preparing$$$152$$$161$$$O	these$$$162$$$167$$$O	compounds$$$168$$$177$$$O	and$$$178$$$181$$$O	the$$$182$$$185$$$O	use$$$186$$$189$$$O	of$$$190$$$192$$$O	these$$$193$$$198$$$O	compounds$$$199$$$208$$$O	as$$$209$$$211$$$O	phosphoinositide$$$212$$$228$$$O	3-kinase$$$229$$$237$$$O	(PI3K)$$$238$$$244$$$O	inhibitors$$$245$$$255$$$O	and$$$256$$$259$$$O	anticancer$$$260$$$270$$$O	agents$$$271$$$277$$$O	are$$$278$$$281$$$O	also$$$282$$$286$$$O	disclosed.$$$287$$$297$$$O
CN101362718A
4-(4-benzamido$$$0$$$14$$$I	phenoxy)-2-(methylcarbamoyl)$$$15$$$43$$$I	pyridine$$$44$$$52$$$I	derivatives,$$$53$$$65$$$O	preparation$$$66$$$77$$$O	method$$$78$$$84$$$O	and$$$85$$$88$$$O	application$$$89$$$100$$$O	thereof$$$101$$$108$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	derivative$$$27$$$37$$$O	of$$$38$$$40$$$O	4-(4-benzoyl$$$41$$$53$$$I	amino-phenoxy)-2-(methyl$$$54$$$78$$$I	ammonia$$$79$$$86$$$I	formyl)$$$87$$$94$$$I	pyridine$$$95$$$103$$$I	and$$$104$$$107$$$O	a$$$108$$$109$$$O	preparation$$$110$$$121$$$O	method$$$122$$$128$$$O	and$$$129$$$132$$$O	purposes$$$133$$$141$$$O	thereof,$$$142$$$150$$$O	belonging$$$151$$$160$$$O	to$$$161$$$163$$$O	the$$$164$$$167$$$O	chemical$$$168$$$176$$$O	medicine$$$177$$$185$$$O	field.$$$186$$$192$$$O	The$$$193$$$196$$$O	structure$$$197$$$206$$$O	of$$$207$$$209$$$O	the$$$210$$$213$$$O	derivative$$$214$$$224$$$O	is$$$225$$$227$$$O	shown$$$228$$$233$$$O	as$$$234$$$236$$$O	Formula$$$237$$$244$$$O	I:$$$245$$$247$$$O	R1$$$248$$$250$$$O	is$$$251$$$253$$$O	hydrogen,$$$254$$$263$$$I	halogenated$$$264$$$275$$$I	base,$$$276$$$281$$$I	trifluoromethyl,$$$282$$$298$$$I	nitro,$$$299$$$305$$$I	alkoxy,$$$306$$$313$$$I	dimethoxy$$$314$$$323$$$I	or$$$324$$$326$$$O	amino;$$$327$$$333$$$I	R2$$$334$$$336$$$O	is$$$337$$$339$$$O	hydrogen,$$$340$$$349$$$I	halogenated$$$350$$$361$$$I	base,$$$362$$$367$$$I	trifluoromethyl,$$$368$$$384$$$I	nitro,$$$385$$$391$$$I	alkoxy,$$$392$$$399$$$I	dimethoxy$$$400$$$409$$$I	or$$$410$$$412$$$O	amino;$$$413$$$419$$$I	R3$$$420$$$422$$$O	is$$$423$$$425$$$O	hydrogen,$$$426$$$435$$$I	halogenated$$$436$$$447$$$I	base,$$$448$$$453$$$I	trifluoromethyl,$$$454$$$470$$$I	nitro,$$$471$$$477$$$I	alkoxy,$$$478$$$485$$$I	dimethoxy$$$486$$$495$$$I	or$$$496$$$498$$$O	amino.$$$499$$$505$$$I	The$$$506$$$509$$$O	derivative$$$510$$$520$$$O	can$$$521$$$524$$$O	be$$$525$$$527$$$O	used$$$528$$$532$$$O	for$$$533$$$536$$$O	preparing$$$537$$$546$$$O	anti-tumor$$$547$$$557$$$O	medicines.$$$558$$$568$$$O
WO2006134489A1
Sulindac$$$0$$$8$$$I	derivatives$$$9$$$20$$$O	for$$$21$$$24$$$O	treatment$$$25$$$34$$$O	of$$$35$$$37$$$O	cancer$$$38$$$44$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	non$$$39$$$42$$$O	steroidal$$$43$$$52$$$O	anti-inflammatory$$$53$$$70$$$O	compounds$$$71$$$80$$$O	(NSAIDs)$$$81$$$89$$$O	derivatives$$$90$$$101$$$O	of$$$102$$$104$$$O	sulindac,$$$105$$$114$$$I	for$$$115$$$118$$$O	the$$$119$$$122$$$O	treatment/prevention,$$$123$$$144$$$O	alone$$$145$$$150$$$O	or$$$151$$$153$$$O	in$$$154$$$156$$$O	combination,$$$157$$$169$$$O	of$$$170$$$172$$$O	cancer.$$$173$$$180$$$O
WO2009080555A3
Carboxyl-$$$0$$$9$$$O	or$$$10$$$12$$$O	hydroxyl-$$$13$$$22$$$O	substituted$$$23$$$34$$$O	benzimidazole$$$35$$$48$$$O	derivatives$$$49$$$60$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	carboxyl-$$$32$$$41$$$O	or$$$42$$$44$$$O	hydroxylsubstituted$$$45$$$64$$$O	benzimidazole$$$65$$$78$$$O	derivatives$$$79$$$90$$$O	of$$$91$$$93$$$O	formula$$$94$$$101$$$O	(I)$$$102$$$105$$$O	wherein$$$106$$$113$$$O	R1$$$114$$$116$$$O	to$$$117$$$119$$$O	R6$$$120$$$122$$$O	are$$$123$$$126$$$O	as$$$127$$$129$$$O	defined$$$130$$$137$$$O	in$$$138$$$140$$$O	the$$$141$$$144$$$O	description$$$145$$$156$$$O	and$$$157$$$160$$$O	in$$$161$$$163$$$O	the$$$164$$$167$$$O	claims,$$$168$$$175$$$O	as$$$176$$$178$$$O	well$$$179$$$183$$$O	as$$$184$$$186$$$O	physiologically$$$187$$$202$$$O	acceptable$$$203$$$213$$$O	salts$$$214$$$219$$$O	and$$$220$$$223$$$O	esters$$$224$$$230$$$O	thereof.$$$231$$$239$$$O	These$$$240$$$245$$$O	compounds$$$246$$$255$$$O	bind$$$256$$$260$$$O	to$$$261$$$263$$$O	FXR$$$264$$$267$$$O	and$$$268$$$271$$$O	can$$$272$$$275$$$O	be$$$276$$$278$$$O	used$$$279$$$283$$$O	as$$$284$$$286$$$O	medicaments.$$$287$$$299$$$O
CN102046202A
Stabilizing$$$0$$$11$$$O	lipid$$$12$$$17$$$O	compositions$$$18$$$30$$$O	for$$$31$$$34$$$O	oral$$$35$$$39$$$O	pharmaceutical$$$40$$$54$$$O	agents$$$55$$$61$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	for$$$62$$$65$$$O	oral$$$66$$$70$$$O	administration$$$71$$$85$$$O	comprising$$$86$$$96$$$O	an$$$97$$$99$$$O	exceptionally$$$100$$$113$$$O	labile$$$114$$$120$$$O	active$$$121$$$127$$$O	agent,$$$128$$$134$$$O	a$$$135$$$136$$$O	stabilizing$$$137$$$148$$$O	vehicle$$$149$$$156$$$O	comprising$$$157$$$167$$$O	liquid$$$168$$$174$$$O	triglycerides$$$175$$$188$$$O	and$$$189$$$192$$$O	a$$$193$$$194$$$O	desiccant,$$$195$$$205$$$O	wherein$$$206$$$213$$$O	the$$$214$$$217$$$O	composition$$$218$$$229$$$O	is$$$230$$$232$$$O	storage$$$233$$$240$$$O	stable$$$241$$$247$$$O	for$$$248$$$251$$$O	an$$$252$$$254$$$O	extended$$$255$$$263$$$O	period$$$264$$$270$$$O	without$$$271$$$278$$$O	substantial$$$279$$$290$$$O	degradation$$$291$$$302$$$O	of$$$303$$$305$$$O	the$$$306$$$309$$$O	active$$$310$$$316$$$O	agent.$$$317$$$323$$$O
CA2255521C
Compositions$$$0$$$12$$$O	for$$$13$$$16$$$O	treatment$$$17$$$26$$$O	of$$$27$$$29$$$O	burns$$$30$$$35$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	a$$$37$$$38$$$O	composition$$$39$$$50$$$O	for$$$51$$$54$$$O	treating$$$55$$$63$$$O	burns.$$$64$$$70$$$O	The$$$71$$$74$$$O	composition$$$75$$$86$$$O	comprises$$$87$$$96$$$O	a$$$97$$$98$$$O	therapeutically$$$99$$$114$$$O	effective$$$115$$$124$$$O	amount$$$125$$$131$$$O	of$$$132$$$134$$$O	a$$$135$$$136$$$O	weak$$$137$$$141$$$O	organic$$$142$$$149$$$O	acid$$$150$$$154$$$O	compatible$$$155$$$165$$$O	with$$$166$$$170$$$O	human$$$171$$$176$$$O	skin,$$$177$$$182$$$O	in$$$183$$$185$$$O	a$$$186$$$187$$$O	suitable$$$188$$$196$$$O	carrier$$$197$$$204$$$O	delivered$$$205$$$214$$$O	at$$$215$$$217$$$O	pH$$$218$$$220$$$O	2.5-4.5.$$$221$$$229$$$O	The$$$230$$$233$$$O	weak$$$234$$$238$$$O	organic$$$239$$$246$$$O	acid$$$247$$$251$$$O	is$$$252$$$254$$$O	preferably$$$255$$$265$$$O	acetic$$$266$$$272$$$I	acid$$$273$$$277$$$I	or$$$278$$$280$$$O	citric$$$281$$$287$$$I	acid$$$288$$$292$$$I	and$$$293$$$296$$$O	the$$$297$$$300$$$O	suitable$$$301$$$309$$$O	carrier$$$310$$$317$$$O	is$$$318$$$320$$$O	preferably$$$321$$$331$$$O	an$$$332$$$334$$$O	aqueous$$$335$$$342$$$O	based$$$343$$$348$$$O	carrier,$$$349$$$357$$$O	more$$$358$$$362$$$O	preferably$$$363$$$373$$$O	a$$$374$$$375$$$O	gel$$$376$$$379$$$O	form,$$$380$$$385$$$O	utilizing$$$386$$$395$$$O	a$$$396$$$397$$$O	Carbopol.TM.$$$398$$$410$$$O	as$$$411$$$413$$$O	a$$$414$$$415$$$O	gelling$$$416$$$423$$$O	agent.$$$424$$$430$$$O	The$$$431$$$434$$$O	composition$$$435$$$446$$$O	may$$$447$$$450$$$O	also$$$451$$$455$$$O	include$$$456$$$463$$$O	one$$$464$$$467$$$O	or$$$468$$$470$$$O	more$$$471$$$475$$$O	other$$$476$$$481$$$O	agents$$$482$$$488$$$O	selected$$$489$$$497$$$O	from$$$498$$$502$$$O	sun$$$503$$$506$$$O	blocking$$$507$$$515$$$O	agents,$$$516$$$523$$$O	skin$$$524$$$528$$$O	moisturizing$$$529$$$541$$$O	agents$$$542$$$548$$$O	and$$$549$$$552$$$O	herb$$$553$$$557$$$O	extracts.$$$558$$$567$$$O
US20090068132
Resveratrol$$$0$$$11$$$O	Ferulate$$$12$$$20$$$O	Compounds,$$$21$$$31$$$O	Compositions$$$32$$$44$$$O	Containing$$$45$$$55$$$O	The$$$56$$$59$$$O	Compounds,$$$60$$$70$$$O	And$$$71$$$74$$$O	Methods$$$75$$$82$$$O	Of$$$83$$$85$$$O	Using$$$86$$$91$$$O	The$$$92$$$95$$$O	Same$$$96$$$100$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	cosmetic$$$33$$$41$$$O	compositions$$$42$$$54$$$O	containing$$$55$$$65$$$O	resveratrol$$$66$$$77$$$O	ferulate$$$78$$$86$$$O	in$$$87$$$89$$$O	a$$$90$$$91$$$O	topically$$$92$$$101$$$O	acceptable$$$102$$$112$$$O	carrier.$$$113$$$121$$$O	Such$$$122$$$126$$$O	compositions$$$127$$$139$$$O	are$$$140$$$143$$$O	particularly$$$144$$$156$$$O	effective$$$157$$$166$$$O	for$$$167$$$170$$$O	skin$$$171$$$175$$$O	lightening$$$176$$$186$$$O	and$$$187$$$190$$$O	anti-aging$$$191$$$201$$$O	applications$$$202$$$214$$$O	and$$$215$$$218$$$O	have$$$219$$$223$$$O	excellent$$$224$$$233$$$O	color$$$234$$$239$$$O	stability$$$240$$$249$$$O	and$$$250$$$253$$$O	extended$$$254$$$262$$$O	shelf$$$263$$$268$$$O	life.$$$269$$$274$$$O
US7927623
Pleasant$$$0$$$8$$$O	taste;$$$9$$$15$$$O	bioabsorbable;$$$16$$$30$$$O	overcoated$$$31$$$41$$$O	water$$$42$$$47$$$O	insoluble$$$48$$$57$$$O	drug$$$58$$$62$$$O	in$$$63$$$65$$$O	alcohol$$$66$$$73$$$I	solvent$$$74$$$81$$$O	and$$$82$$$85$$$O	water$$$86$$$91$$$O	soluble$$$92$$$99$$$O	binder;$$$100$$$107$$$O	mixing,$$$108$$$115$$$O	compression$$$116$$$127$$$O
Intraorally$$$0$$$11$$$O	rapidly$$$12$$$19$$$O	disintegrating$$$20$$$34$$$O	tablets$$$35$$$42$$$O	which,$$$43$$$49$$$O	when$$$50$$$54$$$O	ingested,$$$55$$$64$$$O	disintegrates$$$65$$$78$$$O	in$$$79$$$81$$$O	the$$$82$$$85$$$O	oral$$$86$$$90$$$O	cavity$$$91$$$97$$$O	rapidly$$$98$$$105$$$O	without$$$106$$$113$$$O	presenting$$$114$$$124$$$O	unpleasant$$$125$$$135$$$O	taste,$$$136$$$142$$$O	can$$$143$$$146$$$O	be$$$147$$$149$$$O	quickly$$$150$$$157$$$O	absorbed$$$158$$$166$$$O	in$$$167$$$169$$$O	the$$$170$$$173$$$O	digestive$$$174$$$183$$$O	tract$$$184$$$189$$$O	and$$$190$$$193$$$O	express$$$194$$$201$$$O	efficacy$$$202$$$210$$$O	are$$$211$$$214$$$O	provided.$$$215$$$224$$$O	The$$$225$$$228$$$O	intraorally$$$229$$$240$$$O	rapidly$$$241$$$248$$$O	disintegrating$$$249$$$263$$$O	tablets$$$264$$$271$$$O	contain$$$272$$$279$$$O	a$$$280$$$281$$$O	drug$$$282$$$286$$$O	being$$$287$$$292$$$O	hardly$$$293$$$299$$$O	water-soluble$$$300$$$313$$$O	under$$$314$$$319$$$O	neutral$$$320$$$327$$$O	or$$$328$$$330$$$O	alkaline$$$331$$$339$$$O	conditions$$$340$$$350$$$O	and$$$351$$$354$$$O	being$$$355$$$360$$$O	highly$$$361$$$367$$$O	water-soluble$$$368$$$381$$$O	under$$$382$$$387$$$O	acidic$$$388$$$394$$$O	conditions$$$395$$$405$$$O	yet$$$406$$$409$$$O	presenting$$$410$$$420$$$O	unpleasant$$$421$$$431$$$O	taste,$$$432$$$438$$$O	which$$$439$$$444$$$O	tablets$$$445$$$452$$$O	can$$$453$$$456$$$O	be$$$457$$$459$$$O	prepared$$$460$$$468$$$O	by$$$469$$$471$$$O	combining$$$472$$$481$$$O	the$$$482$$$485$$$O	medicinal$$$486$$$495$$$O	substance$$$496$$$505$$$O	with$$$506$$$510$$$O	a$$$511$$$512$$$O	water-soluble$$$513$$$526$$$O	acidic$$$527$$$533$$$O	substance,$$$534$$$544$$$O	coating$$$545$$$552$$$O	either$$$553$$$559$$$O	or$$$560$$$562$$$O	both$$$563$$$567$$$O	of$$$568$$$570$$$O	the$$$571$$$574$$$O	substances$$$575$$$585$$$O	with$$$586$$$590$$$O	a$$$591$$$592$$$O	water-soluble$$$593$$$606$$$O	coating$$$607$$$614$$$O	agent$$$615$$$620$$$O	being$$$621$$$626$$$O	insoluble$$$627$$$636$$$O	in$$$637$$$639$$$O	alcoholic$$$640$$$649$$$O	solvent,$$$650$$$658$$$O	further$$$659$$$666$$$O	adding$$$667$$$673$$$O	a$$$674$$$675$$$O	water-soluble$$$676$$$689$$$O	binding$$$690$$$697$$$O	agent$$$698$$$703$$$O	being$$$704$$$709$$$O	soluble$$$710$$$717$$$O	in$$$718$$$720$$$O	alcoholic$$$721$$$730$$$O	solvent$$$731$$$738$$$O	and$$$739$$$742$$$O	a$$$743$$$744$$$O	water-soluble$$$745$$$758$$$O	saccharide,$$$759$$$770$$$O	subjecting$$$771$$$781$$$O	the$$$782$$$785$$$O	resultant$$$786$$$795$$$O	mixture$$$796$$$803$$$O	to$$$804$$$806$$$O	compression,$$$807$$$819$$$O	and$$$820$$$823$$$O	treating$$$824$$$832$$$O	the$$$833$$$836$$$O	products$$$837$$$845$$$O	with$$$846$$$850$$$O	an$$$851$$$853$$$O	alcoholic$$$854$$$863$$$O	solvent.$$$864$$$872$$$O
WO2014143669A1
Compositions$$$0$$$12$$$O	for$$$13$$$16$$$O	use$$$17$$$20$$$O	in$$$21$$$23$$$O	treating$$$24$$$32$$$O	heavy$$$33$$$38$$$O	menstrual$$$39$$$48$$$O	bleeding$$$49$$$57$$$O	and$$$58$$$61$$$O	uterine$$$62$$$69$$$O	fibroids$$$70$$$78$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	method$$$37$$$43$$$O	of$$$44$$$46$$$O	treating$$$47$$$55$$$O	heavy$$$56$$$61$$$O	menstrual$$$62$$$71$$$O	bleeding$$$72$$$80$$$O	in$$$81$$$83$$$O	a$$$84$$$85$$$O	subject$$$86$$$93$$$O	with$$$94$$$98$$$O	or$$$99$$$101$$$O	without$$$102$$$109$$$O	uterine$$$110$$$117$$$O	fibroids$$$118$$$126$$$O	and$$$127$$$130$$$O	in$$$131$$$133$$$O	need$$$134$$$138$$$O	of$$$139$$$141$$$O	treatment$$$142$$$151$$$O	by$$$152$$$154$$$O	administering$$$155$$$168$$$O	an$$$169$$$171$$$O	effective$$$172$$$181$$$O	amount$$$182$$$188$$$O	of$$$189$$$191$$$O	4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-$$$192$$$272$$$I	methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-l-yl]-l-phenyl-ethylamino)-butyric$$$273$$$349$$$I	acid$$$350$$$354$$$I	or$$$355$$$357$$$O	a$$$358$$$359$$$O	pharmaceutically$$$360$$$376$$$O	acceptable$$$377$$$387$$$O	salt$$$388$$$392$$$O	thereof,$$$393$$$401$$$O	in$$$402$$$404$$$O	combination$$$405$$$416$$$O	with$$$417$$$421$$$O	estrogens$$$422$$$431$$$O	and$$$432$$$435$$$O	progestogens.$$$436$$$449$$$O
US20050048128
Using$$$0$$$5$$$O	ascorbic$$$6$$$14$$$I	acid$$$15$$$19$$$I	and$$$20$$$23$$$O	petroleum$$$24$$$33$$$O	jelly$$$34$$$39$$$O
The$$$0$$$3$$$O	object$$$4$$$10$$$O	of$$$11$$$13$$$O	the$$$14$$$17$$$O	present$$$18$$$25$$$O	invention$$$26$$$35$$$O	is$$$36$$$38$$$O	to$$$39$$$41$$$O	provide$$$42$$$49$$$O	a$$$50$$$51$$$O	means$$$52$$$57$$$O	which$$$58$$$63$$$O	continuously$$$64$$$76$$$O	exerts$$$77$$$83$$$O	an$$$84$$$86$$$O	action$$$87$$$93$$$O	of$$$94$$$96$$$O	enhancing$$$97$$$106$$$O	the$$$107$$$110$$$O	collagen$$$111$$$119$$$O	production$$$120$$$130$$$O	by$$$131$$$133$$$O	L-ascorbic$$$134$$$144$$$I	acid,$$$145$$$150$$$I	and$$$151$$$154$$$O	the$$$155$$$158$$$O	object$$$159$$$165$$$O	is$$$166$$$168$$$O	solved$$$169$$$175$$$O	by$$$176$$$178$$$O	providing$$$179$$$188$$$O	the$$$189$$$192$$$O	collagen-production$$$193$$$212$$$O	enhancer$$$213$$$221$$$O	which$$$222$$$227$$$O	comprises$$$228$$$237$$$O	L-ascorbic$$$238$$$248$$$I	acid$$$249$$$253$$$I	and/or$$$254$$$260$$$O	the$$$261$$$264$$$O	like$$$265$$$269$$$O	and$$$270$$$273$$$O	royal$$$274$$$279$$$O	jelly$$$280$$$285$$$O	and/or$$$286$$$292$$$O	the$$$293$$$296$$$O	like.$$$297$$$302$$$O
EP1828149A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	the$$$11$$$14$$$O	production$$$15$$$25$$$O	of$$$26$$$28$$$O	oxazoles$$$29$$$37$$$I	by$$$38$$$40$$$O	condensing$$$41$$$51$$$O	aromatic$$$52$$$60$$$I	aldehydes$$$61$$$70$$$I	with$$$71$$$75$$$O	a-ketoximes$$$76$$$87$$$I	to$$$88$$$90$$$O	n-oxides$$$91$$$99$$$I	and$$$100$$$103$$$O	then$$$104$$$108$$$O	reacting$$$109$$$117$$$O	the$$$118$$$121$$$O	same$$$122$$$126$$$O	with$$$127$$$131$$$O	activated$$$132$$$141$$$O	acid$$$142$$$146$$$O	derivatives$$$147$$$158$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	method$$$15$$$21$$$O	for$$$22$$$25$$$O	producing$$$26$$$35$$$O	oxazoles$$$36$$$44$$$I	of$$$45$$$47$$$O	formula$$$48$$$55$$$O	IV$$$56$$$58$$$O	by$$$59$$$61$$$O	condensing$$$62$$$72$$$O	aromatic$$$73$$$81$$$I	aldehydes$$$82$$$91$$$I	with$$$92$$$96$$$O	a-ketoximes$$$97$$$108$$$I	to$$$109$$$111$$$O	N-oxides$$$112$$$120$$$I	and$$$121$$$124$$$O	then$$$125$$$129$$$O	reacting$$$130$$$138$$$O	the$$$139$$$142$$$O	same$$$143$$$147$$$O	with$$$148$$$152$$$O	activated$$$153$$$162$$$O	acid$$$163$$$167$$$O	derivatives.$$$168$$$180$$$O	The$$$181$$$184$$$O	invention$$$185$$$194$$$O	relates$$$195$$$202$$$O	to$$$203$$$205$$$O	a$$$206$$$207$$$O	method$$$208$$$214$$$O	for$$$215$$$218$$$O	producing$$$219$$$228$$$O	oxazoles$$$229$$$237$$$I	by$$$238$$$240$$$O	condensing$$$241$$$251$$$O	aldehydes$$$252$$$261$$$I	with$$$262$$$266$$$O	a-ketoximes$$$267$$$278$$$I	to$$$279$$$281$$$O	N-oxides$$$282$$$290$$$I	in$$$291$$$293$$$O	the$$$294$$$297$$$O	form$$$298$$$302$$$O	of$$$303$$$305$$$O	the$$$306$$$309$$$O	salts$$$310$$$315$$$O	thereof$$$316$$$323$$$O	or$$$324$$$326$$$O	as$$$327$$$329$$$O	free$$$330$$$334$$$O	bases$$$335$$$340$$$O	and$$$341$$$344$$$O	then$$$345$$$349$$$O	reacting$$$350$$$358$$$O	the$$$359$$$362$$$O	same$$$363$$$367$$$O	with$$$368$$$372$$$O	activated$$$373$$$382$$$O	acid$$$383$$$387$$$O	derivatives$$$388$$$399$$$O	so$$$400$$$402$$$O	as$$$403$$$405$$$O	to$$$406$$$408$$$O	obtain$$$409$$$415$$$O	oxazoles$$$416$$$424$$$I	in$$$425$$$427$$$O	the$$$428$$$431$$$O	form$$$432$$$436$$$O	of$$$437$$$439$$$O	the$$$440$$$443$$$O	salts$$$444$$$449$$$O	thereof$$$450$$$457$$$O	or$$$458$$$460$$$O	as$$$461$$$463$$$O	free$$$464$$$468$$$O	bases.$$$469$$$475$$$O
CN102784070A
Stable$$$0$$$6$$$O	hydroquinone-containing$$$7$$$30$$$I	polyol-in-oil$$$31$$$44$$$O	composition$$$45$$$56$$$O	and$$$57$$$60$$$O	preparation$$$61$$$72$$$O	method$$$73$$$79$$$O	thereof$$$80$$$87$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	stable$$$27$$$33$$$O	hydroquinone-containing$$$34$$$57$$$I	polyol-in-oil$$$58$$$71$$$O	composition,$$$72$$$84$$$O	including:$$$85$$$95$$$O	based$$$96$$$101$$$O	on$$$102$$$104$$$O	the$$$105$$$108$$$O	total$$$109$$$114$$$O	weight$$$115$$$121$$$O	of$$$122$$$124$$$O	the$$$125$$$128$$$O	composition,$$$129$$$141$$$O	10-45$$$142$$$147$$$O	wt%$$$148$$$151$$$O	of$$$152$$$154$$$O	an$$$155$$$157$$$O	oil$$$158$$$161$$$O	phase$$$162$$$167$$$O	component,$$$168$$$178$$$O	40-80$$$179$$$184$$$O	wt%$$$185$$$188$$$O	of$$$189$$$191$$$O	a$$$192$$$193$$$O	polyol$$$194$$$200$$$O	component,$$$201$$$211$$$O	0.5-5$$$212$$$217$$$O	wt%$$$218$$$221$$$O	of$$$222$$$224$$$O	an$$$225$$$227$$$O	emulsifier,$$$228$$$239$$$O	0.1-5$$$240$$$245$$$O	wt%$$$246$$$249$$$O	of$$$250$$$252$$$O	a$$$253$$$254$$$O	stabilizer,$$$255$$$266$$$O	0.01-5$$$267$$$273$$$O	wt%$$$274$$$277$$$O	of$$$278$$$280$$$O	hydroquinone$$$281$$$293$$$I	and$$$294$$$297$$$O	0.01-2$$$298$$$304$$$O	wt%$$$305$$$308$$$O	of$$$309$$$311$$$O	vitamin$$$312$$$319$$$I	C,$$$320$$$322$$$I	wherein$$$323$$$330$$$O	the$$$331$$$334$$$O	ratio$$$335$$$340$$$O	of$$$341$$$343$$$O	water$$$344$$$349$$$O	in$$$350$$$352$$$O	the$$$353$$$356$$$O	total$$$357$$$362$$$O	weight$$$363$$$369$$$O	of$$$370$$$372$$$O	the$$$373$$$376$$$O	composition$$$377$$$388$$$O	is$$$389$$$391$$$O	less$$$392$$$396$$$O	than$$$397$$$401$$$O	1$$$402$$$403$$$O	wt%.$$$404$$$408$$$O	The$$$409$$$412$$$O	hydroquinone$$$413$$$425$$$I	in$$$426$$$428$$$O	the$$$429$$$432$$$O	composition$$$433$$$444$$$O	of$$$445$$$447$$$O	the$$$448$$$451$$$O	invention$$$452$$$461$$$O	is$$$462$$$464$$$O	preferably$$$465$$$475$$$O	present$$$476$$$483$$$O	in$$$484$$$486$$$O	the$$$487$$$490$$$O	polyol$$$491$$$497$$$O	component$$$498$$$507$$$O	in$$$508$$$510$$$O	a$$$511$$$512$$$O	dissolved$$$513$$$522$$$O	form.$$$523$$$528$$$O	The$$$529$$$532$$$O	present$$$533$$$540$$$O	invention$$$541$$$550$$$O	also$$$551$$$555$$$O	provides$$$556$$$564$$$O	a$$$565$$$566$$$O	preparation$$$567$$$578$$$O	method$$$579$$$585$$$O	for$$$586$$$589$$$O	the$$$590$$$593$$$O	composition.$$$594$$$606$$$O	The$$$607$$$610$$$O	composition$$$611$$$622$$$O	of$$$623$$$625$$$O	the$$$626$$$629$$$O	present$$$630$$$637$$$O	invention$$$638$$$647$$$O	can$$$648$$$651$$$O	effectively$$$652$$$663$$$O	improve$$$664$$$671$$$O	the$$$672$$$675$$$O	storage$$$676$$$683$$$O	stability$$$684$$$693$$$O	of$$$694$$$696$$$O	the$$$697$$$700$$$O	hydroquinone,$$$701$$$714$$$I	and$$$715$$$718$$$O	the$$$719$$$722$$$O	system$$$723$$$729$$$O	is$$$730$$$732$$$O	an$$$733$$$735$$$O	anhydrous$$$736$$$745$$$O	formula$$$746$$$753$$$O	without$$$754$$$761$$$O	adding$$$762$$$768$$$O	preservatives,$$$769$$$783$$$O	and$$$784$$$787$$$O	is$$$788$$$790$$$O	safe$$$791$$$795$$$O	and$$$796$$$799$$$O	healthy.$$$800$$$808$$$O	The$$$809$$$812$$$O	cream$$$813$$$818$$$O	prepared$$$819$$$827$$$O	by$$$828$$$830$$$O	the$$$831$$$834$$$O	composition$$$835$$$846$$$O	of$$$847$$$849$$$O	the$$$850$$$853$$$O	present$$$854$$$861$$$O	invention$$$862$$$871$$$O	has$$$872$$$875$$$O	the$$$876$$$879$$$O	characteristics$$$880$$$895$$$O	of$$$896$$$898$$$O	white$$$899$$$904$$$O	appearance$$$905$$$915$$$O	and$$$916$$$919$$$O	good$$$920$$$924$$$O	stability,$$$925$$$935$$$O	and$$$936$$$939$$$O	can$$$940$$$943$$$O	be$$$944$$$946$$$O	widely$$$947$$$953$$$O	used$$$954$$$958$$$O	in$$$959$$$961$$$O	pharmaceuticals$$$962$$$977$$$O	and$$$978$$$981$$$O	cosmetic$$$982$$$990$$$O	products.$$$991$$$1000$$$O
US7572774
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	glutamate$$$21$$$30$$$I	cytotoxicity$$$31$$$43$$$O	with$$$44$$$48$$$O	beta-naphthoquinone$$$49$$$68$$$I	compounds$$$69$$$78$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	beta-naphthoquinone$$$44$$$63$$$I	derivatives,$$$64$$$76$$$O	and$$$77$$$80$$$O	salts$$$81$$$86$$$O	thereof,$$$87$$$95$$$O	for$$$96$$$99$$$O	the$$$100$$$103$$$O	prevention$$$104$$$114$$$O	and/or$$$115$$$121$$$O	the$$$122$$$125$$$O	treatment$$$126$$$135$$$O	of$$$136$$$138$$$O	glutamate$$$139$$$148$$$I	cytotoxicity.$$$149$$$162$$$O	It$$$163$$$165$$$O	further$$$166$$$173$$$O	relates$$$174$$$181$$$O	to$$$182$$$184$$$O	the$$$185$$$188$$$O	use$$$189$$$192$$$O	of$$$193$$$195$$$O	beta-naphthoquinone$$$196$$$215$$$I	derivatives,$$$216$$$228$$$O	and$$$229$$$232$$$O	salts$$$233$$$238$$$O	thereof,$$$239$$$247$$$O	for$$$248$$$251$$$O	preventing$$$252$$$262$$$O	and/or$$$263$$$269$$$O	treating$$$270$$$278$$$O	glutamate$$$279$$$288$$$I	induced$$$289$$$296$$$O	neurological$$$297$$$309$$$O	disorders.$$$310$$$320$$$O	Additionally,$$$321$$$334$$$O	it$$$335$$$337$$$O	concerns$$$338$$$346$$$O	the$$$347$$$350$$$O	use$$$351$$$354$$$O	of$$$355$$$357$$$O	beta-naphthoquinone$$$358$$$377$$$I	derivatives,$$$378$$$390$$$O	and$$$391$$$394$$$O	salts$$$395$$$400$$$O	thereof,$$$401$$$409$$$O	for$$$410$$$413$$$O	making$$$414$$$420$$$O	drugs$$$421$$$426$$$O	exerting$$$427$$$435$$$O	an$$$436$$$438$$$O	inhibitory$$$439$$$449$$$O	effect$$$450$$$456$$$O	on$$$457$$$459$$$O	the$$$460$$$463$$$O	release$$$464$$$471$$$O	of$$$472$$$474$$$O	glutamate.$$$475$$$485$$$I
CN103058999A
Novel$$$0$$$5$$$O	pantoprazole$$$6$$$18$$$I	sodium$$$19$$$25$$$I	compound$$$26$$$34$$$O	and$$$35$$$38$$$O	pharmaceutical$$$39$$$53$$$O	composition$$$54$$$65$$$O	thereof$$$66$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	novel$$$26$$$31$$$O	pantoprazole$$$32$$$44$$$I	sodium$$$45$$$51$$$I	compound.$$$52$$$61$$$O	The$$$62$$$65$$$O	purity$$$66$$$72$$$O	of$$$73$$$75$$$O	the$$$76$$$79$$$O	novel$$$80$$$85$$$O	pantoprazole$$$86$$$98$$$I	sodium$$$99$$$105$$$I	compound$$$106$$$114$$$O	reaches$$$115$$$122$$$O	more$$$123$$$127$$$O	than$$$128$$$132$$$O	99.8%.$$$133$$$139$$$O	Meanwhile,$$$140$$$150$$$O	the$$$151$$$154$$$O	invention$$$155$$$164$$$O	also$$$165$$$169$$$O	discloses$$$170$$$179$$$O	a$$$180$$$181$$$O	pharmaceutical$$$182$$$196$$$O	composition$$$197$$$208$$$O	of$$$209$$$211$$$O	the$$$212$$$215$$$O	novel$$$216$$$221$$$O	pantoprazole$$$222$$$234$$$I	sodium$$$235$$$241$$$I	compound.$$$242$$$251$$$O	The$$$252$$$255$$$O	pharmaceutical$$$256$$$270$$$O	composition$$$271$$$282$$$O	comprises$$$283$$$292$$$O	the$$$293$$$296$$$O	following$$$297$$$306$$$O	components$$$307$$$317$$$O	in$$$318$$$320$$$O	parts$$$321$$$326$$$O	by$$$327$$$329$$$O	weight:$$$330$$$337$$$O	45-80$$$338$$$343$$$O	parts$$$344$$$349$$$O	of$$$350$$$352$$$O	pantoprazole$$$353$$$365$$$I	sodium,$$$366$$$373$$$I	3-20$$$374$$$378$$$O	parts$$$379$$$384$$$O	of$$$385$$$387$$$O	ethylene$$$388$$$396$$$I	diamine$$$397$$$404$$$I	tetraacetic$$$405$$$416$$$I	acid,$$$417$$$422$$$I	0.5-3$$$423$$$428$$$O	parts$$$429$$$434$$$O	of$$$435$$$437$$$O	sodium$$$438$$$444$$$I	tartrate$$$445$$$453$$$I	and$$$454$$$457$$$O	4-52$$$458$$$462$$$O	parts$$$463$$$468$$$O	of$$$469$$$471$$$O	mannitol.$$$472$$$481$$$I	According$$$482$$$491$$$O	to$$$492$$$494$$$O	the$$$495$$$498$$$O	pharmaceutical$$$499$$$513$$$O	composition$$$514$$$525$$$O	of$$$526$$$528$$$O	the$$$529$$$532$$$O	novel$$$533$$$538$$$O	pantoprazole$$$539$$$551$$$I	sodium$$$552$$$558$$$I	compound,$$$559$$$568$$$O	a$$$569$$$570$$$O	synergistic$$$571$$$582$$$O	effect$$$583$$$589$$$O	is$$$590$$$592$$$O	generated$$$593$$$602$$$O	between$$$603$$$610$$$O	ethylene$$$611$$$619$$$I	diamine$$$620$$$627$$$I	tetraacetic$$$628$$$639$$$I	acid$$$640$$$644$$$I	and$$$645$$$648$$$O	sodium$$$649$$$655$$$I	tartrate,$$$656$$$665$$$I	so$$$666$$$668$$$O	that$$$669$$$673$$$O	the$$$674$$$677$$$O	stability$$$678$$$687$$$O	of$$$688$$$690$$$O	pantoprazole$$$691$$$703$$$I	sodium$$$704$$$710$$$I	is$$$711$$$713$$$O	remarkably$$$714$$$724$$$O	improved,$$$725$$$734$$$O	and$$$735$$$738$$$O	the$$$739$$$742$$$O	pharmaceutical$$$743$$$757$$$O	composition$$$758$$$769$$$O	has$$$770$$$773$$$O	important$$$774$$$783$$$O	significance$$$784$$$796$$$O	for$$$797$$$800$$$O	pantoprazole$$$801$$$813$$$I	sodium$$$814$$$820$$$I	in$$$821$$$823$$$O	clinical$$$824$$$832$$$O	popularization$$$833$$$847$$$O	and$$$848$$$851$$$O	application.$$$852$$$864$$$O
EP1532133A1
Nf-:b$$$0$$$5$$$O	inhibitors$$$6$$$16$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	novel$$$31$$$36$$$O	compounds$$$37$$$46$$$O	and$$$47$$$50$$$O	methods$$$51$$$58$$$O	for$$$59$$$62$$$O	using$$$63$$$68$$$O	them$$$69$$$73$$$O	to$$$74$$$76$$$O	treat$$$77$$$82$$$O	diseases$$$83$$$91$$$O	with$$$92$$$96$$$O	aminothiophene$$$97$$$111$$$I	inhibitors$$$112$$$122$$$O	of$$$123$$$125$$$O	IKK-Ã$$$126$$$132$$$O	phosphorylation$$$133$$$148$$$O	of$$$149$$$151$$$O	I:B.$$$152$$$156$$$O	In$$$157$$$159$$$O	so$$$160$$$162$$$O	doing$$$163$$$168$$$O	these$$$169$$$174$$$I	aminothiophene$$$175$$$189$$$I	inhibitors$$$190$$$200$$$O	block$$$201$$$206$$$O	pathological$$$207$$$219$$$O	activation$$$220$$$230$$$O	of$$$231$$$233$$$O	transcription$$$234$$$247$$$O	factor$$$248$$$254$$$O	NF-:B$$$255$$$260$$$O	in$$$261$$$263$$$O	which$$$264$$$269$$$O	diseases$$$270$$$278$$$O	excessive$$$279$$$288$$$O	activation$$$289$$$299$$$O	of$$$300$$$302$$$O	NF-:B$$$303$$$308$$$O	is$$$309$$$311$$$O	implicated.$$$312$$$323$$$O
US20110217371
Controlled-release$$$0$$$18$$$O	microparticles$$$19$$$33$$$O	and$$$34$$$37$$$O	method$$$38$$$44$$$O	of$$$45$$$47$$$O	preparing$$$48$$$57$$$O	same$$$58$$$62$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	controlled-release$$$15$$$33$$$O	microparticle:$$$34$$$48$$$O	including$$$49$$$58$$$O	a$$$59$$$60$$$O	matrix$$$61$$$67$$$O	comprising$$$68$$$78$$$O	a$$$79$$$80$$$O	pharmacologically$$$81$$$98$$$O	active$$$99$$$105$$$O	component;$$$106$$$116$$$O	and$$$117$$$120$$$O	a$$$121$$$122$$$O	controlled-release$$$123$$$141$$$O	layer$$$142$$$147$$$O	comprising$$$148$$$158$$$O	a$$$159$$$160$$$O	substance$$$161$$$170$$$O	which$$$171$$$176$$$O	forms$$$177$$$182$$$O	a$$$183$$$184$$$O	controlled-release$$$185$$$203$$$O	stratum$$$204$$$211$$$O	on$$$212$$$214$$$O	the$$$215$$$218$$$O	matrix.$$$219$$$226$$$O	The$$$227$$$230$$$O	disclosed$$$231$$$240$$$O	controlled-release$$$241$$$259$$$O	microparticle$$$260$$$273$$$O	not$$$274$$$277$$$O	only$$$278$$$282$$$O	allows$$$283$$$289$$$O	effective$$$290$$$299$$$O	dual$$$300$$$304$$$O	release$$$305$$$312$$$O	control$$$313$$$320$$$O	of$$$321$$$323$$$O	a$$$324$$$325$$$O	drug$$$326$$$330$$$O	but$$$331$$$334$$$O	can$$$335$$$338$$$O	also$$$339$$$343$$$O	exhibit$$$344$$$351$$$O	outstanding$$$352$$$363$$$O	dissolution$$$364$$$375$$$O	characteristics$$$376$$$391$$$O	even$$$392$$$396$$$O	when$$$397$$$401$$$O	a$$$402$$$403$$$O	small$$$404$$$409$$$O	amount$$$410$$$416$$$O	of$$$417$$$419$$$O	coating$$$420$$$427$$$O	substance$$$428$$$437$$$O	is$$$438$$$440$$$O	used.$$$441$$$446$$$O
US8535899
Assay$$$0$$$5$$$O	for$$$6$$$9$$$O	identifying$$$10$$$21$$$O	a$$$22$$$23$$$O	modulator$$$24$$$33$$$O	of$$$34$$$36$$$O	HIF$$$37$$$40$$$O	hydroxylase$$$41$$$52$$$O
A$$$0$$$1$$$O	novel$$$2$$$7$$$O	class$$$8$$$13$$$O	of$$$14$$$16$$$O	hydroxylases$$$17$$$29$$$O	is$$$30$$$32$$$O	described$$$33$$$42$$$O	having$$$43$$$49$$$O	the$$$50$$$53$$$O	amino$$$54$$$59$$$O	acid$$$60$$$64$$$O	sequence$$$65$$$73$$$O	of$$$74$$$76$$$O	SEQ$$$77$$$80$$$O	ID$$$81$$$83$$$O	NO:$$$84$$$87$$$O	2,$$$88$$$90$$$O	4,$$$91$$$93$$$O	6$$$94$$$95$$$O	and$$$96$$$99$$$O	8,$$$100$$$102$$$O	and$$$103$$$106$$$O	variants$$$107$$$115$$$O	and$$$116$$$119$$$O	fragments$$$120$$$129$$$O	thereof$$$130$$$137$$$O	having$$$138$$$144$$$O	HIF$$$145$$$148$$$O	hydroxylation$$$149$$$162$$$O	activity.$$$163$$$172$$$O	The$$$173$$$176$$$O	polypeptides$$$177$$$189$$$O	of$$$190$$$192$$$O	the$$$193$$$196$$$O	invention$$$197$$$206$$$O	have$$$207$$$211$$$O	in$$$212$$$214$$$O	particular$$$215$$$225$$$O	prolyl$$$226$$$232$$$O	hydroxylase$$$233$$$244$$$O	activity.$$$245$$$254$$$O	An$$$255$$$257$$$O	assay$$$258$$$263$$$O	method$$$264$$$270$$$O	monitors$$$271$$$279$$$O	the$$$280$$$283$$$O	interaction$$$284$$$295$$$O	of$$$296$$$298$$$O	the$$$299$$$302$$$O	HIF$$$303$$$306$$$O	hydroxylase$$$307$$$318$$$O	with$$$319$$$323$$$O	a$$$324$$$325$$$O	substrate.$$$326$$$336$$$O	Modulators$$$337$$$347$$$O	of$$$348$$$350$$$O	HIF$$$351$$$354$$$O	hydroxylase$$$355$$$366$$$O	are$$$367$$$370$$$O	provided$$$371$$$379$$$O	for$$$380$$$383$$$O	use$$$384$$$387$$$O	in$$$388$$$390$$$O	the$$$391$$$394$$$O	treatment$$$395$$$404$$$O	of$$$405$$$407$$$O	a$$$408$$$409$$$O	condition$$$410$$$419$$$O	associated$$$420$$$430$$$O	with$$$431$$$435$$$O	increased$$$436$$$445$$$O	or$$$446$$$448$$$O	decreased$$$449$$$458$$$O	HIF$$$459$$$462$$$O	levels$$$463$$$469$$$O	or$$$470$$$472$$$O	activity$$$473$$$481$$$O	or$$$482$$$484$$$O	for$$$485$$$488$$$O	the$$$489$$$492$$$O	treatment$$$493$$$502$$$O	of$$$503$$$505$$$O	a$$$506$$$507$$$O	condition$$$508$$$517$$$O	where$$$518$$$523$$$O	it$$$524$$$526$$$O	is$$$527$$$529$$$O	desirable$$$530$$$539$$$O	to$$$540$$$542$$$O	modulate$$$543$$$551$$$O	HIF$$$552$$$555$$$O	levels$$$556$$$562$$$O	or$$$563$$$565$$$O	activity.$$$566$$$575$$$O
US20080292654
Human$$$0$$$5$$$O	Bocavirus$$$6$$$15$$$O	and$$$16$$$19$$$O	Methods$$$20$$$27$$$O	of$$$28$$$30$$$O	Diagnosis$$$31$$$40$$$O	and$$$41$$$44$$$O	Treatment$$$45$$$54$$$O
Human$$$0$$$5$$$O	parvovirus,$$$6$$$17$$$O	genus$$$18$$$23$$$O	Bocavirus,$$$24$$$34$$$O	associated$$$35$$$45$$$O	with$$$46$$$50$$$O	respiratory$$$51$$$62$$$O	tract$$$63$$$68$$$O	infections$$$69$$$79$$$O	in$$$80$$$82$$$O	children.$$$83$$$92$$$O	Nucleic$$$93$$$100$$$O	acid$$$101$$$105$$$O	and$$$106$$$109$$$O	polypeptide$$$110$$$121$$$O	sequences$$$122$$$131$$$O	of$$$132$$$134$$$O	the$$$135$$$138$$$O	virus.$$$139$$$145$$$O	Methods$$$146$$$153$$$O	and$$$154$$$157$$$O	products$$$158$$$166$$$O	for$$$167$$$170$$$O	diagnosing$$$171$$$181$$$O	presence$$$182$$$190$$$O	of$$$191$$$193$$$O	bocavirus$$$194$$$203$$$O	in$$$204$$$206$$$O	a$$$207$$$208$$$O	sample$$$209$$$215$$$O	using$$$216$$$221$$$O	nucleic$$$222$$$229$$$O	acid$$$230$$$234$$$O	probes$$$235$$$241$$$O	or$$$242$$$244$$$O	primers,$$$245$$$253$$$O	or$$$254$$$256$$$O	specific$$$257$$$265$$$O	binding$$$266$$$273$$$O	members$$$274$$$281$$$O	such$$$282$$$286$$$O	as$$$287$$$289$$$O	antibodies.$$$290$$$301$$$O	Methods$$$302$$$309$$$O	and$$$310$$$313$$$O	products$$$314$$$322$$$O	for$$$323$$$326$$$O	diagnosing$$$327$$$337$$$O	past$$$338$$$342$$$O	or$$$343$$$345$$$O	present$$$346$$$353$$$O	infection$$$354$$$363$$$O	of$$$364$$$366$$$O	bocavirus$$$367$$$376$$$O	in$$$377$$$379$$$O	an$$$380$$$382$$$O	individual$$$383$$$393$$$O	e.g.$$$394$$$398$$$O	by$$$399$$$401$$$O	serology$$$402$$$410$$$O	testing.$$$411$$$419$$$O	Viral$$$420$$$425$$$O	nucleic$$$426$$$433$$$O	acid,$$$434$$$439$$$O	polypeptide$$$440$$$451$$$O	and/or$$$452$$$458$$$O	viral$$$459$$$464$$$O	particles$$$465$$$474$$$O	for$$$475$$$478$$$O	generating$$$479$$$489$$$O	immune$$$490$$$496$$$O	response$$$497$$$505$$$O	in$$$506$$$508$$$O	an$$$509$$$511$$$O	individual,$$$512$$$523$$$O	including$$$524$$$533$$$O	vaccine$$$534$$$541$$$O	compositions.$$$542$$$555$$$O
US7919612
Comprises$$$0$$$9$$$O	modified$$$10$$$18$$$O	nucleotide$$$19$$$29$$$O	sequences$$$30$$$39$$$O	for$$$40$$$43$$$O	use$$$44$$$47$$$O	in$$$48$$$50$$$O	gene$$$51$$$55$$$O	expression$$$56$$$66$$$O	inhibition,$$$67$$$78$$$O	viral$$$79$$$84$$$O	defense,$$$85$$$93$$$O	transposon$$$94$$$104$$$O	silencing$$$105$$$114$$$O	and$$$115$$$118$$$O	treatment$$$119$$$128$$$O	of$$$129$$$131$$$O	metabolic$$$132$$$141$$$O	disorders;$$$142$$$152$$$O	antisense$$$153$$$162$$$O	agents$$$163$$$169$$$O
Compositions$$$0$$$12$$$O	comprising$$$13$$$23$$$O	first$$$24$$$29$$$O	and$$$30$$$33$$$O	second$$$34$$$40$$$O	oligomers$$$41$$$50$$$I	are$$$51$$$54$$$O	provided$$$55$$$63$$$O	wherein$$$64$$$71$$$O	at$$$72$$$74$$$O	least$$$75$$$80$$$O	a$$$81$$$82$$$O	portion$$$83$$$90$$$O	of$$$91$$$93$$$O	the$$$94$$$97$$$O	first$$$98$$$103$$$O	oligomer$$$104$$$112$$$I	is$$$113$$$115$$$O	capable$$$116$$$123$$$O	of$$$124$$$126$$$O	hybridizing$$$127$$$138$$$O	with$$$139$$$143$$$O	at$$$144$$$146$$$O	least$$$147$$$152$$$O	a$$$153$$$154$$$O	portion$$$155$$$162$$$O	of$$$163$$$165$$$O	the$$$166$$$169$$$O	second$$$170$$$176$$$O	oligomer,$$$177$$$186$$$I	at$$$187$$$189$$$O	least$$$190$$$195$$$O	a$$$196$$$197$$$O	portion$$$198$$$205$$$O	of$$$206$$$208$$$O	the$$$209$$$212$$$O	first$$$213$$$218$$$O	oligomer$$$219$$$227$$$I	is$$$228$$$230$$$O	complementary$$$231$$$244$$$O	to$$$245$$$247$$$O	and$$$248$$$251$$$O	capable$$$252$$$259$$$O	of$$$260$$$262$$$O	hybridizing$$$263$$$274$$$O	to$$$275$$$277$$$O	a$$$278$$$279$$$O	selected$$$280$$$288$$$O	target$$$289$$$295$$$O	nucleic$$$296$$$303$$$O	acid,$$$304$$$309$$$O	and$$$310$$$313$$$O	at$$$314$$$316$$$O	least$$$317$$$322$$$O	one$$$323$$$326$$$O	of$$$327$$$329$$$O	the$$$330$$$333$$$O	first$$$334$$$339$$$O	or$$$340$$$342$$$O	second$$$343$$$349$$$O	oligomers$$$350$$$359$$$I	includes$$$360$$$368$$$O	a$$$369$$$370$$$O	modified$$$371$$$379$$$O	sugar$$$380$$$385$$$I	and/or$$$386$$$392$$$O	backbone$$$393$$$401$$$O	modification.$$$402$$$415$$$O	In$$$416$$$418$$$O	some$$$419$$$423$$$O	embodiments$$$424$$$435$$$O	the$$$436$$$439$$$O	modification$$$440$$$452$$$O	is$$$453$$$455$$$O	a$$$456$$$457$$$O	2â²$$$458$$$462$$$O	substituent$$$463$$$474$$$O	group$$$475$$$480$$$O	on$$$481$$$483$$$O	a$$$484$$$485$$$I	sugar$$$486$$$491$$$I	moiety$$$492$$$498$$$O	that$$$499$$$503$$$O	is$$$504$$$506$$$O	not$$$507$$$510$$$I	H$$$511$$$512$$$O	or$$$513$$$515$$$I	OH.$$$516$$$519$$$I	Oligomer/protein$$$520$$$536$$$I	compositions$$$537$$$549$$$O	are$$$550$$$553$$$O	also$$$554$$$558$$$O	provided$$$559$$$567$$$O	comprising$$$568$$$578$$$O	an$$$579$$$581$$$I	oligomer$$$582$$$590$$$I	complementary$$$591$$$604$$$O	to$$$605$$$607$$$O	and$$$608$$$611$$$O	capable$$$612$$$619$$$O	of$$$620$$$622$$$O	hybridizing$$$623$$$634$$$O	to$$$635$$$637$$$O	a$$$638$$$639$$$O	selected$$$640$$$648$$$O	target$$$649$$$655$$$O	nucleic$$$656$$$663$$$O	acid$$$664$$$668$$$O	and$$$669$$$672$$$O	at$$$673$$$675$$$O	least$$$676$$$681$$$O	one$$$682$$$685$$$O	protein$$$686$$$693$$$O	comprising$$$694$$$704$$$O	at$$$705$$$707$$$O	least$$$708$$$713$$$O	a$$$714$$$715$$$O	portion$$$716$$$723$$$O	of$$$724$$$726$$$O	an$$$727$$$729$$$O	RNA-induced$$$730$$$741$$$O	silencing$$$742$$$751$$$O	complex$$$752$$$759$$$O	(RISC),$$$760$$$767$$$O	wherein$$$768$$$775$$$O	at$$$776$$$778$$$O	least$$$779$$$784$$$O	one$$$785$$$788$$$O	nucleotide$$$789$$$799$$$O	of$$$800$$$802$$$O	the$$$803$$$806$$$O	oligomer$$$807$$$815$$$O	has$$$816$$$819$$$O	a$$$820$$$821$$$O	modified$$$822$$$830$$$I	sugar$$$831$$$836$$$I	and/or$$$837$$$843$$$O	backbone$$$844$$$852$$$O	modification.$$$853$$$866$$$O
EP2582812A1
Novel$$$0$$$5$$$O	modified$$$6$$$14$$$O	release$$$15$$$22$$$O	dosage$$$23$$$29$$$O	forms$$$30$$$35$$$O	of$$$36$$$38$$$O	xanthine$$$39$$$47$$$I	oxidoreductase$$$48$$$62$$$O	inhibitor$$$63$$$72$$$O	or$$$73$$$75$$$O	xanthine$$$76$$$84$$$I	oxidase$$$85$$$92$$$O	inhibitors$$$93$$$103$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	relates$$$23$$$30$$$O	to$$$31$$$33$$$O	novel$$$34$$$39$$$O	dosage$$$40$$$46$$$O	forms$$$47$$$52$$$O	of$$$53$$$55$$$O	xanthine$$$56$$$64$$$I	oxidoreductase$$$65$$$79$$$O	inhibitors.$$$80$$$91$$$O
US20070088006
Preemptive$$$0$$$10$$$O	Prophylaxis$$$11$$$22$$$O	of$$$23$$$25$$$O	Migraine$$$26$$$34$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	preventing$$$12$$$22$$$O	the$$$23$$$26$$$O	headache$$$27$$$35$$$O	phase$$$36$$$41$$$O	of$$$42$$$44$$$O	migraine$$$45$$$53$$$O	in$$$54$$$56$$$O	a$$$57$$$58$$$O	human$$$59$$$64$$$O	comprises$$$65$$$74$$$O	administration$$$75$$$89$$$O	of$$$90$$$92$$$O	a$$$93$$$94$$$O	5HT1$$$95$$$99$$$O	receptor$$$100$$$108$$$O	agonist$$$109$$$116$$$O	or$$$117$$$119$$$O	administration$$$120$$$134$$$O	of$$$135$$$137$$$O	an$$$138$$$140$$$O	over-the-counter$$$141$$$157$$$O	or$$$158$$$160$$$O	nonprescription$$$161$$$176$$$O	drug$$$177$$$181$$$O	to$$$182$$$184$$$O	said$$$185$$$189$$$O	human$$$190$$$195$$$O	exhibiting$$$196$$$206$$$O	prodrome$$$207$$$215$$$O	symptoms$$$216$$$224$$$O	of$$$225$$$227$$$O	migraine.$$$228$$$237$$$O	Suitably,$$$238$$$247$$$O	the$$$248$$$251$$$O	method$$$252$$$258$$$O	comprises$$$259$$$268$$$O	administration$$$269$$$283$$$O	of$$$284$$$286$$$O	a$$$287$$$288$$$O	migraine$$$289$$$297$$$O	headache$$$298$$$306$$$O	phase-preventing$$$307$$$323$$$O	effective$$$324$$$333$$$O	amount$$$334$$$340$$$O	of$$$341$$$343$$$O	the$$$344$$$347$$$O	5HT1$$$348$$$352$$$O	or$$$353$$$355$$$O	over-the-counter$$$356$$$372$$$O	or$$$373$$$375$$$O	nonprescription$$$376$$$391$$$O	drug.$$$392$$$397$$$O	There$$$398$$$403$$$O	is$$$404$$$406$$$O	disclosed$$$407$$$416$$$O	a$$$417$$$418$$$O	preemptive$$$419$$$429$$$O	prophylaxis$$$430$$$441$$$O	migraine$$$442$$$450$$$O	method$$$451$$$457$$$O	using$$$458$$$463$$$O	the$$$464$$$467$$$O	following$$$468$$$477$$$O	cognitive$$$478$$$487$$$O	tests:$$$488$$$494$$$O	Simple$$$495$$$501$$$O	Reaction$$$502$$$510$$$O	Time;$$$511$$$516$$$O	Running$$$517$$$524$$$O	Memory$$$525$$$531$$$O	Continuous$$$532$$$542$$$O	Performance$$$543$$$554$$$O	Task;$$$555$$$560$$$O	Matching$$$561$$$569$$$O	to$$$570$$$572$$$O	Sample;$$$573$$$580$$$O	Mathematical$$$581$$$593$$$O	Processing$$$594$$$604$$$O	Task;$$$605$$$610$$$O	and$$$611$$$614$$$O	interpreting$$$615$$$627$$$O	the$$$628$$$631$$$O	results$$$632$$$639$$$O	as$$$640$$$642$$$O	a$$$643$$$644$$$O	percent$$$645$$$652$$$O	of$$$653$$$655$$$O	baseline$$$656$$$664$$$O	indicator$$$665$$$674$$$O	of$$$675$$$677$$$O	need$$$678$$$682$$$O	for$$$683$$$686$$$O	prophylaxis.$$$687$$$699$$$O
WO2014065710A1
(3-arylsulfonyl-quinoline-8-yl)-dialkyl-amines$$$0$$$46$$$I	as$$$47$$$49$$$O	selective$$$50$$$59$$$O	antagonists$$$60$$$71$$$O	of$$$72$$$74$$$O	serotonin$$$75$$$84$$$I	5-ht6$$$85$$$90$$$O	receptors,$$$91$$$101$$$O	methods$$$102$$$109$$$O	for$$$110$$$113$$$O	the$$$114$$$117$$$O	production$$$118$$$128$$$O	and$$$129$$$132$$$O	use$$$133$$$136$$$O	thereof$$$137$$$144$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	(3-arylsulfonyl-quinoline-8-yl)-dialkyl-amines$$$31$$$77$$$I	of$$$78$$$80$$$O	general$$$81$$$88$$$O	formula$$$89$$$96$$$O	1,$$$97$$$99$$$O	or$$$100$$$102$$$O	pharmaceutically$$$103$$$119$$$O	acceptable$$$120$$$130$$$O	salts$$$131$$$136$$$O	thereof,$$$137$$$145$$$O	which$$$146$$$151$$$O	are$$$152$$$155$$$O	selective$$$156$$$165$$$O	serotonin$$$166$$$175$$$O	5-HT6$$$176$$$181$$$O	receptor$$$182$$$190$$$O	antagonists.$$$191$$$203$$$O	The$$$204$$$207$$$O	compounds$$$208$$$217$$$O	can$$$218$$$221$$$O	be$$$222$$$224$$$O	used$$$225$$$229$$$O	as$$$230$$$232$$$O	a$$$233$$$234$$$O	medicinal$$$235$$$244$$$O	principle$$$245$$$254$$$O	in$$$255$$$257$$$O	pharmaceutical$$$258$$$272$$$O	compositions$$$273$$$285$$$O	and$$$286$$$289$$$O	drugs$$$290$$$295$$$O	for$$$296$$$299$$$O	treating$$$300$$$308$$$O	diseases$$$309$$$317$$$O	of$$$318$$$320$$$O	the$$$321$$$324$$$O	central$$$325$$$332$$$O	nervous$$$333$$$340$$$O	system$$$341$$$347$$$O	(CNS),$$$348$$$354$$$O	the$$$355$$$358$$$O	pathogenesis$$$359$$$371$$$O	of$$$372$$$374$$$O	which$$$375$$$380$$$O	is$$$381$$$383$$$O	associated$$$384$$$394$$$O	with$$$395$$$399$$$O	5-HT6$$$400$$$405$$$O	receptors.$$$406$$$416$$$O	In$$$417$$$419$$$O	particular,$$$420$$$431$$$O	the$$$432$$$435$$$O	compounds$$$436$$$445$$$O	can$$$446$$$449$$$O	be$$$450$$$452$$$O	used$$$453$$$457$$$O	in$$$458$$$460$$$O	the$$$461$$$464$$$O	treatment$$$465$$$474$$$O	of$$$475$$$477$$$O	neurodegenerative$$$478$$$495$$$O	diseases,$$$496$$$505$$$O	Alzheimer's$$$506$$$517$$$O	disease,$$$518$$$526$$$O	Parkinson's$$$527$$$538$$$O	disease,$$$539$$$547$$$O	Huntington's$$$548$$$560$$$O	disease,$$$561$$$569$$$O	and$$$570$$$573$$$O	cognitive$$$574$$$583$$$O	or$$$584$$$586$$$O	anxiety$$$587$$$594$$$O	disorders,$$$595$$$605$$$O	and$$$606$$$609$$$O	to$$$610$$$612$$$O	improve$$$613$$$620$$$O	intellectual$$$621$$$633$$$O	abilities.$$$634$$$644$$$O	In$$$645$$$647$$$O	general$$$648$$$655$$$O	formula$$$656$$$663$$$O	1,$$$664$$$666$$$O	Ar$$$667$$$669$$$O	is$$$670$$$672$$$O	a$$$673$$$674$$$O	phenyl,$$$675$$$682$$$O	optionally$$$683$$$693$$$O	substituted$$$694$$$705$$$O	with$$$706$$$710$$$O	a$$$711$$$712$$$O	halogen$$$713$$$720$$$O	atom$$$721$$$725$$$O	in$$$726$$$728$$$O	position$$$729$$$737$$$O	3,$$$738$$$740$$$O	or$$$741$$$743$$$O	a$$$744$$$745$$$O	naphthyl;$$$746$$$755$$$O	R$$$756$$$757$$$O	1$$$758$$$759$$$O	and$$$760$$$763$$$O	R2$$$764$$$766$$$O	are$$$767$$$770$$$O	an$$$771$$$773$$$O	unsubstituted$$$774$$$787$$$O	methyl$$$788$$$794$$$O	or$$$795$$$797$$$O	an$$$798$$$800$$$O	ethyl.$$$801$$$807$$$O
US20080070826
Cholesterol-reducing$$$0$$$20$$$I	diet$$$21$$$25$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	treating$$$12$$$20$$$O	cholesterol$$$21$$$32$$$I	imbalance,$$$33$$$43$$$O	high$$$44$$$48$$$O	LDLs,$$$49$$$54$$$O	and$$$55$$$58$$$O	other$$$59$$$64$$$O	metabolic$$$65$$$74$$$O	syndrome$$$75$$$83$$$O	problems$$$84$$$92$$$O	and$$$93$$$96$$$O	symptoms$$$97$$$105$$$O	of$$$106$$$108$$$O	osteoarthritis.$$$109$$$124$$$O	The$$$125$$$128$$$O	regimen$$$129$$$136$$$O	preferred$$$137$$$146$$$O	embodiment$$$147$$$157$$$O	includes$$$158$$$166$$$O	lipids$$$167$$$173$$$O	as$$$174$$$176$$$O	60%$$$177$$$180$$$O	or$$$181$$$183$$$O	more$$$184$$$188$$$O	of$$$189$$$191$$$O	daily$$$192$$$197$$$O	caloric$$$198$$$205$$$O	content,$$$206$$$214$$$O	protein$$$215$$$222$$$O	up$$$223$$$225$$$O	to$$$226$$$228$$$O	10%-15%$$$229$$$236$$$O	of$$$237$$$239$$$O	daily$$$240$$$245$$$O	caloric$$$246$$$253$$$O	content;$$$254$$$262$$$O	and$$$263$$$266$$$O	carbohydrates$$$267$$$280$$$I	up$$$281$$$283$$$O	to$$$284$$$286$$$O	25%$$$287$$$290$$$O	or$$$291$$$293$$$O	less$$$294$$$298$$$O	of$$$299$$$301$$$O	daily$$$302$$$307$$$O	caloric$$$308$$$315$$$O	content,$$$316$$$324$$$O	primarily$$$325$$$334$$$O	in$$$335$$$337$$$O	the$$$338$$$341$$$O	form$$$342$$$346$$$O	of$$$347$$$349$$$O	non-starchy,$$$350$$$362$$$O	low-glycemic$$$363$$$375$$$O	fresh$$$376$$$381$$$O	fruit$$$382$$$387$$$O	and$$$388$$$391$$$O	vegetables,$$$392$$$403$$$O	and$$$404$$$407$$$O	nuts,$$$408$$$413$$$O	along$$$414$$$419$$$O	with$$$420$$$424$$$O	a$$$425$$$426$$$O	daily$$$427$$$432$$$O	intake$$$433$$$439$$$O	of$$$440$$$442$$$O	35$$$443$$$445$$$O	grams$$$446$$$451$$$O	of$$$452$$$454$$$O	dietary$$$455$$$462$$$O	fiber,$$$463$$$469$$$O	with$$$470$$$474$$$O	a$$$475$$$476$$$O	significant$$$477$$$488$$$O	percentage$$$489$$$499$$$O	of$$$500$$$502$$$O	this$$$503$$$507$$$O	as$$$508$$$510$$$O	soluble$$$511$$$518$$$O	fiber;$$$519$$$525$$$O	average$$$526$$$533$$$O	daily$$$534$$$539$$$O	cholesterol$$$540$$$551$$$I	intake$$$552$$$558$$$O	of$$$559$$$561$$$O	less$$$562$$$566$$$O	than$$$567$$$571$$$O	10$$$572$$$574$$$O	mg,$$$575$$$578$$$O	and$$$579$$$582$$$O	30$$$583$$$585$$$O	grams$$$586$$$591$$$O	of$$$592$$$594$$$O	cocoa$$$595$$$600$$$O	solids.$$$601$$$608$$$O
CA2853872A1
Therapeutic$$$0$$$11$$$O	combination$$$12$$$23$$$O	of$$$24$$$26$$$O	memantine$$$27$$$36$$$I	and$$$37$$$40$$$O	baclofen$$$41$$$49$$$I	and$$$50$$$53$$$O	pharmaceutical$$$54$$$68$$$O	composition$$$69$$$80$$$O	containing$$$81$$$91$$$O	them$$$92$$$96$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	combination$$$37$$$48$$$O	of$$$49$$$51$$$O	memantine$$$52$$$61$$$I	and$$$62$$$65$$$O	baclofen$$$66$$$74$$$I	active$$$75$$$81$$$O	ingredients,$$$82$$$94$$$O	and$$$95$$$98$$$O	also$$$99$$$103$$$O	to$$$104$$$106$$$O	the$$$107$$$110$$$O	method$$$111$$$117$$$O	for$$$118$$$121$$$O	achieving$$$122$$$131$$$O	body$$$132$$$136$$$O	weight$$$137$$$143$$$O	loss$$$144$$$148$$$O	and$$$149$$$152$$$O	thereby$$$153$$$160$$$O	treating$$$161$$$169$$$O	obesity$$$170$$$177$$$O	and$$$178$$$181$$$O	related$$$182$$$189$$$O	co-morbidities$$$190$$$204$$$O	by$$$205$$$207$$$O	co-administration$$$208$$$225$$$O	of$$$226$$$228$$$O	baclofen$$$229$$$237$$$I	and$$$238$$$241$$$O	memantine.$$$242$$$252$$$I
US20110312940
Tetra-aza-heterocycles$$$0$$$22$$$I	as$$$23$$$25$$$O	phosphatidylinositol-3-kinases$$$26$$$56$$$O	(p13-kinases)$$$57$$$70$$$O	inhibitor$$$71$$$80$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	encompasses$$$22$$$33$$$O	compounds$$$34$$$43$$$O	of$$$44$$$46$$$O	general$$$47$$$54$$$O	formula$$$55$$$62$$$O	(1)$$$63$$$66$$$O	wherein$$$67$$$74$$$O	R1$$$75$$$77$$$O	to$$$78$$$80$$$O	R4,$$$81$$$84$$$O	A,$$$85$$$87$$$O	X,$$$88$$$90$$$O	m$$$91$$$92$$$O	and$$$93$$$96$$$O	k$$$97$$$98$$$O	are$$$99$$$102$$$O	defined$$$103$$$110$$$O	as$$$111$$$113$$$O	in$$$114$$$116$$$O	claim$$$117$$$122$$$O	1,$$$123$$$125$$$O	which$$$126$$$131$$$O	are$$$132$$$135$$$O	suitable$$$136$$$144$$$O	for$$$145$$$148$$$O	the$$$149$$$152$$$O	treatment$$$153$$$162$$$O	of$$$163$$$165$$$O	diseases$$$166$$$174$$$O	characterised$$$175$$$188$$$O	by$$$189$$$191$$$O	excessive$$$192$$$201$$$O	or$$$202$$$204$$$O	abnormal$$$205$$$213$$$O	cell$$$214$$$218$$$O	proliferation,$$$219$$$233$$$O	and$$$234$$$237$$$O	the$$$238$$$241$$$O	use$$$242$$$245$$$O	thereof$$$246$$$253$$$O	for$$$254$$$257$$$O	preparing$$$258$$$267$$$O	a$$$268$$$269$$$O	medicament$$$270$$$280$$$O	having$$$281$$$287$$$O	the$$$288$$$291$$$O	above-mentioned$$$292$$$307$$$O	properties.$$$308$$$319$$$O
US20080221018
Crystalline$$$0$$$11$$$O	solid$$$12$$$17$$$O	and$$$18$$$21$$$O	amorphous$$$22$$$31$$$O	forms$$$32$$$37$$$O	of$$$38$$$40$$$O	(-)-$$$41$$$45$$$I	halofenate$$$46$$$56$$$I	and$$$57$$$60$$$O	methods$$$61$$$68$$$O	related$$$69$$$76$$$O	thereto$$$77$$$84$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	crystalline$$$31$$$42$$$O	solid$$$43$$$48$$$O	and$$$49$$$52$$$O	amorphous$$$53$$$62$$$O	forms$$$63$$$68$$$O	of$$$69$$$71$$$O	(â)-halofenate.$$$72$$$89$$$I	The$$$90$$$93$$$O	crystalline$$$94$$$105$$$O	solid$$$106$$$111$$$O	forms$$$112$$$117$$$O	may$$$118$$$121$$$O	be$$$122$$$124$$$O	used$$$125$$$129$$$O	in$$$130$$$132$$$O	various$$$133$$$140$$$O	pharmaceutical$$$141$$$155$$$O	compositions,$$$156$$$169$$$O	and$$$170$$$173$$$O	are$$$174$$$177$$$O	particularly$$$178$$$190$$$O	effective$$$191$$$200$$$O	for$$$201$$$204$$$O	the$$$205$$$208$$$O	prevention$$$209$$$219$$$O	and/or$$$220$$$226$$$O	treatment$$$227$$$236$$$O	of$$$237$$$239$$$O	conditions$$$240$$$250$$$O	associated$$$251$$$261$$$O	with$$$262$$$266$$$O	blood$$$267$$$272$$$O	lipid$$$273$$$278$$$O	deposition$$$279$$$289$$$O	in$$$290$$$292$$$O	a$$$293$$$294$$$O	mammal,$$$295$$$302$$$O	particularly$$$303$$$315$$$O	those$$$316$$$321$$$O	diseases$$$322$$$330$$$O	related$$$331$$$338$$$O	to$$$339$$$341$$$O	Type$$$342$$$346$$$O	2$$$347$$$348$$$O	diabetes$$$349$$$357$$$O	and$$$358$$$361$$$O	hyperlipidemia.$$$362$$$377$$$O	The$$$378$$$381$$$O	invention$$$382$$$391$$$O	also$$$392$$$396$$$O	relates$$$397$$$404$$$O	to$$$405$$$407$$$O	a$$$408$$$409$$$O	method$$$410$$$416$$$O	for$$$417$$$420$$$O	preventing$$$421$$$431$$$O	or$$$432$$$434$$$O	treating$$$435$$$443$$$O	Type$$$444$$$448$$$O	2$$$449$$$450$$$O	diabetes$$$451$$$459$$$O	and$$$460$$$463$$$O	hyperlipidemia$$$464$$$478$$$O	in$$$479$$$481$$$O	a$$$482$$$483$$$O	mammal$$$484$$$490$$$O	comprising$$$491$$$501$$$O	the$$$502$$$505$$$O	step$$$506$$$510$$$O	of$$$511$$$513$$$O	administering$$$514$$$527$$$O	a$$$528$$$529$$$O	therapeutically$$$530$$$545$$$O	effective$$$546$$$555$$$O	amount$$$556$$$562$$$O	of$$$563$$$565$$$O	crystalline$$$566$$$577$$$O	solid$$$578$$$583$$$O	and$$$584$$$587$$$O	amorphous$$$588$$$597$$$O	forms$$$598$$$603$$$O	of$$$604$$$606$$$I	(â)-halofenate.$$$607$$$624$$$I
WO2009135135A3
Fibromodulin$$$0$$$12$$$O	formulation$$$13$$$24$$$O	for$$$25$$$28$$$O	reducing$$$29$$$37$$$O	corneal$$$38$$$45$$$O	scarring$$$46$$$54$$$O
A$$$0$$$1$$$O	formulation$$$2$$$13$$$O	for$$$14$$$17$$$O	reducing$$$18$$$26$$$O	corneal$$$27$$$34$$$O	scarring$$$35$$$43$$$O	and$$$44$$$47$$$O	related$$$48$$$55$$$O	eye$$$56$$$59$$$O	conditions,$$$60$$$71$$$O	is$$$72$$$74$$$O	disclosed.$$$75$$$85$$$O	The$$$86$$$89$$$O	formulation$$$90$$$101$$$O	comprises$$$102$$$111$$$O	an$$$112$$$114$$$O	effective$$$115$$$124$$$O	amount$$$125$$$131$$$O	of$$$132$$$134$$$O	fibromodulin$$$135$$$147$$$O	and$$$148$$$151$$$O	can$$$152$$$155$$$O	be$$$156$$$158$$$O	administered$$$159$$$171$$$O	intraocularly,$$$172$$$186$$$O	such$$$187$$$191$$$O	as$$$192$$$194$$$O	by$$$195$$$197$$$O	topical$$$198$$$205$$$O	application,$$$206$$$218$$$O	injection$$$219$$$228$$$O	into$$$229$$$233$$$O	the$$$234$$$237$$$O	eye,$$$238$$$242$$$O	or$$$243$$$245$$$O	implantation$$$246$$$258$$$O	in$$$259$$$261$$$O	or$$$262$$$264$$$O	on$$$265$$$267$$$O	the$$$268$$$271$$$O	eye.$$$272$$$276$$$O
WO2013013308A1
Spirocyclic$$$0$$$11$$$O	molecules$$$12$$$21$$$O	as$$$22$$$24$$$O	protein$$$25$$$32$$$O	kinase$$$33$$$39$$$O	inhibitors$$$40$$$50$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	spirocyclic$$$33$$$44$$$O	compounds$$$45$$$54$$$O	of$$$55$$$57$$$O	formula$$$58$$$65$$$O	I,$$$66$$$68$$$O	namely$$$69$$$75$$$O	spirocyclic$$$76$$$87$$$O	(1H-pyrazol-4-yl)-3-($$$88$$$109$$$I	1-(2,6-dichloro-3-$$$110$$$128$$$I	fiuorophenyl)$$$129$$$142$$$I	ethoxy)pyridin-2-amines$$$143$$$166$$$I	having$$$167$$$173$$$O	protein$$$174$$$181$$$O	kinase$$$182$$$188$$$O	inhibitory$$$189$$$199$$$O	activity,$$$200$$$209$$$O	and$$$210$$$213$$$O	methods$$$214$$$221$$$O	of$$$222$$$224$$$O	synthesizing$$$225$$$237$$$O	and$$$238$$$241$$$O	using$$$242$$$247$$$O	such$$$248$$$252$$$O	compounds.$$$253$$$263$$$O	Preferred$$$264$$$273$$$O	compounds$$$274$$$283$$$O	are$$$284$$$287$$$O	c-Met$$$288$$$293$$$O	and/or$$$294$$$300$$$O	ALK$$$301$$$304$$$O	inhibitors$$$305$$$315$$$O	useful$$$316$$$322$$$O	for$$$323$$$326$$$O	the$$$327$$$330$$$O	treatment$$$331$$$340$$$O	of$$$341$$$343$$$O	abnormal$$$344$$$352$$$O	cell$$$353$$$357$$$O	growth,$$$358$$$365$$$O	such$$$366$$$370$$$O	as$$$371$$$373$$$O	cancers.$$$374$$$382$$$O
US20110257111
Hydroxyethlamino$$$0$$$16$$$I	Sulfonamide$$$17$$$28$$$I	Derivatives$$$29$$$40$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	novel$$$26$$$31$$$O	hydroxyethylamino$$$32$$$49$$$I	sulfonamides$$$50$$$62$$$I	and$$$63$$$66$$$O	pharmaceutically$$$67$$$83$$$O	acceptable$$$84$$$94$$$O	salts$$$95$$$100$$$O	thereof.$$$101$$$109$$$O	This$$$110$$$114$$$O	invention$$$115$$$124$$$O	also$$$125$$$129$$$O	provides$$$130$$$138$$$O	compositions$$$139$$$151$$$O	comprising$$$152$$$162$$$O	a$$$163$$$164$$$O	compound$$$165$$$173$$$O	of$$$174$$$176$$$O	this$$$177$$$181$$$O	invention$$$182$$$191$$$O	and$$$192$$$195$$$O	the$$$196$$$199$$$O	use$$$200$$$203$$$O	of$$$204$$$206$$$O	such$$$207$$$211$$$O	compositions$$$212$$$224$$$O	in$$$225$$$227$$$O	methods$$$228$$$235$$$O	of$$$236$$$238$$$O	treating$$$239$$$247$$$O	diseases$$$248$$$256$$$O	and$$$257$$$260$$$O	conditions$$$261$$$271$$$O	that$$$272$$$276$$$O	are$$$277$$$280$$$O	beneficially$$$281$$$293$$$O	treated$$$294$$$301$$$O	by$$$302$$$304$$$O	administering$$$305$$$318$$$O	a$$$319$$$320$$$O	compound$$$321$$$329$$$O	with$$$330$$$334$$$O	the$$$335$$$338$$$O	ability$$$339$$$346$$$O	to$$$347$$$349$$$O	act$$$350$$$353$$$O	as$$$354$$$356$$$O	an$$$357$$$359$$$O	HIV$$$360$$$363$$$O	(human$$$364$$$370$$$O	immunodeficiency$$$371$$$387$$$O	virus)$$$388$$$394$$$O	protease$$$395$$$403$$$O	inhibitor.$$$404$$$414$$$O
US6858722
Oligomer$$$0$$$8$$$I	phosphoramidite$$$9$$$24$$$I	compositions$$$25$$$37$$$O	and$$$38$$$41$$$O	processes$$$42$$$51$$$O	for$$$52$$$55$$$O	synthesizing$$$56$$$68$$$O	the$$$69$$$72$$$O	same$$$73$$$77$$$O
Synthetic$$$0$$$9$$$O	processes$$$10$$$19$$$O	are$$$20$$$23$$$O	provided$$$24$$$32$$$O	wherein$$$33$$$40$$$O	oligomers$$$41$$$50$$$I	are$$$51$$$54$$$O	prepared$$$55$$$63$$$O	using$$$64$$$69$$$O	phosphoramidite$$$70$$$85$$$I	compositions.$$$86$$$99$$$O	Oligomers$$$100$$$109$$$I	having$$$110$$$116$$$O	phosphodiester,$$$117$$$132$$$I	phosphorothioate,$$$133$$$150$$$I	phosphorodithioate$$$151$$$169$$$I	covalent$$$170$$$178$$$O	linkages$$$179$$$187$$$O	are$$$188$$$191$$$O	prepared$$$192$$$200$$$O	that$$$201$$$205$$$O	can$$$206$$$209$$$O	include$$$210$$$217$$$O	other$$$218$$$223$$$O	covalent$$$224$$$232$$$O	linkages.$$$233$$$242$$$O	Also$$$243$$$247$$$O	provided$$$248$$$256$$$O	are$$$257$$$260$$$O	compositions$$$261$$$273$$$O	useful$$$274$$$280$$$O	in$$$281$$$283$$$O	such$$$284$$$288$$$O	processes.$$$289$$$299$$$O
CN101219220A
Remifentanil$$$0$$$12$$$I	polymer$$$13$$$20$$$O	sustained-release$$$21$$$38$$$O	analgesic$$$39$$$48$$$O	and$$$49$$$52$$$O	its$$$53$$$56$$$O	preparing$$$57$$$66$$$O	process$$$67$$$74$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	remifentanil$$$27$$$39$$$I	polymer$$$40$$$47$$$O	slow-release$$$48$$$60$$$O	and$$$61$$$64$$$O	analgesic$$$65$$$74$$$O	drug$$$75$$$79$$$O	which$$$80$$$85$$$O	is$$$86$$$88$$$O	prepared$$$89$$$97$$$O	by$$$98$$$100$$$O	the$$$101$$$104$$$O	reaction$$$105$$$113$$$O	of$$$114$$$116$$$O	remifentanil$$$117$$$129$$$I	used$$$130$$$134$$$O	as$$$135$$$137$$$O	a$$$138$$$139$$$O	polymerization$$$140$$$154$$$O	terminator$$$155$$$165$$$O	and$$$166$$$169$$$O	caprolactone.$$$170$$$183$$$I	The$$$184$$$187$$$O	preparation$$$188$$$199$$$O	method$$$200$$$206$$$O	is$$$207$$$209$$$O	that:$$$210$$$215$$$O	(1)$$$216$$$219$$$O	raw$$$220$$$223$$$O	materials:$$$224$$$234$$$O	the$$$235$$$238$$$O	caprolactone$$$239$$$251$$$I	1-10$$$252$$$256$$$O	weight$$$257$$$263$$$O	proportions,$$$264$$$276$$$O	the$$$277$$$280$$$O	remifentanil$$$281$$$293$$$I	0.001-0.016$$$294$$$305$$$O	weight$$$306$$$312$$$O	proportions,$$$313$$$325$$$O	solvent$$$326$$$333$$$O	1-200$$$334$$$339$$$O	weight$$$340$$$346$$$O	proportions$$$347$$$358$$$O	and$$$359$$$362$$$O	a$$$363$$$364$$$O	catalyst$$$365$$$373$$$O	0.001-2$$$374$$$381$$$O	weight$$$382$$$388$$$O	proportions;$$$389$$$401$$$O	(2)$$$402$$$405$$$O	polymerization:$$$406$$$421$$$O	the$$$422$$$425$$$O	caprolactone$$$426$$$438$$$I	and$$$439$$$442$$$O	the$$$443$$$446$$$O	catalyst$$$447$$$455$$$O	are$$$456$$$459$$$O	added$$$460$$$465$$$O	into$$$466$$$470$$$O	the$$$471$$$474$$$O	solvent,$$$475$$$483$$$O	polymerized$$$484$$$495$$$O	in$$$496$$$498$$$O	inert$$$499$$$504$$$O	gas,$$$505$$$509$$$O	at$$$510$$$512$$$O	the$$$513$$$516$$$O	temperature$$$517$$$528$$$O	of$$$529$$$531$$$O	30-150$$$532$$$538$$$O	DEG$$$539$$$542$$$O	C$$$543$$$544$$$O	and$$$545$$$548$$$O	for$$$549$$$552$$$O	2-40$$$553$$$557$$$O	hours,$$$558$$$564$$$O	and$$$565$$$568$$$O	then$$$569$$$573$$$O	the$$$574$$$577$$$O	remifentanil$$$578$$$590$$$I	is$$$591$$$593$$$O	added,$$$594$$$600$$$O	and$$$601$$$604$$$O	the$$$605$$$608$$$O	reaction$$$609$$$617$$$O	is$$$618$$$620$$$O	processed$$$621$$$630$$$O	at$$$631$$$633$$$O	the$$$634$$$637$$$O	temperature$$$638$$$649$$$O	of$$$650$$$652$$$O	30-150$$$653$$$659$$$O	DEG$$$660$$$663$$$O	C$$$664$$$665$$$O	for$$$666$$$669$$$O	0.5-2$$$670$$$675$$$O	hour(s);$$$676$$$684$$$O	or$$$685$$$687$$$O	the$$$688$$$691$$$O	catalyst$$$692$$$700$$$O	is$$$701$$$703$$$O	added$$$704$$$709$$$O	into$$$710$$$714$$$O	the$$$715$$$718$$$O	caprolactone,$$$719$$$732$$$I	polymerized$$$733$$$744$$$O	in$$$745$$$747$$$O	inert$$$748$$$753$$$O	gas,$$$754$$$758$$$O	at$$$759$$$761$$$O	the$$$762$$$765$$$O	temperature$$$766$$$777$$$O	of$$$778$$$780$$$O	30-150$$$781$$$787$$$O	DEG$$$788$$$791$$$O	C$$$792$$$793$$$O	for$$$794$$$797$$$O	2-40$$$798$$$802$$$O	hours,$$$803$$$809$$$O	and$$$810$$$813$$$O	then$$$814$$$818$$$O	the$$$819$$$822$$$O	remifentanil$$$823$$$835$$$I	is$$$836$$$838$$$O	added,$$$839$$$845$$$O	and$$$846$$$849$$$O	the$$$850$$$853$$$O	reaction$$$854$$$862$$$O	is$$$863$$$865$$$O	processed$$$866$$$875$$$O	at$$$876$$$878$$$O	30-150$$$879$$$885$$$O	DEG$$$886$$$889$$$O	C$$$890$$$891$$$O	for$$$892$$$895$$$O	0.5-4$$$896$$$901$$$O	hour(s).$$$902$$$910$$$O	(3)$$$911$$$914$$$O	The$$$915$$$918$$$O	remifentanil$$$919$$$931$$$I	polymer$$$932$$$939$$$O	slow-release$$$940$$$952$$$O	and$$$953$$$956$$$O	analgesic$$$957$$$966$$$O	drug$$$967$$$971$$$O	is$$$972$$$974$$$O	collected$$$975$$$984$$$O	from$$$985$$$989$$$O	reaction$$$990$$$998$$$O	mixture$$$999$$$1006$$$O	when$$$1007$$$1011$$$O	the$$$1012$$$1015$$$O	polymerization$$$1016$$$1030$$$O	is$$$1031$$$1033$$$O	completed.$$$1034$$$1044$$$O
CN103417764A
Health$$$0$$$6$$$O	care$$$7$$$11$$$O	product$$$12$$$19$$$O	containing$$$20$$$30$$$O	L-carnitine$$$31$$$42$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	health$$$26$$$32$$$O	care$$$33$$$37$$$O	product$$$38$$$45$$$O	having$$$46$$$52$$$O	an$$$53$$$55$$$O	effect$$$56$$$62$$$O	of$$$63$$$65$$$O	losing$$$66$$$72$$$O	weight.$$$73$$$80$$$O	The$$$81$$$84$$$O	health$$$85$$$91$$$O	care$$$92$$$96$$$O	product$$$97$$$104$$$O	adopts$$$105$$$111$$$O	L-carnitine,$$$112$$$124$$$I	konjaku$$$125$$$132$$$O	flour$$$133$$$138$$$O	and$$$139$$$142$$$O	tea$$$143$$$146$$$O	polyphenols$$$147$$$158$$$O	as$$$159$$$161$$$O	raw$$$162$$$165$$$O	materials.$$$166$$$176$$$O	The$$$177$$$180$$$O	raw$$$181$$$184$$$O	materials$$$185$$$194$$$O	are$$$195$$$198$$$O	prepared$$$199$$$207$$$O	into$$$208$$$212$$$O	capsules$$$213$$$221$$$O	and$$$222$$$225$$$O	other$$$226$$$231$$$O	preparation$$$232$$$243$$$O	forms$$$244$$$249$$$O	according$$$250$$$259$$$O	to$$$260$$$262$$$O	a$$$263$$$264$$$O	ratio.$$$265$$$271$$$O	The$$$272$$$275$$$O	health$$$276$$$282$$$O	care$$$283$$$287$$$O	product$$$288$$$295$$$O	has$$$296$$$299$$$O	a$$$300$$$301$$$O	reasonable$$$302$$$312$$$O	formula$$$313$$$320$$$O	and$$$321$$$324$$$O	a$$$325$$$326$$$O	unique$$$327$$$333$$$O	preparation$$$334$$$345$$$O	method,$$$346$$$353$$$O	and$$$354$$$357$$$O	has$$$358$$$361$$$O	the$$$362$$$365$$$O	effect$$$366$$$372$$$O	of$$$373$$$375$$$O	losing$$$376$$$382$$$O	weight.$$$383$$$390$$$O
US20120237568
Bioactive$$$0$$$9$$$O	Load-Bearing$$$10$$$22$$$O	Composites$$$23$$$33$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	preparing$$$11$$$20$$$O	bioactive$$$21$$$30$$$O	composites$$$31$$$41$$$O	are$$$42$$$45$$$O	described.$$$46$$$56$$$O	Also$$$57$$$61$$$O	described$$$62$$$71$$$O	are$$$72$$$75$$$O	methods$$$76$$$83$$$O	of$$$84$$$86$$$O	molding$$$87$$$94$$$O	such$$$95$$$99$$$O	composites.$$$100$$$111$$$O	Shaped$$$112$$$118$$$O	bodies$$$119$$$125$$$O	comprising$$$126$$$136$$$O	bioactive$$$137$$$146$$$O	composites$$$147$$$157$$$O	are$$$158$$$161$$$O	further$$$162$$$169$$$O	described.$$$170$$$180$$$O
CN101732305B
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	iridoid$$$15$$$22$$$I	compounds$$$23$$$32$$$O	in$$$33$$$35$$$O	preparing$$$36$$$45$$$O	medicament$$$46$$$56$$$O	for$$$57$$$60$$$O	treating$$$61$$$69$$$O	benign$$$70$$$76$$$O	prostatic$$$77$$$86$$$O	hyperplasia$$$87$$$98$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	iridoid$$$39$$$46$$$I	compounds$$$47$$$56$$$O	in$$$57$$$59$$$O	preparing$$$60$$$69$$$O	a$$$70$$$71$$$O	medicament$$$72$$$82$$$O	for$$$83$$$86$$$O	treating$$$87$$$95$$$O	benign$$$96$$$102$$$O	prostatic$$$103$$$112$$$O	hyperplasia.$$$113$$$125$$$O	The$$$126$$$129$$$O	compounds$$$130$$$139$$$O	are$$$140$$$143$$$O	from$$$144$$$148$$$O	valerianaceae$$$149$$$162$$$O	plants.$$$163$$$170$$$O	The$$$171$$$174$$$O	valerianaceae$$$175$$$188$$$O	plants$$$189$$$195$$$O	have$$$196$$$200$$$O	long$$$201$$$205$$$O	medicinal$$$206$$$215$$$O	history$$$216$$$223$$$O	and$$$224$$$227$$$O	good$$$228$$$232$$$O	safety.$$$233$$$240$$$O	The$$$241$$$244$$$O	compounds$$$245$$$254$$$O	of$$$255$$$257$$$O	the$$$258$$$261$$$O	invention$$$262$$$271$$$O	show$$$272$$$276$$$O	more$$$277$$$281$$$O	definite$$$282$$$290$$$O	medicinal$$$291$$$300$$$O	effect$$$301$$$307$$$O	substances$$$308$$$318$$$O	compared$$$319$$$327$$$O	with$$$328$$$332$$$O	the$$$333$$$336$$$O	conventional$$$337$$$349$$$O	valeriana$$$350$$$359$$$O	root$$$360$$$364$$$O	plant$$$365$$$370$$$O	extract,$$$371$$$379$$$O	and$$$380$$$383$$$O	provide$$$384$$$391$$$O	possibility$$$392$$$403$$$O	for$$$404$$$407$$$O	preparing$$$408$$$417$$$O	a$$$418$$$419$$$O	new$$$420$$$423$$$O	medicament$$$424$$$434$$$O	which$$$435$$$440$$$O	resists$$$441$$$448$$$O	benign$$$449$$$455$$$O	prostatic$$$456$$$465$$$O	hyperplasia$$$466$$$477$$$O	and$$$478$$$481$$$O	has$$$482$$$485$$$O	good$$$486$$$490$$$O	market$$$491$$$497$$$O	prospect.$$$498$$$507$$$O
CN1582913A
Drops$$$0$$$5$$$O	of$$$6$$$8$$$O	benzohydroxymethylamine$$$9$$$32$$$I	and$$$33$$$36$$$O	their$$$37$$$42$$$O	preparation$$$43$$$54$$$O
A$$$0$$$1$$$O	dripping$$$2$$$10$$$O	pill$$$11$$$15$$$O	of$$$16$$$18$$$O	phenylhydroxyformamine$$$19$$$41$$$I	hydrochloride$$$42$$$55$$$I	is$$$56$$$58$$$O	prepared$$$59$$$67$$$O	by$$$68$$$70$$$O	superfine$$$71$$$80$$$O	pulverizing$$$81$$$92$$$O	and$$$93$$$96$$$O	conventional$$$97$$$109$$$O	process$$$110$$$117$$$O	for$$$118$$$121$$$O	preparing$$$122$$$131$$$O	dripping$$$132$$$140$$$O	pills.$$$141$$$147$$$O
CN1843393A
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	pharmaceutical$$$7$$$21$$$O	composition$$$22$$$33$$$O	containing$$$34$$$44$$$O	aceglutamide$$$45$$$57$$$I	and$$$58$$$61$$$O	safflower$$$62$$$71$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	the$$$24$$$27$$$O	use$$$28$$$31$$$O	of$$$32$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	containing$$$62$$$72$$$O	aceglutamide$$$73$$$85$$$I	and$$$86$$$89$$$O	safflower$$$90$$$99$$$O	extract$$$100$$$107$$$O	in$$$108$$$110$$$O	preparing$$$111$$$120$$$O	medicament$$$121$$$131$$$O	for$$$132$$$135$$$O	tissue$$$136$$$142$$$O	damage$$$143$$$149$$$O	assimilation$$$150$$$162$$$O	and$$$163$$$166$$$O	recovery,$$$167$$$176$$$O	wherein$$$177$$$184$$$O	animal$$$185$$$191$$$O	and$$$192$$$195$$$O	human$$$196$$$201$$$O	body$$$202$$$206$$$O	clinical$$$207$$$215$$$O	experiments$$$216$$$227$$$O	show$$$228$$$232$$$O	that$$$233$$$237$$$O	the$$$238$$$241$$$O	composition$$$242$$$253$$$O	can$$$254$$$257$$$O	be$$$258$$$260$$$O	used$$$261$$$265$$$O	for$$$266$$$269$$$O	preparing$$$270$$$279$$$O	medicament$$$280$$$290$$$O	for$$$291$$$294$$$O	promoting$$$295$$$304$$$O	assimilation$$$305$$$317$$$O	and$$$318$$$321$$$O	recovery$$$322$$$330$$$O	of$$$331$$$333$$$O	bone$$$334$$$338$$$O	fracture$$$339$$$347$$$O	injury,$$$348$$$355$$$O	surgical$$$356$$$364$$$O	operation$$$365$$$374$$$O	wound$$$375$$$380$$$O	and$$$381$$$384$$$O	neurotrauma.$$$385$$$397$$$O
WO2013002420A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	producing$$$11$$$20$$$O	fine$$$21$$$25$$$O	particles$$$26$$$35$$$O	of$$$36$$$38$$$O	aripiprazole$$$39$$$51$$$I	anhydride$$$52$$$61$$$I	crystals$$$62$$$70$$$O	b$$$71$$$72$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	novel$$$33$$$38$$$O	method$$$39$$$45$$$O	for$$$46$$$49$$$O	producing$$$50$$$59$$$O	fine$$$60$$$64$$$O	particles$$$65$$$74$$$O	of$$$75$$$77$$$O	aripiprazole$$$78$$$90$$$I	anhydride$$$91$$$100$$$I	crystals$$$101$$$109$$$O	B.$$$110$$$112$$$O	The$$$113$$$116$$$O	method$$$117$$$123$$$O	for$$$124$$$127$$$O	producing$$$128$$$137$$$O	fine$$$138$$$142$$$O	particles$$$143$$$152$$$O	of$$$153$$$155$$$O	aripiprazole$$$156$$$168$$$I	anhydride$$$169$$$178$$$I	crystals$$$179$$$187$$$O	B$$$188$$$189$$$O	comprises$$$190$$$199$$$O	the$$$200$$$203$$$O	steps$$$204$$$209$$$O	of:$$$210$$$213$$$O	(1)$$$214$$$217$$$O	heating$$$218$$$225$$$O	and$$$226$$$229$$$O	dissolving$$$230$$$240$$$O	crude$$$241$$$246$$$O	aripiprazole$$$247$$$259$$$I	in$$$260$$$262$$$O	a$$$263$$$264$$$O	lower$$$265$$$270$$$O	alcohol,$$$271$$$279$$$I	and$$$280$$$283$$$O	subsequently$$$284$$$296$$$O	cooling$$$297$$$304$$$O	the$$$305$$$308$$$O	resulting$$$309$$$318$$$O	mixture$$$319$$$326$$$O	to$$$327$$$329$$$O	precipitate$$$330$$$341$$$O	crystals$$$342$$$350$$$O	to$$$351$$$353$$$O	obtain$$$354$$$360$$$O	crystals$$$361$$$369$$$O	of$$$370$$$372$$$O	aripiprazole$$$373$$$385$$$I	lower$$$386$$$391$$$O	alcohol$$$392$$$399$$$I	solvate;$$$400$$$408$$$O	(2)$$$409$$$412$$$O	subjecting$$$413$$$423$$$O	the$$$424$$$427$$$O	crystals$$$428$$$436$$$O	of$$$437$$$439$$$O	aripiprazole$$$440$$$452$$$I	lower$$$453$$$458$$$O	alcohol$$$459$$$466$$$I	solvate$$$467$$$474$$$O	to$$$475$$$477$$$O	wet-milling$$$478$$$489$$$O	in$$$490$$$492$$$O	the$$$493$$$496$$$O	form$$$497$$$501$$$O	of$$$502$$$504$$$O	a$$$505$$$506$$$O	slurry$$$507$$$513$$$O	containing$$$514$$$524$$$O	the$$$525$$$528$$$O	lower$$$529$$$534$$$O	alcohol;$$$535$$$543$$$I	and$$$544$$$547$$$O	(3)$$$548$$$551$$$O	subjecting$$$552$$$562$$$O	the$$$563$$$566$$$O	dispersion$$$567$$$577$$$O	of$$$578$$$580$$$O	the$$$581$$$584$$$O	wet-milled$$$585$$$595$$$O	crystals$$$596$$$604$$$O	to$$$605$$$607$$$O	solid-liquid$$$608$$$620$$$O	separation$$$621$$$631$$$O	to$$$632$$$634$$$O	obtain$$$635$$$641$$$O	the$$$642$$$645$$$O	crystals,$$$646$$$655$$$O	and$$$656$$$659$$$O	heating$$$660$$$667$$$O	the$$$668$$$671$$$O	crystals.$$$672$$$681$$$O
US20100113512
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	treatment$$$10$$$19$$$O	using$$$20$$$25$$$O	novel$$$26$$$31$$$O	antagonists$$$32$$$43$$$O	or$$$44$$$46$$$O	inverse$$$47$$$54$$$O	agonists$$$55$$$63$$$O	at$$$64$$$66$$$O	opioid$$$67$$$73$$$I	receptors$$$74$$$83$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	treatment$$$12$$$21$$$O	using$$$22$$$27$$$O	pharmaceutical$$$28$$$42$$$O	compositions$$$43$$$55$$$O	containing$$$56$$$66$$$O	novel$$$67$$$72$$$O	antagonists$$$73$$$84$$$O	or$$$85$$$87$$$O	inverse$$$88$$$95$$$O	agonists$$$96$$$104$$$O	at$$$105$$$107$$$O	opioid$$$108$$$114$$$I	receptors$$$115$$$124$$$O	for$$$125$$$128$$$O	the$$$129$$$132$$$O	treatment$$$133$$$142$$$O	of$$$143$$$145$$$O	binge$$$146$$$151$$$O	eating$$$152$$$158$$$O	disorder,$$$159$$$168$$$O	anorexia$$$169$$$177$$$O	nervosa,$$$178$$$186$$$O	bulimia$$$187$$$194$$$O	nervosa,$$$195$$$203$$$O	excess$$$204$$$210$$$O	drug$$$211$$$215$$$O	or$$$216$$$218$$$O	alcohol$$$219$$$226$$$I	use,$$$227$$$231$$$O	or$$$232$$$234$$$O	eating$$$235$$$241$$$O	disorder$$$242$$$250$$$O	not$$$251$$$254$$$O	otherwise$$$255$$$264$$$O	specified.$$$265$$$275$$$O
WO2006040148A1
Tricyclic$$$0$$$9$$$I	indole$$$10$$$16$$$I	derivatives$$$17$$$28$$$O	for$$$29$$$32$$$O	use$$$33$$$36$$$O	in$$$37$$$39$$$O	the$$$40$$$43$$$O	treatment$$$44$$$53$$$O	of$$$54$$$56$$$O	alzheimerâs$$$57$$$70$$$O	disease$$$71$$$78$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	ketone$$$39$$$45$$$I	compounds$$$46$$$55$$$O	of$$$56$$$58$$$O	formula$$$59$$$66$$$O	(I)$$$67$$$70$$$O	having$$$71$$$77$$$O	Asp2$$$78$$$82$$$O	(Î²-secretase,$$$83$$$97$$$O	BACE1$$$98$$$103$$$O	or$$$104$$$106$$$O	Memapsin-2)$$$107$$$118$$$O	inhibitory$$$119$$$129$$$O	activity,$$$130$$$139$$$O	processes$$$140$$$149$$$O	for$$$150$$$153$$$O	their$$$154$$$159$$$O	preparation,$$$160$$$172$$$O	to$$$173$$$175$$$O	compositions$$$176$$$188$$$O	containing$$$189$$$199$$$O	them$$$200$$$204$$$O	and$$$205$$$208$$$O	to$$$209$$$211$$$O	their$$$212$$$217$$$O	use$$$218$$$221$$$O	in$$$222$$$224$$$O	the$$$225$$$228$$$O	treatment$$$229$$$238$$$O	of$$$239$$$241$$$O	diseases$$$242$$$250$$$O	characterised$$$251$$$264$$$O	by$$$265$$$267$$$O	elevated$$$268$$$276$$$O	Î²-$$$277$$$280$$$O	amyloid$$$281$$$288$$$O	levels$$$289$$$295$$$O	or$$$296$$$298$$$O	Î²-amyloid$$$299$$$309$$$O	deposits,$$$310$$$319$$$O	particularly$$$320$$$332$$$O	Alzheimer's$$$333$$$344$$$O	disease.$$$345$$$353$$$O
CN102302479A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	lycopene$$$15$$$23$$$O	in$$$24$$$26$$$O	preparation$$$27$$$38$$$O	of$$$39$$$41$$$O	medicament$$$42$$$52$$$O	for$$$53$$$56$$$O	treating$$$57$$$65$$$O	cerebral$$$66$$$74$$$O	ischemia$$$75$$$83$$$O	injury$$$84$$$90$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	lycopene$$$39$$$47$$$O	in$$$48$$$50$$$O	preparation$$$51$$$62$$$O	of$$$63$$$65$$$O	a$$$66$$$67$$$O	medicament$$$68$$$78$$$O	for$$$79$$$82$$$O	treating$$$83$$$91$$$O	cerebral$$$92$$$100$$$O	ischemia$$$101$$$109$$$O	injury.$$$110$$$117$$$O	In$$$118$$$120$$$O	the$$$121$$$124$$$O	application,$$$125$$$137$$$O	the$$$138$$$141$$$O	medicament$$$142$$$152$$$O	for$$$153$$$156$$$O	treating$$$157$$$165$$$O	cerebral$$$166$$$174$$$O	ischemia$$$175$$$183$$$O	injury$$$184$$$190$$$O	is$$$191$$$193$$$O	at$$$194$$$196$$$O	least$$$197$$$202$$$O	one$$$203$$$206$$$O	of$$$207$$$209$$$O	the$$$210$$$213$$$O	following$$$214$$$223$$$O	components$$$224$$$234$$$O	as$$$235$$$237$$$O	shown$$$238$$$243$$$O	in$$$244$$$246$$$O	1)$$$247$$$249$$$O	to$$$250$$$252$$$O	3):$$$253$$$256$$$O	1)$$$257$$$259$$$O	a$$$260$$$261$$$O	medicament$$$262$$$272$$$O	for$$$273$$$276$$$O	treating$$$277$$$285$$$O	encephaledema;$$$286$$$300$$$O	2)$$$301$$$303$$$O	a$$$304$$$305$$$O	medicament$$$306$$$316$$$O	for$$$317$$$320$$$O	treating$$$321$$$329$$$O	cerebral$$$330$$$338$$$O	infarction;$$$339$$$350$$$O	and$$$351$$$354$$$O	3)$$$355$$$357$$$O	a$$$358$$$359$$$O	medicament$$$360$$$370$$$O	for$$$371$$$374$$$O	treating$$$375$$$383$$$O	nerve$$$384$$$389$$$O	injury.$$$390$$$397$$$O	The$$$398$$$401$$$O	invention$$$402$$$411$$$O	provides$$$412$$$420$$$O	a$$$421$$$422$$$O	possible$$$423$$$431$$$O	acute-phase$$$432$$$443$$$O	treatment$$$444$$$453$$$O	medicament$$$454$$$464$$$O	urgently$$$465$$$473$$$O	needed$$$474$$$480$$$O	in$$$481$$$483$$$O	clinic,$$$484$$$491$$$O	and$$$492$$$495$$$O	the$$$496$$$499$$$O	medicament$$$500$$$510$$$O	has$$$511$$$514$$$O	treatment$$$515$$$524$$$O	and$$$525$$$528$$$O	protection$$$529$$$539$$$O	effects$$$540$$$547$$$O	in$$$548$$$550$$$O	acute$$$551$$$556$$$O	cerebral$$$557$$$565$$$O	ischemia-reperfusion$$$566$$$586$$$O	injury$$$587$$$593$$$O	phase,$$$594$$$600$$$O	and$$$601$$$604$$$O	has$$$605$$$608$$$O	strong$$$609$$$615$$$O	clinical$$$616$$$624$$$O	pertinence.$$$625$$$636$$$O	Researches$$$637$$$647$$$O	of$$$648$$$650$$$O	the$$$651$$$654$$$O	invention$$$655$$$664$$$O	indicate$$$665$$$673$$$O	that$$$674$$$678$$$O	lycopene$$$679$$$687$$$O	still$$$688$$$693$$$O	can$$$694$$$697$$$O	play$$$698$$$702$$$O	a$$$703$$$704$$$O	good$$$705$$$709$$$O	effect$$$710$$$716$$$O	of$$$717$$$719$$$O	resisting$$$720$$$729$$$O	cerebral$$$730$$$738$$$O	infarction$$$739$$$749$$$O	and$$$750$$$753$$$O	protecting$$$754$$$764$$$O	nerves$$$765$$$771$$$O	in$$$772$$$774$$$O	reperfusion$$$775$$$786$$$O	phase$$$787$$$792$$$O	administration$$$793$$$807$$$O	of$$$808$$$810$$$O	acute$$$811$$$816$$$O	cerebral$$$817$$$825$$$O	ischemia,$$$826$$$835$$$O	thus$$$836$$$840$$$O	the$$$841$$$844$$$O	invention$$$845$$$854$$$O	has$$$855$$$858$$$O	real$$$859$$$863$$$O	clinical$$$864$$$872$$$O	therapeutics$$$873$$$885$$$O	meaning$$$886$$$893$$$O	and$$$894$$$897$$$O	great$$$898$$$903$$$O	clinical$$$904$$$912$$$O	advantage.$$$913$$$923$$$O
WO2011036303A1
New$$$0$$$3$$$O	aminoacid$$$4$$$13$$$I	derivatives,$$$14$$$26$$$O	their$$$27$$$32$$$O	process$$$33$$$40$$$O	of$$$41$$$43$$$O	preparation$$$44$$$55$$$O	and$$$56$$$59$$$O	their$$$60$$$65$$$O	therapeutical$$$66$$$79$$$O	uses$$$80$$$84$$$O	as$$$85$$$87$$$O	inhibitors$$$88$$$98$$$O	of$$$99$$$101$$$O	oncogenic$$$102$$$111$$$O	signals$$$112$$$119$$$O	by$$$120$$$122$$$O	the$$$123$$$126$$$O	met$$$127$$$130$$$O	family$$$131$$$137$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	concerns$$$22$$$30$$$O	novel$$$31$$$36$$$O	aminoacids$$$37$$$47$$$I	derivatives,$$$48$$$60$$$O	in$$$61$$$63$$$O	particular$$$64$$$74$$$O	some$$$75$$$79$$$O	aminoacid$$$80$$$89$$$I	amides$$$90$$$96$$$I	derivatives,$$$97$$$109$$$O	their$$$110$$$115$$$O	process$$$116$$$123$$$O	of$$$124$$$126$$$O	preparation$$$127$$$138$$$O	and$$$139$$$142$$$O	their$$$143$$$148$$$O	use$$$149$$$152$$$O	for$$$153$$$156$$$O	inhibiting$$$157$$$167$$$O	Met-triggered$$$168$$$181$$$O	disorders,$$$182$$$192$$$O	in$$$193$$$195$$$O	particular$$$196$$$206$$$O	cancer.$$$207$$$214$$$O
US20120053200
Bace$$$0$$$4$$$O	2$$$5$$$6$$$O	inhibitors$$$7$$$17$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	N-1-Benzyl-2-hydroxy-3-(hetero)arylamino-propyl)-isophthalamides$$$33$$$97$$$O	of$$$98$$$100$$$O	formula$$$101$$$108$$$O	I$$$109$$$110$$$O	having$$$148$$$154$$$O	BACE2$$$155$$$160$$$O	inhibitory$$$161$$$171$$$O	activity$$$172$$$180$$$O	and$$$181$$$184$$$O	their$$$185$$$190$$$O	use$$$191$$$194$$$O	as$$$195$$$197$$$O	therapeutically$$$198$$$213$$$O	active$$$214$$$220$$$O	substances,$$$221$$$232$$$O	their$$$233$$$238$$$O	manufacture$$$239$$$250$$$O	and$$$251$$$254$$$O	pharmaceutical$$$255$$$269$$$O	compositions.$$$270$$$283$$$O	The$$$284$$$287$$$O	active$$$288$$$294$$$O	compounds$$$295$$$304$$$O	of$$$305$$$307$$$O	the$$$308$$$311$$$O	present$$$312$$$319$$$O	invention$$$320$$$329$$$O	are$$$330$$$333$$$O	useful$$$334$$$340$$$O	in$$$341$$$343$$$O	the$$$344$$$347$$$O	therapeutic$$$348$$$359$$$O	and/or$$$360$$$366$$$O	prophylactic$$$367$$$379$$$O	treatment$$$380$$$389$$$O	of$$$390$$$392$$$O	e.g.$$$393$$$397$$$O	type$$$398$$$402$$$O	2$$$403$$$404$$$O	diabetes.$$$405$$$414$$$O
CN102690326A
Novel$$$0$$$5$$$O	gossypol$$$6$$$14$$$I	derivate$$$15$$$23$$$O	with$$$24$$$28$$$O	anti-HIV$$$29$$$37$$$O	activity$$$38$$$46$$$O	and$$$47$$$50$$$O	preparation$$$51$$$62$$$O	method$$$63$$$69$$$O	thereof$$$70$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	novel$$$26$$$31$$$O	gossypol$$$32$$$40$$$I	derivate$$$41$$$49$$$O	with$$$50$$$54$$$O	anti-HIV$$$55$$$63$$$O	(human$$$64$$$70$$$O	immunodeficiency$$$71$$$87$$$O	virus)$$$88$$$94$$$O	activity$$$95$$$103$$$O	and$$$104$$$107$$$O	a$$$108$$$109$$$O	preparation$$$110$$$121$$$O	method$$$122$$$128$$$O	thereof.$$$129$$$137$$$O	The$$$138$$$141$$$O	novel$$$142$$$147$$$O	gossypol$$$148$$$156$$$I	derivate$$$157$$$165$$$O	particularly$$$166$$$178$$$O	comprises$$$179$$$188$$$O	a$$$189$$$190$$$O	gossypol$$$191$$$199$$$I	dipeptide$$$200$$$209$$$I	conjugate,$$$210$$$220$$$O	a$$$221$$$222$$$O	gossypol$$$223$$$231$$$I	tripeptide$$$232$$$242$$$I	conjugate$$$243$$$252$$$O	and$$$253$$$256$$$O	a$$$257$$$258$$$O	gossypol$$$259$$$267$$$I	glucosamine$$$268$$$279$$$I	conjugate.$$$280$$$290$$$O	The$$$291$$$294$$$O	preparation$$$295$$$306$$$O	method$$$307$$$313$$$O	comprises$$$314$$$323$$$O	the$$$324$$$327$$$O	following$$$328$$$337$$$O	steps:$$$338$$$344$$$O	taking$$$345$$$351$$$O	dipeptide,$$$352$$$362$$$I	tripeptide$$$363$$$373$$$I	or$$$374$$$376$$$O	D-glucosamine$$$377$$$390$$$I	hydrochloride,$$$391$$$405$$$I	dissolving$$$406$$$416$$$O	dipeptide,$$$417$$$427$$$I	tripeptide$$$428$$$438$$$I	or$$$439$$$441$$$O	D-glucosamine$$$442$$$455$$$I	hydrochloride$$$456$$$469$$$I	and$$$470$$$473$$$O	alkali$$$474$$$480$$$O	into$$$481$$$485$$$O	organic$$$486$$$493$$$O	solvent,$$$494$$$502$$$O	adding$$$503$$$509$$$O	gossypol$$$510$$$518$$$I	organic$$$519$$$526$$$O	solvent,$$$527$$$535$$$O	controlling$$$536$$$547$$$O	the$$$548$$$551$$$O	PH$$$552$$$554$$$O	value$$$555$$$560$$$O	to$$$561$$$563$$$O	be$$$564$$$566$$$O	7.0$$$567$$$570$$$O	to$$$571$$$573$$$O	7.5,$$$574$$$578$$$O	conducting$$$579$$$589$$$O	stirring$$$590$$$598$$$O	reaction$$$599$$$607$$$O	for$$$608$$$611$$$O	6$$$612$$$613$$$O	to$$$614$$$616$$$O	24$$$617$$$619$$$O	hours$$$620$$$625$$$O	under$$$626$$$631$$$O	the$$$632$$$635$$$O	nitrogen$$$636$$$644$$$I	protection$$$645$$$655$$$O	at$$$656$$$658$$$O	25$$$659$$$661$$$O	to$$$662$$$664$$$O	30$$$665$$$667$$$O	DEG$$$668$$$671$$$O	C,$$$672$$$674$$$O	drying$$$675$$$681$$$O	reaction$$$682$$$690$$$O	liquid$$$691$$$697$$$O	by$$$698$$$700$$$O	anhydrous$$$701$$$710$$$O	sodium$$$711$$$717$$$I	sulfate,$$$718$$$726$$$I	collecting$$$727$$$737$$$O	filtrate,$$$738$$$747$$$O	conducting$$$748$$$758$$$O	reduced$$$759$$$766$$$O	pressure$$$767$$$775$$$O	distillation$$$776$$$788$$$O	to$$$789$$$791$$$O	remove$$$792$$$798$$$O	the$$$799$$$802$$$O	organic$$$803$$$810$$$O	solvent,$$$811$$$819$$$O	and$$$820$$$823$$$O	preparing$$$824$$$833$$$O	the$$$834$$$837$$$O	novel$$$838$$$843$$$O	gossypol$$$844$$$852$$$I	derivate$$$853$$$861$$$O	through$$$862$$$869$$$O	vacuum$$$870$$$876$$$O	drying$$$877$$$883$$$O	at$$$884$$$886$$$O	35$$$887$$$889$$$O	DEG$$$890$$$893$$$O	C.$$$894$$$896$$$O	The$$$897$$$900$$$O	novel$$$901$$$906$$$O	gossypol$$$907$$$915$$$I	derivate$$$916$$$924$$$O	takes$$$925$$$930$$$O	a$$$931$$$932$$$O	stronger$$$933$$$941$$$O	effect$$$942$$$948$$$O	of$$$949$$$951$$$O	inhibiting$$$952$$$962$$$O	the$$$963$$$966$$$O	activity$$$967$$$975$$$O	on$$$976$$$978$$$O	HIV-1IIIB$$$979$$$988$$$O	standard$$$989$$$997$$$O	strains.$$$998$$$1006$$$O
US20090023728
1,2,3,4-Tetrahydroisoquinoline$$$0$$$30$$$I	Derivatives,$$$31$$$43$$$O	Preparations$$$44$$$56$$$O	Thereof$$$57$$$64$$$O	and$$$65$$$68$$$O	Uses$$$69$$$73$$$O	Thereof$$$74$$$81$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	general$$$13$$$20$$$O	formula$$$21$$$28$$$O	(I)$$$29$$$32$$$O	wherein$$$33$$$40$$$O	D,$$$41$$$43$$$O	E,$$$44$$$46$$$O	R1,$$$47$$$50$$$O	R2,$$$51$$$54$$$O	R3,$$$55$$$58$$$O	R4,$$$59$$$62$$$O	R5,$$$63$$$66$$$O	R6$$$67$$$69$$$O	and$$$70$$$73$$$O	R7$$$74$$$76$$$O	are$$$77$$$80$$$O	as$$$81$$$83$$$O	defined$$$84$$$91$$$O	in$$$92$$$94$$$O	the$$$95$$$98$$$O	specification,$$$99$$$113$$$O	as$$$114$$$116$$$O	well$$$117$$$121$$$O	as$$$122$$$124$$$O	salts,$$$125$$$131$$$O	enantiomers$$$132$$$143$$$O	thereof$$$144$$$151$$$O	and$$$152$$$155$$$O	pharmaceutical$$$156$$$170$$$O	compositions$$$171$$$183$$$O	including$$$184$$$193$$$O	the$$$194$$$197$$$O	compounds$$$198$$$207$$$O	are$$$208$$$211$$$O	prepared.$$$212$$$221$$$O	They$$$222$$$226$$$O	are$$$227$$$230$$$O	useful$$$231$$$237$$$O	in$$$238$$$240$$$O	therapy,$$$241$$$249$$$O	in$$$250$$$252$$$O	particular$$$253$$$263$$$O	in$$$264$$$266$$$O	the$$$267$$$270$$$O	management$$$271$$$281$$$O	of$$$282$$$284$$$O	pain.$$$285$$$290$$$O
EP2514742A2
Orally$$$0$$$6$$$O	bioavailable$$$7$$$19$$$O	cafeic$$$20$$$26$$$O	acid$$$27$$$31$$$O	related$$$32$$$39$$$O	anticancer$$$40$$$50$$$O	drugs$$$51$$$56$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	concerns$$$22$$$30$$$O	compounds$$$31$$$40$$$O	and$$$41$$$44$$$O	their$$$45$$$50$$$O	use$$$51$$$54$$$O	to$$$55$$$57$$$O	treat$$$58$$$63$$$O	cell$$$64$$$68$$$O	proliferative$$$69$$$82$$$O	diseases$$$83$$$91$$$O	such$$$92$$$96$$$O	as$$$97$$$99$$$O	cancer.$$$100$$$107$$$O	Compounds$$$108$$$117$$$O	of$$$118$$$120$$$O	the$$$121$$$124$$$O	present$$$125$$$132$$$O	invention$$$133$$$142$$$O	display$$$143$$$150$$$O	significant$$$151$$$162$$$O	potency$$$163$$$170$$$O	as$$$171$$$173$$$O	inhibitors$$$174$$$184$$$O	of$$$185$$$187$$$O	Jak2/STAT3$$$188$$$198$$$O	pathways$$$199$$$207$$$O	and$$$208$$$211$$$O	downstream$$$212$$$222$$$O	targets$$$223$$$230$$$O	and$$$231$$$234$$$O	inhibit$$$235$$$242$$$O	the$$$243$$$246$$$O	growth$$$247$$$253$$$O	and$$$254$$$257$$$O	survival$$$258$$$266$$$O	of$$$267$$$269$$$O	cancerous$$$270$$$279$$$O	cell$$$280$$$284$$$O	lines.$$$285$$$291$$$O
EP2397481A1
Inhibitor$$$0$$$9$$$O	of$$$10$$$12$$$O	casein$$$13$$$19$$$O	kinase$$$20$$$26$$$O	1delta$$$27$$$33$$$O	and$$$35$$$38$$$O	casein$$$39$$$45$$$O	kinase$$$46$$$52$$$O	1epsilon$$$53$$$61$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	an$$$18$$$20$$$O	inhibitor$$$21$$$30$$$O	that$$$31$$$35$$$O	inhibits$$$36$$$44$$$O	casein$$$45$$$51$$$O	kinase$$$52$$$58$$$O	1Î´$$$59$$$62$$$O	and$$$63$$$66$$$O	casein$$$67$$$73$$$O	kinase$$$74$$$80$$$O	1Îµ,$$$81$$$85$$$O	and$$$86$$$89$$$O	thus,$$$90$$$95$$$O	there$$$96$$$101$$$O	is$$$102$$$104$$$O	also$$$105$$$109$$$O	provided$$$110$$$118$$$O	a$$$119$$$120$$$O	pharmaceutical$$$121$$$135$$$O	agent$$$136$$$141$$$O	useful$$$142$$$148$$$O	for$$$149$$$152$$$O	the$$$153$$$156$$$O	treatment$$$157$$$166$$$O	and/or$$$167$$$173$$$O	prevention$$$174$$$184$$$O	of$$$185$$$187$$$O	a$$$188$$$189$$$O	disease,$$$190$$$198$$$O	with$$$199$$$203$$$O	the$$$204$$$207$$$O	pathological$$$208$$$220$$$O	condition$$$221$$$230$$$O	of$$$231$$$233$$$O	which$$$234$$$239$$$O	the$$$240$$$243$$$O	mechanism$$$244$$$253$$$O	of$$$254$$$256$$$O	activation$$$257$$$267$$$O	of$$$268$$$270$$$O	casein$$$271$$$277$$$O	kinase$$$278$$$284$$$O	1Î´$$$285$$$288$$$O	or$$$289$$$291$$$O	casein$$$292$$$298$$$O	kinase$$$299$$$305$$$O	1Îµ$$$306$$$309$$$O	is$$$310$$$312$$$O	associated.$$$313$$$324$$$O	Particularly,$$$325$$$338$$$O	the$$$339$$$342$$$O	above-described$$$343$$$358$$$O	inhibitor$$$359$$$368$$$O	is$$$369$$$371$$$O	used$$$372$$$376$$$O	to$$$377$$$379$$$O	provide$$$380$$$387$$$O	a$$$388$$$389$$$O	pharmaceutical$$$390$$$404$$$O	agent$$$405$$$410$$$O	useful$$$411$$$417$$$O	for$$$418$$$421$$$O	the$$$422$$$425$$$O	treatment$$$426$$$435$$$O	of$$$436$$$438$$$O	circadian$$$439$$$448$$$O	rhythm$$$449$$$455$$$O	disorder$$$456$$$464$$$O	(including$$$465$$$475$$$O	sleep$$$476$$$481$$$O	disorder),$$$482$$$492$$$O	central$$$493$$$500$$$O	neurodegenerative$$$501$$$518$$$O	disease,$$$519$$$527$$$O	and$$$528$$$531$$$O	cancer.$$$532$$$539$$$O	An$$$544$$$546$$$O	inhibitor$$$547$$$556$$$O	of$$$557$$$559$$$O	casein$$$560$$$566$$$O	kinase$$$567$$$573$$$O	1Î´$$$574$$$577$$$O	and$$$578$$$581$$$O	casein$$$582$$$588$$$O	kinase$$$589$$$595$$$O	1Îµ,$$$596$$$600$$$O	which$$$601$$$606$$$O	comprises,$$$607$$$617$$$O	as$$$618$$$620$$$O	an$$$621$$$623$$$O	active$$$624$$$630$$$O	ingredient,$$$631$$$642$$$I	an$$$643$$$645$$$I	oxazolone$$$646$$$655$$$I	derivative$$$656$$$666$$$O	represented$$$667$$$678$$$O	by$$$679$$$681$$$O	the$$$682$$$685$$$O	following$$$686$$$695$$$O	general$$$696$$$703$$$O	formula$$$704$$$711$$$O	(1),$$$712$$$716$$$O	a$$$717$$$718$$$O	salt$$$719$$$723$$$O	thereof,$$$724$$$732$$$O	a$$$733$$$734$$$O	solvate$$$735$$$742$$$O	thereof,$$$743$$$751$$$O	or$$$752$$$754$$$O	a$$$755$$$756$$$O	hydrate$$$757$$$764$$$O	thereof:$$$765$$$773$$$O	[wherein,$$$781$$$790$$$O	in$$$791$$$793$$$O	the$$$794$$$797$$$O	formula$$$798$$$805$$$O	(1),$$$806$$$810$$$O	each$$$811$$$815$$$O	of$$$816$$$818$$$O	R1$$$819$$$821$$$O	and$$$822$$$825$$$O	R2$$$826$$$828$$$O	independently$$$829$$$842$$$O	represents$$$843$$$853$$$O	any$$$854$$$857$$$O	one$$$858$$$861$$$O	of$$$862$$$864$$$O	a$$$865$$$866$$$O	substituted$$$867$$$878$$$O	or$$$879$$$881$$$O	unsubstituted$$$882$$$895$$$O	6-membered$$$896$$$906$$$O	or$$$907$$$909$$$O	5-membered$$$910$$$920$$$O	heterocyclic$$$921$$$933$$$O	group$$$934$$$939$$$O	optionally$$$940$$$950$$$O	having$$$951$$$957$$$O	a$$$958$$$959$$$O	condensed$$$960$$$969$$$O	ring,$$$970$$$975$$$O	a$$$976$$$977$$$O	substituted$$$978$$$989$$$O	or$$$990$$$992$$$O	unsubstituted$$$993$$$1006$$$I	aromatic$$$1007$$$1015$$$I	hydrocarbon$$$1016$$$1027$$$I	group$$$1028$$$1033$$$O	optionally$$$1034$$$1044$$$O	having$$$1045$$$1051$$$O	a$$$1052$$$1053$$$O	condensed$$$1054$$$1063$$$O	ring,$$$1064$$$1069$$$O	and$$$1070$$$1073$$$O	a$$$1074$$$1075$$$O	substituted$$$1076$$$1087$$$O	or$$$1088$$$1090$$$O	unsubstituted$$$1091$$$1104$$$I	aromatic$$$1105$$$1113$$$I	hydrocarbon$$$1114$$$1125$$$I	lower$$$1126$$$1131$$$I	alkyl$$$1132$$$1137$$$O	group$$$1138$$$1143$$$I	or$$$1144$$$1146$$$I	aromatic$$$1147$$$1155$$$I	hydrocarbon$$$1156$$$1167$$$I	lower$$$1168$$$1173$$$I	alkenyl$$$1174$$$1181$$$I	group$$$1182$$$1187$$$O	optionally$$$1188$$$1198$$$O	having$$$1199$$$1205$$$O	a$$$1206$$$1207$$$O	condensed$$$1208$$$1217$$$O	ring.]$$$1218$$$1224$$$O
US20090111806
Azaquinolone$$$0$$$12$$$I	based$$$13$$$18$$$O	compounds$$$19$$$28$$$O	exhibiting$$$29$$$39$$$O	prolyl$$$40$$$46$$$I	hydroxylase$$$47$$$58$$$O	Inhibitory$$$59$$$69$$$O	activity,$$$70$$$79$$$O	compositions,$$$80$$$93$$$O	and$$$94$$$97$$$O	uses$$$98$$$102$$$O	thereof$$$103$$$110$$$O
are$$$0$$$3$$$O	useful$$$4$$$10$$$O	as$$$11$$$13$$$O	inhibitors$$$14$$$24$$$O	of$$$25$$$27$$$O	HIF$$$28$$$31$$$O	prolyl$$$32$$$38$$$I	hydroxylases$$$39$$$51$$$O	where$$$52$$$57$$$O	the$$$58$$$61$$$O	definitions$$$62$$$73$$$O	of$$$74$$$76$$$O	the$$$77$$$80$$$O	variables$$$81$$$90$$$O	are$$$91$$$94$$$O	provided$$$95$$$103$$$O	herein.$$$104$$$111$$$O
EP2709729A1
4-amino-5-fluoro-3-$$$0$$$19$$$I	[6-$$$20$$$23$$$I	(4$$$24$$$26$$$I	-methylpiperazin-$$$27$$$44$$$I	1$$$45$$$46$$$I	-$$$47$$$48$$$I	yl)$$$49$$$52$$$I	-$$$53$$$54$$$I	1h$$$55$$$57$$$I	-$$$58$$$59$$$I	benzimidazol$$$60$$$72$$$I	-$$$73$$$74$$$I	2$$$75$$$76$$$I	-$$$77$$$78$$$I	yl]-$$$79$$$83$$$I	1h$$$84$$$86$$$I	-$$$87$$$88$$$I	quinoli$$$89$$$96$$$I	n-2-one$$$97$$$104$$$I	for$$$105$$$108$$$O	use$$$109$$$112$$$O	in$$$113$$$115$$$O	the$$$116$$$119$$$O	treatment$$$120$$$129$$$O	of$$$130$$$132$$$O	adenoid$$$133$$$140$$$O	cystic$$$141$$$147$$$O	carcinoma$$$148$$$157$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	describes$$$22$$$31$$$O	a$$$32$$$33$$$O	method$$$34$$$40$$$O	of$$$41$$$43$$$O	reducing$$$44$$$52$$$O	solid$$$53$$$58$$$O	tumors$$$59$$$65$$$O	in$$$66$$$68$$$O	a$$$69$$$70$$$O	subject$$$71$$$78$$$O	having$$$79$$$85$$$O	an$$$86$$$88$$$O	adenoid$$$89$$$96$$$O	cystic$$$97$$$103$$$O	carcinoma$$$104$$$113$$$O	comprising$$$114$$$124$$$O	administering$$$125$$$138$$$O	a$$$139$$$140$$$O	therapeutically$$$141$$$156$$$O	effective$$$157$$$166$$$O	amount$$$167$$$173$$$O	of$$$174$$$176$$$O	4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one$$$177$$$263$$$I	or$$$264$$$266$$$O	a$$$267$$$268$$$O	pharmaceutically$$$269$$$285$$$O	acceptable$$$286$$$296$$$O	salt$$$297$$$301$$$O	thereof.$$$302$$$310$$$O
WO2012012886A1
Compounds$$$0$$$9$$$O	and$$$10$$$13$$$O	extracts$$$14$$$22$$$O	from$$$23$$$27$$$O	gnetum$$$28$$$34$$$O	africanum$$$35$$$44$$$O	and$$$45$$$48$$$O	anti-inflammatory$$$49$$$66$$$O	activity$$$67$$$75$$$O	related$$$76$$$83$$$O	thereto$$$84$$$91$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	extracts$$$25$$$33$$$O	and$$$34$$$37$$$O	compositions$$$38$$$50$$$O	from$$$51$$$55$$$O	Gnetum$$$56$$$62$$$O	africanum$$$63$$$72$$$O	and$$$73$$$76$$$O	methods$$$77$$$84$$$O	for$$$85$$$88$$$O	obtaining$$$89$$$98$$$O	the$$$99$$$102$$$O	extracts,$$$103$$$112$$$O	wherein$$$113$$$120$$$O	the$$$121$$$124$$$O	extracts$$$125$$$133$$$O	comprise$$$134$$$142$$$O	resveratrol$$$143$$$154$$$I	and$$$155$$$158$$$O	have$$$159$$$163$$$O	anti-inflammatory$$$164$$$181$$$O	activity.$$$182$$$191$$$O	Methods$$$192$$$199$$$O	of$$$200$$$202$$$O	using$$$203$$$208$$$O	the$$$209$$$212$$$O	extracts$$$213$$$221$$$O	for$$$222$$$225$$$O	the$$$226$$$229$$$O	prevention$$$230$$$240$$$O	and/or$$$241$$$247$$$O	treatment$$$248$$$257$$$O	of$$$258$$$260$$$O	inflammatory$$$261$$$273$$$O	diseases,$$$274$$$283$$$O	and$$$284$$$287$$$O	compositions$$$288$$$300$$$O	which$$$301$$$306$$$O	comprise$$$307$$$315$$$O	the$$$316$$$319$$$O	extracts$$$320$$$328$$$O	including$$$329$$$338$$$O	cosmetic$$$339$$$347$$$O	compositions$$$348$$$360$$$O	are$$$361$$$364$$$O	also$$$365$$$369$$$O	encompassed.$$$370$$$382$$$O
CN102600288A
Compound$$$0$$$8$$$O	yellow$$$9$$$15$$$O	pine$$$16$$$20$$$O	gel$$$21$$$24$$$O	medicament$$$25$$$35$$$O	for$$$36$$$39$$$O	treating$$$40$$$48$$$O	vaginitis$$$49$$$58$$$O	and$$$59$$$62$$$O	preparation$$$63$$$74$$$O	method$$$75$$$81$$$O	thereof$$$82$$$89$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	compound$$$26$$$34$$$O	yellow$$$35$$$41$$$O	pine$$$42$$$46$$$O	gel$$$47$$$50$$$O	medicament$$$51$$$61$$$O	for$$$62$$$65$$$O	treating$$$66$$$74$$$O	vaginitis,$$$75$$$85$$$O	which$$$86$$$91$$$O	comprises$$$92$$$101$$$O	the$$$102$$$105$$$O	following$$$106$$$115$$$O	active$$$116$$$122$$$O	components,$$$123$$$134$$$O	auxiliary$$$135$$$144$$$O	components$$$145$$$155$$$O	and$$$156$$$159$$$O	a$$$160$$$161$$$O	gel$$$162$$$165$$$O	matrix$$$166$$$172$$$O	in$$$173$$$175$$$O	parts$$$176$$$181$$$O	by$$$182$$$184$$$O	weight:$$$185$$$192$$$O	5$$$193$$$194$$$O	to$$$195$$$197$$$O	15$$$198$$$200$$$O	parts$$$201$$$206$$$O	of$$$207$$$209$$$O	baeckea$$$210$$$217$$$O	oil,$$$218$$$222$$$O	2$$$223$$$224$$$O	to$$$225$$$227$$$O	20$$$228$$$230$$$O	parts$$$231$$$236$$$O	of$$$237$$$239$$$O	encalyptus$$$240$$$250$$$O	robusta$$$251$$$258$$$O	oil,$$$259$$$263$$$O	1$$$264$$$265$$$O	to$$$266$$$268$$$O	6$$$269$$$270$$$O	parts$$$271$$$276$$$O	of$$$277$$$279$$$O	schisandraceane$$$280$$$295$$$O	oil,$$$296$$$300$$$O	0.5$$$301$$$304$$$O	to$$$305$$$307$$$O	3$$$308$$$309$$$O	parts$$$310$$$315$$$O	of$$$316$$$318$$$O	common$$$319$$$325$$$O	cnidium$$$326$$$333$$$O	fruit$$$334$$$339$$$O	oil,$$$340$$$344$$$O	40$$$345$$$347$$$O	to$$$348$$$350$$$O	100$$$351$$$354$$$O	parts$$$355$$$360$$$O	of$$$361$$$363$$$O	groundsel,$$$364$$$374$$$O	20$$$375$$$377$$$O	to$$$378$$$380$$$O	80$$$381$$$383$$$O	parts$$$384$$$389$$$O	of$$$390$$$392$$$O	belvedere$$$393$$$402$$$O	fruit,$$$403$$$409$$$O	10$$$410$$$412$$$O	to$$$413$$$415$$$O	20$$$416$$$418$$$O	parts$$$419$$$424$$$O	of$$$425$$$427$$$O	phellodendron,$$$428$$$442$$$O	0.5$$$443$$$446$$$O	to$$$447$$$449$$$O	3$$$450$$$451$$$O	parts$$$452$$$457$$$O	of$$$458$$$460$$$O	chlorhexidine$$$461$$$474$$$I	acetate,$$$475$$$483$$$I	10$$$484$$$486$$$O	to$$$487$$$489$$$O	30$$$490$$$492$$$O	parts$$$493$$$498$$$O	of$$$499$$$501$$$O	polysorbate-80,$$$502$$$517$$$I	1$$$518$$$519$$$O	to$$$520$$$522$$$O	6$$$523$$$524$$$O	parts$$$525$$$530$$$O	of$$$531$$$533$$$O	sodium$$$534$$$540$$$I	benzoate,$$$541$$$550$$$I	0.5$$$551$$$554$$$O	to$$$555$$$557$$$O	4$$$558$$$559$$$O	parts$$$560$$$565$$$O	of$$$566$$$568$$$O	sodium$$$569$$$575$$$I	sulfite,$$$576$$$584$$$I	10$$$585$$$587$$$O	to$$$588$$$590$$$O	20$$$591$$$593$$$O	parts$$$594$$$599$$$O	of$$$600$$$602$$$O	carbomer,5$$$603$$$613$$$O	to$$$614$$$616$$$O	10$$$617$$$619$$$O	parts$$$620$$$625$$$O	of$$$626$$$628$$$O	sodium$$$629$$$635$$$O	carboxymethylcellulose,$$$636$$$659$$$O	5$$$660$$$661$$$O	to$$$662$$$664$$$O	20$$$665$$$667$$$O	parts$$$668$$$673$$$O	of$$$674$$$676$$$O	laurocapram,$$$677$$$689$$$I	100$$$690$$$693$$$O	to$$$694$$$696$$$O	150$$$697$$$700$$$O	parts$$$701$$$706$$$O	of$$$707$$$709$$$O	glycerol,$$$710$$$719$$$I	40$$$720$$$722$$$O	to$$$723$$$725$$$O	140$$$726$$$729$$$O	parts$$$730$$$735$$$O	of$$$736$$$738$$$O	propylene$$$739$$$748$$$I	glycol,$$$749$$$756$$$I	0.5$$$757$$$760$$$O	to$$$761$$$763$$$O	3$$$764$$$765$$$O	parts$$$766$$$771$$$O	of$$$772$$$774$$$O	triethanolamine,$$$775$$$791$$$I	and$$$792$$$795$$$O	200$$$796$$$799$$$O	to$$$800$$$802$$$O	400$$$803$$$806$$$O	parts$$$807$$$812$$$O	of$$$813$$$815$$$O	purified$$$816$$$824$$$O	water.$$$825$$$831$$$O	The$$$832$$$835$$$O	compound$$$836$$$844$$$O	yellow$$$845$$$851$$$O	pine$$$852$$$856$$$O	gel$$$857$$$860$$$O	medicament$$$861$$$871$$$O	can$$$872$$$875$$$O	be$$$876$$$878$$$O	used$$$879$$$883$$$O	for$$$884$$$887$$$O	treating$$$888$$$896$$$O	the$$$897$$$900$$$O	vaginitis$$$901$$$910$$$O	by$$$911$$$913$$$O	directly$$$914$$$922$$$O	placing$$$923$$$930$$$O	gel$$$931$$$934$$$O	into$$$935$$$939$$$O	vagina,$$$940$$$947$$$O	so$$$948$$$950$$$O	that$$$951$$$955$$$O	clinical$$$956$$$964$$$O	administration$$$965$$$979$$$O	to$$$980$$$982$$$O	a$$$983$$$984$$$O	patient$$$985$$$992$$$O	is$$$993$$$995$$$O	facilitated.$$$996$$$1008$$$O
CN101917995A
POLO-like$$$0$$$9$$$O	kinase$$$10$$$16$$$O	inhibitors$$$17$$$27$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	the$$$13$$$16$$$O	following$$$17$$$26$$$O	formula$$$27$$$34$$$O	are$$$35$$$38$$$O	provided$$$39$$$47$$$O	for$$$48$$$51$$$O	use$$$52$$$55$$$O	with$$$56$$$60$$$O	kinases:$$$61$$$69$$$O	(I)$$$70$$$73$$$O	wherein$$$74$$$81$$$O	the$$$82$$$85$$$O	variables$$$86$$$95$$$O	are$$$96$$$99$$$O	as$$$100$$$102$$$O	defined$$$103$$$110$$$O	herein.$$$111$$$118$$$O	Also$$$119$$$123$$$O	provided$$$124$$$132$$$O	are$$$133$$$136$$$O	pharmaceutical$$$137$$$151$$$O	compositions,$$$152$$$165$$$O	kits$$$166$$$170$$$O	and$$$171$$$174$$$O	articles$$$175$$$183$$$O	of$$$184$$$186$$$O	manufacture$$$187$$$198$$$O	comprising$$$199$$$209$$$O	such$$$210$$$214$$$O	compounds;$$$215$$$225$$$O	methods$$$226$$$233$$$O	and$$$234$$$237$$$O	intermediates$$$238$$$251$$$O	useful$$$252$$$258$$$O	for$$$259$$$262$$$O	making$$$263$$$269$$$O	the$$$270$$$273$$$O	compounds;$$$274$$$284$$$O	and$$$285$$$288$$$O	methods$$$289$$$296$$$O	of$$$297$$$299$$$O	using$$$300$$$305$$$O	said$$$306$$$310$$$O	compounds.$$$311$$$321$$$O
US20090054452
Thienopyridine$$$0$$$14$$$I	Derivatives$$$15$$$26$$$O	and$$$27$$$30$$$O	the$$$31$$$34$$$O	Use$$$35$$$38$$$O	Thereof$$$39$$$46$$$O	as$$$47$$$49$$$O	Hsp90$$$50$$$55$$$O	Modulators$$$56$$$66$$$O
Novel$$$0$$$5$$$O	thienopyridine$$$6$$$20$$$I	derivatives$$$21$$$32$$$O	of$$$33$$$35$$$O	the$$$36$$$39$$$O	formula$$$40$$$47$$$O	(I),$$$48$$$52$$$O	in$$$53$$$55$$$O	which$$$56$$$61$$$O	R1,$$$62$$$65$$$O	R2,$$$66$$$69$$$O	R3$$$70$$$72$$$O	and$$$73$$$76$$$O	Y$$$77$$$78$$$O	have$$$79$$$83$$$O	the$$$84$$$87$$$O	meanings$$$88$$$96$$$O	indicated$$$97$$$106$$$O	in$$$107$$$109$$$O	Claim$$$110$$$115$$$O	1,$$$116$$$118$$$O	are$$$119$$$122$$$O	HSP90$$$123$$$128$$$O	inhibitors$$$129$$$139$$$O	and$$$140$$$143$$$O	can$$$144$$$147$$$O	be$$$148$$$150$$$O	used$$$151$$$155$$$O	for$$$156$$$159$$$O	the$$$160$$$163$$$O	preparation$$$164$$$175$$$O	of$$$176$$$178$$$O	a$$$179$$$180$$$O	medicament$$$181$$$191$$$O	for$$$192$$$195$$$O	the$$$196$$$199$$$O	treatment$$$200$$$209$$$O	of$$$210$$$212$$$O	diseases$$$213$$$221$$$O	in$$$222$$$224$$$O	which$$$225$$$230$$$O	the$$$231$$$234$$$O	inhibition,$$$235$$$246$$$O	regulation$$$247$$$257$$$O	and/or$$$258$$$264$$$O	modulation$$$265$$$275$$$O	of$$$276$$$278$$$O	HSP90$$$279$$$284$$$O	plays$$$285$$$290$$$O	a$$$291$$$292$$$O	role.$$$293$$$298$$$O
US7211562
cytotoxic$$$0$$$9$$$O	agents$$$10$$$16$$$O	followed$$$17$$$25$$$O	by$$$26$$$28$$$O	a$$$29$$$30$$$O	heat$$$31$$$35$$$O	shock$$$36$$$41$$$O	protein$$$42$$$49$$$O	90$$$50$$$52$$$O	inhibitor,$$$53$$$63$$$O	has$$$64$$$67$$$O	a$$$68$$$69$$$O	synergistic$$$70$$$81$$$O	effect$$$82$$$88$$$O	on$$$89$$$91$$$O	the$$$92$$$95$$$O	growth$$$96$$$102$$$O	inhibition$$$103$$$113$$$O	of$$$114$$$116$$$O	cells;$$$117$$$123$$$O	destroying$$$124$$$134$$$O	cells$$$135$$$140$$$O	having$$$141$$$147$$$O	a$$$148$$$149$$$O	cell$$$150$$$154$$$O	proliferative$$$155$$$168$$$O	disorder$$$169$$$177$$$O	with$$$178$$$182$$$O	wild-type$$$183$$$192$$$O	retinoblastoma$$$193$$$207$$$O	gene$$$208$$$212$$$O
The$$$0$$$3$$$O	administration$$$4$$$18$$$O	of$$$19$$$21$$$O	cytotoxic$$$22$$$31$$$O	agents$$$32$$$38$$$O	followed$$$39$$$47$$$O	by$$$48$$$50$$$O	the$$$51$$$54$$$O	administration$$$55$$$69$$$O	of$$$70$$$72$$$O	heat$$$73$$$77$$$O	shock$$$78$$$83$$$O	protein$$$84$$$91$$$O	90$$$92$$$94$$$O	inhibitors,$$$95$$$106$$$O	such$$$107$$$111$$$O	as$$$112$$$114$$$O	ansamycins,$$$115$$$126$$$I	has$$$127$$$130$$$O	a$$$131$$$132$$$O	synergistic$$$133$$$144$$$O	effect$$$145$$$151$$$O	on$$$152$$$154$$$O	the$$$155$$$158$$$O	growth$$$159$$$165$$$O	inhibition$$$166$$$176$$$O	of$$$177$$$179$$$O	cells.$$$180$$$186$$$O	This$$$187$$$191$$$O	synergy$$$192$$$199$$$O	occurs$$$200$$$206$$$O	at$$$207$$$209$$$O	doses$$$210$$$215$$$O	of$$$216$$$218$$$O	each$$$219$$$223$$$O	cytotoxic$$$224$$$233$$$O	agent$$$234$$$239$$$O	that$$$240$$$244$$$O	normally$$$245$$$253$$$O	only$$$254$$$258$$$O	causes$$$259$$$265$$$O	minimal$$$266$$$273$$$O	growth$$$274$$$280$$$O	inhibition$$$281$$$291$$$O	of$$$292$$$294$$$O	cells.$$$295$$$301$$$O	Such$$$302$$$306$$$O	combination$$$307$$$318$$$O	therapy$$$319$$$326$$$O	thus$$$327$$$331$$$O	allows$$$332$$$338$$$O	one$$$339$$$342$$$O	to$$$343$$$345$$$O	use$$$346$$$349$$$O	lower$$$350$$$355$$$O	doses$$$356$$$361$$$O	of$$$362$$$364$$$O	cytotoxic$$$365$$$374$$$O	agents$$$375$$$381$$$O	to$$$382$$$384$$$O	avoid$$$385$$$390$$$O	or$$$391$$$393$$$O	reduce$$$394$$$400$$$O	their$$$401$$$406$$$O	respective$$$407$$$417$$$O	toxicity$$$418$$$426$$$O	to$$$427$$$429$$$O	patients$$$430$$$438$$$O	without$$$439$$$446$$$O	compromising$$$447$$$459$$$O	their$$$460$$$465$$$O	growth$$$466$$$472$$$O	inhibitory$$$473$$$483$$$O	effects.$$$484$$$492$$$O	Thus,$$$493$$$498$$$O	these$$$499$$$504$$$O	combinations$$$505$$$517$$$O	can$$$518$$$521$$$O	be$$$522$$$524$$$O	used$$$525$$$529$$$O	for$$$530$$$533$$$O	the$$$534$$$537$$$O	treatment$$$538$$$547$$$O	of$$$548$$$550$$$O	an$$$551$$$553$$$O	animal,$$$554$$$561$$$O	preferably$$$562$$$572$$$O	a$$$573$$$574$$$O	mammal,$$$575$$$582$$$O	that$$$583$$$587$$$O	has$$$588$$$591$$$O	a$$$592$$$593$$$O	cell$$$594$$$598$$$O	proliferative$$$599$$$612$$$O	disorder,$$$613$$$622$$$O	whether$$$623$$$630$$$O	the$$$631$$$634$$$O	cells$$$635$$$640$$$O	have$$$641$$$645$$$O	wild-type$$$646$$$655$$$O	Rb$$$656$$$658$$$O	or$$$659$$$661$$$O	are$$$662$$$665$$$O	Rb$$$666$$$668$$$O	deficient$$$669$$$678$$$O	or$$$679$$$681$$$O	Rb$$$682$$$684$$$O	negative.$$$685$$$694$$$O	One$$$695$$$698$$$O	such$$$699$$$703$$$O	method,$$$704$$$711$$$O	directed$$$712$$$720$$$O	to$$$721$$$723$$$O	treating$$$724$$$732$$$O	cell$$$733$$$737$$$O	proliferative$$$738$$$751$$$O	disorders$$$752$$$761$$$O	includes$$$762$$$770$$$O	the$$$771$$$774$$$O	step$$$775$$$779$$$O	of$$$780$$$782$$$O	administering$$$783$$$796$$$O	a$$$797$$$798$$$O	therapeutic$$$799$$$810$$$O	effective$$$811$$$820$$$O	amount$$$821$$$827$$$O	of$$$828$$$830$$$O	a$$$831$$$832$$$O	cytotoxic$$$833$$$842$$$O	agent$$$843$$$848$$$O	followed$$$849$$$857$$$O	by$$$858$$$860$$$O	administering$$$861$$$874$$$O	a$$$875$$$876$$$O	therapeutic$$$877$$$888$$$O	effective$$$889$$$898$$$O	amount$$$899$$$905$$$O	of$$$906$$$908$$$O	a$$$909$$$910$$$O	heat$$$911$$$915$$$O	shock$$$916$$$921$$$O	protein$$$922$$$929$$$O	90$$$930$$$932$$$O	inhibitor.$$$933$$$943$$$O	The$$$944$$$947$$$O	cytotoxic$$$948$$$957$$$O	agent$$$958$$$963$$$O	may$$$964$$$967$$$O	be$$$968$$$970$$$O	a$$$971$$$972$$$O	microtubule-affecting$$$973$$$994$$$O	agent,$$$995$$$1001$$$O	topoisomerase$$$1002$$$1015$$$O	II$$$1016$$$1018$$$O	inhibitor,$$$1019$$$1029$$$O	a$$$1030$$$1031$$$O	platinum$$$1032$$$1040$$$I	complex,$$$1041$$$1049$$$O	paclitaxel,$$$1050$$$1061$$$I	or$$$1062$$$1064$$$O	a$$$1065$$$1066$$$O	paclitaxel$$$1067$$$1077$$$I	derivative.$$$1078$$$1089$$$O	The$$$1090$$$1093$$$O	HSP90$$$1094$$$1099$$$O	inhibitor$$$1100$$$1109$$$O	may$$$1110$$$1113$$$O	be$$$1114$$$1116$$$O	an$$$1117$$$1119$$$O	ansamycin,$$$1120$$$1130$$$I	radicicol$$$1131$$$1140$$$I	or$$$1141$$$1143$$$O	a$$$1144$$$1145$$$O	synthetic$$$1146$$$1155$$$O	compound$$$1156$$$1164$$$O	that$$$1165$$$1169$$$O	binds$$$1170$$$1175$$$O	to$$$1176$$$1178$$$O	the$$$1179$$$1182$$$O	ATP-binding$$$1183$$$1194$$$O	site$$$1195$$$1199$$$O	of$$$1200$$$1202$$$O	HSP90.$$$1203$$$1209$$$O
EP1530724B1
Diagnosis$$$0$$$9$$$O	and$$$10$$$13$$$O	prevention$$$14$$$24$$$O	of$$$25$$$27$$$O	cancer$$$28$$$34$$$O	cell$$$35$$$39$$$O	invasion$$$40$$$48$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	diagnostic$$$33$$$43$$$O	and$$$44$$$47$$$O	therapeutic$$$48$$$59$$$O	methods$$$60$$$67$$$O	in$$$68$$$70$$$O	the$$$71$$$74$$$O	field$$$75$$$80$$$O	of$$$81$$$83$$$O	malignant$$$84$$$93$$$O	disorders.$$$94$$$104$$$O	More$$$105$$$109$$$O	particularly,$$$110$$$123$$$O	the$$$124$$$127$$$O	invention$$$128$$$137$$$O	provides$$$138$$$146$$$O	methods$$$147$$$154$$$O	of$$$155$$$157$$$O	determining$$$158$$$169$$$O	the$$$170$$$173$$$O	invasivity$$$174$$$184$$$O	of$$$185$$$187$$$O	malignant$$$188$$$197$$$O	disorders$$$198$$$207$$$O	and$$$208$$$211$$$O	methods$$$212$$$219$$$O	for$$$220$$$223$$$O	reducing$$$224$$$232$$$O	the$$$233$$$236$$$O	invasivity$$$237$$$247$$$O	of$$$248$$$250$$$O	malignant$$$251$$$260$$$O	disorders$$$261$$$270$$$O	including$$$271$$$280$$$O	the$$$281$$$284$$$O	prevention$$$285$$$295$$$O	or$$$296$$$298$$$O	treatment$$$299$$$308$$$O	of$$$309$$$311$$$O	cancer$$$312$$$318$$$O	cell$$$319$$$323$$$O	invasion.$$$324$$$333$$$O
CN1586484A
Dipyridamole$$$0$$$12$$$I	soft$$$13$$$17$$$O	capsule$$$18$$$25$$$O	preparation$$$26$$$37$$$O	and$$$38$$$41$$$O	its$$$42$$$45$$$O	preparing$$$46$$$55$$$O	method$$$56$$$62$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	one$$$32$$$35$$$O	kind$$$36$$$40$$$O	of$$$41$$$43$$$O	soft$$$44$$$48$$$O	diphyidamole$$$49$$$61$$$I	capsule$$$62$$$69$$$O	and$$$70$$$73$$$O	its$$$74$$$77$$$O	preparation$$$78$$$89$$$O	process.$$$90$$$98$$$O	The$$$99$$$102$$$O	medicine$$$103$$$111$$$O	consists$$$112$$$120$$$O	of$$$121$$$123$$$O	medicine$$$124$$$132$$$O	liquid$$$133$$$139$$$O	and$$$140$$$143$$$O	capsule$$$144$$$151$$$O	shell,$$$152$$$158$$$O	the$$$159$$$162$$$O	medicine$$$163$$$171$$$O	liquid$$$172$$$178$$$O	contains$$$179$$$187$$$O	diphyidamole,$$$188$$$201$$$I	matrix$$$202$$$208$$$O	and$$$209$$$212$$$O	stabilizer,$$$213$$$224$$$O	and$$$225$$$228$$$O	the$$$229$$$232$$$O	capsule$$$233$$$240$$$O	shell$$$241$$$246$$$O	contains$$$247$$$255$$$O	gelatin,$$$256$$$264$$$O	glycerin,$$$265$$$274$$$I	water,$$$275$$$281$$$O	preservative$$$282$$$294$$$O	and$$$295$$$298$$$O	light$$$299$$$304$$$O	screening$$$305$$$314$$$O	agent.$$$315$$$321$$$O	Compared$$$322$$$330$$$O	with$$$331$$$335$$$O	available$$$336$$$345$$$O	diphyidamole$$$346$$$358$$$I	preparations,$$$359$$$372$$$O	the$$$373$$$376$$$O	present$$$377$$$384$$$O	invention$$$385$$$394$$$O	is$$$395$$$397$$$O	even$$$398$$$402$$$O	suitable$$$403$$$411$$$O	for$$$412$$$415$$$O	children$$$416$$$424$$$O	and$$$425$$$428$$$O	other$$$429$$$434$$$O	people$$$435$$$441$$$O	incapable$$$442$$$451$$$O	of$$$452$$$454$$$O	taking$$$455$$$461$$$O	care$$$462$$$466$$$O	of$$$467$$$469$$$O	himself$$$470$$$477$$$O	to$$$478$$$480$$$O	take$$$481$$$485$$$O	and$$$486$$$489$$$O	has$$$490$$$493$$$O	the$$$494$$$497$$$O	advantages$$$498$$$508$$$O	of$$$509$$$511$$$O	high$$$512$$$516$$$O	bioavailability,$$$517$$$533$$$O	high$$$534$$$538$$$O	stability,$$$539$$$549$$$O	accurate$$$550$$$558$$$O	content,$$$559$$$567$$$O	etc.$$$568$$$572$$$O
WO2013041468A1
Benzoic$$$0$$$7$$$I	acid$$$8$$$12$$$I	derivatives$$$13$$$24$$$O	as$$$25$$$27$$$O	eif4e$$$28$$$33$$$O	inhibitors$$$34$$$44$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	compounds$$$14$$$23$$$O	with$$$24$$$28$$$O	the$$$29$$$32$$$O	formula$$$33$$$40$$$O	(I),$$$41$$$45$$$O	where$$$46$$$51$$$O	R1$$$52$$$54$$$O	and$$$55$$$58$$$O	R2$$$59$$$61$$$O	are$$$62$$$65$$$O	as$$$66$$$68$$$O	disclosed$$$69$$$78$$$O	herein,$$$79$$$86$$$O	which$$$87$$$92$$$O	are$$$93$$$96$$$O	eIF4E$$$97$$$102$$$O	inhibitors$$$103$$$113$$$O	useful$$$114$$$120$$$O	in$$$121$$$123$$$O	the$$$124$$$127$$$O	treatment$$$128$$$137$$$O	of$$$138$$$140$$$O	cancers.$$$141$$$149$$$O	Also$$$150$$$154$$$O	disclosed$$$155$$$164$$$O	are$$$165$$$168$$$O	compositions$$$169$$$181$$$O	comprising$$$182$$$192$$$O	the$$$193$$$196$$$O	compounds,$$$197$$$207$$$O	as$$$208$$$210$$$O	well$$$211$$$215$$$O	as$$$216$$$218$$$O	methods$$$219$$$226$$$O	of$$$227$$$229$$$O	treating$$$230$$$238$$$O	cancer$$$239$$$245$$$O	using$$$246$$$251$$$O	the$$$252$$$255$$$O	compounds.$$$256$$$266$$$O
WO2014091876A1
Fluorine-substituted$$$0$$$20$$$I	piperidine$$$21$$$31$$$I	compound$$$32$$$40$$$O
The$$$0$$$3$$$O	fluorine-substituted$$$4$$$24$$$I	piperidine$$$25$$$35$$$I	compound$$$36$$$44$$$O	represented$$$45$$$56$$$O	in$$$57$$$59$$$O	formula$$$60$$$67$$$O	(I)$$$68$$$71$$$O	or$$$72$$$74$$$O	a$$$75$$$76$$$O	pharmaceutically$$$77$$$93$$$O	acceptable$$$94$$$104$$$O	salt$$$105$$$109$$$O	thereof$$$110$$$117$$$O	is$$$118$$$120$$$O	useful$$$121$$$127$$$O	in$$$128$$$130$$$O	the$$$131$$$134$$$O	treatment$$$135$$$144$$$O	or$$$145$$$147$$$O	prevention$$$148$$$158$$$O	of$$$159$$$161$$$O	disorders$$$162$$$171$$$O	that$$$172$$$176$$$O	are$$$177$$$180$$$O	on$$$181$$$183$$$O	the$$$184$$$187$$$O	basis$$$188$$$193$$$O	of$$$194$$$196$$$O	orexin$$$197$$$203$$$O	(OX)$$$204$$$208$$$O	receptor$$$209$$$217$$$O	antagonism$$$218$$$228$$$O	including$$$229$$$238$$$O	sleep$$$239$$$244$$$O	disorders,$$$245$$$255$$$O	depression,$$$256$$$267$$$O	anxiety$$$268$$$275$$$O	disorders,$$$276$$$286$$$O	panic$$$287$$$292$$$O	disorders,$$$293$$$303$$$O	schizophrenia,$$$304$$$318$$$O	drug$$$319$$$323$$$O	dependence,$$$324$$$335$$$O	Alzheimer's$$$336$$$347$$$O	disease,$$$348$$$356$$$O	Parkinson's$$$357$$$368$$$O	disease,$$$369$$$377$$$O	Huntington's$$$378$$$390$$$O	disease,$$$391$$$399$$$O	eating$$$400$$$406$$$O	disorders,$$$407$$$417$$$O	headaches,$$$418$$$428$$$O	migraines,$$$429$$$439$$$O	pain,$$$440$$$445$$$O	gastrointestinal$$$446$$$462$$$O	diseases,$$$463$$$472$$$O	epilepsy,$$$473$$$482$$$O	inflammation,$$$483$$$496$$$O	immunological$$$497$$$510$$$O	disorders,$$$511$$$521$$$O	endocrine$$$522$$$531$$$O	disorders,$$$532$$$542$$$O	and$$$543$$$546$$$O	high$$$547$$$551$$$O	blood$$$552$$$557$$$O	pressure.$$$558$$$567$$$O
CN1823793A
Atfuweibi$$$0$$$9$$$O	terveleryl$$$10$$$20$$$O	oxo$$$21$$$24$$$O	methyl$$$25$$$31$$$O	ester$$$32$$$37$$$O	enteric$$$38$$$45$$$O	micropill$$$46$$$55$$$O	and$$$56$$$59$$$O	its$$$60$$$63$$$O	preparation$$$64$$$75$$$O	method$$$76$$$82$$$O
An$$$0$$$2$$$O	enteric$$$3$$$10$$$O	micropill$$$11$$$20$$$O	is$$$21$$$23$$$O	prepared$$$24$$$32$$$O	from$$$33$$$37$$$O	adefovirdipivoxil$$$38$$$55$$$I	dipivalyloxy$$$56$$$68$$$I	methylester$$$69$$$80$$$I	as$$$81$$$83$$$O	active$$$84$$$90$$$O	component,$$$91$$$101$$$O	hydroxypropylmethyl$$$102$$$121$$$O	cellulose$$$122$$$131$$$O	phthalate$$$132$$$141$$$O	as$$$142$$$144$$$O	enteric$$$145$$$152$$$O	material,$$$153$$$162$$$O	and$$$163$$$166$$$O	detackifier.$$$167$$$179$$$O	Its$$$180$$$183$$$O	preparing$$$184$$$193$$$O	process$$$194$$$201$$$O	is$$$202$$$204$$$O	also$$$205$$$209$$$O	disclosed.$$$210$$$220$$$O
US20050209169
Respiratory$$$0$$$11$$$O	disorders$$$12$$$21$$$O	such$$$22$$$26$$$O	as$$$27$$$29$$$O	pulmonary$$$30$$$39$$$O	emphysema,$$$40$$$50$$$O	acute$$$51$$$56$$$O	respiratory$$$57$$$68$$$O	distress$$$69$$$77$$$O	syndrome,$$$78$$$87$$$O	shock$$$88$$$93$$$O	lung,$$$94$$$99$$$O	cystic$$$100$$$106$$$O	fibrosis$$$107$$$115$$$O	(mucoviscidosis),$$$116$$$133$$$O	chronic$$$134$$$141$$$O	bronchitis,$$$142$$$153$$$O	glomerulonephritis$$$154$$$172$$$O	and$$$173$$$176$$$O	rheumatoid$$$177$$$187$$$O	arthritis$$$188$$$197$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	the$$$23$$$26$$$O	use$$$27$$$30$$$O	of$$$31$$$33$$$O	pure$$$34$$$38$$$O	boswellic$$$39$$$48$$$I	acid,$$$49$$$54$$$I	a$$$55$$$56$$$O	physiologically$$$57$$$72$$$O	acceptable$$$73$$$83$$$O	salt,$$$84$$$89$$$O	a$$$90$$$91$$$O	derivative,$$$92$$$103$$$O	a$$$104$$$105$$$O	salt$$$106$$$110$$$O	of$$$111$$$113$$$O	the$$$114$$$117$$$O	derivative$$$118$$$128$$$O	or$$$129$$$131$$$O	a$$$132$$$133$$$O	plant$$$134$$$139$$$O	preparation$$$140$$$151$$$O	containing$$$152$$$162$$$O	boswellic$$$163$$$172$$$I	acid$$$173$$$177$$$I	for$$$178$$$181$$$O	preventing$$$182$$$192$$$O	and/or$$$193$$$199$$$O	combatting$$$200$$$210$$$O	diseases$$$211$$$219$$$O	which$$$220$$$225$$$O	are$$$226$$$229$$$O	caused$$$230$$$236$$$O	by$$$237$$$239$$$O	increased$$$240$$$249$$$O	leucocytic$$$250$$$260$$$O	elastase$$$261$$$269$$$O	or$$$270$$$272$$$O	plasmin$$$273$$$280$$$O	activity$$$281$$$289$$$O	or$$$290$$$292$$$O	can$$$293$$$296$$$O	be$$$297$$$299$$$O	treated$$$300$$$307$$$O	by$$$308$$$310$$$O	the$$$311$$$314$$$O	inhibition$$$315$$$325$$$O	of:$$$326$$$329$$$O	normal$$$330$$$336$$$O	leucocytic$$$337$$$347$$$O	elastase$$$348$$$356$$$O	or$$$357$$$359$$$O	plasmin$$$360$$$367$$$O	activity,$$$368$$$377$$$O	in$$$378$$$380$$$O	human$$$381$$$386$$$O	or$$$387$$$389$$$O	veterinary$$$390$$$400$$$O	medicine.$$$401$$$410$$$O	The$$$411$$$414$$$O	invention$$$415$$$424$$$O	further$$$425$$$432$$$O	concerns$$$433$$$441$$$O	the$$$442$$$445$$$O	use$$$446$$$449$$$O	of$$$450$$$452$$$O	pure$$$453$$$457$$$O	boswellic$$$458$$$467$$$I	acid$$$468$$$472$$$I	or$$$473$$$475$$$O	a$$$476$$$477$$$O	physiologically$$$478$$$493$$$O	acceptable$$$494$$$504$$$O	salt,$$$505$$$510$$$O	a$$$511$$$512$$$O	derivative,$$$513$$$524$$$O	a$$$525$$$526$$$O	salt$$$527$$$531$$$O	of$$$532$$$534$$$O	the$$$535$$$538$$$O	derivative$$$539$$$549$$$O	or$$$550$$$552$$$O	a$$$553$$$554$$$O	plant$$$555$$$560$$$O	preparation$$$561$$$572$$$O	containing$$$573$$$583$$$O	boswellic$$$584$$$593$$$I	acid$$$594$$$598$$$I	for$$$599$$$602$$$O	preparing$$$603$$$612$$$O	a$$$613$$$614$$$O	medicament$$$615$$$625$$$O	for$$$626$$$629$$$O	treating$$$630$$$638$$$O	diseases$$$639$$$647$$$O	which$$$648$$$653$$$O	are$$$654$$$657$$$O	caused$$$658$$$664$$$O	by$$$665$$$667$$$O	increased$$$668$$$677$$$O	leucocytic$$$678$$$688$$$O	elastase$$$689$$$697$$$O	or$$$698$$$700$$$O	plasmin$$$701$$$708$$$O	activity$$$709$$$717$$$O	or$$$718$$$720$$$O	can$$$721$$$724$$$O	be$$$725$$$727$$$O	treated$$$728$$$735$$$O	by$$$736$$$738$$$O	the$$$739$$$742$$$O	inhibition$$$743$$$753$$$O	of$$$754$$$756$$$O	normal$$$757$$$763$$$O	leucocytic$$$764$$$774$$$O	elastase$$$775$$$783$$$O	or$$$784$$$786$$$O	plasmin$$$787$$$794$$$O	activity,$$$795$$$804$$$O	in$$$805$$$807$$$O	human$$$808$$$813$$$O	or$$$814$$$816$$$O	veterinary$$$817$$$827$$$O	medicine.$$$828$$$837$$$O
US20110059907
Chiral$$$0$$$6$$$O	Complexes$$$7$$$16$$$O	of$$$17$$$19$$$O	Ascorbic$$$20$$$28$$$I	Acid$$$29$$$33$$$I	with$$$34$$$38$$$O	Natural$$$39$$$46$$$O	Antioxidant$$$47$$$58$$$O	and$$$59$$$62$$$O	Anti-Inflammatory$$$63$$$80$$$O	Ketones$$$81$$$88$$$I	Including$$$89$$$98$$$O	Aloe,$$$99$$$104$$$O	Citrus,$$$105$$$112$$$O	Ginger,$$$113$$$120$$$O	and$$$121$$$124$$$O	Mango$$$125$$$130$$$O	for$$$131$$$134$$$O	Skin$$$135$$$139$$$O	and$$$140$$$143$$$O	Hair$$$144$$$148$$$O	Care$$$149$$$153$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	certain$$$26$$$33$$$O	complexes$$$34$$$43$$$O	of$$$44$$$46$$$O	ascorbic$$$47$$$55$$$I	acid$$$56$$$60$$$I	and$$$61$$$64$$$O	its$$$65$$$68$$$O	derivatives$$$69$$$80$$$O	with$$$81$$$85$$$O	certain$$$86$$$93$$$O	natural$$$94$$$101$$$O	antioxidant$$$102$$$113$$$O	and$$$114$$$117$$$O	anti-inflammatory$$$118$$$135$$$O	ketones$$$136$$$143$$$I	for$$$144$$$147$$$O	topical$$$148$$$155$$$O	or$$$156$$$158$$$O	oral$$$159$$$163$$$O	application;$$$164$$$176$$$O	said$$$177$$$181$$$O	complexes$$$182$$$191$$$O	having$$$192$$$198$$$O	general$$$199$$$206$$$O	chemical$$$207$$$215$$$O	formula$$$216$$$223$$$O	(I),$$$224$$$228$$$O	its$$$229$$$232$$$O	isomers,$$$233$$$241$$$O	and$$$242$$$245$$$O	salts$$$246$$$251$$$O	thereof,$$$252$$$260$$$O	including$$$261$$$270$$$O	their$$$271$$$276$$$O	optically$$$277$$$286$$$O	active$$$287$$$293$$$O	or$$$294$$$296$$$O	racemic$$$297$$$304$$$O	forms.$$$305$$$311$$$O	This$$$312$$$316$$$O	invention$$$317$$$326$$$O	also$$$327$$$331$$$O	relates$$$332$$$339$$$O	to$$$340$$$342$$$O	a$$$343$$$344$$$O	method$$$345$$$351$$$O	of$$$352$$$354$$$O	treatment$$$355$$$364$$$O	of$$$365$$$367$$$O	skin$$$368$$$372$$$O	condition,$$$373$$$383$$$O	including$$$384$$$393$$$O	dark$$$394$$$398$$$O	skin,$$$399$$$404$$$O	age$$$405$$$408$$$O	spots,$$$409$$$415$$$O	acne,$$$416$$$421$$$O	inflammation,$$$422$$$435$$$O	loss$$$436$$$440$$$O	of$$$441$$$443$$$O	cellular$$$444$$$452$$$O	antioxidants,$$$453$$$466$$$O	collagen$$$467$$$475$$$O	loss$$$476$$$480$$$O	with$$$481$$$485$$$O	aging,$$$486$$$492$$$O	loss$$$493$$$497$$$O	of$$$498$$$500$$$O	skin$$$501$$$505$$$O	pliability,$$$506$$$517$$$O	loss$$$518$$$522$$$O	of$$$523$$$525$$$O	skin$$$526$$$530$$$O	suppleness,$$$531$$$542$$$O	skin$$$543$$$547$$$O	wrinkles,$$$548$$$557$$$O	oxidation,$$$558$$$568$$$O	damage$$$569$$$575$$$O	from$$$576$$$580$$$O	radiation,$$$581$$$591$$$O	malfunction$$$592$$$603$$$O	of$$$604$$$606$$$O	matrix$$$607$$$613$$$O	metalloproteases,$$$614$$$631$$$O	malfunction$$$632$$$643$$$O	of$$$644$$$646$$$O	tyrosinases,$$$647$$$659$$$O	damage$$$660$$$666$$$O	from$$$667$$$671$$$O	free$$$672$$$676$$$O	radicals,$$$677$$$686$$$O	photo-damage,$$$687$$$700$$$O	nutritional$$$701$$$712$$$O	deficiency,$$$713$$$724$$$O	and$$$725$$$728$$$O	combinations$$$729$$$741$$$O	thereof;$$$742$$$750$$$O
WO2008117269A3
Heterotri$$$0$$$9$$$I	cyciii$$$10$$$16$$$I	c$$$17$$$18$$$I	compounds$$$19$$$28$$$O	as$$$29$$$31$$$O	serotonergic$$$32$$$44$$$O	and/or$$$45$$$51$$$O	dopaminergic$$$52$$$64$$$O	agents$$$65$$$71$$$O	and$$$72$$$75$$$O	uses$$$76$$$80$$$O	thereof$$$81$$$88$$$O
Novel$$$0$$$5$$$O	heterocyclic$$$6$$$18$$$I	compounds$$$19$$$28$$$O	of$$$29$$$31$$$O	formula$$$32$$$39$$$O	I:$$$40$$$42$$$O	A-B-D$$$43$$$48$$$O	Formula$$$49$$$56$$$O	I$$$57$$$58$$$O	or$$$59$$$61$$$O	a$$$62$$$63$$$O	pharmaceutically$$$64$$$80$$$O	acceptable$$$81$$$91$$$O	salt$$$92$$$96$$$O	thereof,$$$97$$$105$$$O	wherein:$$$106$$$114$$$O	A$$$115$$$116$$$O	is$$$117$$$119$$$O	selected$$$120$$$128$$$O	from$$$129$$$133$$$O	the$$$134$$$137$$$O	group$$$138$$$143$$$O	consisting$$$144$$$154$$$O	of$$$155$$$157$$$O	a$$$158$$$159$$$O	moiety$$$160$$$166$$$O	having$$$167$$$173$$$O	general$$$174$$$181$$$O	Formula$$$182$$$189$$$O	II$$$190$$$192$$$O	and$$$193$$$196$$$O	a$$$197$$$198$$$O	moiety$$$199$$$205$$$O	having$$$206$$$212$$$O	general$$$213$$$220$$$O	Formula$$$221$$$228$$$O	III:$$$229$$$233$$$O	Formula$$$234$$$241$$$O	II$$$242$$$244$$$O	Formula$$$245$$$252$$$O	III$$$253$$$256$$$O	B$$$257$$$258$$$O	is$$$259$$$261$$$O	a$$$262$$$263$$$O	moiety$$$264$$$270$$$O	selected$$$271$$$279$$$O	from$$$280$$$284$$$O	the$$$285$$$288$$$O	group$$$289$$$294$$$O	consisting$$$295$$$305$$$O	of:$$$306$$$309$$$O	O$$$310$$$311$$$O	D$$$312$$$313$$$O	is$$$314$$$316$$$O	a$$$317$$$318$$$O	moiety$$$319$$$325$$$O	selected$$$326$$$334$$$O	from$$$335$$$339$$$O	the$$$340$$$343$$$O	group$$$344$$$349$$$O	consisting$$$350$$$360$$$O	of:$$$361$$$364$$$O	N$$$365$$$366$$$I	and$$$367$$$370$$$O	which$$$371$$$376$$$O	exhibit$$$377$$$384$$$O	a$$$385$$$386$$$O	dopamine$$$387$$$395$$$I	receptor$$$396$$$404$$$O	(preferably$$$405$$$416$$$O	a$$$417$$$418$$$O	D4$$$419$$$421$$$O	receptor)$$$422$$$431$$$O	and/or$$$432$$$438$$$O	a$$$439$$$440$$$O	serotonine$$$441$$$451$$$I	receptor$$$452$$$460$$$O	(preferably$$$461$$$472$$$O	5HTAi$$$473$$$478$$$O	agonistic$$$479$$$488$$$O	activity),$$$489$$$499$$$O	processes$$$500$$$509$$$O	of$$$510$$$512$$$O	preparing$$$513$$$522$$$O	same,$$$523$$$528$$$O	pharmaceutical$$$529$$$543$$$O	compositions$$$544$$$556$$$O	containing$$$557$$$567$$$O	same$$$568$$$572$$$O	and$$$573$$$576$$$O	uses$$$577$$$581$$$O	thereof$$$582$$$589$$$O	in$$$590$$$592$$$O	the$$$593$$$596$$$O	treatment$$$597$$$606$$$O	of$$$607$$$609$$$O	medical$$$610$$$617$$$O	conditions$$$618$$$628$$$O	associated$$$629$$$639$$$O	with$$$640$$$644$$$O	the$$$645$$$648$$$O	dopaminergic$$$649$$$661$$$O	and/or$$$662$$$668$$$O	serotonergic$$$669$$$681$$$O	systems$$$682$$$689$$$O	(e.g.,$$$690$$$696$$$O	sexual$$$697$$$703$$$O	disorders,$$$704$$$714$$$O	dyskinesia,$$$715$$$726$$$O	anxiety)$$$727$$$735$$$O	are$$$736$$$739$$$O	disclosed.$$$740$$$750$$$O
US20090076153
Deuterium-enriched$$$0$$$18$$$I	tigecycline$$$19$$$30$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	application$$$12$$$23$$$O	describes$$$24$$$33$$$O	deuterium-enriched$$$34$$$52$$$I	tigecycline,$$$53$$$65$$$I	pharmaceutically$$$66$$$82$$$O	acceptable$$$83$$$93$$$O	salt$$$94$$$98$$$O	forms$$$99$$$104$$$O	thereof,$$$105$$$113$$$O	and$$$114$$$117$$$O	methods$$$118$$$125$$$O	of$$$126$$$128$$$O	treating$$$129$$$137$$$O	using$$$138$$$143$$$O	the$$$144$$$147$$$O	same.$$$148$$$153$$$O
US20050131049
Derivatives$$$0$$$11$$$O	of$$$12$$$14$$$O	aryl$$$15$$$19$$$I	(or$$$20$$$23$$$I	heteroaryl)$$$24$$$35$$$I	azolylcarbinoles$$$36$$$52$$$I	for$$$53$$$56$$$O	the$$$57$$$60$$$O	treatment$$$61$$$70$$$O	of$$$71$$$73$$$O	urinary$$$74$$$81$$$O	incontinence$$$82$$$94$$$O
Derivatives$$$0$$$11$$$O	of$$$12$$$14$$$O	aryl(or$$$15$$$22$$$I	heteroaryl)azolylcarbinoles$$$23$$$50$$$I	of$$$51$$$53$$$O	general$$$54$$$61$$$O	formula$$$62$$$69$$$O	(I),$$$70$$$74$$$O	in$$$75$$$77$$$O	which$$$78$$$83$$$O	Ar$$$84$$$86$$$O	represents$$$87$$$97$$$O	a$$$98$$$99$$$O	phenyl$$$100$$$106$$$I	radical$$$107$$$114$$$O	or$$$115$$$117$$$O	a$$$118$$$119$$$O	thienyl$$$120$$$127$$$I	radical,$$$128$$$136$$$I	optionally$$$137$$$147$$$O	substituted,$$$148$$$160$$$O	R1$$$161$$$163$$$O	represents$$$164$$$174$$$O	a$$$175$$$176$$$O	hydrogen$$$177$$$185$$$I	atom$$$186$$$190$$$O	or$$$191$$$193$$$O	a$$$194$$$195$$$O	lower$$$196$$$201$$$O	alkyl$$$202$$$207$$$I	group,$$$208$$$214$$$O	R2$$$215$$$217$$$O	represents$$$218$$$228$$$O	a$$$229$$$230$$$O	dialkylaminoalkyl$$$231$$$248$$$I	or$$$249$$$251$$$O	azaheterocylclylalkyl$$$252$$$273$$$I	and$$$274$$$277$$$O	Het$$$278$$$281$$$I	represents$$$282$$$292$$$O	an$$$293$$$295$$$O	azole$$$296$$$301$$$I	unsubstituted$$$302$$$315$$$O	or$$$316$$$318$$$O	optionally$$$319$$$329$$$O	substituted$$$330$$$341$$$O	by$$$342$$$344$$$O	one$$$345$$$348$$$O	or$$$349$$$351$$$O	two$$$352$$$355$$$O	substituents,$$$356$$$369$$$O	and$$$370$$$373$$$O	their$$$374$$$379$$$O	physiologically$$$380$$$395$$$O	acceptable$$$396$$$406$$$O	salts;$$$407$$$413$$$O	are$$$414$$$417$$$O	useful$$$418$$$424$$$O	as$$$425$$$427$$$O	drugs$$$428$$$433$$$O	in$$$434$$$436$$$O	human$$$437$$$442$$$O	and/or$$$443$$$449$$$O	veterinary$$$450$$$460$$$O	therapeutics$$$461$$$473$$$O	to$$$474$$$476$$$O	treat$$$477$$$482$$$O	urinary$$$483$$$490$$$O	incontinence$$$491$$$503$$$O	in$$$504$$$506$$$O	mammals,$$$507$$$515$$$O	including$$$516$$$525$$$O	man.$$$526$$$530$$$O
CN101940749A
Novel$$$0$$$5$$$O	antitussive$$$6$$$17$$$O	spray$$$18$$$23$$$O	and$$$24$$$27$$$O	preparation$$$28$$$39$$$O	process$$$40$$$47$$$O	thereof$$$48$$$55$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	novel$$$24$$$29$$$O	antitussive$$$30$$$41$$$O	spray,$$$42$$$48$$$O	which$$$49$$$54$$$O	has$$$55$$$58$$$O	main$$$59$$$63$$$O	ingredients$$$64$$$75$$$O	that:$$$76$$$81$$$O	each$$$82$$$86$$$O	kilogram$$$87$$$95$$$O	of$$$96$$$98$$$O	high-degree$$$99$$$110$$$O	liquor$$$111$$$117$$$O	contains$$$118$$$126$$$O	13$$$127$$$129$$$O	grams$$$130$$$135$$$O	of$$$136$$$138$$$O	clove,$$$139$$$145$$$O	10$$$146$$$148$$$O	grams$$$149$$$154$$$O	of$$$155$$$157$$$O	lesser$$$158$$$164$$$O	galangal$$$165$$$173$$$O	rhizome,$$$174$$$182$$$O	11$$$183$$$185$$$O	grams$$$186$$$191$$$O	of$$$192$$$194$$$O	garden$$$195$$$201$$$O	balsam$$$202$$$208$$$O	stem,$$$209$$$214$$$O	10$$$215$$$217$$$O	grams$$$218$$$223$$$O	of$$$224$$$226$$$O	Chinese$$$227$$$234$$$O	angelica,$$$235$$$244$$$O	9$$$245$$$246$$$O	grams$$$247$$$252$$$O	of$$$253$$$255$$$O	liquoric$$$256$$$264$$$O	root,$$$265$$$270$$$O	1,000$$$271$$$276$$$O	grams$$$277$$$282$$$O	of$$$283$$$285$$$O	liquor$$$286$$$292$$$O	and$$$293$$$296$$$O	4$$$297$$$298$$$O	grams$$$299$$$304$$$O	of$$$305$$$307$$$O	brown$$$308$$$313$$$O	sugar.$$$314$$$320$$$I	The$$$321$$$324$$$O	preparation$$$325$$$336$$$O	process$$$337$$$344$$$O	comprises$$$345$$$354$$$O	the$$$355$$$358$$$O	following$$$359$$$368$$$O	steps$$$369$$$374$$$O	of:$$$375$$$378$$$O	1,$$$379$$$381$$$O	selecting,$$$382$$$392$$$O	washing,$$$393$$$401$$$O	drying$$$402$$$408$$$O	and$$$409$$$412$$$O	crushing$$$413$$$421$$$O	the$$$422$$$425$$$O	medicinal$$$426$$$435$$$O	materials;$$$436$$$446$$$O	2,$$$447$$$449$$$O	mixing$$$450$$$456$$$O	the$$$457$$$460$$$O	crushed$$$461$$$468$$$O	medicinal$$$469$$$478$$$O	materials$$$479$$$488$$$O	according$$$489$$$498$$$O	to$$$499$$$501$$$O	a$$$502$$$503$$$O	proportion,$$$504$$$515$$$O	spraying$$$516$$$524$$$O	500$$$525$$$528$$$O	grams$$$529$$$534$$$O	of$$$535$$$537$$$O	liquor,$$$538$$$545$$$O	storing$$$546$$$553$$$O	for$$$554$$$557$$$O	48$$$558$$$560$$$O	hours,$$$561$$$567$$$O	and$$$568$$$571$$$O	fermenting;$$$572$$$583$$$O	3,$$$584$$$586$$$O	after$$$587$$$592$$$O	48$$$593$$$595$$$O	hours,$$$596$$$602$$$O	soaking$$$603$$$610$$$O	the$$$611$$$614$$$O	medicinal$$$615$$$624$$$O	materials$$$625$$$634$$$O	in$$$635$$$637$$$O	a$$$638$$$639$$$O	liquor$$$640$$$646$$$O	jar$$$647$$$650$$$O	filled$$$651$$$657$$$O	with$$$658$$$662$$$O	over$$$663$$$667$$$O	60-degree$$$668$$$677$$$O	high-degree$$$678$$$689$$$O	liquor;$$$690$$$697$$$O	4,$$$698$$$700$$$O	frying$$$701$$$707$$$O	the$$$708$$$711$$$O	sugar;$$$712$$$718$$$I	5,$$$719$$$721$$$O	putting$$$722$$$729$$$O	the$$$730$$$733$$$O	high-quality$$$734$$$746$$$O	brown$$$747$$$752$$$O	sugar$$$753$$$758$$$I	into$$$759$$$763$$$O	an$$$764$$$766$$$O	iron$$$767$$$771$$$I	pan,$$$772$$$776$$$O	adding$$$777$$$783$$$O	mineral$$$784$$$791$$$O	water,$$$792$$$798$$$O	heating,$$$799$$$807$$$O	and$$$808$$$811$$$O	adding$$$812$$$818$$$O	water$$$819$$$824$$$O	at$$$825$$$827$$$O	the$$$828$$$831$$$O	right$$$832$$$837$$$O	time$$$838$$$842$$$O	until$$$843$$$848$$$O	the$$$849$$$852$$$O	sugar$$$853$$$858$$$I	and$$$859$$$862$$$O	the$$$863$$$866$$$O	water$$$867$$$872$$$O	are$$$873$$$876$$$O	fried$$$877$$$882$$$O	into$$$883$$$887$$$O	a$$$888$$$889$$$O	paste;$$$890$$$896$$$O	and$$$897$$$900$$$O	6,$$$901$$$903$$$O	putting$$$904$$$911$$$O	the$$$912$$$915$$$O	fried$$$916$$$921$$$O	syrup$$$922$$$927$$$O	into$$$928$$$932$$$O	the$$$933$$$936$$$O	jar$$$937$$$940$$$O	for$$$941$$$944$$$O	soaking$$$945$$$952$$$O	the$$$953$$$956$$$O	medicinal$$$957$$$966$$$O	materials,$$$967$$$977$$$O	rapidly$$$978$$$985$$$O	stirring$$$986$$$994$$$O	uniformly,$$$995$$$1005$$$O	after$$$1006$$$1011$$$O	the$$$1012$$$1015$$$O	medicinal$$$1016$$$1025$$$O	materials$$$1026$$$1035$$$O	are$$$1036$$$1039$$$O	all$$$1040$$$1043$$$O	dissolved,$$$1044$$$1054$$$O	taking$$$1055$$$1061$$$O	the$$$1062$$$1065$$$O	medicine$$$1066$$$1074$$$O	bag$$$1075$$$1078$$$O	out,$$$1079$$$1083$$$O	squeezing,$$$1084$$$1094$$$O	and$$$1095$$$1098$$$O	pouring$$$1099$$$1106$$$O	the$$$1107$$$1110$$$O	medicine$$$1111$$$1119$$$O	liquid$$$1120$$$1126$$$O	back$$$1127$$$1131$$$O	to$$$1132$$$1134$$$O	the$$$1135$$$1138$$$O	jar$$$1139$$$1142$$$O	for$$$1143$$$1146$$$O	redissolving.$$$1147$$$1160$$$O	The$$$1161$$$1164$$$O	antitussive$$$1165$$$1176$$$O	spray$$$1177$$$1182$$$O	has$$$1183$$$1186$$$O	the$$$1187$$$1190$$$O	advantages$$$1191$$$1201$$$O	of$$$1202$$$1204$$$O	good$$$1205$$$1209$$$O	curative$$$1210$$$1218$$$O	effect,$$$1219$$$1226$$$O	readily$$$1227$$$1234$$$O	available$$$1235$$$1244$$$O	medicinal$$$1245$$$1254$$$O	materials,$$$1255$$$1265$$$O	simple$$$1266$$$1272$$$O	ingredients$$$1273$$$1284$$$O	and$$$1285$$$1288$$$O	preparation,$$$1289$$$1301$$$O	and$$$1302$$$1305$$$O	low$$$1306$$$1309$$$O	cost.$$$1310$$$1315$$$O
US20110152348
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	androgen$$$21$$$29$$$I	receptor$$$30$$$38$$$O	dependent$$$39$$$48$$$O	disorders$$$49$$$58$$$O	including$$$59$$$68$$$O	cancers$$$69$$$76$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	the$$$23$$$26$$$O	combination$$$27$$$38$$$O	use$$$39$$$42$$$O	of$$$43$$$45$$$O	antisense$$$46$$$55$$$O	oligomers$$$56$$$65$$$O	targeting$$$66$$$75$$$O	androgen$$$76$$$84$$$I	receptor$$$85$$$93$$$O	mRNA$$$94$$$98$$$O	and$$$99$$$102$$$O	androgen$$$103$$$111$$$I	receptor$$$112$$$120$$$O	binding$$$121$$$128$$$O	inhibitors$$$129$$$139$$$O	that$$$140$$$144$$$O	reduce$$$145$$$151$$$O	androgen$$$152$$$160$$$I	receptor$$$161$$$169$$$O	activity$$$170$$$178$$$O	for$$$179$$$182$$$O	the$$$183$$$186$$$O	treatment$$$187$$$196$$$O	of$$$197$$$199$$$O	androgen$$$200$$$208$$$I	receptor$$$209$$$217$$$O	related$$$218$$$225$$$O	medical$$$226$$$233$$$O	disorders,$$$234$$$244$$$O	such$$$245$$$249$$$O	as$$$250$$$252$$$O	cancers,$$$253$$$261$$$O	particularly$$$262$$$274$$$O	prostate$$$275$$$283$$$O	cancers$$$284$$$291$$$O	and$$$292$$$295$$$O	breast$$$296$$$302$$$O	cancers.$$$303$$$311$$$O
US7040314
Aerosol$$$0$$$7$$$O	generating$$$8$$$18$$$O	devices$$$19$$$26$$$O	and$$$27$$$30$$$O	methods$$$31$$$38$$$O	for$$$39$$$42$$$O	generating$$$43$$$53$$$O	aerosols$$$54$$$62$$$O	suitable$$$63$$$71$$$O	for$$$72$$$75$$$O	forming$$$76$$$83$$$O	propellant-free$$$84$$$99$$$O	aerosols$$$100$$$108$$$O
Liquid$$$0$$$6$$$O	aerosol$$$7$$$14$$$O	formulations$$$15$$$27$$$O	for$$$28$$$31$$$O	generating$$$32$$$42$$$O	aerosols$$$43$$$51$$$O	include$$$52$$$59$$$O	at$$$60$$$62$$$O	least$$$63$$$68$$$O	one$$$69$$$72$$$O	high$$$73$$$77$$$O	volatility$$$78$$$88$$$O	carrier$$$89$$$96$$$O	and$$$97$$$100$$$O	a$$$101$$$102$$$O	second$$$103$$$109$$$O	component.$$$110$$$120$$$O	In$$$121$$$123$$$O	some$$$124$$$128$$$O	embodiments,$$$129$$$141$$$O	the$$$142$$$145$$$O	liquid$$$146$$$152$$$O	aerosol$$$153$$$160$$$O	formulation$$$161$$$172$$$O	is$$$173$$$175$$$O	propellant$$$176$$$186$$$O	free.$$$187$$$192$$$O	An$$$193$$$195$$$O	aerosol$$$196$$$203$$$O	generating$$$204$$$214$$$O	device$$$215$$$221$$$O	generates$$$222$$$231$$$O	an$$$232$$$234$$$O	aerosol$$$235$$$242$$$O	by$$$243$$$245$$$O	passing$$$246$$$253$$$O	liquid$$$254$$$260$$$O	aerosol$$$261$$$268$$$O	formulation$$$269$$$280$$$O	through$$$281$$$288$$$O	a$$$289$$$290$$$O	flow$$$291$$$295$$$O	passage$$$296$$$303$$$O	heated$$$304$$$310$$$O	to$$$311$$$313$$$O	convert$$$314$$$321$$$O	the$$$322$$$325$$$O	liquid$$$326$$$332$$$O	into$$$333$$$337$$$O	a$$$338$$$339$$$O	vapor,$$$340$$$346$$$O	which$$$347$$$352$$$O	is$$$353$$$355$$$O	mixed$$$356$$$361$$$O	with$$$362$$$366$$$O	air$$$367$$$370$$$O	to$$$371$$$373$$$O	form$$$374$$$378$$$O	an$$$379$$$381$$$O	aerosol.$$$382$$$390$$$O	In$$$391$$$393$$$O	some$$$394$$$398$$$O	embodiments,$$$399$$$411$$$O	particles$$$412$$$421$$$O	of$$$422$$$424$$$O	the$$$425$$$428$$$O	aerosol$$$429$$$436$$$O	consist$$$437$$$444$$$O	essentially$$$445$$$456$$$O	of$$$457$$$459$$$O	the$$$460$$$463$$$O	second$$$464$$$470$$$O	component.$$$471$$$481$$$O	The$$$482$$$485$$$O	aerosol$$$486$$$493$$$O	generator$$$494$$$503$$$O	can$$$504$$$507$$$O	be$$$508$$$510$$$O	incorporated$$$511$$$523$$$O	in$$$524$$$526$$$O	a$$$527$$$528$$$O	hand$$$529$$$533$$$O	held$$$534$$$538$$$O	inhaler.$$$539$$$547$$$O	The$$$548$$$551$$$O	aerosol$$$552$$$559$$$O	can$$$560$$$563$$$O	be$$$564$$$566$$$O	delivered$$$567$$$576$$$O	to$$$577$$$579$$$O	a$$$580$$$581$$$O	targeted$$$582$$$590$$$O	portion$$$591$$$598$$$O	of$$$599$$$601$$$O	the$$$602$$$605$$$O	lung$$$606$$$610$$$O	using$$$611$$$616$$$O	the$$$617$$$620$$$O	inhaler.$$$621$$$629$$$O
WO2005012352A1
SOLUBLE$$$0$$$7$$$O	HUMAN$$$8$$$13$$$O	INTERLEUKIN$$$14$$$25$$$O	18$$$26$$$28$$$O	RECEPTOR-Î±,$$$29$$$41$$$O	METHOD$$$42$$$48$$$O	OF$$$49$$$51$$$O	ASSAYING$$$52$$$60$$$O	THE$$$61$$$64$$$O	SAME,$$$65$$$70$$$O	ASSAY$$$71$$$76$$$O	KIT$$$77$$$80$$$O	AND$$$81$$$84$$$O	MEDICINAL$$$85$$$94$$$O	COMPOSITION$$$95$$$106$$$O
[PROBLEMS]$$$0$$$10$$$O	To$$$11$$$13$$$O	confirm$$$14$$$21$$$O	the$$$22$$$25$$$O	presence$$$26$$$34$$$O	of$$$35$$$37$$$O	a$$$38$$$39$$$O	solubilized$$$40$$$51$$$O	human$$$52$$$57$$$O	IL-18$$$58$$$63$$$O	receptor-Î±$$$64$$$75$$$O	by$$$76$$$78$$$O	a$$$79$$$80$$$O	novel$$$81$$$86$$$O	ELISA$$$87$$$92$$$O	method$$$93$$$99$$$O	and$$$100$$$103$$$O	provide$$$104$$$111$$$O	an$$$112$$$114$$$O	assay$$$115$$$120$$$O	kit$$$121$$$124$$$O	and$$$125$$$128$$$O	a$$$129$$$130$$$O	medicinal$$$131$$$140$$$O	composition$$$141$$$152$$$O	containing$$$153$$$163$$$O	the$$$164$$$167$$$O	solubilized$$$168$$$179$$$O	human$$$180$$$185$$$O	IL-18$$$186$$$191$$$O	receptor-Î±$$$192$$$203$$$O	as$$$204$$$206$$$O	the$$$207$$$210$$$O	active$$$211$$$217$$$O	ingredient.$$$218$$$229$$$O	[MENAS$$$230$$$236$$$O	FOR$$$237$$$240$$$O	SOLVING$$$241$$$248$$$O	PROBLEMS]$$$249$$$258$$$O	A$$$259$$$260$$$O	solubilized$$$261$$$272$$$O	human$$$273$$$278$$$O	interleukin-18$$$279$$$293$$$O	receptor-Î±,$$$294$$$306$$$O	a$$$307$$$308$$$O	method$$$309$$$315$$$O	of$$$316$$$318$$$O	assaying$$$319$$$327$$$O	the$$$328$$$331$$$O	solubilized$$$332$$$343$$$O	human$$$344$$$349$$$O	interleukin-18$$$350$$$364$$$O	receptor-Î±$$$365$$$376$$$O	by$$$377$$$379$$$O	an$$$380$$$382$$$O	enzyme$$$383$$$389$$$O	immunoassay$$$390$$$401$$$O	method$$$402$$$408$$$O	characterized$$$409$$$422$$$O	by$$$423$$$425$$$O	using$$$426$$$431$$$O	the$$$432$$$435$$$O	following$$$436$$$445$$$O	antibody$$$446$$$454$$$O	(A),$$$455$$$459$$$O	a$$$460$$$461$$$O	kit$$$462$$$465$$$O	for$$$466$$$469$$$O	assaying$$$470$$$478$$$O	the$$$479$$$482$$$O	solubilized$$$483$$$494$$$O	human$$$495$$$500$$$O	interleukin-18$$$501$$$515$$$O	receptor-Î±$$$516$$$527$$$O	and$$$528$$$531$$$O	a$$$532$$$533$$$O	medicinal$$$534$$$543$$$O	composition$$$544$$$555$$$O	containing$$$556$$$566$$$O	the$$$567$$$570$$$O	solubilized$$$571$$$582$$$O	human$$$583$$$588$$$O	IL-18$$$589$$$594$$$O	receptor-Î±.$$$595$$$607$$$O	(A)$$$608$$$611$$$O	An$$$612$$$614$$$O	anti-human$$$615$$$625$$$O	interleukin-18$$$626$$$640$$$O	receptor-Î±$$$641$$$652$$$O	monoclonal$$$653$$$663$$$O	antibody$$$664$$$672$$$O	capable$$$673$$$680$$$O	of$$$681$$$683$$$O	recognizing$$$684$$$695$$$O	the$$$696$$$699$$$O	same$$$700$$$704$$$O	epitope$$$705$$$712$$$O	as$$$713$$$715$$$O	an$$$716$$$718$$$O	H44$$$719$$$722$$$O	mouse$$$723$$$728$$$O	anti-human$$$729$$$739$$$O	interleukin-18$$$740$$$754$$$O	receptor-Î±$$$755$$$766$$$O	monoclonal$$$767$$$777$$$O	antibody.$$$778$$$787$$$O
EP1559374A1
Cyanine$$$0$$$7$$$I	dyes$$$8$$$12$$$O
Sensitivity$$$0$$$11$$$O	and$$$12$$$15$$$O	specificity$$$16$$$27$$$O	of$$$28$$$30$$$O	an$$$31$$$33$$$O	optical$$$34$$$41$$$O	modality$$$42$$$50$$$O	can$$$51$$$54$$$O	be$$$55$$$57$$$O	enhanced$$$58$$$66$$$O	by$$$67$$$69$$$O	the$$$70$$$73$$$O	use$$$74$$$77$$$O	of$$$78$$$80$$$O	highly$$$81$$$87$$$O	absorbing$$$88$$$97$$$O	dyes$$$98$$$102$$$O	as$$$103$$$105$$$O	contrast$$$106$$$114$$$O	agents.$$$115$$$122$$$O	Cyanine$$$123$$$130$$$I	dyes$$$131$$$135$$$O	that$$$136$$$140$$$O	absorb$$$141$$$147$$$O	and$$$148$$$151$$$O	emit$$$152$$$156$$$O	light$$$157$$$162$$$O	in$$$163$$$165$$$O	the$$$166$$$169$$$O	near$$$170$$$174$$$O	infrared$$$175$$$183$$$O	region$$$184$$$190$$$O	of$$$191$$$193$$$O	the$$$194$$$197$$$O	electromagnetic$$$198$$$213$$$O	spectrum$$$214$$$222$$$O	are$$$223$$$226$$$O	disclosed.$$$227$$$237$$$O	These$$$238$$$243$$$O	dyes$$$244$$$248$$$O	are$$$249$$$252$$$O	useful$$$253$$$259$$$O	for$$$260$$$263$$$O	imaging,$$$264$$$272$$$O	diagnosis$$$273$$$282$$$O	and$$$283$$$286$$$O	therapy$$$287$$$294$$$O	of$$$295$$$297$$$O	various$$$298$$$305$$$O	diseased$$$306$$$314$$$O	states.$$$315$$$322$$$O	Particularly,$$$323$$$336$$$O	the$$$337$$$340$$$O	molecules$$$341$$$350$$$O	of$$$351$$$353$$$O	the$$$354$$$357$$$O	invention$$$358$$$367$$$O	are$$$368$$$371$$$O	useful$$$372$$$378$$$O	for$$$379$$$382$$$O	optical$$$383$$$390$$$O	diagnostic$$$391$$$401$$$O	imaging$$$402$$$409$$$O	and$$$410$$$413$$$O	therapy,$$$414$$$422$$$O	in$$$423$$$425$$$O	endoscopic$$$426$$$436$$$O	applications$$$437$$$449$$$O	for$$$450$$$453$$$O	the$$$454$$$457$$$O	detection$$$458$$$467$$$O	of$$$468$$$470$$$O	tumors$$$471$$$477$$$O	and$$$478$$$481$$$O	other$$$482$$$487$$$O	abnormalities,$$$488$$$502$$$O	for$$$503$$$506$$$O	localized$$$507$$$516$$$O	therapy,$$$517$$$525$$$O	for$$$526$$$529$$$O	photoacoustic$$$530$$$543$$$O	tumor$$$544$$$549$$$O	imaging,$$$550$$$558$$$O	detection$$$559$$$568$$$O	and$$$569$$$572$$$O	therapy,$$$573$$$581$$$O	and$$$582$$$585$$$O	for$$$586$$$589$$$O	sonofluorescence$$$590$$$606$$$O	tumor$$$607$$$612$$$O	imaging,$$$613$$$621$$$O	detection$$$622$$$631$$$O	and$$$632$$$635$$$O	therapy.$$$636$$$644$$$O
WO2012054862A2
Agents,$$$0$$$7$$$O	compositions,$$$8$$$21$$$O	and$$$22$$$25$$$O	methods$$$26$$$33$$$O	for$$$34$$$37$$$O	treating$$$38$$$46$$$O	pruritis$$$47$$$55$$$O	and$$$56$$$59$$$O	related$$$60$$$67$$$O	skin$$$68$$$72$$$O	conditions$$$73$$$83$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	generally$$$23$$$32$$$O	to$$$33$$$35$$$O	a$$$36$$$37$$$O	therapeutic$$$38$$$49$$$O	use$$$50$$$53$$$O	of$$$54$$$56$$$O	TLR3$$$57$$$61$$$O	and$$$62$$$65$$$O	TLR7$$$66$$$70$$$O	inhibitors$$$71$$$81$$$O	to$$$82$$$84$$$O	treat$$$85$$$90$$$O	or$$$91$$$93$$$O	reduce$$$94$$$100$$$O	pruritus$$$101$$$109$$$O	in$$$110$$$112$$$O	a$$$113$$$114$$$O	subject.$$$115$$$123$$$O
CN101874761A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	coating$$$11$$$18$$$O	leucine$$$19$$$26$$$I	microcapsule$$$27$$$39$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	method$$$26$$$32$$$O	for$$$33$$$36$$$O	coating$$$37$$$44$$$O	leucine$$$45$$$52$$$I	microcapsule.$$$53$$$66$$$O	The$$$67$$$70$$$O	method$$$71$$$77$$$O	mainly$$$78$$$84$$$O	comprises$$$85$$$94$$$O	the$$$95$$$98$$$O	steps$$$99$$$104$$$O	of$$$105$$$107$$$O	selecting$$$108$$$117$$$O	stearic$$$118$$$125$$$I	acid$$$126$$$130$$$I	as$$$131$$$133$$$O	the$$$134$$$137$$$O	microcapsule$$$138$$$150$$$O	coating$$$151$$$158$$$O	material,$$$159$$$168$$$O	placing$$$169$$$176$$$O	the$$$177$$$180$$$O	leucine$$$181$$$188$$$I	particle$$$189$$$197$$$O	in$$$198$$$200$$$O	a$$$201$$$202$$$O	coating$$$203$$$210$$$O	chamber,$$$211$$$219$$$O	and$$$220$$$223$$$O	ventilating$$$224$$$235$$$O	upward$$$236$$$242$$$O	with$$$243$$$247$$$O	compressed$$$248$$$258$$$O	air$$$259$$$262$$$O	via$$$263$$$266$$$O	a$$$267$$$268$$$O	fluidized$$$269$$$278$$$O	bed$$$279$$$282$$$O	air$$$283$$$286$$$O	dispersion$$$287$$$297$$$O	plate,$$$298$$$304$$$O	wherein$$$305$$$312$$$O	the$$$313$$$316$$$O	leucine$$$317$$$324$$$I	particle$$$325$$$333$$$O	expands$$$334$$$341$$$O	in$$$342$$$344$$$O	suspension$$$345$$$355$$$O	under$$$356$$$361$$$O	the$$$362$$$365$$$O	push$$$366$$$370$$$O	of$$$371$$$373$$$O	upward$$$374$$$380$$$O	airflow$$$381$$$388$$$O	and$$$389$$$392$$$O	is$$$393$$$395$$$O	flowable,$$$396$$$405$$$O	a$$$406$$$407$$$O	nozzle$$$408$$$414$$$O	sprays$$$415$$$421$$$O	the$$$422$$$425$$$O	coating$$$426$$$433$$$O	material$$$434$$$442$$$O	stearic$$$443$$$450$$$I	acid$$$451$$$455$$$I	in$$$456$$$458$$$O	the$$$459$$$462$$$O	form$$$463$$$467$$$O	of$$$468$$$470$$$O	solution$$$471$$$479$$$O	on$$$480$$$482$$$O	the$$$483$$$486$$$O	fluidized$$$487$$$496$$$O	particle$$$497$$$505$$$O	to$$$506$$$508$$$O	coat$$$509$$$513$$$O	the$$$514$$$517$$$O	leucine$$$518$$$525$$$I	particle.$$$526$$$535$$$O	The$$$536$$$539$$$O	method$$$540$$$546$$$O	can$$$547$$$550$$$O	be$$$551$$$553$$$O	used$$$554$$$558$$$O	for$$$559$$$562$$$O	preparing$$$563$$$572$$$O	ruminant$$$573$$$581$$$O	feed$$$582$$$586$$$O	additive$$$587$$$595$$$O	rumen$$$596$$$601$$$O	protective$$$602$$$612$$$O	leucine$$$613$$$620$$$I	microcapsule$$$621$$$633$$$O	which$$$634$$$639$$$O	can$$$640$$$643$$$O	reduce$$$644$$$650$$$O	degradation$$$651$$$662$$$O	of$$$663$$$665$$$O	leucine$$$666$$$673$$$I	in$$$674$$$676$$$O	the$$$677$$$680$$$O	rumen,$$$681$$$687$$$O	increase$$$688$$$696$$$O	the$$$697$$$700$$$O	amount$$$701$$$707$$$O	of$$$708$$$710$$$O	leucine$$$711$$$718$$$I	in$$$719$$$721$$$O	small$$$722$$$727$$$O	intestine$$$728$$$737$$$O	and$$$738$$$741$$$O	overcome$$$742$$$750$$$O	the$$$751$$$754$$$O	defects$$$755$$$762$$$O	of$$$763$$$765$$$O	poor$$$766$$$770$$$O	humidity$$$771$$$779$$$O	resistance$$$780$$$790$$$O	and$$$791$$$794$$$O	inconvenient$$$795$$$807$$$O	storage$$$808$$$815$$$O	of$$$816$$$818$$$O	leucine.$$$819$$$827$$$I	The$$$828$$$831$$$O	coating$$$832$$$839$$$O	method$$$840$$$846$$$O	has$$$847$$$850$$$O	the$$$851$$$854$$$O	advantages$$$855$$$865$$$O	of$$$866$$$868$$$O	short$$$869$$$874$$$O	time,$$$875$$$880$$$O	high$$$881$$$885$$$O	efficiency,$$$886$$$897$$$O	even$$$898$$$902$$$O	particle$$$903$$$911$$$O	preparation,$$$912$$$924$$$O	and$$$925$$$928$$$O	the$$$929$$$932$$$O	like.$$$933$$$938$$$O
CN101244072A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	asiaticoside$$$15$$$27$$$I	in$$$28$$$30$$$O	pulmonary$$$31$$$40$$$O	fibrosis$$$41$$$49$$$O	resistant$$$50$$$59$$$O	delayed$$$60$$$67$$$O	period$$$68$$$74$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	new$$$26$$$29$$$O	application$$$30$$$41$$$O	in$$$42$$$44$$$O	a$$$45$$$46$$$O	preparation$$$47$$$58$$$O	using$$$59$$$64$$$O	asiaticoside$$$65$$$77$$$I	in$$$78$$$80$$$O	a$$$81$$$82$$$O	drug$$$83$$$87$$$O	against$$$88$$$95$$$O	delayed$$$96$$$103$$$O	lung$$$104$$$108$$$O	fibrosis.$$$109$$$118$$$O	At$$$119$$$121$$$O	the$$$122$$$125$$$O	end$$$126$$$129$$$O	of$$$130$$$132$$$O	the$$$133$$$136$$$O	delayed$$$137$$$144$$$O	lung$$$145$$$149$$$O	fibrosis,$$$150$$$159$$$O	the$$$160$$$163$$$O	asiaticoside$$$164$$$176$$$I	has$$$177$$$180$$$O	an$$$181$$$183$$$O	effect$$$184$$$190$$$O	against$$$191$$$198$$$O	the$$$199$$$202$$$O	lung$$$203$$$207$$$O	fibrosis$$$208$$$216$$$O	under$$$217$$$222$$$O	an$$$223$$$225$$$O	action$$$226$$$232$$$O	of$$$233$$$235$$$O	a$$$236$$$237$$$O	promoting$$$238$$$247$$$O	fibrosis$$$248$$$256$$$O	cytokine$$$257$$$265$$$O	in$$$266$$$268$$$O	vivo.$$$269$$$274$$$O	The$$$275$$$278$$$O	invention$$$279$$$288$$$O	also$$$289$$$293$$$O	discloses$$$294$$$303$$$O	a$$$304$$$305$$$O	drug$$$306$$$310$$$O	composition$$$311$$$322$$$O	against$$$323$$$330$$$O	delayed$$$331$$$338$$$O	lung$$$339$$$343$$$O	fibrosis,$$$344$$$353$$$O	which$$$354$$$359$$$O	active$$$360$$$366$$$O	component$$$367$$$376$$$O	comprises$$$377$$$386$$$O	the$$$387$$$390$$$O	asiaticoside$$$391$$$403$$$O	and$$$404$$$407$$$O	the$$$408$$$411$$$O	exogenous$$$412$$$421$$$O	promoting$$$422$$$431$$$O	fibrosis$$$432$$$440$$$O	cytokine.$$$441$$$450$$$O
US8765747
Fused$$$0$$$5$$$O	2-aminothiazole$$$6$$$21$$$I	compounds$$$22$$$31$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	application$$$12$$$23$$$O	relates$$$24$$$31$$$O	to$$$32$$$34$$$O	therapeutic$$$35$$$46$$$O	organic$$$47$$$54$$$O	compounds$$$55$$$64$$$O	of$$$65$$$67$$$O	formula$$$68$$$75$$$O	(I),$$$76$$$80$$$O	wherein$$$100$$$107$$$O	Q,$$$108$$$110$$$O	R1,$$$111$$$114$$$O	R2,$$$115$$$118$$$O	R3,$$$119$$$122$$$O	and$$$123$$$126$$$O	R4$$$127$$$129$$$O	are$$$130$$$133$$$O	defined$$$134$$$141$$$O	herein.$$$142$$$149$$$O	The$$$150$$$153$$$O	invention$$$154$$$163$$$O	also$$$164$$$168$$$O	relates$$$169$$$176$$$O	to$$$177$$$179$$$O	pharmaceutical$$$180$$$194$$$O	compositions$$$195$$$207$$$O	comprising$$$208$$$218$$$O	an$$$219$$$221$$$O	effective$$$222$$$231$$$O	amount$$$232$$$238$$$O	of$$$239$$$241$$$O	a$$$242$$$243$$$O	therapeutic$$$244$$$255$$$O	organic$$$256$$$263$$$O	compound;$$$264$$$273$$$O	and$$$274$$$277$$$O	methods$$$278$$$285$$$O	for$$$286$$$289$$$O	treating$$$290$$$298$$$O	and$$$299$$$302$$$O	preventing$$$303$$$313$$$O	disease$$$314$$$321$$$O	such$$$322$$$326$$$O	as$$$327$$$329$$$O	cancer$$$330$$$336$$$O	comprising$$$337$$$347$$$O	administering$$$348$$$361$$$O	and$$$362$$$365$$$O	effective$$$366$$$375$$$O	amount$$$376$$$382$$$O	of$$$383$$$385$$$O	a$$$386$$$387$$$O	therapeutic$$$388$$$399$$$O	organic$$$400$$$407$$$O	compound$$$408$$$416$$$O	to$$$417$$$419$$$O	a$$$420$$$421$$$O	subject$$$422$$$429$$$O	in$$$430$$$432$$$O	need$$$433$$$437$$$O	thereof.$$$438$$$446$$$O
WO2013176054A1
Agent$$$0$$$5$$$O	containing$$$6$$$16$$$O	ascorbic$$$17$$$25$$$I	acid$$$26$$$30$$$I	derivative,$$$31$$$42$$$O	and$$$43$$$46$$$O	use$$$47$$$50$$$O	for$$$51$$$54$$$O	said$$$55$$$59$$$O	agent$$$60$$$65$$$O
The$$$0$$$3$$$O	purpose$$$4$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	present$$$19$$$26$$$O	invention$$$27$$$36$$$O	is$$$37$$$39$$$O	to$$$40$$$42$$$O	provide$$$43$$$50$$$O	an$$$51$$$53$$$O	active$$$54$$$60$$$O	ingredient$$$61$$$71$$$O	which$$$72$$$77$$$O	can$$$78$$$81$$$O	notably$$$82$$$89$$$O	exert$$$90$$$95$$$O	an$$$96$$$98$$$O	effect$$$99$$$105$$$O	of$$$106$$$108$$$O	promoting$$$109$$$118$$$O	the$$$119$$$122$$$O	bone$$$123$$$127$$$O	formation$$$128$$$137$$$O	or$$$138$$$140$$$O	an$$$141$$$143$$$O	effect$$$144$$$150$$$O	of$$$151$$$153$$$O	preventing$$$154$$$164$$$O	and/or$$$165$$$171$$$O	improving$$$172$$$181$$$O	osteoporosis,$$$182$$$195$$$O	and$$$196$$$199$$$O	which$$$200$$$205$$$O	can$$$206$$$209$$$O	be$$$210$$$212$$$O	used$$$213$$$217$$$O	in$$$218$$$220$$$O	food$$$221$$$225$$$O	or$$$226$$$228$$$O	beverages.$$$229$$$239$$$O	The$$$240$$$243$$$O	present$$$244$$$251$$$O	invention$$$252$$$261$$$O	provides:$$$262$$$271$$$O	an$$$272$$$274$$$O	agent$$$275$$$280$$$O	for$$$281$$$284$$$O	the$$$285$$$288$$$O	prevention$$$289$$$299$$$O	and/or$$$300$$$306$$$O	improvement$$$307$$$318$$$O	of$$$319$$$321$$$O	osteoporosis,$$$322$$$335$$$O	the$$$336$$$339$$$O	agent$$$340$$$345$$$O	containing$$$346$$$356$$$O	an$$$357$$$359$$$O	ascorbic$$$360$$$368$$$I	acid$$$369$$$373$$$I	derivative$$$374$$$384$$$O	(component$$$385$$$395$$$O	(A))$$$396$$$400$$$O	as$$$401$$$403$$$O	the$$$404$$$407$$$O	active$$$408$$$414$$$O	ingredient;$$$415$$$426$$$O	a$$$427$$$428$$$O	composition$$$429$$$440$$$O	containing$$$441$$$451$$$O	said$$$452$$$456$$$O	agent;$$$457$$$463$$$O	an$$$464$$$466$$$O	orally-administered$$$467$$$486$$$O	composition$$$487$$$498$$$O	containing$$$499$$$509$$$O	component$$$510$$$519$$$O	(A)$$$520$$$523$$$O	and$$$524$$$527$$$O	an$$$528$$$530$$$O	extract$$$531$$$538$$$O	from$$$539$$$543$$$O	a$$$544$$$545$$$O	Piperaceae$$$546$$$556$$$O	plant$$$557$$$562$$$O	(component$$$563$$$573$$$O	(B))$$$574$$$578$$$O	as$$$579$$$581$$$O	the$$$582$$$585$$$O	active$$$586$$$592$$$O	ingredients;$$$593$$$605$$$O	a$$$606$$$607$$$O	bone$$$608$$$612$$$O	formation$$$613$$$622$$$O	promoting$$$623$$$632$$$O	composition$$$633$$$644$$$O	containing$$$645$$$655$$$O	component$$$656$$$665$$$O	(A)$$$666$$$669$$$O	and$$$670$$$673$$$O	sorbitol$$$674$$$682$$$O	and/or$$$683$$$689$$$O	a$$$690$$$691$$$O	derivative$$$692$$$702$$$O	thereof$$$703$$$710$$$O	(component$$$711$$$721$$$O	(D))$$$722$$$726$$$O	as$$$727$$$729$$$O	the$$$730$$$733$$$O	active$$$734$$$740$$$O	ingredients;$$$741$$$753$$$O	and$$$754$$$757$$$O	a$$$758$$$759$$$O	composition$$$760$$$771$$$O	for$$$772$$$775$$$O	a$$$776$$$777$$$O	pharmaceutical$$$778$$$792$$$O	product,$$$793$$$801$$$O	quasi-pharmaceutical$$$802$$$822$$$O	product,$$$823$$$831$$$O	or$$$832$$$834$$$O	food$$$835$$$839$$$O	and$$$840$$$843$$$O	beverage$$$844$$$852$$$O	containing$$$853$$$863$$$O	one$$$864$$$867$$$O	of$$$868$$$870$$$O	the$$$871$$$874$$$O	aforementioned$$$875$$$889$$$O	compositions.$$$890$$$903$$$O
US20110207785
2-Aryl-Propionic$$$0$$$16$$$I	Acids$$$17$$$22$$$I	and$$$23$$$26$$$O	Derivatives$$$27$$$38$$$O	and$$$39$$$42$$$O	Pharmaceutical$$$43$$$57$$$O	Compositions$$$58$$$70$$$O	Containing$$$71$$$81$$$O	Them$$$82$$$86$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	(R,S)$$$33$$$38$$$I	2-aryl-propionic$$$39$$$55$$$I	acids$$$56$$$61$$$I	and$$$62$$$65$$$O	derivatives,$$$66$$$78$$$O	their$$$79$$$84$$$O	single$$$85$$$91$$$O	enantiomer$$$92$$$102$$$O	(S)$$$103$$$106$$$O	and$$$107$$$110$$$O	to$$$111$$$113$$$O	pharmaceutical$$$114$$$128$$$O	compositions$$$129$$$141$$$O	containing$$$142$$$152$$$O	them,$$$153$$$158$$$O	which$$$159$$$164$$$O	are$$$165$$$168$$$O	used$$$169$$$173$$$O	in$$$174$$$176$$$O	the$$$177$$$180$$$O	prevention$$$181$$$191$$$O	and$$$192$$$195$$$O	treatment$$$196$$$205$$$O	of$$$206$$$208$$$O	tissue$$$209$$$215$$$O	damage$$$216$$$222$$$O	due$$$223$$$226$$$O	to$$$227$$$229$$$O	the$$$230$$$233$$$O	exacerbated$$$234$$$245$$$O	recruitment$$$246$$$257$$$O	of$$$258$$$260$$$O	polymorphonucleated$$$261$$$280$$$O	neutrophils$$$281$$$292$$$O	(PIvTN$$$293$$$299$$$O	leukocytes)$$$300$$$311$$$O	at$$$312$$$314$$$O	inflammation$$$315$$$327$$$O	sites.$$$328$$$334$$$O	The$$$335$$$338$$$O	present$$$339$$$346$$$O	invention$$$347$$$356$$$O	provides$$$357$$$365$$$O	compounds$$$366$$$375$$$O	for$$$376$$$379$$$O	use$$$380$$$383$$$O	in$$$384$$$386$$$O	the$$$387$$$390$$$O	treatment$$$391$$$400$$$O	of$$$401$$$403$$$O	transient$$$404$$$413$$$O	cerebral$$$414$$$422$$$O	ischemia,$$$423$$$432$$$O	bullous$$$433$$$440$$$O	pemphigo,$$$441$$$450$$$O	rheumatoid$$$451$$$461$$$O	arthritis,$$$462$$$472$$$O	idiopathic$$$473$$$483$$$O	fibrosis,$$$484$$$493$$$O	glomerulonephritis$$$494$$$512$$$O	and$$$513$$$516$$$O	damages$$$517$$$524$$$O	caused$$$525$$$531$$$O	by$$$532$$$534$$$O	ischemia$$$535$$$543$$$O	and$$$544$$$547$$$O	reperfusion.$$$548$$$560$$$O	(Formula$$$561$$$569$$$O	(I)$$$570$$$573$$$O
US20090023810
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	translation$$$11$$$22$$$O	and/or$$$23$$$29$$$O	inflammation$$$30$$$42$$$O	blockade$$$43$$$51$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	of$$$42$$$44$$$O	translation$$$45$$$56$$$O	or$$$57$$$59$$$O	inflammatory$$$60$$$72$$$O	response$$$73$$$81$$$O	blockade$$$82$$$90$$$O	by$$$91$$$93$$$O	using$$$94$$$99$$$O	a$$$100$$$101$$$O	compound$$$102$$$110$$$O	that$$$111$$$115$$$O	binds$$$116$$$121$$$O	to$$$122$$$124$$$O	eIF4A,$$$125$$$131$$$O	which$$$132$$$137$$$O	is$$$138$$$140$$$O	the$$$141$$$144$$$O	264th$$$145$$$150$$$O	amino$$$151$$$156$$$I	acid$$$157$$$161$$$I	residue,$$$162$$$170$$$O	a$$$171$$$172$$$O	method$$$173$$$179$$$O	of$$$180$$$182$$$O	developing$$$183$$$193$$$O	an$$$194$$$196$$$O	anti-inflammation,$$$197$$$215$$$O	anti-cancer$$$216$$$227$$$O	or$$$228$$$230$$$O	anti-viral$$$231$$$241$$$O	agent$$$242$$$247$$$O	by$$$248$$$250$$$O	screening$$$251$$$260$$$O	a$$$261$$$262$$$O	compound$$$263$$$271$$$O	that$$$272$$$276$$$O	binds$$$277$$$282$$$O	to$$$283$$$285$$$O	eIF4A.$$$286$$$292$$$O
US20110306559
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	treating$$$29$$$37$$$O	neuropathic$$$38$$$49$$$O	pain$$$50$$$54$$$O
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	the$$$29$$$32$$$O	treatment$$$33$$$42$$$O	of$$$43$$$45$$$O	neuropathic$$$46$$$57$$$O	pain$$$58$$$62$$$O	are$$$63$$$66$$$O	provided.$$$67$$$76$$$O	Compositions$$$77$$$89$$$O	of$$$90$$$92$$$O	the$$$93$$$96$$$O	invention$$$97$$$106$$$O	may$$$107$$$110$$$O	comprise$$$111$$$119$$$O	proteins$$$120$$$128$$$O	with$$$129$$$133$$$O	a$$$134$$$135$$$O	zinc-finger$$$136$$$147$$$I	domain$$$148$$$154$$$O	fused$$$155$$$160$$$O	to$$$161$$$163$$$O	a$$$164$$$165$$$O	regulatory$$$166$$$176$$$O	domain$$$177$$$183$$$O	that$$$184$$$188$$$O	is$$$189$$$191$$$O	capable$$$192$$$199$$$O	of$$$200$$$202$$$O	either$$$203$$$209$$$O	activating$$$210$$$220$$$O	or$$$221$$$223$$$O	repressing$$$224$$$234$$$O	the$$$235$$$238$$$O	expression$$$239$$$249$$$O	of$$$250$$$252$$$O	a$$$253$$$254$$$O	target$$$255$$$261$$$O	gene$$$262$$$266$$$O	involved$$$267$$$275$$$O	in$$$276$$$278$$$O	neuropathic$$$279$$$290$$$O	pain.$$$291$$$296$$$O	Alternatively,$$$297$$$311$$$O	compositions$$$312$$$324$$$O	of$$$325$$$327$$$O	the$$$328$$$331$$$O	invention$$$332$$$341$$$O	may$$$342$$$345$$$O	comprise$$$346$$$354$$$O	a$$$355$$$356$$$O	nucleic$$$357$$$364$$$O	acid$$$365$$$369$$$O	sequence$$$370$$$378$$$O	encoding$$$379$$$387$$$O	a$$$388$$$389$$$O	protein$$$390$$$397$$$O	of$$$398$$$400$$$O	the$$$401$$$404$$$O	invention,$$$405$$$415$$$O	which$$$416$$$421$$$O	nucleic$$$422$$$429$$$O	acid$$$430$$$434$$$O	sequence$$$435$$$443$$$O	may$$$444$$$447$$$O	optionally$$$448$$$458$$$O	be$$$459$$$461$$$O	provided$$$462$$$470$$$O	as$$$471$$$473$$$O	a$$$474$$$475$$$O	plasmid$$$476$$$483$$$O	or$$$484$$$486$$$O	within$$$487$$$493$$$O	a$$$494$$$495$$$O	virus$$$496$$$501$$$O	or$$$502$$$504$$$O	other$$$505$$$510$$$O	vector$$$511$$$517$$$O	for$$$518$$$521$$$O	delivery$$$522$$$530$$$O	to$$$531$$$533$$$O	a$$$534$$$535$$$O	target$$$536$$$542$$$O	cell$$$543$$$547$$$O	or$$$548$$$550$$$O	tissue.$$$551$$$558$$$O	Methods$$$559$$$566$$$O	of$$$567$$$569$$$O	treating$$$570$$$578$$$O	neuropathic$$$579$$$590$$$O	pain$$$591$$$595$$$O	involving$$$596$$$605$$$O	treatment$$$606$$$615$$$O	of$$$616$$$618$$$O	subject$$$619$$$626$$$O	with$$$627$$$631$$$O	the$$$632$$$635$$$O	compositions$$$636$$$648$$$O	of$$$649$$$651$$$O	the$$$652$$$655$$$O	invention$$$656$$$665$$$O	are$$$666$$$669$$$O	also$$$670$$$674$$$O	provided.$$$675$$$684$$$O	Exemplary$$$685$$$694$$$O	target$$$695$$$701$$$O	genes$$$702$$$707$$$O	for$$$708$$$711$$$O	the$$$712$$$715$$$O	treatment$$$716$$$725$$$O	of$$$726$$$728$$$O	neuropathic$$$729$$$740$$$O	pain$$$741$$$745$$$O	include$$$746$$$753$$$O	VR1,$$$754$$$758$$$O	NaV1.8,$$$759$$$766$$$O	and$$$767$$$770$$$O	TrkA.$$$771$$$776$$$O
WO2011085209A3
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	compositions$$$12$$$24$$$O	for$$$25$$$28$$$O	applying$$$29$$$37$$$O	moxifloxacin$$$38$$$50$$$I	to$$$51$$$53$$$O	the$$$54$$$57$$$O	ear$$$58$$$61$$$O
Methods$$$0$$$7$$$O	and$$$8$$$11$$$O	materials$$$12$$$21$$$O	useful$$$22$$$28$$$O	for$$$29$$$32$$$O	applying$$$33$$$41$$$O	moxifloxacin$$$42$$$54$$$I	to$$$55$$$57$$$O	the$$$58$$$61$$$O	ear$$$62$$$65$$$O	are$$$66$$$69$$$O	described.$$$70$$$80$$$O	The$$$81$$$84$$$O	methods$$$85$$$92$$$O	involve$$$93$$$100$$$O	delivering$$$101$$$111$$$O	a$$$112$$$113$$$O	composition$$$114$$$125$$$O	that$$$126$$$130$$$O	contains$$$131$$$139$$$O	at$$$140$$$142$$$O	least$$$143$$$148$$$O	one$$$149$$$152$$$O	viscogenic$$$153$$$163$$$O	agent$$$164$$$169$$$O	and$$$170$$$173$$$O	moxifloxacin$$$174$$$186$$$I	or$$$187$$$189$$$O	a$$$190$$$191$$$O	salt$$$192$$$196$$$O	thereof$$$197$$$204$$$O	to$$$205$$$207$$$O	the$$$208$$$211$$$O	epidermal$$$212$$$221$$$O	surface$$$222$$$229$$$O	of$$$230$$$232$$$O	the$$$233$$$236$$$O	tympanic$$$237$$$245$$$O	membrane$$$246$$$254$$$O	via$$$255$$$258$$$O	the$$$259$$$262$$$O	ear$$$263$$$266$$$O	canal.$$$267$$$273$$$O	The$$$274$$$277$$$O	composition$$$278$$$289$$$O	is$$$290$$$292$$$O	delivered$$$293$$$302$$$O	to$$$303$$$305$$$O	the$$$306$$$309$$$O	tympanic$$$310$$$318$$$O	membrane$$$319$$$327$$$O	in$$$328$$$330$$$O	a$$$331$$$332$$$O	flowable$$$333$$$341$$$O	form$$$342$$$346$$$O	and,$$$347$$$351$$$O	after$$$352$$$357$$$O	delivery$$$358$$$366$$$O	to$$$367$$$369$$$O	the$$$370$$$373$$$O	tympanic$$$374$$$382$$$O	membrane,$$$383$$$392$$$O	becomes$$$393$$$400$$$O	sufficiently$$$401$$$413$$$O	viscous$$$414$$$421$$$O	such$$$422$$$426$$$O	that$$$427$$$431$$$O	the$$$432$$$435$$$O	moxifloxacin$$$436$$$448$$$I	is$$$449$$$451$$$O	localized$$$452$$$461$$$O	against$$$462$$$469$$$O	the$$$470$$$473$$$O	tympanic$$$474$$$482$$$O	membrane.$$$483$$$492$$$O	Such$$$493$$$497$$$O	compositions$$$498$$$510$$$O	can$$$511$$$514$$$O	be$$$515$$$517$$$O	used$$$518$$$522$$$O	to$$$523$$$525$$$O	prophylactically$$$526$$$542$$$O	and/or$$$543$$$549$$$O	therapeutically$$$550$$$565$$$O	treat$$$566$$$571$$$O	middle$$$572$$$578$$$O	and$$$579$$$582$$$O	inner$$$583$$$588$$$O	ear$$$589$$$592$$$O	conditions,$$$593$$$604$$$O	including$$$605$$$614$$$O	otitis$$$615$$$621$$$O	media.$$$622$$$628$$$O
CN1733765A
Purple$$$0$$$6$$$O	bergenia$$$7$$$15$$$O	element$$$16$$$23$$$O	pentaacetylate$$$24$$$38$$$I	and$$$39$$$42$$$O	its$$$43$$$46$$$O	uses$$$47$$$51$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	Bergenini$$$25$$$34$$$I	penta-acetyl,$$$35$$$48$$$I	whose$$$49$$$54$$$O	chemical$$$55$$$63$$$O	name$$$64$$$68$$$O	is$$$69$$$71$$$O	(2R,3R,4R,4aS,10bS)-2-(acetoxymethyl)-9-methoxy-6-oxo-2,3,4,4a,6,10b-hexahydr$$$72$$$149$$$I	o$$$150$$$151$$$I	pyrano[3,2-c]isochromene-3,4,8,10-tetrayl$$$152$$$193$$$I	tetraacetate,$$$194$$$207$$$I	and$$$208$$$211$$$O	is$$$212$$$214$$$O	prepared$$$215$$$223$$$O	from$$$224$$$228$$$O	Bergenini$$$229$$$238$$$O	as$$$239$$$241$$$O	lead$$$242$$$246$$$O	compound$$$247$$$255$$$O	through$$$256$$$263$$$O	butanoylation$$$264$$$277$$$O	reaction,$$$278$$$287$$$O	the$$$288$$$291$$$O	hydroxyl$$$292$$$300$$$I	on$$$301$$$303$$$O	the$$$304$$$307$$$O	precursor$$$308$$$317$$$O	is$$$318$$$320$$$O	blocked$$$321$$$328$$$O	so$$$329$$$331$$$O	as$$$332$$$334$$$O	to$$$335$$$337$$$O	enhance$$$338$$$345$$$O	the$$$346$$$349$$$O	lipophilicity.$$$350$$$364$$$O	The$$$365$$$368$$$O	Bergenini$$$369$$$378$$$O	penta-acetyl$$$379$$$391$$$O	can$$$392$$$395$$$O	be$$$396$$$398$$$O	used$$$399$$$403$$$O	for$$$404$$$407$$$O	preparing$$$408$$$417$$$O	medicine$$$418$$$426$$$O	for$$$427$$$430$$$O	relieving$$$431$$$440$$$O	cough.$$$441$$$447$$$O	The$$$448$$$451$$$O	invention$$$452$$$461$$$O	further$$$462$$$469$$$O	provides$$$470$$$478$$$O	a$$$479$$$480$$$O	compound$$$481$$$489$$$O	preparation$$$490$$$501$$$O	containing$$$502$$$512$$$O	the$$$513$$$516$$$O	Bergenini$$$517$$$526$$$O	penta-acetyl.$$$527$$$540$$$O
WO2006106423A3
Amino$$$0$$$5$$$I	sulfonyl$$$6$$$14$$$I	derivatives$$$15$$$26$$$O	as$$$27$$$29$$$O	inhibitors$$$30$$$40$$$O	of$$$41$$$43$$$O	human$$$44$$$49$$$O	11-.beta.-hydrosysteroid$$$50$$$74$$$I	dehydrogenase$$$75$$$88$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	with$$$43$$$47$$$O	Formula$$$48$$$55$$$O	(I)$$$56$$$59$$$O	or$$$60$$$62$$$O	a$$$63$$$64$$$O	pharmaceutically$$$65$$$81$$$O	acceptable$$$82$$$92$$$O	salt$$$93$$$97$$$O	thereof:$$$98$$$106$$$O	Formula$$$107$$$114$$$O	(I);$$$115$$$119$$$O	wherein$$$120$$$127$$$O	R1$$$128$$$130$$$O	is$$$131$$$133$$$O	an$$$134$$$136$$$O	optionally$$$137$$$147$$$O	fused$$$148$$$153$$$O	pyridine$$$154$$$162$$$I	ring$$$163$$$167$$$O	and$$$168$$$171$$$O	R2$$$172$$$174$$$O	and$$$175$$$178$$$O	R3$$$179$$$181$$$O	together$$$182$$$190$$$O	form$$$191$$$195$$$O	a$$$196$$$197$$$O	heterocyclic$$$198$$$210$$$I	ring.$$$211$$$216$$$O	The$$$217$$$220$$$O	invention$$$221$$$230$$$O	also$$$231$$$235$$$O	relates$$$236$$$243$$$O	to$$$244$$$246$$$O	pharmaceutical$$$247$$$261$$$O	compositions$$$262$$$274$$$O	comprising$$$275$$$285$$$O	the$$$286$$$289$$$O	compounds$$$290$$$299$$$O	of$$$300$$$302$$$O	Formula$$$303$$$310$$$O	(I)$$$311$$$314$$$O	and$$$315$$$318$$$O	methods$$$319$$$326$$$O	of$$$327$$$329$$$O	treating$$$330$$$338$$$O	a$$$339$$$340$$$O	condition$$$341$$$350$$$O	that$$$351$$$355$$$O	is$$$356$$$358$$$O	mediated$$$359$$$367$$$O	by$$$368$$$370$$$O	the$$$371$$$374$$$O	modulation$$$375$$$385$$$O	of$$$386$$$388$$$O	the$$$389$$$392$$$O	11-Î²-hsd-1$$$393$$$404$$$O	enzyme.$$$405$$$412$$$O
US7285660
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	preparation$$$16$$$27$$$O	of$$$28$$$30$$$O	L-ribavirin$$$31$$$42$$$I
A$$$0$$$1$$$O	process$$$2$$$9$$$O	for$$$10$$$13$$$O	the$$$14$$$17$$$O	preparation$$$18$$$29$$$O	of$$$30$$$32$$$O	L-ribavirin$$$33$$$44$$$I	on$$$45$$$47$$$O	an$$$48$$$50$$$O	industrial$$$51$$$61$$$O	scale$$$62$$$67$$$O	is$$$68$$$70$$$O	described$$$71$$$80$$$O	which$$$81$$$86$$$O	comprises$$$87$$$96$$$O	the$$$97$$$100$$$O	reaction$$$101$$$109$$$O	of$$$110$$$112$$$O	glycosylation$$$113$$$126$$$O	of$$$127$$$129$$$O	3-substituted$$$130$$$143$$$I	triazoles$$$144$$$153$$$I	in$$$154$$$156$$$O	the$$$157$$$160$$$O	presence$$$161$$$169$$$O	of$$$170$$$172$$$O	a$$$173$$$174$$$O	Lewis$$$175$$$180$$$I	acid.$$$181$$$186$$$I	Said$$$187$$$191$$$O	process$$$192$$$199$$$O	comprises:$$$200$$$210$$$O	a)$$$214$$$216$$$O	the$$$217$$$220$$$O	reaction$$$221$$$229$$$O	of$$$230$$$232$$$O	a$$$233$$$234$$$O	triazole$$$235$$$243$$$I	of$$$244$$$246$$$O	the$$$247$$$250$$$O	formula$$$251$$$258$$$O	with$$$376$$$380$$$O	a$$$381$$$382$$$O	protected$$$383$$$392$$$O	ribofuranose$$$393$$$405$$$I	of$$$406$$$408$$$O	the$$$409$$$412$$$O	formula$$$413$$$420$$$O	(II)$$$421$$$425$$$O	b)$$$571$$$573$$$O	the$$$574$$$577$$$O	removal$$$578$$$585$$$O	of$$$586$$$588$$$O	the$$$589$$$592$$$O	Pg$$$593$$$595$$$O	groups$$$596$$$602$$$O	and,$$$603$$$607$$$O	optionally,$$$608$$$619$$$O	the$$$620$$$623$$$O	conversion$$$624$$$634$$$O	into$$$635$$$639$$$O	a$$$640$$$641$$$O	carboxyamide$$$642$$$654$$$I	group$$$655$$$660$$$O	of$$$661$$$663$$$O	the$$$664$$$667$$$O	R2$$$668$$$670$$$O	group$$$671$$$676$$$O	of$$$677$$$679$$$O	the$$$680$$$683$$$O	compound$$$684$$$692$$$O	obtained$$$693$$$701$$$O	of$$$702$$$704$$$O	the$$$705$$$708$$$O	formula$$$709$$$716$$$O	(III)$$$717$$$722$$$O
WO2012119151A2
Method$$$0$$$6$$$O	and$$$7$$$10$$$O	apparatus$$$11$$$20$$$O	for$$$21$$$24$$$O	alcohol$$$25$$$32$$$I	administration$$$33$$$47$$$O
The$$$0$$$3$$$O	method$$$4$$$10$$$O	and$$$11$$$14$$$O	apparatus$$$15$$$24$$$O	for$$$25$$$28$$$O	the$$$29$$$32$$$O	administration$$$33$$$47$$$O	of$$$48$$$50$$$O	alcohol$$$51$$$58$$$I	to$$$59$$$61$$$O	a$$$62$$$63$$$O	person$$$64$$$70$$$O	provides$$$71$$$79$$$O	an$$$80$$$82$$$O	alcohol$$$83$$$90$$$I	"patch"$$$91$$$98$$$O	in$$$99$$$101$$$O	the$$$102$$$105$$$O	form$$$106$$$110$$$O	of$$$111$$$113$$$O	an$$$114$$$116$$$O	adhesive$$$117$$$125$$$O	patch$$$126$$$131$$$O	or$$$132$$$134$$$O	bandage-like$$$135$$$147$$$O	structure$$$148$$$157$$$O	bearing$$$158$$$165$$$O	a$$$166$$$167$$$O	quantity$$$168$$$176$$$O	of$$$177$$$179$$$O	alcohol$$$180$$$187$$$I	for$$$188$$$191$$$O	transdermal$$$192$$$203$$$O	delivery$$$204$$$212$$$O	to$$$213$$$215$$$O	the$$$216$$$219$$$O	user.$$$220$$$225$$$O	Permeation$$$226$$$236$$$O	enhancers,$$$237$$$247$$$O	either$$$248$$$254$$$O	chemical$$$255$$$263$$$O	or$$$264$$$266$$$O	structural,$$$267$$$278$$$O	may$$$279$$$282$$$O	be$$$283$$$285$$$O	included$$$286$$$294$$$O	for$$$295$$$298$$$O	increased$$$299$$$308$$$O	efficacy$$$309$$$317$$$O	of$$$318$$$320$$$O	delivery$$$321$$$329$$$O	of$$$330$$$332$$$O	the$$$333$$$336$$$O	alcohol$$$337$$$344$$$I	to$$$345$$$347$$$O	the$$$348$$$351$$$O	user.$$$352$$$357$$$O	The$$$358$$$361$$$O	alcohol$$$362$$$369$$$I	to$$$370$$$372$$$O	be$$$373$$$375$$$O	delivered$$$376$$$385$$$O	via$$$386$$$389$$$O	the$$$390$$$393$$$O	inventive$$$394$$$403$$$O	apparatus$$$404$$$413$$$O	may$$$414$$$417$$$O	be$$$418$$$420$$$O	plain$$$421$$$426$$$O	ethyl$$$427$$$432$$$I	alcohol$$$433$$$440$$$I	(ethanol)$$$441$$$450$$$I	of$$$451$$$453$$$O	any$$$454$$$457$$$O	suitable$$$458$$$466$$$O	concentration$$$467$$$480$$$O	or$$$481$$$483$$$O	proof.$$$484$$$490$$$O	Alternatively,$$$491$$$505$$$O	the$$$506$$$509$$$O	alcohol$$$510$$$517$$$I	may$$$518$$$521$$$O	be$$$522$$$524$$$O	in$$$525$$$527$$$O	the$$$528$$$531$$$O	form$$$532$$$536$$$O	of$$$537$$$539$$$O	various$$$540$$$547$$$O	distilled$$$548$$$557$$$O	or$$$558$$$560$$$O	undistilled$$$561$$$572$$$O	spirits.$$$573$$$581$$$O
EP2590951A1
Benzenesulfonamides$$$0$$$19$$$I	useful$$$20$$$26$$$O	as$$$27$$$29$$$O	sodium$$$30$$$36$$$I	channel$$$37$$$44$$$O	inhibitors$$$45$$$55$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	sulfonamide$$$25$$$36$$$I	derivatives,$$$37$$$49$$$O	to$$$50$$$52$$$O	their$$$53$$$58$$$O	use$$$59$$$62$$$O	i$$$63$$$64$$$O	n$$$65$$$66$$$O	medicine,$$$67$$$76$$$O	to$$$77$$$79$$$O	compositions$$$80$$$92$$$O	containing$$$93$$$103$$$O	them,$$$104$$$109$$$O	to$$$110$$$112$$$O	processes$$$113$$$122$$$O	for$$$123$$$126$$$O	their$$$127$$$132$$$O	preparation$$$133$$$144$$$O	and$$$145$$$148$$$O	to$$$149$$$151$$$O	intermediates$$$152$$$165$$$O	used$$$166$$$170$$$O	in$$$171$$$173$$$O	such$$$174$$$178$$$O	processes.$$$179$$$189$$$O	More$$$190$$$194$$$O	particularly$$$195$$$207$$$O	the$$$208$$$211$$$O	invention$$$212$$$221$$$O	relates$$$222$$$229$$$O	to$$$230$$$232$$$O	new$$$233$$$236$$$O	sulfonamide$$$237$$$248$$$I	Nav1.7$$$249$$$255$$$O	inhibitors$$$256$$$266$$$O	of$$$267$$$269$$$O	formula$$$270$$$277$$$O	(I):$$$278$$$282$$$O	or$$$283$$$285$$$O	pharmaceutically$$$286$$$302$$$O	acceptable$$$303$$$313$$$O	salts$$$314$$$319$$$O	thereof,$$$320$$$328$$$O	wherein$$$329$$$336$$$O	Z1,$$$337$$$340$$$O	Ra,$$$341$$$344$$$O	Rb,$$$345$$$348$$$O	R1,$$$349$$$352$$$O	R2,$$$353$$$356$$$O	R3,$$$357$$$360$$$O	R4$$$361$$$363$$$O	and$$$364$$$367$$$O	R5$$$368$$$370$$$O	are$$$371$$$374$$$O	as$$$375$$$377$$$O	defined$$$378$$$385$$$O	in$$$386$$$388$$$O	the$$$389$$$392$$$O	description.$$$393$$$405$$$O	Nav$$$406$$$409$$$O	1.7$$$410$$$413$$$O	inhibitors$$$414$$$424$$$O	are$$$425$$$428$$$O	potentially$$$429$$$440$$$O	useful$$$441$$$447$$$O	in$$$448$$$450$$$O	the$$$451$$$454$$$O	treatment$$$455$$$464$$$O	of$$$465$$$467$$$O	a$$$468$$$469$$$O	wide$$$470$$$474$$$O	range$$$475$$$480$$$O	of$$$481$$$483$$$O	disorders,$$$484$$$494$$$O	particularly$$$495$$$507$$$O	pain.$$$508$$$513$$$O
EP2440548A1
2-$$$0$$$2$$$I	($$$3$$$4$$$I	lh-pyrazol-4$$$5$$$17$$$I	-ylamino$$$18$$$26$$$I	)$$$27$$$28$$$I	-pyrimidine$$$29$$$40$$$I	as$$$41$$$43$$$O	kinase$$$44$$$50$$$O	inhibitors$$$51$$$61$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	formula$$$46$$$53$$$O	(I)$$$54$$$57$$$O	or$$$58$$$60$$$O	pharmaceutical$$$61$$$75$$$O	acceptable$$$76$$$86$$$O	salts:$$$87$$$93$$$O	wherein$$$94$$$101$$$O	A1,$$$102$$$105$$$O	A2,$$$106$$$109$$$O	A3,$$$110$$$113$$$O	A4,$$$114$$$117$$$O	X$$$118$$$119$$$O	and$$$120$$$123$$$O	Y$$$124$$$125$$$O	are$$$126$$$129$$$O	defined$$$130$$$137$$$O	in$$$138$$$140$$$O	the$$$141$$$144$$$O	description.$$$145$$$157$$$O	The$$$158$$$161$$$O	present$$$162$$$169$$$O	invention$$$170$$$179$$$O	relates$$$180$$$187$$$O	also$$$188$$$192$$$O	to$$$193$$$195$$$O	methods$$$196$$$203$$$O	of$$$204$$$206$$$O	making$$$207$$$213$$$O	said$$$214$$$218$$$O	compounds,$$$219$$$229$$$O	and$$$230$$$233$$$O	compositions$$$234$$$246$$$O	containing$$$247$$$257$$$O	said$$$258$$$262$$$O	compounds$$$263$$$272$$$O	which$$$273$$$278$$$O	are$$$279$$$282$$$O	useful$$$283$$$289$$$O	for$$$290$$$293$$$O	inhibiting$$$294$$$304$$$O	kinases$$$305$$$312$$$O	such$$$313$$$317$$$O	as$$$318$$$320$$$O	aurora$$$321$$$327$$$O	and$$$328$$$331$$$O	KDR.$$$332$$$336$$$O
US20110135622
Presbyopia$$$0$$$10$$$O	Treatment$$$11$$$20$$$O	by$$$21$$$23$$$O	Lens$$$24$$$28$$$O	Alteration$$$29$$$39$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	effects$$$15$$$22$$$O	a$$$23$$$24$$$O	change$$$25$$$31$$$O	in$$$32$$$34$$$O	the$$$35$$$38$$$O	accommodation$$$39$$$52$$$O	of$$$53$$$55$$$O	the$$$56$$$59$$$O	human$$$60$$$65$$$O	lens$$$66$$$70$$$O	affected$$$71$$$79$$$O	by$$$80$$$82$$$O	presbyopia$$$83$$$93$$$O	through$$$94$$$101$$$O	the$$$102$$$105$$$O	use$$$106$$$109$$$O	of$$$110$$$112$$$O	various$$$113$$$120$$$O	reducing$$$121$$$129$$$O	agents$$$130$$$136$$$O	that$$$137$$$141$$$O	change$$$142$$$148$$$O	accommodative$$$149$$$162$$$O	abilities$$$163$$$172$$$O	of$$$173$$$175$$$O	the$$$176$$$179$$$O	human$$$180$$$185$$$O	lens,$$$186$$$191$$$O	and/or$$$192$$$198$$$O	by$$$199$$$201$$$O	applying$$$202$$$210$$$O	energy$$$211$$$217$$$O	to$$$218$$$220$$$O	affect$$$221$$$227$$$O	a$$$228$$$229$$$O	change$$$230$$$236$$$O	in$$$237$$$239$$$O	the$$$240$$$243$$$O	accommodative$$$244$$$257$$$O	abilities$$$258$$$267$$$O	of$$$268$$$270$$$O	the$$$271$$$274$$$O	human$$$275$$$280$$$O	lens.$$$281$$$286$$$O	This$$$287$$$291$$$O	invention$$$292$$$301$$$O	both$$$302$$$306$$$O	prevents$$$307$$$315$$$O	the$$$316$$$319$$$O	onset$$$320$$$325$$$O	of$$$326$$$328$$$O	presbyopia$$$329$$$339$$$O	as$$$340$$$342$$$O	well$$$343$$$347$$$O	as$$$348$$$350$$$O	treats$$$351$$$357$$$O	it.$$$358$$$361$$$O	By$$$362$$$364$$$O	breaking$$$365$$$373$$$O	and/or$$$374$$$380$$$O	preventing$$$381$$$391$$$O	the$$$392$$$395$$$O	formation$$$396$$$405$$$O	of$$$406$$$408$$$O	bonds$$$409$$$414$$$O	that$$$415$$$419$$$O	adhere$$$420$$$426$$$O	lens$$$427$$$431$$$O	fibers$$$432$$$438$$$O	together$$$439$$$447$$$O	causing$$$448$$$455$$$O	hardening$$$456$$$465$$$O	of$$$466$$$468$$$O	the$$$469$$$472$$$O	lens,$$$473$$$478$$$O	the$$$479$$$482$$$O	present$$$483$$$490$$$O	invention$$$491$$$500$$$O	increases$$$501$$$510$$$O	the$$$511$$$514$$$O	elasticity$$$515$$$525$$$O	and$$$526$$$529$$$O	distensibility$$$530$$$544$$$O	of$$$545$$$547$$$O	the$$$548$$$551$$$O	lens$$$552$$$556$$$O	and/or$$$557$$$563$$$O	lens$$$564$$$568$$$O	capsule.$$$569$$$577$$$O
CN1857207A
Slow$$$0$$$4$$$O	released$$$5$$$13$$$O	compound$$$14$$$22$$$O	anticancer$$$23$$$33$$$O	injection$$$34$$$43$$$O	containing$$$44$$$54$$$O	blood$$$55$$$60$$$O	vessel$$$61$$$67$$$O	inhibitor$$$68$$$77$$$O
The$$$0$$$3$$$O	slow$$$4$$$8$$$O	released$$$9$$$17$$$O	compound$$$18$$$26$$$O	anticancer$$$27$$$37$$$O	injection$$$38$$$47$$$O	containing$$$48$$$58$$$O	blood$$$59$$$64$$$O	vessel$$$65$$$71$$$O	inhibitor$$$72$$$81$$$O	and$$$82$$$85$$$O	its$$$86$$$89$$$O	synergist$$$90$$$99$$$O	consists$$$100$$$108$$$O	of$$$109$$$111$$$O	slow$$$112$$$116$$$O	released$$$117$$$125$$$O	microsphere$$$126$$$137$$$O	and$$$138$$$141$$$O	solvent.$$$142$$$150$$$O	The$$$151$$$154$$$O	slow$$$155$$$159$$$O	released$$$160$$$168$$$O	microsphere$$$169$$$180$$$O	includes$$$181$$$189$$$O	effective$$$190$$$199$$$O	anticancer$$$200$$$210$$$O	component$$$211$$$220$$$O	and$$$221$$$224$$$O	slow$$$225$$$229$$$O	releasing$$$230$$$239$$$O	supplementary$$$240$$$253$$$O	material,$$$254$$$263$$$O	and$$$264$$$267$$$O	the$$$268$$$271$$$O	solvent$$$272$$$279$$$O	is$$$280$$$282$$$O	common$$$283$$$289$$$O	solvent$$$290$$$297$$$O	or$$$298$$$300$$$O	special$$$301$$$308$$$O	solvent$$$309$$$316$$$O	containing$$$317$$$327$$$O	suspending$$$328$$$338$$$O	agent.$$$339$$$345$$$O	The$$$346$$$349$$$O	effective$$$350$$$359$$$O	anticancer$$$360$$$370$$$O	component$$$371$$$380$$$O	is$$$381$$$383$$$O	blood$$$384$$$389$$$O	vessel$$$390$$$396$$$O	inhibitor$$$397$$$406$$$O	and/or$$$407$$$413$$$O	blood$$$414$$$419$$$O	vessel$$$420$$$426$$$O	inhibitor$$$427$$$436$$$O	synergist$$$437$$$446$$$O	selected$$$447$$$455$$$O	from$$$456$$$460$$$O	antitumor$$$461$$$470$$$O	antibiotic$$$471$$$481$$$O	and$$$482$$$485$$$O	antimetabolite.$$$486$$$501$$$O	The$$$502$$$505$$$O	slow$$$506$$$510$$$O	releasing$$$511$$$520$$$O	supplementary$$$521$$$534$$$O	material$$$535$$$543$$$O	is$$$544$$$546$$$O	selected$$$547$$$555$$$O	from$$$556$$$560$$$O	difatty$$$561$$$568$$$I	acid-sebacic$$$569$$$581$$$I	acid$$$582$$$586$$$I	copolymer,$$$587$$$597$$$O	poly(erucic$$$598$$$609$$$I	acid$$$610$$$614$$$I	dipolymer-sebacic$$$615$$$632$$$I	acid),$$$633$$$639$$$I	poly(fumaric$$$640$$$652$$$I	acid-sebacic$$$653$$$665$$$I	acid),$$$666$$$672$$$I	etc$$$673$$$676$$$O	or$$$677$$$679$$$O	their$$$680$$$685$$$O	composition.$$$686$$$698$$$O	The$$$699$$$702$$$O	suspending$$$703$$$713$$$O	agent$$$714$$$719$$$O	is$$$720$$$722$$$O	carboxymethyl$$$723$$$736$$$O	cellulose,$$$737$$$747$$$O	etc.$$$748$$$752$$$O	and$$$753$$$756$$$O	has$$$757$$$760$$$O	viscosity$$$761$$$770$$$O	of$$$771$$$773$$$O	80-3000$$$774$$$781$$$O	cp$$$782$$$784$$$O	at$$$785$$$787$$$O	20-30$$$788$$$793$$$O	deg.c.$$$794$$$800$$$O	The$$$801$$$804$$$O	slow$$$805$$$809$$$O	released$$$810$$$818$$$O	microsphere$$$819$$$830$$$O	may$$$831$$$834$$$O	be$$$835$$$837$$$O	also$$$838$$$842$$$O	prepared$$$843$$$851$$$O	into$$$852$$$856$$$O	slow$$$857$$$861$$$O	released$$$862$$$870$$$O	implanting$$$871$$$881$$$O	agent$$$882$$$887$$$O	for$$$888$$$891$$$O	use$$$892$$$895$$$O	alone$$$896$$$901$$$O	or$$$902$$$904$$$O	together$$$905$$$913$$$O	with$$$914$$$918$$$O	chemotherapeutic$$$919$$$935$$$O	and/or$$$936$$$942$$$O	radiotherapeutic$$$943$$$959$$$O	medicine..$$$960$$$970$$$O
US20090048235
Substituted$$$0$$$11$$$O	5-vinylphenyl-1-phenyl-pyrazole$$$12$$$43$$$I	cannabinoid$$$44$$$55$$$I	modulators$$$56$$$66$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	is$$$15$$$17$$$O	directed$$$18$$$26$$$O	to$$$27$$$29$$$O	a$$$30$$$31$$$O	cannabinoid$$$32$$$43$$$I	modulator$$$44$$$53$$$O	compound$$$54$$$62$$$O	of$$$63$$$65$$$O	formula$$$66$$$73$$$O	(I):$$$74$$$78$$$O	or$$$116$$$118$$$O	a$$$119$$$120$$$O	form$$$121$$$125$$$O	thereof,$$$126$$$134$$$O	and$$$135$$$138$$$O	methods$$$139$$$146$$$O	for$$$147$$$150$$$O	use$$$151$$$154$$$O	in$$$155$$$157$$$O	treating,$$$158$$$167$$$O	ameliorating$$$168$$$180$$$O	or$$$181$$$183$$$O	preventing$$$184$$$194$$$O	a$$$195$$$196$$$O	cannabinoid$$$197$$$208$$$I	receptor$$$209$$$217$$$O	mediated$$$218$$$226$$$O	syndrome,$$$227$$$236$$$O	disorder$$$237$$$245$$$O	or$$$246$$$248$$$O	disease.$$$249$$$257$$$O
EP1861101A2
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	amides$$$7$$$13$$$I	of$$$14$$$16$$$I	sulfadimidine$$$17$$$30$$$I	for$$$31$$$34$$$O	the$$$35$$$38$$$O	treatment$$$39$$$48$$$O	of$$$49$$$51$$$O	intestinal$$$52$$$62$$$O	diseases$$$63$$$71$$$O	in$$$72$$$74$$$O	veterinary$$$75$$$85$$$O	science$$$86$$$93$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	treatment$$$27$$$36$$$O	of$$$37$$$39$$$O	diseases$$$40$$$48$$$O	of$$$49$$$51$$$O	the$$$52$$$55$$$O	digestive$$$56$$$65$$$O	tract$$$66$$$71$$$O	of$$$72$$$74$$$O	animals$$$75$$$82$$$O	using$$$83$$$88$$$O	an$$$89$$$91$$$O	amide$$$92$$$97$$$I	of$$$98$$$100$$$I	sulfadimidine,$$$101$$$115$$$I	wherein$$$116$$$123$$$O	the$$$124$$$127$$$O	amide$$$128$$$133$$$I	is$$$134$$$136$$$O	essentially$$$137$$$148$$$O	non-absorbable$$$149$$$163$$$O	in$$$164$$$166$$$O	the$$$167$$$170$$$O	intestine.$$$171$$$181$$$O	Subject$$$182$$$189$$$O	of$$$190$$$192$$$O	the$$$193$$$196$$$O	invention$$$197$$$206$$$O	are$$$207$$$210$$$O	food$$$211$$$215$$$O	and$$$216$$$219$$$O	beverage$$$220$$$228$$$O	preparations$$$229$$$241$$$O	and$$$242$$$245$$$O	a$$$246$$$247$$$O	medicament.$$$248$$$259$$$O
CN103251599A
Pharmaceutical$$$0$$$14$$$O	preparation$$$15$$$26$$$O	for$$$27$$$30$$$O	rapidly$$$31$$$38$$$O	releasing$$$39$$$48$$$O	citric$$$49$$$55$$$I	acid$$$56$$$60$$$I	benzene$$$61$$$68$$$I	ring$$$69$$$73$$$I	tinib$$$74$$$79$$$O	and$$$80$$$83$$$O	preparation$$$84$$$95$$$O	method$$$96$$$102$$$O	thereof$$$103$$$110$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pharmaceutical$$$27$$$41$$$O	preparation$$$42$$$53$$$O	for$$$54$$$57$$$O	rapidly$$$58$$$65$$$O	releasing$$$66$$$75$$$O	citric$$$76$$$82$$$I	acid$$$83$$$87$$$I	benzene$$$88$$$95$$$I	ring$$$96$$$100$$$I	tinib$$$101$$$106$$$O	and$$$107$$$110$$$O	a$$$111$$$112$$$O	preparation$$$113$$$124$$$O	method$$$125$$$131$$$O	thereof.$$$132$$$140$$$O	The$$$141$$$144$$$O	citric$$$145$$$151$$$I	acid$$$152$$$156$$$I	benzene$$$157$$$164$$$I	ring$$$165$$$169$$$I	tinib$$$170$$$175$$$O	and$$$176$$$179$$$O	a$$$180$$$181$$$O	medicinal$$$182$$$191$$$O	excipient$$$192$$$201$$$O	are$$$202$$$205$$$O	prepared$$$206$$$214$$$O	into$$$215$$$219$$$O	tablets;$$$220$$$228$$$O	the$$$229$$$232$$$O	pharmaceutical$$$233$$$247$$$O	preparation$$$248$$$259$$$O	comprises$$$260$$$269$$$O	the$$$270$$$273$$$O	following$$$274$$$283$$$O	components$$$284$$$294$$$O	by$$$295$$$297$$$O	weight$$$298$$$304$$$O	percent:$$$305$$$313$$$O	40-65%$$$314$$$320$$$O	of$$$321$$$323$$$O	citric$$$324$$$330$$$I	acid$$$331$$$335$$$I	benzene$$$336$$$343$$$I	ring$$$344$$$348$$$I	tinib;$$$349$$$355$$$O	and$$$356$$$359$$$O	the$$$360$$$363$$$O	medicinal$$$364$$$373$$$O	excipient$$$374$$$383$$$O	is$$$384$$$386$$$O	a$$$387$$$388$$$O	disintegrating$$$389$$$403$$$O	agent,$$$404$$$410$$$O	a$$$411$$$412$$$O	filler$$$413$$$419$$$O	and$$$420$$$423$$$O	a$$$424$$$425$$$O	lubricating$$$426$$$437$$$O	agent,$$$438$$$444$$$O	and$$$445$$$448$$$O	contains$$$449$$$457$$$O	the$$$458$$$461$$$O	components$$$462$$$472$$$O	by$$$473$$$475$$$O	weight$$$476$$$482$$$O	percent:$$$483$$$491$$$O	5-25%$$$492$$$497$$$O	of$$$498$$$500$$$O	disintegrating$$$501$$$515$$$O	agent,$$$516$$$522$$$O	20-50%$$$523$$$529$$$O	of$$$530$$$532$$$O	filler$$$533$$$539$$$O	and$$$540$$$543$$$O	0.5-5%$$$544$$$550$$$O	of$$$551$$$553$$$O	lubricating$$$554$$$565$$$O	agent.$$$566$$$572$$$O	The$$$573$$$576$$$O	medicine$$$577$$$585$$$O	tablet$$$586$$$592$$$O	of$$$593$$$595$$$O	the$$$596$$$599$$$O	citric$$$600$$$606$$$I	acid$$$607$$$611$$$I	benzene$$$612$$$619$$$I	ring$$$620$$$624$$$I	tinib$$$625$$$630$$$O	provided$$$631$$$639$$$O	by$$$640$$$642$$$O	the$$$643$$$646$$$O	invention$$$647$$$656$$$O	can$$$657$$$660$$$O	achieve$$$661$$$668$$$O	the$$$669$$$672$$$O	complete$$$673$$$681$$$O	release$$$682$$$689$$$O	target$$$690$$$696$$$O	after$$$697$$$702$$$O	8$$$703$$$704$$$O	minutes;$$$705$$$713$$$O	use$$$714$$$717$$$O	of$$$718$$$720$$$O	a$$$721$$$722$$$O	granulating$$$723$$$734$$$O	organic$$$735$$$742$$$O	solvent$$$743$$$750$$$O	is$$$751$$$753$$$O	avoided$$$754$$$761$$$O	by$$$762$$$764$$$O	adopting$$$765$$$773$$$O	a$$$774$$$775$$$O	dry$$$776$$$779$$$O	granulation$$$780$$$791$$$O	method;$$$792$$$799$$$O	meanwhile,$$$800$$$810$$$O	the$$$811$$$814$$$O	granulation$$$815$$$826$$$O	time$$$827$$$831$$$O	is$$$832$$$834$$$O	shortened;$$$835$$$845$$$O	and$$$846$$$849$$$O	the$$$850$$$853$$$O	production$$$854$$$864$$$O	safety$$$865$$$871$$$O	is$$$872$$$874$$$O	greatly$$$875$$$882$$$O	improved.$$$883$$$892$$$O	The$$$893$$$896$$$O	medicine$$$897$$$905$$$O	tablet$$$906$$$912$$$O	of$$$913$$$915$$$O	the$$$916$$$919$$$O	citric$$$920$$$926$$$I	acid$$$927$$$931$$$I	benzene$$$932$$$939$$$I	ring$$$940$$$944$$$I	tinib$$$945$$$950$$$O	provided$$$951$$$959$$$O	by$$$960$$$962$$$O	the$$$963$$$966$$$O	invention$$$967$$$976$$$O	belongs$$$977$$$984$$$O	to$$$985$$$987$$$O	a$$$988$$$989$$$O	tetrahydronaphthalene$$$990$$$1011$$$I	amide$$$1012$$$1017$$$I	compound,$$$1018$$$1027$$$O	and$$$1028$$$1031$$$O	can$$$1032$$$1035$$$O	be$$$1036$$$1038$$$O	used$$$1039$$$1043$$$O	for$$$1044$$$1047$$$O	treating$$$1048$$$1056$$$O	chronic$$$1057$$$1064$$$O	myelogenous$$$1065$$$1076$$$O	granulocyte$$$1077$$$1088$$$O	leukemia,$$$1089$$$1098$$$O	gastrointestinal$$$1099$$$1115$$$O	stromal$$$1116$$$1123$$$O	tumor$$$1124$$$1129$$$O	and$$$1130$$$1133$$$O	the$$$1134$$$1137$$$O	like.$$$1138$$$1143$$$O
WO2012146644A1
Salt$$$0$$$4$$$O	of$$$5$$$7$$$O	an$$$8$$$10$$$O	inhibitor$$$11$$$20$$$O	of$$$21$$$23$$$O	phosphodiesterase$$$24$$$41$$$O	10$$$42$$$44$$$O	enzyme$$$45$$$51$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	salt$$$28$$$32$$$O	of$$$33$$$35$$$O	3-[6-(2-methoxyethyl)-3-pyridinyl]-2-methyl-8-(4-$$$36$$$85$$$I	morpholinyl)-imidazo[1,2-b]pyridazine,$$$86$$$124$$$I	a$$$125$$$126$$$O	phosphodiesterase$$$127$$$144$$$O	10$$$145$$$147$$$O	enzyme$$$148$$$154$$$O	(PDE10)$$$155$$$162$$$O	inhibitor,$$$163$$$173$$$O	as$$$174$$$176$$$O	well$$$177$$$181$$$O	as$$$182$$$184$$$O	to$$$185$$$187$$$O	pharmaceutical$$$188$$$202$$$O	compositions$$$203$$$215$$$O	comprising$$$216$$$226$$$O	the$$$227$$$230$$$O	same,$$$231$$$236$$$O	the$$$237$$$240$$$O	salt$$$241$$$245$$$O	for$$$246$$$249$$$O	use$$$250$$$253$$$O	in$$$254$$$256$$$O	the$$$257$$$260$$$O	treatment$$$261$$$270$$$O	or$$$271$$$273$$$O	prevention$$$274$$$284$$$O	of$$$285$$$287$$$O	a$$$288$$$289$$$O	central$$$290$$$297$$$O	nervous$$$298$$$305$$$O	system$$$306$$$312$$$O	disorder,$$$313$$$322$$$O	or$$$323$$$325$$$O	a$$$326$$$327$$$O	metabolic$$$328$$$337$$$O	disorderand$$$338$$$349$$$O	methods$$$350$$$357$$$O	of$$$358$$$360$$$O	treatment$$$361$$$370$$$O	using$$$371$$$376$$$O	the$$$377$$$380$$$O	same.$$$381$$$386$$$O
CN101538299A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	synthesizing$$$11$$$23$$$O	5,6,4'-trihydroxyflavone-7-O-D-glucuronic$$$24$$$65$$$I	acid$$$66$$$70$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	chemical$$$25$$$33$$$O	method$$$34$$$40$$$O	for$$$41$$$44$$$O	preparing$$$45$$$54$$$O	5,6,4'-trihydroxyflavone-7-O-D-glucuronic$$$55$$$96$$$I	acid$$$97$$$101$$$I	to$$$102$$$104$$$O	solve$$$105$$$110$$$O	problems$$$111$$$119$$$O	of$$$120$$$122$$$O	unavailable$$$123$$$134$$$O	raw$$$135$$$138$$$O	materials,$$$139$$$149$$$O	long$$$150$$$154$$$O	synthetic$$$155$$$164$$$O	route$$$165$$$170$$$O	and$$$171$$$174$$$O	low$$$175$$$178$$$O	synthesis$$$179$$$188$$$O	yield$$$189$$$194$$$O	in$$$195$$$197$$$O	the$$$198$$$201$$$O	existing$$$202$$$210$$$O	synthetic$$$211$$$220$$$O	method.$$$221$$$228$$$O	The$$$229$$$232$$$O	method$$$233$$$239$$$O	comprises$$$240$$$249$$$O	a$$$250$$$251$$$O	plurality$$$252$$$261$$$O	of$$$262$$$264$$$O	chemical$$$265$$$273$$$O	reaction$$$274$$$282$$$O	steps:$$$283$$$289$$$O	first,$$$290$$$296$$$O	taking$$$297$$$303$$$O	3,4,5-trimethoxy$$$304$$$320$$$I	phenol$$$321$$$327$$$I	and$$$328$$$331$$$O	p-methoxy$$$332$$$341$$$I	cinnamoyl$$$342$$$351$$$I	chloride$$$352$$$360$$$I	as$$$361$$$363$$$O	the$$$364$$$367$$$O	raw$$$368$$$371$$$O	materials$$$372$$$381$$$O	to$$$382$$$384$$$O	construct$$$385$$$394$$$O	a$$$395$$$396$$$O	chalcone$$$397$$$405$$$O	structure$$$406$$$415$$$O	by$$$416$$$418$$$O	a$$$419$$$420$$$O	Friedel-Crafts$$$421$$$435$$$O	acylation$$$436$$$445$$$O	reaction,$$$446$$$455$$$O	and$$$456$$$459$$$O	cycloetherifying$$$460$$$476$$$O	to$$$477$$$479$$$O	obtain$$$480$$$486$$$O	a$$$487$$$488$$$O	flavone$$$489$$$496$$$I	parent$$$497$$$503$$$O	substance;$$$504$$$514$$$O	then$$$515$$$519$$$O	protecting$$$520$$$530$$$O	and$$$531$$$534$$$O	selectively$$$535$$$546$$$O	deprotecting$$$547$$$559$$$O	phenolic$$$560$$$568$$$I	hydroxyl$$$569$$$577$$$I	of$$$578$$$580$$$O	the$$$581$$$584$$$O	flavone$$$585$$$592$$$I	parent$$$593$$$599$$$O	substance,$$$600$$$610$$$O	and$$$611$$$614$$$O	glycosylating$$$615$$$628$$$O	7-phenolic$$$629$$$639$$$I	hydroxyl;$$$640$$$649$$$I	and$$$650$$$653$$$O	finally$$$654$$$661$$$O	removing$$$662$$$670$$$O	a$$$671$$$672$$$O	protective$$$673$$$683$$$O	group$$$684$$$689$$$O	to$$$690$$$692$$$O	obtain$$$693$$$699$$$O	the$$$700$$$703$$$O	target$$$704$$$710$$$O	compound.$$$711$$$720$$$O	The$$$721$$$724$$$O	obtained$$$725$$$733$$$O	product$$$734$$$741$$$O	has$$$742$$$745$$$O	a$$$746$$$747$$$O	beta-steric$$$748$$$759$$$O	configuration.$$$760$$$774$$$O	The$$$775$$$778$$$O	method$$$779$$$785$$$O	can$$$786$$$789$$$O	be$$$790$$$792$$$O	used$$$793$$$797$$$O	for$$$798$$$801$$$O	preparing$$$802$$$811$$$O	high-purity$$$812$$$823$$$O	and$$$824$$$827$$$O	high-quality$$$828$$$840$$$O	5,6,4'-trihydroxyflavone-7-O-D-glucuronic$$$841$$$882$$$I	acid$$$883$$$887$$$I	products.$$$888$$$897$$$O
CN102579403A
Duloxetine$$$0$$$10$$$I	hydrochloride$$$11$$$24$$$I	drug$$$25$$$29$$$O	composition$$$30$$$41$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	sustained-release$$$26$$$43$$$O	duloxetine$$$44$$$54$$$I	hydrochloride$$$55$$$68$$$I	drug$$$69$$$73$$$O	composition,$$$74$$$86$$$O	which$$$87$$$92$$$O	is$$$93$$$95$$$O	characterized$$$96$$$109$$$O	in$$$110$$$112$$$O	that$$$113$$$117$$$O	the$$$118$$$121$$$O	drug$$$122$$$126$$$O	composition$$$127$$$138$$$O	is$$$139$$$141$$$O	a$$$142$$$143$$$O	duloxetine$$$144$$$154$$$I	hydrochloride$$$155$$$168$$$I	sustained-release$$$169$$$186$$$O	capsule,$$$187$$$195$$$O	and$$$196$$$199$$$O	consists$$$200$$$208$$$O	of$$$209$$$211$$$O	duloxetine$$$212$$$222$$$I	hydrochloride$$$223$$$236$$$I	sustained-release$$$237$$$254$$$O	pellets$$$255$$$262$$$O	and$$$263$$$266$$$O	duloxetine$$$267$$$277$$$I	hydrochloride$$$278$$$291$$$I	sustained-release$$$292$$$309$$$O	pellets$$$310$$$317$$$O	which$$$318$$$323$$$O	are$$$324$$$327$$$O	released$$$328$$$336$$$O	by$$$337$$$339$$$O	a$$$340$$$341$$$O	time$$$342$$$346$$$O	delay$$$347$$$352$$$O	of$$$353$$$355$$$O	4h$$$356$$$358$$$O	according$$$359$$$368$$$O	to$$$369$$$371$$$O	a$$$372$$$373$$$O	ratio$$$374$$$379$$$O	of$$$380$$$382$$$O	1:1.$$$383$$$387$$$O	The$$$388$$$391$$$O	duloxetine$$$392$$$402$$$I	hydrochloride$$$403$$$416$$$I	drug$$$417$$$421$$$O	composition$$$422$$$433$$$O	has$$$434$$$437$$$O	good$$$438$$$442$$$O	stability,$$$443$$$453$$$O	and$$$454$$$457$$$O	also$$$458$$$462$$$O	has$$$463$$$466$$$O	the$$$467$$$470$$$O	more$$$471$$$475$$$O	obvious$$$476$$$483$$$O	advantages$$$484$$$494$$$O	of$$$495$$$497$$$O	improving$$$498$$$507$$$O	the$$$508$$$511$$$O	product$$$512$$$519$$$O	yield,$$$520$$$526$$$O	lowering$$$527$$$535$$$O	the$$$536$$$539$$$O	cost,$$$540$$$545$$$O	realizing$$$546$$$555$$$O	the$$$556$$$559$$$O	industrialization$$$560$$$577$$$O	and$$$578$$$581$$$O	being$$$582$$$587$$$O	better$$$588$$$594$$$O	applied$$$595$$$602$$$O	clinically.$$$603$$$614$$$O
US7872140
contacting$$$0$$$10$$$O	(S)-omeprazole$$$11$$$25$$$I	freebase$$$26$$$34$$$O	or$$$35$$$37$$$O	its$$$38$$$41$$$O	sodium/potassium$$$42$$$58$$$I	salt$$$59$$$63$$$O	with$$$64$$$68$$$O	inorganic$$$69$$$78$$$O	or$$$79$$$81$$$O	organic$$$82$$$89$$$I	acid$$$90$$$94$$$I	salt$$$95$$$99$$$O	of$$$100$$$102$$$O	the$$$103$$$106$$$O	barium$$$107$$$113$$$I	(barium$$$114$$$121$$$I	chloride,$$$122$$$131$$$I	barium$$$132$$$138$$$I	sulfate,$$$139$$$147$$$I	barium$$$148$$$154$$$I	oxalate,$$$155$$$163$$$I	barium$$$164$$$170$$$I	acetate)$$$171$$$179$$$I	in$$$180$$$182$$$O	a$$$183$$$184$$$O	suitable$$$185$$$193$$$O	solvent$$$194$$$201$$$O	($$$202$$$203$$$O	methanol)in$$$204$$$215$$$I	presence$$$216$$$224$$$O	of$$$225$$$227$$$O	a$$$228$$$229$$$O	base$$$230$$$234$$$O	($$$235$$$236$$$O	NaOH)$$$237$$$242$$$I	to$$$243$$$245$$$O	form$$$246$$$250$$$O	(S)-omeprazole$$$251$$$265$$$I	barium;$$$266$$$273$$$I	helicobacter$$$274$$$286$$$O	infections$$$287$$$297$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	crystalline$$$25$$$36$$$O	barium$$$37$$$43$$$I	salt$$$44$$$48$$$O	of$$$49$$$51$$$O	(S)-omeprazole,$$$52$$$67$$$I	which$$$68$$$73$$$O	is$$$74$$$76$$$O	(S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole.$$$77$$$166$$$I	The$$$167$$$170$$$O	invention$$$171$$$180$$$O	also$$$181$$$185$$$O	relates$$$186$$$193$$$O	to$$$194$$$196$$$O	processes$$$197$$$206$$$O	for$$$207$$$210$$$O	preparing$$$211$$$220$$$O	crystalline$$$221$$$232$$$O	barium$$$233$$$239$$$I	salt$$$240$$$244$$$O	of$$$245$$$247$$$O	(S)-omeprazole$$$248$$$262$$$I	and$$$263$$$266$$$O	pharmaceutical$$$267$$$281$$$O	compositions$$$282$$$294$$$O	that$$$295$$$299$$$O	include$$$300$$$307$$$O	the$$$308$$$311$$$O	crystalline$$$312$$$323$$$O	barium$$$324$$$330$$$I	salt$$$331$$$335$$$O	of$$$336$$$338$$$O	(S)-omeprazole$$$339$$$353$$$I	so$$$354$$$356$$$O	prepared.$$$357$$$366$$$O
CN103182044A
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	wind-heat$$$22$$$31$$$O	type$$$32$$$36$$$O	cough$$$37$$$42$$$O	and$$$43$$$46$$$O	preparation$$$47$$$58$$$O	method$$$59$$$65$$$O	thereof$$$66$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicine$$$26$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	wind-heat$$$48$$$57$$$O	type$$$58$$$62$$$O	cough.$$$63$$$69$$$O	The$$$70$$$73$$$O	medicine$$$74$$$82$$$O	is$$$83$$$85$$$O	prepared$$$86$$$94$$$O	from$$$95$$$99$$$O	the$$$100$$$103$$$O	following$$$104$$$113$$$O	ingredients$$$114$$$125$$$O	by$$$126$$$128$$$O	weight:$$$129$$$136$$$O	11.1-15.6$$$137$$$146$$$O	parts$$$147$$$152$$$O	of$$$153$$$155$$$O	fritillaria$$$156$$$167$$$O	cirrhosa,$$$168$$$177$$$O	9.5-11.8$$$178$$$186$$$O	parts$$$187$$$192$$$O	of$$$193$$$195$$$O	semen$$$196$$$201$$$O	armeniacae$$$202$$$212$$$O	amarae,$$$213$$$220$$$O	7.8-10.9$$$221$$$229$$$O	parts$$$230$$$235$$$O	of$$$236$$$238$$$O	radix$$$239$$$244$$$O	stemonae,$$$245$$$254$$$O	9.5-11.8$$$255$$$263$$$O	parts$$$264$$$269$$$O	of$$$270$$$272$$$O	common$$$273$$$279$$$O	hogfennel$$$280$$$289$$$O	root,$$$290$$$295$$$O	7.8-10.9$$$296$$$304$$$O	parts$$$305$$$310$$$O	of$$$311$$$313$$$O	fructus$$$314$$$321$$$O	perillae,$$$322$$$331$$$O	8.2-10.5$$$332$$$340$$$O	parts$$$341$$$346$$$O	of$$$347$$$349$$$O	white$$$350$$$355$$$O	mulberry$$$356$$$364$$$O	root-bark,$$$365$$$375$$$O	16.3-20.9$$$376$$$385$$$O	parts$$$386$$$391$$$O	of$$$392$$$394$$$O	gypsum,$$$395$$$402$$$O	8.2-10.5$$$403$$$411$$$O	parts$$$412$$$417$$$O	of$$$418$$$420$$$O	earthworm,$$$421$$$431$$$O	and$$$432$$$435$$$O	7.8-10.5$$$436$$$444$$$O	parts$$$445$$$450$$$O	of$$$451$$$453$$$O	radix$$$454$$$459$$$O	glehniae.$$$460$$$469$$$O	The$$$470$$$473$$$O	medicine$$$474$$$482$$$O	is$$$483$$$485$$$O	simple$$$486$$$492$$$O	and$$$493$$$496$$$O	reasonable$$$497$$$507$$$O	in$$$508$$$510$$$O	composition,$$$511$$$523$$$O	and$$$524$$$527$$$O	has$$$528$$$531$$$O	the$$$532$$$535$$$O	functions$$$536$$$545$$$O	of$$$546$$$548$$$O	clearing$$$549$$$557$$$O	heat$$$558$$$562$$$O	and$$$563$$$566$$$O	freeing$$$567$$$574$$$O	lung$$$575$$$579$$$O	and$$$580$$$583$$$O	preventing$$$584$$$594$$$O	phlegm$$$595$$$601$$$O	from$$$602$$$606$$$O	forming$$$607$$$614$$$O	and$$$615$$$618$$$O	stopping$$$619$$$627$$$O	coughing.$$$628$$$637$$$O	The$$$638$$$641$$$O	invention$$$642$$$651$$$O	further$$$652$$$659$$$O	discloses$$$660$$$669$$$O	a$$$670$$$671$$$O	preparation$$$672$$$683$$$O	method$$$684$$$690$$$O	of$$$691$$$693$$$O	the$$$694$$$697$$$O	medicine,$$$698$$$707$$$O	which$$$708$$$713$$$O	comprises$$$714$$$723$$$O	the$$$724$$$727$$$O	following$$$728$$$737$$$O	steps:$$$738$$$744$$$O	taking$$$745$$$751$$$O	the$$$752$$$755$$$O	gypsum$$$756$$$762$$$O	to$$$763$$$765$$$O	prepare$$$766$$$773$$$O	gypsum$$$774$$$780$$$O	extracting$$$781$$$791$$$O	solution,$$$792$$$801$$$O	and$$$802$$$805$$$O	concentrating$$$806$$$819$$$O	the$$$820$$$823$$$O	solution,$$$824$$$833$$$O	drying$$$834$$$840$$$O	the$$$841$$$844$$$O	rest$$$845$$$849$$$O	of$$$850$$$852$$$O	ingredients$$$853$$$864$$$O	according$$$865$$$874$$$O	to$$$875$$$877$$$O	the$$$878$$$881$$$O	mass$$$882$$$886$$$O	percent,$$$887$$$895$$$O	and$$$896$$$899$$$O	crushing$$$900$$$908$$$O	the$$$909$$$912$$$O	ingredients$$$913$$$924$$$O	and$$$925$$$928$$$O	mixing$$$929$$$935$$$O	uniformly,$$$936$$$946$$$O	placing$$$947$$$954$$$O	the$$$955$$$958$$$O	mixture$$$959$$$966$$$O	into$$$967$$$971$$$O	a$$$972$$$973$$$O	supersonic$$$974$$$984$$$O	extractor,$$$985$$$995$$$O	adding$$$996$$$1002$$$O	70%$$$1003$$$1006$$$O	ethanol$$$1007$$$1014$$$O	to$$$1015$$$1017$$$O	extract$$$1018$$$1025$$$O	so$$$1026$$$1028$$$O	as$$$1029$$$1031$$$O	to$$$1032$$$1034$$$O	obtain$$$1035$$$1041$$$O	the$$$1042$$$1045$$$O	intermediate$$$1046$$$1058$$$O	extracting$$$1059$$$1069$$$O	liquid$$$1070$$$1076$$$O	with$$$1077$$$1081$$$O	effective$$$1082$$$1091$$$O	components,$$$1092$$$1103$$$O	placing$$$1104$$$1111$$$O	the$$$1112$$$1115$$$O	intermediate$$$1116$$$1128$$$O	extracting$$$1129$$$1139$$$O	liquid$$$1140$$$1146$$$O	with$$$1147$$$1151$$$O	effective$$$1152$$$1161$$$O	components$$$1162$$$1172$$$O	still$$$1173$$$1178$$$O	for$$$1179$$$1182$$$O	48-72h,$$$1183$$$1190$$$O	taking$$$1191$$$1197$$$O	and$$$1198$$$1201$$$O	filtering$$$1202$$$1211$$$O	supernatant,$$$1212$$$1224$$$O	recycling$$$1225$$$1234$$$O	ethanol,$$$1235$$$1243$$$I	and$$$1244$$$1247$$$O	mixing$$$1248$$$1254$$$O	the$$$1255$$$1258$$$O	filtered$$$1259$$$1267$$$O	solution$$$1268$$$1276$$$O	with$$$1277$$$1281$$$O	the$$$1282$$$1285$$$O	gypsum$$$1286$$$1292$$$O	concentrate$$$1293$$$1304$$$O	to$$$1305$$$1307$$$O	obtain$$$1308$$$1314$$$O	the$$$1315$$$1318$$$O	concentrated$$$1319$$$1331$$$O	extract$$$1332$$$1339$$$O	with$$$1340$$$1344$$$O	effective$$$1345$$$1354$$$O	components.$$$1355$$$1366$$$O
US20070134308
Non-steroidal$$$0$$$13$$$O	anti-inflammatory$$$14$$$31$$$O	drug$$$32$$$36$$$O	formulations$$$37$$$49$$$O	for$$$50$$$53$$$O	topical$$$54$$$61$$$O	applications$$$62$$$74$$$O	to$$$75$$$77$$$O	the$$$78$$$81$$$O	skin$$$82$$$86$$$O
Topical$$$0$$$7$$$O	alcoholic$$$8$$$17$$$O	or$$$18$$$20$$$O	aqueous$$$21$$$28$$$O	alcoholic$$$29$$$38$$$O	gels$$$39$$$43$$$O	containing$$$44$$$54$$$O	ibuprofen$$$55$$$64$$$I	or$$$65$$$67$$$O	other$$$68$$$73$$$O	NSAIDs,$$$74$$$81$$$O	such$$$82$$$86$$$O	as,$$$87$$$90$$$O	naproxen,$$$91$$$100$$$I	in$$$101$$$103$$$O	substantially$$$104$$$117$$$O	neutral$$$118$$$125$$$O	salt$$$126$$$130$$$O	form,$$$131$$$136$$$O	have$$$137$$$141$$$O	enhanced$$$142$$$150$$$O	penetration$$$151$$$162$$$O	through$$$163$$$170$$$O	skin$$$171$$$175$$$O	and$$$176$$$179$$$O	may$$$180$$$183$$$O	provide$$$184$$$191$$$O	rapid$$$192$$$197$$$O	pain/inflammation$$$198$$$215$$$O	relief$$$216$$$222$$$O	by$$$223$$$225$$$O	including$$$226$$$235$$$O	in$$$236$$$238$$$O	the$$$239$$$242$$$O	formulation$$$243$$$254$$$O	2-n-nonyl-1,3-dioxolane$$$255$$$278$$$I	or$$$279$$$281$$$O	other$$$282$$$287$$$O	hydrocarbyl$$$288$$$299$$$I	derivative$$$300$$$310$$$O	of$$$311$$$313$$$O	1,3-dioxolane$$$314$$$327$$$I	or$$$328$$$330$$$O	1,3-dioxane$$$331$$$342$$$I	or$$$343$$$345$$$O	acetal,$$$346$$$353$$$I	as$$$354$$$356$$$O	skin$$$357$$$361$$$O	penetration$$$362$$$373$$$O	enhancing$$$374$$$383$$$O	compound.$$$384$$$393$$$O	The$$$394$$$397$$$O	amount$$$398$$$404$$$O	of$$$405$$$407$$$O	propylene$$$408$$$417$$$I	glycol$$$418$$$424$$$I	may$$$425$$$428$$$O	be$$$429$$$431$$$O	varied$$$432$$$438$$$O	to$$$439$$$441$$$O	adjust$$$442$$$448$$$O	the$$$449$$$452$$$O	initial$$$453$$$460$$$O	flux$$$461$$$465$$$O	of$$$466$$$468$$$O	the$$$469$$$472$$$O	NSAID$$$473$$$478$$$O	through$$$479$$$486$$$O	the$$$487$$$490$$$O	skin,$$$491$$$496$$$O	especially$$$497$$$507$$$O	for$$$508$$$511$$$O	ibuprofen,$$$512$$$522$$$I	naproxen,$$$523$$$532$$$I	and$$$533$$$536$$$O	ketorolac.$$$537$$$547$$$I
US20100124554
Redox-active$$$0$$$12$$$O	compounds$$$13$$$22$$$O	and$$$23$$$26$$$O	related$$$27$$$34$$$O	compounds,$$$35$$$45$$$O	compositions,$$$46$$$59$$$O	methods$$$60$$$67$$$O	and$$$68$$$71$$$O	systems$$$72$$$79$$$O
Compounds$$$0$$$9$$$O	able$$$10$$$14$$$O	to$$$15$$$17$$$O	affect$$$18$$$24$$$O	production$$$25$$$35$$$O	and/or$$$36$$$42$$$O	activity$$$43$$$51$$$O	of$$$52$$$54$$$O	a$$$55$$$56$$$O	redox$$$57$$$62$$$O	active$$$63$$$69$$$O	compound,$$$70$$$79$$$O	which$$$80$$$85$$$O	include$$$86$$$93$$$O	candidate$$$94$$$103$$$O	therapeutic$$$104$$$115$$$O	compounds$$$116$$$125$$$O	and$$$126$$$129$$$O	candidate$$$130$$$139$$$O	compounds$$$140$$$149$$$O	for$$$150$$$153$$$O	enhancing$$$154$$$163$$$O	power$$$164$$$169$$$O	output$$$170$$$176$$$O	of$$$177$$$179$$$O	a$$$180$$$181$$$O	microbial$$$182$$$191$$$O	fuel$$$192$$$196$$$O	cell,$$$197$$$202$$$O	and$$$203$$$206$$$O	related$$$207$$$214$$$O	compositions,$$$215$$$228$$$O	methods$$$229$$$236$$$O	and$$$237$$$240$$$O	systems.$$$241$$$249$$$O
US20100234440
Novel$$$0$$$5$$$O	crystal$$$6$$$13$$$O	of$$$14$$$16$$$O	substituted$$$17$$$28$$$O	phenylalkanoic$$$29$$$43$$$I	acid$$$44$$$48$$$I	ester$$$49$$$54$$$I	and$$$55$$$58$$$O	process$$$59$$$66$$$O	for$$$67$$$70$$$O	producing$$$71$$$80$$$O	the$$$81$$$84$$$O	same$$$85$$$89$$$O
[Object]$$$0$$$8$$$O	In$$$9$$$11$$$O	the$$$12$$$15$$$O	case$$$16$$$20$$$O	of$$$21$$$23$$$O	using$$$24$$$29$$$O	3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic$$$30$$$103$$$I	acid,$$$104$$$109$$$I	methyl$$$110$$$116$$$I	3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate,$$$117$$$192$$$I	or$$$193$$$195$$$O	methyl$$$196$$$202$$$I	3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate$$$203$$$277$$$I	as$$$278$$$280$$$O	a$$$281$$$282$$$O	medicine,$$$283$$$292$$$O	more$$$293$$$297$$$O	preferable$$$298$$$308$$$O	aspects$$$309$$$316$$$O	or$$$317$$$319$$$O	improved$$$320$$$328$$$O	methods$$$329$$$336$$$O	are$$$337$$$340$$$O	provided.$$$341$$$350$$$O	[Means]$$$355$$$362$$$O	Crystals$$$363$$$371$$$O	of$$$372$$$374$$$O	any$$$375$$$378$$$O	compound$$$379$$$387$$$O	among$$$388$$$393$$$O	3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic$$$394$$$467$$$I	acid,$$$468$$$473$$$I	methyl$$$474$$$480$$$I	3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate,$$$481$$$556$$$I	and$$$557$$$560$$$O	methyl$$$561$$$567$$$I	3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate,$$$568$$$643$$$I	and$$$644$$$647$$$O	methods$$$648$$$655$$$O	of$$$656$$$658$$$O	producing$$$659$$$668$$$O	the$$$669$$$672$$$O	same$$$673$$$677$$$O	are$$$678$$$681$$$O	provided.$$$682$$$691$$$O
EP1832179A1
Carbohydrate$$$0$$$12$$$I	fraction$$$13$$$21$$$O	composition$$$22$$$33$$$O	and$$$34$$$37$$$O	flat$$$38$$$42$$$O	glucose$$$43$$$50$$$I	response$$$51$$$59$$$O
A$$$0$$$1$$$O	low-glycemic$$$2$$$14$$$O	available$$$15$$$24$$$O	carbohydrate$$$25$$$37$$$I	composition$$$38$$$49$$$O	of$$$50$$$52$$$O	the$$$53$$$56$$$O	invention$$$57$$$66$$$O	contains$$$67$$$75$$$O	the$$$76$$$79$$$O	following$$$80$$$89$$$O	components:$$$90$$$101$$$O	(i)$$$102$$$105$$$O	5-60$$$106$$$110$$$O	wt.%$$$111$$$115$$$O	of$$$116$$$118$$$O	one$$$119$$$122$$$O	or$$$123$$$125$$$O	more$$$126$$$130$$$O	monosaccharides$$$131$$$146$$$I	selected$$$147$$$155$$$O	from$$$156$$$160$$$O	monosaccharides$$$161$$$176$$$I	other$$$177$$$182$$$O	than$$$183$$$187$$$O	glucose$$$188$$$195$$$I	and$$$196$$$199$$$O	fructose,$$$200$$$209$$$I	in$$$210$$$212$$$O	particular$$$213$$$223$$$O	galactose,$$$224$$$234$$$I	ribose$$$235$$$241$$$I	and$$$242$$$245$$$O	mannose;$$$246$$$254$$$I	(ii)$$$255$$$259$$$O	15-95$$$260$$$265$$$O	wt.%$$$266$$$270$$$O	of$$$271$$$273$$$O	oligosaccharides$$$274$$$290$$$I	having$$$291$$$297$$$O	a$$$298$$$299$$$O	length$$$300$$$306$$$O	of$$$307$$$309$$$O	2$$$310$$$311$$$O	to$$$312$$$314$$$O	20$$$315$$$317$$$O	anhydromonose$$$318$$$331$$$O	units,$$$332$$$338$$$O	at$$$339$$$341$$$O	least$$$342$$$347$$$O	half$$$348$$$352$$$O	of$$$353$$$355$$$O	which$$$356$$$361$$$O	are$$$362$$$365$$$O	anhydroglucose$$$366$$$380$$$O	units$$$381$$$386$$$O	linked$$$387$$$393$$$O	by$$$394$$$396$$$O	non-Î±-1,4$$$397$$$407$$$O	bonds;$$$408$$$414$$$O	these$$$415$$$420$$$I	oligosaccharides$$$421$$$437$$$I	preferably$$$438$$$448$$$O	comprising$$$449$$$459$$$I	disaccharides$$$460$$$473$$$I	such$$$474$$$478$$$O	as$$$479$$$481$$$I	palatinose,$$$482$$$493$$$I	isomaltose$$$494$$$504$$$I	and$$$505$$$508$$$I	trehalose$$$509$$$518$$$I	and/or$$$519$$$525$$$O	non-Î±-1,4$$$526$$$536$$$O	linked$$$537$$$543$$$O	higher$$$544$$$550$$$I	glucose-containing$$$551$$$569$$$I	oligosaccharides;$$$570$$$587$$$I	(iii)$$$588$$$593$$$O	0-45$$$594$$$598$$$O	wt.%$$$599$$$603$$$O	of$$$604$$$606$$$O	other$$$607$$$612$$$O	available$$$613$$$622$$$I	carbohydrates,$$$623$$$637$$$I	such$$$638$$$642$$$O	as$$$643$$$645$$$I	glucose$$$646$$$653$$$I	and$$$654$$$657$$$O	maltodextrins.$$$658$$$672$$$O	This$$$677$$$681$$$I	carbohydrate$$$682$$$694$$$I	composition$$$695$$$706$$$O	can$$$707$$$710$$$O	be$$$711$$$713$$$O	part$$$714$$$718$$$O	of$$$719$$$721$$$O	a$$$722$$$723$$$O	foodcomposition$$$724$$$739$$$O	for$$$740$$$743$$$O	the$$$744$$$747$$$O	treatment$$$748$$$757$$$O	of$$$758$$$760$$$O	diabetes,$$$761$$$770$$$O	obesitas,$$$771$$$780$$$O	insulin$$$781$$$788$$$O	resistance,$$$789$$$800$$$O	or$$$801$$$803$$$O	for$$$804$$$807$$$O	postprandial$$$808$$$820$$$I	glucose$$$821$$$828$$$I	response.$$$829$$$838$$$O
US20130005785
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	treating$$$11$$$19$$$O	bacterial$$$20$$$29$$$O	vaginosis$$$30$$$39$$$O	with$$$40$$$44$$$O	aqueous-based$$$45$$$58$$$O	metronidazole$$$59$$$72$$$I	gel$$$73$$$76$$$O	formulations$$$77$$$89$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	provides$$$23$$$31$$$O	mucoadhesive$$$32$$$44$$$O	aqueous-based$$$45$$$58$$$O	gel$$$59$$$62$$$O	formulations$$$63$$$75$$$O	of$$$76$$$78$$$O	metronidazole$$$79$$$92$$$I	useful$$$93$$$99$$$O	for$$$100$$$103$$$O	a$$$104$$$105$$$O	variety$$$106$$$113$$$O	of$$$114$$$116$$$O	purposes,$$$117$$$126$$$O	including$$$127$$$136$$$O	intravaginal$$$137$$$149$$$O	application$$$150$$$161$$$O	as$$$162$$$164$$$O	a$$$165$$$166$$$O	therapeutic$$$167$$$178$$$O	approach$$$179$$$187$$$O	towards$$$188$$$195$$$O	the$$$196$$$199$$$O	treatment$$$200$$$209$$$O	of$$$210$$$212$$$O	individuals$$$213$$$224$$$O	suffering$$$225$$$234$$$O	from$$$235$$$239$$$O	and/or$$$240$$$246$$$O	diagnosed$$$247$$$256$$$O	with$$$257$$$261$$$O	bacterial$$$262$$$271$$$O	vaginosis.$$$272$$$282$$$O
US20090214529
Kinesin$$$0$$$7$$$O	inhibitors$$$8$$$18$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	the$$$26$$$29$$$O	compounds$$$30$$$39$$$O	of$$$40$$$42$$$O	formula$$$43$$$50$$$O	(I)$$$51$$$54$$$O	shown$$$55$$$60$$$O	below.$$$61$$$67$$$O	Each$$$68$$$72$$$O	variable$$$73$$$81$$$O	in$$$82$$$84$$$O	formula$$$85$$$92$$$O	(I)$$$93$$$96$$$O	is$$$97$$$99$$$O	defined$$$100$$$107$$$O	in$$$108$$$110$$$O	the$$$111$$$114$$$O	specification.$$$115$$$129$$$O	These$$$130$$$135$$$O	compounds$$$136$$$145$$$O	can$$$146$$$149$$$O	be$$$150$$$152$$$O	used$$$153$$$157$$$O	to$$$158$$$160$$$O	treat$$$161$$$166$$$O	a$$$167$$$168$$$O	kinesin$$$169$$$176$$$O	Eg5$$$177$$$180$$$O	protein-mediated$$$181$$$197$$$O	disorder.$$$198$$$207$$$O
EP1190248B1
Screening$$$0$$$9$$$O	methods$$$10$$$17$$$O	for$$$18$$$21$$$O	compounds$$$22$$$31$$$O	which$$$32$$$37$$$O	affect$$$38$$$44$$$O	melanogenesis$$$45$$$58$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	screening$$$11$$$20$$$O	for$$$21$$$24$$$O	compounds$$$25$$$34$$$O	that$$$35$$$39$$$O	affect$$$40$$$46$$$O	melanogenesis$$$47$$$60$$$O	and$$$61$$$64$$$O	the$$$65$$$68$$$O	function$$$69$$$77$$$O	of$$$78$$$80$$$O	P$$$81$$$82$$$O	protein$$$83$$$90$$$O	in$$$91$$$93$$$O	organisms,$$$94$$$104$$$O	cells,$$$105$$$111$$$O	or$$$112$$$114$$$O	cell-free$$$115$$$124$$$O	systems$$$125$$$132$$$O	are$$$133$$$136$$$O	provided.$$$137$$$146$$$O	The$$$147$$$150$$$O	invention$$$151$$$160$$$O	further$$$161$$$168$$$O	relates$$$169$$$176$$$O	to$$$177$$$179$$$O	the$$$180$$$183$$$O	pharmacologic$$$184$$$197$$$O	and$$$198$$$201$$$O	cosmetic$$$202$$$210$$$O	uses$$$211$$$215$$$O	of$$$216$$$218$$$O	such$$$219$$$223$$$O	compounds$$$224$$$233$$$O	to$$$234$$$236$$$O	reduce$$$237$$$243$$$O	or$$$244$$$246$$$O	increase$$$247$$$255$$$O	the$$$256$$$259$$$O	synthesis$$$260$$$269$$$O	of$$$270$$$272$$$O	melanin$$$273$$$280$$$O	in$$$281$$$283$$$O	animal$$$284$$$290$$$O	and$$$291$$$294$$$O	human$$$295$$$300$$$O	melanocytes$$$301$$$312$$$O	and$$$313$$$316$$$O	melanocyte-derived$$$317$$$335$$$O	cells.$$$336$$$342$$$O
WO2008124907A3
Resveratrol-containing$$$0$$$22$$$I	composition$$$23$$$34$$$O	for$$$35$$$38$$$O	modulating$$$39$$$49$$$O	bone$$$50$$$54$$$O	formation$$$55$$$64$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	pharmaceutical$$$33$$$47$$$O	product$$$48$$$55$$$O	and$$$56$$$59$$$O	a$$$60$$$61$$$O	process$$$62$$$69$$$O	for$$$70$$$73$$$O	bone$$$74$$$78$$$O	regeneration$$$79$$$91$$$O	and$$$92$$$95$$$O	neoformation,$$$96$$$109$$$O	which$$$110$$$115$$$O	uses$$$116$$$120$$$O	sirtuin$$$121$$$128$$$O	modulators$$$129$$$139$$$O	such$$$140$$$144$$$O	as$$$145$$$147$$$O	resveratrol$$$148$$$159$$$I	and/or$$$160$$$166$$$O	trans-resveratrol.$$$167$$$185$$$I	Among$$$186$$$191$$$O	the$$$192$$$195$$$O	several$$$196$$$203$$$O	advantages$$$204$$$214$$$O	of$$$215$$$217$$$O	the$$$218$$$221$$$O	invention,$$$222$$$232$$$O	worth$$$233$$$238$$$O	of$$$239$$$241$$$O	notice$$$242$$$248$$$O	is$$$249$$$251$$$O	the$$$252$$$255$$$O	substantial$$$256$$$267$$$O	acceleration$$$268$$$280$$$O	in$$$281$$$283$$$O	the$$$284$$$287$$$O	process$$$288$$$295$$$O	of$$$296$$$298$$$O	integration$$$299$$$310$$$O	of$$$311$$$313$$$O	biomaterials$$$314$$$326$$$O	to$$$327$$$329$$$O	the$$$330$$$333$$$O	body,$$$334$$$339$$$O	substantially$$$340$$$353$$$O	shortening$$$354$$$364$$$O	the$$$365$$$368$$$O	recovery$$$369$$$377$$$O	period$$$378$$$384$$$O	of$$$385$$$387$$$O	the$$$388$$$391$$$O	injured$$$392$$$399$$$O	or$$$400$$$402$$$O	lost$$$403$$$407$$$O	organ.$$$408$$$414$$$O
WO2014080633A1
Polymorph$$$0$$$9$$$O	forms$$$10$$$15$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	crystal$$$39$$$46$$$O	forms$$$47$$$52$$$O	of$$$53$$$55$$$O	4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic$$$56$$$179$$$I	acid.$$$180$$$185$$$I	More$$$186$$$190$$$O	particularly,$$$191$$$204$$$O	the$$$205$$$208$$$O	invention$$$209$$$218$$$O	relates$$$219$$$226$$$O	to$$$227$$$229$$$O	polymorph$$$230$$$239$$$O	forms$$$240$$$245$$$O	(Polymorph$$$246$$$256$$$O	Form$$$257$$$261$$$O	I,$$$262$$$264$$$O	Polymorph$$$265$$$274$$$O	Form$$$275$$$279$$$O	II,$$$280$$$283$$$O	Polymorph$$$284$$$293$$$O	Form$$$294$$$298$$$O	III,$$$299$$$303$$$O	Polymorph$$$304$$$313$$$O	Form$$$314$$$318$$$O	IV,$$$319$$$322$$$O	Polymorph$$$323$$$332$$$O	Form$$$333$$$337$$$O	V,$$$338$$$340$$$O	and$$$341$$$344$$$O	Polymorph$$$345$$$354$$$O	Form$$$355$$$359$$$O	VI),$$$360$$$364$$$O	and$$$365$$$368$$$O	to$$$369$$$371$$$O	processes$$$372$$$381$$$O	for$$$382$$$385$$$O	the$$$386$$$389$$$O	preparation$$$390$$$401$$$O	of,$$$402$$$405$$$O	compositions$$$406$$$418$$$O	containing$$$419$$$429$$$O	and$$$430$$$433$$$O	to$$$434$$$436$$$O	uses$$$437$$$441$$$O	of,$$$442$$$445$$$O	such$$$446$$$450$$$O	polymorph$$$451$$$460$$$O	forms.$$$461$$$467$$$O
US7772212
Isomaltooligosaccharides$$$0$$$24$$$I	to$$$25$$$27$$$O	inhibit$$$28$$$35$$$O	avian$$$36$$$41$$$O	pathogenic$$$42$$$52$$$O	intestinal$$$53$$$63$$$O	bacteria$$$64$$$72$$$O
Isomaltooligosaccharides$$$0$$$24$$$I	(IMOs)$$$25$$$31$$$I	produced$$$32$$$40$$$O	by$$$41$$$43$$$O	Leuconostoc$$$44$$$55$$$O	mesenteroides$$$56$$$69$$$O	ATCC$$$70$$$74$$$O	13146$$$75$$$80$$$O	fermentation$$$81$$$93$$$O	with$$$94$$$98$$$O	a$$$99$$$100$$$O	sucrose:maltose$$$101$$$116$$$I	ratio$$$117$$$122$$$O	of$$$123$$$125$$$O	2:1$$$126$$$129$$$O	have$$$130$$$134$$$O	been$$$135$$$139$$$O	discovered$$$140$$$150$$$O	to$$$151$$$153$$$O	be$$$154$$$156$$$O	effective$$$157$$$166$$$O	prebiotics$$$167$$$177$$$O	in$$$178$$$180$$$O	mixed$$$181$$$186$$$O	cultures$$$187$$$195$$$O	of$$$196$$$198$$$O	microbial$$$199$$$208$$$O	populations,$$$209$$$221$$$O	including$$$222$$$231$$$O	cultures$$$232$$$240$$$O	from$$$241$$$245$$$O	chicken$$$246$$$253$$$O	ceca.$$$254$$$259$$$O	Surprisingly$$$260$$$272$$$O	in$$$273$$$275$$$O	mixed$$$276$$$281$$$O	microbial$$$282$$$291$$$O	cultures$$$292$$$300$$$O	this$$$301$$$305$$$O	IMO$$$306$$$309$$$I	composition$$$310$$$321$$$O	proved$$$322$$$328$$$O	as$$$329$$$331$$$O	effective$$$332$$$341$$$O	as$$$342$$$344$$$O	FOS.$$$345$$$349$$$O	Thus,$$$350$$$355$$$O	these$$$356$$$361$$$O	IMOs$$$362$$$366$$$I	can$$$367$$$370$$$O	be$$$371$$$373$$$O	used$$$374$$$378$$$O	as$$$379$$$381$$$O	effective$$$382$$$391$$$O	prebiotics$$$392$$$402$$$O	for$$$403$$$406$$$O	both$$$407$$$411$$$O	birds$$$412$$$417$$$O	and$$$418$$$421$$$O	mammals.$$$422$$$430$$$O	Moreover,$$$431$$$440$$$O	the$$$441$$$444$$$O	IMOs$$$445$$$449$$$I	were$$$450$$$454$$$O	discovered$$$455$$$465$$$O	to$$$466$$$468$$$O	be$$$469$$$471$$$O	effective$$$472$$$481$$$O	non-competitive$$$482$$$497$$$O	inhibitors$$$498$$$508$$$O	of$$$509$$$511$$$O	Î±-glucosidase.$$$512$$$527$$$O	These$$$528$$$533$$$I	IMOs$$$534$$$538$$$I	also$$$539$$$543$$$O	will$$$544$$$548$$$O	be$$$549$$$551$$$O	useful,$$$552$$$559$$$O	as$$$560$$$562$$$O	an$$$563$$$565$$$O	Î±-glucosidase$$$566$$$580$$$O	inhibitor,$$$581$$$591$$$O	in$$$592$$$594$$$O	a$$$595$$$596$$$O	therapeutic$$$597$$$608$$$O	application$$$609$$$620$$$O	for$$$621$$$624$$$O	several$$$625$$$632$$$O	diseases,$$$633$$$642$$$O	including$$$643$$$652$$$O	obesity,$$$653$$$661$$$O	diabetes$$$662$$$670$$$O	mellitus,$$$671$$$680$$$O	pre-diabetes,$$$681$$$694$$$O	gastritis,$$$695$$$705$$$O	gastric$$$706$$$713$$$O	ulcer,$$$714$$$720$$$O	duodenal$$$721$$$729$$$O	ulcer,$$$730$$$736$$$O	caries,$$$737$$$744$$$O	cancer,$$$745$$$752$$$O	viral$$$753$$$758$$$O	disease$$$759$$$766$$$O	such$$$767$$$771$$$O	as$$$772$$$774$$$O	hepatitis$$$775$$$784$$$O	B$$$785$$$786$$$O	and$$$787$$$790$$$O	C,$$$791$$$793$$$O	HIV,$$$794$$$798$$$O	and$$$799$$$802$$$O	AIDS.$$$803$$$808$$$O	A$$$809$$$810$$$O	diet$$$811$$$815$$$O	with$$$816$$$820$$$O	5-20%$$$821$$$826$$$I	IMOs$$$827$$$831$$$I	was$$$832$$$835$$$O	also$$$836$$$840$$$O	shown$$$841$$$846$$$O	to$$$847$$$849$$$O	reduce$$$850$$$856$$$O	the$$$857$$$860$$$O	abdominal$$$861$$$870$$$O	fat$$$871$$$874$$$O	tissue$$$875$$$881$$$O	in$$$882$$$884$$$O	mammals.$$$885$$$893$$$O
US20060234977
Antiviral$$$0$$$9$$$O	compostion$$$10$$$20$$$O	comprising$$$21$$$31$$$O	a$$$32$$$33$$$O	sulphated$$$34$$$43$$$O	glucose$$$44$$$51$$$I	polymer$$$52$$$59$$$O	and$$$60$$$63$$$O	a$$$64$$$65$$$O	bacteriostatic$$$66$$$80$$$O	agent$$$81$$$86$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	described$$$9$$$18$$$O	a$$$19$$$20$$$O	pharmaceutical$$$21$$$35$$$O	composition$$$36$$$47$$$O	comprising$$$48$$$58$$$O	a$$$59$$$60$$$O	glucose$$$61$$$68$$$I	polymer$$$69$$$76$$$O	or$$$77$$$79$$$O	a$$$80$$$81$$$O	mixture$$$82$$$89$$$O	of$$$90$$$92$$$O	glucose$$$93$$$100$$$I	polymers$$$101$$$109$$$O	and$$$110$$$113$$$O	optionally,$$$114$$$125$$$O	salts$$$126$$$131$$$O	thereof$$$132$$$139$$$O	and$$$140$$$143$$$O	a$$$144$$$145$$$O	non-sensitising$$$146$$$161$$$O	bacteriostatic$$$162$$$176$$$O	agent,$$$177$$$183$$$O	such$$$184$$$188$$$O	as$$$189$$$191$$$O	sorbic$$$192$$$198$$$I	acid.$$$199$$$204$$$I	There$$$205$$$210$$$O	is$$$211$$$213$$$O	also$$$214$$$218$$$O	described$$$219$$$228$$$O	a$$$229$$$230$$$O	method$$$231$$$237$$$O	of$$$238$$$240$$$O	treatment,$$$241$$$251$$$O	alleviation$$$252$$$263$$$O	or$$$264$$$266$$$O	prevention$$$267$$$277$$$O	of$$$278$$$280$$$O	HIV-1$$$281$$$286$$$O	or$$$287$$$289$$$O	a$$$290$$$291$$$O	related$$$292$$$299$$$O	virus$$$300$$$305$$$O	or$$$306$$$308$$$O	other$$$309$$$314$$$O	sexually$$$315$$$323$$$O	transmitted$$$324$$$335$$$O	diseases$$$336$$$344$$$O	by$$$345$$$347$$$O	the$$$348$$$351$$$O	administration$$$352$$$366$$$O	of$$$367$$$369$$$O	a$$$370$$$371$$$O	such$$$372$$$376$$$O	a$$$377$$$378$$$O	composition.$$$379$$$391$$$O
CN101810615A
Azatadine-containing$$$0$$$20$$$I	composition$$$21$$$32$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	azatadine-containing$$$28$$$48$$$I	composition,$$$49$$$61$$$O	the$$$62$$$65$$$O	active$$$66$$$72$$$O	component$$$73$$$82$$$O	of$$$83$$$85$$$O	which$$$86$$$91$$$O	is$$$92$$$94$$$O	of$$$95$$$97$$$O	azatadine.$$$98$$$108$$$I	Assistant$$$109$$$118$$$O	of$$$119$$$121$$$O	the$$$122$$$125$$$O	composition$$$126$$$137$$$O	comprises$$$138$$$147$$$O	poloxamer,$$$148$$$158$$$O	acetamide,$$$159$$$169$$$I	polysorbate-80,$$$170$$$185$$$I	polyvinyl$$$186$$$195$$$I	alcohol,$$$196$$$204$$$I	sorbierite,$$$205$$$216$$$I	monoprop,$$$217$$$226$$$O	saccharin$$$227$$$236$$$I	sodium$$$237$$$243$$$I	and$$$244$$$247$$$O	strawberry$$$248$$$258$$$O	essence.$$$259$$$267$$$O	The$$$268$$$271$$$O	azatadine-containing$$$272$$$292$$$I	composition$$$293$$$304$$$O	has$$$305$$$308$$$O	good$$$309$$$313$$$O	curative$$$314$$$322$$$O	effect$$$323$$$329$$$O	and$$$330$$$333$$$O	small$$$334$$$339$$$O	toxic$$$340$$$345$$$O	and$$$346$$$349$$$O	side$$$350$$$354$$$O	effect,$$$355$$$362$$$O	and$$$363$$$366$$$O	is$$$367$$$369$$$O	particularly$$$370$$$382$$$O	applicable$$$383$$$393$$$O	to$$$394$$$396$$$O	the$$$397$$$400$$$O	children$$$401$$$409$$$O	and$$$410$$$413$$$O	the$$$414$$$417$$$O	old$$$418$$$421$$$O	people.$$$422$$$429$$$O
CN101235373A
RG$$$0$$$2$$$O	gene$$$3$$$7$$$O	sequence$$$8$$$16$$$O	for$$$17$$$20$$$O	diffusivity$$$21$$$32$$$O	large$$$33$$$38$$$O	B$$$39$$$40$$$O	cell$$$41$$$45$$$O	lymphoma$$$46$$$54$$$O	correlation$$$55$$$66$$$O	antigen$$$67$$$74$$$O	specific$$$75$$$83$$$O	TCR$$$84$$$87$$$O	Vbeta13$$$88$$$95$$$O	subfamily$$$96$$$105$$$O	and$$$106$$$109$$$O	application$$$110$$$121$$$O	thereof$$$122$$$129$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	nucleotide$$$26$$$36$$$I	sequence$$$37$$$45$$$O	which$$$46$$$51$$$O	aims$$$52$$$56$$$O	at$$$57$$$59$$$O	the$$$60$$$63$$$O	specificity$$$64$$$75$$$O	T$$$76$$$77$$$O	cell$$$78$$$82$$$O	receptor$$$83$$$91$$$O	of$$$92$$$94$$$O	relative$$$95$$$103$$$O	antigen$$$104$$$111$$$O	of$$$112$$$114$$$O	diffuse$$$115$$$122$$$O	large$$$123$$$128$$$O	b-cell$$$129$$$135$$$O	lymphoma$$$136$$$144$$$O	and$$$145$$$148$$$O	the$$$149$$$152$$$O	application,$$$153$$$165$$$O	TCR$$$166$$$169$$$O	V$$$170$$$171$$$O	beta$$$172$$$176$$$O	13$$$177$$$179$$$O	sub-family$$$180$$$190$$$O	in$$$191$$$193$$$O	peripheral$$$194$$$204$$$O	blood$$$205$$$210$$$O	of$$$211$$$213$$$O	DLBL$$$214$$$218$$$O	patients$$$219$$$227$$$O	is$$$228$$$230$$$O	scanned$$$231$$$238$$$O	and$$$239$$$242$$$O	analyzed$$$243$$$251$$$O	to$$$252$$$254$$$O	take$$$255$$$259$$$O	obvious$$$260$$$267$$$O	monoclone$$$268$$$277$$$O	through$$$278$$$285$$$O	RT-PCR$$$286$$$292$$$O	gens,$$$293$$$298$$$O	a$$$299$$$300$$$O	V-NDN-J$$$301$$$308$$$O	area$$$309$$$313$$$O	of$$$314$$$316$$$O	specificity$$$317$$$328$$$O	TCR$$$329$$$332$$$O	sequence$$$333$$$341$$$O	for$$$342$$$345$$$O	sequencing$$$346$$$356$$$O	PCR$$$357$$$360$$$O	products$$$361$$$369$$$O	namely$$$370$$$376$$$O	a$$$377$$$378$$$O	complementary-determining$$$379$$$404$$$O	region$$$405$$$411$$$O	3$$$412$$$413$$$O	is$$$414$$$416$$$O	a$$$417$$$418$$$O	portion$$$419$$$426$$$O	which$$$427$$$432$$$O	combines$$$433$$$441$$$O	with$$$442$$$446$$$O	antigen$$$447$$$454$$$O	specificity$$$455$$$466$$$O	recognition,$$$467$$$479$$$O	which$$$480$$$485$$$O	expresses$$$486$$$495$$$O	specificity$$$496$$$507$$$O	TCR$$$508$$$511$$$O	which$$$512$$$517$$$O	is$$$518$$$520$$$O	produced$$$521$$$529$$$O	by$$$530$$$532$$$O	the$$$533$$$536$$$O	stimulation$$$537$$$548$$$O	of$$$549$$$551$$$O	TCR$$$552$$$555$$$O	of$$$556$$$558$$$O	clonal$$$559$$$565$$$O	T$$$566$$$567$$$O	cell$$$568$$$572$$$O	for$$$573$$$576$$$O	relative$$$577$$$585$$$O	antigen$$$586$$$593$$$O	of$$$594$$$596$$$O	DLBL.$$$597$$$602$$$O	The$$$603$$$606$$$O	nucleotide$$$607$$$617$$$I	sequence$$$618$$$626$$$O	is$$$627$$$629$$$O	a$$$630$$$631$$$O	base$$$632$$$636$$$O	and$$$637$$$640$$$O	a$$$641$$$642$$$O	key$$$643$$$646$$$O	for$$$647$$$650$$$O	adoptive$$$651$$$659$$$O	cellular$$$660$$$668$$$O	immunotherapy$$$669$$$682$$$O	of$$$683$$$685$$$O	DLBL$$$686$$$690$$$O	molecular$$$691$$$700$$$O	target$$$701$$$707$$$O	through$$$708$$$715$$$O	TCR$$$716$$$719$$$O	transgenic$$$720$$$730$$$O	technology.$$$731$$$742$$$O	The$$$743$$$746$$$O	nucleotide$$$747$$$757$$$I	sequence$$$758$$$766$$$O	of$$$767$$$769$$$O	the$$$770$$$773$$$O	specificity$$$774$$$785$$$O	TCR$$$786$$$789$$$O	is$$$790$$$792$$$O	an$$$793$$$795$$$O	important$$$796$$$805$$$O	base$$$806$$$810$$$O	for$$$811$$$814$$$O	further$$$815$$$822$$$O	developing$$$823$$$833$$$O	specific$$$834$$$842$$$O	cell$$$843$$$847$$$O	immunization$$$848$$$860$$$O	therapy$$$861$$$868$$$O	which$$$869$$$874$$$O	aims$$$875$$$879$$$O	at$$$880$$$882$$$O	lymphoma.$$$883$$$892$$$O
CN103724262A
Fluoroquinolonesilver$$$0$$$21$$$I	compound$$$22$$$30$$$O	as$$$31$$$33$$$O	well$$$34$$$38$$$O	as$$$39$$$41$$$O	preparation$$$42$$$53$$$O	method$$$54$$$60$$$O	and$$$61$$$64$$$O	application$$$65$$$76$$$O	thereof$$$77$$$84$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	fluoroquinolonesilver,$$$25$$$47$$$I	and$$$48$$$51$$$O	a$$$52$$$53$$$O	preparation$$$54$$$65$$$O	method$$$66$$$72$$$O	and$$$73$$$76$$$O	medical$$$77$$$84$$$O	application$$$85$$$96$$$O	of$$$97$$$99$$$O	the$$$100$$$103$$$O	fluoroquinolonesilver.$$$104$$$126$$$I	The$$$127$$$130$$$O	fluoroquinolonesilver$$$131$$$152$$$I	has$$$153$$$156$$$O	a$$$157$$$158$$$O	structure$$$159$$$168$$$O	shown$$$169$$$174$$$O	in$$$175$$$177$$$O	a$$$178$$$179$$$O	general$$$180$$$187$$$O	formula$$$188$$$195$$$O	(I)$$$196$$$199$$$O	(refer$$$200$$$206$$$O	to$$$207$$$209$$$O	the$$$210$$$213$$$O	Specification).$$$214$$$229$$$O	Silver$$$230$$$236$$$I	ions$$$237$$$241$$$I	and$$$242$$$245$$$O	fluoroquinolone$$$246$$$261$$$I	are$$$262$$$265$$$O	combined$$$266$$$274$$$O	together,$$$275$$$284$$$O	and$$$285$$$288$$$O	through$$$289$$$296$$$O	the$$$297$$$300$$$O	synergistic$$$301$$$312$$$O	effect$$$313$$$319$$$O	of$$$320$$$322$$$O	the$$$323$$$326$$$O	silver$$$327$$$333$$$O	ions$$$334$$$338$$$O	and$$$339$$$342$$$O	fluoroquinolone,$$$343$$$359$$$I	the$$$360$$$363$$$O	antibacterial$$$364$$$377$$$O	effect$$$378$$$384$$$O	is$$$385$$$387$$$O	further$$$388$$$395$$$O	enhanced,$$$396$$$405$$$O	and$$$406$$$409$$$O	the$$$410$$$413$$$O	problem$$$414$$$421$$$O	of$$$422$$$424$$$O	the$$$425$$$428$$$O	drug$$$429$$$433$$$O	resistance$$$434$$$444$$$O	of$$$445$$$447$$$O	the$$$448$$$451$$$O	existing$$$452$$$460$$$O	fluoroquinolone$$$461$$$476$$$I	drugs$$$477$$$482$$$O	can$$$483$$$486$$$O	be$$$487$$$489$$$O	solved$$$490$$$496$$$O	to$$$497$$$499$$$O	a$$$500$$$501$$$O	certain$$$502$$$509$$$O	degree.$$$510$$$517$$$O	The$$$518$$$521$$$O	fluoroquinolonesilver$$$522$$$543$$$I	is$$$544$$$546$$$O	simple$$$547$$$553$$$O	in$$$554$$$556$$$O	preparation$$$557$$$568$$$O	process,$$$569$$$577$$$O	and$$$578$$$581$$$O	stable$$$582$$$588$$$O	in$$$589$$$591$$$O	productivity(refer$$$592$$$610$$$O	to$$$611$$$613$$$O	the$$$614$$$617$$$O	Specification$$$618$$$631$$$O	for$$$632$$$635$$$O	the$$$636$$$639$$$O	formula$$$640$$$647$$$O	I).$$$648$$$651$$$O
CA2460135C
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	pyridazinone$$$7$$$19$$$I	compounds$$$20$$$29$$$O	as$$$30$$$32$$$O	phosphodiesterase$$$33$$$50$$$O	iv$$$51$$$53$$$O	inhibitors$$$54$$$64$$$O	for$$$65$$$68$$$O	treating$$$69$$$77$$$O	cancer$$$78$$$84$$$O	and$$$85$$$88$$$O	other$$$89$$$94$$$O	diseases$$$95$$$103$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	Phosphodiesterase$$$36$$$53$$$O	IV$$$54$$$56$$$O	inhibitors$$$57$$$67$$$O	and/or$$$68$$$74$$$O	the$$$75$$$78$$$O	physiologically$$$79$$$94$$$O	acceptable$$$95$$$105$$$O	salts$$$106$$$111$$$O	thereof$$$112$$$119$$$O	in$$$120$$$122$$$O	the$$$123$$$126$$$O	production$$$127$$$137$$$O	of$$$138$$$140$$$O	a$$$141$$$142$$$O	medicament$$$143$$$153$$$O	for$$$154$$$157$$$O	the$$$158$$$161$$$O	treatment$$$162$$$171$$$O	of$$$172$$$174$$$O	osteoporosis,$$$175$$$188$$$O	tumors,$$$189$$$196$$$O	tumor$$$197$$$202$$$O	metastases,$$$203$$$214$$$O	atherosclerosis,$$$215$$$231$$$O	rheumatoid$$$232$$$242$$$O	arthritis,$$$243$$$253$$$O	multiple$$$254$$$262$$$O	sclerosis,$$$263$$$273$$$O	diabetes$$$274$$$282$$$O	mellitus,$$$283$$$292$$$O	ulzerative$$$293$$$303$$$O	colitis$$$304$$$311$$$O	and$$$312$$$315$$$O	AIDS.$$$316$$$321$$$O
EP1690852A1
Novel$$$0$$$5$$$O	target$$$6$$$12$$$O	protein$$$13$$$20$$$O	of$$$21$$$23$$$O	anticancer$$$24$$$34$$$O	agent$$$35$$$40$$$O	and$$$41$$$44$$$O	novel$$$45$$$50$$$O	anticancer$$$51$$$61$$$O	agent$$$62$$$67$$$O	(spnal)$$$68$$$75$$$O	corresponding$$$76$$$89$$$O	thereto$$$90$$$97$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	pharmaceutical$$$33$$$47$$$O	composition$$$48$$$59$$$O	containing,$$$60$$$71$$$O	as$$$72$$$74$$$O	an$$$75$$$77$$$O	active$$$78$$$84$$$O	ingredient,$$$85$$$96$$$O	a$$$97$$$98$$$O	compound$$$99$$$107$$$O	that$$$108$$$112$$$O	specifically$$$113$$$125$$$O	binds$$$126$$$131$$$O	to$$$132$$$134$$$O	KSRP$$$135$$$139$$$O	or$$$140$$$142$$$O	a$$$143$$$144$$$O	functional$$$145$$$155$$$O	fragment$$$156$$$164$$$O	thereof,$$$165$$$173$$$O	and$$$174$$$177$$$O	a$$$178$$$179$$$O	screening$$$180$$$189$$$O	method$$$190$$$196$$$O	for$$$197$$$200$$$O	the$$$201$$$204$$$O	compound.$$$205$$$214$$$O	KSRP$$$215$$$219$$$O	is$$$220$$$222$$$O	a$$$223$$$224$$$O	novel$$$225$$$230$$$O	target$$$231$$$237$$$O	protein$$$238$$$245$$$O	for$$$246$$$249$$$O	anticancer$$$250$$$260$$$O	agents;$$$261$$$268$$$O	a$$$269$$$270$$$O	compound$$$271$$$279$$$O	capable$$$280$$$287$$$O	of$$$288$$$290$$$O	regulating$$$291$$$301$$$O	the$$$302$$$305$$$O	expression$$$306$$$316$$$O	and$$$317$$$320$$$O	activity$$$321$$$329$$$O	of$$$330$$$332$$$O	such$$$333$$$337$$$O	a$$$338$$$339$$$O	protein$$$340$$$347$$$O	and$$$348$$$351$$$O	a$$$352$$$353$$$O	pharmaceutical$$$354$$$368$$$O	composition$$$369$$$380$$$O	containing$$$381$$$391$$$O	it$$$392$$$394$$$O	are$$$395$$$398$$$O	highly$$$399$$$405$$$O	useful$$$406$$$412$$$O	for$$$413$$$416$$$O	proliferative$$$417$$$430$$$O	diseases,$$$431$$$440$$$O	particularly$$$441$$$453$$$O	as$$$454$$$456$$$O	anticancer$$$457$$$467$$$O	agents.$$$468$$$475$$$O	By$$$476$$$478$$$O	providing$$$479$$$488$$$O	the$$$489$$$492$$$O	novel$$$493$$$498$$$O	target$$$499$$$505$$$O	protein,$$$506$$$514$$$O	the$$$515$$$518$$$O	mechanism$$$519$$$528$$$O	behind$$$529$$$535$$$O	the$$$536$$$539$$$O	anticancer$$$540$$$550$$$O	effect$$$551$$$557$$$O	that$$$558$$$562$$$O	has$$$563$$$566$$$O	conventionally$$$567$$$581$$$O	been$$$582$$$586$$$O	unexplainable$$$587$$$600$$$O	can$$$601$$$604$$$O	be$$$605$$$607$$$O	elucidated.$$$608$$$619$$$O
US20090318472
Aminopyrazine$$$0$$$13$$$I	derivatives$$$14$$$25$$$O	and$$$26$$$29$$$O	compositions$$$30$$$42$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	aminopyrazine$$$33$$$46$$$I	derivatives,$$$47$$$59$$$O	compositions$$$60$$$72$$$O	and$$$73$$$76$$$O	medicaments$$$77$$$88$$$O	containing$$$89$$$99$$$O	the$$$100$$$103$$$O	same,$$$104$$$109$$$O	as$$$110$$$112$$$O	well$$$113$$$117$$$O	as$$$118$$$120$$$O	processes$$$121$$$130$$$O	for$$$131$$$134$$$O	the$$$135$$$138$$$O	preparation$$$139$$$150$$$O	and$$$151$$$154$$$O	use$$$155$$$158$$$O	of$$$159$$$161$$$O	such$$$162$$$166$$$O	compounds,$$$167$$$177$$$O	compositions$$$178$$$190$$$O	and$$$191$$$194$$$O	medicaments.$$$195$$$207$$$O	Such$$$208$$$212$$$O	aminopyrazine$$$213$$$226$$$I	derivatives$$$227$$$238$$$O	are$$$239$$$242$$$O	useful$$$243$$$249$$$O	in$$$250$$$252$$$O	the$$$253$$$256$$$O	treatment$$$257$$$266$$$O	of$$$267$$$269$$$O	diseases$$$270$$$278$$$O	associated$$$279$$$289$$$O	with$$$290$$$294$$$O	inappropriate$$$295$$$308$$$O	tyrosine$$$309$$$317$$$I	and/or$$$318$$$324$$$O	serine/threonine$$$325$$$341$$$I	kinase$$$342$$$348$$$O	activity.$$$349$$$358$$$O
DE102007037018A1
Composition,$$$0$$$12$$$O	useful$$$13$$$19$$$O	for$$$20$$$23$$$O	treating$$$24$$$32$$$O	or$$$33$$$35$$$O	caring$$$36$$$42$$$O	skin$$$43$$$47$$$O	and$$$48$$$51$$$O	hair,$$$52$$$57$$$O	comprises$$$58$$$67$$$O	nitro-carbonyl$$$68$$$82$$$I	compound$$$83$$$91$$$O	and$$$92$$$95$$$O	further$$$96$$$103$$$O	e.g.$$$104$$$108$$$O	monoalcohol,$$$109$$$121$$$I	polyol,$$$122$$$129$$$I	diethanolamine,$$$130$$$145$$$I	fatty$$$146$$$151$$$I	acid,$$$152$$$157$$$I	silicon$$$158$$$165$$$I	substituted$$$166$$$177$$$O	compound$$$178$$$186$$$O	and$$$187$$$190$$$O	nonionic$$$191$$$199$$$O	emulsifier$$$200$$$210$$$O
Composition$$$0$$$11$$$O	(I)$$$12$$$15$$$O	comprises$$$16$$$25$$$O	one$$$26$$$29$$$O	or$$$30$$$32$$$O	more$$$33$$$37$$$O	nitro-carbonyl$$$38$$$52$$$I	compound$$$53$$$61$$$O	(II).$$$62$$$67$$$O	Composition$$$68$$$79$$$O	(I)$$$80$$$83$$$O	comprises$$$84$$$93$$$O	one$$$94$$$97$$$O	or$$$98$$$100$$$O	more$$$101$$$105$$$O	nitro-carbonyl$$$106$$$120$$$I	compound$$$121$$$129$$$O	of$$$130$$$132$$$O	formula$$$133$$$140$$$O	(R$$$141$$$143$$$O	1>-C(=O)-O-(CH$$$144$$$158$$$I	2)$$$159$$$161$$$I	2-N$$$162$$$165$$$I	+>(CH$$$166$$$171$$$I	3)$$$172$$$174$$$I	2-(CH$$$175$$$180$$$I	2)$$$181$$$183$$$I	2-O-C(=O)-R$$$184$$$195$$$I	2>)$$$196$$$199$$$O	(II).$$$200$$$205$$$O	R$$$206$$$207$$$O	1>,$$$208$$$211$$$O	R$$$212$$$213$$$O	2>18-24C,$$$214$$$223$$$I	preferably$$$224$$$234$$$O	17-23C-acyl;$$$235$$$247$$$I	and$$$248$$$251$$$O	A$$$252$$$253$$$O	->a$$$254$$$257$$$O	counter$$$258$$$265$$$O	ion,$$$266$$$270$$$O	preferably$$$271$$$281$$$O	Cl,$$$282$$$285$$$I	methosulfate$$$286$$$298$$$I	(both$$$299$$$304$$$O	preferred),$$$305$$$316$$$O	Br,$$$317$$$320$$$I	tosylate,$$$321$$$330$$$I	phosphate,$$$331$$$341$$$I	sulfate,$$$342$$$350$$$I	hydrogen$$$351$$$359$$$I	sulfate,$$$360$$$368$$$I	lactate$$$369$$$376$$$I	or$$$377$$$379$$$O	citrate.$$$380$$$388$$$I
US20120076859
Targeted$$$0$$$8$$$O	Lung$$$9$$$13$$$O	Delivery$$$14$$$22$$$O	of$$$23$$$25$$$O	Citrulline$$$26$$$36$$$O	and/or$$$37$$$43$$$O	Another$$$44$$$51$$$O	Nitric$$$52$$$58$$$I	Oxide$$$59$$$64$$$I	Precursor$$$65$$$74$$$O	and$$$75$$$78$$$O	a$$$79$$$80$$$O	Method$$$81$$$87$$$O	for$$$88$$$91$$$O	Treatment$$$92$$$101$$$O	of$$$102$$$104$$$O	Pulmonary$$$105$$$114$$$O	Deficiency$$$115$$$125$$$O	of$$$126$$$128$$$O	Nitric$$$129$$$135$$$I	Oxide$$$136$$$141$$$I	in$$$142$$$144$$$O	Cystic$$$145$$$151$$$O	Fibrosis$$$152$$$160$$$O	and$$$161$$$164$$$O	Other$$$165$$$170$$$O	Pulmonary$$$171$$$180$$$O	Diseases$$$181$$$189$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	treatment$$$12$$$21$$$O	of$$$22$$$24$$$O	cystic$$$25$$$31$$$O	fibrosis$$$32$$$40$$$O	and$$$41$$$44$$$O	other$$$45$$$50$$$O	pulmonary$$$51$$$60$$$O	diseases$$$61$$$69$$$O	identified$$$70$$$80$$$O	by$$$81$$$83$$$O	nitric$$$84$$$90$$$I	oxide$$$91$$$96$$$I	deficiency,$$$97$$$108$$$O	comprising$$$109$$$119$$$O	administration$$$120$$$134$$$O	of$$$135$$$137$$$O	a$$$138$$$139$$$O	nebulized$$$140$$$149$$$O	solution$$$150$$$158$$$O	of$$$159$$$161$$$O	citrulline$$$162$$$172$$$I	and/or$$$173$$$179$$$O	another$$$180$$$187$$$O	nitric$$$188$$$194$$$I	oxide$$$195$$$200$$$I	precursor$$$201$$$210$$$O	as$$$211$$$213$$$O	an$$$214$$$216$$$O	inhalable$$$217$$$226$$$O	aerosol$$$227$$$234$$$O	or$$$235$$$237$$$O	an$$$238$$$240$$$O	inhalable$$$241$$$250$$$O	dry$$$251$$$254$$$O	powder$$$255$$$261$$$O	for$$$262$$$265$$$O	targeted$$$266$$$274$$$O	delivery$$$275$$$283$$$O	into$$$284$$$288$$$O	conducting$$$289$$$299$$$O	and$$$300$$$303$$$O	central$$$304$$$311$$$O	airways.$$$312$$$320$$$O	Citrulline$$$321$$$331$$$I	or$$$332$$$334$$$O	another$$$335$$$342$$$O	nitric$$$343$$$349$$$I	oxide$$$350$$$355$$$I	precursor$$$356$$$365$$$O	is$$$366$$$368$$$O	formulated$$$369$$$379$$$O	as$$$380$$$382$$$O	a$$$383$$$384$$$O	composition$$$385$$$396$$$O	having$$$397$$$403$$$O	predetermined$$$404$$$417$$$O	limited$$$418$$$425$$$O	volume,$$$426$$$433$$$O	salinity,$$$434$$$443$$$O	pH$$$444$$$446$$$O	and$$$447$$$450$$$O	osmolality.$$$451$$$462$$$O	The$$$463$$$466$$$O	composition$$$467$$$478$$$O	is$$$479$$$481$$$O	nebulized$$$482$$$491$$$O	into$$$492$$$496$$$O	an$$$497$$$499$$$O	aerosol$$$500$$$507$$$O	having$$$508$$$514$$$O	a$$$515$$$516$$$O	mass$$$517$$$521$$$O	median$$$522$$$528$$$O	aerodynamic$$$529$$$540$$$O	diameter$$$541$$$549$$$O	(MMAD)$$$550$$$556$$$O	between$$$557$$$564$$$O	2$$$565$$$566$$$O	Î¼m$$$567$$$570$$$O	and$$$571$$$574$$$O	6$$$575$$$576$$$O	Î¼m.$$$577$$$581$$$O
CN101885725A
Pyrro-quinoline$$$0$$$15$$$I	quinine$$$16$$$23$$$I	sodium$$$24$$$30$$$I	salt$$$31$$$35$$$I	derivative$$$36$$$46$$$O	and$$$47$$$50$$$O	preparation$$$51$$$62$$$O	method$$$63$$$69$$$O	thereof$$$70$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pyrro-quinoline$$$27$$$42$$$I	quinine$$$43$$$50$$$I	(PQQ)$$$51$$$56$$$I	sodium$$$57$$$63$$$I	salt$$$64$$$68$$$I	derivative$$$69$$$79$$$O	and$$$80$$$83$$$O	a$$$84$$$85$$$O	preparation$$$86$$$97$$$O	method$$$98$$$104$$$O	thereof,$$$105$$$113$$$O	belonging$$$114$$$123$$$O	to$$$124$$$126$$$O	the$$$127$$$130$$$O	field$$$131$$$136$$$O	of$$$137$$$139$$$O	pharmacy.$$$140$$$149$$$O	In$$$150$$$152$$$O	the$$$153$$$156$$$O	preparation$$$157$$$168$$$O	method,$$$169$$$176$$$O	PQQ$$$177$$$180$$$I	is$$$181$$$183$$$O	used$$$184$$$188$$$O	as$$$189$$$191$$$O	a$$$192$$$193$$$O	raw$$$194$$$197$$$O	material,$$$198$$$207$$$O	and$$$208$$$211$$$O	an$$$212$$$214$$$O	acid-base$$$215$$$224$$$O	neutralization$$$225$$$239$$$O	reaction$$$240$$$248$$$O	with$$$249$$$253$$$O	PQQ$$$254$$$257$$$I	is$$$258$$$260$$$O	carried$$$261$$$268$$$O	out$$$269$$$272$$$O	in$$$273$$$275$$$O	a$$$276$$$277$$$O	basic$$$278$$$283$$$O	solvent$$$284$$$291$$$O	of$$$292$$$294$$$O	sodium$$$295$$$301$$$I	hydroxide$$$302$$$311$$$I	to$$$312$$$314$$$O	prepare$$$315$$$322$$$O	the$$$323$$$326$$$O	PQQ$$$327$$$330$$$I	sodium$$$331$$$337$$$I	salt$$$338$$$342$$$I	derivative$$$343$$$353$$$O	represented$$$354$$$365$$$O	in$$$366$$$368$$$O	the$$$369$$$372$$$O	structural$$$373$$$383$$$O	formula$$$384$$$391$$$O	(I),$$$392$$$396$$$O	wherein$$$397$$$404$$$O	R1,$$$405$$$408$$$O	R2$$$409$$$411$$$O	and$$$412$$$415$$$O	R3$$$416$$$418$$$O	can$$$419$$$422$$$O	be$$$423$$$425$$$O	identical$$$426$$$435$$$O	or$$$436$$$438$$$O	different$$$439$$$448$$$O	and$$$449$$$452$$$O	respectively$$$453$$$465$$$O	represents$$$466$$$476$$$O	H,$$$477$$$479$$$I	ammonium$$$480$$$488$$$I	ion$$$489$$$492$$$I	(NH3),$$$493$$$499$$$I	potassium$$$500$$$509$$$I	ion,$$$510$$$514$$$I	sodium$$$515$$$521$$$I	ion,$$$522$$$526$$$I	magnesium$$$527$$$536$$$I	ion,$$$537$$$541$$$I	calcium$$$542$$$549$$$I	ion$$$550$$$553$$$I	or$$$554$$$556$$$O	zinc$$$557$$$561$$$I	ion,$$$562$$$566$$$I	and$$$567$$$570$$$O	at$$$571$$$573$$$O	least$$$574$$$579$$$O	one$$$580$$$583$$$O	of$$$584$$$586$$$O	R1,$$$587$$$590$$$O	R2$$$591$$$593$$$O	and$$$594$$$597$$$O	R3$$$598$$$600$$$O	is$$$601$$$603$$$O	sodium$$$604$$$610$$$I	ion.$$$611$$$615$$$I	The$$$616$$$619$$$O	invention$$$620$$$629$$$O	has$$$630$$$633$$$O	mild$$$634$$$638$$$O	reaction$$$639$$$647$$$O	conditions,$$$648$$$659$$$O	easy$$$660$$$664$$$O	product$$$665$$$672$$$O	refining$$$673$$$681$$$O	and$$$682$$$685$$$O	purification,$$$686$$$699$$$O	simple$$$700$$$706$$$O	preparation$$$707$$$718$$$O	steps$$$719$$$724$$$O	and$$$725$$$728$$$O	high$$$729$$$733$$$O	yield$$$734$$$739$$$O	more$$$740$$$744$$$O	than$$$745$$$749$$$O	80%.$$$750$$$754$$$O	The$$$755$$$758$$$O	PQQ$$$759$$$762$$$I	sodium$$$763$$$769$$$I	salt$$$770$$$774$$$I	derivative$$$775$$$785$$$O	has$$$786$$$789$$$O	the$$$790$$$793$$$O	functions$$$794$$$803$$$O	of$$$804$$$806$$$O	inhibiting$$$807$$$817$$$O	GSK-3$$$818$$$823$$$O	activity,$$$824$$$833$$$O	reducing$$$834$$$842$$$O	senile$$$843$$$849$$$O	pigment$$$850$$$857$$$O	formation$$$858$$$867$$$O	in$$$868$$$870$$$O	a$$$871$$$872$$$O	transgenic$$$873$$$883$$$O	mouse$$$884$$$889$$$O	brain,$$$890$$$896$$$O	reducing$$$897$$$905$$$O	tau$$$906$$$909$$$O	protein$$$910$$$917$$$O	phosphorylation$$$918$$$933$$$O	and$$$934$$$937$$$O	the$$$938$$$941$$$O	like.$$$942$$$947$$$O	Thus,$$$948$$$953$$$O	the$$$954$$$957$$$O	PQQ$$$958$$$961$$$I	sodium$$$962$$$968$$$I	salt$$$969$$$973$$$I	derivative$$$974$$$984$$$O	can$$$985$$$988$$$O	be$$$989$$$991$$$O	medically$$$992$$$1001$$$O	used$$$1002$$$1006$$$O	for$$$1007$$$1010$$$O	treating$$$1011$$$1019$$$O	senile$$$1020$$$1026$$$O	dementia$$$1027$$$1035$$$O	and$$$1036$$$1039$$$O	other$$$1040$$$1045$$$O	diseases.$$$1046$$$1055$$$O
EP1231894B1
Pharmaceutical$$$0$$$14$$$O	formulations$$$15$$$27$$$O	of$$$28$$$30$$$O	salmeterol$$$31$$$41$$$I
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	according$$$18$$$27$$$O	to$$$28$$$30$$$O	the$$$31$$$34$$$O	invention$$$35$$$44$$$O	a$$$45$$$46$$$O	pharmaceutical$$$47$$$61$$$O	aerosol$$$62$$$69$$$O	formulation$$$70$$$81$$$O	which$$$82$$$87$$$O	comprises:$$$88$$$98$$$O	(i)$$$99$$$102$$$O	salmeterol$$$103$$$113$$$I	or$$$114$$$116$$$O	a$$$117$$$118$$$O	pharmaceutically$$$119$$$135$$$O	acceptable$$$136$$$146$$$O	salt$$$147$$$151$$$O	thereof$$$152$$$159$$$O	and$$$160$$$163$$$O	(ii)$$$164$$$168$$$O	a$$$169$$$170$$$O	hydrofluoroalkane$$$172$$$189$$$I	(HFA)$$$190$$$195$$$I	propellant,$$$196$$$207$$$O	characterised$$$208$$$221$$$O	in$$$222$$$224$$$O	that$$$225$$$229$$$O	the$$$230$$$233$$$O	salmeterol$$$234$$$244$$$I	or$$$245$$$247$$$O	pharmaceutically$$$248$$$264$$$O	acceptable$$$265$$$275$$$O	salt$$$276$$$280$$$O	thereof$$$281$$$288$$$O	is$$$289$$$291$$$O	completely$$$292$$$302$$$O	dissolved$$$303$$$312$$$O	in$$$313$$$315$$$O	the$$$316$$$319$$$O	formulation.$$$320$$$332$$$O
US20110027340
Implantable$$$0$$$11$$$O	drug$$$12$$$16$$$O	depot$$$17$$$22$$$O	for$$$23$$$26$$$O	weight$$$27$$$33$$$O	control$$$34$$$41$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	an$$$37$$$39$$$O	implantable$$$40$$$51$$$O	drug$$$52$$$56$$$O	depot$$$57$$$62$$$O	for$$$63$$$66$$$O	weight$$$67$$$73$$$O	control.$$$74$$$82$$$O	The$$$83$$$86$$$O	drug$$$87$$$91$$$O	depot$$$92$$$97$$$O	includes$$$98$$$106$$$O	at$$$107$$$109$$$O	least$$$110$$$115$$$O	one$$$116$$$119$$$O	biodegradeable$$$120$$$134$$$O	polymer$$$135$$$142$$$O	and$$$143$$$146$$$O	at$$$147$$$149$$$O	least$$$150$$$155$$$O	one$$$156$$$159$$$O	biologically$$$160$$$172$$$O	active$$$173$$$179$$$O	agent.$$$180$$$186$$$O	Through$$$187$$$194$$$O	the$$$195$$$198$$$O	administration$$$199$$$213$$$O	of$$$214$$$216$$$O	an$$$217$$$219$$$O	effective$$$220$$$229$$$O	amount$$$230$$$236$$$O	of$$$237$$$239$$$O	the$$$240$$$243$$$O	biologically$$$244$$$256$$$O	active$$$257$$$263$$$O	agent$$$264$$$269$$$O	at$$$270$$$272$$$O	or$$$273$$$275$$$O	near$$$276$$$280$$$O	a$$$281$$$282$$$O	target$$$283$$$289$$$O	site,$$$290$$$295$$$O	one$$$296$$$299$$$O	can$$$300$$$303$$$O	control$$$304$$$311$$$O	weight$$$312$$$318$$$O	gain$$$319$$$323$$$O	and/or$$$324$$$330$$$O	reduce,$$$331$$$338$$$O	prevent$$$339$$$346$$$O	or$$$347$$$349$$$O	treat$$$350$$$355$$$O	obesity.$$$356$$$364$$$O	When$$$365$$$369$$$O	appropriate$$$370$$$381$$$O	formulations$$$382$$$394$$$O	are$$$395$$$398$$$O	provided$$$399$$$407$$$O	within$$$408$$$414$$$O	biodegradable$$$415$$$428$$$O	polymers,$$$429$$$438$$$O	weight$$$439$$$445$$$O	control$$$446$$$453$$$O	or$$$454$$$456$$$O	treatment$$$457$$$466$$$O	can$$$467$$$470$$$O	be$$$471$$$473$$$O	conducted$$$474$$$483$$$O	for$$$484$$$487$$$O	at$$$488$$$490$$$O	least$$$491$$$496$$$O	five$$$497$$$501$$$O	days$$$502$$$506$$$O	and$$$507$$$510$$$O	up$$$511$$$513$$$O	to$$$514$$$516$$$O	one$$$517$$$520$$$O	hundred$$$521$$$528$$$O	and$$$529$$$532$$$O	thirty-five$$$533$$$544$$$O	days.$$$545$$$550$$$O
CN102766122A
Derivatives$$$0$$$11$$$O	of$$$12$$$14$$$O	dihydroaurone,$$$15$$$29$$$I	benzofuran$$$30$$$40$$$I	and$$$41$$$44$$$O	orange$$$45$$$51$$$O	alkane,$$$52$$$59$$$I	and$$$60$$$63$$$O	uses$$$64$$$68$$$O	thereof$$$69$$$76$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	pharmaceutical,$$$48$$$63$$$O	and$$$64$$$67$$$O	relates$$$68$$$75$$$O	to$$$76$$$78$$$O	derivatives$$$79$$$90$$$O	of$$$91$$$93$$$O	dihydroaurone,$$$94$$$108$$$I	benzofuran,$$$109$$$120$$$I	and$$$121$$$124$$$O	orange$$$125$$$131$$$O	alkane.$$$132$$$139$$$I	The$$$140$$$143$$$O	structures$$$144$$$154$$$O	of$$$155$$$157$$$O	the$$$158$$$161$$$O	derivatives$$$162$$$173$$$O	are$$$174$$$177$$$O	as$$$178$$$180$$$O	shown$$$181$$$186$$$O	in$$$187$$$189$$$O	formula$$$190$$$197$$$O	(1):$$$198$$$202$$$O	wherein,$$$203$$$211$$$O	when$$$212$$$216$$$O	Xl$$$217$$$219$$$O	and$$$220$$$223$$$O	X2$$$224$$$226$$$O	together$$$227$$$235$$$O	represent$$$236$$$245$$$O	oxygen,$$$246$$$253$$$I	and$$$254$$$257$$$O	-Y-Z-$$$258$$$263$$$O	is$$$264$$$266$$$O	-C-CH-,$$$267$$$274$$$I	the$$$275$$$278$$$O	structures$$$279$$$289$$$O	are$$$290$$$293$$$O	dihydroaurone$$$294$$$307$$$I	compounds;$$$308$$$318$$$O	when$$$319$$$323$$$O	Xl$$$324$$$326$$$O	and$$$327$$$330$$$O	X2$$$331$$$333$$$O	together$$$334$$$342$$$O	represent$$$343$$$352$$$O	hydrogen,$$$353$$$362$$$I	and$$$363$$$366$$$O	-Y-Z-$$$367$$$372$$$O	is$$$373$$$375$$$O	-C=C-,$$$376$$$382$$$I	the$$$383$$$386$$$O	structures$$$387$$$397$$$O	are$$$398$$$401$$$O	benzofuran$$$402$$$412$$$I	compounds;$$$413$$$423$$$O	or$$$424$$$426$$$O	when$$$427$$$431$$$O	Xl$$$432$$$434$$$O	and$$$435$$$438$$$O	X2$$$439$$$441$$$O	simultaneously$$$442$$$456$$$O	and$$$457$$$460$$$O	respectively$$$461$$$473$$$O	represent$$$474$$$483$$$O	hydrogen,$$$484$$$493$$$I	and$$$494$$$497$$$O	-Y-Z-$$$498$$$503$$$O	is$$$504$$$506$$$O	-C-CH-,$$$507$$$514$$$I	the$$$515$$$518$$$O	structures$$$519$$$529$$$O	are$$$530$$$533$$$O	orange$$$534$$$540$$$O	alkane$$$541$$$547$$$I	compounds.$$$548$$$558$$$O	The$$$559$$$562$$$O	invention$$$563$$$572$$$O	also$$$573$$$577$$$O	provides$$$578$$$586$$$O	pharmaceutically$$$587$$$603$$$O	acceptable$$$604$$$614$$$O	non-toxic$$$615$$$624$$$O	salts$$$625$$$630$$$O	and$$$631$$$634$$$O	hydrates$$$635$$$643$$$I	formed$$$644$$$650$$$O	from$$$651$$$655$$$O	the$$$656$$$659$$$O	derivatives$$$660$$$671$$$O	shown$$$672$$$677$$$O	in$$$678$$$680$$$O	the$$$681$$$684$$$O	structural$$$685$$$695$$$O	formula.$$$696$$$704$$$O	The$$$705$$$708$$$O	pharmaceutically$$$709$$$725$$$O	acceptable$$$726$$$736$$$O	non-toxic$$$737$$$746$$$O	salts$$$747$$$752$$$O	include$$$753$$$760$$$O	the$$$761$$$764$$$O	salts$$$765$$$770$$$O	formed$$$771$$$777$$$O	by$$$778$$$780$$$O	the$$$781$$$784$$$O	derivatives$$$785$$$796$$$O	and$$$797$$$800$$$O	acids.$$$801$$$807$$$O	Pharmacological$$$808$$$823$$$O	activity$$$824$$$832$$$O	test$$$833$$$837$$$O	results$$$838$$$845$$$O	show$$$846$$$850$$$O	that$$$851$$$855$$$O	the$$$856$$$859$$$O	derivatives$$$860$$$871$$$O	have$$$872$$$876$$$O	good$$$877$$$881$$$O	antitumor$$$882$$$891$$$O	activities$$$892$$$902$$$O	and$$$903$$$906$$$O	can$$$907$$$910$$$O	be$$$911$$$913$$$O	used$$$914$$$918$$$O	as$$$919$$$921$$$O	a$$$922$$$923$$$O	tumor$$$924$$$929$$$O	cell$$$930$$$934$$$O	proliferation$$$935$$$948$$$O	inhibitor$$$949$$$958$$$O	in$$$959$$$961$$$O	the$$$962$$$965$$$O	preparation$$$966$$$977$$$O	of$$$978$$$980$$$O	tumor$$$981$$$986$$$O	pharmaceuticals.$$$987$$$1003$$$O
US20080132825
Transcutaneous$$$0$$$14$$$O	infusion$$$15$$$23$$$O	of$$$24$$$26$$$O	carbon$$$27$$$33$$$I	dioxide$$$34$$$41$$$I	for$$$42$$$45$$$O	local$$$46$$$51$$$O	relief$$$52$$$58$$$O	of$$$59$$$61$$$O	pain$$$62$$$66$$$O	and$$$67$$$70$$$O	other$$$71$$$76$$$O	ailments$$$77$$$85$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	methods$$$25$$$32$$$O	for$$$33$$$36$$$O	transcutaneous$$$37$$$51$$$O	and$$$52$$$55$$$O	transmucosal$$$56$$$68$$$O	application$$$69$$$80$$$O	of$$$81$$$83$$$O	carbon$$$84$$$90$$$I	dioxide$$$91$$$98$$$I	in$$$99$$$101$$$O	the$$$102$$$105$$$O	form$$$106$$$110$$$O	of$$$111$$$113$$$O	a$$$114$$$115$$$O	gas$$$116$$$119$$$O	and$$$120$$$123$$$O	in$$$124$$$126$$$O	the$$$127$$$130$$$O	form$$$131$$$135$$$O	of$$$136$$$138$$$O	a$$$139$$$140$$$O	capnic$$$141$$$147$$$O	solution$$$148$$$156$$$O	(such$$$157$$$162$$$O	as$$$163$$$165$$$O	carbonated$$$166$$$176$$$O	water)$$$177$$$183$$$O	for$$$184$$$187$$$O	the$$$188$$$191$$$O	relief$$$192$$$198$$$O	of$$$199$$$201$$$O	pain,$$$202$$$207$$$O	including$$$208$$$217$$$O	musculoskeletal$$$218$$$233$$$O	disorders,$$$234$$$244$$$O	neuralgias,$$$245$$$256$$$O	rhinitis$$$257$$$265$$$O	and$$$266$$$269$$$O	other$$$270$$$275$$$O	ailments.$$$276$$$285$$$O	Gaseous$$$286$$$293$$$O	carbon$$$294$$$300$$$I	dioxide$$$301$$$308$$$I	is$$$309$$$311$$$O	applied$$$312$$$319$$$O	to$$$320$$$322$$$O	the$$$323$$$326$$$O	skin$$$327$$$331$$$O	for$$$332$$$335$$$O	at$$$336$$$338$$$O	least$$$339$$$344$$$O	three$$$345$$$350$$$O	minutes,$$$351$$$359$$$O	and$$$360$$$363$$$O	the$$$364$$$367$$$O	capnic$$$368$$$374$$$O	solution$$$375$$$383$$$O	may$$$384$$$387$$$O	be$$$388$$$390$$$O	held$$$391$$$395$$$O	on$$$396$$$398$$$O	the$$$399$$$402$$$O	skin$$$403$$$407$$$O	for$$$408$$$411$$$O	at$$$412$$$414$$$O	least$$$415$$$420$$$O	three$$$421$$$426$$$O	minutes,$$$427$$$435$$$O	which$$$436$$$441$$$O	provides$$$442$$$450$$$O	relief$$$451$$$457$$$O	of$$$458$$$460$$$O	symptoms.$$$461$$$470$$$O	The$$$471$$$474$$$O	capnic$$$475$$$481$$$O	solution$$$482$$$490$$$O	may$$$491$$$494$$$O	also$$$495$$$499$$$O	be$$$500$$$502$$$O	sprayed$$$503$$$510$$$O	onto$$$511$$$515$$$O	mucous$$$516$$$522$$$O	membranes$$$523$$$532$$$O	such$$$533$$$537$$$O	as$$$538$$$540$$$O	the$$$541$$$544$$$O	nose$$$545$$$549$$$O	for$$$550$$$553$$$O	relief$$$554$$$560$$$O	of$$$561$$$563$$$O	symptoms$$$564$$$572$$$O	such$$$573$$$577$$$O	as$$$578$$$580$$$O	allergic$$$581$$$589$$$O	rhinitis.$$$590$$$599$$$O
US20120156312
Compositions$$$0$$$12$$$O	for$$$13$$$16$$$O	Inhibiting$$$17$$$27$$$O	Growth$$$28$$$34$$$O	of$$$35$$$37$$$O	Cancer$$$38$$$44$$$O	Stem$$$45$$$49$$$O	Cells$$$50$$$55$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	a$$$25$$$26$$$O	biomarker$$$27$$$36$$$O	of$$$37$$$39$$$O	chemotherapeutic$$$40$$$56$$$O	drug-resistant$$$57$$$71$$$O	cancer$$$72$$$78$$$O	stem$$$79$$$83$$$O	cells$$$84$$$89$$$O	and$$$90$$$93$$$O	a$$$94$$$95$$$O	method$$$96$$$102$$$O	of$$$103$$$105$$$O	inhibiting$$$106$$$116$$$O	the$$$117$$$120$$$O	growth$$$121$$$127$$$O	of$$$128$$$130$$$O	drug-resistant$$$131$$$145$$$O	cancer$$$146$$$152$$$O	stem$$$153$$$157$$$O	cells.$$$158$$$164$$$O	In$$$165$$$167$$$O	one$$$168$$$171$$$O	embodiment$$$172$$$182$$$O	the$$$183$$$186$$$O	cancer$$$187$$$193$$$O	stem$$$194$$$198$$$O	cells$$$199$$$204$$$O	are$$$205$$$208$$$O	testicular$$$209$$$219$$$O	cancer$$$220$$$226$$$O	germ$$$227$$$231$$$O	cells.$$$232$$$238$$$O	In$$$239$$$241$$$O	another$$$242$$$249$$$O	embodiment$$$250$$$260$$$O	the$$$261$$$264$$$O	present$$$265$$$272$$$O	invention$$$273$$$282$$$O	is$$$283$$$285$$$O	a$$$286$$$287$$$O	method$$$288$$$294$$$O	of$$$295$$$297$$$O	overcoming$$$298$$$308$$$O	drug$$$309$$$313$$$O	resistance$$$314$$$324$$$O	in$$$325$$$327$$$O	cancer$$$328$$$334$$$O	treatment$$$335$$$344$$$O	where$$$345$$$350$$$O	the$$$351$$$354$$$O	combination$$$355$$$366$$$O	of$$$367$$$369$$$O	low$$$370$$$373$$$O	dose$$$374$$$378$$$O	decitabine$$$379$$$389$$$O	and$$$390$$$393$$$O	administration$$$394$$$408$$$O	of$$$409$$$411$$$O	a$$$412$$$413$$$O	chemotherapeutic$$$414$$$430$$$O	drug$$$431$$$435$$$O	to$$$436$$$438$$$O	which$$$439$$$444$$$O	cancer$$$445$$$451$$$O	cells$$$452$$$457$$$O	were$$$458$$$462$$$O	resistant$$$463$$$472$$$O	results$$$473$$$480$$$O	in$$$481$$$483$$$O	successful$$$484$$$494$$$O	cancer$$$495$$$501$$$O	treatment.$$$502$$$512$$$O
CN102106822A
Fluconazole$$$0$$$11$$$I	injection$$$12$$$21$$$O	power$$$22$$$27$$$O	and$$$28$$$31$$$O	preparation$$$32$$$43$$$O	method$$$44$$$50$$$O	thereof$$$51$$$58$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	fluconazole$$$24$$$35$$$I	injection$$$36$$$45$$$O	power$$$46$$$51$$$O	and$$$52$$$55$$$O	the$$$56$$$59$$$O	preparation$$$60$$$71$$$O	method$$$72$$$78$$$O	thereof.$$$79$$$87$$$O	The$$$88$$$91$$$O	fluconazole$$$92$$$103$$$I	injection$$$104$$$113$$$O	power$$$114$$$119$$$O	comprises$$$120$$$129$$$O	the$$$130$$$133$$$O	following$$$134$$$143$$$O	components$$$144$$$154$$$O	by$$$155$$$157$$$O	weight:$$$158$$$165$$$O	1$$$166$$$167$$$O	part$$$168$$$172$$$O	of$$$173$$$175$$$O	fluconazole,$$$176$$$188$$$I	4.5-30$$$189$$$195$$$O	parts$$$196$$$201$$$O	of$$$202$$$204$$$O	beta-cyclodextrin$$$205$$$222$$$O	derivative,$$$223$$$234$$$O	0-10$$$235$$$239$$$O	parts$$$240$$$245$$$O	of$$$246$$$248$$$O	excipient$$$249$$$258$$$O	and$$$259$$$262$$$O	10-100$$$263$$$269$$$O	parts$$$270$$$275$$$O	of$$$276$$$278$$$O	water$$$279$$$284$$$O	for$$$285$$$288$$$O	injection.$$$289$$$299$$$O	The$$$300$$$303$$$O	preparation$$$304$$$315$$$O	method$$$316$$$322$$$O	comprises$$$323$$$332$$$O	the$$$333$$$336$$$O	following$$$337$$$346$$$O	steps$$$347$$$352$$$O	of$$$353$$$355$$$O	feeding$$$356$$$363$$$O	the$$$364$$$367$$$O	beta-cyclodextrin$$$368$$$385$$$O	derivative$$$386$$$396$$$O	represented$$$397$$$408$$$O	by$$$409$$$411$$$O	hydroxypropyl-beta$$$412$$$430$$$O	cyclodextrin$$$431$$$443$$$O	in$$$444$$$446$$$O	the$$$447$$$450$$$O	water$$$451$$$456$$$O	for$$$457$$$460$$$O	injection$$$461$$$470$$$O	and$$$471$$$474$$$O	dissolving;$$$475$$$486$$$O	then$$$487$$$491$$$O	adding$$$492$$$498$$$O	the$$$499$$$502$$$O	fluconazole,$$$503$$$515$$$I	stirring$$$516$$$524$$$O	or$$$525$$$527$$$O	grinding$$$528$$$536$$$O	or$$$537$$$539$$$O	carrying$$$540$$$548$$$O	out$$$549$$$552$$$O	ultrasonography$$$553$$$568$$$O	to$$$569$$$571$$$O	obtain$$$572$$$578$$$O	a$$$579$$$580$$$O	fluconazole$$$581$$$592$$$I	inclusion$$$593$$$602$$$O	compound$$$603$$$611$$$O	solution$$$612$$$620$$$O	for$$$621$$$624$$$O	preparing$$$625$$$634$$$O	the$$$635$$$638$$$O	fluconazole$$$639$$$650$$$I	ifluconazole$$$651$$$663$$$I	injection$$$664$$$673$$$O	power.$$$674$$$680$$$O	The$$$681$$$684$$$O	fluconazole$$$685$$$696$$$I	injection$$$697$$$706$$$O	power$$$707$$$712$$$O	is$$$713$$$715$$$O	safer$$$716$$$721$$$O	and$$$722$$$725$$$O	more$$$726$$$730$$$O	stable.$$$731$$$738$$$O
CN1561985A
Novel$$$0$$$5$$$O	sodium$$$6$$$12$$$I	houttuyfonate$$$13$$$26$$$I	powder$$$27$$$33$$$O	injection$$$34$$$43$$$O
A$$$0$$$1$$$O	powder$$$2$$$8$$$O	injection$$$9$$$18$$$O	of$$$19$$$21$$$O	sodium$$$22$$$28$$$I	neohouttuyfonate$$$29$$$45$$$I	for$$$46$$$49$$$O	treating$$$50$$$58$$$O	pelvic$$$59$$$65$$$O	inflammation,$$$66$$$79$$$O	adnexitis,$$$80$$$90$$$O	chronic$$$91$$$98$$$O	cervicitis,$$$99$$$110$$$O	upper$$$111$$$116$$$O	respiratory$$$117$$$128$$$O	tract$$$129$$$134$$$O	infection,$$$135$$$145$$$O	etc$$$146$$$149$$$O	contains$$$150$$$158$$$O	sodium$$$159$$$165$$$I	neohouttuyfonate,$$$166$$$183$$$I	solubilizer,and$$$184$$$199$$$O	excipient.$$$200$$$210$$$O
US7727999
substituted$$$0$$$11$$$O	1,3,8-triaza-spiro[4.5]decan-2-one$$$12$$$46$$$I	compounds,$$$47$$$57$$$O	used$$$58$$$62$$$O	as$$$63$$$65$$$O	selective$$$66$$$75$$$O	serotonin$$$76$$$85$$$I	receptor$$$86$$$94$$$O	antagonists,$$$95$$$107$$$O	used$$$108$$$112$$$O	rfor$$$113$$$117$$$O	the$$$118$$$121$$$O	treatment$$$122$$$131$$$O	of$$$132$$$134$$$O	schizophrenia,$$$135$$$149$$$O	psychosis,$$$150$$$160$$$O	headaches,$$$161$$$171$$$O	hypertension,$$$172$$$185$$$O	thrombosis,$$$186$$$197$$$O	vasospasm,$$$198$$$208$$$O	depression,$$$209$$$220$$$O	anxiety,$$$221$$$229$$$O	sleep$$$230$$$235$$$O	disorders$$$236$$$245$$$O	and$$$246$$$249$$$O	appetite$$$250$$$258$$$O	disorders$$$259$$$268$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	optionally$$$33$$$43$$$O	substituted$$$44$$$55$$$O	1,3,8-triaza-spiro[4.5]decan-2-one$$$56$$$90$$$I	compounds$$$91$$$100$$$O	as$$$101$$$103$$$O	monoamine$$$104$$$113$$$I	receptor$$$114$$$122$$$O	modulators;$$$123$$$134$$$O	compositions$$$135$$$147$$$O	comprising$$$148$$$158$$$O	the$$$159$$$162$$$O	same;$$$163$$$168$$$O	methods$$$169$$$176$$$O	of$$$177$$$179$$$O	inhibiting$$$180$$$190$$$O	an$$$191$$$193$$$O	activity$$$194$$$202$$$O	of$$$203$$$205$$$O	a$$$206$$$207$$$O	monoamine$$$208$$$217$$$I	receptor$$$218$$$226$$$O	with$$$227$$$231$$$O	said$$$232$$$236$$$O	compounds;$$$237$$$247$$$O	methods$$$248$$$255$$$O	of$$$256$$$258$$$O	treating$$$259$$$267$$$O	a$$$268$$$269$$$O	disease$$$270$$$277$$$O	condition$$$278$$$287$$$O	associated$$$288$$$298$$$O	with$$$299$$$303$$$O	a$$$304$$$305$$$O	monoamine$$$306$$$315$$$I	receptor$$$316$$$324$$$O	using$$$325$$$330$$$O	said$$$331$$$335$$$O	compounds;$$$336$$$346$$$O	and$$$347$$$350$$$O	methods$$$351$$$358$$$O	for$$$359$$$362$$$O	identifying$$$363$$$374$$$O	a$$$375$$$376$$$O	subject$$$377$$$384$$$O	suitable$$$385$$$393$$$O	for$$$394$$$397$$$O	treatment$$$398$$$407$$$O	using$$$408$$$413$$$O	said$$$414$$$418$$$O	compounds.$$$419$$$429$$$O
WO2005012289A1
Novel$$$0$$$5$$$O	salt$$$6$$$10$$$O	of$$$11$$$13$$$O	(r)$$$14$$$17$$$I	-$$$18$$$19$$$I	pantoprazole$$$20$$$32$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	(+)-pantoprazole$$$25$$$41$$$I	magnesium$$$42$$$51$$$I	hydrates$$$52$$$60$$$I	and$$$61$$$64$$$O	to$$$65$$$67$$$O	medicaments$$$68$$$79$$$O	comprising$$$80$$$90$$$O	these$$$91$$$96$$$O	compounds.$$$97$$$107$$$O
CN103505735A
Composition$$$0$$$11$$$O	containing$$$12$$$22$$$O	r-aminobutyric$$$23$$$37$$$I	acid,$$$38$$$43$$$I	taurine$$$44$$$51$$$I	and$$$52$$$55$$$O	antiepileptic$$$56$$$69$$$O	drugs$$$70$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	composition$$$27$$$38$$$O	containing$$$39$$$49$$$O	r-aminobutyric$$$50$$$64$$$I	acid,$$$65$$$70$$$I	taurine$$$71$$$78$$$I	and$$$79$$$82$$$O	antiepileptic$$$83$$$96$$$O	drugs$$$97$$$102$$$O	selected$$$103$$$111$$$O	from$$$112$$$116$$$O	gabapentin,$$$117$$$128$$$I	oxcarbazepine,$$$129$$$143$$$I	valproic$$$144$$$152$$$I	acid,$$$153$$$158$$$I	topiramate,$$$159$$$170$$$I	phenytoin$$$171$$$180$$$I	and$$$181$$$184$$$O	the$$$185$$$188$$$O	like,$$$189$$$194$$$O	and$$$195$$$198$$$O	relates$$$199$$$206$$$O	to$$$207$$$209$$$O	purposes$$$210$$$218$$$O	thereof$$$219$$$226$$$O	in$$$227$$$229$$$O	the$$$230$$$233$$$O	aspects$$$234$$$241$$$O	of$$$242$$$244$$$O	preventing,$$$245$$$256$$$O	delaying$$$257$$$265$$$O	or$$$266$$$268$$$O	treating$$$269$$$277$$$O	the$$$278$$$281$$$O	epileptic$$$282$$$291$$$O	seizure,$$$292$$$300$$$O	in$$$301$$$303$$$O	particular$$$304$$$314$$$O	resisting$$$315$$$324$$$O	epilepsia,$$$325$$$335$$$O	scavenging$$$336$$$346$$$O	free$$$347$$$351$$$O	radicals$$$352$$$360$$$O	and$$$361$$$364$$$O	restraining$$$365$$$376$$$O	lipid$$$377$$$382$$$O	peroxidation$$$383$$$395$$$O	in$$$396$$$398$$$O	the$$$399$$$402$$$O	epileptic$$$403$$$412$$$O	seizure.$$$413$$$421$$$O
CN103374014A
Salt$$$0$$$4$$$O	of$$$5$$$7$$$O	chelidonine$$$8$$$19$$$I	derivative$$$20$$$30$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	chelidonine,$$$25$$$37$$$I	fumarate$$$38$$$46$$$I	of$$$47$$$49$$$O	a$$$50$$$51$$$O	derivative$$$52$$$62$$$O	of$$$63$$$65$$$O	the$$$66$$$69$$$O	chelidonine$$$70$$$81$$$I	or$$$82$$$84$$$O	a$$$85$$$86$$$O	pharmaceutically$$$87$$$103$$$O	acceptable$$$104$$$114$$$O	solvate$$$115$$$122$$$O	of$$$123$$$125$$$O	the$$$126$$$129$$$O	chelidonine$$$130$$$141$$$I	and$$$142$$$145$$$O	applications$$$146$$$158$$$O	of$$$159$$$161$$$O	the$$$162$$$165$$$O	chelidonine,$$$166$$$178$$$I	the$$$179$$$182$$$O	fumarate$$$183$$$191$$$I	and$$$192$$$195$$$O	the$$$196$$$199$$$O	solvate$$$200$$$207$$$O	in$$$208$$$210$$$O	preparation$$$211$$$222$$$O	of$$$223$$$225$$$O	medicaments$$$226$$$237$$$O	for$$$238$$$241$$$O	treating$$$242$$$250$$$O	hepatitis$$$251$$$260$$$O	B.$$$261$$$263$$$O
US7928146
Topical$$$0$$$7$$$O	applying$$$8$$$16$$$O	adrenergic$$$17$$$27$$$O	blocking$$$28$$$36$$$O	agent,$$$37$$$43$$$O	nitric$$$44$$$50$$$I	oxide$$$51$$$56$$$I	synthase$$$57$$$65$$$O	inhibitor,$$$66$$$76$$$O	prostaglandin,$$$77$$$91$$$I	dopamine,$$$92$$$101$$$I	morphine$$$102$$$110$$$I	and$$$111$$$114$$$O	5-hydroxytryptamine;$$$115$$$135$$$I	topical$$$136$$$143$$$O	applying$$$144$$$152$$$O
Fecal$$$0$$$5$$$O	incontinence$$$6$$$18$$$O	and$$$19$$$22$$$O	anal$$$23$$$27$$$O	itch$$$28$$$32$$$O	can$$$33$$$36$$$O	be$$$37$$$39$$$O	treated$$$40$$$47$$$O	by$$$48$$$50$$$O	administration,$$$51$$$66$$$O	more$$$67$$$71$$$O	particularly$$$72$$$84$$$O	by$$$85$$$87$$$O	local$$$88$$$93$$$O	application$$$94$$$105$$$O	to$$$106$$$108$$$O	the$$$109$$$112$$$O	anus,$$$113$$$118$$$O	of$$$119$$$121$$$O	an$$$122$$$124$$$O	Î±adrenergic$$$125$$$137$$$O	blocker,$$$138$$$146$$$I	nitric$$$147$$$153$$$I	oxide$$$154$$$159$$$I	synthase$$$160$$$168$$$O	inhibitor,$$$169$$$179$$$I	prostaglandin$$$180$$$193$$$I	F2Î±,$$$194$$$199$$$I	dopamine,$$$200$$$209$$$I	morphine,$$$210$$$219$$$I	Î²-blockers,$$$220$$$232$$$O	and$$$233$$$236$$$I	5-Hydroxytryptamine.$$$237$$$257$$$I	The$$$258$$$261$$$O	patients$$$262$$$270$$$O	who$$$271$$$274$$$O	benefit$$$275$$$282$$$O	most$$$283$$$287$$$O	from$$$288$$$292$$$O	the$$$293$$$296$$$O	invention$$$297$$$306$$$O	are$$$307$$$310$$$O	those$$$311$$$316$$$O	who$$$317$$$320$$$O	have$$$321$$$325$$$O	a$$$326$$$327$$$O	normal$$$328$$$334$$$O	or$$$335$$$337$$$O	low$$$338$$$341$$$O	maximum$$$342$$$349$$$O	anal$$$350$$$354$$$O	resting$$$355$$$362$$$O	pressure$$$363$$$371$$$O	and$$$372$$$375$$$O	a$$$376$$$377$$$O	structurally$$$378$$$390$$$O	intact$$$391$$$397$$$O	internal$$$398$$$406$$$O	anal$$$407$$$411$$$O	sphincter$$$412$$$421$$$O	muscle,$$$422$$$429$$$O	and$$$430$$$433$$$O	patients$$$434$$$442$$$O	who$$$443$$$446$$$O	have$$$447$$$451$$$O	had$$$452$$$455$$$O	major$$$456$$$461$$$O	bowel$$$462$$$467$$$O	resection$$$468$$$477$$$O	and$$$478$$$481$$$O	reanastomisis.$$$482$$$496$$$O
EP1786802A1
Pyrimidinylimidazoles$$$0$$$21$$$I	as$$$22$$$24$$$O	tgf-beta$$$25$$$33$$$O	inhibitors$$$34$$$44$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I)$$$21$$$24$$$O	possess$$$25$$$32$$$O	unexpectedly$$$33$$$45$$$O	high$$$46$$$50$$$O	affinity$$$51$$$59$$$O	for$$$60$$$63$$$O	Alk$$$64$$$67$$$O	5$$$68$$$69$$$O	and/or$$$70$$$76$$$O	Alk$$$77$$$80$$$O	4,$$$81$$$83$$$O	and$$$84$$$87$$$O	can$$$88$$$91$$$O	be$$$92$$$94$$$O	useful$$$95$$$101$$$O	as$$$102$$$104$$$O	antagonists$$$105$$$116$$$O	thereof$$$117$$$124$$$O	for$$$125$$$128$$$O	preventing$$$129$$$139$$$O	and/or$$$140$$$146$$$O	treating$$$147$$$155$$$O	numerous$$$156$$$164$$$O	diseases,$$$165$$$174$$$O	including$$$175$$$184$$$O	fibrotic$$$185$$$193$$$O	disorders.$$$194$$$204$$$O	The$$$205$$$208$$$O	invention$$$209$$$218$$$O	features$$$219$$$227$$$O	a$$$228$$$229$$$O	compound$$$230$$$238$$$O	of$$$239$$$241$$$O	the$$$242$$$245$$$O	general$$$246$$$253$$$O	formula$$$254$$$261$$$O	(I)$$$262$$$265$$$O	and$$$266$$$269$$$O	uses$$$270$$$274$$$O	thereof.$$$275$$$283$$$O
US20120289476
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	methylmalonic$$$21$$$34$$$I	acidemia$$$35$$$43$$$O
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	methylmalonic$$$21$$$34$$$I	acidemia$$$35$$$43$$$O	in$$$44$$$46$$$O	which$$$47$$$52$$$O	at$$$53$$$55$$$O	least$$$56$$$61$$$O	one$$$62$$$65$$$O	allele$$$66$$$72$$$O	of$$$73$$$75$$$O	a$$$76$$$77$$$O	gene$$$78$$$82$$$O	associated$$$83$$$93$$$O	with$$$94$$$98$$$O	MMA$$$99$$$102$$$O	(e.g.,$$$103$$$109$$$O	the$$$110$$$113$$$O	MUT,$$$114$$$118$$$O	MMAA,$$$119$$$124$$$O	or$$$125$$$127$$$O	MMAB$$$128$$$132$$$O	gene)$$$133$$$138$$$O	contains$$$139$$$147$$$O	a$$$148$$$149$$$O	mutation$$$150$$$158$$$O	(e.g.,$$$159$$$165$$$O	nonsense$$$166$$$174$$$O	mutation)$$$175$$$184$$$O	that$$$185$$$189$$$O	results$$$190$$$197$$$O	in$$$198$$$200$$$O	a$$$201$$$202$$$O	premature$$$203$$$212$$$O	stop$$$213$$$217$$$O	codon$$$218$$$223$$$O	in$$$224$$$226$$$O	RNA$$$227$$$230$$$O	encoded$$$231$$$238$$$O	by$$$239$$$241$$$O	an$$$242$$$244$$$O	allele$$$245$$$251$$$O	of$$$252$$$254$$$O	the$$$255$$$258$$$O	gene$$$259$$$263$$$O	associated$$$264$$$274$$$O	with$$$275$$$279$$$O	MMA$$$280$$$283$$$O	involving$$$284$$$293$$$O	the$$$294$$$297$$$O	administration$$$298$$$312$$$O	of$$$313$$$315$$$O	a$$$316$$$317$$$O	compound$$$318$$$326$$$O	that$$$327$$$331$$$O	promotes$$$332$$$340$$$O	readthrough$$$341$$$352$$$O	of$$$353$$$355$$$O	RNA$$$356$$$359$$$O	(e.g.,$$$360$$$366$$$O	messenger$$$367$$$376$$$O	RNA)$$$377$$$381$$$O	containing$$$382$$$392$$$O	a$$$393$$$394$$$O	premature$$$395$$$404$$$O	stop$$$405$$$409$$$O	codon$$$410$$$415$$$O	encoded$$$416$$$423$$$O	by$$$424$$$426$$$O	an$$$427$$$429$$$O	allele$$$430$$$436$$$O	of$$$437$$$439$$$O	the$$$440$$$443$$$O	gene$$$444$$$448$$$O	associated$$$449$$$459$$$O	with$$$460$$$464$$$O	MMA$$$465$$$468$$$O	are$$$469$$$472$$$O	described.$$$473$$$483$$$O	The$$$484$$$487$$$O	compound$$$488$$$496$$$O	can$$$497$$$500$$$O	be$$$501$$$503$$$O	administered$$$504$$$516$$$O	as$$$517$$$519$$$O	a$$$520$$$521$$$O	single-agent$$$522$$$534$$$O	therapy$$$535$$$542$$$O	or$$$543$$$545$$$O	in$$$546$$$548$$$O	combination$$$549$$$560$$$O	with$$$561$$$565$$$O	one$$$566$$$569$$$O	or$$$570$$$572$$$O	more$$$573$$$577$$$O	additional$$$578$$$588$$$O	therapies$$$589$$$598$$$O	to$$$599$$$601$$$O	a$$$602$$$603$$$O	human$$$604$$$609$$$O	in$$$610$$$612$$$O	need$$$613$$$617$$$O	of$$$618$$$620$$$O	such$$$621$$$625$$$O	treatment.$$$626$$$636$$$O
US20080038358
Dry$$$0$$$3$$$O	powder$$$4$$$10$$$O	formulations$$$11$$$23$$$O	of$$$24$$$26$$$O	antihistamine$$$27$$$40$$$I	for$$$41$$$44$$$O	nasal$$$45$$$50$$$O	administration$$$51$$$65$$$O
Dry$$$0$$$3$$$O	powder$$$4$$$10$$$O	formulations$$$11$$$23$$$O	of$$$24$$$26$$$O	drugs$$$27$$$32$$$O	such$$$33$$$37$$$O	as$$$38$$$40$$$O	antihistamine$$$41$$$54$$$I	for$$$55$$$58$$$O	nasal$$$59$$$64$$$O	administration$$$65$$$79$$$O	are$$$80$$$83$$$O	provided$$$84$$$92$$$O	where$$$93$$$98$$$O	the$$$99$$$102$$$O	drug$$$103$$$107$$$O	is$$$108$$$110$$$O	retained$$$111$$$119$$$O	in$$$120$$$122$$$O	the$$$123$$$126$$$O	nasal$$$127$$$132$$$O	cavity,$$$133$$$140$$$O	and$$$141$$$144$$$O	systemic$$$145$$$153$$$O	side$$$154$$$158$$$O	effects$$$159$$$166$$$O	minimized$$$167$$$176$$$O	or$$$177$$$179$$$O	eliminated,$$$180$$$191$$$O	through$$$192$$$199$$$O	the$$$200$$$203$$$O	selection$$$204$$$213$$$O	of$$$214$$$216$$$O	a$$$217$$$218$$$O	narrow$$$219$$$225$$$O	particle$$$226$$$234$$$O	size$$$235$$$239$$$O	range,$$$240$$$246$$$O	between$$$247$$$254$$$O	approximately$$$255$$$268$$$O	10$$$269$$$271$$$O	and$$$272$$$275$$$O	20$$$276$$$278$$$O	microns$$$279$$$286$$$O	in$$$287$$$289$$$O	diameter.$$$290$$$299$$$O	In$$$300$$$302$$$O	a$$$303$$$304$$$O	preferred$$$305$$$314$$$O	embodiment$$$315$$$325$$$O	wherein$$$326$$$333$$$O	the$$$334$$$337$$$O	drug$$$338$$$342$$$O	is$$$343$$$345$$$O	an$$$346$$$348$$$O	antihistamine,$$$349$$$363$$$I	retention$$$364$$$373$$$O	of$$$374$$$376$$$O	the$$$377$$$380$$$O	antihistamine$$$381$$$394$$$I	at$$$395$$$397$$$O	the$$$398$$$401$$$O	nasal$$$402$$$407$$$O	mucosa$$$408$$$414$$$O	is$$$415$$$417$$$O	improved$$$418$$$426$$$O	and$$$427$$$430$$$O	the$$$431$$$434$$$O	bitter$$$435$$$441$$$O	aftertaste$$$442$$$452$$$O	associated$$$453$$$463$$$O	with$$$464$$$468$$$O	liquid$$$469$$$475$$$O	antihistamine$$$476$$$489$$$I	formulations$$$490$$$502$$$O	significantly$$$503$$$516$$$O	reduced.$$$517$$$525$$$O	By$$$526$$$528$$$O	making$$$529$$$535$$$O	a$$$536$$$537$$$O	dry$$$538$$$541$$$O	powder$$$542$$$548$$$O	formulation$$$549$$$560$$$O	of$$$561$$$563$$$O	an$$$564$$$566$$$O	antihistamine$$$567$$$580$$$I	(e.g.,$$$581$$$587$$$O	azelastine)$$$588$$$599$$$I	having$$$600$$$606$$$O	an$$$607$$$609$$$O	average$$$610$$$617$$$O	particle$$$618$$$626$$$O	size$$$627$$$631$$$O	of$$$632$$$634$$$O	between$$$635$$$642$$$O	10$$$643$$$645$$$O	and$$$646$$$649$$$O	20$$$650$$$652$$$O	microns,$$$653$$$661$$$O	the$$$662$$$665$$$O	antihistamine$$$666$$$679$$$I	is$$$680$$$682$$$O	restricted$$$683$$$693$$$O	primarily$$$694$$$703$$$O	to$$$704$$$706$$$O	the$$$707$$$710$$$O	desired$$$711$$$718$$$O	target$$$719$$$725$$$O	organ,$$$726$$$732$$$O	the$$$733$$$736$$$O	nasal$$$737$$$742$$$O	mucosa.$$$743$$$750$$$O	Because$$$751$$$758$$$O	the$$$759$$$762$$$O	active$$$763$$$769$$$O	ingredient$$$770$$$780$$$O	stays$$$781$$$786$$$O	in$$$787$$$789$$$O	the$$$790$$$793$$$O	nasal$$$794$$$799$$$O	region,$$$800$$$807$$$O	a$$$808$$$809$$$O	lower$$$810$$$815$$$O	dose$$$816$$$820$$$O	can$$$821$$$824$$$O	be$$$825$$$827$$$O	used$$$828$$$832$$$O	to$$$833$$$835$$$O	achieve$$$836$$$843$$$O	the$$$844$$$847$$$O	same$$$848$$$852$$$O	desired$$$853$$$860$$$O	effect.$$$861$$$868$$$O	As$$$869$$$871$$$O	demonstrated$$$872$$$884$$$O	by$$$885$$$887$$$O	the$$$888$$$891$$$O	examples,$$$892$$$901$$$O	this$$$902$$$906$$$O	lower$$$907$$$912$$$O	dose$$$913$$$917$$$O	reduces$$$918$$$925$$$O	the$$$926$$$929$$$O	incidence$$$930$$$939$$$O	of$$$940$$$942$$$O	somnolence,$$$943$$$954$$$O	and$$$955$$$958$$$O	because$$$959$$$966$$$O	the$$$967$$$970$$$O	active$$$971$$$977$$$O	ingredient$$$978$$$988$$$O	remains$$$989$$$996$$$O	at$$$997$$$999$$$O	the$$$1000$$$1003$$$O	target$$$1004$$$1010$$$O	organ$$$1011$$$1016$$$O	and$$$1017$$$1020$$$O	does$$$1021$$$1025$$$O	not$$$1026$$$1029$$$O	accumulate$$$1030$$$1040$$$O	in$$$1041$$$1043$$$O	the$$$1044$$$1047$$$O	back$$$1048$$$1052$$$O	of$$$1053$$$1055$$$O	the$$$1056$$$1059$$$O	throat$$$1060$$$1066$$$O	and$$$1067$$$1070$$$O	mouth,$$$1071$$$1077$$$O	this$$$1078$$$1082$$$O	formulation$$$1083$$$1094$$$O	does$$$1095$$$1099$$$O	not$$$1100$$$1103$$$O	impart$$$1104$$$1110$$$O	a$$$1111$$$1112$$$O	bitter$$$1113$$$1119$$$O	taste.$$$1120$$$1126$$$O
CN1602866A
Dripping$$$0$$$8$$$O	pills$$$9$$$14$$$O	of$$$15$$$17$$$O	tripelennamine$$$18$$$32$$$I	hydrochloride$$$33$$$46$$$I	and$$$47$$$50$$$O	its$$$51$$$54$$$O	preparation$$$55$$$66$$$O	method$$$67$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	tripelennamine$$$26$$$40$$$I	hydrochloride$$$41$$$54$$$I	pill$$$55$$$59$$$O	prepared$$$60$$$68$$$O	by$$$69$$$71$$$O	superfine$$$72$$$81$$$O	crushing$$$82$$$90$$$O	and$$$91$$$94$$$O	pill$$$95$$$99$$$O	producing$$$100$$$109$$$O	technique,$$$110$$$120$$$O	and$$$121$$$124$$$O	can$$$125$$$128$$$O	achieve$$$129$$$136$$$O	the$$$137$$$140$$$O	purposes$$$141$$$149$$$O	of$$$150$$$152$$$O	increasing$$$153$$$163$$$O	disintegration$$$164$$$178$$$O	and$$$179$$$182$$$O	dispersion$$$183$$$193$$$O	speeds,$$$194$$$201$$$O	quickly$$$202$$$209$$$O	taking$$$210$$$216$$$O	effect,$$$217$$$224$$$O	improving$$$225$$$234$$$O	drug$$$235$$$239$$$O	stability,$$$240$$$250$$$O	reducing$$$251$$$259$$$O	auxiliary$$$260$$$269$$$O	use,$$$270$$$274$$$O	reducing$$$275$$$283$$$O	production$$$284$$$294$$$O	cost,$$$295$$$300$$$O	being$$$301$$$306$$$O	convenient$$$307$$$317$$$O	to$$$318$$$320$$$O	carry$$$321$$$326$$$O	and$$$327$$$330$$$O	take.$$$331$$$336$$$O	It$$$337$$$339$$$O	can$$$340$$$343$$$O	be$$$344$$$346$$$O	both$$$347$$$351$$$O	sucked$$$352$$$358$$$O	and$$$359$$$362$$$O	swallowed,$$$363$$$373$$$O	and$$$374$$$377$$$O	its$$$378$$$381$$$O	compliance$$$382$$$392$$$O	is$$$393$$$395$$$O	good$$$396$$$400$$$O	and$$$401$$$404$$$O	especially$$$405$$$415$$$O	suitable$$$416$$$424$$$O	for$$$425$$$428$$$O	children,$$$429$$$438$$$O	the$$$439$$$442$$$O	aged,$$$443$$$448$$$O	patients$$$449$$$457$$$O	in$$$458$$$460$$$O	bed$$$461$$$464$$$O	and$$$465$$$468$$$O	patients$$$469$$$477$$$O	difficult$$$478$$$487$$$O	in$$$488$$$490$$$O	swallowing$$$491$$$501$$$O	to$$$502$$$504$$$O	take.$$$505$$$510$$$O
CA2624220A1
1-$$$0$$$2$$$I	(1h-$$$3$$$7$$$I	indol-$$$8$$$14$$$I	1-yl)$$$15$$$20$$$I	-3-$$$21$$$24$$$I	(methylamino)$$$25$$$38$$$I	-1-$$$39$$$42$$$I	phenylpropan-2-ol$$$43$$$60$$$I	derivatives$$$61$$$72$$$O	and$$$73$$$76$$$O	related$$$77$$$84$$$O	compounds$$$85$$$94$$$O	as$$$95$$$97$$$O	modulators$$$98$$$108$$$O	of$$$109$$$111$$$O	the$$$112$$$115$$$O	monoamine$$$116$$$125$$$I	reuptake$$$126$$$134$$$O	for$$$135$$$138$$$O	the$$$139$$$142$$$O	treatment$$$143$$$152$$$O	of$$$153$$$155$$$O	vasomotor$$$156$$$165$$$O	symptoms$$$166$$$174$$$O	(vms)$$$175$$$180$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	phenylaminopropanol$$$37$$$56$$$I	derivatives$$$57$$$68$$$O	of$$$69$$$71$$$O	formulae$$$72$$$80$$$O	(I),$$$81$$$85$$$O	(II),$$$86$$$91$$$O	and$$$92$$$95$$$O	(III);$$$96$$$102$$$O	or$$$103$$$105$$$O	a$$$106$$$107$$$O	pharmaceutically$$$108$$$124$$$O	acceptable$$$125$$$135$$$O	salt$$$136$$$140$$$O	thereof,$$$141$$$149$$$O	compositions$$$150$$$162$$$O	containing$$$163$$$173$$$O	these$$$174$$$179$$$O	derivatives,$$$180$$$192$$$O	and$$$193$$$196$$$O	methods$$$197$$$204$$$O	of$$$205$$$207$$$O	their$$$208$$$213$$$O	use$$$214$$$217$$$O	for$$$218$$$221$$$O	the$$$222$$$225$$$O	prevention$$$226$$$236$$$O	and$$$237$$$240$$$O	treatment$$$241$$$250$$$O	of$$$251$$$253$$$O	conditions$$$254$$$264$$$O	ameliorated$$$265$$$276$$$O	by$$$277$$$279$$$O	monoamine$$$280$$$289$$$O	reuptake$$$290$$$298$$$O	including,$$$299$$$309$$$O	inter$$$310$$$315$$$O	alia,$$$316$$$321$$$O	vasomotor$$$322$$$331$$$O	symptoms$$$332$$$340$$$O	(VMS),$$$341$$$347$$$O	sexual$$$348$$$354$$$O	dysfunction,$$$355$$$367$$$O	gastrointestinal$$$368$$$384$$$O	and$$$385$$$388$$$O	genitourinary$$$389$$$402$$$O	disorders,$$$403$$$413$$$O	chronic$$$414$$$421$$$O	fatigue$$$422$$$429$$$O	syndrome,$$$430$$$439$$$O	fibromylagia$$$440$$$452$$$O	syndrome,$$$453$$$462$$$O	nervous$$$463$$$470$$$O	system$$$471$$$477$$$O	disorders,$$$478$$$488$$$O	and$$$489$$$492$$$O	combinations$$$493$$$505$$$O	thereof,$$$506$$$514$$$O	particularly$$$515$$$527$$$O	those$$$528$$$533$$$O	conditions$$$534$$$544$$$O	selected$$$545$$$553$$$O	from$$$554$$$558$$$O	the$$$559$$$562$$$O	group$$$563$$$568$$$O	consisting$$$569$$$579$$$O	of$$$580$$$582$$$O	major$$$583$$$588$$$O	depressive$$$589$$$599$$$O	disorder,$$$600$$$609$$$O	vasomotor$$$610$$$619$$$O	symptoms,$$$620$$$629$$$O	stress$$$630$$$636$$$O	and$$$637$$$640$$$O	urge$$$641$$$645$$$O	urinary$$$646$$$653$$$O	incontinence,$$$654$$$667$$$O	fibromyalgia,$$$668$$$681$$$O	pain,$$$682$$$687$$$O	diabetic$$$688$$$696$$$O	neuropathy,$$$697$$$708$$$O	schizophrenia,$$$709$$$723$$$O	and$$$724$$$727$$$O	combinations$$$728$$$740$$$O	thereof.$$$741$$$749$$$O
CN102335266A
Health$$$0$$$6$$$O	care$$$7$$$11$$$O	product$$$12$$$19$$$O	for$$$20$$$23$$$O	supplementing$$$24$$$37$$$O	calcium$$$38$$$45$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	health$$$25$$$31$$$O	care$$$32$$$36$$$O	product$$$37$$$44$$$O	for$$$45$$$48$$$O	supplementing$$$49$$$62$$$O	calcium.$$$63$$$71$$$I	The$$$72$$$75$$$O	health$$$76$$$82$$$O	care$$$83$$$87$$$O	product$$$88$$$95$$$O	consists$$$96$$$104$$$O	of$$$105$$$107$$$O	calcium$$$108$$$115$$$I	glycinate,$$$116$$$126$$$I	ferrous$$$127$$$134$$$I	glycine,$$$135$$$143$$$I	epimedium$$$144$$$153$$$O	herb,$$$154$$$159$$$O	beef$$$160$$$164$$$O	bone,$$$165$$$170$$$O	tangerine$$$171$$$180$$$O	peel,$$$181$$$186$$$O	costustoot,$$$187$$$198$$$O	and$$$199$$$202$$$O	vitamin$$$203$$$210$$$I	D.$$$211$$$213$$$I	The$$$214$$$217$$$O	health$$$218$$$224$$$O	care$$$225$$$229$$$O	product$$$230$$$237$$$O	can$$$238$$$241$$$O	improve$$$242$$$249$$$O	immunity$$$250$$$258$$$O	of$$$259$$$261$$$O	a$$$262$$$263$$$O	human$$$264$$$269$$$O	body,$$$270$$$275$$$O	has$$$276$$$279$$$O	the$$$280$$$283$$$O	anti-fatigue$$$284$$$296$$$O	and$$$297$$$300$$$O	anti-aging$$$301$$$311$$$O	effects,$$$312$$$320$$$O	and$$$321$$$324$$$O	strengthens$$$325$$$336$$$O	bones$$$337$$$342$$$O	and$$$343$$$346$$$O	muscles,$$$347$$$355$$$O	tonifies$$$356$$$364$$$O	the$$$365$$$368$$$O	kidney$$$369$$$375$$$O	and$$$376$$$379$$$O	controls$$$380$$$388$$$O	nocturnal$$$389$$$398$$$O	emission,$$$399$$$408$$$O	and$$$409$$$412$$$O	delays$$$413$$$419$$$O	ageing.$$$420$$$427$$$O
US20080319047
Novel$$$0$$$5$$$O	Glucitol$$$6$$$14$$$I	Derivative,$$$15$$$26$$$O	Prodrug$$$27$$$34$$$O	Thereof$$$35$$$42$$$O	And$$$43$$$46$$$O	Salt$$$47$$$51$$$O	Thereof,$$$52$$$60$$$O	And$$$61$$$64$$$O	Therapeutic$$$65$$$76$$$O	Agent$$$77$$$82$$$O	Containing$$$83$$$93$$$O	The$$$94$$$97$$$O	Same$$$98$$$102$$$O	For$$$103$$$106$$$O	Diabetes$$$107$$$115$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	glucitol$$$25$$$33$$$I	derivative$$$34$$$44$$$O	having$$$45$$$51$$$O	the$$$52$$$55$$$O	function$$$56$$$64$$$O	of$$$65$$$67$$$O	reducing$$$68$$$76$$$O	a$$$77$$$78$$$O	blood$$$79$$$84$$$O	sugar$$$85$$$90$$$I	level$$$91$$$96$$$O	and$$$97$$$100$$$O	having$$$101$$$107$$$O	preferable$$$108$$$118$$$O	properties$$$119$$$129$$$O	required$$$130$$$138$$$O	of$$$139$$$141$$$O	medicines,$$$142$$$152$$$O	such$$$153$$$157$$$O	as$$$158$$$160$$$O	long-lasting$$$161$$$173$$$O	drug$$$174$$$178$$$O	activity;$$$179$$$188$$$O	and$$$189$$$192$$$O	a$$$193$$$194$$$O	medicinal$$$195$$$204$$$O	composition$$$205$$$216$$$O	for$$$217$$$220$$$O	use$$$221$$$224$$$O	in$$$225$$$227$$$O	the$$$228$$$231$$$O	prevention$$$232$$$242$$$O	or$$$243$$$245$$$O	treatment$$$246$$$255$$$O	of$$$256$$$258$$$O	diseases$$$259$$$267$$$O	attributable$$$268$$$280$$$O	to$$$281$$$283$$$O	hyperglycemia,$$$284$$$298$$$O	such$$$299$$$303$$$O	as$$$304$$$306$$$O	diabetes,$$$307$$$316$$$O	complications$$$317$$$330$$$O	of$$$331$$$333$$$O	diabetes,$$$334$$$343$$$O	and$$$344$$$347$$$O	obesity.$$$348$$$356$$$O	The$$$357$$$360$$$O	derivative$$$361$$$371$$$O	is$$$372$$$374$$$O	a$$$375$$$376$$$O	compound$$$377$$$385$$$O	represented$$$386$$$397$$$O	by$$$398$$$400$$$O	the$$$401$$$404$$$O	formula$$$405$$$412$$$O	(I):$$$413$$$417$$$O	wherein$$$455$$$462$$$O	m$$$463$$$464$$$O	is$$$465$$$467$$$O	an$$$468$$$470$$$O	integer$$$471$$$478$$$O	selected$$$479$$$487$$$O	among$$$488$$$493$$$O	1-3;$$$494$$$498$$$O	R1$$$499$$$501$$$O	to$$$502$$$504$$$O	R4$$$505$$$507$$$O	each$$$508$$$512$$$O	independently$$$513$$$526$$$O	is$$$527$$$529$$$O	optionally$$$530$$$540$$$O	substituted$$$541$$$552$$$O	alkyl,$$$553$$$559$$$I	etc.;$$$560$$$565$$$O	Ar1$$$566$$$569$$$O	is$$$570$$$572$$$O	optionally$$$573$$$583$$$O	substituted$$$584$$$595$$$O	naphthyl;$$$596$$$605$$$I	and$$$606$$$609$$$O	A$$$610$$$611$$$O	is$$$612$$$614$$$O	optionally$$$615$$$625$$$O	substituted$$$626$$$637$$$O	heteroaryl,$$$638$$$649$$$I	a$$$650$$$651$$$O	prodrug$$$652$$$659$$$O	of$$$660$$$662$$$O	the$$$663$$$666$$$O	compound,$$$667$$$676$$$O	or$$$677$$$679$$$O	a$$$680$$$681$$$O	pharmaceutically$$$682$$$698$$$O	acceptable$$$699$$$709$$$O	salt$$$710$$$714$$$O	of$$$715$$$717$$$O	either.$$$718$$$725$$$O	Also$$$726$$$730$$$O	provided$$$731$$$739$$$O	are$$$740$$$743$$$O	a$$$744$$$745$$$O	medicine,$$$746$$$755$$$O	a$$$756$$$757$$$O	medicinal$$$758$$$767$$$O	composition,$$$768$$$780$$$O	and$$$781$$$784$$$O	the$$$785$$$788$$$O	like$$$789$$$793$$$O	each$$$794$$$798$$$O	containing$$$799$$$809$$$O	the$$$810$$$813$$$O	compound.$$$814$$$823$$$O
WO2011067560A1
Combination$$$0$$$11$$$O	of$$$12$$$14$$$O	droloxifene$$$15$$$26$$$O	and$$$27$$$30$$$O	clopidogrel$$$31$$$42$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	composition$$$29$$$40$$$O	and$$$41$$$44$$$O	use$$$45$$$48$$$O	of$$$49$$$51$$$O	a$$$52$$$53$$$O	medicament$$$54$$$64$$$O	comprising$$$65$$$75$$$O	a$$$76$$$77$$$O	fixed$$$78$$$83$$$O	dose$$$84$$$88$$$O	combination$$$89$$$100$$$O	of$$$101$$$103$$$O	droloxifene$$$104$$$115$$$O	and$$$116$$$119$$$O	clopidogrel.$$$120$$$132$$$O
CN101045149A
Medicine$$$0$$$8$$$O	composition$$$9$$$20$$$O	and$$$21$$$24$$$O	its$$$25$$$28$$$O	preparing$$$29$$$38$$$O	method$$$39$$$45$$$O
A$$$0$$$1$$$O	medicinal$$$2$$$11$$$O	composition$$$12$$$23$$$O	is$$$24$$$26$$$O	prepared$$$27$$$35$$$O	from$$$36$$$40$$$O	gentamycin,$$$41$$$52$$$I	amitriptyline,$$$53$$$67$$$I	honey,$$$68$$$74$$$O	and$$$75$$$78$$$O	11$$$79$$$81$$$O	Chinese-medicinal$$$82$$$99$$$O	materials$$$100$$$109$$$O	including$$$110$$$119$$$O	notoginseng,$$$120$$$132$$$O	peach$$$133$$$138$$$O	kernel,$$$139$$$146$$$O	fennel,$$$147$$$154$$$O	borax,$$$155$$$161$$$I	etc.$$$162$$$166$$$O	Its$$$167$$$170$$$O	preparing$$$171$$$180$$$O	process$$$181$$$188$$$O	is$$$189$$$191$$$O	also$$$192$$$196$$$O	disclosed.$$$197$$$207$$$O
CN101219110A
Sustained-release$$$0$$$17$$$O	injection$$$18$$$27$$$O	containing$$$28$$$38$$$O	methotrexate$$$39$$$51$$$I	potentiating$$$52$$$64$$$O	agent$$$65$$$70$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	anticancer$$$26$$$36$$$O	drug$$$37$$$41$$$O	sustained$$$42$$$51$$$O	release$$$52$$$59$$$O	agent$$$60$$$65$$$O	containing$$$66$$$76$$$O	amethopterin,$$$77$$$90$$$I	which$$$91$$$96$$$O	is$$$97$$$99$$$O	a$$$100$$$101$$$O	sustained$$$102$$$111$$$O	release$$$112$$$119$$$O	injection$$$120$$$129$$$O	consisting$$$130$$$140$$$O	of$$$141$$$143$$$O	sustained$$$144$$$153$$$O	release$$$154$$$161$$$O	microspheres$$$162$$$174$$$O	and$$$175$$$178$$$O	solvent,$$$179$$$187$$$O	wherein,$$$188$$$196$$$O	the$$$197$$$200$$$O	sustained$$$201$$$210$$$O	release$$$211$$$218$$$O	microspheres$$$219$$$231$$$O	comprise$$$232$$$240$$$O	effective$$$241$$$250$$$O	anticancer$$$251$$$261$$$O	components$$$262$$$272$$$O	and$$$273$$$276$$$O	sustained-release$$$277$$$294$$$O	excipient,$$$295$$$305$$$O	and$$$306$$$309$$$O	the$$$310$$$313$$$O	solvent$$$314$$$321$$$O	is$$$322$$$324$$$O	normal$$$325$$$331$$$O	solvent$$$332$$$339$$$O	or$$$340$$$342$$$O	special$$$343$$$350$$$O	solvent$$$351$$$358$$$O	containing$$$359$$$369$$$O	a$$$370$$$371$$$O	suspending$$$372$$$382$$$O	agent.$$$383$$$389$$$O	The$$$390$$$393$$$O	effective$$$394$$$403$$$O	anticancer$$$404$$$414$$$O	components$$$415$$$425$$$O	are$$$426$$$429$$$O	amethopterin$$$430$$$442$$$I	and$$$443$$$446$$$O	the$$$447$$$450$$$O	combination$$$451$$$462$$$O	of$$$463$$$465$$$O	amethopterin$$$466$$$478$$$I	synergist$$$479$$$488$$$O	chosen$$$489$$$495$$$O	from$$$496$$$500$$$O	antitumor$$$501$$$510$$$O	antibiotics$$$511$$$522$$$O	and/or$$$523$$$529$$$O	taxane.$$$530$$$537$$$I	The$$$538$$$541$$$O	sustained-release$$$542$$$559$$$O	excipient$$$560$$$569$$$O	is$$$570$$$572$$$O	one$$$573$$$576$$$O	of$$$577$$$579$$$O	or$$$580$$$582$$$O	the$$$583$$$586$$$O	combination$$$587$$$598$$$O	of$$$599$$$601$$$O	copolymer$$$602$$$611$$$O	of$$$612$$$614$$$O	polylactic$$$615$$$625$$$I	acid,$$$626$$$631$$$I	polyglycolic$$$632$$$644$$$I	acid$$$645$$$649$$$I	and$$$650$$$653$$$O	glycolic$$$654$$$662$$$I	acid,$$$663$$$668$$$I	ethylene$$$669$$$677$$$I	vinyl$$$678$$$683$$$I	acetate$$$684$$$691$$$I	copolymer,$$$692$$$702$$$O	Polifeprosan$$$703$$$715$$$I	and$$$716$$$719$$$O	FAD$$$720$$$723$$$I	and$$$724$$$727$$$O	sebacie$$$728$$$735$$$I	acid$$$736$$$740$$$I	copolymer.$$$741$$$751$$$O	The$$$752$$$755$$$O	suspending$$$756$$$766$$$O	agent$$$767$$$772$$$O	is$$$773$$$775$$$O	chosen$$$776$$$782$$$O	from$$$783$$$787$$$O	one$$$788$$$791$$$O	of$$$792$$$794$$$O	or$$$795$$$797$$$O	the$$$798$$$801$$$O	combination$$$802$$$813$$$O	of$$$814$$$816$$$O	sodium$$$817$$$823$$$O	carboxymethylcellulose,$$$824$$$847$$$O	mannitol,$$$848$$$857$$$I	sorbitol,$$$858$$$867$$$I	Tween$$$868$$$873$$$I	80$$$874$$$876$$$I	or$$$877$$$879$$$O	the$$$880$$$883$$$O	combination$$$884$$$895$$$O	thereof.$$$896$$$904$$$O	The$$$905$$$908$$$O	sustained$$$909$$$918$$$O	release$$$919$$$926$$$O	microspheres$$$927$$$939$$$O	can$$$940$$$943$$$O	also$$$944$$$948$$$O	be$$$949$$$951$$$O	produced$$$952$$$960$$$O	into$$$961$$$965$$$O	a$$$966$$$967$$$O	sustained-release$$$968$$$985$$$O	implant.$$$986$$$994$$$O	The$$$995$$$998$$$O	sustained-release$$$999$$$1016$$$O	agent$$$1017$$$1022$$$O	is$$$1023$$$1025$$$O	arranged$$$1026$$$1034$$$O	around$$$1035$$$1041$$$O	the$$$1042$$$1045$$$O	tumor$$$1046$$$1051$$$O	or$$$1052$$$1054$$$O	injected$$$1055$$$1063$$$O	in$$$1064$$$1066$$$O	the$$$1067$$$1070$$$O	tumor,$$$1071$$$1077$$$O	which$$$1078$$$1083$$$O	not$$$1084$$$1087$$$O	only$$$1088$$$1092$$$O	reduces$$$1093$$$1100$$$O	toxic$$$1101$$$1106$$$O	reaction$$$1107$$$1115$$$O	of$$$1116$$$1118$$$O	the$$$1119$$$1122$$$O	whole$$$1123$$$1128$$$O	body,$$$1129$$$1134$$$O	but$$$1135$$$1138$$$O	also$$$1139$$$1143$$$O	increases$$$1144$$$1153$$$O	the$$$1154$$$1157$$$O	drug$$$1158$$$1162$$$O	concentration$$$1163$$$1176$$$O	at$$$1177$$$1179$$$O	the$$$1180$$$1183$$$O	local$$$1184$$$1189$$$O	tumor$$$1190$$$1195$$$O	selectively,$$$1196$$$1208$$$O	thereby$$$1209$$$1216$$$O	improving$$$1217$$$1226$$$O	treatment$$$1227$$$1236$$$O	effect$$$1237$$$1243$$$O	of$$$1244$$$1246$$$O	chemotherapeutics,$$$1247$$$1265$$$O	radiotherapeutics$$$1266$$$1283$$$O	and$$$1284$$$1287$$$O	other$$$1288$$$1293$$$O	non-operative$$$1294$$$1307$$$O	treatment.$$$1308$$$1318$$$O
US20050100902
5-cyano-1h-indole$$$0$$$17$$$I	derivatives$$$18$$$29$$$O	as$$$30$$$32$$$O	antagonist$$$33$$$43$$$O	of$$$44$$$46$$$O	the$$$47$$$50$$$O	inerleukine-8$$$51$$$64$$$O	receptors$$$65$$$74$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	derivatives$$$33$$$44$$$O	of$$$45$$$47$$$O	5-cyano-1H-indole$$$48$$$65$$$I	of$$$66$$$68$$$O	formula$$$69$$$76$$$O	(I):$$$77$$$81$$$O	in$$$100$$$102$$$O	which$$$103$$$108$$$O	R1,$$$109$$$112$$$O	R2,$$$113$$$116$$$O	X$$$117$$$118$$$O	and$$$119$$$122$$$O	n$$$123$$$124$$$O	are$$$125$$$128$$$O	as$$$129$$$131$$$O	defined$$$132$$$139$$$O	in$$$140$$$142$$$O	claim$$$143$$$148$$$O	1,$$$149$$$151$$$O	as$$$152$$$154$$$O	well$$$155$$$159$$$O	as$$$160$$$162$$$O	to$$$163$$$165$$$O	their$$$166$$$171$$$O	pharmaceutically$$$172$$$188$$$O	acceptable$$$189$$$199$$$O	salts,$$$200$$$206$$$O	solvates$$$207$$$215$$$O	and$$$216$$$219$$$O	hydrates.$$$220$$$229$$$I	Pharmaceutical$$$230$$$244$$$O	compositions$$$245$$$257$$$O	containing$$$258$$$268$$$O	them,$$$269$$$274$$$O	as$$$275$$$277$$$O	well$$$278$$$282$$$O	as$$$283$$$285$$$O	their$$$286$$$291$$$O	use$$$292$$$295$$$O	for$$$296$$$299$$$O	the$$$300$$$303$$$O	preparation$$$304$$$315$$$O	of$$$316$$$318$$$O	medicaments$$$319$$$330$$$O	intended$$$331$$$339$$$O	for$$$340$$$343$$$O	the$$$344$$$347$$$O	preventative$$$348$$$360$$$O	or$$$361$$$363$$$O	curative$$$364$$$372$$$O	treatment$$$373$$$382$$$O	of$$$383$$$385$$$O	illnesses$$$386$$$395$$$O	which$$$396$$$401$$$O	are$$$402$$$405$$$O	dependent$$$406$$$415$$$O	upon$$$416$$$420$$$O	the$$$421$$$424$$$O	activation$$$425$$$435$$$O	of$$$436$$$438$$$O	the$$$439$$$442$$$O	interleukin$$$443$$$454$$$O	CXCR2$$$455$$$460$$$O	receptor$$$461$$$469$$$O	and$$$470$$$473$$$O	of$$$474$$$476$$$O	the$$$477$$$480$$$O	chemokines$$$481$$$491$$$O	of$$$492$$$494$$$O	the$$$495$$$498$$$O	same$$$499$$$503$$$O	family,$$$504$$$511$$$O	are$$$512$$$515$$$O	also$$$516$$$520$$$O	subjects$$$521$$$529$$$O	of$$$530$$$532$$$O	the$$$533$$$536$$$O	invention.$$$537$$$547$$$O
WO2014002053A1
Pyrrolidine$$$0$$$11$$$I	derivatives$$$12$$$23$$$O	and$$$24$$$27$$$O	their$$$28$$$33$$$O	use$$$34$$$37$$$O	as$$$38$$$40$$$O	complement$$$41$$$51$$$O	pathway$$$52$$$59$$$O	modulators$$$60$$$70$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	compound$$$33$$$41$$$O	of$$$42$$$44$$$O	formula$$$45$$$52$$$O	(I)$$$53$$$56$$$O	a$$$57$$$58$$$O	method$$$59$$$65$$$O	for$$$66$$$69$$$O	manufacturing$$$70$$$83$$$O	the$$$84$$$87$$$O	compounds$$$88$$$97$$$O	of$$$98$$$100$$$O	the$$$101$$$104$$$O	invention$$$105$$$114$$$O	and$$$115$$$118$$$O	its$$$119$$$122$$$O	therapeutic$$$123$$$134$$$O	uses$$$135$$$139$$$O	as$$$140$$$142$$$O	complement$$$143$$$153$$$O	pathway$$$154$$$161$$$O	modulators$$$162$$$172$$$O	for$$$173$$$176$$$O	the$$$177$$$180$$$O	treatment$$$181$$$190$$$O	of$$$191$$$193$$$O	ocular$$$194$$$200$$$O	diseases.$$$201$$$210$$$O	The$$$211$$$214$$$O	present$$$215$$$222$$$O	invention$$$223$$$232$$$O	further$$$233$$$240$$$O	provides$$$241$$$249$$$O	a$$$250$$$251$$$O	combination$$$252$$$263$$$O	of$$$264$$$266$$$O	pharmacologically$$$267$$$284$$$O	active$$$285$$$291$$$O	agents$$$292$$$298$$$O	and$$$299$$$302$$$O	a$$$303$$$304$$$O	pharmaceutical$$$305$$$319$$$O	composition.$$$320$$$332$$$O
CN1931159B
Superfine$$$0$$$9$$$O	Iguratimod$$$10$$$20$$$I	powder$$$21$$$27$$$O	and$$$28$$$31$$$O	quick$$$32$$$37$$$O	released$$$38$$$46$$$O	oral$$$47$$$51$$$O	preparation$$$52$$$63$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	micronizing$$$37$$$48$$$O	technology$$$49$$$59$$$O	for$$$60$$$63$$$O	insoluble$$$64$$$73$$$O	polycrystal$$$74$$$85$$$O	medicine$$$86$$$94$$$O	Iguratimod,$$$95$$$106$$$I	and$$$107$$$110$$$O	the$$$111$$$114$$$O	micronized$$$115$$$125$$$O	Iguratimod$$$126$$$136$$$I	has$$$137$$$140$$$O	new$$$141$$$144$$$O	crystallization$$$145$$$160$$$O	and$$$161$$$164$$$O	powder$$$165$$$171$$$O	size$$$172$$$176$$$O	of$$$177$$$179$$$O	1-10$$$180$$$184$$$O	microns.$$$185$$$193$$$O	The$$$194$$$197$$$O	orally$$$198$$$204$$$O	taken$$$205$$$210$$$O	quick$$$211$$$216$$$O	release$$$217$$$224$$$O	preparation$$$225$$$236$$$O	with$$$237$$$241$$$O	micronized$$$242$$$252$$$O	Iguratimod$$$253$$$263$$$I	as$$$264$$$266$$$O	active$$$267$$$273$$$O	component,$$$274$$$284$$$O	high$$$285$$$289$$$O	efficiency$$$290$$$300$$$O	disintegrant,$$$301$$$314$$$O	surfactant,$$$315$$$326$$$O	diluent,$$$327$$$335$$$O	etc$$$336$$$339$$$O	has$$$340$$$343$$$O	obviously$$$344$$$353$$$O	improved$$$354$$$362$$$O	in$$$363$$$365$$$O	vitro$$$366$$$371$$$O	leaching$$$372$$$380$$$O	rate$$$381$$$385$$$O	and$$$386$$$389$$$O	in$$$390$$$392$$$O	vivo$$$393$$$397$$$O	absorption$$$398$$$408$$$O	rate,$$$409$$$414$$$O	and$$$415$$$418$$$O	obviously$$$419$$$428$$$O	raised$$$429$$$435$$$O	bioavailability.$$$436$$$452$$$O
CN101606955A
Tamariskoid$$$0$$$11$$$O	spikemoss$$$12$$$21$$$O	herb$$$22$$$26$$$O	effective$$$27$$$36$$$O	part$$$37$$$41$$$O	for$$$42$$$45$$$O	reducing$$$46$$$54$$$O	blood$$$55$$$60$$$O	lipid,$$$61$$$67$$$O	extraction$$$68$$$78$$$O	method$$$79$$$85$$$O	and$$$86$$$89$$$O	application$$$90$$$101$$$O	thereof,$$$102$$$110$$$O	and$$$111$$$114$$$O	extraction$$$115$$$125$$$O	method$$$126$$$132$$$O	of$$$133$$$135$$$O	amentoflavone$$$136$$$149$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	tamariskoid$$$26$$$37$$$O	spikemoss$$$38$$$47$$$O	herb$$$48$$$52$$$O	effective$$$53$$$62$$$O	part$$$63$$$67$$$O	for$$$68$$$71$$$O	reducing$$$72$$$80$$$O	blood$$$81$$$86$$$O	lipid,$$$87$$$93$$$O	and$$$94$$$97$$$O	an$$$98$$$100$$$O	extraction$$$101$$$111$$$O	method$$$112$$$118$$$O	and$$$119$$$122$$$O	application$$$123$$$134$$$O	thereof.$$$135$$$143$$$O	The$$$144$$$147$$$O	effective$$$148$$$157$$$O	part$$$158$$$162$$$O	is$$$163$$$165$$$O	an$$$166$$$168$$$O	ethyl$$$169$$$174$$$I	acetate$$$175$$$182$$$I	part$$$183$$$187$$$O	obtained$$$188$$$196$$$O	by$$$197$$$199$$$O	extracting$$$200$$$210$$$O	tamariskoid$$$211$$$222$$$O	spikemoss$$$223$$$232$$$O	herb$$$233$$$237$$$O	by$$$238$$$240$$$O	acetone$$$241$$$248$$$I	water,$$$249$$$255$$$O	concentrating$$$256$$$269$$$O	and$$$270$$$273$$$O	extracting$$$274$$$284$$$O	by$$$285$$$287$$$O	ethyl$$$288$$$293$$$I	acetate.$$$294$$$302$$$I	The$$$303$$$306$$$O	tamariskoid$$$307$$$318$$$O	spikemoss$$$319$$$328$$$O	herb$$$329$$$333$$$O	effective$$$334$$$343$$$O	part$$$344$$$348$$$O	for$$$349$$$352$$$O	reducing$$$353$$$361$$$O	blood$$$362$$$367$$$O	lipid$$$368$$$373$$$O	is$$$374$$$376$$$O	obtained$$$377$$$385$$$O	by$$$386$$$388$$$O	extracting$$$389$$$399$$$O	from$$$400$$$404$$$O	lipid$$$405$$$410$$$O	solubility$$$411$$$421$$$O	part$$$422$$$426$$$O	of$$$427$$$429$$$O	tamariskoid$$$430$$$441$$$O	spikemoss$$$442$$$451$$$O	herb$$$452$$$456$$$O	and$$$457$$$460$$$O	the$$$461$$$464$$$O	tamariskoid$$$465$$$476$$$O	spikemoss$$$477$$$486$$$O	herb$$$487$$$491$$$O	is$$$492$$$494$$$O	distributed$$$495$$$506$$$O	widely$$$507$$$513$$$O	in$$$514$$$516$$$O	nature,$$$517$$$524$$$O	so$$$525$$$527$$$O	that$$$528$$$532$$$O	the$$$533$$$536$$$O	raw$$$537$$$540$$$O	material$$$541$$$549$$$O	is$$$550$$$552$$$O	easy$$$553$$$557$$$O	to$$$558$$$560$$$O	obtain$$$561$$$567$$$O	and$$$568$$$571$$$O	low$$$572$$$575$$$O	in$$$576$$$578$$$O	cost.$$$579$$$584$$$O	In$$$585$$$587$$$O	addition,$$$588$$$597$$$O	the$$$598$$$601$$$O	extraction$$$602$$$612$$$O	method$$$613$$$619$$$O	has$$$620$$$623$$$O	simple$$$624$$$630$$$O	technological$$$631$$$644$$$O	process$$$645$$$652$$$O	and$$$653$$$656$$$O	easy$$$657$$$661$$$O	operation.$$$662$$$672$$$O	Experiment$$$673$$$683$$$O	shows$$$684$$$689$$$O	that$$$690$$$694$$$O	the$$$695$$$698$$$O	amentoflavone$$$699$$$712$$$I	obtained$$$713$$$721$$$O	by$$$722$$$724$$$O	further$$$725$$$732$$$O	extracting$$$733$$$743$$$O	the$$$744$$$747$$$O	tamariskoid$$$748$$$759$$$O	spikemoss$$$760$$$769$$$O	herb$$$770$$$774$$$O	effective$$$775$$$784$$$O	part$$$785$$$789$$$O	for$$$790$$$793$$$O	reducing$$$794$$$802$$$O	blood$$$803$$$808$$$O	lipid$$$809$$$814$$$O	has$$$815$$$818$$$O	good$$$819$$$823$$$O	function$$$824$$$832$$$O	of$$$833$$$835$$$O	reducing$$$836$$$844$$$O	blood$$$845$$$850$$$O	lipid.$$$851$$$857$$$O	Experiment$$$858$$$868$$$O	in$$$869$$$871$$$O	vivo$$$872$$$876$$$O	shows$$$877$$$882$$$O	that$$$883$$$887$$$O	the$$$888$$$891$$$O	blood$$$892$$$897$$$O	lipid$$$898$$$903$$$O	level$$$904$$$909$$$O	can$$$910$$$913$$$O	be$$$914$$$916$$$O	reduced$$$917$$$924$$$O	by$$$925$$$927$$$O	reducing$$$928$$$936$$$O	serum$$$937$$$942$$$O	total$$$943$$$948$$$O	cholesterol$$$949$$$960$$$I	and$$$961$$$964$$$O	low-density$$$965$$$976$$$O	lipoprotein$$$977$$$988$$$O	cholesterol$$$989$$$1000$$$I	of$$$1001$$$1003$$$O	hyperlipidemic$$$1004$$$1018$$$O	mouse.$$$1019$$$1025$$$O	The$$$1026$$$1029$$$O	amentoflavone$$$1030$$$1043$$$I	has$$$1044$$$1047$$$O	higher$$$1048$$$1054$$$O	extraction$$$1055$$$1065$$$O	rate,$$$1066$$$1071$$$O	and$$$1072$$$1075$$$O	the$$$1076$$$1079$$$O	once$$$1080$$$1084$$$O	extraction$$$1085$$$1095$$$O	rate$$$1096$$$1100$$$O	can$$$1101$$$1104$$$O	reach$$$1105$$$1110$$$O	as$$$1111$$$1113$$$O	high$$$1114$$$1118$$$O	as$$$1119$$$1121$$$O	30$$$1122$$$1124$$$O	to$$$1125$$$1127$$$O	40$$$1128$$$1130$$$O	percent.$$$1131$$$1139$$$O
US20060058345
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	papaverine-like$$$7$$$22$$$I	vasodilator$$$23$$$34$$$O	and$$$35$$$38$$$O	pharmaceutical$$$39$$$53$$$O	composition$$$54$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	the$$$23$$$26$$$O	use$$$27$$$30$$$O	of$$$31$$$33$$$O	papaverine-like$$$34$$$49$$$I	vasodilator$$$50$$$61$$$O	for$$$62$$$65$$$O	the$$$66$$$69$$$O	production$$$70$$$80$$$O	of$$$81$$$83$$$O	a$$$84$$$85$$$O	pharmaceutical$$$86$$$100$$$O	composition$$$101$$$112$$$O	for$$$113$$$116$$$O	the$$$117$$$120$$$O	treatment$$$121$$$130$$$O	of$$$131$$$133$$$O	ophthalmological$$$134$$$150$$$O	dysfunctions$$$151$$$163$$$O	which$$$164$$$169$$$O	are$$$170$$$173$$$O	linked$$$174$$$180$$$O	to$$$181$$$183$$$O	circulatory$$$184$$$195$$$O	disturbances$$$196$$$208$$$O	of$$$209$$$211$$$O	the$$$212$$$215$$$O	eye$$$216$$$219$$$O	or$$$220$$$222$$$O	which$$$223$$$228$$$O	are$$$229$$$232$$$O	to$$$233$$$235$$$O	be$$$236$$$238$$$O	attributed$$$239$$$249$$$O	to$$$250$$$252$$$O	circulatory$$$253$$$264$$$O	disturbances$$$265$$$277$$$O	of$$$278$$$280$$$O	the$$$281$$$284$$$O	eye,$$$285$$$289$$$O	wherein$$$290$$$297$$$O	the$$$298$$$301$$$O	pharmaceutical$$$302$$$316$$$O	composition$$$317$$$328$$$O	is$$$329$$$331$$$O	to$$$332$$$334$$$O	be$$$335$$$337$$$O	applied$$$338$$$345$$$O	topically$$$346$$$355$$$O	to$$$356$$$358$$$O	the$$$359$$$362$$$O	eye.$$$363$$$367$$$O	The$$$368$$$371$$$O	invention$$$372$$$381$$$O	further$$$382$$$389$$$O	concerns$$$390$$$398$$$O	a$$$399$$$400$$$O	pharmaceutical$$$401$$$415$$$O	composition$$$416$$$427$$$O	which$$$428$$$433$$$O	includes$$$434$$$442$$$O	papaverine-like$$$443$$$458$$$I	vasodilator$$$459$$$470$$$O	and$$$471$$$474$$$O	pharmacologically$$$475$$$492$$$O	compatible$$$493$$$503$$$O	viscosity$$$504$$$513$$$O	regulator.$$$514$$$524$$$O
WO2008050871A1
Crystalline$$$0$$$11$$$O	carbapenem$$$12$$$22$$$I	compounds$$$23$$$32$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	crystalline$$$23$$$34$$$O	substances$$$35$$$45$$$O	each$$$46$$$50$$$O	consisting$$$51$$$61$$$O	of$$$62$$$64$$$O	the$$$65$$$68$$$O	carbapenem$$$69$$$79$$$I	compound$$$80$$$88$$$O	represented$$$89$$$100$$$O	by$$$101$$$103$$$O	formula$$$104$$$111$$$O	(I)$$$112$$$115$$$O	or$$$116$$$118$$$O	a$$$119$$$120$$$O	solvate$$$121$$$128$$$O	of$$$129$$$131$$$O	the$$$132$$$135$$$O	compound.$$$136$$$145$$$O	The$$$146$$$149$$$O	crystalline$$$150$$$161$$$O	substances$$$162$$$172$$$O	are$$$173$$$176$$$O	excellent$$$177$$$186$$$O	in$$$187$$$189$$$O	handleability$$$190$$$203$$$O	and$$$204$$$207$$$O	storage$$$208$$$215$$$O	stability.$$$216$$$226$$$O	Further,$$$227$$$235$$$O	the$$$236$$$239$$$O	invention$$$240$$$249$$$O	also$$$250$$$254$$$O	provides$$$255$$$263$$$O	solid$$$264$$$269$$$O	compositions$$$270$$$282$$$O	each$$$283$$$287$$$O	containing$$$288$$$298$$$O	both$$$299$$$303$$$O	the$$$304$$$307$$$O	compound$$$308$$$316$$$O	of$$$317$$$319$$$O	formula$$$320$$$327$$$O	(I)$$$328$$$331$$$O	and$$$332$$$335$$$O	an$$$336$$$338$$$O	alkali$$$339$$$345$$$O	metal$$$346$$$351$$$O	halide.$$$352$$$359$$$I	The$$$360$$$363$$$O	crystalline$$$364$$$375$$$O	substances$$$376$$$386$$$O	and$$$387$$$390$$$O	the$$$391$$$394$$$O	solid$$$395$$$400$$$O	compositions$$$401$$$413$$$O	exhibit$$$414$$$421$$$O	excellent$$$422$$$431$$$O	antimicrobial$$$432$$$445$$$O	activity.$$$446$$$455$$$O
EP2265271A1
Crystalline$$$0$$$11$$$O	2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide$$$12$$$99$$$I
Crystalline$$$0$$$11$$$O	R-2-(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-y1)-propionamide$$$12$$$100$$$I	and$$$101$$$104$$$O	methods$$$105$$$112$$$O	of$$$113$$$115$$$O	its$$$116$$$119$$$O	preparation$$$120$$$131$$$O	and$$$132$$$135$$$O	use$$$136$$$139$$$O	are$$$140$$$143$$$O	disclosed.$$$144$$$154$$$O
CN101721713B
Cyclodextrin$$$0$$$12$$$O	inclusion$$$13$$$22$$$O	compound$$$23$$$31$$$O	of$$$32$$$34$$$O	3,5-dyhydroxyl-4-isopropyl$$$35$$$61$$$I	toluylene$$$62$$$71$$$I	and$$$72$$$75$$$O	preparation$$$76$$$87$$$O	method$$$88$$$94$$$O	thereof$$$95$$$102$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	cyclodextrin$$$26$$$38$$$O	inclusion$$$39$$$48$$$O	compound$$$49$$$57$$$O	of$$$58$$$60$$$O	3,5-dyhydroxyl-4-isopropyl$$$61$$$87$$$I	toluylene$$$88$$$97$$$I	and$$$98$$$101$$$O	a$$$102$$$103$$$O	preparation$$$104$$$115$$$O	method$$$116$$$122$$$O	thereof.$$$123$$$131$$$O	In$$$132$$$134$$$O	the$$$135$$$138$$$O	invention,$$$139$$$149$$$O	by$$$150$$$152$$$O	adopting$$$153$$$161$$$O	cyclodextrin$$$162$$$174$$$O	to$$$175$$$177$$$O	wrapping$$$178$$$186$$$O	a$$$187$$$188$$$O	medicine,$$$189$$$198$$$O	the$$$199$$$202$$$O	solubility$$$203$$$213$$$O	and$$$214$$$217$$$O	the$$$218$$$221$$$O	dissolution$$$222$$$233$$$O	of$$$234$$$236$$$O	the$$$237$$$240$$$O	medicine$$$241$$$249$$$O	are$$$250$$$253$$$O	increased,$$$254$$$264$$$O	the$$$265$$$268$$$O	stability$$$269$$$278$$$O	and$$$279$$$282$$$O	the$$$283$$$286$$$O	bioavailability$$$287$$$302$$$O	of$$$303$$$305$$$O	the$$$306$$$309$$$O	medicine$$$310$$$318$$$O	are$$$319$$$322$$$O	improved,$$$323$$$332$$$O	and$$$333$$$336$$$O	the$$$337$$$340$$$O	aim$$$341$$$344$$$O	of$$$345$$$347$$$O	slowly-controlled$$$348$$$365$$$O	release$$$366$$$373$$$O	of$$$374$$$376$$$O	the$$$377$$$380$$$O	medicine$$$381$$$389$$$O	can$$$390$$$393$$$O	be$$$394$$$396$$$O	simultaneously$$$397$$$411$$$O	achieved.$$$412$$$421$$$O	The$$$422$$$425$$$O	invention$$$426$$$435$$$O	also$$$436$$$440$$$O	provides$$$441$$$449$$$O	the$$$450$$$453$$$O	preparation$$$454$$$465$$$O	method$$$466$$$472$$$O	of$$$473$$$475$$$O	the$$$476$$$479$$$O	cyclodextrin$$$480$$$492$$$O	inclusion$$$493$$$502$$$O	compound$$$503$$$511$$$O	of$$$512$$$514$$$O	the$$$515$$$518$$$O	3,5-dyhydroxyl-4-isopropyl$$$519$$$545$$$I	toluylene,$$$546$$$556$$$I	which$$$557$$$562$$$O	is$$$563$$$565$$$O	simple$$$566$$$572$$$O	in$$$573$$$575$$$O	operation,$$$576$$$586$$$O	safe$$$587$$$591$$$O	and$$$592$$$595$$$O	convenient,$$$596$$$607$$$O	and$$$608$$$611$$$O	high$$$612$$$616$$$O	in$$$617$$$619$$$O	production$$$620$$$630$$$O	efficiency;$$$631$$$642$$$O	and$$$643$$$646$$$O	the$$$647$$$650$$$O	prepared$$$651$$$659$$$O	inclusion$$$660$$$669$$$O	compound$$$670$$$678$$$O	can$$$679$$$682$$$O	be$$$683$$$685$$$O	used$$$686$$$690$$$O	as$$$691$$$693$$$O	a$$$694$$$695$$$O	slow-release$$$696$$$708$$$O	and$$$709$$$712$$$O	targeting$$$713$$$722$$$O	preparation$$$723$$$734$$$O	and$$$735$$$738$$$O	provides$$$739$$$747$$$O	a$$$748$$$749$$$O	new$$$750$$$753$$$O	dosage$$$754$$$760$$$O	form$$$761$$$765$$$O	for$$$766$$$769$$$O	medicine$$$770$$$778$$$O	production.$$$779$$$790$$$O
CA2820201A1
Identification$$$0$$$14$$$O	of$$$15$$$17$$$O	tumor-associated$$$18$$$34$$$O	antigens$$$35$$$43$$$O	for$$$44$$$47$$$O	diagnosis$$$48$$$57$$$O	and$$$58$$$61$$$O	therapy$$$62$$$69$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	genetic$$$25$$$32$$$O	products$$$33$$$41$$$O	the$$$42$$$45$$$O	expression$$$46$$$56$$$O	of$$$57$$$59$$$O	which$$$60$$$65$$$O	is$$$66$$$68$$$O	associated$$$69$$$79$$$O	with$$$80$$$84$$$O	cancer$$$85$$$91$$$O	diseases.$$$92$$$101$$$O	The$$$102$$$105$$$O	invention$$$106$$$115$$$O	also$$$116$$$120$$$O	relates$$$121$$$128$$$O	to$$$129$$$131$$$O	the$$$132$$$135$$$O	therapy$$$136$$$143$$$O	and$$$144$$$147$$$O	diagnosis$$$148$$$157$$$O	of$$$158$$$160$$$O	diseases$$$161$$$169$$$O	in$$$170$$$172$$$O	which$$$173$$$178$$$O	the$$$179$$$182$$$O	genetic$$$183$$$190$$$O	products$$$191$$$199$$$O	are$$$200$$$203$$$O	expressed$$$204$$$213$$$O	or$$$214$$$216$$$O	aberrantly$$$217$$$227$$$O	expressed,$$$228$$$238$$$O	in$$$239$$$241$$$O	particular$$$242$$$252$$$O	cancer$$$253$$$259$$$O	diseases.$$$260$$$269$$$O
CN103751115A
Tetrahydropalmatine$$$0$$$19$$$I	intra-gastric$$$20$$$33$$$O	floating$$$34$$$42$$$O	oral$$$43$$$47$$$O	microsphere$$$48$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	tetrahydropalmatine$$$25$$$44$$$I	intra-gastric$$$45$$$58$$$O	floating$$$59$$$67$$$O	oral$$$68$$$72$$$O	microsphere.$$$73$$$85$$$O	The$$$86$$$89$$$O	microsphere$$$90$$$101$$$O	is$$$102$$$104$$$O	prepared$$$105$$$113$$$O	by$$$114$$$116$$$O	the$$$117$$$120$$$O	method$$$121$$$127$$$O	comprising$$$128$$$138$$$O	the$$$139$$$142$$$O	following$$$143$$$152$$$O	steps:$$$153$$$159$$$O	uniformly$$$160$$$169$$$O	mixing$$$170$$$176$$$O	the$$$177$$$180$$$O	tetrahydropalmatine$$$181$$$200$$$I	and$$$201$$$204$$$O	pharmaceutically$$$205$$$221$$$O	acceptable$$$222$$$232$$$O	carrier$$$233$$$240$$$O	materials,$$$241$$$251$$$O	dissolving$$$252$$$262$$$O	in$$$263$$$265$$$O	a$$$266$$$267$$$O	pharmaceutically$$$268$$$284$$$O	acceptable$$$285$$$295$$$O	organic$$$296$$$303$$$O	solvent$$$304$$$311$$$O	to$$$312$$$314$$$O	form$$$315$$$319$$$O	an$$$320$$$322$$$O	organic$$$323$$$330$$$O	phase;$$$331$$$337$$$O	preparing$$$338$$$347$$$O	a$$$348$$$349$$$O	pharmaceutically$$$350$$$366$$$O	acceptable$$$367$$$377$$$O	hydrophilic$$$378$$$389$$$O	emulsifier$$$390$$$400$$$O	aqueous$$$401$$$408$$$O	solution$$$409$$$417$$$O	as$$$418$$$420$$$O	an$$$421$$$423$$$O	aqueous$$$424$$$431$$$O	solution;$$$432$$$441$$$O	slowly$$$442$$$448$$$O	dripping$$$449$$$457$$$O	the$$$458$$$461$$$O	organic$$$462$$$469$$$O	phase$$$470$$$475$$$O	into$$$476$$$480$$$O	the$$$481$$$484$$$O	aqueous$$$485$$$492$$$O	phase$$$493$$$498$$$O	under$$$499$$$504$$$O	a$$$505$$$506$$$O	stirring$$$507$$$515$$$O	state,$$$516$$$522$$$O	constantly$$$523$$$533$$$O	stirring$$$534$$$542$$$O	until$$$543$$$548$$$O	the$$$549$$$552$$$O	organic$$$553$$$560$$$O	solvent$$$561$$$568$$$O	is$$$569$$$571$$$O	volatized,$$$572$$$582$$$O	standing,$$$583$$$592$$$O	filtering,$$$593$$$603$$$O	removing$$$604$$$612$$$O	the$$$613$$$616$$$O	filtrate,$$$617$$$626$$$O	washing$$$627$$$634$$$O	the$$$635$$$638$$$O	filter$$$639$$$645$$$O	cake$$$646$$$650$$$O	with$$$651$$$655$$$O	distilled$$$656$$$665$$$O	water,$$$666$$$672$$$O	and$$$673$$$676$$$O	drying$$$677$$$683$$$O	in$$$684$$$686$$$O	vacuum$$$687$$$693$$$O	to$$$694$$$696$$$O	obtain$$$697$$$703$$$O	the$$$704$$$707$$$O	tetrahydropalmatine$$$708$$$727$$$I	intra-gastric$$$728$$$741$$$O	floating$$$742$$$750$$$O	oral$$$751$$$755$$$O	microsphere.$$$756$$$768$$$O	The$$$769$$$772$$$O	tetrahydropalmatine$$$773$$$792$$$I	intra-gastric$$$793$$$806$$$O	floating$$$807$$$815$$$O	oral$$$816$$$820$$$O	microsphere$$$821$$$832$$$O	is$$$833$$$835$$$O	simple$$$836$$$842$$$O	in$$$843$$$845$$$O	preparation$$$846$$$857$$$O	process,$$$858$$$866$$$O	good$$$867$$$871$$$O	in$$$872$$$874$$$O	reproducibility,$$$875$$$891$$$O	high$$$892$$$896$$$O	in$$$897$$$899$$$O	drug-loading$$$900$$$912$$$O	capacity$$$913$$$921$$$O	and$$$922$$$925$$$O	encapsulation$$$926$$$939$$$O	efficiency,$$$940$$$951$$$O	good$$$952$$$956$$$O	in$$$957$$$959$$$O	intra-gastric$$$960$$$973$$$O	floating$$$974$$$982$$$O	and$$$983$$$986$$$O	sustained-releasing$$$987$$$1006$$$O	performance$$$1007$$$1018$$$O	and$$$1019$$$1022$$$O	can$$$1023$$$1026$$$O	constantly$$$1027$$$1037$$$O	float$$$1038$$$1043$$$O	and$$$1044$$$1047$$$O	slowly$$$1048$$$1054$$$O	release$$$1055$$$1062$$$O	drugs$$$1063$$$1068$$$O	at$$$1069$$$1071$$$O	constant$$$1072$$$1080$$$O	speed$$$1081$$$1086$$$O	in$$$1087$$$1089$$$O	12$$$1090$$$1092$$$O	hours,$$$1093$$$1099$$$O	and$$$1100$$$1103$$$O	the$$$1104$$$1107$$$O	drug$$$1108$$$1112$$$O	can$$$1113$$$1116$$$O	be$$$1117$$$1119$$$O	released$$$1120$$$1128$$$O	over$$$1129$$$1133$$$O	90$$$1134$$$1136$$$O	percent$$$1137$$$1144$$$O	in$$$1145$$$1147$$$O	accumulation$$$1148$$$1160$$$O	of$$$1161$$$1163$$$O	12$$$1164$$$1166$$$O	hours,$$$1167$$$1173$$$O	so$$$1174$$$1176$$$O	that$$$1177$$$1181$$$O	the$$$1182$$$1185$$$O	drug$$$1186$$$1190$$$O	can$$$1191$$$1194$$$O	be$$$1195$$$1197$$$O	released$$$1198$$$1206$$$O	stably,$$$1207$$$1214$$$O	slowly$$$1215$$$1221$$$O	and$$$1222$$$1225$$$O	directionally.$$$1226$$$1240$$$O
EP2349998A2
A$$$0$$$1$$$O	novel$$$2$$$7$$$O	process$$$8$$$15$$$O	for$$$16$$$19$$$O	the$$$20$$$23$$$O	preparation$$$24$$$35$$$O	of$$$36$$$38$$$O	eletriptan$$$39$$$49$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	novel$$$35$$$40$$$O	process$$$41$$$48$$$O	for$$$49$$$52$$$O	the$$$53$$$56$$$O	preparation$$$57$$$68$$$O	of$$$69$$$71$$$O	(R)-3-((1-methylpyrrolidin-2-yl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole$$$72$$$149$$$I	and$$$150$$$153$$$O	its$$$154$$$157$$$O	intermediates$$$158$$$171$$$O	thereof.$$$172$$$180$$$O	The$$$181$$$184$$$O	present$$$185$$$192$$$O	invention$$$193$$$202$$$O	provides$$$203$$$211$$$O	significant$$$212$$$223$$$O	advantages$$$224$$$234$$$O	over$$$235$$$239$$$O	the$$$240$$$243$$$O	existing$$$244$$$252$$$O	processes.$$$253$$$263$$$O
WO2006014787A2
Compositions$$$0$$$12$$$O	containing$$$13$$$23$$$O	policosanol$$$24$$$35$$$I	and$$$36$$$39$$$O	b$$$40$$$41$$$I	vitamins$$$42$$$50$$$I	and$$$51$$$54$$$O	their$$$55$$$60$$$O	pharmaceutical$$$61$$$75$$$O	uses$$$76$$$80$$$O
A$$$0$$$1$$$O	composition$$$2$$$13$$$O	is$$$14$$$16$$$O	provided$$$17$$$25$$$O	which$$$26$$$31$$$O	contains$$$32$$$40$$$O	policosanol$$$41$$$52$$$I	and$$$53$$$56$$$O	B$$$57$$$58$$$I	vitamins$$$59$$$67$$$I	and$$$68$$$71$$$O	which$$$72$$$77$$$O	may$$$78$$$81$$$O	be$$$82$$$84$$$O	used$$$85$$$89$$$O	for$$$90$$$93$$$O	treating$$$94$$$102$$$O	and$$$103$$$106$$$O	or$$$107$$$109$$$O	reducing$$$110$$$118$$$O	hypercholesterolemia$$$119$$$139$$$O	and$$$140$$$143$$$O	hyperhomocysteinemia$$$144$$$164$$$O	diseases,$$$165$$$174$$$O	total$$$175$$$180$$$O	cholesterol,$$$181$$$193$$$I	LDL-cholesterol,$$$194$$$210$$$I	LDL/HDL$$$211$$$218$$$O	ratio,$$$219$$$225$$$O	Lp(a),$$$226$$$232$$$O	triglycerides,$$$233$$$247$$$I	homocysteine,$$$248$$$261$$$I	coronary$$$262$$$270$$$O	heart$$$271$$$276$$$O	disease$$$277$$$284$$$O	(heart$$$285$$$291$$$O	attacks$$$292$$$299$$$O	and$$$300$$$303$$$O	strokes),$$$304$$$313$$$O	carotid$$$314$$$321$$$O	artery$$$322$$$328$$$O	disease,$$$329$$$337$$$O	inflammation,$$$338$$$351$$$O	deep-vein$$$352$$$361$$$O	thrombosis,$$$362$$$373$$$O	immunoregulatory$$$374$$$390$$$O	diseases,$$$391$$$400$$$O	cardiovascular$$$401$$$415$$$O	diseases,$$$416$$$425$$$O	anxiety,$$$426$$$434$$$O	depression,$$$435$$$446$$$O	neurodegenerative$$$447$$$464$$$O	disorders$$$465$$$474$$$O	(such$$$475$$$480$$$O	as$$$481$$$483$$$O	but$$$484$$$487$$$O	not$$$488$$$491$$$O	limited$$$492$$$499$$$O	to$$$500$$$502$$$O	Alzheimers),$$$503$$$515$$$O	and/or$$$516$$$522$$$O	raise$$$523$$$528$$$O	HDL$$$529$$$532$$$O	cholesterol$$$533$$$544$$$I	in$$$545$$$547$$$O	humans$$$548$$$554$$$O	and$$$555$$$558$$$O	animals.$$$559$$$567$$$O	The$$$568$$$571$$$O	method$$$572$$$578$$$O	comprises$$$579$$$588$$$O	administering$$$589$$$602$$$O	policosanol$$$603$$$614$$$I	and$$$615$$$618$$$O	B$$$619$$$620$$$I	vitamins$$$621$$$629$$$I	which$$$630$$$635$$$O	together$$$636$$$644$$$O	effectively$$$645$$$656$$$O	lower$$$657$$$662$$$O	the$$$663$$$666$$$O	risk$$$667$$$671$$$O	of$$$672$$$674$$$O	heart$$$675$$$680$$$O	disease.$$$681$$$689$$$O	Typically,$$$690$$$700$$$O	the$$$701$$$704$$$O	administered$$$705$$$717$$$O	composition$$$718$$$729$$$O	includes$$$730$$$738$$$O	about$$$739$$$744$$$O	0.1-10:1$$$745$$$753$$$O	parts$$$754$$$759$$$O	by$$$760$$$762$$$O	weight$$$763$$$769$$$O	of$$$770$$$772$$$O	policosanol$$$773$$$784$$$I	to$$$785$$$787$$$O	B$$$788$$$789$$$I	vitamins.$$$790$$$799$$$I
US6861431
Detoxification$$$0$$$14$$$O	of$$$15$$$17$$$O	cells,$$$18$$$24$$$O	tissues$$$25$$$32$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	modulating$$$11$$$21$$$O	the$$$22$$$25$$$O	activity$$$26$$$34$$$O	of$$$35$$$37$$$O	multidrug$$$38$$$47$$$O	transporters$$$48$$$60$$$O	are$$$61$$$64$$$O	disclosed.$$$65$$$75$$$O	The$$$76$$$79$$$O	methods$$$80$$$87$$$O	of$$$88$$$90$$$O	modulating$$$91$$$101$$$O	the$$$102$$$105$$$O	activity$$$106$$$114$$$O	of$$$115$$$117$$$O	multidrug$$$118$$$127$$$O	transporters$$$128$$$140$$$O	use$$$141$$$144$$$O	compounds$$$145$$$154$$$O	that$$$155$$$159$$$O	selectively$$$160$$$171$$$O	increase$$$172$$$180$$$O	or$$$181$$$183$$$O	decrease$$$184$$$192$$$O	the$$$193$$$196$$$O	efflux$$$197$$$203$$$O	capabilities$$$204$$$216$$$O	of$$$217$$$219$$$O	the$$$220$$$223$$$O	multidrug$$$224$$$233$$$O	transporter.$$$234$$$246$$$O	The$$$247$$$250$$$O	methods$$$251$$$258$$$O	can$$$259$$$262$$$O	be$$$263$$$265$$$O	used$$$266$$$270$$$O	therapeutically$$$271$$$286$$$O	to$$$287$$$289$$$O	enhance$$$290$$$297$$$O	performance$$$298$$$309$$$O	of$$$310$$$312$$$O	therapeutic$$$313$$$324$$$O	drugs,$$$325$$$331$$$O	like$$$332$$$336$$$O	chemotherapeutic$$$337$$$353$$$O	drugs$$$354$$$359$$$O	and$$$360$$$363$$$O	antibiotics;$$$364$$$376$$$O	to$$$377$$$379$$$O	promote$$$380$$$387$$$O	detoxification$$$388$$$402$$$O	of$$$403$$$405$$$O	cells$$$406$$$411$$$O	and$$$412$$$415$$$O	tissues;$$$416$$$424$$$O	and$$$425$$$428$$$O	to$$$429$$$431$$$O	increase$$$432$$$440$$$O	or$$$441$$$443$$$O	decrease$$$444$$$452$$$O	the$$$453$$$456$$$O	efficacy$$$457$$$465$$$O	of$$$466$$$468$$$O	the$$$469$$$472$$$O	blood-brain$$$473$$$484$$$O	barrier$$$485$$$492$$$O	or$$$493$$$495$$$O	placental$$$496$$$505$$$O	barrier.$$$506$$$514$$$O
US20100137357
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	hyperhidrosis$$$29$$$42$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	disclosure$$$12$$$22$$$O	relates,$$$23$$$31$$$O	according$$$32$$$41$$$O	to$$$42$$$44$$$O	some$$$45$$$49$$$O	embodiments,$$$50$$$62$$$O	to$$$63$$$65$$$O	compositions,$$$66$$$79$$$O	systems,$$$80$$$88$$$O	and$$$89$$$92$$$O	methods$$$93$$$100$$$O	for$$$101$$$104$$$O	ameliorating,$$$105$$$118$$$O	preventing,$$$119$$$130$$$O	and/or$$$131$$$137$$$O	treating$$$138$$$146$$$O	(collectively$$$147$$$160$$$O	âtreatingâ)$$$161$$$176$$$O	hyperhidrosis$$$177$$$190$$$O	and/or$$$191$$$197$$$O	excessive$$$198$$$207$$$O	perspiration$$$208$$$220$$$O	(collectively$$$221$$$234$$$O	âhyperhidrosisâ).$$$235$$$256$$$O	For$$$257$$$260$$$O	example,$$$261$$$269$$$O	a$$$270$$$271$$$O	method$$$272$$$278$$$O	for$$$279$$$282$$$O	treating$$$283$$$291$$$O	hyperhidrosis$$$292$$$305$$$O	may$$$306$$$309$$$O	comprise$$$310$$$318$$$O	administering$$$319$$$332$$$O	(e.g.,$$$333$$$339$$$O	topically$$$340$$$349$$$O	administering)$$$350$$$364$$$O	a$$$365$$$366$$$O	composition$$$367$$$378$$$O	comprising$$$379$$$389$$$O	an$$$390$$$392$$$O	anticholinergic$$$393$$$408$$$O	compound$$$409$$$417$$$O	(e.g.,$$$418$$$424$$$I	an$$$425$$$427$$$I	ipratropium$$$428$$$439$$$I	compound)$$$440$$$449$$$O	to$$$450$$$452$$$O	a$$$453$$$454$$$O	mammal.$$$455$$$462$$$O	A$$$463$$$464$$$O	composition$$$465$$$476$$$O	(e.g.,$$$477$$$483$$$O	a$$$484$$$485$$$O	topical$$$486$$$493$$$O	composition)$$$494$$$506$$$O	for$$$507$$$510$$$O	treating$$$511$$$519$$$O	hyperhidrosis$$$520$$$533$$$O	may$$$534$$$537$$$O	comprise$$$538$$$546$$$O	an$$$547$$$549$$$O	anticholinergic$$$550$$$565$$$O	compound$$$566$$$574$$$O	(e.g.,$$$575$$$581$$$I	an$$$582$$$584$$$I	ipratropium$$$585$$$596$$$I	compound)$$$597$$$606$$$O	and$$$607$$$610$$$O	a$$$611$$$612$$$O	vehicle$$$613$$$620$$$O	(e.g.,$$$621$$$627$$$O	a$$$628$$$629$$$O	physiologically$$$630$$$645$$$O	acceptable$$$646$$$656$$$O	vehicle).$$$657$$$666$$$O	In$$$667$$$669$$$O	some$$$670$$$674$$$O	embodiments,$$$675$$$687$$$O	administering$$$688$$$701$$$O	a$$$702$$$703$$$O	composition$$$704$$$715$$$O	comprising$$$716$$$726$$$O	an$$$727$$$729$$$O	anticholinergic$$$730$$$745$$$O	compound$$$746$$$754$$$O	may$$$755$$$758$$$O	comprise$$$759$$$767$$$O	contacting$$$768$$$778$$$O	the$$$779$$$782$$$O	subject$$$783$$$790$$$O	with$$$791$$$795$$$O	a$$$796$$$797$$$O	medicated$$$798$$$807$$$O	article$$$808$$$815$$$O	comprising$$$816$$$826$$$O	the$$$827$$$830$$$O	composition.$$$831$$$843$$$O
EP1434570B1
Pharmaceutical$$$0$$$14$$$O	formulations$$$15$$$27$$$O	for$$$28$$$31$$$O	the$$$32$$$35$$$O	controlled$$$36$$$46$$$O	release$$$47$$$54$$$O	of$$$55$$$57$$$O	4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline$$$58$$$162$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	controlled-release$$$25$$$43$$$O	pharmaceutical$$$44$$$58$$$O	formulation$$$59$$$70$$$O	for$$$71$$$74$$$O	oral$$$75$$$79$$$O	administration$$$80$$$94$$$O	comprising$$$95$$$105$$$O	4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline,$$$106$$$211$$$I	or$$$212$$$214$$$O	a$$$215$$$216$$$O	pharmaceutically$$$217$$$233$$$O	acceptable$$$234$$$244$$$O	salt$$$245$$$249$$$O	thereof;$$$250$$$258$$$O	and$$$259$$$262$$$O	a$$$263$$$264$$$O	pharmaceutically$$$265$$$281$$$O	acceptable$$$282$$$292$$$O	adjuvant,$$$293$$$302$$$O	diluent$$$303$$$310$$$O	or$$$311$$$313$$$O	carrier;$$$314$$$322$$$O	characterized$$$323$$$336$$$O	in$$$337$$$339$$$O	that$$$340$$$344$$$O	the$$$345$$$348$$$O	formulation$$$349$$$360$$$O	is$$$361$$$363$$$O	adapted$$$364$$$371$$$O	to$$$372$$$374$$$O	release$$$375$$$382$$$O	at$$$383$$$385$$$O	least$$$386$$$391$$$O	50%$$$392$$$395$$$O	by$$$396$$$398$$$O	weight$$$399$$$405$$$O	of$$$406$$$408$$$O	the$$$409$$$412$$$O	4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline,$$$413$$$519$$$I	or$$$520$$$522$$$O	the$$$523$$$526$$$O	pharmaceutically$$$527$$$543$$$O	acceptable$$$544$$$554$$$O	salt$$$555$$$559$$$O	thereof,$$$560$$$568$$$O	after$$$569$$$574$$$O	6$$$575$$$576$$$O	hours$$$577$$$582$$$O	in$$$583$$$585$$$O	Apparatus$$$586$$$595$$$O	1$$$596$$$597$$$O	described$$$598$$$607$$$O	in$$$608$$$610$$$O	the$$$611$$$614$$$O	United$$$615$$$621$$$O	States$$$622$$$628$$$O	Pharmacopoeia$$$629$$$642$$$O	24$$$643$$$645$$$O	(2000),$$$646$$$653$$$O	pp$$$654$$$656$$$O	1941-1943,$$$657$$$667$$$O	having$$$668$$$674$$$O	1$$$675$$$676$$$O	litre$$$677$$$682$$$O	vessels,$$$683$$$691$$$O	baskets$$$692$$$699$$$O	of$$$700$$$702$$$O	40$$$703$$$705$$$O	mesh$$$706$$$710$$$O	(0.4$$$711$$$715$$$O	mm$$$716$$$718$$$O	apertures),$$$719$$$730$$$O	a$$$731$$$732$$$O	rotation$$$733$$$741$$$O	speed$$$742$$$747$$$O	of$$$748$$$750$$$O	100$$$751$$$754$$$O	rpm,$$$755$$$759$$$O	and$$$760$$$763$$$O	a$$$764$$$765$$$O	dissolution$$$766$$$777$$$O	medium$$$778$$$784$$$O	consisting$$$785$$$795$$$O	of$$$796$$$798$$$O	900$$$799$$$802$$$O	ml$$$803$$$805$$$O	of$$$806$$$808$$$O	0.01$$$809$$$813$$$O	M$$$814$$$815$$$O	hydrochloric$$$816$$$828$$$I	acid$$$829$$$833$$$I	containing$$$834$$$844$$$O	0.7%$$$845$$$849$$$O	w/v$$$850$$$853$$$O	sodium$$$854$$$860$$$I	chloride$$$861$$$869$$$I	at$$$870$$$872$$$O	37$$$873$$$875$$$O	DEG$$$877$$$880$$$O	C.$$$881$$$883$$$O	Formulations$$$884$$$896$$$O	according$$$897$$$906$$$O	to$$$907$$$909$$$O	the$$$910$$$913$$$O	invention$$$914$$$923$$$O	are$$$924$$$927$$$O	suitable$$$928$$$936$$$O	for$$$937$$$940$$$O	the$$$941$$$944$$$O	treatment$$$945$$$954$$$O	of$$$955$$$957$$$O	BPH.$$$958$$$962$$$O
US20080113953
Administering$$$0$$$13$$$O	ethinyl$$$14$$$21$$$I	estradiol$$$22$$$31$$$I	or$$$32$$$34$$$O	prodrug$$$35$$$42$$$O	thereof$$$43$$$50$$$O	to$$$51$$$53$$$O	patient$$$54$$$61$$$O	with$$$62$$$66$$$O	improved$$$67$$$75$$$O	bioavailability$$$76$$$91$$$O	by$$$92$$$94$$$O	orally$$$95$$$101$$$O	administering$$$102$$$115$$$O	solid$$$116$$$121$$$O	dosage$$$122$$$128$$$O	form$$$129$$$133$$$O	that$$$134$$$138$$$O	releases$$$139$$$147$$$O	effective$$$148$$$157$$$O	amount$$$158$$$164$$$O	of$$$165$$$167$$$O	ethinyl$$$168$$$175$$$I	estradiol$$$176$$$185$$$I	or$$$186$$$188$$$O	prodrug$$$189$$$196$$$O	thereof$$$197$$$204$$$O	in$$$205$$$207$$$O	oral$$$208$$$212$$$O	cavity$$$213$$$219$$$O	for$$$220$$$223$$$O	absorption$$$224$$$234$$$O	through$$$235$$$242$$$O	oral$$$243$$$247$$$O	mucosa;$$$248$$$255$$$O	for$$$256$$$259$$$O	hormone$$$260$$$267$$$O	replacement$$$268$$$279$$$O	therapy$$$280$$$287$$$O	or$$$288$$$290$$$O	contraception$$$291$$$304$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	improving$$$11$$$20$$$O	the$$$21$$$24$$$O	bioavailability$$$25$$$40$$$O	of$$$41$$$43$$$O	ethinyl$$$44$$$51$$$I	estradiol$$$52$$$61$$$I	by$$$62$$$64$$$O	orally$$$65$$$71$$$O	administering$$$72$$$85$$$O	to$$$86$$$88$$$O	a$$$89$$$90$$$O	patient$$$91$$$98$$$O	a$$$99$$$100$$$O	solid$$$101$$$106$$$O	dosage$$$107$$$113$$$O	form$$$114$$$118$$$O	containing$$$119$$$129$$$O	ethinyl$$$130$$$137$$$I	estradiol$$$138$$$147$$$I	or$$$148$$$150$$$O	prodrug$$$151$$$158$$$O	thereof$$$159$$$166$$$O	where$$$167$$$172$$$O	that$$$173$$$177$$$O	dosage$$$178$$$184$$$O	form$$$185$$$189$$$O	releases$$$190$$$198$$$O	at$$$199$$$201$$$O	least$$$202$$$207$$$O	some$$$208$$$212$$$O	of$$$213$$$215$$$O	the$$$216$$$219$$$O	ethinyl$$$220$$$227$$$I	estradiol$$$228$$$237$$$I	or$$$238$$$240$$$O	prodrug$$$241$$$248$$$O	thereof$$$249$$$256$$$O	in$$$257$$$259$$$O	the$$$260$$$263$$$O	oral$$$264$$$268$$$O	cavity$$$269$$$275$$$O	for$$$276$$$279$$$O	absorption$$$280$$$290$$$O	through$$$291$$$298$$$O	the$$$299$$$302$$$O	oral$$$303$$$307$$$O	mucosa$$$308$$$314$$$O	to$$$315$$$317$$$O	treat$$$318$$$323$$$O	the$$$324$$$327$$$O	patient$$$328$$$335$$$O	for$$$336$$$339$$$O	a$$$340$$$341$$$O	predetermined$$$342$$$355$$$O	indication$$$356$$$366$$$O	such$$$367$$$371$$$O	as,$$$372$$$375$$$O	for$$$376$$$379$$$O	example,$$$380$$$388$$$O	hormone$$$389$$$396$$$O	replacement$$$397$$$408$$$O	therapy$$$409$$$416$$$O	or$$$417$$$419$$$O	contraception.$$$420$$$434$$$O	The$$$435$$$438$$$O	solid$$$439$$$444$$$O	dosage$$$445$$$451$$$O	forms$$$452$$$457$$$O	may$$$458$$$461$$$O	be$$$462$$$464$$$O	selected$$$465$$$473$$$O	from,$$$474$$$479$$$O	among$$$480$$$485$$$O	others,$$$486$$$493$$$O	chewable$$$494$$$502$$$O	tablets,$$$503$$$511$$$O	fast$$$512$$$516$$$O	melt$$$517$$$521$$$O	tablets,$$$522$$$530$$$O	films,$$$531$$$537$$$O	dissolving$$$538$$$548$$$O	films,$$$549$$$555$$$O	mucoadhesive$$$556$$$568$$$O	tablets,$$$569$$$577$$$O	lozenges,$$$578$$$587$$$O	and$$$588$$$591$$$O	chewing$$$592$$$599$$$O	gum.$$$600$$$604$$$O
CA2203237C
Aminotetrazole$$$0$$$14$$$I	derivatives$$$15$$$26$$$O	useful$$$27$$$33$$$O	as$$$34$$$36$$$O	nitric$$$37$$$43$$$I	oxide$$$44$$$49$$$I	synthase$$$50$$$58$$$O	inhibitors$$$59$$$69$$$O
Compounds$$$0$$$9$$$O	having$$$10$$$16$$$O	formula$$$17$$$24$$$O	(I)$$$25$$$28$$$O	and$$$29$$$32$$$O	pharmaceutically$$$33$$$49$$$O	acceptable$$$50$$$60$$$O	salts$$$61$$$66$$$O	thereof,$$$67$$$75$$$O	wherein$$$76$$$83$$$O	B$$$84$$$85$$$O	is$$$86$$$88$$$O	NR5R11,$$$89$$$96$$$O	wherein$$$97$$$104$$$O	R5$$$105$$$107$$$O	is$$$108$$$110$$$O	selected$$$111$$$119$$$O	from$$$120$$$124$$$O	the$$$125$$$128$$$O	group$$$129$$$134$$$O	consisting$$$135$$$145$$$O	of$$$146$$$148$$$O	hydrogen,$$$149$$$158$$$I	lower$$$159$$$164$$$O	alkyl,$$$165$$$171$$$I	lower$$$172$$$177$$$O	alkenyl,$$$178$$$186$$$I	lower$$$187$$$192$$$O	alkynyl$$$193$$$200$$$I	and$$$201$$$204$$$O	aryl,$$$205$$$210$$$I	and$$$211$$$214$$$O	R11$$$215$$$218$$$O	is$$$219$$$221$$$O	selected$$$222$$$230$$$O	from$$$231$$$235$$$O	a$$$236$$$237$$$O	3$$$238$$$239$$$O	to$$$240$$$242$$$O	8$$$243$$$244$$$O	member$$$245$$$251$$$O	heterocyclyl$$$252$$$264$$$O	radical$$$265$$$272$$$O	in$$$273$$$275$$$O	which$$$276$$$281$$$O	at$$$282$$$284$$$O	least$$$285$$$290$$$O	one$$$291$$$294$$$O	member$$$295$$$301$$$O	of$$$302$$$304$$$O	the$$$305$$$308$$$O	ring$$$309$$$313$$$O	is$$$314$$$316$$$O	carbon$$$317$$$323$$$I	and$$$324$$$327$$$O	in$$$328$$$330$$$O	which$$$331$$$336$$$O	1$$$337$$$338$$$O	to$$$339$$$341$$$O	about$$$342$$$347$$$O	4$$$348$$$349$$$O	members$$$350$$$357$$$O	are$$$358$$$361$$$O	heteroatoms$$$362$$$373$$$O	independently$$$374$$$387$$$O	selected$$$388$$$396$$$O	from$$$397$$$401$$$O	oxygen,$$$402$$$409$$$I	nitrogen$$$410$$$418$$$I	and$$$419$$$422$$$O	sulfur$$$423$$$429$$$I	and$$$430$$$433$$$O	said$$$434$$$438$$$O	heterocyclyl$$$439$$$451$$$O	radical$$$452$$$459$$$O	may$$$460$$$463$$$O	be$$$464$$$466$$$O	optionally$$$467$$$477$$$O	substituted,$$$478$$$490$$$O	useful$$$491$$$497$$$O	as$$$498$$$500$$$O	nitric$$$501$$$507$$$I	oxide$$$508$$$513$$$I	synthase$$$514$$$522$$$O	inhibitors.$$$523$$$534$$$O
CN101732477A
Slush$$$0$$$5$$$O	ice$$$6$$$9$$$O	prepared$$$10$$$18$$$O	from$$$19$$$23$$$O	various$$$24$$$31$$$O	plants$$$32$$$38$$$O	and$$$39$$$42$$$O	used$$$43$$$47$$$O	for$$$48$$$51$$$O	blackening$$$52$$$62$$$O	and$$$63$$$66$$$O	nourishing$$$67$$$77$$$O	hair$$$78$$$82$$$O	and$$$83$$$86$$$O	preparation$$$87$$$98$$$O	method$$$99$$$105$$$O	thereof$$$106$$$113$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	slush$$$24$$$29$$$O	ice$$$30$$$33$$$O	prepared$$$34$$$42$$$O	from$$$43$$$47$$$O	various$$$48$$$55$$$O	plants$$$56$$$62$$$O	and$$$63$$$66$$$O	used$$$67$$$71$$$O	for$$$72$$$75$$$O	blackening$$$76$$$86$$$O	and$$$87$$$90$$$O	nourishing$$$91$$$101$$$O	hair$$$102$$$106$$$O	and$$$107$$$110$$$O	a$$$111$$$112$$$O	preparation$$$113$$$124$$$O	method$$$125$$$131$$$O	thereof.$$$132$$$140$$$O	The$$$141$$$144$$$O	slush$$$145$$$150$$$O	ice$$$151$$$154$$$O	is$$$155$$$157$$$O	prepared$$$158$$$166$$$O	by$$$167$$$169$$$O	mixing$$$170$$$176$$$O	and$$$177$$$180$$$O	processing$$$181$$$191$$$O	fleece-flower$$$192$$$205$$$O	root,$$$206$$$211$$$O	nutgall,$$$212$$$220$$$O	mulberry$$$221$$$229$$$O	fruit,$$$230$$$236$$$O	radix$$$237$$$242$$$O	rehmanniae,$$$243$$$254$$$O	herba$$$255$$$260$$$O	ecliptae$$$261$$$269$$$O	and$$$270$$$273$$$O	ebony.$$$274$$$280$$$O	In$$$281$$$283$$$O	the$$$284$$$287$$$O	medicine,$$$288$$$297$$$O	the$$$298$$$301$$$O	fleece-flower$$$302$$$315$$$O	root,$$$316$$$321$$$O	the$$$322$$$325$$$O	nutgall,$$$326$$$334$$$O	the$$$335$$$338$$$O	mulberry$$$339$$$347$$$O	fruit,$$$348$$$354$$$O	the$$$355$$$358$$$O	radix$$$359$$$364$$$O	rehmanniae,$$$365$$$376$$$O	the$$$377$$$380$$$O	herba$$$381$$$386$$$O	ecliptae$$$387$$$395$$$O	and$$$396$$$399$$$O	the$$$400$$$403$$$O	ebony$$$404$$$409$$$O	are$$$410$$$413$$$O	selected$$$414$$$422$$$O	and$$$423$$$426$$$O	combined,$$$427$$$436$$$O	because$$$437$$$444$$$O	of$$$445$$$447$$$O	the$$$448$$$451$$$O	combination$$$452$$$463$$$O	of$$$464$$$466$$$O	above$$$467$$$472$$$O	medicines,$$$473$$$483$$$O	the$$$484$$$487$$$O	effect$$$488$$$494$$$O	of$$$495$$$497$$$O	each$$$498$$$502$$$O	medicine$$$503$$$511$$$O	generates$$$512$$$521$$$O	a$$$522$$$523$$$O	synergistic$$$524$$$535$$$O	action,$$$536$$$543$$$O	thereby$$$544$$$551$$$O	tonifying$$$552$$$561$$$O	the$$$562$$$565$$$O	liver$$$566$$$571$$$O	and$$$572$$$575$$$O	the$$$576$$$579$$$O	kidney,$$$580$$$587$$$O	benefiting$$$588$$$598$$$O	the$$$599$$$602$$$O	essence$$$603$$$610$$$O	and$$$611$$$614$$$O	the$$$615$$$618$$$O	blood,$$$619$$$625$$$O	darkening$$$626$$$635$$$O	the$$$636$$$639$$$O	beard$$$640$$$645$$$O	and$$$646$$$649$$$O	the$$$650$$$653$$$O	hair$$$654$$$658$$$O	and$$$659$$$662$$$O	strengthening$$$663$$$676$$$O	the$$$677$$$680$$$O	bones$$$681$$$686$$$O	and$$$687$$$690$$$O	the$$$691$$$694$$$O	muscles$$$695$$$702$$$O	effectively;$$$703$$$715$$$O	the$$$716$$$719$$$O	substances$$$720$$$730$$$O	are$$$731$$$734$$$O	mixed$$$735$$$740$$$O	to$$$741$$$743$$$O	generate$$$744$$$752$$$O	the$$$753$$$756$$$O	synergistic$$$757$$$768$$$O	action,$$$769$$$776$$$O	thereby$$$777$$$784$$$O	tonifying$$$785$$$794$$$O	the$$$795$$$798$$$O	liver$$$799$$$804$$$O	and$$$805$$$808$$$O	the$$$809$$$812$$$O	kidney,$$$813$$$820$$$O	benefiting$$$821$$$831$$$O	the$$$832$$$835$$$O	essence$$$836$$$843$$$O	and$$$844$$$847$$$O	the$$$848$$$851$$$O	blood,$$$852$$$858$$$O	darkening$$$859$$$868$$$O	the$$$869$$$872$$$O	beard$$$873$$$878$$$O	and$$$879$$$882$$$O	the$$$883$$$886$$$O	hair$$$887$$$891$$$O	and$$$892$$$895$$$O	strengthening$$$896$$$909$$$O	the$$$910$$$913$$$O	bones$$$914$$$919$$$O	and$$$920$$$923$$$O	the$$$924$$$927$$$O	muscles$$$928$$$935$$$O	effectively;$$$936$$$948$$$O	and$$$949$$$952$$$O	radix$$$953$$$958$$$O	polygoni$$$959$$$967$$$O	multiflori$$$968$$$978$$$O	preparata$$$979$$$988$$$O	in$$$989$$$991$$$O	the$$$992$$$995$$$O	invention$$$996$$$1005$$$O	is$$$1006$$$1008$$$O	used$$$1009$$$1013$$$O	for$$$1014$$$1017$$$O	tonifying$$$1018$$$1027$$$O	the$$$1028$$$1031$$$O	liver$$$1032$$$1037$$$O	and$$$1038$$$1041$$$O	the$$$1042$$$1045$$$O	kidney,$$$1046$$$1053$$$O	benefiting$$$1054$$$1064$$$O	the$$$1065$$$1068$$$O	essence$$$1069$$$1076$$$O	and$$$1077$$$1080$$$O	the$$$1081$$$1084$$$O	blood,$$$1085$$$1091$$$O	darkening$$$1092$$$1101$$$O	the$$$1102$$$1105$$$O	beard$$$1106$$$1111$$$O	and$$$1112$$$1115$$$O	the$$$1116$$$1119$$$O	hair$$$1120$$$1124$$$O	and$$$1125$$$1128$$$O	strengthening$$$1129$$$1142$$$O	the$$$1143$$$1146$$$O	bones$$$1147$$$1152$$$O	and$$$1153$$$1156$$$O	the$$$1157$$$1160$$$O	muscles.$$$1161$$$1169$$$O	The$$$1170$$$1173$$$O	product$$$1174$$$1181$$$O	is$$$1182$$$1184$$$O	applied$$$1185$$$1192$$$O	to$$$1193$$$1195$$$O	the$$$1196$$$1199$$$O	hair$$$1200$$$1204$$$O	in$$$1205$$$1207$$$O	a$$$1208$$$1209$$$O	way$$$1210$$$1213$$$O	similar$$$1214$$$1221$$$O	to$$$1222$$$1224$$$O	hair$$$1225$$$1229$$$O	putty,$$$1230$$$1236$$$O	can$$$1237$$$1240$$$O	dye$$$1241$$$1244$$$O	the$$$1245$$$1248$$$O	hair$$$1249$$$1253$$$O	by$$$1254$$$1256$$$O	plants$$$1257$$$1263$$$O	and$$$1264$$$1267$$$O	can$$$1268$$$1271$$$O	also$$$1272$$$1276$$$O	regenerate$$$1277$$$1287$$$O	black$$$1288$$$1293$$$O	hair.$$$1294$$$1299$$$O	Compared$$$1300$$$1308$$$O	with$$$1309$$$1313$$$O	the$$$1314$$$1317$$$O	prior$$$1318$$$1323$$$O	art,$$$1324$$$1328$$$O	the$$$1329$$$1332$$$O	invention$$$1333$$$1342$$$O	has$$$1343$$$1346$$$O	convenient$$$1347$$$1357$$$O	use$$$1358$$$1361$$$O	and$$$1362$$$1365$$$O	little$$$1366$$$1372$$$O	side$$$1373$$$1377$$$O	effect,$$$1378$$$1385$$$O	treats$$$1386$$$1392$$$O	both$$$1393$$$1397$$$O	the$$$1398$$$1401$$$O	principal$$$1402$$$1411$$$O	and$$$1412$$$1415$$$O	secondary$$$1416$$$1425$$$O	aspects$$$1426$$$1433$$$O	of$$$1434$$$1436$$$O	a$$$1437$$$1438$$$O	disease,$$$1439$$$1447$$$O	is$$$1448$$$1450$$$O	easily$$$1451$$$1457$$$O	accepted$$$1458$$$1466$$$O	by$$$1467$$$1469$$$O	a$$$1470$$$1471$$$O	patient,$$$1472$$$1480$$$O	can$$$1481$$$1484$$$O	dye$$$1485$$$1488$$$O	hair$$$1489$$$1493$$$O	by$$$1494$$$1496$$$O	plants$$$1497$$$1503$$$O	and$$$1504$$$1507$$$O	can$$$1508$$$1511$$$O	also$$$1512$$$1516$$$O	regenerate$$$1517$$$1527$$$O	black$$$1528$$$1533$$$O	hair.$$$1534$$$1539$$$O
WO2013151699A1
Composition$$$0$$$11$$$O	and$$$12$$$15$$$O	method$$$16$$$22$$$O	for$$$23$$$26$$$O	corneal$$$27$$$34$$$O	proliferation$$$35$$$48$$$O
Disclosed$$$0$$$9$$$O	herein$$$10$$$16$$$O	in$$$17$$$19$$$O	exemplary$$$20$$$29$$$O	embodiments$$$30$$$41$$$O	are$$$42$$$45$$$O	methods$$$46$$$53$$$O	and$$$54$$$57$$$O	compositions$$$58$$$70$$$O	for$$$71$$$74$$$O	repairing$$$75$$$84$$$O	or$$$85$$$87$$$O	treating$$$88$$$96$$$O	a$$$97$$$98$$$O	defected$$$99$$$107$$$O	cornea$$$108$$$114$$$O	in$$$115$$$117$$$O	a$$$118$$$119$$$O	patient$$$120$$$127$$$O	in$$$128$$$130$$$O	need.$$$131$$$136$$$O	The$$$137$$$140$$$O	methods$$$141$$$148$$$O	and$$$149$$$152$$$O	compositions$$$153$$$165$$$O	including,$$$166$$$176$$$O	for$$$177$$$180$$$O	example,$$$181$$$189$$$O	administering$$$190$$$203$$$O	a$$$204$$$205$$$O	dose$$$206$$$210$$$O	of$$$211$$$213$$$O	a$$$214$$$215$$$O	composition$$$216$$$227$$$O	to$$$228$$$230$$$O	the$$$231$$$234$$$O	patient,$$$235$$$243$$$O	wherein$$$244$$$251$$$O	the$$$252$$$255$$$O	composition$$$256$$$267$$$O	comprises$$$268$$$277$$$O	may$$$278$$$281$$$O	be$$$282$$$284$$$O	administered$$$285$$$297$$$O	to$$$298$$$300$$$O	an$$$301$$$303$$$O	intraocular$$$304$$$315$$$O	area$$$316$$$320$$$O	of$$$321$$$323$$$O	the$$$324$$$327$$$O	patient$$$328$$$335$$$O	via$$$336$$$339$$$O	a$$$340$$$341$$$O	container$$$342$$$351$$$O	having$$$352$$$358$$$O	a$$$359$$$360$$$O	spout$$$361$$$366$$$O	for$$$367$$$370$$$O	ophthalmic$$$371$$$381$$$O	delivery.$$$382$$$391$$$O	The$$$392$$$395$$$O	methods$$$396$$$403$$$O	and$$$404$$$407$$$O	compositions$$$408$$$420$$$O	promote$$$421$$$428$$$O	progenitor$$$429$$$439$$$O	cell$$$440$$$444$$$O	migration$$$445$$$454$$$O	and$$$455$$$458$$$O	increase$$$459$$$467$$$O	cellular$$$468$$$476$$$O	proliferation$$$477$$$490$$$O	in$$$491$$$493$$$O	the$$$494$$$497$$$O	cornea$$$498$$$504$$$O	of$$$505$$$507$$$O	the$$$508$$$511$$$O	patient.$$$512$$$520$$$O
CA2597616A1
Cycloalkylfused$$$0$$$15$$$I	indole,$$$16$$$23$$$I	benzothiophene,$$$24$$$39$$$I	benzofuran$$$40$$$50$$$I	and$$$51$$$54$$$O	indene$$$55$$$61$$$I	derivatives$$$62$$$73$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	cycloalkylfused$$$31$$$46$$$I	indole,$$$47$$$54$$$I	benzothiophene,$$$55$$$70$$$I	benzofuran,$$$71$$$82$$$I	and$$$83$$$86$$$O	indene$$$87$$$93$$$I	derivatives,$$$94$$$106$$$O	and$$$107$$$110$$$O	methods$$$111$$$118$$$O	for$$$119$$$122$$$O	using$$$123$$$128$$$O	them$$$129$$$133$$$O	to,$$$134$$$137$$$O	for$$$138$$$141$$$O	example,$$$142$$$150$$$O	treat,$$$151$$$157$$$O	prevent$$$158$$$165$$$O	and/or$$$166$$$172$$$O	ameliorate$$$173$$$183$$$O	central$$$184$$$191$$$O	nervous$$$192$$$199$$$O	system$$$200$$$206$$$O	diseases$$$207$$$215$$$O	by$$$216$$$218$$$O	antagonizing$$$219$$$231$$$O	5-HT1A$$$232$$$238$$$O	receptors$$$239$$$248$$$O	and$$$249$$$252$$$O	modulating$$$253$$$263$$$O	serotonin$$$264$$$273$$$O	levels.$$$274$$$281$$$O
US20080113997
Compounds,$$$0$$$10$$$O	compositions,$$$11$$$24$$$O	processes$$$25$$$34$$$O	of$$$35$$$37$$$O	making,$$$38$$$45$$$O	and$$$46$$$49$$$O	methods$$$50$$$57$$$O	of$$$58$$$60$$$O	use$$$61$$$64$$$O	related$$$65$$$72$$$O	to$$$73$$$75$$$O	inhibiting$$$76$$$86$$$O	macrophage$$$87$$$97$$$O	migration$$$98$$$107$$$O	inhibitory$$$108$$$118$$$O	factor$$$119$$$125$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	compound$$$33$$$41$$$O	having$$$42$$$48$$$O	Formula$$$49$$$56$$$O	I$$$57$$$58$$$O	or$$$59$$$61$$$O	II:$$$62$$$65$$$O	wherein$$$103$$$110$$$O	B,$$$111$$$113$$$O	R,$$$114$$$116$$$O	X,$$$117$$$119$$$O	Ar,$$$120$$$123$$$I	and$$$124$$$127$$$O	Y$$$128$$$129$$$O	are$$$130$$$133$$$O	defined$$$134$$$141$$$O	herein,$$$142$$$149$$$O	pharmaceutically$$$150$$$166$$$O	acceptable$$$167$$$177$$$O	salts$$$178$$$183$$$O	thereof$$$184$$$191$$$O	and$$$192$$$195$$$O	pharmaceutically$$$196$$$212$$$O	acceptable$$$213$$$223$$$O	prodrugs$$$224$$$232$$$O	thereof.$$$233$$$241$$$O	The$$$242$$$245$$$O	present$$$246$$$253$$$O	invention$$$254$$$263$$$O	also$$$264$$$268$$$O	provides$$$269$$$277$$$O	methods$$$278$$$285$$$O	of$$$286$$$288$$$O	making$$$289$$$295$$$O	and$$$296$$$299$$$O	using$$$300$$$305$$$O	the$$$306$$$309$$$O	compound.$$$310$$$319$$$O
WO2007048351A1
The$$$0$$$3$$$O	oral$$$4$$$8$$$O	agent$$$9$$$14$$$O	for$$$15$$$18$$$O	improving$$$19$$$28$$$O	and$$$29$$$32$$$O	protecting$$$33$$$43$$$O	the$$$44$$$47$$$O	function$$$48$$$56$$$O	of$$$57$$$59$$$O	joint$$$60$$$65$$$O	comprising$$$66$$$76$$$O	hyaluronic$$$77$$$87$$$I	acid-phospholipid$$$88$$$105$$$I	complexes$$$106$$$115$$$O
An$$$0$$$2$$$O	oral$$$3$$$7$$$O	formulation$$$8$$$19$$$O	compring$$$20$$$28$$$O	hyaluronid$$$29$$$39$$$I	acid-$$$40$$$45$$$I	phospholipid$$$46$$$58$$$O	complexes$$$59$$$68$$$O	as$$$69$$$71$$$O	active$$$72$$$78$$$O	ingredient$$$79$$$89$$$O	and$$$90$$$93$$$O	the$$$94$$$97$$$O	application$$$98$$$109$$$O	of$$$110$$$112$$$O	hyaluronic$$$113$$$123$$$I	acid-$$$124$$$129$$$I	phosphlipid$$$130$$$141$$$O	complexes$$$142$$$151$$$O	in$$$152$$$154$$$O	preparation$$$155$$$166$$$O	of$$$167$$$169$$$O	the$$$170$$$173$$$O	product$$$174$$$181$$$O	for$$$182$$$185$$$O	improving$$$186$$$195$$$O	and$$$196$$$199$$$O	protecting$$$200$$$210$$$O	the$$$211$$$214$$$O	function$$$215$$$223$$$O	of$$$224$$$226$$$O	joint.$$$227$$$233$$$O
WO2009118655A2
Highly$$$0$$$6$$$O	pure$$$7$$$11$$$O	paliperidone$$$12$$$24$$$I	or$$$25$$$27$$$O	a$$$28$$$29$$$O	pharmaceutically$$$30$$$46$$$O	acceptable$$$47$$$57$$$O	salt$$$58$$$62$$$O	thereof$$$63$$$70$$$O	substantially$$$71$$$84$$$O	free$$$85$$$89$$$O	of$$$90$$$92$$$O	keto$$$93$$$97$$$O	impurity$$$98$$$106$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	is$$$16$$$18$$$O	a$$$19$$$20$$$O	highly$$$21$$$27$$$O	pure$$$28$$$32$$$O	paliperidone$$$33$$$45$$$I	or$$$46$$$48$$$O	a$$$49$$$50$$$O	pharmaceutically$$$51$$$67$$$O	acceptable$$$68$$$78$$$O	salt$$$79$$$83$$$O	thereof$$$84$$$91$$$O	substantially$$$92$$$105$$$O	free$$$106$$$110$$$O	of$$$111$$$113$$$O	keto$$$114$$$118$$$O	impurity,$$$119$$$128$$$O	3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-y1)-1-$$$129$$$172$$$I	piperidinyl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4,9-dione,$$$173$$$249$$$I	a$$$250$$$251$$$O	process$$$252$$$259$$$O	for$$$260$$$263$$$O	the$$$264$$$267$$$O	preparation$$$268$$$279$$$O	thereof,$$$280$$$288$$$O	and$$$289$$$292$$$O	pharmaceutical$$$293$$$307$$$O	compositions$$$308$$$320$$$O	comprising$$$321$$$331$$$O	highly$$$332$$$338$$$O	pure$$$339$$$343$$$O	paliperidone$$$344$$$356$$$I	or$$$357$$$359$$$O	a$$$360$$$361$$$O	pharmaceutically$$$362$$$378$$$O	acceptable$$$379$$$389$$$O	salt$$$390$$$394$$$O	thereof$$$395$$$402$$$O	substantially$$$403$$$416$$$O	free$$$417$$$421$$$O	of$$$422$$$424$$$O	keto$$$425$$$429$$$O	impurity.$$$430$$$439$$$O
CN101479238A
Amine$$$0$$$5$$$I	derivative$$$6$$$16$$$O	having$$$17$$$23$$$O	npyy5$$$24$$$29$$$O	receptor$$$30$$$38$$$O	antagonist$$$39$$$49$$$O	activity$$$50$$$58$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	a$$$24$$$25$$$O	compound$$$26$$$34$$$O	of$$$35$$$37$$$O	the$$$38$$$41$$$O	formula$$$42$$$49$$$O	(I):$$$50$$$54$$$O	a$$$55$$$56$$$O	pharmaceutically$$$57$$$73$$$O	acceptable$$$74$$$84$$$O	salt$$$85$$$89$$$O	or$$$90$$$92$$$O	solvate$$$93$$$100$$$O	thereof,$$$101$$$109$$$O	wherein$$$110$$$117$$$O	R<1>$$$118$$$122$$$O	is$$$123$$$125$$$O	optionally$$$126$$$136$$$O	substituted$$$137$$$148$$$O	lower$$$149$$$154$$$O	alkyl,$$$155$$$161$$$I	Y$$$162$$$163$$$O	is$$$164$$$166$$$O	-S(O)n-$$$167$$$174$$$I	wherein$$$175$$$182$$$O	n$$$183$$$184$$$O	is$$$185$$$187$$$O	1$$$188$$$189$$$O	or$$$190$$$192$$$O	2,$$$193$$$195$$$O	or$$$196$$$198$$$O	-CO-,$$$199$$$204$$$I	R<2>$$$205$$$209$$$O	is$$$210$$$212$$$O	hydrogen$$$213$$$221$$$I	or$$$222$$$224$$$O	lower$$$225$$$230$$$O	alkyl,$$$231$$$237$$$I	R<7>$$$238$$$242$$$O	is$$$243$$$245$$$O	hydrogen$$$246$$$254$$$I	or$$$255$$$257$$$O	lower$$$258$$$263$$$O	alkyl,$$$264$$$270$$$I	X$$$271$$$272$$$O	is$$$273$$$275$$$O	lower$$$276$$$281$$$O	alkylene,$$$282$$$291$$$I	lower$$$292$$$297$$$O	alkenylene,$$$298$$$309$$$I	arylene,$$$310$$$318$$$I	cycloalkylene$$$319$$$332$$$I	or$$$333$$$335$$$O	the$$$336$$$339$$$O	like,$$$340$$$345$$$O	and$$$346$$$349$$$O	Z$$$350$$$351$$$O	is$$$352$$$354$$$O	lower$$$355$$$360$$$O	alkyl,$$$361$$$367$$$I	optionally$$$368$$$378$$$O	substituted$$$379$$$390$$$O	carbocyclyl,$$$391$$$403$$$I	optionally$$$404$$$414$$$O	substituted$$$415$$$426$$$O	heterocyclyl$$$427$$$439$$$I	or$$$440$$$442$$$O	the$$$443$$$446$$$O	like.$$$447$$$452$$$O
EP1667678B1
Animal$$$0$$$6$$$O	feed$$$7$$$11$$$O	composition$$$12$$$23$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	animal$$$36$$$42$$$O	feed$$$43$$$47$$$O	composition$$$48$$$59$$$O	that$$$60$$$64$$$O	comprises$$$65$$$74$$$O	free$$$75$$$79$$$O	indole$$$80$$$86$$$I	acetic$$$87$$$93$$$I	acid$$$94$$$98$$$I	(free$$$99$$$104$$$O	IAA)$$$105$$$109$$$I	or$$$110$$$112$$$O	a$$$113$$$114$$$O	derivative$$$115$$$125$$$O	thereof.$$$126$$$134$$$O	The$$$135$$$138$$$O	invention$$$139$$$148$$$O	also$$$149$$$153$$$O	relates$$$154$$$161$$$O	to$$$162$$$164$$$O	a$$$165$$$166$$$O	method$$$167$$$173$$$O	for$$$174$$$177$$$O	enhancing$$$178$$$187$$$O	animal$$$188$$$194$$$O	growth$$$195$$$201$$$O	by$$$202$$$204$$$O	feeding$$$205$$$212$$$O	the$$$213$$$216$$$O	animal$$$217$$$223$$$O	with$$$224$$$228$$$O	a$$$229$$$230$$$O	composition$$$231$$$242$$$O	according$$$243$$$252$$$O	to$$$253$$$255$$$O	the$$$256$$$259$$$O	invention.$$$260$$$270$$$O	The$$$271$$$274$$$O	invention$$$275$$$284$$$O	also$$$285$$$289$$$O	relates$$$290$$$297$$$O	to$$$298$$$300$$$O	the$$$301$$$304$$$O	use$$$305$$$308$$$O	of$$$309$$$311$$$O	free$$$312$$$316$$$O	IAA$$$317$$$320$$$I	or$$$321$$$323$$$O	a$$$324$$$325$$$O	derivative$$$326$$$336$$$O	thereof$$$337$$$344$$$O	in$$$345$$$347$$$O	a$$$348$$$349$$$O	method$$$350$$$356$$$O	of$$$357$$$359$$$O	therapy$$$360$$$367$$$O	of$$$368$$$370$$$O	animals$$$371$$$378$$$O	in$$$379$$$381$$$O	need$$$382$$$386$$$O	of$$$387$$$389$$$O	a$$$390$$$391$$$O	growth-promoting$$$392$$$408$$$O	treatment,$$$409$$$419$$$O	such$$$420$$$424$$$O	as$$$425$$$427$$$O	immunocompromised$$$428$$$445$$$O	animals,$$$446$$$454$$$O	animals$$$455$$$462$$$O	with$$$463$$$467$$$O	a$$$468$$$469$$$O	growth$$$470$$$476$$$O	deficit$$$477$$$484$$$O	or$$$485$$$487$$$O	slow$$$488$$$492$$$O	growing$$$493$$$500$$$O	animals.$$$501$$$509$$$O	The$$$510$$$513$$$O	invention$$$514$$$523$$$O	also$$$524$$$528$$$O	relates$$$529$$$536$$$O	to$$$537$$$539$$$O	the$$$540$$$543$$$O	use$$$544$$$547$$$O	of$$$548$$$550$$$O	free$$$551$$$555$$$O	IAA$$$556$$$559$$$I	or$$$560$$$562$$$O	a$$$563$$$564$$$O	derivative$$$565$$$575$$$O	thereof$$$576$$$583$$$O	for$$$584$$$587$$$O	the$$$588$$$591$$$O	preparation$$$592$$$603$$$O	of$$$604$$$606$$$O	a$$$607$$$608$$$O	therapeutical$$$609$$$622$$$O	composition$$$623$$$634$$$O	for$$$635$$$638$$$O	increasing$$$639$$$649$$$O	the$$$650$$$653$$$O	growth$$$654$$$660$$$O	rate$$$661$$$665$$$O	and/or$$$666$$$672$$$O	the$$$673$$$676$$$O	feed$$$677$$$681$$$O	conversion$$$682$$$692$$$O	rate$$$693$$$697$$$O	and/or$$$698$$$704$$$O	the$$$705$$$708$$$O	immunity$$$709$$$717$$$O	of$$$718$$$720$$$O	animals$$$721$$$728$$$O	in$$$729$$$731$$$O	need$$$732$$$736$$$O	of$$$737$$$739$$$O	such$$$740$$$744$$$O	a$$$745$$$746$$$O	treatment,$$$747$$$757$$$O	in$$$758$$$760$$$O	particular$$$761$$$771$$$O	immunocompromised$$$772$$$789$$$O	or$$$790$$$792$$$O	slow$$$793$$$797$$$O	growing$$$798$$$805$$$O	animals.$$$806$$$814$$$O	A$$$815$$$816$$$O	composition$$$817$$$828$$$O	according$$$829$$$838$$$O	to$$$839$$$841$$$O	the$$$842$$$845$$$O	invention$$$846$$$855$$$O	may$$$856$$$859$$$O	preferably$$$860$$$870$$$O	be$$$871$$$873$$$O	in$$$874$$$876$$$O	the$$$877$$$880$$$O	form$$$881$$$885$$$O	of$$$886$$$888$$$O	a$$$889$$$890$$$O	food$$$891$$$895$$$O	or$$$896$$$898$$$O	feed$$$899$$$903$$$O	supplement.$$$904$$$915$$$O
CN1788581A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	fat-reducing$$$22$$$34$$$O	blood$$$35$$$40$$$O	sugar-reducing$$$41$$$55$$$I	milk$$$56$$$60$$$O	powder$$$61$$$67$$$O	containing$$$68$$$78$$$O	micro$$$79$$$84$$$O	gingko$$$85$$$91$$$O	leaf,$$$92$$$97$$$O	Gymostamma$$$98$$$108$$$O	pentaphyllum,$$$109$$$122$$$O	haw$$$123$$$126$$$O	and$$$127$$$130$$$O	konnjaku$$$131$$$139$$$O	powder$$$140$$$146$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	slimming$$$25$$$33$$$O	hypoglycemic$$$34$$$46$$$O	milk$$$47$$$51$$$O	powder$$$52$$$58$$$O	prepared$$$59$$$67$$$O	through$$$68$$$75$$$O	adding$$$76$$$82$$$O	airflow$$$83$$$90$$$O	crushed$$$91$$$98$$$O	micron$$$99$$$105$$$O	level$$$106$$$111$$$O	gingko$$$112$$$118$$$O	leaf$$$119$$$123$$$O	powder,$$$124$$$131$$$O	micron$$$132$$$138$$$O	level$$$139$$$144$$$O	gynostemma$$$145$$$155$$$O	pentaphylla$$$156$$$167$$$O	powder,$$$168$$$175$$$O	micron$$$176$$$182$$$O	level$$$183$$$188$$$O	haw$$$189$$$192$$$O	powder,$$$193$$$200$$$O	micron$$$201$$$207$$$O	level$$$208$$$213$$$O	konjack$$$214$$$221$$$O	powder,$$$222$$$229$$$O	chitosan$$$230$$$238$$$O	and$$$239$$$242$$$O	isomaltose$$$243$$$253$$$I	into$$$254$$$258$$$O	traditional$$$259$$$270$$$O	milk$$$271$$$275$$$O	powder.$$$276$$$283$$$O	The$$$284$$$287$$$O	slimming$$$288$$$296$$$O	hypoglycemic$$$297$$$309$$$O	milk$$$310$$$314$$$O	powder$$$315$$$321$$$O	has$$$322$$$325$$$O	obvious$$$326$$$333$$$O	effects$$$334$$$341$$$O	of$$$342$$$344$$$O	slimming,$$$345$$$354$$$O	reducing$$$355$$$363$$$O	blood$$$364$$$369$$$O	fat$$$370$$$373$$$O	and$$$374$$$377$$$O	strengthening$$$378$$$391$$$O	immunity.$$$392$$$401$$$O	The$$$402$$$405$$$O	present$$$406$$$413$$$O	invention$$$414$$$423$$$O	makes$$$424$$$429$$$O	it$$$430$$$432$$$O	possible$$$433$$$441$$$O	for$$$442$$$445$$$O	obese$$$446$$$451$$$O	medium$$$452$$$458$$$O	aged$$$459$$$463$$$O	and$$$464$$$467$$$O	old$$$468$$$471$$$O	people$$$472$$$478$$$O	to$$$479$$$481$$$O	absorb$$$482$$$488$$$O	the$$$489$$$492$$$O	effective$$$493$$$502$$$O	components$$$503$$$513$$$O	of$$$514$$$516$$$O	konjack$$$517$$$524$$$O	powder,$$$525$$$532$$$O	gingko$$$533$$$539$$$O	leaf$$$540$$$544$$$O	powder,$$$545$$$552$$$O	gynostemma$$$553$$$563$$$O	pentaphylla$$$564$$$575$$$O	flower$$$576$$$582$$$O	powder,$$$583$$$590$$$O	etc.$$$591$$$595$$$O	to$$$596$$$598$$$O	strengthen$$$599$$$609$$$O	health$$$610$$$616$$$O	functions$$$617$$$626$$$O	of$$$627$$$629$$$O	promoting$$$630$$$639$$$O	blood$$$640$$$645$$$O	circulation,$$$646$$$658$$$O	reducing$$$659$$$667$$$O	blood$$$668$$$673$$$O	fat,$$$674$$$678$$$O	dispersing$$$679$$$689$$$O	blood$$$690$$$695$$$O	clots$$$696$$$701$$$O	and$$$702$$$705$$$O	reducing$$$706$$$714$$$O	weight$$$715$$$721$$$O	while$$$722$$$727$$$O	obtaining$$$728$$$737$$$O	various$$$738$$$745$$$O	vitamins,$$$746$$$755$$$I	minerals,$$$756$$$765$$$I	etc.$$$766$$$770$$$O
WO2012159593A2
A$$$0$$$1$$$O	combined$$$2$$$10$$$O	oral$$$11$$$15$$$O	formulation$$$16$$$27$$$O	with$$$28$$$32$$$O	controlled$$$33$$$43$$$O	release$$$44$$$51$$$O	of$$$52$$$54$$$O	acetylsalicylic$$$55$$$70$$$I	acid$$$71$$$75$$$I	and$$$76$$$79$$$O	a$$$80$$$81$$$O	method$$$82$$$88$$$O	for$$$89$$$92$$$O	the$$$93$$$96$$$O	preparation$$$97$$$108$$$O
A$$$0$$$1$$$O	combined$$$2$$$10$$$O	oral$$$11$$$15$$$O	solid$$$16$$$21$$$O	pharmaceutical$$$22$$$36$$$O	formulation$$$37$$$48$$$O	with$$$49$$$53$$$O	controlled$$$54$$$64$$$O	release$$$65$$$72$$$O	of$$$73$$$75$$$O	acetylsalicylic$$$76$$$91$$$I	acid,$$$92$$$97$$$I	which$$$98$$$103$$$O	comprises$$$104$$$113$$$O	at$$$114$$$116$$$O	least$$$117$$$122$$$O	one$$$123$$$126$$$O	further$$$127$$$134$$$O	active$$$135$$$141$$$O	ingredient$$$142$$$152$$$O	selected$$$153$$$161$$$O	from$$$162$$$166$$$O	the$$$167$$$170$$$O	group$$$171$$$176$$$O	of$$$177$$$179$$$O	non-narcotic$$$180$$$192$$$O	analgesics$$$193$$$203$$$O	and/or$$$204$$$210$$$O	natural$$$211$$$218$$$O	psychotropic$$$219$$$231$$$O	agents,$$$232$$$239$$$O	and$$$240$$$243$$$O	stearic$$$244$$$251$$$I	acid$$$252$$$256$$$I	and$$$257$$$260$$$O	starch$$$261$$$267$$$O	as$$$268$$$270$$$O	excipients$$$271$$$281$$$O	in$$$282$$$284$$$O	a$$$285$$$286$$$O	specific$$$287$$$295$$$O	ratio,$$$296$$$302$$$O	and$$$303$$$306$$$O	a$$$307$$$308$$$O	method$$$309$$$315$$$O	for$$$316$$$319$$$O	the$$$320$$$323$$$O	preparation$$$324$$$335$$$O	thereof.$$$336$$$344$$$O
CN103636907A
Fruit$$$0$$$5$$$O	sugar$$$6$$$11$$$O	capable$$$12$$$19$$$O	of$$$20$$$22$$$O	sobering$$$23$$$31$$$O	up,$$$32$$$35$$$O	protecting$$$36$$$46$$$O	liver$$$47$$$52$$$O	and$$$53$$$56$$$O	quickly$$$57$$$64$$$O	supplementing$$$65$$$78$$$O	human$$$79$$$84$$$O	energy$$$85$$$91$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	fruit$$$26$$$31$$$O	sugar$$$32$$$37$$$I	capable$$$38$$$45$$$O	of$$$46$$$48$$$O	sobering$$$49$$$57$$$O	up,$$$58$$$61$$$O	protecting$$$62$$$72$$$O	liver$$$73$$$78$$$O	and$$$79$$$82$$$O	quickly$$$83$$$90$$$O	supplementing$$$91$$$104$$$O	human$$$105$$$110$$$O	energy.$$$111$$$118$$$O	The$$$119$$$122$$$O	raw$$$123$$$126$$$O	material$$$127$$$135$$$O	medicine$$$136$$$144$$$O	of$$$145$$$147$$$O	the$$$148$$$151$$$O	fruit$$$152$$$157$$$O	sugar$$$158$$$163$$$I	is$$$164$$$166$$$O	composed$$$167$$$175$$$O	of$$$176$$$178$$$O	grape$$$179$$$184$$$O	seed$$$185$$$189$$$O	extract,$$$190$$$198$$$O	red$$$199$$$202$$$O	bayberry$$$203$$$211$$$O	extract,$$$212$$$220$$$O	ginseng,$$$221$$$229$$$O	pueraria$$$230$$$238$$$O	lobata,$$$239$$$246$$$O	mulberry,$$$247$$$256$$$O	honeysuckle,$$$257$$$269$$$O	hovenia$$$270$$$277$$$O	dulcis$$$278$$$284$$$O	thunb,$$$285$$$291$$$O	fructus$$$292$$$299$$$O	amomi,$$$300$$$306$$$O	tuckahoe,$$$307$$$316$$$O	lophatherum$$$317$$$328$$$O	gracile,$$$329$$$337$$$O	mint,$$$338$$$343$$$O	vitamin$$$344$$$351$$$I	C,$$$352$$$354$$$I	vitamin$$$355$$$362$$$I	B6,$$$363$$$366$$$I	turmeric$$$367$$$375$$$O	and$$$376$$$379$$$O	protein$$$380$$$387$$$O	powder.$$$388$$$395$$$O	The$$$396$$$399$$$O	fruit$$$400$$$405$$$O	sugar$$$406$$$411$$$I	disclosed$$$412$$$421$$$O	by$$$422$$$424$$$O	the$$$425$$$428$$$O	invention$$$429$$$438$$$O	is$$$439$$$441$$$O	good$$$442$$$446$$$O	in$$$447$$$449$$$O	taste,$$$450$$$456$$$O	strong$$$457$$$463$$$O	in$$$464$$$466$$$O	function$$$467$$$475$$$O	and$$$476$$$479$$$O	strong$$$480$$$486$$$O	in$$$487$$$489$$$O	hangover$$$490$$$498$$$O	effect,$$$499$$$506$$$O	quickly$$$507$$$514$$$O	plays$$$515$$$520$$$O	pharmacodynamic$$$521$$$536$$$O	action$$$537$$$543$$$O	and$$$544$$$547$$$O	has$$$548$$$551$$$O	a$$$552$$$553$$$O	certain$$$554$$$561$$$O	inhibitory$$$562$$$572$$$O	effect$$$573$$$579$$$O	on$$$580$$$582$$$O	alcoholism$$$583$$$593$$$O	caused$$$594$$$600$$$O	by$$$601$$$603$$$O	excessive$$$604$$$613$$$O	drinking$$$614$$$622$$$O	so$$$623$$$625$$$O	as$$$626$$$628$$$O	to$$$629$$$631$$$O	protect$$$632$$$639$$$O	the$$$640$$$643$$$O	liver.$$$644$$$650$$$O	Meanwhile,$$$651$$$661$$$O	the$$$662$$$665$$$O	fruit$$$666$$$671$$$O	sugar$$$672$$$677$$$I	is$$$678$$$680$$$O	convenient$$$681$$$691$$$O	to$$$692$$$694$$$O	carry,$$$695$$$701$$$O	simple$$$702$$$708$$$O	to$$$709$$$711$$$O	eat$$$712$$$715$$$O	and$$$716$$$719$$$O	suitable$$$720$$$728$$$O	for$$$729$$$732$$$O	various$$$733$$$740$$$O	different$$$741$$$750$$$O	occasions.$$$751$$$761$$$O
CN101254188A
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	medicament$$$7$$$17$$$O	of$$$18$$$20$$$O	geldanamycin$$$21$$$33$$$I	derivative$$$34$$$44$$$O	for$$$45$$$48$$$O	preparing$$$49$$$58$$$O	medicament$$$59$$$69$$$O	for$$$70$$$73$$$O	curing$$$74$$$80$$$O	chemotherapy$$$81$$$93$$$O	induction$$$94$$$103$$$O	alopecia$$$104$$$112$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	new$$$29$$$32$$$O	use$$$33$$$36$$$O	of$$$37$$$39$$$O	geldanamycin$$$40$$$52$$$I	derivative,$$$53$$$64$$$O	particularly$$$65$$$77$$$O	to$$$78$$$80$$$O	an$$$81$$$83$$$O	application$$$84$$$95$$$O	of$$$96$$$98$$$O	the$$$99$$$102$$$O	geldanamycin$$$103$$$115$$$I	derivative$$$116$$$126$$$O	in$$$127$$$129$$$O	preparing$$$130$$$139$$$O	drugs$$$140$$$145$$$O	for$$$146$$$149$$$O	treating$$$150$$$158$$$O	chemotherapy-induced$$$159$$$179$$$O	alopecia.$$$180$$$189$$$O	The$$$190$$$193$$$O	invention$$$194$$$203$$$O	provides$$$204$$$212$$$O	an$$$213$$$215$$$O	application$$$216$$$227$$$O	of$$$228$$$230$$$O	geldanamycin$$$231$$$243$$$I	derivative$$$244$$$254$$$O	17-allylaniino-17-demethoxy-geldanamycin$$$255$$$295$$$I	(17-AAG)$$$296$$$304$$$I	in$$$305$$$307$$$O	preparing$$$308$$$317$$$O	drugs$$$318$$$323$$$O	for$$$324$$$327$$$O	treating$$$328$$$336$$$O	chemotherapy-induced$$$337$$$357$$$O	alopecia.$$$358$$$367$$$O	The$$$368$$$371$$$O	inventive$$$372$$$381$$$O	geldanamycin$$$382$$$394$$$I	derivative$$$395$$$405$$$O	17-AAG$$$406$$$412$$$I	can$$$413$$$416$$$O	be$$$417$$$419$$$O	used$$$420$$$424$$$O	for$$$425$$$428$$$O	developing$$$429$$$439$$$O	new$$$440$$$443$$$O	drugs$$$444$$$449$$$O	for$$$450$$$453$$$O	treating$$$454$$$462$$$O	chemotherapy-induced$$$463$$$483$$$O	alopecia,$$$484$$$493$$$O	which$$$494$$$499$$$O	have$$$500$$$504$$$O	reliable$$$505$$$513$$$O	safety$$$514$$$520$$$O	and$$$521$$$524$$$O	can$$$525$$$528$$$O	remarkably$$$529$$$539$$$O	improve$$$540$$$547$$$O	the$$$548$$$551$$$O	life$$$552$$$556$$$O	quality$$$557$$$564$$$O	of$$$565$$$567$$$O	chemotherapy$$$568$$$580$$$O	patients$$$581$$$589$$$O	and$$$590$$$593$$$O	relieve$$$594$$$601$$$O	mental$$$602$$$608$$$O	pressure$$$609$$$617$$$O	of$$$618$$$620$$$O	patients,$$$621$$$630$$$O	so$$$631$$$633$$$O	as$$$634$$$636$$$O	to$$$637$$$639$$$O	better$$$640$$$646$$$O	cooperate$$$647$$$656$$$O	with$$$657$$$661$$$O	cancer$$$662$$$668$$$O	treatment.$$$669$$$679$$$O
US20120165310
Ether$$$0$$$5$$$I	derivatives$$$6$$$17$$$O	of$$$18$$$20$$$O	bicyclic$$$21$$$29$$$I	heteroaryls$$$30$$$41$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	formula$$$38$$$45$$$O	I,$$$46$$$48$$$O	wherein$$$86$$$93$$$O	the$$$94$$$97$$$O	substituents$$$98$$$110$$$O	are$$$111$$$114$$$O	as$$$115$$$117$$$O	defined$$$118$$$125$$$O	in$$$126$$$128$$$O	the$$$129$$$132$$$O	specification;$$$133$$$147$$$O	to$$$148$$$150$$$O	processes$$$151$$$160$$$O	for$$$161$$$164$$$O	the$$$165$$$168$$$O	preparation$$$169$$$180$$$O	of$$$181$$$183$$$O	such$$$184$$$188$$$O	compounds;$$$189$$$199$$$O	pharmaceutical$$$200$$$214$$$O	compositions$$$215$$$227$$$O	comprising$$$228$$$238$$$O	such$$$239$$$243$$$O	compounds;$$$244$$$254$$$O	such$$$255$$$259$$$O	compounds$$$260$$$269$$$O	as$$$270$$$272$$$O	a$$$273$$$274$$$O	medicament;$$$275$$$286$$$O	such$$$287$$$291$$$O	compounds$$$292$$$301$$$O	for$$$302$$$305$$$O	the$$$306$$$309$$$O	treatment$$$310$$$319$$$O	of$$$320$$$322$$$O	a$$$323$$$324$$$O	proliferative$$$325$$$338$$$O	disease.$$$339$$$347$$$O
EP1121355B1
Quinoline$$$0$$$9$$$I	derivatives$$$10$$$21$$$O	and$$$22$$$25$$$O	their$$$26$$$31$$$O	use$$$32$$$35$$$O	as$$$36$$$38$$$O	antibacterial$$$39$$$52$$$O	agents$$$53$$$59$$$O
Piperidine$$$0$$$10$$$I	derivatives$$$11$$$22$$$O	and$$$23$$$26$$$O	pharmaceutical$$$27$$$41$$$O	derivatives$$$42$$$53$$$O	thereof$$$54$$$61$$$O	useful$$$62$$$68$$$O	in$$$69$$$71$$$O	methods$$$72$$$79$$$O	of$$$80$$$82$$$O	treatment$$$83$$$92$$$O	of$$$93$$$95$$$O	bacterial$$$96$$$105$$$O	infections$$$106$$$116$$$O	in$$$117$$$119$$$O	mammals,$$$120$$$128$$$O	particularly$$$129$$$141$$$O	in$$$142$$$144$$$O	man.$$$145$$$149$$$O
US7122187
Treating$$$0$$$8$$$O	autoimmune$$$9$$$19$$$O	diseases$$$20$$$28$$$O	with$$$29$$$33$$$O	humanized$$$34$$$43$$$O	anti-CD40L$$$44$$$54$$$O	antibody$$$55$$$63$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	humanized$$$37$$$46$$$O	antibodies$$$47$$$57$$$O	which$$$58$$$63$$$O	bind$$$64$$$68$$$O	human$$$69$$$74$$$O	gp39$$$75$$$79$$$O	and$$$80$$$83$$$O	their$$$84$$$89$$$O	use$$$90$$$93$$$O	as$$$94$$$96$$$O	therapeutic$$$97$$$108$$$O	agents.$$$109$$$116$$$O	These$$$117$$$122$$$O	humanized$$$123$$$132$$$O	antibodies$$$133$$$143$$$O	are$$$144$$$147$$$O	especially$$$148$$$158$$$O	useful$$$159$$$165$$$O	for$$$166$$$169$$$O	treatment$$$170$$$179$$$O	of$$$180$$$182$$$O	autoimmune$$$183$$$193$$$O	diseases;$$$194$$$203$$$O	and$$$204$$$207$$$O	an$$$208$$$210$$$O	immunosuppressant$$$211$$$228$$$O	during$$$229$$$235$$$O	transplantation$$$236$$$251$$$O	of$$$252$$$254$$$O	heterologous$$$255$$$267$$$O	cells,$$$268$$$274$$$O	tissues$$$275$$$282$$$O	or$$$283$$$285$$$O	organs,$$$286$$$293$$$O	cell$$$294$$$298$$$O	therapy,$$$299$$$307$$$O	and$$$308$$$311$$$O	gene$$$312$$$316$$$O	therapy.$$$317$$$325$$$O
US20100069410
acyclovir$$$0$$$9$$$I	formulations$$$10$$$22$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	acyclovir$$$33$$$42$$$I	formulations$$$43$$$55$$$O	having$$$56$$$62$$$O	improved$$$63$$$71$$$O	bioavailability$$$72$$$87$$$O	resulting$$$88$$$97$$$O	in$$$98$$$100$$$O	better$$$101$$$107$$$O	efficacy$$$108$$$116$$$O	and/or$$$117$$$123$$$O	requiring$$$124$$$133$$$O	less$$$134$$$138$$$O	frequent$$$139$$$147$$$O	administration.$$$148$$$163$$$O
WO2011154630A1
Krypton-based$$$0$$$13$$$O	inhalable$$$14$$$23$$$O	gaseous$$$24$$$31$$$O	medicinal$$$32$$$41$$$O	product$$$42$$$49$$$O	for$$$50$$$53$$$O	combatting$$$54$$$64$$$O	deficiencies$$$65$$$77$$$O	or$$$78$$$80$$$O	failure$$$81$$$88$$$O	of$$$89$$$91$$$O	peripheral$$$92$$$102$$$O	organs$$$103$$$109$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	gaseous$$$27$$$34$$$O	composition$$$35$$$46$$$O	containing$$$47$$$57$$$O	an$$$58$$$60$$$O	effective$$$61$$$70$$$O	amount$$$71$$$77$$$O	of$$$78$$$80$$$O	gaseous$$$81$$$88$$$O	krypton$$$89$$$96$$$O	for$$$97$$$100$$$O	use$$$101$$$104$$$O	via$$$105$$$108$$$O	inhalation$$$109$$$119$$$O	for$$$120$$$123$$$O	preventing$$$124$$$134$$$O	or$$$135$$$137$$$O	treating$$$138$$$146$$$O	a$$$147$$$148$$$O	deficiency$$$149$$$159$$$O	or$$$160$$$162$$$O	failure$$$163$$$170$$$O	of$$$171$$$173$$$O	at$$$174$$$176$$$O	least$$$177$$$182$$$O	one$$$183$$$186$$$O	peripheral$$$187$$$197$$$O	organ$$$198$$$203$$$O	in$$$204$$$206$$$O	a$$$207$$$208$$$O	patient.$$$209$$$217$$$O	Preferably,$$$218$$$229$$$O	it$$$230$$$232$$$O	contains$$$233$$$241$$$O	between$$$242$$$249$$$O	15$$$250$$$252$$$O	and$$$253$$$256$$$O	80%$$$257$$$260$$$O	by$$$261$$$263$$$O	volume$$$264$$$270$$$O	of$$$271$$$273$$$O	krypton$$$274$$$281$$$O	and$$$282$$$285$$$O	oxygen.$$$286$$$293$$$I	The$$$294$$$297$$$O	organ$$$298$$$303$$$O	deficiency$$$304$$$314$$$O	or$$$315$$$317$$$O	failure$$$318$$$325$$$O	results$$$326$$$333$$$O	in$$$334$$$336$$$O	particular$$$337$$$347$$$O	from$$$348$$$352$$$O	an$$$353$$$355$$$O	organic$$$356$$$363$$$O	or$$$364$$$366$$$O	functional$$$367$$$377$$$O	anomaly.$$$378$$$386$$$O	The$$$387$$$390$$$O	organ$$$391$$$396$$$O	is$$$397$$$399$$$O	chosen$$$400$$$406$$$O	from$$$407$$$411$$$O	the$$$412$$$415$$$O	liver,$$$416$$$422$$$O	kidneys,$$$423$$$431$$$O	heart$$$432$$$437$$$O	and$$$438$$$441$$$O	lungs.$$$442$$$448$$$O
US20060140872
Novel$$$0$$$5$$$O	signaling$$$6$$$15$$$O	pathway$$$16$$$23$$$O	for$$$24$$$27$$$O	the$$$28$$$31$$$O	production$$$32$$$42$$$O	of$$$43$$$45$$$O	inglammatory$$$46$$$58$$$O	pain$$$59$$$63$$$O	and$$$64$$$67$$$O	neuropathy$$$68$$$78$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	remedy$$$28$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	allergic$$$48$$$56$$$O	contact$$$57$$$64$$$O	dermatitis$$$65$$$75$$$O	containing$$$76$$$86$$$O	a$$$87$$$88$$$O	substance$$$89$$$98$$$O	having$$$99$$$105$$$O	MEK$$$106$$$109$$$O	inhibitory$$$110$$$120$$$O	action$$$121$$$127$$$O	as$$$128$$$130$$$O	its$$$131$$$134$$$O	effective$$$135$$$144$$$O	component.$$$145$$$155$$$O
EP0972037B1
Beta-catenin,$$$0$$$13$$$O	tcf-4,$$$14$$$20$$$O	and$$$21$$$24$$$O	apc$$$25$$$28$$$O	interact$$$29$$$37$$$O	to$$$38$$$40$$$O	prevent$$$41$$$48$$$O	cancer$$$49$$$55$$$O
The$$$0$$$3$$$O	APC$$$4$$$7$$$O	tumor$$$8$$$13$$$O	suppressor$$$14$$$24$$$O	protein$$$25$$$32$$$O	binds$$$33$$$38$$$O	to$$$39$$$41$$$O	beta$$$43$$$47$$$O	-catenin,$$$48$$$57$$$O	a$$$58$$$59$$$O	protein$$$60$$$67$$$O	recently$$$68$$$76$$$O	shown$$$77$$$82$$$O	to$$$83$$$85$$$O	interact$$$86$$$94$$$O	with$$$95$$$99$$$O	Tcf/Lef$$$100$$$107$$$O	transcription$$$108$$$121$$$O	factors.$$$122$$$130$$$O	Here,$$$131$$$136$$$O	the$$$137$$$140$$$O	gene$$$141$$$145$$$O	encoding$$$146$$$154$$$O	a$$$155$$$156$$$O	Tcf$$$157$$$160$$$O	family$$$161$$$167$$$O	member$$$168$$$174$$$O	that$$$175$$$179$$$O	is$$$180$$$182$$$O	expressed$$$183$$$192$$$O	in$$$193$$$195$$$O	colonic$$$196$$$203$$$O	epithelium$$$204$$$214$$$O	(hTcf-4)$$$215$$$223$$$O	was$$$224$$$227$$$O	cloned$$$228$$$234$$$O	and$$$235$$$238$$$O	characterized.$$$239$$$253$$$O	hTcf-4$$$254$$$260$$$O	transactivates$$$261$$$275$$$O	transcription$$$276$$$289$$$O	only$$$290$$$294$$$O	when$$$295$$$299$$$O	associated$$$300$$$310$$$O	with$$$311$$$315$$$O	beta$$$317$$$321$$$O	-catenin.$$$322$$$331$$$O	Nuclei$$$332$$$338$$$O	of$$$339$$$341$$$O	APC<-/->$$$342$$$350$$$O	colon$$$351$$$356$$$O	carcinoma$$$357$$$366$$$O	cells$$$367$$$372$$$O	were$$$373$$$377$$$O	found$$$378$$$383$$$O	to$$$384$$$386$$$O	contain$$$387$$$394$$$O	a$$$395$$$396$$$O	stable$$$397$$$403$$$O	beta$$$405$$$409$$$O	-catenin-hTCF-4$$$410$$$425$$$O	complex$$$426$$$433$$$O	that$$$434$$$438$$$O	was$$$439$$$442$$$O	constitutively$$$443$$$457$$$O	active,$$$458$$$465$$$O	as$$$466$$$468$$$O	measured$$$469$$$477$$$O	by$$$478$$$480$$$O	transcription$$$481$$$494$$$O	of$$$495$$$497$$$O	a$$$498$$$499$$$O	Tcf$$$500$$$503$$$O	reporter$$$504$$$512$$$O	gene.$$$513$$$518$$$O	Reintroduction$$$519$$$533$$$O	of$$$534$$$536$$$O	APC$$$537$$$540$$$O	removed$$$541$$$548$$$O	beta$$$550$$$554$$$O	-catenin$$$555$$$563$$$O	from$$$564$$$568$$$O	hTcf4$$$569$$$574$$$O	and$$$575$$$578$$$O	abrogated$$$579$$$588$$$O	the$$$589$$$592$$$O	transcriptional$$$593$$$608$$$O	transactivation.$$$609$$$625$$$O	Constitutive$$$626$$$638$$$O	transcription$$$639$$$652$$$O	of$$$653$$$655$$$O	TCF$$$656$$$659$$$O	target$$$660$$$666$$$O	genes,$$$667$$$673$$$O	caused$$$674$$$680$$$O	by$$$681$$$683$$$O	loss$$$684$$$688$$$O	of$$$689$$$691$$$O	APC$$$692$$$695$$$O	function,$$$696$$$705$$$O	may$$$706$$$709$$$O	be$$$710$$$712$$$O	a$$$713$$$714$$$O	crucial$$$715$$$722$$$O	event$$$723$$$728$$$O	in$$$729$$$731$$$O	the$$$732$$$735$$$O	early$$$736$$$741$$$O	transformation$$$742$$$756$$$O	of$$$757$$$759$$$O	colonic$$$760$$$767$$$O	epithelium.$$$768$$$779$$$O	It$$$780$$$782$$$O	is$$$783$$$785$$$O	also$$$786$$$790$$$O	shown$$$791$$$796$$$O	here$$$797$$$801$$$O	that$$$802$$$806$$$O	the$$$807$$$810$$$O	products$$$811$$$819$$$O	of$$$820$$$822$$$O	mutant$$$823$$$829$$$O	APC$$$830$$$833$$$O	genes$$$834$$$839$$$O	found$$$840$$$845$$$O	in$$$846$$$848$$$O	colorectal$$$849$$$859$$$O	tumors$$$860$$$866$$$O	are$$$867$$$870$$$O	defective$$$871$$$880$$$O	in$$$881$$$883$$$O	regulating$$$884$$$894$$$O	beta$$$896$$$900$$$O	-catenin/Tcf-4$$$901$$$915$$$O	transcriptional$$$916$$$931$$$O	activation.$$$932$$$943$$$O	Furthermore,$$$944$$$956$$$O	colorectal$$$957$$$967$$$O	tumors$$$968$$$974$$$O	with$$$975$$$979$$$O	intact$$$980$$$986$$$O	APC$$$987$$$990$$$O	genes$$$991$$$996$$$O	were$$$997$$$1001$$$O	shown$$$1002$$$1007$$$O	to$$$1008$$$1010$$$O	contain$$$1011$$$1018$$$O	subtle$$$1019$$$1025$$$O	activating$$$1026$$$1036$$$O	mutations$$$1037$$$1046$$$O	of$$$1047$$$1049$$$O	beta$$$1051$$$1055$$$O	-catenin$$$1056$$$1064$$$O	that$$$1065$$$1069$$$O	altered$$$1070$$$1077$$$O	functionally$$$1078$$$1090$$$O	significant$$$1091$$$1102$$$O	phosphorylation$$$1103$$$1118$$$O	sites.$$$1119$$$1125$$$O	These$$$1126$$$1131$$$O	results$$$1132$$$1139$$$O	indicate$$$1140$$$1148$$$O	that$$$1149$$$1153$$$O	regulation$$$1154$$$1164$$$O	of$$$1165$$$1167$$$O	beta$$$1169$$$1173$$$O	-catenin$$$1174$$$1182$$$O	is$$$1183$$$1185$$$O	critical$$$1186$$$1194$$$O	to$$$1195$$$1197$$$O	APC's$$$1198$$$1203$$$O	tumor$$$1204$$$1209$$$O	suppressive$$$1210$$$1221$$$O	effect$$$1222$$$1228$$$O	and$$$1229$$$1232$$$O	that$$$1233$$$1237$$$O	this$$$1238$$$1242$$$O	regulation$$$1243$$$1253$$$O	can$$$1254$$$1257$$$O	be$$$1258$$$1260$$$O	circumvented$$$1261$$$1273$$$O	by$$$1274$$$1276$$$O	mutations$$$1277$$$1286$$$O	in$$$1287$$$1289$$$O	either$$$1290$$$1296$$$O	APC$$$1297$$$1300$$$O	or$$$1301$$$1303$$$O	beta$$$1305$$$1309$$$O	-catenin.$$$1310$$$1319$$$O
CN102000035A
Zoledronic$$$0$$$10$$$I	acid$$$11$$$15$$$I	composition$$$16$$$27$$$O	for$$$28$$$31$$$O	injection$$$32$$$41$$$O	and$$$42$$$45$$$O	preparation$$$46$$$57$$$O	method$$$58$$$64$$$O	thereof$$$65$$$72$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	zoledronic$$$25$$$35$$$I	acid$$$36$$$40$$$I	composition$$$41$$$52$$$O	for$$$53$$$56$$$O	injection.$$$57$$$67$$$O	The$$$68$$$71$$$O	zoledronic$$$72$$$82$$$I	acid$$$83$$$87$$$I	composition$$$88$$$99$$$O	for$$$100$$$103$$$O	injection$$$104$$$113$$$O	is$$$114$$$116$$$O	prepared$$$117$$$125$$$O	by$$$126$$$128$$$O	the$$$129$$$132$$$O	following$$$133$$$142$$$O	steps$$$143$$$148$$$O	of:$$$149$$$152$$$O	1)$$$153$$$155$$$O	preparing$$$156$$$165$$$O	medicinal$$$166$$$175$$$O	liquid,$$$176$$$183$$$O	namely$$$184$$$190$$$O	selecting$$$191$$$200$$$O	zoledronic$$$201$$$211$$$I	acid$$$212$$$216$$$I	and$$$217$$$220$$$O	trisodium$$$221$$$230$$$I	citrate$$$231$$$238$$$I	as$$$239$$$241$$$O	raw$$$242$$$245$$$O	materials$$$246$$$255$$$O	according$$$256$$$265$$$O	to$$$266$$$268$$$O	the$$$269$$$272$$$O	weight$$$273$$$279$$$O	ratio$$$280$$$285$$$O	of$$$286$$$288$$$O	the$$$289$$$292$$$O	zoledronic$$$293$$$303$$$I	acid$$$304$$$308$$$I	to$$$309$$$311$$$O	the$$$312$$$315$$$O	trisodium$$$316$$$325$$$I	citrate$$$326$$$333$$$I	of$$$334$$$336$$$O	1:0.5-2,$$$337$$$345$$$O	weighing$$$346$$$354$$$O	a$$$355$$$356$$$O	proper$$$357$$$363$$$O	amount$$$364$$$370$$$O	of$$$371$$$373$$$O	the$$$374$$$377$$$O	raw$$$378$$$381$$$O	materials$$$382$$$391$$$O	and$$$392$$$395$$$O	placing$$$396$$$403$$$O	the$$$404$$$407$$$O	raw$$$408$$$411$$$O	materials$$$412$$$421$$$O	into$$$422$$$426$$$O	a$$$427$$$428$$$O	preparation$$$429$$$440$$$O	tank,$$$441$$$446$$$O	adding$$$447$$$453$$$O	water$$$454$$$459$$$O	for$$$460$$$463$$$O	injection$$$464$$$473$$$O	until$$$474$$$479$$$O	the$$$480$$$483$$$O	weight$$$484$$$490$$$O	of$$$491$$$493$$$O	the$$$494$$$497$$$O	solution$$$498$$$506$$$O	is$$$507$$$509$$$O	250$$$510$$$513$$$O	to$$$514$$$516$$$O	1,250$$$517$$$522$$$O	times$$$523$$$528$$$O	that$$$529$$$533$$$O	of$$$534$$$536$$$O	the$$$537$$$540$$$O	zoledronic$$$541$$$551$$$I	acid,$$$552$$$557$$$I	stirring$$$558$$$566$$$O	the$$$567$$$570$$$O	solution$$$571$$$579$$$O	to$$$580$$$582$$$O	dissolve$$$583$$$591$$$O	the$$$592$$$595$$$O	raw$$$596$$$599$$$O	materials$$$600$$$609$$$O	and$$$610$$$613$$$O	mixing$$$614$$$620$$$O	the$$$621$$$624$$$O	raw$$$625$$$628$$$O	materials$$$629$$$638$$$O	uniformly$$$639$$$648$$$O	and$$$649$$$652$$$O	adjusting$$$653$$$662$$$O	the$$$663$$$666$$$O	pH$$$667$$$669$$$O	value$$$670$$$675$$$O	of$$$676$$$678$$$O	the$$$679$$$682$$$O	solution$$$683$$$691$$$O	to$$$692$$$694$$$O	be$$$695$$$697$$$O	4.0$$$698$$$701$$$O	to$$$702$$$704$$$O	6.0;$$$705$$$709$$$O	2)$$$710$$$712$$$O	performing$$$713$$$723$$$O	active$$$724$$$730$$$O	carbon$$$731$$$737$$$I	finishing;$$$738$$$748$$$O	3)$$$749$$$751$$$O	performing$$$752$$$762$$$O	adsorption;$$$763$$$774$$$O	4)$$$775$$$777$$$O	performing$$$778$$$788$$$O	aseptic$$$789$$$796$$$O	filtration$$$797$$$807$$$O	and$$$808$$$811$$$O	subpackaging;$$$812$$$825$$$O	and$$$826$$$829$$$O	5)$$$830$$$832$$$O	performing$$$833$$$843$$$O	vacuum$$$844$$$850$$$O	freeze$$$851$$$857$$$O	drying$$$858$$$864$$$O	to$$$865$$$867$$$O	obtain$$$868$$$874$$$O	the$$$875$$$878$$$O	zoledronic$$$879$$$889$$$I	acid$$$890$$$894$$$I	composition$$$895$$$906$$$O	for$$$907$$$910$$$O	injection.$$$911$$$921$$$O	By$$$922$$$924$$$O	the$$$925$$$928$$$O	zoledronic$$$929$$$939$$$I	acid$$$940$$$944$$$I	composition$$$945$$$956$$$O	for$$$957$$$960$$$O	injection$$$961$$$970$$$O	and$$$971$$$974$$$O	the$$$975$$$978$$$O	preparation$$$979$$$990$$$O	method$$$991$$$997$$$O	thereof,$$$998$$$1006$$$O	for$$$1007$$$1010$$$O	injection$$$1011$$$1020$$$O	of$$$1021$$$1023$$$O	which$$$1024$$$1029$$$O	the$$$1030$$$1033$$$O	clarity$$$1034$$$1041$$$O	is$$$1042$$$1044$$$O	influenced$$$1045$$$1055$$$O	by$$$1056$$$1058$$$O	active$$$1059$$$1065$$$O	carbon$$$1066$$$1072$$$O	greatly,$$$1073$$$1081$$$O	such$$$1082$$$1086$$$O	as$$$1087$$$1089$$$O	the$$$1090$$$1093$$$O	zoledronic$$$1094$$$1104$$$I	acid$$$1105$$$1109$$$I	and$$$1110$$$1113$$$O	the$$$1114$$$1117$$$O	like,$$$1118$$$1123$$$O	the$$$1124$$$1127$$$O	heat$$$1128$$$1132$$$O	source,$$$1133$$$1140$$$O	the$$$1141$$$1144$$$O	clarity$$$1145$$$1152$$$O	and$$$1153$$$1156$$$O	insoluble$$$1157$$$1166$$$O	particles$$$1167$$$1176$$$O	of$$$1177$$$1179$$$O	the$$$1180$$$1183$$$O	product$$$1184$$$1191$$$O	can$$$1192$$$1195$$$O	meet$$$1196$$$1200$$$O	the$$$1201$$$1204$$$O	requirements$$$1205$$$1217$$$O	of$$$1218$$$1220$$$O	the$$$1221$$$1224$$$O	injection.$$$1225$$$1235$$$O
CN101700256A
Pharmaceutical$$$0$$$14$$$O	composite$$$15$$$24$$$O	for$$$25$$$28$$$O	reducing$$$29$$$37$$$O	blood$$$38$$$43$$$O	fat$$$44$$$47$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pharmaceutical$$$27$$$41$$$O	composite$$$42$$$51$$$O	for$$$52$$$55$$$O	reducing$$$56$$$64$$$O	blood$$$65$$$70$$$O	fat,$$$71$$$75$$$O	which$$$76$$$81$$$O	comprises$$$82$$$91$$$O	sea$$$92$$$95$$$O	buckthorn,$$$96$$$106$$$O	vitamin$$$107$$$114$$$I	B$$$115$$$116$$$I	complex,$$$117$$$125$$$O	vitamin$$$126$$$133$$$I	E$$$134$$$135$$$I	and$$$136$$$139$$$O	trace$$$140$$$145$$$O	elements$$$146$$$154$$$O	of$$$155$$$157$$$O	zinc,$$$158$$$163$$$I	selenium,$$$164$$$173$$$I	chromium$$$174$$$182$$$I	and$$$183$$$186$$$O	molybdenum.$$$187$$$198$$$I	The$$$199$$$202$$$O	pharmaceutical$$$203$$$217$$$O	composite$$$218$$$227$$$O	is$$$228$$$230$$$O	used$$$231$$$235$$$O	for$$$236$$$239$$$O	people$$$240$$$246$$$O	suffering$$$247$$$256$$$O	from$$$257$$$261$$$O	hyperlipaemia,$$$262$$$276$$$O	has$$$277$$$280$$$O	very$$$281$$$285$$$O	good$$$286$$$290$$$O	effect$$$291$$$297$$$O	on$$$298$$$300$$$O	reducing$$$301$$$309$$$O	blood$$$310$$$315$$$O	fat,$$$316$$$320$$$O	and$$$321$$$324$$$O	can$$$325$$$328$$$O	be$$$329$$$331$$$O	applied$$$332$$$339$$$O	to$$$340$$$342$$$O	a$$$343$$$344$$$O	long$$$345$$$349$$$O	time$$$350$$$354$$$O	or$$$355$$$357$$$O	in$$$358$$$360$$$O	course$$$361$$$367$$$O	of$$$368$$$370$$$O	treatment.$$$371$$$381$$$O
CN103193860A
Tanshinone$$$0$$$10$$$I	compounds,$$$11$$$21$$$O	preparation$$$22$$$33$$$O	method$$$34$$$40$$$O	and$$$41$$$44$$$O	use$$$45$$$48$$$O	thereof$$$49$$$56$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	tanshinone$$$23$$$33$$$I	compounds,$$$34$$$44$$$O	a$$$45$$$46$$$O	preparation$$$47$$$58$$$O	method$$$59$$$65$$$O	and$$$66$$$69$$$O	use$$$70$$$73$$$O	thereof,$$$74$$$82$$$O	and$$$83$$$86$$$O	relates$$$87$$$94$$$O	to$$$95$$$97$$$O	the$$$98$$$101$$$O	technical$$$102$$$111$$$O	field$$$112$$$117$$$O	of$$$118$$$120$$$O	pharmaceutical$$$121$$$135$$$O	chemistry.$$$136$$$146$$$O	The$$$147$$$150$$$O	tanshinone$$$151$$$161$$$I	compounds$$$162$$$171$$$O	possess$$$172$$$179$$$O	a$$$180$$$181$$$O	structure$$$182$$$191$$$O	formula$$$192$$$199$$$O	I$$$200$$$201$$$O	or$$$202$$$204$$$O	II$$$205$$$207$$$O	as$$$208$$$210$$$O	shown$$$211$$$216$$$O	in$$$217$$$219$$$O	the$$$220$$$223$$$O	specification.$$$224$$$238$$$O	The$$$239$$$242$$$O	use$$$243$$$246$$$O	of$$$247$$$249$$$O	the$$$250$$$253$$$O	tanshinone$$$254$$$264$$$I	compounds$$$265$$$274$$$O	includes$$$275$$$283$$$O	but$$$284$$$287$$$O	not$$$288$$$291$$$O	limited$$$292$$$299$$$O	to$$$300$$$302$$$O	anticancer$$$303$$$313$$$O	drugs,$$$314$$$320$$$O	particularly$$$321$$$333$$$O	the$$$334$$$337$$$O	treatment$$$338$$$347$$$O	of$$$348$$$350$$$O	prostate$$$351$$$359$$$O	cancer$$$360$$$366$$$O	and$$$367$$$370$$$O	bladder$$$371$$$378$$$O	cancer,$$$379$$$386$$$O	and$$$387$$$390$$$O	induction$$$391$$$400$$$O	of$$$401$$$403$$$O	androgen$$$404$$$412$$$I	receptor$$$413$$$421$$$O	antagonist$$$422$$$432$$$O	activity$$$433$$$441$$$O	when$$$442$$$446$$$O	patients$$$447$$$455$$$O	have$$$456$$$460$$$O	androgen-related$$$461$$$477$$$I	diseases,$$$478$$$487$$$O	wherein$$$488$$$495$$$O	the$$$496$$$499$$$O	androgen-related$$$500$$$516$$$I	diseases$$$517$$$525$$$O	include$$$526$$$533$$$O	but$$$534$$$537$$$O	not$$$538$$$541$$$O	limited$$$542$$$549$$$O	to$$$550$$$552$$$O	multi-disease,$$$553$$$567$$$O	acne,$$$568$$$573$$$O	and$$$574$$$577$$$O	spermatogenesis$$$578$$$593$$$O	without$$$594$$$601$$$O	inhibition$$$602$$$612$$$O	in$$$613$$$615$$$O	need$$$616$$$620$$$O	of$$$621$$$623$$$O	suppressing$$$624$$$635$$$O	spermatogenesis.$$$636$$$652$$$O
CN101275135A
Antisense$$$0$$$9$$$O	oligonucleotide$$$10$$$25$$$I	for$$$26$$$29$$$O	tissue-specific$$$30$$$45$$$O	regulation$$$46$$$56$$$O	of$$$57$$$59$$$O	POKEMON$$$60$$$67$$$O	gene$$$68$$$72$$$O	expression$$$73$$$83$$$O	and$$$84$$$87$$$O	application$$$88$$$99$$$O	thereof$$$100$$$107$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	an$$$31$$$33$$$O	antisense$$$34$$$43$$$O	oligonucleotide$$$44$$$59$$$I	of$$$60$$$62$$$O	tissue-specific$$$63$$$78$$$O	regulation$$$79$$$89$$$O	POKEMON$$$90$$$97$$$O	gene$$$98$$$102$$$O	expression$$$103$$$113$$$O	and$$$114$$$117$$$O	its$$$118$$$121$$$O	application.$$$122$$$134$$$O	The$$$135$$$138$$$O	antisense$$$139$$$148$$$O	oligonucleotide$$$149$$$164$$$I	is$$$165$$$167$$$O	one$$$168$$$171$$$O	of$$$172$$$174$$$O	the$$$175$$$178$$$O	following$$$179$$$188$$$O	formulas:$$$189$$$198$$$O	CxCxAxCxGyCyCyGyCyCyGyGyCyCyAxTxCxTx;$$$199$$$236$$$O	CxGxCxTxGxAyCyGyAyAyGyTyCyGyAxTxCxTx;$$$237$$$274$$$O	GxGxCxCxCyGyGyCyCyCyAyTyAyGyAxAxGxTx;$$$275$$$312$$$O	TxTxCxAxGxGyTyCyGyTyAyGyTyTyGxTxGxGx;$$$313$$$350$$$O	TxTxCxAxGyGyTyCyGyTyAyGyTyTyGxTxGxGx.$$$351$$$388$$$O	X$$$389$$$390$$$O	is$$$391$$$393$$$O	bond$$$394$$$398$$$O	between$$$399$$$406$$$O	thiophosphate$$$407$$$420$$$I	nucleoside.$$$421$$$432$$$O	The$$$433$$$436$$$O	antisense$$$437$$$446$$$O	oligonucleotide$$$447$$$462$$$I	of$$$463$$$465$$$O	the$$$466$$$469$$$O	invention$$$470$$$479$$$O	is$$$480$$$482$$$O	used$$$483$$$487$$$O	for$$$488$$$491$$$O	preparing$$$492$$$501$$$O	gene$$$502$$$506$$$O	therapeutic$$$507$$$518$$$O	drug$$$519$$$523$$$O	for$$$524$$$527$$$O	curing$$$528$$$534$$$O	disease$$$535$$$542$$$O	caused$$$543$$$549$$$O	by$$$550$$$552$$$O	POKEMON$$$553$$$560$$$O	high$$$561$$$565$$$O	expression.$$$566$$$577$$$O
CA2801535A1
Composition$$$0$$$11$$$O	and$$$12$$$15$$$O	method$$$16$$$22$$$O	for$$$23$$$26$$$O	inner$$$27$$$32$$$O	ear$$$33$$$36$$$O	sensory$$$37$$$44$$$O	hair$$$45$$$49$$$O	cell$$$50$$$54$$$O	regeneration$$$55$$$67$$$O	or$$$68$$$70$$$O	replacement$$$71$$$82$$$O
A$$$0$$$1$$$O	composition$$$2$$$13$$$O	and$$$14$$$17$$$O	method$$$18$$$24$$$O	for$$$25$$$28$$$O	replacement$$$29$$$40$$$O	and$$$41$$$44$$$O	regeneration$$$45$$$57$$$O	of$$$58$$$60$$$O	hair$$$61$$$65$$$O	cells$$$66$$$71$$$O	of$$$72$$$74$$$O	the$$$75$$$78$$$O	inner$$$79$$$84$$$O	ear$$$85$$$88$$$O	is$$$89$$$91$$$O	provided.$$$92$$$101$$$O	The$$$102$$$105$$$O	composition$$$106$$$117$$$O	comprises$$$118$$$127$$$O	an$$$128$$$130$$$O	active$$$131$$$137$$$O	agent$$$138$$$143$$$O	in$$$144$$$146$$$O	an$$$147$$$149$$$O	amount$$$150$$$156$$$O	effective$$$157$$$166$$$O	to$$$167$$$169$$$O	decrease$$$170$$$178$$$O	Hesl$$$179$$$183$$$O	gene$$$184$$$188$$$O	expression$$$189$$$199$$$O	in$$$200$$$202$$$O	a$$$203$$$204$$$O	tissue$$$205$$$211$$$O	of$$$212$$$214$$$O	the$$$215$$$218$$$O	inner$$$219$$$224$$$O	ear.$$$225$$$229$$$O	The$$$230$$$233$$$O	active$$$234$$$240$$$O	agent$$$241$$$246$$$O	can$$$247$$$250$$$O	be$$$251$$$253$$$O	short$$$254$$$259$$$O	interfering$$$260$$$271$$$O	RNA$$$272$$$275$$$O	(siRNA)$$$276$$$283$$$O	molecules$$$284$$$293$$$O	encapsulated$$$294$$$306$$$O	in$$$307$$$309$$$O	a$$$310$$$311$$$O	biodegradable$$$312$$$325$$$O	nanoparticle.$$$326$$$339$$$O	The$$$340$$$343$$$O	method$$$344$$$350$$$O	involves$$$351$$$359$$$O	administering$$$360$$$373$$$O	a$$$374$$$375$$$O	solution$$$376$$$384$$$O	to$$$385$$$387$$$O	the$$$388$$$391$$$O	inner$$$392$$$397$$$O	ear$$$398$$$401$$$O	where$$$402$$$407$$$O	the$$$408$$$411$$$O	solution$$$412$$$420$$$O	contains$$$421$$$429$$$O	an$$$430$$$432$$$O	active$$$433$$$439$$$O	agent$$$440$$$445$$$O	in$$$446$$$448$$$O	an$$$449$$$451$$$O	amount$$$452$$$458$$$O	effective$$$459$$$468$$$O	to$$$469$$$471$$$O	decrease$$$472$$$480$$$O	Hesl$$$481$$$485$$$O	gene$$$486$$$490$$$O	expression.$$$491$$$502$$$O
CN101270163B
Single-chain$$$0$$$12$$$O	fragment$$$13$$$21$$$O	antibody-polypeptide$$$22$$$42$$$O	amalgamation$$$43$$$55$$$O	protein$$$56$$$63$$$O	and$$$64$$$67$$$O	uses$$$68$$$72$$$O	thereof$$$73$$$80$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	single$$$33$$$39$$$O	chain$$$40$$$45$$$O	fragment$$$46$$$54$$$O	antibody-polypeptide$$$55$$$75$$$O	fusion$$$76$$$82$$$O	protein$$$83$$$90$$$O	and$$$91$$$94$$$O	applications$$$95$$$107$$$O	thereof,$$$108$$$116$$$O	the$$$117$$$120$$$O	protein$$$121$$$128$$$O	is$$$129$$$131$$$O	a$$$132$$$133$$$O	fusion$$$134$$$140$$$O	protein$$$141$$$148$$$O	which$$$149$$$154$$$O	can$$$155$$$158$$$O	be$$$159$$$161$$$O	combined$$$162$$$170$$$O	with$$$171$$$175$$$O	Her2$$$176$$$180$$$O	receptors$$$181$$$190$$$O	and$$$191$$$194$$$O	can$$$195$$$198$$$O	carry$$$199$$$204$$$O	anti-cancer$$$205$$$216$$$O	siRNA$$$217$$$222$$$O	drug,$$$223$$$228$$$O	and$$$229$$$232$$$O	the$$$233$$$236$$$O	fusion$$$237$$$243$$$O	protein$$$244$$$251$$$O	can$$$252$$$255$$$O	serve$$$256$$$261$$$O	as$$$262$$$264$$$O	the$$$265$$$268$$$O	vector$$$269$$$275$$$O	of$$$276$$$278$$$O	the$$$279$$$282$$$O	anti-cancer$$$283$$$294$$$O	siRNA$$$295$$$300$$$O	drug.$$$301$$$306$$$O	The$$$307$$$310$$$O	single$$$311$$$317$$$O	chain$$$318$$$323$$$O	fragment$$$324$$$332$$$O	antibody$$$333$$$341$$$O	is$$$342$$$344$$$O	Her2-ScFv,$$$345$$$355$$$O	and$$$356$$$359$$$O	the$$$360$$$363$$$O	polypeptide$$$364$$$375$$$O	is$$$376$$$378$$$O	nucleoprotamine$$$379$$$394$$$O	fragment$$$395$$$403$$$O	polypeptide.$$$404$$$416$$$O	The$$$417$$$420$$$O	sequence$$$421$$$429$$$O	of$$$430$$$432$$$O	the$$$433$$$436$$$O	single$$$437$$$443$$$O	chain$$$444$$$449$$$O	fragment$$$450$$$458$$$O	antibody-polypeptide$$$459$$$479$$$O	fusion$$$480$$$486$$$O	protein$$$487$$$494$$$O	is$$$495$$$497$$$O	shown$$$498$$$503$$$O	as$$$504$$$506$$$O	SEQ$$$507$$$510$$$O	ID$$$511$$$513$$$O	NO.1.$$$514$$$519$$$O	The$$$520$$$523$$$O	Her2$$$524$$$528$$$O	single$$$529$$$535$$$O	chain$$$536$$$541$$$O	fragment$$$542$$$550$$$O	antibody$$$551$$$559$$$O	and$$$560$$$563$$$O	the$$$564$$$567$$$O	nucleoprotamine$$$568$$$583$$$O	polypeptide$$$584$$$595$$$O	fusion$$$596$$$602$$$O	protein,$$$603$$$611$$$O	which$$$612$$$617$$$O	are$$$618$$$621$$$O	constructed$$$622$$$633$$$O	by$$$634$$$636$$$O	the$$$637$$$640$$$O	present$$$641$$$648$$$O	invention,$$$649$$$659$$$O	can$$$660$$$663$$$O	be$$$664$$$666$$$O	combined$$$667$$$675$$$O	with$$$676$$$680$$$O	Her2$$$681$$$685$$$O	receptors$$$686$$$695$$$O	and$$$696$$$699$$$O	can$$$700$$$703$$$O	carry$$$704$$$709$$$O	the$$$710$$$713$$$O	anti-cancer$$$714$$$725$$$O	siRNA$$$726$$$731$$$O	drug.$$$732$$$737$$$O	The$$$738$$$741$$$O	fusion$$$742$$$748$$$O	protein$$$749$$$756$$$O	of$$$757$$$759$$$O	the$$$760$$$763$$$O	present$$$764$$$771$$$O	invention$$$772$$$781$$$O	can$$$782$$$785$$$O	directionallyintroduce$$$786$$$808$$$O	the$$$809$$$812$$$O	anti-cancer$$$813$$$824$$$O	siRNA$$$825$$$830$$$O	drug$$$831$$$835$$$O	into$$$836$$$840$$$O	target$$$841$$$847$$$O	cancer$$$848$$$854$$$O	cells,$$$855$$$861$$$O	and$$$862$$$865$$$O	a$$$866$$$867$$$O	non-viral$$$868$$$877$$$O	vector$$$878$$$884$$$O	tool$$$885$$$889$$$O	is$$$890$$$892$$$O	developed$$$893$$$902$$$O	to$$$903$$$905$$$O	speed$$$906$$$911$$$O	up$$$912$$$914$$$O	the$$$915$$$918$$$O	application$$$919$$$930$$$O	of$$$931$$$933$$$O	the$$$934$$$937$$$O	RNAi$$$938$$$942$$$O	technology$$$943$$$953$$$O	in$$$954$$$956$$$O	clinic.$$$957$$$964$$$O
US20100021506
Nitric$$$0$$$6$$$O	oxide$$$7$$$12$$$O	gel$$$13$$$16$$$O	apparatus$$$17$$$26$$$O	and$$$27$$$30$$$O	method$$$31$$$37$$$O
Gel$$$0$$$3$$$O	strips$$$4$$$10$$$O	containing$$$11$$$21$$$O	reactants$$$22$$$31$$$O	capable$$$32$$$39$$$O	of$$$40$$$42$$$O	reacting$$$43$$$51$$$O	to$$$52$$$54$$$O	form$$$55$$$59$$$O	nitric$$$60$$$66$$$O	oxide$$$67$$$72$$$O	are$$$73$$$76$$$O	maintained$$$77$$$87$$$O	separate$$$88$$$96$$$O	until$$$97$$$102$$$O	application.$$$103$$$115$$$O	Upon$$$116$$$120$$$O	application,$$$121$$$133$$$O	the$$$134$$$137$$$O	gel$$$138$$$141$$$O	strips$$$142$$$148$$$O	are$$$149$$$152$$$O	placed$$$153$$$159$$$O	in$$$160$$$162$$$O	contact$$$163$$$170$$$O	with$$$171$$$175$$$O	one$$$176$$$179$$$O	another,$$$180$$$188$$$O	and$$$189$$$192$$$O	may$$$193$$$196$$$O	mix,$$$197$$$201$$$O	or$$$202$$$204$$$O	operate$$$205$$$212$$$O	by$$$213$$$215$$$O	diffusion,$$$216$$$226$$$O	to$$$227$$$229$$$O	deliver$$$230$$$237$$$O	nitric$$$238$$$244$$$O	oxide$$$245$$$250$$$O	directly$$$251$$$259$$$O	to$$$260$$$262$$$O	the$$$263$$$266$$$O	stream$$$267$$$273$$$O	of$$$274$$$276$$$O	breathing$$$277$$$286$$$O	air$$$287$$$290$$$O	of$$$291$$$293$$$O	a$$$294$$$295$$$O	user.$$$296$$$301$$$O	Adhesive$$$302$$$310$$$O	strips$$$311$$$317$$$O	bonded$$$318$$$324$$$O	to$$$325$$$327$$$O	a$$$328$$$329$$$O	substrate$$$330$$$339$$$O	supporting$$$340$$$350$$$O	the$$$351$$$354$$$O	gel$$$355$$$358$$$O	strips$$$359$$$365$$$O	may$$$366$$$369$$$O	provide$$$370$$$377$$$O	for$$$378$$$381$$$O	securing$$$382$$$390$$$O	the$$$391$$$394$$$O	nitric$$$395$$$401$$$O	oxide$$$402$$$407$$$O	generator$$$408$$$417$$$O	directly$$$418$$$426$$$O	to$$$427$$$429$$$O	an$$$430$$$432$$$O	upper$$$433$$$438$$$O	lip$$$439$$$442$$$O	of$$$443$$$445$$$O	a$$$446$$$447$$$O	user$$$448$$$452$$$O	for$$$453$$$456$$$O	breathing$$$457$$$466$$$O	the$$$467$$$470$$$O	nitric$$$471$$$477$$$O	oxide$$$478$$$483$$$O	through$$$484$$$491$$$O	the$$$492$$$495$$$O	nostrils.$$$496$$$505$$$O
WO2005007099A2
Pkb$$$0$$$3$$$O	inhibitors$$$4$$$14$$$O	as$$$15$$$17$$$O	anti-tumor$$$18$$$28$$$O	agents$$$29$$$35$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	directed$$$17$$$25$$$O	to$$$26$$$28$$$O	biaryl$$$29$$$35$$$I	compounds$$$36$$$45$$$O	with$$$46$$$50$$$O	two$$$51$$$54$$$O	six$$$55$$$58$$$O	membered$$$59$$$67$$$O	rings$$$68$$$73$$$O	fused$$$74$$$79$$$O	wherein$$$80$$$87$$$O	at$$$88$$$90$$$O	least$$$91$$$96$$$O	one$$$97$$$100$$$O	six$$$101$$$104$$$O	membered$$$105$$$113$$$O	ring$$$114$$$118$$$O	is$$$119$$$121$$$O	substituted$$$122$$$133$$$O	with$$$134$$$138$$$O	a$$$139$$$140$$$O	thiophenyl$$$141$$$151$$$I	or$$$152$$$154$$$O	furanyl$$$155$$$162$$$I	ring.$$$163$$$168$$$O	Useful$$$169$$$175$$$O	in$$$176$$$178$$$O	the$$$179$$$182$$$O	inhibition$$$183$$$193$$$O	of$$$194$$$196$$$O	PKB$$$197$$$200$$$O	kinase,$$$201$$$208$$$O	the$$$209$$$212$$$O	treatment$$$213$$$222$$$O	of$$$223$$$225$$$O	cancer,$$$226$$$233$$$O	or$$$234$$$236$$$O	the$$$237$$$240$$$O	inhibition$$$241$$$251$$$O	of$$$252$$$254$$$O	tumor$$$255$$$260$$$O	growth.$$$261$$$268$$$O
WO2007124433A1
Hemostatic$$$0$$$10$$$O	compositions$$$11$$$23$$$O	and$$$24$$$27$$$O	methods$$$28$$$35$$$O	for$$$36$$$39$$$O	controlling$$$40$$$51$$$O	bleeding$$$52$$$60$$$O
The$$$0$$$3$$$O	disclosure$$$4$$$14$$$O	provides$$$15$$$23$$$O	hemostatic$$$24$$$34$$$O	compositions$$$35$$$47$$$O	useful$$$48$$$54$$$O	to$$$55$$$57$$$O	promote$$$58$$$65$$$O	hemostasis$$$66$$$76$$$O	at$$$77$$$79$$$O	active$$$80$$$86$$$O	bleeding$$$87$$$95$$$O	wound$$$96$$$101$$$O	sites.$$$102$$$108$$$O	The$$$109$$$112$$$O	hemostatic$$$113$$$123$$$O	compositions$$$124$$$136$$$O	include$$$137$$$144$$$O	an$$$145$$$147$$$O	article$$$148$$$155$$$O	containing$$$156$$$166$$$O	cellulose,$$$167$$$177$$$O	e.g.,$$$178$$$183$$$O	cotton$$$184$$$190$$$O	gauze,$$$191$$$197$$$O	and$$$198$$$201$$$O	a$$$202$$$203$$$O	cross-linked$$$204$$$216$$$O	polysaccharide$$$217$$$231$$$O	ionically$$$232$$$241$$$O	linked$$$242$$$248$$$O	to$$$249$$$251$$$O	the$$$252$$$255$$$O	cellulose.$$$256$$$266$$$O	Methods$$$267$$$274$$$O	of$$$275$$$277$$$O	making$$$278$$$284$$$O	and$$$285$$$288$$$O	using$$$289$$$294$$$O	the$$$295$$$298$$$O	hemostatic$$$299$$$309$$$O	compositions$$$310$$$322$$$O	are$$$323$$$326$$$O	also$$$327$$$331$$$O	provided.$$$332$$$341$$$O
WO2010027094A1
NKT$$$0$$$3$$$O	CELL-DERIVED$$$4$$$16$$$O	iPS$$$17$$$20$$$O	CELLS$$$21$$$26$$$O	AND$$$27$$$30$$$O	NKT$$$31$$$34$$$O	CELLS$$$35$$$40$$$O	DERIVED$$$41$$$48$$$O	THEREFROM$$$49$$$58$$$O
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	iPS$$$14$$$17$$$O	cells$$$18$$$23$$$O	derived$$$24$$$31$$$O	from$$$32$$$36$$$O	somatic$$$37$$$44$$$O	cells,$$$45$$$51$$$O	such$$$52$$$56$$$O	as$$$57$$$59$$$O	NKT$$$60$$$63$$$O	cells,$$$64$$$70$$$O	in$$$71$$$73$$$O	which$$$74$$$79$$$O	the$$$80$$$83$$$O	Î±-chain$$$84$$$92$$$O	region$$$93$$$99$$$O	of$$$100$$$102$$$O	the$$$103$$$106$$$O	T-cell$$$107$$$113$$$O	antigen$$$114$$$121$$$O	receptor$$$122$$$130$$$O	gene$$$131$$$135$$$O	has$$$136$$$139$$$O	been$$$140$$$144$$$O	rearranged$$$145$$$155$$$O	to$$$156$$$158$$$O	a$$$159$$$160$$$O	uniform$$$161$$$168$$$O	VÎ±-JÎ±$$$169$$$176$$$O	arrangement$$$177$$$188$$$O	in$$$189$$$191$$$O	the$$$192$$$195$$$O	mode$$$196$$$200$$$O	specific$$$201$$$209$$$O	to$$$210$$$212$$$O	NKT-cell$$$213$$$221$$$O	receptors,$$$222$$$232$$$O	NKT$$$233$$$236$$$O	cells$$$237$$$242$$$O	that$$$243$$$247$$$O	have$$$248$$$252$$$O	been$$$253$$$257$$$O	differentiated$$$258$$$272$$$O	from$$$273$$$277$$$O	said$$$278$$$282$$$O	iPS$$$283$$$286$$$O	cells,$$$287$$$293$$$O	and$$$294$$$297$$$O	methods$$$298$$$305$$$O	for$$$306$$$309$$$O	producing$$$310$$$319$$$O	the$$$320$$$323$$$O	same,$$$324$$$329$$$O	as$$$330$$$332$$$O	well$$$333$$$337$$$O	as$$$338$$$340$$$O	immuno-cell$$$341$$$352$$$O	therapeutic$$$353$$$364$$$O	agents$$$365$$$371$$$O	using$$$372$$$377$$$O	cells$$$378$$$383$$$O	differentiated$$$384$$$398$$$O	from$$$399$$$403$$$O	said$$$404$$$408$$$O	iPS$$$409$$$412$$$O	cells.$$$413$$$419$$$O	Disclosed$$$420$$$429$$$O	are$$$430$$$433$$$O	iPS$$$434$$$437$$$O	cells$$$438$$$443$$$O	(NKT-iPS$$$444$$$452$$$O	cells),$$$453$$$460$$$O	such$$$461$$$465$$$O	as$$$466$$$468$$$O	NKT$$$469$$$472$$$O	cells,$$$473$$$479$$$O	in$$$480$$$482$$$O	which$$$483$$$488$$$O	TCRÎ±$$$489$$$494$$$O	has$$$495$$$498$$$O	been$$$499$$$503$$$O	rearranged$$$504$$$514$$$O	to$$$515$$$517$$$O	an$$$518$$$520$$$O	NKT-TCR$$$521$$$528$$$O	arrangement$$$529$$$540$$$O	and$$$541$$$544$$$O	that$$$545$$$549$$$O	are$$$550$$$553$$$O	obtained$$$554$$$562$$$O	by$$$563$$$565$$$O	bringing$$$566$$$574$$$O	a$$$575$$$576$$$O	nuclear$$$577$$$584$$$O	reprogramming$$$585$$$598$$$O	factor$$$599$$$605$$$O	in$$$606$$$608$$$O	contact$$$609$$$616$$$O	with$$$617$$$621$$$O	somatic$$$622$$$629$$$O	cells$$$630$$$635$$$O	in$$$636$$$638$$$O	which$$$639$$$644$$$O	the$$$645$$$648$$$O	a-chain$$$649$$$656$$$O	region$$$657$$$663$$$O	of$$$664$$$666$$$O	the$$$667$$$670$$$O	T-cell$$$671$$$677$$$O	antigen$$$678$$$685$$$O	receptor$$$686$$$694$$$O	gene$$$695$$$699$$$O	has$$$700$$$703$$$O	been$$$704$$$708$$$O	rearranged$$$709$$$719$$$O	to$$$720$$$722$$$O	a$$$723$$$724$$$O	uniform$$$725$$$732$$$O	VÎ±-JÎ±$$$733$$$740$$$O	arrangement$$$741$$$752$$$O	in$$$753$$$755$$$O	the$$$756$$$759$$$O	mode$$$760$$$764$$$O	specific$$$765$$$773$$$O	to$$$774$$$776$$$O	NKT-cell$$$777$$$785$$$O	receptors,$$$786$$$796$$$O	and$$$797$$$800$$$O	NKT$$$801$$$804$$$O	cells$$$805$$$810$$$O	(iPS-NKT$$$811$$$819$$$O	cells)$$$820$$$826$$$O	obtained$$$827$$$835$$$O	and$$$836$$$839$$$O	isolated$$$840$$$848$$$O	by$$$849$$$851$$$O	in$$$852$$$854$$$O	vitro$$$855$$$860$$$O	differentiation$$$861$$$876$$$O	of$$$877$$$879$$$O	said$$$880$$$884$$$O	cells.$$$885$$$891$$$O	Also$$$892$$$896$$$O	disclosed$$$897$$$906$$$O	are$$$907$$$910$$$O	a$$$911$$$912$$$O	method$$$913$$$919$$$O	for$$$920$$$923$$$O	preparing$$$924$$$933$$$O	CD4/CD8$$$934$$$941$$$O	double-positive$$$942$$$957$$$O	NKT$$$958$$$961$$$O	cells$$$962$$$967$$$O	(DP-NKT$$$968$$$975$$$O	cells)$$$976$$$982$$$O	and$$$983$$$986$$$O	mature$$$987$$$993$$$O	NKT$$$994$$$997$$$O	cells$$$998$$$1003$$$O	from$$$1004$$$1008$$$O	NKT-iPS$$$1009$$$1016$$$O	cells$$$1017$$$1022$$$O	by$$$1023$$$1025$$$O	changing$$$1026$$$1034$$$O	the$$$1035$$$1038$$$O	combination$$$1039$$$1050$$$O	of$$$1051$$$1053$$$O	feeder$$$1054$$$1060$$$O	cells$$$1061$$$1066$$$O	and/or$$$1067$$$1073$$$O	cytokines,$$$1074$$$1084$$$O	and$$$1085$$$1088$$$O	a$$$1089$$$1090$$$O	method$$$1091$$$1097$$$O	for$$$1098$$$1101$$$O	proliferating$$$1102$$$1115$$$O	these$$$1116$$$1121$$$O	iPS-NKT$$$1122$$$1129$$$O	cells.$$$1130$$$1136$$$O	Further$$$1137$$$1144$$$O	disclosed$$$1145$$$1154$$$O	is$$$1155$$$1157$$$O	an$$$1158$$$1160$$$O	NKT$$$1161$$$1164$$$O	cell$$$1165$$$1169$$$O	therapeutic$$$1170$$$1181$$$O	agent$$$1182$$$1187$$$O	that$$$1188$$$1192$$$O	contains$$$1193$$$1201$$$O	NKT$$$1202$$$1205$$$O	cells$$$1206$$$1211$$$O	that$$$1212$$$1216$$$O	have$$$1217$$$1221$$$O	been$$$1222$$$1226$$$O	activated$$$1227$$$1236$$$I	by$$$1237$$$1239$$$I	Î±-galactosylceramide$$$1240$$$1261$$$I	(Î±-GalCer),$$$1262$$$1274$$$I	or$$$1275$$$1277$$$O	is$$$1278$$$1280$$$O	composed$$$1281$$$1289$$$O	of$$$1290$$$1292$$$O	iPS-NKT$$$1293$$$1300$$$O	cells$$$1301$$$1306$$$I	and$$$1307$$$1310$$$I	Î±-GalCer.$$$1311$$$1321$$$I
WO2009145299A1
Ceramide$$$0$$$8$$$O	dispersion$$$9$$$19$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	ceramide$$$15$$$23$$$O	dispersion$$$24$$$34$$$O	made$$$35$$$39$$$O	by$$$40$$$42$$$O	incorporating$$$43$$$56$$$O	at$$$57$$$59$$$O	least$$$60$$$65$$$O	particles$$$66$$$75$$$O	containing$$$76$$$86$$$O	a$$$87$$$88$$$O	natural$$$89$$$96$$$O	ceramide,$$$97$$$106$$$O	dispersed$$$107$$$116$$$O	in$$$117$$$119$$$O	an$$$120$$$122$$$O	aqueous$$$123$$$130$$$O	phase$$$131$$$136$$$O	as$$$137$$$139$$$O	an$$$140$$$142$$$O	oil$$$143$$$146$$$O	phase$$$147$$$152$$$O	constituent,$$$153$$$165$$$O	and$$$166$$$169$$$O	a$$$170$$$171$$$O	surfactant,$$$172$$$183$$$O	wherein$$$184$$$191$$$O	the$$$192$$$195$$$O	aforementioned$$$196$$$210$$$O	particles$$$211$$$220$$$O	containing$$$221$$$231$$$O	a$$$232$$$233$$$O	natural$$$234$$$241$$$O	ceramide$$$242$$$250$$$O	contain$$$251$$$258$$$O	at$$$259$$$261$$$O	least$$$262$$$267$$$O	one$$$268$$$271$$$O	selected$$$272$$$280$$$O	natural$$$281$$$288$$$O	ceramide$$$289$$$297$$$O	at$$$298$$$300$$$O	50$$$301$$$303$$$O	mass%$$$304$$$309$$$O	or$$$310$$$312$$$O	more$$$313$$$317$$$O	with$$$318$$$322$$$O	respect$$$323$$$330$$$O	to$$$331$$$333$$$O	the$$$334$$$337$$$O	total$$$338$$$343$$$O	mass$$$344$$$348$$$O	of$$$349$$$351$$$O	oil$$$352$$$355$$$O	constituents$$$356$$$368$$$O	included$$$369$$$377$$$O	in$$$378$$$380$$$O	the$$$381$$$384$$$O	oil$$$385$$$388$$$O	phase,$$$389$$$395$$$O	and$$$396$$$399$$$O	are$$$400$$$403$$$O	particles$$$404$$$413$$$O	having$$$414$$$420$$$O	a$$$421$$$422$$$O	volume$$$423$$$429$$$O	average$$$430$$$437$$$O	particle$$$438$$$446$$$O	size$$$447$$$451$$$O	of$$$452$$$454$$$O	at$$$455$$$457$$$O	least$$$458$$$463$$$O	0.5$$$464$$$467$$$O	nm$$$468$$$470$$$O	and$$$471$$$474$$$O	no$$$475$$$477$$$O	more$$$478$$$482$$$O	than$$$483$$$487$$$O	100$$$488$$$491$$$O	nm,$$$492$$$495$$$O	and$$$496$$$499$$$O	at$$$500$$$502$$$O	least$$$503$$$508$$$O	one$$$509$$$512$$$O	polyglycerol$$$513$$$525$$$I	fatty$$$526$$$531$$$I	acid$$$532$$$536$$$I	ester$$$537$$$542$$$I	having$$$543$$$549$$$O	an$$$550$$$552$$$O	HLB$$$553$$$556$$$O	of$$$557$$$559$$$O	at$$$560$$$562$$$O	least$$$563$$$568$$$O	10$$$569$$$571$$$O	and$$$572$$$575$$$O	no$$$576$$$578$$$O	more$$$579$$$583$$$O	than$$$584$$$588$$$O	16$$$589$$$591$$$O	is$$$592$$$594$$$O	contained$$$595$$$604$$$O	as$$$605$$$607$$$O	the$$$608$$$611$$$O	aforementioned$$$612$$$626$$$O	surfactant.$$$627$$$638$$$O
CN103380115A
Sulfur$$$0$$$6$$$I	derivatives$$$7$$$18$$$O	as$$$19$$$21$$$O	chemokine$$$22$$$31$$$O	receptor$$$32$$$40$$$O	modulators$$$41$$$51$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	novel$$$33$$$38$$$O	sulfur$$$39$$$45$$$I	derivatives,$$$46$$$58$$$O	processes$$$59$$$68$$$O	for$$$69$$$72$$$O	preparing$$$73$$$82$$$O	them,$$$83$$$88$$$O	pharmaceutical$$$89$$$103$$$O	compositions$$$104$$$116$$$O	containing$$$117$$$127$$$O	them$$$128$$$132$$$O	and$$$133$$$136$$$O	their$$$137$$$142$$$O	use$$$143$$$146$$$O	as$$$147$$$149$$$O	pharmaceuticals$$$150$$$165$$$O	as$$$166$$$168$$$O	modulators$$$169$$$179$$$O	of$$$180$$$182$$$O	chemokine$$$183$$$192$$$O	receptors.$$$193$$$203$$$O
CN1931355A
Arthritis$$$0$$$9$$$O	treating$$$10$$$18$$$O	and$$$19$$$22$$$O	swelling$$$23$$$31$$$O	eliminating$$$32$$$43$$$O	medicine$$$44$$$52$$$O	powder$$$53$$$59$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	one$$$25$$$28$$$O	medicine$$$29$$$37$$$O	powder$$$38$$$44$$$O	for$$$45$$$48$$$O	treating$$$49$$$57$$$O	arthritis$$$58$$$67$$$O	and$$$68$$$71$$$O	eliminating$$$72$$$83$$$O	swelling$$$84$$$92$$$O	and$$$93$$$96$$$O	belongs$$$97$$$104$$$O	to$$$105$$$107$$$O	the$$$108$$$111$$$O	field$$$112$$$117$$$O	of$$$118$$$120$$$O	medicine$$$121$$$129$$$O	technology.$$$130$$$141$$$O	The$$$142$$$145$$$O	medicine$$$146$$$154$$$O	powder$$$155$$$161$$$O	as$$$162$$$164$$$O	one$$$165$$$168$$$O	kind$$$169$$$173$$$O	of$$$174$$$176$$$O	externally$$$177$$$187$$$O	applied$$$188$$$195$$$O	medicine$$$196$$$204$$$O	includes$$$205$$$213$$$O	medicinal$$$214$$$223$$$O	actinolite.$$$224$$$235$$$O	When$$$236$$$240$$$O	the$$$241$$$244$$$O	medicine$$$245$$$253$$$O	powder$$$254$$$260$$$O	is$$$261$$$263$$$O	applied,$$$264$$$272$$$O	the$$$273$$$276$$$O	affected$$$277$$$285$$$O	is$$$286$$$288$$$O	banded$$$289$$$295$$$O	with$$$296$$$300$$$O	permeable$$$301$$$310$$$O	gauze$$$311$$$316$$$O	for$$$317$$$320$$$O	the$$$321$$$324$$$O	toxin$$$325$$$330$$$O	drawn$$$331$$$336$$$O	out$$$337$$$340$$$O	to$$$341$$$343$$$O	volatilize.$$$344$$$355$$$O	The$$$356$$$359$$$O	medicine$$$360$$$368$$$O	powder$$$369$$$375$$$O	is$$$376$$$378$$$O	for$$$379$$$382$$$O	treating$$$383$$$391$$$O	acute$$$392$$$397$$$O	arthritis$$$398$$$407$$$O	and$$$408$$$411$$$O	swelling$$$412$$$420$$$O	and$$$421$$$424$$$O	symmetrical$$$425$$$436$$$O	rheumatoid$$$437$$$447$$$O	arthritis$$$448$$$457$$$O	and$$$458$$$461$$$O	swelling$$$462$$$470$$$O	caused$$$471$$$477$$$O	by$$$478$$$480$$$O	wind,$$$481$$$486$$$O	cold$$$487$$$491$$$O	and$$$492$$$495$$$O	damp$$$496$$$500$$$O	specially.$$$501$$$511$$$O	The$$$512$$$515$$$O	medicine$$$516$$$524$$$O	powder$$$525$$$531$$$O	has$$$532$$$535$$$O	no$$$536$$$538$$$O	side$$$539$$$543$$$O	effect.$$$544$$$551$$$O
WO2008006702A1
11beta-hydroxysteroid$$$0$$$21$$$I	dehydrogenase$$$22$$$35$$$O	type$$$36$$$40$$$O	1$$$41$$$42$$$O	active$$$43$$$49$$$O	compounds$$$50$$$59$$$O
The$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	substituted$$$11$$$22$$$O	amides$$$23$$$29$$$I	for$$$30$$$33$$$O	modulating$$$34$$$44$$$O	the$$$45$$$48$$$O	activity$$$49$$$57$$$O	of$$$58$$$60$$$O	11Î²-hydroxysteroid$$$61$$$80$$$I	dehydrogenase$$$81$$$94$$$O	type$$$95$$$99$$$O	1$$$100$$$101$$$O	(11Î²HSD1$$$102$$$111$$$O	)$$$112$$$113$$$O	and$$$114$$$117$$$O	the$$$118$$$121$$$O	use$$$122$$$125$$$O	of$$$126$$$128$$$O	these$$$129$$$134$$$O	compounds$$$135$$$144$$$O	as$$$145$$$147$$$O	pharmaceutical$$$148$$$162$$$O	compositions,$$$163$$$176$$$O	are$$$177$$$180$$$O	described.$$$181$$$191$$$O	Also$$$192$$$196$$$O	a$$$197$$$198$$$O	novel$$$199$$$204$$$O	class$$$205$$$210$$$O	of$$$211$$$213$$$O	substituted$$$214$$$225$$$I	amides,$$$226$$$233$$$I	of$$$234$$$236$$$O	the$$$237$$$240$$$O	general$$$241$$$248$$$O	formula$$$249$$$256$$$O	I.$$$257$$$259$$$O	Their$$$260$$$265$$$O	use$$$266$$$269$$$O	in$$$270$$$272$$$O	therapy,$$$273$$$281$$$O	pharmaceutical$$$282$$$296$$$O	compositions$$$297$$$309$$$O	comprising$$$310$$$320$$$O	the$$$321$$$324$$$O	compounds,$$$325$$$335$$$O	as$$$336$$$338$$$O	well$$$339$$$343$$$O	as$$$344$$$346$$$O	their$$$347$$$352$$$O	use$$$353$$$356$$$O	in$$$357$$$359$$$O	the$$$360$$$363$$$O	manufacture$$$364$$$375$$$O	of$$$376$$$378$$$O	medicaments$$$379$$$390$$$O	are$$$391$$$394$$$O	described.$$$395$$$405$$$O	The$$$406$$$409$$$O	present$$$410$$$417$$$O	compounds$$$418$$$427$$$O	are$$$428$$$431$$$O	modulators$$$432$$$442$$$O	and$$$443$$$446$$$O	more$$$447$$$451$$$O	specifically$$$452$$$464$$$O	inhibitors$$$465$$$475$$$O	of$$$476$$$478$$$O	the$$$479$$$482$$$O	activity$$$483$$$491$$$O	of$$$492$$$494$$$O	11Î²HSDI$$$495$$$503$$$O	and$$$504$$$507$$$O	may$$$508$$$511$$$O	be$$$512$$$514$$$O	useful$$$515$$$521$$$O	in$$$522$$$524$$$O	the$$$525$$$528$$$O	treatment$$$529$$$538$$$O	of$$$539$$$541$$$O	a$$$542$$$543$$$O	range$$$544$$$549$$$O	of$$$550$$$552$$$O	medical$$$553$$$560$$$O	disorders$$$561$$$570$$$O	where$$$571$$$576$$$O	a$$$577$$$578$$$O	decreased$$$579$$$588$$$O	intracellular$$$589$$$602$$$O	concentration$$$603$$$616$$$O	of$$$617$$$619$$$O	active$$$620$$$626$$$I	glucocorticoid$$$627$$$641$$$I	is$$$642$$$644$$$O	desirable.$$$645$$$655$$$O
EP2002731A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	pinolenic$$$7$$$16$$$I	acid$$$17$$$21$$$I	for$$$22$$$25$$$O	increasing$$$26$$$36$$$O	lean$$$37$$$41$$$O	body$$$42$$$46$$$O	mass$$$47$$$51$$$O
Pinolenic$$$0$$$9$$$I	acid$$$10$$$14$$$I	or$$$15$$$17$$$O	a$$$18$$$19$$$O	derivative$$$20$$$30$$$O	thereof$$$31$$$38$$$O	may$$$39$$$42$$$O	be$$$43$$$45$$$O	used$$$46$$$50$$$O	for$$$51$$$54$$$O	increasing$$$55$$$65$$$O	lean$$$66$$$70$$$O	body$$$71$$$75$$$O	mass.$$$76$$$81$$$O
CN101531649A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	andrographolide$$$21$$$36$$$I	derivatives$$$37$$$48$$$O	and$$$49$$$52$$$O	preparation$$$53$$$64$$$O	thereof$$$65$$$72$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method$$$27$$$33$$$O	for$$$34$$$37$$$O	preparing$$$38$$$47$$$O	andrographolide$$$48$$$63$$$I	derivatives,$$$64$$$76$$$O	and$$$77$$$80$$$O	a$$$81$$$82$$$O	preparation$$$83$$$94$$$O	thereof.$$$95$$$103$$$O	The$$$104$$$107$$$O	preparation$$$108$$$119$$$O	is$$$120$$$122$$$O	a$$$123$$$124$$$O	salt$$$125$$$129$$$O	which$$$130$$$135$$$O	consists$$$136$$$144$$$O	of$$$145$$$147$$$O	Kalii$$$148$$$153$$$O	Dethydroandrographolidi$$$154$$$177$$$O	Succinas$$$178$$$186$$$O	and$$$187$$$190$$$O	Adamantanes$$$191$$$202$$$O	and$$$203$$$206$$$O	has$$$207$$$210$$$O	the$$$211$$$214$$$O	effect$$$215$$$221$$$O	of$$$222$$$224$$$O	synergistic$$$225$$$236$$$O	interaction.$$$237$$$249$$$O	The$$$250$$$253$$$O	curative$$$254$$$262$$$O	effect$$$263$$$269$$$O	of$$$270$$$272$$$O	the$$$273$$$276$$$O	preparation$$$277$$$288$$$O	is$$$289$$$291$$$O	better$$$292$$$298$$$O	than$$$299$$$303$$$O	that$$$304$$$308$$$O	of$$$309$$$311$$$O	the$$$312$$$315$$$O	independent$$$316$$$327$$$O	use$$$328$$$331$$$O	of$$$332$$$334$$$O	Kalii$$$335$$$340$$$O	Dethydroandrographolidi$$$341$$$364$$$O	Succinas$$$365$$$373$$$O	and$$$374$$$377$$$O	Adamantanes.$$$378$$$390$$$I
US20120283204
Talarazole$$$0$$$10$$$I	metabolites$$$11$$$22$$$O
Novel$$$0$$$5$$$O	metabolites$$$6$$$17$$$O	of$$$18$$$20$$$O	talarazole$$$21$$$31$$$I	of$$$32$$$34$$$O	formula$$$35$$$42$$$O	(I)$$$43$$$46$$$O	have$$$47$$$51$$$O	been$$$52$$$56$$$O	isolated$$$57$$$65$$$O	and$$$66$$$69$$$O	characterized,$$$70$$$84$$$O	wherein$$$85$$$92$$$O	RâH,$$$93$$$99$$$I	OH,$$$100$$$103$$$I	OSO3H$$$104$$$109$$$I	or$$$110$$$112$$$I	O-gly;$$$113$$$119$$$I	R1,$$$120$$$123$$$I	âH,$$$124$$$129$$$I	OH,$$$130$$$133$$$I	OSO3H,$$$134$$$140$$$I	O-gly$$$141$$$146$$$I	or$$$147$$$149$$$I	=0;$$$150$$$153$$$O	and$$$154$$$157$$$I	gly=a$$$158$$$163$$$I	glucuronate,$$$164$$$176$$$I	or$$$177$$$179$$$O	a$$$180$$$181$$$O	pharmaceutically$$$182$$$198$$$O	acceptable$$$199$$$209$$$O	salt$$$210$$$214$$$O	thereof.$$$215$$$223$$$O	These$$$224$$$229$$$O	compounds$$$230$$$239$$$O	are$$$240$$$243$$$O	targeted$$$244$$$252$$$O	for$$$253$$$256$$$O	the$$$257$$$260$$$O	treatment$$$261$$$270$$$O	of$$$271$$$273$$$O	various$$$274$$$281$$$O	skin-,$$$282$$$288$$$O	hair-$$$289$$$294$$$O	and$$$295$$$298$$$O	nail-associated$$$299$$$314$$$O	disorders.$$$315$$$325$$$O
CN101222850B
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	treating$$$12$$$20$$$O	drug$$$21$$$25$$$O	resistant$$$26$$$35$$$O	cancer$$$36$$$42$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	drug-resistant$$$22$$$36$$$O	cancer,$$$37$$$44$$$O	includes:$$$45$$$54$$$O	administering$$$55$$$68$$$O	to$$$69$$$71$$$O	a$$$72$$$73$$$O	patient$$$74$$$81$$$O	in$$$82$$$84$$$O	need$$$85$$$89$$$O	thereof,$$$90$$$98$$$O	a$$$99$$$100$$$O	compound$$$101$$$109$$$O	of$$$110$$$112$$$O	formula$$$113$$$120$$$O	I,$$$121$$$123$$$O	a$$$124$$$125$$$O	tautomer$$$126$$$134$$$O	of$$$135$$$137$$$O	the$$$138$$$141$$$O	compound,$$$142$$$151$$$O	a$$$152$$$153$$$O	salt$$$154$$$158$$$O	of$$$159$$$161$$$O	the$$$162$$$165$$$O	compound,$$$166$$$175$$$O	a$$$176$$$177$$$O	salt$$$178$$$182$$$O	of$$$183$$$185$$$O	the$$$186$$$189$$$O	tautomer,$$$190$$$199$$$O	a$$$200$$$201$$$O	mixture$$$202$$$209$$$O	thereof,$$$210$$$218$$$O	or$$$219$$$221$$$O	a$$$222$$$223$$$O	pharmaceutical$$$224$$$238$$$O	composition$$$239$$$250$$$O	comprising$$$251$$$261$$$O	the$$$262$$$265$$$O	compound,$$$266$$$275$$$O	the$$$276$$$279$$$O	tautomer,$$$280$$$289$$$O	the$$$290$$$293$$$O	salt$$$294$$$298$$$O	of$$$299$$$301$$$O	the$$$302$$$305$$$O	compound,$$$306$$$315$$$O	the$$$316$$$319$$$O	salt$$$320$$$324$$$O	of$$$325$$$327$$$O	the$$$328$$$331$$$O	tautomer,$$$332$$$341$$$O	or$$$342$$$344$$$O	the$$$345$$$348$$$O	mixture,$$$349$$$357$$$O	wherein$$$358$$$365$$$O	the$$$366$$$369$$$O	patient$$$370$$$377$$$O	is$$$378$$$380$$$O	a$$$381$$$382$$$O	cancer$$$383$$$389$$$O	patient$$$390$$$397$$$O	with$$$398$$$402$$$O	drug-resistant$$$403$$$417$$$O	cancer,$$$418$$$425$$$O	wherein$$$426$$$433$$$O	the$$$434$$$437$$$O	compound$$$438$$$446$$$O	of$$$447$$$449$$$O	Formula$$$450$$$457$$$O	I$$$458$$$459$$$O	is$$$460$$$462$$$O	as$$$463$$$465$$$O	defined$$$466$$$473$$$O	in$$$474$$$476$$$O	the$$$477$$$480$$$O	application.$$$481$$$493$$$O
WO2014090168A1
Nanoscale$$$0$$$9$$$O	docetaxel$$$10$$$19$$$I	and$$$20$$$23$$$O	preparation$$$24$$$35$$$O	method$$$36$$$42$$$O	thereof$$$43$$$50$$$O
Nanoscale$$$0$$$9$$$O	docetaxel$$$10$$$19$$$I	particles$$$20$$$29$$$O	and$$$30$$$33$$$O	a$$$34$$$35$$$O	preparation$$$36$$$47$$$O	method$$$48$$$54$$$O	thereof.$$$55$$$63$$$O	The$$$64$$$67$$$O	nanoscale$$$68$$$77$$$O	docetaxel$$$78$$$87$$$I	particles$$$88$$$97$$$O	use$$$98$$$101$$$O	silicon$$$102$$$109$$$I	dioxide$$$110$$$117$$$I	aerogel$$$118$$$125$$$O	as$$$126$$$128$$$O	a$$$129$$$130$$$O	carrier$$$131$$$138$$$O	of$$$139$$$141$$$O	the$$$142$$$145$$$O	docetaxel.$$$146$$$156$$$I	The$$$157$$$160$$$O	preparation$$$161$$$172$$$O	method$$$173$$$179$$$O	is$$$180$$$182$$$O	as$$$183$$$185$$$O	follows:$$$186$$$194$$$O	first$$$195$$$200$$$O	dissolving$$$201$$$211$$$O	the$$$212$$$215$$$O	docetaxel$$$216$$$225$$$I	in$$$226$$$228$$$O	anhydrous$$$229$$$238$$$O	ethanol,$$$239$$$247$$$I	then$$$248$$$252$$$O	adding$$$253$$$259$$$O	the$$$260$$$263$$$O	silicon$$$264$$$271$$$I	dioxide$$$272$$$279$$$I	aerogel,$$$280$$$288$$$O	drying$$$289$$$295$$$O	after$$$296$$$301$$$O	full$$$302$$$306$$$O	adsorption,$$$307$$$318$$$O	subsequently$$$319$$$331$$$O	adding$$$332$$$338$$$O	purified$$$339$$$347$$$O	water,$$$348$$$354$$$O	feeding$$$355$$$362$$$O	into$$$363$$$367$$$O	an$$$368$$$370$$$O	emulsifying$$$371$$$382$$$O	machine$$$383$$$390$$$O	for$$$391$$$394$$$O	emulsification,$$$395$$$410$$$O	homogenizing$$$411$$$423$$$O	through$$$424$$$431$$$O	a$$$432$$$433$$$O	high$$$434$$$438$$$O	pressure$$$439$$$447$$$O	homogenizer,$$$448$$$460$$$O	and$$$461$$$464$$$O	drying$$$465$$$471$$$O	the$$$472$$$475$$$O	obtained$$$476$$$484$$$O	homogenate$$$485$$$495$$$O	to$$$496$$$498$$$O	obtain$$$499$$$505$$$O	the$$$506$$$509$$$O	nanoscale$$$510$$$519$$$O	docetaxel$$$520$$$529$$$I	particles.$$$530$$$540$$$O
US20090092573
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	manufacturing$$$10$$$23$$$O	a$$$24$$$25$$$O	nicotine$$$26$$$34$$$I	delivery$$$35$$$43$$$O	product$$$44$$$51$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	manufacturing$$$12$$$25$$$O	a$$$26$$$27$$$O	nicotine$$$28$$$36$$$I	delivery$$$37$$$45$$$O	product$$$46$$$53$$$O	comprising$$$54$$$64$$$O	nicotine$$$65$$$73$$$I	and$$$74$$$77$$$O	a$$$78$$$79$$$O	cation$$$80$$$86$$$O	exchange$$$87$$$95$$$O	resin.$$$96$$$102$$$O	More$$$103$$$107$$$O	precisely,$$$108$$$118$$$O	to$$$119$$$121$$$O	a$$$122$$$123$$$O	method$$$124$$$130$$$O	for$$$131$$$134$$$O	preparing$$$135$$$144$$$O	a$$$145$$$146$$$O	nicotine$$$147$$$155$$$I	delivery$$$156$$$164$$$O	product$$$165$$$172$$$O	said$$$173$$$177$$$O	method$$$178$$$184$$$O	comprising$$$185$$$195$$$O	(a)$$$196$$$199$$$O	mixing$$$200$$$206$$$O	nicotine,$$$207$$$216$$$I	a$$$217$$$218$$$O	cation$$$219$$$225$$$O	exchange$$$226$$$234$$$O	resin,$$$235$$$241$$$O	an$$$242$$$244$$$O	organic$$$245$$$252$$$O	polyol$$$253$$$259$$$O	and$$$260$$$263$$$O	water$$$264$$$269$$$O	to$$$270$$$272$$$O	form$$$273$$$277$$$O	a$$$278$$$279$$$O	mixture$$$280$$$287$$$O	wherein$$$288$$$295$$$O	the$$$296$$$299$$$O	total$$$300$$$305$$$O	amount$$$306$$$312$$$O	of$$$313$$$315$$$O	water$$$316$$$321$$$O	is$$$322$$$324$$$O	from$$$325$$$329$$$O	26$$$330$$$332$$$O	to$$$333$$$335$$$O	45%$$$336$$$339$$$O	by$$$340$$$342$$$O	weight$$$343$$$349$$$O	of$$$350$$$352$$$O	the$$$353$$$356$$$O	total$$$357$$$362$$$O	mixture,$$$363$$$371$$$O	and$$$372$$$375$$$O	(b)$$$376$$$379$$$O	removing$$$380$$$388$$$O	water$$$389$$$394$$$O	from$$$395$$$399$$$O	the$$$400$$$403$$$O	mixture$$$404$$$411$$$O	to$$$412$$$414$$$O	produce$$$415$$$422$$$O	said$$$423$$$427$$$O	nicotine$$$428$$$436$$$I	delivery$$$437$$$445$$$O	product.$$$446$$$454$$$O
US20080280856
Fibroblast$$$0$$$10$$$O	Activation$$$11$$$21$$$O	Protein$$$22$$$29$$$O	Inhibitor$$$30$$$39$$$O	Compounds$$$40$$$49$$$O	and$$$50$$$53$$$O	Methods$$$54$$$61$$$O
Amino$$$0$$$5$$$I	terminus-blocked$$$6$$$22$$$I	peptide$$$23$$$30$$$I	boronate$$$31$$$39$$$I	compounds$$$40$$$49$$$O	of$$$50$$$52$$$O	Formulas$$$53$$$61$$$O	I$$$62$$$63$$$O	and$$$64$$$67$$$O	II$$$68$$$70$$$O	are$$$71$$$74$$$O	useful$$$75$$$81$$$O	for$$$82$$$85$$$O	inhibiting$$$86$$$96$$$O	Fibroblast$$$97$$$107$$$O	Activation$$$108$$$118$$$O	Protein$$$119$$$126$$$O	(FAP)$$$127$$$132$$$O	and$$$133$$$136$$$O	other$$$137$$$142$$$O	proteases,$$$143$$$153$$$O	and$$$154$$$157$$$O	for$$$158$$$161$$$O	treating$$$162$$$170$$$O	disorders$$$171$$$180$$$O	mediated$$$181$$$189$$$O	by$$$190$$$192$$$O	FAP.$$$193$$$197$$$O	Methods$$$198$$$205$$$O	of$$$206$$$208$$$O	using$$$209$$$214$$$O	the$$$215$$$218$$$O	amino$$$219$$$224$$$I	terminus$$$225$$$233$$$I	blocked$$$234$$$241$$$I	peptide$$$242$$$249$$$I	boronate$$$250$$$258$$$I	compounds,$$$259$$$269$$$O	and$$$270$$$273$$$O	stereoisomers,$$$274$$$288$$$O	tautomers,$$$289$$$299$$$O	solvates$$$300$$$308$$$O	and$$$309$$$312$$$O	pharmaceutically$$$313$$$329$$$O	acceptable$$$330$$$340$$$O	salts$$$341$$$346$$$O	thereof,$$$347$$$355$$$O	for$$$356$$$359$$$O	in$$$360$$$362$$$O	vitro,$$$363$$$369$$$O	in$$$370$$$372$$$O	situ,$$$373$$$378$$$O	and$$$379$$$382$$$O	in$$$383$$$385$$$O	vivo$$$386$$$390$$$O	diagnosis,$$$391$$$401$$$O	prevention$$$402$$$412$$$O	or$$$413$$$415$$$O	treatment$$$416$$$425$$$O	of$$$426$$$428$$$O	such$$$429$$$433$$$O	disorders$$$434$$$443$$$O	in$$$444$$$446$$$O	mammalian$$$447$$$456$$$O	cells,$$$457$$$463$$$O	or$$$464$$$466$$$O	associated$$$467$$$477$$$O	pathological$$$478$$$490$$$O	conditions$$$491$$$501$$$O	are$$$502$$$505$$$O	disclosed.$$$506$$$516$$$O
CN1729991A
Dripping$$$0$$$8$$$O	pills$$$9$$$14$$$O	of$$$15$$$17$$$O	tripterigium$$$18$$$30$$$O	wilfordi$$$31$$$39$$$O	glycosides$$$40$$$50$$$O	and$$$51$$$54$$$O	its$$$55$$$58$$$O	preparation$$$59$$$70$$$O	process$$$71$$$78$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicinal$$$26$$$35$$$O	composition$$$36$$$47$$$O	for$$$48$$$51$$$O	treating$$$52$$$60$$$O	rheumatoid$$$61$$$71$$$O	arthritis,$$$72$$$82$$$O	kidney$$$83$$$89$$$O	disease$$$90$$$97$$$O	and$$$98$$$101$$$O	autoimmune$$$102$$$112$$$O	hepatitis,$$$113$$$123$$$O	especially$$$124$$$134$$$O	a$$$135$$$136$$$O	dripping$$$137$$$145$$$O	pill$$$146$$$150$$$O	of$$$151$$$153$$$O	tripterigium$$$154$$$166$$$O	wilfordi$$$167$$$175$$$O	glycosides$$$176$$$186$$$O	and$$$187$$$190$$$O	its$$$191$$$194$$$O	preparation$$$195$$$206$$$O	process,$$$207$$$215$$$O	wherein$$$216$$$223$$$O	the$$$224$$$227$$$O	composition$$$228$$$239$$$O	is$$$240$$$242$$$O	prepared$$$243$$$251$$$O	from$$$252$$$256$$$O	tripterigium$$$257$$$269$$$O	wilfordi$$$270$$$278$$$O	glycosides$$$279$$$289$$$O	as$$$290$$$292$$$O	raw$$$293$$$296$$$O	material,$$$297$$$306$$$O	and$$$307$$$310$$$O	medicinal$$$311$$$320$$$O	carrying$$$321$$$329$$$O	agent$$$330$$$335$$$O	as$$$336$$$338$$$O	the$$$339$$$342$$$O	base$$$343$$$347$$$O	material.$$$348$$$357$$$O
WO2006059637A1
Agent$$$0$$$5$$$O	for$$$6$$$9$$$O	diagnosing,$$$10$$$21$$$O	preventing$$$22$$$32$$$O	and$$$33$$$36$$$O	treating$$$37$$$45$$$O	adhesion$$$46$$$54$$$O	with$$$55$$$59$$$O	the$$$60$$$63$$$O	use$$$64$$$67$$$O	of$$$68$$$70$$$O	ccr8$$$71$$$75$$$O	inhibitor$$$76$$$85$$$O
A$$$0$$$1$$$O	medicinal$$$2$$$11$$$O	composition$$$12$$$23$$$O	for$$$24$$$27$$$O	preventing$$$28$$$38$$$O	or$$$39$$$41$$$O	treating$$$42$$$50$$$O	adhesion$$$51$$$59$$$O	which$$$60$$$65$$$O	contains$$$66$$$74$$$O	a$$$75$$$76$$$O	CCR8$$$77$$$81$$$O	inhibitor$$$82$$$91$$$O	as$$$92$$$94$$$O	the$$$95$$$98$$$O	active$$$99$$$105$$$O	ingredient.$$$106$$$117$$$O	The$$$118$$$121$$$O	CCR8$$$122$$$126$$$O	inhibitor$$$127$$$136$$$O	is$$$137$$$139$$$O	preferably$$$140$$$150$$$O	a$$$151$$$152$$$O	member$$$153$$$159$$$O	selected$$$160$$$168$$$O	from$$$169$$$173$$$O	the$$$174$$$177$$$O	group$$$178$$$183$$$O	consisting$$$184$$$194$$$O	of$$$195$$$197$$$O	an$$$198$$$200$$$O	antibody$$$201$$$209$$$O	binding$$$210$$$217$$$O	to$$$218$$$220$$$O	CCR8,$$$221$$$226$$$O	a$$$227$$$228$$$O	neutralizing$$$229$$$241$$$O	antibody$$$242$$$250$$$O	against$$$251$$$258$$$O	a$$$259$$$260$$$O	CCR8$$$261$$$265$$$O	ligand$$$266$$$272$$$O	CCL1,$$$273$$$278$$$O	aptamers$$$279$$$287$$$O	to$$$288$$$290$$$O	CCR8$$$291$$$295$$$O	and$$$296$$$299$$$O	CCL1,$$$300$$$305$$$O	an$$$306$$$308$$$O	antagonist$$$309$$$319$$$O	to$$$320$$$322$$$O	CCR8,$$$323$$$328$$$O	antisense$$$329$$$338$$$O	oligonucleotides$$$339$$$355$$$I	to$$$356$$$358$$$O	CCR8$$$359$$$363$$$O	and$$$364$$$367$$$O	CCL1$$$368$$$372$$$O	genes$$$373$$$378$$$O	and$$$379$$$382$$$O	siRNAs$$$383$$$389$$$O	thereto.$$$390$$$398$$$O	A$$$399$$$400$$$O	method$$$401$$$407$$$O	of$$$408$$$410$$$O	diagnosing$$$411$$$421$$$O	adhesion$$$422$$$430$$$O	which$$$431$$$436$$$O	comprises$$$437$$$446$$$O	detecting$$$447$$$456$$$O	the$$$457$$$460$$$O	expression$$$461$$$471$$$O	of$$$472$$$474$$$O	a$$$475$$$476$$$O	CCR8$$$477$$$481$$$O	gene$$$482$$$486$$$O	or$$$487$$$489$$$O	a$$$490$$$491$$$O	CCL1$$$492$$$496$$$O	gene$$$497$$$501$$$O	in$$$502$$$504$$$O	test$$$505$$$509$$$O	cells$$$510$$$515$$$O	or$$$516$$$518$$$O	detecting$$$519$$$528$$$O	the$$$529$$$532$$$O	content$$$533$$$540$$$O	of$$$541$$$543$$$O	CCR8$$$544$$$548$$$O	or$$$549$$$551$$$O	CCL1$$$552$$$556$$$O	in$$$557$$$559$$$O	the$$$560$$$563$$$O	test$$$564$$$568$$$O	cells.$$$569$$$575$$$O	A$$$576$$$577$$$O	method$$$578$$$584$$$O	of$$$585$$$587$$$O	screening$$$588$$$597$$$O	a$$$598$$$599$$$O	substance$$$600$$$609$$$O	which$$$610$$$615$$$O	is$$$616$$$618$$$O	useful$$$619$$$625$$$O	in$$$626$$$628$$$O	preventing$$$629$$$639$$$O	and$$$640$$$643$$$O	treating$$$644$$$652$$$O	adhesion.$$$653$$$662$$$O
US20110076315
Grafts$$$0$$$6$$$O	and$$$7$$$10$$$O	Stents$$$11$$$17$$$O	Having$$$18$$$24$$$O	Inorganic$$$25$$$34$$$O	Bio-Compatible$$$35$$$49$$$O	Calcium$$$50$$$57$$$O	Salt$$$58$$$62$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	application$$$12$$$23$$$O	discusses$$$24$$$33$$$O	techniques$$$34$$$44$$$O	and$$$45$$$48$$$O	structures$$$49$$$59$$$O	that$$$60$$$64$$$O	incorporate$$$65$$$76$$$O	calcium$$$77$$$84$$$O	salts$$$85$$$90$$$O	in$$$91$$$93$$$O	the$$$94$$$97$$$O	luminal$$$98$$$105$$$O	surface$$$106$$$113$$$O	of$$$114$$$116$$$O	grafts.$$$117$$$124$$$O	In$$$125$$$127$$$O	an$$$128$$$130$$$O	embodiment,$$$131$$$142$$$O	a$$$143$$$144$$$O	graft,$$$145$$$151$$$O	stent-graft$$$152$$$163$$$O	or$$$164$$$166$$$O	TIPS$$$167$$$171$$$O	may$$$172$$$175$$$O	incorporate$$$176$$$187$$$O	bio-compatible$$$188$$$202$$$O	calcium$$$203$$$210$$$O	salt,$$$211$$$216$$$O	which$$$217$$$222$$$O	is$$$223$$$225$$$O	essentially$$$226$$$237$$$O	non-osteoinductive$$$238$$$256$$$O	in$$$257$$$259$$$O	nature,$$$260$$$267$$$O	on$$$268$$$270$$$O	the$$$271$$$274$$$O	surfaces$$$275$$$283$$$O	of$$$284$$$286$$$O	the$$$287$$$290$$$O	implantable$$$291$$$302$$$O	device.$$$303$$$310$$$O
WO2010064172A3
Isolated$$$0$$$8$$$O	compounds$$$9$$$18$$$O	from$$$19$$$23$$$O	phaleria$$$24$$$32$$$O	macrocarpa$$$33$$$43$$$O	as$$$44$$$46$$$O	anti-cancer$$$47$$$58$$$O	agents$$$59$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	concerns$$$14$$$22$$$O	compounds$$$23$$$32$$$O	DLBS1425E2.2$$$33$$$45$$$I	and$$$46$$$49$$$O	DLBS1425F1$$$50$$$60$$$I	isolated$$$61$$$69$$$O	and$$$70$$$73$$$O	identified$$$74$$$84$$$O	from$$$85$$$89$$$O	the$$$90$$$93$$$O	extract$$$94$$$101$$$O	of$$$102$$$104$$$O	the$$$105$$$108$$$O	plant$$$109$$$114$$$O	Phaleria$$$115$$$123$$$O	macrocarpa$$$124$$$134$$$O	(Scheff.)$$$135$$$144$$$O	Boerl.$$$145$$$151$$$O	The$$$152$$$155$$$O	invention$$$156$$$165$$$O	also$$$166$$$170$$$O	relates$$$171$$$178$$$O	to$$$179$$$181$$$O	the$$$182$$$185$$$O	use$$$186$$$189$$$O	of$$$190$$$192$$$O	said$$$193$$$197$$$O	compounds,$$$198$$$208$$$O	either$$$209$$$215$$$O	as$$$216$$$218$$$O	a$$$219$$$220$$$O	single$$$221$$$227$$$O	active$$$228$$$234$$$O	compound$$$235$$$243$$$O	or$$$244$$$246$$$O	in$$$247$$$249$$$O	combination,$$$250$$$262$$$O	in$$$263$$$265$$$O	a$$$266$$$267$$$O	pharmaceutical$$$268$$$282$$$O	dosage$$$283$$$289$$$O	form$$$290$$$294$$$O	that$$$295$$$299$$$O	has$$$300$$$303$$$O	anti-proliferative$$$304$$$322$$$O	activity$$$323$$$331$$$O	of$$$332$$$334$$$O	cancer$$$335$$$341$$$O	cells,$$$342$$$348$$$O	and$$$349$$$352$$$O	its$$$353$$$356$$$O	use$$$357$$$360$$$O	relating$$$361$$$369$$$O	to$$$370$$$372$$$O	female$$$373$$$379$$$O	related$$$380$$$387$$$O	diseases.$$$388$$$397$$$O	Formula$$$398$$$405$$$O	(I).$$$406$$$410$$$O
US20130011494
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	treating$$$16$$$24$$$O	decubitus$$$25$$$34$$$O	ulcers$$$35$$$41$$$O	in$$$42$$$44$$$O	diabetic$$$45$$$53$$$O	and$$$54$$$57$$$O	non-diabetic$$$58$$$70$$$O	patients$$$71$$$79$$$O
The$$$0$$$3$$$O	various$$$4$$$11$$$O	embodiments$$$12$$$23$$$O	herein$$$24$$$30$$$O	disclose$$$31$$$39$$$O	a$$$40$$$41$$$O	composition$$$42$$$53$$$O	in$$$54$$$56$$$O	the$$$57$$$60$$$O	form$$$61$$$65$$$O	of$$$66$$$68$$$O	an$$$69$$$71$$$O	ointment$$$72$$$80$$$O	for$$$81$$$84$$$O	treating$$$85$$$93$$$O	decubitus$$$94$$$103$$$O	ulcers$$$104$$$110$$$O	in$$$111$$$113$$$O	diabetic$$$114$$$122$$$O	and$$$123$$$126$$$O	non$$$127$$$130$$$O	diabetic$$$131$$$139$$$O	patients.$$$140$$$149$$$O	The$$$150$$$153$$$O	composition$$$154$$$165$$$O	comprises$$$166$$$175$$$O	of$$$176$$$178$$$O	therapeutic$$$179$$$190$$$O	agents,$$$191$$$198$$$O	zinc$$$199$$$203$$$O	oxide,$$$204$$$210$$$O	vegetable$$$211$$$220$$$O	oils$$$221$$$225$$$O	and$$$226$$$229$$$O	powdered$$$230$$$238$$$O	talc.$$$239$$$244$$$O	The$$$245$$$248$$$O	therapeutic$$$249$$$260$$$O	agents$$$261$$$267$$$O	include$$$268$$$275$$$O	salts$$$276$$$281$$$O	of$$$282$$$284$$$O	nystatin,$$$285$$$294$$$I	tetracycline$$$295$$$307$$$I	and$$$308$$$311$$$O	neomycin,$$$312$$$321$$$I	respectively.$$$322$$$335$$$O	The$$$336$$$339$$$O	vegetable$$$340$$$349$$$O	oils$$$350$$$354$$$O	include$$$355$$$362$$$O	an$$$363$$$365$$$O	olive$$$366$$$371$$$O	oil,$$$372$$$376$$$O	a$$$377$$$378$$$O	soya$$$379$$$383$$$O	oil$$$384$$$387$$$O	and$$$388$$$391$$$O	a$$$392$$$393$$$O	sweet$$$394$$$399$$$O	almond$$$400$$$406$$$O	oil.$$$407$$$411$$$O	The$$$412$$$415$$$O	composition$$$416$$$427$$$O	is$$$428$$$430$$$O	effective$$$431$$$440$$$O	in$$$441$$$443$$$O	treatment$$$444$$$453$$$O	of$$$454$$$456$$$O	bed$$$457$$$460$$$O	sore$$$461$$$465$$$O	ulcers$$$466$$$472$$$O	or$$$473$$$475$$$O	decubitus$$$476$$$485$$$O	ulcers$$$486$$$492$$$O	in,$$$493$$$496$$$O	both$$$497$$$501$$$O	diabetic$$$502$$$510$$$O	and$$$511$$$514$$$O	non-diabetic$$$515$$$527$$$O	patients.$$$528$$$537$$$O	A$$$538$$$539$$$O	method$$$540$$$546$$$O	is$$$547$$$549$$$O	also$$$550$$$554$$$O	provided$$$555$$$563$$$O	for$$$564$$$567$$$O	preparing$$$568$$$577$$$O	a$$$578$$$579$$$O	composition$$$580$$$591$$$O	in$$$592$$$594$$$O	the$$$595$$$598$$$O	form$$$599$$$603$$$O	of$$$604$$$606$$$O	an$$$607$$$609$$$O	ointment$$$610$$$618$$$O	for$$$619$$$622$$$O	treating$$$623$$$631$$$O	decubitus$$$632$$$641$$$O	ulcers.$$$642$$$649$$$O
CN101574444A
Rehabilitation$$$0$$$14$$$O	medication$$$15$$$25$$$O	combination$$$26$$$37$$$O	for$$$38$$$41$$$O	curing$$$42$$$48$$$O	addiction$$$49$$$58$$$O	to$$$59$$$61$$$O	morphine$$$62$$$70$$$I	drugs$$$71$$$76$$$O	and$$$77$$$80$$$O	preparation$$$81$$$92$$$O	method$$$93$$$99$$$O	thereof$$$100$$$107$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	rehabilitation$$$27$$$41$$$O	medication$$$42$$$52$$$O	combination$$$53$$$64$$$O	for$$$65$$$68$$$O	curing$$$69$$$75$$$O	addiction$$$76$$$85$$$O	to$$$86$$$88$$$O	morphine$$$89$$$97$$$I	drugs$$$98$$$103$$$O	and$$$104$$$107$$$O	a$$$108$$$109$$$O	preparation$$$110$$$121$$$O	method$$$122$$$128$$$O	thereof.$$$129$$$137$$$O	The$$$138$$$141$$$O	medication$$$142$$$152$$$O	combination$$$153$$$164$$$O	is$$$165$$$167$$$O	prepared$$$168$$$176$$$O	from$$$177$$$181$$$O	the$$$182$$$185$$$O	following$$$186$$$195$$$O	raw$$$196$$$199$$$O	drugs$$$200$$$205$$$O	by$$$206$$$208$$$O	weight$$$209$$$215$$$O	percentage:$$$216$$$227$$$O	11%$$$228$$$231$$$O	to$$$232$$$234$$$O	19%$$$235$$$238$$$O	of$$$239$$$241$$$O	pine$$$242$$$246$$$O	needle$$$247$$$253$$$O	juice,$$$254$$$260$$$O	32%$$$261$$$264$$$O	to$$$265$$$267$$$O	41%$$$268$$$271$$$O	of$$$272$$$274$$$O	rhizoma$$$275$$$282$$$O	corydalis,$$$283$$$293$$$O	1%$$$294$$$296$$$O	to$$$297$$$299$$$O	6%$$$300$$$302$$$O	of$$$303$$$305$$$O	henbane$$$306$$$313$$$O	seed,$$$314$$$319$$$O	6%$$$320$$$322$$$O	to$$$323$$$325$$$O	16%$$$326$$$329$$$O	of$$$330$$$332$$$O	ginseng,$$$333$$$341$$$O	2%$$$342$$$344$$$O	to$$$345$$$347$$$O	9%$$$348$$$350$$$O	of$$$351$$$353$$$O	radix$$$354$$$359$$$O	jasmini$$$360$$$367$$$O	sambac,$$$368$$$375$$$O	4%$$$376$$$378$$$O	to$$$379$$$381$$$O	12%$$$382$$$385$$$O	of$$$386$$$388$$$O	amber,$$$389$$$395$$$O	4%$$$396$$$398$$$O	to$$$399$$$401$$$O	12%$$$402$$$405$$$O	of$$$406$$$408$$$O	rheum$$$409$$$414$$$O	officinale$$$415$$$425$$$O	and$$$426$$$429$$$O	15%$$$430$$$433$$$O	to$$$434$$$436$$$O	23%$$$437$$$440$$$O	of$$$441$$$443$$$O	honey.$$$444$$$450$$$O	The$$$451$$$454$$$O	invention$$$455$$$464$$$O	provides$$$465$$$473$$$O	a$$$474$$$475$$$O	rehabilitation$$$476$$$490$$$O	medication$$$491$$$501$$$O	combination$$$502$$$513$$$O	for$$$514$$$517$$$O	curing$$$518$$$524$$$O	addiction$$$525$$$534$$$O	to$$$535$$$537$$$O	morphine$$$538$$$546$$$I	drugs$$$547$$$552$$$O	and$$$553$$$556$$$O	a$$$557$$$558$$$O	preparation$$$559$$$570$$$O	method$$$571$$$577$$$O	thereof$$$578$$$585$$$O	for$$$586$$$589$$$O	fundamentally$$$590$$$603$$$O	relieving$$$604$$$613$$$O	a$$$614$$$615$$$O	series$$$616$$$622$$$O	of$$$623$$$625$$$O	protracted$$$626$$$636$$$O	abstinent$$$637$$$646$$$O	syndromes$$$647$$$656$$$O	after$$$657$$$662$$$O	the$$$663$$$666$$$O	rehabilitation,$$$667$$$682$$$O	solving$$$683$$$690$$$O	the$$$691$$$694$$$O	problems$$$695$$$703$$$O	that$$$704$$$708$$$O	the$$$709$$$712$$$O	drug$$$713$$$717$$$O	addicts$$$718$$$725$$$O	cannot$$$726$$$732$$$O	extricate$$$733$$$742$$$O	themselves$$$743$$$753$$$O	from$$$754$$$758$$$O	the$$$759$$$762$$$O	severe$$$763$$$769$$$O	pain,$$$770$$$775$$$O	strengthening$$$776$$$789$$$O	the$$$790$$$793$$$O	body$$$794$$$798$$$O	constitution,$$$799$$$812$$$O	helping$$$813$$$820$$$O	the$$$821$$$824$$$O	drug$$$825$$$829$$$O	addicts$$$830$$$837$$$O	strengthen$$$838$$$848$$$O	the$$$849$$$852$$$O	willpower$$$853$$$862$$$O	and$$$863$$$866$$$O	effectively$$$867$$$878$$$O	preventing$$$879$$$889$$$O	the$$$890$$$893$$$O	drug$$$894$$$898$$$O	addicts$$$899$$$906$$$O	from$$$907$$$911$$$O	relapsing.$$$912$$$922$$$O
WO2007095812A1
Substituted$$$0$$$11$$$O	[1,3,5]$$$12$$$19$$$I	triazine$$$20$$$28$$$I	compounds,$$$29$$$39$$$O	their$$$40$$$45$$$O	processes$$$46$$$55$$$O	for$$$56$$$59$$$O	preparation$$$60$$$71$$$O	and$$$72$$$75$$$O	uses$$$76$$$80$$$O	thereof$$$81$$$88$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	discloses$$$15$$$24$$$O	the$$$25$$$28$$$O	substituted$$$29$$$40$$$O	[1,3,5]$$$41$$$48$$$I	triazine$$$49$$$57$$$I	compounds$$$58$$$67$$$O	of$$$68$$$70$$$O	following$$$71$$$80$$$O	formula,$$$81$$$89$$$O	their$$$90$$$95$$$O	pharmaceutically$$$96$$$112$$$O	acceptable$$$113$$$123$$$O	salts$$$124$$$129$$$O	and$$$130$$$133$$$O	solvates$$$134$$$142$$$O	or$$$143$$$145$$$O	hydrates,$$$146$$$155$$$O	the$$$156$$$159$$$O	pharmaceutical$$$160$$$174$$$O	compositions$$$175$$$187$$$O	containing$$$188$$$198$$$O	the$$$199$$$202$$$O	compounds$$$203$$$212$$$O	and$$$213$$$216$$$O	the$$$217$$$220$$$O	uses$$$221$$$225$$$O	thereof.$$$226$$$234$$$O	The$$$235$$$238$$$O	compositions$$$239$$$251$$$O	of$$$252$$$254$$$O	the$$$255$$$258$$$O	present$$$259$$$266$$$O	invention$$$267$$$276$$$O	may$$$277$$$280$$$O	be$$$281$$$283$$$O	used$$$284$$$288$$$O	for$$$289$$$292$$$O	the$$$293$$$296$$$O	prevention$$$297$$$307$$$O	and/or$$$308$$$314$$$O	treatment$$$315$$$324$$$O	of$$$325$$$327$$$O	inflammation$$$328$$$340$$$O	diseases,$$$341$$$350$$$O	which$$$351$$$356$$$O	have$$$357$$$361$$$O	good$$$362$$$366$$$O	effect.$$$367$$$374$$$O	The$$$375$$$378$$$O	substituted$$$379$$$390$$$O	[1,3,5]$$$391$$$398$$$I	triazine$$$399$$$407$$$I	compounds$$$408$$$417$$$O	or$$$418$$$420$$$O	their$$$421$$$426$$$O	pharmaceutically$$$427$$$443$$$O	acceptable$$$444$$$454$$$O	salts$$$455$$$460$$$O	show$$$461$$$465$$$O	remarkable$$$466$$$476$$$O	EGFR$$$477$$$481$$$O	enzyme$$$482$$$488$$$O	inhibitory$$$489$$$499$$$O	activity$$$500$$$508$$$O	and$$$509$$$512$$$O	antitumor$$$513$$$522$$$O	activity$$$523$$$531$$$O	in$$$532$$$534$$$O	a$$$535$$$536$$$O	serious$$$537$$$544$$$O	of$$$545$$$547$$$O	selective$$$548$$$557$$$O	tests$$$558$$$563$$$O	of$$$564$$$566$$$O	EGFR$$$567$$$571$$$O	enzyme$$$572$$$578$$$O	level$$$579$$$584$$$O	and$$$585$$$588$$$O	tumor$$$589$$$594$$$O	cell$$$595$$$599$$$O	level$$$600$$$605$$$O	(human$$$606$$$612$$$O	HT-29$$$613$$$618$$$O	and$$$619$$$622$$$O	HCT-116).$$$623$$$632$$$O	So$$$633$$$635$$$O	The$$$636$$$639$$$O	compositions$$$640$$$652$$$O	of$$$653$$$655$$$O	the$$$656$$$659$$$O	present$$$660$$$667$$$O	invention$$$668$$$677$$$O	may$$$678$$$681$$$O	be$$$682$$$684$$$O	used$$$685$$$689$$$O	for$$$690$$$693$$$O	the$$$694$$$697$$$O	prevention$$$698$$$708$$$O	and/or$$$709$$$715$$$O	treatment$$$716$$$725$$$O	and/or$$$726$$$732$$$O	aid$$$733$$$736$$$O	treatment$$$737$$$746$$$O	of$$$747$$$749$$$O	tumor$$$750$$$755$$$O	diseases.$$$756$$$765$$$O
CN101045155A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	the$$$11$$$14$$$O	therapeutic$$$15$$$26$$$O	management$$$27$$$37$$$O	of$$$38$$$40$$$O	extrauterine$$$41$$$53$$$O	proliferation$$$54$$$67$$$O	of$$$68$$$70$$$O	endometrial$$$71$$$82$$$O	tissue,$$$83$$$90$$$O	chronic$$$91$$$98$$$O	pelvic$$$99$$$105$$$O	pain$$$106$$$110$$$O	and$$$111$$$114$$$O	fallopian$$$115$$$124$$$O	tube$$$125$$$129$$$O	obstruction$$$130$$$141$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	method$$$33$$$39$$$O	for$$$40$$$43$$$O	therapeutic$$$44$$$55$$$O	management$$$56$$$66$$$O	of$$$67$$$69$$$O	extrauterine$$$70$$$82$$$O	proliferation$$$83$$$96$$$O	of$$$97$$$99$$$O	endometrial$$$100$$$111$$$O	tissue,$$$112$$$119$$$O	chronic$$$120$$$127$$$O	pelvic$$$128$$$134$$$O	pain$$$135$$$139$$$O	and$$$140$$$143$$$O	fallopian$$$144$$$153$$$O	tube$$$154$$$158$$$O	obstruction$$$159$$$170$$$O	by$$$171$$$173$$$O	short$$$174$$$179$$$O	term$$$180$$$184$$$O	induction$$$185$$$194$$$O	treatment$$$195$$$204$$$O	with$$$205$$$209$$$O	an$$$210$$$212$$$O	LH-RH$$$213$$$218$$$O	antagonist$$$219$$$229$$$O	for$$$230$$$233$$$O	4$$$234$$$235$$$O	to$$$236$$$238$$$O	12$$$239$$$241$$$O	weeks.$$$242$$$248$$$O	According$$$249$$$258$$$O	to$$$259$$$261$$$O	another$$$262$$$269$$$O	aspect$$$270$$$276$$$O	of$$$277$$$279$$$O	the$$$280$$$283$$$O	present$$$284$$$291$$$O	invention,$$$292$$$302$$$O	the$$$303$$$306$$$O	short$$$307$$$312$$$O	term$$$313$$$317$$$O	LH-RH$$$318$$$323$$$O	treatment$$$324$$$333$$$O	is$$$334$$$336$$$O	followed$$$337$$$345$$$O	by$$$346$$$348$$$O	the$$$349$$$352$$$O	combined$$$353$$$361$$$O	or$$$362$$$364$$$O	separate$$$365$$$373$$$O	administration$$$374$$$388$$$O	of$$$389$$$391$$$O	one$$$392$$$395$$$O	or$$$396$$$398$$$O	more$$$399$$$403$$$O	active$$$404$$$410$$$O	agents$$$411$$$417$$$O	selected$$$418$$$426$$$O	from$$$427$$$431$$$O	the$$$432$$$435$$$O	group$$$436$$$441$$$O	consisting$$$442$$$452$$$O	of$$$453$$$455$$$O	a$$$456$$$457$$$O	contraceptive,$$$458$$$472$$$O	preferably$$$473$$$483$$$O	an$$$484$$$486$$$O	oral$$$487$$$491$$$O	contraceptive,$$$492$$$506$$$O	a$$$507$$$508$$$O	non-steroidal$$$509$$$522$$$O	anti-rheumatic$$$523$$$537$$$O	agent,$$$538$$$544$$$O	an$$$545$$$547$$$O	analgetic,$$$548$$$558$$$O	an$$$559$$$561$$$O	androgen$$$562$$$570$$$I	other$$$571$$$576$$$O	than$$$577$$$581$$$O	a$$$582$$$583$$$O	17-alpha-alkyl$$$584$$$598$$$I	substituted$$$599$$$610$$$O	testosterone$$$611$$$623$$$I	or$$$624$$$626$$$O	any$$$627$$$630$$$O	combinations$$$631$$$643$$$O	thereof.$$$644$$$652$$$O	According$$$653$$$662$$$O	to$$$663$$$665$$$O	a$$$666$$$667$$$O	further$$$668$$$675$$$O	aspect$$$676$$$682$$$O	of$$$683$$$685$$$O	the$$$686$$$689$$$O	present$$$690$$$697$$$O	invention$$$698$$$707$$$O	a$$$708$$$709$$$O	pharmaceutical$$$710$$$724$$$O	composition$$$725$$$736$$$O	comprising$$$737$$$747$$$O	an$$$748$$$750$$$O	LHRH$$$751$$$755$$$O	antagonist$$$756$$$766$$$O	and$$$767$$$770$$$O	one$$$771$$$774$$$O	or$$$775$$$777$$$O	more$$$778$$$782$$$O	active$$$783$$$789$$$O	agents$$$790$$$796$$$O	selected$$$797$$$805$$$O	from$$$806$$$810$$$O	the$$$811$$$814$$$O	group$$$815$$$820$$$O	consisting$$$821$$$831$$$O	of$$$832$$$834$$$O	a$$$835$$$836$$$O	contraceptive,$$$837$$$851$$$O	preferably$$$852$$$862$$$O	an$$$863$$$865$$$O	oral$$$866$$$870$$$O	contraceptive,$$$871$$$885$$$O	a$$$886$$$887$$$O	non-steroidal$$$888$$$901$$$O	anti-rheumatic$$$902$$$916$$$O	agent,$$$917$$$923$$$O	an$$$924$$$926$$$O	analgetic,$$$927$$$937$$$O	an$$$938$$$940$$$O	androgen$$$941$$$949$$$I	other$$$950$$$955$$$O	than$$$956$$$960$$$O	a$$$961$$$962$$$O	17-alpha-alkyl$$$963$$$977$$$I	substituted$$$978$$$989$$$O	testosterone$$$990$$$1002$$$I	or$$$1003$$$1005$$$O	any$$$1006$$$1009$$$O	combinations$$$1010$$$1022$$$O	thereof$$$1023$$$1030$$$O	are$$$1031$$$1034$$$O	provided.$$$1035$$$1044$$$O
CN103349751A
Mongolian$$$0$$$9$$$O	medicine$$$10$$$18$$$O	composition$$$19$$$30$$$O	for$$$31$$$34$$$O	treating$$$35$$$43$$$O	diabetic$$$44$$$52$$$O	nephropathy$$$53$$$64$$$O	and$$$65$$$68$$$O	preparation$$$69$$$80$$$O	method$$$81$$$87$$$O	thereof$$$88$$$95$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	mongolian$$$26$$$35$$$O	medicine$$$36$$$44$$$O	composition$$$45$$$56$$$O	for$$$57$$$60$$$O	treating$$$61$$$69$$$O	diabetic$$$70$$$78$$$O	nephropathy.$$$79$$$91$$$O	The$$$92$$$95$$$O	mongolian$$$96$$$105$$$O	medicine$$$106$$$114$$$O	composition$$$115$$$126$$$O	is$$$127$$$129$$$O	prepared$$$130$$$138$$$O	from$$$139$$$143$$$O	the$$$144$$$147$$$O	following$$$148$$$157$$$O	materials$$$158$$$167$$$O	in$$$168$$$170$$$O	parts$$$171$$$176$$$O	by$$$177$$$179$$$O	weight:$$$180$$$187$$$O	15-25$$$188$$$193$$$O	parts$$$194$$$199$$$O	of$$$200$$$202$$$O	gypsum,$$$203$$$210$$$O	15-25$$$211$$$216$$$O	parts$$$217$$$222$$$O	of$$$223$$$225$$$O	flowers$$$226$$$233$$$O	carthami,$$$234$$$243$$$O	15-25$$$244$$$249$$$O	parts$$$250$$$255$$$O	of$$$256$$$258$$$O	clove,$$$259$$$265$$$O	15-25$$$266$$$271$$$O	parts$$$272$$$277$$$O	of$$$278$$$280$$$O	myristica$$$281$$$290$$$O	fragrans,$$$291$$$300$$$O	15-25$$$301$$$306$$$O	parts$$$307$$$312$$$O	of$$$313$$$315$$$O	amomum$$$316$$$322$$$O	cardamomum,$$$323$$$334$$$O	15-25$$$335$$$340$$$O	parts$$$341$$$346$$$O	of$$$347$$$349$$$O	amomum$$$350$$$356$$$O	tsao-ko,$$$357$$$365$$$O	15-25$$$366$$$371$$$O	parts$$$372$$$377$$$O	of$$$378$$$380$$$O	rhizoma$$$381$$$388$$$O	polygonati,$$$389$$$400$$$O	15-25$$$401$$$406$$$O	parts$$$407$$$412$$$O	of$$$413$$$415$$$O	radix$$$416$$$421$$$O	polygonati$$$422$$$432$$$O	officinalis,$$$433$$$445$$$O	15-25$$$446$$$451$$$O	parts$$$452$$$457$$$O	of$$$458$$$460$$$O	bletilla$$$461$$$469$$$O	striata,$$$470$$$478$$$O	15-25$$$479$$$484$$$O	parts$$$485$$$490$$$O	of$$$491$$$493$$$O	radix$$$494$$$499$$$O	asparagi,$$$500$$$509$$$O	15-25$$$510$$$515$$$O	parts$$$516$$$521$$$O	of$$$522$$$524$$$O	fructus$$$525$$$532$$$O	choerospondiatis,$$$533$$$550$$$O	90-150$$$551$$$557$$$O	parts$$$558$$$563$$$O	of$$$564$$$566$$$O	ginseng,$$$567$$$575$$$O	and$$$576$$$579$$$O	82.5-138$$$580$$$588$$$O	parts$$$589$$$594$$$O	of$$$595$$$597$$$O	polygonum$$$598$$$607$$$O	bistorta.$$$608$$$617$$$O	Meanwhile,$$$618$$$628$$$O	the$$$629$$$632$$$O	invention$$$633$$$642$$$O	also$$$643$$$647$$$O	discloses$$$648$$$657$$$O	a$$$658$$$659$$$O	corresponding$$$660$$$673$$$O	preparation$$$674$$$685$$$O	method.$$$686$$$693$$$O	The$$$694$$$697$$$O	product$$$698$$$705$$$O	disclosed$$$706$$$715$$$O	by$$$716$$$718$$$O	the$$$719$$$722$$$O	invention$$$723$$$732$$$O	has$$$733$$$736$$$O	good$$$737$$$741$$$O	effects$$$742$$$749$$$O	of$$$750$$$752$$$O	improving$$$753$$$762$$$O	symptoms$$$763$$$771$$$O	and$$$772$$$775$$$O	protecting$$$776$$$786$$$O	the$$$787$$$790$$$O	kidney.$$$791$$$798$$$O	The$$$799$$$802$$$O	preparation$$$803$$$814$$$O	method$$$815$$$821$$$O	is$$$822$$$824$$$O	simple$$$825$$$831$$$O	and$$$832$$$835$$$O	easy$$$836$$$840$$$O	to$$$841$$$843$$$O	popularize.$$$844$$$855$$$O
CA2776971A1
Treatment$$$0$$$9$$$O	with$$$10$$$14$$$O	cholinergic$$$15$$$26$$$O	agonists$$$27$$$35$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	treating$$$11$$$19$$$O	disorders$$$20$$$29$$$O	with$$$30$$$34$$$O	cholinergic$$$35$$$46$$$O	agonists$$$47$$$55$$$O	for$$$56$$$59$$$O	example,$$$60$$$68$$$O	muscarinic$$$69$$$79$$$O	receptor$$$80$$$88$$$O	agonists$$$89$$$97$$$O	such$$$98$$$102$$$O	as$$$103$$$105$$$O	pilocarpine$$$106$$$117$$$I	and$$$118$$$121$$$O	cevimeline$$$122$$$132$$$I	are$$$133$$$136$$$O	provided.$$$137$$$146$$$O	In$$$147$$$149$$$O	particular,$$$150$$$161$$$O	methods$$$162$$$169$$$O	of$$$170$$$172$$$O	treating$$$173$$$181$$$O	and/or$$$182$$$188$$$O	preventing$$$189$$$199$$$O	interstitial$$$200$$$212$$$O	cystitis,$$$213$$$222$$$O	yeast$$$223$$$228$$$O	infections,$$$229$$$240$$$O	urinary$$$241$$$248$$$O	tract$$$249$$$254$$$O	infections,$$$255$$$266$$$O	atrophic$$$267$$$275$$$O	vaginitis,$$$276$$$286$$$O	vaginal$$$287$$$294$$$O	dryness,$$$295$$$303$$$O	and$$$304$$$307$$$O	sexual$$$308$$$314$$$O	dysfunction$$$315$$$326$$$O	associated$$$327$$$337$$$O	with$$$338$$$342$$$O	vaginal$$$343$$$350$$$O	dryness$$$351$$$358$$$O	by$$$359$$$361$$$O	administering$$$362$$$375$$$O	a$$$376$$$377$$$O	cholinergic$$$378$$$389$$$I	agonist$$$390$$$397$$$O	to$$$398$$$400$$$O	the$$$401$$$404$$$O	subject$$$405$$$412$$$O	suffering$$$413$$$422$$$O	from$$$423$$$427$$$O	the$$$428$$$431$$$O	disorders$$$432$$$441$$$O	are$$$442$$$445$$$O	provided.$$$446$$$455$$$O	In$$$456$$$458$$$O	addition,$$$459$$$468$$$O	intra-$$$469$$$475$$$O	vaginal$$$476$$$483$$$O	administration$$$484$$$498$$$O	of$$$499$$$501$$$O	cholinergic$$$502$$$513$$$O	agonists$$$514$$$522$$$O	such$$$523$$$527$$$O	as$$$528$$$530$$$O	muscarinic$$$531$$$541$$$O	receptor$$$542$$$550$$$O	agonists$$$551$$$559$$$O	to$$$560$$$562$$$O	patients$$$563$$$571$$$O	suffering$$$572$$$581$$$O	from$$$582$$$586$$$O	interstitial$$$587$$$599$$$O	cystitis,$$$600$$$609$$$O	vaginal$$$610$$$617$$$O	dryness,$$$618$$$626$$$O	and$$$627$$$630$$$O	sexual$$$631$$$637$$$O	dysfunction$$$638$$$649$$$O	associated$$$650$$$660$$$O	with$$$661$$$665$$$O	vaginal$$$666$$$673$$$O	dryness$$$674$$$681$$$O	is$$$682$$$684$$$O	also$$$685$$$689$$$O	provided.$$$690$$$699$$$O
US20100069464
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	modulating$$$29$$$39$$$O	activity$$$40$$$48$$$O	of$$$49$$$51$$$O	capped$$$52$$$58$$$O	small$$$59$$$64$$$O	rnas$$$65$$$69$$$O
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	modulating$$$29$$$39$$$O	transcription$$$40$$$53$$$O	by$$$54$$$56$$$O	RNA$$$57$$$60$$$O	polymerases$$$61$$$72$$$O	are$$$73$$$76$$$O	described.$$$77$$$87$$$O
EP2270505A1
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	screening$$$12$$$21$$$O	a$$$22$$$23$$$O	cell$$$24$$$28$$$O	death$$$29$$$34$$$O	inhibitor$$$35$$$44$$$O	using$$$45$$$50$$$O	macrophage$$$51$$$61$$$O	migration$$$62$$$71$$$O	inhibitory$$$72$$$82$$$O	factor$$$83$$$89$$$O	(MIF)$$$90$$$95$$$O
There$$$0$$$5$$$O	are$$$6$$$9$$$O	disclosed$$$10$$$19$$$O	a$$$20$$$21$$$O	method$$$22$$$28$$$O	of$$$29$$$31$$$O	screening$$$32$$$41$$$O	a$$$42$$$43$$$O	cell$$$44$$$48$$$O	death$$$49$$$54$$$O	inhibitor,$$$55$$$65$$$O	which$$$66$$$71$$$O	comprises$$$72$$$81$$$O	using$$$82$$$87$$$O	macrophage$$$88$$$98$$$O	migration$$$99$$$108$$$O	inhibitory$$$109$$$119$$$O	factor,$$$120$$$127$$$O	a$$$128$$$129$$$O	kit$$$130$$$133$$$O	for$$$134$$$137$$$O	screening$$$138$$$147$$$O	a$$$148$$$149$$$O	cell$$$150$$$154$$$O	death$$$155$$$160$$$O	inhibitor,$$$161$$$171$$$O	comprising$$$172$$$182$$$O	macrophage$$$183$$$193$$$O	migration$$$194$$$203$$$O	inhibitory$$$204$$$214$$$O	factor$$$215$$$221$$$O	and$$$222$$$225$$$O	a$$$226$$$227$$$O	method$$$228$$$234$$$O	for$$$235$$$238$$$O	quantification$$$239$$$253$$$O	of$$$254$$$256$$$O	macrophage$$$257$$$267$$$O	migration$$$268$$$277$$$O	inhibitory$$$278$$$288$$$O	factor,$$$289$$$296$$$O	which$$$297$$$302$$$O	comprises$$$303$$$312$$$O	using$$$313$$$318$$$O	a$$$319$$$320$$$O	substance$$$321$$$330$$$O	capable$$$331$$$338$$$O	of$$$339$$$341$$$O	binding$$$342$$$349$$$O	to$$$350$$$352$$$O	macrophage$$$353$$$363$$$O	migration$$$364$$$373$$$O	inhibitory$$$374$$$384$$$O	factor.$$$385$$$392$$$O
WO2006138038A1
Intralesional$$$0$$$13$$$O	treatment$$$14$$$23$$$O	of$$$24$$$26$$$O	psoriasis$$$27$$$36$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	includes$$$22$$$30$$$O	the$$$31$$$34$$$O	treatment$$$35$$$44$$$O	of$$$45$$$47$$$O	psoriasis$$$48$$$57$$$O	in$$$58$$$60$$$O	a$$$61$$$62$$$O	human$$$63$$$68$$$O	comprising$$$69$$$79$$$O	the$$$80$$$83$$$O	intralesional$$$84$$$97$$$O	administration$$$98$$$112$$$O	of$$$113$$$115$$$O	a$$$116$$$117$$$O	phenothiazine,$$$118$$$132$$$I	preferably$$$133$$$143$$$O	fluphenazine,$$$144$$$157$$$I	to$$$158$$$160$$$O	a$$$161$$$162$$$O	psoriatic$$$163$$$172$$$O	plaque$$$173$$$179$$$O	in$$$180$$$182$$$O	the$$$183$$$186$$$O	patient.$$$187$$$195$$$O
WO2010132959A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	dynamin$$$7$$$14$$$O	ring$$$15$$$19$$$O	stabilizers$$$20$$$31$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	a$$$18$$$19$$$O	method$$$20$$$26$$$O	for$$$27$$$30$$$O	promoting$$$31$$$40$$$O	dynamin$$$41$$$48$$$O	ring$$$49$$$53$$$O	formation$$$54$$$63$$$O	and/or$$$64$$$70$$$O	maintenance$$$71$$$82$$$O	of$$$83$$$85$$$O	dynamin$$$86$$$93$$$O	rings$$$94$$$99$$$O	in$$$100$$$102$$$O	a$$$103$$$104$$$O	cell,$$$105$$$110$$$O	comprising$$$111$$$121$$$O	treating$$$122$$$130$$$O	the$$$131$$$134$$$O	cell$$$135$$$139$$$O	with$$$140$$$144$$$O	an$$$145$$$147$$$O	effective$$$148$$$157$$$O	amount$$$158$$$164$$$O	of$$$165$$$167$$$O	a$$$168$$$169$$$O	dynamin$$$170$$$177$$$O	ring$$$178$$$182$$$O	stabilizer,$$$183$$$194$$$O	or$$$195$$$197$$$O	a$$$198$$$199$$$O	prodrug$$$200$$$207$$$O	or$$$208$$$210$$$O	pharmaceutically$$$211$$$227$$$O	acceptable$$$228$$$238$$$O	salt$$$239$$$243$$$O	of$$$244$$$246$$$O	the$$$247$$$250$$$O	dynamin$$$251$$$258$$$O	ring$$$259$$$263$$$O	stabilizer.$$$264$$$275$$$O	The$$$276$$$279$$$O	maintenance$$$280$$$291$$$O	or$$$292$$$294$$$O	accumulation$$$295$$$307$$$O	of$$$308$$$310$$$O	dynamin$$$311$$$318$$$O	ring$$$319$$$323$$$O	formation$$$324$$$333$$$O	has$$$334$$$337$$$O	particular$$$338$$$348$$$O	application$$$349$$$360$$$O	in$$$361$$$363$$$O	the$$$364$$$367$$$O	prophylaxis$$$368$$$379$$$O	or$$$380$$$382$$$O	treatment$$$383$$$392$$$O	of$$$393$$$395$$$O	a$$$396$$$397$$$O	kidney$$$398$$$404$$$O	disease$$$405$$$412$$$O	or$$$413$$$415$$$O	condition$$$416$$$425$$$O	characterized$$$426$$$439$$$O	by$$$440$$$442$$$O	proteinuria.$$$443$$$455$$$O	A$$$456$$$457$$$O	dynamin$$$458$$$465$$$O	ring$$$466$$$470$$$O	stabilizer$$$471$$$481$$$O	can$$$482$$$485$$$O	be$$$486$$$488$$$O	any$$$489$$$492$$$O	agent$$$493$$$498$$$O	that$$$499$$$503$$$O	interacts$$$504$$$513$$$O	with$$$514$$$518$$$O	dynamin$$$519$$$526$$$O	to$$$527$$$529$$$O	promote$$$530$$$537$$$O	dynamin$$$538$$$545$$$O	ring$$$546$$$550$$$O	assembly$$$551$$$559$$$O	and/or$$$560$$$566$$$O	inhibit$$$567$$$574$$$O	dynamin$$$575$$$582$$$O	ring$$$583$$$587$$$O	disassembly.$$$588$$$600$$$O	There$$$601$$$606$$$O	are$$$607$$$610$$$O	also$$$611$$$615$$$O	provided$$$616$$$624$$$O	methods$$$625$$$632$$$O	for$$$633$$$636$$$O	prophylaxis$$$637$$$648$$$O	or$$$649$$$651$$$O	treatment$$$652$$$661$$$O	of$$$662$$$664$$$O	podocyte$$$665$$$673$$$O	dysfunction$$$674$$$685$$$O	and/or$$$686$$$692$$$O	maintaining$$$693$$$704$$$O	or$$$705$$$707$$$O	inducing$$$708$$$716$$$O	actin$$$717$$$722$$$O	cytoskeleton$$$723$$$735$$$O	formation$$$736$$$745$$$O	in$$$746$$$748$$$O	a$$$749$$$750$$$O	cell$$$751$$$755$$$O	utilizing$$$756$$$765$$$O	dynamin$$$766$$$773$$$O	ring$$$774$$$778$$$O	stabilizers,$$$779$$$791$$$O	and$$$792$$$795$$$O	for$$$796$$$799$$$O	screening$$$800$$$809$$$O	a$$$810$$$811$$$O	test$$$812$$$816$$$O	agent$$$817$$$822$$$O	for$$$823$$$826$$$O	use$$$827$$$830$$$O	as$$$831$$$833$$$O	a$$$834$$$835$$$O	dynamin$$$836$$$843$$$O	ring$$$844$$$848$$$O	stabilizer.$$$849$$$860$$$O
WO2007003554A1
Novel$$$0$$$5$$$O	medicinal$$$6$$$15$$$O	combinations$$$16$$$28$$$O	which$$$29$$$34$$$O	are$$$35$$$38$$$O	used$$$39$$$43$$$O	for$$$44$$$47$$$O	treating$$$48$$$56$$$O	respiratory$$$57$$$68$$$O	tract$$$69$$$74$$$O	diseases$$$75$$$83$$$O	and$$$84$$$87$$$O	contain$$$88$$$95$$$O	beta-2$$$96$$$102$$$O	long-acting$$$103$$$114$$$O	agonists$$$115$$$123$$$O	and$$$124$$$127$$$O	at$$$128$$$130$$$O	least$$$131$$$136$$$O	one$$$137$$$140$$$O	other$$$141$$$146$$$O	type$$$147$$$151$$$O	of$$$152$$$154$$$O	active$$$155$$$161$$$O	substance.$$$162$$$172$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	novel$$$25$$$30$$$O	medicinal$$$31$$$40$$$O	combinations$$$41$$$53$$$O	preferably$$$54$$$64$$$O	comprising$$$65$$$75$$$O	a$$$76$$$77$$$O	compound$$$78$$$86$$$O	of$$$87$$$89$$$O	formula$$$90$$$97$$$O	(I),$$$98$$$102$$$O	wherein$$$103$$$110$$$O	the$$$111$$$114$$$O	groups$$$115$$$121$$$O	X,$$$122$$$124$$$O	Ra,$$$125$$$128$$$O	Rb,$$$129$$$132$$$O	R1,$$$133$$$136$$$O	R1',$$$137$$$141$$$O	R2,$$$142$$$145$$$O	R2',$$$146$$$150$$$O	R2'',$$$151$$$156$$$O	R2''',$$$157$$$163$$$O	V$$$164$$$165$$$O	and$$$166$$$169$$$O	n$$$170$$$171$$$O	can$$$172$$$175$$$O	have$$$176$$$180$$$O	a$$$181$$$182$$$O	significance$$$183$$$195$$$O	specified$$$196$$$205$$$O	in$$$206$$$208$$$O	claims$$$209$$$215$$$O	and$$$216$$$219$$$O	in$$$220$$$222$$$O	a$$$223$$$224$$$O	description,$$$225$$$237$$$O	or$$$238$$$240$$$O	several$$$241$$$248$$$O	of$$$249$$$251$$$O	said$$$252$$$256$$$O	compounds$$$257$$$266$$$O	and$$$267$$$270$$$O	at$$$271$$$273$$$O	least$$$274$$$279$$$O	one$$$280$$$283$$$O	type$$$284$$$288$$$O	of$$$289$$$291$$$O	other$$$292$$$297$$$O	active$$$298$$$304$$$O	substance$$$305$$$314$$$O	2.$$$315$$$317$$$O	Methods$$$318$$$325$$$O	for$$$326$$$329$$$O	the$$$330$$$333$$$O	production$$$334$$$344$$$O	of$$$345$$$347$$$O	the$$$348$$$351$$$O	inventive$$$352$$$361$$$O	compounds$$$362$$$371$$$O	and$$$372$$$375$$$O	the$$$376$$$379$$$O	use$$$380$$$383$$$O	thereof$$$384$$$391$$$O	in$$$392$$$394$$$O	the$$$395$$$398$$$O	form$$$399$$$403$$$O	of$$$404$$$406$$$O	drugs$$$407$$$412$$$O	are$$$413$$$416$$$O	also$$$417$$$421$$$O	disclosed.$$$422$$$432$$$O
EP2193117A1
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	beta$$$14$$$18$$$O	amyloid$$$19$$$26$$$O	production$$$27$$$37$$$O
Novel$$$0$$$5$$$O	sulfonamide$$$6$$$17$$$I	compounds$$$18$$$27$$$O	useful$$$28$$$34$$$O	in$$$35$$$37$$$O	the$$$38$$$41$$$O	treatment$$$42$$$51$$$O	of$$$52$$$54$$$O	conditions$$$55$$$65$$$O	related$$$66$$$73$$$O	to$$$74$$$76$$$O	the$$$77$$$80$$$O	production$$$81$$$91$$$O	of$$$92$$$94$$$O	beta-amyloid$$$95$$$107$$$O	are$$$108$$$111$$$O	described,$$$112$$$122$$$O	as$$$123$$$125$$$O	are$$$126$$$129$$$O	routes$$$130$$$136$$$O	to$$$137$$$139$$$O	their$$$140$$$145$$$O	preparation.$$$146$$$158$$$O	The$$$159$$$162$$$O	sulfonamide$$$163$$$174$$$I	compounds$$$175$$$184$$$O	are$$$185$$$188$$$O	of$$$189$$$191$$$O	the$$$192$$$195$$$O	following$$$196$$$205$$$O	structure,$$$206$$$216$$$O	wherein$$$217$$$224$$$O	R4-R3$$$225$$$230$$$O	are$$$231$$$234$$$O	defined$$$235$$$242$$$O	herein.$$$243$$$250$$$O	Also$$$251$$$255$$$O	provided$$$256$$$264$$$O	are$$$265$$$268$$$O	pharmaceutical$$$269$$$283$$$O	compositions$$$284$$$296$$$O	containing$$$297$$$307$$$O	these$$$308$$$313$$$O	compounds$$$314$$$323$$$O	and/or$$$324$$$330$$$O	prodrugs$$$331$$$339$$$O	of$$$340$$$342$$$O	these$$$343$$$348$$$O	compounds$$$349$$$358$$$O	and$$$359$$$362$$$O	a$$$363$$$364$$$O	physiologically$$$365$$$380$$$O	compatible$$$381$$$391$$$O	carrier.$$$392$$$400$$$O	These$$$401$$$406$$$O	compounds$$$407$$$416$$$O	are$$$417$$$420$$$O	specifically$$$421$$$433$$$O	useful$$$434$$$440$$$O	for$$$441$$$444$$$O	inhibiting$$$445$$$455$$$O	beta$$$456$$$460$$$O	amyloid$$$461$$$468$$$O	production,$$$469$$$480$$$O	and$$$481$$$484$$$O	treating$$$485$$$493$$$O	Alzheimer's$$$494$$$505$$$O	Disease,$$$506$$$514$$$O	amyloid$$$515$$$522$$$O	angiopathy,$$$523$$$534$$$O	cerebral$$$535$$$543$$$O	amyloid$$$544$$$551$$$O	angiopathy,$$$552$$$563$$$O	systemic$$$564$$$572$$$O	amyloidosis,$$$573$$$585$$$O	hereditary$$$586$$$596$$$O	cerebral$$$597$$$605$$$O	hemorrhage$$$606$$$616$$$O	with$$$617$$$621$$$O	amyloidosis$$$622$$$633$$$O	of$$$634$$$636$$$O	the$$$637$$$640$$$O	Dutch$$$641$$$646$$$O	type,$$$647$$$652$$$O	inclusion$$$653$$$662$$$O	body$$$663$$$667$$$O	myositis,$$$668$$$677$$$O	mild$$$678$$$682$$$O	cognitive$$$683$$$692$$$O	impairment$$$693$$$703$$$O	(MCI)$$$704$$$709$$$O	and$$$710$$$713$$$O	Down's$$$714$$$720$$$O	syndrome.$$$721$$$730$$$O
US20110076250
Biodegradable$$$0$$$13$$$O	Absorbents$$$14$$$24$$$O	and$$$25$$$28$$$O	Methods$$$29$$$36$$$O	of$$$37$$$39$$$O	Preparation$$$40$$$51$$$O
A$$$0$$$1$$$O	biodegradable$$$2$$$15$$$O	microfiber$$$16$$$26$$$O	absorbent$$$27$$$36$$$O	comprises$$$37$$$46$$$O	a$$$47$$$48$$$O	substantially$$$49$$$62$$$O	homogeneous$$$63$$$74$$$O	mixture$$$75$$$82$$$O	of$$$83$$$85$$$O	at$$$86$$$88$$$O	least$$$89$$$94$$$O	one$$$95$$$98$$$O	hydrophilic$$$99$$$110$$$O	polymer$$$111$$$118$$$O	and$$$119$$$122$$$O	at$$$123$$$125$$$O	least$$$126$$$131$$$O	one$$$132$$$135$$$O	biodegradable$$$136$$$149$$$O	polymer.$$$150$$$158$$$O	The$$$159$$$162$$$O	absorbent$$$163$$$172$$$O	can$$$173$$$176$$$O	be$$$177$$$179$$$O	prepared$$$180$$$188$$$O	by$$$189$$$191$$$O	an$$$192$$$194$$$O	electro$$$195$$$202$$$O	hydrodynamic$$$203$$$215$$$O	spinning$$$216$$$224$$$O	of$$$225$$$227$$$O	a$$$228$$$229$$$O	substantially$$$230$$$243$$$O	homogeneous$$$244$$$255$$$O	polymer$$$256$$$263$$$O	mixture.$$$264$$$272$$$O	Medical$$$273$$$280$$$O	dressings$$$281$$$290$$$O	for$$$291$$$294$$$O	burns$$$295$$$300$$$O	and$$$301$$$304$$$O	wounds,$$$305$$$312$$$O	cavity$$$313$$$319$$$O	dressings,$$$320$$$330$$$O	drug$$$331$$$335$$$O	delivery$$$336$$$344$$$O	patches,$$$345$$$353$$$O	face$$$354$$$358$$$O	masks,$$$359$$$365$$$O	implants,$$$366$$$375$$$O	drug$$$376$$$380$$$O	carriers$$$381$$$389$$$O	that$$$390$$$394$$$O	comprises$$$395$$$404$$$O	at$$$405$$$407$$$O	least$$$408$$$413$$$O	one$$$414$$$417$$$O	microfiber$$$418$$$428$$$O	electrospun$$$429$$$440$$$O	from$$$441$$$445$$$O	a$$$446$$$447$$$O	polymer$$$448$$$455$$$O	mixture$$$456$$$463$$$O	are$$$464$$$467$$$O	provided.$$$468$$$477$$$O	The$$$478$$$481$$$O	dressings$$$482$$$491$$$O	can$$$492$$$495$$$O	have$$$496$$$500$$$O	variable$$$501$$$509$$$O	water$$$510$$$515$$$O	vapor$$$516$$$521$$$O	penetration$$$522$$$533$$$O	characteristics$$$534$$$549$$$O	and$$$550$$$553$$$O	variable$$$554$$$562$$$O	biodegradation$$$563$$$577$$$O	times.$$$578$$$584$$$O
WO2009005674A3
Novel$$$0$$$5$$$O	hiv$$$6$$$9$$$O	reverse$$$10$$$17$$$O	transcriptase$$$18$$$31$$$O	inhibitors$$$32$$$42$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	related$$$17$$$24$$$O	to$$$25$$$27$$$O	compounds$$$28$$$37$$$O	of$$$38$$$40$$$O	Formula$$$41$$$48$$$O	(I)$$$49$$$52$$$O	or$$$53$$$55$$$O	a$$$56$$$57$$$O	pharmaceutically$$$58$$$74$$$O	acceptable$$$75$$$85$$$O	salt,$$$86$$$91$$$O	solvate,$$$92$$$100$$$O	ester,$$$101$$$107$$$O	and/$$$108$$$112$$$O	or$$$113$$$115$$$O	phosphonate$$$116$$$127$$$I	thereof,$$$128$$$136$$$O	compositions$$$137$$$149$$$O	containing$$$150$$$160$$$O	such$$$161$$$165$$$O	compounds,$$$166$$$176$$$O	and$$$177$$$180$$$O	therapeutic$$$181$$$192$$$O	methods$$$193$$$200$$$O	that$$$201$$$205$$$O	include$$$206$$$213$$$O	the$$$214$$$217$$$O	administration$$$218$$$232$$$O	of$$$233$$$235$$$O	such$$$236$$$240$$$O	compounds.$$$241$$$251$$$O
US20120214860
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	regulating$$$10$$$20$$$O	the$$$21$$$24$$$O	expression$$$25$$$35$$$O	level$$$36$$$41$$$O	of$$$42$$$44$$$O	survival$$$45$$$53$$$O	of$$$54$$$56$$$O	motor$$$57$$$62$$$O	neuron$$$63$$$69$$$O	1$$$70$$$71$$$O	(smn1)$$$72$$$78$$$O	and$$$79$$$82$$$O	detecting$$$83$$$92$$$O	enzyme$$$93$$$99$$$O	activity$$$100$$$108$$$O	of$$$109$$$111$$$O	ubiquitin$$$112$$$121$$$O	carboxyl-terminal$$$122$$$139$$$I	hydrolase$$$140$$$149$$$O	l1$$$150$$$152$$$O	(uchl1)$$$153$$$160$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	of$$$42$$$44$$$O	regulating$$$45$$$55$$$O	the$$$56$$$59$$$O	expression$$$60$$$70$$$O	level$$$71$$$76$$$O	of$$$77$$$79$$$O	survival$$$80$$$88$$$O	of$$$89$$$91$$$O	motor$$$92$$$97$$$O	neuron$$$98$$$104$$$O	1$$$105$$$106$$$O	(SMN1)$$$107$$$113$$$O	comprising$$$114$$$124$$$O	administering$$$125$$$138$$$O	to$$$139$$$141$$$O	a$$$142$$$143$$$O	subject$$$144$$$151$$$O	in$$$152$$$154$$$O	need$$$155$$$159$$$O	thereof$$$160$$$167$$$O	a$$$168$$$169$$$O	therapeutically$$$170$$$185$$$O	effective$$$186$$$195$$$O	amount$$$196$$$202$$$O	of$$$203$$$205$$$O	ubiquitin$$$206$$$215$$$O	carboxyl-terminal$$$216$$$233$$$I	hydrolase$$$234$$$243$$$O	L1$$$244$$$246$$$O	(UCHL1)$$$247$$$254$$$O	regulator$$$255$$$264$$$O	and$$$265$$$268$$$O	a$$$269$$$270$$$O	pharmaceutically$$$271$$$287$$$O	acceptable$$$288$$$298$$$O	carrier.$$$299$$$307$$$O	The$$$308$$$311$$$O	present$$$312$$$319$$$O	invention$$$320$$$329$$$O	also$$$330$$$334$$$O	relates$$$335$$$342$$$O	to$$$343$$$345$$$O	a$$$346$$$347$$$O	method$$$348$$$354$$$O	of$$$355$$$357$$$O	detecting$$$358$$$367$$$O	enzyme$$$368$$$374$$$O	activity$$$375$$$383$$$O	of$$$384$$$386$$$O	ubiquitin$$$387$$$396$$$O	carboxyl-terminal$$$397$$$414$$$I	hydrolase$$$415$$$424$$$O	L1$$$425$$$427$$$O	(UCHL1)$$$428$$$435$$$O	in$$$436$$$438$$$O	human$$$439$$$444$$$O	fibroblasts$$$445$$$456$$$O	comprising$$$457$$$467$$$O	detecting$$$468$$$477$$$O	protein$$$478$$$485$$$O	expression$$$486$$$496$$$O	level$$$497$$$502$$$O	of$$$503$$$505$$$O	survival$$$506$$$514$$$O	of$$$515$$$517$$$O	motor$$$518$$$523$$$O	neuron$$$524$$$530$$$O	1$$$531$$$532$$$O	(SMN1).$$$533$$$540$$$O
US20080003275
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	Premature$$$13$$$22$$$O	Ejaculation$$$23$$$34$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	methods$$$25$$$32$$$O	and$$$33$$$36$$$O	compositions$$$37$$$49$$$O	for$$$50$$$53$$$O	treating$$$54$$$62$$$O	premature$$$63$$$72$$$O	ejaculation$$$73$$$84$$$O	in$$$85$$$87$$$O	a$$$88$$$89$$$O	male$$$90$$$94$$$O	or$$$95$$$97$$$O	prolonging$$$98$$$108$$$O	intercourse$$$109$$$120$$$O	comprising$$$121$$$131$$$O	administering$$$132$$$145$$$O	to$$$146$$$148$$$O	the$$$149$$$152$$$O	male$$$153$$$157$$$O	an$$$158$$$160$$$O	antidepressant$$$161$$$175$$$O	via$$$176$$$179$$$O	a$$$180$$$181$$$O	route$$$182$$$187$$$O	selected$$$188$$$196$$$O	from$$$197$$$201$$$O	the$$$202$$$205$$$O	group$$$206$$$211$$$O	consisting$$$212$$$222$$$O	of$$$223$$$225$$$O	mucosal$$$226$$$233$$$O	administration$$$234$$$248$$$O	(preferably$$$249$$$260$$$O	nasal,$$$261$$$267$$$O	buccal$$$268$$$274$$$O	or$$$275$$$277$$$O	rectal),$$$278$$$286$$$O	administration$$$287$$$301$$$O	to$$$302$$$304$$$O	the$$$305$$$308$$$O	lungs$$$309$$$314$$$O	(preferably$$$315$$$326$$$O	by$$$327$$$329$$$O	inhalation),$$$330$$$342$$$O	local$$$343$$$348$$$O	administration$$$349$$$363$$$O	to$$$364$$$366$$$O	at$$$367$$$369$$$O	least$$$370$$$375$$$O	a$$$376$$$377$$$O	part$$$378$$$382$$$O	of$$$383$$$385$$$O	the$$$386$$$389$$$O	male$$$390$$$394$$$O	genitalia$$$395$$$404$$$O	(applied$$$405$$$413$$$O	to$$$414$$$416$$$O	the$$$417$$$420$$$O	penis$$$421$$$426$$$O	for$$$427$$$430$$$O	example,$$$431$$$439$$$O	in$$$440$$$442$$$O	the$$$443$$$446$$$O	form$$$447$$$451$$$O	of$$$452$$$454$$$O	a$$$455$$$456$$$O	gel)$$$457$$$461$$$O	and$$$462$$$465$$$O	combinations$$$466$$$478$$$O	thereof.$$$479$$$487$$$O
CN102228540A
Externally$$$0$$$10$$$O	applied$$$11$$$18$$$O	liquid$$$19$$$25$$$O	medicine$$$26$$$34$$$O	for$$$35$$$38$$$O	treating$$$39$$$47$$$O	burns$$$48$$$53$$$O	and$$$54$$$57$$$O	scalds$$$58$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	externally$$$27$$$37$$$O	applied$$$38$$$45$$$O	liquid$$$46$$$52$$$O	medicine$$$53$$$61$$$O	for$$$62$$$65$$$O	treating$$$66$$$74$$$O	burns$$$75$$$80$$$O	and$$$81$$$84$$$O	scalds.$$$85$$$92$$$O	The$$$93$$$96$$$O	raw$$$97$$$100$$$O	materials$$$101$$$110$$$O	used$$$111$$$115$$$O	for$$$116$$$119$$$O	the$$$120$$$123$$$O	preparation$$$124$$$135$$$O	of$$$136$$$138$$$O	the$$$139$$$142$$$O	medicine$$$143$$$151$$$O	comprise$$$152$$$160$$$O	8$$$161$$$162$$$O	to$$$163$$$165$$$O	12$$$166$$$168$$$O	g$$$169$$$170$$$O	of$$$171$$$173$$$O	Sargentodoxa$$$174$$$186$$$O	cuneata,$$$187$$$195$$$O	8$$$196$$$197$$$O	to$$$198$$$200$$$O	12$$$201$$$203$$$O	g$$$204$$$205$$$O	of$$$206$$$208$$$O	rheum$$$209$$$214$$$O	officinale,$$$215$$$226$$$O	8$$$227$$$228$$$O	to$$$229$$$231$$$O	12$$$232$$$234$$$O	g$$$235$$$236$$$O	of$$$237$$$239$$$O	coptis,$$$240$$$247$$$O	8$$$248$$$249$$$O	to$$$250$$$252$$$O	12$$$253$$$255$$$O	g$$$256$$$257$$$O	of$$$258$$$260$$$O	lithospermum,$$$261$$$274$$$O	8$$$275$$$276$$$O	to$$$277$$$279$$$O	12$$$280$$$282$$$O	g$$$283$$$284$$$O	of$$$285$$$287$$$O	garden$$$288$$$294$$$O	burnet,$$$295$$$302$$$O	8$$$303$$$304$$$O	to$$$305$$$307$$$O	12$$$308$$$310$$$O	g$$$311$$$312$$$O	of$$$313$$$315$$$O	honeysuckle$$$316$$$327$$$O	flower,$$$328$$$335$$$O	8$$$336$$$337$$$O	to$$$338$$$340$$$O	12$$$341$$$343$$$O	g$$$344$$$345$$$O	of$$$346$$$348$$$O	gentrin$$$349$$$356$$$O	knotweed,$$$357$$$366$$$O	4$$$367$$$368$$$O	to$$$369$$$371$$$O	6$$$372$$$373$$$O	g$$$374$$$375$$$O	of$$$376$$$378$$$O	pseudo-ginseng,$$$379$$$394$$$O	4$$$395$$$396$$$O	to6$$$397$$$400$$$O	g$$$401$$$402$$$O	of$$$403$$$405$$$O	safflower,$$$406$$$416$$$O	4$$$417$$$418$$$O	to$$$419$$$421$$$O	6$$$422$$$423$$$O	g$$$424$$$425$$$O	of$$$426$$$428$$$O	dahurian$$$429$$$437$$$O	angelica$$$438$$$446$$$O	root,$$$447$$$452$$$O	4$$$453$$$454$$$O	to$$$455$$$457$$$O	6$$$458$$$459$$$O	g$$$460$$$461$$$O	of$$$462$$$464$$$O	catechu$$$465$$$472$$$O	and$$$473$$$476$$$O	950$$$477$$$480$$$O	to$$$481$$$483$$$O	1050$$$484$$$488$$$O	g$$$489$$$490$$$O	of$$$491$$$493$$$O	liquor.$$$494$$$501$$$O	The$$$502$$$505$$$O	liquid$$$506$$$512$$$O	medicine$$$513$$$521$$$O	provided$$$522$$$530$$$O	in$$$531$$$533$$$O	the$$$534$$$537$$$O	invention$$$538$$$547$$$O	has$$$548$$$551$$$O	the$$$552$$$555$$$O	effects$$$556$$$563$$$O	of$$$564$$$566$$$O	clearing$$$567$$$575$$$O	heat,$$$576$$$581$$$O	cooling$$$582$$$589$$$O	blood,$$$590$$$596$$$O	invigorating$$$597$$$609$$$O	blood$$$610$$$615$$$O	circulation,$$$616$$$628$$$O	eliminating$$$629$$$640$$$O	inflammation,$$$641$$$654$$$O	relieving$$$655$$$664$$$O	pain,$$$665$$$670$$$O	stopping$$$671$$$679$$$O	bleeding$$$680$$$688$$$O	and$$$689$$$692$$$O	engendering$$$693$$$704$$$O	flesh,$$$705$$$711$$$O	has$$$712$$$715$$$O	a$$$716$$$717$$$O	100%$$$718$$$722$$$O	curative$$$723$$$731$$$O	rate$$$732$$$736$$$O	and$$$737$$$740$$$O	enables$$$741$$$748$$$O	no$$$749$$$751$$$O	scar$$$752$$$756$$$O	after$$$757$$$762$$$O	treatment$$$763$$$772$$$O	to$$$773$$$775$$$O	leave.$$$776$$$782$$$O
CN1813731A
Terfenadine$$$0$$$11$$$I	dropping$$$12$$$20$$$O	pill$$$21$$$25$$$O	and$$$26$$$29$$$O	its$$$30$$$33$$$O	preparing$$$34$$$43$$$O	method$$$44$$$50$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	a$$$32$$$33$$$O	medicine$$$34$$$42$$$O	terfenadine$$$43$$$54$$$I	dripping$$$55$$$63$$$O	pills$$$64$$$69$$$O	preparation$$$70$$$81$$$O	for$$$82$$$85$$$O	effectively$$$86$$$97$$$O	curing$$$98$$$104$$$O	the$$$105$$$108$$$O	diseases$$$109$$$117$$$O	of$$$118$$$120$$$O	seasonal$$$121$$$129$$$O	and$$$130$$$133$$$O	non-seasonal$$$134$$$146$$$O	allergic$$$147$$$155$$$O	rhinitis,$$$156$$$165$$$O	urticaria$$$166$$$175$$$O	and$$$176$$$179$$$O	hay$$$180$$$183$$$O	fever$$$184$$$189$$$O	and$$$190$$$193$$$O	its$$$194$$$197$$$O	preparation$$$198$$$209$$$O	process.$$$210$$$218$$$O	It$$$219$$$221$$$O	is$$$222$$$224$$$O	made$$$225$$$229$$$O	up$$$230$$$232$$$O	by$$$233$$$235$$$O	using$$$236$$$241$$$O	terfenadine$$$242$$$253$$$I	and$$$254$$$257$$$O	matrix$$$258$$$264$$$O	for$$$265$$$268$$$O	making$$$269$$$275$$$O	dripping$$$276$$$284$$$O	pills.$$$285$$$291$$$O
US7846967
isolated$$$0$$$8$$$O	from$$$9$$$13$$$O	Cnidium$$$14$$$21$$$O	officinale$$$22$$$32$$$O	and$$$33$$$36$$$O	Ligusticum$$$37$$$47$$$O	chuanxiong;$$$48$$$59$$$O	inhibiting$$$60$$$70$$$O	melanocyte-stimulating$$$71$$$93$$$O	hormone$$$94$$$101$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	cosmetic$$$33$$$41$$$O	compositions$$$42$$$54$$$O	and$$$55$$$58$$$O	more$$$59$$$63$$$O	particularly$$$64$$$76$$$O	to$$$77$$$79$$$O	skin-whitening$$$80$$$94$$$O	cosmetic$$$95$$$103$$$O	compositions$$$104$$$116$$$O	comprising$$$117$$$127$$$O	senkyunolide$$$128$$$140$$$I	A$$$141$$$142$$$I	as$$$143$$$145$$$O	an$$$146$$$148$$$O	active$$$149$$$155$$$O	ingredient.$$$156$$$167$$$O	The$$$168$$$171$$$O	present$$$172$$$179$$$O	invention$$$180$$$189$$$O	discloses$$$190$$$199$$$O	the$$$200$$$203$$$O	novel$$$204$$$209$$$O	inhibitory$$$210$$$220$$$O	function$$$221$$$229$$$O	of$$$230$$$232$$$O	senkyunolide$$$233$$$245$$$I	A$$$246$$$247$$$I	isolated$$$248$$$256$$$O	from$$$257$$$261$$$O	Cnidium$$$262$$$269$$$O	officinale$$$270$$$280$$$O	and$$$281$$$284$$$O	Ligusticum$$$285$$$295$$$O	chuanxiong$$$296$$$306$$$O	on$$$307$$$309$$$O	the$$$310$$$313$$$O	melanocyte-stimulating$$$314$$$336$$$O	hormone$$$337$$$344$$$O	(MSH),$$$345$$$351$$$O	and$$$352$$$355$$$O	provides$$$356$$$364$$$O	MSH-inhibitory$$$365$$$379$$$O	compositions$$$380$$$392$$$O	and$$$393$$$396$$$O	skin-whitening$$$397$$$411$$$O	cosmetic$$$412$$$420$$$O	compositions$$$421$$$433$$$O	comprising$$$434$$$444$$$O	the$$$445$$$448$$$O	senkyunolide$$$449$$$461$$$I	A.$$$462$$$464$$$I	The$$$465$$$468$$$O	compositions$$$469$$$481$$$O	of$$$482$$$484$$$O	the$$$485$$$488$$$O	present$$$489$$$496$$$O	invention$$$497$$$506$$$O	show$$$507$$$511$$$O	significantly$$$512$$$525$$$O	enhanced$$$526$$$534$$$O	skin-whitening$$$535$$$549$$$O	effect$$$550$$$556$$$O	owing$$$557$$$562$$$O	to$$$563$$$565$$$O	its$$$566$$$569$$$O	efficient$$$570$$$579$$$O	inhibition$$$580$$$590$$$O	of$$$591$$$593$$$O	MSH$$$594$$$597$$$O	even$$$598$$$602$$$O	in$$$603$$$605$$$O	lower$$$606$$$611$$$O	concentration.$$$612$$$626$$$O
US20120219527
Compositions$$$0$$$12$$$O	for$$$13$$$16$$$O	reducing$$$17$$$25$$$O	gastro-intestinal$$$26$$$43$$$O	methanogenesis$$$44$$$58$$$O	in$$$59$$$61$$$O	ruminants$$$62$$$71$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	concerns$$$22$$$30$$$O	the$$$31$$$34$$$O	reduction$$$35$$$44$$$O	of$$$45$$$47$$$O	gastro-intestinal$$$48$$$65$$$O	methanogenesis$$$66$$$80$$$O	in$$$81$$$83$$$O	ruminants$$$84$$$93$$$O	with$$$94$$$98$$$O	the$$$99$$$102$$$O	aid$$$103$$$106$$$O	of$$$107$$$109$$$O	agents$$$110$$$116$$$O	that$$$117$$$121$$$O	compete$$$122$$$129$$$O	for$$$130$$$133$$$O	the$$$134$$$137$$$O	hydrogen$$$138$$$146$$$I	atoms$$$147$$$152$$$O	required$$$153$$$161$$$O	by$$$162$$$164$$$O	methanogens$$$165$$$176$$$O	during$$$177$$$183$$$O	normal$$$184$$$190$$$O	fermentation$$$191$$$203$$$O	of$$$204$$$206$$$O	ingested$$$207$$$215$$$O	feed.$$$216$$$221$$$O	The$$$222$$$225$$$O	invention$$$226$$$235$$$O	in$$$236$$$238$$$O	one$$$239$$$242$$$O	aspect$$$243$$$249$$$O	resides$$$250$$$257$$$O	in$$$258$$$260$$$O	the$$$261$$$264$$$O	findings$$$265$$$273$$$O	that$$$274$$$278$$$O	both$$$279$$$283$$$O	nitrate$$$284$$$291$$$I	reductive$$$292$$$301$$$O	pathways$$$302$$$310$$$O	as$$$311$$$313$$$O	well$$$314$$$318$$$O	as$$$319$$$321$$$O	sulphate$$$322$$$330$$$I	reductive$$$331$$$340$$$O	pathways$$$341$$$349$$$O	outcompete$$$350$$$360$$$O	gastro-intestinal$$$361$$$378$$$O	methanogenesis$$$379$$$393$$$O	in$$$394$$$396$$$O	ruminants$$$397$$$406$$$O	and,$$$407$$$411$$$O	that$$$412$$$416$$$O	the$$$417$$$420$$$O	methanogenesis$$$421$$$435$$$O	reducing$$$436$$$444$$$O	effects$$$445$$$452$$$O	of$$$453$$$455$$$O	nitrate$$$456$$$463$$$I	and$$$464$$$467$$$O	sulphate$$$468$$$476$$$I	are$$$477$$$480$$$O	completely$$$481$$$491$$$O	additive.$$$492$$$501$$$O	At$$$502$$$504$$$O	the$$$505$$$508$$$O	same$$$509$$$513$$$O	time$$$514$$$518$$$O	the$$$519$$$522$$$O	combined$$$523$$$531$$$O	administration$$$532$$$546$$$O	of$$$547$$$549$$$O	nitrate$$$550$$$557$$$I	and$$$558$$$561$$$O	sulphate$$$562$$$570$$$I	was$$$571$$$574$$$O	found$$$575$$$580$$$O	to$$$581$$$583$$$O	be$$$584$$$586$$$O	fully$$$587$$$592$$$O	effective$$$593$$$602$$$O	to$$$603$$$605$$$O	avoid$$$606$$$611$$$O	or$$$612$$$614$$$O	mitigate$$$615$$$623$$$O	the$$$624$$$627$$$O	potential$$$628$$$637$$$O	problems$$$638$$$646$$$O	of$$$647$$$649$$$O	nitrite$$$650$$$657$$$I	intoxication$$$658$$$670$$$O	normally$$$671$$$679$$$O	encountered$$$680$$$691$$$O	when$$$692$$$696$$$O	using$$$697$$$702$$$O	nitrate$$$703$$$710$$$I	alone,$$$711$$$717$$$O	which$$$718$$$723$$$O	effect$$$724$$$730$$$O	is$$$731$$$733$$$O	further$$$734$$$741$$$O	enhanced,$$$742$$$751$$$O	where$$$752$$$757$$$O	necessary,$$$758$$$768$$$O	by$$$769$$$771$$$O	the$$$772$$$775$$$O	addition$$$776$$$784$$$O	of$$$785$$$787$$$O	a$$$788$$$789$$$O	nitrite$$$790$$$797$$$I	reducing$$$798$$$806$$$O	probiotic$$$807$$$816$$$O	micoroorganism.$$$817$$$832$$$O	Hence,$$$833$$$839$$$O	products$$$840$$$848$$$O	are$$$849$$$852$$$O	provided$$$853$$$861$$$O	comprising$$$862$$$872$$$O	high$$$873$$$877$$$O	amounts$$$878$$$885$$$O	of$$$886$$$888$$$O	a$$$889$$$890$$$O	combination$$$891$$$902$$$O	of$$$903$$$905$$$O	a$$$906$$$907$$$O	nitrate$$$908$$$915$$$I	compound$$$916$$$924$$$O	and$$$925$$$928$$$O	a$$$929$$$930$$$O	sulphate$$$931$$$939$$$I	compound$$$940$$$948$$$O	and$$$949$$$952$$$O	optionally$$$953$$$963$$$O	a$$$964$$$965$$$O	nitrite$$$966$$$973$$$I	reducing$$$974$$$982$$$O	probiotic$$$983$$$992$$$O	microorganism,$$$993$$$1007$$$O	as$$$1008$$$1010$$$O	well$$$1011$$$1015$$$O	as$$$1016$$$1018$$$O	methods$$$1019$$$1026$$$O	of$$$1027$$$1029$$$O	reducing$$$1030$$$1038$$$O	gastro-intestinal$$$1039$$$1056$$$O	methanogenesis$$$1057$$$1071$$$O	in$$$1072$$$1074$$$O	ruminants$$$1075$$$1084$$$O	using$$$1085$$$1090$$$O	such$$$1091$$$1095$$$O	compositions.$$$1096$$$1109$$$O
CA2437603C
Fluoroether$$$0$$$11$$$I	compositions$$$12$$$24$$$O	and$$$25$$$28$$$O	methods$$$29$$$36$$$O	for$$$37$$$40$$$O	inhibiting$$$41$$$51$$$O	their$$$52$$$57$$$O	degradation$$$58$$$69$$$O	in$$$70$$$72$$$O	the$$$73$$$76$$$O	presence$$$77$$$85$$$O	of$$$86$$$88$$$O	a$$$89$$$90$$$O	lewis$$$91$$$96$$$I	acid$$$97$$$101$$$I
Degradation$$$0$$$11$$$O	of$$$12$$$14$$$O	a$$$15$$$16$$$O	Lewis$$$17$$$22$$$I	acid$$$23$$$27$$$I	by$$$28$$$30$$$O	a$$$31$$$32$$$O	quantity$$$33$$$41$$$O	of$$$42$$$44$$$O	sevoflurane$$$45$$$56$$$I	is$$$57$$$59$$$O	provided$$$60$$$68$$$O	by$$$69$$$71$$$O	combining$$$72$$$81$$$O	the$$$82$$$85$$$O	quantity$$$86$$$94$$$O	of$$$95$$$97$$$O	sevoflurane$$$98$$$109$$$I	with$$$110$$$114$$$O	a$$$115$$$116$$$O	Lewis$$$117$$$122$$$I	acid$$$123$$$127$$$I	inhibitor,$$$128$$$138$$$O	for$$$139$$$142$$$O	example,$$$143$$$151$$$O	water,$$$152$$$158$$$O	butylated$$$159$$$168$$$I	hydroxytoluene,$$$169$$$184$$$I	methylparaben,$$$185$$$199$$$I	propylparben,$$$200$$$213$$$I	propofol$$$214$$$222$$$I	and$$$223$$$226$$$O	thymol.$$$227$$$234$$$I	A$$$235$$$236$$$O	method$$$237$$$243$$$O	of$$$244$$$246$$$O	the$$$247$$$250$$$O	invention$$$251$$$260$$$O	involves$$$261$$$269$$$O	a$$$270$$$271$$$O	method$$$272$$$278$$$O	for$$$279$$$282$$$O	storing$$$283$$$290$$$O	a$$$291$$$292$$$O	quantity$$$293$$$301$$$O	of$$$302$$$304$$$O	sevoflurane,$$$305$$$317$$$I	the$$$318$$$321$$$O	method$$$322$$$328$$$O	comprising$$$329$$$339$$$O	the$$$340$$$343$$$O	steps$$$344$$$349$$$O	of$$$350$$$352$$$O	providing$$$353$$$362$$$O	a$$$363$$$364$$$O	container$$$365$$$374$$$O	defining$$$375$$$383$$$O	an$$$384$$$386$$$O	interior$$$387$$$395$$$O	space,$$$396$$$402$$$O	the$$$403$$$406$$$O	container$$$407$$$416$$$O	having$$$417$$$423$$$O	an$$$424$$$426$$$O	interior$$$427$$$435$$$O	wall$$$436$$$440$$$O	adjacent$$$441$$$449$$$O	the$$$450$$$453$$$O	interior$$$454$$$462$$$O	space$$$463$$$468$$$O	defined$$$469$$$476$$$O	by$$$477$$$479$$$O	the$$$480$$$483$$$O	container;$$$484$$$494$$$O	providing$$$495$$$504$$$O	a$$$505$$$506$$$O	quantity$$$507$$$515$$$O	of$$$516$$$518$$$O	sevoflurane;$$$519$$$531$$$I	coating$$$532$$$539$$$O	the$$$540$$$543$$$O	interior$$$544$$$552$$$O	wall$$$553$$$557$$$O	of$$$558$$$560$$$O	the$$$561$$$564$$$O	container$$$565$$$574$$$O	with$$$575$$$579$$$O	the$$$580$$$583$$$O	Lewis$$$584$$$589$$$I	acid$$$590$$$594$$$I	inhibitor;$$$595$$$605$$$O	placing$$$606$$$613$$$O	the$$$614$$$617$$$O	quantity$$$618$$$626$$$O	of$$$627$$$629$$$O	sevoflurane$$$630$$$641$$$I	in$$$642$$$644$$$O	the$$$645$$$648$$$O	interior$$$649$$$657$$$O	space$$$658$$$663$$$O	defined$$$664$$$671$$$O	by$$$672$$$674$$$O	the$$$675$$$678$$$O	container.$$$679$$$689$$$O
EP2453746A1
Tazarotene$$$0$$$10$$$I	derivatives$$$11$$$22$$$O
The$$$0$$$3$$$O	presently$$$4$$$13$$$O	described$$$14$$$23$$$O	subject$$$24$$$31$$$O	matter$$$32$$$38$$$O	relates$$$39$$$46$$$O	to$$$47$$$49$$$O	new$$$50$$$53$$$O	derivatives$$$54$$$65$$$O	of$$$66$$$68$$$O	tazarotene$$$69$$$79$$$I	that$$$80$$$84$$$O	also$$$85$$$89$$$O	exhibit$$$90$$$97$$$O	retinoid$$$98$$$106$$$O	activity,$$$107$$$116$$$O	pharmaceutical$$$117$$$131$$$O	compositions$$$132$$$144$$$O	comprising$$$145$$$155$$$O	the$$$156$$$159$$$O	derivatives,$$$160$$$172$$$O	method$$$173$$$179$$$O	of$$$180$$$182$$$O	treating$$$183$$$191$$$O	skin$$$192$$$196$$$O	disorders$$$197$$$206$$$O	with$$$207$$$211$$$O	the$$$212$$$215$$$O	pharmaceutical$$$216$$$230$$$O	compositions,$$$231$$$244$$$O	and$$$245$$$248$$$O	process$$$249$$$256$$$O	of$$$257$$$259$$$O	making$$$260$$$266$$$O	the$$$267$$$270$$$O	derivatives.$$$271$$$283$$$O
CN102579325A
Ethaselen$$$0$$$9$$$I	intravenous$$$10$$$21$$$O	injection$$$22$$$31$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	formula$$$27$$$34$$$O	and$$$35$$$38$$$O	a$$$39$$$40$$$O	preparation$$$41$$$52$$$O	method$$$53$$$59$$$O	of$$$60$$$62$$$O	an$$$63$$$65$$$O	ethaselen$$$66$$$75$$$I	intravenous$$$76$$$87$$$O	injection.$$$88$$$98$$$O	The$$$99$$$102$$$O	formula$$$103$$$110$$$O	comprises$$$111$$$120$$$O	an$$$121$$$123$$$O	active$$$124$$$130$$$O	component$$$131$$$140$$$O	and$$$141$$$144$$$O	auxiliary$$$145$$$154$$$O	materials,$$$155$$$165$$$O	wherein$$$166$$$173$$$O	the$$$174$$$177$$$O	active$$$178$$$184$$$O	component$$$185$$$194$$$O	is$$$195$$$197$$$O	ethaselen$$$198$$$207$$$I	or$$$208$$$210$$$O	analogue$$$211$$$219$$$O	thereof,$$$220$$$228$$$O	and$$$229$$$232$$$O	the$$$233$$$236$$$O	auxiliary$$$237$$$246$$$O	materials$$$247$$$256$$$O	include$$$257$$$264$$$O	stabilizing$$$265$$$276$$$O	agents$$$277$$$283$$$O	and$$$284$$$287$$$O	an$$$288$$$290$$$O	organic$$$291$$$298$$$O	solvent.$$$299$$$307$$$O	The$$$308$$$311$$$O	active$$$312$$$318$$$O	component$$$319$$$328$$$O	and$$$329$$$332$$$O	the$$$333$$$336$$$O	auxiliary$$$337$$$346$$$O	materials$$$347$$$356$$$O	are$$$357$$$360$$$O	prepared$$$361$$$369$$$O	into$$$370$$$374$$$O	an$$$375$$$377$$$O	injection$$$378$$$387$$$O	which$$$388$$$393$$$O	is$$$394$$$396$$$O	used$$$397$$$401$$$O	for$$$402$$$405$$$O	intravenous$$$406$$$417$$$O	injection$$$418$$$427$$$O	after$$$428$$$433$$$O	being$$$434$$$439$$$O	diluted$$$440$$$447$$$O	appropriately$$$448$$$461$$$O	during$$$462$$$468$$$O	clinical$$$469$$$477$$$O	use.$$$478$$$482$$$O
CN1895598B
Chinese-medicinal$$$0$$$17$$$O	powder$$$18$$$24$$$O	for$$$25$$$28$$$O	nourishing$$$29$$$39$$$O	kidney$$$40$$$46$$$O	of$$$47$$$49$$$O	fowl$$$50$$$54$$$O
A$$$0$$$1$$$O	fowl$$$2$$$6$$$O	Chinese-medicinal$$$7$$$24$$$O	powder$$$25$$$31$$$O	for$$$32$$$35$$$O	nourishing$$$36$$$46$$$O	kidney$$$47$$$53$$$O	and$$$54$$$57$$$O	protecting$$$58$$$68$$$O	liver$$$69$$$74$$$O	relates$$$75$$$82$$$O	to$$$83$$$85$$$O	a$$$86$$$87$$$O	fowl$$$88$$$92$$$O	Chinese-medicinal$$$93$$$110$$$O	powder,$$$111$$$118$$$O	and$$$119$$$122$$$O	is$$$123$$$125$$$O	especially$$$126$$$136$$$O	suitable$$$137$$$145$$$O	for$$$146$$$149$$$O	preventing$$$150$$$160$$$O	and$$$161$$$164$$$O	treating$$$165$$$173$$$O	the$$$174$$$177$$$O	renal$$$178$$$183$$$O	swelling$$$184$$$192$$$O	and$$$193$$$196$$$O	hepatitis$$$197$$$206$$$O	of$$$207$$$209$$$O	domestic$$$210$$$218$$$O	fowls$$$219$$$224$$$O	is$$$225$$$227$$$O	prepared$$$228$$$236$$$O	from$$$237$$$241$$$O	7$$$242$$$243$$$O	Chinese-medicinal$$$244$$$261$$$O	materials$$$262$$$271$$$O	including,$$$272$$$282$$$O	by$$$283$$$285$$$O	weight,$$$286$$$293$$$O	5-20$$$294$$$298$$$O	parts$$$299$$$304$$$O	of$$$305$$$307$$$O	rhubarb,$$$308$$$316$$$O	5-20$$$317$$$321$$$O	parts$$$322$$$327$$$O	of$$$328$$$330$$$O	burreed$$$331$$$338$$$O	tuber,$$$339$$$345$$$O	10-30$$$346$$$351$$$O	parts$$$352$$$357$$$O	of$$$358$$$360$$$O	long$$$361$$$365$$$O	tube$$$366$$$370$$$O	ground$$$371$$$377$$$O	ivy$$$378$$$381$$$O	herb,$$$382$$$387$$$O	5-15$$$388$$$392$$$O	parts$$$393$$$398$$$O	of$$$399$$$401$$$O	hiraute$$$402$$$409$$$O	shiny$$$410$$$415$$$O	bugleweek$$$416$$$425$$$O	herb,$$$426$$$431$$$O	5-15$$$432$$$436$$$O	parts$$$437$$$442$$$O	of$$$443$$$445$$$O	danshen$$$446$$$453$$$O	root,$$$454$$$459$$$O	5-15$$$460$$$464$$$O	parts$$$465$$$470$$$O	of$$$471$$$473$$$O	borax$$$474$$$479$$$I	and$$$480$$$483$$$O	10-30$$$484$$$489$$$O	parts$$$490$$$495$$$O	of$$$496$$$498$$$O	tiger$$$499$$$504$$$O	stick$$$505$$$510$$$O	through$$$511$$$518$$$O	checking,$$$519$$$528$$$O	washing,$$$529$$$537$$$O	drying,$$$538$$$545$$$O	pulverizing$$$546$$$557$$$O	by$$$558$$$560$$$O	grinder,$$$561$$$569$$$O	sieving$$$570$$$577$$$O	to$$$578$$$580$$$O	reach$$$581$$$586$$$O	the$$$587$$$590$$$O	demand$$$591$$$597$$$O	of$$$598$$$600$$$O	particle$$$601$$$609$$$O	size$$$610$$$614$$$O	20-300$$$615$$$621$$$O	of$$$622$$$624$$$O	the$$$625$$$628$$$O	end$$$629$$$632$$$O	product,$$$633$$$641$$$O	and$$$642$$$645$$$O	proportionally$$$646$$$660$$$O	and$$$661$$$664$$$O	uniformly$$$665$$$674$$$O	mixing$$$675$$$681$$$O	according$$$682$$$691$$$O	to$$$692$$$694$$$O	above$$$695$$$700$$$O	proportion$$$701$$$711$$$O	to$$$712$$$714$$$O	obtain$$$715$$$721$$$O	the$$$722$$$725$$$O	particle$$$726$$$734$$$O	size$$$735$$$739$$$O	20-300$$$740$$$746$$$O	khaki$$$747$$$752$$$O	powder$$$753$$$759$$$O	end$$$760$$$763$$$O	product$$$764$$$771$$$O	which$$$772$$$777$$$O	is$$$778$$$780$$$O	nice$$$781$$$785$$$O	on$$$786$$$788$$$O	smell$$$789$$$794$$$O	and$$$795$$$798$$$O	bitter$$$799$$$805$$$O	on$$$806$$$808$$$O	taste.$$$809$$$815$$$O	The$$$816$$$819$$$O	invention$$$820$$$829$$$O	can$$$830$$$833$$$O	get$$$834$$$837$$$O	an$$$838$$$840$$$O	effect$$$841$$$847$$$O	of$$$848$$$850$$$O	preventing$$$851$$$861$$$O	and$$$862$$$865$$$O	treating$$$866$$$874$$$O	the$$$875$$$878$$$O	renal$$$879$$$884$$$O	swelling$$$885$$$893$$$O	and$$$894$$$897$$$O	hepatitis$$$898$$$907$$$O	of$$$908$$$910$$$O	domestic$$$911$$$919$$$O	fowls.$$$920$$$926$$$O	The$$$927$$$930$$$O	invention$$$931$$$940$$$O	can$$$941$$$944$$$O	improve$$$945$$$952$$$O	the$$$953$$$956$$$O	resistance$$$957$$$967$$$O	ability$$$968$$$975$$$O	of$$$976$$$978$$$O	fowls$$$979$$$984$$$O	and$$$985$$$988$$$O	has$$$989$$$992$$$O	better$$$993$$$999$$$O	treatment$$$1000$$$1009$$$O	and$$$1010$$$1013$$$O	remission$$$1014$$$1023$$$O	effect$$$1024$$$1030$$$O	for$$$1031$$$1034$$$O	renal$$$1035$$$1040$$$O	swelling$$$1041$$$1049$$$O	and$$$1050$$$1053$$$O	kidney$$$1054$$$1060$$$O	disease$$$1061$$$1068$$$O	evocated$$$1069$$$1077$$$O	by$$$1078$$$1080$$$O	a$$$1081$$$1082$$$O	plurality$$$1083$$$1092$$$O	of$$$1093$$$1095$$$O	diseases$$$1096$$$1104$$$O	to$$$1105$$$1107$$$O	achieve$$$1108$$$1115$$$O	an$$$1116$$$1118$$$O	aim$$$1119$$$1122$$$O	of$$$1123$$$1125$$$O	nourishing$$$1126$$$1136$$$O	kidney$$$1137$$$1143$$$O	and$$$1144$$$1147$$$O	protecting$$$1148$$$1158$$$O	liver.$$$1159$$$1165$$$O
EP1896466A1
N-linked$$$0$$$8$$$I	heterocyclic$$$9$$$21$$$I	antagonists$$$22$$$33$$$O	of$$$34$$$36$$$O	p2y1$$$37$$$41$$$O	receptor$$$42$$$50$$$O	useful$$$51$$$57$$$O	in$$$58$$$60$$$O	the$$$61$$$64$$$O	treatment$$$65$$$74$$$O	of$$$75$$$77$$$O	thrombotic$$$78$$$88$$$O	conditions$$$89$$$99$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	novel$$$31$$$36$$$O	ureas$$$37$$$42$$$I	containing$$$43$$$53$$$O	N/-aryl$$$54$$$61$$$I	or$$$62$$$64$$$I	N-heteroaryl$$$65$$$77$$$I	substituted$$$78$$$89$$$I	heterocycles$$$90$$$102$$$I	of$$$103$$$105$$$O	Formula$$$106$$$113$$$O	(I):$$$114$$$118$$$O	or$$$119$$$121$$$O	a$$$122$$$123$$$O	stereoisomer,$$$124$$$137$$$O	tautomer,$$$138$$$147$$$O	pharmaceutically$$$148$$$164$$$O	acceptable$$$165$$$175$$$O	salt$$$176$$$180$$$O	or$$$181$$$183$$$O	solvate$$$184$$$191$$$O	form$$$192$$$196$$$O	thereof,$$$197$$$205$$$O	wherein$$$206$$$213$$$O	the$$$214$$$217$$$O	variables$$$218$$$227$$$O	A,$$$228$$$230$$$O	B,$$$231$$$233$$$O	D$$$234$$$235$$$O	and$$$236$$$239$$$O	W$$$240$$$241$$$O	are$$$242$$$245$$$O	defined$$$246$$$253$$$O	herein.$$$254$$$261$$$O	These$$$262$$$267$$$O	compounds$$$268$$$277$$$O	are$$$278$$$281$$$O	selective$$$282$$$291$$$O	inhibitors$$$292$$$302$$$O	of$$$303$$$305$$$O	the$$$306$$$309$$$O	human$$$310$$$315$$$O	P2Y,$$$316$$$320$$$O	receptor$$$321$$$329$$$O	which$$$330$$$335$$$O	can$$$336$$$339$$$O	be$$$340$$$342$$$O	used$$$343$$$347$$$O	as$$$348$$$350$$$O	medicaments$$$351$$$362$$$O	for$$$363$$$366$$$O	treating$$$367$$$375$$$O	thromboembolic$$$376$$$390$$$O	disorders.$$$391$$$401$$$O
CN103613490A
Drop$$$0$$$4$$$O	diterpenoid$$$5$$$16$$$I	type$$$17$$$21$$$O	compound$$$22$$$30$$$O	as$$$31$$$33$$$O	well$$$34$$$38$$$O	as$$$39$$$41$$$O	preparation$$$42$$$53$$$O	method$$$54$$$60$$$O	and$$$61$$$64$$$O	application$$$65$$$76$$$O	thereof$$$77$$$84$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	insecticides,$$$38$$$51$$$O	bacteriostats$$$52$$$65$$$O	and$$$66$$$69$$$O	tumor$$$70$$$75$$$O	cell$$$76$$$80$$$O	inhibitors,$$$81$$$92$$$O	and$$$93$$$96$$$O	in$$$97$$$99$$$O	particular$$$100$$$110$$$O	relates$$$111$$$118$$$O	to$$$119$$$121$$$O	a$$$122$$$123$$$O	drop$$$124$$$128$$$O	diterpenoid$$$129$$$140$$$I	type$$$141$$$145$$$O	compound$$$146$$$154$$$O	from$$$155$$$159$$$O	seaweed$$$160$$$167$$$O	endophytes$$$168$$$178$$$O	as$$$179$$$181$$$O	well$$$182$$$186$$$O	as$$$187$$$189$$$O	a$$$190$$$191$$$O	preparation$$$192$$$203$$$O	method$$$204$$$210$$$O	and$$$211$$$214$$$O	application$$$215$$$226$$$O	of$$$227$$$229$$$O	the$$$230$$$233$$$O	drop$$$234$$$238$$$O	diterpenoid$$$239$$$250$$$I	type$$$251$$$255$$$O	compound.$$$256$$$265$$$O	The$$$266$$$269$$$O	drop$$$270$$$274$$$O	diterpenoid$$$275$$$286$$$I	type$$$287$$$291$$$O	compound$$$292$$$300$$$O	has$$$301$$$304$$$O	a$$$305$$$306$$$O	structural$$$307$$$317$$$O	formula$$$318$$$325$$$O	shown$$$326$$$331$$$O	by$$$332$$$334$$$O	a$$$335$$$336$$$O	formula$$$337$$$344$$$O	(I).$$$345$$$349$$$O	The$$$350$$$353$$$O	preparation$$$354$$$365$$$O	method$$$366$$$372$$$O	of$$$373$$$375$$$O	the$$$376$$$379$$$O	compound$$$380$$$388$$$O	comprises$$$389$$$398$$$O	the$$$399$$$402$$$O	steps$$$403$$$408$$$O	of$$$409$$$411$$$O	inoculating$$$412$$$423$$$O	Aspergillus$$$424$$$435$$$O	wentii$$$436$$$442$$$O	NA3$$$443$$$446$$$O	to$$$447$$$449$$$O	a$$$450$$$451$$$O	fungus$$$452$$$458$$$O	liquid$$$459$$$465$$$O	culture$$$466$$$473$$$O	medium$$$474$$$480$$$O	for$$$481$$$484$$$O	fermentation$$$485$$$497$$$O	culture,$$$498$$$506$$$O	and$$$507$$$510$$$O	purifying$$$511$$$520$$$O	a$$$521$$$522$$$O	fermentation$$$523$$$535$$$O	product$$$536$$$543$$$O	to$$$544$$$546$$$O	obtain$$$547$$$553$$$O	the$$$554$$$557$$$O	drop$$$558$$$562$$$O	diterpenoid$$$563$$$574$$$I	type$$$575$$$579$$$O	compound$$$580$$$588$$$O	shown$$$589$$$594$$$O	by$$$595$$$597$$$O	the$$$598$$$601$$$O	formula$$$602$$$609$$$O	(I).$$$610$$$614$$$O	An$$$615$$$617$$$O	insecticidal$$$618$$$630$$$O	activity$$$631$$$639$$$O	test$$$640$$$644$$$O	shows$$$645$$$650$$$O	that$$$651$$$655$$$O	the$$$656$$$659$$$O	median$$$660$$$666$$$O	lethal$$$667$$$673$$$O	concentration$$$674$$$687$$$O	of$$$688$$$690$$$O	the$$$691$$$694$$$O	drop$$$695$$$699$$$O	diterpenoid$$$700$$$711$$$I	type$$$712$$$716$$$O	compound$$$717$$$725$$$O	obtained$$$726$$$734$$$O	by$$$735$$$737$$$O	the$$$738$$$741$$$O	preparation$$$742$$$753$$$O	method$$$754$$$760$$$O	disclosed$$$761$$$770$$$O	by$$$771$$$773$$$O	the$$$774$$$777$$$O	invention$$$778$$$787$$$O	is$$$788$$$790$$$O	1.81$$$791$$$795$$$O	micrograms$$$796$$$806$$$O	per$$$807$$$810$$$O	milliliter,$$$811$$$822$$$O	and$$$823$$$826$$$O	meanwhile,$$$827$$$837$$$O	the$$$838$$$841$$$O	compound$$$842$$$850$$$O	has$$$851$$$854$$$O	activities$$$855$$$865$$$O	of$$$866$$$868$$$O	inhibiting$$$869$$$879$$$O	bacteria$$$880$$$888$$$O	and$$$889$$$892$$$O	tumor$$$893$$$898$$$O	cells.$$$899$$$905$$$O
US7148207
For$$$0$$$3$$$O	therapy$$$4$$$11$$$O	of$$$12$$$14$$$O	cancer;$$$15$$$22$$$O	quick$$$23$$$28$$$O	release$$$29$$$36$$$O	tablet$$$37$$$43$$$O	of$$$44$$$46$$$O	fludarabine$$$47$$$58$$$I	phosphate$$$59$$$68$$$I	in$$$69$$$71$$$O	a$$$72$$$73$$$O	defined$$$74$$$81$$$O	composition$$$82$$$93$$$O	of$$$94$$$96$$$O	residual$$$97$$$105$$$O	contaminants$$$106$$$118$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	quick-release$$$28$$$41$$$O	tablet$$$42$$$48$$$O	formulation$$$49$$$60$$$O	with$$$61$$$65$$$O	>99.19%$$$66$$$73$$$O	pure$$$74$$$78$$$O	fludara$$$79$$$86$$$I	(high-purity$$$87$$$99$$$O	fludara)$$$100$$$108$$$I	as$$$109$$$111$$$O	an$$$112$$$114$$$O	active$$$115$$$121$$$O	ingredient$$$122$$$132$$$O	in$$$133$$$135$$$O	a$$$136$$$137$$$O	defined$$$138$$$145$$$O	composition$$$146$$$157$$$O	of$$$158$$$160$$$O	residual$$$161$$$169$$$O	contaminants.$$$170$$$183$$$O
WO2007009778A1
Piperidine$$$0$$$10$$$I	carboxamide$$$11$$$22$$$I	derivate$$$23$$$31$$$O	suitable$$$32$$$40$$$O	as$$$41$$$43$$$O	tachykinin$$$44$$$54$$$O	receptor$$$55$$$63$$$O	antagonist$$$64$$$74$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	compound$$$37$$$45$$$O	of$$$46$$$48$$$O	formula$$$49$$$56$$$O	(I)$$$57$$$60$$$O	or$$$61$$$63$$$O	pharmaceutically$$$64$$$80$$$O	acceptable$$$81$$$91$$$O	salts$$$92$$$97$$$O	or$$$98$$$100$$$O	solvates$$$101$$$109$$$O	thereof,$$$110$$$118$$$O	process$$$119$$$126$$$O	for$$$127$$$130$$$O	their$$$131$$$136$$$O	preparation,$$$137$$$149$$$O	their$$$150$$$155$$$O	use$$$156$$$159$$$O	in$$$160$$$162$$$O	the$$$163$$$166$$$O	treatment$$$167$$$176$$$O	of$$$177$$$179$$$O	conditions$$$180$$$190$$$O	mediated$$$191$$$199$$$O	by$$$200$$$202$$$O	tachykinins$$$203$$$214$$$O	and$$$215$$$218$$$O	pharmaceutical$$$219$$$233$$$O	compositions$$$234$$$246$$$O	containing$$$247$$$257$$$O	them.$$$258$$$263$$$O
CN103183719A
Saponin$$$0$$$7$$$I	derivative$$$8$$$18$$$O	and$$$19$$$22$$$O	application$$$23$$$34$$$O	thereof$$$35$$$42$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	saponin$$$26$$$33$$$I	derivative$$$34$$$44$$$O	which$$$45$$$50$$$O	has$$$51$$$54$$$O	a$$$55$$$56$$$O	structure$$$57$$$66$$$O	presented$$$67$$$76$$$O	in$$$77$$$79$$$O	a$$$80$$$81$$$O	formula$$$82$$$89$$$O	as$$$90$$$92$$$O	follows.$$$93$$$101$$$O	An$$$102$$$104$$$O	animal$$$105$$$111$$$O	experiment$$$112$$$122$$$O	proves$$$123$$$129$$$O	that$$$130$$$134$$$O	the$$$135$$$138$$$O	saponin$$$139$$$146$$$I	derivative$$$147$$$157$$$O	has$$$158$$$161$$$O	a$$$162$$$163$$$O	remarkable$$$164$$$174$$$O	anti-depression$$$175$$$190$$$O	pharmacological$$$191$$$206$$$O	activity,$$$207$$$216$$$O	so$$$217$$$219$$$O	that$$$220$$$224$$$O	the$$$225$$$228$$$O	saponin$$$229$$$236$$$I	derivative$$$237$$$247$$$O	can$$$248$$$251$$$O	be$$$252$$$254$$$O	used$$$255$$$259$$$O	as$$$260$$$262$$$O	an$$$263$$$265$$$O	active$$$266$$$272$$$O	ingredient$$$273$$$283$$$O	to$$$284$$$286$$$O	prepare$$$287$$$294$$$O	medicines,$$$295$$$305$$$O	food$$$306$$$310$$$O	and$$$311$$$314$$$O	health$$$315$$$321$$$O	care$$$322$$$326$$$O	products,$$$327$$$336$$$O	and$$$337$$$340$$$O	can$$$341$$$344$$$O	be$$$345$$$347$$$O	used$$$348$$$352$$$O	independently$$$353$$$366$$$O	or$$$367$$$369$$$O	be$$$370$$$372$$$O	combined$$$373$$$381$$$O	with$$$382$$$386$$$O	other$$$387$$$392$$$O	substances$$$393$$$403$$$O	for$$$404$$$407$$$O	prevention$$$408$$$418$$$O	and$$$419$$$422$$$O	treatment$$$423$$$432$$$O	of$$$433$$$435$$$O	tristimania.$$$436$$$448$$$O
US20130018022
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	including$$$27$$$36$$$O	a$$$37$$$38$$$O	testis$$$39$$$45$$$O	extract$$$46$$$53$$$O	as$$$54$$$56$$$O	an$$$57$$$59$$$O	active$$$60$$$66$$$O	ingredient$$$67$$$77$$$O	for$$$78$$$81$$$O	treating$$$82$$$90$$$O	and$$$91$$$94$$$O	preventing$$$95$$$105$$$O	anemia$$$106$$$112$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	including$$$62$$$71$$$O	a$$$72$$$73$$$O	testis$$$74$$$80$$$O	extract$$$81$$$88$$$O	serving$$$89$$$96$$$O	as$$$97$$$99$$$O	an$$$100$$$102$$$O	active$$$103$$$109$$$O	ingredient$$$110$$$120$$$O	for$$$121$$$124$$$O	treating$$$125$$$133$$$O	and$$$134$$$137$$$O	preventing$$$138$$$148$$$O	anemia,$$$149$$$156$$$O	in$$$157$$$159$$$O	which$$$160$$$165$$$O	since$$$166$$$171$$$O	the$$$172$$$175$$$O	testis$$$176$$$182$$$O	extract$$$183$$$190$$$O	induces$$$191$$$198$$$O	proliferation$$$199$$$212$$$O	of$$$213$$$215$$$O	hematopoietic$$$216$$$229$$$O	stem$$$230$$$234$$$O	cell,$$$235$$$240$$$O	an$$$241$$$243$$$O	increase$$$244$$$252$$$O	in$$$253$$$255$$$O	the$$$256$$$259$$$O	number$$$260$$$266$$$O	of$$$267$$$269$$$O	red$$$270$$$273$$$O	blood$$$274$$$279$$$O	cell,$$$280$$$285$$$O	and$$$286$$$289$$$O	an$$$290$$$292$$$O	increase$$$293$$$301$$$O	in$$$302$$$304$$$O	the$$$305$$$308$$$O	amount$$$309$$$315$$$O	of$$$316$$$318$$$O	hemoglobin,$$$319$$$330$$$O	it$$$331$$$333$$$O	is$$$334$$$336$$$O	effectively$$$337$$$348$$$O	used$$$349$$$353$$$O	as$$$354$$$356$$$O	a$$$357$$$358$$$O	therapeutic$$$359$$$370$$$O	agent$$$371$$$376$$$O	for$$$377$$$380$$$O	treating$$$381$$$389$$$O	anemia$$$390$$$396$$$O	related$$$397$$$404$$$O	to$$$405$$$407$$$O	red$$$408$$$411$$$O	blood$$$412$$$417$$$O	cell$$$418$$$422$$$O	and$$$423$$$426$$$O	hemoglobin$$$427$$$437$$$O	in$$$438$$$440$$$O	women$$$441$$$446$$$O	of$$$447$$$449$$$O	childbearing$$$450$$$462$$$O	age,$$$463$$$467$$$O	post-childbearing$$$468$$$485$$$O	age,$$$486$$$490$$$O	and$$$491$$$494$$$O	during$$$495$$$501$$$O	pregnancy,$$$502$$$512$$$O	as$$$513$$$515$$$O	well$$$516$$$520$$$O	as$$$521$$$523$$$O	in$$$524$$$526$$$O	men.$$$527$$$531$$$O
CN101041079A
Novel$$$0$$$5$$$O	colloid$$$6$$$13$$$O	synthetic$$$14$$$23$$$O	vectors$$$24$$$31$$$O	for$$$32$$$35$$$O	gene$$$36$$$40$$$O	therapy$$$41$$$48$$$O
Non-naturally$$$0$$$13$$$O	occurring$$$14$$$23$$$O	vector$$$24$$$30$$$O	for$$$31$$$34$$$O	gene$$$35$$$39$$$O	therapy$$$40$$$47$$$O	are$$$48$$$51$$$O	provided,$$$52$$$61$$$O	comprised$$$62$$$71$$$O	of$$$72$$$74$$$O	chemically$$$75$$$85$$$O	defined$$$86$$$93$$$O	reagents,$$$94$$$103$$$O	where$$$104$$$109$$$O	the$$$110$$$113$$$O	vector$$$114$$$120$$$O	is$$$121$$$123$$$O	self-assembling$$$124$$$139$$$O	and$$$140$$$143$$$O	where$$$144$$$149$$$O	the$$$150$$$153$$$O	vector$$$154$$$160$$$O	comprises$$$161$$$170$$$O	(1)$$$171$$$174$$$O	a$$$175$$$176$$$O	core$$$177$$$181$$$O	complex$$$182$$$189$$$O	comprising$$$190$$$200$$$O	a$$$201$$$202$$$O	nucleic$$$203$$$210$$$O	acid$$$211$$$215$$$O	and$$$216$$$219$$$O	(2)$$$220$$$223$$$O	at$$$224$$$226$$$O	least$$$227$$$232$$$O	one$$$233$$$236$$$O	complex$$$237$$$244$$$O	forming$$$245$$$252$$$O	reagent,$$$253$$$261$$$O	where$$$262$$$267$$$O	the$$$268$$$271$$$O	vector$$$272$$$278$$$O	has$$$279$$$282$$$O	fusogenic$$$283$$$292$$$O	activity.$$$293$$$302$$$O	The$$$303$$$306$$$O	vector$$$307$$$313$$$O	optionally$$$314$$$324$$$O	may$$$325$$$328$$$O	contain$$$329$$$336$$$O	reagents$$$337$$$345$$$O	permitting$$$346$$$356$$$O	fusion$$$357$$$363$$$O	with$$$364$$$368$$$O	cell$$$369$$$373$$$O	membranes$$$374$$$383$$$O	and$$$384$$$387$$$O	nuclear$$$388$$$395$$$O	uptake.$$$396$$$403$$$O	The$$$404$$$407$$$O	vector$$$408$$$414$$$O	also$$$415$$$419$$$O	may$$$420$$$423$$$O	contain$$$424$$$431$$$O	an$$$432$$$434$$$O	outer$$$435$$$440$$$O	shell$$$441$$$446$$$O	moiety$$$447$$$453$$$O	that$$$454$$$458$$$O	is$$$459$$$461$$$O	anchored$$$462$$$470$$$O	to$$$471$$$473$$$O	the$$$474$$$477$$$O	core$$$478$$$482$$$O	complex,$$$483$$$491$$$O	whereby$$$492$$$499$$$O	the$$$500$$$503$$$O	outer$$$504$$$509$$$O	shell$$$510$$$515$$$O	stabilizes$$$516$$$526$$$O	the$$$527$$$530$$$O	complex,$$$531$$$539$$$O	protects$$$540$$$548$$$O	it$$$549$$$551$$$O	from$$$552$$$556$$$O	unwanted$$$557$$$565$$$O	interactions$$$566$$$578$$$O	and$$$579$$$582$$$O	enhances$$$583$$$591$$$O	delivery$$$592$$$600$$$O	of$$$601$$$603$$$O	the$$$604$$$607$$$O	nucleic$$$608$$$615$$$O	acid$$$616$$$620$$$O	into$$$621$$$625$$$O	a$$$626$$$627$$$O	target$$$628$$$634$$$O	tissue$$$635$$$641$$$O	or$$$642$$$644$$$O	cell.$$$645$$$650$$$O	The$$$651$$$654$$$O	outer$$$655$$$660$$$O	shell$$$661$$$666$$$O	optionally$$$667$$$677$$$O	may$$$678$$$681$$$O	be$$$682$$$684$$$O	sheddable,$$$685$$$695$$$O	that$$$696$$$700$$$O	is,$$$701$$$704$$$O	it$$$705$$$707$$$O	may$$$708$$$711$$$O	be$$$712$$$714$$$O	designed$$$715$$$723$$$O	such$$$724$$$728$$$O	that$$$729$$$733$$$O	it$$$734$$$736$$$O	dissociates$$$737$$$748$$$O	from$$$749$$$753$$$O	the$$$754$$$757$$$O	vector$$$758$$$764$$$O	upon$$$765$$$769$$$O	entry$$$770$$$775$$$O	into$$$776$$$780$$$O	the$$$781$$$784$$$O	target$$$785$$$791$$$O	cell$$$792$$$796$$$O	or$$$797$$$799$$$O	tissue.$$$800$$$807$$$O
EP1944297A1
Solid$$$0$$$5$$$O	and$$$6$$$9$$$O	crystalline$$$10$$$21$$$O	rimonabant$$$22$$$32$$$I	and$$$33$$$36$$$O	processes$$$37$$$46$$$O	for$$$47$$$50$$$O	preparation,$$$51$$$63$$$O	and$$$64$$$67$$$O	pharmaceutical$$$68$$$82$$$O	composition$$$83$$$94$$$O	thereof$$$95$$$102$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	solid$$$37$$$42$$$O	state$$$43$$$48$$$O	chemistry$$$49$$$58$$$O	of$$$59$$$61$$$O	N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazolecarboxamide$$$62$$$147$$$I	which$$$148$$$153$$$O	international$$$154$$$167$$$O	nonproprietary$$$168$$$182$$$O	name$$$183$$$187$$$O	is$$$188$$$190$$$O	rimonabant,$$$191$$$202$$$I	its$$$203$$$206$$$O	preparation$$$207$$$218$$$O	and$$$219$$$222$$$O	pharmaceutical$$$223$$$237$$$O	compositions$$$238$$$250$$$O	containing$$$251$$$261$$$O	said$$$262$$$266$$$O	novel$$$267$$$272$$$O	polymorph.$$$273$$$283$$$O	Thus,$$$288$$$293$$$O	the$$$294$$$297$$$O	subject$$$298$$$305$$$O	of$$$306$$$308$$$O	the$$$309$$$312$$$O	present$$$313$$$320$$$O	invention$$$321$$$330$$$O	is$$$331$$$333$$$O	a$$$334$$$335$$$O	novel$$$336$$$341$$$O	polymorphic$$$342$$$353$$$O	form$$$354$$$358$$$O	of$$$359$$$361$$$O	rimonabant,$$$362$$$373$$$I	called$$$374$$$380$$$O	form$$$381$$$385$$$O	III,$$$386$$$390$$$O	it$$$391$$$393$$$O	also$$$394$$$398$$$O	relates$$$399$$$406$$$O	to$$$407$$$409$$$O	methods$$$410$$$417$$$O	for$$$418$$$421$$$O	preparing$$$422$$$431$$$O	rimonabant$$$432$$$442$$$O	in$$$443$$$445$$$O	its$$$446$$$449$$$O	polymorphic$$$450$$$461$$$O	form$$$462$$$466$$$O	III,$$$467$$$471$$$O	and$$$472$$$475$$$O	an$$$476$$$478$$$O	amorphous$$$479$$$488$$$O	form$$$489$$$493$$$O
EP2007394A1
Novel$$$0$$$5$$$O	use$$$6$$$9$$$O	of$$$10$$$12$$$O	antihistamine$$$13$$$26$$$O	agents$$$27$$$33$$$O	for$$$34$$$37$$$O	the$$$38$$$41$$$O	preventive$$$42$$$52$$$O	or$$$53$$$55$$$O	early$$$56$$$61$$$O	treatment$$$62$$$71$$$O	of$$$72$$$74$$$O	inflammatory$$$75$$$87$$$O	syndromes,$$$88$$$98$$$O	in$$$99$$$101$$$O	particular$$$102$$$112$$$O	those$$$113$$$118$$$O	triggered$$$119$$$128$$$O	by$$$129$$$131$$$O	togaviruses$$$132$$$143$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	use$$$37$$$40$$$O	of$$$41$$$43$$$O	at$$$44$$$46$$$O	least$$$47$$$52$$$O	one$$$53$$$56$$$O	antihistamine$$$57$$$70$$$O	agent$$$71$$$76$$$O	for$$$77$$$80$$$O	the$$$81$$$84$$$O	preparation$$$85$$$96$$$O	of$$$97$$$99$$$O	a$$$100$$$101$$$O	medicament$$$102$$$112$$$O	for$$$113$$$116$$$O	use$$$117$$$120$$$O	in$$$121$$$123$$$O	the$$$124$$$127$$$O	preventive$$$128$$$138$$$O	or$$$139$$$141$$$O	early$$$142$$$147$$$O	treatment$$$148$$$157$$$O	of$$$158$$$160$$$O	inflammatory$$$161$$$173$$$O	syndromes$$$174$$$183$$$O	of$$$184$$$186$$$O	viral$$$187$$$192$$$O	origin,$$$193$$$200$$$O	in$$$201$$$203$$$O	particular$$$204$$$214$$$O	arthritis$$$215$$$224$$$O	of$$$225$$$227$$$O	the$$$228$$$231$$$O	distal$$$232$$$238$$$O	joints,$$$239$$$246$$$O	more$$$247$$$251$$$O	particularly$$$252$$$264$$$O	those$$$265$$$270$$$O	triggered$$$271$$$280$$$O	by$$$281$$$283$$$O	togaviruses.$$$284$$$296$$$O	The$$$297$$$300$$$O	invention$$$301$$$310$$$O	also$$$311$$$315$$$O	relates$$$316$$$323$$$O	to$$$324$$$326$$$O	a$$$327$$$328$$$O	combination$$$329$$$340$$$O	product$$$341$$$348$$$O	of$$$349$$$351$$$O	at$$$352$$$354$$$O	least$$$355$$$360$$$O	one$$$361$$$364$$$O	antihistamine$$$365$$$378$$$O	agent$$$379$$$384$$$O	and$$$385$$$388$$$O	of$$$389$$$391$$$O	at$$$392$$$394$$$O	least$$$395$$$400$$$O	one$$$401$$$404$$$O	antiserotonin$$$405$$$418$$$O	agent$$$419$$$424$$$O	for$$$425$$$428$$$O	its$$$429$$$432$$$O	simultaneous,$$$433$$$446$$$O	separate$$$447$$$455$$$O	or$$$456$$$458$$$O	sequential$$$459$$$469$$$O	use$$$470$$$473$$$O	in$$$474$$$476$$$O	preventive$$$477$$$487$$$O	or$$$488$$$490$$$O	early$$$491$$$496$$$O	therapy$$$497$$$504$$$O	for$$$505$$$508$$$O	inflammatory$$$509$$$521$$$O	syndromes$$$522$$$531$$$O	of$$$532$$$534$$$O	viral$$$535$$$540$$$O	origin,$$$541$$$548$$$O	in$$$549$$$551$$$O	particular$$$552$$$562$$$O	arthritis$$$563$$$572$$$O	of$$$573$$$575$$$O	the$$$576$$$579$$$O	distal$$$580$$$586$$$O	joints,$$$587$$$594$$$O	more$$$595$$$599$$$O	particularly$$$600$$$612$$$O	those$$$613$$$618$$$O	triggered$$$619$$$628$$$O	by$$$629$$$631$$$O	togaviruses.$$$632$$$644$$$O
CN102497866A
Oxazolidinone$$$0$$$13$$$I	containing$$$14$$$24$$$O	dimer$$$25$$$30$$$O	compounds,$$$31$$$41$$$O	compositions$$$42$$$54$$$O	and$$$55$$$58$$$O	methods$$$59$$$66$$$O	to$$$67$$$69$$$O	make$$$70$$$74$$$O	and$$$75$$$78$$$O	use$$$79$$$82$$$O
Dosage$$$0$$$6$$$O	forms$$$7$$$12$$$O	or$$$13$$$15$$$O	pharmaceutical$$$16$$$30$$$O	compositions$$$31$$$43$$$O	comprise$$$44$$$52$$$O	a$$$53$$$54$$$O	compound$$$55$$$63$$$O	having$$$64$$$70$$$O	the$$$71$$$74$$$O	structure$$$75$$$84$$$O	of$$$85$$$87$$$O	Formula$$$88$$$95$$$O	(IV)$$$96$$$100$$$O	wherein$$$101$$$108$$$O	n$$$109$$$110$$$O	is$$$111$$$113$$$O	a$$$114$$$115$$$O	non-negative$$$116$$$128$$$O	integer;$$$129$$$137$$$O	wherein$$$138$$$145$$$O	each$$$146$$$150$$$O	Z$$$151$$$152$$$O	is$$$153$$$155$$$O	an$$$156$$$158$$$O	oxazolidinone-containing$$$159$$$183$$$I	moiety$$$184$$$190$$$O	having$$$191$$$197$$$O	antibiotic$$$198$$$208$$$O	activity$$$209$$$217$$$O	in$$$218$$$220$$$O	vivo$$$221$$$225$$$O	upon$$$226$$$230$$$O	cleaving,$$$231$$$240$$$O	wherein$$$241$$$248$$$O	M$$$249$$$250$$$O	is$$$251$$$253$$$O	independently$$$254$$$267$$$O	OR1$$$268$$$271$$$I	or$$$272$$$274$$$O	NR1R2;$$$275$$$281$$$I	wherein$$$282$$$289$$$O	R1$$$290$$$292$$$O	and$$$293$$$296$$$O	R2$$$297$$$299$$$O	are$$$300$$$303$$$O	independently$$$304$$$317$$$O	selected$$$318$$$326$$$O	from$$$327$$$331$$$O	the$$$332$$$335$$$O	group$$$336$$$341$$$O	consisting$$$342$$$352$$$O	of$$$353$$$355$$$O	H,$$$356$$$358$$$I	an$$$359$$$361$$$O	optionally-substituted$$$362$$$384$$$O	hydrocarbyl$$$385$$$396$$$I	residue$$$397$$$404$$$O	or$$$405$$$407$$$O	a$$$408$$$409$$$O	pharmaceutically$$$410$$$426$$$O	acceptable$$$427$$$437$$$O	cation;$$$438$$$445$$$O	wherein$$$446$$$453$$$O	the$$$454$$$457$$$O	compound$$$458$$$466$$$O	in$$$467$$$469$$$O	the$$$470$$$473$$$O	dosage$$$474$$$480$$$O	form$$$481$$$485$$$O	or$$$486$$$488$$$O	a$$$489$$$490$$$O	pharmaceutical$$$491$$$505$$$O	composition$$$506$$$517$$$O	is$$$518$$$520$$$O	present$$$521$$$528$$$O	in$$$529$$$531$$$O	an$$$532$$$534$$$O	amount$$$535$$$541$$$O	effective$$$542$$$551$$$O	for$$$552$$$555$$$O	treating$$$556$$$564$$$O	or$$$565$$$567$$$O	preventing$$$568$$$578$$$O	an$$$579$$$581$$$O	antibacterial$$$582$$$595$$$O	infection$$$596$$$605$$$O	in$$$606$$$608$$$O	a$$$609$$$610$$$O	mammalian$$$611$$$620$$$O	subject.$$$621$$$629$$$O	Methods$$$630$$$637$$$O	of$$$638$$$640$$$O	preparing$$$641$$$650$$$O	and$$$651$$$654$$$O	using$$$655$$$660$$$O	these$$$661$$$666$$$O	dosage$$$667$$$673$$$O	forms$$$674$$$679$$$O	or$$$680$$$682$$$O	pharmaceutical$$$683$$$697$$$O	compositions$$$698$$$710$$$O	are$$$711$$$714$$$O	also$$$715$$$719$$$O	disclosed.$$$720$$$730$$$O
CN103622923A
Drug$$$0$$$4$$$O	delivery$$$5$$$13$$$O	system$$$14$$$20$$$O	for$$$21$$$24$$$O	16-dehydropregnenolone$$$25$$$47$$$I	lipidosome$$$48$$$58$$$O	for$$$59$$$62$$$O	injection$$$63$$$72$$$O	and$$$73$$$76$$$O	preparation$$$77$$$88$$$O	method$$$89$$$95$$$O	of$$$96$$$98$$$O	same$$$99$$$103$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	drug$$$25$$$29$$$O	delivery$$$30$$$38$$$O	system$$$39$$$45$$$O	for$$$46$$$49$$$O	16-dehydropregnenolone$$$50$$$72$$$I	(DHP)$$$73$$$78$$$I	lipidosome$$$79$$$89$$$O	for$$$90$$$93$$$O	injection$$$94$$$103$$$O	and$$$104$$$107$$$O	a$$$108$$$109$$$O	preparation$$$110$$$121$$$O	method.$$$122$$$129$$$O	The$$$130$$$133$$$O	drug$$$134$$$138$$$O	delivery$$$139$$$147$$$O	system$$$148$$$154$$$O	comprises$$$155$$$164$$$O	effective$$$165$$$174$$$O	amount$$$175$$$181$$$O	of$$$182$$$184$$$O	16-dehydropregnenolone,$$$185$$$208$$$I	a$$$209$$$210$$$O	phospholipid$$$211$$$223$$$I	membrane,$$$224$$$233$$$O	a$$$234$$$235$$$O	membrane$$$236$$$244$$$O	stabilization$$$245$$$258$$$O	material$$$259$$$267$$$O	and$$$268$$$271$$$O	pharmaceutically-acceptable$$$272$$$299$$$O	auxiliary$$$300$$$309$$$O	materials,$$$310$$$320$$$O	wherein$$$321$$$328$$$O	the$$$329$$$332$$$O	weight$$$333$$$339$$$O	ratio$$$340$$$345$$$O	of$$$346$$$348$$$O	the$$$349$$$352$$$O	16-dehydropregnenolone$$$353$$$375$$$I	to$$$376$$$378$$$O	the$$$379$$$382$$$O	phospholipid$$$383$$$395$$$I	membrane$$$396$$$404$$$O	to$$$405$$$407$$$O	the$$$408$$$411$$$O	membrane$$$412$$$420$$$O	stabilization$$$421$$$434$$$O	material$$$435$$$443$$$O	is$$$444$$$446$$$O	1:5:0.2-1:50:50.$$$447$$$463$$$O	The$$$464$$$467$$$O	preparation$$$468$$$479$$$O	technology$$$480$$$490$$$O	comprises$$$491$$$500$$$O	the$$$501$$$504$$$O	steps$$$505$$$510$$$O	of$$$511$$$513$$$O	preparing$$$514$$$523$$$O	multi-chamber$$$524$$$537$$$O	lipidosome,$$$538$$$549$$$O	homogenizing$$$550$$$562$$$O	the$$$563$$$566$$$O	lipidosome,$$$567$$$578$$$O	metering$$$579$$$587$$$O	volume,$$$588$$$595$$$O	sterilizing,$$$596$$$608$$$O	subpackaging,$$$609$$$622$$$O	freeze-drying$$$623$$$636$$$O	and$$$637$$$640$$$O	the$$$641$$$644$$$O	like.$$$645$$$650$$$O	The$$$651$$$654$$$O	lipidosome$$$655$$$665$$$O	prepared$$$666$$$674$$$O	by$$$675$$$677$$$O	the$$$678$$$681$$$O	method$$$682$$$688$$$O	is$$$689$$$691$$$O	small$$$692$$$697$$$O	in$$$698$$$700$$$O	average$$$701$$$708$$$O	grain$$$709$$$714$$$O	diameter,$$$715$$$724$$$O	narrow$$$725$$$731$$$O	in$$$732$$$734$$$O	distribution,$$$735$$$748$$$O	high$$$749$$$753$$$O	in$$$754$$$756$$$O	encapsulation$$$757$$$770$$$O	efficiency,$$$771$$$782$$$O	high$$$783$$$787$$$O	in$$$788$$$790$$$O	drug$$$791$$$795$$$O	loading$$$796$$$803$$$O	capacity,$$$804$$$813$$$O	good$$$814$$$818$$$O	in$$$819$$$821$$$O	repeatability$$$822$$$835$$$O	and$$$836$$$839$$$O	good$$$840$$$844$$$O	in$$$845$$$847$$$O	stability,$$$848$$$858$$$O	and$$$859$$$862$$$O	can$$$863$$$866$$$O	satisfy$$$867$$$874$$$O	the$$$875$$$878$$$O	requirements$$$879$$$891$$$O	on$$$892$$$894$$$O	intravenous$$$895$$$906$$$O	injection.$$$907$$$917$$$O	The$$$918$$$921$$$O	results$$$922$$$929$$$O	of$$$930$$$932$$$O	anti-tumor$$$933$$$943$$$O	in$$$944$$$946$$$O	vivo$$$947$$$951$$$O	experiments$$$952$$$963$$$O	show$$$964$$$968$$$O	that$$$969$$$973$$$O	16-DHP$$$974$$$980$$$I	lipidosome$$$981$$$991$$$O	prepared$$$992$$$1000$$$O	by$$$1001$$$1003$$$O	the$$$1004$$$1007$$$O	invention$$$1008$$$1017$$$O	can$$$1018$$$1021$$$O	remarkably$$$1022$$$1032$$$O	inhibit$$$1033$$$1040$$$O	growth$$$1041$$$1047$$$O	of$$$1048$$$1050$$$O	a$$$1051$$$1052$$$O	transplantation$$$1053$$$1068$$$O	tumor$$$1069$$$1074$$$O	of$$$1075$$$1077$$$O	a$$$1078$$$1079$$$O	nude$$$1080$$$1084$$$O	mouse$$$1085$$$1090$$$O	bearing$$$1091$$$1098$$$O	the$$$1099$$$1102$$$O	tumor$$$1103$$$1108$$$O	and$$$1109$$$1112$$$O	has$$$1113$$$1116$$$O	a$$$1117$$$1118$$$O	relatively$$$1119$$$1129$$$O	good$$$1130$$$1134$$$O	anti-tumor$$$1135$$$1145$$$O	effect.$$$1146$$$1153$$$O	An$$$1154$$$1156$$$O	experiment$$$1157$$$1167$$$O	result$$$1168$$$1174$$$O	of$$$1175$$$1177$$$O	rat$$$1178$$$1181$$$O	pharmacokinetics$$$1182$$$1198$$$O	shows$$$1199$$$1204$$$O	that$$$1205$$$1209$$$O	the$$$1210$$$1213$$$O	16-DHP$$$1214$$$1220$$$I	lipidosome$$$1221$$$1231$$$O	prepared$$$1232$$$1240$$$O	by$$$1241$$$1243$$$O	the$$$1244$$$1247$$$O	invention$$$1248$$$1257$$$O	can$$$1258$$$1261$$$O	prolong$$$1262$$$1269$$$O	the$$$1270$$$1273$$$O	time$$$1274$$$1278$$$O	that$$$1279$$$1283$$$O	a$$$1284$$$1285$$$O	medicine$$$1286$$$1294$$$O	stays$$$1295$$$1300$$$O	in$$$1301$$$1303$$$O	the$$$1304$$$1307$$$O	body$$$1308$$$1312$$$O	and$$$1313$$$1316$$$O	improve$$$1317$$$1324$$$O	the$$$1325$$$1328$$$O	amount$$$1329$$$1335$$$O	of$$$1336$$$1338$$$O	the$$$1339$$$1342$$$O	medicine$$$1343$$$1351$$$O	that$$$1352$$$1356$$$O	enters$$$1357$$$1363$$$O	systemic$$$1364$$$1372$$$O	circulation$$$1373$$$1384$$$O	of$$$1385$$$1387$$$O	a$$$1388$$$1389$$$O	rat.$$$1390$$$1394$$$O
CN102139107B
Anticancer$$$0$$$10$$$O	effect$$$11$$$17$$$O	of$$$18$$$20$$$O	antagonist$$$21$$$31$$$O	of$$$32$$$34$$$O	neurokinin$$$35$$$45$$$O	receptor$$$46$$$54$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	anticancer$$$29$$$39$$$O	effect$$$40$$$46$$$O	of$$$47$$$49$$$O	an$$$50$$$52$$$O	antagonist$$$53$$$63$$$O	of$$$64$$$66$$$O	a$$$67$$$68$$$O	neurokinin$$$69$$$79$$$O	receptor,$$$80$$$89$$$O	in$$$90$$$92$$$O	particular$$$93$$$103$$$O	to$$$104$$$106$$$O	a$$$107$$$108$$$O	method$$$109$$$115$$$O	of$$$116$$$118$$$O	treating$$$119$$$127$$$O	cancers$$$128$$$135$$$O	in$$$136$$$138$$$O	subjects,$$$139$$$148$$$O	relieving$$$149$$$158$$$O	cancer$$$159$$$165$$$O	symptoms$$$166$$$174$$$O	in$$$175$$$177$$$O	the$$$178$$$181$$$O	subjects,$$$182$$$191$$$O	or$$$192$$$194$$$O	inhibiting$$$195$$$205$$$O	the$$$206$$$209$$$O	proliferation$$$210$$$223$$$O	of$$$224$$$226$$$O	cancer$$$227$$$233$$$O	cells,$$$234$$$240$$$O	use$$$241$$$244$$$O	of$$$245$$$247$$$O	the$$$248$$$251$$$O	antagonist$$$252$$$262$$$O	of$$$263$$$265$$$O	the$$$266$$$269$$$O	neurokinin$$$270$$$280$$$O	receptor$$$281$$$289$$$O	in$$$290$$$292$$$O	the$$$293$$$296$$$O	preparation$$$297$$$308$$$O	of$$$309$$$311$$$O	medicines,$$$312$$$322$$$O	medicaments$$$323$$$334$$$O	or$$$335$$$337$$$O	pharmaceutical$$$338$$$352$$$O	compositions$$$353$$$365$$$O	for$$$366$$$369$$$O	treating$$$370$$$378$$$O	the$$$379$$$382$$$O	cancers,$$$383$$$391$$$O	relieving$$$392$$$401$$$O	the$$$402$$$405$$$O	cancer$$$406$$$412$$$O	symptoms,$$$413$$$422$$$O	or$$$423$$$425$$$O	inhibiting$$$426$$$436$$$O	the$$$437$$$440$$$O	proliferation$$$441$$$454$$$O	of$$$455$$$457$$$O	the$$$458$$$461$$$O	cancer$$$462$$$468$$$O	cells,$$$469$$$475$$$O	as$$$476$$$478$$$O	well$$$479$$$483$$$O	as$$$484$$$486$$$O	a$$$487$$$488$$$O	pharmaceutical$$$489$$$503$$$O	product$$$504$$$511$$$O	which$$$512$$$517$$$O	comprises$$$518$$$527$$$O	the$$$528$$$531$$$O	antagonist$$$532$$$542$$$O	of$$$543$$$545$$$O	the$$$546$$$549$$$O	neurokinin$$$550$$$560$$$O	receptor$$$561$$$569$$$O	as$$$570$$$572$$$O	an$$$573$$$575$$$O	active$$$576$$$582$$$O	component,$$$583$$$593$$$O	and$$$594$$$597$$$O	aspecification$$$598$$$612$$$O	comprising$$$613$$$623$$$O	the$$$624$$$627$$$O	pharmaceutical$$$628$$$642$$$O	product.$$$643$$$651$$$O
WO2012067447A2
Composition$$$0$$$11$$$O	containing$$$12$$$22$$$O	styraxlignolide$$$23$$$38$$$I	a$$$39$$$40$$$O	or$$$41$$$43$$$O	the$$$44$$$47$$$O	aglycone$$$48$$$56$$$I	thereof$$$57$$$64$$$O	as$$$65$$$67$$$O	an$$$68$$$70$$$O	active$$$71$$$77$$$O	ingredient$$$78$$$88$$$O	for$$$89$$$92$$$O	preventing$$$93$$$103$$$O	or$$$104$$$106$$$O	treating$$$107$$$115$$$O	asthma$$$116$$$122$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	containing$$$62$$$72$$$O	styraxlignolide$$$73$$$88$$$I	A$$$89$$$90$$$I	or$$$91$$$93$$$O	the$$$94$$$97$$$O	aglycone$$$98$$$106$$$I	thereof$$$107$$$114$$$O	as$$$115$$$117$$$O	an$$$118$$$120$$$O	active$$$121$$$127$$$O	ingredient$$$128$$$138$$$O	for$$$139$$$142$$$O	preventing$$$143$$$153$$$O	or$$$154$$$156$$$O	treating$$$157$$$165$$$O	asthma.$$$166$$$173$$$O	More$$$174$$$178$$$O	particularly,$$$179$$$192$$$O	the$$$193$$$196$$$O	styraxlignolide$$$197$$$212$$$I	A$$$213$$$214$$$I	compound$$$215$$$223$$$O	is$$$224$$$226$$$O	separated$$$227$$$236$$$O	from$$$237$$$241$$$O	the$$$242$$$245$$$O	stem$$$246$$$250$$$O	and$$$251$$$254$$$O	bark$$$255$$$259$$$O	of$$$260$$$262$$$O	Styrax$$$263$$$269$$$O	japonica,$$$270$$$279$$$O	and$$$280$$$283$$$O	the$$$284$$$287$$$O	styraxlignolide$$$288$$$303$$$I	A$$$304$$$305$$$I	or$$$306$$$308$$$O	homoegonol,$$$309$$$320$$$I	which$$$321$$$326$$$O	is$$$327$$$329$$$O	the$$$330$$$333$$$O	aglycone$$$334$$$342$$$I	of$$$343$$$345$$$O	styraxlignolide$$$346$$$361$$$I	A$$$362$$$363$$$I	and$$$364$$$367$$$O	which$$$368$$$373$$$O	has$$$374$$$377$$$O	improved$$$378$$$386$$$O	safety,$$$387$$$394$$$O	has$$$395$$$398$$$O	the$$$399$$$402$$$O	effect$$$403$$$409$$$O	of$$$410$$$412$$$O	attenuating$$$413$$$424$$$O	weight$$$425$$$431$$$O	loss$$$432$$$436$$$O	and$$$437$$$440$$$O	hypersensitivity$$$441$$$457$$$O	of$$$458$$$460$$$O	the$$$461$$$464$$$O	airway,$$$465$$$472$$$O	inhibiting$$$473$$$483$$$O	the$$$484$$$487$$$O	generation$$$488$$$498$$$O	of$$$499$$$501$$$O	active$$$502$$$508$$$O	oxygen$$$509$$$515$$$I	in$$$516$$$518$$$O	the$$$519$$$522$$$O	airway,$$$523$$$530$$$O	inhibiting$$$531$$$541$$$O	the$$$542$$$545$$$O	generation$$$546$$$556$$$O	of$$$557$$$559$$$O	IgE,$$$560$$$564$$$O	TGF-Ã¢1,$$$565$$$573$$$O	and$$$574$$$577$$$O	IL-17$$$578$$$583$$$O	in$$$584$$$586$$$O	the$$$587$$$590$$$O	serum$$$591$$$596$$$O	and$$$597$$$600$$$O	bronchoalveolar$$$601$$$616$$$O	lavage$$$617$$$623$$$O	fluid,$$$624$$$630$$$O	inhibiting$$$631$$$641$$$O	inflammatory$$$642$$$654$$$O	cell$$$655$$$659$$$O	infiltration$$$660$$$672$$$O	in$$$673$$$675$$$O	the$$$676$$$679$$$O	bronchial$$$680$$$689$$$O	tubes,$$$690$$$696$$$O	and$$$697$$$700$$$O	inhibiting$$$701$$$711$$$O	the$$$712$$$715$$$O	formation$$$716$$$725$$$O	of$$$726$$$728$$$O	a$$$729$$$730$$$O	mucous$$$731$$$737$$$O	plug$$$738$$$742$$$O	and$$$743$$$746$$$O	subepithelial$$$747$$$760$$$O	fibrosis$$$761$$$769$$$O	in$$$770$$$772$$$O	an$$$773$$$775$$$O	asthmatic$$$776$$$785$$$O	mouse$$$786$$$791$$$O	model.$$$792$$$798$$$O	Therefore,$$$799$$$809$$$O	the$$$810$$$813$$$O	above-described$$$814$$$829$$$I	styraxlignolide$$$830$$$845$$$I	or$$$846$$$848$$$I	homoegonol$$$849$$$859$$$I	can$$$860$$$863$$$O	be$$$864$$$866$$$O	effectively$$$867$$$878$$$O	used$$$879$$$883$$$O	as$$$884$$$886$$$O	the$$$887$$$890$$$O	active$$$891$$$897$$$O	ingredient$$$898$$$908$$$O	of$$$909$$$911$$$O	a$$$912$$$913$$$O	pharmaceutical$$$914$$$928$$$O	composition$$$929$$$940$$$O	for$$$941$$$944$$$O	preventing$$$945$$$955$$$O	or$$$956$$$958$$$O	treating$$$959$$$967$$$O	bronchial$$$968$$$977$$$O	asthma$$$978$$$984$$$O	in$$$985$$$987$$$O	which$$$988$$$993$$$O	airway$$$994$$$1000$$$O	remodeling$$$1001$$$1011$$$O	has$$$1012$$$1015$$$O	progressed.$$$1016$$$1027$$$O
WO2008109007A1
Bridged$$$0$$$7$$$O	phenanthridines$$$8$$$23$$$I
Bridged$$$0$$$7$$$O	phenanthridine$$$8$$$22$$$I	compounds$$$23$$$32$$$O	having$$$33$$$39$$$O	the$$$40$$$43$$$O	structure$$$44$$$53$$$O	of$$$54$$$56$$$O	formula$$$57$$$64$$$O	I$$$65$$$66$$$O	or$$$67$$$69$$$O	of$$$70$$$72$$$O	formula$$$73$$$80$$$O	II$$$81$$$83$$$O	are$$$84$$$87$$$O	provided.$$$88$$$97$$$O	These$$$98$$$103$$$O	compounds$$$104$$$113$$$O	are$$$114$$$117$$$O	useful$$$118$$$124$$$O	as$$$125$$$127$$$O	cannabinoid$$$128$$$139$$$I	receptor$$$140$$$148$$$O	ligands$$$149$$$156$$$O	and$$$157$$$160$$$O	can$$$161$$$164$$$O	be$$$165$$$167$$$O	prepared$$$168$$$176$$$O	as$$$177$$$179$$$O	pharmaceutical$$$180$$$194$$$O	compositions$$$195$$$207$$$O	for$$$208$$$211$$$O	the$$$212$$$215$$$O	prophylaxis$$$216$$$227$$$O	or$$$228$$$230$$$O	treatment$$$231$$$240$$$O	of$$$241$$$243$$$O	a$$$244$$$245$$$O	variety$$$246$$$253$$$O	of$$$254$$$256$$$O	diseases,$$$257$$$266$$$O	disorders$$$267$$$276$$$O	and$$$277$$$280$$$O	conditions$$$281$$$291$$$O	including$$$292$$$301$$$O	inflammatory$$$302$$$314$$$O	pain,$$$315$$$320$$$O	visceral$$$321$$$329$$$O	pain,$$$330$$$335$$$O	postoperative$$$336$$$349$$$O	pain,$$$350$$$355$$$O	cancer$$$356$$$362$$$O	pain,$$$363$$$368$$$O	neuropathic$$$369$$$380$$$O	pain,$$$381$$$386$$$O	musculoskeletal$$$387$$$402$$$O	pain,$$$403$$$408$$$O	dysmenorrhea,$$$409$$$422$$$O	menstrual$$$423$$$432$$$O	pain,$$$433$$$438$$$O	migraine,$$$439$$$448$$$O	headache$$$449$$$457$$$O	as$$$458$$$460$$$O	well$$$461$$$465$$$O	as$$$466$$$468$$$O	inflammatory$$$469$$$481$$$O	diseases$$$482$$$490$$$O	such$$$491$$$495$$$O	as$$$496$$$498$$$O	rheumatoid$$$499$$$509$$$O	arthritis,$$$510$$$520$$$O	systemic$$$521$$$529$$$O	lupus$$$530$$$535$$$O	erythematosus,$$$536$$$550$$$O	Crohn's$$$551$$$558$$$O	disease,$$$559$$$567$$$O	psoriasis,$$$568$$$578$$$O	eczema,$$$579$$$586$$$O	multiple$$$587$$$595$$$O	sclerosis,$$$596$$$606$$$O	diabetes$$$607$$$615$$$O	and$$$616$$$619$$$O	thyroiditis.$$$620$$$632$$$O	The$$$633$$$636$$$O	compounds$$$637$$$646$$$O	can$$$647$$$650$$$O	also$$$651$$$655$$$O	be$$$656$$$658$$$O	used$$$659$$$663$$$O	in$$$664$$$666$$$O	the$$$667$$$670$$$O	treatment$$$671$$$680$$$O	of$$$681$$$683$$$O	skin$$$684$$$688$$$O	disorders,$$$689$$$699$$$O	lung$$$700$$$704$$$O	disorders,$$$705$$$715$$$O	ophthalmic$$$716$$$726$$$O	disorders,$$$727$$$737$$$O	gastrointestinal$$$738$$$754$$$O	disorders,$$$755$$$765$$$O	cardiovascular$$$766$$$780$$$O	disorders,$$$781$$$791$$$O	as$$$792$$$794$$$O	well$$$795$$$799$$$O	as$$$800$$$802$$$O	neurodegenerative,$$$803$$$821$$$O	neuroinflammatory$$$822$$$839$$$O	and$$$840$$$843$$$O	certain$$$844$$$851$$$O	psychiatric$$$852$$$863$$$O	disorders.$$$864$$$874$$$O
WO2014074017A1
New$$$0$$$3$$$O	medicinal$$$4$$$13$$$O	composition$$$14$$$25$$$O	for$$$26$$$29$$$O	pain$$$30$$$34$$$O	management$$$35$$$45$$$O	in$$$46$$$48$$$O	the$$$49$$$52$$$O	case$$$53$$$57$$$O	of$$$58$$$60$$$O	smooth$$$61$$$67$$$O	muscle$$$68$$$74$$$O	spasm$$$75$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	pharmaceutics$$$38$$$51$$$O	and$$$52$$$55$$$O	medicine,$$$56$$$65$$$O	and$$$66$$$69$$$O	more$$$70$$$74$$$O	particularly$$$75$$$87$$$O	to$$$88$$$90$$$O	agents$$$91$$$97$$$O	used$$$98$$$102$$$O	in$$$103$$$105$$$O	the$$$106$$$109$$$O	case$$$110$$$114$$$O	of$$$115$$$117$$$O	various$$$118$$$125$$$O	spastic$$$126$$$133$$$O	states$$$134$$$140$$$O	of$$$141$$$143$$$O	smooth$$$144$$$150$$$O	muscle,$$$151$$$158$$$O	particularly$$$159$$$171$$$O	in$$$172$$$174$$$O	the$$$175$$$178$$$O	case$$$179$$$183$$$O	of$$$184$$$186$$$O	irritable$$$187$$$196$$$O	bowel$$$197$$$202$$$O	syndrome$$$203$$$211$$$O	(IBS).$$$212$$$218$$$O	A$$$219$$$220$$$O	medicinal$$$221$$$230$$$O	composition$$$231$$$242$$$O	in$$$243$$$245$$$O	the$$$246$$$249$$$O	form$$$250$$$254$$$O	of$$$255$$$257$$$O	an$$$258$$$260$$$O	orodispersible$$$261$$$275$$$O	tablet$$$276$$$282$$$O	for$$$283$$$286$$$O	pain$$$287$$$291$$$O	management$$$292$$$302$$$O	in$$$303$$$305$$$O	the$$$306$$$309$$$O	case$$$310$$$314$$$O	of$$$315$$$317$$$O	smooth$$$318$$$324$$$O	muscle$$$325$$$331$$$O	spasm,$$$332$$$338$$$O	characterized$$$339$$$352$$$O	in$$$353$$$355$$$O	that$$$356$$$360$$$O	it$$$361$$$363$$$O	contains$$$364$$$372$$$O	a$$$373$$$374$$$O	combination$$$375$$$386$$$O	of$$$387$$$389$$$O	hyoscine$$$390$$$398$$$I	butylbromide$$$399$$$411$$$I	and$$$412$$$415$$$O	a$$$416$$$417$$$O	non-steroidal$$$418$$$431$$$O	anti-inflammatory$$$432$$$449$$$O	drug$$$450$$$454$$$O	(NSAID)$$$455$$$462$$$O	in$$$463$$$465$$$O	therapeutically$$$466$$$481$$$O	effective$$$482$$$491$$$O	quantities$$$492$$$502$$$O	as$$$503$$$505$$$O	active$$$506$$$512$$$O	ingredients$$$513$$$524$$$O	and$$$525$$$528$$$O	pharmaceutically$$$529$$$545$$$O	acceptable$$$546$$$556$$$O	excipients.$$$557$$$568$$$O	The$$$569$$$572$$$O	tablets$$$573$$$580$$$O	have$$$581$$$585$$$O	increased$$$586$$$595$$$O	effectiveness$$$596$$$609$$$O	and$$$610$$$613$$$O	improved$$$614$$$622$$$O	bioavailability$$$623$$$638$$$O	of$$$639$$$641$$$O	the$$$642$$$645$$$O	active$$$646$$$652$$$O	ingredient.$$$653$$$664$$$O
CN101273013A
Sulfonamide$$$0$$$11$$$I	derivative$$$12$$$22$$$O	having$$$23$$$29$$$O	PGD2$$$30$$$34$$$I	receptor$$$35$$$43$$$O	antagonistic$$$44$$$56$$$O	activity$$$57$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	sulfonamide$$$25$$$36$$$I	derivative$$$37$$$47$$$O	having$$$48$$$54$$$O	DP$$$55$$$57$$$O	receptor$$$58$$$66$$$O	antagonistic$$$67$$$79$$$O	activity;$$$80$$$89$$$O	and$$$90$$$93$$$O	a$$$94$$$95$$$O	medicinal$$$96$$$105$$$O	composition$$$106$$$117$$$O	and$$$118$$$121$$$O	a$$$122$$$123$$$O	therapeutic$$$124$$$135$$$O	agent$$$136$$$141$$$O	for$$$142$$$145$$$O	allergic$$$146$$$154$$$O	diseases$$$155$$$163$$$O	which$$$164$$$169$$$O	each$$$170$$$174$$$O	contains$$$175$$$183$$$O	the$$$184$$$187$$$O	compound$$$188$$$196$$$O	as$$$197$$$199$$$O	an$$$200$$$202$$$O	active$$$203$$$209$$$O	ingredient.$$$210$$$221$$$O	The$$$222$$$225$$$O	derivative$$$226$$$236$$$O	is$$$237$$$239$$$O	a$$$240$$$241$$$O	compound$$$242$$$250$$$O	represented$$$251$$$262$$$O	by$$$263$$$265$$$O	the$$$266$$$269$$$O	general$$$270$$$277$$$O	formula$$$278$$$285$$$O	(II):$$$286$$$291$$$O	(II)$$$292$$$296$$$O	(wherein$$$297$$$305$$$O	ring$$$306$$$310$$$O	A$$$311$$$312$$$O	is$$$313$$$315$$$O	an$$$316$$$318$$$O	aromatic$$$319$$$327$$$O	carbocycle,$$$328$$$339$$$I	etc.;$$$340$$$345$$$O	ring$$$346$$$350$$$O	B$$$351$$$352$$$O	is$$$353$$$355$$$O	a$$$356$$$357$$$O	nitrogenous$$$358$$$369$$$O	nonaromatic$$$370$$$381$$$O	heterocycle,$$$382$$$394$$$I	etc.;$$$395$$$400$$$O	ring$$$401$$$405$$$O	C$$$406$$$407$$$O	is$$$408$$$410$$$O	an$$$411$$$413$$$O	aromaticcarbocycle,$$$414$$$433$$$I	etc.;$$$434$$$439$$$O	R<1>$$$440$$$444$$$O	is$$$445$$$447$$$O	carboxy,$$$448$$$456$$$I	etc.;$$$457$$$462$$$O	R<2>'s$$$463$$$469$$$O	each$$$470$$$474$$$O	independently$$$475$$$488$$$O	is$$$489$$$491$$$O	halogeno,$$$492$$$501$$$I	etc.;$$$502$$$507$$$O	R<3>$$$508$$$512$$$O	is$$$513$$$515$$$O	optionally$$$516$$$526$$$O	substituted$$$527$$$538$$$O	alkyloxy,$$$539$$$548$$$I	etc.;$$$549$$$554$$$O	R<4>'s$$$555$$$561$$$O	each$$$562$$$566$$$O	independently$$$567$$$580$$$O	is$$$581$$$583$$$O	halogeno,$$$584$$$593$$$I	etc.;$$$594$$$599$$$O	R<5>'s$$$600$$$606$$$O	each$$$607$$$611$$$O	independently$$$612$$$625$$$O	is$$$626$$$628$$$O	optionally$$$629$$$639$$$O	substituted$$$640$$$651$$$O	alkyl,$$$652$$$658$$$I	etc.;$$$659$$$664$$$O	M$$$665$$$666$$$O	is$$$667$$$669$$$O	sulfonyl,$$$670$$$679$$$I	etc.;$$$680$$$685$$$O	Y$$$686$$$687$$$O	is$$$688$$$690$$$O	a$$$691$$$692$$$O	single$$$693$$$699$$$O	bond,$$$700$$$705$$$O	etc.;$$$706$$$711$$$O	L<1>$$$712$$$716$$$O	is$$$717$$$719$$$O	a$$$720$$$721$$$O	single$$$722$$$728$$$O	bond,$$$729$$$734$$$O	etc.;$$$735$$$740$$$O	L<2>$$$741$$$745$$$O	is$$$746$$$748$$$O	a$$$749$$$750$$$O	single$$$751$$$757$$$O	bond,$$$758$$$763$$$O	etc.;$$$764$$$769$$$O	k$$$770$$$771$$$O	is$$$772$$$774$$$O	0,$$$775$$$777$$$O	1,$$$778$$$780$$$O	2,$$$781$$$783$$$O	3,$$$784$$$786$$$O	or$$$787$$$789$$$O	4;$$$790$$$792$$$O	n$$$793$$$794$$$O	is$$$795$$$797$$$O	0,$$$798$$$800$$$O	1,$$$801$$$803$$$O	or$$$804$$$806$$$O	2;$$$807$$$809$$$O	and$$$810$$$813$$$O	q$$$814$$$815$$$O	is$$$816$$$818$$$O	0,1,$$$819$$$823$$$O	2,$$$824$$$826$$$O	or$$$827$$$829$$$O	3,$$$830$$$832$$$O	provided$$$833$$$841$$$O	that,$$$842$$$847$$$O	for$$$848$$$851$$$O	example,$$$852$$$860$$$O	a)$$$861$$$863$$$O	when$$$864$$$868$$$O	ring$$$869$$$873$$$O	B$$$874$$$875$$$O	is$$$876$$$878$$$O	a$$$879$$$880$$$O	6-membered$$$881$$$891$$$O	nitrogenous$$$892$$$903$$$O	heterocycle$$$904$$$915$$$I	containing$$$916$$$926$$$O	one$$$927$$$930$$$O	or$$$931$$$933$$$O	two$$$934$$$937$$$O	nitrogen$$$938$$$946$$$I	atoms$$$947$$$952$$$O	and$$$953$$$956$$$O	ring$$$957$$$961$$$O	C$$$962$$$963$$$O	is$$$964$$$966$$$O	a$$$967$$$968$$$O	benzene$$$969$$$976$$$I	ring,$$$977$$$982$$$O	then$$$983$$$987$$$O	k$$$988$$$989$$$O	is$$$990$$$992$$$O	not$$$993$$$996$$$O	0),$$$997$$$1000$$$O	a$$$1001$$$1002$$$O	pharmaceutically$$$1003$$$1019$$$O	acceptable$$$1020$$$1030$$$O	salt$$$1031$$$1035$$$O	of$$$1036$$$1038$$$O	the$$$1039$$$1042$$$O	compound,$$$1043$$$1052$$$O	or$$$1053$$$1055$$$O	a$$$1056$$$1057$$$O	hydrate$$$1058$$$1065$$$I	of$$$1066$$$1068$$$O	either.$$$1069$$$1076$$$O
US7169813
metabolite$$$0$$$10$$$O	of$$$11$$$13$$$O	fenretinide;$$$14$$$26$$$I	4-oxo-N-(4-hydroxyphenyl)$$$28$$$53$$$I	retinamide$$$54$$$64$$$I	(4-oxo-4-HPR);$$$65$$$79$$$I	antiproliferative;$$$80$$$98$$$O	antitumor;$$$99$$$109$$$O	ovarian$$$110$$$117$$$O	carcinoma,$$$118$$$128$$$O	breast$$$129$$$135$$$O	tumor,$$$136$$$142$$$O	neuroblastoma;$$$143$$$157$$$O	overcomes$$$158$$$167$$$O	4-HPR$$$168$$$173$$$I	resistance$$$174$$$184$$$O
A$$$0$$$1$$$O	drug$$$2$$$6$$$O	based$$$7$$$12$$$O	on$$$13$$$15$$$O	a$$$16$$$17$$$O	metabolite$$$18$$$28$$$O	of$$$29$$$31$$$O	fenretinide,$$$32$$$44$$$I	or$$$45$$$47$$$O	N-(4hydroxyphenyl)$$$48$$$66$$$I	retinamide$$$67$$$77$$$I	(4-HPR),$$$78$$$86$$$I	specifically$$$87$$$99$$$O	4-oxo-N-(4-hydroxyphenyl)$$$100$$$125$$$I	retinamide$$$126$$$136$$$I	(4-oxo-4-HPR),$$$137$$$151$$$I	is$$$152$$$154$$$O	used$$$155$$$159$$$O	in$$$160$$$162$$$O	the$$$163$$$166$$$O	treatment$$$167$$$176$$$O	of$$$177$$$179$$$O	different$$$180$$$189$$$O	kinds$$$190$$$195$$$O	of$$$196$$$198$$$O	tumors,$$$199$$$206$$$O	in$$$207$$$209$$$O	particular$$$210$$$220$$$O	in$$$221$$$223$$$O	the$$$224$$$227$$$O	treatment$$$228$$$237$$$O	of$$$238$$$240$$$O	ovarian$$$241$$$248$$$O	carcinoma,$$$249$$$259$$$O	breast$$$260$$$266$$$O	tumor$$$267$$$272$$$O	and$$$273$$$276$$$O	neuroblastoma.$$$277$$$291$$$O	The$$$292$$$295$$$O	drug$$$296$$$300$$$O	is$$$301$$$303$$$O	more$$$304$$$308$$$O	potent$$$309$$$315$$$O	than$$$316$$$320$$$O	fenretinide$$$321$$$332$$$I	alone,$$$333$$$339$$$O	and$$$340$$$343$$$O	enhances$$$344$$$352$$$O	the$$$353$$$356$$$O	effects$$$357$$$364$$$O	of$$$365$$$367$$$O	fenretinide$$$368$$$379$$$I	when$$$380$$$384$$$O	administered$$$385$$$397$$$O	together$$$398$$$406$$$O	with$$$407$$$411$$$O	fenretinide.$$$412$$$424$$$I
US20090022819
Bacterial$$$0$$$9$$$O	extracts$$$10$$$18$$$O	cultured$$$19$$$27$$$O	in$$$28$$$30$$$O	thermal$$$31$$$38$$$O	waters$$$39$$$45$$$O	for$$$46$$$49$$$O	the$$$50$$$53$$$O	treatment$$$54$$$63$$$O	of$$$64$$$66$$$O	dry$$$67$$$70$$$O	skin$$$71$$$75$$$O
Dryness$$$0$$$7$$$O	of$$$8$$$10$$$O	keratin$$$11$$$18$$$O	materials,$$$19$$$29$$$O	in$$$30$$$32$$$O	particular$$$33$$$43$$$O	dryness$$$44$$$51$$$O	of$$$52$$$54$$$O	the$$$55$$$58$$$O	skin,$$$59$$$64$$$O	and$$$65$$$68$$$O	especially$$$69$$$79$$$O	disorders$$$80$$$89$$$O	associated$$$90$$$100$$$O	with$$$101$$$105$$$O	dry$$$106$$$109$$$O	and/or$$$110$$$116$$$O	hyposeborrheic$$$117$$$131$$$O	skin$$$132$$$136$$$O	are$$$137$$$140$$$O	treated$$$141$$$148$$$O	by$$$149$$$151$$$O	administering$$$152$$$165$$$O	to$$$166$$$168$$$O	individuals$$$169$$$180$$$O	afflicted$$$181$$$190$$$O	therewith,$$$191$$$201$$$O	thus$$$202$$$206$$$O	effective$$$207$$$216$$$O	amounts$$$217$$$224$$$O	of$$$225$$$227$$$O	at$$$228$$$230$$$O	least$$$231$$$236$$$O	one$$$237$$$240$$$O	extract$$$241$$$248$$$O	of$$$249$$$251$$$O	a$$$252$$$253$$$O	non-photosynthetic$$$254$$$272$$$O	and$$$273$$$276$$$O	non-fruiting$$$277$$$289$$$O	filamentous$$$290$$$301$$$O	bacterium$$$302$$$311$$$O	cultured$$$312$$$320$$$O	in$$$321$$$323$$$O	a$$$324$$$325$$$O	medium$$$326$$$332$$$O	which$$$333$$$338$$$O	includes$$$339$$$347$$$O	at$$$348$$$350$$$O	least$$$351$$$356$$$O	one$$$357$$$360$$$O	non-sulfurous$$$361$$$374$$$I	mineral$$$375$$$382$$$I	and/or$$$383$$$389$$$O	thermal$$$390$$$397$$$O	water,$$$398$$$404$$$O	e.g.,$$$405$$$410$$$O	an$$$411$$$413$$$O	extract$$$414$$$421$$$O	derived$$$422$$$429$$$O	from$$$430$$$434$$$O	the$$$435$$$438$$$O	bacterium$$$439$$$448$$$O	Vitreoscilla$$$449$$$461$$$O	filiformis,$$$462$$$473$$$O	in$$$474$$$476$$$O	particular$$$477$$$487$$$O	the$$$488$$$491$$$O	strain$$$492$$$498$$$O	ATCC$$$499$$$503$$$O	15551,$$$504$$$510$$$O	cultured$$$511$$$519$$$O	in$$$520$$$522$$$O	a$$$523$$$524$$$O	medium$$$525$$$531$$$O	enriched$$$532$$$540$$$O	with$$$541$$$545$$$O	water$$$546$$$551$$$O	from$$$552$$$556$$$O	La$$$557$$$559$$$O	Roche$$$560$$$565$$$O	Posay.$$$566$$$572$$$O
CN1563069A
6$$$0$$$1$$$O	gene$$$2$$$6$$$O	of$$$7$$$9$$$O	neurenergen$$$10$$$21$$$O	sourced$$$22$$$29$$$O	from$$$30$$$34$$$O	human,$$$35$$$41$$$O	and$$$42$$$45$$$O	application$$$46$$$57$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	base$$$25$$$29$$$O	sequence$$$30$$$38$$$O	of$$$39$$$41$$$O	new$$$42$$$45$$$O	neurotrophin-humanized$$$46$$$68$$$O	neurotrophin-6-(NT-6)$$$69$$$90$$$O	and$$$91$$$94$$$O	proves$$$95$$$101$$$O	application$$$102$$$113$$$O	of$$$114$$$116$$$O	said$$$117$$$121$$$O	hummnized$$$122$$$131$$$O	NT-6$$$132$$$136$$$O	gene.$$$137$$$142$$$O	the$$$143$$$146$$$O	humanized$$$147$$$156$$$O	NT-6$$$157$$$161$$$O	gene$$$162$$$166$$$O	described$$$167$$$176$$$O	by$$$177$$$179$$$O	said$$$180$$$184$$$O	invention$$$185$$$194$$$O	can$$$195$$$198$$$O	be$$$199$$$201$$$O	obtained$$$202$$$210$$$O	from$$$211$$$215$$$O	RNA$$$216$$$219$$$O	of$$$220$$$222$$$O	brain$$$223$$$228$$$O	tissue$$$229$$$235$$$O	of$$$236$$$238$$$O	abortus$$$239$$$246$$$O	by$$$247$$$249$$$O	adopting$$$250$$$258$$$O	reverse$$$259$$$266$$$O	transcriptase-polymerase$$$267$$$291$$$O	chain$$$292$$$297$$$O	reaction$$$298$$$306$$$O	method.$$$307$$$314$$$O	the$$$315$$$318$$$O	experiments$$$319$$$330$$$O	show$$$331$$$335$$$O	that$$$336$$$340$$$O	the$$$341$$$344$$$O	prokaryotic$$$345$$$356$$$O	expression$$$357$$$367$$$O	product$$$368$$$375$$$O	of$$$376$$$378$$$O	coded$$$379$$$384$$$O	mature$$$385$$$391$$$O	peptide$$$392$$$399$$$O	fragment$$$400$$$408$$$O	in$$$409$$$411$$$O	the$$$412$$$415$$$O	above-mentioned$$$416$$$431$$$O	humanized$$$432$$$441$$$O	NT-6$$$442$$$446$$$O	cDNA$$$447$$$451$$$O	has$$$452$$$455$$$O	trophic$$$456$$$463$$$O	action$$$464$$$470$$$O	on$$$471$$$473$$$O	neuron,$$$474$$$481$$$O	and$$$482$$$485$$$O	can$$$486$$$489$$$O	resist$$$490$$$496$$$O	the$$$497$$$500$$$O	neuronal$$$501$$$509$$$O	degeneration$$$510$$$522$$$O	due$$$523$$$526$$$O	to$$$527$$$529$$$O	axonal$$$530$$$536$$$O	injury,$$$537$$$544$$$O	so$$$545$$$547$$$O	that$$$548$$$552$$$O	the$$$553$$$556$$$O	medicine$$$557$$$565$$$O	containing$$$566$$$576$$$O	the$$$577$$$580$$$O	above-mentioned$$$581$$$596$$$O	humanized$$$597$$$606$$$O	NT-6$$$607$$$611$$$O	gene$$$612$$$616$$$O	can$$$617$$$620$$$O	be$$$621$$$623$$$O	prepared,$$$624$$$633$$$O	and$$$634$$$637$$$O	used$$$638$$$642$$$O	for$$$643$$$646$$$O	curing$$$647$$$653$$$O	the$$$654$$$657$$$O	diseaxes$$$658$$$666$$$O	of$$$667$$$669$$$O	traumatic$$$670$$$679$$$O	pathologic$$$680$$$690$$$O	changes$$$691$$$698$$$O	of$$$699$$$701$$$O	nervous$$$702$$$709$$$O	system.$$$710$$$717$$$O
CN102552203A
Pirfenidone$$$0$$$11$$$I	tablet$$$12$$$18$$$O	and$$$19$$$22$$$O	preparation$$$23$$$34$$$O	method$$$35$$$41$$$O	thereof$$$42$$$49$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	pirfenidone$$$26$$$37$$$I	tablet$$$38$$$44$$$O	and$$$45$$$48$$$O	a$$$49$$$50$$$O	preparation$$$51$$$62$$$O	method$$$63$$$69$$$O	thereof.$$$70$$$78$$$O	According$$$79$$$88$$$O	to$$$89$$$91$$$O	the$$$92$$$95$$$O	pirfenidone$$$96$$$107$$$I	tablet$$$108$$$114$$$O	and$$$115$$$118$$$O	the$$$119$$$122$$$O	preparation$$$123$$$134$$$O	method$$$135$$$141$$$O	thereof,$$$142$$$150$$$O	the$$$151$$$154$$$O	compressibility$$$155$$$170$$$O	and$$$171$$$174$$$O	formability$$$175$$$186$$$O	of$$$187$$$189$$$O	the$$$190$$$193$$$O	tablet$$$194$$$200$$$O	can$$$201$$$204$$$O	be$$$205$$$207$$$O	effectively$$$208$$$219$$$O	improved$$$220$$$228$$$O	by$$$229$$$231$$$O	changing$$$232$$$240$$$O	the$$$241$$$244$$$O	proportion$$$245$$$255$$$O	of$$$256$$$258$$$O	lactose$$$259$$$266$$$I	to$$$267$$$269$$$O	microcrystalline$$$270$$$286$$$O	cellulose$$$287$$$296$$$O	in$$$297$$$299$$$O	the$$$300$$$303$$$O	filler;$$$304$$$311$$$O	and$$$312$$$315$$$O	the$$$316$$$319$$$O	preparation$$$320$$$331$$$O	process$$$332$$$339$$$O	has$$$340$$$343$$$O	the$$$344$$$347$$$O	advantages$$$348$$$358$$$O	of$$$359$$$361$$$O	simpleness$$$362$$$372$$$O	and$$$373$$$376$$$O	feasibility,$$$377$$$389$$$O	high$$$390$$$394$$$O	stability$$$395$$$404$$$O	and$$$405$$$408$$$O	wide$$$409$$$413$$$O	application$$$414$$$425$$$O	range,$$$426$$$432$$$O	and$$$433$$$436$$$O	is$$$437$$$439$$$O	suitable$$$440$$$448$$$O	for$$$449$$$452$$$O	production$$$453$$$463$$$O	in$$$464$$$466$$$O	scale.$$$467$$$473$$$O
US20060100195
Remedies$$$0$$$8$$$O	for$$$9$$$12$$$O	urinary$$$13$$$20$$$O	frequency$$$21$$$30$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	agent$$$36$$$41$$$O	for$$$42$$$45$$$O	the$$$46$$$49$$$O	treatment$$$50$$$59$$$O	and/or$$$60$$$66$$$O	prevention$$$67$$$77$$$O	of$$$78$$$80$$$O	pollakiuria$$$81$$$92$$$O	comprising$$$93$$$103$$$O	a$$$104$$$105$$$O	compound$$$106$$$114$$$O	having$$$115$$$121$$$O	an$$$122$$$124$$$O	antagonism$$$125$$$135$$$O	to$$$136$$$138$$$O	an$$$139$$$141$$$O	EP1$$$142$$$145$$$O	receptor$$$146$$$154$$$O	which$$$155$$$160$$$O	is$$$161$$$163$$$O	a$$$164$$$165$$$O	prostaglandin$$$166$$$179$$$I	E2$$$180$$$182$$$I	receptor$$$183$$$191$$$O	subtype.$$$192$$$200$$$O	A$$$201$$$202$$$O	compound$$$203$$$211$$$O	having$$$212$$$218$$$O	an$$$219$$$221$$$O	antagonism$$$222$$$232$$$O	to$$$233$$$235$$$O	an$$$236$$$238$$$O	EP1$$$239$$$242$$$O	receptor$$$243$$$251$$$O	antagonistically$$$252$$$268$$$O	acts$$$269$$$273$$$O	on$$$274$$$276$$$O	an$$$277$$$279$$$O	EP1$$$280$$$283$$$O	receptor$$$284$$$292$$$O	which$$$293$$$298$$$O	is$$$299$$$301$$$O	a$$$302$$$303$$$O	prostaglandin$$$304$$$317$$$I	PGE2$$$318$$$322$$$I	receptor$$$323$$$331$$$O	subtype$$$332$$$339$$$O	and$$$340$$$343$$$O	significantly$$$344$$$357$$$O	shows$$$358$$$363$$$O	a$$$364$$$365$$$O	suppressive$$$366$$$377$$$O	activity$$$378$$$386$$$O	for$$$387$$$390$$$O	urination$$$391$$$400$$$O	frequency$$$401$$$410$$$O	in$$$411$$$413$$$O	models$$$414$$$420$$$O	where$$$421$$$426$$$O	pollakiuria$$$427$$$438$$$O	is$$$439$$$441$$$O	induced.$$$442$$$450$$$O	Therefore,$$$451$$$461$$$O	it$$$462$$$464$$$O	is$$$465$$$467$$$O	effective$$$468$$$477$$$O	for$$$478$$$481$$$O	the$$$482$$$485$$$O	treatment$$$486$$$495$$$O	and/or$$$496$$$502$$$O	prevention$$$503$$$513$$$O	of$$$514$$$516$$$O	pollakiuria$$$517$$$528$$$O	(that$$$529$$$534$$$O	which$$$535$$$540$$$O	is$$$541$$$543$$$O	due$$$544$$$547$$$O	to$$$548$$$550$$$O	nurogenic$$$551$$$560$$$O	bladder,$$$561$$$569$$$O	nervous$$$570$$$577$$$O	bladder,$$$578$$$586$$$O	stimulated$$$587$$$597$$$O	bladder,$$$598$$$606$$$O	unstable$$$607$$$615$$$O	bladder,$$$616$$$624$$$O	benign$$$625$$$631$$$O	prostatic$$$632$$$641$$$O	hypertrophy,$$$642$$$654$$$O	etc.).$$$655$$$661$$$O
CN102512415A
Clopidogrel$$$0$$$11$$$I	bisulfate$$$12$$$21$$$I	medicine$$$22$$$30$$$O	composition$$$31$$$42$$$O	and$$$43$$$46$$$O	preparation$$$47$$$58$$$O	method$$$59$$$65$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	clopidogrel$$$27$$$38$$$I	bisulfate$$$39$$$48$$$I	medicine$$$49$$$57$$$O	composition$$$58$$$69$$$O	and$$$70$$$73$$$O	a$$$74$$$75$$$O	preparation$$$76$$$87$$$O	method.$$$88$$$95$$$O	The$$$96$$$99$$$O	composition$$$100$$$111$$$O	contains$$$112$$$120$$$O	clopidogrel$$$121$$$132$$$I	bisulfate,$$$133$$$143$$$I	as$$$144$$$146$$$O	well$$$147$$$151$$$O	as$$$152$$$154$$$O	proper$$$155$$$161$$$O	filler,$$$162$$$169$$$O	disintegrant$$$170$$$182$$$O	and$$$183$$$186$$$O	lubricant,$$$187$$$197$$$O	wherein$$$198$$$205$$$O	the$$$206$$$209$$$O	content$$$210$$$217$$$O	of$$$218$$$220$$$O	the$$$221$$$224$$$O	clopidogrel$$$225$$$236$$$I	bisulfate$$$237$$$246$$$I	is$$$247$$$249$$$O	25-60%,$$$250$$$257$$$O	the$$$258$$$261$$$O	content$$$262$$$269$$$O	of$$$270$$$272$$$O	the$$$273$$$276$$$O	filler$$$277$$$283$$$O	is$$$284$$$286$$$O	35-65%,$$$287$$$294$$$O	the$$$295$$$298$$$O	content$$$299$$$306$$$O	of$$$307$$$309$$$O	the$$$310$$$313$$$O	disintegrant$$$314$$$326$$$O	is$$$327$$$329$$$O	2.5-8%,$$$330$$$337$$$O	and$$$338$$$341$$$O	the$$$342$$$345$$$O	content$$$346$$$353$$$O	of$$$354$$$356$$$O	the$$$357$$$360$$$O	lubricant$$$361$$$370$$$O	is$$$371$$$373$$$O	2-6%.$$$374$$$379$$$O	Additionally,$$$380$$$393$$$O	the$$$394$$$397$$$O	invention$$$398$$$407$$$O	further$$$408$$$415$$$O	provides$$$416$$$424$$$O	a$$$425$$$426$$$O	preparation$$$427$$$438$$$O	method$$$439$$$445$$$O	for$$$446$$$449$$$O	preparing$$$450$$$459$$$O	tablets$$$460$$$467$$$O	from$$$468$$$472$$$O	the$$$473$$$476$$$O	composition.$$$477$$$489$$$O	Each$$$490$$$494$$$O	component$$$495$$$504$$$O	in$$$505$$$507$$$O	the$$$508$$$511$$$O	composition$$$512$$$523$$$O	disclosed$$$524$$$533$$$O	by$$$534$$$536$$$O	the$$$537$$$540$$$O	invention$$$541$$$550$$$O	is$$$551$$$553$$$O	good$$$554$$$558$$$O	in$$$559$$$561$$$O	compatibility,$$$562$$$576$$$O	low$$$577$$$580$$$O	in$$$581$$$583$$$O	price$$$584$$$589$$$O	and$$$590$$$593$$$O	easy$$$594$$$598$$$O	to$$$599$$$601$$$O	get;$$$602$$$606$$$O	and$$$607$$$610$$$O	the$$$611$$$614$$$O	preparation$$$615$$$626$$$O	for$$$627$$$630$$$O	tablets$$$631$$$638$$$O	is$$$639$$$641$$$O	simple$$$642$$$648$$$O	in$$$649$$$651$$$O	process$$$652$$$659$$$O	and$$$660$$$663$$$O	without$$$664$$$671$$$O	the$$$672$$$675$$$O	need$$$676$$$680$$$O	to$$$681$$$683$$$O	add$$$684$$$687$$$O	new$$$688$$$691$$$O	equipment,$$$692$$$702$$$O	capable$$$703$$$710$$$O	of$$$711$$$713$$$O	efficiently$$$714$$$725$$$O	solving$$$726$$$733$$$O	the$$$734$$$737$$$O	problem$$$738$$$745$$$O	of$$$746$$$748$$$O	sticking$$$749$$$757$$$O	appearing$$$758$$$767$$$O	during$$$768$$$774$$$O	preparation$$$775$$$786$$$O	process,$$$787$$$795$$$O	andsuitable$$$796$$$807$$$O	for$$$808$$$811$$$O	industrialized$$$812$$$826$$$O	production.$$$827$$$838$$$O
US20100179202
Orally$$$0$$$6$$$O	disintegrating$$$7$$$21$$$O	composition$$$22$$$33$$$O	of$$$34$$$36$$$O	zolmitriptan$$$37$$$49$$$I
A$$$0$$$1$$$O	composition$$$2$$$13$$$O	containing$$$14$$$24$$$O	Zolmitriptan$$$25$$$37$$$I	in$$$38$$$40$$$O	the$$$41$$$44$$$O	form$$$45$$$49$$$O	of$$$50$$$52$$$O	oral$$$53$$$57$$$O	disintegrating$$$58$$$72$$$O	tablet$$$73$$$79$$$O	for$$$80$$$83$$$O	the$$$84$$$87$$$O	acute$$$88$$$93$$$O	treatment$$$94$$$103$$$O	of$$$104$$$106$$$O	migraines$$$107$$$116$$$O	is$$$117$$$119$$$O	disclosed.$$$120$$$130$$$O	The$$$131$$$134$$$O	said$$$135$$$139$$$O	composition$$$140$$$151$$$O	comprises$$$152$$$161$$$O	(a)$$$162$$$165$$$O	Zolmitriptan,$$$166$$$179$$$I	a$$$180$$$181$$$O	salt$$$182$$$186$$$O	or$$$187$$$189$$$O	solvate$$$190$$$197$$$O	or$$$198$$$200$$$O	polymorph$$$201$$$210$$$O	thereof$$$211$$$218$$$O	as$$$219$$$221$$$O	active$$$222$$$228$$$O	ingredient,$$$229$$$240$$$O	(b)$$$241$$$244$$$O	mannitol,$$$245$$$254$$$I	and$$$255$$$258$$$O	(c)$$$259$$$262$$$O	calcium$$$263$$$270$$$I	silicate,$$$271$$$280$$$I	and$$$281$$$284$$$O	(d)$$$285$$$288$$$O	optionally,$$$289$$$300$$$O	one$$$301$$$304$$$O	or$$$305$$$307$$$O	more$$$308$$$312$$$O	polysaccharides$$$313$$$328$$$O	along$$$329$$$334$$$O	with$$$335$$$339$$$O	one$$$340$$$343$$$O	or$$$344$$$346$$$O	more$$$347$$$351$$$O	pharmaceutically$$$352$$$368$$$O	acceptable$$$369$$$379$$$O	excipients.$$$380$$$391$$$O
CN101148445A
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	o-dihydroxyflavone-selenium$$$21$$$48$$$I	complexes$$$49$$$58$$$O	and$$$59$$$62$$$O	medical$$$63$$$70$$$O	use$$$71$$$74$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	synthesis$$$33$$$42$$$O	process$$$43$$$50$$$O	and$$$51$$$54$$$O	medicinal$$$55$$$64$$$O	use$$$65$$$68$$$O	of$$$69$$$71$$$O	o-dihydroxyflavone-selenium$$$72$$$99$$$I	complex.$$$100$$$108$$$O	The$$$109$$$112$$$O	o-dihydroxyflavone-selenium$$$113$$$140$$$I	complex$$$141$$$148$$$O	in$$$149$$$151$$$O	the$$$152$$$155$$$O	structure$$$156$$$165$$$O	as$$$166$$$168$$$O	shown$$$169$$$174$$$O	may$$$175$$$178$$$O	be$$$179$$$181$$$O	applied$$$182$$$189$$$O	in$$$190$$$192$$$O	preparing$$$193$$$202$$$O	health$$$203$$$209$$$O	product,$$$210$$$218$$$O	pesticide,$$$219$$$229$$$O	plant$$$230$$$235$$$O	growth$$$236$$$242$$$O	regulator,$$$243$$$253$$$O	feed$$$254$$$258$$$O	additive,$$$259$$$268$$$O	immunomodulator,$$$269$$$285$$$O	antitumor$$$286$$$295$$$O	medicine,$$$296$$$305$$$O	antibacterial$$$306$$$319$$$O	medicine,$$$320$$$329$$$O	etc.$$$330$$$334$$$O
WO2010113183A3
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	preparation$$$16$$$27$$$O	of$$$28$$$30$$$O	1-[[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]sulfonyl]$$$31$$$93$$$I	pyrrolidine$$$94$$$105$$$I	and$$$106$$$109$$$O	its$$$110$$$113$$$O	pharmaceutically$$$114$$$130$$$O	acceptable$$$131$$$141$$$O	salts$$$142$$$147$$$O
A$$$0$$$1$$$O	process$$$2$$$9$$$O	for$$$10$$$13$$$O	preparation$$$14$$$25$$$O	of$$$26$$$28$$$O	1-[[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine$$$29$$$102$$$I	of$$$103$$$105$$$O	Formula$$$106$$$113$$$O	(1),$$$114$$$118$$$O	which$$$119$$$124$$$O	is$$$125$$$127$$$O	commonly$$$128$$$136$$$O	known$$$137$$$142$$$O	as$$$143$$$145$$$O	Almotriptan,$$$146$$$158$$$I	and$$$159$$$162$$$O	its$$$163$$$166$$$O	pharmaceutically$$$167$$$183$$$O	acceptable$$$184$$$194$$$O	salts$$$195$$$200$$$O	is$$$201$$$203$$$O	provided.$$$204$$$213$$$O	The$$$214$$$217$$$O	required$$$218$$$226$$$O	purity$$$227$$$233$$$O	of$$$234$$$236$$$O	almotriptan$$$237$$$248$$$I	malate$$$249$$$255$$$I	free$$$256$$$260$$$O	of$$$261$$$263$$$O	impurities$$$264$$$274$$$O	is$$$275$$$277$$$O	attained$$$278$$$286$$$O	in$$$287$$$289$$$O	three$$$290$$$295$$$O	different$$$296$$$305$$$O	ways,$$$306$$$311$$$O	including$$$312$$$321$$$O	by$$$322$$$324$$$O	preparing$$$325$$$334$$$O	the$$$335$$$338$$$O	acid$$$339$$$343$$$O	addition$$$344$$$352$$$O	salts$$$353$$$358$$$O	of$$$359$$$361$$$O	amino$$$362$$$367$$$I	indole$$$368$$$374$$$I	compound,$$$375$$$384$$$O	by$$$385$$$387$$$O	proceeding$$$388$$$398$$$O	through$$$399$$$406$$$O	the$$$407$$$410$$$O	almotriptan$$$411$$$422$$$I	succinate$$$423$$$432$$$I	and$$$433$$$436$$$O	by$$$437$$$439$$$O	specific$$$440$$$448$$$O	purification$$$449$$$461$$$O	of$$$462$$$464$$$O	almotriptan$$$465$$$476$$$I	malate$$$477$$$483$$$I	from$$$484$$$488$$$O	a$$$489$$$490$$$O	suitable$$$491$$$499$$$O	solvent.$$$500$$$508$$$O
CN101492426B
Thiazole$$$0$$$8$$$I	schiff$$$9$$$15$$$I	base$$$16$$$20$$$I	containing$$$21$$$31$$$O	nitryl,$$$32$$$39$$$I	preparation$$$40$$$51$$$O	and$$$52$$$55$$$O	uses$$$56$$$60$$$O	thereof$$$61$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	thiazole$$$24$$$32$$$I	Schiff$$$33$$$39$$$I	base$$$40$$$44$$$I	(I,$$$45$$$48$$$O	II)$$$49$$$52$$$O	containing$$$53$$$63$$$O	nitryl$$$64$$$70$$$I	with$$$71$$$75$$$O	a$$$76$$$77$$$O	chemical$$$78$$$86$$$O	structural$$$87$$$97$$$O	formula$$$98$$$105$$$O	as$$$106$$$108$$$O	follows.$$$109$$$117$$$O	A$$$118$$$119$$$O	method$$$120$$$126$$$O	for$$$127$$$130$$$O	preparing$$$131$$$140$$$O	the$$$141$$$144$$$O	thiazole$$$145$$$153$$$I	Schiff$$$154$$$160$$$I	base$$$161$$$165$$$I	containing$$$166$$$176$$$O	the$$$177$$$180$$$O	nitryl$$$181$$$187$$$I	comprises$$$188$$$197$$$O	the$$$198$$$201$$$O	steps$$$202$$$207$$$O	as$$$208$$$210$$$O	follows:$$$211$$$219$$$O	nitrobenzene$$$220$$$232$$$I	formaldehyde$$$233$$$245$$$I	takes$$$246$$$251$$$O	reflux$$$252$$$258$$$O	reaction$$$259$$$267$$$O	with$$$268$$$272$$$O	5-(4-chlorobenzyl)-4-tert-butyl-2-amido$$$273$$$312$$$I	thiazole$$$313$$$321$$$I	in$$$322$$$324$$$O	ethanol$$$325$$$332$$$O	to$$$333$$$335$$$O	prepare$$$336$$$343$$$O	and$$$344$$$347$$$O	obtain$$$348$$$354$$$O	the$$$355$$$358$$$O	thiazole$$$359$$$367$$$I	Schiff$$$368$$$374$$$I	base$$$375$$$379$$$I	[I$$$380$$$382$$$O	with$$$383$$$387$$$O	chemical$$$388$$$396$$$O	name$$$397$$$401$$$O	of$$$402$$$404$$$O	5-(4-chlorobenzyl)-4-tert-butyl-2-(nitrobenzyl$$$405$$$451$$$I	imino)$$$452$$$458$$$I	thiazole]$$$459$$$468$$$I	containing$$$469$$$479$$$O	the$$$480$$$483$$$O	nitryl;$$$484$$$491$$$I	or$$$492$$$494$$$O	salicylaldehyde$$$495$$$510$$$I	takes$$$511$$$516$$$O	reflux$$$517$$$523$$$O	reaction$$$524$$$532$$$O	with$$$533$$$537$$$O	4-(nitrophenyl)-2-amido$$$538$$$561$$$I	thiazole$$$562$$$570$$$I	in$$$571$$$573$$$O	the$$$574$$$577$$$O	ethanol$$$578$$$585$$$I	to$$$586$$$588$$$O	prepare$$$589$$$596$$$O	and$$$597$$$600$$$O	obtain$$$601$$$607$$$O	the$$$608$$$611$$$O	thiazole$$$612$$$620$$$I	Schiff$$$621$$$627$$$I	base$$$628$$$632$$$I	[II$$$633$$$636$$$O	with$$$637$$$641$$$O	chemical$$$642$$$650$$$O	name$$$651$$$655$$$O	of$$$656$$$658$$$O	4-($$$659$$$662$$$I	nitrophenyl)-2-(2-hydroxy$$$663$$$688$$$I	benzyl$$$689$$$695$$$I	imino)$$$696$$$702$$$I	thiazole]$$$703$$$712$$$I	containing$$$713$$$723$$$O	the$$$724$$$727$$$O	nitryl.$$$728$$$735$$$I	The$$$736$$$739$$$O	thiazole$$$740$$$748$$$I	Schiff$$$749$$$755$$$I	base$$$756$$$760$$$I	containing$$$761$$$771$$$O	the$$$772$$$775$$$O	nitryl$$$776$$$782$$$I	can$$$783$$$786$$$O	be$$$787$$$789$$$O	used$$$790$$$794$$$O	for$$$795$$$798$$$O	preparing$$$799$$$808$$$O	anti-inflammatory$$$809$$$826$$$O	analgesics.$$$827$$$838$$$O
CN1857733A
Preparing$$$0$$$9$$$O	process$$$10$$$17$$$O	of$$$18$$$20$$$O	bioadhesive$$$21$$$32$$$O	chitosan$$$33$$$41$$$O	particle$$$42$$$50$$$O	for$$$51$$$54$$$O	embedding$$$55$$$64$$$O	and$$$65$$$68$$$O	transferring$$$69$$$81$$$O	active$$$82$$$88$$$O	medicine$$$89$$$97$$$O
The$$$0$$$3$$$O	preparation$$$4$$$15$$$O	process$$$16$$$23$$$O	of$$$24$$$26$$$O	bioadhesive$$$27$$$38$$$O	chitosan$$$39$$$47$$$O	particle$$$48$$$56$$$O	for$$$57$$$60$$$O	embedding$$$61$$$70$$$O	and$$$71$$$74$$$O	transferring$$$75$$$87$$$O	active$$$88$$$94$$$O	medicine$$$95$$$103$$$O	includes$$$104$$$112$$$O	the$$$113$$$116$$$O	following$$$117$$$126$$$O	steps:$$$127$$$133$$$O	compounding$$$134$$$145$$$O	water-in-oil$$$146$$$158$$$O	emulsion$$$159$$$167$$$O	including$$$168$$$177$$$O	chitosan$$$178$$$186$$$O	solution$$$187$$$195$$$O	with$$$196$$$200$$$O	dissolved$$$201$$$210$$$O	active$$$211$$$217$$$O	medicine$$$218$$$226$$$O	as$$$227$$$229$$$O	dispersed$$$230$$$239$$$O	phase,$$$240$$$246$$$O	vegetable$$$247$$$256$$$O	oil$$$257$$$260$$$O	as$$$261$$$263$$$O	continuous$$$264$$$274$$$O	phase,$$$275$$$281$$$O	surfactant$$$282$$$292$$$O	and$$$293$$$296$$$O	dispersant;$$$297$$$308$$$O	cross-linking$$$309$$$322$$$O	the$$$323$$$326$$$O	chitosan$$$327$$$335$$$O	with$$$336$$$340$$$O	glutaraldehyde;$$$341$$$356$$$I	and$$$357$$$360$$$O	separating$$$361$$$371$$$O	oil$$$372$$$375$$$O	phase$$$376$$$381$$$O	and$$$382$$$385$$$O	water$$$386$$$391$$$O	phase$$$392$$$397$$$O	to$$$398$$$400$$$O	obtain$$$401$$$407$$$O	chitosan$$$408$$$416$$$O	particle$$$417$$$425$$$O	with$$$426$$$430$$$O	embedded$$$431$$$439$$$O	active$$$440$$$446$$$O	medicine.$$$447$$$456$$$O	The$$$457$$$460$$$O	preparation$$$461$$$472$$$O	process$$$473$$$480$$$O	is$$$481$$$483$$$O	simple,$$$484$$$491$$$O	has$$$492$$$495$$$O	mild$$$496$$$500$$$O	preparing$$$501$$$510$$$O	condition$$$511$$$520$$$O	and$$$521$$$524$$$O	facile$$$525$$$531$$$O	and$$$532$$$535$$$O	cheap$$$536$$$541$$$O	material,$$$542$$$551$$$O	and$$$552$$$555$$$O	can$$$556$$$559$$$O	obtain$$$560$$$566$$$O	chitosan$$$567$$$575$$$O	particle$$$576$$$584$$$O	of$$$585$$$587$$$O	hundreds$$$588$$$596$$$O	nanometer$$$597$$$606$$$O	size$$$607$$$611$$$O	via$$$612$$$615$$$O	controlling$$$616$$$627$$$O	the$$$628$$$631$$$O	reaction$$$632$$$640$$$O	condition.$$$641$$$651$$$O	The$$$652$$$655$$$O	prepared$$$656$$$664$$$O	chitosan$$$665$$$673$$$O	particle$$$674$$$682$$$O	has$$$683$$$686$$$O	excellent$$$687$$$696$$$O	adhesion$$$697$$$705$$$O	on$$$706$$$708$$$O	teeth$$$709$$$714$$$O	simulating$$$715$$$725$$$O	matter$$$726$$$732$$$O	hydroapetite$$$733$$$745$$$O	and$$$746$$$749$$$O	glass,$$$750$$$756$$$O	and$$$757$$$760$$$O	may$$$761$$$764$$$O	be$$$765$$$767$$$O	used$$$768$$$772$$$O	in$$$773$$$775$$$O	embedding$$$776$$$785$$$O	and$$$786$$$789$$$O	transferring$$$790$$$802$$$O	active$$$803$$$809$$$O	medicine$$$810$$$818$$$O	for$$$819$$$822$$$O	slow$$$823$$$827$$$O	and$$$828$$$831$$$O	continuous$$$832$$$842$$$O	release$$$843$$$850$$$O	of$$$851$$$853$$$O	active$$$854$$$860$$$O	medicine.$$$861$$$870$$$O	The$$$871$$$874$$$O	particle$$$875$$$883$$$O	can$$$884$$$887$$$O	set$$$888$$$891$$$O	stably$$$892$$$898$$$O	in$$$899$$$901$$$O	toothpaste$$$902$$$912$$$O	matrix$$$913$$$919$$$O	to$$$920$$$922$$$O	prolong$$$923$$$930$$$O	the$$$931$$$934$$$O	active$$$935$$$941$$$O	period$$$942$$$948$$$O	of$$$949$$$951$$$O	active$$$952$$$958$$$O	matter$$$959$$$965$$$O	on$$$966$$$968$$$O	the$$$969$$$972$$$O	teeth$$$973$$$978$$$O	surface$$$979$$$986$$$O	for$$$987$$$990$$$O	sterilizing$$$991$$$1002$$$O	and$$$1003$$$1006$$$O	strengthening$$$1007$$$1020$$$O	teeth.$$$1021$$$1027$$$O
CN1927351A
Heat$$$0$$$4$$$O	clearing$$$5$$$13$$$O	and$$$14$$$17$$$O	detoxicating$$$18$$$30$$$O	drug$$$31$$$35$$$O	for$$$36$$$39$$$O	abating$$$40$$$47$$$O	fever$$$48$$$53$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicinal$$$26$$$35$$$O	composition$$$36$$$47$$$O	for$$$48$$$51$$$O	treating$$$52$$$60$$$O	fever,$$$61$$$67$$$O	which$$$68$$$73$$$O	is$$$74$$$76$$$O	prepared$$$77$$$85$$$O	from$$$86$$$90$$$O	raw$$$91$$$94$$$O	materials$$$95$$$104$$$O	including$$$105$$$114$$$O	honeysuckle$$$115$$$126$$$O	flower,$$$127$$$134$$$O	capsule$$$135$$$142$$$O	of$$$143$$$145$$$O	weeping$$$146$$$153$$$O	forsythia,$$$154$$$164$$$O	plaster$$$165$$$172$$$O	stone,$$$173$$$179$$$O	clerodendroa$$$180$$$192$$$O	cyrtophyllum,$$$193$$$206$$$O	wild$$$207$$$211$$$O	chrysanthemum$$$212$$$225$$$O	flower,$$$226$$$233$$$O	mentha,$$$234$$$241$$$O	mulberry$$$242$$$250$$$O	leaf,$$$251$$$256$$$O	corktree$$$257$$$265$$$O	bark,$$$266$$$271$$$O	root$$$272$$$276$$$O	bark$$$277$$$281$$$O	of$$$282$$$284$$$O	chinese$$$285$$$292$$$O	wolf$$$293$$$297$$$O	berry,$$$298$$$304$$$O	reed$$$305$$$309$$$O	rhizome,$$$310$$$318$$$O	bitter$$$319$$$325$$$O	apricot$$$326$$$333$$$O	seed,$$$334$$$339$$$O	baikal$$$340$$$346$$$O	skullcap$$$347$$$355$$$O	root,$$$356$$$361$$$O	talcum,$$$362$$$369$$$O	anemarrhena$$$370$$$381$$$O	rhizome,$$$382$$$390$$$O	pericarpium$$$391$$$402$$$O	trichosanthis,$$$403$$$417$$$O	stem$$$418$$$422$$$O	pith$$$423$$$427$$$O	of$$$428$$$430$$$O	the$$$431$$$434$$$O	ricepapr$$$435$$$443$$$O	plant$$$444$$$449$$$O	and$$$450$$$453$$$O	cicada$$$454$$$460$$$O	skin.$$$461$$$466$$$O
US20080200484
Pharmaceutical$$$0$$$14$$$O	Compositions$$$15$$$27$$$O	Comprising$$$28$$$38$$$O	A$$$39$$$40$$$O	Multifunctional$$$41$$$56$$$O	Phosphodiesterase$$$57$$$74$$$O	Inhibitor$$$75$$$84$$$O	and$$$85$$$88$$$O	An$$$89$$$91$$$O	Adenosine$$$92$$$101$$$I	Uptake$$$102$$$108$$$O	Inhibitor$$$109$$$118$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	pharmaceutical$$$33$$$47$$$O	compositions$$$48$$$60$$$O	comprising$$$61$$$71$$$O	at$$$72$$$74$$$O	least$$$75$$$80$$$O	one$$$81$$$84$$$O	multifunctional$$$85$$$100$$$O	phosphodiesterase$$$101$$$118$$$O	inhibitor$$$119$$$128$$$O	(MPDEI)$$$129$$$136$$$O	and$$$137$$$140$$$O	at$$$141$$$143$$$O	least$$$144$$$149$$$O	one$$$150$$$153$$$O	adenosine$$$154$$$163$$$I	uptake$$$164$$$170$$$O	inhibitor.$$$171$$$181$$$O	The$$$182$$$185$$$O	present$$$186$$$193$$$O	invention$$$194$$$203$$$O	also$$$204$$$208$$$O	relates$$$209$$$216$$$O	to$$$217$$$219$$$O	compositions$$$220$$$232$$$O	comprising$$$233$$$243$$$O	cilostazol$$$244$$$254$$$I	and$$$255$$$258$$$O	dipyridamole$$$259$$$271$$$I	and$$$272$$$275$$$O	their$$$276$$$281$$$O	use.$$$282$$$286$$$O
CN103083279A
Polysaccharide$$$0$$$14$$$O	sulfate$$$15$$$22$$$O	soft$$$23$$$27$$$O	capsule$$$28$$$35$$$O
The$$$0$$$3$$$O	application$$$4$$$15$$$O	relates$$$16$$$23$$$O	to$$$24$$$26$$$O	a$$$27$$$28$$$O	soft$$$29$$$33$$$O	capsule,$$$34$$$42$$$O	and$$$43$$$46$$$O	particularly$$$47$$$59$$$O	relates$$$60$$$67$$$O	to$$$68$$$70$$$O	the$$$71$$$74$$$O	soft$$$75$$$79$$$O	capsule$$$80$$$87$$$O	containing$$$88$$$98$$$O	polysaccharide$$$99$$$113$$$O	sulfate$$$114$$$121$$$O	clathrate$$$122$$$131$$$O	compound.$$$132$$$141$$$O
CN101658646B
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	for$$$27$$$30$$$O	curing$$$31$$$37$$$O	summer-heat$$$38$$$49$$$O	cold$$$50$$$54$$$O	and$$$55$$$58$$$O	preparation$$$59$$$70$$$O	method$$$71$$$77$$$O	thereof$$$78$$$85$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pharmaceutical$$$27$$$41$$$O	composition$$$42$$$53$$$O	for$$$54$$$57$$$O	curing$$$58$$$64$$$O	summer-heat$$$65$$$76$$$O	cold$$$77$$$81$$$O	and$$$82$$$85$$$O	a$$$86$$$87$$$O	preparation$$$88$$$99$$$O	method$$$100$$$106$$$O	thereof.$$$107$$$115$$$O	The$$$116$$$119$$$O	pharmaceutical$$$120$$$134$$$O	composition$$$135$$$146$$$O	comprises$$$147$$$156$$$O	the$$$157$$$160$$$O	following$$$161$$$170$$$O	raw$$$171$$$174$$$O	materials$$$175$$$184$$$O	according$$$185$$$194$$$O	to$$$195$$$197$$$O	parts$$$198$$$203$$$O	by$$$204$$$206$$$O	weight$$$207$$$213$$$O	and$$$214$$$217$$$O	the$$$218$$$221$$$O	following$$$222$$$231$$$O	pharmaceutically-accepted$$$232$$$257$$$O	auxiliary$$$258$$$267$$$O	materials:$$$268$$$278$$$O	100-295$$$279$$$286$$$O	parts$$$287$$$292$$$O	of$$$293$$$295$$$O	forsythia$$$296$$$305$$$O	fruit,$$$306$$$312$$$O	50-140$$$313$$$319$$$O	parts$$$320$$$325$$$O	of$$$326$$$328$$$O	bamboo$$$329$$$335$$$O	leaf,$$$336$$$341$$$O	100-245$$$342$$$349$$$O	parts$$$350$$$355$$$O	of$$$356$$$358$$$O	adenophora$$$359$$$369$$$O	stricta,$$$370$$$378$$$O	100-245$$$379$$$386$$$O	parts$$$387$$$392$$$O	of$$$393$$$395$$$O	bamboo$$$396$$$402$$$O	shavings,$$$403$$$412$$$O	250-450$$$413$$$420$$$O	parts$$$421$$$426$$$O	of$$$427$$$429$$$O	lotus$$$430$$$435$$$O	leaf,$$$436$$$441$$$O	250-450$$$442$$$449$$$O	parts$$$450$$$455$$$O	of$$$456$$$458$$$O	raw$$$459$$$462$$$O	gypsum,$$$463$$$470$$$O	150-250$$$471$$$478$$$O	parts$$$479$$$484$$$O	of$$$485$$$487$$$O	anemarrhena$$$488$$$499$$$O	rhizome,$$$500$$$508$$$O	150-250$$$509$$$516$$$O	parts$$$517$$$522$$$O	of$$$523$$$525$$$O	fortune$$$526$$$533$$$O	eupatorium$$$534$$$544$$$O	herb,$$$545$$$550$$$O	100-250$$$551$$$558$$$O	parts$$$559$$$564$$$O	of$$$565$$$567$$$O	suakwa$$$568$$$574$$$O	vegetable$$$575$$$584$$$O	sponge,$$$585$$$592$$$O	100-250$$$593$$$600$$$O	parts$$$601$$$606$$$O	of$$$607$$$609$$$O	elslholtzia$$$610$$$621$$$O	and$$$622$$$625$$$O	100-250$$$626$$$633$$$O	parts$$$634$$$639$$$O	of$$$640$$$642$$$O	chryanthemum.$$$643$$$656$$$O	The$$$657$$$660$$$O	preparation$$$661$$$672$$$O	method$$$673$$$679$$$O	of$$$680$$$682$$$O	the$$$683$$$686$$$O	pharmaceutical$$$687$$$701$$$O	composition$$$702$$$713$$$O	comprises$$$714$$$723$$$O	the$$$724$$$727$$$O	following$$$728$$$737$$$O	steps$$$738$$$743$$$O	of:$$$744$$$747$$$O	weighing$$$748$$$756$$$O	the$$$757$$$760$$$O	raw$$$761$$$764$$$O	materials$$$765$$$774$$$O	according$$$775$$$784$$$O	to$$$785$$$787$$$O	parts$$$788$$$793$$$O	by$$$794$$$796$$$O	weight,$$$797$$$804$$$O	adding$$$805$$$811$$$O	in$$$812$$$814$$$O	water$$$815$$$820$$$O	for$$$821$$$824$$$O	decoction$$$825$$$834$$$O	for$$$835$$$838$$$O	two$$$839$$$842$$$O	times,$$$843$$$849$$$O	merging$$$850$$$857$$$O	the$$$858$$$861$$$O	decoction$$$862$$$871$$$O	liquids,$$$872$$$880$$$O	filtering$$$881$$$890$$$O	to$$$891$$$893$$$O	remove$$$894$$$900$$$O	the$$$901$$$904$$$O	insoluble$$$905$$$914$$$O	substances,$$$915$$$926$$$O	condensing$$$927$$$937$$$O	the$$$938$$$941$$$O	filtered$$$942$$$950$$$O	decoction$$$951$$$960$$$O	liquid$$$961$$$967$$$O	into$$$968$$$972$$$O	plaster$$$973$$$980$$$O	for$$$981$$$984$$$O	later$$$985$$$990$$$O	use,$$$991$$$995$$$O	andadding$$$996$$$1005$$$O	a$$$1006$$$1007$$$O	proper$$$1008$$$1014$$$O	amount$$$1015$$$1021$$$O	of$$$1022$$$1024$$$O	the$$$1025$$$1028$$$O	auxiliary$$$1029$$$1038$$$O	materials$$$1039$$$1048$$$O	in$$$1049$$$1051$$$O	the$$$1052$$$1055$$$O	plaster$$$1056$$$1063$$$O	to$$$1064$$$1066$$$O	be$$$1067$$$1069$$$O	prepared$$$1070$$$1078$$$O	into$$$1079$$$1083$$$O	the$$$1084$$$1087$$$O	required$$$1088$$$1096$$$O	dosage$$$1097$$$1103$$$O	form.$$$1104$$$1109$$$O	The$$$1110$$$1113$$$O	pharmaceutical$$$1114$$$1128$$$O	composition$$$1129$$$1140$$$O	has$$$1141$$$1144$$$O	the$$$1145$$$1148$$$O	definite$$$1149$$$1157$$$O	therapeutic$$$1158$$$1169$$$O	effect$$$1170$$$1176$$$O	on$$$1177$$$1179$$$O	summer-heat$$$1180$$$1191$$$O	cold$$$1192$$$1196$$$O	and$$$1197$$$1200$$$O	has$$$1201$$$1204$$$O	no$$$1205$$$1207$$$O	any$$$1208$$$1211$$$O	toxic$$$1212$$$1217$$$O	side$$$1218$$$1222$$$O	effect$$$1223$$$1229$$$O	and$$$1230$$$1233$$$O	adverse$$$1234$$$1241$$$O	reaction.$$$1242$$$1251$$$O
EP2155771A1
Azido$$$0$$$5$$$I	purine$$$6$$$12$$$I	nucleosides$$$13$$$24$$$I	for$$$25$$$28$$$O	treatment$$$29$$$38$$$O	of$$$39$$$41$$$O	viral$$$42$$$47$$$O	infections$$$48$$$58$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	compounds,$$$37$$$47$$$O	compositions$$$48$$$60$$$O	and$$$61$$$64$$$O	methods$$$65$$$72$$$O	for$$$73$$$76$$$O	treating$$$77$$$85$$$O	or$$$86$$$88$$$O	preventing$$$89$$$99$$$O	viral$$$100$$$105$$$O	infections,$$$106$$$117$$$O	in$$$118$$$120$$$O	particular,$$$121$$$132$$$O	HIV,$$$133$$$137$$$O	HBV,$$$138$$$142$$$O	and$$$143$$$146$$$O	HCV,$$$147$$$151$$$O	in$$$152$$$154$$$O	human$$$155$$$160$$$O	patients$$$161$$$169$$$O	or$$$170$$$172$$$O	other$$$173$$$178$$$O	animal$$$179$$$185$$$O	hosts.$$$186$$$192$$$O	The$$$193$$$196$$$O	compounds$$$197$$$206$$$O	are$$$207$$$210$$$O	3'-azido-2',3'-dideoxy$$$211$$$233$$$I	purine$$$234$$$240$$$I	nucleosides$$$241$$$252$$$I	or$$$253$$$255$$$O	phosphonates,$$$256$$$269$$$I	and$$$270$$$273$$$O	pharmaceutically$$$274$$$290$$$O	acceptable,$$$291$$$302$$$O	salts,$$$303$$$309$$$O	prodrugs,$$$310$$$319$$$O	and$$$320$$$323$$$O	other$$$324$$$329$$$O	derivatives$$$330$$$341$$$O	thereof.$$$342$$$350$$$O	In$$$351$$$353$$$O	particular,$$$354$$$365$$$O	the$$$366$$$369$$$O	compounds$$$370$$$379$$$O	show$$$380$$$384$$$O	potent$$$385$$$391$$$O	antiviral$$$392$$$401$$$O	activity$$$402$$$410$$$O	against$$$411$$$418$$$O	HIV-1$$$419$$$424$$$O	resistance$$$425$$$435$$$O	mutants$$$436$$$443$$$O	including$$$444$$$453$$$O	HIV-1K65R,$$$454$$$464$$$O	HTV-1K70E,$$$465$$$475$$$O	HIV-1L74V,$$$476$$$486$$$O	HIV-1M184V,$$$487$$$498$$$O	HIV-1Q151M$$$499$$$509$$$O	and$$$510$$$513$$$O	inhibitory$$$514$$$524$$$O	activity$$$525$$$533$$$O	against$$$534$$$541$$$O	HIV-1$$$542$$$547$$$O	RT$$$548$$$550$$$O	harboring$$$551$$$560$$$O	TAMS$$$561$$$565$$$O	or$$$566$$$568$$$O	insertion$$$569$$$578$$$O	mutations$$$579$$$588$$$O	including$$$589$$$598$$$O	HIV-1AZT3,$$$599$$$609$$$O	HIV-1AZT7,$$$610$$$620$$$O	HIV-1AZT9,$$$621$$$631$$$O	HIV-$$$632$$$636$$$O	1Q151M,$$$637$$$644$$$O	or$$$645$$$647$$$O	HIV-169insertion.$$$648$$$665$$$O	In$$$666$$$668$$$O	one$$$669$$$672$$$O	embodiment,$$$673$$$684$$$O	the$$$685$$$688$$$O	compounds$$$689$$$698$$$O	are$$$699$$$702$$$O	3'-azido-ddA,$$$703$$$716$$$I	3'-azido-ddG,$$$717$$$730$$$I	or$$$731$$$733$$$O	combinations$$$734$$$746$$$O	thereof,$$$747$$$755$$$O	administered$$$756$$$768$$$O	with$$$769$$$773$$$O	one$$$774$$$777$$$O	or$$$778$$$780$$$O	more$$$781$$$785$$$O	additional$$$786$$$796$$$O	antiviral$$$797$$$806$$$O	agents$$$807$$$813$$$O	that$$$814$$$818$$$O	select$$$819$$$825$$$O	for$$$826$$$829$$$O	TAM$$$830$$$833$$$O	mutations$$$834$$$843$$$O	and/or$$$844$$$850$$$O	the$$$851$$$854$$$O	M$$$855$$$856$$$O	184V$$$857$$$861$$$O	mutation,$$$862$$$871$$$O	along$$$872$$$877$$$O	with$$$878$$$882$$$O	a$$$883$$$884$$$O	pharmaceutically$$$885$$$901$$$O	acceptable$$$902$$$912$$$O	carrier.$$$913$$$921$$$O
US20080255224
Administering$$$0$$$13$$$O	a$$$14$$$15$$$O	cannabinoid$$$16$$$27$$$I	agonist$$$28$$$35$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	generally$$$30$$$39$$$O	to$$$40$$$42$$$O	the$$$43$$$46$$$O	prevention$$$47$$$57$$$O	and$$$58$$$61$$$O	treatment$$$62$$$71$$$O	of$$$72$$$74$$$O	psoriasis$$$75$$$84$$$O	and$$$85$$$88$$$O	psoriatic-related$$$89$$$106$$$O	skin$$$107$$$111$$$O	conditions$$$112$$$122$$$O	via$$$123$$$126$$$O	administration$$$127$$$141$$$O	of$$$142$$$144$$$O	a$$$145$$$146$$$O	cannabinoid$$$147$$$158$$$I	agonist,$$$159$$$167$$$O	especially$$$168$$$178$$$O	nabinone,$$$179$$$188$$$I	either$$$189$$$195$$$O	alone$$$196$$$201$$$O	or$$$202$$$204$$$O	in$$$205$$$207$$$O	combination$$$208$$$219$$$O	with$$$220$$$224$$$O	other$$$225$$$230$$$O	agents$$$231$$$237$$$O	that$$$238$$$242$$$O	possess$$$243$$$250$$$O	anti-psoriatic$$$251$$$265$$$O	pharmacological$$$266$$$281$$$O	activity.$$$282$$$291$$$O
WO2009130326A1
Combination$$$0$$$11$$$O	therapy$$$12$$$19$$$O	for$$$20$$$23$$$O	acne$$$24$$$28$$$O	vulgaris$$$29$$$37$$$O	comprising$$$38$$$48$$$O	adapalene$$$49$$$58$$$O	0.3%$$$59$$$63$$$O	gel$$$64$$$67$$$O	with$$$68$$$72$$$O	clindamycin/benzoyl$$$73$$$92$$$I	peroxide$$$93$$$101$$$I	gel$$$102$$$105$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	new$$$33$$$36$$$O	regimen$$$37$$$44$$$O	of$$$45$$$47$$$O	acne$$$48$$$52$$$O	related$$$53$$$60$$$O	diseases$$$61$$$69$$$O	and$$$70$$$73$$$O	particularly$$$74$$$86$$$O	acne$$$87$$$91$$$O	vulgaris,$$$92$$$101$$$O	said$$$102$$$106$$$O	regimen$$$107$$$114$$$O	comprising$$$115$$$125$$$O	administering$$$126$$$139$$$O	to$$$140$$$142$$$O	a$$$143$$$144$$$O	patient$$$145$$$152$$$O	in$$$153$$$155$$$O	need$$$156$$$160$$$O	a$$$161$$$162$$$O	therapeutical$$$163$$$176$$$O	effective$$$177$$$186$$$O	amount$$$187$$$193$$$O	of$$$194$$$196$$$O	Differin$$$197$$$205$$$O	gel$$$206$$$209$$$O	0.3%$$$210$$$214$$$O	(adapalene)$$$215$$$226$$$I	in$$$227$$$229$$$O	association$$$230$$$241$$$O	or$$$242$$$244$$$O	combination$$$245$$$256$$$O	with$$$257$$$261$$$O	a$$$262$$$263$$$O	combined$$$264$$$272$$$O	Clindamycin/Benzoyl$$$273$$$292$$$I	Peroxide$$$293$$$301$$$I	Gel$$$302$$$305$$$O	product$$$306$$$313$$$O	such$$$314$$$318$$$O	as$$$319$$$321$$$O	a$$$322$$$323$$$O	DUACÂ®$$$324$$$330$$$I	product.$$$331$$$339$$$O
US7531557
oral$$$0$$$4$$$O	bioavailablility,$$$5$$$22$$$O	oral$$$23$$$27$$$O	administration;$$$28$$$43$$$O	inhibition$$$44$$$54$$$O	of$$$55$$$57$$$O	orexigenic$$$58$$$68$$$O	effects;$$$69$$$77$$$O	side$$$78$$$82$$$O	effects$$$83$$$90$$$O	reduction;$$$91$$$101$$$O	alcoholism;$$$102$$$113$$$O	6-(2-Fluoro-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-nicotinamide$$$114$$$197$$$I
Compound$$$0$$$8$$$O	6-(2-fluoro-4-[[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl]-phenoxy)-nicotinamide,$$$9$$$93$$$I	or$$$94$$$96$$$O	a$$$97$$$98$$$O	pharmaceutically$$$99$$$115$$$O	acceptable$$$116$$$126$$$O	salt$$$127$$$131$$$O	thereof,$$$132$$$140$$$O	is$$$141$$$143$$$O	useful$$$144$$$150$$$O	for$$$151$$$154$$$O	the$$$155$$$158$$$O	treatment$$$159$$$168$$$O	of$$$169$$$171$$$O	alcoholism.$$$172$$$183$$$O
CN103705044A
Medicine$$$0$$$8$$$O	pillow$$$9$$$15$$$O	for$$$16$$$19$$$O	treating$$$20$$$28$$$O	pre-senile$$$29$$$39$$$O	poliosis$$$40$$$48$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medicine$$$27$$$35$$$O	pillow$$$36$$$42$$$O	for$$$43$$$46$$$O	treating$$$47$$$55$$$O	the$$$56$$$59$$$O	pre-senile$$$60$$$70$$$O	poliosis.$$$71$$$80$$$O	The$$$81$$$84$$$O	medicine$$$85$$$93$$$O	pillow$$$94$$$100$$$O	comprises$$$101$$$110$$$O	a$$$111$$$112$$$O	pillow$$$113$$$119$$$O	interior,$$$120$$$129$$$O	and$$$130$$$133$$$O	the$$$134$$$137$$$O	pillow$$$138$$$144$$$O	interior$$$145$$$153$$$O	is$$$154$$$156$$$O	filled$$$157$$$163$$$O	with$$$164$$$168$$$O	medicinal$$$169$$$178$$$O	material$$$179$$$187$$$O	powder$$$188$$$194$$$O	comprising,$$$195$$$206$$$O	by$$$207$$$209$$$O	weight,$$$210$$$217$$$O	60$$$218$$$220$$$O	parts$$$221$$$226$$$O	of$$$227$$$229$$$O	american$$$230$$$238$$$O	lotus,$$$239$$$245$$$O	80$$$246$$$248$$$O	parts$$$249$$$254$$$O	of$$$255$$$257$$$O	red$$$258$$$261$$$O	rhodobryum,$$$262$$$273$$$O	30$$$274$$$276$$$O	parts$$$277$$$282$$$O	of$$$283$$$285$$$O	poria$$$286$$$291$$$O	with$$$292$$$296$$$O	hostwood,$$$297$$$306$$$O	50$$$307$$$309$$$O	parts$$$310$$$315$$$O	of$$$316$$$318$$$O	herba$$$319$$$324$$$O	eupatorii,$$$325$$$335$$$O	60$$$336$$$338$$$O	parts$$$339$$$344$$$O	of$$$345$$$347$$$O	all-grass$$$348$$$357$$$O	of$$$358$$$360$$$O	bulley$$$361$$$367$$$O	herminium,$$$368$$$378$$$O	10$$$379$$$381$$$O	parts$$$382$$$387$$$O	of$$$388$$$390$$$O	agilawood,$$$391$$$401$$$O	20$$$402$$$404$$$O	parts$$$405$$$410$$$O	of$$$411$$$413$$$O	ziziphora$$$414$$$423$$$O	clinopodioides,$$$424$$$439$$$O	20$$$440$$$442$$$O	parts$$$443$$$448$$$O	of$$$449$$$451$$$O	broad-leaved$$$452$$$464$$$O	epiphyllum,$$$465$$$476$$$O	15$$$477$$$479$$$O	parts$$$480$$$485$$$O	of$$$486$$$488$$$O	selenitum,$$$489$$$499$$$O	10$$$500$$$502$$$O	parts$$$503$$$508$$$O	of$$$509$$$511$$$O	rosso$$$512$$$517$$$O	itiuba$$$518$$$524$$$O	and$$$525$$$528$$$O	12$$$529$$$531$$$O	parts$$$532$$$537$$$O	of$$$538$$$540$$$O	securinega$$$541$$$551$$$O	suffruticosa.$$$552$$$565$$$O	After$$$566$$$571$$$O	probation,$$$572$$$582$$$O	it$$$583$$$585$$$O	is$$$586$$$588$$$O	proved$$$589$$$595$$$O	that$$$596$$$600$$$O	the$$$601$$$604$$$O	medicine$$$605$$$613$$$O	pillow$$$614$$$620$$$O	has$$$621$$$624$$$O	the$$$625$$$628$$$O	exact$$$629$$$634$$$O	effect$$$635$$$641$$$O	for$$$642$$$645$$$O	treating$$$646$$$654$$$O	the$$$655$$$658$$$O	pre-senile$$$659$$$669$$$O	poliosis$$$670$$$678$$$O	and$$$679$$$682$$$O	is$$$683$$$685$$$O	safe$$$686$$$690$$$O	in$$$691$$$693$$$O	use,$$$694$$$698$$$O	and$$$699$$$702$$$O	untoward$$$703$$$711$$$O	effects$$$712$$$719$$$O	are$$$720$$$723$$$O	not$$$724$$$727$$$O	obviously$$$728$$$737$$$O	found$$$738$$$743$$$O	after$$$744$$$749$$$O	long-time$$$750$$$759$$$O	use.$$$760$$$764$$$O	The$$$765$$$768$$$O	medicine$$$769$$$777$$$O	pillow$$$778$$$784$$$O	is$$$785$$$787$$$O	easy$$$788$$$792$$$O	to$$$793$$$795$$$O	manufacture,$$$796$$$808$$$O	low$$$809$$$812$$$O	in$$$813$$$815$$$O	cost$$$816$$$820$$$O	and$$$821$$$824$$$O	suitable$$$825$$$833$$$O	for$$$834$$$837$$$O	popularization$$$838$$$852$$$O	and$$$853$$$856$$$O	use.$$$857$$$861$$$O
WO2008036843A3
Nitrogen$$$0$$$8$$$I	containing$$$9$$$19$$$I	substituted$$$20$$$31$$$I	heterocycles$$$32$$$44$$$I	as$$$45$$$47$$$O	platelet$$$48$$$56$$$O	adp$$$57$$$60$$$O	receptor$$$61$$$69$$$O	inhibitors$$$70$$$80$$$O
Compounds$$$0$$$9$$$O	are$$$10$$$13$$$O	provided$$$14$$$22$$$O	which$$$23$$$28$$$O	are$$$29$$$32$$$O	useful$$$33$$$39$$$O	as$$$40$$$42$$$O	platelet$$$43$$$51$$$O	ADP$$$52$$$55$$$O	receptor$$$56$$$64$$$O	inhibitors,$$$65$$$76$$$O	for$$$77$$$80$$$O	treating$$$81$$$89$$$O	thrombosis$$$90$$$100$$$O	and$$$101$$$104$$$O	for$$$105$$$108$$$O	reducing$$$109$$$117$$$O	the$$$118$$$121$$$O	likelihood$$$122$$$132$$$O	and/or$$$133$$$139$$$O	severity$$$140$$$148$$$O	of$$$149$$$151$$$O	a$$$152$$$153$$$O	secondary$$$154$$$163$$$O	ischemic$$$164$$$172$$$O	event$$$173$$$178$$$O	in$$$179$$$181$$$O	a$$$182$$$183$$$O	patient.$$$184$$$192$$$O
CN101019847A
Slow$$$0$$$4$$$O	released$$$5$$$13$$$O	diacetyl$$$14$$$22$$$I	rheinic$$$23$$$30$$$I	acid$$$31$$$35$$$I	prepn$$$36$$$41$$$O	and$$$42$$$45$$$O	its$$$46$$$49$$$O	prepn$$$50$$$55$$$O	process$$$56$$$63$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	slow$$$25$$$29$$$O	released$$$30$$$38$$$O	diacetyl$$$39$$$47$$$I	rheinic$$$48$$$55$$$I	acid$$$56$$$60$$$I	preparation$$$61$$$72$$$O	and$$$73$$$76$$$O	its$$$77$$$80$$$O	preparation$$$81$$$92$$$O	process.$$$93$$$101$$$O	The$$$102$$$105$$$O	slow$$$106$$$110$$$O	released$$$111$$$119$$$O	diacetyl$$$120$$$128$$$I	rheinic$$$129$$$136$$$I	acid$$$137$$$141$$$I	preparation,$$$142$$$154$$$O	which$$$155$$$160$$$O	may$$$161$$$164$$$O	be$$$165$$$167$$$O	granule,$$$168$$$176$$$O	tablet$$$177$$$183$$$O	or$$$184$$$186$$$O	capsule,$$$187$$$195$$$O	is$$$196$$$198$$$O	prepared$$$199$$$207$$$O	with$$$208$$$212$$$O	diacetyl$$$213$$$221$$$I	rheinic$$$222$$$229$$$I	acid$$$230$$$234$$$I	as$$$235$$$237$$$O	main$$$238$$$242$$$O	material$$$243$$$251$$$O	and$$$252$$$255$$$O	other$$$256$$$261$$$O	supplementary$$$262$$$275$$$O	material.$$$276$$$285$$$O	The$$$286$$$289$$$O	slow$$$290$$$294$$$O	released$$$295$$$303$$$O	diacetyl$$$304$$$312$$$I	rheinic$$$313$$$320$$$I	acid$$$321$$$325$$$I	preparation$$$326$$$337$$$O	of$$$338$$$340$$$O	the$$$341$$$344$$$O	present$$$345$$$352$$$O	invention$$$353$$$362$$$O	has$$$363$$$366$$$O	excellent$$$367$$$376$$$O	slow$$$377$$$381$$$O	releasing$$$382$$$391$$$O	effect$$$392$$$398$$$O	and$$$399$$$402$$$O	simple$$$403$$$409$$$O	preparation$$$410$$$421$$$O	process.$$$422$$$430$$$O
WO2007115938A1
5-amido-2-carboxamide$$$0$$$21$$$I	indoles$$$22$$$29$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	formula$$$46$$$53$$$O	(I)$$$54$$$57$$$O	wherein$$$58$$$65$$$O	G$$$66$$$67$$$O	and$$$68$$$71$$$O	R$$$72$$$73$$$O	to$$$74$$$76$$$O	R$$$77$$$78$$$O	and$$$79$$$82$$$O	R$$$83$$$84$$$O	are$$$85$$$88$$$O	as$$$89$$$91$$$O	defined$$$92$$$99$$$O	in$$$100$$$102$$$O	the$$$103$$$106$$$O	description$$$107$$$118$$$O	and$$$119$$$122$$$O	claims,$$$123$$$130$$$O	and$$$131$$$134$$$O	pharmaceutically$$$135$$$151$$$O	acceptable$$$152$$$162$$$O	salts$$$163$$$168$$$O	thereof.$$$169$$$177$$$O	The$$$178$$$181$$$O	compounds$$$182$$$191$$$O	are$$$192$$$195$$$O	useful$$$196$$$202$$$O	for$$$203$$$206$$$O	the$$$207$$$210$$$O	treatment$$$211$$$220$$$O	and/or$$$221$$$227$$$O	prevention$$$228$$$238$$$O	of$$$239$$$241$$$O	diseases$$$242$$$250$$$O	which$$$251$$$256$$$O	are$$$257$$$260$$$O	associated$$$261$$$271$$$O	with$$$272$$$276$$$O	the$$$277$$$280$$$O	modulation$$$281$$$291$$$O	of$$$292$$$294$$$O	H3$$$295$$$297$$$O	receptors.$$$298$$$308$$$O
CN101062194B
Medicine$$$0$$$8$$$O	for$$$9$$$12$$$O	treating$$$13$$$21$$$O	bone$$$22$$$26$$$O	disease$$$27$$$34$$$O	and$$$35$$$38$$$O	fracture$$$39$$$47$$$O	and$$$48$$$51$$$O	the$$$52$$$55$$$O	preparing$$$56$$$65$$$O	method$$$66$$$72$$$O	thereof$$$73$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pharmaceutical$$$27$$$41$$$O	composition$$$42$$$53$$$O	for$$$54$$$57$$$O	treating$$$58$$$66$$$O	osteonosus$$$67$$$77$$$O	and$$$78$$$81$$$O	bone$$$82$$$86$$$O	fracture$$$87$$$95$$$O	and$$$96$$$99$$$O	process$$$100$$$107$$$O	for$$$108$$$111$$$O	preparation,$$$112$$$124$$$O	wherein$$$125$$$132$$$O	the$$$133$$$136$$$O	raw$$$137$$$140$$$O	materials$$$141$$$150$$$O	include$$$151$$$158$$$O	achyranthes$$$159$$$170$$$O	and$$$171$$$174$$$O	cyathula$$$175$$$183$$$O	root,$$$184$$$189$$$O	native$$$190$$$196$$$O	copper,$$$197$$$204$$$I	drynaria,$$$205$$$214$$$O	frankincense,$$$215$$$228$$$O	myrrh,$$$229$$$235$$$O	ledebouriella$$$236$$$249$$$O	root,$$$250$$$255$$$O	buck$$$256$$$260$$$O	grass,$$$261$$$267$$$O	wood$$$268$$$272$$$O	louse,$$$273$$$279$$$O	cortex$$$280$$$286$$$O	acanthopanacis$$$287$$$301$$$O	and$$$302$$$305$$$O	root$$$306$$$310$$$O	bark$$$311$$$315$$$O	of$$$316$$$318$$$O	chinese$$$319$$$326$$$O	wolf$$$327$$$331$$$O	berry.$$$332$$$338$$$O	The$$$339$$$342$$$O	medicament$$$343$$$353$$$O	can$$$354$$$357$$$O	be$$$358$$$360$$$O	prepared$$$361$$$369$$$O	into$$$370$$$374$$$O	various$$$375$$$382$$$O	dosage$$$383$$$389$$$O	forms$$$390$$$395$$$O	including$$$396$$$405$$$O	electuary,$$$406$$$416$$$O	ointment,$$$417$$$426$$$O	sprays$$$427$$$433$$$O	and$$$434$$$437$$$O	lotions.$$$438$$$446$$$O
EP1539686A1
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	factor$$$14$$$20$$$O	xa$$$21$$$23$$$O	and$$$24$$$27$$$O	other$$$28$$$33$$$O	serine$$$34$$$40$$$I	proteases$$$41$$$50$$$O	involved$$$51$$$59$$$O	in$$$60$$$62$$$O	the$$$63$$$66$$$O	coagulation$$$67$$$78$$$O	cascade$$$79$$$86$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	discloses$$$15$$$24$$$O	amino$$$25$$$30$$$I	acid$$$31$$$35$$$I	derivatives$$$36$$$47$$$O	which$$$48$$$53$$$O	display$$$54$$$61$$$O	inhibitory$$$62$$$72$$$O	effects$$$73$$$80$$$O	on$$$81$$$83$$$O	the$$$84$$$87$$$O	serine$$$88$$$94$$$O	protease$$$95$$$103$$$O	factor$$$104$$$110$$$O	Xa.$$$111$$$114$$$O	The$$$115$$$118$$$O	invention$$$119$$$128$$$O	also$$$129$$$133$$$O	discloses$$$134$$$143$$$O	pharmaceutically$$$144$$$160$$$O	acceptable$$$161$$$171$$$O	salts$$$172$$$177$$$O	of$$$178$$$180$$$O	the$$$181$$$184$$$O	compounds,$$$185$$$195$$$O	pharmaceutically$$$196$$$212$$$O	acceptable$$$213$$$223$$$O	compositions$$$224$$$236$$$O	comprising$$$237$$$247$$$O	the$$$248$$$251$$$O	compounds$$$252$$$261$$$O	or$$$262$$$264$$$O	their$$$265$$$270$$$O	salts,$$$271$$$277$$$O	methods$$$278$$$285$$$O	for$$$286$$$289$$$O	the$$$290$$$293$$$O	preparation$$$294$$$305$$$O	of$$$306$$$308$$$O	the$$$309$$$312$$$O	compounds,$$$313$$$323$$$O	and$$$324$$$327$$$O	methods$$$328$$$335$$$O	of$$$336$$$338$$$O	using$$$339$$$344$$$O	them$$$345$$$349$$$O	as$$$350$$$352$$$O	therapeutic$$$353$$$364$$$O	agents$$$365$$$371$$$O	for$$$372$$$375$$$O	treating$$$376$$$384$$$O	or$$$385$$$387$$$O	preventing$$$388$$$398$$$O	disease$$$399$$$406$$$O	states$$$407$$$413$$$O	in$$$414$$$416$$$O	mammals$$$417$$$424$$$O	characterized$$$425$$$438$$$O	by$$$439$$$441$$$O	abnormal$$$442$$$450$$$O	thrombosis.$$$451$$$462$$$O
US20120283312
Modulation$$$0$$$10$$$O	of$$$11$$$13$$$O	eif4e$$$14$$$19$$$O	expression$$$20$$$30$$$O
Oligomeric$$$0$$$10$$$O	compounds,$$$11$$$21$$$O	compositions$$$22$$$34$$$O	and$$$35$$$38$$$O	methods$$$39$$$46$$$O	are$$$47$$$50$$$O	provided$$$51$$$59$$$O	for$$$60$$$63$$$O	modulating$$$64$$$74$$$O	the$$$75$$$78$$$O	expression$$$79$$$89$$$O	of$$$90$$$92$$$O	eIF4E.$$$93$$$99$$$O	The$$$100$$$103$$$O	antisense$$$104$$$113$$$O	compounds$$$114$$$123$$$O	may$$$124$$$127$$$O	be$$$128$$$130$$$O	single-$$$131$$$138$$$O	or$$$139$$$141$$$O	double-stranded$$$142$$$157$$$O	and$$$158$$$161$$$O	are$$$162$$$165$$$O	targeted$$$166$$$174$$$O	to$$$175$$$177$$$O	nucleic$$$178$$$185$$$O	acid$$$186$$$190$$$O	encoding$$$191$$$199$$$O	eIF4E.$$$200$$$206$$$O	Methods$$$207$$$214$$$O	of$$$215$$$217$$$O	using$$$218$$$223$$$O	these$$$224$$$229$$$O	compounds$$$230$$$239$$$O	for$$$240$$$243$$$O	modulation$$$244$$$254$$$O	of$$$255$$$257$$$O	eIF4E$$$258$$$263$$$O	expression$$$264$$$274$$$O	and$$$275$$$278$$$O	for$$$279$$$282$$$O	diagnosis$$$283$$$292$$$O	and$$$293$$$296$$$O	treatment$$$297$$$306$$$O	of$$$307$$$309$$$O	diseases$$$310$$$318$$$O	and$$$319$$$322$$$O	conditions$$$323$$$333$$$O	associated$$$334$$$344$$$O	with$$$345$$$349$$$O	expression$$$350$$$360$$$O	of$$$361$$$363$$$O	eIF4E$$$364$$$369$$$O	are$$$370$$$373$$$O	provided.$$$374$$$383$$$O
US20100135952
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	treatment$$$16$$$25$$$O	of$$$26$$$28$$$O	renal$$$29$$$34$$$O	failure$$$35$$$42$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	methods$$$33$$$40$$$O	for$$$41$$$44$$$O	treating$$$45$$$53$$$O	renal$$$54$$$59$$$O	failure.$$$60$$$68$$$O	Particularly,$$$69$$$82$$$O	the$$$83$$$86$$$O	present$$$87$$$94$$$O	invention$$$95$$$104$$$O	relates$$$105$$$112$$$O	to$$$113$$$115$$$O	methods$$$116$$$123$$$O	for$$$124$$$127$$$O	treating$$$128$$$136$$$O	renal$$$137$$$142$$$O	failure$$$143$$$150$$$O	by$$$151$$$153$$$O	administering$$$154$$$167$$$O	to$$$168$$$170$$$O	a$$$171$$$172$$$O	subject$$$173$$$180$$$O	complexes$$$181$$$190$$$O	that$$$191$$$195$$$O	include$$$196$$$203$$$O	a$$$204$$$205$$$O	member$$$206$$$212$$$O	of$$$213$$$215$$$O	the$$$216$$$219$$$O	IL-6$$$220$$$224$$$O	family$$$225$$$231$$$O	linked$$$232$$$238$$$O	to$$$239$$$241$$$O	a$$$242$$$243$$$O	soluble$$$244$$$251$$$O	receptor$$$252$$$260$$$O	of$$$261$$$263$$$O	the$$$264$$$267$$$O	member$$$268$$$274$$$O	of$$$275$$$277$$$O	the$$$278$$$281$$$O	IL-6$$$282$$$286$$$O	family,$$$287$$$294$$$O	or$$$295$$$297$$$O	isolated$$$298$$$306$$$O	polynucleotides$$$307$$$322$$$O	encoding$$$323$$$331$$$O	same,$$$332$$$337$$$O	the$$$338$$$341$$$O	complexes$$$342$$$351$$$O	capable$$$352$$$359$$$O	of$$$360$$$362$$$O	activating$$$363$$$373$$$O	a$$$374$$$375$$$O	gp130$$$376$$$381$$$O	mediated$$$382$$$390$$$O	signaling$$$391$$$400$$$O	pathway,$$$401$$$409$$$O	thereby$$$410$$$417$$$O	treating$$$418$$$426$$$O	acute$$$427$$$432$$$O	or$$$433$$$435$$$O	chronic$$$436$$$443$$$O	renal$$$444$$$449$$$O	failure.$$$450$$$458$$$O
CN102731586A
Preparation$$$0$$$11$$$O	technology$$$12$$$22$$$O	of$$$23$$$25$$$O	stilbene$$$26$$$34$$$I	glucoside$$$35$$$44$$$I	in$$$45$$$47$$$O	polygonum$$$48$$$57$$$O	multiflorum$$$58$$$69$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	technology$$$38$$$48$$$O	of$$$49$$$51$$$O	a$$$52$$$53$$$O	stilbene$$$54$$$62$$$I	glucoside$$$63$$$72$$$I	extract$$$73$$$80$$$O	product$$$81$$$88$$$O	in$$$89$$$91$$$O	polygonum$$$92$$$101$$$O	multiflorum$$$102$$$113$$$O	and$$$114$$$117$$$O	a$$$118$$$119$$$O	production$$$120$$$130$$$O	technology$$$131$$$141$$$O	of$$$142$$$144$$$O	a$$$145$$$146$$$O	stilbene$$$147$$$155$$$I	glucoside$$$156$$$165$$$I	fine$$$166$$$170$$$O	product$$$171$$$178$$$O	by$$$179$$$181$$$O	using$$$182$$$187$$$O	a$$$188$$$189$$$O	stilbene$$$190$$$198$$$I	glucoside$$$199$$$208$$$I	crude$$$209$$$214$$$O	product$$$215$$$222$$$O	as$$$223$$$225$$$O	a$$$226$$$227$$$O	raw$$$228$$$231$$$O	material.$$$232$$$241$$$O	The$$$242$$$245$$$O	preparation$$$246$$$257$$$O	technology$$$258$$$268$$$O	of$$$269$$$271$$$O	the$$$272$$$275$$$O	stilbene$$$276$$$284$$$I	glucoside$$$285$$$294$$$I	extract$$$295$$$302$$$O	product$$$303$$$310$$$O	comprises$$$311$$$320$$$O	the$$$321$$$324$$$O	following$$$325$$$334$$$O	steps$$$335$$$340$$$O	of:$$$341$$$344$$$O	extracting$$$345$$$355$$$O	the$$$356$$$359$$$O	medicinal$$$360$$$369$$$O	material$$$370$$$378$$$O	polygonum$$$379$$$388$$$O	multiflorum$$$389$$$400$$$O	by$$$401$$$403$$$O	a$$$404$$$405$$$O	dilute$$$406$$$412$$$O	ethanol$$$413$$$420$$$I	heating$$$421$$$428$$$O	reflux$$$429$$$435$$$O	method,$$$436$$$443$$$O	condensing$$$444$$$454$$$O	the$$$455$$$458$$$O	extract$$$459$$$466$$$O	to$$$467$$$469$$$O	a$$$470$$$471$$$O	certain$$$472$$$479$$$O	volume,$$$480$$$487$$$O	cooling$$$488$$$495$$$O	and$$$496$$$499$$$O	standing,$$$500$$$509$$$O	filtering,$$$510$$$520$$$O	extracting$$$521$$$531$$$O	by$$$532$$$534$$$O	the$$$535$$$538$$$O	adding$$$539$$$545$$$O	ethyl$$$546$$$551$$$I	acetate$$$552$$$559$$$I	into$$$560$$$564$$$O	a$$$565$$$566$$$O	filtrate,$$$567$$$576$$$O	merging$$$577$$$584$$$O	the$$$585$$$588$$$O	extracts,$$$589$$$598$$$O	condensing$$$599$$$609$$$O	to$$$610$$$612$$$O	a$$$613$$$614$$$O	stiff$$$615$$$620$$$O	paste,$$$621$$$627$$$O	followed$$$628$$$636$$$O	by$$$637$$$639$$$O	vacuum$$$640$$$646$$$O	drying$$$647$$$653$$$O	of$$$654$$$656$$$O	the$$$657$$$660$$$O	stiff$$$661$$$666$$$O	paste$$$667$$$672$$$O	and$$$673$$$676$$$O	crushing,$$$677$$$686$$$O	redissolving$$$687$$$699$$$O	by$$$700$$$702$$$O	the$$$703$$$706$$$O	use$$$707$$$710$$$O	of$$$711$$$713$$$O	water$$$714$$$719$$$O	or$$$720$$$722$$$O	an$$$723$$$725$$$O	ethanol$$$726$$$733$$$I	aqueous$$$734$$$741$$$O	solution,$$$742$$$751$$$O	performing$$$752$$$762$$$O	vacuum$$$763$$$769$$$O	drying$$$770$$$776$$$O	and$$$777$$$780$$$O	crushing$$$781$$$789$$$O	to$$$790$$$792$$$O	obtain$$$793$$$799$$$O	the$$$800$$$803$$$O	stilbene$$$804$$$812$$$I	glucoside$$$813$$$822$$$I	extract$$$823$$$830$$$O	product.$$$831$$$839$$$O	The$$$840$$$843$$$O	technology$$$844$$$854$$$O	preparation$$$855$$$866$$$O	of$$$867$$$869$$$O	the$$$870$$$873$$$O	stilbene$$$874$$$882$$$I	glucoside$$$883$$$892$$$I	fine$$$893$$$897$$$O	product$$$898$$$905$$$O	comprises$$$906$$$915$$$O	the$$$916$$$919$$$O	following$$$920$$$929$$$O	steps$$$930$$$935$$$O	of:$$$936$$$939$$$O	using$$$940$$$945$$$O	the$$$946$$$949$$$O	stilbene$$$950$$$958$$$I	glucoside$$$959$$$968$$$I	crude$$$969$$$974$$$O	product$$$975$$$982$$$O	as$$$983$$$985$$$O	a$$$986$$$987$$$O	raw$$$988$$$991$$$O	material,$$$992$$$1001$$$O	separating$$$1002$$$1012$$$O	by$$$1013$$$1015$$$O	silica$$$1016$$$1022$$$O	gel$$$1023$$$1026$$$O	column$$$1027$$$1033$$$O	chromatography,$$$1034$$$1049$$$O	and$$$1050$$$1053$$$O	purifying$$$1054$$$1063$$$O	by$$$1064$$$1066$$$O	Sephadex$$$1067$$$1075$$$O	LH-20$$$1076$$$1081$$$O	column$$$1082$$$1088$$$O	chromatography$$$1089$$$1103$$$O	to$$$1104$$$1106$$$O	obtain$$$1107$$$1113$$$O	the$$$1114$$$1117$$$O	stilbene$$$1118$$$1126$$$I	glucoside$$$1127$$$1136$$$I	fine$$$1137$$$1141$$$O	product.$$$1142$$$1150$$$O	The$$$1151$$$1154$$$O	technology$$$1155$$$1165$$$O	provided$$$1166$$$1174$$$O	by$$$1175$$$1177$$$O	the$$$1178$$$1181$$$O	invention$$$1182$$$1191$$$O	has$$$1192$$$1195$$$O	advantages$$$1196$$$1206$$$O	of$$$1207$$$1209$$$O	simple$$$1210$$$1216$$$O	operation,$$$1217$$$1227$$$O	high$$$1228$$$1232$$$O	recovery$$$1233$$$1241$$$O	rate$$$1242$$$1246$$$O	and$$$1247$$$1250$$$O	good$$$1251$$$1255$$$O	stability,$$$1256$$$1266$$$O	and$$$1267$$$1270$$$O	is$$$1271$$$1273$$$O	suitable$$$1274$$$1282$$$O	for$$$1283$$$1286$$$O	industrial$$$1287$$$1297$$$O	production.$$$1298$$$1309$$$O
US20100249141
Novel$$$0$$$5$$$O	inhibitors$$$6$$$16$$$O	of$$$17$$$19$$$O	folic$$$20$$$25$$$I	acid-dependent$$$26$$$40$$$I	enzymes$$$41$$$48$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	of$$$35$$$37$$$O	the$$$38$$$41$$$O	formula$$$42$$$49$$$O	I,$$$50$$$52$$$O	or$$$53$$$55$$$O	pharmaceutically$$$56$$$72$$$O	acceptable$$$73$$$83$$$O	salts$$$84$$$89$$$O	thereof:$$$90$$$98$$$O	wherein:$$$144$$$152$$$O	Z=O$$$165$$$168$$$I	or$$$169$$$171$$$O	S;$$$172$$$174$$$I	n=1-3;$$$187$$$193$$$O	R3=âCO2R8,$$$206$$$218$$$I	âC(O)SR8,$$$219$$$230$$$I	âC(O)NHR8,$$$231$$$243$$$I	âC(S)OR8,$$$244$$$255$$$I	âC(S)SR8,$$$256$$$267$$$I	âC(S)NHR8,$$$268$$$280$$$I	âC(NH)SR8$$$281$$$292$$$I	or$$$293$$$295$$$O	âC(NH)NHR8,$$$296$$$309$$$O	wherein$$$319$$$326$$$I	R8$$$327$$$329$$$I	is$$$330$$$332$$$O	âH$$$333$$$337$$$O	or$$$338$$$340$$$O	alkyl;$$$341$$$347$$$I	R4=âH,$$$362$$$370$$$I	âCH2R5$$$371$$$379$$$O	or$$$380$$$382$$$O	âCH2CH2R5,$$$383$$$395$$$O	wherein$$$405$$$412$$$O	R5$$$413$$$415$$$O	independently$$$416$$$429$$$O	has$$$430$$$433$$$O	one$$$434$$$437$$$O	of$$$438$$$440$$$O	the$$$441$$$444$$$O	meanings$$$445$$$453$$$I	of$$$454$$$456$$$I	R3;$$$457$$$460$$$I	B=âNR2â,$$$475$$$487$$$I	âCH2NR2â,$$$488$$$501$$$I	âCH2CH2NR2â,$$$502$$$518$$$I	âCH2CHR7â$$$519$$$532$$$I	or$$$533$$$535$$$I	âCH2Oâ,$$$536$$$547$$$I	wherein$$$557$$$564$$$I	R2$$$565$$$567$$$O	is$$$568$$$570$$$O	H$$$571$$$572$$$O	or$$$573$$$575$$$O	a$$$576$$$577$$$O	C1-3$$$578$$$582$$$I	alkyl,$$$583$$$589$$$I	alkenyl$$$590$$$597$$$I	or$$$598$$$600$$$I	alkynyl$$$601$$$608$$$I	group,$$$609$$$615$$$I	and$$$616$$$619$$$O	Râ²$$$620$$$624$$$O	is$$$625$$$627$$$O	H$$$628$$$629$$$O	or$$$630$$$632$$$O	a$$$633$$$634$$$O	C1-3$$$635$$$639$$$O	alkyl$$$640$$$645$$$O	or$$$646$$$648$$$O	alkoxy$$$649$$$655$$$O	group;$$$656$$$662$$$O	A=$$$677$$$679$$$O	wherein$$$737$$$744$$$O	R1=âNH2$$$745$$$754$$$O	or$$$755$$$757$$$O	âOH,$$$758$$$764$$$O	and$$$765$$$768$$$O	C$$$769$$$770$$$O	and$$$771$$$774$$$O	D$$$775$$$776$$$O	are$$$777$$$780$$$O	each,$$$781$$$786$$$O	independently,$$$787$$$801$$$O	a$$$802$$$803$$$O	5-$$$804$$$806$$$O	or$$$807$$$809$$$O	6-membered,$$$810$$$821$$$O	substituted$$$822$$$833$$$O	or$$$834$$$836$$$O	unsubstituted,$$$837$$$851$$$O	aromatic$$$852$$$860$$$O	or$$$861$$$863$$$O	non-aromatic$$$864$$$876$$$O	ring$$$877$$$881$$$O	which$$$882$$$887$$$O	may$$$888$$$891$$$O	also$$$892$$$896$$$O	contain$$$897$$$904$$$O	one$$$905$$$908$$$O	or$$$909$$$911$$$O	more$$$912$$$916$$$O	heteroatoms,$$$917$$$929$$$O	and$$$930$$$933$$$O	C$$$934$$$935$$$O	is$$$936$$$938$$$O	connected$$$939$$$948$$$O	to$$$949$$$951$$$O	group$$$952$$$957$$$O	B$$$958$$$959$$$O	in$$$960$$$962$$$O	any$$$963$$$966$$$O	available$$$967$$$976$$$O	position.$$$977$$$986$$$O
CN1839828A
Ramatroban$$$0$$$10$$$I	cyclodextrin$$$11$$$23$$$O	inclusion$$$24$$$33$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	inclusion$$$27$$$36$$$O	complex$$$37$$$44$$$O	of$$$45$$$47$$$O	ramatroban$$$48$$$58$$$I	and$$$59$$$62$$$O	beta-cyclodextrin$$$63$$$80$$$O	and$$$81$$$84$$$O	its$$$85$$$88$$$O	preparing$$$89$$$98$$$O	process,$$$99$$$107$$$O	with$$$108$$$112$$$O	the$$$113$$$116$$$O	use$$$117$$$120$$$O	of$$$121$$$123$$$O	cyclodextrin$$$124$$$136$$$O	inclusion$$$137$$$146$$$O	method,$$$147$$$154$$$O	the$$$155$$$158$$$O	dissolvability$$$159$$$173$$$O	and$$$174$$$177$$$O	bioavailability$$$178$$$193$$$O	of$$$194$$$196$$$O	the$$$197$$$200$$$O	medicament$$$201$$$211$$$O	is$$$212$$$214$$$O	improved.$$$215$$$224$$$O	The$$$225$$$228$$$O	cyclodextrin$$$229$$$241$$$O	inclusion$$$242$$$251$$$O	complex$$$252$$$259$$$O	can$$$260$$$263$$$O	be$$$264$$$266$$$O	further$$$267$$$274$$$O	used$$$275$$$279$$$O	for$$$280$$$283$$$O	the$$$284$$$287$$$O	preparation$$$288$$$299$$$O	of$$$300$$$302$$$O	oral$$$303$$$307$$$O	medicinal$$$308$$$317$$$O	compositions.$$$318$$$331$$$O
WO2009082346A1
New$$$0$$$3$$$O	acetyl$$$4$$$10$$$I	coenzyme$$$11$$$19$$$O	a$$$20$$$21$$$O	carboxylase$$$22$$$33$$$O	(acc)$$$34$$$39$$$O	inhibitors$$$40$$$50$$$O	and$$$51$$$54$$$O	uses$$$55$$$59$$$O	in$$$60$$$62$$$O	treatments$$$63$$$73$$$O	of$$$74$$$76$$$O	obesity$$$77$$$84$$$O	and$$$85$$$88$$$O	diabetes$$$89$$$97$$$O	mellitus$$$98$$$106$$$O	-$$$107$$$108$$$O	087$$$109$$$112$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	Acetyl$$$33$$$39$$$I	Coenzyme$$$40$$$48$$$O	A$$$49$$$50$$$O	Carboxylase$$$51$$$62$$$O	(ACC)$$$63$$$68$$$O	inhibitors$$$69$$$79$$$O	according$$$80$$$89$$$O	to$$$90$$$92$$$O	formula$$$93$$$100$$$O	(I),$$$101$$$105$$$O	or$$$106$$$108$$$O	an$$$109$$$111$$$O	enantiomer$$$112$$$122$$$O	thereof,$$$123$$$131$$$O	or$$$132$$$134$$$O	a$$$135$$$136$$$O	pharmaceutically$$$137$$$153$$$O	acceptable$$$154$$$164$$$O	salt$$$165$$$169$$$O	thereof,$$$170$$$178$$$O	where$$$179$$$184$$$O	R1,$$$185$$$188$$$O	R2,$$$189$$$192$$$O	R3,$$$193$$$196$$$O	R4,$$$197$$$200$$$O	R5,$$$201$$$204$$$O	E,$$$205$$$207$$$O	L,$$$208$$$210$$$O	Z$$$211$$$212$$$O	and$$$213$$$216$$$O	n$$$217$$$218$$$O	are$$$219$$$222$$$O	as$$$223$$$225$$$O	defined$$$226$$$233$$$O	herein,$$$234$$$241$$$O	to$$$242$$$244$$$O	processes$$$245$$$254$$$O	for$$$255$$$258$$$O	preparing$$$259$$$268$$$O	such$$$269$$$273$$$O	compounds,$$$274$$$284$$$O	to$$$285$$$287$$$O	pharmaceutical$$$288$$$302$$$O	compositions$$$303$$$315$$$O	containing$$$316$$$326$$$O	them,$$$327$$$332$$$O	to$$$333$$$335$$$O	the$$$336$$$339$$$O	use$$$340$$$343$$$O	of$$$344$$$346$$$O	such$$$347$$$351$$$O	inhibitors$$$352$$$362$$$O	and$$$363$$$366$$$O	to$$$367$$$369$$$O	methods$$$370$$$377$$$O	for$$$378$$$381$$$O	th$$$382$$$384$$$O	eir$$$385$$$388$$$O	therapeutic$$$389$$$400$$$O	use,$$$401$$$405$$$O	particularly$$$406$$$418$$$O	in$$$419$$$421$$$O	the$$$422$$$425$$$O	treatments$$$426$$$436$$$O	of$$$437$$$439$$$O	obesity$$$440$$$447$$$O	and$$$448$$$451$$$O	diabetes$$$452$$$460$$$O	mellitus.$$$461$$$470$$$O
CN103288614A
Monocyclic$$$0$$$10$$$I	phloroglucinol$$$11$$$25$$$I	compounds$$$26$$$35$$$O	with$$$36$$$40$$$O	antineoplastic$$$41$$$55$$$O	activity$$$56$$$64$$$O	and$$$65$$$68$$$O	pharmaceutical$$$69$$$83$$$O	composition$$$84$$$95$$$O	thereof$$$96$$$103$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	monocyclic$$$25$$$35$$$I	phloroglucinol$$$36$$$50$$$I	compounds$$$51$$$60$$$O	Rxd-41$$$61$$$67$$$O	and$$$68$$$71$$$O	Rxd-43$$$72$$$78$$$O	or$$$79$$$81$$$O	officinal$$$82$$$91$$$O	salt$$$92$$$96$$$O	and$$$97$$$100$$$O	a$$$101$$$102$$$O	pharmaceutical$$$103$$$117$$$O	composition$$$118$$$129$$$O	consisting$$$130$$$140$$$O	of$$$141$$$143$$$O	an$$$144$$$146$$$O	effective$$$147$$$156$$$O	component$$$157$$$166$$$O	and$$$167$$$170$$$O	at$$$171$$$173$$$O	least$$$174$$$179$$$O	one$$$180$$$183$$$O	pharmaceutically$$$184$$$200$$$O	acceptable$$$201$$$211$$$O	carrier,$$$212$$$220$$$O	a$$$221$$$222$$$O	preparation$$$223$$$234$$$O	method$$$235$$$241$$$O	thereof$$$242$$$249$$$O	and$$$250$$$253$$$O	an$$$254$$$256$$$O	application$$$257$$$268$$$O	of$$$269$$$271$$$O	the$$$272$$$275$$$O	monocyclic$$$276$$$286$$$I	phloroglucinol$$$287$$$301$$$I	compounds$$$302$$$311$$$O	in$$$312$$$314$$$O	preparation$$$315$$$326$$$O	of$$$327$$$329$$$O	antineoplastic$$$330$$$344$$$O	drugs.$$$345$$$351$$$O	Rxd-41$$$352$$$358$$$O	and$$$359$$$362$$$O	Rxd-43$$$363$$$369$$$O	are$$$370$$$373$$$O	monocyclic$$$374$$$384$$$I	phloroglucinol$$$385$$$399$$$I	compounds$$$400$$$409$$$O	with$$$410$$$414$$$O	five-membered$$$415$$$428$$$O	ring$$$429$$$433$$$O	side$$$434$$$438$$$O	chains$$$439$$$445$$$O	and$$$446$$$449$$$O	are$$$450$$$453$$$O	remarkable$$$454$$$464$$$O	in$$$465$$$467$$$O	vitro$$$468$$$473$$$O	cytotoxic$$$474$$$483$$$O	activity,$$$484$$$493$$$O	novel$$$494$$$499$$$O	in$$$500$$$502$$$O	chemical$$$503$$$511$$$O	structure$$$512$$$521$$$O	and$$$522$$$525$$$O	strong$$$526$$$532$$$O	in$$$533$$$535$$$O	activity.$$$536$$$545$$$O	The$$$546$$$549$$$O	compounds$$$550$$$559$$$O	used$$$560$$$564$$$O	as$$$565$$$567$$$O	antineoplastic$$$568$$$582$$$O	drugs$$$583$$$588$$$O	have$$$589$$$593$$$O	many$$$594$$$598$$$O	advantages.$$$599$$$610$$$O
WO2010079255A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	inverse$$$7$$$14$$$O	antagonists$$$15$$$26$$$O	and/or$$$27$$$33$$$O	agonists$$$34$$$42$$$O	of$$$43$$$45$$$O	cb1$$$46$$$49$$$O	receptors$$$50$$$59$$$O	for$$$60$$$63$$$O	preparing$$$64$$$73$$$O	drugs$$$74$$$79$$$O	to$$$80$$$82$$$O	increase$$$83$$$91$$$O	motor$$$92$$$97$$$O	neurone$$$98$$$105$$$O	excitability$$$106$$$118$$$O
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	an$$$7$$$9$$$O	inverse$$$10$$$17$$$O	antagonist$$$18$$$28$$$O	and/or$$$29$$$35$$$O	agonist$$$36$$$43$$$O	of$$$44$$$46$$$O	CB1$$$47$$$50$$$O	receptors,$$$51$$$61$$$O	preferably$$$62$$$72$$$O	rimonabant,$$$73$$$84$$$I	for$$$85$$$88$$$O	preparing$$$89$$$98$$$O	drugs$$$99$$$104$$$O	that$$$105$$$109$$$O	are$$$110$$$113$$$O	useful$$$114$$$120$$$O	for$$$121$$$124$$$O	increasing$$$125$$$135$$$O	motor$$$136$$$141$$$O	neurone$$$142$$$149$$$O	excitability$$$150$$$162$$$O	at$$$163$$$165$$$O	the$$$166$$$169$$$O	level$$$170$$$175$$$O	of$$$176$$$178$$$O	the$$$179$$$182$$$O	cerebral$$$183$$$191$$$O	cortex$$$192$$$198$$$O	and/or$$$199$$$205$$$O	the$$$206$$$209$$$O	brainstem$$$210$$$219$$$O	and/or$$$220$$$226$$$O	at$$$227$$$229$$$O	the$$$230$$$233$$$O	spinal$$$234$$$240$$$O	level,$$$241$$$247$$$O	and$$$248$$$251$$$O	also$$$252$$$256$$$O	a$$$257$$$258$$$O	method$$$259$$$265$$$O	for$$$266$$$269$$$O	increasing$$$270$$$280$$$O	motor$$$281$$$286$$$O	neurone$$$287$$$294$$$O	excitability$$$295$$$307$$$O	by$$$308$$$310$$$O	means$$$311$$$316$$$O	of$$$317$$$319$$$O	the$$$320$$$323$$$O	administration$$$324$$$338$$$O	of$$$339$$$341$$$O	an$$$342$$$344$$$O	inverse$$$345$$$352$$$O	antagonist/agonist$$$353$$$371$$$O	of$$$372$$$374$$$O	CB1$$$375$$$378$$$O	receptors,$$$379$$$389$$$O	and$$$390$$$393$$$O	to$$$394$$$396$$$O	the$$$397$$$400$$$O	use$$$401$$$404$$$O	of$$$405$$$407$$$O	a$$$408$$$409$$$O	pharmaceutical$$$410$$$424$$$O	composition$$$425$$$436$$$O	that$$$437$$$441$$$O	comprises$$$442$$$451$$$O	an$$$452$$$454$$$O	inverse$$$455$$$462$$$O	antagonist$$$463$$$473$$$O	and/or$$$474$$$480$$$O	agonist$$$481$$$488$$$O	of$$$489$$$491$$$O	CB1$$$492$$$495$$$O	receptors,$$$496$$$506$$$O	preferably$$$507$$$517$$$O	rimonabant,$$$518$$$529$$$I	for$$$530$$$533$$$O	increasing$$$534$$$544$$$O	motor$$$545$$$550$$$O	neurone$$$551$$$558$$$O	excitability$$$559$$$571$$$O	at$$$572$$$574$$$O	the$$$575$$$578$$$O	level$$$579$$$584$$$O	of$$$585$$$587$$$O	the$$$588$$$591$$$O	cerebral$$$592$$$600$$$O	cortex$$$601$$$607$$$O	and/or$$$608$$$614$$$O	the$$$615$$$618$$$O	brainstem$$$619$$$628$$$O	and/or$$$629$$$635$$$O	at$$$636$$$638$$$O	the$$$639$$$642$$$O	spinal$$$643$$$649$$$O	level.$$$650$$$656$$$O
EP1280515B1
Pharmaceutical$$$0$$$14$$$O	compositions$$$15$$$27$$$O	comprising$$$28$$$38$$$O	cannabis$$$39$$$47$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	improved$$$36$$$44$$$O	mode$$$45$$$49$$$O	of$$$50$$$52$$$O	administration$$$53$$$67$$$O	for$$$68$$$71$$$O	cannabis$$$72$$$80$$$O	and$$$81$$$84$$$O	its$$$85$$$88$$$O	natural$$$89$$$96$$$O	and$$$97$$$100$$$O	synthetic$$$101$$$110$$$O	derivatives.$$$111$$$123$$$O	A$$$124$$$125$$$O	pharmaceutical$$$126$$$140$$$O	composition$$$141$$$152$$$O	suitable$$$153$$$161$$$O	for$$$162$$$165$$$O	sublingual$$$166$$$176$$$O	aerosol$$$177$$$184$$$O	or$$$185$$$187$$$O	spray$$$188$$$193$$$O	delivery$$$194$$$202$$$O	of$$$203$$$205$$$O	cannabis$$$206$$$214$$$O	is$$$215$$$217$$$O	provided.$$$218$$$227$$$O	The$$$228$$$231$$$O	formulation$$$232$$$243$$$O	may$$$244$$$247$$$O	be$$$248$$$250$$$O	dispensed$$$251$$$260$$$O	using$$$261$$$266$$$O	a$$$267$$$268$$$O	pump$$$269$$$273$$$O	spray$$$274$$$279$$$O	or$$$280$$$282$$$O	the$$$283$$$286$$$O	formulation$$$287$$$298$$$O	may$$$299$$$302$$$O	include$$$303$$$310$$$O	a$$$311$$$312$$$O	propellant,$$$313$$$324$$$O	such$$$325$$$329$$$O	as$$$330$$$332$$$O	butane,$$$333$$$340$$$O	1,1,1,2-tetrafuorethane$$$341$$$364$$$O	(HFC-134a)$$$365$$$375$$$O	or$$$376$$$378$$$O	1,1,1,2,3,3,3-heptafluropropane$$$379$$$410$$$O	(HFC-227).$$$411$$$421$$$O	The$$$422$$$425$$$O	term$$$426$$$430$$$O	cannabis$$$431$$$439$$$O	is$$$440$$$442$$$O	used$$$443$$$447$$$O	herein$$$448$$$454$$$O	to$$$455$$$457$$$O	refer$$$458$$$463$$$O	to$$$464$$$466$$$O	all$$$467$$$470$$$O	physiologically$$$471$$$486$$$O	active$$$487$$$493$$$O	substances$$$494$$$504$$$O	derived$$$505$$$512$$$O	from$$$513$$$517$$$O	the$$$518$$$521$$$O	cannabis$$$522$$$530$$$O	family$$$531$$$537$$$O	of$$$538$$$540$$$O	plants$$$541$$$547$$$O	and$$$548$$$551$$$O	synthetic$$$552$$$561$$$O	cannabis$$$562$$$570$$$O	analogues$$$571$$$580$$$O	and$$$581$$$584$$$O	derivatives,$$$585$$$597$$$O	precursors,$$$598$$$609$$$O	metabolites$$$610$$$621$$$O	etc.,$$$622$$$627$$$O	or$$$628$$$630$$$O	related$$$631$$$638$$$O	substances$$$639$$$649$$$O	having$$$650$$$656$$$O	cannabis-like$$$657$$$670$$$O	physiological$$$671$$$684$$$O	effects.$$$685$$$693$$$O
CN103330812A
Drug$$$0$$$4$$$O	for$$$5$$$8$$$O	treating$$$9$$$17$$$O	dermatitis$$$18$$$28$$$O	rhus$$$29$$$33$$$O	and$$$34$$$37$$$O	preparation$$$38$$$49$$$O	method$$$50$$$56$$$O	thereof$$$57$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	drug$$$26$$$30$$$O	for$$$31$$$34$$$O	treating$$$35$$$43$$$O	dermatitis$$$44$$$54$$$O	rhus.$$$55$$$60$$$O	The$$$61$$$64$$$O	drug$$$65$$$69$$$O	is$$$70$$$72$$$O	mainly$$$73$$$79$$$O	prepared$$$80$$$88$$$O	from$$$89$$$93$$$O	the$$$94$$$97$$$O	drugs$$$98$$$103$$$O	such$$$104$$$108$$$O	as$$$109$$$111$$$O	plaster,$$$112$$$120$$$O	medicated$$$121$$$130$$$O	leaven,$$$131$$$138$$$O	calomel,$$$139$$$147$$$O	orpiment$$$148$$$156$$$O	and$$$157$$$160$$$O	the$$$161$$$164$$$O	like$$$165$$$169$$$O	according$$$170$$$179$$$O	to$$$180$$$182$$$O	a$$$183$$$184$$$O	certain$$$185$$$192$$$O	weight$$$193$$$199$$$O	ratio.$$$200$$$206$$$O	The$$$207$$$210$$$O	drug$$$211$$$215$$$O	has$$$216$$$219$$$O	the$$$220$$$223$$$O	functions$$$224$$$233$$$O	of$$$234$$$236$$$O	heat$$$237$$$241$$$O	clearing,$$$242$$$251$$$O	detoxifying,$$$252$$$264$$$O	sterilizing,$$$265$$$277$$$O	itching$$$278$$$285$$$O	relieving,$$$286$$$296$$$O	dampness$$$297$$$305$$$O	draining$$$306$$$314$$$O	and$$$315$$$318$$$O	inflammation$$$319$$$331$$$O	eliminating$$$332$$$343$$$O	and$$$344$$$347$$$O	takes$$$348$$$353$$$O	effect$$$354$$$360$$$O	quickly$$$361$$$368$$$O	and$$$369$$$372$$$O	has$$$373$$$376$$$O	good$$$377$$$381$$$O	curative$$$382$$$390$$$O	effects$$$391$$$398$$$O	and$$$399$$$402$$$O	high$$$403$$$407$$$O	cure$$$408$$$412$$$O	rate$$$413$$$417$$$O	when$$$418$$$422$$$O	being$$$423$$$428$$$O	used$$$429$$$433$$$O	for$$$434$$$437$$$O	treating$$$438$$$446$$$O	dermatitis$$$447$$$457$$$O	rhus.$$$458$$$463$$$O
WO2012055034A1
Sulfonamides$$$0$$$12$$$I	as$$$13$$$15$$$O	hiv$$$16$$$19$$$O	protease$$$20$$$28$$$O	inhibitors$$$29$$$39$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	Formula$$$13$$$20$$$O	I$$$21$$$22$$$O	are$$$23$$$26$$$O	disclosed:$$$27$$$37$$$O	wherein$$$38$$$45$$$O	L,$$$46$$$48$$$O	A,$$$49$$$51$$$O	R1,$$$52$$$55$$$O	R2,$$$56$$$59$$$O	R3A,$$$60$$$64$$$O	R3B,$$$65$$$69$$$O	R4A,$$$70$$$74$$$O	R4B,$$$75$$$79$$$O	R5,$$$80$$$83$$$O	R6$$$84$$$86$$$O	and$$$87$$$90$$$O	R7$$$91$$$93$$$O	are$$$94$$$97$$$O	defined$$$98$$$105$$$O	herein.$$$106$$$113$$$O	The$$$114$$$117$$$O	compounds$$$118$$$127$$$O	encompassed$$$128$$$139$$$O	by$$$140$$$142$$$O	Formula$$$143$$$150$$$O	I$$$151$$$152$$$O	include$$$153$$$160$$$O	compounds$$$161$$$170$$$O	which$$$171$$$176$$$O	are$$$177$$$180$$$O	HIV$$$181$$$184$$$O	protease$$$185$$$193$$$O	inhibitors$$$194$$$204$$$O	and$$$205$$$208$$$O	other$$$209$$$214$$$O	compounds$$$215$$$224$$$O	which$$$225$$$230$$$O	can$$$231$$$234$$$O	be$$$235$$$237$$$O	metabolized$$$238$$$249$$$O	in$$$250$$$252$$$O	vivo$$$253$$$257$$$O	to$$$258$$$260$$$O	HIV$$$261$$$264$$$O	protease$$$265$$$273$$$O	inhibitors.$$$274$$$285$$$O	The$$$286$$$289$$$O	compounds$$$290$$$299$$$O	and$$$300$$$303$$$O	their$$$304$$$309$$$O	pharmaceutically$$$310$$$326$$$O	acceptable$$$327$$$337$$$O	salts$$$338$$$343$$$O	are$$$344$$$347$$$O	useful$$$348$$$354$$$O	for$$$355$$$358$$$O	the$$$359$$$362$$$O	prophylaxis$$$363$$$374$$$O	or$$$375$$$377$$$O	treatment$$$378$$$387$$$O	of$$$388$$$390$$$O	infection$$$391$$$400$$$O	by$$$401$$$403$$$O	HIV$$$404$$$407$$$O	and$$$408$$$411$$$O	the$$$412$$$415$$$O	prophylaxis,$$$416$$$428$$$O	treatment,$$$429$$$439$$$O	or$$$440$$$442$$$O	delay$$$443$$$448$$$O	in$$$449$$$451$$$O	the$$$452$$$455$$$O	onset$$$456$$$461$$$O	of$$$462$$$464$$$O	AIDS.$$$465$$$470$$$O	The$$$471$$$474$$$O	compounds$$$475$$$484$$$O	and$$$485$$$488$$$O	their$$$489$$$494$$$O	salts$$$495$$$500$$$O	can$$$501$$$504$$$O	be$$$505$$$507$$$O	employed$$$508$$$516$$$O	as$$$517$$$519$$$O	ingredients$$$520$$$531$$$O	in$$$532$$$534$$$O	pharmaceutical$$$535$$$549$$$O	compositions,$$$550$$$563$$$O	optionally$$$564$$$574$$$O	in$$$575$$$577$$$O	combination$$$578$$$589$$$O	with$$$590$$$594$$$O	other$$$595$$$600$$$O	antivirals,$$$601$$$612$$$O	immunomodulators,$$$613$$$630$$$O	antibiotics$$$631$$$642$$$O	or$$$643$$$645$$$O	vaccines.$$$646$$$655$$$O
EP2370075A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	geranyl-geranyl$$$7$$$22$$$I	transferase$$$23$$$34$$$O	in$$$35$$$37$$$O	treating$$$38$$$46$$$O	spinal$$$47$$$53$$$O	cord$$$54$$$58$$$O	lesions$$$59$$$66$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	formula$$$46$$$53$$$O	(I).$$$54$$$58$$$O	In$$$59$$$61$$$O	particular,$$$62$$$73$$$O	the$$$74$$$77$$$O	present$$$78$$$85$$$O	invention$$$86$$$95$$$O	relates$$$96$$$103$$$O	to$$$104$$$106$$$O	the$$$107$$$110$$$O	use$$$111$$$114$$$O	of$$$115$$$117$$$O	said$$$118$$$122$$$O	compounds$$$123$$$132$$$O	as$$$133$$$135$$$O	a$$$136$$$137$$$O	drug,$$$138$$$143$$$O	particularly$$$144$$$156$$$O	for$$$157$$$160$$$O	the$$$161$$$164$$$O	treatment$$$165$$$174$$$O	of$$$175$$$177$$$O	central$$$178$$$185$$$O	nervous$$$186$$$193$$$O	system$$$194$$$200$$$O	lesions,$$$201$$$209$$$O	particularly$$$210$$$222$$$O	for$$$223$$$226$$$O	treating$$$227$$$235$$$O	spinal$$$236$$$242$$$O	cord$$$243$$$247$$$O	lesions.$$$248$$$256$$$O	The$$$257$$$260$$$O	present$$$261$$$268$$$O	invention$$$269$$$278$$$O	is$$$279$$$281$$$O	particularly$$$282$$$294$$$O	useful$$$295$$$301$$$O	in$$$302$$$304$$$O	the$$$305$$$308$$$O	medical$$$309$$$316$$$O	or$$$317$$$319$$$O	veterinary$$$320$$$330$$$O	fields.$$$331$$$338$$$O
CN101066980A
Crystalline$$$0$$$11$$$O	tenofovir$$$12$$$21$$$I	fumarate$$$22$$$30$$$I	and$$$31$$$34$$$O	its$$$35$$$38$$$O	medicine$$$39$$$47$$$O	prepn$$$48$$$53$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	crystalline$$$31$$$42$$$O	tenofovir$$$43$$$52$$$I	disoproxil$$$53$$$63$$$I	fumarate$$$64$$$72$$$I	(TDF)$$$73$$$78$$$I	A$$$79$$$80$$$O	and$$$81$$$84$$$O	TDF$$$85$$$88$$$O	B$$$89$$$90$$$O	in$$$91$$$93$$$O	different$$$94$$$103$$$O	crystal$$$104$$$111$$$O	forms$$$112$$$117$$$O	and$$$118$$$121$$$O	their$$$122$$$127$$$O	preparation$$$128$$$139$$$O	process.$$$140$$$148$$$O	The$$$149$$$152$$$O	preparations$$$153$$$165$$$O	may$$$166$$$169$$$O	be$$$170$$$172$$$O	used$$$173$$$177$$$O	in$$$178$$$180$$$O	preventing$$$181$$$191$$$O	and$$$192$$$195$$$O	treating$$$196$$$204$$$O	hepatitis$$$205$$$214$$$O	B$$$215$$$216$$$O	and$$$217$$$220$$$O	AIDS.$$$221$$$226$$$O
CN202761909U
Ginger$$$0$$$6$$$O	medicine$$$7$$$15$$$O	hot$$$16$$$19$$$O	push$$$20$$$24$$$O	capsule$$$25$$$32$$$O
The$$$0$$$3$$$O	utility$$$4$$$11$$$O	model$$$12$$$17$$$O	discloses$$$18$$$27$$$O	a$$$28$$$29$$$O	ginger$$$30$$$36$$$O	medicine$$$37$$$45$$$O	hot$$$46$$$49$$$O	push$$$50$$$54$$$O	capsule$$$55$$$62$$$O	which$$$63$$$68$$$O	comprises$$$69$$$78$$$O	a$$$79$$$80$$$O	medicine$$$81$$$89$$$O	core$$$90$$$94$$$O	(1),$$$95$$$99$$$O	a$$$100$$$101$$$O	gauze$$$102$$$107$$$O	layer$$$108$$$113$$$O	(2),$$$114$$$118$$$O	a$$$119$$$120$$$O	ginger$$$121$$$127$$$O	layer$$$128$$$133$$$O	(3)$$$134$$$137$$$O	and$$$138$$$141$$$O	a$$$142$$$143$$$O	cotton$$$144$$$150$$$O	layer$$$151$$$156$$$O	(4),$$$157$$$161$$$O	wherein$$$162$$$169$$$O	the$$$170$$$173$$$O	gauze$$$174$$$179$$$O	layer$$$180$$$185$$$O	(2)$$$186$$$189$$$O	wraps$$$190$$$195$$$O	the$$$196$$$199$$$O	medicine$$$200$$$208$$$O	core$$$209$$$213$$$O	(1);$$$214$$$218$$$O	the$$$219$$$222$$$O	ginger$$$223$$$229$$$O	layer$$$230$$$235$$$O	(3)$$$236$$$239$$$O	is$$$240$$$242$$$O	wound$$$243$$$248$$$O	on$$$249$$$251$$$O	the$$$252$$$255$$$O	outer$$$256$$$261$$$O	side$$$262$$$266$$$O	of$$$267$$$269$$$O	the$$$270$$$273$$$O	gauze$$$274$$$279$$$O	layer$$$280$$$285$$$O	(2);$$$286$$$290$$$O	and$$$291$$$294$$$O	the$$$295$$$298$$$O	cotton$$$299$$$305$$$O	layer$$$306$$$311$$$O	(4)$$$312$$$315$$$O	wraps$$$316$$$321$$$O	the$$$322$$$325$$$O	ginger$$$326$$$332$$$O	layer$$$333$$$338$$$O	(3).$$$339$$$343$$$O	The$$$344$$$347$$$O	ginger$$$348$$$354$$$O	medicine$$$355$$$363$$$O	hot$$$364$$$367$$$O	push$$$368$$$372$$$O	capsule$$$373$$$380$$$O	has$$$381$$$384$$$O	the$$$385$$$388$$$O	advantages$$$389$$$399$$$O	of$$$400$$$402$$$O	simplicity$$$403$$$413$$$O	and$$$414$$$417$$$O	convenience$$$418$$$429$$$O	in$$$430$$$432$$$O	use,$$$433$$$437$$$O	safety,$$$438$$$445$$$O	remarkable$$$446$$$456$$$O	treatment$$$457$$$466$$$O	effect,$$$467$$$474$$$O	low$$$475$$$478$$$O	cost,$$$479$$$484$$$O	fragrance$$$485$$$494$$$O	and$$$495$$$498$$$O	comfort,$$$499$$$507$$$O	and$$$508$$$511$$$O	is$$$512$$$514$$$O	popular$$$515$$$522$$$O	with$$$523$$$527$$$O	a$$$528$$$529$$$O	majority$$$530$$$538$$$O	of$$$539$$$541$$$O	patients.$$$542$$$551$$$O
CN101977597A
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	inhibiting$$$11$$$21$$$O	bacterial$$$22$$$31$$$O	virulence$$$32$$$41$$$O	and$$$42$$$45$$$O	compounds$$$46$$$55$$$O	relating$$$56$$$64$$$O	thereto$$$65$$$72$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	and$$$43$$$46$$$O	methods$$$47$$$54$$$O	for$$$55$$$58$$$O	the$$$59$$$62$$$O	treatment$$$63$$$72$$$O	of$$$73$$$75$$$O	bacterial$$$76$$$85$$$O	infections.$$$86$$$97$$$O	Because$$$98$$$105$$$O	their$$$106$$$111$$$O	mechanism$$$112$$$121$$$O	of$$$122$$$124$$$O	action$$$125$$$131$$$O	does$$$132$$$136$$$O	not$$$137$$$140$$$O	involve$$$141$$$148$$$O	killing$$$149$$$156$$$O	of$$$157$$$159$$$O	bacteria$$$160$$$168$$$O	or$$$169$$$171$$$O	inhibiting$$$172$$$182$$$O	their$$$183$$$188$$$O	growth,$$$189$$$196$$$O	the$$$197$$$200$$$O	potential$$$201$$$210$$$O	for$$$211$$$214$$$O	these$$$215$$$220$$$O	compounds$$$221$$$230$$$O	to$$$231$$$233$$$O	induce$$$234$$$240$$$O	drug$$$241$$$245$$$O	resistance$$$246$$$256$$$O	in$$$257$$$259$$$O	bacteria$$$260$$$268$$$O	is$$$269$$$271$$$O	minimized.$$$272$$$282$$$O	Through$$$283$$$290$$$O	inhibiting$$$291$$$301$$$O	bacterial$$$302$$$311$$$O	virulence,$$$312$$$322$$$O	the$$$323$$$326$$$O	present$$$327$$$334$$$O	invention$$$335$$$344$$$O	provides$$$345$$$353$$$O	a$$$354$$$355$$$O	novel$$$356$$$361$$$O	means$$$362$$$367$$$O	of$$$368$$$370$$$O	treating$$$371$$$379$$$O	bacterial$$$380$$$389$$$O	infections.$$$390$$$401$$$O
US20100028368
Sulfide,$$$0$$$8$$$I	sulfoxide$$$9$$$18$$$I	and$$$19$$$22$$$O	sulfone$$$23$$$30$$$I	chalcone$$$31$$$39$$$I	analogues,$$$40$$$50$$$O	derivatives$$$51$$$62$$$O	thereof$$$63$$$70$$$O	and$$$71$$$74$$$O	therapeutic$$$75$$$86$$$O	uses$$$87$$$91$$$O	thereof$$$92$$$99$$$O
Compounds$$$0$$$9$$$O	useful$$$10$$$16$$$O	as$$$17$$$19$$$O	antiproliferative$$$20$$$37$$$O	agents$$$38$$$44$$$O	according$$$45$$$54$$$O	to$$$55$$$57$$$O	formula$$$58$$$65$$$O	(I):$$$66$$$70$$$O	wherein$$$71$$$78$$$O	Ar1,$$$79$$$83$$$I	Ar2,$$$84$$$88$$$I	Ar3,$$$89$$$93$$$I	m$$$94$$$95$$$O	and$$$96$$$99$$$O	n$$$100$$$101$$$O	are$$$102$$$105$$$O	as$$$106$$$108$$$O	defined$$$109$$$116$$$O	herein,$$$117$$$124$$$O	salts,$$$125$$$131$$$O	antibody$$$132$$$140$$$O	conjugates,$$$141$$$152$$$O	pharmaceutical$$$153$$$167$$$O	compositions,$$$168$$$181$$$O	methods$$$182$$$189$$$O	of$$$190$$$192$$$O	treatment,$$$193$$$203$$$O	and$$$204$$$207$$$O	synthetic$$$208$$$217$$$O	methods$$$218$$$225$$$O	are$$$226$$$229$$$O	provided.$$$230$$$239$$$O
CN102000153A
Hair$$$0$$$4$$$O	growth$$$5$$$11$$$O	lotion$$$12$$$18$$$O	for$$$19$$$22$$$O	promoting$$$23$$$32$$$O	hair$$$33$$$37$$$O	to$$$38$$$40$$$O	grow$$$41$$$45$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	hair$$$25$$$29$$$O	growth$$$30$$$36$$$O	lotion$$$37$$$43$$$O	for$$$44$$$47$$$O	promoting$$$48$$$57$$$O	hair$$$58$$$62$$$O	to$$$63$$$65$$$O	grow,$$$66$$$71$$$O	which$$$72$$$77$$$O	is$$$78$$$80$$$O	synthesized$$$81$$$92$$$O	by$$$93$$$95$$$O	mixing$$$96$$$102$$$O	ethanol$$$103$$$110$$$I	lixivium$$$111$$$119$$$I	(solution$$$120$$$129$$$O	A)$$$130$$$132$$$O	prepared$$$133$$$141$$$O	from$$$142$$$146$$$O	cockscomb$$$147$$$156$$$O	flower,$$$157$$$164$$$O	malaytea$$$165$$$173$$$O	scurfpea$$$174$$$182$$$O	fruit,$$$183$$$189$$$O	szechwan$$$190$$$198$$$O	chinaberry$$$199$$$209$$$O	fruit,$$$210$$$216$$$O	blister$$$217$$$224$$$O	beetle$$$225$$$231$$$O	and$$$232$$$235$$$O	absolute$$$236$$$244$$$O	ethanol,$$$245$$$253$$$I	ethanol$$$254$$$261$$$I	solution$$$262$$$270$$$O	(solution$$$271$$$280$$$O	B)$$$281$$$283$$$O	prepared$$$284$$$292$$$O	from$$$293$$$297$$$O	retinoic$$$298$$$306$$$I	acid,$$$307$$$312$$$I	erucic$$$313$$$319$$$I	acid,$$$320$$$325$$$I	peppermint$$$326$$$336$$$O	oil,$$$337$$$341$$$O	pepper$$$342$$$348$$$O	oil,$$$349$$$353$$$O	ginger$$$354$$$360$$$O	oil,$$$361$$$365$$$O	glycerol,$$$366$$$375$$$I	laurocapram,$$$376$$$388$$$I	alkylp$$$389$$$395$$$I	henol$$$396$$$401$$$I	polyoxyethylene,$$$402$$$418$$$I	twain$$$419$$$424$$$I	80$$$425$$$427$$$I	and$$$428$$$431$$$O	the$$$432$$$435$$$O	absolute$$$436$$$444$$$O	ethanol$$$445$$$452$$$I	and$$$453$$$456$$$O	aqueous$$$457$$$464$$$O	solution$$$465$$$473$$$O	(solution$$$474$$$483$$$O	C)$$$484$$$486$$$O	prepared$$$487$$$495$$$O	from$$$496$$$500$$$O	vitamin$$$501$$$508$$$I	B6,$$$509$$$512$$$I	vitamin$$$513$$$520$$$I	C,$$$521$$$523$$$I	allantoin$$$524$$$533$$$I	and$$$534$$$537$$$O	distilled$$$538$$$547$$$O	water$$$548$$$553$$$O	sequentially$$$554$$$566$$$O	and$$$567$$$570$$$O	uniformly.$$$571$$$581$$$O	The$$$582$$$585$$$O	hair$$$586$$$590$$$O	growth$$$591$$$597$$$O	lotion$$$598$$$604$$$O	has$$$605$$$608$$$O	the$$$609$$$612$$$O	effects$$$613$$$620$$$O	of$$$621$$$623$$$O	regulating$$$624$$$634$$$O	the$$$635$$$638$$$O	synthesis$$$639$$$648$$$O	of$$$649$$$651$$$O	fatty$$$652$$$657$$$I	acid,$$$658$$$663$$$I	inhibiting$$$664$$$674$$$O	secretion$$$675$$$684$$$O	of$$$685$$$687$$$O	sebum,$$$688$$$694$$$O	reducing$$$695$$$703$$$O	grease$$$704$$$710$$$O	aggregating$$$711$$$722$$$O	on$$$723$$$725$$$O	scalps,$$$726$$$733$$$O	increasing$$$734$$$744$$$O	the$$$745$$$748$$$O	nutrition$$$749$$$758$$$O	of$$$759$$$761$$$O	hair$$$762$$$766$$$O	tissue,$$$767$$$774$$$O	maintaining$$$775$$$786$$$O	normal$$$787$$$793$$$O	metabolism$$$794$$$804$$$O	and$$$805$$$808$$$O	stimulating$$$809$$$820$$$O	and$$$821$$$824$$$O	promoting$$$825$$$834$$$O	the$$$835$$$838$$$O	hair$$$839$$$843$$$O	to$$$844$$$846$$$O	grow,$$$847$$$852$$$O	and$$$853$$$856$$$O	has$$$857$$$860$$$O	the$$$861$$$864$$$O	obvious$$$865$$$872$$$O	curative$$$873$$$881$$$O	effect$$$882$$$888$$$O	on$$$889$$$891$$$O	diseases$$$892$$$900$$$O	such$$$901$$$905$$$O	as$$$906$$$908$$$O	scalp$$$909$$$914$$$O	folliculitis,$$$915$$$928$$$O	alopecia,$$$929$$$938$$$O	alopecia$$$939$$$947$$$O	areata,$$$948$$$955$$$O	baldness$$$956$$$964$$$O	and$$$965$$$968$$$O	the$$$969$$$972$$$O	like.$$$973$$$978$$$O
US20100179186
USE$$$0$$$3$$$O	OF$$$4$$$6$$$O	A$$$7$$$8$$$O	NOVEL$$$9$$$14$$$O	ALPHA-7$$$15$$$22$$$O	nAChR$$$23$$$28$$$O	ANTAGONIST$$$29$$$39$$$O	TO$$$40$$$42$$$O	SUPPRESS$$$43$$$51$$$O	PATHOGENIC$$$52$$$62$$$O	SIGNAL$$$63$$$69$$$O	TRANSDUCTION$$$70$$$82$$$O	IN$$$83$$$85$$$O	CANCER$$$86$$$92$$$O	AND$$$93$$$96$$$O	AIDS$$$97$$$101$$$O
This$$$0$$$4$$$O	application$$$5$$$16$$$O	provides$$$17$$$25$$$O	a$$$26$$$27$$$O	method$$$28$$$34$$$O	for$$$35$$$38$$$O	the$$$39$$$42$$$O	use$$$43$$$46$$$O	of$$$47$$$49$$$O	select$$$50$$$56$$$O	quaternary$$$57$$$67$$$I	ammonium$$$68$$$76$$$I	antagonists$$$77$$$88$$$O	to$$$89$$$91$$$O	alpha-7$$$92$$$99$$$O	nAChR$$$100$$$105$$$O	for$$$106$$$109$$$O	the$$$110$$$113$$$O	treatment$$$114$$$123$$$O	of$$$124$$$126$$$O	cancer$$$127$$$133$$$O	and$$$134$$$137$$$O	HIV$$$138$$$141$$$O	and$$$142$$$145$$$O	AIDS.$$$146$$$151$$$O
US20080275046
1-(3-{4-[4-(piperidin-1-ylmethyl)-1,3-oxazol-2-yl]phenoxy}propyl)piperidine;$$$0$$$76$$$I	4,4-difluoro-1-[(4-methyl-2-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1,3-thiazol-5-yl)carbonyl]piperidine;$$$77$$$189$$$I	histamine$$$190$$$199$$$I	H3-receptor$$$200$$$211$$$O	antagonists;$$$212$$$224$$$O	Parkinson's$$$225$$$236$$$O	and$$$237$$$240$$$O	Alzheimer's$$$241$$$252$$$O	diseases;$$$253$$$262$$$O	sleep$$$263$$$268$$$O	disorders;$$$269$$$279$$$O	antiepileptics$$$280$$$294$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	comprising$$$43$$$53$$$O	an$$$54$$$56$$$O	oxazole$$$57$$$64$$$I	or$$$65$$$67$$$O	thiazole$$$68$$$76$$$I	moiety$$$77$$$83$$$O	of$$$84$$$86$$$O	formula$$$87$$$94$$$O	(I),$$$95$$$99$$$O	processes$$$100$$$109$$$O	for$$$110$$$113$$$O	preparing$$$114$$$123$$$O	them,$$$124$$$129$$$O	pharmaceutical$$$130$$$144$$$O	compositions$$$145$$$157$$$O	comprising$$$158$$$168$$$O	said$$$169$$$173$$$O	compounds$$$174$$$183$$$O	and$$$184$$$187$$$O	their$$$188$$$193$$$O	uses$$$194$$$198$$$O	as$$$199$$$201$$$O	H3-receptor$$$202$$$213$$$O	ligands,$$$214$$$222$$$O	Formula$$$223$$$230$$$O	(I),$$$231$$$235$$$O	wherein,$$$236$$$244$$$O	A1$$$245$$$247$$$O	is$$$248$$$250$$$O	CH,$$$251$$$254$$$I	C(alkyl),$$$255$$$264$$$I	C-halogen$$$265$$$274$$$I	or$$$275$$$277$$$O	N;$$$278$$$280$$$I	R1$$$281$$$283$$$O	is$$$284$$$286$$$O	hydrogen,$$$287$$$296$$$I	halogen,$$$297$$$305$$$I	C1-6$$$306$$$310$$$I	alkyl$$$311$$$316$$$I	or$$$317$$$319$$$O	alkoxy;$$$320$$$327$$$I	R2$$$328$$$330$$$O	is,$$$331$$$334$$$O	Formula$$$335$$$342$$$O	(IIâ²),$$$343$$$351$$$O	A3$$$352$$$354$$$O	is$$$355$$$357$$$I	O$$$358$$$359$$$O	or$$$360$$$362$$$I	S;$$$363$$$365$$$O	R3$$$366$$$368$$$O	is$$$369$$$371$$$I	hydrogen,$$$372$$$381$$$I	halogen,$$$382$$$390$$$I	C1-6$$$391$$$395$$$I	alkyl$$$396$$$401$$$I	or$$$402$$$404$$$I	alkoxy;$$$405$$$412$$$I	R4$$$413$$$415$$$O	is$$$416$$$418$$$I	hydrogen,$$$419$$$428$$$I	halogen,$$$429$$$437$$$I	C1-6$$$438$$$442$$$I	alkyl,$$$443$$$449$$$I	alkoxy$$$450$$$456$$$I	or$$$457$$$459$$$I	âO-L;$$$460$$$467$$$I	R5$$$468$$$470$$$I	is$$$471$$$473$$$I	hydrogen$$$474$$$482$$$I	or$$$483$$$485$$$I	âO-L,$$$486$$$493$$$I	wherein$$$494$$$501$$$O	L$$$502$$$503$$$O	is$$$504$$$506$$$I	an$$$507$$$509$$$I	aminoalkyl$$$510$$$520$$$I	group$$$521$$$526$$$O	and$$$527$$$530$$$O	at$$$531$$$533$$$O	least$$$534$$$539$$$O	one$$$540$$$543$$$O	of$$$544$$$546$$$O	R4$$$547$$$549$$$O	and$$$550$$$553$$$O	R5$$$554$$$556$$$O	should$$$557$$$563$$$I	be$$$564$$$566$$$I	âO-L.$$$567$$$574$$$O
WO2010119741A1
Preparation$$$0$$$11$$$O	for$$$12$$$15$$$O	external$$$16$$$24$$$O	use$$$25$$$28$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	new$$$14$$$17$$$O	external$$$18$$$26$$$O	preparation$$$27$$$38$$$O	of$$$39$$$41$$$O	a$$$42$$$43$$$O	tertiary$$$44$$$52$$$I	amine$$$53$$$58$$$I	compound$$$59$$$67$$$O	that$$$68$$$72$$$O	exhibits$$$73$$$81$$$O	a$$$82$$$83$$$O	CXCR4-antagonizing$$$84$$$102$$$O	action,$$$103$$$110$$$O	said$$$111$$$115$$$O	preparation$$$116$$$127$$$O	being$$$128$$$133$$$O	a$$$134$$$135$$$O	nonaqueous$$$136$$$146$$$O	preparation$$$147$$$158$$$O	containing$$$159$$$169$$$O	a$$$170$$$171$$$O	tertiary$$$172$$$180$$$I	amine$$$181$$$186$$$I	compound$$$187$$$195$$$O	indicated$$$196$$$205$$$O	by$$$206$$$208$$$O	general$$$209$$$216$$$O	formula$$$217$$$224$$$O	(1),$$$225$$$229$$$O	in$$$230$$$232$$$O	solution$$$233$$$241$$$O	in$$$242$$$244$$$O	a$$$245$$$246$$$O	fatty$$$247$$$252$$$I	acid$$$253$$$257$$$I	ionic$$$258$$$263$$$O	liquid.$$$264$$$271$$$O	(1)$$$272$$$275$$$O	(In$$$276$$$279$$$O	general$$$280$$$287$$$O	formula$$$288$$$295$$$O	(1),$$$296$$$300$$$O	R1$$$301$$$303$$$O	through$$$304$$$311$$$O	R6$$$312$$$314$$$O	each$$$315$$$319$$$O	independently$$$320$$$333$$$O	represent$$$334$$$343$$$O	either$$$344$$$350$$$O	a$$$351$$$352$$$O	hydrogen$$$353$$$361$$$I	atom$$$362$$$366$$$O	or$$$367$$$369$$$O	a$$$370$$$371$$$O	C1â4$$$372$$$378$$$I	lower$$$379$$$384$$$I	alkyl$$$385$$$390$$$I	group;$$$391$$$397$$$O	n$$$398$$$399$$$O	1$$$400$$$401$$$O	through$$$402$$$409$$$O	n$$$410$$$411$$$O	3$$$412$$$413$$$O	are$$$414$$$417$$$O	integers$$$418$$$426$$$O	from$$$427$$$431$$$O	1$$$432$$$433$$$O	to$$$434$$$436$$$O	4,$$$437$$$439$$$O	inclusive;$$$440$$$450$$$O	A1$$$451$$$453$$$O	and$$$454$$$457$$$O	A2$$$458$$$460$$$O	represent$$$461$$$470$$$O	substituted$$$471$$$482$$$O	or$$$483$$$485$$$O	unsubstituted$$$486$$$499$$$I	heteroaromatic$$$500$$$514$$$I	ring$$$515$$$519$$$O	groups;$$$520$$$527$$$O	W$$$528$$$529$$$O	represents$$$530$$$540$$$O	a$$$541$$$542$$$O	substituted$$$543$$$554$$$O	or$$$555$$$557$$$O	unsubstituted$$$558$$$571$$$I	phenylene$$$572$$$581$$$I	group;$$$582$$$588$$$O	X$$$589$$$590$$$O	represents$$$591$$$601$$$O	an$$$602$$$604$$$I	N-(carboxymethyl)methylene$$$605$$$631$$$I	group;$$$632$$$638$$$O	and$$$639$$$642$$$O	D$$$643$$$644$$$O	represents$$$645$$$655$$$O	a$$$656$$$657$$$I	C1â5$$$658$$$664$$$I	lower$$$665$$$670$$$I	alkylene$$$671$$$679$$$I	group$$$680$$$685$$$O	substituted$$$686$$$697$$$O	with$$$698$$$702$$$O	a$$$703$$$704$$$O	secondary$$$705$$$714$$$I	amino$$$715$$$720$$$I	group$$$721$$$726$$$O	having$$$727$$$733$$$I	a$$$734$$$735$$$I	C1â4$$$736$$$742$$$I	lower$$$743$$$748$$$I	alkyl$$$749$$$754$$$O	group.)$$$755$$$762$$$O
US20090270496
Antifungal$$$0$$$10$$$O	compounds$$$11$$$20$$$O
Antifungal$$$0$$$10$$$O	compounds$$$11$$$20$$$O	having$$$21$$$27$$$O	a$$$28$$$29$$$O	benzofuran$$$30$$$40$$$I	structure.$$$41$$$51$$$O	Antifungals$$$52$$$63$$$O	exhibit$$$64$$$71$$$O	much$$$72$$$76$$$O	less$$$77$$$81$$$O	toxicity$$$82$$$90$$$O	to$$$91$$$93$$$O	human$$$94$$$99$$$O	cells$$$100$$$105$$$O	than$$$106$$$110$$$O	amiodarone.$$$111$$$122$$$I	These$$$123$$$128$$$O	compounds$$$129$$$138$$$O	are$$$139$$$142$$$O	useful$$$143$$$149$$$O	alone$$$150$$$155$$$O	or$$$156$$$158$$$O	in$$$159$$$161$$$O	combination$$$162$$$173$$$O	with$$$174$$$178$$$O	other$$$179$$$184$$$O	compounds$$$185$$$194$$$O	having$$$195$$$201$$$O	antifungal$$$202$$$212$$$O	activity.$$$213$$$222$$$O	Compounds$$$223$$$232$$$O	of$$$233$$$235$$$O	this$$$236$$$240$$$O	invention$$$241$$$250$$$O	exhibit$$$251$$$258$$$O	synergistic$$$259$$$270$$$O	antifungal$$$271$$$281$$$O	activity$$$282$$$290$$$O	in$$$291$$$293$$$O	combination$$$294$$$305$$$O	with$$$306$$$310$$$O	antifungal$$$311$$$321$$$O	amiodarone$$$322$$$332$$$I	compounds.$$$333$$$343$$$O	The$$$344$$$347$$$O	invention$$$348$$$357$$$O	provides$$$358$$$366$$$O	pharmaceutical$$$367$$$381$$$O	compositions$$$382$$$394$$$O	useful$$$395$$$401$$$O	for$$$402$$$405$$$O	treating$$$406$$$414$$$O	fungal$$$415$$$421$$$O	infections,$$$422$$$433$$$O	methods$$$434$$$441$$$O	for$$$442$$$445$$$O	treating$$$446$$$454$$$O	fungal$$$455$$$461$$$O	infections$$$462$$$472$$$O	and$$$473$$$476$$$O	compounds$$$477$$$486$$$O	useful$$$487$$$493$$$O	in$$$494$$$496$$$O	such$$$497$$$501$$$O	compositions$$$502$$$514$$$O	for$$$515$$$518$$$O	treating$$$519$$$527$$$O	fungal$$$528$$$534$$$O	infections.$$$535$$$546$$$O	Compounds$$$547$$$556$$$O	of$$$557$$$559$$$O	this$$$560$$$564$$$O	invention$$$565$$$574$$$O	are$$$575$$$578$$$O	further$$$579$$$586$$$O	useful$$$587$$$593$$$O	as$$$594$$$596$$$O	antifungal$$$597$$$607$$$O	agents$$$608$$$614$$$O	for$$$615$$$618$$$O	the$$$619$$$622$$$O	prevention$$$623$$$633$$$O	and$$$634$$$637$$$O	or$$$638$$$640$$$O	treatment$$$641$$$650$$$O	of$$$651$$$653$$$O	fungal$$$654$$$660$$$O	infections$$$661$$$671$$$O	in$$$672$$$674$$$O	plants.$$$675$$$682$$$O	The$$$683$$$686$$$O	invention$$$687$$$696$$$O	includes$$$697$$$705$$$O	agriculturally$$$706$$$720$$$O	useful$$$721$$$727$$$O	compositions$$$728$$$740$$$O	comprising$$$741$$$751$$$O	one$$$752$$$755$$$O	or$$$756$$$758$$$O	more$$$759$$$763$$$O	compounds$$$764$$$773$$$O	of$$$774$$$776$$$O	this$$$777$$$781$$$O	invention$$$782$$$791$$$O	which$$$792$$$797$$$O	exhibit$$$798$$$805$$$O	fungistatic$$$806$$$817$$$O	or$$$818$$$820$$$O	fungicidal$$$821$$$831$$$O	function$$$832$$$840$$$O	against$$$841$$$848$$$O	one$$$849$$$852$$$O	or$$$853$$$855$$$O	more$$$856$$$860$$$O	plant$$$861$$$866$$$O	pathogen$$$867$$$875$$$O	is$$$876$$$878$$$O	a$$$879$$$880$$$O	fungus.$$$881$$$888$$$O
CA2586384A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	treating$$$11$$$19$$$O	hiv$$$20$$$23$$$O	infection$$$24$$$33$$$O	through$$$34$$$41$$$O	co-administration$$$42$$$59$$$O	of$$$60$$$62$$$O	tipranavir$$$63$$$73$$$I	and$$$74$$$77$$$O	gw873140$$$78$$$86$$$I
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	treating$$$11$$$19$$$O	HIV$$$20$$$23$$$O	infection$$$24$$$33$$$O	through$$$34$$$41$$$O	co-administration$$$42$$$59$$$O	of$$$60$$$62$$$O	tipranavir$$$63$$$73$$$I	and$$$74$$$77$$$O	GW873140.$$$78$$$87$$$I
US20110224244
Adamantyl$$$0$$$9$$$I	Benzamide$$$10$$$19$$$I	Derivatives$$$20$$$31$$$O
Embodiments$$$0$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	present$$$19$$$26$$$O	invention$$$27$$$36$$$O	provide$$$37$$$44$$$O	adamantyl$$$45$$$54$$$I	benzamide$$$55$$$64$$$I	derivtives$$$65$$$75$$$O	and$$$76$$$79$$$O	pharmaceutical$$$80$$$94$$$O	compositions$$$95$$$107$$$O	comprising$$$108$$$118$$$O	adamantyl$$$119$$$128$$$I	benzamide$$$129$$$138$$$I	derivatives.$$$139$$$151$$$O	Methods$$$152$$$159$$$O	of$$$160$$$162$$$O	use$$$163$$$166$$$O	of$$$167$$$169$$$O	such$$$170$$$174$$$O	compounds$$$175$$$184$$$O	and$$$185$$$188$$$O	compositions$$$189$$$201$$$O	to$$$202$$$204$$$O	modulate$$$205$$$213$$$O	the$$$214$$$217$$$O	activity$$$218$$$226$$$O	of$$$227$$$229$$$O	11Î²-hydroxysteroid$$$230$$$249$$$I	dehydrogenase$$$250$$$263$$$O	type$$$264$$$268$$$O	1$$$269$$$270$$$O	(11Î²HSD1)$$$271$$$281$$$O	in$$$282$$$284$$$O	a$$$285$$$286$$$O	subject$$$287$$$294$$$O	are$$$295$$$298$$$O	also$$$299$$$303$$$O	provided.$$$304$$$313$$$O
US20120035257
Histone$$$0$$$7$$$I	Deacetylase$$$8$$$19$$$O	Inhibitors$$$20$$$30$$$O
Histone$$$0$$$7$$$I	deacetylase$$$8$$$19$$$O	is$$$20$$$22$$$O	a$$$23$$$24$$$O	metallo-enzyme$$$25$$$39$$$O	with$$$40$$$44$$$O	zinc$$$45$$$49$$$I	at$$$50$$$52$$$O	the$$$53$$$56$$$O	active$$$57$$$63$$$O	site.$$$64$$$69$$$O	Compounds$$$70$$$79$$$O	having$$$80$$$86$$$O	a$$$87$$$88$$$O	zinc-binding$$$89$$$101$$$I	moiety,$$$102$$$109$$$O	such$$$110$$$114$$$O	as,$$$115$$$118$$$O	for$$$119$$$122$$$O	example,$$$123$$$131$$$O	a$$$132$$$133$$$O	hydroxamic$$$134$$$144$$$I	acid$$$145$$$149$$$I	group$$$150$$$155$$$O	or$$$156$$$158$$$O	a$$$159$$$160$$$O	carboxylic$$$161$$$171$$$I	acid$$$172$$$176$$$I	group,$$$177$$$183$$$O	can$$$184$$$187$$$O	inhibit$$$188$$$195$$$O	histone$$$196$$$203$$$I	deacetylase.$$$204$$$216$$$O	Histone$$$217$$$224$$$I	deacetylase$$$225$$$236$$$O	can$$$237$$$240$$$O	repress$$$241$$$248$$$O	gene$$$249$$$253$$$O	expression,$$$254$$$265$$$O	including$$$266$$$275$$$O	expression$$$276$$$286$$$O	of$$$287$$$289$$$O	genes$$$290$$$295$$$O	related$$$296$$$303$$$O	to$$$304$$$306$$$O	tumor$$$307$$$312$$$O	suppression.$$$313$$$325$$$O	Accordingly,$$$326$$$338$$$O	inhibition$$$339$$$349$$$O	of$$$350$$$352$$$O	histone$$$353$$$360$$$I	deacetylase$$$361$$$372$$$O	can$$$373$$$376$$$O	provide$$$377$$$384$$$O	an$$$385$$$387$$$O	alternate$$$388$$$397$$$O	route$$$398$$$403$$$O	for$$$404$$$407$$$O	treating$$$408$$$416$$$O	cancer,$$$417$$$424$$$O	hematological$$$425$$$438$$$O	disorders,$$$439$$$449$$$O	e.g.,$$$450$$$455$$$O	hemoglobinopathies,$$$456$$$475$$$O	and$$$476$$$479$$$O	genetic$$$480$$$487$$$O	related$$$488$$$495$$$O	metabolic$$$496$$$505$$$O	disorders,$$$506$$$516$$$O	e.g.,$$$517$$$522$$$O	cystic$$$523$$$529$$$O	fibrosis$$$530$$$538$$$O	and$$$539$$$542$$$O	adrenoleukodystrophy.$$$543$$$564$$$O
US20110229566
Single$$$0$$$6$$$O	Unit$$$7$$$11$$$O	Oral$$$12$$$16$$$O	Dose$$$17$$$21$$$O	Pharmaceutical$$$22$$$36$$$O	Composition$$$37$$$48$$$O	Comprising$$$49$$$59$$$O	Levodopa,$$$60$$$69$$$I	Carbidopa$$$70$$$79$$$I	And$$$80$$$83$$$O	Entacapone$$$84$$$94$$$I	Or$$$95$$$97$$$O	Salts$$$98$$$103$$$O	Thereof$$$104$$$111$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	a$$$18$$$19$$$O	single$$$20$$$26$$$O	unit$$$27$$$31$$$O	oral$$$32$$$36$$$O	dose$$$37$$$41$$$O	pharmaceutical$$$42$$$56$$$O	composition$$$57$$$68$$$O	comprising$$$69$$$79$$$O	a)$$$80$$$82$$$O	levodopa$$$83$$$91$$$I	or$$$92$$$94$$$O	salts$$$95$$$100$$$O	thereof$$$101$$$108$$$O	from$$$109$$$113$$$O	about$$$114$$$119$$$O	50$$$120$$$122$$$O	mg$$$123$$$125$$$O	to$$$126$$$128$$$O	about$$$129$$$134$$$O	300$$$135$$$138$$$O	mg$$$139$$$141$$$O	in$$$142$$$144$$$O	extended$$$145$$$153$$$O	release$$$154$$$161$$$O	form,$$$162$$$167$$$O	b)$$$168$$$170$$$O	carbidopa$$$171$$$180$$$I	or$$$181$$$183$$$O	salts$$$184$$$189$$$O	thereof$$$190$$$197$$$O	from$$$198$$$202$$$O	about$$$203$$$208$$$O	10$$$209$$$211$$$O	mg$$$212$$$214$$$O	to$$$215$$$217$$$O	about$$$218$$$223$$$O	100$$$224$$$227$$$O	mg$$$228$$$230$$$O	in$$$231$$$233$$$O	extended$$$234$$$242$$$O	release$$$243$$$250$$$O	and$$$251$$$254$$$O	c)$$$255$$$257$$$O	entacapone$$$258$$$268$$$I	or$$$269$$$271$$$O	salts$$$272$$$277$$$O	thereof$$$278$$$285$$$O	from$$$286$$$290$$$O	about$$$291$$$296$$$O	100$$$297$$$300$$$O	mg$$$301$$$303$$$O	to$$$304$$$306$$$O	about$$$307$$$312$$$O	1000$$$313$$$317$$$O	mg$$$318$$$320$$$O	in$$$321$$$323$$$O	immediate$$$324$$$333$$$O	release$$$334$$$341$$$O	form,$$$342$$$347$$$O	optionally$$$348$$$358$$$O	with$$$359$$$363$$$O	other$$$364$$$369$$$O	pharmaceutically$$$370$$$386$$$O	acceptable$$$387$$$397$$$O	excipients.$$$398$$$409$$$O	The$$$410$$$413$$$O	invention$$$414$$$423$$$O	also$$$424$$$428$$$O	relates$$$429$$$436$$$O	to$$$437$$$439$$$O	process$$$440$$$447$$$O	of$$$448$$$450$$$O	preparation$$$451$$$462$$$O	of$$$463$$$465$$$O	such$$$466$$$470$$$O	compositions.$$$471$$$484$$$O
CN101028454A
Externally-applied$$$0$$$18$$$O	bone-set$$$19$$$27$$$O	plaster$$$28$$$35$$$O	and$$$36$$$39$$$O	its$$$40$$$43$$$O	production$$$44$$$54$$$O
An$$$0$$$2$$$O	exterior-applied$$$3$$$19$$$O	plaster$$$20$$$27$$$O	for$$$28$$$31$$$O	setting$$$32$$$39$$$O	up$$$40$$$42$$$O	bone$$$43$$$47$$$O	is$$$48$$$50$$$O	prepared$$$51$$$59$$$O	from$$$60$$$64$$$O	8$$$65$$$66$$$O	Chinese-medicinal$$$67$$$84$$$O	materials$$$85$$$94$$$O	including$$$95$$$104$$$O	Dragon's$$$105$$$113$$$O	blood,$$$114$$$120$$$O	frankincense,$$$121$$$134$$$O	myrrh,$$$135$$$141$$$O	sea-horse,$$$142$$$152$$$O	etc$$$153$$$156$$$O	through$$$157$$$164$$$O	respective$$$165$$$175$$$O	baking,$$$176$$$183$$$O	grinding,$$$184$$$193$$$O	proportional$$$194$$$206$$$O	mixing,$$$207$$$214$$$O	stirring,$$$215$$$224$$$O	adding$$$225$$$231$$$O	the$$$232$$$235$$$O	mixture$$$236$$$243$$$O	in$$$244$$$246$$$O	boiling$$$247$$$254$$$O	rice$$$255$$$259$$$O	vinegar,$$$260$$$268$$$I	and$$$269$$$272$$$O	decocting$$$273$$$282$$$O	until$$$283$$$288$$$O	it$$$289$$$291$$$O	becomes$$$292$$$299$$$O	paste.$$$300$$$306$$$O
WO2009022756A1
Diagnosis$$$0$$$9$$$O	and$$$10$$$13$$$O	treatment$$$14$$$23$$$O	of$$$24$$$26$$$O	ischemic$$$27$$$35$$$O	disease$$$36$$$43$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	pharmaceutical$$$25$$$39$$$O	composition$$$40$$$51$$$O	for$$$52$$$55$$$O	treating$$$56$$$64$$$O	or$$$65$$$67$$$O	preventing$$$68$$$78$$$O	an$$$79$$$81$$$O	ischemic$$$82$$$90$$$O	disease,$$$91$$$99$$$O	an$$$100$$$102$$$O	ischemic$$$103$$$111$$$O	damage,$$$112$$$119$$$O	or$$$120$$$122$$$O	an$$$123$$$125$$$O	ischemic$$$126$$$134$$$O	condition$$$135$$$144$$$O	in$$$145$$$147$$$O	the$$$148$$$151$$$O	central$$$152$$$159$$$O	nervous$$$160$$$167$$$O	system$$$168$$$174$$$O	containing$$$175$$$185$$$O	a$$$186$$$187$$$O	liposome,$$$188$$$197$$$O	and$$$198$$$201$$$O	sialyl$$$202$$$208$$$O	Lewis$$$209$$$214$$$O	X$$$215$$$216$$$O	(SLX)$$$217$$$222$$$O	or$$$223$$$225$$$O	an$$$226$$$228$$$O	SLX$$$229$$$232$$$O	group.$$$233$$$239$$$O	The$$$241$$$244$$$O	invention$$$245$$$254$$$O	also$$$255$$$259$$$O	provides$$$260$$$268$$$O	a$$$269$$$270$$$O	diagnostic$$$271$$$281$$$O	composition$$$282$$$293$$$O	for$$$294$$$297$$$O	diagnosing$$$298$$$308$$$O	an$$$309$$$311$$$O	ischemic$$$312$$$320$$$O	disease,$$$321$$$329$$$O	an$$$330$$$332$$$O	ischemic$$$333$$$341$$$O	damage,$$$342$$$349$$$O	or$$$350$$$352$$$O	an$$$353$$$355$$$O	ischemic$$$356$$$364$$$O	condition$$$365$$$374$$$O	in$$$375$$$377$$$O	the$$$378$$$381$$$O	central$$$382$$$389$$$O	nervous$$$390$$$397$$$O	system.$$$398$$$405$$$O	This$$$407$$$411$$$O	diagnostic$$$412$$$422$$$O	composition$$$423$$$434$$$O	contains$$$435$$$443$$$O	A)$$$444$$$446$$$O	a$$$447$$$448$$$O	liposome,$$$449$$$458$$$O	B)$$$459$$$461$$$O	sialyl$$$462$$$468$$$O	Lewis$$$469$$$474$$$O	X$$$475$$$476$$$O	(SLX)$$$477$$$482$$$O	or$$$483$$$485$$$O	an$$$486$$$488$$$O	SLX$$$489$$$492$$$O	group,$$$493$$$499$$$O	and$$$500$$$503$$$O	C)$$$504$$$506$$$O	a$$$507$$$508$$$O	labeling$$$509$$$517$$$O	substance.$$$518$$$528$$$O	The$$$530$$$533$$$O	invention$$$534$$$543$$$O	also$$$544$$$548$$$O	provides$$$549$$$557$$$O	a$$$558$$$559$$$O	method$$$560$$$566$$$O	for$$$567$$$570$$$O	treating$$$571$$$579$$$O	or$$$580$$$582$$$O	preventing$$$583$$$593$$$O	an$$$594$$$596$$$O	ischemic$$$597$$$605$$$O	disease,$$$606$$$614$$$O	an$$$615$$$617$$$O	ischemic$$$618$$$626$$$O	damage,$$$627$$$634$$$O	or$$$635$$$637$$$O	an$$$638$$$640$$$O	ischemic$$$641$$$649$$$O	condition$$$650$$$659$$$O	in$$$660$$$662$$$O	the$$$663$$$666$$$O	central$$$667$$$674$$$O	nervous$$$675$$$682$$$O	system.$$$683$$$690$$$O	The$$$692$$$695$$$O	invention$$$696$$$705$$$O	also$$$706$$$710$$$O	provides$$$711$$$719$$$O	a$$$720$$$721$$$O	method$$$722$$$728$$$O	for$$$729$$$732$$$O	detecting$$$733$$$742$$$O	an$$$743$$$745$$$O	ischemic$$$746$$$754$$$O	site$$$755$$$759$$$O	in$$$760$$$762$$$O	the$$$763$$$766$$$O	central$$$767$$$774$$$O	nervous$$$775$$$782$$$O	system.$$$783$$$790$$$O	The$$$792$$$795$$$O	invention$$$796$$$805$$$O	also$$$806$$$810$$$O	provides$$$811$$$819$$$O	use$$$820$$$823$$$O	of$$$824$$$826$$$O	SLX$$$827$$$830$$$O	in$$$831$$$833$$$O	production$$$834$$$844$$$O	of$$$845$$$847$$$O	a$$$848$$$849$$$O	pharmaceutical$$$850$$$864$$$O	for$$$865$$$868$$$O	treating,$$$869$$$878$$$O	preventing,$$$879$$$890$$$O	detecting,$$$891$$$901$$$O	or$$$902$$$904$$$O	diagnosing$$$905$$$915$$$O	an$$$916$$$918$$$O	ischemic$$$919$$$927$$$O	disease,$$$928$$$936$$$O	an$$$937$$$939$$$O	ischemic$$$940$$$948$$$O	damage,$$$949$$$956$$$O	or$$$957$$$959$$$O	an$$$960$$$962$$$O	ischemic$$$963$$$971$$$O	condition$$$972$$$981$$$O	in$$$982$$$984$$$O	the$$$985$$$988$$$O	central$$$989$$$996$$$O	nervous$$$997$$$1004$$$O	system.$$$1005$$$1012$$$O	The$$$1014$$$1017$$$O	invention$$$1018$$$1027$$$O	also$$$1028$$$1032$$$O	provides$$$1033$$$1041$$$O	a$$$1042$$$1043$$$O	delivery$$$1044$$$1052$$$O	medium$$$1053$$$1059$$$O	for$$$1060$$$1063$$$O	delivering$$$1064$$$1074$$$O	a$$$1075$$$1076$$$O	target$$$1077$$$1083$$$O	substance$$$1084$$$1093$$$O	to$$$1094$$$1096$$$O	the$$$1097$$$1100$$$O	inside$$$1101$$$1107$$$O	of$$$1108$$$1110$$$O	cells.$$$1111$$$1117$$$O
WO2011065905A1
Solid$$$0$$$5$$$O	forms$$$6$$$11$$$O	of$$$12$$$14$$$O	4-{(r)-(3-aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-n,n-diethylbenzamide,$$$15$$$101$$$I	compositions$$$102$$$114$$$O	thereof,$$$115$$$123$$$O	and$$$124$$$127$$$O	uses$$$128$$$132$$$O	therewith$$$133$$$142$$$O
Solid$$$0$$$5$$$O	forms$$$6$$$11$$$O	comprising$$$12$$$22$$$O	salts$$$23$$$28$$$O	of$$$29$$$31$$$O	4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-$$$32$$$85$$$I	yl]methyl}-N,N-diethylbenzamide,$$$86$$$118$$$I	compositions$$$119$$$131$$$O	comprising$$$132$$$142$$$O	the$$$143$$$146$$$O	solid$$$147$$$152$$$O	forms,$$$153$$$159$$$O	methods$$$160$$$167$$$O	of$$$168$$$170$$$O	making$$$171$$$177$$$O	the$$$178$$$181$$$O	solid$$$182$$$187$$$O	forms,$$$188$$$194$$$O	and$$$195$$$198$$$O	methods$$$199$$$206$$$O	of$$$207$$$209$$$O	their$$$210$$$215$$$O	use$$$216$$$219$$$O	for$$$220$$$223$$$O	the$$$224$$$227$$$O	treatment$$$228$$$237$$$O	of$$$238$$$240$$$O	various$$$241$$$248$$$O	diseases$$$249$$$257$$$O	and/or$$$258$$$264$$$O	disorders$$$265$$$274$$$O	are$$$275$$$278$$$O	provided$$$279$$$287$$$O	herein.$$$288$$$295$$$O
US20050032754
the$$$0$$$3$$$O	2-position$$$4$$$14$$$O	is$$$15$$$17$$$O	substituted,$$$18$$$30$$$O	the$$$31$$$34$$$O	steric$$$35$$$41$$$O	configuration$$$42$$$55$$$O	at$$$56$$$58$$$O	the$$$59$$$62$$$O	20-position$$$63$$$74$$$O	is$$$75$$$77$$$O	native$$$78$$$84$$$O	or$$$85$$$87$$$O	epimerized,$$$88$$$99$$$O	and$$$100$$$103$$$O	the$$$104$$$107$$$O	double$$$108$$$114$$$O	bond$$$115$$$119$$$O	at$$$120$$$122$$$O	the$$$123$$$126$$$O	5-position$$$127$$$137$$$O	is$$$138$$$140$$$O	in$$$141$$$143$$$O	E$$$144$$$145$$$O	configuration;$$$146$$$160$$$O	calcium$$$161$$$168$$$I	metabolism$$$169$$$179$$$O	regulating$$$180$$$190$$$O	agent;$$$191$$$197$$$O	does$$$198$$$202$$$O	not$$$203$$$206$$$O	cause$$$207$$$212$$$O	hypercalcemia$$$213$$$226$$$O	during$$$227$$$233$$$O	long-term$$$234$$$243$$$O	use$$$244$$$247$$$O
Object$$$0$$$6$$$O	of$$$7$$$9$$$O	the$$$10$$$13$$$O	present$$$14$$$21$$$O	invention$$$22$$$31$$$O	is$$$32$$$34$$$O	to$$$35$$$37$$$O	synthesize$$$38$$$48$$$O	novel$$$49$$$54$$$O	vitamin$$$55$$$62$$$I	D$$$63$$$64$$$I	derivatives.$$$65$$$77$$$O	The$$$80$$$83$$$O	present$$$84$$$91$$$O	invention$$$92$$$101$$$O	provides$$$102$$$110$$$O	5,6-trans-2-alkyl-substituted$$$111$$$140$$$I	vitamin$$$141$$$148$$$I	D$$$149$$$150$$$I	derivatives$$$151$$$162$$$O	of$$$163$$$165$$$O	Formula$$$166$$$173$$$O	(1):$$$174$$$178$$$O	wherein$$$194$$$201$$$O	R1$$$206$$$208$$$O	is$$$209$$$211$$$O	straight$$$212$$$220$$$O	or$$$221$$$223$$$O	branched-chain$$$224$$$238$$$O	alkyl;$$$239$$$245$$$I	and$$$246$$$249$$$O	R2$$$251$$$253$$$O	is$$$254$$$256$$$O	straight$$$257$$$265$$$O	or$$$266$$$268$$$O	branched-chain$$$269$$$283$$$O	alkyl$$$284$$$289$$$I	optionally$$$290$$$300$$$O	substituted$$$301$$$312$$$O	with$$$313$$$317$$$O	hydroxy.$$$318$$$326$$$I
CN101307306A
Target$$$0$$$6$$$O	point$$$7$$$12$$$O	protein$$$13$$$20$$$O	for$$$21$$$24$$$O	screening$$$25$$$34$$$O	antitubercular$$$35$$$49$$$O	agent$$$50$$$55$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	belongs$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	medicinal$$$29$$$38$$$O	technical$$$39$$$48$$$O	field$$$49$$$54$$$O	and$$$55$$$58$$$O	particularly$$$59$$$71$$$O	relates$$$72$$$79$$$O	to$$$80$$$82$$$O	a$$$83$$$84$$$O	target$$$85$$$91$$$O	protein$$$92$$$99$$$O	for$$$100$$$103$$$O	screening$$$104$$$113$$$O	antituberculosis$$$114$$$130$$$O	drugs.$$$131$$$137$$$O	The$$$138$$$141$$$O	target$$$142$$$148$$$O	protein$$$149$$$156$$$O	is$$$157$$$159$$$O	an$$$160$$$162$$$O	indole-3-glycerophosphoric$$$163$$$189$$$I	acid$$$190$$$194$$$I	synthetase$$$195$$$205$$$O	IGPS$$$206$$$210$$$O	sourcing$$$211$$$219$$$O	from$$$220$$$224$$$O	tubercule$$$225$$$234$$$O	bacillus$$$235$$$243$$$O	H37Rv.$$$244$$$250$$$O	A$$$251$$$252$$$O	inhibitor$$$253$$$262$$$O	compound$$$263$$$271$$$O	I(N-phenyl-6-piperidino-N'-quinine-8-$$$272$$$309$$$I	pyridazine-1,3,5-triazine-2,4-diamine)$$$310$$$348$$$I	and$$$349$$$352$$$O	a$$$353$$$354$$$O	compound$$$355$$$363$$$O	II(5-[3-(3,5-dimethyl-1-hydrogen-pyrazole)-2-hydroxy-propoxy]-2-methyl-1-(p-benzyl)indole-3-carboxylic$$$364$$$466$$$I	acid)$$$467$$$472$$$I	of$$$473$$$475$$$O	the$$$476$$$479$$$O	target$$$480$$$486$$$O	protein$$$487$$$494$$$O	of$$$495$$$497$$$O	the$$$498$$$501$$$O	target$$$502$$$508$$$O	protein$$$509$$$516$$$O	can$$$517$$$520$$$O	remarkably$$$521$$$531$$$O	inhibit$$$532$$$539$$$O	the$$$540$$$543$$$O	growth$$$544$$$550$$$O	of$$$551$$$553$$$O	tubercule$$$554$$$563$$$O	bacillus$$$564$$$572$$$O	in$$$573$$$575$$$O	a$$$576$$$577$$$O	in-vitro$$$578$$$586$$$O	inhibition$$$587$$$597$$$O	experiment$$$598$$$608$$$O	for$$$609$$$612$$$O	the$$$613$$$616$$$O	growth$$$617$$$623$$$O	of$$$624$$$626$$$O	tubercule$$$627$$$636$$$O	bacillus,$$$637$$$646$$$O	wherein$$$647$$$654$$$O	the$$$655$$$658$$$O	compound$$$659$$$667$$$O	I$$$668$$$669$$$O	has$$$670$$$673$$$O	a$$$674$$$675$$$O	minimal$$$676$$$683$$$O	inhibitory$$$684$$$694$$$O	concentration$$$695$$$708$$$O	of$$$709$$$711$$$O	0.625$$$712$$$717$$$O	mu$$$718$$$720$$$O	g/ml$$$721$$$725$$$O	concerning$$$726$$$736$$$O	the$$$737$$$740$$$O	tubercule$$$741$$$750$$$O	bacillus$$$751$$$759$$$O	H37Rv,$$$760$$$766$$$O	the$$$767$$$770$$$O	compound$$$771$$$779$$$O	II$$$780$$$782$$$O	has$$$783$$$786$$$O	a$$$787$$$788$$$O	minimal$$$789$$$796$$$O	inhibitory$$$797$$$807$$$O	concentration$$$808$$$821$$$O	of$$$822$$$824$$$O	0.2$$$825$$$828$$$O	mu$$$829$$$831$$$O	g/ml$$$832$$$836$$$O	concerning$$$837$$$847$$$O	the$$$848$$$851$$$O	tubercule$$$852$$$861$$$O	bacillus$$$862$$$870$$$O	H37Rv,$$$871$$$877$$$O	the$$$878$$$881$$$O	compound$$$882$$$890$$$O	I$$$891$$$892$$$O	and$$$893$$$896$$$O	the$$$897$$$900$$$O	compound$$$901$$$909$$$O	II$$$910$$$912$$$O	both$$$913$$$917$$$O	have$$$918$$$922$$$O	a$$$923$$$924$$$O	minimal$$$925$$$932$$$O	inhibitory$$$933$$$943$$$O	concentration$$$944$$$957$$$O	of$$$958$$$960$$$O	0.1mu$$$961$$$966$$$O	g/ml$$$967$$$971$$$O	concerning$$$972$$$982$$$O	the$$$983$$$986$$$O	standard$$$987$$$995$$$O	strain$$$996$$$1002$$$O	H37Rv,$$$1003$$$1009$$$O	and$$$1010$$$1013$$$O	the$$$1014$$$1017$$$O	compound$$$1018$$$1026$$$O	I$$$1027$$$1028$$$O	and$$$1029$$$1032$$$O	the$$$1033$$$1036$$$O	compound$$$1037$$$1045$$$O	II$$$1046$$$1048$$$O	both$$$1049$$$1053$$$O	have$$$1054$$$1058$$$O	a$$$1059$$$1060$$$O	minimal$$$1061$$$1068$$$O	inhibitory$$$1069$$$1079$$$O	concentration$$$1080$$$1093$$$O	of$$$1094$$$1096$$$O	0.1mu$$$1097$$$1102$$$O	g/ml$$$1103$$$1107$$$O	concerning$$$1108$$$1118$$$O	the$$$1119$$$1122$$$O	clinical$$$1123$$$1131$$$O	drug-resistant$$$1132$$$1146$$$O	strain$$$1147$$$1153$$$O	of$$$1154$$$1156$$$O	tubercule$$$1157$$$1166$$$O	bacillus.$$$1167$$$1176$$$O
WO2013181742A1
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	inhibiting$$$11$$$21$$$O	rsk$$$22$$$25$$$O	for$$$26$$$29$$$O	treatment$$$30$$$39$$$O	of$$$40$$$42$$$O	breast$$$43$$$49$$$O	cancer$$$50$$$56$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	treating$$$12$$$20$$$O	triple$$$21$$$27$$$O	negative$$$28$$$36$$$O	breast$$$37$$$43$$$O	cancer$$$44$$$50$$$O	in$$$51$$$53$$$O	a$$$54$$$55$$$O	subject$$$56$$$63$$$O	is$$$64$$$66$$$O	provided.$$$67$$$76$$$O	The$$$77$$$80$$$O	method$$$81$$$87$$$O	involves$$$88$$$96$$$O	administering$$$97$$$110$$$O	an$$$111$$$113$$$O	effective$$$114$$$123$$$O	dose$$$124$$$128$$$O	of$$$129$$$131$$$O	an$$$132$$$134$$$O	inhibitor$$$135$$$144$$$O	against$$$145$$$152$$$O	the$$$153$$$156$$$O	p90$$$157$$$160$$$O	ribosomal$$$161$$$170$$$O	S6$$$171$$$173$$$O	kinase$$$174$$$180$$$O	(RSK)$$$181$$$186$$$O	family$$$187$$$193$$$O	of$$$194$$$196$$$O	kinases$$$197$$$204$$$O	to$$$205$$$207$$$O	the$$$208$$$211$$$O	subject.$$$212$$$220$$$O	The$$$221$$$224$$$O	method$$$225$$$231$$$O	may$$$232$$$235$$$O	involve$$$236$$$243$$$O	selective$$$244$$$253$$$O	inhibition$$$254$$$264$$$O	of$$$265$$$267$$$O	RSK1$$$268$$$272$$$O	or$$$273$$$275$$$O	RSK2.$$$276$$$281$$$O	The$$$282$$$285$$$O	inhibitor$$$286$$$295$$$O	may$$$296$$$299$$$O	be$$$300$$$302$$$O	a$$$303$$$304$$$O	siRNA,$$$305$$$311$$$O	BI-D1870$$$312$$$320$$$I	or$$$321$$$323$$$O	SL0101.$$$324$$$331$$$I
CN1792380A
Digestive$$$0$$$9$$$O	tract$$$10$$$15$$$O	stent$$$16$$$21$$$O	with$$$22$$$26$$$O	anti-cancer$$$27$$$38$$$O	medicinal$$$39$$$48$$$O	particles$$$49$$$58$$$O
A$$$0$$$1$$$O	scaffold$$$2$$$10$$$O	of$$$11$$$13$$$O	the$$$14$$$17$$$O	granular$$$18$$$26$$$O	anticancer$$$27$$$37$$$O	medicine$$$38$$$46$$$O	for$$$47$$$50$$$O	treating$$$51$$$59$$$O	the$$$60$$$63$$$O	benign$$$64$$$70$$$O	or$$$71$$$73$$$O	malignant$$$74$$$83$$$O	stenosis$$$84$$$92$$$O	of$$$93$$$95$$$O	esophagus$$$96$$$105$$$O	and$$$106$$$109$$$O	digestive$$$110$$$119$$$O	tract$$$120$$$125$$$O	is$$$126$$$128$$$O	disclosed,$$$129$$$139$$$O	which$$$140$$$145$$$O	has$$$146$$$149$$$O	4$$$150$$$151$$$O	structures$$$152$$$162$$$O	consisting$$$163$$$173$$$O	of$$$174$$$176$$$O	scaffold,$$$177$$$186$$$O	granular$$$187$$$195$$$O	anticancer$$$196$$$206$$$O	medicine,$$$207$$$216$$$O	selective$$$217$$$226$$$O	coated$$$227$$$233$$$O	film$$$234$$$238$$$O	on$$$239$$$241$$$O	the$$$242$$$245$$$O	surface$$$246$$$253$$$O	of$$$254$$$256$$$O	scaffold,$$$257$$$266$$$O	and$$$267$$$270$$$O	selective$$$271$$$280$$$O	external$$$281$$$289$$$O	protective$$$290$$$300$$$O	layer.$$$301$$$307$$$O
US7893297
Amorphous$$$0$$$9$$$O	sodium$$$10$$$16$$$I	4-[4-chloro-2-hydroxybenzoyl)amino]butanoate$$$17$$$61$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	amorphous$$$33$$$42$$$O	and$$$43$$$46$$$O	polymorphic$$$47$$$58$$$O	forms$$$59$$$64$$$O	of$$$65$$$67$$$O	sodium$$$68$$$74$$$I	4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate$$$75$$$120$$$I	and$$$121$$$124$$$O	their$$$125$$$130$$$O	use$$$131$$$134$$$O	for$$$135$$$138$$$O	facilitating$$$139$$$151$$$O	the$$$152$$$155$$$O	delivery$$$156$$$164$$$O	of$$$165$$$167$$$O	active$$$168$$$174$$$O	agents,$$$175$$$182$$$O	such$$$183$$$187$$$O	as$$$188$$$190$$$O	insulin,$$$191$$$199$$$O	to$$$200$$$202$$$O	a$$$203$$$204$$$O	target.$$$205$$$212$$$O
EP2148675A1
Anti-cancer$$$0$$$11$$$O	medicine$$$12$$$20$$$O	both$$$21$$$25$$$O	for$$$26$$$29$$$O	diagnosing$$$30$$$40$$$O	and$$$41$$$44$$$O	treating$$$45$$$53$$$O	cancer$$$54$$$60$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	an$$$13$$$15$$$O	anti-cancer$$$16$$$27$$$O	medicine$$$28$$$36$$$O	comprising$$$37$$$47$$$O	a$$$48$$$49$$$O	chain$$$50$$$55$$$O	end$$$56$$$59$$$O	functionalized$$$60$$$74$$$O	polymer,$$$75$$$83$$$O	a$$$84$$$85$$$O	contrast$$$86$$$94$$$O	material$$$95$$$103$$$O	such$$$104$$$108$$$O	as$$$109$$$111$$$O	iron$$$112$$$116$$$I	oxide$$$117$$$122$$$I	and$$$123$$$126$$$O	a$$$127$$$128$$$O	chemother$$$129$$$138$$$O	apeut$$$139$$$144$$$O	i$$$145$$$146$$$O	c$$$147$$$148$$$O	agent$$$149$$$154$$$O	such$$$155$$$159$$$O	as$$$160$$$162$$$O	doxorubicin$$$163$$$174$$$I	or$$$175$$$177$$$O	pharmaceutically$$$178$$$194$$$O	acceptable$$$195$$$205$$$O	salts$$$206$$$211$$$O	thereof.$$$212$$$220$$$O	The$$$221$$$224$$$O	anti-cancer$$$225$$$236$$$O	medicine$$$237$$$245$$$O	performs$$$246$$$254$$$O	diagnosis$$$255$$$264$$$O	and$$$265$$$268$$$O	treatment$$$269$$$278$$$O	of$$$279$$$281$$$O	cancer$$$282$$$288$$$O	at$$$289$$$291$$$O	the$$$292$$$295$$$O	same$$$296$$$300$$$O	time,$$$301$$$306$$$O	remarkably$$$307$$$317$$$O	reduces$$$318$$$325$$$O	a$$$326$$$327$$$O	cardiotoxic$$$328$$$339$$$O	side$$$340$$$344$$$O	effect$$$345$$$351$$$O	of$$$352$$$354$$$O	the$$$355$$$358$$$O	doxorubicin$$$359$$$370$$$I	and$$$371$$$374$$$O	has$$$375$$$378$$$O	an$$$379$$$381$$$O	excellent$$$382$$$391$$$O	targeting$$$392$$$401$$$O	function$$$402$$$410$$$O	to$$$411$$$413$$$O	the$$$414$$$417$$$O	cancer$$$418$$$424$$$O	part$$$425$$$429$$$O	to$$$430$$$432$$$O	considerably$$$433$$$445$$$O	increase$$$446$$$454$$$O	the$$$455$$$458$$$O	anti-cancer$$$459$$$470$$$O	effect.$$$471$$$478$$$O	At$$$479$$$481$$$O	the$$$482$$$485$$$O	same$$$486$$$490$$$O	time,$$$491$$$496$$$O	the$$$497$$$500$$$O	anti-cancer$$$501$$$512$$$O	medicine$$$513$$$521$$$O	is$$$522$$$524$$$O	provided$$$525$$$533$$$O	as$$$534$$$536$$$O	MRI$$$537$$$540$$$O	contrast$$$541$$$549$$$O	medium$$$550$$$556$$$O	which$$$557$$$562$$$O	can$$$563$$$566$$$O	diagnose$$$567$$$575$$$O	the$$$576$$$579$$$O	cancer$$$580$$$586$$$O	and$$$587$$$590$$$O	monitor$$$591$$$598$$$O	a$$$599$$$600$$$O	progress$$$601$$$609$$$O	of$$$610$$$612$$$O	the$$$613$$$616$$$O	disease.$$$617$$$625$$$O	In$$$626$$$628$$$O	particular,$$$629$$$640$$$O	the$$$641$$$644$$$O	anti-cancer$$$645$$$656$$$O	medicine$$$657$$$665$$$O	is$$$666$$$668$$$O	disclosed$$$669$$$678$$$O	which$$$679$$$684$$$O	is$$$685$$$687$$$O	superior$$$688$$$696$$$O	to$$$697$$$699$$$O	the$$$700$$$703$$$O	diagnosis$$$704$$$713$$$O	and$$$714$$$717$$$O	treatment$$$718$$$727$$$O	of$$$728$$$730$$$O	the$$$731$$$734$$$O	solid$$$735$$$740$$$O	cancer$$$741$$$747$$$O	and$$$748$$$751$$$O	can$$$752$$$755$$$O	effectively$$$756$$$767$$$O	perform$$$768$$$775$$$O	the$$$776$$$779$$$O	diagnosis$$$780$$$789$$$O	and$$$790$$$793$$$O	treatment$$$794$$$803$$$O	of$$$804$$$806$$$O	the$$$807$$$810$$$O	metastatic$$$811$$$821$$$O	cancer$$$822$$$828$$$O	as$$$829$$$831$$$O	well$$$832$$$836$$$O	as$$$837$$$839$$$O	the$$$840$$$843$$$O	primary$$$844$$$851$$$O	cancer$$$852$$$858$$$O	at$$$859$$$861$$$O	the$$$862$$$865$$$O	same$$$866$$$870$$$O	time.$$$871$$$876$$$O
WO2008040967A1
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	fibrosis$$$13$$$21$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	methods$$$33$$$40$$$O	and$$$41$$$44$$$O	compositions$$$45$$$57$$$O	for$$$58$$$61$$$O	treating$$$62$$$70$$$O	fibrosis.$$$71$$$80$$$O	In$$$81$$$83$$$O	one$$$84$$$87$$$O	aspect$$$88$$$94$$$O	the$$$95$$$98$$$O	invention$$$99$$$108$$$O	provides$$$109$$$117$$$O	the$$$118$$$121$$$O	use$$$122$$$125$$$O	of$$$126$$$128$$$O	an$$$129$$$131$$$O	agent$$$132$$$137$$$O	capable$$$138$$$145$$$O	of$$$146$$$148$$$O	increasing$$$149$$$159$$$O	the$$$160$$$163$$$O	number$$$164$$$170$$$O	of$$$171$$$173$$$O	stem$$$174$$$178$$$O	cells$$$179$$$184$$$O	and/or$$$185$$$191$$$O	progenitor$$$192$$$202$$$O	cells$$$203$$$208$$$O	available$$$209$$$218$$$O	to$$$219$$$221$$$O	and/or$$$222$$$228$$$O	engraftment$$$229$$$240$$$O	at$$$241$$$243$$$O	a$$$244$$$245$$$O	site$$$246$$$250$$$O	of$$$251$$$253$$$O	fibrosis$$$254$$$262$$$O	in$$$263$$$265$$$O	the$$$266$$$269$$$O	manufacture$$$270$$$281$$$O	of$$$282$$$284$$$O	a$$$285$$$286$$$O	medicament$$$287$$$297$$$O	for$$$298$$$301$$$O	use$$$302$$$305$$$O	in$$$306$$$308$$$O	conjunction$$$309$$$320$$$O	with$$$321$$$325$$$O	an$$$326$$$328$$$O	anti-$$$329$$$334$$$O	fibrotic$$$335$$$343$$$O	agent$$$344$$$349$$$O	for$$$350$$$353$$$O	the$$$354$$$357$$$O	treatment$$$358$$$367$$$O	of$$$368$$$370$$$O	fibrosis.$$$371$$$380$$$O	The$$$381$$$384$$$O	anti-fibrotic$$$385$$$398$$$O	agent$$$399$$$404$$$O	can$$$405$$$408$$$O	be$$$409$$$411$$$O	supplied$$$412$$$420$$$O	to$$$421$$$423$$$O	the$$$424$$$427$$$O	subject$$$428$$$435$$$O	before,$$$436$$$443$$$O	at$$$444$$$446$$$O	the$$$447$$$450$$$O	same$$$451$$$455$$$O	time,$$$456$$$461$$$O	or$$$462$$$464$$$O	after$$$465$$$470$$$O	the$$$471$$$474$$$O	agent$$$475$$$480$$$O	capable$$$481$$$488$$$O	of$$$489$$$491$$$O	increasing$$$492$$$502$$$O	the$$$503$$$506$$$O	number$$$507$$$513$$$O	of$$$514$$$516$$$O	stem$$$517$$$521$$$O	cells$$$522$$$527$$$O	and/or$$$528$$$534$$$O	progenitor$$$535$$$545$$$O	cells$$$546$$$551$$$O	available$$$552$$$561$$$O	to$$$562$$$564$$$O	and/or$$$565$$$571$$$O	engraftment$$$572$$$583$$$O	at$$$584$$$586$$$O	a$$$587$$$588$$$O	site$$$589$$$593$$$O	of$$$594$$$596$$$O	fibrosis.$$$597$$$606$$$O	The$$$607$$$610$$$O	fibrosis$$$611$$$619$$$O	may$$$620$$$623$$$O	be$$$624$$$626$$$O	idiopathic$$$627$$$637$$$O	pulmonary$$$638$$$647$$$O	fibrosis.$$$648$$$657$$$O	The$$$658$$$661$$$O	anti-fibrotic$$$662$$$675$$$O	agent$$$676$$$681$$$O	can$$$682$$$685$$$O	be$$$686$$$688$$$O	a$$$689$$$690$$$O	modulator$$$691$$$700$$$O	of$$$701$$$703$$$O	RhoA,$$$704$$$709$$$O	RhoA$$$710$$$714$$$O	GTPases,$$$715$$$723$$$O	TGF-Î²l$$$724$$$731$$$O	or$$$732$$$734$$$O	CTGF,$$$735$$$740$$$O	or$$$741$$$743$$$O	any$$$744$$$747$$$O	other$$$748$$$753$$$O	member$$$754$$$760$$$O	of$$$761$$$763$$$O	the$$$764$$$767$$$O	RhoA$$$768$$$772$$$O	signalling$$$773$$$783$$$O	pathway;$$$784$$$792$$$O	or$$$793$$$795$$$O	can$$$796$$$799$$$O	modulate$$$800$$$808$$$O	the$$$809$$$812$$$O	effect$$$813$$$819$$$O	of$$$820$$$822$$$O	suppressor$$$823$$$833$$$O	of$$$834$$$836$$$O	cytokine$$$837$$$845$$$O	signalling$$$846$$$856$$$O	1$$$857$$$858$$$O	(SOCS$$$859$$$864$$$O	1),$$$865$$$868$$$O	suppressor$$$869$$$879$$$O	of$$$880$$$882$$$O	cytokine$$$883$$$891$$$O	signalling$$$892$$$902$$$O	3$$$903$$$904$$$O	(SOCS$$$905$$$910$$$O	3)$$$911$$$913$$$O	or$$$914$$$916$$$O	TLR9;$$$917$$$922$$$O	or$$$923$$$925$$$O	can$$$926$$$929$$$O	be$$$930$$$932$$$O	a$$$933$$$934$$$O	statin$$$935$$$941$$$O	compound$$$942$$$950$$$O	or$$$951$$$953$$$O	derivative$$$954$$$964$$$O	thereof.$$$965$$$973$$$O
WO2009152584A1
Synthesis$$$0$$$9$$$O	of$$$10$$$12$$$O	ageladine$$$13$$$22$$$I	a$$$23$$$24$$$O	and$$$25$$$28$$$O	analogs$$$29$$$36$$$O	thereof$$$37$$$44$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	describes$$$14$$$23$$$O	a$$$24$$$25$$$O	one$$$26$$$29$$$O	pot$$$30$$$33$$$O	process$$$34$$$41$$$O	for$$$42$$$45$$$O	synthesizing$$$46$$$58$$$O	a$$$59$$$60$$$O	compound$$$61$$$69$$$O	of$$$70$$$72$$$O	structure$$$73$$$82$$$O	(I),$$$83$$$87$$$O	or$$$88$$$90$$$O	a$$$91$$$92$$$O	tautomer$$$93$$$101$$$O	thereof.$$$102$$$110$$$O	A$$$111$$$112$$$O	compound$$$113$$$121$$$O	of$$$122$$$124$$$O	structure$$$125$$$134$$$O	(II),$$$135$$$140$$$O	or$$$141$$$143$$$O	a$$$144$$$145$$$O	tautomer$$$146$$$154$$$O	thereof,$$$155$$$163$$$O	and$$$164$$$167$$$O	an$$$168$$$170$$$O	aldehyde$$$171$$$179$$$I	of$$$180$$$182$$$O	structure$$$183$$$192$$$O	RdCHO$$$193$$$198$$$I	are$$$199$$$202$$$O	condensed$$$203$$$212$$$O	to$$$213$$$215$$$O	form$$$216$$$220$$$O	a$$$221$$$222$$$O	condensation$$$223$$$235$$$O	product.$$$236$$$244$$$O	The$$$245$$$248$$$O	resulting$$$249$$$258$$$O	condensation$$$259$$$271$$$O	product$$$272$$$279$$$O	is$$$280$$$282$$$O	then$$$283$$$287$$$O	oxidized$$$288$$$296$$$O	in$$$297$$$299$$$O	the$$$300$$$303$$$O	same$$$304$$$308$$$O	reaction$$$309$$$317$$$O	mixture$$$318$$$325$$$O	to$$$326$$$328$$$O	produce$$$329$$$336$$$O	the$$$337$$$340$$$O	compound$$$341$$$349$$$O	of$$$350$$$352$$$O	structure$$$353$$$362$$$O	(I)$$$363$$$366$$$O	or$$$367$$$369$$$O	a$$$370$$$371$$$O	tautomer$$$372$$$380$$$O	thereof.$$$381$$$389$$$O
EP1615640B1
Antineoplastic$$$0$$$14$$$O	combinations$$$15$$$27$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	the$$$24$$$27$$$O	use$$$28$$$31$$$O	of$$$32$$$34$$$O	a$$$35$$$36$$$O	combination$$$37$$$48$$$O	of$$$49$$$51$$$O	CCI-779$$$52$$$59$$$I	and$$$60$$$63$$$O	interferon$$$64$$$74$$$O	alfa$$$75$$$79$$$O	(Î±)$$$80$$$84$$$O	in$$$85$$$87$$$O	the$$$88$$$91$$$O	treatment$$$92$$$101$$$O	of$$$102$$$104$$$O	neoplasms.$$$105$$$115$$$O
WO2014000033A1
Polymer-nsaid$$$0$$$13$$$O	conjugate$$$14$$$23$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	polymer-drug$$$25$$$37$$$O	conjugate$$$38$$$47$$$O	for$$$48$$$51$$$O	delivering$$$52$$$62$$$O	a$$$63$$$64$$$O	substituted$$$65$$$76$$$O	alkanoic$$$77$$$85$$$O	acid$$$86$$$90$$$O	non-steroidal$$$91$$$104$$$O	anti-inflammatory$$$105$$$122$$$O	drug$$$123$$$127$$$O	(NSAID).$$$128$$$136$$$O	The$$$137$$$140$$$O	invention$$$141$$$150$$$O	also$$$151$$$155$$$O	relates$$$156$$$163$$$O	to$$$164$$$166$$$O	drug$$$167$$$171$$$O	delivery$$$172$$$180$$$O	systems$$$181$$$188$$$O	comprising$$$189$$$199$$$O	the$$$200$$$203$$$O	polymer-NSAID$$$204$$$217$$$O	conjugate.$$$218$$$228$$$O	The$$$229$$$232$$$O	polymer-NSAID$$$233$$$246$$$O	conjugates$$$247$$$257$$$O	comprise$$$258$$$266$$$O	a$$$267$$$268$$$O	substituted$$$269$$$280$$$O	alkanoic$$$281$$$289$$$O	acid$$$290$$$294$$$O	non-steroidal$$$295$$$308$$$O	anti-inflammatory$$$309$$$326$$$O	drug$$$327$$$331$$$O	(NSAID)$$$332$$$339$$$O	conjugated$$$340$$$350$$$O	to$$$351$$$353$$$O	a$$$354$$$355$$$O	biodegradable$$$356$$$369$$$O	polymer$$$370$$$377$$$O	backbone$$$378$$$386$$$O	by$$$387$$$389$$$O	an$$$390$$$392$$$O	ester$$$393$$$398$$$O	linkage.$$$399$$$407$$$O
CN102757460A
Dihydroartemisinin$$$0$$$18$$$I	sesquioxide$$$19$$$30$$$I	germanium$$$31$$$40$$$I	compound$$$41$$$49$$$O	and$$$50$$$53$$$O	preparation$$$54$$$65$$$O	method$$$66$$$72$$$O	as$$$73$$$75$$$O	well$$$76$$$80$$$O	as$$$81$$$83$$$O	application$$$84$$$95$$$O	thereof$$$96$$$103$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	dihydroartemisinin$$$26$$$44$$$I	sesquioxide$$$45$$$56$$$I	germanium$$$57$$$66$$$I	compound$$$67$$$75$$$O	and$$$76$$$79$$$O	a$$$80$$$81$$$O	preparation$$$82$$$93$$$O	method$$$94$$$100$$$O	as$$$101$$$103$$$O	well$$$104$$$108$$$O	as$$$109$$$111$$$O	an$$$112$$$114$$$O	application$$$115$$$126$$$O	thereof.$$$127$$$135$$$O	The$$$136$$$139$$$O	structural$$$140$$$150$$$O	formula$$$151$$$158$$$O	of$$$159$$$161$$$O	the$$$162$$$165$$$O	dihydroartemisinin$$$166$$$184$$$I	sesquioxide$$$185$$$196$$$I	germanium$$$197$$$206$$$I	compound$$$207$$$215$$$O	is$$$216$$$218$$$O	shown$$$219$$$224$$$O	as$$$225$$$227$$$O	a$$$228$$$229$$$O	formula$$$230$$$237$$$O	(I);$$$238$$$242$$$O	and$$$243$$$246$$$O	the$$$247$$$250$$$O	dihydroartemisinin$$$251$$$269$$$I	sesquioxide$$$270$$$281$$$I	germanium$$$282$$$291$$$I	compound$$$292$$$300$$$O	includes$$$301$$$309$$$O	a$$$310$$$311$$$O	Ge-132$$$312$$$318$$$O	backbone$$$319$$$327$$$O	with$$$328$$$332$$$O	antineoplastic$$$333$$$347$$$O	activity$$$348$$$356$$$O	and$$$357$$$360$$$O	a$$$361$$$362$$$O	dihydroartemisinin$$$363$$$381$$$I	backbone$$$382$$$390$$$O	with$$$391$$$395$$$O	antineoplastic$$$396$$$410$$$O	activity,$$$411$$$420$$$O	and$$$421$$$424$$$O	plays$$$425$$$430$$$O	dual$$$431$$$435$$$O	antineoplastic$$$436$$$450$$$O	activity$$$451$$$459$$$O	of$$$460$$$462$$$O	Ge-132$$$463$$$469$$$O	and$$$470$$$473$$$O	dihydroartemisinin.$$$474$$$493$$$I	Experiments$$$494$$$505$$$O	proves$$$506$$$512$$$O	that$$$513$$$517$$$O	the$$$518$$$521$$$O	dihydroartemisinin$$$522$$$540$$$I	sesquioxide$$$541$$$552$$$I	germanium$$$553$$$562$$$I	compound$$$563$$$571$$$O	has$$$572$$$575$$$O	higher$$$576$$$582$$$O	activity$$$583$$$591$$$O	than$$$592$$$596$$$O	dihydroartemisinin$$$597$$$615$$$I	and$$$616$$$619$$$O	Ge-132,$$$620$$$627$$$O	and$$$628$$$631$$$O	has$$$632$$$635$$$O	a$$$636$$$637$$$O	good$$$638$$$642$$$O	application$$$643$$$654$$$O	prospect$$$655$$$663$$$O	in$$$664$$$666$$$O	the$$$667$$$670$$$O	preparation$$$671$$$682$$$O	of$$$683$$$685$$$O	anti-tumor,$$$686$$$697$$$O	antimalarial,$$$698$$$711$$$O	antibacterial,$$$712$$$726$$$O	or$$$727$$$729$$$O	immunomodulatory$$$730$$$746$$$O	drugs.$$$747$$$753$$$O
US7591949
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	the$$$11$$$14$$$O	improvement$$$15$$$26$$$O	of$$$27$$$29$$$O	transport$$$30$$$39$$$O	across$$$40$$$46$$$O	adaptable$$$47$$$56$$$O	semi-permeable$$$57$$$71$$$O	barriers$$$72$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	method,$$$27$$$34$$$O	a$$$35$$$36$$$O	kit$$$37$$$40$$$O	and$$$41$$$44$$$O	a$$$45$$$46$$$O	device$$$47$$$53$$$O	for$$$54$$$57$$$O	controlling$$$58$$$69$$$O	the$$$70$$$73$$$O	flux$$$74$$$78$$$O	of$$$79$$$81$$$O	penetrants$$$82$$$92$$$O	across$$$93$$$99$$$O	an$$$100$$$102$$$O	adaptable$$$103$$$112$$$O	semi-permeable$$$113$$$127$$$O	porous$$$128$$$134$$$O	barrier,$$$135$$$143$$$O	the$$$144$$$147$$$O	method$$$148$$$154$$$O	comprising$$$155$$$165$$$O	the$$$166$$$169$$$O	steps$$$170$$$175$$$O	of:$$$176$$$179$$$O	preparing$$$180$$$189$$$O	a$$$190$$$191$$$O	formulation$$$192$$$203$$$O	by$$$204$$$206$$$O	suspending$$$207$$$217$$$O	or$$$218$$$220$$$O	dispersing$$$221$$$231$$$O	said$$$232$$$236$$$O	penetrants$$$237$$$247$$$O	in$$$248$$$250$$$O	a$$$251$$$252$$$O	polar$$$253$$$258$$$O	liquid$$$259$$$265$$$O	in$$$266$$$268$$$O	the$$$269$$$272$$$O	form$$$273$$$277$$$O	of$$$278$$$280$$$O	fluid$$$281$$$286$$$O	droplets$$$287$$$295$$$O	surrounded$$$296$$$306$$$O	by$$$307$$$309$$$O	a$$$310$$$311$$$O	membrane-like$$$312$$$325$$$O	coating$$$326$$$333$$$O	of$$$334$$$336$$$O	one$$$337$$$340$$$O	or$$$341$$$343$$$O	several$$$344$$$351$$$O	layers,$$$352$$$359$$$O	said$$$360$$$364$$$O	coating$$$365$$$372$$$O	comprising$$$373$$$383$$$O	at$$$384$$$386$$$O	least$$$387$$$392$$$O	two$$$393$$$396$$$O	kinds$$$397$$$402$$$O	of$$$403$$$405$$$O	forms$$$406$$$411$$$O	of$$$412$$$414$$$O	amphiphilic$$$415$$$426$$$O	substances$$$427$$$437$$$O	with$$$438$$$442$$$O	a$$$443$$$444$$$O	tendency$$$445$$$453$$$O	to$$$454$$$456$$$O	aggregate,$$$457$$$467$$$O	said$$$468$$$472$$$O	penetrants$$$473$$$483$$$O	being$$$484$$$489$$$O	able$$$490$$$494$$$O	to$$$495$$$497$$$O	transport$$$498$$$507$$$O	agents$$$508$$$514$$$O	through$$$515$$$522$$$O	the$$$523$$$526$$$O	pores$$$527$$$532$$$O	of$$$533$$$535$$$O	said$$$536$$$540$$$O	barrier$$$541$$$548$$$O	or$$$549$$$551$$$O	to$$$552$$$554$$$O	enable$$$555$$$561$$$O	agent$$$562$$$567$$$O	permeation$$$568$$$578$$$O	through$$$579$$$586$$$O	the$$$587$$$590$$$O	pores$$$591$$$596$$$O	of$$$597$$$599$$$O	said$$$600$$$604$$$O	barrier$$$605$$$612$$$O	after$$$613$$$618$$$O	penetrants$$$619$$$629$$$O	have$$$630$$$634$$$O	entered$$$635$$$642$$$O	the$$$643$$$646$$$O	pores,$$$647$$$653$$$O	selecting$$$654$$$663$$$O	a$$$664$$$665$$$O	dose$$$666$$$670$$$O	amount$$$671$$$677$$$O	of$$$678$$$680$$$O	said$$$681$$$685$$$O	penetrants$$$686$$$696$$$O	to$$$697$$$699$$$O	be$$$700$$$702$$$O	applied$$$703$$$710$$$O	on$$$711$$$713$$$O	a$$$714$$$715$$$O	predetermined$$$716$$$729$$$O	area$$$730$$$734$$$O	of$$$735$$$737$$$O	said$$$738$$$742$$$O	barrier$$$743$$$750$$$O	to$$$751$$$753$$$O	control$$$754$$$761$$$O	the$$$762$$$765$$$O	flux$$$766$$$770$$$O	of$$$771$$$773$$$O	said$$$774$$$778$$$O	penetrants$$$779$$$789$$$O	across$$$790$$$796$$$O	said$$$797$$$801$$$O	barrier,$$$802$$$810$$$O	and$$$811$$$814$$$O	applying$$$815$$$823$$$O	the$$$824$$$827$$$O	selected$$$828$$$836$$$O	dose$$$837$$$841$$$O	amount$$$842$$$848$$$O	of$$$849$$$851$$$O	said$$$852$$$856$$$O	formulation$$$857$$$868$$$O	containing$$$869$$$879$$$O	said$$$880$$$884$$$O	penetrants$$$885$$$895$$$O	onto$$$896$$$900$$$O	said$$$901$$$905$$$O	area$$$906$$$910$$$O	of$$$911$$$913$$$O	said$$$914$$$918$$$O	porous$$$919$$$925$$$O	barrier.$$$926$$$934$$$O
US20090074777
Wnt$$$0$$$3$$$O	proteins$$$4$$$12$$$O	and$$$13$$$16$$$O	detection$$$17$$$26$$$O	and$$$27$$$30$$$O	treatment$$$31$$$40$$$O	of$$$41$$$43$$$O	cancer$$$44$$$50$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	specification$$$12$$$25$$$O	provides,$$$26$$$35$$$O	inter$$$36$$$41$$$O	alia,$$$42$$$47$$$O	methods$$$48$$$55$$$O	of$$$56$$$58$$$O	using$$$59$$$64$$$O	Wnt$$$65$$$68$$$O	and$$$69$$$72$$$O	FZD$$$73$$$76$$$O	proteins,$$$77$$$86$$$O	genes,$$$87$$$93$$$O	FZD$$$94$$$97$$$O	and$$$98$$$101$$$O	Wnt-specific$$$102$$$114$$$O	antibodies$$$115$$$125$$$O	and$$$126$$$129$$$O	probes$$$130$$$136$$$O	in$$$137$$$139$$$O	diagnosis$$$140$$$149$$$O	and$$$150$$$153$$$O	treatment$$$154$$$163$$$O	of$$$164$$$166$$$O	cancer$$$167$$$173$$$O	and$$$174$$$177$$$O	for$$$178$$$181$$$O	screening$$$182$$$191$$$O	test$$$192$$$196$$$O	compounds$$$197$$$206$$$O	for$$$207$$$210$$$O	an$$$211$$$213$$$O	ability$$$214$$$221$$$O	to$$$222$$$224$$$O	treat$$$225$$$230$$$O	cancer.$$$231$$$238$$$O	Also$$$239$$$243$$$O	disclosed$$$244$$$253$$$O	are$$$254$$$257$$$O	compounds$$$258$$$267$$$O	useful$$$268$$$274$$$O	for$$$275$$$278$$$O	treating$$$279$$$287$$$O	cancer$$$288$$$294$$$O	such$$$295$$$299$$$O	as$$$300$$$302$$$O	liver$$$303$$$308$$$O	cancer.$$$309$$$316$$$O
CN103202317A
Silver$$$0$$$6$$$I	iodine$$$7$$$13$$$I	complexing$$$14$$$24$$$O	antibacterial$$$25$$$38$$$O	agent$$$39$$$44$$$O	and$$$45$$$48$$$O	preparation$$$49$$$60$$$O	method$$$61$$$67$$$O	thereof$$$68$$$75$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	silver$$$26$$$32$$$I	iodine$$$33$$$39$$$I	complexing$$$40$$$50$$$O	antibacterial$$$51$$$64$$$O	agent$$$65$$$70$$$O	and$$$71$$$74$$$O	a$$$75$$$76$$$O	preparation$$$77$$$88$$$O	method$$$89$$$95$$$O	thereof.$$$96$$$104$$$O	The$$$105$$$108$$$O	preparation$$$109$$$120$$$O	method$$$121$$$127$$$O	comprises$$$128$$$137$$$O	the$$$138$$$141$$$O	following$$$142$$$151$$$O	steps$$$152$$$157$$$O	of:$$$158$$$161$$$O	preparing$$$162$$$171$$$O	an$$$172$$$174$$$O	iodate$$$175$$$181$$$O	aqueous$$$182$$$189$$$O	solution$$$190$$$198$$$O	and$$$199$$$202$$$O	a$$$203$$$204$$$O	silver$$$205$$$211$$$I	salt$$$212$$$216$$$O	aqueous$$$217$$$224$$$O	solution,$$$225$$$234$$$O	the$$$235$$$238$$$O	molar$$$239$$$244$$$O	concentrations$$$245$$$259$$$O	of$$$260$$$262$$$O	which$$$263$$$268$$$O	are$$$269$$$272$$$O	respectively$$$273$$$285$$$O	0.01-1.0mol/L,$$$286$$$300$$$O	controlling$$$301$$$312$$$O	flow$$$313$$$317$$$O	rate$$$318$$$322$$$O	under$$$323$$$328$$$O	the$$$329$$$332$$$O	conditions$$$333$$$343$$$O	of$$$344$$$346$$$O	stirring$$$347$$$355$$$O	and$$$356$$$359$$$O	at$$$360$$$362$$$O	the$$$363$$$366$$$O	temperature$$$367$$$378$$$O	of$$$379$$$381$$$O	20-90$$$382$$$387$$$O	DEG$$$388$$$391$$$O	C,$$$392$$$394$$$O	injecting$$$395$$$404$$$O	the$$$405$$$408$$$O	matters$$$409$$$416$$$O	into$$$417$$$421$$$O	a$$$422$$$423$$$O	macromolecule$$$424$$$437$$$O	complexing$$$438$$$448$$$O	agent$$$449$$$454$$$O	aqueous$$$455$$$462$$$O	solution,$$$463$$$472$$$O	generating$$$473$$$483$$$O	the$$$484$$$487$$$O	silver$$$488$$$494$$$I	iodine$$$495$$$501$$$I	in$$$502$$$504$$$O	site$$$505$$$509$$$O	in$$$510$$$512$$$O	the$$$513$$$516$$$O	macromolecule$$$517$$$530$$$O	complexing$$$531$$$541$$$O	agent,$$$542$$$548$$$O	and$$$549$$$552$$$O	then$$$553$$$557$$$O	carrying$$$558$$$566$$$O	out$$$567$$$570$$$O	ultrasound$$$571$$$581$$$O	treatment$$$582$$$591$$$O	for$$$592$$$595$$$O	30-60$$$596$$$601$$$O	minutes$$$602$$$609$$$O	under$$$610$$$615$$$O	the$$$616$$$619$$$O	condition$$$620$$$629$$$O	of$$$630$$$632$$$O	reaction$$$633$$$641$$$O	temperature$$$642$$$653$$$O	to$$$654$$$656$$$O	obtain$$$657$$$663$$$O	a$$$664$$$665$$$O	silver$$$666$$$672$$$I	iodine$$$673$$$679$$$I	complex$$$680$$$687$$$O	dispersion$$$688$$$698$$$O	liquid.$$$699$$$706$$$O	According$$$707$$$716$$$O	to$$$717$$$719$$$O	the$$$720$$$723$$$O	preparation$$$724$$$735$$$O	method,$$$736$$$743$$$O	the$$$744$$$747$$$O	nanometer$$$748$$$757$$$O	silver$$$758$$$764$$$I	iodine$$$765$$$771$$$I	is$$$772$$$774$$$O	generated$$$775$$$784$$$O	in$$$785$$$787$$$O	site$$$788$$$792$$$O	in$$$793$$$795$$$O	the$$$796$$$799$$$O	macromolecule$$$800$$$813$$$O	complexing$$$814$$$824$$$O	agent$$$825$$$830$$$O	by$$$831$$$833$$$O	using$$$834$$$839$$$O	the$$$840$$$843$$$O	inhibition$$$844$$$854$$$O	effect$$$855$$$861$$$O	of$$$862$$$864$$$O	the$$$865$$$868$$$O	macromolecule$$$869$$$882$$$O	complexing$$$883$$$893$$$O	agent,$$$894$$$900$$$O	and$$$901$$$904$$$O	the$$$905$$$908$$$O	prepared$$$909$$$917$$$O	silver$$$918$$$924$$$I	iodine$$$925$$$931$$$I	has$$$932$$$935$$$O	small$$$936$$$941$$$O	particle$$$942$$$950$$$O	size,$$$951$$$956$$$O	is$$$957$$$959$$$O	narrow$$$960$$$966$$$O	in$$$967$$$969$$$O	distribution$$$970$$$982$$$O	and$$$983$$$986$$$O	is$$$987$$$989$$$O	easy$$$990$$$994$$$O	to$$$995$$$997$$$O	stably$$$998$$$1004$$$O	disperse$$$1005$$$1013$$$O	in$$$1014$$$1016$$$O	water.$$$1017$$$1023$$$O	The$$$1024$$$1027$$$O	silver$$$1028$$$1034$$$I	iodine$$$1035$$$1041$$$I	complexing$$$1042$$$1052$$$O	antibacterial$$$1053$$$1066$$$O	agent$$$1067$$$1072$$$O	provided$$$1073$$$1081$$$O	by$$$1082$$$1084$$$O	the$$$1085$$$1088$$$O	invention$$$1089$$$1098$$$O	has$$$1099$$$1102$$$O	the$$$1103$$$1106$$$O	sterilizing$$$1107$$$1118$$$O	rate$$$1119$$$1123$$$O	up$$$1124$$$1126$$$O	to$$$1127$$$1129$$$O	99.9%$$$1130$$$1135$$$O	and$$$1136$$$1139$$$O	can$$$1140$$$1143$$$O	be$$$1144$$$1146$$$O	added$$$1147$$$1152$$$O	to$$$1153$$$1155$$$O	other$$$1156$$$1161$$$O	materials,$$$1162$$$1172$$$O	so$$$1173$$$1175$$$O	that$$$1176$$$1180$$$O	the$$$1181$$$1184$$$O	antibacterial$$$1185$$$1198$$$O	property$$$1199$$$1207$$$O	of$$$1208$$$1210$$$O	the$$$1211$$$1214$$$O	materials$$$1215$$$1224$$$O	is$$$1225$$$1227$$$O	improved;$$$1228$$$1237$$$O	and$$$1238$$$1241$$$O	the$$$1242$$$1245$$$O	silver$$$1246$$$1252$$$I	iodine$$$1253$$$1259$$$I	complexing$$$1260$$$1270$$$O	antibacterial$$$1271$$$1284$$$O	agent$$$1285$$$1290$$$O	can$$$1291$$$1294$$$O	be$$$1295$$$1297$$$O	used$$$1298$$$1302$$$O	for$$$1303$$$1306$$$O	disinfection$$$1307$$$1319$$$O	and$$$1320$$$1323$$$O	sterilization$$$1324$$$1337$$$O	of$$$1338$$$1340$$$O	the$$$1341$$$1344$$$O	surfaces$$$1345$$$1353$$$O	of$$$1354$$$1356$$$O	skins,$$$1357$$$1363$$$O	medical$$$1364$$$1371$$$O	apparatus$$$1372$$$1381$$$O	and$$$1382$$$1385$$$O	instruments,$$$1386$$$1398$$$O	household$$$1399$$$1408$$$O	ware$$$1409$$$1413$$$O	and$$$1414$$$1417$$$O	the$$$1418$$$1421$$$O	like.$$$1422$$$1427$$$O
CN1629159A
Preparation$$$0$$$11$$$O	of$$$12$$$14$$$O	13-hexyl$$$15$$$23$$$I	fibrauretine$$$24$$$36$$$I	and$$$37$$$40$$$O	its$$$41$$$44$$$O	anti-virus$$$45$$$55$$$O	and$$$56$$$59$$$O	antibacterial$$$60$$$73$$$O	action$$$74$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	novel$$$26$$$31$$$O	orthogonally$$$32$$$44$$$O	optimized$$$45$$$54$$$O	derivative$$$55$$$65$$$O	preparing$$$66$$$75$$$O	method$$$76$$$82$$$O	for$$$83$$$86$$$O	preparing$$$87$$$96$$$O	13-hexylpalmatine.$$$97$$$115$$$I	Animal$$$116$$$122$$$O	test$$$123$$$127$$$O	and$$$128$$$131$$$O	microbiological$$$132$$$147$$$O	test$$$148$$$152$$$O	have$$$153$$$157$$$O	shown$$$158$$$163$$$O	that,$$$164$$$169$$$O	the$$$170$$$173$$$O	substance$$$174$$$183$$$O	has$$$184$$$187$$$O	high$$$188$$$192$$$O	effectiveness$$$193$$$206$$$O	of$$$207$$$209$$$O	antiviral$$$210$$$219$$$O	and$$$220$$$223$$$O	antibiotic$$$224$$$234$$$O	actions.$$$235$$$243$$$O
US8609656
Heteroarylphenylurea$$$0$$$20$$$I	derivative$$$21$$$31$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	compound$$$33$$$41$$$O	represented$$$42$$$53$$$O	by$$$54$$$56$$$O	the$$$57$$$60$$$O	formula$$$61$$$68$$$O	(1):$$$69$$$73$$$O	wherein$$$187$$$194$$$O	R1,$$$207$$$210$$$O	R2$$$211$$$213$$$O	and$$$214$$$217$$$O	R5$$$218$$$220$$$O	are$$$221$$$224$$$O	each$$$225$$$229$$$O	independently$$$230$$$243$$$O	selected$$$244$$$252$$$O	from$$$253$$$257$$$O	a$$$258$$$259$$$O	hydrogen$$$260$$$268$$$I	atom,$$$269$$$274$$$O	a$$$275$$$276$$$O	halogen$$$277$$$284$$$I	atom,$$$285$$$290$$$O	a$$$291$$$292$$$O	C1-C6$$$293$$$298$$$I	alkyl$$$299$$$304$$$I	is$$$305$$$307$$$O	substituted$$$308$$$319$$$O	with$$$320$$$324$$$O	a$$$325$$$326$$$O	halogen$$$327$$$334$$$I	atom$$$335$$$339$$$O	and$$$340$$$343$$$O	the$$$344$$$347$$$O	like;$$$348$$$353$$$O	R3$$$366$$$368$$$O	and$$$369$$$372$$$O	R4$$$373$$$375$$$O	are$$$376$$$379$$$O	each$$$380$$$384$$$O	independently$$$385$$$398$$$O	selected$$$399$$$407$$$O	from$$$408$$$412$$$O	a$$$413$$$414$$$O	hydrogen$$$415$$$423$$$I	atom,$$$424$$$429$$$O	a$$$430$$$431$$$O	halogen$$$432$$$439$$$I	atom,$$$440$$$445$$$O	a$$$446$$$447$$$O	substituted$$$448$$$459$$$O	C1-C6$$$460$$$465$$$I	alkyl$$$466$$$471$$$I	group$$$472$$$477$$$O	and$$$478$$$481$$$O	the$$$482$$$485$$$O	like;$$$486$$$491$$$O	R6$$$504$$$506$$$O	and$$$507$$$510$$$O	R7$$$511$$$513$$$O	are$$$514$$$517$$$O	each$$$518$$$522$$$O	independently$$$523$$$536$$$O	selected$$$537$$$545$$$O	from$$$546$$$550$$$O	a$$$551$$$552$$$O	hydrogen$$$553$$$561$$$I	atom$$$562$$$566$$$O	and$$$567$$$570$$$O	a$$$571$$$572$$$O	halogen$$$573$$$580$$$I	atom;$$$581$$$586$$$O	Z1$$$599$$$601$$$O	and$$$602$$$605$$$O	Z2$$$606$$$608$$$O	are$$$609$$$612$$$O	each$$$613$$$617$$$O	independently$$$618$$$631$$$O	selected$$$632$$$640$$$O	from$$$641$$$645$$$O	a$$$646$$$647$$$O	hydrogen$$$648$$$656$$$I	atom,$$$657$$$662$$$O	a$$$663$$$664$$$O	hydroxyl$$$665$$$673$$$I	group$$$674$$$679$$$O	and$$$680$$$683$$$O	âO(CHR11)OC(âO)R12;$$$684$$$707$$$I	Q$$$720$$$721$$$O	is$$$722$$$724$$$O	a$$$725$$$726$$$O	group$$$727$$$732$$$O	of$$$733$$$735$$$O	the$$$736$$$739$$$O	formula:$$$740$$$748$$$O	(wherein$$$894$$$902$$$O	G1$$$915$$$917$$$I	is$$$918$$$920$$$I	CâY2$$$921$$$927$$$I	or$$$928$$$930$$$O	N;$$$931$$$933$$$O	a$$$946$$$947$$$O	ring$$$948$$$952$$$O	A$$$953$$$954$$$I	is$$$955$$$957$$$I	a$$$958$$$959$$$I	benzene$$$960$$$967$$$I	ring$$$968$$$972$$$I	or$$$973$$$975$$$I	a$$$976$$$977$$$I	5-$$$978$$$980$$$I	to$$$981$$$983$$$I	6-membered$$$984$$$994$$$I	unsaturated$$$995$$$1006$$$I	heterocycle)$$$1007$$$1019$$$I	a$$$1021$$$1022$$$O	pharmaceutically$$$1023$$$1039$$$O	acceptable$$$1040$$$1050$$$O	salt$$$1051$$$1055$$$O	thereof$$$1056$$$1063$$$O	or$$$1064$$$1066$$$O	a$$$1067$$$1068$$$O	prodrug$$$1069$$$1076$$$O	thereof.$$$1077$$$1085$$$O
WO2012050465A1
Novel$$$0$$$5$$$O	esters$$$6$$$12$$$I	of$$$13$$$15$$$I	(acyloxymethyl)acrylamide,$$$16$$$42$$$I	a$$$43$$$44$$$O	pharmaceutical$$$45$$$59$$$O	composition$$$60$$$71$$$O	containing$$$72$$$82$$$O	them,$$$83$$$88$$$O	and$$$89$$$92$$$O	their$$$93$$$98$$$O	use$$$99$$$102$$$O	as$$$103$$$105$$$O	inhibitors$$$106$$$116$$$O	of$$$117$$$119$$$O	the$$$120$$$123$$$O	thioredoxin$$$124$$$135$$$O	-$$$136$$$137$$$O	thioredoxin$$$138$$$149$$$O	reductase$$$150$$$159$$$O	system$$$160$$$166$$$O
The$$$0$$$3$$$O	subject$$$4$$$11$$$O	of$$$12$$$14$$$O	the$$$15$$$18$$$O	present$$$19$$$26$$$O	invention$$$27$$$36$$$O	are$$$37$$$40$$$O	novel$$$41$$$46$$$O	esters$$$47$$$53$$$I	of$$$54$$$56$$$I	(acyloxymethyl)acrylamide,$$$57$$$83$$$I	a$$$84$$$85$$$O	pharmaceutical$$$86$$$100$$$O	composition$$$101$$$112$$$O	containing$$$113$$$123$$$O	them$$$124$$$128$$$O	and$$$129$$$132$$$O	their$$$133$$$138$$$O	use$$$139$$$142$$$O	in$$$143$$$145$$$O	the$$$146$$$149$$$O	production$$$150$$$160$$$O	of$$$161$$$163$$$O	drugs$$$164$$$169$$$O	for$$$170$$$173$$$O	the$$$174$$$177$$$O	prophylaxis$$$178$$$189$$$O	or$$$190$$$192$$$O	treatment$$$193$$$202$$$O	of$$$203$$$205$$$O	oncogenic$$$206$$$215$$$O	diseases$$$216$$$224$$$O	and$$$225$$$228$$$O	diseases$$$229$$$237$$$O	connected$$$238$$$247$$$O	with$$$248$$$252$$$O	increased$$$253$$$262$$$O	cell$$$263$$$267$$$O	proliferation.$$$268$$$282$$$O
US20100197709
Non-sedating$$$0$$$12$$$O	barbiturate$$$13$$$24$$$I	compounds$$$25$$$34$$$O	as$$$35$$$37$$$O	neuroprotective$$$38$$$53$$$O	agents$$$54$$$60$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	providing$$$11$$$20$$$O	neuroprotection$$$21$$$36$$$O	are$$$37$$$40$$$O	disclosed$$$41$$$50$$$O	comprising$$$51$$$61$$$O	administering$$$62$$$75$$$O	a$$$76$$$77$$$O	non-sedative$$$78$$$90$$$O	barbiturate$$$91$$$102$$$I	compound$$$103$$$111$$$O	in$$$112$$$114$$$O	an$$$115$$$117$$$O	amount$$$118$$$124$$$O	sufficient$$$125$$$135$$$O	to$$$136$$$138$$$O	achieve$$$139$$$146$$$O	neuroprotection$$$147$$$162$$$O	in$$$163$$$165$$$O	a$$$166$$$167$$$O	mammalian$$$168$$$177$$$O	subject.$$$178$$$186$$$O	Preferred$$$187$$$196$$$O	compounds$$$197$$$206$$$O	are$$$207$$$210$$$O	in$$$211$$$213$$$O	the$$$214$$$217$$$O	family$$$218$$$224$$$O	of$$$225$$$227$$$O	diphenylbarbituric$$$228$$$246$$$I	acid$$$247$$$251$$$I	and$$$252$$$255$$$O	analogs.$$$256$$$264$$$O	Preferred$$$265$$$274$$$O	doses$$$275$$$280$$$O	for$$$281$$$284$$$O	a$$$285$$$286$$$O	neuroprotective$$$287$$$302$$$O	effect$$$303$$$309$$$O	exceed$$$310$$$316$$$O	the$$$317$$$320$$$O	dosage$$$321$$$327$$$O	of$$$328$$$330$$$O	a$$$331$$$332$$$O	corresponding$$$333$$$346$$$O	sedative$$$347$$$355$$$O	barbiturate$$$356$$$367$$$I	without$$$368$$$375$$$O	sedative$$$376$$$384$$$O	side-effects$$$385$$$397$$$O	such$$$398$$$402$$$O	as$$$403$$$405$$$O	anesthesia$$$406$$$416$$$O	and$$$417$$$420$$$O	death.$$$421$$$427$$$O
CN101020059B
Medicine$$$0$$$8$$$O	composition$$$9$$$20$$$O	containing$$$21$$$31$$$O	docetaxel$$$32$$$41$$$I	matter$$$42$$$48$$$O	and$$$49$$$52$$$O	its$$$53$$$56$$$O	preparation$$$57$$$68$$$O	process$$$69$$$76$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	medicine$$$33$$$41$$$O	composition$$$42$$$53$$$O	containing$$$54$$$64$$$O	docetaxel$$$65$$$74$$$I	matter$$$75$$$81$$$O	suitable$$$82$$$90$$$O	for$$$91$$$94$$$O	injection$$$95$$$104$$$O	and$$$105$$$108$$$O	its$$$109$$$112$$$O	preparation$$$113$$$124$$$O	process.$$$125$$$133$$$O	The$$$134$$$137$$$O	medicine$$$138$$$146$$$O	composition$$$147$$$158$$$O	has$$$159$$$162$$$O	docetaxel$$$163$$$172$$$I	or$$$173$$$175$$$O	its$$$176$$$179$$$O	salt$$$180$$$184$$$O	or$$$185$$$187$$$O	hydrate$$$188$$$195$$$O	as$$$196$$$198$$$O	the$$$199$$$202$$$O	active$$$203$$$209$$$O	component,$$$210$$$220$$$O	and$$$221$$$224$$$O	cyclodextrin$$$225$$$237$$$O	and$$$238$$$241$$$O	amino$$$242$$$247$$$I	acid$$$248$$$252$$$I	as$$$253$$$255$$$O	complex$$$256$$$263$$$O	solubilizing$$$264$$$276$$$O	agent.$$$277$$$283$$$O	The$$$284$$$287$$$O	injection$$$288$$$297$$$O	of$$$298$$$300$$$O	the$$$301$$$304$$$O	medicine$$$305$$$313$$$O	composition$$$314$$$325$$$O	of$$$326$$$328$$$O	the$$$329$$$332$$$O	present$$$333$$$340$$$O	invention$$$341$$$350$$$O	has$$$351$$$354$$$O	high$$$355$$$359$$$O	stability,$$$360$$$370$$$O	less$$$371$$$375$$$O	toxic$$$376$$$381$$$O	side$$$382$$$386$$$O	effect$$$387$$$393$$$O	and$$$394$$$397$$$O	other$$$398$$$403$$$O	advantages.$$$404$$$415$$$O
US20110269741
Novel$$$0$$$5$$$O	compositions$$$6$$$18$$$O	and$$$19$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	use$$$34$$$37$$$O
Described$$$0$$$9$$$O	herein$$$10$$$16$$$O	are$$$17$$$20$$$O	novel$$$21$$$26$$$O	enzyme$$$27$$$33$$$O	inhibitors.$$$34$$$45$$$O	In$$$46$$$48$$$O	some$$$49$$$53$$$O	embodiments$$$54$$$65$$$O	the$$$66$$$69$$$O	enzyme$$$70$$$76$$$O	inhibitors$$$77$$$87$$$O	are$$$88$$$91$$$O	integrase$$$92$$$101$$$O	inhibitors,$$$102$$$113$$$O	particularly$$$114$$$126$$$O	HIV$$$127$$$130$$$O	integrase$$$131$$$140$$$O	inhibitors.$$$141$$$152$$$O	Also$$$153$$$157$$$O	described$$$158$$$167$$$O	herein$$$168$$$174$$$O	are$$$175$$$178$$$O	compositions$$$179$$$191$$$O	containing$$$192$$$202$$$O	them$$$203$$$207$$$O	and$$$208$$$211$$$O	methods$$$212$$$219$$$O	of$$$220$$$222$$$O	using$$$223$$$228$$$O	them.$$$229$$$234$$$O	Thus,$$$235$$$240$$$O	the$$$241$$$244$$$O	compounds$$$245$$$254$$$O	and$$$255$$$258$$$O	compositions$$$259$$$271$$$O	described$$$272$$$281$$$O	herein$$$282$$$288$$$O	are$$$289$$$292$$$O	useful$$$293$$$299$$$O	for$$$300$$$303$$$O	the$$$304$$$307$$$O	in$$$308$$$310$$$O	vitro$$$311$$$316$$$O	and$$$317$$$320$$$O	in$$$321$$$323$$$O	vivo$$$324$$$328$$$O	inhibition$$$329$$$339$$$O	of$$$340$$$342$$$O	HIV$$$343$$$346$$$O	integrase$$$347$$$356$$$O	as$$$357$$$359$$$O	a$$$360$$$361$$$O	method$$$362$$$368$$$O	of$$$369$$$371$$$O	treating$$$372$$$380$$$O	or$$$381$$$383$$$O	preventing$$$384$$$394$$$O	HIV,$$$395$$$399$$$O	AIDS$$$400$$$404$$$O	or$$$405$$$407$$$O	related$$$408$$$415$$$O	disorders.$$$416$$$426$$$O
US20110190316
Substituted$$$0$$$11$$$O	pyridines,$$$12$$$22$$$I	and$$$23$$$26$$$O	use$$$27$$$30$$$O	thereof$$$31$$$38$$$O	as$$$39$$$41$$$O	Gsk3$$$42$$$46$$$O	inhibitors$$$47$$$57$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	substituted$$$25$$$36$$$O	pyridines$$$37$$$46$$$I	and$$$47$$$50$$$O	to$$$51$$$53$$$O	processes$$$54$$$63$$$O	for$$$64$$$67$$$O	preparation$$$68$$$79$$$O	thereof,$$$80$$$88$$$O	and$$$89$$$92$$$O	to$$$93$$$95$$$O	the$$$96$$$99$$$O	use$$$100$$$103$$$O	thereof$$$104$$$111$$$O	for$$$112$$$115$$$O	production$$$116$$$126$$$O	of$$$127$$$129$$$O	medicaments$$$130$$$141$$$O	for$$$142$$$145$$$O	treatment$$$146$$$155$$$O	and/or$$$156$$$162$$$O	prophylaxis$$$163$$$174$$$O	of$$$175$$$177$$$O	diseases,$$$178$$$187$$$O	especially$$$188$$$198$$$O	of$$$199$$$201$$$O	haematological$$$202$$$216$$$O	disorders,$$$217$$$227$$$O	preferably$$$228$$$238$$$O	of$$$239$$$241$$$O	leukopenia$$$242$$$252$$$O	and$$$253$$$256$$$O	neutropenia.$$$257$$$269$$$O
CN101773463A
Selenium-enriched$$$0$$$17$$$I	nano$$$18$$$22$$$O	pearl$$$23$$$28$$$O	powder$$$29$$$35$$$O	formula$$$36$$$43$$$O	and$$$44$$$47$$$O	production$$$48$$$58$$$O	method$$$59$$$65$$$O	thereof$$$66$$$73$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	selenium-enriched$$$27$$$44$$$I	nano$$$45$$$49$$$O	pearl$$$50$$$55$$$O	powder$$$56$$$62$$$O	formula$$$63$$$70$$$O	and$$$71$$$74$$$O	a$$$75$$$76$$$O	production$$$77$$$87$$$O	method$$$88$$$94$$$O	thereof,$$$95$$$103$$$O	and$$$104$$$107$$$O	the$$$108$$$111$$$O	selenium-enriched$$$112$$$129$$$I	nano$$$130$$$134$$$O	pearl$$$135$$$140$$$O	powder$$$141$$$147$$$O	comprises$$$148$$$157$$$O	25$$$158$$$160$$$O	raw$$$161$$$164$$$O	materials$$$165$$$174$$$O	of$$$175$$$177$$$O	the$$$178$$$181$$$O	following$$$182$$$191$$$O	active$$$192$$$198$$$O	ingredients$$$199$$$210$$$O	in$$$211$$$213$$$O	parts$$$214$$$219$$$O	by$$$220$$$222$$$O	weight:$$$223$$$230$$$O	20-40$$$231$$$236$$$O	parts$$$237$$$242$$$O	of$$$243$$$245$$$O	pearl,$$$246$$$252$$$O	1-2$$$253$$$256$$$O	parts$$$257$$$262$$$O	of$$$263$$$265$$$O	essence,$$$266$$$274$$$O	0.2-0.4$$$275$$$282$$$O	part$$$283$$$287$$$O	of$$$288$$$290$$$O	alpha-linolenic$$$291$$$306$$$I	acid,$$$307$$$312$$$I	0.8-1.5$$$313$$$320$$$O	parts$$$321$$$326$$$O	of$$$327$$$329$$$O	titanium$$$330$$$338$$$I	dioxide$$$339$$$346$$$I	and$$$347$$$350$$$O	the$$$351$$$354$$$O	like.$$$355$$$360$$$O	The$$$361$$$364$$$O	production$$$365$$$375$$$O	process$$$376$$$383$$$O	comprises$$$384$$$393$$$O	the$$$394$$$397$$$O	following$$$398$$$407$$$O	steps:$$$408$$$414$$$O	grinding$$$415$$$423$$$O	the$$$424$$$427$$$O	pearls$$$428$$$434$$$O	to$$$435$$$437$$$O	200$$$438$$$441$$$O	meshes,$$$442$$$449$$$O	ultrasonic$$$450$$$460$$$O	grinding,$$$461$$$470$$$O	scattering,$$$471$$$482$$$O	nano$$$483$$$487$$$O	grinding,$$$488$$$497$$$O	mixing$$$498$$$504$$$O	and$$$505$$$508$$$O	filling.$$$509$$$517$$$O	The$$$518$$$521$$$O	formula$$$522$$$529$$$O	can$$$530$$$533$$$O	lead$$$534$$$538$$$O	skin$$$539$$$543$$$O	to$$$544$$$546$$$O	become$$$547$$$553$$$O	white$$$554$$$559$$$O	and$$$560$$$563$$$O	lustrous$$$564$$$572$$$O	and$$$573$$$576$$$O	alleviate$$$577$$$586$$$O	stains,$$$587$$$594$$$O	chloasma,$$$595$$$604$$$O	black$$$605$$$610$$$O	stains$$$611$$$617$$$O	and$$$618$$$621$$$O	freckle$$$622$$$629$$$O	traces$$$630$$$636$$$O	and$$$637$$$640$$$O	has$$$641$$$644$$$O	no$$$645$$$647$$$O	toxic$$$648$$$653$$$O	or$$$654$$$656$$$O	side$$$657$$$661$$$O	effect.$$$662$$$669$$$O	The$$$670$$$673$$$O	selenium-enriched$$$674$$$691$$$I	nano$$$692$$$696$$$O	pearl$$$697$$$702$$$O	powder$$$703$$$709$$$O	can$$$710$$$713$$$O	be$$$714$$$716$$$O	prepared$$$717$$$725$$$O	into$$$726$$$730$$$O	face$$$731$$$735$$$O	cream,$$$736$$$742$$$O	sunscreen$$$743$$$752$$$O	cream,$$$753$$$759$$$O	skin-care$$$760$$$769$$$O	cream,$$$770$$$776$$$O	facial$$$777$$$783$$$O	masks$$$784$$$789$$$O	and$$$790$$$793$$$O	the$$$794$$$797$$$O	like.$$$798$$$803$$$O	The$$$804$$$807$$$O	selenium-enriched$$$808$$$825$$$I	nano$$$826$$$830$$$O	pearl$$$831$$$836$$$O	powder$$$837$$$843$$$O	can$$$844$$$847$$$O	be$$$848$$$850$$$O	applied$$$851$$$858$$$O	to$$$859$$$861$$$O	partial$$$862$$$869$$$O	human$$$870$$$875$$$O	skin$$$876$$$880$$$O	and$$$881$$$884$$$O	can$$$885$$$888$$$O	eliminate$$$889$$$898$$$O	hand$$$899$$$903$$$O	and$$$904$$$907$$$O	facial$$$908$$$914$$$O	wrinkles$$$915$$$923$$$O	and$$$924$$$927$$$O	whiten$$$928$$$934$$$O	the$$$935$$$938$$$O	skin.$$$939$$$944$$$O	As$$$945$$$947$$$O	a$$$948$$$949$$$O	nutrition$$$950$$$959$$$O	enhancing$$$960$$$969$$$O	and$$$970$$$973$$$O	health-care$$$974$$$985$$$O	food$$$986$$$990$$$O	additive,$$$991$$$1000$$$O	the$$$1001$$$1004$$$O	nano$$$1005$$$1009$$$O	pearl$$$1010$$$1015$$$O	power$$$1016$$$1021$$$O	of$$$1022$$$1024$$$O	the$$$1025$$$1028$$$O	formula$$$1029$$$1036$$$O	can$$$1037$$$1040$$$O	be$$$1041$$$1043$$$O	used$$$1044$$$1048$$$O	for$$$1049$$$1052$$$O	developing$$$1053$$$1063$$$O	health-care$$$1064$$$1075$$$O	food,$$$1076$$$1081$$$O	beverages,$$$1082$$$1092$$$O	white$$$1093$$$1098$$$O	spirits,$$$1099$$$1107$$$O	beer,$$$1108$$$1113$$$O	medicines$$$1114$$$1123$$$O	and$$$1124$$$1127$$$O	the$$$1128$$$1131$$$O	like.$$$1132$$$1137$$$O
CA2176796C
Substituted$$$0$$$11$$$O	benzyloxycarbonylguanidines,$$$12$$$40$$$I	process$$$41$$$48$$$O	for$$$49$$$52$$$O	their$$$53$$$58$$$O	preparation,$$$59$$$71$$$O	their$$$72$$$77$$$O	use$$$78$$$81$$$O	as$$$82$$$84$$$O	a$$$85$$$86$$$O	medicament$$$87$$$97$$$O	or$$$98$$$100$$$O	diagnostic,$$$101$$$112$$$O	and$$$113$$$116$$$O	medicament$$$117$$$127$$$O	containing$$$128$$$138$$$O	them$$$139$$$143$$$O
There$$$0$$$5$$$O	are$$$6$$$9$$$O	described$$$10$$$19$$$O	compounds$$$20$$$29$$$O	of$$$30$$$32$$$O	the$$$33$$$36$$$O	formula$$$37$$$44$$$O	I$$$45$$$46$$$O	(see$$$47$$$51$$$O	formula$$$52$$$59$$$O	I)$$$60$$$62$$$O	and$$$63$$$66$$$O	their$$$67$$$72$$$O	pharmaceutically$$$73$$$89$$$O	tolerable$$$90$$$99$$$O	salts.$$$100$$$106$$$O	These$$$107$$$112$$$O	are$$$113$$$116$$$O	effective$$$117$$$126$$$O	inhibitors$$$127$$$137$$$O	of$$$138$$$140$$$O	the$$$141$$$144$$$O	cellular$$$145$$$153$$$O	sodium$$$154$$$160$$$I	proton$$$161$$$167$$$O	antiporter$$$168$$$178$$$O	(Na+/H+$$$179$$$186$$$I	exchanger).$$$187$$$198$$$O	They$$$199$$$203$$$O	are$$$204$$$207$$$O	therefore$$$208$$$217$$$O	outstandingly$$$218$$$231$$$O	suitable$$$232$$$240$$$O	for$$$241$$$244$$$O	the$$$245$$$248$$$O	treatment$$$249$$$258$$$O	of$$$259$$$261$$$O	all$$$262$$$265$$$O	diseases$$$266$$$274$$$O	which$$$275$$$280$$$O	can$$$281$$$284$$$O	be$$$285$$$287$$$O	attributed$$$288$$$298$$$O	to$$$299$$$301$$$O	increased$$$302$$$311$$$O	Na+/H+$$$312$$$318$$$I	exchange.$$$319$$$328$$$O
EP1721609A2
Pyridylpyrimidine$$$0$$$17$$$I	derivatives$$$18$$$29$$$O	as$$$30$$$32$$$O	effective$$$33$$$42$$$O	compounds$$$43$$$52$$$O	against$$$53$$$60$$$O	prion$$$61$$$66$$$O	infections$$$67$$$77$$$O	and$$$78$$$81$$$O	prion$$$82$$$87$$$O	diseases$$$88$$$96$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	pyridylpyrimidine$$$33$$$50$$$I	derivatives$$$51$$$62$$$O	of$$$63$$$65$$$O	the$$$66$$$69$$$O	general$$$70$$$77$$$O	formula$$$78$$$85$$$O	(I):$$$86$$$90$$$O	wherein$$$98$$$105$$$O	R$$$106$$$107$$$O	represents$$$108$$$118$$$O	hydrogen$$$119$$$127$$$I	or$$$128$$$130$$$O	methyl$$$131$$$137$$$I	and$$$138$$$141$$$O	Z$$$142$$$143$$$O	represents$$$144$$$154$$$O	nitrogen$$$155$$$163$$$I	containing$$$164$$$174$$$O	functional$$$175$$$185$$$O	groups,$$$186$$$193$$$O	the$$$194$$$197$$$O	use$$$198$$$201$$$O	of$$$202$$$204$$$O	the$$$205$$$208$$$O	pyridylpyrimidine$$$209$$$226$$$I	derivatives$$$227$$$238$$$O	as$$$239$$$241$$$O	pharmaceutically$$$242$$$258$$$O	active$$$259$$$265$$$O	agents,$$$266$$$273$$$O	especially$$$274$$$284$$$O	for$$$285$$$288$$$O	the$$$289$$$292$$$O	prophylaxis$$$293$$$304$$$O	and/or$$$305$$$311$$$O	treatment$$$312$$$321$$$O	of$$$322$$$324$$$O	prion$$$325$$$330$$$O	infections$$$331$$$341$$$O	and$$$342$$$345$$$O	prion$$$346$$$351$$$O	diseases,$$$352$$$361$$$O	as$$$362$$$364$$$O	well$$$365$$$369$$$O	as$$$370$$$372$$$O	compositions$$$373$$$385$$$O	containing$$$386$$$396$$$O	at$$$397$$$399$$$O	least$$$400$$$405$$$O	one$$$406$$$409$$$O	pyridylpyrimidine$$$410$$$427$$$I	derivative$$$428$$$438$$$O	and/or$$$439$$$445$$$O	pharmaceutically$$$446$$$462$$$O	acceptable$$$463$$$473$$$O	salt$$$474$$$478$$$O	thereof.$$$479$$$487$$$O	Furthermore,$$$488$$$500$$$O	the$$$501$$$504$$$O	present$$$505$$$512$$$O	invention$$$513$$$522$$$O	is$$$523$$$525$$$O	directed$$$526$$$534$$$O	to$$$535$$$537$$$O	methods$$$538$$$545$$$O	for$$$546$$$549$$$O	preventing$$$550$$$560$$$O	and/or$$$561$$$567$$$O	treating$$$568$$$576$$$O	prion$$$577$$$582$$$O	infections$$$583$$$593$$$O	and$$$594$$$597$$$O	prion$$$598$$$603$$$O	diseases$$$604$$$612$$$O	using$$$613$$$618$$$O	said$$$619$$$623$$$O	pyridylpyrimidine$$$624$$$641$$$I	derivatives.$$$642$$$654$$$O	Human$$$655$$$660$$$O	cellular$$$661$$$669$$$O	protein$$$670$$$677$$$O	kinases,$$$678$$$686$$$O	phosphatases$$$687$$$699$$$O	and$$$700$$$703$$$O	cellular$$$704$$$712$$$O	signal$$$713$$$719$$$O	transduction$$$720$$$732$$$O	molecules$$$733$$$742$$$O	are$$$743$$$746$$$O	disclosed$$$747$$$756$$$O	as$$$757$$$759$$$O	targets$$$760$$$767$$$O	for$$$768$$$771$$$O	detecting,$$$772$$$782$$$O	preventing$$$783$$$793$$$O	and/or$$$794$$$800$$$O	treating$$$801$$$809$$$O	prion$$$810$$$815$$$O	infections$$$816$$$826$$$O	and$$$827$$$830$$$O	diseases,$$$831$$$840$$$O	especially$$$841$$$851$$$O	BSE,$$$852$$$856$$$O	vCJD,$$$857$$$862$$$O	or$$$863$$$865$$$O	CJD$$$866$$$869$$$O	which$$$870$$$875$$$O	can$$$876$$$879$$$O	be$$$880$$$882$$$O	inhibited$$$883$$$892$$$O	by$$$893$$$895$$$O	the$$$896$$$899$$$O	inventive$$$900$$$909$$$O	pyridylpyrimidine$$$910$$$927$$$I	derivatives.$$$928$$$940$$$O
US20090182029
2-indolinone$$$0$$$12$$$I	derivatives$$$13$$$24$$$O	as$$$25$$$27$$$O	selective$$$28$$$37$$$O	histone$$$38$$$45$$$O	deacetylase$$$46$$$57$$$O	inhibitors$$$58$$$68$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	isolated$$$20$$$28$$$O	compounds$$$29$$$38$$$O	of$$$39$$$41$$$O	formula$$$42$$$49$$$O	1:$$$50$$$52$$$O	processes$$$90$$$99$$$O	for$$$100$$$103$$$O	their$$$104$$$109$$$O	preparation$$$110$$$121$$$O	and$$$122$$$125$$$O	isolation,$$$126$$$136$$$O	as$$$137$$$139$$$O	well$$$140$$$144$$$O	as$$$145$$$147$$$O	pharmaceutical$$$148$$$162$$$O	compositions$$$163$$$175$$$O	which$$$176$$$181$$$O	comprise$$$182$$$190$$$O	these$$$191$$$196$$$O	therapeutic$$$197$$$208$$$O	agents,$$$209$$$216$$$O	and$$$217$$$220$$$O	methods$$$221$$$228$$$O	of$$$229$$$231$$$O	use$$$232$$$235$$$O	therefore$$$236$$$245$$$O	the$$$246$$$249$$$O	treatment$$$250$$$259$$$O	and/or$$$260$$$266$$$O	control$$$267$$$274$$$O	of$$$275$$$277$$$O	conditions$$$278$$$288$$$O	associated$$$289$$$299$$$O	with$$$300$$$304$$$O	or$$$305$$$307$$$O	mediated$$$308$$$316$$$O	by$$$317$$$319$$$O	effects$$$320$$$327$$$O	of$$$328$$$330$$$O	histone$$$331$$$338$$$O	deacetylase.$$$339$$$351$$$O
US6894042
Azabicyclic$$$0$$$11$$$I	compounds$$$12$$$21$$$O	for$$$22$$$25$$$O	the$$$26$$$29$$$O	treatment$$$30$$$39$$$O	of$$$40$$$42$$$O	disease$$$43$$$50$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds$$$23$$$32$$$O	of$$$33$$$35$$$O	Formula$$$36$$$43$$$O	I:$$$44$$$46$$$O	wherein$$$62$$$69$$$O	Azabicyclo$$$70$$$80$$$I	is$$$81$$$83$$$O	These$$$103$$$108$$$O	compounds$$$109$$$118$$$O	may$$$119$$$122$$$O	be$$$123$$$125$$$O	in$$$126$$$128$$$O	the$$$129$$$132$$$O	form$$$133$$$137$$$O	of$$$138$$$140$$$O	pharmaceutical$$$141$$$155$$$O	salts$$$156$$$161$$$O	or$$$162$$$164$$$O	compositions,$$$165$$$178$$$O	may$$$179$$$182$$$O	be$$$183$$$185$$$O	in$$$186$$$188$$$O	pure$$$189$$$193$$$O	enantiomeric$$$194$$$206$$$O	form$$$207$$$211$$$O	or$$$212$$$214$$$O	racemic$$$215$$$222$$$O	mixtures,$$$223$$$232$$$O	and$$$233$$$236$$$O	are$$$237$$$240$$$O	useful$$$241$$$247$$$O	in$$$248$$$250$$$O	pharmaceuticals$$$251$$$266$$$O	in$$$267$$$269$$$O	which$$$270$$$275$$$O	Î±7$$$276$$$279$$$O	is$$$280$$$282$$$O	known$$$283$$$288$$$O	to$$$289$$$291$$$O	be$$$292$$$294$$$O	involved.$$$295$$$304$$$O
CN102085211A
Water-soluble$$$0$$$13$$$O	rutin$$$14$$$19$$$I	solid$$$20$$$25$$$O	dispersoid$$$26$$$36$$$O	and$$$37$$$40$$$O	preparation$$$41$$$52$$$O	method$$$53$$$59$$$O	thereof$$$60$$$67$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	water-soluble$$$26$$$39$$$O	rutin$$$40$$$45$$$I	solid$$$46$$$51$$$O	dispersoid,$$$52$$$63$$$O	which$$$64$$$69$$$O	is$$$70$$$72$$$O	characterized$$$73$$$86$$$O	by$$$87$$$89$$$O	being$$$90$$$95$$$O	prepared$$$96$$$104$$$O	from$$$105$$$109$$$O	rutin,$$$110$$$116$$$I	an$$$117$$$119$$$O	organic$$$120$$$127$$$O	solvent$$$128$$$135$$$O	and$$$136$$$139$$$O	a$$$140$$$141$$$O	carrier$$$142$$$149$$$O	accessory$$$150$$$159$$$O	in$$$160$$$162$$$O	a$$$163$$$164$$$O	formula.$$$165$$$173$$$O	The$$$174$$$177$$$O	preparation$$$178$$$189$$$O	method$$$190$$$196$$$O	of$$$197$$$199$$$O	the$$$200$$$203$$$O	water-soluble$$$204$$$217$$$O	rutin$$$218$$$223$$$I	solid$$$224$$$229$$$O	dispersoid$$$230$$$240$$$O	comprises$$$241$$$250$$$O	the$$$251$$$254$$$O	steps$$$255$$$260$$$O	of:$$$261$$$264$$$O	adding$$$265$$$271$$$O	the$$$272$$$275$$$O	rutin$$$276$$$281$$$I	into$$$282$$$286$$$O	the$$$287$$$290$$$O	organic$$$291$$$298$$$O	solvent$$$299$$$306$$$O	with$$$307$$$311$$$O	the$$$312$$$315$$$O	volume$$$316$$$322$$$O	4-15$$$323$$$327$$$O	times$$$328$$$333$$$O	of$$$334$$$336$$$O	that$$$337$$$341$$$O	of$$$342$$$344$$$O	the$$$345$$$348$$$O	rutin,$$$349$$$355$$$I	and$$$356$$$359$$$O	heating$$$360$$$367$$$O	till$$$368$$$372$$$O	the$$$373$$$376$$$O	rutin$$$377$$$382$$$I	is$$$383$$$385$$$O	dissolved;$$$386$$$396$$$O	adding$$$397$$$403$$$O	the$$$404$$$407$$$O	carrier$$$408$$$415$$$O	accessory,$$$416$$$426$$$O	heating$$$427$$$434$$$O	to$$$435$$$437$$$O	dissolve$$$438$$$446$$$O	the$$$447$$$450$$$O	carrier$$$451$$$458$$$O	accessory$$$459$$$468$$$O	and$$$469$$$472$$$O	stopping$$$473$$$481$$$O	heating,$$$482$$$490$$$O	wherein$$$491$$$498$$$O	the$$$499$$$502$$$O	weight$$$503$$$509$$$O	ratio$$$510$$$515$$$O	of$$$516$$$518$$$O	the$$$519$$$522$$$O	rutin$$$523$$$528$$$I	to$$$529$$$531$$$O	the$$$532$$$535$$$O	carrier$$$536$$$543$$$O	accessory$$$544$$$553$$$O	is$$$554$$$556$$$O	1:1$$$557$$$560$$$O	to$$$561$$$563$$$O	1:10;$$$564$$$569$$$O	carrying$$$570$$$578$$$O	out$$$579$$$582$$$O	rotary$$$583$$$589$$$O	evaporation$$$590$$$601$$$O	till$$$602$$$606$$$O	no$$$607$$$609$$$O	liquid$$$610$$$616$$$O	droplet$$$617$$$624$$$O	exists;$$$625$$$632$$$O	placing$$$633$$$640$$$O	into$$$641$$$645$$$O	a$$$646$$$647$$$O	vacuum$$$648$$$654$$$O	drying$$$655$$$661$$$O	oven$$$662$$$666$$$O	for$$$667$$$670$$$O	drying$$$671$$$677$$$O	for$$$678$$$681$$$O	24$$$682$$$684$$$O	hours,$$$685$$$691$$$O	storing$$$692$$$699$$$O	for$$$700$$$703$$$O	24-48$$$704$$$709$$$O	hours$$$710$$$715$$$O	at$$$716$$$718$$$O	-20$$$719$$$722$$$O	DEG$$$723$$$726$$$O	C,$$$727$$$729$$$O	and$$$730$$$733$$$O	taking$$$734$$$740$$$O	out$$$741$$$744$$$O	a$$$745$$$746$$$O	product$$$747$$$754$$$O	which$$$755$$$760$$$O	is$$$761$$$763$$$O	the$$$764$$$767$$$O	dried$$$768$$$773$$$O	water-soluble$$$774$$$787$$$O	rutin$$$788$$$793$$$I	solid$$$794$$$799$$$O	dispersoid;$$$800$$$811$$$O	and$$$812$$$815$$$O	then,$$$816$$$821$$$O	sieving$$$822$$$829$$$O	through$$$830$$$837$$$O	a$$$838$$$839$$$O	80-mesh$$$840$$$847$$$O	sieve$$$848$$$853$$$O	and$$$854$$$857$$$O	storing.$$$858$$$866$$$O	The$$$867$$$870$$$O	preparation$$$871$$$882$$$O	method$$$883$$$889$$$O	has$$$890$$$893$$$O	the$$$894$$$897$$$O	superiorities$$$898$$$911$$$O	that$$$912$$$916$$$O	the$$$917$$$920$$$O	crystal$$$921$$$928$$$O	form$$$929$$$933$$$O	of$$$934$$$936$$$O	the$$$937$$$940$$$O	rutin$$$941$$$946$$$I	in$$$947$$$949$$$O	the$$$950$$$953$$$O	solid$$$954$$$959$$$O	dispersoid$$$960$$$970$$$O	exists$$$971$$$977$$$O	in$$$978$$$980$$$O	an$$$981$$$983$$$O	amorphous$$$984$$$993$$$O	state$$$994$$$999$$$O	so$$$1000$$$1002$$$O	that$$$1003$$$1007$$$O	the$$$1008$$$1011$$$O	water$$$1012$$$1017$$$O	solubility$$$1018$$$1028$$$O	of$$$1029$$$1031$$$O	the$$$1032$$$1035$$$O	rutin$$$1036$$$1041$$$I	is$$$1042$$$1044$$$O	enhanced$$$1045$$$1053$$$O	and$$$1054$$$1057$$$O	the$$$1058$$$1061$$$O	solubility$$$1062$$$1072$$$O	of$$$1073$$$1075$$$O	the$$$1076$$$1079$$$O	rutin$$$1080$$$1085$$$I	in$$$1086$$$1088$$$O	the$$$1089$$$1092$$$O	water$$$1093$$$1098$$$O	is$$$1099$$$1101$$$O	greatly$$$1102$$$1109$$$O	increased,$$$1110$$$1120$$$O	and$$$1121$$$1124$$$O	thus,$$$1125$$$1130$$$O	the$$$1131$$$1134$$$O	absorption$$$1135$$$1145$$$O	condition$$$1146$$$1155$$$O	of$$$1156$$$1158$$$O	the$$$1159$$$1162$$$O	rutin$$$1163$$$1168$$$I	in$$$1169$$$1171$$$O	vivo$$$1172$$$1176$$$O	is$$$1177$$$1179$$$O	improved;$$$1180$$$1189$$$O	in$$$1190$$$1192$$$O	addition,$$$1193$$$1202$$$O	the$$$1203$$$1206$$$O	preparation$$$1207$$$1218$$$O	method$$$1219$$$1225$$$O	has$$$1226$$$1229$$$O	the$$$1230$$$1233$$$O	other$$$1234$$$1239$$$O	advantage$$$1240$$$1249$$$O	of$$$1250$$$1252$$$O	simple,$$$1253$$$1260$$$O	convenient$$$1261$$$1271$$$O	and$$$1272$$$1275$$$O	feasible$$$1276$$$1284$$$O	process,$$$1285$$$1293$$$O	and$$$1294$$$1297$$$O	can$$$1298$$$1301$$$O	be$$$1302$$$1304$$$O	used$$$1305$$$1309$$$O	for$$$1310$$$1313$$$O	large-scale$$$1314$$$1325$$$O	industrial$$$1326$$$1336$$$O	production.$$$1337$$$1348$$$O
WO2013111801A1
Triblock$$$0$$$8$$$O	copolymer$$$9$$$18$$$O	and$$$19$$$22$$$O	use$$$23$$$26$$$O	thereof$$$27$$$34$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	triblock$$$14$$$22$$$O	copolymer$$$23$$$32$$$O	represented$$$33$$$44$$$O	by$$$45$$$47$$$O	general$$$48$$$55$$$O	formula$$$56$$$63$$$O	(I):$$$64$$$68$$$O	CNR-PEG-CNR$$$69$$$80$$$I	(wherein$$$81$$$89$$$O	CNR's$$$90$$$95$$$O	independently$$$96$$$109$$$O	represent$$$110$$$119$$$O	a$$$120$$$121$$$O	polymer$$$122$$$129$$$O	segment$$$130$$$137$$$O	that$$$138$$$142$$$O	contains$$$143$$$151$$$O	a$$$152$$$153$$$O	repeating$$$154$$$163$$$O	unit$$$164$$$168$$$O	containing,$$$169$$$180$$$O	as$$$181$$$183$$$O	a$$$184$$$185$$$O	part$$$186$$$190$$$O	of$$$191$$$193$$$O	a$$$194$$$195$$$O	pendant$$$196$$$203$$$O	group,$$$204$$$210$$$O	a$$$211$$$212$$$O	cyclic$$$213$$$219$$$O	nitroxide$$$220$$$229$$$I	radical$$$230$$$237$$$O	capable$$$238$$$245$$$O	of$$$246$$$248$$$O	binding$$$249$$$256$$$O	to$$$257$$$259$$$O	the$$$260$$$263$$$O	polymer$$$264$$$271$$$O	main$$$272$$$276$$$O	chain$$$277$$$282$$$O	through$$$283$$$290$$$O	a$$$291$$$292$$$O	linking$$$293$$$300$$$O	group$$$301$$$306$$$O	having$$$307$$$313$$$O	at$$$314$$$316$$$O	least$$$317$$$322$$$O	one$$$323$$$326$$$O	imino$$$327$$$332$$$I	group$$$333$$$338$$$O	or$$$339$$$341$$$O	ether$$$342$$$347$$$I	bond;$$$348$$$353$$$O	and$$$354$$$357$$$O	PEG$$$358$$$361$$$I	represents$$$362$$$372$$$O	a$$$373$$$374$$$O	segment$$$375$$$382$$$O	containing$$$383$$$393$$$O	poly(ethylene$$$394$$$407$$$I	glycol))$$$408$$$416$$$I	or$$$417$$$419$$$O	a$$$420$$$421$$$O	polycation$$$422$$$432$$$O	thereof.$$$433$$$441$$$O
WO2011085155A3
Formulations$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	dissolving$$$29$$$39$$$O	cerumen$$$40$$$47$$$O
Formulations,$$$0$$$13$$$O	kits,$$$14$$$19$$$O	and$$$20$$$23$$$O	methods$$$24$$$31$$$O	are$$$32$$$35$$$O	described$$$36$$$45$$$O	herein$$$46$$$52$$$O	for$$$53$$$56$$$O	relieving$$$57$$$66$$$O	symptoms$$$67$$$75$$$O	and$$$76$$$79$$$O	complications$$$80$$$93$$$O	from$$$94$$$98$$$O	excessive$$$99$$$108$$$O	or$$$109$$$111$$$O	impacted$$$112$$$120$$$O	cerumen.$$$121$$$129$$$O	The$$$130$$$133$$$O	formulations$$$134$$$146$$$O	comprise$$$147$$$155$$$O	effective$$$156$$$165$$$O	amounts$$$166$$$173$$$O	of$$$174$$$176$$$O	limonene,$$$177$$$186$$$I	one$$$187$$$190$$$O	or$$$191$$$193$$$O	more$$$194$$$198$$$O	bile$$$199$$$203$$$I	salts,$$$204$$$210$$$I	and/or$$$211$$$217$$$O	sodium$$$218$$$224$$$I	bicarbonate.$$$225$$$237$$$I
CN103566331A
Blood$$$0$$$5$$$O	matching$$$6$$$14$$$O	injection$$$15$$$24$$$O	of$$$25$$$27$$$O	Aiaikang$$$28$$$36$$$O	capsules$$$37$$$45$$$O	and$$$46$$$49$$$O	activated$$$50$$$59$$$O	carbon$$$60$$$66$$$I	nanoparticles$$$67$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	blood$$$26$$$31$$$O	matching$$$32$$$40$$$O	injection$$$41$$$50$$$O	of$$$51$$$53$$$O	Aiaikang$$$54$$$62$$$O	capsules$$$63$$$71$$$O	and$$$72$$$75$$$O	activated$$$76$$$85$$$O	carbon$$$86$$$92$$$I	nanoparticles.$$$93$$$107$$$O	The$$$108$$$111$$$O	Aiaikang$$$112$$$120$$$O	capsules$$$121$$$129$$$O	are$$$130$$$133$$$O	prepared$$$134$$$142$$$O	from$$$143$$$147$$$O	green$$$148$$$153$$$O	activated$$$154$$$163$$$O	carbon$$$164$$$170$$$I	nanoparticles,$$$171$$$185$$$O	nucleic$$$186$$$193$$$O	acid,$$$194$$$199$$$O	calcium,$$$200$$$208$$$I	corn$$$209$$$213$$$O	stigma,$$$214$$$221$$$O	honeysuckle,$$$222$$$234$$$O	herba$$$235$$$240$$$O	violae,$$$241$$$248$$$O	hedge$$$249$$$254$$$O	glorybind$$$255$$$264$$$O	flower,$$$265$$$272$$$O	fructus$$$273$$$280$$$O	forsythiae,$$$281$$$292$$$O	pulsatilla$$$293$$$303$$$O	root,$$$304$$$309$$$O	perilla$$$310$$$317$$$O	leaf,$$$318$$$323$$$O	astragalus$$$324$$$334$$$O	membranaceus,$$$335$$$348$$$O	herba$$$349$$$354$$$O	cistanche,$$$355$$$365$$$O	fructus$$$366$$$373$$$O	psoraleae,$$$374$$$384$$$O	acorus$$$385$$$391$$$O	calamus,$$$392$$$400$$$O	frankincense,$$$401$$$414$$$O	myrrh,$$$415$$$421$$$O	mimatsu$$$422$$$429$$$O	bark,$$$430$$$435$$$O	ailanthus$$$436$$$445$$$O	altissima,$$$446$$$456$$$O	folium$$$457$$$463$$$O	ginkgo$$$464$$$470$$$O	bilobae,$$$471$$$479$$$O	euphorbia$$$480$$$489$$$O	lunulata$$$490$$$498$$$O	seeds,$$$499$$$505$$$O	Chinese-date,$$$506$$$519$$$O	camphor,$$$520$$$528$$$O	borneol,$$$529$$$537$$$O	snake$$$538$$$543$$$O	grape$$$544$$$549$$$O	root,$$$550$$$555$$$O	oldenlandia$$$556$$$567$$$O	diffusa,$$$568$$$576$$$O	sculellaria$$$577$$$588$$$O	barbata,$$$589$$$597$$$O	rhizoma$$$598$$$605$$$O	phragmitis,$$$606$$$617$$$O	stir-baked$$$618$$$628$$$O	squama$$$629$$$635$$$O	manitis,$$$636$$$644$$$O	folium$$$645$$$651$$$O	artemisiae$$$652$$$662$$$O	argyi,$$$663$$$669$$$O	propolis,$$$670$$$679$$$O	semen$$$680$$$685$$$O	cuscutae,$$$686$$$695$$$O	radix$$$696$$$701$$$O	sophorae$$$702$$$710$$$O	flavescentis,$$$711$$$724$$$O	scorpio,$$$725$$$733$$$O	herba$$$734$$$739$$$O	geranii,$$$740$$$748$$$O	ginger$$$749$$$755$$$O	powder,$$$756$$$763$$$O	square-stem,$$$764$$$776$$$O	bighead$$$777$$$784$$$O	atractylodes$$$785$$$797$$$O	rhizome,$$$798$$$806$$$O	horseleech$$$807$$$817$$$O	and$$$818$$$821$$$O	the$$$822$$$825$$$O	like$$$826$$$830$$$O	in$$$831$$$833$$$O	a$$$834$$$835$$$O	manner$$$836$$$842$$$O	of$$$843$$$845$$$O	crushing$$$846$$$854$$$O	by$$$855$$$857$$$O	2-10fold$$$858$$$866$$$O	airflow$$$867$$$874$$$O	at$$$875$$$877$$$O	a$$$878$$$879$$$O	supersonic$$$880$$$890$$$O	speed,$$$891$$$897$$$O	wherein$$$898$$$905$$$O	the$$$906$$$909$$$O	activated$$$910$$$919$$$O	carbon$$$920$$$926$$$O	nanoparticles$$$927$$$940$$$O	for$$$941$$$944$$$O	the$$$945$$$948$$$O	capsule$$$949$$$956$$$O	achieve$$$957$$$964$$$O	over$$$965$$$969$$$O	3000$$$970$$$974$$$O	meshes;$$$975$$$982$$$O	the$$$983$$$986$$$O	other$$$987$$$992$$$O	medicines$$$993$$$1002$$$O	are$$$1003$$$1006$$$O	over$$$1007$$$1011$$$O	2000$$$1012$$$1016$$$O	meshes;$$$1017$$$1024$$$O	the$$$1025$$$1028$$$O	green$$$1029$$$1034$$$O	activated$$$1035$$$1044$$$O	carbon$$$1045$$$1051$$$O	nanoparticles$$$1052$$$1065$$$O	for$$$1066$$$1069$$$O	injection$$$1070$$$1079$$$O	are$$$1080$$$1083$$$O	over$$$1084$$$1088$$$O	30000$$$1089$$$1094$$$O	meshes.$$$1095$$$1102$$$O	The$$$1103$$$1106$$$O	blood$$$1107$$$1112$$$O	matching$$$1113$$$1121$$$O	injection$$$1122$$$1131$$$O	is$$$1132$$$1134$$$O	ultra-micro$$$1135$$$1146$$$O	in$$$1147$$$1149$$$O	particle$$$1150$$$1158$$$O	size,$$$1159$$$1164$$$O	and$$$1165$$$1168$$$O	over-large$$$1169$$$1179$$$O	in$$$1180$$$1182$$$O	activity,$$$1183$$$1192$$$O	and$$$1193$$$1196$$$O	can$$$1197$$$1200$$$O	enter$$$1201$$$1206$$$O	inside$$$1207$$$1213$$$O	cell$$$1214$$$1218$$$O	nucleus$$$1219$$$1226$$$O	to$$$1227$$$1229$$$O	kill$$$1230$$$1234$$$O	viruses;$$$1235$$$1243$$$O	an$$$1244$$$1246$$$O	infected$$$1247$$$1255$$$O	cell$$$1256$$$1260$$$O	repair$$$1261$$$1267$$$O	function$$$1268$$$1276$$$O	can$$$1277$$$1280$$$O	be$$$1281$$$1283$$$O	rescued;$$$1284$$$1292$$$O	the$$$1293$$$1296$$$O	nutrients$$$1297$$$1306$$$O	in$$$1307$$$1309$$$O	the$$$1310$$$1313$$$O	medicine$$$1314$$$1322$$$O	or$$$1323$$$1325$$$O	blood$$$1326$$$1331$$$O	can$$$1332$$$1335$$$O	be$$$1336$$$1338$$$O	obtained;$$$1339$$$1348$$$O	the$$$1349$$$1352$$$O	vigor$$$1353$$$1358$$$O	and$$$1359$$$1362$$$O	vitality$$$1363$$$1371$$$O	of$$$1372$$$1374$$$O	the$$$1375$$$1378$$$O	cells$$$1379$$$1384$$$O	are$$$1385$$$1388$$$O	enhanced;$$$1389$$$1398$$$O	an$$$1399$$$1401$$$O	antibody$$$1402$$$1410$$$O	can$$$1411$$$1414$$$O	be$$$1415$$$1417$$$O	generated$$$1418$$$1427$$$O	after$$$1428$$$1433$$$O	recovery.$$$1434$$$1443$$$O	Thus,$$$1444$$$1449$$$O	the$$$1450$$$1453$$$O	blood$$$1454$$$1459$$$O	matching$$$1460$$$1468$$$O	injection$$$1469$$$1478$$$O	is$$$1479$$$1481$$$O	applicable$$$1482$$$1492$$$O	to$$$1493$$$1495$$$O	curing$$$1496$$$1502$$$O	uremia$$$1503$$$1509$$$O	avian$$$1510$$$1515$$$O	influenza$$$1516$$$1525$$$O	of$$$1526$$$1528$$$O	aids$$$1529$$$1533$$$O	cancer$$$1534$$$1540$$$O	septicemia$$$1541$$$1551$$$O	and$$$1552$$$1555$$$O	an$$$1556$$$1558$$$O	intractable$$$1559$$$1570$$$O	skin$$$1571$$$1575$$$O	disease$$$1576$$$1583$$$O	once$$$1584$$$1588$$$O	and$$$1589$$$1592$$$O	for$$$1593$$$1596$$$O	all.$$$1597$$$1601$$$O
CN101112366A
Skin-protecting$$$0$$$15$$$O	wiping$$$16$$$22$$$O	slice$$$23$$$28$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	skin$$$35$$$39$$$O	protection$$$40$$$50$$$O	wipe,$$$51$$$56$$$O	which$$$57$$$62$$$O	is$$$63$$$65$$$O	composed$$$66$$$74$$$O	of$$$75$$$77$$$O	base$$$78$$$82$$$O	material$$$83$$$91$$$O	and$$$92$$$95$$$O	skin$$$96$$$100$$$O	protection$$$101$$$111$$$O	agent;$$$112$$$118$$$O	the$$$119$$$122$$$O	present$$$123$$$130$$$O	invention$$$131$$$140$$$O	is$$$141$$$143$$$O	characterized$$$144$$$157$$$O	in$$$158$$$160$$$O	that:$$$161$$$166$$$O	the$$$167$$$170$$$O	components$$$171$$$181$$$O	and$$$182$$$185$$$O	parts$$$186$$$191$$$O	by$$$192$$$194$$$O	weight$$$195$$$201$$$O	of$$$202$$$204$$$O	the$$$205$$$208$$$O	skin$$$209$$$213$$$O	protection$$$214$$$224$$$O	agent$$$225$$$230$$$O	are:$$$231$$$235$$$O	isopropanol:$$$236$$$248$$$I	20$$$249$$$251$$$O	to$$$252$$$254$$$O	75$$$255$$$257$$$O	parts;$$$258$$$264$$$O	acetyl$$$265$$$271$$$I	tributyl$$$272$$$280$$$I	citrate:$$$281$$$289$$$I	8$$$290$$$291$$$O	to$$$292$$$294$$$O	30$$$295$$$297$$$O	parts;$$$298$$$304$$$O	butyl$$$305$$$310$$$I	PVM$$$311$$$314$$$I	/$$$315$$$316$$$O	MA$$$317$$$319$$$O	copolymer:$$$320$$$330$$$O	15$$$331$$$333$$$O	to$$$334$$$336$$$O	55$$$337$$$339$$$O	parts.$$$340$$$346$$$O	As$$$347$$$349$$$O	the$$$350$$$353$$$O	present$$$354$$$361$$$O	invention$$$362$$$371$$$O	uses$$$372$$$376$$$O	the$$$377$$$380$$$O	isopropanol,$$$381$$$393$$$I	acetyl$$$394$$$400$$$I	tributyl$$$401$$$409$$$I	citrate$$$410$$$417$$$I	and$$$418$$$421$$$O	butyl$$$422$$$427$$$I	PVM/MA$$$428$$$434$$$I	copolymer$$$435$$$444$$$O	as$$$445$$$447$$$O	the$$$448$$$451$$$O	raw$$$452$$$455$$$O	materials,$$$456$$$466$$$O	the$$$467$$$470$$$O	present$$$471$$$478$$$O	invention$$$479$$$488$$$O	not$$$489$$$492$$$O	only$$$493$$$497$$$O	has$$$498$$$501$$$O	strong$$$502$$$508$$$O	sterilization,$$$509$$$523$$$O	disinfection$$$524$$$536$$$O	and$$$537$$$540$$$O	skin$$$541$$$545$$$O	cleaning$$$546$$$554$$$O	capability,$$$555$$$566$$$O	but$$$567$$$570$$$O	can$$$571$$$574$$$O	also$$$575$$$579$$$O	produce$$$580$$$587$$$O	a$$$588$$$589$$$O	layer$$$590$$$595$$$O	of$$$596$$$598$$$O	protection$$$599$$$609$$$O	membrane$$$610$$$618$$$O	on$$$619$$$621$$$O	the$$$622$$$625$$$O	skin$$$626$$$630$$$O	surface$$$631$$$638$$$O	to$$$639$$$641$$$O	isolate$$$642$$$649$$$O	the$$$650$$$653$$$O	skin,$$$654$$$659$$$O	thus$$$660$$$664$$$O	ensuring$$$665$$$673$$$O	the$$$674$$$677$$$O	chemical$$$678$$$686$$$O	components$$$687$$$697$$$O	which$$$698$$$703$$$O	have$$$704$$$708$$$O	the$$$709$$$712$$$O	stimulating$$$713$$$724$$$O	effect$$$725$$$731$$$O	not$$$732$$$735$$$O	to$$$736$$$738$$$O	contact$$$739$$$746$$$O	with$$$747$$$751$$$O	the$$$752$$$755$$$O	skin$$$756$$$760$$$O	directly$$$761$$$769$$$O	and$$$770$$$773$$$O	avoiding$$$774$$$782$$$O	the$$$783$$$786$$$O	allergic$$$787$$$795$$$O	reactions.$$$796$$$806$$$O	The$$$807$$$810$$$O	present$$$811$$$818$$$O	invention$$$819$$$828$$$O	adopts$$$829$$$835$$$O	the$$$836$$$839$$$O	form$$$840$$$844$$$O	of$$$845$$$847$$$O	the$$$848$$$851$$$O	wipe,$$$852$$$857$$$O	which$$$858$$$863$$$O	is$$$864$$$866$$$O	very$$$867$$$871$$$O	convenient$$$872$$$882$$$O	to$$$883$$$885$$$O	carry$$$886$$$891$$$O	and$$$892$$$895$$$O	particularly$$$896$$$908$$$O	applicable$$$909$$$919$$$O	to$$$920$$$922$$$O	the$$$923$$$926$$$O	medical$$$927$$$934$$$O	staff$$$935$$$940$$$O	for$$$941$$$944$$$O	visiting$$$945$$$953$$$O	at$$$954$$$956$$$O	the$$$957$$$960$$$O	site$$$961$$$965$$$O	of$$$966$$$968$$$O	the$$$969$$$972$$$O	sudden$$$973$$$979$$$O	accidents.$$$980$$$990$$$O
US6916793
Treating$$$0$$$8$$$O	tumor$$$9$$$14$$$O	cells$$$15$$$20$$$O	with$$$21$$$25$$$O	a$$$26$$$27$$$O	selenium$$$28$$$36$$$I	prodrug$$$37$$$44$$$O	lyase$$$45$$$50$$$O	and$$$51$$$54$$$O	a$$$55$$$56$$$O	selenium-containing$$$57$$$76$$$I	prodrug$$$77$$$84$$$O	such$$$85$$$89$$$O	as$$$90$$$92$$$O	selenocysteine,$$$93$$$108$$$I	selenohomocysteine,$$$109$$$128$$$I	selenomethionine$$$129$$$145$$$O	or$$$146$$$148$$$O	selenoethionine.$$$149$$$165$$$I
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	inhibiting$$$12$$$22$$$O	the$$$23$$$26$$$O	growth$$$27$$$33$$$O	of$$$34$$$36$$$O	tumor$$$37$$$42$$$O	cells$$$43$$$48$$$O	by$$$49$$$51$$$O	combination$$$52$$$63$$$O	treatment$$$64$$$73$$$O	with$$$74$$$78$$$O	a$$$79$$$80$$$O	selenium-containing$$$81$$$100$$$I	prodrug$$$101$$$108$$$O	and$$$109$$$112$$$O	an$$$113$$$115$$$O	enzyme$$$116$$$122$$$O	for$$$123$$$126$$$O	which$$$127$$$132$$$O	it$$$133$$$135$$$O	is$$$136$$$138$$$O	a$$$139$$$140$$$O	substrate$$$141$$$150$$$O	are$$$151$$$154$$$O	described.$$$155$$$165$$$O	The$$$166$$$169$$$O	treatment$$$170$$$179$$$O	also$$$180$$$184$$$O	enhances$$$185$$$193$$$O	the$$$194$$$197$$$O	effect$$$198$$$204$$$O	of$$$205$$$207$$$O	anti-tumor$$$208$$$218$$$O	agents.$$$219$$$226$$$O
CN101480453B
Hepatinica$$$0$$$10$$$O	for$$$11$$$14$$$O	egg-shaped$$$15$$$25$$$O	pompano$$$26$$$33$$$O
Hepatinica$$$0$$$10$$$O	used$$$11$$$15$$$O	for$$$16$$$19$$$O	golden$$$20$$$26$$$O	pompano$$$27$$$34$$$O	is$$$35$$$37$$$O	prepared$$$38$$$46$$$O	from$$$47$$$51$$$O	the$$$52$$$55$$$O	following$$$56$$$65$$$O	components$$$66$$$76$$$O	by$$$77$$$79$$$O	weight:$$$80$$$87$$$O	20$$$88$$$90$$$O	to$$$91$$$93$$$O	30$$$94$$$96$$$O	percent$$$97$$$104$$$O	of$$$105$$$107$$$O	vitamin$$$108$$$115$$$I	E,$$$116$$$118$$$I	20$$$119$$$121$$$O	to$$$122$$$124$$$O	30$$$125$$$127$$$O	percent$$$128$$$135$$$O	of$$$136$$$138$$$O	vitamin$$$139$$$146$$$I	C-$$$147$$$149$$$I	polyphosphonate,$$$150$$$166$$$I	10$$$167$$$169$$$O	to$$$170$$$172$$$O	15$$$173$$$175$$$O	percent$$$176$$$183$$$O	of$$$184$$$186$$$O	sinkaline,$$$187$$$197$$$O	5$$$198$$$199$$$O	to$$$200$$$202$$$O	10$$$203$$$205$$$O	percent$$$206$$$213$$$O	of$$$214$$$216$$$O	L-Carnitine,$$$217$$$229$$$I	5$$$230$$$231$$$O	to$$$232$$$234$$$O	10$$$235$$$237$$$O	percent$$$238$$$245$$$O	of$$$246$$$248$$$O	lecithin,$$$249$$$258$$$I	5$$$259$$$260$$$O	to$$$261$$$263$$$O	10$$$264$$$266$$$O	percent$$$267$$$274$$$O	of$$$275$$$277$$$O	Rhizoma$$$278$$$285$$$O	Atractylodis$$$286$$$298$$$O	Macrocephalae,$$$299$$$313$$$O	5$$$314$$$315$$$O	to$$$316$$$318$$$O	10$$$319$$$321$$$O	percent$$$322$$$329$$$O	of$$$330$$$332$$$O	medlar,$$$333$$$340$$$O	and$$$341$$$344$$$O	5$$$345$$$346$$$O	to$$$347$$$349$$$O	10$$$350$$$352$$$O	percent$$$353$$$360$$$O	of$$$361$$$363$$$O	Alisma$$$364$$$370$$$O	orientale.$$$371$$$381$$$O	The$$$382$$$385$$$O	hepatinica$$$386$$$396$$$O	can$$$397$$$400$$$O	be$$$401$$$403$$$O	used$$$404$$$408$$$O	as$$$409$$$411$$$O	additive$$$412$$$420$$$O	of$$$421$$$423$$$O	golden$$$424$$$430$$$O	pompano$$$431$$$438$$$O	feed$$$439$$$443$$$O	and$$$444$$$447$$$O	is$$$448$$$450$$$O	added$$$451$$$456$$$O	in$$$457$$$459$$$O	the$$$460$$$463$$$O	golden$$$464$$$470$$$O	pompano$$$471$$$478$$$O	feed$$$479$$$483$$$O	only$$$484$$$488$$$O	by$$$489$$$491$$$O	0.1$$$492$$$495$$$O	to$$$496$$$498$$$O	0.2$$$499$$$502$$$O	percent,$$$503$$$511$$$O	can$$$512$$$515$$$O	prevent$$$516$$$523$$$O	fatty$$$524$$$529$$$O	infiltration$$$530$$$542$$$O	of$$$543$$$545$$$O	the$$$546$$$549$$$O	golden$$$550$$$556$$$O	pompano,$$$557$$$565$$$O	strengthen$$$566$$$576$$$O	the$$$577$$$580$$$O	liver$$$581$$$586$$$O	function,$$$587$$$596$$$O	improve$$$597$$$604$$$O	the$$$605$$$608$$$O	feed$$$609$$$613$$$O	efficiency$$$614$$$624$$$O	and$$$625$$$628$$$O	promote$$$629$$$636$$$O	the$$$637$$$640$$$O	growth$$$641$$$647$$$O	of$$$648$$$650$$$O	the$$$651$$$654$$$O	golden$$$655$$$661$$$O	pompano,$$$662$$$670$$$O	improves$$$671$$$679$$$O	the$$$680$$$683$$$O	survival$$$684$$$692$$$O	rate$$$693$$$697$$$O	of$$$698$$$700$$$O	golden$$$701$$$707$$$O	pompano,$$$708$$$716$$$O	has$$$717$$$720$$$O	no$$$721$$$723$$$O	poor$$$724$$$728$$$O	influence$$$729$$$738$$$O	to$$$739$$$741$$$O	the$$$742$$$745$$$O	palatability$$$746$$$758$$$O	of$$$759$$$761$$$O	feed,$$$762$$$767$$$O	and$$$768$$$771$$$O	has$$$772$$$775$$$O	stable$$$776$$$782$$$O	raw$$$783$$$786$$$O	material$$$787$$$795$$$O	resources,$$$796$$$806$$$O	low$$$807$$$810$$$O	price$$$811$$$816$$$O	and$$$817$$$820$$$O	simple$$$821$$$827$$$O	production$$$828$$$838$$$O	technology.$$$839$$$850$$$O
US20090209516
9-amino-acridine$$$0$$$16$$$I	derivatives$$$17$$$28$$$O	and$$$29$$$32$$$O	method$$$33$$$39$$$O	of$$$40$$$42$$$O	treating$$$43$$$51$$$O	autoimmune$$$52$$$62$$$O	diseases$$$63$$$71$$$O	using$$$72$$$77$$$O	the$$$78$$$81$$$O	same$$$82$$$86$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	according$$$35$$$44$$$O	to$$$45$$$47$$$O	general$$$48$$$55$$$O	formula$$$56$$$63$$$O	(1)$$$64$$$67$$$O	and/or$$$68$$$74$$$O	their$$$75$$$80$$$O	enantiomers,$$$81$$$93$$$O	diastereomers,$$$94$$$108$$$O	and$$$109$$$112$$$O	their$$$113$$$118$$$O	pharmaceutically$$$119$$$135$$$O	compatible$$$136$$$146$$$O	salts,$$$147$$$153$$$O	and$$$154$$$157$$$O	their$$$158$$$163$$$O	use$$$164$$$167$$$O	to$$$168$$$170$$$O	manufacture$$$171$$$182$$$O	a$$$183$$$184$$$O	medication$$$185$$$195$$$O	as$$$196$$$198$$$O	well$$$199$$$203$$$O	as$$$204$$$206$$$O	medications.$$$207$$$219$$$O	The$$$220$$$223$$$O	compounds$$$224$$$233$$$O	are$$$234$$$237$$$O	suited$$$238$$$244$$$O	for$$$245$$$248$$$O	treatment$$$249$$$258$$$O	of$$$259$$$261$$$O	diseases$$$262$$$270$$$O	connected$$$271$$$280$$$O	with$$$281$$$285$$$O	misfolded$$$286$$$295$$$O	proteins.$$$296$$$305$$$O
EP1719518A1
Compositions$$$0$$$12$$$O	comprising$$$13$$$23$$$O	bacillus$$$24$$$32$$$O	coagulans$$$33$$$42$$$O	for$$$43$$$46$$$O	increasing$$$47$$$57$$$O	the$$$58$$$61$$$O	solubility$$$62$$$72$$$O	and$$$73$$$76$$$O	bioavailability$$$77$$$92$$$O	of$$$93$$$95$$$O	nutritional$$$96$$$107$$$O	minerals$$$108$$$116$$$O
A$$$0$$$1$$$O	non-therapeutic$$$2$$$17$$$O	use$$$18$$$21$$$O	of$$$22$$$24$$$O	one$$$25$$$28$$$O	or$$$29$$$31$$$O	more$$$32$$$36$$$O	non-pathogenic,$$$37$$$52$$$O	lactic$$$53$$$59$$$I	acid-producing$$$60$$$74$$$I	strains$$$75$$$82$$$O	of$$$83$$$85$$$O	Bacillus$$$86$$$94$$$O	coagulans,$$$95$$$105$$$O	or$$$106$$$108$$$O	of$$$109$$$111$$$O	an$$$112$$$114$$$O	extracellular$$$115$$$128$$$O	supernatant$$$129$$$140$$$O	derived$$$141$$$148$$$O	from$$$149$$$153$$$O	a$$$154$$$155$$$O	culture$$$156$$$163$$$O	of$$$164$$$166$$$O	one$$$167$$$170$$$O	or$$$171$$$173$$$O	more$$$174$$$178$$$O	such$$$179$$$183$$$O	strains,$$$184$$$192$$$O	within$$$193$$$199$$$O	a$$$200$$$201$$$O	nutritionally-acceptable$$$202$$$226$$$O	carrier$$$227$$$234$$$O	as$$$235$$$237$$$O	a$$$238$$$239$$$O	nutritional$$$240$$$251$$$O	composition$$$252$$$263$$$O	for$$$264$$$267$$$O	increasing$$$268$$$278$$$O	the$$$279$$$282$$$O	solubility$$$283$$$293$$$O	and$$$294$$$297$$$O	bioavailability$$$298$$$313$$$O	of$$$314$$$316$$$O	nutritional$$$317$$$328$$$O	minerals$$$329$$$337$$$O	within$$$338$$$344$$$O	the$$$345$$$348$$$O	gastrointestinal$$$349$$$365$$$O	tract$$$366$$$371$$$O	of$$$372$$$374$$$O	the$$$375$$$378$$$O	animal.$$$379$$$386$$$O	The$$$387$$$390$$$O	one$$$391$$$394$$$O	or$$$395$$$397$$$O	more$$$398$$$402$$$O	strains$$$403$$$410$$$O	of$$$411$$$413$$$O	Bacillus$$$414$$$422$$$O	coagulans$$$423$$$432$$$O	may$$$433$$$436$$$O	be$$$437$$$439$$$O	selected$$$440$$$448$$$O	from$$$449$$$453$$$O	Bacillus$$$454$$$462$$$O	coagulans,$$$463$$$473$$$O	Bacillus$$$474$$$482$$$O	coagulans$$$483$$$492$$$O	Hammer,$$$493$$$500$$$O	Bacillus$$$501$$$509$$$O	brevis$$$510$$$516$$$O	subspecies$$$517$$$527$$$O	coagulans$$$528$$$537$$$O	and$$$538$$$541$$$O	any$$$542$$$545$$$O	genetic$$$546$$$553$$$O	variants$$$554$$$562$$$O	thereof.$$$563$$$571$$$O	The$$$572$$$575$$$O	nutritional$$$576$$$587$$$O	minerals$$$588$$$596$$$O	may$$$597$$$600$$$O	be$$$601$$$603$$$O	present$$$604$$$611$$$O	in$$$612$$$614$$$O	the$$$615$$$618$$$O	form$$$619$$$623$$$O	of$$$624$$$626$$$O	gluconates$$$627$$$637$$$I	or$$$638$$$640$$$O	citrates.$$$641$$$650$$$I
US7094421
Plaster$$$0$$$7$$$O	containing$$$8$$$18$$$O	4-biphenylacetic$$$19$$$35$$$I	acid$$$36$$$40$$$I
It$$$0$$$2$$$O	is$$$3$$$5$$$O	provided$$$6$$$14$$$O	the$$$15$$$18$$$O	plaster$$$19$$$26$$$O	of$$$27$$$29$$$O	anti-inflammatory$$$30$$$47$$$O	and$$$48$$$51$$$O	analgesic,$$$52$$$62$$$O	improving$$$63$$$72$$$O	the$$$73$$$76$$$O	sustained$$$77$$$86$$$O	releasing$$$87$$$96$$$O	of$$$97$$$99$$$O	4-biphenylacetic$$$100$$$116$$$I	acid$$$117$$$121$$$I	from$$$122$$$126$$$O	the$$$127$$$130$$$O	base$$$131$$$135$$$O	adhesive$$$136$$$144$$$O	material$$$145$$$153$$$O	and$$$154$$$157$$$O	low$$$158$$$161$$$O	skin$$$162$$$166$$$O	irritation,$$$167$$$178$$$O	by$$$179$$$181$$$O	using$$$182$$$187$$$O	more$$$188$$$192$$$O	than$$$193$$$197$$$O	two$$$198$$$201$$$O	kinds$$$202$$$207$$$O	of$$$208$$$210$$$O	resolvent$$$211$$$220$$$O	for$$$221$$$224$$$O	4-biphenylacetic$$$225$$$241$$$I	acid$$$242$$$246$$$I	having$$$247$$$253$$$O	low$$$254$$$257$$$O	solubility$$$258$$$268$$$O	in$$$269$$$271$$$O	solvents.$$$272$$$281$$$O	More$$$282$$$286$$$O	specifically,$$$287$$$300$$$O	it$$$301$$$303$$$O	is$$$304$$$306$$$O	provided$$$307$$$315$$$O	plasters$$$316$$$324$$$O	essentially$$$325$$$336$$$O	containing$$$337$$$347$$$O	5â50%$$$348$$$355$$$O	by$$$356$$$358$$$O	weight$$$359$$$365$$$O	of$$$366$$$368$$$I	styrene-isoprene-styrene$$$369$$$393$$$I	block$$$394$$$399$$$O	copolymer,$$$400$$$410$$$O	0.05â20%$$$411$$$421$$$O	by$$$422$$$424$$$O	weight$$$425$$$431$$$I	of$$$432$$$434$$$I	N-methyl-2-pyrrolidone,$$$435$$$458$$$I	0.1â20%$$$459$$$468$$$O	by$$$469$$$471$$$O	weight$$$472$$$478$$$I	of$$$479$$$481$$$I	polyethylene$$$482$$$494$$$I	glycol$$$495$$$501$$$I	and$$$502$$$505$$$O	0.1â20%$$$506$$$515$$$O	by$$$516$$$518$$$O	weight$$$519$$$525$$$I	of$$$526$$$528$$$I	4-biphenylacetic$$$529$$$545$$$I	acid.$$$546$$$551$$$O
US20100266592
Therapeutic$$$0$$$11$$$O	antennapedia-antibody$$$12$$$33$$$O	molecules$$$34$$$43$$$O	and$$$44$$$47$$$O	methods$$$48$$$55$$$O	of$$$56$$$58$$$O	use$$$59$$$62$$$O	thereof$$$63$$$70$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	based$$$25$$$30$$$O	on$$$31$$$33$$$O	the$$$34$$$37$$$O	seminal$$$38$$$45$$$O	discovery$$$46$$$55$$$O	that$$$56$$$60$$$O	an$$$61$$$63$$$O	antibody$$$64$$$72$$$O	or$$$73$$$75$$$O	fragment$$$76$$$84$$$O	thereof$$$85$$$92$$$O	combined$$$93$$$101$$$O	with$$$102$$$106$$$O	Antennapedia$$$107$$$119$$$O	or$$$120$$$122$$$O	a$$$123$$$124$$$O	fragment$$$125$$$133$$$O	thereof,$$$134$$$142$$$O	is$$$143$$$145$$$O	an$$$146$$$148$$$O	effective$$$149$$$158$$$O	therapeutic$$$159$$$170$$$O	agent.$$$171$$$177$$$O	The$$$178$$$181$$$O	invention$$$182$$$191$$$O	describes$$$192$$$201$$$O	the$$$202$$$205$$$O	construction$$$206$$$218$$$O	of$$$219$$$221$$$O	antibody$$$222$$$230$$$O	or$$$231$$$233$$$O	antibody$$$234$$$242$$$O	fragment$$$243$$$251$$$O	fused$$$252$$$257$$$O	or$$$258$$$260$$$O	chemically$$$261$$$271$$$O	conjugated$$$272$$$282$$$O	with$$$283$$$287$$$O	Antennapedia$$$288$$$300$$$O	at$$$301$$$303$$$O	its$$$304$$$307$$$O	carboxyl$$$308$$$316$$$I	or$$$317$$$319$$$O	its$$$320$$$323$$$O	amino$$$324$$$329$$$I	terminus$$$330$$$338$$$O	(a$$$339$$$341$$$O	âcargo-carrierâ$$$342$$$361$$$O	construct).$$$362$$$373$$$O
US7871635
comprising$$$0$$$10$$$O	a$$$11$$$12$$$O	cosmetically$$$13$$$25$$$O	acceptable$$$26$$$36$$$O	medium$$$37$$$43$$$O	and$$$44$$$47$$$O	a$$$48$$$49$$$O	compound$$$50$$$58$$$O	N-($$$59$$$62$$$I	omega$$$63$$$68$$$I	-undecylenoyl)$$$69$$$83$$$I	phenylalanine;$$$84$$$98$$$I	inactivates$$$99$$$110$$$O	adenylate$$$111$$$120$$$O	cyclase$$$121$$$128$$$O	and$$$129$$$132$$$O	has$$$133$$$136$$$O	an$$$137$$$139$$$O	affinity$$$140$$$148$$$O	for$$$149$$$152$$$O	the$$$153$$$156$$$O	melocytic$$$157$$$166$$$O	specific$$$167$$$175$$$O	hormone$$$176$$$183$$$O	($$$184$$$185$$$O	alpha$$$186$$$191$$$O	-MSH)$$$192$$$197$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	using$$$12$$$17$$$O	a$$$18$$$19$$$O	compound$$$20$$$28$$$O	to$$$29$$$31$$$O	lighten$$$32$$$39$$$O	the$$$40$$$43$$$O	skin$$$44$$$48$$$O	by$$$49$$$51$$$O	inactivating$$$52$$$64$$$O	protein$$$65$$$72$$$O	kinase$$$73$$$79$$$O	A.$$$80$$$82$$$O	The$$$83$$$86$$$O	compound$$$87$$$95$$$O	may$$$96$$$99$$$O	be$$$100$$$102$$$O	in$$$103$$$105$$$O	a$$$106$$$107$$$O	composition$$$108$$$119$$$O	with$$$120$$$124$$$O	either$$$125$$$131$$$O	a$$$132$$$133$$$O	pharmacologically$$$134$$$151$$$O	or$$$152$$$154$$$O	cosmetically$$$155$$$167$$$O	acceptable$$$168$$$178$$$O	medium.$$$179$$$186$$$O	Depending$$$187$$$196$$$O	upon$$$197$$$201$$$O	the$$$202$$$205$$$O	medium$$$206$$$212$$$O	and$$$213$$$216$$$O	concentration$$$217$$$230$$$O	of$$$231$$$233$$$O	the$$$234$$$237$$$O	compound,$$$238$$$247$$$O	the$$$248$$$251$$$O	composition$$$252$$$263$$$O	may$$$264$$$267$$$O	be$$$268$$$270$$$O	used$$$271$$$275$$$O	either$$$276$$$282$$$O	therapeutically$$$283$$$298$$$O	or$$$299$$$301$$$O	non-therapeutically.$$$302$$$322$$$O
US7265131
For$$$0$$$3$$$O	therapy$$$4$$$11$$$O	of$$$12$$$14$$$O	disease-states$$$15$$$29$$$O	associated$$$30$$$40$$$O	with$$$41$$$45$$$O	nuclear$$$46$$$53$$$O	receptor$$$54$$$62$$$O	activity$$$63$$$71$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	(I):$$$21$$$25$$$O	wherein$$$45$$$52$$$O	n,$$$53$$$55$$$O	R1,$$$56$$$59$$$O	R2,$$$60$$$63$$$O	R3$$$64$$$66$$$O	and$$$67$$$70$$$O	R7$$$71$$$73$$$O	are$$$74$$$77$$$O	disclosed$$$78$$$87$$$O	herein,$$$88$$$95$$$O	are$$$96$$$99$$$O	useful$$$100$$$106$$$O	in$$$107$$$109$$$O	treating$$$110$$$118$$$O	disease-states$$$119$$$133$$$O	associated$$$134$$$144$$$O	with$$$145$$$149$$$O	nuclear$$$150$$$157$$$O	receptor$$$158$$$166$$$O	activity.$$$167$$$176$$$O	Pharmaceutical$$$177$$$191$$$O	compositions$$$192$$$204$$$O	comprising$$$205$$$215$$$O	and$$$216$$$219$$$O	methods$$$220$$$227$$$O	of$$$228$$$230$$$O	using$$$231$$$236$$$O	said$$$237$$$241$$$O	compounds$$$242$$$251$$$O	are$$$252$$$255$$$O	also$$$256$$$260$$$O	disclosed$$$261$$$270$$$O	herein.$$$271$$$278$$$O
WO2012052668A1
Novel$$$0$$$5$$$O	benzothiophene$$$6$$$20$$$I	derivatives$$$21$$$32$$$O	with$$$33$$$37$$$O	tnap-inhibiting$$$38$$$53$$$O	activity$$$54$$$62$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	formula$$$46$$$53$$$O	(I):$$$54$$$58$$$O	in$$$59$$$61$$$O	which$$$62$$$67$$$O	R1,$$$68$$$71$$$O	R2,$$$72$$$75$$$O	R3,$$$76$$$79$$$O	R4,$$$80$$$83$$$O	R5,$$$84$$$87$$$O	R6,$$$88$$$91$$$O	X$$$92$$$93$$$O	and$$$94$$$97$$$O	Y$$$98$$$99$$$O	are$$$100$$$103$$$O	as$$$104$$$106$$$O	defined$$$107$$$114$$$O	in$$$115$$$117$$$O	claim$$$118$$$123$$$O	1,$$$124$$$126$$$O	to$$$127$$$129$$$O	the$$$130$$$133$$$O	use$$$134$$$137$$$O	thereof$$$138$$$145$$$O	as$$$146$$$148$$$O	a$$$149$$$150$$$O	medicament,$$$151$$$162$$$O	and$$$163$$$166$$$O	in$$$167$$$169$$$O	particular$$$170$$$180$$$O	for$$$181$$$184$$$O	treating$$$185$$$193$$$O	arthrosis$$$194$$$203$$$O	or$$$204$$$206$$$O	vascular$$$207$$$215$$$O	calcifications,$$$216$$$231$$$O	and$$$232$$$235$$$O	also$$$236$$$240$$$O	to$$$241$$$243$$$O	the$$$244$$$247$$$O	pharmaceutical$$$248$$$262$$$O	compositions$$$263$$$275$$$O	containing$$$276$$$286$$$O	same,$$$287$$$292$$$O	in$$$293$$$295$$$O	combination$$$296$$$307$$$O	with$$$308$$$312$$$O	at$$$313$$$315$$$O	least$$$316$$$321$$$O	one$$$322$$$325$$$O	pharmaceutically$$$326$$$342$$$O	acceptable$$$343$$$353$$$O	excipient.$$$354$$$364$$$O
WO2007055378A1
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	treatment$$$11$$$20$$$O	or$$$21$$$23$$$O	prevention$$$24$$$34$$$O	of$$$35$$$37$$$O	disease$$$38$$$45$$$O	associated$$$46$$$56$$$O	with$$$57$$$61$$$O	functional$$$62$$$72$$$O	disorder$$$73$$$81$$$O	of$$$82$$$84$$$O	regulatory$$$85$$$95$$$O	t$$$96$$$97$$$O	cell$$$98$$$102$$$O
Examine$$$0$$$7$$$O	is$$$8$$$10$$$O	made$$$11$$$15$$$O	on$$$16$$$18$$$O	the$$$19$$$22$$$O	role$$$23$$$27$$$O	of$$$28$$$30$$$O	MK$$$31$$$33$$$O	in$$$34$$$36$$$O	experimental$$$37$$$49$$$O	autoimmune$$$50$$$60$$$O	encephalomyelitis$$$61$$$78$$$O	which$$$79$$$84$$$O	is$$$85$$$87$$$O	a$$$88$$$89$$$O	human$$$90$$$95$$$O	multiple$$$96$$$104$$$O	sclerosis$$$105$$$114$$$O	model.$$$115$$$121$$$O	As$$$122$$$124$$$O	a$$$125$$$126$$$O	result,$$$127$$$134$$$O	it$$$135$$$137$$$O	is$$$138$$$140$$$O	found$$$141$$$146$$$O	that$$$147$$$151$$$O	MK$$$152$$$154$$$O	has$$$155$$$158$$$O	An$$$159$$$161$$$O	inhibitory$$$162$$$172$$$O	effect$$$173$$$179$$$O	on$$$180$$$182$$$O	a$$$183$$$184$$$O	regulatory$$$185$$$195$$$O	T$$$196$$$197$$$O	cell$$$198$$$202$$$O	and$$$203$$$206$$$O	that$$$207$$$211$$$O	the$$$212$$$215$$$O	amount$$$216$$$222$$$O	of$$$223$$$225$$$O	a$$$226$$$227$$$O	regulatory$$$228$$$238$$$O	T$$$239$$$240$$$O	cell$$$241$$$245$$$O	can$$$246$$$249$$$O	be$$$250$$$252$$$O	increased$$$253$$$262$$$O	and$$$263$$$266$$$O	the$$$267$$$270$$$O	autoimmunity$$$271$$$283$$$O	mechanism$$$284$$$293$$$O	induced$$$294$$$301$$$O	by$$$302$$$304$$$O	type$$$305$$$309$$$O	1$$$310$$$311$$$O	helper$$$312$$$318$$$O	T$$$319$$$320$$$O	cell$$$321$$$325$$$O	can$$$326$$$329$$$O	be$$$330$$$332$$$O	suppressed$$$333$$$343$$$O	by$$$344$$$346$$$O	inhibiting$$$347$$$357$$$O	the$$$358$$$361$$$O	expression$$$362$$$372$$$O	or$$$373$$$375$$$O	activity$$$376$$$384$$$O	of$$$385$$$387$$$O	MK.$$$388$$$391$$$O	It$$$392$$$394$$$O	is$$$395$$$397$$$O	also$$$398$$$402$$$O	found$$$403$$$408$$$O	that$$$409$$$413$$$O	a$$$414$$$415$$$O	disease$$$416$$$423$$$O	associated$$$424$$$434$$$O	with$$$435$$$439$$$O	functional$$$440$$$450$$$O	disorder$$$451$$$459$$$O	of$$$460$$$462$$$O	a$$$463$$$464$$$O	regulatory$$$465$$$475$$$O	T$$$476$$$477$$$O	cell$$$478$$$482$$$O	can$$$483$$$486$$$O	be$$$487$$$489$$$O	treated$$$490$$$497$$$O	by$$$498$$$500$$$O	administering$$$501$$$514$$$O	an$$$515$$$517$$$O	inhibitor$$$518$$$527$$$O	capable$$$528$$$535$$$O	of$$$536$$$538$$$O	inhibiting$$$539$$$549$$$O	the$$$550$$$553$$$O	expression$$$554$$$564$$$O	or$$$565$$$567$$$O	activity$$$568$$$576$$$O	of$$$577$$$579$$$O	MK.$$$580$$$583$$$O
US20060083692
Combination$$$0$$$11$$$O	of$$$12$$$14$$$O	formoterol$$$15$$$25$$$I	and$$$26$$$29$$$O	a$$$30$$$31$$$O	tiotropium$$$32$$$42$$$I	salt$$$43$$$47$$$O
A$$$0$$$1$$$O	medicament$$$2$$$12$$$O	containing,$$$13$$$24$$$O	separately$$$25$$$35$$$O	or$$$36$$$38$$$O	together,$$$39$$$48$$$O	(A)$$$49$$$52$$$O	formoterol$$$53$$$63$$$I	or$$$64$$$66$$$O	a$$$67$$$68$$$O	pharmaceutically$$$69$$$85$$$O	acceptable$$$86$$$96$$$O	salt$$$97$$$101$$$O	thereof$$$102$$$109$$$O	or$$$110$$$112$$$O	a$$$113$$$114$$$O	solvate$$$115$$$122$$$O	of$$$123$$$125$$$O	formoterol$$$126$$$136$$$I	or$$$137$$$139$$$O	said$$$140$$$144$$$O	salt$$$145$$$149$$$O	and$$$150$$$153$$$O	(B)$$$154$$$157$$$O	a$$$158$$$159$$$O	tiotropium$$$160$$$170$$$I	salt$$$171$$$175$$$O	of$$$176$$$178$$$O	a$$$179$$$180$$$O	pharmaceutically$$$181$$$197$$$O	acceptable$$$198$$$208$$$O	acid,$$$209$$$214$$$O	for$$$215$$$218$$$O	simultaneous,$$$219$$$232$$$O	sequential$$$233$$$243$$$O	or$$$244$$$246$$$O	separate$$$247$$$255$$$O	administration$$$256$$$270$$$O	in$$$271$$$273$$$O	the$$$274$$$277$$$O	treatment$$$278$$$287$$$O	of$$$288$$$290$$$O	an$$$291$$$293$$$O	inflammatory$$$294$$$306$$$O	or$$$307$$$309$$$O	obstructive$$$310$$$321$$$O	airways$$$322$$$329$$$O	disease.$$$330$$$338$$$O
WO2013191242A1
Test$$$0$$$4$$$O	method$$$5$$$11$$$O	and$$$12$$$15$$$O	treatment$$$16$$$25$$$O	means$$$26$$$31$$$O	for$$$32$$$35$$$O	small$$$36$$$41$$$O	cell$$$42$$$46$$$O	lung$$$47$$$51$$$O	cancer$$$52$$$58$$$O	having$$$59$$$65$$$O	poor$$$66$$$70$$$O	prognosis$$$71$$$80$$$O
[Problem]$$$0$$$9$$$O	In$$$10$$$12$$$O	small$$$13$$$18$$$O	cell$$$19$$$23$$$O	lung$$$24$$$28$$$O	cancer$$$29$$$35$$$O	(SCLC),$$$36$$$43$$$O	there$$$44$$$49$$$O	are$$$50$$$53$$$O	a$$$54$$$55$$$O	type$$$56$$$60$$$O	having$$$61$$$67$$$O	poor$$$68$$$72$$$O	prognosis$$$73$$$82$$$O	and$$$83$$$86$$$O	a$$$87$$$88$$$O	type$$$89$$$93$$$O	having$$$94$$$100$$$O	good$$$101$$$105$$$O	prognosis.$$$106$$$116$$$O	It$$$117$$$119$$$O	has$$$120$$$123$$$O	been$$$124$$$128$$$O	demanded$$$129$$$137$$$O	to$$$138$$$140$$$O	detect$$$141$$$147$$$O	small$$$148$$$153$$$O	cell$$$154$$$158$$$O	lung$$$159$$$163$$$O	cancer$$$164$$$170$$$O	at$$$171$$$173$$$O	an$$$174$$$176$$$O	earlier$$$177$$$184$$$O	stage$$$185$$$190$$$O	and$$$191$$$194$$$O	establish$$$195$$$204$$$O	a$$$205$$$206$$$O	treatment$$$207$$$216$$$O	method$$$217$$$223$$$O	for$$$224$$$227$$$O	small$$$228$$$233$$$O	cell$$$234$$$238$$$O	lung$$$239$$$243$$$O	cancer.$$$244$$$251$$$O	The$$$252$$$255$$$O	present$$$256$$$263$$$O	invention$$$264$$$273$$$O	provides:$$$274$$$283$$$O	a$$$284$$$285$$$O	test$$$286$$$290$$$O	method$$$291$$$297$$$O	which$$$298$$$303$$$O	can$$$304$$$307$$$O	detect$$$308$$$314$$$O	small$$$315$$$320$$$O	cell$$$321$$$325$$$O	lung$$$326$$$330$$$O	cancer$$$331$$$337$$$O	having$$$338$$$344$$$O	poor$$$345$$$349$$$O	prognosis;$$$350$$$360$$$O	a$$$361$$$362$$$O	means$$$363$$$368$$$O	for$$$369$$$372$$$O	treating$$$373$$$381$$$O	small$$$382$$$387$$$O	cell$$$388$$$392$$$O	lung$$$393$$$397$$$O	cancer$$$398$$$404$$$O	having$$$405$$$411$$$O	poor$$$412$$$416$$$O	prognosis;$$$417$$$427$$$O	and$$$428$$$431$$$O	a$$$432$$$433$$$O	method$$$434$$$440$$$O	for$$$441$$$444$$$O	screening$$$445$$$454$$$O	for$$$455$$$458$$$O	a$$$459$$$460$$$O	drug$$$461$$$465$$$O	for$$$466$$$469$$$O	treating$$$470$$$478$$$O	small$$$479$$$484$$$O	cell$$$485$$$489$$$O	lung$$$490$$$494$$$O	cancer$$$495$$$501$$$O	having$$$502$$$508$$$O	poor$$$509$$$513$$$O	prognosis.$$$514$$$524$$$O	[Solution]$$$525$$$535$$$O	It$$$536$$$538$$$O	is$$$539$$$541$$$O	found$$$542$$$547$$$O	that$$$548$$$552$$$O	HOTAIR$$$553$$$559$$$O	(for$$$560$$$564$$$O	which$$$565$$$570$$$O	cDNA$$$571$$$575$$$O	comprises$$$576$$$585$$$O	the$$$586$$$589$$$O	nucleotide$$$590$$$600$$$O	sequence$$$601$$$609$$$O	represented$$$610$$$621$$$O	by$$$622$$$624$$$O	SEQ$$$625$$$628$$$O	ID$$$629$$$631$$$O	NO:$$$632$$$635$$$O	1),$$$636$$$639$$$O	which$$$640$$$645$$$O	is$$$646$$$648$$$O	lincRNA,$$$649$$$657$$$O	is$$$658$$$660$$$O	highly$$$661$$$667$$$O	expressed$$$668$$$677$$$O	in$$$678$$$680$$$O	small$$$681$$$686$$$O	cell$$$687$$$691$$$O	lung$$$692$$$696$$$O	cancer$$$697$$$703$$$O	having$$$704$$$710$$$O	poor$$$711$$$715$$$O	prognosis.$$$716$$$726$$$O	The$$$727$$$730$$$O	present$$$731$$$738$$$O	invention$$$739$$$748$$$O	is$$$749$$$751$$$O	a$$$752$$$753$$$O	diagnosis$$$754$$$763$$$O	method$$$764$$$770$$$O	for$$$771$$$774$$$O	determining$$$775$$$786$$$O	whether$$$787$$$794$$$O	or$$$795$$$797$$$O	not$$$798$$$801$$$O	small$$$802$$$807$$$O	cell$$$808$$$812$$$O	lung$$$813$$$817$$$O	cancer$$$818$$$824$$$O	is$$$825$$$827$$$O	one$$$828$$$831$$$O	having$$$832$$$838$$$O	poor$$$839$$$843$$$O	prognosis,$$$844$$$854$$$O	wherein$$$855$$$862$$$O	the$$$863$$$866$$$O	prognosis$$$867$$$876$$$O	of$$$877$$$879$$$O	the$$$880$$$883$$$O	small$$$884$$$889$$$O	cell$$$890$$$894$$$O	lung$$$895$$$899$$$O	cancer$$$900$$$906$$$O	is$$$907$$$909$$$O	determined$$$910$$$920$$$O	as$$$921$$$923$$$O	being$$$924$$$929$$$O	poorer$$$930$$$936$$$O	when$$$937$$$941$$$O	the$$$942$$$945$$$O	amount$$$946$$$952$$$O	of$$$953$$$955$$$O	HOTAIR,$$$956$$$963$$$O	which$$$964$$$969$$$O	is$$$970$$$972$$$O	lincRNA,$$$973$$$981$$$O	expressed$$$982$$$991$$$O	in$$$992$$$994$$$O	a$$$995$$$996$$$O	sample$$$997$$$1003$$$O	of$$$1004$$$1006$$$O	the$$$1007$$$1010$$$O	small$$$1011$$$1016$$$O	cell$$$1017$$$1021$$$O	lung$$$1022$$$1026$$$O	cancer$$$1027$$$1033$$$O	is$$$1034$$$1036$$$O	higher.$$$1037$$$1044$$$O	Further,$$$1045$$$1053$$$O	siRNA$$$1054$$$1059$$$O	which$$$1060$$$1065$$$O	can$$$1066$$$1069$$$O	inhibit$$$1070$$$1077$$$O	the$$$1078$$$1081$$$O	proliferation$$$1082$$$1095$$$O	of$$$1096$$$1098$$$O	small$$$1099$$$1104$$$O	cell$$$1105$$$1109$$$O	lung$$$1110$$$1114$$$O	cancer$$$1115$$$1121$$$O	in$$$1122$$$1124$$$O	which$$$1125$$$1130$$$O	HOTAIR$$$1131$$$1137$$$O	is$$$1138$$$1140$$$O	highly$$$1141$$$1147$$$O	expressed$$$1148$$$1157$$$O	is$$$1158$$$1160$$$O	discovered.$$$1161$$$1172$$$O
US20080260878
Topical;$$$0$$$8$$$O	adenosine$$$9$$$18$$$I	5'-monophosphates$$$19$$$36$$$I	and$$$37$$$40$$$O	salts$$$41$$$46$$$O	thereof;$$$47$$$55$$$O	arbutins,$$$56$$$65$$$I	ellagic$$$66$$$73$$$I	acid,$$$74$$$79$$$I	4-alkylresorcinols,$$$80$$$99$$$I	linolic$$$100$$$107$$$I	acid,$$$108$$$113$$$I	tranexamic$$$114$$$124$$$I	acid,$$$125$$$130$$$I	chamomile$$$131$$$140$$$O	extracts,$$$141$$$150$$$O	ubiquinones;$$$151$$$163$$$I	chloasma,$$$164$$$173$$$O	freckles$$$174$$$182$$$O
A$$$0$$$1$$$O	composition$$$2$$$13$$$O	for$$$14$$$17$$$O	the$$$18$$$21$$$O	prevention$$$22$$$32$$$O	or$$$33$$$35$$$O	alleviation$$$36$$$47$$$O	of$$$48$$$50$$$O	pigmentation$$$51$$$63$$$O	which$$$64$$$69$$$O	can$$$70$$$73$$$O	produce$$$74$$$81$$$O	the$$$82$$$85$$$O	higher$$$86$$$92$$$O	effect$$$93$$$99$$$O	of$$$100$$$102$$$O	preventing$$$103$$$113$$$O	or$$$114$$$116$$$O	alleviating$$$117$$$128$$$O	pigmentation.$$$129$$$142$$$O	The$$$143$$$146$$$O	composition$$$147$$$158$$$O	for$$$159$$$162$$$O	the$$$163$$$166$$$O	prevention$$$167$$$177$$$O	or$$$178$$$180$$$O	alleviation$$$181$$$192$$$O	of$$$193$$$195$$$O	pigmentation$$$196$$$208$$$O	comprises$$$209$$$218$$$O	a$$$219$$$220$$$O	combination$$$221$$$232$$$O	of$$$233$$$235$$$O	(A)$$$236$$$239$$$O	at$$$240$$$242$$$O	least$$$243$$$248$$$O	one$$$249$$$252$$$O	member$$$253$$$259$$$O	selected$$$260$$$268$$$O	from$$$269$$$273$$$O	the$$$274$$$277$$$O	group$$$278$$$283$$$O	consisting$$$284$$$294$$$O	of$$$295$$$297$$$O	adenosine$$$298$$$307$$$I	5â²-monophosphate$$$308$$$326$$$I	and$$$327$$$330$$$O	salts$$$331$$$336$$$O	thereof$$$337$$$344$$$O	with$$$345$$$349$$$O	(B)$$$350$$$353$$$O	at$$$354$$$356$$$O	least$$$357$$$362$$$O	one$$$363$$$366$$$O	member$$$367$$$373$$$O	selected$$$374$$$382$$$O	from$$$383$$$387$$$O	the$$$388$$$391$$$O	group$$$392$$$397$$$O	consisting$$$398$$$408$$$O	of$$$409$$$411$$$I	arbutin,$$$412$$$420$$$I	ellagic$$$421$$$428$$$I	acid,$$$429$$$434$$$I	4-alkylresorcinols,$$$435$$$454$$$I	linoleic$$$455$$$463$$$I	acid,$$$464$$$469$$$I	tranexamic$$$470$$$480$$$I	acid,$$$481$$$486$$$I	salts$$$487$$$492$$$O	of$$$493$$$495$$$O	these,$$$496$$$502$$$O	Chamomilla$$$503$$$513$$$O	recuita$$$514$$$521$$$O	extract,$$$522$$$530$$$O	and$$$531$$$534$$$I	Ubiquinone.$$$535$$$546$$$I
US7090846
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	polycation$$$21$$$31$$$O	based$$$32$$$37$$$O	bioconjugates$$$38$$$51$$$O	suitable$$$52$$$60$$$O	for$$$61$$$64$$$O	transporting$$$65$$$77$$$O	different$$$78$$$87$$$O	kinds$$$88$$$93$$$O	of$$$94$$$96$$$O	active$$$97$$$103$$$O	substances$$$104$$$114$$$O	within$$$115$$$121$$$O	the$$$122$$$125$$$O	body$$$126$$$130$$$O
Polycation$$$0$$$10$$$O	bioconjugates$$$11$$$24$$$O	and$$$25$$$28$$$O	a$$$29$$$30$$$O	method$$$31$$$37$$$O	for$$$38$$$41$$$O	producing$$$42$$$51$$$O	them.$$$52$$$57$$$O	The$$$58$$$61$$$O	polycations$$$62$$$73$$$O	are$$$74$$$77$$$O	capable$$$78$$$85$$$O	of$$$86$$$88$$$O	transporting$$$89$$$101$$$O	active$$$102$$$108$$$O	substances$$$109$$$119$$$O	of$$$120$$$122$$$O	different$$$123$$$132$$$O	types.$$$133$$$139$$$O	The$$$140$$$143$$$O	polycations$$$144$$$155$$$O	function$$$156$$$164$$$O	as$$$165$$$167$$$O	carrier$$$168$$$175$$$O	molecules$$$176$$$185$$$O	that$$$186$$$190$$$O	transport$$$191$$$200$$$O	enhancer$$$201$$$209$$$O	molecules,$$$210$$$220$$$O	thereby$$$221$$$228$$$O	enhancing$$$229$$$238$$$O	the$$$239$$$242$$$O	biological$$$243$$$253$$$O	effectiveness$$$254$$$267$$$O	of$$$268$$$270$$$O	the$$$271$$$274$$$O	transported$$$275$$$286$$$O	molecules.$$$287$$$297$$$O	The$$$298$$$301$$$O	polycation$$$302$$$312$$$O	bioconjugates$$$313$$$326$$$O	of$$$327$$$329$$$O	the$$$330$$$333$$$O	present$$$334$$$341$$$O	invention$$$342$$$351$$$O	may$$$352$$$355$$$O	inhibit$$$356$$$363$$$O	malignant$$$364$$$373$$$O	cell$$$374$$$378$$$O	proliferation,$$$379$$$393$$$O	possess$$$394$$$401$$$O	antimicrobial$$$402$$$415$$$O	effect,$$$416$$$423$$$O	or$$$424$$$426$$$O	be$$$427$$$429$$$O	configured$$$430$$$440$$$O	for$$$441$$$444$$$O	gene$$$445$$$449$$$O	transport.$$$450$$$460$$$O
WO2014111069A1
Helquat$$$0$$$7$$$I	derivatives,$$$8$$$20$$$O	preparation$$$21$$$32$$$O	thereof,$$$33$$$41$$$O	and$$$42$$$45$$$O	use$$$46$$$49$$$O	thereof$$$50$$$57$$$O	as$$$58$$$60$$$O	medicaments$$$61$$$72$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	helquat$$$23$$$30$$$I	derivatives$$$31$$$42$$$O	of$$$43$$$45$$$O	general$$$46$$$53$$$O	formula$$$54$$$61$$$O	I,$$$62$$$64$$$O	wherein$$$65$$$72$$$O	substituents$$$73$$$85$$$O	R1$$$86$$$88$$$O	and$$$89$$$92$$$O	R2$$$93$$$95$$$O	are$$$96$$$99$$$O	independently$$$100$$$113$$$O	selected$$$114$$$122$$$O	from$$$123$$$127$$$O	a$$$128$$$129$$$O	group$$$130$$$135$$$O	comprising$$$136$$$146$$$O	H$$$147$$$148$$$I	and$$$149$$$152$$$O	C1$$$153$$$155$$$I	to$$$156$$$158$$$I	C3$$$159$$$161$$$I	alkyl;$$$162$$$168$$$I	up$$$169$$$171$$$O	to$$$172$$$174$$$O	three$$$175$$$180$$$O	of$$$181$$$183$$$O	S1,2,$$$184$$$189$$$O	S1',2',$$$190$$$197$$$O	S3,4$$$198$$$202$$$O	and$$$203$$$206$$$O	S3',4'$$$207$$$213$$$O	are$$$214$$$217$$$O	present,$$$218$$$226$$$O	each$$$227$$$231$$$O	of$$$232$$$234$$$O	S1,2,$$$235$$$240$$$O	S1',2',$$$241$$$248$$$O	S3,4$$$249$$$253$$$O	and$$$254$$$257$$$O	S3',4'$$$258$$$264$$$O	independently$$$265$$$278$$$O	represents$$$279$$$289$$$O	a$$$290$$$291$$$O	linker$$$292$$$298$$$O	consisting$$$299$$$309$$$O	of$$$310$$$312$$$O	a$$$313$$$314$$$O	bivalent$$$315$$$323$$$O	hydrocarbon$$$324$$$335$$$I	chain$$$336$$$341$$$O	having$$$342$$$348$$$O	3-6$$$349$$$352$$$O	carbon$$$353$$$359$$$I	atoms;$$$360$$$366$$$O	one$$$367$$$370$$$O	or$$$371$$$373$$$O	two$$$374$$$377$$$O	atoms$$$378$$$383$$$O	selected$$$384$$$392$$$O	from$$$393$$$397$$$O	the$$$398$$$401$$$O	carbon$$$402$$$408$$$I	atoms$$$409$$$414$$$O	with$$$415$$$419$$$O	the$$$420$$$423$$$O	descriptor$$$424$$$434$$$O	2,$$$435$$$437$$$O	4,$$$438$$$440$$$O	2',$$$441$$$444$$$O	and$$$445$$$448$$$O	4'$$$449$$$451$$$O	are$$$452$$$455$$$O	substituted$$$456$$$467$$$O	with$$$468$$$472$$$O	a$$$473$$$474$$$O	substituent$$$475$$$486$$$O	R3$$$487$$$489$$$O	of$$$490$$$492$$$O	general$$$493$$$500$$$O	formula$$$501$$$508$$$O	(II)$$$509$$$513$$$O	or$$$514$$$516$$$O	general$$$517$$$524$$$O	formula$$$525$$$532$$$O	(III)$$$533$$$538$$$O	wherein$$$539$$$546$$$O	R4$$$547$$$549$$$O	is$$$550$$$552$$$O	substituted$$$553$$$564$$$O	or$$$565$$$567$$$O	unsubstituted$$$568$$$581$$$O	aryl;$$$582$$$587$$$I	T1$$$588$$$590$$$O	and$$$591$$$594$$$O	T2$$$595$$$597$$$O	independently$$$598$$$611$$$O	represent$$$612$$$621$$$O	a$$$622$$$623$$$O	bivalent$$$624$$$632$$$O	hydrocarbon$$$633$$$644$$$I	chain$$$645$$$650$$$O	having$$$651$$$657$$$O	2-5$$$658$$$661$$$O	carbon$$$662$$$668$$$I	atoms;$$$669$$$675$$$O	and$$$676$$$679$$$O	anions$$$680$$$686$$$O	(X1)-$$$687$$$692$$$O	and$$$693$$$696$$$O	(X2)-$$$697$$$702$$$O	independently$$$703$$$716$$$O	represent$$$717$$$726$$$O	anions$$$727$$$733$$$O	of$$$734$$$736$$$O	pharmaceutically$$$737$$$753$$$O	acceptable$$$754$$$764$$$O	salts.$$$765$$$771$$$O	The$$$772$$$775$$$O	helquat$$$776$$$783$$$I	derivatives$$$784$$$795$$$O	are$$$796$$$799$$$O	useful$$$800$$$806$$$O	as$$$807$$$809$$$O	medicaments$$$810$$$821$$$O	in$$$822$$$824$$$O	the$$$825$$$828$$$O	treatment$$$829$$$838$$$O	of$$$839$$$841$$$O	diseases$$$842$$$850$$$O	related$$$851$$$858$$$O	to$$$859$$$861$$$O	increased$$$862$$$871$$$O	cellular$$$872$$$880$$$O	proliferation,$$$881$$$895$$$O	such$$$896$$$900$$$O	as$$$901$$$903$$$O	oncologic$$$904$$$913$$$O	diseases.$$$914$$$923$$$O	Ë$$$924$$$926$$$O
WO2013028880A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	zileuton$$$7$$$15$$$I	for$$$16$$$19$$$O	the$$$20$$$23$$$O	treatment$$$24$$$33$$$O	of$$$34$$$36$$$O	nasal$$$37$$$42$$$O	polyps$$$43$$$49$$$O	in$$$50$$$52$$$O	cystic$$$53$$$59$$$O	fibrosis$$$60$$$68$$$O	patients$$$69$$$77$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	methods$$$31$$$38$$$O	of$$$39$$$41$$$O	treating$$$42$$$50$$$O	nasal$$$51$$$56$$$O	polyps$$$57$$$63$$$O	in$$$64$$$66$$$O	cystic$$$67$$$73$$$O	fibrosis$$$74$$$82$$$O	patients$$$83$$$91$$$O	using$$$92$$$97$$$O	zileuton.$$$98$$$107$$$I	The$$$108$$$111$$$O	present$$$112$$$119$$$O	invention$$$120$$$129$$$O	also$$$130$$$134$$$O	provides$$$135$$$143$$$O	methods$$$144$$$151$$$O	of$$$152$$$154$$$O	treating$$$155$$$163$$$O	nasal$$$164$$$169$$$O	polyps$$$170$$$176$$$O	in$$$177$$$179$$$O	cystic$$$180$$$186$$$O	fibrosis$$$187$$$195$$$O	patients$$$196$$$204$$$O	using$$$205$$$210$$$O	zileuton$$$211$$$219$$$I	in$$$220$$$222$$$O	combination$$$223$$$234$$$O	with$$$235$$$239$$$O	surgical$$$240$$$248$$$O	debridement$$$249$$$260$$$O	and/or$$$261$$$267$$$O	steroid$$$268$$$275$$$I	treatment.$$$276$$$286$$$O
US20080090909
negative$$$0$$$8$$$O	regulator$$$9$$$18$$$O	of$$$19$$$21$$$O	cell$$$22$$$26$$$O	growth$$$27$$$33$$$O	factor$$$34$$$40$$$O	receptor;$$$41$$$50$$$O	pelorol$$$51$$$58$$$I	(benzo(a)fluorene)$$$59$$$77$$$I	related$$$78$$$85$$$O	compounds$$$86$$$95$$$O	from$$$96$$$100$$$O	marine$$$101$$$107$$$O	sponge$$$108$$$114$$$O	species;$$$115$$$123$$$O	antiinflammatory,$$$124$$$141$$$O	antitumor$$$142$$$151$$$O	agent,$$$152$$$158$$$O	immunostimulant;$$$159$$$175$$$O	control$$$176$$$183$$$O	gene$$$184$$$188$$$O	expression,$$$189$$$200$$$O	differentiation,$$$201$$$217$$$O	metabolism,$$$218$$$229$$$O	phospholipid$$$230$$$242$$$I	signaling$$$243$$$252$$$O	pathway,$$$253$$$261$$$O	signal$$$262$$$268$$$O	tansduction$$$269$$$280$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	includes$$$22$$$30$$$O	the$$$31$$$34$$$O	use$$$35$$$38$$$O	of$$$39$$$41$$$O	pelorol,$$$42$$$50$$$I	related$$$51$$$58$$$O	compounds$$$59$$$68$$$O	and$$$69$$$72$$$O	pharmaceutical$$$73$$$87$$$O	compositions$$$88$$$100$$$O	thereof$$$101$$$108$$$O	as$$$109$$$111$$$O	modulators$$$112$$$122$$$O	of$$$123$$$125$$$O	SHIP$$$126$$$130$$$O	1$$$131$$$132$$$O	activity.$$$133$$$142$$$O	This$$$143$$$147$$$O	invention$$$148$$$157$$$O	also$$$158$$$162$$$O	provides$$$163$$$171$$$O	novel$$$172$$$177$$$O	terpene$$$178$$$185$$$I	compounds$$$186$$$195$$$O	capable$$$196$$$203$$$O	of$$$204$$$206$$$O	modulating$$$207$$$217$$$O	SHIP$$$218$$$222$$$O	1$$$223$$$224$$$O	activity$$$225$$$233$$$O	and$$$234$$$237$$$O	methods$$$238$$$245$$$O	of$$$246$$$248$$$O	synthesis$$$249$$$258$$$O	thereof.$$$259$$$267$$$O
EP1244445B1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	azoles$$$7$$$13$$$I	for$$$14$$$17$$$O	preventing$$$18$$$28$$$O	skin$$$29$$$33$$$O	cancer$$$34$$$40$$$O	due$$$41$$$44$$$O	to$$$45$$$47$$$O	radiation$$$48$$$57$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	azoles$$$25$$$31$$$I	which$$$32$$$37$$$O	are$$$38$$$41$$$O	suitable$$$42$$$50$$$O	for$$$51$$$54$$$O	the$$$55$$$58$$$O	prevention$$$59$$$69$$$O	of$$$70$$$72$$$O	irradiation-induced$$$73$$$92$$$O	skin$$$93$$$97$$$O	cancer.$$$98$$$105$$$O
WO2008016677A2
Preparation$$$0$$$11$$$O	and$$$12$$$15$$$O	utility$$$16$$$23$$$O	of$$$24$$$26$$$O	deuterated$$$27$$$37$$$O	amphetamines$$$38$$$50$$$I
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	deuterated$$$20$$$30$$$O	amphetamines,$$$31$$$44$$$I	processes$$$45$$$54$$$O	of$$$55$$$57$$$O	preparation$$$58$$$69$$$O	and$$$70$$$73$$$O	pharmaceutical$$$74$$$88$$$O	compositions$$$89$$$101$$$O	thereof.$$$102$$$110$$$O	Also$$$111$$$115$$$O	provided$$$116$$$124$$$O	are$$$125$$$128$$$O	methods$$$129$$$136$$$O	of$$$137$$$139$$$O	their$$$140$$$145$$$O	use$$$146$$$149$$$O	for$$$150$$$153$$$O	the$$$154$$$157$$$O	treatment$$$158$$$167$$$O	and/or$$$168$$$174$$$O	management$$$175$$$185$$$O	of$$$186$$$188$$$O	trauma$$$189$$$195$$$O	associated$$$196$$$206$$$O	with$$$207$$$211$$$O	a$$$212$$$213$$$O	terminal$$$214$$$222$$$O	disease,$$$223$$$231$$$O	a$$$232$$$233$$$O	post-traumatic-$$$234$$$249$$$O	stress-disorder,$$$250$$$266$$$O	or$$$267$$$269$$$O	a$$$270$$$271$$$O	psychological$$$272$$$285$$$O	disorder.$$$286$$$295$$$O
US7074921
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	preparation$$$16$$$27$$$O	of$$$28$$$30$$$O	3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine$$$31$$$89$$$I	compounds$$$90$$$99$$$O
Methods$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	synthesis$$$16$$$25$$$O	of$$$26$$$28$$$O	benzodiazepine$$$29$$$43$$$I	compounds$$$44$$$53$$$O	having$$$54$$$60$$$O	farnesyl$$$61$$$69$$$I	protein$$$70$$$77$$$O	transferase$$$78$$$89$$$O	inhibitory$$$90$$$100$$$O	activity.$$$101$$$110$$$O
CN103130791A
Novel$$$0$$$5$$$O	benzamides$$$6$$$16$$$I	compound$$$17$$$25$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	field$$$29$$$34$$$O	of$$$35$$$37$$$O	medicinal$$$38$$$47$$$O	chemistry,$$$48$$$58$$$O	in$$$59$$$61$$$O	particular$$$62$$$72$$$O	to$$$73$$$75$$$O	a$$$76$$$77$$$O	novel$$$78$$$83$$$O	benzamides$$$84$$$94$$$I	compound$$$95$$$103$$$O	or$$$104$$$106$$$O	a$$$107$$$108$$$O	salt$$$109$$$113$$$O	acceptable$$$114$$$124$$$O	in$$$125$$$127$$$O	parmacy$$$128$$$135$$$O	of$$$136$$$138$$$O	the$$$139$$$142$$$O	novel$$$143$$$148$$$O	benzamides$$$149$$$159$$$I	compound,$$$160$$$169$$$O	a$$$170$$$171$$$O	preparation$$$172$$$183$$$O	method$$$184$$$190$$$O	of$$$191$$$193$$$O	the$$$194$$$197$$$O	novel$$$198$$$203$$$O	benzamides$$$204$$$214$$$I	compound,$$$215$$$224$$$O	a$$$225$$$226$$$O	pharmaceutical$$$227$$$241$$$O	composition$$$242$$$253$$$O	containing$$$254$$$264$$$O	the$$$265$$$268$$$O	novel$$$269$$$274$$$O	benzamides$$$275$$$285$$$I	compound$$$286$$$294$$$O	and$$$295$$$298$$$O	an$$$299$$$301$$$O	application$$$302$$$313$$$O	of$$$314$$$316$$$O	the$$$317$$$320$$$O	pharmaceutical$$$321$$$335$$$O	composition$$$336$$$347$$$O	in$$$348$$$350$$$O	preparation$$$351$$$362$$$O	of$$$363$$$365$$$O	antineoplastic$$$366$$$380$$$O	drugs.$$$381$$$387$$$O
WO2014136116A1
Lipid$$$0$$$5$$$O	conjugates$$$6$$$16$$$O	in$$$17$$$19$$$O	the$$$20$$$23$$$O	treatment$$$24$$$33$$$O	of$$$34$$$36$$$O	bronchitis$$$37$$$47$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	are$$$16$$$19$$$O	methods$$$20$$$27$$$O	of$$$28$$$30$$$O	treating,$$$31$$$40$$$O	suppressing,$$$41$$$53$$$O	inhibiting,$$$54$$$65$$$O	or$$$66$$$68$$$O	preventing$$$69$$$79$$$O	bronchitis$$$80$$$90$$$O	in$$$91$$$93$$$O	a$$$94$$$95$$$O	subject$$$96$$$103$$$O	comprising$$$104$$$114$$$O	the$$$115$$$118$$$O	step$$$119$$$123$$$O	of$$$124$$$126$$$O	administering$$$127$$$140$$$O	to$$$141$$$143$$$O	a$$$144$$$145$$$O	subject$$$146$$$153$$$O	a$$$154$$$155$$$O	compound$$$156$$$164$$$O	comprising$$$165$$$175$$$O	a$$$176$$$177$$$O	lipid$$$178$$$183$$$O	or$$$184$$$186$$$O	phospholipid$$$187$$$199$$$O	moiety$$$200$$$206$$$O	bond$$$207$$$211$$$O	to$$$212$$$214$$$O	a$$$215$$$216$$$O	physiologically$$$217$$$232$$$O	acceptable$$$233$$$243$$$O	monomer,$$$244$$$252$$$O	dimer,$$$253$$$259$$$O	oligomer,$$$260$$$269$$$O	or$$$270$$$272$$$O	polymer,$$$273$$$281$$$O	and/or$$$282$$$288$$$O	a$$$289$$$290$$$O	pharmaceutically$$$291$$$307$$$O	acceptable$$$308$$$318$$$O	salt$$$319$$$323$$$O	or$$$324$$$326$$$O	a$$$327$$$328$$$O	pharmaceutical$$$329$$$343$$$O	product$$$344$$$351$$$O	thereof.$$$352$$$360$$$O
CN1846708A
Prepn$$$0$$$5$$$O	process$$$6$$$13$$$O	of$$$14$$$16$$$O	glucose$$$17$$$24$$$I	eye$$$25$$$28$$$O	lotion$$$29$$$35$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	preparation$$$25$$$36$$$O	process$$$37$$$44$$$O	of$$$45$$$47$$$O	glucose$$$48$$$55$$$I	eye$$$56$$$59$$$O	lotion$$$60$$$66$$$O	and$$$67$$$70$$$O	belongs$$$71$$$78$$$O	to$$$79$$$81$$$O	the$$$82$$$85$$$O	field$$$86$$$91$$$O	of$$$92$$$94$$$O	Chinese$$$95$$$102$$$O	and$$$103$$$106$$$O	Western$$$107$$$114$$$O	medicine$$$115$$$123$$$O	preparation$$$124$$$135$$$O	technology.$$$136$$$147$$$O	The$$$148$$$151$$$O	glucose$$$152$$$159$$$I	eye$$$160$$$163$$$O	lotion$$$164$$$170$$$O	is$$$171$$$173$$$O	compounded$$$174$$$184$$$O	with$$$185$$$189$$$O	glucose,$$$190$$$198$$$I	taurine,$$$199$$$207$$$I	anhydrous$$$208$$$217$$$O	sodium$$$218$$$224$$$I	sulfate,$$$225$$$233$$$I	distilled$$$234$$$243$$$O	water,$$$244$$$250$$$O	etc.$$$251$$$255$$$O	It$$$256$$$258$$$O	is$$$259$$$261$$$O	used$$$262$$$266$$$O	to$$$267$$$269$$$O	clean$$$270$$$275$$$O	eyes,$$$276$$$281$$$O	prevent$$$282$$$289$$$O	and$$$290$$$293$$$O	treat$$$294$$$299$$$O	eye$$$300$$$303$$$O	diseases$$$304$$$312$$$O	and$$$313$$$316$$$O	nourish$$$317$$$324$$$O	eyes.$$$325$$$330$$$O
WO2008102128A2
Pharmaceutical$$$0$$$14$$$O	combinations$$$15$$$27$$$O	of$$$28$$$30$$$O	at$$$31$$$33$$$O	least$$$34$$$39$$$O	two$$$40$$$43$$$O	bronchodilators$$$44$$$59$$$O	or$$$60$$$62$$$O	of$$$63$$$65$$$O	a$$$66$$$67$$$O	bronchodilator$$$68$$$82$$$O	with$$$83$$$87$$$O	a$$$88$$$89$$$O	corticosteroid$$$90$$$104$$$I
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	combination$$$17$$$28$$$O	comprising$$$29$$$39$$$O	(a)$$$40$$$43$$$O	a$$$44$$$45$$$O	combination$$$46$$$57$$$O	of$$$58$$$60$$$O	two$$$61$$$64$$$O	or$$$65$$$67$$$O	more$$$68$$$72$$$O	bronchodilators;$$$73$$$89$$$O	or$$$90$$$92$$$O	(b)$$$93$$$96$$$O	a$$$97$$$98$$$O	combination$$$99$$$110$$$O	of$$$111$$$113$$$O	at$$$114$$$116$$$O	least$$$117$$$122$$$O	one$$$123$$$126$$$O	bronchodilator$$$127$$$141$$$O	in$$$142$$$144$$$O	combination$$$145$$$156$$$O	with$$$157$$$161$$$O	at$$$162$$$164$$$O	least$$$165$$$170$$$O	one$$$171$$$174$$$O	corticosteroid.$$$175$$$190$$$I
CN101098867B
Substituted$$$0$$$11$$$O	sulfoxide$$$12$$$21$$$I	compound$$$22$$$30$$$O	and$$$31$$$34$$$O	its$$$35$$$38$$$O	preparing$$$39$$$48$$$O	method$$$49$$$55$$$O	and$$$56$$$59$$$O	application$$$60$$$71$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	an$$$32$$$34$$$O	optical$$$35$$$42$$$O	pure$$$43$$$47$$$O	compound$$$48$$$56$$$O	in$$$57$$$59$$$O	Formula$$$60$$$67$$$O	I,$$$68$$$70$$$O	the$$$71$$$74$$$O	salt$$$75$$$79$$$O	and$$$80$$$83$$$O	the$$$84$$$87$$$O	solvate$$$88$$$95$$$O	which$$$96$$$101$$$O	are$$$102$$$105$$$O	acceptable$$$106$$$116$$$O	for$$$117$$$120$$$O	the$$$121$$$124$$$O	medicine$$$125$$$133$$$O	of$$$134$$$136$$$O	the$$$137$$$140$$$O	compound,$$$141$$$150$$$O	and$$$151$$$154$$$O	the$$$155$$$158$$$O	usage$$$159$$$164$$$O	of$$$165$$$167$$$O	the$$$168$$$171$$$O	salt$$$172$$$176$$$O	and$$$177$$$180$$$O	the$$$181$$$184$$$O	solvate$$$185$$$192$$$O	in$$$193$$$195$$$O	preparing$$$196$$$205$$$O	medicine$$$206$$$214$$$O	and$$$215$$$218$$$O	medicine$$$219$$$227$$$O	compound.$$$228$$$237$$$O	The$$$238$$$241$$$O	present$$$242$$$249$$$O	invention$$$250$$$259$$$O	also$$$260$$$264$$$O	provides$$$265$$$273$$$O	the$$$274$$$277$$$O	preparation$$$278$$$289$$$O	method$$$290$$$296$$$O	for$$$297$$$300$$$O	the$$$301$$$304$$$O	compound$$$305$$$313$$$O	defined$$$314$$$321$$$O	in$$$322$$$324$$$O	the$$$325$$$328$$$O	invention.$$$329$$$339$$$O
EP1700597A1
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	containing$$$27$$$37$$$O	in$$$38$$$40$$$O	association$$$41$$$52$$$O	ubidecarenone,$$$53$$$67$$$I	dexpanthenol$$$68$$$80$$$I	and$$$81$$$84$$$O	chlorhexidine$$$85$$$98$$$I	or$$$99$$$101$$$O	a$$$102$$$103$$$O	pharmaceutically$$$104$$$120$$$O	acceptable$$$121$$$131$$$O	salt$$$132$$$136$$$O	thereof$$$137$$$144$$$O	for$$$145$$$148$$$O	cutaneous$$$149$$$158$$$O	application$$$159$$$170$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	pharmaceutical$$$35$$$49$$$O	composition$$$50$$$61$$$O	that$$$62$$$66$$$O	combines$$$67$$$75$$$O	a$$$76$$$77$$$O	substance$$$78$$$87$$$O	with$$$88$$$92$$$O	anti-oxidant$$$93$$$105$$$O	activity,$$$106$$$115$$$O	ubidecarenone,$$$116$$$130$$$I	with$$$131$$$135$$$O	a$$$136$$$137$$$O	healing$$$138$$$145$$$O	inducing$$$146$$$154$$$O	substance,$$$155$$$165$$$O	dexpanthenol,$$$166$$$179$$$I	and$$$180$$$183$$$O	with$$$184$$$188$$$O	a$$$189$$$190$$$O	substance$$$191$$$200$$$O	with$$$201$$$205$$$O	antiseptic$$$206$$$216$$$O	and$$$217$$$220$$$O	disinfectant$$$221$$$233$$$O	activity,$$$234$$$243$$$O	chlorhexidine$$$244$$$257$$$I	or$$$258$$$260$$$O	a$$$261$$$262$$$O	salt$$$263$$$267$$$O	thereof,$$$268$$$276$$$O	as$$$277$$$279$$$O	well$$$280$$$284$$$O	as$$$285$$$287$$$O	a$$$288$$$289$$$O	method$$$290$$$296$$$O	to$$$297$$$299$$$O	prepare$$$300$$$307$$$O	the$$$308$$$311$$$O	pharmaceutical$$$312$$$326$$$O	composition$$$327$$$338$$$O	which$$$339$$$344$$$O	includes$$$345$$$353$$$O	the$$$354$$$357$$$O	said$$$358$$$362$$$O	association$$$363$$$374$$$O	and$$$375$$$378$$$O	to$$$379$$$381$$$O	the$$$382$$$385$$$O	respective$$$386$$$396$$$O	use$$$397$$$400$$$O	for$$$401$$$404$$$O	the$$$405$$$408$$$O	treatment$$$409$$$418$$$O	of$$$419$$$421$$$O	anal$$$422$$$426$$$O	diseases,$$$427$$$436$$$O	examples$$$437$$$445$$$O	of$$$446$$$448$$$O	which$$$449$$$454$$$O	are$$$455$$$458$$$O	anal$$$459$$$463$$$O	fissures$$$464$$$472$$$O	(acute,$$$473$$$480$$$O	chronic$$$481$$$488$$$O	and$$$489$$$492$$$O	secondary$$$493$$$502$$$O	to$$$503$$$505$$$O	other$$$506$$$511$$$O	clinical$$$512$$$520$$$O	conditions).$$$521$$$533$$$O
CN101343299A
Lxeris$$$0$$$6$$$O	sonchifolia(bunge)hance$$$7$$$30$$$O	flavone$$$31$$$38$$$I	extract,$$$39$$$47$$$O	preparation$$$48$$$59$$$O	method$$$60$$$66$$$O	and$$$67$$$70$$$O	application$$$71$$$82$$$O	thereof$$$83$$$90$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	an$$$13$$$15$$$O	extract$$$16$$$23$$$O	of$$$24$$$26$$$O	flavonoid$$$27$$$36$$$I	of$$$37$$$39$$$O	ixeris$$$40$$$46$$$O	sonchifolia$$$47$$$58$$$O	hance$$$59$$$64$$$O	and$$$65$$$68$$$O	a$$$69$$$70$$$O	preparation$$$71$$$82$$$O	method$$$83$$$89$$$O	and$$$90$$$93$$$O	an$$$94$$$96$$$O	application$$$97$$$108$$$O	thereof.$$$109$$$117$$$O	The$$$118$$$121$$$O	invention$$$122$$$131$$$O	discloses$$$132$$$141$$$O	a$$$142$$$143$$$O	novel$$$144$$$149$$$O	preparation$$$150$$$161$$$O	method$$$162$$$168$$$O	of$$$169$$$171$$$O	an$$$172$$$174$$$O	extract$$$175$$$182$$$O	of$$$183$$$185$$$O	flavonoid$$$186$$$195$$$I	of$$$196$$$198$$$O	ixeris$$$199$$$205$$$O	sonchifolia$$$206$$$217$$$O	hance$$$218$$$223$$$O	whose$$$224$$$229$$$O	content$$$230$$$237$$$O	of$$$238$$$240$$$O	luteolin-7-O-Beta-D$$$241$$$260$$$I	glucopyranose$$$261$$$274$$$I	aldehyde$$$275$$$283$$$I	acid$$$284$$$288$$$I	glycoside$$$289$$$298$$$I	is$$$299$$$301$$$O	25$$$302$$$304$$$O	percent$$$305$$$312$$$O	to$$$313$$$315$$$O	99.5$$$316$$$320$$$O	percent,$$$321$$$329$$$O	discloses$$$330$$$339$$$O	a$$$340$$$341$$$O	novel$$$342$$$347$$$O	preparation$$$348$$$359$$$O	method$$$360$$$366$$$O	of$$$367$$$369$$$O	a$$$370$$$371$$$O	reference$$$372$$$381$$$O	substance$$$382$$$391$$$O	of$$$392$$$394$$$O	luteolin-7-O-Beta-D$$$395$$$414$$$I	glucopyranose$$$415$$$428$$$I	aldehyde$$$429$$$437$$$I	acid$$$438$$$442$$$I	glycoside$$$443$$$452$$$I	and$$$453$$$456$$$O	an$$$457$$$459$$$O	application$$$460$$$471$$$O	thereof$$$472$$$479$$$O	in$$$480$$$482$$$O	controlling$$$483$$$494$$$O	the$$$495$$$498$$$O	quality$$$499$$$506$$$O	of$$$507$$$509$$$O	the$$$510$$$513$$$O	ixeris$$$514$$$520$$$O	sonchifolia$$$521$$$532$$$O	hance$$$533$$$538$$$O	and$$$539$$$542$$$O	pharmaceutical$$$543$$$557$$$O	preparations$$$558$$$570$$$O	containing$$$571$$$581$$$O	the$$$582$$$585$$$O	extract$$$586$$$593$$$O	of$$$594$$$596$$$O	the$$$597$$$600$$$O	ixeris$$$601$$$607$$$O	sonchifolia$$$608$$$619$$$O	hance,$$$620$$$626$$$O	and$$$627$$$630$$$O	also$$$631$$$635$$$O	discloses$$$636$$$645$$$O	an$$$646$$$648$$$O	application$$$649$$$660$$$O	of$$$661$$$663$$$O	the$$$664$$$667$$$O	extract$$$668$$$675$$$O	in$$$676$$$678$$$O	preparing$$$679$$$688$$$O	drugs$$$689$$$694$$$O	for$$$695$$$698$$$O	treating$$$699$$$707$$$O	the$$$708$$$711$$$O	coronary$$$712$$$720$$$O	heart$$$721$$$726$$$O	disease,$$$727$$$735$$$O	the$$$736$$$739$$$O	cerebral$$$740$$$748$$$O	infarction$$$749$$$759$$$O	and$$$760$$$763$$$O	the$$$764$$$767$$$O	fracture.$$$768$$$777$$$O
CN102302478A
Health-care$$$0$$$11$$$O	medicine$$$12$$$20$$$O	for$$$21$$$24$$$O	treating$$$25$$$33$$$O	various$$$34$$$41$$$O	traumas$$$42$$$49$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	health-care$$$26$$$37$$$O	medicine$$$38$$$46$$$O	for$$$47$$$50$$$O	treating$$$51$$$59$$$O	various$$$60$$$67$$$O	traumas.$$$68$$$76$$$O	As$$$77$$$79$$$O	long$$$80$$$84$$$O	as$$$85$$$87$$$O	a$$$88$$$89$$$O	wound$$$90$$$95$$$O	is$$$96$$$98$$$O	directly$$$99$$$107$$$O	immersed$$$108$$$116$$$O	in$$$117$$$119$$$O	(gasoline)$$$120$$$130$$$I	liquor,$$$131$$$138$$$O	the$$$139$$$142$$$O	medicine$$$143$$$151$$$O	can$$$152$$$155$$$O	permeate$$$156$$$164$$$O	the$$$165$$$168$$$O	skin$$$169$$$173$$$O	of$$$174$$$176$$$O	the$$$177$$$180$$$O	wound,$$$181$$$187$$$O	and$$$188$$$191$$$O	intolerant$$$192$$$202$$$O	feeling$$$203$$$210$$$O	such$$$211$$$215$$$O	as$$$216$$$218$$$O	burning$$$219$$$226$$$O	pain,$$$227$$$232$$$O	anxiety$$$233$$$240$$$O	and$$$241$$$244$$$O	the$$$245$$$248$$$O	like$$$249$$$253$$$O	on$$$254$$$256$$$O	the$$$257$$$260$$$O	wound$$$261$$$266$$$O	can$$$267$$$270$$$O	disappear$$$271$$$280$$$O	forever;$$$281$$$289$$$O	even$$$290$$$294$$$O	if$$$295$$$297$$$O	grown$$$298$$$303$$$O	vesicles$$$304$$$312$$$O	are$$$313$$$316$$$O	squeezed$$$317$$$325$$$O	and$$$326$$$329$$$O	broken,$$$330$$$337$$$O	a$$$338$$$339$$$O	patient$$$340$$$347$$$O	does$$$348$$$352$$$O	not$$$353$$$356$$$O	feel$$$357$$$361$$$O	pain$$$362$$$366$$$O	and$$$367$$$370$$$O	can$$$371$$$374$$$O	immediately$$$375$$$386$$$O	return$$$387$$$393$$$O	to$$$394$$$396$$$O	normal$$$397$$$403$$$O	work;$$$404$$$409$$$O	the$$$410$$$413$$$O	liquor$$$414$$$420$$$O	is$$$421$$$423$$$O	coated$$$424$$$430$$$O	on$$$431$$$433$$$O	the$$$434$$$437$$$O	wound$$$438$$$443$$$O	every$$$444$$$449$$$O	six$$$450$$$453$$$O	hours$$$454$$$459$$$O	in$$$460$$$462$$$O	five$$$463$$$467$$$O	days,$$$468$$$473$$$O	the$$$474$$$477$$$O	wound$$$478$$$483$$$O	cannot$$$484$$$490$$$O	be$$$491$$$493$$$O	inflamed$$$494$$$502$$$O	even$$$503$$$507$$$O	if$$$508$$$510$$$O	medicines$$$511$$$520$$$O	are$$$521$$$524$$$O	not$$$525$$$528$$$O	taken,$$$529$$$535$$$O	muscles$$$536$$$543$$$O	can$$$544$$$547$$$O	be$$$548$$$550$$$O	quickly$$$551$$$558$$$O	regrown,$$$559$$$567$$$O	the$$$568$$$571$$$O	wound$$$572$$$577$$$O	can$$$578$$$581$$$O	be$$$582$$$584$$$O	cured$$$585$$$590$$$O	after$$$591$$$596$$$O	about$$$597$$$602$$$O	ten$$$603$$$606$$$O	days,$$$607$$$612$$$O	and$$$613$$$616$$$O	a$$$617$$$618$$$O	scar$$$619$$$623$$$O	is$$$624$$$626$$$O	not$$$627$$$630$$$O	left$$$631$$$635$$$O	after$$$636$$$641$$$O	the$$$642$$$645$$$O	wound$$$646$$$651$$$O	is$$$652$$$654$$$O	cured;$$$655$$$661$$$O	if$$$662$$$664$$$O	(the$$$665$$$669$$$O	gasoline)$$$670$$$679$$$I	the$$$680$$$683$$$O	liquor$$$684$$$690$$$O	is$$$691$$$693$$$O	injected$$$694$$$702$$$O	into$$$703$$$707$$$O	an$$$708$$$710$$$O	iron$$$711$$$715$$$I	tank,$$$716$$$721$$$O	a$$$722$$$723$$$O	medicine$$$724$$$732$$$O	tank$$$733$$$737$$$O	is$$$738$$$740$$$O	put$$$741$$$744$$$O	in$$$745$$$747$$$O	a$$$748$$$749$$$O	slightly$$$750$$$758$$$O	larger$$$759$$$765$$$O	iron$$$766$$$770$$$I	frame$$$771$$$776$$$O	at$$$777$$$779$$$O	ordinary$$$780$$$788$$$O	times,$$$789$$$795$$$O	and$$$796$$$799$$$O	the$$$800$$$803$$$O	iron$$$804$$$808$$$I	frame$$$809$$$814$$$O	is$$$815$$$817$$$O	nailed$$$818$$$824$$$O	to$$$825$$$827$$$O	a$$$828$$$829$$$O	brick$$$830$$$835$$$O	wall$$$836$$$840$$$O	which$$$841$$$846$$$O	is$$$847$$$849$$$O	far$$$850$$$853$$$O	away$$$854$$$858$$$O	from$$$859$$$863$$$O	firelight$$$864$$$873$$$O	and$$$874$$$877$$$O	has$$$878$$$881$$$O	the$$$882$$$885$$$O	height$$$886$$$892$$$O	of$$$893$$$895$$$O	1.8m;$$$896$$$901$$$O	the$$$902$$$905$$$O	medicine$$$906$$$914$$$O	tank$$$915$$$919$$$O	is$$$920$$$922$$$O	taken$$$923$$$928$$$O	down$$$929$$$933$$$O	by$$$934$$$936$$$O	hands$$$937$$$942$$$O	when$$$943$$$947$$$O	used$$$948$$$952$$$O	and$$$953$$$956$$$O	is$$$957$$$959$$$O	put$$$960$$$963$$$O	back$$$964$$$968$$$O	to$$$969$$$971$$$O	the$$$972$$$975$$$O	original$$$976$$$984$$$O	position$$$985$$$993$$$O	after$$$994$$$999$$$O	being$$$1000$$$1005$$$O	used;$$$1006$$$1011$$$O	and$$$1012$$$1015$$$O	combustible$$$1016$$$1027$$$O	gasoline$$$1028$$$1036$$$I	which$$$1037$$$1042$$$O	is$$$1043$$$1045$$$O	a$$$1046$$$1047$$$O	first-aid$$$1048$$$1057$$$O	magic$$$1058$$$1063$$$O	medicine$$$1064$$$1072$$$O	for$$$1073$$$1076$$$O	all$$$1077$$$1080$$$O	the$$$1081$$$1084$$$O	traumas$$$1085$$$1092$$$O	of$$$1093$$$1095$$$O	a$$$1096$$$1097$$$O	person$$$1098$$$1104$$$O	is$$$1105$$$1107$$$O	stored$$$1108$$$1114$$$O	in$$$1115$$$1117$$$O	a$$$1118$$$1119$$$O	protection$$$1120$$$1130$$$O	frame$$$1131$$$1136$$$O	forever,$$$1137$$$1145$$$O	the$$$1146$$$1149$$$O	fire$$$1150$$$1154$$$O	safety$$$1155$$$1161$$$O	of$$$1162$$$1164$$$O	a$$$1165$$$1166$$$O	user$$$1167$$$1171$$$O	is$$$1172$$$1174$$$O	maintained,$$$1175$$$1186$$$O	and$$$1187$$$1190$$$O	convenience$$$1191$$$1202$$$O	and$$$1203$$$1206$$$O	confidence$$$1207$$$1217$$$O	are$$$1218$$$1221$$$O	brought$$$1222$$$1229$$$O	to$$$1230$$$1232$$$O	a$$$1233$$$1234$$$O	holder$$$1235$$$1241$$$O	of$$$1242$$$1244$$$O	the$$$1245$$$1248$$$O	liquor.$$$1249$$$1256$$$O
CN1944442A
Preparation$$$0$$$11$$$O	of$$$12$$$14$$$O	3,7,10-tri-substuent$$$15$$$35$$$O	hetero$$$36$$$42$$$O	nitrogen$$$43$$$51$$$I	silicon$$$52$$$59$$$O	tricyclic$$$60$$$69$$$O	and$$$70$$$73$$$O	5-Fu$$$74$$$78$$$I	combined$$$79$$$87$$$O	substance$$$88$$$97$$$O	and$$$98$$$101$$$O	its$$$102$$$105$$$O	use$$$106$$$109$$$O	in$$$110$$$112$$$O	pharmacy$$$113$$$121$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	conjugate$$$33$$$42$$$O	of$$$43$$$45$$$O	3,$$$46$$$48$$$I	7,$$$49$$$51$$$I	10-trisubstituent$$$52$$$69$$$I	silatrane$$$70$$$79$$$I	and$$$80$$$83$$$O	5-FU,$$$84$$$89$$$I	which$$$90$$$95$$$O	may$$$96$$$99$$$O	be$$$100$$$102$$$O	used$$$103$$$107$$$O	in$$$108$$$110$$$O	preparing$$$111$$$120$$$O	medicine$$$121$$$129$$$O	for$$$130$$$133$$$O	treating$$$134$$$142$$$O	leukemia,$$$143$$$152$$$O	liver$$$153$$$158$$$O	cancer,$$$159$$$166$$$O	rectum$$$167$$$173$$$O	cancer,$$$174$$$181$$$O	gastric$$$182$$$189$$$O	cancer,$$$190$$$197$$$O	breast$$$198$$$204$$$O	cancer$$$205$$$211$$$O	and$$$212$$$215$$$O	other$$$216$$$221$$$O	tumors,$$$222$$$229$$$O	and$$$230$$$233$$$O	has$$$234$$$237$$$O	the$$$238$$$241$$$O	structural$$$242$$$252$$$O	formula$$$253$$$260$$$O	as$$$261$$$263$$$O	shown.$$$264$$$270$$$O
US20100215780
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	treating$$$11$$$19$$$O	onychoschizia$$$20$$$33$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	directed$$$25$$$33$$$O	to$$$34$$$36$$$O	compositions$$$37$$$49$$$O	containing$$$50$$$60$$$O	a$$$61$$$62$$$O	combination$$$63$$$74$$$O	of$$$75$$$77$$$O	a$$$78$$$79$$$O	herb$$$80$$$84$$$O	from$$$85$$$89$$$O	the$$$90$$$93$$$O	genus$$$94$$$99$$$O	Equisetum$$$100$$$109$$$O	together$$$110$$$118$$$O	with$$$119$$$123$$$O	one$$$124$$$127$$$O	film$$$128$$$132$$$O	forming$$$133$$$140$$$O	agent$$$141$$$146$$$O	and$$$147$$$150$$$O	its$$$151$$$154$$$O	use$$$155$$$158$$$O	as$$$159$$$161$$$O	a$$$162$$$163$$$O	nail$$$164$$$168$$$O	topical$$$169$$$176$$$O	formulation,$$$177$$$189$$$O	like$$$190$$$194$$$O	nail$$$195$$$199$$$O	varnish,$$$200$$$208$$$O	cream,$$$209$$$215$$$O	gel,$$$216$$$220$$$O	lotion$$$221$$$227$$$O	or$$$228$$$230$$$O	foam.$$$231$$$236$$$O	The$$$237$$$240$$$O	present$$$241$$$248$$$O	invention$$$249$$$258$$$O	is$$$259$$$261$$$O	further$$$262$$$269$$$O	directed$$$270$$$278$$$O	to$$$279$$$281$$$O	the$$$282$$$285$$$O	use$$$286$$$289$$$O	of$$$290$$$292$$$O	a$$$293$$$294$$$O	water$$$295$$$300$$$O	soluble$$$301$$$308$$$O	film$$$309$$$313$$$O	forming$$$314$$$321$$$O	agent$$$322$$$327$$$O	as$$$328$$$330$$$O	an$$$331$$$333$$$O	additive$$$334$$$342$$$O	in$$$343$$$345$$$O	a$$$346$$$347$$$O	nail$$$348$$$352$$$O	topical$$$353$$$360$$$O	formulation.$$$361$$$373$$$O	These$$$374$$$379$$$O	compositions$$$380$$$392$$$O	can$$$393$$$396$$$O	be$$$397$$$399$$$O	used$$$400$$$404$$$O	to$$$405$$$407$$$O	treat$$$408$$$413$$$O	specific$$$414$$$422$$$O	alterations$$$423$$$434$$$O	of$$$435$$$437$$$O	the$$$438$$$441$$$O	ungual$$$442$$$448$$$O	structure,$$$449$$$459$$$O	with$$$460$$$464$$$O	onychoschizia$$$465$$$478$$$O	which$$$479$$$484$$$O	is$$$485$$$487$$$O	a$$$488$$$489$$$O	specific$$$490$$$498$$$O	alteration$$$499$$$509$$$O	of$$$510$$$512$$$O	the$$$513$$$516$$$O	ungual$$$517$$$523$$$O	structure,$$$524$$$534$$$O	characterized$$$535$$$548$$$O	by$$$549$$$551$$$O	lamellar$$$552$$$560$$$O	splitting$$$561$$$570$$$O	of$$$571$$$573$$$O	the$$$574$$$577$$$O	nail$$$578$$$582$$$O	plate.$$$583$$$589$$$O
CN1839837A
Nicorandil$$$0$$$10$$$I	freeze-drying$$$11$$$24$$$O	powder$$$25$$$31$$$O	preparation$$$32$$$43$$$O	method$$$44$$$50$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	process$$$26$$$33$$$O	for$$$34$$$37$$$O	preparing$$$38$$$47$$$O	Nicorandil$$$48$$$58$$$I	freeze-dried$$$59$$$71$$$O	powder,$$$72$$$79$$$O	which$$$80$$$85$$$O	consists$$$86$$$94$$$O	of$$$95$$$97$$$O	charging$$$98$$$106$$$O	0.1-50.0$$$107$$$115$$$O	wt%$$$116$$$119$$$O	of$$$120$$$122$$$O	Nicorandil$$$123$$$133$$$I	into$$$134$$$138$$$O	water$$$139$$$144$$$O	for$$$145$$$148$$$O	injection,$$$149$$$159$$$O	dissolving$$$160$$$170$$$O	excipient$$$171$$$180$$$O	simultaneously,$$$181$$$196$$$O	degerming$$$197$$$206$$$O	and$$$207$$$210$$$O	filtering,$$$211$$$221$$$O	loading,$$$222$$$230$$$O	and$$$231$$$234$$$O	finally$$$235$$$242$$$O	freeze$$$243$$$249$$$O	drying.$$$250$$$257$$$O
CN103126987A
Fluvastatin$$$0$$$11$$$I	quantification$$$12$$$26$$$O	aerosol$$$27$$$34$$$O	preparation$$$35$$$46$$$O	and$$$47$$$50$$$O	application$$$51$$$62$$$O	of$$$63$$$65$$$O	fluvastatin$$$66$$$77$$$I	quantification$$$78$$$92$$$O	aerosol$$$93$$$100$$$O	in$$$101$$$103$$$O	lung$$$104$$$108$$$O	inflammatory$$$109$$$121$$$O	disease$$$122$$$129$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	fluvastatin$$$24$$$35$$$I	quantification$$$36$$$50$$$O	aerosol$$$51$$$58$$$O	preparation$$$59$$$70$$$O	and$$$71$$$74$$$O	application$$$75$$$86$$$O	of$$$87$$$89$$$O	the$$$90$$$93$$$O	fluvastatin$$$94$$$105$$$I	quantification$$$106$$$120$$$O	aerosol$$$121$$$128$$$O	in$$$129$$$131$$$O	a$$$132$$$133$$$O	lung$$$134$$$138$$$O	inflammatory$$$139$$$151$$$O	disease.$$$152$$$160$$$O	The$$$161$$$164$$$O	aerosol$$$165$$$172$$$O	is$$$173$$$175$$$O	a$$$176$$$177$$$O	tetrafluoroethane$$$178$$$195$$$O	(HFA-134a)$$$196$$$206$$$O	solution-type$$$207$$$220$$$O	formula,$$$221$$$229$$$O	and$$$230$$$233$$$O	is$$$234$$$236$$$O	characterized$$$237$$$250$$$O	in$$$251$$$253$$$O	that$$$254$$$258$$$O	minor$$$259$$$264$$$O	lepton$$$265$$$271$$$O	fractions$$$272$$$281$$$O	(FPF)$$$282$$$287$$$O	are$$$288$$$291$$$O	high,$$$292$$$297$$$O	and$$$298$$$301$$$O	aerial$$$302$$$308$$$O	fog$$$309$$$312$$$O	is$$$313$$$315$$$O	inhaled$$$316$$$323$$$O	in$$$324$$$326$$$O	the$$$327$$$330$$$O	lung$$$331$$$335$$$O	and$$$336$$$339$$$O	distributed$$$340$$$351$$$O	evenly$$$352$$$358$$$O	and$$$359$$$362$$$O	is$$$363$$$365$$$O	high$$$366$$$370$$$O	in$$$371$$$373$$$O	drug$$$374$$$378$$$O	concentration.$$$379$$$393$$$O	A$$$394$$$395$$$O	pharmacological$$$396$$$411$$$O	test$$$412$$$416$$$O	shows$$$417$$$422$$$O	that$$$423$$$427$$$O	the$$$428$$$431$$$O	fluvastatin$$$432$$$443$$$I	quantification$$$444$$$458$$$O	aerosol$$$459$$$466$$$O	has$$$467$$$470$$$O	good$$$471$$$475$$$O	functions$$$476$$$485$$$O	of$$$486$$$488$$$O	airway$$$489$$$495$$$O	inflammation$$$496$$$508$$$O	prevention,$$$509$$$520$$$O	airway$$$521$$$527$$$O	hyperresponsiveness$$$528$$$547$$$O	and$$$548$$$551$$$O	airway$$$552$$$558$$$O	remodeling,$$$559$$$570$$$O	and$$$571$$$574$$$O	the$$$575$$$578$$$O	fluvastatin$$$579$$$590$$$I	quantification$$$591$$$605$$$O	aerosol$$$606$$$613$$$O	can$$$614$$$617$$$O	be$$$618$$$620$$$O	used$$$621$$$625$$$O	for$$$626$$$629$$$O	treating$$$630$$$638$$$O	bronchial$$$639$$$648$$$O	asthma$$$649$$$655$$$O	and$$$656$$$659$$$O	a$$$660$$$661$$$O	chronic$$$662$$$669$$$O	obstructive$$$670$$$681$$$O	pulmonary$$$682$$$691$$$O	disease$$$692$$$699$$$O	(COPD).$$$700$$$707$$$O
CN1764432A
Gargle$$$0$$$6$$$O	for$$$7$$$10$$$O	treating$$$11$$$19$$$O	or$$$20$$$22$$$O	preventing$$$23$$$33$$$O	bacterial$$$34$$$43$$$O	infection$$$44$$$53$$$O	and$$$54$$$57$$$O	fungus$$$58$$$64$$$O	infection$$$65$$$74$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	mouthwash$$$15$$$24$$$O	composition,$$$25$$$37$$$O	and$$$38$$$41$$$O	a$$$42$$$43$$$O	related$$$44$$$51$$$O	use$$$52$$$55$$$O	and$$$56$$$59$$$O	method,$$$60$$$67$$$O	for$$$68$$$71$$$O	the$$$72$$$75$$$O	treatment$$$76$$$85$$$O	or$$$86$$$88$$$O	prevention$$$89$$$99$$$O	of$$$100$$$102$$$O	bacterial$$$103$$$112$$$O	and$$$113$$$116$$$O	fungal$$$117$$$123$$$O	infection$$$124$$$133$$$O	in$$$134$$$136$$$O	the$$$137$$$140$$$O	oral$$$141$$$145$$$O	cavity,$$$146$$$153$$$O	the$$$154$$$157$$$O	mouthwash$$$158$$$167$$$O	composition$$$168$$$179$$$O	comprising$$$180$$$190$$$O	an$$$191$$$193$$$O	effective$$$194$$$203$$$O	amount$$$204$$$210$$$O	of$$$211$$$213$$$O	metronidazole$$$214$$$227$$$I	and$$$228$$$231$$$O	nystatin,$$$232$$$241$$$I	together$$$242$$$250$$$O	with$$$251$$$255$$$O	an$$$256$$$258$$$O	orally-acceptable$$$259$$$276$$$O	carrier.$$$277$$$285$$$O
CN102038692A
Medical$$$0$$$7$$$O	composition$$$8$$$19$$$O	with$$$20$$$24$$$O	antiplatelet$$$25$$$37$$$O	condensation$$$38$$$50$$$O	activity$$$51$$$59$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medical$$$27$$$34$$$O	composition$$$35$$$46$$$O	with$$$47$$$51$$$O	antiplatelet$$$52$$$64$$$O	condensation$$$65$$$77$$$O	activity.$$$78$$$87$$$O	The$$$88$$$91$$$O	medical$$$92$$$99$$$O	composition$$$100$$$111$$$O	with$$$112$$$116$$$O	antiplatelet$$$117$$$129$$$O	condensation$$$130$$$142$$$O	activity$$$143$$$151$$$O	comprises$$$152$$$161$$$O	clopidogrel$$$162$$$173$$$O	and$$$174$$$177$$$O	triflusal,$$$178$$$188$$$O	wherein$$$189$$$196$$$O	the$$$197$$$200$$$O	ratio$$$201$$$206$$$O	of$$$207$$$209$$$O	the$$$210$$$213$$$O	clopidogrel$$$214$$$225$$$O	to$$$226$$$228$$$O	the$$$229$$$232$$$O	triflusal$$$233$$$242$$$O	is$$$243$$$245$$$O	1:4,$$$246$$$250$$$O	1:6$$$251$$$254$$$O	or$$$255$$$257$$$O	1:12.$$$258$$$263$$$O	The$$$264$$$267$$$O	medical$$$268$$$275$$$O	composition,$$$276$$$288$$$O	i.e.$$$289$$$293$$$O	a$$$294$$$295$$$O	composition$$$296$$$307$$$O	of$$$308$$$310$$$O	the$$$311$$$314$$$O	clopidogrel$$$315$$$326$$$O	and$$$327$$$330$$$O	the$$$331$$$334$$$O	triflusal$$$335$$$344$$$O	in$$$345$$$347$$$O	specific$$$348$$$356$$$O	ratio$$$357$$$362$$$O	has$$$363$$$366$$$O	an$$$367$$$369$$$O	antithrombogenic$$$370$$$386$$$O	effect,$$$387$$$394$$$O	can$$$395$$$398$$$O	inhibit$$$399$$$406$$$O	the$$$407$$$410$$$O	release$$$411$$$418$$$O	reaction$$$419$$$427$$$O	of$$$428$$$430$$$O	blood$$$431$$$436$$$O	platelets,$$$437$$$447$$$O	inhibit$$$448$$$455$$$O	the$$$456$$$459$$$O	aggregation$$$460$$$471$$$O	of$$$472$$$474$$$O	the$$$475$$$478$$$O	blood$$$479$$$484$$$O	platelets$$$485$$$494$$$O	and$$$495$$$498$$$O	prevent$$$499$$$506$$$O	thrombosis,$$$507$$$518$$$O	is$$$519$$$521$$$O	expected$$$522$$$530$$$O	to$$$531$$$533$$$O	replace$$$534$$$541$$$O	aspirin,$$$542$$$550$$$O	the$$$551$$$554$$$O	clopidogrel$$$555$$$566$$$O	or$$$567$$$569$$$O	the$$$570$$$573$$$O	medicament$$$574$$$584$$$O	composition$$$585$$$596$$$O	of$$$597$$$599$$$O	the$$$600$$$603$$$O	aspirin$$$604$$$611$$$O	and$$$612$$$615$$$O	the$$$616$$$619$$$O	clopidogrel$$$620$$$631$$$O	and$$$632$$$635$$$O	is$$$636$$$638$$$O	used$$$639$$$643$$$O	for$$$644$$$647$$$O	preventing$$$648$$$658$$$O	outbreak$$$659$$$667$$$O	of$$$668$$$670$$$O	heart$$$671$$$676$$$O	cerebrovascular$$$677$$$692$$$O	diseases.$$$693$$$702$$$O
US20120238520
Novel$$$0$$$5$$$O	Medical$$$6$$$13$$$O	Use$$$14$$$17$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	compound$$$35$$$43$$$O	which$$$44$$$49$$$O	is$$$50$$$52$$$O	(2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol$$$53$$$193$$$I	or$$$231$$$233$$$O	a$$$234$$$235$$$O	pharmaceutically$$$236$$$252$$$O	acceptable$$$253$$$263$$$O	salt$$$264$$$268$$$O	thereof$$$269$$$276$$$O	for$$$277$$$280$$$O	use$$$281$$$284$$$O	in$$$285$$$287$$$O	the$$$288$$$291$$$O	treatment$$$292$$$301$$$O	or$$$302$$$304$$$O	prevention$$$305$$$315$$$O	of$$$316$$$318$$$O	inflammatory$$$319$$$331$$$O	and$$$332$$$335$$$O	non-inflammatory$$$336$$$352$$$O	diseases$$$353$$$361$$$O	abd$$$362$$$365$$$O	conditions$$$366$$$376$$$O	associated$$$377$$$387$$$O	with$$$388$$$392$$$O	alveolar$$$393$$$401$$$O	filling.$$$402$$$410$$$O
US20080107707
Polymerizable$$$0$$$13$$$O	antimicrobial$$$14$$$27$$$O	composition$$$28$$$39$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	a$$$31$$$32$$$O	polymerizable$$$33$$$46$$$O	antimicrobial$$$47$$$60$$$O	composition$$$61$$$72$$$O	and$$$73$$$76$$$O	a$$$77$$$78$$$O	method$$$79$$$85$$$O	for$$$86$$$89$$$O	using$$$90$$$95$$$O	the$$$96$$$99$$$O	same.$$$100$$$105$$$O	The$$$106$$$109$$$O	polymerizable$$$110$$$123$$$O	antimicrobial$$$124$$$137$$$O	composition$$$138$$$149$$$O	of$$$150$$$152$$$O	the$$$153$$$156$$$O	invention$$$157$$$166$$$O	comprises$$$167$$$176$$$O	an$$$177$$$179$$$O	antimicrobial$$$180$$$193$$$O	compound,$$$194$$$203$$$O	a$$$204$$$205$$$O	linker,$$$206$$$213$$$O	and$$$214$$$217$$$O	a$$$218$$$219$$$O	polymerizable$$$220$$$233$$$O	function$$$234$$$242$$$O	group.$$$243$$$249$$$O
CN102716085A
Topotecan$$$0$$$9$$$I	hydrochloride$$$10$$$23$$$I	liposome$$$24$$$32$$$O	injection$$$33$$$42$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	topotecan$$$26$$$35$$$I	hydrochloride$$$36$$$49$$$I	liposome$$$50$$$58$$$O	injection$$$59$$$68$$$O	and$$$69$$$72$$$O	a$$$73$$$74$$$O	preparation$$$75$$$86$$$O	method$$$87$$$93$$$O	thereof.$$$94$$$102$$$O	The$$$103$$$106$$$O	liposome$$$107$$$115$$$O	injection$$$116$$$125$$$O	is$$$126$$$128$$$O	prepared$$$129$$$137$$$O	from$$$138$$$142$$$O	topotecan$$$143$$$152$$$I	hydrochloride,$$$153$$$167$$$I	cholesterol$$$168$$$179$$$I	succinate,$$$180$$$190$$$I	lauroyl$$$191$$$198$$$I	phosphatidylcholine,$$$199$$$219$$$I	polyethylene$$$220$$$232$$$I	glycol$$$233$$$239$$$I	(PEG)$$$240$$$245$$$I	600,$$$246$$$250$$$O	tween$$$251$$$256$$$O	60,$$$257$$$260$$$O	trehalose$$$261$$$270$$$I	and$$$271$$$274$$$O	mannitol$$$275$$$283$$$I	in$$$284$$$286$$$O	a$$$287$$$288$$$O	specific$$$289$$$297$$$O	weight$$$298$$$304$$$O	ratio.$$$305$$$311$$$O	The$$$312$$$315$$$O	liposome$$$316$$$324$$$O	injection$$$325$$$334$$$O	is$$$335$$$337$$$O	high$$$338$$$342$$$O	in$$$343$$$345$$$O	preparation$$$346$$$357$$$O	stability;$$$358$$$368$$$O	during$$$369$$$375$$$O	freezing,$$$376$$$385$$$O	liposome$$$386$$$394$$$O	is$$$395$$$397$$$O	not$$$398$$$401$$$O	cracked$$$402$$$409$$$O	due$$$410$$$413$$$O	to$$$414$$$416$$$O	fusion,$$$417$$$424$$$O	ice$$$425$$$428$$$O	crystals$$$429$$$437$$$O	and$$$438$$$441$$$O	the$$$442$$$445$$$O	like;$$$446$$$451$$$O	and$$$452$$$455$$$O	after$$$456$$$461$$$O	being$$$462$$$467$$$O	stored$$$468$$$474$$$O	for$$$475$$$478$$$O	a$$$479$$$480$$$O	long$$$481$$$485$$$O	time,$$$486$$$491$$$O	the$$$492$$$495$$$O	liposome$$$496$$$504$$$O	still$$$505$$$510$$$O	keeps$$$511$$$516$$$O	high$$$517$$$521$$$O	entrapment$$$522$$$532$$$O	efficiency.$$$533$$$544$$$O	The$$$545$$$548$$$O	solubility$$$549$$$559$$$O	of$$$560$$$562$$$O	topotecan$$$563$$$572$$$I	hydrochloride$$$573$$$586$$$I	and$$$587$$$590$$$O	the$$$591$$$594$$$O	quality$$$595$$$602$$$O	of$$$603$$$605$$$O	a$$$606$$$607$$$O	preparation$$$608$$$619$$$O	product$$$620$$$627$$$O	are$$$628$$$631$$$O	improved,$$$632$$$641$$$O	the$$$642$$$645$$$O	toxic$$$646$$$651$$$O	and$$$652$$$655$$$O	side$$$656$$$660$$$O	effects$$$661$$$668$$$O	are$$$669$$$672$$$O	reduced,$$$673$$$681$$$O	the$$$682$$$685$$$O	retention$$$686$$$695$$$O	time$$$696$$$700$$$O	of$$$701$$$703$$$O	a$$$704$$$705$$$O	medicine$$$706$$$714$$$O	in$$$715$$$717$$$O	the$$$718$$$721$$$O	process$$$722$$$729$$$O	of$$$730$$$732$$$O	systemic$$$733$$$741$$$O	circulation$$$742$$$753$$$O	is$$$754$$$756$$$O	increased,$$$757$$$767$$$O	the$$$768$$$771$$$O	bioavailability$$$772$$$787$$$O	of$$$788$$$790$$$O	the$$$791$$$794$$$O	medicine$$$795$$$803$$$O	is$$$804$$$806$$$O	improved,$$$807$$$816$$$O	and$$$817$$$820$$$O	the$$$821$$$824$$$O	curative$$$825$$$833$$$O	effect$$$834$$$840$$$O	is$$$841$$$843$$$O	improved$$$844$$$852$$$O	obviously;$$$853$$$863$$$O	and$$$864$$$867$$$O	the$$$868$$$871$$$O	preparation$$$872$$$883$$$O	method$$$884$$$890$$$O	is$$$891$$$893$$$O	simple,$$$894$$$901$$$O	and$$$902$$$905$$$O	the$$$906$$$909$$$O	topotecan$$$910$$$919$$$I	hydrochloride$$$920$$$933$$$I	liposome$$$934$$$942$$$O	injection$$$943$$$952$$$O	is$$$953$$$955$$$O	suitable$$$956$$$964$$$O	to$$$965$$$967$$$O	be$$$968$$$970$$$O	industrially$$$971$$$983$$$O	produced$$$984$$$992$$$O	on$$$993$$$995$$$O	large$$$996$$$1001$$$O	scale.$$$1002$$$1008$$$O
WO2013004332A1
Substituted$$$0$$$11$$$O	azaheterocycles$$$12$$$27$$$I	for$$$28$$$31$$$O	the$$$32$$$35$$$O	treatment$$$36$$$45$$$O	of$$$46$$$48$$$O	cancer$$$49$$$55$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	novel$$$23$$$28$$$O	substituted$$$29$$$40$$$O	azaheterocyclic$$$41$$$56$$$I	compounds$$$57$$$66$$$O	according$$$67$$$76$$$O	to$$$77$$$79$$$O	Formula$$$80$$$87$$$O	(I),$$$88$$$92$$$O	their$$$93$$$98$$$O	manufacture$$$99$$$110$$$O	and$$$111$$$114$$$O	use$$$115$$$118$$$O	for$$$119$$$122$$$O	the$$$123$$$126$$$O	treatment$$$127$$$136$$$O	of$$$137$$$139$$$O	hyperproliferative$$$140$$$158$$$O	diseases,$$$159$$$168$$$O	such$$$169$$$173$$$O	as$$$174$$$176$$$O	cancer.$$$177$$$184$$$O
CN102342936A
Medicinal$$$0$$$9$$$O	composition$$$10$$$21$$$O	of$$$22$$$24$$$O	amlodipine$$$25$$$35$$$I	and$$$36$$$39$$$O	atorvastatin$$$40$$$52$$$I	calcium$$$53$$$60$$$I	and$$$61$$$64$$$O	its$$$65$$$68$$$O	preparation$$$69$$$80$$$O	method$$$81$$$87$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medicinal$$$27$$$36$$$O	composition$$$37$$$48$$$O	by$$$49$$$51$$$O	taking$$$52$$$58$$$O	amlodipine$$$59$$$69$$$I	and$$$70$$$73$$$O	atorvastatin$$$74$$$86$$$I	calcium$$$87$$$94$$$I	as$$$95$$$97$$$O	active$$$98$$$104$$$O	components,$$$105$$$116$$$O	the$$$117$$$120$$$O	medicinal$$$121$$$130$$$O	composition$$$131$$$142$$$O	comprises$$$143$$$152$$$O	amlodipine,$$$153$$$164$$$I	atorvastatin$$$165$$$177$$$I	calcium,$$$178$$$186$$$I	a$$$187$$$188$$$O	filler,$$$189$$$196$$$O	a$$$197$$$198$$$O	disintegrant$$$199$$$211$$$O	and$$$212$$$215$$$O	a$$$216$$$217$$$O	lubricant;$$$218$$$228$$$O	the$$$229$$$232$$$O	active$$$233$$$239$$$O	components$$$240$$$250$$$O	are$$$251$$$254$$$O	composed$$$255$$$263$$$O	of$$$264$$$266$$$O	2-20$$$267$$$271$$$O	parts$$$272$$$277$$$O	of$$$278$$$280$$$O	amlodipine$$$281$$$291$$$I	and$$$292$$$295$$$O	5-120$$$296$$$301$$$O	parts$$$302$$$307$$$O	of$$$308$$$310$$$O	atorvastatin$$$311$$$323$$$I	calcium;$$$324$$$332$$$I	the$$$333$$$336$$$O	amlodipine$$$337$$$347$$$I	is$$$348$$$350$$$O	a$$$351$$$352$$$O	maleic$$$353$$$359$$$I	acid$$$360$$$364$$$I	amlodipine$$$365$$$375$$$I	hydrate$$$376$$$383$$$I	crystal.$$$384$$$392$$$O	The$$$393$$$396$$$O	molecular$$$397$$$406$$$O	formula$$$407$$$414$$$O	of$$$415$$$417$$$O	the$$$418$$$421$$$O	maleic$$$422$$$428$$$I	acid$$$429$$$433$$$I	amlodipine$$$434$$$444$$$I	hydrate$$$445$$$452$$$I	crystal$$$453$$$460$$$O	is$$$461$$$463$$$O	C24H29C1N2O9.1.5H2O.$$$464$$$484$$$I	The$$$485$$$488$$$O	amlodipine$$$489$$$499$$$I	in$$$500$$$502$$$O	the$$$503$$$506$$$O	medicinal$$$507$$$516$$$O	composition$$$517$$$528$$$O	has$$$529$$$532$$$O	the$$$533$$$536$$$O	advantages$$$537$$$547$$$O	of$$$548$$$550$$$O	fast$$$551$$$555$$$O	effectiveness$$$556$$$569$$$O	and$$$570$$$573$$$O	stability,$$$574$$$584$$$O	and$$$585$$$588$$$O	is$$$589$$$591$$$O	capable$$$592$$$599$$$O	of$$$600$$$602$$$O	steadily$$$603$$$611$$$O	releasing$$$612$$$621$$$O	the$$$622$$$625$$$O	drug$$$626$$$630$$$O	effect$$$631$$$637$$$O	in$$$638$$$640$$$O	24$$$641$$$643$$$O	hours,$$$644$$$650$$$O	the$$$651$$$654$$$O	medicinal$$$655$$$664$$$O	composition$$$665$$$676$$$O	has$$$677$$$680$$$O	strong$$$681$$$687$$$O	synergy,$$$688$$$696$$$O	accumulation$$$697$$$709$$$O	and$$$710$$$713$$$O	complementary$$$714$$$727$$$O	effects,$$$728$$$736$$$O	and$$$737$$$740$$$O	the$$$741$$$744$$$O	bioavailability$$$745$$$760$$$O	is$$$761$$$763$$$O	high.$$$764$$$769$$$O
CN103717592A
Halogen-alkyl-1,3$$$0$$$17$$$I	oxazines$$$18$$$26$$$I	as$$$27$$$29$$$O	BACE1$$$30$$$35$$$O	and/or$$$36$$$42$$$O	BACE2$$$43$$$48$$$O	inhibitors$$$49$$$59$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	compounds$$$31$$$40$$$O	of$$$41$$$43$$$O	formula$$$44$$$51$$$O	(I)$$$52$$$55$$$O	having$$$56$$$62$$$O	BACE1$$$63$$$68$$$O	and/or$$$69$$$75$$$O	BACE2$$$76$$$81$$$O	inhibitory$$$82$$$92$$$O	activity,$$$93$$$102$$$O	their$$$103$$$108$$$O	manufacture,$$$109$$$121$$$O	pharmaceutical$$$122$$$136$$$O	compositions$$$137$$$149$$$O	containing$$$150$$$160$$$O	them$$$161$$$165$$$O	and$$$166$$$169$$$O	their$$$170$$$175$$$O	use$$$176$$$179$$$O	as$$$180$$$182$$$O	therapeutically$$$183$$$198$$$O	active$$$199$$$205$$$O	substances.$$$206$$$217$$$O	The$$$218$$$221$$$O	active$$$222$$$228$$$O	compounds$$$229$$$238$$$O	of$$$239$$$241$$$O	the$$$242$$$245$$$O	present$$$246$$$253$$$O	invention$$$254$$$263$$$O	are$$$264$$$267$$$O	useful$$$268$$$274$$$O	in$$$275$$$277$$$O	the$$$278$$$281$$$O	therapeutic$$$282$$$293$$$O	and/or$$$294$$$300$$$O	prophylactic$$$301$$$313$$$O	treatment$$$314$$$323$$$O	of$$$324$$$326$$$O	e.g.$$$327$$$331$$$O	Alzheimer's$$$332$$$343$$$O	disease$$$344$$$351$$$O	and$$$352$$$355$$$O	type$$$356$$$360$$$O	2$$$361$$$362$$$O	diabetes.$$$363$$$372$$$O
EP2729449A1
5-$$$0$$$2$$$I	or$$$3$$$5$$$I	6$$$6$$$7$$$I	-$$$8$$$9$$$I	substituted$$$10$$$21$$$I	3$$$22$$$23$$$I	-$$$24$$$25$$$I	hydroxy$$$26$$$33$$$I	-$$$34$$$35$$$I	2$$$36$$$37$$$I	($$$38$$$39$$$I	1h)$$$40$$$43$$$I	-$$$44$$$45$$$I	pyridinones$$$46$$$57$$$I	as$$$58$$$60$$$O	d-amino$$$61$$$68$$$I	acid$$$69$$$73$$$I	oxidase$$$74$$$81$$$O	(daao)$$$82$$$88$$$O	inhibitors$$$89$$$99$$$O	in$$$100$$$102$$$O	therapy$$$103$$$110$$$O	of$$$111$$$113$$$O	diseases$$$114$$$122$$$O	such$$$123$$$127$$$O	as$$$128$$$130$$$O	schizophrenia,$$$131$$$145$$$O	cognitive$$$146$$$155$$$O	disorder$$$156$$$164$$$O	and$$$165$$$168$$$O	pain$$$169$$$173$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	compounds$$$31$$$40$$$O	of$$$41$$$43$$$O	formula$$$44$$$51$$$O	(I)$$$52$$$55$$$O	and$$$56$$$59$$$O	pharmaceutically$$$60$$$76$$$O	acceptable$$$77$$$87$$$O	salts$$$88$$$93$$$O	thereof,$$$94$$$102$$$O	wherein$$$103$$$110$$$O	R1$$$111$$$113$$$O	is$$$114$$$116$$$O	hydrogen$$$117$$$125$$$I	or$$$126$$$128$$$O	fluorine,$$$129$$$138$$$I	one$$$139$$$142$$$O	of$$$143$$$145$$$O	A$$$146$$$147$$$O	and$$$148$$$151$$$O	B$$$152$$$153$$$O	is$$$154$$$156$$$O	R2,$$$157$$$160$$$O	the$$$161$$$164$$$O	other$$$165$$$170$$$O	is$$$171$$$173$$$O	a$$$174$$$175$$$O	group$$$176$$$181$$$O	-X-Y-R3.$$$182$$$190$$$O	R3$$$191$$$193$$$O	represents$$$194$$$204$$$O	a$$$205$$$206$$$O	carbocyclic$$$207$$$218$$$I	or$$$219$$$221$$$O	heterocyclic$$$222$$$234$$$I	ring.$$$235$$$240$$$O	Further$$$241$$$248$$$O	variables$$$249$$$258$$$O	are$$$259$$$262$$$O	as$$$263$$$265$$$O	defined$$$266$$$273$$$O	in$$$274$$$276$$$O	the$$$277$$$280$$$O	specification.$$$281$$$295$$$O	Also$$$296$$$300$$$O	claimed$$$301$$$308$$$O	are-$$$309$$$313$$$O	processes$$$314$$$323$$$O	for$$$324$$$327$$$O	their$$$328$$$333$$$O	preparation,$$$334$$$346$$$O	pharmaceutical$$$347$$$361$$$O	compositions$$$362$$$374$$$O	containing$$$375$$$385$$$O	them$$$386$$$390$$$O	and$$$391$$$394$$$O	their$$$395$$$400$$$O	use$$$401$$$404$$$O	in$$$405$$$407$$$O	therapy$$$408$$$415$$$O	of$$$416$$$418$$$O	diseases$$$419$$$427$$$O	such$$$428$$$432$$$O	as$$$433$$$435$$$O	schizophrenia,$$$436$$$450$$$O	cognitive$$$451$$$460$$$O	disorders$$$461$$$470$$$O	and$$$471$$$474$$$O	pain$$$475$$$479$$$O	by$$$480$$$482$$$O	modulating$$$483$$$493$$$O	the$$$494$$$497$$$O	D-amino$$$498$$$505$$$I	acid$$$506$$$510$$$I	oxidase$$$511$$$518$$$O	enzyme$$$519$$$525$$$O	(DAAO).$$$526$$$533$$$O
US20120183554
Biomarker$$$0$$$9$$$O
Described$$$0$$$9$$$O	are$$$10$$$13$$$O	gastrointestinal$$$14$$$30$$$O	cancer$$$31$$$37$$$O	specific$$$38$$$46$$$O	biomarkers$$$47$$$57$$$O	comprising$$$58$$$68$$$O	the$$$69$$$72$$$O	nucleic$$$73$$$80$$$O	acid$$$81$$$85$$$O	sequence$$$86$$$94$$$O	of$$$95$$$97$$$O	the$$$98$$$101$$$O	Engrailed-2$$$102$$$113$$$O	(EN2)$$$114$$$119$$$O	gene$$$120$$$124$$$O	or$$$125$$$127$$$O	the$$$128$$$131$$$O	amino$$$132$$$137$$$I	acid$$$138$$$142$$$I	sequence$$$143$$$151$$$O	of$$$152$$$154$$$O	the$$$155$$$158$$$O	encoded$$$159$$$166$$$O	EN2$$$167$$$170$$$O	protein.$$$171$$$179$$$O	Also$$$180$$$184$$$O	described$$$185$$$194$$$O	are$$$195$$$198$$$O	uses$$$199$$$203$$$O	of$$$204$$$206$$$O	the$$$207$$$210$$$O	biomarkers$$$211$$$221$$$O	in$$$222$$$224$$$O	the$$$225$$$228$$$O	treatment,$$$229$$$239$$$O	diagnosis,$$$240$$$250$$$O	monitoring$$$251$$$261$$$O	and$$$262$$$265$$$O	imaging$$$266$$$273$$$O	of$$$274$$$276$$$O	gastrointestinal$$$277$$$293$$$O	cancer.$$$294$$$301$$$O
CN1640394A
Andrographolide$$$0$$$15$$$I	sulfonic$$$16$$$24$$$I	acid$$$25$$$29$$$I	sodium$$$30$$$36$$$I	lyophilized$$$37$$$48$$$O	powder$$$49$$$55$$$O	for$$$56$$$59$$$O	injection$$$60$$$69$$$O	and$$$70$$$73$$$O	its$$$74$$$77$$$O	preparing$$$78$$$87$$$O	method$$$88$$$94$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	an$$$33$$$35$$$O	andrographolide$$$36$$$51$$$I	sodium$$$52$$$58$$$I	sulfonate$$$59$$$68$$$I	freeze-dried$$$69$$$81$$$O	powder$$$82$$$88$$$O	injection$$$89$$$98$$$O	preparation.$$$99$$$111$$$O	Said$$$112$$$116$$$O	freeze-dried$$$117$$$129$$$O	powder$$$130$$$136$$$O	injection$$$137$$$146$$$O	preparation$$$147$$$158$$$O	contains$$$159$$$167$$$O	unit$$$168$$$172$$$O	dose$$$173$$$177$$$O	10-1500$$$178$$$185$$$O	mg$$$186$$$188$$$O	of$$$189$$$191$$$O	andrographolide$$$192$$$207$$$I	sodium$$$208$$$214$$$I	sulfonate,$$$215$$$225$$$I	and$$$226$$$229$$$O	at$$$230$$$232$$$O	least$$$233$$$238$$$O	contains$$$239$$$247$$$O	one$$$248$$$251$$$O	pharmaceutically-acceptable$$$252$$$279$$$O	carrier,$$$280$$$288$$$O	said$$$289$$$293$$$O	carrier$$$294$$$301$$$O	includes$$$302$$$310$$$O	excipient,$$$311$$$321$$$O	pH$$$322$$$324$$$O	regulating$$$325$$$335$$$O	agent,$$$336$$$342$$$O	anti-oxidant$$$343$$$355$$$O	and$$$356$$$359$$$O	stabilizing$$$360$$$371$$$O	agent.$$$372$$$378$$$O	Said$$$379$$$383$$$O	invented$$$384$$$392$$$O	powder$$$393$$$399$$$O	injection$$$400$$$409$$$O	preparation$$$410$$$421$$$O	can$$$422$$$425$$$O	be$$$426$$$428$$$O	mainly$$$429$$$435$$$O	used$$$436$$$440$$$O	for$$$441$$$444$$$O	curing$$$445$$$451$$$O	the$$$452$$$455$$$O	diseases$$$456$$$464$$$O	of$$$465$$$467$$$O	bronchitis,$$$468$$$479$$$O	cystauchenitis,$$$480$$$495$$$O	urethritis,$$$496$$$507$$$O	pelvic$$$508$$$514$$$O	inflammation,$$$515$$$528$$$O	acute$$$529$$$534$$$O	icterohepatitis$$$535$$$550$$$O	anjd$$$551$$$555$$$O	prostatitis,$$$556$$$568$$$O	etc.$$$569$$$573$$$O	Besides,$$$574$$$582$$$O	said$$$583$$$587$$$O	invention$$$588$$$597$$$O	also$$$598$$$602$$$O	provides$$$603$$$611$$$O	its$$$612$$$615$$$O	preparation$$$616$$$627$$$O	process.$$$628$$$636$$$O
EP1175399B1
Inhibitors$$$0$$$10$$$O	of$$$11$$$13$$$O	c-jun$$$14$$$19$$$O	n-terminal$$$20$$$30$$$O	kinases$$$31$$$38$$$O	(jnk)$$$39$$$44$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	formula$$$46$$$53$$$O	(I)$$$54$$$57$$$O	or$$$58$$$60$$$O	(II),$$$61$$$66$$$O	or$$$67$$$69$$$O	a$$$70$$$71$$$O	pharmaceutically$$$72$$$88$$$O	acceptable$$$89$$$99$$$O	derivative$$$100$$$110$$$O	or$$$111$$$113$$$O	prodrug$$$114$$$121$$$O	thereof;$$$122$$$130$$$O	wherein$$$131$$$138$$$O	Y$$$139$$$140$$$O	is$$$141$$$143$$$O	selected$$$144$$$152$$$O	from$$$153$$$157$$$O	-(CH2)-Q1;$$$158$$$168$$$I	-(CO)-Q1;$$$169$$$178$$$I	-(CO)NH-Q1;$$$179$$$190$$$I	-(CO)-O-Q1;$$$191$$$202$$$I	-(SO2)-Q1$$$203$$$212$$$I	or$$$213$$$215$$$O	-(SO2)NH-Q1;$$$216$$$228$$$I	Q1$$$229$$$231$$$O	is$$$232$$$234$$$O	a$$$235$$$236$$$O	C1-C6$$$237$$$242$$$O	straight$$$243$$$251$$$O	chain$$$252$$$257$$$O	or$$$258$$$260$$$O	branched$$$261$$$269$$$O	alkyl$$$270$$$275$$$I	or$$$276$$$278$$$O	alkenyl$$$279$$$286$$$I	group;$$$287$$$293$$$O	a$$$294$$$295$$$O	5-7$$$296$$$299$$$O	membered$$$300$$$308$$$O	aromatic$$$309$$$317$$$I	or$$$318$$$320$$$O	non-aromatic$$$321$$$333$$$I	carbocyclic$$$334$$$345$$$I	or$$$346$$$348$$$O	heterocyclic$$$349$$$361$$$I	ring;$$$362$$$367$$$O	or$$$368$$$370$$$O	a$$$371$$$372$$$O	9-14$$$373$$$377$$$O	membered$$$378$$$386$$$O	bicyclic$$$387$$$395$$$I	or$$$396$$$398$$$O	tricyclic$$$399$$$408$$$I	aromatic$$$409$$$417$$$I	or$$$418$$$420$$$O	non-aromatic$$$421$$$433$$$I	carbocyclic$$$434$$$445$$$I	or$$$446$$$448$$$O	heterocyclic$$$449$$$461$$$I	ring$$$462$$$466$$$O	system,$$$467$$$474$$$O	W$$$475$$$476$$$O	is$$$477$$$479$$$O	N$$$480$$$481$$$I	or$$$482$$$484$$$O	C;$$$485$$$487$$$I	Z$$$488$$$489$$$O	is$$$490$$$492$$$O	CH$$$493$$$495$$$I	or$$$496$$$498$$$O	N,$$$499$$$501$$$I	which$$$502$$$507$$$O	are$$$508$$$511$$$O	inhibitors$$$512$$$522$$$O	of$$$523$$$525$$$O	JNK,$$$526$$$530$$$O	a$$$531$$$532$$$O	mammalian$$$533$$$542$$$O	protein$$$543$$$550$$$O	kinase$$$551$$$557$$$O	involved$$$558$$$566$$$O	cell$$$567$$$571$$$O	proliferation,$$$572$$$586$$$O	cell$$$587$$$591$$$O	death$$$592$$$597$$$O	and$$$598$$$601$$$O	response$$$602$$$610$$$O	to$$$611$$$613$$$O	extracellular$$$614$$$627$$$O	stimuli.$$$628$$$636$$$O	The$$$637$$$640$$$O	invention$$$641$$$650$$$O	also$$$651$$$655$$$O	relates$$$656$$$663$$$O	to$$$664$$$666$$$O	methods$$$667$$$674$$$O	for$$$675$$$678$$$O	producing$$$679$$$688$$$O	these$$$689$$$694$$$O	inhibitors.$$$695$$$706$$$O	The$$$707$$$710$$$O	invention$$$711$$$720$$$O	also$$$721$$$725$$$O	provides$$$726$$$734$$$O	pharmaceutical$$$735$$$749$$$O	compositions$$$750$$$762$$$O	comprising$$$763$$$773$$$O	the$$$774$$$777$$$O	inhibitors$$$778$$$788$$$O	of$$$789$$$791$$$O	the$$$792$$$795$$$O	invention$$$796$$$805$$$O	and$$$806$$$809$$$O	methods$$$810$$$817$$$O	of$$$818$$$820$$$O	utilizing$$$821$$$830$$$O	those$$$831$$$836$$$O	compositions$$$837$$$849$$$O	in$$$850$$$852$$$O	the$$$853$$$856$$$O	treatment$$$857$$$866$$$O	and$$$867$$$870$$$O	prevention$$$871$$$881$$$O	of$$$882$$$884$$$O	various$$$885$$$892$$$O	disorders.$$$893$$$903$$$O
EP1367886B1
Scce$$$0$$$4$$$O	transgenic$$$5$$$15$$$O	mice$$$16$$$20$$$O	and$$$21$$$24$$$O	their$$$25$$$30$$$O	use$$$31$$$34$$$O	as$$$35$$$37$$$O	models$$$38$$$44$$$O	of$$$45$$$47$$$O	human$$$48$$$53$$$O	disease$$$54$$$61$$$O
Genetic$$$0$$$7$$$O	evidence$$$8$$$16$$$O	that$$$17$$$21$$$O	an$$$22$$$24$$$O	imbalance$$$25$$$34$$$O	in$$$35$$$37$$$O	the$$$38$$$41$$$O	activity$$$42$$$50$$$O	of$$$51$$$53$$$O	serine$$$54$$$60$$$I	proteases$$$61$$$70$$$O	can$$$71$$$74$$$O	cause$$$75$$$80$$$O	severe$$$81$$$87$$$O	skin$$$88$$$92$$$O	disease$$$93$$$100$$$O	has$$$101$$$104$$$O	recently$$$105$$$113$$$O	been$$$114$$$118$$$O	presented.$$$119$$$129$$$O	The$$$130$$$133$$$O	serine$$$134$$$140$$$I	protease$$$141$$$149$$$O	SCCE$$$150$$$154$$$O	is$$$155$$$157$$$O	preferentially$$$158$$$172$$$O	expressed$$$173$$$182$$$O	in$$$183$$$185$$$O	cornifying$$$186$$$196$$$O	epithelia.$$$197$$$207$$$O	Increased$$$208$$$217$$$O	expression$$$218$$$228$$$O	of$$$229$$$231$$$O	SCCE$$$232$$$236$$$O	in$$$237$$$239$$$O	psoriasis$$$240$$$249$$$O	has$$$250$$$253$$$O	previously$$$254$$$264$$$O	been$$$265$$$269$$$O	reported.$$$270$$$279$$$O	Increased$$$280$$$289$$$O	SCCE$$$290$$$294$$$O	expression$$$295$$$305$$$O	also$$$306$$$310$$$O	in$$$311$$$313$$$O	chronic$$$314$$$321$$$O	lesions$$$322$$$329$$$O	of$$$330$$$332$$$O	atopic$$$333$$$339$$$O	dermatitis$$$340$$$350$$$O	is$$$351$$$353$$$O	described$$$354$$$363$$$O	herein.$$$364$$$371$$$O	Transgenic$$$372$$$382$$$O	mice$$$383$$$387$$$O	expressing$$$388$$$398$$$O	human$$$399$$$404$$$O	SCCE$$$405$$$409$$$O	in$$$410$$$412$$$O	suprabasal$$$413$$$423$$$O	epidermal$$$424$$$433$$$O	keratinocytes$$$434$$$447$$$O	were$$$448$$$452$$$O	found$$$453$$$458$$$O	to$$$459$$$461$$$O	develop$$$462$$$469$$$O	pathological$$$470$$$482$$$O	skin$$$483$$$487$$$O	changes$$$488$$$495$$$O	with$$$496$$$500$$$O	increased$$$501$$$510$$$O	epidermal$$$511$$$520$$$O	thickness,$$$521$$$531$$$O	hyperkeratosis,$$$532$$$547$$$O	dermal$$$548$$$554$$$O	inflammation,$$$555$$$568$$$O	and$$$569$$$572$$$O	severe$$$573$$$579$$$O	pruritus.$$$580$$$589$$$O	The$$$590$$$593$$$O	results$$$594$$$601$$$O	strengthen$$$602$$$612$$$O	the$$$613$$$616$$$O	idea$$$617$$$621$$$O	that$$$622$$$626$$$O	SCCE$$$627$$$631$$$O	may$$$632$$$635$$$O	be$$$636$$$638$$$O	involved$$$639$$$647$$$O	in$$$648$$$650$$$O	the$$$651$$$654$$$O	pathogenesis$$$655$$$667$$$O	of$$$668$$$670$$$O	inflammatory$$$671$$$683$$$O	skin$$$684$$$688$$$O	diseases,$$$689$$$698$$$O	and$$$699$$$702$$$O	may$$$703$$$706$$$O	offer$$$707$$$712$$$O	a$$$713$$$714$$$O	new$$$715$$$718$$$O	therapeutic$$$719$$$730$$$O	target.$$$731$$$738$$$O
DE102009049551A1
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	the$$$7$$$10$$$O	active$$$11$$$17$$$O	substance$$$18$$$27$$$O	propyphenazone$$$28$$$42$$$I	for$$$43$$$46$$$O	the$$$47$$$50$$$O	therapeutic$$$51$$$62$$$O	treatment$$$63$$$72$$$O	of$$$73$$$75$$$O	tumor,$$$76$$$82$$$O	where$$$83$$$88$$$O	the$$$89$$$92$$$O	active$$$93$$$99$$$O	substance$$$100$$$109$$$O	inhibits$$$110$$$118$$$O	the$$$119$$$122$$$O	growth$$$123$$$129$$$O	of$$$130$$$132$$$O	tumor$$$133$$$138$$$O	cells$$$139$$$144$$$O	and/or$$$145$$$151$$$O	degenerates$$$152$$$163$$$O	the$$$164$$$167$$$O	tumor$$$168$$$173$$$O	cells$$$174$$$179$$$O
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	the$$$7$$$10$$$O	active$$$11$$$17$$$O	substance$$$18$$$27$$$O	propyphenazone$$$28$$$42$$$I	for$$$43$$$46$$$O	the$$$47$$$50$$$O	therapeutic$$$51$$$62$$$O	treatment$$$63$$$72$$$O	of$$$73$$$75$$$O	tumor,$$$76$$$82$$$O	is$$$83$$$85$$$O	claimed.$$$86$$$94$$$O	The$$$95$$$98$$$O	active$$$99$$$105$$$O	substance$$$106$$$115$$$O	inhibits$$$116$$$124$$$O	the$$$125$$$128$$$O	growth$$$129$$$135$$$O	of$$$136$$$138$$$O	tumor$$$139$$$144$$$O	cells$$$145$$$150$$$O	and/or$$$151$$$157$$$O	degenerates$$$158$$$169$$$O	the$$$170$$$173$$$O	tumor$$$174$$$179$$$O	cells.$$$180$$$186$$$O	-$$$187$$$188$$$O	ACTIVITY$$$189$$$197$$$O	:$$$198$$$199$$$O	Cytostatic.$$$200$$$211$$$O	No$$$212$$$214$$$O	biological$$$215$$$225$$$O	data$$$226$$$230$$$O	given.$$$231$$$237$$$O	-$$$238$$$239$$$O	MECHANISM$$$240$$$249$$$O	OF$$$250$$$252$$$O	ACTION$$$253$$$259$$$O	:$$$260$$$261$$$O	None$$$262$$$266$$$O	given.$$$267$$$273$$$O
CN103319371A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	and$$$19$$$22$$$O	application$$$23$$$34$$$O	of$$$35$$$37$$$O	N-substituted$$$38$$$51$$$I	hydroxamic$$$52$$$62$$$I	acid$$$63$$$67$$$I	compound$$$68$$$76$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	and$$$45$$$48$$$O	application$$$49$$$60$$$O	of$$$61$$$63$$$O	an$$$64$$$66$$$O	N-substituted$$$67$$$80$$$I	hydroxamic$$$81$$$91$$$I	acid$$$92$$$96$$$I	compound.$$$97$$$106$$$O	The$$$107$$$110$$$O	histone$$$111$$$118$$$O	compound$$$119$$$127$$$O	with$$$128$$$132$$$O	a$$$133$$$134$$$O	4-benzamido-N-hydroxy-N-benzoylphenyl$$$135$$$172$$$I	ammonia$$$173$$$180$$$I	structure,$$$181$$$191$$$O	i.e.,$$$192$$$197$$$O	the$$$198$$$201$$$O	N-substituted$$$202$$$215$$$I	hydroxamic$$$216$$$226$$$I	acid$$$227$$$231$$$I	compound,$$$232$$$241$$$O	is$$$242$$$244$$$O	represented$$$245$$$256$$$O	by$$$257$$$259$$$O	formula$$$260$$$267$$$O	1$$$268$$$269$$$O	as$$$270$$$272$$$O	described$$$273$$$282$$$O	in$$$283$$$285$$$O	the$$$286$$$289$$$O	specification.$$$290$$$304$$$O	The$$$305$$$308$$$O	preparation$$$309$$$320$$$O	method$$$321$$$327$$$O	comprises$$$328$$$337$$$O	the$$$338$$$341$$$O	following$$$342$$$351$$$O	steps:$$$352$$$358$$$O	with$$$359$$$363$$$O	methyl$$$364$$$370$$$I	p-aminobenzoate,$$$371$$$387$$$I	benzoyl$$$388$$$395$$$I	chloride$$$396$$$404$$$I	and$$$405$$$408$$$O	nitrobenzene$$$409$$$421$$$I	as$$$422$$$424$$$O	raw$$$425$$$428$$$O	materials,$$$429$$$439$$$O	allowing$$$440$$$448$$$O	methyl$$$449$$$455$$$I	p-aminobenzoate$$$456$$$471$$$I	and$$$472$$$475$$$O	benzoyl$$$476$$$483$$$I	chloride$$$484$$$492$$$I	to$$$493$$$495$$$O	undergo$$$496$$$503$$$O	aminoacylation$$$504$$$518$$$O	and$$$519$$$522$$$O	subjecting$$$523$$$533$$$O	a$$$534$$$535$$$O	reaction$$$536$$$544$$$O	product$$$545$$$552$$$O	to$$$553$$$555$$$O	hydrolysis$$$556$$$566$$$O	and$$$567$$$570$$$O	acylation$$$571$$$580$$$O	so$$$581$$$583$$$O	as$$$584$$$586$$$O	to$$$587$$$589$$$O	prepare$$$590$$$597$$$O	4-benzamido-benzoyl$$$598$$$617$$$I	chloride$$$618$$$626$$$I	or$$$627$$$629$$$O	4-(4-chlorphenyl-formamido)benzoyl$$$630$$$664$$$I	chloride$$$665$$$673$$$I	or$$$674$$$676$$$O	4-phenylacetamido-benzoyl$$$677$$$702$$$I	chloride;$$$703$$$712$$$I	and$$$713$$$716$$$O	reducing$$$717$$$725$$$O	nitrobenzene$$$726$$$738$$$I	into$$$739$$$743$$$O	N-hydroxy$$$744$$$753$$$I	aniline$$$754$$$761$$$I	under$$$762$$$767$$$O	the$$$768$$$771$$$O	catalysis$$$772$$$781$$$O	of$$$782$$$784$$$O	Raney$$$785$$$790$$$I	nickel$$$791$$$797$$$I	and$$$798$$$801$$$O	reacting$$$802$$$810$$$O	N-hydroxy$$$811$$$820$$$I	aniline$$$821$$$828$$$I	with$$$829$$$833$$$O	4-benzamido-benzoyl$$$834$$$853$$$I	chloride$$$854$$$862$$$I	so$$$863$$$865$$$O	as$$$866$$$868$$$O	to$$$869$$$871$$$O	obtain$$$872$$$878$$$O	the$$$879$$$882$$$O	target$$$883$$$889$$$O	compound.$$$890$$$899$$$O
EP1280500B1
Synergistic$$$0$$$11$$$O	antiplaque/antigingivitis$$$12$$$37$$$O	oral$$$38$$$42$$$O	composition$$$43$$$54$$$O
An$$$0$$$2$$$O	oral$$$3$$$7$$$O	care$$$8$$$12$$$O	composition$$$13$$$24$$$O	containing$$$25$$$35$$$O	a$$$36$$$37$$$O	synergistic$$$38$$$49$$$O	antiplaque/antigingivitis$$$50$$$75$$$O	combination$$$76$$$87$$$O	of$$$88$$$90$$$O	a$$$91$$$92$$$O	nonionic$$$93$$$101$$$O	halogenated$$$102$$$113$$$O	diphenyl$$$114$$$122$$$I	ether$$$123$$$128$$$I	compound$$$129$$$137$$$O	such$$$138$$$142$$$O	as$$$143$$$145$$$O	Triclosan$$$146$$$155$$$I	and$$$156$$$159$$$O	an$$$160$$$162$$$O	extract$$$163$$$170$$$O	of$$$171$$$173$$$O	Magnolia$$$174$$$182$$$O	Officinalas$$$183$$$194$$$O	containing$$$195$$$205$$$O	honokiol$$$206$$$214$$$I	and$$$215$$$218$$$O	magnolol.$$$219$$$228$$$I
US20080249096
Pharmaceutical$$$0$$$14$$$O	Forms$$$15$$$20$$$O	with$$$21$$$25$$$O	Improved$$$26$$$34$$$O	Pharmacokinetic$$$35$$$50$$$O	Properties$$$51$$$61$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	application$$$12$$$23$$$O	relates$$$24$$$31$$$O	to$$$32$$$34$$$O	novel$$$35$$$40$$$O	drug$$$41$$$45$$$O	formulations$$$46$$$58$$$O	of$$$59$$$61$$$O	vardenafil$$$62$$$72$$$I	which$$$73$$$78$$$O	dissolve$$$79$$$87$$$O	rapidly$$$88$$$95$$$O	in$$$96$$$98$$$O	the$$$99$$$102$$$O	mouth$$$103$$$108$$$O	and$$$109$$$112$$$O	lead$$$113$$$117$$$O	to$$$118$$$120$$$O	increased$$$121$$$130$$$O	bioavailability$$$131$$$146$$$O	and$$$147$$$150$$$O	to$$$151$$$153$$$O	a$$$154$$$155$$$O	plateau-like$$$156$$$168$$$O	plasma$$$169$$$175$$$O	concentration$$$176$$$189$$$O	profile,$$$190$$$198$$$O	and$$$199$$$202$$$O	to$$$203$$$205$$$O	processes$$$206$$$215$$$O	for$$$216$$$219$$$O	their$$$220$$$225$$$O	preparation.$$$226$$$238$$$O
WO2010017827A1
6-substituted$$$0$$$13$$$I	1-sulfonyl-2,$$$14$$$27$$$I	3-dihydro-indole$$$28$$$44$$$I	derivatives$$$45$$$56$$$O	for$$$57$$$60$$$O	the$$$61$$$64$$$O	treatment$$$65$$$74$$$O	of$$$75$$$77$$$O	proliferative$$$78$$$91$$$O	diseases$$$92$$$100$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	indoline-sulfonamide$$$33$$$53$$$I	compounds$$$54$$$63$$$O	according$$$64$$$73$$$O	to$$$74$$$76$$$O	general$$$77$$$84$$$O	structural$$$85$$$95$$$O	formula$$$96$$$103$$$O	(I),$$$104$$$108$$$O	pharmaceutical$$$109$$$123$$$O	compositions$$$124$$$136$$$O	comprising$$$137$$$147$$$O	a$$$148$$$149$$$O	compound$$$150$$$158$$$O	of$$$159$$$161$$$O	the$$$162$$$165$$$O	invention.$$$166$$$176$$$O	Further$$$177$$$184$$$O	provided$$$185$$$193$$$O	is$$$194$$$196$$$O	the$$$197$$$200$$$O	use$$$201$$$204$$$O	of$$$205$$$207$$$O	a$$$208$$$209$$$O	compound$$$210$$$218$$$O	or$$$219$$$221$$$O	a$$$222$$$223$$$O	composition$$$224$$$235$$$O	according$$$236$$$245$$$O	to$$$246$$$248$$$O	the$$$249$$$252$$$O	invention$$$253$$$262$$$O	for$$$263$$$266$$$O	the$$$267$$$270$$$O	preparation$$$271$$$282$$$O	of$$$283$$$285$$$O	a$$$286$$$287$$$O	medicament$$$288$$$298$$$O	for$$$299$$$302$$$O	the$$$303$$$306$$$O	treatment$$$307$$$316$$$O	of$$$317$$$319$$$O	a$$$320$$$321$$$O	proliferative$$$322$$$335$$$O	disease,$$$336$$$344$$$O	in$$$345$$$347$$$O	particular$$$348$$$358$$$O	the$$$359$$$362$$$O	treatment$$$363$$$372$$$O	of$$$373$$$375$$$O	cancer.$$$376$$$383$$$O
EP2331520A1
Rosamine$$$0$$$8$$$I	derivatives$$$9$$$20$$$O	as$$$21$$$23$$$O	agents$$$24$$$30$$$O	for$$$31$$$34$$$O	the$$$35$$$38$$$O	treatment$$$39$$$48$$$O	of$$$49$$$51$$$O	cancer$$$52$$$58$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	new$$$35$$$38$$$O	class$$$39$$$44$$$O	of$$$45$$$47$$$O	rosamine$$$48$$$56$$$I	derivatives,$$$57$$$69$$$O	in$$$70$$$72$$$O	one$$$73$$$76$$$O	embodiment,$$$77$$$88$$$O	the$$$89$$$92$$$O	compounds$$$93$$$102$$$O	have$$$103$$$107$$$O	the$$$108$$$111$$$O	structure$$$112$$$121$$$O	(I)$$$122$$$125$$$O	or$$$126$$$128$$$O	any$$$129$$$132$$$O	pharmaceutically$$$133$$$149$$$O	acceptable$$$150$$$160$$$O	salt$$$161$$$165$$$O	or$$$166$$$168$$$O	solvate$$$169$$$176$$$O	thereof,$$$177$$$185$$$O	wherein:$$$186$$$194$$$O	R1$$$195$$$197$$$O	represents$$$198$$$208$$$O	aryl,$$$209$$$214$$$I	Het1$$$215$$$219$$$O	or$$$220$$$222$$$O	C1-6$$$223$$$227$$$I	alkyl,$$$228$$$234$$$I	which$$$235$$$240$$$O	latter$$$241$$$247$$$O	group$$$248$$$253$$$O	is$$$254$$$256$$$O	optionally$$$257$$$267$$$O	substituted$$$268$$$279$$$O	by$$$280$$$282$$$O	aryl$$$283$$$287$$$I	or$$$288$$$290$$$O	Het2;$$$291$$$296$$$O	R2a$$$297$$$300$$$O	and$$$301$$$304$$$O	R2b$$$305$$$308$$$O	together$$$309$$$317$$$O	form$$$318$$$322$$$O	C3.8$$$323$$$327$$$I	n-alkylene,$$$328$$$339$$$I	which$$$340$$$345$$$O	alkylene$$$346$$$354$$$I	group$$$355$$$360$$$O	is$$$361$$$363$$$O	optionally$$$364$$$374$$$O	substituted$$$375$$$386$$$O	by$$$387$$$389$$$O	one$$$390$$$393$$$O	or$$$394$$$396$$$O	more$$$397$$$401$$$O	substituents$$$402$$$414$$$O	selected$$$415$$$423$$$O	from$$$424$$$428$$$O	halo,$$$429$$$434$$$I	C1-4$$$435$$$439$$$I	alkyl,$$$440$$$446$$$I	C(O)OH$$$447$$$453$$$I	and$$$454$$$457$$$O	C(O)O-C1-4,$$$458$$$469$$$I	alkyl.and$$$470$$$479$$$I	which$$$480$$$485$$$O	alkylene$$$486$$$494$$$I	group$$$495$$$500$$$O	is$$$501$$$503$$$O	optionally$$$504$$$514$$$O	interrupted$$$515$$$526$$$O	by$$$527$$$529$$$O	X1;$$$530$$$533$$$O	R3a$$$534$$$537$$$O	and$$$538$$$541$$$O	R3b$$$542$$$545$$$O	together$$$546$$$554$$$O	form$$$555$$$559$$$O	C3-6$$$560$$$564$$$I	/7-alkylene,$$$565$$$577$$$I	which$$$578$$$583$$$O	alkylene$$$584$$$592$$$I	group$$$593$$$598$$$O	is$$$599$$$601$$$O	optionally$$$602$$$612$$$O	substituted$$$613$$$624$$$O	by$$$625$$$627$$$O	one$$$628$$$631$$$O	or$$$632$$$634$$$O	more$$$635$$$639$$$O	substituents$$$640$$$652$$$O	selected$$$653$$$661$$$O	from$$$662$$$666$$$O	halo,$$$667$$$672$$$I	C1-4$$$673$$$677$$$I	alkyl,$$$678$$$684$$$I	C(O)OH$$$685$$$691$$$I	and$$$692$$$695$$$O	C(O)O-C1-4$$$696$$$706$$$I	alkyl,$$$707$$$713$$$I	and$$$714$$$717$$$O	which$$$718$$$723$$$O	alkylene$$$724$$$732$$$I	group$$$733$$$738$$$O	is$$$739$$$741$$$O	optionally$$$742$$$752$$$O	interrupted$$$753$$$764$$$O	by$$$765$$$767$$$O	X2;$$$768$$$771$$$O	X1$$$772$$$774$$$O	and$$$775$$$778$$$O	X2$$$779$$$781$$$O	independently$$$782$$$795$$$O	represent$$$796$$$805$$$O	O,$$$806$$$808$$$I	S,$$$809$$$811$$$I	or$$$812$$$814$$$O	NR4;$$$815$$$819$$$I	R4$$$820$$$822$$$O	represents,$$$823$$$834$$$O	independently$$$835$$$848$$$O	at$$$849$$$851$$$O	each$$$852$$$856$$$O	occurrence,$$$857$$$868$$$O	H,$$$869$$$871$$$I	C(O)OR5,$$$872$$$880$$$I	C(0)R6a,$$$881$$$889$$$I	C(O)N(R6b)R6c$$$890$$$903$$$I	or$$$904$$$906$$$O	C1-6,$$$907$$$912$$$I	alkyl,$$$913$$$919$$$I	which$$$920$$$925$$$O	latter$$$926$$$932$$$O	group$$$933$$$938$$$O	is$$$939$$$941$$$O	optionally$$$942$$$952$$$O	substituted$$$953$$$964$$$O	by$$$965$$$967$$$O	one$$$968$$$971$$$O	or$$$972$$$974$$$O	more$$$975$$$979$$$O	substituents$$$980$$$992$$$O	selected$$$993$$$1001$$$O	from$$$1002$$$1006$$$O	halo,$$$1007$$$1012$$$I	aryl$$$1013$$$1017$$$I	and$$$1018$$$1021$$$O	Het3$$$1022$$$1026$$$O	or$$$1027$$$1029$$$O	is$$$1030$$$1032$$$O	substituted$$$1033$$$1044$$$O	by$$$1045$$$1047$$$O	a$$$1048$$$1049$$$O	single$$$1050$$$1056$$$O	C(0)0R1a$$$1057$$$1065$$$I	group;$$$1066$$$1072$$$O	R4a$$$1073$$$1076$$$O	represents$$$1077$$$1087$$$O	H$$$1088$$$1089$$$I	or$$$1090$$$1092$$$O	C1-4$$$1093$$$1097$$$I	alkyl;$$$1098$$$1104$$$I	R5$$$1105$$$1107$$$O	represents$$$1108$$$1118$$$O	aryl,$$$1119$$$1124$$$I	Het4$$$1125$$$1129$$$O	or$$$1130$$$1132$$$O	C1-6$$$1133$$$1137$$$I	alkyl$$$1138$$$1143$$$I	optionally$$$1144$$$1154$$$O	substituted$$$1155$$$1166$$$O	by$$$1167$$$1169$$$O	one$$$1170$$$1173$$$O	or$$$1174$$$1176$$$O	more$$$1177$$$1181$$$O	substituents$$$1182$$$1194$$$O	selected$$$1195$$$1203$$$O	from$$$1204$$$1208$$$O	halo,$$$1209$$$1214$$$I	aryl$$$1215$$$1219$$$I	and$$$1220$$$1223$$$O	Het5;$$$1224$$$1229$$$O	R5e$$$1230$$$1233$$$O	to$$$1234$$$1236$$$O	R6d$$$1237$$$1240$$$O	independently$$$1241$$$1254$$$O	represent$$$1255$$$1264$$$O	H$$$1265$$$1266$$$I	or$$$1267$$$1269$$$O	R5;$$$1270$$$1273$$$O	each$$$1274$$$1278$$$O	aryl$$$1279$$$1283$$$I	independently$$$1284$$$1297$$$O	represents$$$1298$$$1308$$$O	a$$$1309$$$1310$$$O	C6-10$$$1311$$$1316$$$I	carbocyclic$$$1317$$$1328$$$I	aromatic$$$1329$$$1337$$$I	group,$$$1338$$$1344$$$O	which$$$1345$$$1350$$$O	group$$$1351$$$1356$$$O	may$$$1357$$$1360$$$O	comprise$$$1361$$$1369$$$O	either$$$1370$$$1376$$$O	one$$$1377$$$1380$$$O	or$$$1381$$$1383$$$O	two$$$1384$$$1387$$$O	rings$$$1388$$$1393$$$O	and$$$1394$$$1397$$$O	may$$$1398$$$1401$$$O	be$$$1402$$$1404$$$O	substituted$$$1405$$$1416$$$O	by$$$1417$$$1419$$$O	one$$$1420$$$1423$$$O	or$$$1424$$$1426$$$O	more$$$1427$$$1431$$$O	substituents$$$1432$$$1444$$$O	selected$$$1445$$$1453$$$O	from$$$1454$$$1458$$$O	halo,$$$1459$$$1464$$$I	CN,$$$1465$$$1468$$$I	C1-6$$$1469$$$1473$$$I	alkyl$$$1474$$$1479$$$I	(which$$$1480$$$1486$$$O	latter$$$1487$$$1493$$$O	group$$$1494$$$1499$$$O	is$$$1500$$$1502$$$O	optionally$$$1503$$$1513$$$O	substituted$$$1514$$$1525$$$O	by$$$1526$$$1528$$$O	one$$$1529$$$1532$$$O	or$$$1533$$$1535$$$O	more$$$1536$$$1540$$$O	substituents$$$1541$$$1553$$$O	selected$$$1554$$$1562$$$O	from$$$1563$$$1567$$$O	halo,$$$1568$$$1573$$$I	OR7,$$$1574$$$1578$$$I	phenyl,$$$1579$$$1586$$$I	naphthyl$$$1587$$$1595$$$I	and$$$1596$$$1599$$$O	Het6)$$$1600$$$1605$$$O	and$$$1606$$$1609$$$O	OR8;$$$1610$$$1614$$$I	R7$$$1615$$$1617$$$O	and$$$1618$$$1621$$$O	R8$$$1622$$$1624$$$O	independently$$$1625$$$1638$$$O	represent$$$1639$$$1648$$$O	H,$$$1649$$$1651$$$I	C1-4$$$1652$$$1656$$$I	alkyl$$$1657$$$1662$$$I	(optionally$$$1663$$$1674$$$O	substituted$$$1675$$$1686$$$O	by$$$1687$$$1689$$$O	one$$$1690$$$1693$$$O	or$$$1694$$$1696$$$O	more$$$1697$$$1701$$$O	halo$$$1702$$$1706$$$I	groups$$$1707$$$1713$$$O	or$$$1714$$$1716$$$O	by$$$1717$$$1719$$$O	a$$$1720$$$1721$$$O	single$$$1722$$$1728$$$O	phenyl$$$1729$$$1735$$$I	or$$$1736$$$1738$$$O	C(O)OR8a$$$1739$$$1747$$$I	substituent),$$$1748$$$1761$$$O	Het7,$$$1762$$$1767$$$O	phenyl$$$1768$$$1774$$$I	or$$$1775$$$1777$$$O	naphthyl;$$$1778$$$1787$$$I	R8a$$$1788$$$1791$$$O	represents$$$1792$$$1802$$$O	H$$$1803$$$1804$$$O	or$$$1805$$$1807$$$O	C1-4$$$1808$$$1812$$$I	alkyl;$$$1813$$$1819$$$I	Het1$$$1820$$$1824$$$O	to$$$1825$$$1827$$$O	Het7$$$1828$$$1832$$$O	independently$$$1833$$$1846$$$O	represent$$$1847$$$1856$$$O	5-$$$1857$$$1859$$$O	to$$$1860$$$1862$$$O	10-membered$$$1863$$$1874$$$O	aromatic,$$$1875$$$1884$$$O	fully$$$1885$$$1890$$$O	saturated$$$1891$$$1900$$$O	or$$$1901$$$1903$$$O	partially$$$1904$$$1913$$$O	unsaturated$$$1914$$$1925$$$O	heterocyclic$$$1926$$$1938$$$O	groups$$$1939$$$1945$$$O	containing$$$1946$$$1956$$$O	one$$$1957$$$1960$$$O	or.more$$$1961$$$1968$$$O	heteroatoms$$$1969$$$1980$$$O	selected$$$1981$$$1989$$$O	from$$$1990$$$1994$$$O	oxygen,$$$1995$$$2002$$$I	nitrogen$$$2003$$$2011$$$I	and/or$$$2012$$$2018$$$O	sulfur,$$$2019$$$2026$$$I	which$$$2027$$$2032$$$O	heterocyclic$$$2033$$$2045$$$I	groups$$$2046$$$2052$$$O	may$$$2053$$$2056$$$O	comprise$$$2057$$$2065$$$O	one$$$2066$$$2069$$$O	or$$$2070$$$2072$$$O	two$$$2073$$$2076$$$O	rings$$$2077$$$2082$$$O	and$$$2083$$$2086$$$O	may$$$2087$$$2090$$$O	be$$$2091$$$2093$$$O	substituted$$$2094$$$2105$$$O	by$$$2106$$$2108$$$O	one$$$2109$$$2112$$$O	or$$$2113$$$2115$$$O	more$$$2116$$$2120$$$O	substituents$$$2121$$$2133$$$O	selected$$$2134$$$2142$$$O	from$$$2143$$$2147$$$O	Halo,$$$2148$$$2153$$$I	CN,$$$2154$$$2157$$$I	C1-6$$$2158$$$2162$$$I	alkyl$$$2163$$$2168$$$I	(which$$$2169$$$2175$$$O	latter$$$2176$$$2182$$$O	group$$$2183$$$2188$$$O	is$$$2189$$$2191$$$O	optionally$$$2192$$$2202$$$O	substituted$$$2203$$$2214$$$O	by$$$2215$$$2217$$$O	one$$$2218$$$2221$$$O	or$$$2222$$$2224$$$O	more$$$2225$$$2229$$$O	substituents$$$2230$$$2242$$$O	selected$$$2243$$$2251$$$O	from$$$2252$$$2256$$$O	halo,$$$2257$$$2262$$$I	OR9$$$2263$$$2266$$$I	and$$$2267$$$2270$$$O	phenyl)$$$2271$$$2278$$$I	and$$$2279$$$2282$$$O	OR10;$$$2283$$$2288$$$I	R9$$$2289$$$2291$$$O	and$$$2292$$$2295$$$O	R10$$$2296$$$2299$$$O	independently$$$2300$$$2313$$$O	represent$$$2314$$$2323$$$O	H,$$$2324$$$2326$$$I	C1-4$$$2327$$$2331$$$I	alkyl$$$2332$$$2337$$$I	or$$$2338$$$2340$$$O	phenyl;$$$2341$$$2348$$$I	unless$$$2349$$$2355$$$O	otherwise$$$2356$$$2365$$$O	specified,$$$2366$$$2376$$$O	alkyl$$$2377$$$2382$$$I	groups$$$2383$$$2389$$$O	are$$$2390$$$2393$$$O	optionally$$$2394$$$2404$$$O	substituted$$$2405$$$2416$$$O	by$$$2417$$$2419$$$O	one$$$2420$$$2423$$$O	or$$$2424$$$2426$$$O	more$$$2427$$$2431$$$O	halo$$$2432$$$2436$$$I	atoms;$$$2437$$$2443$$$O	and$$$2444$$$2447$$$O	A'$$$2448$$$2450$$$O	represents$$$2451$$$2461$$$O	a$$$2462$$$2463$$$O	pharmaceutically$$$2464$$$2480$$$O	acceptable$$$2481$$$2491$$$O	anion.$$$2492$$$2498$$$O	Also$$$2499$$$2503$$$O	disclosed$$$2504$$$2513$$$O	are$$$2514$$$2517$$$O	methods$$$2518$$$2525$$$O	for$$$2526$$$2529$$$O	making$$$2530$$$2536$$$O	and$$$2537$$$2540$$$O	using$$$2541$$$2546$$$O	'$$$2547$$$2548$$$O	compounds$$$2549$$$2558$$$O	as$$$2559$$$2561$$$O	well$$$2562$$$2566$$$O	as$$$2567$$$2569$$$O	pharmaceutical$$$2570$$$2584$$$O	compositions.$$$2585$$$2598$$$O
WO2010133793A1
Drug$$$0$$$4$$$O	containing$$$5$$$15$$$O	calcium$$$16$$$23$$$I	and$$$24$$$27$$$O	vitamin$$$28$$$35$$$I	d$$$36$$$37$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	drug$$$35$$$39$$$O	to$$$40$$$42$$$O	be$$$43$$$45$$$O	used$$$46$$$50$$$O	for$$$51$$$54$$$O	preventing$$$55$$$65$$$O	and$$$66$$$69$$$O	treating$$$70$$$78$$$O	osteoporosis,$$$79$$$92$$$O	characterized$$$93$$$106$$$O	in$$$107$$$109$$$O	that$$$110$$$114$$$O	it$$$115$$$117$$$O	includes$$$118$$$126$$$O	two$$$127$$$130$$$O	separate$$$131$$$139$$$O	pharmaceutical$$$140$$$154$$$O	compositions$$$155$$$167$$$O	(A)$$$168$$$171$$$O	and$$$172$$$175$$$O	(B),$$$176$$$180$$$O	the$$$181$$$184$$$O	pharmaceutical$$$185$$$199$$$O	composition$$$200$$$211$$$O	(A)$$$212$$$215$$$O	containing$$$216$$$226$$$O	vitamin$$$227$$$234$$$O	D$$$235$$$236$$$O	and$$$237$$$240$$$O	the$$$241$$$244$$$O	pharmaceutical$$$245$$$259$$$O	composition$$$260$$$271$$$O	(B)$$$272$$$275$$$O	containing$$$276$$$286$$$O	calcium,$$$287$$$295$$$I	for$$$296$$$299$$$O	administration$$$300$$$314$$$O	at$$$315$$$317$$$O	separate$$$318$$$326$$$O	points$$$327$$$333$$$O	in$$$334$$$336$$$O	time,$$$337$$$342$$$O	the$$$343$$$346$$$O	pharmaceutical$$$347$$$361$$$O	composition$$$362$$$373$$$O	(A)$$$374$$$377$$$O	being$$$378$$$383$$$O	administered$$$384$$$396$$$O	before$$$397$$$403$$$O	the$$$404$$$407$$$O	pharmaceutical$$$408$$$422$$$O	composition$$$423$$$434$$$O	(B).$$$435$$$439$$$O
CN103054880A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	tanshinone$$$15$$$25$$$I	IIA$$$26$$$29$$$I	as$$$30$$$32$$$O	inhibitor$$$33$$$42$$$O	for$$$43$$$46$$$O	redox$$$47$$$52$$$O	function$$$53$$$61$$$O	of$$$62$$$64$$$O	APE1$$$65$$$69$$$O	and$$$70$$$73$$$O	application$$$74$$$85$$$O	of$$$86$$$88$$$O	tanshinone$$$89$$$99$$$I	IIA$$$100$$$103$$$I	in$$$104$$$106$$$O	preparation$$$107$$$118$$$O	of$$$119$$$121$$$O	drugs$$$122$$$127$$$O	used$$$128$$$132$$$O	for$$$133$$$136$$$O	treating$$$137$$$145$$$O	cancers$$$146$$$153$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	technical$$$29$$$38$$$O	field$$$39$$$44$$$O	of$$$45$$$47$$$O	natural$$$48$$$55$$$O	drugs,$$$56$$$62$$$O	especially$$$63$$$73$$$O	to$$$74$$$76$$$O	application$$$77$$$88$$$O	of$$$89$$$91$$$O	tanshinone$$$92$$$102$$$I	IIA$$$103$$$106$$$I	as$$$107$$$109$$$O	an$$$110$$$112$$$O	inhibitor$$$113$$$122$$$O	for$$$123$$$126$$$O	the$$$127$$$130$$$O	redox$$$131$$$136$$$O	function$$$137$$$145$$$O	of$$$146$$$148$$$O	APE1$$$149$$$153$$$O	and$$$154$$$157$$$O	application$$$158$$$169$$$O	of$$$170$$$172$$$O	tanshinone$$$173$$$183$$$I	IIA$$$184$$$187$$$I	in$$$188$$$190$$$O	preparation$$$191$$$202$$$O	of$$$203$$$205$$$O	drugs$$$206$$$211$$$O	used$$$212$$$216$$$O	for$$$217$$$220$$$O	treating$$$221$$$229$$$O	cancers.$$$230$$$238$$$O	Tanshinone$$$239$$$249$$$I	IIA$$$250$$$253$$$I	can$$$254$$$257$$$O	inhibit$$$258$$$265$$$O	the$$$266$$$269$$$O	redox$$$270$$$275$$$O	function$$$276$$$284$$$O	of$$$285$$$287$$$O	APE1$$$288$$$292$$$O	and$$$293$$$296$$$O	directly$$$297$$$305$$$O	kill$$$306$$$310$$$O	tumor$$$311$$$316$$$O	cells$$$317$$$322$$$O	through$$$323$$$330$$$O	inhibition$$$331$$$341$$$O	of$$$342$$$344$$$O	the$$$345$$$348$$$O	redox$$$349$$$354$$$O	function$$$355$$$363$$$O	of$$$364$$$366$$$O	APE1;$$$367$$$372$$$O	tanshinone$$$373$$$383$$$I	IIA$$$384$$$387$$$I	can$$$388$$$391$$$O	also$$$392$$$396$$$O	reverse$$$397$$$404$$$O	overactivity$$$405$$$417$$$O	of$$$418$$$420$$$O	the$$$421$$$424$$$O	redox$$$425$$$430$$$O	function$$$431$$$439$$$O	caused$$$440$$$446$$$O	by$$$447$$$449$$$O	high$$$450$$$454$$$O	expression$$$455$$$465$$$O	of$$$466$$$468$$$O	APE1$$$469$$$473$$$O	in$$$474$$$476$$$O	the$$$477$$$480$$$O	tumor$$$481$$$486$$$O	cells,$$$487$$$493$$$O	inhibit$$$494$$$501$$$O	propagation$$$502$$$513$$$O	and$$$514$$$517$$$O	infiltration$$$518$$$530$$$O	of$$$531$$$533$$$O	tumor$$$534$$$539$$$O	cells,$$$540$$$546$$$O	reverse$$$547$$$554$$$O	anti-apoptosis$$$555$$$569$$$O	of$$$570$$$572$$$O	the$$$573$$$576$$$O	tumor$$$577$$$582$$$O	cells$$$583$$$588$$$O	and$$$589$$$592$$$O	prevent$$$593$$$600$$$O	metastasis$$$601$$$611$$$O	of$$$612$$$614$$$O	the$$$615$$$618$$$O	tumor$$$619$$$624$$$O	cells;$$$625$$$631$$$O	tanshinone$$$632$$$642$$$I	IIA$$$643$$$646$$$I	can$$$647$$$650$$$O	further$$$651$$$658$$$O	reverse$$$659$$$666$$$O	drug$$$667$$$671$$$O	resistance$$$672$$$682$$$O	of$$$683$$$685$$$O	the$$$686$$$689$$$O	tumor$$$690$$$695$$$O	cells$$$696$$$701$$$O	to$$$702$$$704$$$O	chemotherapeutics$$$705$$$722$$$O	caused$$$723$$$729$$$O	by$$$730$$$732$$$O	high$$$733$$$737$$$O	expression$$$738$$$748$$$O	of$$$749$$$751$$$O	APE1$$$752$$$756$$$O	in$$$757$$$759$$$O	the$$$760$$$763$$$O	tumor$$$764$$$769$$$O	cells;$$$770$$$776$$$O	moreover,$$$777$$$786$$$O	while$$$787$$$792$$$O	having$$$793$$$799$$$O	anticancer$$$800$$$810$$$O	and$$$811$$$814$$$O	chemosensitization$$$815$$$833$$$O	performances,$$$834$$$847$$$O	tanshinone$$$848$$$858$$$I	IIA$$$859$$$862$$$I	has$$$863$$$866$$$O	a$$$867$$$868$$$O	usage$$$869$$$874$$$O	and$$$875$$$878$$$O	development$$$879$$$890$$$O	potential$$$891$$$900$$$O	due$$$901$$$904$$$O	to$$$905$$$907$$$O	small$$$908$$$913$$$O	toxic$$$914$$$919$$$O	and$$$920$$$923$$$O	side$$$924$$$928$$$O	effects.$$$929$$$937$$$O
US20090042874
Antidepressant$$$0$$$14$$$O	heteroaryl$$$15$$$25$$$I	derivatives$$$26$$$37$$$I	of$$$38$$$40$$$I	heterocycle-fused$$$41$$$58$$$I	benzodioxans$$$59$$$71$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds$$$23$$$32$$$O	of$$$33$$$35$$$O	the$$$36$$$39$$$O	Formula:$$$40$$$48$$$O	that$$$86$$$90$$$O	are$$$91$$$94$$$O	useful$$$95$$$101$$$O	for$$$102$$$105$$$O	the$$$106$$$109$$$O	treatment$$$110$$$119$$$O	of$$$120$$$122$$$O	depression$$$123$$$133$$$O	(including$$$134$$$144$$$O	but$$$145$$$148$$$O	not$$$149$$$152$$$O	limited$$$153$$$160$$$O	to$$$161$$$163$$$O	major$$$164$$$169$$$O	depressive$$$170$$$180$$$O	disorder,$$$181$$$190$$$O	childhood$$$191$$$200$$$O	depression$$$201$$$211$$$O	and$$$212$$$215$$$O	dysthymia),$$$216$$$227$$$O	anxiety,$$$228$$$236$$$O	panic$$$237$$$242$$$O	disorder,$$$243$$$252$$$O	post-traumatic$$$253$$$267$$$O	stress$$$268$$$274$$$O	disorder,$$$275$$$284$$$O	premenstrual$$$285$$$297$$$O	dysphoric$$$298$$$307$$$O	disorder$$$308$$$316$$$O	(also$$$317$$$322$$$O	known$$$323$$$328$$$O	as$$$329$$$331$$$O	pre-menstrual$$$332$$$345$$$O	syndrome),$$$346$$$356$$$O	attention$$$357$$$366$$$O	deficit$$$367$$$374$$$O	disorder$$$375$$$383$$$O	(with$$$384$$$389$$$O	and$$$390$$$393$$$O	without$$$394$$$401$$$O	hyperactivity),$$$402$$$417$$$O	obsessive$$$418$$$427$$$O	compulsive$$$428$$$438$$$O	disorder,$$$439$$$448$$$O	social$$$449$$$455$$$O	anxiety$$$456$$$463$$$O	disorder,$$$464$$$473$$$O	generalized$$$474$$$485$$$O	anxiety$$$486$$$493$$$O	disorder,$$$494$$$503$$$O	obesity,$$$504$$$512$$$O	eating$$$513$$$519$$$O	disorders$$$520$$$529$$$O	such$$$530$$$534$$$O	as$$$535$$$537$$$O	anorexia$$$538$$$546$$$O	nervosa,$$$547$$$555$$$O	bulimia$$$556$$$563$$$O	nervosa,$$$564$$$572$$$O	vasomotor$$$573$$$582$$$O	flushing,$$$583$$$592$$$O	cocaine$$$593$$$600$$$O	and$$$601$$$604$$$O	alcohol$$$605$$$612$$$O	addiction,$$$613$$$623$$$O	sexual$$$624$$$630$$$O	dysfunction$$$631$$$642$$$O	and$$$643$$$646$$$O	related$$$647$$$654$$$O	illnesses.$$$655$$$665$$$O
US7253188
Aminobenzamide$$$0$$$14$$$I	derivative$$$15$$$25$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	a$$$26$$$27$$$O	novel$$$28$$$33$$$O	compound$$$34$$$42$$$O	represented$$$43$$$54$$$O	by$$$55$$$57$$$O	the$$$58$$$61$$$O	formula$$$62$$$69$$$O	(I):$$$70$$$74$$$O	or$$$94$$$96$$$O	a$$$97$$$98$$$O	pharmaceutically$$$99$$$115$$$O	acceptable$$$116$$$126$$$O	salt$$$127$$$131$$$O	thereof,$$$132$$$140$$$O	wherein$$$144$$$151$$$O	R1$$$152$$$154$$$O	is$$$155$$$157$$$O	âS(O)p-A,$$$158$$$169$$$I	âSâ(O)q-B$$$170$$$183$$$I	or$$$184$$$186$$$I	âO-D,$$$187$$$194$$$O	wherein$$$195$$$202$$$O	p$$$203$$$204$$$O	and$$$205$$$208$$$O	q,$$$209$$$211$$$O	which$$$212$$$217$$$O	are$$$218$$$221$$$O	the$$$222$$$225$$$O	same$$$226$$$230$$$O	or$$$231$$$233$$$O	different,$$$234$$$244$$$O	each$$$245$$$249$$$O	represent$$$250$$$259$$$O	an$$$260$$$262$$$O	integer$$$263$$$270$$$O	from$$$271$$$275$$$O	0$$$276$$$277$$$O	to$$$278$$$280$$$O	2,$$$281$$$283$$$O	A$$$284$$$285$$$O	is$$$286$$$288$$$O	a$$$289$$$290$$$O	straight$$$291$$$299$$$I	chain$$$300$$$305$$$I	C1-C10$$$306$$$312$$$I	alkyl$$$313$$$318$$$O	group$$$319$$$324$$$O	which$$$325$$$330$$$O	may$$$331$$$334$$$O	be$$$335$$$337$$$O	substituted$$$338$$$349$$$O	by$$$350$$$352$$$O	R10,$$$353$$$357$$$O	and$$$358$$$361$$$O	B$$$362$$$363$$$O	and$$$364$$$367$$$O	D$$$368$$$369$$$O	each$$$370$$$374$$$O	independently$$$375$$$388$$$O	represent$$$389$$$398$$$O	R12$$$399$$$402$$$O	which$$$403$$$408$$$O	may$$$409$$$412$$$O	be$$$413$$$415$$$O	substituted$$$416$$$427$$$O	by$$$428$$$430$$$O	R10;$$$431$$$435$$$O	R2$$$436$$$438$$$I	is$$$439$$$441$$$I	a$$$442$$$443$$$I	hydrogen$$$444$$$452$$$I	atom,$$$453$$$458$$$I	a$$$459$$$460$$$I	halogen$$$461$$$468$$$O	atom,$$$469$$$474$$$O	or$$$475$$$477$$$O	a$$$478$$$479$$$O	straight$$$480$$$488$$$O	chain$$$489$$$494$$$O	or$$$495$$$497$$$O	branched$$$498$$$506$$$I	C1-C6$$$507$$$512$$$I	alkyl$$$513$$$518$$$O	group$$$519$$$524$$$O	which$$$525$$$530$$$O	may$$$531$$$534$$$O	be$$$535$$$537$$$O	substituted$$$538$$$549$$$O	by$$$550$$$552$$$O	R10;$$$553$$$557$$$O	X1$$$558$$$560$$$O	and$$$561$$$564$$$O	X2$$$565$$$567$$$O	each$$$568$$$572$$$O	independently$$$573$$$586$$$O	represent$$$587$$$596$$$I	N$$$597$$$598$$$O	or$$$599$$$601$$$O	CH,$$$602$$$605$$$O	but$$$606$$$609$$$O	cannot$$$610$$$616$$$O	both$$$617$$$621$$$I	be$$$622$$$624$$$O	N;$$$625$$$627$$$O	the$$$628$$$631$$$O	formula$$$632$$$639$$$O	(II):$$$640$$$645$$$O	shows$$$669$$$674$$$I	a$$$675$$$676$$$I	monocyclic$$$677$$$687$$$I	or$$$688$$$690$$$I	bicyclic$$$691$$$699$$$I	heteroaryl$$$700$$$710$$$I	group$$$711$$$716$$$O	which$$$717$$$722$$$I	has$$$723$$$726$$$I	a$$$727$$$728$$$I	nitrogen$$$729$$$737$$$I	atom$$$738$$$742$$$O	adjacent$$$743$$$751$$$I	to$$$752$$$754$$$I	the$$$755$$$758$$$I	carbon$$$759$$$765$$$O	atom$$$766$$$770$$$O	bonded$$$771$$$777$$$I	to$$$778$$$780$$$I	the$$$781$$$784$$$I	amide$$$785$$$790$$$O	group,$$$791$$$797$$$O	and$$$798$$$801$$$I	the$$$802$$$805$$$I	heteroaryl$$$806$$$816$$$I	group$$$817$$$822$$$O	may$$$823$$$826$$$O	be$$$827$$$829$$$O	substituted$$$830$$$841$$$O	by$$$842$$$844$$$O	R10;$$$845$$$849$$$O	R10$$$853$$$856$$$O	is$$$857$$$859$$$O	R11,$$$860$$$864$$$I	or$$$865$$$867$$$I	a$$$868$$$869$$$I	hydrocarbon$$$870$$$881$$$I	group$$$882$$$887$$$O	which$$$888$$$893$$$O	may$$$894$$$897$$$O	be$$$898$$$900$$$O	substituted$$$901$$$912$$$O	by$$$913$$$915$$$O	R11;$$$916$$$920$$$O	R11$$$921$$$924$$$O	is,$$$925$$$928$$$O	for$$$929$$$932$$$O	example,$$$933$$$941$$$I	a$$$942$$$943$$$I	hydrogen$$$944$$$952$$$I	atom$$$953$$$957$$$I	or$$$958$$$960$$$I	amino;$$$961$$$967$$$O	and$$$968$$$971$$$O	R12$$$972$$$975$$$O	is,$$$976$$$979$$$O	for$$$980$$$983$$$O	example,$$$984$$$992$$$I	phenyl,$$$993$$$1000$$$I	thiazolyl,$$$1001$$$1011$$$I	pyridyl$$$1012$$$1019$$$I	or$$$1020$$$1022$$$I	methylene$$$1023$$$1032$$$I	dioxyphenyl.$$$1033$$$1045$$$I	The$$$1054$$$1057$$$O	compound$$$1058$$$1066$$$O	according$$$1067$$$1076$$$O	to$$$1077$$$1079$$$O	this$$$1080$$$1084$$$O	invention$$$1085$$$1094$$$O	has$$$1095$$$1098$$$O	a$$$1099$$$1100$$$O	glucokinase$$$1101$$$1112$$$O	activation$$$1113$$$1123$$$O	effect,$$$1124$$$1131$$$O	and$$$1132$$$1135$$$O	for$$$1136$$$1139$$$O	example,$$$1140$$$1148$$$O	is$$$1149$$$1151$$$O	useful$$$1152$$$1158$$$O	in$$$1159$$$1161$$$O	the$$$1162$$$1165$$$O	treatment$$$1166$$$1175$$$O	and$$$1176$$$1179$$$O	prevention$$$1180$$$1190$$$O	of$$$1191$$$1193$$$O	diabetes$$$1194$$$1202$$$O	mellitus,$$$1203$$$1212$$$O	and$$$1213$$$1216$$$O	in$$$1217$$$1219$$$O	the$$$1220$$$1223$$$O	prevention$$$1224$$$1234$$$O	of$$$1235$$$1237$$$O	its$$$1238$$$1241$$$O	complications$$$1242$$$1255$$$O	such$$$1256$$$1260$$$O	as$$$1261$$$1263$$$O	diabetic$$$1264$$$1272$$$O	nephropathy,$$$1273$$$1285$$$O	diabetic$$$1286$$$1294$$$O	retinopathy,$$$1295$$$1307$$$O	diabetic$$$1308$$$1316$$$O	neuropathy$$$1317$$$1327$$$O	and$$$1328$$$1331$$$O	diabetic$$$1332$$$1340$$$O	arteriosclerosis.$$$1341$$$1358$$$O
WO2012145737A1
Fatty$$$0$$$5$$$I	acid$$$6$$$10$$$I	amide$$$11$$$16$$$I	hydrolase$$$17$$$26$$$O	inhibitors$$$27$$$37$$$O	for$$$38$$$41$$$O	treating$$$42$$$50$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	Formula$$$13$$$20$$$O	1$$$21$$$22$$$O	are$$$23$$$26$$$O	described$$$27$$$36$$$O	herein.$$$37$$$44$$$O	These$$$45$$$50$$$O	compounds$$$51$$$60$$$O	may$$$61$$$64$$$O	be$$$65$$$67$$$O	administered$$$68$$$80$$$O	to$$$81$$$83$$$O	a$$$84$$$85$$$O	patient$$$86$$$93$$$O	for$$$94$$$97$$$O	treatment$$$98$$$107$$$O	of$$$108$$$110$$$O	suffering$$$111$$$120$$$O	from$$$121$$$125$$$O	pain$$$126$$$130$$$O	or$$$131$$$133$$$O	other$$$134$$$139$$$O	FAAH$$$140$$$144$$$O	mediated$$$145$$$153$$$O	conditions.$$$154$$$165$$$O
CN101366694A
Tribiofosfor$$$0$$$12$$$I	injection$$$13$$$22$$$O	and$$$23$$$26$$$O	preparation$$$27$$$38$$$O	method$$$39$$$45$$$O	thereof$$$46$$$53$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	adenosine$$$24$$$33$$$I	disodium$$$34$$$42$$$I	triphosphate$$$43$$$55$$$I	injection$$$56$$$65$$$O	and$$$66$$$69$$$O	a$$$70$$$71$$$O	method$$$72$$$78$$$O	for$$$79$$$82$$$O	preparing$$$83$$$92$$$O	the$$$93$$$96$$$O	same.$$$97$$$102$$$O	A$$$103$$$104$$$O	stabilizer$$$105$$$115$$$O	is$$$116$$$118$$$O	guanidine$$$119$$$128$$$I	carbonate;$$$129$$$139$$$I	the$$$140$$$143$$$O	preparation$$$144$$$155$$$O	method$$$156$$$162$$$O	comprises$$$163$$$172$$$O	the$$$173$$$176$$$O	following$$$177$$$186$$$O	steps:$$$187$$$193$$$O	adenosine$$$194$$$203$$$I	triphosphate$$$204$$$216$$$I	is$$$217$$$219$$$O	dissolved$$$220$$$229$$$O	in$$$230$$$232$$$O	injection$$$233$$$242$$$O	water$$$243$$$248$$$O	accounting$$$249$$$259$$$O	for$$$260$$$263$$$O	30$$$264$$$266$$$O	to$$$267$$$269$$$O	40$$$270$$$272$$$O	percent$$$273$$$280$$$O	of$$$281$$$283$$$O	the$$$284$$$287$$$O	total$$$288$$$293$$$O	volume$$$294$$$300$$$O	at$$$301$$$303$$$O	the$$$304$$$307$$$O	temperature$$$308$$$319$$$O	of$$$320$$$322$$$O	between$$$323$$$330$$$O	30$$$331$$$333$$$O	and$$$334$$$337$$$O	40$$$338$$$340$$$O	DEG$$$341$$$344$$$O	C$$$345$$$346$$$O	in$$$347$$$349$$$O	order$$$350$$$355$$$O	that$$$356$$$360$$$O	the$$$361$$$364$$$O	adenosine$$$365$$$374$$$I	triphosphate$$$375$$$387$$$I	is$$$388$$$390$$$O	dissolved$$$391$$$400$$$O	out;$$$401$$$405$$$O	the$$$406$$$409$$$O	guanidine$$$410$$$419$$$I	carbonate,$$$420$$$430$$$I	anhydrous$$$431$$$440$$$O	sodium$$$441$$$447$$$I	sulfite,$$$448$$$456$$$I	sodium$$$457$$$463$$$I	dihydrogen$$$464$$$474$$$I	phosphate$$$475$$$484$$$I	and$$$485$$$488$$$O	disodium$$$489$$$497$$$I	hydrogen$$$498$$$506$$$I	phosphate$$$507$$$516$$$I	are$$$517$$$520$$$O	added$$$521$$$526$$$O	into$$$527$$$531$$$O	the$$$532$$$535$$$O	solution,$$$536$$$545$$$O	evenly$$$546$$$552$$$O	stirred,$$$553$$$561$$$O	added$$$562$$$567$$$O	with$$$568$$$572$$$O	active$$$573$$$579$$$O	carbon$$$580$$$586$$$O	for$$$587$$$590$$$O	a$$$591$$$592$$$O	needle,$$$593$$$600$$$O	stirred$$$601$$$608$$$O	and$$$609$$$612$$$O	adsorbed;$$$613$$$622$$$O	the$$$623$$$626$$$O	active$$$627$$$633$$$O	carbon$$$634$$$640$$$O	is$$$641$$$643$$$O	filtered$$$644$$$652$$$O	out;$$$653$$$657$$$O	the$$$658$$$661$$$O	injection$$$662$$$671$$$O	water$$$672$$$677$$$O	at$$$678$$$680$$$O	the$$$681$$$684$$$O	temperature$$$685$$$696$$$O	of$$$697$$$699$$$O	between$$$700$$$707$$$O	20$$$708$$$710$$$O	and$$$711$$$714$$$O	30$$$715$$$717$$$O	DEG$$$718$$$721$$$O	C$$$722$$$723$$$O	is$$$724$$$726$$$O	added$$$727$$$732$$$O	to$$$733$$$735$$$O	the$$$736$$$739$$$O	total$$$740$$$745$$$O	amount;$$$746$$$753$$$O	a$$$754$$$755$$$O	sulphuric$$$756$$$765$$$I	acid$$$766$$$770$$$I	solution$$$771$$$779$$$O	in$$$780$$$782$$$O	proper$$$783$$$789$$$O	amount$$$790$$$796$$$O	is$$$797$$$799$$$O	added$$$800$$$805$$$O	to$$$806$$$808$$$O	adjust$$$809$$$815$$$O	the$$$816$$$819$$$O	PH$$$820$$$822$$$O	value$$$823$$$828$$$O	to$$$829$$$831$$$O	between$$$832$$$839$$$O	8.8$$$840$$$843$$$O	and$$$844$$$847$$$O	9.5$$$848$$$851$$$O	and$$$852$$$855$$$O	is$$$856$$$858$$$O	evenly$$$859$$$865$$$O	mixed;$$$866$$$872$$$O	and$$$873$$$876$$$O	medicine$$$877$$$885$$$O	liquid$$$886$$$892$$$O	is$$$893$$$895$$$O	filtered$$$896$$$904$$$O	by$$$905$$$907$$$O	a$$$908$$$909$$$O	microporous$$$910$$$921$$$O	filtering$$$922$$$931$$$O	film$$$932$$$936$$$O	and$$$937$$$940$$$O	encapsulated.$$$941$$$954$$$O	Compared$$$955$$$963$$$O	with$$$964$$$968$$$O	the$$$969$$$972$$$O	prior$$$973$$$978$$$O	art,$$$979$$$983$$$O	the$$$984$$$987$$$O	adenosine$$$988$$$997$$$I	disodium$$$998$$$1006$$$I	triphosphate$$$1007$$$1019$$$I	injection$$$1020$$$1029$$$O	is$$$1030$$$1032$$$O	not$$$1033$$$1036$$$O	added$$$1037$$$1042$$$O	with$$$1043$$$1047$$$O	tween$$$1048$$$1053$$$O	80,$$$1054$$$1057$$$O	improves$$$1058$$$1066$$$O	the$$$1067$$$1070$$$O	purity$$$1071$$$1077$$$O	of$$$1078$$$1080$$$O	the$$$1081$$$1084$$$O	adenosine$$$1085$$$1094$$$I	triphosphate$$$1095$$$1107$$$I	as$$$1108$$$1110$$$O	an$$$1111$$$1113$$$O	effective$$$1114$$$1123$$$O	component,$$$1124$$$1134$$$O	reduces$$$1135$$$1142$$$O	the$$$1143$$$1146$$$O	content$$$1147$$$1154$$$O	of$$$1155$$$1157$$$O	relevant$$$1158$$$1166$$$O	materials$$$1167$$$1176$$$O	and$$$1177$$$1180$$$O	toxic$$$1181$$$1186$$$O	and$$$1187$$$1190$$$O	side$$$1191$$$1195$$$O	effects,$$$1196$$$1204$$$O	is$$$1205$$$1207$$$O	convenient$$$1208$$$1218$$$O	to$$$1219$$$1221$$$O	use$$$1222$$$1225$$$O	in$$$1226$$$1228$$$O	clinic,$$$1229$$$1236$$$O	is$$$1237$$$1239$$$O	directly$$$1240$$$1248$$$O	used$$$1249$$$1253$$$O	for$$$1254$$$1257$$$O	intramuscular$$$1258$$$1271$$$O	injection$$$1272$$$1281$$$O	without$$$1282$$$1289$$$O	dilution$$$1290$$$1298$$$O	and$$$1299$$$1302$$$O	has$$$1303$$$1306$$$O	good$$$1307$$$1311$$$O	treatment$$$1312$$$1321$$$O	effect$$$1322$$$1328$$$O	and$$$1329$$$1332$$$O	patient$$$1333$$$1340$$$O	tolerance.$$$1341$$$1351$$$O
CN101390848B
Medicine$$$0$$$8$$$O	composition$$$9$$$20$$$O	azithromycin$$$21$$$33$$$I	enteric-coated$$$34$$$48$$$O	capsules$$$49$$$57$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicine$$$26$$$34$$$O	combination$$$35$$$46$$$O	of$$$47$$$49$$$O	azithromycin$$$50$$$62$$$I	enteric-coated$$$63$$$77$$$O	capsule,$$$78$$$86$$$O	which$$$87$$$92$$$O	contains$$$93$$$101$$$O	capsule$$$102$$$109$$$O	shell,$$$110$$$116$$$O	a$$$117$$$118$$$O	small$$$119$$$124$$$O	pill$$$125$$$129$$$O	arranged$$$130$$$138$$$O	in$$$139$$$141$$$O	the$$$142$$$145$$$O	capsule$$$146$$$153$$$O	shell$$$154$$$159$$$O	and$$$160$$$163$$$O	adopts$$$164$$$170$$$O	azithromycin$$$171$$$183$$$I	as$$$184$$$186$$$O	the$$$187$$$190$$$O	main$$$191$$$195$$$O	ingredient;$$$196$$$207$$$O	the$$$208$$$211$$$O	surface$$$212$$$219$$$O	of$$$220$$$222$$$O	each$$$223$$$227$$$O	pill$$$228$$$232$$$O	is$$$233$$$235$$$O	coated$$$236$$$242$$$O	with$$$243$$$247$$$O	enteric$$$248$$$255$$$O	coating;$$$256$$$264$$$O	the$$$265$$$268$$$O	capsule$$$269$$$276$$$O	shell$$$277$$$282$$$O	is$$$283$$$285$$$O	common$$$286$$$292$$$O	capsule$$$293$$$300$$$O	shell.$$$301$$$307$$$O	The$$$308$$$311$$$O	preparation$$$312$$$323$$$O	method$$$324$$$330$$$O	includes$$$331$$$339$$$O	that:$$$340$$$345$$$O	a.$$$346$$$348$$$O	azithromycin,$$$349$$$362$$$I	dextrin$$$363$$$370$$$O	and$$$371$$$374$$$O	starch$$$375$$$381$$$O	are$$$382$$$385$$$O	respectively$$$386$$$398$$$O	sieved$$$399$$$405$$$O	and$$$406$$$409$$$O	mixed$$$410$$$415$$$O	evenly;$$$416$$$423$$$O	b.$$$424$$$426$$$O	hydroxypropyl$$$427$$$440$$$O	methylcellulose$$$441$$$456$$$O	with$$$457$$$461$$$O	the$$$462$$$465$$$O	concentration$$$466$$$479$$$O	of$$$480$$$482$$$O	4%$$$483$$$485$$$O	is$$$486$$$488$$$O	added$$$489$$$494$$$O	to$$$495$$$497$$$O	the$$$498$$$501$$$O	mixture$$$502$$$509$$$O	of$$$510$$$512$$$O	azithromycin,$$$513$$$526$$$I	dextrin$$$527$$$534$$$O	and$$$535$$$538$$$O	starch$$$539$$$545$$$O	to$$$546$$$548$$$O	prepare$$$549$$$556$$$O	adhesion$$$557$$$565$$$O	agent;$$$566$$$572$$$O	c.$$$573$$$575$$$O	the$$$576$$$579$$$O	adhesion$$$580$$$588$$$O	agent$$$589$$$594$$$O	is$$$595$$$597$$$O	placed$$$598$$$604$$$O	in$$$605$$$607$$$O	an$$$608$$$610$$$O	extruder$$$611$$$619$$$O	to$$$620$$$622$$$O	extrude$$$623$$$630$$$O	granules$$$631$$$639$$$O	and$$$640$$$643$$$O	rolled$$$644$$$650$$$O	to$$$651$$$653$$$O	be$$$654$$$656$$$O	circle$$$657$$$663$$$O	in$$$664$$$666$$$O	a$$$667$$$668$$$O	rolling-circle$$$669$$$683$$$O	machine,$$$684$$$692$$$O	so$$$693$$$695$$$O	as$$$696$$$698$$$O	to$$$699$$$701$$$O	obtain$$$702$$$708$$$O	pills$$$709$$$714$$$O	after$$$715$$$720$$$O	drying;$$$721$$$728$$$O	d.$$$729$$$731$$$O	enteric$$$732$$$739$$$O	coating$$$740$$$747$$$O	liquid$$$748$$$754$$$O	is$$$755$$$757$$$O	prepared,$$$758$$$767$$$O	then$$$768$$$772$$$O	the$$$773$$$776$$$O	pills$$$777$$$782$$$O	are$$$783$$$786$$$O	coated$$$787$$$793$$$O	with$$$794$$$798$$$O	the$$$799$$$802$$$O	enteric$$$803$$$810$$$O	coating;$$$811$$$819$$$O	e.$$$820$$$822$$$O	the$$$823$$$826$$$O	coated$$$827$$$833$$$O	pills$$$834$$$839$$$O	are$$$840$$$843$$$O	cured;$$$844$$$850$$$O	f.$$$851$$$853$$$O	the$$$854$$$857$$$O	steps$$$858$$$863$$$O	of$$$864$$$866$$$O	intermediate$$$867$$$879$$$O	product$$$880$$$887$$$O	diction,$$$888$$$896$$$O	encapsulation,$$$897$$$911$$$O	whole$$$912$$$917$$$O	inspection,$$$918$$$929$$$O	packing$$$930$$$937$$$O	and$$$938$$$941$$$O	storage$$$942$$$949$$$O	are$$$950$$$953$$$O	carried$$$954$$$961$$$O	out.$$$962$$$966$$$O	The$$$967$$$970$$$O	extrusion$$$971$$$980$$$O	granulation$$$981$$$992$$$O	rolling-circle$$$993$$$1007$$$O	method$$$1008$$$1014$$$O	is$$$1015$$$1017$$$O	adopted$$$1018$$$1025$$$O	to$$$1026$$$1028$$$O	prepare$$$1029$$$1036$$$O	pills$$$1037$$$1042$$$O	and$$$1043$$$1046$$$O	the$$$1047$$$1050$$$O	enteric$$$1051$$$1058$$$O	coating$$$1059$$$1066$$$O	is$$$1067$$$1069$$$O	processed$$$1070$$$1079$$$O	so$$$1080$$$1082$$$O	that$$$1083$$$1087$$$O	the$$$1088$$$1091$$$O	gastric$$$1092$$$1099$$$O	stimulation$$$1100$$$1111$$$O	caused$$$1112$$$1118$$$O	by$$$1119$$$1121$$$O	the$$$1122$$$1125$$$O	azithromycin$$$1126$$$1138$$$I	is$$$1139$$$1141$$$O	further$$$1142$$$1149$$$O	reduced;$$$1150$$$1158$$$O	the$$$1159$$$1162$$$O	release$$$1163$$$1170$$$O	failure$$$1171$$$1178$$$O	of$$$1179$$$1181$$$O	azithromycin$$$1182$$$1194$$$I	caused$$$1195$$$1201$$$O	by$$$1202$$$1204$$$O	the$$$1205$$$1208$$$O	gastric$$$1209$$$1216$$$O	acid$$$1217$$$1221$$$O	is$$$1222$$$1224$$$O	prevented$$$1225$$$1234$$$O	so$$$1235$$$1237$$$O	that$$$1238$$$1242$$$O	the$$$1243$$$1246$$$O	bioavailability$$$1247$$$1262$$$O	is$$$1263$$$1265$$$O	improved$$$1266$$$1274$$$O	and$$$1275$$$1278$$$O	the$$$1279$$$1282$$$O	side$$$1283$$$1287$$$O	effects$$$1288$$$1295$$$O	are$$$1296$$$1299$$$O	reduced.$$$1300$$$1308$$$O
US20140186345
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	administering$$$10$$$23$$$O	an$$$24$$$26$$$O	antibody$$$27$$$35$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	method$$$15$$$21$$$O	for$$$22$$$25$$$O	treating$$$26$$$34$$$O	a$$$35$$$36$$$O	human$$$37$$$42$$$O	having$$$43$$$49$$$O	a$$$50$$$51$$$O	disease$$$52$$$59$$$O	associated$$$60$$$70$$$O	with$$$71$$$75$$$O	leukocyte$$$76$$$85$$$O	infiltration$$$86$$$98$$$O	of$$$99$$$101$$$O	mucosal$$$102$$$109$$$O	tissues,$$$110$$$118$$$O	comprising$$$119$$$129$$$O	administering$$$130$$$143$$$O	to$$$144$$$146$$$O	said$$$147$$$151$$$O	human$$$152$$$157$$$O	an$$$158$$$160$$$O	effective$$$161$$$170$$$O	amount$$$171$$$177$$$O	of$$$178$$$180$$$O	a$$$181$$$182$$$O	human$$$183$$$188$$$O	or$$$189$$$191$$$O	humanized$$$192$$$201$$$O	immunoglobulin$$$202$$$216$$$O	or$$$217$$$219$$$O	antigen-binding$$$220$$$235$$$O	fragment$$$236$$$244$$$O	thereof$$$245$$$252$$$O	having$$$253$$$259$$$O	binding$$$260$$$267$$$O	specificity$$$268$$$279$$$O	for$$$280$$$283$$$O	Î±4Î²7$$$284$$$290$$$O	integrin.$$$291$$$300$$$O	Preferably,$$$301$$$312$$$O	no$$$313$$$315$$$O	more$$$316$$$320$$$O	than$$$321$$$325$$$O	about$$$326$$$331$$$O	8$$$332$$$333$$$O	mg$$$334$$$336$$$O	immunoglobulin$$$337$$$351$$$O	or$$$352$$$354$$$O	fragment$$$355$$$363$$$O	per$$$364$$$367$$$O	kg$$$368$$$370$$$O	body$$$371$$$375$$$O	weight$$$376$$$382$$$O	are$$$383$$$386$$$O	administered$$$387$$$399$$$O	during$$$400$$$406$$$O	a$$$407$$$408$$$O	period$$$409$$$415$$$O	of$$$416$$$418$$$O	about$$$419$$$424$$$O	one$$$425$$$428$$$O	month.$$$429$$$435$$$O
US7132248
Uses$$$0$$$4$$$O	of$$$5$$$7$$$O	galanin$$$8$$$15$$$O	GALR2$$$16$$$21$$$O	receptors$$$22$$$31$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	provides$$$15$$$23$$$O	isolated$$$24$$$32$$$O	nucleic$$$33$$$40$$$O	acids$$$41$$$46$$$O	encoding$$$47$$$55$$$O	mammalian$$$56$$$65$$$O	galanin$$$66$$$73$$$O	receptors,$$$74$$$84$$$O	isolated$$$85$$$93$$$O	galanin$$$94$$$101$$$O	receptor$$$102$$$110$$$O	proteins,$$$111$$$120$$$O	vectors$$$121$$$128$$$O	comprising$$$129$$$139$$$O	isolated$$$140$$$148$$$O	nucleic$$$149$$$156$$$O	acid$$$157$$$161$$$O	encoding$$$162$$$170$$$O	a$$$171$$$172$$$O	mammalian$$$173$$$182$$$O	galanin$$$183$$$190$$$O	receptor,$$$191$$$200$$$O	cells$$$201$$$206$$$O	comprising$$$207$$$217$$$O	such$$$218$$$222$$$O	vectors,$$$223$$$231$$$O	antibodies$$$232$$$242$$$O	directed$$$243$$$251$$$O	to$$$252$$$254$$$O	a$$$255$$$256$$$O	mammalian$$$257$$$266$$$O	galanin$$$267$$$274$$$O	receptor,$$$275$$$284$$$O	nucleic$$$285$$$292$$$O	acid$$$293$$$297$$$O	probes$$$298$$$304$$$O	useful$$$305$$$311$$$O	for$$$312$$$315$$$O	detecting$$$316$$$325$$$O	nucleic$$$326$$$333$$$O	acid$$$334$$$338$$$O	encoding$$$339$$$347$$$O	a$$$348$$$349$$$O	mammalian$$$350$$$359$$$O	galanin$$$360$$$367$$$O	receptor,$$$368$$$377$$$O	antisense$$$378$$$387$$$O	oligonucleotides$$$388$$$404$$$O	complementary$$$405$$$418$$$O	to$$$419$$$421$$$O	unique$$$422$$$428$$$O	sequences$$$429$$$438$$$O	of$$$439$$$441$$$O	nucleic$$$442$$$449$$$O	acid$$$450$$$454$$$O	encoding$$$455$$$463$$$O	a$$$464$$$465$$$O	mammalian$$$466$$$475$$$O	galanin$$$476$$$483$$$O	receptor,$$$484$$$493$$$O	nonhuman$$$494$$$502$$$O	transgenic$$$503$$$513$$$O	animals$$$514$$$521$$$O	which$$$522$$$527$$$O	express$$$528$$$535$$$O	DNA$$$536$$$539$$$O	encoding$$$540$$$548$$$O	a$$$549$$$550$$$O	normal$$$551$$$557$$$O	or$$$558$$$560$$$O	a$$$561$$$562$$$O	mutant$$$563$$$569$$$O	mammalian$$$570$$$579$$$O	galanin$$$580$$$587$$$O	receptor,$$$588$$$597$$$O	as$$$598$$$600$$$O	well$$$601$$$605$$$O	as$$$606$$$608$$$O	methods$$$609$$$616$$$O	of$$$617$$$619$$$O	determining$$$620$$$631$$$O	binding$$$632$$$639$$$O	of$$$640$$$642$$$O	compounds$$$643$$$652$$$O	to$$$653$$$655$$$O	mammalian$$$656$$$665$$$O	galanin$$$666$$$673$$$O	receptors.$$$674$$$684$$$O
US20080187536
Immunological$$$0$$$13$$$O	modulation$$$14$$$24$$$O	of$$$25$$$27$$$O	insulin-like$$$28$$$40$$$O	growth$$$41$$$47$$$O	factor$$$48$$$54$$$O	1$$$55$$$56$$$O	for$$$57$$$60$$$O	cancer$$$61$$$67$$$O	prevention/treatment$$$68$$$88$$$O	and$$$89$$$92$$$O	prolonging$$$93$$$103$$$O	longevity$$$104$$$113$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	simple$$$14$$$20$$$O	and$$$21$$$24$$$O	safe$$$25$$$29$$$O	immunization$$$30$$$42$$$O	procedure$$$43$$$52$$$O	to$$$53$$$55$$$O	reduce$$$56$$$62$$$O	cancer$$$63$$$69$$$O	incidence$$$70$$$79$$$O	and$$$80$$$83$$$O	increase$$$84$$$92$$$O	longevity$$$93$$$102$$$O	by$$$103$$$105$$$O	modulating$$$106$$$116$$$O	IGF-1$$$117$$$122$$$O	levels$$$123$$$129$$$O	in$$$130$$$132$$$O	the$$$133$$$136$$$O	body.$$$137$$$142$$$O	Described$$$143$$$152$$$O	are$$$153$$$156$$$O	cancer$$$157$$$163$$$O	preventive$$$164$$$174$$$O	vaccines$$$175$$$183$$$O	and$$$184$$$187$$$O	methods$$$188$$$195$$$O	that$$$196$$$200$$$O	elicit$$$201$$$207$$$O	circulating$$$208$$$219$$$O	antibodies$$$220$$$230$$$O	specific$$$231$$$239$$$O	to$$$240$$$242$$$O	insulin-like$$$243$$$255$$$O	growth$$$256$$$262$$$O	factor$$$263$$$269$$$O	1$$$270$$$271$$$O	(IGF-1)$$$272$$$279$$$O	in$$$280$$$282$$$O	the$$$283$$$286$$$O	body.$$$287$$$292$$$O	Many$$$293$$$297$$$O	cancers$$$298$$$305$$$O	will$$$306$$$310$$$O	be$$$311$$$313$$$O	less$$$314$$$318$$$O	likely$$$319$$$325$$$O	to$$$326$$$328$$$O	occur$$$329$$$334$$$O	and$$$335$$$338$$$O	spread$$$339$$$345$$$O	in$$$346$$$348$$$O	the$$$349$$$352$$$O	absence$$$353$$$360$$$O	or$$$361$$$363$$$O	reduced$$$364$$$371$$$O	levels$$$372$$$378$$$O	of$$$379$$$381$$$O	the$$$382$$$385$$$O	stimulatory$$$386$$$397$$$O	signals$$$398$$$405$$$O	provided$$$406$$$414$$$O	by$$$415$$$417$$$O	IGF-1.$$$418$$$424$$$O	Longevity$$$425$$$434$$$O	also$$$435$$$439$$$O	can$$$440$$$443$$$O	be$$$444$$$446$$$O	extended$$$447$$$455$$$O	by$$$456$$$458$$$O	immunologically$$$459$$$474$$$O	lowering$$$475$$$483$$$O	the$$$484$$$487$$$O	level$$$488$$$493$$$O	of$$$494$$$496$$$O	bioavailable$$$497$$$509$$$O	IGF-1$$$510$$$515$$$O	in$$$516$$$518$$$O	adult$$$519$$$524$$$O	animals.$$$525$$$533$$$O	This$$$534$$$538$$$O	prolongation$$$539$$$551$$$O	of$$$552$$$554$$$O	lifespan$$$555$$$563$$$O	resulting$$$564$$$573$$$O	from$$$574$$$578$$$O	lower$$$579$$$584$$$O	IGF-1$$$585$$$590$$$O	levels$$$591$$$597$$$O	is$$$598$$$600$$$O	produced$$$601$$$609$$$O	independently$$$610$$$623$$$O	of$$$624$$$626$$$O	the$$$627$$$630$$$O	inhibitory$$$631$$$641$$$O	effects$$$642$$$649$$$O	on$$$650$$$652$$$O	carcinogenesis.$$$653$$$668$$$O	However,$$$669$$$677$$$O	the$$$678$$$681$$$O	two$$$682$$$685$$$O	IGF-1-mediated$$$686$$$700$$$O	processes$$$701$$$710$$$O	are$$$711$$$714$$$O	linked$$$715$$$721$$$O	mechanistically.$$$722$$$738$$$O	Methods$$$739$$$746$$$O	of$$$747$$$749$$$O	active$$$750$$$756$$$O	and$$$757$$$760$$$O	passive$$$761$$$768$$$O	immunization$$$769$$$781$$$O	to$$$782$$$784$$$O	suppress$$$785$$$793$$$O	IGF-1$$$794$$$799$$$O	activity$$$800$$$808$$$O	are$$$809$$$812$$$O	included.$$$813$$$822$$$O	Also$$$823$$$827$$$O	described$$$828$$$837$$$O	are$$$838$$$841$$$O	methods$$$842$$$849$$$O	for$$$850$$$853$$$O	increasing$$$854$$$864$$$O	longevity$$$865$$$874$$$O	or$$$875$$$877$$$O	reducing$$$878$$$886$$$O	one$$$887$$$890$$$O	or$$$891$$$893$$$O	more$$$894$$$898$$$O	symptoms$$$899$$$907$$$O	of$$$908$$$910$$$O	aging$$$911$$$916$$$O	in$$$917$$$919$$$O	a$$$920$$$921$$$O	warm-blooded$$$922$$$934$$$O	animal$$$935$$$941$$$O	comprising$$$942$$$952$$$O	administering$$$953$$$966$$$O	anti-IGF-1$$$967$$$977$$$O	antibodies$$$978$$$988$$$O	such$$$989$$$993$$$O	that$$$994$$$998$$$O	IGF-1$$$999$$$1004$$$O	is$$$1005$$$1007$$$O	inactivated$$$1008$$$1019$$$O	or$$$1020$$$1022$$$O	suppressed$$$1023$$$1033$$$O	or$$$1034$$$1036$$$O	administering$$$1037$$$1050$$$O	IGF-1$$$1051$$$1056$$$O	antigen$$$1057$$$1064$$$O	such$$$1065$$$1069$$$O	that$$$1070$$$1074$$$O	the$$$1075$$$1078$$$O	animal$$$1079$$$1085$$$O	produces$$$1086$$$1094$$$O	endogenous$$$1095$$$1105$$$O	antibodies$$$1106$$$1116$$$O	to$$$1117$$$1119$$$O	IGF-1.$$$1120$$$1126$$$O
CN102895255A
Pharmaceutical$$$0$$$14$$$O	composition$$$15$$$26$$$O	of$$$27$$$29$$$O	adenine$$$30$$$37$$$I	arabinoside$$$38$$$49$$$I	monophosphate$$$50$$$63$$$I	and$$$64$$$67$$$O	preparation$$$68$$$79$$$O	method$$$80$$$86$$$O	for$$$87$$$90$$$O	pharmaceutical$$$91$$$105$$$O	composition$$$106$$$117$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pharmaceutical$$$27$$$41$$$O	composition$$$42$$$53$$$O	of$$$54$$$56$$$O	adenine$$$57$$$64$$$I	arabinoside$$$65$$$76$$$I	monophosphate$$$77$$$90$$$I	and$$$91$$$94$$$O	a$$$95$$$96$$$O	preparation$$$97$$$108$$$O	method$$$109$$$115$$$O	for$$$116$$$119$$$O	the$$$120$$$123$$$O	pharmaceutical$$$124$$$138$$$O	composition.$$$139$$$151$$$O	The$$$152$$$155$$$O	pharmaceutical$$$156$$$170$$$O	composition$$$171$$$182$$$O	contains$$$183$$$191$$$O	the$$$192$$$195$$$O	adenine$$$196$$$203$$$I	arabinoside$$$204$$$215$$$I	monophosphate$$$216$$$229$$$I	and$$$230$$$233$$$O	water-soluble$$$234$$$247$$$O	cyclodextrin$$$248$$$260$$$O	or$$$261$$$263$$$O	water-soluble$$$264$$$277$$$O	cyclodextrin$$$278$$$290$$$O	derivatives,$$$291$$$303$$$O	wherein$$$304$$$311$$$O	the$$$312$$$315$$$O	molar$$$316$$$321$$$O	ratio$$$322$$$327$$$O	of$$$328$$$330$$$O	the$$$331$$$334$$$O	adenine$$$335$$$342$$$I	arabinoside$$$343$$$354$$$I	monophosphate$$$355$$$368$$$I	to$$$369$$$371$$$O	the$$$372$$$375$$$O	water-soluble$$$376$$$389$$$O	cyclodextrin$$$390$$$402$$$O	or$$$403$$$405$$$O	the$$$406$$$409$$$O	water-soluble$$$410$$$423$$$O	cyclodextrin$$$424$$$436$$$O	derivatives$$$437$$$448$$$O	is$$$449$$$451$$$O	1:(1-5).The$$$452$$$463$$$O	irritation$$$464$$$474$$$O	of$$$475$$$477$$$O	the$$$478$$$481$$$O	pharmaceutical$$$482$$$496$$$O	composition$$$497$$$508$$$O	of$$$509$$$511$$$O	theadenine$$$512$$$522$$$I	arabinoside$$$523$$$534$$$I	monophosphate$$$535$$$548$$$I	to$$$549$$$551$$$O	muscles$$$552$$$559$$$O	and$$$560$$$563$$$O	blood$$$564$$$569$$$O	vessels$$$570$$$577$$$O	is$$$578$$$580$$$O	remarkably$$$581$$$591$$$O	reduced,$$$592$$$600$$$O	and$$$601$$$604$$$O	the$$$605$$$608$$$O	long-term$$$609$$$618$$$O	storage$$$619$$$626$$$O	stability$$$627$$$636$$$O	is$$$637$$$639$$$O	higher.$$$640$$$647$$$O	A$$$648$$$649$$$O	preparation$$$650$$$661$$$O	method$$$662$$$668$$$O	for$$$669$$$672$$$O	the$$$673$$$676$$$O	adenine$$$677$$$684$$$I	arabinoside$$$685$$$696$$$I	monophosphate$$$697$$$710$$$I	is$$$711$$$713$$$O	simple$$$714$$$720$$$O	and$$$721$$$724$$$O	feasible$$$725$$$733$$$O	and$$$734$$$737$$$O	is$$$738$$$740$$$O	suitable$$$741$$$749$$$O	for$$$750$$$753$$$O	industrial$$$754$$$764$$$O	large-scale$$$765$$$776$$$O	production.$$$777$$$788$$$O
CN101856495A
Medical$$$0$$$7$$$O	composition$$$8$$$19$$$O	and$$$20$$$23$$$O	mixture$$$24$$$31$$$O	for$$$32$$$35$$$O	treating$$$36$$$44$$$O	chicken$$$45$$$52$$$O	infectious$$$53$$$63$$$O	bursal$$$64$$$70$$$O	disease$$$71$$$78$$$O	and$$$79$$$82$$$O	preparation$$$83$$$94$$$O	method$$$95$$$101$$$O	thereof$$$102$$$109$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	medical$$$27$$$34$$$O	composition$$$35$$$46$$$O	and$$$47$$$50$$$O	a$$$51$$$52$$$O	mixture$$$53$$$60$$$O	for$$$61$$$64$$$O	treating$$$65$$$73$$$O	chicken$$$74$$$81$$$O	infectious$$$82$$$92$$$O	bursal$$$93$$$99$$$O	disease$$$100$$$107$$$O	and$$$108$$$111$$$O	a$$$112$$$113$$$O	preparation$$$114$$$125$$$O	method$$$126$$$132$$$O	thereof.$$$133$$$141$$$O	The$$$142$$$145$$$O	medical$$$146$$$153$$$O	composition$$$154$$$165$$$O	(100$$$166$$$170$$$O	grams)$$$171$$$177$$$O	comprises:$$$178$$$188$$$O	1$$$189$$$190$$$O	to$$$191$$$193$$$O	10$$$194$$$196$$$O	grams$$$197$$$202$$$O	of$$$203$$$205$$$O	astragalus$$$206$$$216$$$O	polysaccharides,$$$217$$$233$$$O	3$$$234$$$235$$$O	to$$$236$$$238$$$O	12$$$239$$$241$$$O	grams$$$242$$$247$$$O	of$$$248$$$250$$$O	taurine,$$$251$$$259$$$I	4$$$260$$$261$$$O	to$$$262$$$264$$$O	15$$$265$$$267$$$O	grams$$$268$$$273$$$O	of$$$274$$$276$$$O	aminopyrine,$$$277$$$289$$$I	2$$$290$$$291$$$O	to$$$292$$$294$$$O	10$$$295$$$297$$$O	grams$$$298$$$303$$$O	of$$$304$$$306$$$O	vitamin$$$307$$$314$$$I	C,$$$315$$$317$$$I	0.04$$$318$$$322$$$O	to$$$323$$$325$$$O	0.2$$$326$$$329$$$O	gram$$$330$$$334$$$O	of$$$335$$$337$$$O	interferon$$$338$$$348$$$O	inducer,$$$349$$$357$$$O	5$$$358$$$359$$$O	to$$$360$$$362$$$O	20$$$363$$$365$$$O	grams$$$366$$$371$$$O	of$$$372$$$374$$$O	alcohol,$$$375$$$383$$$I	0.1$$$384$$$387$$$O	to$$$388$$$390$$$O	0.4$$$391$$$394$$$O	gram$$$395$$$399$$$O	of$$$400$$$402$$$O	sodium$$$403$$$409$$$I	benzoate,$$$410$$$419$$$I	and$$$420$$$423$$$O	the$$$424$$$427$$$O	balance$$$428$$$435$$$O	of$$$436$$$438$$$O	water$$$439$$$444$$$O	for$$$445$$$448$$$O	injection.$$$449$$$459$$$O	The$$$460$$$463$$$O	product$$$464$$$471$$$O	is$$$472$$$474$$$O	characterized$$$475$$$488$$$O	by$$$489$$$491$$$O	reasonable$$$492$$$502$$$O	formula$$$503$$$510$$$O	composition,$$$511$$$523$$$O	stable$$$524$$$530$$$O	physical$$$531$$$539$$$O	and$$$540$$$543$$$O	chemical$$$544$$$552$$$O	properties,$$$553$$$564$$$O	accurate$$$565$$$573$$$O	dose,$$$574$$$579$$$O	quick$$$580$$$585$$$O	effect,$$$586$$$593$$$O	long-lasting$$$594$$$606$$$O	medicament$$$607$$$617$$$O	effect,$$$618$$$625$$$O	high$$$626$$$630$$$O	bioavailability,$$$631$$$647$$$O	safe$$$648$$$652$$$O	use$$$653$$$656$$$O	and$$$657$$$660$$$O	exact$$$661$$$666$$$O	treatment$$$667$$$676$$$O	effect.$$$677$$$684$$$O
US20080132483
Administering$$$0$$$13$$$O	(3R,5S)-N-propanesulfonyl-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide;$$$14$$$155$$$I	cerebral$$$156$$$164$$$O	infarction$$$165$$$175$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	an$$$31$$$33$$$O	agent$$$34$$$39$$$O	for$$$40$$$43$$$O	preventing$$$44$$$54$$$O	or$$$55$$$57$$$O	treating$$$58$$$66$$$O	organ$$$67$$$72$$$O	functional$$$73$$$83$$$O	disorders,$$$84$$$94$$$O	an$$$95$$$97$$$O	agent$$$98$$$103$$$O	for$$$104$$$107$$$O	preventing$$$108$$$118$$$O	or$$$119$$$121$$$O	treating$$$122$$$130$$$O	organ$$$131$$$136$$$O	dysfunction$$$137$$$148$$$O	and$$$149$$$152$$$O	an$$$153$$$155$$$O	agent$$$156$$$161$$$O	for$$$162$$$165$$$O	preventing$$$166$$$176$$$O	or$$$177$$$179$$$O	treating$$$180$$$188$$$O	obesity$$$189$$$196$$$O	and$$$197$$$200$$$O	deuteropathy$$$201$$$213$$$O	thereof,$$$214$$$222$$$O	each$$$223$$$227$$$O	of$$$228$$$230$$$O	which$$$231$$$236$$$O	comprises$$$237$$$246$$$O	a$$$247$$$248$$$O	compound$$$249$$$257$$$O	having$$$258$$$264$$$O	an$$$265$$$267$$$O	effect$$$268$$$274$$$O	of$$$275$$$277$$$O	increasing$$$278$$$288$$$O	ubiquinone$$$289$$$299$$$I	or$$$300$$$302$$$O	a$$$303$$$304$$$O	salt$$$305$$$309$$$O	thereof$$$310$$$317$$$O	or$$$318$$$320$$$O	a$$$321$$$322$$$O	prodrug$$$323$$$330$$$O	thereof;$$$331$$$339$$$O	as$$$340$$$342$$$O	well$$$343$$$347$$$O	as$$$348$$$350$$$O	a$$$351$$$352$$$O	ubiquinone$$$353$$$363$$$I	increasing$$$364$$$374$$$O	agent$$$375$$$380$$$O	comprising$$$381$$$391$$$O	a$$$392$$$393$$$O	compound$$$394$$$402$$$O	having$$$403$$$409$$$O	a$$$410$$$411$$$O	squalene$$$412$$$420$$$O	synthase$$$421$$$429$$$O	inhibitory$$$430$$$440$$$O	effect$$$441$$$447$$$O	or$$$448$$$450$$$O	a$$$451$$$452$$$O	salt$$$453$$$457$$$O	thereof$$$458$$$465$$$O	or$$$466$$$468$$$O	a$$$469$$$470$$$O	prodrug$$$471$$$478$$$O	thereof.$$$479$$$487$$$O
US20120189684
Skincare$$$0$$$8$$$O	Compositions$$$9$$$21$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	relates$$$15$$$22$$$O	to$$$23$$$25$$$O	skincare$$$26$$$34$$$O	compositions,$$$35$$$48$$$O	in$$$49$$$51$$$O	particular$$$52$$$62$$$O	compositions$$$63$$$75$$$O	effective$$$76$$$85$$$O	in$$$86$$$88$$$O	the$$$89$$$92$$$O	treatment$$$93$$$102$$$O	of$$$103$$$105$$$O	acne$$$106$$$110$$$O	vulgaris,$$$111$$$120$$$O	and$$$121$$$124$$$O	to$$$125$$$127$$$O	methods$$$128$$$135$$$O	of$$$136$$$138$$$O	treatment$$$139$$$148$$$O	of$$$149$$$151$$$O	the$$$152$$$155$$$O	skin$$$156$$$160$$$O	that$$$161$$$165$$$O	involve$$$166$$$173$$$O	the$$$174$$$177$$$O	application$$$178$$$189$$$O	of$$$190$$$192$$$O	such$$$193$$$197$$$O	compositions,$$$198$$$211$$$O	wherein$$$212$$$219$$$O	the$$$220$$$223$$$O	compositions$$$224$$$236$$$O	comprise$$$237$$$245$$$O	salicylic$$$246$$$255$$$I	acid$$$256$$$260$$$I	or$$$261$$$263$$$O	a$$$264$$$265$$$O	salt$$$266$$$270$$$O	thereof$$$271$$$278$$$O	in$$$279$$$281$$$O	combination$$$282$$$293$$$O	with$$$294$$$298$$$O	at$$$299$$$301$$$O	2$$$302$$$303$$$O	actives$$$304$$$311$$$O	selected$$$312$$$320$$$O	from$$$321$$$325$$$O	the$$$326$$$329$$$O	group$$$330$$$335$$$O	consisting$$$336$$$346$$$O	of$$$347$$$349$$$O	lactic$$$350$$$356$$$I	acid$$$357$$$361$$$I	or$$$362$$$364$$$O	a$$$365$$$366$$$O	salt$$$367$$$371$$$O	thereof;$$$372$$$380$$$O	glycyrrhizinic$$$381$$$395$$$I	acid$$$396$$$400$$$I	or$$$401$$$403$$$O	a$$$404$$$405$$$O	salt$$$406$$$410$$$O	or$$$411$$$413$$$O	derivative$$$414$$$424$$$O	thereof;$$$425$$$433$$$O	bisabolol;$$$434$$$444$$$O	cetylhydroxyproline$$$445$$$464$$$I	palmitamide;$$$465$$$477$$$I	allantoin;$$$478$$$488$$$I	niacinamide;$$$489$$$501$$$I	and$$$502$$$505$$$O	epilobium$$$506$$$515$$$O	angustifolium$$$516$$$529$$$O	extract.$$$530$$$538$$$O
US20050181506
Chromosome-based$$$0$$$16$$$O	platforms$$$17$$$26$$$O
Artificial$$$0$$$10$$$O	chromosomes,$$$11$$$23$$$O	including$$$24$$$33$$$O	ACes,$$$34$$$39$$$O	that$$$40$$$44$$$O	have$$$45$$$49$$$O	been$$$50$$$54$$$O	engineered$$$55$$$65$$$O	to$$$66$$$68$$$O	contain$$$69$$$76$$$O	available$$$77$$$86$$$O	sites$$$87$$$92$$$O	for$$$93$$$96$$$O	site-specific,$$$97$$$111$$$O	recombination-directed$$$112$$$134$$$O	integration$$$135$$$146$$$O	of$$$147$$$149$$$O	DNA$$$150$$$153$$$O	of$$$154$$$156$$$O	interest$$$157$$$165$$$O	are$$$166$$$169$$$O	provided.$$$170$$$179$$$O	These$$$180$$$185$$$O	artificial$$$186$$$196$$$O	chromosomes$$$197$$$208$$$O	permit$$$209$$$215$$$O	tractable,$$$216$$$226$$$O	efficient,$$$227$$$237$$$O	rational$$$238$$$246$$$O	engineering$$$247$$$258$$$O	of$$$259$$$261$$$O	the$$$262$$$265$$$O	chromosome$$$266$$$276$$$O	for$$$277$$$280$$$O	a$$$281$$$282$$$O	variety$$$283$$$290$$$O	of$$$291$$$293$$$O	applications.$$$294$$$307$$$O
US8119644
Thiadiazole-substituted$$$0$$$23$$$I	arylamides$$$24$$$34$$$I	as$$$35$$$37$$$O	P2X3$$$38$$$42$$$O	and$$$43$$$46$$$O	P2X2/3$$$47$$$53$$$O	antagonists$$$54$$$65$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	the$$$13$$$16$$$O	formula$$$17$$$24$$$O	I:$$$25$$$27$$$O	or$$$47$$$49$$$O	a$$$50$$$51$$$O	pharmaceutically$$$52$$$68$$$O	acceptable$$$69$$$79$$$O	salt$$$80$$$84$$$O	thereof,$$$85$$$93$$$O	wherein,$$$94$$$102$$$O	R1$$$103$$$105$$$O	is$$$106$$$108$$$O	optionally$$$109$$$119$$$O	substituted$$$120$$$131$$$O	thiadiazolyl,$$$132$$$145$$$I	and$$$146$$$149$$$O	R2,$$$150$$$153$$$O	R3,$$$154$$$157$$$O	R4,$$$158$$$161$$$O	R5,$$$162$$$165$$$O	R6,$$$166$$$169$$$O	R7$$$170$$$172$$$O	and$$$173$$$176$$$O	R8$$$177$$$179$$$O	are$$$180$$$183$$$O	as$$$184$$$186$$$O	defined$$$187$$$194$$$O	herein.$$$195$$$202$$$O	Also$$$203$$$207$$$O	disclosed$$$208$$$217$$$O	are$$$218$$$221$$$O	methods$$$222$$$229$$$O	of$$$230$$$232$$$O	using$$$233$$$238$$$O	the$$$239$$$242$$$O	compounds$$$243$$$252$$$O	for$$$253$$$256$$$O	treating$$$257$$$265$$$O	diseases$$$266$$$274$$$O	associated$$$275$$$285$$$O	with$$$286$$$290$$$O	P2X3$$$291$$$295$$$O	and/or$$$296$$$302$$$O	a$$$303$$$304$$$O	P2X2/3$$$305$$$311$$$O	receptor$$$312$$$320$$$O	antagonists$$$321$$$332$$$O	and$$$333$$$336$$$O	methods$$$337$$$344$$$O	of$$$345$$$347$$$O	making$$$348$$$354$$$O	the$$$355$$$358$$$O	compounds.$$$359$$$369$$$O
WO2007128109A1
Aptamers$$$0$$$8$$$O	that$$$9$$$13$$$O	recognize$$$14$$$23$$$O	the$$$24$$$27$$$O	carbohydrate$$$28$$$40$$$I	n-acetylgalactosamine$$$41$$$62$$$I	(galnac)$$$63$$$71$$$I
Novel$$$0$$$5$$$O	oligonucleotides,$$$6$$$23$$$I	termed$$$24$$$30$$$O	aptamers,$$$31$$$40$$$O	that$$$41$$$45$$$O	bind$$$46$$$50$$$O	to$$$51$$$53$$$O	GalNac$$$54$$$60$$$I	of$$$61$$$63$$$O	the$$$64$$$67$$$O	Tn$$$68$$$70$$$O	antigen.$$$71$$$79$$$O	In$$$80$$$82$$$O	particular,$$$83$$$94$$$O	aptamers$$$95$$$103$$$O	that$$$104$$$108$$$O	recognize$$$109$$$118$$$O	the$$$119$$$122$$$O	Tn$$$123$$$125$$$O	antigen$$$126$$$133$$$O	on$$$134$$$136$$$O	a$$$137$$$138$$$O	cancer$$$139$$$145$$$O	cell$$$146$$$150$$$O	or$$$151$$$153$$$O	underglycosylated$$$154$$$171$$$O	protein$$$172$$$179$$$O	are$$$180$$$183$$$O	disclosed.$$$184$$$194$$$O	Uses$$$195$$$199$$$O	of$$$200$$$202$$$O	the$$$203$$$206$$$O	aptamers$$$207$$$215$$$O	to$$$216$$$218$$$O	detect,$$$219$$$226$$$O	monitor$$$227$$$234$$$O	or$$$235$$$237$$$O	treat$$$238$$$243$$$O	cancer$$$244$$$250$$$O	are$$$251$$$254$$$O	also$$$255$$$259$$$O	described.$$$260$$$270$$$O
EP2776023A1
Meglumine$$$0$$$9$$$I	salt$$$10$$$14$$$O	formulations$$$15$$$27$$$O	of$$$28$$$30$$$O	1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic$$$31$$$97$$$I	acid$$$98$$$102$$$I
The$$$0$$$3$$$O	meglumine$$$4$$$13$$$I	salt$$$14$$$18$$$O	of$$$19$$$21$$$O	1-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic$$$22$$$88$$$I	acid$$$89$$$93$$$I	(compound$$$94$$$103$$$O	(1))$$$104$$$108$$$O	and$$$109$$$112$$$O	pharmaceutically$$$113$$$129$$$O	acceptable$$$130$$$140$$$O	formulations$$$141$$$153$$$O	thereof$$$154$$$161$$$O	are$$$162$$$165$$$O	described.$$$166$$$176$$$O	Such$$$177$$$181$$$O	compounds$$$182$$$191$$$O	may$$$192$$$195$$$O	be$$$196$$$198$$$O	used$$$199$$$203$$$O	in$$$204$$$206$$$O	pharmaceutical$$$207$$$221$$$O	compositions$$$222$$$234$$$O	and$$$235$$$238$$$O	methods$$$239$$$246$$$O	for$$$247$$$250$$$O	the$$$251$$$254$$$O	treatment$$$255$$$264$$$O	of$$$265$$$267$$$O	disease$$$268$$$275$$$O	states,$$$276$$$283$$$O	disorders,$$$284$$$294$$$O	and$$$295$$$298$$$O	conditions$$$299$$$309$$$O	mediated$$$310$$$318$$$O	by$$$319$$$321$$$O	prolyl$$$322$$$328$$$O	hydroxylase$$$329$$$340$$$O	activity.$$$341$$$350$$$O
CN101032490A
External$$$0$$$8$$$O	agent$$$9$$$14$$$O	for$$$15$$$18$$$O	losing$$$19$$$25$$$O	weight$$$26$$$32$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	application$$$37$$$48$$$O	of$$$49$$$51$$$O	azone$$$52$$$57$$$O	as$$$58$$$60$$$O	active$$$61$$$67$$$O	medicine$$$68$$$76$$$O	component$$$77$$$86$$$O	in$$$87$$$89$$$O	preparing$$$90$$$99$$$O	externally$$$100$$$110$$$O	applied$$$111$$$118$$$O	slimming$$$119$$$127$$$O	medicine,$$$128$$$137$$$O	externally$$$138$$$148$$$O	applied$$$149$$$156$$$O	slimming$$$157$$$165$$$O	health$$$166$$$172$$$O	product$$$173$$$180$$$O	and$$$181$$$184$$$O	slimming$$$185$$$193$$$O	cosmetic.$$$194$$$203$$$O	The$$$204$$$207$$$O	present$$$208$$$215$$$O	invention$$$216$$$225$$$O	uses$$$226$$$230$$$O	azone$$$231$$$236$$$O	as$$$237$$$239$$$O	active$$$240$$$246$$$O	medicine$$$247$$$255$$$O	component$$$256$$$265$$$O	except$$$266$$$272$$$O	being$$$273$$$278$$$O	used$$$279$$$283$$$O	as$$$284$$$286$$$O	permeation$$$287$$$297$$$O	assistant.$$$298$$$308$$$O	The$$$309$$$312$$$O	externally$$$313$$$323$$$O	applied$$$324$$$331$$$O	slimming$$$332$$$340$$$O	preparations$$$341$$$353$$$O	with$$$354$$$358$$$O	azone$$$359$$$364$$$O	as$$$365$$$367$$$O	active$$$368$$$374$$$O	medicine$$$375$$$383$$$O	component$$$384$$$393$$$O	has$$$394$$$397$$$O	obvious$$$398$$$405$$$O	curative$$$406$$$414$$$O	effect,$$$415$$$422$$$O	fast$$$423$$$427$$$O	acting$$$428$$$434$$$O	and$$$435$$$438$$$O	no$$$439$$$441$$$O	toxic$$$442$$$447$$$O	side$$$448$$$452$$$O	effect,$$$453$$$460$$$O	and$$$461$$$464$$$O	are$$$465$$$468$$$O	prepared$$$469$$$477$$$O	preferably$$$478$$$488$$$O	as$$$489$$$491$$$O	navel$$$492$$$497$$$O	administrating$$$498$$$512$$$O	preparation,$$$513$$$525$$$O	such$$$526$$$530$$$O	as$$$531$$$533$$$O	navel$$$534$$$539$$$O	plaster,$$$540$$$548$$$O	drops,$$$549$$$555$$$O	etc.$$$556$$$560$$$O
CN101816667A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	forsythiaside$$$15$$$28$$$I	A$$$29$$$30$$$I	in$$$31$$$33$$$O	preparation$$$34$$$45$$$O	of$$$46$$$48$$$O	drugs$$$49$$$54$$$O	for$$$55$$$58$$$O	preventing$$$59$$$69$$$O	and$$$70$$$73$$$O	treating$$$74$$$82$$$O	cardiovascular$$$83$$$97$$$O	and$$$98$$$101$$$O	cerebrovascular$$$102$$$117$$$O	diseases$$$118$$$126$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	proves$$$14$$$20$$$O	that$$$21$$$25$$$O	forsythiaside$$$26$$$39$$$I	A$$$40$$$41$$$I	has$$$42$$$45$$$O	the$$$46$$$49$$$O	function$$$50$$$58$$$O	of$$$59$$$61$$$O	inhibiting$$$62$$$72$$$O	platelet$$$73$$$81$$$O	aggregation$$$82$$$93$$$O	and$$$94$$$97$$$O	simultaneously$$$98$$$112$$$O	has$$$113$$$116$$$O	the$$$117$$$120$$$O	obvious$$$121$$$128$$$O	anticoagulation$$$129$$$144$$$O	role$$$145$$$149$$$O	by$$$150$$$152$$$O	studying$$$153$$$161$$$O	the$$$162$$$165$$$O	impacts$$$166$$$173$$$O	of$$$174$$$176$$$O	the$$$177$$$180$$$O	forsythiaside$$$181$$$194$$$I	A$$$195$$$196$$$I	on$$$197$$$199$$$O	ADP-induced$$$200$$$211$$$I	platelet$$$212$$$220$$$O	aggregation$$$221$$$232$$$O	in$$$233$$$235$$$O	vitro$$$236$$$241$$$O	of$$$242$$$244$$$O	rats,$$$245$$$250$$$O	the$$$251$$$254$$$O	impacts$$$255$$$262$$$O	on$$$263$$$265$$$O	plasma$$$266$$$272$$$O	prothrombin$$$273$$$284$$$O	time$$$285$$$289$$$O	(PT)$$$290$$$294$$$O	of$$$295$$$297$$$O	the$$$298$$$301$$$O	rats$$$302$$$306$$$O	and$$$307$$$310$$$O	the$$$311$$$314$$$O	impacts$$$315$$$322$$$O	on$$$323$$$325$$$O	plasma$$$326$$$332$$$O	thrombin$$$333$$$341$$$O	time$$$342$$$346$$$O	(TT)$$$347$$$351$$$O	of$$$352$$$354$$$O	the$$$355$$$358$$$O	rats.$$$359$$$364$$$O	The$$$365$$$368$$$O	forsythiaside$$$369$$$382$$$I	A$$$383$$$384$$$I	can$$$385$$$388$$$O	be$$$389$$$391$$$O	used$$$392$$$396$$$O	for$$$397$$$400$$$O	preparing$$$401$$$410$$$O	drugs$$$411$$$416$$$O	for$$$417$$$420$$$O	preventing$$$421$$$431$$$O	and$$$432$$$435$$$O	treating$$$436$$$444$$$O	cardiovascular$$$445$$$459$$$O	and$$$460$$$463$$$O	cerebrovascular$$$464$$$479$$$O	diseases.$$$480$$$489$$$O	The$$$490$$$493$$$O	forsythiaside$$$494$$$507$$$I	A$$$508$$$509$$$I	can$$$510$$$513$$$O	also$$$514$$$518$$$O	be$$$519$$$521$$$O	used$$$522$$$526$$$O	as$$$527$$$529$$$O	a$$$530$$$531$$$O	food$$$532$$$536$$$O	additive$$$537$$$545$$$O	for$$$546$$$549$$$O	preparing$$$550$$$559$$$O	functional$$$560$$$570$$$O	foods$$$571$$$576$$$O	for$$$577$$$580$$$O	preventing$$$581$$$591$$$O	and$$$592$$$595$$$O	treating$$$596$$$604$$$O	the$$$605$$$608$$$O	cardiovascular$$$609$$$623$$$O	and$$$624$$$627$$$O	cerebrovascular$$$628$$$643$$$O	diseases.$$$644$$$653$$$O
CN102784145A
Veterinary$$$0$$$10$$$O	compound$$$11$$$19$$$O	florfenicol$$$20$$$31$$$I	injection$$$32$$$41$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	aims$$$14$$$18$$$O	to$$$19$$$21$$$O	provide$$$22$$$29$$$O	a$$$30$$$31$$$O	veterinary$$$32$$$42$$$O	compound$$$43$$$51$$$O	florfenicol$$$52$$$63$$$I	injection,$$$64$$$74$$$O	which$$$75$$$80$$$O	is$$$81$$$83$$$O	used$$$84$$$88$$$O	for$$$89$$$92$$$O	efficiently$$$93$$$104$$$O	treating$$$105$$$113$$$O	porcine$$$114$$$121$$$O	respiratory$$$122$$$133$$$O	disease$$$134$$$141$$$O	complex$$$142$$$149$$$O	and$$$150$$$153$$$O	porcine$$$154$$$161$$$O	digestive$$$162$$$171$$$O	tract$$$172$$$177$$$O	disease.$$$178$$$186$$$O	Each$$$187$$$191$$$O	100ml$$$192$$$197$$$O	of$$$198$$$200$$$O	veterinary$$$201$$$211$$$O	compound$$$212$$$220$$$O	florfenicol$$$221$$$232$$$I	injection$$$233$$$242$$$O	contains$$$243$$$251$$$O	10-30g$$$252$$$258$$$O	of$$$259$$$261$$$O	florfenicol,$$$262$$$274$$$I	1-5g$$$275$$$279$$$O	of$$$280$$$282$$$O	andrographolide,$$$283$$$299$$$I	1-3g$$$300$$$304$$$O	of$$$305$$$307$$$O	TMP$$$308$$$311$$$O	(Trimethoprim),$$$312$$$327$$$I	0.1-0.2g$$$328$$$336$$$O	of$$$337$$$339$$$O	antioxygen,$$$340$$$351$$$O	0.01-0.02g$$$352$$$362$$$O	of$$$363$$$365$$$O	ethylenediaminetetraacetic$$$366$$$392$$$I	acid$$$393$$$397$$$I	disodium,$$$398$$$407$$$I	and$$$408$$$411$$$O	the$$$412$$$415$$$O	balance$$$416$$$423$$$O	of$$$424$$$426$$$O	solvent$$$427$$$434$$$O	for$$$435$$$438$$$O	injection.$$$439$$$449$$$O	The$$$450$$$453$$$O	veterinary$$$454$$$464$$$O	compound$$$465$$$473$$$O	florfenicol$$$474$$$485$$$I	injection$$$486$$$495$$$O	is$$$496$$$498$$$O	a$$$499$$$500$$$O	composition$$$501$$$512$$$O	of$$$513$$$515$$$O	the$$$516$$$519$$$O	florfenicol,$$$520$$$532$$$I	the$$$533$$$536$$$O	andrographolide$$$537$$$552$$$O	and$$$553$$$556$$$O	the$$$557$$$560$$$O	TMP$$$561$$$564$$$O	which$$$565$$$570$$$O	have$$$571$$$575$$$O	significant$$$576$$$587$$$O	effects$$$588$$$595$$$O	on$$$596$$$598$$$O	the$$$599$$$602$$$O	porcine$$$603$$$610$$$O	respiratory$$$611$$$622$$$O	disease$$$623$$$630$$$O	complex,$$$631$$$639$$$O	and$$$640$$$643$$$O	is$$$644$$$646$$$O	administrated$$$647$$$660$$$O	through$$$661$$$668$$$O	an$$$669$$$671$$$O	injection$$$672$$$681$$$O	way,$$$682$$$686$$$O	the$$$687$$$690$$$O	dosage$$$691$$$697$$$O	is$$$698$$$700$$$O	accurate,$$$701$$$710$$$O	the$$$711$$$714$$$O	absorption$$$715$$$725$$$O	is$$$726$$$728$$$O	quick,$$$729$$$735$$$O	the$$$736$$$739$$$O	blood$$$740$$$745$$$O	concentration$$$746$$$759$$$O	is$$$760$$$762$$$O	high,$$$763$$$768$$$O	the$$$769$$$772$$$O	distribution$$$773$$$785$$$O	is$$$786$$$788$$$O	wide,$$$789$$$794$$$O	the$$$795$$$798$$$O	half-life$$$799$$$808$$$O	period$$$809$$$815$$$O	is$$$816$$$818$$$O	long,$$$819$$$824$$$O	the$$$825$$$828$$$O	effective$$$829$$$838$$$O	concentration$$$839$$$852$$$O	maintenance$$$853$$$864$$$O	time$$$865$$$869$$$O	is$$$870$$$872$$$O	long,$$$873$$$878$$$O	and$$$879$$$882$$$O	compared$$$883$$$891$$$O	with$$$892$$$896$$$O	the$$$897$$$900$$$O	pesticide$$$901$$$910$$$O	effect$$$911$$$917$$$O	of$$$918$$$920$$$O	the$$$921$$$924$$$O	existing$$$925$$$933$$$O	florfenicol$$$934$$$945$$$I	injection$$$946$$$955$$$O	and$$$956$$$959$$$O	the$$$960$$$963$$$O	herba$$$964$$$969$$$O	andrographitis$$$970$$$984$$$O	injection,$$$985$$$995$$$O	the$$$996$$$999$$$O	pesticide$$$1000$$$1009$$$O	effect$$$1010$$$1016$$$O	of$$$1017$$$1019$$$O	the$$$1020$$$1023$$$O	veterinary$$$1024$$$1034$$$O	compound$$$1035$$$1043$$$O	florfenicol$$$1044$$$1055$$$I	injection$$$1056$$$1065$$$O	is$$$1066$$$1068$$$O	obviously$$$1069$$$1078$$$O	enhanced.$$$1079$$$1088$$$O
CN102584535A
Bisabolane$$$0$$$10$$$I	sesquiterpenoid,$$$11$$$27$$$I	preparation$$$28$$$39$$$O	method$$$40$$$46$$$O	thereof$$$47$$$54$$$O	and$$$55$$$58$$$O	application$$$59$$$70$$$O	thereof$$$71$$$78$$$O	as$$$79$$$81$$$O	selective$$$82$$$91$$$O	antibacterial$$$92$$$105$$$O	agent$$$106$$$111$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	bisabolane$$$26$$$36$$$I	sesquiterpenoid,$$$37$$$53$$$I	a$$$54$$$55$$$O	preparation$$$56$$$67$$$O	method$$$68$$$74$$$O	thereof$$$75$$$82$$$O	and$$$83$$$86$$$O	application$$$87$$$98$$$O	thereof$$$99$$$106$$$O	as$$$107$$$109$$$O	a$$$110$$$111$$$O	selective$$$112$$$121$$$O	antibacterial$$$122$$$135$$$O	agent.$$$136$$$142$$$O	The$$$143$$$146$$$O	method$$$147$$$153$$$O	comprises$$$154$$$163$$$O	the$$$164$$$167$$$O	following$$$168$$$177$$$O	steps$$$178$$$183$$$O	of:$$$184$$$187$$$O	performing$$$188$$$198$$$O	strain$$$199$$$205$$$O	culturing$$$206$$$215$$$O	on$$$216$$$218$$$O	a$$$219$$$220$$$O	sponge$$$221$$$227$$$O	endophytic$$$228$$$238$$$O	fungi,$$$239$$$245$$$O	i.e.$$$246$$$250$$$O	Asergillus$$$251$$$261$$$O	sp.$$$262$$$265$$$O	(HM565949)$$$266$$$276$$$O	in$$$277$$$279$$$O	a$$$280$$$281$$$O	strain$$$282$$$288$$$O	medium;$$$289$$$296$$$O	cultivating$$$297$$$308$$$O	the$$$309$$$312$$$O	fungi$$$313$$$318$$$O	by$$$319$$$321$$$O	fermenting$$$322$$$332$$$O	in$$$333$$$335$$$O	a$$$336$$$337$$$O	fermentation$$$338$$$350$$$O	medium;$$$351$$$358$$$O	filtering$$$359$$$368$$$O	the$$$369$$$372$$$O	obtained$$$373$$$381$$$O	fermentation$$$382$$$394$$$O	broth$$$395$$$400$$$O	to$$$401$$$403$$$O	remove$$$404$$$410$$$O	thallus,$$$411$$$419$$$O	concentrating$$$420$$$433$$$O	the$$$434$$$437$$$O	filtrate,$$$438$$$447$$$O	and$$$448$$$451$$$O	extracting$$$452$$$462$$$O	the$$$463$$$466$$$O	filtrate$$$467$$$475$$$O	with$$$476$$$480$$$O	ethyl$$$481$$$486$$$I	acetate;$$$487$$$495$$$I	and$$$496$$$499$$$O	performing$$$500$$$510$$$O	chromatographic$$$511$$$526$$$O	separation$$$527$$$537$$$O	on$$$538$$$540$$$O	the$$$541$$$544$$$O	concentrate$$$545$$$556$$$O	and$$$557$$$560$$$O	respectively$$$561$$$573$$$O	concentrating$$$574$$$587$$$O	the$$$588$$$591$$$O	obtained$$$592$$$600$$$O	eluent$$$601$$$607$$$O	to$$$608$$$610$$$O	obtain$$$611$$$617$$$O	white$$$618$$$623$$$O	powder,$$$624$$$631$$$O	i.e.$$$632$$$636$$$O	the$$$637$$$640$$$O	aspergterpeinoid$$$641$$$657$$$I	A,$$$658$$$660$$$I	aspergiterpenoid$$$661$$$677$$$I	C$$$678$$$679$$$I	and$$$680$$$683$$$O	aspergiterpenoid$$$684$$$700$$$I	D.$$$701$$$703$$$I	The$$$704$$$707$$$O	bisabolane$$$708$$$718$$$I	sesquiterpenoid$$$719$$$734$$$I	obtained$$$735$$$743$$$O	from$$$744$$$748$$$O	a$$$749$$$750$$$O	marine$$$751$$$757$$$O	fungi$$$758$$$763$$$O	can$$$764$$$767$$$O	selectively$$$768$$$779$$$O	inhibit$$$780$$$787$$$O	the$$$788$$$791$$$O	activities$$$792$$$802$$$O	of$$$803$$$805$$$O	Staphylococcus$$$806$$$820$$$O	albus,$$$821$$$827$$$O	Bacillus$$$828$$$836$$$O	subtilis,$$$837$$$846$$$O	Bacillus$$$847$$$855$$$O	cereus,$$$856$$$863$$$O	Sarcina$$$864$$$871$$$O	lutea,$$$872$$$878$$$O	Escherichia$$$879$$$890$$$O	coli,$$$891$$$896$$$O	Micrococcus$$$897$$$908$$$O	tetrgenus,$$$909$$$919$$$O	marine$$$920$$$926$$$O	bacterial$$$927$$$936$$$O	Vibrio$$$937$$$943$$$O	parahaemolyticus$$$944$$$960$$$O	and$$$961$$$964$$$O	marine$$$965$$$971$$$O	bacterial$$$972$$$981$$$O	Vibrio$$$982$$$988$$$O	anguillarum,$$$989$$$1001$$$O	and$$$1002$$$1005$$$O	can$$$1006$$$1009$$$O	be$$$1010$$$1012$$$O	used$$$1013$$$1017$$$O	for$$$1018$$$1021$$$O	developing$$$1022$$$1032$$$O	the$$$1033$$$1036$$$O	selective$$$1037$$$1046$$$O	antibacterial$$$1047$$$1060$$$O	agent.$$$1061$$$1067$$$O	In$$$1068$$$1070$$$O	addition,$$$1071$$$1080$$$O	the$$$1081$$$1084$$$O	raw$$$1085$$$1088$$$O	materials$$$1089$$$1098$$$O	can$$$1099$$$1102$$$O	be$$$1103$$$1105$$$O	massively$$$1106$$$1115$$$O	produced$$$1116$$$1124$$$O	and$$$1125$$$1128$$$O	are$$$1129$$$1132$$$O	free$$$1133$$$1137$$$O	of$$$1138$$$1140$$$O	the$$$1141$$$1144$$$O	limitation$$$1145$$$1155$$$O	of$$$1156$$$1158$$$O	resources.$$$1159$$$1169$$$O	Therefore,$$$1170$$$1180$$$O	the$$$1181$$$1184$$$O	bisabolane$$$1185$$$1195$$$I	sesquiterpenoid$$$1196$$$1211$$$I	has$$$1212$$$1215$$$O	wide$$$1216$$$1220$$$O	application$$$1221$$$1232$$$O	prospect.$$$1233$$$1242$$$O
US20090247455
Isolation$$$0$$$9$$$O	of$$$10$$$12$$$O	Inhibitors$$$13$$$23$$$O	of$$$24$$$26$$$O	IRES-Mediated$$$27$$$40$$$O	Translation$$$41$$$52$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	for$$$42$$$45$$$O	identifying$$$46$$$57$$$O	or$$$58$$$60$$$O	determining$$$61$$$72$$$O	a$$$73$$$74$$$O	compound$$$75$$$83$$$O	that$$$84$$$88$$$O	inhibits$$$89$$$97$$$O	or$$$98$$$100$$$O	reduces$$$101$$$108$$$O	internal$$$109$$$117$$$O	ribosome$$$118$$$126$$$O	entry$$$127$$$132$$$O	site$$$133$$$137$$$O	(IRES)$$$138$$$144$$$O	mediated$$$145$$$153$$$O	translation.$$$154$$$166$$$O	For$$$167$$$170$$$O	example,$$$171$$$179$$$O	the$$$180$$$183$$$O	present$$$184$$$191$$$O	invention$$$192$$$201$$$O	provides$$$202$$$210$$$O	a$$$211$$$212$$$O	method$$$213$$$219$$$O	for$$$220$$$223$$$O	determining$$$224$$$235$$$O	a$$$236$$$237$$$O	compound$$$238$$$246$$$O	that$$$247$$$251$$$O	inhibits$$$252$$$260$$$O	IRES-mediated$$$261$$$274$$$O	translation,$$$275$$$287$$$O	said$$$288$$$292$$$O	method$$$293$$$299$$$O	comprising$$$300$$$310$$$O	expressing$$$311$$$321$$$O	in$$$322$$$324$$$O	a$$$325$$$326$$$O	cell$$$327$$$331$$$O	a$$$332$$$333$$$O	counter$$$334$$$341$$$O	selectable$$$342$$$352$$$O	marker$$$353$$$359$$$O	operably$$$360$$$368$$$O	under$$$369$$$374$$$O	the$$$375$$$378$$$O	control$$$379$$$386$$$O	of$$$387$$$389$$$O	an$$$390$$$392$$$O	IRES.$$$393$$$398$$$O	A$$$399$$$400$$$O	candidate$$$401$$$410$$$O	compound$$$411$$$419$$$O	is$$$420$$$422$$$O	then$$$423$$$427$$$O	introduced$$$428$$$438$$$O	into$$$439$$$443$$$O	the$$$444$$$447$$$O	cell$$$448$$$452$$$O	or$$$453$$$455$$$O	contacted$$$456$$$465$$$O	with$$$466$$$470$$$O	the$$$471$$$474$$$O	cell$$$475$$$479$$$O	and$$$480$$$483$$$O	the$$$484$$$487$$$O	cell$$$488$$$492$$$O	maintained$$$493$$$503$$$O	under$$$504$$$509$$$O	conditions$$$510$$$520$$$O	that$$$521$$$525$$$O	select$$$526$$$532$$$O	against$$$533$$$540$$$O	a$$$541$$$542$$$O	cell$$$543$$$547$$$O	expressing$$$548$$$558$$$O	the$$$559$$$562$$$O	counter-selectable$$$563$$$581$$$O	marker$$$582$$$588$$$O	gene.$$$589$$$594$$$O	Accordingly,$$$595$$$607$$$O	a$$$608$$$609$$$O	cell$$$610$$$614$$$O	in$$$615$$$617$$$O	which$$$618$$$623$$$O	IRES-mediated$$$624$$$637$$$O	translation$$$638$$$649$$$O	of$$$650$$$652$$$O	the$$$653$$$656$$$O	counter-selectable$$$657$$$675$$$O	reporter$$$676$$$684$$$O	gene$$$685$$$689$$$O	is$$$690$$$692$$$O	selected,$$$693$$$702$$$O	thereby$$$703$$$710$$$O	identifying$$$711$$$722$$$O	a$$$723$$$724$$$O	compound$$$725$$$733$$$O	that$$$734$$$738$$$O	inhibits$$$739$$$747$$$O	IRES-mediated$$$748$$$761$$$O	translation.$$$762$$$774$$$O	The$$$775$$$778$$$O	present$$$779$$$786$$$O	invention$$$787$$$796$$$O	also$$$797$$$801$$$O	provides$$$802$$$810$$$O	compounds$$$811$$$820$$$O	identified$$$821$$$831$$$O	by$$$832$$$834$$$O	the$$$835$$$838$$$O	method.$$$839$$$846$$$O
US20080181864
Reducing$$$0$$$8$$$O	mitochondrial$$$9$$$22$$$O	membrane$$$23$$$31$$$O	potential$$$32$$$41$$$O	in$$$42$$$44$$$O	mammalian$$$45$$$54$$$O	cell$$$55$$$59$$$O	by$$$60$$$62$$$O	administering$$$63$$$76$$$O	an$$$77$$$79$$$O	major$$$80$$$85$$$O	histocompatibility$$$86$$$104$$$O	complex$$$105$$$112$$$O	(MHC)$$$113$$$118$$$O	class$$$119$$$124$$$O	II$$$125$$$127$$$O	HLA-DR$$$128$$$134$$$O	(human$$$135$$$141$$$O	leukocyte$$$142$$$151$$$O	antigen)$$$152$$$160$$$O	ligand;$$$161$$$168$$$O	control$$$169$$$176$$$O	disease$$$177$$$184$$$O	by$$$185$$$187$$$O	manipulating$$$188$$$200$$$O	mitochondrial$$$201$$$214$$$O	metabolism;$$$215$$$226$$$O	drug$$$227$$$231$$$O	screening$$$232$$$241$$$O	antitumor$$$242$$$251$$$O	drug;$$$252$$$257$$$O	treating$$$258$$$266$$$O	human$$$267$$$272$$$O	breast$$$273$$$279$$$O	cancer$$$280$$$286$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	involves$$$14$$$22$$$O	methods$$$23$$$30$$$O	of$$$31$$$33$$$O	regulating$$$34$$$44$$$O	cell$$$45$$$49$$$O	growth$$$50$$$56$$$O	and$$$57$$$60$$$O	division$$$61$$$69$$$O	to$$$70$$$72$$$O	control$$$73$$$80$$$O	disease$$$81$$$88$$$O	processes$$$89$$$98$$$O	by$$$99$$$101$$$O	manipulating$$$102$$$114$$$O	mitochondrial$$$115$$$128$$$O	metabolism$$$129$$$139$$$O	and$$$140$$$143$$$O	the$$$144$$$147$$$O	expression$$$148$$$158$$$O	of$$$159$$$161$$$O	cell$$$162$$$166$$$O	surface$$$167$$$174$$$O	immune$$$175$$$181$$$O	proteins.$$$182$$$191$$$O	The$$$192$$$195$$$O	invention$$$196$$$205$$$O	also$$$206$$$210$$$O	involves$$$211$$$219$$$O	related$$$220$$$227$$$O	compositions$$$228$$$240$$$O	and$$$241$$$244$$$O	screening$$$245$$$254$$$O	assays.$$$255$$$262$$$O
CN103601727A
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	novel$$$7$$$12$$$O	amine$$$13$$$18$$$I	compound$$$19$$$27$$$O	modified$$$28$$$36$$$O	protoporphyrin$$$37$$$51$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	discloses$$$22$$$31$$$O	a$$$32$$$33$$$O	use$$$34$$$37$$$O	of$$$38$$$40$$$O	N,N-dimethylethylenediamine$$$41$$$68$$$I	or$$$69$$$71$$$O	N,N-diethylethylenediamine$$$72$$$98$$$I	or$$$99$$$101$$$O	N-(2-aminoethyl)-trimethyl$$$102$$$128$$$I	ammonium$$$129$$$137$$$I	iodide$$$138$$$144$$$I	or$$$145$$$147$$$O	N-(2-aminoethyl)-triethyl$$$148$$$173$$$I	ammonium$$$174$$$182$$$I	iodide$$$183$$$189$$$I	modified$$$190$$$198$$$O	protoporphyrin.$$$199$$$214$$$I	The$$$215$$$218$$$O	N,N-dimethylethylenediamine$$$219$$$246$$$I	or$$$247$$$249$$$O	N,N-diethylethylenediamine$$$250$$$276$$$I	or$$$277$$$279$$$O	N-(2-aminoethyl)-trimethyl$$$280$$$306$$$I	ammonium$$$307$$$315$$$I	iodide$$$316$$$322$$$I	or$$$323$$$325$$$O	N-(2-aminoethyl)-triethyl$$$326$$$351$$$I	ammonium$$$352$$$360$$$I	iodide$$$361$$$367$$$I	modified$$$368$$$376$$$O	protoporphyrin$$$377$$$391$$$I	has$$$392$$$395$$$O	the$$$396$$$399$$$O	following$$$400$$$409$$$O	structure.$$$410$$$420$$$O	Experiment$$$421$$$431$$$O	results$$$432$$$439$$$O	show$$$440$$$444$$$O	that:$$$445$$$450$$$O	the$$$451$$$454$$$O	N,N-dimethylethylenediamine$$$455$$$482$$$I	or$$$483$$$485$$$O	N,N-diethylethylenediamine$$$486$$$512$$$I	or$$$513$$$515$$$O	N-(2-aminoethyl)-trimethyl$$$516$$$542$$$I	ammonium$$$543$$$551$$$I	iodide$$$552$$$558$$$I	or$$$559$$$561$$$O	N-(2-aminoethyl)-triethyl$$$562$$$587$$$I	ammonium$$$588$$$596$$$I	iodide$$$597$$$603$$$I	modified$$$604$$$612$$$O	protoporphyrin$$$613$$$627$$$I	has$$$628$$$631$$$O	a$$$632$$$633$$$O	good$$$634$$$638$$$O	in$$$639$$$641$$$O	vitro$$$642$$$647$$$O	photodynamic$$$648$$$660$$$O	antibacterial$$$661$$$674$$$O	performance,$$$675$$$687$$$O	and$$$688$$$691$$$O	provides$$$692$$$700$$$O	good$$$701$$$705$$$O	treatment$$$706$$$715$$$O	effects$$$716$$$723$$$O	for$$$724$$$727$$$O	photodynamic$$$728$$$740$$$O	treatments$$$741$$$751$$$O	of$$$752$$$754$$$O	mice$$$755$$$759$$$O	infections$$$760$$$770$$$O	caused$$$771$$$777$$$O	by$$$778$$$780$$$O	bacteria,$$$781$$$790$$$O	fungi$$$791$$$796$$$O	and$$$797$$$800$$$O	the$$$801$$$804$$$O	like.$$$805$$$810$$$O
WO2006080043A3
Organic$$$0$$$7$$$O	compounds$$$8$$$17$$$O	useful$$$18$$$24$$$O	for$$$25$$$28$$$O	the$$$29$$$32$$$O	treatment$$$33$$$42$$$O	of$$$43$$$45$$$O	alzheimer's$$$46$$$57$$$O	disease,$$$58$$$66$$$O	their$$$67$$$72$$$O	use$$$73$$$76$$$O	and$$$77$$$80$$$O	method$$$81$$$87$$$O	of$$$88$$$90$$$O	preparation$$$91$$$102$$$O
Compounds$$$0$$$9$$$O	identified$$$10$$$20$$$O	by$$$21$$$23$$$O	the$$$24$$$27$$$O	general$$$28$$$35$$$O	formula$$$36$$$43$$$O	(I)$$$44$$$47$$$O	are$$$48$$$51$$$O	used$$$52$$$56$$$O	for$$$57$$$60$$$O	the$$$61$$$64$$$O	treatment$$$65$$$74$$$O	of$$$75$$$77$$$O	Alzheimer's$$$78$$$89$$$O	disease.$$$90$$$98$$$O
EP2523691A1
Halogenated$$$0$$$11$$$I	ether$$$12$$$17$$$I	complex$$$18$$$25$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	complex$$$27$$$34$$$O	made$$$35$$$39$$$O	of$$$40$$$42$$$O	Î±-cyclodextrin$$$43$$$58$$$O	and$$$59$$$62$$$O	a$$$63$$$64$$$I	halogenated$$$65$$$76$$$I	ether,$$$77$$$83$$$I	characterized$$$84$$$97$$$O	by$$$98$$$100$$$O	a$$$101$$$102$$$O	content$$$103$$$110$$$O	of$$$111$$$113$$$O	the$$$114$$$117$$$I	halogenated$$$118$$$129$$$I	ether$$$130$$$135$$$I	of$$$136$$$138$$$O	at$$$139$$$141$$$O	least$$$142$$$147$$$O	3$$$148$$$149$$$O	wt%$$$150$$$153$$$O	of$$$154$$$156$$$O	the$$$157$$$160$$$O	total$$$161$$$166$$$O	weight$$$167$$$173$$$O	of$$$174$$$176$$$O	the$$$177$$$180$$$O	complex.$$$181$$$189$$$O
CN103520086A
Miconazole$$$0$$$10$$$I	nitrate$$$11$$$18$$$I	expandable$$$19$$$29$$$O	vaginal$$$30$$$37$$$O	suppository,$$$38$$$50$$$O	and$$$51$$$54$$$O	preparation$$$55$$$66$$$O	method$$$67$$$73$$$O	and$$$74$$$77$$$O	detection$$$78$$$87$$$O	method$$$88$$$94$$$O	thereof$$$95$$$102$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	miconazole$$$27$$$37$$$I	nitrate$$$38$$$45$$$I	expandable$$$46$$$56$$$O	vaginal$$$57$$$64$$$O	suppository,$$$65$$$77$$$O	and$$$78$$$81$$$O	a$$$82$$$83$$$O	preparation$$$84$$$95$$$O	method$$$96$$$102$$$O	and$$$103$$$106$$$O	a$$$107$$$108$$$O	detection$$$109$$$118$$$O	method$$$119$$$125$$$O	thereof.$$$126$$$134$$$O	The$$$135$$$138$$$O	expandable$$$139$$$149$$$O	vaginal$$$150$$$157$$$O	suppository$$$158$$$169$$$O	comprises$$$170$$$179$$$O	a$$$180$$$181$$$O	drug-containing$$$182$$$197$$$O	matrix$$$198$$$204$$$O	formed$$$205$$$211$$$O	by$$$212$$$214$$$O	miconazole$$$215$$$225$$$I	nitrate$$$226$$$233$$$I	and$$$234$$$237$$$O	a$$$238$$$239$$$O	matrix,$$$240$$$247$$$O	and$$$248$$$251$$$O	an$$$252$$$254$$$O	expansion$$$255$$$264$$$O	carrier.$$$265$$$273$$$O	Miconazole$$$274$$$284$$$I	nitrate$$$285$$$292$$$I	and$$$293$$$296$$$O	a$$$297$$$298$$$O	specific$$$299$$$307$$$O	solid$$$308$$$313$$$O	dispersion$$$314$$$324$$$O	carrier$$$325$$$332$$$O	are$$$333$$$336$$$O	prepared$$$337$$$345$$$O	into$$$346$$$350$$$O	a$$$351$$$352$$$O	solid$$$353$$$358$$$O	dispersion$$$359$$$369$$$O	to$$$370$$$372$$$O	improve$$$373$$$380$$$O	the$$$381$$$384$$$O	stability$$$385$$$394$$$O	of$$$395$$$397$$$O	the$$$398$$$401$$$O	suppository$$$402$$$413$$$O	and$$$414$$$417$$$O	solubility$$$418$$$428$$$O	of$$$429$$$431$$$O	active$$$432$$$438$$$O	ingredients,$$$439$$$451$$$O	and$$$452$$$455$$$O	increase$$$456$$$464$$$O	bioavailability$$$465$$$480$$$O	of$$$481$$$483$$$O	the$$$484$$$487$$$O	suppository.$$$488$$$500$$$O	The$$$501$$$504$$$O	outer$$$505$$$510$$$O	layer$$$511$$$516$$$O	of$$$517$$$519$$$O	the$$$520$$$523$$$O	expandable$$$524$$$534$$$O	vaginal$$$535$$$542$$$O	suppository$$$543$$$554$$$O	is$$$555$$$557$$$O	coated$$$558$$$564$$$O	with$$$565$$$569$$$O	a$$$570$$$571$$$O	film$$$572$$$576$$$O	coating$$$577$$$584$$$O	to$$$585$$$587$$$O	prolong$$$588$$$595$$$O	the$$$596$$$599$$$O	action$$$600$$$606$$$O	time$$$607$$$611$$$O	of$$$612$$$614$$$O	the$$$615$$$618$$$O	suppository$$$619$$$630$$$O	on$$$631$$$633$$$O	the$$$634$$$637$$$O	vagina$$$638$$$644$$$O	and$$$645$$$648$$$O	improve$$$649$$$656$$$O	the$$$657$$$660$$$O	stability$$$661$$$670$$$O	of$$$671$$$673$$$O	the$$$674$$$677$$$O	suppository.$$$678$$$690$$$O	The$$$691$$$694$$$O	miconazole$$$695$$$705$$$I	nitrate$$$706$$$713$$$I	expandable$$$714$$$724$$$O	vaginal$$$725$$$732$$$O	suppository$$$733$$$744$$$O	provided$$$745$$$753$$$O	by$$$754$$$756$$$O	the$$$757$$$760$$$O	invention$$$761$$$770$$$O	employs$$$771$$$778$$$O	seven$$$779$$$784$$$O	originally$$$785$$$795$$$O	created$$$796$$$803$$$O	leading$$$804$$$811$$$O	technologies,$$$812$$$825$$$O	and$$$826$$$829$$$O	has$$$830$$$833$$$O	the$$$834$$$837$$$O	beneficial$$$838$$$848$$$O	effects$$$849$$$856$$$O	of$$$857$$$859$$$O	prevention$$$860$$$870$$$O	of$$$871$$$873$$$O	outflow$$$874$$$881$$$O	liquid,$$$882$$$889$$$O	high$$$890$$$894$$$O	stability,$$$895$$$905$$$O	lasting$$$906$$$913$$$O	effect$$$914$$$920$$$O	and$$$921$$$924$$$O	prevention$$$925$$$935$$$O	of$$$936$$$938$$$O	secondary$$$939$$$948$$$O	infection.$$$949$$$959$$$O
WO2014060366A1
N-substituted$$$0$$$13$$$I	3,4-bis$$$14$$$21$$$I	(catechol)$$$22$$$32$$$I	pyrrole$$$33$$$40$$$I	compounds,$$$41$$$51$$$O	and$$$52$$$55$$$O	the$$$56$$$59$$$O	preparation$$$60$$$71$$$O	and$$$72$$$75$$$O	use$$$76$$$79$$$O	thereof$$$80$$$87$$$O	in$$$88$$$90$$$O	the$$$91$$$94$$$O	treatment$$$95$$$104$$$O	of$$$105$$$107$$$O	cancer$$$108$$$114$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	compound$$$35$$$43$$$O	of$$$44$$$46$$$O	formula$$$47$$$54$$$O	(I)$$$55$$$58$$$O	in$$$59$$$61$$$O	which:$$$62$$$68$$$O	-$$$69$$$70$$$O	m$$$71$$$72$$$O	is$$$73$$$75$$$O	an$$$76$$$78$$$O	integer$$$79$$$86$$$O	from$$$87$$$91$$$O	0$$$92$$$93$$$O	to$$$94$$$96$$$O	3,$$$97$$$99$$$O	preferably$$$100$$$110$$$O	from$$$111$$$115$$$O	0$$$116$$$117$$$O	to$$$118$$$120$$$O	2;$$$121$$$123$$$O	n$$$124$$$125$$$O	is$$$126$$$128$$$O	an$$$129$$$131$$$O	integer$$$132$$$139$$$O	from$$$140$$$144$$$O	0$$$145$$$146$$$O	to$$$147$$$149$$$O	3,$$$150$$$152$$$O	preferably$$$153$$$163$$$O	from$$$164$$$168$$$O	0$$$169$$$170$$$O	to$$$171$$$173$$$O	2;$$$174$$$176$$$O	m$$$177$$$178$$$O	+$$$179$$$180$$$O	n$$$181$$$182$$$O	â¥$$$183$$$186$$$O	1;$$$187$$$189$$$O	EAG$$$190$$$193$$$O	is$$$194$$$196$$$O	an$$$197$$$199$$$O	electro-attractive$$$200$$$218$$$O	group$$$219$$$224$$$O	chosen$$$225$$$231$$$O	independently$$$232$$$245$$$O	from$$$246$$$250$$$O	among$$$251$$$256$$$O	a$$$257$$$258$$$I	halogen$$$259$$$266$$$I	atom,$$$267$$$272$$$O	an$$$273$$$275$$$I	NO2,$$$276$$$280$$$I	CF3,$$$281$$$285$$$I	CCI3,$$$286$$$291$$$I	CN,$$$292$$$295$$$I	CO2H,$$$296$$$301$$$I	(C=O)NR2,$$$302$$$311$$$I	CH=NR,$$$312$$$318$$$I	(C=S)OR,$$$319$$$327$$$I	(C=O)SR,$$$328$$$336$$$I	CS2R,$$$337$$$342$$$I	SO2R,$$$343$$$348$$$I	SO2NR2,$$$349$$$356$$$I	SO3R,$$$357$$$362$$$I	P(O)(OR)2,$$$363$$$373$$$I	P(O)(R)2,$$$374$$$383$$$I	B(OR)2$$$384$$$390$$$I	group$$$391$$$396$$$O	where$$$397$$$402$$$O	R$$$403$$$404$$$O	is$$$405$$$407$$$O	a$$$408$$$409$$$I	(C1$$$410$$$413$$$I	â$$$414$$$417$$$I	C6)$$$418$$$421$$$I	alkyl$$$422$$$427$$$I	radical,$$$428$$$436$$$I	a$$$437$$$438$$$I	phenyl$$$439$$$445$$$I	group$$$446$$$451$$$O	or$$$452$$$454$$$I	a$$$455$$$456$$$I	hydrogen$$$457$$$465$$$I	atom;$$$466$$$471$$$O	A$$$472$$$473$$$O	is$$$474$$$476$$$O	a$$$477$$$478$$$O	saturated$$$479$$$488$$$O	or$$$489$$$491$$$O	unsaturated,$$$492$$$504$$$O	linear$$$505$$$511$$$O	or$$$512$$$514$$$O	branched$$$515$$$523$$$I	hydrocarbon$$$524$$$535$$$I	chain$$$536$$$541$$$O	including$$$542$$$551$$$O	1$$$552$$$553$$$O	to$$$554$$$556$$$O	10$$$557$$$559$$$O	atoms$$$560$$$565$$$I	of$$$566$$$568$$$I	carbon;$$$569$$$576$$$I	and$$$577$$$580$$$O	R1$$$581$$$583$$$O	and$$$584$$$587$$$O	R2$$$588$$$590$$$O	each$$$591$$$595$$$O	represent$$$596$$$605$$$O	independently$$$606$$$619$$$O	from$$$620$$$624$$$O	one$$$625$$$628$$$O	another$$$629$$$636$$$I	a$$$637$$$638$$$I	hydrogen$$$639$$$647$$$I	atom,$$$648$$$653$$$I	a$$$654$$$655$$$I	CO-(Ci$$$656$$$662$$$I	-$$$663$$$664$$$I	C6)-alkyl,$$$665$$$675$$$I	(C1$$$676$$$679$$$I	â$$$680$$$683$$$I	C6)$$$684$$$687$$$I	alkyl,$$$688$$$694$$$I	phenyl$$$695$$$701$$$I	or$$$702$$$704$$$I	phenyl-(C1$$$705$$$715$$$I	â$$$716$$$719$$$I	C6)-alkyl$$$720$$$729$$$I	group,$$$730$$$736$$$O	in$$$737$$$739$$$O	which$$$740$$$745$$$O	R1$$$746$$$748$$$O	and$$$749$$$752$$$O	R2$$$753$$$755$$$O	form,$$$756$$$761$$$O	together$$$762$$$770$$$O	with$$$771$$$775$$$I	the$$$776$$$779$$$I	nitrogen$$$780$$$788$$$I	atom$$$789$$$793$$$O	they$$$794$$$798$$$O	carry,$$$799$$$805$$$O	a$$$806$$$807$$$O	5-$$$808$$$810$$$O	to$$$811$$$813$$$O	15-member$$$814$$$823$$$I	heterocycle,$$$824$$$836$$$I	optionally$$$837$$$847$$$O	substituted$$$848$$$859$$$I	by$$$860$$$862$$$I	a$$$863$$$864$$$I	(C1$$$865$$$868$$$I	â$$$869$$$872$$$I	C6)$$$873$$$876$$$O	alkyl$$$877$$$882$$$O	group;$$$883$$$889$$$O	including$$$890$$$899$$$O	its$$$900$$$903$$$O	stereoisomers$$$904$$$917$$$O	and$$$918$$$921$$$O	the$$$922$$$925$$$O	mixtures$$$926$$$934$$$O	thereof,$$$935$$$943$$$O	or$$$944$$$946$$$O	a$$$947$$$948$$$O	pharmaceutically$$$949$$$965$$$O	acceptable$$$966$$$976$$$O	salt$$$977$$$981$$$O	of$$$982$$$984$$$O	same.$$$985$$$990$$$O
CN102056902A
Imidazolidine$$$0$$$13$$$O	derivatives$$$14$$$25$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	is$$$14$$$16$$$O	concerned$$$17$$$26$$$O	with$$$27$$$31$$$O	novel$$$32$$$37$$$O	imidazolidine$$$38$$$51$$$O	derivatives$$$52$$$63$$$O	of$$$64$$$66$$$O	formula$$$67$$$74$$$O	(I):$$$75$$$79$$$O	wherein$$$80$$$87$$$O	R1$$$88$$$90$$$O	to$$$91$$$93$$$O	R3,$$$94$$$97$$$O	A,$$$98$$$100$$$O	D$$$101$$$102$$$O	and$$$103$$$106$$$O	E$$$107$$$108$$$O	are$$$109$$$112$$$O	as$$$113$$$115$$$O	defined$$$116$$$123$$$O	in$$$124$$$126$$$O	the$$$127$$$130$$$O	description$$$131$$$142$$$O	and$$$143$$$146$$$O	in$$$147$$$149$$$O	the$$$150$$$153$$$O	claims,$$$154$$$161$$$O	as$$$162$$$164$$$O	well$$$165$$$169$$$O	as$$$170$$$172$$$O	physiologically$$$173$$$188$$$O	acceptable$$$189$$$199$$$O	salts$$$200$$$205$$$O	and$$$206$$$209$$$O	esters$$$210$$$216$$$O	thereof.$$$217$$$225$$$O	These$$$226$$$231$$$O	compounds$$$232$$$241$$$O	bind$$$242$$$246$$$O	to$$$247$$$249$$$O	LXR$$$250$$$253$$$O	alpha$$$254$$$259$$$O	and$$$260$$$263$$$O	LXR$$$264$$$267$$$O	beta$$$268$$$272$$$O	and$$$273$$$276$$$O	can$$$277$$$280$$$O	be$$$281$$$283$$$O	used$$$284$$$288$$$O	as$$$289$$$291$$$O	medicaments.$$$292$$$304$$$O
EP1284653B1
Infrared$$$0$$$8$$$O	thermography$$$9$$$21$$$O	and$$$22$$$25$$$O	treatment$$$26$$$35$$$O	of$$$36$$$38$$$O	sexual$$$39$$$45$$$O	dysfunctions$$$46$$$58$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	describes$$$22$$$31$$$O	rapid$$$32$$$37$$$O	non-invasive$$$38$$$50$$$O	methods$$$51$$$58$$$O	for$$$59$$$62$$$O	measuring$$$63$$$72$$$O	vasodilation$$$73$$$85$$$O	or$$$86$$$88$$$O	changes$$$89$$$96$$$O	in$$$97$$$99$$$O	blood$$$100$$$105$$$O	flow$$$106$$$110$$$O	in$$$111$$$113$$$O	a$$$114$$$115$$$O	patient$$$116$$$123$$$O	following$$$124$$$133$$$O	administration$$$134$$$148$$$O	of$$$149$$$151$$$O	at$$$152$$$154$$$O	least$$$155$$$160$$$O	one$$$161$$$164$$$O	compound$$$165$$$173$$$O	that$$$174$$$178$$$O	donates,$$$179$$$187$$$O	transfers$$$188$$$197$$$O	or$$$198$$$200$$$O	releases$$$201$$$209$$$O	nitric$$$210$$$216$$$I	oxide,$$$217$$$223$$$I	elevates$$$224$$$232$$$O	endogenous$$$233$$$243$$$O	levels$$$244$$$250$$$O	of$$$251$$$253$$$O	endothelium-derived$$$254$$$273$$$O	relaxing$$$274$$$282$$$O	factor,$$$283$$$290$$$O	stimulates$$$291$$$301$$$O	endogenous$$$302$$$312$$$O	synthesis$$$313$$$322$$$O	of$$$323$$$325$$$O	nitric$$$326$$$332$$$I	oxide$$$333$$$338$$$I	or$$$339$$$341$$$O	is$$$342$$$344$$$O	a$$$345$$$346$$$O	substrate$$$347$$$356$$$O	for$$$357$$$360$$$O	nitric$$$361$$$367$$$I	oxide$$$368$$$373$$$I	synthase$$$374$$$382$$$O	and/or$$$383$$$389$$$O	at$$$390$$$392$$$O	least$$$393$$$398$$$O	one$$$399$$$402$$$O	vasoactive$$$403$$$413$$$O	agent.$$$414$$$420$$$O	The$$$421$$$424$$$O	method$$$425$$$431$$$O	comprises$$$432$$$441$$$O	administration$$$442$$$456$$$O	of$$$457$$$459$$$O	at$$$460$$$462$$$O	least$$$463$$$468$$$O	one$$$469$$$472$$$O	compound$$$473$$$481$$$O	to$$$482$$$484$$$O	the$$$485$$$488$$$O	patient$$$489$$$496$$$O	followed$$$497$$$505$$$O	by$$$506$$$508$$$O	monitoring$$$509$$$519$$$O	the$$$520$$$523$$$O	temperature$$$524$$$535$$$O	change$$$536$$$542$$$O	of$$$543$$$545$$$O	an$$$546$$$548$$$O	area$$$549$$$553$$$O	of$$$554$$$556$$$O	interest$$$557$$$565$$$O	using$$$566$$$571$$$O	infrared$$$572$$$580$$$O	thermography.$$$581$$$594$$$O
WO2011158931A1
Useful$$$0$$$6$$$O	salts$$$7$$$12$$$O	of$$$13$$$15$$$O	indazole$$$16$$$24$$$I	derivative$$$25$$$35$$$O
Provided$$$0$$$8$$$O	are$$$9$$$12$$$O	a$$$13$$$14$$$O	p-toluenesulfonate$$$15$$$33$$$I	of$$$34$$$36$$$O	compound$$$37$$$45$$$O	(I),$$$46$$$50$$$O	a$$$51$$$52$$$O	hydrochloride$$$53$$$66$$$I	and$$$67$$$70$$$O	other$$$71$$$76$$$O	salts$$$77$$$82$$$O	of$$$83$$$85$$$O	said$$$86$$$90$$$O	compound$$$91$$$99$$$O	(I),$$$100$$$104$$$O	and$$$105$$$108$$$O	a$$$109$$$110$$$O	pharmaceutical$$$111$$$125$$$O	composition$$$126$$$137$$$O	containing$$$138$$$148$$$O	the$$$149$$$152$$$O	p-toluenesulfonate,$$$153$$$172$$$I	the$$$173$$$176$$$O	hydrochloride,$$$177$$$191$$$I	or$$$192$$$194$$$O	the$$$195$$$198$$$O	like$$$199$$$203$$$O	of$$$204$$$206$$$O	said$$$207$$$211$$$O	compound$$$212$$$220$$$O	(I)$$$221$$$224$$$O	that$$$225$$$229$$$O	have$$$230$$$234$$$O	excellent$$$235$$$244$$$O	physical$$$245$$$253$$$O	properties$$$254$$$264$$$O	and$$$265$$$268$$$O	quality$$$269$$$276$$$O	and$$$277$$$280$$$O	that$$$281$$$285$$$O	are$$$286$$$289$$$O	useful$$$290$$$296$$$O	in$$$297$$$299$$$O	treating$$$300$$$308$$$O	abnormal$$$309$$$317$$$O	cell$$$318$$$322$$$O	growth,$$$323$$$330$$$O	such$$$331$$$335$$$O	as$$$336$$$338$$$O	cancer,$$$339$$$346$$$O	by$$$347$$$349$$$O	the$$$350$$$353$$$O	action$$$354$$$360$$$O	of$$$361$$$363$$$O	inhibiting$$$364$$$374$$$O	the$$$375$$$378$$$O	type$$$379$$$383$$$O	I$$$384$$$385$$$O	insulin-like$$$386$$$398$$$O	growth$$$399$$$405$$$O	factor$$$406$$$412$$$O	receptor$$$413$$$421$$$O	(IGF-1R).$$$422$$$431$$$O
WO2014146494A1
Î-aminocarbonyl$$$0$$$16$$$I	compound,$$$17$$$26$$$O	preparation$$$27$$$38$$$O	method,$$$39$$$46$$$O	pharmaceutical$$$47$$$61$$$O	composition$$$62$$$73$$$O	and$$$74$$$77$$$O	use$$$78$$$81$$$O	thereof$$$82$$$89$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	belongs$$$22$$$29$$$O	to$$$30$$$32$$$O	the$$$33$$$36$$$O	field$$$37$$$42$$$O	of$$$43$$$45$$$O	medicinal$$$46$$$55$$$O	chemistry.$$$56$$$66$$$O	In$$$67$$$69$$$O	particular,$$$70$$$81$$$O	the$$$82$$$85$$$O	present$$$86$$$93$$$O	invention$$$94$$$103$$$O	relates$$$104$$$111$$$O	to$$$112$$$114$$$O	a$$$115$$$116$$$O	novel$$$117$$$122$$$O	Î²-aminocarbonyl$$$123$$$139$$$I	compound$$$140$$$148$$$O	as$$$149$$$151$$$O	represented$$$152$$$163$$$O	by$$$164$$$166$$$O	general$$$167$$$174$$$O	formula$$$175$$$182$$$O	I,$$$183$$$185$$$O	or$$$186$$$188$$$O	tautomer,$$$189$$$198$$$O	enantiomer,$$$199$$$210$$$O	racemate$$$211$$$219$$$O	and$$$220$$$223$$$O	pharmaceutically$$$224$$$240$$$O	acceptable$$$241$$$251$$$O	salt$$$252$$$256$$$O	thereof,$$$257$$$265$$$O	preparation$$$266$$$277$$$O	method$$$278$$$284$$$O	and$$$285$$$288$$$O	pharmaceutical$$$289$$$303$$$O	composition$$$304$$$315$$$O	thereof,$$$316$$$324$$$O	and$$$325$$$328$$$O	use$$$329$$$332$$$O	thereof$$$333$$$340$$$O	as$$$341$$$343$$$O	a$$$344$$$345$$$O	dipeptidyl$$$346$$$356$$$O	peptidase$$$357$$$366$$$O	IV$$$367$$$369$$$O	(DPP-4)$$$370$$$377$$$O	inhibitor.$$$378$$$388$$$O	The$$$389$$$392$$$O	compound$$$393$$$401$$$O	or$$$402$$$404$$$O	pharmaceutical$$$405$$$419$$$O	composition$$$420$$$431$$$O	thereof$$$432$$$439$$$O	can$$$440$$$443$$$O	be$$$444$$$446$$$O	used$$$447$$$451$$$O	as$$$452$$$454$$$O	a$$$455$$$456$$$O	DPP-4$$$457$$$462$$$O	inhibitor$$$463$$$472$$$O	to$$$473$$$475$$$O	treat$$$476$$$481$$$O	type$$$482$$$486$$$O	II$$$487$$$489$$$O	diabetes,$$$490$$$499$$$O	hyperglycaemia,$$$500$$$515$$$O	obesity,$$$516$$$524$$$O	or$$$525$$$527$$$O	insulin-resistance$$$528$$$546$$$O	syndromes.$$$547$$$557$$$O
CN101397330A
Novel$$$0$$$5$$$O	nitrogen-containing$$$6$$$25$$$I	medicament$$$26$$$36$$$O	with$$$37$$$41$$$O	anti-inflammatory$$$42$$$59$$$O	activity$$$60$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	androstane$$$28$$$38$$$I	azotic$$$39$$$45$$$O	glucocorticoid$$$46$$$60$$$O	receptor$$$61$$$69$$$O	stimulant$$$70$$$79$$$O	compound$$$80$$$88$$$O	and$$$89$$$92$$$O	a$$$93$$$94$$$O	preparation$$$95$$$106$$$O	method$$$107$$$113$$$O	thereof.$$$114$$$122$$$O	The$$$123$$$126$$$O	invention$$$127$$$136$$$O	further$$$137$$$144$$$O	relates$$$145$$$152$$$O	to$$$153$$$155$$$O	the$$$156$$$159$$$O	pharmaceutical$$$160$$$174$$$O	preparations$$$175$$$187$$$O	comprising$$$188$$$198$$$O	the$$$199$$$202$$$O	compound$$$203$$$211$$$O	and$$$212$$$215$$$O	the$$$216$$$219$$$O	therapeutic$$$220$$$231$$$O	use$$$232$$$235$$$O	of$$$236$$$238$$$O	the$$$239$$$242$$$O	compound,$$$243$$$252$$$O	in$$$253$$$255$$$O	particular$$$256$$$266$$$O	to$$$267$$$269$$$O	inflammatory$$$270$$$282$$$O	disease,$$$283$$$291$$$O	allergic$$$292$$$300$$$O	disease$$$301$$$308$$$O	or$$$309$$$311$$$O	anaphylactic$$$312$$$324$$$O	disease.$$$325$$$333$$$O
CN103142633A
Compound$$$0$$$8$$$O	amino$$$9$$$14$$$I	acid$$$15$$$19$$$I	capsule$$$20$$$27$$$O	including$$$28$$$37$$$O	eight$$$38$$$43$$$O	amino$$$44$$$49$$$I	acids$$$50$$$55$$$I	and$$$56$$$59$$$O	eleven$$$60$$$66$$$O	vitamins$$$67$$$75$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	compound$$$27$$$35$$$O	amino$$$36$$$41$$$I	acid$$$42$$$46$$$I	capsule$$$47$$$54$$$O	(8-11)$$$55$$$61$$$O	and$$$62$$$65$$$O	a$$$66$$$67$$$O	preparation$$$68$$$79$$$O	method$$$80$$$86$$$O	thereof,$$$87$$$95$$$O	specifically$$$96$$$108$$$O	to$$$109$$$111$$$O	a$$$112$$$113$$$O	capsule$$$114$$$121$$$O	including$$$122$$$131$$$O	pellets$$$132$$$139$$$O	of$$$140$$$142$$$O	eight$$$143$$$148$$$O	amino$$$149$$$154$$$I	acids$$$155$$$160$$$I	and$$$161$$$164$$$O	eleven$$$165$$$171$$$O	vitamins$$$172$$$180$$$I	and$$$181$$$184$$$O	a$$$185$$$186$$$O	preparation$$$187$$$198$$$O	method$$$199$$$205$$$O	thereof.$$$206$$$214$$$O	The$$$215$$$218$$$O	capsule$$$219$$$226$$$O	comprises$$$227$$$236$$$O	7$$$237$$$238$$$O	spherical$$$239$$$248$$$O	pellets$$$249$$$256$$$O	which$$$257$$$262$$$O	are$$$263$$$266$$$O	composed$$$267$$$275$$$O	of$$$276$$$278$$$O	the$$$279$$$282$$$O	following$$$283$$$292$$$O	raw$$$293$$$296$$$O	materials$$$297$$$306$$$O	by$$$307$$$309$$$O	weight:$$$310$$$317$$$O	2.66$$$318$$$322$$$O	to$$$323$$$325$$$O	9.9$$$326$$$329$$$O	parts$$$330$$$335$$$O	of$$$336$$$338$$$O	a$$$339$$$340$$$O	thiamine$$$341$$$349$$$I	mononitrate$$$350$$$361$$$I	pellet,$$$362$$$369$$$O	16.35$$$370$$$375$$$O	to$$$376$$$378$$$O	20.5$$$379$$$383$$$O	parts$$$384$$$389$$$O	of$$$390$$$392$$$O	a$$$393$$$394$$$O	vitamin$$$395$$$402$$$I	pellet$$$403$$$409$$$O	a,$$$410$$$412$$$O	35.0$$$413$$$417$$$O	to$$$418$$$420$$$O	44.1$$$421$$$425$$$O	parts$$$426$$$431$$$O	of$$$432$$$434$$$O	an$$$435$$$437$$$O	amino$$$438$$$443$$$I	acid$$$444$$$448$$$I	pellet$$$449$$$455$$$O	a,$$$456$$$458$$$O	11.4$$$459$$$463$$$O	to$$$464$$$466$$$O	14.4$$$467$$$471$$$O	parts$$$472$$$477$$$O	of$$$478$$$480$$$O	a$$$481$$$482$$$O	vitamin$$$483$$$490$$$I	pellet$$$491$$$497$$$O	b,$$$498$$$500$$$O	6.65$$$501$$$505$$$O	to$$$506$$$508$$$O	10.5$$$509$$$513$$$O	parts$$$514$$$519$$$O	of$$$520$$$522$$$O	an$$$523$$$525$$$O	amino$$$526$$$531$$$I	acid$$$532$$$536$$$I	pellet$$$537$$$543$$$O	b,$$$544$$$546$$$O	12.$$$547$$$550$$$O	73$$$551$$$553$$$O	to$$$554$$$556$$$O	16.0$$$557$$$561$$$O	parts$$$562$$$567$$$O	of$$$568$$$570$$$O	a$$$571$$$572$$$O	vitamin$$$573$$$580$$$I	C$$$581$$$582$$$I	pellet$$$583$$$589$$$O	and$$$590$$$593$$$O	5.7$$$594$$$597$$$O	to$$$598$$$600$$$O	9.36$$$601$$$605$$$O	parts$$$606$$$611$$$O	of$$$612$$$614$$$O	a$$$615$$$616$$$O	vitamin$$$617$$$624$$$I	AD$$$625$$$627$$$I	bead.$$$628$$$633$$$O	The$$$634$$$637$$$O	capsule$$$638$$$645$$$O	provided$$$646$$$654$$$O	by$$$655$$$657$$$O	the$$$658$$$661$$$O	invention$$$662$$$671$$$O	has$$$672$$$675$$$O	the$$$676$$$679$$$O	advantages$$$680$$$690$$$O	of$$$691$$$693$$$O	a$$$694$$$695$$$O	scientific$$$696$$$706$$$O	and$$$707$$$710$$$O	reasonable$$$711$$$721$$$O	ratio,$$$722$$$728$$$O	good$$$729$$$733$$$O	stability,$$$734$$$744$$$O	no$$$745$$$747$$$O	toxic$$$748$$$753$$$O	and$$$754$$$757$$$O	side$$$758$$$762$$$O	effects,$$$763$$$771$$$O	high$$$772$$$776$$$O	security$$$777$$$785$$$O	and$$$786$$$789$$$O	good$$$790$$$794$$$O	biological$$$795$$$805$$$O	effects$$$806$$$813$$$O	and$$$814$$$817$$$O	can$$$818$$$821$$$O	be$$$822$$$824$$$O	applied$$$825$$$832$$$O	in$$$833$$$835$$$O	preparation$$$836$$$847$$$O	of$$$848$$$850$$$O	medicines$$$851$$$860$$$O	used$$$861$$$865$$$O	for$$$866$$$869$$$O	treating$$$870$$$878$$$O	chronic$$$879$$$886$$$O	liver$$$887$$$892$$$O	and$$$893$$$896$$$O	kidney$$$897$$$903$$$O	diseases$$$904$$$912$$$O	and$$$913$$$916$$$O	of$$$917$$$919$$$O	foodstuffs$$$920$$$930$$$O	used$$$931$$$935$$$O	for$$$936$$$939$$$O	alleviating$$$940$$$951$$$O	and$$$952$$$955$$$O	eliminating$$$956$$$967$$$O	physical$$$968$$$976$$$O	fatigue$$$977$$$984$$$O	caused$$$985$$$991$$$O	by$$$992$$$994$$$O	exercise$$$995$$$1003$$$O	training.$$$1004$$$1013$$$O	The$$$1014$$$1017$$$O	capsule$$$1018$$$1025$$$O	provided$$$1026$$$1034$$$O	by$$$1035$$$1037$$$O	the$$$1038$$$1041$$$O	invention$$$1042$$$1051$$$O	has$$$1052$$$1055$$$O	characteristics$$$1056$$$1071$$$O	superior$$$1072$$$1080$$$O	to$$$1081$$$1083$$$O	those$$$1084$$$1089$$$O	of$$$1090$$$1092$$$O	the$$$1093$$$1096$$$O	prior$$$1097$$$1102$$$O	art.$$$1103$$$1107$$$O
CA2143752C
Method$$$0$$$6$$$O	of$$$7$$$9$$$O	preventing$$$10$$$20$$$O	nmda$$$21$$$25$$$O	receptor-mediated$$$26$$$43$$$O	neuronal$$$44$$$52$$$O	damage$$$53$$$59$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	method$$$15$$$21$$$O	for$$$22$$$25$$$O	reducing$$$26$$$34$$$O	non-ischemic$$$35$$$47$$$O	NMDA$$$48$$$52$$$O	receptor-mediated$$$53$$$70$$$O	neuronal$$$71$$$79$$$O	damage$$$80$$$86$$$O	in$$$87$$$89$$$O	a$$$90$$$91$$$O	mammal$$$92$$$98$$$O	by$$$99$$$101$$$O	administering$$$102$$$115$$$O	to$$$116$$$118$$$O	the$$$119$$$122$$$O	mammal$$$123$$$129$$$O	a$$$130$$$131$$$O	compound$$$132$$$140$$$O	of$$$141$$$143$$$O	the$$$144$$$147$$$O	formula$$$148$$$155$$$O	shown$$$156$$$161$$$O	in$$$162$$$164$$$O	Fig.$$$165$$$169$$$O	1$$$170$$$171$$$O	(or$$$172$$$175$$$O	a$$$176$$$177$$$O	physiologically-acceptable$$$178$$$204$$$O	salt$$$205$$$209$$$O	thereof),$$$210$$$219$$$O	wherein$$$220$$$227$$$O	R1$$$228$$$230$$$O	includes$$$231$$$239$$$O	an$$$240$$$242$$$O	amino$$$243$$$248$$$I	group,$$$249$$$255$$$O	R2-R17$$$256$$$262$$$O	are$$$263$$$266$$$O	independently$$$267$$$280$$$O	H$$$281$$$282$$$I	or$$$283$$$285$$$O	a$$$286$$$287$$$O	short$$$288$$$293$$$O	chain$$$294$$$299$$$O	aliphatic$$$300$$$309$$$I	group$$$310$$$315$$$O	comprising$$$316$$$326$$$O	1-5$$$327$$$330$$$O	carbons,$$$331$$$339$$$I	and$$$340$$$343$$$O	R4$$$344$$$346$$$O	and$$$347$$$350$$$O	R10$$$351$$$354$$$O	also$$$355$$$359$$$O	may$$$360$$$363$$$O	(independently)$$$364$$$379$$$O	be$$$380$$$382$$$O	a$$$383$$$384$$$O	halogen$$$385$$$392$$$I	or$$$393$$$395$$$O	an$$$396$$$398$$$O	acyl$$$399$$$403$$$I	group.$$$404$$$410$$$O	Also$$$411$$$415$$$O	disclosed$$$416$$$425$$$O	is$$$426$$$428$$$O	a$$$429$$$430$$$O	screen$$$431$$$437$$$O	for$$$438$$$441$$$O	antagonists$$$442$$$453$$$O	of$$$454$$$456$$$O	NMDA$$$457$$$461$$$O	receptor$$$462$$$470$$$O	mediated$$$471$$$479$$$O	neurotoxicity$$$480$$$493$$$O	which$$$494$$$499$$$O	have$$$500$$$504$$$O	an$$$505$$$507$$$O	enhanced$$$508$$$516$$$O	prospect$$$517$$$525$$$O	for$$$526$$$529$$$O	being$$$530$$$535$$$O	clinically$$$536$$$546$$$O	tolerated$$$547$$$556$$$O	and$$$557$$$560$$$O	selective$$$561$$$570$$$O	against$$$571$$$578$$$O	such$$$579$$$583$$$O	neurotoxicity.$$$584$$$598$$$O
US20100261772
Cycloalkylidene$$$0$$$15$$$O	Compounds$$$16$$$25$$$O	As$$$26$$$28$$$O	Selective$$$29$$$38$$$O	Estrogen$$$39$$$47$$$O	Receptor$$$48$$$56$$$O	Modulators$$$57$$$67$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compounds$$$33$$$42$$$O	of$$$43$$$45$$$O	formula$$$46$$$53$$$O	(I)$$$54$$$57$$$O	with$$$58$$$62$$$O	a$$$63$$$64$$$O	variety$$$65$$$72$$$O	of$$$73$$$75$$$O	therapeutic$$$76$$$87$$$O	uses,$$$88$$$93$$$O	more$$$94$$$98$$$O	particularly$$$99$$$111$$$O	the$$$112$$$115$$$O	substituted$$$116$$$127$$$O	cyclic$$$128$$$134$$$O	alkylidene$$$135$$$145$$$O	compounds$$$146$$$155$$$O	are$$$156$$$159$$$O	useful$$$160$$$166$$$O	for$$$167$$$170$$$O	selective$$$171$$$180$$$O	estrogen$$$181$$$189$$$O	receptor$$$190$$$198$$$O	modulation.$$$199$$$210$$$O
US20120164122
Phytoestrogenic$$$0$$$15$$$O	formulations$$$16$$$28$$$O	for$$$29$$$32$$$O	alleviation$$$33$$$44$$$O	or$$$45$$$47$$$O	prevention$$$48$$$58$$$O	of$$$59$$$61$$$O	neurodegenerative$$$62$$$79$$$O	diseases$$$80$$$88$$$O
Select$$$0$$$6$$$O	phytoestrogen$$$7$$$20$$$O	pharmaceutical$$$21$$$35$$$O	compositions$$$36$$$48$$$O	and$$$49$$$52$$$O	methods$$$53$$$60$$$O	of$$$61$$$63$$$O	use$$$64$$$67$$$O	for$$$68$$$71$$$O	promoting$$$72$$$81$$$O	neurological$$$82$$$94$$$O	heath$$$95$$$100$$$O	and$$$101$$$104$$$O	prevention$$$105$$$115$$$O	of$$$116$$$118$$$O	age-related$$$119$$$130$$$O	neurodegeneration,$$$131$$$149$$$O	such$$$150$$$154$$$O	as$$$155$$$157$$$O	AD,$$$158$$$161$$$O	have$$$162$$$166$$$O	been$$$167$$$171$$$O	developed.$$$172$$$182$$$O	These$$$183$$$188$$$O	select$$$189$$$195$$$O	phytoestrogen$$$196$$$209$$$O	formulations$$$210$$$222$$$O	are$$$223$$$226$$$O	composed$$$227$$$235$$$O	of$$$236$$$238$$$O	a$$$239$$$240$$$O	number$$$241$$$247$$$O	of$$$248$$$250$$$O	plant-derived$$$251$$$264$$$O	estrogenic$$$265$$$275$$$O	molecules$$$276$$$285$$$O	and/or$$$286$$$292$$$O	their$$$293$$$298$$$O	structural$$$299$$$309$$$O	analogues$$$310$$$319$$$O	and$$$320$$$323$$$O	exhibit$$$324$$$331$$$O	binding$$$332$$$339$$$O	preference$$$340$$$350$$$O	to$$$351$$$353$$$O	ERÎ²$$$354$$$358$$$O	over$$$359$$$363$$$O	ERÎ±$$$364$$$368$$$O	and$$$369$$$372$$$O	agonist$$$373$$$380$$$O	activity$$$381$$$389$$$O	in$$$390$$$392$$$O	the$$$393$$$396$$$O	brain.$$$397$$$403$$$O	These$$$404$$$409$$$O	ERÎ²-selective$$$410$$$424$$$O	phytoestrogen$$$425$$$438$$$O	formulations$$$439$$$451$$$O	cross$$$452$$$457$$$O	the$$$458$$$461$$$O	blood-brain-barrier$$$462$$$481$$$O	and$$$482$$$485$$$O	promote$$$486$$$493$$$I	estrogen-associated$$$494$$$513$$$I	neurotrophism$$$514$$$527$$$O	and$$$528$$$531$$$O	neuroprotections$$$532$$$548$$$O	mechanisms$$$549$$$559$$$O	in$$$560$$$562$$$O	the$$$563$$$566$$$O	brain,$$$567$$$573$$$O	without$$$574$$$581$$$O	activating$$$582$$$592$$$O	proliferative$$$593$$$606$$$O	mechanisms$$$607$$$617$$$O	in$$$618$$$620$$$O	the$$$621$$$624$$$O	reproductive$$$625$$$637$$$O	tissues$$$638$$$645$$$O	and$$$646$$$649$$$O	are$$$650$$$653$$$O	therefore$$$654$$$663$$$O	devoid$$$664$$$670$$$O	of$$$671$$$673$$$O	other$$$674$$$679$$$I	estrogen-associated$$$680$$$699$$$I	problematic$$$700$$$711$$$O	aspects.$$$712$$$720$$$O	These$$$721$$$726$$$O	are$$$727$$$730$$$O	administered$$$731$$$743$$$O	enterally,$$$744$$$754$$$O	transdermally,$$$755$$$769$$$O	transmucosally,$$$770$$$785$$$O	intranasally$$$786$$$798$$$O	or$$$799$$$801$$$O	parenterally,$$$802$$$815$$$O	in$$$816$$$818$$$O	a$$$819$$$820$$$O	dosage$$$821$$$827$$$O	effective$$$828$$$837$$$O	to$$$838$$$840$$$O	prevent$$$841$$$848$$$O	or$$$849$$$851$$$O	alleviate$$$852$$$861$$$O	neuronal$$$862$$$870$$$O	damage,$$$871$$$878$$$O	effect$$$879$$$885$$$O	neuronal$$$886$$$894$$$O	regeneration$$$895$$$907$$$O	or$$$908$$$910$$$O	sustain$$$911$$$918$$$O	viability,$$$919$$$929$$$O	increase$$$930$$$938$$$O	expression$$$939$$$949$$$O	of$$$950$$$952$$$O	anti-apoptotic$$$953$$$967$$$O	proteins,$$$968$$$977$$$O	and/or$$$978$$$984$$$O	decrease$$$985$$$993$$$O	indicators$$$994$$$1004$$$O	of$$$1005$$$1007$$$O	Alzheimer's$$$1008$$$1019$$$O	Disease.$$$1020$$$1028$$$O
WO2010069979A1
Pyran$$$0$$$5$$$I	derivatives$$$6$$$17$$$O	as$$$18$$$20$$$O	ccr3$$$21$$$25$$$O	modulators$$$26$$$36$$$O
The$$$0$$$3$$$O	compounds$$$4$$$13$$$O	of$$$14$$$16$$$O	formula$$$17$$$24$$$O	(1)$$$25$$$28$$$O	wherein$$$29$$$36$$$O	A,$$$37$$$39$$$O	B,$$$40$$$42$$$O	R1,$$$43$$$46$$$O	R2$$$47$$$49$$$O	and$$$50$$$53$$$O	R3$$$54$$$56$$$O	have$$$57$$$61$$$O	the$$$62$$$65$$$O	meanings$$$66$$$74$$$O	as$$$75$$$77$$$O	given$$$78$$$83$$$O	in$$$84$$$86$$$O	the$$$87$$$90$$$O	description,$$$91$$$103$$$O	the$$$104$$$107$$$O	stereoisomers,$$$108$$$122$$$O	as$$$123$$$125$$$O	well$$$126$$$130$$$O	as$$$131$$$133$$$O	the$$$134$$$137$$$O	salts$$$138$$$143$$$O	of$$$144$$$146$$$O	the$$$147$$$150$$$O	stereoisomers$$$151$$$164$$$O	thereof$$$165$$$172$$$O	are$$$173$$$176$$$O	effective$$$177$$$186$$$O	CCR3$$$187$$$191$$$O	modulators.$$$192$$$203$$$O
US6946118
comprises$$$0$$$9$$$O	tetracycline$$$10$$$22$$$I	derivative$$$23$$$33$$$O	that$$$34$$$38$$$O	is$$$39$$$41$$$O	poorly$$$42$$$48$$$O	absorbed$$$49$$$57$$$O	from$$$58$$$62$$$O	the$$$63$$$66$$$O	gastrointestinal$$$67$$$83$$$O	tract;$$$84$$$90$$$O	may$$$91$$$94$$$O	include$$$95$$$102$$$O	fungicide;$$$103$$$113$$$O	side$$$114$$$118$$$O	effect$$$119$$$125$$$O	reduction;$$$126$$$136$$$O	aersols;$$$137$$$145$$$O	mouthwashes$$$146$$$157$$$O
Mucositis$$$0$$$9$$$O	is$$$10$$$12$$$O	treated$$$13$$$20$$$O	and/or$$$21$$$27$$$O	prevented$$$28$$$37$$$O	by$$$38$$$40$$$O	administrating$$$41$$$55$$$O	to$$$56$$$58$$$O	a$$$59$$$60$$$O	patient$$$61$$$68$$$O	a$$$69$$$70$$$O	formulation$$$71$$$82$$$O	comprising$$$83$$$93$$$O	a$$$94$$$95$$$O	tetracycline$$$96$$$108$$$I	that$$$109$$$113$$$O	is$$$114$$$116$$$O	poorly$$$117$$$123$$$O	absorbed$$$124$$$132$$$O	from$$$133$$$137$$$O	the$$$138$$$141$$$O	gastro-intestinal$$$142$$$159$$$O	tract.$$$160$$$166$$$O	The$$$167$$$170$$$O	tetracycline$$$171$$$183$$$I	may$$$184$$$187$$$O	be$$$188$$$190$$$O	in$$$191$$$193$$$O	the$$$194$$$197$$$O	form$$$198$$$202$$$O	of$$$203$$$205$$$O	a$$$206$$$207$$$O	pharmaceutically$$$208$$$224$$$O	acceptable$$$225$$$235$$$O	salt$$$236$$$240$$$O	or$$$241$$$243$$$O	a$$$244$$$245$$$O	base.$$$246$$$251$$$O	The$$$252$$$255$$$O	formulations$$$256$$$268$$$O	may$$$269$$$272$$$O	optionally$$$273$$$283$$$O	also$$$284$$$288$$$O	contain$$$289$$$296$$$O	an$$$297$$$299$$$O	antifungal$$$300$$$310$$$O	agent$$$311$$$316$$$O	to$$$317$$$319$$$O	prevent$$$320$$$327$$$O	fungal$$$328$$$334$$$O	overgrowth$$$335$$$345$$$O	due$$$346$$$349$$$O	to$$$350$$$352$$$O	reduction$$$353$$$362$$$O	in$$$363$$$365$$$O	the$$$366$$$369$$$O	normal$$$370$$$376$$$O	oral$$$377$$$381$$$O	flora$$$382$$$387$$$O	by$$$388$$$390$$$O	the$$$391$$$394$$$O	tetracycline.$$$395$$$408$$$I	Such$$$409$$$413$$$O	compositions$$$414$$$426$$$O	have$$$427$$$431$$$O	the$$$432$$$435$$$O	advantage$$$436$$$445$$$O	of$$$446$$$448$$$O	treating$$$449$$$457$$$O	the$$$458$$$461$$$O	entire$$$462$$$468$$$O	gastro-intestinal$$$469$$$486$$$O	tract$$$487$$$492$$$O	since$$$493$$$498$$$O	the$$$499$$$502$$$O	active$$$503$$$509$$$O	ingredient$$$510$$$520$$$O	is$$$521$$$523$$$O	not$$$524$$$527$$$O	removed$$$528$$$535$$$O	from$$$536$$$540$$$O	the$$$541$$$544$$$O	tract$$$545$$$550$$$O	via$$$551$$$554$$$O	absorption.$$$555$$$566$$$O	Further,$$$567$$$575$$$O	such$$$576$$$580$$$O	compositions$$$581$$$593$$$O	minimize$$$594$$$602$$$O	systemic$$$603$$$611$$$O	exposure$$$612$$$620$$$O	and$$$621$$$624$$$O	accompanying$$$625$$$637$$$O	side$$$638$$$642$$$O	effects.$$$643$$$651$$$O
CN203436580U
Smooth$$$0$$$6$$$O	slimming$$$7$$$15$$$O	capsule$$$16$$$23$$$O	structure$$$24$$$33$$$O	capable$$$34$$$41$$$O	of$$$42$$$44$$$O	preventing$$$45$$$55$$$O	and$$$56$$$59$$$O	treating$$$60$$$68$$$O	obesity$$$69$$$76$$$O	and$$$77$$$80$$$O	promoting$$$81$$$90$$$O	micro-lipid$$$91$$$102$$$O	metabolism$$$103$$$113$$$O
The$$$0$$$3$$$O	utility$$$4$$$11$$$O	model$$$12$$$17$$$O	discloses$$$18$$$27$$$O	a$$$28$$$29$$$O	smooth$$$30$$$36$$$O	slimming$$$37$$$45$$$O	capsule$$$46$$$53$$$O	structure$$$54$$$63$$$O	capable$$$64$$$71$$$O	of$$$72$$$74$$$O	preventing$$$75$$$85$$$O	and$$$86$$$89$$$O	treating$$$90$$$98$$$O	obesity$$$99$$$106$$$O	and$$$107$$$110$$$O	promoting$$$111$$$120$$$O	micro-lipid$$$121$$$132$$$O	metabolism.$$$133$$$144$$$O	The$$$145$$$148$$$O	smooth$$$149$$$155$$$O	slimming$$$156$$$164$$$O	capsule$$$165$$$172$$$O	structure$$$173$$$182$$$O	comprises$$$183$$$192$$$O	a$$$193$$$194$$$O	sealed$$$195$$$201$$$O	bag,$$$202$$$206$$$O	a$$$207$$$208$$$O	plurality$$$209$$$218$$$O	of$$$219$$$221$$$O	first$$$222$$$227$$$O	capsule$$$228$$$235$$$O	bags$$$236$$$240$$$O	which$$$241$$$246$$$O	are$$$247$$$250$$$O	filled$$$251$$$257$$$O	with$$$258$$$262$$$O	lotus$$$263$$$268$$$O	leaves,$$$269$$$276$$$O	tea$$$277$$$280$$$O	polyphenol$$$281$$$291$$$I	and$$$292$$$295$$$O	L-carnitine$$$296$$$307$$$I	extract,$$$308$$$316$$$O	and$$$317$$$320$$$O	a$$$321$$$322$$$O	plurality$$$323$$$332$$$O	of$$$333$$$335$$$O	second$$$336$$$342$$$O	capsule$$$343$$$350$$$O	bags$$$351$$$355$$$O	which$$$356$$$361$$$O	are$$$362$$$365$$$O	filled$$$366$$$372$$$O	with$$$373$$$377$$$O	semen$$$378$$$383$$$O	cassiae$$$384$$$391$$$O	extract.$$$392$$$400$$$O	The$$$401$$$404$$$O	sealed$$$405$$$411$$$O	bag$$$412$$$415$$$O	comprises$$$416$$$425$$$O	a$$$426$$$427$$$O	carrier$$$428$$$435$$$O	and$$$436$$$439$$$O	sealing$$$440$$$447$$$O	aluminum$$$448$$$456$$$I	foil,$$$457$$$462$$$O	wherein$$$463$$$470$$$O	the$$$471$$$474$$$O	carrier$$$475$$$482$$$O	comprises$$$483$$$492$$$O	a$$$493$$$494$$$O	plurality$$$495$$$504$$$O	of$$$505$$$507$$$O	capsule$$$508$$$515$$$O	cavities;$$$516$$$525$$$O	each$$$526$$$530$$$O	capsule$$$531$$$538$$$O	cavity$$$539$$$545$$$O	is$$$546$$$548$$$O	provided$$$549$$$557$$$O	with$$$558$$$562$$$O	one$$$563$$$566$$$O	first$$$567$$$572$$$O	capsule$$$573$$$580$$$O	bag$$$581$$$584$$$O	and$$$585$$$588$$$O	one$$$589$$$592$$$O	second$$$593$$$599$$$O	capsule$$$600$$$607$$$O	bag;$$$608$$$612$$$O	the$$$613$$$616$$$O	sealing$$$617$$$624$$$O	aluminum$$$625$$$633$$$I	foil$$$634$$$638$$$O	coats$$$639$$$644$$$O	the$$$645$$$648$$$O	carrier$$$649$$$656$$$O	and$$$657$$$660$$$O	seals$$$661$$$666$$$O	the$$$667$$$670$$$O	capsule$$$671$$$678$$$O	cavities;$$$679$$$688$$$O	the$$$689$$$692$$$O	thickness$$$693$$$702$$$O	of$$$703$$$705$$$O	the$$$706$$$709$$$O	second$$$710$$$716$$$O	capsule$$$717$$$724$$$O	bags$$$725$$$729$$$O	is$$$730$$$732$$$O	larger$$$733$$$739$$$O	than$$$740$$$744$$$O	that$$$745$$$749$$$O	of$$$750$$$752$$$O	the$$$753$$$756$$$O	first$$$757$$$762$$$O	capsule$$$763$$$770$$$O	bags;$$$771$$$776$$$O	thus,$$$777$$$782$$$O	one$$$783$$$786$$$O	first$$$787$$$792$$$O	capsule$$$793$$$800$$$O	bag$$$801$$$804$$$O	and$$$805$$$808$$$O	one$$$809$$$812$$$O	second$$$813$$$819$$$O	capsule$$$820$$$827$$$O	bag$$$828$$$831$$$O	can$$$832$$$835$$$O	be$$$836$$$838$$$O	put$$$839$$$842$$$O	in$$$843$$$845$$$O	one$$$846$$$849$$$O	capsule$$$850$$$857$$$O	cavity.$$$858$$$865$$$O	When$$$866$$$870$$$O	a$$$871$$$872$$$O	user$$$873$$$877$$$O	opens$$$878$$$883$$$O	one$$$884$$$887$$$O	capsule$$$888$$$895$$$O	cavitie,$$$896$$$904$$$O	the$$$905$$$908$$$O	user$$$909$$$913$$$O	can$$$914$$$917$$$O	take$$$918$$$922$$$O	out$$$923$$$926$$$O	the$$$927$$$930$$$O	first$$$931$$$936$$$O	capsule$$$937$$$944$$$O	bag$$$945$$$948$$$O	and$$$949$$$952$$$O	the$$$953$$$956$$$O	second$$$957$$$963$$$O	capsule$$$964$$$971$$$O	bag$$$972$$$975$$$O	together.$$$976$$$985$$$O	As$$$986$$$988$$$O	the$$$989$$$992$$$O	first$$$993$$$998$$$O	capsule$$$999$$$1006$$$O	bags$$$1007$$$1011$$$O	and$$$1012$$$1015$$$O	the$$$1016$$$1019$$$O	second$$$1020$$$1026$$$O	capsule$$$1027$$$1034$$$O	bags$$$1035$$$1039$$$O	are$$$1040$$$1043$$$O	different$$$1044$$$1053$$$O	in$$$1054$$$1056$$$O	thickness,$$$1057$$$1067$$$O	and$$$1068$$$1071$$$O	has$$$1072$$$1075$$$O	different$$$1076$$$1085$$$O	action$$$1086$$$1092$$$O	time$$$1093$$$1097$$$O	after$$$1098$$$1103$$$O	being$$$1104$$$1109$$$O	eaten,$$$1110$$$1116$$$O	the$$$1117$$$1120$$$O	first$$$1121$$$1126$$$O	capsule$$$1127$$$1134$$$O	bags$$$1135$$$1139$$$O	and$$$1140$$$1143$$$O	the$$$1144$$$1147$$$O	second$$$1148$$$1154$$$O	capsule$$$1155$$$1162$$$O	bags$$$1163$$$1167$$$O	can$$$1168$$$1171$$$O	fully$$$1172$$$1177$$$O	bring$$$1178$$$1183$$$O	the$$$1184$$$1187$$$O	effects$$$1188$$$1195$$$O	of$$$1196$$$1198$$$O	preventing$$$1199$$$1209$$$O	and$$$1210$$$1213$$$O	treating$$$1214$$$1222$$$O	obesity$$$1223$$$1230$$$O	and$$$1231$$$1234$$$O	promoting$$$1235$$$1244$$$O	micro-lipid$$$1245$$$1256$$$O	metabolism$$$1257$$$1267$$$O	of$$$1268$$$1270$$$O	the$$$1271$$$1274$$$O	lotus$$$1275$$$1280$$$O	leaves,$$$1281$$$1288$$$O	the$$$1289$$$1292$$$O	tea$$$1293$$$1296$$$O	polyphenol,$$$1297$$$1308$$$I	the$$$1309$$$1312$$$O	L-carnitine$$$1313$$$1324$$$I	extract$$$1325$$$1332$$$O	and$$$1333$$$1336$$$O	the$$$1337$$$1340$$$O	semen$$$1341$$$1346$$$O	cassiae$$$1347$$$1354$$$O	extract$$$1355$$$1362$$$O	into$$$1363$$$1367$$$O	play.$$$1368$$$1373$$$O
EP2328412A1
Iap$$$0$$$3$$$O	inhibitors$$$4$$$14$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	describes$$$22$$$31$$$O	compounds,$$$32$$$42$$$O	processes$$$43$$$52$$$O	for$$$53$$$56$$$O	their$$$57$$$62$$$O	preparation,$$$63$$$75$$$O	pharmaceutical$$$76$$$90$$$O	compositions$$$91$$$103$$$O	containing$$$104$$$114$$$O	them,$$$115$$$120$$$O	and$$$121$$$124$$$O	their$$$125$$$130$$$O	use$$$131$$$134$$$O	in$$$135$$$137$$$O	therapy.$$$138$$$146$$$O
CN103012429A
Novel$$$0$$$5$$$O	amoxicillin$$$6$$$17$$$I	sodium$$$18$$$24$$$I	compound$$$25$$$33$$$O	and$$$34$$$37$$$O	composition$$$38$$$49$$$O	of$$$50$$$52$$$O	amoxicillin$$$53$$$64$$$I	sodium$$$65$$$71$$$I	compound$$$72$$$80$$$O	and$$$81$$$84$$$O	sulbactam$$$85$$$94$$$I	sodium$$$95$$$101$$$I	compound$$$102$$$110$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	novel$$$26$$$31$$$O	amoxicillin$$$32$$$43$$$I	sodium$$$44$$$50$$$I	compound.$$$51$$$60$$$O	The$$$61$$$64$$$O	purity$$$65$$$71$$$O	of$$$72$$$74$$$O	the$$$75$$$78$$$O	amoxicillin$$$79$$$90$$$I	sodium$$$91$$$97$$$I	compound$$$98$$$106$$$O	is$$$107$$$109$$$O	more$$$110$$$114$$$O	than$$$115$$$119$$$O	99%,$$$120$$$124$$$O	the$$$125$$$128$$$O	specific$$$129$$$137$$$O	rotation$$$138$$$146$$$O	of$$$147$$$149$$$O	the$$$150$$$153$$$O	amoxicillin$$$154$$$165$$$I	sodium$$$166$$$172$$$I	compound$$$173$$$181$$$O	is$$$182$$$184$$$O	between$$$185$$$192$$$O	+260$$$193$$$197$$$O	degrees$$$198$$$205$$$O	and$$$206$$$209$$$O	+280$$$210$$$214$$$O	degrees.$$$215$$$223$$$O	The$$$224$$$227$$$O	invention$$$228$$$237$$$O	also$$$238$$$242$$$O	discloses$$$243$$$252$$$O	a$$$253$$$254$$$O	composition$$$255$$$266$$$O	of$$$267$$$269$$$O	the$$$270$$$273$$$O	amoxicillin$$$274$$$285$$$I	sodium$$$286$$$292$$$I	compound$$$293$$$301$$$O	and$$$302$$$305$$$O	the$$$306$$$309$$$O	sulbactam$$$310$$$319$$$I	sodium$$$320$$$326$$$I	compound,$$$327$$$336$$$O	which$$$337$$$342$$$O	comprises$$$343$$$352$$$O	the$$$353$$$356$$$O	following$$$357$$$366$$$O	components$$$367$$$377$$$O	in$$$378$$$380$$$O	parts$$$381$$$386$$$O	by$$$387$$$389$$$O	weight:$$$390$$$397$$$O	50-100$$$398$$$404$$$O	parts$$$405$$$410$$$O	of$$$411$$$413$$$O	amoxicillin$$$414$$$425$$$I	sodium,$$$426$$$433$$$I	25-50$$$434$$$439$$$O	parts$$$440$$$445$$$O	of$$$446$$$448$$$O	sulbactam$$$449$$$458$$$I	sodium,$$$459$$$466$$$I	3-9$$$467$$$470$$$O	parts$$$471$$$476$$$O	of$$$477$$$479$$$O	vitamin$$$480$$$487$$$I	C,$$$488$$$490$$$I	1-6$$$491$$$494$$$O	parts$$$495$$$500$$$O	of$$$501$$$503$$$O	proline,$$$504$$$512$$$I	and$$$513$$$516$$$O	2-8$$$517$$$520$$$O	parts$$$521$$$526$$$O	of$$$527$$$529$$$O	nicotinamide.$$$530$$$543$$$I	According$$$544$$$553$$$O	to$$$554$$$556$$$O	the$$$557$$$560$$$O	composition$$$561$$$572$$$O	of$$$573$$$575$$$O	the$$$576$$$579$$$O	amoxicillin$$$580$$$591$$$I	sodium$$$592$$$598$$$I	compound$$$599$$$607$$$O	and$$$608$$$611$$$O	the$$$612$$$615$$$O	sulbactam$$$616$$$625$$$I	sodium$$$626$$$632$$$I	compound,$$$633$$$642$$$O	the$$$643$$$646$$$O	vitamin$$$647$$$654$$$I	C,$$$655$$$657$$$I	the$$$658$$$661$$$O	proline$$$662$$$669$$$I	and$$$670$$$673$$$O	the$$$674$$$677$$$O	nicotinamide$$$678$$$690$$$I	are$$$691$$$694$$$O	taken$$$695$$$700$$$O	as$$$701$$$703$$$O	stabilizers$$$704$$$715$$$O	and$$$716$$$719$$$O	play$$$720$$$724$$$O	synergistic$$$725$$$736$$$O	effect$$$737$$$743$$$O	so$$$744$$$746$$$O	as$$$747$$$749$$$O	to$$$750$$$752$$$O	improve$$$753$$$760$$$O	the$$$761$$$764$$$O	stability$$$765$$$774$$$O	of$$$775$$$777$$$O	the$$$778$$$781$$$O	composition$$$782$$$793$$$O	of$$$794$$$796$$$O	the$$$797$$$800$$$O	amoxicillin$$$801$$$812$$$I	sodium$$$813$$$819$$$I	compound$$$820$$$828$$$O	and$$$829$$$832$$$O	the$$$833$$$836$$$O	sulbactam$$$837$$$846$$$I	sodium$$$847$$$853$$$I	compound$$$854$$$862$$$O	effectively,$$$863$$$875$$$O	the$$$876$$$879$$$O	composition$$$880$$$891$$$O	can$$$892$$$895$$$O	be$$$896$$$898$$$O	prepared$$$899$$$907$$$O	into$$$908$$$912$$$O	stable$$$913$$$919$$$O	injection$$$920$$$929$$$O	which$$$930$$$935$$$O	is$$$936$$$938$$$O	not$$$939$$$942$$$O	easy$$$943$$$947$$$O	to$$$948$$$950$$$O	deteriorate$$$951$$$962$$$O	due$$$963$$$966$$$O	to$$$967$$$969$$$O	oxygenolysis$$$970$$$982$$$O	after$$$983$$$988$$$O	being$$$989$$$994$$$O	laid$$$995$$$999$$$O	for$$$1000$$$1003$$$O	a$$$1004$$$1005$$$O	period,$$$1006$$$1013$$$O	and$$$1014$$$1017$$$O	the$$$1018$$$1021$$$O	injection$$$1022$$$1031$$$O	does$$$1032$$$1036$$$O	not$$$1037$$$1040$$$O	need$$$1041$$$1045$$$O	to$$$1046$$$1048$$$O	be$$$1049$$$1051$$$O	prepared$$$1052$$$1060$$$O	when$$$1061$$$1065$$$O	being$$$1066$$$1071$$$O	used,$$$1072$$$1077$$$O	thus$$$1078$$$1082$$$O	being$$$1083$$$1088$$$O	convenient$$$1089$$$1099$$$O	to$$$1100$$$1102$$$O	use.$$$1103$$$1107$$$O
CN103284985A
Stable$$$0$$$6$$$O	(S)-alpha-methyl-4-(2-methylpropyl)$$$7$$$42$$$I	phenylacetic$$$43$$$55$$$I	acid$$$56$$$60$$$I	medicine$$$61$$$69$$$O	composition$$$70$$$81$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	stable$$$27$$$33$$$O	(S)-alpha-methyl-4-(2-methylpropyl)$$$34$$$69$$$I	phenylacetic$$$70$$$82$$$I	acid$$$83$$$87$$$I	medicine$$$88$$$96$$$O	composition,$$$97$$$109$$$O	and$$$110$$$113$$$O	in$$$114$$$116$$$O	particular$$$117$$$127$$$O	relates$$$128$$$135$$$O	to$$$136$$$138$$$O	a$$$139$$$140$$$O	medicine$$$141$$$149$$$O	composition$$$150$$$161$$$O	which$$$162$$$167$$$O	is$$$168$$$170$$$O	basically$$$171$$$180$$$O	homogeneous$$$181$$$192$$$O	in$$$193$$$195$$$O	physics.$$$196$$$204$$$O	The$$$205$$$208$$$O	medicine$$$209$$$217$$$O	composition$$$218$$$229$$$O	comprises$$$230$$$239$$$O	a$$$240$$$241$$$O	compound$$$242$$$250$$$O	used$$$251$$$255$$$O	as$$$256$$$258$$$O	an$$$259$$$261$$$O	active$$$262$$$268$$$O	ingredient$$$269$$$279$$$O	and$$$280$$$283$$$O	shown$$$284$$$289$$$O	in$$$290$$$292$$$O	the$$$293$$$296$$$O	formula$$$297$$$304$$$O	I,$$$305$$$307$$$O	and$$$308$$$311$$$O	pharmaceutically$$$312$$$328$$$O	acceptable$$$329$$$339$$$O	auxiliary$$$340$$$349$$$O	materials.$$$350$$$360$$$O	The$$$361$$$364$$$O	medicine$$$365$$$373$$$O	composition$$$374$$$385$$$O	disclosed$$$386$$$395$$$O	by$$$396$$$398$$$O	the$$$399$$$402$$$O	invention$$$403$$$412$$$O	has$$$413$$$416$$$O	good$$$417$$$421$$$O	properties.$$$422$$$433$$$O
CN103520152A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	andrographolide$$$15$$$30$$$I	in$$$31$$$33$$$O	resistance$$$34$$$44$$$O	of$$$45$$$47$$$O	endometriosis$$$48$$$61$$$O	proliferative$$$62$$$75$$$O	diseases$$$76$$$84$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	application$$$28$$$39$$$O	of$$$40$$$42$$$O	andrographolide$$$43$$$58$$$I	in$$$59$$$61$$$O	the$$$62$$$65$$$O	resistance$$$66$$$76$$$O	of$$$77$$$79$$$O	endometriosis$$$80$$$93$$$O	proliferative$$$94$$$107$$$O	diseases.$$$108$$$117$$$O	When$$$118$$$122$$$O	the$$$123$$$126$$$O	andrographolide$$$127$$$142$$$I	is$$$143$$$145$$$O	used$$$146$$$150$$$O	for$$$151$$$154$$$O	treating$$$155$$$163$$$O	endometriosis,$$$164$$$178$$$O	the$$$179$$$182$$$O	andrographolide$$$183$$$198$$$I	has$$$199$$$202$$$O	an$$$203$$$205$$$O	obvious$$$206$$$213$$$O	improvement$$$214$$$225$$$O	effect$$$226$$$232$$$O	on$$$233$$$235$$$O	the$$$236$$$239$$$O	pain$$$240$$$244$$$O	symptom$$$245$$$252$$$O	of$$$253$$$255$$$O	the$$$256$$$259$$$O	endometriosis.$$$260$$$274$$$O	The$$$275$$$278$$$O	andrographolide$$$279$$$294$$$I	has$$$295$$$298$$$O	a$$$299$$$300$$$O	treatment$$$301$$$310$$$O	effect$$$311$$$317$$$O	on$$$318$$$320$$$O	the$$$321$$$324$$$O	adenomyosis$$$325$$$336$$$O	of$$$337$$$339$$$O	uterus$$$340$$$346$$$O	(adenomyoma)$$$347$$$359$$$O	and$$$360$$$363$$$O	can$$$364$$$367$$$O	be$$$368$$$370$$$O	used$$$371$$$375$$$O	for$$$376$$$379$$$O	increasing$$$380$$$390$$$O	the$$$391$$$394$$$O	threshold$$$395$$$404$$$O	of$$$405$$$407$$$O	pain,$$$408$$$413$$$O	reducing$$$414$$$422$$$O	the$$$423$$$426$$$O	weight$$$427$$$433$$$O	of$$$434$$$436$$$O	the$$$437$$$440$$$O	uterus,$$$441$$$448$$$O	reducing$$$449$$$457$$$O	the$$$458$$$461$$$O	adenomyosis$$$462$$$473$$$O	of$$$474$$$476$$$O	uterus$$$477$$$483$$$O	and$$$484$$$487$$$O	the$$$488$$$491$$$O	infiltration$$$492$$$504$$$O	tendency$$$505$$$513$$$O	and$$$514$$$517$$$O	reducing$$$518$$$526$$$O	the$$$527$$$530$$$O	volume$$$531$$$537$$$O	of$$$538$$$540$$$O	an$$$541$$$543$$$O	ectopic$$$544$$$551$$$O	uterus.$$$552$$$559$$$O
CN101336900A
Anticancer$$$0$$$10$$$O	sustained-released$$$11$$$29$$$O	injection$$$30$$$39$$$O	containing$$$40$$$50$$$O	taxane$$$51$$$57$$$I
An$$$0$$$2$$$O	anticancer$$$3$$$13$$$O	sustained-released$$$14$$$32$$$O	injection$$$33$$$42$$$O	containing$$$43$$$53$$$O	taxane$$$54$$$60$$$I	comprises$$$61$$$70$$$O	sustained-released$$$71$$$89$$$O	microspheres$$$90$$$102$$$O	and$$$103$$$106$$$O	a$$$107$$$108$$$O	solvent.$$$109$$$117$$$O	The$$$118$$$121$$$O	sustained-released$$$122$$$140$$$O	microspheres$$$141$$$153$$$O	comprise$$$154$$$162$$$O	an$$$163$$$165$$$O	anticancer$$$166$$$176$$$O	effective$$$177$$$186$$$O	ingredient$$$187$$$197$$$O	and$$$198$$$201$$$O	a$$$202$$$203$$$O	sustained-released$$$204$$$222$$$O	adjuvant,$$$223$$$232$$$O	and$$$233$$$236$$$O	the$$$237$$$240$$$O	solvent$$$241$$$248$$$O	is$$$249$$$251$$$O	a$$$252$$$253$$$O	common$$$254$$$260$$$O	solvent$$$261$$$268$$$O	or$$$269$$$271$$$O	a$$$272$$$273$$$O	special$$$274$$$281$$$O	solvent$$$282$$$289$$$O	containing$$$290$$$300$$$O	a$$$301$$$302$$$O	suspending$$$303$$$313$$$O	agent.$$$314$$$320$$$O	The$$$321$$$324$$$O	anticancer$$$325$$$335$$$O	effective$$$336$$$345$$$O	ingredient$$$346$$$356$$$O	is$$$357$$$359$$$O	taxane$$$360$$$366$$$I	and/or$$$367$$$373$$$O	taxane$$$374$$$380$$$I	synergist;$$$381$$$391$$$O	the$$$392$$$395$$$O	taxane$$$396$$$402$$$I	synergist$$$403$$$412$$$O	is$$$413$$$415$$$O	selected$$$416$$$424$$$O	from$$$425$$$429$$$O	an$$$430$$$432$$$O	antitumor$$$433$$$442$$$O	antibiotic,$$$443$$$454$$$O	an$$$455$$$457$$$O	anti-metabolism$$$458$$$473$$$O	drug$$$474$$$478$$$O	and/or$$$479$$$485$$$O	a$$$486$$$487$$$O	plant$$$488$$$493$$$O	alkaloid;$$$494$$$503$$$O	the$$$504$$$507$$$O	sustained-released$$$508$$$526$$$O	adjuvant$$$527$$$535$$$O	is$$$536$$$538$$$O	selected$$$539$$$547$$$O	from$$$548$$$552$$$O	poly(lactic$$$553$$$564$$$I	acid),$$$565$$$571$$$I	polyactic$$$572$$$581$$$I	acid-polyglycolic$$$582$$$599$$$I	acid$$$600$$$604$$$I	copolymer,$$$605$$$615$$$O	ethylene-vinyl$$$616$$$630$$$I	acetate$$$631$$$638$$$I	copolymer,$$$639$$$649$$$O	polifeprosan,$$$650$$$663$$$O	difatty$$$664$$$671$$$I	acid$$$672$$$676$$$I	and$$$677$$$680$$$O	sebacic$$$681$$$688$$$I	acid$$$689$$$693$$$I	copolymer,$$$694$$$704$$$O	etc.;$$$705$$$710$$$O	and$$$711$$$714$$$O	the$$$715$$$718$$$O	suspending$$$719$$$729$$$O	agent$$$730$$$735$$$O	has$$$736$$$739$$$O	a$$$740$$$741$$$O	viscosity$$$742$$$751$$$O	of$$$752$$$754$$$O	100-3,000cp$$$755$$$766$$$O	(20-30$$$767$$$773$$$O	DEG$$$774$$$777$$$O	C)$$$778$$$780$$$O	and$$$781$$$784$$$O	is$$$785$$$787$$$O	selected$$$788$$$796$$$O	from$$$797$$$801$$$O	sodium$$$802$$$808$$$O	carboxymethyl$$$809$$$822$$$O	cellulose,$$$823$$$833$$$O	Tween$$$834$$$839$$$O	80,$$$840$$$843$$$O	etc.$$$844$$$848$$$O	The$$$849$$$852$$$O	sustained-released$$$853$$$871$$$O	microspheres$$$872$$$884$$$O	can$$$885$$$888$$$O	also$$$889$$$893$$$O	be$$$894$$$896$$$O	made$$$897$$$901$$$O	into$$$902$$$906$$$O	a$$$907$$$908$$$O	sustained-released$$$909$$$927$$$O	implant,$$$928$$$936$$$O	which$$$937$$$942$$$O	can$$$943$$$946$$$O	sustain$$$947$$$954$$$O	effective$$$955$$$964$$$O	drug$$$965$$$969$$$O	concentration$$$970$$$983$$$O	by$$$984$$$986$$$O	intratumoral$$$987$$$999$$$O	or$$$1000$$$1002$$$O	peritumoral$$$1003$$$1014$$$O	injection$$$1015$$$1024$$$O	or$$$1025$$$1027$$$O	placement,$$$1028$$$1038$$$O	and$$$1039$$$1042$$$O	can$$$1043$$$1046$$$O	distinctly$$$1047$$$1057$$$O	reduce$$$1058$$$1064$$$O	the$$$1065$$$1068$$$O	systemic$$$1069$$$1077$$$O	toxic$$$1078$$$1083$$$O	reaction$$$1084$$$1092$$$O	of$$$1093$$$1095$$$O	drug$$$1096$$$1100$$$O	and$$$1101$$$1104$$$O	selectively$$$1105$$$1116$$$O	enhance$$$1117$$$1124$$$O	the$$$1125$$$1128$$$O	curative$$$1129$$$1137$$$O	effect$$$1138$$$1144$$$O	of$$$1145$$$1147$$$O	non-operative$$$1148$$$1161$$$O	treatments$$$1162$$$1172$$$O	such$$$1173$$$1177$$$O	as$$$1178$$$1180$$$O	chemotherapy$$$1181$$$1193$$$O	and$$$1194$$$1197$$$O	radiotherapy.$$$1198$$$1211$$$O
EP1562570A4
Treatment$$$0$$$9$$$O	of$$$10$$$12$$$O	amyotrophic$$$13$$$24$$$O	lateral$$$25$$$32$$$O	sclerosis$$$33$$$42$$$O	with$$$43$$$47$$$O	nimesulide$$$48$$$58$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	methods$$$33$$$40$$$O	for$$$41$$$44$$$O	delaying$$$45$$$53$$$O	the$$$54$$$57$$$O	onset$$$58$$$63$$$O	or$$$64$$$66$$$O	progression$$$67$$$78$$$O	of$$$79$$$81$$$O	motor$$$82$$$87$$$O	impairment$$$88$$$98$$$O	associated$$$99$$$109$$$O	with$$$110$$$114$$$O	amyotrophic$$$115$$$126$$$O	lateral$$$127$$$134$$$O	sclerosis$$$135$$$144$$$O	in$$$145$$$147$$$O	a$$$148$$$149$$$O	subject$$$150$$$157$$$O	by$$$158$$$160$$$O	administering$$$161$$$174$$$O	to$$$175$$$177$$$O	the$$$178$$$181$$$O	subject$$$182$$$189$$$O	a$$$190$$$191$$$O	therapeutically$$$192$$$207$$$O	effective$$$208$$$217$$$O	amount$$$218$$$224$$$O	of$$$225$$$227$$$O	nimesulide.$$$228$$$239$$$I	It$$$240$$$242$$$O	further$$$243$$$250$$$O	provides$$$251$$$259$$$O	for$$$260$$$263$$$O	a$$$264$$$265$$$O	means$$$266$$$271$$$O	of$$$272$$$274$$$O	detecting$$$275$$$284$$$O	and$$$285$$$288$$$O	monitoring$$$289$$$299$$$O	the$$$300$$$303$$$O	progression$$$304$$$315$$$O	of$$$316$$$318$$$O	amyotrophic$$$319$$$330$$$O	lateral$$$331$$$338$$$O	sclerosis$$$339$$$348$$$O	via$$$349$$$352$$$O	a$$$353$$$354$$$O	protein$$$355$$$362$$$O	biomarker$$$363$$$372$$$O	for$$$373$$$376$$$O	the$$$377$$$380$$$O	disease.$$$381$$$389$$$O
WO2007004692A1
Prophylactic/therapeutic$$$0$$$24$$$O	agent$$$25$$$30$$$O	and$$$31$$$34$$$O	diagnostic$$$35$$$45$$$O	agent$$$46$$$51$$$O	for$$$52$$$55$$$O	non-small$$$56$$$65$$$O	cell$$$66$$$70$$$O	lung$$$71$$$75$$$O	cancer$$$76$$$82$$$O
An$$$0$$$2$$$O	antibody$$$3$$$11$$$O	directed$$$12$$$20$$$O	against$$$21$$$28$$$O	a$$$29$$$30$$$O	protein$$$31$$$38$$$O	having$$$39$$$45$$$O	an$$$46$$$48$$$O	amino$$$49$$$54$$$I	acid$$$55$$$59$$$I	sequence$$$60$$$68$$$O	depicted$$$69$$$77$$$O	in$$$78$$$80$$$O	SEQ$$$81$$$84$$$O	ID$$$85$$$87$$$O	NO:3,$$$88$$$93$$$O	5,$$$94$$$96$$$O	7,$$$97$$$99$$$O	13,$$$100$$$103$$$O	19,$$$104$$$107$$$O	25,$$$108$$$111$$$O	27,$$$112$$$115$$$O	29,$$$116$$$119$$$O	31,$$$120$$$123$$$O	33$$$124$$$126$$$O	or$$$127$$$129$$$O	35,$$$130$$$133$$$O	a$$$134$$$135$$$O	compound$$$136$$$144$$$O	capable$$$145$$$152$$$O	of$$$153$$$155$$$O	inhibiting$$$156$$$166$$$O	the$$$167$$$170$$$O	activity$$$171$$$179$$$O	or$$$180$$$182$$$O	function$$$183$$$191$$$O	of$$$192$$$194$$$O	the$$$195$$$198$$$O	protein$$$199$$$206$$$O	or$$$207$$$209$$$O	a$$$210$$$211$$$O	salt$$$212$$$216$$$O	thereof,$$$217$$$225$$$O	a$$$226$$$227$$$O	compound$$$228$$$236$$$O	capable$$$237$$$244$$$O	of$$$245$$$247$$$O	inhibiting$$$248$$$258$$$O	the$$$259$$$262$$$O	expression$$$263$$$273$$$O	of$$$274$$$276$$$O	the$$$277$$$280$$$O	protein$$$281$$$288$$$O	or$$$289$$$291$$$O	a$$$292$$$293$$$O	salt$$$294$$$298$$$O	thereof$$$299$$$306$$$O	or$$$307$$$309$$$O	the$$$310$$$313$$$O	like$$$314$$$318$$$O	is$$$319$$$321$$$O	useful$$$322$$$328$$$O	as$$$329$$$331$$$O	a$$$332$$$333$$$O	prophylactic/therapeutic$$$334$$$358$$$O	agent$$$359$$$364$$$O	and$$$365$$$368$$$O	(or)$$$369$$$373$$$O	a$$$374$$$375$$$O	recurrence-preventive$$$376$$$397$$$O	agent$$$398$$$403$$$O	for$$$404$$$407$$$O	non-small$$$408$$$417$$$O	cell$$$418$$$422$$$O	lung.$$$423$$$428$$$O	A$$$429$$$430$$$O	protein$$$431$$$438$$$O	having$$$439$$$445$$$O	an$$$446$$$448$$$O	amino$$$449$$$454$$$I	acid$$$455$$$459$$$I	sequence$$$460$$$468$$$O	depicted$$$469$$$477$$$O	in$$$478$$$480$$$O	SEQ$$$481$$$484$$$O	ID$$$485$$$487$$$O	NO:1,$$$488$$$493$$$O	9,$$$494$$$496$$$O	11,$$$497$$$500$$$O	15,$$$501$$$504$$$O	17,$$$505$$$508$$$O	21,$$$509$$$512$$$O	23$$$513$$$515$$$O	or$$$516$$$518$$$O	37,$$$519$$$522$$$O	DNA$$$523$$$526$$$O	encoding$$$527$$$535$$$O	the$$$536$$$539$$$O	protein,$$$540$$$548$$$O	a$$$549$$$550$$$O	compound$$$551$$$559$$$O	capable$$$560$$$567$$$O	of$$$568$$$570$$$O	promoting$$$571$$$580$$$O	the$$$581$$$584$$$O	activity$$$585$$$593$$$O	or$$$594$$$596$$$O	function$$$597$$$605$$$O	of$$$606$$$608$$$O	the$$$609$$$612$$$O	protein$$$613$$$620$$$O	or$$$621$$$623$$$O	a$$$624$$$625$$$O	salt$$$626$$$630$$$O	thereof,$$$631$$$639$$$O	a$$$640$$$641$$$O	compound$$$642$$$650$$$O	capable$$$651$$$658$$$O	of$$$659$$$661$$$O	promoting$$$662$$$671$$$O	the$$$672$$$675$$$O	expression$$$676$$$686$$$O	of$$$687$$$689$$$O	the$$$690$$$693$$$O	protein$$$694$$$701$$$O	or$$$702$$$704$$$O	a$$$705$$$706$$$O	salt$$$707$$$711$$$O	thereof$$$712$$$719$$$O	or$$$720$$$722$$$O	the$$$723$$$726$$$O	like$$$727$$$731$$$O	is$$$732$$$734$$$O	also$$$735$$$739$$$O	useful$$$740$$$746$$$O	as$$$747$$$749$$$O	a$$$750$$$751$$$O	prophylactic/therapeutic$$$752$$$776$$$O	agent$$$777$$$782$$$O	and$$$783$$$786$$$O	(or)$$$787$$$791$$$O	a$$$792$$$793$$$O	recurrence-preventive$$$794$$$815$$$O	agent$$$816$$$821$$$O	for$$$822$$$825$$$O	non-small$$$826$$$835$$$O	cell$$$836$$$840$$$O	lung.$$$841$$$846$$$O	An$$$847$$$849$$$O	antibody$$$850$$$858$$$O	directed$$$859$$$867$$$O	against$$$868$$$875$$$O	the$$$876$$$879$$$O	protein,$$$880$$$888$$$O	DNA$$$889$$$892$$$O	encoding$$$893$$$901$$$O	the$$$902$$$905$$$O	protein$$$906$$$913$$$O	or$$$914$$$916$$$O	the$$$917$$$920$$$O	like$$$921$$$925$$$O	is$$$926$$$928$$$O	also$$$929$$$933$$$O	useful$$$934$$$940$$$O	as$$$941$$$943$$$O	a$$$944$$$945$$$O	diagnostic$$$946$$$956$$$O	agent$$$957$$$962$$$O	for$$$963$$$966$$$O	the$$$967$$$970$$$O	grade$$$971$$$976$$$O	of$$$977$$$979$$$O	malignancy$$$980$$$990$$$O	of$$$991$$$993$$$O	non-small$$$994$$$1003$$$O	cell$$$1004$$$1008$$$O	lung$$$1009$$$1013$$$O	cancer.$$$1014$$$1021$$$O
EP2507237A1
Imidazoquinolines$$$0$$$17$$$I	which$$$18$$$23$$$O	act$$$24$$$27$$$O	via$$$28$$$31$$$O	toll$$$32$$$36$$$O	-$$$37$$$38$$$O	like$$$39$$$43$$$O	receptors$$$44$$$53$$$O	(tlr)$$$54$$$59$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	compounds$$$31$$$40$$$O	of$$$41$$$43$$$O	formula$$$44$$$51$$$O	(I):$$$52$$$56$$$O	wherein$$$57$$$64$$$O	Ra,$$$65$$$68$$$O	Rb,$$$69$$$72$$$O	Rc,$$$73$$$76$$$O	R1,$$$77$$$80$$$O	R2,$$$81$$$84$$$O	R3,$$$85$$$88$$$O	X1,$$$89$$$92$$$O	Y1,$$$93$$$96$$$O	Z1,$$$97$$$100$$$O	A,$$$101$$$103$$$O	n$$$104$$$105$$$O	and$$$106$$$109$$$O	m$$$110$$$111$$$O	are$$$112$$$115$$$O	as$$$116$$$118$$$O	defined$$$119$$$126$$$O	in$$$127$$$129$$$O	the$$$130$$$133$$$O	specification,$$$134$$$148$$$O	and$$$149$$$152$$$O	pharmaceutically$$$153$$$169$$$O	acceptable$$$170$$$180$$$O	salts$$$181$$$186$$$O	thereof,$$$187$$$195$$$O	as$$$196$$$198$$$O	well$$$199$$$203$$$O	as$$$204$$$206$$$O	processes$$$207$$$216$$$O	for$$$217$$$220$$$O	their$$$221$$$226$$$O	preparation,$$$227$$$239$$$O	pharmaceutical$$$240$$$254$$$O	compositions$$$255$$$267$$$O	containing$$$268$$$278$$$O	them$$$279$$$283$$$O	and$$$284$$$287$$$O	their$$$288$$$293$$$O	use$$$294$$$297$$$O	in$$$298$$$300$$$O	therapy.$$$301$$$309$$$O
CN102675330A
Furan-flavone$$$0$$$13$$$I	compound$$$14$$$22$$$O	in$$$23$$$25$$$O	arundina$$$26$$$34$$$O	graminifolia,$$$35$$$48$$$O	preparation$$$49$$$60$$$O	method$$$61$$$67$$$O	and$$$68$$$71$$$O	application$$$72$$$83$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	furan-flavone$$$26$$$39$$$I	compound$$$40$$$48$$$O	in$$$49$$$51$$$O	arundina$$$52$$$60$$$O	graminifolia,$$$61$$$74$$$O	a$$$75$$$76$$$O	preparation$$$77$$$88$$$O	method$$$89$$$95$$$O	and$$$96$$$99$$$O	application,$$$100$$$112$$$O	belongs$$$113$$$120$$$O	to$$$121$$$123$$$O	the$$$124$$$127$$$O	field$$$128$$$133$$$O	of$$$134$$$136$$$O	plant$$$137$$$142$$$O	chemical$$$143$$$151$$$O	research,$$$152$$$161$$$O	and$$$162$$$165$$$O	in$$$166$$$168$$$O	particular$$$169$$$179$$$O	relates$$$180$$$187$$$O	to$$$188$$$190$$$O	a$$$191$$$192$$$O	new$$$193$$$196$$$O	furan-flavone$$$197$$$210$$$I	compound$$$211$$$219$$$O	separated$$$220$$$229$$$O	from$$$230$$$234$$$O	arundina$$$235$$$243$$$O	graminifolia,$$$244$$$257$$$O	a$$$258$$$259$$$O	preparation$$$260$$$271$$$O	method$$$272$$$278$$$O	for$$$279$$$282$$$O	the$$$283$$$286$$$O	compound$$$287$$$295$$$O	and$$$296$$$299$$$O	application$$$300$$$311$$$O	of$$$312$$$314$$$O	the$$$315$$$318$$$O	compound$$$319$$$327$$$O	in$$$328$$$330$$$O	anti-cancer$$$331$$$342$$$O	medicaments.$$$343$$$355$$$O	The$$$356$$$359$$$O	preparation$$$360$$$371$$$O	method$$$372$$$378$$$O	for$$$379$$$382$$$O	the$$$383$$$386$$$O	compound$$$387$$$395$$$O	comprises$$$396$$$405$$$O	the$$$406$$$409$$$O	following$$$410$$$419$$$O	steps$$$420$$$425$$$O	of:$$$426$$$429$$$O	crushing$$$430$$$438$$$O	an$$$439$$$441$$$O	arundina$$$442$$$450$$$O	graminifolia$$$451$$$463$$$O	sample,$$$464$$$471$$$O	performing$$$472$$$482$$$O	ultrasonic$$$483$$$493$$$O	extraction$$$494$$$504$$$O	by$$$505$$$507$$$O	using$$$508$$$513$$$O	95$$$514$$$516$$$O	weight$$$517$$$523$$$O	percent$$$524$$$531$$$O	ethanol,$$$532$$$540$$$I	and$$$541$$$544$$$O	combining$$$545$$$554$$$O	extracting$$$555$$$565$$$O	solutions;$$$566$$$576$$$O	and$$$577$$$580$$$O	evaporating$$$581$$$592$$$O	the$$$593$$$596$$$O	solvent$$$597$$$604$$$O	from$$$605$$$609$$$O	the$$$610$$$613$$$O	extracting$$$614$$$624$$$O	solution$$$625$$$633$$$O	under$$$634$$$639$$$O	reduced$$$640$$$647$$$O	pressure$$$648$$$656$$$O	to$$$657$$$659$$$O	obtain$$$660$$$666$$$O	extract,$$$667$$$675$$$O	stirring$$$676$$$684$$$O	the$$$685$$$688$$$O	extract$$$689$$$696$$$O	by$$$697$$$699$$$O	using$$$700$$$705$$$O	silica$$$706$$$712$$$O	gel,$$$713$$$717$$$O	performing$$$718$$$728$$$O	chromatography$$$729$$$743$$$O	and$$$744$$$747$$$O	primary$$$748$$$755$$$O	separation$$$756$$$766$$$O	by$$$767$$$769$$$O	using$$$770$$$775$$$O	a$$$776$$$777$$$O	silica$$$778$$$784$$$I	gel$$$785$$$788$$$I	column,$$$789$$$796$$$O	performing$$$797$$$807$$$O	secondary$$$808$$$817$$$O	separation$$$818$$$828$$$O	by$$$829$$$831$$$O	adopting$$$832$$$840$$$O	high$$$841$$$845$$$O	performance$$$846$$$857$$$O	liquid$$$858$$$864$$$O	chromatography,$$$865$$$880$$$O	and$$$881$$$884$$$O	thus$$$885$$$889$$$O	obtaining$$$890$$$899$$$O	the$$$900$$$903$$$O	required$$$904$$$912$$$O	compound.$$$913$$$922$$$O	The$$$923$$$926$$$O	compound$$$927$$$935$$$O	has$$$936$$$939$$$O	high$$$940$$$944$$$O	activity$$$945$$$953$$$O	for$$$954$$$957$$$O	human$$$958$$$963$$$O	liver$$$964$$$969$$$O	cancer$$$970$$$976$$$O	cells$$$977$$$982$$$O	(Be1-7402),$$$983$$$994$$$O	has$$$995$$$998$$$O	certain$$$999$$$1006$$$O	activity$$$1007$$$1015$$$O	for$$$1016$$$1019$$$O	human$$$1020$$$1025$$$O	chronic$$$1026$$$1033$$$O	granulocytic$$$1034$$$1046$$$O	leukemia$$$1047$$$1055$$$O	cell$$$1056$$$1060$$$O	strains$$$1061$$$1068$$$O	(K562)$$$1069$$$1075$$$O	and$$$1076$$$1079$$$O	gastric$$$1080$$$1087$$$O	cancer$$$1088$$$1094$$$O	cell$$$1095$$$1099$$$O	strains$$$1100$$$1107$$$O	(MKN-28),$$$1108$$$1117$$$O	and$$$1118$$$1121$$$O	can$$$1122$$$1125$$$O	be$$$1126$$$1128$$$O	used$$$1129$$$1133$$$O	as$$$1134$$$1136$$$O	a$$$1137$$$1138$$$O	pilot$$$1139$$$1144$$$O	compound$$$1145$$$1153$$$O	for$$$1154$$$1157$$$O	developing$$$1158$$$1168$$$O	the$$$1169$$$1172$$$O	anti-cancer$$$1173$$$1184$$$O	medicaments.$$$1185$$$1197$$$O
CA2231545C
Oral$$$0$$$4$$$O	gel$$$5$$$8$$$O	capsule$$$9$$$16$$$O	formulation$$$17$$$28$$$O	of$$$29$$$31$$$O	1,2,4-benzotriazine$$$32$$$51$$$I	oxides$$$52$$$58$$$I
Disclosed$$$0$$$9$$$O	are$$$10$$$13$$$O	anticancer$$$14$$$24$$$O	tumor$$$25$$$30$$$O	soft$$$31$$$35$$$O	gelatin$$$36$$$43$$$O	capsules$$$44$$$52$$$O	comprising$$$53$$$63$$$O	a$$$64$$$65$$$O	1,2,4-benzotriazine$$$66$$$85$$$I	oxide$$$86$$$91$$$I	and$$$92$$$95$$$O	an$$$96$$$98$$$O	oily$$$99$$$103$$$O	excipient$$$104$$$113$$$O	selected$$$114$$$122$$$O	from$$$123$$$127$$$O	the$$$128$$$131$$$O	group$$$132$$$137$$$O	consisting$$$138$$$148$$$O	of$$$149$$$151$$$O	soybean$$$152$$$159$$$O	oil$$$160$$$163$$$O	and$$$164$$$167$$$O	fractionated$$$168$$$180$$$O	coconut$$$181$$$188$$$O	oil.$$$189$$$193$$$O
CN101062049A
Medical$$$0$$$7$$$O	combination$$$8$$$19$$$O	of$$$20$$$22$$$O	teniposide,$$$23$$$34$$$I	the$$$35$$$38$$$O	preparing$$$39$$$48$$$O	method$$$49$$$55$$$O	and$$$56$$$59$$$O	the$$$60$$$63$$$O	function$$$64$$$72$$$O	thereof$$$73$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicinal$$$26$$$35$$$O	component$$$36$$$45$$$O	of$$$46$$$48$$$O	substitute$$$49$$$59$$$O	nipa$$$60$$$64$$$O	glycosides,$$$65$$$76$$$I	which$$$77$$$82$$$O	is$$$83$$$85$$$O	characterized$$$86$$$99$$$O	by$$$100$$$102$$$O	the$$$103$$$106$$$O	following:$$$107$$$117$$$O	incorporating$$$118$$$131$$$O	substitute$$$132$$$142$$$O	nipa$$$143$$$147$$$O	glycosides,$$$148$$$159$$$I	Tuwen$$$160$$$165$$$O	surface$$$166$$$173$$$O	activator,$$$174$$$184$$$O	assisting$$$185$$$194$$$O	solvent$$$195$$$202$$$O	and$$$203$$$206$$$O	inorganic$$$207$$$216$$$O	salt;$$$217$$$222$$$O	choosing$$$223$$$231$$$O	the$$$232$$$235$$$O	assisting$$$236$$$245$$$O	solvent$$$246$$$253$$$O	as$$$254$$$256$$$O	mixture$$$257$$$264$$$O	of$$$265$$$267$$$O	dimethyl$$$268$$$276$$$I	ethanolamine$$$277$$$289$$$I	and$$$290$$$293$$$O	carbowax;$$$294$$$303$$$O	choosing$$$304$$$312$$$O	the$$$313$$$316$$$O	inorganic$$$317$$$326$$$O	salt$$$327$$$331$$$O	from$$$332$$$336$$$O	one$$$337$$$340$$$O	or$$$341$$$343$$$O	multiple$$$344$$$352$$$O	common$$$353$$$359$$$O	salt,$$$360$$$365$$$I	potassium$$$366$$$375$$$I	chloride,$$$376$$$385$$$I	sulphate$$$386$$$394$$$I	and$$$395$$$398$$$O	sulphate;$$$399$$$408$$$I	setting$$$409$$$416$$$O	this$$$417$$$421$$$O	component$$$422$$$431$$$O	as$$$432$$$434$$$O	injection$$$435$$$444$$$O	or$$$445$$$447$$$O	freeze$$$448$$$454$$$O	dry$$$455$$$458$$$O	powder$$$459$$$465$$$O	needle;$$$466$$$473$$$O	adding$$$474$$$480$$$O	into$$$481$$$485$$$O	Tuwen$$$486$$$491$$$O	and$$$492$$$495$$$O	the$$$496$$$499$$$O	assisting$$$500$$$509$$$O	dissolvent;$$$510$$$521$$$O	adding$$$522$$$528$$$O	into$$$529$$$533$$$O	the$$$534$$$537$$$O	inorganic$$$538$$$547$$$O	salt$$$548$$$552$$$O	at$$$553$$$555$$$O	the$$$556$$$559$$$O	same$$$560$$$564$$$O	time;$$$565$$$570$$$O	increasing$$$571$$$581$$$O	solubility$$$582$$$592$$$O	of$$$593$$$595$$$O	substitute$$$596$$$606$$$O	nipa$$$607$$$611$$$O	glycosides.$$$612$$$623$$$I	This$$$624$$$628$$$O	invention$$$629$$$638$$$O	also$$$639$$$643$$$O	relates$$$644$$$651$$$O	to$$$652$$$654$$$O	the$$$655$$$658$$$O	preparing$$$659$$$668$$$O	method$$$669$$$675$$$O	and$$$676$$$679$$$O	usage$$$680$$$685$$$O	of$$$686$$$688$$$O	this$$$689$$$693$$$O	medicinal$$$694$$$703$$$O	component.$$$704$$$714$$$O
CN101549039A
Application$$$0$$$11$$$O	of$$$12$$$14$$$O	schisandra$$$15$$$25$$$O	fruit$$$26$$$31$$$O	or$$$32$$$34$$$O	related$$$35$$$42$$$O	monomeric$$$43$$$52$$$O	compound$$$53$$$61$$$O	thereof$$$62$$$69$$$O	for$$$70$$$73$$$O	preventing$$$74$$$84$$$O	or$$$85$$$87$$$O	curing$$$88$$$94$$$O	fatty$$$95$$$100$$$O	liver$$$101$$$106$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	an$$$24$$$26$$$O	application$$$27$$$38$$$O	of$$$39$$$41$$$O	schisandra$$$42$$$52$$$O	fruit,$$$53$$$59$$$O	schisandra$$$60$$$70$$$O	fruit$$$71$$$76$$$O	monomeric$$$77$$$86$$$O	compound$$$87$$$95$$$O	or$$$96$$$98$$$O	other$$$99$$$104$$$O	related$$$105$$$112$$$O	artificially$$$113$$$125$$$O	synthesized$$$126$$$137$$$O	monomeric$$$138$$$147$$$O	compounds$$$148$$$157$$$O	(bifendate$$$158$$$168$$$I	or$$$169$$$171$$$O	bicyclol)$$$172$$$181$$$I	during$$$182$$$188$$$O	the$$$189$$$192$$$O	preparation$$$193$$$204$$$O	of$$$205$$$207$$$O	a$$$208$$$209$$$O	drug$$$210$$$214$$$O	for$$$215$$$218$$$O	preventing$$$219$$$229$$$O	and$$$230$$$233$$$O	curing$$$234$$$240$$$O	the$$$241$$$244$$$O	fatty$$$245$$$250$$$O	liver.$$$251$$$257$$$O	The$$$258$$$261$$$O	experiments$$$262$$$273$$$O	show$$$274$$$278$$$O	that$$$279$$$283$$$O	the$$$284$$$287$$$O	schisandra$$$288$$$298$$$O	fruit$$$299$$$304$$$O	extract$$$305$$$312$$$O	or$$$313$$$315$$$O	the$$$316$$$319$$$O	related$$$320$$$327$$$O	monomeric$$$328$$$337$$$O	compound$$$338$$$346$$$O	(Gamma-schizandrin,$$$347$$$366$$$I	bifendate$$$367$$$376$$$I	or$$$377$$$379$$$O	bicyclol)$$$380$$$389$$$I	thereof$$$390$$$397$$$O	can$$$398$$$401$$$O	effectively$$$402$$$413$$$O	reduce$$$414$$$420$$$O	the$$$421$$$424$$$O	content$$$425$$$432$$$O	of$$$433$$$435$$$O	the$$$436$$$439$$$O	triglyceride$$$440$$$452$$$I	and$$$453$$$456$$$O	the$$$457$$$460$$$O	total$$$461$$$466$$$O	cholesterol$$$467$$$478$$$I	of$$$479$$$481$$$O	the$$$482$$$485$$$O	liver$$$486$$$491$$$O	of$$$492$$$494$$$O	the$$$495$$$498$$$O	fatty$$$499$$$504$$$O	liver$$$505$$$510$$$O	model$$$511$$$516$$$O	animal,$$$517$$$524$$$O	and$$$525$$$528$$$O	the$$$529$$$532$$$O	medicament$$$533$$$543$$$O	is$$$544$$$546$$$O	especially$$$547$$$557$$$O	suitable$$$558$$$566$$$O	for$$$567$$$570$$$O	curing$$$571$$$577$$$O	the$$$578$$$581$$$O	fatty$$$582$$$587$$$O	liver$$$588$$$593$$$O	patients$$$594$$$602$$$O	with$$$603$$$607$$$O	low$$$608$$$611$$$O	blood$$$612$$$617$$$O	fat$$$618$$$621$$$O	level.$$$622$$$628$$$O
CN101829139A
Preparation$$$0$$$11$$$O	process$$$12$$$19$$$O	and$$$20$$$23$$$O	application$$$24$$$35$$$O	of$$$36$$$38$$$O	cinobufagin$$$39$$$50$$$I	and$$$51$$$54$$$O	angelica$$$55$$$63$$$O	sinensis$$$64$$$72$$$O	total$$$73$$$78$$$O	polysaccharide$$$79$$$93$$$O	sustained-release$$$94$$$111$$$O	tablet$$$112$$$118$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	preparation$$$29$$$40$$$O	process$$$41$$$48$$$O	and$$$49$$$52$$$O	the$$$53$$$56$$$O	application$$$57$$$68$$$O	of$$$69$$$71$$$O	cinobufagin$$$72$$$83$$$I	and$$$84$$$87$$$O	angelica$$$88$$$96$$$O	sinensis$$$97$$$105$$$O	total$$$106$$$111$$$O	polysaccharide$$$112$$$126$$$O	sustained-release$$$127$$$144$$$O	tablet$$$145$$$151$$$O	which$$$152$$$157$$$O	takes$$$158$$$163$$$O	the$$$164$$$167$$$O	cinobufagin$$$168$$$179$$$I	and$$$180$$$183$$$O	the$$$184$$$187$$$O	angelica$$$188$$$196$$$O	sinensis$$$197$$$205$$$O	total$$$206$$$211$$$O	polysaccharide$$$212$$$226$$$O	as$$$227$$$229$$$O	the$$$230$$$233$$$O	main$$$234$$$238$$$O	components$$$239$$$249$$$O	and$$$250$$$253$$$O	are$$$254$$$257$$$O	used$$$258$$$262$$$O	for$$$263$$$266$$$O	treating$$$267$$$275$$$O	the$$$276$$$279$$$O	malignant$$$280$$$289$$$O	tumor$$$290$$$295$$$O	in$$$296$$$298$$$O	the$$$299$$$302$$$O	digestive$$$303$$$312$$$O	system,$$$313$$$320$$$O	belonging$$$321$$$330$$$O	to$$$331$$$333$$$O	the$$$334$$$337$$$O	field$$$338$$$343$$$O	of$$$344$$$346$$$O	the$$$347$$$350$$$O	pharmaceutical$$$351$$$365$$$O	preparation$$$366$$$377$$$O	and$$$378$$$381$$$O	the$$$382$$$385$$$O	clinical$$$386$$$394$$$O	application.$$$395$$$407$$$O	The$$$408$$$411$$$O	sustained-release$$$412$$$429$$$O	tablet$$$430$$$436$$$O	is$$$437$$$439$$$O	characterized$$$440$$$453$$$O	by$$$454$$$456$$$O	comprising$$$457$$$467$$$O	3-15$$$468$$$472$$$O	percent$$$473$$$480$$$O	of$$$481$$$483$$$O	cinobufagin,$$$484$$$496$$$I	5-30$$$497$$$501$$$O	percent$$$502$$$509$$$O	of$$$510$$$512$$$O	angelica$$$513$$$521$$$O	sinensis$$$522$$$530$$$O	total$$$531$$$536$$$O	polysaccharide,$$$537$$$552$$$O	5-30$$$553$$$557$$$O	percent$$$558$$$565$$$O	of$$$566$$$568$$$O	lactose,$$$569$$$577$$$I	20-40$$$578$$$583$$$O	percent$$$584$$$591$$$O	of$$$592$$$594$$$O	hydroxypropyl$$$595$$$608$$$O	methyl$$$609$$$615$$$O	cellulose,$$$616$$$626$$$O	0.5-8$$$627$$$632$$$O	percent$$$633$$$640$$$O	of$$$641$$$643$$$O	ethyl$$$644$$$649$$$O	cellulose,$$$650$$$660$$$O	2-10$$$661$$$665$$$O	percent$$$666$$$673$$$O	of$$$674$$$676$$$O	polyvinylpyrrolidone,$$$677$$$698$$$I	and$$$699$$$702$$$O	0.5-5$$$703$$$708$$$O	percent$$$709$$$716$$$O	of$$$717$$$719$$$O	magnesium$$$720$$$729$$$I	stearate.$$$730$$$739$$$I	The$$$740$$$743$$$O	method$$$744$$$750$$$O	for$$$751$$$754$$$O	preparing$$$755$$$764$$$O	the$$$765$$$768$$$O	sustained-release$$$769$$$786$$$O	tablet$$$787$$$793$$$O	comprises$$$794$$$803$$$O	the$$$804$$$807$$$O	following$$$808$$$817$$$O	steps:$$$818$$$824$$$O	dissolving$$$825$$$835$$$O	the$$$836$$$839$$$O	angelica$$$840$$$848$$$O	sinensis$$$849$$$857$$$O	total$$$858$$$863$$$O	polysaccharide$$$864$$$878$$$O	and$$$879$$$882$$$O	the$$$883$$$886$$$O	ethyl$$$887$$$892$$$O	cellulose$$$893$$$902$$$O	with$$$903$$$907$$$O	water,$$$908$$$914$$$O	stirring$$$915$$$923$$$O	evenly$$$924$$$930$$$O	the$$$931$$$934$$$O	angelica$$$935$$$943$$$O	sinensis$$$944$$$952$$$O	total$$$953$$$958$$$O	polysaccharide$$$959$$$973$$$O	and$$$974$$$977$$$O	the$$$978$$$981$$$O	ethyl$$$982$$$987$$$O	cellulose$$$988$$$997$$$O	in$$$998$$$1000$$$O	the$$$1001$$$1004$$$O	cinobufagin,$$$1005$$$1017$$$I	the$$$1018$$$1021$$$O	polyvinylpyrrolidone$$$1022$$$1042$$$I	and$$$1043$$$1046$$$O	the$$$1047$$$1050$$$O	lactose,$$$1051$$$1059$$$I	drying$$$1060$$$1066$$$O	the$$$1067$$$1070$$$O	mixture$$$1071$$$1078$$$O	in$$$1079$$$1081$$$O	vacuum,$$$1082$$$1089$$$O	grinding$$$1090$$$1098$$$O	the$$$1099$$$1102$$$O	mixture,$$$1103$$$1111$$$O	mixing$$$1112$$$1118$$$O	evenly$$$1119$$$1125$$$O	the$$$1126$$$1129$$$O	ground$$$1130$$$1136$$$O	mixture$$$1137$$$1144$$$O	with$$$1145$$$1149$$$O	the$$$1150$$$1153$$$O	hydroxypropyl$$$1154$$$1167$$$O	methyl$$$1168$$$1174$$$O	cellulose,$$$1175$$$1185$$$O	adding$$$1186$$$1192$$$O	the$$$1193$$$1196$$$O	magnesium$$$1197$$$1206$$$I	stearate$$$1207$$$1215$$$I	to$$$1216$$$1218$$$O	the$$$1219$$$1222$$$O	new$$$1223$$$1226$$$O	mixture,$$$1227$$$1235$$$O	and$$$1236$$$1239$$$O	tabletting$$$1240$$$1250$$$O	the$$$1251$$$1254$$$O	new$$$1255$$$1258$$$O	mixture.$$$1259$$$1267$$$O	The$$$1268$$$1271$$$O	sustained-release$$$1272$$$1289$$$O	tablet$$$1290$$$1296$$$O	is$$$1297$$$1299$$$O	used$$$1300$$$1304$$$O	for$$$1305$$$1308$$$O	treating$$$1309$$$1317$$$O	esophageal$$$1318$$$1328$$$O	cancer,$$$1329$$$1336$$$O	gastric$$$1337$$$1344$$$O	cancer,$$$1345$$$1352$$$O	liver$$$1353$$$1358$$$O	cancer,$$$1359$$$1366$$$O	colorectal$$$1367$$$1377$$$O	cancer$$$1378$$$1384$$$O	and$$$1385$$$1388$$$O	other$$$1389$$$1394$$$O	cancers,$$$1395$$$1403$$$O	is$$$1404$$$1406$$$O	effective,$$$1407$$$1417$$$O	has$$$1418$$$1421$$$O	low$$$1422$$$1425$$$O	toxicity$$$1426$$$1434$$$O	and$$$1435$$$1438$$$O	clear$$$1439$$$1444$$$O	active$$$1445$$$1451$$$O	components,$$$1452$$$1463$$$O	and$$$1464$$$1467$$$O	is$$$1468$$$1470$$$O	easy$$$1471$$$1475$$$O	to$$$1476$$$1478$$$O	take.$$$1479$$$1484$$$O
US20110015160
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	treating$$$11$$$19$$$O	neurological$$$20$$$32$$$O	diseases$$$33$$$41$$$O	using$$$42$$$47$$$O	docosahexaenoic$$$48$$$63$$$I	acid$$$64$$$68$$$I	and$$$69$$$72$$$O	arachidonic$$$73$$$84$$$I	acid$$$85$$$89$$$I	compositions$$$90$$$102$$$O
A$$$0$$$1$$$O	method$$$2$$$8$$$O	of$$$9$$$11$$$O	treating$$$12$$$20$$$O	a$$$21$$$22$$$O	neurological$$$23$$$35$$$O	disorder$$$36$$$44$$$O	comprises$$$45$$$54$$$O	administering$$$55$$$68$$$O	to$$$69$$$71$$$O	a$$$72$$$73$$$O	person$$$74$$$80$$$O	affected$$$81$$$89$$$O	from$$$90$$$94$$$O	such$$$95$$$99$$$O	a$$$100$$$101$$$O	disorder$$$102$$$110$$$O	a$$$111$$$112$$$O	microbial$$$113$$$122$$$O	oil$$$123$$$126$$$O	comprising$$$127$$$137$$$O	DHA,$$$138$$$142$$$I	a$$$143$$$144$$$O	microbial$$$145$$$154$$$O	oil$$$155$$$158$$$O	comprising$$$159$$$169$$$O	ARA$$$170$$$173$$$I	or$$$174$$$176$$$O	a$$$177$$$178$$$O	combination$$$179$$$190$$$O	of$$$191$$$193$$$O	DHA$$$194$$$197$$$I	and$$$198$$$201$$$O	ARA$$$202$$$205$$$I	oils$$$206$$$210$$$O	in$$$211$$$213$$$O	an$$$214$$$216$$$O	amount$$$217$$$223$$$O	sufficient$$$224$$$234$$$O	to$$$235$$$237$$$O	elevate$$$238$$$245$$$O	the$$$246$$$249$$$O	levels$$$250$$$256$$$O	of$$$257$$$259$$$O	circulating$$$260$$$271$$$O	DHA$$$272$$$275$$$I	and/or$$$276$$$282$$$O	ARA$$$283$$$286$$$I	in$$$287$$$289$$$O	the$$$290$$$293$$$O	person's$$$294$$$302$$$O	blood$$$303$$$308$$$O	to$$$309$$$311$$$O	at$$$312$$$314$$$O	least$$$315$$$320$$$O	normal$$$321$$$327$$$O	levels.$$$328$$$335$$$O
CN103393692A
Applications$$$0$$$12$$$O	of$$$13$$$15$$$O	compound$$$16$$$24$$$O	in$$$25$$$27$$$O	preparation$$$28$$$39$$$O	anti$$$40$$$44$$$O	human$$$45$$$50$$$O	body$$$51$$$55$$$O	fungus$$$56$$$62$$$O	drugs$$$63$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	applications$$$25$$$37$$$O	of$$$38$$$40$$$O	Kadcoccitones$$$41$$$54$$$I	A$$$55$$$56$$$I	in$$$57$$$59$$$O	preparation$$$60$$$71$$$O	anti$$$72$$$76$$$O	human$$$77$$$82$$$O	body$$$83$$$87$$$O	fungus$$$88$$$94$$$O	drugs,$$$95$$$101$$$O	and$$$102$$$105$$$O	belongs$$$106$$$113$$$O	to$$$114$$$116$$$O	the$$$117$$$120$$$O	field$$$121$$$126$$$O	of$$$127$$$129$$$O	medicine.$$$130$$$139$$$O	Kadcoccitones$$$140$$$153$$$I	A$$$154$$$155$$$I	has$$$156$$$159$$$O	strong$$$160$$$166$$$O	functions$$$167$$$176$$$O	of$$$177$$$179$$$O	inhibiting$$$180$$$190$$$O	trichophyton$$$191$$$203$$$O	rubrum,$$$204$$$211$$$O	microsporum$$$212$$$223$$$O	lanosum$$$224$$$231$$$O	or$$$232$$$234$$$O	trichophyton$$$235$$$247$$$O	tonsurans,$$$248$$$258$$$O	so$$$259$$$261$$$O	that$$$262$$$266$$$O	Kadcoccitones$$$267$$$280$$$I	A$$$281$$$282$$$I	can$$$283$$$286$$$O	be$$$287$$$289$$$O	taken$$$290$$$295$$$O	as$$$296$$$298$$$O	a$$$299$$$300$$$O	compound$$$301$$$309$$$O	with$$$310$$$314$$$O	the$$$315$$$318$$$O	function$$$319$$$327$$$O	of$$$328$$$330$$$O	anti$$$331$$$335$$$O	human$$$336$$$341$$$O	body$$$342$$$346$$$O	fungi,$$$347$$$353$$$O	and$$$354$$$357$$$O	is$$$358$$$360$$$O	advantageously$$$361$$$375$$$O	used$$$376$$$380$$$O	for$$$381$$$384$$$O	corresponding$$$385$$$398$$$O	drugs.$$$399$$$405$$$O
WO2008154898A3
Preparation$$$0$$$11$$$O	for$$$12$$$15$$$O	the$$$16$$$19$$$O	treatment$$$20$$$29$$$O	of$$$30$$$32$$$O	equine$$$33$$$39$$$O	laminitis$$$40$$$49$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	the$$$13$$$16$$$O	use$$$17$$$20$$$O	of$$$21$$$23$$$O	active$$$24$$$30$$$O	substances$$$31$$$41$$$O	known$$$42$$$47$$$O	from$$$48$$$52$$$O	human$$$53$$$58$$$O	medicine$$$59$$$67$$$O	for$$$68$$$71$$$O	treating$$$72$$$80$$$O	gout$$$81$$$85$$$O	in$$$86$$$88$$$O	order$$$89$$$94$$$O	to$$$95$$$97$$$O	pharmaceutically$$$98$$$114$$$O	treat$$$115$$$120$$$O	equine$$$121$$$127$$$O	laminitis,$$$128$$$138$$$O	especially$$$139$$$149$$$O	the$$$150$$$153$$$O	use$$$154$$$157$$$O	of$$$158$$$160$$$O	a$$$161$$$162$$$O	preparation$$$163$$$174$$$O	containing$$$175$$$185$$$O	at$$$186$$$188$$$O	least$$$189$$$194$$$O	allopurinol$$$195$$$206$$$I	and/or$$$207$$$213$$$O	hydrocortisone$$$214$$$228$$$I	and/or$$$229$$$235$$$O	powdered$$$236$$$244$$$O	opium$$$245$$$250$$$O	and/or$$$251$$$257$$$O	prednisolone$$$258$$$270$$$I	and/or$$$271$$$277$$$O	prednisone.$$$278$$$289$$$I
CN102210823A
Medicament$$$0$$$10$$$O	for$$$11$$$14$$$O	treating$$$15$$$23$$$O	atony$$$24$$$29$$$O	of$$$30$$$32$$$O	forestomach$$$33$$$44$$$O	in$$$45$$$47$$$O	sheep$$$48$$$53$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	medicament$$$26$$$36$$$O	for$$$37$$$40$$$O	treating$$$41$$$49$$$O	atony$$$50$$$55$$$O	of$$$56$$$58$$$O	forestomach$$$59$$$70$$$O	in$$$71$$$73$$$O	sheep,$$$74$$$80$$$O	prepared$$$81$$$89$$$O	from$$$90$$$94$$$O	the$$$95$$$98$$$O	following$$$99$$$108$$$O	raw$$$109$$$112$$$O	materials$$$113$$$122$$$O	in$$$123$$$125$$$O	weight:$$$126$$$133$$$O	20g$$$134$$$137$$$O	of$$$138$$$140$$$O	roasted$$$141$$$148$$$O	malt,$$$149$$$154$$$O	20g$$$155$$$158$$$O	of$$$159$$$161$$$O	medicated$$$162$$$171$$$O	leaven,$$$172$$$179$$$O	15g$$$180$$$183$$$O	of$$$184$$$186$$$O	costus$$$187$$$193$$$O	root,$$$194$$$199$$$O	20g$$$200$$$203$$$O	of$$$204$$$206$$$O	officinal$$$207$$$216$$$O	magnolia$$$217$$$225$$$O	bark,$$$226$$$231$$$O	20g$$$232$$$235$$$O	of$$$236$$$238$$$O	betel$$$239$$$244$$$O	palm,$$$245$$$250$$$O	20g$$$251$$$254$$$O	of$$$255$$$257$$$O	tuckahoe,$$$258$$$267$$$O	10g$$$268$$$271$$$O	of$$$272$$$274$$$O	corydalis$$$275$$$284$$$O	root,$$$285$$$290$$$O	20g$$$291$$$294$$$O	of$$$295$$$297$$$O	angelica,$$$298$$$307$$$O	20g$$$308$$$311$$$O	of$$$312$$$314$$$O	bighead$$$315$$$322$$$O	atractylodes$$$323$$$335$$$O	rhizome,$$$336$$$344$$$O	20g$$$345$$$348$$$O	of$$$349$$$351$$$O	Chinese$$$352$$$359$$$O	atractylodes,$$$360$$$373$$$O	15g$$$374$$$377$$$O	of$$$378$$$380$$$O	dried$$$381$$$386$$$O	orange$$$387$$$393$$$O	peel,$$$394$$$399$$$O	20g$$$400$$$403$$$O	of$$$404$$$406$$$O	mirabilite,$$$407$$$418$$$O	10g$$$419$$$422$$$O	of$$$423$$$425$$$O	licorice$$$426$$$434$$$O	and$$$435$$$438$$$O	30g$$$439$$$442$$$O	of$$$443$$$445$$$O	rhubarb.$$$446$$$454$$$O	The$$$455$$$458$$$O	medicament$$$459$$$469$$$O	disclosed$$$470$$$479$$$O	by$$$480$$$482$$$O	the$$$483$$$486$$$O	invention$$$487$$$496$$$O	has$$$497$$$500$$$O	easy$$$501$$$505$$$O	availability$$$506$$$518$$$O	of$$$519$$$521$$$O	raw$$$522$$$525$$$O	materials,$$$526$$$536$$$O	is$$$537$$$539$$$O	simple$$$540$$$546$$$O	to$$$547$$$549$$$O	prepare,$$$550$$$558$$$O	and$$$559$$$562$$$O	has$$$563$$$566$$$O	the$$$567$$$570$$$O	efficacies$$$571$$$581$$$O	of$$$582$$$584$$$O	strengthening$$$585$$$598$$$O	the$$$599$$$602$$$O	spleen,$$$603$$$610$$$O	regulating$$$611$$$621$$$O	the$$$622$$$625$$$O	flow$$$626$$$630$$$O	of$$$631$$$633$$$O	qi,$$$634$$$637$$$O	promoting$$$638$$$647$$$O	digestion,$$$648$$$658$$$O	resolving$$$659$$$668$$$O	food$$$669$$$673$$$O	stagnancy$$$674$$$683$$$O	and$$$684$$$687$$$O	enhancing$$$688$$$697$$$O	gastrointestinal$$$698$$$714$$$O	peristalsis.$$$715$$$727$$$O
EP1144371B1
Benzenesulphonamide$$$0$$$19$$$I	derivatives$$$20$$$31$$$O	and$$$32$$$35$$$O	their$$$36$$$41$$$O	use$$$42$$$45$$$O	as$$$46$$$48$$$O	mek$$$49$$$52$$$O	inhibitors$$$53$$$63$$$O
Benzenesulfonamides$$$0$$$19$$$I	of$$$20$$$22$$$O	formula$$$23$$$30$$$O	(I),$$$31$$$35$$$O	in$$$36$$$38$$$O	which$$$39$$$44$$$O	W$$$45$$$46$$$O	is$$$47$$$49$$$O	OR1,$$$50$$$54$$$I	NR2OR1,$$$55$$$62$$$I	NRARB,$$$63$$$69$$$I	NR2NRARB,$$$70$$$79$$$I	or$$$80$$$82$$$O	NR2(CH2)2-4NRARB$$$83$$$99$$$I	and$$$100$$$103$$$O	the$$$104$$$107$$$O	other$$$108$$$113$$$O	variables$$$114$$$123$$$O	as$$$124$$$126$$$O	de$$$127$$$129$$$O	fined$$$130$$$135$$$O	in$$$136$$$138$$$O	the$$$139$$$142$$$O	claims,$$$143$$$150$$$O	are$$$151$$$154$$$O	inhibitors$$$155$$$165$$$O	of$$$166$$$168$$$O	MEK$$$169$$$172$$$O	and$$$173$$$176$$$O	are$$$177$$$180$$$O	effective$$$181$$$190$$$O	in$$$191$$$193$$$O	the$$$194$$$197$$$O	treatment$$$198$$$207$$$O	of$$$208$$$210$$$O	proliferative$$$211$$$224$$$O	diseases,$$$225$$$234$$$O	cancer,$$$235$$$242$$$O	stroke,$$$243$$$250$$$O	heart$$$251$$$256$$$O	failure,$$$257$$$265$$$O	xenograft$$$266$$$275$$$O	rejection,$$$276$$$286$$$O	arthritis,$$$287$$$297$$$O	cystic$$$298$$$304$$$O	fibrosis,$$$305$$$314$$$O	hepatomegaly,$$$315$$$328$$$O	cardiomegaly,$$$329$$$342$$$O	Alzheimer's$$$343$$$354$$$O	disease,$$$355$$$363$$$O	complications$$$364$$$377$$$O	of$$$378$$$380$$$O	diabetes,$$$381$$$390$$$O	septic$$$391$$$397$$$O	shock,$$$398$$$404$$$O	and$$$405$$$408$$$O	viral$$$409$$$414$$$O	infection.$$$415$$$425$$$O
CN200939251Y
Se-garlic$$$0$$$9$$$I	capsules$$$10$$$18$$$O
The$$$0$$$3$$$O	utility$$$4$$$11$$$O	model$$$12$$$17$$$O	discloses$$$18$$$27$$$O	a$$$28$$$29$$$O	selenium$$$30$$$38$$$I	garlic$$$39$$$45$$$O	capsule,$$$46$$$54$$$O	comprising$$$55$$$65$$$O	an$$$66$$$68$$$O	edible$$$69$$$75$$$O	capsule$$$76$$$83$$$O	shell,$$$84$$$90$$$O	which$$$91$$$96$$$O	is$$$97$$$99$$$O	loaded$$$100$$$106$$$O	with$$$107$$$111$$$O	the$$$112$$$115$$$O	selenium$$$116$$$124$$$I	garlic$$$125$$$131$$$O	powder$$$132$$$138$$$O	particles$$$139$$$148$$$O	for$$$149$$$152$$$O	sustained$$$153$$$162$$$O	release$$$163$$$170$$$O	of$$$171$$$173$$$O	film.$$$174$$$179$$$O	The$$$180$$$183$$$O	utility$$$184$$$191$$$O	model$$$192$$$197$$$O	of$$$198$$$200$$$O	the$$$201$$$204$$$O	selenium$$$205$$$213$$$I	garlic$$$214$$$220$$$O	capsule$$$221$$$228$$$O	is$$$229$$$231$$$O	easy$$$232$$$236$$$O	to$$$237$$$239$$$O	swallow$$$240$$$247$$$O	and$$$248$$$251$$$O	easy$$$252$$$256$$$O	to$$$257$$$259$$$O	control$$$260$$$267$$$O	the$$$268$$$271$$$O	dose;$$$272$$$277$$$O	and$$$278$$$281$$$O	that$$$282$$$286$$$O	the$$$287$$$290$$$O	selenium$$$291$$$299$$$I	garlic$$$300$$$306$$$O	powder$$$307$$$313$$$O	is$$$314$$$316$$$O	loaded$$$317$$$323$$$O	with$$$324$$$328$$$O	a$$$329$$$330$$$O	film$$$331$$$335$$$O	for$$$336$$$339$$$O	sustained$$$340$$$349$$$O	release$$$350$$$357$$$O	thus$$$358$$$362$$$O	easy$$$363$$$367$$$O	and$$$368$$$371$$$O	efficient$$$372$$$381$$$O	for$$$382$$$385$$$O	human$$$386$$$391$$$O	body$$$392$$$396$$$O	to$$$397$$$399$$$O	absorb$$$400$$$406$$$O	after$$$407$$$412$$$O	having$$$413$$$419$$$O	had$$$420$$$423$$$O	the$$$424$$$427$$$O	capsule.$$$428$$$436$$$O	The$$$437$$$440$$$O	utility$$$441$$$448$$$O	model$$$449$$$454$$$O	has$$$455$$$458$$$O	the$$$459$$$462$$$O	advantages$$$463$$$473$$$O	in$$$474$$$476$$$O	the$$$477$$$480$$$O	prevention$$$481$$$491$$$O	and$$$492$$$495$$$O	control$$$496$$$503$$$O	of$$$504$$$506$$$O	cancer,$$$507$$$514$$$O	the$$$515$$$518$$$O	interruption$$$519$$$531$$$O	of$$$532$$$534$$$O	the$$$535$$$538$$$O	spreading$$$539$$$548$$$O	of$$$549$$$551$$$O	AIDS,$$$552$$$557$$$O	the$$$558$$$561$$$O	cure$$$562$$$566$$$O	of$$$567$$$569$$$O	anti-allergy$$$570$$$582$$$O	and$$$583$$$586$$$O	anti-metamorphosis$$$587$$$605$$$O	reactive$$$606$$$614$$$O	disease$$$615$$$622$$$O	and$$$623$$$626$$$O	has$$$627$$$630$$$O	a$$$631$$$632$$$O	good$$$633$$$637$$$O	health$$$638$$$644$$$O	and$$$645$$$648$$$O	care$$$649$$$653$$$O	effect$$$654$$$660$$$O	in$$$661$$$663$$$O	all$$$664$$$667$$$O	respects$$$668$$$676$$$O	to$$$677$$$679$$$O	human$$$680$$$685$$$O	body.$$$686$$$691$$$O
CN103193659A
Novel$$$0$$$5$$$O	crystal$$$6$$$13$$$O	form$$$14$$$18$$$O	of$$$19$$$21$$$O	(-)-(1R,$$$22$$$30$$$I	2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)$$$31$$$77$$$I	phenol$$$78$$$84$$$I	hydrochloride$$$85$$$98$$$I	and$$$99$$$102$$$O	preparation$$$103$$$114$$$O	method$$$115$$$121$$$O	thereof$$$122$$$129$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	novel$$$27$$$32$$$O	crystal$$$33$$$40$$$O	form$$$41$$$45$$$O	of$$$46$$$48$$$O	(-)-(1R,$$$49$$$57$$$I	2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)$$$58$$$104$$$I	crystal-type$$$105$$$117$$$O	phenol$$$118$$$124$$$I	hydrochloride$$$125$$$138$$$I	and$$$139$$$142$$$O	a$$$143$$$144$$$O	preparation$$$145$$$156$$$O	method$$$157$$$163$$$O	thereof.$$$164$$$172$$$O	The$$$173$$$176$$$O	chemical$$$177$$$185$$$O	name$$$186$$$190$$$O	of$$$191$$$193$$$O	tapentadol$$$194$$$204$$$I	hydrochloride$$$205$$$218$$$I	is$$$219$$$221$$$O	called$$$222$$$228$$$O	as$$$229$$$231$$$O	(-)-(1R,$$$232$$$240$$$I	2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)$$$241$$$287$$$I	phenol$$$288$$$294$$$I	hydrochloride$$$295$$$308$$$I	which$$$309$$$314$$$O	is$$$315$$$317$$$O	used$$$318$$$322$$$O	for$$$323$$$326$$$O	preparing$$$327$$$336$$$O	medicines$$$337$$$346$$$O	for$$$347$$$350$$$O	relieving$$$351$$$360$$$O	moderately$$$361$$$371$$$O	and$$$372$$$375$$$O	seriously$$$376$$$385$$$O	acute$$$386$$$391$$$O	pain.$$$392$$$397$$$O
CN101585799B
Method$$$0$$$6$$$O	for$$$7$$$10$$$O	preparing$$$11$$$20$$$O	unsymmetrical$$$21$$$34$$$O	bis(indolyl)methane$$$35$$$54$$$I	compound$$$55$$$63$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	for$$$42$$$45$$$O	preparing$$$46$$$55$$$O	unsymmetrical$$$56$$$69$$$O	bis-indolyl$$$70$$$81$$$I	substituted$$$82$$$93$$$I	methane$$$94$$$101$$$I	compound.$$$102$$$111$$$O	The$$$112$$$115$$$O	method$$$116$$$122$$$O	is$$$123$$$125$$$O	realized$$$126$$$134$$$O	by$$$135$$$137$$$O	using$$$138$$$143$$$O	Friedel-Crafts$$$144$$$158$$$O	reaction$$$159$$$167$$$O	catalyzed$$$168$$$177$$$O	by$$$178$$$180$$$O	InX3.$$$181$$$186$$$O	The$$$187$$$190$$$O	method$$$191$$$197$$$O	has$$$198$$$201$$$O	the$$$202$$$205$$$O	advantages$$$206$$$216$$$O	of$$$217$$$219$$$O	moderate$$$220$$$228$$$O	reaction$$$229$$$237$$$O	condition,$$$238$$$248$$$O	easy$$$249$$$253$$$O	and$$$254$$$257$$$O	simple$$$258$$$264$$$O	operation,$$$265$$$275$$$O	good$$$276$$$280$$$O	substrate$$$281$$$290$$$O	adaptability$$$291$$$303$$$O	with$$$304$$$308$$$O	water$$$309$$$314$$$O	as$$$315$$$317$$$O	dissolvant,$$$318$$$329$$$O	friendly$$$330$$$338$$$O	environment,$$$339$$$351$$$O	convenient$$$352$$$362$$$O	separation$$$363$$$373$$$O	and$$$374$$$377$$$O	purification,$$$378$$$391$$$O	application$$$392$$$403$$$O	prospect$$$404$$$412$$$O	for$$$413$$$416$$$O	synthesizing$$$417$$$429$$$O	unsymmetrical$$$430$$$443$$$O	bis(indolyl)methane$$$444$$$463$$$I	compound$$$464$$$472$$$O	in$$$473$$$475$$$O	a$$$476$$$477$$$O	large$$$478$$$483$$$O	scale.$$$484$$$490$$$O
CN102940634A
Isoniazid-anethol$$$0$$$17$$$I	trithione$$$18$$$27$$$I	composition$$$28$$$39$$$O	and$$$40$$$43$$$O	its$$$44$$$47$$$O	oral$$$48$$$52$$$O	preparation$$$53$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	an$$$23$$$25$$$O	isoniazid-anethol$$$26$$$43$$$I	trithione$$$44$$$53$$$I	composition$$$54$$$65$$$O	and$$$66$$$69$$$O	its$$$70$$$73$$$O	oral$$$74$$$78$$$O	preparation,$$$79$$$91$$$O	relating$$$92$$$100$$$O	the$$$101$$$104$$$O	technical$$$105$$$114$$$O	field$$$115$$$120$$$O	of$$$121$$$123$$$O	medicines$$$124$$$133$$$O	and$$$134$$$137$$$O	medicine$$$138$$$146$$$O	making.$$$147$$$154$$$O	The$$$155$$$158$$$O	composition$$$159$$$170$$$O	contains$$$171$$$179$$$O	0.1-99.9wt%$$$180$$$191$$$O	of$$$192$$$194$$$O	isoniazid$$$195$$$204$$$I	and$$$205$$$208$$$O	99.9-0.1wt%$$$209$$$220$$$O	of$$$221$$$223$$$O	anethol$$$224$$$231$$$I	trithione.$$$232$$$242$$$I	According$$$243$$$252$$$O	to$$$253$$$255$$$O	the$$$256$$$259$$$O	invention,$$$260$$$270$$$O	isoniazid$$$271$$$280$$$I	and$$$281$$$284$$$O	anethol$$$285$$$292$$$I	trithione$$$293$$$302$$$I	have$$$303$$$307$$$O	good$$$308$$$312$$$O	synergistic$$$313$$$324$$$O	effect,$$$325$$$332$$$O	the$$$333$$$336$$$O	capacity$$$337$$$345$$$O	of$$$346$$$348$$$O	anethol$$$349$$$356$$$I	trithione$$$357$$$366$$$I	in$$$367$$$369$$$O	raising$$$370$$$377$$$O	cellular$$$378$$$386$$$O	capabilities$$$387$$$399$$$O	increases$$$400$$$409$$$O	biliation,$$$410$$$420$$$O	thus$$$421$$$425$$$O	liver$$$426$$$431$$$O	damage$$$432$$$438$$$O	caused$$$439$$$445$$$O	by$$$446$$$448$$$O	isoniazid$$$449$$$458$$$I	can$$$459$$$462$$$O	be$$$463$$$465$$$O	effectively$$$466$$$477$$$O	treated;$$$478$$$486$$$O	the$$$487$$$490$$$O	combined$$$491$$$499$$$O	use$$$500$$$503$$$O	of$$$504$$$506$$$O	isoniazid$$$507$$$516$$$I	and$$$517$$$520$$$O	anethol$$$521$$$528$$$I	trithione$$$529$$$538$$$I	can$$$539$$$542$$$O	reduce$$$543$$$549$$$O	the$$$550$$$553$$$O	adverse$$$554$$$561$$$O	reaction$$$562$$$570$$$O	caused$$$571$$$577$$$O	by$$$578$$$580$$$O	isoniazid,$$$581$$$591$$$I	reduce$$$592$$$598$$$O	liver$$$599$$$604$$$O	damage,$$$605$$$612$$$O	and$$$613$$$616$$$O	has$$$617$$$620$$$O	good$$$621$$$625$$$O	therapeutic$$$626$$$637$$$O	effect$$$638$$$644$$$O	on$$$645$$$647$$$O	tuberculosis$$$648$$$660$$$O	patients.$$$661$$$670$$$O
CN102596197A
Combination$$$0$$$11$$$O	therapy$$$12$$$19$$$O	for$$$20$$$23$$$O	treating$$$24$$$32$$$O	proliferative$$$33$$$46$$$O	diseases$$$47$$$55$$$O
A$$$0$$$1$$$O	pharmaceutical$$$2$$$16$$$O	composition$$$17$$$28$$$O	of$$$29$$$31$$$O	a$$$32$$$33$$$O	tubulin$$$34$$$41$$$O	polymerisation$$$42$$$56$$$O	inhibitor$$$57$$$66$$$O	and$$$67$$$70$$$O	an$$$71$$$73$$$O	mTOR$$$74$$$78$$$O	inhibitor$$$79$$$88$$$O	and$$$89$$$92$$$O	a$$$93$$$94$$$O	method$$$95$$$101$$$O	of$$$102$$$104$$$O	treating$$$105$$$113$$$O	proliferative$$$114$$$127$$$O	disease$$$128$$$135$$$O	with$$$136$$$140$$$O	a$$$141$$$142$$$O	combination$$$143$$$154$$$O	of$$$155$$$157$$$O	a$$$158$$$159$$$O	tubulin$$$160$$$167$$$O	polymerisation$$$168$$$182$$$O	inhibitor$$$183$$$192$$$O	and$$$193$$$196$$$O	an$$$197$$$199$$$O	mTOR$$$200$$$204$$$O	inhibitor$$$205$$$214$$$O
EP2335692A1
Silicone$$$0$$$8$$$I	liquid$$$9$$$15$$$O	and$$$16$$$19$$$O	fluorinated$$$20$$$31$$$O	liquid$$$32$$$38$$$O	for$$$39$$$42$$$O	sequential$$$43$$$53$$$O	use$$$54$$$57$$$O	in$$$58$$$60$$$O	the$$$61$$$64$$$O	treatment$$$65$$$74$$$O	of$$$75$$$77$$$O	retinal$$$78$$$85$$$O	tears$$$86$$$91$$$O	and/or$$$92$$$98$$$O	detachments$$$99$$$110$$$O
A$$$0$$$1$$$O	first$$$2$$$7$$$O	liquid$$$8$$$14$$$O	having$$$15$$$21$$$O	a$$$22$$$23$$$O	density$$$24$$$31$$$O	lower$$$32$$$37$$$O	than$$$38$$$42$$$O	1.00$$$43$$$47$$$O	g/cm3$$$48$$$53$$$O	and$$$54$$$57$$$O	a$$$58$$$59$$$O	second$$$60$$$66$$$O	liquid$$$67$$$73$$$O	having$$$74$$$80$$$O	a$$$81$$$82$$$O	density$$$83$$$90$$$O	higher$$$91$$$97$$$O	than$$$98$$$102$$$O	1.00$$$103$$$107$$$O	g/cm3$$$108$$$113$$$O	for$$$114$$$117$$$O	sequential$$$118$$$128$$$O	use$$$129$$$132$$$O	in$$$133$$$135$$$O	the$$$136$$$139$$$O	surgical$$$140$$$148$$$O	treatment$$$149$$$158$$$O	of$$$159$$$161$$$O	tears$$$162$$$167$$$O	and/or$$$168$$$174$$$O	detachments$$$175$$$186$$$O	of$$$187$$$189$$$O	the$$$190$$$193$$$O	retina,$$$194$$$201$$$O	where$$$202$$$207$$$O	the$$$208$$$211$$$O	said$$$212$$$216$$$O	liquids$$$217$$$224$$$O	are$$$225$$$228$$$O	injected$$$229$$$237$$$O	separately$$$238$$$248$$$O	into$$$249$$$253$$$O	the$$$254$$$257$$$O	vitreous$$$258$$$266$$$O	cavity$$$267$$$273$$$O	after$$$274$$$279$$$O	removal$$$280$$$287$$$O	of$$$288$$$290$$$O	the$$$291$$$294$$$O	vitreous$$$295$$$303$$$O	humour.$$$304$$$311$$$O	In$$$312$$$314$$$O	particular,$$$315$$$326$$$O	is$$$327$$$329$$$O	silicone$$$330$$$338$$$I	liquid$$$339$$$345$$$O	and$$$346$$$349$$$O	is$$$350$$$352$$$O	injected$$$353$$$361$$$O	first$$$362$$$367$$$O	and$$$368$$$371$$$O	kept$$$372$$$376$$$O	within$$$377$$$383$$$O	the$$$384$$$387$$$O	vitreous$$$388$$$396$$$O	cavity$$$397$$$403$$$O	for$$$404$$$407$$$O	a$$$408$$$409$$$O	determined$$$410$$$420$$$O	period$$$421$$$427$$$O	of$$$428$$$430$$$O	time.$$$431$$$436$$$O	Subsequently,$$$437$$$450$$$O	the$$$451$$$454$$$O	second$$$455$$$461$$$O	liquid$$$462$$$468$$$O	is$$$469$$$471$$$O	injected,$$$472$$$481$$$O	which$$$482$$$487$$$O	is$$$488$$$490$$$O	a$$$491$$$492$$$O	fluorinated$$$493$$$504$$$O	liquid,$$$505$$$512$$$O	which,$$$513$$$519$$$O	being$$$520$$$525$$$O	miscible$$$526$$$534$$$O	with$$$535$$$539$$$O	the$$$540$$$543$$$O	first$$$544$$$549$$$O	liquid,$$$550$$$557$$$O	forms$$$558$$$563$$$O	a$$$564$$$565$$$O	homogenous$$$566$$$576$$$O	solution$$$577$$$585$$$O	with$$$586$$$590$$$O	the$$$591$$$594$$$O	latter,$$$595$$$602$$$O	with$$$603$$$607$$$O	no$$$608$$$610$$$O	phase$$$611$$$616$$$O	separation$$$617$$$627$$$O	and$$$628$$$631$$$O	a$$$632$$$633$$$O	density$$$634$$$641$$$O	higher$$$642$$$648$$$O	than$$$649$$$653$$$O	1.00$$$654$$$658$$$O	g/cm3.$$$659$$$665$$$O	This$$$666$$$670$$$O	solution$$$671$$$679$$$O	exerts$$$680$$$686$$$O	a$$$687$$$688$$$O	tamponing$$$689$$$698$$$O	action$$$699$$$705$$$O	also$$$706$$$710$$$O	on$$$711$$$713$$$O	the$$$714$$$717$$$O	lower$$$718$$$723$$$O	portion$$$724$$$731$$$O	of$$$732$$$734$$$O	the$$$735$$$738$$$O	retina,$$$739$$$746$$$O	replacing$$$747$$$756$$$O	the$$$757$$$760$$$O	aqueous$$$761$$$768$$$O	phase$$$769$$$774$$$O	where$$$775$$$780$$$O	PVR$$$781$$$784$$$O	would$$$785$$$790$$$O	otherwise$$$791$$$800$$$O	tend$$$801$$$805$$$O	to$$$806$$$808$$$O	develop.$$$809$$$817$$$O
US20080039412
Short$$$0$$$5$$$O	interfering$$$6$$$17$$$O	RNA$$$18$$$21$$$O	sequences$$$22$$$31$$$O	for$$$32$$$35$$$O	use$$$36$$$39$$$O	in$$$40$$$42$$$O	therapeutic,$$$43$$$55$$$O	veterinary,$$$56$$$67$$$O	agricultural,$$$68$$$81$$$O	diagnostic,$$$82$$$93$$$O	target$$$94$$$100$$$O	validation,$$$101$$$112$$$O	and$$$113$$$116$$$O	genomic$$$117$$$124$$$O	discovery$$$125$$$134$$$O	applications$$$135$$$147$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	concerns$$$22$$$30$$$O	methods$$$31$$$38$$$O	and$$$39$$$42$$$O	nucleic$$$43$$$50$$$O	acid$$$51$$$55$$$O	based$$$56$$$61$$$O	reagents$$$62$$$70$$$O	useful$$$71$$$77$$$O	in$$$78$$$80$$$O	modulating$$$81$$$91$$$O	gene$$$92$$$96$$$O	expression$$$97$$$107$$$O	in$$$108$$$110$$$O	a$$$111$$$112$$$O	variety$$$113$$$120$$$O	of$$$121$$$123$$$O	applications,$$$124$$$137$$$O	including$$$138$$$147$$$O	use$$$148$$$151$$$O	in$$$152$$$154$$$O	therapeutic,$$$155$$$167$$$O	veterinary,$$$168$$$179$$$O	agricultural,$$$180$$$193$$$O	diagnostic,$$$194$$$205$$$O	target$$$206$$$212$$$O	validation,$$$213$$$224$$$O	and$$$225$$$228$$$O	genomic$$$229$$$236$$$O	discovery$$$237$$$246$$$O	applications.$$$247$$$260$$$O	Specifically,$$$261$$$274$$$O	the$$$275$$$278$$$O	invention$$$279$$$288$$$O	relates$$$289$$$296$$$O	to$$$297$$$299$$$O	multifunctional$$$300$$$315$$$O	short$$$316$$$321$$$O	interfering$$$322$$$333$$$O	nucleic$$$334$$$341$$$O	acid$$$342$$$346$$$O	(multifunctional$$$347$$$363$$$O	siNA)$$$364$$$369$$$O	molecules$$$370$$$379$$$O	that$$$380$$$384$$$O	modulate$$$385$$$393$$$O	the$$$394$$$397$$$O	expression$$$398$$$408$$$O	of$$$409$$$411$$$O	one$$$412$$$415$$$O	or$$$416$$$418$$$O	more$$$419$$$423$$$O	genes$$$424$$$429$$$O	in$$$430$$$432$$$O	a$$$433$$$434$$$O	biologic$$$435$$$443$$$O	system,$$$444$$$451$$$O	such$$$452$$$456$$$O	as$$$457$$$459$$$O	a$$$460$$$461$$$O	cell,$$$462$$$467$$$O	tissue,$$$468$$$475$$$O	or$$$476$$$478$$$O	organism$$$479$$$487$$$O	via$$$488$$$491$$$O	RNA$$$492$$$495$$$O	interference$$$496$$$508$$$O	(RNAi).$$$509$$$516$$$O	The$$$517$$$520$$$O	bifunctional$$$521$$$533$$$O	short$$$534$$$539$$$O	interfering$$$540$$$551$$$O	nucleic$$$552$$$559$$$O	acid$$$560$$$564$$$O	(multifunctional$$$565$$$581$$$O	siNA)$$$582$$$587$$$O	molecules$$$588$$$597$$$O	of$$$598$$$600$$$O	the$$$601$$$604$$$O	invention$$$605$$$614$$$O	can$$$615$$$618$$$O	target$$$619$$$625$$$O	more$$$626$$$630$$$O	than$$$631$$$635$$$O	one$$$636$$$639$$$O	regions$$$640$$$647$$$O	of$$$648$$$650$$$O	nucleic$$$651$$$658$$$O	acid$$$659$$$663$$$O	sequence$$$664$$$672$$$O	in$$$673$$$675$$$O	a$$$676$$$677$$$O	single$$$678$$$684$$$O	target$$$685$$$691$$$O	nucleic$$$692$$$699$$$O	acid$$$700$$$704$$$O	molecule$$$705$$$713$$$O	or$$$714$$$716$$$O	can$$$717$$$720$$$O	target$$$721$$$727$$$O	regions$$$728$$$735$$$O	of$$$736$$$738$$$O	nucleic$$$739$$$746$$$O	acid$$$747$$$751$$$O	sequence$$$752$$$760$$$O	in$$$761$$$763$$$O	differing$$$764$$$773$$$O	target$$$774$$$780$$$O	nucleic$$$781$$$788$$$O	acid$$$789$$$793$$$O	molecules.$$$794$$$804$$$O	The$$$805$$$808$$$O	self$$$809$$$813$$$O	multifunctional$$$814$$$829$$$O	siNA$$$830$$$834$$$O	molecules$$$835$$$844$$$O	are$$$845$$$848$$$O	useful$$$849$$$855$$$O	in$$$856$$$858$$$O	the$$$859$$$862$$$O	treatment$$$863$$$872$$$O	of$$$873$$$875$$$O	any$$$876$$$879$$$O	disease$$$880$$$887$$$O	or$$$888$$$890$$$O	condition$$$891$$$900$$$O	that$$$901$$$905$$$O	responds$$$906$$$914$$$O	to$$$915$$$917$$$O	modulation$$$918$$$928$$$O	of$$$929$$$931$$$O	gene$$$932$$$936$$$O	expression$$$937$$$947$$$O	or$$$948$$$950$$$O	activity$$$951$$$959$$$O	in$$$960$$$962$$$O	a$$$963$$$964$$$O	cell,$$$965$$$970$$$O	tissue,$$$971$$$978$$$O	or$$$979$$$981$$$O	organism.$$$982$$$991$$$O
WO2008072952A2
Anti-inflammatory$$$0$$$17$$$O	compounds$$$18$$$27$$$O	containing$$$28$$$38$$$O	compositions$$$39$$$51$$$O	for$$$52$$$55$$$O	treatment$$$56$$$65$$$O	of$$$66$$$68$$$O	cancer$$$69$$$75$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	compositions$$$33$$$45$$$O	comprising$$$46$$$56$$$O	non-steroidal$$$57$$$70$$$O	anti-inflammatory$$$71$$$88$$$O	compounds,$$$89$$$99$$$O	and$$$100$$$103$$$O	especially$$$104$$$114$$$O	to$$$115$$$117$$$O	the$$$118$$$121$$$O	use$$$122$$$125$$$O	of$$$126$$$128$$$O	such$$$129$$$133$$$O	compositions$$$134$$$146$$$O	in$$$147$$$149$$$O	the$$$150$$$153$$$O	treatment$$$154$$$163$$$O	of$$$164$$$166$$$O	cancer$$$167$$$173$$$O	or$$$174$$$176$$$O	in$$$177$$$179$$$O	the$$$180$$$183$$$O	inhibition$$$184$$$194$$$O	of$$$195$$$197$$$O	cancer$$$198$$$204$$$O	growth.$$$205$$$212$$$O	More$$$213$$$217$$$O	specifically,$$$218$$$231$$$O	the$$$232$$$235$$$O	invention$$$236$$$245$$$O	relates$$$246$$$253$$$O	to$$$254$$$256$$$O	a$$$257$$$258$$$O	method$$$259$$$265$$$O	for$$$266$$$269$$$O	targeting$$$270$$$279$$$O	an$$$280$$$282$$$O	anti-inflammatory$$$283$$$300$$$O	compound$$$301$$$309$$$O	to$$$310$$$312$$$O	tumor$$$313$$$318$$$O	tissue.$$$319$$$326$$$O
US20110229524
Composition$$$0$$$11$$$O	of$$$12$$$14$$$O	tumor-associated$$$15$$$31$$$O	peptides$$$32$$$40$$$O	and$$$41$$$44$$$O	related$$$45$$$52$$$O	anti-cancer$$$53$$$64$$$O	vaccine$$$65$$$72$$$O	for$$$73$$$76$$$O	the$$$77$$$80$$$O	treatment$$$81$$$90$$$O	of$$$91$$$93$$$O	Gastric$$$94$$$101$$$O	Cancer$$$102$$$108$$$O	and$$$109$$$112$$$O	other$$$113$$$118$$$O	cancers$$$119$$$126$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	immunotherapeutic$$$33$$$50$$$O	peptides$$$51$$$59$$$O	and$$$60$$$63$$$O	their$$$64$$$69$$$O	use$$$70$$$73$$$O	in$$$74$$$76$$$O	immunotherapy,$$$77$$$91$$$O	in$$$92$$$94$$$O	particular$$$95$$$105$$$O	the$$$106$$$109$$$O	immunotherapy$$$110$$$123$$$O	of$$$124$$$126$$$O	cancer.$$$127$$$134$$$O	The$$$135$$$138$$$O	present$$$139$$$146$$$O	invention$$$147$$$156$$$O	discloses$$$157$$$166$$$O	tumor-associated$$$167$$$183$$$O	T-helper$$$184$$$192$$$O	cell$$$193$$$197$$$O	peptide$$$198$$$205$$$O	epitopes,$$$206$$$215$$$O	alone$$$216$$$221$$$O	or$$$222$$$224$$$O	in$$$225$$$227$$$O	combination$$$228$$$239$$$O	with$$$240$$$244$$$O	other$$$245$$$250$$$O	tumor-associated$$$251$$$267$$$O	peptides$$$268$$$276$$$O	that$$$277$$$281$$$O	serve$$$282$$$287$$$O	as$$$288$$$290$$$O	active$$$291$$$297$$$O	pharmaceutical$$$298$$$312$$$O	ingredients$$$313$$$324$$$O	of$$$325$$$327$$$O	vaccine$$$328$$$335$$$O	compositions$$$336$$$348$$$O	which$$$349$$$354$$$O	stimulate$$$355$$$364$$$O	anti-tumor$$$365$$$375$$$O	immune$$$376$$$382$$$O	responses.$$$383$$$393$$$O	In$$$394$$$396$$$O	particular,$$$397$$$408$$$O	the$$$409$$$412$$$O	composition$$$413$$$424$$$O	of$$$425$$$427$$$O	the$$$428$$$431$$$O	peptides$$$432$$$440$$$O	of$$$441$$$443$$$O	the$$$444$$$447$$$O	present$$$448$$$455$$$O	invention$$$456$$$465$$$O	can$$$466$$$469$$$O	be$$$470$$$472$$$O	used$$$473$$$477$$$O	in$$$478$$$480$$$O	vaccine$$$481$$$488$$$O	compositions$$$489$$$501$$$O	for$$$502$$$505$$$O	eliciting$$$506$$$515$$$O	anti-tumor$$$516$$$526$$$O	immune$$$527$$$533$$$O	responses$$$534$$$543$$$O	against$$$544$$$551$$$O	gastric$$$552$$$559$$$O	cancers$$$560$$$567$$$O	(GC).$$$568$$$573$$$O
WO2011148657A1
Composition$$$0$$$11$$$O	for$$$12$$$15$$$O	prevention,$$$16$$$27$$$O	amelioration$$$28$$$40$$$O	or$$$41$$$43$$$O	treatment$$$44$$$53$$$O	of$$$54$$$56$$$O	metabolic$$$57$$$66$$$O	syndrome$$$67$$$75$$$O
Disclosed$$$0$$$9$$$O	are:$$$10$$$14$$$O	a$$$15$$$16$$$O	composition$$$17$$$28$$$O	comprising$$$29$$$39$$$O	the$$$40$$$43$$$O	components$$$44$$$54$$$O	(a)$$$55$$$58$$$O	and$$$59$$$62$$$O	(b)$$$63$$$66$$$O	mentioned$$$67$$$76$$$O	below,$$$77$$$83$$$O	wherein$$$84$$$91$$$O	the$$$92$$$95$$$O	ratio$$$96$$$101$$$O	of$$$102$$$104$$$O	the$$$105$$$108$$$O	component$$$109$$$118$$$O	(a)$$$119$$$122$$$O	to$$$123$$$125$$$O	the$$$126$$$129$$$O	component$$$130$$$139$$$O	(b)$$$140$$$143$$$O	is$$$144$$$146$$$O	1:(0.001$$$147$$$155$$$O	to$$$156$$$158$$$O	5)$$$159$$$161$$$O	by$$$162$$$164$$$O	mass;$$$165$$$170$$$O	and$$$171$$$174$$$O	a$$$175$$$176$$$O	food,$$$177$$$182$$$O	a$$$183$$$184$$$O	beverage,$$$185$$$194$$$O	a$$$195$$$196$$$O	medicinal$$$197$$$206$$$O	agent$$$207$$$212$$$O	or$$$213$$$215$$$O	the$$$216$$$219$$$O	like,$$$220$$$225$$$O	which$$$226$$$231$$$O	contains$$$232$$$240$$$O	the$$$241$$$244$$$O	composition.$$$245$$$257$$$O	The$$$258$$$261$$$O	composition$$$262$$$273$$$O	and$$$274$$$277$$$O	the$$$278$$$281$$$O	food,$$$282$$$287$$$O	the$$$288$$$291$$$O	beverage,$$$292$$$301$$$O	the$$$302$$$305$$$O	medicinal$$$306$$$315$$$O	agent$$$316$$$321$$$O	or$$$322$$$324$$$O	the$$$325$$$328$$$O	like$$$329$$$333$$$O	are$$$334$$$337$$$O	useful$$$338$$$344$$$O	for$$$345$$$348$$$O	the$$$349$$$352$$$O	prevention,$$$353$$$364$$$O	amelioration$$$365$$$377$$$O	or$$$378$$$380$$$O	treatment$$$381$$$390$$$O	of$$$391$$$393$$$O	metabolic$$$394$$$403$$$O	syndrome,$$$404$$$413$$$O	lipid$$$414$$$419$$$O	metabolism$$$420$$$430$$$O	disorder$$$431$$$439$$$O	(e.g.,$$$440$$$446$$$O	fatty$$$447$$$452$$$O	liver,$$$453$$$459$$$O	hyperlipemia),$$$460$$$474$$$O	obesity$$$475$$$482$$$O	(e.g.,$$$483$$$489$$$O	visceral$$$490$$$498$$$O	fat$$$499$$$502$$$O	accumulation,$$$503$$$516$$$O	subcutaneous$$$517$$$529$$$O	fat$$$530$$$533$$$O	accumulation),$$$534$$$548$$$O	or$$$549$$$551$$$O	the$$$552$$$555$$$O	like.$$$556$$$561$$$O	(a)$$$562$$$565$$$O	At$$$566$$$568$$$O	least$$$569$$$574$$$O	one$$$575$$$578$$$O	polyphenol$$$579$$$589$$$I	selected$$$590$$$598$$$O	from$$$599$$$603$$$O	the$$$604$$$607$$$O	group$$$608$$$613$$$O	consisting$$$614$$$624$$$O	of$$$625$$$627$$$O	a$$$628$$$629$$$O	polyphenol$$$630$$$640$$$I	containing$$$641$$$651$$$O	15$$$652$$$654$$$O	mass%$$$655$$$660$$$O	or$$$661$$$663$$$O	more$$$664$$$668$$$O	of$$$669$$$671$$$O	a$$$672$$$673$$$O	proanthocyanidin$$$674$$$690$$$I	having$$$691$$$697$$$O	a$$$698$$$699$$$O	polymerization$$$700$$$714$$$O	degree$$$715$$$721$$$O	of$$$722$$$724$$$O	1$$$725$$$726$$$O	to$$$727$$$729$$$O	3,$$$730$$$732$$$O	hesperidin,$$$733$$$744$$$I	a$$$745$$$746$$$O	hesperidin$$$747$$$757$$$I	derivative,$$$758$$$769$$$O	and$$$770$$$773$$$O	hesperetin.$$$774$$$785$$$I	(b)$$$786$$$789$$$O	At$$$790$$$792$$$O	least$$$793$$$798$$$O	one$$$799$$$802$$$O	xanthine$$$803$$$811$$$I	derivative.$$$812$$$823$$$O
WO2008106731A1
A$$$0$$$1$$$O	target$$$2$$$8$$$O	for$$$9$$$12$$$O	breast$$$13$$$19$$$O	cancer$$$20$$$26$$$O	therapy$$$27$$$34$$$O	and/or$$$35$$$41$$$O	diagnosis$$$42$$$51$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	breast$$$33$$$39$$$O	cancer$$$40$$$46$$$O	and$$$47$$$50$$$O	methods$$$51$$$58$$$O	for$$$59$$$62$$$O	identifying$$$63$$$74$$$O	therapeutics$$$75$$$87$$$O	and$$$88$$$91$$$O	diagnosis.$$$92$$$102$$$O	In$$$103$$$105$$$O	general,$$$106$$$114$$$O	methods$$$115$$$122$$$O	for$$$123$$$126$$$O	identifying$$$127$$$138$$$O	therapeutic$$$139$$$150$$$O	agents$$$151$$$157$$$O	directed$$$158$$$166$$$O	to$$$167$$$169$$$O	calcium$$$170$$$177$$$I	flow$$$178$$$182$$$O	are$$$183$$$186$$$O	disclosed.$$$187$$$197$$$O	Also$$$198$$$202$$$O	provided$$$203$$$211$$$O	are$$$212$$$215$$$O	methods$$$216$$$223$$$O	for$$$224$$$227$$$O	diagnosis$$$228$$$237$$$O	of$$$238$$$240$$$O	breast$$$241$$$247$$$O	cancer$$$248$$$254$$$O	and/or$$$255$$$261$$$O	a$$$262$$$263$$$O	predisposition$$$264$$$278$$$O	to$$$279$$$281$$$O	breast$$$282$$$288$$$O	cancer$$$289$$$295$$$O	and$$$296$$$299$$$O	methods$$$300$$$307$$$O	of$$$308$$$310$$$O	treatment$$$311$$$320$$$O	of$$$321$$$323$$$O	breast$$$324$$$330$$$O	cancer.$$$331$$$338$$$O	The$$$339$$$342$$$O	methods$$$343$$$350$$$O	include$$$351$$$358$$$O	identifying$$$359$$$370$$$O	therapeutic$$$371$$$382$$$O	agents$$$383$$$389$$$O	which$$$390$$$395$$$O	modulate$$$396$$$404$$$O	a$$$405$$$406$$$O	CRAC$$$407$$$411$$$O	channel$$$412$$$419$$$O	and/or$$$420$$$426$$$O	a$$$427$$$428$$$O	glycoprotein$$$429$$$441$$$O	activator$$$442$$$451$$$O	of$$$452$$$454$$$O	a$$$455$$$456$$$O	CRAC$$$457$$$461$$$O	channel.$$$462$$$470$$$O	Also$$$471$$$475$$$O	provided$$$476$$$484$$$O	are$$$485$$$488$$$O	diagnostic$$$489$$$499$$$O	methods$$$500$$$507$$$O	that$$$508$$$512$$$O	ultilise$$$513$$$521$$$O	a$$$522$$$523$$$O	CRAC$$$524$$$528$$$O	channel$$$529$$$536$$$O	and/or$$$537$$$543$$$O	a$$$544$$$545$$$O	glycoprotein$$$546$$$558$$$O	activator$$$559$$$568$$$O	of$$$569$$$571$$$O	a$$$572$$$573$$$O	CRAC$$$574$$$578$$$O	channel.$$$579$$$587$$$O
CN101269047A
Tolterodine$$$0$$$11$$$I	tartrate$$$12$$$20$$$I	sustained-release$$$21$$$38$$$O	dropping$$$39$$$47$$$O	pill$$$48$$$52$$$O	and$$$53$$$56$$$O	preparation$$$57$$$68$$$O	method$$$69$$$75$$$O	thereof$$$76$$$83$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	drug$$$26$$$30$$$O	compound$$$31$$$39$$$O	for$$$40$$$43$$$O	treating$$$44$$$52$$$O	urinary$$$53$$$60$$$O	incontinence,$$$61$$$74$$$O	frequency$$$75$$$84$$$O	of$$$85$$$87$$$O	micturition$$$88$$$99$$$O	and$$$100$$$103$$$O	urgency$$$104$$$111$$$O	of$$$112$$$114$$$O	micturition$$$115$$$126$$$O	due$$$127$$$130$$$O	to$$$131$$$133$$$O	bladder$$$134$$$141$$$O	stimulation$$$142$$$153$$$O	and$$$154$$$157$$$O	particularly$$$158$$$170$$$O	relates$$$171$$$178$$$O	to$$$179$$$181$$$O	a$$$182$$$183$$$O	prepared$$$184$$$192$$$O	sustained-release$$$193$$$210$$$O	tolterodine$$$211$$$222$$$I	tartrate$$$223$$$231$$$I	dropping$$$232$$$240$$$O	pill$$$241$$$245$$$O	adopting$$$246$$$254$$$O	tolterodine$$$255$$$266$$$I	tartrate$$$267$$$275$$$I	as$$$276$$$278$$$O	the$$$279$$$282$$$O	ingredient.$$$283$$$294$$$O	The$$$295$$$298$$$O	drug$$$299$$$303$$$O	compound$$$304$$$312$$$O	aims$$$313$$$317$$$O	to$$$318$$$320$$$O	supplement$$$321$$$331$$$O	the$$$332$$$335$$$O	deficiency$$$336$$$346$$$O	of$$$347$$$349$$$O	the$$$350$$$353$$$O	prior$$$354$$$359$$$O	art$$$360$$$363$$$O	and$$$364$$$367$$$O	provide$$$368$$$375$$$O	a$$$376$$$377$$$O	sustained-release$$$378$$$395$$$O	tolterodine$$$396$$$407$$$I	tartrate$$$408$$$416$$$I	dropping$$$417$$$425$$$O	pill$$$426$$$430$$$O	formulation.$$$431$$$443$$$O	The$$$444$$$447$$$O	sustained-release$$$448$$$465$$$O	tolterodine$$$466$$$477$$$I	tartrate$$$478$$$486$$$I	dropping$$$487$$$495$$$O	pill$$$496$$$500$$$O	is$$$501$$$503$$$O	prepared$$$504$$$512$$$O	by$$$513$$$515$$$O	adding$$$516$$$522$$$O	stabilize$$$523$$$532$$$O	Vitamin$$$533$$$540$$$I	A$$$541$$$542$$$I	and$$$543$$$546$$$O	hydrophobic$$$547$$$558$$$O	framework$$$559$$$568$$$O	ingredients$$$569$$$580$$$O	to$$$581$$$583$$$O	the$$$584$$$587$$$O	ingredients$$$588$$$599$$$O	adopted$$$600$$$607$$$O	by$$$608$$$610$$$O	the$$$611$$$614$$$O	prior$$$615$$$620$$$O	art,$$$621$$$625$$$O	thereby$$$626$$$633$$$O	overcoming$$$634$$$644$$$O	the$$$645$$$648$$$O	defects$$$649$$$656$$$O	in$$$657$$$659$$$O	the$$$660$$$663$$$O	prior$$$664$$$669$$$O	art$$$670$$$673$$$O	effectively,$$$674$$$686$$$O	guaranteeing$$$687$$$699$$$O	no$$$700$$$702$$$O	occurrence$$$703$$$713$$$O	of$$$714$$$716$$$O	an$$$717$$$719$$$O	obvious$$$720$$$727$$$O	change$$$728$$$734$$$O	related$$$735$$$742$$$O	to$$$743$$$745$$$O	the$$$746$$$749$$$O	substance$$$750$$$759$$$O	content$$$760$$$767$$$O	for$$$768$$$771$$$O	the$$$772$$$775$$$O	drug$$$776$$$780$$$O	during$$$781$$$787$$$O	the$$$788$$$791$$$O	effective$$$792$$$801$$$O	storage$$$802$$$809$$$O	period$$$810$$$816$$$O	and$$$817$$$820$$$O	having$$$821$$$827$$$O	the$$$828$$$831$$$O	advantages$$$832$$$842$$$O	of$$$843$$$845$$$O	full$$$846$$$850$$$O	release,$$$851$$$859$$$O	controllable$$$860$$$872$$$O	release$$$873$$$880$$$O	time$$$881$$$885$$$O	and$$$886$$$889$$$O	high$$$890$$$894$$$O	bioavailability$$$895$$$910$$$O	simultaneously.$$$911$$$926$$$O	The$$$927$$$930$$$O	sustained-release$$$931$$$948$$$O	tolterodine$$$949$$$960$$$I	tartrate$$$961$$$969$$$I	dropping$$$970$$$978$$$O	pill$$$979$$$983$$$O	is$$$984$$$986$$$O	suitable$$$987$$$995$$$O	for$$$996$$$999$$$O	clinical$$$1000$$$1008$$$O	and$$$1009$$$1012$$$O	family$$$1013$$$1019$$$O	use.$$$1020$$$1024$$$O
WO2012122451A3
Polymorphs$$$0$$$10$$$O	of$$$11$$$13$$$O	maxacalcitol$$$14$$$26$$$I	and$$$27$$$30$$$O	process$$$31$$$38$$$O	for$$$39$$$42$$$O	the$$$43$$$46$$$O	preparation$$$47$$$58$$$O	of$$$59$$$61$$$O	maxacalcitol$$$62$$$74$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	Maxacalcitol$$$33$$$45$$$I	polymorphs$$$46$$$56$$$O	and$$$57$$$60$$$O	Maxacalcitol$$$61$$$73$$$I	having$$$74$$$80$$$O	low$$$81$$$84$$$O	residual$$$85$$$93$$$O	solvent$$$94$$$101$$$O	content$$$102$$$109$$$O	as$$$110$$$112$$$O	well$$$113$$$117$$$O	as$$$118$$$120$$$O	processes$$$121$$$130$$$O	for$$$131$$$134$$$O	their$$$135$$$140$$$O	preparation.$$$141$$$153$$$O	The$$$154$$$157$$$O	present$$$158$$$165$$$O	invention$$$166$$$175$$$O	also$$$176$$$180$$$O	relates$$$181$$$188$$$O	to$$$189$$$191$$$O	pharmaceutical$$$192$$$206$$$O	compositions$$$207$$$219$$$O	containing$$$220$$$230$$$O	Maxacalcitol$$$231$$$243$$$I	polymorphs$$$244$$$254$$$O	or$$$255$$$257$$$O	Maxacalcitol$$$258$$$270$$$I	having$$$271$$$277$$$O	low$$$278$$$281$$$O	residual$$$282$$$290$$$O	solvent$$$291$$$298$$$O	content$$$299$$$306$$$O	and$$$307$$$310$$$O	treatment$$$311$$$320$$$O	methods$$$321$$$328$$$O	using$$$329$$$334$$$O	the$$$335$$$338$$$O	pharmaceutical$$$339$$$353$$$O	compositions.$$$354$$$367$$$O
WO2012099452A1
Curcumin$$$0$$$8$$$O	compounds$$$9$$$18$$$O	with$$$19$$$23$$$O	superior$$$24$$$32$$$O	structural$$$33$$$43$$$O	stability$$$44$$$53$$$O	and$$$54$$$57$$$O	processes$$$58$$$67$$$O	for$$$68$$$71$$$O	their$$$72$$$77$$$O	preparation$$$78$$$89$$$O
Accordingly,$$$0$$$12$$$O	the$$$13$$$16$$$O	invention$$$17$$$26$$$O	discloses$$$27$$$36$$$O	compounds$$$37$$$46$$$O	with$$$47$$$51$$$O	enhanced$$$52$$$60$$$O	bioavailability$$$61$$$76$$$O	for$$$77$$$80$$$O	the$$$81$$$84$$$O	prevention$$$85$$$95$$$O	and$$$96$$$99$$$O	treatment$$$100$$$109$$$O	of$$$110$$$112$$$O	anti-human$$$113$$$123$$$O	immunodeficiency$$$124$$$140$$$O	virus$$$141$$$146$$$O	(HIV),$$$147$$$153$$$O	anti-tuberculosis$$$154$$$171$$$O	(TB),$$$172$$$177$$$O	anti-Alzheimer$$$178$$$192$$$O	or$$$193$$$195$$$O	anti-cancer.$$$196$$$208$$$O	The$$$209$$$212$$$O	invention$$$213$$$222$$$O	also$$$223$$$227$$$O	discloses$$$228$$$237$$$O	the$$$238$$$241$$$O	method$$$242$$$248$$$O	in$$$249$$$251$$$O	synthesizing$$$252$$$264$$$O	these$$$265$$$270$$$O	compounds$$$271$$$280$$$O	wherein$$$281$$$288$$$O	the$$$289$$$292$$$O	steps$$$293$$$298$$$O	includes$$$299$$$307$$$O	mixing$$$308$$$314$$$O	curcumin,$$$315$$$324$$$O	isatin$$$325$$$331$$$O	derivatives$$$332$$$343$$$O	or$$$344$$$346$$$O	ninhydrin$$$347$$$356$$$O	and$$$357$$$360$$$O	proline$$$361$$$368$$$O	in$$$369$$$371$$$O	20$$$372$$$374$$$O	mL$$$375$$$377$$$O	methanol.$$$378$$$387$$$O	The$$$388$$$391$$$O	mixture$$$392$$$399$$$O	was$$$400$$$403$$$O	then$$$404$$$408$$$O	refluxed$$$409$$$417$$$O	with$$$418$$$422$$$O	a$$$423$$$424$$$O	solvent$$$425$$$432$$$O	on$$$433$$$435$$$O	a$$$436$$$437$$$O	water$$$438$$$443$$$O	bath$$$444$$$448$$$O	and$$$449$$$452$$$O	excess$$$453$$$459$$$O	solvent$$$460$$$467$$$O	was$$$468$$$471$$$O	removed$$$472$$$479$$$O	under$$$480$$$485$$$O	vacuum.$$$486$$$493$$$O	The$$$494$$$497$$$O	residue$$$498$$$505$$$O	subjected$$$506$$$515$$$O	to$$$516$$$518$$$O	flash$$$519$$$524$$$O	column$$$525$$$531$$$O	chromatography$$$532$$$546$$$O	using$$$547$$$552$$$O	petroleum$$$553$$$562$$$O	ether:$$$563$$$569$$$O	ethyl$$$570$$$575$$$O	acetate$$$576$$$583$$$O	mixture$$$584$$$591$$$O	(4:1)$$$592$$$597$$$O	as$$$598$$$600$$$O	eluent$$$601$$$607$$$O	to$$$608$$$610$$$O	afford$$$611$$$617$$$O	the$$$618$$$621$$$O	product.$$$622$$$630$$$O	The$$$631$$$634$$$O	ratio$$$635$$$640$$$O	for$$$641$$$644$$$O	curcumin:$$$645$$$654$$$O	isatin$$$655$$$661$$$O	derivative/ninhydrin:proline$$$662$$$690$$$O	is$$$691$$$693$$$O	1$$$694$$$695$$$O	:1$$$696$$$698$$$O	:2$$$699$$$701$$$O	and$$$702$$$705$$$O	1$$$706$$$707$$$O	:2:4.$$$708$$$713$$$O
CN1879863B
Dew$$$0$$$3$$$O	for$$$4$$$7$$$O	treating$$$8$$$16$$$O	tragomaschalia$$$17$$$31$$$O
Disclosed$$$0$$$9$$$O	is$$$10$$$12$$$O	a$$$13$$$14$$$O	medicinal$$$15$$$24$$$O	liquid$$$25$$$31$$$O	for$$$32$$$35$$$O	treating$$$36$$$44$$$O	body$$$45$$$49$$$O	odor,$$$50$$$55$$$O	which$$$56$$$61$$$O	is$$$62$$$64$$$O	prepared$$$65$$$73$$$O	from$$$74$$$78$$$O	raw$$$79$$$82$$$O	materials$$$83$$$92$$$O	including$$$93$$$102$$$O	sweet$$$103$$$108$$$O	basil,$$$109$$$115$$$O	orpiment,$$$116$$$125$$$O	goldthread$$$126$$$136$$$O	root,$$$137$$$142$$$O	fresh$$$143$$$148$$$O	ginger,$$$149$$$156$$$O	perfume$$$157$$$164$$$O	compound$$$165$$$173$$$O	and$$$174$$$177$$$O	ethanol.$$$178$$$186$$$I	The$$$187$$$190$$$O	medicament$$$191$$$201$$$O	has$$$202$$$205$$$O	non-irritating$$$206$$$220$$$O	property,$$$221$$$230$$$O	and$$$231$$$234$$$O	no$$$235$$$237$$$O	side$$$238$$$242$$$O	effects$$$243$$$250$$$O	are$$$251$$$254$$$O	found.$$$255$$$261$$$O
US7320803
Free$$$0$$$4$$$O	from$$$5$$$9$$$O	water$$$10$$$15$$$O	of$$$16$$$18$$$O	crystallization;$$$19$$$35$$$O	use$$$36$$$39$$$O	in$$$40$$$42$$$O	foods,$$$43$$$49$$$O	animal$$$50$$$56$$$O	feeds,$$$57$$$63$$$O	or$$$64$$$66$$$O	in$$$67$$$69$$$O	food$$$70$$$74$$$O	supplements$$$75$$$86$$$O
Crystalline$$$0$$$11$$$O	ascorbate,$$$12$$$22$$$I	in$$$23$$$25$$$O	particular$$$26$$$36$$$O	choline$$$37$$$44$$$I	ascorbate$$$45$$$54$$$I	in$$$55$$$57$$$O	the$$$58$$$61$$$O	form$$$62$$$66$$$O	of$$$67$$$69$$$O	crystals$$$70$$$78$$$O	free$$$79$$$83$$$O	from$$$84$$$88$$$O	water$$$89$$$94$$$O	of$$$95$$$97$$$O	crystallization,$$$98$$$114$$$O	processes$$$115$$$124$$$O	for$$$125$$$128$$$O	its$$$129$$$132$$$O	preparation,$$$133$$$145$$$O	and$$$146$$$149$$$O	its$$$150$$$153$$$O	used$$$154$$$158$$$O	are$$$159$$$162$$$O	described.$$$163$$$173$$$O
CN101475458B
Mitissimol$$$0$$$10$$$I	with$$$11$$$15$$$O	antineoplastic$$$16$$$30$$$O	activity,$$$31$$$40$$$O	preparation$$$41$$$52$$$O	and$$$53$$$56$$$O	use$$$57$$$60$$$O	thereof$$$61$$$68$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	Luctarius$$$23$$$32$$$O	rhzomorph$$$33$$$42$$$O	with$$$43$$$47$$$O	anti-tumor$$$48$$$58$$$O	activity.$$$59$$$68$$$O	The$$$69$$$72$$$O	method$$$73$$$79$$$O	for$$$80$$$83$$$O	preparing$$$84$$$93$$$O	the$$$94$$$97$$$O	Luctarius$$$98$$$107$$$O	rhzomorph$$$108$$$117$$$O	is$$$118$$$120$$$O	to$$$121$$$123$$$O	extract$$$124$$$131$$$O	from$$$132$$$136$$$O	higher$$$137$$$143$$$O	fungi$$$144$$$149$$$O	Lactarius$$$150$$$159$$$O	mitissimus,$$$160$$$171$$$O	Lctarius$$$172$$$180$$$O	hirtipes$$$181$$$189$$$O	J.Z.Ying$$$190$$$198$$$O	and$$$199$$$202$$$O	other$$$203$$$208$$$O	fruiting$$$209$$$217$$$O	bodies$$$218$$$224$$$O	by$$$225$$$227$$$O	one$$$228$$$231$$$O	or$$$232$$$234$$$O	more$$$235$$$239$$$O	solvents$$$240$$$248$$$O	of$$$249$$$251$$$O	ethanol,$$$252$$$260$$$I	methanol,$$$261$$$270$$$I	chloroform,$$$271$$$282$$$I	ethyl$$$283$$$288$$$I	acetate,$$$289$$$297$$$I	acetone$$$298$$$305$$$I	and$$$306$$$309$$$O	sherwood$$$310$$$318$$$O	oil,$$$319$$$323$$$O	and$$$324$$$327$$$O	chromatographically$$$328$$$347$$$O	separate$$$348$$$356$$$O	the$$$357$$$360$$$O	prepared$$$361$$$369$$$O	extractive$$$370$$$380$$$O	by$$$381$$$383$$$O	a$$$384$$$385$$$O	silica$$$386$$$392$$$O	gel$$$393$$$396$$$O	column$$$397$$$403$$$O	repeatedly.$$$404$$$415$$$O	The$$$416$$$419$$$O	invention$$$420$$$429$$$O	also$$$430$$$434$$$O	provides$$$435$$$443$$$O	application$$$444$$$455$$$O	direction$$$456$$$465$$$O	of$$$466$$$468$$$O	the$$$469$$$472$$$O	Luctarius$$$473$$$482$$$O	rhzomorph$$$483$$$492$$$O	in$$$493$$$495$$$O	preparation$$$496$$$507$$$O	of$$$508$$$510$$$O	an$$$511$$$513$$$O	anti-tumor$$$514$$$524$$$O	medicine,$$$525$$$534$$$O	including$$$535$$$544$$$O	preparation$$$545$$$556$$$O	of$$$557$$$559$$$O	an$$$560$$$562$$$O	anti-tumor$$$563$$$573$$$O	medicine$$$574$$$582$$$O	taking$$$583$$$589$$$O	the$$$590$$$593$$$O	Luctarius$$$594$$$603$$$O	rhzomorph$$$604$$$613$$$O	as$$$614$$$616$$$O	an$$$617$$$619$$$O	effective$$$620$$$629$$$O	ingredient$$$630$$$640$$$O	clinically.$$$641$$$652$$$O	The$$$653$$$656$$$O	Luctarius$$$657$$$666$$$O	rhzomorph$$$667$$$676$$$O	has$$$677$$$680$$$O	stronger$$$681$$$689$$$O	anti-tumor$$$690$$$700$$$O	activity$$$701$$$709$$$O	through$$$710$$$717$$$O	in-vitro$$$718$$$726$$$O	experiments,$$$727$$$739$$$O	wherein$$$740$$$747$$$O	the$$$748$$$751$$$O	activity$$$752$$$760$$$O	of$$$761$$$763$$$O	Luctarius$$$764$$$773$$$O	rhzomorph$$$774$$$783$$$O	Mitissimol$$$784$$$794$$$I	D$$$795$$$796$$$I	is$$$797$$$799$$$O	the$$$800$$$803$$$O	strongest$$$804$$$813$$$O	with$$$814$$$818$$$O	half$$$819$$$823$$$O	inhibition$$$824$$$834$$$O	concentration$$$835$$$848$$$O	IC50$$$849$$$853$$$O	to$$$854$$$856$$$O	A549$$$857$$$861$$$O	(lung$$$862$$$867$$$O	adenocarcinoma$$$868$$$882$$$O	cell$$$883$$$887$$$O	line),$$$888$$$894$$$O	HCT-8$$$895$$$900$$$O	(human$$$901$$$907$$$O	colon$$$908$$$913$$$O	cancer$$$914$$$920$$$O	cell$$$921$$$925$$$O	line),$$$926$$$932$$$O	Bel-7402$$$933$$$941$$$O	(human$$$942$$$948$$$O	hepatoma$$$949$$$957$$$O	cell$$$958$$$962$$$O	line)$$$963$$$968$$$O	and$$$969$$$972$$$O	Hela$$$973$$$977$$$O	(human$$$978$$$984$$$O	cervical$$$985$$$993$$$O	carcinoma$$$994$$$1003$$$O	cell$$$1004$$$1008$$$O	line)$$$1009$$$1014$$$O	of$$$1015$$$1017$$$O	2.5,$$$1018$$$1022$$$O	11.0,$$$1023$$$1028$$$O	3.6$$$1029$$$1032$$$O	and$$$1033$$$1036$$$O	4.6$$$1037$$$1040$$$O	mu$$$1041$$$1043$$$O	g/ml$$$1044$$$1048$$$O	respectively,$$$1049$$$1062$$$O	and$$$1063$$$1066$$$O	is$$$1067$$$1069$$$O	almost$$$1070$$$1076$$$O	equivalent$$$1077$$$1087$$$O	to$$$1088$$$1090$$$O	positive$$$1091$$$1099$$$O	control$$$1100$$$1107$$$O	drug$$$1108$$$1112$$$O	cisplatin.$$$1113$$$1123$$$I	Therefore,$$$1124$$$1134$$$O	the$$$1135$$$1138$$$O	compounds$$$1139$$$1148$$$O	are$$$1149$$$1152$$$O	expected$$$1153$$$1161$$$O	to$$$1162$$$1164$$$O	be$$$1165$$$1167$$$O	novel$$$1168$$$1173$$$O	anti-tumor$$$1174$$$1184$$$O	medicines.$$$1185$$$1195$$$O
US20120053194
Optically$$$0$$$9$$$O	active$$$10$$$16$$$O	pyrazolylaminoquinazoline,$$$17$$$43$$$I	and$$$44$$$47$$$O	pharmaceutical$$$48$$$62$$$O	compositions$$$63$$$75$$$O	and$$$76$$$79$$$O	methods$$$80$$$87$$$O	of$$$88$$$90$$$O	use$$$91$$$94$$$O	thereof$$$95$$$102$$$O
Provided$$$0$$$8$$$O	herein$$$9$$$15$$$O	is$$$16$$$18$$$O	an$$$19$$$21$$$O	optically$$$22$$$31$$$O	active$$$32$$$38$$$O	pyrozolylaminoquinazaline,$$$39$$$65$$$I	and$$$66$$$69$$$O	pharmaceutical$$$70$$$84$$$O	compositions$$$85$$$97$$$O	thereof.$$$98$$$106$$$O	Also$$$107$$$111$$$O	provided$$$112$$$120$$$O	herein$$$121$$$127$$$O	is$$$128$$$130$$$O	a$$$131$$$132$$$O	method$$$133$$$139$$$O	for$$$140$$$143$$$O	treating,$$$144$$$153$$$O	preventing,$$$154$$$165$$$O	or$$$166$$$168$$$O	ameliorating$$$169$$$181$$$O	one$$$182$$$185$$$O	or$$$186$$$188$$$O	more$$$189$$$193$$$O	symptoms$$$194$$$202$$$O	of$$$203$$$205$$$O	a$$$206$$$207$$$O	JAK-mediated$$$208$$$220$$$O	condition,$$$221$$$231$$$O	disorder,$$$232$$$241$$$O	or$$$242$$$244$$$O	disease.$$$245$$$253$$$O	Further$$$254$$$261$$$O	provided$$$262$$$270$$$O	herein$$$271$$$277$$$O	is$$$278$$$280$$$O	a$$$281$$$282$$$O	method$$$283$$$289$$$O	for$$$290$$$293$$$O	treating,$$$294$$$303$$$O	preventing,$$$304$$$315$$$O	or$$$316$$$318$$$O	ameliorating$$$319$$$331$$$O	one$$$332$$$335$$$O	or$$$336$$$338$$$O	more$$$339$$$343$$$O	symptoms$$$344$$$352$$$O	of$$$353$$$355$$$O	a$$$356$$$357$$$O	proliferative$$$358$$$371$$$O	disease,$$$372$$$380$$$O	inflammatory$$$381$$$393$$$O	disease,$$$394$$$402$$$O	or$$$403$$$405$$$O	renal$$$406$$$411$$$O	disease.$$$412$$$420$$$O
WO2006137772A1
New$$$0$$$3$$$O	physical$$$4$$$12$$$O	form$$$13$$$17$$$O	of$$$18$$$20$$$O	n,nÂ´-$$$21$$$27$$$O	disubstituted$$$28$$$41$$$O	oxabispidines$$$42$$$55$$$O
There$$$0$$$5$$$O	is$$$6$$$8$$$O	provided$$$9$$$17$$$O	a$$$18$$$19$$$O	crystalline$$$20$$$31$$$O	material$$$32$$$40$$$O	consisting$$$41$$$51$$$O	essentially$$$52$$$63$$$O	of$$$64$$$66$$$O	a$$$67$$$68$$$O	compound$$$69$$$77$$$O	of$$$78$$$80$$$O	formula$$$81$$$88$$$O	I,$$$89$$$91$$$O	wherein$$$92$$$99$$$O	R1$$$100$$$102$$$O	to$$$103$$$105$$$O	R4,$$$106$$$109$$$O	A,$$$110$$$112$$$O	B$$$113$$$114$$$O	and$$$115$$$118$$$O	D$$$119$$$120$$$O	have$$$121$$$125$$$O	meanings$$$126$$$134$$$O	given$$$135$$$140$$$O	in$$$141$$$143$$$O	the$$$144$$$147$$$O	description,$$$148$$$160$$$O	which$$$161$$$166$$$O	crystalline$$$167$$$178$$$O	material$$$179$$$187$$$O	is$$$188$$$190$$$O	characterised$$$191$$$204$$$O	in$$$205$$$207$$$O	that$$$208$$$212$$$O	is$$$213$$$215$$$O	has$$$216$$$219$$$O	surface$$$220$$$227$$$O	area$$$228$$$232$$$O	of$$$233$$$235$$$O	less$$$236$$$240$$$O	than$$$241$$$245$$$O	0.7$$$246$$$249$$$O	m2g-1.$$$250$$$256$$$O	There$$$257$$$262$$$O	are$$$263$$$266$$$O	also$$$267$$$271$$$O	provided$$$272$$$280$$$O	processes$$$281$$$290$$$O	for$$$291$$$294$$$O	preparing$$$295$$$304$$$O	such$$$305$$$309$$$O	crystalline$$$310$$$321$$$O	materials.$$$322$$$332$$$O
CN101890049A
Pediatric$$$0$$$9$$$O	paracetamol$$$10$$$21$$$I	oral$$$22$$$26$$$O	solution$$$27$$$35$$$O	formula$$$36$$$43$$$O	and$$$44$$$47$$$O	preparation$$$48$$$59$$$O	method$$$60$$$66$$$O	thereof$$$67$$$74$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	pediatric$$$27$$$36$$$O	paracetamol$$$37$$$48$$$I	oral$$$49$$$53$$$O	solution$$$54$$$62$$$O	formula$$$63$$$70$$$O	and$$$71$$$74$$$O	a$$$75$$$76$$$O	preparation$$$77$$$88$$$O	method$$$89$$$95$$$O	thereof,$$$96$$$104$$$O	and$$$105$$$108$$$O	oral$$$109$$$113$$$O	solution$$$114$$$122$$$O	thereof$$$123$$$130$$$O	is$$$131$$$133$$$O	a$$$134$$$135$$$O	compound$$$136$$$144$$$O	preparation$$$145$$$156$$$O	which$$$157$$$162$$$O	mainly$$$163$$$169$$$O	comprises$$$170$$$179$$$O	acetaminophen,$$$180$$$194$$$I	artificial$$$195$$$205$$$O	bezoar,$$$206$$$213$$$O	chlorpheniramine$$$214$$$230$$$I	maleate$$$231$$$238$$$I	and$$$239$$$242$$$O	glacial$$$243$$$250$$$I	acetic$$$251$$$257$$$I	acid$$$258$$$262$$$I	or$$$263$$$265$$$O	citric$$$266$$$272$$$I	acid.$$$273$$$278$$$I	The$$$279$$$282$$$O	key$$$283$$$286$$$O	of$$$287$$$289$$$O	the$$$290$$$293$$$O	preparation$$$294$$$305$$$O	method$$$306$$$312$$$O	is$$$313$$$315$$$O	to$$$316$$$318$$$O	use$$$319$$$322$$$O	the$$$323$$$326$$$O	glacial$$$327$$$334$$$I	acetic$$$335$$$341$$$I	acid$$$342$$$346$$$I	or$$$347$$$349$$$O	the$$$350$$$353$$$O	citric$$$354$$$360$$$I	acid$$$361$$$365$$$I	to$$$366$$$368$$$O	dissolve$$$369$$$377$$$O	the$$$378$$$381$$$O	artificial$$$382$$$392$$$O	bezoar,$$$393$$$400$$$O	thereby$$$401$$$408$$$O	improving$$$409$$$418$$$O	the$$$419$$$422$$$O	solubility$$$423$$$433$$$O	of$$$434$$$436$$$O	cholic$$$437$$$443$$$I	acid$$$444$$$448$$$I	which$$$449$$$454$$$O	is$$$455$$$457$$$O	a$$$458$$$459$$$O	main$$$460$$$464$$$O	active$$$465$$$471$$$O	ingredient$$$472$$$482$$$O	in$$$483$$$485$$$O	the$$$486$$$489$$$O	artificial$$$490$$$500$$$O	bezoar$$$501$$$507$$$O	from$$$508$$$512$$$O	77%$$$513$$$516$$$O	by$$$517$$$519$$$O	solid$$$520$$$525$$$O	particles$$$526$$$535$$$O	to$$$536$$$538$$$O	above$$$539$$$544$$$O	95%,$$$545$$$549$$$O	further$$$550$$$557$$$O	greatly$$$558$$$565$$$O	improving$$$566$$$575$$$O	the$$$576$$$579$$$O	human$$$580$$$585$$$O	bioavailability$$$586$$$601$$$O	of$$$602$$$604$$$O	the$$$605$$$608$$$O	cholic$$$609$$$615$$$I	acid.$$$616$$$621$$$I
EP2022497A1
Oral$$$0$$$4$$$O	composition$$$5$$$16$$$O	comprising$$$17$$$27$$$O	3-[5-[4-(cyclopentyloxy)$$$28$$$52$$$I	-2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6-$$$53$$$105$$$I	yl)methoxyÂ¨phenylÂ¨propionic$$$106$$$135$$$I	acid$$$136$$$140$$$I	or$$$141$$$143$$$O	salt$$$144$$$148$$$O	thereof$$$149$$$156$$$O
An$$$0$$$2$$$O	oral$$$3$$$7$$$O	composition$$$8$$$19$$$O	contains$$$20$$$28$$$O	3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]phenyl}propionic$$$29$$$132$$$I	acid$$$133$$$137$$$I	or$$$138$$$140$$$O	a$$$141$$$142$$$O	salt$$$143$$$147$$$O	thereof$$$148$$$155$$$O	and$$$156$$$159$$$O	polyvinylpyrrolidone$$$160$$$180$$$I	is$$$181$$$183$$$O	advantageous$$$184$$$196$$$O	as$$$197$$$199$$$O	an$$$200$$$202$$$O	oral$$$203$$$207$$$O	medication$$$208$$$218$$$O	composition$$$219$$$230$$$O	(1)$$$231$$$234$$$O	which$$$235$$$240$$$O	can$$$241$$$244$$$O	be$$$245$$$247$$$O	produced$$$248$$$256$$$O	without$$$257$$$264$$$O	requiring$$$265$$$274$$$O	new$$$275$$$278$$$O	manufacturing$$$279$$$292$$$O	equipment;$$$293$$$303$$$O	(2)$$$304$$$307$$$O	which$$$308$$$313$$$O	can$$$314$$$317$$$O	be$$$318$$$320$$$O	produced$$$321$$$329$$$O	with$$$330$$$334$$$O	simple$$$335$$$341$$$O	steps;$$$342$$$348$$$O	(3)$$$349$$$352$$$O	which$$$353$$$358$$$O	maintains$$$359$$$368$$$O	stable$$$369$$$375$$$O	solubility$$$376$$$386$$$O	even$$$387$$$391$$$O	with$$$392$$$396$$$O	changes$$$397$$$404$$$O	in$$$405$$$407$$$O	the$$$408$$$411$$$O	pH$$$412$$$414$$$O	of$$$415$$$417$$$O	the$$$418$$$421$$$O	gastrointestinal$$$422$$$438$$$O	tract$$$439$$$444$$$O	and$$$445$$$448$$$O	of$$$449$$$451$$$O	which$$$452$$$457$$$O	gastrointestinal$$$458$$$474$$$O	tract$$$475$$$480$$$O	absorption$$$481$$$491$$$O	is$$$492$$$494$$$O	improved.$$$495$$$504$$$O
US7229991
Substituted$$$0$$$11$$$O	5-aminomethyl-1H-pyrrole-2-carboxamides$$$12$$$51$$$I
5-aminomethyl-1H-pyrrole-2-carboxylic$$$0$$$37$$$I	acid$$$38$$$42$$$I	amide$$$43$$$48$$$I	compounds$$$49$$$58$$$O	corresponding$$$59$$$72$$$O	to$$$73$$$75$$$O	formula$$$76$$$83$$$O	I$$$84$$$85$$$O	and$$$105$$$108$$$O	processes$$$109$$$118$$$O	for$$$119$$$122$$$O	the$$$123$$$126$$$O	production$$$127$$$137$$$O	thereof.$$$138$$$146$$$O	Pharmaceutical$$$147$$$161$$$O	preparations$$$162$$$174$$$O	containing$$$175$$$185$$$O	these$$$186$$$191$$$O	compounds$$$192$$$201$$$O	and$$$202$$$205$$$O	the$$$206$$$209$$$O	use$$$210$$$213$$$O	of$$$214$$$216$$$O	these$$$217$$$222$$$O	compounds$$$223$$$232$$$O	for$$$233$$$236$$$O	the$$$237$$$240$$$O	production$$$241$$$251$$$O	of$$$252$$$254$$$O	pharmaceutical$$$255$$$269$$$O	preparations$$$270$$$282$$$O	and$$$283$$$286$$$O	in$$$287$$$289$$$O	related$$$290$$$297$$$O	treatment$$$298$$$307$$$O	methods.$$$308$$$316$$$O
CN101076520B
Imidazoline$$$0$$$11$$$I	derivatives$$$12$$$23$$$O	having$$$24$$$30$$$O	cb1-antagonistic$$$31$$$47$$$O	activity$$$48$$$56$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	1,2,4-tri-substituted$$$33$$$54$$$I	imidazoline$$$55$$$66$$$I	derivatives,$$$67$$$79$$$O	to$$$80$$$82$$$O	methods$$$83$$$90$$$O	for$$$91$$$94$$$O	the$$$95$$$98$$$O	preparation$$$99$$$110$$$O	of$$$111$$$113$$$O	these$$$114$$$119$$$O	compounds,$$$120$$$130$$$O	to$$$131$$$133$$$O	novel$$$134$$$139$$$O	intermediates$$$140$$$153$$$O	useful$$$154$$$160$$$O	for$$$161$$$164$$$O	the$$$165$$$168$$$O	synthesis$$$169$$$178$$$O	of$$$179$$$181$$$O	said$$$182$$$186$$$O	imidazoline$$$187$$$198$$$I	derivatives,$$$199$$$211$$$O	to$$$212$$$214$$$O	methods$$$215$$$222$$$O	for$$$223$$$226$$$O	the$$$227$$$230$$$O	preparation$$$231$$$242$$$O	of$$$243$$$245$$$O	these$$$246$$$251$$$O	intermediates,$$$252$$$266$$$O	to$$$267$$$269$$$O	pharmaceutical$$$270$$$284$$$O	compositions$$$285$$$297$$$O	containing$$$298$$$308$$$O	one$$$309$$$312$$$O	or$$$313$$$315$$$O	more$$$316$$$320$$$O	of$$$321$$$323$$$O	these$$$324$$$329$$$O	imidazoline$$$330$$$341$$$I	derivatives$$$342$$$353$$$O	as$$$354$$$356$$$O	active$$$357$$$363$$$O	ingredient,$$$364$$$375$$$O	as$$$376$$$378$$$O	well$$$379$$$383$$$O	as$$$384$$$386$$$O	to$$$387$$$389$$$O	the$$$390$$$393$$$O	use$$$394$$$397$$$O	of$$$398$$$400$$$O	these$$$401$$$406$$$O	pharmaceutical$$$407$$$421$$$O	compositions$$$422$$$434$$$O	for$$$435$$$438$$$O	the$$$439$$$442$$$O	treatment$$$443$$$452$$$O	of$$$453$$$455$$$O	psychiatric$$$456$$$467$$$O	and$$$468$$$471$$$O	neurological$$$472$$$484$$$O	disorders.$$$485$$$495$$$O	The$$$496$$$499$$$O	compounds$$$500$$$509$$$O	have$$$510$$$514$$$O	the$$$515$$$518$$$O	general$$$519$$$526$$$O	formula$$$527$$$534$$$O	(I)$$$535$$$538$$$O	wherein$$$539$$$546$$$O	the$$$547$$$550$$$O	symbols$$$551$$$558$$$O	have$$$559$$$563$$$O	the$$$564$$$567$$$O	meanings$$$568$$$576$$$O	given$$$577$$$582$$$O	in$$$583$$$585$$$O	the$$$586$$$589$$$O	specification.$$$590$$$604$$$O
US20080032964
Process$$$0$$$7$$$O	for$$$8$$$11$$$O	the$$$12$$$15$$$O	synthesis$$$16$$$25$$$O	of$$$26$$$28$$$O	azetidinone$$$29$$$40$$$I
Provided$$$0$$$8$$$O	are$$$9$$$12$$$O	intermediates$$$13$$$26$$$O	useful$$$27$$$33$$$O	for$$$34$$$37$$$O	the$$$38$$$41$$$O	synthesis$$$42$$$51$$$O	of$$$52$$$54$$$O	hydroxyl-alkyl$$$55$$$69$$$I	substituted$$$70$$$81$$$I	azetidinones,$$$82$$$95$$$I	processes$$$96$$$105$$$O	of$$$106$$$108$$$O	their$$$109$$$114$$$O	preparation,$$$115$$$127$$$O	and$$$128$$$131$$$O	processes$$$132$$$141$$$O	for$$$142$$$145$$$O	the$$$146$$$149$$$O	synthesis$$$150$$$159$$$O	of$$$160$$$162$$$O	certain$$$163$$$170$$$O	hydroxyl-alkyl$$$171$$$185$$$I	substituted$$$186$$$197$$$I	azetidinones.$$$198$$$211$$$I	Also$$$212$$$216$$$O	provided$$$217$$$225$$$O	are$$$226$$$229$$$O	processes$$$230$$$239$$$O	for$$$240$$$243$$$O	the$$$244$$$247$$$O	synthesis$$$248$$$257$$$O	of$$$258$$$260$$$O	1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone,$$$261$$$362$$$I	or$$$363$$$365$$$O	ezetimibe.$$$366$$$376$$$I
WO2007020653A1
Thioether$$$0$$$9$$$I	derivatives$$$10$$$21$$$O	as$$$22$$$24$$$O	functional$$$25$$$35$$$O	5-ht6$$$36$$$41$$$O	ligands$$$42$$$49$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	provides$$$22$$$30$$$O	thioether$$$31$$$40$$$I	derivatives$$$41$$$52$$$O	of$$$53$$$55$$$O	formula$$$56$$$63$$$O	(I),$$$64$$$68$$$O	useful$$$69$$$75$$$O	in$$$76$$$78$$$O	treatment$$$79$$$88$$$O	of$$$89$$$91$$$O	a$$$92$$$93$$$O	CNS$$$94$$$97$$$O	disorder$$$98$$$106$$$O	related$$$107$$$114$$$O	to$$$115$$$117$$$O	or$$$118$$$120$$$O	affected$$$121$$$129$$$O	by$$$130$$$132$$$O	the$$$133$$$136$$$O	5-HT6$$$137$$$142$$$O	receptor.$$$143$$$152$$$O	Pharmacological$$$153$$$168$$$O	profile$$$169$$$176$$$O	of$$$177$$$179$$$O	these$$$180$$$185$$$O	compounds$$$186$$$195$$$O	includes$$$196$$$204$$$O	high$$$205$$$209$$$O	affinity$$$210$$$218$$$O	binding$$$219$$$226$$$O	with$$$227$$$231$$$O	5-HT6$$$232$$$237$$$O	receptor$$$238$$$246$$$O	along$$$247$$$252$$$O	with$$$253$$$257$$$O	selectivity$$$258$$$269$$$O	towards$$$270$$$277$$$O	the$$$278$$$281$$$O	said$$$282$$$286$$$O	receptor.$$$287$$$296$$$O	The$$$297$$$300$$$O	present$$$301$$$308$$$O	invention$$$309$$$318$$$O	also$$$319$$$323$$$O	includes$$$324$$$332$$$O	the$$$333$$$336$$$O	stereoisomers,$$$337$$$351$$$O	the$$$352$$$355$$$O	salts,$$$356$$$362$$$O	methods$$$363$$$370$$$O	of$$$371$$$373$$$O	preparation$$$374$$$385$$$O	and$$$386$$$389$$$O	medicine$$$390$$$398$$$O	containing$$$399$$$409$$$O	the$$$410$$$413$$$O	said$$$414$$$418$$$O	thioether$$$419$$$428$$$I	derivatives.$$$429$$$441$$$O
CN101530426A
Kazakstan$$$0$$$9$$$O	skeleton$$$10$$$18$$$O	softening$$$19$$$28$$$O	medicine$$$29$$$37$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	kazakstan$$$24$$$33$$$O	skeleton$$$34$$$42$$$O	softening$$$43$$$52$$$O	medicine,$$$53$$$62$$$O	which$$$63$$$68$$$O	is$$$69$$$71$$$O	prepared$$$72$$$80$$$O	by$$$81$$$83$$$O	horse$$$84$$$89$$$O	flesh$$$90$$$95$$$O	oil$$$96$$$99$$$O	and$$$100$$$103$$$O	panela$$$104$$$110$$$O	according$$$111$$$120$$$O	to$$$121$$$123$$$O	certain$$$124$$$131$$$O	weight$$$132$$$138$$$O	ratio.$$$139$$$145$$$O	The$$$146$$$149$$$O	medicine$$$150$$$158$$$O	can$$$159$$$162$$$O	be$$$163$$$165$$$O	prepared$$$166$$$174$$$O	into$$$175$$$179$$$O	paste$$$180$$$185$$$O	for$$$186$$$189$$$O	external$$$190$$$198$$$O	use,$$$199$$$203$$$O	which$$$204$$$209$$$O	has$$$210$$$213$$$O	the$$$214$$$217$$$O	function$$$218$$$226$$$O	of$$$227$$$229$$$O	softening$$$230$$$239$$$O	skeleton,$$$240$$$249$$$O	relieving$$$250$$$259$$$O	the$$$260$$$263$$$O	pain$$$264$$$268$$$O	of$$$269$$$271$$$O	users,$$$272$$$278$$$O	having$$$279$$$285$$$O	no$$$286$$$288$$$O	toxic$$$289$$$294$$$O	side$$$295$$$299$$$O	effect$$$300$$$306$$$O	and$$$307$$$310$$$O	being$$$311$$$316$$$O	effective$$$317$$$326$$$O	in$$$327$$$329$$$O	treatment.$$$330$$$340$$$O
US20100286207
Novel$$$0$$$5$$$O	2-Oxo-Heterocyclic$$$6$$$24$$$I	Compounds$$$25$$$34$$$O	And$$$35$$$38$$$O	The$$$39$$$42$$$O	Pharmaceutical$$$43$$$57$$$O	Compositions$$$58$$$70$$$O	Comprising$$$71$$$81$$$O	The$$$82$$$85$$$O	Same$$$86$$$90$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	is$$$22$$$24$$$O	related$$$25$$$32$$$O	to$$$33$$$35$$$O	new$$$36$$$39$$$O	2-oxo-cyclic$$$40$$$52$$$I	compound,$$$53$$$62$$$O	the$$$63$$$66$$$O	process$$$67$$$74$$$O	for$$$75$$$78$$$O	preparing$$$79$$$88$$$O	them$$$89$$$93$$$O	and$$$94$$$97$$$O	a$$$98$$$99$$$O	pharmaceutical$$$100$$$114$$$O	composition$$$115$$$126$$$O	comprising$$$127$$$137$$$O	the$$$138$$$141$$$O	same.$$$142$$$147$$$O	The$$$148$$$151$$$O	present$$$152$$$159$$$O	invention$$$160$$$169$$$O	provides$$$170$$$178$$$O	a$$$179$$$180$$$O	pharmaceutical$$$181$$$195$$$O	composition$$$196$$$207$$$O	for$$$208$$$211$$$O	preventing$$$212$$$222$$$O	and$$$223$$$226$$$O	treating$$$227$$$235$$$O	the$$$236$$$239$$$O	inflammatory$$$240$$$252$$$O	disease$$$253$$$260$$$O	comprising$$$261$$$271$$$O	the$$$272$$$275$$$O	pain$$$276$$$280$$$O	or$$$281$$$283$$$O	inflammation$$$284$$$296$$$O	caused$$$297$$$303$$$O	by$$$304$$$306$$$O	rheumatic$$$307$$$316$$$O	disease,$$$317$$$325$$$O	for$$$326$$$329$$$O	example,$$$330$$$338$$$O	rheumatoid$$$339$$$349$$$O	arthritis,$$$350$$$360$$$O	spondyloarthopathies,$$$361$$$382$$$O	gout,$$$383$$$388$$$O	osteoarthritis,$$$389$$$404$$$O	systemic$$$405$$$413$$$O	lupus$$$414$$$419$$$O	erythematosus$$$420$$$433$$$O	and$$$434$$$437$$$O	juvenile$$$438$$$446$$$O	arthritis,$$$447$$$457$$$O	and$$$458$$$461$$$O	inflammatory$$$462$$$474$$$O	syndrome$$$475$$$483$$$O	for$$$484$$$487$$$O	example,$$$488$$$496$$$O	from$$$497$$$501$$$O	myositis,$$$502$$$511$$$O	gingivitis,$$$512$$$523$$$O	synovitis,$$$524$$$534$$$O	ankylosing$$$535$$$545$$$O	spondylitis,$$$546$$$558$$$O	burstitis,$$$559$$$569$$$O	burns$$$570$$$575$$$O	and$$$576$$$579$$$O	scar,$$$580$$$585$$$O	inflammatory$$$586$$$598$$$O	Crohn's$$$599$$$606$$$O	disease,$$$607$$$615$$$O	Types$$$616$$$621$$$O	I$$$622$$$623$$$O	diabetes.$$$624$$$633$$$O	therefore,$$$634$$$644$$$O	it$$$645$$$647$$$O	can$$$648$$$651$$$O	be$$$652$$$654$$$O	used$$$655$$$659$$$O	as$$$660$$$662$$$O	the$$$663$$$666$$$O	therapeutics$$$667$$$679$$$O	for$$$680$$$683$$$O	treating$$$684$$$692$$$O	and$$$693$$$696$$$O	preventing$$$697$$$707$$$O	inflammatory$$$708$$$720$$$O	diseases.$$$721$$$730$$$O
EP1469809B1
Multiple$$$0$$$8$$$O	acting$$$9$$$15$$$O	anti-angiogenic$$$16$$$31$$$O	and$$$32$$$35$$$O	cytotoxic$$$36$$$45$$$O	compounds$$$46$$$55$$$O	and$$$56$$$59$$$O	methods$$$60$$$67$$$O	for$$$68$$$71$$$O	using$$$72$$$77$$$O	the$$$78$$$81$$$O	same$$$82$$$86$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	discloses$$$15$$$24$$$O	pyrimidine$$$25$$$35$$$I	compounds,$$$36$$$46$$$O	and$$$47$$$50$$$O	pharmaceutically$$$51$$$67$$$O	acceptable$$$68$$$78$$$O	salts,$$$79$$$85$$$O	solvates$$$86$$$94$$$O	and$$$95$$$98$$$O	prodrugs$$$99$$$107$$$O	thereof,$$$108$$$116$$$O	useful$$$117$$$123$$$O	in$$$124$$$126$$$O	therapeutically$$$127$$$142$$$O	and/or$$$143$$$149$$$O	prophylactically$$$150$$$166$$$O	treating$$$167$$$175$$$O	patients$$$176$$$184$$$O	with$$$185$$$189$$$O	cancer$$$190$$$196$$$O	by$$$197$$$199$$$O	inhibiting$$$200$$$210$$$O	receptor$$$211$$$219$$$O	tyrosine$$$220$$$228$$$I	kinases$$$229$$$236$$$O	and/or$$$237$$$243$$$O	dihydrofolate$$$244$$$257$$$I	reductase$$$258$$$267$$$O	and/or$$$268$$$274$$$O	thymidylate$$$275$$$286$$$I	synthase.$$$287$$$296$$$O	The$$$297$$$300$$$O	compounds,$$$301$$$311$$$O	and$$$312$$$315$$$O	methods$$$316$$$323$$$O	of$$$324$$$326$$$O	using$$$327$$$332$$$O	these$$$333$$$338$$$O	compounds,$$$339$$$349$$$O	are$$$350$$$353$$$O	disclosed.$$$354$$$364$$$O
CA2210022C
Paroxetine$$$0$$$10$$$I	hydrochloride$$$11$$$24$$$I	solvates$$$25$$$33$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	paroxetine$$$33$$$43$$$I	hydrochloride$$$44$$$57$$$I	anhydrate$$$58$$$67$$$I	(see$$$68$$$72$$$O	formula$$$73$$$80$$$O	I)$$$81$$$83$$$O	substantially$$$84$$$97$$$O	free$$$98$$$102$$$O	of$$$103$$$105$$$O	bound$$$106$$$111$$$O	propan$$$112$$$118$$$I	2-ol,$$$119$$$124$$$I	several$$$125$$$132$$$O	forms$$$133$$$138$$$O	of$$$139$$$141$$$O	the$$$142$$$145$$$O	above,$$$146$$$152$$$O	processes$$$153$$$162$$$O	for$$$163$$$166$$$O	preparing$$$167$$$176$$$O	the$$$177$$$180$$$O	above,$$$181$$$187$$$O	new$$$188$$$191$$$O	intermediates$$$192$$$205$$$O	useful$$$206$$$212$$$O	in$$$213$$$215$$$O	preparing$$$216$$$225$$$O	the$$$226$$$229$$$O	above$$$230$$$235$$$O	and$$$236$$$239$$$O	methods$$$240$$$247$$$O	of$$$248$$$250$$$O	treating$$$251$$$259$$$O	and/or$$$260$$$266$$$O	preventing$$$267$$$277$$$O	certain$$$278$$$285$$$O	diseases$$$286$$$294$$$O	by$$$295$$$297$$$O	administering$$$298$$$311$$$O	the$$$312$$$315$$$O	compounds$$$316$$$325$$$O	of$$$326$$$328$$$O	the$$$329$$$332$$$O	invention$$$333$$$342$$$O	to$$$343$$$345$$$O	a$$$346$$$347$$$O	sufferer$$$348$$$356$$$O	in$$$357$$$359$$$O	need$$$360$$$364$$$O	thereof.$$$365$$$373$$$O
US20060269613
Composition$$$0$$$11$$$O	containing$$$12$$$22$$$O	nanoparticles$$$23$$$36$$$O	containing$$$37$$$47$$$O	water-soluble$$$48$$$61$$$O	basic$$$62$$$67$$$O	drug$$$68$$$72$$$O	encpsulated$$$73$$$84$$$O	therein$$$85$$$92$$$O
A$$$0$$$1$$$O	drug$$$2$$$6$$$O	and$$$7$$$10$$$O	a$$$11$$$12$$$O	biodegradable$$$13$$$26$$$O	polymer$$$27$$$34$$$O	having$$$35$$$41$$$O	at$$$42$$$44$$$O	least$$$45$$$50$$$O	one$$$51$$$54$$$O	carboxyl$$$55$$$63$$$I	group$$$64$$$69$$$O	are$$$70$$$73$$$O	encapsulated$$$74$$$86$$$O	into$$$87$$$91$$$O	nanoparticle$$$92$$$104$$$O	which$$$105$$$110$$$O	is$$$111$$$113$$$O	formed$$$114$$$120$$$O	by$$$121$$$123$$$O	a$$$124$$$125$$$O	block$$$126$$$131$$$O	copolymer$$$132$$$141$$$O	having$$$142$$$148$$$O	a$$$149$$$150$$$O	hydrophilic$$$151$$$162$$$O	segment$$$163$$$170$$$O	and$$$171$$$174$$$O	a$$$175$$$176$$$O	hydrophobic$$$177$$$188$$$O	segment.$$$189$$$197$$$O	This$$$198$$$202$$$O	invention$$$203$$$212$$$O	thus$$$213$$$217$$$O	provides$$$218$$$226$$$O	a$$$227$$$228$$$O	drug-encapsulated$$$229$$$246$$$O	nanoparticle$$$247$$$259$$$O	which$$$260$$$265$$$O	shows$$$266$$$271$$$O	an$$$272$$$274$$$O	increased$$$275$$$284$$$O	in$$$285$$$287$$$O	vivo$$$288$$$292$$$O	drug-stability.$$$293$$$308$$$O
US20120035254
Inhibitor$$$0$$$9$$$O	for$$$10$$$13$$$O	elevation$$$14$$$23$$$O	of$$$24$$$26$$$O	gip$$$27$$$30$$$O	level$$$31$$$36$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	GIP-increase$$$14$$$26$$$O	inhibitor,$$$27$$$37$$$O	which$$$38$$$43$$$O	is$$$44$$$46$$$O	customary$$$47$$$56$$$O	used$$$57$$$61$$$O	for$$$62$$$65$$$O	food$$$66$$$70$$$O	production,$$$71$$$82$$$O	is$$$83$$$85$$$O	excellent$$$86$$$95$$$O	in$$$96$$$98$$$O	safety,$$$99$$$106$$$O	and$$$107$$$110$$$O	is$$$111$$$113$$$O	useful$$$114$$$120$$$O	for,$$$121$$$125$$$O	for$$$126$$$129$$$O	example,$$$130$$$138$$$O	a$$$139$$$140$$$O	medicine$$$141$$$149$$$O	or$$$150$$$152$$$O	a$$$153$$$154$$$O	food.$$$155$$$160$$$O	The$$$161$$$164$$$O	GIP-increase$$$165$$$177$$$O	inhibitor$$$178$$$187$$$O	contains$$$188$$$196$$$O	catechins$$$197$$$206$$$I	as$$$207$$$209$$$O	active$$$210$$$216$$$O	ingredient.$$$217$$$228$$$O
CN102151257A
Busulfan$$$0$$$8$$$I	injection$$$9$$$18$$$O	and$$$19$$$22$$$O	preparation$$$23$$$34$$$O	method$$$35$$$41$$$O	thereof$$$42$$$49$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	a$$$23$$$24$$$O	busulfan$$$25$$$33$$$I	injection.$$$34$$$44$$$O	Busulfan$$$45$$$53$$$I	is$$$54$$$56$$$O	dissolved$$$57$$$66$$$O	in$$$67$$$69$$$O	a$$$70$$$71$$$O	mixed$$$72$$$77$$$O	solvent$$$78$$$85$$$O	of$$$86$$$88$$$O	N,N-dimethyl$$$89$$$101$$$I	acetamide$$$102$$$111$$$I	with$$$112$$$116$$$O	a$$$117$$$118$$$O	volume$$$119$$$125$$$O	ratio$$$126$$$131$$$O	of$$$132$$$134$$$O	33%$$$135$$$138$$$O	and$$$139$$$142$$$O	polyethylene$$$143$$$155$$$I	glycol$$$156$$$162$$$I	400$$$163$$$166$$$I	with$$$167$$$171$$$O	a$$$172$$$173$$$O	volume$$$174$$$180$$$O	ratio$$$181$$$186$$$O	of$$$187$$$189$$$O	67%,$$$190$$$194$$$O	wherein$$$195$$$202$$$O	the$$$203$$$206$$$O	concentration$$$207$$$220$$$O	of$$$221$$$223$$$O	the$$$224$$$227$$$O	busulfan$$$228$$$236$$$I	is$$$237$$$239$$$O	6mg/ml,$$$240$$$247$$$O	and$$$248$$$251$$$O	the$$$252$$$255$$$O	mixed$$$256$$$261$$$O	solvent$$$262$$$269$$$O	contains$$$270$$$278$$$O	organic$$$279$$$286$$$O	acid$$$287$$$291$$$O	and$$$292$$$295$$$O	alkali$$$296$$$302$$$O	metal$$$303$$$308$$$O	or$$$309$$$311$$$O	alkaline$$$312$$$320$$$O	earth$$$321$$$326$$$I	metal$$$327$$$332$$$I	salt$$$333$$$337$$$O	of$$$338$$$340$$$O	organic$$$341$$$348$$$O	acid,$$$349$$$354$$$O	which$$$355$$$360$$$O	account$$$361$$$368$$$O	for$$$369$$$372$$$O	0.01-5%w/v$$$373$$$383$$$O	of$$$384$$$386$$$O	the$$$387$$$390$$$O	total$$$391$$$396$$$O	amount$$$397$$$403$$$O	of$$$404$$$406$$$O	the$$$407$$$410$$$O	mixed$$$411$$$416$$$O	solvent;$$$417$$$425$$$O	and$$$426$$$429$$$O	the$$$430$$$433$$$O	organic$$$434$$$441$$$O	acid$$$442$$$446$$$O	contains$$$447$$$455$$$O	more$$$456$$$460$$$O	than$$$461$$$465$$$O	two$$$466$$$469$$$O	carboxyl$$$470$$$478$$$I	groups.$$$479$$$486$$$O	The$$$487$$$490$$$O	stability$$$491$$$500$$$O	of$$$501$$$503$$$O	main$$$504$$$508$$$O	constituents$$$509$$$521$$$O	of$$$522$$$524$$$O	the$$$525$$$528$$$O	busulfan$$$529$$$537$$$I	injection$$$538$$$547$$$O	provided$$$548$$$556$$$O	by$$$557$$$559$$$O	the$$$560$$$563$$$O	invention$$$564$$$573$$$O	can$$$574$$$577$$$O	be$$$578$$$580$$$O	improved$$$581$$$589$$$O	remarkably$$$590$$$600$$$O	so$$$601$$$603$$$O	that$$$604$$$608$$$O	the$$$609$$$612$$$O	quality$$$613$$$620$$$O	guarantee$$$621$$$630$$$O	period$$$631$$$637$$$O	of$$$638$$$640$$$O	products$$$641$$$649$$$O	is$$$650$$$652$$$O	prolonged$$$653$$$662$$$O	to$$$663$$$665$$$O	more$$$666$$$670$$$O	than$$$671$$$675$$$O	24$$$676$$$678$$$O	months;$$$679$$$686$$$O	and$$$687$$$690$$$O	various$$$691$$$698$$$O	indices$$$699$$$706$$$O	(such$$$707$$$712$$$O	as$$$713$$$715$$$O	appearance,$$$716$$$727$$$O	content$$$728$$$735$$$O	of$$$736$$$738$$$O	tetrahydrofuran,$$$739$$$755$$$I	content$$$756$$$763$$$O	of$$$764$$$766$$$O	main$$$767$$$771$$$O	constituents,$$$772$$$785$$$O	content$$$786$$$793$$$O	of$$$794$$$796$$$O	impurities,$$$797$$$808$$$O	endotoxin,$$$809$$$819$$$O	sterility$$$820$$$829$$$O	test$$$830$$$834$$$O	and$$$835$$$838$$$O	the$$$839$$$842$$$O	like)$$$843$$$848$$$O	conform$$$849$$$856$$$O	to$$$857$$$859$$$O	the$$$860$$$863$$$O	requirement$$$864$$$875$$$O	of$$$876$$$878$$$O	the$$$879$$$882$$$O	quality$$$883$$$890$$$O	standard.$$$891$$$900$$$O	The$$$901$$$904$$$O	active$$$905$$$911$$$O	constituents$$$912$$$924$$$O	and$$$925$$$928$$$O	the$$$929$$$932$$$O	auxiliary$$$933$$$942$$$O	materials$$$943$$$952$$$O	of$$$953$$$955$$$O	the$$$956$$$959$$$O	injection$$$960$$$969$$$O	provided$$$970$$$978$$$O	by$$$979$$$981$$$O	the$$$982$$$985$$$O	invention$$$986$$$995$$$O	have$$$996$$$1000$$$O	no$$$1001$$$1003$$$O	injection$$$1004$$$1013$$$O	stimulation,$$$1014$$$1026$$$O	and$$$1027$$$1030$$$O	the$$$1031$$$1034$$$O	injection$$$1035$$$1044$$$O	can$$$1045$$$1048$$$O	be$$$1049$$$1051$$$O	used$$$1052$$$1056$$$O	for$$$1057$$$1060$$$O	clinical$$$1061$$$1069$$$O	injection$$$1070$$$1079$$$O	and$$$1080$$$1083$$$O	can$$$1084$$$1087$$$O	ensure$$$1088$$$1094$$$O	that$$$1095$$$1099$$$O	the$$$1100$$$1103$$$O	medication$$$1104$$$1114$$$O	safety$$$1115$$$1121$$$O	cannot$$$1122$$$1128$$$O	be$$$1129$$$1131$$$O	lowered$$$1132$$$1139$$$O	while$$$1140$$$1145$$$O	the$$$1146$$$1149$$$O	stability$$$1150$$$1159$$$O	of$$$1160$$$1162$$$O	products$$$1163$$$1171$$$O	is$$$1172$$$1174$$$O	improved.$$$1175$$$1184$$$O
EP1569915A2
Spirocyclic$$$0$$$11$$$I	ureas,$$$12$$$18$$$I	compositions$$$19$$$31$$$O	containing$$$32$$$42$$$O	such$$$43$$$47$$$O	compounds$$$48$$$57$$$O	and$$$58$$$61$$$O	methods$$$62$$$69$$$O	of$$$70$$$72$$$O	use$$$73$$$76$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	spirocyclic$$$33$$$44$$$I	ureas,$$$45$$$51$$$I	compositions$$$52$$$64$$$O	containing$$$65$$$75$$$O	such$$$76$$$80$$$O	compounds$$$81$$$90$$$O	and$$$91$$$94$$$O	methods$$$95$$$102$$$O	of$$$103$$$105$$$O	treatment$$$106$$$115$$$O	The$$$116$$$119$$$O	compounds$$$120$$$129$$$O	are$$$130$$$133$$$O	glucagon$$$134$$$142$$$O	receptor$$$143$$$151$$$O	antagonists$$$152$$$163$$$O	and$$$164$$$167$$$O	thus$$$168$$$172$$$O	are$$$173$$$176$$$O	useful$$$177$$$183$$$O	for$$$184$$$187$$$O	treating,$$$188$$$197$$$O	preventing$$$198$$$208$$$O	or$$$209$$$211$$$O	delaying$$$212$$$220$$$O	the$$$221$$$224$$$O	onset$$$225$$$230$$$O	of$$$231$$$233$$$O	type$$$234$$$238$$$O	2$$$239$$$240$$$O	diabetes$$$241$$$249$$$O	mellitus.$$$250$$$259$$$O
EP1562617B1
New$$$0$$$3$$$O	use$$$4$$$7$$$O	of$$$8$$$10$$$O	pipataline$$$11$$$21$$$I
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	a$$$33$$$34$$$O	method$$$35$$$41$$$O	for$$$42$$$45$$$O	providing$$$46$$$55$$$O	alpha$$$56$$$61$$$O	-glucosidase$$$62$$$74$$$O	inhibition$$$75$$$85$$$O	to$$$86$$$88$$$O	a$$$89$$$90$$$O	subject$$$91$$$98$$$O	by$$$99$$$101$$$O	administering$$$102$$$115$$$O	a$$$116$$$117$$$O	pharmaceutical$$$118$$$132$$$O	composition$$$133$$$144$$$O	comprising$$$145$$$155$$$O	a$$$156$$$157$$$O	alpha$$$158$$$163$$$O	-glucosidase$$$164$$$176$$$O	inhibitory$$$177$$$187$$$O	agent$$$188$$$193$$$O	selected$$$194$$$202$$$O	from$$$203$$$207$$$O	pipataline$$$208$$$218$$$I	(formula$$$219$$$227$$$O	1a),$$$228$$$232$$$O	sesamin$$$233$$$240$$$I	(formula$$$241$$$249$$$O	1b),$$$250$$$254$$$O	pellitorine$$$255$$$266$$$I	(Formula$$$267$$$275$$$O	1c),$$$276$$$280$$$O	guineensine$$$281$$$292$$$I	(Formula$$$293$$$301$$$O	1d)$$$302$$$305$$$O	and$$$306$$$309$$$O	brachystamide-B$$$310$$$325$$$I	(formula$$$326$$$334$$$O	1e)$$$335$$$338$$$O	having$$$339$$$345$$$O	therapeutic$$$346$$$357$$$O	application$$$358$$$369$$$O	for$$$370$$$373$$$O	diabetes$$$374$$$382$$$O	mellitus,$$$383$$$392$$$O	cancer,$$$393$$$400$$$O	viral$$$401$$$406$$$O	diseases$$$407$$$415$$$O	such$$$416$$$420$$$O	as$$$421$$$423$$$O	hepatitis$$$424$$$433$$$O	B$$$434$$$435$$$O	and$$$436$$$439$$$O	C,$$$440$$$442$$$O	HIV,$$$443$$$447$$$O	AIDS$$$448$$$452$$$O	etc;$$$453$$$457$$$O	also$$$458$$$462$$$O	the$$$463$$$466$$$O	invention$$$467$$$476$$$O	provides$$$477$$$485$$$O	a$$$486$$$487$$$O	process$$$488$$$495$$$O	for$$$496$$$499$$$O	the$$$500$$$503$$$O	isolation$$$504$$$513$$$O	of$$$514$$$516$$$O	said$$$517$$$521$$$O	alpha$$$522$$$527$$$O	-glucosidase$$$528$$$540$$$O	inhibitory$$$541$$$551$$$O	agent$$$552$$$557$$$O	from$$$558$$$562$$$O	the$$$563$$$566$$$O	plant$$$567$$$572$$$O	source$$$573$$$579$$$O	Piper$$$580$$$585$$$O	longum$$$586$$$592$$$O	in$$$593$$$595$$$O	significant$$$596$$$607$$$O	yields.$$$608$$$615$$$O
CN101810605A
Salvianic$$$0$$$9$$$I	acid$$$10$$$14$$$I	A$$$15$$$16$$$I	pharmaceutical$$$17$$$31$$$O	composition$$$32$$$43$$$O	and$$$44$$$47$$$O	preparation$$$48$$$59$$$O	method$$$60$$$66$$$O	thereof$$$67$$$74$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	salvianic$$$27$$$36$$$I	acid$$$37$$$41$$$I	A$$$42$$$43$$$I	pharmaceutical$$$44$$$58$$$O	composition$$$59$$$70$$$O	and$$$71$$$74$$$O	a$$$75$$$76$$$O	preparation$$$77$$$88$$$O	method$$$89$$$95$$$O	thereof.$$$96$$$104$$$O	Salvianic$$$105$$$114$$$I	acid$$$115$$$119$$$I	A$$$120$$$121$$$I	can$$$122$$$125$$$O	be$$$126$$$128$$$O	dissolved$$$129$$$138$$$O	in$$$139$$$141$$$O	water,$$$142$$$148$$$O	but$$$149$$$152$$$O	the$$$153$$$156$$$O	preparation$$$157$$$168$$$O	of$$$169$$$171$$$O	the$$$172$$$175$$$O	salvianic$$$176$$$185$$$I	acid$$$186$$$190$$$I	A$$$191$$$192$$$I	has$$$193$$$196$$$O	poor$$$197$$$201$$$O	stability,$$$202$$$212$$$O	is$$$213$$$215$$$O	easy$$$216$$$220$$$O	for$$$221$$$224$$$O	oxidization,$$$225$$$237$$$O	is$$$238$$$240$$$O	sensitive$$$241$$$250$$$O	to$$$251$$$253$$$O	light$$$254$$$259$$$O	and$$$260$$$263$$$O	heat,$$$264$$$269$$$O	and$$$270$$$273$$$O	causes$$$274$$$280$$$O	content$$$281$$$288$$$O	reduction$$$289$$$298$$$O	and$$$299$$$302$$$O	impurity$$$303$$$311$$$O	increase,$$$312$$$321$$$O	and$$$322$$$325$$$O	the$$$326$$$329$$$O	guarantee$$$330$$$339$$$O	on$$$340$$$342$$$O	the$$$343$$$346$$$O	stability$$$347$$$356$$$O	is$$$357$$$359$$$O	a$$$360$$$361$$$O	technical$$$362$$$371$$$O	problem.$$$372$$$380$$$O	The$$$381$$$384$$$O	salvianic$$$385$$$394$$$I	acid$$$395$$$399$$$I	A$$$400$$$401$$$I	pharmaceutical$$$402$$$416$$$O	composition$$$417$$$428$$$O	comprises$$$429$$$438$$$O	the$$$439$$$442$$$O	salvianic$$$443$$$452$$$I	acid$$$453$$$457$$$I	A,$$$458$$$460$$$I	a$$$461$$$462$$$O	pharmacological$$$463$$$478$$$O	allowable$$$479$$$488$$$O	pH$$$489$$$491$$$O	adjusting$$$492$$$501$$$O	substance,$$$502$$$512$$$O	a$$$513$$$514$$$O	stabilizing$$$515$$$526$$$O	agent$$$527$$$532$$$O	and$$$533$$$536$$$O	an$$$537$$$539$$$O	excipient.$$$540$$$550$$$O	The$$$551$$$554$$$O	salvianic$$$555$$$564$$$I	acid$$$565$$$569$$$I	A$$$570$$$571$$$I	in$$$572$$$574$$$O	the$$$575$$$578$$$O	salvianic$$$579$$$588$$$I	acid$$$589$$$593$$$I	A$$$594$$$595$$$I	pharmaceutical$$$596$$$610$$$O	composition$$$611$$$622$$$O	has$$$623$$$626$$$O	the$$$627$$$630$$$O	concentration$$$631$$$644$$$O	of$$$645$$$647$$$O	0.5-2,000mg.$$$648$$$660$$$O	The$$$661$$$664$$$O	weight$$$665$$$671$$$O	part$$$672$$$676$$$O	of$$$677$$$679$$$O	the$$$680$$$683$$$O	pH$$$684$$$686$$$O	adjusting$$$687$$$696$$$O	substance$$$697$$$706$$$O	is$$$707$$$709$$$O	the$$$710$$$713$$$O	adding$$$714$$$720$$$O	dosage$$$721$$$727$$$O	when$$$728$$$732$$$O	a$$$733$$$734$$$O	pH$$$735$$$737$$$O	value$$$738$$$743$$$O	is$$$744$$$746$$$O	adjusted$$$747$$$755$$$O	to$$$756$$$758$$$O	2.5-7.5,$$$759$$$767$$$O	and$$$768$$$771$$$O	the$$$772$$$775$$$O	stabilizing$$$776$$$787$$$O	agent$$$788$$$793$$$O	in$$$794$$$796$$$O	the$$$797$$$800$$$O	salvianic$$$801$$$810$$$I	acid$$$811$$$815$$$I	A$$$816$$$817$$$I	pharmaceutical$$$818$$$832$$$O	composition$$$833$$$844$$$O	has$$$845$$$848$$$O	the$$$849$$$852$$$O	concentration$$$853$$$866$$$O	of$$$867$$$869$$$O	1mg-0.5g.$$$870$$$879$$$O	The$$$880$$$883$$$O	salvianic$$$884$$$893$$$I	acid$$$894$$$898$$$I	A$$$899$$$900$$$I	pharmaceutical$$$901$$$915$$$O	composition$$$916$$$927$$$O	is$$$928$$$930$$$O	used$$$931$$$935$$$O	as$$$936$$$938$$$O	an$$$939$$$941$$$O	injection$$$942$$$951$$$O	with$$$952$$$956$$$O	the$$$957$$$960$$$O	effects$$$961$$$968$$$O	of$$$969$$$971$$$O	protecting$$$972$$$982$$$O	the$$$983$$$986$$$O	cardiac$$$987$$$994$$$O	muscle,$$$995$$$1002$$$O	promoting$$$1003$$$1012$$$O	blood$$$1013$$$1018$$$O	circulation,$$$1019$$$1031$$$O	removing$$$1032$$$1040$$$O	blood$$$1041$$$1046$$$O	stasis,$$$1047$$$1054$$$O	resisting$$$1055$$$1064$$$O	bacteria,$$$1065$$$1074$$$O	eliminating$$$1075$$$1086$$$O	inflammation,$$$1087$$$1100$$$O	strengthening$$$1101$$$1114$$$O	body$$$1115$$$1119$$$O	immunity,$$$1120$$$1129$$$O	resisting$$$1130$$$1139$$$O	atherosclerosis,$$$1140$$$1156$$$O	reducing$$$1157$$$1165$$$O	blood$$$1166$$$1171$$$O	fat,$$$1172$$$1176$$$O	resisting$$$1177$$$1186$$$O	platelet$$$1187$$$1195$$$O	aggregation,$$$1196$$$1208$$$O	resisting$$$1209$$$1218$$$O	thrombosis,$$$1219$$$1230$$$O	expanding$$$1231$$$1240$$$O	the$$$1241$$$1244$$$O	coronary$$$1245$$$1253$$$O	artery,$$$1254$$$1261$$$O	treating$$$1262$$$1270$$$O	liver$$$1271$$$1276$$$O	injury,$$$1277$$$1284$$$O	resisting$$$1285$$$1294$$$O	cerebral$$$1295$$$1303$$$O	ischemia$$$1304$$$1312$$$O	injury,$$$1313$$$1320$$$O	resisting$$$1321$$$1330$$$O	tumors,$$$1331$$$1338$$$O	and$$$1339$$$1342$$$O	the$$$1343$$$1346$$$O	like$$$1347$$$1351$$$O	and$$$1352$$$1355$$$O	a$$$1356$$$1357$$$O	therapeutical$$$1358$$$1371$$$O	effect$$$1372$$$1378$$$O	on$$$1379$$$1381$$$O	pulmonary$$$1382$$$1391$$$O	heart$$$1392$$$1397$$$O	disease,$$$1398$$$1406$$$O	psoriasis,$$$1407$$$1417$$$O	altitude$$$1418$$$1426$$$O	disease,$$$1427$$$1435$$$O	and$$$1436$$$1439$$$O	the$$$1440$$$1443$$$O	like.$$$1444$$$1449$$$O
WO2007012479A3
Benzylpiperazine$$$0$$$16$$$I	derivates$$$17$$$26$$$O	and$$$27$$$30$$$O	their$$$31$$$36$$$O	medical$$$37$$$44$$$O	use$$$45$$$48$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	relates$$$22$$$29$$$O	to$$$30$$$32$$$O	benzylpiperazine$$$33$$$49$$$I	derivatives$$$50$$$61$$$O	such$$$62$$$66$$$O	as$$$67$$$69$$$O	compounds$$$70$$$79$$$O	of$$$80$$$82$$$O	formula$$$83$$$90$$$O	(I),$$$91$$$95$$$O	which$$$96$$$101$$$O	have$$$102$$$106$$$O	activity$$$107$$$115$$$O	as$$$116$$$118$$$O	agonists$$$119$$$127$$$O	of$$$128$$$130$$$O	the$$$131$$$134$$$O	GPR38$$$135$$$140$$$O	receptor$$$141$$$149$$$O	and$$$150$$$153$$$O	the$$$154$$$157$$$O	use$$$158$$$161$$$O	of$$$162$$$164$$$O	such$$$165$$$169$$$O	compounds$$$170$$$179$$$O	or$$$180$$$182$$$O	pharmaceutical$$$183$$$197$$$O	compositions$$$198$$$210$$$O	thereof$$$211$$$218$$$O	in$$$219$$$221$$$O	the$$$222$$$225$$$O	preparation$$$226$$$237$$$O	of$$$238$$$240$$$O	medicaments$$$241$$$252$$$O	suitable$$$253$$$261$$$O	for$$$262$$$265$$$O	the$$$266$$$269$$$O	treatment$$$270$$$279$$$O	of$$$280$$$282$$$O	gastrointestinal$$$283$$$299$$$O	disorders.$$$300$$$310$$$O
US7820717
4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide;$$$0$$$66$$$I	inflammatory$$$67$$$79$$$O	bowl$$$80$$$84$$$O	disease$$$85$$$92$$$O	such$$$93$$$97$$$O	as$$$98$$$100$$$O	Crohn's$$$101$$$108$$$O	disease$$$109$$$116$$$O	or$$$117$$$119$$$O	Colitis$$$120$$$127$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	compounds$$$25$$$34$$$O	represented$$$35$$$46$$$O	by$$$47$$$49$$$O	Structural$$$50$$$60$$$O	Formula$$$61$$$68$$$O	I,$$$69$$$71$$$O	which$$$72$$$77$$$O	can$$$78$$$81$$$O	bind$$$82$$$86$$$O	to$$$87$$$89$$$O	CCR9$$$90$$$94$$$O	receptors$$$95$$$104$$$O	and$$$105$$$108$$$O	block$$$109$$$114$$$O	the$$$115$$$118$$$O	binding$$$119$$$126$$$O	of$$$127$$$129$$$O	a$$$130$$$131$$$O	ligand$$$132$$$138$$$O	(e.g.,$$$139$$$145$$$O	TECK)$$$146$$$151$$$O	to$$$152$$$154$$$O	the$$$155$$$158$$$O	receptors.$$$159$$$169$$$O	The$$$170$$$173$$$O	invention$$$174$$$183$$$O	also$$$184$$$188$$$O	relates$$$189$$$196$$$O	to$$$197$$$199$$$O	a$$$200$$$201$$$O	method$$$202$$$208$$$O	of$$$209$$$211$$$O	inhibiting$$$212$$$222$$$O	a$$$223$$$224$$$O	function$$$225$$$233$$$O	of$$$234$$$236$$$O	CCR9,$$$237$$$242$$$O	and$$$243$$$246$$$O	to$$$247$$$249$$$O	the$$$250$$$253$$$O	use$$$254$$$257$$$O	compounds$$$258$$$267$$$O	represented$$$268$$$279$$$O	by$$$280$$$282$$$O	Structural$$$283$$$293$$$O	Formula$$$294$$$301$$$O	I$$$302$$$303$$$O	in$$$304$$$306$$$O	research,$$$307$$$316$$$O	therapeutic,$$$317$$$329$$$O	prophylactic$$$330$$$342$$$O	and$$$343$$$346$$$O	diagnostic$$$347$$$357$$$O	methods.$$$358$$$366$$$O
WO2012002464A1
Ï3$$$0$$$3$$$I	FATTY$$$4$$$9$$$I	ACID$$$10$$$14$$$I	COMPOUND$$$15$$$23$$$O	PREPARATION$$$24$$$35$$$O
Provided$$$0$$$8$$$O	is$$$9$$$11$$$O	a$$$12$$$13$$$O	compound$$$14$$$22$$$O	preparation$$$23$$$34$$$O	which$$$35$$$40$$$O	comprises$$$41$$$50$$$O	at$$$51$$$53$$$O	least$$$54$$$59$$$O	one$$$60$$$63$$$O	selected$$$64$$$72$$$O	from$$$73$$$77$$$O	the$$$78$$$81$$$O	group$$$82$$$87$$$O	consisting$$$88$$$98$$$O	of$$$99$$$101$$$O	Ï3$$$102$$$105$$$O	polyvalent$$$106$$$116$$$O	unsaturated$$$117$$$128$$$I	fatty$$$129$$$134$$$I	acids$$$135$$$140$$$I	and$$$141$$$144$$$O	pharmaceutically$$$145$$$161$$$O	acceptable$$$162$$$172$$$O	salts$$$173$$$178$$$O	and$$$179$$$182$$$O	esters$$$183$$$189$$$O	thereof,$$$190$$$198$$$O	and$$$199$$$202$$$O	comprises$$$203$$$212$$$O	at$$$213$$$215$$$O	least$$$216$$$221$$$O	one$$$222$$$225$$$O	selected$$$226$$$234$$$O	from$$$235$$$239$$$O	the$$$240$$$243$$$O	group$$$244$$$249$$$O	consisting$$$250$$$260$$$O	of$$$261$$$263$$$O	statin$$$264$$$270$$$O	compounds$$$271$$$280$$$O	and$$$281$$$284$$$O	pharmaceutically$$$285$$$301$$$O	acceptable$$$302$$$312$$$O	salts$$$313$$$318$$$O	thereof.$$$319$$$327$$$O	The$$$328$$$331$$$O	compound$$$332$$$340$$$O	preparation$$$341$$$352$$$O	has$$$353$$$356$$$O	a$$$357$$$358$$$O	capsule$$$359$$$366$$$O	film$$$367$$$371$$$O	pH$$$372$$$374$$$O	of$$$375$$$377$$$O	7.0$$$378$$$381$$$O	to$$$382$$$384$$$O	9.5$$$385$$$388$$$O	and$$$389$$$392$$$O	is$$$393$$$395$$$O	in$$$396$$$398$$$O	the$$$399$$$402$$$O	form$$$403$$$407$$$O	of$$$408$$$410$$$O	a$$$411$$$412$$$O	soft$$$413$$$417$$$O	capsule.$$$418$$$426$$$O	The$$$427$$$430$$$O	compound$$$431$$$439$$$O	preparation$$$440$$$451$$$O	inhibits$$$452$$$460$$$O	decomposition$$$461$$$474$$$O	of$$$475$$$477$$$O	the$$$478$$$481$$$O	statin$$$482$$$488$$$O	compounds$$$489$$$498$$$O	and/or$$$499$$$505$$$O	degeneration/insolubilization$$$506$$$535$$$O	of$$$536$$$538$$$O	the$$$539$$$542$$$O	capsule$$$543$$$550$$$O	film.$$$551$$$556$$$O	A$$$557$$$558$$$O	medical$$$559$$$566$$$O	use$$$567$$$570$$$O	for$$$571$$$574$$$O	the$$$575$$$578$$$O	compound$$$579$$$587$$$O	preparation,$$$588$$$600$$$O	a$$$601$$$602$$$O	method$$$603$$$609$$$O	for$$$610$$$613$$$O	producing$$$614$$$623$$$O	the$$$624$$$627$$$O	compound$$$628$$$636$$$O	preparation,$$$637$$$649$$$O	and$$$650$$$653$$$O	a$$$654$$$655$$$O	method$$$656$$$662$$$O	for$$$663$$$666$$$O	using$$$667$$$672$$$O	the$$$673$$$676$$$O	compound$$$677$$$685$$$O	preparation$$$686$$$697$$$O	are$$$698$$$701$$$O	also$$$702$$$706$$$O	provided.$$$707$$$716$$$O
WO2009062662A1
Pharmaceutical$$$0$$$14$$$O	and$$$15$$$18$$$O	nutraceutical$$$19$$$32$$$O	compositions$$$33$$$45$$$O	based$$$46$$$51$$$O	on$$$52$$$54$$$O	menaquinols$$$55$$$66$$$I
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	pharmaceutical$$$25$$$39$$$O	and$$$40$$$43$$$O	nutraceutical$$$44$$$57$$$O	compositions$$$58$$$70$$$O	containing$$$71$$$81$$$O	as$$$82$$$84$$$O	the$$$85$$$88$$$O	active$$$89$$$95$$$O	ingredient$$$96$$$106$$$O	a$$$107$$$108$$$O	menaquinol$$$109$$$119$$$O	of$$$120$$$122$$$O	formula$$$123$$$130$$$O	(I)$$$131$$$134$$$O	wherein$$$135$$$142$$$O	n$$$143$$$144$$$O	is$$$145$$$147$$$O	as$$$148$$$150$$$O	defined$$$151$$$158$$$O	in$$$159$$$161$$$O	the$$$162$$$165$$$O	description,$$$166$$$178$$$O	for$$$179$$$182$$$O	the$$$183$$$186$$$O	prevention$$$187$$$197$$$O	of$$$198$$$200$$$O	cardiovascular$$$201$$$215$$$O	diseases$$$216$$$224$$$O	and$$$225$$$228$$$O	bone$$$229$$$233$$$O	metabolism$$$234$$$244$$$O	disorders.$$$245$$$255$$$O
WO2008138920A1
Dihydroquinone$$$0$$$14$$$I	and$$$15$$$18$$$O	dihydronaphthridine$$$19$$$38$$$I	inhibitors$$$39$$$49$$$O	of$$$50$$$52$$$O	jnk$$$53$$$56$$$O
Compounds$$$0$$$9$$$O	of$$$10$$$12$$$O	formula$$$13$$$20$$$O	I$$$21$$$22$$$O	or$$$23$$$25$$$O	a$$$26$$$27$$$O	pharmaceutically$$$28$$$44$$$O	acceptable$$$45$$$55$$$O	salt$$$56$$$60$$$O	thereof$$$61$$$68$$$O	are$$$69$$$72$$$O	effective$$$73$$$82$$$O	modulators$$$83$$$93$$$O	of$$$94$$$96$$$O	JNK:$$$97$$$101$$$O	(formula)$$$102$$$111$$$O	wherein$$$112$$$119$$$O	X,$$$120$$$122$$$O	Y,$$$123$$$125$$$O	Z,$$$126$$$128$$$O	R4,$$$129$$$132$$$O	R5,$$$133$$$136$$$O	R6$$$137$$$139$$$O	and$$$140$$$143$$$O	R7$$$144$$$146$$$O	are$$$147$$$150$$$O	as$$$151$$$153$$$O	defined$$$154$$$161$$$O	herein.$$$162$$$169$$$O
CN103083274A
Slow-release$$$0$$$12$$$O	composition$$$13$$$24$$$O	containing$$$25$$$35$$$O	L-milnacipran$$$36$$$49$$$I	and$$$50$$$53$$$O	preparation$$$54$$$65$$$O	method$$$66$$$72$$$O	thereof$$$73$$$80$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	slow-release$$$27$$$39$$$O	composition$$$40$$$51$$$O	containing$$$52$$$62$$$O	L-milnacipran$$$63$$$76$$$I	and$$$77$$$80$$$O	a$$$81$$$82$$$O	preparation$$$83$$$94$$$O	method$$$95$$$101$$$O	thereof.$$$102$$$110$$$O	The$$$111$$$114$$$O	composition$$$115$$$126$$$O	contains$$$127$$$135$$$O	the$$$136$$$139$$$O	L-milnacipran$$$140$$$153$$$I	serving$$$154$$$161$$$O	as$$$162$$$164$$$O	an$$$165$$$167$$$O	active$$$168$$$174$$$O	ingredient$$$175$$$185$$$O	or$$$186$$$188$$$O	pharmaceutically$$$189$$$205$$$O	acceptable$$$206$$$216$$$O	salt$$$217$$$221$$$O	thereof.$$$222$$$230$$$O	The$$$231$$$234$$$O	composition$$$235$$$246$$$O	is$$$247$$$249$$$O	characterized$$$250$$$263$$$O	by$$$264$$$266$$$O	also$$$267$$$271$$$O	comprising$$$272$$$282$$$O	high-viscosity$$$283$$$297$$$O	hydroxypropyl$$$298$$$311$$$O	methylcellulose$$$312$$$327$$$O	serving$$$328$$$335$$$O	as$$$336$$$338$$$O	a$$$339$$$340$$$O	hydrophilic$$$341$$$352$$$O	gel$$$353$$$356$$$O	slow-release$$$357$$$369$$$O	skeleton$$$370$$$378$$$O	material$$$379$$$387$$$O	and$$$388$$$391$$$O	acrylic$$$392$$$399$$$I	resin$$$400$$$405$$$O	serving$$$406$$$413$$$O	as$$$414$$$416$$$O	a$$$417$$$418$$$O	pH$$$419$$$421$$$O	adjustor,$$$422$$$431$$$O	wherein$$$432$$$439$$$O	the$$$440$$$443$$$O	composition$$$444$$$455$$$O	comprises$$$456$$$465$$$O	the$$$466$$$469$$$O	following$$$470$$$479$$$O	components$$$480$$$490$$$O	in$$$491$$$493$$$O	parts$$$494$$$499$$$O	by$$$500$$$502$$$O	weight:$$$503$$$510$$$O	10$$$511$$$513$$$O	to$$$514$$$516$$$O	70$$$517$$$519$$$O	parts$$$520$$$525$$$O	of$$$526$$$528$$$O	L-milnacipran$$$529$$$542$$$I	or$$$543$$$545$$$O	pharmaceutically$$$546$$$562$$$O	acceptable$$$563$$$573$$$O	salt,$$$574$$$579$$$O	5$$$580$$$581$$$O	to$$$582$$$584$$$O	30$$$585$$$587$$$O	parts$$$588$$$593$$$O	of$$$594$$$596$$$O	hydroxypropyl$$$597$$$610$$$O	methylcellulose,$$$611$$$627$$$O	and$$$628$$$631$$$O	3.5$$$632$$$635$$$O	to$$$636$$$638$$$O	7.5$$$639$$$642$$$O	parts$$$643$$$648$$$O	of$$$649$$$651$$$O	acrylic$$$652$$$659$$$I	resin;$$$660$$$666$$$O	and$$$667$$$670$$$O	during$$$671$$$677$$$O	preparation,$$$678$$$690$$$O	the$$$691$$$694$$$O	L-milnacipran,$$$695$$$709$$$I	the$$$710$$$713$$$O	hydroxypropyl$$$714$$$727$$$O	methylcellulose$$$728$$$743$$$O	and$$$744$$$747$$$O	the$$$748$$$751$$$O	acrylic$$$752$$$759$$$I	resin$$$760$$$765$$$O	are$$$766$$$769$$$O	bound$$$770$$$775$$$O	to$$$776$$$778$$$O	be$$$779$$$781$$$O	mixed$$$782$$$787$$$O	uniformly.$$$788$$$798$$$O	The$$$799$$$802$$$O	composition$$$803$$$814$$$O	can$$$815$$$818$$$O	realize$$$819$$$826$$$O	consistency$$$827$$$838$$$O	of$$$839$$$841$$$O	release$$$842$$$849$$$O	behaviors$$$850$$$859$$$O	in$$$860$$$862$$$O	artificial$$$863$$$873$$$O	gastric$$$874$$$881$$$O	juice$$$882$$$887$$$O	and$$$888$$$891$$$O	artificial$$$892$$$902$$$O	intestinal$$$903$$$913$$$O	juice$$$914$$$919$$$O	and$$$920$$$923$$$O	keep$$$924$$$928$$$O	12-hour$$$929$$$936$$$O	continuous$$$937$$$947$$$O	release$$$948$$$955$$$O	effect,$$$956$$$963$$$O	and$$$964$$$967$$$O	is$$$968$$$970$$$O	low$$$971$$$974$$$O	in$$$975$$$977$$$O	preparation$$$978$$$989$$$O	loss,$$$990$$$995$$$O	high$$$996$$$1000$$$O	in$$$1001$$$1003$$$O	efficiency,$$$1004$$$1015$$$O	high$$$1016$$$1020$$$O	in$$$1021$$$1023$$$O	stability,$$$1024$$$1034$$$O	easy$$$1035$$$1039$$$O	to$$$1040$$$1042$$$O	operate$$$1043$$$1050$$$O	and$$$1051$$$1054$$$O	easy$$$1055$$$1059$$$O	to$$$1060$$$1062$$$O	popularize.$$$1063$$$1074$$$O
CA2156289C
Drug$$$0$$$4$$$O	composition$$$5$$$16$$$O	containing$$$17$$$27$$$O	nucleic$$$28$$$35$$$O	acid$$$36$$$40$$$O	copolymer$$$41$$$50$$$O
This$$$0$$$4$$$O	invention$$$5$$$14$$$O	has$$$15$$$18$$$O	for$$$19$$$22$$$O	its$$$23$$$26$$$O	object$$$27$$$33$$$O	to$$$34$$$36$$$O	insure$$$37$$$43$$$O	an$$$44$$$46$$$O	effective$$$47$$$56$$$O	utilization$$$57$$$68$$$O	of$$$69$$$71$$$O	single-stranded$$$72$$$87$$$O	nucleic$$$88$$$95$$$O	acid$$$96$$$100$$$O	copolymers,$$$101$$$112$$$O	particularly$$$113$$$125$$$O	poly(adenylic$$$126$$$139$$$I	acid-uridylic$$$140$$$153$$$I	acid),$$$154$$$160$$$I	and$$$161$$$164$$$O	to$$$165$$$167$$$O	provide$$$168$$$175$$$O	a$$$176$$$177$$$O	pharmaceutical$$$178$$$192$$$O	composition$$$193$$$204$$$O	having$$$205$$$211$$$O	antitumor$$$212$$$221$$$O	activity.$$$222$$$231$$$O	The$$$237$$$240$$$O	invention$$$241$$$250$$$O	typically$$$251$$$260$$$O	relates$$$261$$$268$$$O	to$$$269$$$271$$$O	a$$$272$$$273$$$O	pharmaceutical$$$274$$$288$$$O	composition$$$289$$$300$$$O	comprising$$$301$$$311$$$O	a$$$312$$$313$$$O	lipid$$$314$$$319$$$O	device$$$320$$$326$$$O	such$$$327$$$331$$$O	as$$$332$$$334$$$O	Lipofectin$$$335$$$345$$$O	(trademark),$$$346$$$358$$$O	3-O-(4-dimethylaminobutanoyl)-1,2-O-dioleylgycerol,$$$359$$$410$$$I	3-O-(2-dimethylamino-ethyl)carbamoyl-1,2-O-dioleylglycerol,$$$411$$$470$$$I	3-O-(2-diethylaminoethyl)$$$471$$$496$$$I	carbamoyl-1,2-O-dioleylgycerol,$$$497$$$528$$$I	or$$$529$$$531$$$O	2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol$$$532$$$589$$$I	and$$$590$$$593$$$O	poly(adenylic$$$594$$$607$$$I	acid-uridylic$$$608$$$621$$$I	acid).$$$622$$$628$$$I
US20080069870
Pulsed$$$0$$$6$$$O	release;$$$7$$$15$$$O	oral$$$16$$$20$$$O	administering$$$21$$$34$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	a$$$25$$$26$$$O	controlled$$$27$$$37$$$O	release$$$38$$$45$$$O	composition$$$46$$$57$$$O	comprising$$$58$$$68$$$O	a$$$69$$$70$$$O	cephalosporin$$$71$$$84$$$I	that$$$85$$$89$$$O	in$$$90$$$92$$$O	operation$$$93$$$102$$$O	delivers$$$103$$$111$$$O	the$$$112$$$115$$$O	drug$$$116$$$120$$$O	in$$$121$$$123$$$O	a$$$124$$$125$$$O	pulsed$$$126$$$132$$$O	or$$$133$$$135$$$O	bimodal$$$136$$$143$$$O	manner$$$144$$$150$$$O	for$$$151$$$154$$$O	the$$$155$$$158$$$O	treatment$$$159$$$168$$$O	of$$$169$$$171$$$O	bacterial$$$172$$$181$$$O	infection.$$$182$$$192$$$O	The$$$193$$$196$$$O	controlled$$$197$$$207$$$O	release$$$208$$$215$$$O	composition$$$216$$$227$$$O	comprises$$$228$$$237$$$O	an$$$238$$$240$$$O	immediate$$$241$$$250$$$O	release$$$251$$$258$$$O	component$$$259$$$268$$$O	and$$$269$$$272$$$O	a$$$273$$$274$$$O	modified$$$275$$$283$$$O	release$$$284$$$291$$$O	component;$$$292$$$302$$$O	the$$$303$$$306$$$O	immediate$$$307$$$316$$$O	release$$$317$$$324$$$O	component$$$325$$$334$$$O	comprising$$$335$$$345$$$O	a$$$346$$$347$$$O	first$$$348$$$353$$$O	population$$$354$$$364$$$O	of$$$365$$$367$$$O	cephalosporin-containing$$$368$$$392$$$I	particles$$$393$$$402$$$O	and$$$403$$$406$$$O	the$$$407$$$410$$$O	modified$$$411$$$419$$$O	release$$$420$$$427$$$O	component$$$428$$$437$$$O	comprising$$$438$$$448$$$O	a$$$449$$$450$$$O	second$$$451$$$457$$$O	population$$$458$$$468$$$O	of$$$469$$$471$$$O	cephalosporin-containing$$$472$$$496$$$I	particles$$$497$$$506$$$O	coated$$$507$$$513$$$O	with$$$514$$$518$$$O	a$$$519$$$520$$$O	controlled$$$521$$$531$$$O	release$$$532$$$539$$$O	coating;$$$540$$$548$$$O	wherein$$$549$$$556$$$O	the$$$557$$$560$$$O	combination$$$561$$$572$$$O	of$$$573$$$575$$$O	the$$$576$$$579$$$O	immediate$$$580$$$589$$$O	release$$$590$$$597$$$O	and$$$598$$$601$$$O	modified$$$602$$$610$$$O	release$$$611$$$618$$$O	components$$$619$$$629$$$O	in$$$630$$$632$$$O	operation$$$633$$$642$$$O	deliver$$$643$$$650$$$O	the$$$651$$$654$$$O	active$$$655$$$661$$$O	ingredient$$$662$$$672$$$O	in$$$673$$$675$$$O	a$$$676$$$677$$$O	pulsed$$$678$$$684$$$O	or$$$685$$$687$$$O	bi-modal$$$688$$$696$$$O	manner.$$$697$$$704$$$O	Preferably,$$$705$$$716$$$O	the$$$717$$$720$$$O	cephalosporin$$$721$$$734$$$I	is$$$735$$$737$$$O	cefcapene$$$738$$$747$$$I	pivoxil$$$748$$$755$$$I	or$$$756$$$758$$$O	a$$$759$$$760$$$O	salt$$$761$$$765$$$O	thereof$$$766$$$773$$$O	which$$$774$$$779$$$O	can$$$780$$$783$$$O	be$$$784$$$786$$$O	released$$$787$$$795$$$O	from$$$796$$$800$$$O	the$$$801$$$804$$$O	dosage$$$805$$$811$$$O	form$$$812$$$816$$$O	in$$$817$$$819$$$O	an$$$820$$$822$$$O	erodable,$$$823$$$832$$$O	diffusion$$$833$$$842$$$O	and/or$$$843$$$849$$$O	osmotic-controlled$$$850$$$868$$$O	release$$$869$$$876$$$O	profile.$$$877$$$885$$$O
US20110207693
Oral$$$0$$$4$$$O	B12$$$5$$$8$$$I	Therapy$$$9$$$16$$$O
Methods$$$0$$$7$$$O	of$$$8$$$10$$$O	normalizing$$$11$$$22$$$O	vitamin$$$23$$$30$$$I	B12$$$31$$$34$$$I	levels$$$35$$$41$$$O	in$$$42$$$44$$$O	patients$$$45$$$53$$$O	with$$$54$$$58$$$O	low$$$59$$$62$$$O	vitamin$$$63$$$70$$$I	B12$$$71$$$74$$$I	and$$$75$$$78$$$O	methods$$$79$$$86$$$O	of$$$87$$$89$$$O	normalizing$$$90$$$101$$$O	intersubject$$$102$$$114$$$O	variability$$$115$$$126$$$O	in$$$127$$$129$$$O	the$$$130$$$133$$$O	treatment$$$134$$$143$$$O	of$$$144$$$146$$$O	such$$$147$$$151$$$O	patients$$$152$$$160$$$O	are$$$161$$$164$$$O	described.$$$165$$$175$$$O	Methods$$$176$$$183$$$O	of$$$184$$$186$$$O	reducing$$$187$$$195$$$O	MMA$$$196$$$199$$$O	and/or$$$200$$$206$$$O	homocysteine$$$207$$$219$$$I	levels,$$$220$$$227$$$O	and$$$228$$$231$$$O	pharmaceutical$$$232$$$246$$$O	compositions$$$247$$$259$$$O	useful$$$260$$$266$$$O	to$$$267$$$269$$$O	effect$$$270$$$276$$$O	such$$$277$$$281$$$O	changes$$$282$$$289$$$O	are$$$290$$$293$$$O	also$$$294$$$298$$$O	described.$$$299$$$309$$$O
WO2012169973A1
A$$$0$$$1$$$O	core-shell$$$2$$$12$$$O	nanoparticle$$$13$$$25$$$O
A$$$0$$$1$$$O	core-shell$$$2$$$12$$$O	nanoparticle$$$13$$$25$$$O	for$$$26$$$29$$$O	drug$$$30$$$34$$$O	delivery$$$35$$$43$$$O	comprising$$$44$$$54$$$O	a$$$55$$$56$$$O	polymeric$$$57$$$66$$$O	shell$$$67$$$72$$$O	encapsulating$$$73$$$86$$$O	core$$$87$$$91$$$O	comprising$$$92$$$102$$$O	a$$$103$$$104$$$O	drug$$$105$$$109$$$O	and$$$110$$$113$$$O	an$$$114$$$116$$$O	imaging$$$117$$$124$$$O	agent.$$$125$$$131$$$O
CN1961872A
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	choline$$$7$$$14$$$I	in$$$15$$$17$$$O	preparation$$$18$$$29$$$O	of$$$30$$$32$$$O	medicament$$$33$$$43$$$O	having$$$44$$$50$$$O	central$$$51$$$58$$$O	or$$$59$$$61$$$O	peripheral$$$62$$$72$$$O	pain$$$73$$$77$$$O	easing$$$78$$$84$$$O	function$$$85$$$93$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	the$$$25$$$28$$$O	use$$$29$$$32$$$O	of$$$33$$$35$$$O	sincaline$$$36$$$45$$$O	compounds$$$46$$$55$$$O	in$$$56$$$58$$$O	the$$$59$$$62$$$O	treatment$$$63$$$72$$$O	of$$$73$$$75$$$O	central$$$76$$$83$$$O	or$$$84$$$86$$$O	peripheral$$$87$$$97$$$O	pains.$$$98$$$104$$$O
WO2013040027A1
Reprogramming$$$0$$$13$$$O	immune$$$14$$$20$$$O	environment$$$21$$$32$$$O	in$$$33$$$35$$$O	breast$$$36$$$42$$$O	cancer$$$43$$$49$$$O	via$$$50$$$53$$$O	dendritic$$$54$$$63$$$O	cells$$$64$$$69$$$O
Compositions$$$0$$$12$$$O	and$$$13$$$16$$$O	methods$$$17$$$24$$$O	for$$$25$$$28$$$O	the$$$29$$$32$$$O	treatment$$$33$$$42$$$O	of$$$43$$$45$$$O	cancer$$$46$$$52$$$O	disclosed$$$53$$$62$$$O	herein.$$$63$$$70$$$O	The$$$71$$$74$$$O	method$$$75$$$81$$$O	of$$$82$$$84$$$O	the$$$85$$$88$$$O	present$$$89$$$96$$$O	invention$$$97$$$106$$$O	comprises$$$107$$$116$$$O	administration$$$117$$$131$$$O	of$$$132$$$134$$$O	compositions$$$135$$$147$$$O	comprising$$$148$$$158$$$O	Î²-glucan,$$$159$$$169$$$O	a$$$170$$$171$$$O	natural$$$172$$$179$$$O	ligand$$$180$$$186$$$O	for$$$187$$$190$$$O	dectin-1,$$$191$$$200$$$O	to$$$201$$$203$$$O	block$$$204$$$209$$$O	OX40L$$$210$$$215$$$O	expression$$$216$$$226$$$O	on$$$227$$$229$$$O	tumor$$$230$$$235$$$O	associated$$$236$$$246$$$O	mDCs$$$247$$$251$$$O	by$$$252$$$254$$$O	blocking$$$255$$$263$$$O	STAT6$$$264$$$269$$$O	phosphorylation.$$$270$$$286$$$O	The$$$287$$$290$$$O	Î²-glucan-treated$$$291$$$308$$$O	mDCs$$$309$$$313$$$O	secrete$$$314$$$321$$$O	higher$$$322$$$328$$$O	levels$$$329$$$335$$$O	of$$$336$$$338$$$O	IL-12p70$$$339$$$347$$$O	and$$$348$$$351$$$O	do$$$352$$$354$$$O	not$$$355$$$358$$$O	expand$$$359$$$365$$$O	TNFÎ±$$$366$$$371$$$O	and$$$372$$$375$$$O	IL-$$$376$$$379$$$O	13$$$380$$$382$$$O	-producing$$$383$$$393$$$O	CD4+$$$394$$$398$$$O	T$$$399$$$400$$$O	cells,$$$401$$$407$$$O	further$$$408$$$415$$$O	resulting$$$416$$$425$$$O	in$$$426$$$428$$$O	inhibition$$$429$$$439$$$O	of$$$440$$$442$$$O	Th2$$$443$$$446$$$O	responses.$$$447$$$457$$$O	Thus,$$$458$$$463$$$O	compositions$$$464$$$476$$$O	disclosed$$$477$$$486$$$O	herein$$$487$$$493$$$O	reprogram$$$494$$$503$$$O	the$$$504$$$507$$$O	function$$$508$$$516$$$O	of$$$517$$$519$$$O	mDCs$$$520$$$524$$$O	in$$$525$$$527$$$O	breast$$$528$$$534$$$O	tumor$$$535$$$540$$$O	microenvironment$$$541$$$557$$$O	and$$$558$$$561$$$O	turn$$$562$$$566$$$O	tumor$$$567$$$572$$$O	promoting$$$573$$$582$$$O	Th2-type$$$583$$$591$$$O	chronic$$$592$$$599$$$O	inflammation$$$600$$$612$$$O	into$$$613$$$617$$$O	Thl-type$$$618$$$626$$$O	acute$$$627$$$632$$$O	inflammation$$$633$$$645$$$O	that$$$646$$$650$$$O	are$$$651$$$654$$$O	able$$$655$$$659$$$O	to$$$660$$$662$$$O	reject$$$663$$$669$$$O	tumors.$$$670$$$677$$$O	The$$$678$$$681$$$O	present$$$682$$$689$$$O	invention$$$690$$$699$$$O	finds$$$700$$$705$$$O	particular$$$706$$$716$$$O	uses$$$717$$$721$$$O	for$$$722$$$725$$$O	the$$$726$$$729$$$O	intratumoral$$$730$$$742$$$O	administration$$$743$$$757$$$O	of$$$758$$$760$$$O	the$$$761$$$764$$$O	composition$$$765$$$776$$$O	thereby$$$777$$$784$$$O	directly$$$785$$$793$$$O	binding$$$794$$$801$$$O	to$$$802$$$804$$$O	and$$$805$$$808$$$O	directing$$$809$$$818$$$O	a$$$819$$$820$$$O	Thl-$$$821$$$825$$$O	type$$$826$$$830$$$O	acute$$$831$$$836$$$O	inflammation.$$$837$$$850$$$O
CN101289455B
Anti-influenza$$$0$$$14$$$O	virus$$$15$$$20$$$O	precursor$$$21$$$30$$$O	drug$$$31$$$35$$$O	and$$$36$$$39$$$O	uses$$$40$$$44$$$O	thereof$$$45$$$52$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	relates$$$14$$$21$$$O	to$$$22$$$24$$$O	an$$$25$$$27$$$O	anti-influenza$$$28$$$42$$$O	virus$$$43$$$48$$$O	prodrug$$$49$$$56$$$O	and$$$57$$$60$$$O	the$$$61$$$64$$$O	application$$$65$$$76$$$O	thereof,$$$77$$$85$$$O	particularly$$$86$$$98$$$O	relates$$$99$$$106$$$O	to$$$107$$$109$$$O	a$$$110$$$111$$$O	6-fluorine-3-hydroxy-pyrazine-2-formamide$$$112$$$153$$$I	anti-influenza$$$154$$$168$$$O	virus$$$169$$$174$$$O	prodrug$$$175$$$182$$$O	and$$$183$$$186$$$O	the$$$187$$$190$$$O	application$$$191$$$202$$$O	thereof.$$$203$$$211$$$O	The$$$212$$$215$$$O	invention$$$216$$$225$$$O	discloses$$$226$$$235$$$O	an$$$236$$$238$$$O	anti-influenza$$$239$$$253$$$O	virus$$$254$$$259$$$O	prodrug$$$260$$$267$$$O	which$$$268$$$273$$$O	is$$$274$$$276$$$O	a$$$277$$$278$$$O	derivative$$$279$$$289$$$O	related$$$290$$$297$$$O	to$$$298$$$300$$$O	1,$$$301$$$303$$$I	3-pyrazine$$$304$$$314$$$I	oxazine-2,$$$315$$$325$$$I	4$$$326$$$327$$$I	diketone$$$328$$$336$$$I	with$$$337$$$341$$$O	a$$$342$$$343$$$O	chemical$$$344$$$352$$$O	structural$$$353$$$363$$$O	formula$$$364$$$371$$$O	(I);$$$372$$$376$$$O	wherein,$$$377$$$385$$$O	R1$$$386$$$388$$$O	and$$$389$$$392$$$O	R2$$$393$$$395$$$O	respectively$$$396$$$408$$$O	stand$$$409$$$414$$$O	for$$$415$$$418$$$O	hydrogen,$$$419$$$428$$$I	halogen,$$$429$$$437$$$I	etc.;$$$438$$$443$$$O	Z$$$444$$$445$$$O	stands$$$446$$$452$$$O	for$$$453$$$456$$$O	NR3,$$$457$$$461$$$I	and$$$462$$$465$$$O	R3$$$466$$$468$$$O	stands$$$469$$$475$$$O	for$$$476$$$479$$$O	hydrogen,$$$480$$$489$$$I	etc.;$$$490$$$495$$$O	X$$$496$$$497$$$O	stands$$$498$$$504$$$O	for$$$505$$$508$$$O	carbonyl$$$509$$$517$$$I	(CO),$$$518$$$523$$$I	etc.;$$$524$$$529$$$O	Y$$$530$$$531$$$O	stands$$$532$$$538$$$O	for$$$539$$$542$$$O	carbonyl$$$543$$$551$$$I	(CO),$$$552$$$557$$$I	imino$$$558$$$563$$$I	group$$$564$$$569$$$O	(C$$$570$$$572$$$I	is$$$573$$$575$$$O	equal$$$576$$$581$$$O	to$$$582$$$584$$$O	N),$$$585$$$588$$$I	thiocarbonyl$$$589$$$601$$$I	(CS).$$$602$$$607$$$I	The$$$608$$$611$$$O	anti-influenza$$$612$$$626$$$O	virus$$$627$$$632$$$O	prodrug$$$633$$$640$$$O	of$$$641$$$643$$$O	the$$$644$$$647$$$O	invention$$$648$$$657$$$O	is$$$658$$$660$$$O	hydrolyzed$$$661$$$671$$$O	slowly$$$672$$$678$$$O	into$$$679$$$683$$$O	drugs$$$684$$$689$$$O	with$$$690$$$694$$$O	antivirus,$$$695$$$705$$$O	anti-influenza$$$706$$$720$$$O	and$$$721$$$724$$$O	anti-bird$$$725$$$734$$$O	flu$$$735$$$738$$$O	under$$$739$$$744$$$O	the$$$745$$$748$$$O	effects$$$749$$$756$$$O	of$$$757$$$759$$$O	body$$$760$$$764$$$O	lactone$$$765$$$772$$$I	and$$$773$$$776$$$O	hydrolass,$$$777$$$787$$$O	and$$$788$$$791$$$O	has$$$792$$$795$$$O	theadvantages$$$796$$$809$$$O	of$$$810$$$812$$$O	high$$$813$$$817$$$O	bioavailability,$$$818$$$834$$$O	long$$$835$$$839$$$O	internal$$$840$$$848$$$O	function$$$849$$$857$$$O	time$$$858$$$862$$$O	and$$$863$$$866$$$O	high$$$867$$$871$$$O	water-solubility.$$$872$$$889$$$O
US20050119224
Use$$$0$$$3$$$O	of$$$4$$$6$$$O	n-acetyl-d-glucosamine$$$7$$$29$$$I	in$$$30$$$32$$$O	the$$$33$$$36$$$O	manufacture$$$37$$$48$$$O	of$$$49$$$51$$$O	pharmaceutical$$$52$$$66$$$O	useful$$$67$$$73$$$O	for$$$74$$$77$$$O	adjuvant$$$78$$$86$$$O	treatment$$$87$$$96$$$O	of$$$97$$$99$$$O	perianal$$$100$$$108$$$O	disease$$$109$$$116$$$O
The$$$0$$$3$$$O	present$$$4$$$11$$$O	invention$$$12$$$21$$$O	has$$$22$$$25$$$O	disclosed$$$26$$$35$$$O	a$$$36$$$37$$$O	use$$$38$$$41$$$O	of$$$42$$$44$$$O	N-acetyl-D-glucosamine$$$45$$$67$$$I	in$$$68$$$70$$$O	the$$$71$$$74$$$O	manufacture$$$75$$$86$$$O	of$$$87$$$89$$$O	a$$$90$$$91$$$O	medicine$$$92$$$100$$$O	for$$$101$$$104$$$O	auxiliary$$$105$$$114$$$O	treatment$$$115$$$124$$$O	of$$$125$$$127$$$O	the$$$128$$$131$$$O	peri-anal$$$132$$$141$$$O	disease.$$$142$$$150$$$O	Through$$$151$$$158$$$O	stabilizing$$$159$$$170$$$O	celluar$$$171$$$178$$$O	lysosome$$$179$$$187$$$O	membrance,$$$188$$$198$$$O	the$$$199$$$202$$$O	degree$$$203$$$209$$$O	and$$$210$$$213$$$O	scope$$$214$$$219$$$O	of$$$220$$$222$$$O	the$$$223$$$226$$$O	injure$$$227$$$233$$$O	extended$$$234$$$242$$$O	by$$$243$$$245$$$O	the$$$246$$$249$$$O	release$$$250$$$257$$$O	of$$$258$$$260$$$O	various$$$261$$$268$$$O	enzymes$$$269$$$276$$$O	in$$$277$$$279$$$O	the$$$280$$$283$$$O	cellular$$$284$$$292$$$O	lysosome$$$293$$$301$$$O	are$$$302$$$305$$$O	decreased;$$$306$$$316$$$O	improving$$$317$$$326$$$O	the$$$327$$$330$$$O	healing$$$331$$$338$$$O	of$$$339$$$341$$$O	the$$$342$$$345$$$O	injured$$$346$$$353$$$O	tissues;$$$354$$$362$$$O	resist$$$363$$$369$$$O	the$$$370$$$373$$$O	field$$$374$$$379$$$O	planting$$$380$$$388$$$O	of$$$389$$$391$$$O	the$$$392$$$395$$$O	microorganism$$$396$$$409$$$O	on$$$410$$$412$$$O	the$$$413$$$416$$$O	traumatic$$$417$$$426$$$O	surface$$$427$$$434$$$O	so$$$435$$$437$$$O	as$$$438$$$440$$$O	to$$$441$$$443$$$O	prevent$$$444$$$451$$$O	the$$$452$$$455$$$O	occurrence$$$456$$$466$$$O	of$$$467$$$469$$$O	infection.$$$470$$$480$$$O	The$$$481$$$484$$$O	preparation$$$485$$$496$$$O	with$$$497$$$501$$$O	N-acetyl-D-glucosamine$$$502$$$524$$$I	as$$$525$$$527$$$O	a$$$528$$$529$$$O	main$$$530$$$534$$$O	active$$$535$$$541$$$O	component$$$542$$$551$$$O	can$$$552$$$555$$$O	be$$$556$$$558$$$O	used$$$559$$$563$$$O	in$$$564$$$566$$$O	the$$$567$$$570$$$O	auxiliary$$$571$$$580$$$O	treatment$$$581$$$590$$$O	of$$$591$$$593$$$O	the$$$594$$$597$$$O	peri-anal$$$598$$$607$$$O	diseases,$$$608$$$617$$$O	with$$$618$$$622$$$O	a$$$623$$$624$$$O	remarkable$$$625$$$635$$$O	curative$$$636$$$644$$$O	effect.$$$645$$$652$$$O
CN101862299A
Preparation$$$0$$$11$$$O	method$$$12$$$18$$$O	of$$$19$$$21$$$O	aspoxicillin$$$22$$$34$$$I	freeze-dried$$$35$$$47$$$O	powder$$$48$$$54$$$O	injection$$$55$$$64$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	preparation$$$26$$$37$$$O	method$$$38$$$44$$$O	of$$$45$$$47$$$O	aspoxicillin$$$48$$$60$$$I	freeze-dried$$$61$$$73$$$O	powder$$$74$$$80$$$O	injection$$$81$$$90$$$O	for$$$91$$$94$$$O	injection,$$$95$$$105$$$O	which$$$106$$$111$$$O	is$$$112$$$114$$$O	characterized$$$115$$$128$$$O	in$$$129$$$131$$$O	that:$$$132$$$137$$$O	adding$$$138$$$144$$$O	aspoxicillin$$$145$$$157$$$I	and$$$158$$$161$$$O	pharmaceutical$$$162$$$176$$$O	excipients$$$177$$$187$$$O	into$$$188$$$192$$$O	0$$$193$$$194$$$O	to$$$195$$$197$$$O	10DEG$$$198$$$203$$$O	C$$$204$$$205$$$O	water,$$$206$$$212$$$O	adding$$$213$$$219$$$O	in$$$220$$$222$$$O	alkali$$$223$$$229$$$O	solution$$$230$$$238$$$O	so$$$239$$$241$$$O	that$$$242$$$246$$$O	the$$$247$$$250$$$O	aspoxicillin$$$251$$$263$$$I	is$$$264$$$266$$$O	dissolved,$$$267$$$277$$$O	maintaining$$$278$$$289$$$O	the$$$290$$$293$$$O	temperature$$$294$$$305$$$O	of$$$306$$$308$$$O	the$$$309$$$312$$$O	liquid$$$313$$$319$$$O	medicine$$$320$$$328$$$O	to$$$329$$$331$$$O	be$$$332$$$334$$$O	0$$$335$$$336$$$O	to$$$337$$$339$$$O	10DEG$$$340$$$345$$$O	C,$$$346$$$348$$$O	using$$$349$$$354$$$O	acid$$$355$$$359$$$O	solution$$$360$$$368$$$O	to$$$369$$$371$$$O	adjust$$$372$$$378$$$O	the$$$379$$$382$$$O	pH$$$383$$$385$$$O	value$$$386$$$391$$$O	to$$$392$$$394$$$O	be$$$395$$$397$$$O	6.5$$$398$$$401$$$O	to$$$402$$$404$$$O	8.0,$$$405$$$409$$$O	filtering,$$$410$$$420$$$O	filling,$$$421$$$429$$$O	freeze-drying$$$430$$$443$$$O	to$$$444$$$446$$$O	obtain$$$447$$$453$$$O	the$$$454$$$457$$$O	aspoxicillin$$$458$$$470$$$I	freeze-dried$$$471$$$483$$$O	powder$$$484$$$490$$$O	injection.$$$491$$$501$$$O	The$$$502$$$505$$$O	process$$$506$$$513$$$O	method$$$514$$$520$$$O	takes$$$521$$$526$$$O	water$$$527$$$532$$$O	as$$$533$$$535$$$O	the$$$536$$$539$$$O	solvent,$$$540$$$548$$$O	controls$$$549$$$557$$$O	the$$$558$$$561$$$O	pH$$$562$$$564$$$O	value$$$565$$$570$$$O	and$$$571$$$574$$$O	the$$$575$$$578$$$O	temperature,$$$579$$$591$$$O	and$$$592$$$595$$$O	the$$$596$$$599$$$O	content$$$600$$$607$$$O	of$$$608$$$610$$$O	relevant$$$611$$$619$$$O	substances$$$620$$$630$$$O	and$$$631$$$634$$$O	polymer$$$635$$$642$$$O	of$$$643$$$645$$$O	a$$$646$$$647$$$O	preparation$$$648$$$659$$$O	is$$$660$$$662$$$O	low.$$$663$$$667$$$O	The$$$668$$$671$$$O	process$$$672$$$679$$$O	method$$$680$$$686$$$O	can$$$687$$$690$$$O	prepare$$$691$$$698$$$O	and$$$699$$$702$$$O	obtain$$$703$$$709$$$O	products$$$710$$$718$$$O	with$$$719$$$723$$$O	more$$$724$$$728$$$O	excellent$$$729$$$738$$$O	quality.$$$739$$$747$$$O
CN101269075A
Medicament$$$0$$$10$$$O	composition$$$11$$$22$$$O	containing$$$23$$$33$$$O	ambroxol$$$34$$$42$$$I	and$$$43$$$46$$$O	benproperine,$$$47$$$60$$$I	and$$$61$$$64$$$O	uses$$$65$$$69$$$O	thereof$$$70$$$77$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	discloses$$$14$$$23$$$O	a$$$24$$$25$$$O	drug$$$26$$$30$$$O	compound$$$31$$$39$$$O	of$$$40$$$42$$$O	medicinal$$$43$$$52$$$O	salt$$$53$$$57$$$O	containing$$$58$$$68$$$O	one$$$69$$$72$$$O	or$$$73$$$75$$$O	the$$$76$$$79$$$O	both$$$80$$$84$$$O	of$$$85$$$87$$$O	ambroxol$$$88$$$96$$$I	and$$$97$$$100$$$O	benproperine,$$$101$$$114$$$I	the$$$115$$$118$$$O	application$$$119$$$130$$$O	and$$$131$$$134$$$O	the$$$135$$$138$$$O	application$$$139$$$150$$$O	of$$$151$$$153$$$O	the$$$154$$$157$$$O	drug$$$158$$$162$$$O	compound$$$163$$$171$$$O	to$$$172$$$174$$$O	the$$$175$$$178$$$O	preparation$$$179$$$190$$$O	of$$$191$$$193$$$O	drugs$$$194$$$199$$$O	of$$$200$$$202$$$O	phlegm$$$203$$$209$$$O	eliminating$$$210$$$221$$$O	or$$$222$$$224$$$O	cough$$$225$$$230$$$O	preventing$$$231$$$241$$$O	and$$$242$$$245$$$O	of$$$246$$$248$$$O	phlegm$$$249$$$255$$$O	eliminating$$$256$$$267$$$O	and$$$268$$$271$$$O	cough$$$272$$$277$$$O	preventing.$$$278$$$289$$$O	The$$$290$$$293$$$O	pharmaceutical$$$294$$$308$$$O	preparation$$$309$$$320$$$O	of$$$321$$$323$$$O	the$$$324$$$327$$$O	invention$$$328$$$337$$$O	containing$$$338$$$348$$$O	the$$$349$$$352$$$O	active$$$353$$$359$$$O	ingredients$$$360$$$371$$$O	of$$$372$$$374$$$O	ambroxol$$$375$$$383$$$I	and$$$384$$$387$$$O	benproperine$$$388$$$400$$$I	has$$$401$$$404$$$O	the$$$405$$$408$$$O	characteristics$$$409$$$424$$$O	of$$$425$$$427$$$O	stable$$$428$$$434$$$O	property,$$$435$$$444$$$O	convenient$$$445$$$455$$$O	use$$$456$$$459$$$O	and$$$460$$$463$$$O	large-scale$$$464$$$475$$$O	production.$$$476$$$487$$$O	The$$$488$$$491$$$O	pharmaceutical$$$492$$$506$$$O	preparation$$$507$$$518$$$O	of$$$519$$$521$$$O	the$$$522$$$525$$$O	invention$$$526$$$535$$$O	has$$$536$$$539$$$O	obvious$$$540$$$547$$$O	synergic$$$548$$$556$$$O	effect-enhancing$$$557$$$573$$$O	effect$$$574$$$580$$$O	particularly$$$581$$$593$$$O	on$$$594$$$596$$$O	cough$$$597$$$602$$$O	preventing$$$603$$$613$$$O	and$$$614$$$617$$$O	phlegm$$$618$$$624$$$O	eliminating$$$625$$$636$$$O	in$$$637$$$639$$$O	the$$$640$$$643$$$O	application$$$644$$$655$$$O	of$$$656$$$658$$$O	preparing$$$659$$$668$$$O	drugs$$$669$$$674$$$O	of$$$675$$$677$$$O	preventing$$$678$$$688$$$O	and$$$689$$$692$$$O	curing$$$693$$$699$$$O	diseases$$$700$$$708$$$O	related$$$709$$$716$$$O	to$$$717$$$719$$$O	the$$$720$$$723$$$O	respiratory$$$724$$$735$$$O	tract.$$$736$$$742$$$O
US7659257
Medicament$$$0$$$10$$$O	for$$$11$$$14$$$O	treating$$$15$$$23$$$O	lung$$$24$$$28$$$O	cancer$$$29$$$35$$$O
Lung$$$0$$$4$$$O	cancer$$$5$$$11$$$O	can$$$12$$$15$$$O	be$$$16$$$18$$$O	treated$$$19$$$26$$$O	effectively$$$27$$$38$$$O	by$$$39$$$41$$$O	combination$$$42$$$53$$$O	of$$$54$$$56$$$O	amrubicin$$$57$$$66$$$I	or$$$67$$$69$$$O	a$$$70$$$71$$$O	pharmaceutically$$$72$$$88$$$O	acceptable$$$89$$$99$$$O	salt$$$100$$$104$$$O	thereof$$$105$$$112$$$O	with$$$113$$$117$$$O	cisplatin.$$$118$$$128$$$I
WO2008016674A1
Agonists$$$0$$$8$$$O	of$$$9$$$11$$$O	the$$$12$$$15$$$O	sphingosine-$$$16$$$28$$$I	1-$$$29$$$31$$$I	phosphate$$$32$$$41$$$I	receptor$$$42$$$50$$$O	(slp)$$$51$$$56$$$O
The$$$0$$$3$$$O	invention$$$4$$$13$$$O	provides$$$14$$$22$$$O	compounds$$$23$$$32$$$O	of$$$33$$$35$$$O	formula$$$36$$$43$$$O	I$$$44$$$45$$$O	and$$$46$$$49$$$O	formula$$$50$$$57$$$O	II,$$$58$$$61$$$O	their$$$62$$$67$$$O	preparation,$$$68$$$80$$$O	a$$$81$$$82$$$O	their$$$83$$$88$$$O	use$$$89$$$92$$$O	as$$$93$$$95$$$O	pharmaceutically$$$96$$$112$$$O	active$$$113$$$119$$$O	immunosuppressive$$$120$$$137$$$O	agents$$$138$$$144$$$O	for$$$145$$$148$$$O	the$$$149$$$152$$$O	treatment$$$153$$$162$$$O	of$$$163$$$165$$$O	autoimmune$$$166$$$176$$$O	disorders,$$$177$$$187$$$O	organ$$$188$$$193$$$O	transplant$$$194$$$204$$$O	rejection,$$$205$$$215$$$O	disorders$$$216$$$225$$$O	associated$$$226$$$236$$$O	with$$$237$$$241$$$O	an$$$242$$$244$$$O	activated$$$245$$$254$$$O	immune$$$255$$$261$$$O	system,$$$262$$$269$$$O	as$$$270$$$272$$$O	well$$$273$$$277$$$O	as$$$278$$$280$$$O	other$$$281$$$286$$$O	disorders$$$287$$$296$$$O	modulated$$$297$$$306$$$O	by$$$307$$$309$$$O	lymphopenia$$$310$$$321$$$O	or$$$322$$$324$$$O	SlP$$$325$$$328$$$O	receptors.$$$329$$$339$$$O
